chebi_id,name,definition,inchi_string,synonym,type,accession_number
0,4798,entacapone,"A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.","InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+",Entacapone,KEGG COMPOUND accession,C07943
1,2341,AACOCF3,A fatty acid derivative that is arachidonic acid in which the OH part of the carboxy group has been replaced by a trifluoromethyl group,"InChI=1S/C21H31F3O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(25)21(22,23)24/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3/b7-6-,10-9-,13-12-,16-15-",AACOCF3,KEGG COMPOUND accession,C01397
2,3223,buspirone,"An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.","InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2",Buspirone,CAS Registry Number,36505-84-7
3,8028,perphenazine,A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.,"InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2",Perphenazine,CAS Registry Number,58-39-9
4,4819,lysergamide,An ergoline alkaloid comprising ergoline lacking hydrogens at positions 9 and 10 and also having a methyl group attached to the piperidine nitrogen.,"InChI=1S/C16H17N3O/c1-19-8-10(16(17)20)5-12-11-3-2-4-13-15(11)9(7-18-13)6-14(12)19/h2-5,7,10,14,18H,6,8H2,1H3,(H2,17,20)/t10-,14-/m1/s1",Ergine,KEGG COMPOUND accession,C09160
5,5672,heptan-2-one,A dialkyl ketone with methyl and pentyl as the alkyl groups.,"InChI=1S/C7H14O/c1-3-4-5-6-7(2)8/h3-6H2,1-2H3",Heptan-2-one,CAS Registry Number,110-43-0
6,6047,isoprothiolane,"A malonate ester that is diisopropyl malonate in which the two methylene hydrogens at position 2 are replaced by a 1,3-dithiolan-2-ylidene group. An insecticide and fungicide used to control a range of diseases including Pyricularia oryzae, Helminthosporium sigmoideum and Fusarium nivale.","InChI=1S/C12H18O4S2/c1-7(2)15-10(13)9(11(14)16-8(3)4)12-17-5-6-18-12/h7-8H,5-6H2,1-4H3",Isoprothiolane,KEGG COMPOUND accession,C11111
7,5555,guanadrel,"A spiroketal resulting from the formal condensation of the keto group of cyclohexanone with the hydroxy groups of 1-(2,3-dihydroxypropyl)guanidine. A postganglionic adrenergic blocking agent formerly used (generally as the sulfate salt) for the management of hypertension, it has been largely superseded by other drugs less likely to cause orthostatic hypotension (dizzy spells on standing up or stretching).","InChI=1S/C10H19N3O2/c11-9(12)13-6-8-7-14-10(15-8)4-2-1-3-5-10/h8H,1-7H2,(H4,11,12,13)",Guanadrel,KEGG COMPOUND accession,C07035
8,1391,"3,4-methylenedioxymethamphetamine","A member of the class of  benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.","InChI=1S/C11H15NO2/c1-8(12-2)5-9-3-4-10-11(6-9)14-7-13-10/h3-4,6,8,12H,5,7H2,1-2H3","3,4-Methylenedioxymethamphetamine",KEGG COMPOUND accession,C07577
9,4331,dauricine,"A bisbenzylisoquinoline alkaloid resulting from the formal oxidative dimerisation of 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenol by attachment of the phenolic oxygen of one molecule to the benzene ring of the second (ortho to the phenolic hydroxy group of the latter).","InChI=1S/C38H44N2O6/c1-39-15-13-26-20-35(42-3)37(44-5)22-29(26)31(39)17-24-7-10-28(11-8-24)46-34-19-25(9-12-33(34)41)18-32-30-23-38(45-6)36(43-4)21-27(30)14-16-40(32)2/h7-12,19-23,31-32,41H,13-18H2,1-6H3/t31-,32-/m1/s1",Dauricine,CAS Registry Number,524-17-4
10,8368,precocene I,A member of the class of chromenes that is 2H-chromene substituted by a methoxy group at position 7 and two methyl groups at position 2.,"InChI=1S/C12H14O2/c1-12(2)7-6-9-4-5-10(13-3)8-11(9)14-12/h4-8H,1-3H3",Precocene 1,KEGG COMPOUND accession,C09017
11,9943,venlafaxine,"A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.","InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3",Venlafaxine,CAS Registry Number,93413-69-5
12,9775,tubulosine,A member of the class of beta-carbolines that is tubulosan bearing methoxy groups at positions 10 and 11 and a hydroxy group at the 8' position.,"InChI=1S/C29H37N3O3/c1-4-17-16-32-10-8-18-13-27(34-2)28(35-3)15-22(18)26(32)12-19(17)11-25-29-21(7-9-30-25)23-14-20(33)5-6-24(23)31-29/h5-6,13-15,17,19,25-26,30-31,33H,4,7-12,16H2,1-3H3/t17-,19-,25+,26-/m0/s1",Tubulosine,CAS Registry Number,2632-29-3
13,2953,azinphos-methyl,"A member of the class of  benzotriazines that is  1,2,3-benzotriazine substituted by an oxo group at position 4 and a [(dimethoxyphosphorothioyl)sulfanyl]methyl group at position 3.","InChI=1S/C10H12N3O3PS2/c1-15-17(18,16-2)19-7-13-10(14)8-5-3-4-6-9(8)11-12-13/h3-6H,7H2,1-2H3",Azinphos methyl,CAS Registry Number,86-50-0
14,2666,amitriptyline,"An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.","InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3",Amitriptyline,KEGG COMPOUND accession,C06824
15,2440,acrovestone,A polyphenol that is isolated from Acronychia pedunculata and exhibits moderate antioxidant and antityrosinase activities.,"InChI=1S/C32H42O8/c1-15(2)10-12-20-27(35)23(18(7)33)30(38)25(28(20)36)22(14-17(5)6)26-29(37)21(13-11-16(3)4)32(40-9)24(19(8)34)31(26)39/h10-11,17,22,35-39H,12-14H2,1-9H3",Acrovestone,CAS Registry Number,24177-16-0
16,8499,propranolol,A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",Propranolol,KEGG COMPOUND accession,C07407
17,5557,guanethidine,A member of the class of  guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.,"InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)",Guanethidine,KEGG COMPOUND accession,C07036
18,119,D-synephrine,The D-enantiomer of synephrine.,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-2-4-8(11)5-3-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",(-)-Sympatol,KEGG COMPOUND accession,C01869
19,3750,clofibrate,The ethyl ester of clofibric acid.,"InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3",Clofibrate,CAS Registry Number,637-07-0
20,3764,clotrimazole,A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to a nitrogen is replaced by a monochlorotrityl group.,"InChI=1S/C22H17ClN2/c23-21-14-8-7-13-20(21)22(25-16-15-24-17-25,18-9-3-1-4-10-18)19-11-5-2-6-12-19/h1-17H",Clotrimazole,KEGG COMPOUND accession,C06922
21,2687,amsacrine,A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits  antineoplastic activity.,"InChI=1S/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)",Amsacrine,KEGG COMPOUND accession,C01553
22,4708,doxazosin,"A member of the class of  quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An  antihypertensive agent, it is used in the treatment of high blood pressure.","InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)",Doxazosin,KEGG COMPOUND accession,C06970
23,3687,chrysophanol,A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.,"InChI=1S/C15H10O4/c1-7-5-9-13(11(17)6-7)15(19)12-8(14(9)18)3-2-4-10(12)16/h2-6,16-17H,1H3",Chrysophanol,KEGG COMPOUND accession,C10315
24,5001,fenofibrate,A chlorobenzophenone that is (4-chlorophenyl)(phenyl)methanone substituted by a [2-methyl-1-oxo-1-(propan-2-yloxy)propan-2-yl]oxy group at position 1 on the phenyl ring.,"InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3",Fenofibrate,KEGG COMPOUND accession,C07586
25,89,(-)-camphene,"A camphene (2,2-dimethyl-3-methylenebicyclo[2.2.1]heptane) that has S configuration at position 1 and R configuration at position 4.","InChI=1S/C10H16/c1-7-8-4-5-9(6-8)10(7,2)3/h8-9H,1,4-6H2,2-3H3/t8-,9+/m1/s1",(-)-Comphene,KEGG COMPOUND accession,C06305
26,2369,abyssinone VI,A member of the class of chalcones that is isolated from the stem of Erythrina abyssinica.,"InChI=1S/C25H28O4/c1-16(2)5-8-19-13-18(14-20(25(19)29)9-6-17(3)4)7-12-23(27)22-11-10-21(26)15-24(22)28/h5-7,10-15,26,28-29H,8-9H2,1-4H3/b12-7+",Abyssinone VI,CAS Registry Number,77263-12-8
27,2415,acetylcaranine,An organic heteropentacyclic compound that is caranine in which the hydroxy group is acetylated.,"InChI=1S/C18H19NO4/c1-10(20)23-14-3-2-11-4-5-19-8-12-6-15-16(22-9-21-15)7-13(12)17(14)18(11)19/h2,6-7,14,17-18H,3-5,8-9H2,1H3/t14-,17-,18-/m1/s1",Acetylcaranine,KEGG COMPOUND accession,C08513
28,7735,olanzapine,"A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.","InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3",Olanzapine,KEGG COMPOUND accession,C07322
29,2673,amobarbital,"A member of the class of  barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.","InChI=1S/C11H18N2O3/c1-4-11(6-5-7(2)3)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",Amobarbital,CAS Registry Number,57-43-2
30,4659,disulfiram,"An organic disulfide that results from the formal oxidative dimerisation of N,N-diethyldithiocarbamic acid.  A multi-enzyme inhibitor that is used in alcohol aversion therapy and also exhibits anticancer properties.","InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3",Disulfiram,KEGG COMPOUND accession,C01692
31,4681,dofetilide,A tertiary amino compound that is N-ethyl-N-methylethanamine substituted by a 4-[(methylsulfonyl)amino]phenoxy and a 4-[(methylsulfonyl)amino]phenyl group at the terminal carbon atoms respectively. It is used as an  anti-arrhythmia drug.,"InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3",Dofetilide,KEGG COMPOUND accession,C07751
32,7856,oxybutynin,A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.,"InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3",Oxybutynin,CAS Registry Number,5633-20-5
33,3259,CCCP,"A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.","InChI=1S/C9H5ClN4/c10-7-2-1-3-8(4-7)13-14-9(5-11)6-12/h1-4,13H",CCCP,CAS Registry Number,555-60-2
34,9398,tamsulosin,"A 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide that has (R)-configuration. A specific alpha1 adrenoceptor antagonist used (generally as its hydrochloride salt, tamsulosin hydrochloride) in the treatment of prostatic hyperplasia, chronic prostatitis, urinary retention, and help with the passage of kidney stones.","InChI=1S/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1",Tamsulosin,KEGG COMPOUND accession,C07124
35,7852,oxycodone,"A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine.  It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.","InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1",Oxycodone,KEGG COMPOUND accession,C08018
36,7809,oxacillin,A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.,"InChI=1S/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1",Oxacillin,KEGG COMPOUND accession,C07334
37,8713,quinapril,"A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.","InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1",Quinapril,KEGG COMPOUND accession,C07398
38,10124,zolmitriptan,"A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.","InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1",311C90,CAS Registry Number,139264-17-8
39,5790,hydromorphone,"A  morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.","InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1",Hydromorphone,KEGG COMPOUND accession,C07042
40,4781,emetine,"A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.","InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1",Emetine,KEGG COMPOUND accession,C09421
41,2981,baicalin,The glycosyloxyflavone which is the 7-O-glucuronide of baicalein. It is an active ingredient of Chinese herbal medicine Scutellaria baicalensis.,"InChI=1S/C21H18O11/c22-9-6-10(8-4-2-1-3-5-8)30-11-7-12(14(23)15(24)13(9)11)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21,23-27H,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1",Baicalin,KEGG COMPOUND accession,C10025
42,5138,fluvoxamine,An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.,"InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+",Fluvoxamine,KEGG COMPOUND accession,C07571
43,4917,eugenol,"A phenylpropanoid formally derived from guaiacol with an allyl chain substituted para to the hydroxy group. It is a major component of clove essential oil, and exhibits antibacterial, analgesic and antioxidant properties. It has been widely used in dentistry to treat toothache and pulpitis.","InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3",Eugenol,CAS Registry Number,97-53-0
44,3131,bithionol,"An aryl sulfide that is diphenyl sulfide in which each phenyl group is substituted at position 2 by hydroxy and at positions 3 and 5 by chlorine. A fungicide and anthelmintic, it was used in various topical drug products for the treatment of liver flukes, but withdrawn after being shown to be a potent photosensitizer with the potential to cause serious skin disorders.","InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H",Bithionol,KEGG COMPOUND accession,C07967
45,2979,baicalein,"A trihydroxyflavone with the hydroxy groups at positions C-5, -6 and -7.","InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H",Baicalein,CAS Registry Number,491-67-8
46,9505,nitro blue tetrazolium dichloride,An organic chloride salt having nitro blue tetrazolium(2+) as the counterion.,"InChI=1S/C40H30N10O6.2ClH/c1-55-37-25-29(13-23-35(37)47-43-39(27-9-5-3-6-10-27)41-45(47)31-15-19-33(20-16-31)49(51)52)30-14-24-36(38(26-30)56-2)48-44-40(28-11-7-4-8-12-28)42-46(48)32-17-21-34(22-18-32)50(53)54;;/h3-26H,1-2H3;2*1H/q+2;;/p-2",Nitro blue tetrazolium,KEGG COMPOUND accession,C13503
47,3903,coumaphos,,"InChI=1S/C14H16ClO5PS/c1-4-17-21(22,18-5-2)20-10-6-7-11-9(3)13(15)14(16)19-12(11)8-10/h6-8H,4-5H2,1-3H3",Coumaphos,KEGG COMPOUND accession,C11025
48,2674,amodiaquine,A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.,"InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)",Amodiaquine,KEGG COMPOUND accession,C07626
49,3127,bisoprolol,,"InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3",Bisoprolol,KEGG COMPOUND accession,C06852
50,5818,hydroxyzine,A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.,"InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2",Hydroxyzine,KEGG COMPOUND accession,C07045
51,7307,N-methylpyrrolidin-2-one,A member of the class of  pyrrolidine-2-ones that is pyrrolidin-2-one in which the hydrogen attached to the nitrogen is replaced by a methyl group.,"InChI=1S/C5H9NO/c1-6-4-2-3-5(6)7/h2-4H2,1H3",N-Methyl-2-pyrrolidinone,KEGG COMPOUND accession,C11118
52,25255,methyl methanesulfonate,A methanesulfonate ester resulting from the formal condensation of methanesulfonic acid with methanol.,"InChI=1S/C2H6O3S/c1-5-6(2,3)4/h1-2H3",CB1540,CAS Registry Number,66-27-3
53,4791,endosulfan,"A cyclic sulfite ester that is 1,5,5a,6,9,9a-hexahydro-6,9-methano-2,4,3-benzodioxathiepine 3-oxide substituted by chloro groups at positions 6, 7, 8, 9, 10 and 10.","InChI=1S/C9H6Cl6O3S/c10-5-6(11)8(13)4-2-18-19(16)17-1-3(4)7(5,12)9(8,14)15/h3-4H,1-2H2",Endosulfan,CAS Registry Number,115-29-7
54,4806,(-)-epigallocatechin 3-gallate,A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.,"InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1",epigallocatechin 3-gallate,KEGG COMPOUND accession,C09731
55,6980,monocrotaline,,"InChI=1S/C16H23NO6/c1-9-13(18)23-11-5-7-17-6-4-10(12(11)17)8-22-14(19)16(3,21)15(9,2)20/h4,9,11-12,20-21H,5-8H2,1-3H3/t9-,11+,12+,15+,16-/m0/s1",Monocrotaline,CAS Registry Number,315-22-0
56,9907,ursodeoxycholic acid,"A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.","InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1",Ursodiol,KEGG COMPOUND accession,C07880
57,6031,isonicotinamide,A pyridinecarboxamide that is the monocarboxylic acid amide derivative of  isonicotinic acid.,"InChI=1S/C6H6N2O/c7-6(9)5-1-3-8-4-2-5/h1-4H,(H2,7,9)",Isonicotineamide,KEGG COMPOUND accession,C02421
58,6443,levonorgestrel,,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1",Levonorgestrel,KEGG COMPOUND accession,C08149
59,8113,phlorizin,An aryl beta-D-glucoside that is  phloretin attached to a  beta-D-glucopyranosyl residue at position 2' via a glycosidic linkage.,"InChI=1S/C21H24O10/c22-9-16-18(27)19(28)20(29)21(31-16)30-15-8-12(24)7-14(26)17(15)13(25)6-3-10-1-4-11(23)5-2-10/h1-2,4-5,7-8,16,18-24,26-29H,3,6,9H2/t16-,18-,19+,20-,21-/m1/s1",Phlorizin,KEGG COMPOUND accession,C01604
60,9536,thiamylal,"A member of the class of  barbiturates that is 2-thioxodihydropyrimidine-4,6(1H,5H)-dione substituted by a pentan-2-yl and prop-2-en-1-yl group at position 5.","InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)",Thiamylal,CAS Registry Number,77-27-0
61,4903,17alpha-ethynylestradiol,A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a  xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.,"InChI=1S/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1",Ethynyl estradiol,CAS Registry Number,57-63-6
62,5862,idazoxan,"A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.","InChI=1S/C11H12N2O2/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,10H,5-7H2,(H,12,13)",Idazoxan,CAS Registry Number,79944-58-4
63,1958,5'-dehydroadenosine,A member of the class of  adenosines that is 5'-dehydro derivative of adenosine.,"InChI=1S/C10H11N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h1-4,6-7,10,17-18H,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1",5'-Dehydroadenosine,KEGG COMPOUND accession,C11500
64,2003,"5,6-dihydroxyindole-2-carboxylic acid",A dihydroxyindole that is indole-2-carboxylic acid substituted by hydroxy groups at positions 5 and 6.,"InChI=1S/C9H7NO4/c11-7-2-4-1-6(9(13)14)10-5(4)3-8(7)12/h1-3,10-12H,(H,13,14)","5,6-Dihydroxyindole-2-carboxylate",KEGG COMPOUND accession,C04185
65,2663,amiodarone,"A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a  cardiovascular drug used for the treatment of cardiac dysrhythmias.","InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3",Amiodarone,CAS Registry Number,1951-25-3
66,2670,ammodendrine,"A piperidine alkaloid that is piperidine substituted by a 1-acetyl-1,4,5,6-tetrahydropyridin-3-yl group at position 2 (the 2R-stereoisomer).","InChI=1S/C12H20N2O/c1-10(15)14-8-4-5-11(9-14)12-6-2-3-7-13-12/h9,12-13H,2-8H2,1H3/t12-/m1/s1",Ammodendrine,KEGG COMPOUND accession,C10125
67,5441,glyburide,An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.,"InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)",Glyburide,KEGG COMPOUND accession,C07022
68,8887,rofecoxib,"A butenolide that is furan-2(5H)-one substituted by a phenyl group at position 3 and by a p-(methylsulfonyl)phenyl group at position 4. A selective cyclooxygenase 2 inhibitor, it was used from 1999 to 2004 for the treatment of ostoarthritis, but was withdrawn following concerns about an associated increased risk of heart attack and stroke.","InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3",Rofecoxib,KEGG COMPOUND accession,C07590
69,2542,alatolide,A germacrane sesquiterpenoid laactone obtained by formal condensation of the carboxy group of isobutyric acid with the secondary hydroxy group of trihydroxygermaeranolide.,"InChI=1S/C19H26O6/c1-11(2)18(22)24-15-7-13(9-20)5-4-6-14(10-21)8-16-17(15)12(3)19(23)25-16/h5,8,11,15-17,20-21H,3-4,6-7,9-10H2,1-2H3/b13-5-,14-8-/t15-,16+,17+/m0/s1",Alatolide,CAS Registry Number,41929-10-6
70,2611,alprazolam,"A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.","InChI=1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3",Alprazolam,KEGG COMPOUND accession,C06817
71,7522,neriifolin,A cardenolide glycoside that is digitoxigenin in which the hydroxy goup at position 3 has been converted to its (6-deoxy-3-O-methyl-alpha-L-glucopyranoside derivative. Found in the seeds of Cerbera odollamand in Thevetia ahouia and Thevitia neriifolia.,"InChI=1S/C30H46O8/c1-16-24(32)26(35-4)25(33)27(37-16)38-19-7-10-28(2)18(14-19)5-6-22-21(28)8-11-29(3)20(9-12-30(22,29)34)17-13-23(31)36-15-17/h13,16,18-22,24-27,32-34H,5-12,14-15H2,1-4H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28-,29+,30-/m0/s1",Neriifolin,KEGG COMPOUND accession,C08876
72,3682,chrysazin,"A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8.","InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H",Chrysazin,KEGG COMPOUND accession,C10312
73,743,pedilstatin,"A phorbol ester that is 4-deoxyphorbol in which the hydroxy groups at positions  12 and 13 have been replaced by octa-2,4-dienoyloxy and acetyloxy groups respectively.","InChI=1S/C30H40O7/c1-7-8-9-10-11-12-24(33)36-27-18(3)29(35)22-13-17(2)25(34)21(22)14-20(16-31)15-23(29)26-28(5,6)30(26,27)37-19(4)32/h9-13,15,18,21-23,26-27,31,35H,7-8,14,16H2,1-6H3/b10-9+,12-11-/t18-,21-,22-,23+,26-,27-,29+,30-/m1/s1","12-O-2Z,4E-Octadienoyl-4-deoxyphorbol 13-acetate",KEGG COMPOUND accession,C09143
74,4042,cypermethrin,"A carboxylic ester resulting from the formal condensation between 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid and the alcoholic hydroxy group of hydroxy(3-phenoxyphenyl)acetonitrile.","InChI=1S/C22H19Cl2NO3/c1-22(2)17(12-19(23)24)20(22)21(26)28-18(13-25)14-7-6-10-16(11-14)27-15-8-4-3-5-9-15/h3-12,17-18,20H,1-2H3",Cypermethrin,CAS Registry Number,52315-07-8
75,7640,nortriptyline,"An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of  amitriptyline.","InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3",Nortriptyline,CAS Registry Number,72-69-5
76,2791,aprobarbital,"A member of the class of  barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by an isopropyl and a  prop-1-en-3-yl group at position 5.","InChI=1S/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)",Aprobarbital,KEGG COMPOUND accession,C07826
77,3210,bufotenin,"A tertiary amine that consists of N,N-dimethyltryptamine bearing an additional hydroxy substituent at position 5.","InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3",Bufotenine,CAS Registry Number,487-93-4
78,9410,taurodeoxycholic acid,A bile acid taurine conjugate of deoxycholic acid.,"InChI=1S/C26H45NO6S/c1-16(4-9-24(30)27-12-13-34(31,32)33)20-7-8-21-19-6-5-17-14-18(28)10-11-25(17,2)22(19)15-23(29)26(20,21)3/h16-23,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17-,18-,19+,20-,21+,22+,23+,25+,26-/m1/s1",Taurodeoxycholate,KEGG COMPOUND accession,C05463
79,2781,apocynin,An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.,"InChI=1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3",Apocynin,KEGG COMPOUND accession,C11380
80,2624,amastatin,"A tetrapeptide comprising (2S,3R)-3-amino-2-hydroxy-5-methylhexanoyl, L-valyl, L-valyl and L-aspartic acid units joined in sequence","InChI=1S/C21H38N4O8/c1-9(2)7-12(22)17(28)20(31)25-16(11(5)6)19(30)24-15(10(3)4)18(29)23-13(21(32)33)8-14(26)27/h9-13,15-17,28H,7-8,22H2,1-6H3,(H,23,29)(H,24,30)(H,25,31)(H,26,27)(H,32,33)/t12-,13+,15+,16+,17+/m1/s1",Amastatin,KEGG COMPOUND accession,C01552
81,2637,amikacin,An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.,"InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1",Amikacin,CAS Registry Number,37517-28-5
82,6872,methylene blue,"An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.","InChI=1S/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1",Methylene blue,KEGG COMPOUND accession,C00220
83,3011,benazepril,A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.,"InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1",Benazepril,KEGG COMPOUND accession,C06843
84,9122,sertindole,"A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.","InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31)",Sertindole,KEGG COMPOUND accession,C07567
85,5692,hexachlorobenzene,"A member of the class of chlorobenzenes that is benzene in which all of the hydrogens are replaced by chlorines. An agricultural fungicide introduced in the mid-1940s and formerly used as a seed treatment, its use has been banned since 1984 under the Stockholm Convention on Persistent Organic Pollutants.",InChI=1S/C6Cl6/c7-1-2(8)4(10)6(12)5(11)3(1)9,Hexachlorobenzene,CAS Registry Number,118-74-1
86,2622,amarogentin,"A secoiridoid glycoside that consists of (4aS,5R,6R)-5-ethenyl-6-hydroxy-4,4a,5,6-tetrahydro-1H,3H-pyrano[3,4-c]pyran-1-one having a  2-O-[(3,3',5-trihydroxybiphenyl-2-yl)carbonyl]-beta-D-glucopyranosyl group attached at position 6 via a glycosidic linkage.","InChI=1S/C29H30O13/c1-2-16-17-6-7-38-26(36)19(17)12-39-28(16)42-29-25(24(35)23(34)21(11-30)40-29)41-27(37)22-18(9-15(32)10-20(22)33)13-4-3-5-14(31)8-13/h2-5,8-10,12,16-17,21,23-25,28-35H,1,6-7,11H2/t16-,17+,21-,23-,24+,25-,28+,29+/m1/s1",Amarogentin,KEGG COMPOUND accession,C09767
87,3015,benomyl,A member of the class of benzimidazoles that is the methyl ester of  [1-(butylcarbamoyl)-1H-benzimidazol-2-yl]carbamic acid. A foliar fungicide used to control a wide range of Ascomycetes and Fungi Imperfecti in a wide range of crops.,"InChI=1S/C14H18N4O3/c1-3-4-9-15-13(19)18-11-8-6-5-7-10(11)16-12(18)17-14(20)21-2/h5-8H,3-4,9H2,1-2H3,(H,15,19)(H,16,17,20)",Benlate,KEGG COMPOUND accession,C10896
88,3639,chlorothalonil,"A dinitrile that is benzene-1,3-dicarbonitrile substituted by four chloro groups. A non-systemic fungicide first introduced in the 1960s, it is used to control a range of diseases in a wide variety of crops.",InChI=1S/C8Cl4N2/c9-5-3(1-13)6(10)8(12)7(11)4(5)2-14,Chlorothalonil,KEGG COMPOUND accession,C11037
89,8050,phenacetin,A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a 4-ethoxyphenyl group.,"InChI=1S/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)",Phenacetin,CAS Registry Number,62-44-2
90,8502,6-propyl-2-thiouracil,A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.,"InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11)",Propylthiouracil,CAS Registry Number,51-52-5
91,4918,O-methyleugenol,,"InChI=1S/C11H14O2/c1-4-5-9-6-7-10(12-2)11(8-9)13-3/h4,6-8H,1,5H2,2-3H3",Eugenol methyl ether,CAS Registry Number,93-15-2
92,2618,amantadine,A member of the class of  adamantanes that is used as an antiviral and  antiparkinson drug.,"InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2",Amantadine,CAS Registry Number,768-94-5
93,9328,sulfadiazine,A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.,"InChI=1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)",Sulfadiazine,KEGG COMPOUND accession,C07658
94,7635,2-hydroxychrysophanol,"A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by a methyl substituent at C-3 and by hydroxy groups at C-1, C-2 and C-8.","InChI=1S/C15H10O5/c1-6-5-8-11(15(20)12(6)17)14(19)10-7(13(8)18)3-2-4-9(10)16/h2-5,16-17,20H,1H3",Norobtusifolin,CAS Registry Number,58322-78-4
95,469,1'-acetoxychavicol acetate,An  acetate ester that is chavicol acetate substituted by an acetoxy group at position 1'.,"InChI=1S/C13H14O4/c1-4-13(17-10(3)15)11-5-7-12(8-6-11)16-9(2)14/h4-8,13H,1H2,2-3H3/t13-/m0/s1",1'-Acetoxychavicol acetate,KEGG COMPOUND accession,C10426
96,9212,sparfloxacin,,"InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+",Sparfloxacin,KEGG COMPOUND accession,C07662
97,508,"1,2-epoxy-3-(4-nitrophenoxy)propane",An epoxide that is oxirane substituted by a (4-nitrophenoxy)methyl group.,"InChI=1S/C9H9NO4/c11-10(12)7-1-3-8(4-2-7)13-5-9-6-14-9/h1-4,9H,5-6H2","1,2-Epoxy-3-(p-Nitrophenoxy)propane",KEGG COMPOUND accession,C04274
98,8055,5-methylphenazinium methyl sulfate,,"InChI=1S/C13H11N2.CH4O4S/c1-15-12-8-4-2-6-10(12)14-11-7-3-5-9-13(11)15;1-5-6(2,3)4/h2-9H,1H3;1H3,(H,2,3,4)/q+1;/p-1",Phenazine methosulfate,KEGG COMPOUND accession,C00200
99,8075,phenoxyacetic acid,"A monocarboxylic acid that is the O-phenyl derivative of glycolic acid. A metabolite of 2-phenoxyethanol, it is used in the manufacture of pharmaceuticals, pesticides, fungicides and dyes.","InChI=1S/C8H8O3/c9-8(10)6-11-7-4-2-1-3-5-7/h1-5H,6H2,(H,9,10)",Phenoxyacetate,CAS Registry Number,122-59-8
100,5337,"(1E,4E)-germacrene B",,"InChI=1S/C15H24/c1-12(2)15-10-8-13(3)6-5-7-14(4)9-11-15/h6,9H,5,7-8,10-11H2,1-4H3/b13-6+,14-9+",Germacrene B,KEGG COMPOUND accession,C09672
101,8464,prontosil,"A diphenyldiazene compound having two amino substituents at the 2- and 4-positions and an aminosulphonyl substituent at the 4'-position. It was the first antibacterial drug, (introduced 1935) and the first of the sulfonamide antibiotics.","InChI=1S/C12H13N5O2S/c13-8-1-6-12(11(14)7-8)17-16-9-2-4-10(5-3-9)20(15,18)19/h1-7H,13-14H2,(H2,15,18,19)/b17-16+",Prontosil,KEGG COMPOUND accession,C07573
102,6601,lycorine,"An  indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it  has been shown to exhibit antimalarial activity.","InChI=1S/C16H17NO4/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19/h3-5,11,14-16,18-19H,1-2,6-7H2/t11-,14-,15+,16+/m0/s1",Lycorine,CAS Registry Number,476-28-8
103,9434,telmisartan,A member of the class of  benzimidazoles  used widely in the treatment of hypertension.,"InChI=1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)",Telmisartan,KEGG COMPOUND accession,C07710
104,5959,irbesartan,A  biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.,"InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)",Irbesartan,CAS Registry Number,138402-11-6
105,6061,isosorbide dinitrate,,"InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1",Isosorbide dinitrate,KEGG COMPOUND accession,C07456
106,1751,chromotropic acid,"A naphthalenesulfonic acid that is naphthalene-2,7-disulfonic acid substituted by hydroxy groups at positions 4 and 5.","InChI=1S/C10H8O8S2/c11-8-3-6(19(13,14)15)1-5-2-7(20(16,17)18)4-9(12)10(5)8/h1-4,11-12H,(H,13,14,15)(H,16,17,18)",Chromotropic acid,CAS Registry Number,148-25-4
107,7466,nandrolone,A 3-oxo Delta(4)-steroid that is estr-4-en-3-one substituted by a beta-hydroxy group at position 17.,"InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1",Nandrolone,KEGG COMPOUND accession,C07254
108,8597,protriptyline,,"InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3",Protriptyline,KEGG COMPOUND accession,C07408
109,3491,cefonicid,"A cephalosporin bearing {[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and (R)-2-hydroxy-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.","InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1",Cefonicid,KEGG COMPOUND accession,C06882
110,9086,(-)-selegiline,,"InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1",Selegiline,CAS Registry Number,14611-51-9
111,8746,(R)-salbutamol,,"InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m0/s1",R-Salbutamol,CAS Registry Number,34391-04-3
112,2364,abrusoside A,"A triterpenoid saponin that is (22S,24Z)-3beta-hydroxy-26-oxo-22,26-epoxy-9beta,19-cyclolanost-24-en-28-oic acid having a beta-D-glucosyl residue attached at position 3 via a glycosidic bond.","InChI=1S/C36H54O10/c1-18-6-7-21(44-29(18)41)19(2)20-10-12-33(4)23-8-9-24-34(5,31(42)43)25(46-30-28(40)27(39)26(38)22(16-37)45-30)11-13-35(24)17-36(23,35)15-14-32(20,33)3/h6,19-28,30,37-40H,7-17H2,1-5H3,(H,42,43)/t19-,20+,21-,22+,23-,24-,25-,26+,27-,28+,30-,32+,33-,34-,35+,36-/m0/s1",Abrusoside A,KEGG COMPOUND accession,C08920
113,2417,acetylcholine chloride,"The chloride salt of acetylcholine, and a parasympatomimetic drug.","InChI=1S/C7H16NO2.ClH/c1-7(9)10-6-5-8(2,3)4;/h5-6H2,1-4H3;1H/q+1;/p-1",Acetylcholine chloride,KEGG COMPOUND accession,C08201
114,2540,alantolactone,"A sesquiterpene lactone that is 3a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2-one bearing two methyl substituents at positions 5 and 8a as well as a methylidene substituent at position 3.","InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h7,9,11,13H,2,4-6,8H2,1,3H3/t9-,11+,13+,15+/m0/s1",Alantolactone,KEGG COMPOUND accession,C09289
115,2636,amifostine,"An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.","InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)",Amifostine,KEGG COMPOUND accession,C06819
116,2942,azadirachtin A,A member of the family of azadirachtins that is isolated from the neem tree (Azadirachta indica).,"InChI=1S/C35H44O16/c1-8-15(2)24(38)49-18-12-19(48-16(3)36)32(26(39)43-6)13-46-21-22(32)31(18)14-47-34(42,27(40)44-7)25(31)29(4,23(21)37)35-20-11-17(30(35,5)51-35)33(41)9-10-45-28(33)50-20/h8-10,17-23,25,28,37,41-42H,11-14H2,1-7H3/b15-8+/t17-,18+,19-,20+,21-,22-,23-,25+,28+,29-,30+,31+,32+,33+,34+,35+/m1/s1",Azadirachtin A,KEGG COMPOUND accession,C08748
117,6682,mangiferin,"A C-glycosyl compound consisting of 1,3,6,7-tetrahydroxyxanthen-9-one having a beta-D-glucosyl residue at the 6-position.","InChI=1S/C19H18O11/c20-4-11-15(25)17(27)18(28)19(30-11)12-8(23)3-10-13(16(12)26)14(24)5-1-6(21)7(22)2-9(5)29-10/h1-3,11,15,17-23,25-28H,4H2/t11-,15-,17+,18-,19+/m1/s1",Mangiferin,CAS Registry Number,4773-96-0
118,6842,methoxychlor,,"InChI=1S/C16H15Cl3O2/c1-20-13-7-3-11(4-8-13)15(16(17,18)19)12-5-9-14(21-2)10-6-12/h3-10,15H,1-2H3",Methoxychlor,CAS Registry Number,72-43-5
119,8828,rhodamine 123,,"InChI=1S/C21H16N2O3.ClH/c1-25-21(24)15-5-3-2-4-14(15)20-16-8-6-12(22)10-18(16)26-19-11-13(23)7-9-17(19)20;/h2-11,22H,23H2,1H3;1H",Rhodamine 123,KEGG COMPOUND accession,C11190
120,8888,ropinirole,,"InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19)",Ropinirole,KEGG COMPOUND accession,C07564
121,9445,terazosin,,"InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)",Terazosin,KEGG COMPOUND accession,C07127
122,9642,N-tosyl-L-phenylalanyl chloromethyl ketone,The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.,"InChI=1S/C17H18ClNO3S/c1-13-7-9-15(10-8-13)23(21,22)19-16(17(20)12-18)11-14-5-3-2-4-6-14/h2-10,16,19H,11-12H2,1H3/t16-/m0/s1",Tos-Phe-CH2Cl,KEGG COMPOUND accession,C02088
123,6128,ketoprofen,An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.,"InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)",Ketoprofen,KEGG COMPOUND accession,C01716
124,29510,abietol,An abietane diterpenoid having the skeleton of abietane with double bonds at C-7 and C-13 and a hydroxy function at C-18.,"InChI=1S/C20H32O/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4/h7,12,14,17-18,21H,5-6,8-11,13H2,1-4H3/t17-,18-,19-,20+/m0/s1",Abietinol,KEGG COMPOUND accession,C11882
125,670,1-phenylethylamine,A phenylethylamine that is ethylamine substituted by a phenyl group at position 1.,"InChI=1S/C8H11N/c1-7(9)8-5-3-2-4-6-8/h2-7H,9H2,1H3",1-Phenylethylamine,KEGG COMPOUND accession,C02455
126,1808,(4-chlorophenoxy)acetic acid,A chlorophenoxyacetic acid that is phenoxyacetic acid carrying a chloro substituent at position 4.,"InChI=1S/C8H7ClO3/c9-6-1-3-7(4-2-6)12-5-8(10)11/h1-4H,5H2,(H,10,11)",4-Chlorophenoxyacetate,KEGG COMPOUND accession,C07088
127,10432,2-naphthol,A naphthol carrying a hydroxy group at position 2.,"InChI=1S/C10H8O/c11-10-6-5-8-3-1-2-4-9(8)7-10/h1-7,11H",beta-Naphthol,CAS Registry Number,135-19-3
128,4623,(carboxymethyl)(dimethyl)sulfonium,,"InChI=1S/C4H8O2S/c1-7(2)3-4(5)6/h3H2,1-2H3/p+1",Dimethylsulfonioacetate,KEGG COMPOUND accession,C03392
129,3540,cephalotaxine,A benzazepine alkaloid isolated from Cephalotaxus harringtonia.,"InChI=1S/C18H21NO4/c1-21-15-9-18-4-2-5-19(18)6-3-11-7-13-14(23-10-22-13)8-12(11)16(18)17(15)20/h7-9,16-17,20H,2-6,10H2,1H3/t16-,17-,18+/m1/s1",Cephalotaxine,KEGG COMPOUND accession,C10580
130,5050,fexofenadine,A piperidine-based anti-histamine compound.,"InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)",Fexofenadine,CAS Registry Number,83799-24-0
131,5141,fomepizole,A member of the class of  pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.,"InChI=1S/C4H6N2/c1-4-2-5-6-3-4/h2-3H,1H3,(H,5,6)",4-Methylpyrazole,KEGG COMPOUND accession,C07837
132,5195,furazolidone,"A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.","InChI=1S/C8H7N3O5/c12-8-10(3-4-15-8)9-5-6-1-2-7(16-6)11(13)14/h1-2,5H,3-4H2",Furazolidone,CAS Registry Number,67-45-8
133,7613,nonacosane,A straight-chain alkane comprising of 29 carbon atoms.,"InChI=1S/C29H60/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-29H2,1-2H3",Nonacosane,KEGG COMPOUND accession,C08384
134,8984,sodium dodecyl sulfate,An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate.,"InChI=1S/C12H26O4S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15;/h2-12H2,1H3,(H,13,14,15);/q;+1/p-1",SDS,KEGG COMPOUND accession,C11166
135,4648,hop-22(29)-ene,A triterpene consisting of hopane having a C=C double bond at the 22(29)-position.,"InChI=1S/C30H50/c1-20(2)21-12-17-27(5)22(21)13-18-29(7)24(27)10-11-25-28(6)16-9-15-26(3,4)23(28)14-19-30(25,29)8/h21-25H,1,9-19H2,2-8H3/t21-,22+,23+,24-,25-,27+,28+,29-,30-/m1/s1",Diploptene,KEGG COMPOUND accession,C06310
136,2424,acetylpyruvic acid,A dioxo monocarboxylic acid that is pentanoic acid carrying two oxo groups at positions 2 and 4.,"InChI=1S/C5H6O4/c1-3(6)2-4(7)5(8)9/h2H2,1H3,(H,8,9)",Acetylpyruvate,KEGG COMPOUND accession,C02132
137,5659,hentriacontane,,"InChI=1S/C31H64/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-31H2,1-2H3",Hentriacontane,KEGG COMPOUND accession,C08376
138,3688,chrysophanol 8-O-beta-D-glucoside,"A beta-D-glucoside in which the aglycone species is chrysophanol, the glycosidic linkage being to the hydroxy group at C-8.","InChI=1S/C21H20O9/c1-8-5-10-14(11(23)6-8)18(26)15-9(16(10)24)3-2-4-12(15)29-21-20(28)19(27)17(25)13(7-22)30-21/h2-6,13,17,19-23,25,27-28H,7H2,1H3/t13-,17-,19+,20-,21-/m1/s1",Chrysophanol 8-O-beta-D-glucoside,KEGG COMPOUND accession,C10316
139,3534,cephalexin,"A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.","InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1",Cefalexin,KEGG COMPOUND accession,C06895
140,4593,dihydroxyfumaric acid,A 2-hydroxydicarboxylic acid consisting of fumaric acid having two hydroxy groups at the 2- and 3-positions.,"InChI=1S/C4H4O6/c5-1(3(7)8)2(6)4(9)10/h5-6H,(H,7,8)(H,9,10)/b2-1+",Dihydroxyfumaric acid,CAS Registry Number,133-38-0
141,10588,1-(3-chlorophenyl)piperazine,A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.,"InChI=1S/C10H13ClN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2",m-Chlorophenylpiperazine,CAS Registry Number,6640-24-0
142,29571,dehydroabietic acid,"An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group.","InChI=1S/C20H28O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h6,8,12-13,17H,5,7,9-11H2,1-4H3,(H,21,22)/t17-,19-,20-/m1/s1",Dehydroabietic acid,KEGG COMPOUND accession,C12078
143,1438,3-(methylthio)propionic acid,"A thia fatty acid acid consisting of propionic acid with a methylthio substituent at the 3-position; an intermediate in mammalian methionine metabolism in vitro. The simplest known phytotoxin, it is a blight-inducing toxin produced by the cassava pathogen Xanthomonas campestris manihotis.","InChI=1S/C4H8O2S/c1-7-3-2-4(5)6/h2-3H2,1H3,(H,5,6)",3-(Methylthio)propionic acid,CAS Registry Number,646-01-5
144,2438,acrophylline,"A quinoline alkaloid that is furo[2,3-b]quinolin-4-one bearing additional 3,3-dimethylallyl and methoxy substituents at positions 9 and 7 respectively.","InChI=1S/C17H17NO3/c1-11(2)6-8-18-15-10-12(20-3)4-5-13(15)16(19)14-7-9-21-17(14)18/h4-7,9-10H,8H2,1-3H3",Acrophylline,KEGG COMPOUND accession,C10634
145,9984,vincaleukoblastine sulfate,,"InChI=1S/C46H58N4O9.H2O4S/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7;1-5(2,3)4/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3;(H2,1,2,3,4)/t28-,37+,38-,39-,42+,43-,44-,45+,46+;/m1./s1",Vinblastine sulfate,KEGG COMPOUND accession,C11626
146,3638,chloroquine,"An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.","InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)",Chloroquine,KEGG COMPOUND accession,C07625
147,3647,chlorpromazine,"A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.","InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3",Chlorpromazine,CAS Registry Number,50-53-3
148,1879,2-(4-hydroxyphenyl)ethanol,A phenol substituted at position 4 by a 2-hydroxyethyl group.,"InChI=1S/C8H10O2/c9-6-5-7-1-3-8(10)4-2-7/h1-4,9-10H,5-6H2",4-Hydroxyphenylethanol,KEGG COMPOUND accession,C06044
149,4868,estramustine,A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.,"InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1",Estramustine,KEGG COMPOUND accession,C11228
150,4883,ethidium bromide,The organic bromide salt of ethidium.,"InChI=1S/C21H19N3.BrH/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14;/h3-13,23H,2,22H2,1H3;1H",Ethidium bromide,CAS Registry Number,1239-45-8
151,5014,fenvalerate,A carboxylic ester obtained by formal condensation between 2-(4-chlorophenyl)-3-methylbutyric acid and cyano(3-phenoxyphenyl)methanol.,"InChI=1S/C25H22ClNO3/c1-17(2)24(18-11-13-20(26)14-12-18)25(28)30-23(16-27)19-7-6-10-22(15-19)29-21-8-4-3-5-9-21/h3-15,17,23-24H,1-2H3",Fenvalerate,KEGG COMPOUND accession,C10988
152,5078,flavonol,A monohydroxyflavone that is the 3-hydroxy derivative of flavone.,"InChI=1S/C15H10O3/c16-13-11-8-4-5-9-12(11)18-15(14(13)17)10-6-2-1-3-7-10/h1-9,17H",Flavonol,KEGG COMPOUND accession,C01495
153,2719,Ile(5)-angiotensin II,An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).,"InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1",Angiotensin II,KEGG COMPOUND accession,C02135
154,2866,ascaridole,A p-menthane monoterpenoid that is p-menth-2-ene with a peroxy group across position 1 to 4.,"InChI=1S/C10H16O2/c1-8(2)10-6-4-9(3,5-7-10)11-12-10/h4,6,8H,5,7H2,1-3H3",Ascaridole,KEGG COMPOUND accession,C09836
155,3104,5-[(8Z)-pentadec-8-enyl]resorcinol,,"InChI=1S/C21H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h7-8,16-18,22-23H,2-6,9-15H2,1H3/b8-7-",Bilobol,CAS Registry Number,22910-86-7
156,4469,(S)-amphetamine,A 1-phenylpropan-2-amine that has S configuration.,"InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1",Dextroamphetamine,KEGG COMPOUND accession,C07884
157,9232,spinosyn D,A spinosyn in which the sugar amino and hydroxy groups are globally methylated with an additional methyl substituent attached to the tetracyclic skeleton. One of the two active ingredients of spinosad.,"InChI=1S/C42H67NO10/c1-11-26-13-12-14-35(53-37-16-15-34(43(6)7)24(4)49-37)23(3)38(45)33-20-31-29(32(33)21-36(44)51-26)17-22(2)28-18-27(19-30(28)31)52-42-41(48-10)40(47-9)39(46-8)25(5)50-42/h17,20,23-32,34-35,37,39-42H,11-16,18-19,21H2,1-10H3/t23-,24-,25+,26+,27-,28+,29-,30-,31-,32+,34+,35+,37+,39+,40-,41-,42+/m1/s1",Spinosyn D,CAS Registry Number,131929-63-0
158,4208,D-mannopyranose,D-Mannose in its six-membered ring form.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6?/m1/s1",D-Mannose,KEGG COMPOUND accession,C00159
159,3766,clozapine,"A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like  schizophrenia.","InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3",Clozapine,KEGG COMPOUND accession,C06924
160,470,1'-acetoxyeugenol acetate,An acetate ester that is eugenol acetate substituted by an acetoxy group at position 1.,"InChI=1S/C14H16O5/c1-5-12(18-9(2)15)11-6-7-13(19-10(3)16)14(8-11)17-4/h5-8,12H,1H2,2-4H3/t12-/m0/s1",1'-Acetoxyeugenol acetate,CAS Registry Number,53890-24-7
161,4775,ellagic acid,"An organic heterotetracyclic compound resulting from the formal dimerisation of gallic acid by oxidative aromatic coupling with intramolecular lactonisation of both carboxylic acid groups of the resulting biaryl. It is found in many fruits and vegetables, including raspberries, strawberries, cranberries, and pomegranates.","InChI=1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-18H",Ellagic acid,KEGG COMPOUND accession,C10788
162,920,"2,4-dinitrotoluene",A dinitrotoluene in which the methyl group is ortho to one of the nitro groups and para to the other. It is the most common isomer of dinitrotoluene.,"InChI=1S/C7H6N2O4/c1-5-2-3-6(8(10)11)4-7(5)9(12)13/h2-4H,1H3","2,4-Dinitrotoluene",KEGG COMPOUND accession,C11006
163,945,"2,6-dichloroindophenol",A  quinone imine that is indophenol substituted by chloro groups at positions 2 and 6.,"InChI=1S/C12H7Cl2NO2/c13-10-5-8(6-11(14)12(10)17)15-7-1-3-9(16)4-2-7/h1-6,16H","2,6-Dichloroindophenol",KEGG COMPOUND accession,C00102
164,9509,thalicarpine,,"InChI=1S/C41H48N2O8/c1-42-12-10-23-16-32(44-3)34(46-5)20-27(23)29(42)15-26-19-33(45-4)36(48-7)22-31(26)51-37-18-25-14-30-39-24(11-13-43(30)2)17-38(49-8)41(50-9)40(39)28(25)21-35(37)47-6/h16-22,29-30H,10-15H2,1-9H3/t29-,30-/m0/s1",Thalicarpine,KEGG COMPOUND accession,C09655
165,10119,ziprasidone,"A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.","InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)",Ziprasidone,KEGG COMPOUND accession,C07568
166,122,(-)-usnic acid,The (-)-enantiomer of usnic acid.,"InChI=1S/C18H16O7/c1-6-14(22)12(8(3)20)16-13(15(6)23)18(4)10(25-16)5-9(21)11(7(2)19)17(18)24/h5,21-23H,1-4H3/t18-/m1/s1",(-)-Usnic acid,KEGG COMPOUND accession,C10101
167,128,(S)-(-)-alpha-terpineol,The (S)-enantiomer of alpha-terpineol.,"InChI=1S/C10H18O/c1-8-4-6-9(7-5-8)10(2,3)11/h4,9,11H,5-7H2,1-3H3/t9-/m1/s1",(-)-alpha-Terpineol,KEGG COMPOUND accession,C11393
168,5107,Fluo-3,,"InChI=1S/C36H30Cl2N2O13/c1-18-2-4-24(39(14-32(43)44)15-33(45)46)30(8-18)51-6-7-52-31-9-19(3-5-25(31)40(16-34(47)48)17-35(49)50)36-20-10-22(37)26(41)12-28(20)53-29-13-27(42)23(38)11-21(29)36/h2-5,8-13,41H,6-7,14-17H2,1H3,(H,43,44)(H,45,46)(H,47,48)(H,49,50)",Fluo-3,KEGG COMPOUND accession,C11369
169,5132,flutamide,,"InChI=1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)",Flutamide,KEGG COMPOUND accession,C07653
170,6099,kaempferide,A monomethoxyflavone that is the 4'-O-methyl derivative of kaempferol.,"InChI=1S/C16H12O6/c1-21-10-4-2-8(3-5-10)16-15(20)14(19)13-11(18)6-9(17)7-12(13)22-16/h2-7,17-18,20H,1H3",Kaempferide,CAS Registry Number,491-54-3
171,6109,kanamycin A sulfate,,"InChI=1S/C18H36N4O11.H2O4S/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17;1-5(2,3)4/h4-18,23-29H,1-3,19-22H2;(H2,1,2,3,4)/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-;/m1./s1",Kanamycin sulfate,KEGG COMPOUND accession,C08046
172,9546,thimerosal,An alkylmercury compound (approximately 49% mercury by weight) used as an antiseptic and antifungal agent.,"InChI=1S/C7H6O2S.C2H5.Hg.Na/c8-7(9)5-3-1-2-4-6(5)10;1-2;;/h1-4,10H,(H,8,9);1H2,2H3;;/q;;2*+1/p-2",Thimerosal,CAS Registry Number,54-64-8
173,6402,leflunomide,"A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.","InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",Leflunomide,KEGG COMPOUND accession,C07905
174,669,1-phenylethanol,An aromatic alcohol that is ethanol substituted by a phenyl group at position 1.,"InChI=1S/C8H10O/c1-7(9)8-5-3-2-4-6-8/h2-7,9H,1H3",1-Phenylethanol,KEGG COMPOUND accession,C07112
175,1911,4-nitroanisole,A member of the class of 4-nitroanisoles that is anisole in which one the hydrogen meta to the methoxy group is replaced by a nitro group.,"InChI=1S/C7H7NO3/c1-11-7-4-2-6(3-5-7)8(9)10/h2-5H,1H3",4-Nitroanisole,CAS Registry Number,100-17-4
176,9925,sodium valproate,The sodium salt of valproic acid.,"InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1",Valproate sodium,KEGG COMPOUND accession,C07842
177,6950,mirtazapine,,"InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3",Mirtazapine,KEGG COMPOUND accession,C07570
178,7563,N-nicotinoylglycine,An N-acylglycine having nicotinoyl as the acyl substituent.,"InChI=1S/C8H8N2O3/c11-7(12)5-10-8(13)6-2-1-3-9-4-6/h1-4H,5H2,(H,10,13)(H,11,12)",Nicotinurate,CAS Registry Number,583-08-4
179,3005,belladine,"A phenethylamine alkaloid that is N-methyl-4-methoxyphenylethylamine carrying an additional N-(3,4-dimethoxybenzyl) substituent.","InChI=1S/C19H25NO3/c1-20(12-11-15-5-8-17(21-2)9-6-15)14-16-7-10-18(22-3)19(13-16)23-4/h5-10,13H,11-12,14H2,1-4H3",Belladine,KEGG COMPOUND accession,C08518
180,1367,"3,3',4,4'-tetrachlorobiphenyl",A tetrachlorobiphenyl that is biphenyl in which the hydrogens at position 3 and 4 on each phenyl group are replaced by chlorines.,InChI=1S/C12H6Cl4/c13-9-3-1-7(5-11(9)15)8-2-4-10(14)12(16)6-8/h1-6H,"3,4,3',4'-Tetrachlorobiphenyl",CAS Registry Number,32598-13-3
181,3605,chloramphenicol palmitate,,"InChI=1S/C27H42Cl2N2O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-24(32)37-20-23(30-27(34)26(28)29)25(33)21-16-18-22(19-17-21)31(35)36/h16-19,23,25-26,33H,2-15,20H2,1H3,(H,30,34)/t23-,25-/m1/s1",Chloramphenicol palmitate,CAS Registry Number,530-43-8
182,7936,paroxetine,"A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.","InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1",Paroxetine,CAS Registry Number,61869-08-7
183,24813,3-(indol-3-yl)lactic acid,A hydroxy monocarboxylic acid that is lactic acid substituted by a 1H-indol-3-yl group at position 3. It is a metabolite of tryptophan.,"InChI=1S/C11H11NO3/c13-10(11(14)15)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,10,12-13H,5H2,(H,14,15)",indole-3-lactic acid,KEGG COMPOUND accession,C02043
184,26271,proline,An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.,"InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)",proline,CAS Registry Number,609-36-9
185,7823,oxazepam,"A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.","InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)",Oxazepam,KEGG COMPOUND accession,C07359
186,8212,pimozide,"A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.","InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)",Pimozide,CAS Registry Number,2062-78-4
187,8214,pindolol,A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.,"InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3",Pindolol,CAS Registry Number,13523-86-9
188,8240,piperonal,"An arenecarbaldehyde that is 1,3-benzodioxole substituted by a formyl substituent at position 5. It has been isolated from Piper nigrum.","InChI=1S/C8H6O3/c9-4-6-1-2-7-8(3-6)11-5-10-7/h1-4H,5H2",Piperonal,KEGG COMPOUND accession,C10812
189,4139,D-galactopyranose,A galactopyranose having D-configuration.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1",D-galactose,KEGG COMPOUND accession,C00124
190,2423,acetylleucyl-leucyl-norleucinal,"A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.","InChI=1S/C20H37N3O4/c1-7-8-9-16(12-24)22-19(26)18(11-14(4)5)23-20(27)17(10-13(2)3)21-15(6)25/h12-14,16-18H,7-11H2,1-6H3,(H,21,25)(H,22,26)(H,23,27)/t16-,17-,18-/m0/s1",Acetylleucyl-leucyl-norleucinal,CAS Registry Number,110044-82-1
191,2437,acronycine,An alkaloid antineoplastic agent isolated from Acronychia baueri.,"InChI=1S/C20H19NO3/c1-20(2)10-9-13-15(24-20)11-16(23-4)17-18(13)21(3)14-8-6-5-7-12(14)19(17)22/h5-11H,1-4H3",Acronycine,CAS Registry Number,7008-42-6
192,7775,ononin,A 4'-methoxyisoflavone that is formononetin attached to a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.,"InChI=1S/C22H22O9/c1-28-12-4-2-11(3-5-12)15-10-29-16-8-13(6-7-14(16)18(15)24)30-22-21(27)20(26)19(25)17(9-23)31-22/h2-8,10,17,19-23,25-27H,9H2,1H3/t17-,19-,20+,21-,22-/m1/s1",Ononin,KEGG COMPOUND accession,C10509
193,4372,(6S)-dehydrovomifoliol,A dehydrovomifoliol that has S-configuration at the chiral centre.,"InChI=1S/C13H18O3/c1-9-7-11(15)8-12(3,4)13(9,16)6-5-10(2)14/h5-7,16H,8H2,1-4H3/b6-5+/t13-/m1/s1",Dehydrovomifoliol,CAS Registry Number,15764-81-5
194,9123,sertraline,"A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.","InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1",Sertraline,KEGG COMPOUND accession,C07246
195,9169,sisomycin,,"InChI=1S/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9-,10+,11-,12+,13-,14-,15+,16-,17-,18-,19+/m1/s1",Antibiotic 6640,CAS Registry Number,32385-11-8
196,10057,9H-xanthene,,"InChI=1S/C13H10O/c1-3-7-12-10(5-1)9-11-6-2-4-8-13(11)14-12/h1-8H,9H2",Xanthan,KEGG COMPOUND accession,C01464
197,10093,yohimbine,An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.,"InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1",Yohimbine,KEGG COMPOUND accession,C09256
198,10101,zalcitabine,"A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.","InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1","2',3'-Dideoxycytidine",CAS Registry Number,7481-89-2
199,8277,podocarpic acid,An abietane diterpenoid lacking the isopropyl substituent with an aromatic C-ring and a hydroxy group at the 12-position.,"InChI=1S/C17H22O3/c1-16-8-3-9-17(2,15(19)20)14(16)7-5-11-4-6-12(18)10-13(11)16/h4,6,10,14,18H,3,5,7-9H2,1-2H3,(H,19,20)/t14-,16-,17+/m1/s1",Podocarpic acid,CAS Registry Number,5947-49-9
200,8346,potassium iodide,A metal iodide salt with a K(+) counterion. It is a scavenger of hydroxyl radicals.,InChI=1S/HI.K/h1H;/q;+1/p-1,Potassium iodide,KEGG COMPOUND accession,C08219
201,8614,psilocybin,"A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional phosphoryloxy substituent at position 4. The major hallucinogenic alkaloid isolated from Psilocybe mushrooms (also known as Teonanacatl or ""magic mushrooms"").","InChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17)",Psilocybin,CAS Registry Number,520-52-5
202,8645,purpurin,"A trihydroxyanthraquinone derived from anthracene by substitution with oxo groups at C-9 and C-10 and with hydroxy groups at C-1, C-2 and C-4.","InChI=1S/C14H8O5/c15-8-5-9(16)14(19)11-10(8)12(17)6-3-1-2-4-7(6)13(11)18/h1-5,15-16,19H",Purpurin,CAS Registry Number,81-54-9
203,8647,purpurogallin,"A cyclic ketone that is 5H-benzocycloheptene bearing an oxo group at position 5 and hydroxy groups at positions 2, 3, 4 and 6.","InChI=1S/C11H8O5/c12-6-3-1-2-5-4-7(13)10(15)11(16)8(5)9(6)14/h1-4,13,15-16H,(H,12,14)",Purpurogallin,KEGG COMPOUND accession,C09964
204,5855,ibuprofen,A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group.,"InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)",Ibuprofen,KEGG COMPOUND accession,C01588
205,9330,sulfamic acid,The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to hydroxy and amino groups and by double bonds to two oxygen atoms.,"InChI=1S/H3NO3S/c1-5(2,3)4/h(H3,1,2,3,4)",Sulfamic acid,CAS Registry Number,5329-14-6
206,9400,tangeretin,"A pentamethoxyflavone flavone with methoxy groups at positions 4', 5, 6 , 7 and 8.","InChI=1S/C20H20O7/c1-22-12-8-6-11(7-9-12)14-10-13(21)15-16(23-2)18(24-3)20(26-5)19(25-4)17(15)27-14/h6-10H,1-5H3",Tangeretin,KEGG COMPOUND accession,C10190
207,47,(+)-syringaresinol,"The (7alpha,7'alpha,8alpha,8'alpha)-stereoisomer of syringaresinol.","InChI=1S/C22H26O8/c1-25-15-5-11(6-16(26-2)19(15)23)21-13-9-30-22(14(13)10-29-21)12-7-17(27-3)20(24)18(8-12)28-4/h5-8,13-14,21-24H,9-10H2,1-4H3/t13-,14-,21+,22+/m0/s1",(+)-Syringaresinol,KEGG COMPOUND accession,C10889
208,1427,3-(3-hydroxyphenyl)propanoic acid,A monocarboxylic acid that is propionic acid carrying a 3-hydroxyphenyl substituent at C-3.,"InChI=1S/C9H10O3/c10-8-3-1-2-7(6-8)4-5-9(11)12/h1-3,6,10H,4-5H2,(H,11,12)",3-(3-Hydroxy-phenyl)-propanoic acid,KEGG COMPOUND accession,C11457
209,6877,trans-isomethyleugenol,,"InChI=1S/C11H14O2/c1-4-5-9-6-7-10(12-2)11(8-9)13-3/h4-8H,1-3H3/b5-4+",trans-Methylisoeugenol,KEGG COMPOUND accession,C10478
210,8093,phenylephrine,A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.,"InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1",Phenylephrine,KEGG COMPOUND accession,C07441
211,3390,carbaryl,A carbamate ester obtained by the formal condensation of  1-naphthol with methylcarbamic acid.,"InChI=1S/C12H11NO2/c1-13-12(14)15-11-8-4-6-9-5-2-3-7-10(9)11/h2-8H,1H3,(H,13,14)",Carbaril,KEGG COMPOUND accession,C07491
212,2567,alendronic acid,"A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.","InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)",Alendronic acid,KEGG COMPOUND accession,C07752
213,8116,phorbol,"A diterpenoid with the structure of tigliane hydroxylated at C-4, -9, -12(beta), -13 and -20, with an oxo group at C-3 and unsaturation at the 1- and 6-positions.","InChI=1S/C20H28O6/c1-9-5-13-18(24,15(9)22)7-11(8-21)6-12-14-17(3,4)20(14,26)16(23)10(2)19(12,13)25/h5-6,10,12-14,16,21,23-26H,7-8H2,1-4H3/t10-,12+,13-,14-,16-,18-,19-,20-/m1/s1",Phorbol,CAS Registry Number,17673-25-5
214,8207,(+)-pilocarpine,The (+)-enantiomer of pilocarpine.,"InChI=1S/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1",Pilocarpine,CAS Registry Number,92-13-7
215,3614,chlorhexidine,A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.,"InChI=1S/C22H30Cl2N10/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34)",Chlorhexidine,CAS Registry Number,55-56-1
216,3654,chlorthalidone,,"InChI=1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)",Chlorthalidone,CAS Registry Number,77-36-1
217,8428,procainamide,A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group.  It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.,"InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)",Procainamide,KEGG COMPOUND accession,C07401
218,8430,procaine,"A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.","InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3",Procaine,KEGG COMPOUND accession,C07375
219,8736,(R)-(+)-propranolol,,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3/t14-/m1/s1",R (+)-Propanolol,KEGG COMPOUND accession,C11193
220,3159,botrydial,A cytotoxic fungal metabolite isolated from plant tissues infected by phytopathogen Botrytis cinerea.,"InChI=1S/C17H26O5/c1-10-6-13(22-11(2)20)14-15(3,4)8-16(5,9-19)17(14,21)12(10)7-18/h7,9-10,12-14,21H,6,8H2,1-5H3/t10-,12+,13+,14+,16-,17-/m1/s1",Botrydial,CAS Registry Number,54986-75-3
221,3179,bromobenzene,"The simplest member of the class of bromobenzenes, that is benzene in which a single hydrogen has been substituted by a bromine. A liquid at room temperature (m.p. -30degreeC; b.p.760 156degreeC), it is used as a solvent, particularly for large-scale crystallisations, and for the introduction of phenyl groups in organic synthesis.",InChI=1S/C6H5Br/c7-6-4-2-1-3-5-6/h1-5H,Bromobenzene,KEGG COMPOUND accession,C11036
222,3441,carvedilol,A member of the class of carbazoles that is an adrenergic antagonist with non-selective beta- and alpha-1 receptor blocking properties which helps in the management of congestive heart failure.,"InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3",Carvedilol,CAS Registry Number,72956-09-3
223,3533,cephaeline,"A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions.","InChI=1S/C28H38N2O4/c1-5-17-16-30-9-7-19-13-27(33-3)28(34-4)15-22(19)24(30)11-20(17)10-23-21-14-26(32-2)25(31)12-18(21)6-8-29-23/h12-15,17,20,23-24,29,31H,5-11,16H2,1-4H3/t17-,20-,23+,24-/m0/s1",Cephaeline,KEGG COMPOUND accession,C09390
224,4638,diphenidol,A tertiary alcohol that is butan-1-ol substituted by two phenyl groups at position 1 and a piperidin-1-yl group at position 4.,"InChI=1S/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2",Diphenidol,CAS Registry Number,972-02-1
225,4640,diphenylamine,"An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union.","InChI=1S/C12H11N/c1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h1-10,13H",Diphenylamine,KEGG COMPOUND accession,C11016
226,9331,sulfamethizole,"A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.","InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)",Sulfamethizole,KEGG COMPOUND accession,C08050
227,10577,gamma-terpinene,One of three isomeric monoterpenes differing in the positions of their two double bonds (alpha- and beta-terpinene being the others). In gamma-terpinene the double bonds are at the 1- and 4-positions of the p-menthane skeleton.,"InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,7-8H,5-6H2,1-3H3",gamma-Terpinene,KEGG COMPOUND accession,C09900
228,10589,m-toluic acid,A methylbenzoic acid carrying a methyl substituent at position 3.,"InChI=1S/C8H8O2/c1-6-3-2-4-7(5-6)8(9)10/h2-5H,1H3,(H,9,10)",m-Toluic Acid,KEGG COMPOUND accession,C07211
229,6498,lipoxin A4,"A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.","InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1",Lipoxin A4,KEGG COMPOUND accession,C06314
230,6541,losartan,"A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position","InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)",Losartan,KEGG COMPOUND accession,C07072
231,6605,lysergic acid diethylamide,An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.,"InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1",Lysergic acid diethylamide,KEGG COMPOUND accession,C07542
232,6695,(+)-marmesin,,"InChI=1S/C14H14O4/c1-14(2,16)12-6-9-5-8-3-4-13(15)18-10(8)7-11(9)17-12/h3-5,7,12,16H,6H2,1-2H3/t12-/m0/s1",Marmesin,CAS Registry Number,13849-08-6
233,6704,mebendazole,A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.,"InChI=1S/C16H13N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,17,18,19,21)",Mebendazole,CAS Registry Number,31431-39-7
234,6714,(+)-medicarpin,The (+)-enantiomer of medicarpin.,"InChI=1S/C16H14O4/c1-18-10-3-5-11-13-8-19-14-6-9(17)2-4-12(14)16(13)20-15(11)7-10/h2-7,13,16-17H,8H2,1H3/t13-,16-/m1/s1",Medicarpin,KEGG COMPOUND accession,C01729
235,7565,nifedipine,,"InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3",Nifedipine,KEGG COMPOUND accession,C07266
236,7573,nilutamide,,"InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)",Nilutamide,CAS Registry Number,63612-50-0
237,8600,prunetin,A hydroxyisoflavone that is  genistein  in which the hydroxy group at position 7 is replaced by a methoxy group.,"InChI=1S/C16H12O5/c1-20-11-6-13(18)15-14(7-11)21-8-12(16(15)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3",Prunetin,KEGG COMPOUND accession,C10521
238,8613,psilocin,"A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional hydroxy substituent at position 4. A hallucinogenic alkaloid isolated in trace amounts from Psilocybe mushrooms (also known as Teonanacatl or ""magic mushrooms"").","InChI=1S/C12H16N2O/c1-14(2)7-6-9-8-13-10-4-3-5-11(15)12(9)10/h3-5,8,13,15H,6-7H2,1-2H3",Psilocin,KEGG COMPOUND accession,C08312
239,5897,indicine,,"InChI=1S/C15H25NO5/c1-9(2)15(20,10(3)17)14(19)21-8-11-4-6-16-7-5-12(18)13(11)16/h4,9-10,12-13,17-18,20H,5-8H2,1-3H3/t10-,12+,13+,15+/m0/s1",Indicine,KEGG COMPOUND accession,C10326
240,8459,promazine,A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.,"InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3",Promazine,KEGG COMPOUND accession,C07379
241,8461,promethazine,"A  tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.","InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3",Promethazine,CAS Registry Number,60-87-7
242,9622,tolterodine,,"InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1",Tolterodine,KEGG COMPOUND accession,C07750
243,9630,tomatine,"A steroid alkaloid that is tomatidine in which the hydroxy group at position 3 is linked to lycotetraose, a tetrasaccharide composed of two units of D-glucose, one unit of D-xylose, and one unit of D-galactose.","InChI=1S/C50H83NO21/c1-20-7-12-50(51-15-20)21(2)32-28(72-50)14-26-24-6-5-22-13-23(8-10-48(22,3)25(24)9-11-49(26,32)4)65-45-40(63)37(60)41(31(18-54)68-45)69-47-43(71-46-39(62)36(59)34(57)29(16-52)66-46)42(35(58)30(17-53)67-47)70-44-38(61)33(56)27(55)19-64-44/h20-47,51-63H,5-19H2,1-4H3/t20-,21-,22-,23-,24+,25-,26-,27+,28-,29+,30+,31+,32-,33-,34+,35+,36-,37+,38+,39+,40+,41-,42-,43+,44-,45+,46-,47-,48-,49-,50-/m0/s1",Tomatine,KEGG COMPOUND accession,C10827
244,9654,trazodone,"An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.","InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2",Trazodone,KEGG COMPOUND accession,C07156
245,2755,anthragallol,"A trihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1, 2 and 3.","InChI=1S/C14H8O5/c15-9-5-8-10(14(19)13(9)18)12(17)7-4-2-1-3-6(7)11(8)16/h1-5,15,18-19H",Anthragallol,KEGG COMPOUND accession,C10297
246,2980,"5,6,7-trimethoxyflavone","A trimethoxyflavone that is the 5,6,7-trimethyl ether derivative of baicalein. It has been isolated from the plant Callicarpa japonica and has been shown to exhibit antiviral activity.","InChI=1S/C18H16O5/c1-20-15-10-14-16(18(22-3)17(15)21-2)12(19)9-13(23-14)11-7-5-4-6-8-11/h4-10H,1-3H3","Baicalein 5,6,7-trimethyl ether",KEGG COMPOUND accession,C10024
247,1189,2-methoxyestrone,A 17-oxo steroid that is estrone in which the hydrogen at position 2 has been replaced by a methoxy group.,"InChI=1S/C19H24O3/c1-19-8-7-12-13(15(19)5-6-18(19)21)4-3-11-9-16(20)17(22-2)10-14(11)12/h9-10,12-13,15,20H,3-8H2,1-2H3/t12-,13+,15-,19-/m0/s1",2-Methoxyestrone,CAS Registry Number,362-08-3
248,1224,2-nitrofluorene,A nitroarene that is  fluorene substituted by a nitro group at position 2.,"InChI=1S/C13H9NO2/c15-14(16)11-5-6-13-10(8-11)7-9-3-1-2-4-12(9)13/h1-6,8H,7H2",2-Nitrofluorene,KEGG COMPOUND accession,C10923
249,1547,3-hydroxykynurenine,A hydroxykynurenine  that is kynurenine substituted by a hydroxy group at position 3.,"InChI=1S/C10H12N2O4/c11-6(10(15)16)4-8(14)5-2-1-3-7(13)9(5)12/h1-3,6,13H,4,11-12H2,(H,15,16)",3-Hydroxykynurenine,KEGG COMPOUND accession,C02794
250,6762,mepyramine,An ethylenediamine derivative that is  ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group.,"InChI=1S/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3",Mepyramine,CAS Registry Number,91-84-9
251,6804,methacholine,A quaternary ammonium ion in which the nitrogen is substituted with three methyl groups and a 2-acetoxypropyl group. Parasympathomimetic bronchoconstrictor drug used in clinical diagnosis.,"InChI=1S/C8H18NO2/c1-7(11-8(2)10)6-9(3,4)5/h7H,6H2,1-5H3/q+1",Methacholine,KEGG COMPOUND accession,C07471
252,6904,metoprolol,A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a  4-(2-methoxyethyl)phenoxy group at position 1.,"InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3",Metoprolol,KEGG COMPOUND accession,C07202
253,6908,trichlorfon,"A phosphonic ester that is dimethyl phosphonate in which the hydrogen atom attched to the phosphorous is substituted by a 2,2,2-trichloro-1-hydroxyethyl group.","InChI=1S/C4H8Cl3O4P/c1-10-12(9,11-2)3(8)4(5,6)7/h3,8H,1-2H3",Metrifonate,CAS Registry Number,52-68-6
254,3918,crocetin,"A 20-carbon dicarboxylic acid which is a diterpenoid and natural carotenoid. Found in the crocus flower, it has been administered as an anti-fatigue dietary supplement.","InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+",Crocetin,KEGG COMPOUND accession,C08588
255,3000,beauvericin,A trimeric cyclodepsipeptide composed from alternating methylphenylalanyl and hydroxyvaleryl residues.,"InChI=1S/C45H57N3O9/c1-28(2)37-40(49)46(7)35(26-32-21-15-11-16-22-32)44(53)56-39(30(5)6)42(51)48(9)36(27-33-23-17-12-18-24-33)45(54)57-38(29(3)4)41(50)47(8)34(43(52)55-37)25-31-19-13-10-14-20-31/h10-24,28-30,34-39H,25-27H2,1-9H3/t34-,35-,36-,37+,38+,39+/m0/s1",Beauvericin,KEGG COMPOUND accession,C11590
256,3001,beclomethasone,"A 17alpha-hydroxy steroid that is prednisolone in which the hydrogens at the 9alpha and 16beta positions are substituted by a chlorine and a methyl group, respectively.","InChI=1S/C22H29ClO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1",Beclomethasone,KEGG COMPOUND accession,C06842
257,3061,bepridil,"A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.","InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3",Bepridil,CAS Registry Number,64706-54-3
258,3089,biapenem,"A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.","InChI=1S/C15H18N4O4S/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)24-9-3-17-5-16-6-18(17)4-9/h5-11,20H,3-4H2,1-2H3/t7-,8-,10-,11-/m1/s1",Biapenem,KEGG COMPOUND accession,C11268
259,4885,ethionamide,A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.,"InChI=1S/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)",Ethionamide,KEGG COMPOUND accession,C07665
260,4911,etoposide,,"InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1",Etoposide,KEGG COMPOUND accession,C01576
261,3962,curcumin,A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.,"InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+",Curcumin,KEGG COMPOUND accession,C10443
262,4027,cyclophosphamide,"A phosphorodiamide that is 1,3,2-oxazaphosphinan-2-amine 2-oxide substituted by two 2-chloroethyl groups at the amino nitrogen atom.","InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)",Cyclophosphamide anhydrous,KEGG COMPOUND accession,C07888
263,4047,L-cysteinylglycine,A dipeptide consisting of glycine having an L-cysteinyl attached to its alpha-amino group. It is an intermediate metabolite in glutathione metabolism.,"InChI=1S/C5H10N2O3S/c6-3(2-11)5(10)7-1-4(8)9/h3,11H,1-2,6H2,(H,7,10)(H,8,9)/t3-/m0/s1",Cys-Gly,CAS Registry Number,19246-18-5
264,5009,fenoxycarb,A carbamate ester that is the O-ethyl carbamate of 2-(4-phenoxyphenoxy)ethylamine.,"InChI=1S/C17H19NO4/c1-2-20-17(19)18-12-13-21-14-8-10-16(11-9-14)22-15-6-4-3-5-7-15/h3-11H,2,12-13H2,1H3,(H,18,19)",Fenoxycarb,CAS Registry Number,72490-01-8
265,5011,fenpyroximate,,"InChI=1S/C24H27N3O4/c1-17-21(22(27(5)26-17)30-20-9-7-6-8-10-20)15-25-29-16-18-11-13-19(14-12-18)23(28)31-24(2,3)4/h6-15H,16H2,1-5H3/b25-15+",Fenpyroximate,KEGG COMPOUND accession,C11098
266,5070,flavanone,The simplest member of the class of  flavanones  that consists of flavan bearing an oxo substituent at position 4.,"InChI=1S/C15H12O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-9,15H,10H2",Flavanone,CAS Registry Number,487-26-3
267,5262,galangin,A 7-hydroxyflavonol with additional hydroxy groups at positions 3 and 5 respectively; a growth inhibitor of breast tumor cells.,"InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H",Galangin,CAS Registry Number,548-83-4
268,9884,5-[bis(2-chloroethyl)amino]uracil,,"InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)",Uracil mustard,CAS Registry Number,66-75-1
269,9908,ursolic acid,A pentacyclic triterpenoid that is urs-12-en-28-oic acid substituted by a beta-hydroxy group at position 3.,"InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1",Ursolic acid,KEGG COMPOUND accession,C08988
270,9951,veratramine,"A piperidine alkaloid comprising the 14,15,16,17-tetradehydro derivative of veratraman having two hydroxy groups at the 3- and 23-positions.","InChI=1S/C27H39NO2/c1-15-11-25(30)26(28-14-15)17(3)20-7-8-21-22-6-5-18-12-19(29)9-10-27(18,4)24(22)13-23(21)16(20)2/h5,7-8,15,17,19,22,24-26,28-30H,6,9-14H2,1-4H3/t15-,17-,19-,22-,24-,25+,26-,27-/m0/s1",Veratramine,KEGG COMPOUND accession,C10829
271,8707,quetiapine,,"InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2",Quetiapine,KEGG COMPOUND accession,C07397
272,8711,quinacrine,"A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.","InChI=1S/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)",Quinacrine,KEGG COMPOUND accession,C07339
273,8768,rabeprazole,,"InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)",Rabeprazole,CAS Registry Number,117976-89-3
274,7777,ophiobolin A,"A sesterterpenoid that is ophiobolane with a hydroxy group at position 3, oxo groups at positions 5 and 25, double bonds at positions 7-8 and 19-20, and an oxygen link between positions 14 and 18.","InChI=1S/C25H36O4/c1-15(2)10-18-11-16(3)25(29-18)9-8-23(4)12-19-22(20(27)13-24(19,5)28)17(14-26)6-7-21(23)25/h6,10,14,16,18-19,21-22,28H,7-9,11-13H2,1-5H3/b17-6-/t16-,18-,19-,21+,22+,23+,24+,25-/m0/s1",Ophiobolin A,CAS Registry Number,4611-05-6
275,7781,orientin,A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.,"InChI=1S/C21H20O11/c22-6-14-17(28)18(29)19(30)21(32-14)16-11(26)4-10(25)15-12(27)5-13(31-20(15)16)7-1-2-8(23)9(24)3-7/h1-5,14,17-19,21-26,28-30H,6H2/t14-,17-,18+,19-,21+/m1/s1",Orientin,CAS Registry Number,28608-75-5
276,4466,dexmedetomidine,,"InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1",Dexmedetomidine,KEGG COMPOUND accession,C07450
277,4488,diallyl disulfide,An organic disulfide where the organic group specified is allyl. It has been isolated from garlic and other species of the genus Allium.,"InChI=1S/C6H10S2/c1-3-5-7-8-6-4-2/h3-4H,1-2,5-6H2",Diallyl disulfide,CAS Registry Number,2179-57-9
278,4511,dicloxacillin,"A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.","InChI=1S/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1",Dicloxacillin,CAS Registry Number,3116-76-5
279,9342,sulfinpyrazone,,"InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2",Sulfinpyrazone,KEGG COMPOUND accession,C07317
280,9349,sulfonyldimethane,,"InChI=1S/C2H6O2S/c1-5(2,3)4/h1-2H3",Sulfonylbismethane,KEGG COMPOUND accession,C11142
281,9352,sulindac,"A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.","InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-",Sulindac,KEGG COMPOUND accession,C01531
282,9355,sulfuretin,,"InChI=1S/C15H10O5/c16-9-2-3-10-13(7-9)20-14(15(10)19)6-8-1-4-11(17)12(18)5-8/h1-7,16-18H/b14-6-",Sulfuretin,KEGG COMPOUND accession,C08730
283,9380,syringin,A monosaccharide derivative that is trans-sinapyl alcohol attached to a beta-D-glucopyranosyl residue at position 1 via a glycosidic linkage.,"InChI=1S/C17H24O9/c1-23-10-6-9(4-3-5-18)7-11(24-2)16(10)26-17-15(22)14(21)13(20)12(8-19)25-17/h3-4,6-7,12-15,17-22H,5,8H2,1-2H3/b4-3+/t12-,13-,14+,15-,17+/m1/s1",Syringin,KEGG COMPOUND accession,C01533
284,9427,2-methylanthraquinone,"An anthraquinone that is 9,10-anthraquinone in which the hydrogen at position 2 is substituted by a methyl group.","InChI=1S/C15H10O2/c1-9-6-7-12-13(8-9)15(17)11-5-3-2-4-10(11)14(12)16/h2-8H,1H3",Tectoquinone,CAS Registry Number,84-54-8
285,9437,temoporfin,,"InChI=1S/C44H32N4O4/c49-29-9-1-5-25(21-29)41-33-13-15-35(45-33)42(26-6-2-10-30(50)22-26)37-17-19-39(47-37)44(28-8-4-12-32(52)24-28)40-20-18-38(48-40)43(36-16-14-34(41)46-36)27-7-3-11-31(51)23-27/h1-17,19,21-24,46-47,49-52H,18,20H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-",Temoporfin,KEGG COMPOUND accession,C11730
286,9457,terpinolene,A p-menthadiene with double bonds at positions 1 and 4(8).,"InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4H,5-7H2,1-3H3",Terpinolene,CAS Registry Number,586-62-9
287,9460,testolactone,,"InChI=1S/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1",Testolactone,KEGG COMPOUND accession,C02197
288,9493,tetrahymanol,A pentacyclic triterpenoid having a 3beta- (21alpha-) hydroxy-substituted gammacerane structure.,"InChI=1S/C30H52O/c1-25(2)15-9-16-27(5)20(25)12-18-29(7)22(27)10-11-23-28(6)17-14-24(31)26(3,4)21(28)13-19-30(23,29)8/h20-24,31H,9-19H2,1-8H3/t20-,21-,22+,23+,24-,27-,28-,29+,30+/m0/s1",Tetrahymanol,KEGG COMPOUND accession,C06083
289,9494,tetramethylchloromethylrosamine,,"InChI=1S/C24H24ClN2O/c1-26(2)18-9-11-20-22(13-18)28-23-14-19(27(3)4)10-12-21(23)24(20)17-7-5-16(15-25)6-8-17/h5-14H,15H2,1-4H3/q+1",Tetramethylrosamine,KEGG COMPOUND accession,C11622
290,9519,thebaine,,"InChI=1S/C19H21NO3/c1-20-9-8-19-12-5-7-15(22-3)18(19)23-17-14(21-2)6-4-11(16(17)19)10-13(12)20/h4-7,13,18H,8-10H2,1-3H3/t13-,18+,19+/m1/s1",Thebaine,KEGG COMPOUND accession,C06173
291,9592,tiglic acid,A 2-methylbut-2-enoic acid having its double bond in trans-configuration.,"InChI=1S/C5H8O2/c1-3-4(2)5(6)7/h3H,1-2H3,(H,6,7)/b4-3+",Tiglic acid,CAS Registry Number,80-59-1
292,6413,letrozole,,"InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H",Letrozole,KEGG COMPOUND accession,C08163
293,6441,levacetylmethadol,,"InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1",Levomethadyl acetate,KEGG COMPOUND accession,C08012
294,7454,nalbuphine,,"InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1",Nalbuphine,KEGG COMPOUND accession,C07251
295,8163,phosphoramide mustard,,"InChI=1S/C4H11Cl2N2O2P/c5-1-3-8(4-2-6)11(7,9)10/h1-4H2,(H3,7,9,10)",Phosphoramide mustard,KEGG COMPOUND accession,C07647
296,8228,pioglitazone,"A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.","InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)",Pioglitazone,CAS Registry Number,111025-46-8
297,8249,piroxicam,"A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide with the exocyclic nitrogen of 2-aminopyridine. A non-steroidal anti-inflammatory drug of the oxicam class, it is used to relieve pain and works by preventing the production of endogenous prostaglandins involved in the mediation of pain, stiffness, tenderness and swelling.","InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)",Piroxicam,KEGG COMPOUND accession,C01608
298,8357,pramocaine,A member of the class of morpholines that is morpholine substituted at the nitrogen atom by a 3-(4-butoxyphenoxy)propyl group.,"InChI=1S/C17H27NO3/c1-2-3-12-20-16-5-7-17(8-6-16)21-13-4-9-18-10-14-19-15-11-18/h5-8H,2-4,9-15H2,1H3",Pramoxine,KEGG COMPOUND accession,C07892
299,10319,1-naphthol,A naphthol carrying a hydroxy group at position 1.,"InChI=1S/C10H8O/c11-10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11H",alpha-Naphthol,CAS Registry Number,90-15-3
300,10335,"2,2':5',2''-terthiophene",,InChI=1S/C12H8S3/c1-3-9(13-7-1)11-5-6-12(15-11)10-4-2-8-14-10/h1-8H,alpha-Terthienyl,CAS Registry Number,1081-34-1
301,7492,nedocromil,,"InChI=1S/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)",Nedocromil,KEGG COMPOUND accession,C07255
302,7494,nefazodone,,"InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3",Nefazodone,KEGG COMPOUND accession,C07256
303,1784,biphenyl-4-amine,An aminobiphenyl that is biphenyl substituted by an amino group at position 4.,"InChI=1S/C12H11N/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9H,13H2",4-Aminobiphenyl,KEGG COMPOUND accession,C10998
304,1800,4-chloro-2-methylphenol,A member of the class of phenols that is o-cresol in which the hydrogen para to the hydroxy group is replaced by a chlorine.,"InChI=1S/C7H7ClO/c1-5-4-6(8)2-3-7(5)9/h2-4,9H,1H3",4-Chloro-2-methylphenol,CAS Registry Number,1570-64-5
305,422,(S)-lactic acid,An optically active form of lactic acid having (S)-configuration.,"InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1",L-Lactic acid,CAS Registry Number,79-33-4
306,479,"1,2,3,4-tetrakis-O-galloyl-alpha-D-glucose","A gallate ester that is the tetraester obtained by the formal condensation of hydroxy groups at positions 1, 2, 3 and 4 of alpha-D-glucose with the carboxy group of four molecules of gallic acid respectively.","InChI=1S/C34H28O22/c35-9-22-27(53-30(48)10-1-14(36)23(44)15(37)2-10)28(54-31(49)11-3-16(38)24(45)17(39)4-11)29(55-32(50)12-5-18(40)25(46)19(41)6-12)34(52-22)56-33(51)13-7-20(42)26(47)21(43)8-13/h1-8,22,27-29,34-47H,9H2/t22-,27-,28+,29-,34-/m1/s1","1,2,3,4-Tetragalloyl-alpha-D-glucose",KEGG COMPOUND accession,C10243
307,1883,4-hydroxystyrene,A member of the class of  phenols that is  styrene carrying a hydroxy substituent at position 4.,"InChI=1S/C8H8O/c1-2-7-3-5-8(9)6-4-7/h2-6,9H,1H2",4-Hydroxystyrene,KEGG COMPOUND accession,C05627
308,2710,"androst-5-ene-3beta,17beta-diol",A 3beta-hydroxy steroid that is 3beta-hydroxyandrost-5-ene carrying an additional hydroxy group at position 17beta.,"InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1","Androst-5-ene-3beta,17beta-diol",CAS Registry Number,521-17-5
309,5530,gramicidin S,,"InChI=1S/C60H92N12O10/c1-35(2)31-43-53(75)67-45(33-39-19-11-9-12-20-39)59(81)71-29-17-25-47(71)55(77)70-50(38(7)8)58(80)64-42(24-16-28-62)52(74)66-44(32-36(3)4)54(76)68-46(34-40-21-13-10-14-22-40)60(82)72-30-18-26-48(72)56(78)69-49(37(5)6)57(79)63-41(23-15-27-61)51(73)65-43/h9-14,19-22,35-38,41-50H,15-18,23-34,61-62H2,1-8H3,(H,63,79)(H,64,80)(H,65,73)(H,66,74)(H,67,75)(H,68,76)(H,69,78)(H,70,77)/t41-,42-,43-,44-,45+,46+,47-,48-,49-,50-/m0/s1",Gramicidin S,CAS Registry Number,113-73-5
310,5552,guaiol,,"InChI=1S/C15H26O/c1-10-5-7-12(15(3,4)16)9-14-11(2)6-8-13(10)14/h10-12,16H,5-9H2,1-4H3/t10-,11-,12+/m0/s1",Guaiol,KEGG COMPOUND accession,C09676
311,5601,(+)-haematoxylin,,"InChI=1S/C16H14O6/c17-10-2-1-8-13-9-4-12(19)11(18)3-7(9)5-16(13,21)6-22-15(8)14(10)20/h1-4,13,17-21H,5-6H2/t13-,16+/m0/s1",Haematoxylin,KEGG COMPOUND accession,C09931
312,5615,halothane,A haloalkane comprising ethane having three flouro substituents at the 1-position as well as bromo- and chloro substituents at the 2-position.,"InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H",Halothane,CAS Registry Number,151-67-7
313,6731,melezitose,A trisaccharide produced by insects such as aphids.,"InChI=1S/C18H32O16/c19-1-5-8(23)11(26)13(28)16(30-5)32-15-10(25)7(3-21)33-18(15,4-22)34-17-14(29)12(27)9(24)6(2-20)31-17/h5-17,19-29H,1-4H2/t5-,6-,7-,8-,9-,10-,11+,12+,13-,14-,15+,16-,17-,18+/m1/s1",Melezitose,KEGG COMPOUND accession,C08243
314,2444,actinodaphnine,"An organic heteropentacyclic compound 6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline bering additional hydroxy and methoxy substituents at positions 10 and 11 respectively.","InChI=1S/C18H17NO4/c1-21-14-7-11-10(5-13(14)20)4-12-16-9(2-3-19-12)6-15-18(17(11)16)23-8-22-15/h5-7,12,19-20H,2-4,8H2,1H3/t12-/m0/s1",Actinodaphnine,CAS Registry Number,517-69-1
315,2512,agathisflavone,A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-6 and C-8 of the two chromene rings.,"InChI=1S/C30H18O10/c31-15-5-1-13(2-6-15)22-11-20(36)26-24(39-22)12-21(37)27(29(26)38)28-18(34)9-17(33)25-19(35)10-23(40-30(25)28)14-3-7-16(32)8-4-14/h1-12,31-34,37-38H",Agathisflavone,CAS Registry Number,28441-98-7
316,2555,aldicarb,"The oxime carbamate resulting from the addition of 2-methyl-2-(methylsulfanyl)propanaldoxime to methyl isocyanate. A member of the class of oxime carbamate insecticides, aldicarb is a mixture of E and Z isomers; it is not known which isomer is more active.","InChI=1S/C7H14N2O2S/c1-7(2,12-4)5-9-11-6(10)8-3/h5H,1-4H3,(H,8,10)",Aldicarb,KEGG COMPOUND accession,C11015
317,3686,chrysophanol-9-anthrone,,"InChI=1S/C15H12O3/c1-8-5-10-7-9-3-2-4-11(16)13(9)15(18)14(10)12(17)6-8/h2-6,16-17H,7H2,1H3",Chrysophanic acid 9-anthrone,KEGG COMPOUND accession,C10314
318,4792,enflurane,"An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.","InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H",Enflurane,KEGG COMPOUND accession,C07516
319,4630,diosmetin,A monomethoxyflavone that is the 4'-methyl ether derivative of luteolin. It is a natural product isolated from citrus fruits which exhibits a range of pharmacological activities.,"InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3",Diosmetin,CAS Registry Number,520-34-3
320,5764,hordenine,,"InChI=1S/C10H15NO/c1-11(2)8-7-9-3-5-10(12)6-4-9/h3-6,12H,7-8H2,1-2H3",Hordenine,CAS Registry Number,539-15-1
321,5768,"(1E,4E,8E)-alpha-humulene","The (1E,4E,8E)-isomer of alpha-humulene.","InChI=1S/C15H24/c1-13-7-5-8-14(2)10-12-15(3,4)11-6-9-13/h6-7,10-11H,5,8-9,12H2,1-4H3/b11-6+,13-7+,14-10+",Humulene,KEGG COMPOUND accession,C09684
322,5779,hydrocodone,A morphinane-like compound that is a semi-synthetic opioid synthesized from codeine.,"InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1",Hydrocodone,KEGG COMPOUND accession,C08024
323,5835,hypericin,,"InChI=1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,31-36H,1-2H3",Hypericin,CAS Registry Number,548-04-9
324,9329,sulfadoxine,A sulfonamide consisting of pyrimidine having methoxy substituents at the 5- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. In combination with the antiprotozoal pyrimethamine (CHEBI:8673) it is used as an antimalarial.,"InChI=1S/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)",Sulfadoxine,KEGG COMPOUND accession,C07630
325,7853,oxyacanthine,"A macrocycle that is oxyacanthan that is substituted by methoxy groups at positions 6, 6', and 7, methyl groups at positions 2 and 2', and a hydroxy group at the 12' position.","InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(41-3)33-21-27(24)28(38)17-23-8-11-30(40)31(18-23)44-26-9-6-22(7-10-26)16-29-35-25(13-15-39(29)2)20-34(42-4)36(43-5)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29+/m1/s1",Oxyacanthine,KEGG COMPOUND accession,C09598
326,9107,senecionine,A pyrrolizidine alkaloid isolated from the plant species of the genus Senecio.,"InChI=1S/C18H25NO5/c1-4-12-9-11(2)18(3,22)17(21)23-10-13-5-7-19-8-6-14(15(13)19)24-16(12)20/h4-5,11,14-15,22H,6-10H2,1-3H3/b12-4-/t11-,14-,15-,18-/m1/s1",Senecionine,KEGG COMPOUND accession,C06176
327,20,(+)-camphene,"A camphene (2,2-dimethyl-3-methylenebicyclo[2.2.1]heptane) that has R configuration at position 1 and S configuration at position 4.","InChI=1S/C10H16/c1-7-8-4-5-9(6-8)10(7,2)3/h8-9H,1,4-6H2,2-3H3/t8-,9+/m0/s1",(+)-Comphene,KEGG COMPOUND accession,C06304
328,100,(-)-medicarpin,The (-)-enantiomer of medicarpin.,"InChI=1S/C16H14O4/c1-18-10-3-5-11-13-8-19-14-6-9(17)2-4-12(14)16(13)20-15(11)7-10/h2-7,13,16-17H,8H2,1H3/t13-,16-/m0/s1",(-)-Medicarpin,KEGG COMPOUND accession,C10503
329,151,D-threo-isocitric acid,The D-threo-diastereomer of isocitric acid.,"InChI=1S/C6H8O7/c7-3(8)1-2(5(10)11)4(9)6(12)13/h2,4,9H,1H2,(H,7,8)(H,10,11)(H,12,13)/t2-,4+/m0/s1",D-threo-Isocitric acid,KEGG COMPOUND accession,C00451
330,2038,5-azacytidine,"An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.","InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1",5-Azacytidine,KEGG COMPOUND accession,C11262
331,2086,"5-methoxy-N,N-dimethyltryptamine","A tryptamine alkaloid that is N,N-dimethyltryptamine substituted by a methoxy group at position 5.","InChI=1S/C13H18N2O/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13/h4-5,8-9,14H,6-7H2,1-3H3","5-Methoxy-N,N-dimethyltryptamine",CAS Registry Number,1019-45-0
332,2089,5-methoxytryptamine,A member of the class of tryptamines that is the methyl ether derivative of serotonin.,"InChI=1S/C11H14N2O/c1-14-9-2-3-11-10(6-9)8(4-5-12)7-13-11/h2-3,6-7,13H,4-5,12H2,1H3",5-Methoxytryptamine,KEGG COMPOUND accession,C05659
333,2120,cardol,Resorcinol substituted at position 5 by a pentadecyl chain.,"InChI=1S/C21H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-16-20(22)18-21(23)17-19/h16-18,22-23H,2-15H2,1H3",5-Pentadecylresorcinol,KEGG COMPOUND accession,C10809
334,2181,L-fucopyranose,The pyranose form of L-fucose.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m0/s1",6-Deoxy-L-galactose,KEGG COMPOUND accession,C01019
335,2197,6-hydroxyluteolin,A pentahydroxyflavone that is luteolin with an additional hydroxy group at position 6.,"InChI=1S/C15H10O7/c16-7-2-1-6(3-8(7)17)11-4-9(18)13-12(22-11)5-10(19)14(20)15(13)21/h1-5,16-17,19-21H",6-Hydroxyluteolin,CAS Registry Number,18003-33-3
336,3333,calycanthine,The principal alkaloid of the plant family Calycanthaceae.,"InChI=1S/C22H26N4/c1-25-13-11-22-16-8-4-5-9-17(16)23-19(25)21(22)12-14-26(2)20(22)24-18-10-6-3-7-15(18)21/h3-10,19-20,23-24H,11-14H2,1-2H3/t19-,20-,21-,22-/m1/s1",Calycanthine,KEGG COMPOUND accession,C10573
337,3374,capsaicin,,"InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+",Capsaicin,KEGG COMPOUND accession,C06866
338,3437,carteolol,,"InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)",Carteolol,KEGG COMPOUND accession,C06874
339,4290,"1,1-dimethyl-4-phenylpiperazinium iodide",,"InChI=1S/C12H19N2.HI/c1-14(2)10-8-13(9-11-14)12-6-4-3-5-7-12;/h3-7H,8-11H2,1-2H3;1H/q+1;/p-1",DMPP,CAS Registry Number,54-77-3
340,6015,isoflurane,,"InChI=1S/C3H2ClF5O/c4-1(3(7,8)9)10-2(5)6/h1-2H",Isoflurane,KEGG COMPOUND accession,C07518
341,6030,isoniazide,A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine.,"InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)",Isoniazid,KEGG COMPOUND accession,C07054
342,6032,isonicotinic acid,A pyridinemonocarboxylic acid in which the carboxy group is at position 4 of the pyridine ring.,"InChI=1S/C6H5NO2/c8-6(9)5-1-3-7-4-2-5/h1-4H,(H,8,9)",Isonicotinic acid,CAS Registry Number,55-22-1
343,6039,isopimaric acid,,"InChI=1S/C20H30O2/c1-5-18(2)12-9-15-14(13-18)7-8-16-19(15,3)10-6-11-20(16,4)17(21)22/h5,7,15-16H,1,6,8-13H2,2-4H3,(H,21,22)/t15-,16+,18-,19+,20+/m0/s1",Isopimaric acid,KEGG COMPOUND accession,C09118
344,6062,isosorbide mononitrate,,"InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1",Isosorbide mononitrate,CAS Registry Number,16051-77-7
345,6123,ketanserin,"A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.","InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)",Ketanserin,KEGG COMPOUND accession,C07464
346,8066,phenindione,,"InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H",Phenindione,CAS Registry Number,83-12-5
347,8080,phentermine,,"InChI=1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3","alpha,alpha-Dimethylphenethylamine",KEGG COMPOUND accession,C07438
348,8082,phenyl acetate,An  acetate ester obtained by the formal condensation of phenol with acetic acid.,"InChI=1S/C8H8O2/c1-7(9)10-8-5-3-2-4-6-8/h2-6H,1H3",Phenyl acetate,KEGG COMPOUND accession,C00548
349,8102,phenylmethanesulfonyl fluoride,An acyl fluoride with phenylmethanesulfonyl as the acyl group.,"InChI=1S/C7H7FO2S/c8-11(9,10)6-7-4-2-1-3-5-7/h1-5H,6H2",Phenylmethanesulfonyl fluoride,CAS Registry Number,329-98-6
350,5098,flucloxacillin,"A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.","InChI=1S/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1",Flucloxacillin,CAS Registry Number,5250-39-5
351,5106,flunisolide,,"InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1",Flunisolide,KEGG COMPOUND accession,C07005
352,5115,monofluorobenzene,The simplest member of the class of  monofluorobenzenes that is benzene carrying a single fluoro substituent.,InChI=1S/C6H5F/c7-6-4-2-1-3-5-6/h1-5H,Fluorobenzene,KEGG COMPOUND accession,C11272
353,10056,xanomeline,,"InChI=1S/C14H23N3OS/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3",Xanomeline,KEGG COMPOUND accession,C11767
354,4814,eprosartan,A member of the class of  imidazoles and  thiophenes  that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.,"InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+",Eprosartan,KEGG COMPOUND accession,C07467
355,9230,spinosyn A,A spinosyn in which the sugar amino and hydroxy groups are globally methylated. One of the two active ingredients of spinosad.,"InChI=1S/C41H65NO10/c1-10-26-12-11-13-34(52-36-17-16-33(42(5)6)23(3)48-36)22(2)37(44)32-20-30-28(31(32)21-35(43)50-26)15-14-25-18-27(19-29(25)30)51-41-40(47-9)39(46-8)38(45-7)24(4)49-41/h14-15,20,22-31,33-34,36,38-41H,10-13,16-19,21H2,1-9H3/t22-,23-,24+,25-,26+,27-,28-,29-,30-,31+,33+,34+,36+,38+,39-,40-,41+/m1/s1",Spinosyn A,CAS Registry Number,131929-60-7
356,9307,succinimide,A dicarboximide that is pyrrolidine which is substituted by oxo groups at positions 2 and 5.,"InChI=1S/C4H5NO2/c6-3-1-2-4(7)5-3/h1-2H2,(H,5,6,7)",Succinimide,KEGG COMPOUND accession,C07273
357,8925,ryanodine,An insecticide alkaloid isolated from South American plant Ryania speciosa.,"InChI=1S/C25H35NO9/c1-12(2)22(31)17(34-16(28)14-7-6-10-26-14)23(32)18(4)11-21(30)19(22,5)25(23,33)24(35-21)15(27)13(3)8-9-20(18,24)29/h6-7,10,12-13,15,17,26-27,29-33H,8-9,11H2,1-5H3/t13-,15+,17+,18-,19+,20-,21-,22+,23+,24+,25+/m0/s1",Ryanodine,CAS Registry Number,15662-33-6
358,9008,salicyluric acid,An N-acylglycine in which the acyl group is specified as 2-hydroxybenzoyl.,"InChI=1S/C9H9NO4/c11-7-4-2-1-3-6(7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)",Salicyluric acid,KEGG COMPOUND accession,C07588
359,301,(-)-alpha-phellandrene,The (R)-(-)-stereoisomer of alpha-phellandrene.,"InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4-6,8,10H,7H2,1-3H3/t10-/m1/s1",(R)-(-)-alpha-Phellandrene,KEGG COMPOUND accession,C09875
360,955,"2,6-dimethoxyphenol",A member of the class of phenols that is phenol substituted by methoxy groups at positions 2 and 6.,"InChI=1S/C8H10O3/c1-10-6-4-3-5-7(11-2)8(6)9/h3-5,9H,1-2H3","2,6-Dimethoxyphenol",KEGG COMPOUND accession,C10787
361,2215,6-methylergoline,An ergoline alkaloid obtained by selective methylation of the N-6 position of ergoline.,"InChI=1S/C15H18N2/c1-17-7-3-5-11-12-4-2-6-13-15(12)10(9-16-13)8-14(11)17/h2,4,6,9,11,14,16H,3,5,7-8H2,1H3/t11-,14-/m1/s1",6-Methylergoline,KEGG COMPOUND accession,C07540
362,2340,docebenone,"A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group.","InChI=1S/C21H26O3/c1-16-17(2)21(24)19(18(3)20(16)23)14-12-10-8-6-4-5-7-9-11-13-15-22/h22H,5,7-10,12,14-15H2,1-3H3",AA861,KEGG COMPOUND accession,C01349
363,2367,abyssinone I,"A monohydroxyflavanone that is (2S)-2',2'-dimethyl-2,3-dihydro-2'H,4H-2,6'-bichromen-4-one carrying a hydroxy substituent at position 7.","InChI=1S/C20H18O4/c1-20(2)8-7-13-9-12(3-6-17(13)24-20)18-11-16(22)15-5-4-14(21)10-19(15)23-18/h3-10,18,21H,11H2,1-2H3/t18-/m0/s1",Abyssinone I,KEGG COMPOUND accession,C09318
364,2368,abyssinone V,"A trihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7 and 4' and prenyl groups at positions 3' and 5' respectively.","InChI=1S/C25H28O5/c1-14(2)5-7-16-9-18(10-17(25(16)29)8-6-15(3)4)22-13-21(28)24-20(27)11-19(26)12-23(24)30-22/h5-6,9-12,22,26-27,29H,7-8,13H2,1-4H3/t22-/m0/s1",Abyssinone V,CAS Registry Number,77263-11-7
365,2375,"(-)-syringaresinol O,O'-bis(beta-D-glucoside)","A beta-D-glucoside that is the 4,4'-bis(beta-D-glucosyl) derivative of (-)-syringaresinol.","InChI=1S/C34H46O18/c1-43-17-5-13(6-18(44-2)31(17)51-33-27(41)25(39)23(37)21(9-35)49-33)29-15-11-48-30(16(15)12-47-29)14-7-19(45-3)32(20(8-14)46-4)52-34-28(42)26(40)24(38)22(10-36)50-34/h5-8,15-16,21-30,33-42H,9-12H2,1-4H3/t15-,16-,21-,22-,23-,24-,25+,26+,27-,28-,29+,30+,33+,34+/m1/s1",Acanthoside D,CAS Registry Number,66791-77-3
366,2379,acebutolol,"An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.","InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)",Acebutolol,KEGG COMPOUND accession,C06803
367,2401,acetophenazine,A member of the class of  phenothiazines that is 10H-phenothiazine substituted by a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the nitogen atom and an acetyl group at position 2.,"InChI=1S/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3",Acetophenazine,KEGG COMPOUND accession,C06807
368,2404,acetosyringone,A member of the class of  acetophenones that is 1-phenylethanone substituted by a hydroxy group at position 4 and methoxy groups at positions 3 and 5.,"InChI=1S/C10H12O4/c1-6(11)7-4-8(13-2)10(12)9(5-7)14-3/h4-5,12H,1-3H3",Acetosyringone,KEGG COMPOUND accession,C10664
369,3175,brimonidine,,"InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)",Brimonidine,KEGG COMPOUND accession,C07886
370,3181,bromocriptine,,"InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1",Bromocriptine,CAS Registry Number,25614-03-3
371,3219,bupropion,An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.,"InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3",Bupropion,KEGG COMPOUND accession,C06860
372,3228,butabarbital,,"InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)",Butabarbital,CAS Registry Number,125-40-6
373,3542,cephalothin sodium,,"InChI=1S/C16H16N2O6S2.Na/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10;/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23);/q;+1/p-1/t12-,15-;/m1./s1",Cephalothin sodium,KEGG COMPOUND accession,C08100
374,3547,cephradine,"A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.","InChI=1S/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1",Cephradine,CAS Registry Number,38821-53-3
375,4387,deltaline,,"InChI=1S/C27H41NO8/c1-7-28-12-23(3)9-8-17(32-5)26-20(23)21(36-14(2)29)27(22(26)28)25(34-13-35-27)11-16(31-4)15-10-24(26,30)19(25)18(15)33-6/h15-22,30H,7-13H2,1-6H3/t15-,16+,17+,18+,19+,20-,21+,22?,23+,24+,25-,26-,27-/m1/s1",Deltaline,KEGG COMPOUND accession,C08679
376,3649,chlorpromazine hydrochloride,The hydrochloride salt of chlorpromazine.,"InChI=1S/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H",Chlorpromazine hydrochloride,CAS Registry Number,69-09-0
377,7872,oxytocin,"A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.","InChI=1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1",Oxytocin,KEGG COMPOUND accession,C00746
378,3515,cefuroxime,A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.,"InChI=1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1",Cefuroxime,KEGG COMPOUND accession,C06894
379,8448,procyclidine,A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.,"InChI=1S/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2",Procyclidine,CAS Registry Number,77-37-2
380,9774,tubocurarine,A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.,"InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1",Tubocurarine,KEGG COMPOUND accession,C07547
381,4317,dantrolene,The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.,"InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)",Dantrolene,CAS Registry Number,7261-97-4
382,9047,schaftoside,A C-glycosyl compound that is apigenin substituted by beta-D-glucopyranosyl and an alpha-L-arabinopyranosyl moieties at positions 6 and 8 via C-glycosidic linkages.,"InChI=1S/C26H28O14/c27-6-13-18(32)21(35)23(37)26(40-13)15-19(33)14-10(29)5-12(8-1-3-9(28)4-2-8)39-24(14)16(20(15)34)25-22(36)17(31)11(30)7-38-25/h1-5,11,13,17-18,21-23,25-28,30-37H,6-7H2/t11-,13+,17-,18+,21-,22+,23+,25-,26-/m0/s1",Schaftoside,KEGG COMPOUND accession,C10181
383,9062,scutellarein,"Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.","InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)11-5-9(17)13-12(21-11)6-10(18)14(19)15(13)20/h1-6,16,18-20H",Scutellarein,CAS Registry Number,529-53-3
384,9093,selenocysteine,An alpha-amino acid that consists of alanine where one of the methyl hydrogens is substituted with a seleno group.,"InChI=1S/C3H7NO2Se/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)",Selenocysteine,CAS Registry Number,3614-08-2
385,9119,serpentine,"An indole alkaloid that is 18-oxayohimban dehydrogenated at positions 3, 4, 5, 6, 16 and 17 and substituted by a methyl group at the 19alpha position and by a methoxycarbonyl group at position 16.","InChI=1S/C21H20N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-8,11-12,15-16H,9-10H2,1-2H3/t12-,15-,16+/m0/s1",Serpentine,KEGG COMPOUND accession,C09241
386,9131,sexangularetin,A 7-hydroxyflavonol that is  kaempferol substituted by a methoxy group at position 8.,"InChI=1S/C16H12O7/c1-22-15-10(19)6-9(18)11-12(20)13(21)14(23-16(11)15)7-2-4-8(17)5-3-7/h2-6,17-19,21H,1H3",Herbacetin 8-methyl ether,CAS Registry Number,571-74-4
387,9141,silver(0),,InChI=1S/Ag,Silver,KEGG COMPOUND accession,C06710
388,9159,sinensetin,"A pentamethoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 3' and 4' respectively.","InChI=1S/C20H20O7/c1-22-13-7-6-11(8-15(13)23-2)14-9-12(21)18-16(27-14)10-17(24-3)19(25-4)20(18)26-5/h6-10H,1-5H3","5,6,7,3',4'-Pentamethoxyflavone",KEGG COMPOUND accession,C10186
389,7,(+)-car-3-ene,"A car-3-ene (3,7,7-trimethylbicyclo[4.1.0]hept-3-ene) that has S configuration at position 1 and R configuration at position 6.","InChI=1S/C10H16/c1-7-4-5-8-9(6-7)10(8,2)3/h4,8-9H,5-6H2,1-3H3/t8-,9+/m1/s1",(+)-3-Carene,KEGG COMPOUND accession,C11382
390,25,(+)-iridodial,"An  iridodial that is (1R,2R)-2-[(2R)-1-oxopropan-2-yl]cyclopentanecarbaldehyde substituted by a methyl group at position 2 (2S-stereoisomer).","InChI=1S/C10H16O2/c1-7-3-4-9(8(2)5-11)10(7)6-12/h5-10H,3-4H2,1-2H3/t7-,8-,9+,10+/m0/s1",(+)-Iridodial,CAS Registry Number,550-45-8
391,31,(+)-menthone,"A menthone that is cyclohexanone substituted by a methyl and an isopropyl group at positions 5 and 2 respectively (the 2R,5S-stereoisomer).","InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-9H,4-6H2,1-3H3/t8-,9+/m0/s1",(+)-Menthone,KEGG COMPOUND accession,C11390
392,53,(+)-beta-phellandrene,A beta-phellandrene in which the chiral centre has S configuration.,"InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,6,8,10H,3,5,7H2,1-2H3/t10-/m0/s1",(+)-beta-Phellandrene,KEGG COMPOUND accession,C09877
393,75,(-)-anaferine,A piperidine alkaloid that is piperidine substituted by a 2-oxo-3-[(2R)-piperidin-2-yl]propyl group at position 2.,"InChI=1S/C13H24N2O/c16-13(9-11-5-1-3-7-14-11)10-12-6-2-4-8-15-12/h11-12,14-15H,1-10H2/t11-,12-/m1/s1",(-)-Anaferine,CAS Registry Number,19519-55-2
394,88,(S)-(-)-citronellol,A  citronellol that is oct-6-ene substituted by a hydroxy group at position 1 and methyl groups at positions 3 and 7 (the 3S-enantiomer).,"InChI=1S/C10H20O/c1-9(2)5-4-6-10(3)7-8-11/h5,10-11H,4,6-8H2,1-3H3/t10-/m0/s1",(-)-Citronellol,KEGG COMPOUND accession,C11386
395,92,(-)-hygrine,A 1-(1-methylpyrrolidin-2-yl)acetone that has S configuration.,"InChI=1S/C8H15NO/c1-7(10)6-8-4-3-5-9(8)2/h8H,3-6H2,1-2H3/t8-/m0/s1",(-)-Hygrine,CAS Registry Number,65941-22-2
396,129,(-)-beta-phellandrene,A beta-phellandrene in which the chiral centre has R configuration.,"InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,6,8,10H,3,5,7H2,1-2H3/t10-/m1/s1",(-)-beta-Phellandrene,KEGG COMPOUND accession,C11392
397,150,(-)-isodihydrocarveol,"The (1R,2R,4S)-stereoisomer of dihydrocarveol.","InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-11H,1,4-6H2,2-3H3/t8-,9+,10-/m1/s1","(1R,2R,4S)-Iso-dihydrocarveol",KEGG COMPOUND accession,C11411
398,152,(+)-neodihydrocarveol,"A dihydrocarveol with a (1R,2S,4R)-configuration.","InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-11H,1,4-6H2,2-3H3/t8-,9-,10+/m1/s1","(1R,2S,4R)-Neo-dihydrocarveol",KEGG COMPOUND accession,C11397
399,158,(-)-neodihydrocarveol,"The (1R,2S,5S)-stereoisomer of dihydrocarveol.","InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-11H,1,4-6H2,2-3H3/t8-,9-,10+/m0/s1","(1S,2R,4S)-Neo-dihydrocarveol",KEGG COMPOUND accession,C11416
400,615,1-carbapenem-3-carboxylic acid,"A carbapenemcarboxylic acid that is the 3-carboxy derivative of 2,3-didehydro-1-carbapenam.","InChI=1S/C7H7NO3/c9-6-3-4-1-2-5(7(10)11)8(4)6/h2,4H,1,3H2,(H,10,11)/t4-/m1/s1",1-Carbapen-2-em-3-carboxylic acid,KEGG COMPOUND accession,C06669
401,641,N-methyl-4-phenylpyridinium,A pyridinium ion that is N-methylpyridinium having a phenyl substituent at the 4-position.,"InChI=1S/C12H12N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-10H,1H3/q+1",1-Methyl-4-phenylpyridinium,CAS Registry Number,48134-75-4
402,744,16-hydroxyphorbol 13-decanoate 12-palmitate,A phorbol ester that consists of 16-hydroxyphorbol bearing O-hexadecanoyl (palmitoyl) and O-decanoyl substituents at position 12 and 13 respectively.,"InChI=1S/C38H60O9/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-31(42)46-34-26(3)37(45)29(32-35(5,24-40)38(32,34)47-27(4)41)21-28(23-39)22-36(44)30(37)20-25(2)33(36)43/h20-21,26,29-30,32,34,39-40,44-45H,6-19,22-24H2,1-5H3/t26-,29+,30-,32-,34-,35-,36-,37-,38-/m1/s1",12-O-Palmitoyl-16-hydroxyphorbol 13-acetate,KEGG COMPOUND accession,C09153
403,756,14-dihydroxycornestin,"A cyclic dicarboxylic anhydride that is 5,6,7,8,9,10-hexahydro-1H-cyclonona[c]furan-1,3(4H)-dione substituted by an ethylidene group at position 9, hydroxy groups at position 5 and 8, a propyl group at position 4 and an oxo group at position 6.","InChI=1S/C16H20O6/c1-3-5-9-13-10(15(20)22-16(13)21)6-8(4-2)11(17)7-12(18)14(9)19/h4,9,11,14,17,19H,3,5-7H2,1-2H3/b8-4-/t9-,11+,14+/m1/s1",Cornexistin,KEGG COMPOUND accession,C08483
404,2065,5-hydroxy-N-formylkynurenine,A non-proteinogenic alpha-amino acid that is 5-hydroxykynurenine bearing an N-formyl substituent.,"InChI=1S/C11H12N2O5/c12-8(11(17)18)4-10(16)7-3-6(15)1-2-9(7)13-5-14/h1-3,5,8,15H,4,12H2,(H,13,14)(H,17,18)",5-Hydroxy-N-formylkynurenine,KEGG COMPOUND accession,C05648
405,2076,5-hydroxykynurenine,A  hydroxykynurenine  that is kynurenine bearing a hydroxy group at the position 5.,"InChI=1S/C10H12N2O4/c11-7-2-1-5(13)3-6(7)9(14)4-8(12)10(15)16/h1-3,8,13H,4,11-12H2,(H,15,16)",5-Hydroxykynurenine,CAS Registry Number,720-00-3
406,2161,"6-(3,3-dimethylallyl)chrysin",A dihydroxyflavone that is  chrysin substituted by a prenyl group at position 6.,"InChI=1S/C20H18O4/c1-12(2)8-9-14-15(21)10-18-19(20(14)23)16(22)11-17(24-18)13-6-4-3-5-7-13/h3-8,10-11,21,23H,9H2,1-2H3","6-(3,3-DMA)chrysin",KEGG COMPOUND accession,C11324
407,2165,6-acetamido-3-oxohexanoic acid,A 3-oxo monocarboxylic acid that is 3-oxohexanoic acid substituted at position 6 by an acetamido group.,"InChI=1S/C8H13NO4/c1-6(10)9-4-2-3-7(11)5-8(12)13/h2-5H2,1H3,(H,9,10)(H,12,13)",6-Acetamido-3-oxohexanoate,KEGG COMPOUND accession,C03682
408,3286,cabergoline,"An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.","InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1",Cabergoline,CAS Registry Number,81409-90-7
409,3306,calcitonin,A 32-membered heterodetic cyclic peptide comprising the sequence Cys-Ser-Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro-NH2 cyclised by a disulfide bridge between the two Cys residues at positions 1 and 7.,"InChI=1S/C145H240N44O48S2/c1-65(2)45-86(175-139(232)110(70(11)12)183-136(229)99-63-239-238-62-79(148)117(210)178-96(59-191)134(227)174-92(52-104(151)202)131(224)172-90(49-69(9)10)129(222)180-98(61-193)135(228)187-114(74(16)197)142(235)181-99)118(211)158-55-106(204)162-80(25-18-20-40-146)120(213)169-89(48-68(7)8)128(221)179-97(60-192)133(226)167-83(34-37-102(149)200)122(215)165-85(36-39-109(207)208)123(216)171-88(47-67(5)6)127(220)173-91(51-77-54-156-64-161-77)130(223)164-81(26-19-21-41-147)121(214)170-87(46-66(3)4)126(219)166-84(35-38-103(150)201)125(218)186-113(73(15)196)141(234)177-94(50-76-30-32-78(199)33-31-76)143(236)189-44-24-29-101(189)137(230)168-82(27-22-42-157-145(154)155)124(217)185-112(72(14)195)140(233)176-93(53-105(152)203)132(225)184-111(71(13)194)138(231)160-56-107(205)163-95(58-190)119(212)159-57-108(206)182-115(75(17)198)144(237)188-43-23-28-100(188)116(153)209/h30-33,54,64-75,79-101,110-115,190-199H,18-29,34-53,55-63,146-148H2,1-17H3,(H2,149,200)(H2,150,201)(H2,151,202)(H2,152,203)(H2,153,209)(H,156,161)(H,158,211)(H,159,212)(H,160,231)(H,162,204)(H,163,205)(H,164,223)(H,165,215)(H,166,219)(H,167,226)(H,168,230)(H,169,213)(H,170,214)(H,171,216)(H,172,224)(H,173,220)(H,174,227)(H,175,232)(H,176,233)(H,177,234)(H,178,210)(H,179,221)(H,180,222)(H,181,235)(H,182,206)(H,183,229)(H,184,225)(H,185,217)(H,186,218)(H,187,228)(H,207,208)(H4,154,155,157)/t71-,72-,73-,74-,75-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,110+,111+,112+,113+,114+,115+/m1/s1",Calcitonin,CAS Registry Number,47931-85-1
410,3311,calcium carbonate,A calcium salt with formula CCaO3.,"InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2",Calcium carbonate,CAS Registry Number,471-34-1
411,3327,calophyllin B,A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1 and 5 and a prenyl group at position 6.,"InChI=1S/C18H16O4/c1-10(2)6-7-11-8-9-12-17(21)15-13(19)4-3-5-14(15)22-18(12)16(11)20/h3-6,8-9,19-20H,7H2,1-2H3","6-(3,3-Dimethylallyl)-1,5-dihydroxyxanthone",KEGG COMPOUND accession,C10054
412,3332,(+)-calycanthidine,,"InChI=1S/C23H28N4/c1-25-14-12-22(16-8-4-6-10-18(16)24-20(22)25)23-13-15-26(2)21(23)27(3)19-11-7-5-9-17(19)23/h4-11,20-21,24H,12-15H2,1-3H3/t20-,21+,22+,23+/m1/s1",Calycanthidine,KEGG COMPOUND accession,C09097
413,3362,canthaxanthin,"A carotenone that consists of beta,beta-carotene bearing two oxo substituents at positions 4 and 4'.","InChI=1S/C40H52O2/c1-29(17-13-19-31(3)21-23-35-33(5)37(41)25-27-39(35,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-36-34(6)38(42)26-28-40(36,9)10/h11-24H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+",Canthaxanthin,KEGG COMPOUND accession,C08583
414,3369,capillin,,"InChI=1S/C12H8O/c1-2-3-5-10-12(13)11-8-6-4-7-9-11/h4,6-9H,1H3",Capillin,CAS Registry Number,495-74-9
415,3378,capsorubin,,"InChI=1S/C40H56O4/c1-29(17-13-19-31(3)21-23-35(43)39(9)27-33(41)25-37(39,5)6)15-11-12-16-30(2)18-14-20-32(4)22-24-36(44)40(10)28-34(42)26-38(40,7)8/h11-24,33-34,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t33-,34-,39-,40-/m0/s1",Capsorubin,CAS Registry Number,470-38-2
416,3388,"carbamazepine-10,11-epoxide",An  epoxide and metabolite of carbamazepine.,"InChI=1S/C15H12N2O2/c16-15(18)17-11-7-3-1-5-9(11)13-14(19-13)10-6-2-4-8-12(10)17/h1-8,13-14H,(H2,16,18)",Carbamazepine epoxide,KEGG COMPOUND accession,C07496
417,3424,carnitinium,A quaternary ammonium ion that is the the conjugate acid of carnitine.,"InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/p+1",Carnitine,KEGG COMPOUND accession,C00487
418,3454,cassaine,A tricyclic diterpenoid isolated from several plant species of the genus Erythrophleum.,"InChI=1S/C24H39NO4/c1-15-16(13-21(28)29-12-11-25(5)6)7-8-17-22(15)18(26)14-19-23(2,3)20(27)9-10-24(17,19)4/h13,15,17,19-20,22,27H,7-12,14H2,1-6H3/b16-13+/t15-,17-,19-,20-,22-,24+/m0/s1",cassaine,KEGG COMPOUND accession,C08670
419,3490,cefmetazole sodium,An organic sodium salt that is the sodium salt of cefmetazole.,"InChI=1S/C15H17N7O5S3.Na/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25;/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25);/q;+1/p-1/t13-,15+;/m1./s1",Cefmetazole sodium,KEGG COMPOUND accession,C08104
420,3492,cefonicid sodium,,"InChI=1S/C18H18N6O8S3.2Na/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32;;/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32);;/q;2*+1/p-2/t11-,13-,16-;;/m1../s1",Cefonicid sodium,CAS Registry Number,61270-78-8
421,3507,cefsulodin,"A pyridinium-substituted semi-synthetic, broad-spectrum, cephalosporin antibiotic.","InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1",Cefsulodin,KEGG COMPOUND accession,C11253
422,763,algestone,A C21-steroid that is pregn-4-ene substituted by oxo groups at position 3 and 20 and hydroxy groups at positions 16 and 17.,"InChI=1S/C21H30O4/c1-12(22)21(25)18(24)11-17-15-5-4-13-10-14(23)6-8-19(13,2)16(15)7-9-20(17,21)3/h10,15-18,24-25H,4-9,11H2,1-3H3/t15-,16+,17+,18-,19+,20+,21-/m1/s1",Algestone,KEGG COMPOUND accession,C06391
423,769,16-methoxytabersonine,The 16-methoxy derivative of tabersonine.,"InChI=1S/C22H26N2O3/c1-4-21-8-5-10-24-11-9-22(20(21)24)16-7-6-14(26-2)12-17(16)23-18(22)15(13-21)19(25)27-3/h5-8,12,20,23H,4,9-11,13H2,1-3H3/t20-,21-,22-/m0/s1",16-Methoxytabersonine,KEGG COMPOUND accession,C11675
424,4126,D-fructofuranuronic acid,The furanose form of D-fructuronic acid.,"InChI=1S/C6H10O7/c7-1-6(12)4(9)2(8)3(13-6)5(10)11/h2-4,7-9,12H,1H2,(H,10,11)/t2-,3+,4+,6?/m1/s1",D-Fructuronate,KEGG COMPOUND accession,C00905
425,4141,D-galactopyranose 6-phosphate,The pyranose form of D-galactose 6-phosphate.,"InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3+,4+,5-,6?/m1/s1",D-Galactose 6-phosphate,KEGG COMPOUND accession,C01113
426,4153,D-galactopyranuronic acid,The pyranose form of D-galacturonic acid,"InChI=1S/C6H10O7/c7-1-2(8)4(5(10)11)13-6(12)3(1)9/h1-4,6-9,12H,(H,10,11)/t1-,2+,3+,4-,6?/m0/s1",D-Galacturonic acid,KEGG COMPOUND accession,C00333
427,4170,D-glucopyranose 6-phosphate,A glucopyranose ring with a phosphate replacing the hydroxy in the hydroxymethyl group at position 6.,"InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3-,4+,5-,6?/m1/s1",D-Glucose 6-phosphate,CAS Registry Number,56-73-5
428,4191,D-gulopyranose,The D-enantiomer of gulopyranose.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4-,5-,6?/m1/s1",D-Gulose,CAS Registry Number,4205-23-6
429,4235,D-ribose 1-diphosphate,,"InChI=1S/C5H12O11P2/c6-1-2-3(7)4(8)5(14-2)15-18(12,13)16-17(9,10)11/h2-8H,1H2,(H,12,13)(H2,9,10,11)/t2-,3-,4-,5?/m1/s1",D-Ribose 1-diphosphate,KEGG COMPOUND accession,C06248
430,4249,D-tagatopyranose,The pyranose form of D-tagatose.,"InChI=1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4+,5+,6?/m1/s1",D-Tagatose,KEGG COMPOUND accession,C00795
431,4251,D-tagatofuranose 6-phosphate,The furanose form of D-tagatose 6-phosphate.,"InChI=1S/C6H13O9P/c7-2-6(10)5(9)4(8)3(15-6)1-14-16(11,12)13/h3-5,7-10H,1-2H2,(H2,11,12,13)/t3-,4+,5+,6?/m1/s1",D-Tagatose 6-phosphate,KEGG COMPOUND accession,C01097
432,4280,"(2R,4S)-2,4-diaminopentanoic acid","The (2R,4S)-diastereomer of 2,4-diaminopentanoic acid","InChI=1S/C5H12N2O2/c1-3(6)2-4(7)5(8)9/h3-4H,2,6-7H2,1H3,(H,8,9)/t3-,4+/m0/s1","D-threo-2,4-Diaminopentanoate",KEGG COMPOUND accession,C03943
433,1665,3-sulfinylpyruvic acid,A pyruvic acid compound having a 3-sulfinyl substituent.,"InChI=1S/C3H4O5S/c4-2(3(5)6)1-9(7)8/h1H2,(H,5,6)(H,7,8)",3-Sulfinylpyruvate,KEGG COMPOUND accession,C05527
434,1670,3-ureidoisobutyric acid,A ureidocarboxylic acid that is 2-methylpropanoic acid substituted by a carbamoylamino group at position 3.,"InChI=1S/C5H10N2O3/c1-3(4(8)9)2-7-5(6)10/h3H,2H2,1H3,(H,8,9)(H3,6,7,10)",3-Ureidoisobutyrate,KEGG COMPOUND accession,C05100
435,1463,3-carboxy-1-hydroxypropylthiamine diphosphate,"A 1,3-thiazolium cation that is 1,3-thiazol-3-ium substituted by a methyl group at position 4, a (4-amino-2-methylpyrimidin-5-yl)methyl group at position 3, a 3-carboxy-1-hydroxypropyl at position 2 and a 2-{[hydroxy(phosphonooxy)phosphoryl]oxy}ethyl group at position 5.","InChI=1S/C16H24N4O10P2S/c1-9-13(5-6-29-32(27,28)30-31(24,25)26)33-16(12(21)3-4-14(22)23)20(9)8-11-7-18-10(2)19-15(11)17/h7,12,21H,3-6,8H2,1-2H3,(H5-,17,18,19,22,23,24,25,26,27,28)/p+1",3-Carboxy-1-hydroxypropyl-ThPP,KEGG COMPOUND accession,C05381
436,5931,insulin (human),"An insulin that is produced in the pancreas and involved in regulating the metabolism of carbohydrates (particularly glucose) and fats. Commonly thought of as a protein, it consists of two peptide chains, one containing 21 amino acid residues and the other containing 30; the chains are joined together by 2 disulfide bonds. Recombinant insulin is identical to human insulin, but is synthesised by inserting the human insulin gene into E. coli, which then produces insulin for human use. It is used in the treatment of type I and type II diabetes.","InChI=1S/C257H383N65O77S6/c1-29-131(23)205(313-193(339)104-259)252(393)317-204(130(21)22)248(389)288-159(75-82-200(349)350)217(358)282-156(71-78-189(263)335)221(362)308-183-116-403-404-117-184-243(384)305-178(111-324)240(381)294-162(88-123(7)8)225(366)295-168(95-140-53-61-146(329)62-54-140)228(369)283-154(69-76-187(261)333)218(359)290-161(87-122(5)6)223(364)285-158(74-81-199(347)348)220(361)302-174(101-190(264)336)235(376)298-170(97-142-57-65-148(331)66-58-142)231(372)309-182(242(383)304-176(255(396)397)103-192(266)338)115-402-401-114-181(214(355)273-107-194(340)278-153(72-79-197(343)344)216(357)281-151(51-42-84-271-257(267)268)212(353)272-108-195(341)279-166(93-138-46-36-32-37-47-138)227(368)297-167(94-139-48-38-33-39-49-139)230(371)299-171(98-143-59-67-149(332)68-60-143)238(379)320-208(135(27)327)254(395)322-85-43-52-186(322)246(387)286-152(50-40-41-83-258)222(363)321-209(136(28)328)256(398)399)311-250(391)203(129(19)20)316-236(377)164(90-125(11)12)292-229(370)169(96-141-55-63-147(330)64-56-141)296-224(365)160(86-121(3)4)289-210(351)133(25)277-215(356)157(73-80-198(345)346)287-247(388)202(128(17)18)315-237(378)165(91-126(13)14)293-233(374)173(100-145-106-270-120-276-145)301-239(380)177(110-323)280-196(342)109-274-213(354)180(113-400-405-118-185(310-244(183)385)245(386)319-207(134(26)326)253(394)306-179(112-325)241(382)318-206(132(24)30-2)251(392)312-184)307-226(367)163(89-124(9)10)291-232(373)172(99-144-105-269-119-275-144)300-219(360)155(70-77-188(262)334)284-234(375)175(102-191(265)337)303-249(390)201(127(15)16)314-211(352)150(260)92-137-44-34-31-35-45-137/h31-39,44-49,53-68,105-106,119-136,150-186,201-209,323-332H,29-30,40-43,50-52,69-104,107-118,258-260H2,1-28H3,(H2,261,333)(H2,262,334)(H2,263,335)(H2,264,336)(H2,265,337)(H2,266,338)(H,269,275)(H,270,276)(H,272,353)(H,273,355)(H,274,354)(H,277,356)(H,278,340)(H,279,341)(H,280,342)(H,281,357)(H,282,358)(H,283,369)(H,284,375)(H,285,364)(H,286,387)(H,287,388)(H,288,389)(H,289,351)(H,290,359)(H,291,373)(H,292,370)(H,293,374)(H,294,381)(H,295,366)(H,296,365)(H,297,368)(H,298,376)(H,299,371)(H,300,360)(H,301,380)(H,302,361)(H,303,390)(H,304,383)(H,305,384)(H,306,394)(H,307,367)(H,308,362)(H,309,372)(H,310,385)(H,311,391)(H,312,392)(H,313,339)(H,314,352)(H,315,378)(H,316,377)(H,317,393)(H,318,382)(H,319,386)(H,320,379)(H,321,363)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,396,397)(H,398,399)(H4,267,268,271)/t131-,132-,133-,134+,135+,136+,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,183-,184-,185-,186-,201-,202-,203-,204-,205-,206-,207-,208-,209-/m0/s1",Insulin,KEGG COMPOUND accession,C00723
437,5941,intermedine,"A carboxylic ester compound formed from condensation between retronecine and (2S,3R)-2,3-dihydroxy-2-isopropylbutanoic acid.","InChI=1S/C15H25NO5/c1-9(2)15(20,10(3)17)14(19)21-8-11-4-6-16-7-5-12(18)13(11)16/h4,9-10,12-13,17-18,20H,5-8H2,1-3H3/t10-,12-,13-,15+/m1/s1",Intermedine,KEGG COMPOUND accession,C10330
438,5950,iodoquinol,A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by iodine.  It is considered the drug of choice for treating asymptomatic or moderate forms of amoebiasis.,"InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H",Iodoquinol,KEGG COMPOUND accession,C07636
439,5964,iridodial,A dialdehyde that is cyclopentanecarbaldehyde substituted by a methyl group at position 2 and a 1-methyl-2-oxoethyl group at position 5.,"InChI=1S/C10H16O2/c1-7-3-4-9(8(2)5-11)10(7)6-12/h5-10H,3-4H2,1-2H3",Iridodial,KEGG COMPOUND accession,C06069
440,6009,isofenphos,,"InChI=1S/C15H24NO4PS/c1-6-18-21(22,16-11(2)3)20-14-10-8-7-9-13(14)15(17)19-12(4)5/h7-12H,6H2,1-5H3,(H,16,22)",Isofenphos,CAS Registry Number,25311-71-1
441,6059,isoscutellarein,A tetrahydroxyflavone that is apigenin with an extra hydroxy group at position 8.,"InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)12-6-10(18)13-9(17)5-11(19)14(20)15(13)21-12/h1-6,16-17,19-20H",Isoscutellarein,CAS Registry Number,41440-05-5
442,6113,karakoline,"An organonitrogen heterocyclic compound that is aconitane bearing hydroxy groups at the 1alpha, 8, and 14alpha positions and substituted at on the nitrogen and at positions 4 and 16beta by ethyl, methyl, and methoxy groups, respectively.","InChI=1S/C22H35NO4/c1-4-23-10-20(2)6-5-16(24)22-12-7-11-14(27-3)9-21(26,17(12)18(11)25)13(19(22)23)8-15(20)22/h11-19,24-26H,4-10H2,1-3H3/t11-,12-,13+,14+,15-,16+,17-,18+,19?,20+,21+,22-/m1/s1",Karakoline,CAS Registry Number,39089-30-0
443,6182,aldehydo-L-arabinose,The open-chain aldehyhde form of L-arabinose.,"InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4-,5+/m0/s1",L-Arabinose,KEGG COMPOUND accession,C11476
444,7219,beta-naphthyl N-acetylphenylalaninate,An alpha-amino acid ester obtained by the fromal condensation of N-acetylphenylalanine with 2-naphthol.,"InChI=1S/C21H19NO3/c1-15(23)22-20(13-16-7-3-2-4-8-16)21(24)25-19-12-11-17-9-5-6-10-18(17)14-19/h2-12,14,20H,13H2,1H3,(H,22,23)",N-Acetylphenylalanine beta-naphthyl ester,KEGG COMPOUND accession,C11341
445,7274,N-formimidoyl-L-glutamic acid,The N-formimidoyl derivative of L-glutamic acid,"InChI=1S/C6H10N2O4/c7-3-8-4(6(11)12)1-2-5(9)10/h3-4H,1-2H2,(H2,7,8)(H,9,10)(H,11,12)/t4-/m0/s1",N-Formimino-L-glutamate,KEGG COMPOUND accession,C00439
446,7351,"N(4)-acetyl-L-2,4-diaminobutyric acid","The N(4)-acetyl derivative of L-2,4-diaminobutyric acid","InChI=1S/C6H12N2O3/c1-4(9)8-3-2-5(7)6(10)11/h5H,2-3,7H2,1H3,(H,8,9)(H,10,11)/t5-/m0/s1",N-gamma-Acetyldiaminobutyrate,KEGG COMPOUND accession,C06442
447,7916,pantothenic acid,A member of the class of pantothenic acids that is an amide formed from pantoic acid and beta-alanine.,"InChI=1S/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)",Pantothenic acid,KEGG COMPOUND accession,C00864
448,7931,paricalcitol,,"InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1",Paricalcitol,KEGG COMPOUND accession,C08127
449,8025,perindopril erbumine,,"InChI=1S/C19H32N2O5.C4H11N/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24;1-4(2,3)5/h12-16,20H,4-11H2,1-3H3,(H,23,24);5H2,1-3H3/t12-,13-,14-,15-,16-;/m0./s1",Perindopril erbumine,KEGG COMPOUND accession,C07707
450,8040,phalloidin,A homodetic bicyclic heptapeptide having a sulfide bridge.,"InChI=1S/C35H48N8O11S/c1-15-27(47)38-22-10-20-19-7-5-6-8-21(19)41-33(20)55-13-24(34(53)43-12-18(46)9-25(43)31(51)37-15)40-32(52)26(17(3)45)42-28(48)16(2)36-30(50)23(39-29(22)49)11-35(4,54)14-44/h5-8,15-18,22-26,41,44-46,54H,9-14H2,1-4H3,(H,36,50)(H,37,51)(H,38,47)(H,39,49)(H,40,52)(H,42,48)/t15-,16-,17-,18-,22-,23-,24-,25-,26+,35+/m0/s1",Phalloidin,KEGG COMPOUND accession,C08439
451,8058,phencyclidine,"A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group.  Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.","InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2",Phencyclidine,CAS Registry Number,77-10-1
452,8062,phenethyl caffeate,An alkyl caffeate ester in which 2-phenylethyl is the alkyl component.,"InChI=1S/C17H16O4/c18-15-8-6-14(12-16(15)19)7-9-17(20)21-11-10-13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2/b9-7+",Caffeic acid phenethyl ester,KEGG COMPOUND accession,C10484
453,8092,"1,3-phenylenediamine",A  phenylenediamine  taht is benzene substituted at positions 1 and 3 with amino functions.,"InChI=1S/C6H8N2/c7-5-2-1-3-6(8)4-5/h1-4H,7-8H2",m-Phenylenediamine,KEGG COMPOUND accession,C02454
454,1472,"3-chloro-cis,cis-muconic acid","A 3-chloromuconic acid that is cis,cis-muconic acid substituted by a chloro substituent at position 3.","InChI=1S/C6H5ClO4/c7-4(3-6(10)11)1-2-5(8)9/h1-3H,(H,8,9)(H,10,11)/b2-1-,4-3+","3-Chloro-cis,cis-muconate",KEGG COMPOUND accession,C03585
455,5403,glucoconringiin(1-),An hydroxy-alkylglucosinolate that is isobutylglucosinolate which has been hydroxylated at the 2-position of the isobutyl chain.,"InChI=1S/C11H21NO10S2/c1-11(2,17)3-6(12-22-24(18,19)20)23-10-9(16)8(15)7(14)5(4-13)21-10/h5,7-10,13-17H,3-4H2,1-2H3,(H,18,19,20)/p-1/t5-,7-,8+,9-,10+/m1/s1",Glucoconringiin,KEGG COMPOUND accession,C08408
456,5406,glucoiberin,,"InChI=1S/C11H21NO10S3/c1-24(17)4-2-3-7(12-22-25(18,19)20)23-11-10(16)9(15)8(14)6(5-13)21-11/h6,8-11,13-16H,2-5H2,1H3,(H,18,19,20)/p-1/t6-,8-,9+,10-,11+,24?/m1/s1",Glucoiberin,KEGG COMPOUND accession,C08411
457,5411,gluconapin(1-),An alkenylglucosinolate that is the conjugate base of gluconapin.,"InChI=1S/C11H19NO9S2/c1-2-3-4-7(12-21-23(17,18)19)22-11-10(16)9(15)8(14)6(5-13)20-11/h2,6,8-11,13-16H,1,3-5H2,(H,17,18,19)/p-1/b12-7-/t6-,8-,9+,10-,11+/m1/s1",Gluconapin,KEGG COMPOUND accession,C08415
458,5414,glucoputranjivin(1-),A alkylglucosinolate that is the conjugate base of glucoputranjivin.,"InChI=1S/C10H19NO9S2/c1-4(2)9(11-20-22(16,17)18)21-10-8(15)7(14)6(13)5(3-12)19-10/h4-8,10,12-15H,3H2,1-2H3,(H,16,17,18)/p-1/b11-9-/t5-,6-,7+,8-,10+/m1/s1",Glucoputranjivin,KEGG COMPOUND accession,C08418
459,5416,glucoraphenin(1-),A glucosinolate resulting from the removal of the proton from the oxime hydrogen sulfate group of glucoraphenin.,"InChI=1S/C12H21NO9S3/c1-24(18)5-3-2-4-8(13-25(19,20)21)23-12-11(17)10(16)9(15)7(6-14)22-12/h3,5,7,9-12,14-17H,2,4,6H2,1H3,(H,19,20,21)/p-1/b5-3?,13-8-/t7-,9-,10+,11-,12+,24?/m1/s1",Glucoraphenin,CAS Registry Number,28463-24-3
460,5435,"piperidine-2,6-dione",A dicarboximide that is piperidine which is substituted by oxo groups at positions 2 and 6.,"InChI=1S/C5H7NO2/c7-4-2-1-3-5(8)6-4/h1-3H2,(H,6,7,8)",Glutarimide,KEGG COMPOUND accession,C07275
461,5088,flavoxate,A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.,"InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3",Flavoxate,KEGG COMPOUND accession,C07809
462,5123,fluphenazine,A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the N-10 position.,"InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2",Fluphenazine,KEGG COMPOUND accession,C07010
463,5135,fluvalinate,,"InChI=1S/C26H22ClF3N2O3/c1-16(2)24(32-22-12-11-18(14-21(22)27)26(28,29)30)25(33)35-23(15-31)17-7-6-10-20(13-17)34-19-8-4-3-5-9-19/h3-14,16,23-24,32H,1-2H3",Fluvalinate,CAS Registry Number,69409-94-5
464,5202,fustin,"A dihydroflavonol that is the 2,3-dihydro derivative of fisetin.","InChI=1S/C15H12O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,14-18,20H/t14-,15-/m1/s1",Fustin,CAS Registry Number,20725-03-5
465,9985,vincamine,,"InChI=1S/C21H26N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-5,7-8,18,25H,3,6,9-13H2,1-2H3/t18-,20+,21+/m1/s1",Vincamine,KEGG COMPOUND accession,C09251
466,10043,wogonin,A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.,"InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3",Wogonin,KEGG COMPOUND accession,C10197
467,10049,XTP,The xanthosine 5'-phosphate in which the 5'-phosphate is a triphosphate group.,"InChI=1S/C10H15N4O15P3/c15-5-3(1-26-31(22,23)29-32(24,25)28-30(19,20)21)27-9(6(5)16)14-2-11-4-7(14)12-10(18)13-8(4)17/h2-3,5-6,9,15-16H,1H2,(H,22,23)(H,24,25)(H2,19,20,21)(H2,12,13,17,18)/t3-,5-,6-,9-/m1/s1",XTP,KEGG COMPOUND accession,C00700
468,10099,N-[(benzyloxy)carbonyl]-L-tyrosyl-N-hydroxy-L-leucinamide,"The dipeptide obtained by coupling N-benzyloxycarbonyl-L-tyrosine with the hydroxamic acid derivative of L-leucine. It is an inhibitor of the metallo-protease enzyme, pseudolysin (EC 3.4.24.36).","InChI=1S/C23H29N3O6/c1-15(2)12-19(22(29)26-31)24-21(28)20(13-16-8-10-18(27)11-9-16)25-23(30)32-14-17-6-4-3-5-7-17/h3-11,15,19-20,27,31H,12-14H2,1-2H3,(H,24,28)(H,25,30)(H,26,29)/t19-,20-/m0/s1",Z-Tyr-Leu-NHOH,KEGG COMPOUND accession,C02203
469,10136,gingerol,A beta-hydroxy ketone that is 5-hydroxydecan-3-one substituted by a 4-hydroxy-3-methoxyphenyl moiety at position 1; believed to inhibit adipogenesis. It is a constituent of fresh ginger.,"InChI=1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-16(20)17(11-13)21-2/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3/t14-/m0/s1",[6]-Gingerol,CAS Registry Number,23513-14-6
470,7101,N(5)-[(Z)-amino(hydroxyimino)methyl]ornithine,,"InChI=1S/C6H14N4O3/c7-4(5(11)12)2-1-3-9-6(8)10-13/h4,13H,1-3,7H2,(H,11,12)(H3,8,9,10)",N-(omega)-Hydroxyarginine,KEGG COMPOUND accession,C05933
471,10723,trans-dec-2-enoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans-dec-2-enoic acid.,"InChI=1S/C31H52N7O17P3S/c1-4-5-6-7-8-9-10-11-22(40)59-15-14-33-21(39)12-13-34-29(43)26(42)31(2,3)17-52-58(49,50)55-57(47,48)51-16-20-25(54-56(44,45)46)24(41)30(53-20)38-19-37-23-27(32)35-18-36-28(23)38/h10-11,18-20,24-26,30,41-42H,4-9,12-17H2,1-3H3,(H,33,39)(H,34,43)(H,47,48)(H,49,50)(H2,32,35,36)(H2,44,45,46)/b11-10+/t20-,24-,25-,26+,30-/m1/s1",trans-Dec-2-enoyl-CoA,KEGG COMPOUND accession,C05275
472,4820,ergocornine,"Ergotaman bearing a hydroxy group at the 12' position, isopropyl groups at the 2' and 5'alpha positions, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid.","InChI=1S/C31H39N5O5/c1-16(2)26-28(38)35-11-7-10-24(35)31(40)36(26)29(39)30(41-31,17(3)4)33-27(37)19-12-21-20-8-6-9-22-25(20)18(14-32-22)13-23(21)34(5)15-19/h6,8-9,12,14,16-17,19,23-24,26,32,40H,7,10-11,13,15H2,1-5H3,(H,33,37)/t19-,23-,24+,26+,30-,31+/m1/s1",Ergocornine,KEGG COMPOUND accession,C09162
473,9211,soyasaponin I,A triterpenoid saponin that is composed of soyasapogenol B having an alpha-L-rhamnopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->2)-beta-D-glucopyranosiduronic acid moiety attached at the 3-position via a glycosidic linkage.,"InChI=1S/C48H78O18/c1-21-29(52)31(54)35(58)40(61-21)65-37-32(55)30(53)24(19-49)62-41(37)66-38-34(57)33(56)36(39(59)60)64-42(38)63-28-12-13-45(5)25(46(28,6)20-50)11-14-48(8)26(45)10-9-22-23-17-43(2,3)18-27(51)44(23,4)15-16-47(22,48)7/h9,21,23-38,40-42,49-58H,10-20H2,1-8H3,(H,59,60)/t21-,23-,24+,25+,26+,27+,28-,29-,30-,31+,32-,33-,34-,35+,36-,37+,38+,40-,41-,42+,44+,45-,46+,47+,48+/m0/s1",Soyasaponin I,KEGG COMPOUND accession,C08983
474,9231,spinosyn B,,"InChI=1S/C40H63NO10/c1-9-25-11-10-12-33(51-35-16-15-32(41-5)22(3)47-35)21(2)36(43)31-19-29-27(30(31)20-34(42)49-25)14-13-24-17-26(18-28(24)29)50-40-39(46-8)38(45-7)37(44-6)23(4)48-40/h13-14,19,21-30,32-33,35,37-41H,9-12,15-18,20H2,1-8H3/t21-,22-,23+,24-,25+,26-,27-,28-,29-,30+,32+,33+,35+,37+,38-,39-,40+/m1/s1",Spinosyn B,KEGG COMPOUND accession,C11055
475,9240,spirolucidine,,"InChI=1S/C30H49N3O2/c1-18-10-21(25-6-5-9-33(20(3)34)28(25)13-18)14-24-7-8-29(35)30(31-24)16-22-11-19(2)12-27-26(22)15-23(30)17-32(27)4/h18-19,21-28,31H,5-17H2,1-4H3/t18-,19+,21+,22-,23+,24+,25+,26+,27-,28-,30-/m0/s1",Spirolucidine,KEGG COMPOUND accession,C09903
476,9300,suberic acid,"An alpha,omega-dicarboxylic acid that is the 1,6-dicarboxy derivative of hexane.","InChI=1S/C8H14O4/c9-7(10)5-3-1-2-4-6-8(11)12/h1-6H2,(H,9,10)(H,11,12)",Suberic acid,KEGG COMPOUND accession,C08278
477,9003,salicin 6-phosphate,A glycoside phosphate that is salicin bearing an O-phospho group at position 6.,"InChI=1S/C13H19O10P/c14-5-7-3-1-2-4-8(7)22-13-12(17)11(16)10(15)9(23-13)6-21-24(18,19)20/h1-4,9-17H,5-6H2,(H2,18,19,20)/t9-,10-,11+,12-,13-/m1/s1",Salicin 6-phosphate,KEGG COMPOUND accession,C06188
478,9016,arsphenamine,,"InChI=1S/C12H12As2N2O2.2ClH/c15-9-5-7(1-3-11(9)17)13-14-8-2-4-12(18)10(16)6-8;;/h1-6,17-18H,15-16H2;2*1H",Salvarsan,CAS Registry Number,139-93-5
479,232,(+)-cis-carveol,"The (1S,5S)-stereoisomer of carveol.","InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3/t9-,10-/m0/s1","(4S,6S)-cis-Carveol",KEGG COMPOUND accession,C11408
480,300,(R)-(+)-alpha-terpineol,The (4R)-stereoiosmer of alpha-terpineol.,"InChI=1S/C10H18O/c1-8-4-6-9(7-5-8)10(2,3)11/h4,9,11H,5-7H2,1-3H3/t9-/m0/s1",(R)-(+)-alpha-Terpineol,KEGG COMPOUND accession,C09902
481,367,(+)-alpha-phellandrene,"The (5S)-stereoisomer of alpha-phellandrene (5-isopropyl-2-methylcyclohexa-1,3-diene).","InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4-6,8,10H,7H2,1-3H3/t10-/m0/s1",(S)-(+)-alpha-Phellandrene,CAS Registry Number,2243-33-6
482,791,17beta-estradiol 17-glucosiduronic acid,A steroid glucosiduronic acid that consists of 17beta-estradiol having a beta-glucuronyl residue attached at position 17 via a glycosidic linkage.,"InChI=1S/C24H32O8/c1-24-9-8-14-13-5-3-12(25)10-11(13)2-4-15(14)16(24)6-7-17(24)31-23-20(28)18(26)19(27)21(32-23)22(29)30/h3,5,10,14-21,23,25-28H,2,4,6-9H2,1H3,(H,29,30)/t14-,15-,16+,17+,18+,19+,20-,21+,23-,24+/m1/s1",17beta-Estradiol 17-(beta-D-glucuronide),KEGG COMPOUND accession,C11237
483,847,2'-O-methylodoratol,A member of the class of  dihydrochalcones that is the 2'-O-methyl derivative of odoratol.,"InChI=1S/C18H20O5/c1-21-13-6-4-12(5-7-13)10-16(19)18(20)15-9-8-14(22-2)11-17(15)23-3/h4-9,11,16,19H,10H2,1-3H3",Methylodoratol,KEGG COMPOUND accession,C09774
484,855,"2,2'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)diphenol","A member of the class of  triazoles that is 1-phenyl-1H-1,2,4-triazole substituted by 2-hydroxyphenyl groups at positions 3 and 5.","InChI=1S/C20H15N3O2/c24-17-12-6-4-10-15(17)19-21-20(16-11-5-7-13-18(16)25)23(22-19)14-8-2-1-3-9-14/h1-13,24-25H","2,2'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)bis-phenol",KEGG COMPOUND accession,C11569
485,857,"2,2'-iminodipropanoic acid","An amino dicarboxylic acid that is 2,2'-iminodiacetic acid substituted by methyl groups at positions 2 and 2'.","InChI=1S/C6H11NO4/c1-3(5(8)9)7-4(2)6(10)11/h3-4,7H,1-2H3,(H,8,9)(H,10,11)","2,2'-Iminodipropanoate",KEGG COMPOUND accession,C03210
486,915,"2,4-dihydroxyhept-2-enedioic acid","A heptenedioic acid having the C=C double bond at the 2,3-position and two hydroxy substituents at the 2- and 4-positions.","InChI=1S/C7H10O6/c8-4(1-2-6(10)11)3-5(9)7(12)13/h3-4,8-9H,1-2H2,(H,10,11)(H,12,13)","2,4-Dihydroxyhept-2-enedioate",KEGG COMPOUND accession,C06201
487,929,"2,5-diamino-6-ribosylamino-4(3H)pyrimidinone 5'-triphosphate","A ribose 5-triphosphate compound having a 2,5-diamino-6-oxo-1,6-dihydropyrimidin-4-ylamino substituent at the 1-position.","InChI=1S/C9H18N5O14P3/c10-3-6(13-9(11)14-7(3)17)12-8-5(16)4(15)2(26-8)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2,4-5,8,15-16H,1,10H2,(H,21,22)(H,23,24)(H2,18,19,20)(H4,11,12,13,14,17)/t2-,4-,5-,8-/m1/s1","2,5-Diaminopyrimidine nucleoside triphosphate",KEGG COMPOUND accession,C05923
488,2212,(R)-6-methoxymellein,An optically active form of 6-methoxymellein having (R)-configuration.,"InChI=1S/C11H12O4/c1-6-3-7-4-8(14-2)5-9(12)10(7)11(13)15-6/h4-6,12H,3H2,1-2H3/t6-/m1/s1",6-Methoxymellein,CAS Registry Number,13410-15-6
489,2233,6-phospho-beta-D-glucosyl-(1->4)-beta-D-glucose,A 6-phospho-beta-D-glucosyl-(1->4)-D-glucose in which the anomeric centre at the reducing end has beta-configuration.,"InChI=1S/C12H23O14P/c13-1-3-10(7(16)8(17)11(19)24-3)26-12-9(18)6(15)5(14)4(25-12)2-23-27(20,21)22/h3-19H,1-2H2,(H2,20,21,22)/t3-,4-,5-,6+,7-,8-,9-,10-,11-,12+/m1/s1","6-Phospho-beta-D-glucosyl-(1,4)-D-glucose",KEGG COMPOUND accession,C04534
490,2247,"7,8-diaminononanoic acid","An amino fatty acid carrying amino substituents at positions 7 and 8. Some of its isomers are naturally occurring intermediates of biotin synthesis, and targets of antimicrobial and herbicide development.","InChI=1S/C9H20N2O2/c1-7(10)8(11)5-3-2-4-6-9(12)13/h7-8H,2-6,10-11H2,1H3,(H,12,13)","7,8-Diaminononanoate",KEGG COMPOUND accession,C01037
491,2268,7-hydroxyflavone,A hydroxyflavonoid in which the flavone nucleus is substituted at position 7 by a hydroxy group.,"InChI=1S/C15H10O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-9,16H",7-Hydroxyflavone,KEGG COMPOUND accession,C11264
492,2290,7alpha-hydroxy-5beta-cholestan-3-one,A 3-oxo-5beta-steroid that is 5beta-cholestan-3-one bearing an additional hydroxy substituent at position 7alpha .,"InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h17-19,21-25,29H,6-16H2,1-5H3/t18-,19+,21-,22+,23+,24-,25+,26+,27-/m1/s1",7alpha-Hydroxy-5beta-cholestan-3-one,KEGG COMPOUND accession,C05451
493,2301,"8-(1,1-dimethylallyl)kaempferide","A 7-hydroxyflavonol that is kaempferide substituted by a 1,1-dimethylallyl group at position 8.","InChI=1S/C21H20O6/c1-5-21(2,3)16-14(23)10-13(22)15-17(24)18(25)19(27-20(15)16)11-6-8-12(26-4)9-7-11/h5-10,22-23,25H,1H2,2-4H3","8-(1,1-DMA)kaempferide",KEGG COMPOUND accession,C11580
494,2317,8-epiiridodial lactol,A lactol that is (+)-iridodial lactol in which the configuration of the carbon at position 7 is inverted from S to R.,"InChI=1S/C10H16O2/c1-6-3-4-8-7(2)5-12-10(11)9(6)8/h5-6,8-11H,3-4H2,1-2H3/t6-,8-,9-,10-/m1/s1",8-Epiiridodial,KEGG COMPOUND accession,C11651
495,2380,acebutolol hydrochloride,"The hydrochloride salt of acebutolol, prepared using equimolar amounts of acebutolol and hydrogen chloride.","InChI=1S/C18H28N2O4.ClH/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3;/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23);1H",Acebutolol hydrochloride,KEGG COMPOUND accession,C07677
496,2394,acetochlor,A monocarboxylic acid amide that is N-phenylacetamide carrying an ethyl and a methyl group at positions 2 and 6 respectively on the benzene ring while one of the methyl hydrogens as well as the hydrogen attached to the nitrogen atom have been replaced by a chloro and an ethoxymethyl group respectively.,"InChI=1S/C14H20ClNO2/c1-4-12-8-6-7-11(3)14(12)16(10-18-5-2)13(17)9-15/h6-8H,4-5,9-10H2,1-3H3",Acetochlor,KEGG COMPOUND accession,C10925
497,2413,acetylblasticidin S,A member of the class of blasticidins that is blasticidin S in which the side-chain amino group is acetylated.,"InChI=1S/C19H28N8O6/c1-10(28)23-11(5-7-26(2)18(21)22)9-14(29)24-12-3-4-15(33-16(12)17(30)31)27-8-6-13(20)25-19(27)32/h3-4,6,8,11-12,15-16H,5,7,9H2,1-2H3,(H3,21,22)(H,23,28)(H,24,29)(H,30,31)(H2,20,25,32)/t11-,12-,15+,16-/m0/s1",Acetylblasticidin S,KEGG COMPOUND accession,C02808
498,2422,acetohydrazide,A carbohydrazide that is hydrazine in which one of the hydrogens is replaced by an acetyl group.,"InChI=1S/C2H6N2O/c1-2(5)4-3/h3H2,1H3,(H,4,5)",Acetylhydrazine,KEGG COMPOUND accession,C07447
499,3136,bixin,"A carotenoic acid that is the 6'-monomethyl ester of 9'-cis-6,6'-diapocarotene-6,6'-dioic acid.","InChI=1S/C25H30O4/c1-20(12-8-14-22(3)16-18-24(26)27)10-6-7-11-21(2)13-9-15-23(4)17-19-25(28)29-5/h6-19H,1-5H3,(H,26,27)/b7-6+,12-8+,13-9+,18-16+,19-17+,20-10+,21-11+,22-14+,23-15-",Bixin,CAS Registry Number,6983-79-5
500,3157,boschniakine,,"InChI=1S/C10H11NO/c1-7-2-3-9-8(6-12)4-11-5-10(7)9/h4-7H,2-3H2,1H3/t7-/m1/s1",Boschniakine,CAS Registry Number,18070-40-1
501,3170,brazilin,A organic heterotetracyclic compound that is a red pigment obtained from the wood of Caesalpinia echinata (Brazil-wood) or Caesalpinia sappan (sappan-wood).,"InChI=1S/C16H14O5/c17-9-1-2-10-14(4-9)21-7-16(20)6-8-3-12(18)13(19)5-11(8)15(10)16/h1-5,15,17-20H,6-7H2/t15-,16+/m0/s1",Brazilin,KEGG COMPOUND accession,C09920
502,3185,broussin,A hydroxyflavan that is (2S)-flavan substituted by a hydroxy group at position 7 and a methoxy group at position 4'.,"InChI=1S/C16H16O3/c1-18-14-7-3-11(4-8-14)15-9-5-12-2-6-13(17)10-16(12)19-15/h2-4,6-8,10,15,17H,5,9H2,1H3/t15-/m0/s1",7-Hydroxy-4'-methoxyflavan,KEGG COMPOUND accession,C09505
503,3205,buclizine,An N-alkylpiperazine carrying (4-chlorophenyl)(phenyl)methyl and 4-tert-butylbenzyl groups.,"InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3",Buclizine,KEGG COMPOUND accession,C07777
504,3545,cephapirin sodium,"The sodium salt of cephapirin. A first-generation cephalosporin antibiotic, it is effective against gram-negative and gram-positive organisms. Being more resistant to beta-lactamases than penicillins, it is effective agains most staphylococci, though not methicillin-resistant staphylococci.","InChI=1S/C17H17N3O6S2.Na/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11;/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25);/q;+1/p-1/t13-,16-;/m1./s1",Cephapirin sodium,CAS Registry Number,24356-60-3
505,3643,chlorphenesin carbamate,"The carbamate ester of the primary hydroxy group of chlorphenesin. A centrally acting skeletal muscle relaxant, it is used in the symptomatic treatment of painful muscle spasm.","InChI=1S/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)",Chlorphenesin carbamate,KEGG COMPOUND accession,C07930
506,3648,chlorpromazine N-oxide,An organochlorine compound that is chlorpromazine in which the acyclic tertiary amino group has been converted into the corresponding N-oxide.,"InChI=1S/C17H19ClN2OS/c1-20(2,21)11-5-10-19-14-6-3-4-7-16(14)22-17-9-8-13(18)12-15(17)19/h3-4,6-9,12H,5,10-11H2,1-2H3",Chlorpromazine N-oxide,KEGG COMPOUND accession,C10966
507,3651,chlorprothixene,,"InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3",Chlorprothixene,KEGG COMPOUND accession,C07953
508,957,"2,6-dinitrotoluene",A dinitrotoluene carrying nitro substituents at positions 2 and 6.,"InChI=1S/C7H6N2O4/c1-5-6(8(10)11)3-2-4-7(5)9(12)13/h2-4H,1H3","2,6-Dinitrotoluene",KEGG COMPOUND accession,C11008
509,4324,daphnoretin,"A member of the class of coumarins that is coumarin substituted by a hydroxy group at position 7, a methoxy group at position 6 and a (2-oxo-2H-chromen-7-yl)oxy group at position 3.","InChI=1S/C19H12O7/c1-23-16-6-11-7-17(19(22)26-15(11)9-13(16)20)24-12-4-2-10-3-5-18(21)25-14(10)8-12/h2-9,20H,1H3",Daphnoretin,CAS Registry Number,2034-69-7
510,4464,dexchlorpheniramine,,"InChI=1S/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1",Dexchlorpheniramine,KEGG COMPOUND accession,C06946
511,4518,dienestrol,"An olefinic compound that is hexa-2,4-diene substituted by 4-hydroxyphenyl groups at positions 3 and 4 respectively.","InChI=1S/C18H18O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h3-12,19-20H,1-2H3",Dienestrol,KEGG COMPOUND accession,C08090
512,4534,difenoxin,"A piperidinemonocarboxylic acid that is 4-phenylpiperidine-4-carboxylic acid in which the hydrogen attached to the nitrogen atom is substituted by a 3-cyano-3,3-diphenylpropyl group.","InChI=1S/C28H28N2O2/c29-22-28(24-12-6-2-7-13-24,25-14-8-3-9-15-25)18-21-30-19-16-27(17-20-30,26(31)32)23-10-4-1-5-11-23/h1-15H,16-21H2,(H,31,32)",Difenoxin,KEGG COMPOUND accession,C07871
513,9375,symphytine,"A but-2-enoate ester obtained by formal condensation of the carboxy group of (2E)-2-methylbut-2-enoic acid with the 1-hydroxy group of (1R,7aR)-7-({[(2S,3S)-2,3-dihydroxy-2-isopropylbutanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1H-pyrrolizin-1-ol.","InChI=1S/C20H31NO6/c1-6-13(4)18(23)27-16-8-10-21-9-7-15(17(16)21)11-26-19(24)20(25,12(2)3)14(5)22/h6-7,12,14,16-17,22,25H,8-11H2,1-5H3/b13-6+/t14-,16+,17+,20-/m0/s1",Symphytine,KEGG COMPOUND accession,C10409
514,9470,tetracenomycin C,,"InChI=1S/C23H20O11/c1-8-14-9(6-11(32-2)15(8)21(29)34-4)5-10-16(17(14)25)20(28)22(30)13(24)7-12(33-3)19(27)23(22,31)18(10)26/h5-7,19,25,27,30-31H,1-4H3/t19-,22-,23-/m1/s1",Tetracenomycin C,KEGG COMPOUND accession,C06801
515,9473,tetrachlorosalicylanilide,"A salicylanilide derivative where the hydrogens at positions 2, 3, 4 and 5 are substituted by chlorine.","InChI=1S/C13H7Cl4NO2/c14-8-7(12(19)11(17)10(16)9(8)15)13(20)18-6-4-2-1-3-5-6/h1-5,19H,(H,18,20)",Tetrachlorosalicylanilide,KEGG COMPOUND accession,C11274
516,9532,thiamine(1+) diphosphate,A thiamine phosphate that is thiamine(1+) in which the hydroxy group has been replaced by a diphosphate group. It is the active form of vitamin B1 and an essential cofactor for enzymes in key metabolic pathways.,"InChI=1S/C12H18N4O7P2S/c1-8-11(3-4-22-25(20,21)23-24(17,18)19)26-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7H,3-4,6H2,1-2H3,(H4-,13,14,15,17,18,19,20,21)/p+1",thiamin diphosphate,KEGG COMPOUND accession,C00068
517,9534,thiamine(1+) triphosphate,A thiamine phosphate that is thiamine(1+) in which the hydroxy group is replaced by a triphosphate group. It is found in low amounts in most vertebrate tissues and can phosphorylate certain proteins.,"InChI=1S/C12H19N4O10P3S/c1-8-11(30-7-16(8)6-10-5-14-9(2)15-12(10)13)3-4-24-28(20,21)26-29(22,23)25-27(17,18)19/h5,7H,3-4,6H2,1-2H3,(H5-,13,14,15,17,18,19,20,21,22,23)/p+1",thiamin triphosphate,FooDB accession,FDB022666
518,2425,achillin,"A sesquiterpene lactone that is (3R,3aS,9aS,9bS)-3,3a,4,5,9a,9b-hexahydroazuleno[4,5-b]furan-2,7-dione carrying three additional methyl substituents at positions 3, 6 and 9.","InChI=1S/C15H18O3/c1-7-4-5-10-9(3)15(17)18-14(10)13-8(2)6-11(16)12(7)13/h6,9-10,13-14H,4-5H2,1-3H3/t9-,10+,13+,14+/m1/s1",Achillin,KEGG COMPOUND accession,C09287
519,2431,acremoauxin A,An indolyl carboxylate ester obtained by formal condensation of one of the primary hydroxy groups of D-arabinitol with the carboxy group of (2R)-2-(indol-3-yl)propanoic acid.,"InChI=1S/C16H21NO6/c1-9(11-6-17-12-5-3-2-4-10(11)12)16(22)23-8-14(20)15(21)13(19)7-18/h2-6,9,13-15,17-21H,7-8H2,1H3/t9-,13-,14-,15-/m1/s1",Acremoauxin A,KEGG COMPOUND accession,C08468
520,2435,acronidine,"An organic heterotetracyclic compound that is 3H-furo[2,3-b]pyrano[3,2-f]quinoline carrying a gem-dimethyl group at position 3 as well as two methoxy substituents at positions 5 and 11.","InChI=1S/C18H17NO4/c1-18(2)7-5-10-14-12(9-13(20-3)15(10)23-18)19-17-11(6-8-22-17)16(14)21-4/h5-9H,1-4H3",Acronidine,CAS Registry Number,518-68-3
521,2436,acronycidine,"A quinoline alkaloid that is furo[2,3-b]quinoline bearing four methoxy substituents at positions 4, 5, 7 and 8.","InChI=1S/C15H15NO5/c1-17-9-7-10(18-2)14(20-4)12-11(9)13(19-3)8-5-6-21-15(8)16-12/h5-7H,1-4H3",Acronycidine,KEGG COMPOUND accession,C10631
522,6211,L-djenkolic acid,A dithioacetal consisting of two molecules of L-cysteine joined via their sulfanyl groups to methylene.,"InChI=1S/C7H14N2O4S2/c8-4(6(10)11)1-14-3-15-2-5(9)7(12)13/h4-5H,1-3,8-9H2,(H,10,11)(H,12,13)/t4-,5-/m0/s1",Djenkolic acid,KEGG COMPOUND accession,C08275
523,6220,alpha-L-fucose 1-phosphate,,"InChI=1S/C6H13O8P/c1-2-3(7)4(8)5(9)6(13-2)14-15(10,11)12/h2-9H,1H3,(H2,10,11,12)/t2-,3+,4+,5-,6-/m0/s1",L-Fuculose 1-phosphate,KEGG COMPOUND accession,C01099
524,6253,L-indospicine,"An  alpha-amino acid that is 2,7-diaminoheptanoic acid substituted by a imino group at position 7 (the 2S stereoisomer).","InChI=1S/C7H15N3O2/c8-5(7(11)12)3-1-2-4-6(9)10/h5H,1-4,8H2,(H3,9,10)(H,11,12)/t5-/m0/s1",Indospicine,CAS Registry Number,16377-00-7
525,6257,L-isoprenaline,An optically active phenylethanolamine compound having an isopropyl substituent attached to the nitrogen atom.,"InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3/t11-/m0/s1",L-Isoprenaline,CAS Registry Number,51-31-0
526,6307,L-tagatofuranose 6-phosphate,The furanose form of L-tagatose 6-phosphate.,"InChI=1S/C6H13O9P/c7-2-6(10)5(9)4(8)3(15-6)1-14-16(11,12)13/h3-5,7-10H,1-2H2,(H2,11,12,13)/t3-,4+,5+,6?/m0/s1",L-Tagatose 6-phosphate,CAS Registry Number,136598-66-8
527,6357,lactucaxanthin,"A tunaxanthin that consists of epsilon,epsilon-carotene bearing hydroxy substituents at positions 3 and 3' (the 3S,3'S,6S,6'S-diastereomer).","InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-26,35-38,41-42H,27-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-,37-,38-/m0/s1",Lactucaxanthin,CAS Registry Number,78306-12-4
528,6373,lancerin,"A C-glycosyl compound that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, and 7 and a 1,5-anhydro-D-glucitol moiety at position 1.","InChI=1S/C19H18O10/c20-5-11-15(25)16(26)17(27)19(29-11)13-9(23)4-8(22)12-14(24)7-3-6(21)1-2-10(7)28-18(12)13/h1-4,11,15-17,19-23,25-27H,5H2/t11-,15-,16+,17-,19+/m1/s1","4-C-Glucosyl-1,3,7-trihydroxyxanthone",CAS Registry Number,81991-99-3
529,6390,laurenobiolide,A germacranolide isolated from Laurus nobilis L. and which has been shown to exhibit allergenic activity.,"InChI=1S/C17H22O4/c1-10-6-5-7-11(2)9-15-16(12(3)17(19)21-15)14(8-10)20-13(4)18/h7-8,14-16H,3,5-6,9H2,1-2,4H3/b10-8+,11-7+/t14-,15?,16?/m0/s1",Laurenobiolide,KEGG COMPOUND accession,C09492
530,6408,lenthionine,,InChI=1S/C2H4S5/c1-3-4-2-6-7-5-1/h1-2H2,Lenthionine,CAS Registry Number,292-46-6
531,6415,Leu-Leu-Tyr,"A tripeptide composed of L-leucine, L-leucine and L-tyrosine joined in sequence by peptide linkages.","InChI=1S/C21H33N3O5/c1-12(2)9-16(22)19(26)23-17(10-13(3)4)20(27)24-18(21(28)29)11-14-5-7-15(25)8-6-14/h5-8,12-13,16-18,25H,9-11,22H2,1-4H3,(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1",leu-leu-tyr,KEGG COMPOUND accession,C11331
532,6437,levetiracetam,"A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.","InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1",Levetiracetam,KEGG COMPOUND accession,C07841
533,6446,levothyroxine sodium anhydrous,The sodium salt of L-thyroxine. It is used as replacement therapy in the treatment of hypothyroidism.,"InChI=1S/C15H11I4NO4.Na/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;/h1-2,4-5,12,21H,3,20H2,(H,22,23);/q;+1/p-1/t12-;/m0./s1",Levothyroxine sodium anhydrous,KEGG COMPOUND accession,C08212
534,7125,2-acetamido-2-deoxy-D-glucopyranose 1-phosphate,A N-acetyl-D-glucosamine 1-phosphate that is 2-deoxy-D-glucopyranose 1-(dihydrogen phosphate) substituted by an acetamido group at position 2.,"InChI=1S/C8H16NO9P/c1-3(11)9-5-7(13)6(12)4(2-10)17-8(5)18-19(14,15)16/h4-8,10,12-13H,2H2,1H3,(H,9,11)(H2,14,15,16)/t4-,5-,6-,7-,8?/m1/s1",N-Acetyl-D-glucosamine 1-phosphate,KEGG COMPOUND accession,C04256
535,6856,methyl caffeate,An alkyl caffeate ester formed by the formal condensation of caffeic acid with methyl alcohol.,"InChI=1S/C10H10O4/c1-14-10(13)5-3-7-2-4-8(11)9(12)6-7/h2-6,11-12H,1H3/b5-3+",Methyl caffeate,KEGG COMPOUND accession,C10477
536,6863,semustine,An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.,"InChI=1S/C10H18ClN3O2/c1-8-2-4-9(5-3-8)12-10(15)14(13-16)7-6-11/h8-9H,2-7H2,1H3,(H,12,15)",Methyl-CCNU,KEGG COMPOUND accession,C07640
537,7468,nandrolone phenpropionate,,"InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1",Nandrolone phenpropionate,CAS Registry Number,62-90-8
538,8233,piperacillin sodium,,"InChI=1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1",Piperacillin sodium,KEGG COMPOUND accession,C07361
539,8248,pirimicarb,"An aminopyrimidine that is N,N,4,5-tetramethylpyrimidin-2-amine substituted by a (dimethylcarbamoyl)oxy group at position 4.",InChI=1S/C11H18N4O2/c1-7-8(2)12-10(14(3)4)13-9(7)17-11(16)15(5)6/h1-6H3,Pirimicarb,CAS Registry Number,23103-98-2
540,10213,alpha-amyrin,A pentacyclic triterpenoid that is ursane which contains a double bond between positions 12 and 13 and in which the hydrogen at the 3beta position is substituted by a hydroxy group.,"InChI=1S/C30H50O/c1-19-11-14-27(5)17-18-29(7)21(25(27)20(19)2)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h9,19-20,22-25,31H,10-18H2,1-8H3/t19-,20+,22+,23-,24+,25+,27-,28+,29-,30-/m1/s1",alpha-Amyrin,KEGG COMPOUND accession,C08615
541,10217,cedrol,,"InChI=1S/C15H26O/c1-10-5-6-11-13(2,3)12-9-15(10,11)8-7-14(12,4)16/h10-12,16H,5-9H2,1-4H3/t10-,11+,12-,14-,15+/m1/s1",Cedrol,KEGG COMPOUND accession,C09631
542,10221,alpha-copaene,"A sesquiterpene that is tricyclo[4.4.0.0(2,7)]dec-3-ene bearing an isopropyl substituent at position 8 and two methyl substituents at positions 1 and 3 (the 1S,6S,7S,8S-diastereomer).","InChI=1S/C15H24/c1-9(2)11-7-8-15(4)12-6-5-10(3)14(15)13(11)12/h5,9,11-14H,6-8H2,1-4H3/t11-,12-,13-,14?,15-/m0/s1",alpha-Copaene,KEGG COMPOUND accession,C09639
543,10275,"(9Z,11E,13E)-octadeca-9,11,13-trienoic acid","A conjugated linolenic acid having three fully-conjugated double bonds at positions 9, 11 and 13, in cis, trans and trans configurations, respectively.","InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h5-10H,2-4,11-17H2,1H3,(H,19,20)/b6-5+,8-7+,10-9-",alpha-Eleostearic acid,KEGG COMPOUND accession,C08315
544,10278,alpha-eudesmol,A eudesmane sesquiterpenoid in which the eudesmane skeleton carries a hydroxy substituent at C-11 and has a double bond between C-3 and C-4.,"InChI=1S/C15H26O/c1-11-6-5-8-15(4)9-7-12(10-13(11)15)14(2,3)16/h6,12-13,16H,5,7-10H2,1-4H3/t12-,13+,15-/m1/s1",alpha-Eudesmol,CAS Registry Number,473-16-5
545,10284,alpha-irone,A methyl ketone that is alpha-ionone in which a hydrogen at position 5 of the cyclohex-2-en-1-yl ring is substituted by a methyl group.,"InChI=1S/C14H22O/c1-10-6-7-11(2)14(4,5)13(10)9-8-12(3)15/h6,8-9,11,13H,7H2,1-5H3/b9-8+",alpha-Irone,KEGG COMPOUND accession,C09690
546,10295,alpha-L-sorbopyranose,,"InChI=1S/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4+,5-,6+/m0/s1",alpha-L-Sorbopyranose,KEGG COMPOUND accession,C08356
547,10352,beta-amyrin,A pentacyclic triterpenoid that is oleanane substituted at the 3beta-position by a hydroxy group and containing a double bond between positions 12 and 13. It is one of the most commonly occurring triterpenoids in higher plants.,"InChI=1S/C30H50O/c1-25(2)15-16-27(5)17-18-29(7)20(21(27)19-25)9-10-23-28(6)13-12-24(31)26(3,4)22(28)11-14-30(23,29)8/h9,21-24,31H,10-19H2,1-8H3/t21-,22-,23+,24-,27+,28-,29+,30+/m0/s1",beta-Amyrin,KEGG COMPOUND accession,C08616
548,10359,(-)-beta-chamigrene,The (6R)-enantiomer of beta-chamigrene.,"InChI=1S/C15H24/c1-12-7-10-15(11-8-12)13(2)6-5-9-14(15,3)4/h7H,2,5-6,8-11H2,1,3-4H3/t15-/m1/s1",beta-Chamigrene,KEGG COMPOUND accession,C09637
549,10362,beta-cryptoxanthin,A carotenol that exhibits antioxidant activity. It has been isolated from fruits such as papaya and oranges.,"InChI=1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,36,41H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-/m1/s1",beta-Cryptoxanthin,KEGG COMPOUND accession,C08591
550,10365,"(5S)-3-acetyl-4-hydroxy-5-{[4-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}-1,5-dihydro-2H-pyrrol-2-one",,"InChI=1S/C20H22N2O3/c1-11(2)7-8-13-5-4-6-15-18(13)14(10-21-15)9-16-19(24)17(12(3)23)20(25)22-16/h4-7,10,16,21,24H,8-9H2,1-3H3,(H,22,25)/t16-/m0/s1",beta-Cyclopiazonate,KEGG COMPOUND accession,C02899
551,10366,D-cymarose,,"InChI=1S/C7H14O4/c1-5(9)7(10)6(11-2)3-4-8/h4-7,9-10H,3H2,1-2H3/t5-,6+,7-/m1/s1",D-Cymarose,KEGG COMPOUND accession,C08234
552,7497,nelfinavir mesylate,A methanesulfonate (mesylate) salt prepared from equimolar amounts of nelfinavir and methanesulfonic acid. It is used for treatment of HIV and also exhibits some anticancer properties.,"InChI=1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1",Nelfinavir mesilate,KEGG COMPOUND accession,C08091
553,8410,primetin,A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 5 and 8.,"InChI=1S/C15H10O4/c16-10-6-7-11(17)15-14(10)12(18)8-13(19-15)9-4-2-1-3-5-9/h1-8,16-17H","5,8-Dihydroxyflavone",CAS Registry Number,548-58-3
554,8412,primidone,"A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an  anticonvulsant for treatment of various types of seizures.","InChI=1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)","5-Phenyl-5-ethyl-Hexahydropyrimidine-4,6-dione",KEGG COMPOUND accession,C07371
555,8413,primin,"A 1,4-benzoquinone having a methoxy substituent at the 2-position and a pentyl substituent at the 6-position.","InChI=1S/C12H16O3/c1-3-4-5-6-9-7-10(13)8-11(15-2)12(9)14/h7-8H,3-6H2,1-2H3",Primin,KEGG COMPOUND accession,C10390
556,1774,(E)-4-(trimethylammonio)but-2-enoic acid,A 4-(trimethylammonio)but-2-enoic acid with a (E)-configuration at the double bond.,"InChI=1S/C7H13NO2/c1-8(2,3)6-4-5-7(9)10/h4-5H,6H2,1-3H3/p+1/b5-4+",4-(Trimethylammonio)but-2-enoate,KEGG COMPOUND accession,C04114
557,2691,isoamyl nitrite,A nitrite ester having isopentyl as the alkyl group.,"InChI=1S/C5H11NO2/c1-5(2)3-4-8-6-7/h5H,3-4H2,1-2H3",Isoamyl nitrite,KEGG COMPOUND accession,C07457
558,433,"[3-(3,4-methylenedioxyphenyl)-2-(mercaptomethyl)-1-oxoprolyl]alanine",A dipeptide consisting of a modified L-proline residue attached to L-alanine via a peptide linkage.,"InChI=1S/C16H20N2O6S/c1-8(16(20)21)17-15(19)11-5-10(12(6-25)18(11)22)9-2-3-13-14(4-9)24-7-23-13/h2-4,8,10-12,22,25H,5-7H2,1H3,(H,17,19)(H,20,21)/t8-,10?,11-,12?/m0/s1","(S)-N-[3-(3,4-Methylenedioxyphenyl)-2-(mercaptomethyl)-1-oxoprolyl]-(S)-alanine",KEGG COMPOUND accession,C01314
559,1107,2-hexaprenyl-6-hydroxyphenol,"A member of the class of  catechols that is benzene-1,2-diol substituted by a (all-trans)-hexaprenyl group at position 3.","InChI=1S/C36H54O2/c1-28(2)14-8-15-29(3)16-9-17-30(4)18-10-19-31(5)20-11-21-32(6)22-12-23-33(7)26-27-34-24-13-25-35(37)36(34)38/h13-14,16,18,20,22,24-26,37-38H,8-12,15,17,19,21,23,27H2,1-7H3/b29-16+,30-18+,31-20+,32-22+,33-26+",2-Hexaprenyl-6-hydroxyphenol,KEGG COMPOUND accession,C05801
560,1010,2-amino-5-oxohexanoate,An alpha-amino-acid anion that is the conjugate base of 2-amino-5-oxohexanoic acid.,"InChI=1S/C6H11NO3/c1-4(8)2-3-5(7)6(9)10/h5H,2-3,7H2,1H3,(H,9,10)/p-1",2-Amino-5-oxohexanoate,KEGG COMPOUND accession,C05825
561,1019,N-(2-phosphonoethyl)cholamide,The N-(2-phosphoethyl0amide of cholic acid.,"InChI=1S/C26H46NO7P/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-22,24,28-30H,4-14H2,1-3H3,(H,27,31)(H2,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,22+,24+,25+,26-/m1/s1",2-Aminoethylphosphocholate,KEGG COMPOUND accession,C05683
562,1060,2-dehydro-3-deoxy-D-arabinonic acid,A 2-oxo monocarboxylic acid that is 2-oxopentanoic acid which is substituted at positions 4 and 5 by hydroxy groups (the 4S-enantiomer).,"InChI=1S/C5H8O5/c6-2-3(7)1-4(8)5(9)10/h3,6-7H,1-2H2,(H,9,10)/t3-/m0/s1",2-Dehydro-3-deoxy-D-xylonate,KEGG COMPOUND accession,C03826
563,1904,4-methylumbelliferone beta-D-glucuronide,"A beta-D-glucosiduronic acid having a 4-methylumbelliferyl substituent at the anomeric position. A hyaluronan synthesis inhibitor, it is  anti-tumourigenic for various malignant tumours.","InChI=1S/C16H16O9/c1-6-4-10(17)24-9-5-7(2-3-8(6)9)23-16-13(20)11(18)12(19)14(25-16)15(21)22/h2-5,11-14,16,18-20H,1H3,(H,21,22)/t11-,12-,13+,14-,16+/m0/s1",4-Methylumbelliferone glucuronide,KEGG COMPOUND accession,C11584
564,1949,4alpha-methylzymosterol,A 3beta-sterol that is  zymosterol substituted by a 4alpha-methyl group.,"InChI=1S/C28H46O/c1-18(2)8-7-9-19(3)22-12-13-24-21-10-11-23-20(4)26(29)15-17-28(23,6)25(21)14-16-27(22,24)5/h8,19-20,22-24,26,29H,7,9-17H2,1-6H3/t19-,20+,22-,23+,24+,26+,27-,28+/m1/s1",4alpha-Methylzymosterol,KEGG COMPOUND accession,C05103
565,5520,gonadorelin,"A ten-membered synthetic oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, glycyl, leucyl, arginyl, prolyl and glycinamide residues joined in sequence.","InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)/t36-,37-,38-,39-,40-,41-,42-,43-/m0/s1",GnRH-I,KEGG COMPOUND accession,C07607
566,5525,gossypin,A glycosyloxyflavone that is  gossypetin attached to a beta-D-glucopyranosyl residue at position 8 via a glycosidic linkage.,"InChI=1S/C21H20O13/c22-5-11-13(27)15(29)17(31)21(32-11)34-19-10(26)4-9(25)12-14(28)16(30)18(33-20(12)19)6-1-2-7(23)8(24)3-6/h1-4,11,13,15,17,21-27,29-31H,5H2/t11-,13-,15+,17-,21+/m1/s1",Gossypetin 8-O-glucoside,KEGG COMPOUND accession,C10051
567,5533,granaticin,,"InChI=1S/C22H20O10/c1-5-11-15(21-8(30-5)4-10(24)32-21)19(27)13-14(17(11)25)20(28)16-12(18(13)26)7-3-9(23)22(16,29)6(2)31-7/h5-9,21,23,26,28-29H,3-4H2,1-2H3/t5?,6-,7-,8+,9-,21-,22-/m1/s1",Granaticin,CAS Registry Number,19879-06-2
568,5542,grayanotoxin I,"A tetracyclic diterpenoid that is grayanotoxane in which the pro-R hydrogen at position 14 is substituted by an acetoxy group and in which the 3beta-, 5-, 6beta-, 10-, and 16- positions are substituted by hydroxy groups.","InChI=1S/C22H36O7/c1-11(23)29-17-12-6-7-13-20(5,27)14-8-15(24)18(2,3)22(14,28)16(25)9-21(13,17)10-19(12,4)26/h12-17,24-28H,6-10H2,1-5H3/t12-,13+,14+,15+,16-,17-,19-,20-,21+,22+/m1/s1",Grayanotoxin I,KEGG COMPOUND accession,C09103
569,5550,guaiazulene,,"InChI=1S/C15H18/c1-10(2)13-7-5-11(3)14-8-6-12(4)15(14)9-13/h5-10H,1-4H3",Guaiazulene,CAS Registry Number,489-84-9
570,5568,guattegaumerine,"An aromatic ether resulting from oxidative dimerisation between the 4-hydroxy group of one molecule of (1R)-1-(4-hydroxybenzyl)-6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol and the 3-position of the 4-hydroxybenzyl group of another.","InChI=1S/C36H40N2O6/c1-37-13-11-24-18-34(42-3)32(40)20-27(24)29(37)15-22-5-8-26(9-6-22)44-36-17-23(7-10-31(36)39)16-30-28-21-33(41)35(43-4)19-25(28)12-14-38(30)2/h5-10,17-21,29-30,39-41H,11-16H2,1-4H3/t29-,30-/m1/s1",Guattegaumerine,KEGG COMPOUND accession,C06511
571,5583,gyromitrin,,"InChI=1S/C4H8N2O/c1-3-5-6(2)4-7/h3-4H,1-2H3",Gyromitrin,KEGG COMPOUND accession,C08305
572,5674,herbimycin,A 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It is an ansamycin antibiotic that induces apoptosis and displays antitumour effects.,"InChI=1S/C30H42N2O9/c1-16-10-9-11-23(37-5)28(41-30(31)36)18(3)12-17(2)27(40-8)24(38-6)13-19(4)26(39-7)21-14-20(33)15-22(25(21)34)32-29(16)35/h9-12,14-15,17,19,23-24,26-28H,13H2,1-8H3,(H2,31,36)(H,32,35)/b11-9-,16-10+,18-12+/t17-,19-,23-,24-,26+,27+,28-/m0/s1",Herbimycin A,KEGG COMPOUND accession,C11225
573,5683,hetacillin,,"InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1",Hetacillin,KEGG COMPOUND accession,C11729
574,5719,himachalol,,"InChI=1S/C15H26O/c1-11-6-7-12-13(10-11)14(2,3)8-5-9-15(12,4)16/h10,12-13,16H,5-9H2,1-4H3/t12-,13+,15-/m1/s1",Himachalol,KEGG COMPOUND accession,C09682
575,5729,His-Leu,A dipeptide formed from L-histidine and L-leucine residues.,"InChI=1S/C12H20N4O3/c1-7(2)3-10(12(18)19)16-11(17)9(13)4-8-5-14-6-15-8/h5-7,9-10H,3-4,13H2,1-2H3,(H,14,15)(H,16,17)(H,18,19)/t9-,10-/m0/s1",His-Leu,KEGG COMPOUND accession,C05010
576,2450,aculeacin A,A lipopeptide that is isolated from Aspergillus aculeatus and exhibits antifungal activity.,"InChI=1S/C51H82N8O17/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-37(66)53-32-23-35(64)47(72)57-49(74)41-42(67)27(2)25-59(41)51(76)39(34(63)24-36(52)65)55-48(73)40(44(69)43(68)29-18-20-30(61)21-19-29)56-46(71)33-22-31(62)26-58(33)50(75)38(28(3)60)54-45(32)70/h18-21,27-28,31-35,38-44,47,60-64,67-69,72H,4-17,22-26H2,1-3H3,(H2,52,65)(H,53,66)(H,54,70)(H,55,73)(H,56,71)(H,57,74)/t27-,28+,31+,32-,33-,34+,35+,38-,39-,40-,41-,42-,43-,44-,47+/m0/s1",Aculeacin A,KEGG COMPOUND accession,C01776
577,2480,adenosylcobinamide,A cobalt-corrinoid hexaamide comprising cobinamide having an adenosyl group attached to cobalt.,"InChI=1S/C48H73N11O8.C10H12N5O3.Co/c1-23(60)22-55-38(67)16-17-45(6)29(18-35(52)64)43-48(9)47(8,21-37(54)66)28(12-15-34(51)63)40(59-48)25(3)42-46(7,20-36(53)65)26(10-13-32(49)61)30(56-42)19-31-44(4,5)27(11-14-33(50)62)39(57-31)24(2)41(45)58-43;1-4-6(16)7(17)10(18-4)15-3-14-5-8(11)12-2-13-9(5)15;/h19,23,26-29,43,60H,10-18,20-22H2,1-9H3,(H14,49,50,51,52,53,54,55,56,57,58,59,61,62,63,64,65,66,67);2-4,6-7,10,16-17H,1H2,(H2,11,12,13);/q;;+2/p-1/t23-,26-,27-,28-,29+,43-,45-,46+,47+,48+;4-,6-,7-,10-;/m11./s1",Adenosyl cobinamide,KEGG COMPOUND accession,C06508
578,2483,adenosylcobyric acid,A cobalt corrinoid that is cobyric acid having a 5'-adenosyl group attached to the central cobalt atom.,"InChI=1S/C45H66N10O8.C10H12N5O3.Co/c1-21-36-24(10-13-30(47)57)41(3,4)28(53-36)18-27-23(9-12-29(46)56)43(6,19-33(50)60)39(52-27)22(2)37-25(11-14-31(48)58)44(7,20-34(51)61)45(8,55-37)40-26(17-32(49)59)42(5,38(21)54-40)16-15-35(62)63;1-4-6(16)7(17)10(18-4)15-3-14-5-8(11)12-2-13-9(5)15;/h18,23-26,40H,9-17,19-20H2,1-8H3,(H14,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63);2-4,6-7,10,16-17H,1H2,(H2,11,12,13);/q;;+2/p-1/t23-,24-,25-,26+,40-,42-,43+,44+,45+;4-,6-,7-,10-;/m11./s1",Adenosyl cobyrinate hexaamide,KEGG COMPOUND accession,C06507
579,2507,afzelechin,"A tetrahydroxyflavan that is  (2S)-flavan substituted by hydroxy groups at positions 3, 5, 7 and 4' respectively.","InChI=1S/C15H14O5/c16-9-3-1-8(2-4-9)15-13(19)7-11-12(18)5-10(17)6-14(11)20-15/h1-6,13,15-19H,7H2/t13-,15+/m0/s1","3,5,7,4'-Tetrahydroxyflavan",KEGG COMPOUND accession,C09320
580,2513,agavoside A,A steroid saponin that consists of (25R)-5alpha-spirostan-3beta-ol substituted by an oxo group at position 12 and a  beta-D-galactopyranosyl moiety at position 3 via a glycosidic linkage.,"InChI=1S/C33H52O9/c1-16-7-10-33(39-15-16)17(2)26-23(42-33)12-22-20-6-5-18-11-19(40-30-29(38)28(37)27(36)24(14-34)41-30)8-9-31(18,3)21(20)13-25(35)32(22,26)4/h16-24,26-30,34,36-38H,5-15H2,1-4H3/t16-,17+,18+,19+,20-,21+,22+,23+,24-,26+,27+,28+,29-,30-,31+,32-,33-/m1/s1",Agavoside A,CAS Registry Number,56857-65-9
581,2523,ajaconine,,"InChI=1S/C22H33NO3/c1-13-14-4-7-22(18(13)25)16(10-14)21-6-3-5-20(2)12-23(8-9-24)19(21)26-17(22)11-15(20)21/h14-19,24-25H,1,3-12H2,2H3/t14-,15+,16-,17+,18+,19?,20-,21-,22+/m0/s1",Ajaconine,CAS Registry Number,545-61-9
582,2538,alangiside,An organic heterotetracyclic compound that is an alkaloidal glycoside isolated from Alangium salviifolium.,"InChI=1S/C25H31NO10/c1-3-12-14-7-16-13-8-17(28)18(33-2)6-11(13)4-5-26(16)23(32)15(14)10-34-24(12)36-25-22(31)21(30)20(29)19(9-27)35-25/h3,6,8,10,12,14,16,19-22,24-25,27-31H,1,4-5,7,9H2,2H3/t12?,14-,16-,19-,20-,21+,22-,24+,25+/m1/s1",Alangiside,CAS Registry Number,34482-51-4
583,2619,amantadine hydrochloride,A hydrochloride obtained by combining amantadine and hydrochloric acid in equimolar amounts.,"InChI=1S/C10H17N.ClH/c11-10-4-7-1-8(5-10)3-9(2-7)6-10;/h7-9H,1-6,11H2;1H",Amantadine hydrochloride,KEGG COMPOUND accession,C07939
584,2623,amaryllisine,"An isoquinoline alkaloid that is 3,4,4a,5,6,10b-hexahydro-5,10b-ethanophenanthridin-9-ol bearing three additional methoxy substituents at positions 3, 7 and 8.","InChI=1S/C18H23NO4/c1-21-11-4-5-18-6-7-19(15(18)8-11)10-12-13(18)9-14(20)17(23-3)16(12)22-2/h4-5,9,11,15,20H,6-8,10H2,1-3H3/t11-,15-,18+/m0/s1",Amaryllisine,KEGG COMPOUND accession,C08516
585,2627,ambenonium,A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.,"InChI=1S/C28H40Cl2N4O2/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30/h9-16H,5-8,17-22H2,1-4H3/p+2",Ambenonium,KEGG COMPOUND accession,C07773
586,2630,hydramethylnon,A member of the class of hydrazones that is used as an insecticide for control of ants and cockroaches.,"InChI=1S/C25H24F6N4/c1-23(2)15-32-22(33-16-23)35-34-21(13-7-17-3-9-19(10-4-17)24(26,27)28)14-8-18-5-11-20(12-6-18)25(29,30)31/h3-14H,15-16H2,1-2H3,(H2,32,33,35)",Hydramethylnon,KEGG COMPOUND accession,C10994
587,2653,aminocarb,A carbamate ester that is phenyl methylcarbamate substituted by a dimethylamino group at position 4 and a methyl group at position 3.,"InChI=1S/C11H16N2O2/c1-8-7-9(15-11(14)12-2)5-6-10(8)13(3)4/h5-7H,1-4H3,(H,12,14)",Aminocarb,KEGG COMPOUND accession,C11071
588,3790,cobalt-precorrin-2,,"InChI=1S/C42H47N4O16.Co/c1-41(17-39(59)60)23(5-9-35(51)52)29-14-27-21(11-37(55)56)19(3-7-33(47)48)25(43-27)13-26-20(4-8-34(49)50)22(12-38(57)58)28(44-26)15-31-42(2,18-40(61)62)24(6-10-36(53)54)30(46-31)16-32(41)45-29;/h14-16,21,23-24H,3-13,17-18H2,1-2H3,(H9,43,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62);/q-1;+2/p-1/b31-15-;/t21?,23-,24-,41+,42+;/m1./s1",Cobalt-precorrin 2,KEGG COMPOUND accession,C11538
589,3791,cobalt-precorrin-3,,"InChI=1S/C43H49N4O16.Co/c1-19-40-23(13-37(58)59)21(5-9-33(50)51)27(46-40)14-26-20(4-8-32(48)49)22(12-36(56)57)28(44-26)15-29-24(6-10-34(52)53)42(2,17-38(60)61)31(45-29)16-30-25(7-11-35(54)55)43(3,18-39(62)63)41(19)47-30;/h15-16,22,24-25H,4-14,17-18H2,1-3H3,(H9,44,45,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63);/q-1;+2/p-1/b41-19-;/t22?,24-,25-,42+,43+;/m1./s1",Cobalt-precorrin 3,KEGG COMPOUND accession,C11539
590,3792,cobalt-precorrin-4,,"InChI=1S/C44H51N4O16.Co/c1-20-44-40-25(14-37(59)60)41(2,12-11-35(55)56)30(47-40)16-27-21(5-8-32(49)50)22(13-36(57)58)26(45-27)15-28-23(6-9-33(51)52)42(3,18-38(61)62)31(46-28)17-29(48-44)24(7-10-34(53)54)43(44,4)19-39(63)64-20;/h15,17,20,23-24H,5-14,16,18-19H2,1-4H3,(H8,46,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62);/q-1;+2/p-1/b28-15-;/t20?,23-,24-,41-,42+,43+,44?;/m1./s1",Cobalt-precorrin 4,KEGG COMPOUND accession,C11540
591,1156,2-hydroxyestrone,A 2-hydroxy steroid that is estrone substituted by a hydroxy group at position 2.,"InChI=1S/C18H22O3/c1-18-7-6-11-12(14(18)4-5-17(18)21)3-2-10-8-15(19)16(20)9-13(10)11/h8-9,11-12,14,19-20H,2-7H2,1H3/t11-,12+,14-,18-/m0/s1",2-Hydroxyestrone,KEGG COMPOUND accession,C05298
592,3684,"chrysin 5,7-dimethyl ether","A dimethoxyflavone that is the  5,7-dimethyl ether derivative of chrysin.","InChI=1S/C17H14O4/c1-19-12-8-15(20-2)17-13(18)10-14(21-16(17)9-12)11-6-4-3-5-7-11/h3-10H,1-2H3","5,7-Dimethoxyflavone",CAS Registry Number,21392-57-4
593,3707,cinerin II,,"InChI=1S/C21H28O5/c1-7-8-9-14-13(3)17(11-16(14)22)26-20(24)18-15(21(18,4)5)10-12(2)19(23)25-6/h7-8,10,15,17-18H,9,11H2,1-6H3/b8-7-,12-10+/t15-,17+,18+/m1/s1",Cinerin II,KEGG COMPOUND accession,C09846
594,4734,"5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)-1,3-benzothiazol-6-yl hydrogen sulfate","An aryl sulfate obtained by sulfation of the phenolic hydroxy group of the anti-inflammatory drug, E3040. It is one of the major metabolites of E3040.","InChI=1S/C16H17N3O4S2/c1-9-12(7-11-5-4-6-18-8-11)13-15(24-16(17-3)19-13)10(2)14(9)23-25(20,21)22/h4-6,8H,7H2,1-3H3,(H,17,19)(H,20,21,22)",E3040 sulfate,KEGG COMPOUND accession,C11594
595,4768,elatine,A diterpene alkaloid isolated from Delphinium shawurense.,"InChI=1S/C38H50N2O10/c1-7-39-17-35(18-48-33(43)21-10-8-9-11-24(21)40-27(41)14-20(2)32(40)42)13-12-26(45-4)37-23-15-22-25(44-3)16-36(28(23)29(22)46-5)38(34(37)39,50-19-49-36)31(47-6)30(35)37/h8-11,20,22-23,25-26,28-31,34H,7,12-19H2,1-6H3/t20?,22-,23-,25+,26+,28-,29+,30-,31+,34?,35+,36-,37+,38-/m1/s1",Elatine,KEGG COMPOUND accession,C08681
596,4780,emetamine,A pyridoisoquinoline consisting of emetine having a fully aromatised isoquinoline.,"InChI=1S/C29H36N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h7,9,13-16,18,21,25H,6,8,10-12,17H2,1-5H3/t18-,21-,25-/m0/s1",Emetamine,CAS Registry Number,483-19-2
597,4581,"7,8-dihydropteroic acid","A pteroic acid derivative arising from formal hydrogenation of the 7,8-double bond of pteroic acid.","InChI=1S/C14H14N6O3/c15-14-19-11-10(12(21)20-14)18-9(6-17-11)5-16-8-3-1-7(2-4-8)13(22)23/h1-4,16H,5-6H2,(H,22,23)(H4,15,17,19,20,21)",Dihydropteroate,KEGG COMPOUND accession,C00921
598,4591,dihydrotachysterol,"A hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent.","InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1",Dihydrotachysterol,KEGG COMPOUND accession,C06957
599,4676,dodecanedioic acid,"An alpha,omega-dicarboxylic acid that is dodecane in which the methyl groups have been oxidised to the corresponding carboxylic acids.","InChI=1S/C12H22O4/c13-11(14)9-7-5-3-1-2-4-6-8-10-12(15)16/h1-10H2,(H,13,14)(H,15,16)",Dodecanedioic acid,KEGG COMPOUND accession,C02678
600,5837,hypolaetin,A pentahydroxyflavone that consists of luteolin substituted by an additional hydroxy group at position 8.,"InChI=1S/C15H10O7/c16-7-2-1-6(3-8(7)17)12-5-10(19)13-9(18)4-11(20)14(21)15(13)22-12/h1-5,16-18,20-21H",Hypolaetin,KEGG COMPOUND accession,C10078
601,5852,ibogaine,An organic heteropentacyclic compound that is ibogamine in which the indole hydrogen para to the indole nitrogen has been replaced by a methoxy group.,"InChI=1S/C20H26N2O/c1-3-13-8-12-9-17-19-15(6-7-22(11-12)20(13)17)16-10-14(23-2)4-5-18(16)21-19/h4-5,10,12-13,17,20-21H,3,6-9,11H2,1-2H3/t12-,13+,17+,20+/m1/s1",Ibogaine,KEGG COMPOUND accession,C09214
602,5882,imipramine hydrochloride,,"InChI=1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21;/h3-6,8-11H,7,12-15H2,1-2H3;1H",Imipramine hydrochloride,KEGG COMPOUND accession,C07982
603,10417,beta-eudesmol,"A carbobicyclic compound that is trans-decalin substituted at positions 2, 4a, and 8 by 2-hydroxypropan-2-yl, methyl and methylidene groups, respectively (the 2R,4aR,8aS-diastereoisomer).","InChI=1S/C15H26O/c1-11-6-5-8-15(4)9-7-12(10-13(11)15)14(2,3)16/h12-13,16H,1,5-10H2,2-4H3/t12-,13+,15-/m1/s1",beta-Eudesmol,KEGG COMPOUND accession,C09664
604,10423,oleandrose,,"InChI=1S/C7H14O4/c1-5(9)7(10)6(11-2)3-4-8/h4-7,9-10H,3H2,1-2H3/t5-,6-,7-/m0/s1",Oleandrose,CAS Registry Number,6786-76-1
605,10441,beta-santalol,,"InChI=1S/C15H24O/c1-11(10-16)5-4-8-15(3)12(2)13-6-7-14(15)9-13/h5,13-14,16H,2,4,6-10H2,1,3H3/b11-5-/t13-,14+,15+/m1/s1",beta-Santalol,CAS Registry Number,77-42-9
606,10443,(+)-beta-selinene,"An optically active form of beta-selinene having (+)-(4aR,7R,8aS)-configuration.","InChI=1S/C15H24/c1-11(2)13-7-9-15(4)8-5-6-12(3)14(15)10-13/h13-14H,1,3,5-10H2,2,4H3/t13-,14+,15-/m1/s1",beta-Selinene,KEGG COMPOUND accession,C09723
607,10556,(-)-trans-epsilon-viniferin,"A stilbenoid that is the (-)-trans-stereoisomer of epsilon-viniferin, obtained by cyclodimerisation of trans-resveratrol.","InChI=1S/C28H22O6/c29-20-7-2-16(3-8-20)1-4-18-11-24(33)15-25-26(18)27(19-12-22(31)14-23(32)13-19)28(34-25)17-5-9-21(30)10-6-17/h1-15,27-33H/b4-1+/t27-,28+/m1/s1",epsilon-Viniferin,KEGG COMPOUND accession,C10289
608,10586,3-carboxyphenyl phenylacetamidomethylphosphonate,An organic 3-carboxyphenyl phosphonate monoester.,"InChI=1S/C16H16NO6P/c18-15(9-12-5-2-1-3-6-12)17-11-24(21,22)23-14-8-4-7-13(10-14)16(19)20/h1-8,10H,9,11H2,(H,17,18)(H,19,20)(H,21,22)",m-Carboxyphenyl phenylacetamidomethylphosphonate,KEGG COMPOUND accession,C04684
609,3793,cobalt-precorrin-5,,"InChI=1S/C45H54N4O16.Co/c1-21-45-40-26(15-37(60)61)41(2,13-12-35(56)57)30(47-40)16-27-22(6-9-32(50)51)25(14-36(58)59)44(5,48-27)18-29-23(7-10-33(52)53)42(3,19-38(62)63)31(46-29)17-28(49-45)24(8-11-34(54)55)43(45,4)20-39(64)65-21;/h16-17,21,24,26H,6-15,18-20H2,1-5H3,(H8,46,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63);/q;+1/p-1/b30-16-;/t21?,24-,26?,41-,42+,43+,44+,45?;/m1./s1",Cobalt-precorrin 5,KEGG COMPOUND accession,C11541
610,3795,cobalt-precorrin-8,A cobalt corrinoid that is precorrin-8 in which the four pyrrole-type nitrogens are bound to a central cobalt atom.,"InChI=1S/C45H60N4O14.Co/c1-21-36-24(9-12-29(50)51)23(3)44(7,48-36)18-28-25(10-13-30(52)53)42(5,19-34(60)61)39(46-28)22(2)37-26(11-14-31(54)55)43(6,20-35(62)63)45(8,49-37)40-27(17-33(58)59)41(4,38(21)47-40)16-15-32(56)57;/h21,26-27,40H,9-20H2,1-8H3,(H8,46,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63);/q;+1/p-1/t21?,26-,27+,40-,41-,42+,43+,44+,45+;/m1./s1",Cobalt-precorrin 8,KEGG COMPOUND accession,C11545
611,3796,cobamide,A cobalt-corrinoid hexaamide that is the parent compound of the class of cobamides.,"InChI=1S/C53H82N11O15P.Co/c1-24(78-80(75,76)79-44-32(23-65)77-48(74)43(44)73)22-60-40(72)16-17-50(6)30(18-37(57)69)47-53(9)52(8,21-39(59)71)29(12-15-36(56)68)42(64-53)26(3)46-51(7,20-38(58)70)27(10-13-34(54)66)31(61-46)19-33-49(4,5)28(11-14-35(55)67)41(62-33)25(2)45(50)63-47;/h19,24,27-30,32,43-44,47-48,65,73-74H,10-18,20-23H2,1-9H3,(H15,54,55,56,57,58,59,60,61,62,63,64,66,67,68,69,70,71,72,75,76);/q;+1/p-1/t24-,27-,28-,29-,30+,32-,43-,44-,47-,48+,50-,51+,52+,53+;/m1./s1",Cobamide,CAS Registry Number,14709-02-5
612,6472,lincomycin,A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.,"InChI=1S/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1",Lincomycin,CAS Registry Number,154-21-2
613,6553,lucenin-2,A C-glycosyl compound that is luteolin substituted by beta-D-glucopyranosyl moieties at positions 6 and 8 respectively.,"InChI=1S/C27H30O16/c28-5-12-17(33)21(37)23(39)26(42-12)15-19(35)14-10(32)4-11(7-1-2-8(30)9(31)3-7)41-25(14)16(20(15)36)27-24(40)22(38)18(34)13(6-29)43-27/h1-4,12-13,17-18,21-24,26-31,33-40H,5-6H2/t12-,13-,17-,18-,21+,22+,23-,24-,26+,27+/m1/s1",Lucenin-2,CAS Registry Number,29428-58-8
614,6556,lucidine B,,"InChI=1S/C30H49N3O/c1-18-11-22-16-28-25(23-15-27(22)29(12-18)32(4)17-23)8-7-24(31-28)14-21-10-19(2)13-30-26(21)6-5-9-33(30)20(3)34/h18-19,21-27,29-30H,5-17H2,1-4H3/t18-,19+,21-,22+,23-,24+,25-,26+,27-,29+,30-/m1/s1",Lucidine B,KEGG COMPOUND accession,C09869
615,6584,luteolinidin,,"InChI=1S/C15H10O5/c16-9-6-12(18)10-2-4-14(20-15(10)7-9)8-1-3-11(17)13(19)5-8/h1-7H,(H3-,16,17,18,19)/p+1",Luteolinidin,KEGG COMPOUND accession,C08652
616,6610,lythramine,A piperidine alkaloid that is lythranidine with the hydroxy group C-10 esterified into an acetate and a methylene bridge formed between the hydroxy at C-9 and the piperidine nitrogen.,"InChI=1S/C29H37NO5/c1-19(31)35-25-11-7-21-9-13-29(33-2)27(15-21)26-14-20(8-12-28(26)32)6-10-24-16-22-4-3-5-23(17-25)30(22)18-34-24/h8-9,12-15,22-25,32H,3-7,10-11,16-18H2,1-2H3/t22-,23-,24+,25+/m1/s1",Lythramine,KEGG COMPOUND accession,C10604
617,6637,magnesium dihydroxide,A magnesium hydroxide in which the magnesium atom is bound to two hydroxide groups.,InChI=1S/Mg.2H2O/h;2*1H2/q+2;;/p-2,Magnesium hydroxide,KEGG COMPOUND accession,C07876
618,6650,malic acid,A 2-hydroxydicarboxylic acid that is succinic acid in which one of the hydrogens attached to a carbon is replaced by a hydroxy group.,"InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)",Malic acid,KEGG COMPOUND accession,C00711
619,3512,ceftizoxime sodium,The sodium salt of ceftizoxime.,"InChI=1S/C13H13N5O5S2.Na/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18;/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22);/q;+1/p-1/b17-7-;/t8-,11-;/m1./s1",Ceftizoxime sodium,KEGG COMPOUND accession,C08118
620,7510,neopinone,"The beta,gamma-unsaturated ketone resulting from the hydrolysis of the methyl enol ether group of thebaine. It is a key intermediate in the biosynthesis of codeine and morphine in the opium poppy, Papaver somniferum.","InChI=1S/C18H19NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-4,6,12,17H,5,7-9H2,1-2H3/t12-,17+,18+/m1/s1",Neopinone,KEGG COMPOUND accession,C06172
621,7521,nereistoxin,"Toxin isolated from marine segmented worm, Lumbriconereis heterodopa. It is also the active insecticide of the proinsecticide thiocyclam.","InChI=1S/C5H11NS2/c1-6(2)5-3-7-8-4-5/h5H,3-4H2,1-2H3",Nereistoxin,KEGG COMPOUND accession,C11474
622,7528,netilmycin,,"InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)15(28)17(13)33-20-21(2,29)18(25-3)14(27)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15+,16-,17+,18-,19-,20-,21-/m1/s1",Netilmicin,CAS Registry Number,56391-56-1
623,7539,"5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid",,"InChI=1S/C9H17NO8/c10-5-3(12)1-9(17,8(15)16)18-7(5)6(14)4(13)2-11/h3-7,11-14,17H,1-2,10H2,(H,15,16)/t3-,4+,5+,6+,7+,9?/m0/s1",Neuraminic acid,KEGG COMPOUND accession,C06469
624,7570,nigerose,A glycosylglucose consisting of D-glucose with undefined anomeric stereochemistry and an alpha-D-glucosyl residue attached at the 3-position.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8-,9-,10+,11?,12-/m1/s1",Nigerose,KEGG COMPOUND accession,C01518
625,7575,nimodipine,"A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.","InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3",Nimodipine,CAS Registry Number,66085-59-4
626,7610,"(2E,6Z)-nona-2,6-dienal","An enal that is (2E,6Z)-nona-2,6-diene substituted by an oxo group at position 1.","InChI=1S/C9H14O/c1-2-3-4-5-6-7-8-9-10/h3-4,7-9H,2,5-6H2,1H3/b4-3-,8-7+","Nona-2,6-dienal",KEGG COMPOUND accession,C08499
627,8588,protodioscin,"A spirostanyl glycoside that consists of the trisaccharide alpha-L-Rha-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Glc attached to position 3 of 26-(beta-D-glucopyranosyloxy)-3beta,22-dihydroxyfurost-5-ene via a glycosidic linkage. Found in several plant species including yams, asparagus and funugreek.","InChI=1S/C51H84O22/c1-20(19-65-45-39(60)38(59)35(56)30(17-52)69-45)9-14-51(64)21(2)32-29(73-51)16-28-26-8-7-24-15-25(10-12-49(24,5)27(26)11-13-50(28,32)6)68-48-44(72-47-41(62)37(58)34(55)23(4)67-47)42(63)43(31(18-53)70-48)71-46-40(61)36(57)33(54)22(3)66-46/h7,20-23,25-48,52-64H,8-19H2,1-6H3/t20-,21+,22+,23+,25+,26-,27+,28+,29+,30-,31-,32+,33+,34+,35-,36-,37-,38+,39-,40-,41-,42+,43-,44-,45-,46+,47+,48-,49+,50+,51-/m1/s1",Protodioscin,CAS Registry Number,55056-80-9
628,8473,propane-1-thiol,An alkanethiol that is propane substituted by a thiol group at position 1.,"InChI=1S/C3H8S/c1-2-3-4/h4H,2-3H2,1H3",Propane-1-thiol,CAS Registry Number,107-03-9
629,8474,propane-2-thiol,An  alkanethiol that is propane substituted by a sulfanyl group at position 2.,"InChI=1S/C3H8S/c1-3(2)4/h3-4H,1-2H3",Propane-2-thiol,KEGG COMPOUND accession,C08391
630,9701,tridihexethyl,,"InChI=1S/C21H36NO/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3/q+1",Tridihexethyl,KEGG COMPOUND accession,C07861
631,9704,tridihexethyl iodide,,"InChI=1S/C21H36NO.HI/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20;/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3;1H/q+1;/p-1",Tridihexethyl iodide,KEGG COMPOUND accession,C07862
632,7621,norajmaline,An organonitrogen heterocyclic compound that is ajmaline which is lacking the methyl substituent attached to the nitrogen of the dihydroindole moiety.,"InChI=1S/C19H24N2O2/c1-2-9-10-7-13-16-19(11-5-3-4-6-12(11)20-16)8-14(15(10)17(19)22)21(13)18(9)23/h3-6,9-10,13-18,20,22-23H,2,7-8H2,1H3/t9-,10-,13-,14-,15-,16-,17+,18+,19+/m0/s1",Norajmaline,KEGG COMPOUND accession,C11810
633,7632,norlichexanthone,"A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3 and 6 and a methyl group at position 8. It has been isolated from Wardomyces anomalus.","InChI=1S/C14H10O5/c1-6-2-7(15)4-10-12(6)14(18)13-9(17)3-8(16)5-11(13)19-10/h2-5,15-17H,1H3","1,3,6-Trihydroxy-8-methyl-9H-xanthen-9-one",KEGG COMPOUND accession,C10087
634,7637,norswertianin,"A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 2, 6 and 8.","InChI=1S/C13H8O6/c14-5-3-7(16)10-9(4-5)19-8-2-1-6(15)12(17)11(8)13(10)18/h1-4,14-17H","1,2,6,8-Tetrahydroxyxanthone",KEGG COMPOUND accession,C10088
635,8630,pterostilbene,A stilbenol that consists of trans-stilbene bearing a hydroxy group at position 4 as well as two methoxy substituents at positions 3' and 5'.,"InChI=1S/C16H16O3/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11,17H,1-2H3/b4-3+",Pterostilbene,CAS Registry Number,537-42-8
636,9728,trimethaphan,"A complex heterocyclic sulfonium compound with an imidazolium core, used to treat hypertension.","InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1",Trimethaphan,CAS Registry Number,7187-66-8
637,2747,anthemis glycoside A,An anthemis glycoside that is found in the cyanogenic achenes of Anthemis altissima.,"InChI=1S/C39H49NO21/c40-12-21(18-4-2-1-3-5-18)59-39-35(52)31(48)28(45)24(61-39)16-56-37-33(50)29(46)22(14-54-37)58-25(42)11-8-17-6-9-19(10-7-17)57-38-34(51)30(47)27(44)23(60-38)15-55-36-32(49)26(43)20(41)13-53-36/h1-11,20-24,26-39,41,43-52H,13-16H2/b11-8+/t20-,21-,22-,23-,24-,26+,27-,28-,29+,30+,31+,32-,33-,34-,35-,36+,37+,38-,39-/m1/s1",Anthemis glycoside A,KEGG COMPOUND accession,C08326
638,2761,dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate,A hydrate that is the trihydrate form of dipotassium bis[mu-tartrato(4-)]diantimonate(2-).,"InChI=1S/2C4H4O6.2K.3H2O.2Sb/c2*5-1(3(7)8)2(6)4(9)10;;;;;;;/h2*1-2H,(H,7,8)(H,9,10);;;3*1H2;;/q2*-2;2*+1;;;;2*+3/p-4",Antimony potassium tartrate,KEGG COMPOUND accession,C11340
639,2807,arbutin 6-phosphate,A beta-D-glucoside compound having a phosphate group at the 6-position and a 4-hydroxyphenyl substituent at the 1-position.,"InChI=1S/C12H17O10P/c13-6-1-3-7(4-2-6)21-12-11(16)10(15)9(14)8(22-12)5-20-23(17,18)19/h1-4,8-16H,5H2,(H2,17,18,19)/t8-,9-,10+,11-,12-/m1/s1",Arbutin 6-phosphate,KEGG COMPOUND accession,C06187
640,2848,artabsin,A tricyclic sesquiterpene lactone found in wormwood.,"InChI=1S/C15H20O3/c1-8-4-5-11-12(8)13-10(6-7-15(11,3)17)9(2)14(16)18-13/h5,9-10,13,17H,4,6-7H2,1-3H3/t9-,10-,13-,15-/m0/s1",Artabsin,CAS Registry Number,24399-20-0
641,2853,artemorin,A germacranolide isolated from Laurus nobilis L..,"InChI=1S/C15H20O3/c1-9-4-7-13(16)10(2)5-6-12-11(3)15(17)18-14(12)8-9/h8,12-14,16H,2-7H2,1H3/b9-8+/t12-,13+,14+/m0/s1",Artemorin,KEGG COMPOUND accession,C09345
642,2871,asebogenin,A member of the class of  dihydrochalcones that is the 4'-methyl ether derivative of phloretin.,"InChI=1S/C16H16O5/c1-21-12-8-14(19)16(15(20)9-12)13(18)7-4-10-2-5-11(17)6-3-10/h2-3,5-6,8-9,17,19-20H,4,7H2,1H3",Phloretin 4'-methyl ether,KEGG COMPOUND accession,C09471
643,2934,avadharidine,A diterpenoid having an aconitane skeleton bearing multiple substituents.,"InChI=1S/C36H51N3O10/c1-6-39-17-33(18-49-31(42)19-9-7-8-10-22(19)38-26(41)12-11-25(37)40)14-13-24(46-3)35-21-15-20-23(45-2)16-34(43,27(21)28(20)47-4)36(44,32(35)39)30(48-5)29(33)35/h7-10,20-21,23-24,27-30,32,43-44H,6,11-18H2,1-5H3,(H2,37,40)(H,38,41)/t20-,21-,23+,24+,27-,28+,29-,30-,32?,33+,34-,35+,36-/m1/s1",Avadharidine,CAS Registry Number,509-16-0
644,2941,axillarin,"A dimethoxyflavone that is the 3,6-dimethyl ether derivative of  quercetagetin.","InChI=1S/C17H14O8/c1-23-16-10(20)6-11-12(13(16)21)14(22)17(24-2)15(25-11)7-3-4-8(18)9(19)5-7/h3-6,18-21H,1-2H3","Quercetagetin 3,6-dimethyl ether",CAS Registry Number,5188-73-8
645,2971,backebergine,A member of the class of isoquinolines carrying two methoxy substituents at positions 6 and 7.,"InChI=1S/C11H11NO2/c1-13-10-5-8-3-4-12-7-9(8)6-11(10)14-2/h3-7H,1-2H3",Backebergine,KEGG COMPOUND accession,C09348
646,10702,"(1R,2R)-cyclohexa-3,5-diene-1,2-diol",,"InChI=1S/C6H8O2/c7-5-3-1-2-4-6(5)8/h1-8H/t5-,6-/m1/s1","trans-1,2-Dihydrobenzene-1,2-diol",KEGG COMPOUND accession,C04221
647,1228,2-O-methylswertianin,A member of the class of  xanthones that is  swertianin in which the hydroxy group at position 2 has been replaced by a methoxy group.,"InChI=1S/C15H12O6/c1-19-7-5-8(16)12-11(6-7)21-9-3-4-10(20-2)14(17)13(9)15(12)18/h3-6,16-17H,1-2H3","1,8-Dihydroxy-2,6-dimethoxyxanthone",KEGG COMPOUND accession,C10083
648,1235,2-methoxy-6-(all-trans-octaprenyl)phenol,A 2-methoxy-6-(all-trans-polyprenyl)phenol in which the substituent at position 6 is an all-trans-octaprenyl moiety.,"InChI=1S/C47H72O2/c1-37(2)19-11-20-38(3)21-12-22-39(4)23-13-24-40(5)25-14-26-41(6)27-15-28-42(7)29-16-30-43(8)31-17-32-44(9)35-36-45-33-18-34-46(49-10)47(45)48/h18-19,21,23,25,27,29,31,33-35,48H,11-17,20,22,24,26,28,30,32,36H2,1-10H3/b38-21+,39-23+,40-25+,41-27+,42-29+,43-31+,44-35+",2-Octaprenyl-6-methoxyphenol,KEGG COMPOUND accession,C05812
649,512,"1,3,4,5-tetracaffeoylquinic acid","A cinnamate ester obtained by the formal condensation of hydroxy groups at positions 1, 3, 4 and 5 of (-)-quinic acid with the carboxy group of four molecules of trans-caffeic acid respectively.","InChI=1S/C43H36O18/c44-27-9-1-23(17-31(27)48)5-13-37(52)58-35-21-43(42(56)57,61-40(55)16-8-26-4-12-30(47)34(51)20-26)22-36(59-38(53)14-6-24-2-10-28(45)32(49)18-24)41(35)60-39(54)15-7-25-3-11-29(46)33(50)19-25/h1-20,35-36,41,44-51H,21-22H2,(H,56,57)/b13-5+,14-6+,15-7+,16-8+/t35-,36-,41-,43+/m1/s1","1,3,4,5-Tetracaffeoylquinic acid",KEGG COMPOUND accession,C10500
650,540,"1,4-dithiane",A  dithiane  that is cyclohexane in which the -CH2- units at positions 1 and 2 have been replaced by sulfur atoms.,InChI=1S/C4H8S2/c1-2-6-4-3-5-1/h1-4H2,"1,4-Dithiane",KEGG COMPOUND accession,C01871
651,1307,24-methylenecycloartanol,"A pentacyclic triterpenoid that is (9beta)-24-methylene-9,19-cyclolanostane which carries a hydroxy group at position 3beta. It is isolated from several plant species including Euphorbia, Epidendrum, Psychotria and Sideritis.","InChI=1S/C31H52O/c1-20(2)21(3)9-10-22(4)23-13-15-29(8)25-12-11-24-27(5,6)26(32)14-16-30(24)19-31(25,30)18-17-28(23,29)7/h20,22-26,32H,3,9-19H2,1-2,4-8H3/t22-,23-,24+,25+,26+,28-,29+,30-,31+/m1/s1",24-methylenecycloartanol,KEGG COMPOUND accession,C08830
652,1372,1-pyrroline-5-carboxylic acid,A 1-pyrrolinecarboxylic acid that is 1-pyrroline in which one of the hydrogens at position 5 is replaced by a carboxy group.,"InChI=1S/C5H7NO2/c7-5(8)4-2-1-3-6-4/h3-4H,1-2H2,(H,7,8)","3,4-Dihydro-2H-Pyrrole-2-carboxylate",KEGG COMPOUND accession,C04322
653,1543,3-hydroxyhexobarbital,"A member of the class of  barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a cyclohex-1-en-1-yl group at position 5, a hydroxy group at position 1 and methyl groups at positions 3 and 5.","InChI=1S/C12H16N2O4/c1-12(8-6-4-3-5-7-8)9(15)13(2)11(17)14(18)10(12)16/h6,18H,3-5,7H2,1-2H3",3-Hydroxyhexobarbital,KEGG COMPOUND accession,C03068
654,6750,(+)-menthofuran,"A menthofuran that is 4,5,6,7-tetrahydro-1-benzofuran substituted by methyl groups at positions 3 and 6 (the 6R-enantiomer).","InChI=1S/C10H14O/c1-7-3-4-9-8(2)6-11-10(9)5-7/h6-7H,3-5H2,1-2H3/t7-/m1/s1",Menthofuran,CAS Registry Number,17957-94-7
655,6785,mesuaxanthone A,A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at bpositions 1 and 5 and a methoxy group at position 3.,"InChI=1S/C14H10O5/c1-18-7-5-10(16)12-11(6-7)19-14-8(13(12)17)3-2-4-9(14)15/h2-6,15-16H,1H3","1,5-Dihydroxy-3-methoxyxanthone",CAS Registry Number,3561-81-7
656,6786,mesuaxanthone B,"A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 5 and 6.","InChI=1S/C13H8O5/c14-7-2-1-3-9-10(7)11(16)6-4-5-8(15)12(17)13(6)18-9/h1-5,14-15,17H","1,5,6-Trihydroxyxanthone",KEGG COMPOUND accession,C10082
657,6809,methamphetamine,A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.,"InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1",Methamphetamine,CAS Registry Number,537-46-2
658,6823,methdilazine,A phenothiazine substituted on nitrogen by a (1-methylpyrrolidin-3-yl)methyl group; a first-generation antihistamine with anticholinergic properties.,"InChI=1S/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3",Methdilazine,KEGG COMPOUND accession,C07175
659,6912,alpha-methyl-L-tyrosine,"An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.","InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1",Metyrosine,CAS Registry Number,672-87-7
660,6951,miserotoxin,A beta-D-glucoside having 3-nitropropyl as the anomeric alkyl group.,"InChI=1S/C9H17NO8/c11-4-5-6(12)7(13)8(14)9(18-5)17-3-1-2-10(15)16/h5-9,11-14H,1-4H2/t5-,6-,7+,8-,9-/m1/s1",Miserotoxin,KEGG COMPOUND accession,C08507
661,3884,corilagin,An ellagitannin with a hexahydroxydiphenoyl group bridging over the 3-O and 6-O of the glucose core.,"InChI=1S/C27H22O18/c28-9-1-6(2-10(29)16(9)32)24(39)45-27-22(38)23-19(35)13(43-27)5-42-25(40)7-3-11(30)17(33)20(36)14(7)15-8(26(41)44-23)4-12(31)18(34)21(15)37/h1-4,13,19,22-23,27-38H,5H2/t13-,19-,22-,23+,27+/m1/s1",Corilagin,KEGG COMPOUND accession,C10219
662,3929,cryogenine,A quinolizidine alkaloid isolated from the flowering plant Heimia salicifolia and exhibits anti-inflammatory properties.,"InChI=1S/C26H29NO5/c1-30-24-14-19-20(15-25(24)31-2)22-13-18(12-17-5-3-4-10-27(17)22)32-26(29)9-7-16-6-8-23(28)21(19)11-16/h6-9,11,14-15,17-18,22,28H,3-5,10,12-13H2,1-2H3/b9-7-/t17-,18+,22+/m1/s1",cryogenine,KEGG COMPOUND accession,C10585
663,2992,barbinine,A diterpene alkaloid that is a phytotoxin produced by several Delphinium species.,"InChI=1S/C36H46N2O10/c1-6-37-16-33(17-48-31(42)19-9-7-8-10-22(19)38-25(39)13-18(2)30(38)41)12-11-24(46-4)35-21-14-20-23(45-3)15-34(43,26(21)27(20)40)36(44,32(35)37)29(47-5)28(33)35/h7-10,18,20-21,23-24,26,28-29,32,43-44H,6,11-17H2,1-5H3/t18-,20+,21+,23-,24-,26+,28+,29-,32?,33-,34+,35-,36+/m0/s1",Barbinine,KEGG COMPOUND accession,C08662
664,3044,benzphetamine,"Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.","InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1",Benzphetamine,KEGG COMPOUND accession,C07538
665,3047,benzthiazide,"7-Sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by chlorine and that at position 3 is substituted by a benzylsulfanylmethyl group. A diuretic, it is used to treat hypertension and edema.","InChI=1S/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)",Benzthiazide,CAS Registry Number,91-33-8
666,3079,betanidin,,"InChI=1S/C18H16N2O8/c21-14-6-9-5-13(18(27)28)20(12(9)7-15(14)22)2-1-8-3-10(16(23)24)19-11(4-8)17(25)26/h1-3,6-7,11,13,21-22H,4-5H2,(H,23,24)(H,25,26)(H,27,28)/t11-,13-/m0/s1",Betanidin,KEGG COMPOUND accession,C08539
667,4896,"ethyl (2E,4Z)-deca-2,4-dienoate","A fatty acid ethyl ester resulting from the formal condensation of the carboxy group of (2E,4E)-deca-2,4-dienoic acid with the hydroxy group of ethanol.","InChI=1S/C12H20O2/c1-3-5-6-7-8-9-10-11-12(13)14-4-2/h8-11H,3-7H2,1-2H3/b9-8-,11-10+","Ethyl trans-2,cis-4-decadienoate",CAS Registry Number,3025-30-7
668,3982,cyanopyrazine,,"InChI=1S/C5H3N3/c6-3-5-4-7-1-2-8-5/h1-2,4H",Cyanopyrazine,CAS Registry Number,19847-12-2
669,4024,cyclopentolate,"A carboxylic ester resulting from the formal condensation of (1-hydroxycyclopentyl)(phenyl)acetic acid with N,N-dimethylethanolamine. A tertiary amine antimuscarinic with actions similar to atropine, it is used as its hydrochloride salt to produce mydriasis (excessive dilation of the pupil) and cycloplegia (paralysis  of the ciliary muscle of the eye) for opthalmic diagnostic procedures. It acts more quickly than atropine and has a shorter duration of action.","InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3",Cyclopentolate,KEGG COMPOUND accession,C06932
670,4035,cyhalothrin,"A carboxylic ester obtained by formal condensation between 3-(2-chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid and cyano(3-phenoxyphenyl)methanol.","InChI=1S/C23H19ClF3NO3/c1-22(2)17(12-19(24)23(25,26)27)20(22)21(29)31-18(13-28)14-7-6-10-16(11-14)30-15-8-4-3-5-9-15/h3-12,17-18,20H,1-2H3/b19-12-",Cyhalothrin,KEGG COMPOUND accession,C10983
671,1579,3-methoxyapigenin,A trihydroxyflavone that is  apigenin substituted by a methoxy group at position 3.,"InChI=1S/C16H12O6/c1-21-16-14(20)13-11(19)6-10(18)7-12(13)22-15(16)8-2-4-9(17)5-3-8/h2-7,17-19H,1H3",3-O-Methylkaempferol,KEGG COMPOUND accession,C05902
672,4991,iron(III) dicitrate(3-),The complex formed between iron(III) and citrate.,"InChI=1S/2C6H8O7.Fe/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;;+3/p-6",Fe(III)dicitrate,PubMed citation,11872840
673,5020,ferricyanide,,InChI=1S/6CN.Fe/c6*1-2;/q;;;;;;-3,Ferricyanide,KEGG COMPOUND accession,C00324
674,5032,ferrocyanide,,InChI=1S/6CN.Fe/c6*1-2;/q;;;;;;-4,Ferrocyanide,CAS Registry Number,13408-63-4
675,5066,fisetinidol,"A tetrahydroxyflavan that is (2S)-flavan substituted by hydroxy groups at positions 3, 7, 3' and 4'.","InChI=1S/C15H14O5/c16-10-3-1-8-5-13(19)15(20-14(8)7-10)9-2-4-11(17)12(18)6-9/h1-4,6-7,13,15-19H,5H2/t13-,15+/m0/s1","3,7,3',4'-Tetrahydroxyflavan",KEGG COMPOUND accession,C09735
676,5263,"galangin 3,5,7-trimethyl ether","A trimethoxyflavone that is the 3,5,7-trimethyl ether derivative of galangin.","InChI=1S/C18H16O5/c1-20-12-9-13(21-2)15-14(10-12)23-17(18(22-3)16(15)19)11-7-5-4-6-8-11/h4-10H,1-3H3","Galangin 3,5,7-trimethyl ether",CAS Registry Number,26964-29-4
677,5283,geissoschizoline,An indole alkaloid that is (16alpha)-curan substituted by a hydroxy group at position 17.,"InChI=1S/C19H26N2O/c1-2-12-10-21-8-7-19-15-5-3-4-6-16(15)20-18(19)14(11-22)13(12)9-17(19)21/h3-6,12-14,17-18,20,22H,2,7-11H2,1H3/t12-,13+,14+,17+,18+,19-/m1/s1",Geissoschizoline,CAS Registry Number,18397-07-4
678,5323,gentisein,"A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3 and 7.","InChI=1S/C13H8O5/c14-6-1-2-10-8(3-6)13(17)12-9(16)4-7(15)5-11(12)18-10/h1-5,14-16H","1,3,7-Trihydroxyxanthone",KEGG COMPOUND accession,C10065
679,5324,gentisin,A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1 and 7 and a methoxy group at position 3.,"InChI=1S/C14H10O5/c1-18-8-5-10(16)13-12(6-8)19-11-3-2-7(15)4-9(11)14(13)17/h2-6,15-16H,1H3","1,7-Dihydroxy-3-methoxyxanthone",CAS Registry Number,437-50-3
680,9746,tripteroside,A xanthone glycoside that is  norathyriol attached to a beta-D-glucopyranosyl residue at position 6 via a glycosidic linkage.,"InChI=1S/C19H18O11/c20-5-13-16(25)17(26)18(27)19(30-13)29-11-4-10-7(3-8(11)22)15(24)14-9(23)1-6(21)2-12(14)28-10/h1-4,13,16-23,25-27H,5H2/t13-,16-,17+,18-,19-/m1/s1",Norathyriol-6-O-beta-D-glucoside,KEGG COMPOUND accession,C10095
681,9752,"tritriacontane-16,18-dione",A beta-diketone that is tritriacontane with oxo groups at positions 16 and 18.,"InChI=1S/C33H64O2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-32(34)31-33(35)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-31H2,1-2H3","Tritriacontane-16,18-dione",CAS Registry Number,24514-86-1
682,9776,tulipinolide,"A germacranolide based on a 2,3,3a,4,5,8,9,11a-octahydrocyclodeca[b]furan-4-yl skeleton.","InChI=1S/C17H22O4/c1-10-6-5-7-11(2)9-15-16(12(3)17(19)21-15)14(8-10)20-13(4)18/h6,9,14-16H,3,5,7-8H2,1-2,4H3/b10-6+,11-9+/t14-,15+,16+/m0/s1",Tulipinolide,KEGG COMPOUND accession,C09564
683,9889,urea-1-carboxylic acid,A member of the class of ureas that is urea in which one of the hydrogens has been replaced by a carboxy group.,"InChI=1S/C2H4N2O3/c3-1(5)4-2(6)7/h(H,6,7)(H3,3,4,5)",Urea-1-carboxylate,KEGG COMPOUND accession,C01010
684,7728,octan-1-amine,An 8-carbon primary aliphatic amine.,"InChI=1S/C8H19N/c1-2-3-4-5-6-7-8-9/h2-9H2,1H3",Octylamine,CAS Registry Number,111-86-4
685,4077,"(4R,5S,6R)-2,4,5,6-tetrahydroxycyclohex-2-en-1-one","A member of the class of  cyclohexenones that is cyclohex-2-en-1-one substituted by hydroxy groups at positions 2, 4, 5 and 6 (the 4R,5S,6R-stereoisomer).","InChI=1S/C6H8O5/c7-2-1-3(8)5(10)6(11)4(2)9/h1-2,4,6-9,11H/t2-,4+,6-/m1/s1","D-2,3-Diketo 4-deoxy-epi-inositol",KEGG COMPOUND accession,C06891
686,8710,quillaic acid,"A pentacyclic triterpenoid that is olean-12-ene substituted by hydroxy groups at positions 3 and 16, an oxo group at position 23 and a carboxy group at position 28 (the 3beta,16alpha stereoisomer).","InChI=1S/C30H46O5/c1-25(2)13-14-30(24(34)35)19(15-25)18-7-8-21-26(3)11-10-22(32)27(4,17-31)20(26)9-12-28(21,5)29(18,6)16-23(30)33/h7,17,19-23,32-33H,8-16H2,1-6H3,(H,34,35)/t19-,20+,21+,22-,23+,26-,27-,28+,29+,30+/m0/s1",Quillaic acid,KEGG COMPOUND accession,C08972
687,8712,quinalphos,,"InChI=1S/C12H15N2O3PS/c1-3-15-18(19,16-4-2)17-12-9-13-10-7-5-6-8-11(10)14-12/h5-9H,3-4H2,1-2H3",Quinalphos,CAS Registry Number,13593-03-8
688,7770,olsalazine,"An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.","InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)",Olsalazine,CAS Registry Number,15722-48-2
689,7799,oseltamivir phosphate,,"InChI=1S/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/m0./s1",Oseltamivir phosphate,KEGG COMPOUND accession,C08093
690,7847,oxmetidine,"A 2-aminopyrimidin-4(1H)-one derivative bearing a 1,3-benzodioxol-5-ylmethyl group at the 5-position and with a 4-(5-methyl-(1H)imidazol-4-yl)-3-thiabutyl substituent attached to the 2-amino group. It is a specific histamine H2-receptor antagonist.","InChI=1S/C19H21N5O3S/c1-12-15(23-10-22-12)9-28-5-4-20-19-21-8-14(18(25)24-19)6-13-2-3-16-17(7-13)27-11-26-16/h2-3,7-8,10H,4-6,9,11H2,1H3,(H,22,23)(H2,20,21,24,25)",Oxmetidine,KEGG COMPOUND accession,C11803
691,7849,oxolucidine B,"An organonitrogen heterocyclic compound that is lucidine B in which the hydrogen at the 4a position of the dodecahydrobenzo[5,6]cyclohepta[1,2-b]pyridinyl moiety is substituted by a hydroxy group.","InChI=1S/C30H49N3O2/c1-18-11-22-15-29-30(35,23-16-26(22)27(12-18)32(4)17-23)8-7-24(31-29)14-21-10-19(2)13-28-25(21)6-5-9-33(28)20(3)34/h18-19,21-28,35H,5-17H2,1-4H3/t18-,19+,21-,22+,23-,24+,25+,26-,27+,28-,30+/m1/s1",Oxolucidine B,CAS Registry Number,71384-25-3
692,8210,"pimara-8(14),15-diene",,"InChI=1S/C20H32/c1-6-19(4)13-10-16-15(14-19)8-9-17-18(2,3)11-7-12-20(16,17)5/h6,14,16-17H,1,7-13H2,2-5H3/t16-,17-,19+,20+/m0/s1",Pimaradiene,KEGG COMPOUND accession,C06086
693,8217,pinidine,,"InChI=1S/C9H17N/c1-3-5-9-7-4-6-8(2)10-9/h3,5,8-10H,4,6-7H2,1-2H3/b5-3+/t8-,9+/m1/s1",Pinidine,CAS Registry Number,501-02-0
694,8224,pinoquercetin,A pentahydroxyflavone that is  quercetin substituted by a methyl group at position 6.,"InChI=1S/C16H12O7/c1-6-9(18)5-11-12(13(6)20)14(21)15(22)16(23-11)7-2-3-8(17)10(19)4-7/h2-5,17-20,22H,1H3",6-C-Methylquercetin,KEGG COMPOUND accession,C10120
695,7265,2-dimethylaminoethylphosphonic acid,A phosphonic acid having a 2-dimethylaminoethyl group attached to the phosphorus.,"InChI=1S/C4H12NO3P/c1-5(2)3-4-9(6,7)8/h3-4H2,1-2H3,(H2,6,7,8)",N-Dimethyl-2-aminoethylphosphonate,KEGG COMPOUND accession,C05680
696,4093,D-allopyranose,The D-enantiomer of allopyranose.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4-,5-,6?/m1/s1",D-Allose,CAS Registry Number,2595-97-3
697,4110,cathinone,The S stereoisomer of 2-aminopropiophenone.,"InChI=1S/C9H11NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7H,10H2,1H3/t7-/m0/s1",D-Cathinone,KEGG COMPOUND accession,C08301
698,8478,propanoyl phosphate,The phosphate ester of propanoic acid.,"InChI=1S/C3H7O5P/c1-2-3(4)8-9(5,6)7/h2H2,1H3,(H2,5,6,7)",Propanoyl phosphate,KEGG COMPOUND accession,C02876
699,9751,tritriacontane,A long-chain alkane consisting of an unbranched chain of 33 carbon atoms.,"InChI=1S/C33H68/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-33H2,1-2H3",Tritriacontane,KEGG COMPOUND accession,C08393
700,2430,aconitine,"A diterpenoid that is 20-ethyl-3alpha,13,15alpha-trihydroxy-1alpha,6alpha,16beta-trimethoxy-4-(methoxymethyl)aconitane-8,14alpha-diol having acetate and benzoate groups at the 8- and 14-positions respectively.","InChI=1S/C34H47NO11/c1-7-35-15-31(16-41-3)20(37)13-21(42-4)33-19-14-32(40)28(45-30(39)18-11-9-8-10-12-18)22(19)34(46-17(2)36,27(38)29(32)44-6)23(26(33)35)24(43-5)25(31)33/h8-12,19-29,37-38,40H,7,13-16H2,1-6H3/t19-,20-,21+,22-,23+,24+,25-,26?,27+,28-,29+,31+,32-,33+,34-/m1/s1",Aconitine,KEGG COMPOUND accession,C06091
701,2443,actinidine,"A member of the class of cyclopentapyridines that is 6,7-dihydrocyclopenta[c]pyridine bearing two methyl substituents at positions 4 and 7.","InChI=1S/C10H13N/c1-7-3-4-9-8(2)5-11-6-10(7)9/h5-7H,3-4H2,1-2H3/t7-/m0/s1",Actinidine,KEGG COMPOUND accession,C09910
702,8041,phantomolin,A  germacranolide isolated from Elephantopus mollis and has been shown to exhibit antineoplastic activity.,"InChI=1S/C21H26O6/c1-7-24-21-9-12(4)8-15(25-19(22)11(2)3)16-14(6)20(23)26-18(16)17(27-21)13(5)10-21/h9-10,15-18H,2,6-8H2,1,3-5H3/b12-9-/t15-,16+,17-,18-,21-/m0/s1",Phantomolin,CAS Registry Number,55306-08-6
703,4660,12-deoxyphorbol 20-acetate 13-(2-methylbutanoate),A phorbol ester that is 12-deoxyphorbol in which the hydroxy groups at positions 13 and 20 have been converted to their  respective 2-methylbutanoate and acetate esters.,"InChI=1S/C27H38O7/c1-8-14(2)23(30)34-26-11-16(4)27(32)19(21(26)24(26,6)7)10-18(13-33-17(5)28)12-25(31)20(27)9-15(3)22(25)29/h9-10,14,16,19-21,31-32H,8,11-13H2,1-7H3/t14?,16-,19+,20-,21-,25-,26+,27-/m1/s1",Diterpenoid EF-D,CAS Registry Number,25090-73-7
704,9050,sciadopitysin,"A biflavonoid that is a 7, 4', 4'''-trimethyl ether derivative of amentoflavone.","InChI=1S/C33H24O10/c1-39-18-7-4-16(5-8-18)27-15-25(38)32-23(36)13-22(35)30(33(32)43-27)20-10-17(6-9-26(20)41-3)28-14-24(37)31-21(34)11-19(40-2)12-29(31)42-28/h4-15,34-36H,1-3H3",Sciadopitysin,CAS Registry Number,521-34-6
705,9082,sedoheptulose 1-phosphate,,"InChI=1S/C7H15O10P/c8-1-3(9)5(11)7(13)6(12)4(10)2-17-18(14,15)16/h3,5-9,11-13H,1-2H2,(H2,14,15,16)/t3-,5-,6-,7-/m1/s1",Sedoheptulose 1-phosphate,KEGG COMPOUND accession,C06222
706,9142,silver(1+) sulfadiazinate,,"InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1",Silver sulfadiazine,CAS Registry Number,22199-08-2
707,10334,alpha-terpinene,One of three isomeric monoterpenes differing in the positions of their two double bonds (beta- and gamma-terpinene being the others). In alpha-terpinene the  double bonds are at the 1- and 3-positions of the p-menthane skeleton.,"InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,6,8H,5,7H2,1-3H3",alpha-Terpinene,KEGG COMPOUND accession,C09898
708,798,19-hydroxytestosterone,A 3-oxo Delta(4)-steroid that is testosterone which is substituted by a hydroxy group at positions 19.,"InChI=1S/C19H28O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10,14-17,20,22H,2-9,11H2,1H3/t14-,15-,16-,17-,18-,19+/m0/s1",19-Hydroxytestosterone,KEGG COMPOUND accession,C05294
709,836,2'-deoxy-5-hydroxymethyl-CTP,A pyrimidine 2'-deoxyribonucleoside 5'-triphosphate that is 2'deoxycytidine-5'-triphosphate substituted by a hydroxymethyl group at position 5.,"InChI=1S/C10H18N3O14P3/c11-9-5(3-14)2-13(10(16)12-9)8-1-6(15)7(25-8)4-24-29(20,21)27-30(22,23)26-28(17,18)19/h2,6-8,14-15H,1,3-4H2,(H,20,21)(H,22,23)(H2,11,12,16)(H2,17,18,19)/t6-,7+,8+/m0/s1",2'-Deoxy-5-hydroxymethylcytidine-5'-triphosphate,KEGG COMPOUND accession,C11039
710,848,2'-phospho-5'-adenylyl sulfate,An adenosine bisphosphate having monophosphate groups at the 2'- and 5'-positions and a sulfo group attached to the phosphate at position 5'.,"InChI=1S/C10H15N5O13P2S/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(27-29(17,18)19)6(16)4(26-10)1-25-30(20,21)28-31(22,23)24/h2-4,6-7,10,16H,1H2,(H,20,21)(H2,11,12,13)(H2,17,18,19)(H,22,23,24)/t4-,6-,7-,10-/m1/s1",2'-Phosphoadenylylsulfate,KEGG COMPOUND accession,C03568
711,168,(-)-dihydrocarvone,"A dihydrocarvone in (S,S) configuration.","InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-9H,1,4-6H2,2-3H3/t8-,9-/m0/s1","(1S,4S)-Dihydrocarvone",KEGG COMPOUND accession,C11415
712,212,(3S)-3-isopropenyl-6-oxoheptanoyl-CoA,An oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of (3S)-3-isopropenyl-6-oxoheptanoic acid.,"InChI=1S/C31H50N7O18P3S/c1-17(2)19(7-6-18(3)39)12-22(41)60-11-10-33-21(40)8-9-34-29(44)26(43)31(4,5)14-53-59(50,51)56-58(48,49)52-13-20-25(55-57(45,46)47)24(42)30(54-20)38-16-37-23-27(32)35-15-36-28(23)38/h15-16,19-20,24-26,30,42-43H,1,6-14H2,2-5H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t19-,20+,24+,25+,26-,30+/m0/s1",(3S)-3-Isopropenyl-6-oxoheptanoyl-CoA,KEGG COMPOUND accession,C11421
713,8886,rodiasine,,"InChI=1S/C38H42N2O6/c1-39-13-11-24-19-33(43-4)34-21-26(24)29(39)17-22-7-9-31(41)27(15-22)28-16-23(8-10-32(28)42-3)18-30-36-25(12-14-40(30)2)20-35(44-5)37(45-6)38(36)46-34/h7-10,15-16,19-21,29-30,41H,11-14,17-18H2,1-6H3/t29-,30+/m1/s1",Rodiasine,KEGG COMPOUND accession,C09624
714,8273,plumbagin,"A  hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone in which the hydrogens at positions 2 and 5 are substituted by methyl and hydroxy groups, respectively.","InChI=1S/C11H8O3/c1-6-5-9(13)10-7(11(6)14)3-2-4-8(10)12/h2-5,12H,1H3",Plumbagin,KEGG COMPOUND accession,C10387
715,8337,porphyrin,,"InChI=1S/C20H14N4/c1-2-14-10-16-5-6-18(23-16)12-20-8-7-19(24-20)11-17-4-3-15(22-17)9-13(1)21-14/h1-12,21,24H/b13-9-,14-10-,15-9-,16-10-,17-11-,18-12-,19-11-,20-12-",Porphyrin,KEGG COMPOUND accession,C05113
716,8354,pralidoxime,A pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2.,"InChI=1S/C7H8N2O/c1-9-5-3-2-4-7(9)6-8-10/h2-6H,1H3/p+1",Pralidoxime,KEGG COMPOUND accession,C07400
717,9279,streptamine 5-phosphate,a scyllo-inositol phosphate compound having a phosphate group in the 5-position and amino groups in place of hydroxy groups in the 1- and 3-positions.,"InChI=1S/C6H15N2O7P/c7-1-3(9)2(8)5(11)6(4(1)10)15-16(12,13)14/h1-6,9-11H,7-8H2,(H2,12,13,14)/t1-,2+,3-,4+,5-,6-",Streptamine phosphate,KEGG COMPOUND accession,C03177
718,1157,isethionic acid,An alkanesulfonic acid in which the sulfo group is directly linked to a  2-hydroxyethyl group.,"InChI=1S/C2H6O4S/c3-1-2-7(4,5)6/h3H,1-2H2,(H,4,5,6)",2-Hydroxyethanesulfonic acid,KEGG COMPOUND accession,C05123
719,10418,trans-beta-farnesene,A beta-farnesene in which the double bond at position 6-7 has E configuration. It is the major or sole alarm pheromone in most species of aphid.,"InChI=1S/C15H24/c1-6-14(4)10-8-12-15(5)11-7-9-13(2)3/h6,9,12H,1,4,7-8,10-11H2,2-3,5H3/b15-12+",beta-Farnesene,CAS Registry Number,18794-84-8
720,9629,tomatidine,A 3beta-hydroxy steroid resulting from the substitution of the 3beta-hydrogen of tomatidane by a hydroxy group.,"InChI=1S/C27H45NO2/c1-16-7-12-27(28-15-16)17(2)24-23(30-27)14-22-20-6-5-18-13-19(29)8-10-25(18,3)21(20)9-11-26(22,24)4/h16-24,28-29H,5-15H2,1-4H3/t16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26-,27-/m0/s1",Tomatidine,KEGG COMPOUND accession,C10826
721,9672,triangularine,,"InChI=1S/C18H25NO5/c1-4-12(3)17(21)24-15-7-9-19-8-6-14(16(15)19)11-23-18(22)13(5-2)10-20/h4-6,15-16,20H,7-11H2,1-3H3/b12-4-,13-5-/t15-,16-/m1/s1",Triangularine,CAS Registry Number,87340-27-0
722,9679,tricalcium bis(phosphate),,"InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6",Tricalcium phosphate,CAS Registry Number,7758-87-4
723,9682,trichlopyr,"A monocarboxylic acid that is (pyridin-2-yloxy)acetic acid substituted by chloro groups at positions 3, 5 and 6. It is an agrochemical used as a herbicide.","InChI=1S/C7H4Cl3NO3/c8-3-1-4(9)7(11-6(3)10)14-2-5(12)13/h1H,2H2,(H,12,13)",Triclopyr,CAS Registry Number,55335-06-3
724,9702,tridihexethyl bromide,,"InChI=1S/C21H36NO.BrH/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20;/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3;1H/q+1;/p-1",Tridihexethyl bromide,KEGG COMPOUND accession,C11761
725,9341,sulfinate,,"InChI=1S/H2O2S/c1-3-2/h3H,(H,1,2)/p-1",Sulfinate,KEGG COMPOUND accession,C01615
726,9347,sulfoglycolithocholic acid,The 3-O-sulfo derivative of glycolithocholic acid.,"InChI=1S/C26H43NO7S/c1-16(4-9-23(28)27-15-24(29)30)20-7-8-21-19-6-5-17-14-18(34-35(31,32)33)10-12-25(17,2)22(19)11-13-26(20,21)3/h16-22H,4-15H2,1-3H3,(H,27,28)(H,29,30)(H,31,32,33)/t16-,17-,18-,19+,20-,21+,22+,25+,26-/m1/s1",Sulfoglycolithocholate,KEGG COMPOUND accession,C11301
727,9367,swainsonine,"An indolizidine alkaloid isolated from the plant Swainsona canescens with three hydroxy substituents at positions 1, 2 and 8.","InChI=1S/C8H15NO3/c10-5-2-1-3-9-4-6(11)8(12)7(5)9/h5-8,10-12H,1-4H2/t5-,6-,7-,8-/m1/s1",Swainsonine,KEGG COMPOUND accession,C10173
728,9391,talampicillin,A penicillanic acid ester that is the 1-phthalidyl ester of ampicillin. It is a prodrug of ampicillin.,"InChI=1S/C24H23N3O6S/c1-24(2)17(22(31)33-23-14-11-7-6-10-13(14)21(30)32-23)27-19(29)16(20(27)34-24)26-18(28)15(25)12-8-4-3-5-9-12/h3-11,15-17,20,23H,25H2,1-2H3,(H,26,28)/t15-,16-,17+,20-,23?/m1/s1",Talampicillin,CAS Registry Number,47747-56-8
729,9405,tartrazine,An organic sodium salt which is the trisodium salt of tartrazine acid. A synthetic lemon yellow azo dye used as a food colouring.,"InChI=1S/C16H12N4O9S2.3Na/c21-15-13(18-17-9-1-5-11(6-2-9)30(24,25)26)14(16(22)23)19-20(15)10-3-7-12(8-4-10)31(27,28)29;;;/h1-8,13H,(H,22,23)(H,24,25,26)(H,27,28,29);;;/q;3*+1/p-3/b18-17+;;;",Tartrazine,KEGG COMPOUND accession,C07574
730,9422,tebufenpyrad,,"InChI=1S/C18H24ClN3O/c1-6-14-15(19)16(22(5)21-14)17(23)20-11-12-7-9-13(10-8-12)18(2,3)4/h7-10H,6,11H2,1-5H3,(H,20,23)",Tebufenpyrad,KEGG COMPOUND accession,C11126
731,10698,"2-cis,6-trans,10-trans-geranylgeranyl diphosphate",,"InChI=1S/C20H36O7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13,15H,6-8,10,12,14,16H2,1-5H3,(H,24,25)(H2,21,22,23)/b18-11+,19-13+,20-15-","trans,trans,cis-Geranylgeranyl diphosphate",KEGG COMPOUND accession,C11356
732,1015,2-aminobenzenesulfonic acid,An aminobenzenesulfonic acid carrying an amino group at position 2.,"InChI=1S/C6H7NO3S/c7-5-3-1-2-4-6(5)11(8,9)10/h1-4H,7H2,(H,8,9,10)",2-Aminobenzenesulfonic acid,CAS Registry Number,88-21-1
733,32,(+)-N-methylconiine,A piperidine that is (+)-coniine bering an N-methyl substituent.,"InChI=1S/C9H19N/c1-3-6-9-7-4-5-8-10(9)2/h9H,3-8H2,1-2H3/t9-/m0/s1",(+)-N-Methylconiine,KEGG COMPOUND accession,C10159
734,41,(+)-piperitone,The (6S)-enantiomer of  piperitone.,"InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)6-10(9)11/h6-7,9H,4-5H2,1-3H3/t9-/m0/s1",(+)-Piperitone,KEGG COMPOUND accession,C09885
735,6146,kuwanone G,A tetrahydroxyflavone isolated from the root barks of Morus alba and has been shown to exhibit anti-inflammatory activity.,"InChI=1S/C40H36O11/c1-18(2)4-8-26-38(50)36-33(48)17-32(47)35(40(36)51-39(26)25-11-7-22(43)16-31(25)46)28-13-19(3)12-27(23-9-5-20(41)14-29(23)44)34(28)37(49)24-10-6-21(42)15-30(24)45/h4-7,9-11,13-17,27-28,34,41-48H,8,12H2,1-3H3/t27-,28-,34-/m0/s1",Kuwanone G,KEGG COMPOUND accession,C10099
736,5380,glepidotin A,A trihydroxyflavone that is  galangin substituted by a prenyl  group at position 8.,"InChI=1S/C20H18O5/c1-11(2)8-9-13-14(21)10-15(22)16-17(23)18(24)19(25-20(13)16)12-6-4-3-5-7-12/h3-8,10,21-22,24H,9H2,1-2H3",8-Prenylgalangin,CAS Registry Number,42193-83-9
737,5395,glucoalyssin,A thia-glucosinolic acid that is glucoberteroin in which the sulfur atom of the methyl thioether group has been oxidised to the corresponding sulfoxide.,"InChI=1S/C13H25NO10S3/c1-26(19)6-4-2-3-5-9(14-24-27(20,21)22)25-13-12(18)11(17)10(16)8(7-15)23-13/h8,10-13,15-18H,2-7H2,1H3,(H,20,21,22)/b14-9-/t8-,10-,11+,12-,13+,26?/m1/s1",Glucoalyssin,KEGG COMPOUND accession,C08400
738,5400,glucocheirolin,,"InChI=1S/C11H21NO11S3/c1-25(17,18)4-2-3-7(12-23-26(19,20)21)24-11-10(16)9(15)8(14)6(5-13)22-11/h6,8-11,13-16H,2-5H2,1H3,(H,19,20,21)/p-1/t6-,8-,9+,10-,11+/m1/s1",Glucocheirolin,KEGG COMPOUND accession,C08405
739,5405,glucoerysolin,,"InChI=1S/C12H23NO11S3/c1-26(18,19)5-3-2-4-8(13-24-27(20,21)22)25-12-11(17)10(16)9(15)7(6-14)23-12/h7,9-12,14-17H,2-6H2,1H3,(H,20,21,22)/p-1/t7-,9-,10+,11-,12+/m1/s1",Glucoerysolin,CAS Registry Number,22149-26-4
740,5407,glucoiberverin(1-),A thia-alkylglucosinolate resulting from the removal of the proton of the hydrogen sulfate group of glucoiberverin.,"InChI=1S/C11H21NO9S3/c1-22-4-2-3-7(12-21-24(17,18)19)23-11-10(16)9(15)8(14)6(5-13)20-11/h6,8-11,13-16H,2-5H2,1H3,(H,17,18,19)/p-1/b12-7-/t6-,8-,9+,10-,11+/m1/s1",Glucoiberverin,KEGG COMPOUND accession,C08412
741,5412,gluconapoleiferin(1-),A glucosinolate that is glucobrassicanapin which has been hydroxylated at the 3-position of the hex-5-enimidoyl chain.,"InChI=1S/C12H21NO10S2/c1-2-3-6(15)4-8(13-23-25(19,20)21)24-12-11(18)10(17)9(16)7(5-14)22-12/h2,6-7,9-12,14-18H,1,3-5H2,(H,19,20,21)/p-1/t6?,7-,9-,10+,11-,12+/m1/s1",Gluconapoleiferin,CAS Registry Number,19764-03-5
742,2069,(E)-5-hydroxyferulic acid,The E-isomer of 5-hydroxyferulic acid.,"InChI=1S/C10H10O5/c1-15-8-5-6(2-3-9(12)13)4-7(11)10(8)14/h2-5,11,14H,1H3,(H,12,13)/b3-2+","(2E)-3-(3,4-dihydroxy-5-methoxyphenyl)-2-propenoic acid",CAS Registry Number,110642-42-7
743,2082,5-hydroxyxanthotoxin,A member of the class of psoralens that is xanthotoxin substituted by a hydroxy group at position 5.,"InChI=1S/C12H8O5/c1-15-12-10-7(4-5-16-10)9(14)6-2-3-8(13)17-11(6)12/h2-5,14H,1H3",5-Hydroxyxanthotoxin,KEGG COMPOUND accession,C02951
744,6499,lipoxin B4,"A C20 hydroxy fatty acid having (5S)-, (14R)- and (15S)-hydroxy groups as well as (6E)- (8Z)-, (10E)- and (12E)-double bonds.","InChI=1S/C20H32O5/c1-2-3-8-14-18(22)19(23)15-10-7-5-4-6-9-12-17(21)13-11-16-20(24)25/h4-7,9-10,12,15,17-19,21-23H,2-3,8,11,13-14,16H2,1H3,(H,24,25)/b6-4-,7-5+,12-9+,15-10+/t17-,18+,19-/m1/s1",Lipoxin B4,KEGG COMPOUND accession,C06315
745,6504,lithium carbonate,,"InChI=1S/CH2O3.2Li/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2",Lithium carbonate,CAS Registry Number,554-13-2
746,5660,"hentriacontane-14,16-dione",A beta-diketone that is hentriacontane in which the hydrogens at position 14 and 16 are replaced by oxo groups.,"InChI=1S/C31H60O2/c1-3-5-7-9-11-13-15-16-18-20-22-24-26-28-31(33)29-30(32)27-25-23-21-19-17-14-12-10-8-6-4-2/h3-29H2,1-2H3","Hentriacontane-14,16-dione",CAS Registry Number,24724-84-3
747,5712,1-hexanamine,A 6-carbon primary aliphatic amine.,"InChI=1S/C6H15N/c1-2-3-4-5-6-7/h2-7H2,1H3",Hexylamine,KEGG COMPOUND accession,C08306
748,2382,acerosin,"A trihydroxyflavone that is 5,7,3'-trihydroxyflavone with methoxy substituents at positions 6, 8 and 4' respectively.","InChI=1S/C18H16O8/c1-23-11-5-4-8(6-9(11)19)12-7-10(20)13-14(21)17(24-2)15(22)18(25-3)16(13)26-12/h4-7,19,21-22H,1-3H3",Acerosin,CAS Registry Number,15835-74-2
749,2414,14-O-acetylbrowniine,An acetate ester obtained by acetylation of the O-14 position of browniine.,"InChI=1S/C27H43NO8/c1-7-28-12-24(13-32-3)9-8-18(34-5)26-16-10-15-17(33-4)11-25(30,19(16)20(15)36-14(2)29)27(31,23(26)28)22(35-6)21(24)26/h15-23,30-31H,7-13H2,1-6H3/t15-,16-,17+,18+,19-,20+,21-,22+,23?,24+,25-,26+,27-/m1/s1",Acetylbrowniine,KEGG COMPOUND accession,C08654
750,2485,adenylyl selenate,The 5'-selenonooxyphosphate ester of adenosine.,"InChI=1S/C10H14N5O10PSe/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-26(18,19)25-27(20,21)22/h2-4,6-7,10,16-17H,1H2,(H,18,19)(H2,11,12,13)(H,20,21,22)/t4-,6-,7-,10-/m1/s1",Adenylylselenate,PubMed citation,2545107
751,2504,aflatoxin B1,"An aflatoxin having a tetrahydrocyclopenta[c]furo[3',2':4,5]furo[2,3-h]chromene skeleton with oxygen functionality at positions 1, 4 and 11.","InChI=1S/C17H12O6/c1-20-10-6-11-14(8-4-5-21-17(8)22-11)15-13(10)7-2-3-9(18)12(7)16(19)23-15/h4-6,8,17H,2-3H2,1H3/t8-,17+/m0/s1",Aflatoxin B1,CAS Registry Number,1162-65-8
752,6754,pethidine,"A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.","InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3",meperidine,KEGG COMPOUND accession,C07128
753,6820,methapyrilene,"A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.","InChI=1S/C14H19N3S/c1-16(2)9-10-17(12-13-6-5-11-18-13)14-7-3-4-8-15-14/h3-8,11H,9-10,12H2,1-2H3",Methapyrilene,KEGG COMPOUND accession,C11114
754,6835,methomyl,A carbamate ester obtained by the formal condensation of  methylcarbamic acid with the hydroxy group of  1-(methylsulfanyl)acetaldoxime.,"InChI=1S/C5H10N2O2S/c1-4(10-3)7-9-5(8)6-2/h1-3H3,(H,6,8)",Methomyl,KEGG COMPOUND accession,C11196
755,8087,N(2)-phenylacetylglutamine,,"InChI=1S/C13H16N2O4/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)(H,18,19)",Phenylacetylglutamine,Beilstein Registry Number,3212660
756,6530,longifolene,,"InChI=1S/C15H24/c1-10-11-6-7-12-13(11)14(2,3)8-5-9-15(10,12)4/h11-13H,1,5-9H2,2-4H3",Longifolene,KEGG COMPOUND accession,C09699
757,6550,loxtidine,"A triazole that consists of 1,2,4-triazole bearing a methyl substituent at position 1, a hydroxymethyl substituent at position 3 and a {3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino group at position 5. A highly potent and selective H2-receptor antagonist.","InChI=1S/C19H29N5O2/c1-23-19(21-18(15-25)22-23)20-9-6-12-26-17-8-5-7-16(13-17)14-24-10-3-2-4-11-24/h5,7-8,13,25H,2-4,6,9-12,14-15H2,1H3,(H,20,21,22)",Loxtidine,KEGG COMPOUND accession,C11805
758,6559,lucumin,A disaccharide derivative that is 6-O-beta-D-xylopyranosyl-beta-D-glucopyranose having an (R)-mandelonitrile group at the anomeric position.,"InChI=1S/C19H25NO10/c20-6-11(9-4-2-1-3-5-9)29-19-17(26)15(24)14(23)12(30-19)8-28-18-16(25)13(22)10(21)7-27-18/h1-5,10-19,21-26H,7-8H2/t10-,11+,12-,13+,14-,15+,16-,17-,18+,19-/m1/s1",Lucumin,KEGG COMPOUND accession,C08335
759,3088,bilanafos,A tripeptide comprising one L-phosphinothricyl and two L-alanyl units joined in sequence.,"InChI=1S/C11H22N3O6P/c1-6(9(15)14-7(2)11(17)18)13-10(16)8(12)4-5-21(3,19)20/h6-8H,4-5,12H2,1-3H3,(H,13,16)(H,14,15)(H,17,18)(H,19,20)/t6-,7-,8-/m0/s1",Bialaphos,CAS Registry Number,35597-43-4
760,3093,bifenthrin,"A carboxylic ester obtained by formal condensation of cis-3-(2-chloro-3,3,3-trifluoroprop-1-enyl)-2,2-dimethylcyclopropanecarboxylic acid and [(2-methyl-1,1'-biphenyl)-3-yl]methanol.","InChI=1S/C23H22ClF3O2/c1-14-16(10-7-11-17(14)15-8-5-4-6-9-15)13-29-21(28)20-18(22(20,2)3)12-19(24)23(25,26)27/h4-12,18,20H,13H2,1-3H3/b19-12-/t18-,20-/m0/s1",Bifenthrin,CAS Registry Number,82657-04-3
761,3095,biguanide,,"InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)",Biguanide,KEGG COMPOUND accession,C07672
762,3110,biotinyl-5'-AMP,,"InChI=1S/C20H28N7O9PS/c21-17-14-18(23-7-22-17)27(8-24-14)19-16(30)15(29)10(35-19)5-34-37(32,33)36-12(28)4-2-1-3-11-13-9(6-38-11)25-20(31)26-13/h7-11,13,15-16,19,29-30H,1-6H2,(H,32,33)(H2,21,22,23)(H2,25,26,31)/t9-,10+,11-,13-,15+,16+,19+/m0/s1",Biotinyl-5'-AMP,KEGG COMPOUND accession,C05921
763,5956,ipratropium,,"InChI=1S/C20H30NO3/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15/h4-8,14,16-19,22H,9-13H2,1-3H3/q+1/t16-,17+,18+,19?,21+",Ipratropium,KEGG COMPOUND accession,C07052
764,5970,irilone,"A hydroxyisoflavone that is 6,7-methylenedioxyisoflavone substituted by hydroxy groups at positions 5 and 4'.","InChI=1S/C16H10O6/c17-9-3-1-8(2-4-9)10-6-20-11-5-12-16(22-7-21-12)15(19)13(11)14(10)18/h1-6,17,19H,7H2",Irilone,KEGG COMPOUND accession,C10467
765,5994,isochamaejasmin,"A biflavonoid that consists of two units of 5,7,4'-trihydroxyflavanone joined together at position 3 and 3''.","InChI=1S/C30H22O10/c31-15-5-1-13(2-6-15)29-25(27(37)23-19(35)9-17(33)11-21(23)39-29)26-28(38)24-20(36)10-18(34)12-22(24)40-30(26)14-3-7-16(32)8-4-14/h1-12,25-26,29-36H/t25-,26+,29+,30-","3,3''-Binaringenin",KEGG COMPOUND accession,C09758
766,2825,aristolochic acid,"A monocarboxylic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic.","InChI=1S/C17H11NO7/c1-23-12-4-2-3-8-9(12)5-11(18(21)22)14-10(17(19)20)6-13-16(15(8)14)25-7-24-13/h2-6H,7H2,1H3,(H,19,20)",Aristolochic acid,KEGG COMPOUND accession,C08469
767,3375,capsanthin,,"InChI=1S/C40H56O3/c1-29(17-13-19-31(3)21-23-36-33(5)25-34(41)26-38(36,6)7)15-11-12-16-30(2)18-14-20-32(4)22-24-37(43)40(10)28-35(42)27-39(40,8)9/h11-24,34-35,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t34-,35+,40+/m1/s1",Capsanthin,KEGG COMPOUND accession,C08584
768,3392,carbendazim,"A member of the class of benzimidazoles that is 2-aminobenzimidazole in which the primary amino group is substituted by a methoxycarbonyl group. A fungicide, carbendazim controls  Ascomycetes, Fungi Imperfecti, and Basidiomycetes on a wide variety of crops, including bananas, cereals, cotton, fruits, grapes, mushrooms, ornamentals, peanuts, sugarbeet, soybeans, tobacco, and vegetables.","InChI=1S/C9H9N3O2/c1-14-9(13)12-8-10-6-4-2-3-5-7(6)11-8/h2-5H,1H3,(H2,10,11,12,13)",Carbendazim,KEGG COMPOUND accession,C10897
769,6198,(S)-azetidine-2-carboxylic acid,The (S)-enantiomer of azetidine-2-carboxylic acid.,"InChI=1S/C4H7NO2/c6-4(7)3-1-2-5-3/h3,5H,1-2H2,(H,6,7)/t3-/m0/s1",L-Azetidine 2-carboxylic acid,KEGG COMPOUND accession,C08267
770,2524,ajmalicine,"A monoterpenoid indole alkaloid with formula C21H24N2O3, isolated from several Rauvolfia and Catharanthus species. It is a selective alpha1-adrenoceptor antagonist used for the treatment of high blood pressure.","InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16+,19-/m0/s1",ajmalicine,KEGG COMPOUND accession,C09024
771,2638,amikacin disulfate,An aminoglycoside sulfate salt obtained by combining amikacin with two molar equivalents of sulfuric acid.,"InChI=1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1",Amikacin sulfate,CAS Registry Number,39831-55-5
772,8198,trans-piceid,A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.,"InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1",Piceid,KEGG COMPOUND accession,C10275
773,8200,picolinamide,A  pyridinecarboxamide that is the  monocarboxylic acid amide derivative of picolinic acid.,"InChI=1S/C6H6N2O/c7-6(9)5-3-1-2-4-8-5/h1-4H,(H2,7,9)",Picolinamide,CAS Registry Number,1452-77-3
774,3680,chrysanthemic acid,A monocarboxylic acid that is cyclopropanecarboxylic acid substituted by two methyl groups at position 2 and a 2-methylprop-1-en-1-yl group at position 3.,"InChI=1S/C10H16O2/c1-6(2)5-7-8(9(11)12)10(7,3)4/h5,7-8H,1-4H3,(H,11,12)",Chrysanthemic acid,KEGG COMPOUND accession,C09842
775,3703,cinchonidine,"8-epi-Cinchonan in which a hydrogen at position 9 is substituted by hydroxy (R configuration). A diasteroisomer of cinchonine, it occurs in the bark of most varieties of Cinchona shrubs, and is frequently used for directing chirality in asymmetric synthesis.","InChI=1S/C19H22N2O/c1-2-13-12-21-10-8-14(13)11-18(21)19(22)16-7-9-20-17-6-4-3-5-15(16)17/h2-7,9,13-14,18-19,22H,1,8,10-12H2/t13-,14-,18-,19+/m0/s1",Cinchonidine,KEGG COMPOUND accession,C11379
776,3706,cinerin I,,"InChI=1S/C20H28O3/c1-7-8-9-14-13(4)17(11-16(14)21)23-19(22)18-15(10-12(2)3)20(18,5)6/h7-8,10,15,17-18H,9,11H2,1-6H3/b8-7-/t15-,17+,18+/m1/s1",Cinerin I,CAS Registry Number,97-12-1
777,8475,propanethial S-oxide,A thiocarbonyl compound that is propanethial in which the sulfur atom carries an oxo group. It is a lachrymatory factor found in onions.,"InChI=1S/C3H6OS/c1-2-3-5-4/h3H,2H2,1H3",propanethial S-oxide,CAS Registry Number,32157-29-2
778,3901,cosyntropin,"A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of adrenocorticotropic hormone (corticotropin). A segment similar in all species, it contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. It is used diagnostically to investigate adrenocortical insufficiency.","InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,109-,110-,111-/m0/s1",Cosyntropin,KEGG COMPOUND accession,C06926
779,3908,coumestrol,A member of the class of coumestans that is coumestan with hydroxy substituents at positions 3 and 9.,"InChI=1S/C15H8O5/c16-7-1-3-9-11(5-7)19-14-10-4-2-8(17)6-12(10)20-15(18)13(9)14/h1-6,16-17H",Coumestrol,CAS Registry Number,479-13-0
780,3944,cucurbitacin E,"A cucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at positions 1, 5 and 23.","InChI=1S/C32H44O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-14,19,21-22,25,34-35,39H,11,15-16H2,1-9H3/b13-12+/t19-,21-,22+,25+,29+,30-,31+,32+/m1/s1",Cucurbitacin E,KEGG COMPOUND accession,C08797
781,3146,N(alpha)-t-butoxycarbonyl-L-asparagine,The N(alpha)-t-butoxycarbonyl derivative of L-asparagine,"InChI=1S/C9H16N2O5/c1-9(2,3)16-8(15)11-5(7(13)14)4-6(10)12/h5H,4H2,1-3H3,(H2,10,12)(H,11,15)(H,13,14)/t5-/m0/s1",Boc-Asn,KEGG COMPOUND accession,C01410
782,3163,bracteatin,"The 3,4,5-trihydrobenzylidene derivative of 4,6-dihydroxy-1-benzofuran-3(2H)-one. Its glucoside is a significant contributor to the yellow colour of Antirrhinum majus (snapdragon) flowers.","InChI=1S/C15H10O7/c16-7-4-8(17)13-11(5-7)22-12(15(13)21)3-6-1-9(18)14(20)10(19)2-6/h1-5,16-20H",Bracteatin,KEGG COMPOUND accession,C08577
783,3241,butoconazole nitrate,"An organic nitrate salt obtained by reaction of equimolar amounts of butaconazole and nitric acid.  An antifungal agent, it is used in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.","InChI=1S/C19H17Cl3N2S.HNO3/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22;2-1(3)4/h1-5,7-8,10-11,13,16H,6,9,12H2;(H,2,3,4)",Butoconazole nitrate,KEGG COMPOUND accession,C08066
784,3436,cartap,,"InChI=1S/C7H15N3O2S2/c1-10(2)5(3-13-6(8)11)4-14-7(9)12/h5H,3-4H2,1-2H3,(H2,8,11)(H2,9,12)",Cartap,KEGG COMPOUND accession,C11080
785,3453,cassaidine,A tricyclic diterpenoid that is is isolated from several plant species including Erythrophleum guineense and Erythrophleum ivorense. It is toxic with a digitalis like effect on the heart and a strong local anesthetic action.,"InChI=1S/C24H41NO4/c1-15-16(13-21(28)29-12-11-25(5)6)7-8-17-22(15)18(26)14-19-23(2,3)20(27)9-10-24(17,19)4/h13,15,17-20,22,26-27H,7-12,14H2,1-6H3/b16-13+/t15-,17-,18-,19-,20-,22-,24+/m0/s1",cassaidine,KEGG COMPOUND accession,C08669
786,4445,desflurane,,"InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H",Desflurane,CAS Registry Number,57041-67-5
787,4496,calcium hydrogenphosphate dihydrate,,"InChI=1S/Ca.H3O4P.2H2O/c;1-5(2,3)4;;/h;(H3,1,2,3,4);2*1H2/q+2;;;/p-2",Dibasic calcium phosphate dihydrate,CAS Registry Number,7789-77-7
788,4559,dihydroconiferyl alcohol,A member of class of phenols that is 2-methoxyphenol substituted by a 3-hydroxypropyl group at position 4.,"InChI=1S/C10H14O3/c1-13-10-7-8(3-2-6-11)4-5-9(10)12/h4-5,7,11-12H,2-3,6H2,1H3",Dihydroconiferyl alcohol,KEGG COMPOUND accession,C10448
789,9243,sporidesmin A,"An organic heteropentacyclic compound that has formula C18H20ClN3O6S2, produced by the saprophyte fungus Pithomyces chartarum. It is a mycotoxin responsible for the hepatogenous photosensitisation disease facial eczema in ruminants.","InChI=1S/C18H20ClN3O6S2/c1-16-14(24)22-13-17(26,12(23)18(22,30-29-16)15(25)21(16)3)7-6-8(19)10(27-4)11(28-5)9(7)20(13)2/h6,12-13,23,26H,1-5H3/t12-,13-,16-,17-,18-/m1/s1",sporidesmin,CAS Registry Number,1456-55-9
790,9261,sterculic acid,"A long-chain, monounsaturated fatty acid composed of 9-octadecenoic acid having a 9,10-cyclopropenyl group.","InChI=1S/C19H34O2/c1-2-3-4-5-7-10-13-17-16-18(17)14-11-8-6-9-12-15-19(20)21/h2-16H2,1H3,(H,20,21)",Sterculic acid,KEGG COMPOUND accession,C08366
791,4250,"D-tagatofuranose 1,6-bisphosphate","The furanose form of D-tagatose 1,6-bisphosphate.","InChI=1S/C6H14O12P2/c7-4-3(1-16-19(10,11)12)18-6(9,5(4)8)2-17-20(13,14)15/h3-5,7-9H,1-2H2,(H2,10,11,12)(H2,13,14,15)/t3-,4+,5+,6?/m1/s1","D-Tagatose 1,6-bisphosphate",KEGG COMPOUND accession,C03785
792,4318,dantrolene sodium (anhydrous),The anhydrous sodium salt of dantrolene.,"InChI=1S/C14H10N4O5.Na/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22;/h1-7H,8H2,(H,16,19,20);/q;+1/p-1",Dantrolene sodium anhydrous,KEGG COMPOUND accession,C07933
793,5569,iminoctadine,"A member of the class of guanidines that is dioctylamine in which a hydrogen from each of the terminal methyl groups is replaced by a guanidino group. Once used as a fungicidal seed dressing, it is no longer approved for use in the European Union.","InChI=1S/C18H41N7/c19-17(20)24-15-11-7-3-1-5-9-13-23-14-10-6-2-4-8-12-16-25-18(21)22/h23H,1-16H2,(H4,19,20,24)(H4,21,22,25)",Guazatine,CAS Registry Number,13516-27-3
794,3740,cleomiscosin A,"An organic heterotricyclic compound that is 2,3-dihydro-9H-[1,4]dioxino[2,3-h]chromen-9-one substituted by 4-hydroxy-3-methoxy phenyl group at position 3, a hydroxymethyl group at position 2 and a methoxy group at position 5 (the 2R,3R stereoisomer). It exhibits anti-inflammatory activity.","InChI=1S/C20H18O8/c1-24-13-7-10(3-5-12(13)22)17-15(9-21)26-20-18-11(4-6-16(23)27-18)8-14(25-2)19(20)28-17/h3-8,15,17,21-22H,9H2,1-2H3/t15-,17-/m1/s1",Cleomiscosin A,KEGG COMPOUND accession,C09922
795,3761,clorazepic acid,"A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.","InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)",Clorazepate,KEGG COMPOUND accession,C06921
796,513,"1,3,4,6-tetrachlorocyclohexa-1,4-diene","A chloroolefin that is cyclohexa-1,4-diene substituted by chloro groups at positions 1, 3, 4 and 6.","InChI=1S/C6H4Cl4/c7-3-1-4(8)6(10)2-5(3)9/h1-3,6H","1,3,4,6-Tetrachloro-1,4-cyclohexadiene",KEGG COMPOUND accession,C06597
797,9495,thiram,"An organic disulfide that results from the formal oxidative dimerisation of N,N-dimethyldithiocarbamic acid. It is widely used as a fungicidal seed treatment.",InChI=1S/C6H12N2S4/c1-7(2)5(9)11-12-6(10)8(3)4/h1-4H3,Tetramethylthioperoxydicarbonic diamide,CAS Registry Number,137-26-8
798,9501,tetraphenylarsonium,An arsonium ion consisting of four phenyl groups attached to a central arsonium.,"InChI=1S/C24H20As/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22,23-17-9-3-10-18-23)24-19-11-4-12-20-24/h1-20H/q+1",Tetraphenylarsonium,CAS Registry Number,15912-80-8
799,9518,theasinensin A,A biflavonoid that is obtained by coupling of two molecules of (-)-epigallocatechin 3-gallate resulting in a bond between positions C-2 of the hydroxyphenyl ring. It is a natural product found in oolong tea.,"InChI=1S/C44H34O22/c45-15-5-21(47)17-11-31(65-43(61)13-1-23(49)35(55)24(50)2-13)41(63-29(17)7-15)19-9-27(53)37(57)39(59)33(19)34-20(10-28(54)38(58)40(34)60)42-32(12-18-22(48)6-16(46)8-30(18)64-42)66-44(62)14-3-25(51)36(56)26(52)4-14/h1-10,31-32,41-42,45-60H,11-12H2/t31-,32-,41-,42-/m1/s1",theasinensin A,KEGG COMPOUND accession,C09972
800,4034,cyfluthrin,"A carboxylic ester obtained by formal condensation between 3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid and (4-fluoro-3-phenoxyphenyl)(hydroxy)acetonitrile.","InChI=1S/C22H18Cl2FNO3/c1-22(2)15(11-19(23)24)20(22)21(27)29-18(12-26)13-8-9-16(25)17(10-13)28-14-6-4-3-5-7-14/h3-11,15,18,20H,1-2H3",Cyfluthrin,CAS Registry Number,68359-37-5
801,4036,cyhexatin,,"InChI=1S/3C6H11.H2O.Sn/c3*1-2-4-6-5-3-1;;/h3*1H,2-6H2;1H2;/q;;;;+1/p-1",Cyhexatin,KEGG COMPOUND accession,C11093
802,76,(-)-annonaine,"An aporphine alkaloid that exhibits anti-cancer, trypanocidal and antiplasmodial activites.","InChI=1S/C17H15NO2/c1-2-4-12-10(3-1)7-13-15-11(5-6-18-13)8-14-17(16(12)15)20-9-19-14/h1-4,8,13,18H,5-7,9H2/t13-/m1/s1",(-)-Annonaine,KEGG COMPOUND accession,C09339
803,99,(-)-maackiain,The (-)-enantiomer of maackiain.,"InChI=1S/C16H12O5/c17-8-1-2-9-12(3-8)18-6-11-10-4-14-15(20-7-19-14)5-13(10)21-16(9)11/h1-5,11,16-17H,6-7H2/t11-,16-/m0/s1",(-)-Maackiain,KEGG COMPOUND accession,C10502
804,153,(-)-neoisodihydrocarveol,"A dihydrocarveol with a (1R,2S,4S)-configuration.","InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-11H,1,4-6H2,2-3H3/t8-,9+,10+/m1/s1","(1R,2S,4S)- Neoiso-dihydrocarveol",KEGG COMPOUND accession,C11410
805,5010,fenoprofen calcium (anhydrous),The anhydrous form of the calcium salt of fenprofen. The dihydrate form is used as a non-steroidal anti-inflammatory drug for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis.,"InChI=1S/2C15H14O3.Ca/c2*1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;/h2*2-11H,1H3,(H,16,17);/q;;+2/p-2",Fenprofen calcium,KEGG COMPOUND accession,C02539
806,5065,fisetin 8-C-glucoside,A  flavone C-glycoside that is fisetin substituted by a beta-D-glucopyranosyl residue at position 8 via a C-glycosidic linkage.,"InChI=1S/C21H20O11/c22-6-12-15(27)16(28)18(30)21(31-12)13-10(24)4-2-8-14(26)17(29)19(32-20(8)13)7-1-3-9(23)11(25)5-7/h1-5,12,15-16,18,21-25,27-30H,6H2/t12-,15-,16+,18-,21+/m1/s1",Fisetin 8-C-glucoside,CAS Registry Number,108335-27-9
807,5092,2-(2-phenylethyl)chromone,"A member of the class of chromones that is chromone which is substituted by a 2-phenylethyl group at position 2. It is found in agarwood, a fragrant resinous heartwood obtained from certain trees in the genus Aquilaria.","InChI=1S/C17H14O2/c18-16-12-14(11-10-13-6-2-1-3-7-13)19-17-9-5-4-8-15(16)17/h1-9,12H,10-11H2",flindersiachromone,KEGG COMPOUND accession,C09007
808,4823,ergosine,An  ergot alkaloid isolated from the fungus Epichloe typhina.,"InChI=1S/C30H37N5O5/c1-16(2)11-23-27(37)34-10-6-9-24(34)30(39)35(23)28(38)29(3,40-30)32-26(36)18-12-20-19-7-5-8-21-25(19)17(14-31-21)13-22(20)33(4)15-18/h5,7-8,12,14,16,18,22-24,31,39H,6,9-11,13,15H2,1-4H3,(H,32,36)/t18-,22-,23+,24+,29-,30+/m1/s1",Ergosine,CAS Registry Number,561-94-4
809,4850,eschscholtzidine,A heteropentacyclic isoquinoline alkaloid having a tertiary amino bridging group.,"InChI=1S/C20H21NO4/c1-21-15-5-12-7-19-20(25-10-24-19)9-14(12)16(21)4-11-6-17(22-2)18(23-3)8-13(11)15/h6-9,15-16H,4-5,10H2,1-3H3/t15-,16-/m0/s1",Eschscholtzidine,KEGG COMPOUND accession,C09426
810,4866,17beta-estradiol 3-sulfate,A steroid sulfate obtained by the formal condensation of sulfuric acid with the 3-hydroxy group of 17beta-estradiol.,"InChI=1S/C18H24O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-17,19H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,17+,18+/m1/s1",Estradiol-17beta 3-sulfate,KEGG COMPOUND accession,C08357
811,6066,isothebaine,,"InChI=1S/C19H21NO3/c1-20-8-7-12-10-15(23-3)19(21)18-16(12)13(20)9-11-5-4-6-14(22-2)17(11)18/h4-6,10,13,21H,7-9H2,1-3H3/t13-/m0/s1",Isothebaine,KEGG COMPOUND accession,C09550
812,10440,(-)-beta-santalene,"A sesquiterpene and carbobicyclic compound that is bicyclo[2.2.1]heptane in which the hydrogens at position 3 are substituted by a methylidene group, while the 2-exo- and 2-endo- hydrogens are subsitituted by 2-methylpent-2-en-5-yl and methyl groups, respectively (the 1S,2R,4R enantiomer).","InChI=1S/C15H24/c1-11(2)6-5-9-15(4)12(3)13-7-8-14(15)10-13/h6,13-14H,3,5,7-10H2,1-2,4H3/t13-,14+,15+/m1/s1",beta-Santalene,CAS Registry Number,511-59-1
813,1254,cis-2-oxohept-3-enedioic acid,The cis-isomer of 2-oxohept-3-enedioic acid.,"InChI=1S/C7H8O5/c8-5(7(11)12)3-1-2-4-6(9)10/h1,3H,2,4H2,(H,9,10)(H,11,12)/b3-1-",2-Oxohept-3-enedioate,KEGG COMPOUND accession,C03063
814,6417,"(2R,3S,4S)-leucodelphinidin","A flavan-3,3',4,4',5,5',7-heptol that has (2R,3S,4S) configuration.","InChI=1S/C15H14O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,13-22H/t13-,14-,15+/m0/s1",Leucodelphinidin,KEGG COMPOUND accession,C05909
815,20106,vanillylmandelic acid,"An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid.","InChI=1S/C9H10O5/c1-14-7-4-5(2-3-6(7)10)8(11)9(12)13/h2-4,8,10-11H,1H3,(H,12,13)",3-methoxy-4-hydroxymandelic acid,KEGG COMPOUND accession,C05584
816,771,16alpha-hydroxypregnenolone,A hydroxypregnenolone that is pregnenolone substituted by a alpha-hydroxy group at position 16.,"InChI=1S/C21H32O3/c1-12(22)19-18(24)11-17-15-5-4-13-10-14(23)6-8-20(13,2)16(15)7-9-21(17,19)3/h4,14-19,23-24H,5-11H2,1-3H3/t14-,15+,16-,17-,18+,19-,20-,21-/m0/s1",16-alpha-Hydroxypregnenolone,KEGG COMPOUND accession,C06390
817,1890,4-methoxyglucobrassicin,An  indolylmethylglucosinolic acid that is glucobrassicin bearing a methoxy substituent at position 4 on the indole ring.,"InChI=1S/C17H22N2O10S2/c1-27-10-4-2-3-9-13(10)8(6-18-9)5-12(19-29-31(24,25)26)30-17-16(23)15(22)14(21)11(7-20)28-17/h2-4,6,11,14-18,20-23H,5,7H2,1H3,(H,24,25,26)/t11-,14-,15+,16-,17+/m1/s1",4-Methoxyglucobrassicin,KEGG COMPOUND accession,C08423
818,9947,veracevine,"A cyclic hemiketal that is cevane that has an oxygen bridge from the 4alpha to the 9 position and is substituted by hydroxy groups at the 3beta, 4beta, 12, 14, 16beta, 17, and 20 positions.","InChI=1S/C27H43NO8/c1-14-4-7-18-22(3,31)26(34)17(12-28(18)11-14)24(33)13-25-16(23(24,32)10-20(26)30)6-5-15-21(25,2)9-8-19(29)27(15,35)36-25/h14-20,29-35H,4-13H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25+,26-,27-/m0/s1",Veracevine,KEGG COMPOUND accession,C10828
819,10015,vobasine,An indole alkaloid that is vobasan in which the bridgehead methyl group is substituted by a methoxycarbonyl group and an additional oxo substituent is present in the 3-position.,"InChI=1S/C21H24N2O3/c1-4-12-11-23(2)17-9-15-13-7-5-6-8-16(13)22-20(15)18(24)10-14(12)19(17)21(25)26-3/h4-8,14,17,19,22H,9-11H2,1-3H3/b12-4-/t14-,17-,19-/m0/s1",Vobasine,CAS Registry Number,2134-83-0
820,10017,volemitol,"A heptitol that is heptane-1,2,3,4,5,6,7-heptol that has R-configuration at positions 2, 3, 5 and 6.","InChI=1S/C7H16O7/c8-1-3(10)5(12)7(14)6(13)4(11)2-9/h3-14H,1-2H2/t3-,4-,5-,6-/m1/s1",D-glycero-D-manno-Heptitol,KEGG COMPOUND accession,C08260
821,10037,wedelolactone,"A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.","InChI=1S/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3",Wedelolactone,KEGG COMPOUND accession,C10541
822,6597,lycopodine,,"InChI=1S/C16H25NO/c1-11-8-12-9-15(18)14-5-3-7-17-6-2-4-13(12)16(14,17)10-11/h11-14H,2-10H2,1H3/t11-,12+,13-,14-,16-/m1/s1",Lycopodine,KEGG COMPOUND accession,C09883
823,6604,lysergic acid,"An ergoline alkaloid comprising 6-methylergoline having additional unsaturation at the 9,10-position and a carboxy group at the 8-position.","InChI=1S/C16H16N2O2/c1-18-8-10(16(19)20)5-12-11-3-2-4-13-15(11)9(7-17-13)6-14(12)18/h2-5,7,10,14,17H,6,8H2,1H3,(H,19,20)/t10-,14-/m1/s1",Lysergic acid,CAS Registry Number,82-58-6
824,6664,malonylapiin,A glycosyloxyflavone that is the 6''-malanoate ester of apiin.,"InChI=1S/C29H30O17/c30-10-29(40)11-42-28(26(29)39)46-25-24(38)23(37)19(9-41-21(36)8-20(34)35)45-27(25)43-14-5-15(32)22-16(33)7-17(44-18(22)6-14)12-1-3-13(31)4-2-12/h1-7,19,23-28,30-32,37-40H,8-11H2,(H,34,35)/t19-,23-,24+,25-,26+,27-,28+,29-/m1/s1",7-O-[beta-D-apiosyl-(1->2)-(6-malonyl-beta-D-glucoside)],KEGG COMPOUND accession,C05622
825,6673,malvalic acid,A long-chain cyclopropenyl fatty acid comprising 8-heptadecenoic acid having a cyclopropene ring arising from the linking of C-8 and C-9 by a methylene substituent.,"InChI=1S/C18H32O2/c1-2-3-4-5-6-9-12-16-15-17(16)13-10-7-8-11-14-18(19)20/h2-15H2,1H3,(H,19,20)",Malvalic acid,KEGG COMPOUND accession,C08321
826,1109,2-hexaprenyl-6-methoxyphenol,A monomethoxybenzene that is 6-methoxyphenol substituted by a (all-trans)-hexaprenyl group at position 2.,"InChI=1S/C37H56O2/c1-29(2)15-9-16-30(3)17-10-18-31(4)19-11-20-32(5)21-12-22-33(6)23-13-24-34(7)27-28-35-25-14-26-36(39-8)37(35)38/h14-15,17,19,21,23,25-27,38H,9-13,16,18,20,22,24,28H2,1-8H3/b30-17+,31-19+,32-21+,33-23+,34-27+",2-Hexaprenyl-6-methoxyphenol,KEGG COMPOUND accession,C05802
827,1113,"cis-2-hydroxypenta-2,4-dienoic acid","The cis-isomer of 2-hydroxypenta-2,4-dienoic acid.","InChI=1S/C5H6O3/c1-2-3-4(6)5(7)8/h2-3,6H,1H2,(H,7,8)/b4-3+","cis-2-Hydroxypenta-2,4-dienoate",KEGG COMPOUND accession,C00596
828,10223,alpha-cryptoxanthin,"A carotenol, the structure of which is (6'R)-beta,epsilon-carotene hydroxy-substituted at C-3' with R-stereochemistry.","InChI=1S/C40H56O/c1-30(18-13-20-32(3)23-25-37-34(5)22-15-27-39(37,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-38-35(6)28-36(41)29-40(38,9)10/h11-14,16-21,23-26,28,36,38,41H,15,22,27,29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+/t36-,38-/m0/s1",alpha-Cryptoxanthin,CAS Registry Number,24480-38-4
829,10276,alpha-ergocryptine,"Ergotaman bearing hydroxy, isopropyl, and 2-methylpropyl groups at the 12', 2' and 5' positions, respectively, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid. Ergocryptine discussed in the literature prior to 1967, when beta-ergocryptine was separated from alpha-ergocryptine, is now referred to as alpha-ergocryptine.","InChI=1S/C32H41N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,13,15,17-18,20,24-26,33,41H,7,10-12,14,16H2,1-5H3,(H,34,38)/t20-,24-,25+,26+,31-,32+/m1/s1",alpha-Ergocryptine,KEGG COMPOUND accession,C07545
830,6885,(S)-2-methyl-3-oxosuccinic acid,,"InChI=1S/C5H6O5/c1-2(4(7)8)3(6)5(9)10/h2H,1H3,(H,7,8)(H,9,10)/t2-/m0/s1",Methyloxaloacetate,KEGG COMPOUND accession,C06030
831,6941,(-)-minovincinine,A monoterpenoid indole alkaloid that is (-)-vincadifformine which carries a hydroxy group at position 19R. A natural product found in several plant species including Catharanthus roseus and Vinca minor.,"InChI=1S/C21H26N2O3/c1-13(24)20-8-5-10-23-11-9-21(19(20)23)15-6-3-4-7-16(15)22-17(21)14(12-20)18(25)26-2/h3-4,6-7,13,19,22,24H,5,8-12H2,1-2H3/t13-,19+,20+,21+/m1/s1",minovincinine,KEGG COMPOUND accession,C11783
832,6993,montelukast sodium,,"InChI=1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1",Montelukast sodium,CAS Registry Number,151767-02-1
833,3543,cephamycin C,"One of three naturally occurring cephamycin antibiotics, differing from the A and B forms in its carbamoyloxymethyl substituent at C-3.","InChI=1S/C16H22N4O9S/c1-28-16(19-9(21)4-2-3-8(17)11(22)23)13(26)20-10(12(24)25)7(5-29-15(18)27)6-30-14(16)20/h8,14H,2-6,17H2,1H3,(H2,18,27)(H,19,21)(H,22,23)(H,24,25)/t8-,14-,16+/m1/s1",Cephamycin C,KEGG COMPOUND accession,C06566
834,2015,"5-(3-buten-1-ynyl)-2,2'-bithiophene","A member of the class of  2,2'-bithiophenes that is 2,2'-bithiophene substituted by a 3-buten-1-ynyl group at position 5.","InChI=1S/C12H8S2/c1-2-3-5-10-7-8-12(14-10)11-6-4-9-13-11/h2,4,6-9H,1H2","5-(3-Buten-1-ynyl)-2,2'-bithienyl",KEGG COMPOUND accession,C08397
835,2022,5-(heptadec-12-enyl)resorcinol,A resorcinol compound having a cis-heptadec-12-enyl substituent at the 5-position.,"InChI=1S/C23H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-18-22(24)20-23(25)19-21/h5-6,18-20,24-25H,2-4,7-17H2,1H3/b6-5-",5-(Heptadec-12-enyl)resorcinol,KEGG COMPOUND accession,C10802
836,7579,"(6S,7R)-2-azaspiro[5.5]undecan-7-ol",,"InChI=1S/C10H19NO/c12-9-4-1-2-5-10(9)6-3-7-11-8-10/h9,11-12H,1-8H2/t9-,10+/m1/s1",Nitramine,KEGG COMPOUND accession,C10163
837,18435,(+)-7-isojasmonic acid,An oxylipin that is [(1S)-3-oxocyclopentyl]acetic acid substituted by a (2Z)-pent-2-en-1-yl group at position 2 on the cyclopentanone ring.,"InChI=1S/C12H18O3/c1-2-3-4-5-10-9(8-12(14)15)6-7-11(10)13/h3-4,9-10H,2,5-8H2,1H3,(H,14,15)/b4-3-/t9-,10+/m1/s1",(+)-7-isojasmonic acid,KEGG COMPOUND accession,C16317
838,3293,3-O-beta-D-glucosyl-trans-caffeic acid,A hydroxycinnamic acid that is trans-caffeic acid in which the phenolic hydroxy group at position 3 has been converted into its beta-D-glucoside.,"InChI=1S/C15H18O9/c16-6-10-12(20)13(21)14(22)15(24-10)23-9-5-7(1-3-8(9)17)2-4-11(18)19/h1-5,10,12-17,20-22H,6H2,(H,18,19)/b4-2+/t10-,12-,13+,14-,15-/m1/s1",Caffeic acid 3-glucoside,KEGG COMPOUND accession,C10431
839,7628,norethisterone acetate,A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.,"InChI=1S/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1",Norethindrone acetate,CAS Registry Number,51-98-9
840,7671,O-acetylhomoserine,An alpha-amino acid that is homoserine in which the alcoholic hydroxy group has been converted to the corresponding acetate.,"InChI=1S/C6H11NO4/c1-4(8)11-3-2-5(7)6(9)10/h5H,2-3,7H2,1H3,(H,9,10)",O-Acetylhomoserine,KEGG COMPOUND accession,C05700
841,10525,dTDP-beta-L-mycarose,A dTDP-sugar having beta-L-mycarose as the sugar component.,"InChI=1S/C17H28N2O14P2/c1-8-6-19(16(23)18-15(8)22)12-4-10(20)11(31-12)7-29-34(25,26)33-35(27,28)32-13-5-17(3,24)14(21)9(2)30-13/h6,9-14,20-21,24H,4-5,7H2,1-3H3,(H,25,26)(H,27,28)(H,18,22,23)/t9-,10-,11+,12+,13+,14-,17+/m0/s1","dTDP-2,6-dideoxy-3-C-methyl-beta-L-ribo-hexose",Reaxys Registry Number,10623922
842,3002,beclomethasone dipropionate,A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.,"InChI=1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1",Beclomethasone dipropionate,KEGG COMPOUND accession,C07813
843,3014,benfuracarb,,"InChI=1S/C20H30N2O5S/c1-7-25-17(23)11-12-22(14(2)3)28-21(6)19(24)26-16-10-8-9-15-13-20(4,5)27-18(15)16/h8-10,14H,7,11-13H2,1-6H3",Benfuracarb,CAS Registry Number,82560-54-1
844,6995,morellin,An organic heterohexacyclic compound that is the major chromenoxanthone pigment present in Garcinia morella Desr.seed coat extract.,"InChI=1S/C33H36O7/c1-17(2)8-9-21-27-20(11-12-30(4,5)38-27)25(35)24-26(36)22-14-19-15-23-31(6,7)40-32(29(19)37,13-10-18(3)16-34)33(22,23)39-28(21)24/h8,10-12,14,16,19,23,35H,9,13,15H2,1-7H3/b18-10-/t19-,23+,32+,33-/m1/s1",Morellin,CAS Registry Number,1183-12-6
845,2160,"6-(3,3-dimethylallyl)galangin",A trihydroxyflavone that is  galangin substituted by a prenyl group at position 6.,"InChI=1S/C20H18O5/c1-11(2)8-9-13-14(21)10-15-16(17(13)22)18(23)19(24)20(25-15)12-6-4-3-5-7-12/h3-8,10,21-22,24H,9H2,1-2H3","6-(3,3-DMA)galangin",KEGG COMPOUND accession,C11576
846,2229,6-phospho-2-dehydro-D-gluconic acid,A ketoaldonic acid phosphate that is the 6-phospho derivative of 2-dehydro-D-gluconic acid.,"InChI=1S/C6H11O10P/c7-2(1-16-17(13,14)15)3(8)4(9)5(10)6(11)12/h2-4,7-9H,1H2,(H,11,12)(H2,13,14,15)/t2-,3-,4+/m1/s1",6-Phospho-2-dehydro-D-gluconate,KEGG COMPOUND accession,C01218
847,2305,"8-(3,3-dimethylallyl)chrysin",A dihydroxyflavone that is chrysin substituted by a prenyl group at position 8.,"InChI=1S/C20H18O4/c1-12(2)8-9-14-15(21)10-16(22)19-17(23)11-18(24-20(14)19)13-6-4-3-5-7-13/h3-8,10-11,21-22H,9H2,1-2H3","8-(3,3-DMA)chrysin",KEGG COMPOUND accession,C11325
848,2323,4-hydroxy-8-methoxyquinaldic acid,A quinolinemonocarboxylic acid that is kynurenic acid which is substituted by a methoxy group at position 8.,"InChI=1S/C11H9NO4/c1-16-9-4-2-3-6-8(13)5-7(11(14)15)12-10(6)9/h2-5H,1H3,(H,12,13)(H,14,15)",8-Methoxykynurenate,KEGG COMPOUND accession,C05830
849,7815,oxalosuccinic acid,A tricarboxylic acid consisting of 2-oxoglutaric acid having a further carboxy group at the 3-position. It is a substrate of the citric acid cycle.,"InChI=1S/C6H6O7/c7-3(8)1-2(5(10)11)4(9)6(12)13/h2H,1H2,(H,7,8)(H,10,11)(H,12,13)",Oxalosuccinate,CAS Registry Number,1948-82-9
850,7824,oxcarbazepine,"A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.","InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)",Oxcarbazepine,KEGG COMPOUND accession,C07492
851,1294,"(20R,22R)-20,22-dihydroxycholesterol","An  oxysterol that is cholesterol substituted  by hydroxy groups at positions 20 and 22 (the 20R,22R-stereoisomer).","InChI=1S/C27H46O3/c1-17(2)6-11-24(29)27(5,30)23-10-9-21-20-8-7-18-16-19(28)12-14-25(18,3)22(20)13-15-26(21,23)4/h7,17,19-24,28-30H,6,8-16H2,1-5H3/t19-,20-,21-,22-,23-,24+,25-,26-,27+/m0/s1","20alpha,22beta-Dihydroxycholesterol",KEGG COMPOUND accession,C05501
852,2805,arbusculin A,A sesquiterpene lactone isolated from Saussureae Radix and has been shown to exhibit inhibitory activity against melanogenesis.,"InChI=1S/C15H22O3/c1-9-10-5-8-14(2)6-4-7-15(3,17)12(14)11(10)18-13(9)16/h10-12,17H,1,4-8H2,2-3H3/t10-,11-,12+,14+,15+/m0/s1",Arbusculin A,KEGG COMPOUND accession,C09295
853,7386,4-acetamidobutanal,,"InChI=1S/C6H11NO2/c1-6(9)7-4-2-3-5-8/h5H,2-4H2,1H3,(H,7,9)",N4-Acetylaminobutanal,KEGG COMPOUND accession,C05936
854,26831,"N,N''-sulfonyldiurea",,"InChI=1S/C2H6N4O4S/c3-1(7)5-11(9,10)6-2(4)8/h(H3,3,5,7)(H3,4,6,8)",sulfonylurea,CAS Registry Number,35507-37-0
855,26836,sulfuric acid,A sulfur oxoacid that consists of two oxo and two hydroxy groups joined covalently to a central sulfur atom.,"InChI=1S/H2O4S/c1-5(2,3)4/h(H2,1,2,3,4)",sulfuric acid,MolBase accession,4
856,23203,cholestenoyl-CoA,A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of any cholestenoic acid.,"InChI=1S/C48H76N7O18P3S/c1-27(32-12-13-33-31-11-10-29-22-30(56)14-17-47(29,5)34(31)15-18-48(32,33)6)8-7-9-28(2)45(61)77-21-20-50-36(57)16-19-51-43(60)40(59)46(3,4)24-70-76(67,68)73-75(65,66)69-23-35-39(72-74(62,63)64)38(58)44(71-35)55-26-54-37-41(49)52-25-53-42(37)55/h22,25-28,31-35,38-40,44,58-59H,7-21,23-24H2,1-6H3,(H,50,57)(H,51,60)(H,65,66)(H,67,68)(H2,49,52,53)(H2,62,63,64)/t27-,28+,31+,32-,33+,34+,35-,38-,39-,40+,44-,47+,48-/m1/s1",cholestenoyl-CoAs,PDBeChem accession,5JB
857,21101,D-altraric acid,The D-enantiomer of altraric acid.,"InChI=1S/C6H10O8/c7-1(3(9)5(11)12)2(8)4(10)6(13)14/h1-4,7-10H,(H,11,12)(H,13,14)/t1-,2+,3-,4-/m0/s1",D-talaric acid,Beilstein Registry Number,1728115
858,20435,p-mercuribenzoate,,"InChI=1S/C7H5O2.Hg/c8-7(9)6-4-2-1-3-5-6;/h2-5H,(H,8,9);/p-1",4-mercuribenzoate,KEGG COMPOUND accession,C00985
859,20440,4-methyl-L-glutamic acid,An amino dicarboxylic acid that is L-glutamic acid substituted by a methyl group at position 4.,"InChI=1S/C6H11NO4/c1-3(5(8)9)2-4(7)6(10)11/h3-4H,2,7H2,1H3,(H,8,9)(H,10,11)/t3?,4-/m0/s1",4-methyl-L-glutamic acid,KEGG COMPOUND accession,C06234
860,20553,5-bromouridine,A uridine having a bromo substituent at the 5-position.,"InChI=1S/C9H11BrN2O6/c10-3-1-12(9(17)11-7(3)16)8-6(15)5(14)4(2-13)18-8/h1,4-6,8,13-15H,2H2,(H,11,16,17)/t4-,5-,6-,8-/m1/s1",5-bromouridine,CAS Registry Number,957-75-5
861,26710,sodium chloride,An inorganic chloride salt having sodium(1+) as the counterion.,InChI=1S/ClH.Na/h1H;/q;+1/p-1,sodium chloride,CAS Registry Number,7647-14-5
862,25147,mandelate,,"InChI=1S/C8H8O3/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7,9H,(H,10,11)/p-1",2-hydroxy-2-(4-hydroxyphenyl)acetate,CAS Registry Number,769-61-9
863,25152,manganate,A divalent inorganic anion obtained by removal of both protons from manganic acid.,InChI=1S/Mn.4O/q;;;2*-1,manganate ion,CAS Registry Number,14333-14-3
864,25198,dimercury(2+),,InChI=1S/2Hg/q2*+1,mercurous ion,Gmelin Registry Number,49273
865,23808,dimethylarsinous acid,,"InChI=1S/C2H7AsO/c1-3(2)4/h4H,1-2H3",dimethylarsinous acid,UM-BBD compID,c0773
866,20831,9-phenanthryl beta-D-glucosiduronic acid,,"InChI=1S/C20H18O7/c21-15-16(22)18(19(24)25)27-20(17(15)23)26-14-9-10-5-1-2-6-11(10)12-7-3-4-8-13(12)14/h1-9,15-18,20-23H,(H,24,25)/t15-,16-,17+,18-,20+/m0/s1",9-phenanthryl-beta-D-glucuronoside,UM-BBD compID,c0531
867,26642,selenous acid,,"InChI=1S/H2O3Se/c1-4(2)3/h(H2,1,2,3)",selenous acid,CAS Registry Number,7783-00-8
868,20680,"6,7-dihydrobiopterin",,"InChI=1S/C9H13N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,15-16H,2H2,1H3,(H3,10,11,13,14,17)","6,7-dihydrobiopterin",KEGG COMPOUND accession,C00268
869,19092,1-pyrroline,,"InChI=1S/C4H7N/c1-2-4-5-3-1/h3H,1-2,4H2",1-pyrroline,Gmelin Registry Number,485825
870,23360,colitose,,"InChI=1S/C6H12O4/c1-4(8)6(10)2-5(9)3-7/h3-6,8-10H,2H2,1H3/t4-,5-,6-/m0/s1","3,6-deoxy-L-galactose",CAS Registry Number,4221-05-0
871,25812,ozone,"An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pleasant odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.",InChI=1S/O3/c1-3-2,ozone,MolBase accession,931
872,26116,phytochromobilin,A member of the class of bilins which functions as the chromophore of light-sensing phytochromes in plants.,"InChI=1S/C33H36N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-15,19,35H,2,9-12H2,1,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b20-7?,26-13-,27-14-,28-15-/t19-/m1/s1",phytochromobilin,PubMed citation,18658149
873,25942,peroxynitrous acid,,InChI=1S/HNO3/c2-1-4-3/h3H,peroxynitrous acid,CAS Registry Number,14691-52-2
874,19371,dibromothymoquinone,,"InChI=1S/C10H10Br2O2/c1-4(2)6-8(12)9(13)5(3)7(11)10(6)14/h4H,1-3H3",DBMIB,Beilstein Registry Number,2265154
875,21347,L-lanthionine,The L-enantiomer of lanthionine.,"InChI=1S/C6H12N2O4S/c7-3(5(9)10)1-13-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1",(R)-S-(2-amino-2-carboxyethyl)-L-cysteine,CAS Registry Number,922-55-4
876,20506,"5,6,7,8-tetrahydrofolic acid",,"InChI=1S/C19H23N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,11-12,21,23H,5-8H2,(H,24,29)(H,27,28)(H,31,32)(H4,20,22,25,26,30)/t11?,12-/m0/s1",THF,KEGG COMPOUND accession,C00101
877,22927,bromine atom,,InChI=1S/Br,Br,WebElements accession,Br
878,23012,carbon disulfide,,InChI=1S/CS2/c2-1-3,carbon disulfide,UM-BBD compID,c0561
879,19963,3-aminobenzenesulfonate,,"InChI=1S/C6H7NO3S/c7-5-2-1-3-6(4-5)11(8,9)10/h1-4H,7H2,(H,8,9,10)/p-1",m-aminobenzenesulfonic acid,Beilstein Registry Number,3906214
880,27036,"trans,trans-muconic acid","The trans,trans-isomer of muconic acid. It is metabolite of benzene in humans and serves as a biomarker of occupational exposure to benzene.","InChI=1S/C6H6O4/c7-5(8)3-1-2-4-6(9)10/h1-4H,(H,7,8)(H,9,10)/b3-1+,4-2+","trans,trans-2,4-hexadienedioic acid",CAS Registry Number,3588-17-8
881,23316,citral,"An enal that consists of octa-2,6-dienal bearing methyl substituents at positions 3 and 7. A mixture of the two geometric isomers geranial and neral, it is the major constituent (75-85%) of oil of lemon grass, the volatile oil of Cymbopogon citratus, or of C. flexuosus. It also occurs in oils of verbena, lemon, and orange.","InChI=1S/C10H16O/c1-9(2)5-4-6-10(3)7-8-11/h5,7-8H,4,6H2,1-3H3","3,7-dimethyl-2,6-octadienal",Reaxys Registry Number,970018
882,24859,iodine atom,Chemical element with atomic number 53.,InChI=1S/I,I,WebElements accession,I
883,27110,trifluoroacetate,,"InChI=1S/C2HF3O2/c3-2(4,5)1(6)7/h(H,6,7)/p-1",trifluoroacetate,CAS Registry Number,14477-72-6
884,25822,p-cumate,A cumate that is the conjugate base of p-cumic acid.,"InChI=1S/C10H12O2/c1-7(2)8-3-5-9(6-4-8)10(11)12/h3-7H,1-2H3,(H,11,12)/p-1",4-(1-methylethyl)benzoate,KEGG COMPOUND accession,C06578
885,21398,L-altraric acid,Altraric acid of L-configuration.,"InChI=1S/C6H10O8/c7-1(3(9)5(11)12)2(8)4(10)6(13)14/h1-4,7-10H,(H,11,12)(H,13,14)/t1-,2+,3-,4-/m1/s1",L-talaric acid,Beilstein Registry Number,1728118
886,8,(+)-8-hydroxycalamenene,"A sesquiterpenoid consisting of 5,6,7,8-tetrahydronaphthalen-1-ol having two methyl substituents at the 3- and 8-positions, an isopropyl substituent at the 5-position and (+)-(5R,8S)-configuration.","InChI=1S/C15H22O/c1-9(2)12-6-5-11(4)15-13(12)7-10(3)8-14(15)16/h7-9,11-12,16H,5-6H2,1-4H3/t11-,12+/m0/s1",(+)-8-Hydroxycalamenene,CAS Registry Number,88642-92-6
887,299,(R)-(+)-citronellal,"The (3R)-stereoisomer of 3,7-dimethyloct-6-enal (citronellal).","InChI=1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,8,10H,4,6-7H2,1-3H3/t10-/m1/s1",(R)-(+)-Citronellal,KEGG COMPOUND accession,C09848
888,368,(S)-(-)-citronellal,"The (3S)-stereoisomer of 3,7-dimethyloct-6-enal (citronellal).","InChI=1S/C10H18O/c1-9(2)5-4-6-10(3)7-8-11/h5,8,10H,4,6-7H2,1-3H3/t10-/m0/s1",(S)-(-)-Citronellal,CAS Registry Number,5949-05-3
889,29737,4-amino-L-phenylalanine,The L-enantiomer of 4-aminophenylalanine.,"InChI=1S/C9H12N2O2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,10-11H2,(H,12,13)/t8-/m0/s1",p-amino-L-phenylalanine,KEGG COMPOUND accession,C12033
890,29739,"5alpha,9beta,10alpha-labda-8(20),13-dien-15-yl diphosphate","The 5alpha,9beta,10alpha-diastereomer of copalyl diphosphate.","InChI=1S/C20H36O7P2/c1-15(11-14-26-29(24,25)27-28(21,22)23)7-9-17-16(2)8-10-18-19(3,4)12-6-13-20(17,18)5/h11,17-18H,2,6-10,12-14H2,1,3-5H3,(H,24,25)(H2,21,22,23)/b15-11+/t17-,18+,20-/m1/s1",syn-Copalyl diphosphate,KEGG COMPOUND accession,C11902
891,211,(3S)-3-isopropenyl-6-oxoheptanoate,An optically active form of 3-isopropenyl-6-oxoheptanoate having (3S)-configuration.,"InChI=1S/C10H16O3/c1-7(2)9(6-10(12)13)5-4-8(3)11/h9H,1,4-6H2,2-3H3,(H,12,13)/p-1/t9-/m0/s1",(3S)-3-Isopropenyl-6-oxoheptanoate,KEGG COMPOUND accession,C11419
892,8898,rotenonone,,"InChI=1S/C23H18O7/c1-10(2)15-8-13-14(28-15)6-5-11-20(24)19-12-7-17(26-3)18(27-4)9-16(12)29-23(25)22(19)30-21(11)13/h5-7,9,15H,1,8H2,2-4H3/t15-/m1/s1",Rotenonone,KEGG COMPOUND accession,C10525
893,2482,"adenosylcob(III)yrinic acid a,c-diamide","A cobalt corrinoid that is cob(III)yrinic acid a,c-diamide having a 5'-adenosyl group attached to the central cobalt atom.","InChI=1S/C45H62N6O12.C10H12N5O3.Co/c1-21-36-24(10-13-32(56)57)41(3,4)28(49-36)18-27-23(9-12-31(54)55)43(6,19-29(46)52)39(48-27)22(2)37-25(11-14-33(58)59)44(7,20-30(47)53)45(8,51-37)40-26(17-35(62)63)42(5,38(21)50-40)16-15-34(60)61;1-4-6(16)7(17)10(18-4)15-3-14-5-8(11)12-2-13-9(5)15;/h18,23-26,40H,9-17,19-20H2,1-8H3,(H10,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63);2-4,6-7,10,16-17H,1H2,(H2,11,12,13);/q;;+2/p-1/t23-,24-,25-,26+,40-,42-,43+,44+,45+;4-,6-,7-,10-;/m11./s1","Adenosyl cobyrinate a,c diamide",KEGG COMPOUND accession,C06506
894,663,2-methylhexano-6-lactone,A epsilon-lactone that is  hexano-6-lactone substituted by a methyl group at position 3.,"InChI=1S/C7H12O2/c1-6-4-2-3-5-9-7(6)8/h6H,2-5H2,1H3",1-Oxa-2-oxo-3-methylcycloheptane,KEGG COMPOUND accession,C10976
895,10330,alpha-santalol,,"InChI=1S/C15H24O/c1-10(9-16)5-4-6-14(2)11-7-12-13(8-11)15(12,14)3/h5,11-13,16H,4,6-9H2,1-3H3/b10-5-/t11-,12?,13?,14-,15+/m1/s1",alpha-Santalol,KEGG COMPOUND accession,C09719
896,29457,"(5Z,7E,9E,14Z,17Z)-icosapentaenoic acid","The (5Z,7E,9E,14Z,17Z)-isomer of icosapentaenoic acid.","InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,11-16H,2,5,8-10,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,12-11+,14-13+,16-15-","(5Z,7E,9E,14Z,17Z)-Eicosapentaenoate",KNApSAcK accession,C00000438
897,4632,diosphenol,"A  cyclic monoterpene ketone that is  cyclohex-2-en-1-one substituted by a hydroxy group at position 2, a methyl group at position 3 and an isopropyl group at position 6.","InChI=1S/C10H16O2/c1-6(2)8-5-4-7(3)9(11)10(8)12/h6,8,11H,4-5H2,1-3H3",Diosphenol,KEGG COMPOUND accession,C09854
898,29467,"2,3-didehydro-gibberellin A9","A C19-gibberellin obtained by formal dehydrogenation across the 2,3-position of gibberellin A9.","InChI=1S/C19H22O4/c1-10-8-18-9-11(10)4-5-12(18)19-7-3-6-17(2,16(22)23-19)14(19)13(18)15(20)21/h3,6,11-14H,1,4-5,7-9H2,2H3,(H,20,21)/t11-,12-,13-,14-,17-,18+,19-/m1/s1","2,3-Dehydro-gibberellin A9",KEGG COMPOUND accession,C11866
899,7810,oxacillin sodium monohydrate,,"InChI=1S/C19H19N3O5S.Na.H2O/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22;;/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26);;1H2/q;+1;/p-1/t13-,14+,17-;;/m1../s1",Oxacillin sodium salt monohydrate,KEGG DRUG accession,D00929
900,29665,pikromycin,A macrolide antibiotic that is biosynthesised by Streptomyces venezuelae.,"InChI=1S/C28H47NO8/c1-10-22-28(7,34)12-11-21(30)15(2)13-16(3)25(18(5)23(31)19(6)26(33)36-22)37-27-24(32)20(29(8)9)14-17(4)35-27/h11-12,15-20,22,24-25,27,32,34H,10,13-14H2,1-9H3/b12-11+/t15-,16+,17-,18+,19-,20+,22-,24-,25+,27+,28+/m1/s1",Pikromycin,KEGG COMPOUND accession,C11999
901,29669,pyochelin,"A member of the class of thiazolidines that is (4R)-3-methyl-1,3-thiazolidine-4-carboxylic acid which is substituted at position 2 by a (4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl group. A siderophore that is produced by Pseudomonas aeruginosa (via condensation of salicylic acid and two molecules of cysteine) as a mixture of two easily interconvertible diastereoisomers, pyochelin I (major) and pyochelin II (minor). The enantiomeric compounds, enant-pyochelin, are produced by Pseudomonas fluorescens.","InChI=1S/C14H16N2O3S2/c1-16-10(14(18)19)7-21-13(16)9-6-20-12(15-9)8-4-2-3-5-11(8)17/h2-5,9-10,13,17H,6-7H2,1H3,(H,18,19)/t9-,10+,13?/m1/s1",Pyochelin,CAS Registry Number,69772-54-9
902,29693,thiostrepton,"A heterodetic cyclic peptide, in which the cyclisation step involves a formal lactonisation between the carboxy group of a quinaldic acid-based residue and a secondary alcohol. An antibiotic that inhibits bacterial protein synthesis. Also acts as an antitumor agent.","InChI=1S/C72H85N19O18S5/c1-14-26(3)47-63(105)78-30(7)57(99)75-28(5)56(98)76-31(8)58(100)91-72-19-18-40(66-85-43(22-111-66)59(101)77-29(6)55(97)74-27(4)54(73)96)81-52(72)42-21-112-67(83-42)49(34(11)109-69(107)41-20-37(32(9)92)36-16-17-39(79-47)51(95)50(36)80-41)89-60(102)44-24-113-68(86-44)53(71(13,108)35(12)94)90-62(104)45-23-110-65(84-45)38(15-2)82-64(106)48(33(10)93)88-61(103)46-25-114-70(72)87-46/h15-17,20-22,24-26,30-35,39,45,47-49,51-53,79,92-95,108H,4-6,14,18-19,23H2,1-3,7-13H3,(H2,73,96)(H,74,97)(H,75,99)(H,76,98)(H,77,101)(H,78,105)(H,82,106)(H,88,103)(H,89,102)(H,90,104)(H,91,100)/b38-15-/t26-,30-,31-,32-,33+,34+,35+,39+,45+,47-,48-,49-,51-,52+,53+,71+,72+/m0/s1",Thiostrepton,KEGG COMPOUND accession,C12054
903,5641,heliosupine,An azabicycloalkane compound having angelyloxy and echimidinyloxymethyl substituents attached to the ring system.,"InChI=1S/C20H31NO7/c1-6-12(2)17(23)28-15-8-10-21-9-7-14(16(15)21)11-27-18(24)20(26,13(3)22)19(4,5)25/h6-7,13,15-16,22,25-26H,8-11H2,1-5H3/b12-6-/t13-,15-,16+,20+/m0/s1",Heliosupine,CAS Registry Number,32728-78-2
904,5658,hentriacontan-16-one,A dialkyl ketone that is hentriacontane in which the hydrogens at position 16 are replaced by an oxo group.,"InChI=1S/C31H62O/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31(32)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h3-30H2,1-2H3",Hentriacontan-16-one,KEGG COMPOUND accession,C08379
905,10368,digitalose,,"InChI=1S/C7H14O5/c1-4(9)6(11)7(12-2)5(10)3-8/h3-7,9-11H,1-2H3/t4-,5+,6+,7-/m1/s1",beta-D-Digitalopyranose,KEGG COMPOUND accession,C08235
906,10435,beta-obscurine,,"InChI=1S/C17H24N2O/c1-11-8-12-9-15-14(5-6-16(20)18-15)17(10-11)13(12)4-3-7-19(17)2/h5-6,11-13H,3-4,7-10H2,1-2H3,(H,18,20)/t11-,12+,13-,17-/m1/s1",beta-Obscurine,KEGG COMPOUND accession,C09890
907,10472,"3-[(5S,6R)-5,6-dihydroxycyclohexa-1,3-dienyl]propanoic acid",,"InChI=1S/C9H12O4/c10-7-3-1-2-6(9(7)13)4-5-8(11)12/h1-3,7,9-10,13H,4-5H2,(H,11,12)/t7-,9+/m0/s1","cis-3-(Carboxy-ethyl)-3,5-cyclo-hexadiene-1,2-diol",KEGG COMPOUND accession,C11588
908,21860,L-pyrrolysine,"A N(6)-acyl-L-lysine having (2R,3R)-3-methyl-3,4-dihydro-2H-pyrrol-2-ylcarbonyl as the N(6)-acyl group.","InChI=1S/C12H21N3O3/c1-8-5-7-14-10(8)11(16)15-6-3-2-4-9(13)12(17)18/h7-10H,2-6,13H2,1H3,(H,15,16)(H,17,18)/t8-,9+,10-/m1/s1",N6-(4-methyl-delta-1-pyrroline-5-carboxyl)-L-lysine,KEGG COMPOUND accession,C16138
909,18743,(S)-2-trans-abscisic acid,A 2-trans-abscisic acid with (S)-configuration at the chiral centre.,"InChI=1S/C15H20O4/c1-10(7-13(17)18)5-6-15(19)11(2)8-12(16)9-14(15,3)4/h5-8,19H,9H2,1-4H3,(H,17,18)/b6-5+,10-7+/t15-/m1/s1",(S)-2-trans-abscisic acid,Beilstein Registry Number,3034278
910,21056,2-amino-2-deoxy-D-mannonic acid,A mannonic acid derivative in which the hydroxy group at position 2 has been replaced by an amino group.,"InChI=1S/C6H13NO6/c7-3(6(12)13)5(11)4(10)2(9)1-8/h2-5,8-11H,1,7H2,(H,12,13)/t2-,3+,4-,5-/m1/s1",D-mannosaminic acid,Reaxys Registry Number,1726032
911,29563,cyclo(DeltaAla-L-Val),"A 2,5-diketopiperazine where the substituents are methylidene and (S)-isopropyl at positions  3 and 6 respectively.","InChI=1S/C8H12N2O2/c1-4(2)6-8(12)9-5(3)7(11)10-6/h4,6H,3H2,1-2H3,(H,9,12)(H,10,11)/t6-/m0/s1",Cyclo(deltaAla-L-Val),KEGG COMPOUND accession,C11846
912,29568,mycinose,,"InChI=1S/C8H16O5/c1-5(10)7(11)8(13-3)6(4-9)12-2/h4-8,10-11H,1-3H3/t5-,6+,7-,8+/m1/s1",D-Mycinose,KEGG COMPOUND accession,C11913
913,29651,neoabietadiene,An abietadiene in which the two double bonds are located at the 8(14)- and 13(15)-positions.,"InChI=1S/C20H32/c1-14(2)15-7-9-17-16(13-15)8-10-18-19(3,4)11-6-12-20(17,18)5/h13,17-18H,6-12H2,1-5H3/t17-,18-,20+/m0/s1",Neoabietadiene,KEGG COMPOUND accession,C11880
914,29658,oleandolide,"A 14-membererd macrolide containing ten stereocentres carrying one epoxymethano, three hydroxy and five methyl substituents. It is the aglycone of the antibiotic oleandomycin.","InChI=1S/C20H34O7/c1-9-7-20(8-26-20)18(24)12(4)16(22)10(2)14(6)27-19(25)13(5)17(23)11(3)15(9)21/h9-17,21-23H,7-8H2,1-6H3/t9-,10-,11+,12+,13+,14+,15-,16-,17-,20+/m0/s1",Oleandolide,CAS Registry Number,68540-16-9
915,2536,alangimarckine,A member of the class of beta-carbolines that is tubulosan bearing methoxy groups at positions 10 and 11 as well as a hydroxy group at position 9.,"InChI=1S/C29H37N3O3/c1-4-17-16-32-12-10-21-22(15-26(34-2)29(35-3)28(21)33)25(32)14-18(17)13-24-27-20(9-11-30-24)19-7-5-6-8-23(19)31-27/h5-8,15,17-18,24-25,30-31,33H,4,9-14,16H2,1-3H3/t17-,18-,24+,25-/m0/s1",Alangimarckine,KEGG COMPOUND accession,C09328
916,6736,melittin,"A 26-membered polypeptide consisting of Gly, Ile, Gly, Ala, Val, Leu, Lys, Val, Leu, Thr, Thr, Gly, Leu, Pro, Ala, Leu, Ile, Ser, Trp, Ile, Lys, Arg, Lys, Arg, Gln and Gln-NH2 residues joined in sequence. It is the principal active component of bee venom.","InChI=1S/C131H229N39O31/c1-23-71(16)102(163-97(176)60-135)122(194)146-62-98(177)148-74(19)109(181)164-100(69(12)13)124(196)160-88(55-65(4)5)116(188)155-84(41-30-33-51-134)115(187)165-101(70(14)15)125(197)161-90(57-67(8)9)118(190)168-106(77(22)173)128(200)169-105(76(21)172)123(195)147-63-99(178)150-92(58-68(10)11)129(201)170-54-36-44-94(170)121(193)149-75(20)108(180)158-89(56-66(6)7)117(189)166-104(73(18)25-3)127(199)162-93(64-171)120(192)159-91(59-78-61-145-80-38-27-26-37-79(78)80)119(191)167-103(72(17)24-2)126(198)157-83(40-29-32-50-133)111(183)154-85(42-34-52-143-130(139)140)112(184)152-82(39-28-31-49-132)110(182)153-86(43-35-53-144-131(141)142)113(185)156-87(46-48-96(137)175)114(186)151-81(107(138)179)45-47-95(136)174/h26-27,37-38,61,65-77,81-94,100-106,145,171-173H,23-25,28-36,39-60,62-64,132-135H2,1-22H3,(H2,136,174)(H2,137,175)(H2,138,179)(H,146,194)(H,147,195)(H,148,177)(H,149,193)(H,150,178)(H,151,186)(H,152,184)(H,153,182)(H,154,183)(H,155,188)(H,156,185)(H,157,198)(H,158,180)(H,159,192)(H,160,196)(H,161,197)(H,162,199)(H,163,176)(H,164,181)(H,165,187)(H,166,189)(H,167,191)(H,168,190)(H,169,200)(H4,139,140,143)(H4,141,142,144)/t71-,72-,73-,74-,75-,76+,77+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,100-,101-,102-,103-,104-,105-,106-/m0/s1",Melitten,KEGG COMPOUND accession,C11198
917,7035,muscimol,"A member of the class of isoxazoles that is 1,2-oxazol-3(2H)-one substituted by an aminomethyl group at position 5. It has been isolated from mushrooms of the genus Amanita.","InChI=1S/C4H6N2O2/c5-2-3-1-4(7)6-8-3/h1H,2,5H2,(H,6,7)",Muscimol,KEGG COMPOUND accession,C08311
918,29507,3-amino-5-hydroxybenzoic acid,A monohydroxybenzoic acid that is 3-hydroxybenzoic acid carrying an additional amino substitutent at position 4.,"InChI=1S/C7H7NO3/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3,9H,8H2,(H,10,11)",AHBA,KEGG COMPOUND accession,C12107
919,29601,gibberellin A53 aldehyde,A C20-gibberellin obtained by selective reduction of the 10beta-carboxy group of gibberellin A53.,"InChI=1S/C20H28O4/c1-12-9-19-11-20(12,24)8-5-14(19)17(2)6-4-7-18(3,16(22)23)15(17)13(19)10-21/h10,13-15,24H,1,4-9,11H2,2-3H3,(H,22,23)/t13-,14-,15-,17-,18+,19+,20-/m0/s1",Gibberellin A53 aldehyde,KEGG COMPOUND accession,C11905
920,29726,dTDP-6-deoxy-alpha-D-allose,A dTDP-sugar having 6-deoxy-alpha-D-allose as the sugar portion.,"InChI=1S/C16H26N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-13,15,19-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,8+,9-,10-,11-,12-,13-,15-/m1/s1",dTDP-6-deoxy-D-allose,KEGG COMPOUND accession,C11912
921,29728,dTDP-alpha-D-mycaminose,"A dTDP-sugar having 3,6-dideoxy-3-dimethylamino-alpha-D-glucose (alpha-D-mycaminose) as the sugar component.","InChI=1S/C18H31N3O14P2/c1-8-6-21(18(26)19-16(8)25)12-5-10(22)11(33-12)7-31-36(27,28)35-37(29,30)34-17-15(24)13(20(3)4)14(23)9(2)32-17/h6,9-15,17,22-24H,5,7H2,1-4H3,(H,27,28)(H,29,30)(H,19,25,26)/t9-,10+,11-,12-,13+,14-,15-,17-/m1/s1",dTDP-D-mycaminose,KEGG COMPOUND accession,C11933
922,29926,hydroxidooxidophosphate(.1-),,InChI=1S/HO2P/c1-3-2/h1H/q-1,hydroxidooxidophosphate(.1-),Gmelin Registry Number,2220649
923,978,2-(1-hydroxyethyl)thiamine diphosphate,A thiamine phosphate having a 1-hydroxyethyl substituent at the 2-position on the thiazolium ring and an O-diphosphate moiety.,"InChI=1S/C14H22N4O8P2S/c1-8-12(4-5-25-28(23,24)26-27(20,21)22)29-14(9(2)19)18(8)7-11-6-16-10(3)17-13(11)15/h6,9,19H,4-5,7H2,1-3H3,(H4-,15,16,17,20,21,22,23,24)/p+1",2-(alpha-Hydroxyethyl)thiamine diphosphate,KEGG COMPOUND accession,C05125
924,4109,cathine,"An amphetamine that is propylbenzene substituted by a hydroxy group at position 1 and by an amino group at position 2 (the 1S,2S-stereoisomer).","InChI=1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9+/m0/s1",D-cathine,KEGG COMPOUND accession,C08300
925,4167,D-glucopyranose,A glucopyranose having D-configuration.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1",D-Glucose,KEGG COMPOUND accession,C00031
926,1449,3-amino-2-oxopropyl phosphate,A oxoalkyl phosphate having 3-amino-2-oxopropyl as the oxoalkyl group.,"InChI=1S/C3H8NO5P/c4-1-3(5)2-9-10(6,7)8/h1-2,4H2,(H2,6,7,8)",3-Amino-2-oxopropyl phosphate,KEGG COMPOUND accession,C11638
927,1865,4-hydroxyglucobrassicin,An indolylmethylglucosinolic acid that is glucobrassicin bearing a hydroxy substituent at position 4 on the indole ring.,"InChI=1S/C16H20N2O10S2/c19-6-10-13(21)14(22)15(23)16(27-10)29-11(18-28-30(24,25)26)4-7-5-17-8-2-1-3-9(20)12(7)8/h1-3,5,10,13-17,19-23H,4,6H2,(H,24,25,26)/t10-,13-,14+,15-,16+/m1/s1",4-Hydroxyglucobrassicin,KEGG COMPOUND accession,C08422
928,1159,2-hydroxyethylphosphonic acid,A phosphonic acid consisting of ethanol with the phospho group at the 2-position.,"InChI=1S/C2H7O4P/c3-1-2-7(4,5)6/h3H,1-2H2,(H2,4,5,6)",2-Hydroxyethylphosphonate,KEGG COMPOUND accession,C06451
929,4853,esculin,A hydroxycoumarin that is the 6-O-beta-D-glucoside of esculetin.,"InChI=1S/C15H16O9/c16-5-10-12(19)13(20)14(21)15(24-10)23-9-3-6-1-2-11(18)22-8(6)4-7(9)17/h1-4,10,12-17,19-21H,5H2/t10-,12-,13+,14-,15-/m1/s1",Esculin,KEGG COMPOUND accession,C09264
930,2533,alachlor,"An aromatic amide that is N-(2,6-diethylphenyl)acetamide substituted by a methoxymethyl group at at the nitrogen atom while one of the hydrogens of the methyl group has been replaced by a chlorine atom.","InChI=1S/C14H20ClNO2/c1-4-11-7-6-8-12(5-2)14(11)16(10-18-3)13(17)9-15/h6-8H,4-5,9-10H2,1-3H3",Alachlor,CAS Registry Number,15972-60-8
931,2361,abacavir sulfate,An azaheterocycle sulfate salt that is the sulfate salt of the HIV-1 reverse transcriptase inhibitor abacavir.,"InChI=1S/2C14H18N6O.H2O4S/c2*15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21;1-5(2,3)4/h2*1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19);(H2,1,2,3,4)/t2*8-,10+;/m11./s1",Abacavir sulfate,CAS Registry Number,188062-50-2
932,6006,isoetin,"A pentahydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 7, 2', 4' and 5'.","InChI=1S/C15H10O7/c16-6-1-11(20)15-12(21)5-13(22-14(15)2-6)7-3-9(18)10(19)4-8(7)17/h1-5,16-20H","5,7,2',4',5'-Pentahydroxyflavone",KEGG COMPOUND accession,C10079
933,6041,(+)-isopiperitenone,,"InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)6-10(9)11/h6,9H,1,4-5H2,2-3H3/t9-/m0/s1",Isopiperitenone,CAS Registry Number,529-01-1
934,3237,butein,"A chalcone that is (E)-chalcone bearing four additional hydroxy substituents at positions 2', 3, 4 and 4'.","InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H/b5-1+",Butein,KEGG COMPOUND accession,C08578
935,4846,erythromycin estolate,,"InChI=1S/C40H71NO14.C12H26O4S/c1-15-27-40(11,48)33(44)22(5)30(43)20(3)18-38(9,47)35(55-37-32(53-28(42)16-2)26(41(12)13)17-21(4)50-37)23(6)31(24(7)36(46)52-27)54-29-19-39(10,49-14)34(45)25(8)51-29;1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h20-27,29,31-35,37,44-45,47-48H,15-19H2,1-14H3;2-12H2,1H3,(H,13,14,15)/t20-,21-,22+,23+,24-,25+,26+,27-,29+,31+,32-,33-,34+,35-,37+,38-,39-,40-;/m1./s1",Erythromycin estolate,KEGG COMPOUND accession,C08031
936,6970,mometasone,,"InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1",Mometasone,KEGG COMPOUND accession,C07816
937,7207,N'-acetylisoniazid,A carbohydrazide resulting from the formal condensation of the carboxy group of isonicotinic acid with hydrazine and subsequent acetylation of the monosubstituted nitrogen atom.,"InChI=1S/C8H9N3O2/c1-6(12)10-11-8(13)7-2-4-9-5-3-7/h2-5H,1H3,(H,10,12)(H,11,13)",N-Acetylisoniazid,KEGG COMPOUND accession,C07585
938,2429,aconifine,A diterpenoid that is aconitine bearing a 10-hydroxy substituent.,"InChI=1S/C34H47NO12/c1-7-35-15-30(16-42-3)19(37)13-20(43-4)33-23(30)22(44-5)21(25(33)35)34(47-17(2)36)24-27(46-29(39)18-11-9-8-10-12-18)31(40,14-32(24,33)41)28(45-6)26(34)38/h8-12,19-28,37-38,40-41H,7,13-16H2,1-6H3/t19-,20+,21+,22+,23-,24+,25?,26+,27-,28+,30+,31-,32+,33-,34+/m1/s1",Aconifine,KEGG COMPOUND accession,C08655
939,7939,parthenolide,A sesquiterpene lactone and active principle of Feverfew (Tanacetum parthenium).,"InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1",Parthenolide,KEGG COMPOUND accession,C07609
940,9036,sarpagine,An indole alkaloid that is sarpagan bearing hydroxy groups at positions 10 and 17.,"InChI=1S/C19H22N2O2/c1-2-10-8-21-17-7-14-13-5-11(23)3-4-16(13)20-19(14)18(21)6-12(10)15(17)9-22/h2-5,12,15,17-18,20,22-23H,6-9H2,1H3/b10-2-/t12-,15+,17-,18-/m0/s1",Sarpagine,CAS Registry Number,482-68-8
941,9066,L-adenosylselenomethionine,A selenomethionine consisting of L-selenomethionine having an adenosyl group attached to the selenium.,"InChI=1S/C15H22N6O5Se/c1-27(3-2-7(16)15(24)25)4-8-10(22)11(23)14(26-8)21-6-20-9-12(17)18-5-19-13(9)21/h5-8,10-11,14,22-23H,2-4,16H2,1H3,(H2-,17,18,19,24,25)/p+1/t7-,8+,10+,11+,14+,27?/m0/s1",Se-Adenosylselenomethionine,KEGG COMPOUND accession,C05691
942,9188,solanine,"A glycoalkaloid poison found in species of the nightshade family (Solanaceae), such as the potato (Solanum tuberosum). It is a trisccharide derivative of solanidine [(22beta)-solanid-5-en-3beta-ol].","InChI=1S/C45H73NO15/c1-19-6-9-27-20(2)31-28(46(27)16-19)15-26-24-8-7-22-14-23(10-12-44(22,4)25(24)11-13-45(26,31)5)57-43-40(61-41-37(54)35(52)32(49)21(3)56-41)39(34(51)30(18-48)59-43)60-42-38(55)36(53)33(50)29(17-47)58-42/h7,19-21,23-43,47-55H,6,8-18H2,1-5H3/t19-,20+,21-,23-,24+,25-,26-,27+,28-,29+,30+,31-,32-,33+,34-,35+,36-,37+,38+,39-,40+,41-,42-,43+,44-,45-/m0/s1",Solanine,CAS Registry Number,20562-02-1
943,5404,glucoerucin(1-),A thia-alkylglucosinolate that has a 4-(methylsulfanyl)butyl side chain attached to the sulfonated oxime group.,"InChI=1S/C12H23NO9S3/c1-23-5-3-2-4-8(13-22-25(18,19)20)24-12-11(17)10(16)9(15)7(6-14)21-12/h7,9-12,14-17H,2-6H2,1H3,(H,18,19,20)/p-1/b13-8-/t7-,9-,10+,11-,12+/m1/s1",Glucoerucin,CAS Registry Number,21973-56-8
944,29489,4-isopropenyl-2-oxocyclohexane-1-carbonyl-CoA,A 3-oxoacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 4-isopropenyl-2-oxocyclohexane-1-carboxylic acid.,"InChI=1S/C31H48N7O18P3S/c1-16(2)17-5-6-18(19(39)11-17)30(44)60-10-9-33-21(40)7-8-34-28(43)25(42)31(3,4)13-53-59(50,51)56-58(48,49)52-12-20-24(55-57(45,46)47)23(41)29(54-20)38-15-37-22-26(32)35-14-36-27(22)38/h14-15,17-18,20,23-25,29,41-42H,1,5-13H2,2-4H3,(H,33,40)(H,34,43)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t17?,18?,20-,23-,24-,25+,29-/m1/s1",4-Isopropenyl-2-oxy-cyclohexanecarboxyl-CoA,KEGG COMPOUND accession,C11935
945,29514,5-amino-5-deoxy-3-dehydroshikimic acid,A gamma-amino acid that is shikimic acid in which the 3- and 5-hydroxy groups are replaced by oxo and amino groups respectively.,"InChI=1S/C7H9NO4/c8-4-1-3(7(11)12)2-5(9)6(4)10/h2,4,6,10H,1,8H2,(H,11,12)/t4-,6+/m1/s1",AminoDHS,KEGG COMPOUND accession,C12108
946,29515,ansamitocin P3,A polyketide antibiotic that is isolated from Actinosynnema pretiosum and also exhibits antitumour activity.,"InChI=1S/C32H43ClN2O9/c1-17(2)29(37)43-25-15-26(36)35(6)21-13-20(14-22(40-7)27(21)33)12-18(3)10-9-11-24(41-8)32(39)16-23(42-30(38)34-32)19(4)28-31(25,5)44-28/h9-11,13-14,17,19,23-25,28,39H,12,15-16H2,1-8H3,(H,34,38)/b11-9+,18-10+/t19-,23+,24-,25+,28+,31+,32+/m1/s1",Antibiotic C15003P3,KEGG COMPOUND accession,C12045
947,29519,aphidicolan-16beta-ol,,"InChI=1S/C20H34O/c1-17(2)8-5-9-18(3)16(17)7-6-14-12-15-13-20(14,18)11-10-19(15,4)21/h14-16,21H,5-13H2,1-4H3/t14-,15+,16-,18-,19+,20-/m0/s1",Aphidicolan-16beta-ol,KEGG COMPOUND accession,C11890
948,29534,avermectin B1a,,"InChI=1S/C48H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,17-19,25-26,28,30-31,33-45,49-50,52H,11,16,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1",Avermectin B1a,KEGG COMPOUND accession,C11983
949,29537,avermectin B1b,,"InChI=1S/C47H70O14/c1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h11-14,16-18,24-25,27,29-30,32-44,48-49,51H,15,19-23H2,1-10H3/b12-11+,26-14+,31-13+/t25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m0/s1",Avermectin B1b,KEGG COMPOUND accession,C11967
950,1184,maleylacetic acid,A 4-oxohex-2-enedioic acid with a Z-configuration.,"InChI=1S/C6H6O5/c7-4(3-6(10)11)1-2-5(8)9/h1-2H,3H2,(H,8,9)(H,10,11)/b2-1-",2-Maleylacetate,CAS Registry Number,24740-88-3
951,9179,sodium nitroprusside dihydrate,A hydrate that is the dihydrate form of sodium nitroprusside.,InChI=1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q;;;;;2*-1;2*+1;;,Sodium nitroprusside dihydrate,KEGG COMPOUND accession,C07695
952,8454,progoitrin(1-),A xi-progoitrin(1-) that is the conjugate base of progoitrin.,"InChI=1S/C11H19NO10S2/c1-2-5(14)3-7(12-22-24(18,19)20)23-11-10(17)9(16)8(15)6(4-13)21-11/h2,5-6,8-11,13-17H,1,3-4H2,(H,18,19,20)/p-1/t5-,6+,8+,9-,10+,11-/m0/s1",Progoitrin,CAS Registry Number,585-95-5
953,6579,luteolin 7-O-(6-O-malonyl-beta-D-glucoside),A glycosyloxyflavone that is luteolin substituted by a 6-O-malonyl-beta-D-glucopyranosyl moiety at position 7 via glycosidic linkage.,"InChI=1S/C24H22O14/c25-11-2-1-9(3-12(11)26)15-6-14(28)20-13(27)4-10(5-16(20)37-15)36-24-23(34)22(33)21(32)17(38-24)8-35-19(31)7-18(29)30/h1-6,17,21-27,32-34H,7-8H2,(H,29,30)/t17-,21-,22+,23-,24-/m1/s1",Luteolin 7-O-(6''-malonylglucoside),KEGG COMPOUND accession,C10103
954,9754,tris,A primary amino compound that is tert-butylamine in which one hydrogen attached to each methyl group is replaced by a hydroxy group. A compound widely used as a biological buffer substance in the pH range 7--9; pKa = 8.3 at 20 degreeC; pKa = 7.82 at 37 degreeC.,"InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2",Tromethamine,KEGG COMPOUND accession,C07182
955,8876,robinetin,"A pentahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 7, 3, 4' and 5'.","InChI=1S/C15H10O7/c16-7-1-2-8-11(5-7)22-15(14(21)12(8)19)6-3-9(17)13(20)10(18)4-6/h1-5,16-18,20-21H",5-Deoxymyricetin,KEGG COMPOUND accession,C10177
956,29706,10-deoxymethymycin,"A macrolide antibiotic that is the 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexoside of 10-deoxymethynolide.","InChI=1S/C25H43NO6/c1-9-21-14(2)10-11-20(27)15(3)12-16(4)23(18(6)24(29)31-21)32-25-22(28)19(26(7)8)13-17(5)30-25/h10-11,14-19,21-23,25,28H,9,12-13H2,1-8H3/b11-10+/t14-,15-,16+,17-,18-,19+,21-,22-,23+,25+/m1/s1",YC-17,KEGG COMPOUND accession,C11994
957,5870,imidacloprid,An imidazolidine that is N-nitroimidazolidin-2-imine bearing a (6-chloro-3-pyridinyl)methyl substituent at position 1.,"InChI=1S/C9H10ClN5O2/c10-8-2-1-7(5-12-8)6-14-4-3-11-9(14)13-15(16)17/h1-2,5H,3-4,6H2,(H,11,13)",Imidacloprid,KEGG COMPOUND accession,C11110
958,6048,isoprothiolane sulfoxide,,"InChI=1S/C12H18O5S2/c1-7(2)16-10(13)9(11(14)17-8(3)4)12-18-5-6-19(12)15/h7-8H,5-6H2,1-4H3",Isoprothiolane sulfoxide,KEGG COMPOUND accession,C11112
959,6149,levobupivacaine,The (S)-(-)-enantiomer of bupivacaine.,"InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1","L-(-)-1-Butyl-2',6'-pipecoloxylidide",CAS Registry Number,27262-47-1
960,6178,L-arabinofuranose,The five-membered ring form of L-arabinose.,"InChI=1S/C5H10O5/c6-1-2-3(7)4(8)5(9)10-2/h2-9H,1H2/t2-,3-,4+,5?/m0/s1",L-Arabinofuranose,KEGG COMPOUND accession,C06115
961,799,"3,17-dioxoandrost-4-en-19-al",An androstanoid that is androst-4-en-19-al substituted by oxo groups at positions 3 and 17.,"InChI=1S/C19H24O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10-11,14-16H,2-9H2,1H3/t14-,15-,16-,18-,19+/m0/s1","19-Oxoandrost-4-ene-3,17-dione",KEGG COMPOUND accession,C05297
962,6439,levobunolol hydrochloride,A hydrochloride obtained by combining equimolar amounts of levobunolol and hydrochloric acid. A non-selective beta-adrenergic antagonist used for treatment of glaucoma.,"InChI=1S/C17H25NO3.ClH/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20;/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3;1H/t12-;/m0./s1",Levobunolol hydrochloride,KEGG COMPOUND accession,C08228
963,6674,malvidin,An anthocyanidin cation that is delphinidin carrying methyl substituents at positions 3' and 5'.,"InChI=1S/C17H14O7/c1-22-14-3-8(4-15(23-2)16(14)21)17-12(20)7-10-11(19)5-9(18)6-13(10)24-17/h3-7H,1-2H3,(H3-,18,19,20,21)/p+1",Malvidin,KEGG COMPOUND accession,C08716
964,228,"(4R,7R)-4-isopropenyl-7-methyloxepan-2-one","The (4R,7R)-stereoisomer of  4-isopropenyl-7-methyloxepan-2-one.","InChI=1S/C10H16O2/c1-7(2)9-5-4-8(3)12-10(11)6-9/h8-9H,1,4-6H2,2-3H3/t8-,9-/m1/s1","(4R,7R)-4-Isopropenyl-7-methyl-2-oxo-oxepanone",KEGG COMPOUND accession,C11402
965,233,"(4S,7R)-4-isopropenyl-7-methyloxepan-2-one","The (4S,7R)-stereoisomer of 4-isopropenyl-7-methyloxepan-2-one.","InChI=1S/C10H16O2/c1-7(2)9-5-4-8(3)12-10(11)6-9/h8-9H,1,4-6H2,2-3H3/t8-,9+/m1/s1","(4S,7R)-4-Isopropenyl-7-methyl-2-oxo-oxepanone",KEGG COMPOUND accession,C11414
966,1458,(Z)-3-butylidene-7-hydroxyphthalide,A 2-benzofuran consisting of phthalide having a butylidene group at the 3-position.,"InChI=1S/C12H12O3/c1-2-3-7-10-8-5-4-6-9(13)11(8)12(14)15-10/h4-7,13H,2-3H2,1H3/b10-7-",3-Butylidene-7-hydroxyphthalide,CAS Registry Number,93236-67-0
967,1467,(2S)-2-isopropyl-3-oxosuccinic acid,An oxo dicarboxylic acid that is 2-ketosuccinic acid (oxalacetic acid) in which the 3-pro-S hydrogen is substituted by an isopropyl group.,"InChI=1S/C7H10O5/c1-3(2)4(6(9)10)5(8)7(11)12/h3-4H,1-2H3,(H,9,10)(H,11,12)/t4-/m0/s1",(2S)-2-Isopropyl-3-oxosuccinate,KEGG COMPOUND accession,C04236
968,7448,nafcillin sodium,,"InChI=1S/C21H22N2O5S.Na/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23;/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27);/q;+1/p-1/t15-,16+,19-;/m1./s1",Nafcillin sodium,CAS Registry Number,985-16-0
969,444,(S)-cis-N-methylstylopine,,"InChI=1S/C20H20NO4/c1-21-5-4-13-7-18-19(24-10-23-18)8-14(13)16(21)6-12-2-3-17-20(15(12)9-21)25-11-22-17/h2-3,7-8,16H,4-6,9-11H2,1H3/q+1/t16-,21-/m0/s1",(S)-cis-N-methylstylopine,KEGG COMPOUND accession,C06163
970,1656,3-phospho-D-erythronic acid,A phosphoerythronic acid that consists of D-erythronic acid bearing an O-phospho substituent at position 3.,"InChI=1S/C4H9O8P/c5-1-2(3(6)4(7)8)12-13(9,10)11/h2-3,5-6H,1H2,(H,7,8)(H2,9,10,11)/t2-,3-/m1/s1",3-Phospho-D-erythronate,KEGG COMPOUND accession,C03356
971,5399,glucocapparin(1-),An alkylglucosinolate that is the conjugate base of glucocapparin.,"InChI=1S/C8H15NO9S2/c1-3(9-18-20(14,15)16)19-8-7(13)6(12)5(11)4(2-10)17-8/h4-8,10-13H,2H2,1H3,(H,14,15,16)/p-1/b9-3-/t4-,5-,6+,7-,8+/m1/s1",Glucocapparin,KEGG COMPOUND accession,C08404
972,5409,glucolimnanthin(1-),An aralkylglucosinolate that is glucotropeolin in which the phenyl group is substituted at position 3 by a methoxy group.,"InChI=1S/C15H21NO10S2/c1-24-9-4-2-3-8(5-9)6-11(16-26-28(21,22)23)27-15-14(20)13(19)12(18)10(7-17)25-15/h2-5,10,12-15,17-20H,6-7H2,1H3,(H,21,22,23)/p-1/b16-11-/t10-,12-,13+,14-,15+/m1/s1",Glucolimnanthin,CAS Registry Number,111810-95-8
973,6320,(-)-stercobilinogen,,"InChI=1S/C33H48N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h16,19-21,26-27,34-35H,7-15H2,1-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/t16-,19-,20-,21-,26+,27+/m1/s1",L-Stercobilinogen,KEGG COMPOUND accession,C05789
974,3383,caranine,An indolizidine alkaloid that is  galanthan substituted by analpha-hydroxy group at position 1 and a methylenedioxy group across position 9 and 10. An alkaloid commonly found in the members of the family amaryllidaceae.,"InChI=1S/C16H17NO3/c18-12-2-1-9-3-4-17-7-10-5-13-14(20-8-19-13)6-11(10)15(12)16(9)17/h1,5-6,12,15-16,18H,2-4,7-8H2/t12-,15-,16-/m1/s1",Caranine,KEGG COMPOUND accession,C08521
975,3440,carvacrol,"A phenol that is a natural monoterpene derivative of cymene. An inhibitor of  bacterial growth, it is used as a food additive. Potent activator of the human ion channels transient receptor potential V3 (TRPV3) and A1 (TRPA1).","InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3",Carvacrol,KEGG COMPOUND accession,C09840
976,3484,cefclidin,"A fourth-generation cephalosporin antibiotic having (4-carbamoyl-1-azoniabicyclo[2.2.2]octan-1-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.","InChI=1S/C21H26N8O6S2/c1-35-26-11(14-25-20(23)37-27-14)15(30)24-12-16(31)28-13(18(32)33)10(9-36-17(12)28)8-29-5-2-21(3-6-29,4-7-29)19(22)34/h12,17H,2-9H2,1H3,(H5-,22,23,24,25,27,30,32,33,34)/b26-11-/t12-,17-,21?,29?/m1/s1",Cefclidin,CAS Registry Number,105239-91-6
977,3506,cefprozil,"A semisynthetic, second-generation cephalosporin, with prop-1-enyl and (R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used to treat bronchitis as well as ear, skin and other bacterial infections.","InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1",Cefprozil anhydrous,KEGG COMPOUND accession,C06888
978,2009,"5-(2'-carboxyethyl)-4,6-dihydroxypicolinate","An  oxo carboxylic acid anion that is the conjugate base of 5-(2'-carboxyethyl)-4,6-dihydroxypicolinic acid.","InChI=1S/C9H9NO6/c11-6-3-5(9(15)16)10-8(14)4(6)1-2-7(12)13/h3H,1-2H2,(H,12,13)(H,15,16)(H2,10,11,14)/p-1","5-(beta-Carboxyethyl)-4,6-dihydroxypicolinate",KEGG COMPOUND accession,C05655
979,2013,"5-(3'-carboxy-3'-oxopropyl)-4,6-dihydroxypicolinate","An  oxo carboxylic acid anion that is the conjugate base of 5-(3'-carboxy-3'-oxopropyl)-4,6-dihydroxypicolinic acid.","InChI=1S/C10H9NO7/c12-6(10(17)18)2-1-4-7(13)3-5(9(15)16)11-8(4)14/h3H,1-2H2,(H,15,16)(H,17,18)(H2,11,13,14)/p-1","5-(gamma-Carboxy-gamma-oxopropyl)-4,6-dihydroxypicolinate",KEGG COMPOUND accession,C05656
980,2040,"(2Z,4E)-5-hydroxypenta-2,4-diene-1,2,5-tricarboxylic acid","The (2Z,4E)-stereoisomer of 5-hydroxypenta-2,4-diene-1,2,5-tricarboxylic acid.","InChI=1S/C8H8O7/c9-5(8(14)15)2-1-4(7(12)13)3-6(10)11/h1-2,9H,3H2,(H,10,11)(H,12,13)(H,14,15)/b4-1-,5-2+",5-Carboxymethyl-2-hydroxymuconate,KEGG COMPOUND accession,C04186
981,6151,"(3R,5S)-1-pyrroline-3-hydroxy-5-carboxylic acid",,"InChI=1S/C5H7NO3/c7-3-1-4(5(8)9)6-2-3/h2-4,7H,1H2,(H,8,9)/t3-,4+/m1/s1",L-1-Pyrroline-3-hydroxy-5-carboxylate,KEGG COMPOUND accession,C04281
982,8716,quinestrol,,"InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1",Quinestrol,CAS Registry Number,152-43-2
983,2255,7beta-aminocephalosporanic acid,"The  alpha,beta-unsaturated monocarboxylic acid that is the active nucleus for the synthesis of cephalosporins and intermediates.","InChI=1S/C10H12N2O5S/c1-4(13)17-2-5-3-18-9-6(11)8(14)12(9)7(5)10(15)16/h6,9H,2-3,11H2,1H3,(H,15,16)/t6-,9-/m1/s1",7-Aminocephalosporanic acid,CAS Registry Number,957-68-6
984,2374,acanthicifoline,"A 2,7-naphthyridine derivative that is 1,4-dihydro-2,7-naphthyridin-3(2H)-one which is substituted at positions 1 and 5 by methyl and methoxy groups, respectively.","InChI=1S/C10H12N2O2/c1-6-8-4-11-5-9(14-2)7(8)3-10(13)12-6/h4-6H,3H2,1-2H3,(H,12,13)",Acanthicifoline,KEGG COMPOUND accession,C09907
985,2433,acrifoline,"A quinolizidine alkaloid that is lycopodine having a C=C double bond at the 11-position, a keto substituent at the 8-position and the keto group at position 5 replaced by a beta-hydroxy group.","InChI=1S/C16H23NO2/c1-10-9-16-12-4-2-6-17(16)7-3-5-13(16)14(18)8-11(12)15(10)19/h4,10-11,13-14,18H,2-3,5-9H2,1H3/t10-,11+,13-,14-,16-/m1/s1",Acrifoline,CAS Registry Number,664-24-4
986,9837,UDP-N-acetyl-alpha-muramoyl-L-alanyl-D-alpha-glutamyl-L-lysine,,"InChI=1S/C34H55N7O24P2/c1-14(28(50)38-17(7-8-22(45)46)30(52)39-18(32(53)54)6-4-5-10-35)36-29(51)15(2)61-27-23(37-16(3)43)33(63-19(12-42)25(27)48)64-67(58,59)65-66(56,57)60-13-20-24(47)26(49)31(62-20)41-11-9-21(44)40-34(41)55/h9,11,14-15,17-20,23-27,31,33,42,47-49H,4-8,10,12-13,35H2,1-3H3,(H,36,51)(H,37,43)(H,38,50)(H,39,52)(H,45,46)(H,53,54)(H,56,57)(H,58,59)(H,40,44,55)/t14-,15+,17+,18-,19+,20+,23+,24+,25+,26+,27+,31+,33+/m0/s1",UDP-N-acetylmuramoyl-L-alanyl-alpha-D-glutamyl-L-lysine,KEGG COMPOUND accession,C04700
987,9859,umbelliferose,,"InChI=1S/C18H32O16/c19-1-5-8(23)11(26)13(28)16(30-5)32-14-12(27)9(24)6(2-20)31-17(14)34-18(4-22)15(29)10(25)7(3-21)33-18/h5-17,19-29H,1-4H2/t5-,6-,7-,8+,9+,10-,11+,12+,13-,14-,15+,16-,17-,18+/m1/s1",Umbelliferose,KEGG COMPOUND accession,C08251
988,9216,spectinomycin dihydrochloride,A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.,"InChI=1S/C14H24N2O7.2ClH/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14;;/h5,7-13,15-16,18-20H,4H2,1-3H3;2*1H/t5-,7-,8+,9+,10+,11-,12-,13+,14+;;/m1../s1",Spectinomycin dihydrochloride,KEGG COMPOUND accession,C11619
989,9322,sulbenicillin,A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.,"InChI=1S/C16H18N2O7S2/c1-16(2)11(15(21)22)18-13(20)9(14(18)26-16)17-12(19)10(27(23,24)25)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,17,19)(H,21,22)(H,23,24,25)/t9-,10?,11+,14-/m1/s1",Sulbenicillin,KEGG COMPOUND accession,C11170
990,9336,phthalylsulfathiazole,"A sulfonamide incorporating 2-carboxybenzamido and 1,3-thiazol-2-yl moieties that is a broad-spectrum antibiotic indicated in the treatment of dysentery, colitis, gastroenteritis and intestinal surgery.","InChI=1S/C17H13N3O5S2/c21-15(13-3-1-2-4-14(13)16(22)23)19-11-5-7-12(8-6-11)27(24,25)20-17-18-9-10-26-17/h1-10H,(H,18,20)(H,19,21)(H,22,23)",Sulfathalidine,KEGG COMPOUND accession,C07659
991,2285,7-(5-phospho-alpha-D-ribosyl)adenine,A purine ribonucleoside 5'-monophosphate compound having 6-aminopurine as the nucleobase.,"InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)14-3-15(5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1",7-alpha-D-Ribosyladenine 5'-phosphate,KEGG COMPOUND accession,C04378
992,2600,methylcarbamoylcarbamate,A  carbamate ester obatined by the formal condensation of  urea-1-carboxylic acid with methanol.,"InChI=1S/C3H6N2O3/c1-8-3(7)5-2(4)6/h1H3,(H3,4,5,6,7)","Allophanic acid, methyl ester",CAS Registry Number,761-89-7
993,2617,amabiline,"A carboxylic ester obtained by formal condensation of the carboxy group of (2S,3S)-2,3-dihydroxy-2-isopropylbutanoic acid with the hydroxy group of (7aS)-2,3,5,7a-tetrahydropyrrolizin-7-ylmethanol.","InChI=1S/C15H25NO4/c1-10(2)15(19,11(3)17)14(18)20-9-12-6-8-16-7-4-5-13(12)16/h6,10-11,13,17,19H,4-5,7-9H2,1-3H3/t11-,13-,15-/m0/s1",Amabiline,KEGG COMPOUND accession,C10263
994,2908,athyriol,"A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 6 and 7 and a methoxy group at position 3.","InChI=1S/C14H10O6/c1-19-6-2-10(17)13-12(3-6)20-11-5-9(16)8(15)4-7(11)14(13)18/h2-5,15-17H,1H3","3-Methoxy-1,6,7-trihydroxyxanthone",KEGG COMPOUND accession,C10052
995,2969,bacampicillin hydrochloride,The hydrochloride salt of bacampicillin.,"InChI=1S/C21H27N3O7S.ClH/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12;/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25);1H/t11?,13-,14-,15+,18-;/m1./s1",Bacampicillin hydrochloride,CAS Registry Number,37661-08-8
996,4286,"4,4'-diisothiocyano-trans-stilbene-2,2'-disulfonic acid",,"InChI=1S/C16H10N2O6S4/c19-27(20,21)15-7-13(17-9-25)5-3-11(15)1-2-12-4-6-14(18-10-26)8-16(12)28(22,23)24/h1-8H,(H,19,20,21)(H,22,23,24)/b2-1+",DIDS,CAS Registry Number,53005-05-3
997,5769,humulone,"An optically active cyclic ketone consisting of 3,5,6-trihydroxycyclohexa-2,4-dien-1-one bearing two 3-methylbut-2-en-1-yl substituents at positions 4 and 6 as well as a 3-methylbutanoyl group at the 2-position.","InChI=1S/C21H30O5/c1-12(2)7-8-15-18(23)17(16(22)11-14(5)6)20(25)21(26,19(15)24)10-9-13(3)4/h7,9,14,23-24,26H,8,10-11H2,1-6H3/t21-/m1/s1",Humulone,KEGG COMPOUND accession,C10695
998,4608,dimethyl disulfide,An organic disulfide that is methane in which one of the hydrogens has been replaced by a methyldisulfanyl group.,InChI=1S/C2H6S2/c1-3-4-2/h1-2H3,Dimethyl disulfide,CAS Registry Number,624-92-0
999,6854,allyl methyl disulfide,An  organic disulfide having allyl and methyl as the two organic groups.,"InChI=1S/C4H8S2/c1-3-4-6-5-2/h3H,1,4H2,2H3",Methyl allyl disulfide,KEGG COMPOUND accession,C08383
1000,7091,N-(5-phospho-beta-D-ribosyl)anthranilic acid,,"InChI=1S/C12H16NO9P/c14-9-8(5-21-23(18,19)20)22-11(10(9)15)13-7-4-2-1-3-6(7)12(16)17/h1-4,8-11,13-15H,5H2,(H,16,17)(H2,18,19,20)/t8-,9-,10-,11-/m1/s1",N-(5-Phosphoribosyl)anthranilic acid,KEGG COMPOUND accession,C04302
1001,29473,2-hydroxy-4-isopropenylcyclohexane-1-carbonyl-CoA,A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-hydroxy-4-isopropenylcyclohexane-1-carboxylic acid.,"InChI=1S/C31H50N7O18P3S/c1-16(2)17-5-6-18(19(39)11-17)30(44)60-10-9-33-21(40)7-8-34-28(43)25(42)31(3,4)13-53-59(50,51)56-58(48,49)52-12-20-24(55-57(45,46)47)23(41)29(54-20)38-15-37-22-26(32)35-14-36-27(22)38/h14-15,17-20,23-25,29,39,41-42H,1,5-13H2,2-4H3,(H,33,40)(H,34,43)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t17?,18?,19?,20-,23-,24-,25+,29-/m1/s1",2-Hydroxy-4-isopropenylcyclohexane-1-carboxyl-CoA,KEGG COMPOUND accession,C11934
1002,29479,methyl 3-hydroxypalmitate,A  fatty acid methyl ester of 3-hydroxypalmitic acid.,"InChI=1S/C17H34O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-16(18)15-17(19)20-2/h16,18H,3-15H2,1-2H3",3-Hydroxy-palmitic acid methyl ester,CAS Registry Number,51883-36-4
1003,9177,sodium deoxycholate,,"InChI=1S/C24H40O4.Na/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3;/h14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-;/m1./s1",Sodium deoxycholate,KEGG COMPOUND accession,C11171
1004,8191,all-trans-phytoene,The all-trans-isomer of phytoene.,"InChI=1S/C40H64/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,19-22,27-30H,13-18,23-26,31-32H2,1-10H3/b12-11+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+",Phytoene,KEGG COMPOUND accession,C05413
1005,6838,methotrimeprazine,A member of the class of  phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.,"InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1",Methotrimeprazine,KEGG COMPOUND accession,C07192
1006,29572,demethyllactenocin,A macrolide antibiotic that is tylonolide having 6-deoxy-beta-D-allopyranosyl and  beta-D-mycaminosyl residues attached to two of its hydroxy groups..,"InChI=1S/C37H61NO14/c1-9-27-24(17-48-36-34(47)33(46)31(44)22(6)49-36)14-18(2)10-11-25(40)19(3)15-23(12-13-39)35(20(4)26(41)16-28(42)51-27)52-37-32(45)29(38(7)8)30(43)21(5)50-37/h10-11,13-14,19-24,26-27,29-37,41,43-47H,9,12,15-17H2,1-8H3/b11-10+,18-14+/t19-,20+,21-,22-,23+,24-,26-,27-,29+,30-,31-,32-,33-,34-,35-,36-,37+/m1/s1",Demethyllactenocin,KEGG COMPOUND accession,C12003
1007,29595,gibberellin A36,,"InChI=1S/C20H26O6/c1-10-7-20-8-11(10)3-4-12(20)19(9-21)6-5-13(22)18(2,17(25)26)15(19)14(20)16(23)24/h9,11-15,22H,1,3-8H2,2H3,(H,23,24)(H,25,26)/t11-,12+,13+,14-,15-,18-,19-,20+/m1/s1",Gibberellin A36,KEGG COMPOUND accession,C11862
1008,29599,gibberellin A51,,"InChI=1S/C19H24O5/c1-9-5-18-6-10(9)3-4-12(18)19-8-11(20)7-17(2,16(23)24-19)14(19)13(18)15(21)22/h10-14,20H,1,3-8H2,2H3,(H,21,22)/t10-,11-,12-,13-,14-,17-,18+,19-/m1/s1",Gibberellin A51,KEGG COMPOUND accession,C11865
1009,29612,cladinose,,"InChI=1S/C8H16O4/c1-6(10)7(11)8(2,12-3)4-5-9/h5-7,10-11H,4H2,1-3H3/t6-,7-,8+/m0/s1",L-Cladinose,KEGG COMPOUND accession,C11917
1010,29614,3-O-(alpha-L-olivosyl)oleandolide,"A macrolide that is oleandolide having a 2,6-dideoxy-alpha-L-arabino-hexopyranosyl (alpha-L-olivosyl) residue attached at position 3.","InChI=1S/C26H44O10/c1-11-9-26(10-33-26)24(31)14(4)21(29)12(2)16(6)35-25(32)15(5)23(13(3)20(11)28)36-19-8-18(27)22(30)17(7)34-19/h11-23,27-30H,8-10H2,1-7H3/t11-,12-,13+,14+,15+,16+,17-,18-,19-,20-,21-,22-,23-,26+/m0/s1",L-Olivosyl-oleandolide,KEGG COMPOUND accession,C11991
1011,29616,"abieta-8(14),12-diene",,"InChI=1S/C20H32/c1-14(2)15-7-9-17-16(13-15)8-10-18-19(3,4)11-6-12-20(17,18)5/h7,13-14,17-18H,6,8-12H2,1-5H3/t17-,18-,20+/m0/s1",Levopimaradiene,KEGG COMPOUND accession,C11879
1012,29640,N-(3-oxohexanoyl)homoserine lactone,A N-acyl homoserine lactone that is the monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-oxohexanoic acid with the amino group of homoserine lactone.,"InChI=1S/C10H15NO4/c1-2-3-7(12)6-9(13)11-8-4-5-15-10(8)14/h8H,2-6H2,1H3,(H,11,13)",N-(3-Oxohexanoyl)homoserine lactone,KEGG COMPOUND accession,C11839
1013,29643,N-butyryl-L-homoserine lactone,An N-acyl-L-homoserine lactone having butyryl as the acyl substituent.,"InChI=1S/C8H13NO3/c1-2-3-7(10)9-6-4-5-12-8(6)11/h6H,2-5H2,1H3,(H,9,10)/t6-/m1/s1",N-Butyryl-L-homoserine lactone,KEGG COMPOUND accession,C11837
1014,29588,gibberellin A14,"A C20-gibberellin, initially identified in Gibberella fujikuroi. It differs from gibberellin A12 in the presence of a beta-OH at C-2 (gibbane numbering).","InChI=1S/C20H28O5/c1-10-8-20-9-11(10)4-5-12(20)18(2)7-6-13(21)19(3,17(24)25)15(18)14(20)16(22)23/h11-15,21H,1,4-9H2,2-3H3,(H,22,23)(H,24,25)/t11-,12+,13+,14-,15+,18+,19-,20+/m1/s1",Gibberellin A14,KEGG COMPOUND accession,C11858
1015,29678,sodium arsenite,An inoganic sodium salt with formula with formula NaAsO2.,"InChI=1S/AsHO2.Na/c2-1-3;/h(H,2,3);/q;+1/p-1",Sodium arsenite,KEGG COMPOUND accession,C11906
1016,1178,(2S)-2-isopropylmalate(2-),A 2-isopropylmalate(2-) with S-configuration at the chiral centre.,"InChI=1S/C7H12O5/c1-4(2)7(12,6(10)11)3-5(8)9/h4,12H,3H2,1-2H3,(H,8,9)(H,10,11)/p-2/t7-/m0/s1",(2S)-2-Isopropylmalate,KEGG COMPOUND accession,C02504
1017,7814,2-oxaloglutaric acid,,"InChI=1S/C7H8O7/c8-4(9)2-1-3(6(11)12)5(10)7(13)14/h3H,1-2H2,(H,8,9)(H,11,12)(H,13,14)",Oxaloglutarate,KEGG COMPOUND accession,C05533
1018,1963,"guanosine 5'-[beta,gamma-methylene]triphosphate","A nucleoside triphosphate analogue that is guanosine substituted at position 5' by a (beta,gamma-methylene)triphosphate group.","InChI=1S/C11H18N5O13P3/c12-11-14-8-5(9(19)15-11)13-2-16(8)10-7(18)6(17)4(28-10)1-27-32(25,26)29-31(23,24)3-30(20,21)22/h2,4,6-7,10,17-18H,1,3H2,(H,23,24)(H,25,26)(H2,20,21,22)(H3,12,14,15,19)/t4-,6-,7-,10-/m1/s1",5'-Guanosyl-methylene-triphosphate,KEGG COMPOUND accession,C06500
1019,3689,chrysosplenetin,"A tetramethoxyflavone that is  the 3,6,7,3'-tetramethyl ether derivative of quercetagetin.","InChI=1S/C19H18O8/c1-23-11-7-9(5-6-10(11)20)17-19(26-4)16(22)14-12(27-17)8-13(24-2)18(25-3)15(14)21/h5-8,20-21H,1-4H3",Chrysosplenetin B,KEGG COMPOUND accession,C10030
1020,3789,cobalt-precorrin-6B,,"InChI=1S/C44H56N4O16.Co/c1-40(13-12-34(55)56)25(15-36(59)60)39-44(5)42(3,20-38(63)64)23(8-11-33(53)54)27(48-44)17-30-41(2,19-37(61)62)22(7-10-32(51)52)28(45-30)18-43(4)24(14-35(57)58)21(6-9-31(49)50)26(47-43)16-29(40)46-39;/h17,23,25,39H,6-16,18-20H2,1-5H3,(H9,45,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64);/q;+2/p-1/t23-,25+,39-,40-,41+,42+,43+,44+;/m1./s1",Cobalt-dihydro-precorrin 6,KEGG COMPOUND accession,C11543
1021,3794,cobalt-precorrin-6A,,"InChI=1S/C44H54N4O16.Co/c1-40(13-12-34(55)56)25(15-36(59)60)39-44(5)42(3,20-38(63)64)23(8-11-33(53)54)27(48-44)17-30-41(2,19-37(61)62)22(7-10-32(51)52)28(45-30)18-43(4)24(14-35(57)58)21(6-9-31(49)50)26(47-43)16-29(40)46-39;/h17,23H,6-16,18-20H2,1-5H3,(H9,45,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64);/q;+2/p-1/t23-,40-,41+,42+,43+,44+;/m1./s1",Cobalt-precorrin 6,KEGG COMPOUND accession,C11542
1022,19289,"N(2),N(2)-dimethylguanosine",A guanosine where the hydrogens of the amine group at C-2 are substituted by methyl groups.,"InChI=1S/C12H17N5O5/c1-16(2)12-14-9-6(10(21)15-12)13-4-17(9)11-8(20)7(19)5(3-18)22-11/h4-5,7-8,11,18-20H,3H2,1-2H3,(H,14,15,21)/t5-,7-,8-,11-/m1/s1","2,2-dimethylguanosine",CAS Registry Number,2140-67-2
1023,2756,"anthracene-1,8,9-triol","An  anthracenetriol that is anthracene substituted by hydroxy groups at positions 1, 8 and 9.","InChI=1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-7,15-17H",Anthralin,CAS Registry Number,480-22-8
1024,8359,pratensein,"A member of the class of 7-hydroxyisoflavones in which isoflavone is substituted by hydroxy groups at the 5, 7, and 3' positions, and by a methoxy group at the 4' position.","InChI=1S/C16H12O6/c1-21-13-3-2-8(4-11(13)18)10-7-22-14-6-9(17)5-12(19)15(14)16(10)20/h2-7,17-19H,1H3",Pratensein,CAS Registry Number,2284-31-3
1025,4388,deltamethrin,"A cyclopropanecarboxylate ester obtained by formal condensation between 3-(2,2-dibromovinyl)-2,2-dimethylcyclopropanecarboxylic acid and cyano(3-phenoxyphenyl)methanol. It is the active insecticide of the proinsecticide tralomethrin.","InChI=1S/C22H19Br2NO3/c1-22(2)17(12-19(23)24)20(22)21(26)28-18(13-25)14-7-6-10-16(11-14)27-15-8-4-3-5-9-15/h3-12,17-18,20H,1-2H3/t17-,18+,20-/m0/s1",Deltamethrin,KEGG COMPOUND accession,C10985
1026,4941,"4-deoxyphorbol 12-acetate 13-(2Z,4E,6E)-deca-2,4,6-trienoate","A phorbol ester that consists of 4-deoxyphorbol bearing O-acetyl and O-[13-(2Z,4E,6E)-deca-2,4,6-trienoyl] substituents at position 12 and 13 respectively.","InChI=1S/C32H42O7/c1-7-8-9-10-11-12-13-14-26(35)39-32-28(30(32,5)6)25-17-22(18-33)16-23-24(15-19(2)27(23)36)31(25,37)20(3)29(32)38-21(4)34/h9-15,17,20,23-25,28-29,33,37H,7-8,16,18H2,1-6H3/b10-9+,12-11+,14-13-/t20-,23+,24-,25+,28-,29-,31+,32-/m1/s1",Euphorbia factor Ti2,CAS Registry Number,64180-96-7
1027,155,(-)-isodihydrocarvone,"The (1R,4S)-stereoisomer of dihydrocarvone.","InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-9H,1,4-6H2,2-3H3/t8-,9+/m1/s1","(1R,4S)-Iso-dihydrocarvone",KEGG COMPOUND accession,C11412
1028,166,(+)-isodihydrocarvone,"The (1S,4R)-stereoisomer of dihydrocarvone.","InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-9H,1,4-6H2,2-3H3/t8-,9+/m0/s1","(1S,4R)-Iso-dihydrocarvone",KEGG COMPOUND accession,C11401
1029,6889,methylprednisolone acetate,An acetate ester resulting from the formal condensation of the 21-hydroxy function of 6alpha-methylprednisolone compound with acetic acid.,"InChI=1S/C24H32O6/c1-13-9-16-17-6-8-24(29,20(28)12-30-14(2)25)23(17,4)11-19(27)21(16)22(3)7-5-15(26)10-18(13)22/h5,7,10,13,16-17,19,21,27,29H,6,8-9,11-12H2,1-4H3/t13-,16-,17-,19-,21+,22-,23-,24-/m0/s1",Methylprednisolone acetate,CAS Registry Number,53-36-1
1030,7027,2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose,The pyranose form of muramic acid.,"InChI=1S/C9H17NO7/c1-3(8(13)14)16-7-5(10)9(15)17-4(2-11)6(7)12/h3-7,9,11-12,15H,2,10H2,1H3,(H,13,14)/t3-,4-,5-,6-,7-,9?/m1/s1",Muramic acid,KEGG COMPOUND accession,C06470
1031,8769,rabeprazole sodium,,"InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1",Rabeprazole sodium,CAS Registry Number,117976-90-6
1032,8944,S-adenosyl-4-methylthio-2-oxobutanoic acid,A sulfonium compound comprising 4-methylthio-2-oxobutanoic acid having an adenosin-5'-yl group attached to the sulfur.,"InChI=1S/C15H19N5O6S/c1-27(3-2-7(21)15(24)25)4-8-10(22)11(23)14(26-8)20-6-19-9-12(16)17-5-18-13(9)20/h5-6,8,10-11,14,22-23H,2-4H2,1H3,(H2-,16,17,18,24,25)/p+1/t8-,10-,11-,14-,27?/m1/s1",S-Adenosyl-4-methylthio-2-oxobutanoate,KEGG COMPOUND accession,C04425
1033,371,(S)-1-pyrroline-5-carboxylic acid,A 1-pyrroline-5-carboxylic acid in which the chiral centre has S configuration.,"InChI=1S/C5H7NO2/c7-5(8)4-2-1-3-6-4/h3-4H,1-2H2,(H,7,8)/t4-/m0/s1",(S)-1-Pyrroline-5-carboxylate,KEGG COMPOUND accession,C03912
1034,9401,taraxasterol,A pentacyclic triterpenoid that is taraxastane with a beta-hydroxy group at position 3.,"InChI=1S/C30H50O/c1-19-11-14-27(5)17-18-29(7)21(25(27)20(19)2)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h20-25,31H,1,9-18H2,2-8H3/t20-,21-,22+,23-,24+,25-,27-,28+,29-,30-/m1/s1",Taraxasterol,KEGG COMPOUND accession,C08636
1035,9416,(+)-taxifolin 3-O-acetate,An acetate ester obtained by formal condensation between the 3-hydroxy group of (+)-taxifolin and acetic acid.,"InChI=1S/C17H14O8/c1-7(18)24-17-15(23)14-12(22)5-9(19)6-13(14)25-16(17)8-2-3-10(20)11(21)4-8/h2-6,16-17,19-22H,1H3/t16-,17+/m1/s1",Taxifolin 3-O-acetate,KEGG COMPOUND accession,C09967
1036,9463,testosterone cypionate,,"InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1",Testosterone cypionate,KEGG COMPOUND accession,C08156
1037,9522,theogallin,A gallate ester resulting from the formal condensation of gallic acid with the (5R)-hydroxy group of (-)-quinic acid (i.e. the hydroxy group on the same side of the cyclohexane ring as the carboxy group).,"InChI=1S/C14H16O10/c15-6-1-5(2-7(16)10(6)18)12(20)24-9-4-14(23,13(21)22)3-8(17)11(9)19/h1-2,8-9,11,15-19,23H,3-4H2,(H,21,22)/t8-,9-,11-,14+/m1/s1",Theogallin,CAS Registry Number,17365-11-6
1038,9533,thiamine(1+) monophosphate,A thiamine phosphate that is thiamin(1+) in which the hydroxy group is replaced by a phosphate group.,"InChI=1S/C12H17N4O4PS/c1-8-11(3-4-20-21(17,18)19)22-7-16(8)6-10-5-14-9(2)15-12(10)13/h5,7H,3-4,6H2,1-2H3,(H3-,13,14,15,17,18,19)/p+1",thiamin monophosphate,KEGG COMPOUND accession,C01081
1039,9662,triacetylene,,InChI=1S/C6H2/c1-3-5-6-4-2/h1-2H,Triacetylene,KEGG COMPOUND accession,C08463
1040,7576,nimustine hydrochloride,A hydrochloride obtained by combining nimustine with one equivalent of hydrochloric acid. An antineoplastic agent especially effective against malignant brain tumors.,"InChI=1S/C9H13ClN6O2.ClH/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10;/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14);1H",Nimustine hydrochloride,CAS Registry Number,55661-38-6
1041,7596,nitroprusside,,InChI=1S/5CN.Fe.NO/c5*1-2;;1-2/q;;;;;2*-1,Nitroprusside,CAS Registry Number,15078-28-1
1042,7630,norgestrel,,"InChI=1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3",Norgestrel,KEGG COMPOUND accession,C08153
1043,7940,patchouli alcohol,"A carbotricyclic compound and sesquiterpenoid tertiary alcohol that is tricyclo[5.3.1.0(3,8)]undecan-3-ol which is substituted at positions 2, 2, 6 and 8 by methyl groups (the 1R,3R,6S,7S,8S-diastereoisomer).","InChI=1S/C15H26O/c1-10-5-8-15(16)13(2,3)11-6-7-14(15,4)12(10)9-11/h10-12,16H,5-9H2,1-4H3/t10-,11+,12-,14-,15+/m0/s1",Patchouli alcohol,KEGG COMPOUND accession,C09705
1044,8492,propiomazine hydrochloride,,"InChI=1S/C20H24N2OS.ClH/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20;/h6-12,14H,5,13H2,1-4H3;1H",Propiomazine hydrochloride,KEGG COMPOUND accession,C07384
1045,963,"2-(2-chlorophenyl)-5-(5-methyl-2-thienyl)-1,3,4-oxadiazole","A  1,3,4-oxadiazole substituted by a 2-chlorophenyl group at position 2 and a 5-methyl-2-thienyl group at position 5.","InChI=1S/C13H9ClN2OS/c1-8-6-7-11(18-8)13-16-15-12(17-13)9-4-2-3-5-10(9)14/h2-7H,1H3","2-(2-Chloro-phenyl)-5-(5-methylthiophen-2-yl)-[1,3,4]oxadiazole",KEGG COMPOUND accession,C11570
1046,991,"2-amino-2-methylpropane-1,3-diol","An aminodiol that is propane-1,3-diol substituted ny an amino and a methyl group at position 2.","InChI=1S/C4H11NO2/c1-4(5,2-6)3-7/h6-7H,2-3,5H2,1H3","2-Amino-2-methyl-1,3-propandiol",KEGG COMPOUND accession,C11260
1047,9068,Se-methylselenocysteine,An alpha-amino acid compound having methylselanylmethyl as the side-chain.,"InChI=1S/C4H9NO2Se/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)",Se-Methylselenocysteine,Beilstein Registry Number,3930828
1048,1864,4-hydroxycyclophosphamide,"A phosphorodiamide that consists of 2-amino-1,3,2-oxazaphosphinan-4-ol 2-oxide having two 2-chloroethyl groups attached to the exocyclic nitrogen.","InChI=1S/C7H15Cl2N2O3P/c8-2-4-11(5-3-9)15(13)10-7(12)1-6-14-15/h7,12H,1-6H2,(H,10,13)",4-Hydroxycyclophosphamide,CAS Registry Number,40277-05-2
1049,1905,4-methylumbelliferone sulfate,A member of the class of coumarins that is umbelliferone sulfate which carries a methyl group at position 4. It is a metabolite of 4-methylumbelliferone.,"InChI=1S/C10H8O6S/c1-6-4-10(11)15-9-5-7(2-3-8(6)9)16-17(12,13)14/h2-5H,1H3,(H,12,13,14)",4-methylumbelliferone sulfate,KEGG COMPOUND accession,C11585
1050,1217,"2-methylthio-1,3-benzothiazole","An organic sulfide that is the methyl thioether of 1,3-benzothiazole-2-thiol.","InChI=1S/C8H7NS2/c1-10-8-9-6-4-2-3-5-7(6)11-8/h2-5H,1H3",2-Methylthiobenzothiazole,KEGG COMPOUND accession,C10910
1051,10329,alpha-ribazole,,"InChI=1S/C14H18N2O4/c1-7-3-9-10(4-8(7)2)16(6-15-9)14-13(19)12(18)11(5-17)20-14/h3-4,6,11-14,17-19H,5H2,1-2H3/t11-,12-,13-,14+/m1/s1",alpha-Ribazole,KEGG COMPOUND accession,C05775
1052,10357,(-)-beta-caryophyllene,"A beta-caryophyllene in which the stereocentre adjacent to the exocyclic double bond has S configuration while the remaining stereocentre has R configuration. It is the most commonly occurring form of beta-caryophyllene, occurring in many essential oils, particularly oil of cloves.","InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6+/t13-,14-/m1/s1",beta-Caryophyllene,KEGG COMPOUND accession,C09629
1053,10454,cis-flupenthixol,A flupenthixol in which the double bond adopts a cis-configuration.,"InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-",cis-(Z)-flupenthixol,CAS Registry Number,53772-82-0
1054,2124,5-pyridoxolactone,"A furopyridine that is furo[3,4-c]pyridin-3(1H)-one substituted by a hydroxy group at position 7 and a methoxy group at position 6. It is a metabolite of vitamin B6.","InChI=1S/C8H7NO3/c1-4-7(10)6-3-12-8(11)5(6)2-9-4/h2,10H,3H2,1H3",5-Pyridoxolactone,KEGG COMPOUND accession,C06052
1055,2179,D-fucopyranose,The six-membered ring form of D-fucose.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m1/s1",6-Deoxy-D-galactose,KEGG COMPOUND accession,C01018
1056,1606,1-methyl-4-imidazoleacetic acid,A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1-methyl-1H-imidazol-4-yl group.,"InChI=1S/C6H8N2O2/c1-8-3-5(7-4-8)2-6(9)10/h3-4H,2H2,1H3,(H,9,10)",Methylimidazoleacetic acid,KEGG COMPOUND accession,C05828
1057,4646,dipivefrin,"The dipivalate ester of (+-)-epinephrine (racepinephrine). A pro-drug of epinephrine, the hydrochloride is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension.","InChI=1S/C19H29NO5/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H3",Dipivefrin,CAS Registry Number,52365-63-6
1058,4672,docetaxel anhydrous,"A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.","InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1",Docetaxel anhydrous,CAS Registry Number,114977-28-5
1059,1283,"(E,E)-2-methyl-6-oxohepta-2,4-dienal","A heptadienal that is hepta-2,4-dienal substituted by an oxo group at position 6 and a methyl group at position 2.","InChI=1S/C8H10O2/c1-7(6-9)4-3-5-8(2)10/h3-6H,1-2H3/b5-3+,7-4+","2-Methyl-6-oxohepta-2,4-dienal",KEGG COMPOUND accession,C11480
1060,5313,gentiacaulein,A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 2 and 8 and methoxy groups at positions 1 and 6.,"InChI=1S/C15H12O6/c1-19-7-5-9(17)12-11(6-7)21-10-4-3-8(16)15(20-2)13(10)14(12)18/h3-6,16-17H,1-2H3","2,8-Dihydroxy-1,6-dimethoxyxanthone",CAS Registry Number,15402-27-4
1061,4174,beta-D-glucosyl-(1->4)-beta-D-mannose,,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8+,9-,10-,11-,12+/m1/s1",D-Glucosyl-D-mannose,KEGG COMPOUND accession,C02964
1062,6566,lunarine,,"InChI=1S/C25H31N3O4/c29-19-8-10-25-11-9-24(31)27-14-2-1-12-26-13-3-15-28-23(30)7-5-18-4-6-21(20(25)16-18)32-22(25)17-19/h4-7,9,11,16,22,26H,1-3,8,10,12-15,17H2,(H,27,31)(H,28,30)/b7-5+,11-9+/t22-,25+/m1/s1",Lunarine,CAS Registry Number,24185-51-1
1063,18887,"cyclohexa-3,5-diene-1,2-diol",,InChI=1S/C6H8O2/c7-5-3-1-2-4-6(5)8/h1-8H,"1,2-dihydrobenzene-1,2-diol",Beilstein Registry Number,3233703
1064,3690,chrysosplenol C,"A trimethoxyflavone that is the 3,7,3'-trimethyl ether derivative of quercetagetin.","InChI=1S/C18H16O8/c1-23-10-6-8(4-5-9(10)19)17-18(25-3)16(22)13-11(26-17)7-12(24-2)14(20)15(13)21/h4-7,19-21H,1-3H3","Quercetagetin 3,7,3'-trimethyl ether",CAS Registry Number,23370-16-3
1065,3752,clomiphene,,"InChI=1S/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3",Clomiphene,KEGG COMPOUND accession,C06917
1066,1941,4-(trimethylammonio)butanoic acid,A quaternary ammonium ion that is the  conjugate acid of 4-(trimethylammonio)butanoate.,"InChI=1S/C7H15NO2/c1-8(2,3)6-4-5-7(9)10/h4-6H2,1-3H3/p+1",4-Trimethylammoniobutanoate,KEGG COMPOUND accession,C01181
1067,2945,azaleatin,A monomethoxyflavone that is quercetin in which the hydroxy group at position 5 is replaced by a methoxy group.,"InChI=1S/C16H12O7/c1-22-11-5-8(17)6-12-13(11)14(20)15(21)16(23-12)7-2-3-9(18)10(19)4-7/h2-6,17-19,21H,1H3",Quercetin 5-methyl ether,KEGG COMPOUND accession,C10022
1068,2999,bayogenin 3-O-cellobioside,A pentacyclic triterpenoid that is bayogenin substituted at the O-3 position by a cellobiosyl residue.,"InChI=1S/C42H68O15/c1-37(2)11-13-42(36(52)53)14-12-40(5)20(21(42)15-37)7-8-26-38(3)16-22(46)33(39(4,19-45)25(38)9-10-41(26,40)6)57-35-31(51)29(49)32(24(18-44)55-35)56-34-30(50)28(48)27(47)23(17-43)54-34/h7,21-35,43-51H,8-19H2,1-6H3,(H,52,53)/t21-,22-,23+,24+,25+,26+,27+,28-,29+,30+,31+,32+,33-,34-,35-,38-,39-,40+,41+,42-/m0/s1",Bayogenin 3-O-cellobioside,KEGG COMPOUND accession,C08932
1069,3218,"2-(tert-butylimino)-5-phenyl-3-(propan-2-yl)-1,3,5-thiadiazinan-4-one",,"InChI=1S/C16H23N3OS/c1-12(2)19-14(17-16(3,4)5)21-11-18(15(19)20)13-9-7-6-8-10-13/h6-10,12H,11H2,1-5H3",Buprofezin,KEGG COMPOUND accession,C10912
1070,3414,carfecillin,,"InChI=1S/C23H22N2O6S/c1-23(2)17(21(28)29)25-19(27)16(20(25)32-23)24-18(26)15(13-9-5-3-6-10-13)22(30)31-14-11-7-4-8-12-14/h3-12,15-17,20H,1-2H3,(H,24,26)(H,28,29)/t15?,16-,17+,20-/m1/s1",Carfecillin,CAS Registry Number,27025-49-6
1071,3434,carpropamid,"A cyclopropylcarboxamide obtained by formal condensation of the carboxy group of 2,2-dichloro-1-ethyl-3-methylcyclopropanecarboxylic acid with the amino group of 1-(4-chlorophenyl)ethylamine. A rice fungicide with specific action against Pyricularia oryzae. It is not highly toxic to mammals but shows a moderate level of toxicity to birds, fish and earthworms.","InChI=1S/C15H18Cl3NO/c1-4-14(10(3)15(14,17)18)13(20)19-9(2)11-5-7-12(16)8-6-11/h5-10H,4H2,1-3H3,(H,19,20)",Carpropamid,KEGG COMPOUND accession,C10932
1072,3546,cepharanthine,A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation.,"InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1",Cepharanthine,CAS Registry Number,481-49-2
1073,29472,2-heptyl-3-hydroxy-4-quinolone,A quinolone consisting of quinolin-4(1H)-one carrying a heptyl substituent at position 2 and a hydroxy group at position 3.,"InChI=1S/C16H21NO2/c1-2-3-4-5-6-11-14-16(19)15(18)12-9-7-8-10-13(12)17-14/h7-10,19H,2-6,11H2,1H3,(H,17,18)",2-Heptyl-3-hydroxy-quinolone,KEGG COMPOUND accession,C11848
1074,29491,5-O-beta-D-mycaminosyltylactone,A macrolide antibiotic that is tylactone having a beta-D-mycaminosyl residue attached at position 5.,"InChI=1S/C31H53NO8/c1-10-22-15-18(4)23(33)13-12-17(3)14-19(5)25(11-2)39-26(35)16-24(34)20(6)30(22)40-31-29(37)27(32(8)9)28(36)21(7)38-31/h12-14,18-22,24-25,27-31,34,36-37H,10-11,15-16H2,1-9H3/b13-12+,17-14+/t18-,19+,20+,21-,22+,24-,25-,27+,28-,29-,30-,31+/m1/s1",5-O-beta-D-Mycaminosyltylactone,KEGG COMPOUND accession,C12001
1075,29560,cyanidin 3-O-(6-O-(E)-4-coumaroyl-beta-D-glucoside),An anthocyanin cation that is cyanidin substituted at position 3 by a 6-O-(trans-4 coumaryl)-beta-D-glucosyl residue,"InChI=1S/C30H26O13/c31-16-5-1-14(2-6-16)3-8-25(36)40-13-24-26(37)27(38)28(39)30(43-24)42-23-12-18-20(34)10-17(32)11-22(18)41-29(23)15-4-7-19(33)21(35)9-15/h1-12,24,26-28,30,37-39H,13H2,(H4-,31,32,33,34,35,36)/p+1/t24-,26-,27+,28-,30-/m1/s1",Cyanidin 3-O-(6-O-p-coumaroyl)glucoside,KEGG COMPOUND accession,C12095
1076,29593,gibberellin A34,,"InChI=1S/C19H24O6/c1-8-5-18-6-9(8)3-4-11(18)19-7-10(20)14(21)17(2,16(24)25-19)13(19)12(18)15(22)23/h9-14,20-21H,1,3-7H2,2H3,(H,22,23)/t9-,10+,11-,12-,13-,14+,17+,18+,19-/m1/s1",Gibberellin A34,KEGG COMPOUND accession,C11868
1077,29605,gibberellin A9,A C19-gibberellin that is a pentacyclic diterpenoid responsible for promoting growth and elongation of cells in plants. Initially identified in Gibberella fujikuroi it differs from gibberellin A1 in the absence of OH groups at C-2 and C-7 (gibbane numberings).,"InChI=1S/C19H24O4/c1-10-8-18-9-11(10)4-5-12(18)19-7-3-6-17(2,16(22)23-19)14(19)13(18)15(20)21/h11-14H,1,3-9H2,2H3,(H,20,21)/t11-,12-,13-,14-,17-,18+,19-/m1/s1",Gibberellin A9,KEGG COMPOUND accession,C11863
1078,29613,3-O-(alpha-L-oleandrosyl)oleandolide,"A macrolide that is oleandolide having a 2,6-dideoxy-3-O-methyl-alpha-Larabino-hexopyranosyl (alpha-L-oleandrosyl) residue attached at position 3.","InChI=1S/C27H46O10/c1-12-10-27(11-34-27)25(31)15(4)22(29)13(2)17(6)36-26(32)16(5)24(14(3)21(12)28)37-20-9-19(33-8)23(30)18(7)35-20/h12-24,28-30H,9-11H2,1-8H3/t12-,13-,14+,15+,16+,17+,18-,19-,20-,21-,22-,23-,24-,27+/m0/s1",L-Oleandrosyl-oleandolide,KEGG COMPOUND accession,C11992
1079,5587,sulfurothioic S-acid,,"InChI=1S/H2O3S2/c1-5(2,3)4/h(H2,1,2,3,4)",H2S2O3,KEGG COMPOUND accession,C05529
1080,783,"(20R)-17alpha,20-dihydroxycholesterol",An  oxysterol that is  cholesterol substituted by hydroxy groups at positions 17 and 20 (the 20R-stereoisomer).,"InChI=1S/C27H46O3/c1-18(2)7-6-13-26(5,29)27(30)16-12-23-21-9-8-19-17-20(28)10-14-24(19,3)22(21)11-15-25(23,27)4/h8,18,20-23,28-30H,6-7,9-17H2,1-5H3/t20-,21+,22-,23-,24-,25-,26+,27+/m0/s1","17alpha,20alpha-Dihydroxycholesterol",KEGG COMPOUND accession,C05499
1081,1040,"6-chloro-1,3,5-triazine-2,4-diol","A dihydroxy-1,3,5-triazine that is 1,3,5-triazine-2,4-diol substituted by a chloro group at position 6.","InChI=1S/C3H2ClN3O2/c4-1-5-2(8)7-3(9)6-1/h(H2,5,6,7,8,9)","2-Chloro-4,6-dihydroxy-1,3,5-triazine",KEGG COMPOUND accession,C08736
1082,7642,norwogonin,"A trihydroxyflavone with the hydroxy groups at positions C-5, -7 and -8.","InChI=1S/C15H10O5/c16-9-6-11(18)14(19)15-13(9)10(17)7-12(20-15)8-4-2-1-3-5-8/h1-7,16,18-19H",Norwogonin,KEGG COMPOUND accession,C10113
1083,8811,resmethrin,,"InChI=1S/C22H26O3/c1-15(2)10-19-20(22(19,3)4)21(23)25-14-17-12-18(24-13-17)11-16-8-6-5-7-9-16/h5-10,12-13,19-20H,11,14H2,1-4H3",Resmethrin,KEGG COMPOUND accession,C10991
1084,9675,triazolealanine,"A non-proteinogenic alpha-amino acid that is alanine in which one of the methyl hydrogens is replaced by a 1,2,4-triazol-3-yl group.","InChI=1S/C5H8N4O2/c6-3(5(10)11)1-4-7-2-8-9-4/h2-3H,1,6H2,(H,10,11)(H,7,8,9)","1,2,4-Triazole-3-alanine",CAS Registry Number,10109-05-4
1085,10502,"dTDP-3-amino-3,4,6-trideoxy-alpha-D-glucose","A dTDP-sugar having 3-amino-3,4,6-trideoxy-alpha-D-glucose as the sugar component.","InChI=1S/C16H27N3O13P2/c1-7-5-19(16(23)18-14(7)22)12-4-10(20)11(30-12)6-28-33(24,25)32-34(26,27)31-15-13(21)9(17)3-8(2)29-15/h5,8-13,15,20-21H,3-4,6,17H2,1-2H3,(H,24,25)(H,26,27)(H,18,22,23)/t8-,9+,10+,11-,12-,13-,15-/m1/s1","dTDP-3-amino-3,4,6-trideoxy-alpha-D-glucose",KEGG COMPOUND accession,C11910
1086,21397,L-altrarate(1-),,"InChI=1S/C6H10O8/c7-1(3(9)5(11)12)2(8)4(10)6(13)14/h1-4,7-10H,(H,11,12)(H,13,14)/p-1/t1-,2+,3-,4-/m1/s1",L-talarate,PubMed citation,17649980
1087,25939,permanganate,,InChI=1S/Mn.4O/q;;;;-1,permanganate ion,CAS Registry Number,14333-13-2
1088,9290,strigol,A strigolactone in which the tricyclic lactone moiety bears a hydroxy substitutuent at the position para to the gem-dimethyl group.,"InChI=1S/C19H22O6/c1-9-6-14(24-17(9)21)23-8-12-10-7-11-13(20)4-5-19(2,3)15(11)16(10)25-18(12)22/h6,8,10,13-14,16,20H,4-5,7H2,1-3H3/b12-8+/t10-,13+,14-,16+/m1/s1",Strigol,KEGG COMPOUND accession,C09190
1089,9555,tioguanine,"A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.","InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)",Thioguanine,KEGG COMPOUND accession,C07648
1090,9690,tricholomic acid,,"InChI=1S/C5H8N2O4/c6-4(5(9)10)2-1-3(8)7-11-2/h2,4H,1,6H2,(H,7,8)(H,9,10)/t2-,4-/m0/s1",Tricholomic acid,KEGG COMPOUND accession,C08298
1091,1989,"(6R)-5,10-methylenetetrahydrofolic acid","The (6R)-stereoisomer of 5,10-methylenetetrahydrofolic acid.","InChI=1S/C20H23N7O6/c21-20-24-16-15(18(31)25-20)27-9-26(8-12(27)7-22-16)11-3-1-10(2-4-11)17(30)23-13(19(32)33)5-6-14(28)29/h1-4,12-13H,5-9H2,(H,23,30)(H,28,29)(H,32,33)(H4,21,22,24,25,31)/t12-,13+/m1/s1","5,10-Methylenetetrahydrofolate",KEGG COMPOUND accession,C00143
1092,22908,borate,,InChI=1S/BO3/c2-1(3)4/q-3,borate ion,Gmelin Registry Number,164057
1093,29589,gibberellin A14 aldehyde,A C20-gibberellin obtained by selective reduction of the 10beta-carboxy group of gibberellin A14.,"InChI=1S/C20H28O4/c1-11-8-20-9-12(11)4-5-14(20)18(2)7-6-15(22)19(3,17(23)24)16(18)13(20)10-21/h10,12-16,22H,1,4-9H2,2-3H3,(H,23,24)/t12-,13+,14+,15+,16+,18+,19-,20-/m1/s1",Gibberellin A14 aldehyde,KEGG COMPOUND accession,C11853
1094,8695,quercetagetin,"A hexahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 5, 6, 7, 3' and 4' respectively.","InChI=1S/C15H10O8/c16-6-2-1-5(3-7(6)17)15-14(22)13(21)10-9(23-15)4-8(18)11(19)12(10)20/h1-4,16-20,22H",Quercetagetin,CAS Registry Number,90-18-6
1095,21547,N-acetyl-L-aspartic acid,An N-acyl-L-aspartic acid in which the acyl group is specified as acetyl.,"InChI=1S/C6H9NO5/c1-3(8)7-4(6(11)12)2-5(9)10/h4H,2H2,1H3,(H,7,8)(H,9,10)(H,11,12)/t4-/m0/s1",(S)-2-(acetylamino)butanedioic acid,CAS Registry Number,997-55-7
1096,6532,loperamide,"A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.","InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3",Loperamide,CAS Registry Number,53179-11-6
1097,6722,megestrol,"A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.","InChI=1S/C22H30O3/c1-13-11-16-17(20(3)8-5-15(24)12-19(13)20)6-9-21(4)18(16)7-10-22(21,25)14(2)23/h11-12,16-18,25H,5-10H2,1-4H3/t16-,17+,18+,20-,21+,22+/m1/s1",Megestrol,KEGG COMPOUND accession,C07120
1098,6827,methicillin,"A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.","InChI=1S/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1",Methicillin,KEGG COMPOUND accession,C07177
1099,7820,oxandrolone,,"InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1",Oxandrolone,KEGG DRUG accession,D00462
1100,8638,"(9Z,11E,13Z)-octadecatrienoic acid","A 9,11,13-octadecatrienoic acid having its double bonds in cis, trans and cis configurations, respectively. It has been isolated from  pomegranate (Punica granatum).","InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h5-10H,2-4,11-17H2,1H3,(H,19,20)/b6-5-,8-7+,10-9-",Punicic acid,CAS Registry Number,544-72-9
1101,5391,glucagon,"A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence.","InChI=1S/C153H225N43O49S/c1-72(2)52-97(133(226)176-96(47-51-246-11)132(225)184-104(60-115(159)209)143(236)196-123(78(10)203)151(244)245)179-137(230)103(58-83-64-167-89-29-19-18-28-87(83)89)183-131(224)95(43-46-114(158)208)177-148(241)120(74(5)6)194-141(234)101(54-79-24-14-12-15-25-79)182-138(231)105(61-117(211)212)185-130(223)94(42-45-113(157)207)171-124(217)75(7)170-127(220)91(31-22-49-165-152(160)161)172-128(221)92(32-23-50-166-153(162)163)174-146(239)110(69-199)191-140(233)107(63-119(215)216)186-134(227)98(53-73(3)4)178-135(228)99(56-81-33-37-85(204)38-34-81)180-129(222)90(30-20-21-48-154)173-145(238)109(68-198)190-136(229)100(57-82-35-39-86(205)40-36-82)181-139(232)106(62-118(213)214)187-147(240)111(70-200)192-150(243)122(77(9)202)195-142(235)102(55-80-26-16-13-17-27-80)188-149(242)121(76(8)201)193-116(210)66-168-126(219)93(41-44-112(156)206)175-144(237)108(67-197)189-125(218)88(155)59-84-65-164-71-169-84/h12-19,24-29,33-40,64-65,71-78,88,90-111,120-123,167,197-205H,20-23,30-32,41-63,66-70,154-155H2,1-11H3,(H2,156,206)(H2,157,207)(H2,158,208)(H2,159,209)(H,164,169)(H,168,219)(H,170,220)(H,171,217)(H,172,221)(H,173,238)(H,174,239)(H,175,237)(H,176,226)(H,177,241)(H,178,228)(H,179,230)(H,180,222)(H,181,232)(H,182,231)(H,183,224)(H,184,225)(H,185,223)(H,186,227)(H,187,240)(H,188,242)(H,189,218)(H,190,229)(H,191,233)(H,192,243)(H,193,210)(H,194,234)(H,195,235)(H,196,236)(H,211,212)(H,213,214)(H,215,216)(H,244,245)(H4,160,161,165)(H4,162,163,166)/t75-,76+,77+,78+,88-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,120-,121-,122-,123-/m0/s1",Glucagon,KEGG COMPOUND accession,C01501
1102,4886,L-ethionine,An S-ethylhomocysteine that has S-configuration at the chiral centre.,"InChI=1S/C6H13NO2S/c1-2-10-4-3-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1",Ethionine,KEGG COMPOUND accession,C11227
1103,6794,metaraminol,"A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A  sympathomimetic agent , it is used in the treatment of hypotension.","InChI=1S/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1",Metaraminol,KEGG COMPOUND accession,C07146
1104,6925,microcystin-LR,"A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.","InChI=1S/C49H74N10O12/c1-26(2)23-37-46(66)58-40(48(69)70)30(6)42(62)55-35(17-14-22-52-49(50)51)45(65)54-34(19-18-27(3)24-28(4)38(71-10)25-33-15-12-11-13-16-33)29(5)41(61)56-36(47(67)68)20-21-39(60)59(9)32(8)44(64)53-31(7)43(63)57-37/h11-13,15-16,18-19,24,26,28-31,34-38,40H,8,14,17,20-23,25H2,1-7,9-10H3,(H,53,64)(H,54,65)(H,55,62)(H,56,61)(H,57,63)(H,58,66)(H,67,68)(H,69,70)(H4,50,51,52)/b19-18+,27-24+/t28-,29-,30-,31+,34-,35-,36+,37-,38-,40+/m0/s1",Microcystin-LR,CAS Registry Number,101043-37-2
1105,6052,isorhamnetin,A monomethoxyflavone that is quercetin in which the hydroxy group at position 3' is replaced by a methoxy group.,"InChI=1S/C16H12O7/c1-22-11-4-7(2-3-9(11)18)16-15(21)14(20)13-10(19)5-8(17)6-12(13)23-16/h2-6,17-19,21H,1H3",Isorhamnetin,KEGG COMPOUND accession,C10084
1106,7465,naltrexone,"An  organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.","InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1",Naltrexone,CAS Registry Number,16590-41-3
1107,9395,tambulin,"A member of the class of  flavonols that is  flavonol substituted by an additional hydroxy group at position 5 and methoxy groups at positions 7, 8 and 4' respectively.","InChI=1S/C18H16O7/c1-22-10-6-4-9(5-7-10)16-15(21)14(20)13-11(19)8-12(23-2)17(24-3)18(13)25-16/h4-8,19,21H,1-3H3","Herbacetin 7,8,4'-trimethyl ether",KEGG COMPOUND accession,C10189
1108,3024,benzenamine sulfate(1-),An organic sulfamate oxoanion obtained by deprotonation of the sulfamate OH group of benzenamine sulfate.,"InChI=1S/C6H7NO3S/c8-11(9,10)7-6-4-2-1-3-5-6/h1-5,7H,(H,8,9,10)/p-1",Benzenamine sulfate,KEGG COMPOUND accession,C06011
1109,2748,anthemis glycoside B,An anthemis glycoside that is found in the cyanogenic achenes of Anthemis altissima.,"InChI=1S/C34H41NO17/c35-12-19(17-4-2-1-3-5-17)50-34-31(45)28(42)25(39)22(52-34)15-47-32-29(43)26(40)21(14-46-32)49-23(37)11-8-16-6-9-18(10-7-16)48-33-30(44)27(41)24(38)20(13-36)51-33/h1-11,19-22,24-34,36,38-45H,13-15H2/b11-8+/t19-,20-,21-,22-,24-,25-,26+,27+,28+,29-,30-,31-,32+,33-,34-/m1/s1",Anthemis glycoside B,KEGG COMPOUND accession,C08327
1110,3245,butyl acrylate,An acrylate ester obtained by the formal condensation of the hydroxy group of  butan-1-ol with the carboxy group of  acrylic acid.,"InChI=1S/C7H12O2/c1-3-5-6-9-7(8)4-2/h4H,2-3,5-6H2,1H3",Butyl acrylate,KEGG COMPOUND accession,C10921
1111,6919,mezlocillin,A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.,"InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1",Mezlin,CAS Registry Number,51481-65-3
1112,10103,zaluzanin C,"A sesquiterpene lactone that is decahydroazuleno[4,5-b]furan-2(3H)-one substituted by methylidene groups at positions 3, 6 and 9 and a hydroxy group at position 8.","InChI=1S/C15H18O3/c1-7-4-5-10-8(2)15(17)18-14(10)13-9(3)12(16)6-11(7)13/h10-14,16H,1-6H2/t10-,11-,12-,13-,14-/m0/s1",Zaluzanin C,KEGG COMPOUND accession,C09606
1113,5326,geraldone,"A dihydroxyflavone that is the 5-deoxy-derivative of 4',5,7-trihydroxy-3'-methoxyflavone (chrysoeriol).","InChI=1S/C16H12O5/c1-20-16-6-9(2-5-12(16)18)14-8-13(19)11-4-3-10(17)7-15(11)21-14/h2-8,17-18H,1H3",5-Deoxychrysoeriol,KEGG COMPOUND accession,C10047
1114,2149,5beta-cyprinol sulfate,A steroid sulfate that is the sulfuric ester derivative of 5beta-cyprinol.,"InChI=1S/C27H48O8S/c1-16(5-4-6-17(14-28)15-35-36(32,33)34)20-7-8-21-25-22(13-24(31)27(20,21)3)26(2)10-9-19(29)11-18(26)12-23(25)30/h16-25,28-31H,4-15H2,1-3H3,(H,32,33,34)/t16-,17?,18+,19-,20-,21+,22+,23-,24+,25+,26+,27-/m1/s1",5beta-Cyprinolsulfate,KEGG COMPOUND accession,C05468
1115,9428,tectoridin,A glycosyloxyisoflavone that is  tectorigenin substituted by a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.,"InChI=1S/C22H22O11/c1-30-21-13(32-22-20(29)19(28)17(26)14(7-23)33-22)6-12-15(18(21)27)16(25)11(8-31-12)9-2-4-10(24)5-3-9/h2-6,8,14,17,19-20,22-24,26-29H,7H2,1H3/t14-,17-,19+,20-,22-/m1/s1",Shekanin,KEGG COMPOUND accession,C10533
1116,5018,ferreirin,"A hydroxyisoflavanone that is isoflavanone substituted by hydroxy groups at positions 5, 7 and 2' and a methoxy group at position 4' respectively.","InChI=1S/C16H14O6/c1-21-9-2-3-10(12(18)6-9)11-7-22-14-5-8(17)4-13(19)15(14)16(11)20/h2-6,11,17-19H,7H2,1H3","2,3-Dihydro-5,7-dihydroxy-3-(2-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one",KEGG COMPOUND accession,C10419
1117,29639,N-(3-oxododecanoyl)homoserine lactone,A N-acyl homoserine lactone that is the monocarboxylic acid amide arising from formal condensation of homoserine lactone with 3-oxododecanoic acid.,"InChI=1S/C16H27NO4/c1-2-3-4-5-6-7-8-9-13(18)12-15(19)17-14-10-11-21-16(14)20/h14H,2-12H2,1H3,(H,17,19)",N-(3-Oxododecanoyl)homoserine lactone,KEGG COMPOUND accession,C11840
1118,9479,tetrahydroalstonine,"A heteropentacyclic compound that is (20alpha)-16,17-didehydro-18-oxayohimban which is substituted at position 16 by a methoxycarbonyl group and at position 19 by a methyl group. It is a metabolite found in several plant species.","InChI=1S/C21H24N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-6,11-12,15-16,19,22H,7-10H2,1-2H3/t12-,15-,16-,19-/m0/s1",tetrahydroalstonine,KEGG COMPOUND accession,C11682
1119,2302,"8-(1,1-dimethylallyl)-3-methylgalangin","A 7-hydroxyflavonol that is  3-methylgalangin substituted by a 1,1-dimethylallyl group at position 8.","InChI=1S/C21H20O5/c1-5-21(2,3)16-14(23)11-13(22)15-17(24)20(25-4)18(26-19(15)16)12-9-7-6-8-10-12/h5-11,22-23H,1H2,2-4H3","8-(1,1-Dimethylallyl)-3-methylgalangin",KEGG COMPOUND accession,C11579
1120,2929,auriculoside,"A  flavan glycoside that is (2S)-flavan substituted by a methoxy group at position 4', hydroxy groups at positions 7 and 5' and a beta-D-glucopyranosyloxy group at position 3 respectively.","InChI=1S/C22H26O10/c1-29-21-13(25)6-11(14-5-3-10-2-4-12(24)8-15(10)30-14)7-16(21)31-22-20(28)19(27)18(26)17(9-23)32-22/h2,4,6-8,14,17-20,22-28H,3,5,9H2,1H3/t14-,17+,18+,19-,20+,22+/m0/s1","7,3',5'-Trihydroxy-4'-methoxyflavan 3'-glucoside",KEGG COMPOUND accession,C09478
1121,3244,butrin,A flavanone glycoside that is  butin substituted by two beta-D-glucopyranosyl residues at positions 7 and 3' respectively.,"InChI=1S/C27H32O15/c28-8-18-20(32)22(34)24(36)26(41-18)38-11-2-3-12-14(31)7-15(39-16(12)6-11)10-1-4-13(30)17(5-10)40-27-25(37)23(35)21(33)19(9-29)42-27/h1-6,15,18-30,32-37H,7-9H2/t15-,18+,19+,20+,21+,22-,23-,24+,25+,26+,27+/m0/s1","Butin 7,3'-di-O-glucoside",KEGG COMPOUND accession,C09616
1122,4631,diosmin,A disaccharide derivative that consists of  diosmetin substituted by a 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.,"InChI=1S/C28H32O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-8,10,19,21-30,32-37H,9H2,1-2H3/t10-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1",Diosmetin 7-O-rutinoside,KEGG COMPOUND accession,C10039
1123,4874,etaconazole,"A member of the class of dioxolanes that is 1,3-dioxolane substituted at position 2 by 2,4-dichlorophenyl and 1,2,4-triazol-1-ylmethyl groups and at position 4 by an ethyl group. An obsolete fungicide that was used to control powdery mildew on fruit and other crops.","InChI=1S/C14H15Cl2N3O2/c1-2-11-6-20-14(21-11,7-19-9-17-8-18-19)12-4-3-10(15)5-13(12)16/h3-5,8-9,11H,2,6-7H2,1H3",CGA 64251,KEGG COMPOUND accession,C11293
1124,4393,(-)-demecolcine,"A secondary amino compound that is (S)-colchicine in which the N-acetyl group is replaced by an N-methyl group. Isolable from the autumn crocus, Colchicum autumnale, it is less toxic than colchicine and is used as an antineoplastic.","InChI=1S/C21H25NO5/c1-22-15-8-6-12-10-18(25-3)20(26-4)21(27-5)19(12)13-7-9-17(24-2)16(23)11-14(13)15/h7,9-11,15,22H,6,8H2,1-5H3/t15-/m0/s1",Colcemid,CAS Registry Number,477-30-5
1125,2156,"6,8-diprenylnaringenin",A trihydroxyflavanone that is (S)-naringenin substituted by prenyl groups at positions 6 and 8.,"InChI=1S/C25H28O5/c1-14(2)5-11-18-23(28)19(12-6-15(3)4)25-22(24(18)29)20(27)13-21(30-25)16-7-9-17(26)10-8-16/h5-10,21,26,28-29H,11-13H2,1-4H3/t21-/m0/s1",Senegalensin,KEGG COMPOUND accession,C09724
1126,7602,nobiletin,"A methoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 8, 3' and 4' respectively.","InChI=1S/C21H22O8/c1-23-13-8-7-11(9-15(13)24-2)14-10-12(22)16-17(25-3)19(26-4)21(28-6)20(27-5)18(16)29-14/h7-10H,1-6H3",Hexamethoxyflavone,CAS Registry Number,478-01-3
1127,7502,neoeriocitrin,A flavanone glycoside that is  eriodictyol substituted by a 2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.,"InChI=1S/C27H32O15/c1-9-20(33)22(35)24(37)26(38-9)42-25-23(36)21(34)18(8-28)41-27(25)39-11-5-14(31)19-15(32)7-16(40-17(19)6-11)10-2-3-12(29)13(30)4-10/h2-6,9,16,18,20-31,33-37H,7-8H2,1H3/t9-,16-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1",Eriodictyol 7-O-neohesperidoside,KEGG COMPOUND accession,C09805
1128,3830,camphene,A monoterpene with a bicyclic skeleton that is bicyclo[2.2.1]heptane substituted by geminal methyl groups at position 2 and a methylidene group at position 3. It is a widespread natural product found in many essential oils.,"InChI=1S/C10H16/c1-7-8-4-5-9(6-8)10(7,2)3/h8-9H,1,4-6H2,2-3H3",Comphene,KEGG COMPOUND accession,C06076
1129,8455,proguanil,"A biguanide compound which has isopropyl and p-chlorophenyl substituents on the terminal N atoms. A prophylactic antimalarial drug, it works by inhibiting the enzyme dihydrofolate reductase, which is involved in the reproduction of the malaria parasites Plasmodium falciparum and P. vivax within the red blood cells.","InChI=1S/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)",Chloroguanide,KEGG COMPOUND accession,C07631
1130,4302,destosyl pyrazolate,A member of the class of pyrazoles that is pyrazolynate in which the tosylate ester has been hydrolysed to the corresponding hydroxy compound. The active herbicide of the proherbicides pyrazolynate and pyrazoxyfen.,"InChI=1S/C12H10Cl2N2O2/c1-6-10(12(18)16(2)15-6)11(17)8-4-3-7(13)5-9(8)14/h3-5,18H,1-2H3",DTP,KEGG COMPOUND accession,C11122
1131,2620,amaralin,"An  azulenofuran that is decahydrooxireno[1,2]azuleno[6,5-b]furan-5(1aH)-one substituted by a hydroxy group at position 8, methyl groups at positions 2 and 7a and a methylidene group at position 6.","InChI=1S/C15H20O4/c1-6-4-9-8(7(2)14(17)18-9)5-15(3)10(6)11-12(19-11)13(15)16/h6,8-13,16H,2,4-5H2,1,3H3/t6-,8-,9+,10-,11-,12-,13+,15+/m1/s1",Amaralin,CAS Registry Number,6831-10-3
1132,74,(S)-anabasine,The (S)-enantiomer of anabasine.,"InChI=1S/C10H14N2/c1-2-7-12-10(5-1)9-4-3-6-11-8-9/h3-4,6,8,10,12H,1-2,5,7H2/t10-/m0/s1",(-)-Anabasine,CAS Registry Number,494-52-0
1133,87,(-)-chimonanthine,"The (3aS,3a'S,8aS,8a'S)-stereoisomer of chimonanthine.","InChI=1S/C22H26N4/c1-25-13-11-21(15-7-3-5-9-17(15)23-19(21)25)22-12-14-26(2)20(22)24-18-10-6-4-8-16(18)22/h3-10,19-20,23-24H,11-14H2,1-2H3/t19-,20-,21+,22+/m0/s1",(-)-Chimonanthine,CAS Registry Number,5545-89-1
1134,10360,(R)-(+)-citronellol,A citronellol that is oct-6-ene substituted by a hydroxy group at position 1 and methyl groups at positions 3 and 7 (the 3R-enantiomer).,"InChI=1S/C10H20O/c1-9(2)5-4-6-10(3)7-8-11/h5,10-11H,4,6-8H2,1-3H3/t10-/m1/s1",(R)-(+)-Citronellol,KEGG COMPOUND accession,C09849
1135,2959,azocyclotin,"A member of the class of triazoles that is 1,2,4-triazole substituted at position 1 by a tricyclohexylstannyl group.","InChI=1S/3C6H11.C2H2N3.Sn/c3*1-2-4-6-5-3-1;1-3-2-5-4-1;/h3*1H,2-6H2;1-2H;/q;;;-1;+1",Azocyclotin,KEGG COMPOUND accession,C11092
1136,2899,trans-astringin,A stilbenoid that is piceatannol substituted at position 3 by a beta-D-glucosyl residue.,"InChI=1S/C20H22O9/c21-9-16-17(25)18(26)19(27)20(29-16)28-13-6-11(5-12(22)8-13)2-1-10-3-4-14(23)15(24)7-10/h1-8,16-27H,9H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1",Astringin,CAS Registry Number,29884-49-9
1137,108,(-)-phaseolin,"A prenylated member of the class of  pterocarpans and an organic heteropentacyclic compound that is 2,3,6b,12b-tetrahydro-1H,7H-chromeno[6',5':4,5]furo[3,2-c]chromen-10-ol in which both of the hydrogens at position 3 have been replaced by methyl groups (the R,R stereoisomer). It is found in found in the seeds of Phaseolus vulgaris (French bean)  and in the stems of Erythrina subumbrans.","InChI=1S/C20H20O4/c1-20(2)8-7-14-16(24-20)6-5-12-15-10-22-17-9-11(21)3-4-13(17)19(15)23-18(12)14/h3-6,9,15,19,21H,7-8,10H2,1-2H3/t15-,19-/m0/s1",(-)-Phaseollin,KEGG COMPOUND accession,C10514
1138,9339,sulfentrazone,"A member of the class of triazoles that is 5-oxo-1,2,4-triazole which is substituted at positions 1, 3, and 4 by 2,4-dichloro-5-[(methylsulfonyl)amino]phenyl, methyl, and difluoromethyl groups, respectively. A protoporphyrinogen oxidase inhibitor, it is used as a herbicide to control broad-leaved weeds in soya and tobacco crops. Not approved for use within the European Union.","InChI=1S/C11H10Cl2F2N4O3S/c1-5-16-19(11(20)18(5)10(14)15)9-4-8(17-23(2,21)22)6(12)3-7(9)13/h3-4,10,17H,1-2H3",F6285,KEGG COMPOUND accession,C11125
1139,29650,narbonolide,"A 14-membererd macrolide containing seven stereocentres carrying one ethyl, one hydroxy and five methyl substituents. It is the aglycone of the antibiotic narbonomycin and an intermediate in the biosynthesis of pikromycin.","InChI=1S/C20H32O5/c1-7-17-11(2)8-9-16(21)12(3)10-13(4)18(22)14(5)19(23)15(6)20(24)25-17/h8-9,11-15,17-18,22H,7,10H2,1-6H3/b9-8+/t11-,12-,13+,14-,15-,17-,18+/m1/s1",Narbonolide,KEGG COMPOUND accession,C11997
1140,2766,aphidicolin,"A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.","InChI=1S/C20H34O4/c1-17(11-21)15-4-3-13-9-14-10-19(13,7-8-20(14,24)12-22)18(15,2)6-5-16(17)23/h13-16,21-24H,3-12H2,1-2H3/t13-,14+,15-,16+,17-,18-,19-,20-/m0/s1",Aphidicolin,KEGG COMPOUND accession,C06088
1141,3907,coumermycin A1,A hydroxycoumarin antibiotic that is obtained from Streptomyces rishiriensis and exhibits potent antibacterial and anticancer activity.,"InChI=1S/C55H59N5O20/c1-21-12-16-29(57-21)48(67)77-42-38(63)52(79-54(6,7)44(42)71-10)73-31-18-14-26-36(61)34(50(69)75-40(26)24(31)4)59-46(65)28-20-56-33(23(28)3)47(66)60-35-37(62)27-15-19-32(25(5)41(27)76-51(35)70)74-53-39(64)43(45(72-11)55(8,9)80-53)78-49(68)30-17-13-22(2)58-30/h12-20,38-39,42-45,52-53,56-58,61-64H,1-11H3,(H,59,65)(H,60,66)/t38-,39-,42+,43+,44-,45-,52-,53-/m1/s1",Coumermycin,KEGG COMPOUND accession,C05073
1142,701,licarbazepine,"A dibenzoazepine that is 5H-dibenzo[b,f]azepine, reduced across the C-10,11 positions and carrying a carbamoyl substituent at the azepine nitrogen and a hydroxy function at C-10. A voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects, it is related to oxcarbazepine and is an active metabolite of oxcarbazepine.","InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)",10-Hydroxycarbazepine,CAS Registry Number,29331-92-8
1143,2439,acroptilin,A sesquiterpene lactone that is isolated from Acroptilon repens and displays anti-allergic properties.,"InChI=1S/C19H23ClO7/c1-8-4-11(26-17(23)18(3,24)6-20)13-9(2)16(22)27-15(13)14-10(8)5-12(21)19(14)7-25-19/h10-15,21,24H,1-2,4-7H2,3H3/t10-,11-,12-,13+,14-,15-,18+,19-/m0/s1",Acroptilin,KEGG COMPOUND accession,C09288
1144,6791,metamitron,"A member of the class of 1,2,4-triazines that is 1,2,4-triazin-5(4H)-one substituted by an amino group at position 4, a methyl group at position 3 and a phenyl group at position 6.","InChI=1S/C10H10N4O/c1-7-12-13-9(10(15)14(7)11)8-5-3-2-4-6-8/h2-6H,11H2,1H3",Goltix,CAS Registry Number,41394-05-2
1145,2607,Aloe emodin,A dihydroxyanthraquinone that is  chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.,"InChI=1S/C15H10O5/c16-6-7-4-9-13(11(18)5-7)15(20)12-8(14(9)19)2-1-3-10(12)17/h1-5,16-18H,6H2",Aloe-emodin,CAS Registry Number,481-72-1
1146,9499,tetraneurin E,"A sesquiterpene lactone that is a (3aS,9bS)-3-methylidenedecahydroazuleno[4,5-b]furan-2(3H)-one heterotricyclic ring system with a hydroxymethyl, hydroxy, acetate, and methyl group substituents at positions 6, 6a, 9, and 9a respectively.","InChI=1S/C17H24O6/c1-9-12-5-4-11(8-18)17(21)7-6-13(22-10(2)19)16(17,3)14(12)23-15(9)20/h11-14,18,21H,1,4-8H2,2-3H3/t11-,12+,13+,14-,16+,17-/m1/s1",Ambrosanolide,CAS Registry Number,25383-30-6
1147,7912,panose,A trisaccharide composed of D-glucopyranose units.,"InChI=1S/C18H32O16/c19-1-5(22)9(24)16(6(23)2-20)34-18-15(30)13(28)11(26)8(33-18)4-31-17-14(29)12(27)10(25)7(3-21)32-17/h1,5-18,20-30H,2-4H2/t5-,6+,7+,8+,9+,10+,11+,12-,13-,14+,15+,16+,17-,18+/m0/s1",Panose,KEGG COMPOUND accession,C00713
1148,8417,pristinamycin IA,"A cyclodepsipeptide that is (together with pristinamycin IIA) a component of pristinamycin, an oral streptogramin antibiotic produced by Streptomyces pristinaespiralis. Pristinamycin exhibits bactericidal activity against Gram positive organisms including methicillin-resistant Staphylococcus aureus.","InChI=1S/C45H54N8O10/c1-6-31-42(59)52-22-11-14-32(52)43(60)51(5)34(24-27-16-18-29(19-17-27)50(3)4)44(61)53-23-20-30(54)25-33(53)39(56)49-37(28-12-8-7-9-13-28)45(62)63-26(2)36(40(57)47-31)48-41(58)38-35(55)15-10-21-46-38/h7-10,12-13,15-19,21,26,31-34,36-37,55H,6,11,14,20,22-25H2,1-5H3,(H,47,57)(H,48,58)(H,49,56)/t26-,31-,32+,33+,34+,36+,37+/m1/s1",Pristinamycin IA,KEGG COMPOUND accession,C11615
1149,488,"1,2-campholide","A delta-lactone that is 2-oxabicyclo[3.2.1]octan-3-one substituted by methyl groups at positions 1, 8 and 8 respectively.","InChI=1S/C10H16O2/c1-9(2)7-4-5-10(9,3)12-8(11)6-7/h7H,4-6H2,1-3H3","1,2-Campholide",KEGG COMPOUND accession,C02108
1150,9955,(R)-(+)-verbenone,"A 4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-one in which both chiral centres have R configuration. It is a component of Spanish verbena oil, from Verbena triphylla.","InChI=1S/C10H14O/c1-6-4-9(11)8-5-7(6)10(8,2)3/h4,7-8H,5H2,1-3H3/t7-,8+/m1/s1",Verbenone,CAS Registry Number,18309-32-5
1151,3751,clomazone,"A oxazolidinone that is 1,2-oxazolidin-3-one substituted by a 2-chlorobenzyl group at position 2 and two methyl groups at position 4.","InChI=1S/C12H14ClNO2/c1-12(2)8-16-14(11(12)15)7-9-5-3-4-6-10(9)13/h3-6H,7-8H2,1-2H3",FMC57020,KEGG COMPOUND accession,C11095
1152,29468,"2,6-diamino-7-hydroxy-azelaic acid","A alpha,omega-dicarboxylic acid that is azelaic acid substituted by amino groups at positions 2 and 6.","InChI=1S/C9H18N2O5/c10-5(7(12)4-8(13)14)2-1-3-6(11)9(15)16/h5-7,12H,1-4,10-11H2,(H,13,14)(H,15,16)","2,6-Diamino-7-hydroxy-azelaic acid",KEGG COMPOUND accession,C12025
1153,2621,amaranthin,A disaccharide derivative that is betanidin in which a beta-D-glucuronosyl-(1->2)-beta-D-glucosyl moiety is attached at position 5.,"InChI=1S/C30H34N2O19/c33-8-17-18(35)20(37)24(51-29-22(39)19(36)21(38)23(50-29)28(46)47)30(49-17)48-16-6-10-5-14(27(44)45)32(13(10)7-15(16)34)2-1-9-3-11(25(40)41)31-12(4-9)26(42)43/h1-3,6-7,12,14,17-24,29-30,33,35-39H,4-5,8H2,(H5,34,40,41,42,43,44,45,46,47)/t12-,14-,17+,18+,19-,20-,21-,22+,23-,24+,29-,30+/m0/s1",Amaranthin,CAS Registry Number,15167-84-7
1154,2625,amataine,A polycyclic indole alkaloid that is obtained from the root bark of Voacanga africana.,"InChI=1S/C43H48N4O6/c1-49-29-9-5-7-27-31(29)47-23-40-21-24-20-38-13-18-51-30(38)10-15-45-16-12-42(27,35(38)45)43(24,47)53-37(40)46-17-11-41-26-6-3-4-8-28(26)44-32(41)25(33(48)50-2)22-39(34(41)46)14-19-52-36(39)40/h3-9,24,30,34-37,44H,10-23H2,1-2H3/t24-,30-,34-,35-,36+,37+,38+,39-,40+,41-,42+,43+/m0/s1",Amataine,KEGG COMPOUND accession,C08433
1155,2739,anisotropine methylbromide,A quaternary ammonium salt resulting from the reaction of the amino group of anisotropine with methyl bromide.,"InChI=1S/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1",Anisotropine methylbromide,KEGG COMPOUND accession,C06830
1156,8064,phenformin,A member of the class of biguanides that is  biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of  lactic acidosis.,"InChI=1S/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)",DBI,CAS Registry Number,114-86-3
1157,5580,gypsogenin,A sapogenin that is olean-12-en-28-oic acid substituted by a beta-hydroxy group at position 3 and an oxo group at position 23.,"InChI=1S/C30H46O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,18,20-23,32H,8-17H2,1-6H3,(H,33,34)/t20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1",Gypsogenin,KEGG COMPOUND accession,C08950
1158,9171,skatole,A methylindole carrying a methyl substituent at position 3. It is produced during the anoxic metabolism of L-tryptophan in the mammalian digestive tract.,"InChI=1S/C9H9N/c1-7-6-10-9-5-3-2-4-8(7)9/h2-6,10H,1H3",Skatole,KEGG COMPOUND accession,C08313
1159,29505,A47934,A cyclic peptide antibiotic produced by a strain of Streptomyces toyocaensis.,"InChI=1S/C58H44Cl3N7O21S/c59-31-7-20-1-4-36(31)87-40-15-25-16-41(51(40)74)88-37-5-3-22(12-32(37)60)49(72)48-57(80)67-47(58(81)82)29-18-27(70)19-35(71)42(29)30-11-24(13-33(61)50(30)73)45(56(79)68-48)65-55(78)46(25)66-54(77)44-23-9-26(69)17-28(10-23)86-39-14-21(2-6-38(39)89-90(83,84)85)43(62)53(76)63-34(8-20)52(75)64-44/h1-7,9-19,34,43-49,69-74H,8,62H2,(H,63,76)(H,64,75)(H,65,78)(H,66,77)(H,67,80)(H,68,79)(H,81,82)(H,83,84,85)/t34-,43+,44-,45+,46+,47+,48-,49+/m0/s1",A47934,KEGG COMPOUND accession,C12016
1160,9087,selegiline hydrochloride,,"InChI=1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1",Selegiline hydrochloride,CAS Registry Number,14611-52-0
1161,3978,cyanin,An anthocyanin cation that is cyanidin(1+) carrying two beta-D-glucosyl residues at positions 3 and 5.,"InChI=1S/C27H30O16/c28-7-17-19(33)21(35)23(37)26(42-17)40-15-5-10(30)4-14-11(15)6-16(25(39-14)9-1-2-12(31)13(32)3-9)41-27-24(38)22(36)20(34)18(8-29)43-27/h1-6,17-24,26-29,33-38H,7-8H2,(H2-,30,31,32)/p+1/t17-,18-,19-,20-,21+,22+,23-,24-,26-,27-/m1/s1",Cyanin,KEGG COMPOUND accession,C08639
1162,5982,isoathyriol,"A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3 and 7 and a methoxy group at position 6.","InChI=1S/C14H10O6/c1-19-11-5-10-7(4-8(11)16)14(18)13-9(17)2-6(15)3-12(13)20-10/h2-5,15-17H,1H3","6-Methoxy-1,3,7-trihydroxyxanthone",KEGG COMPOUND accession,C10069
1163,6017,isogentisin,A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1 and 3 and a methoxy group at position 7.,"InChI=1S/C14H10O5/c1-18-8-2-3-11-9(6-8)14(17)13-10(16)4-7(15)5-12(13)19-11/h2-6,15-16H,1H3","1,3-Dihydroxy--7-methoxyxanthone",KEGG COMPOUND accession,C10070
1164,6438,levobunolol,"A cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma.","InChI=1S/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1",Levobunolol,KEGG COMPOUND accession,C07914
1165,2505,"8,9-dihydro-8-(S-glutathionyl)-9-hydroxyaflatoxin B1","A member of the class of aflatoxins that is 8,9-dihydro-9-hydroxyaflatoxin B1 having an S-glutathionyl moiety attached at position 8.","InChI=1S/C27H29N3O13S/c1-40-13-6-14-19(22-18(13)9-2-4-12(31)17(9)25(39)42-22)20-21(35)27(43-26(20)41-14)44-8-11(23(36)29-7-16(33)34)30-15(32)5-3-10(28)24(37)38/h6,10-11,20-21,26-27,35H,2-5,7-8,28H2,1H3,(H,29,36)(H,30,32)(H,33,34)(H,37,38)/t10-,11-,20+,21+,26-,27-/m0/s1","Aflatoxin B1exo-8,9-epoxide-GSH",KEGG COMPOUND accession,C11278
1166,9506,tetrodotoxin,A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.,"InChI=1S/C11H17N3O8/c12-8-13-6(17)2-4-9(19,1-15)5-3(16)10(2,14-8)7(18)11(20,21-4)22-5/h2-7,15-20H,1H2,(H3,12,13,14)/t2-,3+,4-,5+,6-,7+,9+,10-,11+/m1/s1",Tetrodotoxin,CAS Registry Number,4368-28-9
1167,4743,ecgonine,"A tropane alkaloid that consists of tropane bearing carboxy and hydroxy substituents at positions 2 and 3 respectively and having (1R,2R,3S,5S)-configuration. It is both a metabolite of and a precursor to cocaine.","InChI=1S/C9H15NO3/c1-10-5-2-3-6(10)8(9(12)13)7(11)4-5/h5-8,11H,2-4H2,1H3,(H,12,13)/t5-,6+,7-,8+/m0/s1",Ecgonine,CAS Registry Number,481-37-8
1168,6636,magnesium dichloride,A magnesium salt comprising of two chlorine atoms bound to a magnesium atom.,InChI=1S/2ClH.Mg/h2*1H;/q;;+2/p-2,Magnesium chloride,CAS Registry Number,7786-30-3
1169,6784,mestranol,"A terminal acetylenic compound that is (17alpha)-17-ethynylestra-1(10),2,4-triene substituted by a methoxy group at position 3 and a hydroxy group at position 17.","InChI=1S/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1",Mestranol,CAS Registry Number,72-33-3
1170,6602,lycoxanthin,"A carotenol that is  carotenol psi,psi-carotene substituted by a hydroxy group.","InChI=1S/C40H56O/c1-33(2)18-12-21-36(5)24-15-27-37(6)25-13-22-34(3)19-10-11-20-35(4)23-14-26-38(7)28-16-29-39(8)30-17-31-40(9)32-41/h10-11,13-16,18-20,22-29,31,41H,12,17,21,30,32H2,1-9H3/b11-10+,22-13+,23-14+,27-15+,28-16+,34-19+,35-20+,36-24+,37-25+,38-26+,39-29+,40-31+",Lycoxanthin,KEGG COMPOUND accession,C08603
1171,9590,tienilic acid,"An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.","InChI=1S/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)",Ticrynafen,KEGG COMPOUND accession,C11702
1172,995,"cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioic acid","The cis,cis-isomer of 2-amino-3-(3-oxoprop-1-enyl)but-2-enedioic acid.","InChI=1S/C7H7NO5/c8-5(7(12)13)4(6(10)11)2-1-3-9/h1-3H,8H2,(H,10,11)(H,12,13)/b2-1-,5-4-",2-Amino-3-carboxymuconate semialdehyde,KEGG COMPOUND accession,C04409
1173,9544,thiethylperazine,A member of the class of phenothiazines that is perazine substituted by a ethylsulfanyl group at position 2.,"InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3",Thiethylperazine,KEGG COMPOUND accession,C07132
1174,8121,phosalone,"A member of the class of  1,3-benzoxazoles carrying a [(diethoxyphosphorothioyl)sulfanyl]methyl group at the nitrogen atom, an oxo group at position 2 and a chloro group at position 6. It is an organothiophosphate insecticide.","InChI=1S/C12H15ClNO4PS2/c1-3-16-19(20,17-4-2)21-8-14-10-6-5-9(13)7-11(10)18-12(14)15/h5-7H,3-4,8H2,1-2H3",Phosalone,KEGG COMPOUND accession,C11028
1175,149,(-)-dihydrocarveol,"The (1R,2R,4R)-stereoisomer of  dihydrocarveol.","InChI=1S/C10H18O/c1-7(2)9-5-4-8(3)10(11)6-9/h8-11H,1,4-6H2,2-3H3/t8-,9-,10-/m1/s1","(1R,2R,4R)-Dihydrocarveol",KEGG COMPOUND accession,C11396
1176,5634,hederagenin 3-O-arabinoside,A triterpenoid saponin that is hederagenin attached to an alpha-L-arabinopyranosyl residue at position 3 via a glycosidic linkage.,"InChI=1S/C35H56O8/c1-30(2)13-15-35(29(40)41)16-14-33(5)20(21(35)17-30)7-8-24-31(3)11-10-25(43-28-27(39)26(38)22(37)18-42-28)32(4,19-36)23(31)9-12-34(24,33)6/h7,21-28,36-39H,8-19H2,1-6H3,(H,40,41)/t21-,22-,23+,24+,25-,26-,27+,28-,31-,32-,33+,34+,35-/m0/s1",Cauloside A,CAS Registry Number,17184-21-3
1177,5279,gartanin,"A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 5 and 8 and prenyl groups at positions 2 and 4.","InChI=1S/C23H24O6/c1-11(2)5-7-13-19(26)14(8-6-12(3)4)22-18(20(13)27)21(28)17-15(24)9-10-16(25)23(17)29-22/h5-6,9-10,24-27H,7-8H2,1-4H3","1,3,5,8-Tetrahydroxy-2,4-diprenylxanthone",KEGG COMPOUND accession,C10063
1178,5623,harman,"An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.","InChI=1S/C12H10N2/c1-8-12-10(6-7-13-8)9-4-2-3-5-11(9)14-12/h2-7,14H,1H3",Harman,CAS Registry Number,486-84-0
1179,2962,kresoxim-methyl,A carboxylic ester that is the methyl ester of (2E)-(methoxyimino){2-[(2-methylphenoxy)methyl]phenyl}acetic acid. A fungicide for the control of scab on apples and pears and other fungal diseases on a wide range of crops.,"InChI=1S/C18H19NO4/c1-13-8-4-7-11-16(13)23-12-14-9-5-6-10-15(14)17(19-22-3)18(20)21-2/h4-11H,12H2,1-3H3/b19-17+",BAS 490 F,CAS Registry Number,143390-89-0
1180,7933,paromamine,"An aminoglycoside that is 4alpha,6alpha-diaminocyclohexane-1beta,2alpha,3beta-triol in which the pro-R hydroxy group has been converted into its 2-amino-alpha-D-glucoside derivative.","InChI=1S/C12H25N3O7/c13-3-1-4(14)11(10(20)7(3)17)22-12-6(15)9(19)8(18)5(2-16)21-12/h3-12,16-20H,1-2,13-15H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1",Paromamine,CAS Registry Number,534-47-4
1181,961,"2,8-dihydroxy-3,4,7-trimethoxydibenzofuran","A member of the class of  dibenzofurans that is  dibenzofuran substituted by methoxy groups at positions 3, 4 and 7 and hydroxy groups at positions 2 and 8.","InChI=1S/C15H14O6/c1-18-12-6-11-7(4-9(12)16)8-5-10(17)14(19-2)15(20-3)13(8)21-11/h4-6,16-17H,1-3H3","2,8-Dihydroxy-3,4,7-trimethoxydibenzofuran",CAS Registry Number,167278-42-4
1182,1110,2-hexaprenylphenol,A 2-polyprenylphenol in which the polyprenyl chain contains 8 prenyl units; major species at pH 7.3.,"InChI=1S/C36H54O/c1-29(2)15-10-16-30(3)17-11-18-31(4)19-12-20-32(5)21-13-22-33(6)23-14-24-34(7)27-28-35-25-8-9-26-36(35)37/h8-9,15,17,19,21,23,25-27,37H,10-14,16,18,20,22,24,28H2,1-7H3/b30-17+,31-19+,32-21+,33-23+,34-27+",2-Hexaprenylphenol,KEGG COMPOUND accession,C05800
1183,2448,actinorhodin,A member of the class of benzoisochromanequinone that is produced by Streptomyces coelicolor A3(2) and exhibits antibiotic activity.,"InChI=1S/C32H26O14/c1-9-21-15(3-11(45-9)5-19(35)36)29(41)23-17(33)7-13(27(39)25(23)31(21)43)14-8-18(34)24-26(28(14)40)32(44)22-10(2)46-12(6-20(37)38)4-16(22)30(24)42/h7-12,33-34,39-40H,3-6H2,1-2H3,(H,35,36)(H,37,38)/t9-,10-,11+,12+/m1/s1",Actinorhodine,CAS Registry Number,1397-77-9
1184,2479,adenosylcobinamide guanosyl diphosphate,A cobalt corrinoid consisting of cobinamide guanosyl diphosphate having a 5'-adenosyl group attached to the central cobalt atom.,"InChI=1S/C58H86N16O18P2.C10H12N5O3.Co/c1-25(91-94(87,88)92-93(85,86)89-23-33-45(82)46(83)52(90-33)74-24-67-44-50(74)71-53(65)72-51(44)84)22-66-41(81)16-17-55(6)31(18-38(62)78)49-58(9)57(8,21-40(64)80)30(12-15-37(61)77)43(73-58)27(3)48-56(7,20-39(63)79)28(10-13-35(59)75)32(68-48)19-34-54(4,5)29(11-14-36(60)76)42(69-34)26(2)47(55)70-49;1-4-6(16)7(17)10(18-4)15-3-14-5-8(11)12-2-13-9(5)15;/h19,24-25,28-31,33,45-46,49,52,82-83H,10-18,20-23H2,1-9H3,(H19,59,60,61,62,63,64,65,66,68,69,70,71,72,73,75,76,77,78,79,80,81,84,85,86,87,88);2-4,6-7,10,16-17H,1H2,(H2,11,12,13);/q;;+2/p-1/t25-,28-,29-,30-,31+,33-,45-,46-,49-,52-,55-,56+,57+,58+;4-,6-,7-,10-;/m11./s1",Adenosine-GDP-cobinamide,KEGG COMPOUND accession,C06510
1185,1403,"3,5-dihydroxyanthranilic acid","A dihydroxybenzoic acid that is 3,5-dihydroxybenzoic acid substituted by an amino group at position 2.","InChI=1S/C7H7NO4/c8-6-4(7(11)12)1-3(9)2-5(6)10/h1-2,9-10H,8H2,(H,11,12)","3,5-Dihydroxyanthranilate",KEGG COMPOUND accession,C11465
1186,2481,adenosylcobinamide phosphate,An O-phosphocorrinoid that is cobinamide phosphate having a 5'-adenosyl group attached to the central cobalt atom.,"InChI=1S/C48H74N11O11P.C10H12N5O3.Co/c1-23(70-71(67,68)69)22-55-38(66)16-17-45(6)29(18-35(52)63)43-48(9)47(8,21-37(54)65)28(12-15-34(51)62)40(59-48)25(3)42-46(7,20-36(53)64)26(10-13-32(49)60)30(56-42)19-31-44(4,5)27(11-14-33(50)61)39(57-31)24(2)41(45)58-43;1-4-6(16)7(17)10(18-4)15-3-14-5-8(11)12-2-13-9(5)15;/h19,23,26-29,43H,10-18,20-22H2,1-9H3,(H16,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69);2-4,6-7,10,16-17H,1H2,(H2,11,12,13);/q;;+2/p-1/t23-,26-,27-,28-,29+,43-,45-,46+,47+,48+;4-,6-,7-,10-;/m11./s1",Adenosyl cobinamide phosphate,KEGG COMPOUND accession,C06509
1187,2534,alamarine,"A member of the class of isoquinolinonaphthyridines that is 5,6-dihydroisoquinolino[2,1-b][2,7]naphthyridin-8-one bearing additional hydroxy, methoxy and 1-hydroxyethyl substituents at positions 2, 3 and 12.","InChI=1S/C19H18N2O4/c1-10(22)14-8-20-9-15-13(14)6-16-12-7-17(23)18(25-2)5-11(12)3-4-21(16)19(15)24/h5-10,22-23H,3-4H2,1-2H3/t10-/m1/s1",Alamarine,KEGG COMPOUND accession,C09326
1188,2535,alangicine,"An isoquinoline alkaloid that is 1',2'-didehydroemetan bearing two hydroxy substituents at positions 6' and 9 as well as three methoxy substituents at positions 7', 10 and 11.","InChI=1S/C28H36N2O5/c1-5-16-15-30-9-7-19-21(14-26(34-3)28(35-4)27(19)32)23(30)11-18(16)10-22-20-13-25(33-2)24(31)12-17(20)6-8-29-22/h12-14,16,18,23,31-32H,5-11,15H2,1-4H3/t16-,18-,23-/m0/s1",Alangicine,KEGG COMPOUND accession,C09327
1189,6427,leuprolide,"An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.","InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1",Leuprorelin,CAS Registry Number,53714-56-0
1190,9577,(-)-alpha-thujone,"The (1S,4R,5R)-stereoisomer of alpha-thujone.","InChI=1S/C10H16O/c1-6(2)10-4-8(10)7(3)9(11)5-10/h6-8H,4-5H2,1-3H3/t7-,8-,10+/m1/s1",Thujone,KEGG COMPOUND accession,C09906
1191,5834,hyperforin,"A cyclic terpene ketone that is a prenylated carbobicyclic acylphloroglucinol derivative produced by St. John's Wort, Hypericum perforatum.","InChI=1S/C35H52O4/c1-22(2)13-12-19-33(11)27(16-14-23(3)4)21-34(20-18-25(7)8)30(37)28(17-15-24(5)6)31(38)35(33,32(34)39)29(36)26(9)10/h13-15,18,26-27,38H,12,16-17,19-21H2,1-11H3/t27-,33+,34+,35-/m0/s1",Hyperforin,KEGG COMPOUND accession,C07608
1192,5778,hydrochlorothiazide,"A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.","InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)",Esidrix (TN),CAS Registry Number,58-93-5
1193,2909,atisine,"A organic heterohexacyclic compound and diterpene alkaloid isolated from Aconitum anthora. In solution, it is a 2:1 mixture of readily interconvertible epimers at position 20 (the carbon attached to both the nitrogen and an oxygen atom).","InChI=1S/C22H33NO2/c1-14-15-4-8-21(18(14)24)9-5-16-20(2)6-3-7-22(16,17(21)12-15)19-23(13-20)10-11-25-19/h15-19,24H,1,3-13H2,2H3/t15-,16+,17+,18+,19?,20-,21-,22-/m0/s1",Atisine,KEGG COMPOUND accession,C08660
1194,8682,pyronin Y,"An organic chloride salt having 6-(dimethylamino)-N,N-dimethyl-3H-xanthen-3-iminium as the cation. Used with methyl green to selectively demonstrate RNA (red) in contrast to DNA (green) with the Unna-Pappenheim method.","InChI=1S/C17H19N2O.ClH/c1-18(2)14-7-5-12-9-13-6-8-15(19(3)4)11-17(13)20-16(12)10-14;/h5-11H,1-4H3;1H/q+1;/p-1",Pyronine Y,CAS Registry Number,92-32-0
1195,3363,canthin-6-one,"An indole alkaloid that is 6H-indolo[3,2,1-de][1,5]naphthyridine substituted by an oxo group at position 6.",InChI=1S/C14H8N2O/c17-13-6-5-11-14-10(7-8-15-11)9-3-1-2-4-12(9)16(13)14/h1-8H,Canthin-6-one,KEGG COMPOUND accession,C09098
1196,8764,mycophenolate mofetil,"A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.","InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RS 61443,KEGG COMPOUND accession,C07908
1197,4530,diethylpropion,"An  aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.","InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3",Diethylpropion,KEGG COMPOUND accession,C06954
1198,2665,amitraz,"A tertiary amino compound that is 1,3,5-triazapenta-1,4-diene substituted by a methyl group at position 3 and 2,4-dimethylphenyl groups at positions 1 and 5.","InChI=1S/C19H23N3/c1-14-6-8-18(16(3)10-14)20-12-22(5)13-21-19-9-7-15(2)11-17(19)4/h6-13H,1-5H3",Amitraz,KEGG COMPOUND accession,C10995
1199,2155,"6,8-di-(3,3-dimethylallyl)chrysin",A dihydroxyflavone that is  chrysin substituted by prenyl groups at positions 6 and 8 respectively.,"InChI=1S/C25H26O4/c1-15(2)10-12-18-23(27)19(13-11-16(3)4)25-22(24(18)28)20(26)14-21(29-25)17-8-6-5-7-9-17/h5-11,14,27-28H,12-13H2,1-4H3","6,8-Di-DMA-chrysin",KEGG COMPOUND accession,C11573
1200,2304,3-O-methyl-8-prenylgalangin,A 7-hydroxyflavonol that is 3-O-methylgalangin  substituted by a prenyl group at position 8.,"InChI=1S/C21H20O5/c1-12(2)9-10-14-15(22)11-16(23)17-18(24)21(25-3)19(26-20(14)17)13-7-5-4-6-8-13/h4-9,11,22-23H,10H2,1-3H3","8-(3,3-Dimethylallyl)-3-methylgalangin",KEGG COMPOUND accession,C11578
1201,835,2'-deoxy-5-hydroxymethyl-CDP,A pyrimidine 2'-deoxyribonucleoside 5'-diphosphate that is 2'-deoxycytidine 5'-diphosphate (CDP) substituted by a hydroxymethyl group at position 5.,"InChI=1S/C10H17N3O11P2/c11-9-5(3-14)2-13(10(16)12-9)8-1-6(15)7(23-8)4-22-26(20,21)24-25(17,18)19/h2,6-8,14-15H,1,3-4H2,(H,20,21)(H2,11,12,16)(H2,17,18,19)/t6-,7+,8+/m0/s1",2'-Deoxy-5-hydroxymethylcytidine-5'-diphosphate,KEGG COMPOUND accession,C11038
1202,888,"2,3-disulfanylpropane-1-sulfonic acid",An alkanesulfonic acid that is propane-1-sulfonic acid substituted by sulfanyl groups at positions 2 and 3.,"InChI=1S/C3H8O3S3/c4-9(5,6)2-3(8)1-7/h3,7-8H,1-2H2,(H,4,5,6)","2,3-Dimercaptopropane-1-sulfonic acid",KEGG COMPOUND accession,C10922
1203,29582,ascomycin,A macrolide that is produced by the fermentation of Streptomyces hygroscopicus and exhibits strong immunosuppressant properties.,"InChI=1S/C43H69NO12/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)44-16-12-11-13-31(44)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-32(45)35(22-29)52-7/h18,20,25,27-33,35-39,45-46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32+,33-,35+,36-,37-,38+,39+,43+/m0/s1",FK520,KEGG COMPOUND accession,C12102
1204,3162,bowdichione,"A hydroxyisoflavone with a quinone structure in ring B. Isolated from Dalbergia parviflora, it exhibits antineoplastic and anti-inflammatory activities.","InChI=1S/C16H10O6/c1-21-15-6-12(18)10(5-13(15)19)11-7-22-14-4-8(17)2-3-9(14)16(11)20/h2-7,17H,1H3",Bowdichione,CAS Registry Number,53774-75-7
1205,6701,maytansine,An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.,"InChI=1S/C34H46ClN3O10/c1-18-11-10-12-26(45-9)34(43)17-25(46-32(42)36-34)19(2)30-33(5,48-30)27(47-31(41)20(3)37(6)21(4)39)16-28(40)38(7)23-14-22(13-18)15-24(44-8)29(23)35/h10-12,14-15,19-20,25-27,30,43H,13,16-17H2,1-9H3,(H,36,42)/b12-10+,18-11+/t19-,20+,25+,26-,27+,30+,33+,34+/m1/s1",Maytansine,KEGG COMPOUND accession,C10606
1206,2537,alangimarine,"A member of the class of isoquinolinonaphthyridines that is 5,6-dihydroisoquinolino[2,1-b][2,7]naphthyridin-8-one bearing additional hydroxy, methoxy and vinyl substituents at positions 2, 3 and 12 respectively.","InChI=1S/C19H16N2O3/c1-3-11-9-20-10-15-13(11)7-16-14-8-17(22)18(24-2)6-12(14)4-5-21(16)19(15)23/h3,6-10,22H,1,4-5H2,2H3",Alangimarine,CAS Registry Number,77156-16-2
1207,9162,sinigrin(1-),An alkenylglucosinolate that is the conjugate base of sinigrin.,"InChI=1S/C10H17NO9S2/c1-2-3-6(11-20-22(16,17)18)21-10-9(15)8(14)7(13)5(4-12)19-10/h2,5,7-10,12-15H,1,3-4H2,(H,16,17,18)/p-1/b11-6-/t5-,7-,8+,9-,10+/m1/s1",Sinigrin,CAS Registry Number,3952-98-5
1208,5396,glucoberteroin(1-),A thia-alkylglucosinolate that has a 5-(methylsulfanyl)pentyl side chain attached to the sulfonated oxime group.,"InChI=1S/C13H25NO9S3/c1-24-6-4-2-3-5-9(14-23-26(19,20)21)25-13-12(18)11(17)10(16)8(7-15)22-13/h8,10-13,15-18H,2-7H2,1H3,(H,19,20,21)/p-1/b14-9-/t8-,10-,11+,12-,13+/m1/s1",Glucoberteroin,KEGG COMPOUND accession,C08401
1209,5413,gluconasturtiin(1-),A aralkylglucosinolate that is the conjugate base of gluconasturtiin.,"InChI=1S/C15H21NO9S2/c17-8-10-12(18)13(19)14(20)15(24-10)26-11(16-25-27(21,22)23)7-6-9-4-2-1-3-5-9/h1-5,10,12-15,17-20H,6-8H2,(H,21,22,23)/p-1/b16-11-/t10-,12-,13+,14-,15+/m1/s1",Gluconasturtiin,KEGG COMPOUND accession,C08417
1210,29474,"(S)-3,5-dihydroxyphenylglycine",A glycine derivative that is L-alpha-phenylglycine substituted at positions 3 and 5 on the phenyl ring by hydroxy groups.,"InChI=1S/C8H9NO4/c9-7(8(12)13)4-1-5(10)3-6(11)2-4/h1-3,7,10-11H,9H2,(H,12,13)/t7-/m0/s1","L-3,5-Dihydroxyphenylglycine",KEGG COMPOUND accession,C12026
1211,4999,fenchone,A carbobicyclic compound that is fenchane in which the hydrogens at position 2 are replaced by an oxo group. It is a component of essential oil from fennel  (Foeniculum vulgare).,"InChI=1S/C10H16O/c1-9(2)7-4-5-10(3,6-7)8(9)11/h7H,4-6H2,1-3H3",Fenchone,CAS Registry Number,1195-79-5
1212,4710,doxepin,"A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an  antidepressant drug.","InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3",Doxepin,KEGG COMPOUND accession,C06971
1213,4808,epimelibiose,A alpha-D-Manp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10+,11+,12+/m1/s1",Epimelibiose,KEGG COMPOUND accession,C05400
1214,9192,solavetivone,"A cyclic ketone derived from spiro[4.5]dec-6-en-8-one by substitution of hydrogens by methyl groups at positions 6 and 10, and by an isopropenyl group at position 2 (the (2R,5S,10R)-diastereoisomer).","InChI=1S/C15H22O/c1-10(2)13-5-6-15(9-13)11(3)7-14(16)8-12(15)4/h7,12-13H,1,5-6,8-9H2,2-4H3/t12-,13-,15-/m1/s1",Solavetivone,KEGG COMPOUND accession,C09737
1215,4460,devazepide,"An indolecarboxamide obtained by formal condensation of the carboxy group of indole-2-carboxylic acid with the exocyclic amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one. A cholecystokinin antagonist used for treatment of gastrointestinal disorders.","InChI=1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1",MK-329,CAS Registry Number,103420-77-5
1216,5019,ferrichrome,A member of the class of ferrichromes that is an iron(III) chelate of a homodetic cyclic peptide made up of a tripeptide of glycine and a tripeptide of N(4)-acetyl-N(4)-hydroxy-L-ornithine.,"InChI=1S/C27H42N9O12.Fe/c1-16(37)34(46)10-4-7-19-25(43)30-14-23(41)28-13-22(40)29-15-24(42)31-20(8-5-11-35(47)17(2)38)26(44)33-21(27(45)32-19)9-6-12-36(48)18(3)39;/h19-21H,4-15H2,1-3H3,(H,28,41)(H,29,40)(H,30,43)(H,31,42)(H,32,45)(H,33,44);/q-3;+3/t19-,20-,21-;/m0./s1",Ferrichrome,KEGG COMPOUND accession,C06228
1217,29703,validamycin A,"A member of the class of validamycins that is (1R,2S,3S,4S,6R)-4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol in which the hydroxy group at position 1 has been converted to its beta-D-glucoside and in which one of the hydrogens attached to the nitrogen is replaced by a (1R,4R,5R,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl group. It is the major validamycin produced by Streptomyces hygroscopicus.","InChI=1S/C20H35NO13/c22-3-6-1-8(12(26)15(29)11(6)25)21-9-2-7(4-23)19(17(31)13(9)27)34-20-18(32)16(30)14(28)10(5-24)33-20/h1,7-32H,2-5H2/t7-,8+,9+,10-,11-,12+,13+,14-,15+,16+,17-,18-,19-,20+/m1/s1",Validamycin,KEGG COMPOUND accession,C12112
1218,9144,silibinin,"A flavonolignan isolated from milk thistle, Silybum marianum, that has been shown to exhibit antioxidant and antineoplastic activities.","InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1",Silymarin,KEGG COMPOUND accession,C07610
1219,9143,silychristin,A flavonolignan isolated from Silybum marianum and has been shown to exhibit inhibitory activities against lipoxygenase and prostaglandin synthetase.,"InChI=1S/C25H22O10/c1-33-18-6-10(2-3-15(18)28)23-14(9-26)13-4-11(5-17(30)25(13)35-23)24-22(32)21(31)20-16(29)7-12(27)8-19(20)34-24/h2-8,14,22-24,26-30,32H,9H2,1H3/t14-,22+,23+,24-/m1/s1",Silychristin,KEGG COMPOUND accession,C08717
1220,2372,acalyphin,"A member of the class of tetrahydropyridines that is 2,3-dihydroxy-4-methoxy-1-methyl-6-oxo-1,2,3,6-tetrahydropyridine-3-carbonitrile having a beta-D-glucosyl residue attached at position 3 via a glycosidic bond.","InChI=1S/C14H20N2O9/c1-16-8(18)3-7(23-2)14(5-15,13(16)22)25-12-11(21)10(20)9(19)6(4-17)24-12/h3,6,9-13,17,19-22H,4H2,1-2H3/t6-,9-,10+,11-,12+,13+,14-/m1/s1",Acalyphin,CAS Registry Number,81861-72-5
1221,2373,acamelin,"A member of the class of 1-benzofurans that is 1-benzofuran-4,7-dione bearing additional methyl and methoxy substituents at positions 2 and 7 respectively.","InChI=1S/C10H8O4/c1-5-3-6-7(11)4-8(13-2)9(12)10(6)14-5/h3-4H,1-2H3",Acamelin,CAS Registry Number,74161-27-6
1222,2412,acetylagmatine,A member of the class of guanidines that is agmatine acetylated at the N4-position.,"InChI=1S/C7H16N4O/c1-6(12)10-4-2-3-5-11-7(8)9/h2-5H2,1H3,(H,10,12)(H4,8,9,11)",Acetylagmatine,KEGG COMPOUND accession,C02131
1223,9371,swertianin,"A member of the class of  xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 2 and 8 and a methoxy group at position 6. It has been isolated from various species of the genus Swertia and has been found to exhibit antioxidant activities.","InChI=1S/C14H10O6/c1-19-6-4-8(16)11-10(5-6)20-9-3-2-7(15)13(17)12(9)14(11)18/h2-5,15-17H,1H3",Swertianin,CAS Registry Number,20882-75-1
1224,6141,knipholone,"An anthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 4 and 6, a methyl group at position 2 and a 3-acetyl-2,6-dihydroxy-4-methoxyphenyl group at position 1. It exhibits antioxidant, cytotoxic and antiplasmodial activities.","InChI=1S/C24H18O8/c1-9-7-13(27)20-21(22(29)11-5-4-6-12(26)18(11)24(20)31)16(9)19-14(28)8-15(32-3)17(10(2)25)23(19)30/h4-8,26-28,30H,1-3H3",Knipholone,CAS Registry Number,94450-08-5
1225,3359,cannabidiolic acid,"A dihydroxybenzoic acid that is olivetolic acid in which the hydrogen at position 3 is substituted by a 3-p-mentha-1,8-dien-3-yl (limonene) group.","InChI=1S/C22H30O4/c1-5-6-7-8-15-12-18(23)20(21(24)19(15)22(25)26)17-11-14(4)9-10-16(17)13(2)3/h11-12,16-17,23-24H,2,5-10H2,1,3-4H3,(H,25,26)/t16-,17+/m0/s1",Cannabidiolic acid,KEGG COMPOUND accession,C10784
1226,3381,(-)-car-3-ene,"A car-3-ene (3,7,7-trimethylbicyclo[4.1.0]hept-3-ene) that has R configuration at position 1 and S configuration at position 6.","InChI=1S/C10H16/c1-7-4-5-8-9(6-7)10(8,2)3/h4,8-9H,5-6H2,1-3H3/t8-,9+/m0/s1",Car-3-ene,KEGG COMPOUND accession,C09839
1227,26,(+)-iridodial lactol,"An iridoid monoterpenoid that is 1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran substituted by methyl groups at positions 4 and 7 and a hydroxy group at position 1 (the 1R,4aS,7S,7aR-stereoisomer).","InChI=1S/C10H16O2/c1-6-3-4-8-7(2)5-12-10(11)9(6)8/h5-6,8-11H,3-4H2,1-2H3/t6-,8+,9+,10+/m0/s1",(+)-Iridodial,KEGG COMPOUND accession,C09804
1228,2164,6-acetamido-3-aminohexanoic acid,"A member of the class of beta-amino acids that is the N(6)-acetyl derivative of 3,6-diaminohexanoic acid.","InChI=1S/C8H16N2O3/c1-6(11)10-4-2-3-7(9)5-8(12)13/h7H,2-5,9H2,1H3,(H,10,11)(H,12,13)",6-Acetamido-3-aminohexanoate,KEGG COMPOUND accession,C03846
1229,2288,"7alpha,12alpha-dihydroxy-5beta-cholestan-3-one",A 3-oxo-5beta-steroid that is 5beta-cholestan-3-one bearing two additional hydroxy substituents at positions 7alpha and 12alpha.,"InChI=1S/C27H46O3/c1-16(2)7-6-8-17(3)20-9-10-21-25-22(15-24(30)27(20,21)5)26(4)12-11-19(28)13-18(26)14-23(25)29/h16-18,20-25,29-30H,6-15H2,1-5H3/t17-,18+,20-,21+,22+,23-,24+,25+,26+,27-/m1/s1","7alpha,12alpha-Dihydroxy-5beta-cholestan-3-one",KEGG COMPOUND accession,C05453
1230,2366,absinthin,A dimeric sesquiterpene lactone that is produced by the plant Artemisia absinthium (Wormwood). The bitter tasting constituent of Absinthe.,"InChI=1S/C30H40O6/c1-12-11-18-20-21(30(12)24(18)29(6,34)10-8-17-14(3)27(32)36-25(17)30)15(4)19-22(20)28(5,33)9-7-16-13(2)26(31)35-23(16)19/h11,13-14,16-18,20-25,33-34H,7-10H2,1-6H3/t13-,14-,16-,17-,18+,20-,21-,22-,23-,24-,25-,28-,29-,30+/m0/s1",Absinthin,KEGG COMPOUND accession,C09286
1231,23925,(+)-5-epi-aristolochene,"A sesquiterpene that is 1,2,3,4,4a,5,6,7-octahydronaphthalene substituted by methyl groups at positions 4 and 4a and a prop-1-en-2-yl group at position 6 (the 4R,4aR,6R-stereoisomer).","InChI=1S/C15H24/c1-11(2)13-8-9-14-7-5-6-12(3)15(14,4)10-13/h9,12-13H,1,5-8,10H2,2-4H3/t12-,13-,15-/m1/s1",epi-aristolochene,Beilstein Registry Number,3588800
1232,2760,"3,4,5-trimethoxyphenol","A member of the class of  phenols that is phenol substituted by methoxy groups at positions 3, 4 and 5.","InChI=1S/C9H12O4/c1-11-7-4-6(10)5-8(12-2)9(7)13-3/h4-5,10H,1-3H3",Antiarol,KEGG COMPOUND accession,C10765
1233,2991,aloin A,"A C-glycosyl compound that is beta-D-glucopyranose in which the anomeric hydroxy group is replaced by a 4,5-dihydroxy-2-(hydroxymethyl)-10-oxo-9,10-dihydroanthracen-9-yl moiety (the 9S diastereoisomer).","InChI=1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13-14,17,19-26,28-29H,6-7H2/t13-,14+,17-,19+,20-,21+/m1/s1",Barbaloin,KEGG COMPOUND accession,C10305
1234,3187,browniine,A diterpenoid that is aconitane bearing an N-ethyl as well as several hydroxy and methoxy substituents.,"InChI=1S/C25H41NO7/c1-6-26-11-22(12-30-2)8-7-16(32-4)24-14-9-13-15(31-3)10-23(28,17(14)18(13)27)25(29,21(24)26)20(33-5)19(22)24/h13-21,27-29H,6-12H2,1-5H3/t13-,14-,15+,16+,17-,18+,19-,20+,21?,22+,23-,24+,25-/m1/s1",Browniine,KEGG COMPOUND accession,C08665
1235,5402,glucocochlearin(1-),An alkylglucosinolate that is the conjugate base of glucocochlearin.,"InChI=1S/C11H21NO9S2/c1-3-5(2)10(12-21-23(17,18)19)22-11-9(16)8(15)7(14)6(4-13)20-11/h5-9,11,13-16H,3-4H2,1-2H3,(H,17,18,19)/p-1/b12-10-/t5?,6-,7-,8+,9-,11+/m1/s1",Glucocochlearin,CAS Registry Number,499-24-1
1236,8081,phentolamine,"A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.","InChI=1S/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)",Phentolamine mesylate,Patent accession,US2503059
1237,29673,rifamycin SV,A member of the class of rifamycins that exhibits antibiotic and antitubercular properties.,"InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1",Rifamycin,KEGG COMPOUND accession,C12044
1238,7612,nonacosan-10-one,A dialkyl ketone that is  nonacosane substituted by an oxo group at position 10.,"InChI=1S/C29H58O/c1-3-5-7-9-11-12-13-14-15-16-17-18-19-20-22-24-26-28-29(30)27-25-23-21-10-8-6-4-2/h3-28H2,1-2H3",Nonacosan-10-one,KEGG COMPOUND accession,C08386
1239,2769,"apigenin 7,4'-dimethyl ether","A dimethoxyflavone  that is the 7,4'-dimethyl ether derivative of apigenin.","InChI=1S/C17H14O5/c1-20-11-5-3-10(4-6-11)15-9-14(19)17-13(18)7-12(21-2)8-16(17)22-15/h3-9,18H,1-2H3",Apigenin dimethylether,CAS Registry Number,5128-44-9
1240,6647,mahuannin D,A proanthocyanidin isolated form Ephedra sinica.,"InChI=1S/C30H24O9/c31-16-5-1-14(2-6-16)28-23(36)11-19-21(34)12-25-27(29(19)37-28)20-13-30(39-25,15-3-7-17(32)8-4-15)38-24-10-18(33)9-22(35)26(20)24/h1-10,12,20,23,28,31-36H,11,13H2/t20?,23-,28-,30+/m1/s1","ent-Apigeniflavan-(2alpha->7,4alpha->8)-epiafzelechin",CAS Registry Number,88010-42-8
1241,8907,rubixanthin,"A carotenol that is a natural xanthophyll pigment. It was formerly used as a food colourant (E161d), but approval for this purpose has been withdrawn throughout the European Union.","InChI=1S/C40H56O/c1-31(2)17-13-20-34(5)23-15-25-35(6)24-14-21-32(3)18-11-12-19-33(4)22-16-26-36(7)27-28-39-37(8)29-38(41)30-40(39,9)10/h11-12,14-19,21-28,38,41H,13,20,29-30H2,1-10H3/b12-11+,21-14+,22-16+,25-15+,28-27+,32-18+,33-19+,34-23+,35-24+,36-26+/t38-/m1/s1",Rubixanthin,CAS Registry Number,3763-55-1
1242,4613,dimethyl telluride,An  organotellurium compound in which the tellurium atom is covalently  bonded to two methyl groups. A xenobiotic metabolite produced by certain strains of bacteria exposed to tellurium containing compounds.,InChI=1S/C2H6Te/c1-3-2/h1-2H3,Dimethyl telluride,CAS Registry Number,593-80-6
1243,4685,dolichodial,A dialdehyde that is cyclopentanecarbaldehyde substituted by a methyl group at position 2 and a 3-oxo-prop-1-en-2yl group at position 5. It has been found to occur in pheromones of insects such as aphids.,"InChI=1S/C10H14O2/c1-7-3-4-9(8(2)5-11)10(7)6-12/h5-7,9-10H,2-4H2,1H3/t7-,9+,10+/m0/s1",Dolichodial,CAS Registry Number,5951-57-5
1244,6147,kuwanone H,A tetrahydroxyflavone isolated from the plant species of the genus Morus.,"InChI=1S/C45H44O11/c1-21(2)6-10-27-33(48)15-14-29(41(27)53)42(54)38-31(26-12-8-24(46)18-34(26)49)16-23(5)17-32(38)39-36(51)20-37(52)40-43(55)30(11-7-22(3)4)44(56-45(39)40)28-13-9-25(47)19-35(28)50/h6-9,12-15,17-20,31-32,38,46-53H,10-11,16H2,1-5H3/t31-,32-,38-/m0/s1",Kuwanone H,KEGG COMPOUND accession,C10100
1245,7719,ochratoxin A,"A phenylalanine derivative resulting from the formal condensation of the amino group of L-phenylalanine with the carboxy group of (3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1H-2-benzopyran-7-carboxylic acid (ochratoxin alpha). It is among the most widely occurring food-contaminating mycotoxins, produced by Aspergillus ochraceus, Aspergillus carbonarius and Penicillium verrucosum.","InChI=1S/C20H18ClNO6/c1-10-7-12-14(21)9-13(17(23)16(12)20(27)28-10)18(24)22-15(19(25)26)8-11-5-3-2-4-6-11/h2-6,9-10,15,23H,7-8H2,1H3,(H,22,24)(H,25,26)/t10-,15+/m1/s1",Ochratoxin A,CAS Registry Number,303-47-9
1246,5765,hoerhammericine,"An Aspidosperma alkaloid with formula C21H24N2O4 found in Catharantheus lanceus. Note that the stereoconfiguration of the epoxy group is based on CHEBI:144374, and of the 19 hydroxy group on CHEBI:144372 (the same enzyme produces the two).","InChI=1S/C21H24N2O4/c1-11(24)21-9-12(18(25)26-2)16-20(13-5-3-4-6-14(13)22-16)7-8-23(19(20)21)10-15-17(21)27-15/h3-6,11,15,17,19,22,24H,7-10H2,1-2H3/t11-,15+,17+,19-,20+,21+/m1/s1",Horhammericine,PubMed citation,21567990
1247,29707,yersiniabactin,"A member of the class of thiazolidines that is (4S)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid which is substituted at position 2 by a (1S)-1-hydroxy-1-{(4R)-2-[(4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl group. A siderophore found in the gram-negative bacterium species, Yersinia enterocolitica and Yersinia pestis.","InChI=1S/C21H27N3O4S3/c1-20(2,18-24-21(3,10-31-18)19(27)28)15(26)12-8-30-17(22-12)13-9-29-16(23-13)11-6-4-5-7-14(11)25/h4-7,12-13,15,17,22,25-26H,8-10H2,1-3H3,(H,27,28)/t12-,13+,15+,17?,21+/m0/s1",yersiniabactin,KEGG COMPOUND accession,C12038
1248,2612,alstonine,"An indole alkaloid with formula C21H20N2O3, isolated from several Rauvolfia species and exhibits antipsychotic activity.","InChI=1S/C21H20N2O3/c1-12-16-10-23-8-7-14-13-5-3-4-6-18(13)22-20(14)19(23)9-15(16)17(11-26-12)21(24)25-2/h3-8,11-12,15-16H,9-10H2,1-2H3/t12-,15-,16-/m0/s1",alstonine,KEGG COMPOUND accession,C09028
1249,7518,cis-trans-nepetalactone,"A cyclopentapyran that is (4aS,7aR)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran substituted at position 1 by an oxo group and at positions 4 and 7 by methyl groups, respectively (the 4aS,7S,7aR-diastereomer). An iridoid monoterpenoid isolated from several Nepeta plant species. It is an aphid sex pheromone and cat attractant, and exhibits antibacterial, antifungal, and analgesic properties.","InChI=1S/C10H14O2/c1-6-3-4-8-7(2)5-12-10(11)9(6)8/h5-6,8-9H,3-4H2,1-2H3/t6-,8+,9+/m0/s1",nepetalactone cis-trans-form,KEGG COMPOUND accession,C09791
1250,7519,trans-cis-nepetalactone,"A cyclopentapyran that is (4aS,7aS)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran substituted at position 1 by an oxo group and at positions 4 and 7 by methyl groups, respectively (the 4aS,7S,7aS-diastereomer). An iridoid monoterpenoid isolated from several Nepeta plant species. It exhibits potent repellant activity against house dust mites and mosquitoes.","InChI=1S/C10H14O2/c1-6-3-4-8-7(2)5-12-10(11)9(6)8/h5-6,8-9H,3-4H2,1-2H3/t6-,8+,9-/m0/s1",nepetalactone trans-cis-form,KEGG COMPOUND accession,C09792
1251,2596,alliin,An L-alanine derivative in which one of the methyl hydrogens of L-alanine has been replaced by an (S)-allylsulfinyl group.,"InChI=1S/C6H11NO3S/c1-2-3-11(10)4-5(7)6(8)9/h2,5H,1,3-4,7H2,(H,8,9)/t5-,11-/m0/s1",Alliin,CAS Registry Number,556-27-4
1252,3535,cephalexin monohydrate,A hydrate of cephalexin consisting of equimolar amounts of hydrate and cephalexin.,"InChI=1S/C16H17N3O4S.H2O/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9;/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23);1H2/t10-,11-,15-;/m1./s1",Cephalexin monohydrate,KEGG COMPOUND accession,C08099
1253,7549,N(gamma)-nitro-L-arginine methyl ester,An alpha-amino acid ester that is the methyl ester of N(gamma)-nitro-L-arginine.,"InChI=1S/C7H15N5O4/c1-16-6(13)5(8)3-2-4-10-7(9)11-12(14)15/h5H,2-4,8H2,1H3,(H3,9,10,11)/t5-/m0/s1",Ngamma-Nitro-L-arginine methyl ester,KEGG COMPOUND accession,C04337
1254,9440,tenuazonic acid,"A member of the class of pyrrolidin-2-ones that is 5-(butan-2-yl)pyrrolidine-2,4-dione carrying an additional acetyl group at position 3. A mycotoxin produced by various plant pathogenic fungi.","InChI=1S/C10H15NO3/c1-4-5(2)8-9(13)7(6(3)12)10(14)11-8/h5,7-8H,4H2,1-3H3,(H,11,14)/t5-,7?,8-/m0/s1",Tenuazonic acid,CAS Registry Number,27778-66-1
1255,5784,hydroflumethiazide,"A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.","InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)",Hydroflumethiazide,CAS Registry Number,135-09-1
1256,7859,oxycodone hydrochloride,"A hydrochloride obtained by reaction of oxycodone with one molar equivalent of hydrochloric acid.  It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.","InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1",Oxycodone hydrochloride,KEGG COMPOUND accession,C08026
1257,4732,E3040,"A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by a methylnitrilo group, (pyridin-3-yl)methyl group, methyl group, hydroxy group and methyl group at position 2,4,5,6 and 7, respectively. It is a dual inhibitor of 5-lipoxygenase and thromboxane A2 synthetase and exhibits anti-inflammatory properties. The drug was being developed by Eisai (Tokyo, Japan) for the treatment of bowel disease.","InChI=1S/C16H17N3OS/c1-9-12(7-11-5-4-6-18-8-11)13-15(10(2)14(9)20)21-16(17-3)19-13/h4-6,8,20H,7H2,1-3H3,(H,17,19)",E3040,KEGG COMPOUND accession,C11593
1258,6972,monardaein,"An anthocyanin cation that is pelargonidin in which the hydroxy group at position 3 is substituted by a 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranosyl group and the hydroxy group at position 5 is substituted by a 4,6-bis-O-(carboxyacetyl)-beta-D-glucopyranosyl group.","InChI=1S/C42H40O23/c43-20-6-1-18(2-7-20)3-10-31(50)58-16-27-34(53)35(54)37(56)41(63-27)62-26-13-23-24(60-39(26)19-4-8-21(44)9-5-19)11-22(45)12-25(23)61-42-38(57)36(55)40(65-33(52)15-30(48)49)28(64-42)17-59-32(51)14-29(46)47/h1-13,27-28,34-38,40-42,53-57H,14-17H2,(H4-,43,44,45,46,47,48,49,50)/p+1/t27-,28-,34-,35+,36-,37-,38-,40-,41-,42-/m1/s1",monardaein,CAS Registry Number,73545-87-6
1259,5832,hypaphorine,An amino acid betaine obtaine by exhaustive methylation of the alpha-amino group of L-tryptophan with concomitant deprotonation of the carboxy group.,"InChI=1S/C14H18N2O2/c1-16(2,3)13(14(17)18)8-10-9-15-12-7-5-4-6-11(10)12/h4-7,9,13,15H,8H2,1-3H3/t13-/m0/s1",Hypaphorine,KEGG COMPOUND accession,C09213
1260,3017,bensulfuron-methyl,"The methyl ester of bensulfuron. An acetolactate synthase inhibitor, it is used as a herbicide for the control of a variety of both annual and perennial weeds in crops, particularly wheat and rice. It is not licensed for use within the UK.","InChI=1S/C16H18N4O7S/c1-25-12-8-13(26-2)18-15(17-12)19-16(22)20-28(23,24)9-10-6-4-5-7-11(10)14(21)27-3/h4-8H,9H2,1-3H3,(H2,17,18,19,20,22)",Methyl bensulfuron,KEGG COMPOUND accession,C10937
1261,4733,E3040 glucuronide,"A member of the class of benzothiazoles that is E3040 in which the hydroxy hydrogen at position 6 has been replaced by a beta-D-glucosiduronic acid group. It is a metabolite of the anti-inflammatory drug, E3040.","InChI=1S/C22H25N3O7S/c1-9-12(7-11-5-4-6-24-8-11)13-19(33-22(23-3)25-13)10(2)17(9)31-21-16(28)14(26)15(27)18(32-21)20(29)30/h4-6,8,14-16,18,21,26-28H,7H2,1-3H3,(H,23,25)(H,29,30)/t14-,15-,16+,18-,21+/m0/s1",E3040 glucuronide,KEGG COMPOUND accession,C11595
1262,3887,(-)-coronaridine,"A monoterpenoid indole alkaloid with formula C21H26N2O2. It is isolated from the flowering plant genus, Tabernaemontana.","InChI=1S/C21H26N2O2/c1-3-14-10-13-11-21(20(24)25-2)18-16(8-9-23(12-13)19(14)21)15-6-4-5-7-17(15)22-18/h4-7,13-14,19,22H,3,8-12H2,1-2H3/t13-,14+,19+,21-/m1/s1",coronaridine,CAS Registry Number,467-77-6
1263,5853,ibogamine,"A monoterpenoid indole alkaloid with formula C19H24N2. It is isolated from the flowering plant genus, Tabernaemontana and exhibits anti-addictive properties.","InChI=1S/C19H24N2/c1-2-13-9-12-10-16-18-15(7-8-21(11-12)19(13)16)14-5-3-4-6-17(14)20-18/h3-6,12-13,16,19-20H,2,7-11H2,1H3/t12-,13+,16+,19+/m1/s1",ibogamine,KEGG COMPOUND accession,C09215
1264,4947,thiocyclam,"An organosulfur heterocyclic compound that is 1,2,3-trithiane in which one of the hydrogens at position 5 has been replaced by a dimethylamino group. A nicotinic acetylcholine receptor agonist, it was used (particularly as its hydrogen oxalate salt, known as thyocyclam oxalate) as a broad-spectrum insecticide, but it is also toxic to bees, fish and other aquatic organisms. It is not approved for use within the European Union.","InChI=1S/C5H11NS3/c1-6(2)5-3-7-9-8-4-5/h5H,3-4H2,1-2H3",Thiocyclam,CAS Registry Number,31895-21-3
1265,8714,quinapril hydrochloride,"A hydrochloride resulting from the reaction of equimolar amounts of quinapril and hydrogen chloride. A prodrug for quinaprilat hydrochloride (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) for the treatment of hypertension and congestive heart failure.","InChI=1S/C25H30N2O5.ClH/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30;/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30);1H/t17-,21-,22-;/m0./s1",Quinapril hydrochloride,KEGG COMPOUND accession,C07340
1266,6839,methoxamine,"An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .","InChI=1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3",Methoxamine,CAS Registry Number,390-28-3
1267,8939,flumioxazin,"A benzoxazine that is N-(prop-2-yn-1-yl)-2H-1,4-benzoxazin-3(4H)-one which is substituted at position 6 by a 1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl group and at position 7 by a fluorine. A protoporphyrinogen oxidase inhibitor, it is used for the control of weeds in soya, peanuts, and a variety of vegetable and fruit crops.","InChI=1S/C19H15FN2O4/c1-2-7-21-15-9-14(13(20)8-16(15)26-10-17(21)23)22-18(24)11-5-3-4-6-12(11)19(22)25/h1,8-9H,3-7,10H2",S-53482,KEGG COMPOUND accession,C11035
1268,29602,gibberellin A6,"A C19-gibberellin, initially identified in Phaseolus coccineus and differing from gibberellin A1 by the conversion of the OH at C-2 (gibbane numbering) into an epoxide across C-2 and C-3.","InChI=1S/C19H22O6/c1-8-5-17-7-18(8,23)4-3-10(17)19-6-9-13(24-9)16(2,15(22)25-19)12(19)11(17)14(20)21/h9-13,23H,1,3-7H2,2H3,(H,20,21)/t9-,10+,11+,12+,13-,16-,17-,18-,19+/m0/s1",Gibberellin A6,KEGG COMPOUND accession,C11856
1269,5373,(S)-glaucine,"An  aporphine alkaloid that is (S)-1,2,9,10-tetrahydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline in which the four phenolic hydrogens have been replaced by methyl groups.","InChI=1S/C21H25NO4/c1-22-7-6-12-9-18(25-4)21(26-5)20-14-11-17(24-3)16(23-2)10-13(14)8-15(22)19(12)20/h9-11,15H,6-8H2,1-5H3/t15-/m0/s1",Glaucine,KEGG COMPOUND accession,C09446
1270,8809,resiniferatoxin,A heteropentacyclic compound found in Euphorbia poissonii with molecular formula C37H40O9. It is an agonist of the transient receptor potential cation channel subfamily V member 1 (TrpV1).,"InChI=1S/C37H40O9/c1-21(2)35-17-23(4)37-27(33(35)44-36(45-35,46-37)19-24-9-7-6-8-10-24)14-26(18-34(41)30(37)13-22(3)32(34)40)20-43-31(39)16-25-11-12-28(38)29(15-25)42-5/h6-15,23,27,30,33,38,41H,1,16-20H2,2-5H3/t23-,27+,30-,33-,34-,35-,36-,37-/m1/s1",resiniferatoxin,CAS Registry Number,57444-62-9
1271,9044,savinin,"A lignan that is dihydrofuran-2(3H)-one (gamma-butyrolactone) substituted by a 1,3-benzodioxol-5-ylmethylidene group at position 3 and a 1,3-benzodioxol-5-ylmethyl group at position 4 (the 3E,4R-isomer). It exhibits antiviral activity against SARS-CoV-2.","InChI=1S/C20H16O6/c21-20-15(6-13-2-4-17-19(8-13)26-11-24-17)14(9-22-20)5-12-1-3-16-18(7-12)25-10-23-16/h1-4,6-8,14H,5,9-11H2/b15-6+/t14-/m0/s1",savinin,KEGG COMPOUND accession,C10880
1272,6964,molinate,"A member of the class of azepanes that is azepane in which the nitrogen is substituted by an (ethylsulfanyl)carbonyl group, -C(=O)SEt. A thiocarbamate herbicide not approved for use in the U.S. or European Union, it is used control grass weeds in rice paddies.","InChI=1S/C9H17NOS/c1-2-12-9(11)10-7-5-3-4-6-8-10/h2-8H2,1H3",molinate,CAS Registry Number,2212-67-1
1273,3503,cefpirome,"A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.","InChI=1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1",Cefpirome,KEGG COMPOUND accession,C11199
1274,29598,gibberellin A5,A C19-gibberellin initially identified in Gibberella fujikuroi and differing from gibberellin A1 by the absence of the OH at C-2 and the presence of a double bond between C-3 and C-3 (gibbane numbering).,"InChI=1S/C19H22O5/c1-10-8-17-9-18(10,23)7-4-11(17)19-6-3-5-16(2,15(22)24-19)13(19)12(17)14(20)21/h3,5,11-13,23H,1,4,6-9H2,2H3,(H,20,21)/t11-,12-,13-,16-,17+,18+,19-/m1/s1",Gibberellin A5,KEGG COMPOUND accession,C11871
1275,3092,bicuculline,"A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.","InChI=1S/C20H17NO6/c1-21-5-4-10-6-14-15(25-8-24-14)7-12(10)17(21)18-11-2-3-13-19(26-9-23-13)16(11)20(22)27-18/h2-3,6-7,17-18H,4-5,8-9H2,1H3/t17-,18+/m0/s1",Bicuculline,KEGG COMPOUND accession,C09364
1276,10022,deoxynivalenol,"A trichothecene mycotoxin produced by Fusarium to which wheat, barley, maize (corn) and their products are susceptible to contamination.","InChI=1S/C15H20O6/c1-7-3-9-14(5-16,11(19)10(7)18)13(2)4-8(17)12(21-9)15(13)6-20-15/h3,8-9,11-12,16-17,19H,4-6H2,1-2H3/t8-,9-,11-,12-,13-,14-,15+/m1/s1",Vomitoxin,CAS Registry Number,51481-10-8
1277,8657,pyrazolynate,"A member of the class of pyrazoles that is 1,3-dimethylpyrazole which is substituted at positions 4 and 5 by 2,4-dichlorobenzoyl and p-tosyloxy groups, respectively. It is an obsolete proherbicide (via hydrolysis of the tosylate group to afford the corresponding 5-hydroxypyrazole), that was used to control weeds in rice paddy fields.","InChI=1S/C19H16Cl2N2O4S/c1-11-4-7-14(8-5-11)28(25,26)27-19-17(12(2)22-23(19)3)18(24)15-9-6-13(20)10-16(15)21/h4-10H,1-3H3","4-(2,4-Dichlorobenzoyl)-1,3-dimethyl-5-pyrazolyl p-toluenesulfonate",CAS Registry Number,58011-68-0
1278,766,estriol 16-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is estriol in which the phenolic hydrogen has been replaced by a beta-D-glucuronyl residue.,"InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(25)8-10(12)2-4-14(13)15(24)9-16(21(24)29)32-23-19(28)17(26)18(27)20(33-23)22(30)31/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/t13-,14-,15+,16-,17+,18+,19-,20+,21+,23-,24+/m1/s1",16-Glucuronide-estriol,KEGG COMPOUND accession,C05504
1279,3496,cefoselis,"A cephalosporin compound having [2-(2-hydroxyethyl)-3-imino-2,3-dihydro-1H-pyrazol-1-yl]methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. A 4th generation broad-spectrum cephalosporin.","InChI=1S/C19H22N8O6S2/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28/h2-3,8,13,17,20,28H,4-7H2,1H3,(H2,21,22)(H,23,29)(H,31,32)/b20-11?,24-12-/t13-,17-/m1/s1",Cefoselis,KEGG COMPOUND accession,C11210
1280,5408,glucolepidiin,"An alkylglucosinolic acid that consists of 1-thio-beta-D-glucopyranose attached to an -N-(sulfooxy)propanimidoyl group at the anomeric sulfur. It occurs in Lepidium sativum (garden cress) and Armoracia lapathifolia (horseraddish). A flavour component; the hydrolysis product, ethyl isothiocyanate, is very pungent and garlic-like.","InChI=1S/C9H17NO9S2/c1-2-5(10-19-21(15,16)17)20-9-8(14)7(13)6(12)4(3-11)18-9/h4,6-9,11-14H,2-3H2,1H3,(H,15,16,17)/b10-5-/t4-,6-,7+,8-,9+/m1/s1",Glucolepidiin,KEGG COMPOUND accession,C08413
1281,969,2-(2-(4-methoxyphenyl)ethyl)chromone,"A member of the class of chromones that is chromone which is substituted by a 2-(4-methoxyphenyl)ethyl group at position 2. It is found in agarwood, a fragrant resinous heartwood from trees of the genus Aquilaria.","InChI=1S/C18H16O3/c1-20-14-9-6-13(7-10-14)8-11-15-12-17(19)16-4-2-3-5-18(16)21-15/h2-7,9-10,12H,8,11H2,1H3",2-(4-methoxyphenethyl)chromone,CAS Registry Number,92911-82-5
1282,9271,stevioside,"A diterpene glycoside that is rubusoside in which the hydroxy group at position 2 of the allylic beta-D-glucoside has been converted to the corresponding beta-D-glucoside. It is a natural herbal sweetener that is 250-300 times sweeter than sucrose (though with a bitter aftertaste), extracted from the Stevia rebaudiana plant native to South America.","InChI=1S/C38H60O18/c1-16-11-37-9-5-20-35(2,7-4-8-36(20,3)34(50)55-32-29(49)26(46)23(43)18(13-40)52-32)21(37)6-10-38(16,15-37)56-33-30(27(47)24(44)19(14-41)53-33)54-31-28(48)25(45)22(42)17(12-39)51-31/h17-33,39-49H,1,4-15H2,2-3H3/t17-,18-,19-,20+,21+,22-,23-,24-,25+,26+,27+,28-,29-,30-,31+,32+,33+,35-,36-,37-,38+/m1/s1",stevioside,KEGG COMPOUND accession,C09189
1283,2718,angiotensin I,"A ten amino acid peptide formed by renin cleavage of angiotensinogen. Angiotensin I has no direct biological function except that high levels can stimulate catecholamine production. It is metabolized to its biologically active byproduct angiotensin II, a potent vasoconstrictor, by angiotensin converting enzyme (ACE) through cleavage of the two terminal amino acids.","InChI=1S/C62H89N17O14/c1-7-35(6)51(78-56(87)44(25-37-17-19-40(80)20-18-37)74-58(89)50(34(4)5)77-53(84)42(15-11-21-68-62(64)65)71-52(83)41(63)28-49(81)82)59(90)75-46(27-39-30-67-32-70-39)60(91)79-22-12-16-48(79)57(88)73-43(24-36-13-9-8-10-14-36)54(85)72-45(26-38-29-66-31-69-38)55(86)76-47(61(92)93)23-33(2)3/h8-10,13-14,17-20,29-35,41-48,50-51,80H,7,11-12,15-16,21-28,63H2,1-6H3,(H,66,69)(H,67,70)(H,71,83)(H,72,85)(H,73,88)(H,74,89)(H,75,90)(H,76,86)(H,77,84)(H,78,87)(H,81,82)(H,92,93)(H4,64,65,68)/t35-,41-,42-,43-,44-,45-,46-,47-,48-,50-,51-/m0/s1",angiotensin I,CAS Registry Number,9041-90-1
1284,3556,cercosporin,"An organic heterohexacyclic compound that is perylo[1,12-def][1,3]dioxepine-6,11-dione substituted by hydroxy groups at positions 5 and 12, by methoxy groups at positions 7 and 10, and by 2-hydroxypropyl groups at positions 8 and 9 (the R,R-stereoisomer). It is a phytotoxin which was first isolated from the pathogenic soybean fungus, Cercospora kikuchii and later found in multiple members of the genus Cercospora.","InChI=1S/C29H26O10/c1-10(30)5-12-18-19-13(6-11(2)31)29(37-4)27(35)21-15(33)8-17-23(25(19)21)22-16(38-9-39-17)7-14(32)20(24(18)22)26(34)28(12)36-3/h7-8,10-11,30-33H,5-6,9H2,1-4H3/t10-,11-/m1/s1",cercosporin,KEGG COMPOUND accession,C10309
1285,8989,SN-38 carboxylate,"A  hydroxy monocarboxylic acid anion that is the conjugate base of SN-38 carboxylic acid, obtained from the deprotonation of the carboxy group. It is the major microspecies at pH 7.3.","InChI=1S/C22H22N2O6/c1-3-12-13-7-11(26)5-6-17(13)23-19-14(12)9-24-18(19)8-16(15(10-25)20(24)27)22(30,4-2)21(28)29/h5-8,25-26,30H,3-4,9-10H2,1-2H3,(H,28,29)/p-1/t22-/m0/s1",SN-38 carboxylate form,KEGG COMPOUND accession,C11366
1286,7542,neurotensin,"A 13 amino acid peptide hormone which is found in the central nervous system and the gastrointestinal tract. It behaves as a neurotransmitter in the brain, as a hormone in the gut, and also as a neuromodulator. It is implicated in the pathophysiology of several CNS disorders (including schizophrenia, Parkinson's disease, drug abuse, pain, cancer, inflammation, eating disorders and central control of blood pressure) due to its association with a wide variety of neurotransmitter systems such as dopaminergic, sertonergic, glutamatergic, GABAergic, and cholinergic systems.","InChI=1S/C78H121N21O20/c1-7-43(6)63(73(115)96-57(76(118)119)37-42(4)5)97-70(112)55(39-45-21-25-47(101)26-22-45)95-72(114)59-18-13-35-99(59)75(117)52(16-11-33-86-78(83)84)90-64(106)48(15-10-32-85-77(81)82)89-71(113)58-17-12-34-98(58)74(116)51(14-8-9-31-79)91-69(111)56(40-60(80)102)94-66(108)50(28-30-62(104)105)88-68(110)54(38-44-19-23-46(100)24-20-44)93-67(109)53(36-41(2)3)92-65(107)49-27-29-61(103)87-49/h19-26,41-43,48-59,63,100-101H,7-18,27-40,79H2,1-6H3,(H2,80,102)(H,87,103)(H,88,110)(H,89,113)(H,90,106)(H,91,111)(H,92,107)(H,93,109)(H,94,108)(H,95,114)(H,96,115)(H,97,112)(H,104,105)(H,118,119)(H4,81,82,85)(H4,83,84,86)/t43-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,63-/m0/s1",neurotensin,CAS Registry Number,58889-67-1
1287,4601,diloxanide furoate,"A carboxylic ester resulting from the formal condensation of the carboxy group of furan-2-carboxylic acid with the hydroxy group of 2,2-dichloro-N-(4-hydroxyphenyl)-N-methylacetamide. It is a drug used for the treatment of asymptomatic amebiasis.","InChI=1S/C14H11Cl2NO4/c1-17(13(18)12(15)16)9-4-6-10(7-5-9)21-14(19)11-3-2-8-20-11/h2-8,12H,1H3",diloxanide furoate,CAS Registry Number,3736-81-0
1288,2501,aethusin,"A polyene that is tridecane carrying trans double bonds at positions 2, 8, and 10 and triple bonds at positions 4 and 6. It is a phytotoxin isolated from the plant, Aethusa cynapium.","InChI=1S/C13H14/c1-3-5-7-9-11-13-12-10-8-6-4-2/h3,5-6,8,10,12H,4H2,1-2H3/b5-3+,8-6+,12-10+",Aethusin,KEGG COMPOUND accession,C08395
1289,3528,cellotriose,A glucotriose consisting of three,"InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11-,12-,13-,14-,15-,16?,17+,18+/m1/s1",Cellotriose,KEGG COMPOUND accession,C06219
1290,6377,lapachol,"A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone substituted by hydroxy and 3-methylbut-2-en-1-yl groups at positions 2 and 3, respectively. It is a natural compound that exhibits antibacterial and anticancer properties, first isolated in 1882 from the bark of Tabebuia avellanedae.","InChI=1S/C15H14O3/c1-9(2)7-8-12-13(16)10-5-3-4-6-11(10)14(17)15(12)18/h3-7,18H,8H2,1-2H3",Lapachol,KEGG COMPOUND accession,C10366
1291,29623,manumycin A,A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties.,"InChI=1S/C31H38N2O7/c1-5-6-11-19(2)16-20(3)17-21(4)30(38)32-22-18-31(39,29-28(40-29)27(22)37)15-10-8-7-9-12-25(36)33-26-23(34)13-14-24(26)35/h7-10,12,15-19,28-29,34,39H,5-6,11,13-14H2,1-4H3,(H,32,38)(H,33,36)/b8-7+,12-9+,15-10+,20-16+,21-17+/t19-,28-,29-,31+/m1/s1",manumycin A,KEGG COMPOUND accession,C12111
1292,6618,Met-enkephalin,"A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-methionine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide with antitumor, analgesic, and immune-boosting properties.","InChI=1S/C27H35N5O7S/c1-40-12-11-21(27(38)39)32-26(37)22(14-17-5-3-2-4-6-17)31-24(35)16-29-23(34)15-30-25(36)20(28)13-18-7-9-19(33)10-8-18/h2-10,20-22,33H,11-16,28H2,1H3,(H,29,34)(H,30,36)(H,31,35)(H,32,37)(H,38,39)/t20-,21-,22-/m0/s1",MET-enkephalin,KEGG COMPOUND accession,C11684
1293,3495,ceforanide,"A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.","InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1",Ceforanide,KEGG COMPOUND accession,C06884
1294,3636,chloroprocaine,"Procaine in which one of the hydrogens ortho- to the carboxylic acid group is substituted by chlorine. It is used as its monohydrochloride salt as a local anaesthetic, particularly for oral surgery. It has the advantage over lidocaine of constricting blood vessels, so reducing bleeding.","InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3",Chloroprocaine,KEGG COMPOUND accession,C07877
1295,3892,corticotropin,"A polypeptide hormone produced and secreted by the pituitary gland comprising 39 amino acid residues coupled in a linear sequence. The N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). It is used in the treatment of certain neurological disorders such as infantile spasms and multiple sclerosis, and diagnostically to investigate adrenocortical insufficiency.","InChI=1S/C207H308N56O58S/c1-108(2)89-140(186(302)240-135(69-74-163(279)280)182(298)254-149(204(320)321)94-117-43-20-15-21-44-117)250-193(309)152-54-35-86-262(152)202(318)147(92-116-41-18-14-19-42-116)252-171(287)114(11)230-175(291)132(66-71-160(273)274)234-170(286)113(10)231-191(307)150(105-265)255-183(299)136(70-75-164(281)282)241-190(306)146(98-165(283)284)249-180(296)133(67-72-161(275)276)235-169(285)112(9)229-157(270)101-225-174(290)145(97-156(213)269)251-194(310)153-55-36-87-263(153)203(319)148(93-119-60-64-123(268)65-61-119)253-199(315)167(110(5)6)257-185(301)129(49-26-30-79-210)243-198(314)168(111(7)8)259-196(312)155-57-38-85-261(155)201(317)139(53-34-83-223-207(218)219)244-178(294)130(51-32-81-221-205(214)215)237-177(293)128(48-25-29-78-209)236-176(292)127(47-24-28-77-208)232-158(271)103-227-197(313)166(109(3)4)258-195(311)154-56-37-84-260(154)200(316)138(50-27-31-80-211)233-159(272)102-226-173(289)143(95-120-99-224-126-46-23-22-45-124(120)126)247-179(295)131(52-33-82-222-206(216)217)238-187(303)142(90-115-39-16-13-17-40-115)246-189(305)144(96-121-100-220-107-228-121)248-181(297)134(68-73-162(277)278)239-184(300)137(76-88-322-12)242-192(308)151(106-266)256-188(304)141(245-172(288)125(212)104-264)91-118-58-62-122(267)63-59-118/h13-23,39-46,58-65,99-100,107-114,125,127-155,166-168,224,264-268H,24-38,47-57,66-98,101-106,208-212H2,1-12H3,(H2,213,269)(H,220,228)(H,225,290)(H,226,289)(H,227,313)(H,229,270)(H,230,291)(H,231,307)(H,232,271)(H,233,272)(H,234,286)(H,235,285)(H,236,292)(H,237,293)(H,238,303)(H,239,300)(H,240,302)(H,241,306)(H,242,308)(H,243,314)(H,244,294)(H,245,288)(H,246,305)(H,247,295)(H,248,297)(H,249,296)(H,250,309)(H,251,310)(H,252,287)(H,253,315)(H,254,298)(H,255,299)(H,256,304)(H,257,301)(H,258,311)(H,259,312)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,320,321)(H4,214,215,221)(H4,216,217,222)(H4,218,219,223)/t112-,113-,114-,125-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,166-,167-,168-/m0/s1",Corticotropin,KEGG COMPOUND accession,C02017
1296,3349,candicidin D,"A 38-membered ring lactone containing seven (E)-double bonds between positions 22 and 35 and substituted by hydroxy groups at positions 9, 11, 13, 17 and 19, oxo groups at positions 3, 7 and 15, a carboxy group at position 18, a 3-amino-3,6-dideoxymannopyranosyloxy group at position 21, a methyl group at position 36 and a 7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl group at position 37. It is the major component of candicidin, a mixture of antifungal heptaene macrolides obtained from a strain of Streptomyces griseus.","InChI=1S/C59H84N2O18/c1-35-18-15-13-11-9-7-5-6-8-10-12-14-16-21-47(78-59-56(74)54(61)55(73)38(4)77-59)33-51(71)53(58(75)76)50(70)31-46(67)30-45(66)29-44(65)28-43(64)27-41(62)19-17-20-42(63)32-52(72)79-57(35)37(3)26-36(2)48(68)34-49(69)39-22-24-40(60)25-23-39/h5-16,18,21-25,35-38,43-45,47-48,50-51,53-57,59,64-66,68,70-71,73-74H,17,19-20,26-34,60-61H2,1-4H3,(H,75,76)/b6-5+,9-7+,10-8+,13-11+,14-12+,18-15+,21-16+/t35?,36?,37?,38-,43?,44?,45?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59?/m1/s1",Candicidin D,KEGG COMPOUND accession,C06690
1297,4753,ecothiopate,"The phosphorothioate obtained by formal condensation of diethyl phosphate with N,N,N-trimethyl-2-sulfanylethanaminium. An irreversible acetylcholinesterase inhibitor, its iodide salt is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inadequate.","InChI=1S/C9H23NO3PS/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5/h6-9H2,1-5H3/q+1",Echothiophate,CAS Registry Number,6736-03-4
1298,4746,echinenone,"A  carotenone that is beta-carotene in which the 4 position has undergone formal oxidation to afford the corresponding ketone. Isolated as orange-red crystals, it is widely distributed in marine invertebrates.","InChI=1S/C40H54O/c1-30(18-13-20-32(3)23-25-36-34(5)22-15-28-39(36,7)8)16-11-12-17-31(2)19-14-21-33(4)24-26-37-35(6)38(41)27-29-40(37,9)10/h11-14,16-21,23-26H,15,22,27-29H2,1-10H3/b12-11+,18-13+,19-14+,25-23+,26-24+,30-16+,31-17+,32-20+,33-21+",Echinenone,KEGG COMPOUND accession,C08592
1299,4953,exemestane,"A 17-oxo steroid that is androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group. A selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer.","InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1",Exemestane,KEGG COMPOUND accession,C08162
1300,34631,chlorpyrifos,"An  organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.","InChI=1S/C9H11Cl3NO3PS/c1-3-14-17(18,15-4-2)16-9-7(11)5-6(10)8(12)13-9/h5H,3-4H2,1-2H3",Chlorpyrifos,KEGG COMPOUND accession,C14322
1301,34607,"bornane-2,3-dione","A bornane monoterpenoid that is bicyclo[2.2.1]heptane substituted by methyl groups at positions 1, 7 and 7 and oxo groups at positions 2 and 3.","InChI=1S/C10H14O2/c1-9(2)6-4-5-10(9,3)8(12)7(6)11/h6H,4-5H2,1-3H3",Camphorquinone,CAS Registry Number,10373-78-1
1302,32357,trans-3-coumaric acid,A 3-coumaric acid that is phenol substituted with trans-2-propenoic acid at position C-3.,"InChI=1S/C9H8O3/c10-8-3-1-2-7(6-8)4-5-9(11)12/h1-6,10H,(H,11,12)/b5-4+",3-Coumaric acid,KEGG COMPOUND accession,C12621
1303,31042,4-(1-hydroxyethyl)phenol,A member of the class of phenols that is phenol substituted by a 1-hydroxyethyl group at position 4.,"InChI=1S/C8H10O2/c1-6(9)7-2-4-8(10)5-3-7/h2-6,9-10H,1H3",1-(4'-Hydroxyphenyl)ethanol,KEGG COMPOUND accession,C13638
1304,34938,propoxur,A carbamate ester that is phenyl methylcarbamate substituted at position 2 by a propan-2-yloxy group.,"InChI=1S/C11H15NO3/c1-8(2)14-9-6-4-5-7-10(9)15-11(13)12-3/h4-8H,1-3H3,(H,12,13)",Propoxur,KEGG COMPOUND accession,C14334
1305,34154,13(S)-HODE,"An HODE (hydroxyoctadecadienoic acid) in which the double bonds are at positions 9 and 11 (E and Z geometry, respectively) and the hydroxy group is at position 13 (with S-configuration).","InChI=1S/C18H32O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15,17,19H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)/b9-7-,15-12+/t17-/m0/s1",13(S)-HODE,KEGG COMPOUND accession,C14762
1306,34204,"2,2',4,4'-tetrachlorobiphenyl",A tetrachlorobiphenyl that is biphenyl in which each of the phenyl groups is substituted at positions 2 and 4 by chlorines.,InChI=1S/C12H6Cl4/c13-7-1-3-9(11(15)5-7)10-4-2-8(14)6-12(10)16/h1-6H,"2,2',4,4'-Tetrachlorobiphenyl",Beilstein Registry Number,2052543
1307,34471,6-hydroxyflavanone,A monohydroxyflavanone that is flavanone substituted by a hydroxy group at position 6.,"InChI=1S/C15H12O3/c16-11-6-7-14-12(8-11)13(17)9-15(18-14)10-4-2-1-3-5-10/h1-8,15-16H,9H2",6-Hydroxyflavanone,KEGG COMPOUND accession,C14221
1308,34247,"2,6-di-tert-butyl-4-methylphenol",A member of the class of  phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.,"InChI=1S/C15H24O/c1-10-8-11(14(2,3)4)13(16)12(9-10)15(5,6)7/h8-9,16H,1-7H3","2,6-di-t-butyl-4-methylphenol",KEGG COMPOUND accession,C14693
1309,32181,tamibarotene,"A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine.","InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-16(9-10-17(18)21)23-19(24)14-5-7-15(8-6-14)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",Tamibarotene,KEGG COMPOUND accession,C12864
1310,34206,"2,2',5,5'-tetrachlorobiphenyl",A tetrachlorobiphenyl that is biphenyl in which the hydrogens at the 2 and 5 position of each benzene ring are replaced by chlorines.,InChI=1S/C12H6Cl4/c13-7-1-3-11(15)9(5-7)10-6-8(14)2-4-12(10)16/h1-6H,"2,2',5,5'-Tetrachlorobiphenyl",CAS Registry Number,35693-99-3
1311,34031,"1,1-dichloroethene",A member of the class of chloroethenes that is ethene in which both of the hydrogens attached to one of the carbons are replaced by chlorines.,InChI=1S/C2H2Cl2/c1-2(3)4/h1H2,"1,1-Dichloroethylene",CAS Registry Number,75-35-4
1312,34692,dicofol,A tertiary alcohol that is DDT in which the benzylic hydrogen has been replaced by a hydroxy group.,"InChI=1S/C14H9Cl5O/c15-11-5-1-9(2-6-11)13(20,14(17,18)19)10-3-7-12(16)8-4-10/h1-8,20H",Dicofol,KEGG COMPOUND accession,C14301
1313,34584,boldenone,"An  3-oxo-Delta(1),Delta(4)-steroid substituted by an oxo group at position 3 and a beta-hydroxy group at position 17. It is an  anabolic androgenic steroid that has been developed for veterinary use.","InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-17,21H,3-6,8,10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1",Boldenone,KEGG COMPOUND accession,C14502
1314,34310,(24S)-24-hydroxycholesterol,A 24-hydroxycholesterol that has S configuration at position 24. It is the major metabolic breakdown product of cholesterol in the brain.,"InChI=1S/C27H46O2/c1-17(2)25(29)11-6-18(3)22-9-10-23-21-8-7-19-16-20(28)12-14-26(19,4)24(21)13-15-27(22,23)5/h7,17-18,20-25,28-29H,6,8-16H2,1-5H3/t18-,20+,21+,22-,23+,24+,25+,26+,27-/m1/s1",24-Hydroxycholesterol,KEGG COMPOUND accession,C13550
1315,34856,morpholine,An organic heteromonocyclic compound whose six-membered ring contains four carbon atoms and one nitrogen atom and one oxygen atom that lies opposite to each other; the parent compound of the morpholine family.,"InChI=1S/C4H9NO/c1-3-6-4-2-5-1/h5H,1-4H2",Morpholine,KEGG COMPOUND accession,C14452
1316,32319,alpha-ionone,,"InChI=1S/C13H20O/c1-10-6-5-9-13(3,4)12(10)8-7-11(2)14/h6-8,12H,5,9H2,1-4H3/b8-7+",alpha-Ionone,KEGG COMPOUND accession,C12286
1317,40083,(2R)-N-hydroxy-2-[(3S)-3-methyl-3-{4-[(2-methylquinolin-4-yl)methoxy]phenyl}-2-oxopyrrolidin-1-yl]propanamide,,"InChI=1S/C25H27N3O4/c1-16-14-18(21-6-4-5-7-22(21)26-16)15-32-20-10-8-19(9-11-20)25(3)12-13-28(24(25)30)17(2)23(29)27-31/h4-11,14,17,31H,12-13,15H2,1-3H3,(H,27,29)/t17-,25+/m1/s1",(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDE,PDBeChem accession,541
1318,40117,"1,4'-bipiperidine",,"InChI=1S/C10H20N2/c1-2-8-12(9-3-1)10-4-6-11-7-5-10/h10-11H,1-9H2",4-PIPERIDINO-PIPERIDINE,PDBeChem accession,4PN
1319,40167,5-iodotubercidin,,"InChI=1S/C11H13IN4O4/c12-4-1-16(10-6(4)9(13)14-3-15-10)11-8(19)7(18)5(2-17)20-11/h1,3,5,7-8,11,17-19H,2H2,(H2,13,14,15)/t5-,7-,8-,11-/m1/s1","(2R,3R,4S,5R)-2-(4-amino-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol",PDBeChem accession,5ID
1320,40332,2-({2-[(3-hydroxyphenyl)amino]pyrimidin-4-yl}amino)benzamide,,"InChI=1S/C17H15N5O2/c18-16(24)13-6-1-2-7-14(13)21-15-8-9-19-17(22-15)20-11-4-3-5-12(23)10-11/h1-10,23H,(H2,18,24)(H2,19,20,21,22)",2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE,PDBeChem accession,859
1321,40538,benzylamine,A primary amine compound having benzyl as the N-substituent. It has been isolated from  Moringa oleifera (horseradish tree).,"InChI=1S/C7H9N/c8-6-7-4-2-1-3-5-7/h1-5H,6,8H2",BENZYLAMINE,PDBeChem accession,ABN
1322,39740,2-fluoroadenosine,,"InChI=1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6-,9-/m1/s1","2-(6-AMINO-2-FLUORO-PURIN-9-YL)-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-3,4-DIOL",PDBeChem accession,2FA
1323,34276,1-ethyl-2-methylbenzene,A member of the class of toluenes carrying an ethyl group at the ortho-position.,"InChI=1S/C9H12/c1-3-9-7-5-4-6-8(9)2/h4-7H,3H2,1-2H3",2-Ethyltoluene,KEGG COMPOUND accession,C14572
1324,34346,3-nitrophenol,A member of the class of 3-nitrophenols that is phenol in which one of the hydrogens that is meta to the hydroxy group has been replaced by a nitro group.,"InChI=1S/C6H5NO3/c8-6-3-1-2-5(4-6)7(9)10/h1-4,8H",3-Nitrophenol,KEGG COMPOUND accession,C14418
1325,34435,toluene-4-sulfonamide,A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4.,"InChI=1S/C7H9NO2S/c1-6-2-4-7(5-3-6)11(8,9)10/h2-5H,1H3,(H2,8,9,10)",4-Toluenesulfonamide,KEGG COMPOUND accession,C14412
1326,39484,"(S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide",,"InChI=1S/C20H22FN3O2/c21-17-8-4-3-6-14(17)9-16(22)11-19(25)24-12-15-7-2-1-5-13(15)10-18(24)20(23)26/h1-8,16,18H,9-12,22H2,(H2,23,26)/t16-,18+/m1/s1","(S)-2-[(R)-3-AMINO-4-(2-FLUORO-PHENYL)-BUTYRYL]-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID AMIDE",PDBeChem accession,008
1327,42478,ethidium,The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.,"InChI=1S/C21H19N3/c1-2-24-20-13-16(23)9-11-18(20)17-10-8-15(22)12-19(17)21(24)14-6-4-3-5-7-14/h3-13,23H,2,22H2,1H3/p+1",ETHIDIUM,PDBeChem accession,ET
1328,41117,N-benzylformamide,,"InChI=1S/C8H9NO/c10-7-9-6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H,9,10)",N-BENZYLFORMAMIDE,PDBeChem accession,BNF
1329,41527,octaethyleneglycol monododecyl ether,The hydroxypolyether that is octaethylene glycol in which one of the hydroxy groups is substituted by dodecyloxy.,"InChI=1S/C28H58O9/c1-2-3-4-5-6-7-8-9-10-11-13-30-15-17-32-19-21-34-23-25-36-27-28-37-26-24-35-22-20-33-18-16-31-14-12-29/h29H,2-28H2,1H3",O-DODECANYL OCTAETHYLENE GLYCOL,PDBeChem accession,CE1
1330,41593,"(2R,3R,4S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)phenyl]chroman-6-ol","A chromanol that is chroman-6-ol which is substituted at positions 2, 3, and 4 by p-(2-pyrrolidin-1-ylethoxy)phenyl, p-hydroxyphenyl, and methyl groups, respectively (the 2R,3R,4S diastereoisomer).","InChI=1S/C28H31NO4/c1-19-25-18-23(31)10-13-26(25)33-28(27(19)20-4-8-22(30)9-5-20)21-6-11-24(12-7-21)32-17-16-29-14-2-3-15-29/h4-13,18-19,27-28,30-31H,2-3,14-17H2,1H3/t19-,27-,28+/m1/s1","(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL",PDBeChem accession,CM4
1331,41469,N-carbamoyl-D-valine,,"InChI=1S/C6H12N2O3/c1-3(2)4(5(9)10)8-6(7)11/h3-4H,1-2H3,(H,9,10)(H3,7,8,11)/t4-/m1/s1",3-METHYL-2-UREIDO-BUTYRIC ACID,PDBeChem accession,CDV
1332,34683,disodium hydrogenphosphate,,"InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2",Dibasic sodium phosphate,CAS Registry Number,7558-79-4
1333,41804,(5-pyridin-3-ylfuran-2-yl)methanamine,A member of the class of furans that is furan which is substituted by aminomethyl and pyridy-3-yl groups at positions 2 and 5 respectively.,"InChI=1S/C10H10N2O/c11-6-9-3-4-10(13-9)8-2-1-5-12-7-8/h1-5,7H,6,11H2",(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE,PDBeChem accession,D3G
1334,42697,"(2R,3R,4S)-2-({[(1S)-2-hydroxy-1-phenylethyl]amino}methyl)pyrrolidine-3,4-diol",,"InChI=1S/C13H20N2O3/c16-8-11(9-4-2-1-3-5-9)14-6-10-13(18)12(17)7-15-10/h1-5,10-18H,6-8H2/t10-,11-,12+,13-/m1/s1","(2R,3R,4S)-2-({[(1S)-2-HYDROXY-1-PHENYLETHYL]AMINO}METHYL)PYRROLIDINE-3,4-DIOL",PDBeChem accession,GB2
1335,42787,"(2R,3R,4S)-2-({[(1R)-2-hydroxy-1-phenylethyl]amino}methyl)pyrrolidine-3,4-diol",,"InChI=1S/C13H20N2O3/c16-8-11(9-4-2-1-3-5-9)14-6-10-13(18)12(17)7-15-10/h1-5,10-18H,6-8H2/t10-,11+,12+,13-/m1/s1","(2R,3R,4S)-2-({[(1R)-2-HYDROXY-1-PHENYLETHYL]AMINO}METHYL)PYRROLIDINE-3,4-DIOL",PDBeChem accession,GB1
1336,42471,forskolin,A labdane diterpenoid isolated from the Indian Coleus plant.,"InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,26-27H,1,9-11H2,2-7H3/t13-,15-,16-,17-,19-,20-,21+,22-/m0/s1",FORSKOLIN,PDBeChem accession,FOK
1337,41320,"1,3-diphenylurea",A member of the class of phenylureas that is urea in which one of the hydrogens of each amino group is replaced by a phenyl group. It is present in coconut milk (Cocos nucifera).,"InChI=1S/C13H12N2O/c16-13(14-11-7-3-1-4-8-11)15-12-9-5-2-6-10-12/h1-10H,(H2,14,15,16)","1,3-DIPHENYLUREA",PDBeChem accession,BSU
1338,41888,(2S)-7-hydroxyflavanone,,"InChI=1S/C15H12O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14,16H,9H2/t14-/m0/s1",7-HYDROXY-2-PHENYL-CHROMAN-4-ONE,PDBeChem accession,DDC
1339,34104,1-nitronaphthalene,A mononitronaphthalene substituted by a nitro group at position 1.,InChI=1S/C10H7NO2/c12-11(13)10-7-3-5-8-4-1-2-6-9(8)10/h1-7H,1-Nitronaphthalene,KEGG COMPOUND accession,C14040
1340,36696,"1,2,3,5-tetrachlorobenzene","A tetrachlorobenzene carrying chloro groups at positions 1, 2, 3 and 5.",InChI=1S/C6H2Cl4/c7-3-1-4(8)6(10)5(9)2-3/h1-2H,"1,2,3,5-Tetrachlorbenzol",CAS Registry Number,634-90-2
1341,34303,2-sec-butylphenol,A member of the class of phenols that is phenol carrying a butan-2-yl group at position 2.,"InChI=1S/C10H14O/c1-3-8(2)9-6-4-5-7-10(9)11/h4-8,11H,3H2,1-2H3",2-sec-Butylphenol,KEGG COMPOUND accession,C14138
1342,40139,"(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid",,"InChI=1S/C6H10N2O4/c7-6(5(11)12)1-3(4(9)10)8-2-6/h3,8H,1-2,7H2,(H,9,10)(H,11,12)/t3-,6-/m1/s1","(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid",Beilstein Registry Number,7411558
1343,35586,1H-purine,The 1H-tautomer of purine.,"InChI=1S/C5H4N4/c1-4-5(8-2-6-1)9-3-7-4/h1-3H,(H,6,7,8,9)",1H-purine,Gmelin Registry Number,2379911
1344,40432,"5,6-diphenyl-N-(2-piperazin-1-ylethyl)furo[2,3-d]pyrimidin-4-amine",,"InChI=1S/C24H25N5O/c1-3-7-18(8-4-1)20-21-23(26-13-16-29-14-11-25-12-15-29)27-17-28-24(21)30-22(20)19-9-5-2-6-10-19/h1-10,17,25H,11-16H2,(H,26,27,28)","5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE",PDBeChem accession,979
1345,39505,1-(1-phenylcyclopentyl)methylamine,,"InChI=1S/C12H17N/c13-10-12(8-4-5-9-12)11-6-2-1-3-7-11/h1-3,6-7H,4-5,8-10,13H2",1-METHYLAMINE-1-BENZYL-CYCLOPENTANE,PDBeChem accession,007
1346,39618,"hexane-1,6-diamine","A C6 alkane-alpha,omega-diamine.",InChI=1S/C6H16N2/c7-5-3-1-2-4-6-8/h1-8H2,"HEXANE-1,6-DIAMINE",Gmelin Registry Number,2578
1347,37908,(S)-nadifloxacin,,"InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)/t10-/m0/s1","(5S)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid",Beilstein Registry Number,7084299
1348,35033,triphenyl phosphate,An  aryl phosphate resulting from the formal condensation of phosphoric acid with 3 mol eq. of phenol.,"InChI=1S/C18H15O4P/c19-23(20-16-10-4-1-5-11-16,21-17-12-6-2-7-13-17)22-18-14-8-3-9-15-18/h1-15H",Triphenyl phosphate,KEGG COMPOUND accession,C14235
1349,35035,triphenylsilanol,An organosilanol in which silicon is bonded to a single hydroxy function and to three phenyl groups.,"InChI=1S/C18H16OSi/c19-20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h1-15,19H",Triphenylsilanol,CAS Registry Number,791-31-1
1350,34653,Congo Red,An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.,"InChI=1S/C32H24N6O6S2.2Na/c33-31-25-7-3-1-5-23(25)29(45(39,40)41)17-27(31)37-35-21-13-9-19(10-14-21)20-11-15-22(16-12-20)36-38-28-18-30(46(42,43)44)24-6-2-4-8-26(24)32(28)34;;/h1-18H,33-34H2,(H,39,40,41)(H,42,43,44);;/q;2*+1/p-2",Congo red,KEGG COMPOUND accession,C14078
1351,36792,(R)-citalopram,"A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has R-configuration at the chiral centre. It is the inactive enantiomer of citalopram.","InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m1/s1","(1R)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile",Beilstein Registry Number,9001443
1352,34785,heptachlor,"A cyclodiene organochlorine insecticide that is 3a,4,7,7a-tetrahydro-1H-4,7-methanoindene substituted by chlorine atoms at positions 1, 4, 5, 6, 7, 8 and 8. Formerly used to kill termites, ants and other insects in agricultural and domestic situations.","InChI=1S/C10H5Cl7/c11-4-2-1-3-5(4)9(15)7(13)6(12)8(3,14)10(9,16)17/h1-5H",Heptachlor,KEGG COMPOUND accession,C14185
1353,34757,fenitrothion,"An organic thiophosphate that is O,O-dimethyl O-phenyl phosphorothioate substituted by a methyl group at position 3 and a nitro group at position 4.","InChI=1S/C9H12NO5PS/c1-7-6-8(4-5-9(7)10(11)12)15-16(17,13-2)14-3/h4-6H,1-3H3",Fenitrothion,KEGG COMPOUND accession,C14442
1354,34665,debrisoquin,,"InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)",Debrisoquin,KEGG COMPOUND accession,C13650
1355,34666,decachlorobiphenyl,A polychlorobiphenyl that is biphenyl in which all of the hydrogens are replaced by chlorines.,InChI=1S/C12Cl10/c13-3-1(4(14)8(18)11(21)7(3)17)2-5(15)9(19)12(22)10(20)6(2)16,Decachlorobiphenyl,CAS Registry Number,2051-24-3
1356,34682,diazinon,"A member of the class of  pyrimidines that is pyrimidine carrying an isopropyl group at position 2, a methyl group at position 6 and a (diethoxyphosphorothioyl)oxy group at position 4.","InChI=1S/C12H21N2O3PS/c1-6-15-18(19,16-7-2)17-11-8-10(5)13-12(14-11)9(3)4/h8-9H,6-7H2,1-5H3",Diazinon,KEGG COMPOUND accession,C14324
1357,34690,dichlorvos,"An alkenyl phosphate that is the 2,2-dichloroethenyl ester of dimethyl phosphate.","InChI=1S/C4H7Cl2O4P/c1-8-11(7,9-2)10-3-4(5)6/h3H,1-2H3",Dichlorvos,KEGG COMPOUND accession,C14430
1358,34691,dicloxacillin sodium,,"InChI=1S/C19H17Cl2N3O5S.Na/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24;/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28);/q;+1/p-1/t13-,14+,17-;/m1./s1",Dicloxacillin sodium,KEGG COMPOUND accession,C13756
1359,34698,diethyl phthalate,"The diethyl ester of benzene-1,2-dicarboxylic acid.","InChI=1S/C12H14O4/c1-3-15-11(13)9-7-5-6-8-10(9)12(14)16-4-2/h5-8H,3-4H2,1-2H3",Diethyl phthalate,KEGG COMPOUND accession,C14175
1360,36012,"trans-stilbene-4,4'-diol",,"InChI=1S/C14H12O2/c15-13-7-3-11(4-8-13)1-2-12-5-9-14(16)10-6-12/h1-10,15-16H/b2-1+","4,4'-(E)-ethene-1,2-diyldiphenol",Gmelin Registry Number,2250544
1361,34202,"2,2',4,4',5,5'-hexachlorobiphenyl",,InChI=1S/C12H4Cl6/c13-7-3-11(17)9(15)1-5(7)6-2-10(16)12(18)4-8(6)14/h1-4H,"2,2',4,4',5,5'-Hexachlorobiphenyl",Beilstein Registry Number,1990497
1362,34219,"2,3,4,5,6-pentachlorobiphenyl",,InChI=1S/C12H5Cl5/c13-8-7(6-4-2-1-3-5-6)9(14)11(16)12(17)10(8)15/h1-5H,"2,3,4,5,6-Pentachlorobiphenyl",Beilstein Registry Number,2056539
1363,34221,"2,3,4,5-tetrachlorobiphenyl",,InChI=1S/C12H6Cl4/c13-9-6-8(7-4-2-1-3-5-7)10(14)12(16)11(9)15/h1-6H,"2,3,4,5-Tetrachlorobiphenyl",Beilstein Registry Number,1971826
1364,34905,paraquat,"An organic cation that consists of 4,4'-bipyridine bearing two N-methyl substituents loctated at the 1- and 1'-positions.","InChI=1S/C12H14N2/c1-13-7-3-11(4-8-13)12-5-9-14(2)10-6-12/h3-10H,1-2H3/q+2",Paraquat,CAS Registry Number,4685-14-7
1365,34911,permethrin,"A cyclopropanecarboxylate ester in which the esterifying alcohol is 3-phenoxybenzyl alcohol and the cyclopropane ring is substituted with a 2,2-dichlorovinyl group and with gem-dimethyl groups.","InChI=1S/C21H20Cl2O3/c1-21(2)17(12-18(22)23)19(21)20(24)25-13-14-7-6-10-16(11-14)26-15-8-4-3-5-9-15/h3-12,17,19H,13H2,1-2H3",Permethrin,KEGG COMPOUND accession,C14388
1366,34921,phthalocyanine,"A tetrapyrrole fundamental parent that consists of four isoindole-type units, with the connecting carbon atoms in the macrocycle replaced by nitrogen.","InChI=1S/C32H18N8/c1-2-10-18-17(9-1)25-33-26(18)38-28-21-13-5-6-14-22(21)30(35-28)40-32-24-16-8-7-15-23(24)31(36-32)39-29-20-12-4-3-11-19(20)27(34-29)37-25/h1-16H,(H2,33,34,35,36,37,38,39,40)",Phthalocyanine,KEGG COMPOUND accession,C14077
1367,35097,sec-butylbenzene,An alkylbenzene that is benzene substituted by a butan-2-yl group.,"InChI=1S/C10H14/c1-3-9(2)10-7-5-4-6-8-10/h4-9H,3H2,1-2H3",sec-Butylbenzene,KEGG COMPOUND accession,C14142
1368,34269,2-chlorobiphenyl,A monochlorobiphenyl carrying a single chloro substituent at position 2.,InChI=1S/C12H9Cl/c13-12-9-5-4-8-11(12)10-6-2-1-3-7-10/h1-9H,2-Chlorobiphenyl,KEGG COMPOUND accession,C14353
1369,34287,2-hydroxydibenzofuran,,"InChI=1S/C12H8O2/c13-8-5-6-12-10(7-8)9-3-1-2-4-11(9)14-12/h1-7,13H",2-Hydroxydibenzofuran,KEGG COMPOUND accession,C14409
1370,40237,sitagliptin,A  triazolopyrazine that exhibits  hypoglycemic activity.,"InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1","(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE",PDBeChem accession,715
1371,40678,anthracen-1-amine,,"InChI=1S/C14H11N/c15-14-7-3-6-12-8-10-4-1-2-5-11(10)9-13(12)14/h1-9H,15H2",ANTHRACEN-1-YLAMINE,PDBeChem accession,ANC
1372,37276,(1-hydroxycyclohexyl)acetic acid,A 3-hydroxy monocarboxylic acid consisting of cyclohexane carrying carboxymethyl and hydroxy substituents both at the 1-position.,"InChI=1S/C8H14O3/c9-7(10)6-8(11)4-2-1-3-5-8/h11H,1-6H2,(H,9,10)",1-hydroxycyclohexaneacetic acid,Beilstein Registry Number,2207501
1373,34250,anthraflavic acid,A  dihydroxyanthraquinone that is anthracene substituted by hydroxy groups at C-3 and C-7 and oxo groups at C-9 and C-10.,"InChI=1S/C14H8O4/c15-7-1-3-9-11(5-7)14(18)10-4-2-8(16)6-12(10)13(9)17/h1-6,15-16H","2,6-Dihydroxyanthraquinone",KEGG COMPOUND accession,C14267
1374,34703,diflubenzuron,"A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group.","InChI=1S/C14H9ClF2N2O2/c15-8-4-6-9(7-5-8)18-14(21)19-13(20)12-10(16)2-1-3-11(12)17/h1-7H,(H2,18,19,20,21)",Diflubenzuron,KEGG COMPOUND accession,C14427
1375,35026,triethylamine,A tertiary amine that is ammonia in which each hydrogen atom is substituted by an ethyl group.,"InChI=1S/C6H15N/c1-4-7(5-2)6-3/h4-6H2,1-3H3",Triethylamine,KEGG COMPOUND accession,C14691
1376,34871,N-hydroxynaphthalen-1-amine,,"InChI=1S/C10H9NO/c12-11-10-7-3-5-8-4-1-2-6-9(8)10/h1-7,11-12H",N-Hydroxy-1-aminonaphthalene,KEGG COMPOUND accession,C14789
1377,35101,trans-stilben-4-ol,,"InChI=1S/C14H12O/c15-14-10-8-13(9-11-14)7-6-12-4-2-1-3-5-12/h1-11,15H/b7-6+",trans-4-Hydroxystilbene,Gmelin Registry Number,2148597
1378,34338,biphenyl-3-ol,A member of the class of hydroxybiphenyls that is phenol in which the hydrogen at position 3 has been replaced by a phenyl group.,"InChI=1S/C12H10O/c13-12-8-4-7-11(9-12)10-5-2-1-3-6-10/h1-9,13H",3-Hydroxybiphenyl,KEGG COMPOUND accession,C14342
1379,34342,3-methylcholanthrene,A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.,"InChI=1S/C21H16/c1-13-6-7-15-12-20-17-5-3-2-4-14(17)8-9-18(20)19-11-10-16(13)21(15)19/h2-9,12H,10-11H2,1H3",3-Methylcholanthrene,KEGG COMPOUND accession,C14470
1380,34361,4'-hydroxyflavanone,,"InChI=1S/C15H12O3/c16-11-7-5-10(6-8-11)15-9-13(17)12-3-1-2-4-14(12)18-15/h1-8,15-16H,9H2",4'-Hydroxyflavanone,KEGG COMPOUND accession,C14241
1381,34364,"4,4'-dichlorobiphenyl",A dichlorobiphenyl carrying chloro groups at positions 4 and 4' respectively.,InChI=1S/C12H8Cl2/c13-11-5-1-9(2-6-11)10-3-7-12(14)8-4-10/h1-8H,"4,4'-Dichlorobiphenyl",KEGG COMPOUND accession,C14248
1382,34367,"biphenyl-4,4'-diol",A member of the class of hydroxybiphenyls that is biphenyl with hydroxy groups at positions 4 and 4'.,"InChI=1S/C12H10O2/c13-11-5-1-9(2-6-11)10-3-7-12(14)8-4-10/h1-8,13-14H","4,4'-Dihydroxybiphenyl",CAS Registry Number,92-88-6
1383,34385,4-aminopyridine,"An aromatic amine that is pyridine bearing a single amino substituent at position 4. An orphan drug in the US, it is used to improve walking in adults with multiple sclerosis.","InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)",4-Aminopyridine,CAS Registry Number,504-24-5
1384,34422,biphenyl-4-ol,A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4.,"InChI=1S/C12H10O/c13-12-8-6-11(7-9-12)10-4-2-1-3-5-10/h1-9,13H",4-Hydroxybiphenyl,KEGG COMPOUND accession,C14224
1385,34440,4-nonylphenol,A member of the class of phenols that is phenol which is para-substituted with a nonyl group.,"InChI=1S/C15H24O/c1-2-3-4-5-6-7-8-9-14-10-12-15(16)13-11-14/h10-13,16H,2-9H2,1H3",4-n-Nonylphenol,KEGG COMPOUND accession,C14550
1386,34718,"1-chloro-2,4-dinitrobenzene",A C-nitro compound that is chlorobenzene carrying a nitro substituent at each of the 2- and 4-positions.,InChI=1S/C6H3ClN2O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H,Dinitrochlorobenzene,KEGG COMPOUND accession,C14397
1387,34483,7-hydroxyflavanone,A monohydroxyflavanone that is flavanone substituted by a hydroxy group at position 7.,"InChI=1S/C15H12O3/c16-11-6-7-12-13(17)9-14(18-15(12)8-11)10-4-2-1-3-5-10/h1-8,14,16H,9H2",7-Hydroxyflavanone,CAS Registry Number,6515-36-2
1388,34488,"(Z,Z,Z)-icosa-8,11,14-trienoylethanolamide",,"InChI=1S/C22H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,24H,2-5,8,11,14-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-","8,11,14-Eicosatrienoylethanolamide",KEGG COMPOUND accession,C13828
1389,34873,N-nitrosodiethylamine,A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.,"InChI=1S/C4H10N2O/c1-3-6(4-2)5-7/h3-4H2,1-2H3",N-Nitrosodiethylamine,KEGG COMPOUND accession,C14422
1390,34260,anthracen-2-amine,,"InChI=1S/C14H11N/c15-14-6-5-12-7-10-3-1-2-4-11(10)8-13(12)9-14/h1-9H,15H2",2-Anthramine,KEGG COMPOUND accession,C14417
1391,32149,sodium sulfate,,"InChI=1S/2Na.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2",Sodium sulfate,KEGG COMPOUND accession,C13199
1392,31225,antipyrine,"A  pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.","InChI=1S/C11H12N2O/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10/h3-8H,1-2H3",Antipyrine,KEGG COMPOUND accession,C13244
1393,34071,1-arachidonoyl-sn-glycerol,A 1-acyl-sn-glycerol where arachidonoyl forms the 1-acyl group.,"InChI=1S/C23H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)27-21-22(25)20-24/h6-7,9-10,12-13,15-16,22,24-25H,2-5,8,11,14,17-21H2,1H3/b7-6-,10-9-,13-12-,16-15-/t22-/m0/s1",1-Arachidonoylglycerol,Beilstein Registry Number,9806383
1394,34073,Delta(1)-progesterone,A 3-oxo Delta(4)-steroid that is progesterone which has been oxidised to introduce a double bond between positions 1 and 2.,"InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h8,10,12,16-19H,4-7,9,11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1",1-Dehydroprogesterone,KEGG COMPOUND accession,C14677
1395,34024,"1,1,1,2-tetrachloroethane",,"InChI=1S/C2H2Cl4/c3-1-2(4,5)6/h1H2","1,1,1,2-Tetrachloroethane",Gmelin Registry Number,404970
1396,34025,"1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane",,"InChI=1S/C14H11Cl3O2/c15-14(16,17)13(9-1-5-11(18)6-2-9)10-3-7-12(19)8-4-10/h1-8,13,18-19H","1,1,1-Trichloro-2,2-bis(4-hydroxyphenyl)ethane",KEGG COMPOUND accession,C14136
1397,34043,"1,2-phenylenediamine",A phenylenediamine in which the two amino groups are ortho to each other.,"InChI=1S/C6H8N2/c7-5-3-1-2-4-6(5)8/h1-4H,7-8H2","1,2-Diaminobenzene",KEGG COMPOUND accession,C14402
1398,34047,"1,2-dihydrostilbene","A diphenylethane that is the 1,2-dihydro derivative of stilbene.","InChI=1S/C14H14/c1-3-7-13(8-4-1)11-12-14-9-5-2-6-10-14/h1-10H,11-12H2","1,2-Dihydrostilbene",KEGG COMPOUND accession,C14685
1399,34052,"1,2-dimethylnaphthalene",A dimethylnaphthalene carrying methyl groups at positions 1 and 2.,"InChI=1S/C12H12/c1-9-7-8-11-5-3-4-6-12(11)10(9)2/h3-8H,1-2H3","1,2-Dimethylnaphthalene",KEGG COMPOUND accession,C14329
1400,34053,"1,2-dinitrobenzene",,InChI=1S/C6H4N2O4/c9-7(10)5-3-1-2-4-6(5)8(11)12/h1-4H,"1,2-Dinitrobenzene",KEGG COMPOUND accession,C14702
1401,34591,bromodichloromethane,A halomethane that is dichloromethane in which oneof the hydrogens has been replaced by a bromine atom. It occurs as a contaminant in drinking water.,InChI=1S/CHBrCl2/c2-1(3)4/h1H,Bromodichloromethane,KEGG COMPOUND accession,C14708
1402,34611,carbofuran,,"InChI=1S/C12H15NO3/c1-12(2)7-8-5-4-6-9(10(8)16-12)15-11(14)13-3/h4-6H,7H2,1-3H3,(H,13,14)",Carbofuran,KEGG COMPOUND accession,C14291
1403,34623,chlordane,,"InChI=1S/C10H6Cl8/c11-3-1-2-4(5(3)12)9(16)7(14)6(13)8(2,15)10(9,17)18/h2-5H,1H2",Chlordane,KEGG COMPOUND accession,C14176
1404,34795,3-isobutyl-1-methyl-7H-xanthine,,"InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)",IBMX,KEGG COMPOUND accession,C13708
1405,34837,methidathion,,"InChI=1S/C6H11N2O4PS3/c1-10-5-7-8(6(9)16-5)4-15-13(14,11-2)12-3/h4H2,1-3H3",Methidathion,KEGG COMPOUND accession,C14431
1406,34838,metholone,,"InChI=1S/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1",Metholone,KEGG COMPOUND accession,C14605
1407,34839,methoprene,,"InChI=1S/C19H34O3/c1-15(2)22-18(20)14-17(4)11-8-10-16(3)12-9-13-19(5,6)21-7/h8,11,14-16H,9-10,12-13H2,1-7H3/b11-8+,17-14+",Methoprene,KEGG COMPOUND accession,C14308
1408,34852,mirex,,"InChI=1S/C10Cl12/c11-1-2(12)7(17)4(14)3(13,5(1,15)9(7,19)20)6(1,16)10(21,22)8(2,4)18",Mirex,KEGG COMPOUND accession,C14184
1409,34063,"naphthalene-1,4-diol",,"InChI=1S/C10H8O2/c11-9-5-6-10(12)8-4-2-1-3-7(8)9/h1-6,11-12H","1,4-Dihydroxynaphthalene",Beilstein Registry Number,1307689
1410,34065,"1,6-dimethylnaphthalene",,"InChI=1S/C12H12/c1-9-6-7-12-10(2)4-3-5-11(12)8-9/h3-8H,1-2H3","1,6-Dimethylnaphthalene",KEGG COMPOUND accession,C14217
1411,34159,"15-deoxy-Delta(12,14)-prostaglandin J2",A prostaglandin J derivative comprising prostaglandin J2 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions.,"InChI=1S/C20H28O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h6-7,9-10,13,15-17H,2-5,8,11-12,14H2,1H3,(H,22,23)/b9-7-,10-6+,18-13+/t17-/m0/s1","15-Deoxy-delta-12,14-PGJ2",LIPID MAPS instance accession,LMFA03010021
1412,34326,"3,5-dichlorobiphenyl","A dichlorobiphenyl that is 1,3-dichlorobenzene in which the hydrogen at position 5 has been replaced by a phenyl group.",InChI=1S/C12H8Cl2/c13-11-6-10(7-12(14)8-11)9-4-2-1-3-5-9/h1-8H,"3,5-Dichlorobiphenyl",KEGG COMPOUND accession,C14356
1413,34223,"2,3,5,6-tetrachloro-1,1'-biphenyl-4,4'-diol","A tetrachlorobenzene formed formally by chlorination of biphenyl-4,4'-diol at C-2, -3, -5 and -6.","InChI=1S/C12H6Cl4O2/c13-8-7(5-1-3-6(17)4-2-5)9(14)11(16)12(18)10(8)15/h1-4,17-18H","2,3,5,6-Tetrachloro-4,4'-biphenyldiol",CAS Registry Number,100702-98-5
1414,34304,fenobucarb,A carbamate ester obtained by the formal condensation of 2-sec-butylphenol with methylcarbamic acid.,"InChI=1S/C12H17NO2/c1-4-9(2)10-7-5-6-8-11(10)15-12(14)13-3/h5-9H,4H2,1-3H3,(H,13,14)",2-sec-Butylphenyl N-methylcarbamate,KEGG COMPOUND accession,C14425
1415,34232,"2,4'-dichlorobiphenyl",A dichlorobiphenyl that is chlorobenzene in which the hydrogen at position 2 has been replaced by a 4-chlorophenyl group.,InChI=1S/C12H8Cl2/c13-10-7-5-9(6-8-10)11-3-1-2-4-12(11)14/h1-8H,"2,4'-Dichlorobiphenyl",KEGG COMPOUND accession,C14246
1416,34251,"2,6-dimethylnaphthalene",A dimethylnaphthalene carrying methyl groups at positions 2 and 6.,"InChI=1S/C12H12/c1-9-3-5-12-8-10(2)4-6-11(12)7-9/h3-8H,1-2H3","2,6-Dimethylnaphthalene",KEGG COMPOUND accession,C14330
1417,34317,"3,3',4,4',5-pentachlorobiphenyl","A pentachlorobiphenyl in which the chlorines are located at the 3, 4, 5, 3', and 4' positions.",InChI=1S/C12H5Cl5/c13-8-2-1-6(3-9(8)14)7-4-10(15)12(17)11(16)5-7/h1-5H,"3,3',4,4',5-Pentachlorobiphenyl",KEGG COMPOUND accession,C14573
1418,32139,sodium hydrogencarbonate,,"InChI=1S/CH2O3.Na/c2-1(3)4;/h(H2,2,3,4);/q;+1/p-1",Sodium bicarbonate,CAS Registry Number,144-55-8
1419,32185,tazettine,,"InChI=1S/C18H21NO5/c1-19-9-18(20)17(4-3-12(21-2)6-16(17)19)13-7-15-14(22-10-23-15)5-11(13)8-24-18/h3-5,7,12,16,20H,6,8-10H2,1-2H3/t12-,16+,17+,18-/m1/s1",Tazettine,KEGG COMPOUND accession,C12179
1420,31459,"3,7,12-trioxo-5beta-cholanic acid","An oxo-5beta-cholanic acid in which three oxo substituents are located at positions 3, 7 and 12 on the cholanic acid skeleton.","InChI=1S/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,22+,23+,24-/m1/s1",Dehydrocholic acid,KEGG COMPOUND accession,C13154
1421,31389,chelidonine,,"InChI=1S/C20H19NO5/c1-21-7-13-11(2-3-15-20(13)26-9-23-15)18-14(22)4-10-5-16-17(25-8-24-16)6-12(10)19(18)21/h2-3,5-6,14,18-19,22H,4,7-9H2,1H3/t14-,18-,19+/m0/s1",Chelidonine,KEGG COMPOUND accession,C12242
1422,31530,edaravone,"A pyrazolone that is 2,4-dihydro-3H-pyrazol-3-one which is substituted at positions 2 and 5 by phenyl and methyl groups, respectively.","InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3",Edaravone,KEGG COMPOUND accession,C13008
1423,31328,butyl acetate,The acetate ester of butanol.,"InChI=1S/C6H12O2/c1-3-4-5-8-6(2)7/h3-5H2,1-2H3",Butyl acetate,KEGG COMPOUND accession,C12304
1424,31697,indolin-2-one,An indolinone carrying an oxo group at position 2.,"InChI=1S/C8H7NO/c10-8-5-6-3-1-2-4-7(6)9-8/h1-4H,5H2,(H,9,10)",Indolin-2-one,KEGG COMPOUND accession,C12312
1425,31788,luteolin 7-O-neohesperidoside,A disaccharide derivative that is luteolin  substituted by a 2-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.,"InChI=1S/C27H30O15/c1-9-20(33)22(35)24(37)26(38-9)42-25-23(36)21(34)18(8-28)41-27(25)39-11-5-14(31)19-15(32)7-16(40-17(19)6-11)10-2-3-12(29)13(30)4-10/h2-7,9,18,20-31,33-37H,8H2,1H3/t9-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1",Luteolin 7-O-neohesperidoside,KEGG COMPOUND accession,C12630
1426,31676,hydrocortisone caproate,The 21-O-hexanoyl derivative of hydrocortisone.,"InChI=1S/C27H40O6/c1-4-5-6-7-23(31)33-16-22(30)27(32)13-11-20-19-9-8-17-14-18(28)10-12-25(17,2)24(19)21(29)15-26(20,27)3/h14,19-21,24,29,32H,4-13,15-16H2,1-3H3/t19-,20-,21-,24+,25-,26-,27-/m0/s1",Hydrocortisone caproate,KEGG COMPOUND accession,C13422
1427,31725,isoamyl acetate,The acetate ester of isoamylol.,"InChI=1S/C7H14O2/c1-6(2)4-5-9-7(3)8/h6H,4-5H2,1-3H3",Isoamyl acetate,KEGG COMPOUND accession,C12296
1428,31746,kainic acid,,"InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1",Kainic acid,KEGG COMPOUND accession,C12819
1429,31751,kinamycin D,,"InChI=1S/C22H18N2O9/c1-7(25)32-20-15-13(19(30)21(22(20,3)31)33-8(2)26)12-14(16(15)24-23)18(29)11-9(17(12)28)5-4-6-10(11)27/h4-6,19-21,27,30-31H,1-3H3/t19-,20+,21+,22+/m0/s1",Kinamycin D,KEGG COMPOUND accession,C12394
1430,31085,2-methylserotonin,,"InChI=1S/C11H14N2O/c1-7-9(4-5-12)10-6-8(14)2-3-11(10)13-7/h2-3,6,13-14H,4-5,12H2,1H3",2-Methyl-5-hydroxytryptamine,KEGG COMPOUND accession,C13665
1431,34556,bendiocarb,,"InChI=1S/C11H13NO4/c1-11(2)15-8-6-4-5-7(9(8)16-11)14-10(13)12-3/h4-6H,1-3H3,(H,12,13)",Bendiocarb,KEGG COMPOUND accession,C14433
1432,34680,dipentyl phthalate,"A  phthalate ester that is the dipentyl ester of benzene-1,2-dicarboxylic acid.","InChI=1S/C18H26O4/c1-3-5-9-13-21-17(19)15-11-7-8-12-16(15)18(20)22-14-10-6-4-2/h7-8,11-12H,3-6,9-10,13-14H2,1-2H3",Di-n-pentyl phthalate,KEGG COMPOUND accession,C14300
1433,32783,tyrosinyl radical,,"InChI=1S/C9H10NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8H,5,10H2,(H,12,13)",tyrosine radical,Beilstein Registry Number,2941069
1434,32787,tyrosinyl radical cation,,"InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/q+1",tyrosine cation radical,Beilstein Registry Number,8630624
1435,32076,zinc pyrithione,,"InChI=1S/2C5H5NOS.Zn/c2*7-6-4-2-1-3-5(6)8;/h2*1-4,8H;/q;;+2/p-2",Pyrithione zinc,KEGG COMPOUND accession,C13427
1436,32082,quercetin 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside,A quercetin O-glucoside that is quercetin attached to a beta-D-sophorosyl residue at position 3 via a glycosidic linkage.,"InChI=1S/C27H30O17/c28-6-14-17(34)20(37)22(39)26(41-14)44-25-21(38)18(35)15(7-29)42-27(25)43-24-19(36)16-12(33)4-9(30)5-13(16)40-23(24)8-1-2-10(31)11(32)3-8/h1-5,14-15,17-18,20-22,25-35,37-39H,6-7H2/t14-,15-,17-,18-,20+,21+,22-,25-,26+,27+/m1/s1",Baimaside,KEGG COMPOUND accession,C12667
1437,32096,rhodomycin D,"An anthracycline that is aklavinone having a 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl residue attached at position 4 via a glycosidic linkage.","InChI=1S/C28H31NO11/c1-4-28(37)9-14(40-15-8-12(29)22(31)10(2)39-15)17-18(21(28)27(36)38-3)26(35)19-20(25(17)34)24(33)16-11(23(19)32)6-5-7-13(16)30/h5-7,10,12,14-15,21-22,30-31,34-35,37H,4,8-9,29H2,1-3H3/t10-,12-,14-,15-,21-,22+,28+/m0/s1",Rhodomycin D,KEGG COMPOUND accession,C12426
1438,30734,nicotine N(1')-oxide,A tertiary amine oxide resulting from the oxidation of the pyrrolidine nitrogen of nicotine.,"InChI=1S/C10H14N2O/c1-12(13)7-3-5-10(12)9-4-2-6-11-8-9/h2,4,6,8,10H,3,5,7H2,1H3",3-(1-methyl-1-oxidopyrrolidin-2-yl)pyridine,CAS Registry Number,63551-14-4
1439,32736,L-cysteinyl radical,A cysteinyl radical derived from L-cysteine.,"InChI=1S/C3H6NO2S/c4-2(1-7)3(5)6/h2H,1,4H2,(H,5,6)/t2-/m0/s1",L-cysteine radical,Beilstein Registry Number,4243259
1440,32150,sodium thiosulfate pentahydrate,A hydrate consisting of sodium thiosulfate with 5 mol eq. of water.,"InChI=1S/2Na.H2O3S2.5H2O/c;;1-5(2,3)4;;;;;/h;;(H2,1,2,3,4);5*1H2/q2*+1;;;;;;/p-2",Sodium thiosulfate,KEGG COMPOUND accession,C12488
1441,32160,sulbenicillin disodium,,"InChI=1S/C16H18N2O7S2.2Na/c1-16(2)11(15(21)22)18-13(20)9(14(18)26-16)17-12(19)10(27(23,24)25)8-6-4-3-5-7-8;;/h3-7,9-11,14H,1-2H3,(H,17,19)(H,21,22)(H,23,24,25);;/q;2*+1/p-2/t9-,10?,11+,14-;;/m1../s1",Sulbenicillin disodium,CAS Registry Number,28002-18-8
1442,32170,sultamicillin tosylate,,"InChI=1S/C25H30N4O9S2.C7H8O3S/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18;1-6-2-4-7(5-3-6)11(8,9)10/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31);2-5H,1H3,(H,8,9,10)/t14-,15-,16-,17+,18+,21-;/m1./s1",Sultamicillin tosilate,KEGG COMPOUND accession,C13129
1443,30788,FADH(.),,"InChI=1S/C27H34N9O15P2/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H2,33,34,42,43)/t14-,15+,16+,19-,20+,21+,26+/m0/s1",flavin adenine dinucleotide semiquinone radical,Beilstein Registry Number,4112594
1444,32234,titanium dioxide,"A titanium oxide with the formula TiO2.  A naturally occurring oxide sourced from ilmenite, rutile and anatase, it has a wide range of applications.",InChI=1S/2O.Ti,Titanium dioxide,KEGG COMPOUND accession,C13409
1445,32253,transfluthrin,"A carboxylic ester obtained by formal condensation of 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid and 2,3,5,6-tetrafluorobenzyl alcohol.","InChI=1S/C15H12Cl2F4O2/c1-15(2)7(3-10(16)17)11(15)14(22)23-5-6-12(20)8(18)4-9(19)13(6)21/h3-4,7,11H,5H2,1-2H3/t7-,11+/m1/s1",Transfluthrin,KEGG COMPOUND accession,C13410
1446,32927,nonadecane,A straight-chain alkane with 19 carbon atoms. It has been found as a component of essential oils isolated from Artemisia armeniaca.,"InChI=1S/C19H40/c1-3-5-7-9-11-13-15-17-19-18-16-14-12-10-8-6-4-2/h3-19H2,1-2H3",nonadecane,CAS Registry Number,629-92-5
1447,31988,phenethyl acetate,The acetate ester of 2-phenylethanol.,"InChI=1S/C10H12O2/c1-9(11)12-8-7-10-5-3-2-4-6-10/h2-6H,7-8H2,1H3",Phenethyl acetate,KEGG COMPOUND accession,C12303
1448,31991,phenol red,"3H-2,1-Benzoxathiole 1,1-dioxide in which both of the hydrogens at position 3 have been substituted by 4-hydroxyphenyl groups. A pH indicator changing colour from yellow below pH 6.8 to bright pink above pH 8.2, it is commonly used as an indicator in cell cultures and in home swimming pool test kits. It is also used in the (now infrequently performed) phenolsulfonphthalein (PSP) test for estimation of overall blood flow through the kidney.","InChI=1S/C19H14O5S/c20-15-9-5-13(6-10-15)19(14-7-11-16(21)12-8-14)17-3-1-2-4-18(17)25(22,23)24-19/h1-12,20-21H",Phenolsulfonphthalein,KEGG COMPOUND accession,C12600
1449,32312,zinc sulfate heptahydrate,A hydrate that is the heptahydrate form of zinc sulfate.,"InChI=1S/H2O4S.7H2O.Zn/c1-5(2,3)4;;;;;;;;/h(H2,1,2,3,4);7*1H2;/q;;;;;;;;+2/p-2",Zinc sulfate,CAS Registry Number,7446-20-0
1450,32329,"cis-cyclohexane-1,2-diol","A cyclohexane-1,2-diol with cis-configuration.","InChI=1S/C6H12O2/c7-5-3-1-2-4-6(5)8/h5-8H,1-4H2/t5-,6+","cis-Cyclohexane-1,2-diol",KEGG COMPOUND accession,C12313
1451,32330,(+)-epitaxifolin,"A taxifolin that has (2S,3R)-configuration.","InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15-/m0/s1",cis-Dihydroquercetin,KEGG COMPOUND accession,C12316
1452,32333,"dTDP-5,5-di-C-methyl-beta-L-lyxose","A dTDP-sugar having 5,5-di-C-methyl-beta-L-lyxose as the sugar component.","InChI=1S/C17H28N2O15P2/c1-7-5-19(16(25)18-14(7)24)10-4-8(20)9(31-10)6-30-35(26,27)34-36(28,29)33-15-12(22)11(21)13(23)17(2,3)32-15/h5,8-13,15,20-23H,4,6H2,1-3H3,(H,26,27)(H,28,29)(H,18,24,25)/t8-,9+,10+,11-,12+,13+,15+/m0/s1",dTDP-5-dimethyl-L-lyxose,KEGG COMPOUND accession,C12481
1453,32336,dTDP-beta-L-vancosamine,A dTDP-sugar having beta-L-vancosamine as the sugar component.,"InChI=1S/C17H29N3O13P2/c1-8-6-20(16(24)19-15(8)23)12-4-10(21)11(31-12)7-29-34(25,26)33-35(27,28)32-13-5-17(3,18)14(22)9(2)30-13/h6,9-14,21-22H,4-5,7,18H2,1-3H3,(H,25,26)(H,27,28)(H,19,23,24)/t9-,10-,11+,12+,13+,14+,17-/m0/s1",dTDP-L-vancosamine,KEGG COMPOUND accession,C12322
1454,33722,tetra-mu3-sulfido-tetrairon(2+),,InChI=1S/4Fe.4S/q;;2*+1;;;;,[Fe4S4](2+),Gmelin Registry Number,82631
1455,32108,rubidium hydroxide,,InChI=1S/H2O.Rb/h1H2;/q;+1/p-1,Rubidium hydroxide,KEGG COMPOUND accession,C13515
1456,32109,(Z)-roxithromycin,A minor geometrical isomer of roxithromycin.,"InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31-/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1",Roxithromycin,KEGG COMPOUND accession,C13173
1457,32115,salvianin,,"InChI=1S/C42H40O24/c43-19-5-3-18(4-6-19)39-26(63-41-37(57)35(55)34(54)27(64-41)15-59-31(51)8-2-17-1-7-22(45)23(46)9-17)12-21-24(61-39)10-20(44)11-25(21)62-42-38(58)36(56)40(66-33(53)14-30(49)50)28(65-42)16-60-32(52)13-29(47)48/h1-12,27-28,34-38,40-42,54-58H,13-16H2,(H5-,43,44,45,46,47,48,49,50,51)/p+1/t27-,28-,34-,35+,36-,37-,38-,40-,41-,42-/m1/s1",Salvianin,KEGG COMPOUND accession,C12647
1458,32129,diamminesilver(1+) fluoride,,InChI=1S/Ag.FH.2H3N/h;1H;2*1H3/q+1;;;/p-1,Silver diammine fluoride,CAS Registry Number,34445-07-3
1459,32138,sodium acetate trihydrate,,"InChI=1S/C2H4O2.Na.3H2O/c1-2(3)4;;;;/h1H3,(H,3,4);;3*1H2/q;+1;;;/p-1",Sodium acetate trihydrate,CAS Registry Number,6131-90-4
1460,32145,sodium hydroxide,,InChI=1S/Na.H2O/h;1H2/q+1;/p-1,Sodium hydroxide,KEGG COMPOUND accession,C12569
1461,32197,tetracenomycin A2,,"InChI=1S/C23H18O8/c1-9-16-10(6-15(30-3)17(9)23(28)31-4)5-12-19(21(16)26)22(27)18-13(20(12)25)7-11(29-2)8-14(18)24/h5-8,24,26H,1-4H3",Tetracenomycin A2,KEGG COMPOUND accession,C12371
1462,32198,tetracenomycin B1,,"InChI=1S/C20H14O6/c1-8-3-10(21)4-9-5-12-17(19(24)15(8)9)20(25)16-13(18(12)23)6-11(26-2)7-14(16)22/h3-7,21-22,24H,1-2H3",Tetracenomycin B1,KEGG COMPOUND accession,C12377
1463,32199,tetracenomycin B2,,"InChI=1S/C22H16O8/c1-8-15-9(5-13(23)16(8)22(28)30-3)4-11-18(20(15)26)21(27)17-12(19(11)25)6-10(29-2)7-14(17)24/h4-7,23-24,26H,1-3H3",Tetracenomycin B2,KEGG COMPOUND accession,C12378
1464,32200,tetracenomycin B3,,"InChI=1S/C21H14O8/c1-7-14-8(4-12(22)15(7)21(27)28)3-10-17(19(14)25)20(26)16-11(18(10)24)5-9(29-2)6-13(16)23/h3-6,22-23,25H,1-2H3,(H,27,28)",Tetracenomycin B3,KEGG COMPOUND accession,C12369
1465,32203,tetracenomycin D3 methyl ester,,"InChI=1S/C21H14O8/c1-7-14-8(4-12(23)15(7)21(28)29-2)3-10-17(19(14)26)20(27)16-11(18(10)25)5-9(22)6-13(16)24/h3-6,22-24,26H,1-2H3",Tetracenomycin D3 methylester,KEGG COMPOUND accession,C12375
1466,32205,tetracenomycin F1,"A tetracenomycin that is 1-methyl-11-oxo-6,11-dihydrotetracene-2-carboxylic acid bearing four hydroxy substituents at positions 3, 8, 10 and 12.","InChI=1S/C20H14O7/c1-7-14-10(5-12(22)15(7)20(26)27)3-8-2-9-4-11(21)6-13(23)16(9)19(25)17(8)18(14)24/h3-6,21-24H,2H2,1H3,(H,26,27)",Tetracenomycin F1,KEGG COMPOUND accession,C12367
1467,32207,tetracenomycin F2,,"InChI=1S/C20H16O8/c1-8(21)16-10(4-13(23)7-15(25)26)2-9-3-11-5-12(22)6-14(24)17(11)20(28)18(9)19(16)27/h2,4-6,22-24,27H,3,7H2,1H3,(H,25,26)/b13-4+",Tetracenomycin F2,KEGG COMPOUND accession,C12366
1468,32208,tetracenomycin M,,"InChI=1S/C19H16O7/c1-19(26)6-9(21)2-7-3-10-14(18(25)15(7)19)17(24)13-11(16(10)23)4-8(20)5-12(13)22/h3-5,9,20-22,25-26H,2,6H2,1H3",Tetracenomycin M,KEGG COMPOUND accession,C12372
1469,32209,tetracenomycin X,,"InChI=1S/C24H20O11/c1-9-15-10(7-12(32-2)16(9)22(30)34-4)6-11-17(18(15)26)21(29)24(35-5)14(25)8-13(33-3)20(28)23(24,31)19(11)27/h6-8,26,31H,1-5H3/t23-,24-/m1/s1",Tetracenomycin X,KEGG COMPOUND accession,C12380
1470,32212,tetrangulol,"A member of the class of tetraphenes that is tetraphene-7,12-dione substituted by hydroxy groups at positions 1 and 8 and a methyl group at position 3.","InChI=1S/C19H12O4/c1-9-7-10-5-6-12-17(15(10)14(21)8-9)19(23)11-3-2-4-13(20)16(11)18(12)22/h2-8,20-21H,1H3",Tetrangulol,KEGG COMPOUND accession,C12397
1471,32215,thiamphenicol,,"InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1",Thiamphenicol,KEGG COMPOUND accession,C12853
1472,31136,5-hydroxyferuloyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 5-hydroxyferulic acid.,"InChI=1S/C31H44N7O20P3S/c1-31(2,26(44)29(45)34-7-6-20(40)33-8-9-62-21(41)5-4-16-10-17(39)23(42)18(11-16)53-3)13-55-61(51,52)58-60(49,50)54-12-19-25(57-59(46,47)48)24(43)30(56-19)38-15-37-22-27(32)35-14-36-28(22)38/h4-5,10-11,14-15,19,24-26,30,39,42-44H,6-9,12-13H2,1-3H3,(H,33,40)(H,34,45)(H,49,50)(H,51,52)(H2,32,35,36)(H2,46,47,48)/t19-,24-,25-,26+,30-/m1/s1",5-Hydroxyferuloyl-CoA,KEGG COMPOUND accession,C12203
1473,31457,decanal,A saturated fatty aldehyde formally arising from reduction of the carboxy group of capric acid (decanoic acid).,"InChI=1S/C10H20O/c1-2-3-4-5-6-7-8-9-10-11/h10H,2-9H2,1H3",Decanal,KEGG COMPOUND accession,C12307
1474,31461,dehydrorabelomycin,,"InChI=1S/C19H12O5/c1-8-5-9-7-13(22)16-17(14(9)12(21)6-8)18(23)10-3-2-4-11(20)15(10)19(16)24/h2-7,20-22H,1H3",Dehydrorabelomycin,KEGG COMPOUND accession,C12390
1475,31463,delphinidin 3-O-beta-D-glucoside,An anthocyanin cation consisting of delphinidin having a beta-D-glucosyl residue attached at the 3-hydroxy position.,"InChI=1S/C21H20O12/c22-6-15-17(28)18(29)19(30)21(33-15)32-14-5-9-10(24)3-8(23)4-13(9)31-20(14)7-1-11(25)16(27)12(26)2-7/h1-5,15,17-19,21-22,28-30H,6H2,(H4-,23,24,25,26,27)/p+1/t15-,17-,18+,19-,21-/m1/s1",Delphinidin 3-O-glucoside,KEGG COMPOUND accession,C12138
1476,31464,2-deoxyribose 5-triphosphate,A 2-deoxyribose triphosphate in which the triphosphate group is located at position 5.,"InChI=1S/C5H13O13P3/c6-3-1-5(7)16-4(3)2-15-20(11,12)18-21(13,14)17-19(8,9)10/h3-7H,1-2H2,(H,11,12)(H,13,14)(H2,8,9,10)/t3-,4+,5+/m0/s1",Deoxyribose triphosphate,KEGG COMPOUND accession,C12347
1477,32275,UDP-alpha-D-kanosamine,A UDP-amino sugar having alpha-D-kanosamine as the amino sugar component.,"InChI=1S/C15H25N3O16P2/c16-8-9(21)5(3-19)32-14(11(8)23)33-36(28,29)34-35(26,27)30-4-6-10(22)12(24)13(31-6)18-2-1-7(20)17-15(18)25/h1-2,5-6,8-14,19,21-24H,3-4,16H2,(H,26,27)(H,28,29)(H,17,20,25)/t5-,6-,8+,9-,10-,11-,12-,13-,14-/m1/s1",UDP-kanosamine,KEGG COMPOUND accession,C12211
1478,32279,urdamycin A,,"InChI=1S/C43H56O17/c1-18-25(44)8-10-32(55-18)60-43-30(46)16-41(5,52)17-42(43,53)13-12-24-35(43)40(51)23-7-6-22(38(49)34(23)39(24)50)28-15-29(37(48)21(4)54-28)59-31-11-9-27(19(2)56-31)58-33-14-26(45)36(47)20(3)57-33/h6-7,12-13,18-21,25-29,31-33,36-37,44-45,47-49,52-53H,8-11,14-17H2,1-5H3/t18-,19-,20+,21+,25-,26+,27-,28+,29+,31-,32-,33-,36+,37+,41-,42-,43-/m0/s1",Urdamycin A,KEGG COMPOUND accession,C12413
1479,31542,epidihydrocholesterin,A 5alpha-chloestane compound having a 3alpha-hydroxy substituent.,"InChI=1S/C27H48O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h18-25,28H,6-17H2,1-5H3/t19-,20+,21-,22+,23-,24+,25+,26+,27-/m1/s1",Epidihydrocholesterin,KEGG COMPOUND accession,C12978
1480,31547,eplerenone,,"InChI=1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1",Eplerenone,KEGG COMPOUND accession,C12512
1481,32350,n-decanohydroxamic acid,,"InChI=1S/C10H21NO2/c1-2-3-4-5-6-7-8-9-10(12)11-13/h13H,2-9H2,1H3,(H,11,12)",n-Decanohydroxamic acid,KEGG COMPOUND accession,C12889
1482,32354,4-hydroxybenzenesulfonic acid,An arenesulfonic acid that is phenol substituted by a sulfo group at C-4.,"InChI=1S/C6H6O4S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4,7H,(H,8,9,10)",p-Phenolsulfonic acid,KEGG COMPOUND accession,C12849
1483,32356,"2,3-dihydroxy-trans-cinnamic acid",,"InChI=1S/C9H8O4/c10-7-3-1-2-6(9(7)13)4-5-8(11)12/h1-5,10,13H,(H,11,12)/b5-4+","trans-2,3-Dihydroxycinnamate",KEGG COMPOUND accession,C12623
1484,31314,5-butyl-1-cyclohexylbarbituric acid,,"InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19)",Bucolome,CAS Registry Number,841-73-6
1485,31319,bufogenin,"A steroid lactone of Chan su (toad venom), a Chinese medicine obtained from the skin venom gland of toads. A specific Na/K-ATPase protein inhibitor, it is used as a cardiotonic and central nervous system (CNS) respiratory agent, an analgesic and anesthetic, and as a remedy for ulcers.","InChI=1S/C24H32O4/c1-22-9-7-16(25)11-15(22)4-5-18-17(22)8-10-23(2)19(12-20-24(18,23)28-20)14-3-6-21(26)27-13-14/h3,6,13,15-20,25H,4-5,7-12H2,1-2H3/t15-,16+,17+,18-,19-,20-,22+,23-,24-/m1/s1",Bufogenin,CAS Registry Number,465-39-4
1486,31325,butenafine hydrochloride,"The hydrochloride salt of butenafine. An inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, it is used for treatment of dermatological fungal infections.","InChI=1S/C23H27N.ClH/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20;/h5-15H,16-17H2,1-4H3;1H",Butenafine hydrochloride,KEGG COMPOUND accession,C12490
1487,31334,(E)-caffeyl alcohol,A caffeyl alcohol in which the double bond has E geochemistry.,"InChI=1S/C9H10O3/c10-5-1-2-7-3-4-8(11)9(12)6-7/h1-4,6,10-12H,5H2/b2-1+",Caffeyl alcohol,PubMed citation,14745009
1488,31336,calcium glycerophosphate,An organic calcium salt having glycerol 2-phosphate(2-) as the counterion.,"InChI=1S/C3H9O6P.Ca/c4-1-3(2-5)9-10(6,7)8;/h3-5H,1-2H2,(H2,6,7,8);/q;+2/p-2",Calcium Glycerophosphate,KEGG COMPOUND accession,C12935
1489,31338,calcium dibromide,,InChI=1S/2BrH.Ca/h2*1H;/q;;+2/p-2,Calcium bromide,KEGG COMPOUND accession,C13189
1490,31341,calcium dihydroxide,,InChI=1S/Ca.2H2O/h;2*1H2/q+2;;/p-2,Calcium hydroxide,KEGG COMPOUND accession,C12277
1491,31344,calcium oxide,A member of the class of calcium oxides of calcium and oxygen in a 1:1 ratio.,InChI=1S/Ca.O,Calcium oxide,KEGG COMPOUND accession,C13140
1492,31346,calcium sulfate,,"InChI=1S/Ca.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",Calcium sulfate,KEGG COMPOUND accession,C13194
1493,31642,gadodiamide hydrate,The hydrate of gadodiamide.,"InChI=1S/C16H29N5O8.Gd.H2O/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);;1H2/q;+3;/p-3",Gadodiamide hydrate,KEGG COMPOUND accession,C13106
1494,31358,carindacillin sodium,,"InChI=1S/C26H26N2O6S.Na/c1-26(2)20(24(31)32)28-22(30)19(23(28)35-26)27-21(29)18(15-7-4-3-5-8-15)25(33)34-17-12-11-14-9-6-10-16(14)13-17;/h3-5,7-8,11-13,18-20,23H,6,9-10H2,1-2H3,(H,27,29)(H,31,32);/q;+1/p-1/t18?,19-,20+,23-;/m1./s1",Carindacillin sodium,KEGG COMPOUND accession,C12712
1495,31699,myo-inositol hexanicotinate,,"InChI=1S/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H/t31-,32-,33-,34+,35-,36-",Inositol hexanicotinate,CAS Registry Number,6556-11-2
1496,31487,dihydro-alpha-ergocryptine mesylate,The methanesulfonic acid salt of dihydro-alpha-ergocryptine.,"InChI=1S/C32H43N5O5.CH4O3S/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20;1-5(2,3)4/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38);1H3,(H,2,3,4)/t20-,22-,24-,25+,26+,31-,32+;/m1./s1",Dihydro-alpha-ergocryptine mesylate,KEGG COMPOUND accession,C13167
1497,31580,ethynodiol diacetate,,"InChI=1S/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1",Ethynodiol diacetate,KEGG COMPOUND accession,C12724
1498,31595,iron tricyanide,,InChI=1S/3CN.Fe/c3*1-2;,Fe(CN)3,KEGG COMPOUND accession,C12217
1499,31793,magnesium carbonate,"A magnesium salt with formula CMgO3. Its hydrated forms, particularly the di-, tri-, and tetrahydrates occur as minerals.","InChI=1S/CH2O3.Mg/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2",Magnesium carbonate,CAS Registry Number,546-93-0
1500,31822,mercaptopurine hydrate,,"InChI=1S/C5H4N4S.H2O/c10-5-3-4(7-1-6-3)8-2-9-5;/h1-2H,(H2,6,7,8,9,10);1H2",Mercaptopurine hydrate,CAS Registry Number,6112-76-1
1501,31823,mercury dichloride,"A mercury coordination entity made up of linear triatomic molecules in which a mercury atom is bonded to two chlorines. Water-soluble, it is highly toxic. Once used in a wide variety of applications, including preserving wood and anatomical specimens, embalming and disinfecting, as an intensifier in photography, as a mordant for rabbit and beaver furs, and freeing gold from lead, its use has markedly declined as less toxic alternatives have been developed.",InChI=1S/2ClH.Hg/h2*1H;/q;;+2/p-2,Mercuric chloride,KEGG COMPOUND accession,C13377
1502,31832,methyl salicylate,A benzoate ester that is the methyl ester of salicylic acid.,"InChI=1S/C8H8O3/c1-11-8(10)6-4-2-3-5-7(6)9/h2-5,9H,1H3",Methyl 2-hydroxybenzoate,KEGG COMPOUND accession,C12305
1503,31648,(E)-geranyl formate,The formate ester of geraniol.,"InChI=1S/C11H18O2/c1-10(2)5-4-6-11(3)7-8-13-9-12/h5,7,9H,4,6,8H2,1-3H3/b11-7+",Geranyl formate,KEGG COMPOUND accession,C12294
1504,31923,novobiocic acid,A hydroxycoumarin that is the aglycone of novobiocin.,"InChI=1S/C22H21NO6/c1-11(2)4-5-13-10-14(6-8-17(13)25)21(27)23-18-19(26)15-7-9-16(24)12(3)20(15)29-22(18)28/h4,6-10,24-26H,5H2,1-3H3,(H,23,27)",Novobiocic acid,KEGG COMPOUND accession,C12474
1505,31927,nystatin A3,,"InChI=1S/C53H85NO20/c1-29-18-16-14-12-10-8-6-7-9-11-13-15-17-19-37(72-52-49(65)46(54)48(64)33(5)71-52)25-42-45(51(66)67)41(61)28-53(68,74-42)27-40(60)38(58)21-20-34(55)22-35(56)23-36(57)24-43(62)69-31(3)30(2)50(29)73-44-26-39(59)47(63)32(4)70-44/h6-7,9,11-19,29-42,44-50,52,55-61,63-65,68H,8,10,20-28,54H2,1-5H3,(H,66,67)/b7-6+,11-9+,14-12+,15-13+,18-16+,19-17+/t29-,30-,31-,32-,33+,34+,35+,36+,37-,38+,39+,40+,41-,42-,44?,45+,46-,47-,48+,49-,50+,52-,53+/m0/s1",nystatin A3,KEGG COMPOUND accession,C12156
1506,31885,N-acetyl-L-2-aminoadipic acid,An N-acetyl-L-amino acid consisting of L-2-aminoadipic acid carrying an N-acetyl substituent.,"InChI=1S/C8H13NO5/c1-5(10)9-6(8(13)14)3-2-4-7(11)12/h6H,2-4H2,1H3,(H,9,10)(H,11,12)(H,13,14)/t6-/m0/s1",N2-Acetyl-L-aminoadipate,KEGG COMPOUND accession,C12986
1507,31887,N-acetyl-L-2-aminoadipic acid 6-phosphate,An aminoacyl phosphate consisting of N-acetyl-L-2-aminoadipic acid having the phosphate group located at the 6-position.,"InChI=1S/C8H14NO8P/c1-5(10)9-6(8(12)13)3-2-4-7(11)17-18(14,15)16/h6H,2-4H2,1H3,(H,9,10)(H,12,13)(H2,14,15,16)/t6-/m0/s1",N2-Acetyl-L-aminoadipyl-delta-phosphate,KEGG COMPOUND accession,C12987
1508,31898,nedaplatin,,"InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1",Nedaplatin,KEGG COMPOUND accession,C12862
1509,31726,isoamyl formate,The formate ester of isoamylol.,"InChI=1S/C6H12O2/c1-6(2)3-4-8-5-7/h5-6H,3-4H2,1-2H3",Isoamyl formate,KEGG COMPOUND accession,C12293
1510,31742,kaempferol 3-O-beta-D-galactoside,"A beta-D-galactoside compound with a 4',5,7-trihydroxychromen-3-yl group at the anomeric position.","InChI=1S/C21H20O11/c22-7-13-15(26)17(28)18(29)21(31-13)32-20-16(27)14-11(25)5-10(24)6-12(14)30-19(20)8-1-3-9(23)4-2-8/h1-6,13,15,17-18,21-26,28-29H,7H2/t13-,15+,17+,18-,21+/m1/s1",Kaempferol 3-O-beta-D-galactoside,KEGG COMPOUND accession,C12626
1511,31753,leucomycin V,"A macrolide antibiotic produced by Streptomyces kitasatoensis, showing activity against a wide spectrum of pathogens.","InChI=1S/C35H59NO13/c1-19-16-23(14-15-37)31(32(44-8)25(39)17-26(40)45-20(2)12-10-9-11-13-24(19)38)49-34-29(41)28(36(6)7)30(21(3)47-34)48-27-18-35(5,43)33(42)22(4)46-27/h9-11,13,15,19-25,27-34,38-39,41-43H,12,14,16-18H2,1-8H3/b10-9+,13-11+/t19-,20-,21-,22+,23+,24+,25-,27+,28-,29-,30-,31+,32+,33+,34+,35-/m1/s1",Leucomycin V,KEGG COMPOUND accession,C13103
1512,32740,cysteinyl radical,An alpha-amino-acid radical derived from  cysteine.,"InChI=1S/C3H6NO2S/c4-2(1-7)3(5)6/h2H,1,4H2,(H,5,6)",cysteine radical,Beilstein Registry Number,1857275
1513,31997,"N,N-dimethylethanolamine phosphate","The N,N-dimethyl derivative of ethanolamine phosphate.","InChI=1S/C4H12NO4P/c1-5(2)3-4-9-10(6,7)8/h3-4H2,1-2H3,(H2,6,7,8)",Phosphodimethylethanolamine,KEGG COMPOUND accession,C13482
1514,32030,potassium bromide,A metal bromide salt with a K(+) counterion.,InChI=1S/BrH.K/h1H;/q;+1/p-1,Potassium bromide,KEGG COMPOUND accession,C13198
1515,32035,potassium hydroxide,,InChI=1S/K.H2O/h;1H2/q+1;/p-1,Potassium hydroxide,KEGG COMPOUND accession,C12568
1516,31028,(-)-epiafzelechin,"A catechin derivative having (2R,3R)-configuration.","InChI=1S/C15H14O5/c16-9-3-1-8(2-4-9)15-13(19)7-11-12(18)5-10(17)6-14(11)20-15/h1-6,13,15-19H,7H2/t13-,15-/m1/s1",(-)-Epiafzelechin,KEGG COMPOUND accession,C12128
1517,31030,(-)-tortuosamine,"5,6,7,8-Tetrahydroquinoline in whith the hydrogens at position 6 are substituted by a 3-azabutyl group and a 3,4-dimethoxyphenyl group. (S configuration). It is found in the herb kanna (Sceletium tortuosum).","InChI=1S/C20H26N2O2/c1-21-12-10-20(9-8-17-15(14-20)5-4-11-22-17)16-6-7-18(23-2)19(13-16)24-3/h4-7,11,13,21H,8-10,12,14H2,1-3H3/t20-/m1/s1",(-)-Tortuosamine,KEGG COMPOUND accession,C12260
1518,31035,"1,2-bis(4-hydroxyphenyl)propan-2-ol",,"InChI=1S/C15H16O3/c1-15(18,12-4-8-14(17)9-5-12)10-11-2-6-13(16)7-3-11/h2-9,16-18H,10H2,1H3","1,2-Bis(4-hydroxyphenyl)-2-propanol",KEGG COMPOUND accession,C13629
1519,31036,"4-[2-(allyloxy)vinyl]-1,2-dimethoxybenzene",,"InChI=1S/C13H16O3/c1-4-8-16-9-7-11-5-6-12(14-2)13(10-11)15-3/h4-7,9-10H,1,8H2,2-3H3/b9-7+","1,2-Dimethoxy-4-[2-(2-propenyloxy)ethenyl]-benzene",KEGG COMPOUND accession,C12263
1520,31039,"1,3-dimethylisoquinoline-6,8-diol","Isoquinoline in which the hydrogens at positions 6 and 8 are substituted by hydroxy groups, and those at positions 1 and 3 are substituted by methyl groups.","InChI=1S/C11H11NO2/c1-6-3-8-4-9(13)5-10(14)11(8)7(2)12-6/h3-5,13-14H,1-2H3","1,3-Dimethyl-6,8-isoquinolinediol",KEGG COMPOUND accession,C12345
1521,31958,pancracine,,"InChI=1S/C16H17NO4/c18-13-2-10-11-6-17(12(10)4-14(13)19)5-8-1-15-16(3-9(8)11)21-7-20-15/h1-3,11-14,18-19H,4-7H2/t11-,12-,13-,14-/m0/s1",Pancracine,KEGG COMPOUND accession,C12186
1522,31965,pelargonidin 3-O-(6-O-malonyl-beta-D-glucoside),An anthocyanin cation consisting of pelargonidin having a 6-O-malonyl-beta-D-glucosyl residue attached at the 3-hydroxy position.,"InChI=1S/C24H22O13/c25-11-3-1-10(2-4-11)23-16(7-13-14(27)5-12(26)6-15(13)35-23)36-24-22(33)21(32)20(31)17(37-24)9-34-19(30)8-18(28)29/h1-7,17,20-22,24,31-33H,8-9H2,(H3-,25,26,27,28,29)/p+1/t17-,20-,21+,22-,24-/m1/s1",Pelargonidin 3-O-(6-O-malonyl-beta-D-glucoside),KEGG COMPOUND accession,C12642
1523,31966,pelargonidin 3-O-(6-O-caffeoyl-beta-D-glucoside) 5-O-beta-D-glucoside,,"InChI=1S/C36H36O18/c37-13-25-28(43)30(45)32(47)35(53-25)51-23-11-18(39)10-22-19(23)12-24(34(50-22)16-3-5-17(38)6-4-16)52-36-33(48)31(46)29(44)26(54-36)14-49-27(42)8-2-15-1-7-20(40)21(41)9-15/h1-12,25-26,28-33,35-37,43-48H,13-14H2,(H3-,38,39,40,41,42)/p+1/t25-,26-,28-,29-,30+,31+,32-,33-,35-,36-/m1/s1",Pelargonidin 3-O-(6-caffeoyl-beta-D-glucoside) 5-O-beta-D-glucoside,KEGG COMPOUND accession,C12640
1524,31967,pelargonidin 3-O-beta-D-glucoside,An anthocyanin cation consisting of pelargonidin having a beta-D-glucosyl residue attached at the 3-hydroxy position.,"InChI=1S/C21H20O10/c22-8-16-17(26)18(27)19(28)21(31-16)30-15-7-12-13(25)5-11(24)6-14(12)29-20(15)9-1-3-10(23)4-2-9/h1-7,16-19,21-22,26-28H,8H2,(H2-,23,24,25)/p+1/t16-,17-,18+,19-,21-/m1/s1",Pelargonidin 3-O-glucoside,KEGG COMPOUND accession,C12137
1525,31968,pelargonidin 3-O-rutinoside,An anthocyanin cation consisting of pelargonidin having a rutinosyl [6-deoxy-alpha-L-mannosyl-(1->6)-beta-D-glucosyl] residue attached at the 3-hydroxy position.,"InChI=1S/C27H30O14/c1-10-19(31)21(33)23(35)26(38-10)37-9-18-20(32)22(34)24(36)27(41-18)40-17-8-14-15(30)6-13(29)7-16(14)39-25(17)11-2-4-12(28)5-3-11/h2-8,10,18-24,26-27,31-36H,9H2,1H3,(H2-,28,29,30)/p+1/t10-,18+,19-,20+,21+,22-,23+,24+,26+,27+/m0/s1",Pelargonidin 3-O-rutinoside,KEGG COMPOUND accession,C12644
1526,31969,pelargonidin 3-O-rutinoside 5-O-beta-D-glucoside,An anthocyanin cation consisting of pelargonidin having a rutinosyl [6-deoxy-alpha-L-mannosyl-(1->6)-beta-D-glucosyl] residue attached at the 3-hydroxy position and a beta-D-glucosyl residue at the 5-hydroxy position.,"InChI=1S/C33H40O19/c1-11-21(37)24(40)27(43)31(47-11)46-10-20-23(39)26(42)29(45)33(52-20)50-18-8-15-16(48-30(18)12-2-4-13(35)5-3-12)6-14(36)7-17(15)49-32-28(44)25(41)22(38)19(9-34)51-32/h2-8,11,19-29,31-34,37-45H,9-10H2,1H3,(H-,35,36)/p+1/t11-,19+,20+,21-,22+,23+,24+,25-,26-,27+,28+,29+,31+,32+,33+/m0/s1",Pelargonidin 3-O-rutinoside 5-O-beta-D-glucoside,KEGG COMPOUND accession,C12645
1527,31985,petunidin 3-O-beta-D-glucoside,An anthocyanin cation that is petunidin substituted at position 3 by a beta-D-glucosyl residue,"InChI=1S/C22H22O12/c1-31-14-3-8(2-12(26)17(14)27)21-15(6-10-11(25)4-9(24)5-13(10)32-21)33-22-20(30)19(29)18(28)16(7-23)34-22/h2-6,16,18-20,22-23,28-30H,7H2,1H3,(H3-,24,25,26,27)/p+1/t16-,18-,19+,20-,22-/m1/s1",Petunidin 3-glucoside,KEGG COMPOUND accession,C12139
1528,31074,"2,5-dichloro-4-oxohex-2-enedioic acid","An alpha,omega-dicarboxylic acid that is hexanedioic acid containing a double bond between positions 2 and 3, an oxo group at position 4, and two chlorine atoms (at positions 2 and 5).","InChI=1S/C6H4Cl2O5/c7-2(5(10)11)1-3(9)4(8)6(12)13/h1,4H,(H,10,11)(H,12,13)","2,5-Dichloro-4-oxohex-2-enedioate",KEGG COMPOUND accession,C12835
1529,31084,2-iodo-6-methoxyphenol,,"InChI=1S/C7H7IO2/c1-10-6-4-2-3-5(8)7(6)9/h2-4,9H,1H3",2-Iodo-6-methoxyphenol,KEGG COMPOUND accession,C12251
1530,31087,"2-phytyl-1,4-naphthoquinone","A phylloquinone that consists of 1,4-naphthoquinone bearing a phytyl group at position 2.","InChI=1S/C30H44O2/c1-22(2)11-8-12-23(3)13-9-14-24(4)15-10-16-25(5)19-20-26-21-29(31)27-17-6-7-18-28(27)30(26)32/h6-7,17-19,21-24H,8-16,20H2,1-5H3/b25-19+/t23-,24-/m1/s1","2-Phytyl-1,4-naphthoquinone",KEGG COMPOUND accession,C13309
1531,32036,potassium sulfate,,"InChI=1S/2K.H2O4S/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2",Potassium sulfate,KEGG COMPOUND accession,C13192
1532,32060,propagermanium,,"InChI=1S/C6H10Ge2O7/c9-5(10)1-3-7(13)15-8(14)4-2-6(11)12/h1-4H2,(H,9,10)(H,11,12)",Propagermanium,KEGG COMPOUND accession,C13086
1533,32062,propicillin potassium,,"InChI=1S/C18H22N2O5S.K/c1-4-11(25-10-8-6-5-7-9-10)14(21)19-12-15(22)20-13(17(23)24)18(2,3)26-16(12)20;/h5-9,11-13,16H,4H2,1-3H3,(H,19,21)(H,23,24);/q;+1/p-1/t11?,12-,13+,16-;/m1./s1",Propicillin potassium,KEGG COMPOUND accession,C13110
1534,34567,benzo[e]pyrene,An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings. It is listed as a Group 3 carcinogen by the IARC.,InChI=1S/C20H12/c1-2-8-16-15(7-1)17-9-3-5-13-11-12-14-6-4-10-18(16)20(14)19(13)17/h1-12H,Benzo[e]pyrene,KEGG COMPOUND accession,C14435
1535,34572,allethrin,,"InChI=1S/C19H26O3/c1-7-8-13-12(4)16(10-15(13)20)22-18(21)17-14(9-11(2)3)19(17,5)6/h7,9,14,16-17H,1,8,10H2,2-6H3",Bioallethrin,KEGG COMPOUND accession,C14337
1536,34579,bisphenol A dimethacrylate,A bisphenol that is bisphenol A condensed with two molecules of methacrylic acid.,"InChI=1S/C23H24O4/c1-15(2)21(24)26-19-11-7-17(8-12-19)23(5,6)18-9-13-20(14-10-18)27-22(25)16(3)4/h7-14H,1,3H2,2,4-6H3","2,2-Di(4-methacryloxyphenyl)propane",KEGG COMPOUND accession,C14345
1537,31145,8-O-methyltetrangulol,,"InChI=1S/C20H14O4/c1-10-8-11-6-7-13-18(16(11)14(21)9-10)20(23)12-4-3-5-15(24-2)17(12)19(13)22/h3-9,21H,1-2H3",8-O-Methyltetrangulol,KEGG COMPOUND accession,C12398
1538,32987,kekulene,,InChI=1S/C48H24/c1-2-26-14-28-5-6-30-16-32-9-10-34-18-36-12-11-35-17-33-8-7-31-15-29-4-3-27-13-25(1)37-19-39(27)41(29)21-43(31)45(33)23-47(35)48(36)24-46(34)44(32)22-42(30)40(28)20-38(26)37/h1-24H,[12]kekulene,Beilstein Registry Number,2198243
1539,31227,apigenin 7-O-neohesperidoside,An apigenin derivative having an alpha-(1->2)-L-rhamnopyranosyl)-beta-D-glucopyranosyl moiety attached to the 7-hydroxy group.,"InChI=1S/C27H30O14/c1-10-20(32)22(34)24(36)26(37-10)41-25-23(35)21(33)18(9-28)40-27(25)38-13-6-14(30)19-15(31)8-16(39-17(19)7-13)11-2-4-12(29)5-3-11/h2-8,10,18,20-30,32-36H,9H2,1H3/t10-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1",Apigenin 7-O-neohesperidoside,KEGG COMPOUND accession,C12627
1540,31157,(+)-abscisic aldehyde,,"InChI=1S/C15H20O3/c1-11(6-8-16)5-7-15(18)12(2)9-13(17)10-14(15,3)4/h5-9,18H,10H2,1-4H3/b7-5+,11-6-/t15-/m1/s1",Abscisic aldehyde,KEGG COMPOUND accession,C13455
1541,31169,N-acetylsulfamethoxazole,"A sulfonamide compound having a 4-acetamidophenyl group attached to the sulfur atom and a 1,2-oxazol-3-yl group attached to the nitrogen atom.","InChI=1S/C12H13N3O4S/c1-8-7-12(14-19-8)15-20(17,18)11-5-3-10(4-6-11)13-9(2)16/h3-7H,1-2H3,(H,13,16)(H,14,15)",Acetylsulfamethoxazole,KEGG COMPOUND accession,C13061
1542,31170,O-acetyltropine,An O-acyltropine in which the acyl group is acetyl.,"InChI=1S/C10H17NO2/c1-7(12)13-10-5-8-3-4-9(6-10)11(8)2/h8-10H,3-6H2,1-2H3/t8-,9+,10+",Acetyltropine,CAS Registry Number,3423-27-6
1543,31196,tris(lactato)aluminium,,"InChI=1S/3C3H6O3.Al/c3*1-2(4)3(5)6;/h3*2,4H,1H3,(H,5,6);/q;;;+3/p-3",Aluminum lactate,CAS Registry Number,18917-91-4
1544,34087,1-O-hexadecanoyl-2-O-[(Z)-octadec-9-enoyl]-sn-glycerol 3-diphosphate,"An optically active 1,2-diacylglycerol 3-diphosphate compound having a 1-hexadecanoyl substituent at the O-1 position and a (Z)-octadec-9-enoyl substituent at the O-2 position.","InChI=1S/C37H72O11P2/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(39)47-35(34-46-50(43,44)48-49(40,41)42)33-45-36(38)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,35H,3-16,19-34H2,1-2H3,(H,43,44)(H2,40,41,42)/b18-17-/t35-/m1/s1",1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-pyrophosphate,KEGG COMPOUND accession,C13890
1545,31046,2-hydroxyhexano-6-lactone,,"InChI=1S/C6H10O3/c7-5-3-1-2-4-9-6(5)8/h5,7H,1-4H2",1-Oxa-2-oxo-3-hydroxycycloheptane,KEGG COMPOUND accession,C12314
1546,31057,13-deoxydaunorubicin,"An aminoglycoside antibiotic that is (1S,3S)-3-ethyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene having a 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl residue attached at position 1 via a glycosidic linkage.","InChI=1S/C27H31NO9/c1-4-27(34)9-13-19(16(10-27)37-17-8-14(28)22(29)11(2)36-17)26(33)21-20(24(13)31)23(30)12-6-5-7-15(35-3)18(12)25(21)32/h5-7,11,14,16-17,22,29,31,33-34H,4,8-10,28H2,1-3H3/t11-,14-,16-,17-,22+,27-/m0/s1",Feudomycin A,KEGG COMPOUND accession,C12429
1547,31062,19-hydroxy-8-O-methyltetrangulol,,"InChI=1S/C20H14O5/c1-25-15-4-2-3-12-17(15)19(23)13-6-5-11-7-10(9-21)8-14(22)16(11)18(13)20(12)24/h2-8,21-22H,9H2,1H3",19-Hydroxy-8-O-methyltetrangulol,KEGG COMPOUND accession,C12400
1548,31063,19-hydroxytetrangulol,,"InChI=1S/C19H12O5/c20-8-9-6-10-4-5-12-17(15(10)14(22)7-9)19(24)11-2-1-3-13(21)16(11)18(12)23/h1-7,20-22H,8H2",19-Hydroxytetrangulol,KEGG COMPOUND accession,C12399
1549,33155,heptaphene,,InChI=1S/C30H18/c1-3-7-21-13-27-17-29-23(15-25(27)11-19(21)5-1)9-10-24-16-26-12-20-6-2-4-8-22(20)14-28(26)18-30(24)29/h1-18H,heptaphene,CAS Registry Number,222-75-3
1550,33156,heptacene,An acene that consists of seven ortho-fused benzene rings in a rectilinear arrangement.,InChI=1S/C30H18/c1-2-6-20-10-24-14-28-18-30-16-26-12-22-8-4-3-7-21(22)11-25(26)15-29(30)17-27(28)13-23(24)9-19(20)5-1/h1-18H,heptacene,Beilstein Registry Number,2295681
1551,31270,beraprost sodium,The organic sodium salt of beraprost. It is used in the treatment of chronic arterial occlusive disease and primary pulmonary hypertension in Japan.,"InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;/t15?,17-,19+,20+,21-,23-;/m0./s1",beraprost sodium,CAS Registry Number,88475-69-8
1552,34127,11(R)-HPETE,,"InChI=1S/C20H32O4/c1-2-3-4-5-7-10-13-16-19(24-23)17-14-11-8-6-9-12-15-18-20(21)22/h6-7,9-11,13-14,16,19,23H,2-5,8,12,15,17-18H2,1H3,(H,21,22)/b9-6-,10-7-,14-11-,16-13+/t19-/m0/s1",11(R)-HPETE,KEGG COMPOUND accession,C14820
1553,34144,12(R)-HETE,"A HETE having a (12R)-hydroxy group and (5Z)-, (8Z)-, (10E)- and (14Z)-double bonds.","InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+/t19-/m1/s1",12(R)-HETE,KEGG COMPOUND accession,C14822
1554,34145,12(R)-HPETE,"A HPETE that is (5Z,8Z,10E,12R,14Z)-icosa-5,8,10,14-tetraenoic acid with the hydroperoxy group located at position 12 (the R-enantiomer).","InChI=1S/C20H32O4/c1-2-3-4-5-10-13-16-19(24-23)17-14-11-8-6-7-9-12-15-18-20(21)22/h7-11,13-14,17,19,23H,2-6,12,15-16,18H2,1H3,(H,21,22)/b9-7-,11-8-,13-10-,17-14+/t19-/m1/s1",12(R)-HPETE,KEGG COMPOUND accession,C14812
1555,34146,12(S)-HETE,"A HETE having a (12S)-hydroxy group and (5Z)-, (8Z)-, (10E)- and (14Z)-double bonds.","InChI=1S/C20H32O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17,19,21H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+/t19-/m0/s1",12(S)-HETE,KEGG COMPOUND accession,C14777
1556,34151,12-oxo-ETE,"An oxoicosatetraenoic acid having a 12-oxo group; and (5Z)-, (8Z), (10E)- and (14Z)-double bonds.","InChI=1S/C20H30O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h7-11,13-14,17H,2-6,12,15-16,18H2,1H3,(H,22,23)/b9-7-,11-8-,13-10-,17-14+",12-OxoETE,KEGG COMPOUND accession,C14807
1557,34153,12alpha-hydroxyprogesterone,,"InChI=1S/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)18(15)11-19(24)21(16,17)3/h10,15-19,24H,4-9,11H2,1-3H3/t15-,16+,17-,18-,19-,20-,21+/m0/s1",12alpha-Hydroxyprogesterone,KEGG COMPOUND accession,C14654
1558,34157,"14,15-EET","An EET obtained by formal epoxidation of the 14,15-double bond of arachidonic acid.","InChI=1S/C20H32O3/c1-2-3-12-15-18-19(23-18)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h4,6-7,9-10,13,18-19H,2-3,5,8,11-12,14-17H2,1H3,(H,21,22)/b6-4-,9-7-,13-10-","(5Z,8Z,11Z)-14,15-Epoxyeicosa-5.8.11-trienoic acid",KEGG COMPOUND accession,C14771
1559,31107,"3-amino-4,7-dihydroxycoumarin","A hydroxycoumarin that is 4,7-dihydroxycoumarin bearing an additional amino substituent at positions 3.","InChI=1S/C9H7NO4/c10-7-8(12)5-2-1-4(11)3-6(5)14-9(7)13/h1-3,11-12H,10H2","3-Amino-4,7-dihydroxycoumarin",KEGG COMPOUND accession,C12468
1560,31133,5-hydroxybisphenol A,"A bisphenol (methylenediphenol) having hydroxy functions at C-3, C-4 and C-4', and gem-dimethyl groups on the methylene bridge.","InChI=1S/C15H16O3/c1-15(2,10-3-6-12(16)7-4-10)11-5-8-13(17)14(18)9-11/h3-9,16-18H,1-2H3",5-Hydroxybisphenol,KEGG COMPOUND accession,C13626
1561,34003,"9-fluoro-17-methyl-5beta-androstane-3alpha,11beta,17beta-triol",,"InChI=1S/C20H33FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h12-16,22-24H,4-11H2,1-3H3/t12-,13-,14+,15+,16+,17+,18+,19+,20+/m1/s1","(3alpha,5beta,11beta,17beta)-9-Fluoro-17-methylandrostane-3,11,17-triol",KEGG COMPOUND accession,C14616
1562,34023,phthalazin-1(2H)-one,,"InChI=1S/C8H6N2O/c11-8-7-4-2-1-3-6(7)5-9-10-8/h1-5H,(H,10,11)",1(2H)-Phthalazinone,KEGG COMPOUND accession,C14473
1563,34034,tert-butyl benzoate,A benzoate ester obtained by the formal condensation of benzoic acid with tert-butanol.,"InChI=1S/C11H14O2/c1-11(2,3)13-10(12)9-7-5-4-6-8-9/h4-8H,1-3H3","1,1-Dimethylethyl benzoate",KEGG COMPOUND accession,C14709
1564,34039,"1,2,4-trimethylbenzene","A trimethylbenzene carrying methyl groups at positions 1, 2 and 4.","InChI=1S/C9H12/c1-7-4-5-8(2)9(3)6-7/h4-6H,1-3H3","1,2,4-Trimethylbenzene",KEGG COMPOUND accession,C14533
1565,34046,"1,2-didodecanoyl-sn-glycero-3-cytidine 5'-diphosphate",A CDP-diacylglycerol in which the acyl groups at positions 1 and 2 are specified as dodecanoyl.,"InChI=1S/C36H65N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-31(40)49-25-28(52-32(41)22-20-18-16-14-12-10-8-6-4-2)26-50-55(45,46)54-56(47,48)51-27-29-33(42)34(43)35(53-29)39-24-23-30(37)38-36(39)44/h23-24,28-29,33-35,42-43H,3-22,25-27H2,1-2H3,(H,45,46)(H,47,48)(H2,37,38,44)/t28-,29-,33-,34-,35-/m1/s1","1,2-Didodecanoyl-sn-glycero-3-cytidine-5'-diphosphate",KEGG COMPOUND accession,C13891
1566,34048,"1,2-dihydroxy-3,4-epoxy-1,2,3,4-tetrahydronaphthalene",,"InChI=1S/C10H10O3/c11-7-5-3-1-2-4-6(5)9-10(13-9)8(7)12/h1-4,7-12H","1,2-Dihydroxy-3,4-epoxy-1,2,3,4-tetrahydronaphthalene",KEGG COMPOUND accession,C14784
1567,34056,"octane-1,2-diol",,"InChI=1S/C8H18O2/c1-2-3-4-5-6-8(10)7-9/h8-10H,2-7H2,1H3","1,2-Octanediol",CAS Registry Number,1117-86-8
1568,34596,"(3S,5R,6R)-3,5-dihydroxy-6,7-didehydro-5,6-dihydro-12'-apo-beta-caroten-12'-al",,"InChI=1S/C25H34O3/c1-19(10-7-8-11-21(3)18-26)12-9-13-20(2)14-15-23-24(4,5)16-22(27)17-25(23,6)28/h7-14,18,22,27-28H,16-17H2,1-6H3/b8-7+,12-9+,19-10+,20-13+,21-11+/t15-,22-,25+/m0/s1",C25-Allenic-apo-aldehyde,KEGG COMPOUND accession,C14044
1569,34609,carbenicillin disodium,,"InChI=1S/C17H18N2O6S.2Na/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8;;/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25);;/q;2*+1/p-2/t9?,10-,11+,14-;;/m1../s1",Carbenicillin sodium,KEGG COMPOUND accession,C13967
1570,34617,cefotetan disodium,The disodium salt of cefotetan.,"InChI=1S/C17H17N7O8S4.2Na/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28;;/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30);;/q;2*+1/p-2/b12-6-;;/t13?,15-,17+;;/m1../s1",Cefotetan disodium,Beilstein Registry Number,5716628
1571,34800,isophorone,"A cyclic ketone, the structure of which is that of cyclohex-2-en-1-one substituted by methyl groups at positions 3, 5 and 5.","InChI=1S/C9H14O/c1-7-4-8(10)6-9(2,3)5-7/h4H,5-6H2,1-3H3",Isophorone,KEGG COMPOUND accession,C14743
1572,34811,lactobacillic acid,"An 11,12-methyleneoctadecanoic acid having (11R,12S)-configuration.","InChI=1S/C19H36O2/c1-2-3-4-10-13-17-16-18(17)14-11-8-6-5-7-9-12-15-19(20)21/h17-18H,2-16H2,1H3,(H,20,21)/t17-,18+/m0/s1","11R,12S-Methylene-octadecanoic acid",KEGG COMPOUND accession,C13838
1573,34820,levuglandin D2,,"InChI=1S/C20H32O5/c1-3-4-7-11-18(23)13-14-19(16(2)22)17(15-21)10-8-5-6-9-12-20(24)25/h5,8,13-15,17-19,23H,3-4,6-7,9-12H2,1-2H3,(H,24,25)/b8-5-,14-13+/t17-,18-,19-/m0/s1",Levuglandin D2,KEGG COMPOUND accession,C13808
1574,34821,levuglandin E2,,"InChI=1S/C20H32O5/c1-3-4-7-10-18(23)14-13-17(15-21)19(16(2)22)11-8-5-6-9-12-20(24)25/h5,8,13-15,17-19,23H,3-4,6-7,9-12H2,1-2H3,(H,24,25)/b8-5-,14-13+/t17-,18-,19-/m0/s1",Levuglandin E2,KEGG COMPOUND accession,C13807
1575,33992,(-)-catechin,The (-)-enantiomer of catechin.,"InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m1/s1",(-)-Catechin,KEGG COMPOUND accession,C14079
1576,31368,cefepime hydrochloride,A hydrochloride that is the monohydrate of the dihydrochloride salt of cefepime.,"InChI=1S/C19H24N6O5S2.2ClH.H2O/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11;;;/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29);2*1H;1H2/b23-12-;;;/t13-,17-;;;/m1.../s1",Cefepime hydrochloride,KEGG COMPOUND accession,C12557
1577,31377,cefpiramide sodium,The sodium salt of cefpiramide.,"InChI=1S/C25H24N8O7S2.Na/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2;/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40);/q;+1/p-1/t17-,18-,23-;/m1./s1",Cefpiramide sodium,KEGG COMPOUND accession,C13376
1578,33278,didesmethyl tocotrienol,A tocotrienol that is chroman-6-ol substituted by a farnesyl chain at position 2.,"InChI=1S/C25H36O2/c1-19(2)8-5-9-20(3)10-6-11-21(4)12-7-13-24-16-14-22-18-23(26)15-17-25(22)27-24/h8,10,12,15,17-18,24,26H,5-7,9,11,13-14,16H2,1-4H3/b20-10+,21-12+/t24-/m1/s1","3,4-dihydro-2-(4,8,12-trimethyltrideca-3'(E),7'(E),11'-trienyl)-2H-1-benzopyran-6-ol",Beilstein Registry Number,8727601
1579,33998,"(1R,2S)-naphthalene 1,2-oxide","A naphthalene 1,2-oxide (the 1R,2S-stereoisomer).","InChI=1S/C10H8O/c1-2-4-8-7(3-1)5-6-9-10(8)11-9/h1-6,9-10H/t9-,10+/m0/s1","(1R,2S)-Naphthalene 1,2-oxide",KEGG COMPOUND accession,C14786
1580,34001,"(1S,2R)-naphthalene 1,2-oxide","A naphthalene 1,2-oxide (the 1S,2R-stereoisomer).","InChI=1S/C10H8O/c1-2-4-8-7(3-1)5-6-9-10(8)11-9/h1-6,9-10H/t9-,10+/m1/s1","(1S,2R)-naphthalene 1,2-oxide",KEGG COMPOUND accession,C14787
1581,34828,ML-236C,,"InChI=1S/C18H26O3/c1-12-6-7-13-4-2-3-5-17(13)16(12)9-8-15-10-14(19)11-18(20)21-15/h4,6-7,12,14-17,19H,2-3,5,8-11H2,1H3/t12-,14+,15+,16-,17-/m0/s1",ML-236C,KEGG COMPOUND accession,C14043
1582,34833,"1,3,5-trimethylbenzene","A trimethylbenzene carrying methyl substituents at positions 1, 3 and 5.","InChI=1S/C9H12/c1-7-4-8(2)6-9(3)5-7/h4-6H,1-3H3",Mesitylene,KEGG COMPOUND accession,C14508
1583,34836,methicillin sodium monohydrate,,"InChI=1S/C17H20N2O6S.Na.H2O/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4;;/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23);;1H2/q;+1;/p-1/t11-,12+,15-;;/m1../s1",Sodium methicillin monohydrate,KEGG COMPOUND accession,C13973
1584,34840,methyl methacrylate,An enoate ester having methacrylic acid as the carboxylic acid component and methanol as the alcohol component.,"InChI=1S/C5H8O2/c1-4(2)5(6)7-3/h1H2,2-3H3",Methyl methacrylate,KEGG COMPOUND accession,C14527
1585,34845,metipranolol hydrochloride,"The hydrochloride salt of metipranolol. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma.","InChI=1S/C17H27NO4.ClH/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4;/h7,10,15,18,20H,8-9H2,1-6H3;1H",Metipranolol hydrochloride,CAS Registry Number,36592-77-5
1586,34847,metrizoic acid,,"InChI=1S/C12H11I3N2O4/c1-4(18)16-10-7(13)6(12(20)21)8(14)11(9(10)15)17(3)5(2)19/h1-3H3,(H,16,18)(H,20,21)",Metrizoic acid,KEGG COMPOUND accession,C14165
1587,34849,mibolerone,An androgen that is nalandrone carrying two methyl substituents at positions 7alpha and 17.,"InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1","17-beta-Hydroxy-7-alpha,17-dimethylestr-4-en-3-one",KEGG COMPOUND accession,C14255
1588,34850,milrinone lactate,,"InChI=1S/C12H9N3O.C3H6O3/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8;1-2(4)3(5)6/h2-6H,1H3,(H,15,16);2,4H,1H3,(H,5,6)",Milrinone lactate,KEGG COMPOUND accession,C13595
1589,34859,mytatrienediol,,"InChI=1S/C20H28O3/c1-19-9-8-15-14-7-5-13(23-3)10-12(14)4-6-16(15)17(19)11-20(2,22)18(19)21/h5,7,10,15-18,21-22H,4,6,8-9,11H2,1-3H3/t15-,16-,17+,18-,19+,20+/m1/s1",Mytatrienediol,KEGG COMPOUND accession,C14242
1590,34860,"N,N'-diphenyl-1,4-phenylenediamine","An N-substituted diamine that is 1,4-phenylenediamine in which one hydrogen from each amino group is replaced by a phenyl group.","InChI=1S/C18H16N2/c1-3-7-15(8-4-1)19-17-11-13-18(14-12-17)20-16-9-5-2-6-10-16/h1-14,19-20H",DPPD,KEGG COMPOUND accession,C14501
1591,34058,"1,3-dibenzyltetramethyldisiloxane",,"InChI=1S/C18H26OSi2/c1-20(2,15-17-11-7-5-8-12-17)19-21(3,4)16-18-13-9-6-10-14-18/h5-14H,15-16H2,1-4H3","1,3-Dibenzyltetramethyldisiloxane",KEGG COMPOUND accession,C14252
1592,34061,"1,3-diphenyltetramethyldisiloxane",,"InChI=1S/C16H22OSi2/c1-18(2,15-11-7-5-8-12-15)17-19(3,4)16-13-9-6-10-14-16/h5-14H,1-4H3","1,3-Diphenyltetramethyldisiloxane",KEGG COMPOUND accession,C14251
1593,32759,L-tyrosinyl radical,,"InChI=1S/C9H10NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8H,5,10H2,(H,12,13)/t8-/m0/s1",L-tyrosine radical,Beilstein Registry Number,2941070
1594,32763,L-tyrosinyl radical cation,,"InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/q+1/t8-/m0/s1",L-tyrosine radical cation,Beilstein Registry Number,8993814
1595,34115,1-O-hexadecyl-sn-glycerol,A 1-n-hexadecyl analogue of an optically active alkylglycerol compound.,"InChI=1S/C19H40O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-22-18-19(21)17-20/h19-21H,2-18H2,1H3/t19-/m0/s1",1-O-Hexadecyl-sn-glycerol,KEGG COMPOUND accession,C13859
1596,34116,(9Z)-1-O-octadec-9-enyl glycerol,,"InChI=1S/C21H42O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24-20-21(23)19-22/h9-10,21-23H,2-8,11-20H2,1H3/b10-9-",1-O-Octadec-9-enyl glycerol,KEGG COMPOUND accession,C13860
1597,31442,cyanidin 3-O-(6-O-malonyl-beta-D-glucoside),An anthocyanin cation consisting of cyanidin having a 6-O-malonyl-beta-D-glucosyl residue attached at the 3-hydroxy position.,"InChI=1S/C24H22O14/c25-10-4-13(27)11-6-16(23(36-15(11)5-10)9-1-2-12(26)14(28)3-9)37-24-22(34)21(33)20(32)17(38-24)8-35-19(31)7-18(29)30/h1-6,17,20-22,24,32-34H,7-8H2,(H4-,25,26,27,28,29,30)/p+1/t17-,20-,21+,22-,24-/m1/s1",Cyanidin 3-O-(6-O-malonyl-beta-D-glucoside),KEGG COMPOUND accession,C12643
1598,31444,cyclacillin,,"InChI=1S/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1",Cyclacillin,KEGG COMPOUND accession,C12766
1599,31445,cyclic ADP-ribose,A cyclic purine nucleotide that is synthesised from NAD+ by ADP-ribosyl cyclase; acts as an agonist at ryanodine receptors.,"InChI=1S/C15H21N5O13P2/c16-12-7-13-18-4-19(12)14-10(23)8(21)5(31-14)1-29-34(25,26)33-35(27,28)30-2-6-9(22)11(24)15(32-6)20(13)3-17-7/h3-6,8-11,14-16,21-24H,1-2H2,(H,25,26)(H,27,28)/t5-,6-,8-,9-,10-,11-,14-,15-/m1/s1",cADPR,KEGG COMPOUND accession,C13050
1600,31450,cyphenothrin,,"InChI=1S/C24H25NO3/c1-16(2)13-20-22(24(20,3)4)23(26)28-21(15-25)17-9-8-12-19(14-17)27-18-10-6-5-7-11-18/h5-14,20-22H,1-4H3",Cyphenothrin,KEGG COMPOUND accession,C12962
1601,34162,16(R)-HETE,A 16-HETE in which the chiral centre at position 16 has R-configuration.,"InChI=1S/C20H32O3/c1-2-3-16-19(21)17-14-12-10-8-6-4-5-7-9-11-13-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14-/t19-/m1/s1",16(R)-HETE,KEGG COMPOUND accession,C14778
1602,34168,"16alpha,17alpha-dihydroxyprogesterone acetophenide",A 20-oxo steroid that is the cyclic ketal resulting from the formal condensation of the hydroxy groups of algestone with acetophenone.,"InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28?,29-/m1/s1","16alpha,17alpha-Dihydroxyprogesterone acetophenide",KEGG COMPOUND accession,C14674
1603,34185,19(S)-HETE,"A HETE having a (19S)-hydroxy group and all-cis double bonds at positions 5, 8, 11 and 14.","InChI=1S/C20H32O3/c1-19(21)17-15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18-20(22)23/h3-6,9-12,19,21H,2,7-8,13-18H2,1H3,(H,22,23)/b5-3-,6-4-,11-9-,12-10-/t19-/m0/s1",19(S)-HETE,KEGG COMPOUND accession,C14749
1604,34189,"2',3',4',5'-tetrachlorobiphenyl-3-ol","An organochlorine compound formed formally by chlorination of biphenyl-3-ol at C-2', -3', -4' and -5'.","InChI=1S/C12H6Cl4O/c13-9-5-8(10(14)12(16)11(9)15)6-2-1-3-7(17)4-6/h1-5,17H","2',3',4',5'-Tetrachloro-3-biphenylol",KEGG COMPOUND accession,C14733
1605,31520,doxapram hydrochloride monohydrate,"The monohydrate form of doxapram hydrochloride. A central and respiratory stimulant with a brief duration of action, it is used as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.","InChI=1S/C24H30N2O2.ClH.H2O/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21;;/h3-12,22H,2,13-19H2,1H3;1H;1H2",Doxapram hydrochloride monohydrate,KEGG DRUG accession,D01872
1606,36226,beta-D-galactopyranosyl-(1->4)-D-galactopyranose,A glycosylgalactose comprising two galactose units joined via an beta-(1->4) linkage.,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10+,11?,12+/m1/s1",beta-D-galactosyl-(1->4)-D-galactose,Beilstein Registry Number,1292748
1607,35309,"(5S,6R)-beta-carotene 5,6-epoxide",,"InChI=1S/C40H56O/c1-31(19-13-21-33(3)24-25-36-35(5)23-15-27-37(36,6)7)17-11-12-18-32(2)20-14-22-34(4)26-30-40-38(8,9)28-16-29-39(40,10)41-40/h11-14,17-22,24-26,30H,15-16,23,27-29H2,1-10H3/b12-11+,19-13+,20-14+,25-24+,30-26+,31-17+,32-18+,33-21+,34-22+/t39-,40+/m0/s1","(5S,6R)-beta-carotene 5,6-epoxide",Beilstein Registry Number,1443891
1608,34325,"3,4-diphenyltetrahydrofuran",,"InChI=1S/C16H16O/c1-3-7-13(8-4-1)15-11-17-12-16(15)14-9-5-2-6-10-14/h1-10,15-16H,11-12H2","3,4-Diphenyltetrahydrofuran",KEGG COMPOUND accession,C14277
1609,34327,3-(dimethylamino)propyl benzoate,,"InChI=1S/C12H17NO2/c1-13(2)9-6-10-15-12(14)11-7-4-3-5-8-11/h3-5,7-8H,6,9-10H2,1-2H3",3-(Dimethylamino)propyl benzoate,KEGG COMPOUND accession,C14168
1610,34329,(2Z)-3-bromohept-2-enoic acid,A hept-2-enoic acid carrying a bromo- substituent at C-3.,"InChI=1S/C7H11BrO2/c1-2-3-4-6(8)5-7(9)10/h5H,2-4H2,1H3,(H,9,10)/b6-5-",3-Bromo-2Z-heptenoic acid,KEGG COMPOUND accession,C13793
1611,34222,"2,3,4-trichlorobiphenyl","A trichlorobiphenyl that is biphenyl in which the hydrogens at positions 2, 3, and 4 on one of the benzene rings are replaced by chlorines.",InChI=1S/C12H7Cl3/c13-10-7-6-9(11(14)12(10)15)8-4-2-1-3-5-8/h1-7H,"2,3,4-Trichlorobiphenyl",KEGG COMPOUND accession,C14357
1612,34224,"2,3,5,6-tetrachlorobiphenyl","A tetrachlorobiphenyl that is biphenyl in which one of the phenyl groups is substituted by chlorines at positions 2, 3, 5, and 6.",InChI=1S/C12H6Cl4/c13-8-6-9(14)12(16)10(11(8)15)7-4-2-1-3-5-7/h1-6H,"2,3,5,6-Tetrachlorobiphenyl",KEGG COMPOUND accession,C14363
1613,34295,2-methoxyhexadecanoic acid,A long chain fatty acid consisting of hexadecanoic (palmitic) acid carrying a methoxy substituent at position 2; naturally occurring only in the phospholipids of sponges.,"InChI=1S/C17H34O3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16(20-2)17(18)19/h16H,3-15H2,1-2H3,(H,18,19)",2-Methoxyhexadecanoic acid,KEGG COMPOUND accession,C13947
1614,34300,2-naphthoyl-CoA,An acyl-CoA thioester that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-naphthoic acid..,"InChI=1S/C32H42N7O17P3S/c1-32(2,26(42)29(43)35-10-9-22(40)34-11-12-60-31(44)20-8-7-18-5-3-4-6-19(18)13-20)15-53-59(50,51)56-58(48,49)52-14-21-25(55-57(45,46)47)24(41)30(54-21)39-17-38-23-27(33)36-16-37-28(23)39/h3-8,13,16-17,21,24-26,30,41-42H,9-12,14-15H2,1-2H3,(H,34,40)(H,35,43)(H,48,49)(H,50,51)(H2,33,36,37)(H2,45,46,47)/t21-,24-,25-,26+,30-/m1/s1",2-Naphthoyl-CoA,KEGG COMPOUND accession,C14120
1615,34306,20-HETE,A HETE that consists of arachidonic acid bearing a hydroxy substituent at position 20.,"InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-",20-HETE,CAS Registry Number,79551-86-3
1616,34311,27-O-demethylrifamycin SV,A member of the class of rifamycins that is rifamycin SV lacking the O-methyl group at position 27.,"InChI=1S/C36H45NO12/c1-15-10-9-11-16(2)35(46)37-22-14-24(40)25-26(31(22)44)30(43)20(6)33-27(25)34(45)36(8,49-33)47-13-12-23(39)17(3)32(48-21(7)38)19(5)29(42)18(4)28(15)41/h9-15,17-19,23,28-29,32,39-44H,1-8H3,(H,37,46)/b10-9+,13-12+,16-11-/t15-,17+,18+,19+,23-,28-,29+,32+,36-/m0/s1",27-O-Demethyl-rifamycin SV,KEGG COMPOUND accession,C14727
1617,36272,tungstic acid,,InChI=1S/2H2O.2O.W/h2*1H2;;;/q;;;;+2/p-2,[WO2(OH)2],Gmelin Registry Number,82224
1618,34229,"2,3-dinor-8-epi-prostaglandin F1alpha",A prostanoid that is prostaglandin F1alpha lacking two methylenes in the carboxyalkyl chain and having inverted stereochemistry at the 8-position.,"InChI=1S/C18H32O5/c1-2-3-4-7-13(19)10-11-15-14(16(20)12-17(15)21)8-5-6-9-18(22)23/h10-11,13-17,19-21H,2-9,12H2,1H3,(H,22,23)/b11-10+/t13-,14-,15+,16-,17+/m0/s1","2,3-Dinor-8-iso prostaglandin F1alpha",KEGG COMPOUND accession,C14795
1619,34230,"2,3-dinor-8-epi-prostaglandin F2alpha",,"InChI=1S/C18H30O5/c1-2-3-4-7-13(19)10-11-15-14(16(20)12-17(15)21)8-5-6-9-18(22)23/h5-6,10-11,13-17,19-21H,2-4,7-9,12H2,1H3,(H,22,23)/b6-5-,11-10+/t13-,14-,15+,16-,17+/m0/s1","2,3-Dinor-8-iso prostaglandin F2alpha",KEGG COMPOUND accession,C14794
1620,34242,"2,4-dinitroaniline",A nitroaniline consisting of an aniline core having two nitro substituents located at the 2- and 4-positions.,"InChI=1S/C6H5N3O4/c7-5-2-1-4(8(10)11)3-6(5)9(12)13/h1-3H,7H2","1-Amino-2,4-dinitrobenzene",KEGG COMPOUND accession,C14713
1621,34245,"2,5-dichloroaniline",A dichloroaniline carrying chloro groups at positions 2 and 5.,"InChI=1S/C6H5Cl2N/c7-4-1-2-5(8)6(9)3-4/h1-3H,9H2","2,5-Dichloroaniline",KEGG COMPOUND accession,C14712
1622,34248,"2,6-dichloro-4'-biphenylol",A member of the class of hydroxybiphenyls that is biphenyl-4-ol with chlorine atoms substituted at positions 2 and 6.,"InChI=1S/C12H8Cl2O/c13-10-2-1-3-11(14)12(10)8-4-6-9(15)7-5-8/h1-7,15H","2,6-Dichloro-4'-biphenylol",KEGG COMPOUND accession,C14192
1623,34249,"2,6-dichlorobiphenyl","A dichlorobiphenyl that is 1,3-dichlorobenzene in which the hydrogen at position 2 is replaced by a phenyl group.",InChI=1S/C12H8Cl2/c13-10-7-4-8-11(14)12(10)9-5-2-1-3-6-9/h1-8H,"2,6-Dichlorobiphenyl",KEGG COMPOUND accession,C14355
1624,35483,adenosine 5'-monophosphate 1-oxide,,"InChI=1S/C10H14N5O8P/c11-8-5-9(13-3-15(8)18)14(2-12-5)10-7(17)6(16)4(23-10)1-22-24(19,20)21/h2-4,6-7,10,16-17H,1,11H2,(H2,19,20,21)/t4-,6-,7-,10-/m1/s1",AMP N1-oxide,Beilstein Registry Number,59433
1625,35485,adenosine 1-oxide,,"InChI=1S/C10H13N5O5/c11-8-5-9(13-3-15(8)19)14(2-12-5)10-7(18)6(17)4(1-16)20-10/h2-4,6-7,10,16-18H,1,11H2/t4-,6-,7-,10-/m1/s1",adenosine N1-oxide,Beilstein Registry Number,1160664
1626,35491,L-cystine zwitterion,,"InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)/t3-,4-/m0/s1","(2R,2'R)-3,3'-dithiobis(2-ammoniopropanoate)",Beilstein Registry Number,1888247
1627,35492,cystine zwitterion,An amino acid zwitterion that is the tautomer of cystine.,"InChI=1S/C6H12N2O4S2/c7-3(5(9)10)1-13-14-2-4(8)6(11)12/h3-4H,1-2,7-8H2,(H,9,10)(H,11,12)","3,3'-dithiobis(2-ammoniopropanoate)",Gmelin Registry Number,51007
1628,34629,chlordimeform,,"InChI=1S/C10H13ClN2/c1-8-6-9(11)4-5-10(8)12-7-13(2)3/h4-7H,1-3H3/b12-7+",Chlorphenamidine,KEGG COMPOUND accession,C14746
1629,34630,chlorpropham,A carbamate ester that is the isopropyl ester of 3-chlorophenylcarbamic acid.,"InChI=1S/C10H12ClNO2/c1-7(2)14-10(13)12-9-5-3-4-8(11)6-9/h3-7H,1-2H3,(H,12,13)",Chloropropham,KEGG COMPOUND accession,C14506
1630,34633,"cholesta-5,7-dien-3beta-ol benzoate",,"InChI=1S/C34H48O2/c1-23(2)10-9-11-24(3)29-16-17-30-28-15-14-26-22-27(36-32(35)25-12-7-6-8-13-25)18-20-33(26,4)31(28)19-21-34(29,30)5/h6-8,12-15,23-24,27,29-31H,9-11,16-22H2,1-5H3/t24-,27+,29-,30+,31+,33+,34-/m1/s1","Cholesta-5,7-dien-3beta-ol benzoate",KEGG COMPOUND accession,C14673
1631,34941,"5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid","An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.","InChI=1S/C14H14N3O12PS2/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-3-2-8(31(23,24)25)4-12(11)32(26,27)28/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28)",PPADS,KEGG COMPOUND accession,C13745
1632,34707,dihydrogenistein,"A hydroxyisoflavanone comprising isoflavanone carrying three hydroxy substituents at positions 5, 7 and 4'.","InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-6,11,16-18H,7H2","4',5,7-Trihydroxyisoflavan-4-one",KEGG COMPOUND accession,C14458
1633,34714,dimethoate,A monocarboxylic acid amide that is N-methylacetamide in which one of the hydrogens of the methyl group attached to the carbonyl moiety is replaced by a (dimethoxyphosphorothioyl)sulfanediyl group.,"InChI=1S/C5H12NO3PS2/c1-6-5(7)4-12-10(11,8-2)9-3/h4H2,1-3H3,(H,6,7)",Dimethoate,KEGG COMPOUND accession,C14326
1634,34784,hepoxilin B3,"A hepoxilin having (5Z,9E,14Z) double bond stereochemistry, a 10-hydroxy substituent and an (11S,12S)-epoxy group.","InChI=1S/C20H32O4/c1-2-3-4-5-9-12-15-18-20(24-18)17(21)14-11-8-6-7-10-13-16-19(22)23/h6-7,9,11-12,14,17-18,20-21H,2-5,8,10,13,15-16H2,1H3,(H,22,23)/b7-6-,12-9-,14-11-/t17?,18-,20-/m0/s1",Hepoxilin B3,KEGG COMPOUND accession,C14810
1635,36817,4'-iodo-5-methoxyvalerophenone (E)-O-(2-aminoethyl)oxime,An oxime O-ether that is the (E)-O-(2-aminoethyl)oxime derived from 4'-iodo-5-methoxyvalerophenone.,"InChI=1S/C14H21IN2O2/c1-18-10-3-2-4-14(17-19-11-9-16)12-5-7-13(15)8-6-12/h5-8H,2-4,9-11,16H2,1H3/b17-14+",4'-iodo-5-methoxyvalerophenone O-(2-aminoethyl)oxime,PubMed citation,7767308
1636,31467,descarbamoylnovobiocin,A hydroxycoumarin that is novobiocin lacking the carbamoyl group from position 3 on the hexose ring.,"InChI=1S/C30H35NO10/c1-14(2)7-8-16-13-17(9-11-19(16)32)27(36)31-21-22(33)18-10-12-20(15(3)25(18)40-28(21)37)39-29-24(35)23(34)26(38-6)30(4,5)41-29/h7,9-13,23-24,26,29,32-35H,8H2,1-6H3,(H,31,36)/t23-,24+,26+,29+/m0/s1",Descarbamoylnovobiocin,KEGG COMPOUND accession,C12476
1637,31490,dihydroergocristine mesylate,"The methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia.","InChI=1S/C35H41N5O5.CH4O3S/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34;1-5(2,3)4/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41);1H3,(H,2,3,4)/t23-,25-,27-,28+,29+,34-,35+;/m1./s1",Dihydroergocristine mesylate,KEGG COMPOUND accession,C13168
1638,31741,kaempferol 3-O-[6-(4-coumaroyl)-beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucoside],A trihydroxyflavone that is kaempferol  substituted at position 3 by a 6-(4-coumaroyl)-beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucosyl moiety via a glycosidic linkage.,"InChI=1S/C42H46O23/c43-13-23-29(51)34(56)39(41(60-23)63-37-31(53)27-21(48)11-20(47)12-22(27)59-36(37)17-4-8-19(46)9-5-17)65-42-38(33(55)28(50)24(14-44)61-42)64-40-35(57)32(54)30(52)25(62-40)15-58-26(49)10-3-16-1-6-18(45)7-2-16/h1-12,23-25,28-30,32-35,38-48,50-52,54-57H,13-15H2/b10-3+/t23-,24-,25-,28-,29-,30-,32+,33+,34+,35-,38-,39-,40+,41+,42+/m1/s1",Kaempferol 3-O-[6-(4-coumaroyl)-beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucoside],KEGG COMPOUND accession,C12636
1639,35752,pentetate(3-),,"InChI=1S/C14H23N3O10/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27)/p-3",H2dtpa(3-),Beilstein Registry Number,6546711
1640,35760,pentetate(4-),,"InChI=1S/C14H23N3O10/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27)/p-4",Hdtpa(4-),Gmelin Registry Number,625543
1641,35669,"(4R)-limonene 1beta,2beta-epoxide",,"InChI=1S/C10H16O/c1-7(2)8-4-5-10(3)9(6-8)11-10/h8-9H,1,4-6H2,2-3H3/t8-,9+,10-/m1/s1","(1R,4R,6S)-4-isopropenyl-1-methyl-7-oxabicyclo[4.1.0]heptane",CAS Registry Number,4680-24-4
1642,34363,"biphenyl-4,4'-dithiol",,"InChI=1S/C12H10S2/c13-11-5-1-9(2-6-11)10-3-7-12(14)8-4-10/h1-8,13-14H","4,4'-Biphenyldithiol",KEGG COMPOUND accession,C14569
1643,34368,"stilbene-4,4'-diol",,"InChI=1S/C14H12O2/c15-13-7-3-11(4-8-13)1-2-12-5-9-14(16)10-6-12/h1-10,15-16H","4,4'-Dihydroxystilbene",CAS Registry Number,659-22-3
1644,34372,"4,4'-sulfonyldiphenol",A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups.,"InChI=1S/C12H10O4S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8,13-14H",Bisphenol S,KEGG COMPOUND accession,C14216
1645,34377,4-(1-benzofuran-2-yl)pyridine,,InChI=1S/C13H9NO/c1-2-4-12-11(3-1)9-13(15-12)10-5-7-14-8-6-10/h1-9H,4-(2-Benzofuranyl)pyridine,KEGG COMPOUND accession,C14591
1646,34391,(4-bromophenyl)thiourea,,"InChI=1S/C7H7BrN2S/c8-5-1-3-6(4-2-5)10-7(9)11/h1-4H,(H3,9,10,11)",4-Bromophenylthiourea,CAS Registry Number,2646-30-2
1647,34638,chromomycin A3,,"InChI=1S/C57H82O26/c1-21-34(79-40-19-37(53(26(6)75-40)77-28(8)59)82-38-16-33(61)52(70-11)25(5)74-38)15-31-13-30-14-32(54(71-12)51(68)46(63)22(2)58)55(50(67)44(30)49(66)43(31)45(21)62)83-41-18-35(47(64)24(4)73-41)80-39-17-36(48(65)23(3)72-39)81-42-20-57(10,69)56(27(7)76-42)78-29(9)60/h13,15,22-27,32-33,35-42,46-48,52-56,58,61-66,69H,14,16-20H2,1-12H3/t22-,23-,24-,25-,26-,27+,32+,33-,35-,36-,37-,38-,39+,40+,41+,42+,46+,47-,48-,52+,53+,54+,55+,56+,57+/m1/s1",Chromomycin A3,KEGG COMPOUND accession,C13569
1648,34642,clavulone I,,"InChI=1S/C25H34O7/c1-5-6-7-8-9-10-17-25(32-20(3)27)18-16-23(28)22(25)13-11-12-21(31-19(2)26)14-15-24(29)30-4/h9-13,16,18,21H,5-8,14-15,17H2,1-4H3/b10-9-,12-11-,22-13-/t21-,25-/m0/s1",Clavulone I,LIPID MAPS instance accession,LMFA03120001
1649,34643,clavulone II,,"InChI=1S/C25H34O7/c1-5-6-7-8-9-10-17-25(32-20(3)27)18-16-23(28)22(25)13-11-12-21(31-19(2)26)14-15-24(29)30-4/h9-13,16,18,21H,5-8,14-15,17H2,1-4H3/b10-9-,12-11+,22-13-/t21-,25-/m0/s1",Clavulone II,CAS Registry Number,85700-43-2
1650,34644,clavulone III,,"InChI=1S/C25H34O7/c1-5-6-7-8-9-10-17-25(32-20(3)27)18-16-23(28)22(25)13-11-12-21(31-19(2)26)14-15-24(29)30-4/h9-13,16,18,21H,5-8,14-15,17H2,1-4H3/b10-9-,12-11+,22-13+/t21-,25-/m0/s1",Clavulone III,LIPID MAPS instance accession,LMFA03120003
1651,34645,clavulone IV,,"InChI=1S/C25H34O7/c1-5-6-7-8-9-10-17-25(32-20(3)27)18-16-23(28)22(25)13-11-12-21(31-19(2)26)14-15-24(29)30-4/h9-13,16,18,21H,5-8,14-15,17H2,1-4H3/b10-9-,12-11-,22-13+/t21-,25-/m0/s1",Clavulone IV,LIPID MAPS instance accession,LMFA03120004
1652,34652,compactin diol lactone,A carbobicyclic compound that is ML-236C substituted by a hydroxy group at position 8S. It is a fungal metabolite isolated from Penicillium citrinum and exhibits anticholesteremic activity.,"InChI=1S/C18H26O4/c1-11-5-6-12-3-2-4-16(20)18(12)15(11)8-7-14-9-13(19)10-17(21)22-14/h3,5-6,11,13-16,18-20H,2,4,7-10H2,1H3/t11-,13+,14+,15-,16-,18-/m0/s1",compactin diol lactone,KEGG COMPOUND accession,C14183
1653,35806,"3,4-dicarboxy-3-hydroxybutanoate",A citrate(1-) that is the conjugate acid of 2-(carboxymethyl)-2-hydroxysuccinate.,"InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/p-1","3,4-dicarboxy-3-hydroxybutanoate",Gmelin Registry Number,330279
1654,34413,"4-hydroxy-2,2',3',4',6'-pentachlorobiphenyl","A member of the class of hydroxybiphenyls that is phenol substituted in the 3-position by chlorine and in the 4-position by a 2,3,4,6-tetrachlorophenyl group.","InChI=1S/C12H5Cl5O/c13-7-3-5(18)1-2-6(7)10-8(14)4-9(15)11(16)12(10)17/h1-4,18H","4-Hydroxy-2,2',3',4',6'-pentachlorobiphenyl",KEGG COMPOUND accession,C14374
1655,34432,4-octylphenol,A member of the class of phenols that is phenol which is substituted at the para- position by an octyl group.,"InChI=1S/C14H22O/c1-2-3-4-5-6-7-8-13-9-11-14(15)12-10-13/h9-12,15H,2-8H2,1H3",p-octylphenol,KEGG COMPOUND accession,C14132
1656,34446,"(Z,Z,Z)-octadeca-4,7,10-trienenitrile","The nitrile obtained by formal condensation of (Z,Z,Z)-octadeca-4,7,10-trienoic acid with ammonia.","InChI=1S/C18H29N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h8-9,11-12,14-15H,2-7,10,13,16-17H2,1H3/b9-8-,12-11-,15-14-","4Z,7Z,10Z-Octadecatrienenitrile",KEGG COMPOUND accession,C13832
1657,34447,"5,6,7,8-tetrahydro-2-naphthoic acid","A monocarboxylic acid that is 1,2,3,4-tetrahydronaphthalene which is substituted at position 6 by a carboxylic acid group.","InChI=1S/C11H12O2/c12-11(13)10-6-5-8-3-1-2-4-9(8)7-10/h5-7H,1-4H2,(H,12,13)","5,6,7,8-Tetrahydro-2-naphthoic acid",KEGG COMPOUND accession,C14111
1658,34448,"5,6,7,8-tetrahydro-2-naphthol","A member of the class tetralins that is 1,2,3,4-tetrahydronaphthalene which is substituted at position 6 by a hydroxy group.","InChI=1S/C10H12O/c11-10-6-5-8-3-1-2-4-9(8)7-10/h5-7,11H,1-4H2","5,6,7,8-Tetrahydro-2-naphthol",KEGG COMPOUND accession,C14309
1659,34720,diphenhydramine salicylate,The salicylic acid salt of diphenhydramine.,"InChI=1S/C17H21NO.C7H6O3/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;8-6-4-2-1-3-5(6)7(9)10/h3-12,17H,13-14H2,1-2H3;1-4,8H,(H,9,10)",Diphenhydramine salicylate,KEGG COMPOUND accession,C14015
1660,34722,diphenyl carbonate,A carbonate ester that is the diphenyl ester of carbonic acid.,InChI=1S/C13H10O3/c14-13(15-11-7-3-1-4-8-11)16-12-9-5-2-6-10-12/h1-10H,Diphenyl carbonate,KEGG COMPOUND accession,C14507
1661,34733,EPN,,"InChI=1S/C14H14NO4PS/c1-2-18-20(21,14-6-4-3-5-7-14)19-13-10-8-12(9-11-13)15(16)17/h3-11H,2H2,1H3",EPN,KEGG COMPOUND accession,C14434
1662,34192,"2',5'-dichlorobiphenyl-3-ol",An member of the class of hydroxybiphenyls formed formally by chlorination of biphenyl-3-ol at C-2' and -5'.,"InChI=1S/C12H8Cl2O/c13-9-4-5-12(14)11(7-9)8-2-1-3-10(15)6-8/h1-7,15H","2',5'-Dichloro-3-hydroxybiphenyl",KEGG COMPOUND accession,C14734
1663,34193,2-({4-[bis(2-chloroethyl)amino]-2-methylphenyl}diazenyl)benzoic acid,,"InChI=1S/C18H19Cl2N3O2/c1-13-12-14(23(10-8-19)11-9-20)6-7-16(13)21-22-17-5-3-2-4-15(17)18(24)25/h2-7,12H,8-11H2,1H3,(H,24,25)/b22-21+",2'-Carboxy-4-[bis(2-chloroethyl)amino]-2-methylazobenzene,KEGG COMPOUND accession,C14626
1664,34480,7-ethoxyresorufin,,"InChI=1S/C14H11NO3/c1-2-17-10-4-6-12-14(8-10)18-13-7-9(16)3-5-11(13)15-12/h3-8H,2H2,1H3",7-Ethoxyresorufin,KEGG COMPOUND accession,C13630
1665,34484,8(R)-HETE,"A HETE having an (8R)-hydroxy group and (5Z)-, (9E)-, (11Z)- and (14Z)-double bonds.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-13-16-19(21)17-14-11-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,14-11-,16-13+/t19-/m0/s1",8(R)-HETE,KEGG COMPOUND accession,C14824
1666,34485,8(R)-HPODE,The 8(R)-isomer of HPODE.,"InChI=1S/C18H32O4/c1-2-3-4-5-6-7-8-11-14-17(22-21)15-12-9-10-13-16-18(19)20/h6-7,11,14,17,21H,2-5,8-10,12-13,15-16H2,1H3,(H,19,20)/b7-6-,14-11-/t17-/m0/s1",8(R)-HPODE,KEGG COMPOUND accession,C14831
1667,34486,8(S)-HETE,"A HETE having an (8S)-hydroxy group and (5Z)-, (9E)-, (11Z)- and (14Z)-double bonds.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-13-16-19(21)17-14-11-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,14-11-,16-13+/t19-/m1/s1",8(S)-HETE,KEGG COMPOUND accession,C14776
1668,34491,8-(5-hexylfuran-2-yl)octanoic acid,,"InChI=1S/C18H30O3/c1-2-3-4-8-11-16-14-15-17(21-16)12-9-6-5-7-10-13-18(19)20/h14-15H,2-13H2,1H3,(H,19,20)",8-(5-Hexyl-furan-2-yl)-octanoic acid,KEGG COMPOUND accession,C13798
1669,34495,9(S)-HETE,"A HETE having a (9S)-hydroxy group and (5Z)-, (7E)-, (11Z)- and (14Z)-double bonds.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-10-13-16-19(21)17-14-11-9-12-15-18-20(22)23/h6-7,9-11,13-14,17,19,21H,2-5,8,12,15-16,18H2,1H3,(H,22,23)/b7-6-,11-9-,13-10-,17-14+/t19-/m0/s1",9(S)-HETE,KEGG COMPOUND accession,C14779
1670,34497,9(S)-HPETE,A 9-HPETE in which the 9-hydroxy group has S stereochemistry.,"InChI=1S/C20H32O4/c1-2-3-4-5-6-7-8-10-13-16-19(24-23)17-14-11-9-12-15-18-20(21)22/h6-7,9-11,13-14,17,19,23H,2-5,8,12,15-16,18H2,1H3,(H,21,22)/b7-6-,11-9-,13-10-,17-14+/t19-/m0/s1",9(S)-HPETE,KEGG COMPOUND accession,C14821
1671,34498,9(S)-HPODE,"An HPODE (hydroperoxy-octadecadienoic acid) in which the double bonds are at positions 10 and 12 (E and Z geometry, respectively) and the hydroperoxy group is at position 9 (S configuration). It is an intermediate in the metabolic pathway for linoleic acid.","InChI=1S/C18H32O4/c1-2-3-4-5-6-8-11-14-17(22-21)15-12-9-7-10-13-16-18(19)20/h6,8,11,14,17,21H,2-5,7,9-10,12-13,15-16H2,1H3,(H,19,20)/b8-6-,14-11+/t17-/m1/s1",9(S)-HPODE,CAS Registry Number,29774-12-7
1672,34505,8-epi-prostaglandin F2alpha,An isoprostane that is prostaglandin F2alpha having inverted stereochemistry at the 8-position.,"InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16-,17+,18-,19+/m0/s1","9,11,15-Trihydroxy-prosta-5,13-dien-1-oic acid",KEGG COMPOUND accession,C13809
1673,34506,pinellic acid,"A trihydroxyoctadecenoic acid with hydroxy groups at positions C-9, -12, and 13, and an E (cis) double bond at position 10.","InChI=1S/C18H34O5/c1-2-3-7-11-16(20)17(21)14-13-15(19)10-8-5-4-6-9-12-18(22)23/h13-17,19-21H,2-12H2,1H3,(H,22,23)/b14-13+/t15-,16-,17-/m0/s1","9,12,13-TriHOME",KEGG COMPOUND accession,C14833
1674,34520,acephate,A  phosphoramide that is  methamidophos in which one of the hydrogens is replaced by an acetyl group.,"InChI=1S/C4H10NO3PS/c1-4(6)5-9(7,8-2)10-3/h1-3H3,(H,5,6,7)",Acephate,KEGG COMPOUND accession,C14426
1675,34528,adipoyl-CoA,"An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of adipic acid.","InChI=1S/C27H44N7O19P3S/c1-27(2,22(40)25(41)30-8-7-16(35)29-9-10-57-18(38)6-4-3-5-17(36)37)12-50-56(47,48)53-55(45,46)49-11-15-21(52-54(42,43)44)20(39)26(51-15)34-14-33-19-23(28)31-13-32-24(19)34/h13-15,20-22,26,39-40H,3-12H2,1-2H3,(H,29,35)(H,30,41)(H,36,37)(H,45,46)(H,47,48)(H2,28,31,32)(H2,42,43,44)/t15-,20-,21-,22+,26-/m1/s1",Adipyl-CoA,KEGG COMPOUND accession,C14143
1676,34535,ampicillin sodium,,"InChI=1S/C16H19N3O4S.Na/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8;/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23);/q;+1/p-1/t9-,10-,11+,14-;/m1./s1",Ampicillin sodium,KEGG COMPOUND accession,C13652
1677,34887,nickel dichloride,A compound of nickel and chloride in which the ratio of nickel (in the +2 oxidation state) to chloride is 1:2.,InChI=1S/2ClH.Ni/h2*1H;/q;;+2/p-2,Nickel chloride,CAS Registry Number,7718-54-9
1678,34900,octadecanamide,A fatty amide of stearic acid.,"InChI=1S/C18H37NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-17H2,1H3,(H2,19,20)",Stearamide,CAS Registry Number,124-26-5
1679,35867,pentamethyl-lambda(5)-arsane,,"InChI=1S/C5H15As/c1-6(2,3,4)5/h1-5H3",pentamethyl-lambda(5)-arsane,Beilstein Registry Number,2408247
1680,35889,ethylphosphine,,"InChI=1S/C2H7P/c1-2-3/h2-3H2,1H3",Ethylphosphin,CAS Registry Number,593-68-0
1681,35030,trimipramine maleate,,"InChI=1S/C20H26N2.C4H4O4/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22;5-3(6)1-2-4(7)8/h4-11,16H,12-15H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-",Trimipramine maleate,KEGG COMPOUND accession,C14029
1682,35032,trioxilin B3,"A trioxilin having (all-cis 5,8,14) double bond configuration; and 10-, (11S)- and (12R)-hydroxy substituents.","InChI=1S/C20H34O5/c1-2-3-4-5-8-11-14-17(21)20(25)18(22)15-12-9-6-7-10-13-16-19(23)24/h6-8,11-12,15,17-18,20-22,25H,2-5,9-10,13-14,16H2,1H3,(H,23,24)/b7-6-,11-8-,15-12-/t17-,18?,20+/m1/s1",Trioxilin B3,KEGG COMPOUND accession,C14811
1683,35036,fentin chloride,"An organotin compound that is triphenylstannane in which the hydrogen attached to tin is replaced by a chloro group.  A fungicide used to control blights on potatoes, leaf spot diseases on sugar beet and anthracnose on beans.",InChI=1S/3C6H5.ClH.Sn/c3*1-2-4-6-5-3-1;;/h3*1-5H;1H;/q;;;;+1/p-1,Triphenyltin chloride,KEGG COMPOUND accession,C14413
1684,35048,xylylcarb,,"InChI=1S/C10H13NO2/c1-7-4-5-9(6-8(7)2)13-10(12)11-3/h4-6H,1-3H3,(H,11,12)",Xylylcarb,KEGG COMPOUND accession,C14579
1685,35056,"adenosine 5'-[alpha,beta-methylene]triphosphate",,"InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-29(19,20)4-30(21,22)28-31(23,24)25/h2-3,5,7-8,11,17-18H,1,4H2,(H,19,20)(H,21,22)(H2,12,13,14)(H2,23,24,25)/t5-,7-,8-,11-/m1/s1","alpha,beta-Methylene ATP",KEGG COMPOUND accession,C13740
1686,35063,alpha-zeacarotene,,"InChI=1S/C40H58/c1-32(2)18-13-21-35(5)24-15-26-36(6)25-14-22-33(3)19-11-12-20-34(4)23-16-27-37(7)29-30-39-38(8)28-17-31-40(39,9)10/h11-12,14,16,18-20,22-25,27-30,39H,13,15,17,21,26,31H2,1-10H3/b12-11+,22-14+,23-16+,30-29+,33-19+,34-20+,35-24+,36-25+,37-27+",alpha-Zeacarotene,KEGG COMPOUND accession,C14146
1687,35095,4-(dimethylamino)benzenediazonium tetrafluoroborate,,"InChI=1S/C8H10N3.BF4/c1-11(2)8-5-3-7(10-9)4-6-8;2-1(3,4)5/h3-6H,1-2H3;/q+1;-1",DDF,KEGG COMPOUND accession,C13681
1688,37283,heptanoyl-CoA,A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of heptanoic acid.,"InChI=1S/C28H48N7O17P3S/c1-4-5-6-7-8-19(37)56-12-11-30-18(36)9-10-31-26(40)23(39)28(2,3)14-49-55(46,47)52-54(44,45)48-13-17-22(51-53(41,42)43)21(38)27(50-17)35-16-34-20-24(29)32-15-33-25(20)35/h15-17,21-23,27,38-39H,4-14H2,1-3H3,(H,30,36)(H,31,40)(H,44,45)(H,46,47)(H2,29,32,33)(H2,41,42,43)/t17-,21-,22-,23+,27-/m1/s1","3'-phosphoadenosine 5'-(3-{(3R)-3-hydroxy-4-[(3-{[2-(heptanoylsulfanyl)ethyl]amino}-3-oxopropyl)amino]-2,2-dimethyl-4-oxobutyl} dihydrogen diphosphate)",Beilstein Registry Number,9607758
1689,36754,vetispirane,,"InChI=1S/C15H28/c1-11(2)14-8-9-15(10-14)12(3)6-5-7-13(15)4/h11-14H,5-10H2,1-4H3",agarospiran,Beilstein Registry Number,2426840
1690,34655,cortancyl,,"InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1",Cortancyl,KEGG COMPOUND accession,C14668
1691,36803,trans-dothiepin,,"InChI=1S/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+","(3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine",Beilstein Registry Number,3616619
1692,34590,bromobutide,"A monocarboxylic acid amide having a 2-phenylpropan-2-yl substituent attached to the amide nitrogen and a 1-bromo-2,2-dimethylpropyl group attached to the carbonyl carbon.","InChI=1S/C15H22BrNO/c1-14(2,3)12(16)13(18)17-15(4,5)11-9-7-6-8-10-11/h6-10,12H,1-5H3,(H,17,18)",Bromobutide,KEGG COMPOUND accession,C14568
1693,34612,carfecillin sodium,,"InChI=1S/C23H22N2O6S.Na/c1-23(2)17(21(28)29)25-19(27)16(20(25)32-23)24-18(26)15(13-9-5-3-6-10-13)22(30)31-14-11-7-4-8-12-14;/h3-12,15-17,20H,1-2H3,(H,24,26)(H,28,29);/q;+1/p-1/t15?,16-,17+,20-;/m1./s1",Carfecillin sodium,KEGG COMPOUND accession,C13976
1694,34677,diheptyl phthalate,"The diheptyl ester of benzene-1,2-dicarboxylic acid.","InChI=1S/C22H34O4/c1-3-5-7-9-13-17-25-21(23)19-15-11-12-16-20(19)22(24)26-18-14-10-8-6-4-2/h11-12,15-16H,3-10,13-14,17-18H2,1-2H3",Di-n-heptyl phthalate,KEGG COMPOUND accession,C14575
1695,34704,dihydro-beta-ergocryptine mesylate,The methanesulfonic acid salt of dihydro-beta-ergocryptine.,"InChI=1S/C32H43N5O5.CH4O3S/c1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20;1-5(2,3)4/h7,9-10,15,17-18,20,22,24-25,27,33,41H,6,8,11-14,16H2,1-5H3,(H,34,38);1H3,(H,2,3,4)/t18?,20-,22-,24-,25+,27+,31-,32+;/m1./s1",Dihydro-beta-ergocryptine mesylate,KEGG COMPOUND accession,C14054
1696,34978,cloxacillin sodium monohydrate,,"InChI=1S/C19H18ClN3O5S.Na.H2O/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23;;/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27);;1H2/q;+1;/p-1/t13-,14+,17-;;/m1../s1",Sodium cloxacillin monohydrate,KEGG COMPOUND accession,C14010
1697,34991,"5,11,17,23-tetrasulfo-25,26,27,28-tetramethoxycalix[4]arene",,"InChI=1S/C32H32O16S4/c1-45-29-17-5-19-11-26(50(36,37)38)13-21(30(19)46-2)7-23-15-28(52(42,43)44)16-24(32(23)48-4)8-22-14-27(51(39,40)41)12-20(31(22)47-3)6-18(29)10-25(9-17)49(33,34)35/h9-16H,5-8H2,1-4H3,(H,33,34,35)(H,36,37,38)(H,39,40,41)(H,42,43,44)",TS-TM-calix(4)arene,KEGG COMPOUND accession,C13704
1698,34995,teicoplanin A2-1,A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.,"InChI=1S/C88H95Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)131-78-75(114)72(111)57(31-100)127-85(78)99-67-55-26-40-27-56(67)126-52-18-14-38(24-47(52)90)77(132-87-68(92-34(2)103)73(112)70(109)58(32-101)129-87)69-84(121)97-66(86(122)123)45-29-42(105)30-54(128-88-76(115)74(113)71(110)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)98-69)95-83(120)65(40)96-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)94-64)20-35-11-17-51(125-55)46(89)19-35/h7-8,11-19,21-30,48,57-59,62-66,68-78,85,87-88,99-102,104-107,109-115H,3-6,9-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,116)(H,95,120)(H,96,119)(H,97,121)(H,98,118)(H,122,123)/b8-7-/t48-,57-,58-,59-,62-,63-,64+,65-,66+,68-,69+,70-,71-,72-,73-,74+,75+,76+,77-,78-,85-,87+,88+/m1/s1",Teicoplanin A2-1,KEGG COMPOUND accession,C13587
1699,34756,fenamic acid,An aminobenzoic acid that is the N-phenyl derivative of  anthranilic acid. It acts as a parent skeleton for the synthesis of several non-steroidal anti-inflammatory drugs.,"InChI=1S/C13H11NO2/c15-13(16)11-8-4-5-9-12(11)14-10-6-2-1-3-7-10/h1-9,14H,(H,15,16)",Fenamic acid,KEGG COMPOUND accession,C13697
1700,34760,fensulfothion,,"InChI=1S/C11H17O4PS2/c1-4-13-16(17,14-5-2)15-10-6-8-11(9-7-10)18(3)12/h6-9H,4-5H2,1-3H3",Fensulfothion,KEGG COMPOUND accession,C14510
1701,34761,fenthion,"An organic thiophosphate that is O,O-dimethyl hydrogen phosphorothioate in which the hydrogen atom of the hydroxy group is replaced by a 3-methyl-4-(methylsulfanyl)phenyl group. It exhibits  acaricidal and insecticidal activities.","InChI=1S/C10H15O3PS2/c1-8-7-9(5-6-10(8)16-4)13-14(15,11-2)12-3/h5-7H,1-4H3",Fenthion,KEGG COMPOUND accession,C14420
1702,34763,flucythrinate,,"InChI=1S/C26H23F2NO4/c1-17(2)24(18-11-13-21(14-12-18)32-26(27)28)25(30)33-23(16-29)19-7-6-10-22(15-19)31-20-8-4-3-5-9-20/h3-15,17,23-24,26H,1-2H3/t23?,24-/m0/s1",Flucythrinate,KEGG COMPOUND accession,C14524
1703,36068,cyclo-trialuminium,,InChI=1S/3Al,Al3,Gmelin Registry Number,952
1704,36071,cyclo-trialuminium(1+),,InChI=1S/3Al/q;;+1,cyclo-trialuminium(1+),Gmelin Registry Number,532353
1705,36077,topaquinone,"A non-proteinogenic alpha-amino acid that is alanine substituted at position 3 by a 2-hydroxy-1,4-benzoquinon-5-yl group.","InChI=1S/C9H9NO5/c10-5(9(14)15)1-4-2-7(12)8(13)3-6(4)11/h2-3,5,13H,1,10H2,(H,14,15)","2,4,5-trihydroxyphenylalanine quinone",Beilstein Registry Number,2850806
1706,35997,tridecaaluminate(1-),,InChI=1S/13Al/q;;;;;;;;;;;;-1,Al13(-),Gmelin Registry Number,1544898
1707,34656,cumene,An alkylbenzene that is benzene carrying an isopropyl group.,"InChI=1S/C9H12/c1-8(2)9-6-4-3-5-7-9/h3-8H,1-2H3",Cumene,KEGG COMPOUND accession,C14396
1708,34659,sodium cyanotriphenylborate,,"InChI=1S/C19H15BN.Na/c21-16-20(17-10-4-1-5-11-17,18-12-6-2-7-13-18)19-14-8-3-9-15-19;/h1-15H;/q-1;+1",Cyanotriphenylborate,KEGG COMPOUND accession,C13721
1709,34663,"4,4'-dinitrostilbene-2,2'-disulfonic acid",,"InChI=1S/C14H10N2O10S2/c17-15(18)11-5-3-9(13(7-11)27(21,22)23)1-2-10-4-6-12(16(19)20)8-14(10)28(24,25)26/h1-8H,(H,21,22,23)(H,24,25,26)",DNDS,KEGG COMPOUND accession,C13706
1710,34675,bis(2-ethylhexyl) adipate,A diester resulting from the formal condensation of the carboxy groups of adipic acid with 2-ethylhexan-1-ol. It is used as a plasticiser in the preparation of various polymers.,"InChI=1S/C22H42O4/c1-5-9-13-19(7-3)17-25-21(23)15-11-12-16-22(24)26-18-20(8-4)14-10-6-2/h19-20H,5-18H2,1-4H3",Di(2-ethylhexyl) adipate,KEGG COMPOUND accession,C14240
1711,34956,ruthenium red,,InChI=1S/6ClH.14H3N.2O.3Ru/h6*1H;14*1H3;;;;;/q;;;;;;;;;;;;;;;;;;;;;;3*+2/p-6,Ruthenium red,KEGG COMPOUND accession,C13932
1712,34976,simetryn,"A diamino-1,3,5-triazine that is N,N'-diethyl-1,3,5-triazine-2,4-diamine substituted by a methylthio group at position 6.","InChI=1S/C8H15N5S/c1-4-9-6-11-7(10-5-2)13-8(12-6)14-3/h4-5H2,1-3H3,(H2,9,10,11,12,13)",Simetryn,KEGG COMPOUND accession,C14457
1713,34993,talampicillin hydrochloride,,"InChI=1S/C24H23N3O6S.ClH/c1-24(2)17(22(31)33-23-14-11-7-6-10-13(14)21(30)32-23)27-19(29)16(20(27)34-24)26-18(28)15(25)12-8-4-3-5-9-12;/h3-11,15-17,20,23H,25H2,1-2H3,(H,26,28);1H/t15-,16-,17+,20-,23?;/m1./s1",Talampicillin hydrochloride,KEGG COMPOUND accession,C13978
1714,34996,teicoplanin A2-3,A teicoplanin A2 that has decanoyl as the variable N-acyl group.,"InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88+/m1/s1",Teicoplanin A2-3,KEGG COMPOUND accession,C13588
1715,34997,teicoplanin A2-4,A teicoplanin A2 that has 8-methyldecanoyl as the variable N-acyl group.,"InChI=1S/C89H99Cl2N9O33/c1-4-34(2)9-7-5-6-8-10-61(109)95-69-75(114)72(111)59(32-102)130-88(69)133-79-56-26-41-27-57(79)127-53-18-14-39(24-48(53)91)78(132-87-68(93-35(3)104)74(113)71(110)58(31-101)129-87)70-85(122)99-67(86(123)124)46-29-43(106)30-55(128-89-77(116)76(115)73(112)60(33-103)131-89)62(46)45-23-38(13-15-50(45)107)64(82(119)100-70)97-84(121)66(41)98-83(120)65-40-21-42(105)28-44(22-40)125-54-25-37(12-16-51(54)108)63(92)81(118)94-49(80(117)96-65)20-36-11-17-52(126-56)47(90)19-36/h11-19,21-30,34,49,58-60,63-78,87-89,101-103,105-108,110-116H,4-10,20,31-33,92H2,1-3H3,(H,93,104)(H,94,118)(H,95,109)(H,96,117)(H,97,121)(H,98,120)(H,99,122)(H,100,119)(H,123,124)/t34?,49-,58-,59-,60-,63-,64-,65+,66-,67+,68-,69-,70+,71-,72-,73-,74-,75-,76+,77+,78-,87+,88+,89+/m1/s1",Teicoplanin A2-4,KEGG COMPOUND accession,C13610
1716,35005,tetrachlorvinphos,,"InChI=1S/C10H9Cl4O4P/c1-16-19(15,17-2)18-10(5-11)6-3-8(13)9(14)4-7(6)12/h3-5H,1-2H3/b10-5-",Tetrachlorvinphos,CAS Registry Number,22248-79-9
1717,35008,tetralin,"An ortho-fused bicyclic hydrocarbon that is 1,2,3,4-tetrahydro derivative of naphthalene.","InChI=1S/C10H12/c1-2-6-10-8-4-3-7-9(10)5-1/h1-2,5-6H,3-4,7-8H2",Tetralin,CAS Registry Number,119-64-2
1718,35009,tetrapentylammonium,,"InChI=1S/C20H44N/c1-5-9-13-17-21(18-14-10-6-2,19-15-11-7-3)20-16-12-8-4/h5-20H2,1-4H3/q+1",Tetrapentylammonium,CAS Registry Number,15959-61-2
1719,35012,thiodiacetic acid,,"InChI=1S/C4H6O4S/c5-3(6)1-9-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)",Thiodiacetic acid,KEGG COMPOUND accession,C14872
1720,35017,ticarcillin disodium,,"InChI=1S/C15H16N2O6S2.2Na/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6;;/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23);;/q;2*+1/p-2/t7-,8-,9+,12-;;/m1../s1",Ticarcillin disodium,KEGG COMPOUND accession,C14021
1721,35019,tributyl phosphate,A trialkyl phosphate that is the tributyl ester of phosphoric acid.,"InChI=1S/C12H27O4P/c1-4-7-10-14-17(13,15-11-8-5-2)16-12-9-6-3/h4-12H2,1-3H3",Tributyl phosphate,KEGG COMPOUND accession,C14439
1722,35020,tributyrin,A triglyceride obtained by formal acylation of the three hydroxy groups of glycerol by butyric acid.,"InChI=1S/C15H26O6/c1-4-7-13(16)19-10-12(21-15(18)9-6-3)11-20-14(17)8-5-2/h12H,4-11H2,1-3H3",Glyceryl tributyrate,KEGG COMPOUND accession,C13870
1723,36102,(2R)-flavan,The (R)-enantiomer of flavan.,"InChI=1S/C15H14O/c1-2-6-12(7-3-1)15-11-10-13-8-4-5-9-14(13)16-15/h1-9,15H,10-11H2/t15-/m1/s1",(2R)-2-phenylchromane,Reaxys Registry Number,15784694
1724,36103,(2S)-flavan,The (S)-enantiomer of flavan.,"InChI=1S/C15H14O/c1-2-6-12(7-3-1)15-11-10-13-8-4-5-9-14(13)16-15/h1-9,15H,10-11H2/t15-/m0/s1",(2S)-2-phenylchromane,Beilstein Registry Number,8683796
1725,36105,(2R)-flavanone,The (R)-enantiomer of flavanone.,"InChI=1S/C15H12O2/c16-13-10-15(11-6-2-1-3-7-11)17-14-9-5-4-8-12(13)14/h1-9,15H,10H2/t15-/m1/s1","(2R)-2-phenyl-2,3-dihydro-4H-chromen-4-one",Beilstein Registry Number,85289
1726,34764,flumethasone,,"InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1","6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione",KEGG COMPOUND accession,C14479
1727,33179,2H-isoindole,,"InChI=1S/C8H7N/c1-2-4-8-6-9-5-7(8)3-1/h1-6,9H",2H-isoindole,CAS Registry Number,270-68-8
1728,36010,cis-pinosylvin,,"InChI=1S/C14H12O2/c15-13-8-12(9-14(16)10-13)7-6-11-4-2-1-3-5-11/h1-10,15-16H/b7-6-","5-[(Z)-2-phenylvinyl]benzene-1,3-diol",Beilstein Registry Number,5254910
1729,34197,"2,2',3,3',5,5'-hexachlorobiphenyl","A hexachlorobiphenyl that is biphenyl in which the hydrogens at the 2, 3, and 5 positions of each of the benzene rings are replaced by chlorines.",InChI=1S/C12H4Cl6/c13-5-1-7(11(17)9(15)3-5)8-2-6(14)4-10(16)12(8)18/h1-4H,"2,2',3,3',5,5'-Hexachlorobiphenyl",Beilstein Registry Number,2288106
1730,34199,"2,2',3,3',6,6'-hexachlorobiphenyl",,InChI=1S/C12H4Cl6/c13-5-1-3-7(15)11(17)9(5)10-6(14)2-4-8(16)12(10)18/h1-4H,"2,2',3,3',6,6'-Hexachlorobiphenyl",Beilstein Registry Number,2294224
1731,34203,"2,2',4,4',6,6'-hexachlorobiphenyl","A hexachlorobiphenyl that is biphenyl in which both of the phenyl rings are substituted at positons 2, 4, and 6 by chlorines.",InChI=1S/C12H4Cl6/c13-5-1-7(15)11(8(16)2-5)12-9(17)3-6(14)4-10(12)18/h1-4H,"2,2',4,4',6,6'-Hexachlorobiphenyl",Beilstein Registry Number,2058693
1732,34216,"2,3,3',4,5-pentachlorobiphenyl",,InChI=1S/C12H5Cl5/c13-7-3-1-2-6(4-7)8-5-9(14)11(16)12(17)10(8)15/h1-5H,"2,3,3',4,5-Pentachlorobiphenyl",Beilstein Registry Number,4464227
1733,34908,pentachloronitrobenzene,"A C-nitro compound that is nitrobenzene in which every hydrogen has been replaced by a chlorine. A fungicide used on a variety of crops, including cotton, rice and seed grains, it is no longer approved for use within the European Union.",InChI=1S/C6Cl5NO2/c7-1-2(8)4(10)6(12(13)14)5(11)3(1)9,Pentachloronitrobenzene,KEGG COMPOUND accession,C14338
1734,34912,perphenazine maleate,,"InChI=1S/C21H26ClN3OS.2C4H4O4/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26;2*5-3(6)1-2-4(7)8/h1-2,4-7,16,26H,3,8-15H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-",Perphenazine maleate,KEGG COMPOUND accession,C13540
1735,34916,phenothrin,,"InChI=1S/C23H26O3/c1-16(2)13-20-21(23(20,3)4)22(24)25-15-17-9-8-12-19(14-17)26-18-10-6-5-7-11-18/h5-14,20-21H,15H2,1-4H3",Phenothrin,KEGG COMPOUND accession,C14387
1736,34917,phenthoate,An organic thiophosphate that is  ethyl mandelate in which the hydroxy group has been replaced by a (dimethoxyphosphorothioyl)sulfanediyl group.,"InChI=1S/C12H17O4PS2/c1-4-16-12(13)11(10-8-6-5-7-9-10)19-17(18,14-2)15-3/h5-9,11H,4H2,1-3H3",Phenthoate,KEGG COMPOUND accession,C14429
1737,34932,prochlorperazine methanesulfonate,,"InChI=1S/C20H24ClN3S.2CH4O3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24;2*1-5(2,3)4/h2-3,5-8,15H,4,9-14H2,1H3;2*1H3,(H,2,3,4)",Prochlorperazine mesylate,KEGG COMPOUND accession,C13524
1738,34934,prometon,"A  methoxy-1,3,5-triazine that is 6-methoxy-1,3,5-triazine-2,4-diamine in which the one of the hydrogens of each amino group is substituted by an isopropyl group.","InChI=1S/C10H19N5O/c1-6(2)11-8-13-9(12-7(3)4)15-10(14-8)16-5/h6-7H,1-5H3,(H2,11,12,13,14,15)",Prometon,KEGG COMPOUND accession,C14186
1739,36163,ferroheme a,,"InChI=1S/C49H58N4O6.Fe/c1-9-34-31(6)39-25-45-49(46(55)18-12-17-30(5)16-11-15-29(4)14-10-13-28(2)3)33(8)40(52-45)24-44-37(27-54)36(20-22-48(58)59)43(53-44)26-42-35(19-21-47(56)57)32(7)38(51-42)23-41(34)50-39;/h9,13,15,17,23-27,46,55H,1,10-12,14,16,18-22H2,2-8H3,(H4,50,51,52,53,54,56,57,58,59);/q;+2/p-2/b29-15+,30-17+,38-23-,39-25-,40-24-,41-23-,42-26-,43-26-,44-24-,45-25-;/t46-;/m0./s1",(cytoporphyrinato)iron(II),Beilstein Registry Number,1206306
1740,34267,"2-chloro-1,1'-biphenyl-4,4'-diol","A member of the class of hydroxybiphenyls that is biphenyl-4,4'-diol in which the hydrogen at position 2 has been replaced by a chlorine.","InChI=1S/C12H9ClO2/c13-12-7-10(15)5-6-11(12)8-1-3-9(14)4-2-8/h1-7,14-15H","2-Chloro-4,4'-biphenyldiol",KEGG COMPOUND accession,C14191
1741,39901,"3,4-dimethylaniline","A  primary arylamine that is aniline in which the hydrogens at the 3- and 4-positions are replaced by methyl groups. A low-melting, crystalline solid, it is used in the production of vitamin B2, dyes, pesticides and other chemicals.","InChI=1S/C8H11N/c1-6-3-4-8(9)5-7(6)2/h3-5H,9H2,1-2H3","3,4-DIMETHYLANILINE",PDBeChem accession,34A
1742,40196,N(6)-methyl-AMP,The purine ribonucleoside 5'-monophosphate that is AMP monomethylated on N(6).,"InChI=1S/C11H16N5O7P/c1-12-9-6-10(14-3-13-9)16(4-15-6)11-8(18)7(17)5(23-11)2-22-24(19,20)21/h3-5,7-8,11,17-18H,2H2,1H3,(H,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1",N6-METHYLADENOSINE-5'-MONOPHOSPHATE,PDBeChem accession,6MZ
1743,39874,3'-deoxyguanosine,A 3'-deoxyribonucleoside having guanine as the nucleobase.,"InChI=1S/C10H13N5O4/c11-10-13-7-6(8(18)14-10)12-3-15(7)9-5(17)1-4(2-16)19-9/h3-5,9,16-17H,1-2H2,(H3,11,13,14,18)/t4-,5+,9+/m0/s1",9-(3-deoxy-beta-D-ribofuranosyl)guanine,PDBeChem accession,3DG
1744,39959,"(1S,2R,5S)-5-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-(2,4,5-trifluorophenyl)cyclohexanamine",A triazolopyrazine that is a rigid cyclohexylamine analogue of sitagliptin.,"InChI=1S/C18H19F6N5/c19-12-7-14(21)13(20)6-11(12)10-2-1-9(5-15(10)25)28-3-4-29-16(8-28)26-27-17(29)18(22,23)24/h6-7,9-10,15H,1-5,8,25H2/t9-,10+,15-/m0/s1","(1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE",PDBeChem accession,417
1745,40413,5-[(4-nitrobenzyl)(phosphonomethyl)amino]valeric acid,"A C-nitro compound that is the N-(4-nitrobenzyl),N-phosphonomethyl derivative of 5-aminovaleric acid.","InChI=1S/C13H19N2O7P/c16-13(17)3-1-2-8-14(10-23(20,21)22)9-11-4-6-12(7-5-11)15(18)19/h4-7H,1-3,8-10H2,(H,16,17)(H2,20,21,22)",1-[N-4'-NITROBENZYL-N-4'-CARBOXYBUTYLAMINO]METHYLPHOSPHONIC ACID,PDBeChem accession,AAH
1746,40454,"[(2R,3R,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl-ADP",,"InChI=1S/C15H24N6O12P2/c16-13-9-14(19-4-18-13)21(5-20-9)15-12(25)11(24)8(32-15)3-31-35(28,29)33-34(26,27)30-2-6-10(23)7(22)1-17-6/h4-8,10-12,15,17,22-25H,1-3H2,(H,26,27)(H,28,29)(H2,16,18,19)/t6-,7+,8-,10-,11-,12-,15-/m1/s1","5'-O-[(S)-{[(S)-{[(2R,3R,4S)-3,4-DIHYDROXYPYRROLIDIN-2-YL]METHOXY}(HYDROXY)PHOSPHORYL]OXY}(HYDROXY)PHOSPHORYL]ADENOSINE",Beilstein Registry Number,7260839
1747,39721,ethyl 2-amino-4-hydroxypyrimidine-5-carboxylate,An aminopyrimidine that is 2-amino-4-hydroxypyrimidine in which the hydrogen at position 5 is substituted by an ethoxycarbonyl group.,"InChI=1S/C7H9N3O3/c1-2-13-6(12)4-3-9-7(8)10-5(4)11/h3H,2H2,1H3,(H3,8,9,10,11)",2-AMINO-4-HYDROXYPYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER,PDBeChem accession,204
1748,39733,(Z)-SB-590885,"An N-{5-[2-{4-[2-(dimethylamino)ethoxy]phenyl}-4-(pyridin-4-yl)-1H-imidazol-5-yl]-2,3-dihydro-1H-inden-1-ylidene}hydroxylamine in which the oxime group has Z configuration.","InChI=1S/C27H27N5O2/c1-32(2)15-16-34-22-7-3-19(4-8-22)27-29-25(18-11-13-28-14-12-18)26(30-27)21-5-9-23-20(17-21)6-10-24(23)31-33/h3-5,7-9,11-14,17,33H,6,10,15-16H2,1-2H3,(H,29,30)/b31-24-","(1Z)-5-(2-{4-[2-(dimethylamino)ethoxy]phenyl}-5-pyridin-4-yl-1H-imidazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime",PDBeChem accession,215
1749,39916,"(S,S)-(furan-2,5-diyldibenzene-4,1-diyl)bis{N-[(1R)-1-methylbutyl]methanediamine}",A substituted diphenylfuran in which two amino[(1-methylbutyl)amino]methyl substituents are located at the two para-positions on the phenyl rings.,"InChI=1S/C28H40N4O/c1-5-7-19(3)31-27(29)23-13-9-21(10-14-23)25-17-18-26(33-25)22-11-15-24(16-12-22)28(30)32-20(4)8-6-2/h9-20,27-28,31-32H,5-8,29-30H2,1-4H3/t19-,20-,27+,28+/m1/s1","2,5-BIS{[4-(2-PENTYL)DIAMINOMETHYL]PHENYL}FURAN",PDBeChem accession,3AF
1750,40114,4-(2-thienyl)butyric acid,A monocarboxylic acid that is butyric acid bearing a 2-thienyl group at position 4.,"InChI=1S/C8H10O2S/c9-8(10)5-1-3-7-4-2-6-11-7/h2,4,6H,1,3,5H2,(H,9,10)",4-thiophen-2-ylbutanoic acid,PDBeChem accession,4TB
1751,37817,cyclodecyne,,InChI=1S/C10H16/c1-2-4-6-8-10-9-7-5-3-1/h1-8H2,cyclodecyne,CAS Registry Number,3022-41-1
1752,38850,perfluorotripropylamine,,"InChI=1S/C9F21N/c10-1(11,4(16,17)18)7(25,26)31(8(27,28)2(12,13)5(19,20)21)9(29,30)3(14,15)6(22,23)24",FTPA,CAS Registry Number,338-83-0
1753,38895,cyanotriphenylborate(1-),,"InChI=1S/C19H15BN/c21-16-20(17-10-4-1-5-11-17,18-12-6-2-7-13-18)19-14-8-3-9-15-19/h1-15H/q-1",(cyano-kappaC)(triphenyl)borate(1-),Beilstein Registry Number,3910397
1754,39152,mercury difulminate,An organomercury compound that is the bis(N-oxide) of mercury(II) cyanide. It is a highly shock- and friction-sensitive explosive.,InChI=1S/2CNO.Hg/c2*1-2-3;,Knallquecksilber,CAS Registry Number,628-86-4
1755,40260,6-hydroxy-FAD,Flavin-adenine dinucleotide (FAD) in which the hydrogen at position 6 of the benzo[g]pteridinedione moiety is substituted by a hydroxy group.,"InChI=1S/C27H33N9O16P2/c1-9-3-11-15(18(39)10(9)2)32-17-24(33-27(44)34-25(17)43)35(11)4-12(37)19(40)13(38)5-49-53(45,46)52-54(47,48)50-6-14-20(41)21(42)26(51-14)36-8-31-16-22(28)29-7-30-23(16)36/h3,7-8,12-14,19-21,26,37-42H,4-6H2,1-2H3,(H,45,46)(H,47,48)(H2,28,29,30)(H,34,43,44)/t12-,13+,14+,19-,20+,21+,26+/m0/s1",6-HYDROXY-FLAVIN-ADENINE DINUCLEOTIDE,CAS Registry Number,52301-43-6
1756,40096,adenosine 5'-(hexahydrogen pentaphosphate),A nucleoside pentaphosphate that is adenosine in which a hexahydrogen pentaphosphate is attached at the 5' position.,"InChI=1S/C10H18N5O19P5/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(30-10)1-29-36(21,22)32-38(25,26)34-39(27,28)33-37(23,24)31-35(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1",ADENOSINE-5'-PENTAPHOSPHATE,PDBeChem accession,5FA
1757,39561,cetyltrimethylammonium ion,A quaternary ammonium ion in which the substituents on nitrogen are one hexadecyl and three methyl groups.,"InChI=1S/C19H42N/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(2,3)4/h5-19H2,1-4H3/q+1",CETYL-TRIMETHYL-AMMONIUM,PDBeChem accession,16A
1758,39610,2-amino-2-deoxy-beta-D-galactopyranose,A deoxygalactose derivative that is beta-D-galactose in which the hydroxy group at position2 has been replaced by an amino group.,"InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4+,5-,6-/m1/s1",2-DEOXY-2-AMINOGALACTOSE,PDBeChem accession,1GN
1759,39631,pentaethylene glycol,,"InChI=1S/C10H22O6/c11-1-3-13-5-7-15-9-10-16-8-6-14-4-2-12/h11-12H,1-10H2",PENTAETHYLENE GLYCOL,CAS Registry Number,4792-15-8
1760,39784,nonaethylene glycol,,"InChI=1S/C18H38O10/c19-1-3-21-5-7-23-9-11-25-13-15-27-17-18-28-16-14-26-12-10-24-8-6-22-4-2-20/h19-20H,1-18H2",NONAETHYLENE GLYCOL,CAS Registry Number,3386-18-3
1761,39930,(3R)-3-hydroxy-8'-apo-beta-carotenol,An apo carotenoid triterpenoid compound consisting of 8'-apo-beta-carotene having a hydroxy group at the 8'-position and an (R)-hydroxy substituent at the 3-position.,"InChI=1S/C30H42O2/c1-23(12-8-9-13-24(2)15-11-17-26(4)22-31)14-10-16-25(3)18-19-29-27(5)20-28(32)21-30(29,6)7/h8-19,28,31-32H,20-22H2,1-7H3/b9-8+,14-10+,15-11+,19-18+,23-12+,24-13+,25-16+,26-17+/t28-/m1/s1",(3R)-3-HYDROXY-8'-APOCAROTENOL,PDBeChem accession,3ON
1762,39955,"(2S,3S)-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-oxo-1-pyrrolidin-1-ylbutan-2-amine","An N-acylpyrrolidine that is the pyrrolidine amide of (2S,3S)-2-amino-3-{3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}butanoic acid.","InChI=1S/C17H22N4O4S/c1-11(14(18)17(22)21-9-3-4-10-21)16-19-15(20-25-16)12-5-7-13(8-6-12)26(2,23)24/h5-8,11,14H,3-4,9-10,18H2,1-2H3/t11-,14-/m0/s1","(2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE",PDBeChem accession,3TP
1763,40070,4-hydroxycoumarin,A hydroxycoumarin that is coumarin in which the hydrogen at position 4 is replaced by a hydroxy group.,"InChI=1S/C9H6O3/c10-7-5-9(11)12-8-4-2-1-3-6(7)8/h1-5,10H",4-HYDROXY-2H-CHROMEN-2-ONE,PDBeChem accession,4HC
1764,40118,"{4-[2,2-bis(5-methyl-1,2,4-oxadiazol-3-yl)-3-phenylpropyl]phenyl}sulfamic acid",,"InChI=1S/C21H21N5O5S/c1-14-22-19(24-30-14)21(20-23-15(2)31-25-20,12-16-6-4-3-5-7-16)13-17-8-10-18(11-9-17)26-32(27,28)29/h3-11,26H,12-13H2,1-2H3,(H,27,28,29)","{4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID",PDBeChem accession,4UN
1765,40149,(3S)-1-cyclohexyl-5-oxo-N-phenylpyrrolidine-3-carboxamide,,"InChI=1S/C17H22N2O2/c20-16-11-13(12-19(16)15-9-5-2-6-10-15)17(21)18-14-7-3-1-4-8-14/h1,3-4,7-8,13,15H,2,5-6,9-12H2,(H,18,21)/t13-/m0/s1",(3S)-1-CYCLOHEXYL-5-OXO-N-PHENYLPYRROLIDINE-3-CARBOXAMIDE,PDBeChem accession,566
1766,39634,"N-{5-[4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}nicotinamide",,"InChI=1S/C24H24N6O/c1-29-9-11-30(12-10-29)20-6-4-17(5-7-20)19-13-21-22(16-27-23(21)26-15-19)28-24(31)18-3-2-8-25-14-18/h2-8,13-16H,9-12H2,1H3,(H,26,27)(H,28,31)","N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE",PDBeChem accession,199
1767,38760,mellein,"An isochromane that is 3,4-dihydroisocoumarin bearing methyl and hydroxy substituents at positions 3 and 8 respectively.","InChI=1S/C10H10O3/c1-6-5-7-3-2-4-8(11)9(7)10(12)13-6/h2-4,6,11H,5H2,1H3",8-hydroxy-3-methylisochroman-1-one,Reaxys Registry Number,83703
1768,38156,avenic acid B,,"InChI=1S/C8H15NO6/c10-4-2-5(7(12)13)9-3-1-6(11)8(14)15/h5-6,9-11H,1-4H2,(H,12,13)(H,14,15)/t5-,6-/m0/s1",N-[(3S)-3-carboxy-3-hydroxypropyl]-L-homoserine,Beilstein Registry Number,5016172
1769,37791,nonaoxidotritungsten,,InChI=1S/9O.3W,[W3O6(mu-O)3],Gmelin Registry Number,534255
1770,37795,cyclo-nonaoxidotritungstate(1-),,InChI=1S/9O.3W/q;;;;;;;;-1;;;,[W3O6(mu-O)3](-),Gmelin Registry Number,2234376
1771,39319,"3-(2-chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid","An organofluorine compound consisting of cyclopropanecarboxylic acid having a 2-chloro-3,3,3-trifluoroprop-1-en-1-yl group at the 3-position and two methyl groups at the 2-position.","InChI=1S/C9H10ClF3O2/c1-8(2)4(6(8)7(14)15)3-5(10)9(11,12)13/h3-4,6H,1-2H3,(H,14,15)","3-(2-chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid",CAS Registry Number,74609-46-4
1772,38715,thiomalate(3-),,"InChI=1S/C4H6O4S/c5-3(6)1-2(9)4(7)8/h2,9H,1H2,(H,5,6)(H,7,8)/p-3",2-sulfidosuccinate,Gmelin Registry Number,327564
1773,38719,(R)-thiomalic acid,,"InChI=1S/C4H6O4S/c5-3(6)1-2(9)4(7)8/h2,9H,1H2,(H,5,6)(H,7,8)/t2-/m1/s1",(2R)-2-mercaptosuccinic acid,Beilstein Registry Number,1723545
1774,38731,N-methyl-2-sulfanylacetamide,A monocarboxylic acid amide resulting from formal condensation between mercaptoacetic acid and methylamine.,"InChI=1S/C3H7NOS/c1-4-3(5)2-6/h6H,2H2,1H3,(H,4,5)",N-methyl-2-sulfanylacetamide,Beilstein Registry Number,1740652
1775,39310,(1S)-trans-(alphaR)-cyfluthrin,,"InChI=1S/C22H18Cl2FNO3/c1-22(2)15(11-19(23)24)20(22)21(27)29-18(12-26)13-8-9-16(25)17(10-13)28-14-6-4-3-5-7-14/h3-11,15,18,20H,1-2H3/t15-,18-,20+/m0/s1","(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate",Beilstein Registry Number,8351888
1776,37776,cyclo-nonaoxidotrimolybdate(1-),,InChI=1S/3Mo.9O/q;;;;;;;;;;;-1,[Mo3O6(mu-O)3](-),Gmelin Registry Number,2426765
1777,37913,5beta-cyprinol,,"InChI=1S/C27H48O5/c1-16(5-4-6-17(14-28)15-29)20-7-8-21-25-22(13-24(32)27(20,21)3)26(2)10-9-19(30)11-18(26)12-23(25)31/h16-25,28-32H,4-15H2,1-3H3/t16-,18+,19-,20-,21+,22+,23-,24+,25+,26+,27-/m1/s1","3alpha,7alpha,12alpha,26,27-pentahydroxy-5beta-cholestane",Beilstein Registry Number,6229965
1778,38103,(7R)-salutaridinol,,"InChI=1S/C19H23NO4/c1-20-7-6-19-10-16(24-3)14(21)9-12(19)13(20)8-11-4-5-15(23-2)18(22)17(11)19/h4-5,9-10,13-14,21-22H,6-8H2,1-3H3/t13-,14-,19+/m1/s1",7-epi-salutaridinol,Beilstein Registry Number,1552913
1779,38872,"1,8-dichloro-perfluorooctane",An organofluorine compound that is perfluorooctane in which a fluorine from each of the terminal trifluoromethyl groups has been replaced by a chlorine.,"InChI=1S/C8Cl2F16/c9-7(23,24)5(19,20)3(15,16)1(11,12)2(13,14)4(17,18)6(21,22)8(10,25)26",PFDCO,Beilstein Registry Number,2483941
1780,38889,tetraborate(2-),,"InChI=1S/B4H4O9/c5-1-9-3(7)11-2(6)12-4(8,10-1)13-3/h5-8H/q-2",[B4O5(OH)4](2-),Gmelin Registry Number,306362
1781,39003,perfluoro-1-methyladamantane,,"InChI=1S/C11F18/c12-2-5(15,16)1(11(27,28)29)6(17,18)3(13,8(2,21)22)10(25,26)4(14,7(1,19)20)9(2,23)24",FMA,CAS Registry Number,60096-00-6
1782,39160,trichostatin D,,"InChI=1S/C23H32N2O8/c1-13(11-14(2)19(28)15-6-8-16(9-7-15)25(3)4)5-10-18(27)24-33-23-22(31)21(30)20(29)17(12-26)32-23/h5-11,14,17,20-23,26,29-31H,12H2,1-4H3,(H,24,27)/b10-5+,13-11+/t14-,17-,20-,21+,22-,23-/m1/s1","1-O-({(2E,4E,6R)-7-[4-(dimethylamino)phenyl]-4,6-dimethyl-7-oxohepta-2,4-dienoyl}amino)-alpha-D-glucopyranose",Beilstein Registry Number,8657680
1783,39030,perfluoro-N-cyclohexylpyrrolidine,,"InChI=1S/C10F19N/c11-1(12)2(13,14)4(17,18)8(25,5(19,20)3(1,15)16)30-9(26,27)6(21,22)7(23,24)10(30,28)29",FCHP,Beilstein Registry Number,3574673
1784,40666,"1,6-anhydro-N-acetyl-beta-muramic acid","An anhydrohexose derivative that is the 1,6-anhydro-derivative of N-acetyl-beta-muramic acid.","InChI=1S/C11H17NO7/c1-4(10(15)16)18-9-7(12-5(2)13)11-17-3-6(19-11)8(9)14/h4,6-9,11,14H,3H2,1-2H3,(H,12,13)(H,15,16)/t4-,6-,7-,8-,9-,11-/m1/s1","2-(2-ACETYLAMINO-4-HYDROXY-6,8-DIOXA-BICYCLO[3.2.1]OCT-3-YLOXY)-PROPIONIC ACID",PDBeChem accession,AH0
1785,39241,beta-farnesene,,"InChI=1S/C15H24/c1-6-14(4)10-8-12-15(5)11-7-9-13(2)3/h6,9,12H,1,4,7-8,10-11H2,2-3,5H3","7,11-dimethyl-3-methylenedodeca-1,6,10-triene",Beilstein Registry Number,1750952
1786,40677,3-(10-methyl-9-anthryl)propanoic acid,Anthracene substituted at C-9 by a propionic acid group and at C-10 by a methyl group.,"InChI=1S/C18H16O2/c1-12-13-6-2-4-8-15(13)17(10-11-18(19)20)16-9-5-3-7-14(12)16/h2-9H,10-11H2,1H3,(H,19,20)",3-(10-METHYL-ANTHRACEN-9-YL)-PROPIONIC ACID,PDBeChem accession,AN1
1787,40467,5'-{[2-(aminooxy)ethyl](methyl)sulfonio}-5'-deoxyadenosine,,"InChI=1S/C13H21N6O4S/c1-24(3-2-22-15)4-7-9(20)10(21)13(23-7)19-6-18-8-11(14)16-5-17-12(8)19/h5-7,9-10,13,20-21H,2-4,15H2,1H3,(H2,14,16,17)/q+1/t7-,9-,10-,13-,24?/m1/s1","(2-AMINOOXY-ETHYL)-[5-(6-AMINO-PURIN-9-YL)-3,4-DIHYDROXY-TETRAHYDRO-FURAN-2-YLMETHYL]-METHYL-SULFONIUM",Beilstein Registry Number,9088644
1788,40697,"(1S)-2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine",,"InChI=1S/C14H23N3O/c1-2-11-7-8-12(9-15)17(11)14(18)13(16)10-5-3-4-6-10/h1,10-13H,3-9,15-16H2/t11-,12-,13-/m0/s1","(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE",PDBeChem accession,AIA
1789,38375,9-dodecenoic acid,A dodecenoic acid having its double bond in the 9-position.,"InChI=1S/C12H22O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h3-4H,2,5-11H2,1H3,(H,13,14)",dodec-9-enoic acid,LIPID MAPS instance accession,LMFA01030041
1790,39485,fkb-001,,"InChI=1S/C35H42F2N2O6/c1-42-30-22-27(23-31(43-2)32(30)44-3)35(36,37)34(41)39-21-8-7-19-29(39)33(40)45-28(17-9-14-25-12-5-4-6-13-25)18-10-15-26-16-11-20-38-24-26/h4-6,11-13,16,20,22-24,28-29H,7-10,14-15,17-19,21H2,1-3H3/t28-,29-/m0/s1","1-[2,2-DIFLUORO-2-(3,4,5-TRIMETHOXY-PHENYL)-ACETYL]-PIPERIDINE-2-CARBOXYLIC ACID 4-PHENYL-1-(3-PYRIDIN-3-YL-PROPYL)-BUTYL ESTER",PDBeChem accession,001
1791,39547,(R)-carnitinium,A carnitinium that is the conjugate acid of (R)-carnitine.,"InChI=1S/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/p+1/t6-/m1/s1",CARNITINE,PDBeChem accession,152
1792,39558,tetratriacontaethylene glycol monomethyl ether,The hydroxypolyether that is tetratriacontaethylene glycol in which one of the hydroxy groups is substituted by methoxy.,"InChI=1S/C69H140O35/c1-71-4-5-73-8-9-75-12-13-77-16-17-79-20-21-81-24-25-83-28-29-85-32-33-87-36-37-89-40-41-91-44-45-93-48-49-95-52-53-97-56-57-99-60-61-101-64-65-103-68-69-104-67-66-102-63-62-100-59-58-98-55-54-96-51-50-94-47-46-92-43-42-90-39-38-88-35-34-86-31-30-84-27-26-82-23-22-80-19-18-78-15-14-76-11-10-74-7-6-72-3-2-70/h70H,2-69H2,1H3",POLYETHYLENE GLYCOL (N=34),PDBeChem accession,15P
1793,32202,tetracenomycin D3,"A tetracenomycin that is 1-methyl-6,11-dioxo-6,11-dihydrotetracene-2-carboxylic acid bearing four hydroxy substituents at positions 3, 8, 10 and 12.","InChI=1S/C20H12O8/c1-6-13-7(3-11(22)14(6)20(27)28)2-9-16(18(13)25)19(26)15-10(17(9)24)4-8(21)5-12(15)23/h2-5,21-23,25H,1H3,(H,27,28)",Tetracenomycin D3,KEGG COMPOUND accession,C12368
1794,32206,tetracenomycin F1 methyl ester,,"InChI=1S/C21H16O7/c1-8-15-11(6-13(23)16(8)21(27)28-2)4-9-3-10-5-12(22)7-14(24)17(10)20(26)18(9)19(15)25/h4-7,22-25H,3H2,1-2H3",Tetracenomycin F1 methylester,KEGG COMPOUND accession,C12373
1795,32211,tetrangomycin,"An angucycline antibiotic that is 3,4-dihydrotetraphene-1,7,12(2H)-trione substituted by hydroxy groups at positions 3 and 8 and a methyl group at position 3 (the 3R stereoisomer) ring system. It is an antibiotic isolated from Streptomyces sp.","InChI=1S/C19H14O5/c1-19(24)7-9-5-6-11-16(14(9)13(21)8-19)18(23)10-3-2-4-12(20)15(10)17(11)22/h2-6,20,24H,7-8H2,1H3/t19-/m1/s1",Tetrangomycin,KEGG COMPOUND accession,C12396
1796,32298,vitexin 2''-O-alpha-L-rhamnoside,A derivative of vitexin having an alpha-L-rhamnosyl residue attached at the 2''-position of the glucitol moiety.,"InChI=1S/C27H30O14/c1-9-19(33)21(35)23(37)27(38-9)41-26-22(36)20(34)16(8-28)40-25(26)18-13(31)6-12(30)17-14(32)7-15(39-24(17)18)10-2-4-11(29)5-3-10/h2-7,9,16,19-23,25-31,33-37H,8H2,1H3/t9-,16+,19-,20+,21+,22-,23+,25-,26+,27-/m0/s1",2''-O-Rhamnosylvitexin,KEGG COMPOUND accession,C12628
1797,32304,"2-cis,4-trans-xanthoxin",,"InChI=1S/C15H22O3/c1-11(6-8-16)5-7-15-13(2,3)9-12(17)10-14(15,4)18-15/h5-8,12,17H,9-10H2,1-4H3/b7-5+,11-6-/t12-,14+,15-/m0/s1",Xanthoxin,KEGG COMPOUND accession,C13453
1798,31082,"2-hydroxy-6-oxonona-2,4,7-trienedioic acid",,"InChI=1S/C9H8O6/c10-6(4-5-8(12)13)2-1-3-7(11)9(14)15/h1-5,11H,(H,12,13)(H,14,15)",2-Hydroxy-6-ketononatrienedioate,KEGG COMPOUND accession,C12624
1799,31121,4'''-demalonylsalvianin,,"InChI=1S/C39H38O21/c40-18-5-3-17(4-6-18)37-25(58-39-36(53)34(51)31(48)26(60-39)14-54-29(46)8-2-16-1-7-21(42)22(43)9-16)12-20-23(56-37)10-19(41)11-24(20)57-38-35(52)33(50)32(49)27(59-38)15-55-30(47)13-28(44)45/h1-12,26-27,31-36,38-39,48-53H,13-15H2,(H4-,40,41,42,43,44,45,46)/p+1/t26-,27-,31-,32-,33+,34+,35-,36-,38-,39-/m1/s1",4'''-Demalonylsalvianin,KEGG COMPOUND accession,C12641
1800,31132,"5-hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylic acid",,"InChI=1S/C5H6N4O5/c6-3(12)7-1-5(14,2(10)11)9-4(13)8-1/h14H,(H,10,11)(H4,6,7,8,9,12,13)","5-Hydroxy-2-oxo-4-ureido-2,5-dihydro-1H-imidazole-5-carboxylate",KEGG COMPOUND accession,C12248
1801,31181,aklavinone,,"InChI=1S/C22H20O8/c1-3-22(29)8-13(24)15-10(17(22)21(28)30-2)7-11-16(20(15)27)19(26)14-9(18(11)25)5-4-6-12(14)23/h4-7,13,17,23-24,27,29H,3,8H2,1-2H3/t13-,17-,22+/m0/s1",Aklavinone,KEGG COMPOUND accession,C12424
1802,39832,methoxyethane,An ether that is the methyl ether derivative of ethanol.,"InChI=1S/C3H8O/c1-3-4-2/h3H2,1-2H3",METHOXYETHANE,PDBeChem accession,2ME
1803,39488,JMV 390-1,,"InChI=1S/C23H35N3O6/c1-5-15(4)20(22(29)24-18(23(30)31)11-14(2)3)25-21(28)17(13-19(27)26-32)12-16-9-7-6-8-10-16/h6-10,14-15,17-18,20,32H,5,11-13H2,1-4H3,(H,24,29)(H,25,28)(H,26,27)(H,30,31)/t15-,17-,18+,20-/m1/s1",N-[(2R)-2-BENZYL-4-(HYDROXYAMINO)-4-OXOBUTANOYL]-L-ISOLEUCYL-L-LEUCINE,PDBeChem accession,002
1804,39540,N-hexadecanoylglycine,An N-acylglycine in which the acyl group is specified as hexadecanoyl (palmitoyl).,"InChI=1S/C18H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(20)19-16-18(21)22/h2-16H2,1H3,(H,19,20)(H,21,22)",N-palmitoylglycine,PDBeChem accession,140
1805,39579,5-benzyloxybenzylacyclouridine,A benzyl ether that consists of acyclouridine bearing a 3-(benzyloxy)benzyl substituent at position 5.,"InChI=1S/C21H22N2O5/c24-9-10-27-15-23-13-18(20(25)22-21(23)26)11-17-7-4-8-19(12-17)28-14-16-5-2-1-3-6-16/h1-8,12-13,24H,9-11,14-15H2,(H,22,25,26)","1-((2-HYDROXYETHOXY)METHYL)-5-(3-(BENZYLOXY)BENZYL)PYRIMIDINE-2,4(1H,3H)-DIONE",PDBeChem accession,183
1806,39723,2'-deoxy-2-fluoroadenosine,,"InChI=1S/C10H12FN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1",5-(6-AMINO-2-FLUORO-PURIN-9-YL)-2-HYDROXYMETHYL-TETRAHYDRO-FURAN-3-OL,PDBeChem accession,2FD
1807,39031,perfluoro-4-methylquinolizidine,An organofluorine compound that is 4-methylquinolizidine in which all of the hydrogens are replaced by fluorines.,"InChI=1S/C10F19N/c11-1(12)3(15,16)7(23)4(17,18)2(13,14)6(21,22)10(28,29)30(7)8(24,5(1,19)20)9(25,26)27",FMOQ,Beilstein Registry Number,6016986
1808,39042,"1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorohexadecane","A fluoroalkane that is hexadecane in which all of the hydrogen atoms at positions 1, 2, 3, 4, 5, and 6 have been replaced by fluorine atoms.","InChI=1S/C16H21F13/c1-2-3-4-5-6-7-8-9-10-11(17,18)12(19,20)13(21,22)14(23,24)15(25,26)16(27,28)29/h2-10H2,1H3",F6H10,Beilstein Registry Number,7543605
1809,40235,"9H-purine-2,6-diamine","A member of the class of 2,6-diaminopurines that is 9H-purine in which the hydrogens at positions 2 and 6 are replaced by amino groups.","InChI=1S/C5H6N6/c6-3-2-4(9-1-8-2)11-5(7)10-3/h1H,(H5,6,7,8,9,10,11)","9H-PURINE-2,6-DIAMINE",PDBeChem accession,6AP
1810,39637,"(1S)-2-[(2S,5R)-2-(aminomethyl)-5-prop-1-yn-1-ylpyrrolidin-1-yl]-1-cyclopentyl-2-oxoethanamine",,"InChI=1S/C15H25N3O/c1-2-5-12-8-9-13(10-16)18(12)15(19)14(17)11-6-3-4-7-11/h11-14H,3-4,6-10,16-17H2,1H3/t12-,13-,14-/m0/s1","(1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE",PDBeChem accession,1AD
1811,40721,adenosine 5'-monophosphate(1+),An organic cation that is the conjugate acid of adenosine 5'-monophosphate (AMP) obtained by selective protonation at position N1 on the purine moiety.,"InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/p+1/t4-,6-,7-,10-/m1/s1",N1-PROTONATED ADENOSINE-5'-MONOPHOSPHATE,PDBeChem accession,AP7
1812,40729,N-acetyl-beta-D-muramic acid,,"InChI=1S/C11H19NO8/c1-4(10(16)17)19-9-7(12-5(2)14)11(18)20-6(3-13)8(9)15/h4,6-9,11,13,15,18H,3H2,1-2H3,(H,12,14)(H,16,17)/t4-,6-,7-,8-,9-,11-/m1/s1",BETA-N-ACETYLMURAMIC ACID,PDBeChem accession,AMU
1813,38292,nido-undecaborane(11),,"InChI=1S/B11H11/c1-2-4-5-3(1)7(1)6(1,2)8(2,4)10(4,5)9(3,5,7)11(6,7,8)10/h1-11H",nido-undecaborane(11),Gmelin Registry Number,1582558
1814,38865,perfluoro-N-(4-methylcyclohexyl)piperidine,,"InChI=1S/C12F23N/c13-1(10(29,30)31)2(14,15)5(20,21)9(28,6(22,23)3(1,16)17)36-11(32,33)7(24,25)4(18,19)8(26,27)12(36,34)35",FMCP,CAS Registry Number,86630-50-4
1815,40520,(S)-2-amino-6-boronohexanoic acid,L-Norleucine substituted at C-6 with a borono group.,"InChI=1S/C6H14BNO4/c8-5(6(9)10)3-1-2-4-7(11)12/h5,11-12H,1-4,8H2,(H,9,10)/t5-/m0/s1",2(S)-AMINO-6-BORONOHEXANOIC ACID,PubMed citation,16141327
1816,38209,chlorophyllide b,,"InChI=1S/C35H34N4O6.Mg/c1-7-18-15(3)22-11-23-16(4)20(9-10-28(41)42)32(38-23)30-31(35(44)45-6)34(43)29-17(5)24(39-33(29)30)12-26-19(8-2)21(14-40)27(37-26)13-25(18)36-22;/h7,11-14,16,20,31H,1,8-10H2,2-6H3,(H3,36,37,38,39,40,41,42,43);/q;+2/p-2/t16-,20-,31+;/m0./s1",Chlorophyllid b,CAS Registry Number,14428-12-7
1817,38701,delphinidin chloride,An anthocyanidin chloride that has delphinidin as the cationic counterpart.,"InChI=1S/C15H10O7.ClH/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6;/h1-5H,(H5-,16,17,18,19,20,21);1H","3,3',4',5,5',7-hexahydroxy-2-phenylbenzopyrylium chloride",Patent accession,EP0390496
1818,39343,(1R)-trans-(alphaS)-cyphenothrin,,"InChI=1S/C24H25NO3/c1-16(2)13-20-22(24(20,3)4)23(26)28-21(15-25)17-9-8-12-19(14-17)27-18-10-6-5-7-11-18/h5-14,20-22H,1-4H3/t20-,21-,22+/m1/s1","(S)-cyano(3-phenoxyphenyl)methyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate",Beilstein Registry Number,3039535
1819,39424,heptafluorobutyric anhydride,An acyclic carboxylic anhydride that is perfluorinated butyric anhydride. It is used as a derivatising reagent for gas chromatographic analyses.,"InChI=1S/C8F14O3/c9-3(10,5(13,14)7(17,18)19)1(23)25-2(24)4(11,12)6(15,16)8(20,21)22",HFBA,CAS Registry Number,336-59-4
1820,39551,"(2S)-3-methyl-2-((2R,3S)-3-[(methylsulfonyl)amino]-1-{[2-(pyrrolidin-1-ylmethyl)-1,3-oxazol-4-yl]carbonyl}pyrrolidin-2-yl)butanoic acid","An N-acylpyrrolidine resulting from the formal condensation of the pyrrolidine nitrogen of (2R,3S)-2-[(2S)-(2-carboxy)isobutyl-3-(methylsulfonylamino)pyrrolidine with the carboxylic acid group of 2-(pyrrolidin-1-ylmethyl)-1,3-oxazole-4-carboxylic acid.","InChI=1S/C19H30N4O6S/c1-12(2)16(19(25)26)17-13(21-30(3,27)28)6-9-23(17)18(24)14-11-29-15(20-14)10-22-7-4-5-8-22/h11-13,16-17,21H,4-10H2,1-3H3,(H,25,26)/t13-,16-,17-/m0/s1","(2S)-3-methyl-2-((2R,3S)-3-[(methylsulfonyl)amino]-1-{[2-(pyrrolidin-1-ylmethyl)-1,3-oxazol-4-yl]carbonyl}pyrrolidin-2-yl)butanoic acid",PDBeChem accession,151
1821,39564,"(1R,6R)-2-succinyl-6-hydroxycyclohexa-2,4-diene-1-carboxylic acid",,"InChI=1S/C11H12O6/c12-7(4-5-9(14)15)6-2-1-3-8(13)10(6)11(16)17/h1-3,8,10,13H,4-5H2,(H,14,15)(H,16,17)/t8-,10-/m1/s1","2-(3-CARBOXYPROPIONYL)-6-HYDROXY-CYCLOHEXA-2,4-DIENE CARBOXYLIC ACID",PDBeChem accession,164
1822,39576,"3,6,9,12,15,18-hexaoxaicosane",,"InChI=1S/C14H30O6/c1-3-15-5-7-17-9-11-19-13-14-20-12-10-18-8-6-16-4-2/h3-14H2,1-2H3","3,6,9,12,15,18-HEXAOXAICOSANE",Beilstein Registry Number,1910162
1823,40594,5-[(2-acetamidoethyl)amino]naphthalene-1-sulfonic acid,An  aminonaphthalenesulfonic acid fluorophore with a structure consisting of ethylenediamine substituted on the nitrogens with acetyl and 5-sulfonyl-1-naphthyl groups.,"InChI=1S/C14H16N2O4S/c1-10(17)15-8-9-16-13-6-2-5-12-11(13)4-3-7-14(12)21(18,19)20/h2-7,16H,8-9H2,1H3,(H,15,17)(H,18,19,20)",5-(1-SULFONAPHTHYL)-ACETYLAMINO-ETHYLAMINE,PDBeChem accession,AEN
1824,34074,1-dodecanoyl-2-hexadecanoyl-3-octadecanoyl-sn-glycerol,"A triacylglycerol 46:0 in which the acyl groups at positions 1, 2 and 3 are specified as dodecanoyl, hexadecanoyl and octadecanoyl respectively.","InChI=1S/C49H94O6/c1-4-7-10-13-16-19-21-23-24-26-27-30-33-36-39-42-48(51)54-45-46(44-53-47(50)41-38-35-32-29-18-15-12-9-6-3)55-49(52)43-40-37-34-31-28-25-22-20-17-14-11-8-5-2/h46H,4-45H2,1-3H3/t46-/m1/s1",1-Dodecanoyl-2-hexadecanoyl-3-octadecanoyl-sn-glycerol,LIPID MAPS instance accession,LMGL03010007
1825,34080,1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol,A phosphatidylglycerol in which the 1- and 2-acyl groups are specified as palmitoyl and oleoyl respectively.,"InChI=1S/C40H77O10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-40(44)50-38(36-49-51(45,46)48-34-37(42)33-41)35-47-39(43)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,37-38,41-42H,3-16,19-36H2,1-2H3,(H,45,46)/b18-17-/t37?,38-/m1/s1",1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-sn-glycerol,KEGG COMPOUND accession,C13883
1826,34086,{1-O-hexadecanoyl-2-O-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}serine,A 3-sn-phosphatidyl-L-serine compound with a palmitoyl group at the 1-position and an oleoyl group at the 2-position.,"InChI=1S/C40H76NO10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(43)51-36(34-49-52(46,47)50-35-37(41)40(44)45)33-48-38(42)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,36-37H,3-16,19-35,41H2,1-2H3,(H,44,45)(H,46,47)/b18-17-/t36-,37+/m1/s1",1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoserine,KEGG COMPOUND accession,C13880
1827,34110,1-O-[(Z)-tetradec-1-enyl]-2-O-[(Z)-octadec-9-enoyl]-sn-glycero-3-phosphocholine,,"InChI=1S/C40H78NO7P/c1-6-8-10-12-14-16-18-20-21-22-23-25-27-29-31-33-40(42)48-39(38-47-49(43,44)46-36-34-41(3,4)5)37-45-35-32-30-28-26-24-19-17-15-13-11-9-7-2/h20-21,32,35,39H,6-19,22-31,33-34,36-38H2,1-5H3/p+1/b21-20-,35-32-/t39-/m1/s1",1-O-(1Z-Tetradecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine,KEGG COMPOUND accession,C13895
1828,31363,carumonam sodium,The disodium salt of carumonam.,"InChI=1S/C12H14N6O10S2.2Na/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21)16-8-5(1-27-12(14)23)18(10(8)22)30(24,25)26;;/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26);;/q;2*+1/p-2/b17-7-;;/t5-,8+;;/m1../s1",Carumonam sodium,KEGG COMPOUND accession,C13016
1829,34479,"7,8-dihydro-7-hydroxy-8S-glutathionylbenzo[a]pyrene","A glutathione derivative in which the hydrogen of the side-chain thiol function of glutathione is substituted by a 7-hydroxy-7,8-dihydrobenzo[pqr]tetraphen-8-yl group.","InChI=1S/C30H29N3O7S/c31-21(30(39)40)9-11-24(34)33-22(29(38)32-13-25(35)36)14-41-23-10-8-18-19-7-6-16-3-1-2-15-4-5-17(27(19)26(15)16)12-20(18)28(23)37/h1-8,10,12,21-23,28,37H,9,11,13-14,31H2,(H,32,38)(H,33,34)(H,35,36)(H,39,40)/t21-,22-,23?,28?/m0/s1","7,8-Dihydro-7-hydroxy-8-S-glutathionyl-benzo[a]pyrene",KEGG COMPOUND accession,C14856
1830,41945,9-(2-deoxy-5-O-phosphono-beta-L-ribofuranosyl)guanine,,"InChI=1S/C10H14N5O7P/c11-10-13-8-7(9(17)14-10)12-3-15(8)6-1-4(16)5(22-6)2-21-23(18,19)20/h3-6,16H,1-2H2,(H2,18,19,20)(H3,11,13,14,17)/t4-,5+,6+/m1/s1",2'-DEOXY-L-RIBO-FURANOSYL GUANINE-5'-MONOPHOSPHATE,Beilstein Registry Number,1231121
1831,41482,(R)-carnitinyl-CoA betaine,,"InChI=1S/C28H49N8O18P3S/c1-28(2,23(41)26(42)31-7-6-18(38)30-8-9-58-19(39)10-16(37)11-36(3,4)5)13-51-57(48,49)54-56(46,47)50-12-17-22(53-55(43,44)45)21(40)27(52-17)35-15-34-20-24(29)32-14-33-25(20)35/h14-17,21-23,27,37,40-41H,6-13H2,1-5H3,(H7-,29,30,31,32,33,38,42,43,44,45,46,47,48,49)/t16-,17-,21-,22-,23+,27-/m1/s1",L-CARNITINYL-COA INNER SALT,PDBeChem accession,CCQ
1832,42548,alpha-L-fucose,An L-fucopyranose having alpha-configuration at the anomeric centre.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6+/m0/s1",ALPHA-L-FUCOSE,PDBeChem accession,FUC
1833,42575,N(7)-methylformycin A,,"InChI=1S/C11H15N5O4/c1-12-11-7-5(13-3-14-11)6(15-16-7)10-9(19)8(18)4(2-17)20-10/h3-4,8-10,17-19H,2H2,1H3,(H,15,16)(H,12,13,14)/t4-,8-,9-,10+/m1/s1","2-HYDROXYMETHYL-5-(7-METHYLAMINO-3H-PYRAZOLO[4,3-D]PYRIMIDIN-3-YL)-TETRAHYDRO-FURAN-3,4-DIOL",PDBeChem accession,FM1
1834,42600,L-fucitol,The L-enantiomer of fucitol. It is found in nutmeg.,"InChI=1S/C6H14O5/c1-3(8)5(10)6(11)4(9)2-7/h3-11H,2H2,1H3/t3-,4+,5+,6-/m0/s1",fucitol,PDBeChem accession,FOC
1835,39524,dodecaethylene glycol,,"InChI=1S/C24H50O13/c25-1-3-27-5-7-29-9-11-31-13-15-33-17-19-35-21-23-37-24-22-36-20-18-34-16-14-32-12-10-30-8-6-28-4-2-26/h25-26H,1-24H2",DODECAETHYLENE GLYCOL,CAS Registry Number,6790-09-6
1836,40850,8-azaxanthine,,"InChI=1S/C4H3N5O2/c10-3-1-2(8-9-7-1)5-4(11)6-3/h(H3,5,6,7,8,9,10,11)",8-AZAXANTHINE,PDBeChem accession,AZA
1837,41150,6-oxouridine 5'-phosphate,A pyrimidine ribonucleoside 5'-monophosphate that is the 6-oxo derivative of UMP.,"InChI=1S/C9H13N2O10P/c12-4-1-5(13)11(9(16)10-4)8-7(15)6(14)3(21-8)2-20-22(17,18)19/h3,6-8,14-15H,1-2H2,(H,10,12,16)(H2,17,18,19)/t3-,6-,7-,8-/m1/s1",1-(5'-PHOSPHO-BETA-D-RIBOFURANOSYL)BARBITURIC ACID,DrugBank accession,DB03668
1838,41214,4-nitrobenzyl alcohol,A member of the class of benzyl alcohols that is benzyl alcohol substituted at the para-position by a nitro group.,"InChI=1S/C7H7NO3/c9-5-6-1-3-7(4-2-6)8(10)11/h1-4,9H,5H2",PARANITROBENZYL ALCOHOL,PDBeChem accession,BPN
1839,41733,2-hydroxy-5-nitrophenyl hydrogen sulfate,An aryl sulfate that is 4-nitrocatechol in which the hydroxy group that is meta to the nitro group has been converted into the corresponding hydrogen sulfate. It is used (commonly as its dipotassium salt) as a chromogenic substrate for sulphatase.,"InChI=1S/C6H5NO7S/c8-5-2-1-4(7(9)10)3-6(5)14-15(11,12)13/h1-3,8H,(H,11,12,13)","N,4-DIHYDROXY-N-OXO-3-(SULFOOXY)BENZENAMINIUM",PDBeChem accession,CSN
1840,41919,1-O-demethyl-6-deoxydoxorubicin,,"InChI=1S/C26H27NO10/c1-10-22(31)14(27)6-18(36-10)37-16-8-26(35,17(30)9-28)7-11-5-13-21(24(33)19(11)16)25(34)20-12(23(13)32)3-2-4-15(20)29/h2-5,10,14,16,18,22,28-29,31,33,35H,6-9,27H2,1H3/t10-,14-,16-,18-,22+,26-/m0/s1",1-O-DEMETHYL-6-DEOXYDOXORUBICIN,PDBeChem accession,DM4
1841,41378,dodecyltrimethylammonium ion,A quarternary ammonium cation having one dodecyl and three methyl substituents around the central nitrogen.,"InChI=1S/C15H34N/c1-5-6-7-8-9-10-11-12-13-14-15-16(2,3)4/h5-15H2,1-4H3/q+1",DODECANE-TRIMETHYLAMINE,PDBeChem accession,CAT
1842,42229,(3S)-3-[(2S)-2-amino-3-hydroxybutyl]pyrrolidin-2-one,,"InChI=1S/C8H16N2O2/c1-5(11)7(9)4-6-2-3-10-8(6)12/h5-7,11H,2-4,9H2,1H3,(H,10,12)/t5?,6-,7-/m0/s1",(3S)-3-[(2S)-2-AMINO-3-HYDROXYBUTYL]PYRROLIDIN-2-ONE,PDBeChem accession,ECQ
1843,40893,"2-L-alanyl-5-tert-butyl-1,3,4-oxadiazole",,"InChI=1S/C9H15N3O2/c1-5(10)6(13)7-11-12-8(14-7)9(2,3)4/h5H,10H2,1-4H3/t5-/m0/s1","(2S)-2-AMINO-1-(5-TERT-BUTYL-1,3,4-OXADIAZOL-2-YL)PROPAN-1-ONE",PDBeChem accession,ATX
1844,42564,alpha-D-fucose,A D-fucopyranose having alpha-configuration at its anomeric centre.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6+/m1/s1",ALPHA-D-FUCOSE,PDBeChem accession,FCA
1845,42588,4-hydroxyphenyl retinamide,"A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.","InChI=1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+",N-(4-HYDROXYPHENYL)ALL-TRANS RETINAMIDE,PDBeChem accession,FEN
1846,42646,flaviolin,"A hydroxy-1,4-naphthoquinone that is 1,4-naphthoquinone having three hydroxy substituents placed at the 2-, 5- and 7-positions.","InChI=1S/C10H6O5/c11-4-1-5-9(6(12)2-4)7(13)3-8(14)10(5)15/h1-3,11-12,14H",FLAVIOLIN,PDBeChem accession,FLV
1847,42677,(2R)-2-hydroxypropylammonium,An ammonium ion obtained by protonation of the amino group of (2R)-1-aminopropan-2-ol.,"InChI=1S/C3H9NO/c1-3(5)2-4/h3,5H,2,4H2,1H3/p+1/t3-/m1/s1",2-HYDROXY-PROPYL-AMMONIUM,PDBeChem accession,FOP
1848,42799,N-sulfo-alpha-D-glucosamine,A N-sulfo-D-glucosamine with an alpha-configuration at the anomeric position.,"InChI=1S/C6H13NO8S/c8-1-2-4(9)5(10)3(6(11)15-2)7-16(12,13)14/h2-11H,1H2,(H,12,13,14)/t2-,3-,4-,5-,6+/m1/s1",N-sulfo-alpha-D-glucosamine,PDBeChem accession,GNS
1849,41476,1-methylcyclopentanecarboxylic acid,,"InChI=1S/C7H12O2/c1-7(6(8)9)4-2-3-5-7/h2-5H2,1H3,(H,8,9)",1-METHYL-1-CARBOXY-CYCLOPENTANE,PDBeChem accession,CCM
1850,41485,"6-(1,3-dihydroxyisobutyl)thymine","A pyrimidone that is thymine in which the hydrogen at position 6 is substituted by a 1,3-dihydroxyisobutyl group.","InChI=1S/C9H14N2O4/c1-5-7(2-6(3-12)4-13)10-9(15)11-8(5)14/h6,12-13H,2-4H2,1H3,(H2,10,11,14,15)","6-[3-HYDROXY-2-(HYDROXYMETHYL)PROPYL]-5-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE",PDBeChem accession,CCV
1851,41617,"(S)-1-(2,5-xylyloxy)-3-morpholinopropan-2-ol",,"InChI=1S/C15H23NO3/c1-12-3-4-13(2)15(9-12)19-11-14(17)10-16-5-7-18-8-6-16/h3-4,9,14,17H,5-8,10-11H2,1-2H3/t14-/m0/s1","(2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol",PDBeChem accession,CMZ
1852,41576,3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin,,"InChI=1S/C32H34N2O12/c1-14-27(37)18(34-6-7-44-13-15(34)11-33)8-22(45-14)46-20-10-32(42,21(36)12-35)9-17-24(20)31(41)26-25(29(17)39)28(38)16-4-3-5-19(43-2)23(16)30(26)40/h3-5,14-15,18,20,22,27,35,37,39,41-42H,6-10,12-13H2,1-2H3/t14-,15?,18-,20-,22-,27+,32-/m0/s1",3'-DESAMINO-3'-(3-CYANO-4-MORPHOLINYL)-DOXORUBICIN,PDBeChem accession,CMD
1853,40918,axerophthene,"A diterpene that is cyclohexene substituted by a (1Z,3E,5E,7E)-3,7-dimethylnona-1,3,5,7-tetraen-1-yl group at position 2 and by methyl groups at positions 1,3 and 3. It is the parent hydrocarbon on which Vitamin A and other retinoids are based.","InChI=1S/C20H30/c1-7-16(2)10-8-11-17(3)13-14-19-18(4)12-9-15-20(19,5)6/h7-8,10-11,13-14H,9,12,15H2,1-6H3/b10-8+,14-13+,16-7+,17-11+","2-[(1E,3E,5E,7E)-3,7-dimethylnona-1,3,5,7-tetraenyl]-1,3,3-trimethylcyclohexene",PDBeChem accession,AZE
1854,37565,GTP(4-),A nucleoside triphosphate(4-) obtained by global deprotonation of the triphosphate OH groups of GTP; major species present at pH 7.3.,"InChI=1S/C10H16N5O14P3/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(17)5(16)3(27-9)1-26-31(22,23)29-32(24,25)28-30(19,20)21/h2-3,5-6,9,16-17H,1H2,(H,22,23)(H,24,25)(H2,19,20,21)(H3,11,13,14,18)/p-4/t3-,5-,6-,9-/m1/s1",gtp,Gmelin Registry Number,1264613
1855,37568,dTTP(4-),A 2'-deoxyribonucleoside 5'-triphosphate(4-) obtained by deprotonation of the four triphosphate OH groups of dTTP; major species at pH 7.3.,"InChI=1S/C10H17N2O14P3/c1-5-3-12(10(15)11-9(5)14)8-2-6(13)7(24-8)4-23-28(19,20)26-29(21,22)25-27(16,17)18/h3,6-8,13H,2,4H2,1H3,(H,19,20)(H,21,22)(H,11,14,15)(H2,16,17,18)/p-4/t6-,7+,8+/m0/s1",thymidine 5'-triphosphate(4-),Beilstein Registry Number,4628471
1856,42053,nemorubicin,,"InChI=1S/C32H37NO13/c1-14-27(36)17(33-7-8-44-22(12-33)43-3)9-21(45-14)46-19-11-32(41,20(35)13-34)10-16-24(19)31(40)26-25(29(16)38)28(37)15-5-4-6-18(42-2)23(15)30(26)39/h4-6,14,17,19,21-22,27,34,36,38,40-41H,7-13H2,1-3H3/t14-,17-,19-,21-,22-,27+,32-/m0/s1",3'-DESAMINO-3'-(2-METHOXY-4-MORPHOLINYL)-DOXORUBICIN,PDBeChem accession,DMM
1857,41425,(7R)-7-(4-carboxybutanamido)cephalosporanic acid,,"InChI=1S/C15H18N2O8S/c1-7(18)25-5-8-6-26-14-11(13(22)17(14)12(8)15(23)24)16-9(19)3-2-4-10(20)21/h11,14H,2-6H2,1H3,(H,16,19)(H,20,21)(H,23,24)/t11-,14-/m1/s1",7BETA-(4CARBOXYBUTANAMIDO) CEPHALOSPORANIC ACID,PDBeChem accession,CEN
1858,42248,"({[(1R,2R)-2-(uracil-1-yl)cyclopentyl]oxy}methyl)phosphonic acid","A phosphonic acid consisting of 1-cyclopentyluracil having a phosphomethoxy group at position 2 on the cyclopentyl ring with (1R,2R)-trans-stereochemistry.","InChI=1S/C10H15N2O6P/c13-9-4-5-12(10(14)11-9)7-2-1-3-8(7)18-6-19(15,16)17/h4-5,7-8H,1-3,6H2,(H,11,13,14)(H2,15,16,17)/t7-,8-/m1/s1",1-trans-(2-phosphonomethoxycyclopentyl)uracil,PDBeChem accession,DRM
1859,42263,"1,2-dimethoxyethane","A diether that is the 1,2-dimethyl ether of ethane-1,2-diol.","InChI=1S/C4H10O2/c1-5-3-4-6-2/h3-4H2,1-2H3","1,2-DIMETHOXYETHANE",CAS Registry Number,110-71-4
1860,41112,N-acetyl-alpha-D-mannosamine,An N-acetylmannosamine having pyranose form and alpha-D-configuration.,"InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5+,6-,7-,8+/m1/s1",2-(ACETYLAMINO)-2-DEOXY-ALPHA-D-MANNOPYRANOSE,PDBeChem accession,BM3
1861,41198,"4-[3-(3-nitrophenyl)-1,2,4-oxadiazol-5-yl]butanoic acid",,"InChI=1S/C12H11N3O5/c16-11(17)6-2-5-10-13-12(14-20-10)8-3-1-4-9(7-8)15(18)19/h1,3-4,7H,2,5-6H2,(H,16,17)","4-[3-(3-NITROPHENYL)-1,2,4-OXADIAZOL-5-YL]BUTANOIC ACID",PDBeChem accession,BTO
1862,42754,beta-garosamine,,"InChI=1S/C7H15NO4/c1-7(11)3-12-6(10)4(9)5(7)8-2/h4-6,8-11H,3H2,1-2H3/t4-,5-,6+,7+/m1/s1","5-METHYL-4-METHYLAMINO-TETRAHYDRO-PYRAN-2,3,5-TRIOL",PDBeChem accession,GE3
1863,42775,"2'-deoxyguanosine 5'-[beta,gamma-methylene]triphosphate",,"InChI=1S/C11H18N5O12P3/c12-11-14-9-8(10(18)15-11)13-3-16(9)7-1-5(17)6(27-7)2-26-31(24,25)28-30(22,23)4-29(19,20)21/h3,5-7,17H,1-2,4H2,(H,22,23)(H,24,25)(H2,19,20,21)(H3,12,14,15,18)/t5-,6+,7+/m0/s1",2'-DEOXY-5'-O-(HYDROXY{[HYDROXY(PHOSPHONOMETHYL)PHOSPHORYL]OXY}PHOSPHORYL)GUANOSINE,PDBeChem accession,GGH
1864,40940,"3-{[(9-cyano-10-methyl-9,10-dihydroacridin-9-yl)carbonyl]amino}propanoic acid",An N-methylated dihydro acridine carrying carbonitrile and N-carboxyethylcarbamoyl substituents at C-9.,"InChI=1S/C19H17N3O3/c1-22-15-8-4-2-6-13(15)19(12-20,14-7-3-5-9-16(14)22)18(25)21-11-10-17(23)24/h2-9H,10-11H2,1H3,(H,21,25)(H,23,24)","3-{[(9-CYANO-9,10-DIHYDRO-10-METHYLACRIDIN-9-YL)CARBONYL]AMINO}PROPANOIC ACID",PDBeChem accession,BC1
1865,41189,"butane-1,4-diol","A butanediol that is butane in which one hydrogen of each of the methyl groups is substituted by a hydroxy group. A colourless, water-miscible, viscous liquid at room temperature (m.p. 16degreeC) with a high boiling point (230degreeC), it is mainly used for the production of other organic chemicals, particularly the solvent oxolane (also known as tetrahydrofuran or THF).","InChI=1S/C4H10O2/c5-3-1-2-4-6/h5-6H,1-4H2","1,4-BUTANEDIOL",PDBeChem accession,BU1
1866,41531,methyl L-cysteinate,An L-cysteinyl ester resulting from the formal condensation of the carboxylic acid group of L-cysteine with methanol. It is used (as the hydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough.,"InChI=1S/C4H9NO2S/c1-7-4(6)3(5)2-8/h3,8H,2,5H2,1H3/t3-/m0/s1",O-METHYLCYSTEINE,PDBeChem accession,CMT
1867,40953,doramapimod,"A member of the class of pyrazoles that is an immunomodulator used for treatment of rheumatoid arthritis, Crohn's disease and psoriasis.","InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)",1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea,PDBeChem accession,B96
1868,41076,beta-D-galactose 6-phosphate,,"InChI=1S/C6H13O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-10H,1H2,(H2,11,12,13)/t2-,3+,4+,5-,6-/m1/s1",BETA-GALACTOSE-6-PHOSPHATE,PDBeChem accession,BGP
1869,41607,crotonaldehyde,An enal consisting of propene having a formyl group at the 1-position.,"InChI=1S/C4H6O/c1-2-3-4-5/h2-4H,1H3/b3-2+",(2E)-BUT-2-ENAL,PDBeChem accession,CRD
1870,41384,butylphosphonic acid,A member of the class of phosphonic acids that is phosphonic acid having a butyl group attached to the phosphorous atom.,"InChI=1S/C4H11O3P/c1-2-3-4-8(5,6)7/h2-4H2,1H3,(H2,5,6,7)",butylphosphonic acid,PDBeChem accession,CCP
1871,41794,"(S,R)-(furan-2,5-diyldibenzene-4,1-diyl)bis(N-cyclopropylmethanediamine)",A substituted diphenylfuran in which two amino(cyclopropylamino)methyl substituents are located at the two para-positions on the phenyl rings.,"InChI=1S/C24H28N4O/c25-23(27-19-9-10-19)17-5-1-15(2-6-17)21-13-14-22(29-21)16-3-7-18(8-4-16)24(26)28-20-11-12-20/h1-8,13-14,19-20,23-24,27-28H,9-12,25-26H2/t23-,24+","2,5-BIS{[4-(N-CYCLOPROPYLDIAMINOMETHYL)PHENYL]}FURAN",PDBeChem accession,D19
1872,42090,L-threitol,The L-enantiomer of threitol.,"InChI=1S/C4H10O4/c5-1-3(7)4(8)2-6/h3-8H,1-2H2/t3-,4-/m0/s1",D-TREITOL,PDBeChem accession,DTL
1873,42319,17beta-estradiol 6-O-(carboxymethyl)oxime,An oxime O-ether that is a derivative of 17beta-estradiol having an O-(carboxymethyl)oxime group at the 6-position.,"InChI=1S/C20H25NO5/c1-20-7-6-13-12-3-2-11(22)8-15(12)17(21-26-10-19(24)25)9-14(13)16(20)4-5-18(20)23/h2-3,8,13-14,16,18,22-23H,4-7,9-10H2,1H3,(H,24,25)/b21-17+/t13-,14-,16+,18+,20+/m1/s1",ESTRADIOL-6 CARBOXYL-METHYL-OXIME,PDBeChem accession,ECO
1874,41965,(2S)-4'-hydroxyflavanone,,"InChI=1S/C15H12O3/c16-11-7-5-10(6-8-11)15-9-13(17)12-3-1-2-4-14(12)18-15/h1-8,15-16H,9H2/t15-/m0/s1",2-(4-HYDROXY-PHENYL)-CHROMAN-4-ONE,Beilstein Registry Number,1288276
1875,41221,piperazine-1-carboxylic acid,,"InChI=1S/C5H10N2O2/c8-5(9)7-3-1-6-2-4-7/h6H,1-4H2,(H,8,9)",N1-CARBOXYPIPERAZINE,Beilstein Registry Number,115888
1876,42371,"(R,R)-5,11-diethyl-5,6,11,12-tetrahydro-2,8-chrysenediol","A carbotetracyclic compound that is 5,6,11,12-tetrahydrochrysene substituted by hydroxy groups at positions 2 and 8 and by ethyl groups at positions 5 and 11 (the 5R,11R-stereoisomer). It is an agonist of ER-alpha and antagonist of ER-beta receptors.","InChI=1S/C22H24O2/c1-3-13-9-15-11-17(23)6-8-20(15)22-14(4-2)10-16-12-18(24)5-7-19(16)21(13)22/h5-8,11-14,23-24H,3-4,9-10H2,1-2H3/t13-,14-/m1/s1","(R,R)-5,11-cis-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol",PDBeChem accession,ETC
1877,42403,"S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate",,"InChI=1S/C16H8F3N3O2S/c17-16(18,19)14-20-15(22-21-14)25-13(23)12-9-8-11(24-12)7-6-10-4-2-1-3-5-10/h1-5,8-9H,(H,20,21,22)","S-[5-(TRIFLUOROMETHYL)-4H-1,2,4-TRIAZOL-3-YL] 5-(PHENYLETHYNYL)FURAN-2-CARBOTHIOATE",PDBeChem accession,F3F
1878,42700,2-deoxy-2-fluoro-beta-L-fucose,An organofluorine compound that is beta-L-fucose in which the hydroxy group at position 2 is replaced by fluorine.,"InChI=1S/C6H11FO4/c1-2-4(8)5(9)3(7)6(10)11-2/h2-6,8-10H,1H3/t2-,3-,4+,5-,6-/m0/s1",2-DEOXY-2-FLUORO-BETA-L-FUCOPYRANOSE,PDBeChem accession,FUF
1879,42702,"6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil","A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by ethoxymethyl, isopropyl, and 3,5-dimethylbenzyl groups, respectively.","InChI=1S/C19H26N2O3/c1-6-24-11-21-16(10-15-8-13(4)7-14(5)9-15)17(12(2)3)18(22)20-19(21)23/h7-9,12H,6,10-11H2,1-5H3,(H,20,22,23)","6-(3',5'-DIMETHYLBENZYL)-1-ETHOXYMETHYL-5-ISOPROPYLURACIL",PDBeChem accession,GCA
1880,42719,benzylpenicilloyl-benzylamine,A monocarboxylic acid amide formed between benzylpenicillin and benzylamine.,"InChI=1S/C23H27N3O4S/c1-23(2)19(22(29)30)26-21(31-23)18(20(28)24-14-16-11-7-4-8-12-16)25-17(27)13-15-9-5-3-6-10-15/h3-12,18-19,21,26H,13-14H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)/t18-,19+,21-/m1/s1","(2R,4S)-2-[(R)-BENZYLCARBAMOYL-PHENYLACETYL-METHYL]-5,5-DIMETHYL-THIAZOLIDINE-4-CARBOXYLIC ACID",PDBeChem accession,G23
1881,42893,1-(2-{4-[(4-carboxybutanoyl)amino]phenyl}ethyl)-1-methylpiperidinium,A dicarboxylic acid monoamide of glutaric acid containing benzene and piperidinium moieties; a transition state analogue hapten used to elicit catalytic antibodies 5C8 and 14B9.,"InChI=1S/C19H28N2O3/c1-21(13-3-2-4-14-21)15-12-16-8-10-17(11-9-16)20-18(22)6-5-7-19(23)24/h8-11H,2-7,12-15H2,1H3,(H-,20,22,23,24)/p+1",N-METHYL-N-(PARA-GLUTARAMIDOPHENYL-ETHYL)-PIPERIDINIUM ION,PDBeChem accession,GEP
1882,40799,"androsta-1,4-diene-3,17-dione",A steroid that consists of androstane having double bonds at positions 1 and 4 and two keto groups at positions 3 and 17.,"InChI=1S/C19H24O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1","ANDROSTA-1,4-DIENE-3,17-DIONE",PDBeChem accession,ANB
1883,40886,beta-L-arabinopyranose,A L-arabinopyranose with a beta-configuration at the anomeric position.,"InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3-,4+,5-/m0/s1",BETA-L-ARABINOSE,PDBeChem accession,ARB
1884,42452,formycin A,,"InChI=1S/C10H13N5O4/c11-10-6-4(12-2-13-10)5(14-15-6)9-8(18)7(17)3(1-16)19-9/h2-3,7-9,16-18H,1H2,(H,14,15)(H2,11,12,13)/t3-,7-,8-,9+/m1/s1",FORMYCIN,PDBeChem accession,FMC
1885,42082,"(4R,5S,6S,7R)-4,7-dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one","A 1,3-diazepanone ring with two 4-(hydroxymethyl)benzyl groups as substituents at positions N-1 and N-4, two benzyl groups at C-4 and C-7, and two hydroxy groups at C-5 and C-6 respectively.","InChI=1S/C35H38N2O5/c38-23-29-15-11-27(12-16-29)21-36-31(19-25-7-3-1-4-8-25)33(40)34(41)32(20-26-9-5-2-6-10-26)37(35(36)42)22-28-13-17-30(24-39)18-14-28/h1-18,31-34,38-41H,19-24H2/t31-,32-,33+,34+/m1/s1","[4-R-(-4-ALPHA,5-ALPHA,6-BETA,7-BETA)]-HEXAHYDRO-5,6-BIS(HYDROXY)-[1,3-BIS([4-HYDROXYMETHYL-PHENYL]METHYL)-4,7-BIS(PHENYLMETHYL)]-2H-1,3-DIAZEPINONE",PDBeChem accession,DMP
1886,41231,N-benzyl-4-sulfamoylbenzamide,A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-sulfamoylbenzoic acid with the amino group of 1-phenylmethanamine. It is a potent inhibitor of carbonic anhydrase II.,"InChI=1S/C14H14N2O3S/c15-20(18,19)13-8-6-12(7-9-13)14(17)16-10-11-4-2-1-3-5-11/h1-9H,10H2,(H,16,17)(H2,15,18,19)",N-benzyl-4-sulfamoyl-benzamide,PDBeChem accession,BSB
1887,41611,3-thiaoctanoyl-CoA,A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (pentylsulfanyl)acetic acid.,"InChI=1S/C28H48N7O17P3S2/c1-4-5-6-10-56-13-19(37)57-11-9-30-18(36)7-8-31-26(40)23(39)28(2,3)14-49-55(46,47)52-54(44,45)48-12-17-22(51-53(41,42)43)21(38)27(50-17)35-16-34-20-24(29)32-15-33-25(20)35/h15-17,21-23,27,38-39H,4-14H2,1-3H3,(H,30,36)(H,31,40)(H,44,45)(H,46,47)(H2,29,32,33)(H2,41,42,43)/t17-,21-,22-,23+,27-/m1/s1",3-THIAOCTANOYL-COENZYME A,PDBeChem accession,CS8
1888,41893,4-deoxy-Delta(4)-beta-D-GlcpA,A uronic acid that is beta-D-glucuronic acid in which the hydroxy group at position 4 and the hydrogen at position 5 have been eliminated with the introduction of a double bond between positions 4 and 5.,"InChI=1S/C6H8O6/c7-2-1-3(5(9)10)12-6(11)4(2)8/h1-2,4,6-8,11H,(H,9,10)/t2-,4+,6+/m0/s1",4-DEOXY-ALPHA-L-THREO-HEX-4-ENOPYRANURONIC ACID,Reaxys Registry Number,5515873
1889,41983,4'-epidoxorubicinium,An anthracycline cation resulting from the protonation of the amino group of 4'-epidoxorubicin.,"InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/p+1/t10-,13-,15-,17-,22-,27-/m0/s1",4'-EPIDOXORUBICIN,PDBeChem accession,DM6
1890,42034,(S)-2-(4-nitrobenzyl)-DOTA,A tetracarboxylic acid that is an optically active twelve-membered tetraazamacrocycle having a carboxymethyl group attached to each of the nitrogens and a 4-nitrobenzyl group at the 2-position.,"InChI=1S/C23H33N5O10/c29-20(30)13-24-5-6-25(14-21(31)32)9-10-27(16-23(35)36)19(12-26(8-7-24)15-22(33)34)11-17-1-3-18(4-2-17)28(37)38/h1-4,19H,5-16H2,(H,29,30)(H,31,32)(H,33,34)(H,35,36)/t19-/m0/s1","2,2',2'',2'''-[(2S)-2-(4-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl]tetraacetic acid",PDBeChem accession,DOF
1891,42037,4'-deoxy-4'-iododoxorubicinium,,"InChI=1S/C27H28INO10/c1-10-22(28)13(29)6-17(38-10)39-15-8-27(36,16(31)9-30)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,30,33,35-36H,6-9,29H2,1-2H3/p+1/t10-,13-,15-,17-,22+,27-/m0/s1",4'-DEOXY-4'-IODODOXORUBICIN,PDBeChem accession,DM7
1892,42085,"(7R,8S)-7,8-diaminononanoic acid","The isomer of 7,8-diaminononanoic acid having (R)- and (S)- configurations at C-7 and C-8, respectively; an intermediate in the biosynthetic pathway of biotin. As biotin is made exclusively in plants and microorganisms, both the chemical structure and biosynthetic enzymes of DAPA are targets for the development of herbicides and antimicrobial drugs.","InChI=1S/C9H20N2O2/c1-7(10)8(11)5-3-2-4-6-9(12)13/h7-8H,2-6,10-11H2,1H3,(H,12,13)/t7-,8+/m0/s1","7,8-DIAMINO-NONANOIC ACID",PDBeChem accession,DNN
1893,42122,(S)-2-{4-[2-(2-hydroxyethylthio)acetamido]benzyl}-DOTA,A tetracarboxylic acid that is an optically active twelve-membered tetraazamacrocycle having a carboxymethyl group attached to each of the nitrogens and a 4-substituted benzyl group at the 2-position.,"InChI=1S/C27H41N5O10S/c33-11-12-43-19-23(34)28-21-3-1-20(2-4-21)13-22-14-31(17-26(39)40)8-7-29(15-24(35)36)5-6-30(16-25(37)38)9-10-32(22)18-27(41)42/h1-4,22,33H,5-19H2,(H,28,34)(H,35,36)(H,37,38)(H,39,40)(H,41,42)/t22-/m0/s1","(S)-2-(4-(2-(2-HYDROXYETHYLTHIO)-ACETAMIDO)-BENZYL)-1,4,7,10-TETRAAZACYCLODODECANE-N,N',N'',N'''-TETRAACETATE",PDBeChem accession,DOE
1894,42112,1-(2-deoxy-5-O-phosphono-beta-L-ribofuranosyl)thymine,,"InChI=1S/C10H15N2O8P/c1-5-3-12(10(15)11-9(5)14)8-2-6(13)7(20-8)4-19-21(16,17)18/h3,6-8,13H,2,4H2,1H3,(H,11,14,15)(H2,16,17,18)/t6-,7+,8+/m1/s1",2'-DEOXY-L-RIBO-FURANOSYL THYMINE-5'-MONOPHOSPHATE,Beilstein Registry Number,764603
1895,42495,6-methylformycin A,,"InChI=1S/C11H15N5O4/c1-16-3-13-5-6(14-15-7(5)11(16)12)10-9(19)8(18)4(2-17)20-10/h3-4,8-10,17-19H,2,12H2,1H3/t4-,8-,9-,10+/m1/s1","2-(7-AMINO-6-METHYL-3H-PYRAZOLO[4,3-D]PYRIMIDIN-3-YL)-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-3,4-DIOL",PDBeChem accession,FM2
1896,42528,alpha-D-GalNpAc-(1->3)-beta-D-GalpNAc,An alpha-D-GalpNAc-(1->3)-D-GalpNAc having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)11(23)7(3-19)28-16(9)29-14-10(18-6(2)22)15(26)27-8(4-20)12(14)24/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12+,13-,14-,15-,16-/m1/s1",FORSMANN ANTIGEN,PDBeChem accession,FSM
1897,42549,3-(5-fluorouracil-1-yl)-L-alanine,"An alanine derivative that is L-alanine bearing a 5-fluorouracil-1-yl substituent at position 3. A more potent and selective AMPA receptor agonist (at hGluR1 and hGluR2) than AMPA itself (Ki = 14.7, 25.1, and 1820 nM for hGluR1, hGluR2 and hGluR5 respectively).","InChI=1S/C7H8FN3O4/c8-3-1-11(2-4(9)6(13)14)7(15)10-5(3)12/h1,4H,2,9H2,(H,13,14)(H,10,12,15)/t4-/m0/s1","2-AMINO-3-(5-FLUORO-2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-PROPIONIC ACID",PDBeChem accession,FWD
1898,42660,GDP-beta-L-galactose,A GDP-L-galactose having beta-configuration at the anomeric centre of the L-galactose fragment.,"InChI=1S/C16H25N5O16P2/c17-16-19-12-6(13(28)20-16)18-3-21(12)14-10(26)8(24)5(34-14)2-33-38(29,30)37-39(31,32)36-15-11(27)9(25)7(23)4(1-22)35-15/h3-5,7-11,14-15,22-27H,1-2H2,(H,29,30)(H,31,32)(H3,17,19,20,28)/t4-,5+,7+,8+,9+,10+,11-,14+,15+/m0/s1",GUANOSINE-5'-DIPHOSPHATE-BETA-L-GALACTOSE,PDBeChem accession,GDC
1899,42465,ethanesulfonic acid,An alkanesulfonic acid in which the alkyl group directly linked to the sulfo functionality is ethyl.,"InChI=1S/C2H6O3S/c1-2-6(3,4)5/h2H2,1H3,(H,3,4,5)",ETHANESULFONIC ACID,PDBeChem accession,ESA
1900,42487,iodoethane,An iodoalkane that is ethane substituted by an iodo group.,"InChI=1S/C2H5I/c1-2-3/h2H2,1H3",IODOETHANE,PDBeChem accession,ETI
1901,42654,formycin B,,"InChI=1S/C10H12N4O5/c15-1-3-7(16)8(17)9(19-3)5-4-6(14-13-5)10(18)12-2-11-4/h2-3,7-9,15-17H,1H2,(H,13,14)(H,11,12,18)/t3-,7-,8-,9+/m1/s1",FORMYCIN B,PDBeChem accession,FMB
1902,40782,"1,3-thiazol-2-amine","A  primary amino compound that is 1,3-thiazole substituted by an amino group at position 2.","InChI=1S/C3H4N2S/c4-3-5-1-2-6-3/h1-2H,(H2,4,5)",2-AMINOTHIAZOLE,PDBeChem accession,AMT
1903,41323,tetraethylene glycol monooctyl ether,,"InChI=1S/C16H34O5/c1-2-3-4-5-6-7-9-18-11-13-20-15-16-21-14-12-19-10-8-17/h17H,2-16H2,1H3",(HYDROXYETHYLOXY)TRI(ETHYLOXY)OCTANE,CAS Registry Number,19327-39-0
1904,34037,"1,2,3-trimethylbenzene","A trimethylbenzene carrying methyl groups at positions 1, 2 and 3. It has been found in  Centaurium erythraea.","InChI=1S/C9H12/c1-7-5-4-6-8(2)9(7)3/h4-6H,1-3H3","1,2,3-Trimethylbenzene",KEGG COMPOUND accession,C14518
1905,31469,desmethyldescarbamoylnovobiocin,A hydroxycoumarin that is novobiocin lacking the 3-O-carbamoyl and 4-O-methyl groups from the hexose ring.,"InChI=1S/C29H33NO10/c1-13(2)6-7-15-12-16(8-10-18(15)31)26(36)30-20-21(32)17-9-11-19(14(3)24(17)39-27(20)37)38-28-23(34)22(33)25(35)29(4,5)40-28/h6,8-12,22-23,25,28,31-35H,7H2,1-5H3,(H,30,36)/t22-,23+,25+,28+/m0/s1",Desmethyldescarbamoylnovobiocin,KEGG COMPOUND accession,C12475
1906,31743,kaempferol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside,A sophoroside that is kaempferol attached to a beta-D-sophorosyl residue at position 3 via a glycosidic linkage.,"InChI=1S/C27H30O16/c28-7-14-17(33)20(36)22(38)26(40-14)43-25-21(37)18(34)15(8-29)41-27(25)42-24-19(35)16-12(32)5-11(31)6-13(16)39-23(24)9-1-3-10(30)4-2-9/h1-6,14-15,17-18,20-22,25-34,36-38H,7-8H2/t14-,15-,17-,18-,20+,21+,22-,25-,26+,27+/m1/s1",Kaempferol-3-O-beta-D-sophoroside,KEGG COMPOUND accession,C12634
1907,31744,kaempferol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucoside,A kaempferol O-glucoside that is kaempferol attached to a beta-D-sophorotriosyl residue at position 3 via a glycosidic linkage.,"InChI=1S/C33H40O21/c34-7-15-19(40)23(44)26(47)31(49-15)53-29-24(45)20(41)17(9-36)51-33(29)54-30-25(46)21(42)16(8-35)50-32(30)52-28-22(43)18-13(39)5-12(38)6-14(18)48-27(28)10-1-3-11(37)4-2-10/h1-6,15-17,19-21,23-26,29-42,44-47H,7-9H2/t15-,16-,17-,19-,20-,21-,23+,24+,25+,26-,29-,30-,31+,32+,33+/m1/s1",Kaempferol 3-sophorotrioside,KEGG COMPOUND accession,C12635
1908,34117,batilol,An alkylglycerol that is glycerol in which one of the primary hydroxy groups has been converted into the corresponding octadecyl ether. It is used in cosmetics as a stabilising ingredient and skin-conditioning agent.,"InChI=1S/C21H44O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24-20-21(23)19-22/h21-23H,2-20H2,1H3",1-O-Octadecylglycerol,KEGG COMPOUND accession,C13858
1909,34862,"N-(30-(9Z,12Z-octadecadienoyloxy)-tricontanoyl)-sphing-4-enine","An N-acylsphingosine in which the ceramide N-acyl group is specified as 30-[(9Z,12Z)-octadeca-9,12-dienoyloxy]triacontanoyl.","InChI=1S/C66H125NO5/c1-3-5-7-9-11-13-15-17-31-36-40-44-48-52-56-60-66(71)72-61-57-53-49-45-41-37-33-30-28-26-24-22-20-18-19-21-23-25-27-29-32-35-39-43-47-51-55-59-65(70)67-63(62-68)64(69)58-54-50-46-42-38-34-16-14-12-10-8-6-4-2/h11,13,17,31,54,58,63-64,68-69H,3-10,12,14-16,18-30,32-53,55-57,59-62H2,1-2H3,(H,67,70)/b13-11-,31-17-,58-54+/t63-,64+/m0/s1","N-(30-(9Z,12Z-octadecadienoyloxy)-tricontanoyl)-sphing-4-enine",KEGG COMPOUND accession,C13918
1910,31047,10-carboxy-13-deoxycarminomycin,An anthracycline antibiotic that is 13-deoxycarminomycin substituted at position 10 by a carboxy group.,"InChI=1S/C27H29NO11/c1-3-27(37)8-13(39-14-7-11(28)21(30)9(2)38-14)16-17(20(27)26(35)36)25(34)18-19(24(16)33)23(32)15-10(22(18)31)5-4-6-12(15)29/h4-6,9,11,13-14,20-21,29-30,33-34,37H,3,7-8,28H2,1-2H3,(H,35,36)/t9-,11-,13-,14-,20-,21+,27+/m0/s1",D 788-1,KEGG COMPOUND accession,C12427
1911,32340,dTDP-beta-L-daunosamine,A dTDP-sugar having beta-L-daunosamine as the sugar component.,"InChI=1S/C16H27N3O13P2/c1-7-5-19(16(23)18-15(7)22)12-4-10(20)11(30-12)6-28-33(24,25)32-34(26,27)31-13-3-9(17)14(21)8(2)29-13/h5,8-14,20-21H,3-4,6,17H2,1-2H3,(H,24,25)(H,26,27)(H,18,22,23)/t8-,9-,10-,11+,12+,13+,14+/m0/s1",dTDP-beta-L-daunosamine,KEGG COMPOUND accession,C12443
1912,32029,potassium acetate,A potassium salt comprising equal numbers of potassium and acetate ions,"InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1",Potassium acetate,KEGG COMPOUND accession,C12554
1913,34487,8(S)-HPETE,"A HPETE in which the hydroperoxy group is located at position 8S and the four double bonds at position 5, 9, 11 and 14 (the 5Z,9E,11Z,14Z-geoisomer).","InChI=1S/C20H32O4/c1-2-3-4-5-6-7-8-9-10-13-16-19(24-23)17-14-11-12-15-18-20(21)22/h6-7,9-11,13-14,16,19,23H,2-5,8,12,15,17-18H2,1H3,(H,21,22)/b7-6-,10-9-,14-11-,16-13+/t19-/m1/s1",8(S)-HPETE,KEGG COMPOUND accession,C14823
1914,39624,1-methylcytosine,A pyrimidone that is cytosine in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group.,"InChI=1S/C5H7N3O/c1-8-3-2-4(6)7-5(8)9/h2-3H,1H3,(H2,6,7,9)",1-METHYLCYTOSINE,PDBeChem accession,1MC
1915,34998,teicoplanin A2-5,A teicoplanin A2 that has 9-methyldecanoyl as the variable N-acyl group.,"InChI=1S/C89H99Cl2N9O33/c1-34(2)9-7-5-4-6-8-10-61(109)95-69-75(114)72(111)59(32-102)130-88(69)133-79-56-26-41-27-57(79)127-53-18-14-39(24-48(53)91)78(132-87-68(93-35(3)104)74(113)71(110)58(31-101)129-87)70-85(122)99-67(86(123)124)46-29-43(106)30-55(128-89-77(116)76(115)73(112)60(33-103)131-89)62(46)45-23-38(13-15-50(45)107)64(82(119)100-70)97-84(121)66(41)98-83(120)65-40-21-42(105)28-44(22-40)125-54-25-37(12-16-51(54)108)63(92)81(118)94-49(80(117)96-65)20-36-11-17-52(126-56)47(90)19-36/h11-19,21-30,34,49,58-60,63-78,87-89,101-103,105-108,110-116H,4-10,20,31-33,92H2,1-3H3,(H,93,104)(H,94,118)(H,95,109)(H,96,117)(H,97,121)(H,98,120)(H,99,122)(H,100,119)(H,123,124)/t49-,58-,59-,60-,63-,64-,65+,66-,67+,68-,69-,70+,71-,72-,73-,74-,75-,76+,77+,78-,87+,88+,89+/m1/s1",Teicoplanin A2-5,KEGG COMPOUND accession,C13612
1916,31799,malvidin 3-O-beta-D-glucoside,An anthocyanin cation consisting of malvidin having a beta-D-glucosyl residue attached at the 3-hydroxy position.,"InChI=1S/C23H24O12/c1-31-14-3-9(4-15(32-2)18(14)27)22-16(7-11-12(26)5-10(25)6-13(11)33-22)34-23-21(30)20(29)19(28)17(8-24)35-23/h3-7,17,19-21,23-24,28-30H,8H2,1-2H3,(H2-,25,26,27)/p+1/t17-,19-,20+,21-,23-/m1/s1",Malvidin 3-O-glucoside,KEGG COMPOUND accession,C12140
1917,31402,cinnamyl acetate,An acetate ester resulting from the formal condensation of cinnamyl alcohol with acetic acid. Found in cinnamon leaf oil.,"InChI=1S/C11H12O2/c1-10(12)13-9-5-8-11-6-3-2-4-7-11/h2-8H,9H2,1H3",Cinnamyl acetate,KEGG COMPOUND accession,C12299
1918,34801,isoxathion,"An organic thiophosphate  that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group is replaced by a 5-phenyl-1,2-oxazol-3-yl group.","InChI=1S/C13H16NO4PS/c1-3-15-19(20,16-4-2)18-13-10-12(17-14-13)11-8-6-5-7-9-11/h5-10H,3-4H2,1-2H3",Isoxathion,KEGG COMPOUND accession,C14580
1919,34507,9-anthroic acid,An anthroic acid carrying the carboxy substituent at position 9.,"InChI=1S/C15H10O2/c16-15(17)14-12-7-3-1-5-10(12)9-11-6-2-4-8-13(11)14/h1-9H,(H,16,17)",9-Anthroic acid,KEGG COMPOUND accession,C13699
1920,31781,lopinavir,"A dicarboxylic acid diamide that is amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha- to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3-methyl-2-(2-oxotetrahydropyrimidin-1-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class, it is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.","InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1",Lopinavir,KEGG COMPOUND accession,C12871
1921,34848,mevastatin,"A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.","InChI=1S/C23H34O5/c1-4-14(2)23(26)28-20-7-5-6-16-9-8-15(3)19(22(16)20)11-10-18-12-17(24)13-21(25)27-18/h6,8-9,14-15,17-20,22,24H,4-5,7,10-13H2,1-3H3/t14-,15-,17+,18+,19-,20-,22-/m0/s1",Mevastatin,KEGG COMPOUND accession,C13963
1922,34357,"4',5,6,7-tetramethoxyflavone",A tetramethoxyflavone that is the tetra-O-methyl derivative of  scutellarein.,"InChI=1S/C19H18O6/c1-21-12-7-5-11(6-8-12)14-9-13(20)17-15(25-14)10-16(22-2)18(23-3)19(17)24-4/h5-10H,1-4H3",Tetra-O-methylscutellarein,KEGG COMPOUND accession,C14472
1923,31034,(S)-DNPA,"A member of the class of naphthopyrans that is 4,10-dihydro-3H-naphtho[2,3-c]pyran-3-yl]acetic acid bearing additional methyl, hydroxy and oxo substituents at positions 1, 9 and 10 respectively.","InChI=1S/C16H14O5/c1-8-14-10(6-11(21-8)7-13(18)19)5-9-3-2-4-12(17)15(9)16(14)20/h2-5,11,17H,6-7H2,1H3,(H,18,19)/t11-/m0/s1","4-Dihydro-9-hydroxy-1-methyl-10-oxo-3-H-naphtho[2,3-c]pyran-3-acetic acid",KEGG COMPOUND accession,C12434
1924,31348,capecitabine,A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.,"InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1","(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester",KEGG COMPOUND accession,C12650
1925,34620,quinomethionate,"A dithioloquinoxaline that results from the formal condensation of 6-methylquinoxaline-2,3-dithiol with phosgene. It has been used as a fungicide and acaricide for the control of mites and powdery mildew on citrus, vegetables, and walnuts, but is not approved for use in the EU.","InChI=1S/C10H6N2OS2/c1-5-2-3-6-7(4-5)12-9-8(11-6)14-10(13)15-9/h2-4H,1H3",Chinomethionat,KEGG COMPOUND accession,C14514
1926,35038,tris(2-butoxyethyl) phosphate,A trialkyl phosphate in which the alkyl group specified is 2-butoxyethyl.,"InChI=1S/C18H39O7P/c1-4-7-10-20-13-16-23-26(19,24-17-14-21-11-8-5-2)25-18-15-22-12-9-6-3/h4-18H2,1-3H3",Tris(butoxyethyl)phosphate,KEGG COMPOUND accession,C14446
1927,37941,clopidogrel,"A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a  methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.","InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1",(+)-Clopidogrel,DrugBank accession,DB00758
1928,34999,teicoplanin A3-1,A glycopeptide consisting of a macropolycyclic heptapeptide in which a phenolic hydroxy group has been converted to its alpha-D-mannoside while a secondary alcohol group has been converted to the corresponding 2-acetamido-2-deoxy-beta-D-glucoside.,"InChI=1S/C72H68Cl2N8O28/c1-24(85)76-55-60(93)58(91)47(22-83)108-71(55)110-63-28-5-9-42(37(74)15-28)106-46-18-30-17-45(57(46)90)105-41-8-2-25(10-36(41)73)11-38-64(96)78-52(29-12-31(86)19-33(13-29)104-43-16-26(3-7-40(43)89)50(75)65(97)77-38)67(99)80-53(30)68(100)79-51-27-4-6-39(88)34(14-27)49-35(54(70(102)103)81-69(101)56(63)82-66(51)98)20-32(87)21-44(49)107-72-62(95)61(94)59(92)48(23-84)109-72/h2-10,12-21,38,47-48,50-56,58-63,71-72,83-84,86-95H,11,22-23,75H2,1H3,(H,76,85)(H,77,97)(H,78,96)(H,79,100)(H,80,99)(H,81,101)(H,82,98)(H,102,103)/t38-,47-,48-,50-,51-,52+,53-,54+,55-,56+,58-,59-,60-,61+,62+,63-,71+,72+/m1/s1",Teicoplanin A3-1,KEGG COMPOUND accession,C13613
1929,32153,stealthin C,"An organic heterotetracyclic compound that is 10H-benzo[b]fluorene substituted by a methyl group at position 1, hydroxy groups at positions 4, 5 and 9, oxo group at position 10, and an amino group at position 11.","InChI=1S/C18H13NO4/c1-7-5-9-12(11(21)6-7)14-15(16(9)19)18(23)13-8(17(14)22)3-2-4-10(13)20/h2-6,20-22H,19H2,1H3",Stealthin C,KEGG COMPOUND accession,C12392
1930,34398,4-chlorochalcone,A member of the class of  chalcones that is trans-chalcone substituted by a chloro group at position 4.,InChI=1S/C15H11ClO/c16-14-9-6-12(7-10-14)8-11-15(17)13-4-2-1-3-5-13/h1-11H/b11-8+,3-(4-Chlorophenyl)-1-phenyl-2-propen-1-one,KEGG COMPOUND accession,C14585
1931,31763,laricitrin,A monomethoxyflavone that is the 3'-O-methyl derivative of myricetin.,"InChI=1S/C16H12O8/c1-23-11-3-6(2-9(19)13(11)20)16-15(22)14(21)12-8(18)4-7(17)5-10(12)24-16/h2-5,17-20,22H,1H3",Laricitrin,KEGG COMPOUND accession,C12633
1932,31432,corynebactin,"A crown compound that is enterobactin in which the pro-R hydrogens at positions 2, 6 and 10 of the trilactone backbone are replaced by methyl groups, and in which a glycine spacer separates the trilactone backbone from each of the catecholamide arms. It is the endogenous siderophore of Bacillus subtilis, used for the acquisition of iron.","InChI=1S/C39H42N6O18/c1-16-28(43-25(49)13-40-34(55)19-7-4-10-22(46)31(19)52)37(58)62-18(3)30(45-27(51)15-42-36(57)21-9-6-12-24(48)33(21)54)39(60)63-17(2)29(38(59)61-16)44-26(50)14-41-35(56)20-8-5-11-23(47)32(20)53/h4-12,16-18,28-30,46-48,52-54H,13-15H2,1-3H3,(H,40,55)(H,41,56)(H,42,57)(H,43,49)(H,44,50)(H,45,51)/t16-,17-,18-,28+,29+,30+/m1/s1",Corynebactin,KEGG COMPOUND accession,C12219
1933,31249,azulene,A mancude carbobicyclic parent consisting of a cycloheptatriene and cyclopentadiene rings.,InChI=1S/C10H8/c1-2-5-9-7-4-8-10(9)6-3-1/h1-8H,Azulene,KEGG COMPOUND accession,C13392
1934,32274,UDP-3-keto-alpha-D-glucose,UDP-sugar having 3-keto-alpha-D-glucose as the sugar component.,"InChI=1S/C15H22N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-9,11-14,18,20-21,23-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8-,9-,11-,12-,13-,14-/m1/s1",UDP-3-ketoglucose,KEGG COMPOUND accession,C12210
1935,35047,xanthomicrol,"A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7 and 8 and hydroxy groups at positions 5 and 4'.","InChI=1S/C18H16O7/c1-22-16-14(21)13-11(20)8-12(9-4-6-10(19)7-5-9)25-15(13)17(23-2)18(16)24-3/h4-8,19,21H,1-3H3","4',5-dihydroxy-6,7,8-trimethoxyflavone",KEGG COMPOUND accession,C14476
1936,34735,edifenphos,"An organic thiophosphate that is the O-ethyl-S,S-diphenyl ester of phosphorodithioic acid.  Used to control a variety of fungal diseases on rice including blast, ear blight and stem rot. Edifenphos is moderately toxic to mammals and fish but poses more of a risk to aquatic invertebrates.","InChI=1S/C14H15O2PS2/c1-2-16-17(15,18-13-9-5-3-6-10-13)19-14-11-7-4-8-12-14/h3-12H,2H2,1H3",Edifenphos,KEGG COMPOUND accession,C14436
1937,34496,9(S)-HODE,A 9-HODE in which the 9-hydroxy group has S-stereochemistry.,"InChI=1S/C18H32O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h6,8,11,14,17,19H,2-5,7,9-10,12-13,15-16H2,1H3,(H,20,21)/b8-6-,14-11+/t17-/m1/s1",9(S)-HODE,KEGG COMPOUND accession,C14767
1938,34910,pentetrazol,"An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.",InChI=1S/C6H10N4/c1-2-4-6-7-8-9-10(6)5-3-1/h1-5H2,Pentylenetetrazole,KEGG COMPOUND accession,C13692
1939,32080,quercetin 3-O-(6-O-malonyl-beta-D-glucoside),A quercetin O-glucoside that is  quercetin attached to a 6-O-malonyl-beta-D-glucopyranosyl residue at position 3 via a glycosidic linkage.,"InChI=1S/C24H22O15/c25-9-4-12(28)17-13(5-9)37-22(8-1-2-10(26)11(27)3-8)23(19(17)33)39-24-21(35)20(34)18(32)14(38-24)7-36-16(31)6-15(29)30/h1-5,14,18,20-21,24-28,32,34-35H,6-7H2,(H,29,30)/t14-,18-,20+,21-,24+/m1/s1",Quercetin 3-O-malonylglucoside,KEGG COMPOUND accession,C12638
1940,32083,quercetin 3-O-beta-D-glucosyl-(1->2)-beta-D-glucosyl-(1->2)-beta-D-glucoside,A quercetin O-glucoside that is quercetin attached to a beta-D-sophorotriosyl residue at position 3 via a glycosidic linkage.,"InChI=1S/C33H40O22/c34-6-15-19(41)23(45)26(48)31(50-15)54-29-24(46)20(42)17(8-36)52-33(29)55-30-25(47)21(43)16(7-35)51-32(30)53-28-22(44)18-13(40)4-10(37)5-14(18)49-27(28)9-1-2-11(38)12(39)3-9/h1-5,15-17,19-21,23-26,29-43,45-48H,6-8H2/t15-,16-,17-,19-,20-,21-,23+,24+,25+,26-,29-,30-,31+,32+,33+/m1/s1",Quercetin 3-sophorotrioside,KEGG COMPOUND accession,C12668
1941,34218,"2,3,4,4'-tetrachlorobiphenyl","A tetrachlorobiphenyl in which the chlorines are positions at positions 2, 3, 4, and 4'.",InChI=1S/C12H6Cl4/c13-8-3-1-7(2-4-8)9-5-6-10(14)12(16)11(9)15/h1-6H,"2,3,4,4'-Tetrachlorobiphenyl",Beilstein Registry Number,5016362
1942,34205,"2,2',4,5-tetrachlorobiphenyl","A tetrachlorobiphenyl that is biphenyl in which the hydrogens at positions 2, 4, 5, and 2' are replaced by chlorines.",InChI=1S/C12H6Cl4/c13-9-4-2-1-3-7(9)8-5-11(15)12(16)6-10(8)14/h1-6H,"2,2',4,5-Tetrachlorobiphenyl",Beilstein Registry Number,6401616
1943,34225,"2,3,6-trichlorobiphenyl","A trichlorobiphenyl that is 1,2,4-trichlorobenzene in which the hydrogen at position 3 has been replaced by a phenyl group.",InChI=1S/C12H7Cl3/c13-9-6-7-10(14)12(15)11(9)8-4-2-1-3-5-8/h1-7H,"2,3,6-Trichlorobiphenyl",KEGG COMPOUND accession,C14359
1944,34233,"2,4,4',6-tetrachlorobiphenyl","A tetrachlorobiphenyl that is 1,3,5-trichlorobenzene in which one of the hydrogens is replaced by a p-chlorophenyl group.",InChI=1S/C12H6Cl4/c13-8-3-1-7(2-4-8)12-10(15)5-9(14)6-11(12)16/h1-6H,"2,4,4',6-Tetrachlorobiphenyl",KEGG COMPOUND accession,C14364
1945,31064,2'-hydroxybiochanin A,A methoxyisoflavone in which the methoxy group is located at position 4' together with three additional hydroxy substituents at positions 2' 5 and 7.,"InChI=1S/C16H12O6/c1-21-9-2-3-10(12(18)6-9)11-7-22-14-5-8(17)4-13(19)15(14)16(11)20/h2-7,17-19H,1H3",2'-Hydroxybiochanin A,KEGG COMPOUND accession,C12135
1946,32730,tryptophanyl radical,An alpha-amino-acid radical derived from tryptophan.,"InChI=1S/C11H11N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9H,5,12H2,(H,14,15)",tryptophan radical,PubMed citation,23458492
1947,32721,glycyl radical,An alpha-amino-acid radical derived from glycine.,"InChI=1S/C2H4NO2/c3-1-2(4)5/h1H,3H2,(H,4,5)",glycine radical,Beilstein Registry Number,1903152
1948,34246,"2,5-dichlorobiphenyl",A dichlorobiphenyl that is p-dichlorobenzene in which one of the hydrogens has been replaced by a phenyl group.,InChI=1S/C12H8Cl2/c13-10-6-7-12(14)11(8-10)9-4-2-1-3-5-9/h1-8H,"2,5-Dichlorobiphenyl",KEGG COMPOUND accession,C14354
1949,34565,benzo[b]fluoranthene,An ortho- and peri-fused polycyclic arene that consists of a benzene ring fused with a acephenanthrylene ring.,InChI=1S/C20H12/c1-2-7-14-13(6-1)12-19-16-9-4-3-8-15(16)18-11-5-10-17(14)20(18)19/h1-12H,Benzo[b]fluoranthene,KEGG COMPOUND accession,C14320
1950,35014,thiophanate-methyl,"A member of the class of thioureas that is the dimethyl ester of (1,2-phenylenedicarbamothioyl)biscarbamic acid. A fungicide effective against a broad spectrum of diseases in fruit, vegetables, turf and other crops including eyespot, scab, powdery mildew and grey mould.","InChI=1S/C12H14N4O4S2/c1-19-11(17)15-9(21)13-7-5-3-4-6-8(7)14-10(22)16-12(18)20-2/h3-6H,1-2H3,(H2,13,15,17,21)(H2,14,16,18,22)","1,2-Di-(3-methoxycarbonyl-2-thioureido)benzene",KEGG COMPOUND accession,C14432
1951,31649,teprenone,"A terpene ketone in which a (9E,13E)-geranylgernayl group is bonded to one of the alpha-methyls of acetone (it is a mixture of 5E- and 5Z-geoisomers in a 3:2 ratio).","InChI=1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17?",Geranylgeranylacetone,KEGG COMPOUND accession,C13297
1952,32325,beta-ionone,"An ionone that is but-3-en-2-one substituted by a 2,6,6-trimethylcyclohex-1-en-1-yl group at position 4.","InChI=1S/C13H20O/c1-10-6-5-9-13(3,4)12(10)8-7-11(2)14/h7-8H,5-6,9H2,1-4H3/b8-7+",beta-Ionone,KEGG COMPOUND accession,C12287
1953,34632,chlorpyrifos-methyl,"An organic thiophosphate that is O,O-dimethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.","InChI=1S/C7H7Cl3NO3PS/c1-12-15(16,13-2)14-7-5(9)3-4(8)6(10)11-7/h3H,1-2H3",Chlorpyrifos-methyl,KEGG COMPOUND accession,C14520
1954,31168,spiramycin II,A macrolide antibiotic produced by various Streptomyces species.,"InChI=1S/C45H76N2O15/c1-25-22-31(20-21-48)41(62-44-39(51)38(47(10)11)40(28(4)58-44)61-37-24-45(7,53)43(52)29(5)57-37)42(54-12)34(59-30(6)49)23-35(50)55-26(2)16-14-13-15-17-33(25)60-36-19-18-32(46(8)9)27(3)56-36/h13-15,17,21,25-29,31-34,36-44,51-53H,16,18-20,22-24H2,1-12H3/b14-13+,17-15+/t25-,26-,27+,28-,29+,31+,32+,33+,34-,36+,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1",Acetylspiramycin,KEGG COMPOUND accession,C12891
1955,34133,11-oxotestosterone,A 3-oxo Delta(4)-steroid that is testosterone carrying an additional oxo substituent at position 11.,"InChI=1S/C19H26O3/c1-18-8-7-12(20)9-11(18)3-4-13-14-5-6-16(22)19(14,2)10-15(21)17(13)18/h9,13-14,16-17,22H,3-8,10H2,1-2H3/t13-,14-,16-,17+,18-,19-/m0/s1",11-Keto-testosterone,KEGG COMPOUND accession,C14256
1956,32182,tandospirone citrate,"A citrate salt of tandospirone , comprising equimolar amounts of citric acid and tandospirone. It is an anxiolytic drug used in the treatment of anxiety disorders.","InChI=1S/C21H29N5O2.C6H8O7/c27-19-17-15-4-5-16(14-15)18(17)20(28)26(19)9-2-1-8-24-10-12-25(13-11-24)21-22-6-3-7-23-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3,6-7,15-18H,1-2,4-5,8-14H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t15-,16+,17+,18-;",tandospirone citrate,KEGG DRUG accession,D01992
1957,31486,dihydro-nogalonic acid methyl ester,A dihydroxyanthraquinone that is chrysazin which is substituted by a 3-hydroxybutanoyl group at position 2 and by a 2-methoxy-2-oxoethyl at position 3.,"InChI=1S/C21H18O8/c1-9(22)6-14(24)16-10(8-15(25)29-2)7-12-18(20(16)27)21(28)17-11(19(12)26)4-3-5-13(17)23/h3-5,7,9,22-23,27H,6,8H2,1-2H3",dihydro-nogalonic acid methyl ester,KEGG COMPOUND accession,C12418
1958,34499,"9,10,13-TriHOME","A TriHOME that is (11E)-octadec-11-enoic acid in which the three hydroxy substituents are located at positions 9, 10 and 13.","InChI=1S/C18H34O5/c1-2-3-7-10-15(19)13-14-17(21)16(20)11-8-5-4-6-9-12-18(22)23/h13-17,19-21H,2-12H2,1H3,(H,22,23)/b14-13+","9,10,13-TriHOME",KEGG COMPOUND accession,C14835
1959,31297,bolandiol dipropionate,A steroid ester resulting from the formal condensation of the carboxy group of propanoic acid with the 3beta and 17beta hydroxy groups of bolandiol.,"InChI=1S/C24H36O4/c1-4-22(25)27-16-7-9-17-15(14-16)6-8-19-18(17)12-13-24(3)20(19)10-11-21(24)28-23(26)5-2/h14,16-21H,4-13H2,1-3H3/t16-,17-,18+,19+,20-,21-,24-/m0/s1",bolandiol dipropionate,KEGG DRUG accession,D01461
1960,34939,prostaglandin D3,"A member of the class of prostaglandins D that is prosta-5,13,17-trien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,13E,15S,17Z-stereoisomer).","InChI=1S/C20H30O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h3-4,6-7,12-13,15-18,21-22H,2,5,8-11,14H2,1H3,(H,24,25)/b6-3-,7-4-,13-12+/t15-,16+,17+,18-/m0/s1",Prostaglandin D3,KEGG COMPOUND accession,C13802
1961,31128,4-hydroxyphenyl acetate,A phenyl acetate obtained by formal condensation of the carboxy group of acetic acid with one of the hydroxy groups of hydroquinone.,"InChI=1S/C8H8O3/c1-6(9)11-8-4-2-7(10)3-5-8/h2-5,10H,1H3",4-Hydroxyphenyl acetate,KEGG COMPOUND accession,C13636
1962,31738,jadomycin B,"A jadomycin that is jadomycin A in which the phenolic hydroxy group at position 12 has been converted to the corresponding 2,6-dideoxy-alpha-L-ribo-hexopyranoside, isolated from Streptomyces venezuelae. It exists as a diastereoisomeric mixture consisting of both 3aS and 3aR isomers.","InChI=1S/C30H31NO9/c1-5-13(3)24-30(37)40-29-16-9-12(2)10-17(32)21(16)23-25(31(24)29)28(36)22-15(27(23)35)7-6-8-19(22)39-20-11-18(33)26(34)14(4)38-20/h6-10,13-14,18,20,24,26,29,32-34H,5,11H2,1-4H3/t13-,14-,18+,20-,24-,26-,29?/m0/s1",jadomycin B,KEGG COMPOUND accession,C12395
1963,32140,sodium caffeine benzoate,A  mixture of caffeine and sodium benzoate. It is used for the treatment of acute respiratory depression associated with overdosage of CNS depressant drugs and also used in combination with ergotamine to prevent vascular headaches.,"InChI=1S/C8H10N4O2.C7H6O2.Na/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2;8-7(9)6-4-2-1-3-5-6;/h4H,1-3H3;1-5H,(H,8,9);/q;;+1/p-1",sodium caffeine benzoate,KEGG COMPOUND accession,C13403
1964,31206,ammonium chloride,An inorganic chloride having ammonium as the counterion.,InChI=1S/ClH.H3N/h1H;1H3,Ammonium chloride,KEGG COMPOUND accession,C12538
1965,31941,oxaliplatin,A platinum coordination entity that is a commonly used chemothrepeutic drug for treatment of colorectal cancer.,"InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1",Oxaliplatin,CAS Registry Number,61825-94-3
1966,34787,heptanal,"An n-alkanal resulting from the oxidation of the alcoholic hydroxy group of heptan-1-ol to the corresponding aldehyde. An endogenous aldehyde coming from membrane lipid oxidation, it is found in the blood of lung cancer patients and has been regarded as a potential biomarker of lung cancer.","InChI=1S/C7H14O/c1-2-3-4-5-6-7-8/h7H,2-6H2,1H3",n-Heptaldehyde,KEGG COMPOUND accession,C14390
1967,34935,propyzamide,"A member of the class of benzamides resulting from the formal condensation of the carboxy group of 3,5-dichlorobenzoic acid with the amino group of 2-methylbut-3-yn-2-amine. It is used as a systemic post-emergent herbicide for the control grass and broadleaf weeds in a wide range of in a wide variety of fruit and root crops.","InChI=1S/C12H11Cl2NO/c1-4-12(2,3)15-11(16)8-5-9(13)7-10(14)6-8/h1,5-7H,2-3H3,(H,15,16)",Pronamide,KEGG COMPOUND accession,C14333
1968,34131,"11,14,15-trihydroxy-(5Z,8Z,12E)-icosatrienoic acid","A trihydroxyicosatrienoic acid that is (5Z,8Z,12E)-icosatrienoic acid in which the three hydroxy groups are located at positions 11, 14 and 15.","InChI=1S/C20H34O5/c1-2-3-9-13-18(22)19(23)16-15-17(21)12-10-7-5-4-6-8-11-14-20(24)25/h4,6-7,10,15-19,21-23H,2-3,5,8-9,11-14H2,1H3,(H,24,25)/b6-4-,10-7-,16-15+","11,14,15-THETA",KEGG COMPOUND accession,C14814
1969,32176,tacalcitol,"A hydroxy seco-steroid that is calciol which carries hydroxy groups at positions 1S and 24R. It is a vitamin D3 analog which is used for the treatment of psoriasis vulgaris in adults, especially on the scalp.","InChI=1S/C27H44O3/c1-17(2)25(29)13-8-18(3)23-11-12-24-20(7-6-14-27(23,24)5)9-10-21-15-22(28)16-26(30)19(21)4/h9-10,17-18,22-26,28-30H,4,6-8,11-16H2,1-3,5H3/b20-9+,21-10-/t18-,22-,23-,24+,25-,26+,27-/m1/s1","(1alpha,24R)-1,24-dihydroxyvitamin D3",KEGG COMPOUND accession,C12919
1970,31752,kinobscurinone,"An organic heterotetracyclic compound that is 10,11-dihydro-5H-benzo[b]fluorene substituted by a methyl group at position 1, hydroxy groups at positions 4 and 9, and oxo groups at positions 5, 10 and 11.","InChI=1S/C18H10O5/c1-7-5-9-12(11(20)6-7)14-15(17(9)22)18(23)13-8(16(14)21)3-2-4-10(13)19/h2-6,19-20H,1H3",Kinobscurinone,KEGG COMPOUND accession,C12391
1971,34696,dieldrin,An organochlorine compound resulting from the epoxidation of the double bond of aldrin. It is the active metabolite of the proinsecticde aldrin.,"InChI=1S/C12H8Cl6O/c13-8-9(14)11(16)5-3-1-2(6-7(3)19-6)4(5)10(8,15)12(11,17)18/h2-7H,1H2/t2-,3+,4+,5-,6-,7+,10+,11-",Dieldrin,KEGG COMPOUND accession,C13718
1972,34118,oct-1-en-3-ol,An alkenyl alcohol with a structure based on a C8 unbranched chain with the hydroxy group at C-2 and unsaturation at C-1-C-2. It is a major volatile compound present in many mushrooms and fungi.,"InChI=1S/C8H16O/c1-3-5-6-7-8(9)4-2/h4,8-9H,2-3,5-7H2,1H3",1-octen-3-ol,KEGG COMPOUND accession,C14272
1973,32246,tolvaptan,A benzazepine derivative incorporating a benzenedicarboxamide function whch is a selective vasopressin V2 receptor antagonist used to treat euvolemic and hypervolemic hyponatremia. It is also used in the treatment of rapidly progressing autosomal dominant polycystic kidney disease to slow the rate of cyst development and renal insufficiency. Tolvaptan is a racemate consisting of a 1:1 mixture of 5R and 5S stereomers.,"InChI=1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)",Tolvaptan,KEGG COMPOUND accession,C12613
1974,31143,7-O-methylvitexin 2''-O-alpha-L-rhamnoside,A derivative of vitexin having a alpha-L-rhamnosyl residue attached at the 2''-position of the glucitol moiety and a methyl group attached at the O-7 position of the chromene.,"InChI=1S/C28H32O14/c1-10-20(33)22(35)24(37)28(39-10)42-27-23(36)21(34)17(9-29)41-26(27)19-16(38-2)8-14(32)18-13(31)7-15(40-25(18)19)11-3-5-12(30)6-4-11/h3-8,10,17,20-24,26-30,32-37H,9H2,1-2H3/t10-,17+,20-,21+,22+,23-,24+,26-,27+,28-/m0/s1",2''-O-Rhamnosylisoswertisin,KEGG COMPOUND accession,C12629
1975,52294,thionine acetate,,"InChI=1S/C12H10N3S.C2H4O2/c13-7-1-3-9-11(5-7)16-12-6-8(14)2-4-10(12)15-9;1-2(3)4/h1-6H,13-14H2;1H3,(H,3,4)/q+1;/p-1",thionin acetate,Beilstein Registry Number,4345073
1976,52605,N'-acetyl-2-hydroxybenzohydrazide,,"InChI=1S/C9H10N2O3/c1-6(12)10-11-9(14)7-4-2-3-5-8(7)13/h2-5,13H,1H3,(H,10,12)(H,11,14)",N-acetylsalicylhydrazidate,Beilstein Registry Number,2647488
1977,52091,3-chloroperbenzoic acid,,"InChI=1S/C7H5ClO3/c8-6-3-1-2-5(4-6)7(9)11-10/h1-4,10H",MCPBA,CAS Registry Number,937-14-4
1978,52310,1-NA-PP1,,"InChI=1S/C19H19N5/c1-19(2,3)24-18-15(17(20)21-11-22-18)16(23-24)14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H2,20,21,22)","4-Amino-1-tert-butyl-3-(1'-naphthyl)pyrazolo[3,4-d]pyrimidine",Beilstein Registry Number,8275174
1979,52119,3-(benzothiazol-2-yl)-7-(diethylamino)-2-oxo-2H-1-benzopyran-4-carbonitrile,,"InChI=1S/C21H17N3O2S/c1-3-24(4-2)13-9-10-14-15(12-22)19(21(25)26-17(14)11-13)20-23-16-7-5-6-8-18(16)27-20/h5-11H,3-4H2,1-2H3",Macrolex Fluorescence Red G,CAS Registry Number,70546-25-7
1980,47520,"(2S,4S)-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine","A 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine in which the dioxolane ring has S configuration at positions 2 and 4.","InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26+/m0/s1","CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE",PDBeChem accession,KTN
1981,53460,"all-cis-icosa-11,14,17-trienoic acid","An icosatrienoic acid having three cis- double bonds at positions 11, 14 and 17.","InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10H,2,5,8,11-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-","(Z,Z,Z)-11,14,17-eicosatrienoic acid",CAS Registry Number,17046-59-2
1982,53455,D-xylopyranose,D-Xylose in its pyranose form.,"InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4-,5?/m1/s1",D-xylose,Beilstein Registry Number,1280757
1983,52030,murideoxycholic acid,A 3alpha-hydroxy steroid that is cholan-24-oic acid substituted by hydroxy groups at positions 3 and 6.,"InChI=1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21-,23-,24-/m1/s1",6beta-Hydroxylithocholate,KEGG COMPOUND accession,C15515
1984,52023,hyodeoxycholic acid,A member of the class of 5beta-cholanic acids that is (5beta)-cholan-24-oic acid substituted by alpha-hydroxy groups at positions 3 and 6.,"InChI=1S/C24H40O4/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15-,16+,17-,18+,19+,20+,21+,23-,24-/m1/s1",6alpha-Hydroxylithocholate,CAS Registry Number,83-49-8
1985,52694,C3-indocyanine,"A C3 cyanine dye having 1-ethyl-3,3-dimethylindoleinine units at each end.","InChI=1S/C27H33N2.HI/c1-7-28-22-16-11-9-14-20(22)26(3,4)24(28)18-13-19-25-27(5,6)21-15-10-12-17-23(21)29(25)8-2;/h9-19H,7-8H2,1-6H3;1H/q+1;/p-1",Indocarbocyanine(C3),Beilstein Registry Number,4088977
1986,52721,2-chloroimidazole,An imidazole compound having a chloro substituent at the 2-position.,"InChI=1S/C3H3ClN2/c4-3-5-1-2-6-3/h1-2H,(H,5,6)",2-chloro-1H-imidazole,Gmelin Registry Number,454299
1987,52307,OG-514 dye,,"InChI=1S/C22H9F5O7S/c23-8-1-6-12(3-10(8)28)34-13-4-11(29)9(24)2-7(13)15(6)16-17(22(32)33)18(25)20(27)21(19(16)26)35-5-14(30)31/h1-4,28H,5H2,(H,30,31)(H,32,33)",Oregon Green 514,Beilstein Registry Number,7674699
1988,51384,D-ascorbic acid,,"InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m1/s1",D-lyxoascorbic acid,CAS Registry Number,10504-35-5
1989,47133,5'-chloro-5'-deoxyadenosine,,"InChI=1S/C10H12ClN5O3/c11-1-4-6(17)7(18)10(19-4)16-3-15-5-8(12)13-2-14-9(5)16/h2-4,6-7,10,17-18H,1H2,(H2,12,13,14)/t4-,6-,7-,10-/m1/s1",5'-CHLORO-5'-DEOXYADENOSINE,CAS Registry Number,892-48-8
1990,47518,"(2S,4R)-ketoconazole","A cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2S,4R)-configuration.","InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m1/s1","1-ACETYL-4-(4-{[(2S,4R)-2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL]METHOXY}PHENYL)PIPERAZINE",PDBeChem accession,KLN
1991,51938,coumarin 460,,"InChI=1S/C14H17NO2/c1-4-15(5-2)11-6-7-12-10(3)8-14(16)17-13(12)9-11/h6-9H,4-5H2,1-3H3",Coumarin 1,CAS Registry Number,91-44-1
1992,51857,methyl (S)-phenyl[(S)-piperidin-2-yl]acetate,A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have S configuration. It is the inactive enantiomer in the racemic drug methylphenidate.,"InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m0/s1",methyl (2S)-phenyl[(2S)-piperidin-2-yl]acetate,Beilstein Registry Number,6116308
1993,46477,methyl vanillate,A benzoate ester that is the methyl ester of  vanillic acid.,"InChI=1S/C9H10O4/c1-12-8-5-6(9(11)13-2)3-4-7(8)10/h3-5,10H,1-2H3",VANILLATE,CAS Registry Number,3943-74-6
1994,46557,zoledronic acid,"An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.","InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)",ZOLEDRONIC ACID,PDBeChem accession,ZOL
1995,46311,8-(pyrimidin-2-ylamino)naphthalene-2-carboximidamide,,"InChI=1S/C15H13N5/c16-14(17)11-6-5-10-3-1-4-13(12(10)9-11)20-15-18-7-2-8-19-15/h1-9H,(H3,16,17)(H,18,19,20)",8-(PYRIMIDIN-2-YLAMINO)NAPHTHALENE-2-CARBOXIMIDAMIDE,PDBeChem accession,UI2
1996,51576,4-bromopyridine,,InChI=1S/C5H4BrN/c6-5-1-3-7-4-2-5/h1-4H,4-pyridyl bromide,CAS Registry Number,1120-87-2
1997,43385,5-(2-methylpiperazine-1-sulfonyl)isoquinoline,,"InChI=1S/C14H17N3O2S/c1-11-9-16-7-8-17(11)20(18,19)14-4-2-3-12-10-15-6-5-13(12)14/h2-6,10-11,16H,7-9H2,1H3",1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE,PDBeChem accession,IQP
1998,44692,phosphonoacetohydroxamic acid,The hydroxamate of phosphonoacetic acid.,"InChI=1S/C2H6NO5P/c4-2(3-5)1-9(6,7)8/h5H,1H2,(H,3,4)(H2,6,7,8)",PHOSPHONOACETOHYDROXAMIC ACID,PDBeChem accession,PAH
1999,45744,N-acetyl-beta-neuraminic acid,N-Acetylneuraminic acid with beta configuration at the anomeric centre.,"InChI=1S/C11H19NO9/c1-4(14)12-7-5(15)2-11(20,10(18)19)21-9(7)8(17)6(16)3-13/h5-9,13,15-17,20H,2-3H2,1H3,(H,12,14)(H,18,19)/t5-,6+,7+,8+,9+,11-/m0/s1",5-N-ACETYL-BETA-D-NEURAMINIC ACID,PDBeChem accession,SLB
2000,46068,N-[4-(D-prolinosulfonyl)benzoyl]-L-glutamic acid,,"InChI=1S/C17H20N2O9S/c20-14(21)8-7-12(16(23)24)18-15(22)10-3-5-11(6-4-10)29(27,28)19-9-1-2-13(19)17(25)26/h3-6,12-13H,1-2,7-9H2,(H,18,22)(H,20,21)(H,23,24)(H,25,26)/t12-,13+/m0/s1",4-[[GLUTAMIC ACID]-CARBONYL]-BENZENE-SULFONYL-D-PROLINE,PDBeChem accession,TP3
2001,43666,(2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine,,"InChI=1S/C20H21N3O/c21-14-18-7-4-12-23(18)20(24)19(22)13-15-8-10-17(11-9-15)16-5-2-1-3-6-16/h1-3,5-6,8-11,18-19H,4,7,12-13,22H2/t18-,19-/m0/s1",1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE,PDBeChem accession,JNH
2002,43424,9-cyclopentyl-6-{2-[3-(4-methylpiperazin-1-yl)propoxy]phenylamino}-9H-purine-2-carbonitrile,,"InChI=1S/C25H32N8O/c1-31-12-14-32(15-13-31)11-6-16-34-21-10-5-4-9-20(21)28-24-23-25(30-22(17-26)29-24)33(18-27-23)19-7-2-3-8-19/h4-5,9-10,18-19H,2-3,6-8,11-16H2,1H3,(H,28,29,30)",9-CYCLOPENTYL-6-{2-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPOXY]-PHENYLAMINO}-9H-PURINE-2-CARBONITRILE,PDBeChem accession,IHJ
2003,45517,"N-[4-(morpholin-4-ylcarbonyl)benzoyl]-L-valyl-N-[(3S)-5,5,6,6,6-pentafluoro-2-methyl-4-oxohexan-3-yl]-L-prolinamide",,"InChI=1S/C29H37F5N4O6/c1-16(2)21(23(39)28(30,31)29(32,33)34)35-25(41)20-6-5-11-38(20)27(43)22(17(3)4)36-24(40)18-7-9-19(10-8-18)26(42)37-12-14-44-15-13-37/h7-10,16-17,20-22H,5-6,11-15H2,1-4H3,(H,35,41)(H,36,40)/t20-,21-,22-/m0/s1","1-{3-METHYL-2-[4-(MORPHOLINE-4-CARBONYL)-BENZOYLAMINO]-BUTYRYL}-PYRROLIDINE-2-CARBOXYLIC ACID (3,3,4,4,4-PENTAFLUORO-1-ISOPROPYL-2-OXO-BUTYL)-AMIDE",PDBeChem accession,SEI
2004,45565,"7-benzyl-1,3-dimethyl-8-piperazin-1-yl-3,7-dihydropurine-2,6-dione",,"InChI=1S/C18H22N6O2/c1-21-15-14(16(25)22(2)18(21)26)24(12-13-6-4-3-5-7-13)17(20-15)23-10-8-19-9-11-23/h3-7,19H,8-12H2,1-2H3","7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE",DrugBank accession,DB08530
2005,43467,immucillin G,,"InChI=1S/C11H15N5O4/c12-11-15-5-3(1-13-7(5)10(20)16-11)6-9(19)8(18)4(2-17)14-6/h1,4,6,8-9,13-14,17-19H,2H2,(H3,12,15,16,20)/t4-,6+,8-,9+/m1/s1","1,4-DIDEOXY-1,4-IMINO-1-(S)-(9-DEAZAGUANIN-9-YL)-D-RIBITOL",PDBeChem accession,IMG
2006,43968,meropenem,A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.,"InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1","(1R,5S,6S)-2-[(3S,5S)-5-DIMETHYLAMINOCARBONYLPYRROLIDIN-3-YLTHIO]-6-[(R)-1-HYDROXYETHYL]-1-METHYLCARBAPEN-2-EM-3-CARBOXYLIC ACID",PDBeChem accession,MER
2007,44639,tert-butylamine,A primary aliphatic amine that is ethylamine substituted by two methyl groups at position 1.,"InChI=1S/C4H11N/c1-4(2,3)5/h5H2,1-3H3",TERTIARY-BUTYLAMINE,PDBeChem accession,NTB
2008,44737,lutidinic acid,A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.,"InChI=1S/C7H5NO4/c9-6(10)4-1-2-8-5(3-4)7(11)12/h1-3H,(H,9,10)(H,11,12)","PYRIDINE-2,4-DICARBOXYLIC ACID",PDBeChem accession,PD2
2009,45265,"1-[4-carboxy-2-(3-pentylamino)phenyl]-5,5-bis(hydroxymethyl)pyrrolidin-2-one","A member of the class of benzoic acids that is benzoic acid in which the hydrogens at positions 3 and 4 have been replaced by pentan-2-ylamino and 2,2-bis(hydroxymethyl)-5-oxopyrrolidin-1-yl groups, respectively.","InChI=1S/C18H26N2O5/c1-3-13(4-2)19-14-9-12(17(24)25)5-6-15(14)20-16(23)7-8-18(20,10-21)11-22/h5-6,9,13,19,21-22H,3-4,7-8,10-11H2,1-2H3,(H,24,25)","1-[4-CARBOXY-2-(3-PENTYLAMINO)PHENYL]-5,5'-DI(HYDROXYMETHYL)PYRROLIDIN-2-ONE",PDBeChem accession,RA2
2010,45293,"(3R)-1'-(9-anthrylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine",,"InChI=1S/C30H35N3O3/c34-29(32-16-18-36-19-17-32)24-8-5-13-33(21-24)25-11-14-31(15-12-25)30(35)28-26-9-3-1-6-22(26)20-23-7-2-4-10-27(23)28/h1-4,6-7,9-10,20,24-25H,5,8,11-19,21H2/t24-/m1/s1","(3R)-1'-(9-anthrylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine",PDBeChem accession,RCP
2011,44111,3-mercaptopropanoic acid,A mercaptopropanoic acid that is propanoic acid carrying a sulfanyl group at position 3.,"InChI=1S/C3H6O2S/c4-3(5)1-2-6/h6H,1-2H2,(H,4,5)",BETA-MERCAPTOPROPIONIC ACID,PDBeChem accession,MPT
2012,43089,N-hydroxyguanidine,A member of the class of guanidines that is guanidine in which one of the hydrogens attached to the nitrogen at position 1 is substituted by a hydroxy group.,"InChI=1S/CH5N3O/c2-1(3)4-5/h5H,(H4,2,3,4)",N-HYDROXYGUANIDINE,Beilstein Registry Number,1741719
2013,51660,"6,8-difluoro-7-hydroxy-4-methylcoumarin",,"InChI=1S/C10H6F2O3/c1-4-2-7(13)15-10-5(4)3-6(11)9(14)8(10)12/h2-3,14H,1H3",DiFMU,Beilstein Registry Number,8060835
2014,43561,N-[2-(methylamino)ethyl]isoquinoline-5-sulfonamide,,"InChI=1S/C12H15N3O2S/c1-13-7-8-15-18(16,17)12-4-2-3-10-9-14-6-5-11(10)12/h2-6,9,13,15H,7-8H2,1H3",N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE,PDBeChem accession,IQS
2015,43799,butan-1-amine,A primary aliphatic amine that is butane substituted by an amino group at position 1.,"InChI=1S/C4H11N/c1-2-3-4-5/h2-5H2,1H3",BUTYLAMINE,PDBeChem accession,LYT
2016,47351,"(1S,3R)-2,2-dichloro-N-[(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide",,"InChI=1S/C15H18Cl3NO/c1-4-14(10(3)15(14,17)18)13(20)19-9(2)11-5-7-12(16)8-6-11/h5-10H,4H2,1-3H3,(H,19,20)/t9-,10-,14+/m1/s1","((1RS,3SR)-2,2-DICHLORO-N-[(R)-1-(4-CHLOROPHENYL)ETHYL]-1-ETHYL-3-METHYLCYCLOPROPANECARBOXAMIDE",PDBeChem accession,CRP
2017,45993,benzothiazole,An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles.,InChI=1S/C7H5NS/c1-2-4-7-6(3-1)8-5-9-7/h1-5H,BENZOTHIAZOLE,PDBeChem accession,THZ
2018,44085,N-methylmesoporphyrin,A mesoporphyrin with an N-methyl substituent at the 22-position.,"InChI=1S/C35H40N4O4/c1-8-22-18(3)28-17-33-23(9-2)21(6)32(39(33)7)16-27-20(5)25(11-13-35(42)43)31(38-27)15-30-24(10-12-34(40)41)19(4)26(36-30)14-29(22)37-28/h14-17,36H,8-13H2,1-7H3,(H,40,41)(H,42,43)/b26-14-,27-16-,28-17-,29-14-,30-15-,31-15-,32-16-,33-17-",N-METHYLMESOPORPHYRIN,PDBeChem accession,MMP
2019,44236,(S)-NADHX,"A tetrahydronicotinamide adenine dinucleotide obtained by formal stereo- and regioselective hydration across the 5,6-double bond in the nicotinyl ring of NADH, with the hydroxy group located at position 6, having (S)-configuration.","InChI=1S/C21H31N7O15P2/c22-17-12-19(25-6-24-17)28(7-26-12)21-16(33)14(31)10(42-21)5-40-45(37,38)43-44(35,36)39-4-9-13(30)15(32)20(41-9)27-3-8(18(23)34)1-2-11(27)29/h3,6-7,9-11,13-16,20-21,29-33H,1-2,4-5H2,(H2,23,34)(H,35,36)(H,37,38)(H2,22,24,25)/t9-,10-,11+,13-,14-,15-,16-,20-,21-/m1/s1","BETA-6-HYDROXY-1,4,5,6-TETRHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE",PDBeChem accession,NAX
2020,44751,"3,6,9,12,15-pentaoxaheptadecane",,"InChI=1S/C12H26O5/c1-3-13-5-7-15-9-11-17-12-10-16-8-6-14-4-2/h3-12H2,1-2H3","3,6,9,12,15-PENTAOXAHEPTADECANE",PDBeChem accession,P3G
2021,44864,"propane-1,3-dithiol",A dithiol that is propane substituted by thiol groups at positions 1 ans 3.,"InChI=1S/C3H8S2/c4-2-1-3-5/h4-5H,1-3H2","1,3-PROPANEDITHIOL",PDBeChem accession,PDT
2022,44920,tetraethylene glycol,,"InChI=1S/C8H18O5/c9-1-3-11-5-7-13-8-6-12-4-2-10/h9-10H,1-8H2",TETRAETHYLENE GLYCOL,PDBeChem accession,PG4
2023,43253,3-isobutyl-1-methyl-9H-xanthine,,"InChI=1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)",3-ISOBUTYL-1-METHYLXANTHINE,PDBeChem accession,IBM
2024,44313,N-acetyl-alpha-D-galactosamine 1-phosphate,The alpha-anomer of N-acetyl-D-galactosamine 1-phosphate.,"InChI=1S/C8H16NO9P/c1-3(11)9-5-7(13)6(12)4(2-10)17-8(5)18-19(14,15)16/h4-8,10,12-13H,2H2,1H3,(H,9,11)(H2,14,15,16)/t4-,5-,6+,7-,8-/m1/s1",N-ACETYL-ALPHA-D-GALACTOSAMINE 1-PHOSPHATE,PDBeChem accession,NG1
2025,43977,"7-methyl-7,8-dihydroguanosine-5'-diphosphate","A purine ribonucleoside 5'-diphosphate having 7-methyl-7,8-dihydroguanine as the nucleobase.","InChI=1S/C11H19N5O11P2/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(26-10)2-25-29(23,24)27-28(20,21)22/h4,6-7,10,17-18H,2-3H2,1H3,(H,23,24)(H2,20,21,22)(H3,12,13,14,19)/t4-,6-,7-,10-/m1/s1",7N-METHYL-8-HYDROGUANOSINE-5'-DIPHOSPHATE,Reaxys Registry Number,1198218
2026,43986,"N(6),N(6)-dimethyl-AMP",A  purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate substituted on N-6 by geminal methyl groups.,"InChI=1S/C12H18N5O7P/c1-16(2)10-7-11(14-4-13-10)17(5-15-7)12-9(19)8(18)6(24-12)3-23-25(20,21)22/h4-6,8-9,12,18-19H,3H2,1-2H3,(H2,20,21,22)/t6-,8-,9-,12-/m1/s1",6N-DIMETHYLADENOSINE-5'-MONOPHOSHATE,PDBeChem accession,MA6
2027,44394,"m-trimethylammonio(2,2,2-trifluoro-1,1-dihydroxyethyl)benzene","A quaternary ammonium ion that is the N,N,N-trimethyl derivative of 3-(2,2,2-trifluoro-1,1-dihydroxyethyl)aniline.","InChI=1S/C11H15F3NO2/c1-15(2,3)9-6-4-5-8(7-9)10(16,17)11(12,13)14/h4-7,16-17H,1-3H3/q+1","M-(N,N,N-TRIMETHYLAMMONIO)-2,2,2-TRIFLUORO-1,1-DIHYDROXYETHYLBENZENE",PDBeChem accession,NAF
2028,44604,6-[(4-hydroxy-3-nitrophenyl)acetamido]caproic acid,An N-acylamino acid consisting of 6-aminohexanoic acid bearing an N-(4-hydroxy-3-nitrophenyl)acetyl substituent.,"InChI=1S/C14H18N2O6/c17-12-6-5-10(8-11(12)16(21)22)9-13(18)15-7-3-1-2-4-14(19)20/h5-6,8,17H,1-4,7,9H2,(H,15,18)(H,19,20)",4-HYDROXY-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID,PDBeChem accession,NP
2029,44515,6-[(4-hydroxy-3-nitrophenyl)acetamido]caproate,"A monocarboxylic acid anion that is the conjugate base of 6-[(4-hydroxy-3-nitrophenyl)acetamido]caproic acid, formed ny proton loss from the carboxy group.","InChI=1S/C14H18N2O6/c17-12-6-5-10(8-11(12)16(21)22)9-13(18)15-7-3-1-2-4-14(19)20/h5-6,8,17H,1-4,7,9H2,(H,15,18)(H,19,20)/p-1",4-HYDROXY-3-NITROPHENYLACETYL-EPSILON-AMINOCAPROIC ACID ANION,PDBeChem accession,NPC
2030,44592,9-(2-carboxyethyl)-10-methylanthracene endoperoxide,A peroxide-bridged anthracene substituted at the bridgeheads with methyl and carboxyethyl groups.,"InChI=1S/C18H16O4/c1-17-12-6-2-4-8-14(12)18(22-21-17,11-10-16(19)20)15-9-5-3-7-13(15)17/h2-9H,10-11H2,1H3,(H,19,20)/t17-,18+",[2'-CARBOXYLETHYL]-10-METHYL-ANTHRACENE ENDOPEROXIDE,PDBeChem accession,OX1
2031,45120,1-O-(1-O-hexadecanoyl-2-O-heptadecanoyl-sn-glycero-3-phosphono)-1D-myo-inositol,A phosphatidylinositol where the 1- and 2-O-acyl groups are hexadecanoyl and heptadecanoyl respectively.,"InChI=1S/C42H81O13P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-36(44)54-34(33-53-56(50,51)55-42-40(48)38(46)37(45)39(47)41(42)49)32-52-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h34,37-42,45-49H,3-33H2,1-2H3,(H,50,51)/t34-,37-,38-,39+,40-,41-,42-/m1/s1","2-[(hydroxy{[(2R,3R,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl)oxy]-1-[(palmitoyloxy)methyl]ethyl heptadecanoate",PDBeChem accession,PII
2032,44794,octaethylene glycol,,"InChI=1S/C16H34O9/c17-1-3-19-5-7-21-9-11-23-13-15-25-16-14-24-12-10-22-8-6-20-4-2-18/h17-18H,1-16H2","3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL",PDBeChem accession,PE8
2033,44817,heptacosaethylene glycol monomethyl ether,,"InChI=1S/C55H112O28/c1-57-4-5-59-8-9-61-12-13-63-16-17-65-20-21-67-24-25-69-28-29-71-32-33-73-36-37-75-40-41-77-44-45-79-48-49-81-52-53-83-55-54-82-51-50-80-47-46-78-43-42-76-39-38-74-35-34-72-31-30-70-27-26-68-23-22-66-19-18-64-15-14-62-11-10-60-7-6-58-3-2-56/h56H,2-55H2,1H3","2,5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80-HEPTACOSAOXADOOCTACONTAN-82-OL",PDBeChem accession,PEU
2034,45126,7-aminomethyl-7-deazaguanine,A pyrrolopyrimidine that is 7-deazaguanine bearing an aminomethyl substituent at the 7 position.,"InChI=1S/C7H9N5O/c8-1-3-2-10-5-4(3)6(13)12-7(9)11-5/h2H,1,8H2,(H4,9,10,11,12,13)",7-DEAZA-7-AMINOMETHYL-GUANINE,PDBeChem accession,PRF
2035,45147,pentasulfide(2-),,InChI=1S/H2S5/c1-3-5-4-2/h1-2H/p-2,PENTASULFIDE-SULFUR,PDBeChem accession,PS5
2036,45719,"(2R,3S,4Z)-2-aminooctadec-4-ene-1,3-diol",,"InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14-/t17-,18+/m1/s1",SPHINGOSINE,PDBeChem accession,SPH
2037,45757,(5S)-5-(carboxymethyl)-L-proline,A L-proline derivative that is L-proline substituted at position 5 by a carboxymethyl group.,"InChI=1S/C7H11NO4/c9-6(10)3-4-1-2-5(8-4)7(11)12/h4-5,8H,1-3H2,(H,9,10)(H,11,12)/t4-,5-/m0/s1","(2S,5S)-5-CARBOXYMETHYLPROLINE",PDBeChem accession,SSC
2038,45791,triethylammonium ion,An organoammonium cation having three ethyl substituents on the nitrogen atom.,"InChI=1S/C6H15N/c1-4-7(5-2)6-3/h4-6H2,1-3H3/p+1",TRIETHYLAMMONIUM ION,PDBeChem accession,TEA
2039,45358,tetramethylrosamine,"An iminium ion that is the 6-dimethylamino derivative of N,N-dimethyl-9-phenyl-3H-xanthen-3-iminium. Used in the form of its chloride salt as a red-orange fluorescent dye.","InChI=1S/C23H23N2O/c1-24(2)17-10-12-19-21(14-17)26-22-15-18(25(3)4)11-13-20(22)23(19)16-8-6-5-7-9-16/h5-15H,1-4H3/q+1","N,N'-TETRAMETHYL-ROSAMINE",PDBeChem accession,ROS
2040,45366,"6-{[(4R,5R)-4-(hydroxymethyl)thymin-5-yl]methyl}thymine","A pyrimidone that is thymine which is substituted at position 6 by a [(4R,5R)-4-(hydroxymethyl)thymin-5-yl]methyl group.","InChI=1S/C12H16N4O5/c1-5-6(13-10(20)15-8(5)18)3-12(2)7(4-17)14-11(21)16-9(12)19/h7,17H,3-4H2,1-2H3,(H2,13,15,18,20)(H2,14,16,19,21)/t7-,12+/m0/s1","6-{[4-(HYDROXYMETHYL)-5-METHYL-2,6-DIOXOHEXAHYDROPYRIMIDIN-5-YL]METHYL}-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE",PDBeChem accession,RCA
2041,44107,malachite green cation,"An iminium ion obtained by dimethylation of the imino group of 4-{[4-(dimethylamino)phenyl](phenyl)methylene}cyclohexa-2,5-dien-1-imine. Used in the form of its chloride salt as a green-coloured dye.","InChI=1S/C23H25N2/c1-24(2)21-14-10-19(11-15-21)23(18-8-6-5-7-9-18)20-12-16-22(17-13-20)25(3)4/h5-17H,1-4H3/q+1","N-(4-{[4-(dimethylamino)phenyl](phenyl)methylidene}cyclohexa-2,5-dien-1-ylidene)-N-methylmethanaminium",PDBeChem accession,MGR
2042,45910,6-benzyl-1-(benzyloxymethyl)-5-isopropyluracil,"A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by benzyloxymethyl, isopropyl, and benzyl groups, respectively.","InChI=1S/C22H24N2O3/c1-16(2)20-19(13-17-9-5-3-6-10-17)24(22(26)23-21(20)25)15-27-14-18-11-7-4-8-12-18/h3-12,16H,13-15H2,1-2H3,(H,23,25,26)",6-BENZYL-1-BENZYLOXYMETHYL-5-ISOPROPYL URACIL,PDBeChem accession,TNK
2043,45969,tricarballylic acid,A tricarboxylic acid that is glutaric acid in which one of the beta-hydrogens is substituted by a carboxy group.,"InChI=1S/C6H8O6/c7-4(8)1-3(6(11)12)2-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)",TRICARBALLYLIC ACID,PDBeChem accession,TRC
2044,46087,"6-[(4-aminobenzyl)amino]-2,3,4,5-tetrahydropyridinium","A carboxamidinium ion consisting of 2,3,4,5-tetrahydropyridinium having a (4-aminobenzyl)amino group at the 2-position.","InChI=1S/C12H17N3/c13-11-6-4-10(5-7-11)9-15-12-3-1-2-8-14-12/h4-7H,1-3,8-9,13H2,(H,14,15)/p+1","2-(4-AMINOBENZYLAMINO)-3,4,5,6-TETRAHYDROPYRIDINIUM",PDBeChem accession,TPM
2045,45657,13-cis-spheroidene,"The cartenoid ether that is the methyl ether of (3E,13cis)-3,4-didehydro-1,2,7',8'-tetrahydro-psi,psi-caroten-1-ol","InChI=1S/C41H60O/c1-34(2)20-14-23-37(5)26-17-29-38(6)27-15-24-35(3)21-12-13-22-36(4)25-16-28-39(7)30-18-31-40(8)32-19-33-41(9,10)42-11/h12-13,15-16,18-22,24-28,30-32H,14,17,23,29,33H2,1-11H3/b13-12+,24-15+,25-16+,30-18+,32-19+,35-21+,36-22-,37-26+,38-27+,39-28+,40-31+",SPHEROIDENE,PDBeChem accession,SPO
2046,45457,"5-[(4,6-diamino-1,3,5-triazin-2-yl)amino]-4-hydroxy-3-[(2-sulfophenyl)diazenyl]naphthalene-2,7-disulfonic acid","A triamino-1,3,5-triazine having a polysubstituted naphthalene group attached to one of the exocyclic nitrogens.","InChI=1S/C19H16N8O10S3/c20-17-23-18(21)25-19(24-17)22-11-7-9(38(29,30)31)5-8-6-13(40(35,36)37)15(16(28)14(8)11)27-26-10-3-1-2-4-12(10)39(32,33)34/h1-7,28H,(H,29,30,31)(H,32,33,34)(H,35,36,37)(H5,20,21,22,23,24,25)/b27-26+","5-(4,6-DIAMINO-[1,3,5]TRIAZIN-2-YLAMINO)-4-HYDROXY-3-(2-SULFO-PHENYLAZO)-NAPHTHALENE-2,7-DISULFONIC ACID",PDBeChem accession,RR1
2047,42941,"(2S,5S)-5-amino-4-oxo-1,2,4,5,6,7-hexahydroazepino[3,2,1-hi]indole-2-carboxylic acid","A non-proteinogenic amino acid derivative consisting of L-proline ortho- and peri-fused on to (3S)-3-amino-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one.","InChI=1S/C13H14N2O3/c14-9-5-4-7-2-1-3-8-6-10(13(17)18)15(11(7)8)12(9)16/h1-3,9-10H,4-6,14H2,(H,17,18)/t9-,10-/m0/s1","(2S,5S)-5-amino-4-oxo-1,2,4,5,6,7-hexahydroazepino[3,2,1-hi]indole-2-carboxylic acid",PDBeChem accession,HAQ
2048,43053,heparin disaccharide I-S(4-),"A monocarboxylic acid anion obtained by deprotonation of the carboxy group, both sulfate groups and sulfamic acid group of HP_dp02_0009.","InChI=1S/C12H19NO19S3/c14-3-1-4(10(16)17)30-12(8(3)32-35(25,26)27)31-9-5(2-28-34(22,23)24)29-11(18)6(7(9)15)13-33(19,20)21/h1,3,5-9,11-15,18H,2H2,(H,16,17)(H,19,20,21)(H,22,23,24)(H,25,26,27)/p-4/t3-,5+,6+,7+,8+,9+,11-,12-/m0/s1","(2R,3R,4S)-2-({(2R,3S,4R,5R,6S)-4,6-dihydroxy-5-(sulfonatoamino)-2-[(sulfonatooxy)methyl]tetrahydro-2H-pyran-3-yl}oxy)-4-hydroxy-3-(sulfonatooxy)-3,4-dihydro-2H-pyran-6-carboxylate (non-preferred name)",PDBeChem accession,H1S
2049,43278,"(1S,2S,5S)-2-(4-glutaridylbenzyl)-5-phenylcyclohexan-1-ol",A gamma-aminobutyric acid (GABA)-based hapten where a 4-substituted benzoyl group is attached to nitrogen.,"InChI=1S/C23H27NO4/c25-21-15-19(16-5-2-1-3-6-16)12-13-20(21)17-8-10-18(11-9-17)23(28)24-14-4-7-22(26)27/h1-3,5-6,8-11,19-21,25H,4,7,12-15H2,(H,24,28)(H,26,27)/t19-,20+,21-/m0/s1","(1S,2S,5S)2-(4-GLUTARIDYLBENZYL)-5-PHENYL-1-CYCLOHEXANOL",PDBeChem accession,HOP
2050,43299,6-(3-hydroxypropyl)thymine,A pyrimidone that is thymine in which the hydrogen at position 6 is substituted by a 3-hydroxypropyl group.,"InChI=1S/C8H12N2O3/c1-5-6(3-2-4-11)9-8(13)10-7(5)12/h11H,2-4H2,1H3,(H2,9,10,12,13)",6-HYDROXYPROPYLTHYMINE,PDBeChem accession,HPT
2051,43394,alpha-L-iduronic acid,A L-idopyranuronic acid with an alpha-configuration at the anomeric position.,"InChI=1S/C6H10O7/c7-1-2(8)4(5(10)11)13-6(12)3(1)9/h1-4,6-9,12H,(H,10,11)/t1-,2-,3+,4+,6+/m0/s1",L-IDURONIC ACID,PDBeChem accession,IDR
2052,43411,"3,4-didehydro-N(4)-deethylbrinzolamide",A sulfonamide consisting of brinzolamide lacking hydrogens at positions 3 and 4 and also lacking the N(4)-ethyl group.,"InChI=1S/C10H15N3O5S3/c1-18-4-2-3-13-6-8(11)7-5-9(20(12,14)15)19-10(7)21(13,16)17/h5-6H,2-4,11H2,1H3,(H2,12,14,15)","4-AMINO-6-[N-(3-METHOXYLPROPYL)-2H-THIENO[3,2-E][1,2]THIAZINE 1,1-DIOXIDE]-SULFONAMIDE",PDBeChem accession,INM
2053,43422,4-iodo-D-phenylalanine,The D-enantiomer of 4-iodophenylalanine.,"InChI=1S/C9H10INO2/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m1/s1",p-iodo-D-phenylalanine,PDBeChem accession,IOY
2054,43577,3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid,The alpha-anomer of 3-deoxy-D-manno-oct-2-ulopyranosonic acid.,"InChI=1S/C8H14O8/c9-2-4(11)6-5(12)3(10)1-8(15,16-6)7(13)14/h3-6,9-12,15H,1-2H2,(H,13,14)/t3-,4-,5-,6-,8-/m1/s1",3-DEOXY-D-MANNO-OCT-2-ULOSONIC ACID,Beilstein Registry Number,4234215
2055,43797,L-propargylglycine,A non-proteinogenic L-alpha-amino acid that is L-alanine in which one of the methyl hydrogens has been replaced by an ethynyl group. It causes the irreversible inactivation of gamma-cystathionase (also known as cystathionine gamma-lyase) and is used as an affinity labeling reagent for gamma-cystathionase and other enzymes.,"InChI=1S/C5H7NO2/c1-2-3-4(6)5(7)8/h1,4H,3,6H2,(H,7,8)/t4-/m0/s1",L-PROPARGYLGLYCINE,PDBeChem accession,LPG
2056,43876,(S)-alpha-methyl-4-carboxyphenylglycine,A non-proteinogenic alpha-amino acid that is alanine in which the alpha-hydrogen is replaced by a 4-carboxyphenyl group (the S-enantiomer). It is a non-selective group I/group II metabotropic glutamate receptor (mGluR) antagonist.,"InChI=1S/C10H11NO4/c1-10(11,9(14)15)7-4-2-6(3-5-7)8(12)13/h2-5H,11H2,1H3,(H,12,13)(H,14,15)/t10-/m0/s1",(S)-(ALPHA)-METHYL-4-CARBOXYPHENYLGLYCINE,PDBeChem accession,MCG
2057,44081,6-methylthioinosine,A thiopurine that is inosine in which the aromatic hydroxy group is replaced by a methylsulfanediyl group.,"InChI=1S/C11H14N4O4S/c1-20-10-6-9(12-3-13-10)15(4-14-6)11-8(18)7(17)5(2-16)19-11/h3-5,7-8,11,16-18H,2H2,1H3/t5-,7-,8-,11-/m1/s1","2-HYDROXYMETHYL-5-(6-METHYLSULFANYL-PURIN-9-YL)-TETRAHYDRO-FURAN-3,4-DIOL",PDBeChem accession,MTP
2058,44224,"(4S)-2-methylpentane-2,4-diol","A glycol that is the (S)-enantiomer of 2-methylpentane-2,4-diol.","InChI=1S/C6H14O2/c1-5(7)4-6(2,3)8/h5,7-8H,4H2,1-3H3/t5-/m0/s1","(4S)-2-methylpentane-2,4-diol",PDBeChem accession,MPD
2059,44632,(S)-pyrrolidin-2-ylmethylamine,,"InChI=1S/C5H12N2/c6-4-5-2-1-3-7-5/h5,7H,1-4,6H2/t5-/m0/s1",(2S)-PYRROLIDIN-2-YLMETHYLAMINE,Beilstein Registry Number,79842
2060,45013,2-phospho-L-lactic acid,The (S)-enantiomer of 2-phospholactic acid.,"InChI=1S/C3H7O6P/c1-2(3(4)5)9-10(6,7)8/h2H,1H3,(H,4,5)(H2,6,7,8)/t2-/m0/s1",L-PHOSPHOLACTATE,PDBeChem accession,PEQ
2061,44995,"3H-pyrazolo[4,3-d]pyrimidin-7-ol",,"InChI=1S/C5H4N4O/c10-5-4-3(1-8-9-4)6-2-7-5/h2H,1H2,(H,6,7,10)","3H-PYRAZOLO[4,3-D]PYRIMIDIN-7-OL",PDBeChem accession,PPO
2062,43927,"5-O-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline",,"InChI=1S/C28H46N4O3/c1-21-19-32(20-22(2)34-21)16-11-9-7-6-8-10-15-29-27(33)35-23-12-13-25-24(18-23)28(3)14-17-30(4)26(28)31(25)5/h12-13,18,21-22,26H,6-11,14-17,19-20H2,1-5H3,(H,29,33)/t21-,22+,26-,28+/m1/s1","CIS-2,6-DIMETHYLMORPHOLINOOCTYLCARBAMYLESEROLINE",CAS Registry Number,154619-51-9
2063,44926,triethylene glycol,"A poly(ethylene glycol) that is octane-1,8-diol in which the carbon atoms at positions 3 and 6 have been replaced by oxygen atoms.","InChI=1S/C6H14O4/c7-1-3-9-5-6-10-4-2-8/h7-8H,1-6H2",2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHANOL,CAS Registry Number,112-27-6
2064,45558,Reactive Red 6 hapten,"A bis(azo) compound that consists of a 1,3,5-triazine core having two (5-hydroxy-1,3-disulfo-2naphthyl)amino groups at positions 2 and 6, each of which is further substituted with a 2-hydroxy-5-sulfophenylazo group.","InChI=1S/C35H25N9O22S6/c45-24-7-1-14(67(49,50)51)9-22(24)41-43-28-26(69(55,56)57)11-18-16(30(28)47)3-5-20(32(18)71(61,62)63)38-34-36-13-37-35(40-34)39-21-6-4-17-19(33(21)72(64,65)66)12-27(70(58,59)60)29(31(17)48)44-42-23-10-15(68(52,53)54)2-8-25(23)46/h1-13,45-48H,(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H2,36,37,38,39,40)/b43-41+,44-42+","5-hydroxy-2-[[4-[[5-hydroxy-6-(2-hydroxy-5-sulfo-phenyl)diazenyl-1,7-disulfo-naphthalen-2-yl]amino]-1,3,5-triazin-2-yl]amino]-6-(2-hydroxy-5-sulfo-phenyl)diazenyl-naphthalene-1,7-disulfonic acid",PDBeChem accession,RR6
2065,45213,3-pyridinemethanol,A member of the class of pyridines that is pyridine which is substituted by a hydroxymethyl group at position 3 .,"InChI=1S/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2",3-pyridylcarbinol,PDBeChem accession,PYF
2066,45223,pyridine-2-thiol,Pyridine substituted at C-2 by a sulfanyl group.,"InChI=1S/C5H5NS/c7-5-3-1-2-4-6-5/h1-4H,(H,6,7)",2-PYRIDINETHIOL,PDBeChem accession,PYS
2067,45890,"(3-amino-2,5-dioxopyrrolidin-1-yl)acetic acid",,"InChI=1S/C6H8N2O4/c7-3-1-4(9)8(6(3)12)2-5(10)11/h3H,1-2,7H2,(H,10,11)","(3-amino-2,5-dioxo-1-pyrrolidinyl)acetic acid",PDBeChem accession,SUI
2068,45422,propionamide,A  monocarboxylic acid amide obtained by the formal condensation of propionic acid with ammonia.,"InChI=1S/C3H7NO/c1-2-3(4)5/h2H2,1H3,(H2,4,5)",PROPIONAMIDE,PDBeChem accession,ROP
2069,45448,"5-iodo-5,6-dihydro-6-azatubercidin",,"InChI=1S/C10H14IN5O4/c11-7-4-8(12)13-2-14-9(4)16(15-7)10-6(19)5(18)3(1-17)20-10/h2-3,5-7,10,15,17-19H,1H2,(H2,12,13,14)/t3-,5-,6-,7+,10-/m1/s1","2-RIBOFURANOSYL-3-IODO-2,3-DIHYDRO-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YLAMINE",PDBeChem accession,RPP
2070,45453,sinefungin,An adenosine that is the the delta-(5'-adenosyl) derivative of ornithine.,"InChI=1S/C15H23N7O5/c16-6(1-2-7(17)15(25)26)3-8-10(23)11(24)14(27-8)22-5-21-9-12(18)19-4-20-13(9)22/h4-8,10-11,14,23-24H,1-3,16-17H2,(H,25,26)(H2,18,19,20)/t6-,7-,8+,10+,11+,14+/m0/s1",ADENOSYL-ORNITHINE,PDBeChem accession,SFG
2071,45496,11alpha-hydroxyprogesterone hemisuccinate,A steroid ester that is the O-succinoyl derivative of 11alpha-hydroxyprogesterone.,"InChI=1S/C25H34O6/c1-14(26)18-6-7-19-17-5-4-15-12-16(27)10-11-24(15,2)23(17)20(13-25(18,19)3)31-22(30)9-8-21(28)29/h12,17-20,23H,4-11,13H2,1-3H3,(H,28,29)/t17-,18+,19-,20+,23+,24-,25+/m0/s1",PROGESTERONE-11-ALPHA-OL-HEMISUCCINATE,PDBeChem accession,SIH
2072,46026,"1-[(1S,2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)bicyclo[3.1.0]hexan-2-yl]thymine","A carbobicyclic compound that is bicyclo[3.1.0]hexane which is substituted at the 2-pro-S, 4-pro-S and 5-pro-R positions by thymin-1-yl, hydroxy, and hydroxymethyl groups, respectively.","InChI=1S/C12H16N2O4/c1-6-4-14(11(18)13-10(6)17)8-2-9(16)12(5-15)3-7(8)12/h4,7-9,15-16H,2-3,5H2,1H3,(H,13,17,18)/t7-,8+,9+,12+/m1/s1","1-[4-HYDROXY-5-(HYDROXYMETHYL)BICYCLO[3.1.0]HEX-2-YL]-5-METHYLPYRIMIDINE-2,4(1H,3H)-DIONE",PDBeChem accession,TMC
2073,43007,"5-(2-amino-5,6-dimethyl-1H-benzimidazol-1-yl)pentanoic acid",A 2-aminobenzimidazole having methyl substituents at the 5- and 6-positions and a 5-carboxypentyl group at the 1-position.,"InChI=1S/C14H19N3O2/c1-9-7-11-12(8-10(9)2)17(14(15)16-11)6-4-3-5-13(18)19/h7-8H,3-6H2,1-2H3,(H2,15,16)(H,18,19)","2-AMINO-5,6-DIMETHYL-BENZIMIDAZOLE-1-PENTANOIC ACID",PDBeChem accession,HAN
2074,43305,"2,6-diamino-2,6-dideoxy-beta-L-idopyranose",A hexosamine that is beta-L-idopyranose in which the hydroxy groups at positions 2 and 6 are replaced by amino groups,"InChI=1S/C6H14N2O4/c7-1-2-4(9)5(10)3(8)6(11)12-2/h2-6,9-11H,1,7-8H2/t2-,3+,4+,5+,6-/m0/s1","O-2,6-DIAMINO-2,6-DIDEOXY-BETA-L-IDOPYRANOSE",PDBeChem accession,IDG
2075,43362,immucillin H,,"InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1","1,4-DIDEOXY-4-AZA-1-(S)-(9-DEAZAHYPOXANTHIN-9-YL)-D-RIBITOL",PDBeChem accession,IMH
2076,44480,4-nitrophenyl (4-carboxybutyl)phosphonate,"An organophosphonate oxoanion that is a nitrophenyl phosphonate hapten and transition-state analogue derived from pentanoic acid, with affinity for the germline precursor to catalytic antibody 48G7.","InChI=1S/C11H14NO7P/c13-11(14)3-1-2-8-20(17,18)19-10-6-4-9(5-7-10)12(15)16/h4-7H,1-3,8H2,(H,13,14)(H,17,18)/p-1",5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID,PDBeChem accession,NPE
2077,44491,"4-({5-[(2-aminoethyl)amino]-2,4-dinitrophenyl}amino)-TEMPO","A C-nitro compound that is the 4-({5-[(2-aminoethyl)amino]-2,4-dinitrophenyl}amino) derivative of TEMPO (PDB entry: 1BAF).","InChI=1S/C17H27N6O5/c1-16(2)9-11(10-17(3,4)23(16)28)20-13-7-12(19-6-5-18)14(21(24)25)8-15(13)22(26)27/h7-8,11,19-20H,5-6,9-10,18H2,1-4H3","N-(2-AMINO-ETHYL)-4,6-DINITRO-N'-(2,2,6,6-TETRAMETHYL-1-OXY-PIPERIDIN-4-YL)-BENZENE-1,3-DIAMINE",PDBeChem accession,NPP
2078,44616,afimoxifene,A tertiary amino compound that is tamoxifen in which the phenyl group which is in a Z- relationship to the ethyl substituent is hydroxylated at the para- position. It is the active metabolite of tamoxifen.,"InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-",4-HYDROXYTAMOXIFEN,PDBeChem accession,OHT
2079,44667,L-ornithinium(2+),The L-enantiomer of ornithinium(2+).,"InChI=1S/C5H12N2O2/c6-3-1-2-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/p+2/t4-/m0/s1",ORNITHINE,Gmelin Registry Number,1068689
2080,44712,(S)-oxalosuccinic acid,,"InChI=1S/C6H6O7/c7-3(8)1-2(5(10)11)4(9)6(12)13/h2H,1H2,(H,7,8)(H,10,11)(H,12,13)/t2-/m0/s1",2-OXALOSUCCINIC ACID,PDBeChem accession,OXS
2081,44143,emivirine,"A pyrimidone that is uracil which is substituted at positions 1, 5 and 6 by ethoxymethyl, isopropyl, and benzyl groups, respectively. A non-nucleoside inhibitor of HIV-1 reverse transcriptase, emivirine was an unsuccessful experimental agent for the treatment of HIV.","InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21)",6-BENZYL-1-ETHOXYMETHYL-5-ISOPROPYL URACIL,PDBeChem accession,MKC
2082,44312,beta-muramic acid,,"InChI=1S/C9H17NO7/c1-3(8(13)14)16-7-5(10)9(15)17-4(2-11)6(7)12/h3-7,9,11-12,15H,2,10H2,1H3,(H,13,14)/t3-,4-,5-,6-,7-,9-/m1/s1",MURAMIC ACID,PDBeChem accession,MUR
2083,44387,L-2-aminopimelic acid,A 2-aminopimelic acid that has S-configuration.,"InChI=1S/C7H13NO4/c8-5(7(11)12)3-1-2-4-6(9)10/h5H,1-4,8H2,(H,9,10)(H,11,12)/t5-/m0/s1",2-AMINOPIMELIC ACID,PDBeChem accession,NPI
2084,44887,"(S)-1,2-distearoylphosphatidylethanolaminium","An ammonium ion that is the conjugate acid of (S)-1,2-distearoylphosphatidylethanolamine, arising from protonation of the amino group.","InChI=1S/C41H82NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h39H,3-38,42H2,1-2H3,(H,45,46)/p+1/t39-/m0/s1",PHOSPHATIDYLETHANOLAMINE,PDBeChem accession,PEE
2085,44934,pentaglyme,,"InChI=1S/C12H26O6/c1-13-3-5-15-7-9-17-11-12-18-10-8-16-6-4-14-2/h3-12H2,1-2H3",1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE,CAS Registry Number,1191-87-3
2086,44699,1-O-dodecanoyl-2-O-pentacosanoyl-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine having a dodecanoyl group at the 1-position and a pentacosanoyl group at the 2-position.","InChI=1S/C45H90NO8P/c1-6-8-10-12-14-16-17-18-19-20-21-22-23-24-25-26-27-28-30-32-34-36-38-45(48)54-43(42-53-55(49,50)52-40-39-46(3,4)5)41-51-44(47)37-35-33-31-29-15-13-11-9-7-2/h43H,6-42H2,1-5H3/p+1/t43-/m1/s1","7-[(DODECANOYLOXY)METHYL]-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-3,5,8-TRIOXA-4-PHOSPHADOTRIACONTAN-1-AMINIUM 4-OXIDE",PDBeChem accession,PC6
2087,44722,"2-(beta-D-glucosyl)-5-methyl-1,3,4-oxadiazole",,"InChI=1S/C9H14N2O6/c1-3-10-11-9(16-3)8-7(15)6(14)5(13)4(2-12)17-8/h4-8,12-15H,2H2,1H3/t4-,5-,6+,7-,8-/m1/s1","2-(BETA-D-GLUCOPYRANOSYL)-5-METHYL-1,3,4-OXADIAZOLE",PDBeChem accession,OX2
2088,45927,triethyl phosphate,A trialkyl phosphate that is the triethy ester derivative of  phosphoric acid.,"InChI=1S/C6H15O4P/c1-4-8-11(7,9-5-2)10-6-3/h4-6H2,1-3H3",TRIETHYL PHOSPHATE,PDBeChem accession,TEN
2089,45957,"2-(acetylamino)naphthalene-1,5-disulfonic acid","A naphthalene-1,5-disulfonic acid with an acetamido group at the 2-position.","InChI=1S/C12H11NO7S2/c1-7(14)13-10-6-5-8-9(12(10)22(18,19)20)3-2-4-11(8)21(15,16)17/h2-6H,1H3,(H,13,14)(H,15,16,17)(H,18,19,20)","2-ACETYLAMINO-NAPTHALENE-1,5-DISULFONIC ACID",PDBeChem accession,TK4
2090,45479,13-cis-retinol,,"InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13-",RETINOL,PDBeChem accession,RTL
2091,45487,13-cis-retinal,"A retinal in which the double bond alpha- to the aldehyde group has cis configuration, whilst the remaining acyclic double bonds have trans configuration.","InChI=1S/C20H28O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,15H,7,10,14H2,1-5H3/b9-6+,12-11+,16-8+,17-13-",RETINAL,Beilstein Registry Number,1914182
2092,45578,ribavirin 5'-triphosphate,A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a triphosphate group. It is the active metabolite of the antiviral agent ribavirin.,"InChI=1S/C8H15N4O14P3/c9-6(15)7-10-2-12(11-7)8-5(14)4(13)3(24-8)1-23-28(19,20)26-29(21,22)25-27(16,17)18/h2-5,8,13-14H,1H2,(H2,9,15)(H,19,20)(H,21,22)(H2,16,17,18)/t3-,4-,5-,8-/m1/s1",ribavirin triphosphate,PDBeChem accession,RTP
2093,44752,hexaethylene glycol monomethyl ether,,"InChI=1S/C13H28O7/c1-15-4-5-17-8-9-19-12-13-20-11-10-18-7-6-16-3-2-14/h14H,2-13H2,1H3","2,5,8,11,14,17-HEXAOXANONADECAN-19-OL",CAS Registry Number,23601-40-3
2094,44762,hexaethylene glycol monophosphate,A hydroxypolyether phosphate consisting of hexaethylene glycol carrying a single O-phospho group.,"InChI=1S/C12H27O10P/c13-1-2-17-3-4-18-5-6-19-7-8-20-9-10-21-11-12-22-23(14,15)16/h13H,1-12H2,(H2,14,15,16)",PHOSPHORYL-HEXAETHYLENE GLYCOL,PDBeChem accession,PE6
2095,45006,"1-O-(1-O,2-O-dioctanoyl-sn-glycero-3-phosphono)-1D-myo-inositol 4,5-bis(phosphate)","A glycerophosphoinositol phosphate having a 1-O,2-O-dioctanoyl-sn-glycero-3-phospho moiety attached at the 1-position of 1D-myo-inositol 4,5-bis(phosphate).","InChI=1S/C25H49O19P3/c1-3-5-7-9-11-13-18(26)39-15-17(41-19(27)14-12-10-8-6-4-2)16-40-47(37,38)44-23-20(28)21(29)24(42-45(31,32)33)25(22(23)30)43-46(34,35)36/h17,20-25,28-30H,3-16H2,1-2H3,(H,37,38)(H2,31,32,33)(H2,34,35,36)/t17-,20+,21-,22-,23+,24+,25+/m0/s1","L-ALPHA-D-MYOPHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE, D(+)SN1,2DI-O-OCTANOYLGLYCERYL",PDBeChem accession,PIO
2096,43219,"(2E,4R)-4-hydroxynon-2-enal",The R stereoisomer of (E)-4-hydroxynon-2-enal.,"InChI=1S/C9H16O2/c1-2-3-4-6-9(11)7-5-8-10/h5,7-9,11H,2-4,6H2,1H3/b7-5+/t9-/m1/s1","(2E,4R)-4-HYDROXYNON-2-ENAL",PDBeChem accession,HNE
2097,42965,beta-D-glucosyl-N-(octadecanoyl)sphinganine,A sphinganine derivative having a beta-D-glucosyl group at the 1-position and an octadecanoyl group attached to the nitrogen.,"InChI=1S/C42H83NO8/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-38(46)43-35(34-50-42-41(49)40(48)39(47)37(33-44)51-42)36(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h35-37,39-42,44-45,47-49H,3-34H2,1-2H3,(H,43,46)/t35-,36+,37+,39+,40-,41+,42+/m0/s1","N-{(1S,2S)-1-[(beta-D-glucopyranosyloxy)methyl]-2-hydroxyoctadecyl}octadecanamide",PDBeChem accession,GM2
2098,42976,L-glycero-alpha-D-manno-heptopyranose,An aldoheptose in pyranose cyclic form with L-glycero-alpha-D-manno stereochemistry.,"InChI=1S/C7H14O7/c8-1-2(9)6-4(11)3(10)5(12)7(13)14-6/h2-13H,1H2/t2-,3-,4-,5-,6+,7-/m0/s1",L-GLYCERO-D-MANNO-HEPTOPYRANOSE,CAS Registry Number,130272-67-2
2099,44800,"(2R,4S)-2-methyltetrahydrofuran-2,3,3,4-tetrol","A tetrahydroxytetrahydrofuran in which the hydroxy groups are located at positions 2, 3, 4, and 4 and which is substituted by a methyl group at position 2 (the 2R,4S diastereoisomer).","InChI=1S/C5H10O5/c1-4(7)5(8,9)3(6)2-10-4/h3,6-9H,2H2,1H3/t3-,4+/m0/s1","(2R,4S)-2-METHYL-2,3,3,4-TETRAHYDROXYTETRAHYDROFURAN",PDBeChem accession,PAV
2100,43542,O-(2-aminopropyl)-O'-(2-methyoxyethyl)octa(propylene glycol),A polyether composed of eight propylene glycol units capped at both ends by methoxyethyl and 2-aminopropyl groups (PBD entry:1NGX).,"InChI=1S/C30H63NO10/c1-22(31)13-33-14-23(2)35-16-25(4)37-18-27(6)39-20-29(8)41-21-30(9)40-19-28(7)38-17-26(5)36-15-24(3)34-12-11-32-10/h22-30H,11-21,31H2,1-10H3/t22-,23+,24-,25+,26+,27-,28+,29-,30+/m0/s1",O-(O-(2-AMINOPROPYL)-O'-(2-METHOXYETHYL)POLYPROPYLENE GLYCOL 500),PDBeChem accession,JEF
2101,43711,(R)-dihydrolipoamide,,"InChI=1S/C8H17NOS2/c9-8(10)4-2-1-3-7(12)5-6-11/h7,11-12H,1-6H2,(H2,9,10)/t7-/m1/s1","6,8-DIMERCAPTO-OCTANOIC ACID AMIDE",PDBeChem accession,LPM
2102,43945,medronic acid,"A 1,1-bis(phosphonic acid) consisting of methane substituted by two phosphonic acid groups.","InChI=1S/CH6O6P2/c2-8(3,4)1-9(5,6)7/h1H2,(H2,2,3,4)(H2,5,6,7)",methanediylbis(phosphonic acid),PDBeChem accession,MDN
2103,43978,trifluoro-L-methionine,"An L-alpha-amino acid, methionine, with the S-methyl group trifluoro-substituted.","InChI=1S/C5H8F3NO2S/c6-5(7,8)12-2-1-3(9)4(10)11/h3H,1-2,9H2,(H,10,11)/t3-/m0/s1",2-AMINO-4-TRIFLUOROMETHYLSULFANYL-BUTYRIC ACID,PDBeChem accession,MF3
2104,43791,"9-{2,5-anhydro-4-[(phosphonooxy)methyl]-alpha-L-lyxofuranosyl}-9H-purin-6-amine","A nucleoside monophosphate analogue derived from the formal condensation of the N(1)-nitrogen of adenine with 2,5-anhydro-4-[(phosphonooxy)methyl]-alpha-L-lyxofuranose.","InChI=1S/C11H14N5O7P/c12-8-5-9(14-3-13-8)16(4-15-5)10-6-7(17)11(23-10,1-21-6)2-22-24(18,19)20/h3-4,6-7,10,17H,1-2H2,(H2,12,13,14)(H2,18,19,20)/t6-,7+,10-,11-/m1/s1","[(1R,3R,4R,7S)-7-hydroxy-3-(adenin-9-yl)-2,5-dioxabicyclo[2.2.1]hept-1-yl]methyl dihydrogen phosphate",PDBeChem accession,LCA
2105,44331,beta-D-Galp-(1->4)-alpha-D-GlcpNAc,An amino disaccharide consisting of beta-D-Galp joined by a (1->4) glycosidic bond to 2-acetamido-2-deoxy-alpha-D-glucopranose.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)12(6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12-,13+,14+/m1/s1",2-(acetylamino)-2-deoxy-4-O-beta-D-galactopyranosyl-alpha-D-glucopyranose,PDBeChem accession,NLC
2106,44777,oregon green 488,"A xanthene dye having two fluoro substituents at the 2- and 7-positions and a 2,4-dicarboxyphenyl group at the 9-position.","InChI=1S/C21H10F2O7/c22-13-4-11-17(6-15(13)24)30-18-7-16(25)14(23)5-12(18)19(11)9-2-1-8(20(26)27)3-10(9)21(28)29/h1-7,24H,(H,26,27)(H,28,29)","4-(2,7-DIFLUORO-6-HYDROXY-3-OXO-3H-XANTHEN-9-YL)ISOPHTHALIC ACID",PDBeChem accession,ORE
2107,44791,tetradecaethylene glycol,A poly(ethylene glycol) containing 14 ethyleneoxy units.,"InChI=1S/C28H58O15/c29-1-3-31-5-7-33-9-11-35-13-15-37-17-19-39-21-23-41-25-27-43-28-26-42-24-22-40-20-18-38-16-14-36-12-10-34-8-6-32-4-2-30/h29-30H,1-28H2","3,6,9,12,15,18,21,24,27,30,33,36,39-TRIDECAOXAHENTETRACONTANE-1,41-DIOL",PDBeChem accession,PE3
2108,44841,"2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4-one","A dihydropterin that is 7,8-dihydropteridin-4-one substituted at positions 2 and 6 by amino and hydroxymethyl groups respectively.","InChI=1S/C7H9N5O2/c8-7-11-5-4(6(14)12-7)10-3(2-13)1-9-5/h13H,1-2H2,(H4,8,9,11,12,14)","2-AMINO-6-HYDROXYMETHYL-7,8-DIHYDRO-3H-PTERIDIN-4-ONE",PDBeChem accession,PH2
2109,43741,"{[5-(5-nitro-2-furyl)-1,3,4-oxadiazol-2-yl]thio}acetic acid",,"InChI=1S/C8H5N3O6S/c12-6(13)3-18-8-10-9-7(17-8)4-1-2-5(16-4)11(14)15/h1-2H,3H2,(H,12,13)","{[5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOL-2-YL]THIO}ACETIC ACID",PDBeChem accession,LIT
2110,45389,(R)-styrene oxide,The (R)-enantiomer of styrene oxide.,"InChI=1S/C8H8O/c1-2-4-7(5-3-1)8-6-9-8/h1-5,8H,6H2/t8-/m0/s1",R-STYRENE OXIDE,PDBeChem accession,RSO
2111,45257,ribostamycin,"An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).","InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1",RIBOSTAMYCIN,PDBeChem accession,RIO
2112,45666,SDZ 35-682,An aromatic ether that consists of glycerol in which the hydrogen of the 1-hydroxy group is substituted by a 4-cyclohexylphenyl moiety and the 3-hydroxy function is substituted by a 4-(pyridin-2-yl)piperazin-1-yl group.,"InChI=1S/C24H33N3O2/c28-22(18-26-14-16-27(17-15-26)24-8-4-5-13-25-24)19-29-23-11-9-21(10-12-23)20-6-2-1-3-7-20/h4-5,8-13,20,22,28H,1-3,6-7,14-19H2",1-[2-HYDROXY-3-(4-CYCLOHEXYL-PHENOXY)-PROPYL]-4-(2-PYRIDYL)-PIPERAZINE,PDBeChem accession,SDZ
2113,45804,beta-D-tagatofuranose 6-phosphate,A D-tagatofuranose 6-phosphate with a beta-configuration at the anomeric position.,"InChI=1S/C6H13O9P/c7-2-6(10)5(9)4(8)3(15-6)1-14-16(11,12)13/h3-5,7-10H,1-2H2,(H2,11,12,13)/t3-,4+,5+,6-/m1/s1",TAGATOSE-6-PHOSPHATE,PDBeChem accession,TA6
2114,45825,tetrabutylammonium,,"InChI=1S/C16H36N/c1-5-9-13-17(14-10-6-2,15-11-7-3)16-12-8-4/h5-16H2,1-4H3/q+1",TETRABUTYLAMMONIUM ION,PDBeChem accession,TBA
2115,45240,"1,2-di-O-myristoyl-sn-glycero-3-phosphocholine","A 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).","InChI=1S/C36H72NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-35(38)42-32-34(33-44-46(40,41)43-31-30-37(3,4)5)45-36(39)29-27-25-23-21-19-17-15-13-11-9-7-2/h34H,6-33H2,1-5H3/t34-/m1/s1","1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE",PDBeChem accession,PX4
2116,45307,seliciclib,"2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.","InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1",R-ROSCOVITINE,PDBeChem accession,RRC
2117,45981,"5-hydroxymethyl-5,6-dihydrofolic acid","A 5,6-dihydrofolic acid that is (6S)-5,6-dihydrofolic acid substituted at position 5 by a hydroxymethyl group.","InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,8,12-13,22,28H,5-7,9H2,(H,24,31)(H,29,30)(H,33,34)(H3,21,25,26,32)/t12-,13-/m0/s1",5-HYDROXYMETHYLENE-6-HYDROFOLIC ACID,PDBeChem accession,THF
2118,45868,dTDP-4-dehydro-beta-L-rhamnose,A dTDP-sugar having 4-dehydro-beta-L-rhamnose as the sugar component. It is an intermediate in dTDP-rhamnose biosynthesis.,"InChI=1S/C16H24N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-10,12-13,15,19,21-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,8-,9+,10+,12+,13+,15+/m0/s1",DTDP-4-KETO-L-RHAMNOSE,PDBeChem accession,TDO
2119,45573,4-(4-styrylphenylcarbamoyl)butyric acid,A dicarboxylic acid monoamide resulting from the formal condensation of one of the carboxyl groups of glutaric acid with the amino group of 4-aminostilbene.,"InChI=1S/C19H19NO3/c21-18(7-4-8-19(22)23)20-17-13-11-16(12-14-17)10-9-15-5-2-1-3-6-15/h1-3,5-6,9-14H,4,7-8H2,(H,20,21)(H,22,23)/b10-9+",4-(4-STYRYL-PHENYLCARBAMOYL)-BUTYRIC ACID,PDBeChem accession,SPB
2120,43208,"(2R,3R)-heptane-1,2,3-triol","Heptane-1,2,3-triol with R-configuration at both the C-2 and C-3 centres.","InChI=1S/C7H16O3/c1-2-3-4-6(9)7(10)5-8/h6-10H,2-5H2,1H3/t6-,7-/m1/s1","HEPTANE-1,2,3-TRIOL",PDBeChem accession,HTO
2121,43088,N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine,,"InChI=1S/C6H14N4O3/c7-4(5(11)12)2-1-3-9-6(8)10-13/h4,13H,1-3,7H2,(H,11,12)(H3,8,9,10)/t4-/m0/s1",N-OMEGA-HYDROXY-L-ARGININE,PDBeChem accession,HAR
2122,43195,9a-(2-hydroxyethyl)dihydrothiochrome diphosphate,A pyrimidinothiazolopyrimidine that is dihydrothiochrome diphosphate in which the hydrogen at position 9a has been replaced by a 2-hydroxyethyl group.,"InChI=1S/C14H22N4O8P2S/c1-8-12(4-5-25-28(23,24)26-27(20,21)22)29-14(9(2)19)17-13-11(7-18(8)14)6-15-10(3)16-13/h6,9,19H,4-5,7H2,1-3H3,(H,23,24)(H,15,16,17)(H2,20,21,22)/t9-,14-/m0/s1",2-HYDROXYETHYL DIHYDROTHIACHROME DIPHOSPHATE,PDBeChem accession,HE3
2123,48987,7-hydroxyquinolin-2(1H)-one,,"InChI=1S/C9H7NO2/c11-7-3-1-6-2-4-9(12)10-8(6)5-7/h1-5,11H,(H,10,12)",7-hydroxy-2-quinolone,Beilstein Registry Number,5506282
2124,47693,keto-D-tagatose,The straight-chain keto form of D-tagatose.,"InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3,5-9,11-12H,1-2H2/t3-,5+,6-/m1/s1",D-tagatose,PDBeChem accession,TAG
2125,48370,"8a-butyl-3,3,6,6-tetramethyltetrahydro-1,8-dioxa-4a-azanaphthalene",,"InChI=1S/C15H29NO2/c1-6-7-8-15-16(9-13(2,3)11-17-15)10-14(4,5)12-18-15/h6-12H2,1-5H3","8a-butyl-3,3,6,6-tetramethyl-1,8-dioxa-quinolizidine",Patent accession,WO2007024836
2126,47812,"(1S)-1,25-dihydroxy-24-oxocalciol",,"InChI=1S/C27H42O4/c1-17(8-13-25(30)26(3,4)31)22-11-12-23-19(7-6-14-27(22,23)5)9-10-20-15-21(28)16-24(29)18(20)2/h9-10,17,21-24,28-29,31H,2,6-8,11-16H2,1,3-5H3/b19-9+,20-10-/t17-,21-,22-,23+,24+,27-/m1/s1","24-oxo-1alpha,25(OH)2D3",LIPID MAPS instance accession,LMST03020186
2127,47813,"(1S)-1,23,25-trihydroxy-24-oxocalciol",,"InChI=1S/C27H42O5/c1-16(13-24(30)25(31)26(3,4)32)21-10-11-22-18(7-6-12-27(21,22)5)8-9-19-14-20(28)15-23(29)17(19)2/h8-9,16,20-24,28-30,32H,2,6-7,10-15H2,1,3-5H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24?,27-/m1/s1","24-oxo-1alpha,23,25(OH)3D3",CAS Registry Number,87147-48-6
2128,47818,"(1S)-1,23-dihydroxy-24,25,26,27-tetranorcalciol",,"InChI=1S/C23H36O3/c1-15(10-12-24)20-8-9-21-17(5-4-11-23(20,21)3)6-7-18-13-19(25)14-22(26)16(18)2/h6-7,15,19-22,24-26H,2,4-5,8-14H2,1,3H3/b17-6+,18-7-/t15-,19-,20-,21+,22+,23-/m1/s1","tetranor 1alpha,23(OH)2D3",LIPID MAPS instance accession,LMST03020020
2129,49432,5-hydroxyectoine,A carboxamidine heterocycle which is obtained by formal condensation of 4-amino-L-allothreonine with acetic acid.,"InChI=1S/C6H10N2O3/c1-3-7-2-4(9)5(8-3)6(10)11/h4-5,9H,2H2,1H3,(H,7,8)(H,10,11)/t4-,5-/m0/s1","(4S,5S)-5-HYDROXY-2-METHYL-1,4,5,6-TETRAHYDROPYRIMIDINE-4-CARBOXYLIC ACID",PDBeChem accession,6CS
2130,51509,(R)-benzoin,,"InChI=1S/C14H12O2/c15-13(11-7-3-1-4-8-11)14(16)12-9-5-2-6-10-12/h1-10,13,15H/t13-/m1/s1","(2R)-2-hydroxy-1,2-diphenylethanone",Beilstein Registry Number,3200191
2131,46835,dipicolinate(1-),A carboxypyridinecarboxylate that is the conjugate base of dipicolinic acid.,"InChI=1S/C7H5NO4/c9-6(10)4-2-1-3-5(8-4)7(11)12/h1-3H,(H,9,10)(H,11,12)/p-1","hydrogen pyridine-2,6-dicarboxylate",Gmelin Registry Number,328958
2132,49177,(6R)-dehydrovomifoliol,A dehydrovomifoliol that has R-configuration at the chiral centre.,"InChI=1S/C13H18O3/c1-9-7-11(15)8-12(3,4)13(9,16)6-5-10(2)14/h5-7,16H,8H2,1-4H3/b6-5+/t13-/m0/s1","(4R)-4-hydroxy-3,5,5-trimethyl-4-[(1E)-3-oxobut-1-en-1-yl]cyclohex-2-en-1-one",Beilstein Registry Number,4415879
2133,51439,cucurbit[10]uril,,"InChI=1S/C60H60N40O20/c101-41-61-1-62-22-24-66(42(62)102)4-70-26-28-74(46(70)106)8-78-30-32-82(50(78)110)12-86-34-36-90(54(86)114)16-94-38-40-98(58(94)118)19-97-39-37-93(57(97)117)15-89-35-33-85(53(89)113)11-81-31-29-77(49(81)109)7-73-27-25-69(45(73)105)3-65(41)23-21(61)63-2-64(22)44(104)68(24)6-72(26)48(108)76(28)10-80(30)52(112)84(32)14-88(34)56(116)92(36)18-96(38)60(120)100(40)20-99(39)59(119)95(37)17-91(35)55(115)87(33)13-83(31)51(111)79(29)9-75(27)47(107)71(25)5-67(23)43(63)103/h21-40H,1-20H2/t21-,22+,23+,24-,25-,26+,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,38+,39+,40-",CB[10],Beilstein Registry Number,10773716
2134,51441,cucurbit[5]uril--cucurbit[10]uril,,"InChI=1S/C60H60N40O20.C30H30N20O10/c101-41-61-1-62-22-24-66(42(62)102)4-70-26-28-74(46(70)106)8-78-30-32-82(50(78)110)12-86-34-36-90(54(86)114)16-94-38-40-98(58(94)118)19-97-39-37-93(57(97)117)15-89-35-33-85(53(89)113)11-81-31-29-77(49(81)109)7-73-27-25-69(45(73)105)3-65(41)23-21(61)63-2-64(22)44(104)68(24)6-72(26)48(108)76(28)10-80(30)52(112)84(32)14-88(34)56(116)92(36)18-96(38)60(120)100(40)20-99(39)59(119)95(37)17-91(35)55(115)87(33)13-83(31)51(111)79(29)9-75(27)47(107)71(25)5-67(23)43(63)103;51-21-31-1-32-12-14-36(22(32)52)4-40-16-18-44(26(40)56)8-48-20-19-47(29(48)59)7-43-17-15-39(25(43)55)3-35(21)13-11(31)33-2-34(12)24(54)38(14)6-42(16)28(58)46(18)10-50(20)30(60)49(19)9-45(17)27(57)41(15)5-37(13)23(33)53/h21-40H,1-20H2;11-20H,1-10H2/t21-,22+,23+,24-,25-,26+,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,38+,39+,40-;11-,12+,13+,14-,15-,16+,17+,18-,19-,20+",cucurbit[5]uril--cucurbit[10]uril complex (1:1),Beilstein Registry Number,10773873
2135,51657,5-carboxytetramethylrhodamine,A tetramethylrhodamine compound having a carboxy substituent at the 5-position,"InChI=1S/C25H22N2O5/c1-26(2)15-6-9-18-21(12-15)32-22-13-16(27(3)4)7-10-19(22)23(18)17-8-5-14(24(28)29)11-20(17)25(30)31/h5-13H,1-4H3,(H-,28,29,30,31)",5-TAMRA,Beilstein Registry Number,8290428
2136,46143,UDP-N-acetyl-alpha-muramoyl-L-alanyl-D-glutamic acid,A UDP-N-acetylmuramoyl-L-alanyl-D-glutamate in which the muramoyl fragment has alpha-configuration at its anomeric centre,"InChI=1S/C28H43N5O23P2/c1-10(23(42)31-13(26(44)45)4-5-17(37)38)29-24(43)11(2)52-22-18(30-12(3)35)27(54-14(8-34)20(22)40)55-58(49,50)56-57(47,48)51-9-15-19(39)21(41)25(53-15)33-7-6-16(36)32-28(33)46/h6-7,10-11,13-15,18-22,25,27,34,39-41H,4-5,8-9H2,1-3H3,(H,29,43)(H,30,35)(H,31,42)(H,37,38)(H,44,45)(H,47,48)(H,49,50)(H,32,36,46)/t10-,11+,13+,14+,15+,18+,19+,20+,21+,22+,25+,27+/m0/s1",URIDINE-5'-DIPHOSPHATE-N-ACETYLMURAMOYL-L-ALANINE-D-GLUTAMATE,PDBeChem accession,UAG
2137,46144,(1S)-1-amino-2-(1H-indol-3-yl)ethanol,A tryptamine derivative in which a hydroxy group attached to the same carbon as the primary amino group (the S-enantiomer).,"InChI=1S/C10H12N2O/c11-10(13)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,10,12-13H,5,11H2/t10-/m0/s1",(1S)-1-AMINO-2-(1H-INDOL-3-YL)ETHANOL,PDBeChem accession,TSC
2138,43745,"pyrimidine-2,4-diamine",An aminopyrimidine in which a pyrimidine nucleus is substituted with amino groups at C-2 and C-4.,"InChI=1S/C4H6N4/c5-3-1-2-7-4(6)8-3/h1-2H,(H4,5,6,7,8)","PYRIMIDINE-2,4-DIAMINE",PDBeChem accession,LG3
2139,47220,chloroacetone,,"InChI=1S/C3H5ClO/c1-3(5)2-4/h2H2,1H3",CHLOROACETONE,PDBeChem accession,ATO
2140,44348,N-ethylsuccinimide,,"InChI=1S/C6H9NO2/c1-2-7-5(8)3-4-6(7)9/h2-4H2,1H3","1-ETHYL-PYRROLIDINE-2,5-DIONE",PDBeChem accession,NEN
2141,47571,N-acetyl-alpha-D-muramic acid,,"InChI=1S/C11H19NO8/c1-4(10(16)17)19-9-7(12-5(2)14)11(18)20-6(3-13)8(9)15/h4,6-9,11,13,15,18H,3H2,1-2H3,(H,12,14)(H,16,17)/t4-,6-,7-,8-,9-,11+/m1/s1",N-ACETYLMURAMIC ACID,PDBeChem accession,MUB
2142,46486,"(3R,5R)-5-amino-3-methyl-D-proline",An  aminopyrrolidine that is D-proline substituted by a amino group at position 5 and a methyl group at position 3.,"InChI=1S/C6H12N2O2/c1-3-2-4(7)8-5(3)6(9)10/h3-5,8H,2,7H2,1H3,(H,9,10)/t3-,4-,5-/m1/s1",5-AMINO-3-METHYL-PYRROLIDINE-2-CARBOXYLIC ACID,PDBeChem accession,X7O
2143,46563,2'-deoxyzebularine 5'-phosphate,,"InChI=1S/C9H13N2O7P/c12-6-4-8(11-3-1-2-10-9(11)13)18-7(6)5-17-19(14,15)16/h1-3,6-8,12H,4-5H2,(H2,14,15,16)/t6-,7+,8+/m0/s1",ZEBULARINE,PDBeChem accession,Z
2144,47889,prednisolone-16alpha-carboxylic acid,,"InChI=1S/C22H28O7/c1-20-6-5-12(24)7-11(20)3-4-13-14-8-15(19(27)28)22(29,17(26)10-23)21(14,2)9-16(25)18(13)20/h5-7,13-16,18,23,25,29H,3-4,8-10H2,1-2H3,(H,27,28)/t13-,14-,15-,16-,18+,20-,21-,22-/m0/s1","(11beta,16alpha)-11,17,21-trihydroxy-3,20-dioxopregna-1,4-diene-16-carboxylic acid",Beilstein Registry Number,6750179
2145,47890,methyl prednisolone-16alpha-carboxylate,,"InChI=1S/C23H30O7/c1-21-7-6-13(25)8-12(21)4-5-14-15-9-16(20(28)30-3)23(29,18(27)11-24)22(15,2)10-17(26)19(14)21/h6-8,14-17,19,24,26,29H,4-5,9-11H2,1-3H3/t14-,15-,16-,17-,19+,21-,22-,23-/m0/s1","methyl (11beta,16alpha)-11,17,21-trihydroxy-3,20-dioxopregna-1,4-diene-16-carboxylate",Beilstein Registry Number,4213580
2146,46873,6-carboxypyridine-3-carboxylate,,"InChI=1S/C7H5NO4/c9-6(10)4-1-2-5(7(11)12)8-3-4/h1-3H,(H,9,10)(H,11,12)/p-1",2-carboxypyridine-5-carboxylate,Gmelin Registry Number,1570387
2147,48995,5-hydroxyquinolin-2(1H)-one,,"InChI=1S/C9H7NO2/c11-8-3-1-2-7-6(8)4-5-9(12)10-7/h1-5,11H,(H,10,12)",5-hydroxy-2-quinolone,Beilstein Registry Number,1450346
2148,47417,"N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide","A leucine derivative obtained by fpormal condensation of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furoic acid and the carboxy group of N-amidino-L-leucylglycine","InChI=1S/C30H37Cl2N7O6/c1-16(2)12-21(36-30(33)34)28(41)35-14-25(40)39-10-8-17(9-11-39)22-13-20(37-38(22)3)19-5-7-23(27(32)26(19)31)44-15-18-4-6-24(45-18)29(42)43/h4-7,13,16-17,21H,8-12,14-15H2,1-3H3,(H,35,41)(H,42,43)(H4,33,34,36)/t21-/m1/s1","5-[2,3-dichloro-4-(5-{1-[2-(2-guanidino-4-methyl-pentanoylamino)-acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-phenoxymethyl]-furan-2-carboxylic acid",PDBeChem accession,FRH
2149,46548,zardaverine,"A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group.  It is a phosphodiesterase inhibitor, selective for PDE3 and 4.","InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17)",6-(4-DIFLUOROMETHOXY-3-METHOXY-PHENYL)-2H-PYRIDAZIN-3-ONE,PDBeChem accession,ZAR
2150,46372,ubiquinone-2,"A compound composed of the 2,3-dimethoxy-5-methylbenzoquinone nucleus common to ubiquinones; and a side chain of two isoprenoid units.","InChI=1S/C19H26O4/c1-12(2)8-7-9-13(3)10-11-15-14(4)16(20)18(22-5)19(23-6)17(15)21/h8,10H,7,9,11H2,1-6H3/b13-10+",UBIQUINONE-2,PDBeChem accession,UQ2
2151,46698,cis-octadec-7-ene,,"InChI=1S/C18H36/c1-3-5-7-9-11-13-15-17-18-16-14-12-10-8-6-4-2/h13,15H,3-12,14,16-18H2,1-2H3/b15-13-",(Z)-octadec-7-ene,Beilstein Registry Number,1722659
2152,51874,auramine O free base,A member of the class of imines that is benzophenone imine carrying two dimethylamino substituents at positions 4 and 4'. The hydrochloride salt is the biological stain 'auramine O',"InChI=1S/C17H21N3/c1-19(2)15-9-5-13(6-10-15)17(18)14-7-11-16(12-8-14)20(3)4/h5-12,18H,1-4H3","4,4'-Dimethylaminobenzophenonimide",CAS Registry Number,492-80-8
2153,49956,xenon(0),,InChI=1S/Xe,XENON,PDBeChem accession,XE
2154,51896,C545T,,"InChI=1S/C26H26N2O2S/c1-25(2)9-11-28-12-10-26(3,4)20-21(28)17(25)14-15-13-16(24(29)30-22(15)20)23-27-18-7-5-6-8-19(18)31-23/h5-8,13-14H,9-12H2,1-4H3",Coumarin 545T,Patent accession,US6727362
2155,46550,decaethylene glycol,,"InChI=1S/C20H42O11/c21-1-3-23-5-7-25-9-11-27-13-15-29-17-19-31-20-18-30-16-14-28-12-10-26-8-6-24-4-2-22/h21-22H,1-20H2","3,6,9,12,15,18,21,24,27-NONAOXANONACOSANE-1,29-DIOL",PDBeChem accession,XPE
2156,50429,(Z)-glutaconic acid,The (Z)-stereoisomer of glutaconic acid.,"InChI=1S/C5H6O4/c6-4(7)2-1-3-5(8)9/h1-2H,3H2,(H,6,7)(H,8,9)/b2-1-",(2Z)-pent-2-enedioic acid,Beilstein Registry Number,1722685
2157,51502,cryptocyanin,,"InChI=1S/C25H25N2.HI/c1-3-26-18-16-20(22-12-5-7-14-24(22)26)10-9-11-21-17-19-27(4-2)25-15-8-6-13-23(21)25;/h5-19H,3-4H2,1-2H3;1H/q+1;/p-1",Cryptocyanine,CAS Registry Number,4727-50-8
2158,45725,spermine(4+),An ammonium ion obtained by the protonation of all four amino groups of spermine.,"InChI=1S/C10H26N4/c11-5-3-9-13-7-1-2-8-14-10-4-6-12/h13-14H,1-12H2/p+4",SPERMINE (FULLY PROTONATED FORM),PDBeChem accession,SPK
2159,49474,argon(0),,InChI=1S/Ar,ARGON,PDBeChem accession,AR
2160,44736,"N-(2-aminoethyl)butane-1,4-diamine",,"InChI=1S/C6H17N3/c7-3-1-2-5-9-6-4-8/h9H,1-8H2",1-(AMINOETHYL)AMINO-4-AMINOBUTANE,Gmelin Registry Number,1006195
2161,44748,heptaethylene glycol,,"InChI=1S/C14H30O8/c15-1-3-17-5-7-19-9-11-21-13-14-22-12-10-20-8-6-18-4-2-16/h15-16H,1-14H2","3,6,9,12,15,18-HEXAOXAICOSANE-1,20-DIOL",PDBeChem accession,P33
2162,44758,formylmethyl hexaethylene glycol,A hydroxypolyether aldehyde comprising hexaethylene glycol having one of the terminal hydroxy groups substituted by formylmethoxy.,"InChI=1S/C14H28O8/c15-1-3-17-5-7-19-9-11-21-13-14-22-12-10-20-8-6-18-4-2-16/h1,16H,2-14H2",O-ACETALDEHYDYL-HEXAETHYLENE GLYCOL,PDBeChem accession,P4C
2163,46449,(SPY-5)-pentaoxotungstate(4-),,InChI=1S/5O.W/q;4*-1;,TUNGSTATE(VI) ION,PDBeChem accession,WO5
2164,46295,vardenafil,"The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.","InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)","2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE",PDBeChem accession,VDN
2165,48490,"quinoline-2,6-diol",A dihydroxyquinoline that is quinoline in which the hydrogens at positions 2 and 6 are replaced by hydroxy groups.,"InChI=1S/C9H7NO2/c11-7-2-3-8-6(5-7)1-4-9(12)10-8/h1-5,11H,(H,10,12)","2,6-dihydroxyquinoline",Patent accession,EP1870402
2166,47218,alpha-Kdo-(2->4)-alpha-Kdo,A disaccharide consisting of two 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl units joined via an alpha-(2->4)-linkage.,"InChI=1S/C16H26O15/c17-3-6(20)11-9(22)5(19)1-16(31-11,14(26)27)29-8-2-15(28,13(24)25)30-12(10(8)23)7(21)4-18/h5-12,17-23,28H,1-4H2,(H,24,25)(H,26,27)/t5-,6-,7-,8-,9-,10-,11-,12-,15-,16-/m1/s1",3-deoxy-4-O-(3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl)-alpha-D-manno-oct-2-ulopyranosonic acid,CAS Registry Number,94722-74-4
2167,42939,cyclohexylammonium,An ammonium ion resulting from the protonation of the amino group of cyclohexylamine.,"InChI=1S/C6H13N/c7-6-4-2-1-3-5-6/h6H,1-5,7H2/p+1",CYCLOHEXYLAMMONIUM ION,PDBeChem accession,HAI
2168,43040,hadacidin,A monocarboxylic acid that is N-hydroxyglycine in which the hydrogen attached to the nitrogen is replaced by a formyl group. It was originally isolated from cultures of Penicillium frequentans.,"InChI=1S/C3H5NO4/c5-2-4(8)1-3(6)7/h2,8H,1H2,(H,6,7)",HADACIDIN,PDBeChem accession,HDA
2169,43060,1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine,"A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.","InChI=1S/C14H16N2O4S/c1-10-12(18)15-14(19)16(9-20-8-7-17)13(10)21-11-5-3-2-4-6-11/h2-6,17H,7-9H2,1H3,(H,15,18,19)",1-(2-HYDROXYETHYLOXYMETHYL)-6-PHENYL THIOTHYMINE,PDBeChem accession,HEF
2170,43074,(3S)-3-hydroxy-3-methylglutaryl-CoA(5-),An acyl-CoA oxoanion that results from the removal of all five protons from the phosphate and carboxylic acid groups of (3S)-3-hydroxy-3-methylglutaryl-CoA.,"InChI=1S/C27H44N7O20P3S/c1-26(2,21(40)24(41)30-5-4-15(35)29-6-7-58-17(38)9-27(3,42)8-16(36)37)11-51-57(48,49)54-56(46,47)50-10-14-20(53-55(43,44)45)19(39)25(52-14)34-13-33-18-22(28)31-12-32-23(18)34/h12-14,19-21,25,39-40,42H,4-11H2,1-3H3,(H,29,35)(H,30,41)(H,36,37)(H,46,47)(H,48,49)(H2,28,31,32)(H2,43,44,45)/p-5/t14-,19-,20-,21+,25-,27+/m1/s1",3-HYDROXY-3-METHYLGLUTARYL-COENZYME A,PDBeChem accession,HMG
2171,46448,ubiquinone-7,"A compound whose structure comprises a 2,3-dimethoxy-5-methylbenzoquinone nucleus, common to ubiquinones; and a side chain of seven isoprenoid units.","InChI=1S/C44H66O4/c1-32(2)18-12-19-33(3)20-13-21-34(4)22-14-23-35(5)24-15-25-36(6)26-16-27-37(7)28-17-29-38(8)30-31-40-39(9)41(45)43(47-10)44(48-11)42(40)46/h18,20,22,24,26,28,30H,12-17,19,21,23,25,27,29,31H2,1-11H3/b33-20+,34-22+,35-24+,36-26+,37-28+,38-30+",UBIQUINONE-7,CAS Registry Number,303-95-7
2172,47631,GS-8373,"A furofuran that consists of hydroxymethylphosphonic acid where the alcoholic OH group is carrying a ({4-[(2S,3R)-2-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl}amino)-3-hydroxy-4-[(4-methoxyphenyl)sulfonyl](2-methylpropyl)amino}butyl]phenyl group.","InChI=1S/C29H41N2O12PS/c1-19(2)15-31(45(37,38)23-10-8-21(39-3)9-11-23)16-26(32)25(14-20-4-6-22(7-5-20)42-18-44(34,35)36)30-29(33)43-27-17-41-28-24(27)12-13-40-28/h4-11,19,24-28,32H,12-18H2,1-3H3,(H,30,33)(H2,34,35,36)/t24-,25-,26+,27-,28+/m0/s1","({4-[(2S,3R)-2-({[(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YLOXY]CARBONYL}AMINO)-3-HYDROXY-4-{ISOBUTYL[(4-METHOXYPHENYL)SULFONYL]AMINO}BUTYL]PHENOXY}METHYL)PHOSPHONIC ACID",PDBeChem accession,QFI
2173,46877,dinicotinate(2-),,"InChI=1S/C7H5NO4/c9-6(10)4-1-5(7(11)12)3-8-2-4/h1-3H,(H,9,10)(H,11,12)/p-2",dinicotinate,Gmelin Registry Number,1484440
2174,47796,(S)-dihydrocamalexic acid,,"InChI=1S/C12H10N2O2S/c15-12(16)10-6-17-11(14-10)8-5-13-9-4-2-1-3-7(8)9/h1-5,10,13H,6H2,(H,15,16)/t10-/m1/s1","(4S)-2-(1H-indol-3-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid",PubMed citation,16766671
2175,48582,"ADP-alpha-D-ribose 1'',2''-cyclic phosphate",,"InChI=1S/C15H22N5O16P3/c16-12-7-13(18-3-17-12)20(4-19-7)14-10(23)8(21)5(32-14)1-30-37(24,25)36-38(26,27)31-2-6-9(22)11-15(33-6)35-39(28,29)34-11/h3-6,8-11,14-15,21-23H,1-2H2,(H,24,25)(H,26,27)(H,28,29)(H2,16,17,18)/t5-,6-,8-,9-,10-,11-,14-,15-/m1/s1",Appr>p,Beilstein Registry Number,7562061
2176,48584,ADP-alpha-D-ribose 1''-phosphate,The 1''-phosphate derivative of ADP-alpha-D-ribose.,"InChI=1S/C15H24N5O17P3/c16-12-7-13(18-3-17-12)20(4-19-7)14-10(23)8(21)5(34-14)1-32-39(28,29)37-40(30,31)33-2-6-9(22)11(24)15(35-6)36-38(25,26)27/h3-6,8-11,14-15,21-24H,1-2H2,(H,28,29)(H,30,31)(H2,16,17,18)(H2,25,26,27)/t5-,6-,8-,9-,10-,11-,14-,15-/m1/s1",Appr1p,PDBeChem accession,HQG
2177,46280,beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc,An amino disaccharide consisting of N-acetyl-beta-D-galactosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.,"InChI=1S/C14H21NO11/c1-4(17)15-8-11(10(20)7(3-16)24-13(8)23)26-14-9(19)5(18)2-6(25-14)12(21)22/h2,5,7-11,13-14,16,18-20,23H,3H2,1H3,(H,15,17)(H,21,22)/t5-,7+,8+,9+,10-,11+,13+,14-/m0/s1","(4S,5R,6R)-6-((2R,3R,4R,5R,6R)-3-ACETAMIDO-2,5-DIHYDROXY-6-(HYDROXYMETHYL)-TETRAHYDRO-2H-PYRAN-4-YLOXY)-4,5-DIHYDROXY-5,6-DIHYDRO-4H-PYRAN-2-CARBOXYLIC ACID",PDBeChem accession,UCD
2178,43035,(R)-hydratropic acid,The (R)-enantiomer of hydratropic acid.,"InChI=1S/C9H10O2/c1-7(9(10)11)8-5-3-2-4-6-8/h2-7H,1H3,(H,10,11)/t7-/m1/s1",R-2-PHENYL-PROPRIONIC ACID,PDBeChem accession,GRO
2179,43081,"8-benzyl-7-hydroxy-4,10-dioxo-1-phenyl-6-oxa-3,9-diaza-7-phosphatetradecan-14-oic acid 7-oxide",An optically active monocarboxylic acid also having amide and phosphonate functional groups.,"InChI=1S/C23H29N2O7P/c26-20(12-7-13-23(28)29)25-22(16-19-10-5-2-6-11-19)33(30,31)32-17-21(27)24-15-14-18-8-3-1-4-9-18/h1-6,8-11,22H,7,12-17H2,(H,24,27)(H,25,26)(H,28,29)(H,30,31)/t22-/m0/s1",N-{[2-({[1-(4-CARBOXYBUTANOYL)AMINO]-2-PHENYLETHYL}-HYDROXYPHOSPHINYL)OXY]ACETYL}-2-PHENYLETHYLAMINE,PDBeChem accession,HAL
2180,49704,iridium(3+),,InChI=1S/Ir/q+3,IRIDIUM (III) ION,PDBeChem accession,IR3
2181,49751,D-monapterin,"A neopterin in which the 1,2,3-trihydroxypropyl side-chain is in 1S,2S configuration.","InChI=1S/C9H11N5O4/c10-9-13-7-5(8(18)14-9)12-3(1-11-7)6(17)4(16)2-15/h1,4,6,15-17H,2H2,(H3,10,11,13,14,18)/t4-,6-/m0/s1",D-MONAPTERIN,PDBeChem accession,MPU
2182,49558,diaminozinc,,InChI=1S/2H2N.Zn/h2*1H2;/q2*-1;+2,diaminozinc,PDBeChem accession,DAZ
2183,50524,catecholate(1-),A phenolate anion that is the conjugate base of catechol.,"InChI=1S/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8H/p-1",pyrocatechol monoanion,Beilstein Registry Number,3904355
2184,50570,trans-2-octadecenoyl-CoA,An octadecenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans-2-octadecenoic acid.,"InChI=1S/C39H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h18-19,26-28,32-34,38,49-50H,4-17,20-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/b19-18+/t28-,32-,33-,34+,38-/m1/s1",(E)-octadec-2-enoyl-CoA,KEGG COMPOUND accession,C16218
2185,45912,D-threonate,,"InChI=1S/C4H8O5/c5-1-2(6)3(7)4(8)9/h2-3,5-7H,1H2,(H,8,9)/p-1/t2-,3+/m1/s1",THREONATE ION,PDBeChem accession,THE
2186,46099,"(S,S)-trans-1-isopropyl-2,3,3,5-tetramethyl-6-succinylindane",A  4-oxo monocarboxylic acid that is a synthetic musk fragrance and hydrophobic hapten with an indane core.,"InChI=1S/C20H28O3/c1-11(2)19-13(4)20(5,6)16-9-12(3)14(10-15(16)19)17(21)7-8-18(22)23/h9-11,13,19H,7-8H2,1-6H3,(H,22,23)/t13-,19-/m0/s1",TRAZEOLIDE,PDBeChem accession,TRZ
2187,46171,4-acetamidobenzoic acid,A amidobenzoic acid that consists of benzoic acid bearing an acetamido substituent at position 4.,"InChI=1S/C9H9NO3/c1-6(11)10-8-4-2-7(3-5-8)9(12)13/h2-5H,1H3,(H,10,11)(H,12,13)",PARA ACETAMIDO BENZOIC ACID,PDBeChem accession,TYZ
2188,50528,FMNH(.),,"InChI=1S/C17H22N4O9P/c1-7-3-9-10(4-8(7)2)21(15-13(18-9)16(25)20-17(26)19-15)5-11(22)14(24)12(23)6-30-31(27,28)29/h3-4,11-12,14,22-24H,5-6H2,1-2H3,(H2,27,28,29)(H2,19,20,25,26)/t11-,12+,14-/m0/s1",flavin mononucleotide semiquinone radical,Beilstein Registry Number,4056977
2189,50726,"CDP-2,3-bis-O-(geranylgeranyl)-sn-glycerol","A nucleotide conjugate consisting of CDP joined at the 1-position of 2,3-bis-O-(geranylgeranyl)-sn-glycerol via a diphosphate linkage.","InChI=1S/C52H85N3O13P2/c1-38(2)17-11-19-40(5)21-13-23-42(7)25-15-27-44(9)30-33-63-35-46(64-34-31-45(10)28-16-26-43(8)24-14-22-41(6)20-12-18-39(3)4)36-65-69(59,60)68-70(61,62)66-37-47-49(56)50(57)51(67-47)55-32-29-48(53)54-52(55)58/h17-18,21-22,25-26,29-32,46-47,49-51,56-57H,11-16,19-20,23-24,27-28,33-37H2,1-10H3,(H,59,60)(H,61,62)(H2,53,54,58)/b40-21+,41-22+,42-25+,43-26+,44-30+,45-31+/t46-,47+,49+,50+,51+/m0/s1","CDP-2,3-digeranylgeranyl sn-G-1-P",KEGG COMPOUND accession,C18059
2190,47249,1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)urea,A member of the class of phenylureas that is urea which is substituted at position 1 by a 3-tert-butyl-1-methylpyrazol-5-yl group and at position 3 by a p-chlorophenyl group.,"InChI=1S/C15H19ClN4O/c1-15(2,3)12-9-13(20(4)19-12)18-14(21)17-11-7-5-10(16)6-8-11/h5-9H,1-4H3,(H2,17,18,21)",1-(5-TERT-BUTYL-2-METHYL-2H-PYRAZOL-3-YL)-3-(4-CHLORO-PHENYL)-UREA,PDBeChem accession,BMU
2191,47191,"diadenosine 5',5'-diphosphate",A diadenosyl diphosphate having two 5'-adenosyl residues attached at the P(1)- and P(2)-positions of the diphosphate.,"InChI=1S/C20H26N10O13P2/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(41-19)1-39-44(35,36)43-45(37,38)40-2-8-12(32)14(34)20(42-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1","BIS{[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL]METHYL} DIHYDROGEN DIPHOSPHATE",PDBeChem accession,A2D
2192,47411,mu-oxodiiron,An iron coordination entity consisting of two iron atoms coordinated to a central oxygen.,InChI=1S/2Fe.O,ferriooxyiron,PDBeChem accession,FEO
2193,46324,trimethyl phosphate,A trialkyl phosphate that is the trimethyl ester of phosphoric acid.,"InChI=1S/C3H9O4P/c1-5-8(4,6-2)7-3/h1-3H3",TRIMETHYL PHOSPHATE,PDBeChem accession,TZZ
2194,48340,"glycidyl 2,2-dinitropropyl formal","A C-nitro compound consisting of methanediol having a glycidyl group attached to one oxygen and a 2,2-dinitropropyl group attached to the other.","InChI=1S/C7H12N2O7/c1-7(8(10)11,9(12)13)4-15-5-14-2-6-3-16-6/h6H,2-5H2,1H3",glycidyldinitropropylformal,Patent accession,US2007056663
2195,47077,dibromomethane,A member of the class of  bromomethanes that is methane substituted by two bromo groups. It is produced by marine algae.,InChI=1S/CH2Br2/c2-1-3/h1H2,DIBROMOMETHANE,Gmelin Registry Number,25649
2196,47459,cis-heme d hydroxychlorin gamma-spirolactone,A metallochlorin that is heme d in which the hydroxy group and the carboxy group of the 6-carboxyethyl substituent have undergone intramolecular condensation to afford the corresponding gamma-spirolactone.,"InChI=1S/C34H33N4O5.Fe/c1-7-20-17(3)23-13-24-19(5)22(9-10-31(39)40)28(37-24)16-30-34(12-11-32(41)43-34)33(6,42)29(38-30)15-27-21(8-2)18(4)25(36-27)14-26(20)35-23;/h7-8,13-16,42H,1-2,9-12H2,3-6H3,(H2-,35,36,37,38,39,40);/q-1;+2/p-1/t33-,34+;/m0./s1",CIS-HEME D HYDROXYCHLORIN GAMMA-SPIROLACTONE,PDBeChem accession,HDD
2197,51932,cascade blue,,"InChI=1S/C33H40N3/c1-6-34-32-24-28(23-27-13-11-12-14-31(27)32)33(25-15-19-29(20-16-25)35(7-2)8-3)26-17-21-30(22-18-26)36(9-4)10-5/h11-24,34H,6-10H2,1-5H3/q+1",CI Pigment Blue 1,CAS Registry Number,1325-87-7
2198,51940,coumarin 504,,"InChI=1S/C18H19NO4/c1-2-22-17(20)14-10-12-9-11-5-3-7-19-8-4-6-13(15(11)19)16(12)23-18(14)21/h9-10H,2-8H2,1H3",Coumarin 314,CAS Registry Number,55804-66-5
2199,50679,methotrexate disodium,An organic sodium salt that is the disodium salt of methotrexate.,"InChI=1S/C20H22N8O5.2Na/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);;/q;2*+1/p-2/t13-;;/m0../s1",methotrexate sodium,Beilstein Registry Number,6045736
2200,50231,"4,4'-propane-1,3-diyldipiperazine-2,6-dione",,"InChI=1S/C11H16N4O4/c16-8-4-14(5-9(17)12-8)2-1-3-15-6-10(18)13-11(19)7-15/h1-7H2,(H,12,16,17)(H,13,18,19)",ICRF-161,Beilstein Registry Number,819231
2201,50009,S-trans-stilbene oxide,,"InChI=1S/C14H12O/c1-3-7-11(8-4-1)13-14(15-13)12-9-5-2-6-10-12/h1-10,13-14H/t13-,14-/m0/s1","(S,S)-stilbene oxide",Beilstein Registry Number,82739
2202,51079,GS26575,"A diamino-1,3,5-triazine that is 1,3,5-triazine-2,4-diamine substituted by a methylsulfanyl group at position 6 and a tert-buty group at the amino nitrogen atom.","InChI=1S/C8H15N5S/c1-8(2,3)13-6-10-5(9)11-7(12-6)14-4/h1-4H3,(H3,9,10,11,12,13)",M1,Beilstein Registry Number,516009
2203,44272,N-acetyl-D-proline,,"InChI=1S/C7H11NO3/c1-5(9)8-4-2-3-6(8)7(10)11/h6H,2-4H2,1H3,(H,10,11)/t6-/m1/s1",1-ACETYL-D-PROLINE,PDBeChem accession,N7P
2204,48310,apiitol,,"InChI=1S/C5H12O5/c6-1-4(9)5(10,2-7)3-8/h4,6-10H,1-3H2","2-(hydroxymethyl)butane-1,2,3,4-tetrol",Beilstein Registry Number,5917048
2205,48364,"3,3,6,6,8a-pentamethyltetrahydro-1,8-dioxa-4a-azanaphthalene",,"InChI=1S/C12H23NO2/c1-10(2)6-13-7-11(3,4)9-15-12(13,5)14-8-10/h6-9H2,1-5H3","3,3,6,6,8a-pentamethyl-1,8-dioxaquinolizidine",Patent accession,WO2007024836
2206,47873,(S)-2-mercaptopropanoic acid,,"InChI=1S/C3H6O2S/c1-2(6)3(4)5/h2,6H,1H3,(H,4,5)/t2-/m0/s1",(2S)-2-mercaptopropanoic acid,Beilstein Registry Number,1720254
2207,43615,2H-imidazol-4-ylacetic acid,An imidazolyl carboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 2H-imidazol-4-yl group.,"InChI=1S/C5H6N2O2/c8-5(9)1-4-2-6-3-7-4/h2H,1,3H2,(H,8,9)",2-(2H-imidazol-4-yl)ethanoic acid,PDBeChem accession,IZC
2208,48732,"5beta-cholestane-3alpha,7alpha,12alpha,24,26-pentol",,"InChI=1S/C27H48O5/c1-15(5-8-22(30)16(2)14-28)19-6-7-20-25-21(13-24(32)27(19,20)4)26(3)10-9-18(29)11-17(26)12-23(25)31/h15-25,28-32H,5-14H2,1-4H3/t15-,16?,17+,18-,19-,20+,21+,22?,23-,24+,25+,26+,27-/m1/s1","5beta-cholestan-3alpha,7alpha,12alpha,24,27-pentol",LIPID MAPS instance accession,LMST04030018
2209,47947,keto-D-tagatose 6-phosphate,A D-tagatose 6-phosphate that is in the open-chain keto-form.,"InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h4-7,9-11H,1-2H2,(H2,12,13,14)/t4-,5-,6+/m1/s1",keto-D-tagatose 6-(dihydrogen phosphate),Beilstein Registry Number,1728992
2210,53329,"anthra[2,3-b]benzo[d]thiophene",A heteroacene compound consisting of benzothiophene fused to anthracene in a rectilinear arrangement.,InChI=1S/C20H12S/c1-2-6-14-10-16-12-20-18(11-15(16)9-13(14)5-1)17-7-3-4-8-19(17)21-20/h1-12H,ABT,Beilstein Registry Number,19241
2211,52222,(2R)-homocitric acid,The (R)-enantiomer of homocitric acid.,"InChI=1S/C7H10O7/c8-4(9)1-2-7(14,6(12)13)3-5(10)11/h14H,1-3H2,(H,8,9)(H,10,11)(H,12,13)/t7-/m1/s1",(R)-homocitric acid,KEGG COMPOUND accession,C01251
2212,52110,DND-167 dye,,"InChI=1S/C24H28N2O2/c1-2-6-20-19(5-1)23(17-25-9-13-27-14-10-25)21-7-3-4-8-22(21)24(20)18-26-11-15-28-16-12-26/h1-8H,9-18H2",LysoSensor Blue DND-167,Beilstein Registry Number,336905
2213,52042,2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3H)-quinazolinone,,"InChI=1S/C14H9Cl2N2O5P/c15-7-1-3-11-9(5-7)14(19)18-13(17-11)10-6-8(16)2-4-12(10)23-24(20,21)22/h1-6H,(H,17,18,19)(H2,20,21,22)",Elf-97,CAS Registry Number,147394-94-3
2214,52247,"platinum(II) 5,10,15,20-tetrakis-(2,3,4,5,6-pentafluorophenyl)porphyrin","A platinum(II) porphyrin compound having four pentafluorophenyl substituents in the 5-, 10-, 15-, and 20-positions.","InChI=1S/C44H8F20N4.Pt/c45-25-21(26(46)34(54)41(61)33(25)53)17-9-1-2-10(65-9)18(22-27(47)35(55)42(62)36(56)28(22)48)12-5-6-14(67-12)20(24-31(51)39(59)44(64)40(60)32(24)52)16-8-7-15(68-16)19(13-4-3-11(17)66-13)23-29(49)37(57)43(63)38(58)30(23)50;/h1-8H;/q-2;+2/b17-9+,17-11+,18-10+,18-12+,19-13+,19-15+,20-14+,20-16+;",PtTFPP,Beilstein Registry Number,11598927
2215,52256,QSY7 succinimidyl ester,,"InChI=1S/C43H39N4O7S.ClH/c1-44(30-11-5-3-6-12-30)32-17-19-34-37(27-32)53-38-28-33(45(2)31-13-7-4-8-14-31)18-20-35(38)42(34)36-15-9-10-16-39(36)55(51,52)46-25-23-29(24-26-46)43(50)54-47-40(48)21-22-41(47)49;/h3-20,27-29H,21-26H2,1-2H3;1H/q+1;/p-1",QSY 7,Beilstein Registry Number,11392862
2216,52893,rhodamine 110(1+),A cationic fluorescent dye derived from 9-phenylxanthene.,"InChI=1S/C20H14N2O3/c21-11-5-7-15-17(9-11)25-18-10-12(22)6-8-16(18)19(15)13-3-1-2-4-14(13)20(23)24/h1-10H,21-22H2/p+1",rhodamine 110 cation,Beilstein Registry Number,1400813
2217,52895,rhodamine 6G(1+),A cationic fluorescent dye derived from 9-phenylxanthene.,"InChI=1S/C28H31N2O3/c1-6-29-23-15-25-21(13-17(23)4)27(19-11-9-10-12-20(19)28(31)32-8-3)22-14-18(5)24(30-7-2)16-26(22)33-25/h9-16,29-30H,6-8H2,1-5H3/q+1",rhodamine 6G cation,CAS Registry Number,47724-48-1
2218,52896,rhodamine B(1+),A cationic fluorescent dye derived from 9-phenylxanthene.,"InChI=1S/C28H30N2O3/c1-5-29(6-2)19-13-15-23-25(17-19)33-26-18-20(30(7-3)8-4)14-16-24(26)27(23)21-11-9-10-12-22(21)28(31)32/h9-18H,5-8H2,1-4H3/p+1",rhodamine B cation,PDBeChem accession,RHB
2219,52050,"(24R,25R)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oyl-CoA","An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (24R,25R)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid.","InChI=1S/C48H80N7O21P3S/c1-24(28-8-9-29-36-30(19-34(59)48(28,29)6)47(5)13-11-27(56)17-26(47)18-32(36)58)7-10-31(57)25(2)45(64)80-16-15-50-35(60)12-14-51-43(63)40(62)46(3,4)21-73-79(70,71)76-78(68,69)72-20-33-39(75-77(65,66)67)38(61)44(74-33)55-23-54-37-41(49)52-22-53-42(37)55/h22-34,36,38-40,44,56-59,61-62H,7-21H2,1-6H3,(H,50,60)(H,51,63)(H,68,69)(H,70,71)(H2,49,52,53)(H2,65,66,67)/t24-,25-,26+,27-,28-,29+,30+,31-,32-,33-,34+,36+,38-,39-,40+,44-,47+,48-/m1/s1","(24R,25R)-3alpha,7alpha,12alpha,24-Tetrahydroxy-5beta-cholestanoyl-CoA",KEGG COMPOUND accession,C15614
2220,52031,glycochenodeoxycholic acid 7-sulfate,,"InChI=1S/C26H43NO8S/c1-15(4-7-22(29)27-14-23(30)31)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)35-36(32,33)34/h15-21,24,28H,4-14H2,1-3H3,(H,27,29)(H,30,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,24+,25+,26-/m1/s1",N-(3alpha-hydroxy-7alpha-sulfooxy-5beta-cholan-24-oyl)glycine,KEGG COMPOUND accession,C15559
2221,52400,2-methoxyacetophenone,,"InChI=1S/C9H10O2/c1-11-7-9(10)8-5-3-2-4-6-8/h2-6H,7H2,1H3",2-methoxy-1-phenylethanone,CAS Registry Number,4079-52-1
2222,52021,6-decylubiquinol,"A member of the class of hydroquinones that is 2,3-dimethoxyhydroquinone in which the hydrogens at positions 5 and 6 have been replaced by a methyl group and a decyl group.","InChI=1S/C19H32O4/c1-5-6-7-8-9-10-11-12-13-15-14(2)16(20)18(22-3)19(23-4)17(15)21/h20-21H,5-13H2,1-4H3",Decylubiquinol,Beilstein Registry Number,11425057
2223,52478,phenyl acetimidate,,"InChI=1S/C8H9NO/c1-7(9)10-8-5-3-2-4-6-8/h2-6,9H,1H3",acetimidic acid phenyl ether,Beilstein Registry Number,3234652
2224,53155,"2,6-dimethylocta-2,4,6-trienedial","An apo carotenoid monoterpenoid compound arising from oxidative degradation of the beta,beta-carotene skeleton at the 8'- and 15-positions.","InChI=1S/C10H12O2/c1-9(6-7-11)4-3-5-10(2)8-12/h3-8H,1-2H3/b4-3+,9-6+,10-5+","apo-8',15-apo-carotene-dial",PubMed citation,15686550
2225,52924,thiazole orange cation,A cationic C1 cyanine dye having 3-methylbenzothiazolium-2-yl and 1-methylquinolinium-4-yl substituents.,"InChI=1S/C19H17N2S/c1-20-12-11-14(15-7-3-4-8-16(15)20)13-19-21(2)17-9-5-6-10-18(17)22-19/h3-13H,1-2H3/q+1",thiazole orange(1+),PDBeChem accession,J0D
2226,52926,thionine cation,"The cationic form of 3,7-diaminophenothiazine.","InChI=1S/C12H10N3S/c13-7-1-3-9-11(5-7)16-12-6-8(14)2-4-10(12)15-9/h1-6H,13-14H2/q+1",thionine(1+),Beilstein Registry Number,3551799
2227,52929,ToTo-1(4+),The tetracation of ToTo-1 dye.,"InChI=1S/C49H58N6S2/c1-50-44-22-11-13-24-46(44)56-48(50)36-38-26-30-52(42-20-9-7-18-40(38)42)28-15-32-54(3,4)34-17-35-55(5,6)33-16-29-53-31-27-39(41-19-8-10-21-43(41)53)37-49-51(2)45-23-12-14-25-47(45)57-49/h7-14,18-27,30-31,36-37H,15-17,28-29,32-35H2,1-6H3/q+4",ToTo-1 cation,PDBeChem accession,TOT
2228,52510,1-chloroindole,,InChI=1S/C8H6ClN/c9-10-6-5-7-3-1-2-4-8(7)10/h1-6H,N-chloroindole,Beilstein Registry Number,1281737
2229,52549,sordarin,An antifungal metabolite of Sordaria araneosa that inhibits protein synthesis. It has a tetracyclic diterpene glycoside structure.,"InChI=1S/C27H40O8/c1-13(2)19-8-16-9-25(11-28)18-7-6-14(3)17(18)10-26(16,27(19,25)24(31)32)12-34-23-21(30)20(29)22(33-5)15(4)35-23/h8,11,13-18,20-23,29-30H,6-7,9-10,12H2,1-5H3,(H,31,32)/t14-,15-,16+,17-,18-,20+,21+,22-,23-,25+,26+,27+/m1/s1",sordarin B,CAS Registry Number,11076-17-8
2230,51772,7-amino-4-(trifluoromethyl)coumarin,,"InChI=1S/C10H6F3NO2/c11-10(12,13)7-4-9(15)16-8-3-5(14)1-2-6(7)8/h1-4H,14H2",coumarin 151,CAS Registry Number,53518-15-3
2231,52904,rose bengal(2-),The anionic form of a fluorescent dye derived from a polyhalogenated fluorescin.,"InChI=1S/C20H4Cl4I4O5/c21-10-8(9(20(31)32)11(22)13(24)12(10)23)7-3-1-5(25)16(29)14(27)18(3)33-19-4(7)2-6(26)17(30)15(19)28/h1-2,29H,(H,31,32)/p-2",rose bengal anion,Beilstein Registry Number,1445395
2232,52920,4-(4-diethylaminostyryl)-1-methylpyridinium,A pyridinium cation obtained by methylation at position 1 of 4-(4-diethylaminostyryl)pyridine,"InChI=1S/C18H23N2/c1-4-20(5-2)18-10-8-16(9-11-18)6-7-17-12-14-19(3)15-13-17/h6-15H,4-5H2,1-3H3/q+1",4-(4-diethylaminostyryl)-1-methylpyridinium cation,Beilstein Registry Number,6094997
2233,53076,4-(ethoxymethylene)-2-phenyloxazol-5-one,"A 1,3-oxazole compound having a phenyl substituent at the 2-position, an ethoxymethylene group at the 4-position, and an oxo group at the 5-position.  It is a chemical allergen used for immunological experiments, particularly for experiments on delayed type hypersensitivity.","InChI=1S/C12H11NO3/c1-2-15-8-10-12(14)16-11(13-10)9-6-4-3-5-7-9/h3-8H,2H2,1H3",oxazolone,PubMed citation,12176098
2234,46274,(Z)-octadec-11-enyl acetate,,"InChI=1S/C20H38O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22-20(2)21/h8-9H,3-7,10-19H2,1-2H3/b9-8-",(Z)-OCTADEC-11-ENYL ACETATE,PDBeChem accession,VA
2235,47544,loracarbef,"A synthetic ""carba"" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.","InChI=1S/C16H16ClN3O4/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24)/t10-,11-,12+/m1/s1",LORACABEF,PDBeChem accession,LOR
2236,48542,"deca-2,4,6,8-tetraenedioic acid",,"InChI=1S/C10H10O4/c11-9(12)7-5-3-1-2-4-6-8-10(13)14/h1-8H,(H,11,12)(H,13,14)","2,4,6,8-decatetraenoic acid",CAS Registry Number,6048-86-8
2237,53209,tetrapropylammonium perruthenate,A quaternary ammonium salt having tetrapropylammonium as the cation and perruthenate as the anion.,"InChI=1S/C12H28N.4O.Ru/c1-5-9-13(10-6-2,11-7-3)12-8-4;;;;;/h5-12H2,1-4H3;;;;;/q+1;;;;-1;",TPAP,Gmelin Registry Number,213564
2238,48571,(S)-gamma-valerolactone,,"InChI=1S/C5H8O2/c1-4-2-3-5(6)7-4/h4H,2-3H2,1H3/t4-/m0/s1",(-)-(S)-5-methyl-2-oxotetrahydrofuran,Beilstein Registry Number,80421
2239,52145,pyrrolidinium ion,The ion formed by protonating nitrogen in pyrrolidine.,"InChI=1S/C4H9N/c1-2-4-5-3-1/h5H,1-4H2/p+1",pyrrolidinium ion,MetaCyc accession,PYRROLIDINE
2240,52160,procaine(1+),An organic cation that is the monoprotonated form of procaine.,"InChI=1S/C13H20N2O2/c1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3/p+1",4-amino-benzoic acid 2-diethylammonio-ethyl ester monocation,Beilstein Registry Number,3674525
2241,52226,epi-cedrol,The 8S-epimer of cedrol.,"InChI=1S/C15H26O/c1-10-5-6-11-13(2,3)12-9-15(10,11)8-7-14(12,4)16/h10-12,16H,5-9H2,1-4H3/t10-,11+,12-,14+,15+/m1/s1",8-epicedrol,Beilstein Registry Number,3195903
2242,52434,temocillin disodium,,"InChI=1S/C16H18N2O7S2.2Na/c1-15(2)9(12(22)23)18-13(24)16(25-3,14(18)27-15)17-10(19)8(11(20)21)7-4-5-26-6-7;;/h4-6,8-9,14H,1-3H3,(H,17,19)(H,20,21)(H,22,23);;/q;2*+1/p-2/t8?,9-,14+,16-;;/m0../s1",temocillin sodium,CAS Registry Number,61545-06-0
2243,52004,Cy3B dye NHS ester,"A fluorescent dye with a maximum emission wavelength of 572 nm, derived from a heteroheptacyclic ring system.","InChI=1S/C35H35N3O8S/c1-34(2)23-15-19(16-31(41)46-38-29(39)9-10-30(38)40)5-7-25(23)36-13-11-27-21(32(34)36)18-22-28(45-27)12-14-37-26-8-6-20(47(42,43)44)17-24(26)35(3,4)33(22)37/h5-8,15,17-18,27-28H,9-14,16H2,1-4H3",Cy3B dye N-hydroxysuccinimidyl ester,Beilstein Registry Number,10509552
2244,51107,"4,4-difluoro-4-bora-3a,4a-diaza-s-indacene",,InChI=1S/C9H7BF2N2/c11-10(12)13-5-1-3-8(13)7-9-4-2-6-14(9)10/h1-7H,BODIPY,Beilstein Registry Number,8139995
2245,52073,parbenate,A benzoate ester that is ethyl benzoate substituted by a dimethylamino group at position 4.,"InChI=1S/C11H15NO2/c1-4-14-11(13)9-5-7-10(8-6-9)12(2)3/h5-8H,4H2,1-3H3",Ethyl-p-Dimethylaminobenzoate,Beilstein Registry Number,2210233
2246,52078,FM 4-64 dye,"A quaternary ammonium salt A liphophilic dye consisting of a dication that is N,N-dibutyl-4-[6-(pyridin-4-yl)hexa-1,3,5-trien-1-yl]aniline in which the nitrogen of the pyridine moiety is substituted by a 3-(triethylammonio)propyl group and two bromide ions. It is used to selectively stain yeast vacuolar membranes with red fluorescence.","InChI=1S/C34H53N3.2BrH/c1-6-11-27-36(28-12-7-2)34-22-20-32(21-23-34)18-15-13-14-16-19-33-24-29-35(30-25-33)26-17-31-37(8-3,9-4)10-5;;/h13-16,18-25,29-30H,6-12,17,26-28,31H2,1-5H3;2*1H/q+2;;/p-2",FM4-64,Reaxys Registry Number,23884566
2247,52082,pibenzimol,,"InChI=1S/C25H24N6O/c1-30-10-12-31(13-11-30)18-5-9-21-23(15-18)29-25(27-21)17-4-8-20-22(14-17)28-24(26-20)16-2-6-19(32)7-3-16/h2-9,14-15,32H,10-13H2,1H3,(H,26,28)(H,27,29)",HOECHST 33258,CAS Registry Number,23491-44-3
2248,52097,"1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine iodide",,"InChI=1S/C25H27Cl4N4.HI/c1-5-30-20-12-16(26)17(27)13-21(20)31(6-2)24(30)10-9-11-25-32(7-3)22-14-18(28)19(29)15-23(22)33(25)8-4;/h9-15H,5-8H2,1-4H3;1H/q+1;/p-1",JC1 dye,CAS Registry Number,3520-43-2
2249,52682,"butane-1,2-diol",A butanediol in which the two hydroxy groups are located at positions 1 and 2.,"InChI=1S/C4H10O2/c1-2-4(6)3-5/h4-6H,2-3H2,1H3","1,2-Butanediol",Beilstein Registry Number,969169
2250,52683,"butane-1,3-diol",A butanediol compound having two hydroxy groups in the 1- and 3-positions.,"InChI=1S/C4H10O2/c1-4(6)2-3-5/h4-6H,2-3H2,1H3","1,3-Butanediol",Beilstein Registry Number,1718945
2251,52548,5-formylporphyrin,,"InChI=1S/C21H14N4O/c26-12-19-20-7-5-17(24-20)10-15-3-1-13(22-15)9-14-2-4-16(23-14)11-18-6-8-21(19)25-18/h1-12,22,25H/b13-9-,14-9-,15-10-,16-11-,17-10-,18-11-,20-19-,21-19-",5-formylporphine,Beilstein Registry Number,6820721
2252,52606,N'-(2-hydroxybenzoyl)biphenyl-4-carbohydrazide,,"InChI=1S/C20H16N2O3/c23-18-9-5-4-8-17(18)20(25)22-21-19(24)16-12-10-15(11-13-16)14-6-2-1-3-7-14/h1-13,23H,(H,21,24)(H,22,25)",N-4-phenylbenzosalicylhydrazine,Beilstein Registry Number,8572057
2253,52608,2-hydroxy-N'-propionylbenzohydrazide,,"InChI=1S/C10H12N2O3/c1-2-9(14)11-12-10(15)7-5-3-4-6-8(7)13/h3-6,13H,2H2,1H3,(H,11,14)(H,12,15)",N-propionylsalicylhydrazidate,Beilstein Registry Number,9196446
2254,52609,N'-acetyl-2-aminobenzohydrazide,,"InChI=1S/C9H11N3O2/c1-6(13)11-12-9(14)7-4-2-3-5-8(7)10/h2-5H,10H2,1H3,(H,11,13)(H,12,14)",N-acetylaminobenzhydrazide,Beilstein Registry Number,2973072
2255,52610,2-(2-hydroxybenzoyl)hydrazinecarboxamide,,"InChI=1S/C8H9N3O3/c9-8(14)11-10-7(13)5-3-1-2-4-6(5)12/h1-4,12H,(H,10,13)(H3,9,11,14)",N-acylaminosalicylhydrazidate,Beilstein Registry Number,2696048
2256,52611,"N'-(2-hydroxybenzoyl)-2,6-dimethoxybenzohydrazide",,"InChI=1S/C16H16N2O5/c1-22-12-8-5-9-13(23-2)14(12)16(21)18-17-15(20)10-6-3-4-7-11(10)19/h3-9,19H,1-2H3,(H,17,20)(H,18,21)","2,6-dimethoxybenzoylsalicylhydrazide",Gmelin Registry Number,2703116
2257,52745,5-(N-hexadecanoyl)aminofluorescin,A fluorescin compound having a hexadecanoylamino substituent at the 5-position.,"InChI=1S/C36H43NO6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-34(40)37-25-16-19-28(31(22-25)36(41)42)35-29-20-17-26(38)23-32(29)43-33-24-27(39)18-21-30(33)35/h16-24,38H,2-15H2,1H3,(H,37,40)(H,41,42)",haf,Beilstein Registry Number,6551409
2258,52770,succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin,A tetrapeptide compound with a succinyl group at the N-terminal and a 7-amino-4-methylcoumarin group at the C-terminal.,"InChI=1S/C40H53N5O10/c1-21(2)16-29(42-33(47)14-15-34(48)49)38(52)43-30(17-22(3)4)39(53)45-36(23(5)6)40(54)44-31(19-25-8-11-27(46)12-9-25)37(51)41-26-10-13-28-24(7)18-35(50)55-32(28)20-26/h8-13,18,20-23,29-31,36,46H,14-17,19H2,1-7H3,(H,41,51)(H,42,47)(H,43,52)(H,44,54)(H,45,53)(H,48,49)/t29-,30-,31-,36-/m0/s1",Suc-Leu-Leu-Val-Tyr-AMC,Beilstein Registry Number,6887904
2259,52991,tin dioxide,A tin oxide compound consisting of tin(IV) covalently bound to two oxygen atoms.,InChI=1S/2O.Sn,stannic oxide,Gmelin Registry Number,9355
2260,53003,"naphthalene-1,5-diamine",A naphthalenediamine compound having amino substituents in the 1- and 5-positions.,"InChI=1S/C10H10N2/c11-9-5-1-3-7-8(9)4-2-6-10(7)12/h1-6H,11-12H2","1,5-naphthalenediamine",Beilstein Registry Number,907947
2261,52052,phenylacetone,A propanone that is propan-2-one substituted by a phenyl group at position 1.,"InChI=1S/C9H10O/c1-8(10)7-9-5-3-2-4-6-9/h2-6H,7H2,1H3",1-Phenyl-2-propanone,CAS Registry Number,103-79-7
2262,52306,"2',7'-difluorofluorescein",A xanthene dye that is fluorescein bearing two fluoro substituents at positions 2' and 7'.,"InChI=1S/C20H10F2O5/c21-13-5-11-17(7-15(13)23)27-18-8-16(24)14(22)6-12(18)19(11)9-3-1-2-4-10(9)20(25)26/h1-8,23H,(H,25,26)",Oregon Green 488,Beilstein Registry Number,7832504
2263,52311,rhodamine 700 perchlorate,,"InChI=1S/C26H26F3N2O.ClHO4/c27-26(28,29)21-19-13-15-5-1-9-30-11-3-7-17(22(15)30)24(19)32-25-18-8-4-12-31-10-2-6-16(23(18)31)14-20(21)25;2-1(3,4)5/h13-14H,1-12H2;(H,2,3,4,5)/q+1;/p-1",rhodamin 700 perchlorate,CAS Registry Number,63561-42-2
2264,52358,"tris(2,2'-bipyridine)ruthenium(II) dichloride","A ruthenium coordination entity consisting of ruthenium(II) chloride bound to three 2,2'-bipyridine units.",InChI=1S/3C10H8N2.2ClH.Ru/c3*1-3-7-11-9(5-1)10-6-2-4-8-12-10;;;/h3*1-8H;2*1H;/q;;;;;+2/p-2,"Tris(2,2'-bipyridine)ruthenium(II) dichloride",CAS Registry Number,14323-06-9
2265,53172,rosafluene,"A 1,12-diol compound having double bonds in the 2-, 4-, 6-, 8-, and 10-positions.","InChI=1S/C14H20O2/c1-13(9-5-11-15)7-3-4-8-14(2)10-6-12-16/h3-10,15-16H,11-12H2,1-2H3/b4-3+,9-5+,10-6+,13-7+,14-8+","4,9-dimethyldodeca-2,4,6,8,10-pentaen-diol",Beilstein Registry Number,2092604
2266,53236,captopril disulfide,An organic disulfide in which the disulfide bond links two units of captopril. It is a secondary metabolite of captopril.,"InChI=1S/C18H28N2O6S2/c1-11(15(21)19-7-3-5-13(19)17(23)24)9-27-28-10-12(2)16(22)20-8-4-6-14(20)18(25)26/h11-14H,3-10H2,1-2H3,(H,23,24)(H,25,26)/t11-,12?,13+,14+/m1/s1",CP-S-S-CP,CAS Registry Number,64806-05-9
2267,53237,4-sulfanilamidobenzoic acid,A sulfonamide that is sulfanilamide substituted at the sulfonamide nitrogen by a 4-carboxyphenyl group.,"InChI=1S/C13H12N2O4S/c14-10-3-7-12(8-4-10)20(18,19)15-11-5-1-9(2-6-11)13(16)17/h1-8,15H,14H2,(H,16,17)",SABA,CAS Registry Number,6336-70-5
2268,52277,tetrakis(o-aminophenyl)porphyrin,,"InChI=1S/C44H34N8/c45-29-13-5-1-9-25(29)41-33-17-19-35(49-33)42(26-10-2-6-14-30(26)46)37-21-23-39(51-37)44(28-12-4-8-16-32(28)48)40-24-22-38(52-40)43(36-20-18-34(41)50-36)27-11-3-7-15-31(27)47/h1-24,49,52H,45-48H2/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-",meso-tetrakis(o-aminophenyl)porphyrin,Beilstein Registry Number,1203884
2269,52278,tetramesitylporphyrin,,"InChI=1S/C56H54N4/c1-29-21-33(5)49(34(6)22-29)53-41-13-15-43(57-41)54(50-35(7)23-30(2)24-36(50)8)45-17-19-47(59-45)56(52-39(11)27-32(4)28-40(52)12)48-20-18-46(60-48)55(44-16-14-42(53)58-44)51-37(9)25-31(3)26-38(51)10/h13-28,57,60H,1-12H3/b53-41+,53-42+,54-43+,54-45+,55-44+,55-46+,56-47+,56-48+","5,10,15,20-tetrakis(2,4,6-trimethylphenyl)-21H,23H-porphine",Beilstein Registry Number,603519
2270,52282,tetramethylrhodamine,,"InChI=1S/C24H22N2O3/c1-25(2)15-9-11-19-21(13-15)29-22-14-16(26(3)4)10-12-20(22)23(19)17-7-5-6-8-18(17)24(27)28/h5-14H,1-4H3",TAMRA,Beilstein Registry Number,1440745
2271,52604,N'-formyl-2-hydroxybenzohydrazide,,"InChI=1S/C8H8N2O3/c11-5-9-10-8(13)6-3-1-2-4-7(6)12/h1-5,12H,(H,9,11)(H,10,13)",N-formylsalicylhydrazidate,Beilstein Registry Number,2722094
2272,50773,"2-decaprenyl-6-methoxy-1,4-benzoquinone",,"InChI=1S/C57H86O3/c1-44(2)22-13-23-45(3)24-14-25-46(4)26-15-27-47(5)28-16-29-48(6)30-17-31-49(7)32-18-33-50(8)34-19-35-51(9)36-20-37-52(10)38-21-39-53(11)40-41-54-42-55(58)43-56(60-12)57(54)59/h22,24,26,28,30,32,34,36,38,40,42-43H,13-21,23,25,27,29,31,33,35,37,39,41H2,1-12H3/b45-24+,46-26+,47-28+,48-30+,49-32+,50-34+,51-36+,52-38+,53-40+","2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-6-methoxycyclohexa-2,5-diene-1,4-dione",Beilstein Registry Number,2688027
2273,52668,"1,4-dihydroxy-2-naphthoyl-CoA","An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 1,4-dihydroxy-2-naphthoic acid.","InChI=1S/C32H42N7O19P3S/c1-32(2,26(44)29(45)35-8-7-21(41)34-9-10-62-31(46)18-11-19(40)16-5-3-4-6-17(16)23(18)42)13-55-61(52,53)58-60(50,51)54-12-20-25(57-59(47,48)49)24(43)30(56-20)39-15-38-22-27(33)36-14-37-28(22)39/h3-6,11,14-15,20,24-26,30,40,42-44H,7-10,12-13H2,1-2H3,(H,34,41)(H,35,45)(H,50,51)(H,52,53)(H2,33,36,37)(H2,47,48,49)/t20-,24-,25-,26+,30-/m1/s1",DHNA-CoA,KEGG COMPOUND accession,C15547
2274,52670,N'-hexanoyl-2-hydroxybenzohydrazide,A 2-hydroxy-substituted benzohydrazide having a hexanoyl group at the N'-position,"InChI=1S/C13H18N2O3/c1-2-3-4-9-12(17)14-15-13(18)10-7-5-6-8-11(10)16/h5-8,16H,2-4,9H2,1H3,(H,14,17)(H,15,18)",N-hexanoylsalicylhydrazide,Beilstein Registry Number,5556793
2275,52700,ortho-iodylbenzoic acid,A benzoic acid compound having an iodyl substituent at the ortho-position.,"InChI=1S/C7H5IO4/c9-7(10)5-3-1-2-4-6(5)8(11)12/h1-4H,(H,9,10)",o-iodylbenzoic acid,Beilstein Registry Number,2445017
2276,52787,dithiazanine,A cationic C3-cyanine dye with 3-ethylbenzothiazol-2-yl groups at both ends.,"InChI=1S/C23H23N2S2/c1-3-24-18-12-8-10-14-20(18)26-22(24)16-6-5-7-17-23-25(4-2)19-13-9-11-15-21(19)27-23/h5-17H,3-4H2,1-2H3/q+1","3,3'-diethylthiadicarbocyanine",CAS Registry Number,7187-55-5
2277,51433,cucurbit[8]uril,,"InChI=1S/C48H48N32O16/c81-33-49-1-50-18-20-54(34(50)82)4-58-22-24-62(38(58)86)8-66-26-28-70(42(66)90)12-74-30-32-78(46(74)94)15-77-31-29-73(45(77)93)11-69-27-25-65(41(69)89)7-61-23-21-57(37(61)85)3-53(33)19-17(49)51-2-52(18)36(84)56(20)6-60(22)40(88)64(24)10-68(26)44(92)72(28)14-76(30)48(96)80(32)16-79(31)47(95)75(29)13-71(27)43(91)67(25)9-63(23)39(87)59(21)5-55(19)35(51)83/h17-32H,1-16H2/t17-,18+,19+,20-,21-,22+,23+,24-,25-,26+,27+,28-,29-,30+,31+,32-",CB[8],Beilstein Registry Number,8895183
2278,51434,cucurbit[7]uril,,"InChI=1S/C42H42N28O14/c71-29-43-1-44-16-18-48(30(44)72)4-52-20-22-56(34(52)76)8-60-24-26-64(38(60)80)12-68-28-27-67(41(68)83)11-63-25-23-59(37(63)79)7-55-21-19-51(33(55)75)3-47(29)17-15(43)45-2-46(16)32(74)50(18)6-54(20)36(78)58(22)10-62(24)40(82)66(26)14-70(28)42(84)69(27)13-65(25)39(81)61(23)9-57(21)35(77)53(19)5-49(17)31(45)73/h15-28H,1-14H2/t15-,16+,17+,18-,19-,20+,21+,22-,23-,24+,25+,26-,27-,28+",CB[7],Beilstein Registry Number,9038507
2279,51435,cucurbit[5]uril,,"InChI=1S/C30H30N20O10/c51-21-31-1-32-12-14-36(22(32)52)4-40-16-18-44(26(40)56)8-48-20-19-47(29(48)59)7-43-17-15-39(25(43)55)3-35(21)13-11(31)33-2-34(12)24(54)38(14)6-42(16)28(58)46(18)10-50(20)30(60)49(19)9-45(17)27(57)41(15)5-37(13)23(33)53/h11-20H,1-10H2/t11-,12+,13+,14-,15-,16+,17+,18-,19-,20+",CB[5],Beilstein Registry Number,9036846
2280,53004,Ins-1-P-Cer(t18:0/2-OH-26:0),A ceramide phosphoinositol compound having a 2-hydroxyhexacosanoyl group attached to the ceramide nitrogen.,"InChI=1S/C50H100NO13P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-42(53)50(60)51-40(39-63-65(61,62)64-49-47(58)45(56)44(55)46(57)48(49)59)43(54)41(52)37-35-33-31-29-27-16-14-12-10-8-6-4-2/h40-49,52-59H,3-39H2,1-2H3,(H,51,60)(H,61,62)/t40-,41-,42-,43-,44-,45-,46+,47+,48+,49-/m0/s1",IPC,PubMed citation,7957179
2281,53005,Ins-1-P-6-Man-beta1-3-Ins-1-P-Cer(t18:0/2-OH-26:0),A inositol phosphomannosylinositol phosphoceramide compound having a 2-hydroxyhexacosanoyl group attached to the ceramide nitrogen.,"InChI=1S/C62H121NO26P2/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-43(65)61(79)63-41(45(66)42(64)37-35-33-31-29-27-16-14-12-10-8-6-4-2)39-84-90(80,81)89-60-55(76)51(72)52(73)58(57(60)78)87-62-56(77)47(68)46(67)44(86-62)40-85-91(82,83)88-59-53(74)49(70)48(69)50(71)54(59)75/h41-60,62,64-78H,3-40H2,1-2H3,(H,63,79)(H,80,81)(H,82,83)/t41-,42+,43?,44+,45-,46+,47-,48-,49-,50+,51-,52-,53+,54+,55+,56-,57+,58+,59-,60-,62-/m0/s1",MIP2C,PubMed citation,7957179
2282,52698,ortho-iodosylbenzoic acid,A benzoic acid compound having an iodosyl substituent at the ortho-position.,"InChI=1S/C7H5IO3/c9-7(10)5-3-1-2-4-6(5)8-11/h1-4H,(H,9,10)",o-iodosylbenzoic acid,Beilstein Registry Number,1939973
2283,52870,malachite green isothiocyanate cation,The iminium cation of malachite green isothiocyanate.,"InChI=1S/C24H24N3S/c1-26(2)22-13-7-19(8-14-22)24(18-5-11-21(12-6-18)25-17-28)20-9-15-23(16-10-20)27(3)4/h5-16H,1-4H3/q+1",malachite green isothiocyanate(1+),Beilstein Registry Number,6938342
2284,49695,krypton(0),,InChI=1S/Kr,KRYPTON,PDBeChem accession,KR
2285,49801,platinum dichloride,A platinum coordination entity consisting of platinum(II) bound to two chlorine atoms.,InChI=1S/2ClH.Pt/h2*1H;/q;;+2/p-2,PLATINUM(II) DI-CHLORIDE,PDBeChem accession,PCL
2286,52093,N-methylmorpholine N-oxide,A morpholine N-oxide resulting from the oxidation of the amino group of N-methylmorpholine.,"InChI=1S/C5H11NO2/c1-6(7)2-4-8-5-3-6/h2-5H2,1H3",NMO,CAS Registry Number,7529-22-8
2287,52445,tetracyanoquinodimethane,A quinodimethane that is p-quinodimethane in which the methylidene hydrogens are replaced by cyano groups.,InChI=1S/C12H4N4/c13-5-11(6-14)9-1-2-10(4-3-9)12(7-15)8-16/h1-4H,TCNQ,Beilstein Registry Number,611604
2288,52012,"1,3-dichloro-7-hydroxy-9,9-dimethyl-9H-acridin-2-one",,"InChI=1S/C15H11Cl2NO2/c1-15(2)8-5-7(19)3-4-10(8)18-11-6-9(16)14(20)13(17)12(11)15/h3-6,19H,1-2H3",DDAO dye,Beilstein Registry Number,5345288
2289,52111,DND-192 dye,,"InChI=1S/C20H24N2/c1-21(2)13-19-15-9-5-7-11-17(15)20(14-22(3)4)18-12-8-6-10-16(18)19/h5-12H,13-14H2,1-4H3",LysoSensor Blue DND-192,Beilstein Registry Number,8215847
2290,52113,DND-160 dye,,"InChI=1S/C20H22N4O3/c1-24(2)12-11-22-19(25)14-26-17-5-3-16(4-6-17)20-23-13-18(27-20)15-7-9-21-10-8-15/h3-10,13H,11-12,14H2,1-2H3,(H,22,25)",LysoSensor YellowBlue DND-160,Beilstein Registry Number,10579934
2291,52120,3-(5-chlorobenzoxazol-2-yl)-7-diethylaminocoumarin,,"InChI=1S/C20H17ClN2O3/c1-3-23(4-2)14-7-5-12-9-15(20(24)26-18(12)11-14)19-22-16-10-13(21)6-8-17(16)25-19/h5-11H,3-4H2,1-2H3",Macrolex Fluorescence Yellow 10GN,CAS Registry Number,35773-43-4
2292,52175,NIR-1 dye,,"InChI=1S/C38H42N2O11S3.2K/c1-6-39-31-19-17-27-28(23-26(53(46,47)48)24-32(27)54(49,50)51)35(31)38(4,5)34(39)15-11-9-7-8-10-14-33-37(2,3)29-22-25(36(41)42)16-18-30(29)40(33)20-12-13-21-52(43,44)45;;/h7-11,14-19,22-24H,6,12-13,20-21H2,1-5H3,(H3-,41,42,43,44,45,46,47,48,49,50,51);;/q;2*+1/p-2",Near infrared cromophore 1,Patent accession,WO03082988
2293,52176,NIR-2 dye,,"InChI=1S/C36H40N2O11S3.2K/c1-6-37-29-17-15-25-26(21-24(51(44,45)46)22-30(25)52(47,48)49)33(29)36(4,5)32(37)13-9-7-8-12-31-35(2,3)27-20-23(34(39)40)14-16-28(27)38(31)18-10-11-19-50(41,42)43;;/h7-9,12-17,20-22H,6,10-11,18-19H2,1-5H3,(H3-,39,40,41,42,43,44,45,46,47,48,49);;/q;2*+1/p-2",Near infrared 2,Patent accession,WO03082988
2294,52177,NIR-3 dye,,"InChI=1S/C36H44N2O11S3.2K/c1-35(2)28-24-26(34(39)40)16-18-30(28)37(20-10-12-22-50(41,42)43)32(35)14-8-6-5-7-9-15-33-36(3,4)29-25-27(52(47,48)49)17-19-31(29)38(33)21-11-13-23-51(44,45)46;;/h5-9,14-19,24-25H,10-13,20-23H2,1-4H3,(H3-,39,40,41,42,43,44,45,46,47,48,49);;/q;2*+1/p-2",NIR3,Patent accession,WO03082988
2295,52179,NIR-4 dye,,"InChI=1S/C34H42N2O11S3.2K/c1-33(2)26-22-24(32(37)38)14-16-28(26)35(18-8-10-20-48(39,40)41)30(33)12-6-5-7-13-31-34(3,4)27-23-25(50(45,46)47)15-17-29(27)36(31)19-9-11-21-49(42,43)44;;/h5-7,12-17,22-23H,8-11,18-21H2,1-4H3,(H3-,37,38,39,40,41,42,43,44,45,46,47);;/q;2*+1/p-2",NIR4,Patent accession,WO03082988
2296,52183,octaethylporphyrin,,"InChI=1S/C36H46N4/c1-9-21-22(10-2)30-18-32-25(13-5)26(14-6)34(39-32)20-36-28(16-8)27(15-7)35(40-36)19-33-24(12-4)23(11-3)31(38-33)17-29(21)37-30/h17-20,37,40H,9-16H2,1-8H3/b29-17-,30-18-,31-17-,32-18-,33-19-,34-20-,35-19-,36-20-",Octaethylporphyrine,Beilstein Registry Number,379798
2297,50983,dimethyl ethynylboronate,,"InChI=1S/C4H7BO2/c1-4-5(6-2)7-3/h1H,2-3H3",dimethyl ethynylboronate,CAS Registry Number,13722-62-8
2298,51674,"8-benzyloxy-5,7-diphenylquinoline(1+)",,"InChI=1S/C28H21NO/c1-4-11-21(12-5-1)20-30-28-26(23-15-8-3-9-16-23)19-25(22-13-6-2-7-14-22)24-17-10-18-29-27(24)28/h1-19H,20H2/p+1","8-Benzyloxy-5,7-diphenylquinoline protonated",Beilstein Registry Number,11044600
2299,52950,"(2S,3R)-3-farnesyl-2,3-dihydro-2,N(alpha)-cyclo-L-tryptophan",A cyclo-L-tryptophan derivative having a farnesyl group attached at the 3a-position.,"InChI=1S/C26H36N2O2/c1-18(2)9-7-10-19(3)11-8-12-20(4)15-16-26-17-23(24(29)30)28-25(26)27-22-14-6-5-13-21(22)26/h5-6,9,11,13-15,23,25,27-28H,7-8,10,12,16-17H2,1-4H3,(H,29,30)/b19-11+,20-15+/t23-,25+,26+/m0/s1","3'-farnesyl-2',3'-dihydro-2',N2-cyclo-L-tryptophan",RESID accession,AA0500
2300,47325,alpha-N-dichloroacetyl-p-aminophenylserinol,"A secondary carboxamide resulting from the formal condensation of the amino group of (1R,2R)-2-amino-1-(4-aminophenyl)propane-1,3-diol with the carboxy group of dichloroacetic acid. It is an intermediate used in the biosynthesis pathway of the antibiotic, chloramphenicol.","InChI=1S/C11H14Cl2N2O3/c12-10(13)11(18)15-8(5-16)9(17)6-1-3-7(14)4-2-6/h1-4,8-10,16-17H,5,14H2,(H,15,18)/t8-,9-/m1/s1","N-[(1R,2R)-2-(4-aminophenyl)-2-hydroxy-1-(hydroxymethyl)ethyl]-2,2-dichloroacetamide",PDBeChem accession,CLK
2301,52007,monodansylcadaverine,A sulfonamide obtained by formal condensation of the sulfo group of 5-(dimethylamino)naphthalene-1-sulfonic acid with one of the amino groups of cadaverine.,"InChI=1S/C17H25N3O2S/c1-20(2)16-10-6-9-15-14(16)8-7-11-17(15)23(21,22)19-13-5-3-4-12-18/h6-11,19H,3-5,12-13,18H2,1-2H3",dansylcadaverine,CAS Registry Number,10121-91-2
2302,47232,bromoethane,A bromoalkane that is ethane carrying a bromo substituent. It is an alkylating agent used as a chemical intermediate in various organic syntheses.,"InChI=1S/C2H5Br/c1-2-3/h2H2,1H3",1-bromoethane,PDBeChem accession,BBX
2303,53508,thyroxine sulfate,"An iodothyronine having iodo substituents in the 3-, 3'-, 5- and 5'-positions and a sulfate group attached to the phenol function.","InChI=1S/C15H11I4NO7S/c16-8-1-6(3-12(20)15(21)22)2-9(17)13(8)26-7-4-10(18)14(11(19)5-7)27-28(23,24)25/h1-2,4-5,12H,3,20H2,(H,21,22)(H,23,24,25)",T4S,CAS Registry Number,77074-49-8
2304,53436,ethylene glycol dimethacrylate,"The enoate ester that is the 1,2-bis(methacryloyl) derivative of ethylene glycol.","InChI=1S/C10H14O4/c1-7(2)9(11)13-5-6-14-10(12)8(3)4/h1,3,5-6H2,2,4H3",EGDMA,Beilstein Registry Number,1776663
2305,53440,2-hydroxypropyl methacrylate,"An enoate ester that is the 1-methacryloyl derivative of propane-1,2-diol.","InChI=1S/C7H12O3/c1-5(2)7(9)10-4-6(3)8/h6,8H,1,4H2,2-3H3",HPMA,Beilstein Registry Number,1752228
2306,53452,N-(1-naphthyl)ethylenediamine dihydrochloride,An ethylenediamine dihydrochloride compound having an N-(1-naphthyl) substituent.,"InChI=1S/C12H14N2.2ClH/c13-8-9-14-12-7-3-5-10-4-1-2-6-11(10)12;;/h1-7,14H,8-9,13H2;2*1H",Marshall's reagent,Beilstein Registry Number,3707471
2307,53454,"5,8,11-icosatriynoic acid","A C20 polyunsaturated fatty acid having three triple bonds in the 5-, 8- and 11-positions.","InChI=1S/C20H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h2-8,11,14,17-19H2,1H3,(H,21,22)","5,8,11-ETI",CAS Registry Number,13488-22-7
2308,53623,aurothiosulfate(3-),An inorganic anion that is a linear coordination complex of gold(I) bound to two thiosulfate ligands.,"InChI=1S/Au.2H2O3S2/c;2*1-5(2,3)4/h;2*(H2,1,2,3,4)/q+1;;/p-4","bis[sulfurothioic O,S-acidato(2-)-kappa(2)O,S]aurate(3-)",PubMed citation,12173648
2309,53635,neamine sulfate,An aminoglycoside sulfate salt that is the sulfate salt of neamine; a component of neomycin sulfate.,"InChI=1S/C12H26N4O6.2H2O4S/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20;2*1-5(2,3)4/h3-12,17-20H,1-2,13-16H2;2*(H2,1,2,3,4)/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-;;/m1../s1",neomycin A sulfate,Beilstein Registry Number,3825127
2310,53646,hydroxysugiresinol,A norlignan that is a derivative of sugiresinol in which the aromatic ring B has an additional hydroxy substituent.,"InChI=1S/C17H18O5/c18-12-4-1-10(2-5-12)17-8-13(16(21)9-22-17)11-3-6-14(19)15(20)7-11/h1-7,13,16-21H,8-9H2/t13-,16+,17+/m0/s1",sequirin B,Beilstein Registry Number,7272673
2311,53451,alpha-D-Manp-(1->3)-D-Manp,A glycosylmannose consisting of two D-mannopyranose residues joined via an alpha-(1->3)-linkage.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10+,11?,12-/m1/s1",M2(3),Beilstein Registry Number,1435318
2312,53456,alpha-L-Fuc-(1->3)-[beta-D-Xyl-(1->2)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)]-D-GlcNAc,A branched pentasaccharide consisting of an D-GlcNAc residue at the reducing end with a beta-D-Xyl(1->2)-beta-D-Man(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4)-linkage and a D-Fuc residue attached via an alpha-(1->3)-linkage.,"InChI=1S/C33H56N2O24/c1-8-17(42)21(46)24(49)32(52-8)58-27-16(35-10(3)40)29(50)53-14(6-38)26(27)57-30-15(34-9(2)39)20(45)25(13(5-37)55-30)56-33-28(22(47)19(44)12(4-36)54-33)59-31-23(48)18(43)11(41)7-51-31/h8,11-33,36-38,41-50H,4-7H2,1-3H3,(H,34,39)(H,35,40)/t8-,11+,12+,13+,14+,15+,16+,17+,18-,19+,20+,21+,22-,23+,24-,25+,26+,27+,28-,29?,30-,31-,32-,33-/m0/s1",00XF(3),PubMed citation,9621106
2313,53458,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched pentasaccharide consisting of a D-GlcNAc residue at the reducing end with an alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4) linkage.,"InChI=1S/C34H58N2O26/c1-8(41)35-15-20(46)27(12(5-39)55-30(15)53)60-31-16(36-9(2)42)21(47)28(13(6-40)58-31)61-34-26(52)29(62-33-25(51)23(49)18(44)11(4-38)57-33)19(45)14(59-34)7-54-32-24(50)22(48)17(43)10(3-37)56-32/h10-34,37-40,43-53H,3-7H2,1-2H3,(H,35,41)(H,36,42)/t10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25+,26+,27-,28-,29+,30?,31+,32+,33-,34+/m1/s1",MM,Beilstein Registry Number,7459252
2314,53462,alpha-L-Fucp-(1->6)-[alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc,A branched heptasaccharide derivative consisting of a GlcNAc residue at the reducing end with a Man-alpha(1->6)-[Xyl-beta(1->2)-Man-alpha(1->3)]-Man-beta(1->4)-GlcNAc moiety attached via a beta-(1->4)-linkage and a Fuc residue attached via an alpha-(1->6)-linkage.,"InChI=1S/C45H76N2O34/c1-10-21(54)28(61)32(65)41(72-10)71-9-18-36(26(59)19(39(68)73-18)46-11(2)51)78-40-20(47-12(3)52)27(60)35(16(6-50)76-40)79-44-34(67)37(25(58)17(77-44)8-70-42-33(66)29(62)23(56)14(4-48)74-42)80-45-38(30(63)24(57)15(5-49)75-45)81-43-31(64)22(55)13(53)7-69-43/h10,13-45,48-50,53-68H,4-9H2,1-3H3,(H,46,51)(H,47,52)/t10-,13-,14-,15-,16-,17-,18-,19-,20-,21+,22+,23-,24-,25-,26-,27-,28+,29+,30+,31-,32-,33+,34+,35-,36-,37+,38+,39?,40+,41+,42+,43+,44+,45-/m1/s1",MMXF(6),PubMed citation,9621106
2315,53464,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino hexasaccharide compound consisting of the linear trisaccharide beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine in which the mannosyl residue has a beta-D-xylosyl residue attached at position 2 as well as two alpha-D-mannosyl residues at positions 3 and 6.,"InChI=1S/C39H66N2O30/c1-9(46)40-17-23(53)30(14(5-44)63-34(17)60)68-35-18(41-10(2)47)24(54)31(15(6-45)66-35)69-39-33(71-37-27(57)19(49)11(48)7-61-37)32(70-38-29(59)26(56)21(51)13(4-43)65-38)22(52)16(67-39)8-62-36-28(58)25(55)20(50)12(3-42)64-36/h11-39,42-45,48-60H,3-8H2,1-2H3,(H,40,46)(H,41,47)/t11-,12-,13-,14-,15-,16-,17-,18-,19+,20-,21-,22-,23-,24-,25+,26+,27-,28+,29+,30-,31-,32+,33+,34?,35+,36+,37+,38-,39+/m1/s1",MMX,PubMed citation,9621106
2316,53465,alpha-L-Fucp-(1->3)-[alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc,A branched amino hexasaccharide compound consisting of a GlcNAc residue at the reducing end with a Man-alpha(1->3)-[Man-alpha(1->6)]-Man-beta(1->4)-GlcNAc moiety attached via a beta-(1->4)-linkage and a Fuc residue attached via an alpha-(1->3)-linkage.,"InChI=1S/C40H68N2O30/c1-9-19(49)24(54)28(58)38(63-9)71-33-18(42-11(3)48)35(61)64-15(7-46)32(33)70-36-17(41-10(2)47)23(53)31(14(6-45)67-36)69-40-30(60)34(72-39-29(59)26(56)21(51)13(5-44)66-39)22(52)16(68-40)8-62-37-27(57)25(55)20(50)12(4-43)65-37/h9,12-40,43-46,49-61H,4-8H2,1-3H3,(H,41,47)(H,42,48)/t9-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27-,28-,29-,30-,31+,32+,33+,34-,35?,36-,37-,38-,39+,40-/m0/s1",MMF(3),PubMed citation,9621106
2317,53469,alpha-L-Fucp-(1->3)-[alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc,A branched amino hexasaccharide consisting of a GlcNAc residue at the reducing end with a Man-alpha(1->6)-[Xyl-beta(1->2)]-Man-beta(1->4)-GlcNAc moiety attached via a beta-(1->4)-linkage and a Fuc residue attached via an alpha-(1->3)-linkage.,"InChI=1S/C39H66N2O29/c1-9-19(48)24(53)29(58)38(62-9)69-32-18(41-11(3)46)34(59)63-15(6-44)31(32)68-35-17(40-10(2)45)23(52)30(14(5-43)65-35)67-39-33(70-37-27(56)20(49)12(47)7-60-37)26(55)22(51)16(66-39)8-61-36-28(57)25(54)21(50)13(4-42)64-36/h9,12-39,42-44,47-59H,4-8H2,1-3H3,(H,40,45)(H,41,46)/t9-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25-,26-,27+,28-,29-,30+,31+,32+,33-,34?,35-,36-,37-,38-,39-/m0/s1",M0XF(3),Beilstein Registry Number,11224917
2318,53490,N-formyl-L-methionyl-L-leucyl-L-phenylalanine,"A tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor.","InChI=1S/C21H31N3O5S/c1-14(2)11-17(23-19(26)16(22-13-25)9-10-30-3)20(27)24-18(21(28)29)12-15-7-5-4-6-8-15/h4-8,13-14,16-18H,9-12H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1",fMetLeuPhe,CAS Registry Number,59880-97-6
2319,53668,3-bromo-L-tyrosine,A  bromoamino acid comprising an L-tyrosine core with a bromo- substituent ortho to the hydroxy group on the benzene ring.,"InChI=1S/C9H10BrNO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1",3-Bromo-L-tyrosine,Beilstein Registry Number,3204809
2320,53678,3-chloro-L-tyrosine,A chloroamino acid comprising a tyrosine core with a chloro- substituent ortho to the phenolic hydroxy group.,"InChI=1S/C9H10ClNO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1",3-chlorotyrosine,CAS Registry Number,7423-93-0
2321,53685,"3,5-dichloro-4-hydroxybenzoic acid",A derivative of p-salicylic acid with chloro- substituents at C-3 and C-5 of the benzene ring.,"InChI=1S/C7H4Cl2O3/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,10H,(H,11,12)",DiClHBz,PubMed citation,15589368
2322,53697,tyrosine-4-azobenzenearsonate,An L-tyrosine derivative having a 4-arsonophenyldiazenyl group at the 3-position of the benzene ring.,"InChI=1S/C15H16AsN3O6/c17-12(15(21)22)7-9-1-6-14(20)13(8-9)19-18-11-4-2-10(3-5-11)16(23,24)25/h1-6,8,12,20H,7,17H2,(H,21,22)(H2,23,24,25)/b19-18+/t12-/m0/s1",mono(p-azobenzenearsonic acid)tyrosine,CAS Registry Number,33650-94-1
2323,53711,hexa-L-lysine monohydrobromide,A compound comprising six covalently linked L-lysine residues ionically bound to hydrogen bromide.,"InChI=1S/C36H74N12O7.BrH/c37-19-7-1-13-25(43)31(49)44-26(14-2-8-20-38)32(50)45-27(15-3-9-21-39)33(51)46-28(16-4-10-22-40)34(52)47-29(17-5-11-23-41)35(53)48-30(36(54)55)18-6-12-24-42;/h25-30H,1-24,37-43H2,(H,44,49)(H,45,50)(H,46,51)(H,47,52)(H,48,53)(H,54,55);1H/t25-,26-,27-,28-,29-,30-;/m0./s1",poly-L-lysine hydrobromide (PLL6),PubMed citation,10930630
2324,53722,linoleylanilide,A fatty amide conjugate of linoleic acid and aniline.,"InChI=1S/C24H37NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-24(26)25-23-20-17-16-18-21-23/h6-7,9-10,16-18,20-21H,2-5,8,11-15,19,22H2,1H3,(H,25,26)/b7-6-,10-9-",linoleic acid anilide,PubMed citation,6205897
2325,53727,sulfamethoxydiazine,A sulfonamide consisting of pyrimidine having a methoxy substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 2-position.,"InChI=1S/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)",sulfamethoxidiazine,Beilstein Registry Number,621130
2326,53728,"2-[(2-{[2-({2,4-dinitro-5-[2,2,6,6-tetramethyl-1-(ylooxy)piperidin-4-ylamino]phenyl}amino)ethyl]amino}-2-oxoethoxy)acetamido]ethyl 1,2-dipalmitoylglycero-3-phosphate",An aminoxyl (nitroxide) free radical dipalmitoyl glycerophosphoethanolamine derivative used as a hapten in immunological investigations.,"InChI=1S/C58H103N7O16P/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-55(68)78-43-48(81-56(69)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)44-80-82(75,76)79-38-37-61-54(67)46-77-45-53(66)60-36-35-59-49-39-50(52(64(72)73)40-51(49)63(70)71)62-47-41-57(3,4)65(74)58(5,6)42-47/h39-40,47-48,59,62H,7-38,41-46H2,1-6H3,(H,60,66)(H,61,67)(H,75,76)/p-1",lipid hapten II,PubMed citation,7076676
2327,53732,4-tolyl isocyanate,An isocyanate comprising a benzene core with isocyanato and methyl substituents para to each other.,"InChI=1S/C8H7NO/c1-7-2-4-8(5-3-7)9-6-10/h2-5H,1H3",PTI,PubMed citation,4037253
2328,53499,D-GalNAc-(1->4)-D-GlcNAc-(1->6)-[D-GalNAc-(1->4)-[L-Fuc-(1->3)]-D-GlcNAc-(1->3)]-D-GalNAc-ol,An oligosaccharide derivative consisting of -D-GalNAc-ol at the reducing end with a D-GalNAc-(1->4)-D-GlcNAc moiety attached via a (1->6)-linkage and a [D-GalNAc-(1->4)-[L-Fuc-(1->3)]-D-GlcNAc] moiety attached via a (1->3)-linkage.,"InChI=1S/C46H79N5O30/c1-13-29(63)36(70)37(71)46(73-13)81-41-28(51-18(6)61)45(77-24(11-56)40(41)80-44-26(49-16(4)59)34(68)32(66)22(9-54)75-44)78-38(19(7-52)47-14(2)57)30(64)20(62)12-72-42-27(50-17(5)60)35(69)39(23(10-55)76-42)79-43-25(48-15(3)58)33(67)31(65)21(8-53)74-43/h13,19-46,52-56,62-71H,7-12H2,1-6H3,(H,47,57)(H,48,58)(H,49,59)(H,50,60)(H,51,61)/t13-,19-,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30-,31-,32-,33+,34+,35+,36+,37-,38+,39+,40+,41+,42?,43?,44?,45?,46?/m0/s1",HPG-Beta2-N7a,PubMed citation,2817893
2329,53501,D-GalNAc-(1->3)-D-GalNAc-(1->3)-[D-GalNAc-(1->2)-L-Fuc-(1->4)]-D-GlcNAc-(1->3)-[L-Fuc-(1->6)]-D-GalNAc-ol,An oligosaccharide derivative consisting of -D-GalNAc-ol at the reducing end with a D-GalNAc-(1->3)-D-GalNAc-(1->3)-[D-GalNAc-(1->2)-L-Fuc-(1->4)]-D-GlcNAc moiety attached via a (1->3)-linkage and a L-Fuc residue attached via a (1->6)-linkage.,"InChI=1S/C52H89N5O34/c1-14-31(69)39(77)41(79)51(81-14)80-13-22(68)33(71)42(21(8-58)53-16(3)63)87-50-30(57-20(7)67)45(90-49-29(56-19(6)66)44(36(74)25(11-61)85-49)89-47-27(54-17(4)64)37(75)34(72)23(9-59)83-47)43(26(12-62)86-50)88-52-46(40(78)32(70)15(2)82-52)91-48-28(55-18(5)65)38(76)35(73)24(10-60)84-48/h14-15,21-52,58-62,68-79H,8-13H2,1-7H3,(H,53,63)(H,54,64)(H,55,65)(H,56,66)(H,57,67)/t14-,15-,21-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33-,34-,35-,36-,37+,38+,39+,40+,41-,42+,43+,44+,45+,46-,47?,48?,49?,50?,51?,52?/m0/s1",HPG-Beta2-N8,PubMed citation,2817893
2330,53614,2-methyl-2-oxazoline,"A 5-membered heterocyclic compound, which is substituted in the 2-position with a methyl group and which is often used as a monomer in polymerisation reactions.","InChI=1S/C4H7NO/c1-4-5-2-3-6-4/h2-3H2,1H3",2-Methyl-2-oxazolin,CAS Registry Number,1120-64-5
2331,53487,"all-cis-docosa-7,10,13,16-tetraenoic acid","The all-cis-isomer of a C22 polyunsaturated fatty acid having four double bonds in the 7-, 10-, 13- and 16-positions. One of the most abundant fatty acids in the early human brain.","InChI=1S/C22H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,23,24)/b7-6-,10-9-,13-12-,16-15-",adrenic acid,PubMed citation,1532827
2332,53480,N-acetyl-D-galactosaminitol,A 2-deoxyhexitol derivative that is galactitol in which the 2-hydroxy substituent is replaced by an acetamido group.,"InChI=1S/C8H17NO6/c1-4(12)9-5(2-10)7(14)8(15)6(13)3-11/h5-8,10-11,13-15H,2-3H2,1H3,(H,9,12)/t5-,6+,7+,8-/m0/s1",HPG-Beta2-N1,Beilstein Registry Number,1727006
2333,53484,3-O-(N-acetyl-D-glucosaminyl)-N-acetyl-D-galactosaminitol,A 2-deoxy-D-glucoside consisting of N-acetyl-D-glucosamine attached to N-acetyl-D-galactosaminitol via a (1->3)-linkage.,"InChI=1S/C16H30N2O11/c1-6(22)17-8(3-19)15(12(25)9(24)4-20)29-16-11(18-7(2)23)14(27)13(26)10(5-21)28-16/h8-16,19-21,24-27H,3-5H2,1-2H3,(H,17,22)(H,18,23)/t8-,9+,10+,11+,12-,13+,14+,15+,16?/m0/s1",HPG-Beta2-N3,PubMed citation,2817893
2334,53485,N-acetyl-D-galactosaminyl-(1->4)-(N-acetyl-D-galactosaminyl)-(1->3)-N-acetyl-D-galactosaminitol,An amino disaccharide compound consisting of N-acetyl-D-galactosaminyl-(1->4)-N-acetyl-D-galactosamine attached to N-acetyl-D-galactosaminitol via a (1->3)-linkage.,"InChI=1S/C24H43N3O16/c1-8(32)25-11(4-28)21(17(36)12(35)5-29)42-24-16(27-10(3)34)20(39)22(14(7-31)41-24)43-23-15(26-9(2)33)19(38)18(37)13(6-30)40-23/h11-24,28-31,35-39H,4-7H2,1-3H3,(H,25,32)(H,26,33)(H,27,34)/t11-,12+,13+,14+,15+,16+,17-,18-,19+,20+,21+,22+,23?,24?/m0/s1",HPG-Beta2-N4a,PubMed citation,2817893
2335,53489,D-GalNAc-(1->3)-[D-GalNAc-(1->4)]-D-GalNAc-(1->3)-D-GalNAc-ol,An amino tetrasaccharide consisting of a D-GalNAc-(1->3)-[D-GalNAc-(1->4)]-D-GalNAc moiety attached to N-acetyl-D-galactosaminitol via a (1->3)-linkage.,"InChI=1S/C32H56N4O21/c1-10(42)33-14(5-37)27(22(47)15(46)6-38)55-32-21(36-13(4)45)29(57-31-20(35-12(3)44)26(51)24(49)17(8-40)53-31)28(18(9-41)54-32)56-30-19(34-11(2)43)25(50)23(48)16(7-39)52-30/h14-32,37-41,46-51H,5-9H2,1-4H3,(H,33,42)(H,34,43)(H,35,44)(H,36,45)/t14-,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-,25+,26+,27+,28+,29+,30?,31?,32?/m0/s1",HPG-Beta2-N4b,PubMed citation,2817893
2336,53755,1-linolenyl-2-linoleyl-PAP,"A  carboxylic ester that is a modified acyl glycerol with linolenyl and linoleyl entities at C-1 and C-2, respectively; and an anilino moiety at C-3.","InChI=1S/C45H71NO4/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34-38-44(47)49-41-43(40-46-42-36-32-31-33-37-42)50-45(48)39-35-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h5,7,11-14,17-20,31-33,36-37,43,46H,3-4,6,8-10,15-16,21-30,34-35,38-41H2,1-2H3/b7-5-,13-11-,14-12-,19-17-,20-18-","N-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trien-1-yloxy]propyl}aniline",PubMed citation,11304127
2337,53775,tergitol NP-9,A tergitol polymer consisting of nonylbenzene with a nine-membered poly(ethylene glycol) moiety attached at position 4.,"InChI=1S/C33H60O10/c1-2-3-4-5-6-7-8-9-32-10-12-33(13-11-32)43-31-30-42-29-28-41-27-26-40-25-24-39-23-22-38-21-20-37-19-18-36-17-16-35-15-14-34/h10-13,34H,2-9,14-31H2,1H3",Tergitol NP9,Beilstein Registry Number,2031786
2338,53786,alverine hydrochloride,The hydrochloride salt of alverine.,"InChI=1S/C20H27N.ClH/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20;/h3-8,11-14H,2,9-10,15-18H2,1H3;1H",Ethylbis(3-phenylpropyl)ammonium chloride,DrugBank accession,DB01616
2339,53790,(S)-aminoglutethimide,The (3R)-enantiomer of aminoglutethimide.,"InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)/t13-/m0/s1",(S)-(-)-aminoglutethimide,Beilstein Registry Number,5480359
2340,53751,linolenic acid anilide,A fatty amide conjugate of alpha-linolenic acid and aniline.,"InChI=1S/C24H35NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-24(26)25-23-20-17-16-18-21-23/h3-4,6-7,9-10,16-18,20-21H,2,5,8,11-15,19,22H2,1H3,(H,25,26)/b4-3-,7-6-,10-9-",linolenic anilide,PubMed citation,11304127
2341,55343,"1-((4-hydroxy-5-iodo-3-nitrophenyl)acetoxy)pyrrolidine-2,5-dione",The ester formed between N-hydroxysuccinimide and (4-hydroxy-5-iodo-3-nitrophenyl)acetic acid.,"InChI=1S/C12H9IN2O7/c13-7-3-6(4-8(12(7)19)15(20)21)5-11(18)22-14-9(16)1-2-10(14)17/h3-4,19H,1-2,5H2",NIP-O-Su,PubMed citation,6967910
2342,55349,deacetyllaurenobiolide,A germacranolide derived from laurenobiolide by deacetylation.,"InChI=1S/C15H20O3/c1-9-5-4-6-10(2)8-13-14(12(16)7-9)11(3)15(17)18-13/h6-7,12-14,16H,3-5,8H2,1-2H3/b9-7+,10-6+/t12-,13?,14?/m0/s1",deacetyl laurenobiolide,Beilstein Registry Number,6999911
2343,55353,"(2E)-but-2-ene-1,2,3-tricarboxylic acid","A tricarboxylic acid compound consisting of but-2-ene having carboxy substituents at the 1-, 2- and 3-positions.","InChI=1S/C7H8O6/c1-3(6(10)11)4(7(12)13)2-5(8)9/h2H2,1H3,(H,8,9)(H,10,11)(H,12,13)/b4-3+",trans-2-methylaconitic acid,PubMed citation,14702315
2344,55475,6-aminopenicilloyl-butylamine,An amide formed between 6-aminopenicillin and butylamine.,"InChI=1S/C12H23N3O3S/c1-4-5-6-14-9(16)7(13)10-15-8(11(17)18)12(2,3)19-10/h7-8,10,15H,4-6,13H2,1-3H3,(H,14,16)(H,17,18)/t7-,8+,10-/m1/s1",6-aminopenicilloyl butylamine,PubMed citation,7716788
2345,55442,6-aminopenicilloyl-benzylamine,Amide formed between 6-aminopenicillanic acid and benzylamine.,"InChI=1S/C15H21N3O3S/c1-15(2)11(14(20)21)18-13(22-15)10(16)12(19)17-8-9-6-4-3-5-7-9/h3-7,10-11,13,18H,8,16H2,1-2H3,(H,17,19)(H,20,21)/t10-,11+,13-/m1/s1","(2R,4S)-2-[(1R)-1-amino-2-(benzylamino)-2-oxoethyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxylic acid",PubMed citation,7544181
2346,55444,"2,5,5-trimethyl-1,3-thiazolidine-4-carboxylic acid","1,3-Thiazolidine substituted with methyl groups at C-2, -5 and -5 and with a carboxy group at C-4, representing the thiazolidine ring of a generalised penicillin structure.","InChI=1S/C7H13NO2S/c1-4-8-5(6(9)10)7(2,3)11-4/h4-5,8H,1-3H3,(H,9,10)",trimethylthiazolidin-4-carboxilic acid,PubMed citation,7589115
2347,55446,6-O-{5-hydroxy-4-oxo-3-[2-(sulfooxy)phenyl]-4H-chromen-6-yl}-L-gulonic acid,A polycyclic compound comprising a 5-hydroxy-4H-chromen-4-one core with 3-sulfooxyphenyl and 6-gulonate substituents; which can act as a non-peptide antigen.,"InChI=1S/C21H20O14S/c22-11(17(24)19(26)20(27)21(28)29)8-34-14-6-5-13-15(18(14)25)16(23)10(7-33-13)9-3-1-2-4-12(9)35-36(30,31)32/h1-7,11,17,19-20,22,24-27H,8H2,(H,28,29)(H,30,31,32)/t11-,17+,19-,20-/m0/s1",PjCHO,PubMed citation,10741415
2348,55447,6-O-{5-hydroxy-4-oxo-3-[2-(sulfooxy)phenyl]-4H-chromen-6-yl}-L-gulonate,The conjugate base of 6-O-{5-hydroxy-4-oxo-3-[2-(sulfooxy)phenyl]-4H-chromen-6-yl}-L-gulonic acid.,"InChI=1S/C21H20O14S/c22-11(17(24)19(26)20(27)21(28)29)8-34-14-6-5-13-15(18(14)25)16(23)10(7-33-13)9-3-1-2-4-12(9)35-36(30,31)32/h1-7,11,17,19-20,22,24-27H,8H2,(H,28,29)(H,30,31,32)/p-1/t11-,17+,19-,20-/m0/s1",PjCHO anion,PubMed citation,10741415
2349,55448,2-[1-({5-hydroxy-4-oxo-3-[2-(sulfonatooxy)phenyl]-4H-chromen-6-yl}oxy)-2-oxoethoxy]-3-oxopropanoate,A compound comprising a 2-(5-hydroxy-4-oxo-4H-chromen-3-yl)phenyl sulfate core with a 9-1-(1-carboxy-2-oxoethoxy)-2-oxoethanolate substituent; a product of 6-O-{5-hydroxy-4-oxo-3-[2-(sulfooxy)phenyl]-4H-chromen-6-yl}-L-gulonic acid oxidation.,"InChI=1S/C20H14O13S/c21-7-15(20(25)26)32-16(8-22)31-14-6-5-13-17(19(14)24)18(23)11(9-30-13)10-3-1-2-4-12(10)33-34(27,28)29/h1-9,15-16,24H,(H,25,26)(H,27,28,29)/p-2",NaIO4-treated PjCHO,PubMed citation,10741415
2350,55449,6-O-[5-hydroxy-3-(2-hydroxyphenyl)-4-oxo-4H-chromen-6-yl]-L-gulonic acid,The product of desulfonating 6-O-{5-hydroxy-4-oxo-3-[2-(sulfooxy)phenyl]-4H-chromen-6-yl}-L-gulonic acid.,"InChI=1S/C21H20O11/c22-11-4-2-1-3-9(11)10-7-31-13-5-6-14(18(26)15(13)16(10)24)32-8-12(23)17(25)19(27)20(28)21(29)30/h1-7,12,17,19-20,22-23,25-28H,8H2,(H,29,30)/t12-,17+,19-,20-/m0/s1",aryl sufatase-treated PjCHO,PubMed citation,10741415
2351,55451,lipoyl-AMP,A purine ribonucleoside 5'-monophosphate having adenine as the nucleobase and a lipoyl group attached to one of the phosphate OH groups.,"InChI=1S/C18H26N5O8PS2/c19-16-13-17(21-8-20-16)23(9-22-13)18-15(26)14(25)11(30-18)7-29-32(27,28)31-12(24)4-2-1-3-10-5-6-33-34-10/h8-11,14-15,18,25-26H,1-7H2,(H,27,28)(H2,19,20,21)/t10?,11-,14-,15-,18-/m1/s1",Lipoyl-AMP,KEGG COMPOUND accession,C16238
2352,55455,delphinidin 3-O-beta-D-glucoside-5-O-beta-D-glucoside,An anthocyanin cation consisting of delphinidin with two beta-D-glucosyl residues attached to the 3- and 5-hydroxy groups.,"InChI=1S/C27H30O17/c28-6-16-19(34)21(36)23(38)26(43-16)41-14-4-9(30)3-13-10(14)5-15(25(40-13)8-1-11(31)18(33)12(32)2-8)42-27-24(39)22(37)20(35)17(7-29)44-27/h1-5,16-17,19-24,26-29,34-39H,6-7H2,(H3-,30,31,32,33)/p+1/t16-,17-,19-,20-,21+,22+,23-,24-,26-,27-/m1/s1",Delphin,KEGG COMPOUND accession,C16312
2353,55473,ampicilloyl-butylamine,An amide formed between ampicillin and butylamine.,"InChI=1S/C20H30N4O4S/c1-4-5-11-22-17(26)14(18-24-15(19(27)28)20(2,3)29-18)23-16(25)13(21)12-9-7-6-8-10-12/h6-10,13-15,18,24H,4-5,11,21H2,1-3H3,(H,22,26)(H,23,25)(H,27,28)/t13-,14-,15+,18-/m1/s1",ampicilloyl butylamine,PubMed citation,7716788
2354,55496,coerulignone,"A dimeric cyclic ketone arising from enzymic oxidation of 2,6-dimethoxyphenol.","InChI=1S/C16H16O6/c1-19-11-5-9(6-12(20-2)15(11)17)10-7-13(21-3)16(18)14(8-10)22-4/h5-8H,1-4H3",Cerulignone,Beilstein Registry Number,1890068
2355,55524,monoethylglycinexylidide hydrochloride,The hydrochloride salt of monoethylglycinexylidide.,"InChI=1S/C12H18N2O.ClH/c1-4-13-8-11(15)14-12-9(2)6-5-7-10(12)3;/h5-7,13H,4,8H2,1-3H3,(H,14,15);1H",MEGX hydrochloride,PubMed citation,9989796
2356,55535,(R)-2-hydroxy-4-methylpentanoate,The anion of (R)-2-hydroxy-4-methylpentanoic acid.,"InChI=1S/C6H12O3/c1-4(2)3-5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)/p-1/t5-/m1/s1",(R)-2-hydroxy-4-methylvalerate,Beilstein Registry Number,5245806
2357,55537,"(2R,3S)-2-hydroxy-3-methylpentanoate","The conjugate base of (2R,3S)-2-hydroxy-3-methylpentanoic acid.","InChI=1S/C6H12O3/c1-3-4(2)5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)/p-1/t4-,5+/m0/s1","(2R,3S)-2-hydroxy-3-methylvalerate",Beilstein Registry Number,3904182
2358,59956,2-methyl-beta-carbolinium-6-ol,An organic cation consisting of beta-carboline having methyl and hydroxy substituents at the 2- and 6-positions respectively.,"InChI=1S/C12H10N2O/c1-14-5-4-9-10-6-8(15)2-3-11(10)13-12(9)7-14/h2-7,15H,1H3/p+1","2-methyl-9H-pyrido[3,4-b]indol-2-ium-6-ol",Beilstein Registry Number,10554962
2359,60653,1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine(1+),"A 1,2-diacyl-sn-glycero-3-phosphocholine in which the phosphatidyl acyl groups at positions 1 and 2 are stearoyl and oleoyl respectively.","InChI=1S/C44H86NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h21,23,42H,6-20,22,24-41H2,1-5H3/p+1/b23-21-/t42-/m1/s1",1-O-stearoyl-2-O-oleoyl-sn-glycero-3-phosphocholine,Reaxys Registry Number,6089730
2360,63692,"9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate","A dioxo monocarboxylic acid anion that is the conjugate base of 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oic acid, arising from deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C13H18O4/c1-13-7-6-10(14)8(2-5-12(16)17)9(13)3-4-11(13)15/h8-9H,2-7H2,1H3,(H,16,17)/p-1/t8-,9-,13-/m0/s1","9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oate(1-)",PubMed citation,16151114
2361,58961,N-arachidonoylglycine,Biologically active derivative of anandamide,"InChI=1S/C22H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21(24)23-20-22(25)26/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-20H2,1H3,(H,23,24)(H,25,26)/b7-6-,10-9-,13-12-,16-15-",NAGly,LIPID MAPS instance accession,LMFA08020003
2362,58963,procion orange MX-2R,"A 2,4-dichloro-1,3,5-triazine with a multi-substituted napthalen-2-yldiazenyl substituent at the 6-position.","InChI=1S/C24H16Cl2N6O10S3/c1-32(24-28-22(25)27-23(26)29-24)12-5-6-13-11(9-12)10-18(44(37,38)39)19(20(13)33)31-30-16-8-7-14-15(21(16)45(40,41)42)3-2-4-17(14)43(34,35)36/h2-10,33H,1H3,(H,34,35,36)(H,37,38,39)(H,40,41,42)",Procion Orange MX2R,CAS Registry Number,73816-75-8
2363,58966,"4,8,12-trimethyltridecanoic acid","A methyl-branched fatty acid consisting of tridecanoic acid having methyl substituents at positions 4, 8 and 12.","InChI=1S/C16H32O2/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-16(17)18/h13-15H,5-12H2,1-4H3,(H,17,18)","4,8,12-TMTD",CAS Registry Number,10339-73-8
2364,58976,p-azobenzenesulfonate,A benzenesulfonate that is the conjugate base of p-azobenzenesulfonic acid.,"InChI=1S/C12H10N2O3S/c15-18(16,17)12-8-6-11(7-9-12)14-13-10-4-2-1-3-5-10/h1-9H,(H,15,16,17)/p-1/b14-13+",4-(2-phenyldiazenyl)-benzenesulfonate,PubMed citation,77841
2365,58991,2-(p-hydroxyphenyl)glycinamide,The amino acid amide that is the amide of 2-(p-hydroxyphenyl)glycine.,"InChI=1S/C8H10N2O2/c9-7(8(10)12)5-1-3-6(11)4-2-5/h1-4,7,11H,9H2,(H2,10,12)",2-Amino-2-(p-hydroxyphenyl)acetamide,Beilstein Registry Number,2833949
2366,58992,"5-(2,3-dimethoxy-4-methylphenyl)pentanoic acid","A monocarboxylic acid consisting of valeric acid having a 2,3-dimethoxy-4-methylphenyl group attached to C-5.","InChI=1S/C14H20O4/c1-10-8-9-11(6-4-5-7-12(15)16)14(18-3)13(10)17-2/h8-9H,4-7H2,1-3H3,(H,15,16)",6-methyl catacid,PubMed citation,10651166
2367,58994,(+)-catechin monohydrate,The monohydrate of (+)-catechin.,"InChI=1S/C15H14O6.H2O/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7;/h1-5,13,15-20H,6H2;1H2/t13-,15+;/m0./s1",Catechin hydrate,CAS Registry Number,88191-48-4
2368,58995,4-(ethoxymethylene)-2-styryloxazol-5-one,"A 1,3-oxazole compound having a beta-styryl substituent at the 2-position, an ethoxymethylene group at the 4-position, and an oxo group at the 5-position.","InChI=1S/C14H13NO3/c1-2-17-10-12-14(16)18-13(15-12)9-8-11-6-4-3-5-7-11/h3-10H,2H2,1H3/b9-8+,12-10?",styryloxazolone,Beilstein Registry Number,21087
2369,59003,alpha-sulfophenylacetate,A monocarboxylic acid anion that is the conjugate base of alpha-sulfophenylacetic acid.,"InChI=1S/C8H8O5S/c9-8(10)7(14(11,12)13)6-4-2-1-3-5-6/h1-5,7H,(H,9,10)(H,11,12,13)/p-1",Alpha sulfophenyl acetate,PubMed citation,6166603
2370,59017,"N-{2-[(1,2-diphenylhydrazinyl)carbonyl]-2-hydroxyhexanoyl}-6-aminohexanoic acid","A  dicarboxylic acid diamide that is a derivative of butyl(hydroxy)malonic acid in which one carboxy group has formed a hydrazide with 1,2-diphenylhydrazine and the other an amide with 6-aminohexanoic acid.","InChI=1S/C25H33N3O5/c1-2-3-18-25(33,23(31)26-19-12-6-11-17-22(29)30)24(32)28(21-15-9-5-10-16-21)27-20-13-7-4-8-14-20/h4-5,7-10,13-16,27,33H,2-3,6,11-12,17-19H2,1H3,(H,26,31)(H,29,30)",Buto,PubMed citation,3425858
2371,59028,acetylstrophanthidin,An acetate ester that is strophanidin acetylated at the 3beta-hydroxy group.,"InChI=1S/C25H34O7/c1-15(27)32-17-3-8-23(14-26)19-4-7-22(2)18(16-11-21(28)31-13-16)6-10-25(22,30)20(19)5-9-24(23,29)12-17/h11,14,17-20,29-30H,3-10,12-13H2,1-2H3/t17-,18+,19-,20+,22+,23-,24-,25-/m0/s1",Acetyl-k-strophanthidine,CAS Registry Number,60-38-8
2372,59039,cromoglycate(2-),The dicarboxylate anion of cromoglycic acid.,"InChI=1S/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)/p-2",cromoglycate,Beilstein Registry Number,3659374
2373,59047,methyl 8-{[alpha-L-fucopyranosyl-(1->3)-[alpha-L-fucopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->4)]-2-acetamido-2-deoxy-beta-D-glucopyranosyl]oxy}nonanoate,An amino tetrasaccharide that is the 9-(methoxycarbonyl)-1-nonyl derivative of the Lewis Y polysaccharide.,"InChI=1S/C36H63NO21/c1-15-22(42)25(45)28(48)34(52-15)57-31-21(37-17(3)40)33(51-12-10-8-6-5-7-9-11-20(41)50-4)55-19(14-39)30(31)56-36-32(27(47)24(44)18(13-38)54-36)58-35-29(49)26(46)23(43)16(2)53-35/h15-16,18-19,21-36,38-39,42-49H,5-14H2,1-4H3,(H,37,40)/t15-,16-,18+,19+,21+,22+,23+,24-,25+,26+,27-,28-,29-,30+,31+,32+,33+,34-,35-,36-/m0/s1",nonoate methyl ester Lewis Y,PubMed citation,7664109
2374,59053,N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide,A carbodiimide having cyclcohexyl and 2-(4-morpholinyl)ethyl as the two N-substituents.,"InChI=1S/C13H23N3O/c1-2-4-13(5-3-1)15-12-14-6-7-16-8-10-17-11-9-16/h13H,1-11H2",CMCT,CAS Registry Number,15580-20-8
2375,59055,(S)-1-(4-bromoacetamidobenzyl)EDTA,A tetracarboxylic acid consisting of ethylenediaminetetraacetic acid having a 4-bromoacetamidobenzyl group at the C1-position and (S)-configuration.,"InChI=1S/C19H24BrN3O9/c20-6-15(24)21-13-3-1-12(2-4-13)5-14(23(10-18(29)30)11-19(31)32)7-22(8-16(25)26)9-17(27)28/h1-4,14H,5-11H2,(H,21,24)(H,25,26)(H,27,28)(H,29,30)(H,31,32)/t14-/m0/s1",Fe-BABE,CAS Registry Number,81677-64-7
2376,59075,4-allyl-2-isopropoxyphenol,A phenylpropanoid that is an analogue of eugenol in which an isopropoxy group replaces the methoxy group.,"InChI=1S/C12H16O2/c1-4-5-10-6-7-11(13)12(8-10)14-9(2)3/h4,6-9,13H,1,5H2,2-3H3",2-isopropoxy-4-allylphenol,PubMed citation,9084914
2377,59127,thiosalicylate(1-),Conjugate base of thiosalicylic acid.,"InChI=1S/C7H6O2S/c8-7(9)5-3-1-2-4-6(5)10/h1-4,10H,(H,8,9)/p-1",thiosalicylate,Gmelin Registry Number,83032
2378,59128,O-methylsalicylate,Conjugate base of O-methylsalicylic acid.,"InChI=1S/C8H8O3/c1-11-7-5-3-2-4-6(7)8(9)10/h2-5H,1H3,(H,9,10)/p-1",o-methoxybenzoic acid anion,Beilstein Registry Number,3905613
2379,59154,"(1R,4R)-4-isopropenyl-1-methyl-2-methylenecyclohexane","An alicyclic compound consisting of cyclohexane carrying methyl, methylidene and isopropenyl groups at positions 1-, 2- and 4 respectively.","InChI=1S/C11H18/c1-8(2)11-6-5-9(3)10(4)7-11/h9,11H,1,4-7H2,2-3H3/t9-,11-/m1/s1","(1R,4R)-1-methyl-2-methylene-4-(prop-1-en-2-yl)cyclohexane",Beilstein Registry Number,10429285
2380,59157,(+)-trans-2-menthene,A chiral monoterpene consisting of cyclohexene having isopropyl and methyl substitents at the 3- and 6-positions respectively.,"InChI=1S/C10H18/c1-8(2)10-6-4-9(3)5-7-10/h4,6,8-10H,5,7H2,1-3H3/t9-,10-/m0/s1",(+)-2-p-menthene,Beilstein Registry Number,2037958
2381,59165,balsalazide(2-),The dianion of balsalazide.,"InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/p-2/b20-19+",balsalazide dianion,Beilstein Registry Number,8233491
2382,59179,(R)-bambuterol,The (R)-enantiomer of bambuterol.,"InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3/t15-/m0/s1",(R)-terbutaline bisdimethylcarbamate,Reaxys Registry Number,14438331
2383,59199,calcium acetate monohydrate,The monohydrate of calcium acetate.,"InChI=1S/2C2H4O2.Ca.H2O/c2*1-2(3)4;;/h2*1H3,(H,3,4);;1H2/q;;+2;/p-2",calcium diacetate monohydrate,Gmelin Registry Number,44753
2384,59208,beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,A branched amino pentasaccharide consisting of the linear sequence beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc having a Neu5Ac residue attached to the inner galactose via an alpha-(2->3) linkage. The oligosaccharide of ganglioside GM1a.,"InChI=1S/C37H62N2O29/c1-9(45)38-17-11(47)3-37(36(58)59,67-30(17)19(49)12(48)4-40)68-31-26(56)35(64-27-15(7-43)60-32(57)24(54)23(27)53)63-16(8-44)28(31)65-33-18(39-10(2)46)29(21(51)14(6-42)61-33)66-34-25(55)22(52)20(50)13(5-41)62-34/h11-35,40-44,47-57H,3-8H2,1-2H3,(H,38,45)(H,39,46)(H,58,59)/t11-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21-,22-,23+,24+,25+,26+,27+,28-,29+,30+,31+,32+,33-,34-,35-,37-/m0/s1",GM1a carbohydrate moiety,Beilstein Registry Number,8754288
2385,59209,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,A branched amino hexasaccharide consisting of the linear sequence alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc having a Neu5Ac residue attached to a galactose via an alpha-(2->3) linkage. The oligosaccharide of ganglioside GD1a.,"InChI=1S/C48H79N3O37/c1-12(58)49-23-15(61)4-47(45(74)75,85-37(23)26(65)17(63)6-52)87-39-29(68)20(9-55)80-43(32(39)71)84-36-25(51-14(3)60)42(79-19(8-54)28(36)67)83-35-22(11-57)81-44(82-34-21(10-56)78-41(73)31(70)30(34)69)33(72)40(35)88-48(46(76)77)5-16(62)24(50-13(2)59)38(86-48)27(66)18(64)7-53/h15-44,52-57,61-73H,4-11H2,1-3H3,(H,49,58)(H,50,59)(H,51,60)(H,74,75)(H,76,77)/t15-,16-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28-,29-,30+,31+,32+,33+,34+,35-,36+,37+,38+,39-,40+,41+,42-,43-,44-,47-,48-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc,PubMed citation,12183547
2386,59210,alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp,"A linear amino tetrasaccharide consisting of two sialyl, one galactose and one glucose residue (at the reducing end) connected by sequential alpha-(2->8)-, alpha-(2->3)- and beta-(1->4)-linkages. The oligosaccharide of ganglioside GD3.","InChI=1S/C34H56N2O27/c1-9(41)35-17-11(43)3-33(31(53)54,61-26(17)19(46)13(45)5-37)60-15(7-39)21(48)27-18(36-10(2)42)12(44)4-34(62-27,32(55)56)63-28-20(47)14(6-38)58-30(24(28)51)59-25-16(8-40)57-29(52)23(50)22(25)49/h11-30,37-40,43-52H,3-8H2,1-2H3,(H,35,41)(H,36,42)(H,53,54)(H,55,56)/t11-,12-,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25+,26+,27+,28-,29+,30-,33+,34-/m0/s1",GD3 carbohydrate moiety,Beilstein Registry Number,5326295
2387,59212,alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-Gal-(1->4)-beta-Glc,"An amino oligosaccharide that is a branched octasaccharide derivative consisting of four sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end.","InChI=1S/C70H113N5O53/c1-18(84)71-35-23(89)6-67(63(106)107,123-53(35)40(95)27(93)10-76)121-31(14-80)44(99)55-37(73-20(3)86)25(91)8-69(125-55,65(110)111)127-57-43(98)30(13-79)116-61(48(57)103)120-52-39(75-22(5)88)60(115-29(12-78)42(52)97)119-51-34(17-83)117-62(118-50-33(16-82)114-59(105)47(102)46(50)101)49(104)58(51)128-70(66(112)113)9-26(92)38(74-21(4)87)56(126-70)45(100)32(15-81)122-68(64(108)109)7-24(90)36(72-19(2)85)54(124-68)41(96)28(94)11-77/h23-62,76-83,89-105H,6-17H2,1-5H3,(H,71,84)(H,72,85)(H,73,86)(H,74,87)(H,75,88)(H,106,107)(H,108,109)(H,110,111)(H,112,113)/t23-,24-,25-,26-,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51-,52+,53+,54+,55+,56+,57-,58+,59+,60-,61-,62-,67+,68+,69-,70-/m0/s1",GQ1b carbohydrate moiety,KEGG GLYCAN accession,G03932
2388,59215,alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,"A branched heptasaccharide derivative consisting of three sialyl residues, two galactose residues, one N-acetylglucosamine and a glucose residue at the reducing end. The oligosaccharide of ganglioside GT1a.","InChI=1S/C59H96N4O45/c1-15(71)60-29-19(75)5-57(54(90)91,104-45(29)33(80)22(78)8-64)103-26(12-68)37(84)47-31(62-17(3)73)21(77)6-58(106-47,55(92)93)107-48-36(83)25(11-67)98-52(40(48)87)102-44-32(63-18(4)74)51(97-24(10-66)35(44)82)101-43-28(14-70)99-53(100-42-27(13-69)96-50(89)39(86)38(42)85)41(88)49(43)108-59(56(94)95)7-20(76)30(61-16(2)72)46(105-59)34(81)23(79)9-65/h19-53,64-70,75-89H,5-14H2,1-4H3,(H,60,71)(H,61,72)(H,62,73)(H,63,74)(H,90,91)(H,92,93)(H,94,95)/t19-,20-,21-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35-,36-,37+,38+,39+,40+,41+,42+,43-,44+,45+,46+,47+,48-,49+,50+,51-,52-,53-,57+,58-,59-/m0/s1",alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc,PubMed citation,17130419
2389,59216,beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp,"An amino tetrasaccharide consisting of beta-D-galactose, N-acetyl-beta-D-galactosamine, beta-D-galactose and beta-D-glucose residues in a linear (1->3), (1->4), (1->4) sequence. It is the carbohydrate portion of ganglioside GA1.","InChI=1S/C26H45NO21/c1-6(32)27-11-22(48-25-18(39)14(35)12(33)7(2-28)44-25)13(34)8(3-29)43-24(11)46-21-10(5-31)45-26(19(40)16(21)37)47-20-9(4-30)42-23(41)17(38)15(20)36/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13+,14+,15-,16-,17-,18-,19-,20-,21+,22-,23-,24+,25+,26+/m1/s1",beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc,PubMed citation,11854201
2390,59217,cephapirin(1-),The anion of cephapirin obtained by removal of a proton form the carboxylic acid group.,"InChI=1S/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/p-1/t13-,16-/m1/s1",cephapirin anion,Beilstein Registry Number,4894074
2391,59218,beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc,"A branched amino pentasaccharide consisting of a linear sequence of two alpha-sialyl residues, a beta-D-galactosyl residue and an N-acetyl-beta-D-glucosamine residue linked respectively (2->8), (2->8) and (1->4), to the galactosyl residue of which is also linked (1->4) an N-acetyl-beta-D-glucosaminyl residue. It is the carbohydrate portion of ganglioside GD2.","InChI=1S/C42H69N3O32/c1-11(51)43-21-14(54)4-41(39(65)66,75-33(21)24(57)16(56)6-46)74-18(8-48)26(59)34-22(44-12(2)52)15(55)5-42(76-34,40(67)68)77-35-30(63)38(72-31-19(9-49)69-36(64)29(62)28(31)61)71-20(10-50)32(35)73-37-23(45-13(3)53)27(60)25(58)17(7-47)70-37/h14-38,46-50,54-64H,4-10H2,1-3H3,(H,43,51)(H,44,52)(H,45,53)(H,65,66)(H,67,68)/t14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26+,27+,28+,29+,30+,31+,32-,33+,34+,35+,36+,37-,38-,41+,42-/m0/s1",beta-D-GalpNAc-(1->4)-[alpha-NeupAc-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,PubMed citation,9317004
2392,59220,beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,A branched amino tetrasaccharide consisting of the linear sequence beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc having a Neu5Ac residue attached to the galactose via an alpha-(2->3) linkage. Corresponds to the carbohydrate portion of ganglioside GM2.,"InChI=1S/C31H52N2O24/c1-8(38)32-15-10(40)3-31(30(49)50,56-25(15)17(42)11(41)4-34)57-26-22(47)29(54-23-13(6-36)51-27(48)21(46)20(23)45)53-14(7-37)24(26)55-28-16(33-9(2)39)19(44)18(43)12(5-35)52-28/h10-29,34-37,40-48H,3-7H2,1-2H3,(H,32,38)(H,33,39)(H,49,50)/t10-,11+,12+,13+,14+,15+,16+,17+,18-,19+,20+,21+,22+,23+,24-,25+,26+,27+,28-,29-,31-/m0/s1",beta-D-GlcNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc,PubMed citation,10949532
2393,59221,beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,An amino hexasaccharide that is the carbohydrate portion of ganglioside GalNAc-GD1a.,"InChI=1S/C56H92N4O42/c1-14(68)57-27-18(72)5-55(53(86)87,99-44(27)31(76)20(74)7-61)101-46-38(83)51(95-40-24(11-65)90-48(85)37(82)36(40)81)93-26(13-67)42(46)97-50-30(60-17(4)71)43(34(79)23(10-64)92-50)98-52-39(84)47(41(25(12-66)94-52)96-49-29(59-16(3)70)35(80)33(78)22(9-63)91-49)102-56(54(88)89)6-19(73)28(58-15(2)69)45(100-56)32(77)21(75)8-62/h18-52,61-67,72-85H,5-13H2,1-4H3,(H,57,68)(H,58,69)(H,59,70)(H,60,71)(H,86,87)(H,88,89)/t18-,19-,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33-,34-,35+,36+,37+,38+,39+,40+,41-,42-,43+,44+,45+,46+,47+,48+,49-,50-,51-,52-,55-,56-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc,GlyTouCan accession,G92175CL
2394,59222,beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Gal-p-(1->4)-beta-D-Glcp,"A branched amino hexasaccharide comprising a beta-D-galactosyl-(1->4)-beta-D-glucose disaccharide, the galactosyl residue of which carries beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl and N-acetyl-alpha-neuraminyl-(2->8)-N-acetyl-alpha-neuraminyl disaccharide units through (2->4) and (2->3) linkages respectively. It is the carbohydrate portion of ganglioside GD1b.","InChI=1S/C48H79N3O37/c1-12(58)49-23-15(61)4-47(45(74)75,86-38(23)26(64)17(63)6-52)85-20(9-55)29(67)39-24(50-13(2)59)16(62)5-48(87-39,46(76)77)88-40-34(72)44(82-35-21(10-56)78-41(73)32(70)31(35)69)81-22(11-57)36(40)83-42-25(51-14(3)60)37(28(66)19(8-54)79-42)84-43-33(71)30(68)27(65)18(7-53)80-43/h15-44,52-57,61-73H,4-11H2,1-3H3,(H,49,58)(H,50,59)(H,51,60)(H,74,75)(H,76,77)/t15-,16-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28-,29+,30-,31+,32+,33+,34+,35+,36-,37+,38+,39+,40+,41+,42-,43-,44-,47+,48-/m0/s1",beta-Gal-(1->3)-beta-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-Gal-(1->4)-beta-Glc,PubMed citation,10949532
2395,59223,ceruletide diethylamine,The diethylamine salt of ceruletide.,"InChI=1S/C58H73N13O21S2.C4H11N/c1-29(72)49(71-57(87)40(23-31-12-14-33(15-13-31)92-94(89,90)91)68-56(86)43(26-48(78)79)69-52(82)37(16-18-44(59)73)65-51(81)36-17-19-45(74)63-36)58(88)62-28-46(75)64-41(24-32-27-61-35-11-7-6-10-34(32)35)54(84)66-38(20-21-93-2)53(83)70-42(25-47(76)77)55(85)67-39(50(60)80)22-30-8-4-3-5-9-30;1-3-5-4-2/h3-15,27,29,36-43,49,61,72H,16-26,28H2,1-2H3,(H2,59,73)(H2,60,80)(H,62,88)(H,63,74)(H,64,75)(H,65,81)(H,66,84)(H,67,85)(H,68,86)(H,69,82)(H,70,83)(H,71,87)(H,76,77)(H,78,79)(H,89,90,91);5H,3-4H2,1-2H3/t29-,36+,37+,38+,39+,40+,41+,42+,43+,49+;/m1./s1",caerulein diethylamine,CAS Registry Number,71247-25-1
2396,59225,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,"A branched amino heptasaccharide  comprising a beta-D-galactosyl-(1->4)-beta-D-glucose disaccharide, the galactosyl residue of which carries an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl trisaccharide unit and an N-acetyl-alpha-neuraminyl-(2->8)-N-acetyl-alpha-neuraminyl disaccharide unit through (2->4) and (2->3) linkages respectively. It corresponds to the carbohydrate portion of ganglioside GT1b.","InChI=1S/C59H96N4O45/c1-15(71)60-29-19(75)5-57(54(90)91,104-45(29)33(80)22(78)8-64)103-26(12-68)37(84)47-31(62-17(3)73)21(77)7-59(106-47,56(94)95)108-49-41(88)53(100-42-27(13-69)96-50(89)39(86)38(42)85)99-28(14-70)43(49)101-51-32(63-18(4)74)44(35(82)24(10-66)97-51)102-52-40(87)48(36(83)25(11-67)98-52)107-58(55(92)93)6-20(76)30(61-16(2)72)46(105-58)34(81)23(79)9-65/h19-53,64-70,75-89H,5-14H2,1-4H3,(H,60,71)(H,61,72)(H,62,73)(H,63,74)(H,90,91)(H,92,93)(H,94,95)/t19-,20-,21-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35-,36-,37+,38+,39+,40+,41+,42+,43-,44+,45+,46+,47+,48-,49+,50+,51-,52-,53-,57+,58-,59-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,PubMed citation,10949532
2397,59236,"4-(18,20-dihydroxy-26-methoxy-25-methyloctacosyl)phenyl 3,6-di-O-methyl-beta-D-Glc-(1->4)-2,3-di-O-methyl-alpha-L-Rha-(1->2)-3-O-methyl-alpha-L-Rha","A lipooligosaccharide consisting of a phenolic phthiocerol core linked to the trisaccharide 3,6-di-O-methyl-alpha-D-glucopyranosyl-(1->4)-2,3-di-O-methyl-alpha-L-rhamnopyranosyl-(1->2)-3-O-methyl-alpha-L-rhamnopyranose.","InChI=1S/C60H108O17/c1-11-47(67-6)40(2)30-28-29-33-45(62)38-44(61)32-27-25-23-21-19-17-15-13-12-14-16-18-20-22-24-26-31-43-34-36-46(37-35-43)74-60-57(54(69-8)49(63)41(3)72-60)77-59-56(71-10)55(70-9)52(42(4)73-59)76-58-51(65)53(68-7)50(64)48(75-58)39-66-5/h34-37,40-42,44-45,47-65H,11-33,38-39H2,1-10H3/t40-,41+,42+,44+,45-,47+,48-,49+,50-,51-,52+,53+,54-,55-,56-,57-,58-,59+,60+/m1/s1",deacylated phenolic glycolipid I,PubMed citation,6193065
2398,59245,5-amino-2-chlorobenzotrifluoride,A monochlorobenzene that is the 3-trifluoromethyl derivative of 4-chloroaniline.,"InChI=1S/C7H5ClF3N/c8-6-2-1-4(12)3-5(6)7(9,10)11/h1-3H,12H2",ACBT,Beilstein Registry Number,641588
2399,59249,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp,A tetrasaccharide comprising four mannosyl residues joined by alpha(1->2) linkages.,"InChI=1S/C24H42O21/c25-1-5-10(30)14(34)18(21(38)39-5)43-23-20(16(36)12(32)7(3-27)41-23)45-24-19(15(35)11(31)8(4-28)42-24)44-22-17(37)13(33)9(29)6(2-26)40-22/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21?,22-,23-,24-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-D-Man,Beilstein Registry Number,4222742
2400,59250,beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-D-Manp,A tetrasaccharide comprising four D-mannose residues joined by beta(1->2) linkages.,"InChI=1S/C24H42O21/c25-1-5-10(30)14(34)18(21(38)39-5)43-23-20(16(36)12(32)7(3-27)41-23)45-24-19(15(35)11(31)8(4-28)42-24)44-22-17(37)13(33)9(29)6(2-26)40-22/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21?,22+,23+,24+/m1/s1",beta-D-Man-(1->2)-beta-D-Man-(1->2)-beta-D-Man-(1->2)-D-Man,PubMed citation,12435690
2401,59273,dexbrompheniramine maleate,"The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine.  A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.","InChI=1S/C16H19BrN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1",(+)-brompheniramine maleate,CAS Registry Number,2391-03-9
2402,59286,alpha-tyvelopyranosyl-(1->3)-alpha-D-mannopyranose,A glycosylmannose consisting of alpha-D-mannopyranose having a tyvelopyranosyl residue attached via an alpha-(1->3)-linkage,"InChI=1S/C12H22O9/c1-4-5(14)2-6(15)12(19-4)21-10-8(16)7(3-13)20-11(18)9(10)17/h4-18H,2-3H2,1H3/t4-,5+,6+,7-,8-,9+,10+,11+,12-/m1/s1",alpha-Tyv-(1->3)-alpha-D-Man,PubMed citation,4139117
2403,59291,alpha-Kdo-(2->8)-alpha-Kdo,A disaccharide consisting of two 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl units joined via an alpha-(2->8)-linkage.,"InChI=1S/C16H26O15/c17-3-7(20)11-10(23)6(19)2-16(31-11,14(26)27)29-4-8(21)12-9(22)5(18)1-15(28,30-12)13(24)25/h5-12,17-23,28H,1-4H2,(H,24,25)(H,26,27)/t5-,6-,7-,8-,9-,10-,11-,12-,15-,16-/m1/s1",3-deoxy-8-O-(3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl)-alpha-D-manno-oct-2-ulopyranosonic acid,PubMed citation,1372290
2404,59294,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc,An alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-D-GlcpNAc where the glucosamine at the reducing end has beta-configuration at its anomeric centre. Commonly known as Lewis x trisaccharide or Le(x).,"InChI=1S/C20H35NO15/c1-5-10(25)12(27)14(29)19(32-5)36-17-9(21-6(2)24)18(31)33-8(4-23)16(17)35-20-15(30)13(28)11(26)7(3-22)34-20/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13-,14-,15+,16+,17+,18+,19-,20-/m0/s1",Lewis x trisaccharide,PubMed citation,11254599
2405,59295,beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc,A beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc where the glucosamine at the reducing end has beta-configuration at its anomeric centre.,"InChI=1S/C20H35NO15/c1-5-10(25)12(27)14(29)19(32-5)35-16-8(4-23)33-18(31)9(21-6(2)24)17(16)36-20-15(30)13(28)11(26)7(3-22)34-20/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13-,14-,15+,16+,17+,18+,19-,20-/m0/s1",beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc,Beilstein Registry Number,9105484
2406,59296,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc,"An amino trisaccharide consisting of alpha-L-fucose, beta-D-galactose and N-acetyl-beta-D-glucosamine residues joined by sequential (1->2)- and (1->3)-linkages.","InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)19(32-5)36-17-14(29)11(26)7(3-22)34-20(17)35-16-9(21-6(2)24)18(31)33-8(4-23)12(16)27/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18+,19-,20-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc,DrugBank accession,DB04679
2407,59308,beta-D-GlcpNAc-(1->3)-[alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->2)]-alpha-L-Rhap,A branched amino pentasaccharide consisting of four alpha-L-rhamnose residues (one at the reducing end) and a single beta-D-N-acetylglucosamine residue.,"InChI=1S/C32H55NO22/c1-7-14(36)20(42)22(44)30(48-7)54-26-21(43)15(37)8(2)50-32(26)52-24-16(38)10(4)49-31(23(24)45)55-27-25(17(39)9(3)47-28(27)46)53-29-13(33-11(5)35)19(41)18(40)12(6-34)51-29/h7-10,12-32,34,36-46H,6H2,1-5H3,(H,33,35)/t7-,8-,9-,10-,12+,13+,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29-,30-,31-,32-/m0/s1",beta-D-GlcNAc-(1->3)-[alpha-L-Rha-(1->2)-alpha-L-Rha-(1->3)-alpha-L-Rha-(1->2)]-alpha-L-Rha,PubMed citation,15186860
2408,59310,alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,"An aminotrisaccharide consisting of two rhamnose residues and one N-acetylglucosamine residue in a linear sequence, joined via alpha-linkages.","InChI=1S/C20H35NO14/c1-5-10(24)13(27)14(28)19(31-5)35-17-11(25)6(2)32-20(15(17)29)34-16-9(21-7(3)23)18(30)33-8(4-22)12(16)26/h5-6,8-20,22,24-30H,4H2,1-3H3,(H,21,23)/t5-,6-,8+,9+,10-,11-,12+,13+,14+,15+,16+,17+,18+,19-,20-/m0/s1",alpha-L-Rha-(1->3)-alpha-L-Rha-(1->3)-beta-D-GlcNAc,PubMed citation,16032350
2409,59312,alpha-L-Rhap-(1->3)-alpha-L-2-deoxy-Rhap-(1->3)-beta-D-GlcpNAc,"A trisaccharide consisting of rhamnose, 2-deoxyrhamnose and N-acetylglucosamine residues in a linear sequence, joined via alpha-linkages.","InChI=1S/C20H35NO13/c1-6-13(24)9(33-20-17(28)16(27)14(25)7(2)31-20)4-11(30-6)34-18-12(21-8(3)23)19(29)32-10(5-22)15(18)26/h6-7,9-20,22,24-29H,4-5H2,1-3H3,(H,21,23)/t6-,7-,9-,10+,11-,12+,13-,14-,15+,16+,17+,18+,19+,20-/m0/s1",alpha-L-Rha-(1->3)-alpha-L-2-deoxy-Rha-(1->3)-beta-D-GlcNAc,PubMed citation,12427018
2410,59313,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap,"A pentasaccharide consisting of four rhamnose residues (one at the reducing end) and one N-acetylglucosamine residue in a linear sequence, joined via alpha-linkages.","InChI=1S/C32H55NO22/c1-7-15(37)20(42)26(28(46)47-7)54-29-13(33-11(5)35)24(18(40)12(6-34)51-29)52-31-23(45)25(17(39)10(4)49-31)53-32-27(21(43)16(38)9(3)50-32)55-30-22(44)19(41)14(36)8(2)48-30/h7-10,12-32,34,36-46H,6H2,1-5H3,(H,33,35)/t7-,8-,9-,10-,12+,13+,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29-,30-,31-,32-/m0/s1",alpha-L-Rha-(1->2)-alpha-L-Rha-(1->3)-alpha-L-Rha-(1->3)-beta-D-GlcNAc-(1->2)-alpha-L-Rha,PubMed citation,12427018
2411,59314,alpha-D-Galp-(1->4)-beta-D-Galp,A disaccharide consisting of beta-D-galactopyranose having a D-galactopyranosyl residue attached at the 4-position via an alpha-linkage.,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10+,11-,12-/m1/s1",alpha-Galp-(1->4)-beta-Galp,Beilstein Registry Number,4845050
2412,59315,N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine,An N-acetyl-beta-D-glycosaminyl glycopeptide consisting of an N-acetyl-beta-D-glycosaminyl-(1->4)-N-acetylmuramoyl moiety attached to the amino terminus of the dipeptide L-alanyl-D-isoglutamine.,"InChI=1S/C27H45N5O16/c1-9(24(42)32-13(23(28)41)5-6-16(37)38)29-25(43)10(2)45-22-18(31-12(4)36)26(44)46-15(8-34)21(22)48-27-17(30-11(3)35)20(40)19(39)14(7-33)47-27/h9-10,13-15,17-22,26-27,33-34,39-40,44H,5-8H2,1-4H3,(H2,28,41)(H,29,43)(H,30,35)(H,31,36)(H,32,42)(H,37,38)/t9-,10+,13+,14+,15+,17+,18+,19+,20+,21+,22+,26+,27-/m0/s1",GMDP,Beilstein Registry Number,5722258
2413,59317,N-acetyl-D-galactosamine-6-phosphocholine,A galactose phosphate consisting of N-acetyl-D-galactosamine having a choline phosphate group at the 6-position.,"InChI=1S/C13H27N2O9P/c1-8(16)14-10-12(18)11(17)9(24-13(10)19)7-23-25(20,21)22-6-5-15(2,3)4/h9-13,17-19H,5-7H2,1-4H3,(H-,14,16,20,21)/p+1/t9-,10-,11+,12-,13?/m1/s1",GalNAc-ChoP,PubMed citation,15267227
2414,59319,alpha-D-Galp-(1->2)-[alpha-D-Abep-(1->3)]-alpha-D-Manp,"A branched trisaccharide consisting of D-abequose, D-galactose and D-mannose residues joined via alpha-linkages with mannose at the reducing end.","InChI=1S/C18H32O14/c1-5-6(21)2-7(22)17(28-5)31-14-11(24)9(4-20)29-16(27)15(14)32-18-13(26)12(25)10(23)8(3-19)30-18/h5-27H,2-4H2,1H3/t5-,6-,7-,8-,9-,10+,11-,12+,13-,14+,15+,16+,17-,18-/m1/s1",alpha-D-Gal(1->2)-[alpha-D-Abe-(1->3)]-alpha-D-Man,PubMed citation,7513555
2415,59349,cefepime(1+),The conjugate acid of cefepime.,"InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/p+1/b23-12-/t13-,17-/m1/s1",cefepime conjugate acid,Beilstein Registry Number,5196242
2416,59355,alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having an alpha-L-rhamnosyl residue attached at the 3-position.,"InChI=1S/C14H25NO10/c1-4-8(18)10(20)11(21)14(23-4)25-12-7(15-5(2)17)13(22)24-6(3-16)9(12)19/h4,6-14,16,18-22H,3H2,1-2H3,(H,15,17)/t4-,6+,7+,8-,9+,10+,11+,12+,13+,14-/m0/s1",alpha-L-Rha-(1->3)-beta-D-GlcNAc,PubMed citation,15979596
2417,59357,beta-D-GalpNAc-(1->4)-alpha-D-GalpNAc,An amino disaccharide consisting of N-acetyl-alpha-D-galactosamine having an N-acetyl-D-galactosaminyl residue attached at the 4-position via a beta-linkage. Important epitope forming part of the O-polysaccharides of some Gram-negative bacteria.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)14(8(4-20)27-15(9)26)29-16-10(18-6(2)22)12(24)11(23)7(3-19)28-16/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12-,13-,14+,15+,16+/m1/s1",beta-D-GalNAc-(1->4)-alpha-D-GalNAc,PubMed citation,16736109
2418,59358,cefotetan(2-),The dianion formed by removal of a proton from each of the carboxylic acid groups of cefotetan.,"InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/p-2/b12-6-/t13?,15-,17+/m1/s1",cefotetan dianion,Beilstein Registry Number,5701969
2419,59365,4-O-methyl-alpha-L-rhamnopyranosyl-(1->4)-2-O-methyl-alpha-L-fucopyranose,A disaccharide derivative consisting of 2-O-methyl-alpha-L-fucopyranose having a 4-O-methyl-alpha-L-rhamnopyranosyl residue attached at the 4-position.,"InChI=1S/C14H26O9/c1-5-10(19-3)7(15)8(16)14(22-5)23-11-6(2)21-13(18)12(20-4)9(11)17/h5-18H,1-4H3/t5-,6-,7-,8+,9+,10-,11+,12-,13+,14-/m0/s1",4-O-methyl-alpha-L-Rha-(1->4)-2-O-methyl-alpha-L-Fuc,PubMed citation,2476400
2420,59368,4-O-methyl-alpha-L-rhamnopyranose,A monosaccharide derivative that is the 4-O-methyl derivative of alpha-L-rhamnopyranose.,"InChI=1S/C7H14O5/c1-3-6(11-2)4(8)5(9)7(10)12-3/h3-10H,1-2H3/t3-,4-,5+,6-,7+/m0/s1",4-O-methyl-alpha-L-Rhap,Beilstein Registry Number,2499867
2421,59369,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,An amino pentasaccharide that is the core polysaccharide sequence for the O-antigen of the Gram-negative bacterium Shigella flexneri.,"InChI=1S/C32H55NO23/c1-7-14(37)18(41)21(44)29(48-7)56-27-20(43)15(38)8(2)49-32(27)55-26-23(46)31(54-25-13(33-10(4)36)28(47)51-12(6-35)17(25)40)50-9(3)24(26)53-30-22(45)19(42)16(39)11(5-34)52-30/h7-9,11-32,34-35,37-47H,5-6H2,1-4H3,(H,33,36)/t7-,8-,9-,11+,12+,13+,14-,15-,16+,17+,18+,19-,20+,21+,22+,23+,24-,25+,26-,27+,28+,29-,30+,31-,32-/m0/s1",6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-[alpha-D-glucopyranosyl-(1->4)]-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranose,PubMed citation,16424198
2422,59371,"4-O-acetyl-2,3-di-O-methyl-alpha-L-fucopyranosyl-(1->3)-alpha-L-rhamnopyranose","A glycosylrhamnose derivative consisting of alpha-L-rhamnopyranose having a 4-O-acetyl-2,3-di-O-methyl-alpha-L-galactopyranosyl residue attached at the 3-position.","InChI=1S/C16H28O10/c1-6-9(18)12(10(19)15(20)23-6)26-16-14(22-5)13(21-4)11(7(2)24-16)25-8(3)17/h6-7,9-16,18-20H,1-5H3/t6-,7-,9-,10+,11+,12+,13+,14-,15+,16-/m0/s1","4-Ac-2,3-di-O-Me-alpha-L-Fuc-(1->3)-alpha-L-Rha",PubMed citation,2476400
2423,59372,"4-O-acetyl-2,3-di-O-methyl-alpha-L-fucopyranose","A monosaccharide derivative  that is the 4-O-acetyl-2,3-di-O-methyl derivative of alpha-L-fucopyranose.","InChI=1S/C10H18O6/c1-5-7(16-6(2)11)8(13-3)9(14-4)10(12)15-5/h5,7-10,12H,1-4H3/t5-,7+,8+,9-,10+/m0/s1","4-Ac-2,3-di-O-Me-alpha-L-Fuc",PubMed citation,2476400
2424,59373,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,The branched decasaccharide formed when two molecules of the Shigella flexneri O-antigen core pentasaccharide alpha-L-Rha-(1->2)-alpha-L-Rha-(1->3)-[alpha-D-Glc-(1->4)]-alpha-L-Rha-(1->3)-beta-D-GlcNAc are joined end to end via beta-(1->2) linkages.,"InChI=1S/C64H108N2O45/c1-13-27(73)35(81)41(87)57(93-13)110-53-39(85)29(75)14(2)94-62(53)107-51-45(91)61(98-18(6)47(51)104-59-43(89)37(83)32(78)22(10-68)102-59)106-49-26(66-20(8)72)56(100-24(12-70)34(49)80)109-52-38(84)28(74)16(4)96-64(52)111-54-40(86)30(76)15(3)95-63(54)108-50-44(90)60(105-48-25(65-19(7)71)55(92)99-23(11-69)33(48)79)97-17(5)46(50)103-58-42(88)36(82)31(77)21(9-67)101-58/h13-18,21-64,67-70,73-92H,9-12H2,1-8H3,(H,65,71)(H,66,72)/t13-,14-,15-,16-,17-,18-,21+,22+,23+,24+,25+,26+,27-,28-,29-,30-,31+,32+,33+,34+,35+,36-,37-,38+,39+,40+,41+,42+,43+,44+,45+,46-,47-,48+,49+,50-,51-,52+,53+,54+,55+,56-,57-,58+,59+,60-,61-,62-,63-,64-/m0/s1",6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-[alpha-D-glucopyranosyl-(1->4)]-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-[alpha-D-glucopyranosyl-(1->4)]-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranose,PubMed citation,19328810
2425,59374,GPL-8,A glycopeptidolipid antigen from clinically prominent members of the Mycobacterium avium serocomplex.,"InChI=1S/C81H140N4O26/c1-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-41-44-56(86)46-59(87)84-57(45-55-42-39-38-40-43-55)74(95)85-60(75(96)83-50(3)73(94)82-49(2)47-102-76-65(92)70(100-10)67(99-9)54(7)107-76)51(4)104-79-72(63(90)61(88)52(5)106-79)110-77-64(91)69(62(89)53(6)105-77)109-78-66(93)71(101-11)68-58(108-78)48-103-81(8,111-68)80(97)98/h38-40,42-43,49-54,56-58,60-72,76-79,86,88-93H,12-37,41,44-48H2,1-11H3,(H,82,94)(H,83,96)(H,84,87)(H,85,95)(H,97,98)/t49-,50+,51+,52-,53-,54-,56?,57+,58+,60+,61+,62-,63+,64+,65+,66+,67-,68+,69+,70-,71+,72+,76?,77-,78-,79?,81-/m0/s1",Mycobacterium avium serocomplex glycopeptidolipid,PubMed citation,2476400
2426,59376,GPL-4,A glycopeptidolipid antigen from clinically prominent members of the Mycobacterium avium serocomplex.,"InChI=1S/C85H150N4O27/c1-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38-39-43-46-59(90)48-61(91)88-60(47-58-44-41-40-42-45-58)79(101)89-62(80(102)87-51(3)78(100)86-50(2)49-107-81-70(99)75(105-12)73(104-11)57(9)111-81)52(4)108-85-77(65(94)63(92)53(5)110-85)116-83-69(98)74(64(93)54(6)109-83)115-84-76(106-13)68(97)72(56(8)113-84)114-82-67(96)66(95)71(103-10)55(7)112-82/h40-42,44-45,50-57,59-60,62-77,81-85,90,92-99H,14-39,43,46-49H2,1-13H3,(H,86,100)(H,87,102)(H,88,91)(H,89,101)/t50-,51+,52+,53-,54-,55-,56-,57-,59?,60+,62+,63+,64-,65+,66-,67+,68+,69+,70+,71-,72+,73-,74+,75-,76-,77+,81?,82-,83-,84-,85?/m0/s1",Mycobacterium avium serocomplex glycopeptidolipid,PubMed citation,2476400
2427,59377,acetyl-GPL-2,A glycopeptidolipid antigen from clinically prominent members of the Mycobacterium avium serocomplex.,"InChI=1S/C81H142N4O24/c1-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38-39-43-46-59(87)48-61(88)84-60(47-58-44-41-40-42-45-58)76(95)85-62(77(96)83-51(3)75(94)82-50(2)49-101-78-67(93)71(98-11)68(97-10)55(7)105-78)52(4)102-80-72(65(91)63(89)53(5)104-80)109-79-66(92)70(64(90)54(6)103-79)108-81-74(100-13)73(99-12)69(56(8)106-81)107-57(9)86/h40-42,44-45,50-56,59-60,62-74,78-81,87,89-93H,14-39,43,46-49H2,1-13H3,(H,82,94)(H,83,96)(H,84,88)(H,85,95)/t50-,51+,52+,53-,54-,55-,56-,59?,60+,62+,63+,64-,65+,66+,67+,68-,69+,70+,71-,72+,73+,74-,78?,79-,80?,81-/m0/s1",Mycobacterium avium serocomplex glycopeptidolipid,PubMed citation,2476400
2428,59378,GPL-9I,A glycopeptidolipid antigen from clinically prominent members of the Mycobacterium avium serocomplex.,"InChI=1S/C95H164N4O34/c1-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38-39-40-41-42-46-49-63(101)51-65(102)98-64(50-62-47-44-43-45-48-62)87(111)99-66(88(112)97-54(3)86(110)96-53(2)52-121-90-73(109)78(116-12)74(115-11)58(7)125-90)55(4)122-93-80(69(105)67(103)56(5)124-93)132-92-72(108)77(68(104)57(6)123-92)130-94-85(120-16)82(118-14)76(60(9)127-94)129-91-71(107)70(106)79(83(133-91)89(113)114)131-95-84(119-15)81(117-13)75(59(8)126-95)128-61(10)100/h43-45,47-48,53-60,63-64,66-85,90-95,101,103-109H,17-42,46,49-52H2,1-16H3,(H,96,110)(H,97,112)(H,98,102)(H,99,111)(H,113,114)/t53-,54+,55+,56-,57-,58-,59-,60-,63?,64+,66+,67+,68-,69+,70+,71+,72+,73+,74-,75+,76+,77+,78-,79-,80+,81+,82+,83-,84-,85-,90?,91+,92-,93?,94-,95-/m0/s1",Mycobacterium avium serocomplex glycopeptidolipid,PubMed citation,2476400
2429,59379,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,The pentadecasaccharide formed when three molecules of the Shigella flexneri O-antigen core pentasaccharide alpha-L-Rha-(1->2)-alpha-L-Rha-(1->3)-[alpha-D-Glc-(1->4)]-alpha-L-Rha-(1->3)-beta-D-GlcNAc are joined end to end via beta-(1->2) linkages.,"InChI=1S/C96H161N3O67/c1-19-40(109)52(121)61(130)85(138-19)164-79-58(127)43(112)20(2)139-92(79)159-75-66(135)90(145-26(8)69(75)154-87-63(132)54(123)47(116)32(14-101)151-87)157-72-38(98-29(11)107)83(148-35(17-104)50(72)119)163-78-57(126)42(111)24(6)143-96(78)166-81-60(129)45(114)22(4)141-94(81)161-76-67(136)91(146-27(9)70(76)155-88-64(133)55(124)48(117)33(15-102)152-88)158-73-39(99-30(12)108)84(149-36(18-105)51(73)120)162-77-56(125)41(110)23(5)142-95(77)165-80-59(128)44(113)21(3)140-93(80)160-74-65(134)89(156-71-37(97-28(10)106)82(137)147-34(16-103)49(71)118)144-25(7)68(74)153-86-62(131)53(122)46(115)31(13-100)150-86/h19-27,31-96,100-105,109-137H,13-18H2,1-12H3,(H,97,106)(H,98,107)(H,99,108)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,31+,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42-,43-,44-,45-,46+,47+,48+,49+,50+,51+,52+,53-,54-,55-,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68-,69-,70-,71+,72+,73+,74-,75-,76-,77+,78+,79+,80+,81+,82+,83-,84-,85-,86+,87+,88+,89-,90-,91-,92-,93-,94-,95-,96-/m0/s1",6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-[alpha-D-glucopyranosyl-(1->4)]-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-[alpha-D-glucopyranosyl-(1->4)]-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranosyl-(1->3)-[alpha-D-glucopyranosyl-(1->4)]-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranose,PubMed citation,16424198
2430,59383,2-Me-alpha-D-Fucp4NAc-(1->4)-beta-D-GlcpA,"An amino disaccharide consisting of beta-D-glucopyranuronic acid having a 4-acetamido-4,6-dideoxy-2-O-methyl-alpha-L-galactopyranosyl attached at the 4-position.","InChI=1S/C15H25NO11/c1-4-6(16-5(2)17)7(18)11(24-3)15(25-4)27-10-8(19)9(20)14(23)26-12(10)13(21)22/h4,6-12,14-15,18-20,23H,1-3H3,(H,16,17)(H,21,22)/t4-,6+,7+,8+,9+,10-,11-,12-,14+,15-/m0/s1",2-Me-alpha-L-Fuc4NAc-(1->4)-beta-D-GlcA,PubMed citation,1284113
2431,59384,alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap,"A branched amino pentasaccharide consisting of a tetrasaccharide chain of alpha-D-glucose, alpha-L-rhamnose, N-acetyl-beta-D-glucosamine and alpha-L-rhamnose residues linked sequentially (1->4), (1->3) and (1->2), to the non-reducing rhamnose residue of which is also linked (1->3) a further alpha-L-rhamnose residue. Derived from the Shigella liposaccharide O-antigen, it shows antigenic properties.","InChI=1S/C32H55NO23/c1-7-15(38)20(43)27(28(47)48-7)56-29-13(33-10(4)36)25(17(40)12(6-35)51-29)54-32-23(46)26(55-30-21(44)18(41)14(37)8(2)49-30)24(9(3)50-32)53-31-22(45)19(42)16(39)11(5-34)52-31/h7-9,11-32,34-35,37-47H,5-6H2,1-4H3,(H,33,36)/t7-,8-,9-,11+,12+,13+,14-,15-,16+,17+,18+,19-,20+,21+,22+,23+,24-,25+,26-,27+,28+,29-,30-,31+,32-/m0/s1",6-deoxy-alpha-L-mannopyranosyl-(1->3)-[alpha-D-glucopyranosyl-(1->4)]-6-deoxy-alpha-L-mannopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->2)-6-deoxy-alpha-L-mannopyranose,PubMed citation,16424198
2432,59387,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-D-Galp,An amino trisaccharide consisting of an N-acetyl-D-glucosamine flanked by two D-galactose residues in a linear sequence.,"InChI=1S/C20H35NO16/c1-5(25)21-9-12(28)16(36-20-14(30)13(29)10(26)6(2-22)34-20)8(4-24)35-19(9)37-17-11(27)7(3-23)33-18(32)15(17)31/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12-,13+,14-,15-,16-,17+,18?,19+,20+/m1/s1",Paragloboside tbeta-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->3)-D-galactopyranoserisaccharide,Beilstein Registry Number,4620254
2433,59390,cephalexin sodium,The sodium salt of cephalexin.,"InChI=1S/C16H17N3O4S.Na/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9;/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23);/q;+1/p-1/t10-,11-,15-;/m1./s1",cefalexin sodium,Beilstein Registry Number,8376600
2434,59393,alpha-D-GlcpNAc-(1->2)-alpha-D-Glcp,An amino disaccharide consisting of an alpha-D-glucose residue having an N-acetyl-alpha-D-glucosaminyl residue attached at the 2-position.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)6(3-17)25-14(7)26-12-11(22)9(20)5(2-16)24-13(12)23/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10-,11+,12-,13+,14-/m1/s1",Salmonella outer core terminal disaccharide,Beilstein Registry Number,8364777
2435,59395,beta-D-Glcp(1->6)-alpha-D-GlcpNAc-(1->3)-alpha-L-QuipNAc-(1->3)-beta-D-GlcpNAc,"A linear tetrasaccharide derivative consisting of beta-D-glucose, N-acetyl-alpha-D-fucosamine, N-acetyl-alpha-L-quinovosamine and N-acetyl-beta-D-glucosamine residues linked sequentially (1->6), (1->3) and (1->3). It forms an important epitope of the Proteus vulgaris O-specific polysaccharide.","InChI=1S/C30H51N3O20/c1-8-18(39)26(17(33-11(4)38)29(48-8)52-25-16(32-10(3)37)27(46)49-13(6-35)21(25)42)53-28-15(31-9(2)36)22(43)20(41)14(51-28)7-47-30-24(45)23(44)19(40)12(5-34)50-30/h8,12-30,34-35,39-46H,5-7H2,1-4H3,(H,31,36)(H,32,37)(H,33,38)/t8-,12+,13+,14+,15+,16+,17-,18-,19+,20+,21+,22+,23-,24+,25+,26-,27+,28+,29-,30+/m0/s1",beta-D-glucopyranosyl-(1->6)-2-acetamido-2-deoxy-alpha-D-glucopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-L-quinovopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucopyranose,PubMed citation,1715274
2436,59399,glutathione amide,The dicarboxylic acid monoamide arising by formal condensation of the carboxylic acid group of the glycine residue of glutathione with ammonia.,"InChI=1S/C10H18N4O5S/c11-5(10(18)19)1-2-8(16)14-6(4-20)9(17)13-3-7(12)15/h5-6,20H,1-4,11H2,(H2,12,15)(H,13,17)(H,14,16)(H,18,19)/t5-,6-/m0/s1",GASH,Beilstein Registry Number,9653842
2437,59400,alpha-D-Galp-(1->2)-[alpha-D-Abep-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap,"A branched tetrasaccharide consisting of alpha-D-galactose, alpha-D-mannose and alpha-L-rhamnose residues linked sequentially (1->2) and (1->4), to the mannose residue of which is also linked (1->3) an alpha-D-abequose residue. The structure constitutes a possible epitope of the O-antigen polysaccharide in Salmonella.","InChI=1S/C24H42O18/c1-6-8(27)3-9(28)22(37-6)41-19-13(30)11(5-26)39-24(40-18-7(2)36-21(35)16(33)15(18)32)20(19)42-23-17(34)14(31)12(29)10(4-25)38-23/h6-35H,3-5H2,1-2H3/t6-,7+,8-,9-,10-,11-,12+,13-,14+,15+,16-,17-,18+,19+,20+,21-,22-,23-,24-/m1/s1",alpha-D-abequopyranosyl-(1->3)-[alpha-D-galactopyranosyl-(1->2)]-alpha-D-mannopyranosyl-(1->4)-alpha-L-rhamnopyranose,PubMed citation,10640784
2438,59404,alpha-D-Abep-(1->3)-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-Galp,"A tetrasaccharide consisting of alpha-D-abequose, alpha-D-mannose, alpha-L-rhamnose and alpha-D-galactose residues linked sequentially (1->3), (1->4) and (1->3); epitope of the O-antigen polysaccharide in Salmonella.","InChI=1S/C24H42O18/c1-6-8(27)3-9(28)22(36-6)41-20-13(30)11(5-26)39-24(17(20)34)40-18-7(2)37-23(15(32)14(18)31)42-19-12(29)10(4-25)38-21(35)16(19)33/h6-35H,3-5H2,1-2H3/t6-,7+,8-,9-,10-,11-,12+,13-,14+,15-,16-,17+,18+,19+,20+,21+,22-,23+,24-/m1/s1",alpha-D-abequopyranosyl-(1->3)-alpha-D-mannopyranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1->3)-alpha-D-galactopyranose,PubMed citation,1378926
2439,59410,3-epi-6-deoxocathasterone,The 3-alpha-hydroxy epimer of 6-deoxocathasterone.,"InChI=1S/C28H50O2/c1-17(2)18(3)15-26(30)19(4)23-9-10-24-22-8-7-20-16-21(29)11-13-27(20,5)25(22)12-14-28(23,24)6/h17-26,29-30H,7-16H2,1-6H3/t18-,19+,20+,21-,22+,23-,24+,25+,26+,27+,28-/m1/s1","(3alpha,5alpha,22S,24R)-ergostane-3,22-diol",Beilstein Registry Number,8522106
2440,59411,"(5alpha,22S,24R)-22-hydroxyergostan-3-one",A brassinosteroid that is 6-deoxocathasterone in which the hydroxy group at position 3 has been oxidised to the corresponding ketone.,"InChI=1S/C28H48O2/c1-17(2)18(3)15-26(30)19(4)23-9-10-24-22-8-7-20-16-21(29)11-13-27(20,5)25(22)12-14-28(23,24)6/h17-20,22-26,30H,7-16H2,1-6H3/t18-,19+,20+,22+,23-,24+,25+,26+,27+,28-/m1/s1","(5alpha,22S,24R)-22-hydroxyergostan-3-one",Beilstein Registry Number,8005941
2441,59415,L-Thr-(N->6)-alpha-D-Galp6d3OAc-(1->3)-beta-D-GalpNAc,"An L-threonine derivative in which L-threonine is linked via its nitrogen to C-6 of the non-reducing-end galactose residue of 3-O-acetyl-alpha-D-galacto-hexodialdo-1,5-pyranosyl-(1->3)-N-acetyl-acetamido-2-deoxy-beta-D-galactosamine; an important threonine-containing epitope of the Proteus penneri O-specific polysaccharide.","InChI=1S/C20H32N2O15/c1-5(24)9(18(31)32)22-17(30)16-12(28)15(34-7(3)26)13(29)20(37-16)36-14-10(21-6(2)25)19(33)35-8(4-23)11(14)27/h5,8-16,19-20,23-24,27-29,33H,4H2,1-3H3,(H,21,25)(H,22,30)(H,31,32)/t5-,8-,9+,10-,11+,12-,13-,14-,15+,16+,19-,20+/m1/s1",L-Thr-6-alpha-D-GalA-3-OAc-(1->3)-beta-D-Gal-NAc,PubMed citation,7541754
2442,59422,2-O-acetyl-alpha-L-rhamnose,A monosaccharide derivative that is the 2-O-acetyl derivative of alpha-L-rhamnose.,"InChI=1S/C8H14O6/c1-3-5(10)6(11)7(8(12)13-3)14-4(2)9/h3,5-8,10-12H,1-2H3/t3-,5-,6+,7+,8+/m0/s1",2-O-acetyl alpha-L-Rhap,PubMed citation,2424840
2443,59423,"1-hexadecanoyl-2-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phosphocholine","A 1,2-diacyl-sn-glycero-3-phosphocholine(1+) in which the acyl groups at C-1 and C-2 are hexadecanoyl and 6-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]hexanoyl respectively.","InChI=1S/C36H62N5O11P/c1-5-6-7-8-9-10-11-12-13-14-15-16-18-21-33(42)48-28-30(29-50-53(46,47)49-27-26-41(2,3)4)51-34(43)22-19-17-20-25-37-31-23-24-32(40(44)45)36-35(31)38-52-39-36/h23-24,30H,5-22,25-29H2,1-4H3,(H-,37,39,46,47)/p+1/t30-/m1/s1","2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine",CAS Registry Number,81005-34-7
2444,59429,"N-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine","An N-acylsphingosine that is sphingosine with the amino nitrogen converted into a 6-{[N-(7-nitrobenzo-2,1,3-oxadiazol-4-yl)amino]}hexananamido group.","InChI=1S/C30H49N5O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-27(37)25(23-36)32-28(38)19-16-14-17-22-31-24-20-21-26(35(39)40)30-29(24)33-41-34-30/h15,18,20-21,25,27,31,36-37H,2-14,16-17,19,22-23H2,1H3,(H,32,38)/b18-15+/t25-,27+/m0/s1","6-((N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl)sphingosine",CAS Registry Number,86701-10-2
2445,59432,alpha-D-Galp-(1->2)-D-Galp,A glycosylgalactose comprising two D-galactose units joined via an alpha-(1->2) linkage.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11?,12-/m1/s1",alpha-D-galactosyl-(1->2)-D-galactose,Beilstein Registry Number,5758734
2446,59433,2-phospho-L-lactate,The dianion obtained by removal of two acidic protons from 2-phospho-L-lactic acid.,"InChI=1S/C3H7O6P/c1-2(3(4)5)9-10(6,7)8/h2H,1H3,(H,4,5)(H2,6,7,8)/p-2/t2-/m0/s1",2-phospho-L-lactate dianion,Beilstein Registry Number,3669296
2447,59435,L-lactyl-2-diphospho-5'-guanosine(3-),The trianion obtained by removal of protons from the carboxylic acid and phosphate groups of L-lactyl-2-diphospho-5'-guanosine.,"InChI=1S/C13H19N5O13P2/c1-4(12(22)23)30-33(26,27)31-32(24,25)28-2-5-7(19)8(20)11(29-5)18-3-15-6-9(18)16-13(14)17-10(6)21/h3-5,7-8,11,19-20H,2H2,1H3,(H,22,23)(H,24,25)(H,26,27)(H3,14,16,17,21)/p-3/t4-,5+,7+,8+,11+/m0/s1",(S)-lactyl-2-diphospho-5'-guanosine(3-),PubMed citation,18260642
2448,59443,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,An alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-Glc having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)12(27)17(31-4)34-15-8(23)5(2-20)32-18(13(15)28)33-14-6(3-21)30-16(29)11(26)10(14)25/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10-,11-,12-,13-,14-,15+,16-,17-,18+/m1/s1",alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucose,Beilstein Registry Number,7343634
2449,59446,1-O-(alpha-D-galactopyranosyl)-N-tetracosanylphytosphingosine,A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and a tetracosanoyl group attached to the nitrogen.,"InChI=1S/C48H95NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-43(52)49-40(39-57-48-47(56)46(55)45(54)42(38-50)58-48)44(53)41(51)36-34-32-30-28-26-16-14-12-10-8-6-4-2/h40-42,44-48,50-51,53-56H,3-39H2,1-2H3,(H,49,52)/t40-,41+,42+,44-,45-,46-,47+,48-/m0/s1","(2S,3S,4R)-1-O-(alpha-D-galactosyl)-N-tetracosanoyl-2-amino-1,3,4-octadecanetriol",Beilstein Registry Number,7326245
2450,59470,"alpha-L-Rhap2,3Me2-(1->2)-alpha-L-Rhap3Me","A disaccharide derivative consisting of 3-O-methyl-alpha-L-rhamnose having a 2,3-di-O-methyl-alpha-L-rhamnosyl residue attached at the 2-position.","InChI=1S/C15H28O9/c1-6-8(16)10(19-3)12(14(18)22-6)24-15-13(21-5)11(20-4)9(17)7(2)23-15/h6-18H,1-5H3/t6-,7-,8-,9-,10+,11+,12+,13+,14+,15-/m0/s1",Mycobacterium leprae PGL-1 inner disaccharide,PubMed citation,9465158
2451,59471,alpha-L-Rhap-(1->2)-[beta-D-GlcpNAc-(1->3)]-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->2)-[beta-D-GlcpNAc-(1->3)]-alpha-L-Rhap,A branched amino hexasaccharide consisting of four alpha-L-rhamnose residues (one at the reducing end) and two beta-D-N-acetylglucosamine residues linked as shown.,"InChI=1S/C40H68N2O27/c1-9-19(47)27(55)28(56)38(60-9)69-34-32(67-37-18(42-14(6)46)26(54)24(52)16(8-44)64-37)22(50)12(4)62-40(34)65-30-20(48)11(3)61-39(29(30)57)68-33-31(21(49)10(2)59-35(33)58)66-36-17(41-13(5)45)25(53)23(51)15(7-43)63-36/h9-12,15-40,43-44,47-58H,7-8H2,1-6H3,(H,41,45)(H,42,46)/t9-,10-,11-,12-,15+,16+,17+,18+,19-,20-,21-,22-,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36-,37-,38-,39-,40-/m0/s1",Hexa 2,PubMed citation,12487612
2452,59478,"1-O-(hexadec-1-enyl)-2-O-octadeca-9,12-dienoyl-sn-glycero-3-phosphoethanolamine","A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine that is the 1-O-(hexadec-1-enyl)-2-O-octadeca-9,12-dienoyl derivative of sn-glycero-3-phosphoethanolamine.","InChI=1S/C39H74NO7P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-39(41)47-38(37-46-48(42,43)45-35-33-40)36-44-34-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,31,34,38H,3-10,12,14-16,18,20-30,32-33,35-37,40H2,1-2H3,(H,42,43)/b13-11+,19-17+,34-31+/t38-/m1/s1",1-O-(hexadec-1-enyl)-2-O-octadecadienoyl-sn-glycero-3-phosphoethanolamine,PubMed citation,10080387
2453,59479,(R)-chlorphenesin,The (R)-enantiomer of chlorphenesin.,"InChI=1S/C9H11ClO3/c10-7-1-3-9(4-2-7)13-6-8(12)5-11/h1-4,8,11-12H,5-6H2/t8-/m1/s1",(R)-p-chlorophenyl-alpha-glyceryl ether,Beilstein Registry Number,6175744
2454,59481,alpha-D-Galp-(1->4)-alpha-D-Galp-(1->4)-beta-D-Glcp,A trisaccharide consisting of two alpha-D-galactose residues and a beta-D-glucose at the reducing end in a linear sequence and joined by (1->4) linkages.,"InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14-,15+,16-,17-,18-/m1/s1",alpha-Gal-(1->4)-alpha-Gal-(1->4)-beta-Glc,PubMed citation,8559043
2455,59484,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->4)-beta-D-Glcp,A linear tetrasaccharide consisting of two adjacent D-galactose residues and two adjacent beta-D-glucose residues (one at the reducing end) joined by (1->4) linkages.,"InChI=1S/C24H42O21/c25-1-5-9(29)10(30)15(35)22(40-5)44-19-7(3-27)42-24(17(37)12(19)32)45-20-8(4-28)41-23(16(36)13(20)33)43-18-6(2-26)39-21(38)14(34)11(18)31/h5-38H,1-4H2/t5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16-,17-,18-,19+,20-,21-,22-,23+,24+/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1->4)-beta-D-Glc,PubMed citation,15784565
2456,59485,L-alpha-D-Hepp-(1->2)-L-alpha-D-Hepp-(1->3)-[beta-Glcp-(1->4)]-L-alpha-D-Hepp,A branched tetrasaccharide consisting of three L-glycero-alpha-D-manno-heptosyl residues (one at the reducing end) and a single beta-D-glucosyl residue.,"InChI=1S/C27H48O24/c28-1-5(32)18-12(38)11(37)16(42)26(47-18)50-22-14(40)13(39)19(6(33)2-29)48-27(22)49-21-17(43)24(44)46-20(7(34)3-30)23(21)51-25-15(41)10(36)9(35)8(4-31)45-25/h5-44H,1-4H2/t5-,6-,7-,8+,9+,10-,11-,12-,13-,14-,15+,16-,17-,18+,19+,20+,21+,22-,23+,24-,25-,26+,27+/m0/s1",L-glycero-alpha-D-manno-Hep-(1->2)-L-glycero-alpha-D-manno-Hep-(1->3)-[beta-Glc-(1->4)]-L-glycero-alpha-D-manno-Hep,PubMed citation,7790083
2457,59486,beta-D-Glcp-(1->4)-L-alpha-D-Hepp,A disaccharide consisting of a D-glucosyl residue in alpha-(1->4)-linkage with L-glycero-alpha-D-manno-heptose.,"InChI=1S/C13H24O12/c14-1-3(16)10-11(7(19)8(20)12(22)24-10)25-13-9(21)6(18)5(17)4(2-15)23-13/h3-22H,1-2H2/t3-,4+,5+,6-,7+,8-,9+,10+,11-,12-,13+/m0/s1",beta-D-Glc-(1->4)-L-alpha-D-Hep,PubMed citation,1910006
2458,59487,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,An amino trisaccharide comprising an N-acetyl beta-D-glucosaminyl residue flanked by two beta-D-galactopyranose residues (one at the reducing end).,"InChI=1S/C20H35NO16/c1-5(25)21-9-12(28)16(36-20-14(30)13(29)10(26)6(2-22)34-20)8(4-24)35-19(9)37-17-11(27)7(3-23)33-18(32)15(17)31/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12-,13+,14-,15-,16-,17+,18-,19+,20+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal,Beilstein Registry Number,5786015
2459,59488,L-alpha-D-Hepp-(1->3)-L-alpha-D-Hepp,A disaccharide consisting of two L-glycero-alpha-D-manno-heptose residues joined by a(1->3)-linkage.,"InChI=1S/C14H26O13/c15-1-3(17)10-6(20)5(19)7(21)14(26-10)27-12-8(22)11(4(18)2-16)25-13(24)9(12)23/h3-24H,1-2H2/t3-,4-,5-,6-,7-,8+,9-,10+,11+,12-,13-,14+/m0/s1",3-O-L-glycero-alpha-D-manno-heptopyranosyl-L-glycero-alpha-D-manno-heptopyranose,PubMed citation,1910006
2460,59489,3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid 5-phosphate,An aldooctose phosphate that is the 5-O-phosphono derivative of 3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid,"InChI=1S/C8H15O11P/c9-2-4(11)5-6(19-20(15,16)17)3(10)1-8(14,18-5)7(12)13/h3-6,9-11,14H,1-2H2,(H,12,13)(H2,15,16,17)/t3-,4-,5-,6-,8-/m1/s1",Kdo5P,PubMed citation,9044290
2461,59491,3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid 4-phosphate,An aldooctose phosphate that is the 4-O-phosphono derivative of 3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid.,"InChI=1S/C8H15O11P/c9-2-3(10)6-5(11)4(19-20(15,16)17)1-8(14,18-6)7(12)13/h3-6,9-11,14H,1-2H2,(H,12,13)(H2,15,16,17)/t3-,4-,5-,6-,8-/m1/s1",Kdo4P,PubMed citation,9044290
2462,59494,beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp,A linear mannopentaose consisting of five D-mannose residues joined sequentially via two beta(1->2) and two alpha(1->2) linkages with alpha anomeric configuration at the reducing end.,"InChI=1S/C30H52O26/c31-1-6-12(37)17(42)22(26(47)48-6)53-28-24(19(44)14(39)8(3-33)50-28)55-30-25(20(45)15(40)10(5-35)52-30)56-29-23(18(43)13(38)9(4-34)51-29)54-27-21(46)16(41)11(36)7(2-32)49-27/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28-,29+,30-/m1/s1",beta-D-Man-(1->2)-beta-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man,PubMed citation,12787022
2463,59498,alpha-L-Rhap-(1->2)-[beta-D-GlcpNAc-(1->3)]-alpha-L-Rhap-(1->3)-alpha-L-Rhap,A branched amino tetrasaccharide consisting of three alpha-L-rhamnose residues linked sequentially (1->2) and (1->3) (one at the reducing end) and a single N-acetyl beta-D-glucosaminyl residue linked (1->3) to the central rhamnose.,"InChI=1S/C26H45NO18/c1-6-12(30)17(35)18(36)25(40-6)45-22-21(44-24-11(27-9(4)29)16(34)15(33)10(5-28)42-24)14(32)8(3)41-26(22)43-20-13(31)7(2)39-23(38)19(20)37/h6-8,10-26,28,30-38H,5H2,1-4H3,(H,27,29)/t6-,7-,8-,10+,11+,12-,13-,14-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26-/m0/s1",alpha-L-Rha-(1->2)-[beta-D-GlcNAc-(1->3)]-alpha-L-Rha-(1->3)-alpha-L-Rha,PubMed citation,1423345
2464,59500,beta-D-GlcpNAc-(1->3)-alpha-L-Rhap,An amino disaccharide consisting of alpha-L-rhamnose having an N-acetyl beta-D-glucosaminyl residue attached at the 3-position.,"InChI=1S/C14H25NO10/c1-4-8(18)12(11(21)13(22)23-4)25-14-7(15-5(2)17)10(20)9(19)6(3-16)24-14/h4,6-14,16,18-22H,3H2,1-2H3,(H,15,17)/t4-,6+,7+,8-,9+,10+,11+,12+,13+,14-/m0/s1",beta-D-GlcNAc-(1->3)-alpha-L-Rha,Beilstein Registry Number,1439882
2465,59502,alpha-L-Rhap-(1->2)-[beta-D-GlcpNAc-(1->3)]-alpha-L-Rhap,A branched amino trisaccharide consisting of two alpha-L-rhamnose residues [linked (1->2); one at the reducing end] with a single N-acetyl beta-D-glucosaminyl residue linked (1->3) to the reducing-end rhamnose.,"InChI=1S/C20H35NO14/c1-5-10(24)14(28)15(29)20(32-5)35-17-16(11(25)6(2)31-18(17)30)34-19-9(21-7(3)23)13(27)12(26)8(4-22)33-19/h5-6,8-20,22,24-30H,4H2,1-3H3,(H,21,23)/t5-,6-,8+,9+,10-,11-,12+,13+,14+,15+,16+,17+,18+,19-,20-/m0/s1",alpha-L-Rha-(1->2)-[beta-D-GlcNAc-(1->3)]-alpha-L-Rha,PubMed citation,12487612
2466,59512,cilastatin(1-),The anion resulting from the removal of a proton from a carboxylic acid group of cilastatin.,"InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/p-1/b12-6-/t10-,11+/m1/s1",cilastatin anion,Beilstein Registry Number,8168990
2467,59518,beta-D-Galp-(1->2)-L-glycero-alpha-D-manno-Hepp-(1->2)-L-glycero-alpha-D-manno-Hepp-(1->3)-L-glycero-alpha-D-manno-Hepp-(1->5)-Kdo,"A linear pentasaccharide consisting of a beta-D-galactose residue, three L-glycero-alpha-D-manno-heptose residues and (at the reducing end) a 3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid (Kdo) residue linked sequentially (1->2), (1->2), (1->3) and (1->5); the structure is that of the pentasaccharide epitope from Haemophilus influenzae MAHI 4.","InChI=1S/C35H60O31/c36-2-8(42)22-16(49)18(51)29(65-33-28(17(50)15(48)23(61-33)9(43)3-37)64-30-19(52)14(47)13(46)12(6-40)58-30)32(60-22)63-27-20(53)24(10(44)4-38)59-31(21(27)54)62-25-7(41)1-35(57,34(55)56)66-26(25)11(45)5-39/h7-33,36-54,57H,1-6H2,(H,55,56)/t7-,8+,9+,10+,11-,12-,13+,14+,15+,16+,17+,18+,19-,20-,21+,22-,23-,24-,25-,26-,27+,28+,29+,30+,31-,32-,33-,35-/m1/s1",beta-D-Gal-(1->2)-L-glycero-alpha-D-manno-Hep-(1->2)-L-glycero-alpha-D-manno-Hep-(1->3)-L-glycero-alpha-D-manno-Hep-(1->5)-Kdo,PubMed citation,8938639
2468,59519,L-glycero-alpha-D-manno-Hepp-(1->2)-L-glycero-alpha-D-manno-Hepp-(1->3)-L-glycero-alpha-D-manno-Hepp-(1->5)-alpha-Kdo,"A linear tetrasaccharide consisting of three L-glycero-alpha-D-manno-heptosyl residues and a 3-deoxy-alpha-D-manno-oct-2-ulosonic acid (Kdo) residue linked sequentially (1->2), (1->2) and (1->5); corresponds to the tetrasaccharide epitope from Haemophilus influenzae MAHI 3.","InChI=1S/C29H50O26/c30-2-7(35)18-12(40)11(39)15(43)25(49-18)54-24-14(42)13(41)19(8(36)3-31)51-27(24)53-23-16(44)20(9(37)4-32)50-26(17(23)45)52-21-6(34)1-29(48,28(46)47)55-22(21)10(38)5-33/h6-27,30-45,48H,1-5H2,(H,46,47)/t6-,7+,8+,9+,10-,11+,12+,13+,14+,15+,16-,17+,18-,19-,20-,21-,22-,23+,24+,25-,26-,27-,29-/m1/s1",L-glycero-alpha-D-manno-Hep-(1->2)-L-glycero-alpha-D-manno-Hep-(1->3)-L-glycero-alpha-D-manno-Hep-(1->5)-alpha-Kdo,PubMed citation,7543887
2469,59532,F420-0,The fragment of coenzyme F420 remaining after formal hydrolytic removal of all of the glutamate residues.,"InChI=1S/C19H22N3O12P/c1-8(18(28)29)34-35(31,32)33-7-14(25)15(26)13(24)6-22-12-5-10(23)3-2-9(12)4-11-16(22)20-19(30)21-17(11)27/h2-5,8,13-15,23-26H,6-7H2,1H3,(H,28,29)(H,31,32)(H,21,27,30)/t8-,13-,14+,15-/m0/s1",coenzyme F420-0,PubMed citation,18252724
2470,59537,coenzyme alpha-F420-3,The amide obtained by formal condensation of the carboxylic acid group of F420-0 with the amino group of L-gamma-glutamyl-L-gamma-glutamyl-L-glutamic acid.,"InChI=1S/C34H43N6O21P/c1-14(29(49)37-20(33(55)56)5-8-25(45)35-18(31(51)52)4-7-24(44)36-19(32(53)54)6-9-26(46)47)61-62(58,59)60-13-23(43)27(48)22(42)12-40-21-11-16(41)3-2-15(21)10-17-28(40)38-34(57)39-30(17)50/h2-3,10-11,14,18-20,22-23,27,41-43,48H,4-9,12-13H2,1H3,(H,35,45)(H,36,44)(H,37,49)(H,46,47)(H,51,52)(H,53,54)(H,55,56)(H,58,59)(H,39,50,57)/t14-,18-,19-,20-,22-,23+,27-/m0/s1",alpha-F420-3,PubMed citation,18252724
2471,59539,coenzyme alpha-F420-3(5-),The penta-anion obtained by removing protons from the phosphate and carboxylic acid groups of coenzyme alpha-F420-3.,"InChI=1S/C34H43N6O21P/c1-14(29(49)37-20(33(55)56)5-8-25(45)35-18(31(51)52)4-7-24(44)36-19(32(53)54)6-9-26(46)47)61-62(58,59)60-13-23(43)27(48)22(42)12-40-21-11-16(41)3-2-15(21)10-17-28(40)38-34(57)39-30(17)50/h2-3,10-11,14,18-20,22-23,27,41-43,48H,4-9,12-13H2,1H3,(H,35,45)(H,36,44)(H,37,49)(H,46,47)(H,51,52)(H,53,54)(H,55,56)(H,58,59)(H,39,50,57)/p-5/t14-,18-,19-,20-,22-,23+,27-/m0/s1",coenzyme alpha-F420-3 penta-anion,PubMed citation,11888293
2472,59543,coenzyme F420-1(3-),The tri-anion obtained by removing protons from the phosphate and carboxylic acid groups of coenzyme F420-1.,"InChI=1S/C24H29N4O15P/c1-10(21(35)25-14(23(37)38)4-5-18(32)33)43-44(40,41)42-9-17(31)19(34)16(30)8-28-15-7-12(29)3-2-11(15)6-13-20(28)26-24(39)27-22(13)36/h2-3,6-7,10,14,16-17,19,29-31,34H,4-5,8-9H2,1H3,(H,25,35)(H,32,33)(H,37,38)(H,40,41)(H,27,36,39)/p-3/t10-,14-,16-,17+,19-/m0/s1",F420-1(3-),PubMed citation,18252724
2473,59552,alpha-L-idopyranose,The alpha-anomer of L-idopyranose.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4-,5+,6+/m0/s1",alpha-L-idose,PubMed citation,16920091
2474,59562,5-hydroxyisouric acid anion,The conjugate base of 5-hydroxyisouric acid.,"InChI=1S/C5H4N4O4/c10-2-5(13)1(6-3(11)8-2)7-4(12)9-5/h13H,(H3,6,7,8,9,10,11,12)/p-1","5-hydroxy-2,6-dioxo-2,5,6,7-tetrahydro-1H-purin-8-ol anion",Beilstein Registry Number,7818573
2475,59571,"alpha-Neu9,NAc2-(2->6)-GalNAc",An amino disaccharide consisting of an N-acetylglucosamine having an N-acetyl-9-O-acetylneuraminic acid attached via an alpha-(2->6)-linkage.,"InChI=1S/C21H34N2O15/c1-7(24)22-13-10(27)4-21(20(33)34,38-18(13)15(29)11(28)5-35-9(3)26)36-6-12-16(30)17(31)14(19(32)37-12)23-8(2)25/h10-19,27-32H,4-6H2,1-3H3,(H,22,24)(H,23,25)(H,33,34)/t10-,11+,12+,13+,14+,15+,16-,17+,18+,19?,21+/m0/s1",9-OAcSA-alpha-(2->6)-GalNAc,PubMed citation,15380274
2476,59575,"3,6-di-O-methyl-beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranose","A disaccharide derivative consisting of alpha-L-rhamnose having a 3,6-di-O-methyl-beta-D-glucosyl residue attached at the 4-position; corresponds to the carbohydrate portion of synthetic antigens containing the Mycobacterium leprae-specific epitope.","InChI=1S/C14H26O10/c1-5-11(8(16)9(17)13(19)22-5)24-14-10(18)12(21-3)7(15)6(23-14)4-20-2/h5-19H,4H2,1-3H3/t5-,6+,7+,8-,9+,10+,11-,12-,13+,14-/m0/s1","3,6-di-O-methyl-beta-D-glucosyl-(1->4)-alpha-L-rhamnose",PubMed citation,3080916
2477,59578,alpha-D-Galp-(1->6)-D-Galp,A glycosylgalactose consisting of D-galactose having an alpha-D-galactosyl residue attached at the 6-position.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11?,12+/m1/s1",alpha-D-galactosyl-(1->6)-D-galactose,Beilstein Registry Number,1292779
2478,59579,Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,A branched N-glycan derivative that is an undecasaccharide derivative consisting of nine D-mannosyl residues and two N-acetylglucosamine residues (one at the reducing end).,"InChI=1S/C70H118N2O56/c1-14(82)71-27-38(93)52(23(10-80)110-60(27)107)121-61-28(72-15(2)83)39(94)53(24(11-81)118-61)122-66-51(106)55(124-69-59(46(101)35(90)21(8-78)116-69)128-70-58(45(100)34(89)22(9-79)117-70)127-65-49(104)42(97)31(86)18(5-75)113-65)37(92)26(120-66)12-108-62-50(105)54(123-68-57(44(99)33(88)20(7-77)115-68)126-64-48(103)41(96)30(85)17(4-74)112-64)36(91)25(119-62)13-109-67-56(43(98)32(87)19(6-76)114-67)125-63-47(102)40(95)29(84)16(3-73)111-63/h16-70,73-81,84-107H,3-13H2,1-2H3,(H,71,82)(H,72,83)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52-,53-,54+,55+,56+,57+,58+,59+,60?,61+,62+,63-,64-,65-,66+,67+,68-,69-,70-/m1/s1",alpha-Manp-(1->2)-alpha-Manp-(1->2)-alpha-Manp-(1->3)-[alpha-Manp-(1->2)-alpha-Manp-(1->3)-[alpha-Manp-(1->2)-alpha-Manp-(1->6)]-alpha-Manp-(1->6)]-beta-Manp-(1->4)-beta-GlcpNAc-(1->4)-GlcpNAc,Beilstein Registry Number,4215262
2479,59580,beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,"A branched amino pentasaccharide consisting of two D-glucose residues (one at the reducing end), one N-acetyl-D-glucosamine residue, one D-galactose residue and one L-fucose residue, linked as shown.","InChI=1S/C32H55NO25/c1-7-14(39)17(42)21(46)30(50-7)56-25-12(6-37)54-32(23(48)27(25)58-31-22(47)18(43)15(40)9(3-34)53-31)57-26-13(33-8(2)38)29(52-10(4-35)16(26)41)55-24-11(5-36)51-28(49)20(45)19(24)44/h7,9-32,34-37,39-49H,3-6H2,1-2H3,(H,33,38)/t7-,9+,10+,11+,12+,13+,14+,15-,16-,17+,18-,19+,20+,21-,22+,23+,24+,25+,26+,27+,28+,29-,30-,31-,32-/m0/s1",beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc,PubMed citation,10640784
2480,59584,alpha-D-Manp-(1->2)-D-Manp,A glycosylmannose consisting of D-mannose having an alpha-D-mannosyl residue attached at the 2-position.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10+,11?,12-/m1/s1",alpha-D-Man-(1->2)-D-Man,Beilstein Registry Number,1625922
2481,59590,clorazepic acid anion,The anion resulting from the removal of a proton from the carboxylic acid group of clorazepic acid.,"InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)/p-1","7-chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylate",Beilstein Registry Number,8125954
2482,59593,5-aminoisatin,Isatin substituted at C-5 by an amino group.,"InChI=1S/C8H6N2O2/c9-4-1-2-6-5(3-4)7(11)8(12)10-6/h1-3H,9H2,(H,10,11,12)","5-aminoindoline-2,3-dione",Beilstein Registry Number,131239
2483,59605,Disperse Blue 124,A monoazo compound consisting of diazene with a 5-nitrothiazol-2-yl group attached to one nitrogen and a substituted 4-aminophenyl group attached to the other; used as a dye standard for the assay of allergy-releasing dyes in textiles.,"InChI=1S/C16H19N5O4S/c1-4-20(7-8-25-12(3)22)13-5-6-14(11(2)9-13)18-19-16-17-10-15(26-16)21(23)24/h5-6,9-10H,4,7-8H2,1-3H3",C.I. Disperse Blue 124,CAS Registry Number,15141-18-1
2484,59609,diclofenac beta-D-glucosiduronic acid,A beta-D-glucosiduronic acid (beta-D-glucuronide) that is a metabolite of diclofenac.,"InChI=1S/C20H19Cl2NO8/c21-10-5-3-6-11(22)14(10)23-12-7-2-1-4-9(12)8-13(24)30-20-17(27)15(25)16(26)18(31-20)19(28)29/h1-7,15-18,20,23,25-27H,8H2,(H,28,29)/t15-,16-,17+,18-,20+/m0/s1",diclofenac acyl glucuronide,Beilstein Registry Number,8521474
2485,59610,4'-hydroxydiclofenac quinone imine,A quinone imine that is a metabolite of diclofenac arising from 4'-hydroxylation followed by oxidation.,"InChI=1S/C14H9Cl2NO3/c15-10-6-9(18)7-11(16)14(10)17-12-4-2-1-3-8(12)5-13(19)20/h1-4,6-7H,5H2,(H,19,20)",4'-hydroxy diclofenac benzoquinone,Beilstein Registry Number,10683401
2486,59611,5-hydroxydiclofenac quinone imine,A quinone imine that is a metabolite of diclofenac arising from 5-hydroxylation followed by oxidation.,"InChI=1S/C14H9Cl2NO3/c15-10-2-1-3-11(16)14(10)17-12-5-4-9(18)6-8(12)7-13(19)20/h1-6H,7H2,(H,19,20)/b17-12+",5-hydroxy diclofenac benzoquinone,Beilstein Registry Number,8851517
2487,59612,5-hydroxydiclofenac,A monocarboxylic acid that is the 5-hydroxylated metabolite of diclofenac.,"InChI=1S/C14H11Cl2NO3/c15-10-2-1-3-11(16)14(10)17-12-5-4-9(18)6-8(12)7-13(19)20/h1-6,17-18H,7H2,(H,19,20)",5-hydroxy diclofenac,Beilstein Registry Number,4199419
2488,59613,4'-hydroxydiclofenac,A monocarboxylic acid that is the 4'-hydroxylated metabolite of diclofenac.,"InChI=1S/C14H11Cl2NO3/c15-10-6-9(18)7-11(16)14(10)17-12-4-2-1-3-8(12)5-13(19)20/h1-4,6-7,17-18H,5H2,(H,19,20)",4'-hydroxy diclofenac,Beilstein Registry Number,4198042
2489,59614,beta-D-Galp6P-(1->4)-alpha-D-Manp,A disaccharide phosphate corresponding to part of the oligosaccharide repeating unit of Leishmania major promastigote lipophosphoglycan.,"InChI=1S/C12H23O14P/c13-1-3-10(7(16)8(17)11(19)24-3)26-12-9(18)6(15)5(14)4(25-12)2-23-27(20,21)22/h3-19H,1-2H2,(H2,20,21,22)/t3-,4-,5+,6+,7-,8+,9-,10-,11+,12+/m1/s1",PO4-6-beta-D-Galp-(1->4)-alpha-D-Manp,PubMed citation,7808469
2490,59615,beta-D-Galp-(1->3)-beta-D-Galp6P-(1->4)-alpha-D-Manp,An oligosaccharide phosphate corresponding to the oligosaccharide repeating unit of Leishmania major promastigote lipophosphoglycan.,"InChI=1S/C18H33O19P/c19-1-4-7(21)9(23)12(26)17(34-4)37-15-8(22)6(3-32-38(29,30)31)35-18(13(15)27)36-14-5(2-20)33-16(28)11(25)10(14)24/h4-28H,1-3H2,(H2,29,30,31)/t4-,5-,6-,7+,8+,9+,10-,11+,12-,13-,14-,15+,16+,17+,18+/m1/s1",PO4-6-[beta-D-Galp-(1->3)]-beta-D-Galp-(1->4)-alpha-D-Manp,PubMed citation,7808469
2491,59617,alpha-L-Araf-(1->2)-beta-D-Galp-(1->3)-beta-D-Galp6P-(1->4)-alpha-D-Manp,A tetrasaccharide derivative that is the tetrasaccharide phosphate corresponding to the oligosaccharide repeating unit of Leishmania major promastigote lipophosphoglycan.,"InChI=1S/C23H41O23P/c24-1-5-9(27)12(30)19(46-21-15(33)10(28)6(2-25)41-21)23(42-5)45-18-11(29)8(4-39-47(36,37)38)43-22(16(18)34)44-17-7(3-26)40-20(35)14(32)13(17)31/h5-35H,1-4H2,(H2,36,37,38)/t5-,6+,7-,8-,9+,10+,11+,12+,13-,14+,15-,16-,17-,18+,19-,20+,21+,22+,23+/m1/s1",PO4-6-[alpha-L-Araf-(1->2)-beta-D-Galp-(1->3)]-beta-D-Galp-(1->4)-alpha-D-Manp,PubMed citation,7808469
2492,59619,beta-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-Galp6P-(1->4)-alpha-D-Manp,A pentasaccharide derivative that is a pentasaccharide phosphate epitope from Leishmania major promastigote lipophosphoglycan.,"InChI=1S/C30H53O29P/c31-1-6-11(35)15(39)18(42)27(52-6)57-23-12(36)7(2-32)53-28(19(23)43)58-24-13(37)8(3-33)54-29(20(24)44)59-25-14(38)10(5-50-60(47,48)49)55-30(21(25)45)56-22-9(4-34)51-26(46)17(41)16(22)40/h6-46H,1-5H2,(H2,47,48,49)/t6-,7-,8-,9-,10-,11+,12+,13+,14+,15+,16-,17+,18-,19-,20-,21-,22-,23+,24+,25+,26+,27+,28+,29+,30+/m1/s1",6-P-[beta-D-Gal-(1->3)-beta-D-Gal-(1->3)-beta-D-Gal-(1->3)]-beta-D-Gal-(1->4)-alpha-D-Man,PubMed citation,7808469
2493,59620,GPL-1,A glycopeptidolipid antigen from clinically prominent members of the Mycobacterium avium serocomplex.,"InChI=1S/C71H126N4O19/c1-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-39-42-53(76)44-55(77)74-54(43-52-40-37-36-38-41-52)67(85)75-56(48(4)90-71-65(60(81)58(79)50(6)92-71)94-70-61(82)59(80)57(78)49(5)91-70)68(86)73-47(3)66(84)72-46(2)45-89-69-62(83)64(88-9)63(87-8)51(7)93-69/h36-38,40-41,46-51,53-54,56-65,69-71,76,78-83H,10-35,39,42-45H2,1-9H3,(H,72,84)(H,73,86)(H,74,77)(H,75,85)/t46-,47+,48+,49-,50-,51-,53?,54+,56+,57-,58+,59+,60+,61+,62+,63-,64-,65+,69?,70-,71?/m0/s1",Mycobacterium avium serocomplex glycopeptidolipid,PubMed citation,2476400
2494,59627,4-isopropyl-1-methylcyclohexane 1-hydroperoxide,A peroxol (hydroperoxide) that is the 1-hydroperoxy derivative of p-menthane.,"InChI=1S/C10H20O2/c1-8(2)9-4-6-10(3,12-11)7-5-9/h8-9,11H,4-7H2,1-3H3",1-methyl-4-(1-methylethyl)cyclohexyl hydroperoxide,PubMed citation,20163165
2495,59631,"beta-D-mannosyl 3,7,11,15,19,23,27,31-octamethyldotriacontyl phosphate",A fully saturated D-mannose polyisoprenoid phosphoglycolipid (C32 chain-length) obtained from Mycobacterium tuberculosis.,"InChI=1S/C46H93O9P/c1-34(2)17-10-18-35(3)19-11-20-36(4)21-12-22-37(5)23-13-24-38(6)25-14-26-39(7)27-15-28-40(8)29-16-30-41(9)31-32-53-56(51,52)55-46-45(50)44(49)43(48)42(33-47)54-46/h34-50H,10-33H2,1-9H3,(H,51,52)/t35?,36?,37?,38?,39?,40?,41?,42-,43-,44+,45+,46+/m1/s1",Mannosyl C32-phosphoisoprenoid,PubMed citation,14551186
2496,59636,PIM6,"A phosphatidylinositol mannoside having the phosphatidyl moiety (with specific O-acyl groups) at the 1-position, a single mannosyl residue at the 2-position and a linear pentamannoside at position 6 of the inositol ring.","InChI=1S/C81H147O43P/c1-4-6-8-10-12-14-15-16-17-18-20-24-28-32-50(86)109-38-43(113-51(87)33-29-25-21-23-27-31-42(3)30-26-22-19-13-11-9-7-5-2)39-112-125(107,108)124-75-71(120-77-68(104)58(94)52(88)44(34-82)114-77)65(101)62(98)66(102)72(75)121-79-70(106)61(97)57(93)49(119-79)40-110-76-67(103)60(96)56(92)48(118-76)41-111-80-73(63(99)54(90)46(36-84)116-80)123-81-74(64(100)55(91)47(37-85)117-81)122-78-69(105)59(95)53(89)45(35-83)115-78/h42-49,52-85,88-106H,4-41H2,1-3H3,(H,107,108)/t42?,43?,44-,45-,46-,47-,48-,49-,52-,53-,54-,55-,56-,57-,58+,59+,60+,61+,62-,63+,64+,65-,66+,67+,68+,69+,70+,71-,72-,73+,74+,75-,76+,77-,78-,79-,80+,81-/m1/s1",PIM6,PubMed citation,7542404
2497,59637,S-nitrosomycothiol,The S-nitroso derivative of mycothiol.,"InChI=1S/C17H29N3O13S/c1-4(22)18-5(3-34-20-31)16(30)19-7-9(24)8(23)6(2-21)32-17(7)33-15-13(28)11(26)10(25)12(27)14(15)29/h5-15,17,21,23-29H,2-3H2,1H3,(H,18,22)(H,19,30)/t5-,6+,7+,8+,9+,10-,11-,12+,13+,14+,15-,17+/m0/s1",MSNO,PubMed citation,12809551
2498,59639,5-(6-aminohexanamido)isatin,Isatin bearing a 6-aminohexanamido group at C-5.,"InChI=1S/C14H17N3O3/c15-7-3-1-2-4-12(18)16-9-5-6-11-10(8-9)13(19)14(20)17-11/h5-6,8H,1-4,7,15H2,(H,16,18)(H,17,19,20)",5-[(6-aminohexanoyl)amino]isatin,PubMed citation,19834914
2499,59641,alpha-L-Rhap-(1->2)-L-Rhap,A glycosylrhamnose consisting of two L-rhamnopyranose units joined by an alpha(1->2) linkage.,"InChI=1S/C12H22O9/c1-3-6(14)8(16)10(11(18)19-3)21-12-9(17)7(15)5(13)4(2)20-12/h3-18H,1-2H3/t3-,4-,5-,6-,7+,8+,9+,10+,11?,12-/m0/s1",alpha-L-Rha-(1->2)-L-Rha,Beilstein Registry Number,1686135
2500,59646,GPL-21,A glycopeptidolipid antigen from clinically prominent members of the Mycobacterium avium serocomplex,"InChI=1S/C81H140N4O26.H2O/c1-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-41-44-56(86)46-59(87)84-57(45-55-42-39-38-40-43-55)74(95)85-60(75(96)83-50(3)73(94)82-49(2)47-102-76-65(92)70(100-10)67(99-9)54(7)107-76)51(4)104-79-72(63(90)61(88)52(5)106-79)110-77-64(91)69(62(89)53(6)105-77)109-78-66(93)71(101-11)68-58(108-78)48-103-81(8,111-68)80(97)98;/h38-40,42-43,49-54,56-58,60-72,76-79,86,88-93H,12-37,41,44-48H2,1-11H3,(H,82,94)(H,83,96)(H,84,87)(H,85,95)(H,97,98);1H2/t49-,50+,51+,52-,53-,54-,56?,57+,58+,60+,61+,62-,63+,64+,65+,66+,67-,68+,69+,70-,71+,72+,76?,77-,78-,79?,81-;/m0./s1",Mycobacterium avium serocomplex glycopeptidolipid,PubMed citation,2476400
2501,59663,colistin A sodium methanesulfonate,"Colistin A in which each of the primary amino groups is converted into the corresponding aminomethanesulfonic acid sodium salt, commonly by treatment with formaldehyde followed by sodium bisulfite.","InChI=1S/C58H110N16O28S5.5Na/c1-9-35(6)12-10-11-13-46(77)65-38(14-20-59-28-103(88,89)90)53(82)74-48(37(8)76)58(87)70-41(17-23-62-31-106(97,98)99)50(79)68-43-19-25-64-57(86)47(36(7)75)73-54(83)42(18-24-63-32-107(100,101)102)67-49(78)39(15-21-60-29-104(91,92)93)69-55(84)44(26-33(2)3)72-56(85)45(27-34(4)5)71-52(81)40(66-51(43)80)16-22-61-30-105(94,95)96;;;;;/h33-45,47-48,59-63,75-76H,9-32H2,1-8H3,(H,64,86)(H,65,77)(H,66,80)(H,67,78)(H,68,79)(H,69,84)(H,70,87)(H,71,81)(H,72,85)(H,73,83)(H,74,82)(H,88,89,90)(H,91,92,93)(H,94,95,96)(H,97,98,99)(H,100,101,102);;;;;/q;5*+1/p-5/t35-,36-,37-,38+,39+,40+,41+,42+,43+,44+,45-,47+,48+;;;;;/m1...../s1",colistin A sulfomethate sodium,PubMed citation,16931410
2502,59691,(S)-cyclopentolate hydrochloride,The hydrochloride salt of (S)-cyclopentolate.,"InChI=1S/C17H25NO3.ClH/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17;/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3;1H/t15-;/m1./s1",(S)-cyclopentolate HCl,DrugBank accession,DB00979
2503,59693,cycrimine hydrochloride,"The hydrochloride salt of cycrimine. A central anticholinergic, it is used as its hydrochloride salt in the management and treatment of Parkinson's disease.","InChI=1S/C19H29NO.ClH/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20;/h1,3-4,9-10,18,21H,2,5-8,11-16H2;1H",(+-)-cycrimine hydrochloride,CAS Registry Number,126-02-3
2504,59694,"(4aS,5R,9R,11S)-1,1,5,8,11-pentamethyl-8-vinyl-1,2,3,4,4a,5,6,7,8,9-decahydro-5,9-methanobenzocyclooctene",A halimane-diterpenoid structure originally proposed as the structure for edaxadiene (CHEBI:59685).,"InChI=1S/C20H32/c1-7-19(5)11-12-20(6)14(2)16(19)13-17-15(20)9-8-10-18(17,3)4/h7,13-16H,1,8-12H2,2-6H3/t14-,15+,16+,19?,20+/m0/s1",edaxadiene,Beilstein Registry Number,12141156
2505,59703,"2,2':6',2'':6'',2''':6''',2'''':6'''',2'''''-sexipyridine",A linear sexipyridine in which six unsubstituted pyridine units are linked by five 2:6'-linkages.,InChI=1S/C30H20N6/c1-3-19-31-21(9-1)23-11-5-13-25(33-23)27-15-7-17-29(35-27)30-18-8-16-28(36-30)26-14-6-12-24(34-26)22-10-2-4-20-32-22/h1-20H,"[2,2':6',2'':6'',2''':6''',2'''':6'''',2''''']sexipyridine",Beilstein Registry Number,60231
2506,59709,(R)-cycrimine hydrochloride,The hydrochloride salt of (R)-cycrimine.,"InChI=1S/C19H29NO.ClH/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20;/h1,3-4,9-10,18,21H,2,5-8,11-16H2;1H/t19-;/m0./s1",(R)-cycrimine HCl,DrugBank accession,DB00942
2507,59710,(S)-cycrimine hydrochloride,The hydrochloride salt of (S)-cycrimine.,"InChI=1S/C19H29NO.ClH/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20;/h1,3-4,9-10,18,21H,2,5-8,11-16H2;1H/t19-;/m1./s1",(S)-cycrimine HCl,DrugBank accession,DB00942
2508,59711,hydrogensquarate,A carbon oxoanion which is a monoanion obtained by the deprotonation of one of the hydroxy groups of squaric acid.,InChI=1S/C4H2O4/c5-1-2(6)4(8)3(1)7/h5-6H/p-1,hydrogensquarate anion,Beilstein Registry Number,4177223
2509,59712,squarate,A carbon oxoanion which is the dianion obtained by the deprotonation of the hydroxy group of hydrogensquarate.,InChI=1S/C4H2O4/c5-1-2(6)4(8)3(1)7/h5-6H/p-2,squarate(2-),Beilstein Registry Number,4231182
2510,59715,sodium squarate,An organic sodium salt which is the disodium salt of squaric acid.,InChI=1S/C4H2O4.2Na/c5-1-2(6)4(8)3(1)7;;/h5-6H;;/q;2*+1/p-2,disodium squarate,Beilstein Registry Number,6541909
2511,59723,prop-1-ene-1-thiol,The thioenol of propene.,"InChI=1S/C3H6S/c1-2-3-4/h2-4H,1H3",allyl mercaptan,Beilstein Registry Number,1900352
2512,59733,amidotrizoic acid dihydrate,The dihydrate form of amidotrizoic acid. Both the dihydrate and the anhydrous form are used as X-ray contrast media.,"InChI=1S/C11H9I3N2O4.2H2O/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);2*1H2","3,5-diacetamido-2,4,6-triiodobenzoic acid dihydrate",CAS Registry Number,50978-11-5
2513,59742,N-methoxy-N-methylbenzamide,The Weinreb amide of benzoic acid.,"InChI=1S/C9H11NO2/c1-10(12-2)9(11)8-6-4-3-5-7-8/h3-7H,1-2H3",N-methyl-N-methoxybenzamide,Beilstein Registry Number,1942902
2514,59747,(S)-diethylpropion,The (S)-enantiomer of amfepramone.,"InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3/t11-/m0/s1",(S)-alpha-diethylaminopropiophenone,Reaxys Registry Number,6719542
2515,59753,"1,12-di-L-ascorbyl dodecanedioate",,"InChI=1S/C24H34O14/c25-13(21-17(29)19(31)23(33)37-21)11-35-15(27)9-7-5-3-1-2-4-6-8-10-16(28)36-12-14(26)22-18(30)20(32)24(34)38-22/h13-14,21-22,25-26,29-32H,1-12H2/t13-,14-,21+,22+/m0/s1",BOLA12,PubMed citation,16734474
2516,59757,dihydroergotamine tartrate,"The L-(+)-tartaric acid salt of dihydroergotamine, a semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine. Both the tartrate and the mesylate salts are used for the treatment of migraine and orthostatic hypotension.","InChI=1S/2C33H37N5O5.C4H6O6/c2*1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;5-1(3(7)8)2(6)4(9)10/h2*3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1-2,5-6H,(H,7,8)(H,9,10)/t2*21-,23-,25-,26+,27+,32-,33+;1-,2-/m111/s1","dihydroergotamine (R,R)-tartrate",KEGG DRUG accession,D07838
2517,59759,ethyl hydrogen phosphate(1-),An organophosphate oxoanion that is the conjugate base of ethyl dihydrogen phosphate arising from deprotonation of one of the OH groups of the phosphate.,"InChI=1S/C2H7O4P/c1-2-6-7(3,4)5/h2H2,1H3,(H2,3,4,5)/p-1",ethyl hydrogen phosphate anion,Beilstein Registry Number,3661970
2518,59760,ethyl phosphate(2-),An organophosphate oxoanion that is the dianion of ethyl phosphate arising from deprotonation of both OH groups of the phosphate.,"InChI=1S/C2H7O4P/c1-2-6-7(3,4)5/h2H2,1H3,(H2,3,4,5)/p-2",MEP,Gmelin Registry Number,324862
2519,59761,methyl phosphate(2-),Dianion of methyl phosphate arising from deprotonation of both OH groups of the phosphate.,"InChI=1S/CH5O4P/c1-5-6(2,3)4/h1H3,(H2,2,3,4)/p-2",methyl phosphate dianion,Gmelin Registry Number,324284
2520,59762,N-(5'-phosphonatopyridoxyl)-D-alaninate(2-),"An organophosphate oxoanion that is the dianion of N-(5'-phosphopyridoxyl)-D-alanine having anionic carboxy, hydroxy and phosphate groups with the secondary amino group and pyridine nitrogen protonated.","InChI=1S/C11H17N2O7P/c1-6-10(14)9(4-13-7(2)11(15)16)8(3-12-6)5-20-21(17,18)19/h3,7,13-14H,4-5H2,1-2H3,(H,15,16)(H2,17,18,19)/p-2/t7-/m1/s1",PPL-D-alanine anion,PubMed citation,16790434
2521,59763,N-(5'-phosphonatopyridoxyl)-L-alaninate(2-),"An organophosphate oxoanion that is the dianion of N-(5'-phosphopyridoxyl)-L-alanine having anionic carboxy, hydroxy and phosphate groups with the secondary amino group and pyridine nitrogen protonated.","InChI=1S/C11H17N2O7P/c1-6-10(14)9(4-13-7(2)11(15)16)8(3-12-6)5-20-21(17,18)19/h3,7,13-14H,4-5H2,1-2H3,(H,15,16)(H2,17,18,19)/p-2/t7-/m0/s1",PPL-L-alanine anion,PubMed citation,16790434
2522,59766,N(6)-acetyl-N(2)-(5'-phosphonatopyridoxyl)-L-lysinate(2-),"An organophosphate oxoanion that is the dianion of N(6)-acetyl-N(2)-(5'-phosphopyridoxyl)-L-alanine having anionic carboxy, hydroxy and phosphate groups with the secondary amino group and pyridine nitrogen protonated.","InChI=1S/C16H26N3O8P/c1-10-15(21)13(12(7-18-10)9-27-28(24,25)26)8-19-14(16(22)23)5-3-4-6-17-11(2)20/h7,14,19,21H,3-6,8-9H2,1-2H3,(H,17,20)(H,22,23)(H2,24,25,26)/p-2/t14-/m0/s1",N(epsilon)-acetyl-N(alpha)-(5'-phosphonatopyridoxyl)-L-lysinate(2-),PubMed citation,16790434
2523,59767,N(6)-acetyl-N(2)-(5'-phosphopyridoxyl)-L-lysine,A N(6)-acyl-L-lysine arising from reductive N-alkylation of N(6)-acetyl-L-lysine by pyridoxal-5-phosphate.,"InChI=1S/C16H26N3O8P/c1-10-15(21)13(12(7-18-10)9-27-28(24,25)26)8-19-14(16(22)23)5-3-4-6-17-11(2)20/h7,14,19,21H,3-6,8-9H2,1-2H3,(H,17,20)(H,22,23)(H2,24,25,26)/t14-/m0/s1",N(epsilon)-acetyl-N(alpha)-(5'-phosphopyridoxyl)-L-lysine,PubMed citation,16790434
2524,59778,8-chlorotheophylline(1-),The anion resulting from the removal of the proton fron the purine ring of 8-chlorotheophylline.,"InChI=1S/C7H7ClN4O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H,9,10,13)/p-1","1,3-dimethyl-8-chloroxanthine anion",Beilstein Registry Number,3678329
2525,59783,2-hydroxy-4-methylvaleric acid,"A valeric acid derivative having a hydroxy substituent at the 2-position and a methyl substituent at the 4-position; an alpha-hydroxy analogue of leucine. A bacterial metabolite, it has also been isolated from amniotic fluid, was found in a patient with dihydrolipoyl dehydrogenase deficiency and is present in the urine of patients with short bowel syndrome.","InChI=1S/C6H12O3/c1-4(2)3-5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)",alpha-Hydroxyisocaproic acid,CAS Registry Number,498-36-2
2526,59805,(S)-dobutamine,The (S)-enantiomer of dobutamine.,"InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3/t13-/m0/s1","(S)-3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine",Reaxys Registry Number,15472663
2527,59825,CMP-3-deoxy-alpha-D-manno-octulosonate(2-),A doubly-charged nucleotide-sugar oxoanion arising from deprotonation of the carboxylic acid and phosphate functions of CMP-3-deoxy-alpha-D-manno-octulosonic acid.,"InChI=1S/C17H26N3O15P/c18-9-1-2-20(16(29)19-9)14-12(26)11(25)8(33-14)5-32-36(30,31)35-17(15(27)28)3-6(22)10(24)13(34-17)7(23)4-21/h1-2,6-8,10-14,21-26H,3-5H2,(H,27,28)(H,30,31)(H2,18,19,29)/p-2/t6-,7-,8-,10-,11-,12-,13-,14-,17+/m1/s1",CMP-3-deoxy-D-manno-octulosonate dianion,MetaCyc accession,CMP-KDO
2528,59861,beta-D-Gal-(1->4)-alpha-D-Glc-(1->3)-[alpha-D-GlcNAc-(1->2)]-alpha-L-Hep,An amino tetrasaccharide and epitope consisting of L-glycero-alpha-D-manno-heptopyranose having a lactosyl moiety attached at the 3-position via an alpha-linkage and an alpha-N-acetylglucosaminyl residue at the 2-position.,"InChI=1S/C27H47NO22/c1-6(33)28-11-14(37)12(35)8(3-30)44-25(11)50-23-22(19(42)20(7(34)2-29)47-24(23)43)49-27-18(41)16(39)21(10(5-32)46-27)48-26-17(40)15(38)13(36)9(4-31)45-26/h7-27,29-32,34-43H,2-5H2,1H3,(H,28,33)/t7-,8+,9+,10+,11+,12+,13-,14+,15-,16+,17+,18+,19+,20+,21+,22-,23-,24-,25+,26-,27+/m0/s1",beta-D-Galp-(1->4)-alpha-D-Glcp-(1->3)-[alpha-D-GlcpNAc-(1->2)]-alpha-L-Hepp,PubMed citation,10593954
2529,59867,3-O-alpha-abequopyranosyl-alpha-D-mannopyranose,A glycosylmannose consisting of alpha-D-mannopyranose having an alpha-abequopyranosyl residue attached at the 3-position.,"InChI=1S/C12H22O9/c1-4-5(14)2-6(15)12(19-4)21-10-8(16)7(3-13)20-11(18)9(10)17/h4-18H,2-3H2,1H3/t4-,5-,6-,7-,8-,9+,10+,11+,12-/m1/s1",alpha-Abe-alpha-(1->3)-D-Man,PubMed citation,6163199
2530,59868,alpha-D-Galp-(1->2)-[alpha-Abep-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-Galp-(1->2)-[alpha-Abep-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap,A branched octasaccharide consisting of two repeating tetrasaccharide units; isolated from phage P22 endo-rhamnosidase cleaved S. typhimurium O-polysaccharide chains.,"InChI=1S/C48H82O35/c1-11-15(53)5-17(55)42(70-11)80-37-25(59)21(9-51)75-47(39(37)82-45-31(65)27(61)23(57)19(7-49)73-45)78-35-14(4)72-44(32(66)29(35)63)79-36-24(58)20(8-50)74-46(33(36)67)83-40-38(81-43-18(56)6-16(54)12(2)71-43)26(60)22(10-52)76-48(40)77-34-13(3)69-41(68)30(64)28(34)62/h11-68H,5-10H2,1-4H3/t11-,12-,13+,14+,15-,16-,17-,18-,19-,20-,21-,22-,23+,24+,25-,26-,27+,28+,29+,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41-,42-,43-,44+,45-,46-,47-,48-/m1/s1",[(->3)-alpha-D-Gal-(1->2)-[alpha-D-Abe-(1->3)]-alpha-D-Man-(1->4)-alpha-L-Rha-(1->)]2,Beilstein Registry Number,5718232
2531,59882,alpha-D-fructuronate,The alpha-anomer of D-fructuronate.,"InChI=1S/C6H10O7/c7-1-6(12)4(9)2(8)3(13-6)5(10)11/h2-4,7-9,12H,1H2,(H,10,11)/p-1/t2-,3+,4+,6+/m1/s1",alpha-D-fructofuranuronate,Beilstein Registry Number,5270986
2532,59884,XDP(3-),Trianion of xanthosine 5'-diphosphate arising from deprotonation of all three OH groups of the diphosphate.,"InChI=1S/C10H14N4O12P2/c15-5-3(1-24-28(22,23)26-27(19,20)21)25-9(6(5)16)14-2-11-4-7(14)12-10(18)13-8(4)17/h2-3,5-6,9,15-16H,1H2,(H,22,23)(H2,19,20,21)(H2,12,13,17,18)/p-3/t3-,5-,6-,9-/m1/s1",xanthosine 5' diphosphate(3--),Beilstein Registry Number,4283676
2533,59900,caspofungin acetate,"The diacetate salt of caspofungin. It is used for the treatment of invasive candidiasis, and of aspergillosis in patients who are refractory to, or intolerant of, other therapy.","InChI=1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+;;/m1../s1",caspofungin diacetate,KEGG DRUG accession,D02501
2534,59902,entecavir hydrate,"The monohydrate form of entecavir. A synthetic analogue of 2'-deoxyguanosine, entecavir is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. It is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. Enteclavir is used for the treatment of chronic hepatitis B.","InChI=1S/C12H15N5O3.H2O/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20;/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20);1H2/t6-,7-,8-;/m0./s1",entecavir monohydrate,KEGG DRUG accession,D04008
2535,59912,dihydroergocristine,Ergocristine in which a single bond replaces the double bond between positions 9 and 10. It is used as the mesylate salt for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease.,"InChI=1S/C35H41N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,18,20,23,25,27-29,36,44H,8,13-17,19H2,1-3H3,(H,37,41)/t23-,25-,27-,28+,29+,34-,35+/m1/s1","9,10-dihydroergocristine",KEGG DRUG accession,D07834
2536,59919,dihydro-alpha-ergocryptine,alpha-Ergocryptine in which a single bond replaces the double bond between positions 9 and 10.,"InChI=1S/C32H43N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38)/t20-,22-,24-,25+,26+,31-,32+/m1/s1","9,10-dihydro-alpha-ergocryptine",Beilstein Registry Number,102178
2537,59922,N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosamine,A chitobiose consisting of D-glucosamine having an N-acetyl-beta-D-glucosaminyl residue attached at the 4-position.,"InChI=1S/C14H26N2O10/c1-4(19)16-8-11(22)9(20)5(2-17)25-14(8)26-12-6(3-18)24-13(23)7(15)10(12)21/h5-14,17-18,20-23H,2-3,15H2,1H3,(H,16,19)/t5-,6-,7-,8-,9-,10-,11-,12-,13?,14+/m1/s1",N-monoacetylchitobiose,Beilstein Registry Number,7889246
2538,59925,dihydro-beta-ergocryptine,beta-Ergocryptine in which a single bond replaces the double bond between positions 9 and 10.,"InChI=1S/C32H43N5O5/c1-6-18(4)27-29(39)36-12-8-11-25(36)32(41)37(27)30(40)31(42-32,17(2)3)34-28(38)20-13-22-21-9-7-10-23-26(21)19(15-33-23)14-24(22)35(5)16-20/h7,9-10,15,17-18,20,22,24-25,27,33,41H,6,8,11-14,16H2,1-5H3,(H,34,38)/t18?,20-,22-,24-,25+,27+,31-,32+/m1/s1","9,10-dihydro-beta-ergocryptine",Beilstein Registry Number,8602493
2539,59927,N-acetyl-beta-D-glucosaminyl-(1->4)-alpha-D-glucosamine,The alpha-anomer of N-acetyl-beta-D-glucosaminyl-(1->4)-D-glucosamine.,"InChI=1S/C14H26N2O10/c1-4(19)16-8-11(22)9(20)5(2-17)25-14(8)26-12-6(3-18)24-13(23)7(15)10(12)21/h5-14,17-18,20-23H,2-3,15H2,1H3,(H,16,19)/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+/m1/s1",4-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-2-amino-2-deoxy-alpha-D-glucopyranose,Beilstein Registry Number,8519017
2540,59936,ciprofloxacin hydrochloride hydrate,The monohydrate form of ciprofloxacin monohydrochloride.,"InChI=1S/C17H18FN3O3.ClH.H2O/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24;;/h7-10,19H,1-6H2,(H,23,24);1H;1H2",ciprofloxacin hydrochloride monohydrate,KEGG COMPOUND accession,C13993
2541,59942,beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-[beta-D-Araf-(1->2)-alpha-D-Araf-(1->3)]-alpha-D-Araf-(1->5)-alpha-D-Araf-OMe,A hexasaccharide derivative that is a hexaarabinofuranoside corresponding to part of the arabinomannanan portion of the lipoarabinomannan from Mycobacterium tuberculosis.,"InChI=1S/C31H52O25/c1-45-26-19(41)16(38)12(52-26)6-46-27-22(44)23(54-31-25(18(40)11(5-35)51-31)56-29-21(43)15(37)9(3-33)49-29)13(53-27)7-47-30-24(17(39)10(4-34)50-30)55-28-20(42)14(36)8(2-32)48-28/h8-44H,2-7H2,1H3/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21+,22+,23-,24+,25+,26+,27+,28+,29+,30+,31-/m1/s1",beta-D-Ara-(1->2)-alpha-D-Ara-(1->5)-[beta-D-Ara-(1->2)-alpha-D-Ara-(1->3)]-alpha-D-Ara-(1->5)-alpha-D-Ara-OMe,Beilstein Registry Number,8671888
2542,59943,beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-OMe,A tetrasaccharide derivative that is a methyl tetraarabinofuranoside corresponding to part of the arabinomannanan portion of the lipoarabinomannan from Mycobacterium tuberculosis.,"InChI=1S/C21H36O17/c1-31-18-14(28)11(25)8(36-18)4-32-19-15(29)12(26)9(37-19)5-33-21-17(13(27)7(3-23)35-21)38-20-16(30)10(24)6(2-22)34-20/h6-30H,2-5H2,1H3/t6-,7-,8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18+,19+,20+,21+/m1/s1",beta-D-Ara-(1->2)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-OMe,Beilstein Registry Number,9106475
2543,59944,beta-D-Araf-(1->2)-alpha-D-Araf-(1->3)-alpha-D-Araf-(1->5)-alpha-D-Araf-OMe,A tetrasaccharide derivative that is a methyl tetraarabinofuranoside corresponding to part of the arabinomannanan portion of the lipoarabinomannan from Mycobacterium tuberculosis.,"InChI=1S/C21H36O17/c1-31-18-13(28)11(26)9(36-18)5-32-19-15(30)16(8(4-24)35-19)37-21-17(12(27)7(3-23)34-21)38-20-14(29)10(25)6(2-22)33-20/h6-30H,2-5H2,1H3/t6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16-,17+,18+,19+,20+,21-/m1/s1",beta-D-Ara-(1->2)-alpha-D-Ara-(1->3)-alpha-D-Ara-(1->5)-alpha-D-Ara-OMe,Beilstein Registry Number,9106003
2544,59946,beta-D-Galp-(1->4)-beta-D-Glcp-(1->4)-[alpha-D-GlcpNAc-(1->2)-3-PEA-L-alpha-D-Hepp-(1->3)]-L-alpha-D-Hepp-(1->5)-alpha-Kdo,A branched hexasaccharide corresponding to part of the lipooligosaccharide from N. gonorrhoeae L8.,"InChI=1S/C44H77N2O38P/c1-11(53)46-19-22(60)20(58)16(8-50)73-38(19)82-37-35(84-85(70,71)72-3-2-45)27(65)29(13(55)5-47)76-42(37)80-34-28(66)41(77-30-12(54)4-44(69,43(67)68)83-32(30)15(57)7-49)78-31(14(56)6-48)36(34)81-40-26(64)24(62)33(18(10-52)75-40)79-39-25(63)23(61)21(59)17(9-51)74-39/h12-42,47-52,54-66,69H,2-10,45H2,1H3,(H,46,53)(H,67,68)(H,70,71)/t12-,13+,14+,15-,16-,17-,18-,19-,20-,21+,22-,23+,24-,25-,26-,27-,28+,29-,30-,31-,32-,33-,34-,35+,36-,37+,38-,39+,40+,41+,42-,44-/m1/s1",N. gonorrhoeae L8 LOS oligosaccharide,PubMed citation,18642671
2545,59948,columbianetin,The angular furanocoumarin analogue of the linear furanocoumarin marmesin.,"InChI=1S/C14H14O4/c1-14(2,16)11-7-9-10(17-11)5-3-8-4-6-12(15)18-13(8)9/h3-6,11,16H,7H2,1-2H3",(+-)-columbianetin,Beilstein Registry Number,200954
2546,59949,N. meningiditis L7 lipoundecasaccharide,A branched undecasaccharide corresponding to part of the lipooligosaccharide of N. meningiditis type L7,"InChI=1S/C106H186N5O67P/c1-5-7-9-11-13-15-17-19-21-23-44(123)27-59(130)110-61-71(138)68(135)57(159-94(61)149)40-156-95-62(111-60(131)28-45(124)24-22-20-18-16-14-12-10-8-6-2)72(139)69(136)58(165-95)41-157-105(103(150)151)30-51(175-106(104(152)153)29-46(125)65(132)83(176-106)48(127)32-113)88(85(177-105)50(129)34-115)170-101-81(148)90(172-102-93(174-96-63(108-42(3)121)73(140)66(133)52(35-116)160-96)91(178-179(154,155)158-26-25-107)79(146)82(166-102)47(126)31-112)92(84(167-101)49(128)33-114)173-99-78(145)76(143)87(56(39-120)164-99)169-100-80(147)89(70(137)54(37-118)162-100)171-97-64(109-43(4)122)74(141)86(55(38-119)163-97)168-98-77(144)75(142)67(134)53(36-117)161-98/h44-58,61-102,112-120,123-129,132-149H,5-41,107H2,1-4H3,(H,108,121)(H,109,122)(H,110,130)(H,111,131)(H,150,151)(H,152,153)(H,154,155)/t44?,45?,46-,47+,48-,49+,50-,51-,52-,53-,54-,55-,56-,57-,58-,61-,62-,63-,64-,65-,66-,67+,68-,69-,70+,71-,72-,73-,74-,75+,76-,77-,78-,79-,80-,81+,82-,83-,84-,85-,86-,87-,88-,89+,90-,91+,92-,93+,94-,95-,96-,97+,98+,99+,100+,101-,102-,105-,106-/m1/s1",Neisseria. meningiditis L7 LOS,PubMed citation,12526840
2547,59952,4-azabenzimidazole,"The [4,5-b]-fused isomer of imidazopyridine.","InChI=1S/C6H5N3/c1-2-5-6(7-3-1)9-4-8-5/h1-4H,(H,7,8,9)",azabenzimidazole,Reaxys Registry Number,2600
2548,59959,"(3R,6E)-nerolidol",A (6E)-nerolidol in which the hydroxy group at positon 3 adopts an R-configuration. It is a fertility-related volatile compound secreted by the queens of higher termites from the subfamily Syntermitinae.,"InChI=1S/C15H26O/c1-6-15(5,16)12-8-11-14(4)10-7-9-13(2)3/h6,9,11,16H,1,7-8,10,12H2,2-5H3/b14-11+/t15-/m0/s1",(3R)-(6E)-nerolidol,PubMed citation,12481088
2549,59963,methylglyoxal-lysine dimer,An imidazolium ion formed via cyclo-dimerisation of L-lysine and methylglyoxal.,"InChI=1S/C16H28N4O4/c1-12-10-19(8-4-2-6-13(17)15(21)22)11-20(12)9-5-3-7-14(18)16(23)24/h10-11,13-14H,2-9,17-18H2,1H3,(H-,21,22,23,24)/p+1/t13-,14-/m0/s1",imidazolysine,PubMed citation,9506998
2550,59965,glyoxal-lysine dimer,An imidazolium ion formed via cyclo-dimerisation of L-lysine and glyoxal.,"InChI=1S/C15H26N4O4/c16-12(14(20)21)5-1-3-7-18-9-10-19(11-18)8-4-2-6-13(17)15(22)23/h9-13H,1-8,16-17H2,(H-,20,21,22,23)/p+1/t12-,13-/m0/s1",GOLD,PubMed citation,15482946
2551,59970,1-butylpyrraline,An N-substituted pyrraline that is pyrraline in which the hydrogen attached to the pyrrole nitrogen has been replaced by a butyl group.,"InChI=1S/C10H15NO2/c1-2-3-6-11-9(7-12)4-5-10(11)8-13/h4-5,7,13H,2-3,6,8H2,1H3",N-butylpyrraline,Reaxys Registry Number,1527772
2552,59972,1-propylpyrraline,An N-substituted pyrraline that is pyrraline in which the hydrogen attached to the pyrrole nitrogen has been replaced by a propyl group.,"InChI=1S/C9H13NO2/c1-2-5-10-8(6-11)3-4-9(10)7-12/h3-4,6,12H,2,5,7H2,1H3",N-propylpyrraline,Reaxys Registry Number,7020681
2553,59973,1-(L-norleucin-6-yl)pyrraline,An N-substituted pyrraline formed via Maillard reaction of L-lysine with glucose.,"InChI=1S/C12H18N2O4/c13-11(12(17)18)3-1-2-6-14-9(7-15)4-5-10(14)8-16/h4-5,7,11,16H,1-3,6,8,13H2,(H,17,18)/t11-/m0/s1",epsilon-lysylpyrraline,Reaxys Registry Number,7096285
2554,59976,3'-O-methyltricetin,The 3'-O-methyl ether of tricetin.,"InChI=1S/C16H12O7/c1-22-14-3-7(2-11(20)16(14)21)12-6-10(19)15-9(18)4-8(17)5-13(15)23-12/h2-6,17-18,20-21H,1H3",tricetin 3'-O-methyl ether,Beilstein Registry Number,6574484
2555,59980,1-propyl-2-hydroxyacetylpyrrole,A pyrrole carrying propyl and hydroxyacetyl groups at the 1- and 2-positions respectively.,"InChI=1S/C9H13NO2/c1-2-5-10-6-3-4-8(10)9(12)7-11/h3-4,6,11H,2,5,7H2,1H3",propyl hydroxyacetyl pyrrole,PubMed citation,2917974
2556,59984,"2,5-furandimethanol",A furan carrying two hydroxymethyl substituents at the 2- and 5-positions.,"InChI=1S/C6H8O3/c7-3-5-1-2-6(4-8)9-5/h1-2,7-8H,3-4H2","2,5-furanylmethanol",Beilstein Registry Number,114239
2557,59986,N(alpha)-formyl-N(epsilon)-fructosyllysine,A glyco-amino acid consisting of a D-fructosyl residue attached to the epsilon-amino group of N(alpha)-formyl-L-lysine.,"InChI=1S/C13H24N2O8/c16-6-10(19)12(21)11(20)9(18)5-14-4-2-1-3-8(13(22)23)15-7-17/h7-8,10-12,14,16,19-21H,1-6H2,(H,15,17)(H,22,23)/t8-,10+,11+,12+/m0/s1",N(alpha)-formyl-N(epsilon)-fructosyl-L-lysine,Beilstein Registry Number,2396807
2558,59988,alpha-tyvelopyranose,The alpha-anomer of the pyranose form of tyvelose.,"InChI=1S/C6H12O4/c1-3-4(7)2-5(8)6(9)10-3/h3-9H,2H2,1H3/t3-,4+,5+,6+/m1/s1",alpha-Tyv,Beilstein Registry Number,6052308
2559,59990,"N,N-dimethyl-4-nitrosoaniline","A member of the class of dimethylanilines that is N,N-dimethylaniline having a nitroso group at the 4-position.","InChI=1S/C8H10N2O/c1-10(2)8-5-3-7(9-11)4-6-8/h3-6H,1-2H3","4-Nitroso-N,N-dimethylaniline",Gmelin Registry Number,27528
2560,59991,"4-(hydroxylamino)-N,N-dimethylaniline","A member of the class of dimethylanilines that is N,N-dimethylaniline having a hydroxylamino substituent at the 4-position.","InChI=1S/C8H12N2O/c1-10(2)8-5-3-7(9-11)4-6-8/h3-6,9,11H,1-2H3","4-(N,N-dimethylamino)phenylhydroxylamine",PubMed citation,4335090
2561,59992,alpha-abequopyranose,The alpha-anomer of the pyranose form of abequose.,"InChI=1S/C6H12O4/c1-3-4(7)2-5(8)6(9)10-3/h3-9H,2H2,1H3/t3-,4-,5-,6+/m1/s1",alpha-Abe,PubMed citation,84796
2562,59994,6-O-(1-O-stearoyl-sn-glycero-3-phosphono)-1D-myo-inositol,A glycerophosphoinositol antigen having a 1-stearoyl-sn-glycero-3-phospho moiety attached at the 6-position of 1D-myo-inositol.,"InChI=1S/C27H53O12P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(29)37-18-20(28)19-38-40(35,36)39-27-25(33)23(31)22(30)24(32)26(27)34/h20,22-28,30-34H,2-19H2,1H3,(H,35,36)/t20-,22-,23+,24+,25+,26-,27-/m1/s1","(2R)-2-hydroxy-3-[(hydroxy{[(1S,2R,3S,4S,5S,6S)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl)oxy]propyl stearate",PubMed citation,10681638
2563,60067,2-phenylethyl isocyanate,An isocyanate having a 2-phenylethyl group attached to the nitrogen.,"InChI=1S/C9H9NO/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2",phenethyl isocyanate,Beilstein Registry Number,1448240
2564,60077,luteolin-7-O-[beta-D-glucuronosyl-(1->2)-beta-D-glucuronide],The glycosyloxyflavone resulting from the condensation of the hydroxy group at position 7 of luteolin with the 1 position of 2-O-beta-D-glucopyranuronosyl-beta-D-glucopyranosiduronic acid.,"InChI=1S/C27H26O18/c28-9-2-1-7(3-10(9)29)13-6-12(31)15-11(30)4-8(5-14(15)42-13)41-27-23(19(35)18(34)22(44-27)25(39)40)45-26-20(36)16(32)17(33)21(43-26)24(37)38/h1-6,16-23,26-30,32-36H,(H,37,38)(H,39,40)/t16-,17-,18-,19-,20+,21-,22-,23+,26-,27+/m0/s1",luteolin-7-O-[beta-glucuronosyl-(1->2)-beta-glucuronide],Beilstein Registry Number,6362694
2565,60084,D-glucitol 6-phosphate(2-),Dianion of D-glucitol 1-phosphate arising from deprotonation of the phosphate OH groups; major species at pH 7.3.,"InChI=1S/C6H15O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h3-11H,1-2H2,(H2,12,13,14)/p-2/t3-,4+,5+,6+/m0/s1",D-glucitol 6-phosphate dianion,Beilstein Registry Number,5566995
2566,60094,sulfolipid-1(1-),The conjugate base of sulfolipid-1 arising from deprotonation of the sulfate OH group.,"InChI=1S/C148H286O20S/c1-29-33-37-41-45-49-53-57-61-62-66-70-74-78-82-109(5)86-110(6)87-111(7)88-112(8)89-115(11)94-120(16)100-126(22)105-131(27)145(156)162-108-136-139(153)141(166-146(157)132(28)106-127(23)101-122(18)96-117(13)91-114(10)93-119(15)98-124(20)103-129(25)134(150)84-80-76-72-68-64-59-55-51-47-43-39-35-31-3)143(165-137(151)85-81-77-73-69-65-60-56-52-48-44-40-36-32-4)148(164-136)167-147-142(168-169(158,159)160)140(154)138(152)135(163-147)107-161-144(155)130(26)104-125(21)99-121(17)95-116(12)90-113(9)92-118(14)97-123(19)102-128(24)133(149)83-79-75-71-67-63-58-54-50-46-42-38-34-30-2/h109-136,138-143,147-150,152-154H,29-108H2,1-28H3,(H,158,159,160)/p-1/t109-,110-,111-,112-,113+,114+,115-,116-,117-,118+,119+,120-,121-,122-,123+,124+,125-,126-,127-,128+,129+,130-,131-,132-,133+,134+,135+,136+,138+,139+,140-,141-,142+,143+,147+,148+/m0/s1",sulfolipid-1,PubMed citation,17592143
2567,60097,"2,5-dimethylphenyl isocyanate",An isocyanate that consists of phenyl isocyanate bearing two additional methyl substituents at positions 2 and 5.,"InChI=1S/C9H9NO/c1-7-3-4-8(2)9(5-7)10-6-11/h3-5H,1-2H3","2,5-dimethyl phenylisocyanate",Beilstein Registry Number,1100841
2568,60098,"3,4-dimethylphenyl isocyanate",An isocyanate that consists of phenyl isocyanate bearing two additional methyl substituents at positions 3 and 4.,"InChI=1S/C9H9NO/c1-7-3-4-9(10-6-11)5-8(7)2/h3-5H,1-2H3","3,4-dimethyl phenylisocyanate",Gmelin Registry Number,561659
2569,60099,2-tolyl isocyanate,An isocyanate comprising a benzene core with isocyanato- and methyl substituents ortho to each other.,"InChI=1S/C8H7NO/c1-7-4-2-3-5-8(7)9-6-10/h2-5H,1H3",2-toluene isocyanate,Beilstein Registry Number,507985
2570,60103,L-cysteinyl sulfurated eukaryotic molybdenum cofactor(2-),MoCo in eukaryotic sulfite oxidase.,"InChI=1S/C10H14N5O6PS2.C3H7NO2S.Mo.2O/c11-10-14-7-4(8(16)15-10)12-3-6(24)5(23)2(21-9(3)13-7)1-20-22(17,18)19;4-2(1-7)3(5)6;;;/h2-3,9,12,23-24H,1H2,(H2,17,18,19)(H4,11,13,14,15,16);2,7H,1,4H2,(H,5,6);;;/q;;+3;;/p-5/t2-,3+,9-;2-;;;/m10.../s1",cysteine ligated molybdenum cofactor,PubMed citation,19675644
2571,60107,N(5)-[(hydroxyamino)(imino)methyl]-L-ornithinium(1+),Conjugate acid of N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine having an anionic carboxy group and protonated amiino and guanidino groups. It is the principal microspecies present at pH 7.3.,"InChI=1S/C6H14N4O3/c7-4(5(11)12)2-1-3-9-6(8)10-13/h4,13H,1-3,7H2,(H,11,12)(H3,8,9,10)/p+1/t4-/m0/s1",N(5)-[(hydroxyamino)(imino)methyl]-L-ornithinium cation,MetaCyc accession,CPD-13518
2572,60152,beta-D-Galp-(1->4)-D-GlcpNAc,A disaccharide consisting of beta-D-galactose linked via a (1->4)-glycosidic bond to N-acetyl-D-glucosamine.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)12(6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12-,13?,14+/m1/s1",beta-D-Galp-(1->4)-D-GlcpNAc,Beilstein Registry Number,1299159
2573,60162,alpha-D-Gal-(1->3)-alpha-D-Gal-OMe,A disaccharide derivative comprising methyl alpha-D-galactoside having an alpha-D-galactosyl residue at the 3-position.,"InChI=1S/C13H24O11/c1-21-12-10(20)11(7(17)5(3-15)22-12)24-13-9(19)8(18)6(16)4(2-14)23-13/h4-20H,2-3H2,1H3/t4-,5-,6+,7+,8+,9-,10-,11+,12+,13-/m1/s1",alpha-D-Galp-(1->3)-alpha-D-Galp-OMe,Beilstein Registry Number,4786729
2574,60167,alpha-D-Gal-(1->6)-alpha-D-Gal-(1->6)-beta-D-Glc-(1<->2)-Fru,"A tetrasaccharide with no free anomeric centre consisting of two galactosyl residues, one glucosyl residue and one fructosyl residue in a liner sequence, linked as shown.","InChI=1S/C24H42O21/c25-1-6-10(28)14(32)17(35)21(41-6)39-3-8-11(29)15(33)18(36)22(42-8)40-4-9-12(30)16(34)19(37)23(43-9)45-24(5-27)20(38)13(31)7(2-26)44-24/h6-23,25-38H,1-5H2/t6-,7-,8-,9-,10+,11+,12-,13-,14+,15+,16+,17-,18-,19-,20+,21+,22+,23+,24?/m1/s1",alpha-D-Galp-(1->6)-alpha-D-Galp-(1->6)-beta-D-Glcp-(1<->2)-Fruf,PubMed citation,19913595
2575,60171,beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc,"A branched amino hexasaccharide made up from three galactose residues, two glucosamine residues and one glucose residue (at the reducing end); a constituent of human breast milk.","InChI=1S/C40H68N2O31/c1-9(48)41-17-23(54)31(70-38-28(59)24(55)19(50)11(3-43)66-38)15(7-47)68-36(17)63-8-16-22(53)34(30(61)40(69-16)71-32-14(6-46)64-35(62)27(58)26(32)57)73-37-18(42-10(2)49)33(21(52)13(5-45)65-37)72-39-29(60)25(56)20(51)12(4-44)67-39/h11-40,43-47,50-62H,3-8H2,1-2H3,(H,41,48)(H,42,49)/t11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21-,22+,23-,24+,25+,26-,27-,28-,29-,30-,31-,32-,33-,34+,35?,36-,37+,38+,39+,40+/m1/s1",beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Galp-(1->4)-D-Glcp,Beilstein Registry Number,11895623
2576,60172,beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc,"A branched amino hexasaccharide, which is a constituent of human breast milk.","InChI=1S/C40H68N2O31/c1-9(48)41-17-22(53)31(70-38-28(59)24(55)19(50)11(3-43)65-38)14(6-46)67-36(17)63-8-16-21(52)34(30(61)40(69-16)72-33-13(5-45)64-35(62)27(58)26(33)57)73-37-18(42-10(2)49)23(54)32(15(7-47)68-37)71-39-29(60)25(56)20(51)12(4-44)66-39/h11-40,43-47,50-62H,3-8H2,1-2H3,(H,41,48)(H,42,49)/t11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21+,22-,23-,24+,25+,26-,27-,28-,29-,30-,31-,32-,33-,34+,35?,36-,37+,38+,39+,40+/m1/s1",beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Galp-(1->4)-D-Glcp,PubMed citation,15158661
2577,60177,alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,"A linear amino pentasaccharide consisting of three galactosyl residues, one N-acetylglucosaminyl residue and one glucosyl residue (at the reducing end), linked as shown.","InChI=1S/C32H55NO26/c1-7(39)33-13-17(43)24(56-31-23(49)27(16(42)10(4-36)53-31)59-30-21(47)18(44)14(40)8(2-34)52-30)12(6-38)55-29(13)58-26-15(41)9(3-35)54-32(22(26)48)57-25-11(5-37)51-28(50)20(46)19(25)45/h8-32,34-38,40-50H,2-6H2,1H3,(H,33,39)/t8-,9-,10-,11-,12-,13-,14+,15+,16+,17-,18+,19-,20-,21-,22-,23-,24-,25-,26+,27+,28?,29+,30-,31+,32+/m1/s1",alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,KEGG GLYCAN accession,G12327
2578,60179,alpha-D-galactosyl-(1->2)-alpha-D-galactose,An alpha-D-galactosyl-(1->2)-D-galactose in which the reducing end anomeric centre has alpha-configuration.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11+,12-/m1/s1",alpha-D-Gal-(1->2)-alpha-D-Gal,Beilstein Registry Number,4845053
2579,60210,precursor Z hydrate,"A linear-fused organic heterotetracyclic compound consisting of a [1,3,2]dioxaphosphinane fused to a pyran ring which is in turn fused to a pteridine ring system. Molybdenum cofactor biosynthesis intermediate. Dehydrated derivative known as precursor Z.","InChI=1S/C10H14N5O8P/c11-9-14-6-3(7(16)15-9)12-4-8(13-6)22-2-1-21-24(19,20)23-5(2)10(4,17)18/h2,4-5,8,12,17-18H,1H2,(H,19,20)(H4,11,13,14,15,16)/t2-,4-,5+,8-/m1/s1",cPMP,KEGG COMPOUND accession,C18239
2580,60212,alpha-D-Gal-(1->6)-beta-D-Glc-(1<->2)-Fru,"A trisaccharide composed of D-galactose, D-fructose, and D-glucose, linked as shown.","InChI=1S/C18H32O16/c19-1-5-8(22)11(25)13(27)16(31-5)30-3-7-9(23)12(26)14(28)17(32-7)34-18(4-21)15(29)10(24)6(2-20)33-18/h5-17,19-29H,1-4H2/t5-,6-,7-,8+,9-,10-,11+,12+,13-,14-,15+,16-,17+,18?/m1/s1",alpha-D-Galp-(1->6)-beta-D-Glcp-(1<->2)-Fruf,PubMed citation,19913595
2581,60213,beta-D-Gal-(1->3)-D-Ara,A glycosylarabinose consisting of D-arabinose having a beta-D-galactosyl residue at the 3-position.,"InChI=1S/C11H20O10/c12-1-4-5(14)6(15)7(16)11(20-4)21-9-3(13)2-19-10(18)8(9)17/h3-18H,1-2H2/t3-,4-,5+,6+,7-,8+,9-,10?,11+/m1/s1",beta-D-Galp-(1->3)-D-Arap,Beilstein Registry Number,1686723
2582,60214,beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-D-Gal,An amino trisaccharide consisting of an N-acetyl-D-glucosamine flanked by two D-galactose residues in a linear sequence with (1->4) and (1->4) linkages.,"InChI=1S/C20H35NO16/c1-5(24)21-9-12(27)17(37-20-16(31)14(29)10(25)6(2-22)35-20)7(3-23)36-19(9)33-4-8-11(26)13(28)15(30)18(32)34-8/h6-20,22-23,25-32H,2-4H2,1H3,(H,21,24)/t6-,7-,8-,9-,10+,11+,12-,13+,14+,15-,16-,17-,18?,19-,20+/m1/s1",beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-D-Galp,KEGG GLYCAN accession,G00334
2583,60216,DKATIGFEVQEE,,"InChI=1S/C59H92N14O23/c1-7-29(4)47(72-58(94)48(31(6)74)73-49(85)30(5)64-51(87)34(15-11-12-24-60)66-50(86)33(61)26-45(83)84)56(92)63-27-41(76)65-39(25-32-13-9-8-10-14-32)55(91)68-37(18-22-43(79)80)54(90)71-46(28(2)3)57(93)69-35(16-20-40(62)75)52(88)67-36(17-21-42(77)78)53(89)70-38(59(95)96)19-23-44(81)82/h8-10,13-14,28-31,33-39,46-48,74H,7,11-12,15-27,60-61H2,1-6H3,(H2,62,75)(H,63,92)(H,64,87)(H,65,76)(H,66,86)(H,67,88)(H,68,91)(H,69,93)(H,70,89)(H,71,90)(H,72,94)(H,73,85)(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,95,96)/t29-,30-,31+,33-,34-,35-,36-,37-,38-,39-,46-,47-,48-/m0/s1",aspartyl-lysyl-alanyl-threonyl-isoleucyl-glycyl-phenylalanyl-glutamyl-valyl-glutaminyl-glutamylglutamic acid,PubMed citation,15128836
2584,60219,benzylpenillic acid,A penillic acid having a benzyl substituent at the 5-position.,"InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-10(8-9-6-4-3-5-7-9)17-11(14(19)20)13(18)23-16/h3-7,11-13H,8H2,1-2H3,(H,19,20)(H,21,22)/t11?,12-,13?/m0/s1",penillic acid,CAS Registry Number,13093-87-3
2585,60220,beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->3)-D-Glc,"An amino tetrasaccharide comprising residues of galactose, N-acetylglucosamine, galactose and glucose in a linear sequence, all joined by beta-(1->3)-linkages.","InChI=1S/C26H45NO21/c1-6(32)27-11-20(46-25-17(38)16(37)12(33)7(2-28)44-25)13(34)9(4-30)43-24(11)47-22-15(36)10(5-31)45-26(19(22)40)48-21-14(35)8(3-29)42-23(41)18(21)39/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13-,14-,15+,16+,17-,18-,19-,20-,21+,22+,23?,24+,25+,26+/m1/s1",beta-D-galactosyl-(1->3)-beta-D-N-acetylglucosaminyl-(1->3)-beta-D-galactosyl-(1->3)-D-glucose,PubMed citation,19913595
2586,60239,beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,"An amino tetrasaccharide comprising residues of galactose, N-acetylglucosamine, galactose and glucose in a linear sequence, all joined by beta-linkages.","InChI=1S/C26H45NO21/c1-6(32)27-11-14(35)20(46-25-18(39)15(36)12(33)7(2-28)43-25)10(5-31)45-24(11)48-22-13(34)8(3-29)44-26(19(22)40)47-21-9(4-30)42-23(41)17(38)16(21)37/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13+,14-,15+,16-,17-,18-,19-,20-,21-,22+,23?,24+,25+,26+/m1/s1",beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,Beilstein Registry Number,1417459
2587,60241,beta-D-Gal-(1->3)-alpha-D-GalNAc-OBn,A beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminide disaccharide consisting of benzyl 2-acetamido-2-deoxy-D-galactoside having a beta-D-galactosyl residue attached at the 3-position.,"InChI=1S/C21H31NO11/c1-10(25)22-14-19(33-21-18(29)17(28)15(26)12(7-23)32-21)16(27)13(8-24)31-20(14)30-9-11-5-3-2-4-6-11/h2-6,12-21,23-24,26-29H,7-9H2,1H3,(H,22,25)/t12-,13-,14-,15+,16+,17+,18-,19-,20+,21+/m1/s1",beta-D-Galp-(1->3)-alpha-D-GalpNAc-OBn,Beilstein Registry Number,1276665
2588,60246,alpha-D-GalNAc-(1->3)-D-Gal,A glycosylgalactose derivative consisting of D-galactose having an alpha-D-N-acetylgalactosaminyl residue attached at the 3-position.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)5(2-16)25-14(7)26-12-9(20)6(3-17)24-13(23)11(12)22/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10-,11-,12+,13?,14-/m1/s1",alpha-D-GalpNAc-(1->3)-D-Galp,Beilstein Registry Number,1356094
2589,60256,"(4R)-N-(2,3-dihydroxytetracosanoyl)-4-hydroxysphinganine","A phytoceramide having (2S,3R)-2,3-dihydroxytetracosanoyl as the N-acyl group.","InChI=1S/C42H85NO6/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-39(46)41(48)42(49)43-37(36-44)40(47)38(45)34-32-30-28-26-24-16-14-12-10-8-6-4-2/h37-41,44-48H,3-36H2,1-2H3,(H,43,49)/t37-,38+,39+,40-,41-/m0/s1",ceramide-4 (C24),PubMed citation,9368039
2590,60274,"1,2-dicaproyl-sn-glycero-3-phosphocholine","A 1,2-diacyl-sn-glycero-3-phosphocholine(1+) that is the dicaproyl diester of phosphatidiylcholine.","InChI=1S/C20H40NO8P/c1-6-8-10-12-19(22)26-16-18(29-20(23)13-11-9-7-2)17-28-30(24,25)27-15-14-21(3,4)5/h18H,6-17H2,1-5H3/p+1/t18-/m1/s1","1,2-Dicaproyl-sn-glycero-3-phosphocholine",PubMed citation,3512434
2591,60285,dioleoyl phosphatidylethanolamine,A phosphatidylethanolamine in which the phosphatidyl acyl groups are both oleoyl.,"InChI=1S/C41H78NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,39H,3-16,21-38,42H2,1-2H3,(H,45,46)/b19-17-,20-18-",DOPE,PubMed citation,1602135
2592,60286,1-palmitoyl-2-oleoyl phosphatidylethanolamine,A phosphatidylethanolamine in which the phosphatidyl acyl groups at C-1 and C-2 are palmitoyl and oleoyl respectively.,"InChI=1S/C39H76NO8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(42)48-37(36-47-49(43,44)46-34-33-40)35-45-38(41)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,37H,3-16,19-36,40H2,1-2H3,(H,43,44)/b18-17-",2-oleoyl-1-palmitoylphosphatidylethanolamine,CAS Registry Number,10015-88-0
2593,60287,1-oleoyl phosphatidylethanolamine,A phosphatidylethanolamine in which the phosphatidyl acyl group at C-1 is oleoyl.,"InChI=1S/C23H46NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(26)29-20-22(25)21-31-32(27,28)30-19-18-24/h9-10,22,25H,2-8,11-21,24H2,1H3,(H,27,28)/b10-9-",monooleoylphosphatidylethanolamine,PubMed citation,2112249
2594,60290,"alpha-Delta(4,5)HexpUA-(1->3)-beta-D-GalpNAc6S-(1->4)-beta-D-GlcpUA-(1->3)-beta-D-GalpNAc6S-(1->4)-beta-D-GlcpUA-(1->3)-beta-D-GalpNAc4S-(1->4)-beta-D-GlcpUA2S-(1->3)-D-GalpNAc6S","An oligosaccharide derivative that is an octasaccharide derivative consisting of an irregular string of NHAcetyl-substituted and O-sulfated monosaccharide residues with a Delta(4,5)HexUAalpha1-3GalNAc(6-O-sulfate) disaccharide unit at the non-reducing end. It has been isolated from a partial chondroitinase ABC digest of a commercial shark cartilage chondroitin sulfate (CS-C) preparation.","InChI=1S/C54H81N3O60S5/c1-8(59)55-15-31(18(62)12(101-47(15)82)5-98-118(83,84)85)107-54-39(117-122(95,96)97)28(72)36(42(115-54)46(80)81)110-53-29(73)37(30(11(4-58)102-53)116-121(92,93)94)111-52-27(71)24(68)35(41(114-52)45(78)79)109-49-17(57-10(3)61)33(20(64)14(104-49)7-100-120(89,90)91)106-51-26(70)23(67)34(40(113-51)44(76)77)108-48-16(56-9(2)60)32(19(63)13(103-48)6-99-119(86,87)88)105-50-25(69)21(65)22(66)38(112-50)43(74)75/h11-21,23-37,39-42,47-54,58,62-73,82H,4-7H2,1-3H3,(H,55,59)(H,56,60)(H,57,61)(H,74,75)(H,76,77)(H,78,79)(H,80,81)(H,83,84,85)(H,86,87,88)(H,89,90,91)(H,92,93,94)(H,95,96,97)/t11-,12-,13-,14-,15-,16-,17-,18+,19+,20+,21?,23-,24-,25?,26-,27-,28+,29-,30+,31-,32-,33-,34+,35+,36+,37-,39-,40+,41+,42+,47+,48+,49+,50+,51-,52-,53-,54+/m1/s1",DeltaHexUAalpha1-3GalNAc(6S)beta1-4GlcUAbeta1-3GalNAc(6S)beta1-4GlcUAbeta1-3GalNAc(4S)beta1-4GlcUA(2S)beta1-3GalNAc(6S),PubMed citation,17884822
2595,60298,beta-D-GalNAc-(1->3)-D-Gal,A glycosylgalactose derivative consisting of D-galactose having a beta-D-N-acetylgalactosaminyl residue attached at the 3-position.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)5(2-16)25-14(7)26-12-9(20)6(3-17)24-13(23)11(12)22/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10-,11-,12+,13?,14+/m1/s1",beta-D-N-acetylgalactosaminyl-(1->3)-D-galactose,PubMed citation,19913595
2596,60299,beta-D-GalNAc-(1->4)-D-Gal,A glycosylgalactose derivative consisting of D-galactose having a beta-D-N-acetylgalactosaminyl residue attached at the 4-position.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)8(19)5(2-16)25-14(7)26-12-6(3-17)24-13(23)11(22)10(12)21/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10-,11-,12+,13?,14+/m1/s1",beta-D-N-acetylgalactosaminyl-(1->4)-D-galactose,PubMed citation,19913595
2597,60300,alpha-D-GalpNAc-(1->3)-D-GalpNAc,A D-GalpNAc-(1->3)-D-GalpNAc in which the 2-acetamidogalactosyl group (attached to position 3 of the 2-acetamidogalactose moiety) has alpha- configuration.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)11(23)7(3-19)28-16(9)29-14-10(18-6(2)22)15(26)27-8(4-20)12(14)24/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12+,13-,14-,15?,16-/m1/s1",alpha-D-N-acetylgalactosaminyl-(1->3)-D-N-acetylgalactosamine,Beilstein Registry Number,1443238
2598,60305,(Z)-testosterone-3-CMO-Hist,The Z (syn) isomer of testosterone-3-CMO-Hist.,"InChI=1S/C26H38N4O3/c1-25-10-7-18(30-33-15-24(32)28-12-9-19-14-27-16-29-19)13-17(25)3-4-20-21-5-6-23(31)26(21,2)11-8-22(20)25/h13-14,16,20-23,31H,3-12,15H2,1-2H3,(H,27,29)(H,28,32)/b30-18-/t20-,21-,22-,23-,25-,26-/m0/s1",syn-testosterone-3-CMO-Hist,PubMed citation,10400384
2599,60306,"8-hydroxy-2-oxabicyclo[3.3.1]non-6-ene-3,5-dicarboxylate",Transition state of the chorismate mutase catalyzed Claisen rearrangement of chorismate to prephenate.,"InChI=1S/C10H12O6/c11-5-1-2-10(9(14)15)3-6(5)16-7(4-10)8(12)13/h1-2,5-7,11H,3-4H2,(H,12,13)(H,14,15)/p-2",endo-oxabicyclic,PubMed citation,16499927
2600,60307,alpha-D-GalNAc-(1->2)-alpha-DD-Hep-(1->6)-alpha-D-GlcNGly-(1->4)-[alpha-LD-Hep-(1->2)-alpha-DD-Hep-(1->2)]-alpha-D-GalA-(1->3)-[alpha-LD-Hep-(1->7)]-alpha-LD-Hep6PEtn-(1->3)-[beta-D-Glc-(1->4)]-alpha-LD-Hep-(1->5)-[alpha-Kdo-(2->4)][beta-L-Arap4N-(1->8)]-alpha-Kdo,"An oligosaccharide derivative that is a tridecasaccharide derivative, the oligosaccharide portion of the Proteus penneri strain 8 (O67) lipopolysaccharide (LPS) core region.","InChI=1S/C93H158N5O78P/c1-19(107)97-35-42(122)39(119)30(13-105)155-79(35)168-73-51(131)49(129)63(24(111)9-101)160-87(73)153-17-32-41(121)43(123)36(98-34(116)6-95)80(157-32)166-71-58(138)75(170-88-74(52(132)50(130)64(161-88)25(112)10-102)169-84-56(136)46(126)48(128)62(159-84)23(110)8-100)89(172-77(71)78(141)142)165-70-57(137)68(33(176-177(148,149)154-3-2-94)18-152-82-54(134)45(125)47(127)61(158-82)22(109)7-99)163-85(59(70)139)167-72-60(140)86(162-66(27(114)12-104)76(72)171-83-55(135)44(124)40(120)31(14-106)156-83)164-69-29(173-93(91(145)146)4-21(108)38(118)65(175-93)26(113)11-103)5-92(147,90(143)144)174-67(69)28(115)16-151-81-53(133)37(117)20(96)15-150-81/h20-33,35-77,79-89,99-106,108-115,117-140,147H,2-18,94-96H2,1H3,(H,97,107)(H,98,116)(H,141,142)(H,143,144)(H,145,146)(H,148,149)/t20-,21+,22-,23-,24+,25+,26+,27-,28+,29+,30+,31+,32+,33-,35+,36+,37-,38+,39-,40+,41+,42+,43+,44-,45-,46-,47-,48-,49-,50-,51-,52-,53+,54-,55+,56-,57+,58-,59-,60-,61+,62+,63+,64+,65+,66+,67+,68+,69+,70-,71+,72+,73-,74-,75+,76+,77-,79+,80+,81+,82-,83-,84+,85+,86+,87-,88+,89-,92+,93+/m0/s1",P. Penneri 8 LPS core oligosaccharide,PubMed citation,18373243
2601,60315,L-homocysteine thiolactone,A thiolactone arising from formal condensation of the mercapto (sulfanyl) and carboxylic acid groups of L-homocysteine.,"InChI=1S/C4H7NOS/c5-3-1-2-7-4(3)6/h3H,1-2,5H2/t3-/m0/s1",homocysteine thiolactone,Beilstein Registry Number,80591
2602,60319,1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine(1+),"A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and 5-oxovaleryl groups at the 1- and 2-positions respectively.","InChI=1S/C29H56NO9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-20-28(32)36-25-27(39-29(33)21-18-19-23-31)26-38-40(34,35)37-24-22-30(2,3)4/h23,27H,5-22,24-26H2,1-4H3/p+1/t27-/m1/s1",POVPC,PubMed citation,9884341
2603,60320,1-O-palmitoyl-2-O-(epoxyisoprostanoyl)-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and epoxyisoprostanoyl groups at the 1- and 2-positions respectively.","InChI=1S/C44H76NO10P/c1-6-8-10-12-14-15-16-17-18-19-20-22-24-28-43(47)51-35-38(36-53-56(49,50)52-33-32-45(3,4)5)54-44(48)29-25-27-41-42(55-41)34-39-37(30-31-40(39)46)26-23-21-13-11-9-7-2/h21,23,30-31,34,37-38,41-42H,6-20,22,24-29,32-33,35-36H2,1-5H3/p+1/b23-21-,39-34+/t37-,38+,41+,42+/m0/s1",PEIPC,Beilstein Registry Number,10142964
2604,60321,alpha-D-Galp-(1->2)-[alpha-D-Tyvp-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-Galp-(1->2)-[alpha-D-Tyvp-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap,A branched octasaccharide consisting of two repeating tetrasaccharide units; part of the O-specific polysaccharide from S. enteritidis .,"InChI=1S/C48H82O35/c1-11-15(53)5-17(55)42(70-11)80-37-25(59)21(9-51)75-47(39(37)82-45-31(65)27(61)23(57)19(7-49)73-45)78-35-14(4)72-44(32(66)29(35)63)79-36-24(58)20(8-50)74-46(33(36)67)83-40-38(81-43-18(56)6-16(54)12(2)71-43)26(60)22(10-52)76-48(40)77-34-13(3)69-41(68)30(64)28(34)62/h11-68H,5-10H2,1-4H3/t11-,12-,13+,14+,15+,16+,17+,18+,19-,20-,21-,22-,23+,24+,25-,26-,27+,28+,29+,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41-,42-,43-,44+,45-,46-,47-,48-/m1/s1",alpha-D-Gal-(1->2)-[alpha-D-Tyv-(1->3)]-alpha-D-Man-(1->4)-alpha-L-Rha-(1->3)-alpha-D-Gal-(1->2)-[alpha-D-Tyv-(1->3)]-alpha-D-Man-(1->4)-alpha-L-Rha,PubMed citation,84796
2605,60322,beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc,"An amino trisaccharide consisting of a 3-O-sulfo-beta-D-glucuronic acid residue, a D-galactosyl residue and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.","InChI=1S/C20H33NO20S/c1-4(24)21-7-9(26)13(6(3-23)36-18(7)32)38-19-11(28)14(8(25)5(2-22)37-19)39-20-12(29)15(41-42(33,34)35)10(27)16(40-20)17(30)31/h5-16,18-20,22-23,25-29,32H,2-3H2,1H3,(H,21,24)(H,30,31)(H,33,34,35)/t5-,6-,7-,8+,9-,10+,11-,12-,13-,14+,15+,16+,18?,19+,20-/m1/s1",3-O-sulfo-beta-D-GlcpA-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc,PubMed citation,8798480
2606,60343,1-methyl-7-nitroisatoic anhydride,"A 3,1-benzoxazin-1,4-dione having an N-methyl substituent and a nitro group at the 7-position.","InChI=1S/C9H6N2O5/c1-10-7-4-5(11(14)15)2-3-6(7)8(12)16-9(10)13/h2-4H,1H3",1M7,Beilstein Registry Number,1128381
2607,60346,alpha-Kdo-(2->8)-alpha-Kdo-OAll,A disaccharide derivative consisting of two 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl units joined via an alpha-(2->8)-linkage with an O-allyl group at the anomeric centre.,"InChI=1S/C19H30O15/c1-2-3-31-18(16(27)28)4-8(21)13(26)15(34-18)11(24)7-32-19(17(29)30)5-9(22)12(25)14(33-19)10(23)6-20/h2,8-15,20-26H,1,3-7H2,(H,27,28)(H,29,30)/t8-,9-,10-,11-,12-,13-,14-,15-,18-,19-/m1/s1",allyl 3-deoxy-8-O-(3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl)-alpha-D-manno-oct-2-ulopyranosonic acid,Beilstein Registry Number,11969612
2608,60347,alpha-Kdo-(2->4)-alpha-Kdo-OAll,A disaccharide derivative consisting of two 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl units joined via an alpha-(2->4)-linkage with an O-allyl group at the anomeric centre.,"InChI=1S/C19H30O15/c1-2-3-31-18(16(27)28)5-11(13(26)15(33-18)10(24)7-21)32-19(17(29)30)4-8(22)12(25)14(34-19)9(23)6-20/h2,8-15,20-26H,1,3-7H2,(H,27,28)(H,29,30)/t8-,9-,10-,11-,12-,13-,14-,15-,18-,19-/m1/s1",allyl 3-deoxy-4-O-(3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl)-alpha-D-manno-oct-2-ulopyranosidonic acid,PubMed citation,14625588
2609,60350,alpha-Kdo-(2->8)-alpha-Kdo-(2->4)-alpha-Kdo-OAll,A trisaccharide derivative consisting of three 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl units in a linear sequence with an O-allyl group at the anomeric centre.,"InChI=1S/C27H42O22/c1-2-3-44-26(23(40)41)6-15(18(37)20(48-26)13(33)8-29)46-27(24(42)43)5-11(31)17(36)21(49-27)14(34)9-45-25(22(38)39)4-10(30)16(35)19(47-25)12(32)7-28/h2,10-21,28-37H,1,3-9H2,(H,38,39)(H,40,41)(H,42,43)/t10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,25-,26-,27-/m1/s1",alpha-Kdo-(2->8)-alpha-Kdo-(2->4)-alpha-Kdo-(2->OAll),PubMed citation,14625588
2610,60351,3'-O-salicyl-AMP,An adenosine 5'-monophosphate having a salicyl group at the 3'-position; intermediate in mycobactin biosynthesis.,"InChI=1S/C17H18N5O9P/c18-14-11-15(20-6-19-14)22(7-21-11)16-12(24)13(10(30-16)5-29-32(26,27)28)31-17(25)8-3-1-2-4-9(8)23/h1-4,6-7,10,12-13,16,23-24H,5H2,(H2,18,19,20)(H2,26,27,28)/t10-,12-,13-,16-/m1/s1",2-hydroxybenzoyl-AMP,PubMed citation,9831524
2611,60356,tetraoleyl cardiolipin,A cardiolipin derivative in which all four of the phosphatidyl acyl groups are specified as oleoyl.,"InChI=1S/C81H150O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-65-78(83)91-71-76(97-80(85)67-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)73-95-99(87,88)93-69-75(82)70-94-100(89,90)96-74-77(98-81(86)68-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)72-92-79(84)66-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2/h33-40,75-77,82H,5-32,41-74H2,1-4H3,(H,87,88)(H,89,90)/b37-33-,38-34-,39-35-,40-36-/t76-,77-/m1/s1",tetraoleylcardiolipin,Beilstein Registry Number,9838546
2612,60361,1-(3-O-sulfo-beta-D-galactosyl)-N-tetracosanoylsphingosine,A D-galactosyl-N-acylsphingosine having a sulfo group at the 3-position on the galactose ring and tetracosanoyl as the N-acyl group.,"InChI=1S/C48H93NO11S/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2)40-58-48-46(54)47(60-61(55,56)57)45(53)43(39-50)59-48/h35,37,41-43,45-48,50-51,53-54H,3-34,36,38-40H2,1-2H3,(H,49,52)(H,55,56,57)/b37-35+/t41-,42+,43+,45-,46+,47-,48+/m0/s1",tetracosanoyl sulfatide,CAS Registry Number,151122-71-3
2613,60366,1-(3-O-sulfo-beta-D-galactosyl)-N-palmitoylsphingosine,A D-galactosyl-N-acylsphingosine having a sulfo group at the 3-position on the galactose ring and palmitoyl as the N-acyl group.,"InChI=1S/C40H77NO11S/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(43)33(32-50-40-38(46)39(52-53(47,48)49)37(45)35(31-42)51-40)41-36(44)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h27,29,33-35,37-40,42-43,45-46H,3-26,28,30-32H2,1-2H3,(H,41,44)(H,47,48,49)/b29-27+/t33-,34+,35+,37-,38+,39-,40+/m0/s1",1-(3-O-sulfo-beta-D-galactosyl)-N-hexadecanoylsphingosine,PubMed citation,16314439
2614,60372,1-(3-O-sulfo-beta-D-galactosyl)sphingosine,A sulfoglycosphingolipid that is sphingosine substituted on O-1 by a 3-O-sulfo-beta-D-galactosyl group; sulfatide in which one acyl chain has been removed by ozonolysis.,"InChI=1S/C24H47NO10S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(27)18(25)17-33-24-22(29)23(35-36(30,31)32)21(28)20(16-26)34-24/h14-15,18-24,26-29H,2-13,16-17,25H2,1H3,(H,30,31,32)/b15-14+/t18-,19+,20+,21-,22+,23-,24+/m0/s1",N-deacylated galactosylceramide sulfate,Beilstein Registry Number,8814990
2615,60375,alpha-Kdo-(2->8)-alpha-7-O-Me-Kdo,A disaccharide derivative consisting of a 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl residue and a 3-deoxy-7-O-methyl-alpha-D-manno-oct-2-ulopyranonosyl joined via an alpha-(2->8)-linkage.,"InChI=1S/C17H28O15/c1-29-9(13-11(23)6(19)2-16(28,31-13)14(24)25)5-30-17(15(26)27)3-7(20)10(22)12(32-17)8(21)4-18/h6-13,18-23,28H,2-5H2,1H3,(H,24,25)(H,26,27)/t6-,7-,8-,9-,10-,11-,12-,13-,16-,17-/m1/s1",alpha-D-Kdo-(2->8)-alpha-D-7-O-Me-Kdo,PubMed citation,19767317
2616,60376,alpha-D-Kdo-(2->4)-alpha-D-Kdo-(2->6)-beta-D-GlcN-4P-(1->6)-alpha-D-GlcN-1P,"An amino tetrasaccharide antigen consisting of two 3-deoxy-D-manno-oct-2-ulose residues and two glucosamine residues (one at the reducing end) in a linear sequence, with two phosphate groups attached.","InChI=1S/C28H50N2O29P2/c29-13-18(39)16(37)11(53-24(13)59-61(48,49)50)5-51-23-14(30)19(40)22(58-60(45,46)47)12(54-23)6-52-27(25(41)42)2-10(17(38)21(56-27)9(35)4-32)55-28(26(43)44)1-7(33)15(36)20(57-28)8(34)3-31/h7-24,31-40H,1-6,29-30H2,(H,41,42)(H,43,44)(H2,45,46,47)(H2,48,49,50)/t7-,8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,27-,28-/m1/s1",3-deoxy-alpha-D-manno-oct-2-ulonosyl-(2->4)-3-deoxy-alpha-D-manno-oct-2-ulonosyl-(2->6)-2-amino-2-deoxy-4-O-phosphono-beta-D-glucosyl-(1->6)-2-amino-2-deoxy-1-O-phosphono-alpha-D-glucose,KEGG GLYCAN accession,G00574
2617,60380,alpha-D-Kdo-(2->8)-alpha-D-Kdo-(2->4)-alpha-D-Kdo-(2->6)-beta-D-GlcNAc-4P-(1->6)-alpha-D-GlcNAc,"An amino pentasaccharide epitope consisting of three 3-deoxy-D-manno-oct-2-ulose residues and two N-acetylglucosamine residues (one at the reducing end) in a linear sequence, with one phosphate group attached.","InChI=1S/C40H65N2O35P/c1-11(45)41-21-27(56)25(54)19(71-33(21)58)9-68-34-22(42-12(2)46)28(57)32(77-78(65,66)67)20(72-34)10-70-39(36(61)62)5-18(26(55)30(75-39)16(50)7-44)73-40(37(63)64)4-14(48)24(53)31(76-40)17(51)8-69-38(35(59)60)3-13(47)23(52)29(74-38)15(49)6-43/h13-34,43-44,47-58H,3-10H2,1-2H3,(H,41,45)(H,42,46)(H,59,60)(H,61,62)(H,63,64)(H2,65,66,67)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33+,34-,38-,39-,40-/m1/s1",Kdo(2->8)Kdo(2->4)Kdo(2->6)GlcNAc4P(1->6)GlcNAcol,PubMed citation,20000757
2618,60381,alpha-D-Kdo-(2->4)-alpha-D-Kdo-(2->4)-alpha-D-Kdo-(2->6)-beta-D-GlcNAc-4P-(1->6)-alpha-D-GlcNAc,"An amino pentasaccharide epitope consisting of three 3-deoxy-D-manno-oct-2-ulose residues and two N-acetylglucosamine residues (one at the reducing end) in a linear sequence, with one phosphate group attached.","InChI=1S/C40H65N2O35P/c1-11(46)41-21-27(56)24(53)19(70-33(21)58)9-68-34-22(42-12(2)47)28(57)32(77-78(65,66)67)20(71-34)10-69-38(35(59)60)4-17(25(54)30(74-38)15(50)7-44)73-40(37(63)64)5-18(26(55)31(76-40)16(51)8-45)72-39(36(61)62)3-13(48)23(52)29(75-39)14(49)6-43/h13-34,43-45,48-58H,3-10H2,1-2H3,(H,41,46)(H,42,47)(H,59,60)(H,61,62)(H,63,64)(H2,65,66,67)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33+,34-,38-,39-,40-/m1/s1",Kdo(2->4)Kdo(2->4)Kdo(2->6)GlcNAc4P(1->6)GlcNAcol,PubMed citation,20000757
2619,60382,alpha-D-Kdo-(2->8)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->4)-alpha-D-Kdo,"A brached tetrasaccharide epitope consisting of four 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl residues, linked as shown.","InChI=1S/C32H50O29/c33-5-11(38)21-17(42)9(36)1-30(59-21,26(48)49)55-8-14(41)24-20(45)16(57-31(27(50)51)2-10(37)18(43)22(60-31)12(39)6-34)4-32(61-24,28(52)53)56-15-3-29(54,25(46)47)58-23(19(15)44)13(40)7-35/h9-24,33-45,54H,1-8H2,(H,46,47)(H,48,49)(H,50,51)(H,52,53)/t9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,29-,30-,31-,32-/m1/s1",Kdo(2->8)[Kdo(2->4)]Kdo(2->4)Kdo,PubMed citation,20000757
2620,60383,alpha-D-Kdo-(2->8)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->4)-alpha-D-Kdo-(2->6)-beta-D-GlcN-4P-(1->6)-alpha-D-GlcN-1P,"A six-membered oligosaccharide phosphate antigen consisting of four 3-deoxy-D-manno-oct-2-ulose residues and two glucosamine residues (one at the reducing end) in a branched sequence, with two phosphate groups attached.","InChI=1S/C44H74N2O43P2/c45-21-28(61)25(58)19(80-36(21)89-91(74,75)76)9-77-35-22(46)29(62)34(88-90(71,72)73)20(81-35)10-79-42(38(65)66)3-17(26(59)32(85-42)15(54)7-49)83-44(40(69)70)4-18(82-43(39(67)68)2-12(51)24(57)31(86-43)14(53)6-48)27(60)33(87-44)16(55)8-78-41(37(63)64)1-11(50)23(56)30(84-41)13(52)5-47/h11-36,47-62H,1-10,45-46H2,(H,63,64)(H,65,66)(H,67,68)(H,69,70)(H2,71,72,73)(H2,74,75,76)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,41-,42-,43-,44-/m1/s1",Kdo(2->8)[Kdo(2->4)]Kdo(2->4)Kdo(2->6)GlcN4P(1->6)GlcN1P,KEGG GLYCAN accession,G05419
2621,60384,"N-(2,3-dihydroxyhexacosanoyl)-(4R)-hydroxysphinganine","A phytoceramide having (2S,3R)-2,3-dihydroxyhexacosanoyl as the N-acyl group.","InChI=1S/C44H89NO6/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-41(48)43(50)44(51)45-39(38-46)42(49)40(47)36-34-32-30-28-26-16-14-12-10-8-6-4-2/h39-43,46-50H,3-38H2,1-2H3,(H,45,51)/t39-,40+,41+,42-,43-/m0/s1",cer4_26,PubMed citation,9368039
2622,60393,alpha-Kdo-(2->8)-[alpha-Kdo-(2->4)]-alpha-Kdo,A trisaccharide consisting of three 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl units in a branched sequence.,"InChI=1S/C24H38O22/c25-4-9(29)16-13(32)7(27)1-23(45-16,20(37)38)42-6-11(31)18-15(34)12(3-22(41,44-18)19(35)36)43-24(21(39)40)2-8(28)14(33)17(46-24)10(30)5-26/h7-18,25-34,41H,1-6H2,(H,35,36)(H,37,38)(H,39,40)/t7-,8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,22-,23-,24-/m1/s1",Kdo(2->8)[Kdo(2->4)]Kdo,PubMed citation,20000757
2623,60399,"2-O-sulfo-3,4-di-O-methyl-alpha-L-rhamnose","The 2-O-sulfo-3,4-di-O-methyl derivative of alpha-L-rhamnopyranose","InChI=1S/C8H16O8S/c1-4-5(13-2)6(14-3)7(8(9)15-4)16-17(10,11)12/h4-9H,1-3H3,(H,10,11,12)/t4-,5-,6+,7+,8+/m0/s1","2-sulfate-3,4-di-O-methyl-alpha-L-rhamnose",PubMed citation,8025677
2624,60402,Ins-1-P-Cer(d18:0/24:0),A ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen.,"InChI=1S/C48H96NO11P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(51)49-40(41(50)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2)39-59-61(57,58)60-48-46(55)44(53)43(52)45(54)47(48)56/h40-41,43-48,50,52-56H,3-39H2,1-2H3,(H,49,51)(H,57,58)/t40-,41+,43-,44-,45+,46+,47+,48-/m0/s1",IPC-A (C24),PubMed citation,9368039
2625,60404,D-glucosyl-N-tetracosanoylsphinganine,A glycodihydroceramide that is a sphinganine derivative having a D-glucosyl group at the 1-position and a tetracosanoyl group attached to the nitrogen.,"InChI=1S/C48H95NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h41-43,45-48,50-51,53-55H,3-40H2,1-2H3,(H,49,52)/t41-,42+,43+,45+,46-,47+,48?/m0/s1",N-lignoceroyldihyroglucocerebroside,PubMed citation,831265
2626,60405,Ins-1-P-Cer(d18:0/26:0),A ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen and no hydroxylation at C-4 of the long-chain base or at C-2 or C-3 of the very-long-chain fatty acid.,"InChI=1S/C50H100NO11P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-44(53)51-42(43(52)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2)41-61-63(59,60)62-50-48(57)46(55)45(54)47(56)49(50)58/h42-43,45-50,52,54-58H,3-41H2,1-2H3,(H,51,53)(H,59,60)/t42-,43+,45-,46-,47+,48+,49+,50-/m0/s1",IPC-A (C26),PubMed citation,9368039
2627,60406,Ins-1-P-Cer(d18:0/2-OH-24:0),"A ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, no hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C48H96NO12P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-37-41(51)48(57)49-39(40(50)36-34-32-30-28-26-24-16-14-12-10-8-6-4-2)38-60-62(58,59)61-47-45(55)43(53)42(52)44(54)46(47)56/h39-47,50-56H,3-38H2,1-2H3,(H,49,57)(H,58,59)/t39-,40+,41-,42-,43-,44+,45+,46+,47-/m0/s1",IPC-B' (C24),PubMed citation,9368039
2628,60407,D-galactosyl-N-tetracosanoylsphinganine,A glycodihydroceramide that is a sphinganine derivative having a D-galactosyl group at the 1-position and a tetracosanoyl group attached to the nitrogen.,"InChI=1S/C48H95NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h41-43,45-48,50-51,53-55H,3-40H2,1-2H3,(H,49,52)/t41-,42+,43+,45-,46-,47+,48?/m0/s1",Gal-24,PubMed citation,831265
2629,60408,D-galactosyl-N-hexadecanoylsphinganine,A  glycodihydroceramide that is a sphinganine derivative having a D-galactosyl group at the 1-position and a hexadecanoyl group attached to the nitrogen.,"InChI=1S/C40H79NO8/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(43)33(32-48-40-39(47)38(46)37(45)35(31-42)49-40)41-36(44)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h33-35,37-40,42-43,45-47H,3-32H2,1-2H3,(H,41,44)/t33-,34+,35+,37-,38-,39+,40?/m0/s1",N-palmitoyldihyrogalactocerebroside,PubMed citation,831265
2630,60409,Ins-1-P-Cer(d18:0/2-OH-26:0),"A ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen, no hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C50H100NO12P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-39-43(53)50(59)51-41(42(52)38-36-34-32-30-28-26-16-14-12-10-8-6-4-2)40-62-64(60,61)63-49-47(57)45(55)44(54)46(56)48(49)58/h41-49,52-58H,3-40H2,1-2H3,(H,51,59)(H,60,61)/t41-,42+,43-,44-,45-,46+,47+,48+,49-/m0/s1",IPC-B' (C26),PubMed citation,9368039
2631,60410,Ins-1-P-Cer(t18:0/24:0),"A ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and no additional hydroxylation of the very-long-chain fatty acid.","InChI=1S/C48H96NO12P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-41(51)49-39(38-60-62(58,59)61-48-46(56)44(54)43(53)45(55)47(48)57)42(52)40(50)36-34-32-30-28-26-16-14-12-10-8-6-4-2/h39-40,42-48,50,52-57H,3-38H2,1-2H3,(H,49,51)(H,58,59)/t39-,40-,42-,43-,44-,45+,46+,47+,48-/m0/s1",IPC-B (C24),PubMed citation,9368039
2632,60412,Ins-1-P-Cer(t18:0/26:0),"A ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and no additional hydroxylation of the very-long-chain fatty acid.","InChI=1S/C50H100NO12P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-43(53)51-41(40-62-64(60,61)63-50-48(58)46(56)45(55)47(57)49(50)59)44(54)42(52)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h41-42,44-50,52,54-59H,3-40H2,1-2H3,(H,51,53)(H,60,61)/t41-,42-,44-,45-,46-,47+,48+,49+,50-/m0/s1",IPC-B (C26),LIPID MAPS instance accession,LMSP03030002
2633,60413,Ins-1-P-Cer(t18:0/2-OH-24:0),"A ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C48H96NO13P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-40(51)48(58)49-38(37-61-63(59,60)62-47-45(56)43(54)42(53)44(55)46(47)57)41(52)39(50)35-33-31-29-27-25-16-14-12-10-8-6-4-2/h38-47,50-57H,3-37H2,1-2H3,(H,49,58)(H,59,60)/t38-,39-,40-,41-,42-,43-,44+,45+,46+,47-/m0/s1",IPC-C (C24),PubMed citation,9368039
2634,60414,"Ins-1-P-Cer(t18:0/2,3-OH-24:0)","A ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 and C-3 of the very-long-chain fatty acid.","InChI=1S/C48H96NO14P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-39(51)41(53)48(59)49-37(36-62-64(60,61)63-47-45(57)43(55)42(54)44(56)46(47)58)40(52)38(50)34-32-30-28-26-24-16-14-12-10-8-6-4-2/h37-47,50-58H,3-36H2,1-2H3,(H,49,59)(H,60,61)/t37-,38+,39+,40-,41-,42-,43-,44+,45+,46+,47-/m0/s1",IPC-D (C24),PubMed citation,9368039
2635,60415,"Ins-1-P-Cer(t18:0/2,3-OH-26:0)","A ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 and C-3 of the very-long-chain fatty acid.","InChI=1S/C50H100NO14P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-41(53)43(55)50(61)51-39(38-64-66(62,63)65-49-47(59)45(57)44(56)46(58)48(49)60)42(54)40(52)36-34-32-30-28-26-16-14-12-10-8-6-4-2/h39-49,52-60H,3-38H2,1-2H3,(H,51,61)(H,62,63)/t39-,40+,41+,42-,43-,44-,45-,46+,47+,48+,49-/m0/s1",IPC-D (C26),PubMed citation,9368039
2636,60416,Man-beta1-6-Ins-1-P-Cer(d18:0/24:0),"A mannosylated ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, with no hydroxylation at C-4 of the long-chain base or on the very-long-chain fatty acid.","InChI=1S/C54H106NO16P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(58)55-41(42(57)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2)40-68-72(66,67)71-53-50(64)48(62)47(61)49(63)52(53)70-54-51(65)46(60)45(59)43(39-56)69-54/h41-43,45-54,56-57,59-65H,3-40H2,1-2H3,(H,55,58)(H,66,67)/t41-,42+,43+,45+,46-,47+,48+,49-,50+,51-,52+,53+,54-/m0/s1",MIPC-A (C24),PubMed citation,9368039
2637,60417,Man-beta1-6-Ins-1-P-Cer(d20:0/26:0),"A mannosylated ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen, with no hydroxylation at C-4 of the long-chain base or on the very-long-chain fatty acid.","InChI=1S/C58H114NO16P/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-42-48(62)59-45(46(61)41-39-37-35-33-31-29-27-18-16-14-12-10-8-6-4-2)44-72-76(70,71)75-57-54(68)52(66)51(65)53(67)56(57)74-58-55(69)50(64)49(63)47(43-60)73-58/h45-47,49-58,60-61,63-69H,3-44H2,1-2H3,(H,59,62)(H,70,71)/t45-,46+,47+,49+,50-,51+,52+,53-,54+,55-,56+,57+,58-/m0/s1",MIPC-A (C26),PubMed citation,9368039
2638,60418,Man-beta1-6-Ins-1-P-Cer(d18:0/2-OH-24:0),"A mannosylated ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, with hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C54H106NO17P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-37-42(58)53(66)55-40(41(57)36-34-32-30-28-26-24-16-14-12-10-8-6-4-2)39-69-73(67,68)72-52-49(64)47(62)46(61)48(63)51(52)71-54-50(65)45(60)44(59)43(38-56)70-54/h40-52,54,56-65H,3-39H2,1-2H3,(H,55,66)(H,67,68)/t40-,41+,42?,43+,44+,45-,46+,47+,48-,49+,50-,51+,52+,54-/m0/s1",MIPC-B' (C24),PubMed citation,9368039
2639,60419,Man-beta1-6-Ins-1-P-Cer(d20:0/2-OH-26:0),"A mannosylated ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen, with hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C58H114NO17P/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-27-29-31-33-35-37-39-41-46(62)57(70)59-44(45(61)40-38-36-34-32-30-28-26-18-16-14-12-10-8-6-4-2)43-73-77(71,72)76-56-53(68)51(66)50(65)52(67)55(56)75-58-54(69)49(64)48(63)47(42-60)74-58/h44-56,58,60-69H,3-43H2,1-2H3,(H,59,70)(H,71,72)/t44-,45+,46?,47+,48+,49-,50+,51+,52-,53+,54-,55+,56+,58?/m0/s1",MIPC-B' (C26),PubMed citation,9368039
2640,60420,Man-beta1-6-Ins-1-P-Cer(t18:0/24:0),"A mannosylated ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, with hydroxylation at C-4 of the long-chain base.","InChI=1S/C54H106NO17P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-43(58)55-40(44(59)41(57)36-34-32-30-28-26-16-14-12-10-8-6-4-2)39-69-73(67,68)72-53-50(65)48(63)47(62)49(64)52(53)71-54-51(66)46(61)45(60)42(38-56)70-54/h40-42,44-54,56-57,59-66H,3-39H2,1-2H3,(H,55,58)(H,67,68)/t40-,41?,42+,44-,45+,46-,47+,48+,49-,50+,51-,52+,53+,54-/m0/s1",MIPC-B (C24),PubMed citation,9368039
2641,60421,Man-beta1-6-Ins-1-P-Cer(t20:0/26:0),"A mannosylated ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen, with hydroxylation at C-4 of the long-chain base.","InChI=1S/C58H114NO17P/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-41-47(62)59-44(48(63)45(61)40-38-36-34-32-30-28-18-16-14-12-10-8-6-4-2)43-73-77(71,72)76-57-54(69)52(67)51(66)53(68)56(57)75-58-55(70)50(65)49(64)46(42-60)74-58/h44-46,48-58,60-61,63-70H,3-43H2,1-2H3,(H,59,62)(H,71,72)/t44-,45?,46+,48-,49+,50-,51+,52+,53-,54+,55-,56+,57+,58?/m0/s1",MIPC-B (C26),PubMed citation,9368039
2642,60422,Man-beta1-6-Ins-1-P-Cer(t18:0/2-OH-24:0),"A mannosylated ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C54H106NO18P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-41(58)53(67)55-39(43(59)40(57)35-33-31-29-27-25-16-14-12-10-8-6-4-2)38-70-74(68,69)73-52-49(65)47(63)46(62)48(64)51(52)72-54-50(66)45(61)44(60)42(37-56)71-54/h39-52,54,56-66H,3-38H2,1-2H3,(H,55,67)(H,68,69)/t39-,40?,41?,42+,43-,44+,45-,46+,47+,48-,49+,50-,51+,52+,54-/m0/s1",MIPC-C (C24),PubMed citation,9368039
2643,60423,Man-beta1-6-Ins-1-P-Cer(t20:0/2-OH-26:0),"A mannosylated ceramide phosphoinositol compound having a hexacosanyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long chain base, and hydroxylation at C-2 of the very long chain fatty acid.","InChI=1S/C58H114NO18P/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-45(62)57(71)59-43(47(63)44(61)39-37-35-33-31-29-27-18-16-14-12-10-8-6-4-2)42-74-78(72,73)77-56-53(69)51(67)50(66)52(68)55(56)76-58-54(70)49(65)48(64)46(41-60)75-58/h43-56,58,60-70H,3-42H2,1-2H3,(H,59,71)(H,72,73)/t43-,44?,45?,46+,47-,48+,49-,50+,51+,52-,53+,54-,55+,56+,58?/m0/s1",MIPC-C (C26),LIPID MAPS instance accession,LMSP03030004
2644,60427,dioleoyl phosphatidic acid,A phosphatidic acid in which the phosphatidyl acyl groups are both oleoyl.,"InChI=1S/C39H73O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,37H,3-16,21-36H2,1-2H3,(H2,42,43,44)/b19-17-,20-18-","1,2-dioleoylglycerol-3-phosphate",LIPID MAPS instance accession,LMGP10010031
2645,60435,"Man-beta1-6-Ins-1-P-Cer(t18:0/2,3-OH-24:0)","A mannosylated ceramide phosphoinositol compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 and C-3 of the very-long-chain fatty acid.","InChI=1S/C54H106NO19P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-40(58)43(60)53(68)55-38(42(59)39(57)34-32-30-28-26-24-16-14-12-10-8-6-4-2)37-71-75(69,70)74-52-49(66)47(64)46(63)48(65)51(52)73-54-50(67)45(62)44(61)41(36-56)72-54/h38-52,54,56-67H,3-37H2,1-2H3,(H,55,68)(H,69,70)/t38-,39?,40?,41+,42-,43?,44+,45-,46+,47+,48-,49+,50-,51+,52+,54-/m0/s1",MIPC-D (C24),PubMed citation,9368039
2646,60436,"Man-beta1-6-Ins-1-P-Cer(t20:0/2,3-OH-26:0)","A mannosylated ceramide phosphoinositol compound having a hexacosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain-base, and hydroxylation at C-2 and C-3 of the very-long-chain fatty acid.","InChI=1S/C58H114NO19P/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-27-29-31-33-35-37-39-44(62)47(64)57(72)59-42(46(63)43(61)38-36-34-32-30-28-26-18-16-14-12-10-8-6-4-2)41-75-79(73,74)78-56-53(70)51(68)50(67)52(69)55(56)77-58-54(71)49(66)48(65)45(40-60)76-58/h42-56,58,60-71H,3-41H2,1-2H3,(H,59,72)(H,73,74)/t42-,43?,44?,45+,46-,47?,48+,49-,50+,51+,52-,53+,54-,55+,56+,58?/m0/s1",MIPC-D (C26),PubMed citation,9368039
2647,60437,[->2)-beta-Man-(1->2)-alpha-Man-(1->2)-[alpha-Glc-(1->3)]-alpha-Man(1->2)-alpha-Man(1->3)-beta-GlcNAc-(1->]2,A dodecasaccharide comprising two branched hexasaccharide units joined via a beta-(1->2) linkage. Part of the lipopolysaccharide obtained from Salmonella serogroup C1.,"InChI=1S/C76H128N2O61/c1-15(91)77-29-54(39(101)25(11-87)117-65(29)116)129-70-60(48(110)36(98)20(6-82)122-70)136-76-64(57(42(104)28(14-90)128-76)132-68-52(114)44(106)32(94)18(4-80)120-68)139-74-62(50(112)38(100)24(10-86)126-74)135-72-58(46(108)34(96)22(8-84)124-72)133-66-30(78-16(2)92)55(40(102)26(12-88)118-66)130-71-61(49(111)37(99)21(7-83)123-71)137-75-63(56(41(103)27(13-89)127-75)131-67-51(113)43(105)31(93)17(3-79)119-67)138-73-59(47(109)35(97)23(9-85)125-73)134-69-53(115)45(107)33(95)19(5-81)121-69/h17-76,79-90,93-116H,3-14H2,1-2H3,(H,77,91)(H,78,92)/t17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43+,44+,45+,46+,47+,48+,49+,50+,51-,52-,53+,54-,55-,56+,57+,58+,59+,60+,61+,62+,63+,64+,65-,66+,67-,68-,69+,70-,71-,72+,73-,74-,75-,76-/m1/s1",[->2)-beta-D-Man-(1->2)-alpha-D-Man-(1->2)-[alpha-D-Glc-(1->3)]-alpha-D-Man(1->2)-alpha-D-Man(1->3)-beta-D-GlcNAc-(1->]2,PubMed citation,7511532
2648,60439,Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(d18:0/24:0),An inositol phosphomannosylinositol phosphoceramide compound having a tetracosanoyl group attached to the ceramide nitrogen.,"InChI=1S/C60H117NO24P2/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(63)61-41(42(62)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2)39-80-86(76,77)85-59-55(74)51(70)50(69)54(73)58(59)83-60-56(75)46(65)45(64)43(82-60)40-81-87(78,79)84-57-52(71)48(67)47(66)49(68)53(57)72/h41-43,45-60,62,64-75H,3-40H2,1-2H3,(H,61,63)(H,76,77)(H,78,79)/t41-,42+,43+,45+,46-,47-,48-,49+,50+,51+,52+,53+,54-,55+,56-,57-,58+,59+,60-/m0/s1",M(IP)2C-A,PubMed citation,18296751
2649,60440,Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(d20:0/26:0),An inositol phosphomannosylinositol phosphoceramide compound having a hexacosanoyl group attached to the ceramide nitrogen.,"InChI=1S/C64H125NO24P2/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-42-48(67)65-45(46(66)41-39-37-35-33-31-29-27-18-16-14-12-10-8-6-4-2)43-84-90(80,81)89-63-59(78)55(74)54(73)58(77)62(63)87-64-60(79)50(69)49(68)47(86-64)44-85-91(82,83)88-61-56(75)52(71)51(70)53(72)57(61)76/h45-47,49-64,66,68-79H,3-44H2,1-2H3,(H,65,67)(H,80,81)(H,82,83)/t45-,46+,47+,49+,50-,51-,52-,53+,54+,55+,56+,57+,58-,59+,60-,61-,62+,63+,64?/m0/s1",M(IP)2C-A (C26),PubMed citation,18296751
2650,60441,Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(d18:0/2-OH-24:0),"A mannosylinositol phosphorylceramide compound having an inositol 1-phosphoryl group attached to the mannose residue and a tetracosanoyl group attached to the ceramide nitrogen, with no hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C60H117NO25P2/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-37-42(63)59(76)61-40(41(62)36-34-32-30-28-26-24-16-14-12-10-8-6-4-2)38-81-87(77,78)86-58-54(74)50(70)49(69)53(73)57(58)84-60-55(75)45(65)44(64)43(83-60)39-82-88(79,80)85-56-51(71)47(67)46(66)48(68)52(56)72/h40-58,60,62-75H,3-39H2,1-2H3,(H,61,76)(H,77,78)(H,79,80)/t40-,41+,42?,43+,44+,45-,46-,47-,48+,49+,50+,51+,52+,53-,54+,55-,56-,57+,58+,60-/m0/s1",M(IP)2C-B' (C24),PubMed citation,18296751
2651,60442,Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(d20:0/2-OH-26:0),"An inositol phosphomannosylinositol phosphoceramide compound having a hexacosaonyl group attached to the ceramide nitrogen, with no hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C64H125NO25P2/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-27-29-31-33-35-37-39-41-46(67)63(80)65-44(45(66)40-38-36-34-32-30-28-26-18-16-14-12-10-8-6-4-2)42-85-91(81,82)90-62-58(78)54(74)53(73)57(77)61(62)88-64-59(79)49(69)48(68)47(87-64)43-86-92(83,84)89-60-55(75)51(71)50(70)52(72)56(60)76/h44-62,64,66-79H,3-43H2,1-2H3,(H,65,80)(H,81,82)(H,83,84)/t44-,45+,46?,47+,48+,49-,50-,51-,52+,53+,54+,55+,56+,57-,58+,59-,60-,61+,62+,64?/m0/s1",M(IP)2C-B' (C26),PubMed citation,18296751
2652,60443,Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t18:0/24:0),"An inositol phosphomannosylinositol phosphoceramide compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and no additional hydroxylation of the very-long-chain fatty acid.","InChI=1S/C60H117NO25P2/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-43(63)61-40(44(64)41(62)36-34-32-30-28-26-16-14-12-10-8-6-4-2)38-81-87(77,78)86-59-55(75)51(71)50(70)54(74)58(59)84-60-56(76)46(66)45(65)42(83-60)39-82-88(79,80)85-57-52(72)48(68)47(67)49(69)53(57)73/h40-42,44-60,62,64-76H,3-39H2,1-2H3,(H,61,63)(H,77,78)(H,79,80)/t40-,41?,42+,44-,45+,46-,47-,48-,49+,50+,51+,52+,53+,54-,55+,56-,57-,58+,59+,60-/m0/s1",M(IP)2C-B (C24),PubMed citation,18296751
2653,60444,Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t20:0/26:0),"An inositol phosphomannosylinositol phosphoceramide compound having a hexacosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and no additional hydroxylation of the very-long-chain fatty acid.","InChI=1S/C64H125NO25P2/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-41-47(67)65-44(48(68)45(66)40-38-36-34-32-30-28-18-16-14-12-10-8-6-4-2)42-85-91(81,82)90-63-59(79)55(75)54(74)58(78)62(63)88-64-60(80)50(70)49(69)46(87-64)43-86-92(83,84)89-61-56(76)52(72)51(71)53(73)57(61)77/h44-46,48-64,66,68-80H,3-43H2,1-2H3,(H,65,67)(H,81,82)(H,83,84)/t44-,45?,46+,48-,49+,50-,51-,52-,53+,54+,55+,56+,57+,58-,59+,60-,61-,62+,63+,64?/m0/s1",M(IP)2C-B (C26),PubMed citation,18296751
2654,60445,Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t18:0/2-OH-24:0),"An inositol phosphomannosylinositol phosphoceramide compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 of the very-long-chain fatty acid.","InChI=1S/C60H117NO26P2/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-41(63)59(77)61-39(43(64)40(62)35-33-31-29-27-25-16-14-12-10-8-6-4-2)37-82-88(78,79)87-58-54(75)50(71)49(70)53(74)57(58)85-60-55(76)45(66)44(65)42(84-60)38-83-89(80,81)86-56-51(72)47(68)46(67)48(69)52(56)73/h39-58,60,62-76H,3-38H2,1-2H3,(H,61,77)(H,78,79)(H,80,81)/t39-,40?,41?,42+,43-,44+,45-,46-,47-,48+,49+,50+,51+,52+,53-,54+,55-,56-,57+,58+,60-/m0/s1",M(IP)2C-C (C24),PubMed citation,18296751
2655,60446,"Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t18:0/2,3-OH-24:0)","An inositol phosphomannosylinositol phosphoceramide compound having a tetracosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 and C-3 of the very-long-chain fatty acid.","InChI=1S/C60H117NO27P2/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-40(63)43(65)59(78)61-38(42(64)39(62)34-32-30-28-26-24-16-14-12-10-8-6-4-2)36-83-89(79,80)88-58-54(76)50(72)49(71)53(75)57(58)86-60-55(77)45(67)44(66)41(85-60)37-84-90(81,82)87-56-51(73)47(69)46(68)48(70)52(56)74/h38-58,60,62-77H,3-37H2,1-2H3,(H,61,78)(H,79,80)(H,81,82)/t38-,39?,40?,41+,42-,43?,44+,45-,46-,47-,48+,49+,50+,51+,52+,53-,54+,55-,56-,57+,58+,60-/m0/s1",M(IP)2C-D (C24),PubMed citation,18296751
2656,60447,"Ins-1-P-6-Man-beta1-6-Ins-1-P-Cer(t20:0/2,3-OH-26:0)","An inositol phosphomannosylinositol phosphoceramide compound having a hexacosanoyl group attached to the ceramide nitrogen, hydroxylation at C-4 of the long-chain base, and hydroxylation at C-2 and C-3 of the very-long-chain fatty acid.","InChI=1S/C64H125NO27P2/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-27-29-31-33-35-37-39-44(67)47(69)63(82)65-42(46(68)43(66)38-36-34-32-30-28-26-18-16-14-12-10-8-6-4-2)40-87-93(83,84)92-62-58(80)54(76)53(75)57(79)61(62)90-64-59(81)49(71)48(70)45(89-64)41-88-94(85,86)91-60-55(77)51(73)50(72)52(74)56(60)78/h42-62,64,66-81H,3-41H2,1-2H3,(H,65,82)(H,83,84)(H,85,86)/t42-,43?,44?,45+,46-,47?,48+,49-,50-,51-,52+,53+,54+,55+,56+,57-,58+,59-,60-,61+,62+,64?/m0/s1",M(IP)2C-D (C26),PubMed citation,18296751
2657,60453,2-O-oleoyl-3-O-palmitoyl-1-O-alpha-D-galactosyl-sn-glycerol,"A 2,3-diacyl-1-alpha-D-galactosyl-sn-glycerol in which the groups at the 2- and 3-positions are oleoyl and palmitoyl respectively.","InChI=1S/C43H80O10/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(45)50-34-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)52-39(46)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h17-18,36-37,40-44,47-49H,3-16,19-35H2,1-2H3/b18-17-/t36-,37+,40-,41-,42+,43-/m0/s1",BbGL-2c,PubMed citation,20080535
2658,60455,1-O-linoleoyl-2-O-oleoyl-3-O-alpha-D-galactosyl-sn-glycerol,"A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are linoleoyl and oleoyl respectively.","InChI=1S/C45H80O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(47)52-36-38(37-53-45-44(51)43(50)42(49)39(35-46)55-45)54-41(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11,13,17-20,38-39,42-46,49-51H,3-10,12,14-16,21-37H2,1-2H3/b13-11-,19-17-,20-18-/t38-,39+,42-,43-,44+,45-/m0/s1",BbGl-2f,PubMed citation,20080535
2659,60467,D-alanyl-D-serine,A dipeptide comprising D-serine with a D-alanyl residue attached to the alpha-nitrogen.,"InChI=1S/C6H12N2O4/c1-3(7)5(10)8-4(2-9)6(11)12/h3-4,9H,2,7H2,1H3,(H,8,10)(H,11,12)/t3-,4-/m1/s1",D-Ala-D-Ser,Beilstein Registry Number,11298782
2660,60476,1-O-(alpha-D-glucopyranuronosyl)-N-tetradecanoyldihydrosphingosine,A glycodihydroceramide having an alpha-D-glucuronic acid residue at the O-1 position and a tetradecanoyl group attached to the nitrogen.,"InChI=1S/C38H73NO9/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-31(40)30(29-47-38-35(44)33(42)34(43)36(48-38)37(45)46)39-32(41)28-26-24-22-20-17-14-12-10-8-6-4-2/h30-31,33-36,38,40,42-44H,3-29H2,1-2H3,(H,39,41)(H,45,46)/t30-,31+,33-,34-,35+,36-,38-/m0/s1",alpha-glucuronyl ceramide,PubMed citation,16007091
2661,60477,beta-D-galactosyl-(1->3)-alpha-D-mannose,A glycosylmannose consisting of an beta-D-galactosyl residue attached to alpha-D-mannose at the 3-position.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5+,6-,7+,8-,9+,10+,11+,12+/m1/s1",beta-D-Galp-(1->3)-alpha-D-Manp,PubMed citation,2472273
2662,60478,[3)alpha-L-Rhap-(1->2)-alpha-D-Galp-(1->3)-alpha-D-GlcpNAc-(1->3)-alpha-L-Rhap(1->]4,The amino hexadecasaccharide obtained when four molecules of the repeating tetrasacchride unit from Shigella dysenteriae O-specific polysaccharide are joined via alpha-(1->3) linkages.,"InChI=1S/C104H174N4O73/c1-21-45(121)61(137)66(142)94(152-21)178-85-62(138)53(129)33(13-109)163-101(85)167-75-42(106-30(10)118)91(160-38(18-114)58(75)134)172-79-47(123)23(3)153-95(68(79)144)176-83-51(127)27(7)157-99(72(83)148)180-87-64(140)55(131)35(15-111)165-103(87)169-77-44(108-32(12)120)93(162-40(20-116)60(77)136)174-81-49(125)25(5)155-97(70(81)146)177-84-52(128)28(8)158-100(73(84)149)181-88-65(141)56(132)36(16-112)166-104(88)170-76-43(107-31(11)119)92(161-39(19-115)59(76)135)173-80-48(124)24(4)154-96(69(80)145)175-82-50(126)26(6)156-98(71(82)147)179-86-63(139)54(130)34(14-110)164-102(86)168-74-41(105-29(9)117)90(159-37(17-113)57(74)133)171-78-46(122)22(2)151-89(150)67(78)143/h21-28,33-104,109-116,121-150H,13-20H2,1-12H3,(H,105,117)(H,106,118)(H,107,119)(H,108,120)/t21-,22-,23-,24-,25-,26-,27-,28-,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57+,58+,59+,60+,61+,62-,63-,64-,65-,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94-,95-,96-,97-,98-,99-,100-,101+,102+,103+,104+/m0/s1",[3)alpha-L-Rha-(1->2)-alpha-D-Gal-(1->3)-alpha-D-GlcNAc-(1->3)-alpha-L-Rha(1->]4,PubMed citation,10220442
2663,60481,"N',N'',N'''-triacetylfusarinine C",An hydroxamate siderophore produced by several fungal species.,"InChI=1S/C39H57N6O15.Fe/c1-25-13-19-58-37(52)31(40-28(4)46)11-8-17-44(56)35(50)23-27(3)15-21-60-39(54)33(42-30(6)48)12-9-18-45(57)36(51)24-26(2)14-20-59-38(53)32(41-29(5)47)10-7-16-43(55)34(49)22-25;/h22-24,31-33H,7-21H2,1-6H3,(H,40,46)(H,41,47)(H,42,48);/q-3;+3/b25-22-,26-24-,27-23-;/t31-,32-,33-;/m0./s1",TAF,CAS Registry Number,59200-35-0
2664,60542,benzylpenilloaldehyde,"Degradation product of benzylpenicillin in which the thiolamino acid penicillamine and carbon dioxide from the labile carboxyl group have been lost, leaving a phenylacetylamino-acetaldehyde.","InChI=1S/C10H11NO2/c12-7-6-11-10(13)8-9-4-2-1-3-5-9/h1-5,7H,6,8H2,(H,11,13)",penilloaldehyde,PubMed citation,14483916
2665,60558,alpha-D-Kdo-4P-(2->6)-beta-D-GlcN-4P-(1->6)-alpha-D-GlcN-1P,"An amino trisaccharide consisting of a 3-deoxy-D-manno-oct-2-ulose residue and two glucosamine residues (one at the reducing end) in a linear sequence, with three phosphate groups attached. Isolated from the lipopolysaccharide obtained from Haemophilus influenzae.","InChI=1S/C20H39N2O25P3/c21-9-13(27)11(25)7(42-18(9)47-50(37,38)39)3-40-17-10(22)14(28)16(46-49(34,35)36)8(43-17)4-41-20(19(29)30)1-6(45-48(31,32)33)12(26)15(44-20)5(24)2-23/h5-18,23-28H,1-4,21-22H2,(H,29,30)(H2,31,32,33)(H2,34,35,36)(H2,37,38,39)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,20-/m1/s1",Kdo4P(2->6)GlcNAc4P(1->6)GlcN1P,KEGG GLYCAN accession,G12260
2666,60559,alpha-D-Kdo-5P-(2->6)-beta-D-GlcN-4P-(1->6)-alpha-D-GlcN-1P,"An amino trisaccharide consisting of a 3-deoxy-D-manno-oct-2-ulose residue and two glucosamine residues (one at the reducing end) in a linear sequence, with three phosphate groups attached. Isolated from the lipopolysaccharide obtained from Haemophilus influenzae.","InChI=1S/C20H39N2O25P3/c21-9-12(27)11(26)7(42-18(9)47-50(37,38)39)3-40-17-10(22)13(28)16(46-49(34,35)36)8(43-17)4-41-20(19(29)30)1-5(24)15(45-48(31,32)33)14(44-20)6(25)2-23/h5-18,23-28H,1-4,21-22H2,(H,29,30)(H2,31,32,33)(H2,34,35,36)(H2,37,38,39)/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,20-/m1/s1",3-deoxy-5-O-phosphono-alpha-D-manno-oct-2-ulonosyl-(2->6)-2-amino-2-deoxy-4-O-phosphono-beta-D-glucosyl-(1->6)-2-amino-2-deoxy-1-O-phosphono-alpha-D-glucose,KEGG GLYCAN accession,G12270
2667,60561,D-Glcp-(1->3)-[alpha-D-GlcpNAc-(1->2)]-6-PEA-L-alpha-D-Hepp-(1->3)-L-alpha-D-Hepp-(1->5)-[alpha-Kdo-(2->4)]-alpha-Kdo,A branched amino hexasaccharide corresponding to part of the lipooligosaccharide from Neisseria meningitidis.,"InChI=1S/C46H79N2O40P/c1-12(55)48-21-25(63)23(61)18(9-52)77-39(21)84-38-37(83-40-27(65)26(64)24(62)19(10-53)78-40)29(67)34(20(11-54)88-89(74,75)76-3-2-47)80-42(38)82-36-28(66)31(14(57)6-49)79-41(30(36)68)81-35-17(5-45(73,43(69)70)86-33(35)16(59)8-51)85-46(44(71)72)4-13(56)22(60)32(87-46)15(58)7-50/h13-42,49-54,56-68,73H,2-11,47H2,1H3,(H,48,55)(H,69,70)(H,71,72)(H,74,75)/t13-,14+,15-,16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26+,27-,28-,29-,30+,31-,32-,33-,34-,35-,36+,37+,38+,39-,40+,41-,42-,45-,46-/m1/s1",D-Glc-(1->3)-[alpha-D-GlcNAc-(1->2)]-6-PEA-L-alpha-D-Hep-(1->3)-L-alpha-D-Hep-(1->5)-[alpha-Kdo-(2->4)]-alpha-Kdo,PubMed citation,18835574
2668,60563,D-alpha-D-Hepp-(1->6)-beta-D-Glcp,A glycosylglucose where the glycosyl component is D-glycero-alpha-D-manno-heptopyranose attached via an alpha-(1->6)-linkage; the epitope of the lipooligosaccharide isolated from Haemophilus ducreyi strain ITM 2665.,"InChI=1S/C13H24O12/c14-1-3(15)11-8(19)7(18)10(21)13(25-11)23-2-4-5(16)6(17)9(20)12(22)24-4/h3-22H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10+,11-,12-,13+/m1/s1",D-alpha-D-Hep-(1->6)-beta-D-Glc,PubMed citation,9234768
2669,60567,p-azophenyltrimethylammonium,An azobenzene derivative carrying two para-trimethylammonium substituents.,"InChI=1S/C18H26N4/c1-21(2,3)17-11-7-15(8-12-17)19-20-16-9-13-18(14-10-16)22(4,5)6/h7-14H,1-6H3/q+2/b20-19+",TMA,CAS Registry Number,21704-61-0
2670,60568,"1,2-dioleoyl-sn-glycero-3-phospho-L-serine",A 3-sn-phosphatidyl L-serine in which the phosphatidyl acyl groups are both oleoyl.,"InChI=1S/C42H78NO10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(44)50-35-38(36-51-54(48,49)52-37-39(43)42(46)47)53-41(45)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,38-39H,3-16,21-37,43H2,1-2H3,(H,46,47)(H,48,49)/b19-17-,20-18-/t38-,39+/m1/s1",DOPS,PubMed citation,10936025
2671,60573,alpha-D-Kdo-5P-OAll,The 1-O-allyl-5-phospho derivative of 3-deoxy-alpha-D-manno-oct-2-ulopyranosonic acid.,"InChI=1S/C11H19O11P/c1-2-3-20-11(10(15)16)4-6(13)9(22-23(17,18)19)8(21-11)7(14)5-12/h2,6-9,12-14H,1,3-5H2,(H,15,16)(H2,17,18,19)/t6-,7-,8-,9-,11-/m1/s1",alpha-Kdo-5P-All,Beilstein Registry Number,4912027
2672,60596,alpha-Neu5Ac-(2->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,A linear amino pentasaccharide comprising lacto-N-neotetraose having an alpha-N-acetylneuraminyl residue attached at the 6-position of the galactosyl residue at the non-reducing end.,"InChI=1S/C37H62N2O29/c1-9(44)38-17-11(46)3-37(36(58)59,68-30(17)19(48)12(47)4-40)60-8-16-20(49)23(52)26(55)34(64-16)65-28-15(7-43)63-33(18(22(28)51)39-10(2)45)67-31-21(50)13(5-41)62-35(27(31)56)66-29-14(6-42)61-32(57)25(54)24(29)53/h11-35,40-43,46-57H,3-8H2,1-2H3,(H,38,44)(H,39,45)(H,58,59)/t11-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21-,22+,23-,24+,25+,26+,27+,28+,29+,30+,31-,32?,33-,34-,35-,37+/m0/s1",alpha-Neu5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,Beilstein Registry Number,4901893
2673,60597,eosin 5-isothiocyanate,"The 2',4',5',7'-tetrabromo-5-isothiocyanato derivative of fluorescein; exhibits phosphorescence with an emission maximum at ~680 nm.","InChI=1S/C21H7Br4NO5S/c22-12-4-10-18(14(24)16(12)27)30-19-11(5-13(23)17(28)15(19)25)21(10)9-2-1-7(26-6-32)3-8(9)20(29)31-21/h1-5,27-28H",EITC,Beilstein Registry Number,8369978
2674,60608,rhodamine B 5-isothiocyanate,The 5-isomer of rhodamine B isothiocyanate.,"InChI=1S/C29H29N3O3S.ClH/c1-5-31(6-2)20-10-13-23-26(16-20)35-27-17-21(32(7-3)8-4)11-14-24(27)28(23)22-12-9-19(30-18-36)15-25(22)29(33)34;/h9-17H,5-8H2,1-4H3;1H",rhodamine B isothiocyanate 5-isomer,Beilstein Registry Number,10753432
2675,60609,rhodamine B 6-isothiocyanate,The 6-isomer of rhodamine B isothiocyanate.,"InChI=1S/C29H29N3O3S/c1-5-31(6-2)20-10-13-23-26(16-20)35-27-17-21(32(7-3)8-4)11-14-24(27)28(23)25-15-19(30-18-36)9-12-22(25)29(33)34/h9-17H,5-8H2,1-4H3/p+1",rhodamine B isothiocyanate 6-isomer,PubMed citation,20371259
2676,60610,4-(trimethylammonium)benzenediazonium,An aromatic diazonium ion consiting of a benzene core with diazonium and trimethylammonium groups para to one another.,"InChI=1S/C9H13N3/c1-12(2,3)9-6-4-8(11-10)5-7-9/h4-7H,1-3H3/q+2",4-(trimethylammonium)benzenediazonium dication,Reaxys Registry Number,1842061
2677,60639,amoxicillin diketopiperazine,"A member of the class of 2,5-diketopiperazines obtained via autoaminolysis of amoxicillin.","InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-14(25-16)10-13(22)17-9(12(21)18-10)7-3-5-8(20)6-4-7/h3-6,9-11,14,19-20H,1-2H3,(H,17,22)(H,18,21)(H,23,24)/t9?,10?,11-,14+/m0/s1","amoxicillin 2,5-diketopiperazine",PubMed citation,19968633
2678,60650,alpha-D-Abep-(1->3)-alpha-D-Manp-(1->4)-alpha-L-Rhap,"A linear trisaccharide, which forms part of the repeating unit of the Salmonella serogroup B oligosaccharide.","InChI=1S/C18H32O13/c1-5-7(20)3-8(21)17(28-5)31-15-10(22)9(4-19)29-18(13(15)25)30-14-6(2)27-16(26)12(24)11(14)23/h5-26H,3-4H2,1-2H3/t5-,6+,7-,8-,9-,10-,11+,12-,13+,14+,15+,16-,17-,18-/m1/s1",alpha-D-Abe-(1->3)-alpha-D-Man-(1->4)-alpha-L-Rha,PubMed citation,1378926
2679,60659,"4,6-O-[(1R)-1-carboxyethylidene]-alpha-D-galactose","A 4,6-O-[(1R)-1-carboxyethylidene]-D-galactose having alpha-configuration at the anomeric centre.","InChI=1S/C9H14O8/c1-9(8(13)14)15-2-3-6(17-9)4(10)5(11)7(12)16-3/h3-7,10-12H,2H2,1H3,(H,13,14)/t3-,4-,5-,6+,7+,9-/m1/s1","4,6-Pydga",Reaxys Registry Number,5565106
2680,60694,2-(trifluoromethyl)benzoic acid,A benzoic acid carrying a trifluoromethyl substituent at the 2-position.,"InChI=1S/C8H5F3O2/c9-8(10,11)6-4-2-1-3-5(6)7(12)13/h1-4H,(H,12,13)",o-(trifluoromethyl)benzoic acid,CAS Registry Number,433-97-6
2681,60695,3-trifluoromethylbenzoic acid,A benzoic acid carrying a trifluoromethyl substituent at the 3-position.,"InChI=1S/C8H5F3O2/c9-8(10,11)6-3-1-2-5(4-6)7(12)13/h1-4H,(H,12,13)",m-(trifluoroformyl)benzoic acid,CAS Registry Number,454-92-2
2682,60697,"2,5-bis(trifluoromethyl)benzoic acid",A benzoic acid carrying trifluoromethyl substituents at the 2- and 5-positions.,"InChI=1S/C9H4F6O2/c10-8(11,12)4-1-2-6(9(13,14)15)5(3-4)7(16)17/h1-3H,(H,16,17)","2,5-bis(trifluoroformyl)benzoic acid",Reaxys Registry Number,1989837
2683,60698,4-bromobenzoic acid,A bromobenzoic acid carrying a single bromo subsituent at the 4-position.,"InChI=1S/C7H5BrO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,(H,9,10)",4-Brom-benzoesaeure,Reaxys Registry Number,1906923
2684,60702,"(2,2,2-trifluoroethoxy)acetic acid","An organofluorine compound consisting of acetic acid carrying a 2-(2,2,2-trifluoroethoxy) substituent.","InChI=1S/C4H5F3O3/c5-4(6,7)2-10-1-3(8)9/h1-2H2,(H,8,9)","(2,2,2-Trifluorethoxy)essigsaeure",Reaxys Registry Number,1858842
2685,60704,(E)-3-(trifluoromethyl)cinnamic acid,A member of the class of   (trifluoromethyl)benzenes consisting of trans-cinnamic acid having a trifluoromethyl substituent at the meta-position.,"InChI=1S/C10H7F3O2/c11-10(12,13)8-3-1-2-7(6-8)4-5-9(14)15/h1-6H,(H,14,15)/b5-4+",(E)-3-trifluoromethylcinnamic acid,Reaxys Registry Number,2504993
2686,60705,(E)-4-(trifluoromethyl)cinnamic acid,A member of the class of  (trifluoromethyl)benzenes consisting of trans-cinnamic acid having a trifluoromethyl substituent at the para-position.,"InChI=1S/C10H7F3O2/c11-10(12,13)8-4-1-7(2-5-8)3-6-9(14)15/h1-6H,(H,14,15)/b6-3+",trans-4-trifluoromethylcinnamic acid,Reaxys Registry Number,2452800
2687,60707,3-[2-(trifluoromethyl)phenyl]propanoic acid,A monocarboxylic acid comprising propionic acid having a 2-(trifluoromethyl)phenyl group at the 3-position.,"InChI=1S/C10H9F3O2/c11-10(12,13)8-4-2-1-3-7(8)5-6-9(14)15/h1-4H,5-6H2,(H,14,15)",3-[2-(trifluoromethyl)phenyl]propionic acid,Reaxys Registry Number,8620814
2688,60722,dilinoleoyl phosphatidylglycerol,A phosphatidylglycerol in which the phosphatidyl acyl groups are both linoleoyl.,"InChI=1S/C42H75O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11-14,17-20,39-40,43-44H,3-10,15-16,21-38H2,1-2H3,(H,47,48)/b13-11-,14-12-,19-17-,20-18-",C18:2 PG,CAS Registry Number,89315-60-6
2689,60723,ditetradecanoyl phosphatidylglycerol,A phosphatidylglycerol in which the phosphatidyl acyl groups are both tetradecanoyl (myristoyl).,"InChI=1S/C34H67O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-33(37)41-29-32(30-43-45(39,40)42-28-31(36)27-35)44-34(38)26-24-22-20-18-16-14-12-10-8-6-4-2/h31-32,35-36H,3-30H2,1-2H3,(H,39,40)/t31-,32+/m0/s1",C14:0 PG,Reaxys Registry Number,6622861
2690,60724,dipalmitoyl phosphatidylglycerol,A phosphatidylglycerol in which the phosphatidyl acyl groups are both palmitoyl.,"InChI=1S/C38H75O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(41)45-33-36(34-47-49(43,44)46-32-35(40)31-39)48-38(42)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h35-36,39-40H,3-34H2,1-2H3,(H,43,44)",C16:0 PG,DrugBank accession,DB02043
2691,60725,dilauroyl phosphatidylglycerol,A phosphatidylglycerol in which the phosphatidyl acyl groups are both lauroyl.,"InChI=1S/C30H59O10P/c1-3-5-7-9-11-13-15-17-19-21-29(33)37-25-28(26-39-41(35,36)38-24-27(32)23-31)40-30(34)22-20-18-16-14-12-10-8-6-4-2/h27-28,31-32H,3-26H2,1-2H3,(H,35,36)","1,2-dilauroylphosphatidylglycerol",Reaxys Registry Number,2196723
2692,60726,procainamide 4-hydroxylamine,A benzamide obtained via formal condensation of 4-hydroxylaminobenzoic acid and 2-(diethylamino)ethylamine; a metabolite in liver microsomes.,"InChI=1S/C13H21N3O2/c1-3-16(4-2)10-9-14-13(17)11-5-7-12(15-18)8-6-11/h5-8,15,18H,3-4,9-10H2,1-2H3,(H,14,17)",procainamide hydroxylamine,Reaxys Registry Number,8987397
2693,60729,4-nitrosoprocainamide,A benzamide obtained via formal condensation of 4-nitrosobenzoic acid and 2-(diethylamino)ethylamine.,"InChI=1S/C13H19N3O2/c1-3-16(4-2)10-9-14-13(17)11-5-7-12(15-18)8-6-11/h5-8H,3-4,9-10H2,1-2H3,(H,14,17)",NOPA,PubMed citation,10368311
2694,60730,beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf,"An arabinotetraose in which the four arabinofuranose residues are in a beta(1->2), alpha(1->5) and alpha(1->5) linear sequence (with alpha-configuration at the reducing end). Corresponds to part of the lipoarabinomannam from Mycobacterium leprae and M. tuberculosis.","InChI=1S/C20H34O17/c21-1-5-9(23)15(29)19(34-5)37-16-12(26)6(2-22)35-20(16)32-4-8-11(25)14(28)18(36-8)31-3-7-10(24)13(27)17(30)33-7/h5-30H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+/m1/s1",beta-D-Ara-(1->2)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara,PubMed citation,12368438
2695,60738,N-Ac-Asp-N(6)-lipoyl-KATIGFEVQEE,"A polypeptide comprising the 12-amino acid sequence KATIGFEVQEE where the N-terminal lysyl (K) residue has an acetyl group at the Nalpha-position and a lipoyl group on the side-chain. A component of the inner lipoyl domain of the second enzyme of the pyruvate dehydrogenase complex (PDC-E2), to which antibodies are raised in the autoimmune disease primary biliary cirrhosis.","InChI=1S/C69H106N14O25S2/c1-8-36(4)57(82-68(106)58(38(6)84)83-59(97)37(5)73-60(98)42(76-65(103)48(33-55(95)96)74-39(7)85)19-14-15-30-71-50(87)20-13-12-18-41-29-31-109-110-41)66(104)72-34-51(88)75-47(32-40-16-10-9-11-17-40)64(102)78-45(23-27-53(91)92)63(101)81-56(35(2)3)67(105)79-43(21-25-49(70)86)61(99)77-44(22-26-52(89)90)62(100)80-46(69(107)108)24-28-54(93)94/h9-11,16-17,35-38,41-48,56-58,84H,8,12-15,18-34H2,1-7H3,(H2,70,86)(H,71,87)(H,72,104)(H,73,98)(H,74,85)(H,75,88)(H,76,103)(H,77,99)(H,78,102)(H,79,105)(H,80,100)(H,81,101)(H,82,106)(H,83,97)(H,89,90)(H,91,92)(H,93,94)(H,95,96)(H,107,108)/t36-,37-,38+,41+,42-,43-,44-,45-,46-,47-,48-,56-,57-,58-/m0/s1","N-Ac-Asp-N(6)-{5-[(3R)-1,2-dithiolan-3-yl]pentanoyl}-Lys-Ala-Thr-Ile-Gly-Phe-Glu-Val-Gln-Glu-Glu",PubMed citation,11509645
2696,60747,alpha-Neu5Ac-(2->3)-beta-Gal-(1->3)-beta-GalNAc-(1->4)-beta-Gal-(1->4)-beta-Glc-(1<->1')-N-stearoylsphingosine,"A sialotetraosylceramide consisting of a linear pentasaccharide made up from one sialyl residues, two galactose residues, one N-acetylglucosamine residue and a glucose residue at the reducing end attached to N-stearoylsphingosine via a beta-linkage.","InChI=1S/C73H131N3O31/c1-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-52(87)76-44(45(84)33-31-29-27-25-23-21-18-16-14-12-10-8-6-2)41-98-69-60(93)58(91)64(50(39-80)101-69)104-70-61(94)59(92)63(51(40-81)102-70)103-68-54(75-43(4)83)65(56(89)48(37-78)99-68)105-71-62(95)67(57(90)49(38-79)100-71)107-73(72(96)97)35-46(85)53(74-42(3)82)66(106-73)55(88)47(86)36-77/h31,33,44-51,53-71,77-81,84-86,88-95H,5-30,32,34-41H2,1-4H3,(H,74,82)(H,75,83)(H,76,87)(H,96,97)/b33-31+/t44-,45+,46-,47+,48+,49+,50+,51+,53+,54+,55+,56-,57-,58+,59+,60+,61+,62+,63-,64+,65+,66+,67-,68-,69+,70-,71-,73-/m0/s1",alpha-Neu5Ac-(2->3)-beta-Galp-(1->3)-beta-GalpNAc-(1->4)-beta-Galp-(1->4)-beta-Glcp-(1<->1')-N-stearoylsphingosine,Reaxys Registry Number,5327003
2697,60785,2-keto-L-xylose,A 2-keto-xylose having L-threo configuration; a degradation product of L-ascorbic acid.,"InChI=1S/C5H8O5/c6-1-3(8)5(10)4(9)2-7/h1,4-5,7,9-10H,2H2/t4-,5-/m0/s1",L-lyxosone,Reaxys Registry Number,1723811
2698,60787,(S)-timolol hemihydrate,"A hydrate, which is the hemihydrate form of the (S)-(-) (more active) enantiomer of timolol.","InChI=1S/2C13H24N4O3S.H2O/c2*1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;/h2*10,14,18H,4-9H2,1-3H3;1H2/t2*10-;/m00./s1",timolol hemihydrate,CAS Registry Number,91524-16-2
2699,60789,bupivacaine hydrochloride hydrate,"A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride hydrate and levobupivacaine hydrochloride hydrate. A piperidinecarboxamide-based local anaesthetic, it has a slow onset and long duration of action.","InChI=1S/C18H28N2O.ClH.H2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H;1H2",bupivacaine monohydrochloride monohydrate,CAS Registry Number,73360-54-0
2700,60812,gentiobiose octaacetate,An acetate ester formed by total acetylation of gentiobiose.,"InChI=1S/C28H38O19/c1-11(29)37-9-19-21(39-12(2)30)23(41-14(4)32)25(43-16(6)34)27(46-19)38-10-20-22(40-13(3)31)24(42-15(5)33)26(44-17(7)35)28(47-20)45-18(8)36/h19-28H,9-10H2,1-8H3/t19-,20-,21-,22-,23+,24+,25-,26-,27-,28?/m1/s1",amygdalose octaacetate,PubMed citation,7691963
2701,60819,diphenyl phthalate,"The diphenyl ester of benzene-1,2-dicarboxylic acid.",InChI=1S/C20H14O4/c21-19(23-15-9-3-1-4-10-15)17-13-7-8-14-18(17)20(22)24-16-11-5-2-6-12-16/h1-14H,"diphenyl benzene-1,2-dicarboxylate",CAS Registry Number,84-62-8
2702,60829,streptothricin D(5+),A primary aliphatic ammonium ion which is obtained from streptothricin D by protonation of the guanidino and amino groups.,"InChI=1S/C31H58N12O10/c32-7-1-4-15(33)10-20(46)37-8-2-5-16(34)11-21(47)38-9-3-6-17(35)12-22(48)40-25-26(49)27(53-30(36)51)19(14-44)52-29(25)43-31-41-23-18(45)13-39-28(50)24(23)42-31/h15-19,23-27,29,44-45,49H,1-14,32-35H2,(H2,36,51)(H,37,46)(H,38,47)(H,39,50)(H,40,48)(H2,41,42,43)/p+5/t15-,16-,17-,18+,19+,23+,24-,25+,26-,27-,29+/m0/s1",streptothricin D penta-cation,PubMed citation,16641084
2703,60830,streptothricin D acid,The streptothricin acid obtained by hydrolysis of the lactam group of streptothricin D.,"InChI=1S/C31H60N12O11/c32-7-1-4-15(34)10-20(46)38-8-2-5-16(35)11-21(47)39-9-3-6-17(36)12-22(48)40-25-26(49)27(54-30(37)52)19(14-44)53-28(25)43-31-41-23(18(45)13-33)24(42-31)29(50)51/h15-19,23-28,44-45,49H,1-14,32-36H2,(H2,37,52)(H,38,46)(H,39,47)(H,40,48)(H,50,51)(H2,41,42,43)/t15-,16-,17-,18+,19+,23+,24-,25+,26-,27-,28+/m0/s1",antibiotic OP 2C acid,PubMed citation,16641084
2704,60833,naptalam,A dicarboxylic acid monoamide which results from addition of one equivalent of 1-naphthylamine to phthalic anhydride.,"InChI=1S/C18H13NO3/c20-17(14-9-3-4-10-15(14)18(21)22)19-16-11-5-7-12-6-1-2-8-13(12)16/h1-11H,(H,19,20)(H,21,22)",NPA,Reaxys Registry Number,2814102
2705,60868,DOSPA trifluoroacetate,"A quaternary ammonium salt in which the quaternary nitrogen is substituted by a 2,3-dioleyloxypropyl group, a [2-(sperminecarboxamido)ethyl group, and two methyl groups, and in which the positive charged is balanced by a trifluoroacetate anion.","InChI=1S/C54H110N6O3.C2HF3O2/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-48-62-51-52(63-49-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2)50-60(3,4)47-46-59-54(61)53(58-45-39-42-56)40-37-43-57-44-38-41-55;3-2(4,5)1(6)7/h19-22,52-53,57-58H,5-18,23-51,55-56H2,1-4H3;(H,6,7)/b21-19-,22-20-;",DOSPA,Reaxys Registry Number,8386142
2706,60869,(3-aminopropyl)(L-aspartyl-1-amino)phosphoryl-5'-adenosine,An organic phosphoramidate that is 5'-O-[amino(3-aminopropoxy)phosphoryl]adenosine in which the nitrogen of the phosphoramidite is acylated by a (2S)-2-amino-3-carboxypropanoyl group.,"InChI=1S/C17H27N8O9P/c18-2-1-3-32-35(31,24-16(30)8(19)4-10(26)27)33-5-9-12(28)13(29)17(34-9)25-7-23-11-14(20)21-6-22-15(11)25/h6-9,12-13,17,28-29H,1-5,18-19H2,(H,26,27)(H2,20,21,22)(H,24,30,31)/t8-,9+,12+,13+,17+,35?/m0/s1",(3-aminopropyl)(L-aspartyl-1-amino)phosphoryl-5'-adenosine,RESID accession,AA0328
2707,60872,leucodopachrome,"Indoline substituted with hydroxy groups at C-5 and -6 and a carboxy group at C-2, and with S stereochemistry at C-2.","InChI=1S/C9H9NO4/c11-7-2-4-1-6(9(13)14)10-5(4)3-8(7)12/h2-3,6,10-12H,1H2,(H,13,14)/t6-/m0/s1",cyclodopa,PubMed citation,11987411
2708,60875,3'-CMP(2-),A  nucleoside 3'-phosphate(2-) which results from the removal of two protons from the phosphate group of 3'-CMP; major species at pH 7.3.,"InChI=1S/C9H14N3O8P/c10-5-1-2-12(9(15)11-5)8-6(14)7(4(3-13)19-8)20-21(16,17)18/h1-2,4,6-8,13-14H,3H2,(H2,10,11,15)(H2,16,17,18)/p-2/t4-,6-,7-,8-/m1/s1",cytidine 3'-phosphate (2-),MetaCyc accession,CPD-3711
2709,60876,D-galactosyl-(1->4)-beta-D-glucose,A glycosylglucose comprising beta-D-glucose having a D-galactosyl residue at the 4-position.,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12?/m1/s1",D-Gal-(1->4)-beta-D-Glc,Reaxys Registry Number,14452624
2710,60877,"2',3'-cyclic CMP(1-)","A 2',3'-cyclic nucleotide(1-) which is obtained from 2',3'-cyclic CMP by removal of a proton from the cyclic phosphate group.","InChI=1S/C9H12N3O7P/c10-5-1-2-12(9(14)11-5)8-7-6(4(3-13)17-8)18-20(15,16)19-7/h1-2,4,6-8,13H,3H2,(H,15,16)(H2,10,11,14)/p-1/t4-,6-,7-,8-/m1/s1","cytidine 2',3'-cyclic monophosphate (1-)",MetaCyc accession,CPD-3713
2711,60880,3'-AMP(2-),The organophosphate oxoanion which results from the removal of two protons from the phosphate group of 3'-AMP; major species at pH 7.3.,"InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-6(17)7(4(1-16)21-10)22-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/p-2/t4-,6-,7-,10-/m1/s1",adenine-3'-monophosphate (2-),MetaCyc accession,CPD-3706
2712,60903,N-(4-aminobenzoyl)-L-glutamate,A dicarboxylic acid dianion which results from the removal of a proton from each of the carboxylic acid groups of N-(4-aminobenzoyl)-L-glutamic acid.,"InChI=1S/C12H14N2O5/c13-8-3-1-7(2-4-8)11(17)14-9(12(18)19)5-6-10(15)16/h1-4,9H,5-6,13H2,(H,14,17)(H,15,16)(H,18,19)/p-2/t9-/m0/s1",4-aminobenzoyl-glutamate,Reaxys Registry Number,8504215
2713,60907,(S)-ethylmalonyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of (2S)-ethylmalonic acid.,"InChI=1S/C26H42N7O19P3S/c1-4-13(24(38)39)25(40)56-8-7-28-15(34)5-6-29-22(37)19(36)26(2,3)10-49-55(46,47)52-54(44,45)48-9-14-18(51-53(41,42)43)17(35)23(50-14)33-12-32-16-20(27)30-11-31-21(16)33/h11-14,17-19,23,35-36H,4-10H2,1-3H3,(H,28,34)(H,29,37)(H,38,39)(H,44,45)(H,46,47)(H2,27,30,31)(H2,41,42,43)/t13-,14+,17+,18+,19-,23+/m0/s1",(S)-2-ethylmalonyl-CoA,Reaxys Registry Number,19783652
2714,60908,(2R)-2-hydroxy-2-methylbutanenitrile,The (2R)-enantiomer of 2-hydroxy-2-methylbutanenitrile.,"InChI=1S/C5H9NO/c1-3-5(2,7)4-6/h7H,3H2,1-2H3/t5-/m1/s1",(R)-butan-2-one cyanohydrin,Reaxys Registry Number,4349475
2715,60909,(S)-ethylmalonyl-CoA(5-),"An acyl-CoA oxoanion arising from deprotonation of the phosphate, diphosphate and carboxy groups of (2S)-ethylmalonyl-CoA.","InChI=1S/C26H42N7O19P3S/c1-4-13(24(38)39)25(40)56-8-7-28-15(34)5-6-29-22(37)19(36)26(2,3)10-49-55(46,47)52-54(44,45)48-9-14-18(51-53(41,42)43)17(35)23(50-14)33-12-32-16-20(27)30-11-31-21(16)33/h11-14,17-19,23,35-36H,4-10H2,1-3H3,(H,28,34)(H,29,37)(H,38,39)(H,44,45)(H,46,47)(H2,27,30,31)(H2,41,42,43)/p-5/t13-,14+,17+,18+,19-,23+/m0/s1",(S)-ethylmalonyl coenzyme A(5-),PubMed citation,17548827
2716,60913,ganglioside GT1b,A sialoheptaosylceramide where the sialoheptaosyl portion contains three sialic acid residues.,"InChI=1S/C95H165N5O47/c1-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-36-64(118)100-52(53(112)35-33-31-29-27-25-23-20-18-16-14-12-10-8-2)47-134-87-75(125)74(124)78(62(45-106)137-87)139-89-77(127)85(147-95(92(132)133)39-56(115)67(98-50(5)110)83(145-95)73(123)61(44-105)142-93(90(128)129)37-54(113)65(96-48(3)108)81(143-93)69(119)57(116)40-101)79(63(46-107)138-89)140-86-68(99-51(6)111)80(71(121)59(42-103)135-86)141-88-76(126)84(72(122)60(43-104)136-88)146-94(91(130)131)38-55(114)66(97-49(4)109)82(144-94)70(120)58(117)41-102/h33,35,52-63,65-89,101-107,112-117,119-127H,7-32,34,36-47H2,1-6H3,(H,96,108)(H,97,109)(H,98,110)(H,99,111)(H,100,118)(H,128,129)(H,130,131)(H,132,133)/b35-33+/t52-,53+,54-,55-,56-,57+,58+,59+,60+,61+,62+,63+,65+,66+,67+,68+,69+,70+,71-,72-,73+,74+,75+,76+,77+,78+,79-,80+,81+,82+,83+,84-,85+,86-,87+,88-,89-,93+,94-,95-/m0/s1",GT1b ganglioside (C36),Reaxys Registry Number,7158857
2717,60916,corynomycolic acid,A thirty-two membered mycolic acid consisting of 3-hydroxystearic acid having a tetradecyl group at the 2-position.,"InChI=1S/C32H64O3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31(33)30(32(34)35)28-26-24-22-20-18-16-14-12-10-8-6-4-2/h30-31,33H,3-29H2,1-2H3,(H,34,35)",synthetic mycolic acid,Reaxys Registry Number,1807083
2718,60923,R. ruber mycolic acid,A forty-six membered mycolic acid consisting of 3-hydroxydotriacontanoic acid having a tetradecyl group at the 2-position.,"InChI=1S/C46H92O3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-33-35-37-39-41-43-45(47)44(46(48)49)42-40-38-36-34-32-16-14-12-10-8-6-4-2/h44-45,47H,3-43H2,1-2H3,(H,48,49)",R. ruber mycolic acid (C46),PubMed citation,20519644
2719,60925,glucose 6-monomycolate (C46),A 6-O-acyl-D-glucose where the acyl group is 3-hydroxy-2-tetradecyldotriacontanoyl.,"InChI=1S/C52H102O8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-33-35-37-39-41-43-46(53)45(42-40-38-36-34-32-16-14-12-10-8-6-4-2)51(57)59-44-47-48(54)49(55)50(56)52(58)60-47/h45-50,52-56,58H,3-44H2,1-2H3/t45?,46?,47-,48-,49+,50-,52?/m1/s1",GMM (C46),PubMed citation,20519644
2720,60927,ciguatoxin JKLM ring fragment,A polycyclic ether comprising a central oxepine ring flanked by two fused tetrahydropyran rings together with a spiro-fused tetrahydrofuran ring. Corresponds to the JKLM ring fragment and epitope of ciguatoxin.,"InChI=1S/C21H34O8/c1-9(22)5-15-14(24)6-16-18(27-15)11(3)17(25)20-19(28-16)10(2)12(4)21(29-20)7-13(23)8-26-21/h10-20,23-25H,5-8H2,1-4H3/t10-,11-,12-,13-,14+,15-,16-,17-,18+,19+,20-,21+/m0/s1",JKLM ring,PubMed citation,18348309
2721,60928,alpha-D-Galp-(1->4)-beta-D-GalpNAc-(1->3)-D-Galp,An amino trisaccharide comprising an N-acetyl beta-D-galactosaminyl residue flanked by two D-galactopyranose residues (one at the reducing end).,"InChI=1S/C20H35NO16/c1-5(25)21-9-12(28)16(36-20-14(30)13(29)10(26)6(2-22)34-20)8(4-24)35-19(9)37-17-11(27)7(3-23)33-18(32)15(17)31/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12-,13+,14-,15-,16+,17+,18?,19+,20-/m1/s1",alpha-D-Gal-(1->4)-beta-D-GalNAc-(1->3)-D-Gal,Reaxys Registry Number,9310401
2722,60930,alpha-D-Galp-(1->4)-D-GalpNAc,An amino disaccharide consisting of N-acetylgalactosamine having an alpha-D-galactosyl residue at the 4-position,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)12(6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12+,13?,14-/m1/s1",alpha-D-Gal-(1->4)-D-GalNAc,Reaxys Registry Number,9298714
2723,60931,alpha-D-Galp-(1->3)-D-GalpNAc,An amino disaccharide consisting of N-acetylgalactosamine having an alpha-D-galactosyl residue at the 3-position,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10+,11-,12-,13?,14-/m1/s1",alpha-D-Gal-(1->3)-D-GalNAc,PubMed citation,17006649
2724,60932,(R)-carnitinyl-CoA(3-),An acyl-CoA oxoanion obtained from (R)-carnitinyl-CoA betaine in which three protons have been removed from the phosphate groups.,"InChI=1S/C28H49N8O18P3S/c1-28(2,23(41)26(42)31-7-6-18(38)30-8-9-58-19(39)10-16(37)11-36(3,4)5)13-51-57(48,49)54-56(46,47)50-12-17-22(53-55(43,44)45)21(40)27(52-17)35-15-34-20-24(29)32-14-33-25(20)35/h14-17,21-23,27,37,40-41H,6-13H2,1-5H3,(H7-,29,30,31,32,33,38,42,43,44,45,46,47,48,49)/p-3/t16-,17-,21-,22-,23+,27-/m1/s1",L-carnitinyl-CoA(3-),MetaCyc accession,L-CARNITINYL-COA
2725,60936,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-GalpNAc,An amino trisaccharide consisting of two D-galactose residues and an N-acetyl-D-galactosamine residue (at the reducing end) in a linear sequence.,"InChI=1S/C20H35NO16/c1-5(25)21-9-11(27)16(7(3-23)33-18(9)32)36-20-15(31)13(29)17(8(4-24)35-20)37-19-14(30)12(28)10(26)6(2-22)34-19/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11-,12+,13-,14-,15-,16+,17+,18?,19-,20+/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-D-GalNAc,PubMed citation,17006649
2726,60944,alpha-D-Galp-(1->3)-alpha-D-GalpNAc,An alpha-D-Galp-(1->3)-D-GalpNAc in which the anomeric centre at the reducing end has alpha-configuration.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10+,11-,12-,13+,14-/m1/s1",alpha-D-Gal-(1->3)-alpha-D-GalNAc,Reaxys Registry Number,7799001
2727,60945,alpha-D-GalpNAc-(1->4)-D-GlcpNAc,An amino disaccharide consisting of N-acetyl-D-glucosamine having an N-acetyl-alpha-D-galactosminyl resiude attached at the 4-position.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)14(8(4-20)27-15(9)26)29-16-10(18-6(2)22)12(24)11(23)7(3-19)28-16/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12-,13-,14-,15?,16-/m1/s1",alpha-D-GalNAc-(1->4)-D-GlcNAc,PubMed citation,17991151
2728,60949,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-D-GlcNAc,An amino trisaccharide consisting of two D-galactose residues and an N-acetyl-D-glucosamine residue (at the reducing end) in a linear sequence.,"InChI=1S/C20H35NO16/c1-5(25)21-9-11(27)16(7(3-23)33-18(9)32)36-20-15(31)13(29)17(8(4-24)35-20)37-19-14(30)12(28)10(26)6(2-22)34-19/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11-,12+,13-,14-,15-,16-,17+,18?,19-,20+/m1/s1",alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-GlcpNAc,KEGG GLYCAN accession,G00439
2729,60957,colneleate,"An oxo fatty acid anion and the conjugate base of colneleic acid, arising from deprotonation of the carboxylic acid group.","InChI=1S/C18H30O3/c1-2-3-4-5-7-10-13-16-21-17-14-11-8-6-9-12-15-18(19)20/h7,10,13-14,16-17H,2-6,8-9,11-12,15H2,1H3,(H,19,20)/p-1/b10-7-,16-13+,17-14+",colneleic acid anion,PubMed citation,11696374
2730,60958,Ac-Cha-Arg-Ala-Met-Ala-Ser-Leu-NH2,"A synthetic seven-membered oligopeptide comprising N-acetyl-3-cyclohexyl-L-alanyl, L-arginyl, L-alanyl, L-methionyl, L-alanyl, L-seryl and L-leucinamide residues coupled in sequence.","InChI=1S/C37H67N11O9S/c1-20(2)17-27(30(38)51)47-36(57)29(19-49)48-32(53)22(4)43-34(55)26(14-16-58-6)45-31(52)21(3)42-33(54)25(13-10-15-41-37(39)40)46-35(56)28(44-23(5)50)18-24-11-8-7-9-12-24/h20-22,24-29,49H,7-19H2,1-6H3,(H2,38,51)(H,42,54)(H,43,55)(H,44,50)(H,45,52)(H,46,56)(H,47,57)(H,48,53)(H4,39,40,41)/t21-,22-,25-,26-,27-,28-,29-/m0/s1",AcChaArgAlaMetAlaSerLeuNH2,Reaxys Registry Number,8671882
2731,60962,"(9S,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate","A (10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate in which the chiral centre has S configuration.","InChI=1S/C18H30O4/c1-2-3-4-5-6-8-11-14-17(22-21)15-12-9-7-10-13-16-18(19)20/h3-4,6,8,11,14,17,21H,2,5,7,9-10,12-13,15-16H2,1H3,(H,19,20)/p-1/b4-3-,8-6-,14-11+/t17-/m1/s1","(9S,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoic acid anion",PubMed citation,11696374
2732,60965,Ac-Cha-Arg-Tic-Met-NH2,"A synthetic tetrapeptide comprising Ac-Cha, Arg, Tic and Met-NH2 residues coupled in sequence.","InChI=1S/C32H50N8O5S/c1-20(41)37-26(17-21-9-4-3-5-10-21)29(43)39-25(13-8-15-36-32(34)35)31(45)40-19-23-12-7-6-11-22(23)18-27(40)30(44)38-24(28(33)42)14-16-46-2/h6-7,11-12,21,24-27H,3-5,8-10,13-19H2,1-2H3,(H2,33,42)(H,37,41)(H,38,44)(H,39,43)(H4,34,35,36)/t24-,25-,26-,27-/m0/s1",Ac-(Cha)R(Tic)M-NH2,PubMed citation,17081730
2733,60966,Ac-Cha-Gpg-Tic-Met-NH2,"A synthetic tetrapeptide comprising Ac-Cha, Cpg, Tic and Met-NH2 residues coupled in sequence.","InChI=1S/C34H52N8O5S/c1-21(43)38-27(18-22-8-4-3-5-9-22)31(45)40-29(23-12-15-41(16-13-23)34(36)37)33(47)42-20-25-11-7-6-10-24(25)19-28(42)32(46)39-26(30(35)44)14-17-48-2/h6-7,10-11,22-23,26-29H,3-5,8-9,12-20H2,1-2H3,(H2,35,44)(H3,36,37)(H,38,43)(H,39,46)(H,40,45)/t26-,27-,28-,29-/m0/s1",AcChaGpgTicMetNH2,PubMed citation,17081730
2734,60967,Ac-Cha-Arg-Disc-Met-NH2,"A synthetic tetrapeptide comprising Ac-Cha, Arg, Disc and Met-NH2 residues coupled in sequence.","InChI=1S/C31H48N8O5S/c1-19(40)36-25(17-20-9-4-3-5-10-20)28(42)38-24(13-8-15-35-31(33)34)30(44)39-18-21-11-6-7-12-22(21)26(39)29(43)37-23(27(32)41)14-16-45-2/h6-7,11-12,20,23-26H,3-5,8-10,13-18H2,1-2H3,(H2,32,41)(H,36,40)(H,37,43)(H,38,42)(H4,33,34,35)/t23-,24-,25-,26-/m0/s1",AcChaArgDiscMetNH2,PubMed citation,17081730
2735,60969,Ac-Cha-Gpg-Disc-Met-NH2,"A synthetic tetrapeptide comprising Ac-Cha, Cpg, Disc and Met-NH2 residues coupled in sequence.","InChI=1S/C33H50N8O5S/c1-20(42)37-26(18-21-8-4-3-5-9-21)30(44)39-27(22-12-15-40(16-13-22)33(35)36)32(46)41-19-23-10-6-7-11-24(23)28(41)31(45)38-25(29(34)43)14-17-47-2/h6-7,10-11,21-22,25-28H,3-5,8-9,12-19H2,1-2H3,(H2,34,43)(H3,35,36)(H,37,42)(H,38,45)(H,39,44)/t25-,26-,27-,28-/m0/s1",Ac-(Cha)(Gpg)(Disc)M-NH2,PubMed citation,17081730
2736,60970,Ac-Cha-Arg-Tic-Met-betaPhPro-NH2,"A synthetic pentapeptide comprising Ac-Cha, Arg, Tic, Met and betaPhPro-NH2 residues coupled in sequence.","InChI=1S/C43H61N9O6S/c1-27(53)48-35(24-28-12-5-3-6-13-28)39(55)49-33(18-11-21-47-43(45)46)42(58)52-26-31-17-10-9-16-30(31)25-36(52)40(56)50-34(20-23-59-2)41(57)51-22-19-32(37(51)38(44)54)29-14-7-4-8-15-29/h4,7-10,14-17,28,32-37H,3,5-6,11-13,18-26H2,1-2H3,(H2,44,54)(H,48,53)(H,49,55)(H,50,56)(H4,45,46,47)/t32-,33+,34+,35+,36+,37+/m1/s1",Ac-(Cha)R(Tic)M(betaPhPro)-NH2,PubMed citation,17081730
2737,60972,Ac-Cha-Arg-Tic-Met-betaPhPro-[S(oxaz)L]-NMe2,"A synthetic six-membered oligopeptide comprising Ac-Cha, Arg, Tic, Met, betaPhPro and [S(oxaz)L]-NMe2 residues coupled in sequence.","InChI=1S/C51H71N11O9S/c1-31(64)55-39(26-32-14-7-5-8-15-32)44(65)56-37(20-13-23-54-51(52)53)50(70)62-28-35-19-12-11-18-34(35)27-42(62)45(66)57-38(22-25-72-4)49(69)61-24-21-36(33-16-9-6-10-17-33)43(61)46(67)58-40(29-63)47-59-41(30-71-47)48(68)60(2)3/h6,9-12,16-19,30,32,36-40,42-43,63H,5,7-8,13-15,20-29H2,1-4H3,(H,55,64)(H,56,65)(H,57,66)(H,58,67)(H4,52,53,54)/t36-,37+,38+,39+,40+,42+,43+/m1/s1",Ac-(Cha)R(Tic)M(betaPhPro)[S(oxaz)L]-NMe2,PubMed citation,17081730
2738,60975,Ac-Cha-Gpg-Tic-Met-betaPhPro-[S(oxaz)L]-NMe2,"A synthetic six-membered oligopeptide comprising Ac-Cha, Gpg, Tic, Met, betaPhPro and [S(oxaz)L]-NMe2 residues coupled in sequence.","InChI=1S/C53H73N11O9S/c1-32(66)56-40(27-33-13-7-5-8-14-33)46(67)60-44(35-19-23-62(24-20-35)53(54)55)52(72)64-29-37-18-12-11-17-36(37)28-43(64)47(68)57-39(22-26-74-4)51(71)63-25-21-38(34-15-9-6-10-16-34)45(63)48(69)58-41(30-65)49-59-42(31-73-49)50(70)61(2)3/h6,9-12,15-18,31,33,35,38-41,43-45,65H,5,7-8,13-14,19-30H2,1-4H3,(H3,54,55)(H,56,66)(H,57,68)(H,58,69)(H,60,67)/t38-,39+,40+,41+,43+,44+,45+/m1/s1",Ac-(Cha)(Cpg)(Tic)M(betaPhPro)[S(oxaz)L]-NMe2,PubMed citation,17081730
2739,60984,Ac-Cha-Arg-Tic-Nle-betaPhPro-[S(oxaz)L]-NMe2,"A synthetic six-membered oligopeptide comprising Ac-Cha, Arg, Tic, Nle, betaPhPro and [S(oxaz)L]-NMe2 residues coupled in sequence.","InChI=1S/C52H73N11O9/c1-5-6-22-38(50(70)62-26-24-37(34-18-11-8-12-19-34)44(62)47(68)59-41(30-64)48-60-42(31-72-48)49(69)61(3)4)58-46(67)43-28-35-20-13-14-21-36(35)29-63(43)51(71)39(23-15-25-55-52(53)54)57-45(66)40(56-32(2)65)27-33-16-9-7-10-17-33/h8,11-14,18-21,31,33,37-41,43-44,64H,5-7,9-10,15-17,22-30H2,1-4H3,(H,56,65)(H,57,66)(H,58,67)(H,59,68)(H4,53,54,55)/t37-,38+,39+,40+,41+,43+,44+/m1/s1",AcChaArgTicNlebetaPhPro[S(oxaz)L]NMe2,PubMed citation,17081730
2740,60985,Ac-Cha-Gpg-Tic-Nle-betaPhPro-[S(oxaz)L]-NMe2,"A synthetic six-membered oligopeptide composed of the non-natural Ac-Cha, Gpg, Tic, Nle, betaPhPro and [S(oxaz)L]-NMe2 residues coupled in sequence.","InChI=1S/C54H75N11O9/c1-5-6-21-40(52(72)64-27-24-39(35-17-11-8-12-18-35)46(64)49(70)59-42(31-66)50-60-43(32-74-50)51(71)62(3)4)58-48(69)44-29-37-19-13-14-20-38(37)30-65(44)53(73)45(36-22-25-63(26-23-36)54(55)56)61-47(68)41(57-33(2)67)28-34-15-9-7-10-16-34/h8,11-14,17-20,32,34,36,39-42,44-46,66H,5-7,9-10,15-16,21-31H2,1-4H3,(H3,55,56)(H,57,67)(H,58,69)(H,59,70)(H,61,68)/t39-,40+,41+,42+,44+,45+,46+/m1/s1",AcChaGpgTicNlebetaPhPro[S(oxaz)L]NMe2,PubMed citation,17081730
2741,60986,Ac-Cha-Gpg-Disc-Nle-betaPhPro-[S(oxaz)L]-NMe2,"A synthetic six-membered oligopeptide composed of the non-natural Ac-Cha, Gpg, Disc, Nle, betaPhPro and [S(oxaz)L]-NMe2 residues coupled in sequence.","InChI=1S/C53H73N11O9/c1-5-6-21-39(51(71)63-27-24-38(34-17-11-8-12-18-34)44(63)47(68)58-41(30-65)49-59-42(31-73-49)50(70)61(3)4)57-48(69)45-37-20-14-13-19-36(37)29-64(45)52(72)43(35-22-25-62(26-23-35)53(54)55)60-46(67)40(56-32(2)66)28-33-15-9-7-10-16-33/h8,11-14,17-20,31,33,35,38-41,43-45,65H,5-7,9-10,15-16,21-30H2,1-4H3,(H3,54,55)(H,56,66)(H,57,69)(H,58,68)(H,60,67)/t38-,39+,40+,41+,43+,44+,45+/m1/s1",AcChaGpgDiscNlebetaPhPro[S(oxaz)L]NMe2,PubMed citation,17081730
2742,60988,Ac-Cha-Arg-Tic-Nle-NHCH2CH2Ph,"A synthetic tetrapeptide comprising Ac-Cha, Arg, Tic and  Nle-NHCH2CH2Ph residues coupled in sequence.","InChI=1S/C41H60N8O5/c1-3-4-20-33(37(51)44-24-22-29-14-7-5-8-15-29)47-39(53)36-26-31-18-11-12-19-32(31)27-49(36)40(54)34(21-13-23-45-41(42)43)48-38(52)35(46-28(2)50)25-30-16-9-6-10-17-30/h5,7-8,11-12,14-15,18-19,30,33-36H,3-4,6,9-10,13,16-17,20-27H2,1-2H3,(H,44,51)(H,46,50)(H,47,53)(H,48,52)(H4,42,43,45)/t33-,34-,35-,36-/m0/s1",AcChaArgTicNleNHCH2CH2Ph,PubMed citation,17081730
2743,60990,"3,5-diiodotyrosyl-3,5-diiodotyrosine",A dipeptide comprising tyrosine with a tyrosyl residue attached to the alpha-nitrogen and with each tyrosine residue being substituted at the 3- and 5-positions by iodine.,"InChI=1S/C18H16I4N2O5/c19-9-1-7(2-10(20)15(9)25)5-13(23)17(27)24-14(18(28)29)6-8-3-11(21)16(26)12(22)4-8/h1-4,13-14,25-26H,5-6,23H2,(H,24,27)(H,28,29)","3,3',5,5'-tetraiododityrosine",Reaxys Registry Number,2795272
2744,60994,Ac-Cha-Gpg-Tic-Nle-NHCH2Ph,"A synthetic tetrapeptide composed of the non-natural Ac-Cha, Gpg, Tic and Nle-NHCH2Ph residues coupled in sequence.","InChI=1S/C42H60N8O5/c1-3-4-19-34(38(52)45-26-30-15-9-6-10-16-30)47-40(54)36-25-32-17-11-12-18-33(32)27-50(36)41(55)37(31-20-22-49(23-21-31)42(43)44)48-39(53)35(46-28(2)51)24-29-13-7-5-8-14-29/h6,9-12,15-18,29,31,34-37H,3-5,7-8,13-14,19-27H2,1-2H3,(H3,43,44)(H,45,52)(H,46,51)(H,47,54)(H,48,53)/t34-,35-,36-,37-/m0/s1",Ac-(Cha)(Gpg)(Tic)(Nle)-NHCH2Ph,PubMed citation,17081730
2745,60995,Ac-Cha-Gpg-Tic-Nle-NMeBn,"A synthetic tetrapeptide composed of the non-natural Ac-Cha, Gpg, Tic and Nle-NMeBn residues coupled in sequence.","InChI=1S/C43H62N8O5/c1-4-5-20-35(41(55)49(3)27-31-16-10-7-11-17-31)47-40(54)37-26-33-18-12-13-19-34(33)28-51(37)42(56)38(32-21-23-50(24-22-32)43(44)45)48-39(53)36(46-29(2)52)25-30-14-8-6-9-15-30/h7,10-13,16-19,30,32,35-38H,4-6,8-9,14-15,20-28H2,1-3H3,(H3,44,45)(H,46,52)(H,47,54)(H,48,53)/t35-,36-,37-,38-/m0/s1",Ac-(Cha)(Gpg)(Tic)(Nle)-NMeBn,PubMed citation,17081730
2746,60997,(2R)-3-sulfopropanediol(1-),An organosulfonate oxoanion resulting from the removal of a proton from the sulfonic acid group of (2R)-3-sulfopropanediol.,"InChI=1S/C3H8O5S/c4-1-3(5)2-9(6,7)8/h3-5H,1-2H2,(H,6,7,8)/p-1/t3-/m1/s1",(2R)-3-sulfopropanediol anion,PubMed citation,20150239
2747,60999,"3,5-diiodotyrosyl-3,5-diiodotyrosyl-3,5-diiodotyrosine",A tripeptide consisting of three tyrosine residues each of which is substituted at the 3- and 5-positions by iodine.,"InChI=1S/C27H23I6N3O7/c28-13-1-10(2-14(29)22(13)37)7-19(34)25(40)35-20(8-11-3-15(30)23(38)16(31)4-11)26(41)36-21(27(42)43)9-12-5-17(32)24(39)18(33)6-12/h1-6,19-21,37-39H,7-9,34H2,(H,35,40)(H,36,41)(H,42,43)",hexaiodotrinitrotyrosine,PubMed citation,15206583
2748,61010,alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal,A branched trisaccharide consisting of beta-D-galactose having an alpha-L-fucosyl residue at the 2-position and an alpha-D-galactosyl residue at the 3-position.,"InChI=1S/C18H32O15/c1-4-7(21)10(24)12(26)17(29-4)33-15-14(9(23)6(3-20)30-16(15)28)32-18-13(27)11(25)8(22)5(2-19)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8-,9-,10+,11-,12-,13+,14-,15+,16+,17-,18+/m0/s1",alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp,Reaxys Registry Number,5858016
2749,61017,sulfadiazine hydroxylamine,A pyrimidine having a 4-hydroxyaminobenzenesulfonamido group at the 2-position.,"InChI=1S/C10H10N4O3S/c15-13-8-2-4-9(5-3-8)18(16,17)14-10-11-6-1-7-12-10/h1-7,13,15H,(H,11,12,14)",sulfadiazine 4-hydroxylamine,Reaxys Registry Number,5967100
2750,61023,nitrososulfapyridine,A pyridine having a 4-nitrosobenzenesulfonamido group at the 2-position.,"InChI=1S/C11H9N3O3S/c15-13-9-4-6-10(7-5-9)18(16,17)14-11-3-1-2-8-12-11/h1-8H,(H,12,14)",nitroso sulfapyridine,PubMed citation,20159253
2751,61025,beta-D-GlcpA-(1->3)-beta-D-GalpNAc,An amino disaccharide consisting of N-acetyl-beta-D-galactosamine having a beta-D-glucuronosyl residue attached at the 3-position.,"InChI=1S/C14H23NO12/c1-3(17)15-5-10(6(18)4(2-16)25-13(5)24)26-14-9(21)7(19)8(20)11(27-14)12(22)23/h4-11,13-14,16,18-21,24H,2H2,1H3,(H,15,17)(H,22,23)/t4-,5-,6+,7+,8+,9-,10-,11+,13-,14-/m1/s1",beta-D-GlcA-(1->3)-beta-D-GalNAc,Reaxys Registry Number,1693896
2752,61029,beta-D-GlcpA-(1->3)-beta-D-GlcpNAc,An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having a beta-D-glucuronosyl residue attached at the 3-position.,"InChI=1S/C14H23NO12/c1-3(17)15-5-10(6(18)4(2-16)25-13(5)24)26-14-9(21)7(19)8(20)11(27-14)12(22)23/h4-11,13-14,16,18-21,24H,2H2,1H3,(H,15,17)(H,22,23)/t4-,5-,6-,7+,8+,9-,10-,11+,13-,14-/m1/s1",beta-D-glucuronosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucose,PubMed citation,6182692
2753,61031,beta-D-GlcpNAc-(1->6)-[beta-D-GlcpA-(1->3)]-beta-D-GlcpNAc,A branched amino trisaccharide consisting of N-acetyl-beta-D-glucosamine having beta-D-glucuronosyl and N-acetyl-beta-D-glucosaminyl residues attached at the 3- and 6-positions respectively.,"InChI=1S/C22H36N2O17/c1-5(26)23-9-13(30)11(28)7(3-25)39-21(9)37-4-8-12(29)17(10(20(36)38-8)24-6(2)27)40-22-16(33)14(31)15(32)18(41-22)19(34)35/h7-18,20-22,25,28-33,36H,3-4H2,1-2H3,(H,23,26)(H,24,27)(H,34,35)/t7-,8-,9-,10-,11-,12-,13-,14+,15+,16-,17-,18+,20-,21-,22-/m1/s1",beta-D-GlcNAc-(1->6)-[beta-D-GlcA-(1->3)]-beta-D-GlcNAc,PubMed citation,16164415
2754,61034,beta-D-GalpNAc-(1->6)-[beta-D-GlcpA-(1->3)]-beta-D-GalpNAc,A branched amino trisaccharide consisting of N-acetyl-beta-D-galactosamine having beta-D-glucuronosyl and N-acetyl-beta-D-galactosaminyl residues attached at the 3- and 6-positions respectively.,"InChI=1S/C22H36N2O17/c1-5(26)23-9-13(30)11(28)7(3-25)39-21(9)37-4-8-12(29)17(10(20(36)38-8)24-6(2)27)40-22-16(33)14(31)15(32)18(41-22)19(34)35/h7-18,20-22,25,28-33,36H,3-4H2,1-2H3,(H,23,26)(H,24,27)(H,34,35)/t7-,8-,9-,10-,11+,12+,13-,14+,15+,16-,17-,18+,20-,21-,22-/m1/s1",beta-D-GalNAc-(1->6)-[beta-D-GlcA-(1->3)]-beta-D-GalNAc,PubMed citation,16164415
2755,61035,beta-D-GlcpA-(1->3)-[beta-D-GlcpA-(1->3)-beta-D-GalpNAc-(1->6)]-beta-D-GalpNAc,A dimeric branched amino tetrasaccharide consisting of beta-D-glucuronosyl-(1->3)-N-acetyl-beta-D-galactosamine having a further beta-D-glucuronosyl-(1->3)-N-acetyl-beta-D-galactosaminyl moiety attached at the 6-position of the galactosamine.,"InChI=1S/C28H44N2O23/c1-5(32)29-9-19(50-27-17(40)13(36)15(38)21(52-27)23(42)43)12(35)8(48-25(9)46)4-47-26-10(30-6(2)33)20(11(34)7(3-31)49-26)51-28-18(41)14(37)16(39)22(53-28)24(44)45/h7-22,25-28,31,34-41,46H,3-4H2,1-2H3,(H,29,32)(H,30,33)(H,42,43)(H,44,45)/t7-,8-,9-,10-,11+,12+,13+,14+,15+,16+,17-,18-,19-,20-,21+,22+,25-,26-,27-,28-/m1/s1",beta-D-GlcA-(1->3)-[beta-D-GlcA-(1->3)-beta-D-GalNAc-(1->6)]-beta-D-GalNAc,PubMed citation,16164415
2756,61037,beta-D-GlcpA-(1->3)-[beta-D-GlcpA-(1->3)-beta-D-GlcpNAc-(1->6)]-beta-D-GlcpNAc,A dimeric branched amino tetrasaccharide consisting of beta-D-glucuronosyl-(1->3)-N-acetyl-beta-D-glucosamine having a further beta-D-glucuronosyl-(1->3)-N-acetyl-beta-D-glucosaminyl moiety attached at the 6-position of the glucosamine.,"InChI=1S/C28H44N2O23/c1-5(32)29-9-19(50-27-17(40)13(36)15(38)21(52-27)23(42)43)12(35)8(48-25(9)46)4-47-26-10(30-6(2)33)20(11(34)7(3-31)49-26)51-28-18(41)14(37)16(39)22(53-28)24(44)45/h7-22,25-28,31,34-41,46H,3-4H2,1-2H3,(H,29,32)(H,30,33)(H,42,43)(H,44,45)/t7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17-,18-,19-,20-,21+,22+,25-,26-,27-,28-/m1/s1",beta-D-glucuronosyl-(1->3)-[beta-D-glucuronosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucosyl-(1->6)]-2-acetamido-2-deoxy-beta-D-glucose,PubMed citation,16164415
2757,61061,N(6)-acetonyllysine,A lysine derivative in which the N(epsilon) of the amino acid carries an acetonyl group.,"InChI=1S/C9H18N2O3/c1-7(12)6-11-5-3-2-4-8(10)9(13)14/h8,11H,2-6,10H2,1H3,(H,13,14)",N(epsilon)-acetonyllysine,PubMed citation,8672512
2758,61066,1-O-(N-benzyloxycarbonylaminoethyl)-3-O-benzoyl-alpha-anthroside,"A doubly-protected aminoglycoside composed of glucose deoxygenated at C-4 and C-6 and having a methyl substituent at C-2, a 3-hydroxy-3-methylbutanamide group at C-4, a benzoyl protecting group at C-3 and a benzyloxycarbonyl (Z)-protected aminoethyl group at C-1","InChI=1S/C29H38N2O9/c1-19-23(31-22(32)17-29(2,3)35)24(40-26(33)21-13-9-6-10-14-21)25(36-4)27(39-19)37-16-15-30-28(34)38-18-20-11-7-5-8-12-20/h5-14,19,23-25,27,35H,15-18H2,1-4H3,(H,30,34)(H,31,32)/t19-,23-,24+,25-,27+/m1/s1","benzyl [2-({3-O-benzoyl-4,6-dideoxy-4-[(3-hydroxy-3-methylbutanoyl)amino]-2-O-methyl-alpha-D-glucosyl}oxy)ethyl]carbamate",PubMed citation,18155682
2759,61070,8-chloro-2'-deoxyguanosine,An organochlorine compound comprising 2'-deoxyguanosine having a chloro substituent at position 8 of the guanine ring system.,"InChI=1S/C10H12ClN5O4/c11-9-13-6-7(14-10(12)15-8(6)19)16(9)5-1-3(18)4(2-17)20-5/h3-5,17-18H,1-2H2,(H3,12,14,15,19)/t3-,4+,5+/m0/s1",8-Cl-2'-dG,Reaxys Registry Number,10193533
2760,61072,8-bromo-2'-deoxyguanosine,An organobromine compound comprising 2'-deoxyguanosine having a bromo substituent at position 8 of the guanine ring system.,"InChI=1S/C10H12BrN5O4/c11-9-13-6-7(14-10(12)15-8(6)19)16(9)5-1-3(18)4(2-17)20-5/h3-5,17-18H,1-2H2,(H3,12,14,15,19)/t3-,4+,5+/m0/s1",8-bromo-2'-dG,PubMed citation,20081197
2761,61074,4-fluorofentanyl,The monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-(4-fluorophenyl)-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.,"InChI=1S/C22H27FN2O/c1-2-22(26)25(20-10-8-19(23)9-11-20)21-13-16-24(17-14-21)15-12-18-6-4-3-5-7-18/h3-11,21H,2,12-17H2,1H3",p-fluorofentanyl,Reaxys Registry Number,4713884
2762,61076,belinostat,A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.,"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+",PXD101,CAS Registry Number,414864-00-9
2763,61077,BML-210,"A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and 1,2-diaminobenzene.","InChI=1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)",N-(2-aminophenyl)-N'-phenyl-octanediamide,PubMed citation,15149697
2764,61088,S-nitroso-L-cysteinylglycine,A dipeptide resulting from the formal condensation of the carboxylic acid group of S-nitroso-L-cysteine with the amino group of glycine.,"InChI=1S/C5H9N3O4S/c6-3(2-13-8-12)5(11)7-1-4(9)10/h3H,1-2,6H2,(H,7,11)(H,9,10)/t3-/m0/s1",Cys(NO)-Gly,Reaxys Registry Number,8547963
2765,61092,3-methylfentanyl,The monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of 3-methyl-N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.,"InChI=1S/C23H30N2O/c1-3-23(26)25(21-12-8-5-9-13-21)22-15-17-24(18-19(22)2)16-14-20-10-6-4-7-11-20/h4-13,19,22H,3,14-18H2,1-2H3",alpha-methylfentanyl,DrugBank accession,DB01571
2766,61099,thienylfentanyl,An anilide resulting from the formal condensation of the aryl amino group of N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.,"InChI=1S/C20H26N2OS/c1-2-20(23)22(17-7-4-3-5-8-17)18-10-13-21(14-11-18)15-12-19-9-6-16-24-19/h3-9,16,18H,2,10-15H2,1H3",thienylfentanil,Reaxys Registry Number,495808
2767,61102,N-methylfentanyl,The monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of 1-methyl-N-phenylpiperidin-4-amine with propanoic acid.,"InChI=1S/C15H22N2O/c1-3-15(18)17(13-7-5-4-6-8-13)14-9-11-16(2)12-10-14/h4-8,14H,3,9-12H2,1-2H3",N-methylfentanil,Reaxys Registry Number,482708
2768,61108,alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-L-Rhap-(1->3)-D-ribitol-5-phosphate,A tetrasaccharide derivative comprising the alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-L-Rhap-(1->3)-D-ribitol phosphorylated at position 5 of ribitol.,"InChI=1S/C23H43O22P/c1-6-11(29)19(16(34)22(40-6)43-18(7(27)2-24)8(28)5-39-46(36,37)38)44-23-17(35)20(13(31)10(4-26)42-23)45-21-15(33)14(32)12(30)9(3-25)41-21/h6-35H,2-5H2,1H3,(H2,36,37,38)/t6-,7-,8+,9+,10+,11-,12+,13+,14-,15+,16+,17+,18-,19+,20-,21+,22-,23+/m0/s1",SPn6C polysaccharide unit,PubMed citation,19856369
2769,61110,alpha-D-Glcp-(1->3)-beta-D-Glcp,A laminarabiose having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8-,9-,10+,11-,12-/m1/s1",alpha-D-Glc-(1->3)-beta-D-Glc,PubMed citation,19856369
2770,61113,"alpha,N-(epsilon,N-DNP-aminocaproyl)-epsilon,N-DNP-L-lysine dicyclohexylammonium salt","An organoammonium salt where dicyclohexylammonium is the cation and  alpha,N-(epsilon,N-DNP-aminocaproyl)-epsilon,N-DNP-L-lysinate is the counterion.","InChI=1S/C24H29N7O11.C12H23N/c32-23(7-2-1-4-12-25-18-10-8-16(28(35)36)14-21(18)30(39)40)27-20(24(33)34)6-3-5-13-26-19-11-9-17(29(37)38)15-22(19)31(41)42;1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h8-11,14-15,20,25-26H,1-7,12-13H2,(H,27,32)(H,33,34);11-13H,1-10H2/t20-;/m0./s1","dicyclohexylammonium N(6)-(2,4-dinitrophenyl)-N(2)-{6-[(2,4-dinitrophenyl)amino]hexanoyl}-L-lysinate",PubMed citation,4139229
2771,61117,sorgoleone,"A member of the family of benzoquinones, sorgoleone is 2-hydroxy-5-methoxy-1,4-benzoquinone in which the hydrogen at position 3 is substituted by a (4Z,7Z)-pentadeca-1,4,7-trien-15-yl group.","InChI=1S/C22H30O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-21(24)19(23)17-20(26-2)22(18)25/h3,5-6,8-9,17,24H,1,4,7,10-16H2,2H3/b6-5-,9-8-","2-hydroxy-5-methoxy-3-(8'Z,11'Z)-pentadeca-8',11',14'-trienyl-p-benzoquinone",PubMed citation,17998204
2772,61123,(E)-4-(trimethylammonio)but-2-enoyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (E)-4-(trimethylammonio)but-2-enoic acid.,"InChI=1S/C28H47N8O17P3S/c1-28(2,23(40)26(41)31-9-8-18(37)30-10-12-57-19(38)7-6-11-36(3,4)5)14-50-56(47,48)53-55(45,46)49-13-17-22(52-54(42,43)44)21(39)27(51-17)35-16-34-20-24(29)32-15-33-25(20)35/h6-7,15-17,21-23,27,39-40H,8-14H2,1-5H3,(H7-,29,30,31,32,33,37,41,42,43,44,45,46,47,48)/p+1/b7-6+/t17-,21-,22-,23+,27-/m1/s1",crotonobetainyl-coenzyme A,PubMed citation,10978161
2773,61163,D-alanyl-(R)-lactic acid,A D-alanyl ester that results from the formal condensation of the alcoholic hydroxy group of (2R)-lactic acid with the carboxylic acid group of D-alanine.,"InChI=1S/C6H11NO4/c1-3(7)6(10)11-4(2)5(8)9/h3-4H,7H2,1-2H3,(H,8,9)/t3-,4-/m1/s1",D-alanyl-D-lactic acid,CAS Registry Number,136577-07-6
2774,61169,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,A trimeric branched amino oligosaccharide consisting of three repeating units of beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc joined by (1->3)-linkages.,"InChI=1S/C60H101N3O43/c1-13-28(73)34(79)38(83)55(90-13)102-47-25(61-16(4)70)52(89)93-22(10-67)44(47)100-59-42(87)50(32(77)20(8-65)95-59)105-54-27(63-18(6)72)49(104-57-40(85)36(81)30(75)15(3)92-57)46(24(12-69)98-54)101-60-43(88)51(33(78)21(9-66)96-60)106-53-26(62-17(5)71)48(103-56-39(84)35(80)29(74)14(2)91-56)45(23(11-68)97-53)99-58-41(86)37(82)31(76)19(7-64)94-58/h13-15,19-60,64-69,73-89H,7-12H2,1-6H3,(H,61,70)(H,62,71)(H,63,72)/t13-,14-,15-,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31-,32-,33-,34+,35+,36+,37-,38-,39-,40-,41+,42+,43+,44+,45+,46+,47+,48+,49+,50-,51-,52+,53-,54-,55-,56-,57-,58-,59-,60-/m0/s1",[3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->]3,PubMed citation,14990315
2775,61171,beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->2)-alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,A branched amino tetrasaccharide consisting of N-acetyl-beta-glucosamine at the reducing end with an alpha-fucosyl-(1->2)-alpha-fucosyl group attached at the 3-position and an N-acetyl-beta-glucosaminyl residue attached at the 4-position.,"InChI=1S/C28H48N2O19/c1-7-15(35)19(39)21(41)27(43-7)49-24-20(40)16(36)8(2)44-28(24)48-23-14(30-10(4)34)25(42)45-12(6-32)22(23)47-26-13(29-9(3)33)18(38)17(37)11(5-31)46-26/h7-8,11-28,31-32,35-42H,5-6H2,1-4H3,(H,29,33)(H,30,34)/t7-,8-,11+,12+,13+,14+,15+,16+,17-,18+,19+,20+,21-,22+,23+,24-,25+,26-,27-,28-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-L-Fuc-(1->2)-alpha-L-Fuc-(1->3)]-beta-D-GlcNAc,PubMed citation,14990315
2776,61173,alpha-L-Fucp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-alpha-D-Galp,A branched amino pentasaccharide consisting of an alpha-D-Gal residue at the reducing end having an alpha-L-Fuc-(1->3)-beta-D-GalNAc-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc moiety attached at the 3-position.,"InChI=1S/C34H58N2O24/c1-8-17(42)21(46)23(48)33(52-8)58-27-15(35-10(3)40)31(55-13(6-38)19(27)44)57-26-14(7-39)56-32(60-29-20(45)12(5-37)54-30(51)25(29)50)16(36-11(4)41)28(26)59-34-24(49)22(47)18(43)9(2)53-34/h8-9,12-34,37-39,42-51H,5-7H2,1-4H3,(H,35,40)(H,36,41)/t8-,9-,12+,13+,14+,15+,16+,17+,18+,19-,20-,21+,22+,23-,24-,25+,26+,27+,28+,29-,30-,31-,32-,33-,34-/m0/s1",alpha-L-Fuc-(1->3)-beta-D-GalNAc-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-alpha-D-Gal,PubMed citation,14990315
2777,61175,alpha-L-Fucp-(1->3)-beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)-alpha-D-Galp,"An amino tetrasaccharide consisting of alpha-fucosyl, N-acetyl-beta-galactosaminyl, N-acetyl-beta-glucosaminyl and alpha-galactose residues joined in a linear sequence.","InChI=1S/C28H48N2O20/c1-7-15(36)19(40)20(41)28(44-7)49-23-14(30-9(3)35)27(46-11(5-32)16(23)37)48-22-12(6-33)47-26(13(18(22)39)29-8(2)34)50-24-17(38)10(4-31)45-25(43)21(24)42/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20-,21+,22+,23+,24-,25-,26-,27-,28-/m0/s1",alpha-L-Fuc-(1->3)-beta-D-GalNAc-(1->4)-beta-D-GlcNAc-(1->3)-alpha-D-Gal,PubMed citation,14990315
2778,61179,beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-alpha-D-Galp,A branched amino tetrasaccharide comprising alpha-D-galactose at the reducing end having a N-acetyl-beta-D-galactosaminyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl moiety attached at the 3-position.,"InChI=1S/C28H48N2O20/c1-7-15(36)19(40)20(41)28(44-7)49-23-14(30-9(3)35)27(50-24-17(38)11(5-32)45-25(43)21(24)42)47-12(6-33)22(23)48-26-13(29-8(2)34)18(39)16(37)10(4-31)46-26/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20-,21+,22+,23+,24-,25-,26-,27-,28-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-alpha-D-Gal,PubMed citation,14990315
2779,61186,"7,8-dihydromonapterin 3-triphosphate(4-)","The organophosphate oxoanion that is the tetraanion of 7,8-dihydromonapterin 3-triphosphate; the major species at pH 7.3.","InChI=1S/C9H16N5O13P3/c10-9-13-7-5(8(17)14-9)12-3(1-11-7)6(16)4(15)2-25-29(21,22)27-30(23,24)26-28(18,19)20/h4,6,15-16H,1-2H2,(H,21,22)(H,23,24)(H2,18,19,20)(H4,10,11,13,14,17)/p-4/t4-,6-/m0/s1","6-(L-threo-1',2',3'-trihydroxypropyl)-7,8-dihydropterin-3'-triphosphate",MetaCyc accession,DIHYDROMONAPTERIN-TRIPHOSPHATE
2780,61187,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)-alpha-D-Galp,A linear amino trisaccharide comprising alpha-D-galactose at the reducing end having a N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl moiety attached at the 3-position.,"InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)13(30)8(3-25)37-21(11)39-18-10(5-27)38-22(12(16(18)33)24-7(2)29)40-19-14(31)9(4-26)36-20(35)17(19)34/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19+,20+,21+,22+/m1/s1",2-acetamido-2-deoxy-beta-D-galactosyl-(1->4)-2-acetamido-2-deoxy-beta-D-glucosyl-(1->3)-alpha-D-galactose,PubMed citation,14990315
2781,61189,beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->2)-alpha-L-Fucp-(1->3)]-D-GlcpNAc,A branched amino tetrasaccharide consisting of N-acetyl-glucosamine at the reducing end with an alpha-fucosyl-(1->2)-alpha-fucosyl group attached at the 3-position and an N-acetyl-beta-glucosaminyl residue attached at the 4-position.,"InChI=1S/C28H48N2O19/c1-7-15(35)19(39)21(41)27(43-7)49-24-20(40)16(36)8(2)44-28(24)48-23-14(30-10(4)34)25(42)45-12(6-32)22(23)47-26-13(29-9(3)33)18(38)17(37)11(5-31)46-26/h7-8,11-28,31-32,35-42H,5-6H2,1-4H3,(H,29,33)(H,30,34)/t7-,8-,11+,12+,13+,14+,15+,16+,17-,18+,19+,20+,21-,22+,23+,24-,25?,26-,27-,28-/m0/s1",GalNAcbeta1-4(Fucalpha1-2Fucalpha1-3)GlcNAc,PubMed citation,11254599
2782,61190,beta-D-GalpNAc-(1->4)-D-GlcpNAc,An amino disaccharide consisting of N-acetylglucosamine having an N-acetylgalactosaminyl resiude attached at the 4-position via a beta-linkage.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)14(8(4-20)27-15(9)26)29-16-10(18-6(2)22)12(24)11(23)7(3-19)28-16/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12-,13-,14-,15?,16+/m1/s1",beta-D-GaNAc-(1->4)-D-GlcNAc,PubMed citation,12681926
2783,61195,beta-D-Tyvp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-OMe,A branched amino tetrasaccharide consisting of methyl N-acetyl-beta-D-glucosaminide having an alpha-L-fucosyl residue at the 2-position and a beta-D-tyvelosyl-(1->3)-N-acetyl-beta-D-galactosaminyl group at the 3-position.,"InChI=1S/C29H50N2O18/c1-9-13(36)6-14(37)26(43-9)48-24-17(30-11(3)34)28(45-15(7-32)20(24)39)47-23-16(8-33)46-27(42-5)18(31-12(4)35)25(23)49-29-22(41)21(40)19(38)10(2)44-29/h9-10,13-29,32-33,36-41H,6-8H2,1-5H3,(H,30,34)(H,31,35)/t9-,10+,13+,14+,15-,16-,17-,18-,19-,20+,21-,22+,23-,24-,25-,26+,27-,28+,29+/m1/s1",beta-D-Tyv-(1->3)-beta-D-GalNAc-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-OMe,PubMed citation,9007282
2784,61198,N-acetyl-D-penicillamine,An N-acetyl-D-amino acid where the amino acid is D-penicillamine,"InChI=1S/C7H13NO3S/c1-4(9)8-5(6(10)11)7(2,3)12/h5,12H,1-3H3,(H,8,9)(H,10,11)/t5-/m0/s1",N-acetyl-3-sulfanyl-D-valine,Reaxys Registry Number,1724742
2785,61200,3-decenoic acid,A decenoic acid having its double bond in the 3-position.,"InChI=1S/C10H18O2/c1-2-3-4-5-6-7-8-9-10(11)12/h7-8H,2-6,9H2,1H3,(H,11,12)","10:1, n-7",Reaxys Registry Number,18891630
2786,61206,2-hexenoic acid,A hexenoic acid having its double bond at position 2.,"InChI=1S/C6H10O2/c1-2-3-4-5-6(7)8/h4-5H,2-3H2,1H3,(H,7,8)",hex-2-enoic acids,Reaxys Registry Number,1720441
2787,61210,beta-D-Tyvp-(1->3)-beta-D-GalpNAc-OCH2CH2SiMe3,An amino disaccharide consisting of 2-(trimethylsilyl)ethyl N-acetyl-beta-D-galactosaminide having a beta-D-tyvelosyl residue attached at the 3-position.,"InChI=1S/C19H37NO9Si/c1-10-12(23)8-13(24)18(27-10)29-17-15(20-11(2)22)19(26-6-7-30(3,4)5)28-14(9-21)16(17)25/h10,12-19,21,23-25H,6-9H2,1-5H3,(H,20,22)/t10-,12+,13+,14-,15-,16+,17-,18+,19-/m1/s1",beta-D-Tyv-(1->3)-beta-D-GalNAc-OCH2CH2SiMe3,Reaxys Registry Number,7752763
2788,61213,methyl beta-D-tyvelopyranoside,A methyl glycoside having beta-D-tyvelose as the glycoside component.,"InChI=1S/C7H14O4/c1-4-5(8)3-6(9)7(10-2)11-4/h4-9H,3H2,1-2H3/t4-,5+,6+,7-/m1/s1",methyl beta-D-tyveloside,PubMed citation,9008846
2789,61217,monosodium benzylpenicilloate,An organic sodium salt having benzylpenicilloate as the counterion.,"InChI=1S/C16H20N2O5S.Na/c1-16(2)12(15(22)23)18-13(24-16)11(14(20)21)17-10(19)8-9-6-4-3-5-7-9;/h3-7,11-13,18H,8H2,1-2H3,(H,17,19)(H,20,21)(H,22,23);/q;+1/p-1/t11-,12-,13+;/m0./s1",monosodium D-alpha-benzylpenicilloate,PubMed citation,13761469
2790,61220,benzylpenicilloate(1-),A penicilloate anion that is the conjugate base of benzylpenicilloic acid arising from zwitterion formation and deprotonation of the remaining carboxy group.,"InChI=1S/C16H20N2O5S/c1-16(2)12(15(22)23)18-13(24-16)11(14(20)21)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-13,18H,8H2,1-2H3,(H,17,19)(H,20,21)(H,22,23)/p-1/t11-,12-,13+/m0/s1",benzylpenicilloate anion,CAS Registry Number,13057-98-2
2791,61222,benzylpenicilloic acid,A penicilloic acid where the side-chain N-acyl group is specified as phenylacetyl.,"InChI=1S/C16H20N2O5S/c1-16(2)12(15(22)23)18-13(24-16)11(14(20)21)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-13,18H,8H2,1-2H3,(H,17,19)(H,20,21)(H,22,23)/t11-,12-,13+/m0/s1",D-benzylpenicilloic acid,KEGG COMPOUND accession,C16672
2792,61224,benzylpenillamine,A monocarboxylic acid that is D-penicillamine in which the amino group has been replaced by a consisting 2-benzyl-1H-imidazol-1-yl moiety.,"InChI=1S/C15H18N2O2S/c1-15(2,20)13(14(18)19)17-9-8-16-12(17)10-11-6-4-3-5-7-11/h3-9,13,20H,10H2,1-2H3,(H,18,19)/t13-/m0/s1",D-benzylpenillamine,Reaxys Registry Number,87115
2793,61243,beta-D-Galp-(1->3)-beta-D-GalpNAc,A beta-D-Gal-(1->3)-D-GalNAc having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10+,11-,12-,13-,14+/m1/s1",beta-D-Gal-(1->3)-beta-D-GalNAc,Reaxys Registry Number,5772782
2794,61246,beta-D-Galp-(1->3)-beta-D-GlcpNAc,An amino disaccharide consisting of beta-D-galactose linked via a (1->3)-glycosidic bond to N-acetyl-beta-D-glucosamine. beta-D-Galp-(1->3)-beta-D-GlcpNAc in which the configuration at the reducing-end anomeric centre is beta.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12-,13-,14+/m1/s1",beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucose,PubMed citation,9871535
2795,61253,"alpha-D-glucosyl ditrans,polycis-undecaprenyl diphosphate",A polyprenyl glucosyl phosphate in which a glucosyl residue is linked to a undecaprenyl group via a diphospho group.,"InChI=1S/C61H102O12P2/c1-46(2)23-13-24-47(3)25-14-26-48(4)27-15-28-49(5)29-16-30-50(6)31-17-32-51(7)33-18-34-52(8)35-19-36-53(9)37-20-38-54(10)39-21-40-55(11)41-22-42-56(12)43-44-70-74(66,67)73-75(68,69)72-61-60(65)59(64)58(63)57(45-62)71-61/h23,25,27,29,31,33,35,37,39,41,43,57-65H,13-22,24,26,28,30,32,34,36,38,40,42,44-45H2,1-12H3,(H,66,67)(H,68,69)/b47-25+,48-27+,49-29-,50-31-,51-33-,52-35-,53-37-,54-39-,55-41-,56-43-/t57-,58-,59+,60-,61-/m1/s1","alpha-D-glucopyranosyl-diphospho-di-trans,poly-cis-undecaprenol",PubMed citation,9537354
2796,61268,5-nitrosalicylate,A monohydroxybenzoate that is obtained by removal of a proton from the carboxylic acid group of 5-nitrosalicylic acid.,"InChI=1S/C7H5NO5/c9-6-2-1-4(8(12)13)3-5(6)7(10)11/h1-3,9H,(H,10,11)/p-1",5-nitrosalicylate,MetaCyc accession,CPD-12696
2797,61279,51-hydroxy ciguatoxin CTX3C,"A ciguatoxin comprising a sequence of twelve trans-fused six-, seven-, eight- and nine-membered oxacycles and a spiro-fused hydroxytetrahydrofuran ring.","InChI=1S/C57H82O17/c1-27-19-39-41(22-45-51(71-39)29(3)49(60)55-52(72-45)28(2)30(4)57(74-55)25-31(58)26-63-57)68-43-24-48-56(5,73-44(43)20-27)47(59)23-42-35(69-48)12-7-6-11-32-33(66-42)14-10-15-34-36(64-32)16-17-37-40(65-34)21-46-54(70-37)50(61)53-38(67-46)13-8-9-18-62-53/h6-10,14,16-17,27-55,58-61H,11-13,15,18-26H2,1-5H3/b7-6-,14-10-/t27-,28+,29+,30+,31+,32-,33+,34-,35+,36+,37-,38+,39+,40+,41-,42-,43+,44-,45+,46-,47-,48-,49+,50-,51-,52-,53+,54-,55+,56+,57-/m1/s1",51-hydroxy CTX3C,Reaxys Registry Number,7968684
2798,61288,5-hydroxymethyl-2'-deoxyuridine,A pyrimidine 2'-deoxyribonucleoside composed of 2'-deoxyuridine having a 5-hydroxymethyl substituent.,"InChI=1S/C10H14N2O6/c13-3-5-2-12(10(17)11-9(5)16)8-1-6(15)7(4-14)18-8/h2,6-8,13-15H,1,3-4H2,(H,11,16,17)/t6-,7+,8+/m0/s1",HMdU,Reaxys Registry Number,31615
2799,61302,cerebronic acid,A very long-chain hydroxy fatty acid composed of lignoceric acid having a 2-hydroxy substituent.,"InChI=1S/C24H48O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23(25)24(26)27/h23,25H,2-22H2,1H3,(H,26,27)",Cerebronsaeure,PubMed citation,1150661
2800,61306,alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-D-Manp,A linear mannotriose consisting of three D-mannose units joined by alpha-(1->3)- and alpha-(1->2)-linkages,"InChI=1S/C18H32O16/c19-1-4-8(23)11(26)15(16(29)30-4)34-18-13(28)14(9(24)6(3-21)32-18)33-17-12(27)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16?,17-,18-/m1/s1",alpha-D-Man-(1->3)-alpha-D-Man-(1->2)-D-Man,KEGG GLYCAN accession,G01079
2801,61308,carbonyl dihydrazine,A carbohydrazide obtained by formal condensation between hydrazinecarboxylic acid and hydrazine.,"InChI=1S/CH6N4O/c2-4-1(6)5-3/h2-3H2,(H2,4,5,6)","1,3-diaminourea",Reaxys Registry Number,1747069
2802,61309,alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp,"A linear mannopentaose composed of five D-mannose units, connected in sequence by one alpha-(1->3) and three alpha-(1->2) linkages.","InChI=1S/C30H52O26/c31-1-6-12(37)17(42)23(26(47)48-6)54-29-25(19(44)14(39)8(3-33)51-29)56-30-24(18(43)13(38)9(4-34)52-30)55-28-21(46)22(15(40)10(5-35)50-28)53-27-20(45)16(41)11(36)7(2-32)49-27/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26?,27-,28-,29-,30-/m1/s1",alpha-D-Man-(1->3)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-D-Man,PubMed citation,2164449
2803,61314,XTP(4-),A nucleoside triphosphate(4-) obtained by global deprotonation of the triphosphate OH groups of XTP; major species present at pH 7.3.,"InChI=1S/C10H15N4O15P3/c15-5-3(1-26-31(22,23)29-32(24,25)28-30(19,20)21)27-9(6(5)16)14-2-11-4-7(14)12-10(18)13-8(4)17/h2-3,5-6,9,15-16H,1H2,(H,22,23)(H,24,25)(H2,19,20,21)(H2,12,13,17,18)/p-4/t3-,5-,6-,9-/m1/s1",xanthosine 5' triphosphate (4-),MetaCyc accession,XTP
2804,61325,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,A six-membered glucosamine oligosaccharide consisting of two repeating units of beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc joined by a (1->3)-linkage.,"InChI=1S/C40H68N2O29/c1-9-19(49)23(53)26(56)37(61-9)69-32-17(41-11(3)47)35(60)63-15(7-45)30(32)68-40-29(59)34(22(52)14(6-44)65-40)71-36-18(42-12(4)48)33(70-38-27(57)24(54)20(50)10(2)62-38)31(16(8-46)66-36)67-39-28(58)25(55)21(51)13(5-43)64-39/h9-10,13-40,43-46,49-60H,5-8H2,1-4H3,(H,41,47)(H,42,48)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23+,24+,25-,26-,27-,28+,29+,30+,31+,32+,33+,34-,35+,36-,37-,38-,39-,40-/m0/s1",[3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->]2,KEGG GLYCAN accession,G00851
2805,61329,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp with configuration alpha at the anomeric centre of the galactose residue at the reducing end.,"InChI=1S/C32H55NO24/c1-7-14(38)18(42)21(45)30(49-7)55-25-13(33-9(3)37)29(56-26-17(41)11(5-35)51-28(48)23(26)47)53-12(6-36)24(25)54-32-27(20(44)16(40)10(4-34)52-32)57-31-22(46)19(43)15(39)8(2)50-31/h7-8,10-32,34-36,38-48H,4-6H2,1-3H3,(H,33,37)/t7-,8-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20-,21-,22-,23+,24+,25+,26-,27+,28+,29-,30-,31-,32-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal,KEGG GLYCAN accession,G00838
2806,61332,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,A branched heptasaccharide derivative consisting of two repeating units of beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc (joined by a (1->3)-linkage) with an alpha-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.,"InChI=1S/C46H78N2O33/c1-10-21(55)26(60)30(64)42(69-10)78-36-19(47-13(4)53)40(68)72-17(8-51)34(36)76-45-33(67)38(25(59)16(7-50)73-45)80-41-20(48-14(5)54)37(79-43-31(65)27(61)22(56)11(2)70-43)35(18(9-52)75-41)77-46-39(29(63)24(58)15(6-49)74-46)81-44-32(66)28(62)23(57)12(3)71-44/h10-12,15-46,49-52,55-68H,6-9H2,1-5H3,(H,47,53)(H,48,54)/t10-,11-,12-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26+,27+,28+,29-,30-,31-,32-,33+,34+,35+,36+,37+,38-,39+,40+,41-,42-,43-,44-,45-,46-/m0/s1",alpha-L-Fuc-(1->2)-[3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->]2,KEGG GLYCAN accession,G02259
2807,61334,alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A branched amino pentasaccharide comprising one fucose, two galactose, one glucosamine and one glucose unit (at the reducing end), linked as shown.","InChI=1S/C32H55NO25/c1-7-14(39)17(42)21(46)30(50-7)56-25-12(6-37)54-29(13(33-8(2)38)26(25)57-31-22(47)18(43)15(40)9(3-34)52-31)58-27-16(41)10(4-35)53-32(23(27)48)55-24-11(5-36)51-28(49)20(45)19(24)44/h7,9-32,34-37,39-49H,3-6H2,1-2H3,(H,33,38)/t7-,9+,10+,11+,12+,13+,14+,15-,16-,17+,18-,19+,20+,21-,22+,23+,24+,25+,26+,27-,28?,29-,30-,31-,32-/m0/s1",alpha-L-Fuc-(1->4)-[beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,PubMed citation,7574700
2808,61343,alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A branched amino hexasaccharide made up from two fucose, two galactose, one glucosamine and one glucose unit (at the reducing end).","InChI=1S/C38H65NO29/c1-8-16(45)20(49)25(54)35(58-8)65-29-14(7-43)63-34(67-31-19(48)12(5-41)61-37(27(31)56)64-28-13(6-42)60-33(57)24(53)23(28)52)15(39-10(3)44)30(29)66-38-32(22(51)18(47)11(4-40)62-38)68-36-26(55)21(50)17(46)9(2)59-36/h8-9,11-38,40-43,45-57H,4-7H2,1-3H3,(H,39,44)/t8-,9-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21+,22-,23+,24+,25-,26-,27+,28+,29+,30+,31-,32+,33?,34-,35-,36-,37-,38-/m0/s1",alpha-L-Fuc-(1->4)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,Reaxys Registry Number,5715887
2809,61345,chrysobactin,"A catechol-type siderophore with a structure of D-lysyl-L-serine substituted on N(2) of the lysyl residue by a 2,3-dihydroxybenzoyl group. It is produced by the Gram-negative bacillus Dickeya dadantii (previously known as Erwinia chrysanthem). Only the catecholate hydroxyl groups participate in metal coordination, so chrysobactin cannot provide full 1:1 coordination of Fe(III); at neutral pH and concentrations of about 0.1 mM, ferric chrysobactin exists as a mixture of bis and tris complexes.","InChI=1S/C16H23N3O7/c17-7-2-1-5-10(15(24)19-11(8-20)16(25)26)18-14(23)9-4-3-6-12(21)13(9)22/h3-4,6,10-11,20-22H,1-2,5,7-8,17H2,(H,18,23)(H,19,24)(H,25,26)/t10-,11+/m1/s1","2-(2,3-dihydroxybenzoyl)-D-lysyl-L-serine",CAS Registry Number,120124-51-8
2810,61352,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,A branched amino pentasaccharide consisting of D-glucose at the reducing end having an alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C32H55NO25/c1-7-14(39)17(42)21(46)30(50-7)57-26-13(33-8(2)38)29(54-12(6-37)25(26)56-31-22(47)18(43)15(40)9(3-34)52-31)58-27-16(41)10(4-35)53-32(23(27)48)55-24-11(5-36)51-28(49)20(45)19(24)44/h7,9-32,34-37,39-49H,3-6H2,1-2H3,(H,33,38)/t7-,9+,10+,11+,12+,13+,14+,15-,16-,17+,18-,19+,20+,21-,22+,23+,24+,25+,26+,27-,28?,29-,30-,31-,32-/m0/s1",alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose,KEGG GLYCAN accession,G00557
2811,61356,alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A branched amino hexasaccharide comprising two fucose, two galactose, one glucosamine and one glucose unit (at the reducing end), linked as shown.","InChI=1S/C38H65NO29/c1-8-16(45)20(49)25(54)35(58-8)66-30-15(39-10(3)44)34(67-31-19(48)12(5-41)61-37(27(31)56)64-28-13(6-42)60-33(57)24(53)23(28)52)63-14(7-43)29(30)65-38-32(22(51)18(47)11(4-40)62-38)68-36-26(55)21(50)17(46)9(2)59-36/h8-9,11-38,40-43,45-57H,4-7H2,1-3H3,(H,39,44)/t8-,9-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21+,22-,23+,24+,25-,26-,27+,28+,29+,30+,31-,32+,33?,34-,35-,36-,37-,38-/m0/s1",alpha-L-Fuc-(1->3)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,PubMed citation,9101720
2812,61367,7-tetradecenoic acid,A tetradecenoic acid having its double bond in the 7-position.,"InChI=1S/C14H26O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h7-8H,2-6,9-13H2,1H3,(H,15,16)",tetradec-7-enoic acids,Reaxys Registry Number,8146988
2813,61378,2'-(5-triphosphoribosyl)-3'-dephospho-CoA(6-),An organophosphate oxoanion that is the hexaanion formed from 2'-(5-triphosphoribosyl)-3'-dephospho-CoA by global loss of protons from the di- and tri-phospho groups.,"InChI=1S/C26H46N7O26P5S/c1-26(2,20(38)23(39)29-4-3-14(34)28-5-6-65)9-53-63(47,48)58-61(43,44)52-8-13-17(36)19(24(54-13)33-11-32-15-21(27)30-10-31-22(15)33)56-25-18(37)16(35)12(55-25)7-51-62(45,46)59-64(49,50)57-60(40,41)42/h10-13,16-20,24-25,35-38,65H,3-9H2,1-2H3,(H,28,34)(H,29,39)(H,43,44)(H,45,46)(H,47,48)(H,49,50)(H2,27,30,31)(H2,40,41,42)/p-6/t12-,13-,16-,17-,18-,19-,20+,24-,25-/m1/s1",2-5-triphosphoribosyl-3-dephospho-CoA(6-),PubMed citation,11052675
2814,61382,dITP(4-),"A 2'-deoxyribonucleoside 5'-triphosphate(4-) that is the tetraanion of 2'-deoxyinosine 5'-triphosphate(dITP), arising from deprotonation of the four free OH groups of the triphosphate; major species at pH 7.3.","InChI=1S/C10H15N4O13P3/c15-5-1-7(14-4-13-8-9(14)11-3-12-10(8)16)25-6(5)2-24-29(20,21)27-30(22,23)26-28(17,18)19/h3-7,15H,1-2H2,(H,20,21)(H,22,23)(H,11,12,16)(H2,17,18,19)/p-4/t5-,6+,7+/m0/s1",2'-deoxyinosine-5'-triphosphate(4-),Reaxys Registry Number,5693691
2815,61391,(S)-chaulmoogric acid,The (S)-enantiomer of chaulmoogric acid.,"InChI=1S/C18H32O2/c19-18(20)16-10-8-6-4-2-1-3-5-7-9-13-17-14-11-12-15-17/h11,14,17H,1-10,12-13,15-16H2,(H,19,20)/t17-/m1/s1",(S)-2-Cyclopentene-1-tridecanoic acid,Reaxys Registry Number,6793245
2816,61393,fructosyllysine(1+),An amino-acid cation comprising fructosyllysine having a deprotonated carboxy group and both amino groups protonated; major species at pH 7.3.,"InChI=1S/C12H24N2O7/c13-7(12(20)21)3-1-2-4-14-5-8(16)10(18)11(19)9(17)6-15/h7,9-11,14-15,17-19H,1-6,13H2,(H,20,21)/p+1/t7-,9+,10+,11+/m0/s1",fructose lysine(1+),MetaCyc accession,FRUCTOSELYSINE
2817,61402,ITP(4-),A nucleoside triphosphate(4-) obtained by global deprotonation of the triphosphate OH groups of ITP; major species present at pH 7.3.,"InChI=1S/C10H15N4O14P3/c15-6-4(1-25-30(21,22)28-31(23,24)27-29(18,19)20)26-10(7(6)16)14-3-13-5-8(14)11-2-12-9(5)17/h2-4,6-7,10,15-16H,1H2,(H,21,22)(H,23,24)(H,11,12,17)(H2,18,19,20)/p-4/t4-,6-,7-,10-/m1/s1",inosine triphosphate(4-),MetaCyc accession,ITP
2818,61430,decanoyl-CoA(4-),An acyl-CoA(4-) species arising from deprotonation of the phosphate and diphosphate OH groups of decanoyl-CoA.,"InChI=1S/C31H54N7O17P3S/c1-4-5-6-7-8-9-10-11-22(40)59-15-14-33-21(39)12-13-34-29(43)26(42)31(2,3)17-52-58(49,50)55-57(47,48)51-16-20-25(54-56(44,45)46)24(41)30(53-20)38-19-37-23-27(32)35-18-36-28(23)38/h18-20,24-26,30,41-42H,4-17H2,1-3H3,(H,33,39)(H,34,43)(H,47,48)(H,49,50)(H2,32,35,36)(H2,44,45,46)/p-4/t20-,24-,25-,26+,30-/m1/s1",decanoyl-coenzyme A(4-),MetaCyc accession,CPD-10267
2819,61437,fructoselysine 6-phosphate,An L-lysine derivative having a 6-phosphofructosyl group attached to the side-chain amino group.,"InChI=1S/C12H25N2O10P/c13-7(12(19)20)3-1-2-4-14-5-8(15)10(17)11(18)9(16)6-24-25(21,22)23/h7,9-11,14,16-18H,1-6,13H2,(H,19,20)(H2,21,22,23)/t7-,9+,10+,11+/m0/s1",fructosyllysine 6-phosphate,KEGG COMPOUND accession,C16489
2820,61457,UDP-beta-L-arabinopyranose(2-),A nucleotide-sugar oxoanion resulting from the removal of two protons from the diphosphate group of UDP-beta-L-arabinopyranose.,"InChI=1S/C14H22N2O16P2/c17-5-3-28-13(11(22)8(5)19)31-34(26,27)32-33(24,25)29-4-6-9(20)10(21)12(30-6)16-2-1-7(18)15-14(16)23/h1-2,5-6,8-13,17,19-22H,3-4H2,(H,24,25)(H,26,27)(H,15,18,23)/p-2/t5-,6+,8-,9+,10+,11+,12+,13+/m0/s1",UDP-beta-L-arabinopyranose dianion,MetaCyc accession,CPD-12513
2821,61460,UDP-beta-L-arabinofuranose,A UDP-sugar having beta-L-arabinose as the sugar component.,"InChI=1S/C14H22N2O16P2/c17-3-5-8(19)11(22)13(30-5)31-34(26,27)32-33(24,25)28-4-6-9(20)10(21)12(29-6)16-2-1-7(18)15-14(16)23/h1-2,5-6,8-13,17,19-22H,3-4H2,(H,24,25)(H,26,27)(H,15,18,23)/t5-,6+,8-,9+,10+,11+,12+,13+/m0/s1",UDP-beta-L-Araf,MetaCyc accession,CPD-12511
2822,61463,UDP-beta-L-arabinofuranose(2-),A nucleotide-sugar oxoanion resulting from the removal of two protons from the diphosphate group of UDP-beta-L-arabinofuranose.,"InChI=1S/C14H22N2O16P2/c17-3-5-8(19)11(22)13(30-5)31-34(26,27)32-33(24,25)28-4-6-9(20)10(21)12(29-6)16-2-1-7(18)15-14(16)23/h1-2,5-6,8-13,17,19-22H,3-4H2,(H,24,25)(H,26,27)(H,15,18,23)/p-2/t5-,6+,8-,9+,10+,11+,12+,13+/m0/s1",UDP-beta-L-arabinofuranose dianion,PubMed citation,17182701
2823,61493,"(2Z,4E)-4-carboxy-2-hydroxyhexa-2,4-dienedioic acid","A 4-carboxy-2-hydroxyhexa-2,4-dienedioic acid having (2Z,4E)-configuration about the C=C double bonds.","InChI=1S/C7H6O7/c8-4(7(13)14)1-3(6(11)12)2-5(9)10/h1-2,8H,(H,9,10)(H,11,12)(H,13,14)/b3-2+,4-1-","(E,Z)-4-hydroxybuta-1,3-diene-1,2,4-tricarboxylic acid",PDBeChem accession,0GY
2824,61494,UDP-3-O-[(3R)-3-hydroxytetradecanoyl]-N-acetylglucosamine(2-),A nucleotide-sugar oxoanion obtained by deprotonation of the diphosphate OH groups of UDP-3-O-[(3R)-3-hydroxytetradecanoyl]-N-acetylglucosamine; major species at pH 7.3.,"InChI=1S/C31H53N3O19P2/c1-3-4-5-6-7-8-9-10-11-12-19(37)15-23(39)51-28-24(32-18(2)36)30(50-20(16-35)26(28)41)52-55(46,47)53-54(44,45)48-17-21-25(40)27(42)29(49-21)34-14-13-22(38)33-31(34)43/h13-14,19-21,24-30,35,37,40-42H,3-12,15-17H2,1-2H3,(H,32,36)(H,44,45)(H,46,47)(H,33,38,43)/p-2/t19-,20-,21-,24-,25-,26-,27-,28-,29-,30-/m1/s1",UDP-3-O-(3-hydroxytetradecanoyl)-N-acetylglucosamine,MetaCyc accession,UDP-OHMYR-ACETYLGLUCOSAMINE
2825,61495,"beta-D-ManNAcA-(1->4)-alpha-D-GlcNAc-1-diphospho-ditrans,polycis-undecaprenol(3-)","An organophosphate oxoanion resulting from deprotonation of the carboxy and phosphate OH groups of beta-D-ManNAcA-(1->4)-alpha-D-GlcNAc-1-diphospho-ditrans,polycis-undecaprenol; major species at pH 7.3.","InChI=1S/C71H116N2O18P2/c1-48(2)25-15-26-49(3)27-16-28-50(4)29-17-30-51(5)31-18-32-52(6)33-19-34-53(7)35-20-36-54(8)37-21-38-55(9)39-22-40-56(10)41-23-42-57(11)43-24-44-58(12)45-46-86-92(82,83)91-93(84,85)90-71-63(73-60(14)76)65(78)67(61(47-74)87-71)88-70-62(72-59(13)75)64(77)66(79)68(89-70)69(80)81/h25,27,29,31,33,35,37,39,41,43,45,61-68,70-71,74,77-79H,15-24,26,28,30,32,34,36,38,40,42,44,46-47H2,1-14H3,(H,72,75)(H,73,76)(H,80,81)(H,82,83)(H,84,85)/p-3/b49-27+,50-29+,51-31-,52-33-,53-35-,54-37-,55-39-,56-41-,57-43-,58-45-/t61-,62+,63-,64-,65-,66+,67-,68+,70-,71-/m1/s1",Undecaprenyl-diphospho-N-acetylglucosamine-N-acetylmannosaminuronate(3-),MetaCyc accession,C55-PP-GLCNAC-MANNACA
2826,61496,alpha-D-FucNAc4-(1->4)-beta-D-ManNAcA-(1->4)-D-GlcNAc-undecaprenyl diphosphate(3-),An organophosphate oxoanion resulting from deprotonation of the carboxy and phosphate OH groups of alpha-D-FucNAc4-(1->4)-beta-D-ManNAcA-(1->4)-alpha-D-GlcNAc-undecaprenyl diphosphate; major species at pH 7.3.,"InChI=1S/C79H129N3O22P2/c1-50(2)27-17-28-51(3)29-18-30-52(4)31-19-32-53(5)33-20-34-54(6)35-21-36-55(7)37-22-38-56(8)39-23-40-57(9)41-24-42-58(10)43-25-44-59(11)45-26-46-60(12)47-48-97-105(93,94)104-106(95,96)103-78-68(82-64(16)86)70(88)73(65(49-83)99-78)100-77-67(81-63(15)85)71(89)74(75(102-77)76(91)92)101-79-72(90)69(87)66(61(13)98-79)80-62(14)84/h27,29,31,33,35,37,39,41,43,45,47,61,65-75,77-79,83,87-90H,17-26,28,30,32,34,36,38,40,42,44,46,48-49H2,1-16H3,(H,80,84)(H,81,85)(H,82,86)(H,91,92)(H,93,94)(H,95,96)/p-3/b51-29+,52-31+,53-33-,54-35-,55-37-,56-39-,57-41-,58-43-,59-45-,60-47-/t61-,65-,66+,67+,68-,69+,70-,71-,72-,73-,74+,75+,77-,78-,79-/m1/s1","Undecaprenyl-diphospho N-acetylglucosamine-N-acetylmannosaminuronate-N-acetamido-4,6-dideoxy-D-galactose",MetaCyc accession,C55-PP-GLCNAC-MANNACA-FUC4NAC
2827,61507,(heptosyl)2-(KDO)2-lipid A(6-),A lipid A oxoanion obtained via deprotonation of the carboxy and phosphate OH groups of L-alpha-D-Hep-(1->3)-L-alpha-D-Hep-(1->5)-[alpha-Kdo-(2->4)]-alpha-Kdo-(2->6)-lipid A; major species at pH 7.3.,"InChI=1S/C124H226N2O51P2/c1-7-13-19-25-31-37-38-44-50-56-62-68-96(141)164-84(66-60-54-48-42-35-29-23-17-11-5)72-98(143)168-115-100(126-94(139)71-83(65-59-53-47-41-34-28-22-16-10-4)163-95(140)67-61-55-49-43-36-30-24-18-12-6)117(161-79-91-102(145)114(167-97(142)70-82(132)64-58-52-46-40-33-27-21-15-9-3)99(118(165-91)177-179(158,159)160)125-93(138)69-81(131)63-57-51-45-39-32-26-20-14-8-2)166-92(113(115)176-178(155,156)157)80-162-123(121(151)152)74-90(173-124(122(153)154)73-85(133)101(144)110(174-124)88(136)77-129)112(111(175-123)89(137)78-130)171-120-107(150)116(106(149)109(170-120)87(135)76-128)172-119-105(148)103(146)104(147)108(169-119)86(134)75-127/h81-92,99-120,127-137,144-150H,7-80H2,1-6H3,(H,125,138)(H,126,139)(H,151,152)(H,153,154)(H2,155,156,157)(H2,158,159,160)/p-6/t81-,82-,83-,84-,85-,86+,87+,88-,89-,90-,91-,92-,99-,100-,101-,102-,103+,104+,105+,106-,107+,108-,109-,110-,111-,112-,113-,114-,115-,116+,117-,118-,119-,120-,123-,124-/m1/s1",heptosyl-heptosyl-kdo2-lipidA,MetaCyc accession,CPD0-930
2828,61509,N-acetyl-L-2-aminoadipate(2-),An N-acyl-L-alpha-amino acid anion arising from deprotonation of both carboxy groups of N-acetyl-L-2-aminoadipic acid; major species at pH 7.3.,"InChI=1S/C8H13NO5/c1-5(10)9-6(8(13)14)3-2-4-7(11)12/h6H,2-4H2,1H3,(H,9,10)(H,11,12)(H,13,14)/p-2/t6-/m0/s1",N(2)-acetyl-L-aminoadipate,MetaCyc accession,N2-ACETYL-ALPHA-AMIN
2829,61513,gamma-butyrobetainyl-CoA(3-),A triply charged acyl-CoA oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of gamma-butyrobetainyl-CoA.,"InChI=1S/C28H49N8O17P3S/c1-28(2,23(40)26(41)31-9-8-18(37)30-10-12-57-19(38)7-6-11-36(3,4)5)14-50-56(47,48)53-55(45,46)49-13-17-22(52-54(42,43)44)21(39)27(51-17)35-16-34-20-24(29)32-15-33-25(20)35/h15-17,21-23,27,39-40H,6-14H2,1-5H3,(H7-,29,30,31,32,33,37,41,42,43,44,45,46,47,48)/p-3/t17-,21-,22-,23+,27-/m1/s1",gamma-butyrobetaine-CoA,MetaCyc accession,GAMMA-BUTYROBETAINYL-COA
2830,61515,N-acetyl-L-2-aminoadipic acid semialdehyde,"An N-acetyl-L-amino acid, where the amino acid is L-2-aminoadipic acid (6-oxo-L-norleucine).","InChI=1S/C8H13NO4/c1-6(11)9-7(8(12)13)4-2-3-5-10/h5,7H,2-4H2,1H3,(H,9,11)(H,12,13)/t7-/m0/s1",N-acetyl-L-2-aminoadipic semialdehyde,KEGG COMPOUND accession,C12988
2831,61517,gamma-butyrobetainyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 4-trimethylammoniobutanoic acid.,"InChI=1S/C28H49N8O17P3S/c1-28(2,23(40)26(41)31-9-8-18(37)30-10-12-57-19(38)7-6-11-36(3,4)5)14-50-56(47,48)53-55(45,46)49-13-17-22(52-54(42,43)44)21(39)27(51-17)35-16-34-20-24(29)32-15-33-25(20)35/h15-17,21-23,27,39-40H,6-14H2,1-5H3,(H7-,29,30,31,32,33,37,41,42,43,44,45,46,47,48)/p+1/t17-,21-,22-,23+,27-/m1/s1",4-trimethylammoniobutanoyl-coenzyme A,Patent accession,WO0024919
2832,61522,(KDO)2-(palmitoleoyl-myristoyl)-lipid A(6-),A lipid A oxoanion obtained via deprotonation of the carboxy and phosphate OH groups of (KDO)2-(palmitoleoyl-myristoyl)-lipid A; major species at pH 7.3.,"InChI=1S/C114H208N2O39P2/c1-7-13-19-25-31-37-39-40-42-48-54-59-65-71-95(126)145-85(69-63-57-51-45-35-29-23-17-11-5)75-94(125)116-100-108(150-98(129)76-86(70-64-58-52-46-36-30-24-18-12-6)146-96(127)72-66-60-53-47-41-38-32-26-20-14-8-2)106(154-156(137,138)139)92(82-144-113(111(133)134)78-90(102(131)105(152-113)89(123)80-118)151-114(112(135)136)77-87(121)101(130)104(153-114)88(122)79-117)148-109(100)143-81-91-103(132)107(149-97(128)74-84(120)68-62-56-50-44-34-28-22-16-10-4)99(110(147-91)155-157(140,141)142)115-93(124)73-83(119)67-61-55-49-43-33-27-21-15-9-3/h37,39,83-92,99-110,117-123,130-132H,7-36,38,40-82H2,1-6H3,(H,115,124)(H,116,125)(H,133,134)(H,135,136)(H2,137,138,139)(H2,140,141,142)/p-6/b39-37-/t83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,113-,114-/m1/s1","(KDO)2-lipid A, cold adapted",MetaCyc accession,KDO2-LIPID-IVA-COLD
2833,61524,(KDO)2-(lauroyl)-lipid IVA(6-),A lipid A oxoanion obtained via deprotonation of the carboxy and phosphate OH groups of (KDO)2-(lauroyl)-lipid IVA; major species at pH 7.3.,"InChI=1S/C96H176N2O38P2/c1-6-11-16-21-26-31-36-41-46-51-66(101)56-76(107)97-81-89(130-79(110)57-67(102)52-47-42-37-32-27-22-17-12-7-2)85(114)74(128-92(81)136-138(122,123)124)64-125-91-82(98-77(108)59-69(54-49-44-39-34-29-24-19-14-9-4)127-78(109)55-50-45-40-35-30-25-20-15-10-5)90(131-80(111)58-68(103)53-48-43-38-33-28-23-18-13-8-3)88(135-137(119,120)121)75(129-91)65-126-95(93(115)116)61-73(84(113)87(133-95)72(106)63-100)132-96(94(117)118)60-70(104)83(112)86(134-96)71(105)62-99/h66-75,81-92,99-106,112-114H,6-65H2,1-5H3,(H,97,107)(H,98,108)(H,115,116)(H,117,118)(H2,119,120,121)(H2,122,123,124)/p-6/t66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,95-,96-/m1/s1",lauroyl-KDO2-lipid IV (A),MetaCyc accession,KDO2-LAUROYL-LIPID-IVA
2834,61526,(E)-hexadec-2-enoyl-CoA(4-),A hexadecenoyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (E)-hexadec-2-enoyl-CoA; major species at pH 7.3.,"InChI=1S/C37H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h16-17,24-26,30-32,36,47-48H,4-15,18-23H2,1-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/p-4/b17-16+/t26-,30-,31-,32+,36-/m1/s1",trans-hexadec-2-enoyl-CoA(4-),MetaCyc accession,CPD0-2117
2835,61540,palmitoleoyl-CoA(4-),A hexadecenoyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of palmitoleyl-CoA.,"InChI=1S/C37H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h9-10,24-26,30-32,36,47-48H,4-8,11-23H2,1-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/p-4/b10-9-/t26-,30-,31-,32+,36-/m1/s1",cis-9-hexadecenoyl-CoA(4-),MetaCyc accession,CPD-10269
2836,61555,dUTP(4-),A 2'-deoxyribonucleoside 5'-triphosphate(4-) resulting from deprotonation of the triphosphate OH groups of 2'-deoxyuridine-5'-triphosphate (dUTP); major species at pH 7.3.,"InChI=1S/C9H15N2O14P3/c12-5-3-8(11-2-1-7(13)10-9(11)14)23-6(5)4-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-2,5-6,8,12H,3-4H2,(H,18,19)(H,20,21)(H,10,13,14)(H2,15,16,17)/p-4/t5-,6+,8+/m0/s1",deoxy-UTP(4-),MetaCyc accession,DUTP
2837,61559,D-psicose 6-phosphate,A ketohexose monophosphate consisting of D-psicose having a phosphate group located at the 6-position.,"InChI=1S/C6H13O9P/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14/h4-7,9-11H,1-2H2,(H2,12,13,14)/t4-,5+,6-/m1/s1",D-allulose 6-phosphate,CAS Registry Number,4300-29-2
2838,61562,"dTDP-4-acetamido-4,6-dideoxy-D-galactose(2-)","The nucleotide-sugar oxoanion which is the dianion formed from dTDP-4-acetamido-4,6-dideoxy-D-galactose by deprotonation of the two phosphate OH groups.","InChI=1S/C18H29N3O15P2/c1-7-5-21(18(27)20-16(7)26)12-4-10(23)11(34-12)6-32-37(28,29)36-38(30,31)35-17-15(25)14(24)13(8(2)33-17)19-9(3)22/h5,8,10-15,17,23-25H,4,6H2,1-3H3,(H,19,22)(H,28,29)(H,30,31)(H,20,26,27)/p-2/t8-,10+,11-,12-,13+,14+,15-,17?/m1/s1",TDP-Fuc4NAc (2-),MetaCyc accession,TDP-FUC4NAC
2839,61564,L-alanyl-gamma-D-glutamyl-meso-diaminopimelic acid,"A tripeptide comprising L-alanyl, gamma-D-glutamyl and meso-diaminopimelic acid residues in a linear sequence.","InChI=1S/C15H26N4O8/c1-7(16)12(21)19-10(15(26)27)5-6-11(20)18-9(14(24)25)4-2-3-8(17)13(22)23/h7-10H,2-6,16-17H2,1H3,(H,18,20)(H,19,21)(H,22,23)(H,24,25)(H,26,27)/t7-,8-,9+,10+/m0/s1",L-Ala-gamma-D-Glu-meso-Dap,Reaxys Registry Number,15589879
2840,61565,L-alanyl-L-glutamic acid,A dipeptide consisting of L-glutamic acid having an L-alanyl attached to its alpha-amino group,"InChI=1S/C8H14N2O5/c1-4(9)7(13)10-5(8(14)15)2-3-6(11)12/h4-5H,2-3,9H2,1H3,(H,10,13)(H,11,12)(H,14,15)/t4-,5-/m0/s1",Ala-Glu,Reaxys Registry Number,1728476
2841,61566,L-alanyl-D-glutamic acid,A dipeptide consisting of D-glutamic acid having an L-alanyl attached to its alpha-amino group,"InChI=1S/C8H14N2O5/c1-4(9)7(13)10-5(8(14)15)2-3-6(11)12/h4-5H,2-3,9H2,1H3,(H,10,13)(H,11,12)(H,14,15)/t4-,5+/m0/s1",L-Alanyl-D-glutaminsaeure,Reaxys Registry Number,1728478
2842,61568,7-epi-Kdo,A ketoaldonic acid comprising a 3-deoxyoctulosonic acid having beta-L-gulo-configuration.,"InChI=1S/C8H14O8/c9-2-4(11)6-5(12)3(10)1-8(15,16-6)7(13)14/h3-6,9-12,15H,1-2H2,(H,13,14)/t3-,4+,5-,6-,8-/m1/s1",7-epi-alpha-Kdo,PubMed citation,18272175
2843,61571,alpha-Kdo-(2->4)-alpha-Kdo-CH2OH,A disaccharide comprising 3-deoxy-alpha-D-manno-oct-2-ulopyranose (Kdo-CH2OH) having a 3-deoxy-alpha-D-manno-oct-2-ulopyranonosyl (Kdo) residue attached at the 4-position.,"InChI=1S/C16H28O14/c17-3-7(21)12-10(23)6(20)1-16(30-12,14(25)26)28-9-2-15(27,5-19)29-13(11(9)24)8(22)4-18/h6-13,17-24,27H,1-5H2,(H,25,26)/t6-,7-,8-,9-,10-,11-,12-,13-,15-,16-/m1/s1",alpha-Kdo-(2->4)-alpha-Kdo-C1red,PubMed citation,18272175
2844,61573,alpha-D-galactosyl-N-tetradecanoylsphinganine,A glycodihydroceramide having alpha-D-galactosyl component and the ceramide N-acyl group specified as tetradecanoyl.,"InChI=1S/C38H75NO8/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-32(41)31(30-46-38-37(45)36(44)35(43)33(29-40)47-38)39-34(42)28-26-24-22-20-17-14-12-10-8-6-4-2/h31-33,35-38,40-41,43-45H,3-30H2,1-2H3,(H,39,42)/t31-,32+,33+,35-,36-,37+,38-/m0/s1",Gal-GSL,Reaxys Registry Number,7322917
2845,61578,alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[beta-D-GlcNAc-(1->6)]-D-GalNAc,A amino tetrasaccharide comprising D-GalNAc having a beta-D-GlcNAc residue at the 6-position and a alpha-Neu5Ac-(2->3)-beta-D-Gal residue at the 3-position.,"InChI=1S/C33H55N3O24/c1-9(40)34-17-12(43)4-33(32(52)53,59-27(17)20(45)13(44)5-37)60-28-22(47)15(7-39)57-31(25(28)50)58-26-19(36-11(3)42)29(51)55-16(23(26)48)8-54-30-18(35-10(2)41)24(49)21(46)14(6-38)56-30/h12-31,37-39,43-51H,4-8H2,1-3H3,(H,34,40)(H,35,41)(H,36,42)(H,52,53)/t12-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24+,25+,26+,27+,28-,29?,30+,31-,33-/m0/s1",alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-[beta-D-GlcpNAc-(1->6)]-D-GalpNAc,PubMed citation,9405387
2846,61579,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-D-GalpNAc,"A linear amino trisaccharide comprising an alpha-N-acetylneuraminyl residue (2->3)-linked to a beta-D-galactosyl residue, which is in turn linked (1->3) to N-acetyl-D-galactosamine.","InChI=1S/C25H42N2O19/c1-7(31)26-13-9(33)3-25(24(40)41,45-20(13)15(35)10(34)4-28)46-21-17(37)12(6-30)43-23(18(21)38)44-19-14(27-8(2)32)22(39)42-11(5-29)16(19)36/h9-23,28-30,33-39H,3-6H2,1-2H3,(H,26,31)(H,27,32)(H,40,41)/t9-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20+,21-,22?,23-,25-/m0/s1",alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-D-glucosamine,PubMed citation,12015815
2847,61580,beta-D-GlcpNAc-(1->6)-D-GalpNAc,An amino disaccharide consisting of N-acetyl-D-galactosamine having a N-acetyl-beta-D-glucosaminyl residue attached at the 6-position.,"InChI=1S/C16H28N2O11/c1-5(20)17-9-13(24)12(23)8(28-15(9)26)4-27-16-10(18-6(2)21)14(25)11(22)7(3-19)29-16/h7-16,19,22-26H,3-4H2,1-2H3,(H,17,20)(H,18,21)/t7-,8-,9-,10-,11-,12+,13-,14-,15?,16-/m1/s1",N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-D-galactosamine,KEGG GLYCAN accession,G02165
2848,61581,beta-D-Gal-(1->3)-[beta-D-GlcNAc-(1->6)]-D-GalNAc,A branched amino trisaccharide comprising N-acetyl-D-galactose having a beta-D-galactosyl residue at the 3-position and a N-acetyl-beta-D-glucosaminyl residue at the 6-position.,"InChI=1S/C22H38N2O16/c1-6(27)23-11-16(32)13(29)8(3-25)38-21(11)36-5-10-15(31)19(12(20(35)37-10)24-7(2)28)40-22-18(34)17(33)14(30)9(4-26)39-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13-,14+,15+,16-,17+,18-,19-,20?,21-,22+/m1/s1",beta-D-Galp-(1->3)-[beta-D-GlcpNAc-(1->6)]-D-GalpNAc,PubMed citation,2055602
2849,61583,6-O-(2-amino-2-deoxy-alpha-D-glucosyl)-1D-myo-inositol 1-(6-mercaptohexyl)phosphate,A myo-inositol monophosphate derivative consisting of 1-O-(6-thiohexylphosphono)-D-myo-inositol having a 2-amino-2-deoxy-alpha-D-glucosyl residue at the 6-position.,"InChI=1S/C18H36NO13PS/c19-9-11(22)10(21)8(7-20)30-18(9)31-16-14(25)12(23)13(24)15(26)17(16)32-33(27,28)29-5-3-1-2-4-6-34/h8-18,20-26,34H,1-7,19H2,(H,27,28)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17-,18-/m1/s1",(2-amino-2-deoxy-alpha-D-glucopyranosyl)-(1->6)-1-O-(6-thiohexylphosphono)-D-myo-inositol,Reaxys Registry Number,10226714
2850,61585,(alpha-D-Man)-(1->4)-(alpha-D-GlcN)-(1->6)-1-O-(6-thiohexylphosphono)-D-myo-inositol,A myo-inositol monophosphate derivative consisting of 1-O-(6-thiohexylphosphono)-D-myo-inositol having an alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl residue at the 6-position.,"InChI=1S/C24H46NO18PS/c25-11-13(29)20(41-24-19(35)14(30)12(28)9(7-26)39-24)10(8-27)40-23(11)42-21-17(33)15(31)16(32)18(34)22(21)43-44(36,37)38-5-3-1-2-4-6-45/h9-24,26-35,45H,1-8,25H2,(H,36,37)/t9-,10-,11-,12-,13-,14+,15-,16-,17+,18-,19+,20-,21-,22-,23-,24-/m1/s1",(alpha-D-mannosyl)-(1->4)-(alpha-D-glucosaminyl)-(1->6)-1-O-(6-thiohexylphosphono)-D-myo-inositol,Reaxys Registry Number,10232884
2851,61587,[alpha-D-Man-(1->6)-alpha-D-Man-(1->4)-alpha-D-GlcN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,A myo-inositol monophosphate derivative consisting of 1-O-(6-thiohexylphosphono)-D-myo-inositol having an alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl residue at the 6-position.,"InChI=1S/C30H56NO23PS/c31-13-16(36)25(52-30-24(44)18(38)15(35)12(51-30)9-47-29-23(43)17(37)14(34)10(7-32)49-29)11(8-33)50-28(13)53-26-21(41)19(39)20(40)22(42)27(26)54-55(45,46)48-5-3-1-2-4-6-56/h10-30,32-44,56H,1-9,31H2,(H,45,46)/t10-,11-,12-,13-,14-,15-,16-,17+,18+,19-,20-,21+,22-,23+,24+,25-,26-,27-,28-,29+,30-/m1/s1",[alpha-D-Manp-(1->6)-alpha-D-Manp-(1->4)-alpha-D-GlcpN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,Reaxys Registry Number,10235540
2852,61588,[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)-alpha-D-Man-(1->4)-alpha-D-GlcN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,A myo-inositol monophosphate derivative consisting of 1-O-(6-thiohexylphosphono)-D-myo-inositol having an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl residue at the 6-position.,"InChI=1S/C36H66NO28PS/c37-15-19(44)29(13(9-40)60-33(15)63-30-25(50)22(47)23(48)26(51)31(30)65-66(54,55)57-5-3-1-2-4-6-67)62-35-28(53)21(46)18(43)14(61-35)10-56-36-32(24(49)17(42)12(8-39)59-36)64-34-27(52)20(45)16(41)11(7-38)58-34/h11-36,38-53,67H,1-10,37H2,(H,54,55)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20+,21+,22-,23-,24+,25+,26-,27+,28+,29-,30-,31-,32+,33-,34-,35-,36+/m1/s1",[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->4)-alpha-D-GlcpN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,PubMed citation,15729674
2853,61590,[6-O-(2-aminoethylphosphono)-alpha-D-Man-(1->2)-alpha-D-Man-(1->6)-alpha-D-Man-(1->4)-alpha-D-GlcN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,A myo-inositol monophosphate derivative consisting of 1-O-(6-thiohexylphosphono)-D-myo-inositol having a 6-O-(2-aminoethylphosphono)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl residue at the 6-position.,"InChI=1S/C38H72N2O31P2S/c39-5-7-62-72(56,57)63-12-16-20(45)23(48)30(55)37(67-16)70-34-26(51)18(43)13(9-41)64-38(34)60-11-15-19(44)22(47)29(54)36(66-15)68-31-14(10-42)65-35(17(40)21(31)46)69-32-27(52)24(49)25(50)28(53)33(32)71-73(58,59)61-6-3-1-2-4-8-74/h13-38,41-55,74H,1-12,39-40H2,(H,56,57)(H,58,59)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24-,25-,26+,27+,28-,29+,30+,31-,32-,33-,34+,35-,36-,37-,38+/m1/s1",[6-O-(2-aminoethylphosphono)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,PubMed citation,15729674
2854,61591,[alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->6)-alpha-D-Man-(1->4)-alpha-D-GlcN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,A myo-inositol monophosphate derivative consisting of 1-O-(6-thiohexylphosphono)-D-myo-inositol having an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl residue at the 6-position.,"InChI=1S/C42H76NO33PS/c43-17-22(52)33(15(10-47)70-38(17)73-34-29(59)25(55)26(56)30(60)35(34)76-77(63,64)66-5-3-1-2-4-6-78)72-40-32(62)24(54)21(51)16(71-40)11-65-41-36(27(57)19(49)13(8-45)68-41)75-42-37(28(58)20(50)14(9-46)69-42)74-39-31(61)23(53)18(48)12(7-44)67-39/h12-42,44-62,78H,1-11,43H2,(H,63,64)/t12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+,24+,25-,26-,27+,28+,29+,30-,31+,32+,33-,34-,35-,36+,37+,38-,39-,40-,41+,42-/m1/s1",[alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,PubMed citation,15729674
2855,61592,[alpha-D-Man-(1->2)-6-PEA-alpha-D-Man-(1->2)-alpha-D-Man-(1->6)-alpha-D-Man-(1->4)-alpha-D-GlcN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,A myo-inositol monophosphate derivative consisting of 1-O-(6-thiohexylphosphono)-D-myo-inositol having an alpha-D-mannosyl-(1->2)-6-O-(2-aminoethylphosphono)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl residue at the 6-position.,"InChI=1S/C44H82N2O36P2S/c45-5-7-71-83(65,66)72-13-18-23(53)30(60)39(80-41-33(63)25(55)20(50)14(9-47)73-41)44(77-18)81-38-29(59)21(51)15(10-48)74-43(38)69-12-17-22(52)26(56)34(64)42(76-17)78-35-16(11-49)75-40(19(46)24(35)54)79-36-31(61)27(57)28(58)32(62)37(36)82-84(67,68)70-6-3-1-2-4-8-85/h14-44,47-64,85H,1-13,45-46H2,(H,65,66)(H,67,68)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25+,26+,27-,28-,29+,30+,31+,32-,33+,34+,35-,36-,37-,38+,39+,40-,41-,42-,43+,44-/m1/s1",[alpha-D-Manp-(1->2)-6-O-(2-aminoethylphosphono)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->4)-alpha-D-GlcpN-(1->6)]-1-O-(6-thiohexylphosphono)-D-myo-inositol,PubMed citation,15729674
2856,61594,beta-D-galactosyl-N-(nonadecanoyl)sphingosine,A D-galactosyl-N-acylsphingosine where the ceramide N-acyl group is nonadecanoyl.,"InChI=1S/C43H83NO8/c1-3-5-7-9-11-13-15-17-18-19-21-23-25-27-29-31-33-39(47)44-36(35-51-43-42(50)41(49)40(48)38(34-45)52-43)37(46)32-30-28-26-24-22-20-16-14-12-10-8-6-4-2/h30,32,36-38,40-43,45-46,48-50H,3-29,31,33-35H2,1-2H3,(H,44,47)/b32-30+/t36-,37+,38+,40-,41-,42+,43+/m0/s1",1-O-beta-D-galactopyranosyl-N-(nonadecanoyl)sphingosine,PubMed citation,18671950
2857,61597,[8)-alpha-Neu5Ac-(2->]6,An N-acetylated alpha-(2->8)-linked homosialopolysaccharide consisting of six alpha-D-N-acetylneuraminyl residues joined by (2->8) linkages (i.e. [8)-alpha-Neu5Ac-(2->]n  where n = 6).,"InChI=1S/C66H104N6O49/c1-19(79)67-37-25(85)7-61(110,55(98)99)116-50(37)44(93)32(14-74)111-63(57(102)103)9-27(87)39(69-21(3)81)52(118-63)46(95)34(16-76)113-65(59(106)107)11-29(89)41(71-23(5)83)54(120-65)48(97)36(18-78)115-66(60(108)109)12-30(90)42(72-24(6)84)53(121-66)47(96)35(17-77)114-64(58(104)105)10-28(88)40(70-22(4)82)51(119-64)45(94)33(15-75)112-62(56(100)101)8-26(86)38(68-20(2)80)49(117-62)43(92)31(91)13-73/h25-54,73-78,85-97,110H,7-18H2,1-6H3,(H,67,79)(H,68,80)(H,69,81)(H,70,82)(H,71,83)(H,72,84)(H,98,99)(H,100,101)(H,102,103)(H,104,105)(H,106,107)(H,108,109)/t25-,26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,61+,62+,63+,64+,65+,66+/m0/s1",alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->8)-alpha-Neu5Ac,PubMed citation,2457648
2858,61600,[8)-alpha-Neu5Pr-(2->]6,An N-propionylated alpha-(2->8)-linked homosialopolysaccharide consisting of six alpha-D-N-propionylneuraminyl residues joined by (2->8) linkages (i.e. [8)-alpha-Neu5Pr-(2->]n  where n = 6).,"InChI=1S/C72H116N6O49/c1-7-37(92)73-43-25(85)13-67(116,61(104)105)122-56(43)50(99)32(20-80)117-69(63(108)109)15-27(87)45(75-39(94)9-3)58(124-69)52(101)34(22-82)119-71(65(112)113)17-29(89)47(77-41(96)11-5)60(126-71)54(103)36(24-84)121-72(66(114)115)18-30(90)48(78-42(97)12-6)59(127-72)53(102)35(23-83)120-70(64(110)111)16-28(88)46(76-40(95)10-4)57(125-70)51(100)33(21-81)118-68(62(106)107)14-26(86)44(74-38(93)8-2)55(123-68)49(98)31(91)19-79/h25-36,43-60,79-91,98-103,116H,7-24H2,1-6H3,(H,73,92)(H,74,93)(H,75,94)(H,76,95)(H,77,96)(H,78,97)(H,104,105)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)/t25-,26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,67+,68+,69+,70+,71+,72+/m0/s1",alpha-Neu5Pr-(2->8)-alpha-Neu5Pr-(2->8)-alpha-Neu5Pr-(2->8)-alpha-Neu5Pr-(2->8)-alpha-Neu5Pr-(2->8)-alpha-Neu5Pr,PubMed citation,2469720
2859,61601,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,A glucosamine oligosaccharide comprising N-acetylglucosamine at the reducing end having an alpha-L-rhamnosyl-(1->2)-alpha-L-rhamnosyl-(1->3)-alpha-L-rhamnosyl group attached at the 3-position.,"InChI=1S/C26H45NO18/c1-6-12(30)16(34)18(36)24(39-6)45-22-17(35)13(31)7(2)41-26(22)44-21-14(32)8(3)40-25(19(21)37)43-20-11(27-9(4)29)23(38)42-10(5-28)15(20)33/h6-8,10-26,28,30-38H,5H2,1-4H3,(H,27,29)/t6-,7-,8-,10+,11+,12-,13-,14-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26-/m0/s1",alpha-L-rhamnosyl-(1->2)-alpha-L-rhamnosyl-(1->3)-alpha-L-rhamnosyl-(1->3)-N-acetyl-beta-D-glucosamine,KEGG GLYCAN accession,G00855
2860,61602,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap,A ten-membered glucosamine oligosaccharide comprising eight alpha-L-rhamnosyl residues (one at the reducing end) and two N-acetyl-beta-D-glucosaminyl residues in a linear sequence.,"InChI=1S/C64H108N2O43/c1-13-28(72)38(82)50(55(90)91-13)105-63-51(39(83)29(73)17(5)97-63)106-56-25(65-21(9)69)46(35(79)23(11-67)99-56)101-60-45(89)49(34(78)20(8)94-60)104-62-54(42(86)32(76)16(4)96-62)109-64-52(40(84)30(74)18(6)98-64)107-57-26(66-22(10)70)47(36(80)24(12-68)100-57)102-59-44(88)48(33(77)19(7)93-59)103-61-53(41(85)31(75)15(3)95-61)108-58-43(87)37(81)27(71)14(2)92-58/h13-20,23-64,67-68,71-90H,11-12H2,1-10H3,(H,65,69)(H,66,70)/t13-,14-,15-,16-,17-,18-,19-,20-,23+,24+,25+,26+,27-,28-,29-,30-,31-,32-,33-,34-,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1",alpha-L-rhamnosyl-(1->2)-alpha-L-rhamnosyl-(1->3)-alpha-L-rhamnosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-L-rhamnosyl-(1->2)-alpha-L-rhamnosyl-(1->3)-alpha-L-rhamnosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-L-rhamnosyl-(1->2)-alpha-L-rhamnose,KEGG GLYCAN accession,G01282
2861,61606,alpha-L-Rhap-(1->6)-D-Glcp,A glycosylglucose in which the glycosyl moiety is L-rhamnose linked alpha to C-6 of D-glucose.,"InChI=1S/C12H22O10/c1-3-5(13)7(15)10(18)12(21-3)20-2-4-6(14)8(16)9(17)11(19)22-4/h3-19H,2H2,1H3/t3-,4+,5-,6+,7+,8-,9+,10+,11?,12+/m0/s1",alpha-L-Rha-(1->6)-D-Glc,KEGG GLYCAN accession,G00283
2862,61609,alpha-D-Manp-(1->2)-alpha-D-Manp,A glycosylmannose consisting of alpha-D-mannose having an alpha-D-mannosyl residue attached at the 2-position,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10+,11+,12-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man,PubMed citation,12829775
2863,61611,alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-D-Manp,A mannotriose consisting of three alpha-(1->6)-linked D-mannopyranose units with undefined stereochemistry at the reducing end.,"InChI=1S/C18H32O16/c19-1-4-7(20)11(24)14(27)17(33-4)31-3-6-9(22)12(25)15(28)18(34-6)30-2-5-8(21)10(23)13(26)16(29)32-5/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16?,17+,18+/m1/s1",alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->6)-D-mannose,PubMed citation,8898075
2864,61612,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-D-Manp,A linear trisaccharide consisting of three D-mannose units joined by alpha-(1->2)- and alpha-(1->6)-linkages,"InChI=1S/C18H32O16/c19-1-4-7(21)11(25)14(28)17(32-4)34-15-12(26)8(22)5(2-20)33-18(15)30-3-6-9(23)10(24)13(27)16(29)31-6/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16?,17-,18+/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->6)-D-Man,KEGG GLYCAN accession,G00840
2865,61613,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp,A linear trisaccharide consisting of three D-mannose units joined by alpha-(1->2)-linkages,"InChI=1S/C18H32O16/c19-1-4-8(23)11(26)14(16(29)30-4)33-18-15(12(27)9(24)6(3-21)32-18)34-17-13(28)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16?,17-,18-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-D-Man,PubMed citation,8898075
2866,61620,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-D-Manp,"A linear tetrasaccharide in which four mannopyranose residues are joined by alpha-(1->2)-, alpha-(1->2)- and alpha-(1->6)-linkages.","InChI=1S/C24H42O21/c25-1-5-9(28)14(33)18(37)22(41-5)44-20-16(35)11(30)7(3-27)43-24(20)45-19-15(34)10(29)6(2-26)42-23(19)39-4-8-12(31)13(32)17(36)21(38)40-8/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21?,22-,23+,24-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->6)-D-Man,KEGG GLYCAN accession,G03287
2867,61621,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-D-Manp,"A linear mannopentaose comprising five D-mannose residues joined by sequential alpha-(1->2)-, alpha-(1->2)-, alpha-(1->2)- and alpha-(1->6)-linkages.","InChI=1S/C30H52O26/c31-1-6-11(35)17(41)22(46)27(50-6)54-24-19(43)13(37)8(3-33)52-29(24)56-25-20(44)14(38)9(4-34)53-30(25)55-23-18(42)12(36)7(2-32)51-28(23)48-5-10-15(39)16(40)21(45)26(47)49-10/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26?,27-,28+,29-,30-/m1/s1",alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-D-mannose,KEGG GLYCAN accession,G07050
2868,61622,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp,A mannopentaose consisting of five D-mannopyranose residues linked by four alpha-(1->2)-linkages.,"InChI=1S/C30H52O26/c31-1-6-12(37)17(42)22(26(47)48-6)53-28-24(19(44)14(39)8(3-33)50-28)55-30-25(20(45)15(40)10(5-35)52-30)56-29-23(18(43)13(38)9(4-34)51-29)54-27-21(46)16(41)11(36)7(2-32)49-27/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26?,27-,28-,29-,30-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-D-Man,Reaxys Registry Number,6050304
2869,61625,alpha-D-Glcp-(1->6)-D-Manp,A D-glucosyl-D-mannose with the two components joined by an alpha-(1->6)-linkage.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10-,11?,12+/m1/s1",alpha-D-glucosyl-(1->6)-D-mannose,PubMed citation,11454337
2870,61626,L-alanyl-gamma-D-glutamyl-L-lysyl-D-alanine,"A tetrapeptide comprising L-alanyl, gamma-D-glutamyl, L-lysyl and D-alanine residues coupled in sequence.","InChI=1S/C17H31N5O7/c1-9(19)14(24)22-12(17(28)29)6-7-13(23)21-11(5-3-4-8-18)15(25)20-10(2)16(26)27/h9-12H,3-8,18-19H2,1-2H3,(H,20,25)(H,21,23)(H,22,24)(H,26,27)(H,28,29)/t9-,10+,11-,12+/m0/s1",L-Ala-gamma-D-Glu-L-Lys-D-Ala,Reaxys Registry Number,10309556
2871,61628,phenyl N-acetyl-alpha-D-glucosaminide,An N-acetyl-alpha-D-glucosaminide having phenyl as the anomeric substituent.,"InChI=1S/C14H19NO6/c1-8(17)15-11-13(19)12(18)10(7-16)21-14(11)20-9-5-3-2-4-6-9/h2-6,10-14,16,18-19H,7H2,1H3,(H,15,17)/t10-,11-,12-,13-,14+/m1/s1",phenyl alpha-N-acetyl-D-glucosaminide,Reaxys Registry Number,92366
2872,61632,phenyl N-acetyl-beta-D-glucosaminide,An N-acetyl-beta-D-glucosaminide having phenyl as the anomeric substituent.,"InChI=1S/C14H19NO6/c1-8(17)15-11-13(19)12(18)10(7-16)21-14(11)20-9-5-3-2-4-6-9/h2-6,10-14,16,18-19H,7H2,1H3,(H,15,17)/t10-,11-,12-,13-,14-/m1/s1",phenyl beta-N-acetyl-D-glucosaminide,Reaxys Registry Number,92364
2873,61635,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-D-GalpNAc,A branched amino tetrasaccharide comprising N-acetyl-D-galactosamine at the reducing end with a N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 3-position.,"InChI=1S/C28H48N2O20/c1-7-15(36)20(41)21(42)27(44-7)50-24-23(49-26-13(29-8(2)34)19(40)16(37)10(4-31)46-26)18(39)12(6-33)47-28(24)48-22-14(30-9(3)35)25(43)45-11(5-32)17(22)38/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17-,18-,19+,20+,21-,22+,23-,24+,25?,26+,27-,28-/m0/s1",alpha-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-D-GalNAc,PubMed citation,14623089
2874,61636,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[beta-D-Glcp-(1->6)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp,A branched amino pentasaccharide comprising the linear sequence alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal with an additional beta-D-Glc residue attached to the GlcNAc at the 6-position.,"InChI=1S/C37H62N2O29/c1-9(44)38-17-11(46)3-37(36(58)59,67-29(17)19(48)12(47)4-40)68-31-22(51)15(7-43)63-35(27(31)56)65-28-16(8-60-34-25(54)24(53)20(49)13(5-41)62-34)64-33(18(23(28)52)39-10(2)45)66-30-21(50)14(6-42)61-32(57)26(30)55/h11-35,40-43,46-57H,3-8H2,1-2H3,(H,38,44)(H,39,45)(H,58,59)/t11-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23+,24-,25+,26+,27+,28+,29+,30-,31-,32+,33-,34+,35-,37-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[beta-D-Glc-(1->6)]-beta-D-GlcNAc-(1->3)-beta-D-Gal,KEGG GLYCAN accession,G02948
2875,61649,cholesteryl 6-O-decanoyl-beta-D-galactoside,A cholesteryl 6-O-acyl-beta-D-galactoside having decanoyl as the 6-O-acyl group.,"InChI=1S/C43H74O7/c1-7-8-9-10-11-12-13-17-37(44)48-27-36-38(45)39(46)40(47)41(50-36)49-31-22-24-42(5)30(26-31)18-19-32-34-21-20-33(29(4)16-14-15-28(2)3)43(34,6)25-23-35(32)42/h18,28-29,31-36,38-41,45-47H,7-17,19-27H2,1-6H3/t29-,31+,32+,33-,34+,35+,36-,38+,39+,40-,41-,42+,43-/m1/s1",cholesteryl 6-O-capryl-beta-D-galactopyranoside,PubMed citation,20143357
2876,61652,cholesteryl 6-O-acetyl-beta-D-galactoside,A cholesteryl 6-O-acyl-beta-D-galactoside having acetyl as the 6-O-acyl group.,"InChI=1S/C35H58O7/c1-20(2)8-7-9-21(3)26-12-13-27-25-11-10-23-18-24(14-16-34(23,5)28(25)15-17-35(26,27)6)41-33-32(39)31(38)30(37)29(42-33)19-40-22(4)36/h10,20-21,24-33,37-39H,7-9,11-19H2,1-6H3/t21-,24+,25+,26-,27+,28+,29-,30+,31+,32-,33-,34+,35-/m1/s1",cholest-5-en-3beta-yl 6-O-acetyl-beta-D-galactoside,Reaxys Registry Number,20379963
2877,61654,cholesteryl 6-O-[15-(ethyldisulfanyl)pentadecanoyl]-beta-D-galactoside,A cholesteryl 6-O-acyl-beta-D-galactoside having 15-(ethyldisulfanyl)pentadecanoyl as the 6-O-acyl group.,"InChI=1S/C50H88O7S2/c1-7-58-59-32-19-17-15-13-11-9-8-10-12-14-16-18-23-44(51)55-34-43-45(52)46(53)47(54)48(57-43)56-38-28-30-49(5)37(33-38)24-25-39-41-27-26-40(36(4)22-20-21-35(2)3)50(41,6)31-29-42(39)49/h24,35-36,38-43,45-48,52-54H,7-23,25-34H2,1-6H3/t36-,38+,39+,40-,41+,42+,43-,45+,46+,47-,48-,49+,50-/m1/s1",ACGal C15SSEt,Reaxys Registry Number,20379968
2878,61665,3-O-(6-O-alpha-D-xylosylphospho-alpha-D-mannopyranosyl)-alpha-D-mannopyranose(1-),An organophosphate oxoanion that results from the removal of a proton from the phosphate group of 3-O-(6-O-alpha-D-xylosylphospho-alpha-D-mannopyranosyl)-alpha-D-mannopyranose.,"InChI=1S/C17H31O18P/c18-1-5-9(22)14(13(26)15(27)32-5)34-17-12(25)10(23)8(21)6(33-17)3-31-36(28,29)35-16-11(24)7(20)4(19)2-30-16/h4-27H,1-3H2,(H,28,29)/p-1/t4-,5-,6-,7+,8-,9-,10+,11-,12+,13+,14+,15+,16-,17-/m1/s1",3-O-(6-O-alpha-D-xylosylphospho-alpha-D-mannopyranosyl)-alpha-D-mannopyranose anion,PubMed citation,19864415
2879,61670,oroxylin A 7-O-beta-D-glucuronide,The glycosyloxyflavone which is the 7-O-glucuronide of oroxylin A.,"InChI=1S/C22H20O11/c1-30-19-13(32-22-18(27)16(25)17(26)20(33-22)21(28)29)8-12-14(15(19)24)10(23)7-11(31-12)9-5-3-2-4-6-9/h2-8,16-18,20,22,24-27H,1H3,(H,28,29)/t16-,17-,18+,20-,22+/m0/s1",oroxylin 7-O-beta-D-glucuronide,Reaxys Registry Number,71387
2880,61675,(R)-hydnocarpic acid,An optically active form of hydnocarpic acid having (R)-configuration.,"InChI=1S/C16H28O2/c17-16(18)14-8-6-4-2-1-3-5-7-11-15-12-9-10-13-15/h9,12,15H,1-8,10-11,13-14H2,(H,17,18)/t15-/m0/s1",11-((R)-Cyclopent-2-enyl)-undecansaeure,PubMed citation,4799554
2881,61683,ubiquinone-8,"A ubiquinone whose structure comprises a 2,3-dimethoxy-5-methylbenzoquinone nucleus (common to all ubiquinones) and a side chain of eight isoprenoid units.","InChI=1S/C49H74O4/c1-36(2)20-13-21-37(3)22-14-23-38(4)24-15-25-39(5)26-16-27-40(6)28-17-29-41(7)30-18-31-42(8)32-19-33-43(9)34-35-45-44(10)46(50)48(52-11)49(53-12)47(45)51/h20,22,24,26,28,30,32,34H,13-19,21,23,25,27,29,31,33,35H2,1-12H3/b37-22+,38-24+,39-26+,40-28+,41-30+,42-32+,43-34+",Coenzyme-Q8,CAS Registry Number,2394-68-5
2882,61684,menaquinol-8,A menaquinol whose structure comprises a 2-methylbenzohydroquinone nucleus and a side chain of eight isoprenoid units.,"InChI=1S/C51H74O2/c1-38(2)20-13-21-39(3)22-14-23-40(4)24-15-25-41(5)26-16-27-42(6)28-17-29-43(7)30-18-31-44(8)32-19-33-45(9)36-37-47-46(10)50(52)48-34-11-12-35-49(48)51(47)53/h11-12,20,22,24,26,28,30,32,34-36,52-53H,13-19,21,23,25,27,29,31,33,37H2,1-10H3/b39-22+,40-24+,41-26+,42-28+,43-30+,44-32+,45-36+",Reduced menaquinone-8,MetaCyc accession,REDUCED-MENAQUINONE
2883,61691,benzenamine sulfate,A sulfamic acid having a phenyl group attached to nitrogen.,"InChI=1S/C6H7NO3S/c8-11(9,10)7-6-4-2-1-3-5-6/h1-5,7H,(H,8,9,10)",N-phenylsulfamic acid,KEGG COMPOUND accession,C06011
2884,61694,L-cysteinylglycine zwitterion,The zwitterion of L-cysteinylglycine resulting from the transfer of a proton from the hydroxy group of glycine to the amino group of cysteine. Major microspecies at pH 7.3.,"InChI=1S/C5H10N2O3S/c6-3(2-11)5(10)7-1-4(8)9/h3,11H,1-2,6H2,(H,7,10)(H,8,9)/t3-/m0/s1",Cys-Gly zwitterion,MetaCyc accession,CYS-GLY
2885,61700,(+)-valencene,"A carbobicyclic compound and sesquiterpene that is 1,2,3,4,4a,5,6,7-octahydronaphthalene which is substituted a prop-1-en-2-yl group at position 3 and by methyl groups at positions 4a and 5  (the 3R,4aS,5R- diastereoisomer).","InChI=1S/C15H24/c1-11(2)13-8-9-14-7-5-6-12(3)15(14,4)10-13/h7,12-13H,1,5-6,8-10H2,2-4H3/t12-,13-,15+/m1/s1","ent-7betaH-eremophila-10(1),11-diene",MetaCyc accession,CPD-7989
2886,61705,3-demethylubiquinol-8,A 3-demethylubiquinol in which the polyprenyl chain contains 8 prenyl units.,"InChI=1S/C48H74O4/c1-35(2)19-12-20-36(3)21-13-22-37(4)23-14-24-38(5)25-15-26-39(6)27-16-28-40(7)29-17-30-41(8)31-18-32-42(9)33-34-44-43(10)45(49)47(51)48(52-11)46(44)50/h19,21,23,25,27,29,31,33,49-51H,12-18,20,22,24,26,28,30,32,34H2,1-11H3/b36-21+,37-23+,38-25+,39-27+,40-29+,41-31+,42-33+","2-octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinol",MetaCyc accession,OCTAPRENYL-METHYL-OH-METHOXY-BENZQ
2887,61708,oxidized dinoflagellate luciferin(2-),A dicarboxylic acid dianion that results from the removal of a proton from each of the carboxylic acid groups of oxidized dinoflagellate luciferin.,"InChI=1S/C33H38N4O7/c1-7-17-13(3)20(11-23-18(8-2)15(5)32(42)36-23)34-22(17)12-21-16(6)25-29(35-21)26(31(41)30(25)40)28-19(9-10-24(38)39)14(4)27(37-28)33(43)44/h8,14,19,23,27,34-35,37H,2,7,9-12H2,1,3-6H3,(H,36,42)(H,38,39)(H,43,44)/p-2/b28-26+/t14-,19-,23?,27-/m0/s1",oxidised dinoflagellate luciferin(2-),MetaCyc accession,CPD-13068
2888,61710,4-{[4-(dimethylamino)phenyl]diazenyl}phenyl-beta-lactoside,A glycoside comprising beta-lactose having a p-(p-dimethylaminophenylazo)phenyl group at the 1-position.,"InChI=1S/C26H35N3O11/c1-29(2)15-7-3-13(4-8-15)27-28-14-5-9-16(10-6-14)37-25-23(36)21(34)24(18(12-31)39-25)40-26-22(35)20(33)19(32)17(11-30)38-26/h3-10,17-26,30-36H,11-12H2,1-2H3/t17-,18-,19+,20+,21-,22-,23-,24-,25-,26+/m1/s1",lac dye,Reaxys Registry Number,72012
2889,61711,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc,"A branched amino tetrasaccharide consisting of a sialyl residue, linked (2->3) to a galactosyl residue that in turn is linked (1->4) to a glucosaminyl residue, which is also carrying a fucosyl residue at the 3-position.","InChI=1S/C31H52N2O23/c1-8-17(41)20(44)21(45)28(50-8)54-25-16(33-10(3)38)27(47)51-14(7-36)23(25)53-29-22(46)26(19(43)13(6-35)52-29)56-31(30(48)49)4-11(39)15(32-9(2)37)24(55-31)18(42)12(40)5-34/h8,11-29,34-36,39-47H,4-7H2,1-3H3,(H,32,37)(H,33,38)(H,48,49)/t8-,11-,12+,13+,14+,15+,16+,17+,18+,19-,20+,21-,22+,23+,24+,25+,26-,27?,28-,29-,31-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal (1->4)-[alpha-L-Fuc-(1->3)]-D-GlcNAc,PubMed citation,16133831
2890,61712,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[beta-D-Glcp-(1->4)]-beta-D-Galp,An amino pentasaccharide consisting of beta-D-galactose at the reducing end having a beta-D-glucosyl residue at the 4-position and an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosyl moiety at the 3-position.,"InChI=1S/C37H62N2O29/c1-9(45)38-17-11(47)3-37(36(58)59,67-29(17)19(49)12(48)4-40)68-30-21(51)14(6-42)62-35(26(30)56)64-27-15(7-43)63-33(18(22(27)52)39-10(2)46)66-31-25(55)32(57)60-16(8-44)28(31)65-34-24(54)23(53)20(50)13(5-41)61-34/h11-35,40-44,47-57H,3-8H2,1-2H3,(H,38,45)(H,39,46)(H,58,59)/t11-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21-,22+,23-,24+,25+,26+,27+,28-,29+,30-,31+,32+,33-,34-,35-,37-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Glc-(1->4)]-beta-D-Gal,CAS Registry Number,84280-28-4
2891,61714,alpha-D-Kdo-(2->8)-alpha-D-Kdo-(2->4)-alpha-D-Kdo-(2->6)-beta-D-GlcN-4P-(1->6)-alpha-D-GlcN-1P,"A six-membered oligosaccharide phosphate antigen consisting of three 3-deoxy-D-manno-oct-2-ulose residues and two glucosamine residues (one at the reducing end) in a linear sequence, with two phosphate groups attached.","InChI=1S/C36H62N2O36P2/c37-17-23(50)21(48)15(67-30(17)74-76(61,62)63)7-64-29-18(38)24(51)28(73-75(58,59)60)16(68-29)8-66-35(32(54)55)3-14(22(49)26(71-35)12(44)5-40)69-36(33(56)57)2-10(42)20(47)27(72-36)13(45)6-65-34(31(52)53)1-9(41)19(46)25(70-34)11(43)4-39/h9-30,39-51H,1-8,37-38H2,(H,52,53)(H,54,55)(H,56,57)(H2,58,59,60)(H2,61,62,63)/t9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,34-,35-,36-/m1/s1",Kdo(2->8)Kdo(2->4)Kdo(2->6)GlcN4P(1->6)GlcN1P,KEGG GLYCAN accession,G02970
2892,61716,alpha-Kdo-CH2OH-(2->4)-alpha-Kdo,A disaccharide comprising 3-deoxy-alpha-D-manno-oct-2-ulopyranose (Kdo) having a 3-deoxy-alpha-D-manno-oct-2-ulopyranosyl (Kdo-CH2OH) residue attached at the 4-position.,"InChI=1S/C16H28O14/c17-3-7(21)12-10(23)6(20)1-15(5-19,29-12)28-9-2-16(27,14(25)26)30-13(11(9)24)8(22)4-18/h6-13,17-24,27H,1-5H2,(H,25,26)/t6-,7-,8-,9-,10-,11-,12-,13-,15-,16-/m1/s1",alpha-KdoC1red-(2->4)-alpha-Kdo,PubMed citation,18272175
2893,61718,p-aminophenylphosphocholine,A phosphocholine that is the 4-aminophenyl ester of choline phosphate.,"InChI=1S/C11H19N2O4P/c1-13(2,3)8-9-16-18(14,15)17-11-6-4-10(12)5-7-11/h4-7H,8-9,12H2,1-3H3",APPC,PubMed citation,6198388
2894,61738,"4,6-pyr-beta-D-GlcpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-L-Rhap","An amino trisaccharide consisting of beta-L-rhamnose at the reducing end having a 4,6-O-[(1S)-1-carboxyethylidene]-N-acetyl-beta-D-glucosaminyl-(1->3)-alpha-D-galactosyl group attached at the 4-position.","InChI=1S/C23H37NO17/c1-6-16(13(29)14(30)19(32)36-6)39-21-15(31)18(11(27)8(4-25)37-21)40-20-10(24-7(2)26)12(28)17-9(38-20)5-35-23(3,41-17)22(33)34/h6,8-21,25,27-32H,4-5H2,1-3H3,(H,24,26)(H,33,34)/t6-,8+,9+,10+,11-,12+,13-,14+,15+,16-,17-,18-,19-,20-,21+,23-/m0/s1","4,6-pyr-beta-D-GlcNAc-(1->3)-alpha-D-Gal-(1->4)-beta-L-Rha",PubMed citation,87460
2895,61739,aureobasidin A,"A cyclodepsipeptide antibiotic, which is isolated from the filamentous fungus Aureobasidium pullulans R106 and is toxic to yeast at low concentrations (0.1-0.5 ug/ml).","InChI=1S/C60H92N8O10/c1-17-39(12)51-55(72)63-47(36(6)7)53(70)61-44(32-41-25-20-18-21-26-41)56(73)65(14)46(33-42-27-22-19-23-28-42)58(75)68-30-24-29-45(68)52(69)64-48(40(13)35(4)5)59(76)66(15)49(37(8)9)54(71)62-43(31-34(2)3)57(74)67(16)50(38(10)11)60(77)78-51/h18-23,25-28,34-40,43-51H,17,24,29-33H2,1-16H3,(H,61,70)(H,62,71)(H,63,72)(H,64,69)/t39-,40-,43+,44+,45+,46+,47?,48-,49+,50+,51+/m1/s1","(3S,6S,9S,12S,15S,18S,21S,24R,27S)-12,24-bis[(2R)-butan-2-yl]-15-(2-hydroxypropan-2-yl)-4,10,16,22-tetramethyl-18-(2-methylpropyl)-3,6-bis(phenylmethyl)-9,21-di(propan-2-yl)-13-oxa-1,4,7,10,16,19,22,25-octazabicyclo[25.3.0]triacontane-2,5,8,11,14,17,20,23,26-nonone",CAS Registry Number,127785-64-2
2896,61740,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-alpha-L-Rhap-(1->2)-alpha-L-Rhap,"A linear tetrasaccharide consisting of four alpha-L-rhamnose units joined by sequential (1->2)-, (1->3)- and (1->2)-linkages.","InChI=1S/C24H42O17/c1-5-10(26)14(30)19(21(34)35-5)40-23-17(33)18(12(28)8(4)37-23)39-24-20(15(31)11(27)7(3)38-24)41-22-16(32)13(29)9(25)6(2)36-22/h5-34H,1-4H3/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-/m0/s1",alpha-L-Rha-(1->2)-alpha-L-Rha-(1->3)-alpha-L-Rha-(1->2)-alpha-L-Rha,PubMed citation,2579417
2897,61747,"4,6-O-[(1R)-1-carboxyethylidene]-D-galactose",A monosaccharide derivative consisting of D-galactose having a 1-carboxyethylidene group masking the 4-and 6-positions.,"InChI=1S/C9H14O8/c1-9(8(13)14)15-2-3-6(17-9)4(10)5(11)7(12)16-3/h3-7,10-12H,2H2,1H3,(H,13,14)/t3-,4-,5-,6+,7?,9-/m1/s1","4,6-pyruvylated D-galactose",Reaxys Registry Number,5281182
2898,61748,(E)-oct-2-enal,The (E)-isomer of oct-2-enal.,"InChI=1S/C8H14O/c1-2-3-4-5-6-7-8-9/h6-8H,2-5H2,1H3/b7-6+",trans-octen-2-al,CAS Registry Number,2548-87-0
2899,61752,5-[2-(2-oxoethoxy)ethoxy]-diclofenac,"A member of the class of phenylacetic acids that is phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position and a 2-(2-oxoethoxy)ethoxy group at the 5-position.","InChI=1S/C18H17Cl2NO5/c19-14-2-1-3-15(20)18(14)21-16-5-4-13(10-12(16)11-17(23)24)26-9-8-25-7-6-22/h1-6,10,21H,7-9,11H2,(H,23,24)",DF5der,PubMed citation,21060839
2900,61754,alpha-L-Rhap-(1->2)-[beta-D-GlcpNAc-(1->3)]-alpha-L-Rhap-OPr,A branched glycoside consiting of propyl alpha-L-rhamnoside having alpha-L-rhamnosyl and N-acetyl-beta-D-glucosaminyl residues at the 2- and 2-positions respectively.,"InChI=1S/C23H41NO14/c1-5-6-33-23-20(38-22-18(32)17(31)13(27)8(2)34-22)19(14(28)9(3)35-23)37-21-12(24-10(4)26)16(30)15(29)11(7-25)36-21/h8-9,11-23,25,27-32H,5-7H2,1-4H3,(H,24,26)/t8-,9-,11+,12+,13-,14-,15+,16+,17+,18+,19+,20+,21-,22-,23+/m0/s1",alpha-L-Rha-(1->2)-[beta-D-GlcNAc-(1->3)]-alpha-L-Rha-OPr,Reaxys Registry Number,4773842
2901,61758,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,A linear amino trisaccharide consisting of beta-D-glucose at the reducing end having an N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl group attached at the 4-position.,"InChI=1S/C20H35NO16/c1-5(25)21-9-12(28)10(26)6(2-22)34-19(9)37-17-11(27)7(3-23)35-20(15(17)31)36-16-8(4-24)33-18(32)14(30)13(16)29/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10-,11+,12-,13-,14-,15-,16-,17+,18-,19+,20+/m1/s1",beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc,KEGG GLYCAN accession,G01380
2902,61760,"D-mannosyl ditrans,polycis-undecaprenyl phosphate","A polyprenyl glycosyl phosphate in which the glycosyl moiety is D-mannosyl and the polyprenyl group is di-trans,poly-cis-undecaprenyl.","InChI=1S/C61H101O9P/c1-46(2)23-13-24-47(3)25-14-26-48(4)27-15-28-49(5)29-16-30-50(6)31-17-32-51(7)33-18-34-52(8)35-19-36-53(9)37-20-38-54(10)39-21-40-55(11)41-22-42-56(12)43-44-68-71(66,67)70-61-60(65)59(64)58(63)57(45-62)69-61/h23,25,27,29,31,33,35,37,39,41,43,57-65H,13-22,24,26,28,30,32,34,36,38,40,42,44-45H2,1-12H3,(H,66,67)/b47-25+,48-27+,49-29-,50-31-,51-33-,52-35-,53-37-,54-39-,55-41-,56-43-/t57-,58-,59+,60+,61?/m1/s1","D-mannosyl ditrans,octacis-undecaprenyl phosphate",KEGG COMPOUND accession,C15542
2903,61762,beta-D-Glcp-(1->2)-beta-D-Glcp-(1->2)-D-Glcp,A glucotriose consisting of three D-glucose units joined by beta-(1->2)-linkages,"InChI=1S/C18H32O16/c19-1-4-8(23)11(26)14(16(29)30-4)33-18-15(12(27)9(24)6(3-21)32-18)34-17-13(28)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16?,17+,18+/m1/s1",beta-D-Glc-(1->2)-beta-D-Glc-(1->2)-D-Glc,KEGG GLYCAN accession,G02498
2904,61763,alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap,A linear trisaccharide consisting of three L-rhamose units joined by alpha-(1->2)-linkages,"InChI=1S/C18H32O13/c1-4-8(20)11(23)14(16(26)27-4)30-18-15(12(24)9(21)6(3)29-18)31-17-13(25)10(22)7(19)5(2)28-17/h4-26H,1-3H3/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17-,18-/m0/s1",alpha-L-Rha-(1->2)-alpha-L-Rha-(1->2)-alpha-L-Rha,KEGG GLYCAN accession,G00768
2905,61764,alpha-L-Rhap-(1->3)-alpha-D-Galp-(1->3)-beta-D-GlcpNAc-(1->4)-alpha-L-Rhap,"A linear amino tetrasaccharide composed of alpha-L-rhamnose, alpha-D-galactose, N-acetyl beta-D-glucosamine and alpha-L-rhamnose units joined by sequential (1->3)-, (1->3)- and (1->4)-linkages.","InChI=1S/C26H45NO19/c1-6-12(31)15(34)18(37)25(41-6)46-22-14(33)10(5-29)43-26(19(22)38)45-21-11(27-8(3)30)24(42-9(4-28)13(21)32)44-20-7(2)40-23(39)17(36)16(20)35/h6-7,9-26,28-29,31-39H,4-5H2,1-3H3,(H,27,30)/t6-,7-,9+,10+,11+,12-,13+,14-,15+,16-,17+,18+,19+,20-,21+,22-,23+,24-,25-,26+/m0/s1",alpha-L-Rha-(1->3)-alpha-D-Gal-(1->3)-beta-D-GlcNAc-(1->4)-alpha-L-Rha,KEGG GLYCAN accession,G02009
2906,61765,beta-(1->6)-galactotriose,A galactotriose composed of three beta-D-galactose units joined by (1->6)-linkages.,"InChI=1S/C18H32O16/c19-1-4-7(20)11(24)14(27)17(33-4)31-3-6-9(22)12(25)15(28)18(34-6)30-2-5-8(21)10(23)13(26)16(29)32-5/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10+,11+,12+,13-,14-,15-,16-,17-,18-/m1/s1",beta-D-Galp-(1->6)-beta-D-Galp-(1->6)-beta-D-Galp,KEGG GLYCAN accession,G00442
2907,61767,4-O-Me-beta-D-GlcpA-(1->6)-beta-D-Galp-(1->6)-beta-D-Galp-(1->6)-beta-D-Galp-(1->6)-D-Galp,A pentasaccharide derivative composed of a 4-O-methyl-beta-D-glucuronic acid (at the non-reducing end) and four beta-D-galactose units all joined via (1->6)-linkages.,"InChI=1S/C31H52O27/c1-49-24-18(40)23(45)31(58-25(24)26(46)47)53-5-9-13(35)17(39)22(44)30(57-9)52-4-8-12(34)16(38)21(43)29(56-8)51-3-7-11(33)15(37)20(42)28(55-7)50-2-6-10(32)14(36)19(41)27(48)54-6/h6-25,27-45,48H,2-5H2,1H3,(H,46,47)/t6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17+,18-,19-,20-,21-,22-,23-,24+,25+,27?,28-,29-,30-,31-/m1/s1",4-O-Me-beta-D-GlcA-(1->6)-beta-D-Gal-(1->6)-beta-D-Gal-(1->6)-beta-D-Gal-(1->6)-D-Gal,KEGG GLYCAN accession,G03070
2908,61768,beta-(1->6)-galactotetraitol,A glycoside composed of three beta-D-galactosyl residues and one galactitol unit all joined via (1->6)-linkages.,"InChI=1S/C24H44O21/c25-1-6(27)11(29)12(30)7(28)3-40-22-20(38)17(35)14(32)9(44-22)5-42-24-21(39)18(36)15(33)10(45-24)4-41-23-19(37)16(34)13(31)8(2-26)43-23/h6-39H,1-5H2/t6-,7+,8+,9+,10+,11+,12-,13-,14-,15-,16-,17-,18-,19+,20+,21+,22+,23+,24+/m0/s1",beta-D-Galp-(1->6)-beta-D-Galp-(1->6)-beta-D-Galp-(1->6)-D-galactitol,PubMed citation,7763824
2909,61770,beta-(1->6)-galactobiose,A glycosylgalactose comprising two beta-D-galactose units joined via a (1->6)-linkage.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11-,12-/m1/s1",beta-D-Galp-(1->6)-beta-D-Galp,Reaxys Registry Number,90859
2910,61771,beta-(1->3)-galactotriose,A galactotriose composed of three beta-D-galactopyranose units joined by (1->3)-linkages.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)11(26)17(31-4)34-15-9(24)6(3-21)32-18(13(15)28)33-14-8(23)5(2-20)30-16(29)12(14)27/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10+,11-,12-,13-,14+,15+,16-,17+,18+/m1/s1",beta-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-Galp,KEGG GLYCAN accession,G00830
2911,61773,alpha-L-Araf-(1->3)-beta-D-Galp-(1->6)-D-Galp,A linear trisaccharide composed of D-galactose having a alpha-L-arabinosyl-(1->3)-beta-D-galactosyl moiety attached at the 6-position,"InChI=1S/C17H30O15/c18-1-4-7(20)12(25)17(31-4)32-14-9(22)5(2-19)30-16(13(14)26)28-3-6-8(21)10(23)11(24)15(27)29-6/h4-27H,1-3H2/t4-,5+,6+,7-,8-,9-,10-,11+,12+,13+,14-,15?,16+,17-/m0/s1",alpha-L-Ara-(1->3)-beta-D-Gal-(1->6)-D-Gal,PubMed citation,7763824
2912,61781,tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine,"A triacyl lipopeptide consisting of the tripeptide L-cysteinyl-L-seryl-L-serine with the cysteinyl residue carrying N-palmitoyl and S-2,3-bis(palmitoyloxy)propyl groups.","InChI=1S/C60H113N3O11S/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-55(66)61-54(59(70)62-52(46-64)58(69)63-53(47-65)60(71)72)50-75-49-51(74-57(68)45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)48-73-56(67)44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h51-54,64-65H,4-50H2,1-3H3,(H,61,66)(H,62,70)(H,63,69)(H,71,72)/t51?,52-,53-,54-/m0/s1",P3CSS,Reaxys Registry Number,15383379
2913,61783,alpha-L-Rhap-(1->3)-alpha-D-Galp,A glycosylgalactose consisting of alpha-D-galactose having an alpha-L-rhamnosyl attached at the 3-position.,"InChI=1S/C12H22O10/c1-3-5(14)7(16)8(17)12(20-3)22-10-6(15)4(2-13)21-11(19)9(10)18/h3-19H,2H2,1H3/t3-,4+,5-,6-,7+,8+,9+,10-,11-,12-/m0/s1",alpha-L-Rha-(1->3)-alpha-D-Gal,Reaxys Registry Number,5284347
2914,61785,"2,3,4-tri-O-methyl-alpha-L-fucosyl-(1->3)-alpha-L-rhamnose","A glycosylrhamnose derivative consisting of alpha-L-rhamnose having a 2,3,4-tri-O-methyl-alpha-L-fucosyl residue attached at the 3-position.","InChI=1S/C15H28O9/c1-6-8(16)11(9(17)14(18)22-6)24-15-13(21-5)12(20-4)10(19-3)7(2)23-15/h6-18H,1-5H3/t6-,7-,8-,9+,10+,11+,12+,13-,14+,15-/m0/s1","2,3,4-tri-O-methyl-alpha-L-Fucp-(1->3)-alpha-L-Rhap",PubMed citation,1898609
2915,61789,beta-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-D-Man,"A mannotetraose in which the four mannose units are joined by sequential beta-(1->2)-, alpha-(1->2)- and alpha-(1->2)-linkages.","InChI=1S/C24H42O21/c25-1-5-10(30)14(34)18(21(38)39-5)43-23-20(16(36)12(32)7(3-27)41-23)45-24-19(15(35)11(31)8(4-28)42-24)44-22-17(37)13(33)9(29)6(2-26)40-22/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21?,22+,23-,24-/m1/s1",beta-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-D-mannose,KEGG GLYCAN accession,G07829
2916,61791,N-acetyl-6-O-sulfo-D-glucosamine,The monosaccharide sulfate formed by sulfating N-acetyl-D-glucosamine at O(6).,"InChI=1S/C7H13NO9S/c1-2(9)8-3-4(10)5(11)7(16-6(3)12)17-18(13,14)15/h3-7,10-12H,1H3,(H,8,9)(H,13,14,15)/t3-,4-,5+,6?,7-/m1/s1",(SO3)->6-GlcNAc,PubMed citation,15697247
2917,61792,beta-anthropyranosyl-(1->3)-alpha-L-rhamnopyranosyl-(1->3)-alpha-L-rhamnopyranose,A linear amino tetrasaccharide comprising beta-anthrose at the non-reducing end and two alpha-L-rhamnose units joined by sequential (1->3)- and (1->2)-linkages.,"InChI=1S/C24H43NO14/c1-8-12(25-11(26)7-24(4,5)33)15(29)20(34-6)23(36-8)39-19-14(28)10(3)37-22(17(19)31)38-18-13(27)9(2)35-21(32)16(18)30/h8-10,12-23,27-33H,7H2,1-6H3,(H,25,26)/t8-,9+,10+,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22+,23+/m1/s1",beta-anthrosyl-(1->3)-alpha-L-rhamnosyl-(1->3)-alpha-L-rhamnose,PubMed citation,20024115
2918,61794,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-D-Manp with alpha configuration at the anomeric centre of the mannose residue at the reducing end.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)12(26)17(32-4)30-3-6-9(23)15(14(28)16(29)31-6)34-18-13(27)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17+,18-/m1/s1",alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man,KEGG GLYCAN accession,G00287
2919,61806,alpha-D-Glcp-(1->3)-alpha-L-Rhap,An alpha-D-Glcp-(1->3)-L-Rhap in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C12H22O10/c1-3-5(14)10(9(18)11(19)20-3)22-12-8(17)7(16)6(15)4(2-13)21-12/h3-19H,2H2,1H3/t3-,4+,5-,6+,7-,8+,9+,10+,11+,12+/m0/s1",alpha-D-Glc-(1->3)-alpha-L-Rha,Reaxys Registry Number,6065186
2920,61807,beta-D-GlcpNAc-(1->2)-beta-D-Glcp,An amino disaccharide consisting of an beta-D-glucose residue having an N-acetyl-beta-D-glucosaminyl residue attached at the 2-position.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)6(3-17)25-14(7)26-12-11(22)9(20)5(2-16)24-13(12)23/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10-,11+,12-,13-,14+/m1/s1",beta-D-GlcNAc-(1->2)-beta-D-Glc,PubMed citation,18665848
2921,61814,beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Sph,A lysoganglioside beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc as the sialoglycosyl component; GM1 lacking the side acyl chain.,"InChI=1S/C55H97N3O30/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(66)27(56)24-79-51-43(75)41(73)45(33(22-62)82-51)84-53-44(76)49(88-55(54(77)78)18-29(67)35(57-25(2)64)48(87-55)37(69)30(68)19-59)46(34(23-63)83-53)85-50-36(58-26(3)65)47(39(71)32(21-61)80-50)86-52-42(74)40(72)38(70)31(20-60)81-52/h16-17,27-53,59-63,66-76H,4-15,18-24,56H2,1-3H3,(H,57,64)(H,58,65)(H,77,78)/b17-16+/t27-,28+,29-,30+,31+,32+,33+,34+,35+,36+,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47+,48+,49+,50-,51+,52-,53-,55-/m0/s1",Lyso-GM1,Reaxys Registry Number,9689423
2922,61817,1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and azelaoyl groups at positions 1 and 2 respectively.","InChI=1S/C33H64NO10P/c1-5-6-7-8-9-10-11-12-13-14-15-18-21-24-32(37)41-28-30(29-43-45(39,40)42-27-26-34(2,3)4)44-33(38)25-22-19-16-17-20-23-31(35)36/h30H,5-29H2,1-4H3,(H-,35,36,39,40)/t30-/m1/s1",1-O-palmitoyl-2-O-azelaoyl-sn-glycero-3-phosphocholine,Reaxys Registry Number,8747555
2923,61822,2-O-glutaroyl-1-O-palmitoyl-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and glutaroyl groups at positions 1 and 2 respectively.","InChI=1S/C29H56NO10P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-20-28(33)37-24-26(40-29(34)21-18-19-27(31)32)25-39-41(35,36)38-23-22-30(2,3)4/h26H,5-25H2,1-4H3,(H-,31,32,35,36)/t26-/m1/s1",1-O-palmitoyl-2-O-glutaroyl-sn-glycero-3-phosphocholine,Reaxys Registry Number,9679963
2924,61829,3beta-hydroxy-5alpha-cholest-8(14)-en-15-one,A 3beta-hydroxysteroid consisting of 3beta-hydroxy-5alpha-cholest-8(14)-ene having an additional oxo group at the 15-position.,"InChI=1S/C27H44O2/c1-17(2)7-6-8-18(3)23-16-24(29)25-21-10-9-19-15-20(28)11-13-26(19,4)22(21)12-14-27(23,25)5/h17-20,22-23,28H,6-16H2,1-5H3/t18-,19+,20+,22+,23-,26+,27-/m1/s1",15-oxo-5alpha-cholest-8(14)-en-3beta-ol,LIPID MAPS instance accession,LMST01010269
2925,61845,[8)-alpha-Neu5Ac-(2->]14,A polysaccharide derivative consisting of fourteen alpha-D-N-acetylneuraminyl residues joined by (2->8) linkages.,"InChI=1S/C154H240N14O113/c1-43(183)155-85-57(197)15-141(254,127(226)227)268-114(85)100(213)72(30-170)255-143(129(230)231)17-59(199)87(157-45(3)185)116(270-143)102(215)74(32-172)257-145(131(234)235)19-61(201)89(159-47(5)187)118(272-145)104(217)76(34-174)259-147(133(238)239)21-63(203)91(161-49(7)189)120(274-147)106(219)78(36-176)261-149(135(242)243)23-65(205)93(163-51(9)191)122(276-149)108(221)80(38-178)263-151(137(246)247)25-67(207)95(165-53(11)193)124(278-151)110(223)82(40-180)265-153(139(250)251)27-69(209)97(167-55(13)195)126(280-153)112(225)84(42-182)267-154(140(252)253)28-70(210)98(168-56(14)196)125(281-154)111(224)83(41-181)266-152(138(248)249)26-68(208)96(166-54(12)194)123(279-152)109(222)81(39-179)264-150(136(244)245)24-66(206)94(164-52(10)192)121(277-150)107(220)79(37-177)262-148(134(240)241)22-64(204)92(162-50(8)190)119(275-148)105(218)77(35-175)260-146(132(236)237)20-62(202)90(160-48(6)188)117(273-146)103(216)75(33-173)258-144(130(232)233)18-60(200)88(158-46(4)186)115(271-144)101(214)73(31-171)256-142(128(228)229)16-58(198)86(156-44(2)184)113(269-142)99(212)71(211)29-169/h57-126,169-182,197-225,254H,15-42H2,1-14H3,(H,155,183)(H,156,184)(H,157,185)(H,158,186)(H,159,187)(H,160,188)(H,161,189)(H,162,190)(H,163,191)(H,164,192)(H,165,193)(H,166,194)(H,167,195)(H,168,196)(H,226,227)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,238,239)(H,240,241)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H,250,251)(H,252,253)/t57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+/m0/s1",[alpha-Neu5Ac-(2->8)]14,PubMed citation,2579148
2926,61856,beta-L-Rhap-(1->4)-beta-D-Glcp-(1->4)-beta-D-Galp,A trisaccharide composed of a beta-L-rhamnosyl residue linked (1->4) to a beta-D-glucosyl residue which is in turn linked (1->4) to beta-D-galactose.,"InChI=1S/C18H32O15/c1-4-7(21)8(22)12(26)17(29-4)32-15-6(3-20)31-18(13(27)10(15)24)33-14-5(2-19)30-16(28)11(25)9(14)23/h4-28H,2-3H2,1H3/t4-,5+,6+,7-,8+,9+,10+,11+,12+,13+,14-,15+,16+,17+,18-/m0/s1",beta-L-Rha-(1->4)-beta-D-Glc-(1->4)-beta-D-Gal,PubMed citation,7509318
2927,61860,beta-D-Glc-(1->4)-[alpha-L-Rha-(1->2)]-3-O-(2-glycerylphospho)-beta-D-Gal-(1->4)-beta-L-Rha,A tetrasaccharide consisting of beta-L-rhamnose having a alpha-L-rhamnosyl-(1->2)-[beta-D-glucosyl-(1->4)]-beta-D-galactosyl moiety attached at the 4-position with an additional 2-glycerylphosphate group attached to the galactosyl residue.,"InChI=1S/C27H49O24P/c1-7-12(32)14(34)18(38)25(44-7)49-23-22(51-52(41,42)50-9(3-28)4-29)21(48-26-19(39)15(35)13(33)10(5-30)45-26)11(6-31)46-27(23)47-20-8(2)43-24(40)17(37)16(20)36/h7-40H,3-6H2,1-2H3,(H,41,42)/t7-,8-,10+,11+,12-,13+,14+,15-,16-,17+,18+,19+,20-,21-,22-,23+,24-,25-,26-,27-/m0/s1",beta-D-Glcp-(1->4)-[alpha-L-Rhap-(1->2)]-3-O-(2-glycerylphospho)-beta-D-Galp-(1->4)-beta-L-Rhap,PubMed citation,7509318
2928,61862,3-O-(H2O3P)-beta-D-Glcp-(1->4)-[alpha-L-Rhap-(1->2)]-beta-D-Galp,An oligosaccharide phosphate consisting of beta-D-galactose having 3-O-phosphono-beta-D-glucosyl and alpha-L-rhamnosyl residues attached at positions 4 and 2 respectively.,"InChI=1S/C18H33O18P/c1-4-7(21)9(23)10(24)17(31-4)35-15-11(25)13(6(3-20)32-16(15)27)34-18-12(26)14(36-37(28,29)30)8(22)5(2-19)33-18/h4-27H,2-3H2,1H3,(H2,28,29,30)/t4-,5+,6+,7-,8+,9+,10+,11-,12+,13-,14-,15+,16+,17-,18-/m0/s1",3-O-(H2O3P)-beta-D-Glc-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Gal,KEGG GLYCAN accession,G07595
2929,61867,alpha-L-Rhap-(1->2)-beta-D-Galp-(1->4)-beta-L-Rhap,A trisaccharide composed of an alpha-L-rhamnosyl residue linked (1->2) to a beta-D-galactosyl residue which is in turn linked (1->4) to beta-L-rhamnose.,"InChI=1S/C18H32O14/c1-4-7(20)9(22)13(26)17(29-4)32-15-10(23)8(21)6(3-19)30-18(15)31-14-5(2)28-16(27)12(25)11(14)24/h4-27H,3H2,1-2H3/t4-,5-,6+,7-,8-,9+,10-,11-,12+,13+,14-,15+,16-,17-,18-/m0/s1",alpha-L-Rha-(1->2)-beta-D-Gal-(1->4)-beta-L-Rha,PubMed citation,7509318
2930,61868,3-O-(H2O3P)-beta-D-Glcp-(1->4)-[alpha-L-Rhap-(1->2)]-beta-D-Galp-(1->4)-beta-L-Rhap,A branched tetrasaccharide derivative consisting of beta-L-rhamnose having a 3-O-phosphono-beta-D-glucosyl-(1->4)-[alpha-L-rhamnosyl-(1->2)]-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C24H43O22P/c1-5-9(27)11(29)14(32)22(40-5)45-20-15(33)18(44-23-16(34)19(46-47(36,37)38)10(28)7(3-25)41-23)8(4-26)42-24(20)43-17-6(2)39-21(35)13(31)12(17)30/h5-35H,3-4H2,1-2H3,(H2,36,37,38)/t5-,6-,7+,8+,9-,10+,11+,12-,13+,14+,15-,16+,17-,18-,19-,20+,21-,22-,23-,24-/m0/s1",3-O-(H2O3P)-beta-D-Glc-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Gal-(1->4)-beta-L-Rha,PubMed citation,7509318
2931,61869,N(6)-L-homocysteinyl-L-lysine,An N(6)-acyl-L-lysine derivative in which the acyl group is L-homocysteinyl.,"InChI=1S/C10H21N3O3S/c11-7(4-6-17)9(14)13-5-2-1-3-8(12)10(15)16/h7-8,17H,1-6,11-12H2,(H,13,14)(H,15,16)/t7-,8-/m0/s1",Nepsilon-Hcy-Lys,PubMed citation,15131313
2932,61872,L-lysyl-L-alanine,A dipeptide formed from L-lysyl and L-alanyl residues.,"InChI=1S/C9H19N3O3/c1-6(9(14)15)12-8(13)7(11)4-2-3-5-10/h6-7H,2-5,10-11H2,1H3,(H,12,13)(H,14,15)/t6-,7-/m0/s1",Lys-Ala,Reaxys Registry Number,1727359
2933,61874,N(6)-(L-homocysteinyl)-L-lysyl-L-alanine,"A tripeptide formed between L-Hcy, L-Lys and L-Ala in a linear sequence, with the peptide bond between Hcy and Lys being from the carboxy group of the Hcy to the epsilon-nitrogen of the lysine.","InChI=1S/C13H26N4O4S/c1-8(13(20)21)17-12(19)9(14)4-2-3-6-16-11(18)10(15)5-7-22/h8-10,22H,2-7,14-15H2,1H3,(H,16,18)(H,17,19)(H,20,21)/t8-,9-,10-/m0/s1",Nepsilon-Hcy-LysAla,PubMed citation,15131313
2934,61875,N(6)-L-homocysteinyl-N(2)-acetyl-L-lysine,A dipeptide in which the carboxy group of L-homocysteine forms an amide bond with the epsilon-nitrogen of N(alpha)-acetylated L-lysine,"InChI=1S/C12H23N3O4S/c1-8(16)15-10(12(18)19)4-2-3-6-14-11(17)9(13)5-7-20/h9-10,20H,2-7,13H2,1H3,(H,14,17)(H,15,16)(H,18,19)/t9-,10-/m0/s1",Nepsilon-Hcy-Nalpha-Ac-Lys,PubMed citation,15131313
2935,61876,L-homocysteinyl-N(6)-acetyl-L-lysine,A dipeptide in which the carboxy group of L-homocysteine forms an amide bond with the alpha-nitrogen of N(epsilon)-acetylated L-lysine.,"InChI=1S/C12H23N3O4S/c1-8(16)14-6-3-2-4-10(12(18)19)15-11(17)9(13)5-7-20/h9-10,20H,2-7,13H2,1H3,(H,14,16)(H,15,17)(H,18,19)/t9-,10-/m0/s1",Nepsilon-Ac-Nalpha-Hcy-Lys,PubMed citation,15131313
2936,61879,N(6)-L-homocysteinyl-N(2)-L-valyl-L-lysine,A branched tripeptide in which L-homocysteine and L-valine are linked via peptide bonds to the epsilon- and alpha-nitrogens respectively of L-lysine.,"InChI=1S/C15H30N4O4S/c1-9(2)12(17)14(21)19-11(15(22)23)5-3-4-7-18-13(20)10(16)6-8-24/h9-12,24H,3-8,16-17H2,1-2H3,(H,18,20)(H,19,21)(H,22,23)/t10-,11-,12-/m0/s1",Val-(Nepsilon-Hcy-Lys),PubMed citation,15131313
2937,61881,N(6)-(L-homocysteinyl)-L-lysyl-L-lysyl-L-lysyl-L-lysine,A pentapeptide in which L-homocysteine is connected to tetralysine via a peptide bond to the epsilon-nitrogen of the N-terminal lysine residue.,"InChI=1S/C28H57N9O6S/c29-14-5-1-10-21(35-25(39)19(32)9-4-8-17-34-24(38)20(33)13-18-44)26(40)36-22(11-2-6-15-30)27(41)37-23(28(42)43)12-3-7-16-31/h19-23,44H,1-18,29-33H2,(H,34,38)(H,35,39)(H,36,40)(H,37,41)(H,42,43)/t19-,20-,21-,22-,23-/m0/s1",Nepsilon-Hcy-tetraLys,PubMed citation,15131313
2938,61887,N-acetylglycinate,An N-acylglycinate arising from deprotonation of the carboxy group of N-acetylglycine; major species at pH 7.3.,"InChI=1S/C4H7NO3/c1-3(6)5-2-4(7)8/h2H2,1H3,(H,5,6)(H,7,8)/p-1",N-acetylglycinate anion,Reaxys Registry Number,3904277
2939,61904,isethionate,The alkanesulfonate that is the anion formed from isethionic acid by loss of a proton from the sulfo group; major microspecies at pH 7.3.,"InChI=1S/C2H6O4S/c3-1-2-7(4,5)6/h3H,1-2H2,(H,4,5,6)/p-1",Isethionate(1-),MetaCyc accession,CPD-3745
2940,61911,butane-1-sulfonate,An alkanesulfonate in which the alkyl group directly linked to the sulfonate functionality is butyl.,"InChI=1S/C4H10O3S/c1-2-3-4-8(5,6)7/h2-4H2,1H3,(H,5,6,7)/p-1",1-butanesulfonic acid (1-),Reaxys Registry Number,3904079
2941,61958,butane-1-sulfonic acid,An alkanesulfonic acid in which the alkyl group directly linked to the sulfo functionality is butyl.,"InChI=1S/C4H10O3S/c1-2-3-4-8(5,6)7/h2-4H2,1H3,(H,5,6,7)",butane sulfonic acid,CAS Registry Number,2386-47-2
2942,61970,N-acetyl-alpha-D-galactosamine 1-phosphate(2-),An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of N-acetyl-alpha-D-galactosamine 1-phosphate; major species at pH 7.3.,"InChI=1S/C8H16NO9P/c1-3(11)9-5-7(13)6(12)4(2-10)17-8(5)18-19(14,15)16/h4-8,10,12-13H,2H2,1H3,(H,9,11)(H2,14,15,16)/p-2/t4-,5-,6+,7-,8-/m1/s1",N-acetyl-D-galactosamine 1-phosphate(2-),MetaCyc accession,CPD-7246
2943,61982,(E)-2-methylgeranyl diphosphate,An alkyl diphosphate where the alkyl group is specified as (E)-2-methylgeranyl.,"InChI=1S/C11H22O7P2/c1-9(2)6-5-7-10(3)11(4)8-17-20(15,16)18-19(12,13)14/h6H,5,7-8H2,1-4H3,(H,15,16)(H2,12,13,14)/b11-10+",(E)-2-methylgeranyl pyrophosphate,Reaxys Registry Number,18894816
2944,61984,(E)-2-methylgeranyl diphosphate(3-),An organophosphate oxoanion resulting from deprotonation of the three diphosphate OH groups of (E)-2-methylgeranyl diphosphate.,"InChI=1S/C11H22O7P2/c1-9(2)6-5-7-10(3)11(4)8-17-20(15,16)18-19(12,13)14/h6H,5,7-8H2,1-4H3,(H,15,16)(H2,12,13,14)/p-3/b11-10+",(E)-2-methylgeranyl pyrophosphate,PubMed citation,18563898
2945,61987,2-methylisoborneol,"An bornane monoterpenoid comprising isoborneol carrying a 2-methyl substituent (the 1R,2R,4R-diastereomer).","InChI=1S/C11H20O/c1-9(2)8-5-6-10(9,3)11(4,12)7-8/h8,12H,5-7H2,1-4H3/t8-,10-,11-/m1/s1",MIB,Reaxys Registry Number,2552192
2946,61994,sulfoacetyl-CoA(5-),"An acyl-CoA oxoanion arising from deprotonation of the phosphate, diphosphate and sulfonate OH groups of sulfoacetyl-CoA; major species at pH 7.3.","InChI=1S/C23H38N7O20P3S2/c1-23(2,18(34)21(35)26-4-3-13(31)25-5-6-54-14(32)8-55(43,44)45)9-47-53(41,42)50-52(39,40)46-7-12-17(49-51(36,37)38)16(33)22(48-12)30-11-29-15-19(24)27-10-28-20(15)30/h10-12,16-18,22,33-34H,3-9H2,1-2H3,(H,25,31)(H,26,35)(H,39,40)(H,41,42)(H2,24,27,28)(H2,36,37,38)(H,43,44,45)/p-5/t12-,16-,17-,18+,22-/m1/s1",sulfoacetyl-CoA,PubMed citation,20693281
2947,62005,5-carbamoylmethyluridine,A member of the class of uridines that is uridine in which the hydrogen at position 5 of the pyrimidine ring is substituted by a 2-amino-2-oxoethyl group.,"InChI=1S/C11H15N3O7/c12-6(16)1-4-2-14(11(20)13-9(4)19)10-8(18)7(17)5(3-15)21-10/h2,5,7-8,10,15,17-18H,1,3H2,(H2,12,16)(H,13,19,20)/t5-,7-,8-,10-/m1/s1","2-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetamide",Reaxys Registry Number,963802
2948,62011,4-carboxy-2-hydroxymuconate semialdehyde hemiacetal,A dicarboxylic acid comprising 2-hydroxy-2H-pyran having two carboxy groups located at the 4- and 6-positions.,"InChI=1S/C7H6O6/c8-5-2-3(6(9)10)1-4(13-5)7(11)12/h1-2,5,8H,(H,9,10)(H,11,12)","2-hydroxy-2-hydropyrone-4,6-dicarboxylic acid",KEGG COMPOUND accession,C05375
2949,62012,5-deoxy-D-ribose,A deoxypentose that is aldehydo-D-ribose in which the hydroxy group at position 5 is substituted by a hydrogen.,"InChI=1S/C5H10O4/c1-3(7)5(9)4(8)2-6/h2-5,7-9H,1H3/t3-,4+,5-/m1/s1",5'-deoxyribose,MetaCyc accession,CPD0-2167
2950,62013,glycerol 1-phosphoserine,A L-serine derivative consisting of L-serine having a 1-glycerophospho group attached to the side-chain hydroxy function.,"InChI=1S/C6H14NO8P/c7-5(6(10)11)3-15-16(12,13)14-2-4(9)1-8/h4-5,8-9H,1-3,7H2,(H,10,11)(H,12,13)/t4?,5-/m0/s1",1-glycerophosphoserine,CAS Registry Number,26289-09-8
2951,62015,L-Ala-gamma-D-Glu-meso-Dap-D-Ala,"A tetrapeptide comprising L-alanyl, gamma-D-glutamyl, meso-diaminopimelyl and L-alanine units in a linear sequence.","InChI=1S/C18H31N5O9/c1-8(19)14(25)23-12(18(31)32)6-7-13(24)22-11(5-3-4-10(20)17(29)30)15(26)21-9(2)16(27)28/h8-12H,3-7,19-20H2,1-2H3,(H,21,26)(H,22,24)(H,23,25)(H,27,28)(H,29,30)(H,31,32)/t8-,9+,10-,11+,12+/m0/s1",L-Ala-gamma-D-Glu-Dap-D-Ala,Reaxys Registry Number,15589905
2952,62018,[8)-alpha-Neu5Pr-(2->]4,An N-propionylated alpha-(2->8)-linked homosialopolysaccharide consisting of four alpha-D-N-propionylneuraminyl residues joined by (2->8) linkages (i.e. [8)-alpha-Neu5Pr-(2->]n where n = 4).,"InChI=1S/C48H78N4O33/c1-5-25(62)49-29-17(57)9-45(78,41(70)71)82-38(29)34(67)22(14-54)79-47(43(74)75)11-19(59)31(51-27(64)7-3)40(84-47)36(69)24(16-56)81-48(44(76)77)12-20(60)32(52-28(65)8-4)39(85-48)35(68)23(15-55)80-46(42(72)73)10-18(58)30(50-26(63)6-2)37(83-46)33(66)21(61)13-53/h17-24,29-40,53-61,66-69,78H,5-16H2,1-4H3,(H,49,62)(H,50,63)(H,51,64)(H,52,65)(H,70,71)(H,72,73)(H,74,75)(H,76,77)/t17-,18-,19-,20-,21+,22+,23+,24+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,45+,46+,47+,48+/m0/s1",[alpha-NeuNPr-(2->8)]4,PubMed citation,9166422
2953,62019,[8)-alpha-Neu5Pr-(2->]5,An N-propionylated alpha-(2->8)-linked homosialopolysaccharide consisting of five alpha-D-N-propionylneuraminyl residues joined by (2->8) linkages (i.e. [8)-alpha-Neu5Pr-(2->]n  where n = 5).,"InChI=1S/C60H97N5O41/c1-6-31(77)61-36-21(71)11-56(97,51(87)88)102-47(36)42(83)27(17-67)98-58(53(91)92)13-23(73)38(63-33(79)8-3)49(104-58)44(85)29(19-69)100-60(55(95)96)15-25(75)40(65-35(81)10-5)50(106-60)45(86)30(20-70)101-59(54(93)94)14-24(74)39(64-34(80)9-4)48(105-59)43(84)28(18-68)99-57(52(89)90)12-22(72)37(62-32(78)7-2)46(103-57)41(82)26(76)16-66/h21-30,36-50,66-76,82-86,97H,6-20H2,1-5H3,(H,61,77)(H,62,78)(H,63,79)(H,64,80)(H,65,81)(H,87,88)(H,89,90)(H,91,92)(H,93,94)(H,95,96)/t21-,22-,23-,24-,25-,26+,27+,28+,29+,30+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,56+,57+,58+,59+,60+/m0/s1",[alpha-NeuNPr-(2->8)]5,PubMed citation,9166422
2954,62020,[8)-alpha-Neu5Pr-(2->]14,A polysaccharide derivative consisting of fourteen alpha-D-N-propionylneuraminyl residues joined by (2->8) linkages.,"InChI=1S/C168H268N14O113/c1-15-85(212)169-99-57(197)29-155(268,141(240)241)282-128(99)114(227)72(44-184)269-157(143(244)245)31-59(199)101(171-87(214)17-3)130(284-157)116(229)74(46-186)271-159(145(248)249)33-61(201)103(173-89(216)19-5)132(286-159)118(231)76(48-188)273-161(147(252)253)35-63(203)105(175-91(218)21-7)134(288-161)120(233)78(50-190)275-163(149(256)257)37-65(205)107(177-93(220)23-9)136(290-163)122(235)80(52-192)277-165(151(260)261)39-67(207)109(179-95(222)25-11)138(292-165)124(237)82(54-194)279-167(153(264)265)41-69(209)111(181-97(224)27-13)140(294-167)126(239)84(56-196)281-168(154(266)267)42-70(210)112(182-98(225)28-14)139(295-168)125(238)83(55-195)280-166(152(262)263)40-68(208)110(180-96(223)26-12)137(293-166)123(236)81(53-193)278-164(150(258)259)38-66(206)108(178-94(221)24-10)135(291-164)121(234)79(51-191)276-162(148(254)255)36-64(204)106(176-92(219)22-8)133(289-162)119(232)77(49-189)274-160(146(250)251)34-62(202)104(174-90(217)20-6)131(287-160)117(230)75(47-187)272-158(144(246)247)32-60(200)102(172-88(215)18-4)129(285-158)115(228)73(45-185)270-156(142(242)243)30-58(198)100(170-86(213)16-2)127(283-156)113(226)71(211)43-183/h57-84,99-140,183-211,226-239,268H,15-56H2,1-14H3,(H,169,212)(H,170,213)(H,171,214)(H,172,215)(H,173,216)(H,174,217)(H,175,218)(H,176,219)(H,177,220)(H,178,221)(H,179,222)(H,180,223)(H,181,224)(H,182,225)(H,240,241)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,254,255)(H,256,257)(H,258,259)(H,260,261)(H,262,263)(H,264,265)(H,266,267)/t57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+/m0/s1",(NeuPr)-14,PubMed citation,9166422
2955,62021,[3)-beta-D-ribosyl-(1->1)-D-ribitol-5-P-(O->]3,A trimeric glycoside phosphate comprising three beta-D-ribosyl-(1->1)-D-ribitol-5-phosphate repeating units that are joined to each other by phosphodiester linkages.,"InChI=1S/C30H59O34P3/c31-1-16-22(43)23(44)28(60-16)54-4-10(34)20(41)14(38)8-58-66(50,51)64-27-18(3-33)62-30(25(27)46)56-6-12(36)21(42)15(39)9-59-67(52,53)63-26-17(2-32)61-29(24(26)45)55-5-11(35)19(40)13(37)7-57-65(47,48)49/h10-46H,1-9H2,(H,50,51)(H,52,53)(H2,47,48,49)/t10-,11-,12-,13+,14+,15+,16+,17+,18+,19-,20-,21-,22+,23+,24+,25+,26+,27+,28+,29+,30+/m0/s1",PRP3,PubMed citation,9076509
2956,62022,3-(progesterone-4-yl)thiopropionic acid,A steroid acid consisting of progesterone having a 2-carboxyethylthio group at the 4-position.,"InChI=1S/C24H34O4S/c1-14(25)16-6-7-17-15-4-5-19-22(29-13-10-21(27)28)20(26)9-12-24(19,3)18(15)8-11-23(16,17)2/h15-18H,4-13H2,1-3H3,(H,27,28)/t15-,16+,17-,18-,23+,24+/m0/s1",4-(2-carboxyethylthio)progesterone,Reaxys Registry Number,5641566
2957,62023,3-(progesterone-7alpha-yl)thiopropionic acid,A steroid acid consisting of progesterone having a 2-carboxyethylthio group at the 7alpha-position.,"InChI=1S/C24H34O4S/c1-14(25)17-4-5-18-22-19(7-10-24(17,18)3)23(2)9-6-16(26)12-15(23)13-20(22)29-11-8-21(27)28/h12,17-20,22H,4-11,13H2,1-3H3,(H,27,28)/t17-,18+,19+,20-,22+,23+,24-/m1/s1","3-(pregn-4-ene-3,20-dione-7alpha-yl)thiopropanoic acid",Reaxys Registry Number,7357523
2958,62024,6-{3-[(progesterone-4-yl)thiopropionyl]amino}hexanoic acid,A steroid acid consisting of 6-[(3-thiopropionyl)amino]hexanoic acid having a progesterone-4-yl group attached to the sulfur.,"InChI=1S/C30H45NO5S/c1-19(32)21-10-11-22-20-8-9-24-28(37-18-14-26(34)31-17-6-4-5-7-27(35)36)25(33)13-16-30(24,3)23(20)12-15-29(21,22)2/h20-23H,4-18H2,1-3H3,(H,31,34)(H,35,36)/t20-,21+,22-,23-,29+,30+/m0/s1",6-{3-[(progesterone-4-yl)thiopropanoyl]amino}hexanoic acid,Reaxys Registry Number,9243291
2959,62025,6-(6-{3-[(progesterone-4-yl)thiopropionyl]aminohexanoyl}amino)hexanoic acid,A steroid acid consisting of 6-{6-[3-(thiopropionyl)aminohexanoyl]amino}hexanoic acid having a progesterone-4-yl group attached to the sulfur.,"InChI=1S/C36H56N2O6S/c1-24(39)26-14-15-27-25-12-13-29-34(30(40)17-20-36(29,3)28(25)16-19-35(26,27)2)45-23-18-32(42)38-22-8-4-6-10-31(41)37-21-9-5-7-11-33(43)44/h25-28H,4-23H2,1-3H3,(H,37,41)(H,38,42)(H,43,44)/t25-,26+,27-,28-,35+,36+/m0/s1","6-(6-{3-[(pregn-4-ene-3,20-dione-4-yl)thiopropionyl]aminohexanoyl}amino)hexanoic acid",Reaxys Registry Number,9246618
2960,62026,"2,5-dioxo-1-pyrrolidinyl 6-(6-{3-[(progesterone-4-yl)thiopropionyl]aminohexanoyl}amino)hexanoate","A steroid sulfide consisting of 2,5-dioxo-1-pyrrolidinyl 6-{6-[3-(thiopropionyl)aminohexanoyl]amino}hexanoate having a progesterone-4-yl group attached to the sulfur.","InChI=1S/C40H59N3O8S/c1-26(44)28-14-15-29-27-12-13-31-38(32(45)19-22-40(31,3)30(27)18-21-39(28,29)2)52-25-20-34(47)42-24-8-4-6-10-33(46)41-23-9-5-7-11-37(50)51-43-35(48)16-17-36(43)49/h27-30H,4-25H2,1-3H3,(H,41,46)(H,42,47)/t27-,28+,29-,30-,39+,40+/m0/s1","2,5-dioxo-1-pyrrolidinyl 6-(6-{3-[(pregn-4-ene-3,20-dione-4-yl)thiopropionyl]aminohexanoyl}amino)hexanoate",Reaxys Registry Number,9248002
2961,62029,N(2)-carboxyethyl-2'-deoxyguanosine,A purine 2'-deoxyribonucleoside consisting of 2'-deoxyguanosine having a 1-carboxyethyl group attached at the N(2)-position.,"InChI=1S/C13H17N5O6/c1-5(12(22)23)15-13-16-10-9(11(21)17-13)14-4-18(10)8-2-6(20)7(3-19)24-8/h4-8,19-20H,2-3H2,1H3,(H,22,23)(H2,15,16,17,21)/t5?,6-,7+,8+/m0/s1",N(2)-(1-carboxyethyl)-2'-deoxyguanosine,Reaxys Registry Number,8136702
2962,62030,N(2)-carboxyethylguanosine,A guanosine derivative having a 1-carboxyethyl group attached at the N(2)-position.,"InChI=1S/C13H17N5O7/c1-4(12(23)24)15-13-16-9-6(10(22)17-13)14-3-18(9)11-8(21)7(20)5(2-19)25-11/h3-5,7-8,11,19-21H,2H2,1H3,(H,23,24)(H2,15,16,17,22)/t4?,5-,7-,8-,11-/m1/s1",N(2)-(1-carboxyethyl)guanosine,Reaxys Registry Number,7835846
2963,62034,N(2)-carboxymethylguanosine,A guanosine derivative having a carboxymethyl group attached at the N(2)-position.,"InChI=1S/C12H15N5O7/c18-2-4-7(21)8(22)11(24-4)17-3-14-6-9(17)15-12(16-10(6)23)13-1-5(19)20/h3-4,7-8,11,18,21-22H,1-2H2,(H,19,20)(H2,13,15,16,23)/t4-,7-,8-,11-/m1/s1",CMG,Reaxys Registry Number,1181843
2964,62035,(R)-N(2)-carboxyethyl-2'-deoxyguanosine,An N(2)-carboxyethyl-2'-deoxyguanosine where the N(2)-carboxyethyl group has (R)-configuration.,"InChI=1S/C13H17N5O6/c1-5(12(22)23)15-13-16-10-9(11(21)17-13)14-4-18(10)8-2-6(20)7(3-19)24-8/h4-8,19-20H,2-3H2,1H3,(H,22,23)(H2,15,16,17,21)/t5-,6+,7-,8-/m1/s1",(R)-N(2)-1-(carboxyethyl)-2'-deoxyguanosine,PubMed citation,15487900
2965,62036,(S)-N(2)-carboxyethyl-2'-deoxyguanosine,An N(2)-carboxyethyl-2'-deoxyguanosine where the N(2)-carboxyethyl group has (S)-configuration.,"InChI=1S/C13H17N5O6/c1-5(12(22)23)15-13-16-10-9(11(21)17-13)14-4-18(10)8-2-6(20)7(3-19)24-8/h4-8,19-20H,2-3H2,1H3,(H,22,23)(H2,15,16,17,21)/t5-,6-,7+,8+/m0/s1",N(2)-(S)-carboxyethyl-2'-deoxyguanosine,PubMed citation,15487900
2966,62038,(R)-N(2)-carboxyethylguanosine,An N(2)-carboxyethylguanosine where the N(2)-carboxyethyl group has (R)-configuration.,"InChI=1S/C13H17N5O7/c1-4(12(23)24)15-13-16-9-6(10(22)17-13)14-3-18(9)11-8(21)7(20)5(2-19)25-11/h3-5,7-8,11,19-21H,2H2,1H3,(H,23,24)(H2,15,16,17,22)/t4-,5-,7-,8-,11-/m1/s1","N-(9-beta-D-ribofuranosyl-6-oxo-6,9-dihydro-1H-purin-2-yl)-D-alanine",PubMed citation,15487900
2967,62039,(S)-N(2)-carboxyethylguanosine,An N(2)-carboxyethylguanosine where the N(2)-carboxyethyl group has (S)-configuration.,"InChI=1S/C13H17N5O7/c1-4(12(23)24)15-13-16-9-6(10(22)17-13)14-3-18(9)11-8(21)7(20)5(2-19)25-11/h3-5,7-8,11,19-21H,2H2,1H3,(H,23,24)(H2,15,16,17,22)/t4-,5+,7+,8+,11+/m0/s1","N-(9-beta-D-ribofuranosyl-6-oxo-6,9-dihydro-1H-purin-2-yl)-L-alanine",PubMed citation,15487900
2968,62040,etiocholanolone hemisuccinate,A sterol ester that is the O-succinoyl derivative of etiocholanolone.,"InChI=1S/C23H34O5/c1-22-11-9-15(28-21(27)8-7-20(25)26)13-14(22)3-4-16-17-5-6-19(24)23(17,2)12-10-18(16)22/h14-18H,3-13H2,1-2H3,(H,25,26)/t14-,15+,16+,17+,18+,22+,23+/m1/s1",etiocholanolone succinate,Reaxys Registry Number,7365236
2969,62041,"P(1),P(5)-bis(5'-adenosyl) pentaphosphate(5-)","An organophosphate oxoanion arising from global deprotonation of the pentaphosphate OH groups of P(1),P(5)-bis(5'-adenosyl) pentaphosphate.","InChI=1S/C20H29N10O22P5/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(47-19)1-45-53(35,36)49-55(39,40)51-57(43,44)52-56(41,42)50-54(37,38)46-2-8-12(32)14(34)20(48-8)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H2,21,23,25)(H2,22,24,26)/p-5/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1","P(1),P(5)-di(adenosine-5'-)pentaphosphate(5-)",Reaxys Registry Number,5230559
2970,62042,progesterone 3-O-(carboxymethyl)oxime,An oxime O-ether consisting of progesterone having an O-(carboxymethyl)oxime group at the 3-position.,"InChI=1S/C23H33NO4/c1-14(25)18-6-7-19-17-5-4-15-12-16(24-28-13-21(26)27)8-10-22(15,2)20(17)9-11-23(18,19)3/h12,17-20H,4-11,13H2,1-3H3,(H,26,27)/t17-,18+,19-,20-,22-,23+/m0/s1",progesterone 3-carboxymethyloxime,Reaxys Registry Number,6241892
2971,62043,3beta-hydroxy-5alpha-pregnan-20-one hemisuccinate,A sterol ester that is the O-succinoyl derivative of 3beta-hydroxy-5alpha-pregnan-20-one.,"InChI=1S/C25H38O5/c1-15(26)19-6-7-20-18-5-4-16-14-17(30-23(29)9-8-22(27)28)10-12-24(16,2)21(18)11-13-25(19,20)3/h16-21H,4-14H2,1-3H3,(H,27,28)/t16-,17-,18-,19+,20-,21-,24-,25+/m0/s1",3beta-hydroxy-5alpha-pregnan-20-one succinate,Reaxys Registry Number,3225990
2972,62044,(20R)-20-(carboxymethyl)oxypregn-4-en-3-one,A steroid acid comprising (20R)-20-hydroxypregn-4-en-3-one having a carboxymethyl group attached to the 20-hydroxy function.,"InChI=1S/C23H34O4/c1-14(27-13-21(25)26)18-6-7-19-17-5-4-15-12-16(24)8-10-22(15,2)20(17)9-11-23(18,19)3/h12,14,17-20H,4-11,13H2,1-3H3,(H,25,26)/t14-,17+,18-,19+,20+,22+,23-/m1/s1",(20R)-20-hydroxypregn-4-en-3-one carboxymethyl ether,PubMed citation,8496956
2973,62046,biotinate sulfoxide(1-),A monocarboxylic acid anion that is the conjugate base of biotin sulfoxide; major species at pH 7.3.,"InChI=1S/C10H16N2O4S/c13-8(14)4-2-1-3-7-9-6(5-17(7)16)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/p-1/t6-,7-,9-,17?/m0/s1",biotin sulfoxide,MetaCyc accession,CPD-722
2974,62047,(S)-carnitinyl-CoA(3-),An acyl-CoA oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of (S)-carnitinyl-CoA; major species at pH 7.3.,"InChI=1S/C28H49N8O18P3S/c1-28(2,23(41)26(42)31-7-6-18(38)30-8-9-58-19(39)10-16(37)11-36(3,4)5)13-51-57(48,49)54-56(46,47)50-12-17-22(53-55(43,44)45)21(40)27(52-17)35-15-34-20-24(29)32-14-33-25(20)35/h14-17,21-23,27,37,40-41H,6-13H2,1-5H3,(H7-,29,30,31,32,33,38,42,43,44,45,46,47,48,49)/p-3/t16-,17+,21+,22+,23-,27+/m0/s1",D-carnitinyl-CoA(3-),MetaCyc accession,D-CARNITINYL-COA
2975,62056,alpha-D-Rhap-(1->2)-alpha-D-Rhap-(1->3)-alpha-D-Rhap,A linear trisaccharide consisting of three alpha-D-rhamose units joined by an alpha-(1->2)- and an alpha-(1->3)- linkage.,"InChI=1S/C18H32O13/c1-4-7(19)10(22)12(24)17(28-4)31-15-11(23)8(20)5(2)29-18(15)30-14-9(21)6(3)27-16(26)13(14)25/h4-26H,1-3H3/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17-,18-/m1/s1",alpha-D-Rha-(1->2)-alpha-D-Rha-(1->3)-alpha-D-Rha,PubMed citation,8932301
2976,62057,"(E)-3-[(5R,6S)-5,6-dihydroxycyclohexa-1,3-dienyl]acrylate","A 3-[(5R,6S)-5,6-dihydroxycyclohexa-1,3-dienyl]acrylate where the acrylic double bond has (E)-configuration.","InChI=1S/C9H10O4/c10-7-3-1-2-6(9(7)13)4-5-8(11)12/h1-5,7,9-10,13H,(H,11,12)/p-1/b5-4+/t7-,9+/m1/s1","(2E)-3-(5,6-dihydroxycyclohexa-1,3-dien-1-yl)prop-2-enoate",MetaCyc accession,CPD-13034
2977,62060,4-deoxy-alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-NHAc,The N-glycosyl compound formed from the deoxy trisaccharide 4-deoxy-alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc by replacement of the OH at the anomeric centre of the glucose residue by an acetylamino group.,"InChI=1S/C20H35NO15/c1-6(25)21-18-14(30)13(29)16(10(5-24)33-18)35-20-15(31)17(12(28)9(4-23)34-20)36-19-11(27)8(26)2-7(3-22)32-19/h7-20,22-24,26-31H,2-5H2,1H3,(H,21,25)/t7-,8-,9+,10+,11+,12-,13+,14+,15+,16+,17-,18+,19+,20-/m0/s1",3-deoxy-alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosylamine,PubMed citation,12151204
2978,62062,6-deoxy-alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-NHAc,The N-glycosyl compound formed from the deoxy trisaccharide 6-deoxy-alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc by replacement of the OH at the anomeric centre of the glucose residue by an acetylamino group.,"InChI=1S/C20H35NO15/c1-5-9(25)11(27)14(30)19(32-5)36-17-10(26)7(3-22)34-20(15(17)31)35-16-8(4-23)33-18(21-6(2)24)13(29)12(16)28/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7-,8-,9+,10+,11+,12-,13-,14-,15-,16-,17+,18-,19-,20+/m1/s1",6-deoxy-alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosylamine,PubMed citation,12151204
2979,62066,beta-D-GlcpNAc-(1->4)-alpha-D-Rhap,An amino disaccharide consisting of an alpha-D-rhamnos residue having an N-acetyl-beta-D-glucosaminyl residue attached at the 4-position.,"InChI=1S/C14H25NO10/c1-4-12(10(20)11(21)13(22)23-4)25-14-7(15-5(2)17)9(19)8(18)6(3-16)24-14/h4,6-14,16,18-22H,3H2,1-2H3,(H,15,17)/t4-,6-,7-,8-,9-,10-,11+,12-,13+,14+/m1/s1",beta-D-GlcNAc-(1->4)-alpha-D-Rha,PubMed citation,8932301
2980,62068,alpha-D-Rhap-(1->3)-alpha-D-Rhap,A glycosylrhamnose consisting of alpha-D-rhamnose having an alpha-D-rhamnosyl residue attached at the 3-position.,"InChI=1S/C12H22O9/c1-3-5(13)7(15)8(16)12(20-3)21-10-6(14)4(2)19-11(18)9(10)17/h3-18H,1-2H3/t3-,4-,5-,6-,7+,8+,9+,10+,11+,12-/m1/s1",alpha-D-Rha-(1->3)-alpha-D-Rha,PubMed citation,8932301
2981,62070,nalidixic acid anion,A monocarboxylic acid anion that is the conjugate base of nalidixic acid; major species at pH 7.3.,"InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)/p-1",nalidixylate,Reaxys Registry Number,3556893
2982,62075,(S)-3-hydroxyhexanoyl-CoA(4-),An acyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate OH groups of (S)-3-hydroxyhexanoyl-CoA; major species at pH 7.3.,"InChI=1S/C27H46N7O18P3S/c1-4-5-15(35)10-18(37)56-9-8-29-17(36)6-7-30-25(40)22(39)27(2,3)12-49-55(46,47)52-54(44,45)48-11-16-21(51-53(41,42)43)20(38)26(50-16)34-14-33-19-23(28)31-13-32-24(19)34/h13-16,20-22,26,35,38-39H,4-12H2,1-3H3,(H,29,36)(H,30,40)(H,44,45)(H,46,47)(H2,28,31,32)(H2,41,42,43)/p-4/t15-,16+,20+,21+,22-,26+/m0/s1",3-hydroxyhexanoyl-CoA(4-),MetaCyc accession,OH-HEXANOYL-COA
2983,62077,trans-hex-2-enoyl-CoA(4-),An acyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate OH groups of trans-hex-2-enoyl-CoA; major species at pH 7.3.,"InChI=1S/C27H44N7O17P3S/c1-4-5-6-7-18(36)55-11-10-29-17(35)8-9-30-25(39)22(38)27(2,3)13-48-54(45,46)51-53(43,44)47-12-16-21(50-52(40,41)42)20(37)26(49-16)34-15-33-19-23(28)31-14-32-24(19)34/h6-7,14-16,20-22,26,37-38H,4-5,8-13H2,1-3H3,(H,29,35)(H,30,39)(H,43,44)(H,45,46)(H2,28,31,32)(H2,40,41,42)/p-4/b7-6+/t16-,20-,21-,22+,26-/m1/s1",hexenoyl-CoA(4-),MetaCyc accession,CPD0-2121
2984,62092,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A linear pentasaccharide consisting of two galactosyl residues, an N-acetylglucosaminyl residue, a further galactosyl residue and a glucosyl residue (at the reducing end), linked in sequence as shown.","InChI=1S/C32H55NO26/c1-7(38)33-13-17(42)25(57-32-24(49)27(16(41)9(3-35)54-32)59-30-22(47)18(43)14(39)8(2-34)53-30)11(5-37)55-29(13)51-6-12-15(40)19(44)23(48)31(56-12)58-26-10(4-36)52-28(50)21(46)20(26)45/h8-32,34-37,39-50H,2-6H2,1H3,(H,33,38)/t8-,9-,10-,11-,12-,13-,14+,15+,16+,17-,18+,19+,20-,21-,22-,23-,24-,25-,26-,27+,28?,29-,30-,31+,32+/m1/s1",alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,KEGG GLYCAN accession,G12327
2985,62098,N(4)-{alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc}-Asn,A glucosaminoglycan consisting of L-asparagine having the pentasaccharide alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc attached at the N(4)-position,"InChI=1S/C38H64N4O28/c1-9(47)40-18-23(53)30(14(6-45)63-33(18)42-17(49)3-11(39)34(60)61)68-35-19(41-10(2)48)24(54)31(15(7-46)66-35)69-38-29(59)32(70-37-28(58)26(56)21(51)13(5-44)65-37)22(52)16(67-38)8-62-36-27(57)25(55)20(50)12(4-43)64-36/h11-16,18-33,35-38,43-46,50-59H,3-8,39H2,1-2H3,(H,40,47)(H,41,48)(H,42,49)(H,60,61)/t11-,12+,13+,14+,15+,16+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27-,28-,29-,30+,31+,32-,33+,35-,36-,37+,38-/m0/s1",N(4)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc}-Asn,KEGG GLYCAN accession,G10652
2986,62103,beta-D-Galp-(1->6)-D-Galp,A glycosylgalactose consisting of D-galactose having a beta-D-galactosyl residue attached at the 6-position.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11?,12-/m1/s1",beta-D-Gal-(1->6)-D-Gal,PubMed citation,2119886
2987,62109,beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine,A beta-D-galactosyl-(1->4)-beta-D-glucosylceramide where the ceramide N-acyl group is specified as docosanoyl.,"InChI=1S/C52H99NO13/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-44(57)53-40(41(56)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2)39-63-51-49(62)47(60)50(43(38-55)65-51)66-52-48(61)46(59)45(58)42(37-54)64-52/h33,35,40-43,45-52,54-56,58-62H,3-32,34,36-39H2,1-2H3,(H,53,57)/b35-33+/t40-,41+,42+,43+,45-,46-,47+,48+,49+,50+,51+,52-/m0/s1",beta-lactosyl-N-(docosanoyl)sphingosine,PubMed citation,15727820
2988,62114,beta-D-Glcp-(1->3)-beta-D-GlcpA-(1->4)-beta-D-Glcp,"A trisaccharide consisting of a beta-D-glucose residue linked (1->3) to a beta-D-glucuronosyl residue, which is in turn linked (1->4) to a beta-D-glucose at the reducing end. Trisaccharide form of serotype 3 pneumococcal capsular polysaccharide.","InChI=1S/C18H30O17/c19-1-3-5(21)6(22)9(25)17(32-3)34-13-10(26)14(15(28)29)35-18(11(13)27)33-12-4(2-20)31-16(30)8(24)7(12)23/h3-14,16-27,30H,1-2H2,(H,28,29)/t3-,4-,5-,6+,7-,8-,9-,10+,11-,12-,13+,14+,16-,17+,18-/m1/s1",beta-D-Glc-(1->3)-beta-D-GlcA-(1->4)-beta-D-Glc,PubMed citation,14638780
2989,62117,6beta-hydroxyprogesterone,A 3-oxo-Delta(4)-steroid that is progesterone in which the hydrogen at the 6beta-position is substituted by a hydroxy group.,"InChI=1S/C21H30O3/c1-12(22)15-4-5-16-14-11-19(24)18-10-13(23)6-8-21(18,3)17(14)7-9-20(15,16)2/h10,14-17,19,24H,4-9,11H2,1-3H3/t14-,15+,16-,17-,19+,20+,21+/m0/s1",6beta-hydroxydeoxycorticosterone,Reaxys Registry Number,3218996
2990,62119,beta-D-GalpNAc-(1->6)-[beta-D-GlcpA-(1->3)]-beta-D-GalpNAc-(1->6)-[beta-D-GlcpA-(1->3)]-beta-D-GalpNAc,A galactosamine oligosaccharide consisting of three (1->6)-linked N-acetyl-beta-D-galactosamine units with two beta-D-glucuronosyl residues attached at the 3- and 3'-positions.,"InChI=1S/C36H57N3O28/c1-7(41)37-13-19(47)16(44)10(4-40)62-33(13)59-6-12-18(46)27(65-36-25(53)21(49)23(51)29(67-36)31(56)57)15(39-9(3)43)34(63-12)60-5-11-17(45)26(14(32(58)61-11)38-8(2)42)64-35-24(52)20(48)22(50)28(66-35)30(54)55/h10-29,32-36,40,44-53,58H,4-6H2,1-3H3,(H,37,41)(H,38,42)(H,39,43)(H,54,55)(H,56,57)/t10-,11-,12-,13-,14-,15-,16+,17+,18+,19-,20+,21+,22+,23+,24-,25-,26-,27-,28+,29+,32-,33-,34-,35-,36-/m1/s1",beta-D-GalNAc-(1->6)-[beta-D-GlcA-(1->3)]-beta-D-GalNAc-(1->6)-[beta-D-GlcA-(1->3)]-beta-D-GalNAc,PubMed citation,12695908
2991,62127,"3-O-[(2E)-2-methylicos-2-enoyl]-2-O-palmitoyl-2'-O-sulfo-alpha,alpha-trehalose","A sulfoglycolipid in which alpha,alpha-trehalose, sulfated at the 2'-position, is acylated at the 2-position with palmitic acid, and at the 3-position with (2E)-2-methylicos-2-enoic acid.","InChI=1S/C49H90O16S/c1-4-6-8-10-12-14-16-18-19-20-22-23-25-27-29-31-33-37(3)47(56)63-44-42(54)39(36-51)61-49(64-48-45(65-66(57,58)59)43(55)41(53)38(35-50)60-48)46(44)62-40(52)34-32-30-28-26-24-21-17-15-13-11-9-7-5-2/h33,38-39,41-46,48-51,53-55H,4-32,34-36H2,1-3H3,(H,57,58,59)/b37-33+/t38-,39-,41-,42-,43+,44+,45-,46-,48-,49-/m1/s1","3-O-[(2E)-2-methylicos-2-enoyl]-2-O-palmitoyl-2'-O-sulfo-alpha,alpha-trehalose",PubMed citation,19454700
2992,62130,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc,"An amino tetrasaccharide comprising residues of galactose, N-acetylglucosamine, galactose and N-acetylglucosamine in a linear sequence, joined by beta-(1->4)-, beta-(1->3)-, and beta-(1->4)-linkages, respectively.","InChI=1S/C28H48N2O21/c1-7(35)29-13-17(39)22(11(5-33)45-25(13)44)50-28-21(43)24(16(38)10(4-32)47-28)51-26-14(30-8(2)36)18(40)23(12(6-34)48-26)49-27-20(42)19(41)15(37)9(3-31)46-27/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15+,16+,17-,18-,19+,20-,21-,22-,23-,24+,25?,26+,27+,28+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc,PubMed citation,6083447
2993,62132,beta-D-Xylp-(1->2)-D-Manp,A glycosylmannose consisting of D-mannose having a beta-D-xylosyl residue attached at the 2-position.,"InChI=1S/C11H20O10/c12-1-4-6(15)7(16)9(10(18)20-4)21-11-8(17)5(14)3(13)2-19-11/h3-18H,1-2H2/t3-,4-,5+,6-,7+,8-,9+,10?,11+/m1/s1",beta-D-Xyl-(1->2)-D-Man,KEGG GLYCAN accession,G09088
2994,62136,beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-OMe,A methyl glycoside derived from a hexasaccharide consisting of three units N-acetyllactosamine coupled in a linear sequence by beta-(1->3') linkages.,"InChI=1S/C43H73N3O31/c1-11(53)44-20-26(59)33(17(8-50)70-38(20)66-4)74-42-31(64)36(24(57)15(6-48)68-42)77-40-22(46-13(3)55)28(61)35(19(10-52)72-40)75-43-32(65)37(25(58)16(7-49)69-43)76-39-21(45-12(2)54)27(60)34(18(9-51)71-39)73-41-30(63)29(62)23(56)14(5-47)67-41/h14-43,47-52,56-65H,5-10H2,1-4H3,(H,44,53)(H,45,54)(H,46,55)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23+,24+,25+,26-,27-,28-,29+,30-,31-,32-,33-,34-,35-,36+,37+,38-,39+,40+,41+,42+,43+/m1/s1",beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-OMe,Reaxys Registry Number,4289455
2995,62137,"2-O-octanoyl-2'-O-sulfo-3-O-[(2E,4S,6S,8S)-2,4,6,8-tetramethyltetracos-2-enoyl]-alpha,alpha-trehalose","A sulfoglycolipid in which alpha,alpha-trehalose, sulfated at the 2'-position, is acylated at the 2-position with octanoic acid, and at the 3-position with (2E,4S,6S,8S)-2,4,6,8-tetramethylteracos-2-enoic acid.","InChI=1S/C48H88O16S/c1-7-9-11-13-14-15-16-17-18-19-20-21-23-24-26-33(3)28-34(4)29-35(5)30-36(6)46(55)62-43-41(53)38(32-50)60-48(45(43)61-39(51)27-25-22-12-10-8-2)63-47-44(64-65(56,57)58)42(54)40(52)37(31-49)59-47/h30,33-35,37-38,40-45,47-50,52-54H,7-29,31-32H2,1-6H3,(H,56,57,58)/b36-30+/t33-,34-,35-,37+,38+,40+,41+,42-,43-,44+,45+,47+,48+/m0/s1","2-O-octanoyl-3-O-[(2E,4S,6S,8S)-2,4,6,8-tetramethyltetracos-2-enoyl]-alpha-D-glucopyranosyl 2-O-sulfo-alpha-D-glucopyranoside",PubMed citation,19454700
2996,62142,beta-D-Galf-(1->5)-beta-D-Galf-(1->6)-alpha-D-Manp-(1->6)-D-Manp,"A tetrasaccharide consisting of two (1->5)-linked beta-D-galactofuranose units, which are in turn linked (1->6) to alpha-D-mannopyranosyl-(1->6)-D-mannopyranose.","InChI=1S/C24H42O21/c25-1-5(27)19-13(32)18(37)24(44-19)42-6(2-26)20-14(33)17(36)23(45-20)40-4-8-10(29)12(31)16(35)22(43-8)39-3-7-9(28)11(30)15(34)21(38)41-7/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11+,12+,13-,14-,15+,16+,17-,18-,19+,20+,21?,22+,23-,24-/m1/s1",beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->6)-alpha-D-mannosyl-(1->6)-D-mannose,PubMed citation,12851285
2997,62143,beta-D-Galf-(1->5)-beta-D-Galf-(1->5)-beta-D-Galf-(1->5)-beta-D-Galf-(1->6)-D-Manp,"A pentasaccharide composed of four (1->5)-linked beta-D-galactofuranose units, which are joined (1->6)-linkage to a D-mannopyranose at the reducing end.","InChI=1S/C30H52O26/c31-1-6(35)22-13(38)19(44)28(53-22)50-8(3-33)24-15(40)21(46)30(55-24)52-9(4-34)25-16(41)20(45)29(56-25)51-7(2-32)23-14(39)18(43)27(54-23)48-5-10-11(36)12(37)17(42)26(47)49-10/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12+,13-,14-,15-,16-,17+,18-,19-,20-,21-,22+,23+,24+,25+,26?,27-,28-,29-,30-/m1/s1",beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->6)-D-mannose,PubMed citation,12851285
2998,62146,alpha-L-Fucp2Me-(1->2)-beta-D-Galp-(1->3)-alpha-D-GalpNAc,An amino trisaccharide consisting of a 2-O-methyl-L-fucosyl residue at the non-reducing end linked (1->2) to an beta-D-galactosyl residue which is in turn linked (1->3) to an N-acetyl-alpha-D-galactosamine.,"InChI=1S/C21H37NO15/c1-6-11(26)14(29)17(32-3)20(33-6)37-18-15(30)12(27)8(4-23)35-21(18)36-16-10(22-7(2)25)19(31)34-9(5-24)13(16)28/h6,8-21,23-24,26-31H,4-5H2,1-3H3,(H,22,25)/t6-,8+,9+,10+,11+,12-,13-,14+,15-,16+,17-,18+,19-,20-,21-/m0/s1",2-O-Me-alpha-L-Fucp-(1-2)-beta-D-Galp-(1-3)-alpha-D-GalpNAc,PubMed citation,17087964
2999,62148,alpha-L-Fucp2Me-(1->2)-beta-D-Galp-(1->3)-beta-D-GalpNAc,An amino trisaccharide consisting of a 2-O-methyl-L-fucosyl residue at the non-reducing end linked (1->2) to an beta-D-galactosyl residue which is in turn linked (1->3) to an N-acetyl-beta-D-galactosamine.,"InChI=1S/C21H37NO15/c1-6-11(26)14(29)17(32-3)20(33-6)37-18-15(30)12(27)8(4-23)35-21(18)36-16-10(22-7(2)25)19(31)34-9(5-24)13(16)28/h6,8-21,23-24,26-31H,4-5H2,1-3H3,(H,22,25)/t6-,8+,9+,10+,11+,12-,13-,14+,15-,16+,17-,18+,19+,20-,21-/m0/s1",2-O-methyl-alpha-L-fucopyranosyl-(1->2)-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-galactopyranose,PubMed citation,17087964
3000,62154,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GalpNAc,"An amino trisaccharide consisting of alpha-L-fucopyranose, beta-D-galactopyranose and N-acetyl-beta-D-galactopyranosamine residues joined in sequence with a (1->2)- and a (1->3)-linkage, respectively; alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-D-GalpNAc in which the configuration at the reducing-end anomeric centre is beta.","InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)19(32-5)36-17-14(29)11(26)7(3-22)34-20(17)35-16-9(21-6(2)24)18(31)33-8(4-23)12(16)27/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12-,13+,14-,15-,16+,17+,18+,19-,20-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc,PubMed citation,17087964
3001,62157,alpha-L-Rhap-(1->4)-D-ribitol-5-phosphate,A disaccharide derivative consisting of D-ribitol-5-phosphate having an alpha-L-rhamnosyl residue attached at the 4-position.,"InChI=1S/C11H23O12P/c1-4-7(14)9(16)10(17)11(22-4)23-6(3-21-24(18,19)20)8(15)5(13)2-12/h4-17H,2-3H2,1H3,(H2,18,19,20)/t4-,5-,6+,7-,8-,9+,10+,11-/m0/s1",alpha-L-Rha-(1->4)-D-ribitol-5-phosphate,PubMed citation,11159969
3002,62159,alpha-L-Rhap-(1->4)-D-ribitol-(5-P-2)-alpha-D-Galp-(1->3)-alpha-D-Glcp,A disaccharide phosphate consisting of alpha-D-galactosyl-(1->3)-alpha-D-glucose having a alpha-L-rhamnosyl-(1->4)-D-ribitol-5-phosphate moiety attached at the 2-position of the galactose via a phosphodiester linkage.,"InChI=1S/C23H43O22P/c1-6-11(28)15(32)17(34)22(40-6)43-10(12(29)7(27)2-24)5-39-46(37,38)45-20-16(33)13(30)8(3-25)42-23(20)44-19-14(31)9(4-26)41-21(36)18(19)35/h6-36H,2-5H2,1H3,(H,37,38)/t6-,7-,8+,9+,10+,11-,12-,13-,14+,15+,16-,17+,18+,19-,20+,21-,22-,23+/m0/s1",alpha-L-rhamnosyl-(1->4)-D-ribitol-(5-P-2)-alpha-D-galactosyl-(1->3)-alpha-D-glucose,PubMed citation,11159969
3003,62161,D-ribitol-(5-P-2)-alpha-D-Galp-(1->3)-alpha-D-Glcp,A disaccharide phosphate consisting of alpha-D-galactosyl-(1->3)-alpha-D-glucose having a D-ribitol-5-phosphate moiety attached at the 2-position of the galactose via a phosphodiester linkage.,"InChI=1S/C17H33O18P/c18-1-5(21)9(23)6(22)4-31-36(29,30)35-15-12(26)10(24)7(2-19)33-17(15)34-14-11(25)8(3-20)32-16(28)13(14)27/h5-28H,1-4H2,(H,29,30)/t5-,6+,7+,8+,9-,10-,11+,12-,13+,14-,15+,16-,17+/m0/s1",D-ribitol-(5-P-2)-alpha-D-galactosyl-(1->3)-alpha-D-glucose,PubMed citation,11159969
3004,62165,N-acetyl-alpha-D-mannosamine 6-phosphate,An N-acetyl-D-mannosamine 6-phosphate having alpha-configuration at the anomeric centre.,"InChI=1S/C8H16NO9P/c1-3(10)9-5-7(12)6(11)4(18-8(5)13)2-17-19(14,15)16/h4-8,11-13H,2H2,1H3,(H,9,10)(H2,14,15,16)/t4-,5+,6-,7-,8+/m1/s1",2-acetamido-2-deoxy-6-O-phosphono-alpha-D-mannose,PDBeChem accession,BMX
3005,62168,N-acetyl-D-mannosamine 6-phosphate,An N-acyl-D-mannosamine 6-phosphate having the N-acyl specified as acetyl.,"InChI=1S/C8H16NO9P/c1-3(10)9-5-7(12)6(11)4(18-8(5)13)2-17-19(14,15)16/h4-8,11-13H,2H2,1H3,(H,9,10)(H2,14,15,16)/t4-,5+,6-,7-,8?/m1/s1",2-acetamido-2-deoxy-6-O-phosphono-D-mannose,Reaxys Registry Number,7860293
3006,62171,alpha-D-ManpAc-(1-P-6)-alpha-D-ManpAc,A phosphate-linked oligosaccharide analogue consisting of two N-acetyl-alpha-D-mannosamine units joined by a (1->6)-phosphodiester linkage.,"InChI=1S/C16H29N2O14P/c1-5(20)17-9-13(24)12(23)8(30-15(9)26)4-29-33(27,28)32-16-10(18-6(2)21)14(25)11(22)7(3-19)31-16/h7-16,19,22-26H,3-4H2,1-2H3,(H,17,20)(H,18,21)(H,27,28)/t7-,8-,9+,10+,11-,12-,13-,14-,15+,16-/m1/s1",alpha-D-ManAc-(1-P-6)-alpha-D-ManAc,PubMed citation,12355530
3007,62174,alpha-D-ManpNAc-(1-P-6)-alpha-D-ManpNAc-(1-P-6)-alpha-D-ManpNAc,A phosphate-linked oligosaccharide analogue consisting of three N-acetyl-alpha-D-mannosamine units joined by (1->6)-phosphodiester linkages.,"InChI=1S/C24H43N3O22P2/c1-7(29)25-13-19(35)17(33)11(45-22(13)38)5-43-50(39,40)49-24-15(27-9(3)31)21(37)18(34)12(47-24)6-44-51(41,42)48-23-14(26-8(2)30)20(36)16(32)10(4-28)46-23/h10-24,28,32-38H,4-6H2,1-3H3,(H,25,29)(H,26,30)(H,27,31)(H,39,40)(H,41,42)/t10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22+,23-,24-/m1/s1",alpha-D-ManNAc-(1-P-6)-alpha-D-ManNAc-(1-P-6)-alpha-D-ManNAc,PubMed citation,12355530
3008,62181,alpha-L-Fucp-(1->3)-D-GlcpNAc,An amino disaccharide consisting of N-acetyl-D-glucosamine having an alpha-L-fucosyl residue attached at the 3-position.,"InChI=1S/C14H25NO10/c1-4-8(18)10(20)11(21)14(23-4)25-12-7(15-5(2)17)13(22)24-6(3-16)9(12)19/h4,6-14,16,18-22H,3H2,1-2H3,(H,15,17)/t4-,6+,7+,8+,9+,10+,11-,12+,13?,14-/m0/s1",alpha-L-Fuc-(1->3)-D-GlcNAc,PubMed citation,10601665
3009,62182,beta-anthropyranosyl-(1->3)-alpha-L-rhamnopyranose,An amino disaccharide consisting of alpha-L-rhamnopyranose having a beta-anthropyranosyl residue attached at the 3-position.,"InChI=1S/C18H33NO10/c1-7-10(19-9(20)6-18(3,4)25)12(22)15(26-5)17(28-7)29-14-11(21)8(2)27-16(24)13(14)23/h7-8,10-17,21-25H,6H2,1-5H3,(H,19,20)/t7-,8+,10-,11+,12+,13-,14-,15-,16-,17+/m1/s1",beta-anthrosyl-(1->3)-alpha-L-rhamnose,PubMed citation,19226390
3010,62183,beta-anthropyranose,"An amino monosaccharide consisting of D-glucose having a 3-hydroxy-3-methylbutanamido group at the 4-position, a 2-O-methyl group and lacking the 6-hydroxy group.","InChI=1S/C12H23NO6/c1-6-8(13-7(14)5-12(2,3)17)9(15)10(18-4)11(16)19-6/h6,8-11,15-17H,5H2,1-4H3,(H,13,14)/t6-,8-,9+,10-,11-/m1/s1",beta-anthrose,Reaxys Registry Number,10015270
3011,62188,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-D-Galp,"An amino pentasaccharide consisting of two units of beta-D-galactopyranosyl-(1->4)-N-acetamido-beta-D-glucosamine, attached by (1->3)- and (1->6)-linkages to a D-galactopyranose.","InChI=1S/C34H58N2O26/c1-8(41)35-15-20(46)27(60-33-24(50)22(48)17(43)10(3-37)56-33)12(5-39)58-31(15)54-7-14-19(45)29(26(52)30(53)55-14)62-32-16(36-9(2)42)21(47)28(13(6-40)59-32)61-34-25(51)23(49)18(44)11(4-38)57-34/h10-34,37-40,43-53H,3-7H2,1-2H3,(H,35,41)(H,36,42)/t10-,11-,12-,13-,14-,15-,16-,17+,18+,19+,20-,21-,22+,23+,24-,25-,26-,27-,28-,29+,30?,31-,32+,33+,34+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-D-Gal,PubMed citation,6194884
3012,62193,biotin sulfoxide,A sulfoxide that is the S-oxide of biotin.,"InChI=1S/C10H16N2O4S/c13-8(14)4-2-1-3-7-9-6(5-17(7)16)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-,17?/m0/s1",biotin S-oxide,Reaxys Registry Number,4492830
3013,62197,"S-[(2E,6E)-farnesyl]-L-cysteine",An S-farnesyl-L-cysteine where the C=C double bonds at the 2- and 6-positions both have (E)-configuration.,"InChI=1S/C18H31NO2S/c1-14(2)7-5-8-15(3)9-6-10-16(4)11-12-22-13-17(19)18(20)21/h7,9,11,17H,5-6,8,10,12-13,19H2,1-4H3,(H,20,21)/b15-9+,16-11+/t17-/m0/s1","S-(2-trans,6-trans)-farnesyl-L-cysteine",PubMed citation,17425716
3014,62208,3-methyl-7H-xanthine,A 3-methylxanthine tautomer where the imidazole proton is located at the 7-position.,"InChI=1S/C6H6N4O2/c1-10-4-3(7-2-8-4)5(11)9-6(10)12/h2H,1H3,(H,7,8)(H,9,11,12)",3-methylxanthine,PubMed citation,14681347
3015,62218,"23,24-dihydrocucurbitacin D","A 23,24-dihydrocucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at position 5.","InChI=1S/C30H46O7/c1-25(2,36)12-11-21(33)30(8,37)23-19(32)14-27(5)20-10-9-16-17(13-18(31)24(35)26(16,3)4)29(20,7)22(34)15-28(23,27)6/h9,17-20,23,31-32,36-37H,10-15H2,1-8H3/t17-,18+,19-,20+,23+,27+,28-,29+,30+/m1/s1","2beta,16alpha,20,25- tetrahydroxy-9beta-methyl-19-nor-10alpha-lanost-5-ene-3,11,22-trione",Reaxys Registry Number,2513994
3016,62242,trans-oct-2-enoyl-CoA(4-),"A trans-2,3-didehydroacyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate OH groups of trans-oct-2-enoyl-CoA; major species at pH 7.3.","InChI=1S/C29H48N7O17P3S/c1-4-5-6-7-8-9-20(38)57-13-12-31-19(37)10-11-32-27(41)24(40)29(2,3)15-50-56(47,48)53-55(45,46)49-14-18-23(52-54(42,43)44)22(39)28(51-18)36-17-35-21-25(30)33-16-34-26(21)36/h8-9,16-18,22-24,28,39-40H,4-7,10-15H2,1-3H3,(H,31,37)(H,32,41)(H,45,46)(H,47,48)(H2,30,33,34)(H2,42,43,44)/p-4/b9-8+/t18-,22-,23-,24+,28-/m1/s1",(2E)-octenoyl-CoA(4-),MetaCyc accession,CPD0-2108
3017,62251,2-(beta-D-glucosyloxy)-cis-cinnamic acid,A beta-D-glucoside consisting of cis-2-coumaric acid having a beta-D-glucosyl residue attached to the phenolic hydroxy group.,"InChI=1S/C15H18O8/c16-7-10-12(19)13(20)14(21)15(23-10)22-9-4-2-1-3-8(9)5-6-11(17)18/h1-6,10,12-16,19-21H,7H2,(H,17,18)/b6-5-/t10-,12-,13+,14-,15-/m1/s1",cis-melilotoside,MetaCyc accession,CPD-7417
3018,62259,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-D-GlcpNAc,"An amino trisaccharide consisting of alpha-L-fucose, beta-D-galactose and N-acetyl-D-glucosamine residues joined by sequential (1->2)- and (1->3)-linkages.","InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)19(32-5)36-17-14(29)11(26)7(3-22)34-20(17)35-16-9(21-6(2)24)18(31)33-8(4-23)12(16)27/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18?,19-,20-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-D-GlcNAc,PubMed citation,7696864
3019,62263,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-D-GlcpNAc,"An amino trisaccharide consisting of alpha-L-fucose, beta-D-galactose and N-acetyl-D-glucosamine residues joined by sequential (1->2)- and (1->4)-linkages.","InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)19(32-5)36-17-14(29)11(26)7(3-22)34-20(17)35-16-8(4-23)33-18(31)9(12(16)27)21-6(2)24/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18?,19-,20-/m0/s1",Fucalpha1-2Galbeta1-4GlcNAc,PubMed citation,6083446
3020,62265,beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc,An amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a galactosyl residue attached at the 3-position via a beta-linkage.,"InChI=1S/C20H35NO15/c1-5-10(25)12(27)14(29)19(32-5)35-16-8(4-23)33-18(31)9(21-6(2)24)17(16)36-20-15(30)13(28)11(26)7(3-22)34-20/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13-,14-,15+,16+,17+,18?,19-,20-/m0/s1",beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-D-glucosamine,KEGG GLYCAN accession,G00250
3021,62273,alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-D-Glcp,An amino trisaccharide consisting of an N-glycoloylneuraminosyl residue linked alpha(2->3) to a lactose moiety.,"InChI=1S/C23H39NO20/c25-2-7(30)12(32)18-11(24-10(31)5-28)6(29)1-23(43-18,22(38)39)44-19-13(33)8(3-26)41-21(16(19)36)42-17-9(4-27)40-20(37)15(35)14(17)34/h6-9,11-21,25-30,32-37H,1-5H2,(H,24,31)(H,38,39)/t6-,7+,8+,9+,11+,12+,13-,14+,15+,16+,17+,18+,19-,20?,21-,23-/m0/s1",Gc2-3Lac,PubMed citation,26630345
3022,62284,beta-D-Galp-(1->4)-alpha-D-GlcpNAc-OMe,A methyl glycoside that is beta-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-glucopyranose in which the anomeric hydroxy group is replaced by methoxy.,"InChI=1S/C15H27NO11/c1-5(19)16-8-10(21)13(7(4-18)26-14(8)24-2)27-15-12(23)11(22)9(20)6(3-17)25-15/h6-15,17-18,20-23H,3-4H2,1-2H3,(H,16,19)/t6-,7-,8-,9+,10-,11+,12-,13-,14+,15+/m1/s1","Gal-beta1,4-GlcNAc-alpha1-O-Me",PubMed citation,6083447
3023,62286,2'-deoxyinosine 5'-diphosphate(3-),A 2'-deoxyribonucleoside 5'-diphosphate obtained by deprotonation of the diphosphate OH groups of 2'-deoxyinosine  5'-diphosphate; major species at pH 7.3.,"InChI=1S/C10H14N4O10P2/c15-5-1-7(14-4-13-8-9(14)11-3-12-10(8)16)23-6(5)2-22-26(20,21)24-25(17,18)19/h3-7,15H,1-2H2,(H,20,21)(H,11,12,16)(H2,17,18,19)/p-3/t5-,6+,7+/m0/s1",deoxyinosine diphosphate(3-),MetaCyc accession,CPD0-2231
3024,62287,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-D-GlcpNAc,An amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 3-position via an alpha-linkage and a galactosyl residue attached at the 4-position via a beta-linkage.,"InChI=1S/C20H35NO15/c1-5-10(25)12(27)14(29)19(32-5)36-17-9(21-6(2)24)18(31)33-8(4-23)16(17)35-20-15(30)13(28)11(26)7(3-22)34-20/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13-,14-,15+,16+,17+,18?,19-,20-/m0/s1",beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-D-glucosamine,PubMed citation,6208947
3025,62294,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc,An amino ctasaccharide that is alpha-L-Fuc-(1->3)-[beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)]-GlcNAc in which the mannosyl group is substituted at positions 3 and 6 by beta-D-GlcNAc-(1->2)-alpha-D-Man groups.,"InChI=1S/C56H94N4O40/c1-13-29(71)38(80)41(83)53(87-13)97-45-28(60-17(5)70)49(85)88-23(11-66)44(45)96-52-27(59-16(4)69)37(79)43(22(10-65)93-52)95-54-42(84)46(98-56-48(40(82)33(75)21(9-64)92-56)100-51-26(58-15(3)68)36(78)31(73)19(7-62)90-51)34(76)24(94-54)12-86-55-47(39(81)32(74)20(8-63)91-55)99-50-25(57-14(2)67)35(77)30(72)18(6-61)89-50/h13,18-56,61-66,71-85H,6-12H2,1-5H3,(H,57,67)(H,58,68)(H,59,69)(H,60,70)/t13-,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39-,40-,41-,42-,43+,44+,45+,46-,47-,48-,49?,50-,51-,52-,53-,54-,55-,56+/m0/s1",beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-GlcNAc-(1->4)-[alpha-L-Fuc-(1->3)]-D-GlcNAc,PubMed citation,12626421
3026,62295,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-D-GlcpNAc,An amino heptasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at positions 3 and 6 by beta-D-GlcNAc-(1->2)-alpha-D-Man groups.,"InChI=1S/C50H84N4O36/c1-12(61)51-23-34(72)39(20(9-59)79-44(23)77)86-47-26(54-15(4)64)35(73)40(21(10-60)84-47)87-48-38(76)41(88-50-43(37(75)30(68)19(8-58)83-50)90-46-25(53-14(3)63)33(71)28(66)17(6-56)81-46)31(69)22(85-48)11-78-49-42(36(74)29(67)18(7-57)82-49)89-45-24(52-13(2)62)32(70)27(65)16(5-55)80-45/h16-50,55-60,65-77H,5-11H2,1-4H3,(H,51,61)(H,52,62)(H,53,63)(H,54,64)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36+,37+,38+,39-,40-,41+,42+,43+,44?,45+,46+,47+,48+,49+,50-/m1/s1",beta-N-acetyl-D-glucosamine-(1-2)-alpha-D-mannose-(1-3)-[beta-N-acetyl-D-glucosamine-(1-2)-alpha-D-mannose-(1-6)]-beta-D-mannose-(1-4)-beta-N-acetyl-D-glucosamine-(1-4)-N-acetyl-D-glucosamine,PubMed citation,12626421
3027,62321,L-lyxopyranose,An L-lyxose in cyclic pyranose form.,"InChI=1S/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4+,5?/m0/s1",L-lyxose,KEGG COMPOUND accession,C01508
3028,62322,"5-acetamido-3,5-dideoxy-L-arabino-hept-2-ulopyranosonic acid",The ketoaldonic acid derivative that is N-acetylneuraminic acid after formal dehydroxylation and subsequent removal of C-8 and C-9.,"InChI=1S/C9H15NO7/c1-4(12)10-7-5(13)2-9(16,8(14)15)17-6(7)3-11/h5-7,11,13,16H,2-3H2,1H3,(H,10,12)(H,14,15)/t5-,6-,7+,9?/m0/s1","N-acetyl-8,9-dinorneuraminic acid",Reaxys Registry Number,2288512
3029,62325,2-amino-2-deoxy-D-mannopyranose,A D-mannosamine in cyclic pyranose form.,"InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3+,4-,5-,6?/m1/s1",2-amino-2-deoxymannopyranose,KEGG COMPOUND accession,C03570
3030,62327,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,An alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C20H35NO16/c1-5(25)21-9-12(28)16(8(4-24)33-18(9)32)36-20-15(31)17(11(27)7(3-23)35-20)37-19-14(30)13(29)10(26)6(2-22)34-19/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12-,13+,14-,15-,16-,17+,18-,19-,20+/m1/s1",alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc,Reaxys Registry Number,7558012
3031,62330,alpha-D-Galp-(1->3)-beta-D-Galp,A glycosylgalactose that consists of beta-D-galactose having an alpha-D-galactosyl residue at the 3-position.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8-,9-,10+,11-,12-/m1/s1",alpha-D-Gal-(1->3)-beta-D-Gal,Reaxys Registry Number,1625914
3032,62331,[6)-alpha-D-Galp-(1->4)-alpha-D-NeupAc-(2->]3,"An amino hexasaccharide made up of three units of alpha-D-Galp-(1->4)-alpha-D-NeupAc, joined together by glycosidic linkages between position 2 of the N-acetylneuraminyl residues and position 6 of the galactosyl residues.","InChI=1S/C51H83N3O40/c1-13(59)52-25-19(4-49(83,46(77)78)92-40(25)28(65)16(62)7-55)86-44-38(75)35(72)32(69)23(90-44)11-84-51(48(81)82)6-21(27(54-15(3)61)42(94-51)30(67)18(64)9-57)88-45-39(76)36(73)33(70)24(91-45)12-85-50(47(79)80)5-20(87-43-37(74)34(71)31(68)22(10-58)89-43)26(53-14(2)60)41(93-50)29(66)17(63)8-56/h16-45,55-58,62-76,83H,4-12H2,1-3H3,(H,52,59)(H,53,60)(H,54,61)(H,77,78)(H,79,80)(H,81,82)/t16-,17-,18-,19+,20+,21+,22-,23-,24-,25-,26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,37-,38-,39-,40-,41-,42-,43+,44+,45+,49-,50-,51-/m1/s1",alpha-D-Galp-(1->4)-alpha-D-NeupAc-(2->6)-alpha-D-Galp-(1->4)-alpha-D-NeupAc-(2->6)-alpha-D-Galp-(1->4)-alpha-D-NeupAc,PubMed citation,17804612
3033,62332,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GalpNAc,A branched amino tetrasaccharide comprising N-acetyl-beta-D-galactosamine at the reducing end with an alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 3-position.,"InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)24(41-6)47-22-21(46-25-19(39)17(37)13(33)8(3-28)43-25)15(35)10(5-30)44-26(22)45-20-11(27-7(2)31)23(40)42-9(4-29)14(20)34/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15-,16+,17-,18-,19+,20+,21-,22+,23+,24-,25+,26-/m0/s1",alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-beta-D-GalNAc,PubMed citation,10442639
3034,62334,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-Galp,A branched tetrasaccharide comprising D-galactose at the reducing end with an alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 3-position.,"InChI=1S/C24H42O20/c1-5-9(28)13(32)15(34)22(38-5)44-20-19(43-23-16(35)14(33)10(29)6(2-25)40-23)12(31)8(4-27)41-24(20)42-18-11(30)7(3-26)39-21(37)17(18)36/h5-37H,2-4H2,1H3/t5-,6+,7+,8+,9+,10-,11-,12-,13+,14-,15-,16+,17+,18-,19-,20+,21+,22-,23+,24-/m0/s1",alpha-L-fucosyl-(1->2)-[alpha-D-galactosyl-(1->3)]-beta-D-galactosyl-(1->3)-beta-D-galactose,PubMed citation,7521740
3035,62335,alpha-D-GalpNAc-(1->3)-beta-D-Galp,An alpha-D-GalNAc-(1->3)-D-Gal having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)5(2-16)25-14(7)26-12-9(20)6(3-17)24-13(23)11(12)22/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10-,11-,12+,13-,14-/m1/s1",alpha-D-GalNAc-(1->3)-beta-D-Gal,Reaxys Registry Number,5635327
3036,62336,alpha-D-GalpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,A linear amino trisaccharide consisting of beta-D-glucose at the reducing end having an N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C20H35NO16/c1-5(25)21-9-12(28)10(26)6(2-22)34-19(9)37-17-11(27)7(3-23)35-20(15(17)31)36-16-8(4-24)33-18(32)14(30)13(16)29/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12-,13-,14-,15-,16-,17+,18-,19-,20+/m1/s1",N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucose,PubMed citation,7521740
3037,62338,O(4)-phosphonato-L-tyrosine(2-),An optically active form of O(4)-phosphonatotyrosine(2-) having L-configuration.,"InChI=1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)/p-2/t8-/m0/s1",O-phospho-L-tyrosine(2-),MetaCyc accession,CPD-3728
3038,62339,alpha-D-GalpNAc-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp,"A linear amino trisaccharide consisting of two alpha-(1->3)-linked N-acetyl-galactosamine units, which are in turn linked beta-(1->3) to an alpha-galactose unit at the reducing end.","InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)13(30)8(3-25)37-21(11)39-18-12(24-7(2)29)22(38-10(5-27)14(18)31)40-19-15(32)9(4-26)36-20(35)17(19)34/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19+,20+,21-,22+/m1/s1",alpha-D-GalNAc-(1->3)-beta-D-GalNAc-(1->3)-alpha-D-Gal,PubMed citation,7521740
3039,62340,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GalpNAc,An alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-D-GalpNAc having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C28H48N2O20/c1-7-15(36)20(41)21(42)27(44-7)50-24-23(49-26-13(29-8(2)34)19(40)16(37)10(4-31)46-26)18(39)12(6-33)47-28(24)48-22-14(30-9(3)35)25(43)45-11(5-32)17(22)38/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17-,18-,19+,20+,21-,22+,23-,24+,25+,26+,27-,28-/m0/s1",N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosamine,PubMed citation,7521740
3040,62346,L-rhamnopyranose,An L-rhamnose in cyclic pyranose form.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3-,4+,5+,6?/m0/s1",L-Rha,KEGG COMPOUND accession,C00507
3041,62347,alpha-L-Rhap-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-L-Rhap,An amino trisaccharide consisting of alpha-L-rhamnose at the reducing end having an alpha-L-rhamnosyl-(1->3)-N-acetyl-beta-D-glucosaminyl moiety attached at the 2-position.,"InChI=1S/C20H35NO14/c1-5-11(25)14(28)17(18(30)31-5)35-19-9(21-7(3)23)16(12(26)8(4-22)33-19)34-20-15(29)13(27)10(24)6(2)32-20/h5-6,8-20,22,24-30H,4H2,1-3H3,(H,21,23)/t5-,6-,8+,9+,10-,11-,12+,13+,14+,15+,16+,17+,18+,19-,20-/m0/s1",alpha-L-Rha-(1->3)-beta-D-GlcNAc-(1->2)-alpha-L-Rha,PubMed citation,7521740
3042,62348,alpha-D-GalpNAc-(1->2)-beta-D-Galp,An amino disaccharide consisting of beta-D-galactose having an N-acetyl-alpha-D-galactosaminyl residue attached at the 2-position.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)6(3-17)25-14(7)26-12-11(22)9(20)5(2-16)24-13(12)23/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10-,11+,12-,13-,14-/m1/s1",alpha-D-GalNAc-(1->2)-beta-D-Gal,PubMed citation,7521740
3043,62351,beta-D-GalpNAc-(1->2)-beta-D-Galp,An amino disaccharide consisting of beta-D-galactose having an N-acetyl-beta-D-galactosaminyl residue attached at the 2-position.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)6(3-17)25-14(7)26-12-11(22)9(20)5(2-16)24-13(12)23/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10-,11+,12-,13-,14+/m1/s1",N-acetyl-beta-D-galactosaminyl-(1->2)-beta-D-galactose,PubMed citation,7521740
3044,62353,alpha-D-Glcp-(1->2)-beta-D-Galp,A glycosylgalactose consisting of beta-D-galactose having an alpha-D-glucosyl residue attached at the 2-position.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10-,11-,12-/m1/s1",alpha-D-glucosyl-(1->2)-beta-D-galactose,PubMed citation,7521740
3045,62355,beta-D-Glcp-(1->2)-beta-D-Galp,A glycosylgalactose consisting of beta-D-galactose having an beta-D-glucosyl residue attached at the 2-position.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10-,11-,12+/m1/s1",betaGlc(1->2)betaGal,Reaxys Registry Number,1292762
3046,62356,beta-D-Glcp-(1->2)-alpha-D-Manp,A D-glucosyl-D-mannose with the two components joined by an beta-(1->2)-linkage and alpha-cofiguration at the reducing end anomeric centre.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9-,10+,11+,12+/m1/s1",betaGlc(1->2)alphaMan,Reaxys Registry Number,1625924
3047,62357,alpha-D-Manp-(1->6)-alpha-D-Manp,An alpha-D-Manp-(1->6)-D-Manp having alpha-configuration at the reducing end anomeric centre.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10+,11+,12+/m1/s1",alpha-D-Man-(1->6)-alpha-D-Man,Reaxys Registry Number,6278823
3048,62362,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp,An alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-Glcp having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C38H65NO30/c1-8-16(46)20(50)25(55)35(59-8)69-32-21(51)17(47)10(3-40)63-38(32)67-30-15(39-9(2)45)34(61-11(4-41)18(30)48)68-31-19(49)12(5-42)62-37(27(31)57)66-29-14(7-44)64-36(26(56)23(29)53)65-28-13(6-43)60-33(58)24(54)22(28)52/h8,10-38,40-44,46-58H,3-7H2,1-2H3,(H,39,45)/t8-,10+,11+,12+,13+,14+,15+,16+,17-,18+,19-,20+,21-,22+,23+,24+,25-,26+,27+,28+,29-,30+,31-,32+,33+,34-,35-,36-,37+,38-/m0/s1",alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucose,PubMed citation,21149694
3049,62365,Ac-Cha-Arg-Ala-Met-Cys(Acm)-Ser-Leu-NH2,"A seven-membered oligopeptide comprising Ac-Cha, Arg, Ala, Met, Cys(Acm), Ser and Leu-NH2 residues coupled in sequence.","InChI=1S/C40H72N12O10S2/c1-22(2)17-29(33(41)56)50-38(61)31(19-53)51-39(62)32(20-64-21-45-24(4)54)52-36(59)28(14-16-63-6)48-34(57)23(3)46-35(58)27(13-10-15-44-40(42)43)49-37(60)30(47-25(5)55)18-26-11-8-7-9-12-26/h22-23,26-32,53H,7-21H2,1-6H3,(H2,41,56)(H,45,54)(H,46,58)(H,47,55)(H,48,57)(H,49,60)(H,50,61)(H,51,62)(H,52,59)(H4,42,43,44)/t23-,27-,28-,29-,30-,31-,32-/m0/s1",Ac-(Cha)RAM(CAcm)SL-NH2,PubMed citation,10841792
3050,62366,Ac-Cha-Arg-Ala-Odapdc-Ser-Leu-NH2,"A synthetic six-membered oligopeptide comprising Ac-Cha, Arg, Ala, Odapdc, Ser and Leu-NH2 residues coupled in sequence.","InChI=1S/C39H66N12O10/c1-21(2)18-27(32(40)55)48-36(59)29(20-52)49-37(60)30-13-9-17-50-31(54)15-14-26(38(61)51(30)50)47-33(56)22(3)44-34(57)25(12-8-16-43-39(41)42)46-35(58)28(45-23(4)53)19-24-10-6-5-7-11-24/h21-22,24-30,52H,5-20H2,1-4H3,(H2,40,55)(H,44,57)(H,45,53)(H,46,58)(H,47,56)(H,48,59)(H,49,60)(H4,41,42,43)/t22-,25-,26-,27-,28-,29-,30-/m0/s1",Ac(Cha)ArgAla(Odapdc)SerLeuNH2,PubMed citation,10841792
3051,62367,Ac-Cha-Arg-MeAla-Haic-NHCH(CH2OH)2,"A synthetic tetrapeptide comprising Ac-Cha, Arg, MeAla and Haic-NHCH(CH2OH)2 residues coupled in sequence.","InChI=1S/C37H57N9O8/c1-21(32(50)43-28-15-14-24-11-7-12-25-18-30(46(31(24)25)36(28)54)34(52)42-26(19-47)20-48)45(3)35(53)27(13-8-16-40-37(38)39)44-33(51)29(41-22(2)49)17-23-9-5-4-6-10-23/h7,11-12,21,23,26-30,47-48H,4-6,8-10,13-20H2,1-3H3,(H,41,49)(H,42,52)(H,43,50)(H,44,51)(H4,38,39,40)/t21-,27-,28?,29-,30?/m0/s1",Ac(Cha)Arg(MeA)(Haic)NHCH(CH2OH)2,PubMed citation,10841792
3052,62368,Ac-Cha-Arg-MePhg-Met-Ala-Ser-tLeu-NH2,"A synthetic seven-membered oligopeptide comprising Ac-Cha, Arg, MePhg, Met, Ala, Ser and tLeu-NH2 residues coupled in sequence.","InChI=1S/C43H71N11O9S/c1-25(36(58)52-32(24-55)39(61)53-34(35(44)57)43(3,4)5)48-37(59)29(20-22-64-7)50-40(62)33(28-17-12-9-13-18-28)54(6)41(63)30(19-14-21-47-42(45)46)51-38(60)31(49-26(2)56)23-27-15-10-8-11-16-27/h9,12-13,17-18,25,27,29-34,55H,8,10-11,14-16,19-24H2,1-7H3,(H2,44,57)(H,48,59)(H,49,56)(H,50,62)(H,51,60)(H,52,58)(H,53,61)(H4,45,46,47)/t25-,29-,30-,31-,32-,33-,34+/m0/s1",Ac(Cha)Arg(MePhg)MetAlaSer(tLeu)-NH2,Reaxys Registry Number,8672300
3053,62372,"UDP-2-acetamido-2,6-dideoxy-beta-L-talose(2-)",Dianion of UDP-N-acetyl-6-deoxy-beta-L-talosamine arising from deprotonation of both free diphosphate OH groups; major species at pH 7.3.,"InChI=1S/C17H27N3O16P2/c1-6-11(23)13(25)10(18-7(2)21)16(33-6)35-38(30,31)36-37(28,29)32-5-8-12(24)14(26)15(34-8)20-4-3-9(22)19-17(20)27/h3-4,6,8,10-16,23-26H,5H2,1-2H3,(H,18,21)(H,28,29)(H,30,31)(H,19,22,27)/p-2/t6-,8+,10+,11+,12+,13-,14+,15+,16+/m0/s1",UDP-L-PneNAc(2-),PubMed citation,15778500
3054,62373,alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)]-beta-D-Manp,A branched trisaccharide consisting of beta-D-mannose having beta-D-xylosyl and alpha-D-mannosyl residues attached at the 2- and 6-positions respectively.,"InChI=1S/C17H30O15/c18-1-5-8(21)10(23)13(26)16(31-5)29-3-6-9(22)11(24)14(15(27)30-6)32-17-12(25)7(20)4(19)2-28-17/h4-27H,1-3H2/t4-,5-,6-,7+,8-,9-,10+,11+,12-,13+,14+,15-,16+,17+/m1/s1",alpha-D-mannosyl-(1->6)-[beta-D-xylosyl-(1->2)]-beta-D-mannose,PubMed citation,21237664
3055,62376,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp,A branched tetrasaccharide consisting of beta-D-mannose having two alpha-D-mannosyl residues attached at the 3- and 6-positions as well as a beta-D-xylosyl residue at the 2-position.,"InChI=1S/C23H40O20/c24-1-6-10(28)13(31)16(34)21(40-6)38-4-8-12(30)18(42-23-17(35)14(32)11(29)7(2-25)41-23)19(20(36)39-8)43-22-15(33)9(27)5(26)3-37-22/h5-36H,1-4H2/t5-,6-,7-,8-,9+,10-,11-,12-,13+,14+,15-,16+,17+,18+,19+,20-,21+,22+,23-/m1/s1",alpha-D-mannosyl-(1->3)-[alpha-D-mannosyl-(1->6)]-[beta-D-xylosyl-(1->2)]-beta-D-mannose,PubMed citation,21237664
3056,62380,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[beta-D-Glcp-(1->6)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)]beta-D-GlcpNAc-(1->3)-beta-D-Galp,A ten-membered branched glucosamine oligosaccharide consisting of two alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[beta-D-Glc-(1->6)]-beta-D-GlcNAc-(1->3)-beta-D-Gal units connected via a beta-(1->4) linkage from the galactose to the glucose.,"InChI=1S/C74H122N4O57/c1-17(87)75-33-21(91)5-73(71(113)114,132-57(33)37(95)23(93)7-79)134-61-42(100)28(12-84)122-69(52(61)110)128-55-31(15-117-66-48(106)46(104)39(97)25(9-81)120-66)126-65(36(45(55)103)78-20(4)90)131-60-41(99)27(11-83)121-68(51(60)109)127-54-30(14-86)124-67(49(107)47(54)105)118-16-32-56(44(102)35(77-19(3)89)64(125-32)130-59-40(98)26(10-82)119-63(112)50(59)108)129-70-53(111)62(43(101)29(13-85)123-70)135-74(72(115)116)6-22(92)34(76-18(2)88)58(133-74)38(96)24(94)8-80/h21-70,79-86,91-112H,5-16H2,1-4H3,(H,75,87)(H,76,88)(H,77,89)(H,78,90)(H,113,114)(H,115,116)/t21-,22-,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42-,43-,44+,45+,46-,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59-,60-,61-,62-,63+,64-,65-,66+,67+,68-,69-,70-,73-,74-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[beta-D-Glc-(1->6)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1->6)]beta-D-GlcNAc-(1->3)-beta-D-Gal,PubMed citation,12700231
3057,62381,alpha-Neup5Pr-(2->3)-beta-D-Galp-(1->4)-[alpha-Neup5Pr-(2->3)-beta-D-Galp-(1->4)-[beta-D-Glcp-(1->6)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)]beta-D-GlcpNAc-(1->3)-beta-D-Galp,A ten-membered branched glucosamine oligosaccharide consisting of two alpha-Neu5Pr-(2->3)-beta-D-Gal-(1->4)-[beta-D-Glc-(1->6)]-beta-D-GlcNAc-(1->3)-beta-D-Gal units connected via a beta-(1->4) linkage from the galactose to the glucose.,"InChI=1S/C76H126N4O57/c1-5-33(95)79-35-21(91)7-75(73(115)116,134-59(35)39(97)23(93)9-81)136-63-44(102)28(14-86)124-71(54(63)112)130-57-31(17-119-68-50(108)48(106)41(99)25(11-83)122-68)128-67(38(47(57)105)78-20(4)90)133-62-43(101)27(13-85)123-70(53(62)111)129-56-30(16-88)126-69(51(109)49(56)107)120-18-32-58(46(104)37(77-19(3)89)66(127-32)132-61-42(100)26(12-84)121-65(114)52(61)110)131-72-55(113)64(45(103)29(15-87)125-72)137-76(74(117)118)8-22(92)36(80-34(96)6-2)60(135-76)40(98)24(94)10-82/h21-32,35-72,81-88,91-94,97-114H,5-18H2,1-4H3,(H,77,89)(H,78,90)(H,79,95)(H,80,96)(H,115,116)(H,117,118)/t21-,22-,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,35+,36+,37+,38+,39+,40+,41+,42-,43-,44-,45-,46+,47+,48-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61-,62-,63-,64-,65+,66-,67-,68+,69+,70-,71-,72-,75-,76-/m0/s1",alpha-Neu5Pr-(2->3)-beta-D-Gal-(1->4)-[alpha-Neu5Pr-(2->3)-beta-D-Gal-(1->4)-[beta-D-Glc-(1->6)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1->6)]beta-D-GlcNAc-(1->3)-beta-D-Gal,PubMed citation,12700231
3058,62383,1D-myo-inositol 2-phosphate,A myo-inositol monophosphate in which the phosphate group is located at the 2-position.,"InChI=1S/C6H13O9P/c7-1-2(8)4(10)6(5(11)3(1)9)15-16(12,13)14/h1-11H,(H2,12,13,14)/t1-,2-,3+,4+,5-,6+",myo-inositol 2-phosphate,Reaxys Registry Number,2467378
3059,62385,CII259-273,"A fifteen-membered glycopeptide comprising glycyl, isoleucyl, alanyl, glycyl, phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C70H112N18O28/c1-5-34(2)55(86-48(92)28-73)68(112)79-35(3)60(104)75-29-51(95)82-44(26-37-12-7-6-8-13-37)66(110)84-40(17-16-38(27-72)115-70-59(103)58(102)57(101)46(33-89)116-70)62(106)77-31-49(93)80-42(19-22-53(97)98)64(108)83-41(18-21-47(74)91)63(107)78-32-52(96)88-25-11-15-45(88)67(111)85-39(14-9-10-24-71)61(105)76-30-50(94)81-43(20-23-54(99)100)65(109)87-56(36(4)90)69(113)114/h6-8,12-13,34-36,38-46,55-59,70,89-90,101-103H,5,9-11,14-33,71-73H2,1-4H3,(H2,74,91)(H,75,104)(H,76,105)(H,77,106)(H,78,107)(H,79,112)(H,80,93)(H,81,94)(H,82,95)(H,83,108)(H,84,110)(H,85,111)(H,86,92)(H,87,109)(H,97,98)(H,99,100)(H,113,114)/t34-,35-,36+,38+,39-,40-,41-,42-,43-,44-,45-,46+,55-,56-,57-,58-,59+,70+/m0/s1",GIAGFK(GalO)GEQGPKGET,PubMed citation,17944452
3060,62386,Gly-Ile-Ala-Gly-Phe(4-F)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, isoleucyl, alanyl, glycyl, 4-fluorophenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C70H111FN18O28/c1-5-33(2)55(87-48(93)27-74)68(113)80-34(3)60(105)76-28-51(96)83-44(25-36-11-13-37(71)14-12-36)66(111)85-40(16-15-38(26-73)116-70-59(104)58(103)57(102)46(32-90)117-70)62(107)78-30-49(94)81-42(18-21-53(98)99)64(109)84-41(17-20-47(75)92)63(108)79-31-52(97)89-24-8-10-45(89)67(112)86-39(9-6-7-23-72)61(106)77-29-50(95)82-43(19-22-54(100)101)65(110)88-56(35(4)91)69(114)115/h11-14,33-35,38-46,55-59,70,90-91,102-104H,5-10,15-32,72-74H2,1-4H3,(H2,75,92)(H,76,105)(H,77,106)(H,78,107)(H,79,108)(H,80,113)(H,81,94)(H,82,95)(H,83,96)(H,84,109)(H,85,111)(H,86,112)(H,87,93)(H,88,110)(H,98,99)(H,100,101)(H,114,115)/t33-,34-,35+,38+,39-,40-,41-,42-,43-,44-,45-,46+,55-,56-,57-,58-,59+,70+/m0/s1",GIAGF(4-F)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3061,62387,Gly-Ile-Ala-Gly-Tyr-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, isoleucyl, alanyl, glycyl, tyrosyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C70H112N18O29/c1-5-33(2)55(86-48(93)27-73)68(113)79-34(3)60(105)75-28-51(96)82-44(25-36-11-13-37(91)14-12-36)66(111)84-40(16-15-38(26-72)116-70-59(104)58(103)57(102)46(32-89)117-70)62(107)77-30-49(94)80-42(18-21-53(98)99)64(109)83-41(17-20-47(74)92)63(108)78-31-52(97)88-24-8-10-45(88)67(112)85-39(9-6-7-23-71)61(106)76-29-50(95)81-43(19-22-54(100)101)65(110)87-56(35(4)90)69(114)115/h11-14,33-35,38-46,55-59,70,89-91,102-104H,5-10,15-32,71-73H2,1-4H3,(H2,74,92)(H,75,105)(H,76,106)(H,77,107)(H,78,108)(H,79,113)(H,80,94)(H,81,95)(H,82,96)(H,83,109)(H,84,111)(H,85,112)(H,86,93)(H,87,110)(H,98,99)(H,100,101)(H,114,115)/t33-,34-,35+,38+,39-,40-,41-,42-,43-,44-,45-,46+,55-,56-,57-,58-,59+,70+/m0/s1",GlyIleAlaGlyPheTyrLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3062,62388,Gly-Ile-Ala-Gly-Ala(thiazol-4-yl)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, isoleucyl, alanyl, glycyl, 3-(1,3-thiazol-4-yl)alanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C67H109N19O28S/c1-5-31(2)52(84-45(90)23-70)65(110)77-32(3)57(102)72-24-48(93)80-41(21-34-29-115-30-76-34)63(108)82-37(12-11-35(22-69)113-67-56(101)55(100)54(99)43(28-87)114-67)59(104)74-26-46(91)78-39(14-17-50(95)96)61(106)81-38(13-16-44(71)89)60(105)75-27-49(94)86-20-8-10-42(86)64(109)83-36(9-6-7-19-68)58(103)73-25-47(92)79-40(15-18-51(97)98)62(107)85-53(33(4)88)66(111)112/h29-33,35-43,52-56,67,87-88,99-101H,5-28,68-70H2,1-4H3,(H2,71,89)(H,72,102)(H,73,103)(H,74,104)(H,75,105)(H,77,110)(H,78,91)(H,79,92)(H,80,93)(H,81,106)(H,82,108)(H,83,109)(H,84,90)(H,85,107)(H,95,96)(H,97,98)(H,111,112)/t31-,32-,33+,35+,36-,37-,38-,39-,40-,41-,42-,43+,52-,53-,54-,55-,56+,67+/m0/s1",GIAGA(thiazol-4-yl)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3063,62389,Gly-Hle-Ala-Gly-Phe(4-F)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, homoleucyl, alanyl, glycyl, 4-fluorophenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C71H113FN18O28/c1-34(2)10-16-43(82-50(94)28-75)65(110)81-35(3)61(106)77-29-53(97)85-46(26-37-11-13-38(72)14-12-37)68(113)87-41(17-15-39(27-74)117-71-60(105)59(104)58(103)48(33-91)118-71)63(108)79-31-51(95)83-44(19-22-55(99)100)66(111)86-42(18-21-49(76)93)64(109)80-32-54(98)90-25-7-9-47(90)69(114)88-40(8-5-6-24-73)62(107)78-30-52(96)84-45(20-23-56(101)102)67(112)89-57(36(4)92)70(115)116/h11-14,34-36,39-48,57-60,71,91-92,103-105H,5-10,15-33,73-75H2,1-4H3,(H2,76,93)(H,77,106)(H,78,107)(H,79,108)(H,80,109)(H,81,110)(H,82,94)(H,83,95)(H,84,96)(H,85,97)(H,86,111)(H,87,113)(H,88,114)(H,89,112)(H,99,100)(H,101,102)(H,115,116)/t35-,36+,39+,40-,41-,42-,43-,44-,45-,46-,47-,48+,57-,58-,59-,60+,71+/m0/s1",Gly(Hle)AlaGlyPhe(4-F)Lys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3064,62390,Gly-Hle-Ala-Gly-Cha-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, homoleucyl, alanyl, glycyl, cyclohexylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C71H120N18O28/c1-35(2)15-17-43(81-50(93)29-74)65(109)80-36(3)61(105)76-30-53(96)84-46(27-38-11-6-5-7-12-38)68(112)86-41(18-16-39(28-73)116-71-60(104)59(103)58(102)48(34-90)117-71)63(107)78-32-51(94)82-44(20-23-55(98)99)66(110)85-42(19-22-49(75)92)64(108)79-33-54(97)89-26-10-14-47(89)69(113)87-40(13-8-9-25-72)62(106)77-31-52(95)83-45(21-24-56(100)101)67(111)88-57(37(4)91)70(114)115/h35-48,57-60,71,90-91,102-104H,5-34,72-74H2,1-4H3,(H2,75,92)(H,76,105)(H,77,106)(H,78,107)(H,79,108)(H,80,109)(H,81,93)(H,82,94)(H,83,95)(H,84,96)(H,85,110)(H,86,112)(H,87,113)(H,88,111)(H,98,99)(H,100,101)(H,114,115)/t36-,37+,39+,40-,41-,42-,43-,44-,45-,46-,47-,48+,57-,58-,59-,60+,71+/m0/s1",G(Hle)AG(Cha)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3065,62391,Gly-Hle-Ala-Gly-Ala(thiazol-4-yl)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, homoleucyl, alanyl, glycyl, 3-(1,3-thiazol-4-yl)alanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C68H111N19O28S/c1-32(2)10-12-40(79-47(91)24-71)62(107)78-33(3)58(103)73-25-50(94)82-43(22-35-30-116-31-77-35)65(110)84-38(13-11-36(23-70)114-68-57(102)56(101)55(100)45(29-88)115-68)60(105)75-27-48(92)80-41(15-18-52(96)97)63(108)83-39(14-17-46(72)90)61(106)76-28-51(95)87-21-7-9-44(87)66(111)85-37(8-5-6-20-69)59(104)74-26-49(93)81-42(16-19-53(98)99)64(109)86-54(34(4)89)67(112)113/h30-34,36-45,54-57,68,88-89,100-102H,5-29,69-71H2,1-4H3,(H2,72,90)(H,73,103)(H,74,104)(H,75,105)(H,76,106)(H,78,107)(H,79,91)(H,80,92)(H,81,93)(H,82,94)(H,83,108)(H,84,110)(H,85,111)(H,86,109)(H,96,97)(H,98,99)(H,112,113)/t33-,34+,36+,37-,38-,39-,40-,41-,42-,43-,44-,45+,54-,55-,56-,57+,68+/m0/s1",Gly(Hle)AlaGlyAla(thiazol-4-yl)Lys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3066,62392,Gly-Cpa-Ala-Gly-Phe(3-Me)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, cyclopropylalanyl, alanyl, glycyl, 3-methylphenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C71H112N18O28/c1-34-8-6-9-38(24-34)26-46(84-53(96)29-76-61(105)35(2)80-67(111)45(25-37-12-13-37)83-50(93)28-74)68(112)86-41(15-14-39(27-73)116-71-60(104)59(103)58(102)48(33-90)117-71)63(107)78-31-51(94)81-43(17-20-55(98)99)65(109)85-42(16-19-49(75)92)64(108)79-32-54(97)89-23-7-11-47(89)69(113)87-40(10-4-5-22-72)62(106)77-30-52(95)82-44(18-21-56(100)101)66(110)88-57(36(3)91)70(114)115/h6,8-9,24,35-37,39-48,57-60,71,90-91,102-104H,4-5,7,10-23,25-33,72-74H2,1-3H3,(H2,75,92)(H,76,105)(H,77,106)(H,78,107)(H,79,108)(H,80,111)(H,81,94)(H,82,95)(H,83,93)(H,84,96)(H,85,109)(H,86,112)(H,87,113)(H,88,110)(H,98,99)(H,100,101)(H,114,115)/t35-,36+,39+,40-,41-,42-,43-,44-,45-,46-,47-,48+,57-,58-,59-,60+,71+/m0/s1",GA(Cy)AGF(3-Me)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3067,62393,Gly-Cpa-Ala-Gly-Cha-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, cyclopropylalanyl, alanyl, glycyl, cyclohexylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C70H116N18O28/c1-34(79-66(110)44(26-37-13-14-37)82-49(92)28-73)60(104)75-29-52(95)83-45(25-36-9-4-3-5-10-36)67(111)85-40(16-15-38(27-72)115-70-59(103)58(102)57(101)47(33-89)116-70)62(106)77-31-50(93)80-42(18-21-54(97)98)64(108)84-41(17-20-48(74)91)63(107)78-32-53(96)88-24-8-12-46(88)68(112)86-39(11-6-7-23-71)61(105)76-30-51(94)81-43(19-22-55(99)100)65(109)87-56(35(2)90)69(113)114/h34-47,56-59,70,89-90,101-103H,3-33,71-73H2,1-2H3,(H2,74,91)(H,75,104)(H,76,105)(H,77,106)(H,78,107)(H,79,110)(H,80,93)(H,81,94)(H,82,92)(H,83,95)(H,84,108)(H,85,111)(H,86,112)(H,87,109)(H,97,98)(H,99,100)(H,113,114)/t34-,35+,38+,39-,40-,41-,42-,43-,44-,45-,46-,47+,56-,57-,58-,59+,70+/m0/s1",GA(Cy)AG(Cha)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3068,62394,Gly-Cpa-Ala-Gly-Ala(4-Py)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, cyclopropylalanyl, alanyl, glycyl, 4-pyridylylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C69H109N19O28/c1-33(79-65(110)43(24-35-8-9-35)82-48(92)27-72)59(104)75-28-51(95)83-44(25-36-18-21-74-22-19-36)66(111)85-39(11-10-37(26-71)115-69-58(103)57(102)56(101)46(32-89)116-69)61(106)77-30-49(93)80-41(13-16-53(97)98)63(108)84-40(12-15-47(73)91)62(107)78-31-52(96)88-23-5-7-45(88)67(112)86-38(6-3-4-20-70)60(105)76-29-50(94)81-42(14-17-54(99)100)64(109)87-55(34(2)90)68(113)114/h18-19,21-22,33-35,37-46,55-58,69,89-90,101-103H,3-17,20,23-32,70-72H2,1-2H3,(H2,73,91)(H,75,104)(H,76,105)(H,77,106)(H,78,107)(H,79,110)(H,80,93)(H,81,94)(H,82,92)(H,83,95)(H,84,108)(H,85,111)(H,86,112)(H,87,109)(H,97,98)(H,99,100)(H,113,114)/t33-,34+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+,55-,56-,57-,58+,69+/m0/s1",GA(Cy)AGA(4-Py)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3069,62395,Gly-Chg-Ala-Gly-Phe(3-Me)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, cyclohexylglycyl, alanyl, glycyl, 3-methylphenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C73H116N18O28/c1-36-11-9-12-39(27-36)28-47(85-54(98)31-78-63(107)37(2)82-71(115)59(89-51(95)30-76)40-13-5-4-6-14-40)69(113)87-43(18-17-41(29-75)118-73-62(106)61(105)60(104)49(35-92)119-73)65(109)80-33-52(96)83-45(20-23-56(100)101)67(111)86-44(19-22-50(77)94)66(110)81-34-55(99)91-26-10-16-48(91)70(114)88-42(15-7-8-25-74)64(108)79-32-53(97)84-46(21-24-57(102)103)68(112)90-58(38(3)93)72(116)117/h9,11-12,27,37-38,40-49,58-62,73,92-93,104-106H,4-8,10,13-26,28-35,74-76H2,1-3H3,(H2,77,94)(H,78,107)(H,79,108)(H,80,109)(H,81,110)(H,82,115)(H,83,96)(H,84,97)(H,85,98)(H,86,111)(H,87,113)(H,88,114)(H,89,95)(H,90,112)(H,100,101)(H,102,103)(H,116,117)/t37-,38+,41+,42-,43-,44-,45-,46-,47-,48-,49+,58-,59-,60-,61-,62+,73+/m0/s1",G(Chg)AGF(3-Me)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3070,62396,Gly-Chg-Ala-Gly-Tyr-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, cyclohexylglycyl, alanyl, glycyl, tyrosyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C72H114N18O29/c1-35(81-70(115)58(88-50(95)29-75)38-9-4-3-5-10-38)62(107)77-30-53(98)84-46(27-37-13-15-39(93)16-14-37)68(113)86-42(18-17-40(28-74)118-72-61(106)60(105)59(104)48(34-91)119-72)64(109)79-32-51(96)82-44(20-23-55(100)101)66(111)85-43(19-22-49(76)94)65(110)80-33-54(99)90-26-8-12-47(90)69(114)87-41(11-6-7-25-73)63(108)78-31-52(97)83-45(21-24-56(102)103)67(112)89-57(36(2)92)71(116)117/h13-16,35-36,38,40-48,57-61,72,91-93,104-106H,3-12,17-34,73-75H2,1-2H3,(H2,76,94)(H,77,107)(H,78,108)(H,79,109)(H,80,110)(H,81,115)(H,82,96)(H,83,97)(H,84,98)(H,85,111)(H,86,113)(H,87,114)(H,88,95)(H,89,112)(H,100,101)(H,102,103)(H,116,117)/t35-,36+,40+,41-,42-,43-,44-,45-,46-,47-,48+,57-,58-,59-,60-,61+,72+/m0/s1",G(Chg)AGYK(5-GalO)GEQGPKGET,PubMed citation,21423632
3071,62397,Gly-Chg-Ala-Gly-Ala(4-Py)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, cyclohexylglycyl, alanyl, glycyl, 4-pyridylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C71H113N19O28/c1-35(81-69(114)57(88-49(94)29-74)38-9-4-3-5-10-38)61(106)77-30-52(97)84-45(27-37-21-24-76-25-22-37)67(112)86-41(14-13-39(28-73)117-71-60(105)59(104)58(103)47(34-91)118-71)63(108)79-32-50(95)82-43(16-19-54(99)100)65(110)85-42(15-18-48(75)93)64(109)80-33-53(98)90-26-8-12-46(90)68(113)87-40(11-6-7-23-72)62(107)78-31-51(96)83-44(17-20-55(101)102)66(111)89-56(36(2)92)70(115)116/h21-22,24-25,35-36,38-47,56-60,71,91-92,103-105H,3-20,23,26-34,72-74H2,1-2H3,(H2,75,93)(H,77,106)(H,78,107)(H,79,108)(H,80,109)(H,81,114)(H,82,95)(H,83,96)(H,84,97)(H,85,110)(H,86,112)(H,87,113)(H,88,94)(H,89,111)(H,99,100)(H,101,102)(H,115,116)/t35-,36+,39+,40-,41-,42-,43-,44-,45-,46-,47+,56-,57-,58-,59-,60+,71+/m0/s1",G(Chg)AGA(4-Py)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3072,62398,Gly-Ala(thiazol-4-yl)-Ala-Gly-Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, 3-(1,3-thiazol-4-yl)alanyl, alanyl, glycyl, phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C70H107N19O28S/c1-34(80-66(111)45(83-49(93)26-73)24-37-32-118-33-79-37)60(105)75-27-52(96)84-44(23-36-9-4-3-5-10-36)67(112)86-40(14-13-38(25-72)116-70-59(104)58(103)57(102)47(31-90)117-70)62(107)77-29-50(94)81-42(16-19-54(98)99)64(109)85-41(15-18-48(74)92)63(108)78-30-53(97)89-22-8-12-46(89)68(113)87-39(11-6-7-21-71)61(106)76-28-51(95)82-43(17-20-55(100)101)65(110)88-56(35(2)91)69(114)115/h3-5,9-10,32-35,38-47,56-59,70,90-91,102-104H,6-8,11-31,71-73H2,1-2H3,(H2,74,92)(H,75,105)(H,76,106)(H,77,107)(H,78,108)(H,80,111)(H,81,94)(H,82,95)(H,83,93)(H,84,96)(H,85,109)(H,86,112)(H,87,113)(H,88,110)(H,98,99)(H,100,101)(H,114,115)/t34-,35+,38+,39-,40-,41-,42-,43-,44-,45-,46-,47+,56-,57-,58-,59+,70+/m0/s1",GlyAla(thiazol-4-yl)AlaGlyPheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3073,62399,Gly-Ala(thiazol-4-yl)-Ala-Gly-Phe(3-Me)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, 3-(1,3-thiazol-4-yl)alanyl, alanyl, glycyl, 3-methylphenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C71H109N19O28S/c1-34-8-6-9-37(22-34)23-45(85-53(97)27-76-61(106)35(2)81-67(112)46(84-50(94)26-74)24-38-32-119-33-80-38)68(113)87-41(13-12-39(25-73)117-71-60(105)59(104)58(103)48(31-91)118-71)63(108)78-29-51(95)82-43(15-18-55(99)100)65(110)86-42(14-17-49(75)93)64(109)79-30-54(98)90-21-7-11-47(90)69(114)88-40(10-4-5-20-72)62(107)77-28-52(96)83-44(16-19-56(101)102)66(111)89-57(36(3)92)70(115)116/h6,8-9,22,32-33,35-36,39-48,57-60,71,91-92,103-105H,4-5,7,10-21,23-31,72-74H2,1-3H3,(H2,75,93)(H,76,106)(H,77,107)(H,78,108)(H,79,109)(H,81,112)(H,82,95)(H,83,96)(H,84,94)(H,85,97)(H,86,110)(H,87,113)(H,88,114)(H,89,111)(H,99,100)(H,101,102)(H,115,116)/t35-,36+,39+,40-,41-,42-,43-,44-,45-,46-,47-,48+,57-,58-,59-,60+,71+/m0/s1",GlyAla(thiazol-4-yl)AlaGlyPhe(3-Me)Lys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3074,62400,Gly-Ala(thiazol-4-yl)-Ala-Gly-Ala(4-Py)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, 3-(1,3-thiazol-4-yl)alanyl, alanyl, glycyl, 4-pyridylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C69H106N20O28S/c1-33(80-65(111)44(83-48(93)25-72)23-36-31-118-32-79-36)59(105)75-26-51(96)84-43(22-35-16-19-74-20-17-35)66(112)86-39(9-8-37(24-71)116-69-58(104)57(103)56(102)46(30-90)117-69)61(107)77-28-49(94)81-41(11-14-53(98)99)63(109)85-40(10-13-47(73)92)62(108)78-29-52(97)89-21-5-7-45(89)67(113)87-38(6-3-4-18-70)60(106)76-27-50(95)82-42(12-15-54(100)101)64(110)88-55(34(2)91)68(114)115/h16-17,19-20,31-34,37-46,55-58,69,90-91,102-104H,3-15,18,21-30,70-72H2,1-2H3,(H2,73,92)(H,75,105)(H,76,106)(H,77,107)(H,78,108)(H,80,111)(H,81,94)(H,82,95)(H,83,93)(H,84,96)(H,85,109)(H,86,112)(H,87,113)(H,88,110)(H,98,99)(H,100,101)(H,114,115)/t33-,34+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+,55-,56-,57-,58+,69+/m0/s1",GlyAla(thiazol-4-yl)AlaGlyAla(4-Py)Lys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3075,62401,Gly-Gln-Ala-Gly-Ala(thiazol-4-yl)-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, glutaminyl, alanyl, glycyl, 3-(1,3-thiazol-4-yl)alanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C66H106N20O29S/c1-30(77-60(107)37(11-15-44(71)90)78-45(91)22-69)56(103)72-23-48(94)81-40(20-32-28-116-29-76-32)63(110)83-35(9-8-33(21-68)114-66-55(102)54(101)53(100)42(27-87)115-66)58(105)74-25-46(92)79-38(12-16-50(96)97)61(108)82-36(10-14-43(70)89)59(106)75-26-49(95)86-19-5-7-41(86)64(111)84-34(6-3-4-18-67)57(104)73-24-47(93)80-39(13-17-51(98)99)62(109)85-52(31(2)88)65(112)113/h28-31,33-42,52-55,66,87-88,100-102H,3-27,67-69H2,1-2H3,(H2,70,89)(H2,71,90)(H,72,103)(H,73,104)(H,74,105)(H,75,106)(H,77,107)(H,78,91)(H,79,92)(H,80,93)(H,81,94)(H,82,108)(H,83,110)(H,84,111)(H,85,109)(H,96,97)(H,98,99)(H,112,113)/t30-,31+,33+,34-,35-,36-,37-,38-,39-,40-,41-,42+,52-,53-,54-,55+,66+/m0/s1",GQAGA(thiazol-4-yl)K(5-GalO)GEQGPKGET,PubMed citation,21423632
3076,62402,Gly-Gln-Ala-Gly-Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, glutaminyl, alanyl, glycyl, phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C69H109N19O29/c1-33(79-63(109)40(16-20-47(74)92)80-48(93)27-72)59(105)75-28-51(96)83-43(25-35-9-4-3-5-10-35)66(112)85-38(14-13-36(26-71)116-69-58(104)57(103)56(102)45(32-89)117-69)61(107)77-30-49(94)81-41(17-21-53(98)99)64(110)84-39(15-19-46(73)91)62(108)78-31-52(97)88-24-8-12-44(88)67(113)86-37(11-6-7-23-70)60(106)76-29-50(95)82-42(18-22-54(100)101)65(111)87-55(34(2)90)68(114)115/h3-5,9-10,33-34,36-45,55-58,69,89-90,102-104H,6-8,11-32,70-72H2,1-2H3,(H2,73,91)(H2,74,92)(H,75,105)(H,76,106)(H,77,107)(H,78,108)(H,79,109)(H,80,93)(H,81,94)(H,82,95)(H,83,96)(H,84,110)(H,85,112)(H,86,113)(H,87,111)(H,98,99)(H,100,101)(H,114,115)/t33-,34+,36+,37-,38-,39-,40-,41-,42-,43-,44-,45+,55-,56-,57-,58+,69+/m0/s1",GlyGlnAlaGlyPheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3077,62403,Gly-Gln-Ala-Gly-Tyr-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, glutaminyl, alanyl, glycyl, tyrosyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C69H109N19O30/c1-32(79-63(110)40(15-19-47(74)93)80-48(94)26-72)59(106)75-27-51(97)83-43(24-34-8-10-35(91)11-9-34)66(113)85-38(13-12-36(25-71)117-69-58(105)57(104)56(103)45(31-89)118-69)61(108)77-29-49(95)81-41(16-20-53(99)100)64(111)84-39(14-18-46(73)92)62(109)78-30-52(98)88-23-5-7-44(88)67(114)86-37(6-3-4-22-70)60(107)76-28-50(96)82-42(17-21-54(101)102)65(112)87-55(33(2)90)68(115)116/h8-11,32-33,36-45,55-58,69,89-91,103-105H,3-7,12-31,70-72H2,1-2H3,(H2,73,92)(H2,74,93)(H,75,106)(H,76,107)(H,77,108)(H,78,109)(H,79,110)(H,80,94)(H,81,95)(H,82,96)(H,83,97)(H,84,111)(H,85,113)(H,86,114)(H,87,112)(H,99,100)(H,101,102)(H,115,116)/t32-,33+,36+,37-,38-,39-,40-,41-,42-,43-,44-,45+,55-,56-,57-,58+,69+/m0/s1",GQAGYK(5-GalO)GEQGPKGET,PubMed citation,21423632
3078,62404,Gly-Aic-Ala-Gly-Cha-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, 2-aminoindane-2-formyl, alanyl, glycyl, cyclohexylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C74H116N18O28/c1-37(83-73(118)74(91-52(96)31-77)28-40-13-6-7-14-41(40)29-74)63(108)79-32-55(99)86-48(27-39-11-4-3-5-12-39)69(114)88-44(18-17-42(30-76)119-72-62(107)61(106)60(105)50(36-93)120-72)65(110)81-34-53(97)84-46(20-23-57(101)102)67(112)87-45(19-22-51(78)95)66(111)82-35-56(100)92-26-10-16-49(92)70(115)89-43(15-8-9-25-75)64(109)80-33-54(98)85-47(21-24-58(103)104)68(113)90-59(38(2)94)71(116)117/h6-7,13-14,37-39,42-50,59-62,72,93-94,105-107H,3-5,8-12,15-36,75-77H2,1-2H3,(H2,78,95)(H,79,108)(H,80,109)(H,81,110)(H,82,111)(H,83,118)(H,84,97)(H,85,98)(H,86,99)(H,87,112)(H,88,114)(H,89,115)(H,90,113)(H,91,96)(H,101,102)(H,103,104)(H,116,117)/t37-,38+,42+,43-,44-,45-,46-,47-,48-,49-,50+,59-,60-,61-,62+,72+/m0/s1",Gly(Aic)AlaGly(Cha)Lys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21423632
3079,62405,Gly-Aic-Ala-Gly-Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A fifteen-membered glycopeptide comprising glycyl, 2-aminoindane-2-formyl, alanyl, glycyl, phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence.","InChI=1S/C74H110N18O28/c1-37(83-73(118)74(91-52(96)31-77)28-40-13-6-7-14-41(40)29-74)63(108)79-32-55(99)86-48(27-39-11-4-3-5-12-39)69(114)88-44(18-17-42(30-76)119-72-62(107)61(106)60(105)50(36-93)120-72)65(110)81-34-53(97)84-46(20-23-57(101)102)67(112)87-45(19-22-51(78)95)66(111)82-35-56(100)92-26-10-16-49(92)70(115)89-43(15-8-9-25-75)64(109)80-33-54(98)85-47(21-24-58(103)104)68(113)90-59(38(2)94)71(116)117/h3-7,11-14,37-38,42-50,59-62,72,93-94,105-107H,8-10,15-36,75-77H2,1-2H3,(H2,78,95)(H,79,108)(H,80,109)(H,81,110)(H,82,111)(H,83,118)(H,84,97)(H,85,98)(H,86,99)(H,87,112)(H,88,114)(H,89,115)(H,90,113)(H,91,96)(H,101,102)(H,103,104)(H,116,117)/t37-,38+,42+,43-,44-,45-,46-,47-,48-,49-,50+,59-,60-,61-,62+,72+/m0/s1",G(Aic)AGFK(5-GalO)GEQGPKGET,PubMed citation,21423632
3080,62407,UDP-N-acetyl-beta-L-fucosamine,A UDP-amino sugar having N-acetyl-beta-L-fucosamine as the amino sugar component.,"InChI=1S/C17H27N3O16P2/c1-6-11(23)13(25)10(18-7(2)21)16(33-6)35-38(30,31)36-37(28,29)32-5-8-12(24)14(26)15(34-8)20-4-3-9(22)19-17(20)27/h3-4,6,8,10-16,23-26H,5H2,1-2H3,(H,18,21)(H,28,29)(H,30,31)(H,19,22,27)/t6-,8+,10-,11+,12+,13-,14+,15+,16+/m0/s1","UDP-2-acetamido-2,6-dideoxy-L-galactose",PubMed citation,15778500
3081,62408,"trans,trans-octa-2,4-dienoyl-CoA","A trans,trans-2,3,4,5-tetradehydroacyl-CoA having trans,trans-octa-2,4-dienoyl as the S-acyl component.","InChI=1S/C29H46N7O17P3S/c1-4-5-6-7-8-9-20(38)57-13-12-31-19(37)10-11-32-27(41)24(40)29(2,3)15-50-56(47,48)53-55(45,46)49-14-18-23(52-54(42,43)44)22(39)28(51-18)36-17-35-21-25(30)33-16-34-26(21)36/h6-9,16-18,22-24,28,39-40H,4-5,10-15H2,1-3H3,(H,31,37)(H,32,41)(H,45,46)(H,47,48)(H2,30,33,34)(H2,42,43,44)/b7-6+,9-8+/t18-,22-,23-,24+,28-/m1/s1","(E,E)-octa-2,4-dienoyl-CoA",Reaxys Registry Number,10324979
3082,62410,"UDP-2-acetamido-3-amino-2,3-dideoxy-alpha-D-glucuronic acid","A UDP-amino sugar having 2-acetamido-3-amino-2,3-dideoxy-alpha-D-glucuronic acid as the amino sugar component.","InChI=1S/C17H26N4O17P2/c1-5(22)19-9-8(18)11(25)13(15(27)28)36-16(9)37-40(32,33)38-39(30,31)34-4-6-10(24)12(26)14(35-6)21-3-2-7(23)20-17(21)29/h2-3,6,8-14,16,24-26H,4,18H2,1H3,(H,19,22)(H,27,28)(H,30,31)(H,32,33)(H,20,23,29)/t6-,8-,9-,10-,11+,12-,13+,14-,16-/m1/s1",UDP-GlcNAc3NA,PubMed citation,20433200
3083,62412,phenazine-1-carboxylic acid,An aromatic carboxylic acid that is phenazine substituted at C-1 with a carboxy group.,"InChI=1S/C13H8N2O2/c16-13(17)8-4-3-7-11-12(8)15-10-6-2-1-5-9(10)14-11/h1-7H,(H,16,17)",1-carboxyphenazine,PubMed citation,12458768
3084,62413,(S)-methylmalonate semialdehyde,2-Methyl-3-oxopropanoate with S configuration at the chiral centre.,"InChI=1S/C4H6O3/c1-3(2-5)4(6)7/h2-3H,1H3,(H,6,7)/p-1/t3-/m0/s1",(S)-2-methyl-3-oxopropanoate (1-),MetaCyc accession,CH3-MALONATE-S-ALD
3085,62414,biotinyl-5'-AMP(1-),The organophosphate oxoanion that is the monoanion formed from biotinyl-5'-AMP by loss of a proton from the phospho group; major microspecies at pH 7.3.,"InChI=1S/C20H28N7O9PS/c21-17-14-18(23-7-22-17)27(8-24-14)19-16(30)15(29)10(35-19)5-34-37(32,33)36-12(28)4-2-1-3-11-13-9(6-38-11)25-20(31)26-13/h7-11,13,15-16,19,29-30H,1-6H2,(H,32,33)(H2,21,22,23)(H2,25,26,31)/p-1/t9-,10+,11-,13-,15+,16+,19+/m0/s1",biotinyl-5'-adenylate (1-),MetaCyc accession,BIO-5-AMP
3086,62418,3-oxohexanoyl-CoA(4-),The organophosphate oxoanion that is the tetraanion formed from 3-oxohexanoyl-CoA by loss of two protons from the 5'-diphospho linkage and two protons from the 3'-phospho group; major micropspecies at pH 7.3.,"InChI=1S/C27H44N7O18P3S/c1-4-5-15(35)10-18(37)56-9-8-29-17(36)6-7-30-25(40)22(39)27(2,3)12-49-55(46,47)52-54(44,45)48-11-16-21(51-53(41,42)43)20(38)26(50-16)34-14-33-19-23(28)31-13-32-24(19)34/h13-14,16,20-22,26,38-39H,4-12H2,1-3H3,(H,29,36)(H,30,40)(H,44,45)(H,46,47)(H2,28,31,32)(H2,41,42,43)/p-4/t16-,20-,21-,22+,26-/m1/s1",ketohexanoyl-CoA (4-),MetaCyc accession,K-HEXANOYL-COA
3087,62419,"(1R,2S)-epoxypropylphosphonate(2-)","An organophosphonate oxoanion obtained by deprotonation of the two phosphonate OH groups of (1R,2S)-epoxypropylphosphonic acid.","InChI=1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/p-2/t2-,3+/m0/s1",fosfomycin,PubMed citation,832538
3088,62423,(2-hydroxyphenyl)acetate,The monocarboxylic acid anion formed from (2-hydroxyphenyl)acetic acid by loss of a proton from the carboxy group; major microspecies at pH 7.3.,"InChI=1S/C8H8O3/c9-7-4-2-1-3-6(7)5-8(10)11/h1-4,9H,5H2,(H,10,11)/p-1",2-hydroxybenzeneacetic acid (1-),Reaxys Registry Number,3665522
3089,62436,(+)-abscisic acid D-glucopyranosyl ester,A carboxylic ester resulting from the condensation of the carboxylic acid group of (+)-abscisic acid with the anomeric hydroxy group of  D-glucopyranose.,"InChI=1S/C21H30O9/c1-11(5-6-21(28)12(2)8-13(23)9-20(21,3)4)7-15(24)30-19-18(27)17(26)16(25)14(10-22)29-19/h5-8,14,16-19,22,25-28H,9-10H2,1-4H3/b6-5+,11-7-/t14-,16-,17+,18-,19?,21-/m1/s1",ABA-GE,PubMed citation,12114582
3090,62437,(S)-2-trans-abscisic acid beta-D-glucopyranosyl ester,An (S)-2-trans-abscisic acid D-glucopyranosyl ester derived from beta-D-glucopyranose.,"InChI=1S/C21H30O9/c1-11(5-6-21(28)12(2)8-13(23)9-20(21,3)4)7-15(24)30-19-18(27)17(26)16(25)14(10-22)29-19/h5-8,14,16-19,22,25-28H,9-10H2,1-4H3/b6-5+,11-7+/t14-,16-,17+,18-,19+,21-/m1/s1",2-trans-(+)-abscisic acid beta-D-glucopyranosyl ester,PubMed citation,12114582
3091,62438,(S)-2-trans-abscisic acid D-glucopyranosyl ester,A carboxylic ester that results from the condensation of the carboxylic acid group of (S)-2-trans-abscisic acid with the anomeric hydroxy group of D-glucopyranose.,"InChI=1S/C21H30O9/c1-11(5-6-21(28)12(2)8-13(23)9-20(21,3)4)7-15(24)30-19-18(27)17(26)16(25)14(10-22)29-19/h5-8,14,16-19,22,25-28H,9-10H2,1-4H3/b6-5+,11-7+/t14-,16-,17+,18-,19?,21-/m1/s1","1-O-{(2E,4S)-5-[(1S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl]-3-methylpenta-2,4-dienoyl}-D-glucopyranose",PubMed citation,12114582
3092,62439,soyasapogenol B 3-O-beta-glucuronide,A triterpenoid saponin that is the 3-O-beta-glucuronide of soyasapogenol B.,"InChI=1S/C36H58O9/c1-31(2)16-20-19-8-9-22-33(4)12-11-24(44-30-27(41)25(39)26(40)28(45-30)29(42)43)34(5,18-37)21(33)10-13-36(22,7)35(19,6)15-14-32(20,3)23(38)17-31/h8,20-28,30,37-41H,9-18H2,1-7H3,(H,42,43)/t20-,21+,22+,23+,24-,25-,26-,27+,28-,30+,32+,33-,34+,35+,36+/m0/s1",soyasapogenol B monoglucuronide,Reaxys Registry Number,8025979
3093,62441,soyasapogenol B 3-O-beta-glucuronate,A monocarboxylic acid anion that results from the removal of a proton from the carboxy group of soyasapogenol B 3-O-beta-glucuronide.,"InChI=1S/C36H58O9/c1-31(2)16-20-19-8-9-22-33(4)12-11-24(44-30-27(41)25(39)26(40)28(45-30)29(42)43)34(5,18-37)21(33)10-13-36(22,7)35(19,6)15-14-32(20,3)23(38)17-31/h8,20-28,30,37-41H,9-18H2,1-7H3,(H,42,43)/p-1/t20-,21+,22+,23+,24-,25-,26-,27+,28-,30+,32+,33-,34+,35+,36+/m0/s1",soyasapogenol B 3-O-beta-glucuronide(1-),PubMed citation,12172845
3094,62442,soyasapogenol A 3-O-beta-glucuronide,A triterpenoid saponin that is the 3-O-beta-glucuronide of soyasapogenol A.,"InChI=1S/C36H58O10/c1-31(2)16-19-18-8-9-21-33(4)12-11-22(45-30-25(40)23(38)24(39)26(46-30)29(43)44)34(5,17-37)20(33)10-13-36(21,7)35(18,6)15-14-32(19,3)28(42)27(31)41/h8,19-28,30,37-42H,9-17H2,1-7H3,(H,43,44)/t19-,20+,21+,22-,23-,24-,25+,26-,27-,28+,30+,32+,33-,34+,35+,36+/m0/s1",soyasapogenol A monoglucuronide,PubMed citation,12172845
3095,62443,soyasapogenol A 3-O-beta-glucuronate,A monocarboxylic acid anion that results from the removal of a proton from the carboxy group of soyasapogenol A 3-O-beta-glucuronide.,"InChI=1S/C36H58O10/c1-31(2)16-19-18-8-9-21-33(4)12-11-22(45-30-25(40)23(38)24(39)26(46-30)29(43)44)34(5,17-37)20(33)10-13-36(21,7)35(18,6)15-14-32(19,3)28(42)27(31)41/h8,19-28,30,37-42H,9-17H2,1-7H3,(H,43,44)/p-1/t19-,20+,21+,22-,23-,24-,25+,26-,27-,28+,30+,32+,33-,34+,35+,36+/m0/s1",soyasapogenol A 3-O-beta-glucuronide(1-),PubMed citation,12172845
3096,62445,soyasapogenol E 3-O-beta-glucuronide,A saponin that is the 3-O-beta-glucuronide of soyasapogenol E.,"InChI=1S/C36H56O9/c1-31(2)16-20-19-8-9-22-33(4)12-11-24(44-30-27(41)25(39)26(40)28(45-30)29(42)43)34(5,18-37)21(33)10-13-36(22,7)35(19,6)15-14-32(20,3)23(38)17-31/h8,20-22,24-28,30,37,39-41H,9-18H2,1-7H3,(H,42,43)/t20-,21+,22+,24-,25-,26-,27+,28-,30+,32+,33-,34+,35+,36+/m0/s1",soyasapogenol E monoglucuronide,PubMed citation,12172845
3097,62451,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-D-GlcpNAc,A branched amino tetrasaccharide comprising N-acetyl-D-glucosamine at the reducing end with a N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 3-position.,"InChI=1S/C28H48N2O20/c1-7-15(36)20(41)21(42)27(44-7)50-24-23(49-26-13(29-8(2)34)19(40)16(37)10(4-31)46-26)18(39)12(6-33)47-28(24)48-22-14(30-9(3)35)25(43)45-11(5-32)17(22)38/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17+,18-,19+,20+,21-,22+,23-,24+,25?,26+,27-,28-/m0/s1",alpha-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-D-GlcNAc,KEGG GLYCAN accession,G00358
3098,62453,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-D-GlcpNAc,A branched amino tetrasaccharide comprising N-acetyl-D-glucosamine at the reducing end with a N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C28H48N2O20/c1-7-15(36)20(41)21(42)27(44-7)50-24-23(49-26-14(30-9(3)35)18(39)16(37)10(4-31)46-26)17(38)11(5-32)47-28(24)48-22-12(6-33)45-25(43)13(19(22)40)29-8(2)34/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20+,21-,22+,23-,24+,25?,26+,27-,28-/m0/s1",alpha-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-D-GlcNAc,KEGG GLYCAN accession,G00440
3099,62461,helvolate,The steroid acid anion formed by loss of a proton from the carboxy group of helvolic acid; major microspecies at pH 7.3.,"InChI=1S/C33H44O8/c1-17(2)10-9-11-21(30(38)39)26-22-12-13-25-31(6)15-14-23(36)18(3)27(31)28(41-20(5)35)29(37)33(25,8)32(22,7)16-24(26)40-19(4)34/h10,14-15,18,22,24-25,27-28H,9,11-13,16H2,1-8H3,(H,38,39)/p-1/b26-21-/t18-,22+,24+,25+,27-,28+,31-,32+,33-/m1/s1","16-(Acetyloxy)-3,7-dioxo-29-nordammara-1,17(20),24-trien-21-oate",PubMed citation,19216560
3100,62463,"7,9,9'-tri-cis-neurosporene","An acyclic carotene having the structure 7',8'-dihydro-psi,psi-carotene with cis-double bonds at C-7, C-9 and C-9'.","InChI=1S/C40H58/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-17,19-22,25-31H,13-14,18,23-24,32H2,1-10H3/b12-11+,25-15+,26-16+,31-17-,35-21+,36-22+,37-27+,38-28+,39-29-,40-30-","7,9,9'-tricis-neurosporene",PubMed citation,15503129
3101,62466,"7,7',9,9'-tetra-cis-lycopene","An acyclic psi,psi-carotene having cis double bonds at C-7, -7', -9 and -9'.","InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17-,32-18-,35-21+,36-22+,37-27+,38-28+,39-29-,40-30-","7,9,7',9'-tetracis-lycopene",PubMed citation,15503129
3102,62469,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,"A linear amino tetrasaccharide consisting of alpha-fucosyl, beta-galactosyl, beta-glucosaminyl and beta-galactose units connected via sequential (1->2)-, (1->3)- and (1->3)-linkages.","InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)25(41-6)47-22-17(37)13(33)8(3-28)44-26(22)45-20-11(27-7(2)31)24(43-10(5-30)14(20)34)46-21-15(35)9(4-29)42-23(40)19(21)39/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14+,15-,16+,17-,18-,19+,20+,21-,22+,23+,24-,25-,26-/m0/s1",alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactose,PubMed citation,3944091
3103,62471,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A linear amino pentasaccharide consisting of alpha-fucosyl, beta-galactosyl, beta-glucosaminyl,  beta-galactosyl and glucose units connected via sequential (1->2)-, (1->4)-, (1->3)- and (1->4)-linkages.","InChI=1S/C32H55NO25/c1-7-14(39)18(43)22(47)30(50-7)58-27-19(44)15(40)9(3-34)53-32(27)56-24-12(6-37)54-29(13(17(24)42)33-8(2)38)57-26-16(41)10(4-35)52-31(23(26)48)55-25-11(5-36)51-28(49)21(46)20(25)45/h7,9-32,34-37,39-49H,3-6H2,1-2H3,(H,33,38)/t7-,9+,10+,11+,12+,13+,14+,15-,16-,17+,18+,19-,20+,21+,22-,23+,24+,25+,26-,27+,28?,29-,30-,31-,32-/m0/s1",alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose,KEGG GLYCAN accession,G12291
3104,62474,"all-trans-3,4-didehydrolycopene",An acyclic carotene having the structure of lycopene with two hydrogen atoms abstracted from the C(3)-C(4) bond to form an extra trans double bond.,"InChI=1S/C40H54/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-13,15-23,25-32H,14,24H2,1-10H3/b12-11+,23-13+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+","3,4-dehydrolycopene",Reaxys Registry Number,1845133
3105,62475,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A seven-membered glucosamine oligosaccharide made up from one glucose, one fucose, two glucosamine and three galactose units in a linear sequence, linked as shown.","InChI=1S/C46H78N2O35/c1-10-21(57)27(63)31(67)43(71-10)83-39-28(64)22(58)13(4-49)75-46(39)80-35-18(9-54)77-42(20(26(35)62)48-12(3)56)81-37-23(59)14(5-50)73-44(32(37)68)78-34-17(8-53)76-41(19(25(34)61)47-11(2)55)82-38-24(60)15(6-51)74-45(33(38)69)79-36-16(7-52)72-40(70)30(66)29(36)65/h10,13-46,49-54,57-70H,4-9H2,1-3H3,(H,47,55)(H,48,56)/t10-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-,25+,26+,27+,28-,29+,30+,31-,32+,33+,34+,35+,36+,37-,38-,39+,40?,41-,42-,43-,44-,45-,46-/m0/s1",alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose,KEGG GLYCAN accession,G12225
3106,62482,4-deoxy-beta-L-threo-hex-4-enopyranuronate,A hexuronate that results from the removal of a proton from the carboxy group of 4-deoxy-beta-L-threo-hex-4-enopyranuronic acid.,"InChI=1S/C6H8O6/c7-2-1-3(5(9)10)12-6(11)4(2)8/h1-2,4,6-8,11H,(H,9,10)/p-1/t2-,4+,6-/m0/s1",4-deoxy-L-threo-5-hexosulose-uronate,MetaCyc accession,CPD-13122
3107,62483,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A branched ten-membered glucosamine oligosaccharide consisting of two fucose, three glucosamine, one glucose (at the reducing end) and four galactose units, linked as shown.","InChI=1S/C66H111N3O49/c1-14-30(80)39(89)45(95)61(101-14)117-55-41(91)32(82)19(6-70)105-65(55)113-50-23(10-74)107-58(27(36(50)86)67-16(3)77)100-13-26-35(85)54(116-60-29(69-18(5)79)38(88)51(25(12-76)109-60)114-66-56(42(92)33(83)20(7-71)106-66)118-62-46(96)40(90)31(81)15(2)102-62)48(98)64(110-26)111-49-24(11-75)108-59(28(37(49)87)68-17(4)78)115-53-34(84)21(8-72)104-63(47(53)97)112-52-22(9-73)103-57(99)44(94)43(52)93/h14-15,19-66,70-76,80-99H,6-13H2,1-5H3,(H,67,77)(H,68,78)(H,69,79)/t14-,15-,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32-,33-,34-,35-,36+,37+,38+,39+,40+,41-,42-,43+,44+,45-,46-,47+,48+,49+,50+,51+,52+,53-,54-,55+,56+,57?,58+,59-,60-,61-,62-,63-,64-,65-,66-/m0/s1",alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose,KEGG GLYCAN accession,G12039
3108,62484,alpha-L-Fucp-(1->2) -[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-alpha-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A branched eight-membered glucosamine oligosaccharide consisting of two fucose, two glucosamine, one glucose (at the reducing end) and three galactose units, linked as shown.","InChI=1S/C52H88N2O39/c1-11-23(63)30(70)35(75)48(79-11)92-43-32(72)25(65)15(5-55)84-51(43)89-40-22(54-14(4)62)47(82-16(6-56)26(40)66)91-42-28(68)18(8-58)85-52(44(42)93-49-36(76)31(71)24(64)12(2)80-49)88-38-20(10-60)86-46(21(29(38)69)53-13(3)61)90-41-27(67)17(7-57)83-50(37(41)77)87-39-19(9-59)81-45(78)34(74)33(39)73/h11-12,15-52,55-60,63-78H,5-10H2,1-4H3,(H,53,61)(H,54,62)/t11-,12-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26+,27-,28-,29+,30+,31+,32-,33+,34+,35-,36-,37+,38+,39+,40+,41-,42-,43+,44+,45?,46-,47+,48-,49-,50-,51-,52-/m0/s1",alpha-L-Fuc-(1->2) -[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-alpha-D-GlcNAc-(1->3)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,PubMed citation,3944091
3109,62485,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc,An alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-D-GlcpNAc having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C28H48N2O20/c1-7-15(36)20(41)21(42)27(44-7)50-24-23(49-26-13(29-8(2)34)19(40)16(37)10(4-31)46-26)18(39)12(6-33)47-28(24)48-22-14(30-9(3)35)25(43)45-11(5-32)17(22)38/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17+,18-,19+,20+,21-,22+,23-,24+,25+,26+,27-,28-/m0/s1",alpha-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-beta-D-GlcNAc,PubMed citation,7800218
3110,62486,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc,A branched amino tetrasaccharide comprising N-acetyl-beta-D-glucosamine at the reducing end with a N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C28H48N2O20/c1-7-15(36)20(41)21(42)27(44-7)50-24-23(49-26-14(30-9(3)35)18(39)16(37)10(4-31)46-26)17(38)11(5-32)47-28(24)48-22-12(6-33)45-25(43)13(19(22)40)29-8(2)34/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20+,21-,22+,23-,24+,25+,26+,27-,28-/m0/s1",N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine,PubMed citation,7800218
3111,62489,alpha-L-Rhap-(1->2)-[alpha-L-Rhap-(1->2)-alpha-D-Galp-(1->3)-beta-D-GlcpNAc-(1->4)]-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->1')-[alpha-L-Rhap-(1->3')]-D-glucitol,An alpha-L-rhamnoside consisting of D-glucitol having an alpha-L-Rhap-(1->2)-[alpha-L-Rhap-(1->2)-alpha-D-Galp-(1->3)-beta-D-GlcpNAc-(1->4)]-alpha-L-Rhap-(1->2)-alpha-L-Rhap moiety attached at the 1-position and an alpha-L-Rhap residue at the 3-position.,"InChI=1S/C50H87NO36/c1-11-22(58)29(65)34(70)45(75-11)83-39(26(62)17(56)7-52)18(57)10-74-48-41(32(68)25(61)14(4)78-48)87-49-43(86-47-36(72)31(67)24(60)13(3)77-47)37(73)38(15(5)79-49)82-44-21(51-16(6)55)40(28(64)20(9-54)80-44)84-50-42(33(69)27(63)19(8-53)81-50)85-46-35(71)30(66)23(59)12(2)76-46/h11-15,17-50,52-54,56-73H,7-10H2,1-6H3,(H,51,55)/t11-,12-,13-,14-,15-,17+,18-,19+,20+,21+,22-,23-,24-,25-,26+,27-,28+,29+,30+,31+,32+,33-,34+,35+,36+,37+,38-,39+,40+,41+,42+,43+,44-,45-,46-,47-,48+,49-,50+/m0/s1",alpha-L-Rha-(1->2)-[alpha-L-Rha-(1->2)-alpha-D-Gal-(1->3)-beta-D-GlcNAc-(1->4)]-alpha-L-Rha-(1->2)-alpha-L-Rha-(1->1')-[alpha-L-Rha-(1->3')]-D-glucitol,KEGG GLYCAN accession,G12685
3112,62500,methacrylyl-CoA(4-),Tetraanion of methacrylyl-CoA arising from deprotonation of the phosphate and diphosphate functions; principal microspecies at pH 7.3.,"InChI=1S/C25H40N7O17P3S/c1-13(2)24(37)53-8-7-27-15(33)5-6-28-22(36)19(35)25(3,4)10-46-52(43,44)49-51(41,42)45-9-14-18(48-50(38,39)40)17(34)23(47-14)32-12-31-16-20(26)29-11-30-21(16)32/h11-12,14,17-19,23,34-35H,1,5-10H2,2-4H3,(H,27,33)(H,28,36)(H,41,42)(H,43,44)(H2,26,29,30)(H2,38,39,40)/p-4/t14-,17-,18-,19+,23-/m1/s1",2-methylprop-2-enoyl-CoA(4-),MetaCyc accession,METHACRYLYL-COA
3113,62503,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,A seven-membered branched glucosamine oligosaccharide consisting of beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp having a beta-D-Galp-(1->4)-beta-D-GlcpNAc attached at the 6-position of the central galactosyl residue.,"InChI=1S/C48H81N3O36/c1-11(58)49-21-28(65)37(83-46-33(70)31(68)24(61)14(4-52)77-46)17(7-55)79-43(21)75-10-20-27(64)41(87-45-23(51-13(3)60)29(66)38(18(8-56)81-45)84-47-34(71)32(69)25(62)15(5-53)78-47)36(73)48(82-20)85-39-19(9-57)80-44(22(30(39)67)50-12(2)59)86-40-26(63)16(6-54)76-42(74)35(40)72/h14-48,52-57,61-74H,4-10H2,1-3H3,(H,49,58)(H,50,59)(H,51,60)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24+,25+,26+,27+,28-,29-,30-,31+,32+,33-,34-,35-,36-,37-,38-,39-,40+,41+,42-,43-,44+,45+,46+,47+,48+/m1/s1",beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactose,PubMed citation,6208947
3114,62504,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A linear amino hexasaccharide made up from two glucosamine, one glucose and three galactose residues, linked as shown.","InChI=1S/C40H68N2O31/c1-9(49)41-17-22(54)30(69-38-27(59)24(56)19(51)11(3-43)64-38)15(7-47)67-36(17)72-33-20(52)12(4-44)65-39(28(33)60)70-31-16(8-48)68-37(18(23(31)55)42-10(2)50)73-34-21(53)13(5-45)66-40(29(34)61)71-32-14(6-46)63-35(62)26(58)25(32)57/h11-40,43-48,51-62H,3-8H2,1-2H3,(H,41,49)(H,42,50)/t11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21+,22-,23-,24+,25-,26-,27-,28-,29-,30-,31-,32-,33+,34+,35?,36+,37+,38+,39+,40+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,KEGG GLYCAN accession,G06069
3115,62506,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc,A linear amino hexasaccharide made up from alternating galactose and glucosamine units linked by alternating beta-(1->4)- an d beta-(1->3)-linkages.,"InChI=1S/C42H71N3O31/c1-10(52)43-19-25(58)32(16(7-49)66-37(19)65)73-41-30(63)35(23(56)14(5-47)68-41)75-39-21(45-12(3)54)27(60)34(18(9-51)71-39)74-42-31(64)36(24(57)15(6-48)69-42)76-38-20(44-11(2)53)26(59)33(17(8-50)70-38)72-40-29(62)28(61)22(55)13(4-46)67-40/h13-42,46-51,55-65H,4-9H2,1-3H3,(H,43,52)(H,44,53)(H,45,54)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25-,26-,27-,28+,29-,30-,31-,32-,33-,34-,35+,36+,37?,38+,39+,40+,41+,42+/m1/s1",beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine,KEGG GLYCAN accession,G00836
3116,62507,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc,A branched amino tetrasaccharide consisting of N-acetyl-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1->2)-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C26H45NO19/c1-6-12(31)15(34)18(37)24(40-6)45-21-11(27-8(3)30)23(39)42-10(5-29)20(21)44-26-22(17(36)14(33)9(4-28)43-26)46-25-19(38)16(35)13(32)7(2)41-25/h6-7,9-26,28-29,31-39H,4-5H2,1-3H3,(H,27,30)/t6-,7-,9+,10+,11+,12+,13+,14-,15+,16+,17-,18-,19-,20+,21+,22+,23?,24-,25-,26-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-D-GlcNAc,KEGG GLYCAN accession,G00256
3117,62511,alpha-Neup5Ac-(2->6)-D-Galp,An amino disaccharide consisting of D-galactose having an alpha-N-acetylneuraminyl residue attached at the 6-position,"InChI=1S/C17H29NO14/c1-5(20)18-9-6(21)2-17(16(28)29,32-14(9)10(23)7(22)3-19)30-4-8-11(24)12(25)13(26)15(27)31-8/h6-15,19,21-27H,2-4H2,1H3,(H,18,20)(H,28,29)/t6-,7+,8+,9+,10+,11-,12-,13+,14+,15?,17+/m0/s1",NeuAcalpha2-6Gal,Reaxys Registry Number,1695303
3118,62512,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc,A linear amino pentasaccharide consisting of the tetrasaccharide beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine having an alpha-N-acetylneuraminyl residue attached at the 3-position of the galactosyl residue at the non-reducing end.,"InChI=1S/C39H65N3O29/c1-10(48)40-19-13(51)4-39(38(61)62,70-31(19)22(53)14(52)5-43)71-33-24(55)16(7-45)65-37(28(33)59)68-30-18(9-47)66-35(21(26(30)57)42-12(3)50)69-32-23(54)15(6-44)64-36(27(32)58)67-29-17(8-46)63-34(60)20(25(29)56)41-11(2)49/h13-37,43-47,51-60H,4-9H2,1-3H3,(H,40,48)(H,41,49)(H,42,50)(H,61,62)/t13-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23-,24-,25+,26+,27+,28+,29+,30+,31+,32-,33-,34?,35-,36-,37-,39-/m0/s1",N-acetylalpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine,KEGG GLYCAN accession,G01098
3119,62515,alpha-D-GalpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc,A amino trisaccharide consisting of N-acetyl-D-glucosamine having an N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl group attached at the 4-position.,"InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)18(10(5-27)36-20(11)35)39-22-17(34)19(14(31)9(4-26)38-22)40-21-12(24-7(2)29)15(32)13(30)8(3-25)37-21/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19+,20?,21-,22+/m1/s1",N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine,KEGG GLYCAN accession,G00939
3120,62516,alpha-D-GalpNAc-(1->3)-beta-D-Galp-(1->3)-D-GlcpNAc,A amino trisaccharide consisting of N-acetyl-D-glucosamine having an N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl group attached at the 3-position.,"InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)13(30)8(3-25)37-21(11)40-19-15(32)10(5-27)38-22(17(19)34)39-18-12(24-7(2)29)20(35)36-9(4-26)14(18)31/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14-,15+,16-,17-,18-,19+,20?,21-,22+/m1/s1",alpha-D-GalNAc-(1->3)-beta-D-Gal-(1->3)-D-GlcNAc,KEGG GLYCAN accession,G00658
3121,62517,tricarballylate,A tricarboxylic acid trianion resulting from the removal of a proton from each of the carboxy groups of tricarballylic acid.,"InChI=1S/C6H8O6/c7-4(8)1-3(6(11)12)2-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/p-3","1,2,3-propanetricarboxylate",MetaCyc accession,CPD-3571
3122,62518,alpha-D-GalpNAc-(1->3)-beta-D-Galp-(1->3)-D-GalNAc-ol,A glycoside consisting of N-acetyl-D-galactosaminitol having an N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl group attached at the 3-position.,"InChI=1S/C22H40N2O16/c1-7(29)23-9(3-25)19(14(32)10(31)4-26)39-22-18(36)20(16(34)12(6-28)38-22)40-21-13(24-8(2)30)17(35)15(33)11(5-27)37-21/h9-22,25-28,31-36H,3-6H2,1-2H3,(H,23,29)(H,24,30)/t9-,10+,11+,12+,13+,14-,15-,16-,17+,18+,19+,20-,21+,22-/m0/s1",GalNAc(alpha1->3)Gal-(beta1->3)GalNAcOH,PubMed citation,6172274
3123,62520,beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp,"A linear amino hexasaccharide consisting of two galactosyl, one glucosamine, two fucose and one glucose residue (at the reducing end) linked as shown.","InChI=1S/C38H65NO29/c1-8-16(45)20(49)23(52)35(58-8)64-28-14(7-43)63-34(15(39-10(3)44)30(28)66-37-25(54)22(51)18(47)11(4-40)61-37)67-31-19(48)12(5-41)62-38(27(31)56)65-29-13(6-42)60-33(57)26(55)32(29)68-36-24(53)21(50)17(46)9(2)59-36/h8-9,11-38,40-43,45-57H,4-7H2,1-3H3,(H,39,44)/t8-,9-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21+,22-,23-,24-,25+,26+,27+,28+,29+,30+,31-,32+,33?,34-,35-,36-,37-,38-/m0/s1",beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-D-Glc,PubMed citation,3274083
3124,62525,beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glc-ol,An alpha-L-fucoside comprising D-glucitol having an alpha-L-fucosyl group attached at the 3-position as well as a beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl group attached at the 4-position.,"InChI=1S/C38H67NO29/c1-9-18(48)22(52)25(55)35(59-9)64-29(12(46)4-40)30(13(47)5-41)65-38-28(58)33(21(51)15(7-43)62-38)68-34-17(39-11(3)45)32(67-37-27(57)24(54)20(50)14(6-42)61-37)31(16(8-44)63-34)66-36-26(56)23(53)19(49)10(2)60-36/h9-10,12-38,40-44,46-58H,4-8H2,1-3H3,(H,39,45)/t9-,10-,12-,13+,14+,15+,16+,17+,18+,19+,20-,21-,22+,23+,24-,25-,26-,27+,28+,29+,30+,31+,32+,33-,34-,35-,36-,37-,38-/m0/s1",beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-D-glucitol,PubMed citation,2908539
3125,62529,alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glc-ol,A glycoside consisting of D-glucitol having a alpha-L-fucosyl-(1->4)-[beta-D-galactosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl group attached at the 4-position.,"InChI=1S/C32H57NO25/c1-8-16(42)20(46)22(48)30(51-8)56-26-14(7-38)54-29(15(33-9(2)39)27(26)57-31-23(49)21(47)18(44)12(5-36)52-31)58-28-19(45)13(6-37)53-32(24(28)50)55-25(11(41)4-35)17(43)10(40)3-34/h8,10-32,34-38,40-50H,3-7H2,1-2H3,(H,33,39)/t8-,10-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21-,22-,23+,24+,25+,26+,27+,28-,29-,30-,31-,32-/m0/s1",alpha-L-Fuc-(1->4)-[beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc-ol,PubMed citation,2908539
3126,62534,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,A branched amino pentasaccharide consisting of the trisaccharide beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactose where the galactosyl residue at the non-reducing end has alpha-L-fucosyl and N-acetyl-alpha-D-galactosaminyl residues attached at the 2- and 3-positions respectively.,"InChI=1S/C34H58N2O25/c1-8-17(43)23(49)24(50)33(53-8)61-29-28(60-31-15(35-9(2)41)22(48)18(44)11(4-37)55-31)21(47)14(7-40)57-34(29)58-26-16(36-10(3)42)32(56-13(6-39)19(26)45)59-27-20(46)12(5-38)54-30(52)25(27)51/h8,11-34,37-40,43-52H,4-7H2,1-3H3,(H,35,41)(H,36,42)/t8-,11+,12+,13+,14+,15+,16+,17+,18-,19+,20-,21-,22+,23+,24-,25+,26+,27-,28-,29+,30+,31+,32-,33-,34-/m0/s1",alpha-L-Fuc-(1->2)-[alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal,PubMed citation,2446741
3127,62536,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp,A branched amino pentasaccharide consisting of the trisaccharide beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactose where the galactosyl residue at the non-reducing end has alpha-L-fucosyl and N-acetyl-alpha-D-galactosaminyl residues attached at the 2- and 3-positions respectively and the glucosaminyl residue has an alpha-L-fucosyl residue attached at the 4-position.,"InChI=1S/C40H68N2O29/c1-9-19(49)25(55)27(57)38(61-9)67-30-16(8-46)66-37(69-32-22(52)14(6-44)63-35(60)29(32)59)18(42-12(4)48)31(30)68-40-34(71-39-28(58)26(56)20(50)10(2)62-39)33(23(53)15(7-45)65-40)70-36-17(41-11(3)47)24(54)21(51)13(5-43)64-36/h9-10,13-40,43-46,49-60H,5-8H2,1-4H3,(H,41,47)(H,42,48)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23-,24+,25+,26+,27-,28-,29+,30+,31+,32-,33-,34+,35+,36+,37-,38-,39-,40-/m0/s1",Fucalpha1->2(GalNAcalpha1->3)Galbeta1->3(Fucalpha1->4)GlcNAcbeta1->3D-Galbeta,PubMed citation,2446741
3128,62538,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,A branched amino pentasaccharide consisting of the trisaccharide beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galctose where the galactosyl residue at the non-reducing end has alpha-L-fucosyl and N-acetyl-alpha-D-galactosaminyl residues attached at the 2- and 3-positions respectively.,"InChI=1S/C34H58N2O25/c1-8-17(43)23(49)24(50)33(53-8)61-29-28(60-31-15(35-9(2)41)21(47)18(44)11(4-37)55-31)20(46)13(6-39)56-34(29)58-26-14(7-40)57-32(16(22(26)48)36-10(3)42)59-27-19(45)12(5-38)54-30(52)25(27)51/h8,11-34,37-40,43-52H,4-7H2,1-3H3,(H,35,41)(H,36,42)/t8-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20-,21+,22+,23+,24-,25+,26+,27-,28-,29+,30+,31+,32-,33-,34-/m0/s1",alpha-L-fucosyl-(1->2)-[N-acetyl-alpha-D-galactosaminyl-(1->3)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galctose,PubMed citation,2446741
3129,62539,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp,A branched amino hexasaccharide consisting of the trisaccharide beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactose where the galactosyl residue at the non-reducing end has alpha-L-fucosyl and N-acetyl-alpha-D-galactosaminylresidues attached at the 2- and 3-positions respectively and the glucosaminyl residue has an alpha-L-fucosyl attached at the 3-position.,"InChI=1S/C40H68N2O29/c1-9-19(49)25(55)27(57)38(61-9)68-31-18(42-12(4)48)37(69-32-22(52)14(6-44)63-35(60)29(32)59)66-16(8-46)30(31)67-40-34(71-39-28(58)26(56)20(50)10(2)62-39)33(23(53)15(7-45)65-40)70-36-17(41-11(3)47)24(54)21(51)13(5-43)64-36/h9-10,13-40,43-46,49-60H,5-8H2,1-4H3,(H,41,47)(H,42,48)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23-,24+,25+,26+,27-,28-,29+,30+,31+,32-,33-,34+,35+,36+,37-,38-,39-,40-/m0/s1",alpha-L-Fuc-(1->2)-[alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal,PubMed citation,2446741
3130,62543,3-oxotetradecanoyl-CoA(4-),Tetraanion of 3-oxotetradecanoyl-CoA arising from deprotonation of the phosphate and diphosphate functions; principal microspecies at pH 7.3.,"InChI=1S/C35H60N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-23(43)18-26(45)64-17-16-37-25(44)14-15-38-33(48)30(47)35(2,3)20-57-63(54,55)60-62(52,53)56-19-24-29(59-61(49,50)51)28(46)34(58-24)42-22-41-27-31(36)39-21-40-32(27)42/h21-22,24,28-30,34,46-47H,4-20H2,1-3H3,(H,37,44)(H,38,48)(H,52,53)(H,54,55)(H2,36,39,40)(H2,49,50,51)/p-4/t24-,28-,29-,30+,34-/m1/s1",3-oxo-myristoyl-CoA(4-),MetaCyc accession,CPD-10284
3131,62555,3-hydroxyisovaleryl-CoA(4-),An acyl-CoA oxoanion resulting from the removal of all four protons from the phosphate groups of 3-hydroxyisovaleryl-CoA. Major species at pH 7.3.,"InChI=1S/C26H44N7O18P3S/c1-25(2,20(37)23(38)29-6-5-15(34)28-7-8-55-16(35)9-26(3,4)39)11-48-54(45,46)51-53(43,44)47-10-14-19(50-52(40,41)42)18(36)24(49-14)33-13-32-17-21(27)30-12-31-22(17)33/h12-14,18-20,24,36-37,39H,5-11H2,1-4H3,(H,28,34)(H,29,38)(H,43,44)(H,45,46)(H2,27,30,31)(H2,40,41,42)/p-4/t14-,18-,19-,20+,24-/m1/s1",3-hydroxy-3-methylbutanoyl-CoA (4-),MetaCyc accession,3-HYDROXY-ISOVALERYL-COA
3132,62556,alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-D-Manp,A mannotetraose in which the four mannose units joined by alpha-(1->6)-linkages.,"InChI=1S/C24H42O21/c25-1-5-9(26)14(31)18(35)22(43-5)40-3-7-11(28)16(33)20(37)24(45-7)41-4-8-12(29)15(32)19(36)23(44-8)39-2-6-10(27)13(30)17(34)21(38)42-6/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21?,22+,23+,24+/m1/s1",alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-D-Man,KEGG GLYCAN accession,G08039
3133,62557,alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-D-Manp,A mannopentaose comprising five mannose units joined by alpha-(1->6)-linkages.,"InChI=1S/C30H52O26/c31-1-6-11(32)17(38)22(43)27(53-6)49-3-8-13(34)19(40)24(45)29(55-8)51-5-10-15(36)20(41)25(46)30(56-10)50-4-9-14(35)18(39)23(44)28(54-9)48-2-7-12(33)16(37)21(42)26(47)52-7/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26?,27+,28+,29+,30+/m1/s1",alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-D-Man,PubMed citation,8898075
3134,62558,(S)-3-hydroxylauroyl-CoA(4-),Tetraanion of (S)-3-hydroxylauroyl-CoA arising from deprotonation of the phosphate and diphosphate functions; principal microspecies at pH 7.3.,"InChI=1S/C33H58N7O18P3S/c1-4-5-6-7-8-9-10-11-21(41)16-24(43)62-15-14-35-23(42)12-13-36-31(46)28(45)33(2,3)18-55-61(52,53)58-60(50,51)54-17-22-27(57-59(47,48)49)26(44)32(56-22)40-20-39-25-29(34)37-19-38-30(25)40/h19-22,26-28,32,41,44-45H,4-18H2,1-3H3,(H,35,42)(H,36,46)(H,50,51)(H,52,53)(H2,34,37,38)(H2,47,48,49)/p-4/t21-,22+,26+,27+,28-,32+/m0/s1",(S)-3-Hydroxydodecanoyl-CoA (4-),MetaCyc accession,CPD0-2107
3135,62559,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-D-GlcpNAc-(1->3)-D-Galp,A linear amino tetrasaccharide comprising D-galactose at the reducing end having an alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosaminyl group attached at the 3-position.,"InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)25(41-6)47-22-17(37)13(33)8(3-28)43-26(22)45-20-10(5-30)44-24(11(15(20)35)27-7(2)31)46-21-14(34)9(4-29)42-23(40)19(21)39/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-,19+,20+,21-,22+,23?,24?,25-,26-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-D-GlcNAc-(1->3)-D-Gal,PubMed citation,3042008
3136,62577,"(E)-2,4,6-trimethyltetracos-2-enoic acid","A branched chain fatty acid with methyl branching at C-2, -4 and -6, and with a double bond at C-2.","InChI=1S/C27H52O2/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-24(2)22-25(3)23-26(4)27(28)29/h23-25H,5-22H2,1-4H3,(H,28,29)/b26-23+",C27-mycolipenic acid,PubMed citation,3930656
3137,62599,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,A branched amino octasaccharide made up from two repeating (1->3)-linked N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl units that are in turn joined to N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactose via a (1->4)-linkage.,"InChI=1S/C54H91N3O39/c1-12-26(67)35(76)37(78)51(82-12)95-45-44(32(73)20(9-61)87-53(45)90-40-22(11-63)89-49(24(34(40)75)56-15(4)65)92-42-30(71)18(7-59)84-47(81)39(42)80)94-50-25(57-16(5)66)41(29(70)19(8-60)86-50)91-54-46(96-52-38(79)36(77)27(68)13(2)83-52)43(31(72)21(10-62)88-54)93-48-23(55-14(3)64)33(74)28(69)17(6-58)85-48/h12-13,17-54,58-63,67-81H,6-11H2,1-5H3,(H,55,64)(H,56,65)(H,57,66)/t12-,13-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28-,29-,30-,31-,32-,33+,34+,35+,36+,37-,38-,39+,40+,41+,42-,43-,44-,45+,46+,47+,48+,49-,50+,51-,52-,53-,54-/m0/s1",alpha-GalNAc-(1->3)-[alpha-Fuc-(1->2)]-beta-Gal-(1->3)-alpha-GalNAc-(1->3)-[alpha-Fuc-(1->2)]-beta-Gal-(1->4)-beta-GlcNAc-(1->3)-beta-Gal,PubMed citation,2446741
3138,62600,2-O-(alpha-D-glucopyranosyl)-3-O-phosphonato-D-glycerate(3-),An organophosphate oxoanion obtained by removal of the protons from the carboxy and phosphate groups of 2-O-(alpha-D-glucopyranosyl)-3-O-phospho-D-glyceric acid; major species at pH 7.3.,"InChI=1S/C9H17O12P/c10-1-3-5(11)6(12)7(13)9(20-3)21-4(8(14)15)2-19-22(16,17)18/h3-7,9-13H,1-2H2,(H,14,15)(H2,16,17,18)/p-3/t3-,4-,5-,6+,7-,9-/m1/s1",2-O-(alpha-D-glucopyranosyl)-3-O-phosphonato-D-glycerate,PubMed citation,16428406
3139,62601,2-O-(alpha-D-glucopyranosyl)-3-O-phospho-D-glyceric acid,A carboxyalkyl phosphate consisting of D-glyceric acid having an alpha-D-glucosyl residue at the 2-position and a phospho group at the 3-position,"InChI=1S/C9H17O12P/c10-1-3-5(11)6(12)7(13)9(20-3)21-4(8(14)15)2-19-22(16,17)18/h3-7,9-13H,1-2H2,(H,14,15)(H2,16,17,18)/t3-,4-,5-,6+,7-,9-/m1/s1",2-(alpha-D-glucopyranosyl)-3-phospho-D-glyceric acid,PubMed citation,18221489
3140,62602,2-O-[alpha-D-mannopyranosyl-(1->2)-alpha-D-glucopyranosyl]-3-O-phosphonato-D-glycerate(3-),An organophosphate oxoanion obtained by removal of a total of three protons from the carboxy and phosphate groups of 2-O-[alpha-D-mannopyranosyl-(1->2)-alpha-D-glucopyranosyl]-3-O-phospho-D-glyceric acid; major species at pH 7.3.,"InChI=1S/C15H27O17P/c16-1-4-7(18)9(20)11(22)14(29-4)32-12-10(21)8(19)5(2-17)30-15(12)31-6(13(23)24)3-28-33(25,26)27/h4-12,14-22H,1-3H2,(H,23,24)(H2,25,26,27)/p-3/t4-,5-,6-,7-,8-,9+,10+,11+,12-,14-,15-/m1/s1",2-O-[alpha-D-mannosyl-(1->2)-alpha-D-glucosyl]-3-O-phosphonato-D-glycerate(3-),PubMed citation,20061481
3141,62603,2-O-[alpha-D-mannopyranosyl-(1->2)-alpha-D-glucopyranosyl]-3-O-phospho-D-glyceric acid,A glycoside consisting of D-glyceric acid having an alpha-D-mannosyl-(1->2)-alpha-D-glucosyl residue at the 2-position and a phospho group at the 3-position,"InChI=1S/C15H27O17P/c16-1-4-7(18)9(20)11(22)14(29-4)32-12-10(21)8(19)5(2-17)30-15(12)31-6(13(23)24)3-28-33(25,26)27/h4-12,14-22H,1-3H2,(H,23,24)(H2,25,26,27)/t4-,5-,6-,7-,8-,9+,10+,11+,12-,14-,15-/m1/s1",2-O-[alpha-D-mannosyl-(1->2)-alpha-D-glucosyl]-3-O-phospho-D-glyceric acid,PubMed citation,20061481
3142,62611,(S)-3-hydroxyisobutyryl-CoA(4-),An acyl-CoA(-) oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of (S)-3-hydroxyisobutyryl-CoA; principal microspecies at pH 7.3.,"InChI=1S/C25H42N7O18P3S/c1-13(8-33)24(38)54-7-6-27-15(34)4-5-28-22(37)19(36)25(2,3)10-47-53(44,45)50-52(42,43)46-9-14-18(49-51(39,40)41)17(35)23(48-14)32-12-31-16-20(26)29-11-30-21(16)32/h11-14,17-19,23,33,35-36H,4-10H2,1-3H3,(H,27,34)(H,28,37)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/p-4/t13-,14+,17+,18+,19-,23+/m0/s1",(S)-3-hydroxyisobutanoyl-CoA(4-),MetaCyc accession,CPD-12173
3143,62613,(S)-3-hydroxypalmitoyl-CoA(4-),An acyl-CoA oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of (S)-3-hydroxypalmitoyl-CoA; principal microspecies at pH 7.3.,"InChI=1S/C37H66N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-25(45)20-28(47)66-19-18-39-27(46)16-17-40-35(50)32(49)37(2,3)22-59-65(56,57)62-64(54,55)58-21-26-31(61-63(51,52)53)30(48)36(60-26)44-24-43-29-33(38)41-23-42-34(29)44/h23-26,30-32,36,45,48-49H,4-22H2,1-3H3,(H,39,46)(H,40,50)(H,54,55)(H,56,57)(H2,38,41,42)(H2,51,52,53)/p-4/t25-,26+,30+,31+,32-,36+/m0/s1",(SS)-3-hydroxyhexadecanoyl-CoA(4-),MetaCyc accession,CPD0-2232
3144,62615,3-oxolauroyl-CoA(4-),An acyl-CoA(4-) oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of 3-oxolauroyl-CoA; major species at pH 7.3.,"InChI=1S/C33H56N7O18P3S/c1-4-5-6-7-8-9-10-11-21(41)16-24(43)62-15-14-35-23(42)12-13-36-31(46)28(45)33(2,3)18-55-61(52,53)58-60(50,51)54-17-22-27(57-59(47,48)49)26(44)32(56-22)40-20-39-25-29(34)37-19-38-30(25)40/h19-20,22,26-28,32,44-45H,4-18H2,1-3H3,(H,35,42)(H,36,46)(H,50,51)(H,52,53)(H2,34,37,38)(H2,47,48,49)/p-4/t22-,26-,27-,28+,32-/m1/s1",3-oxododecanoyl-CoA(4-),MetaCyc accession,CPD0-2105
3145,62619,3-oxooctanoyl-CoA(4-),An acyl-CoA(4-) oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of 3-oxooctanoyl-CoA; major species at pH 7.3.,"InChI=1S/C29H48N7O18P3S/c1-4-5-6-7-17(37)12-20(39)58-11-10-31-19(38)8-9-32-27(42)24(41)29(2,3)14-51-57(48,49)54-56(46,47)50-13-18-23(53-55(43,44)45)22(40)28(52-18)36-16-35-21-25(30)33-15-34-26(21)36/h15-16,18,22-24,28,40-41H,4-14H2,1-3H3,(H,31,38)(H,32,42)(H,46,47)(H,48,49)(H2,30,33,34)(H2,43,44,45)/p-4/t18-,22-,23-,24+,28-/m1/s1",3-ketooctanoyl-CoA(4-),MetaCyc accession,CPD0-2106
3146,62620,hexanoyl-CoA(4-),An acyl-CoA(4-) oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of hexanoyl-CoA; major species at pH 7.3.,"InChI=1S/C27H46N7O17P3S/c1-4-5-6-7-18(36)55-11-10-29-17(35)8-9-30-25(39)22(38)27(2,3)13-48-54(45,46)51-53(43,44)47-12-16-21(50-52(40,41)42)20(37)26(49-16)34-15-33-19-23(28)31-14-32-24(19)34/h14-16,20-22,26,37-38H,4-13H2,1-3H3,(H,29,35)(H,30,39)(H,43,44)(H,45,46)(H2,28,31,32)(H2,40,41,42)/p-4/t16-,20-,21-,22+,26-/m1/s1",caproyl-CoA(4-),MetaCyc accession,HEXANOYL-COA
3147,62622,(5-hydroxyindol-3-yl)acetate,The indol-3-yl carboxylic acid anion formed by loss of a proton from the carboxy group of (5-hydroxyindol-3-yl)acetic acid; principal microspecies at pH 7.3,"InChI=1S/C10H9NO3/c12-7-1-2-9-8(4-7)6(5-11-9)3-10(13)14/h1-2,4-5,11-12H,3H2,(H,13,14)/p-1",5-hydroxyindoleacetate(1-),Reaxys Registry Number,8630548
3148,62637,L-4-hydroxyglutamate semialdehyde zwitterion,The L-alpha-amino acid zwitterion formed from L-4-hydroxyglutamic semialdehyde by transfer of a proton from the carboxy to the amine group; it is the principal microspecies at pH 7.3.,"InChI=1S/C5H9NO4/c6-4(5(9)10)1-3(8)2-7/h2-4,8H,1,6H2,(H,9,10)/t3-,4+/m1/s1",4-hydroxyglutamate semialdehyde,MetaCyc accession,L-4-HYDROXYGLUTAMATE_SEMIALDEHYDE
3149,62639,"2-cis,6-trans,10-trans-geranylgeranyl diphosphate(3-)","The organophosphate oxoanion formed by global deprotonation of the diphosphate group in 2-cis,6-trans,10-trans-geranylgeranyl diphosphate; principal microspecies at pH 7.3.","InChI=1S/C20H36O7P2/c1-17(2)9-6-10-18(3)11-7-12-19(4)13-8-14-20(5)15-16-26-29(24,25)27-28(21,22)23/h9,11,13,15H,6-8,10,12,14,16H2,1-5H3,(H,24,25)(H2,21,22,23)/p-3/b18-11+,19-13+,20-15-","di-trans,poly-cis-geranylgeranyl diphosphate",MetaCyc accession,CPD0-1028
3150,62641,perillate,The monocarboxylic acid anion formed by loss of a proton from the carboxy group of perillic acid; principal microspecies at pH 7.3.,"InChI=1S/C10H14O2/c1-7(2)8-3-5-9(6-4-8)10(11)12/h5,8H,1,3-4,6H2,2H3,(H,11,12)/p-1",perillyl carboxylate,MetaCyc accession,CPD-12443
3151,62642,beta-D-Glc-(1->4)-[beta-D-Glc-(1->3)]-[alpha-D-Glc-(1->2)-beta-D-Glc-(1->6)]-alpha-D-Glc-(1->5)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->6)-beta-D-GlcN4P-(1->6)-alpha-D-GlcN-1P,"A nine-membered branched glucosamine oligosaccharide made up from five glucose, two Kdo and two glucosamine residues bearing two phospho substituents. Corresponds to a truncated inner core part of Moraxella catarrhalis lipopolysaccharide (LPS).","InChI=1S/C58H100N2O54P2/c59-23-31(76)30(75)20(103-49(23)114-116(93,94)95)9-96-48-24(60)32(77)43(113-115(90,91)92)22(104-48)11-98-57(55(86)87)2-15(110-58(56(88)89)1-12(67)25(70)41(111-58)13(68)3-61)44(42(112-57)14(69)4-62)106-53-40(85)46(108-51-38(83)34(79)27(72)17(6-64)100-51)45(107-50-37(82)33(78)26(71)16(5-63)99-50)21(105-53)10-97-54-47(36(81)29(74)19(8-66)102-54)109-52-39(84)35(80)28(73)18(7-65)101-52/h12-54,61-85H,1-11,59-60H2,(H,86,87)(H,88,89)(H2,90,91,92)(H2,93,94,95)/t12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33+,34+,35+,36+,37-,38-,39-,40-,41-,42-,43-,44-,45+,46+,47-,48-,49-,50+,51+,52-,53-,54-,57-,58-/m1/s1",beta-Glc-(1->4)-[beta-Glc-(1->3)]-[alpha-Glc-(1->2)-beta-Glc-(1->6)]-alpha-Glc-(1->5)-[alpha-Kdo-(2->4)]-alpha-Kdo-(2->6)-beta-GlcN4P-(1->6)-alpha-GlcN-1P,PubMed citation,21590368
3152,62644,alpha-D-Glcp-(1->3)-[alpha-D-Glcp-(1->3)-alpha-D-GalpNAc-(1->4)-alpha-D-Glcp-(1->4)]-alpha-D-GalpNAc-(1->4)-alpha-D-Manp,A branched amino hexasaccharide consisting of alpha-D-glucosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-(1->4)-alpha-D-mannose having a alpha-D-glucosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-(1->4)-alpha-D-glucosyl group attached at the 4'-position (on the galactosaminyl residue).,"InChI=1S/C40H68N2O31/c1-9(49)41-17-33(72-38-27(59)22(54)19(51)11(3-43)65-38)21(53)13(5-45)64-36(17)70-31-15(7-47)68-40(29(61)25(31)57)71-32-16(8-48)67-37(69-30-14(6-46)63-35(62)26(58)24(30)56)18(42-10(2)50)34(32)73-39-28(60)23(55)20(52)12(4-44)66-39/h11-40,43-48,51-62H,3-8H2,1-2H3,(H,41,49)(H,42,50)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21+,22+,23+,24-,25-,26+,27-,28-,29-,30-,31-,32+,33-,34-,35+,36+,37+,38+,39+,40-/m1/s1",alpha-D-Glc-(1->3)-[alpha-D-Glc-(1->3)-alpha-D-GalNAc-(1->4)-alpha-D-Glc-(1->4)]-alpha-D-GalNAc-(1->4)-alpha-D-Man,PubMed citation,21609839
3153,62645,cholesteryl 6-O-oleoyl-beta-D-glucoside,A cholesteryl 6-O-acyl-beta-D-glucoside having oleoyl as the 6-O-acyl group.,"InChI=1S/C51H88O7/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-45(52)56-35-44-46(53)47(54)48(55)49(58-44)57-39-30-32-50(5)38(34-39)26-27-40-42-29-28-41(37(4)24-22-23-36(2)3)51(42,6)33-31-43(40)50/h14-15,26,36-37,39-44,46-49,53-55H,7-13,16-25,27-35H2,1-6H3/b15-14-/t37-,39+,40+,41-,42+,43+,44-,46-,47+,48-,49-,50+,51-/m1/s1",ACGlc C18:1,PubMed citation,19307181
3154,62647,beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-D-Galp,A branched amino pentasaccharide consisting of beta-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-D-galactose in which the galactosyl residue at the non-reducing end has alpha-sialyl and N-acetyl-beta-D-glucosaminyl residues attached via glycosidic linkages at positions 3 and 4 respectively. Corresponds to the Sda + pentasaccharide from Tamm-Horsfall glycoprotein.,"InChI=1S/C39H65N3O29/c1-10(48)40-19-13(51)4-39(38(61)62,70-31(19)22(53)14(52)5-43)71-33-28(59)37(66-18(9-47)30(33)68-35-20(41-11(2)49)25(56)23(54)15(6-44)64-35)67-29-17(8-46)65-36(21(26(29)57)42-12(3)50)69-32-24(55)16(7-45)63-34(60)27(32)58/h13-37,43-47,51-60H,4-9H2,1-3H3,(H,40,48)(H,41,49)(H,42,50)(H,61,62)/t13-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23-,24-,25+,26+,27+,28+,29+,30-,31+,32-,33+,34?,35-,36-,37-,39-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-D-Gal,KEGG GLYCAN accession,G00736
3155,62657,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp,A branched mannopentaose consisting of alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-D-mannosewhere the mannosyl residue at the non-reducing end has two further alpha-D-mannosyl residues attached at positions 3 and 6 respectively.,"InChI=1S/C30H52O26/c31-1-6-13(37)18(42)24(26(47)49-6)55-30-25(19(43)14(38)9(4-34)52-30)56-29-22(46)23(54-28-21(45)17(41)12(36)8(3-33)51-28)15(39)10(53-29)5-48-27-20(44)16(40)11(35)7(2-32)50-27/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26?,27+,28-,29-,30-/m1/s1",alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-D-Man,KEGG GLYCAN accession,G07153
3156,62658,beta-D-Galp-(1->6)-D-GlcNAcp,An amino disaccharide consisting of N-acetyl-D-glucosamine having a beta-D-galactosyl residue attached at the 6-position.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)9(19)6(25-13(7)23)3-24-14-12(22)11(21)8(18)5(2-16)26-14/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6-,7-,8+,9-,10-,11+,12-,13?,14-/m1/s1",beta-D-galactosyl-(1->6)-N-acetyl-D-glucosamine,PubMed citation,12950254
3157,62659,ethyl N-acetyl-beta-D-glucosaminide,An N-acetyl-beta-D-glucosaminide having ethyl as the anomeric substituent.,"InChI=1S/C10H19NO6/c1-3-16-10-7(11-5(2)13)9(15)8(14)6(4-12)17-10/h6-10,12,14-15H,3-4H2,1-2H3,(H,11,13)/t6-,7-,8-,9-,10-/m1/s1",ethyl 2-acetamido-2-deoxy-beta-D-glucoside,Reaxys Registry Number,86743
3158,62660,beta-D-GlcNAc-(1->3)-[beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc-ol,A tetrasaccharide derivative consisting of D-glucitol having an N-acetyl-beta-D-glucosaminyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl group attached at the 4-position.,"InChI=1S/C28H50N2O21/c1-8(35)29-15-21(43)18(40)12(5-33)47-26(15)46-7-14-20(42)25(51-27-16(30-9(2)36)22(44)19(41)13(6-34)48-27)23(45)28(49-14)50-24(11(38)4-32)17(39)10(37)3-31/h10-28,31-34,37-45H,3-7H2,1-2H3,(H,29,35)(H,30,36)/t10-,11+,12+,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25-,26+,27-,28-/m0/s1",N-acetyl-beta-D-glucosaminyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-D-glucitol,PubMed citation,4112563
3159,62661,beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc-ol,A pentasaccharide derivative consisting of D-glucitol having a beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl attached at the 4-position.,"InChI=1S/C34H60N2O26/c1-9(42)35-17-24(51)20(47)13(5-39)56-31(17)55-8-16-23(50)30(27(54)34(59-16)60-28(12(45)4-38)19(46)11(44)3-37)62-32-18(36-10(2)43)29(22(49)15(7-41)57-32)61-33-26(53)25(52)21(48)14(6-40)58-33/h11-34,37-41,44-54H,3-8H2,1-2H3,(H,35,42)(H,36,43)/t11-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21-,22+,23-,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-/m0/s1",beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-D-glucitol,PubMed citation,4112563
3160,62662,beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-D-Gal-OH,A glycosyl alditol consisting of galactitol having a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl group attached at the 6-position.,"InChI=1S/C20H37NO16/c1-6(25)21-11-15(31)18(37-20-17(33)16(32)14(30)9(3-23)35-20)10(4-24)36-19(11)34-5-8(27)13(29)12(28)7(26)2-22/h7-20,22-24,26-33H,2-5H2,1H3,(H,21,25)/t7-,8+,9+,10+,11+,12+,13-,14-,15+,16-,17+,18+,19+,20-/m0/s1",beta-D-Galp-(1->4)-beta-D-GlpcNAc-(1->6)-D-Gal-ol,PubMed citation,4112563
3161,62664,alpha-D-GlcNAc-(1->2)-beta-D-Glc-(1->4)-[beta-D-Glc-(1->3)]-[alpha-D-Glc-(1->2)-beta-D-Glc-(1->6)]-alpha-D-Glc-(1->5)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->6)-beta-D-GlcN4P-(1->6)-alpha-D-GlcN-1P,"A ten-membered branched glucosamine oligosaccharide made up from five glucose, two Kdo, one N-acetylglucosamine and two glucosamine residues bearing two phospho substituents. Corresponds to a truncated inner core part of Moraxella catarrhalis lipopolysaccharide (LPS).","InChI=1S/C66H113N3O59P2/c1-14(77)69-29-39(90)31(82)19(6-72)111-57(29)122-54-43(94)35(86)23(10-76)115-62(54)120-51-25(12-109-61-53(42(93)34(85)22(9-75)114-61)123-59-45(96)41(92)33(84)21(8-74)113-59)118-60(46(97)52(51)121-58-44(95)40(91)32(83)20(7-73)112-58)119-50-18(124-66(64(100)101)2-15(78)30(81)47(125-66)16(79)4-70)3-65(63(98)99,126-48(50)17(80)5-71)110-13-26-49(127-129(102,103)104)38(89)28(68)55(117-26)108-11-24-36(87)37(88)27(67)56(116-24)128-130(105,106)107/h15-62,70-76,78-97H,2-13,67-68H2,1H3,(H,69,77)(H,98,99)(H,100,101)(H2,102,103,104)(H2,105,106,107)/t15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58+,59-,60-,61-,62+,65-,66-/m1/s1",alpha-GlcNAc-(1->2)-beta-Glc-(1->4)-[beta-Glc-(1->3)]-[alpha-Glc-(1->2)-beta-Glc-(1->6)]-alpha-Glc-(1->5)-[alpha-Kdo-(2->4)]-alpha-Kdo-(2->6)-beta-GlcN4P-(1->6)-alpha-GlcN-1P,PubMed citation,21590368
3162,62672,11alpha-hydroxyprogesterone 11-glucosiduronic acid,A steroid glucosiduronic acid comprising 11alpha-hydroxyprogesterone having a beta-Dglucosiduronic acid residue attached to the 11-hydroxy group via a glycosidic linkage.,"InChI=1S/C27H38O9/c1-12(28)16-6-7-17-15-5-4-13-10-14(29)8-9-26(13,2)19(15)18(11-27(16,17)3)35-25-22(32)20(30)21(31)23(36-25)24(33)34/h10,15-23,25,30-32H,4-9,11H2,1-3H3,(H,33,34)/t15-,16+,17-,18+,19+,20-,21-,22+,23-,25+,26-,27+/m0/s1",progesterone 11alpha-glucuronide,PubMed citation,1908822
3163,62673,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,A branched heptasaccharide derivative consisting of the tetrasaccharide derivative beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose where the galactosyl residue at the non-reducing end has alpha-L-fucosyl and N-acetyl-alpha-D-galactosaminyl residues attached at the 2- and 3-positions respectively and the glucosaminyl residue has an alpha-L-fucosyl residue attached at the 4-position.,"InChI=1S/C46H78N2O34/c1-10-21(56)27(62)31(66)43(70-10)78-35-18(9-53)76-42(80-37-24(59)15(6-50)74-45(33(37)68)77-34-17(8-52)72-40(69)30(65)29(34)64)20(48-13(4)55)36(35)79-46-39(82-44-32(67)28(63)22(57)11(2)71-44)38(25(60)16(7-51)75-46)81-41-19(47-12(3)54)26(61)23(58)14(5-49)73-41/h10-11,14-46,49-53,56-69H,5-9H2,1-4H3,(H,47,54)(H,48,55)/t10-,11-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23-,24-,25-,26+,27+,28+,29+,30+,31-,32-,33+,34+,35+,36+,37-,38-,39+,40?,41+,42-,43-,44-,45-,46-/m0/s1",Fucalpha1->2(GalNAcalpha1->3)Galbeta1->3(Fucalpha1->4)GlcNAcbeta1->3D-Galbeta1->4Glc,KEGG GLYCAN accession,G12190
3164,62674,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,A branched derivative heptasaccharide consisting of the tetrasaccharide derivative beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose where the galactosyl residue at the non-reducing end has alpha-L-fucosyl and N-acetyl-alpha-D-galactosaminyl residues attached at the 2- and 3-positions respectively and the glucosaminyl residue has an alpha-L-fucosyl residue attached at the 3-position.,"InChI=1S/C46H78N2O34/c1-10-21(56)27(62)31(66)43(70-10)79-36-20(48-13(4)55)42(80-37-24(59)15(6-50)74-45(33(37)68)77-34-17(8-52)72-40(69)30(65)29(34)64)76-18(9-53)35(36)78-46-39(82-44-32(67)28(63)22(57)11(2)71-44)38(25(60)16(7-51)75-46)81-41-19(47-12(3)54)26(61)23(58)14(5-49)73-41/h10-11,14-46,49-53,56-69H,5-9H2,1-4H3,(H,47,54)(H,48,55)/t10-,11-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23-,24-,25-,26+,27+,28+,29+,30+,31-,32-,33+,34+,35+,36+,37-,38-,39+,40?,41+,42-,43-,44-,45-,46-/m0/s1",alpha-L-fucosyl-(1->2)-[N-acetyl-alpha-D-galactosaminyl-(1->3)]-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-D-glucose,KEGG GLYCAN accession,G01936
3165,62675,beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-D-Glc,A branched amino pentasaccharide consisting of the linear sequence beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an alpha-(2->3) linkage.,"InChI=1S/C37H62N2O29/c1-9(45)38-17-11(47)3-37(36(58)59,67-30(17)19(49)12(48)4-40)68-31-26(56)35(64-27-15(7-43)60-32(57)24(54)23(27)53)63-16(8-44)28(31)65-33-18(39-10(2)46)29(21(51)14(6-42)61-33)66-34-25(55)22(52)20(50)13(5-41)62-34/h11-35,40-44,47-57H,3-8H2,1-2H3,(H,38,45)(H,39,46)(H,58,59)/t11-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21-,22-,23+,24+,25+,26+,27+,28-,29+,30+,31+,32?,33-,34-,35-,37-/m0/s1",beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-D-Glcp,KEGG GLYCAN accession,G10360
3166,62676,beta-D-GlcpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-D-Glcp,A branched amino tetrasaccharide consisting of the linear sequence beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-D-Glc having a Neu5Ac residue attached to the galactose via an alpha-(2->3) linkage.,"InChI=1S/C31H52N2O24/c1-8(38)32-15-10(40)3-31(30(49)50,56-25(15)17(42)11(41)4-34)57-26-22(47)29(54-23-13(6-36)51-27(48)21(46)20(23)45)53-14(7-37)24(26)55-28-16(33-9(2)39)19(44)18(43)12(5-35)52-28/h10-29,34-37,40-48H,3-7H2,1-2H3,(H,32,38)(H,33,39)(H,49,50)/t10-,11+,12+,13+,14+,15+,16+,17+,18-,19+,20+,21+,22+,23+,24-,25+,26+,27?,28-,29-,31-/m0/s1",N-acetyl-beta-D-galactosaminyl-(1->4)-[alpha-N-acetylneuraminosyl-(2->3)]-beta-D-galactosyl-(1->4)-D-glucose,KEGG GLYCAN accession,G02267
3167,62678,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-D-GalpNAc,A branched amino tetrasaccharide comprising N-acetyl-D-galactosamine at the reducing end with an alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 3-position.,"InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)24(41-6)47-22-21(46-25-19(39)17(37)13(33)8(3-28)43-25)15(35)10(5-30)44-26(22)45-20-11(27-7(2)31)23(40)42-9(4-29)14(20)34/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15-,16+,17-,18-,19+,20+,21-,22+,23?,24-,25+,26-/m0/s1",alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal-(1->3)-D-GalNAc,KEGG GLYCAN accession,G00912
3168,62679,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc,A branched amino tetrasaccharide comprising N-acetyl-beta-D-glucosamine at the reducing end with a alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)24(41-6)47-22-21(46-25-19(39)17(37)13(33)8(3-28)43-25)14(34)9(4-29)44-26(22)45-20-10(5-30)42-23(40)11(15(20)35)27-7(2)31/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-,19+,20+,21-,22+,23+,24-,25+,26-/m0/s1",alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine,PubMed citation,10442639
3169,62680,4-nitrophenyl beta-sophoroside,The sophoroside derivative of 4-nitrophenol.,"InChI=1S/C18H25NO13/c20-5-9-11(22)13(24)15(26)17(30-9)32-16-14(25)12(23)10(6-21)31-18(16)29-8-3-1-7(2-4-8)19(27)28/h1-4,9-18,20-26H,5-6H2/t9-,10-,11-,12-,13+,14+,15-,16-,17+,18-/m1/s1",Glc-(1->2)-Glc-phi-NO2,Reaxys Registry Number,4894752
3170,62681,alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc,"A branched amino tetrasaccharide consisting of a sialyl residue, linked (2->3) to a galactosyl residue that in turn is linked (1->3) to a glucosaminyl residue at the reducing end, which is also carrying a fucosyl residue at the 4-position.","InChI=1S/C31H52N2O23/c1-8-17(41)20(44)21(45)28(50-8)53-23-14(7-36)51-27(47)16(33-10(3)38)25(23)54-29-22(46)26(19(43)13(6-35)52-29)56-31(30(48)49)4-11(39)15(32-9(2)37)24(55-31)18(42)12(40)5-34/h8,11-29,34-36,39-47H,4-7H2,1-3H3,(H,32,37)(H,33,38)(H,48,49)/t8-,11-,12+,13+,14+,15+,16+,17+,18+,19-,20+,21-,22+,23+,24+,25+,26-,27+,28-,29-,31-/m0/s1",alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc,PubMed citation,18565751
3171,62685,norfentanyl,A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of 4-(N'-phenyl)piperidin-4-amine with propanoic acid. A major metabolite of fentanyl.,"InChI=1S/C14H20N2O/c1-2-14(17)16(12-6-4-3-5-7-12)13-8-10-15-11-9-13/h3-7,13,15H,2,8-11H2,1H3",4-(N-propionylanilino)piperidine,PubMed citation,16302812
3172,62686,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,A branched amino hexasaccharide consisting of the linear sequence alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-D-Glc having a Neu5Ac residue attached to the inner galactose via an alpha-(2->3) linkage.,"InChI=1S/C43H72N2O33/c1-10-21(55)25(59)29(63)39(68-10)76-36-26(60)23(57)15(6-47)71-41(36)75-33-20(45-12(3)52)38(70-16(7-48)24(33)58)74-32-18(9-50)72-40(73-31-17(8-49)69-37(65)28(62)27(31)61)30(64)35(32)78-43(42(66)67)4-13(53)19(44-11(2)51)34(77-43)22(56)14(54)5-46/h10,13-41,46-50,53-65H,4-9H2,1-3H3,(H,44,51)(H,45,52)(H,66,67)/t10-,13-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23-,24-,25+,26-,27+,28+,29-,30+,31+,32-,33+,34+,35+,36+,37+,38-,39-,40-,41-,43-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc,PubMed citation,19695255
3173,62690,2-O-demethyl-beta-anthrosyl-(1->3)-alpha-L-rhamnosyl-(1->3)-alpha-L-rhamnose,A linear amino tetrasaccharide comprising 2-O-demethyl-beta-anthrose at the non-reducing end and two alpha-L-rhamnose units joined by sequential (1->3)- and (1->2)-linkages.,"InChI=1S/C23H41NO14/c1-7-11(24-10(25)6-23(4,5)33)14(28)15(29)21(35-7)38-19-13(27)9(3)36-22(17(19)31)37-18-12(26)8(2)34-20(32)16(18)30/h7-9,11-22,26-33H,6H2,1-5H3,(H,24,25)/t7-,8+,9+,11-,12+,13+,14+,15-,16-,17-,18-,19-,20-,21+,22+/m1/s1",2-O-demethyl-beta-anthropyranosyl-(1->3)-alpha-L-rhamnopyranosyl-(1->3)-alpha-L-rhamnopyranose,PubMed citation,20024115
3174,62692,alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,An eleven-membered branched mannooligosaccharide consisting of nine D-mannosyl residues and two N-acetylglucosamine residues (one at the reducing end).,"InChI=1S/C70H118N2O56/c1-14(82)71-27-38(93)52(23(10-80)110-60(27)107)121-61-28(72-15(2)83)39(94)53(24(11-81)118-61)122-66-51(106)55(124-69-59(46(101)35(90)21(8-78)116-69)128-70-58(45(100)34(89)22(9-79)117-70)127-65-49(104)42(97)31(86)18(5-75)113-65)37(92)26(120-66)12-108-62-50(105)54(123-68-57(44(99)33(88)20(7-77)115-68)126-64-48(103)41(96)30(85)17(4-74)112-64)36(91)25(119-62)13-109-67-56(43(98)32(87)19(6-76)114-67)125-63-47(102)40(95)29(84)16(3-73)111-63/h16-70,73-81,84-107H,3-13H2,1-2H3,(H,71,82)(H,72,83)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52-,53-,54+,55+,56+,57+,58+,59+,60-,61+,62+,63-,64-,65-,66+,67+,68-,69-,70-/m1/s1",alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,PubMed citation,2429766
3175,62693,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-D-Glcp,A branched amino octasaccharide consisting of a beta-D-galactosyl-(1->4)-D-glucose moiety with the galactosyl residue having an alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl group attached at the 3-position and an alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl group at the 6-position.,"InChI=1S/C52H88N2O39/c1-11-23(62)28(67)34(73)48(80-11)89-41-19(9-59)86-47(22(54-14(4)61)43(41)92-51-37(76)31(70)26(65)16(6-56)84-51)93-44-27(66)20(87-52(38(44)77)88-39-17(7-57)82-45(78)33(72)32(39)71)10-79-46-21(53-13(3)60)42(91-49-35(74)29(68)24(63)12(2)81-49)40(18(8-58)85-46)90-50-36(75)30(69)25(64)15(5-55)83-50/h11-12,15-52,55-59,62-78H,5-10H2,1-4H3,(H,53,60)(H,54,61)/t11-,12-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27-,28+,29+,30-,31-,32+,33+,34-,35-,36+,37+,38+,39+,40+,41+,42+,43+,44-,45?,46+,47-,48-,49-,50-,51-,52-/m0/s1",alpha-Fuc-(1->3)-[beta-Gal-(1->4)]-beta-GlcNAc-(1->6)-[beta-Gal-(1->3)-[alpha-Fuc-(1->4)]-beta-GlcNAc-(1->3)]-beta-Gal-(1->4)-Glc,KEGG GLYCAN accession,G01159
3176,62694,alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"A branched amino octasaccharide made up from three galactose residues, two N-acetylglucosamine residues, one glucose residue and two fucose residues.","InChI=1S/C52H88N2O39/c1-11-23(63)28(68)33(73)48(79-11)88-39-19(9-59)85-47(22(54-14(4)62)42(39)91-50-35(75)30(70)25(65)15(5-55)82-50)93-44-27(67)17(7-57)84-52(37(44)77)89-40-20(10-60)86-46(21(53-13(3)61)41(40)90-49-34(74)29(69)24(64)12(2)80-49)92-43-26(66)16(6-56)83-51(36(43)76)87-38-18(8-58)81-45(78)32(72)31(38)71/h11-12,15-52,55-60,63-78H,5-10H2,1-4H3,(H,53,61)(H,54,62)/t11-,12-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27-,28+,29+,30-,31+,32+,33-,34-,35+,36+,37+,38+,39+,40+,41+,42+,43-,44-,45?,46-,47-,48-,49-,50-,51-,52-/m0/s1",alpha-L-Fuc-(1->4)-[beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-Glc,KEGG GLYCAN accession,G01161
3177,62723,beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(2-hydroxydocosanoyl)sphingosine,A beta-D-galactosyl-(1->4)-beta-D-glucosylceramide where the ceramide N-acyl group is specified as 2-hydroxydocosanoyl.,"InChI=1S/C52H99NO14/c1-3-5-7-9-11-13-15-17-18-19-20-21-23-25-27-29-31-33-35-41(57)50(63)53-39(40(56)34-32-30-28-26-24-22-16-14-12-10-8-6-4-2)38-64-51-48(62)46(60)49(43(37-55)66-51)67-52-47(61)45(59)44(58)42(36-54)65-52/h32,34,39-49,51-52,54-62H,3-31,33,35-38H2,1-2H3,(H,53,63)/b34-32+/t39-,40+,41?,42+,43+,44-,45-,46+,47+,48+,49+,51+,52-/m0/s1",beta-lactosyl-N-(2-hydroxydocosanoyl)sphingosine,PubMed citation,1574084
3178,62725,4-methoxyglucobrassicin(1-),"An indolylmethylglucosinolate that is the conjugate base of 4-methoxyglucobrassicin, obtained by deprotonation of the sulfo group.","InChI=1S/C17H22N2O10S2/c1-27-10-4-2-3-9-13(10)8(6-18-9)5-12(19-29-31(24,25)26)30-17-16(23)15(22)14(21)11(7-20)28-17/h2-4,6,11,14-18,20-23H,5,7H2,1H3,(H,24,25,26)/p-1/t11-,14-,15+,16-,17+/m1/s1",4-methoxyglucobrassicin anion,KEGG COMPOUND accession,C08423
3179,62726,nitrosoperoxycarbonate(1-),"A carbon oxoanion that results from the removal of a proton from nitrosoperoxycarbonic acid. It is formed in vivo by nucleophilic reaction of peroxynitrite with carbon dioxide, and is an important reactive species in inflammation processes.","InChI=1S/CHNO5/c3-1(4)6-7-2-5/h(H,3,4)/p-1",ONOOCO2(-),PubMed citation,18053331
3180,62727,molybdopterin adenine dinucleotide(3-),An organophosphate oxoanion that is molybdopterin adenine dinucleotide protonated to pH 7.3.,"InChI=1S/C20H26N10O12P2S2/c21-14-8-16(24-3-23-14)30(4-25-8)19-11(32)10(31)5(41-19)1-38-43(34,35)42-44(36,37)39-2-6-12(45)13(46)7-18(40-6)27-15-9(26-7)17(33)29-20(22)28-15/h3-7,10-11,18-19,26,31-32,45-46H,1-2H2,(H,34,35)(H,36,37)(H2,21,23,24)(H4,22,27,28,29,33)/p-3/t5-,6-,7+,10-,11-,18-,19-/m1/s1",adenylyl-molybdopterin(3-),PubMed citation,15504727
3181,62728,molybdopterin adenine dinucleotide,A molybdopterin dinucleotide resulting from the formal condensation of the phosphate groups of molybdopterin and adenosine 5'-monophosphate to give a diphosphate linkage.,"InChI=1S/C20H26N10O12P2S2/c21-14-8-16(24-3-23-14)30(4-25-8)19-11(32)10(31)5(41-19)1-38-43(34,35)42-44(36,37)39-2-6-12(45)13(46)7-18(40-6)27-15-9(26-7)17(33)29-20(22)28-15/h3-7,10-11,18-19,26,31-32,45-46H,1-2H2,(H,34,35)(H,36,37)(H2,21,23,24)(H4,22,27,28,29,33)/t5-,6-,7+,10-,11-,18-,19-/m1/s1",adenylyl-molybdopterin,PubMed citation,15504727
3182,62742,"all-trans-4,4'-diapo-zeta-carotene","A 4,4'-diapo-zeta-carotene in which the double bonds at positions 6, 8, 10, 12, 14, 16, and 18 have E- (trans-) geometry.","InChI=1S/C30H44/c1-25(2)15-11-19-29(7)23-13-21-27(5)17-9-10-18-28(6)22-14-24-30(8)20-12-16-26(3)4/h9-10,13-18,21-24H,11-12,19-20H2,1-8H3/b10-9+,21-13+,22-14+,27-17+,28-18+,29-23+,30-24+","4,4'-diapo-zeta-carotene",PubMed citation,10498735
3183,62767,crocetin(2-),A dicarboxylic acid dianion resulting from the removal of a proton from both of the carboxy groups of crocetin. The major species at pH 7.3.,"InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)/p-2/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+","8,8'-diapocarotenedioate",MetaCyc accession,CPD-8662
3184,62771,beta-D-gentiobiosyl beta-D-glucosyl crocetin,A diester resulting from the formal condensation of the carboxylic acid group of beta-D-gentiobiosyl crocetin with the anomeric hydroxy group of beta-D-glucopyranose.,"InChI=1S/C38H54O19/c1-18(11-7-13-20(3)34(50)56-37-32(48)29(45)26(42)23(16-40)54-37)9-5-6-10-19(2)12-8-14-21(4)35(51)57-38-33(49)30(46)27(43)24(55-38)17-52-36-31(47)28(44)25(41)22(15-39)53-36/h5-14,22-33,36-49H,15-17H2,1-4H3/b6-5+,11-7+,12-8+,18-9+,19-10+,20-13+,21-14+/t22-,23-,24-,25-,26-,27-,28+,29+,30+,31-,32-,33-,36-,37+,38+/m1/s1",trans-crocetin (beta-D-glucosyl)(beta-D-gentibiosyl) ester,PubMed citation,15605174
3185,62784,coenzyme F390-A,8-OH adenylated form of the deazaflavin coenzyme F420.,"InChI=1S/C39H48N10O24P2/c1-15(34(58)45-20(38(62)63)4-6-25(52)44-19(37(60)61)5-7-26(53)54)72-74(65,66)69-11-23(51)28(55)22(50)10-48-21-9-17(3-2-16(21)8-18-32(48)46-39(64)47-35(18)59)73-75(67,68)70-12-24-29(56)30(57)36(71-24)49-14-43-27-31(40)41-13-42-33(27)49/h2-3,8-9,13-15,19-20,22-24,28-30,36,50-51,55-57H,4-7,10-12H2,1H3,(H,44,52)(H,45,58)(H,53,54)(H,60,61)(H,62,63)(H,65,66)(H,67,68)(H2,40,41,42)(H,47,59,64)/t15-,19-,20-,22-,23+,24+,28-,29+,30+,36+/m0/s1",8-hydroxyadenylylated-coenzyme F420,PubMed citation,1647779
3186,62786,coenzyme F390-G,8-OH guanylated form of the deazaflavin coenzyme F420.,"InChI=1S/C39H48N10O25P2/c1-14(32(58)43-19(37(63)64)4-6-24(52)42-18(36(61)62)5-7-25(53)54)73-75(66,67)70-11-22(51)27(55)21(50)10-48-20-9-16(3-2-15(20)8-17-30(48)45-39(65)47-33(17)59)74-76(68,69)71-12-23-28(56)29(57)35(72-23)49-13-41-26-31(49)44-38(40)46-34(26)60/h2-3,8-9,13-14,18-19,21-23,27-29,35,50-51,55-57H,4-7,10-12H2,1H3,(H,42,52)(H,43,58)(H,53,54)(H,61,62)(H,63,64)(H,66,67)(H,68,69)(H,47,59,65)(H3,40,44,46,60)/t14-,18-,19-,21-,22+,23+,27-,28+,29+,35+/m0/s1",8-hydroxyguanylylated-coenzyme F420,PubMed citation,7957247
3187,62788,"3-nonaprenyl-4,5-dihydroxybenzoic acid","A dihydroxybenzoic acid that is 3,4-dihydroxybenzoic acid in which the hydrogen at position 5 is substituted by a nonaprenyl group.","InChI=1S/C52H78O4/c1-39(2)19-11-20-40(3)21-12-22-41(4)23-13-24-42(5)25-14-26-43(6)27-15-28-44(7)29-16-30-45(8)31-17-32-46(9)33-18-34-47(10)35-36-48-37-49(52(55)56)38-50(53)51(48)54/h19,21,23,25,27,29,31,33,35,37-38,53-54H,11-18,20,22,24,26,28,30,32,34,36H2,1-10H3,(H,55,56)/b40-21+,41-23+,42-25+,43-27+,44-29+,45-31+,46-33+,47-35+","3,4-dihydroxy-5-nonaprenylbenzoic acid",MetaCyc accession,CPD-9896
3188,62789,"3-nonaprenyl-4,5-dihydroxybenzoate","A 3,4-dihydroxy-5-polyprenylbenzoate in which the polyprenyl chain contains 9 prenyl units; major species at pH 7.3.","InChI=1S/C52H78O4/c1-39(2)19-11-20-40(3)21-12-22-41(4)23-13-24-42(5)25-14-26-43(6)27-15-28-44(7)29-16-30-45(8)31-17-32-46(9)33-18-34-47(10)35-36-48-37-49(52(55)56)38-50(53)51(48)54/h19,21,23,25,27,29,31,33,35,37-38,53-54H,11-18,20,22,24,26,28,30,32,34,36H2,1-10H3,(H,55,56)/p-1/b40-21+,41-23+,42-25+,43-27+,44-29+,45-31+,46-33+,47-35+","3,4-dihydroxy-5-nonaprenylbenzoate",MetaCyc accession,CPD-9896
3189,62791,3-nonaprenyl-4-hydroxy-5-methoxybenzoate,A 3-methoxy-4-hydroxy-5-all-trans-polyprenylbenzoate in which the polyprenyl chain contains 9 prenyl units; major species at pH 7.3.,"InChI=1S/C53H80O4/c1-40(2)20-12-21-41(3)22-13-23-42(4)24-14-25-43(5)26-15-27-44(6)28-16-29-45(7)30-17-31-46(8)32-18-33-47(9)34-19-35-48(10)36-37-49-38-50(53(55)56)39-51(57-11)52(49)54/h20,22,24,26,28,30,32,34,36,38-39,54H,12-19,21,23,25,27,29,31,33,35,37H2,1-11H3,(H,55,56)/p-1/b41-22+,42-24+,43-26+,44-28+,45-30+,46-32+,47-34+,48-36+",all-trans-3-nonaprenyl-4-hydroxy-5-methoxybenzoate,MetaCyc accession,CPD-9898
3190,62795,beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp,A trisaccharide consisting of three beta-D-mannose units connected via (1->4) linkages.,"InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17+,18+/m1/s1",beta-D-mannosyl-(1->4)-beta-D-mannosyl-(1->4)-beta-D-mannose,Reaxys Registry Number,1358949
3191,62797,beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-beta-D-Xylp,A trisaccharide consisting of three beta-D-xylose units connected via (1->4)-linkages.,"InChI=1S/C15H26O13/c16-4-1-25-14(11(21)7(4)17)28-6-3-26-15(12(22)9(6)19)27-5-2-24-13(23)10(20)8(5)18/h4-23H,1-3H2/t4-,5-,6-,7+,8+,9+,10-,11-,12-,13-,14+,15+/m1/s1",beta-D-xylosyl-(1->4)-beta-D-xylosyl-(1->4)-beta-D-xylosyl,Reaxys Registry Number,1298372
3192,62798,alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-D-Glcp,A trisaccharide consisting of three alpha-D-glucose units connected via (1->3) linkages. Also known as alpha-nigerotriose.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)11(26)17(31-4)34-15-9(24)6(3-21)32-18(13(15)28)33-14-8(23)5(2-20)30-16(29)12(14)27/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11-,12-,13-,14+,15+,16+,17-,18-/m1/s1",alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-D-Glcp,Reaxys Registry Number,1443473
3193,62801,ethyl,An organic radical derived from ethane.,"InChI=1S/C2H5/c1-2/h1H2,2H3",CH3CH2(.),Reaxys Registry Number,1696838
3194,62805,isooctane,An alkane that consists of pentane bearing two methyl substituents at position 2 and a single methyl substituent at position 4.,"InChI=1S/C8H18/c1-7(2)6-8(3,4)5/h7H,6H2,1-5H3",iso-octane,Reaxys Registry Number,1696876
3195,62809,trans-heme d hydroxychlorin gamma-spirolactone(1-),A monocarboxylic acid anion resulting from the removal of a proton from the carboxylic acid group of trans-heme d hydroxychlorin gamma-spirolactone.,"InChI=1S/C34H33N4O5.Fe/c1-7-20-17(3)23-13-24-19(5)22(9-10-31(39)40)28(37-24)16-30-34(12-11-32(41)43-34)33(6,42)29(38-30)15-27-21(8-2)18(4)25(36-27)14-26(20)35-23;/h7-8,13-16,42H,1-2,9-12H2,3-6H3,(H2-,35,36,37,38,39,40);/q-1;+2/p-2/t33-,34-;/m0./s1","{3-[(2SR,5'SR)-9',14'-diethenyl-5'-hydroxy-5',10',15',19'-tetramethyl-5-oxo-4,5-dihydro-3H-spiro[furan-2,4'-[21,22,23,24]tetraazapentacyclo[16.2.1.1(3,6).1(8,11).1(13,16)]tetracosa[1,3(24),6,8,10,12,14,16(22),17,19]decaen]-20'-yl-kappa(4)N(21'),N(22'),N(23'),N(24')]propanoato(3-)}ferrate(1-)",PubMed citation,8621527
3196,62811,heme d cis-diol,A metallochlorin that is ferroheme b which is cis-dihydroxylated at positions 5 and 6.,"InChI=1S/C34H36N4O6.Fe/c1-7-20-17(3)23-13-24-19(5)22(9-10-31(39)40)28(37-24)16-30-34(44,12-11-32(41)42)33(6,43)29(38-30)15-27-21(8-2)18(4)25(36-27)14-26(20)35-23;/h7-8,13-16,43-44H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-2/t33-,34+;/m0./s1",ferroheme d,MetaCyc accession,HEME_D
3197,62812,heme d trans-diol,A metallochlorin that is ferroheme b which is trans-dihydroxylated at positions 5 and 6.,"InChI=1S/C34H36N4O6.Fe/c1-7-20-17(3)23-13-24-19(5)22(9-10-31(39)40)28(37-24)16-30-34(44,12-11-32(41)42)33(6,43)29(38-30)15-27-21(8-2)18(4)25(36-27)14-26(20)35-23;/h7-8,13-16,43-44H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-2/t33-,34-;/m1./s1",haem d trans-diol,PubMed citation,8621527
3198,62814,heme d cis-diol(2-),A dicarboxylic acid dianion resulting from the removal of a proton from both of the carboxy groups of heme d cis-diol.,"InChI=1S/C34H36N4O6.Fe/c1-7-20-17(3)23-13-24-19(5)22(9-10-31(39)40)28(37-24)16-30-34(44,12-11-32(41)42)33(6,43)29(38-30)15-27-21(8-2)18(4)25(36-27)14-26(20)35-23;/h7-8,13-16,43-44H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);/q;+2/p-4/t33-,34+;/m0./s1",haem d cis-diol(2-),PubMed citation,8621527
3199,62815,alpha-D-GlcNS(6S)-(1->4)-L-IdoUA(2S),A two-membered oligosaccharide sulfate that consists of 2-O-sulfo-L-idopyranuronic acid having a 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl residue attached at the 4-position.,"InChI=1S/C12H21NO20S3/c14-4-2(1-29-35(23,24)25)30-12(3(5(4)15)13-34(20,21)22)32-7-6(16)8(33-36(26,27)28)11(19)31-9(7)10(17)18/h2-9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/t2-,3-,4-,5-,6+,7+,8-,9-,11?,12-/m1/s1",GlcNS6OS-IdoA2OS,PubMed citation,16860191
3200,62817,alpha-D-GlcNS(6S)-(1->4)-alpha-L-IdoUA(2S)-(1->4)-D-GlcNS(6S),"A three-membered linear oligosaccharide sulfate that consists of a 2-O-sulfo-L-idopyranuronic acid residue flanked by two 6-O-sulfo-2-(sulfoamino)-D-glucopyranose residues, connected via alpha-(1->4)-linkages.","InChI=1S/C18H32N2O30S5/c21-7-3(1-43-53(34,35)36)46-17(6(8(7)22)20-52(31,32)33)48-12-10(24)13(50-55(40,41)42)18(49-14(12)15(25)26)47-11-4(2-44-54(37,38)39)45-16(27)5(9(11)23)19-51(28,29)30/h3-14,16-24,27H,1-2H2,(H,25,26)(H,28,29,30)(H,31,32,33)(H,34,35,36)(H,37,38,39)(H,40,41,42)/t3-,4-,5-,6-,7-,8-,9-,10+,11-,12+,13-,14-,16?,17-,18-/m1/s1",GlcNS6OS-IdoA2OS-GlcNS6OS,PubMed citation,16860191
3201,62818,alpha-L-IdoUA-(1->4)-D-GlcNS(6S),A two-membered oligosaccharide sulfate that consists of 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucose having an alpha-L-idopyranuronosyl residue attached at the 4-position.,"InChI=1S/C12H21NO17S2/c14-4-3(13-31(21,22)23)11(20)28-2(1-27-32(24,25)26)8(4)29-12-7(17)5(15)6(16)9(30-12)10(18)19/h2-9,11-17,20H,1H2,(H,18,19)(H,21,22,23)(H,24,25,26)/t2-,3-,4-,5+,6+,7-,8-,9-,11?,12-/m1/s1",IdoA-GlcNS6OS,PubMed citation,16860191
3202,62824,"2',3'-secoguanosine",A triol obtained by sequential periodate-oxidation and borohydride-reduction of guanosine.,"InChI=1S/C10H15N5O5/c11-10-13-8-7(9(19)14-10)12-4-15(8)6(3-18)20-5(1-16)2-17/h4-6,16-18H,1-3H2,(H3,11,13,14,19)/t6-/m1/s1","periodate-oxidised, borohydride-reduced guanosine",Reaxys Registry Number,5764364
3203,62827,dibromobimane,"A pyrazolopyrazole that consists of 1H,7H-pyrazolo[1,2-a]pyrazole-1,7-dione bearing two methyl substituents at positions 2 and 6 as well as two bromomethyl substituents at positions 3 and 5.","InChI=1S/C10H10Br2N2O2/c1-5-7(3-11)13-8(4-12)6(2)10(16)14(13)9(5)15/h3-4H2,1-2H3",dBBr,Reaxys Registry Number,4189453
3204,62828,methylbimane,"A pyrazolopyrazole that consists of 1H,7H-pyrazolo[1,2-a]pyrazole-1,7-dione bearing four methyl substituents at positions 2, 3, 5 and 6.",InChI=1S/C10H12N2O2/c1-5-7(3)11-8(4)6(2)10(14)12(11)9(5)13/h1-4H3,syn-bimane,Reaxys Registry Number,743974
3205,62830,dTDP-4-dehydro-beta-L-rhamnose(2-),The nucleotide-sugar oxoanion that is the dianion formed from dTDP-4-dehydro-beta-L-rhamnose by loss of two protons from its diphospho group.  Intermediate in dTDP-rhamnose biosynthesis.,"InChI=1S/C16H24N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-10,12-13,15,19,21-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/p-2/t7-,8-,9+,10+,12+,13+,15+/m0/s1",dTDP-L-lyxo-hexulose,PubMed citation,11302803
3206,62833,1-myristoyl-sn-glycerol 3-phosphate,A 1-acyl-sn-glycerol 3-phosphate having myristoyl (tetradecanoyl) as the 1-O-acyl group.,"InChI=1S/C17H35O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-17(19)23-14-16(18)15-24-25(20,21)22/h16,18H,2-15H2,1H3,(H2,20,21,22)/t16-/m1/s1",1-myristoylglycerol 3-phosphate,PubMed citation,17887800
3207,62834,1-linoleoyl-sn-glycerol 3-phosphate,"A 1-acyl-sn-glycerol 3-phosphate having linoleyl (9Z,12Z-octadecadienoyl) as the 1-O-acyl group.","InChI=1S/C21H39O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)27-18-20(22)19-28-29(24,25)26/h6-7,9-10,20,22H,2-5,8,11-19H2,1H3,(H2,24,25,26)/b7-6-,10-9-/t20-/m1/s1",1-O-linoleyl-sn-glycerol 3-phosphate,LIPID MAPS instance accession,LMGP10050017
3208,62835,1-(18-mercaptooctadecanoyl)-sn-glycerol 3-phosphate,A 1-acyl-sn-glycerol 3-phosphate having 18-mercaptooctadecanoyl as the 1-O-acyl group.,"InChI=1S/C21H43O7PS/c22-20(19-28-29(24,25)26)18-27-21(23)16-14-12-10-8-6-4-2-1-3-5-7-9-11-13-15-17-30/h20,22,30H,1-19H2,(H2,24,25,26)/t20-/m1/s1",1-O-(18-mercaptooctadecanoyl)-sn-glycerol 3-phosphate,PubMed citation,21392506
3209,62837,1-oleoyl-sn-glycerol 3-phosphate,A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.,"InChI=1S/C21H41O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)27-18-20(22)19-28-29(24,25)26/h9-10,20,22H,2-8,11-19H2,1H3,(H2,24,25,26)/b10-9-/t20-/m1/s1",18:1 LPA,LIPID MAPS instance accession,LMGP10050008
3210,62838,"1-oleoyl-sn-glycerol 2,3-cyclic phosphate","A 1-acyl-sn-glycerol 2,3-cyclic phosphate having oleoyl as the 1-O-acyl group.","InChI=1S/C21H39O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(22)25-18-20-19-26-28(23,24)27-20/h9-10,20H,2-8,11-19H2,1H3,(H,23,24)/b10-9-/t20-/m1/s1","1-oleyl-sn-glycerol 2,3-cyclic phosphate",LIPID MAPS instance accession,LMGP00000056
3211,62840,1-lauroyl-sn-glycerol 3-phosphate,A 1-acyl-sn-glycerol 3-phosphate having lauroyl (dodecanoyl) as the 1-O-acyl group.,"InChI=1S/C15H31O7P/c1-2-3-4-5-6-7-8-9-10-11-15(17)21-12-14(16)13-22-23(18,19)20/h14,16H,2-13H2,1H3,(H2,18,19,20)/t14-/m1/s1",1-dodecanoyl-sn-glycerol 3-phosphate,LIPID MAPS instance accession,LMGP10050015
3212,62842,beryllium oxide,"A beryllium molecular entity consisting of beryllium (+2 oxidation state) and oxide in the ratio 1:1. In the solid state, BeO adopts the hexagonal wurtzite structure form while in the vapour phase, it is present as discrete diatomic covalent molecules.",InChI=1S/Be.O,BeO,Wikipedia accession,Beryllium_oxide
3213,62848,11beta-hydroxy-17beta-estradiol,A 4-hydroxy steroid that consists of 17beta-estradiol bearing an additional 11beta-hydroxy substituent.,"InChI=1S/C18H24O3/c1-18-9-15(20)17-12-5-3-11(19)8-10(12)2-4-13(17)14(18)6-7-16(18)21/h3,5,8,13-17,19-21H,2,4,6-7,9H2,1H3/t13-,14-,15-,16-,17+,18-/m0/s1",11beta-hydroxyestradiol,Reaxys Registry Number,3210438
3214,62850,"6,7-didehydro-17beta-estradiol",A 3-hydroxy steroid that is obtained by formal dehydrogenation across positions 6 and 7 of 17beta-estradiol.,"InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h2-5,10,14-17,19-20H,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1",6-dehydro-17beta-estradiol,KEGG COMPOUND accession,C14590
3215,62851,"7,8-didehydro-17beta-estradiol",A 3-hydroxy steroid that is obtained by formal dehydrogenation across positions 7 and 8 of 17beta-estradiol.,"InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16-17,19-20H,2,6-9H2,1H3/t14-,16+,17+,18+/m1/s1",7-dehydro-17beta-estradiol,CAS Registry Number,3563-27-7
3216,62852,6beta-[N-(carboxymethylamino)carbonyl]methoxy-17beta-estradiol,A steroid acid that consists of 17beta-estradiol bearing an N-(carboxymethylamino)carbonylmethoxy at the 6beta-position,"InChI=1S/C22H29NO6/c1-22-7-6-14-13-3-2-12(24)8-16(13)18(29-11-20(26)23-10-21(27)28)9-15(14)17(22)4-5-19(22)25/h2-3,8,14-15,17-19,24-25H,4-7,9-11H2,1H3,(H,23,26)(H,27,28)/t14-,15-,17+,18-,19+,22+/m1/s1",6beta-EMC-17beta-estradiol,PubMed citation,11812141
3217,62855,(-)-beta-elemene,"The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.","InChI=1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3/t13-,14+,15-/m1/s1",beta-elemene,CAS Registry Number,515-13-9
3218,62856,L-homolanthionine,A sulfur-containing amino acid in which the gamma-carbon atoms of two molecules of L-aminobutyric acid are joined via a thioether linkage. It is a byproduct of cystathionine-gamma-lyase and a possible human hyperhomocysteinemia marker.,"InChI=1S/C8H16N2O4S/c9-5(7(11)12)1-3-15-4-2-6(10)8(13)14/h5-6H,1-4,9-10H2,(H,11,12)(H,13,14)/t5-,6-/m0/s1",homolanthionine,PubMed citation,19261609
3219,62858,"4,6-Me(COOH)C-beta-D-Man-(1->4)-beta-D-GlcA-(1->2)-alpha-D-Man-(1->3)-beta-D-Glc-(1->4)-alpha-D-Glc-1-diphospho-ditrans,polycis-undecaprenol","An oligosaccharide phosphate that is beta-D-Man-(1->4)-beta-D-GlcA-(1->2)-alpha-D-Man-(1->3)-beta-D-Glc-(1->4)-alpha-D-Glc-1-diphospho-ditrans,polycis-undecaprenol in which the terminal mannosyl group has been converted to its 4,6-O-1-carboxyethylidene derivative.","InChI=1S/C88H142O35P2/c1-50(2)24-14-25-51(3)26-15-27-52(4)28-16-29-53(5)30-17-31-54(6)32-18-33-55(7)34-19-35-56(8)36-20-37-57(9)38-21-39-58(10)40-22-41-59(11)42-23-43-60(12)44-45-111-124(106,107)123-125(108,109)122-85-73(100)68(95)75(63(48-91)114-85)116-84-74(101)77(66(93)62(47-90)112-84)117-86-79(67(94)65(92)61(46-89)113-86)119-83-72(99)70(97)78(80(120-83)81(102)103)118-82-71(98)69(96)76-64(115-82)49-110-88(13,121-76)87(104)105/h24,26,28,30,32,34,36,38,40,42,44,61-80,82-86,89-101H,14-23,25,27,29,31,33,35,37,39,41,43,45-49H2,1-13H3,(H,102,103)(H,104,105)(H,106,107)(H,108,109)/b51-26+,52-28+,53-30-,54-32-,55-34-,56-36-,57-38-,58-40-,59-42-,60-44-/t61-,62-,63-,64-,65-,66-,67+,68-,69-,70-,71+,72-,73-,74-,75-,76-,77+,78+,79+,80+,82+,83-,84+,85-,86-,88?/m1/s1","4,6-O-(1-carboxyethylidene)-beta-D-Man-(1->4)-beta-D-GlcA-(1->2)-alpha-D-Man-(1->3)-beta-D-Glc-(1->4)-alpha-D-Glc-1-diphospho-ditrans,polycis-undecaprenol",PubMed citation,1657892
3220,62859,alpha-D-GalpN-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp,alpha-D-GalpN-(1->3)-[alpha-L-Fucp-(1->2)]-D-Galp in which the configuration of the anomeric carbon of the galactose residue at the reducing end is beta.,"InChI=1S/C18H33NO14/c1-4-8(22)12(26)13(27)18(29-4)33-15-14(10(24)6(3-21)30-16(15)28)32-17-7(19)11(25)9(23)5(2-20)31-17/h4-18,20-28H,2-3,19H2,1H3/t4-,5+,6+,7+,8+,9-,10-,11+,12+,13-,14-,15+,16+,17+,18-/m0/s1",alpha-L-fucosyl-(1->2)-[alpha-D-galactosaminyl-(1->3)]-beta-D-galactose,PubMed citation,16133833
3221,62861,tetrastearoyl cardiolipin,A cardiolipin derivative in which all four of the phosphatidyl acyl groups are specified as stearoyl (octadecanoyl).,"InChI=1S/C81H158O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-65-78(83)91-71-76(97-80(85)67-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)73-95-99(87,88)93-69-75(82)70-94-100(89,90)96-74-77(98-81(86)68-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)72-92-79(84)66-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2/h75-77,82H,5-74H2,1-4H3,(H,87,88)(H,89,90)/t76-,77-/m1/s1","1,1'2,2'-tetrastearoylcardiolipin",Reaxys Registry Number,1900028
3222,62862,tetramyristoyl cardiolipin,A cardiolipin derivative in which all four of the phosphatidyl acyl groups are specified as myristoyl (tetradecanoyl).,"InChI=1S/C65H126O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-62(67)75-55-60(81-64(69)51-47-43-39-35-31-27-23-19-15-11-7-3)57-79-83(71,72)77-53-59(66)54-78-84(73,74)80-58-61(82-65(70)52-48-44-40-36-32-28-24-20-16-12-8-4)56-76-63(68)50-46-42-38-34-30-26-22-18-14-10-6-2/h59-61,66H,5-58H2,1-4H3,(H,71,72)(H,73,74)/t60-,61-/m1/s1",tetramyristoylcardiolipin,Reaxys Registry Number,6130339
3223,62863,"1,1'-dilinoleyl 2,2'-dilysocardiolipin","A 2,2'-dilyso cardiolipin in which both of the phosphatidyl acyl groups are specified as linoleoyl.","InChI=1S/C45H82O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-44(49)55-35-41(46)37-57-61(51,52)59-39-43(48)40-60-62(53,54)58-38-42(47)36-56-45(50)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11-14,17-20,41-43,46-48H,3-10,15-16,21-40H2,1-2H3,(H,51,52)(H,53,54)/b13-11-,14-12-,19-17-,20-18-/t41-,42-/m1/s1","1,1'-dilinoleoyl 2,2'-dilysocardiolipin",LIPID MAPS instance accession,LMGP12070001
3224,62865,"ethanolamine-P-6-alpha-Man-(1->2)-alpha-Man-(1->6)-[alpha-Gal-(1->2)-alpha-Gal-(1->6)-[alpha-Gal-(1->2)]-alpha-Gal-(1->3)]-alpha-Man-(1->4)-alpha-GlcN-(1->6)-inositol-1,2-cyclic phosphate","A myo-inositol cyclic phosphate that consists of 1D-myo-inositol 1,2-cyclic phosphate having an octasaccharide moiety made up from four alpha-galactosyl residues, three alpha-mannosyl residues and one alpha-glucosaminyl residue, which at the reducing end is attached at position 6 via a glycosidic linkage.","InChI=1S/C56H98N2O49P2/c57-1-2-108(85,86)91-10-18-24(68)30(74)39(83)52(98-18)104-46-33(77)23(67)14(6-62)95-55(46)90-9-17-26(70)42(40(84)53(97-17)100-41-15(7-63)96-49(19(58)27(41)71)102-43-35(79)31(75)36(80)44-48(43)107-109(87,88)106-44)101-56-47(105-51-38(82)29(73)21(65)12(4-60)93-51)34(78)25(69)16(99-56)8-89-54-45(32(76)22(66)13(5-61)94-54)103-50-37(81)28(72)20(64)11(3-59)92-50/h11-56,59-84H,1-10,57-58H2,(H,85,86)(H,87,88)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20+,21+,22+,23-,24-,25+,26-,27-,28+,29+,30+,31+,32+,33+,34+,35+,36-,37-,38-,39+,40+,41-,42+,43-,44-,45-,46+,47-,48+,49-,50-,51-,52-,53-,54+,55+,56-/m1/s1","ethanolamine-P-6-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-[alpha-D-Galp-(1->2)-alpha-D-Galp-(1->6)-[alpha-D-Galp-(1->2)]-alpha-D-Galp-(1->3)]-alpha-D-Manp-(1->4)-alpha-D-GlcpN-(1->6)-inositol-1,2-cyclic phosphate",PubMed citation,2458923
3225,62882,IWR-1-endo,"A dicarboximide having an endo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group.","InChI=1S/C25H19N3O3/c29-23(27-19-5-1-3-14-4-2-12-26-22(14)19)15-8-10-18(11-9-15)28-24(30)20-16-6-7-17(13-16)21(20)25(28)31/h1-12,16-17,20-21H,13H2,(H,27,29)/t16-,17+,20-,21+",IRW1,Patent accession,WO2009155001
3226,62888,allyl diphosphate,An organic diphosphate formed by condensation of diphosphoric acid with allyl alcohol.,"InChI=1S/C3H8O7P2/c1-2-3-9-12(7,8)10-11(4,5)6/h2H,1,3H2,(H,7,8)(H2,4,5,6)",allyl pyrophosphate,Reaxys Registry Number,1912908
3227,62890,2-(2-carboxy-4-methylthiazol-5-yl)ethyl phosphate(3-),The organophosphate oxoanion that is 2-(2-carboxy-4-methylthiazol-5-yl)ethyl phosphate protonated to pH 7.3,"InChI=1S/C7H10NO6PS/c1-4-5(2-3-14-15(11,12)13)16-6(8-4)7(9)10/h2-3H2,1H3,(H,9,10)(H2,11,12,13)/p-3",cThz-P,PubMed citation,21534620
3228,62892,crotyl diphosphate,An organic diphosphate formed by condensation of diphosphoric acid with crotyl alcohol.,"InChI=1S/C4H10O7P2/c1-2-3-4-10-13(8,9)11-12(5,6)7/h2-3H,4H2,1H3,(H,8,9)(H2,5,6,7)",crotyl pyrophosphate,PubMed citation,7753173
3229,62896,dimethylallyl-UTP,"An organic triphosphate formed by condensation between the gamma-phospho group of uridine 5'-triphosphate and prenol (gamma,gamma-dimethylallyl alcohol).","InChI=1S/C14H23N2O15P3/c1-8(2)4-6-27-32(21,22)30-34(25,26)31-33(23,24)28-7-9-11(18)12(19)13(29-9)16-5-3-10(17)15-14(16)20/h3-5,9,11-13,18-19H,6-7H2,1-2H3,(H,21,22)(H,23,24)(H,25,26)(H,15,17,20)/t9-,11-,12-,13-/m1/s1","gamma,gamma-dimethylallyl uridine-triphosphate",PubMed citation,7753173
3230,62897,isopentenyl-UTP,An organic triphosphate formed by condensation between the gamma-phospho group of uridine 5'-triphosphate and isopentenyl alcohol.,"InChI=1S/C14H23N2O15P3/c1-8(2)4-6-27-32(21,22)30-34(25,26)31-33(23,24)28-7-9-11(18)12(19)13(29-9)16-5-3-10(17)15-14(16)20/h3,5,9,11-13,18-19H,1,4,6-7H2,2H3,(H,21,22)(H,23,24)(H,25,26)(H,15,17,20)/t9-,11-,12-,13-/m1/s1",isopentenyl uridine-triphosphate,Reaxys Registry Number,11937611
3231,62899,"(R,Z)- 2-carboxylato-4-methyl-5-[(2-phosphonatooxy)ethylidene]-2,5-dihydrothiazole(3-)","The organophosphate oxoanion that is the 2R,5Z isomer of 2-carboxylato-4-methyl-5-[(2-phosphonatooxy)ethylidene]-2,5-dihydrothiazole(3-); protonated to pH 7.3.","InChI=1S/C7H10NO6PS/c1-4-5(2-3-14-15(11,12)13)16-6(8-4)7(9)10/h2,6H,3H2,1H3,(H,9,10)(H2,11,12,13)/p-3/b5-2-/t6-/m1/s1",cThz*-P,PubMed citation,21534620
3232,62900,ethyl-dTTP,An organic triphosphate formed by condensation between the gamma-phospho group of thymidine 5'-triphosphate and ethanol.,"InChI=1S/C12H21N2O14P3/c1-3-24-29(18,19)27-31(22,23)28-30(20,21)25-6-9-8(15)4-10(26-9)14-5-7(2)11(16)13-12(14)17/h5,8-10,15H,3-4,6H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)(H,13,16,17)/t8-,9+,10+/m0/s1",gamma-monoethyl thymidine triphosphate,PubMed citation,7753173
3233,62904,ethyl-dTDP,An organic diphosphate formed by condensation between the beta-phospho group of thymidine diphosphate and ethanol.,"InChI=1S/C12H20N2O11P2/c1-3-22-26(18,19)25-27(20,21)23-6-9-8(15)4-10(24-9)14-5-7(2)11(16)13-12(14)17/h5,8-10,15H,3-4,6H2,1-2H3,(H,18,19)(H,20,21)(H,13,16,17)/t8-,9+,10+/m0/s1",beta-ethyl 2'-deoxythymidine diphosphate,PubMed citation,7753173
3234,62905,ethyl-UTP,An organic triphosphate formed by condensation between the gamma-phospho group of uridine 5'-triphosphate and ethanol.,"InChI=1S/C11H19N2O15P3/c1-2-24-29(18,19)27-31(22,23)28-30(20,21)25-5-6-8(15)9(16)10(26-6)13-4-3-7(14)12-11(13)17/h3-4,6,8-10,15-16H,2,5H2,1H3,(H,18,19)(H,20,21)(H,22,23)(H,12,14,17)/t6-,8-,9-,10-/m1/s1",gamma-ethyl uridine triphosphate,Reaxys Registry Number,14951955
3235,62906,ethyl-XTP,An organic triphosphate formed by condensation between the gamma-phospho group of xanthosine 5'-triphosphate and ethanol.,"InChI=1S/C12H19N4O15P3/c1-2-27-32(21,22)30-34(25,26)31-33(23,24)28-3-5-7(17)8(18)11(29-5)16-4-13-6-9(16)14-12(20)15-10(6)19/h4-5,7-8,11,17-18H,2-3H2,1H3,(H,21,22)(H,23,24)(H,25,26)(H2,14,15,19,20)/t5-,7-,8-,11-/m1/s1",gamma-ethyl xanthosine triphosphate,PubMed citation,7753173
3236,62907,ethyl-ITP,An organic triphosphate formed by condensation between the gamma-phospho group of inosine 5'-triphosphate and ethanol.,"InChI=1S/C12H19N4O14P3/c1-2-26-31(20,21)29-33(24,25)30-32(22,23)27-3-6-8(17)9(18)12(28-6)16-5-15-7-10(16)13-4-14-11(7)19/h4-6,8-9,12,17-18H,2-3H2,1H3,(H,20,21)(H,22,23)(H,24,25)(H,13,14,19)/t6-,8-,9-,12-/m1/s1",inosine 5'-(P(3)-ethyl trihydrogen triphosphate),PubMed citation,7753173
3237,62909,ethyl-CTP,An organic triphosphate formed by condensation between the gamma-phospho group of cytidine 5'-triphosphate and ethanol.,"InChI=1S/C11H20N3O14P3/c1-2-24-29(18,19)27-31(22,23)28-30(20,21)25-5-6-8(15)9(16)10(26-6)14-4-3-7(12)13-11(14)17/h3-4,6,8-10,15-16H,2,5H2,1H3,(H,18,19)(H,20,21)(H,22,23)(H2,12,13,17)/t6-,8-,9-,10-/m1/s1",monoethyl cytidine-triphosphate,PubMed citation,7753173
3238,62910,ethyl-ATP,An organic triphosphate formed by condensation between the gamma-phospho group of adenosine 5'-triphosphate and ethanol.,"InChI=1S/C12H20N5O13P3/c1-2-26-31(20,21)29-33(24,25)30-32(22,23)27-3-6-8(18)9(19)12(28-6)17-5-16-7-10(13)14-4-15-11(7)17/h4-6,8-9,12,18-19H,2-3H2,1H3,(H,20,21)(H,22,23)(H,24,25)(H2,13,14,15)/t6-,8-,9-,12-/m1/s1",monoethyl adenosine-triphosphate,PubMed citation,7753173
3239,62923,"1,5-bis(diphospho)-1D-myo-inositol 2,3,4,6-tetrakisphosphate",A 1D-myo-inositol bis(diphosphate) tetrakisphosphate having the two diphospho groups located at positions 1 and 5.,"InChI=1S/C6H20O30P8/c7-37(8,9)29-1-2(30-38(10,11)12)5(33-43(25,26)35-41(19,20)21)4(32-40(16,17)18)6(3(1)31-39(13,14)15)34-44(27,28)36-42(22,23)24/h1-6H,(H,25,26)(H,27,28)(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24)/t1-,2-,3-,4-,5+,6-/m1/s1","1,5-(PP)2-IP4",MetaCyc accession,CPD-11938
3240,62924,"3,5-bis(diphospho)-1D-myo-inositol 1,2,4,6-tetrakisphosphate",A 1D-myo-inositol bis(diphosphate) tetrakisphosphate having the two diphospho groups located at positions 3 and 5.,"InChI=1S/C6H20O30P8/c7-37(8,9)29-1-2(30-38(10,11)12)5(33-43(25,26)35-41(19,20)21)4(32-40(16,17)18)6(3(1)31-39(13,14)15)34-44(27,28)36-42(22,23)24/h1-6H,(H,25,26)(H,27,28)(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24)/t1-,2-,3-,4-,5+,6-/m0/s1","3,5-(PP)2-IP4",PDBeChem accession,2YN
3241,62949,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-Galp,A alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-D-Galp that has beta-configuration at the anomeric hydroxy group.,"InChI=1S/C18H32O15/c1-4-7(21)10(24)12(26)17(29-4)33-15-11(25)8(22)5(2-19)31-18(15)32-14-9(23)6(3-20)30-16(28)13(14)27/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8-,9-,10+,11-,12-,13+,14-,15+,16+,17-,18-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-Gal,PubMed citation,8737251
3242,62951,alpha-D-Gal-(1->3)-alpha-D-Gal-(1->4)-D-GlcNAc-(CH2)5CO2H,A glycoside that consists of alpha-D-galactosyl-(1->3)-alpha-D-galactosyl-(1->4)-N-acetyl-D-glucosamine in which the hydrogen at the reducing end is substituted by a carboxypentyl group.,"InChI=1S/C26H45NO18/c1-10(31)27-15-18(36)22(13(9-30)43-24(15)40-6-4-2-3-5-14(32)33)44-26-21(39)23(17(35)12(8-29)42-26)45-25-20(38)19(37)16(34)11(7-28)41-25/h11-13,15-26,28-30,34-39H,2-9H2,1H3,(H,27,31)(H,32,33)/t11-,12-,13-,15-,16+,17+,18-,19+,20-,21-,22-,23+,24?,25-,26-/m1/s1",alpha-D-Galp-(1->3)-alpha-D-Galp-(1->4)-D-GlcpNAc-(CH2)5CO2H p,PubMed citation,12538718
3243,62955,sodium 2-(N-morpholino)ethanesulfonate,The organic sodium salt that is the sodium salt of 2-(N-morpholino)ethanesulfonic acid.,"InChI=1S/C6H13NO4S.Na/c8-12(9,10)6-3-7-1-4-11-5-2-7;/h1-6H2,(H,8,9,10);/q;+1/p-1",2-(N-Morpholino)ethanesulfonic acid sodium salt,CAS Registry Number,71119-23-8
3244,62956,sodium dimethylarsinate,The organic sodium salt of dimethylarsinate.,"InChI=1S/C2H7AsO2.Na/c1-3(2,4)5;/h1-2H3,(H,4,5);/q;+1/p-1",sodium cacodylate,CAS Registry Number,124-65-2
3245,62964,magnesium acetate,The magnesium salt of acetic acid.,"InChI=1S/2C2H4O2.Mg/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2",magnesium diacetate,CAS Registry Number,142-72-3
3246,62965,sodium formate,An organic sodium salt which is the monosodium salt of formic acid.,"InChI=1S/CH2O2.Na/c2-1-3;/h1H,(H,2,3);/q;+1/p-1","formic acid, sodium salt",Reaxys Registry Number,3595134
3247,62982,ammonium dihydrogen phosphate,The ammonium salt of phosphoric acid (molar ratio 1:1).,"InChI=1S/H3N.H3O4P/c;1-5(2,3)4/h1H3;(H3,1,2,3,4)",monoammonium phosphate,CAS Registry Number,7722-76-1
3248,62983,sodium malonate,The organic sodium salt formed between sodium and malonic acid (molar ratio 2:1).,"InChI=1S/C3H4O4.2Na/c4-2(5)1-3(6)7;;/h1H2,(H,4,5)(H,6,7);;/q;2*+1/p-2",disodium malonate,CAS Registry Number,141-95-7
3249,62984,zinc acetate,An acetate salt in which the cationic component is zinc(2+).,"InChI=1S/2C2H4O2.Zn/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2",Zn(OAc)2,PubMed citation,21381680
3250,62988,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc,A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosamine having alpha-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine. Corresponds to a partial structure of blood group A type 1 oligosaccharide.,"InChI=1S/C34H58N2O24/c1-8-17(42)22(47)24(49)32(52-8)57-26-14(7-39)54-30(51)16(36-11(4)41)27(26)58-34-29(60-33-25(50)23(48)18(43)9(2)53-33)28(20(45)13(6-38)56-34)59-31-15(35-10(3)40)21(46)19(44)12(5-37)55-31/h8-9,12-34,37-39,42-51H,5-7H2,1-4H3,(H,35,40)(H,36,41)/t8-,9-,12+,13+,14+,15+,16+,17+,18+,19-,20-,21+,22+,23+,24-,25-,26+,27+,28-,29+,30+,31+,32-,33-,34-/m0/s1",alpha-L-Fuc-(1->2)-[alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc,PubMed citation,75942
3251,62994,beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc,"A tetrasaccharide comprising residues of galactose, N-acetylglucosamine, galactose and N-acetylglucosamine units in a linear sequence, all joined by beta-linkages.","InChI=1S/C28H48N2O21/c1-7(35)29-13-18(40)22(12(6-34)45-25(13)44)49-28-21(43)24(17(39)11(5-33)48-28)51-26-14(30-8(2)36)23(16(38)10(4-32)46-26)50-27-20(42)19(41)15(37)9(3-31)47-27/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15+,16-,17+,18-,19+,20-,21-,22-,23-,24+,25?,26+,27+,28+/m1/s1",beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine,KEGG GLYCAN accession,G01494
3252,62995,"2-methylpentane-2,4-diol",A glycol in which the two hydroxy groups are at positions 2 and 4 of 2-methylpentane (isopentane).,"InChI=1S/C6H14O2/c1-5(7)4-6(2,3)8/h5,7-8H,4H2,1-3H3",MPD,CAS Registry Number,107-41-5
3253,62996,alpha-D-GlcNAc-(1->2)-beta-D-Glc-(1->4)-[beta-D-Glc-(1->3)]-[alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-alpha-D-Glc-(1->2)-beta-D-Glc-(1->6)]-alpha-D-Glc-(1->5)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->6)-Lipid A,"A lipid A derivative that consists of a branched decasaccharide made up from two galactose, give glucose, one N-acetylglucosamine and two Kdo (one at the reducing end) units connected to lipid A via an alpha-(2->6)-linkage.","InChI=1S/C160H285N3O79P2/c1-8-14-20-26-32-38-39-45-51-57-63-69-110(182)218-92(67-61-55-49-43-36-30-24-18-12-5)73-112(184)230-143-115(163-108(180)72-91(66-60-54-48-42-35-29-23-17-11-4)217-109(181)68-62-56-50-44-37-31-25-19-13-6)147(214-85-104-122(191)142(229-111(183)71-90(175)65-59-53-47-41-34-28-22-16-10-3)114(149(226-104)242-244(211,212)213)162-107(179)70-89(174)64-58-52-46-40-33-27-21-15-9-2)227-106(141(143)241-243(208,209)210)87-216-159(157(204)205)75-96(238-160(158(206)207)74-93(176)116(185)135(239-160)94(177)76-164)139(136(240-159)95(178)77-165)233-154-134(203)144(235-151-131(200)125(194)119(188)99(80-168)221-151)140(234-156-146(127(196)121(190)101(82-170)223-156)236-148-113(161-88(7)173)123(192)117(186)97(78-166)219-148)105(228-154)86-215-155-145(126(195)120(189)100(81-169)222-155)237-153-133(202)129(198)138(103(84-172)225-153)232-152-132(201)128(197)137(102(83-171)224-152)231-150-130(199)124(193)118(187)98(79-167)220-150/h89-106,113-156,164-172,174-178,185-203H,8-87H2,1-7H3,(H,161,173)(H,162,179)(H,163,180)(H,204,205)(H,206,207)(H2,208,209,210)(H2,211,212,213)/t89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-,118+,119-,120-,121-,122-,123-,124+,125+,126+,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137+,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151+,152+,153-,154-,155-,156+,159-,160-/m1/s1",alpha-D-GlcpNAc-(1->2)-beta-D-Glcp-(1->4)-[beta-D-Glcp-(1->3)]-[alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-alpha-D-Glcp-(1->2)-beta-D-Glcp-(1->6)]-alpha-D-Glcp-(1->5)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->6)-Lipid A,PubMed citation,21590368
3254,62997,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-alpha-D-Glc-(1->2)-beta-D-Glc-(1->4)-[beta-D-Glc-(1->3)]-[alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-alpha-D-Glc-(1->2)-beta-D-Glc-(1->6)]-alpha-D-Glc-(1->5)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->6)-Lipid A,"A lipid A derivative that consists of a branched dodecasaccharide made up from four galactose, six glucose and two Kdo (one at the reducing end) units connected to lipid A via an alpha-(2->6)-linkage.","InChI=1S/C170H302N2O89P2/c1-7-13-19-25-31-37-38-44-50-56-62-68-112(192)233-92(66-60-54-48-42-35-29-23-17-11-5)72-114(194)247-151-116(172-110(190)71-91(65-59-53-47-41-34-28-22-16-10-4)232-111(191)67-61-55-49-43-36-30-24-18-12-6)155(229-86-106-123(201)150(246-113(193)70-90(185)64-58-52-46-40-33-27-21-15-9-3)115(156(243-106)261-263(226,227)228)171-109(189)69-89(184)63-57-51-45-39-32-26-20-14-8-2)244-108(149(151)260-262(223,224)225)88-231-169(167(219)220)74-96(257-170(168(221)222)73-93(186)117(195)141(258-170)94(187)75-173)147(142(259-169)95(188)76-174)252-164-140(218)152(254-159-135(213)126(204)120(198)99(79-177)236-159)148(253-166-154(128(206)122(200)101(81-179)238-166)256-163-139(217)132(210)146(105(85-183)242-163)251-161-137(215)130(208)144(103(83-181)240-161)249-158-134(212)125(203)119(197)98(78-176)235-158)107(245-164)87-230-165-153(127(205)121(199)100(80-178)237-165)255-162-138(216)131(209)145(104(84-182)241-162)250-160-136(214)129(207)143(102(82-180)239-160)248-157-133(211)124(202)118(196)97(77-175)234-157/h89-108,115-166,173-188,195-218H,7-88H2,1-6H3,(H,171,189)(H,172,190)(H,219,220)(H,221,222)(H2,223,224,225)(H2,226,227,228)/t89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118+,119+,120-,121-,122-,123-,124+,125+,126+,127+,128+,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143+,144+,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159+,160+,161+,162-,163-,164-,165-,166+,169-,170-/m1/s1",alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-alpha-D-Glcp-(1->2)-beta-D-Glcp-(1->4)-[beta-D-Glcp-(1->3)]-[alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-alpha-D-Glcp-(1->2)-beta-D-Glcp-(1->6)]-alpha-D-Glc-(1->5)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->6)-Lipid A,PubMed citation,21590368
3255,62998,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-alpha-D-GlcNAc-(1->2)-beta-D-Glc-(1->4)-[beta-D-Glc-(1->3)]-[alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-alpha-D-Glc-(1->2)-beta-D-Glc-(1->6)]-alpha-D-Glc-(1->5)-[alpha-D-Kdo-(2->4)]-alpha-D-Kdo-(2->6)-Lipid A,"A lipid A derivative that consists of a branched dodecasaccharide made up from four galactose, five glucose, one N-acetylglucosamine and two Kdo (one at the reducing end) units connected to lipid A via an alpha-(2->6)-linkage.","InChI=1S/C172H305N3O89P2/c1-8-14-20-26-32-38-39-45-51-57-63-69-114(196)236-94(67-61-55-49-43-36-30-24-18-12-5)73-116(198)250-153-119(175-112(194)72-93(66-60-54-48-42-35-29-23-17-11-4)235-113(195)68-62-56-50-44-37-31-25-19-13-6)157(232-87-108-126(205)152(249-115(197)71-92(189)65-59-53-47-41-34-28-22-16-10-3)118(159(246-108)264-266(229,230)231)174-111(193)70-91(188)64-58-52-46-40-33-27-21-15-9-2)247-110(151(153)263-265(226,227)228)89-234-171(169(222)223)75-98(260-172(170(224)225)74-95(190)120(199)143(261-172)96(191)76-176)149(144(262-171)97(192)77-177)255-166-142(221)154(257-162-138(217)130(209)123(202)101(80-180)239-162)150(256-168-156(132(211)125(204)103(82-182)241-168)258-158-117(173-90(7)187)127(206)145(104(83-183)242-158)251-163-139(218)133(212)146(105(84-184)243-163)252-160-136(215)128(207)121(200)99(78-178)237-160)109(248-166)88-233-167-155(131(210)124(203)102(81-181)240-167)259-165-141(220)135(214)148(107(86-186)245-165)254-164-140(219)134(213)147(106(85-185)244-164)253-161-137(216)129(208)122(201)100(79-179)238-161/h91-110,117-168,176-186,188-192,199-221H,8-89H2,1-7H3,(H,173,187)(H,174,193)(H,175,194)(H,222,223)(H,224,225)(H2,226,227,228)(H2,229,230,231)/t91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,117-,118-,119-,120-,121+,122+,123-,124-,125-,126-,127-,128+,129+,130+,131+,132+,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146+,147+,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162+,163+,164+,165-,166-,167-,168+,171-,172-/m1/s1",alpha-Gal-(1->4)-beta-Gal-(1->4)-alpha-GlcNAc-(1->2)-beta-Glc-(1->4)-[beta-Glc-(1->3)]-[alpha-Gal-(1->4)-beta-Gal-(1->4)-alpha-Glc-(1->2)-beta-Glc-(1->6)]-alpha-Glc-(1->5)-[alpha-Kdo-(2->4)]-alpha-Kdo-(2->6)-Lipid A,PubMed citation,21590368
3256,62999,beta-D-Galp-(1->6)-beta-D-Galp-(1->6)-beta-D-Galp-(1->6)-D-Galp,A galactotetraose in which the four D-galactose units are connected by three beta-(1->6)-linkages.,"InChI=1S/C24H42O21/c25-1-5-9(26)14(31)18(35)22(43-5)40-3-7-11(28)16(33)20(37)24(45-7)41-4-8-12(29)15(32)19(36)23(44-8)39-2-6-10(27)13(30)17(34)21(38)42-6/h5-38H,1-4H2/t5-,6-,7-,8-,9+,10+,11+,12+,13+,14+,15+,16+,17-,18-,19-,20-,21?,22-,23-,24-/m1/s1",Galbeta1-6Galbeta1-6Galbeta1-6Gal,KEGG GLYCAN accession,G00998
3257,63000,"1-O-(alpha-D-glucopyranosyl)-N-icosa-11,14-dienoylphytosphingosine","A glycophytoceramide having an alpha-D-glucopyranosyl residue at the O-1 position and an icosa-11,14-dienoyl group attached to the nitrogen.","InChI=1S/C44H83NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-23-25-27-29-31-33-39(48)45-36(35-53-44-43(52)42(51)41(50)38(34-46)54-44)40(49)37(47)32-30-28-26-24-22-16-14-12-10-8-6-4-2/h11,13,17-18,36-38,40-44,46-47,49-52H,3-10,12,14-16,19-35H2,1-2H3,(H,45,48)/b13-11-,18-17-/t36-,37+,38+,40-,41+,42-,43+,44-/m0/s1",Glcalpha-Cer(t18:0/20:2),Reaxys Registry Number,20453350
3258,63002,1-O-(3-deoxy-alpha-D-galactopyranosyl)-N-hexacosanoylsphinganine,A glycodohydroceramide having a 3-deoxy-alpha-D-galactopyranosyl residue at the O-1 position and an hexacosanoyl group attached to the nitrogen.,"InChI=1S/C50H99NO7/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-49(56)51-44(43-57-50-47(55)41-46(54)48(42-52)58-50)45(53)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2/h44-48,50,52-55H,3-43H2,1-2H3,(H,51,56)/t44-,45+,46+,47+,48+,50-/m0/s1","3',4''-deoxy-alpha-GalCer",PubMed citation,19535248
3259,63003,1-O-(4-deoxy-alpha-D-xylo-hexopyranosyl)-N-hexacosanoylsphinganine,A glycodohydroceramide having a 4-deoxy-alpha-D-xylo-hexopyranosyl residue at the O-1 position and an hexacosanoyl group attached to the nitrogen.,"InChI=1S/C50H99NO7/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-48(55)51-45(43-57-50-49(56)47(54)41-44(42-52)58-50)46(53)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2/h44-47,49-50,52-54,56H,3-43H2,1-2H3,(H,51,55)/t44-,45-,46+,47-,49+,50-/m0/s1","N-{(2S,3R)-1-[(4-deoxy-alpha-D-galactopyranosyl)oxy]-3-hydroxyoctadecan-2-yl}hexacosanamide",PubMed citation,19535248
3260,63004,sodium bromide,An inorganic sodium salt having bromide as the counterion.,InChI=1S/BrH.Na/h1H;/q;+1/p-1,NaBr,CAS Registry Number,7647-15-6
3261,63005,sodium nitrate,The inorganic nitrate salt of sodium.,InChI=1S/NO3.Na/c2-1(3)4;/q-1;+1,Chile saltpeter,Wikipedia accession,Sodium_nitrate
3262,63006,magnesium formate dihydrate,"The magnesium salt of formic acid, which exists in the solid state as a dihydrate.","InChI=1S/2CH2O2.Mg.2H2O/c2*2-1-3;;;/h2*1H,(H,2,3);;2*1H2/q;;+2;;/p-2",formic acid magnesium salt,CAS Registry Number,6150-82-9
3263,63007,1-O-(4-deoxy-alpha-D-xylo-hexopyranosyl)-N-hexacosanoylphytosphingosine,A glycophytoceramide having an 4-deoxy-alpha-D-xylo-hexopyranosyl residue at the O-1 position and an hexacosanoyl group attached to the nitrogen.,"InChI=1S/C50H99NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-47(55)51-44(42-58-50-49(57)46(54)40-43(41-52)59-50)48(56)45(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h43-46,48-50,52-54,56-57H,3-42H2,1-2H3,(H,51,55)/t43-,44-,45+,46-,48-,49+,50-/m0/s1",4'-deoxy-alpha-GalCer,PubMed citation,21376639
3264,63008,1-O-(alpha-D-galactopyranosyl)-N-hexacosanoylsphinganine,A glycodihydroceramide having an alpha-D-galactopyranosyl residue at the O-1 position and an hexacosanoyl group attached to the nitrogen.,"InChI=1S/C50H99NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-46(54)51-43(42-58-50-49(57)48(56)47(55)45(41-52)59-50)44(53)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2/h43-45,47-50,52-53,55-57H,3-42H2,1-2H3,(H,51,54)/t43-,44+,45+,47-,48-,49+,50-/m0/s1",Galalpha-Cer(d18:0/26:0),Reaxys Registry Number,10235517
3265,63012,1-O-(alpha-D-glucopyranosyl)-N-tetracosanylphytosphingosine,A glycophytoceramide having an alpha-D-glucopyranosyl residue at the O-1 position and an tetracosanoyl group attached to the nitrogen.,"InChI=1S/C48H95NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-43(52)49-40(39-57-48-47(56)46(55)45(54)42(38-50)58-48)44(53)41(51)36-34-32-30-28-26-16-14-12-10-8-6-4-2/h40-42,44-48,50-51,53-56H,3-39H2,1-2H3,(H,49,52)/t40-,41+,42+,44-,45+,46-,47+,48-/m0/s1","(2S,3S,4R)-1-O-(alpha-D-glucosyl)-N-tetracosanoyl-2-amino-1,3,4-octadecanetriol",PubMed citation,20529677
3266,63013,beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-Glcp,A linear amino tetrasaccharide consisting of D-glucose at the reducing end having an N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C26H45NO21/c1-6(32)27-11-14(35)12(33)7(2-28)43-24(11)48-22-13(34)8(3-29)44-26(19(22)40)47-21-10(5-31)45-25(18(39)16(21)37)46-20-9(4-30)42-23(41)17(38)15(20)36/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13+,14-,15-,16-,17-,18-,19-,20-,21+,22+,23?,24+,25+,26-/m1/s1",GalNAcbeta1-3Galalpha1-4Galbeta1-4Glc,KEGG GLYCAN accession,G02369
3267,63014,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp-O(CH2)2S(CH2)2CO2Me,A glycoside that consists of alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucose having a 2-(2-methoxycarbonylethylthio)ethyl (CETE) moiety attached to the reducing end anomeric centre.,"InChI=1S/C24H42O18S/c1-36-12(28)2-4-43-5-3-37-22-18(34)15(31)20(10(7-26)39-22)42-24-19(35)16(32)21(11(8-27)40-24)41-23-17(33)14(30)13(29)9(6-25)38-23/h9-11,13-27,29-35H,2-8H2,1H3/t9-,10-,11-,13+,14+,15-,16-,17-,18-,19-,20-,21+,22-,23-,24+/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-O(CH2)2S(CH2)2CO2Me,Reaxys Registry Number,5692077
3268,63015,alpha-D-Galp-(1->4)-beta-D-Galp-O(CH2)2S(CH2)2CO2Me,A glycoside that consists of alpha-D-galactosyl-(1->4)-beta-D-galactose having a 2-(2-methoxycarbonylethylthio)ethyl (CETE) moiety attached to the reducing end anomeric centre.,"InChI=1S/C18H32O13S/c1-27-10(21)2-4-32-5-3-28-17-15(26)13(24)16(9(7-20)30-17)31-18-14(25)12(23)11(22)8(6-19)29-18/h8-9,11-20,22-26H,2-7H2,1H3/t8-,9-,11+,12+,13-,14-,15-,16+,17-,18-/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-O-CETE,Reaxys Registry Number,5660241
3269,63018,potassium L-tartrate,The potassium salt of L-tartaric acid.,"InChI=1S/C4H6O6.2K/c5-1(3(7)8)2(6)4(9)10;;/h1-2,5-6H,(H,7,8)(H,9,10);;/q;2*+1/p-2/t1-,2-;;/m1../s1",dipotassium tartrate,CAS Registry Number,921-53-9
3270,63019,potassium sodium L-tartrate,The organic sodium and potassium salt of L-tartaric acid (mol ratio 1:1:1).,"InChI=1S/C4H6O6.K.Na/c5-1(3(7)8)2(6)4(9)10;;/h1-2,5-6H,(H,7,8)(H,9,10);;/q;2*+1/p-2/t1-,2-;;/m1../s1",ROCHELLE SALTS,Reaxys Registry Number,5789357
3271,63020,yttrium chloride,The inorganic chloride salt of yttrium(III),InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3,yttrium(III) chloride,CAS Registry Number,10361-92-9
3272,63021,hexaamminecobalt(III) chloride,A cobalt coordination entity consisting of a hexaamminecobalt(III) cation in association with three chloride anions as counterions.,InChI=1S/3ClH.Co.6H3N/h3*1H;;6*1H3/q;;;+3;;;;;;/p-3,cobalt hexammine chloride,CAS Registry Number,10534-89-1
3273,63022,beta-D-Galp-(1->4)-beta-D-Glcp-SC6H4-p-NH2,An S-glycosyl compound that consists of 4-aminothiophenol having a beta-lactosyl moiety attached to the sulfur via a thioglycosidic bond.,"InChI=1S/C18H27NO10S/c19-7-1-3-8(4-2-7)30-18-15(26)13(24)16(10(6-21)28-18)29-17-14(25)12(23)11(22)9(5-20)27-17/h1-4,9-18,20-26H,5-6,19H2/t9-,10-,11+,12+,13-,14-,15-,16-,17+,18+/m1/s1",beta-D-Gal-(1->4)-beta-D-Glc-SC6H4NH2,PubMed citation,2456994
3274,63023,alpha-D-Gal-(1->4)-alpha-D-Gal-OMe,A methyl glycoside that consists of methyl alpha-D-galactoside having an alpha-D-galactosyl residue at the 4-position.,"InChI=1S/C13H24O11/c1-21-12-10(20)8(18)11(5(3-15)23-12)24-13-9(19)7(17)6(16)4(2-14)22-13/h4-20H,2-3H2,1H3/t4-,5-,6+,7+,8-,9-,10-,11+,12+,13-/m1/s1",alpha-D-Galp-(1->4)-alpha-D-Galp-OMe,Reaxys Registry Number,1435815
3275,63025,alpha-D-Gal-(1->4)-beta-D-Gal-OEt,A glycoside that consists of ethyl beta-D-galactoside having an alpha-D-galactosyl residue at the 4-position.,"InChI=1S/C14H26O11/c1-2-22-13-11(21)9(19)12(6(4-16)24-13)25-14-10(20)8(18)7(17)5(3-15)23-14/h5-21H,2-4H2,1H3/t5-,6-,7+,8+,9-,10-,11-,12+,13-,14-/m1/s1",ethyl alpha-D-galactosyl-(1->4)-beta-D-galactoside,Reaxys Registry Number,5762078
3276,63026,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc-OEt,A glycoside that consists of ethyl N-acetyl-beta-D-glucosaminide having an alpha-D-galactosyl-(1->4)-beta-D-galactosyl group attached at the 4-position.,"InChI=1S/C22H39NO16/c1-3-34-20-11(23-7(2)27)13(29)18(9(5-25)36-20)38-22-17(33)15(31)19(10(6-26)37-22)39-21-16(32)14(30)12(28)8(4-24)35-21/h8-22,24-26,28-33H,3-6H2,1-2H3,(H,23,27)/t8-,9-,10-,11-,12+,13-,14+,15-,16-,17-,18-,19+,20-,21-,22+/m1/s1",ethyl alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminide,Reaxys Registry Number,5684153
3277,63027,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp-O(CH2)2S(CH2)2CONH2,A glycoside that consists of alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucose having a 2-(2-aminocarbonylethylthio)ethyl moiety attached to the reducing end anomeric centre.,"InChI=1S/C23H41NO17S/c24-11(28)1-3-42-4-2-36-21-17(34)14(31)19(9(6-26)38-21)41-23-18(35)15(32)20(10(7-27)39-23)40-22-16(33)13(30)12(29)8(5-25)37-22/h8-10,12-23,25-27,29-35H,1-7H2,(H2,24,28)/t8-,9-,10-,12+,13+,14-,15-,16-,17-,18-,19-,20+,21-,22-,23+/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-O(CH2)2S(CH2)2CONH2,PubMed citation,2456994
3278,63028,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-O(CH2)2S(CH2)2CONH2,A glycoside that consists of alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine having a 2-(2-aminocarbonylethylthio)ethyl moiety attached to the reducing end anomeric centre.,"InChI=1S/C25H44N2O17S/c1-9(31)27-14-16(34)21(11(7-29)41-23(14)39-3-5-45-4-2-13(26)32)43-25-20(38)18(36)22(12(8-30)42-25)44-24-19(37)17(35)15(33)10(6-28)40-24/h10-12,14-25,28-30,33-38H,2-8H2,1H3,(H2,26,32)(H,27,31)/t10-,11-,12-,14-,15+,16-,17+,18-,19-,20-,21-,22+,23-,24-,25+/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc-O(CH2)2S(CH2)2CONH2,PubMed citation,2456994
3279,63029,alpha-D-Galp-(1->4)-beta-D-Galp-O(CH2)2S(CH2)2CONH2,A glycoside that consists of alpha-D-galactosyl-(1->4)-beta-D-galactose having a 2-(2-aminocarbonylethylthio)ethyl moiety attached to the reducing end anomeric centre.,"InChI=1S/C17H31NO12S/c18-9(21)1-3-31-4-2-27-16-14(26)12(24)15(8(6-20)29-16)30-17-13(25)11(23)10(22)7(5-19)28-17/h7-8,10-17,19-20,22-26H,1-6H2,(H2,18,21)/t7-,8-,10+,11+,12-,13-,14-,15+,16-,17-/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-O(CH2)2S(CH2)2CONH2,PubMed citation,2456994
3280,63030,p-aminophenyl alpha-D-mannoside,An alpha-D-mannoside having 4-aminophenyl as the anomeric substituent.,"InChI=1S/C12H17NO6/c13-6-1-3-7(4-2-6)18-12-11(17)10(16)9(15)8(5-14)19-12/h1-4,8-12,14-17H,5,13H2/t8-,9-,10+,11+,12+/m1/s1",alpha-D-Manp-OC6H4NH2,Reaxys Registry Number,89668
3281,63031,"1,2-di-O-myristoyl-sn-glycero-3-phosphosulfocholine","A 1,2-diacyl-sn-glycero-3-phosphosulfocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl).","InChI=1S/C35H69O8PS/c1-5-7-9-11-13-15-17-19-21-23-25-27-34(36)40-31-33(32-42-44(38,39)41-29-30-45(3)4)43-35(37)28-26-24-22-20-18-16-14-12-10-8-6-2/h33H,5-32H2,1-4H3/t33-/m1/s1",DMPSC,Reaxys Registry Number,4058280
3282,63036,potassium dihydrogen phosphate,A potassium salt in which dihydrogen phosphate(1-) is the counterion.,"InChI=1S/K.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+1;/p-1",Potassium phosphate monobasic,Wikipedia accession,Monopotassium_phosphate
3283,63037,triammonium citrate,A citrate salt in which all three carboxy groups are deprotonated and associated with ammonium ions as counter-cations.,"InChI=1S/C6H8O7.3H3N/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);3*1H3",ammonium citrate tribasic,Reaxys Registry Number,3779194
3284,63039,caesium chloride,The inorganic chloride salt of caesium; each caesium ion is coordinated by eight chlorine ions.,InChI=1S/ClH.Cs/h1H;/q;+1/p-1,cesium chloride,CAS Registry Number,7647-17-8
3285,63040,ammonium iodide,The iodide salt of ammonia.,InChI=1S/HI.H3N/h1H;1H3,azanium iodide,Reaxys Registry Number,15705643
3286,63041,manganese(II) chloride,"An inorganic chloride in which manganese(II) is coordinated to two chloride ions. In its anhydrous state manganese(II) chloride is a polymeric solid, which adopts a layered cadmium chloride-like structure.",InChI=1S/2ClH.Mn/h2*1H;/q;;+2/p-2,manganous chloride,CAS Registry Number,7773-01-5
3287,63043,potassium nitrate,The inorganic nitrate salt of potassium.,InChI=1S/K.NO3/c;2-1(3)4/q+1;-1,saltpetre,CAS Registry Number,7757-79-1
3288,63045,lithium acetate,An acetate salt comprising equal numbers of acetate and lithium ions.,"InChI=1S/C2H4O2.Li/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1",acetic acid lithium salt,Reaxys Registry Number,3564320
3289,63050,ammonium formate,The ammonium salt of formic acid.,"InChI=1S/CH2O2.H3N/c2-1-3;/h1H,(H,2,3);1H3",formic acid ammonium salt,CAS Registry Number,540-69-2
3290,63055,disodium PIPES,"An organic salt, being the disodium salt of 2,2'-piperazine-1,4-diylbisethanesulfonic acid (PIPES), a buffering agent.","InChI=1S/C8H18N2O6S2.2Na/c11-17(12,13)7-5-9-1-2-10(4-3-9)6-8-18(14,15)16;;/h1-8H2,(H,11,12,13)(H,14,15,16);;/q;2*+1/p-2",PIPES disodium salt,Reaxys Registry Number,9453872
3291,63070,beta-alaninate,A beta-amino-acid anion that is the conjugate base of beta-alanine.,"InChI=1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)/p-1",beta-alaninate anion,Reaxys Registry Number,3536336
3292,63072,L-homocysteinate,"An L-alpha-amino acid anion that is the conjugate base of L-homocysteine, obtained by deprotonation of the carboxy group.","InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/p-1/t3-/m0/s1",L-homocysteinate anion,Reaxys Registry Number,6965804
3293,63075,diammonium L-tartrate,An organic salt that is the diammonium salt of L-(+)-tartaric acid.,"InChI=1S/C4H6O6.2H3N/c5-1(3(7)8)2(6)4(9)10;;/h1-2,5-6H,(H,7,8)(H,9,10);2*1H3/t1-,2-;;/m1../s1",L-(+)-tartaric acid diammonium salt,Reaxys Registry Number,16699195
3294,63076,diammonium citrate,A citrate salt in which two of the three carboxy groups are deprotonated and associated with ammonium ions as counter-cations.,"InChI=1S/C6H8O7.2H3N/c7-3(8)1-6(13,5(11)12)2-4(9)10;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);2*1H3",diammonium hydrogen citrate,Reaxys Registry Number,13697855
3295,63077,monosodium PIPES,"An organic salt that is the monosodium salt of 2,2'-piperazine-1,4-diylbisethanesulfonic acid (PIPES), a buffering agent.","InChI=1S/C8H18N2O6S2.Na/c11-17(12,13)7-5-9-1-2-10(4-3-9)6-8-18(14,15)16;/h1-8H2,(H,11,12,13)(H,14,15,16);/q;+1/p-1","1,4-piperazinediethanesulfonic acid sodium salt",Reaxys Registry Number,4630397
3296,63080,1-O-(6-acetamido-6-deoxy-alpha-D-galactosyl)-N-[(15Z)-tetracos-15-enoyl]phytosphingosine,A glycophytoceramide that consists of phytosphingosine having a 6-acetamido-6-deoxy-alpha-D-galactosyl attached at the O-1 position via a glycosidic linkage and a (Z)-tetracos-15-enoyl group attached to the nitrogen.,"InChI=1S/C50H96N2O9/c1-4-6-8-10-12-14-16-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-45(55)52-42(40-60-50-49(59)48(58)47(57)44(61-50)39-51-41(3)53)46(56)43(54)37-35-33-31-29-27-17-15-13-11-9-7-5-2/h18-19,42-44,46-50,54,56-59H,4-17,20-40H2,1-3H3,(H,51,53)(H,52,55)/b19-18-/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1",PBS57,Reaxys Registry Number,15721779
3297,63081,"(S,S)-formoterol",An N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide in which both of the stereocentres have S configuration.,"InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m0/s1",(+)-formoterol,Reaxys Registry Number,7861826
3298,63082,N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide,A phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent.,"InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)",2'-hydroxy-5'-(1-hydroxy-2-((p-methoxy-alpha-methylphenethyl)amino)ethyl)formanilide,KEGG COMPOUND accession,C07805
3299,63087,N-purin-6-oylglycine,A purine derivative that consists of glycine having a purin-6-oyl group attached to the amino function via an amide bond.,"InChI=1S/C8H7N5O3/c14-4(15)1-9-8(16)6-5-7(12-2-10-5)13-3-11-6/h2-3H,1H2,(H,9,16)(H,14,15)(H,10,11,12,13)",N-purin-6-oyl-glycine,PubMed citation,14253484
3300,63088,purine-6-caboxamide,An  aromatic amide that is purine bearing a carboxamido substituent at position 6.,"InChI=1S/C6H5N5O/c7-5(12)3-4-6(10-1-8-3)11-2-9-4/h1-2H,(H2,7,12)(H,8,9,10,11)",6-carboxamidopurine,Reaxys Registry Number,517129
3301,63091,9-methylpurine,Purine bearing a methyl substituent at position 6.,"InChI=1S/C6H6N4/c1-10-4-9-5-2-7-3-8-6(5)10/h2-4H,1H3",N(9)-methylpurine,Reaxys Registry Number,4668
3302,63092,methyl purine-6-carboxylate,A methyl ester that is purine bearing a methoxycarbonyl substituent at position 6.,"InChI=1S/C7H6N4O2/c1-13-7(12)5-4-6(10-2-8-4)11-3-9-5/h2-3H,1H3,(H,8,9,10,11)",purine-6-caboxylic acid methyl ester,Reaxys Registry Number,521857
3303,63093,purine-6-carboxylic acid,A purinemonocarboxylic acid that consists of purine having the carboxy group located at position 6.,"InChI=1S/C6H4N4O2/c11-6(12)4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H,11,12)(H,7,8,9,10)",6-carboxypurine,Reaxys Registry Number,610875
3304,63104,"1,1,1,3,3,3-hexafluoropropan-2-ol",An organofluorine compound formed by substitution of all the methyl protons in propan-2-ol by fluorine. It is a metabolite of inhalation anesthetic sevoflurane.,"InChI=1S/C3H2F6O/c4-2(5,6)1(10)3(7,8)9/h1,10H",hexafluoroisopropanol,CAS Registry Number,920-66-1
3305,63112,fingolimod hydrochloride,"The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod).","InChI=1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H","2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride",Reaxys Registry Number,7837310
3306,63116,alpha-D-Gal-(1->3)-beta-D-Gal-(1->3)-D-GlcNAc,"An amino trisaccharide consisting of two D-galactose residues, linked alpha(1->3), and an N-acetyl-D-glucosamine residue, linked beta(1->3), at the reducing end.","InChI=1S/C20H35NO16/c1-5(25)21-9-16(11(27)7(3-23)33-18(9)32)36-20-15(31)17(12(28)8(4-24)35-20)37-19-14(30)13(29)10(26)6(2-22)34-19/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11-,12+,13+,14-,15-,16-,17+,18?,19-,20+/m1/s1",alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-D-glucosamine,KEGG GLYCAN accession,G01040
3307,63117,alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-3-deoxy-D-GlcNAc,"A three-membered deoxy oligosaccharide which has a 2-acetamido-2,3-dideoxy-D-ribo-hexose unit at the reducing end with an alpha-D-galactosyl-(1->3)-beta-D-galactosyl group attached at the 4-position.","InChI=1S/C20H35NO15/c1-6(25)21-7-2-8(9(3-22)32-18(7)31)33-20-16(30)17(13(27)11(5-24)35-20)36-19-15(29)14(28)12(26)10(4-23)34-19/h7-20,22-24,26-31H,2-5H2,1H3,(H,21,25)/t7-,8+,9-,10-,11-,12+,13+,14+,15-,16-,17+,18?,19-,20-/m1/s1",alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-3-deoxy-D-GlcNAc,PubMed citation,9753344
3308,63118,alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-6-deoxy-D-GlcNAc,A three-membered deoxy oligosaccharide which has a 6-deoxy-N-acetyl-D-glucosamine unit at the reducing end with an alpha-D-galactosyl-(1->3)-beta-D-galactosyl group attached at the 4-position.,"InChI=1S/C20H35NO15/c1-5-16(12(27)9(18(31)32-5)21-6(2)24)35-20-15(30)17(11(26)8(4-23)34-20)36-19-14(29)13(28)10(25)7(3-22)33-19/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7-,8-,9-,10+,11+,12-,13+,14-,15-,16-,17+,18?,19-,20+/m1/s1",alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-6-deoxy-N-acetyl-D-glucosamine,PubMed citation,9753344
3309,63122,"N(1),N(5)-bis(2-deoxy-beta-D-glucopyranos-2-yl)-N(2)-(N(3)-DNCP-beta-alanyl)glutaminamide","A dipeptide that consists of beta-alanyl-L-glutamine amide bearing a 2-carboxy-4,6-dinitrophenyl (DNCP) substituent at the amino terminus while the amides at the carboxy terminus and side-chain are substituted by beta-D-glucopyranos-2-yl groups.","InChI=1S/C27H38N6O19/c34-7-13-20(38)22(40)18(26(45)51-13)30-15(36)2-1-11(24(42)31-19-23(41)21(39)14(8-35)52-27(19)46)29-16(37)3-4-28-17-10(25(43)44)5-9(32(47)48)6-12(17)33(49)50/h5-6,11,13-14,18-23,26-28,34-35,38-41,45-46H,1-4,7-8H2,(H,29,37)(H,30,36)(H,31,42)(H,43,44)/t11-,13+,14+,18+,19+,20+,21+,22+,23+,26+,27+/m0/s1","N(1),N(5)-bis(2-deoxy-beta-D-glucopyranos-2-yl)-N(2)-(N(3)-DNCP-beta-alanyl)glutamine amide",Reaxys Registry Number,6560814
3310,63123,"N(1),N(6)-bis-DNCP-1,6-hexanediamine","An N-substituted diamine that consists of 1,6-hexanediamine bearing two 2-carboxy-4,6-dinitrophenyl (DNCP) substituents at the N(1)- and N(6)-positions.","InChI=1S/C20H20N6O12/c27-19(28)13-7-11(23(31)32)9-15(25(35)36)17(13)21-5-3-1-2-4-6-22-18-14(20(29)30)8-12(24(33)34)10-16(18)26(37)38/h7-10,21-22H,1-6H2,(H,27,28)(H,29,30)","N(1),N(6)-bis-(2-carboxy-4,6-dinitrophenyl)-1,6-hexanediamine",PubMed citation,4093152
3311,63125,EDTA trisodium salt,The organic sodium salt of ethylenediaminetetraacetic acid (EDTA) in which three sodium cations are associated with one trianion of EDTA.,"InChI=1S/C10H16N2O8.3Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;3*+1/p-3",ethylenediaminetetraacetic acid trisodium salt,Reaxys Registry Number,5843772
3312,63126,IlePsi[(E)-CH=CH]Ala-Gly-Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A glycopeptide that consists of glycyl, phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence with an isostere-modified IlePsi[(E)-CH=CH]Ala group attached to the amino terminus.","InChI=1S/C69H110N16O26/c1-5-35(2)40(72)18-16-36(3)60(100)74-30-52(91)80-46(28-38-12-7-6-8-13-38)66(106)82-42(19-17-39(29-71)110-69-59(99)58(98)57(97)48(34-86)111-69)62(102)76-32-50(89)78-44(21-24-54(93)94)64(104)81-43(20-23-49(73)88)63(103)77-33-53(92)85-27-11-15-47(85)67(107)83-41(14-9-10-26-70)61(101)75-31-51(90)79-45(22-25-55(95)96)65(105)84-56(37(4)87)68(108)109/h6-8,12-13,16,18,35-37,39-48,56-59,69,86-87,97-99H,5,9-11,14-15,17,19-34,70-72H2,1-4H3,(H2,73,88)(H,74,100)(H,75,101)(H,76,102)(H,77,103)(H,78,89)(H,79,90)(H,80,91)(H,81,104)(H,82,106)(H,83,107)(H,84,105)(H,93,94)(H,95,96)(H,108,109)/b18-16+/t35-,36+,37+,39+,40+,41-,42-,43-,44-,45-,46-,47-,48+,56-,57-,58-,59+,69+/m0/s1",IlePsi[(E)-CH=CH]AlaGlyPheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21766871
3313,63128,IlePsi(CH2CH2)Ala-Gly-Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A glycopeptide that consists of glycyl, phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence with an isostere-modified IlePsi(CH2CH2)Ala group attached to the amino terminus.","InChI=1S/C69H112N16O26/c1-5-35(2)40(72)18-16-36(3)60(100)74-30-52(91)80-46(28-38-12-7-6-8-13-38)66(106)82-42(19-17-39(29-71)110-69-59(99)58(98)57(97)48(34-86)111-69)62(102)76-32-50(89)78-44(21-24-54(93)94)64(104)81-43(20-23-49(73)88)63(103)77-33-53(92)85-27-11-15-47(85)67(107)83-41(14-9-10-26-70)61(101)75-31-51(90)79-45(22-25-55(95)96)65(105)84-56(37(4)87)68(108)109/h6-8,12-13,35-37,39-48,56-59,69,86-87,97-99H,5,9-11,14-34,70-72H2,1-4H3,(H2,73,88)(H,74,100)(H,75,101)(H,76,102)(H,77,103)(H,78,89)(H,79,90)(H,80,91)(H,81,104)(H,82,106)(H,83,107)(H,84,105)(H,93,94)(H,95,96)(H,108,109)/t35-,36+,37+,39+,40+,41-,42-,43-,44-,45-,46-,47-,48+,56-,57-,58-,59+,69+/m0/s1",IlePsi(CH2CH2)AlaGlyPheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21766871
3314,63129,Ile-AlaPsi[(E)-CH=CH]Gly-Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A glycopeptide that consists of phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence with an isostere-modified Ile-AlaPsi[(E)-CH=CH]Gly tripeptoid unit attached to the amino terminus.","InChI=1S/C69H110N16O26/c1-5-35(2)55(73)67(107)77-36(3)13-11-18-49(89)80-45(29-38-14-7-6-8-15-38)65(105)82-41(20-19-39(30-71)110-69-59(99)58(98)57(97)47(34-86)111-69)61(101)75-32-50(90)78-43(22-25-53(93)94)63(103)81-42(21-24-48(72)88)62(102)76-33-52(92)85-28-12-17-46(85)66(106)83-40(16-9-10-27-70)60(100)74-31-51(91)79-44(23-26-54(95)96)64(104)84-56(37(4)87)68(108)109/h6-8,11,13-15,35-37,39-47,55-59,69,86-87,97-99H,5,9-10,12,16-34,70-71,73H2,1-4H3,(H2,72,88)(H,74,100)(H,75,101)(H,76,102)(H,77,107)(H,78,90)(H,79,91)(H,80,89)(H,81,103)(H,82,105)(H,83,106)(H,84,104)(H,93,94)(H,95,96)(H,108,109)/b13-11+/t35-,36-,37+,39+,40-,41-,42-,43-,44-,45-,46-,47+,55-,56-,57-,58-,59+,69+/m0/s1",IleAlaPsi[(E)-CH=CH]GlyPheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21766871
3315,63130,Ile-AlaPsi(CH2CH2)Gly-Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A glycopeptide that consists of phenylalanyl, (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence with an isostere-modified Ile-AlaPsi(CH2CH2)Gly tripeptoid unit attached to the amino terminus.","InChI=1S/C69H112N16O26/c1-5-35(2)55(73)67(107)77-36(3)13-11-18-49(89)80-45(29-38-14-7-6-8-15-38)65(105)82-41(20-19-39(30-71)110-69-59(99)58(98)57(97)47(34-86)111-69)61(101)75-32-50(90)78-43(22-25-53(93)94)63(103)81-42(21-24-48(72)88)62(102)76-33-52(92)85-28-12-17-46(85)66(106)83-40(16-9-10-27-70)60(100)74-31-51(91)79-44(23-26-54(95)96)64(104)84-56(37(4)87)68(108)109/h6-8,14-15,35-37,39-47,55-59,69,86-87,97-99H,5,9-13,16-34,70-71,73H2,1-4H3,(H2,72,88)(H,74,100)(H,75,101)(H,76,102)(H,77,107)(H,78,90)(H,79,91)(H,80,89)(H,81,103)(H,82,105)(H,83,106)(H,84,104)(H,93,94)(H,95,96)(H,108,109)/t35-,36-,37+,39+,40-,41-,42-,43-,44-,45-,46-,47+,55-,56-,57-,58-,59+,69+/m0/s1",IleAlaPsi(CH2CH2)GlyPheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21766871
3316,63132,Ile-Ala-GlyPsi[(E)-CH=CH]Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A glycopeptide that consists of (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence with an isostere-modified Ile-Ala-GlyPsi[(E)-CH=CH]Phe tetrapeptoid unit attached to the amino terminus.","InChI=1S/C69H110N16O26/c1-5-35(2)54(73)67(107)78-36(3)59(99)74-27-11-15-39(29-38-13-7-6-8-14-38)60(100)81-42(19-18-40(30-71)110-69-58(98)57(97)56(96)47(34-86)111-69)62(102)76-32-49(89)79-44(21-24-52(92)93)64(104)82-43(20-23-48(72)88)63(103)77-33-51(91)85-28-12-17-46(85)66(106)83-41(16-9-10-26-70)61(101)75-31-50(90)80-45(22-25-53(94)95)65(105)84-55(37(4)87)68(108)109/h6-8,11,13-15,35-37,39-47,54-58,69,86-87,96-98H,5,9-10,12,16-34,70-71,73H2,1-4H3,(H2,72,88)(H,74,99)(H,75,101)(H,76,102)(H,77,103)(H,78,107)(H,79,89)(H,80,90)(H,81,100)(H,82,104)(H,83,106)(H,84,105)(H,92,93)(H,94,95)(H,108,109)/b15-11+/t35-,36-,37+,39-,40+,41-,42-,43-,44-,45-,46-,47+,54-,55-,56-,57-,58+,69+/m0/s1",IleAlaGlyPsi[(E)-CH=CH]PheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21766871
3317,63133,Ile-Ala-GlyPsi(CH2CH2)Phe-Lys(5-GalO)-Gly-Glu-Gln-Gly-Pro-Lys-Gly-Glu-Thr,"A glycopeptide that consists of (5R)-5-(beta-D-galactopyranosyloxy)lysyl, glycyl. alpha-glutamyl, glutaminyl, glycyl, prolyl, lysyl, glycyl, alpha-glutamyl and threonine residues coupled in sequence with an isostere-modified Ile-Ala-GlyPsi(CH2CH2)Phe tetrapeptoid unit attached to the amino terminus.","InChI=1S/C69H112N16O26/c1-5-35(2)54(73)67(107)78-36(3)59(99)74-27-11-15-39(29-38-13-7-6-8-14-38)60(100)81-42(19-18-40(30-71)110-69-58(98)57(97)56(96)47(34-86)111-69)62(102)76-32-49(89)79-44(21-24-52(92)93)64(104)82-43(20-23-48(72)88)63(103)77-33-51(91)85-28-12-17-46(85)66(106)83-41(16-9-10-26-70)61(101)75-31-50(90)80-45(22-25-53(94)95)65(105)84-55(37(4)87)68(108)109/h6-8,13-14,35-37,39-47,54-58,69,86-87,96-98H,5,9-12,15-34,70-71,73H2,1-4H3,(H2,72,88)(H,74,99)(H,75,101)(H,76,102)(H,77,103)(H,78,107)(H,79,89)(H,80,90)(H,81,100)(H,82,104)(H,83,106)(H,84,105)(H,92,93)(H,94,95)(H,108,109)/t35-,36-,37+,39-,40+,41-,42-,43-,44-,45-,46-,47+,54-,55-,56-,57-,58+,69+/m0/s1",IleAlaGlyPsi(CH2CH2)PheLys(5-GalO)GlyGluGlnGlyProLysGlyGluThr,PubMed citation,21766871
3318,63134,Gly-L-Ala-L-Ala-D-Ala-D-Ala,"A pentapeptide that consists of one glycyl, two L-alanyl and two D-alanyl residues coupled in sequence.","InChI=1S/C14H25N5O6/c1-6(16-10(20)5-15)11(21)17-7(2)12(22)18-8(3)13(23)19-9(4)14(24)25/h6-9H,5,15H2,1-4H3,(H,16,20)(H,17,21)(H,18,22)(H,19,23)(H,24,25)/t6-,7-,8+,9+/m0/s1",GAAaa,PubMed citation,3929745
3319,63139,D-galactal,A glycal derived from D-galactopyranose,"InChI=1S/C6H10O4/c7-3-5-6(9)4(8)1-2-10-5/h1-2,4-9H,3H2/t4-,5-,6-/m1/s1",galactal,Reaxys Registry Number,81690
3320,63141,beta-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-Glcp,A linear trisaccharide comprising D-glucose (at the reducing end) having a beta-D-galactosyl-(1->4)-beta-D-galactosyl moiety at the 4-position.,"InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14-,15+,16?,17+,18+/m1/s1",beta-D-Gal-(1->4)-beta-D-Gal-(1->4)-D-Glc,KEGG GLYCAN accession,G00359
3321,63145,penta-O-acetyl-alpha-D-galactose,An O-acyl carbohydrate that consists of alpha-D-galactopyranose bearing five O-acetyl substituents.,"InChI=1S/C16H22O11/c1-7(17)22-6-12-13(23-8(2)18)14(24-9(3)19)15(25-10(4)20)16(27-12)26-11(5)21/h12-16H,6H2,1-5H3/t12-,13+,14+,15-,16+/m1/s1",alpha-D-galactose pentaacetate,Reaxys Registry Number,98854
3322,63152,alpha-D-rhamnose,A D-rhamnopyranose having alpha-configuration at its anomeric centre.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3-,4+,5+,6+/m1/s1",alpha-D-Rhap,KEGG COMPOUND accession,C01684
3323,63154,N-acetyl-beta-D-mannosamine,An N-acetyl-D-mannosamine having beta-configuration at its anomeric centre.,"InChI=1S/C8H15NO6/c1-3(11)9-5-7(13)6(12)4(2-10)15-8(5)14/h4-8,10,12-14H,2H2,1H3,(H,9,11)/t4-,5+,6-,7-,8-/m1/s1",beta-ManNAc,Reaxys Registry Number,1346524
3324,63155,alpha-Neup5Ac-(2->3)-beta-D-Galp,An amino disaccharide consisting of beta-D-galactose having an alpha-N-acetylneuraminyl residue attached at the 3-position,"InChI=1S/C17H29NO14/c1-5(21)18-9-6(22)2-17(16(28)29,31-13(9)10(24)7(23)3-19)32-14-11(25)8(4-20)30-15(27)12(14)26/h6-15,19-20,22-27H,2-4H2,1H3,(H,18,21)(H,28,29)/t6-,7+,8+,9+,10+,11-,12+,13+,14-,15+,17-/m0/s1",alphaNeuAc2-3betaGal,Reaxys Registry Number,4611129
3325,63170,N-succinyl-Leu-Tyr-7-amido-4-methylcoumarin,Coumarin carrying a methyl group at C-4 and a succinyl-leucyl-tryrosyl side-chain at C-7.,"InChI=1S/C29H33N3O8/c1-16(2)12-22(31-25(34)10-11-26(35)36)29(39)32-23(14-18-4-7-20(33)8-5-18)28(38)30-19-6-9-21-17(3)13-27(37)40-24(21)15-19/h4-9,13,15-16,22-23,33H,10-12,14H2,1-3H3,(H,30,38)(H,31,34)(H,32,39)(H,35,36)/t22-,23-/m0/s1",Suc-Leu-Tyr-AMC,CAS Registry Number,94367-20-1
3326,63208,2-hydroxy-dATP,A purine 2'-deoxyribonucleoside 5'-triphosphate in which the 2'-deoxyribonucleoside moiety is 2'-deoxy-2-hydroxyadenosine.,"InChI=1S/C10H16N5O13P3/c11-8-7-9(14-10(17)13-8)15(3-12-7)6-1-4(16)5(26-6)2-25-30(21,22)28-31(23,24)27-29(18,19)20/h3-6,16H,1-2H2,(H,21,22)(H,23,24)(H2,18,19,20)(H3,11,13,14,17)/t4-,5+,6+/m0/s1",2-OH-dATP,Reaxys Registry Number,9455763
3327,63211,2-hydroxy-dAMP,A purine 2'-deoxyribonucleoside 5'-monophosphate in which the purine moiety is 2-hydroxyadenine.,"InChI=1S/C10H14N5O7P/c11-8-7-9(14-10(17)13-8)15(3-12-7)6-1-4(16)5(22-6)2-21-23(18,19)20/h3-6,16H,1-2H2,(H2,18,19,20)(H3,11,13,14,17)/t4-,5+,6+/m0/s1",2-OH-dAMP,PubMed citation,11756418
3328,63221,N-benzoylampicillin,A penicillin that is the N-benzoyl derivative of ampicillin.,"InChI=1S/C23H23N3O5S/c1-23(2)17(22(30)31)26-20(29)16(21(26)32-23)25-19(28)15(13-9-5-3-6-10-13)24-18(27)14-11-7-4-8-12-14/h3-12,15-17,21H,1-2H3,(H,24,27)(H,25,28)(H,30,31)/t15-,16-,17+,21-/m1/s1",benzoylampicillin,PubMed citation,11397088
3329,63228,alpha-D-GalpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,A linear amino trisaccharide consisting of D-glucose at the reducing end having an N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C20H35NO16/c1-5(25)21-9-12(28)10(26)6(2-22)34-19(9)37-17-11(27)7(3-23)35-20(15(17)31)36-16-8(4-24)33-18(32)14(30)13(16)29/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12-,13-,14-,15-,16-,17+,18?,19-,20+/m1/s1",alphaGalNAc(1->3)betaGal(1->4)Glc,KEGG GLYCAN accession,G01077
3330,63229,alpha-D-GalNpAc-(1->3)-beta-D-GalpNAc-OMe,A methyl glycoside that is N-acetyl-alpha-D-galactosaminyl-(1->3)-N-acetyl-beta-D-galactosamine in which the anomeric hydroxy group is replaced by methoxy.,"InChI=1S/C17H30N2O11/c1-6(22)18-10-14(26)12(24)8(4-20)29-17(10)30-15-11(19-7(2)23)16(27-3)28-9(5-21)13(15)25/h8-17,20-21,24-26H,4-5H2,1-3H3,(H,18,22)(H,19,23)/t8-,9-,10-,11-,12+,13+,14-,15-,16-,17-/m1/s1",GalNAcalpha1->3GalNAcbeta1->OMe,Reaxys Registry Number,6830300
3331,63230,alpha-D-GalNpAc-(1->3)-alpha-D-GalpNAc-OMe,A methyl glycoside that is N-acetyl-alpha-D-galactosaminyl-(1->3)-N-acetyl-alpha-D-galactosamine in which the anomeric hydroxy group is replaced by methoxy.,"InChI=1S/C17H30N2O11/c1-6(22)18-10-14(26)12(24)8(4-20)29-17(10)30-15-11(19-7(2)23)16(27-3)28-9(5-21)13(15)25/h8-17,20-21,24-26H,4-5H2,1-3H3,(H,18,22)(H,19,23)/t8-,9-,10-,11-,12+,13+,14-,15-,16+,17-/m1/s1",alphaGalNAc(1->3)alphaGalNAcOMe,PubMed citation,15864747
3332,63232,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,"A linear amino trisaccharide consisting of a galactosyl residue at the non-reducing end linked beta-(1->3) to an N-acetylgalactosaminyl residue, which is in turn linked beta-(1->3) to a beta-galactose unit at the reducing end.","InChI=1S/C20H35NO16/c1-5(25)21-9-16(36-20-14(30)13(29)10(26)6(2-22)35-20)11(27)8(4-24)34-19(9)37-17-12(28)7(3-23)33-18(32)15(17)31/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11-,12+,13+,14-,15-,16-,17+,18-,19+,20+/m1/s1",beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosyl-(1->3)-beta-D-galactose,PubMed citation,1609521
3333,63233,beta-D-Galp-(1->3)-[alpha-Neup5Ac-(2->6)]-alpha-D-GalpNAc,A branched amino trisaccharide that consists of N-acetyl-alpha-D-galactosamine having a beta-D-galactosyl residue attached at the 3-position and an alpha-N-acetylneuraminosyl residue attached at the 6-position.,"InChI=1S/C25H42N2O19/c1-7(30)26-13-9(32)3-25(24(40)41,46-21(13)15(34)10(33)4-28)42-6-12-17(36)20(14(22(39)43-12)27-8(2)31)45-23-19(38)18(37)16(35)11(5-29)44-23/h9-23,28-29,32-39H,3-6H2,1-2H3,(H,26,30)(H,27,31)(H,40,41)/t9-,10+,11+,12+,13+,14+,15+,16-,17-,18-,19+,20+,21+,22-,23-,25+/m0/s1",beta-D-Gal-(1->3)-[alpha-Neu5Ac-(2->6)]-alpha-D-GalNAc,Reaxys Registry Number,20005454
3334,63235,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc,A branched amino pentasaccharide consisting of the linear trisaccharide alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosamine having alpha-L-fucosyl residues attached at position 2 of the galactose and position 4 of the glucosamine.,"InChI=1S/C32H55NO24/c1-7-14(38)18(42)21(45)29(49-7)54-24-12(6-36)51-28(48)13(33-9(3)37)25(24)55-32-27(57-30-22(46)19(43)15(39)8(2)50-30)26(17(41)11(5-35)53-32)56-31-23(47)20(44)16(40)10(4-34)52-31/h7-8,10-32,34-36,38-48H,4-6H2,1-3H3,(H,33,37)/t7-,8-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20-,21-,22-,23+,24+,25+,26-,27+,28+,29-,30-,31+,32-/m0/s1",alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc,PubMed citation,1609521
3335,63240,pacific blue succinimidyl ester,"An N-hydroxysuccinimide ester derived from 6,8-difluoro-7-hydroxycoumarin-3-carboxylic acid (pacific blue). A fluorescent dye of excitation wavelength 403 nm and emission wavelength 455 nm.","InChI=1S/C14H7F2NO7/c15-7-4-5-3-6(13(21)23-12(5)10(16)11(7)20)14(22)24-17-8(18)1-2-9(17)19/h3-4,20H,1-2H2",pacific blue N-hydroxysuccinimidyl ester,Reaxys Registry Number,19944851
3336,63241,"(9R,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate","A (10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate that has R configuration at the chiral centre.","InChI=1S/C18H30O4/c1-2-3-4-5-6-8-11-14-17(22-21)15-12-9-7-10-13-16-18(19)20/h3-4,6,8,11,14,17,21H,2,5,7,9-10,12-13,15-16H2,1H3,(H,19,20)/p-1/b4-3-,8-6-,14-11+/t17-/m0/s1","(10E,12Z,15Z)-(9R)-9-hydroperoxyoctadeca-10,12,15-trienoate",PubMed citation,20043865
3337,63242,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc with beta configuration at the anomeric carbon of the GlcNAc residue at the reducing end.,"InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)24(41-6)47-22-21(46-25-19(39)17(37)13(33)8(3-28)43-25)15(35)10(5-30)44-26(22)45-20-11(27-7(2)31)23(40)42-9(4-29)14(20)34/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14+,15-,16+,17-,18-,19+,20+,21-,22+,23+,24-,25+,26-/m0/s1",alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-beta-D-GlcNAc,PubMed citation,1609521
3338,63249,(Z)-2-methylureidoperacrylic acid,The peracid of (Z)-2-methylureidoacrylic acid where the acidic -OH group has been replaced by an -OOH group.,"InChI=1S/C5H8N2O4/c1-3(4(8)11-10)2-7-5(6)9/h2,10H,1H3,(H3,6,7,9)/b3-2-",(Z)-2-methyl-ureidoacrylate peracid,PubMed citation,20400551
3339,63250,(Z)-2-methyl-3-aminoperacrylic acid,The peracid of aminoacrylic acid where the acidic -OH group has been replaced by an -OOH group.,"InChI=1S/C4H7NO3/c1-3(2-5)4(6)8-7/h2,7H,5H2,1H3/b3-2-",(Z)-2-methyl-3-peroxyaminoacrylate,PubMed citation,20400551
3340,63253,"3-oxo-5,6-dehydrosuberyl-CoA","An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxo-5,6-dehydrosuberic acid.","InChI=1S/C29H44N7O20P3S/c1-29(2,24(43)27(44)32-8-7-18(38)31-9-10-60-20(41)11-16(37)5-3-4-6-19(39)40)13-53-59(50,51)56-58(48,49)52-12-17-23(55-57(45,46)47)22(42)28(54-17)36-15-35-21-25(30)33-14-34-26(21)36/h3-4,14-15,17,22-24,28,42-43H,5-13H2,1-2H3,(H,31,38)(H,32,44)(H,39,40)(H,48,49)(H,50,51)(H2,30,33,34)(H2,45,46,47)/t17-,22-,23-,24+,28-/m1/s1","3'-phosphoadenosine 5'-{3-[(3R)-4-({3-[(2-{[3-oxo-5,6-dehydro-7-carboxyheptanoyl]sulfanyl}ethyl)amino]-3-oxopropyl}amino)-3-hydroxy-2,2-dimethyl-4-oxobutyl] dihydrogen diphosphate}",MetaCyc accession,CPD0-2364
3341,63254,beta-D-Delta(4)-GlcpA-(1->4)-beta-D-Glcp-(1->4)-alpha-L-Rhap-(1->3)-beta-D-Glcp(1-),A carbohydrate acid anion that results from the deprotonation of the carboxylic acid group of beta-D-Delta(4)-GlcpA-(1->4)-beta-D-Glcp-(1->4)-alpha-L-Rhap-(1->3)-beta-D-Glcp. The major species at pH 7.3.,"InChI=1S/C24H38O20/c1-5-17(12(30)14(32)23(38-5)44-19-11(29)8(3-25)39-21(37)16(19)34)42-24-15(33)13(31)18(9(4-26)41-24)43-22-10(28)6(27)2-7(40-22)20(35)36/h2,5-6,8-19,21-34,37H,3-4H2,1H3,(H,35,36)/p-1/t5-,6-,8+,9+,10+,11+,12-,13+,14+,15+,16+,17-,18+,19-,21+,22-,23-,24-/m0/s1",beta-D-4-deoxy-Delta(4)-GlcAp-(1->4)-beta-D-Glcp-(1->4)-alpha-L-Rhap-(1->3)-beta-D-Glcp(1-),PubMed citation,21147778
3342,63256,"3,8-dioxooct-5-enoyl-CoA","An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3,8-dioxooct-5-enoic acid.","InChI=1S/C29H44N7O19P3S/c1-29(2,24(42)27(43)32-8-7-19(39)31-9-11-59-20(40)12-17(38)6-4-3-5-10-37)14-52-58(49,50)55-57(47,48)51-13-18-23(54-56(44,45)46)22(41)28(53-18)36-16-35-21-25(30)33-15-34-26(21)36/h3-4,10,15-16,18,22-24,28,41-42H,5-9,11-14H2,1-2H3,(H,31,39)(H,32,43)(H,47,48)(H,49,50)(H2,30,33,34)(H2,44,45,46)/t18-,22-,23-,24+,28-/m1/s1","3,8-dioxo-5,6-dehydrooctanoyl-CoA",PubMed citation,20660314
3343,63264,"dTDP-3-amino-3,6-dideoxy-alpha-D-glucose","A dTDP-sugar having 3-amino-3,6-dideoxy-alpha-D-glucose as the sugar component.","InChI=1S/C16H27N3O14P2/c1-6-4-19(16(24)18-14(6)23)10-3-8(20)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)11(17)12(21)7(2)30-15/h4,7-13,15,20-22H,3,5,17H2,1-2H3,(H,25,26)(H,27,28)(H,18,23,24)/t7-,8+,9-,10-,11+,12-,13-,15-/m1/s1","dTDP-3-amino-3,6-dideoxy-alpha-D-glucopyranose",KEGG COMPOUND accession,C11925
3344,63269,dTDP-3-dehydro-6-deoxy-alpha-D-glucose(2-),A doubly-charged nucleotide-sugar oxoanion arising from deprotonation of the diphosphate OH groups of dTDP-3-dehydro-6-deoxy-alpha-D-glucose.,"InChI=1S/C16H24N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-11,13,15,19-20,22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/p-2/t7-,8+,9-,10-,11-,13-,15-/m1/s1",dTDP-3-keto-6-deoxy-alpha-D-glucose(2-),Reaxys Registry Number,7327255
3345,63270,N-acetyl-beta-D-galactosamine 6-sulfate(1-),An organosulfate oxoanion resulting from the removal of a proton from the sulfate group of N-acetyl-beta-D-galactosamine 6-sulfate.,"InChI=1S/C8H15NO9S/c1-3(10)9-5-7(12)6(11)4(18-8(5)13)2-17-19(14,15)16/h4-8,11-13H,2H2,1H3,(H,9,10)(H,14,15,16)/p-1/t4-,5-,6+,7-,8-/m1/s1",2-(acetylamino)-2-deoxy-6-O-sulfonato-beta-D-galactopyranose,PubMed citation,19416976
3346,63271,4-deoxy-Delta(4)-beta-D-GlcpA2S-(1->3)-beta-D-GalpNAc,An oligosaccharide sulfate that is 2-acetamido-2-deoxy-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl)-beta-D-galactopyranose in which the hydroxy group at position 2 of the 4-deoxy-hex-4-enopyranuronosyl moiety is converted to the corresponding sulfate derivative.,"InChI=1S/C14H21NO14S/c1-4(17)15-8-11(9(19)7(3-16)26-13(8)22)28-14-10(29-30(23,24)25)5(18)2-6(27-14)12(20)21/h2,5,7-11,13-14,16,18-19,22H,3H2,1H3,(H,15,17)(H,20,21)(H,23,24,25)/t5-,7+,8+,9-,10+,11+,13+,14-/m0/s1",2-(acetylamino)-2-deoxy-3-O-(4-deoxy-2-O-sulfo-alpha-L-threo-hex-4-enopyranuronosyl)-beta-D-galactopyranose,PubMed citation,19416976
3347,63277,"UDP-2-acetamido-4-azaniumyl-2,4,6-trideoxy-alpha-D-glucose(1-)","A nucleotide-sugar oxoanion that is the conjugate base of UDP-2-acetamido-4-amino-2,4,6-trideoxy-alpha-D-glucose, arising from deprotonation of the diphosphate group and protonation of the amino group; major species at pH 7.3.","InChI=1S/C17H28N4O15P2/c1-6-10(18)13(25)11(19-7(2)22)16(33-6)35-38(30,31)36-37(28,29)32-5-8-12(24)14(26)15(34-8)21-4-3-9(23)20-17(21)27/h3-4,6,8,10-16,24-26H,5,18H2,1-2H3,(H,19,22)(H,28,29)(H,30,31)(H,20,23,27)/p-1/t6-,8-,10-,11-,12-,13+,14-,15-,16-/m1/s1","4-azaniumyl-4,6-dideoxy-N-acetyl-alpha-D-glucosamine(1-)",PubMed citation,17087520
3348,63280,beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc(1-),A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc.,"InChI=1S/C14H21NO11/c1-4(17)15-8-11(10(20)7(3-16)24-13(8)23)26-14-9(19)5(18)2-6(25-14)12(21)22/h2,5,7-11,13-14,16,18-20,23H,3H2,1H3,(H,15,17)(H,21,22)/p-1/t5-,7+,8+,9+,10+,11+,13+,14-/m0/s1",beta-D-4-deoxy-Delta(4)-GlcA-(1->3)-beta-D-GlcNAc(1),PubMed citation,19416976
3349,63288,3-O-(alpha-L-olivosyl)erythronolide B,"A macrolide that is erythronolide B having a 2,6-dideoxy-alpha-L-arabino-hexopyranosyl (alpha-L-olivosyl) residue attached at position 3.","InChI=1S/C27H48O10/c1-9-19-13(3)22(30)14(4)21(29)12(2)11-27(8,34)25(32)15(5)24(16(6)26(33)36-19)37-20-10-18(28)23(31)17(7)35-20/h12-20,22-25,28,30-32,34H,9-11H2,1-8H3/t12-,13+,14+,15+,16-,17+,18+,19-,20+,22+,23+,24+,25-,27-/m1/s1",3-L-olivosyl-erythronolide B,PubMed citation,11514520
3350,63289,3-O-(alpha-L-oleandrosyl)erythronolide B,"A macrolide that is erythronolide B having a 2,6-dideoxy-3-O-methyl-alpha-Larabino-hexopyranosyl (alpha-L-oleandrosyl) residue attached at position 3.","InChI=1S/C28H50O10/c1-10-19-14(3)23(30)15(4)22(29)13(2)12-28(8,34)26(32)16(5)25(17(6)27(33)37-19)38-21-11-20(35-9)24(31)18(7)36-21/h13-21,23-26,30-32,34H,10-12H2,1-9H3/t13-,14+,15+,16+,17-,18+,19-,20+,21+,23+,24+,25+,26-,28-/m1/s1",3-L-oleandrosyl-erythronolide B,PubMed citation,11514520
3351,63312,O-benzoylecgonine 5-carboxypentyl ester,An azabicycloalkane that consists of ecgonine having benzoyl and 5-carboxypentyl groups attached to the hydroxy and carboxy functions respectively.,"InChI=1S/C22H29NO6/c1-23-16-11-12-17(23)20(22(27)28-13-7-3-6-10-19(24)25)18(14-16)29-21(26)15-8-4-2-5-9-15/h2,4-5,8-9,16-18,20H,3,6-7,10-14H2,1H3,(H,24,25)/t16-,17+,18-,20+/m0/s1",ecgonine benzoate 5-carboxypentyl ester,Reaxys Registry Number,9957318
3352,63313,"1,5-dihydrocoenzyme F420-6","The 1,5-dihydro derivative of coenzyme F420-6. Species of coenzyme F420(red.) specific to Mycobacterium tuberculosis.","InChI=1S/C49H66N9O30P/c1-20(88-89(85,86)87-19-32(61)39(69)31(60)18-58-30-17-22(59)3-2-21(30)16-23-40(58)56-49(84)57-42(23)71)41(70)55-29(48(82)83)8-14-37(66)53-27(46(78)79)6-12-35(64)51-25(44(74)75)4-10-33(62)50-24(43(72)73)5-11-34(63)52-26(45(76)77)7-13-36(65)54-28(47(80)81)9-15-38(67)68/h2-3,17,20,24-29,31-32,39,59-61,69H,4-16,18-19H2,1H3,(H,50,62)(H,51,64)(H,52,63)(H,53,66)(H,54,65)(H,55,70)(H,67,68)(H,72,73)(H,74,75)(H,76,77)(H,78,79)(H,80,81)(H,82,83)(H,85,86)(H2,56,57,71,84)/t20-,24-,25-,26-,27-,28-,29-,31-,32+,39-/m0/s1",F420420-6(red.),PubMed citation,18434308
3353,63314,coenzyme F420-6,A coenzyme variant specific to Mycobacterium tuberculosis.,"InChI=1S/C49H64N9O30P/c1-20(88-89(85,86)87-19-32(61)39(69)31(60)18-58-30-17-22(59)3-2-21(30)16-23-40(58)56-49(84)57-42(23)71)41(70)55-29(48(82)83)8-14-37(66)53-27(46(78)79)6-12-35(64)51-25(44(74)75)4-10-33(62)50-24(43(72)73)5-11-34(63)52-26(45(76)77)7-13-36(65)54-28(47(80)81)9-15-38(67)68/h2-3,16-17,20,24-29,31-32,39,59-61,69H,4-15,18-19H2,1H3,(H,50,62)(H,51,64)(H,52,63)(H,53,66)(H,54,65)(H,55,70)(H,67,68)(H,72,73)(H,74,75)(H,76,77)(H,78,79)(H,80,81)(H,82,83)(H,85,86)(H,57,71,84)/t20-,24-,25-,26-,27-,28-,29-,31-,32+,39-/m0/s1",F420-6(ox.),PubMed citation,18434308
3354,63316,potassium formate,The potassium salt of formic acid.,"InChI=1S/CH2O2.K/c2-1-3;/h1H,(H,2,3);/q;+1/p-1",Formic acid potassium salt,CAS Registry Number,590-29-4
3355,63318,NDSB 221,An ammonium betaine derivative of 3-(piperidin-1-yl)propane-1-sulfonic acid. One of a group of non-detergent sulfobetaines having a sulfobetaine hydrophilic group and a short hydrophobic group that cannot aggregate to form micelles.,"InChI=1S/C9H19NO3S/c1-10(6-3-2-4-7-10)8-5-9-14(11,12)13/h2-9H2,1H3",3-(1-methylpiperidinio)-1-propanesulfonate,CAS Registry Number,160788-56-7
3356,63321,3-dehydro-L-erythrose 4-phosphate,The ketoaldose phosphate that is the 4-phosphate of 3-dehydro-L-erythrose.,"InChI=1S/C4H7O7P/c5-1-3(6)4(7)2-11-12(8,9)10/h1,3,6H,2H2,(H2,8,9,10)/t3-/m1/s1",3-keto-L-erythrose 4-phosphate,PubMed citation,163226
3357,63333,L-arginyl-L-glutamic acid monoacetate,The acetate salt of L-arginyl-L-glutamic acid.,"InChI=1S/C11H21N5O5.C2H4O2/c12-6(2-1-5-15-11(13)14)9(19)16-7(10(20)21)3-4-8(17)18;1-2(3)4/h6-7H,1-5,12H2,(H,16,19)(H,17,18)(H,20,21)(H4,13,14,15);1H3,(H,3,4)/t6-,7-;/m0./s1",L-Arginyl-L-glutamic acid acetate salt,Reaxys Registry Number,5209730
3358,63417,"UDP-2,4-diacetamido-2,4,6-trideoxy-beta-L-altrose(2-)","Dianion of UDP-4-amino-UDP-2,4-diacetamido-2,4,6-trideoxy-beta-L-altrose arising from deprotonation of the diphosphate; major species at pH 7.3.","InChI=1S/C19H30N4O16P2/c1-7-12(20-8(2)24)15(28)13(21-9(3)25)18(36-7)38-41(33,34)39-40(31,32)35-6-10-14(27)16(29)17(37-10)23-5-4-11(26)22-19(23)30/h4-5,7,10,12-18,27-29H,6H2,1-3H3,(H,20,24)(H,21,25)(H,31,32)(H,33,34)(H,22,26,30)/p-2/t7-,10+,12-,13+,14+,15-,16+,17+,18+/m0/s1","UDP-2,4-bis(acetylamino)-2,4,6-trideoxy-beta-L-altropyranose",PubMed citation,16728396
3359,63449,SU5402,An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 3-(2-carboxyethyl)-4-methyl-1H-pyrrol-2-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.,"InChI=1S/C17H16N2O3/c1-10-9-18-15(11(10)6-7-16(20)21)8-13-12-4-2-3-5-14(12)19-17(13)22/h2-5,8-9,18H,6-7H2,1H3,(H,19,22)(H,20,21)",3-[3-(2-carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone,Reaxys Registry Number,8004406
3360,63469,3-hydroxy-3-phenylpropionate,A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of 3-hydroxy-3-phenylpropionic acid.,"InChI=1S/C9H10O3/c10-8(6-9(11)12)7-4-2-1-3-5-7/h1-5,8,10H,6H2,(H,11,12)/p-1",3-hydroxy-3-phenylpropionic acid anion,MetaCyc accession,CPD-12218
3361,63481,(3-bromo-4-hydroxy-5-nitrophenyl)acetyl azide,An azide carrying a (3-bromo-4-hydroxy-5-nitrophenyl)acetyl substituent.,"InChI=1S/C8H5BrN4O4/c9-5-1-4(3-7(14)11-12-10)2-6(8(5)15)13(16)17/h1-2,15H,3H2",(5-bromo-4-hydroxy-3-nitrophenyl)acetyl azide,PubMed citation,6183362
3362,63497,3-epi-digoxigenin,"A hydroxy steroid that consists of 5beta-cardanolide having a double bond at the 20(22)-position as well as hydroxy groups at the 3alpha,- 12beta- and 14beta-positions.","InChI=1S/C23H34O5/c1-21-7-5-15(24)10-14(21)3-4-17-18(21)11-19(25)22(2)16(6-8-23(17,22)27)13-9-20(26)28-12-13/h9,14-19,24-25,27H,3-8,10-12H2,1-2H3/t14-,15-,16-,17-,18+,19-,21+,22+,23+/m1/s1",3-epidigoxigenin,Reaxys Registry Number,96478
3363,63508,oleandrigenin,A steroid ester that is the 16-acetyl derivative of gitoxigenin.,"InChI=1S/C25H36O6/c1-14(26)31-20-12-25(29)19-5-4-16-11-17(27)6-8-23(16,2)18(19)7-9-24(25,3)22(20)15-10-21(28)30-13-15/h10,16-20,22,27,29H,4-9,11-13H2,1-3H3/t16-,17+,18+,19-,20+,22+,23+,24-,25+/m1/s1",16-O-acetylgitoxigenin,Reaxys Registry Number,98733
3364,63514,erysimoside,"A cardenolide glycoside that consists of strophanthidin having a beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl moiety attached at position 3.","InChI=1S/C35H52O14/c1-17-30(49-31-29(42)28(41)27(40)24(14-36)48-31)23(38)12-26(46-17)47-19-3-8-33(16-37)21-4-7-32(2)20(18-11-25(39)45-15-18)6-10-35(32,44)22(21)5-9-34(33,43)13-19/h11,16-17,19-24,26-31,36,38,40-44H,3-10,12-15H2,1-2H3/t17-,19+,20-,21+,22-,23+,24-,26+,27-,28+,29-,30-,31+,32-,33+,34+,35+/m1/s1",strophanthidin digilanobioside,Reaxys Registry Number,79099
3365,63518,3-(hexadecylsulfonyl)-2-[(hexadecylsulfonyl)methyl]propyl alpha-D-galactosyl-(1->4)-beta-D-galactoside,A glycoside that consists of alpha-D-galactosyl-(1->4)-beta-D-galactose where the hydrogen of the anomeric OH group is substituted by a 3-(hexadecylsulfonyl)-2-[(hexadecylsulfonyl)methyl]propyl group.,"InChI=1S/C48H94O15S2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-64(56,57)36-38(37-65(58,59)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)35-60-47-45(55)43(53)46(40(34-50)62-47)63-48-44(54)42(52)41(51)39(33-49)61-48/h38-55H,3-37H2,1-2H3/t39-,40-,41+,42+,43-,44-,45-,46+,47-,48-/m1/s1",Gal2-bisulfone,Reaxys Registry Number,4229107
3366,63531,3-(hexadecylsulfonyl)-2-[(hexadecylsulfonyl)methyl]propyl beta-D-galactosyl-(1->4)-beta-D-glucoside,A glycoside that consists of beta-D-galactosyl-(1->4)-beta-D-glucose where the hydrogen of the anomeric OH group is substituted by a 3-(hexadecylsulfonyl)-2-[(hexadecylsulfonyl)methyl]propyl group.,"InChI=1S/C48H94O15S2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-64(56,57)36-38(37-65(58,59)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)35-60-47-45(55)43(53)46(40(34-50)62-47)63-48-44(54)42(52)41(51)39(33-49)61-48/h38-55H,3-37H2,1-2H3/t39-,40-,41+,42+,43-,44-,45-,46-,47-,48+/m1/s1",lactose-bisulfone,Reaxys Registry Number,4229106
3367,63532,GM3 lactam,"A lactam obtained via formal condensation of the carboxy group of an N-acetylneuraminyl residue and the amino group of the adjacent galactosamine residue in the ganglioside (2S,3R,4E)-3-hydroxy-2-(stearoylamino)octadec-4-en-1-yl N-acetylneuraminyl-(2->3)-beta-D-galactosaminyl-(1->4)-beta-D-glucoside.","InChI=1S/C59H107N3O19/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-46(70)61-40(41(67)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)38-76-57-52(74)51(73)53(45(37-65)78-57)79-56-48-55(50(72)44(36-64)77-56)81-59(58(75)62-48)34-42(68)47(60-39(3)66)54(80-59)49(71)43(69)35-63/h30,32,40-45,47-57,63-65,67-69,71-74H,4-29,31,33-38H2,1-3H3,(H,60,66)(H,61,70)(H,62,75)/b32-30+/t40-,41+,42-,43+,44+,45+,47+,48+,49+,50-,51+,52+,53+,54+,55+,56-,57+,59-/m0/s1",GM3-lactam ceramide,Reaxys Registry Number,7245914
3368,63536,5-[(2-aminobenzimidazol-6-yl)amino]-5-oxopentanoic acid,"A dicarboxylic acid monoamide obtained by formal condensation of the 6-amino group of 2,6-diaminobenzimidazole with one of the carboxy groups of glutaric acid.","InChI=1S/C12H14N4O3/c13-12-15-8-5-4-7(6-9(8)16-12)14-10(17)2-1-3-11(18)19/h4-6H,1-3H2,(H,14,17)(H,18,19)(H3,13,15,16)",5-[(2-amino-3H-benzimidazol-5-yl)amino]-5-oxopentanoic acid,Reaxys Registry Number,10458230
3369,63538,(Z)-4-glutaramidostilbene,A stilbenoid obtained by formal condensation of the amino group of (Z)-4-aminostilbene with one of the carboxy groups of glutaric acid.,"InChI=1S/C19H19NO3/c21-18(7-4-8-19(22)23)20-17-13-11-16(12-14-17)10-9-15-5-2-1-3-6-15/h1-3,5-6,9-14H,4,7-8H2,(H,20,21)(H,22,23)/b10-9-",cis-4-glutaramidostilbene,PubMed citation,11030644
3370,63540,"(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosahexaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosahexaenoic acid. It is a member of n-3 PUFA and a product of alpha-linolenoic acid metabolism.","InChI=1S/C45H70N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-36(54)73-29-28-47-35(53)26-27-48-43(57)40(56)45(2,3)31-66-72(63,64)69-71(61,62)65-30-34-39(68-70(58,59)60)38(55)44(67-34)52-33-51-37-41(46)49-32-50-42(37)52/h5-6,8-9,11-12,14-15,17-18,20-21,32-34,38-40,44,55-56H,4,7,10,13,16,19,22-31H2,1-3H3,(H,47,53)(H,48,57)(H,61,62)(H,63,64)(H2,46,49,50)(H2,58,59,60)/b6-5-,9-8-,12-11-,15-14-,18-17-,21-20-/t34-,38-,39-,40+,44-/m1/s1",tetracosahexaenoyl-CoA,KEGG COMPOUND accession,C16168
3371,63541,"(7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid. It is a member of n-3 PUFA and a product of alpha-linolenic acid metabolism","InChI=1S/C43H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-34(52)71-27-26-45-33(51)24-25-46-41(55)38(54)43(2,3)29-64-70(61,62)67-69(59,60)63-28-32-37(66-68(56,57)58)36(53)42(65-32)50-31-49-35-39(44)47-30-48-40(35)50/h5-6,8-9,11-12,14-15,17-18,30-32,36-38,42,53-54H,4,7,10,13,16,19-29H2,1-3H3,(H,45,51)(H,46,55)(H,59,60)(H,61,62)(H2,44,47,48)(H2,56,57,58)/b6-5-,9-8-,12-11-,15-14-,18-17-/t32-,36-,37-,38+,42-/m1/s1",docosapentaenoyl-CoA,KEGG COMPOUND accession,C16166
3372,63543,"(9Z,12Z,15Z,18Z,21Z)-tetracosapentaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z,12Z,15Z,18Z,21Z)-tetracosapentaenoic acid. It is a member of the n-3 PUFA and is the product of alpha-linolenic acid metabolism.","InChI=1S/C45H72N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-36(54)73-29-28-47-35(53)26-27-48-43(57)40(56)45(2,3)31-66-72(63,64)69-71(61,62)65-30-34-39(68-70(58,59)60)38(55)44(67-34)52-33-51-37-41(46)49-32-50-42(37)52/h5-6,8-9,11-12,14-15,17-18,32-34,38-40,44,55-56H,4,7,10,13,16,19-31H2,1-3H3,(H,47,53)(H,48,57)(H,61,62)(H,63,64)(H2,46,49,50)(H2,58,59,60)/b6-5-,9-8-,12-11-,15-14-,18-17-/t34-,38-,39-,40+,44-/m1/s1",tetracosapentaenoyl-CoA,LIPID MAPS instance accession,LMFA07050049
3373,63544,"(7Z,10Z,13Z,16Z)-docosatetraenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (7Z,10Z,13Z,16Z)-docosatetraenoic acid. It is a member of the n-6 PUFA and is the product of linoleic acid metabolism.","InChI=1S/C43H70N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-34(52)71-27-26-45-33(51)24-25-46-41(55)38(54)43(2,3)29-64-70(61,62)67-69(59,60)63-28-32-37(66-68(56,57)58)36(53)42(65-32)50-31-49-35-39(44)47-30-48-40(35)50/h8-9,11-12,14-15,17-18,30-32,36-38,42,53-54H,4-7,10,13,16,19-29H2,1-3H3,(H,45,51)(H,46,55)(H,59,60)(H,61,62)(H2,44,47,48)(H2,56,57,58)/b9-8-,12-11-,15-14-,18-17-/t32-,36-,37-,38+,42-/m1/s1",docosatetraenoyl-CoA,LIPID MAPS instance accession,LMFA07050040
3374,63546,"(6Z,9Z,12Z,15Z,18Z)-tetracosapentaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (6Z,9Z,12Z,15Z,18Z)-tetracosapentaenoic acid. It is a member of the n-6 PUFA and is the product of linoleic acid metabolism.","InChI=1S/C45H72N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-36(54)73-29-28-47-35(53)26-27-48-43(57)40(56)45(2,3)31-66-72(63,64)69-71(61,62)65-30-34-39(68-70(58,59)60)38(55)44(67-34)52-33-51-37-41(46)49-32-50-42(37)52/h8-9,11-12,14-15,17-18,20-21,32-34,38-40,44,55-56H,4-7,10,13,16,19,22-31H2,1-3H3,(H,47,53)(H,48,57)(H,61,62)(H,63,64)(H2,46,49,50)(H2,58,59,60)/b9-8-,12-11-,15-14-,18-17-,21-20-/t34-,38-,39-,40+,44-/m1/s1",tetracosapentaenoyl-CoA,KEGG COMPOUND accession,C16172
3375,63548,"(9Z,12Z,15Z,18Z)-tetracosatetraenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z,12Z,15Z,18Z)-tetracosatetraenoic acid. It is a member of the n-6 PUFA and is the product of linoleic acid metabolism.","InChI=1S/C45H74N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-36(54)73-29-28-47-35(53)26-27-48-43(57)40(56)45(2,3)31-66-72(63,64)69-71(61,62)65-30-34-39(68-70(58,59)60)38(55)44(67-34)52-33-51-37-41(46)49-32-50-42(37)52/h8-9,11-12,14-15,17-18,32-34,38-40,44,55-56H,4-7,10,13,16,19-31H2,1-3H3,(H,47,53)(H,48,57)(H,61,62)(H,63,64)(H2,46,49,50)(H2,58,59,60)/b9-8-,12-11-,15-14-,18-17-/t34-,38-,39-,40+,44-/m1/s1",tetracosatetraenoyl-CoA,KEGG COMPOUND accession,C16171
3376,63643,(S)-2-(4-(2-bromoacetamido)benzyl)-DOTA,An optically active twelve-membered tetraazamacrocycle having a carboxymethyl group attached to each of the nitrogens and a 4-(2-bromoacetamido)benzyl group at the 2-position.,"InChI=1S/C25H36BrN5O9/c26-12-21(32)27-19-3-1-18(2-4-19)11-20-13-30(16-24(37)38)8-7-28(14-22(33)34)5-6-29(15-23(35)36)9-10-31(20)17-25(39)40/h1-4,20H,5-17H2,(H,27,32)(H,33,34)(H,35,36)(H,37,38)(H,39,40)/t20-/m0/s1",(S)BAD,PubMed citation,14653738
3377,63672,"3-methoxy-4',5-dihydroxy-trans-stilbene",A stilbenoid that is trans-resveratrol in which one of the meta-hydroxy groups is converted to the corresponding methyl ether.,"InChI=1S/C15H14O3/c1-18-15-9-12(8-14(17)10-15)3-2-11-4-6-13(16)7-5-11/h2-10,16-17H,1H3/b3-2+",resveratrol monomethyl ether,PubMed citation,18799660
3378,63675,sodium succinate (anhydrous),A sodium salt that is the disodium salt of succinic acid. The hexahydrate form is used as an ingredient of topical preparations for the treatment of cataract.,"InChI=1S/C4H6O4.2Na/c5-3(6)1-2-4(7)8;;/h1-2H2,(H,5,6)(H,7,8);;/q;2*+1/p-2",Succinic acid disodium salt,Reaxys Registry Number,3917246
3379,63681,"[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol",An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.,"InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2","alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol",Reaxys Registry Number,766168
3380,63686,sodium succinate hexahydrate,A hydrate that is the hexahydrate form of sodium succinate. It is used as an ingredient of topical preparations for the treatment of cataract.,"InChI=1S/C4H6O4.2Na.6H2O/c5-3(6)1-2-4(7)8;;;;;;;;/h1-2H2,(H,5,6)(H,7,8);;;6*1H2/q;2*+1;;;;;;/p-2",disodium succinate.6H2O,CAS Registry Number,6106-21-4
3381,63694,D-synephrine(1+),"An organic cation that is the conjugate acid of D-synephrine, arising from protonation of the secondary amino group; major species at pH 7.3.","InChI=1S/C9H13NO2/c1-10-6-9(12)7-2-4-8(11)5-3-7/h2-5,9-12H,6H2,1H3/p+1/t9-/m0/s1",(R)-synephrine,PubMed citation,3729420
3382,63695,"(11R,16S)-misoprostol","A methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that has 8S,11S,12S,16R-configuration. It is the pharmacologically active diastereoisomeric component of misoprostol.","InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22+/m1/s1","methyl 11R,16S-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate",Reaxys Registry Number,6092906
3383,63718,tenofovir disoproxil fumarate,A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.,"InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1",TDF,Reaxys Registry Number,9831556
3384,63728,8-oxo-dGDP,A purine 2'-deoxyribonucleoside 5'-diphosphate having 8-oxoguanine as the nucleobase.,"InChI=1S/C10H15N5O11P2/c11-9-13-7-6(8(17)14-9)12-10(18)15(7)5-1-3(16)4(25-5)2-24-28(22,23)26-27(19,20)21/h3-5,16H,1-2H2,(H,12,18)(H,22,23)(H2,19,20,21)(H3,11,13,14,17)/t3-,4+,5+/m0/s1",8-oxo-2'-deoxyguanosine-5'-diphosphate,Reaxys Registry Number,8595504
3385,63729,7-methylguanosine 5'-diphosphate,A guanosine 5'-phosphate that consists of guanosine 5'-diphosphate bearing a 7-methyl substituent and having a negatively charged diphosphate group.,"InChI=1S/C11H17N5O11P2/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(26-10)2-25-29(23,24)27-28(20,21)22/h3-4,6-7,10,17-18H,2H2,1H3,(H5-,12,13,14,19,20,21,22,23,24)/t4-,6-,7-,10-/m1/s1",7-methylguanosine 5'-diphosphate betaine,Reaxys Registry Number,4170881
3386,63730,7-methylguanosine 5'-diphosphate(1+),A guanosine 5'-phosphate that consists of guanosine 5'-diphosphate bearing a 7-methyl substituent.,"InChI=1S/C11H17N5O11P2/c1-15-3-16(8-5(15)9(19)14-11(12)13-8)10-7(18)6(17)4(26-10)2-25-29(23,24)27-28(20,21)22/h3-4,6-7,10,17-18H,2H2,1H3,(H5-,12,13,14,19,20,21,22,23,24)/p+1/t4-,6-,7-,10-/m1/s1",7-methyl-GDP(1+),Reaxys Registry Number,4061822
3387,63743,"dTDP-3-acetamido-3,6-dideoxy-alpha-D-galactopyranose","A dTDP-sugar having 3-acetamido-3,6-dideoxy-alpha-D-galactopyranose (3-amino-3-deoxy-alpha-D-fucopyranose) as the sugar component.","InChI=1S/C18H29N3O15P2/c1-7-5-21(18(27)20-16(7)26)12-4-10(23)11(34-12)6-32-37(28,29)36-38(30,31)35-17-15(25)13(19-9(3)22)14(24)8(2)33-17/h5,8,10-15,17,23-25H,4,6H2,1-3H3,(H,19,22)(H,28,29)(H,30,31)(H,20,26,27)/t8-,10+,11-,12-,13+,14+,15-,17-/m1/s1","dTDP-3-acetamido-3,6-dideoxy-alpha-D-galactose",PubMed citation,12740380
3388,63747,6-{[5-(p-nitrophenoxy)-5-oxopentanoyl]amino}hexanoic acid,A monocarboxylic acid amide  compound having an N-(5-carboxypentyl) substituent and a C-[4-(4-nitrophenoxy)-4-oxobutyl)] substituent.,"InChI=1S/C17H22N2O7/c20-15(18-12-3-1-2-6-16(21)22)5-4-7-17(23)26-14-10-8-13(9-11-14)19(24)25/h8-11H,1-7,12H2,(H,18,20)(H,21,22)",nP-E1,PubMed citation,9826512
3389,63752,"1,2-dipalmitoyl-3-alpha-D-galactosyl-sn-glycerol","A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are both palmitoyl.","InChI=1S/C41H78O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(43)48-32-34(33-49-41-40(47)39(46)38(45)35(31-42)51-41)50-37(44)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h34-35,38-42,45-47H,3-33H2,1-2H3/t34-,35-,38+,39+,40-,41+/m1/s1","1,2-di-O-palmitoyl-3-O-(alpha-D-galactosyl)-sn-glycerol",Reaxys Registry Number,5841974
3390,63754,"1,2-dioleoyl-3-alpha-D-galactosyl-sn-glycerol","A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are both oleoyl.","InChI=1S/C45H82O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(47)52-36-38(37-53-45-44(51)43(50)42(49)39(35-46)55-45)54-41(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,38-39,42-46,49-51H,3-16,21-37H2,1-2H3/b19-17-,20-18-/t38-,39-,42+,43+,44-,45+/m1/s1","1,2-di-O-oleoyl-3-O-(alpha-D-galactosyl)-sn-glycerol",Reaxys Registry Number,21669296
3391,63757,1-palmitoyl-2-oleoyl-3-alpha-D-galactosyl-sn-glycerol,"A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are palmitoyl and oleoyl respectively.","InChI=1S/C43H80O10/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(46)52-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)34-50-38(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,36-37,40-44,47-49H,3-16,19-35H2,1-2H3/b18-17-/t36-,37-,40+,41+,42-,43+/m1/s1",(2S)-1-(alpha-D-galactopyranosyloxy)-3-(palmitoyloxy)propyl (9Z)-octadec-9-enoate,Reaxys Registry Number,10233811
3392,63761,1-oleoyl-2-palmitoyl-3-alpha-D-galactosyl-sn-glycerol,"A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are oleoyl and palmitoyl respectively.","InChI=1S/C43H80O10/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(45)50-34-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)52-39(46)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h17-18,36-37,40-44,47-49H,3-16,19-35H2,1-2H3/b18-17-/t36-,37-,40+,41+,42-,43+/m1/s1",3-O-alpha-D-Galp-1-O-Ole-2-O-Pal-sn-GRO,Reaxys Registry Number,7898464
3393,63762,"2,3-dipalmitoyl-1-alpha-D-galactosyl-sn-glycerol","A 2,3-diacyl-1-alpha-D-galactosyl-sn-glycerol in which the groups at the 2- and 3-positions are both palmitoyl.","InChI=1S/C41H78O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(43)48-32-34(33-49-41-40(47)39(46)38(45)35(31-42)51-41)50-37(44)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h34-35,38-42,45-47H,3-33H2,1-2H3/t34-,35+,38-,39-,40+,41-/m0/s1","2,3-di-O-hexadecanoyl-1-O-(alpha-D-galactosyl)-sn-glycerol",Reaxys Registry Number,21669290
3394,63764,"2,3-dioleoyl-1-alpha-D-galactosyl-sn-glycerol","A 2,3-diacyl-1-alpha-D-galactosyl-sn-glycerol in which the groups at the 2- and 3-positions are both oleoyl.","InChI=1S/C45H82O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(47)52-36-38(37-53-45-44(51)43(50)42(49)39(35-46)55-45)54-41(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,38-39,42-46,49-51H,3-16,21-37H2,1-2H3/b19-17-,20-18-/t38-,39+,42-,43-,44+,45-/m0/s1","2,3-di-O-oleoyl-1-O-(alpha-D-galactopyranosyl)-sn-glycero",Reaxys Registry Number,21669295
3395,63765,1-alpha-D-galactosyl-2-oleoyl-3-palmitoyl-sn-glycerol,"A 2,3-diacyl-1-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are palmitoyl and oleoyl respectively.","InChI=1S/C43H80O10/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(46)52-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)34-50-38(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,36-37,40-44,47-49H,3-16,19-35H2,1-2H3/b18-17-/t36-,37+,40-,41-,42+,43-/m0/s1",1-O-(alpha-D-galactosyl)-2-O-oleoyl-3-O-palmitoyl-sn-glycerol,Reaxys Registry Number,21669292
3396,63767,"1,2-distearoyl-3-alpha-D-galactosyl-sn-glycerol","A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are both stearoyl.","InChI=1S/C45H86O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(47)52-36-38(37-53-45-44(51)43(50)42(49)39(35-46)55-45)54-41(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h38-39,42-46,49-51H,3-37H2,1-2H3/t38-,39-,42+,43+,44-,45+/m1/s1","1,2-di-O-octadecanoyl-3-O-(alpha-D-galactosyl)-sn-glycerol",Reaxys Registry Number,15476286
3397,63768,1-stearoyl-2-palmitoyl-3-alpha-D-galactosyl-sn-glycerol,"A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are stearoyl and palmitoyl respectively.","InChI=1S/C43H82O10/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(45)50-34-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)52-39(46)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h36-37,40-44,47-49H,3-35H2,1-2H3/t36-,37-,40+,41+,42-,43+/m1/s1",1-O-octadecanoyl-2-O-hexadecanoyl-3-O-(alpha-D-galactopyranosyl)-sn-glycerol,Reaxys Registry Number,21669291
3398,63769,1-palmitoyl-3-alpha-D-galactosyl-sn-glycerol,A 1-acyl-3-alpha-D-galactosyl-sn-glycerol where the 1-acyl group is specified as palmitoyl.,"InChI=1S/C25H48O9/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-21(28)32-17-19(27)18-33-25-24(31)23(30)22(29)20(16-26)34-25/h19-20,22-27,29-31H,2-18H2,1H3/t19-,20-,22+,23+,24-,25+/m1/s1",1-hexadecanoyl-3-alpha-D-galactosyl-sn-glycerol,Reaxys Registry Number,21669280
3399,63772,1-oleoyl-3-alpha-D-galactosyl-sn-glycerol,A 1-acyl-3-alpha-D-galactosyl-sn-glycerol where the 1-acyl group is specified as oleoyl.,"InChI=1S/C27H52O9/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(30)34-19-21(29)20-35-27-26(33)25(32)24(31)22(18-28)36-27/h21-22,24-29,31-33H,2-20H2,1H3/t21-,22-,24+,25+,26-,27+/m1/s1",(9Z)-octadec-9-enoyl-3-alpha-D-galactosyl-sn-glycerol,PubMed citation,21601180
3400,63774,"1,2-dipalmitoyl-3-beta-D-galactosyl-sn-glycerol","A 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are both palmitoyl.","InChI=1S/C41H78O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(43)48-32-34(33-49-41-40(47)39(46)38(45)35(31-42)51-41)50-37(44)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h34-35,38-42,45-47H,3-33H2,1-2H3/t34-,35-,38+,39+,40-,41-/m1/s1","1,2-di-O-hexadecanoyl-3-O-(beta-D-galactopyranosyl)-sn-glycerol",Reaxys Registry Number,1633071
3401,63775,"1,2-dioleoyl-3-beta-D-galactosyl-sn-glycerol","A 1,2-diacyl-3-beta-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are both oleoyl.","InChI=1S/C45H82O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(47)52-36-38(37-53-45-44(51)43(50)42(49)39(35-46)55-45)54-41(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,38-39,42-46,49-51H,3-16,21-37H2,1-2H3/b19-17-,20-18-/t38-,39-,42+,43+,44-,45-/m1/s1","1,2-di-O-oleoyl-3-O-(beta-D-galactopyranosyl)-sn-glycerol",Reaxys Registry Number,9248316
3402,63777,"6-O-butyryl-N-acetylmuramyl-L-alanyl-D-isoglutamine N-hydroxy-5-norbornene-2,3-dicarboxylmidyl ester","A glycopeptide obtained by formal condensation of the carboxy group of 6-O-butyrylated muramyl dipeptide with the hydroxy group of N-hydroxy-5-norbornene-2,3-dicarboxylmide.","InChI=1S/C32H45N5O14/c1-5-6-20(39)48-12-19-25(41)26(24(32(47)50-19)35-15(4)38)49-14(3)29(44)34-13(2)28(43)36-18(27(33)42)9-10-21(40)51-37-30(45)22-16-7-8-17(11-16)23(22)31(37)46/h7-8,13-14,16-19,22-26,32,41,47H,5-6,9-12H2,1-4H3,(H2,33,42)(H,34,44)(H,35,38)(H,36,43)/t13-,14+,16?,17?,18+,19+,22?,23?,24+,25+,26+,32?/m0/s1",L4-MDP-ONB,PubMed citation,2933141
3403,63789,N-(3-oxohexanoyl)-L-homoserine lactone,An N-acyl-L-homoserine lactone having 3-oxohexanoyl as the acyl substituent.,"InChI=1S/C10H15NO4/c1-2-3-7(12)6-9(13)11-8-4-5-15-10(8)14/h8H,2-6H2,1H3,(H,11,13)/t8-/m0/s1",(S)-3-(3-oxohexanamido)-2-oxotetrahydrofuran,Reaxys Registry Number,7479823
3404,63801,N(alpha)-citryl-N(epsilon)-acetyl-N(epsilon)-hydroxylysine,An L-lysine derivative that is N(alpha)-citryl-L-lysine having hydroxy and acetyl substituents attached to the side-chain amino group.,"InChI=1S/C14H22N2O10/c1-8(17)16(26)5-3-2-4-9(12(21)22)15-10(18)6-14(25,13(23)24)7-11(19)20/h9,25-26H,2-7H2,1H3,(H,15,18)(H,19,20)(H,21,22)(H,23,24)/t9-,14?/m0/s1",N(2)-citryl-N(6)-acetyl-N(6)-hydroxylysine,PubMed citation,3087960
3405,63802,9-cis-4-hydroxyretinoic acid,A retinoid that consists of 9-cis-retinoic acid bearing a hydroxy substituent at position 4 on the cyclohexenyl ring.,"InChI=1S/C20H28O3/c1-14(7-6-8-15(2)13-19(22)23)9-10-17-16(3)18(21)11-12-20(17,4)5/h6-10,13,18,21H,11-12H2,1-5H3,(H,22,23)/b8-6+,10-9+,14-7-,15-13+",4-hydroxy-9-cis-retinoic acid,Reaxys Registry Number,9576608
3406,63813,adenosine 5'-pentaphosphate(6-),An organophosphate oxoanion resulting from the removal of all six protons from the phosphate groups of adenosine 5'-pentaphosphate; the major species at pH 7.3.,"InChI=1S/C10H18N5O19P5/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(30-10)1-29-36(21,22)32-38(25,26)34-39(27,28)33-37(23,24)31-35(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28)(H2,11,12,13)(H2,18,19,20)/p-6/t4-,6-,7-,10-/m1/s1",adenosine 5'-pentaphosphate hexa-anion,MetaCyc accession,CPD-11561
3407,63818,1-hexadecyl-sn-glycerol 3-phosphate,A 1-alkyl-sn-glycerol 3-phosphate in which the 1-alkyl group is specified as hexadecyl.,"InChI=1S/C19H41O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-24-17-19(20)18-25-26(21,22)23/h19-20H,2-18H2,1H3,(H2,21,22,23)/t19-/m1/s1",1-hexadecyl-sn-glycerol 3-phosphate,Reaxys Registry Number,9018057
3408,63827,bromosulfophthalein sodium,An organic sodium salt that is the disodium salt of bromosulfophthalein.,"InChI=1S/C20H10Br4O10S2.2Na/c21-15-13-14(16(22)18(24)17(15)23)20(34-19(13)27,7-1-3-9(25)11(5-7)35(28,29)30)8-2-4-10(26)12(6-8)36(31,32)33;;/h1-6,25-26H,(H,28,29,30)(H,31,32,33);;/q;2*+1/p-2",bromosulfophthalein disodium salt,Reaxys Registry Number,7110446
3409,63832,bromosulfophthalein(2-),An organosulfonate oxoanion obtained by deprotonation of both sulfonyl groups of bromosulfophthalein.,"InChI=1S/C20H10Br4O10S2/c21-15-13-14(16(22)18(24)17(15)23)20(34-19(13)27,7-1-3-9(25)11(5-7)35(28,29)30)8-2-4-10(26)12(6-8)36(31,32)33/h1-6,25-26H,(H,28,29,30)(H,31,32,33)/p-2",bromosulfophthalein dianion,Reaxys Registry Number,1416698
3410,63843,"17alpha-hydroxypregn-5-ene-3,20-dione",A C21-steroid that is pregnane which contains a double bond between positions 5 and 6 and is substituted by oxo groups at positions 3 and 20 as well as a hydroxy group at position 17.,"InChI=1S/C21H30O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4,16-18,24H,5-12H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1","pregn-5-ene-3,20-dione-17-ol",Reaxys Registry Number,3104241
3411,63857,sulfacetamide(1-),An organic nitrogen anion that is the conjugate base of sulfacetamide arising from deprotonation of the N-acylsulfonamide function.,"InChI=1S/C8H10N2O3S/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8/h2-5H,9H2,1H3,(H,10,11)/p-1",sulfacetamide anion,Reaxys Registry Number,3673976
3412,63859,6-hydroxypaclitaxel,A taxane diterpenoid that consists of paclitaxel bearing an additional hydroxy substituent at the 6alpha-position.,"InChI=1S/C47H51NO15/c1-24-30(61-43(57)33(51)32(27-16-10-7-11-17-27)48-41(55)28-18-12-8-13-19-28)22-47(58)40(62-42(56)29-20-14-9-15-21-29)36-45(6,38(54)35(60-25(2)49)31(24)44(47,4)5)37(53)34(52)39-46(36,23-59-39)63-26(3)50/h7-21,30,32-37,39-40,51-53,58H,22-23H2,1-6H3,(H,48,55)/t30-,32-,33+,34-,35+,36-,37-,39+,40-,45-,46+,47+/m0/s1",6-hydroxytaxol,Reaxys Registry Number,8105272
3413,63860,(S)-nicotinium N-alpha-D-glucosiduronate,An N-glycosylpyridine that is the N-alpha-D-glucosiduronyl derivative of (S)-nicotine.,"InChI=1S/C16H22N2O6/c1-17-6-3-5-10(17)9-4-2-7-18(8-9)15-13(21)11(19)12(20)14(24-15)16(22)23/h2,4,7-8,10-15,19-21H,3,5-6H2,1H3/t10-,11-,12-,13+,14-,15-/m0/s1",nicotine N-glucuronide,CAS Registry Number,152306-59-7
3414,63862,3'-N-debenzoyltaxol,A taxane diterpenoid that is paclitaxel which is lacking the N-benzoyl group. It is a biosynthetic precursor of paclitaxel.,"InChI=1S/C40H47NO13/c1-20-25(52-36(48)30(45)29(41)23-13-9-7-10-14-23)18-40(49)34(53-35(47)24-15-11-8-12-16-24)32-38(6,26(44)17-27-39(32,19-50-27)54-22(3)43)33(46)31(51-21(2)42)28(20)37(40,4)5/h7-16,25-27,29-32,34,44-45,49H,17-19,41H2,1-6H3/t25-,26-,27+,29-,30+,31+,32-,34-,38+,39-,40+/m0/s1",13-O-3-phenylisoserinoyl baccatin III,Reaxys Registry Number,4287446
3415,63866,octadecan-1-amine,An 18-carbon primary aliphatic amine.,"InChI=1S/C18H39N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h2-19H2,1H3",Stearylamine,CAS Registry Number,124-30-1
3416,63867,N-(hexanoyl)sphing-4-enine,An N-acylsphingosine consisting of sphing-4-enine bearing a hexanoyl group on nitrogen.,"InChI=1S/C24H47NO3/c1-3-5-7-8-9-10-11-12-13-14-15-16-18-19-23(27)22(21-26)25-24(28)20-17-6-4-2/h18-19,22-23,26-27H,3-17,20-21H2,1-2H3,(H,25,28)/b19-18+/t22-,23+/m0/s1",Cer(d18:1/6:0),Reaxys Registry Number,8068040
3417,63869,N-[3-({[N-{2-[(alpha-Glu-Leu-Ala)NH]ethyl}-N-(indol-3-ylacetyl)Gly]amino}methyl)benzoyl]-Leu-Thr-Val,"An oligopeptide composed of the tripeptide unit L-alpha-glutamyl-L-leucyl-L-alanyl which is attached via an amide bond to the amino terminus of the pseudopeptide fragment 3-({[N-(2-aminoethyl)-N-(indol-3-ylacetyl)glycyl]amino}methyl)benzoyl, which is in turn attached via an amide bond to the amino terminus of the tripeptide unit L-leucyl-L-threonyl-L-valine.","InChI=1S/C51H74N10O13/c1-27(2)20-38(58-47(69)36(52)16-17-42(65)66)48(70)56-30(7)45(67)53-18-19-61(41(64)23-34-25-54-37-15-10-9-14-35(34)37)26-40(63)55-24-32-12-11-13-33(22-32)46(68)57-39(21-28(3)4)49(71)60-44(31(8)62)50(72)59-43(29(5)6)51(73)74/h9-15,22,25,27-31,36,38-39,43-44,54,62H,16-21,23-24,26,52H2,1-8H3,(H,53,67)(H,55,63)(H,56,70)(H,57,68)(H,58,69)(H,59,72)(H,60,71)(H,65,66)(H,73,74)/t30-,31+,36-,38-,39-,43-,44-/m0/s1",ELA-NH-(CH2)2-(COCH2indole)G-(3-aminomethylbenzoic acid)-LTV,PubMed citation,20806940
3418,63871,N-(3-{[(N-{2-[(beta-Ala-Leu-Ala)NH]ethyl}-Trp)amino]methyl}benzoyl)-Leu-Thr-Val,An oligopeptide composed of the tripeptide unit beta-alanyl-L-leucyl-L-alanyl which is connected via an aminoethyl spacer to the amino terminus of the pseudopeptide fragment N-{3-[(L-tryptophylamino)methyl]benzoyl}-L-leucyl-L-threonyl-L-valine.,"InChI=1S/C48H72N10O10/c1-26(2)20-37(55-39(60)16-17-49)45(64)54-29(7)42(61)51-19-18-50-36(23-33-25-52-35-15-10-9-14-34(33)35)44(63)53-24-31-12-11-13-32(22-31)43(62)56-38(21-27(3)4)46(65)58-41(30(8)59)47(66)57-40(28(5)6)48(67)68/h9-15,22,25-30,36-38,40-41,50,52,59H,16-21,23-24,49H2,1-8H3,(H,51,61)(H,53,63)(H,54,64)(H,55,60)(H,56,62)(H,57,66)(H,58,65)(H,67,68)/t29-,30+,36-,37-,38-,40-,41-/m0/s1",N-(3-{[(N-{2-[(beta-alanylleucylalanyl)amino]ethyl}tryptophyl)amino]methyl}benzoyl)leucylthreonylvaline,PubMed citation,20806940
3419,63882,ethylammonium nitrate,"An organoammonium salt resulting from the mixing of equimolar amounts of nitric acid and ethylamine. First prepared in 1914, it was one of the first ionic liquids found that had a melting point below room temperature (m.p. 12degreeC).","InChI=1S/C2H7N.NO3/c1-2-3;2-1(3)4/h2-3H2,1H3;/q;-1/p+1",ethylamine nitrate,Reaxys Registry Number,3911152
3420,63887,"1,2-dioleoyl-3-beta-D-galactosylglycerol",A beta-D-galactopyranosyl diglyceride in which the acyl groups at the 1- and 2-positions are both oleoyl.,"InChI=1S/C45H82O10/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(47)52-36-38(37-53-45-44(51)43(50)42(49)39(35-46)55-45)54-41(48)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,38-39,42-46,49-51H,3-16,21-37H2,1-2H3/b19-17-,20-18-/t38?,39-,42+,43+,44-,45-/m1/s1","3-O-beta-D-Galp-1,2-di-O-Ole-GRO",Reaxys Registry Number,11028807
3421,63894,pivalate,A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of pivalic acid.,"InChI=1S/C5H10O2/c1-5(2,3)4(6)7/h1-3H3,(H,6,7)/p-1",trimethylacetate,Reaxys Registry Number,3601483
3422,63898,"toluene 2,6-diisothiocyanate",A toluene meta-diisothiocyanate in which the isothiocyanato groups are at positions 2 and 6 relative to the methyl group on the benzene ring.,"InChI=1S/C9H6N2S2/c1-7-8(10-5-12)3-2-4-9(7)11-6-13/h2-4H,1H3","2,6-TITC",Reaxys Registry Number,2367268
3423,63917,symphytine oxide,A pyrrolizine that is the N-oxido derivative of symphytine. Isolated from extracts of comfrey root.,"InChI=1S/C20H31NO7/c1-6-13(4)18(23)28-16-8-10-21(26)9-7-15(17(16)21)11-27-19(24)20(25,12(2)3)14(5)22/h6-7,12,14,16-17,22,25H,8-11H2,1-5H3/b13-6+/t14-,16+,17+,20-,21?/m0/s1",N-oxidosymphytine,CAS Registry Number,72698-57-8
3424,63919,"3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol",A fluorotelomer alcohol that is ethanol substituted at position 2 by a perfluorooctyl group.,"InChI=1S/C10H5F17O/c11-3(12,1-2-28)4(13,14)5(15,16)6(17,18)7(19,20)8(21,22)9(23,24)10(25,26)27/h28H,1-2H2",2-perfluorooctylethanol,Reaxys Registry Number,2227487
3425,63928,menadione sodium sulfonate,"An organic sodium salt that is the monosodium salt of menadione sulfonate. A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted into active vitamin K2, menaquinone, after alkylation in vivo.","InChI=1S/C11H10O5S.Na/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13;/h2-5H,6H2,1H3,(H,14,15,16);/q;+1/p-1",sodium dihydromenadione-2-sulfonate,Reaxys Registry Number,3922400
3426,63938,cadmium dichloride hemipentahydrate,A hydrate that is the hemipentahydrate form of cadmium dichloride.,InChI=1S/2Cd.4ClH.5H2O/h;;4*1H;5*1H2/q2*+2;;;;;;;;;/p-4,cadmium dichloride hydrate,CAS Registry Number,7790-78-5
3427,63941,"22,23-dihydroavermectin B1a",A macrocyclic lactone that is avermectin B1a in which the double bond present in the spirocyclic ring system has been reduced to a single bond. It is the major component of ivermectin.,"InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1","5-O-demethyl-22,23-dihydroavermectin A1a",Reaxys Registry Number,4643153
3428,63943,"22,23-dihydroavermectin B1b",A macrocyclic lactone that is avermectin B1b in which the double bond present in the spirocyclic ring system has been reduced to a single bond. It is the minor component of ivermectin.,"InChI=1S/C47H72O14/c1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b12-11+,26-14+,31-13+/t25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m0/s1",dihydroavermectin B1b,CAS Registry Number,70209-81-3
3429,63945,ferrozine(2-),"An organosulfonate oxoanion obtained by deprotonation of the sulfo groups of 4,4'-[3-(pyridin-2-yl)-1,2,4-triazine-5,6-diyl]dibenzenesulfonic acid.","InChI=1S/C20H14N4O6S2/c25-31(26,27)15-8-4-13(5-9-15)18-19(14-6-10-16(11-7-14)32(28,29)30)23-24-20(22-18)17-3-1-2-12-21-17/h1-12H,(H,25,26,27)(H,28,29,30)/p-2",ferrozine cation,Reaxys Registry Number,19533553
3430,63949,"2,3-bis(4-hydroxyphenyl)propionitrile",A nitrile that is acetonitrile in which one of the hydrogens is replaced by a 4-hydroxyphenyl group while a second hydrogen is replaced by a 4-hydroxybenzyl group. It is a specific agonist for estrogen receptor beta (ERbeta).,"InChI=1S/C15H13NO2/c16-10-13(12-3-7-15(18)8-4-12)9-11-1-5-14(17)6-2-11/h1-8,13,17-18H,9H2","2,3-bis(4-hydroxyphenyl)-propionitrile",Reaxys Registry Number,3337109
3431,63961,glycyl-glycyl-glycine,A tripeptide in which three glycine units are linked via peptide bonds in a linear sequence.,"InChI=1S/C6H11N3O4/c7-1-4(10)8-2-5(11)9-3-6(12)13/h1-3,7H2,(H,8,10)(H,9,11)(H,12,13)",triglycine,Beilstein Registry Number,1711130
3432,63964,N(6)-acetimidoyl-L-lysine dihydrochloride,A hydrochloride salt prepared from N(6)-acetimidoyl-L-lysine and two equivalents of hydrogen chloride. A selective inhibitor of inducible nitric oxide synthase.,"InChI=1S/C8H17N3O2.2ClH/c1-6(9)11-5-3-2-4-7(10)8(12)13;;/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13);2*1H/t7-;;/m0../s1",N(6)-acetimidoyl-L-lysine hydrochloride,Reaxys Registry Number,7083584
3433,63975,"15-deoxy-Delta(12,14)-prostaglandin A2",A prostaglandin A derivative that is prostaglandin A2 lacking the 15-hydroxy group and having C=C double bonds at positions 12(13) and 14(15).,"InChI=1S/C20H28O3/c1-2-3-4-5-6-9-12-17-15-16-19(21)18(17)13-10-7-8-11-14-20(22)23/h6-7,9-10,12,15-16,18H,2-5,8,11,13-14H2,1H3,(H,22,23)/b9-6+,10-7-,17-12-/t18-/m1/s1",15d-PGA2,Reaxys Registry Number,2661205
3434,63976,"13,14-dihydro-15-keto-PGF2alpha","A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F2alpha.","InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,16-19,22-23H,2-3,5-6,8-14H2,1H3,(H,24,25)/b7-4-/t16-,17-,18+,19-/m1/s1",dhk-PGF2alpha,Reaxys Registry Number,6227023
3435,63977,12S-HHTrE,"A trienoic fatty acid that consists of (5Z,8E,10E)-heptadeca-5,8,10-trienoic acid bearing an additional 12S-hydroxy substituent.","InChI=1S/C17H28O3/c1-2-3-10-13-16(18)14-11-8-6-4-5-7-9-12-15-17(19)20/h5-8,11,14,16,18H,2-4,9-10,12-13,15H2,1H3,(H,19,20)/b7-5-,8-6+,14-11+/t16-/m0/s1",12S-HHT,Reaxys Registry Number,8340574
3436,63978,"N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide","A hydrobromide salt prepared from N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.","InChI=1S/C19H21NO2.BrH/c1-2-9-20-10-8-15-11-18(21)19(22)12-16(15)17(13-20)14-6-4-3-5-7-14;/h2-7,11-12,17,21-22H,1,8-10,13H2;1H",SKF 77434 hydrobromide,Reaxys Registry Number,8658505
3437,63980,18-hydroxy-18-oxo-dinorleukotriene B4,"An octadecatetraenedioic acid obtained by oxidative degradation of leukotriene B4, a process that results in the removal of C19 and C20 with concomitant dioxygenation of C18.","InChI=1S/C18H26O6/c19-15(11-6-3-7-13-17(21)22)9-4-1-2-5-10-16(20)12-8-14-18(23)24/h1-6,9-10,15-16,19-20H,7-8,11-14H2,(H,21,22)(H,23,24)/b2-1+,6-3-,9-4+,10-5-/t15-,16+/m0/s1",18-carboxy dinor LTB4,Reaxys Registry Number,8356778
3438,63981,6-trans-leukotriene B4,A leukotriene that is the 6-trans-isomer of leukotriene B4.,"InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11+/t18-,19-/m1/s1",6-trans-LTB4,Reaxys Registry Number,4235310
3439,63982,Delta(6)-trans-12-epi-leukotriene B4,"A leukotriene that is the 6-trans,12S-isomer of leukotriene B4.","InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18-19,21-22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11+/t18-,19+/m0/s1",6-trans-12-epi-LTB4,Reaxys Registry Number,4696047
3440,63983,eoxin A4,"An oxylipin that is the (14S,15S)-epoxy derivative of (5Z,8Z,10E,12E)-icosa-5,8,10,12-tetraenoic acid.","InChI=1S/C20H30O3/c1-2-3-12-15-18-19(23-18)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h4,6-10,13,16,18-19H,2-3,5,11-12,14-15,17H2,1H3,(H,21,22)/b6-4-,9-7-,10-8+,16-13+/t18-,19-/m0/s1",EXA4,LIPID MAPS instance accession,LMFA03020037
3441,63984,eoxin C4,"A leukotriene that is the 14R-(S-glutathionyl),15S-hydroxy derivative of (5Z,8Z,10E,12E)-icosa-7,9,11,14-tetraenoic acid.","InChI=1S/C30H47N3O9S/c1-2-3-12-15-24(34)25(16-13-10-8-6-4-5-7-9-11-14-17-27(36)37)43-21-23(29(40)32-20-28(38)39)33-26(35)19-18-22(31)30(41)42/h4,6-10,13,16,22-25,34H,2-3,5,11-12,14-15,17-21,31H2,1H3,(H,32,40)(H,33,35)(H,36,37)(H,38,39)(H,41,42)/b6-4-,9-7-,10-8+,16-13+/t22-,23-,24-,25+/m0/s1",EXC4,LIPID MAPS instance accession,LMFA03020031
3442,63985,eoxin D4,"A leukotriene that is the 14R-(S-cysteinylglycyl),15S-hydroxy derivative of (5Z,8Z,10E,12E)-icosa-7,9,11,14-tetraenoic acid.","InChI=1S/C25H40N2O6S/c1-2-3-12-15-21(28)22(34-19-20(26)25(33)27-18-24(31)32)16-13-10-8-6-4-5-7-9-11-14-17-23(29)30/h4,6-10,13,16,20-22,28H,2-3,5,11-12,14-15,17-19,26H2,1H3,(H,27,33)(H,29,30)(H,31,32)/b6-4-,9-7-,10-8+,16-13+/t20-,21-,22+/m0/s1",EXD4,LIPID MAPS instance accession,LMFA03020032
3443,63986,eoxin E4,"A leukotriene that is the 14R-(S-cysteinyl),15S-hydroxy derivative of (5Z,8Z,10E,12E)-icosa-7,9,11,14-tetraenoic acid.","InChI=1S/C23H37NO5S/c1-2-3-12-15-20(25)21(30-18-19(24)23(28)29)16-13-10-8-6-4-5-7-9-11-14-17-22(26)27/h4,6-10,13,16,19-21,25H,2-3,5,11-12,14-15,17-18,24H2,1H3,(H,26,27)(H,28,29)/b6-4-,9-7-,10-8+,16-13+/t19-,20-,21+/m0/s1",EXE4,LIPID MAPS instance accession,LMFA03020033
3444,63988,"N-allyl-1-phenyl-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol","A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1, an allyl substituent at position 3 and two hydroxy substituents at positions 7 and 8. Selective dopamine D1-like receptor partial agonist (IC50 values are 19.7 and 2425 nM for binding to D1-like and D2-like receptors respectively). Centrally active following systemic administration in vivo.","InChI=1S/C19H21NO2/c1-2-9-20-10-8-15-11-18(21)19(22)12-16(15)17(13-20)14-6-4-3-5-7-14/h2-7,11-12,17,21-22H,1,8-10,13H2",SKF 77434,Reaxys Registry Number,1546935
3445,63993,"13,14-dihydro-15-oxolipoxin A4","A C20 hydroxy fatty acid obtained by formal hydrogenation across the 13,-14-double bond of 15-oxolipoxin A4.","InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,10,14,18-19,22-23H,2-3,8-9,11-13,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,14-10+/t18-,19+/m1/s1",dhk-LXA4,LIPID MAPS instance accession,LMFA03040008
3446,63996,"N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide","A hydrobromide salt prepared from N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. Dopamine D1-like receptor partial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonising the behavioral effects of cocaine.","InChI=1S/C18H20ClNO2.BrH/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19;/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3;1H",SKF 83959 hydrobromide,Reaxys Registry Number,5196089
3447,63999,"15-deoxy-Delta(12,14)-prostaglandin D2",A prostaglandin D derivative that is prostaglandin D2 lacking the 15-hydroxy group and having C=C double bonds at positions 12(13) and 14(15).,"InChI=1S/C20H30O3/c1-2-3-4-5-6-9-12-17-15-16-19(21)18(17)13-10-7-8-11-14-20(22)23/h6-7,9-10,12,15-16,18-19,21H,2-5,8,11,13-14H2,1H3,(H,22,23)/b9-6+,10-7-,17-12-/t18-,19+/m1/s1",15d-PGD2,LIPID MAPS instance accession,LMFA03010051
3448,64001,"N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol","A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a 3-methylphenyl substituent at position 1, a methyl substituent at position 3, a chloro substituent at position 6 and two hydroxy substituents at positions 7 and 8. Dopamine D1-like receptor partial agonist (Ki values are 1.18, 7.56, 920 and 399 nM for rat D1, D5, D2 and D3 receptors respectively). May act as an antagonist in vivo, producing anti-Parkinsonian effects and antagonising the behavioral effects of cocaine.","InChI=1S/C18H20ClNO2/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3",SKF 83959,Reaxys Registry Number,1549255
3449,64002,"N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide","A hydrobromide salt prepared from N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol and one equivalent of hydrogen bromide. High affinity, selective dopamine D1-like receptor agonist. Ki values are 3.2, 3.1, 186, 66, 335, 1167, 1251 and 1385 nM at recombinant D1, D5, D2, D3, D4, 5-HT2A, alpha1A and alpha1B receptors respectively. Stimulates adenylyl cyclase (EC50 = 65 nM) but not phosphoinositide hydrolysis. Induces extreme arousal and hyperlocomotion following subcutaneous administration in monkeys.","InChI=1S/C20H22ClNO2.BrH/c1-3-8-22-9-7-15-16(11-18(23)20(24)19(15)21)17(12-22)14-6-4-5-13(2)10-14;/h3-6,10-11,17,23-24H,1,7-9,12H2,2H3;1H",SKF 83822 hydrobromide,Reaxys Registry Number,5198936
3450,64004,"N-allyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepinium-7,8-diol","A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a 3-methylphenyl substituent at position 1, an allyl substituent at position 3, a chloro substituent at position 6 and two hydroxy substituents at positions 7 and 8. High affinity, selective dopamine D1-like receptor agonist. Ki values are 3.2, 3.1, 186, 66, 335, 1167, 1251 and 1385 nM at recombinant D1, D5, D2, D3, D4, 5-HT2A, alpha1A and alpha1B receptors respectively. Stimulates adenylyl cyclase (EC50 = 65 nM) but not phosphoinositide hydrolysis. Induces extreme arousal and hyperlocomotion following subcutaneous administration in monkeys.","InChI=1S/C20H22ClNO2/c1-3-8-22-9-7-15-16(11-18(23)20(24)19(15)21)17(12-22)14-6-4-5-13(2)10-14/h3-6,10-11,17,23-24H,1,7-9,12H2,2H3",SKF 83822,Reaxys Registry Number,1551889
3451,64017,"(5Z,8Z,11Z,13E)-15-HETE","A HETE that is (5Z,8Z,11Z,13E)-15-hydroxyicosa-5,8,11,13-tetraenoic acid bearing a hydroxy substituent at position 15.","InChI=1S/C20H32O3/c1-2-3-13-16-19(21)17-14-11-9-7-5-4-6-8-10-12-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14+","15-hydroxy-5Z,8Z,11Z,13E-icosatetraenoic acid",LIPID MAPS instance accession,LMFA03060087
3452,64020,"(R,S,S,S)-nebivolol","A 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] that has (1S,1'S,2R,2'S)-configuration.","InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2/t17-,18-,21-,22+/m0/s1","(R,S,S,S)-nebivolol",Reaxys Registry Number,4789058
3453,64021,"(S,R,R,R)-nebivolol","A 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] that has (1R,1'R,2R,2'S)-configuration.","InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2/t17-,18-,21-,22+/m1/s1","(S,R,R,R)-nebivolol",Reaxys Registry Number,4789057
3454,64024,beta-D-GlcpA-(1->3)-D-GlcpNAc,An amino disaccharide consisting of N-acetyl-D-glucosamine having a beta-D-glucuronosyl residue attached at the 3-position.,"InChI=1S/C14H23NO12/c1-3(17)15-5-10(6(18)4(2-16)25-13(5)24)26-14-9(21)7(19)8(20)11(27-14)12(22)23/h4-11,13-14,16,18-21,24H,2H2,1H3,(H,15,17)(H,22,23)/t4-,5-,6-,7+,8+,9-,10-,11+,13?,14-/m1/s1",beta-D-GlcA-(1->3)-D-GlcNAc,KEGG GLYCAN accession,G10008
3455,64025,beta-D-GlcpNAc-(1->4)-beta-D-GlcpA-(1->3)-D-GlcpNAc,An amino trisaccharide consisting of N-acetyl-D-glucosamine having an N-acetyl-D-glucosaminyl-(1->4)- beta-D-glucuronosyl moiety attached at position 3.,"InChI=1S/C22H36N2O17/c1-5(27)23-9-13(31)11(29)7(3-25)38-21(9)40-17-14(32)15(33)22(41-18(17)19(34)35)39-16-10(24-6(2)28)20(36)37-8(4-26)12(16)30/h7-18,20-22,25-26,29-33,36H,3-4H2,1-2H3,(H,23,27)(H,24,28)(H,34,35)/t7-,8-,9-,10-,11-,12-,13-,14-,15-,16-,17+,18+,20?,21+,22-/m1/s1",beta-D-GlcNAc-(1->4)-beta-D-GlcA-(1->3)-D-GlcNAc,KEGG GLYCAN accession,G00711
3456,64026,beta-D-GlcpA-(1->3)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpA-(1->3)-D-GlcpNAc,A linear amino tetrasaccharide comprising two beta-D-GlcA-(1->3)-D-GlcNAc units connected via a beta-(1->4)-linkage.,"InChI=1S/C28H44N2O23/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45)/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25?,26+,27-,28-/m1/s1",beta-D-GlcA-(1->3)-beta-D-GlcNAc-(1->4)-beta-D-GlcA-(1->3)-D-GlcNAc,KEGG GLYCAN accession,G00526
3457,64043,desmethyl loperamide,"A monocarboxylic acid amide that is the methylamide of 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenylbutanoic acid.","InChI=1S/C28H31ClN2O2/c1-30-26(32)28(23-8-4-2-5-9-23,24-10-6-3-7-11-24)18-21-31-19-16-27(33,17-20-31)22-12-14-25(29)15-13-22/h2-15,33H,16-21H2,1H3,(H,30,32)",monodesmethyl loperamide,Reaxys Registry Number,1517638
3458,64046,alpha-D-Glc-(1->3)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,"A high-mannose oligosaccharide consisting of one D-glucosyl residue, eight D-mannosyl residues and two N-acetylglucosamine residues, one of which is at the reducing end.","InChI=1S/C70H118N2O56/c1-14(82)71-27-38(93)52(23(10-80)110-60(27)107)121-61-28(72-15(2)83)39(94)53(24(11-81)118-61)122-67-51(106)56(125-69-59(45(100)34(89)20(7-77)116-69)128-70-58(44(99)33(88)21(8-78)117-70)127-66-50(105)54(35(90)22(9-79)114-66)123-63-46(101)40(95)29(84)16(3-73)111-63)37(92)26(120-67)12-108-62-49(104)55(124-64-47(102)41(96)30(85)17(4-74)112-64)36(91)25(119-62)13-109-68-57(43(98)32(87)19(6-76)115-68)126-65-48(103)42(97)31(86)18(5-75)113-65/h16-70,73-81,84-107H,3-13H2,1-2H3,(H,71,82)(H,72,83)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44+,45+,46-,47+,48+,49+,50+,51+,52-,53-,54+,55+,56+,57+,58+,59+,60?,61+,62+,63-,64-,65-,66-,67+,68+,69-,70-/m1/s1",alpha-Glc-(1->3)-alpha-Man-(1->2)-alpha-Man-(1->2)-alpha-Man-(1->3)-[alpha-Man-(1->3)-[alpha-Man-(1->2)-alpha-Man-(1->6)]-alpha-Man-(1->6)]-beta-Man-(1->4)-beta-GlcNAc-(1->4)-GlcNAc,KEGG GLYCAN accession,G01831
3459,64048,alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,"A branched ten-membered mannooligosaccharide derivative consisting of eight D-mannosyl residues and two N-acetylglucosamine residues, one of which is at the reducing end.","InChI=1S/C64H108N2O51/c1-13(75)65-25-35(85)48(21(9-73)101-55(25)98)111-56-26(66-14(2)76)36(86)49(22(10-74)108-56)112-61-47(97)51(114-63-54(42(92)32(82)19(7-71)106-63)117-64-53(41(91)31(81)20(8-72)107-64)116-60-45(95)39(89)29(79)17(5-69)104-60)34(84)24(110-61)11-99-57-46(96)50(113-58-43(93)37(87)27(77)15(3-67)102-58)33(83)23(109-57)12-100-62-52(40(90)30(80)18(6-70)105-62)115-59-44(94)38(88)28(78)16(4-68)103-59/h15-64,67-74,77-98H,3-12H2,1-2H3,(H,65,75)(H,66,76)/t15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48-,49-,50+,51+,52+,53+,54+,55?,56+,57+,58-,59-,60-,61+,62+,63-,64-/m1/s1",alpha-Man-(1->2)-alpha-Man-(1->2)-alpha-Man-(1->3)-[alpha-Man-(1->3)-[alpha-Man-(1->2)-alpha-Man-(1->6)]-alpha-Man-(1->6)]-beta-Man-(1->4)-beta-GlcNAc-(1->4)-GlcNAc,PubMed citation,12361949
3460,64052,alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,"A branched ten-membered mannooligosaccharide derivative consisting of eight D-mannosyl residues and two N-acetylglucosamine residues, one of which is at the reducing end.","InChI=1S/C64H108N2O51/c1-13(75)65-25-35(85)48(21(9-73)101-55(25)98)111-56-26(66-14(2)76)36(86)49(22(10-74)108-56)112-61-47(97)51(114-63-54(42(92)32(82)19(7-71)106-63)117-64-53(41(91)31(81)20(8-72)107-64)116-60-45(95)39(89)29(79)17(5-69)104-60)34(84)24(110-61)12-100-58-46(96)50(33(83)23(109-58)11-99-57-43(93)37(87)27(77)15(3-67)102-57)113-62-52(40(90)30(80)18(6-70)105-62)115-59-44(94)38(88)28(78)16(4-68)103-59/h15-64,67-74,77-98H,3-12H2,1-2H3,(H,65,75)(H,66,76)/t15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48-,49-,50+,51+,52+,53+,54+,55?,56+,57+,58+,59-,60-,61+,62-,63-,64-/m1/s1",alpha-Man-(1->2)-alpha-Man-(1->2)-alpha-Man-(1->3)-[alpha-Man-(1->6)-[alpha-Man-(1->2)-alpha-Man-(1->3)]-alpha-Man-(1->6)]-beta-Man-(1->4)-beta-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,11676012
3461,64053,"4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline dimaleate","A maleate salt that is the dimaleate salt of 4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline. A 5-hydroxytryptamine receptor 1B (5-HT1B) full agonist, 10-fold selective over 5-HT1A and 1000-fold selective over 5-HT2C receptors. Centrally active following systemic administration.","InChI=1S/C17H17F3N4.2C4H4O4/c1-22-7-9-23(10-8-22)16-15-3-2-6-24(15)14-5-4-12(17(18,19)20)11-13(14)21-16;2*5-3(6)1-2-4(7)8/h2-6,11H,7-10H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-",CGS 12066B dimaleate,CAS Registry Number,109028-10-6
3462,64055,"4-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline","A pyrroloquinoxaline that is pyrrolo[1,2-a]quinoxaline bearing additional 4-methylpiperazin-1-yl and trifluoromethyl substituents at positions 4 and 7 respectively. A 5-hydroxytryptamine receptor 1B (5-HT1B) full agonist, 10-fold selective over 5-HT1A and 1000-fold selective over 5-HT2C receptors. Centrally active following systemic administration.","InChI=1S/C17H17F3N4/c1-22-7-9-23(10-8-22)16-15-3-2-6-24(15)14-5-4-12(17(18,19)20)11-13(14)21-16/h2-6,11H,7-10H2,1H3",CGS 12066B,Reaxys Registry Number,4206934
3463,64057,"3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol hydrochloride","A hydrochloride that is the monohydrochloride salt of 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.","InChI=1S/C25H27ClN2O.ClH/c26-22-12-7-13-23(18-22)28-16-14-27(15-17-28)19-24(29)25(20-8-3-1-4-9-20)21-10-5-2-6-11-21;/h1-13,18,24-25,29H,14-17,19H2;1H",BRL 15572 hydrochloride,Reaxys Registry Number,9024485
3464,64060,"3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenylpropan-2-ol","An N-alkylpiperazine that is 1-(3-chlorophenyl)piperazine carrying a 3,3-diphenyl-2-hydroxyprop-1-yl group at position 4. A selective h5-HT1D antagonist, displaying 60-fold selectivity over h5-HT1B, and exhibiting little or no affinity for a range of other receptor types.","InChI=1S/C25H27ClN2O/c26-22-12-7-13-23(18-22)28-16-14-27(15-17-28)19-24(29)25(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-13,18,24-25,29H,14-17,19H2",BRL 15572,Reaxys Registry Number,9004321
3465,64062,(R)-salmeterol,2-(Hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol in which the stereocentre has R configuration.,"InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2/t25-/m0/s1",2-(hydroxymethyl)-4-[(1R)-1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl]phenol,Reaxys Registry Number,7082712
3466,64069,SB 224289,"A member of the class of benzamides obtained by formal condensation of the carboxy group of 2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carboxylic acid with the secondary amino group of 1'-methyl-6,7-dihydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine]. Selective 5-HT1B receptor antagonist (pKi = 8.2). Displays >60-fold selectivity over 5-HT1D, 5-HT1A, 5-HT1E, 5-HT1F, 5-HT2A and 5-HT2C receptors in radioligand binding and functional assays. Centrally active following oral administration in vivo.","InChI=1S/C32H32N4O3/c1-20-16-25(30-33-21(2)39-34-30)8-9-26(20)22-4-6-23(7-5-22)31(37)36-13-10-24-17-29-27(18-28(24)36)32(19-38-29)11-14-35(3)15-12-32/h4-9,16-18H,10-15,19H2,1-3H3",SB224289,CAS Registry Number,180083-23-2
3467,64070,"2-(3-methoxybenzyl)-5-[5-(2-thienyl)-2-thienyl]-1,3,4-oxadiazole","A 2,2'-bithiophene that is 1,3,4-oxadiazole bearing 2,2'-bithiophen-5-yl and 4-methoxybenzyl groups at positions 2 and 5 respectively.","InChI=1S/C18H14N2O2S2/c1-21-13-6-4-12(5-7-13)11-17-19-20-18(22-17)16-9-8-15(24-16)14-3-2-10-23-14/h2-10H,11H2,1H3",HTS11125,PubMed citation,21277283
3468,64072,ethyl 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylate,The ethyl ester of 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylic acid.,"InChI=1S/C19H15ClF3N3O4S/c1-2-30-18(27)16-11-24-26(17(16)19(21,22)23)14-7-5-13(6-8-14)25-31(28,29)15-9-3-12(20)4-10-15/h3-11,25H,2H2,1H3",GK02432,PubMed citation,21277283
3469,64073,exendin-4,A bioactive polypeptide of 39 amino acid residues isolated from the saliva of the Gila monster (Heloderma suspectum). High-affinity glucagon-like peptide 1 (GLP-1) receptor agonist (Kd = 136 pM); potently induces cAMP formation without stimulating amylase release in pancreatic acini; potentiates glucose-induced insulin secretion in isolated rat islets; protects against glutamate-induced neurotoxicity. A synthetic version is called exenatide.,"InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94?,95-,96-,97?,98?,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1",His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2,CAS Registry Number,141758-74-9
3470,64078,"(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride","A hydrochloride salt obtained by mixing equimolar amounts of (1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol with hydrochloric acid. Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo.","InChI=1S/C20H27NO3.ClH/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20;/h1-2,11-13,17-18,22-23H,3-10,21H2;1H/t11?,12?,13?,17-,18-,20?;/m0./s1",A 77636 hydrochloride,Reaxys Registry Number,5859104
3471,64080,"(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol","An isochromene that is 3,4-dihydroisochromene-5,6-diol bearing additional aminomethyl and 1-adamantyl substituents at positions 1 and 3 respectively (the 1R,3S-diastereomer). Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo.","InChI=1S/C20H27NO3/c21-10-17-14-1-2-16(22)19(23)15(14)6-18(24-17)20-7-11-3-12(8-20)5-13(4-11)9-20/h1-2,11-13,17-18,22-23H,3-10,21H2/t11?,12?,13?,17-,18-,20?/m0/s1",A-77636,Reaxys Registry Number,5855679
3472,64083,RS 39604,"An aromatic ether that is the 3,5-dimethoxybenzyl derivative of N-(2-{4-[3-(4-amino-5-chloro-2-hydroxyphenyl)-3-oxopropyl]piperidin-1-yl}ethyl)methanesulfonamide. A potent and selective 5-HT4 antagonist, with a pKi of 9.1 at 5-HT4 receptors in guinea pig striatal membranes and greater than 1000-fold selectivity over 5-HT1A, 2C, 3 and D1, D2, M1, M2, AT1, B1 and alpha1C receptors. The ketone group gives RS 39604 a relatively long half life; it is also orally active and so suitable for in vivo studies.","InChI=1S/C26H36ClN3O6S/c1-34-20-12-19(13-21(14-20)35-2)17-36-26-16-24(28)23(27)15-22(26)25(31)5-4-18-6-9-30(10-7-18)11-8-29-37(3,32)33/h12-16,18,29H,4-11,17,28H2,1-3H3",RS-67506,Reaxys Registry Number,8524141
3473,64084,(S)-NADPHX,"A tetrahydronicotinamide adenine dinucleotide obtained by formal stereo- and regioselective hydration across the 2,3-double bond in the nicotinyl ring of NADPH, with the hydroxy group located at position 2, having (S)-configuration.","InChI=1S/C21H32N7O18P3/c22-17-12-19(25-6-24-17)28(7-26-12)21-16(45-47(34,35)36)14(31)10(44-21)5-42-49(39,40)46-48(37,38)41-4-9-13(30)15(32)20(43-9)27-3-8(18(23)33)1-2-11(27)29/h3,6-7,9-11,13-16,20-21,29-32H,1-2,4-5H2,(H2,23,33)(H,37,38)(H,39,40)(H2,22,24,25)(H2,34,35,36)/t9-,10-,11+,13-,14-,15-,16-,20-,21-/m1/s1","(6S)-6beta-hydroxy-1,4,5,6-tetrahydronicotinamide adenine dinucleotide phosphate",PubMed citation,21994945
3474,64086,vanoxerine dihydrochloride,"A hydrochloride salt that is obtained by reaction of vanoxerine with two equivalents of hydrogen chloride. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.","InChI=1S/C28H32F2N2O.2ClH/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23;;/h1-3,5-6,8-15,28H,4,7,16-22H2;2*1H",GBR 12909 dihydrochloride,Reaxys Registry Number,5696321
3475,64089,vanoxerine,"An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.","InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2",GBR12909,Reaxys Registry Number,587912
3476,64091,1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride,A hydrochloride salt that is obtained by reaction of 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine with two equivalents of hydrogen chloride. Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).,"InChI=1S/C28H34N2O.2ClH/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27;;/h1-9,11-12,14-17,28H,10,13,18-24H2;2*1H",GBR 12935 dihydrochloride,Reaxys Registry Number,5689635
3477,64093,1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine,An N-alkylpiperazine that consists of piperazine bearing 2-(benzhydryloxy)ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).,"InChI=1S/C28H34N2O/c1-4-11-25(12-5-1)13-10-18-29-19-21-30(22-20-29)23-24-31-28(26-14-6-2-7-15-26)27-16-8-3-9-17-27/h1-9,11-12,14-17,28H,10,13,18-24H2",GBR12935,Reaxys Registry Number,578614
3478,64094,"N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine hydrochloride","A hydrochloride salt that is obtained by reaction of N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine with one equivalent of hydrogen chloride. An alpha1A-adrenergic selective antagonist.","InChI=1S/C19H23NO5.ClH/c1-21-17-8-5-9-18(22-2)19(17)23-11-10-20-12-14-13-24-15-6-3-4-7-16(15)25-14;/h3-9,14,20H,10-13H2,1-2H3;1H",WB4101 hydrochloride,Reaxys Registry Number,4221569
3479,64099,4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide hydrochloride,"A hydrochloride salt that is obtained by reaction of 4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide with one equivalent of hydrogen chloride. Highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo.","InChI=1S/C24H26FN3O2.ClH/c1-30-21-10-7-18-3-2-4-23(22(18)17-21)28-15-13-27(14-16-28)12-11-26-24(29)19-5-8-20(25)9-6-19;/h2-10,17H,11-16H2,1H3,(H,26,29);1H",S14506 monohydrochloride,Reaxys Registry Number,8374093
3480,64101,4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide,"A benzamide obtained by formal condensation of the carboxy group of 4-fluorobenzoic acid with the primary amino group of 2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethylamine. Highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo.","InChI=1S/C24H26FN3O2/c1-30-21-10-7-18-3-2-4-23(22(18)17-21)28-15-13-27(14-16-28)12-11-26-24(29)19-5-8-20(25)9-6-19/h2-10,17H,11-16H2,1H3,(H,26,29)",S-14506,Reaxys Registry Number,8167507
3481,64104,"sodium 8-bromo-3',5'-cyclic GMP","An organic sodium salt having 8-bromoguanosine 3',5'-cyclic phosphate as the counterion. A membrane permeable cGMP analogue that activates protein kinase G (PKG). It is 4.3-fold more potent than cGMP in activating PKG1alpha and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro.","InChI=1S/C10H11BrN5O7P.Na/c11-9-13-3-6(14-10(12)15-7(3)18)16(9)8-4(17)5-2(22-8)1-21-24(19,20)23-5;/h2,4-5,8,17H,1H2,(H,19,20)(H3,12,14,15,18);/q;+1/p-1/t2-,4-,5-,8-;/m1./s1",8-bromo cGMP sodium salt,Reaxys Registry Number,8378760
3482,64107,"8-bromo-3',5'-cyclic GMP(1-)","An organophosphate oxoanion that is the conjugate base of 8-bromo-3',5'-cyclic GMP, arising from deprotonation of the phosphate OH group.","InChI=1S/C10H11BrN5O7P/c11-9-13-3-6(14-10(12)15-7(3)18)16(9)8-4(17)5-2(22-8)1-21-24(19,20)23-5/h2,4-5,8,17H,1H2,(H,19,20)(H3,12,14,15,18)/p-1/t2-,4-,5-,8-/m1/s1","8-bromoguanosine 3',5'-cyclic phosphate",Reaxys Registry Number,8170644
3483,64111,GR 127935 hydrochloride,"A hydrochloride obtained by reaction of GR 127935 with one equivalent of hydrochloric acid. Potent and selective 5-HT1B/1D receptor antagonist (pKi values are 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors). Displays > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Centrally active following oral administration.","InChI=1S/C29H31N5O3.ClH/c1-19-17-23(28-30-20(2)37-32-28)9-11-25(19)21-5-7-22(8-6-21)29(35)31-24-10-12-27(36-4)26(18-24)34-15-13-33(3)14-16-34;/h5-12,17-18H,13-16H2,1-4H3,(H,31,35);1H",GR127935 hydrochloride,Reaxys Registry Number,8530522
3484,64112,abacavir monophosphate,The organic phosphate that is the 5'-monophosphate of abacavir.,"InChI=1S/C14H19N6O4P/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-24-25(21,22)23/h1,4,7-10H,2-3,5-6H2,(H2,21,22,23)(H3,15,17,18,19)/t8-,10+/m1/s1",abacavir 5'-monophosphate,Reaxys Registry Number,8357356
3485,64115,"(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin hydrochloride","A hydrochloride obtained by reaction of (1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin with one equivalent of hydrochloric acid. Dopamine receptor antagonist with preferential action at presynaptic receptors (pKi values are 6.95, 6.67, 6.37, 6.21 and 6.07 at hD3. hD4, hD2S, hD2L and rD2 receptors respectively).","InChI=1S/C15H23NO.ClH/c1-4-10-16-14-9-8-13-12(11(14)2)6-5-7-15(13)17-3;/h5-7,11,14,16H,4,8-10H2,1-3H3;1H/t11-,14+;/m0./s1",(+)-AJ 76 hydrochloride,Reaxys Registry Number,6076657
3486,64116,carbovir monophosphate,The organic phosphate that is the 5'-monophosphate of (-)-carbovir.,"InChI=1S/C11H14N5O5P/c12-11-14-9-8(10(17)15-11)13-5-16(9)7-2-1-6(3-7)4-21-22(18,19)20/h1-2,5-7H,3-4H2,(H2,18,19,20)(H3,12,14,15,17)/t6-,7+/m1/s1",carbovir 5'-monophosphate,Reaxys Registry Number,4912434
3487,64117,"(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin","A secondary amino compound that consists of tetralin bearing methyl, propylamino and methoxy groups at positions 1, 2 and 5 respectively. Dopamine receptor antagonist with preferential action at presynaptic receptors (pKi values are 6.95, 6.67, 6.37, 6.21 and 6.07 at hD3. hD4, hD2S, hD2L and rD2 receptors respectively).","InChI=1S/C15H23NO/c1-4-10-16-14-9-8-13-12(11(14)2)6-5-7-15(13)17-3/h5-7,11,14,16H,4,8-10H2,1-3H3/t11-,14+/m0/s1",(+)-AJ 76,Reaxys Registry Number,4745495
3488,64122,(R)-(+)-sulpiride,An optically active form of sulpiride having (R)-configuration. The active enantiomer of the racemic drug sulpiride.,"InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m1/s1",(R)-sulpiride,Reaxys Registry Number,4298776
3489,64123,NAN 190 hydrobromide,A hydrobromide obtained by reaction of NAN 190 with one equivalent of hydrobromic acid.,"InChI=1S/C23H27N3O3.BrH/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28;/h2-5,8-11H,6-7,12-17H2,1H3;1H",NAN190 hydrobromide,Reaxys Registry Number,4775818
3490,64124,phytosphingosine(1+),"A cationic sphingoid that is the conjugate acid of phytosphingosine, obtained by protonation of the primary amino function; major species at pH 7.3.","InChI=1S/C18H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(21)18(22)16(19)15-20/h16-18,20-22H,2-15,19H2,1H3/p+1/t16-,17+,18-/m0/s1",4-hydroxysphinganine(1+),MetaCyc accession,PHYTOSPINGOSINE
3491,64125,"3,5-diacetyl-1,4-diphenyl-1,4-dihydropyridine","A 1,4-dihydropyridine substituted with acetyl groups at C-3 and C-5 and with phenyl groups at N-1 and C-4.","InChI=1S/C21H19NO2/c1-15(23)19-13-22(18-11-7-4-8-12-18)14-20(16(2)24)21(19)17-9-5-3-6-10-17/h3-14,21H,1-2H3","1-(5-acetyl-1,4-diphenyl-1,4-dihydropyridin-3-yl)ethan-1-one",Reaxys Registry Number,265798
3492,64131,NAN 190,An N-alkylpiperazine that consists of (2-methoxyphenyl)piperazine in which the amine hydrogen is substituted by a 4-(2-phthalimido)butyl group.,"InChI=1S/C23H27N3O3/c1-29-21-11-5-4-10-20(21)25-16-14-24(15-17-25)12-6-7-13-26-22(27)18-8-2-3-9-19(18)23(26)28/h2-5,8-11H,6-7,12-17H2,1H3",NAN190,Reaxys Registry Number,4273016
3493,64139,"(2R,3S)-EHNA hydrochloride","A hydrochloride salt obtained by reaction of (2R,3S)-EHNA with one equivalent of hydrochloric acid. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase.","InChI=1S/C14H23N5O.ClH/c1-3-4-5-6-7-11(10(2)20)19-9-18-12-13(15)16-8-17-14(12)19;/h8-11,20H,3-7H2,1-2H3,(H2,15,16,17);1H/t10-,11+;/m1./s1","(2R,3S)-EHNA.HCl",Reaxys Registry Number,4729841
3494,64141,beta-D-GalNAc-(1->3)-beta-D-Gal,beta-D-GalNAc-(1->3)-D-Gal with beta configuration at the anomeric carbon of the Gal residue.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)5(2-16)25-14(7)26-12-9(20)6(3-17)24-13(23)11(12)22/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10-,11-,12+,13-,14+/m1/s1",beta-D-GalpNAc-(1->3)-beta-D-Galp,PubMed citation,1720505
3495,64144,1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine maleate,A maleate salt obtained by reaction of 1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine with one equivalent of maleic acid. A potent dopamine re-uptake inhibitor with a behavioral profile different from that of PCP and similar to that of cocaine.,"InChI=1S/C19H25NS.C4H4O4/c1-5-11-19(12-6-1,20-13-7-2-8-14-20)18-15-16-9-3-4-10-17(16)21-18;5-3(6)1-2-4(7)8/h3-4,9-10,15H,1-2,5-8,11-14H2;1-2H,(H,5,6)(H,7,8)/b;2-1-",BTCP maleate,Chemspider accession,8426776
3496,64147,5-nonyloxytryptamine oxalate,"An oxalate salt obtained by reaction of 5-nonyloxytryptamine with one equivalent of oxalic acid. 5-HT1B selective agonist, several times more potent than sumatriptan and inactive as a 5-HT1A agonist (Ki at 5-HT1B = 1 nM, selectivity over 5-HT1A > 300-fold).","InChI=1S/C19H30N2O.C2H2O4/c1-2-3-4-5-6-7-8-13-22-17-9-10-19-18(14-17)16(11-12-20)15-21-19;3-1(4)2(5)6/h9-10,14-15,21H,2-8,11-13,20H2,1H3;(H,3,4)(H,5,6)",O-nonylserotonin oxalate,Reaxys Registry Number,7065207
3497,64149,5-nonyloxytryptamine,"A tryptamine derivative that consists of serotonin bearing an additional O-nonyl substituent. 5-HT1B selective agonist, several times more potent than sumatriptan and inactive as a 5-HT1A agonist (Ki at 5-HT1B = 1 nM, selectivity over 5-HT1A > 300-fold).","InChI=1S/C19H30N2O/c1-2-3-4-5-6-7-8-13-22-17-9-10-19-18(14-17)16(11-12-20)15-21-19/h9-10,14-15,21H,2-8,11-13,20H2,1H3",3-(2-aminoethyl)-5-nonyloxyindole,Reaxys Registry Number,7077925
3498,64151,imetit dihydrobromide,"A hydrobromide salt obtained by reaction of imetit with two equivalents of hydrobromic acid. An extremely potent, high affinity agonist at H3 and H4 receptors (Ki values are 0.3 and 2.7 nM respectively). Induces shape change in eosinophils with an EC50 of 25 nM. Centrally active following systemic administration.","InChI=1S/C6H10N4S.2BrH/c7-6(8)11-2-1-5-3-9-4-10-5;;/h3-4H,1-2H2,(H3,7,8)(H,9,10);2*1H",imetit hydrobromide,Reaxys Registry Number,5833853
3499,64158,2-methyl-6-(phenylethynyl)pyridine hydrochloride,A hydrochloride salt obtained by reaction of 2-methyl-6-(phenylethynyl)pyridine with one equivalent of hydrochloric acid. Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw.,"InChI=1S/C14H11N.ClH/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13;/h2-9H,1H3;1H",MPEP hydrochloride,Reaxys Registry Number,9652435
3500,64165,clobenpropit dihydrobromide,A hydrobromide salt obtained by reaction of clobenpropit with two equivalents of hydrobromic acid. An extremely potent histamine H3 antagonist/inverse agonist (pA2 = 9.93). Also displays partial agonist activity at H4 receptors; induces eosinophil shape change with an EC50 of 3 nM.,"InChI=1S/C14H17ClN4S.2BrH/c15-12-5-3-11(4-6-12)8-18-14(16)20-7-1-2-13-9-17-10-19-13;;/h3-6,9-10H,1-2,7-8H2,(H2,16,18)(H,17,19);2*1H",clobenpropit hydrobromide,Reaxys Registry Number,584034
3501,64166,alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp,alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp having alpha-configuration at the reducing end anomeric centre.,"InChI=1S/C24H42O21/c25-1-5-10(30)14(34)19(21(38)39-5)44-24-20(15(35)11(31)7(3-27)42-24)45-23-17(37)18(12(32)8(4-28)41-23)43-22-16(36)13(33)9(29)6(2-26)40-22/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-/m1/s1",alpha-D-mannosyl-(1->3)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannose,Reaxys Registry Number,1416322
3502,64168,beta-D-Manp-(1->2)-alpha-D-Manp,A glycosylmannose consisting of alpha-D-mannose having a beta-D-mannosyl residue attached at the 2-position.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10+,11+,12+/m1/s1",beta-D-Man-(1->2)-alpha-D-Man,Reaxys Registry Number,5482422
3503,64170,beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-alpha-D-Manp,A linear trisaccharide consisting of three D-mannose units joined by beta-(1->2)-linkages (with alpha-configuration at the reducing-end anomeric centre). Present in the cell wall phosphomannan of Candida albicans.,"InChI=1S/C18H32O16/c19-1-4-8(23)11(26)14(16(29)30-4)33-18-15(12(27)9(24)6(3-21)32-18)34-17-13(28)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17+,18+/m1/s1",beta-D-Man-(1->2)-beta-D-Man-(1->2)-alpha-D-Man,Reaxys Registry Number,19194456
3504,64171,(6S)-6-C-methyl-D-mannopyranose,A deoxyheptose that is L-glycero-D-manno-heptopyranose in which the 7-hydroxy group is substituted by hydrogen.,"InChI=1S/C7H14O6/c1-2(8)6-4(10)3(9)5(11)7(12)13-6/h2-12H,1H3/t2-,3-,4-,5-,6+,7?/m0/s1",6-C-methyl-D-mannopyranose,Reaxys Registry Number,10256012
3505,64175,6-C-Me-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-alpha-D-Manp,"A linear tetrasaccharide that consists of a 6-C-methyl-D-mannosyl residue at the non-reducing end and three D-mannosyl resides joined by sequential alpha-(1->2)-, alpha-(1->2)- and alpha-(1->3)-linkages.","InChI=1S/C25H44O21/c1-5(29)18-15(36)12(33)16(37)23(43-18)45-20-13(34)9(30)7(3-27)42-25(20)46-21-14(35)10(31)6(2-26)41-24(21)44-19-11(32)8(4-28)40-22(39)17(19)38/h5-39H,2-4H2,1H3/t5-,6+,7+,8+,9+,10+,11+,12-,13-,14-,15-,16-,17-,18+,19-,20-,21-,22-,23+,24+,25+/m0/s1",6-C-Me-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-alpha-D-Man,Reaxys Registry Number,21055504
3506,64179,3-O-Ac-alpha-D-GalpANAc-(1->4)-3-O-Ac-alpha-D-GalpANAc,An amino disaccharide that consists of two 2-acetamido-3-O-acetyl-2-deoxy-alpha-D-galactopyranuronosyl units joined by a (1->4)-linkage.,"InChI=1S/C20H28N2O15/c1-5(23)21-9-13(34-8(4)26)15(16(18(30)31)35-19(9)32)37-20-10(22-6(2)24)12(33-7(3)25)11(27)14(36-20)17(28)29/h9-16,19-20,27,32H,1-4H3,(H,21,23)(H,22,24)(H,28,29)(H,30,31)/t9-,10-,11-,12-,13-,14+,15-,16+,19+,20-/m1/s1",3-O-Ac-alpha-D-GalANAc-(1->4)-3-O-Ac-alpha-D-GalANAc,PubMed citation,22095754
3507,64180,2-decaprenyl-6-methoxyhydroquinone,A polyprenylhydroquinone in which the polyprenyl substituent is decaprenyl at C-2; a methoxy group is also present at C-6.,"InChI=1S/C57H88O3/c1-44(2)22-13-23-45(3)24-14-25-46(4)26-15-27-47(5)28-16-29-48(6)30-17-31-49(7)32-18-33-50(8)34-19-35-51(9)36-20-37-52(10)38-21-39-53(11)40-41-54-42-55(58)43-56(60-12)57(54)59/h22,24,26,28,30,32,34,36,38,40,42-43,58-59H,13-21,23,25,27,29,31,33,35,37,39,41H2,1-12H3/b45-24+,46-26+,47-28+,48-30+,49-32+,50-34+,51-36+,52-38+,53-40+","6-all-trans-decaprenyl-2-methoxy-1,4-benzoquinol",MetaCyc accession,CPD-9869
3508,64181,2-decaprenyl-6-methoxy-3-methylhydroquinone,A polyprenylhydroquinone in which the polyprenyl substituent is decaprenyl at C-2; additional methyl and methoxy groups are also present at positions C-3 and C-6 respectively.,"InChI=1S/C58H90O3/c1-44(2)23-14-24-45(3)25-15-26-46(4)27-16-28-47(5)29-17-30-48(6)31-18-32-49(7)33-19-34-50(8)35-20-36-51(9)37-21-38-52(10)39-22-40-53(11)41-42-55-54(12)56(59)43-57(61-13)58(55)60/h23,25,27,29,31,33,35,37,39,41,43,59-60H,14-22,24,26,28,30,32,34,36,38,40,42H2,1-13H3/b45-25+,46-27+,47-29+,48-31+,49-33+,50-35+,51-37+,52-39+,53-41+","6-methoxy-3-methyl-2-all-trans-decaprenyl-1,4-benzoquinol",MetaCyc accession,CPD-9871
3509,64183,ubiquinol-10,A ubiquinol in which the polyprenyl substituent is decaprenyl.,"InChI=1S/C59H92O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42,60-61H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+",ubiquinol(10),Reaxys Registry Number,2034916
3510,64184,3-O-Ac-alpha-D-GalpANAc-(1->4)-3-O-Ac-alpha-D-GalpANAc-(1->4)-3-O-Ac-alpha-D-GalpANAc,A linear amino trisaccharide that consists of three 2-acetamido-3-O-acetyl-2-deoxy-alpha-D-galactopyranuronosyl units joined by (1->4)-linkages.,"InChI=1S/C30H41N3O22/c1-7(34)31-13-18(49-11(5)38)21(23(26(43)44)51-28(13)47)53-30-15(33-9(3)36)19(50-12(6)39)22(24(55-30)27(45)46)54-29-14(32-8(2)35)17(48-10(4)37)16(40)20(52-29)25(41)42/h13-24,28-30,40,47H,1-6H3,(H,31,34)(H,32,35)(H,33,36)(H,41,42)(H,43,44)(H,45,46)/t13-,14-,15-,16-,17-,18-,19-,20+,21-,22-,23+,24+,28+,29-,30+/m1/s1",[4)-3-O-Ac-alpha-D-GalpANAc(1->]3,PubMed citation,22095754
3511,64185,3-O-Ac-alpha-D-GalpANAc-(1->4)-3-O-Ac-alpha-D-GalpANAc-(1->4)-3-O-Ac-alpha-D-GalpANAc-(1->4)-3-O-Ac-alpha-D-GalpANAc,A linear amino tetrasaccharide that consists of four 2-acetamido-3-O-acetyl-2-deoxy-alpha-D-galactopyranuronosyl units joined by (1->4)-linkages.,"InChI=1S/C40H54N4O29/c1-9(45)41-17-23(64-14(6)50)27(30(34(56)57)67-37(17)62)69-39-19(43-11(3)47)25(66-16(8)52)29(32(72-39)36(60)61)71-40-20(44-12(4)48)24(65-15(7)51)28(31(73-40)35(58)59)70-38-18(42-10(2)46)22(63-13(5)49)21(53)26(68-38)33(54)55/h17-32,37-40,53,62H,1-8H3,(H,41,45)(H,42,46)(H,43,47)(H,44,48)(H,54,55)(H,56,57)(H,58,59)(H,60,61)/t17-,18-,19-,20-,21-,22-,23-,24-,25-,26+,27-,28-,29-,30+,31+,32+,37+,38-,39+,40+/m1/s1",[4)-3-O-Ac-alpha-D-GalpANAc(1->]4,PubMed citation,22095754
3512,64192,abacavir 5'-carboxylic acid,"A monocarboxylic acid oxidation product of abacavir, in which the C-5' hydroxymethyl group has been oxidised to a carboxy group. One of the two major metabolites of abacavir in humans (the other is the 5'-glucuronide, CHEBI:64189).","InChI=1S/C14H16N6O2/c15-14-18-11(17-8-2-3-8)10-12(19-14)20(6-16-10)9-4-1-7(5-9)13(21)22/h1,4,6-9H,2-3,5H2,(H,21,22)(H3,15,17,18,19)/t7-,9+/m1/s1",abacavir carboxylate,PubMed citation,22032494
3513,64207,spiramide,"An azaspiro compound that consists of 1,3,8-triazaspiro[4.5]decan-4-one having a phenyl group attached to N-1 and a 3-(4-fluorophenoxy)propyl attached to N-8. Selective 5-HT antagonist, which binds to 5-HT2 sites as potently as spiperone but has lower affinity for 5-HT2C receptors. Also a high affinity D2 receptor antagonist (Ki = 3 nM). Lacks the disruptive effect of spiperone on animal behaviour.","InChI=1S/C22H26FN3O2/c23-18-7-9-20(10-8-18)28-16-4-13-25-14-11-22(12-15-25)21(27)24-17-26(22)19-5-2-1-3-6-19/h1-3,5-10H,4,11-17H2,(H,24,27)",AMI-193,Reaxys Registry Number,631679
3514,64210,"4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid","An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.","InChI=1S/C22H25NO3/c1-21(2)11-12-22(3,4)18-13-15(7-10-17(18)21)19(24)23-16-8-5-14(6-9-16)20(25)26/h5-10,13H,11-12H2,1-4H3,(H,23,24)(H,25,26)",AM580,PDB accession,3KMR
3515,64219,"(2R,3R)-nemonapride","An optically active form of nemonapride having (2R,3R)-configuration.","InChI=1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26)/t14-,18-/m1/s1",(+)-nemonapride,Reaxys Registry Number,15801779
3516,64220,monosodium glutamate,An organic sodium salt that is the monosodium salt of glutamic acid.,"InChI=1S/C5H9NO4.Na/c6-3(5(9)10)1-2-4(7)8;/h3H,1-2,6H2,(H,7,8)(H,9,10);/q;+1/p-1",sodium glutamate,Reaxys Registry Number,17003240
3517,64228,tunicamycin A0,"A nucleoside that is one of the homologues in the mixture that is tunicamycin, characterised by an 11-methyldodec-2-enoyl fatty acyl substituent on the amino group of the tunicamine moiety.","InChI=1S/C36H58N4O16/c1-17(2)11-9-7-5-4-6-8-10-12-22(44)38-25-29(49)26(46)20(53-35(25)56-34-24(37-18(3)42)28(48)27(47)21(16-41)54-34)15-19(43)32-30(50)31(51)33(55-32)40-14-13-23(45)39-36(40)52/h10,12-14,17,19-21,24-35,41,43,46-51H,4-9,11,15-16H2,1-3H3,(H,37,42)(H,38,44)(H,39,45,52)/b12-10+/t19-,20-,21-,24-,25-,26+,27-,28-,29-,30+,31-,32-,33-,34-,35+/m1/s1",tunicamycin I,PubMed citation,7061468
3518,64245,tunicamycin A1,"A nucleoside that is one of the homologues in the mixture that is tunicamycin, characterised by a 12-methyltridec-2-enoyl fatty acyl substituent on the amino group of the tunicamine moiety.","InChI=1S/C37H60N4O16/c1-18(2)12-10-8-6-4-5-7-9-11-13-23(45)39-26-30(50)27(47)21(54-36(26)57-35-25(38-19(3)43)29(49)28(48)22(17-42)55-35)16-20(44)33-31(51)32(52)34(56-33)41-15-14-24(46)40-37(41)53/h11,13-15,18,20-22,25-36,42,44,47-52H,4-10,12,16-17H2,1-3H3,(H,38,43)(H,39,45)(H,40,46,53)/b13-11+/t20-,21-,22-,25-,26-,27+,28-,29-,30-,31+,32-,33-,34-,35-,36+/m1/s1",tunicamycin II,PubMed citation,7061468
3519,64250,tunicamycin B2,"A nucleoside that is one of the homologues in the mixture that is tunicamycin, characterised by a 13-methyltetradec-2-enoyl fatty acyl substituent on the amino group of the tunicamine moiety.","InChI=1S/C38H62N4O16/c1-19(2)13-11-9-7-5-4-6-8-10-12-14-24(46)40-27-31(51)28(48)22(55-37(27)58-36-26(39-20(3)44)30(50)29(49)23(18-43)56-36)17-21(45)34-32(52)33(53)35(57-34)42-16-15-25(47)41-38(42)54/h12,14-16,19,21-23,26-37,43,45,48-53H,4-11,13,17-18H2,1-3H3,(H,39,44)(H,40,46)(H,41,47,54)/b14-12+/t21-,22-,23-,26-,27-,28+,29-,30-,31-,32+,33-,34-,35-,36-,37+/m1/s1",tunicamycin A,PubMed citation,7061468
3520,64252,cyclic dehypoxanthinylfutalosine,A oxaspiro compound obtained by formal spirocyclisation of dehypoxanthinylfutalosine.,"InChI=1S/C14H14O7/c15-9-3-4-14(11(17)10(16)13(20)21-14)8-2-1-6(12(18)19)5-7(8)9/h1-2,5,10-11,13,16-17,20H,3-4H2,(H,18,19)/t10-,11+,13?,14-/m1/s1",cyclic DHFL,Reaxys Registry Number,19930668
3521,64253,3-demethylubiquinol-6,A 3-demethylubiquinol in which the polyprenyl chain contains 6 prenyl units.,"InChI=1S/C38H58O4/c1-27(2)15-10-16-28(3)17-11-18-29(4)19-12-20-30(5)21-13-22-31(6)23-14-24-32(7)25-26-34-33(8)35(39)37(41)38(42-9)36(34)40/h15,17,19,21,23,25,39-41H,10-14,16,18,20,22,24,26H2,1-9H3/b28-17+,29-19+,30-21+,31-23+,32-25+","2-hexaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinol",MetaCyc accession,2-HEXAPRENYL-3-METHYL-5-HYDROXY-6-METHOX
3522,64256,tunicamycin C1,"A nucleoside that is one of the homologues in the mixture that is tunicamycin, characterised by a 14-methylpentadec-2-enoyl fatty acyl substituent on the amino group of the tunicamine moiety.","InChI=1S/C39H64N4O16/c1-20(2)14-12-10-8-6-4-5-7-9-11-13-15-25(47)41-28-32(52)29(49)23(56-38(28)59-37-27(40-21(3)45)31(51)30(50)24(19-44)57-37)18-22(46)35-33(53)34(54)36(58-35)43-17-16-26(48)42-39(43)55/h13,15-17,20,22-24,27-38,44,46,49-54H,4-12,14,18-19H2,1-3H3,(H,40,45)(H,41,47)(H,42,48,55)/b15-13+/t22-,23-,24-,27-,28-,29+,30-,31-,32-,33+,34-,35-,36-,37-,38+/m1/s1",tunicamycin VII,PubMed citation,7061468
3523,64260,aminodeoxyfutalosine,An andenosine derivative that is futalosine in which the hypoxanthine moiety is replaced by adenine.,"InChI=1S/C19H19N5O6/c20-16-13-17(22-7-21-16)24(8-23-13)18-15(27)14(26)12(30-18)5-4-11(25)9-2-1-3-10(6-9)19(28)29/h1-3,6-8,12,14-15,18,26-27H,4-5H2,(H,28,29)(H2,20,21,22)/t12-,14-,15-,18-/m1/s1",AFL,PubMed citation,21098241
3524,64270,cyclic dehypoxanthinylfutalosinate(1-),"A benzoate anion that is the conjugate base of cyclic dehypoxanthinylfutalosine, arising from deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C14H14O7/c15-9-3-4-14(11(17)10(16)13(20)21-14)8-2-1-6(12(18)19)5-7(8)9/h1-2,5,10-11,13,16-17,20H,3-4H2,(H,18,19)/p-1/t10-,11+,13?,14-/m1/s1",cyclic dehypoxanthinylfutalosinate,MetaCyc accession,CPD-11419
3525,64285,(-)-bornyl diphosphate(3-),An organophosphate oxoanion obtained by deprotonation of the diphosphate OH groups of (-)-bornyl diphosphate; major species at pH 7.3.,"InChI=1S/C10H20O7P2/c1-9(2)7-4-5-10(9,3)8(6-7)16-19(14,15)17-18(11,12)13/h7-8H,4-6H2,1-3H3,(H,14,15)(H2,11,12,13)/p-3/t7-,8+,10+/m0/s1","(2R,4S)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl diphosphate",PubMed citation,2178556
3526,64289,5-methyltetrahydrosarcinapterin,"A tetrahydromethanopterin that is the 5-methyl derivative of 5,6,7,8-tetrahydrosarcinapterin.","InChI=1S/C36H54N7O19P/c1-15(26-16(2)39-31-27(43(26)3)33(54)42-36(37)41-31)38-18-6-4-17(5-7-18)12-20(44)28(50)21(45)13-59-35-30(52)29(51)23(61-35)14-60-63(57,58)62-22(9-11-25(48)49)32(53)40-19(34(55)56)8-10-24(46)47/h4-7,15-16,19-23,26,28-30,35,38,44-45,50-52H,8-14H2,1-3H3,(H,40,53)(H,46,47)(H,48,49)(H,55,56)(H,57,58)(H4,37,39,41,42,54)/t15-,16+,19+,20+,21-,22+,23-,26+,28+,29-,30-,35+/m1/s1","5-methyl-5,6,7,8-tetrahydrosarcinapterin",KEGG COMPOUND accession,C18799
3527,64294,7-ketocholesterol,A cholestanoid that consists of cholesterol bearing an oxo substituent at position 7.,"InChI=1S/C27H44O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-23,25,28H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,25+,26+,27-/m1/s1",7-oxocholesterol,Reaxys Registry Number,2169084
3528,64296,alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man,alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-D-Man having alpha-configuration at the reducing end anomeric centre.,"InChI=1S/C24H42O21/c25-1-5-10(30)14(34)18(21(38)39-5)43-23-20(16(36)12(32)7(3-27)41-23)45-24-19(15(35)11(31)8(4-28)42-24)44-22-17(37)13(33)9(29)6(2-26)40-22/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-/m1/s1",alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp,Reaxys Registry Number,1614218
3529,64298,(-)-bornyl diphosphate,A monoterpenyl phosphate that is the O-diphospho derivative of (-)-borneol.,"InChI=1S/C10H20O7P2/c1-9(2)7-4-5-10(9,3)8(6-7)16-19(14,15)17-18(11,12)13/h7-8H,4-6H2,1-3H3,(H,14,15)(H2,11,12,13)/t7-,8+,10+/m0/s1",(-)-bornyl pyrophosphate,PubMed citation,3759972
3530,64306,O-4''-alpha-D-mannosylqueuosine,A 7-deazaguanine ribonucleoside that is queuosine having a alpha-D-mannosyl residue attached at position 4''.,"InChI=1S/C23H33N5O12/c24-23-26-19-12(20(37)27-23)7(4-28(19)21-17(35)15(33)10(5-29)38-21)3-25-8-1-2-9(13(8)31)39-22-18(36)16(34)14(32)11(6-30)40-22/h1-2,4,8-11,13-18,21-22,25,29-36H,3,5-6H2,(H3,24,26,27,37)/t8-,9-,10+,11+,13+,14+,15+,16-,17+,18-,21+,22-/m0/s1",alpha-D-mannosylqueuosine,PubMed citation,34880214
3531,64307,"2,4-diaminobutyric acid",A diamino acid that is butyric acid in which a hydrogen at position 2 and a hydrogen at position 4 are replaced by amino groups.,"InChI=1S/C4H10N2O2/c5-2-1-3(6)4(7)8/h3H,1-2,5-6H2,(H,7,8)",Dbu,Reaxys Registry Number,1721676
3532,64323,memantine hydrochloride,A hydrochloride obtained by reaction of memantine with one equivalent of hydrochloric acid. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.,"InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H",memantine.HCl,DrugBank accession,DB01043
3533,64328,lysidine,Cytidine in which the 2-keto group on the cytosine ring is substituted by an epsilon-Llysyl residue.,"InChI=1S/C15H25N5O6/c16-8(14(24)25)3-1-2-5-18-15-19-10(17)4-6-20(15)13-12(23)11(22)9(7-21)26-13/h4,6,8-9,11-13,21-23H,1-3,5,7,16H2,(H,24,25)(H2,17,18,19)/t8-,9+,11+,12+,13+/m0/s1",k(2)C,Wikipedia accession,Lysidine_(nucleoside)
3534,64330,wybutoxosine,A nucleoside analogue obtained by formal hydroperoxidation at the beta-position on the side chain of wybutosine.,"InChI=1S/C21H28N6O11/c1-8-9(5-10(38-34)12(19(32)35-3)24-21(33)36-4)27-17(31)13-16(25(2)20(27)23-8)26(7-22-13)18-15(30)14(29)11(6-28)37-18/h7,10-12,14-15,18,28-30,34H,5-6H2,1-4H3,(H,24,33)/t10?,11-,12+,14-,15-,18-/m1/s1",wybutoxosin,CAS Registry Number,78355-49-4
3535,64335,N(1)-aminopropylagmatine(3+),A guanidinium ion obtained by protonation of the guanidino as well as the primary and secondary amino functions of N(1)-aminopropylagmatine; major species at pH 7.3.,"InChI=1S/C8H21N5/c9-4-3-6-12-5-1-2-7-13-8(10)11/h12H,1-7,9H2,(H4,10,11,13)/p+3",3-azaniumylpropyl-[4-(diaminomethylideneazaniumyl)butyl]azanium,PubMed citation,17429571
3536,64336,5-carboxymethylaminomethyl-2-thiouridine,A thiouridine that is 2-thiouridine bearing an additional carboxymethylaminomethyl substituent at position 5 on the thiouracil ring.,"InChI=1S/C12H17N3O7S/c16-4-6-8(19)9(20)11(22-6)15-3-5(1-13-2-7(17)18)10(21)14-12(15)23/h3,6,8-9,11,13,16,19-20H,1-2,4H2,(H,17,18)(H,14,21,23)/t6-,8-,9-,11-/m1/s1",cmnm(5)s(2)u,Reaxys Registry Number,4575275
3537,64337,5-(carboxymethylaminomethyl)uridine,"A derivative of uridine, bearing an additional carboxymethylaminomethyl substituent at position 5 on the uracil ring.","InChI=1S/C12H17N3O8/c16-4-6-8(19)9(20)11(23-6)15-3-5(1-13-2-7(17)18)10(21)14-12(15)22/h3,6,8-9,11,13,16,19-20H,1-2,4H2,(H,17,18)(H,14,21,22)/t6-,8-,9-,11-/m1/s1",5-carboxymethylaminomethyluridine,Reaxys Registry Number,4575274
3538,64339,N(1)-aminoaminopropylagmatine,A guanidine that consists of agmatine having a 3-aminopropyl group attached to the N-1 position.,"InChI=1S/C8H21N5/c9-4-3-6-12-5-1-2-7-13-8(10)11/h12H,1-7,9H2,(H4,10,11,13)",N(1)-(3-aminoaminopropyl)agmatine,PubMed citation,17429571
3539,64340,alpha-cyano-4-hydroxycinnamic acid,A monohydroxycinnamic acid that is 4-hydroxycinnamic acid in which the hydrogen alpha- to the carboxy group is replaced by a cyano group. It is used as a matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry for the analysis of peptides and oligonucleotides.,"InChI=1S/C10H7NO3/c11-6-8(10(13)14)5-7-1-3-9(12)4-2-7/h1-5,12H,(H,13,14)/b8-5+",CHCA,Wikipedia accession,Alpha-cyano-4-hydroxycinnamic_acid
3540,64343,trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene]malononitrile,"A dinitrile that is tert-butylbenzene in which the hydrogen at the para- position is substituted by a 4,4-dicyano-2-methylbuta-1,3-dien-1-yl group (the trans isomer). It is used as a matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry.","InChI=1S/C17H18N2/c1-13(10-15(11-18)12-19)9-14-5-7-16(8-6-14)17(2,3)4/h5-10H,1-4H3/b13-9+",DCTB,Reaxys Registry Number,8913051
3541,64344,"2',4',6'-trihydroxyacetophenone","A benzenetriol that is acetophenone in which the hydrogens at positions 2, 4, and 6 on the phenyl group are replaced by hydroxy groups. It is used as a matrix in matrix-assisted laser desorption/ionization (MALDI) mass spectrometry for the analysis of acidic glycans and glycopeptides.","InChI=1S/C8H8O4/c1-4(9)8-6(11)2-5(10)3-7(8)12/h2-3,10-12H,1H3",THAP,CAS Registry Number,480-66-0
3542,64349,N(6)-methyllysine,A lysine derivative that is lysine in which one of the hydrogens attached to N(6) is substituted by a methyl group.,"InChI=1S/C7H16N2O2/c1-9-5-3-2-4-6(8)7(10)11/h6,9H,2-5,8H2,1H3,(H,10,11)",N(epsilon)-methyllysine,Reaxys Registry Number,1705267
3543,64350,N-methylisoleucine,An isoleucine derivative that is isoleucine in which one of the hydrogens attached to the alpha-nitrogen is substituted by a methyl group.,"InChI=1S/C7H15NO2/c1-4-5(2)6(8-3)7(9)10/h5-6,8H,4H2,1-3H3,(H,9,10)",3-methyl-2-methylaminopentanoic acid,Reaxys Registry Number,1722061
3544,64353,UDP-N-acetyl-alpha-D-glucosamine 3-phosphate(4-),A quadruply-charged nucleotide-sugar oxoanion obtained via deprotonation of the phosphate and diphosphate OH groups of UDP-N-acetyl-alpha-D-glucosamine 3-phosphate; major species at pH 7.3.,"InChI=1S/C17H28N3O20P3/c1-6(22)18-10-14(38-41(28,29)30)12(25)7(4-21)37-16(10)39-43(33,34)40-42(31,32)35-5-8-11(24)13(26)15(36-8)20-3-2-9(23)19-17(20)27/h2-3,7-8,10-16,21,24-26H,4-5H2,1H3,(H,18,22)(H,31,32)(H,33,34)(H,19,23,27)(H2,28,29,30)/p-4/t7-,8-,10-,11-,12-,13-,14-,15-,16-/m1/s1",UNAG-3P,PubMed citation,21445328
3545,64361,beta-sesquiphellandrene,A sesquiterpene that is cyclohexene in which the hydrogens at position 6 are replaced by a methylidene group and in which the pro-R hydrogen at position 3 is replaced by a (2S)-6-methylhept-5-en-2-yl group.,"InChI=1S/C15H24/c1-12(2)6-5-7-14(4)15-10-8-13(3)9-11-15/h6,8,10,14-15H,3,5,7,9,11H2,1-2,4H3/t14-,15+/m0/s1",beta-sesquiphellandrene,CAS Registry Number,20307-83-9
3546,64362,UDP-N-acetyl-alpha-D-glucosamine 3-phosphate,A UDP-amino sugar having 3-O-phosphono-N-acetyl-alpha-D-glucosamine as the amino sugar component.,"InChI=1S/C17H28N3O20P3/c1-6(22)18-10-14(38-41(28,29)30)12(25)7(4-21)37-16(10)39-43(33,34)40-42(31,32)35-5-8-11(24)13(26)15(36-8)20-3-2-9(23)19-17(20)27/h2-3,7-8,10-16,21,24-26H,4-5H2,1H3,(H,18,22)(H,31,32)(H,33,34)(H,19,23,27)(H2,28,29,30)/t7-,8-,10-,11-,12-,13-,14-,15-,16-/m1/s1",UDP-N-acetyl-alpha-D-glucosamine 3'-phosphate,PubMed citation,21445328
3547,64363,rivastigmine(1+),An organic cation obtained by protonation of the tertiary amino function of rivastigmine.,"InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/p+1/t11-/m0/s1",rivastigmine cation,Reaxys Registry Number,25271873
3548,64367,N-ethyl-L-asparagine,An optically active form of N-ethylasparagine having L-configuration.,"InChI=1S/C6H12N2O3/c1-2-8-4(6(10)11)3-5(7)9/h4,8H,2-3H2,1H3,(H2,7,9)(H,10,11)/t4-/m0/s1",N(2)-ethyl-L-asparagine,CAS Registry Number,7195-20-2
3549,64368,3-hydroxyproline,A monohydroxyproline in which the hydroxy substituent is located at position C3.,"InChI=1S/C5H9NO3/c7-3-1-2-6-4(3)5(8)9/h3-4,6-7H,1-2H2,(H,8,9)",3-hydroxyprolines,Reaxys Registry Number,471957
3550,64396,1-oleyl-sn-glycero-3-phosphocholine,A 1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as oleyl (9Z-octadecenyl).,"InChI=1S/C26H54NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-31-24-26(28)25-33-34(29,30)32-23-21-27(2,3)4/h12-13,26,28H,5-11,14-25H2,1-4H3/b13-12-/t26-/m1/s1",1-[(9Z)-octadec-9-en-1-yl]-sn-glycero-3-phosphocholine,LIPID MAPS instance accession,LMGP01060039
3551,64410,gerfelin,"A member of the class of benzoic acids that is salicylic acid which is substituted at position 6 by a methyl group and at position 4 by a 2,3-dihydroxy-5-methylphenoxy group.","InChI=1S/C15H14O6/c1-7-3-11(17)14(18)12(4-7)21-9-5-8(2)13(15(19)20)10(16)6-9/h3-6,16-18H,1-2H3,(H,19,20)","4-(2,3-dihydroxy-5-methylphenoxy)-2-hydroxy-6-methylbenzoic acid",Reaxys Registry Number,11076226
3552,64412,10-deoxygerfelin,A member of the class of benzoic acids that is salicylic acid which is substituted at position 6 by a methyl group and at position 4 by a 3-hydroxy-5-methylphenoxy group.,"InChI=1S/C15H14O5/c1-8-3-10(16)6-11(4-8)20-12-5-9(2)14(15(18)19)13(17)7-12/h3-7,16-17H,1-2H3,(H,18,19)",C-10-deoxy gerfelin,Reaxys Registry Number,2663280
3553,64420,"UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminoheptanedioate-D-alanine(4-)",,"InChI=1S/C38H60N8O27P2/c1-14(30(54)44-20(36(61)62)8-9-23(49)43-19(7-5-6-18(39)35(59)60)32(56)41-15(2)34(57)58)40-31(55)16(3)69-29-25(42-17(4)48)37(71-21(12-47)27(29)52)72-75(66,67)73-74(64,65)68-13-22-26(51)28(53)33(70-22)46-11-10-24(50)45-38(46)63/h10-11,14-16,18-22,25-29,33,37,47,51-53H,5-9,12-13,39H2,1-4H3,(H,40,55)(H,41,56)(H,42,48)(H,43,49)(H,44,54)(H,57,58)(H,59,60)(H,61,62)(H,64,65)(H,66,67)(H,45,50,63)/p-4/t14-,15+,16?,18+,19-,20+,21+,22+,25+,26+,27+,28+,29+,33+,37?/m0/s1",UDP-MurNAc-tetrapeptide (4-),MetaCyc accession,UDP-MURNAC-TETRAPEPTIDE
3554,64432,2-diazoniobenzoate,The aromatic diazonium ion that is diazotised 2-aminobenzoic acid.,InChI=1S/C7H4N2O2/c8-9-6-4-2-1-3-5(6)7(10)11/h1-4H,o-diazoniobenzoate,Reaxys Registry Number,1427831
3555,64443,4-diazoniobenzoate,The aromatic diazonium ion that is diazotised 4-aminobenzoic acid.,InChI=1S/C7H4N2O2/c8-9-6-3-1-5(2-4-6)7(10)11/h1-4H,"4-carboxybenzenediazonium, inner salt",Reaxys Registry Number,1819372
3556,64444,hydroxy(phenyl)2-thienylacetic acid,A 2-hydroxy monocarboxylic acid that is phenylacetic acid bearing hydroxy and 2-thenyl substituents at position 2.,"InChI=1S/C12H10O3S/c13-11(14)12(15,10-7-4-8-16-10)9-5-2-1-3-6-9/h1-8,15H,(H,13,14)",2-hydroxy-2-phenyl-2-(2-thienyl)acetic acid,Reaxys Registry Number,188636
3557,64452,2-diazoniobenzenesulfonate,The aromatic diazonium ion that is diazotised 2-aminobenzenesulfonic acid.,"InChI=1S/C6H4N2O3S/c7-8-5-3-1-2-4-6(5)12(9,10)11/h1-4H",ortho-azobenzenesulfonate,PubMed citation,13912955
3558,64457,benzenesulfonate,"The simplest of the class of benzenesulfonates, in which the benzene nucleus carries no other substituents.","InChI=1S/C6H6O3S/c7-10(8,9)6-4-2-1-3-5-6/h1-5H,(H,7,8,9)/p-1",benzenemonosulfonate,Reaxys Registry Number,1638927
3559,64458,3-diazoniobenzenesulfonate,The aromatic diazonium ion that is diazotised 3-aminobenzenesulfonic acid.,"InChI=1S/C6H4N2O3S/c7-8-5-2-1-3-6(4-5)12(9,10)11/h1-4H",3-diazoniobenzenesulfonate,PubMed citation,13912955
3560,64468,3-nitrobenzenediazonium,The aromatic diazonium ion formed from diazotisation of the amino group in 3-nitroaniline.,InChI=1S/C6H4N3O2/c7-8-5-2-1-3-6(4-5)9(10)11/h1-4H/q+1,3-nitrobenzenediazonium cation,Reaxys Registry Number,1683014
3561,64469,4-nitrobenzenediazonium,The aromatic diazonium ion formed from diazotisation of the amino group in 4-nitroaniline.,InChI=1S/C6H4N3O2/c7-8-5-1-3-6(4-2-5)9(10)11/h1-4H/q+1,p-nitrobenzeneazo,PubMed citation,13912955
3562,64484,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino octasaccharide that consists of the linear tetrasaccharide beta-D-Xyl-(1->2)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-GlcNAc in which the Man residue is substituted at positions 3 and 6 by beta-D-GlcNAc-(1->2)-alpha-D-Man groups.,"InChI=1S/C55H92N4O40/c1-13(66)56-25-37(79)42(22(9-64)87-48(25)84)94-51-28(59-16(4)69)38(80)43(23(10-65)92-51)95-55-47(99-52-41(83)29(71)17(70)11-85-52)44(96-54-46(40(82)33(75)21(8-63)91-54)98-50-27(58-15(3)68)36(78)31(73)19(6-61)89-50)34(76)24(93-55)12-86-53-45(39(81)32(74)20(7-62)90-53)97-49-26(57-14(2)67)35(77)30(72)18(5-60)88-49/h17-55,60-65,70-84H,5-12H2,1-4H3,(H,56,66)(H,57,67)(H,58,68)(H,59,69)/t17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29+,30-,31-,32-,33-,34-,35-,36-,37-,38-,39+,40+,41-,42-,43-,44+,45+,46+,47+,48?,49+,50+,51+,52+,53+,54-,55+/m1/s1",beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,12423885
3563,64486,N-myristoylsphingosine-1-phosphocholine,A sphingomyelin d18:1 in which the N-acyl group is specified as tetradecanoyl (myristoyl).,"InChI=1S/C37H75N2O6P/c1-6-8-10-12-14-16-18-19-21-22-24-26-28-30-36(40)35(34-45-46(42,43)44-33-32-39(3,4)5)38-37(41)31-29-27-25-23-20-17-15-13-11-9-7-2/h28,30,35-36,40H,6-27,29,31-34H2,1-5H3,(H-,38,41,42,43)/b30-28+/t35-,36+/m0/s1",SM(32:1),PubMed citation,19347970
3564,64491,"L-erythro-5,6,7,8-tetrahydrobiopterin","5,6,7,8-Tetrahydrobiopterin in which the 1,2-dihydroxypropyl side-chain has L-erythro-configuration.","InChI=1S/C9H15N5O3/c1-3(15)6(16)4-2-11-7-5(12-4)8(17)14-9(10)13-7/h3-4,6,12,15-16H,2H2,1H3,(H4,10,11,13,14,17)/t3-,4?,6-/m0/s1",L-erythro-tetrahydrobiopterin,Reaxys Registry Number,6277924
3565,64527,alpha-D-galactosyl-(1->2)-beta-D-galactose,An alpha-D-galactosyl-(1->2)-D-galactose in which the reducing end anomeric centre has beta-configuration.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11-,12-/m1/s1",Galalpha1-2Galbeta,Reaxys Registry Number,4845052
3566,64528,alpha-D-Galp-(1->3)-beta-D-GalpNAc,An alpha-D-Galp-(1->3)-D-GalpNAc in which the anomeric centre at the reducing end has beta-configuration.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10+,11-,12-,13-,14-/m1/s1",Galalpha1-3-GalNAcbeta,PubMed citation,12626386
3567,64530,brevianamide F,"A pyrrolopyrazine that is hexahydropyrrolo[1,2-a]pyrazine-1,4-dione bearing an indol-3-ylmethyl substituent at position 3 (the 3S,8aS-diastereomer, obtained by formal cyclocondensation of L-tryptophan and L-proline).","InChI=1S/C16H17N3O2/c20-15-14-6-3-7-19(14)16(21)13(18-15)8-10-9-17-12-5-2-1-4-11(10)12/h1-2,4-5,9,13-14,17H,3,6-8H2,(H,18,20)/t13-,14-/m0/s1",cyclo-(Trp-Pro),Reaxys Registry Number,625131
3568,64552,2-hydroxybutyrate,"A hydroxy fatty acid anion that is the conjugate base of 2-hydroxybutyric acid, obtained by deprotonation of the carboxy group.","InChI=1S/C4H8O3/c1-2-3(5)4(6)7/h3,5H,2H2,1H3,(H,6,7)/p-1",alpha-hydroxybutanoate,Reaxys Registry Number,3661492
3569,64598,"1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one","A differentiation-inducing factor that is hexaphenone bearing two chloro substituents at positions 3 and 5, two hydroxy substituents at positions 2 and 6 as well as a single methoxy substituent at position 4. A secreted, chlorinated molecule that controls cell fate during development of Dictyostelium cells.","InChI=1S/C13H16Cl2O4/c1-3-4-5-6-7(16)8-11(17)9(14)13(19-2)10(15)12(8)18/h17-18H,3-6H2,1-2H3",DIF-1,Reaxys Registry Number,9789620
3570,64610,tenocyclidine,"A tertiary amino compound that consists of cyclohexane having piperidin-1-yl and thiophen-2-yl groups attached at position 1. A dissociative anaesthetic drug with halluccinogenic and stimulant effects. Its effects are similar to those of phencyclidine (PCP, an analogue with the thienyl group replaced by phenyl), but it is rather more potent.","InChI=1S/C15H23NS/c1-3-9-15(10-4-1,14-8-7-13-17-14)16-11-5-2-6-12-16/h7-8,13H,1-6,9-12H2",1-[1-(thiophen-2-yl)cyclohexyl]piperidine,Reaxys Registry Number,1246605
3571,64630,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-D-GlcpNAc,A branched amino tetrasaccharide that consists of the linear trisaccharide alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->3)-N-acetyl-D-glucosamine having an alpha-L-fucosyl residue attached at the 2-position of the central galactose.,"InChI=1S/C26H45NO20/c1-6-12(32)16(36)18(38)24(41-6)47-22-21(46-25-19(39)17(37)13(33)8(3-28)43-25)15(35)10(5-30)44-26(22)45-20-11(27-7(2)31)23(40)42-9(4-29)14(20)34/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14+,15-,16+,17-,18-,19+,20+,21-,22+,23?,24-,25+,26-/m0/s1",6-deoxy-alpha-L-galactopyranosyl-(1->2)-[alpha-D-galactopyranosyl-(1->3)]-beta-D-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-D-glucopyranose,PubMed citation,21981750
3572,64643,N(6)-[(3R)-3-methyl-D-ornithyl]-L-lysine(2+),A peptide cation obtained by deprotonation of the carboxy group and protonation of the three amino groups of N(6)-[(3R)-3-methyl-D-ornithyl]-L-lysine; major species at pH 7.3.,"InChI=1S/C12H26N4O3/c1-8(5-6-13)10(15)11(17)16-7-3-2-4-9(14)12(18)19/h8-10H,2-7,13-15H2,1H3,(H,16,17)(H,18,19)/p+2/t8-,9+,10-/m1/s1","(2R,3R)-3-methylornithyl-N(6)-lysine",PubMed citation,22095926
3573,64650,enniatin B4,An enniatin obtained from formal cyclocondensation of one N-[(2R)-2-hydroxy-3-methylbutanoyl]-N-methyl-L-leucine and two N-[(2R)-2-hydroxy-3-methylbutanoyl]-N-methyl-L-valine units.,"InChI=1S/C34H59N3O9/c1-17(2)16-23-32(41)44-27(21(9)10)30(39)36(14)25(19(5)6)34(43)46-28(22(11)12)31(40)37(15)24(18(3)4)33(42)45-26(20(7)8)29(38)35(23)13/h17-28H,16H2,1-15H3/t23-,24-,25-,26+,27+,28+/m0/s1",enniatin D,Reaxys Registry Number,9306191
3574,64668,geranylgeranyl-chlorophyll a,A chlorophyll that is the ester obtained by formal condensation between the carboxy group of chlorophyllide a and the hydroxy group of geranylgeraniol.,"InChI=1S/C55H67N4O5.Mg/c1-13-39-35(8)42-28-44-37(10)41(24-25-48(60)64-27-26-34(7)23-17-22-33(6)21-16-20-32(5)19-15-18-31(3)4)52(58-44)50-51(55(62)63-12)54(61)49-38(11)45(59-53(49)50)30-47-40(14-2)36(9)43(57-47)29-46(39)56-42;/h13,18,20,22,26,28-30,37,41,51H,1,14-17,19,21,23-25,27H2,2-12H3,(H-,56,57,58,59,61);/q-1;+2/p-1/b32-20+,33-22+,34-26+;/t37-,41-,51+;/m0./s1",geranylgeranyl-chl a,PubMed citation,6249390
3575,64686,7-formamidino-7-deazaguanine,A pyrrolopyrimidine that is 7-deazaguanine bearing a carboxamidine substituent at the 7 position.,"InChI=1S/C7H8N6O/c8-4(9)2-1-11-5-3(2)6(14)13-7(10)12-5/h1H,(H3,8,9)(H4,10,11,12,13,14)",archaeosine base,PubMed citation,22032275
3576,64689,mycophenolic acid O-acyl-glucuronide,A carboxylic ester resulting from the formal condensation of the carboxylic acid group of mycophenolic acid with the anomeric hydroxy group of beta-D-glucuronic acid.,"InChI=1S/C23H28O12/c1-9(4-6-11-15(25)14-12(8-33-22(14)31)10(2)19(11)32-3)5-7-13(24)34-23-18(28)16(26)17(27)20(35-23)21(29)30/h4,16-18,20,23,25-28H,5-8H2,1-3H3,(H,29,30)/b9-4+/t16-,17-,18+,20-,23+/m0/s1",AcMPAG,Reaxys Registry Number,9103529
3577,64701,cadaverine dihydrochloride,A hydrochloride resulting from the reaction of cadaverine with 2 mol eq. of hydrogen chloride.,InChI=1S/C5H14N2.2ClH/c6-4-2-1-3-5-7;;/h1-7H2;2*1H,cadaverine hydrochloride,Reaxys Registry Number,3611329
3578,64703,p-aminohippurate,"A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.","InChI=1S/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)/p-1",4-aminohippurate(1-),Reaxys Registry Number,5953141
3579,64706,decarboxytiaprofenic acid,A thiophene substituted at C-2 by benzoyl and at C-4 by an ethyl group.,"InChI=1S/C13H12OS/c1-2-11-8-9-12(15-11)13(14)10-6-4-3-5-7-10/h3-9H,2H2,1H3",5-ethyl-2-benzoylthiophene,Reaxys Registry Number,151561
3580,64733,potassium citrate (anhydrous),The anhydrous form of the tripotassium salt of citric acid.,"InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3",potassium citrate,CAS Registry Number,866-84-2
3581,64734,EDTA disodium salt (anhydrous),An organic sodium salt that is the anhydrous form of the disodium salt of ethylenediaminetetraacetic acid (EDTA).,"InChI=1S/C10H16N2O8.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;2*+1/p-2",(ethylenedinitrilo)tetraacetic acid disodium salt,CAS Registry Number,139-33-3
3582,64744,phytochelatin 2,"A phytochelatin that is a pentapeptide consisting of 2 units of gamma-Glu-Cys, with a glycyl unit at the C-terminus.","InChI=1S/C18H29N5O10S2/c19-8(17(30)31)1-3-12(24)22-11(7-35)16(29)23-9(18(32)33)2-4-13(25)21-10(6-34)15(28)20-5-14(26)27/h8-11,34-35H,1-7,19H2,(H,20,28)(H,21,25)(H,22,24)(H,23,29)(H,26,27)(H,30,31)(H,32,33)/t8-,9-,10-,11-/m0/s1",PC2,Reaxys Registry Number,4303219
3583,64746,potassium citrate monohydrate,A hydrate that is the monohydrate form of potassium citrate.,"InChI=1S/C6H8O7.3K.H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;1H2/q;3*+1;/p-3",potassium citrate.H2O,CAS Registry Number,6100-05-6
3584,64747,phytochelatin 4,"A phytochelatin that is a nonapeptide consisting of 4 units of gamma-Glu-Cys, with a glycyl unit at the C-terminus.","InChI=1S/C34H53N9O18S4/c35-14(31(54)55)1-5-22(44)38-19(11-63)28(51)41-16(33(58)59)3-7-24(46)40-21(13-65)30(53)43-17(34(60)61)4-8-25(47)39-20(12-64)29(52)42-15(32(56)57)2-6-23(45)37-18(10-62)27(50)36-9-26(48)49/h14-21,62-65H,1-13,35H2,(H,36,50)(H,37,45)(H,38,44)(H,39,47)(H,40,46)(H,41,51)(H,42,52)(H,43,53)(H,48,49)(H,54,55)(H,56,57)(H,58,59)(H,60,61)/t14-,15-,16-,17-,18-,19-,20-,21-/m0/s1",PC4,Reaxys Registry Number,4289225
3585,64757,3-palmitoyl-sn-glycerol,A 3-acyl-sn-glycerol in which the acyl group is specified as palmitoyl (hexadecanoyl).,"InChI=1S/C19H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(22)23-17-18(21)16-20/h18,20-21H,2-17H2,1H3/t18-/m1/s1",3-hexadecanoyl-sn-glycerol,Reaxys Registry Number,1728236
3586,64779,2-amino-Delta(2)-thiazoline-4-carboxylic acid zwitterion,An amino acid zwitterion obtained from 2-amino-Delta(2)-thiazoline-4-carboxylic acid by the transfer of a proton from the carboxy group to the thiazoline nitrogen. The major species at pH 7.3.,"InChI=1S/C4H6N2O2S/c5-4-6-2(1-9-4)3(7)8/h2H,1H2,(H2,5,6)(H,7,8)",2-amino-2-thiazoline-4-carboxylic acid zwitterion,PubMed citation,22350333
3587,64782,(+)-artemisinate,A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of (+)-artemisinic acid. The major species at pH 7.3.,"InChI=1S/C15H22O2/c1-9-4-6-12-10(2)5-7-13(14(12)8-9)11(3)15(16)17/h8,10,12-14H,3-7H2,1-2H3,(H,16,17)/p-1/t10-,12+,13+,14+/m1/s1",artemisinate,PubMed citation,16458889
3588,64788,"3,4-dihydro-4-hydroxyphenylpyruvate","A 2-oxo monocarboxylic acid anion that is the conjugate base of 3,4-dihydro-4-hydroxyphenylpyruvic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C9H10O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-3,7,10H,4-5H2,(H,12,13)/p-1",H2HPP,MetaCyc accession,CPD8J2-4
3589,64789,3-(4-hydroxycyclohex-2-en-1-ylidene)pyruvate,"A 2-oxo monocarboxylic acid anion that is the conjugate base of 3-(4-hydroxycyclohex-2-en-1-ylidene)pyruvic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C9H10O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1,3,5,7,10H,2,4H2,(H,12,13)/p-1",3-(4-hydroxycyclohex-2-enylidene)-2-oxopropanoate,MetaCyc accession,CPD8J2-5
3590,64790,tetrahydro-4-hydroxyphenylpyruvate,"A 2-oxo monocarboxylic acid anion that is the conjugate base of tetrahydro-4-hydroxyphenylpyruvic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C9H12O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1,3,6-7,10H,2,4-5H2,(H,12,13)/p-1",H4HPP,MetaCyc accession,CPD8J2-6
3591,64791,tetrahydrotyrosine zwitterion,An amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of tetrahydrotyrosine; major species at pH 7.3.,"InChI=1S/C9H15NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1,3,6-8,11H,2,4-5,10H2,(H,12,13)",H4Tyr,MetaCyc accession,CPD8J2-7
3592,64800,sativene,"A sesquiterpene that is octahydro-1H-1,4-methanoindene bearing methyl, isopropyl and methylene substituents at positions 4, 7 and 8 respectively (the 1R,3aS,4R,7R,7aR-isomer).","InChI=1S/C15H24/c1-9(2)11-7-8-15(4)10(3)12-5-6-13(15)14(11)12/h9,11-14H,3,5-8H2,1-2,4H3/t11-,12+,13+,14-,15+/m1/s1",(+)-sativene,Reaxys Registry Number,6566324
3593,64807,tetrahydrotyrosine,An alpha-amino acid that is alanine substituted at position 3 by a 4-hydroxycyclohex-2-en-1-yl group,"InChI=1S/C9H15NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1,3,6-8,11H,2,4-5,10H2,(H,12,13)","4,7,8,9-tetrahydrotyrosine",PubMed citation,20052993
3594,64814,6-hydroxycamphor,A cyclic monoterpene ketone that is camphor bearing a hydroxy substituent at position 6.,"InChI=1S/C10H16O2/c1-9(2)6-4-7(11)10(9,3)8(12)5-6/h6-7,11H,4-5H2,1-3H3",6-hydroxycamphors,Reaxys Registry Number,2439004
3595,64819,"[(2R)-3,3,4-trimethyl-6-oxo-3,6-dihydro-1H-pyran-2-yl]acetyl-CoA","An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2R)-3,3,4-trimethyl-6-oxo-3,6-dihydro-1H-pyran-2-yl]acetic acid.","InChI=1S/C31H48N7O19P3S/c1-16-10-20(40)55-18(31(16,4)5)11-21(41)61-9-8-33-19(39)6-7-34-28(44)25(43)30(2,3)13-53-60(50,51)57-59(48,49)52-12-17-24(56-58(45,46)47)23(42)29(54-17)38-15-37-22-26(32)35-14-36-27(22)38/h10,14-15,17-18,23-25,29,42-43H,6-9,11-13H2,1-5H3,(H,33,39)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t17-,18-,23-,24-,25+,29-/m1/s1","[(2R)-3,3,4-trimethyl-6-oxo-3,6-dihydro-1H-pyran-2-yl]acetyl-coenzyme A",PubMed citation,22267661
3596,64832,"2,4,6-trimethylbenzoate","A trimethylbenzoate in which the three methyl substituents are located at positions 2, 4 and 6.","InChI=1S/C10H12O2/c1-6-4-7(2)9(10(11)12)8(3)5-6/h4-5H,1-3H3,(H,11,12)/p-1","2,4,6-trimethylbenzoate anion",Reaxys Registry Number,3905883
3597,64833,6-kestotriose,A trisaccharide that consists of sucrose having an additional fructosyl residue attached to the fructose residue via a beta-(2->6)-linkage.,"InChI=1S/C18H32O16/c19-1-6-9(23)12(26)13(27)16(31-6)34-18(5-22)15(29)11(25)8(33-18)3-30-17(4-21)14(28)10(24)7(2-20)32-17/h6-16,19-29H,1-5H2/t6-,7-,8-,9-,10-,11-,12+,13-,14+,15+,16-,17-,18+/m1/s1",6-kestose,KEGG GLYCAN accession,G02540
3598,64839,1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate(2-),An anionic phospholipid obtained by deprotonation of the phosphate OH groups of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate; major species at pH 7.3.,"InChI=1S/C37H71O8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(39)45-35(34-44-46(40,41)42)33-43-36(38)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,35H,3-16,19-34H2,1-2H3,(H2,40,41,42)/p-2/b18-17-/t35-/m1/s1",PA(16:0/18:1),Reaxys Registry Number,9313156
3599,64846,glycyl-AMP(1-),An organophosphate oxoanion obtained by removal of the proton from the phosphate group of glycyl-AMP.,"InChI=1S/C12H17N6O8P/c13-1-6(19)26-27(22,23)24-2-5-8(20)9(21)12(25-5)18-4-17-7-10(14)15-3-16-11(7)18/h3-5,8-9,12,20-21H,1-2,13H2,(H,22,23)(H2,14,15,16)/p-1/t5-,8-,9-,12-/m1/s1",glycyl-adenylate(1-),MetaCyc accession,CPD-9993
3600,64847,L-threonyl-AMP(1-),An organophosphate oxoanion obtained by removal of the proton from the phosphate group of L-threonyl-AMP.,"InChI=1S/C14H21N6O9P/c1-5(21)7(15)14(24)29-30(25,26)27-2-6-9(22)10(23)13(28-6)20-4-19-8-11(16)17-3-18-12(8)20/h3-7,9-10,13,21-23H,2,15H2,1H3,(H,25,26)(H2,16,17,18)/p-1/t5-,6-,7+,9-,10-,13-/m1/s1",L-threonyl-adenylate(1-),MetaCyc accession,CPD-9994
3601,64851,L-threonyl-AMP,A purine ribonucleoside 5'-monophosphate that is adenosine 5'-monophosphate in which one of the hydroxy groups of the phosphate has been condensed with the carboxylic acid group of L-threonine.,"InChI=1S/C14H21N6O9P/c1-5(21)7(15)14(24)29-30(25,26)27-2-6-9(22)10(23)13(28-6)20-4-19-8-11(16)17-3-18-12(8)20/h3-7,9-10,13,21-23H,2,15H2,1H3,(H,25,26)(H2,16,17,18)/t5-,6-,7+,9-,10-,13-/m1/s1",5'-adenylic acid L-threonine anhydride,PubMed citation,182209
3602,64853,N(epsilon)-(5'-guanylyl)-N(alpha)-acetyl-L-lysine methyl ester(1-),An organic phosphoramidate anion obtained by removal of the proton from the phosphoramidate OH group of N(epsilon)-(5'-guanylyl)-N(alpha)-acetyl-L-lysine methyl ester; major species at pH 7.3.,"InChI=1S/C19H30N7O10P/c1-9(27)23-10(18(31)34-2)5-3-4-6-22-37(32,33)35-7-11-13(28)14(29)17(36-11)26-8-21-12-15(26)24-19(20)25-16(12)30/h8,10-11,13-14,17,28-29H,3-7H2,1-2H3,(H,23,27)(H2,22,32,33)(H3,20,24,25,30)/p-1/t10-,11+,13+,14+,17+/m0/s1",GMP-N-epsilon-(N-alpha-acetyl lysine methyl ester) 5'-phosphoramidate,MetaCyc accession,GMP-LYSINE-PHOSPHORAMIDATE
3603,64856,N(epsilon)-GMP-N(alpha)-acetyl-L-lysine methyl ester,A organic phosphoramidate that is guanosine 5'-monophosphate in which one of the hydroxy groups of the phosphate has been condensed with the side chain amino group of N(alpha)-acetyl-L-lysine methyl ester.,"InChI=1S/C19H30N7O10P/c1-9(27)23-10(18(31)34-2)5-3-4-6-22-37(32,33)35-7-11-13(28)14(29)17(36-11)26-8-21-12-15(26)24-19(20)25-16(12)30/h8,10-11,13-14,17,28-29H,3-7H2,1-2H3,(H,23,27)(H2,22,32,33)(H3,20,24,25,30)/t10-,11+,13+,14+,17+/m0/s1",N(epsilon)-GMP-N(alpha)-acetyllysine methyl ester,MetaCyc accession,GMP-LYSINE-PHOSPHORAMIDATE
3604,64858,aminopropylcadaverine(3+),A triply-charged organic cation obtained by protonation of all three amino groups of aminopropylcadaverine; major species at pH 7.3.,"InChI=1S/C8H21N3/c9-5-2-1-3-7-11-8-4-6-10/h11H,1-10H2/p+3","N-3-aminopropyl-1,5-diaminopentane",MetaCyc accession,CPD0-1065
3605,64859,N(alpha)-acetyl-L-lysine methyl ester,An alpha-amino acid ester obtained by formal condensation of the carboxy group of N(alpha)-acetyl-L-lysine with the hydroxy group of methanol.,"InChI=1S/C9H18N2O3/c1-7(12)11-8(9(13)14-2)5-3-4-6-10/h8H,3-6,10H2,1-2H3,(H,11,12)/t8-/m0/s1",methyl N-acetyl-L-lysinate,Reaxys Registry Number,2255115
3606,64870,(S)-malyl N-acetyl-alpha-D-glucosaminide(2-),A carbohydrate acid derivative anion obtained by deprotonation of both carboxy groups of (S)-malyl N-acetyl-alpha-D-glucosaminide; major species at pH 7.3.,"InChI=1S/C12H19NO10/c1-4(15)13-8-10(19)9(18)6(3-14)23-12(8)22-5(11(20)21)2-7(16)17/h5-6,8-10,12,14,18-19H,2-3H2,1H3,(H,13,15)(H,16,17)(H,20,21)/p-2/t5-,6+,8+,9+,10+,12-/m0/s1",GlcNAc-Mal(2-),MetaCyc accession,CPD8J2-1
3607,64871,(S)-malyl alpha-D-glucosaminide(1-),A carbohydrate acid derivative anion obtained by deprotonation of both carboxy groups and protonation of the amino group of (S)-malyl alpha-D-glucosaminide; major species at pH 7.3.,"InChI=1S/C10H17NO9/c11-6-8(16)7(15)4(2-12)20-10(6)19-3(9(17)18)1-5(13)14/h3-4,6-8,10,12,15-16H,1-2,11H2,(H,13,14)(H,17,18)/p-1/t3-,4+,6+,7+,8+,10-/m0/s1",GlcN-Mal(1-),MetaCyc accession,CPD8J2-2
3608,64876,bacillithiol(1-),A carbohydrate acid derivative anion obtained by deprotonation of both carboxy groups and protonation of the amino group of bacillithiol; major species at pH 7.3.,"InChI=1S/C13H22N2O10S/c14-4(3-26)11(21)15-8-10(20)9(19)6(2-16)25-13(8)24-5(12(22)23)1-7(17)18/h4-6,8-10,13,16,19-20,26H,1-3,14H2,(H,15,21)(H,17,18)(H,22,23)/p-1/t4-,5-,6+,8+,9+,10+,13-/m0/s1",BSH,MetaCyc accession,CPD8J2-3
3609,64882,(S)-malyl N-acetyl-alpha-D-glucosaminide,An N-acetyl-alpha-D-glucosaminide having (S)-malyl as the anomeric substituent.,"InChI=1S/C12H19NO10/c1-4(15)13-8-10(19)9(18)6(3-14)23-12(8)22-5(11(20)21)2-7(16)17/h5-6,8-10,12,14,18-19H,2-3H2,1H3,(H,13,15)(H,16,17)(H,20,21)/t5-,6+,8+,9+,10+,12-/m0/s1",alpha-D-GlcNAc-L-Mal,MetaCyc accession,CPD8J2-1
3610,64904,"4,10-dihydroxyperylene-3,9-dione","A perylene that consists of dihydroxyperylene-3,9-dione bering hydroxy groups at positions 4 and 10.","InChI=1S/C20H12O4/c21-13-5-1-9-10-2-6-15(23)20-16(24)8-4-12(18(10)20)11-3-7-14(22)19(13)17(9)11/h1-9,17,21,24H",quinone-6,CAS Registry Number,10190-97-3
3611,64910,C20 phytosphingosine,A sphingoid that is C20 sphinganine bearing an additional 4R-hydroxy substituent.,"InChI=1S/C20H43NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19(23)20(24)18(21)17-22/h18-20,22-24H,2-17,21H2,1H3/t18-,19+,20-/m0/s1","(2S,3S,4R)-2-aminoeicosane-1,3,4-triol",Reaxys Registry Number,7290433
3612,64927,2-oxohex-3-enedioic acid,The oxo dicarboxylic acid that is hex-3-enedioic acid oxo-substituted at C-2; the stereochemistry of the C=C double bond is unspecified.,"InChI=1S/C6H6O5/c7-4(6(10)11)2-1-3-5(8)9/h1-2H,3H2,(H,8,9)(H,10,11)",4-oxalocrotonic acid,CAS Registry Number,31540-68-8
3613,64939,"3,4-dihydro-4-hydroxyphenylpyruvic acid","A 2-oxo monocarboxylic acid that is pyruvic acid substituted at position 3 by a 4-hydroxycyclohexa-1,5-dien-1-yl group","InChI=1S/C9H10O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1-3,7,10H,4-5H2,(H,12,13)",dihydro-4-hydroxyphenylpyruvic acid,MetaCyc accession,CPD8J2-4
3614,64945,sn-glycero-3-phosphoserine,A glycerol 1-phosphoserine in which the glycero portion has R-configuration.,"InChI=1S/C6H14NO8P/c7-5(6(10)11)3-15-16(12,13)14-2-4(9)1-8/h4-5,8-9H,1-3,7H2,(H,10,11)(H,12,13)/t4-,5+/m1/s1",sn-glyceryl-3-phosphoserine,Reaxys Registry Number,1714603
3615,64974,(-)-microperfuranone,"A butenolide that is furan-2(5H)-one which is substituted by a phenyl group at position 3, a benzyl group at position 4, and a hydroxy group at position 5 (the (-)-enantiomer). A secondary metabolite obtained from Aspergillus nidulans.","InChI=1S/C17H14O3/c18-16-14(11-12-7-3-1-4-8-12)15(17(19)20-16)13-9-5-2-6-10-13/h1-10,16,18H,11H2",(-)-4-benzyl-5-hydroxy-3-phenylfuran-2(5H)-one,PubMed citation,16595963
3616,65009,indol-3-ylmethylamine,An aralkylamino compound that is indole substituted at position 3 by an aminomethyl group.,"InChI=1S/C9H10N2/c10-5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5,10H2",1H-indol-3-ylmethanamine,Reaxys Registry Number,4082
3617,65016,6'-oxoparomamine(3+),An ammonium ion resulting from the protonation of all three amino groups of 6'-oxoparomamine. The major species at pH 7.3.,"InChI=1S/C12H23N3O7/c13-3-1-4(14)11(10(20)7(3)17)22-12-6(15)9(19)8(18)5(2-16)21-12/h2-12,17-20H,1,13-15H2/p+3/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1",6'-dehydro-6'-oxoparomamine(3+),MetaCyc accession,CPD-14155
3618,65019,methyl indole-3-carboxylate,The methyl ester of indole-3-carboxylic acid.,"InChI=1S/C10H9NO2/c1-13-10(12)8-6-11-9-5-3-2-4-7(8)9/h2-6,11H,1H3",indole-3-carboxylic acid methyl ester,MetaCyc accession,CPDQT-423
3619,65022,gammaGluCys(IAN),An S-conjugate dipeptide consisting of L-gamma-glutamyl-L-cysteine in which the the cysteine side chain is substituted by a cyano(indol-3-yl)methyl group.,"InChI=1S/C18H20N4O5S/c19-7-15(11-8-21-13-4-2-1-3-10(11)13)28-9-14(18(26)27)22-16(23)6-5-12(20)17(24)25/h1-4,8,12,14-15,21H,5-6,9,20H2,(H,22,23)(H,24,25)(H,26,27)/t12-,14-,15?/m0/s1",indole-3-acetonitrile-L-gamma-glutamyl-L-cysteine conjugate,PubMed citation,19567706
3620,65025,6-(D-glucosyloxy)indole-3-carboxylic acid,An indolyl carbohydrate that is 6-hydroxyindole-3-carboxylic acid in which the hydroxy group is substituted by a D-glucosyl residue.,"InChI=1S/C15H17NO8/c17-5-10-11(18)12(19)13(20)15(24-10)23-6-1-2-7-8(14(21)22)4-16-9(7)3-6/h1-4,10-13,15-20H,5H2,(H,21,22)/t10-,11-,12+,13-,15?/m1/s1",6-glucosyloxyindole-3-carboxylic acid,PubMed citation,19567706
3621,65026,D-glucosyl 6-hydroxyindole-3-carboxylate,An O-acyl carbohydrate obtained by formal condensation of the carboxy group of 6-hydroxyindole-3-carboxylic acid with the anomeric hydroxy group of D-glucose.,"InChI=1S/C15H17NO8/c17-5-10-11(19)12(20)13(21)15(23-10)24-14(22)8-4-16-9-3-6(18)1-2-7(8)9/h1-4,10-13,15-21H,5H2/t10-,11-,12+,13-,15?/m1/s1",6-OH-I3CO2Glc,PubMed citation,19567706
3622,65028,ribostamycin(4+),An organic cation obtained by protonation of the four amino groups of ribostamycin; major species at pH 7.3.,"InChI=1S/C17H34N4O10/c18-2-6-10(24)12(26)8(21)16(28-6)30-14-5(20)1-4(19)9(23)15(14)31-17-13(27)11(25)7(3-22)29-17/h4-17,22-27H,1-3,18-21H2/p+4/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1",ribostamycin(4+),MetaCyc accession,CPD-14143
3623,65044,2'''-acetyl-6'''-hydroxyneomycin C,An aminoglycoside derived from neomycin and consisting of neamine substituted at position 3 by a 2-acetamido-2-deoxy-alpha-D-glucopyranosyl-(1->3)-beta-D-ribofuranosyl group.,"InChI=1S/C25H47N5O15/c1-6(33)30-13-18(38)16(36)10(4-31)41-24(13)44-21-11(5-32)42-25(19(21)39)45-22-14(34)7(27)2-8(28)20(22)43-23-12(29)17(37)15(35)9(3-26)40-23/h7-25,31-32,34-39H,2-5,26-29H2,1H3,(H,30,33)/t7-,8+,9-,10-,11-,12-,13-,14+,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25+/m1/s1",2'''-acetyl-6'''-deamino 6'''-hydroxyneomycin C,Reaxys Registry Number,19612306
3624,65045,festuclavine(1+),An organic cation obtained by deprotonation of the tertiary amino group of festuclavine; major species at pH 7.3.,"InChI=1S/C16H20N2/c1-10-6-13-12-4-3-5-14-16(12)11(8-17-14)7-15(13)18(2)9-10/h3-5,8,10,13,15,17H,6-7,9H2,1-2H3/p+1/t10-,13-,15-/m1/s1",festuclavinium(1+),PubMed citation,20435769
3625,65068,6'''-oxoneomycin C(5+),An organic cation obtained by protonation of all five free amino groups of 6'''-oxoneomycin C; major species at pH 7.3.,"InChI=1S/C23H43N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)40-18-6(26)1-5(25)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(28)16(35)14(33)8(3-29)38-22/h3,5-23,30-36H,1-2,4,24-28H2/p+5/t5-,6+,7-,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",6'''-deamino-6'''-oxoneomycin C(5+),KEGG COMPOUND accession,C17589
3626,65087,(9Z)-myristoleoyl-CoA,An unsaturated fatty acyl-CoA resulting from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z)-myristoleic acid.,"InChI=1S/C35H60N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h7-8,22-24,28-30,34,45-46H,4-6,9-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/b8-7-/t24-,28-,29-,30+,34-/m1/s1",(9Z)-myristoleoyl-coenzyme A,Reaxys Registry Number,9836159
3627,65088,docosanoyl-CoA,A very long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of docosanoic (behenic) acid.,"InChI=1S/C43H78N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-34(52)71-27-26-45-33(51)24-25-46-41(55)38(54)43(2,3)29-64-70(61,62)67-69(59,60)63-28-32-37(66-68(56,57)58)36(53)42(65-32)50-31-49-35-39(44)47-30-48-40(35)50/h30-32,36-38,42,53-54H,4-29H2,1-3H3,(H,45,51)(H,46,55)(H,59,60)(H,61,62)(H2,44,47,48)(H2,56,57,58)/t32-,36-,37-,38+,42-/m1/s1",docosanoyl-coenzyme A,KEGG COMPOUND accession,C16528
3628,65096,"trans,octacis-decaprenylphospho-beta-D-arabinofuranose","A polyprenyl glycosyl phosphate consisting of beta-D-arabinofuranose attached at the 1-position to trans,octacis-decaprenyl phosphate.","InChI=1S/C55H91O8P/c1-42(2)21-12-22-43(3)23-13-24-44(4)25-14-26-45(5)27-15-28-46(6)29-16-30-47(7)31-17-32-48(8)33-18-34-49(9)35-19-36-50(10)37-20-38-51(11)39-40-61-64(59,60)63-55-54(58)53(57)52(41-56)62-55/h21,23,25,27,29,31,33,35,37,39,52-58H,12-20,22,24,26,28,30,32,34,36,38,40-41H2,1-11H3,(H,59,60)/b43-23+,44-25-,45-27-,46-29-,47-31-,48-33-,49-35-,50-37-,51-39-/t52-,53-,54+,55+/m1/s1",beta-D-arabinofuranosyl-1-monophosphoryldecaprenol,Reaxys Registry Number,10516958
3629,65112,butirosin A,A butirosin that consists of neamine in which is substituted at position 2 by a beta-D-xylofuranosyl and at position 4 by an (S)-2-hydroxy-4-aminobutyryl group.,"InChI=1S/C21H41N5O12/c22-2-1-8(28)19(34)26-7-3-6(24)17(37-20-11(25)15(32)13(30)9(4-23)35-20)18(12(7)29)38-21-16(33)14(31)10(5-27)36-21/h6-18,20-21,27-33H,1-5,22-25H2,(H,26,34)/t6-,7+,8-,9+,10+,11+,12-,13+,14-,15+,16+,17+,18+,20+,21-/m0/s1",Ambutyrosin A,CAS Registry Number,34291-02-6
3630,65113,5''-phosphoribostamycin,A glycoside phosphate that is ribostamycin (vistamycin) in which the ribofuranosyl residue is substituted at position 5 by a phosphate group.,"InChI=1S/C17H35N4O13P/c18-2-6-10(23)12(25)8(21)16(31-6)33-14-5(20)1-4(19)9(22)15(14)34-17-13(26)11(24)7(32-17)3-30-35(27,28)29/h4-17,22-26H,1-3,18-21H2,(H2,27,28,29)/t4-,5+,6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17+/m1/s1",5''-phosphovistamycin,KEGG COMPOUND accession,C18004
3631,65117,"CDP-N,N-dimethylethanolamine(1-)","An organophosphate oxoanion that is the conjugate base of CDP-N,N-dimethylethanolamine, obtained by deprotonation of the diphosphate OH groups and protonation of the tertiary amino group; major species at pH 7.3.","InChI=1S/C13H24N4O11P2/c1-16(2)5-6-25-29(21,22)28-30(23,24)26-7-8-10(18)11(19)12(27-8)17-4-3-9(14)15-13(17)20/h3-4,8,10-12,18-19H,5-7H2,1-2H3,(H,21,22)(H,23,24)(H2,14,15,20)/p-1/t8-,10-,11-,12-/m1/s1",CDP-PDME,PubMed citation,1847919
3632,65124,beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,A linear amino pentasaccharide comprising five N-acetylglucosaminyl residues linked beta(1->4).,"InChI=1S/C40H67N5O26/c1-11(51)41-21-28(58)32(17(7-47)63-36(21)62)68-38-23(43-13(3)53)30(60)34(19(9-49)65-38)70-40-25(45-15(5)55)31(61)35(20(10-50)67-40)71-39-24(44-14(4)54)29(59)33(18(8-48)66-39)69-37-22(42-12(2)52)27(57)26(56)16(6-46)64-37/h16-40,46-50,56-62H,6-10H2,1-5H3,(H,41,51)(H,42,52)(H,43,53)(H,44,54)(H,45,55)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39+,40+/m1/s1",beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,PubMed citation,19443021
3633,65128,beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,A linear amino hexasaccharide comprising six N-acetylglucosaminyl residues linked beta(1->4).,"InChI=1S/C48H80N6O31/c1-13(61)49-25-33(69)38(20(8-56)75-43(25)74)81-45-27(51-15(3)63)35(71)40(22(10-58)77-45)83-47-29(53-17(5)65)37(73)42(24(12-60)79-47)85-48-30(54-18(6)66)36(72)41(23(11-59)80-48)84-46-28(52-16(4)64)34(70)39(21(9-57)78-46)82-44-26(50-14(2)62)32(68)31(67)19(7-55)76-44/h19-48,55-60,67-74H,7-12H2,1-6H3,(H,49,61)(H,50,62)(H,51,63)(H,52,64)(H,53,65)(H,54,66)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44+,45+,46+,47+,48+/m1/s1",(GlcNAc1-4)6beta,PubMed citation,19443021
3634,65132,"(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid. It is a member of n-3 PUFA and a product of alpha-linolenoic acid metabolism.","InChI=1S/C43H66N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-34(52)71-27-26-45-33(51)24-25-46-41(55)38(54)43(2,3)29-64-70(61,62)67-69(59,60)63-28-32-37(66-68(56,57)58)36(53)42(65-32)50-31-49-35-39(44)47-30-48-40(35)50/h5-6,8-9,11-12,14-15,17-18,20-21,30-32,36-38,42,53-54H,4,7,10,13,16,19,22-29H2,1-3H3,(H,45,51)(H,46,55)(H,59,60)(H,61,62)(H2,44,47,48)(H2,56,57,58)/b6-5-,9-8-,12-11-,15-14-,18-17-,21-20-/t32-,36-,37-,38+,42-/m1/s1",DHA-CoA,KEGG COMPOUND accession,C16169
3635,65139,"(2E,6Z,9Z,12Z,15Z,18Z,21Z)-tetracosaheptaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2E,6Z,9Z,12Z,15Z,18Z,21Z)-tetracosaheptaenoic acid. It is a member of n-3 PUFA and a product of alpha-linolenoic acid metabolism.","InChI=1S/C45H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-36(54)73-29-28-47-35(53)26-27-48-43(57)40(56)45(2,3)31-66-72(63,64)69-71(61,62)65-30-34-39(68-70(58,59)60)38(55)44(67-34)52-33-51-37-41(46)49-32-50-42(37)52/h5-6,8-9,11-12,14-15,17-18,20-21,24-25,32-34,38-40,44,55-56H,4,7,10,13,16,19,22-23,26-31H2,1-3H3,(H,47,53)(H,48,57)(H,61,62)(H,63,64)(H2,46,49,50)(H2,58,59,60)/b6-5-,9-8-,12-11-,15-14-,18-17-,21-20-,25-24+/t34-,38-,39-,40+,44-/m1/s1",THA-CoA,LIPID MAPS instance accession,LMFA07050066
3636,65145,"3',4'-O-disulfo-N-acetyllactosamine","An amino disaccharide that consists of N-acetyl-beta-D-glucosamine having a 3,4-di-O-sulfo-beta-D-galactosyl residue attached at position 4.","InChI=1S/C14H25NO17S2/c1-4(18)15-7-8(19)10(5(2-16)28-13(7)21)30-14-9(20)12(32-34(25,26)27)11(6(3-17)29-14)31-33(22,23)24/h5-14,16-17,19-21H,2-3H2,1H3,(H,15,18)(H,22,23,24)(H,25,26,27)/t5-,6-,7-,8-,9-,10-,11+,12-,13-,14+/m1/s1","3,4-di-O-sulfo-beta-D-Gal-(1->4)-beta-D-GlcNAc",PubMed citation,19443021
3637,65146,"3,6-di-O-sulfo-beta-D-galactosyl-(1->4)-6-O-sulfo-N-acetyl-beta-D-glucosamine","An amino disaccharide that consists of 6-O-sulfo-N-acetyl-beta-D-glucosamine having a 3,6-di-O-sulfo-beta-D-galactosyl residue attached at position 4.","InChI=1S/C14H25NO20S3/c1-4(16)15-7-9(18)11(6(32-13(7)20)3-31-37(24,25)26)34-14-10(19)12(35-38(27,28)29)8(17)5(33-14)2-30-36(21,22)23/h5-14,17-20H,2-3H2,1H3,(H,15,16)(H,21,22,23)(H,24,25,26)(H,27,28,29)/t5-,6-,7-,8+,9-,10-,11-,12+,13-,14+/m1/s1","3,6-di-O-sulfo-beta-D-Galp-(1->4)-6-O-sulfo-beta-D-GlcpNAc",PubMed citation,19443021
3638,65147,"3,6-di-O-sulfo-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine","An amino disaccharide that consists of N-acetyl-beta-D-glucosamine having a 3,6-di-O-sulfo-beta-D-galactosyl residue attached at position 4.","InChI=1S/C14H25NO17S2/c1-4(17)15-7-9(19)11(5(2-16)29-13(7)21)31-14-10(20)12(32-34(25,26)27)8(18)6(30-14)3-28-33(22,23)24/h5-14,16,18-21H,2-3H2,1H3,(H,15,17)(H,22,23,24)(H,25,26,27)/t5-,6-,7-,8+,9-,10-,11-,12+,13-,14+/m1/s1","3,6-di-O-sulfo-beta-D-Galp-(1->4)-beta-D-GlcpNAc",PubMed citation,19443021
3639,65149,alpha-L-Fucp-(1->4)-[beta-D-Galp3S-(1->3)]-beta-D-GlcpNAc,A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an alpha-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a beta-linkage.,"InChI=1S/C20H35NO18S/c1-5-10(25)12(27)13(28)19(34-5)37-15-8(4-23)35-18(30)9(21-6(2)24)16(15)38-20-14(29)17(39-40(31,32)33)11(26)7(3-22)36-20/h5,7-20,22-23,25-30H,3-4H2,1-2H3,(H,21,24)(H,31,32,33)/t5-,7+,8+,9+,10+,11-,12+,13-,14+,15+,16+,17-,18+,19-,20-/m0/s1",alpha-L-Fuc-(1->4)-[beta-D-Gal3S-(1->3)]-beta-D-GlcNAc,Reaxys Registry Number,19308702
3640,65150,beta-D-Galp3S-(1->3-)-alpha-D-GalpNAc,An amino disaccharide composed of 3-sulfated beta-D-galactose and N-acetyl-alpha-D-galactosaminyl residues in beta-(1->3) linkage.,"InChI=1S/C14H25NO14S/c1-4(18)15-7-11(8(19)5(2-16)26-13(7)22)28-14-10(21)12(29-30(23,24)25)9(20)6(3-17)27-14/h5-14,16-17,19-22H,2-3H2,1H3,(H,15,18)(H,23,24,25)/t5-,6-,7-,8+,9+,10-,11-,12+,13+,14+/m1/s1",beta-D-Gal3S-(1->3-)-alpha-D-GalNAc,PubMed citation,19443021
3641,65151,beta-D-Galp3S-(1->3-)-beta-D-GlcpNAc,An amino disaccharide composed of 3-sulfated beta-D-galactose and N-acetyl-beta-D-glucosaminyl residues in beta-(1->3) linkage.,"InChI=1S/C14H25NO14S/c1-4(18)15-7-11(8(19)5(2-16)26-13(7)22)28-14-10(21)12(29-30(23,24)25)9(20)6(3-17)27-14/h5-14,16-17,19-22H,2-3H2,1H3,(H,15,18)(H,23,24,25)/t5-,6-,7-,8-,9+,10-,11-,12+,13-,14+/m1/s1",beta-D-Gal3S-(1->3-)-beta-D-GlcNAc,PubMed citation,19443021
3642,65152,beta-D-Galp3S-(1->4)-beta-D-Glcp6S,A glycosylglucose derivative that is beta-lactose bearing two sulfo substituents at position 3 of the galactosyl residue and position 6 of the glucose.,"InChI=1S/C12H22O17S2/c13-1-3-5(14)10(29-31(22,23)24)8(17)12(27-3)28-9-4(2-25-30(19,20)21)26-11(18)7(16)6(9)15/h3-18H,1-2H2,(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6-,7-,8-,9-,10+,11-,12+/m1/s1",beta-D-Gal3S-(1->4)-beta-D-Glc6S,PubMed citation,19443021
3643,65153,beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp6S,A trisaccharide derivative that consists of 6-sulfated D-glucose having an alpha-L-fucosyl residue attached at position 3 and a 3-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C18H32O21S2/c1-4-7(20)9(22)10(23)17(34-4)38-15-11(24)16(26)35-6(3-33-40(27,28)29)13(15)37-18-12(25)14(39-41(30,31)32)8(21)5(2-19)36-18/h4-26H,2-3H2,1H3,(H,27,28,29)(H,30,31,32)/t4-,5+,6+,7+,8-,9+,10-,11+,12+,13+,14-,15+,16?,17-,18-/m0/s1",beta-D-Gal3S-(1->4)-[alpha-L-Fuc-(1->3)]-D-Glc6S,PubMed citation,19443021
3644,65171,beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,An amino trisaccharide that consists of N-acetyl-beta-D-glucosamine having an alpha-L-fucosyl residue attached at position 3 and a 3-sulfated beta-D-galactosyl residue attached at position 4; beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end residue is beta.,"InChI=1S/C20H35NO18S/c1-5-10(25)12(27)13(28)19(34-5)38-16-9(21-6(2)24)18(30)35-8(4-23)15(16)37-20-14(29)17(39-40(31,32)33)11(26)7(3-22)36-20/h5,7-20,22-23,25-30H,3-4H2,1-2H3,(H,21,24)(H,31,32,33)/t5-,7+,8+,9+,10+,11-,12+,13-,14+,15+,16+,17-,18+,19-,20-/m0/s1",beta-D-Gal3S-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc,Reaxys Registry Number,19308701
3645,65174,beta-D-Galp3S-(1->4)-beta-D-GlcpNAc6S,An amino disaccharide that consists of 6-sulfated N-acetyl-beta-D-glucosamine having a 3-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C14H25NO17S2/c1-4(17)15-7-9(19)11(6(29-13(7)21)3-28-33(22,23)24)31-14-10(20)12(32-34(25,26)27)8(18)5(2-16)30-14/h5-14,16,18-21H,2-3H2,1H3,(H,15,17)(H,22,23,24)(H,25,26,27)/t5-,6-,7-,8+,9-,10-,11-,12+,13-,14+/m1/s1",[3OSO3]Galbeta1-4[6OSO3]GlcNAcbeta,PubMed citation,19443021
3646,65175,beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc6S,An amino trisaccharide that consists of 6-sulfated N-acetyl-D-glucosamine having an alpha-L-fucosyl residue attached at position 3 and a 3-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C20H35NO21S2/c1-5-10(24)12(26)13(27)19(37-5)41-16-9(21-6(2)23)18(29)38-8(4-36-43(30,31)32)15(16)40-20-14(28)17(42-44(33,34)35)11(25)7(3-22)39-20/h5,7-20,22,24-29H,3-4H2,1-2H3,(H,21,23)(H,30,31,32)(H,33,34,35)/t5-,7+,8+,9+,10+,11-,12+,13-,14+,15+,16+,17-,18?,19-,20-/m0/s1",[3OSO3]Galbeta1-4[Fucalpha1-3][6OSO3]GlcNAc,PubMed citation,19443021
3647,65176,beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc,An amino trisaccharide that consists of N-acetyl-D-glucosamine having an alpha-L-fucosyl residue attached at position 3 and a 3-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C20H35NO18S/c1-5-10(25)12(27)13(28)19(34-5)38-16-9(21-6(2)24)18(30)35-8(4-23)15(16)37-20-14(29)17(39-40(31,32)33)11(26)7(3-22)36-20/h5,7-20,22-23,25-30H,3-4H2,1-2H3,(H,21,24)(H,31,32,33)/t5-,7+,8+,9+,10+,11-,12+,13-,14+,15+,16+,17-,18?,19-,20-/m0/s1",beta-D-Gal3S-(1->4)-[alpha-L-Fuc-(1->3)]-D-GlcNAc,KEGG GLYCAN accession,G01078
3648,65178,beta-D-Galp3S-(1->4)-beta-D-GlcpNAc,An amino disaccharide that consists of N-acetyl-beta-D-glucosamine having a 3-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C14H25NO14S/c1-4(18)15-7-9(20)11(6(3-17)26-13(7)22)28-14-10(21)12(29-30(23,24)25)8(19)5(2-16)27-14/h5-14,16-17,19-22H,2-3H2,1H3,(H,15,18)(H,23,24,25)/t5-,6-,7-,8+,9-,10-,11-,12+,13-,14+/m1/s1",beta-D-Gal3S-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3649,65179,beta-D-Galp3S-(1->4)-beta-D-Glcp,A glycosylglucose derivative that consists of beta-D-glucose having a 3-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C12H22O14S/c13-1-3-5(15)10(26-27(20,21)22)8(18)12(24-3)25-9-4(2-14)23-11(19)7(17)6(9)16/h3-19H,1-2H2,(H,20,21,22)/t3-,4-,5+,6-,7-,8-,9-,10+,11-,12+/m1/s1",3-O-sulfo-beta-D-galactosyl-(1->4)-beta-D-glucose,Reaxys Registry Number,8365153
3650,65183,beta-D-Galp6S-(1->4)-beta-D-GlcpNAc6S,An amino disaccharide that consists of N-acetyl-6-O-sulfo-beta-D-glucosamine having a 6-O-sulfo-beta-D-galactosyl residue attached at position 4.,"InChI=1S/C14H25NO17S2/c1-4(16)15-7-9(18)12(6(30-13(7)21)3-29-34(25,26)27)32-14-11(20)10(19)8(17)5(31-14)2-28-33(22,23)24/h5-14,17-21H,2-3H2,1H3,(H,15,16)(H,22,23,24)(H,25,26,27)/t5-,6-,7-,8+,9-,10+,11-,12-,13-,14+/m1/s1",6-O-sulfo-beta-D-galactosyl-(1->4)-6-O-sulfo-N-acetyl-beta-D-glucosamine,PubMed citation,19443021
3651,65185,beta-D-Galp6S-(1->4)-beta-D-GlcpNAc,An amino disaccharide that consists of N-acetyl-beta-D-glucosamine having a 6-O-sulfo-beta-D-galactosyl residue attached at position 4.,"InChI=1S/C14H25NO14S/c1-4(17)15-7-9(19)12(5(2-16)27-13(7)22)29-14-11(21)10(20)8(18)6(28-14)3-26-30(23,24)25/h5-14,16,18-22H,2-3H2,1H3,(H,15,17)(H,23,24,25)/t5-,6-,7-,8+,9-,10+,11-,12-,13-,14+/m1/s1",beta-D-Gal6S-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3652,65186,beta-D-Galp6S-(1->4)-beta-D-Glcp,A glycosylglucose derivative that consists of beta-D-glucose having a 6-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C12H22O14S/c13-1-3-10(7(16)8(17)11(19)24-3)26-12-9(18)6(15)5(14)4(25-12)2-23-27(20,21)22/h3-19H,1-2H2,(H,20,21,22)/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1",[6OSO3]Galbeta1-4Glcbeta,PubMed citation,19443021
3653,65188,9-deoxy-9-acetamido-N-acetyl-alpha-neuraminic acid,An N-acetylneuraminic acid that is N-acetyl-alpha-neuraminic acid in which the 9-hydroxy group has been replaced by an acetamido group.,"InChI=1S/C13H22N2O9/c1-5(16)14-4-8(19)10(20)11-9(15-6(2)17)7(18)3-13(23,24-11)12(21)22/h7-11,18-20,23H,3-4H2,1-2H3,(H,14,16)(H,15,17)(H,21,22)/t7-,8+,9+,10+,11+,13+/m0/s1",9-deoxy-9-(acetylamino)-N-acetyl-alpha-neuraminic acid,PubMed citation,19443021
3654,65189,9-deoxy-9-acetamido-alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine,An amino trisaccharide consisting of a 9-deoxy-9-acetamido-N-acetyl-alpha-neuraminyl residue attached to the galactose residue of N-acetyllactosamine via an alpha-(2->6)-linkage.,"InChI=1S/C27H45N3O19/c1-8(32)28-5-12(36)17(37)23-15(29-9(2)33)11(35)4-27(49-23,26(43)44)45-7-14-18(38)20(40)21(41)25(47-14)48-22-13(6-31)46-24(42)16(19(22)39)30-10(3)34/h11-25,31,35-42H,4-7H2,1-3H3,(H,28,32)(H,29,33)(H,30,34)(H,43,44)/t11-,12+,13+,14+,15+,16+,17+,18-,19+,20-,21+,22+,23+,24+,25-,27+/m0/s1",9-NAc-alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,PubMed citation,19443021
3655,65192,alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->6)]-D-GalNAc,"A seven-membered branched galactosamine oligosaccharide that consists of a branched tetrasaccharide unit alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc, attached by a glycosidic linkage to position 6 of the GalNAc residue of the trisaccharide alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-D-GalNAc.","InChI=1S/C56H92N4O41/c1-14-31(74)37(80)38(81)50(90-14)97-45-30(60-18(5)69)49(94-25(12-65)41(45)95-51-39(82)46(34(77)23(10-63)92-51)100-55(53(85)86)6-19(70)27(57-15(2)66)43(98-55)32(75)21(72)8-61)89-13-26-36(79)42(29(48(84)91-26)59-17(4)68)96-52-40(83)47(35(78)24(11-64)93-52)101-56(54(87)88)7-20(71)28(58-16(3)67)44(99-56)33(76)22(73)9-62/h14,19-52,61-65,70-84H,6-13H2,1-5H3,(H,57,66)(H,58,67)(H,59,68)(H,60,69)(H,85,86)(H,87,88)/t14-,19-,20-,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35-,36-,37+,38-,39+,40+,41+,42+,43+,44+,45+,46-,47-,48?,49+,50-,51-,52-,55-,56-/m0/s1",alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->6)]-D-GalpNAc,PubMed citation,19443021
3656,65195,alpha-L-Fucp-(1->2)-beta-D-Galp6S-(1->4)-D-Glcp,"A linear trisaccharide derivative that consists of alpha-L-fucose, 6-sulfated beta-D-galactose and D-glucose units connected in sequence by (1->2) and (1->4) links, respectively.","InChI=1S/C18H32O18S/c1-4-7(20)9(22)13(26)17(32-4)36-15-10(23)8(21)6(3-31-37(28,29)30)34-18(15)35-14-5(2-19)33-16(27)12(25)11(14)24/h4-27H,2-3H2,1H3,(H,28,29,30)/t4-,5+,6+,7+,8-,9+,10-,11+,12+,13-,14+,15+,16?,17-,18-/m0/s1",Fucalpha1-2[6OSO3]Galbeta1-4Glc,PubMed citation,19443021
3657,65197,alpha-L-Fucp-(1->2)-beta-D-Galp6S-(1->4)-D-Glcp6S,"A linear trisaccharide derivative that consists of alpha-L-fucose, 6-sulfated beta-D-galactose and 6-sulfated D-glucose units connected in sequence by (1->2) and (1->4) links, respectively.","InChI=1S/C18H32O21S2/c1-4-7(19)9(21)13(25)17(35-4)39-15-10(22)8(20)5(2-33-40(27,28)29)37-18(15)38-14-6(3-34-41(30,31)32)36-16(26)12(24)11(14)23/h4-26H,2-3H2,1H3,(H,27,28,29)(H,30,31,32)/t4-,5+,6+,7+,8-,9+,10-,11+,12+,13-,14+,15+,16?,17-,18-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal6S-(1->4)-D-Glc6S,PubMed citation,19443021
3658,65198,alpha-L-Fucp-(1->2)-beta-D-Galp6S-(1->4)-D-GlcpNAc,"A linear amino trisaccharide that consists of alpha-L-fucose, 6-sulfated beta-D-galactose and N-acetyl-D-glucosamine units connected in sequence by (1->2) and (1->4) links, respectively.","InChI=1S/C20H35NO18S/c1-5-10(24)13(27)15(29)19(35-5)39-17-14(28)11(25)8(4-34-40(31,32)33)37-20(17)38-16-7(3-22)36-18(30)9(12(16)26)21-6(2)23/h5,7-20,22,24-30H,3-4H2,1-2H3,(H,21,23)(H,31,32,33)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18?,19-,20-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal6S-(1->4)-D-GlcNAc,PubMed citation,19443021
3659,65199,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,A thirteen-membered glucosamine oligosaccharide that consists of the linear trisaccharide beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc to which two alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc-(1->2)-alpha-D-Man units are attached at positions 3 and 6 of the mannosyl residue.,"InChI=1S/C86H144N4O62/c1-18-39(103)50(114)58(122)78(129-18)144-65-32(15-97)139-76(37(89-24(7)101)67(65)146-84-72(56(120)45(109)27(10-92)135-84)151-80-60(124)52(116)41(105)20(3)131-80)149-70-54(118)43(107)26(9-91)134-83(70)128-17-34-47(111)69(62(126)82(141-34)143-64-31(14-96)138-75(36(49(64)113)88-23(6)100)142-63-30(13-95)133-74(127)35(48(63)112)87-22(5)99)148-86-71(55(119)44(108)29(12-94)137-86)150-77-38(90-25(8)102)68(66(33(16-98)140-77)145-79-59(123)51(115)40(104)19(2)130-79)147-85-73(57(121)46(110)28(11-93)136-85)152-81-61(125)53(117)42(106)21(4)132-81/h18-21,26-86,91-98,103-127H,9-17H2,1-8H3,(H,87,99)(H,88,100)(H,89,101)(H,90,102)/t18-,19-,20-,21-,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45-,46-,47+,48+,49+,50+,51+,52+,53+,54-,55-,56-,57-,58-,59-,60-,61-,62-,63+,64+,65+,66+,67+,68+,69-,70-,71-,72+,73+,74+,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86+/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3660,65209,E-3810 free base,A naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine.,"InChI=1S/C26H25N3O4/c1-28-25(30)19-5-3-4-16-12-17(6-7-18(16)19)33-22-8-11-29-21-14-24(23(31-2)13-20(21)22)32-15-26(27)9-10-26/h3-8,11-14H,9-10,15,27H2,1-2H3,(H,28,30)",E-3810 amine,Reaxys Registry Number,18478470
3661,65211,"1,2-dilauroyl-sn-glycero-3-phosphocholine",A phosphatidylcholine 24:0 in which the acyl groups at positions 1 and 2 are specified as lauroyl (dodecanoyl).,"InChI=1S/C32H64NO8P/c1-6-8-10-12-14-16-18-20-22-24-31(34)38-28-30(29-40-42(36,37)39-27-26-33(3,4)5)41-32(35)25-23-21-19-17-15-13-11-9-7-2/h30H,6-29H2,1-5H3/t30-/m1/s1",DLPC,Reaxys Registry Number,5676925
3662,65247,"1,2-dilauroyl-sn-glycero-3-phosphoserine",A 3-sn-phosphatidyl-L-serine in which the two phosphatidyl acyl groups are specified as lauroyl (dodecanoyl).,"InChI=1S/C30H58NO10P/c1-3-5-7-9-11-13-15-17-19-21-28(32)38-23-26(24-39-42(36,37)40-25-27(31)30(34)35)41-29(33)22-20-18-16-14-12-10-8-6-4-2/h26-27H,3-25,31H2,1-2H3,(H,34,35)(H,36,37)/t26-,27+/m1/s1","1,2-didodecanoyl-sn-glycero-3-phospho-L-serine",LIPID MAPS instance accession,LMGP03010027
3663,65257,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-alpha-D-GalpNAc,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-D-GalpNAc in which the configuration at the GalNAc anomeric carbon is alpha.,"InChI=1S/C25H42N2O19/c1-7(31)26-13-9(33)3-25(24(40)41,45-20(13)15(35)10(34)4-28)46-21-17(37)12(6-30)43-23(18(21)38)44-19-14(27-8(2)32)22(39)42-11(5-29)16(19)36/h9-23,28-30,33-39H,3-6H2,1-2H3,(H,26,31)(H,27,32)(H,40,41)/t9-,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20+,21-,22-,23-,25-/m0/s1",Neu5Acalpha2-3Galbeta1-3GalNAcalpha,PubMed citation,19443021
3664,65269,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"An amino oligosaccharide that is an undecasaccharide in which two tetrasaccharide branches, each formed from fucose, galactose, N-acetylglucosamine and mannose residues linked alpha(1->2), beta(1->3) and beta(1->2) respectively, are linked alpha(1->3) and alpha(1->6) to the mannose residue of a trisaccharide chain consisting of mannose and two N-acetylglucosamine residues all linked beta(1->4) with a beta-configuration of the anomeric carbon of the N-acetylglucosamine residue at the reducing end.","InChI=1S/C74H124N4O54/c1-16-35(91)46(102)52(108)68(113-16)131-62-50(106)39(95)23(8-80)119-72(62)126-57-33(77-20(5)89)66(116-26(11-83)41(57)97)129-60-48(104)37(93)22(7-79)118-71(60)112-15-30-43(99)59(54(110)70(123-30)125-56-29(14-86)122-65(32(45(56)101)76-19(4)88)124-55-28(13-85)115-64(111)31(44(55)100)75-18(3)87)128-74-61(49(105)38(94)25(10-82)121-74)130-67-34(78-21(6)90)58(42(98)27(12-84)117-67)127-73-63(51(107)40(96)24(9-81)120-73)132-69-53(109)47(103)36(92)17(2)114-69/h16-17,22-74,79-86,91-111H,7-15H2,1-6H3,(H,75,87)(H,76,88)(H,77,89)(H,78,90)/t16-,17-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39-,40-,41+,42+,43+,44+,45+,46+,47+,48-,49-,50-,51-,52-,53-,54-,55+,56+,57+,58+,59-,60-,61-,62+,63+,64+,65-,66-,67-,68-,69-,70-,71-,72-,73-,74+/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3665,65277,dihydroascorbigen 5'-O-beta-D-glucoside,A dihydroascorbigen hexoside in which the hexoside component is a beta-D-glucosyl residue attached at position 5 via a glycosidic bond.,"InChI=1S/C21H27NO11/c23-7-12-14(25)15(26)16(27)19(31-12)32-13(8-24)17-18(28)21(30,20(29)33-17)5-9-6-22-11-4-2-1-3-10(9)11/h1-4,6,12-19,22-28,30H,5,7-8H2/t12-,13+,14-,15+,16-,17-,18-,19+,21+/m1/s1",5'-O-beta-D-glucosyl dihydroascorbigen,Reaxys Registry Number,20690741
3666,65307,corticotropin-releasing hormone (ovine),"A corticotropin-releasing hormone from sheep composed of Ser, Gln, Glu, Pro, Pro, Ile, Ser, Leu, Asp, Leu, Val, Phe, His, Leu, Leu, Arg, Glu, Val, Leu, Glu, Met, Thr, Lys, Ala, Asp, Gln, Leu, Ala, Gln, Gln, Ala, His, Ser, Asn, Arg, Lys, Leu, Leu, Asp, Ile and Ala-NH2 residues joined in sequence.","InChI=1S/C206H341N59O62S/c1-31-106(23)161(200(323)226-108(25)164(215)287)261-194(317)143(88-158(285)286)254-185(308)133(78-100(11)12)247-183(306)131(76-98(7)8)245-173(296)118(47-37-39-68-208)232-171(294)119(48-40-69-222-205(216)217)234-190(313)140(85-152(214)274)252-195(318)144(92-267)257-189(312)138(83-114-89-220-94-224-114)242-166(289)110(27)228-170(293)121(52-59-148(210)270)235-174(297)122(53-60-149(211)271)230-165(288)109(26)229-180(303)129(74-96(3)4)244-177(300)124(55-62-151(213)273)237-191(314)141(86-156(281)282)243-167(290)111(28)227-169(292)117(46-36-38-67-207)240-202(325)163(112(29)269)263-179(302)127(66-73-328-30)239-175(298)125(56-63-153(275)276)238-182(305)135(80-102(15)16)255-198(321)159(104(19)20)259-178(301)126(57-64-154(277)278)236-172(295)120(49-41-70-223-206(218)219)233-181(304)130(75-97(5)6)246-184(307)132(77-99(9)10)248-188(311)139(84-115-90-221-95-225-115)251-187(310)137(82-113-44-34-33-35-45-113)256-199(322)160(105(21)22)260-193(316)136(81-103(17)18)249-192(315)142(87-157(283)284)253-186(309)134(79-101(13)14)250-196(319)145(93-268)258-201(324)162(107(24)32-2)262-197(320)146-50-42-71-264(146)204(327)147-51-43-72-265(147)203(326)128(58-65-155(279)280)241-176(299)123(54-61-150(212)272)231-168(291)116(209)91-266/h33-35,44-45,89-90,94-112,116-147,159-163,266-269H,31-32,36-43,46-88,91-93,207-209H2,1-30H3,(H2,210,270)(H2,211,271)(H2,212,272)(H2,213,273)(H2,214,274)(H2,215,287)(H,220,224)(H,221,225)(H,226,323)(H,227,292)(H,228,293)(H,229,303)(H,230,288)(H,231,291)(H,232,294)(H,233,304)(H,234,313)(H,235,297)(H,236,295)(H,237,314)(H,238,305)(H,239,298)(H,240,325)(H,241,299)(H,242,289)(H,243,290)(H,244,300)(H,245,296)(H,246,307)(H,247,306)(H,248,311)(H,249,315)(H,250,319)(H,251,310)(H,252,318)(H,253,309)(H,254,308)(H,255,321)(H,256,322)(H,257,312)(H,258,324)(H,259,301)(H,260,316)(H,261,317)(H,262,320)(H,263,302)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H4,216,217,222)(H4,218,219,223)/t106-,107-,108-,109-,110-,111-,112+,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,159-,160-,161-,162-,163-/m0/s1",sheep corticotropin-releasing hormone,CAS Registry Number,79804-71-0
3667,65312,corticotropin-releasing hormone (human),"A corticotropin-releasing hormone from human/rat composed of Ser, Glu, Glu, Pro, Pro, Ile, Ser, Leu, Asp, Leu, Val, Phe, His, Leu, Leu, Arg, Glu, Val, Leu, Glu, Met, Ala, Arg, Ala, Glu, Gln, Leu, Ala, Gln, Gln, Ala, His, Ser, Asn, Arg, Lys, Leu, Met, Glu, Ile and Ile-NH2 residues joined in sequence.","InChI=1S/C209H346N60O62S2/c1-31-108(22)163(166(216)291)265-204(329)165(110(24)33-3)266-185(310)130(59-68-158(285)286)244-183(308)132(71-79-333-30)247-188(313)135(81-100(6)7)251-177(302)119(46-37-38-72-210)238-175(300)121(48-40-74-226-208(219)220)240-195(320)144(90-153(215)276)257-198(323)146(95-271)261-194(319)142(88-116-92-223-97-228-116)249-170(295)114(28)231-173(298)123(52-61-150(212)273)241-178(303)124(53-62-151(213)274)235-169(294)113(27)233-186(311)134(80-99(4)5)250-182(307)125(54-63-152(214)275)242-179(304)126(55-64-154(277)278)236-168(293)112(26)230-172(297)120(47-39-73-225-207(217)218)234-167(292)111(25)232-174(299)131(70-78-332-29)246-180(305)128(57-66-156(281)282)245-189(314)139(85-104(14)15)259-201(326)161(106(18)19)263-184(309)129(58-67-157(283)284)243-176(301)122(49-41-75-227-209(221)222)239-187(312)136(82-101(8)9)252-190(315)137(83-102(10)11)253-193(318)143(89-117-93-224-98-229-117)256-192(317)141(87-115-44-35-34-36-45-115)260-202(327)162(107(20)21)264-197(322)140(86-105(16)17)254-196(321)145(91-160(289)290)258-191(316)138(84-103(12)13)255-199(324)147(96-272)262-203(328)164(109(23)32-2)267-200(325)148-50-42-76-268(148)206(331)149-51-43-77-269(149)205(330)133(60-69-159(287)288)248-181(306)127(56-65-155(279)280)237-171(296)118(211)94-270/h34-36,44-45,92-93,97-114,118-149,161-165,270-272H,31-33,37-43,46-91,94-96,210-211H2,1-30H3,(H2,212,273)(H2,213,274)(H2,214,275)(H2,215,276)(H2,216,291)(H,223,228)(H,224,229)(H,230,297)(H,231,298)(H,232,299)(H,233,311)(H,234,292)(H,235,294)(H,236,293)(H,237,296)(H,238,300)(H,239,312)(H,240,320)(H,241,303)(H,242,304)(H,243,301)(H,244,308)(H,245,314)(H,246,305)(H,247,313)(H,248,306)(H,249,295)(H,250,307)(H,251,302)(H,252,315)(H,253,318)(H,254,321)(H,255,324)(H,256,317)(H,257,323)(H,258,316)(H,259,326)(H,260,327)(H,261,319)(H,262,328)(H,263,309)(H,264,322)(H,265,329)(H,266,310)(H,267,325)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H4,217,218,225)(H4,219,220,226)(H4,221,222,227)/t108-,109-,110-,111-,112-,113-,114-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,161-,162-,163-,164-,165-/m0/s1",corticotropin-releasing factor (human),KEGG COMPOUND accession,C16079
3668,66867,"trans,polycis-decaprenyl phosphate","A polyprenol phosphate having ten prenyl units in the chain (the 2Z,6Z,10Z,14Z,18Z,22Z,26Z,30Z,34E-isomer)","InChI=1S/C50H83O4P/c1-41(2)21-12-22-42(3)23-13-24-43(4)25-14-26-44(5)27-15-28-45(6)29-16-30-46(7)31-17-32-47(8)33-18-34-48(9)35-19-36-49(10)37-20-38-50(11)39-40-54-55(51,52)53/h21,23,25,27,29,31,33,35,37,39H,12-20,22,24,26,28,30,32,34,36,38,40H2,1-11H3,(H2,51,52,53)/b42-23+,43-25-,44-27-,45-29-,46-31-,47-33-,48-35-,49-37-,50-39-","trans,octa-cis-decaprenyl phosphate",KEGG COMPOUND accession,C02970
3669,66868,carboxyspermidine,"The L-alpha-amino acid that is spermidine (1,5,10-triazadecane) carboxylated with S-configuration at the 2-position.","InChI=1S/C8H19N3O2/c9-4-2-6-11-5-1-3-7(10)8(12)13/h7,11H,1-6,9-10H2,(H,12,13)/t7-/m0/s1",(2S)-2-azanyl-5-(3-azanylpropylamino)pentanoic acid,PubMed citation,19196710
3670,66870,sodium dithionite,An inorganic sodium salt that is the disodium salt of dithionous acid.,"InChI=1S/2Na.H2O4S2/c;;1-5(2)6(3)4/h;;(H,1,2)(H,3,4)/q2*+1;/p-2",sodium hydrosulfite,CAS Registry Number,7775-14-6
3671,66874,carnosinate,"An N-acyl-L-alpha-amino acid anion that is the conjugate base of carnosine, obtained by deprotonation of the carboxy group.","InChI=1S/C9H14N4O3/c10-2-1-8(14)13-7(9(15)16)3-6-4-11-5-12-6/h4-5,7H,1-3,10H2,(H,11,12)(H,13,14)(H,15,16)/p-1/t7-/m0/s1",carnosinate(1-),Reaxys Registry Number,6337985
3672,66875,alpha-D-GalpN-(1->3)-[alpha-L-Fucp-(1->2)]-D-Galp,A branched amino trisaccharide consisting of D-galactose having an alpha-L-fucosyl residue at the 2-position and an alpha-D-galactosaminyl residue at the 3-position.,"InChI=1S/C18H33NO14/c1-4-8(22)12(26)13(27)18(29-4)33-15-14(10(24)6(3-21)30-16(15)28)32-17-7(19)11(25)9(23)5(2-20)31-17/h4-18,20-28H,2-3,19H2,1H3/t4-,5+,6+,7+,8+,9-,10-,11+,12+,13-,14-,15+,16?,17+,18-/m0/s1",GalNalpha1->3(Fucalpha1->2)Gal,PubMed citation,21981750
3673,66879,4-oxo-4-(pyridin-3-yl)butanal,A member of the class of butanals that is succinic semialdehyde in which the hydroxy group of the carboxylic acid function is replaced by a pyridin-3-yl group.,"InChI=1S/C9H9NO2/c11-6-2-4-9(12)8-3-1-5-10-7-8/h1,3,5-7H,2,4H2",3-succinoylsemialdehyde-pyridine,Reaxys Registry Number,907964
3674,66929,"trans,octacis-decaprenylphospho-beta-D-ribofuranose","A polyprenyl glycosyl phosphate consisting of beta-D-ribose attached at the 1-position to trans,octacis-decaprenyl phosphate.","InChI=1S/C55H91O8P/c1-42(2)21-12-22-43(3)23-13-24-44(4)25-14-26-45(5)27-15-28-46(6)29-16-30-47(7)31-17-32-48(8)33-18-34-49(9)35-19-36-50(10)37-20-38-51(11)39-40-61-64(59,60)63-55-54(58)53(57)52(41-56)62-55/h21,23,25,27,29,31,33,35,37,39,52-58H,12-20,22,24,26,28,30,32,34,36,38,40-41H2,1-11H3,(H,59,60)/b43-23+,44-25-,45-27-,46-29-,47-31-,48-33-,49-35-,50-37-,51-39-/t52-,53-,54-,55+/m1/s1",beta-D-ribofuranosyl-1-monophosphoryldecaprenol,Reaxys Registry Number,10640701
3675,66958,4-hydroxy-6-pentylpyran-2-one,A pyranone that is 2H-pyran-2-one in which the hydrogens at positions 4 and 6 are substituted by hydroxy and pentyl groups respectively.,"InChI=1S/C10H14O3/c1-2-3-4-5-9-6-8(11)7-10(12)13-9/h6-7,11H,2-5H2,1H3",PDAL,Reaxys Registry Number,4402254
3676,66959,4-hydroxy-6-(2-oxoheptyl)pyran-2-one,A pyranone that is 2H-pyran-2-one in which the hydrogens at positions 4 and 6 are substituted by hydroxy and 2-oxoheptyl groups respectively.,"InChI=1S/C12H16O4/c1-2-3-4-5-9(13)6-11-7-10(14)8-12(15)16-11/h7-8,14H,2-6H2,1H3",HTAL,Reaxys Registry Number,9915653
3677,66963,Delta(9)-tetrahydrocannabinolate,"A hydroxy monocarboxylic acid anion that is the conjugate base of Delta(9)-tetrahydrocannabinolic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C22H30O4/c1-5-6-7-8-14-12-17-19(20(23)18(14)21(24)25)15-11-13(2)9-10-16(15)22(3,4)26-17/h11-12,15-16,23H,5-10H2,1-4H3,(H,24,25)/p-1/t15-,16-/m1/s1",Delta(1)-tetrahydrocannabinolate,PubMed citation,16511162
3678,66983,N-(2-hydroxydocosanoyl)eicosasphinganine,A ceramide that is the N-2-hydroxydocosanoyl derivative of eicosasphinganine.,"InChI=1S/C42H85NO4/c1-3-5-7-9-11-13-15-17-19-20-21-23-25-27-29-31-33-35-37-41(46)42(47)43-39(38-44)40(45)36-34-32-30-28-26-24-22-18-16-14-12-10-8-6-4-2/h39-41,44-46H,3-38H2,1-2H3,(H,43,47)/t39-,40+,41?/m0/s1",DHC-B' 20:0/22:0,LIPID MAPS instance accession,LMSP02020038
3679,66984,N-(docosanoyl)eicosasphinganine,A ceramide that is the N-docosanoyl derivative of eicosasphinganine.,"InChI=1S/C42H85NO3/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-42(46)43-40(39-44)41(45)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h40-41,44-45H,3-39H2,1-2H3,(H,43,46)/t40-,41+/m0/s1",Cer(d20:0/22:0),LIPID MAPS instance accession,LMSP02020026
3680,66985,N-(docosanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-docosanoyl derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C42H85NO4/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-25-27-29-31-33-35-37-41(46)43-39(38-44)42(47)40(45)36-34-32-30-28-26-24-18-16-14-12-10-8-6-4-2/h39-40,42,44-45,47H,3-38H2,1-2H3,(H,43,46)/t39-,40+,42-/m0/s1",PHC-B 20:0/22:0,Reaxys Registry Number,7318771
3681,66986,N-(2-hydroxydocosanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-(2-hydroxydocosanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C42H85NO5/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-40(46)42(48)43-38(37-44)41(47)39(45)35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h38-41,44-47H,3-37H2,1-2H3,(H,43,48)/t38-,39+,40?,41-/m0/s1",PHC-C 20:0/22:0,LIPID MAPS instance accession,LMSP02030022
3682,66988,N-(tetracosanoyl)eicosasphinganine,A ceramide that is the N-tetracosanoyl derivative of eicosasphinganine.,"InChI=1S/C44H89NO3/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-26-28-30-32-34-36-38-40-44(48)45-42(41-46)43(47)39-37-35-33-31-29-27-25-18-16-14-12-10-8-6-4-2/h42-43,46-47H,3-41H2,1-2H3,(H,45,48)/t42-,43+/m0/s1",DHC-A 20:0/24:0,LIPID MAPS instance accession,LMSP02020027
3683,66989,N-(2-hydroxytetracosanoyl)eicosasphinganine,A ceramide that is the N-(2-hydroxytetracosanoyl) derivative of eicosasphinganine.,"InChI=1S/C44H89NO4/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-25-27-29-31-33-35-37-39-43(48)44(49)45-41(40-46)42(47)38-36-34-32-30-28-26-24-18-16-14-12-10-8-6-4-2/h41-43,46-48H,3-40H2,1-2H3,(H,45,49)/t41-,42+,43?/m0/s1",DHC-B' 20:0/24:0,LIPID MAPS instance accession,LMSP02020039
3684,66990,N-(tetracosanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-tetracosanoyl derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C44H89NO4/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-27-29-31-33-35-37-39-43(48)45-41(40-46)44(49)42(47)38-36-34-32-30-28-26-18-16-14-12-10-8-6-4-2/h41-42,44,46-47,49H,3-40H2,1-2H3,(H,45,48)/t41-,42+,44-/m0/s1",PHC-B 20:0/24:0,LIPID MAPS instance accession,LMSP02030013
3685,66992,N-(2-hydroxytetracosanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-(2-hydroxytetracosanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C44H89NO5/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-26-28-30-32-34-36-38-42(48)44(50)45-40(39-46)43(49)41(47)37-35-33-31-29-27-25-18-16-14-12-10-8-6-4-2/h40-43,46-49H,3-39H2,1-2H3,(H,45,50)/t40-,41+,42?,43-/m0/s1",PHC-C 20:0/24:0,LIPID MAPS instance accession,LMSP02030023
3686,66995,N-(2-hydroxyhexacosanoyl)eicosasphinganine,A ceramide that is the N-(2-hydroxyhexacosanoyl) derivative of eicosasphinganine.,"InChI=1S/C46H93NO4/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-27-29-31-33-35-37-39-41-45(50)46(51)47-43(42-48)44(49)40-38-36-34-32-30-28-26-18-16-14-12-10-8-6-4-2/h43-45,48-50H,3-42H2,1-2H3,(H,47,51)/t43-,44+,45?/m0/s1",DHC-B' 20:0/26:0,LIPID MAPS instance accession,LMSP02020040
3687,66996,N-(2-hydroxyhexacosanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-(2-hydroxyhexacosanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C46H93NO5/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-44(50)46(52)47-42(41-48)45(51)43(49)39-37-35-33-31-29-27-18-16-14-12-10-8-6-4-2/h42-45,48-51H,3-41H2,1-2H3,(H,47,52)/t42-,43+,44?,45-/m0/s1",PHC-C 20:0/26:0,LIPID MAPS instance accession,LMSP02030024
3688,66997,N-(eicosanoyl)eicosasphinganine,A ceramide that is the N-eicosanoyl derivative of eicosasphinganine.,"InChI=1S/C40H81NO3/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-40(44)41-38(37-42)39(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h38-39,42-43H,3-37H2,1-2H3,(H,41,44)/t38-,39+/m0/s1",DHC-A 20:0/20:0,LIPID MAPS instance accession,LMSP02020025
3689,66999,N-(2-hydroxyeicosanoyl)eicosasphinganine,A ceramide that is the N-(2-hydroxyeicosanoyl) derivative of eicosasphinganine.,"InChI=1S/C40H81NO4/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-39(44)40(45)41-37(36-42)38(43)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h37-39,42-44H,3-36H2,1-2H3,(H,41,45)/t37-,38+,39?/m0/s1",DHC-B' 20:0/20:0,LIPID MAPS instance accession,LMSP02020037
3690,67000,N-(eicosanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-eicosanoyl derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C40H81NO4/c1-3-5-7-9-11-13-15-17-19-20-21-23-25-27-29-31-33-35-39(44)41-37(36-42)40(45)38(43)34-32-30-28-26-24-22-18-16-14-12-10-8-6-4-2/h37-38,40,42-43,45H,3-36H2,1-2H3,(H,41,44)/t37-,38+,40-/m0/s1",PHC-B 20:0/20:0,LIPID MAPS instance accession,LMSP02030011
3691,67002,beta-D-Galp-(1->3)-[beta-Neup5Ac-(2->6)]-alpha-D-GalpNAc,A branched amino trisaccharide that consists of N-acetyl-alpha-D-galactosamine having a beta-D-galactosyl residue attached at the 3-position and a beta-N-acetylneuraminosyl residue attached at the 6-position.,"InChI=1S/C25H42N2O19/c1-7(30)26-13-9(32)3-25(24(40)41,46-21(13)15(34)10(33)4-28)42-6-12-17(36)20(14(22(39)43-12)27-8(2)31)45-23-19(38)18(37)16(35)11(5-29)44-23/h9-23,28-29,32-39H,3-6H2,1-2H3,(H,26,30)(H,27,31)(H,40,41)/t9-,10+,11+,12+,13+,14+,15+,16-,17-,18-,19+,20+,21+,22-,23-,25-/m0/s1",beta-D-galactosyl-(1->3)-[beta-N-acetylneuraminosyl-(2->6)]-N-acetyl-alpha-D-galactosamine,PubMed citation,19695255
3692,67003,N-(2-hydroxyeicosanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-(2-hydroxyeicosanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C40H81NO5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-38(44)40(46)41-36(35-42)39(45)37(43)33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h36-39,42-45H,3-35H2,1-2H3,(H,41,46)/t36-,37+,38?,39-/m0/s1",PHC-C 20:0/20:0,LIPID MAPS instance accession,LMSP02030021
3693,67004,N-(octadecanoyl)eicosasphinganine,A ceramide that is the N-stearoyl (octadecanoyl) derivative of eicosasphinganine.,"InChI=1S/C38H77NO3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-37(41)36(35-40)39-38(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h36-37,40-41H,3-35H2,1-2H3,(H,39,42)/t36-,37+/m0/s1",DHC-A 20:0/18:0,LIPID MAPS instance accession,LMSP02020024
3694,67005,N-(2-hydroxyoctadecanoyl)eicosasphinganine,A ceramide that is the N-(2-hydroxyoctadecanoyl) derivative of eicosasphinganine.,"InChI=1S/C38H77NO4/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-36(41)35(34-40)39-38(43)37(42)33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h35-37,40-42H,3-34H2,1-2H3,(H,39,43)/t35-,36+,37?/m0/s1",DHC-B' 20:0/18:0,LIPID MAPS instance accession,LMSP02020036
3695,67006,N-(octadecanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-stearoyl (octadecanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C38H77NO4/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-37(42)39-35(34-40)38(43)36(41)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h35-36,38,40-41,43H,3-34H2,1-2H3,(H,39,42)/t35-,36+,38-/m0/s1",PHC-B 20:0/18:0,LIPID MAPS instance accession,LMSP02030010
3696,67007,N-(2-hydroxyoctadecanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-(2-hydroxyoctadecanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C38H77NO5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-35(41)37(43)34(33-40)39-38(44)36(42)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h34-37,40-43H,3-33H2,1-2H3,(H,39,44)/t34-,35+,36?,37-/m0/s1",PHC-C 20:0/18:0,LIPID MAPS instance accession,LMSP02030020
3697,67017,N-(hexadecanoyl)eicosasphinganine,A ceramide that is the N-palmitoyl (hexadecanoyl) derivative of eicosasphinganine.,"InChI=1S/C36H73NO3/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-35(39)34(33-38)37-36(40)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h34-35,38-39H,3-33H2,1-2H3,(H,37,40)/t34-,35+/m0/s1",DHC-A 20:0/16:0,LIPID MAPS instance accession,LMSP02020023
3698,67018,N-(2-hydroxyhexadecanoyl)eicosasphinganine,A ceramide that is the N-(2-hydroxyhexadecanoyl) derivative of eicosasphinganine.,"InChI=1S/C36H73NO4/c1-3-5-7-9-11-13-15-17-18-19-21-22-24-26-28-30-34(39)33(32-38)37-36(41)35(40)31-29-27-25-23-20-16-14-12-10-8-6-4-2/h33-35,38-40H,3-32H2,1-2H3,(H,37,41)/t33-,34+,35?/m0/s1",DHC-B' 20:0/16:0,LIPID MAPS instance accession,LMSP02020035
3699,67019,N-(hexadecanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-palmitoyl (hexadecanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C36H73NO4/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-34(39)36(41)33(32-38)37-35(40)31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h33-34,36,38-39,41H,3-32H2,1-2H3,(H,37,40)/t33-,34+,36-/m0/s1",PHC-B 20:0/16:0,LIPID MAPS instance accession,LMSP02030009
3700,67020,N-(2-hydroxyhexadecanoyl)-4-hydroxyeicosasphinganine,A ceramide that is the N-(2-hydroxyhexadecanoyl) derivative of 4-hydroxyeicosasphinganine.,"InChI=1S/C36H73NO5/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-33(39)35(41)32(31-38)37-36(42)34(40)30-28-26-24-22-19-16-14-12-10-8-6-4-2/h32-35,38-41H,3-31H2,1-2H3,(H,37,42)/t32-,33+,34?,35-/m0/s1",PHC-C 20:0/16:0,LIPID MAPS instance accession,LMSP02030019
3701,67021,N-docosanoylsphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as docosanoyl (behenoyl).,"InChI=1S/C40H81NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-40(44)41-38(37-42)39(43)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h38-39,42-43H,3-37H2,1-2H3,(H,41,44)/t38-,39+/m0/s1",DHC-A 18:0/22:0,LIPID MAPS instance accession,LMSP02020010
3702,67023,N-(2-hydroxydocosanoyl)sphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as 2-hydroxydocosanoyl.,"InChI=1S/C40H81NO4/c1-3-5-7-9-11-13-15-17-18-19-20-21-23-25-27-29-31-33-35-39(44)40(45)41-37(36-42)38(43)34-32-30-28-26-24-22-16-14-12-10-8-6-4-2/h37-39,42-44H,3-36H2,1-2H3,(H,41,45)/t37-,38+,39?/m0/s1",DHC-B' 18:0/22:0,LIPID MAPS instance accession,LMSP02020032
3703,67024,N-docosanoyl-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as docosanoyl (behenoyl).,"InChI=1S/C40H81NO4/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-39(44)41-37(36-42)40(45)38(43)34-32-30-28-26-24-16-14-12-10-8-6-4-2/h37-38,40,42-43,45H,3-36H2,1-2H3,(H,41,44)/t37-,38+,40-/m0/s1",PHC-B 18:0/22:0,Reaxys Registry Number,6828511
3704,67025,N-(2-hydroxydocosanoyl)-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as 2-hydroxydocosanoyl.,"InChI=1S/C40H81NO5/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-38(44)40(46)41-36(35-42)39(45)37(43)33-31-29-27-25-23-16-14-12-10-8-6-4-2/h36-39,42-45H,3-35H2,1-2H3,(H,41,46)/t36-,37+,38?,39-/m0/s1",PHC-C 18:0/22:0,LIPID MAPS instance accession,LMSP02030018
3705,67027,N-eicosanoylsphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as eicosanoyl,"InChI=1S/C38H77NO3/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-38(42)39-36(35-40)37(41)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h36-37,40-41H,3-35H2,1-2H3,(H,39,42)/t36-,37+/m0/s1",DHC-A 18:0/20:0,LIPID MAPS instance accession,LMSP02020009
3706,67028,N-(2-hydroxyeicosanoyl)sphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as 2-hydroxyeicosanoyl.,"InChI=1S/C38H77NO4/c1-3-5-7-9-11-13-15-17-18-19-21-23-25-27-29-31-33-37(42)38(43)39-35(34-40)36(41)32-30-28-26-24-22-20-16-14-12-10-8-6-4-2/h35-37,40-42H,3-34H2,1-2H3,(H,39,43)/t35-,36+,37?/m0/s1",DHC-B' 18:0/20:0,LIPID MAPS instance accession,LMSP02020031
3707,67029,N-eicosanoyl-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as eicosanoyl.,"InChI=1S/C38H77NO4/c1-3-5-7-9-11-13-15-17-18-19-20-21-23-25-27-29-31-33-37(42)39-35(34-40)38(43)36(41)32-30-28-26-24-22-16-14-12-10-8-6-4-2/h35-36,38,40-41,43H,3-34H2,1-2H3,(H,39,42)/t35-,36+,38-/m0/s1",PHC-B 18:0/20:0,LIPID MAPS instance accession,LMSP02030007
3708,67030,N-(2-hydroxyeicosanoyl)-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as 2-hydroxyeicosanoyl.,"InChI=1S/C38H77NO5/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-36(42)38(44)39-34(33-40)37(43)35(41)31-29-27-25-23-21-16-14-12-10-8-6-4-2/h34-37,40-43H,3-33H2,1-2H3,(H,39,44)/t34-,35+,36?,37-/m0/s1",PHC-C 18:0/20:0,LIPID MAPS instance accession,LMSP02030017
3709,67033,N-octodecanoylsphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as octadecanoyl (stearoyl).,"InChI=1S/C36H73NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h34-35,38-39H,3-33H2,1-2H3,(H,37,40)/t34-,35+/m0/s1",DHC-A 18:0/18:0,LIPID MAPS instance accession,LMSP02020008
3710,67034,N-(2-hydroxyoctadecanoyl)sphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as 2-hydroxyoctadecanoyl.,"InChI=1S/C36H73NO4/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-35(40)36(41)37-33(32-38)34(39)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h33-35,38-40H,3-32H2,1-2H3,(H,37,41)/t33-,34+,35?/m0/s1",DHC-B' 18:0/18:0,LIPID MAPS instance accession,LMSP02020030
3711,67035,N-octadecanoyl-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as octadecanoyl (stearoyl).,"InChI=1S/C36H73NO4/c1-3-5-7-9-11-13-15-17-18-19-21-23-25-27-29-31-35(40)37-33(32-38)36(41)34(39)30-28-26-24-22-20-16-14-12-10-8-6-4-2/h33-34,36,38-39,41H,3-32H2,1-2H3,(H,37,40)/t33-,34+,36-/m0/s1",PHC-B 18:0/18:0,LIPID MAPS instance accession,LMSP02030006
3712,67041,N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as 2-hydroxyoctadecanoyl,"InChI=1S/C36H73NO5/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-34(40)36(42)37-32(31-38)35(41)33(39)29-27-25-23-21-19-16-14-12-10-8-6-4-2/h32-35,38-41H,3-31H2,1-2H3,(H,37,42)/t32-,33+,34?,35-/m0/s1",PHC-C 18:0/18:0,LIPID MAPS instance accession,LMSP02030016
3713,67042,N-hexadecanoylsphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as hexadecanoyl (palmitoyl).,"InChI=1S/C34H69NO3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-33(37)32(31-36)35-34(38)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h32-33,36-37H,3-31H2,1-2H3,(H,35,38)/t32-,33+/m0/s1",DHC-A 18:0/16:0,LIPID MAPS instance accession,LMSP02020001
3714,67043,N-(2-hydroxyhexadecanoyl)sphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as 2-hydroxyhexadecanoyl,"InChI=1S/C34H69NO4/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-32(37)31(30-36)35-34(39)33(38)29-27-25-23-21-18-16-14-12-10-8-6-4-2/h31-33,36-38H,3-30H2,1-2H3,(H,35,39)/t31-,32+,33?/m0/s1",DHC-B' 18:0/16:0,Reaxys Registry Number,13494592
3715,67044,N-(2-hydroxyhexadecanoyl)-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as 2-hydroxyhexadecanoyl,"InChI=1S/C34H69NO5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-31(37)33(39)30(29-36)35-34(40)32(38)28-26-24-22-20-18-16-14-12-10-8-6-4-2/h30-33,36-39H,3-29H2,1-2H3,(H,35,40)/t30-,31+,32?,33-/m0/s1",PHC-C 18:0/16:0,MetaCyc accession,CPD-8452
3716,67045,N-tetradecanoylsphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as tetradecanoyl (myristoyl).,"InChI=1S/C32H65NO3/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-31(35)30(29-34)33-32(36)28-26-24-22-20-17-14-12-10-8-6-4-2/h30-31,34-35H,3-29H2,1-2H3,(H,33,36)/t30-,31+/m0/s1",DHC-A 18:0/14:0,LIPID MAPS instance accession,LMSP02020016
3717,67047,N-tetradecanoyl-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as tetradecanoyl (myristoyl).,"InChI=1S/C32H65NO4/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-30(35)32(37)29(28-34)33-31(36)27-25-23-21-19-16-14-12-10-8-6-4-2/h29-30,32,34-35,37H,3-28H2,1-2H3,(H,33,36)/t29-,30+,32-/m0/s1",PHC-B 18:0/14:0,Reaxys Registry Number,10777630
3718,67048,N-(2-hydroxytetradecanoyl)-4-hydroxysphinganine,A phytoceramide in which the ceramide N-acyl group is specified as 2-hydroxytetradecanoyl.,"InChI=1S/C32H65NO5/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-29(35)31(37)28(27-34)33-32(38)30(36)26-24-22-20-17-14-12-10-8-6-4-2/h28-31,34-37H,3-27H2,1-2H3,(H,33,38)/t28-,29+,30?,31-/m0/s1",PHC-C 18:0/14:0,MetaCyc accession,CPD-8450
3719,67094,alpha-L-Fucp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc,A branched amino tetrasaccharide that consists of the linear trisaccharide alpha-L-fucosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-D-glucosamine in which an alpha-L-fucosyl residue is attached at position 3 of the glucoamine.,"InChI=1S/C28H48N2O19/c1-7-15(35)18(38)20(40)27(43-7)48-23-14(30-10(4)34)26(46-11(5-31)17(23)37)47-22-12(6-32)45-25(42)13(29-9(3)33)24(22)49-28-21(41)19(39)16(36)8(2)44-28/h7-8,11-28,31-32,35-42H,5-6H2,1-4H3,(H,29,33)(H,30,34)/t7-,8-,11+,12+,13+,14+,15+,16+,17-,18+,19+,20-,21-,22+,23+,24+,25?,26-,27-,28-/m0/s1",alpha-L-fucosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-D-glucosamine,PubMed citation,22241826
3720,67098,tris phosphate,A phosphate salt resulting from the reaction of equimolar amounts of tris and phosphoric acid.,"InChI=1S/C4H11NO3.H3O4P/c5-4(1-6,2-7)3-8;1-5(2,3)4/h6-8H,1-3,5H2;(H3,1,2,3,4)",mono(tris[hydroxymethyl]aminomethane) phosphate,CAS Registry Number,6992-39-8
3721,67099,potassium 2-(N-morpholino)ethanesulfonate,The organic potassium salt that is the potassium salt of 2-(N-morpholino)ethanesulfonic acid.,"InChI=1S/C6H13NO4S.K/c8-12(9,10)6-3-7-1-4-11-5-2-7;/h1-6H2,(H,8,9,10);/q;+1/p-1",2-(N-morpholino)ethanesulfonic acid potassium salt,Reaxys Registry Number,16743380
3722,67100,tris maleate,A maleate salt resulting from the reaction of tris and maleic acid in the molar ratio tris:maleic acid = 2:1.,"InChI=1S/2C4H11NO3.C4H4O4/c2*5-4(1-6,2-7)3-8;5-3(6)1-2-4(7)8/h2*6-8H,1-3,5H2;1-2H,(H,5,6)(H,7,8)/b;;2-1-",tris(hydroxymethyl)aminomethane maleate salt,CAS Registry Number,72200-76-1
3723,67102,alpha-L-Fucp-(1->3)-beta-D-GalpNAc-(1->4)-D-GlcpNAc,"A linear amino trisaccharide consisting of alpha-L-fucose,N-acetyl-beta-D-galactosamine and N-acetyl-D-glucosamine residues joined in sequence by (1->3)- and (1->4)-linkages respectively.","InChI=1S/C22H38N2O15/c1-6-13(29)16(32)17(33)22(35-6)39-19-12(24-8(3)28)21(37-9(4-25)14(19)30)38-18-10(5-26)36-20(34)11(15(18)31)23-7(2)27/h6,9-22,25-26,29-34H,4-5H2,1-3H3,(H,23,27)(H,24,28)/t6-,9+,10+,11+,12+,13+,14-,15+,16+,17-,18+,19+,20?,21-,22-/m0/s1",alpha-L-Fuc-(1->3)-beta-D-GalNAc-(1->4)-D-GlcNAc,PubMed citation,22241826
3724,67103,"(2E,4Z)-4-hydroxy-6-oxohexa-2,4-dienoic acid","A muconic semialdehyde that is hexa-2,4-dienoic acid substituted at positions 4 and 6 by hydroxy and oxo groups respectively (the 2E,4Z-isomer).","InChI=1S/C6H6O4/c7-4-3-5(8)1-2-6(9)10/h1-4,8H,(H,9,10)/b2-1+,5-3-","(2E,4Z)-4-hydroxymuconic semialdehyde",MetaCyc accession,4-HYDROXYMUCONIC-SEMIALDEHYDE
3725,67108,1-deoxymethylsphinganine(1+),A cationic sphingoid obtained by the protonation of the amino group of 1-deoxymethylsphinganine.,"InChI=1S/C17H37NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(19)16-18/h17,19H,2-16,18H2,1H3/p+1/t17-/m1/s1",m17:0,PubMed citation,21942574
3726,67109,1-deoxysphinganine(1+),A cationic sphingoid obtained by protonation of the amino group of 1-deoxysphinganine; major species at pH 7.3.,"InChI=1S/C18H39NO/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18(20)17(2)19/h17-18,20H,3-16,19H2,1-2H3/p+1/t17-,18+/m0/s1",m(18:0),PubMed citation,19095642
3727,67116,"4-nitro-1,2-phenylenediamine","The primary amino compound that is 1,2-phenylenediamine (o-phenylenediamine) substituted at the 4- (para-) position by a nitro group.","InChI=1S/C6H7N3O2/c7-5-2-1-4(9(10)11)3-6(5)8/h1-3H,7-8H2",p-nitro-o-phenylenediamine,PubMed citation,1650428
3728,67117,"trans,octacis-decaprenylphospho-beta-D-ribofuranose 5-phosphate","A polyprenyl glycosyl phosphate consisting of beta-D-ribose-5-phosphate attached at the 1-position to trans,octacis-decaprenyl phosphate via a glycosyl phosphate linkage.","InChI=1S/C55H92O11P2/c1-42(2)21-12-22-43(3)23-13-24-44(4)25-14-26-45(5)27-15-28-46(6)29-16-30-47(7)31-17-32-48(8)33-18-34-49(9)35-19-36-50(10)37-20-38-51(11)39-40-63-68(61,62)66-55-54(57)53(56)52(65-55)41-64-67(58,59)60/h21,23,25,27,29,31,33,35,37,39,52-57H,12-20,22,24,26,28,30,32,34,36,38,40-41H2,1-11H3,(H,61,62)(H2,58,59,60)/b43-23+,44-25-,45-27-,46-29-,47-31-,48-33-,49-35-,50-37-,51-39-/t52-,53-,54-,55+/m1/s1","trans,polycis-decaprenylphospho-beta-D-ribofuranose 5-phosphate",MetaCyc accession,CPD-12039
3729,67119,UDP-alpha-D-galactose,A UDP-D-galactose in which the anomeric centre of the galactose moiety has alpha-configuration.,"InChI=1S/C15H24N2O17P2/c18-3-5-8(20)10(22)12(24)14(32-5)33-36(28,29)34-35(26,27)30-4-6-9(21)11(23)13(31-6)17-2-1-7(19)16-15(17)25/h1-2,5-6,8-14,18,20-24H,3-4H2,(H,26,27)(H,28,29)(H,16,19,25)/t5-,6-,8+,9-,10+,11-,12-,13-,14-/m1/s1",UDP-alpha-D-galactopyranose,Reaxys Registry Number,102009
3730,67158,(R)-3-ammonio-3-phenylpropanoate,An optically active form of 3-ammonio-3-phenylpropanoate having (R)-configuration.,"InChI=1S/C9H11NO2/c10-8(6-9(11)12)7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1",(R)-beta-phenylalanine,PubMed citation,21361343
3731,67160,alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc,A branched amino heptasaccharide consisting of three repeating units of beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc joined by (1->3)-linkages with an alpha-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.,"InChI=1S/C66H111N3O47/c1-14-30(79)37(86)42(91)60(98-14)111-51-27(67-18(5)76)57(97)102-24(11-73)48(51)108-64-46(95)54(35(84)22(9-71)103-64)114-58-28(68-19(6)77)52(112-61-43(92)38(87)31(80)15(2)99-61)49(25(12-74)106-58)109-65-47(96)55(36(85)23(10-72)104-65)115-59-29(69-20(7)78)53(113-62-44(93)39(88)32(81)16(3)100-62)50(26(13-75)107-59)110-66-56(41(90)34(83)21(8-70)105-66)116-63-45(94)40(89)33(82)17(4)101-63/h14-17,21-66,70-75,79-97H,8-13H2,1-7H3,(H,67,76)(H,68,77)(H,69,78)/t14-,15-,16-,17-,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35-,36-,37+,38+,39+,40+,41-,42-,43-,44-,45-,46+,47+,48+,49+,50+,51+,52+,53+,54-,55-,56+,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-/m0/s1",alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,PubMed citation,25568069
3732,67163,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,A linear heptasaccharide derivative comprising a fucose residue linked alpha(1->2) to a chain of three beta(1->3)-linked galactosyl-(1->4)-N-acetylglucosamine units.,"InChI=1S/C48H81N3O35/c1-11-24(61)31(68)33(70)45(74-11)86-41-32(69)25(62)15(5-52)78-48(41)83-38-20(10-57)80-44(23(30(38)67)51-14(4)60)85-40-27(64)17(7-54)77-47(35(40)72)82-37-19(9-56)79-43(22(29(37)66)50-13(3)59)84-39-26(63)16(6-53)76-46(34(39)71)81-36-18(8-55)75-42(73)21(28(36)65)49-12(2)58/h11,15-48,52-57,61-73H,5-10H2,1-4H3,(H,49,58)(H,50,59)(H,51,60)/t11-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27-,28+,29+,30+,31+,32-,33-,34+,35+,36+,37+,38+,39-,40-,41+,42+,43-,44-,45-,46-,47-,48-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3733,67172,(R)-3-amino-3-phenylpropanoic acid,An optically active form of 3-amino-3-phenylpropanoic acid having R-configuration.,"InChI=1S/C9H11NO2/c10-8(6-9(11)12)7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1",(R)-beta-phenylalanine,Reaxys Registry Number,2087717
3734,67175,cortistatin D,A member of the class of cortistatins that is cortistatin C in which the hydrogen at position 17 has been replaced by a hydroxy group.,"InChI=1S/C30H34N2O5/c1-27-8-6-19-13-21-25(34)26(35)22(32(2)3)15-28(21)9-10-29(19,37-28)23(27)14-24(33)30(27,36)20-5-4-17-7-11-31-16-18(17)12-20/h4-7,11-13,16,22-23,25-26,34-36H,8-10,14-15H2,1-3H3/t22-,23+,25+,26+,27-,28+,29+,30+/m0/s1",(-)-cortistatin D,Reaxys Registry Number,10504489
3735,67183,pyochelin I,"A pyochelin that has R-stereochemistry at the thioaminal centre; the diastereoisomer with S-stereochemistry at this centre is pyochelin II. Pseudomonas aeruginosa produces a mixture of pyochelin I (major) and pyochelin II (minor) via condensation of salicylic acid and two molecules of cysteine. The enantiomeric compounds, enant-pyochelin I and II, are produced by Pseudomonas fluorescens.","InChI=1S/C14H16N2O3S2/c1-16-10(14(18)19)7-21-13(16)9-6-20-12(15-9)8-4-2-3-5-11(8)17/h2-5,9-10,13,17H,6-7H2,1H3,(H,18,19)/t9-,10+,13-/m1/s1","(4'R,2''R,4''R)-2'-(2-hydroxyphenyl)-3''-methyl-2'',3'',4'',4',5'-hexahydro-[2,4']-bisthiazolyl-4''-carboxylic acid",Reaxys Registry Number,7255526
3736,67205,"(2S,4S)-4-hydroxy-2,3,4,5-tetrahydrodipicolinic acid","The dicarboxylic acid that is 2,3,4,5-tetrahydrodipicolinic acid hydroxylated at C-4 and with configuration 2S,4S.","InChI=1S/C7H9NO5/c9-3-1-4(6(10)11)8-5(2-3)7(12)13/h3-4,9H,1-2H2,(H,10,11)(H,12,13)/t3-,4-/m0/s1","(4S)-4-hydroxy-2,3,4,5-tetrahydro-(2S)-dipicolinic acid",Reaxys Registry Number,21027218
3737,67217,1-{4-[(2-hydroxyethyl)carbamoyl]benzyl}-1-methylpiperidinium chloride,An organic chloride salt in which the cationic component is 1-{4-[(2-hydroxyethyl)carbamoyl]benzyl}-1-methylpiperidinium.,"InChI=1S/C16H24N2O2.ClH/c1-18(10-3-2-4-11-18)13-14-5-7-15(8-6-14)16(20)17-9-12-19;/h5-8,19H,2-4,9-13H2,1H3;1H",N-((4'-((hydroxyethyl)carbamido)phenyl)methyl)-N-methylpiperidinium chloride,Reaxys Registry Number,4897508
3738,67226,(-)-conduritol B,"A conduritol which has 1R,2S,3S,4R configuration.","InChI=1S/C6H10O4/c7-3-1-2-4(8)6(10)5(3)9/h1-10H/t3-,4-,5+,6+/m1/s1","(1R,2S,3S,4R)-1,2,3,4,tetrahydroxy-5-cyclohexene",Reaxys Registry Number,2613487
3739,67241,"beta-D-Galf-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-GlcpNAc-1-diphospho-trans,octacis-decaprenol","A polyprenyl glycosyl phosphate consisting of beta-D-galactofuranosyl-(1->4)-alpha-L-rhamnosyl-(1->3)-N-acetyl-alpha-D-glucosamine attached at the 1-position to trans,octacis-decaprenyl phosphate.","InChI=1S/C70H117NO21P2/c1-45(2)23-14-24-46(3)25-15-26-47(4)27-16-28-48(5)29-17-30-49(6)31-18-32-50(7)33-19-34-51(8)35-20-36-52(9)37-21-38-53(10)39-22-40-54(11)41-42-85-93(81,82)92-94(83,84)91-68-59(71-56(13)74)67(60(76)58(44-73)87-68)90-69-63(79)61(77)65(55(12)86-69)88-70-64(80)62(78)66(89-70)57(75)43-72/h23,25,27,29,31,33,35,37,39,41,55,57-70,72-73,75-80H,14-22,24,26,28,30,32,34,36,38,40,42-44H2,1-13H3,(H,71,74)(H,81,82)(H,83,84)/b46-25+,47-27-,48-29-,49-31-,50-33-,51-35-,52-37-,53-39-,54-41-/t55-,57+,58+,59+,60+,61-,62+,63+,64+,65-,66-,67+,68+,69-,70+/m0/s1","beta-D-galactofuranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-glucopyranosyl-1-diphospho-trans,octacis-decaprenol",MetaCyc accession,CPD-12029
3740,67253,"alpha-L-Rhap-(1->3)-alpha-D-GlcpNAc-1-diphospho-trans,octacis-decaprenol","A polyprenyl glycosyl phosphate consisting of alpha-L-rhamnosyl-(1->3)-N-acetyl-alpha-D-glucosamine attached at the 1-position to trans,octacis-decaprenyl phosphate.","InChI=1S/C64H107NO16P2/c1-44(2)23-14-24-45(3)25-15-26-46(4)27-16-28-47(5)29-17-30-48(6)31-18-32-49(7)33-19-34-50(8)35-20-36-51(9)37-21-38-52(10)39-22-40-53(11)41-42-76-82(72,73)81-83(74,75)80-63-57(65-55(13)67)62(59(69)56(43-66)78-63)79-64-61(71)60(70)58(68)54(12)77-64/h23,25,27,29,31,33,35,37,39,41,54,56-64,66,68-71H,14-22,24,26,28,30,32,34,36,38,40,42-43H2,1-13H3,(H,65,67)(H,72,73)(H,74,75)/b45-25+,46-27-,47-29-,48-31-,49-33-,50-35-,51-37-,52-39-,53-41-/t54-,56+,57+,58-,59+,60+,61+,62+,63+,64-/m0/s1","alpha-L-Rha-(1->3)-alpha-D-GlcNAc-1-diphospho-trans,octacis-decaprenol",MetaCyc accession,CPD-12028
3741,67256,"beta-D-Galf-(1->5)-beta-D-Galf-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-GlcpNAc-1-diphospho-trans,octacis-decaprenol","A polyprenyl glycosyl phosphate consisting of beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->4)-alpha-L-rhamnosyl-(1->3)-N-acetyl-alpha-D-glucosamine attached at the 1-position to trans,octacis-decaprenyl phosphate.","InChI=1S/C76H127NO26P2/c1-46(2)23-14-24-47(3)25-15-26-48(4)27-16-28-49(5)29-17-30-50(6)31-18-32-51(7)33-19-34-52(8)35-20-36-53(9)37-21-38-54(10)39-22-40-55(11)41-42-94-104(90,91)103-105(92,93)102-73-61(77-57(13)81)72(62(83)59(44-79)96-73)101-74-66(87)63(84)69(56(12)95-74)98-76-68(89)65(86)71(100-76)60(45-80)97-75-67(88)64(85)70(99-75)58(82)43-78/h23,25,27,29,31,33,35,37,39,41,56,58-76,78-80,82-89H,14-22,24,26,28,30,32,34,36,38,40,42-45H2,1-13H3,(H,77,81)(H,90,91)(H,92,93)/b47-25+,48-27-,49-29-,50-31-,51-33-,52-35-,53-37-,54-39-,55-41-/t56-,58+,59+,60+,61+,62+,63-,64+,65+,66+,67+,68+,69-,70-,71-,72+,73+,74-,75+,76+/m0/s1","beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-glucopyranosyl-1-diphospho-trans,octacis-decaprenol",PubMed citation,16952951
3742,68430,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,An amino hexasaccharide in which an alpha-L-fucosyl residue is linked (1->2) to the mannosyl residue furthest from the reducing end of an alpha-D-GalNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc linear pentasaccharide.,"InChI=1S/C42H71N3O30/c1-10-22(54)29(61)30(62)40(65-10)75-36-35(74-38-20(44-12(3)52)26(58)23(55)14(5-46)67-38)25(57)16(7-48)69-42(36)72-33-18(9-50)70-39(21(28(33)60)45-13(4)53)73-34-24(56)15(6-47)68-41(31(34)63)71-32-17(8-49)66-37(64)19(27(32)59)43-11(2)51/h10,14-42,46-50,54-64H,5-9H2,1-4H3,(H,43,51)(H,44,52)(H,45,53)/t10-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23-,24-,25-,26+,27+,28+,29+,30-,31+,32+,33+,34-,35-,36+,37+,38+,39-,40-,41-,42-/m0/s1",alpha-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-GlcNAc,PubMed citation,19443021
3743,68435,alpha-D-GalpNAc-(1->4)-[alpha-D-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc,An amino tetrasaccharide in which an alpha-L-fucosyl residue is linked (1->2) to the middle galactosyl residue of an N-acetyl-alpha-D-galactosaminyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine trisaccharide.,"InChI=1S/C28H48N2O20/c1-7-15(36)19(40)20(41)27(44-7)50-24-21(42)23(48-26-14(30-9(3)35)17(38)16(37)10(4-31)46-26)12(6-33)47-28(24)49-22-11(5-32)45-25(43)13(18(22)39)29-8(2)34/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17+,18+,19+,20-,21-,22+,23-,24+,25+,26+,27-,28-/m0/s1",alpha-D-GalNAc-(1->4)-[alpha-D-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3744,68436,beta-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp,An amino trisaccharide in which an N-acetyl-D-galactosamine and an L-fucose link beta(1->3) and alpha(1->2) respectively to beta-D-galactose.,"InChI=1S/C20H35NO15/c1-5-10(25)14(29)15(30)20(32-5)36-17-16(12(27)8(4-23)33-18(17)31)35-19-9(21-6(2)24)13(28)11(26)7(3-22)34-19/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12-,13+,14+,15-,16-,17+,18+,19-,20-/m0/s1",beta-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal,PubMed citation,19443021
3745,68448,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc,beta-D-GalpNAc-(1->4)-D-GlcpNAc with beta configuration at the reducing-end anomeric centre.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)14(8(4-20)27-15(9)26)29-16-10(18-6(2)22)12(24)11(23)7(3-19)28-16/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12-,13-,14-,15-,16+/m1/s1",beta-D-GaNAc-(1->4)-beta-D-GlcNAc,Reaxys Registry Number,7522570
3746,68463,alpha-D-Talp-(1->2)-[alpha-D-Abep-(1->3)]-alpha-D-Manp,"A trisaccharide comprised of alpha-D-abequose and alpha-D-talose residues linked (1->3) and (1->2), respectively, to alpha-D-mannose.","InChI=1S/C18H32O14/c1-5-6(21)2-7(22)17(28-5)31-14-11(24)9(4-20)29-16(27)15(14)32-18-13(26)12(25)10(23)8(3-19)30-18/h5-27H,2-4H2,1H3/t5-,6-,7-,8-,9-,10+,11-,12+,13+,14+,15+,16+,17-,18-/m1/s1",alpha-D-Abe-(1->3)-[alpha-D-Tal-(1->2)]-alpha-D-Man,PubMed citation,22128847
3747,68468,alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-{alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)}-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,"An amino oligosaccharide that is a tridecasaccharide derivative in which two pentasaccharide branches, each formed from alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannose, are linked (1->3) and (1->6) to the mannose residue of a trisaccharide chain consisting of mannose and two N-acetylglucosamine residues all linked beta(1->4) with a beta-configuration of the anomeric carbon of the N-acetylglucosamine residue at the reducing end.","InChI=1S/C86H144N4O64/c1-18-39(105)52(118)58(124)78(131-18)153-72-68(149-80-60(126)54(120)41(107)24(7-91)134-80)45(111)28(11-95)138-85(72)146-65-32(15-99)141-76(37(50(65)116)89-22(5)103)151-70-56(122)43(109)26(9-93)136-83(70)130-17-34-47(113)67(62(128)82(143-34)145-64-31(14-98)140-75(36(49(64)115)88-21(4)102)144-63-30(13-97)133-74(129)35(48(63)114)87-20(3)101)148-84-71(57(123)44(110)27(10-94)137-84)152-77-38(90-23(6)104)51(117)66(33(16-100)142-77)147-86-73(154-79-59(125)53(119)40(106)19(2)132-79)69(46(112)29(12-96)139-86)150-81-61(127)55(121)42(108)25(8-92)135-81/h18-19,24-86,91-100,105-129H,7-17H2,1-6H3,(H,87,101)(H,88,102)(H,89,103)(H,90,104)/t18-,19-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41-,42-,43+,44+,45-,46-,47+,48+,49+,50+,51+,52+,53+,54-,55-,56-,57-,58-,59-,60+,61+,62-,63+,64+,65+,66+,67-,68-,69-,70-,71-,72+,73+,74+,75-,76-,77-,78-,79-,80+,81+,82-,83-,84+,85-,86-/m0/s1",alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-{alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3748,68477,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,A branched amino tetrasaccharide comprised of an L-alpha-fucosyl residue linked (1->3) to the GlcNAc residue of alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosamine.,"InChI=1S/C26H45NO20/c1-6-12(32)15(35)17(37)24(41-6)46-21-11(27-7(2)31)23(40)42-10(5-30)20(21)45-26-19(39)22(14(34)9(4-29)44-26)47-25-18(38)16(36)13(33)8(3-28)43-25/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15+,16-,17-,18+,19+,20+,21+,22-,23+,24-,25+,26-/m0/s1",alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc,PubMed citation,19443021
3749,68482,alpha-D-Galp-(1->4)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc,An amino tetrasaccharide in which an alpha-L-fucosyl residue is linked (1->2) to the middle galactosyl residue of an alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine trisaccharide.,"InChI=1S/C26H45NO20/c1-6-12(32)15(35)17(37)24(41-6)47-22-19(39)21(45-25-18(38)16(36)13(33)8(3-28)43-25)10(5-30)44-26(22)46-20-9(4-29)42-23(40)11(14(20)34)27-7(2)31/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14+,15+,16-,17-,18+,19-,20+,21-,22+,23+,24-,25+,26-/m0/s1",alpha-D-Gal-(1->4)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3750,68484,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-DGlcp,"An amino pentasaccharide consisting of alpha-D-galactose, beta-D-galactose N-acetyl-alpha-D-glucosamine, beta-D-galactose, and beta-D-glucose residues joined in sequence with ((1->4)-, (1->4)-, (1->3)- and (1->4)-linkages, respectively.","InChI=1S/C32H55NO26/c1-7(39)33-13-16(42)24(56-31-22(48)19(45)26(12(6-38)55-31)57-30-21(47)17(43)14(40)8(2-34)52-30)11(5-37)54-29(13)59-27-15(41)9(3-35)53-32(23(27)49)58-25-10(4-36)51-28(50)20(46)18(25)44/h8-32,34-38,40-50H,2-6H2,1H3,(H,33,39)/t8-,9-,10-,11-,12-,13-,14+,15+,16-,17+,18-,19-,20-,21-,22-,23-,24-,25-,26+,27+,28-,29+,30-,31+,32+/m1/s1",alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucose,PubMed citation,19443021
3751,68485,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-Glcp with beta-configuration at the reducing end anomeric centre.,"InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14-,15+,16-,17-,18+/m1/s1",alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-D-Glc,PubMed citation,19443021
3752,68496,3-methoxysalicylic acid,Benzoic acid substituted with a hydroxy group at position C-2 and a methoxy group at position C-3.,"InChI=1S/C8H8O4/c1-12-6-4-2-3-5(7(6)9)8(10)11/h2-4,9H,1H3,(H,10,11)",o-vanillic acid,PubMed citation,22770225
3753,68500,m-methylhippuric acid,An N-acylglycine that is the 3-methyl derivative of hippuric acid.,"InChI=1S/C10H11NO3/c1-7-3-2-4-8(5-7)10(14)11-6-9(12)13/h2-5H,6H2,1H3,(H,11,14)(H,12,13)",3-methylhippuric acid,Reaxys Registry Number,2103978
3754,68517,"17beta(H),21beta(H)-bishomohopanol",A pentacyclic triterpenoid that is hopane in which a hydrogen attached to C-29 is replaced by a 2-hydroxyethyl group.,"InChI=1S/C32H56O/c1-22(10-8-21-33)23-13-18-29(4)24(23)14-19-31(6)26(29)11-12-27-30(5)17-9-16-28(2,3)25(30)15-20-32(27,31)7/h22-27,33H,8-21H2,1-7H3/t22?,23-,24+,25+,26-,27-,29+,30+,31-,32-/m1/s1","17beta(H),21beta(H) bishomohopanol",Reaxys Registry Number,7625942
3755,68525,(S)-3-amino-3-phenylpropanoic acid,An optically active form of 3-amino-3-phenylpropanoic acid having S-configuration.,"InChI=1S/C9H11NO2/c10-8(6-9(11)12)7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1",(S)-beta-phenylalanine,PDBeChem accession,SFE
3756,68526,1-palmitoyl-2-cis-vaccenoyl-3-alpha-D-galactosyl-sn-glycerol,"A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the acyl groups at positions 1 and 2 are palmitoyl (hexadecanoyl) and cis-vaccenoyl [(11Z)-octadec-11-enoyl] respectively.","InChI=1S/C43H80O10/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(46)52-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)34-50-38(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h13,15,36-37,40-44,47-49H,3-12,14,16-35H2,1-2H3/b15-13-/t36-,37-,40+,41+,42-,43+/m1/s1",Gal-DAG-s2,PubMed citation,22069376
3757,68529,2-palmitoyl-1-cis-vaccenoyl-3-alpha-D-galactosyl-sn-glycerol,"A 1,2-diacyl-3-alpha-D-galactosyl-sn-glycerol in which the acyl groups at positions 1 and 2 are cis-vaccenoyl [(11Z)-octadec-11-enoyl] and palmitoyl (hexadecanoyl) respectively.","InChI=1S/C43H80O10/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(45)50-34-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)52-39(46)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h13,15,36-37,40-44,47-49H,3-12,14,16-35H2,1-2H3/b15-13-/t36-,37-,40+,41+,42-,43+/m1/s1",1-O-cis-vaccenoyl-2-O-palmitoyl-3-O-alpha-D-galactosyl-sn-glycerol,PubMed citation,22069376
3758,68530,"[beta-D-Galf-(1->5)-beta-D-Galf-(1->6)]14-beta-D-Galf-(1->5)-beta-D-Galf-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-GlcpNAc-1-diphospho-trans,octacis-decaprenol","A polyprenyl glycosyl phosphate consisting of the 32-membered glycosyl moiety, [beta-D-Galf-(1->5)-beta-D-Galf-(1->6)]14-beta-D-Galf-(1->5)-beta-D-Galf-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-GlcpNAc attached at the 1-position to trans,octacis-decaprenyl phosphate.","InChI=1S/C244H407NO166P2/c1-74(2)23-14-24-75(3)25-15-26-76(4)27-16-28-77(5)29-17-30-78(6)31-18-32-79(7)33-19-34-80(8)35-20-36-81(9)37-21-38-82(10)39-22-40-83(11)41-42-360-412(342,343)411-413(344,345)410-213-117(245-85(13)263)212(118(279)101(44-247)362-213)409-228-164(325)119(280)181(84(12)361-228)378-244-180(341)149(310)211(408-244)116(59-262)377-243-179(340)134(295)196(393-243)100(278)73-359-227-163(324)148(309)210(407-227)115(58-261)376-242-178(339)133(294)195(392-242)99(277)72-358-226-162(323)147(308)209(406-226)114(57-260)375-241-177(338)132(293)194(391-241)98(276)71-357-225-161(322)146(307)208(405-225)113(56-259)374-240-176(337)131(292)193(390-240)97(275)70-356-224-160(321)145(306)207(404-224)112(55-258)373-239-175(336)130(291)192(389-239)96(274)69-355-223-159(320)144(305)206(403-223)111(54-257)372-238-174(335)129(290)191(388-238)95(273)68-354-222-158(319)143(304)205(402-222)110(53-256)371-237-173(334)128(289)190(387-237)94(272)67-353-221-157(318)142(303)204(401-221)109(52-255)370-236-172(333)127(288)189(386-236)93(271)66-352-220-156(317)141(302)203(400-220)108(51-254)369-235-171(332)126(287)188(385-235)92(270)65-351-219-155(316)140(301)202(399-219)107(50-253)368-234-170(331)125(286)187(384-234)91(269)64-350-218-154(315)139(300)201(398-218)106(49-252)367-233-169(330)124(285)186(383-233)90(268)63-349-217-153(314)138(299)200(397-217)105(48-251)366-232-168(329)123(284)185(382-232)89(267)62-348-216-152(313)137(298)199(396-216)104(47-250)365-231-167(328)122(283)184(381-231)88(266)61-347-215-151(312)136(297)198(395-215)103(46-249)364-230-166(327)121(282)183(380-230)87(265)60-346-214-150(311)135(296)197(394-214)102(45-248)363-229-165(326)120(281)182(379-229)86(264)43-246/h23,25,27,29,31,33,35,37,39,41,84,86-244,246-262,264-341H,14-22,24,26,28,30,32,34,36,38,40,42-73H2,1-13H3,(H,245,263)(H,342,343)(H,344,345)/b75-25+,76-27-,77-29-,78-31-,79-33-,80-35-,81-37-,82-39-,83-41-/t84-,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119-,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,181-,182-,183-,184-,185-,186-,187-,188-,189-,190-,191-,192-,193-,194-,195-,196-,197-,198-,199-,200-,201-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212+,213+,214+,215+,216+,217+,218+,219+,220+,221+,222+,223+,224+,225+,226+,227+,228-,229+,230+,231+,232+,233+,234+,235+,236+,237+,238+,239+,240+,241+,242+,243+,244+/m0/s1","[beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->6)]14-beta-D-galactofuranosyl-(1->5)-beta-D-galactofuranosyl-(1->4)-alpha-L-rhamnopyranosyl-(1->3)-N-acetyl-alpha-D-glucosaminyl-diphospho-trans,octacis-decaprenol",PubMed citation,18423586
3759,68538,N-desmethylenzalutamide,"A benzamide obtained by formal condensation of the carboxy group of 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluorobenzoic acid with ammonia.","InChI=1S/C20H14F4N4O2S/c1-19(2)17(30)27(11-4-3-10(9-25)14(7-11)20(22,23)24)18(31)28(19)12-5-6-13(16(26)29)15(21)8-12/h3-8H,1-2H3,(H2,26,29)",N-desmethyl enzalutamide,Reaxys Registry Number,20830878
3760,68539,2-oleoyl-1-palmitoyl-3-alpha-D-glucosyl-sn-glycerol,"An alpha-D-Glc-(1->3')-1,2-diacylglycerol in which the groups at the 1- and 2-positions are palmitoyl and oleoyl respectively.","InChI=1S/C43H80O10/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(46)52-36(35-51-43-42(49)41(48)40(47)37(33-44)53-43)34-50-38(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,36-37,40-44,47-49H,3-16,19-35H2,1-2H3/b18-17-/t36-,37-,40-,41+,42-,43+/m1/s1",Glc-DAG-s5,PubMed citation,21892173
3761,68556,icatibant,"A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acute attacks of hereditary angioedema in adult patients.","InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1",H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH,CAS Registry Number,130308-48-4
3762,68565,tuberculostearic acid,"A methyl-branched fatty acid, the structure of which is that of stearic acid carrying a methyl group at C-10.","InChI=1S/C19H38O2/c1-3-4-5-6-9-12-15-18(2)16-13-10-7-8-11-14-17-19(20)21/h18H,3-17H2,1-2H3,(H,20,21)",10-methyloctadecanoic acid,CAS Registry Number,542-47-2
3763,68582,beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,"A branched amino hexasaccharide comprising a linear chain of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamine, linked (1->3), (1->3) and (1->4) respectively, with an alpha-L-fucose residue linked to each N-acetyl-beta-D-glucosamine residue, (1->3)-linked to the reducing-end GlcNAc and (1->4)linked to the GlcNAc at the non-reducing end.","InChI=1S/C40H68N2O29/c1-9-19(49)23(53)26(56)37(61-9)67-31-16(8-46)66-36(18(42-12(4)48)33(31)70-39-28(58)25(55)21(51)13(5-43)64-39)71-34-22(52)14(6-44)65-40(29(34)59)68-30-15(7-45)63-35(60)17(41-11(3)47)32(30)69-38-27(57)24(54)20(50)10(2)62-38/h9-10,13-40,43-46,49-60H,5-8H2,1-4H3,(H,41,47)(H,42,48)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23+,24+,25-,26-,27-,28+,29+,30+,31+,32+,33+,34-,35+,36-,37-,38-,39-,40-/m0/s1",beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosamine,PubMed citation,19443021
3764,68587,beta-D-Galp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-beta-D-GalpNAc,beta-D-Galp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-D-GalpNAc with beta-configuration at the anomeric centre of the reducing-end GalNAc residue.,"InChI=1S/C28H48N2O21/c1-7(34)29-13-18(39)23(50-27-21(42)19(40)15(36)9(3-31)47-27)11(5-33)49-26(13)45-6-12-17(38)24(14(25(44)46-12)30-8(2)35)51-28-22(43)20(41)16(37)10(4-32)48-28/h9-28,31-33,36-44H,3-6H2,1-2H3,(H,29,34)(H,30,35)/t9-,10-,11-,12-,13-,14-,15+,16+,17+,18-,19+,20+,21-,22-,23-,24-,25-,26-,27+,28+/m1/s1",beta-D-galactosyl-(1->3)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-beta-D-galactosamine,PubMed citation,19443021
3765,68602,rilpivirine hydrochloride,A hydrochloride obtained by reaction of rilpivirine with one equivalent of hydrochloric acid. Used for treatment of HIV.,"InChI=1S/C22H18N6.ClH/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19;/h3-9,11-13H,1-2H3,(H2,25,26,27,28);1H/b4-3+;",rilpivirine monohydrochloride,CAS Registry Number,700361-47-3
3766,68635,"trisodium guanosine 5'-[beta,gamma-methylene]triphosphate","An organic sodium salt that is the trisodium salt of guanosine 5'-(beta,gamma-methylene)triphosphate.","InChI=1S/C11H18N5O13P3.3Na/c12-11-14-8-5(9(19)15-11)13-2-16(8)10-7(18)6(17)4(28-10)1-27-32(25,26)29-31(23,24)3-30(20,21)22;;;/h2,4,6-7,10,17-18H,1,3H2,(H,23,24)(H,25,26)(H2,20,21,22)(H3,12,14,15,19);;;/q;3*+1/p-3/t4-,6-,7-,10-;;;/m1.../s1","beta,gamma-methyleneguanosine 5'-triphosphate sodium salt",CAS Registry Number,10470-57-2
3767,68636,p-hydroxyphenylbut-3-ene-2-one,An enone in which a 4-hydroxyphenyl group is attached to the beta-carbon atom of but-3-en-2-one.,"InChI=1S/C10H10O2/c1-8(11)2-3-9-4-6-10(12)7-5-9/h2-7,12H,1H3",p-hydroxybenzalacetone,PubMed citation,12226219
3768,68648,dimethyl ditelluride,An organotellurium compound that is ditellane in which the two hydrogens are replaced by methyl groups.,InChI=1S/C2H6Te2/c1-3-4-2/h1-2H3,DMDTe,Reaxys Registry Number,1696898
3769,68657,zingerone,A methyl ketone that is 4-phenylbutan-2-one in which the phenyl ring is substituted at positions 3 and 4 by methoxy and hydroxy groups respectively. The major pungent component in ginger.,"InChI=1S/C11H14O3/c1-8(12)3-4-9-5-6-10(13)11(7-9)14-2/h5-7,13H,3-4H2,1-2H3",4-(3-methoxy-4-hydroxyphenyl)butan-2-one,PubMed citation,21802408
3770,68663,D-ethionine,An S-ethylhomocysteine that has R-configuration at the chiral centre.,"InChI=1S/C6H13NO2S/c1-2-10-4-3-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m1/s1",D-S-ethylhomocysteine,MetaCyc accession,ETHIONINE
3771,68668,legionaminate(1+),An organic cation that is the conjugate acid of legionaminic acid obtained by protonation of both amino groups and deprotonation of the carboxy group; major species at pH 7.3.,"InChI=1S/C9H18N2O6/c1-3(12)5(10)7-6(11)4(13)2-9(16,17-7)8(14)15/h3-7,12-13,16H,2,10-11H2,1H3,(H,14,15)/p+1/t3-,4+,5-,6-,7+,9+/m1/s1","5,7-diammmonio-3,5,7,9-tetradeoxy-D-glycero-D-galacto-non-2-ulosonate",PubMed citation,18275154
3772,68673,alpha-L-Fucp-(1->2)-[beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-D-Glcp,"An amino pentasaccharide comprised of a tetrasaccharide chain of beta-D-galactosyl, N-acetyl-alpha-D-galactosaminyl, beta-D-galactosyl and D-glucosyl residues linked sequentially (1->3), (1->3) and (1->4), with an alpha-L-fucosyl residue linked (1->2) to the galactosyl residue proximal to the reducing-end glucosyl residue.","InChI=1S/C32H55NO25/c1-7-14(39)18(43)22(47)30(50-7)58-27-26(17(42)11(5-36)54-32(27)55-24-12(6-37)51-28(49)21(46)20(24)45)57-29-13(33-8(2)38)25(16(41)10(4-35)52-29)56-31-23(48)19(44)15(40)9(3-34)53-31/h7,9-32,34-37,39-49H,3-6H2,1-2H3,(H,33,38)/t7-,9+,10+,11+,12+,13+,14+,15-,16-,17-,18+,19-,20+,21+,22-,23+,24+,25+,26-,27+,28?,29+,30-,31-,32-/m0/s1",alpha-L-Fuc-(1->2)-[beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->4)-D-Glc,PubMed citation,19443021
3773,68685,alpha-D-ribose 1-methylphosphonate 5-triphosphate(4-),An organophosphate oxoanion obtained by deprotonation of the phosphonate OH and three of the four triphosphate OH groups of alpha-D-ribose 1-methylphosphonate 5-triphosphate.,"InChI=1S/C6H16O16P4/c1-23(9,10)20-6-5(8)4(7)3(19-6)2-18-25(14,15)22-26(16,17)21-24(11,12)13/h3-8H,2H2,1H3,(H,9,10)(H,14,15)(H,16,17)(H2,11,12,13)/p-4/t3-,4-,5-,6-/m1/s1",RPnTP,PubMed citation,22089136
3774,68689,"5-phospho-alpha-D-ribose cyclic-1,2-phosphate","A ribose bisphosphate that is the cyclic-1,2-phosphate derivative of 5-phospho-alpha-D-ribose.","InChI=1S/C5H10O10P2/c6-3-2(1-12-16(7,8)9)13-5-4(3)14-17(10,11)15-5/h2-6H,1H2,(H,10,11)(H2,7,8,9)/t2-,3-,4-,5-/m1/s1","alpha-D-ribose 1,2-cyclic phosphate 5-phosphate",Reaxys Registry Number,37426
3775,68705,globosumone A,"A benzoate ester obtained by the formal condensation of o-orsellinic acid with (3E)-1-hydroxypent-3-en-2-one. Isolated from Chaetomium globosum, it exhibits cytotoxic activity towards cancer cell lines.","InChI=1S/C13H14O5/c1-3-4-9(14)7-18-13(17)12-8(2)5-10(15)6-11(12)16/h3-6,15-16H,7H2,1-2H3/b4-3+",2'-oxo-pent-3'-enyl orsellinate,Chemspider accession,9611487
3776,68708,"7,8-dihydroxy-3-methyl-10-oxo-10H-chromeno[3,2-c]pyridine-9-carboxylic acid","A  pyridochromene that is 10H-chromeno[3,2-c]pyridine substituted by hydroxy groups at positions 7 and 8, a methyl group at position 3, an oxo group at position 10 and a carboxy group at position 9. Isolated from Chaetomium funicola, it exhibits inhibitory activity against metallo-beta-lactamases.","InChI=1S/C14H9NO6/c1-5-2-8-6(4-15-5)12(17)10-9(21-8)3-7(16)13(18)11(10)14(19)20/h2-4,16,18H,1H3,(H,19,20)",SB236049,Chemspider accession,8036394
3777,68710,"7,8-dihydroxy-1-methoxy-3-methyl-10-oxo-1H,10H-pyrano[4,3-b]chromene-9-carboxylic acid","An organic heterotricyclic compound that is 1H,10H-pyrano[4,3-b]chromene substituted by hydroxy groups at positions 7 and 8, a methoxy group at position 1, a methyl group at position 3 and an oxo group at position 10. Isolated from Chaetomium funicola, it exhibits inhibitory activity against metallo-beta-lactamases.","InChI=1S/C15H12O8/c1-5-3-7-10(15(21-2)22-5)13(18)9-8(23-7)4-6(16)12(17)11(9)14(19)20/h3-4,15-17H,1-2H3,(H,19,20)",SB238569,Chemspider accession,8059216
3778,68749,sch 210972,A member of the class of pyrrolidin-2-ones isolated from the fungal fermentation broth of  Chaetomium globosum and shown to exhibit inhibitory activity against chemokine receptor CCR-5.,"InChI=1S/C25H35NO6/c1-6-13(3)16-8-7-15-10-12(2)9-14(4)18(15)19(16)22(28)20-21(27)17(26-23(20)29)11-25(5,32)24(30)31/h6-8,12,14-19,28,32H,9-11H2,1-5H3,(H,26,29)(H,30,31)/b13-6+,22-20-/t12-,14+,15-,16+,17-,18-,19-,25-/m0/s1",sch210972,PubMed citation,16872138
3779,68819,"alpha-D-ribose 1,5-bisphosphate","A D-ribose 1,5-diphosphate in which the anomeric centre has alpha-configuration.","InChI=1S/C5H12O11P2/c6-3-2(1-14-17(8,9)10)15-5(4(3)7)16-18(11,12)13/h2-7H,1H2,(H2,8,9,10)(H2,11,12,13)/t2-,3-,4-,5-/m1/s1","alpha-D-ribose 1,5-diphosphate",Reaxys Registry Number,40197
3780,68822,methylphosphonate(2-),An organophosphonate oxoanion obtained by deprotonation of the phosphonate OH groups of methylphosphonic acid.,"InChI=1S/CH5O3P/c1-5(2,3)4/h1H3,(H2,2,3,4)/p-2",methylphosphonate dianion,Reaxys Registry Number,3903770
3781,68823,alpha-D-ribose 1-methylphosphonate 5-triphosphate(5-),An organophosphate oxoanion obtained by deprotonation of the triphosphate and phosphonate OH groups of alpha-D-ribose 1-methylphosphonate 5-triphosphate.,"InChI=1S/C6H16O16P4/c1-23(9,10)20-6-5(8)4(7)3(19-6)2-18-25(14,15)22-26(16,17)21-24(11,12)13/h3-8H,2H2,1H3,(H,9,10)(H,14,15)(H,16,17)(H2,11,12,13)/p-5/t3-,4-,5-,6-/m1/s1",alpha-D-ribose 1-methylphosphonate 5-triphosphate pentaanion,MetaCyc accession,CPD0-2479
3782,68826,"N-acetyl-alpha-D-galactosaminyl-(1->3)-N,N'-diacetyl-alpha-D-bacillosaminyl-tritrans,heptacis-undecaprenyl diphosphate","A polyprenyl glycosyl phosphate consisting of N-acetyl-alpha-D-galactosaminyl-(1->3)-N,N'-diacetyl-alpha-D-bacillosamine linked via a diphospho group to tritrans,heptacis-undecaprenol.","InChI=1S/C73H121N3O16P2/c1-50(2)27-17-28-51(3)29-18-30-52(4)31-19-32-53(5)33-20-34-54(6)35-21-36-55(7)37-22-38-56(8)39-23-40-57(9)41-24-42-58(10)43-25-44-59(11)45-26-46-60(12)47-48-87-93(83,84)92-94(85,86)91-73-68(76-64(16)80)71(66(61(13)88-73)74-62(14)78)90-72-67(75-63(15)79)70(82)69(81)65(49-77)89-72/h27,29,31,33,35,37,39,41,43,45,47,61,65-73,77,81-82H,17-26,28,30,32,34,36,38,40,42,44,46,48-49H2,1-16H3,(H,74,78)(H,75,79)(H,76,80)(H,83,84)(H,85,86)/b51-29+,52-31+,53-33+,54-35-,55-37-,56-39-,57-41-,58-43-,59-45-,60-47-/t61-,65-,66-,67-,68-,69+,70-,71+,72-,73-/m1/s1","alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac-tritrans,heptacis-undecaprenyl diphosphate",Reaxys Registry Number,10417093
3783,68827,"alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac-tritrans,heptacis-undecaprenyl diphosphate","A polyprenyl glycosyl phosphate consisting of the trisaccharide alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac linked via a diphospho group to tritrans,heptacis-undecaprenol.","InChI=1S/C81H134N4O21P2/c1-52(2)28-18-29-53(3)30-19-31-54(4)32-20-33-55(5)34-21-35-56(6)36-22-37-57(7)38-23-39-58(8)40-24-41-59(9)42-25-43-60(10)44-26-45-61(11)46-27-47-62(12)48-49-99-107(95,96)106-108(97,98)105-81-73(85-67(17)91)78(70(63(13)100-81)82-64(14)88)104-80-72(84-66(16)90)76(94)77(69(51-87)102-80)103-79-71(83-65(15)89)75(93)74(92)68(50-86)101-79/h28,30,32,34,36,38,40,42,44,46,48,63,68-81,86-87,92-94H,18-27,29,31,33,35,37,39,41,43,45,47,49-51H2,1-17H3,(H,82,88)(H,83,89)(H,84,90)(H,85,91)(H,95,96)(H,97,98)/b53-30+,54-32+,55-34+,56-36-,57-38-,58-40-,59-42-,60-44-,61-46-,62-48-/t63-,68-,69-,70-,71-,72-,73-,74+,75-,76-,77+,78+,79-,80-,81-/m1/s1","N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->3)-N,N'-diacetyl-alpha-D-bacillosaminyl-tritrans,heptacis-undecaprenyl diphosphate",Reaxys Registry Number,19645880
3784,68829,"[alpha-D-GalNAc-(1->4)]4-alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac-tritrans,heptacis-undecaprenyl diphosphate","A polyprenyl glycosyl phosphate consisting of the hexasaccharide [alpha-D-GalNAc-(1->4)]4-alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac linked via a diphospho group to tritrans,heptacis-undecaprenol.","InChI=1S/C105H173N7O36P2/c1-58(2)31-21-32-59(3)33-22-34-60(4)35-23-36-61(5)37-24-38-62(6)39-25-40-63(7)41-26-42-64(8)43-27-44-65(9)45-28-46-66(10)47-29-48-67(11)49-30-50-68(12)51-52-135-149(131,132)148-150(133,134)147-105-88(112-76(20)124)99(82(69(13)136-105)106-70(14)118)146-104-87(111-75(19)123)94(130)98(81(57-117)141-104)145-103-86(110-74(18)122)93(129)97(80(56-116)140-103)144-102-85(109-73(17)121)92(128)96(79(55-115)139-102)143-101-84(108-72(16)120)91(127)95(78(54-114)138-101)142-100-83(107-71(15)119)90(126)89(125)77(53-113)137-100/h31,33,35,37,39,41,43,45,47,49,51,69,77-105,113-117,125-130H,21-30,32,34,36,38,40,42,44,46,48,50,52-57H2,1-20H3,(H,106,118)(H,107,119)(H,108,120)(H,109,121)(H,110,122)(H,111,123)(H,112,124)(H,131,132)(H,133,134)/b59-33+,60-35+,61-37+,62-39-,63-41-,64-43-,65-45-,66-47-,67-49-,68-51-/t69-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89+,90-,91-,92-,93-,94-,95+,96+,97+,98+,99+,100-,101-,102-,103-,104-,105-/m1/s1","[N-acetyl-alpha-D-galactosaminyl-(1->4)]4-N-acetyl-alpha-D-galactosaminyl-(1->3)-N,N'-diacetyl-alpha-D-bacillosaminyl-tritrans,heptacis-undecaprenyl diphosphate",PubMed citation,16186480
3785,68831,"[alpha-D-GalNAc-(1->4)]2-[beta-D-Glc-(1->3)]-[alpha-D-GalNAc-(1->4)]2-alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac-tritrans,heptacis-undecaprenyl diphosphate","A polyprenyl glycosyl phosphate consisting of the heptasaccharide [alpha-D-GalNAc-(1->4)]2-[beta-D-Glc-(1->3)]-[alpha-D-GalNAc-(1->4)]2-alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac linked via a diphospho group to tritrans,heptacis-undecaprenol.","InChI=1S/C111H183N7O41P2/c1-59(2)31-21-32-60(3)33-22-34-61(4)35-23-36-62(5)37-24-38-63(6)39-25-40-64(7)41-26-42-65(8)43-27-44-66(9)45-28-46-67(10)47-29-48-68(11)49-30-50-69(12)51-52-144-160(140,141)159-161(142,143)158-110-89(117-76(19)130)103(84(70(13)145-110)112-71(14)125)156-108-88(116-75(18)129)96(137)100(81(56-122)150-108)153-106-86(114-73(16)127)94(135)101(82(57-123)148-106)154-109-90(118-77(20)131)104(157-111-98(139)97(138)92(133)79(54-120)147-111)102(83(58-124)151-109)155-107-87(115-74(17)128)95(136)99(80(55-121)149-107)152-105-85(113-72(15)126)93(134)91(132)78(53-119)146-105/h31,33,35,37,39,41,43,45,47,49,51,70,78-111,119-124,132-139H,21-30,32,34,36,38,40,42,44,46,48,50,52-58H2,1-20H3,(H,112,125)(H,113,126)(H,114,127)(H,115,128)(H,116,129)(H,117,130)(H,118,131)(H,140,141)(H,142,143)/b60-33+,61-35+,62-37+,63-39-,64-41-,65-43-,66-45-,67-47-,68-49-,69-51-/t70-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92-,93-,94-,95-,96-,97+,98-,99+,100+,101+,102+,103+,104-,105-,106-,107-,108-,109-,110-,111+/m1/s1","alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-[beta-D-Glc-(1->3)]-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->3)-alpha-D-diNAcBac-tritrans,heptacis-undecaprenyl diphosphate",PubMed citation,16547029
3786,68834,dehydroisoandrosterone 3-glucuronide,A steroid glucosiduronic acid having dehydroepiandrosterone as the steroid component.,"InChI=1S/C25H36O8/c1-24-9-7-13(32-23-20(29)18(27)19(28)21(33-23)22(30)31)11-12(24)3-4-14-15-5-6-17(26)25(15,2)10-8-16(14)24/h3,13-16,18-21,23,27-29H,4-11H2,1-2H3,(H,30,31)/t13-,14-,15-,16-,18-,19-,20+,21-,23+,24-,25-/m0/s1",dehydroepiandrosterone 3-glucuronide,HMDB accession,HMDB0010327
3787,68843,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,"A tetrasaccharide comprising residues of galactose, N-acetylglucosamine, galactose and N-acetylglucosamine units in a linear sequence, joined sequentially via beta(1->3), beta(1->3), and beta(1->4) linkages. beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc with beta-configuration at the anomeric centre of the reducing-end N-acetylglucosamine residue.","InChI=1S/C28H48N2O21/c1-7(35)29-13-18(40)22(12(6-34)45-25(13)44)49-28-21(43)24(17(39)11(5-33)48-28)51-26-14(30-8(2)36)23(16(38)10(4-32)46-26)50-27-20(42)19(41)15(37)9(3-31)47-27/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15+,16-,17+,18-,19+,20-,21-,22-,23-,24+,25-,26+,27+,28+/m1/s1",Galbeta1-3GlcNAcbeta1-3Galbeta1-4GlcNAcbeta,PubMed citation,19443021
3788,74736,N(1)-methyladenosine 5'-monophosphate,A purine ribonucleoside 5'-monophosphate that is AMP monomethylated on N(1).,"InChI=1S/C11H16N5O7P/c1-15-3-14-10-6(9(15)12)13-4-16(10)11-8(18)7(17)5(23-11)2-22-24(19,20)21/h3-5,7-8,11-12,17-18H,2H2,1H3,(H2,19,20,21)/t5-,7-,8-,11-/m1/s1",N(1)-methyladenosine 5'-phosphate,Reaxys Registry Number,631171
3789,70712,(5Z)-tetradecenoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (5Z)-tetradecenoic acid.,"InChI=1S/C35H60N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h11-12,22-24,28-30,34,45-46H,4-10,13-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/b12-11-/t24-,28-,29-,30+,34-/m1/s1",Z-tetradec-5-enoyl-CoA,PubMed citation,1326520
3790,70754,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->4)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,"A branched amino hexasaccharide comprised of a linear chain of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, and N-acetyl-beta-D-glucosamine residues, all linked sequentially (1->4), to each N-acetyl-D-glucosamine residue of which is (1->3)-linked an alpha-L-fucosyl residue.","InChI=1S/C40H68N2O29/c1-9-19(49)22(52)26(56)37(61-9)70-33-17(41-11(3)47)35(60)63-15(7-45)31(33)68-40-29(59)25(55)30(14(6-44)66-40)67-36-18(42-12(4)48)34(71-38-27(57)23(53)20(50)10(2)62-38)32(16(8-46)65-36)69-39-28(58)24(54)21(51)13(5-43)64-39/h9-10,13-40,43-46,49-60H,5-8H2,1-4H3,(H,41,47)(H,42,48)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22+,23+,24-,25+,26-,27-,28+,29+,30-,31+,32+,33+,34+,35+,36-,37-,38-,39-,40-/m0/s1",alpha-L-fucosyl-(1->3)-[alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->4)-beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosamine,PubMed citation,19443021
3791,70762,all-trans-retinyl linoleate,A fatty acid ester formed between linoleic acid and all-trans-retinol.,"InChI=1S/C38H60O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27-37(39)40-32-30-34(3)25-22-24-33(2)28-29-36-35(4)26-23-31-38(36,5)6/h11-12,14-15,22,24-25,28-30H,7-10,13,16-21,23,26-27,31-32H2,1-6H3/b12-11-,15-14-,25-22+,29-28+,33-24+,34-30+",O-linoleoyl-all-trans-retinol,CAS Registry Number,631-89-0
3792,70764,"tritrans,heptacis-undecaprenyl phosphate",An undecaprenyl phosphate having three (E)- and seven (Z)-double bonds.,"InChI=1S/C55H91O4P/c1-45(2)23-13-24-46(3)25-14-26-47(4)27-15-28-48(5)29-16-30-49(6)31-17-32-50(7)33-18-34-51(8)35-19-36-52(9)37-20-38-53(10)39-21-40-54(11)41-22-42-55(12)43-44-59-60(56,57)58/h23,25,27,29,31,33,35,37,39,41,43H,13-22,24,26,28,30,32,34,36,38,40,42,44H2,1-12H3,(H2,56,57,58)/b46-25+,47-27+,48-29+,49-31-,50-33-,51-35-,52-37-,53-39-,54-41-,55-43-","tritrans,polycis-undecaprenyl phosphate",PubMed citation,16618123
3793,70771,15-methylhexadecasphing-4-enine(1+),"A cationic sphingoid that is the conjugate acid of 15-methylhexadecasphing-4-enine, obtained by protonation of the amino group; major species at pH 7.3.","InChI=1S/C17H35NO2/c1-15(2)12-10-8-6-4-3-5-7-9-11-13-17(20)16(18)14-19/h11,13,15-17,19-20H,3-10,12,14,18H2,1-2H3/p+1/b13-11+/t16-,17+/m0/s1","15-methyl-2-aminohexadec-4-en-1,3-diol",LIPID MAPS instance accession,LMSP01080005
3794,70778,GW 7647,A monocarboxylic acid that is 2-(phenylsulfanyl)isobutyric acid in which the phenyl group is substituted at the para- position by a 3-aza-7-cyclohexylhept-1-yl group in which the nitrogen is acylated by a (cyclohexylamino)carbonyl group.,"InChI=1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)",GW-7647,CAS Registry Number,265129-71-3
3795,70785,"CDP-3,6-dideoxy-alpha-D-glucose(2-)","A CDP-3,6-dideoxy-D-glucose(2-) in which the anomeric centre of the pyranose fragment has alpha-configuration.","InChI=1S/C15H25N3O14P2/c1-6-7(19)4-8(20)14(29-6)31-34(26,27)32-33(24,25)28-5-9-11(21)12(22)13(30-9)18-3-2-10(16)17-15(18)23/h2-3,6-9,11-14,19-22H,4-5H2,1H3,(H,24,25)(H,26,27)(H2,16,17,23)/p-2/t6-,7+,8-,9-,11-,12-,13-,14-/m1/s1","CDP-3,6-dideoxy-alpha-D-glucose",PubMed citation,9538012
3796,70797,1-deoxy-11-oxopentalenic acid,A tricyclic sesquiterpenoid that is pentalenene in which the 13-methyl group is oxidsed to the carboxylic acid and a keto group is located at position 11.,"InChI=1S/C15H20O3/c1-8-12(16)5-11-10(13(17)18)4-9-6-14(2,3)7-15(8,9)11/h4,8-9,11H,5-7H2,1-3H3,(H,17,18)/t8-,9-,11+,15-/m1/s1",1-deoxy-11-ketopentalenic acid,MetaCyc accession,CPD-13625
3797,70802,"CDP-3,6-dideoxy-alpha-D-glucose","A CDP-3,6-dideoxy-D-glucose in which the anomeric centre of the pyranose fragment has alpha-configuration.","InChI=1S/C15H25N3O14P2/c1-6-7(19)4-8(20)14(29-6)31-34(26,27)32-33(24,25)28-5-9-11(21)12(22)13(30-9)18-3-2-10(16)17-15(18)23/h2-3,6-9,11-14,19-22H,4-5H2,1H3,(H,24,25)(H,26,27)(H2,16,17,23)/t6-,7+,8-,9-,11-,12-,13-,14-/m1/s1",CDP-alpha-D-paratose,KEGG COMPOUND accession,C03598
3798,70808,3-(imidazol-1-yl)lactic acid,An imidazolyl carboxylic acid that is lactic acid in which one of the methyl hydrogens is substituted by an imidazol-1-yl group.,"InChI=1S/C6H8N2O3/c9-5(6(10)11)3-8-2-1-7-4-8/h1-2,4-5,9H,3H2,(H,10,11)",2-hydroxy-3-(1H-imidazol-1-yl)propanoic acid,PubMed citation,22770225
3799,70832,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp6S,A trisaccharide derivative that consists of 6-sulfated D-glucose having an alpha-L-fucosyl residue attached at position 3 and a beta-D-galactosyl residue attached at position 4.,"InChI=1S/C18H32O18S/c1-4-7(20)9(22)11(24)17(32-4)36-15-13(26)16(27)33-6(3-31-37(28,29)30)14(15)35-18-12(25)10(23)8(21)5(2-19)34-18/h4-27H,2-3H2,1H3,(H,28,29,30)/t4-,5+,6+,7+,8-,9+,10-,11-,12+,13+,14+,15+,16?,17-,18-/m0/s1",alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-6-O-sulfo-D-glucose,PubMed citation,19443021
3800,70836,"guanosine 5'-[beta,gamma-methylene]triphosphate(4-)","An organophosphate oxoanion obtained by deprotonation of the phosphate and phosphonate OH groups of guanosine 5'-[beta,gamma-methylene]triphosphate.","InChI=1S/C11H18N5O13P3/c12-11-14-8-5(9(19)15-11)13-2-16(8)10-7(18)6(17)4(28-10)1-27-32(25,26)29-31(23,24)3-30(20,21)22/h2,4,6-7,10,17-18H,1,3H2,(H,23,24)(H,25,26)(H2,20,21,22)(H3,12,14,15,19)/p-4/t4-,6-,7-,10-/m1/s1",GppCp(4-),Reaxys Registry Number,11047236
3801,70849,beta-D-Galp-(1->4)-alpha-D-GlcpNAc-(1->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,"A linear amino tetrasaccharide comprised of beta-D-galactose, N-acetyl-alpha-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamineresidues linked sequentially (1->4), (1->6) and (1->4).","InChI=1S/C28H48N2O21/c1-7(34)29-13-17(38)23(10(4-32)46-25(13)44)50-28-22(43)20(41)16(37)12(49-28)6-45-26-14(30-8(2)35)18(39)24(11(5-33)48-26)51-27-21(42)19(40)15(36)9(3-31)47-27/h9-28,31-33,36-44H,3-6H2,1-2H3,(H,29,34)(H,30,35)/t9-,10-,11-,12-,13-,14-,15+,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26+,27+,28+/m1/s1",beta-D-Gal-(1->4)-alpha-D-GlcNAc-(1->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3802,70850,isoheptadecanoic acid,A branched-chain saturated fatty acid comprising hexadecanoic (palmitic) acid substituted at position 15 by a methyl group.,"InChI=1S/C17H34O2/c1-16(2)14-12-10-8-6-4-3-5-7-9-11-13-15-17(18)19/h16H,3-15H2,1-2H3,(H,18,19)",15-methylpalmitic acid,PubMed citation,18676815
3803,70852,15-methylhexadecasphinganine,A sphingoid that is hexadecasphinganine substituted at position 15 by a methyl group.,"InChI=1S/C17H37NO2/c1-15(2)12-10-8-6-4-3-5-7-9-11-13-17(20)16(18)14-19/h15-17,19-20H,3-14,18H2,1-2H3/t16-,17+/m0/s1",15-methylhexadecadihydrosphingosine,Reaxys Registry Number,18599379
3804,70964,8-hydroxy-dAMP,A purine 2'-deoxyribonucleoside 5'-monophosphate that is that is dAMP in which the hydrogen at position 8 of the purine base has been replaced by a hydroxy group.,"InChI=1S/C10H14N5O7P/c11-8-7-9(13-3-12-8)15(10(17)14-7)6-1-4(16)5(22-6)2-21-23(18,19)20/h3-6,16H,1-2H2,(H,14,17)(H2,11,12,13)(H2,18,19,20)/t4-,5+,6+/m0/s1",8-hydroxy-2'-deoxyadenosine 5'-monophosphate,PubMed citation,22556419
3805,71009,hexadecasphinganine(1+),"A cationic sphingoid that is the conjugate acid of hexadecasphinganine, obtained by protonation of the primary amino function; major species at pH 7.3.","InChI=1S/C16H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-16(19)15(17)14-18/h15-16,18-19H,2-14,17H2,1H3/p+1/t15-,16+/m0/s1",C16-SA,LIPID MAPS instance accession,LMSP01040001
3806,71011,hexadecasphing-4-enine(1+),"A cationic sphingoid that is the conjugate acid of hexadecasphing-4-enine, obtained by protonation of the primary amino function; major species at pH 7.3.","InChI=1S/C16H33NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-16(19)15(17)14-18/h12-13,15-16,18-19H,2-11,14,17H2,1H3/p+1/b13-12+/t15-,16+/m0/s1",hexadecasphingosine(1+),LIPID MAPS instance accession,LMSP01040008
3807,71038,3-hydroxyadipyl-CoA,An acyl-CoA that results from formal condensation of the thiol group of coenzyme A with the 1-carboxy group of 3-hydroxyadipic acid.,"InChI=1S/C27H44N7O20P3S/c1-27(2,22(41)25(42)30-6-5-16(36)29-7-8-58-18(39)9-14(35)3-4-17(37)38)11-51-57(48,49)54-56(46,47)50-10-15-21(53-55(43,44)45)20(40)26(52-15)34-13-33-19-23(28)31-12-32-24(19)34/h12-15,20-22,26,35,40-41H,3-11H2,1-2H3,(H,29,36)(H,30,42)(H,37,38)(H,46,47)(H,48,49)(H2,28,31,32)(H2,43,44,45)/t14?,15-,20-,21-,22+,26-/m1/s1",3-hydroxyadipoyl-CoA,MetaCyc accession,3-HYDROXYADIPYL-COA
3808,71046,tetradecasphinganine,A sphingoid obtained by formal hydrogenation of the C=C bond of tetradecasphingosine,"InChI=1S/C14H31NO2/c1-2-3-4-5-6-7-8-9-10-11-14(17)13(15)12-16/h13-14,16-17H,2-12,15H2,1H3/t13-,14+/m0/s1",C14 dihydrosphingosine,PubMed citation,18023840
3809,71047,3-hydroxybenzenesulfonic acid,An arenesulfonic acid that is phenol substituted by a sulfo group at C-3.,"InChI=1S/C6H6O4S/c7-5-2-1-3-6(4-5)11(8,9)10/h1-4,7H,(H,8,9,10)",phenol-3-sulfonic acid,PubMed citation,22770225
3810,71049,2-hydroxybenzenesulfonic acid,An arenesulfonic acid that is phenol substituted by a sulfo group at C-2.,"InChI=1S/C6H6O4S/c7-5-3-1-2-4-6(5)11(8,9)10/h1-4,7H,(H,8,9,10)",phenol-2-sulfonic acid,PubMed citation,22770225
3811,71055,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc,"A linear amino tetrasaccharide consisting of a sequence of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamine residues linked (1->4), (1->3) and (1->3).","InChI=1S/C28H48N2O21/c1-7(35)29-13-18(40)22(49-27-20(42)19(41)15(37)9(3-31)46-27)12(6-34)48-26(13)51-24-17(39)11(5-33)47-28(21(24)43)50-23-14(30-8(2)36)25(44)45-10(4-32)16(23)38/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15+,16-,17+,18-,19+,20-,21-,22-,23-,24+,25-,26+,27+,28+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->3)-beta-D-GlcNAc,PubMed citation,19443021
3812,71058,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,"A branched amino octasaccharide comprised of a sequence of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine,beta-D-galactose and N-acetyl-beta-D-glucosamine residues, linked (1->4), (1->3), (1->4), (1->3) and (1->4), to the reducing-end and centrally positioned GlcNAc residues of which are also (1->3)-linked alpha-L-fucose residues.","InChI=1S/C54H91N3O39/c1-12-26(67)32(73)35(76)50(82-12)93-43-24(56-15(4)65)47(81)84-21(10-62)41(43)91-53-39(80)46(30(71)19(8-60)86-53)96-49-25(57-16(5)66)44(94-51-36(77)33(74)27(68)13(2)83-51)42(22(11-63)89-49)92-54-38(79)45(29(70)18(7-59)87-54)95-48-23(55-14(3)64)31(72)40(20(9-61)88-48)90-52-37(78)34(75)28(69)17(6-58)85-52/h12-13,17-54,58-63,67-81H,6-11H2,1-5H3,(H,55,64)(H,56,65)(H,57,66)/t12-,13-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28-,29-,30-,31+,32+,33+,34-,35-,36-,37+,38+,39+,40+,41+,42+,43+,44+,45-,46-,47+,48-,49-,50-,51-,52-,53-,54-/m0/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc,PubMed citation,19443021
3813,71163,"2,3-didehydroadipoyl-CoA",A 2-enoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the enoic carboxy group of hex-2-enedioic acid.,"InChI=1S/C27H42N7O19P3S/c1-27(2,22(40)25(41)30-8-7-16(35)29-9-10-57-18(38)6-4-3-5-17(36)37)12-50-56(47,48)53-55(45,46)49-11-15-21(52-54(42,43)44)20(39)26(51-15)34-14-33-19-23(28)31-13-32-24(19)34/h4,6,13-15,20-22,26,39-40H,3,5,7-12H2,1-2H3,(H,29,35)(H,30,41)(H,36,37)(H,45,46)(H,47,48)(H2,28,31,32)(H2,42,43,44)/t15-,20-,21-,22+,26-/m1/s1","2,3-didehydroadipoyl-coenzyme A",PubMed citation,20660314
3814,71164,(R)-lactoyl-CoA,A lactoyl-CoA in which the lactoyl residue has (R)-configuration.,"InChI=1S/C24H40N7O18P3S/c1-12(32)23(37)53-7-6-26-14(33)4-5-27-21(36)18(35)24(2,3)9-46-52(43,44)49-51(41,42)45-8-13-17(48-50(38,39)40)16(34)22(47-13)31-11-30-15-19(25)28-10-29-20(15)31/h10-13,16-18,22,32,34-35H,4-9H2,1-3H3,(H,26,33)(H,27,36)(H,41,42)(H,43,44)(H2,25,28,29)(H2,38,39,40)/t12-,13-,16-,17-,18+,22-/m1/s1",D-lactoyl-CoA,Reaxys Registry Number,21247354
3815,71177,tetrahydromonapterin,"A tetrahydropterin that is monapterin tetrahydrogenated at positions 5, 6, 7 and 8.","InChI=1S/C9H15N5O4/c10-9-13-7-5(8(18)14-9)12-3(1-11-7)6(17)4(16)2-15/h3-4,6,12,15-17H,1-2H2,(H4,10,11,13,14,18)/t3?,4-,6-/m0/s1",H4-MPt,MetaCyc accession,CPD0-2101
3816,71189,iminodiacetonitrile,A secondary amino compound that is ammonia in which two of the hydrogens are substituted by cyanomethyl groups.,"InChI=1S/C4H5N3/c5-1-3-7-4-2-6/h7H,3-4H2",2-[(cyanomethyl)amino]acetonitrile,Reaxys Registry Number,773803
3817,71203,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc in which the configuration of the anomeric centre of the reducing-end N-acetylglucosamine residue is beta.,"InChI=1S/C28H48N2O21/c1-7(35)29-13-17(39)22(11(5-33)45-25(13)44)50-28-21(43)24(16(38)10(4-32)47-28)51-26-14(30-8(2)36)18(40)23(12(6-34)48-26)49-27-20(42)19(41)15(37)9(3-31)46-27/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15+,16+,17-,18-,19+,20-,21-,22-,23-,24+,25-,26+,27+,28+/m1/s1",Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta,PubMed citation,19443021
3818,71204,bepotastine,"An ether that is (S)-(4-chlorophenyl)(pyridin-2-yl)methanol in which the hydroxyl hydrogen is substituted by a 1-(3-carboxypropyl)piperidin-4-yl group. A topical, selective and non-sedating histamine (H1) receptor antagonist used (as its benzenesulfonate salt) for treatment of itching associated with allergic conjunctivitis.","InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1",betotastine,KEGG DRUG accession,D09705
3819,71205,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc in which the configuration of the anomeric centre of the reducing-end N-acetylglucosamine residue is beta.,"InChI=1S/C42H71N3O31/c1-10(52)43-19-25(58)32(16(7-49)66-37(19)65)73-41-30(63)35(23(56)14(5-47)68-41)75-39-21(45-12(3)54)27(60)34(18(9-51)71-39)74-42-31(64)36(24(57)15(6-48)69-42)76-38-20(44-11(2)53)26(59)33(17(8-50)70-38)72-40-29(62)28(61)22(55)13(4-46)67-40/h13-42,46-51,55-65H,4-9H2,1-3H3,(H,43,52)(H,44,53)(H,45,54)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25-,26-,27-,28+,29-,30-,31-,32-,33-,34-,35+,36+,37-,38+,39+,40+,41+,42+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3820,71206,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-alpha-D-GalpNAc,"An amino trisaccharide comprised of a linear sequence of beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-alpha-D-galactosamine linked (1->4) and (1->6); beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-D-GalpNAc with alpha anomeric configuration at the reducing-end.","InChI=1S/C22H38N2O16/c1-6(27)23-11-15(31)14(30)10(37-20(11)35)5-36-21-12(24-7(2)28)16(32)19(9(4-26)39-21)40-22-18(34)17(33)13(29)8(3-25)38-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13+,14+,15-,16-,17+,18-,19-,20+,21-,22+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-alpha-D-GalNAc,PubMed citation,19443021
3821,71208,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,"An amino tetrasaccharide comprised of a linear sequence of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamine residues linked (1->4), (1->6) and (1->4).","InChI=1S/C28H48N2O21/c1-7(34)29-13-17(38)23(10(4-32)46-25(13)44)50-28-22(43)20(41)16(37)12(49-28)6-45-26-14(30-8(2)35)18(39)24(11(5-33)48-26)51-27-21(42)19(40)15(36)9(3-31)47-27/h9-28,31-33,36-44H,3-6H2,1-2H3,(H,29,34)(H,30,35)/t9-,10-,11-,12-,13-,14-,15+,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27+,28+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3822,71209,N-(cyanomethyl)glycine,A nitrile that is the N-cyanomethyl derivative of glycine.,"InChI=1S/C4H6N2O2/c5-1-2-6-3-4(7)8/h6H,2-3H2,(H,7,8)",alpha-(cyanomethylamino)acetic acid,Reaxys Registry Number,6186843
3823,71213,3-oxocyclopentanecarboxylic acid,An alicyclic ketone that is oxocyclopentanone substituted at position 3 by a carboxy group.,"InChI=1S/C6H8O3/c7-5-2-1-4(3-5)6(8)9/h4H,1-3H2,(H,8,9)",3-ketocyclopentanecarboxylic acid,Reaxys Registry Number,2084326
3824,71214,4-methoxy-4-oxo-3-phenylbutanoic acid,A dicarboxylic acid monoester that is methyl succinate substituted at position 2 by a phenyl group.,"InChI=1S/C11H12O4/c1-15-11(14)9(7-10(12)13)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3,(H,12,13)",3-methoxycarbonyl-3-phenylbutyric acid,Reaxys Registry Number,1971098
3825,71215,(4-coumaroyl)acetyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (4-coumaroyl)acetic acid.,"InChI=1S/C32H44N7O19P3S/c1-32(2,27(45)30(46)35-10-9-22(42)34-11-12-62-23(43)13-20(41)8-5-18-3-6-19(40)7-4-18)15-55-61(52,53)58-60(50,51)54-14-21-26(57-59(47,48)49)25(44)31(56-21)39-17-38-24-28(33)36-16-37-29(24)39/h3-8,16-17,21,25-27,31,40,44-45H,9-15H2,1-2H3,(H,34,42)(H,35,46)(H,50,51)(H,52,53)(H2,33,36,37)(H2,47,48,49)/t21-,25-,26-,27+,31-/m1/s1",(p-coumaroyl)acetyl-CoA,KEGG COMPOUND accession,C17740
3826,71225,(-)-gallocatechin,"A a gallocatechin that has (2S,3R)-configuration.","InChI=1S/C15H14O7/c16-7-3-9(17)8-5-12(20)15(22-13(8)4-7)6-1-10(18)14(21)11(19)2-6/h1-4,12,15-21H,5H2/t12-,15+/m1/s1",ent-gallocatechin,Wikipedia accession,Gallocatechol
3827,71235,4-hydroxy-3-nitrophenylacetaldehyde,A C-nitro compound that is phenylacetaldehyde substituted at positions 3 and 4 by nitro and hydroxy groups respectively.,"InChI=1S/C8H7NO4/c10-4-3-6-1-2-8(11)7(5-6)9(12)13/h1-2,4-5,11H,3H2",2-(4-hydroxy-3-nitrophenyl)acetaldehyde,PubMed citation,18658270
3828,71244,malonyl-CoA methyl ester,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of malonic acid monomethyl ester.,"InChI=1S/C25H40N7O19P3S/c1-25(2,20(37)23(38)28-5-4-14(33)27-6-7-55-16(35)8-15(34)46-3)10-48-54(44,45)51-53(42,43)47-9-13-19(50-52(39,40)41)18(36)24(49-13)32-12-31-17-21(26)29-11-30-22(17)32/h11-13,18-20,24,36-37H,4-10H2,1-3H3,(H,27,33)(H,28,38)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t13-,18-,19-,20?,24-/m1/s1",malonyl-coenzyme A methyl ester,MetaCyc accession,CPD-12454
3829,71254,N(6)-(glycylglycyl)-L-lysine,"An L-alpha-amino acid consisting of L-lysine, to the epsilon amino group of which is attached a glycylglycine dipeptide through an isopeptide bond.","InChI=1S/C10H20N4O4/c11-5-8(15)14-6-9(16)13-4-2-1-3-7(12)10(17)18/h7H,1-6,11-12H2,(H,13,16)(H,14,15)(H,17,18)/t7-/m0/s1",K-GG,PubMed citation,22871113
3830,71259,selenodiglutathione(2-),A carboxylic acid anion resulting from the deprotonation of all four carboxy groups and the protonation of both of the primary amino groups of selenodiglutathione. The major species at pH 7.3.,"InChI=1S/C20H32N6O12S2Se/c21-9(19(35)36)1-3-13(27)25-11(17(33)23-5-15(29)30)7-39-41-40-8-12(18(34)24-6-16(31)32)26-14(28)4-2-10(22)20(37)38/h9-12H,1-8,21-22H2,(H,23,33)(H,24,34)(H,25,27)(H,26,28)(H,29,30)(H,31,32)(H,35,36)(H,37,38)/p-2/t9-,10-,11-,12-/m0/s1",GSSeSG(2-),MetaCyc accession,CPD-13908
3831,71260,pitavastatin(1-),"A hydroxy monocarboxylic acid anion that is the conjugate base of pitavastatin, obtained by deprotonation of the carboxy group.","InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/p-1/b12-11+/t18-,19-/m1/s1",pitavastatin cation,KEGG COMPOUND accession,C13334
3832,71264,4-pyridylacetylglycine,An N-acylglycine in which the acyl group is specified as 4-pyridylacetyl.,"InChI=1S/C9H10N2O3/c12-8(11-6-9(13)14)5-7-1-3-10-4-2-7/h1-4H,5-6H2,(H,11,12)(H,13,14)",N-(4-pyridinylacetyl)glycine,Reaxys Registry Number,14247153
3833,71269,alpha-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,"A linear amino trisaccharide comprising N-acetyl-alpha-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamine residues linked sequentially (1->3) and (1->4).","InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)18(10(5-27)36-20(11)35)39-22-17(34)19(14(31)9(4-26)38-22)40-21-12(24-7(2)29)15(32)13(30)8(3-25)37-21/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17-,18-,19+,20-,21-,22+/m1/s1",alpha-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3834,71270,alpha-D-GlcpNAc-(1->4)-beta-D-Galp-(1->3)-D-GalpNAc,"An amino trisaccharide consisting of N-acetyl-alpha-D-glucosamine, beta-D-galactose and N-acetyl-D-galactosamine residues linked sequentially (1->4) and (1->3).","InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)13(30)8(3-25)37-21(11)39-18-10(5-27)38-22(17(34)16(18)33)40-19-12(24-7(2)29)20(35)36-9(4-26)14(19)31/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17-,18+,19-,20?,21-,22+/m1/s1",alpha-D-GlcNAc-(1->4)-beta-D-Gal-(1->3)-D-GalNAc,PubMed citation,19443021
3835,71282,alpha-D-GlcpNAc-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,A linear amino pentasaccharide comprising beta-D-glucose at the reducing end with an N-acetyl-beta-D-glucosaminyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-beta-D-galactosyl moiety at the 4-position.,"InChI=1S/C34H58N2O26/c1-8(42)35-15-19(46)17(44)10(3-37)55-31(15)59-28-14(7-41)58-33(24(51)22(28)49)60-26-13(6-40)57-32(16(20(26)47)36-9(2)43)62-29-18(45)11(4-38)56-34(25(29)52)61-27-12(5-39)54-30(53)23(50)21(27)48/h10-34,37-41,44-53H,3-7H2,1-2H3,(H,35,42)(H,36,43)/t10-,11-,12-,13-,14-,15-,16-,17-,18+,19-,20-,21-,22-,23-,24-,25-,26-,27-,28+,29+,30-,31-,32+,33+,34+/m1/s1",N-acetyl-alpha-D-glucosaminyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-alpha-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucose,PubMed citation,19443021
3836,71286,3-nitrotyramine zwitterion,A zwitterion obtained by transfer of a proton from the phenol to the amino group of 3-nitrotyramine; major species at pH 7.3,"InChI=1S/C8H10N2O3/c9-4-3-6-1-2-8(11)7(5-6)10(12)13/h1-2,5,11H,3-4,9H2",4-(2-aminoethyl)-2-nitrophenol,PubMed citation,18658270
3837,71287,4-hydroxy-3-nitrophenylacetaldehyde(1-),A phenolate anion that is the conjugate base of 4-hydroxy-3-nitrophenylacetaldehyde; major species at pH 7.3,"InChI=1S/C8H7NO4/c10-4-3-6-1-2-8(11)7(5-6)9(12)13/h1-2,4-5,11H,3H2/p-1",2-(4-hydroxy-3-nitrophenyl)acetaldehyde,PubMed citation,18658270
3838,71290,3-hydroxy-3-phenylpropionyl-CoA,A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxy-3-phenylpropionic acid.,"InChI=1S/C30H44N7O18P3S/c1-30(2,25(42)28(43)33-9-8-20(39)32-10-11-59-21(40)12-18(38)17-6-4-3-5-7-17)14-52-58(49,50)55-57(47,48)51-13-19-24(54-56(44,45)46)23(41)29(53-19)37-16-36-22-26(31)34-15-35-27(22)37/h3-7,15-16,18-19,23-25,29,38,41-42H,8-14H2,1-2H3,(H,32,39)(H,33,43)(H,47,48)(H,49,50)(H2,31,34,35)(H2,44,45,46)/t18?,19-,23-,24-,25+,29-/m1/s1",3-hydroxy-3-phenylpropanoyl-CoA,MetaCyc accession,CPD-513
3839,71294,3-hydroxy-3-phenylpropionyl-CoA(4-),An acyl-CoA(4-) oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of 3-hydroxy-3-phenylpropionyl-CoA; major species at pH 7.3.,"InChI=1S/C30H44N7O18P3S/c1-30(2,25(42)28(43)33-9-8-20(39)32-10-11-59-21(40)12-18(38)17-6-4-3-5-7-17)14-52-58(49,50)55-57(47,48)51-13-19-24(54-56(44,45)46)23(41)29(53-19)37-16-36-22-26(31)34-15-35-27(22)37/h3-7,15-16,18-19,23-25,29,38,41-42H,8-14H2,1-2H3,(H,32,39)(H,33,43)(H,47,48)(H,49,50)(H2,31,34,35)(H2,44,45,46)/p-4/t18?,19-,23-,24-,25+,29-/m1/s1",beta-hydroxyphenylpropionyl-coenzyme A(4-),MetaCyc accession,CPD-513
3840,71316,"(2R,4S)-2-methyl-2,4-dihydroxydihydrofuran-3-one",A tetrahydrofuranone that is tetrahydrofuran-3-one substituted at positions 2 and 4 by hydroxy groups and at position 2 by a methyl group.,"InChI=1S/C5H8O4/c1-5(8)4(7)3(6)2-9-5/h3,6,8H,2H2,1H3/t3-,5+/m0/s1",(R)-DHMF,Reaxys Registry Number,9845113
3841,71319,alpha-D-GlcpNAc-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,"A branched amino nonasaccharide comprised of a sequence of N-acetyl-alpha-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamine residues linked (1->4), (1->4), (1->3), (1->4), (1->3) and (1->4), with alpha-L-fucosyl residues linked (1->3) both to the N-acetyl-alpha-D-glucosamine residue at the reducing end and the one proximal to it in the sequence.","InChI=1S/C62H104N4O44/c1-14-31(78)38(85)41(88)58(94-14)107-50-29(65-18(5)76)54(93)96-25(12-72)48(50)105-61-45(92)53(35(82)22(9-69)98-61)110-57-30(66-19(6)77)51(108-59-42(89)39(86)32(79)15(2)95-59)49(26(13-73)101-57)106-62-44(91)52(34(81)21(8-68)99-62)109-56-28(64-17(4)75)37(84)46(23(10-70)100-56)104-60-43(90)40(87)47(24(11-71)102-60)103-55-27(63-16(3)74)36(83)33(80)20(7-67)97-55/h14-15,20-62,67-73,78-93H,7-13H2,1-6H3,(H,63,74)(H,64,75)(H,65,76)(H,66,77)/t14-,15-,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35-,36+,37+,38+,39+,40+,41-,42-,43+,44+,45+,46+,47-,48+,49+,50+,51+,52-,53-,54+,55+,56-,57-,58-,59-,60-,61-,62-/m0/s1",GlcNAcalpha-4Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta,PubMed citation,19443021
3842,71323,alpha-D-GlcpNAc-(1->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,"An amino trisaccharide consisting of N-acetyl-alpha-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamine residues linked sequentially (1->6) and (1->4).","InChI=1S/C22H38N2O16/c1-6(27)23-11-16(32)19(9(4-26)37-20(11)35)40-22-18(34)17(33)14(30)10(39-22)5-36-21-12(24-7(2)28)15(31)13(29)8(3-25)38-21/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17+,18-,19-,20-,21+,22+/m1/s1",alpha-D-GlcNAc-(1->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3843,71325,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-beta-D-GlcpNAc,An amino heptasaccharide consisting of two N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannose disaccharide units linked (1->3) and (1->6) to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine trisaccharide. The anomer of beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end N-acetyl-D-glucosamine residue is beta.,"InChI=1S/C50H84N4O36/c1-12(61)51-23-34(72)39(20(9-59)79-44(23)77)86-47-26(54-15(4)64)35(73)40(21(10-60)84-47)87-48-38(76)41(88-50-43(37(75)30(68)19(8-58)83-50)90-46-25(53-14(3)63)33(71)28(66)17(6-56)81-46)31(69)22(85-48)11-78-49-42(36(74)29(67)18(7-57)82-49)89-45-24(52-13(2)62)32(70)27(65)16(5-55)80-45/h16-50,55-60,65-77H,5-11H2,1-4H3,(H,51,61)(H,52,62)(H,53,63)(H,54,64)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36+,37+,38+,39-,40-,41+,42+,43+,44-,45+,46+,47+,48+,49+,50-/m1/s1",N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine,PubMed citation,19443021
3844,71330,(Z)-dehydrocyclopeptine,A geoisomer of dehydrocyclopeptine in which the C=C bond of the benzylidene substituent has Z-configuration.,"InChI=1S/C17H14N2O2/c1-19-15(11-12-7-3-2-4-8-12)16(20)18-14-10-6-5-9-13(14)17(19)21/h2-11H,1H3,(H,18,20)/b15-11-","(Z)-3,10-dehydrocyclopeptine",Reaxys Registry Number,754106
3845,71331,(E)-dehydrocyclopeptine,A geoisomer of dehydrocyclopeptine in which the C=C bond of the benzylidene substituent has E-configuration.,"InChI=1S/C17H14N2O2/c1-19-15(11-12-7-3-2-4-8-12)16(20)18-14-10-6-5-9-13(14)17(19)21/h2-11H,1H3,(H,18,20)/b15-11+","(E)-3,10-dehydrocyclopeptine",Reaxys Registry Number,754107
3846,71332,(3-nitro-4-oxidophenyl)acetate,The dianion obtained by deprotonation of the phenol and carboxy functions of  (4-hydroxy-3-nitrophenyl)acetic acid.,"InChI=1S/C8H7NO5/c10-7-2-1-5(4-8(11)12)3-6(7)9(13)14/h1-3,10H,4H2,(H,11,12)/p-2",4-hydroxy-3-nitrophenylacetate,PubMed citation,18658270
3847,71336,3'-O-(N-methylanthraniloyl)adenosine 5'-diphosphate,A purine ribonucleoside 5'-diphosphate that is ADP substituted at position 3' by an N-methylanthraniloyl group.,"InChI=1S/C18H22N6O11P2/c1-20-10-5-3-2-4-9(10)18(26)34-14-11(6-32-37(30,31)35-36(27,28)29)33-17(13(14)25)24-8-23-12-15(19)21-7-22-16(12)24/h2-5,7-8,11,13-14,17,20,25H,6H2,1H3,(H,30,31)(H2,19,21,22)(H2,27,28,29)/t11-,13-,14-,17-/m1/s1",MANT-ADP,PubMed citation,7989299
3848,71340,beta-D-GlcpNAc-(1->3)-[beta-D-GlcpNAc-(1->4)]-[beta-D-GlcpNAc-(1->6)]-D-GlcpNAc,"A branched amino tetrasaccharide in which three N-acetyl-beta-D-glucosamine residues are linked (1->3), (1->4) and (1->6) to an N-acetyl-D-glucosamine residue with unspecified configuration at its anomeric centre.","InChI=1S/C32H54N4O21/c1-9(40)33-17-24(47)21(44)13(5-37)53-30(17)51-8-16-27(56-31-18(34-10(2)41)25(48)22(45)14(6-38)54-31)28(20(29(50)52-16)36-12(4)43)57-32-19(35-11(3)42)26(49)23(46)15(7-39)55-32/h13-32,37-39,44-50H,5-8H2,1-4H3,(H,33,40)(H,34,41)(H,35,42)(H,36,43)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29?,30-,31+,32+/m1/s1",beta-D-GlcNAc-(1->3)-[beta-D-GlcNAc-(1->4)]-[beta-D-GlcNAc-(1->6)]-D-GlcNAc,PubMed citation,19443021
3849,71341,beta-D-GlcpNAc-(1->3)-[beta-D-GlcpNAc-(1->6)]-alpha-D-GalpNAc,"A branched amino trisaccharide comprising an N -acetyl-alpha-D-galactosamine residue at the reducing end, to which are (1->3)- and (1->6)-linked  two N -acetyl-alpha-D-glucosamine residues.","InChI=1S/C24H41N3O16/c1-7(30)25-13-19(36)16(33)10(4-28)41-23(13)39-6-12-18(35)21(15(22(38)40-12)27-9(3)32)43-24-14(26-8(2)31)20(37)17(34)11(5-29)42-24/h10-24,28-29,33-38H,4-6H2,1-3H3,(H,25,30)(H,26,31)(H,27,32)/t10-,11-,12-,13-,14-,15-,16-,17-,18+,19-,20-,21-,22+,23-,24+/m1/s1",beta-D-GlcNAc-(1->3)-[beta-D-GlcNAc-(1->6)]-alpha-D-GalNAc,PubMed citation,19443021
3850,71342,beta-D-GlcpNAc-(1->3)-[beta-D-GlcpNAc-(1->6)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc,"A branched amino tetrasaccharide comprising a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine disaccharide, to the galactosyl residue of which are (1->3)- and (1->6)-linked two N-acetyl-beta-D-glucosamine residues.","InChI=1S/C30H51N3O21/c1-8(37)31-15-23(45)25(13(6-36)49-27(15)47)53-30-24(46)26(54-29-17(33-10(3)39)22(44)19(41)12(5-35)51-29)20(42)14(52-30)7-48-28-16(32-9(2)38)21(43)18(40)11(4-34)50-28/h11-30,34-36,40-47H,4-7H2,1-3H3,(H,31,37)(H,32,38)(H,33,39)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20+,21-,22-,23-,24-,25-,26+,27-,28-,29+,30+/m1/s1",beta-D-GlcNAc-(1->3)-[beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3851,71343,Mo(VI)-molybdopterin guanine dinucleotide,A molybdopterin dinucleotide in which the other nucleobase is guanine and the coordinated molybdenum species is MoO2.,"InChI=1S/C20H26N10O13P2S2.Mo.2O/c21-19-26-13-7(15(33)28-19)24-6-12(47)11(46)5(41-17(6)25-13)2-40-45(37,38)43-44(35,36)39-1-4-9(31)10(32)18(42-4)30-3-23-8-14(30)27-20(22)29-16(8)34;;;/h3-6,9-10,17-18,24,31-32,46-47H,1-2H2,(H,35,36)(H,37,38)(H3,22,27,29,34)(H4,21,25,26,28,33);;;/q;+2;;/p-2/t4-,5-,6+,9-,10-,17-,18-;;;/m1.../s1",MoO2-molybdopterin guanine dinucleotide,MetaCyc accession,CPD-582
3852,71344,beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,An amino disaccharide comprising an N-acetyl-beta-D-glucosamine residue linked (1->3) to an N-acetyl-beta-D-galactosamine residue at the reducing end.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)11(23)7(3-19)28-16(9)29-14-10(18-6(2)22)15(26)27-8(4-20)12(14)24/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11-,12+,13-,14-,15+,16+/m1/s1",beta-D-GlcNAc-(1->3)-alpha-D-GalNAc,PubMed citation,19443021
3853,71350,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->3)-alpha-D-GalpNAc,"A linear amino trisaccharide comprised of a (1->3)-linked sequence of N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-galactosamine residues.","InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)13(30)8(3-25)37-21(11)40-19-15(32)10(5-27)38-22(17(19)34)39-18-12(24-7(2)29)20(35)36-9(4-26)14(18)31/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14+,15+,16-,17-,18-,19+,20+,21+,22+/m1/s1",beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->3)-alpha-D-GalNAc,PubMed citation,19443021
3854,71353,Mo(VI)-molybdopterin cytosine dinucleotide,A molybdopterin dinucleotide in which the other nucleobase is cytosine and the coordinated molybdenum species is MoO2.,"InChI=1S/C19H26N8O13P2S2.Mo.2O/c20-7-1-2-27(19(31)22-7)17-11(29)10(28)5(39-17)3-36-41(32,33)40-42(34,35)37-4-6-12(43)13(44)8-16(38-6)24-14-9(23-8)15(30)26-18(21)25-14;;;/h1-2,5-6,8,10-11,16-17,23,28-29,43-44H,3-4H2,(H,32,33)(H,34,35)(H2,20,22,31)(H4,21,24,25,26,30);;;/q;+2;;/p-2/t5-,6-,8+,10-,11-,16-,17-;;;/m1.../s1",MoO2-molybdopterin cytosine dinucleotide,MetaCyc accession,CPD0-1882
3855,71364,2-oxoglutaryl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the 1-carboxy group of 2-oxoglutaric acid.,"InChI=1S/C26H40N7O20P3S/c1-26(2,20(39)23(40)29-6-5-15(35)28-7-8-57-25(41)13(34)3-4-16(36)37)10-50-56(47,48)53-55(45,46)49-9-14-19(52-54(42,43)44)18(38)24(51-14)33-12-32-17-21(27)30-11-31-22(17)33/h11-12,14,18-20,24,38-39H,3-10H2,1-2H3,(H,28,35)(H,29,40)(H,36,37)(H,45,46)(H,47,48)(H2,27,30,31)(H2,42,43,44)/t14-,18-,19-,20?,24-/m1/s1",4-carboxy-2-oxobutanoyl-CoA,MetaCyc accession,CPD-14112
3856,71394,adenosine thiamine triphosphate,An adenosine 5'-phosphate obtained by formal condensation of the hydroxy group of thiamine with the triphosphate group of ATP.,"InChI=1S/C22H30N9O13P3S/c1-11-15(48-10-30(11)6-13-5-25-12(2)29-19(13)23)3-4-40-45(34,35)43-47(38,39)44-46(36,37)41-7-14-17(32)18(33)22(42-14)31-9-28-16-20(24)26-8-27-21(16)31/h5,8-10,14,17-18,22,32-33H,3-4,6-7H2,1-2H3,(H6-,23,24,25,26,27,29,34,35,36,37,38,39)/p+1/t14-,17-,18-,22-/m1/s1",ATP-thiamine,PubMed citation,21697640
3857,71397,8-oxo-dADP,A purine 2'-deoxyribonucleoside 5'-diphosphate that is the 8-oxo derivative of dADP.,"InChI=1S/C10H15N5O10P2/c11-8-7-9(13-3-12-8)15(10(17)14-7)6-1-4(16)5(24-6)2-23-27(21,22)25-26(18,19)20/h3-6,16H,1-2H2,(H,14,17)(H,21,22)(H2,11,12,13)(H2,18,19,20)/t4-,5+,6+/m0/s1",8-oxo-2'-deoxyadenosine-5'-diphosphate,PDBeChem accession,8DD
3858,71403,8-oxo-dAMP,A purine 2'-deoxyribonucleoside 5'-diphosphate that is the 8-oxo derivative of dADP.,"InChI=1S/C10H14N5O7P/c11-8-7-9(13-3-12-8)15(10(17)14-7)6-1-4(16)5(22-6)2-21-23(18,19)20/h3-6,16H,1-2H2,(H,14,17)(H2,11,12,13)(H2,18,19,20)/t4-,5+,6+/m0/s1",8-oxo-2'-deoxyadenosine-5'-phosphate,Reaxys Registry Number,8869265
3859,71405,beta-D-GlcNAc-(1->4)-MDP-Lys(L18),"A glycopeptidolipid consisting of L-lysine, to the N-2 of which is attached an N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetylmuramoyl moiety connected to the amino terminus of the dipeptide L-alanyl-D-isoglutamine, and to the N-6 of which is attached a stearoyl group.","InChI=1S/C51H91N7O18/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-38(63)53-27-22-21-23-35(49(70)71)57-39(64)26-25-34(46(52)67)58-47(68)30(2)54-48(69)31(3)73-45-41(56-33(5)62)50(72)74-37(29-60)44(45)76-51-40(55-32(4)61)43(66)42(65)36(28-59)75-51/h30-31,34-37,40-45,50-51,59-60,65-66,72H,6-29H2,1-5H3,(H2,52,67)(H,53,63)(H,54,69)(H,55,61)(H,56,62)(H,57,64)(H,58,68)(H,70,71)/t30-,31+,34+,35+,36+,37+,40+,41+,42+,43+,44+,45+,50+,51-/m0/s1",N(2)-{[4-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-N-acetylmuramyl]-L-alanyl-D-isoglutaminyl}-N(6)-stearoyl-L-lysine,PubMed citation,19443021
3860,71407,3-oxooctadecanoyl-CoA(4-),A 3-oxo-fatty acyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate groups of 3-oxooctadecanoyl-CoA; major species at pH 7.3.,"InChI=1S/C39H68N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-27(47)22-30(49)68-21-20-41-29(48)18-19-42-37(52)34(51)39(2,3)24-61-67(58,59)64-66(56,57)60-23-28-33(63-65(53,54)55)32(50)38(62-28)46-26-45-31-35(40)43-25-44-36(31)46/h25-26,28,32-34,38,50-51H,4-24H2,1-3H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/p-4/t28-,32-,33-,34+,38-/m1/s1",3-ketostearoyl-CoA(4-),MetaCyc accession,CPD-10260
3861,71412,trans-2-octadecenoyl-CoA(4-),"A 2,3-trans-enoyl CoA(4-) arising from deprotonation of the phosphate and diphosphate groups of trans-2-octadecenoyl-CoA; major species at pH 7.3.","InChI=1S/C39H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h18-19,26-28,32-34,38,49-50H,4-17,20-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/p-4/b19-18+/t28-,32-,33-,34+,38-/m1/s1",(2E)-octadecenoyl-CoA(4-),MetaCyc accession,CPD-10262
3862,71429,deaminoneuraminic acid,A ketoaldonic acid obtained formally by deamination of neuraminic acid. Although not containing nitrogen it is regarded as being a member of the sialic acid family.,"InChI=1S/C9H16O9/c10-2-4(12)6(14)7-5(13)3(11)1-9(17,18-7)8(15)16/h3-7,10-14,17H,1-2H2,(H,15,16)/t3-,4+,5+,6+,7+,9?/m0/s1",KDN,PubMed citation,22975979
3863,71432,deamino-alpha-neuraminic acid,Deaminoneuraminic acid in which the anomric configuration is alpha.,"InChI=1S/C9H16O9/c10-2-4(12)6(14)7-5(13)3(11)1-9(17,18-7)8(15)16/h3-7,10-14,17H,1-2H2,(H,15,16)/t3-,4+,5+,6+,7+,9+/m0/s1",alphaKDN,PubMed citation,10542227
3864,71433,isopalmitoyl-CoA,A methyl-branched fatty acyl-CoA obtained from the formal condensation of the thiol group of coenzyme A with the carboxy group of isopalmitic acid,"InChI=1S/C37H66N7O17P3S/c1-25(2)15-13-11-9-7-5-6-8-10-12-14-16-28(46)65-20-19-39-27(45)17-18-40-35(49)32(48)37(3,4)22-58-64(55,56)61-63(53,54)57-21-26-31(60-62(50,51)52)30(47)36(59-26)44-24-43-29-33(38)41-23-42-34(29)44/h23-26,30-32,36,47-48H,5-22H2,1-4H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/t26-,30-,31-,32+,36-/m1/s1",isopalmitoyl-coenzyme A,PubMed citation,8521864
3865,71434,alpha-KDN-(2->3)-beta-D-Galp-(1->3)-alpha-D-GalpNAc,"An amino trisaccharide consisting of alpha-KDN, beta-D-galactose and N-acetyl-alpha-D-galactosamine residues linked sequentially (2->3) and (1->3).","InChI=1S/C23H39NO19/c1-6(28)24-11-17(14(33)9(4-26)39-20(11)36)41-21-16(35)19(15(34)10(5-27)40-21)43-23(22(37)38)2-7(29)12(31)18(42-23)13(32)8(30)3-25/h7-21,25-27,29-36H,2-5H2,1H3,(H,24,28)(H,37,38)/t7-,8+,9+,10+,11+,12+,13+,14-,15-,16+,17+,18+,19-,20-,21-,23-/m0/s1",KDNalpha2-3Galbeta1-3GalNAcalpha,PubMed citation,19443021
3866,71438,alpha-KDN-(2->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc,"A linear amino trisaccharide consisting of alpha-KDN, beta-D-galactose and N-acetyl-beta-D-glucosamine residues linked sequentially (2->3) and (1->3).","InChI=1S/C23H39NO19/c1-6(28)24-11-17(14(33)9(4-26)39-20(11)36)41-21-16(35)19(15(34)10(5-27)40-21)43-23(22(37)38)2-7(29)12(31)18(42-23)13(32)8(30)3-25/h7-21,25-27,29-36H,2-5H2,1H3,(H,24,28)(H,37,38)/t7-,8+,9+,10+,11+,12+,13+,14+,15-,16+,17+,18+,19-,20+,21-,23-/m0/s1",deamino-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosamine,PubMed citation,19443021
3867,71444,alpha-KDN-(2->6)-beta-D-Galp-(1->4)-D-GlcpNAc,"A linear amino trisaccharide consisting of alpha-KDN, beta-D-galactose and N-acetyl-D-glucosamine residues linked sequentially (2->6) and (1->4).","InChI=1S/C23H39NO19/c1-6(27)24-11-15(33)18(9(4-26)40-20(11)36)42-21-17(35)16(34)14(32)10(41-21)5-39-23(22(37)38)2-7(28)12(30)19(43-23)13(31)8(29)3-25/h7-21,25-26,28-36H,2-5H2,1H3,(H,24,27)(H,37,38)/t7-,8+,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+,19+,20?,21-,23+/m0/s1",KDNalpha2-6Galbeta1-4GlcNAc,PubMed citation,19443021
3868,71445,3-oxoisoheptadecanoyl-CoA(4-),A 3-oxo-fatty acyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate functions of 3-oxoisoheptadecanoyl-CoA.,"InChI=1S/C38H66N7O18P3S/c1-25(2)14-12-10-8-6-5-7-9-11-13-15-26(46)20-29(48)67-19-18-40-28(47)16-17-41-36(51)33(50)38(3,4)22-60-66(57,58)63-65(55,56)59-21-27-32(62-64(52,53)54)31(49)37(61-27)45-24-44-30-34(39)42-23-43-35(30)45/h23-25,27,31-33,37,49-50H,5-22H2,1-4H3,(H,40,47)(H,41,51)(H,55,56)(H,57,58)(H2,39,42,43)(H2,52,53,54)/p-4/t27-,31-,32-,33+,37-/m1/s1",15-methyl-3-oxohexadecanoyl-CoA(4-),PubMed citation,18390550
3869,71446,3-hydroxyisoheptadecanoyl-CoA(4-),An acyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate OH groups of 3-hydroxyisoheptadecanoyl-CoA.,"InChI=1S/C38H68N7O18P3S/c1-25(2)14-12-10-8-6-5-7-9-11-13-15-26(46)20-29(48)67-19-18-40-28(47)16-17-41-36(51)33(50)38(3,4)22-60-66(57,58)63-65(55,56)59-21-27-32(62-64(52,53)54)31(49)37(61-27)45-24-44-30-34(39)42-23-43-35(30)45/h23-27,31-33,37,46,49-50H,5-22H2,1-4H3,(H,40,47)(H,41,51)(H,55,56)(H,57,58)(H2,39,42,43)(H2,52,53,54)/p-4/t26?,27-,31-,32-,33+,37-/m1/s1",3-hydroxy-15-methylpalmitoyl-CoA(4-),PubMed citation,18390550
3870,71453,3-oxoisoheptadecanoyl-CoA,A methyl-branched fatty acyl-CoA obtained from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxoisoheptadecanoic acid.,"InChI=1S/C38H66N7O18P3S/c1-25(2)14-12-10-8-6-5-7-9-11-13-15-26(46)20-29(48)67-19-18-40-28(47)16-17-41-36(51)33(50)38(3,4)22-60-66(57,58)63-65(55,56)59-21-27-32(62-64(52,53)54)31(49)37(61-27)45-24-44-30-34(39)42-23-43-35(30)45/h23-25,27,31-33,37,49-50H,5-22H2,1-4H3,(H,40,47)(H,41,51)(H,55,56)(H,57,58)(H2,39,42,43)(H2,52,53,54)/t27-,31-,32-,33+,37-/m1/s1",15-methyl-3-oxopalmitoyl-coenzyme,PubMed citation,18390550
3871,71464,palmitoyl ethanolamide,An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.,"InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)",hexadecanoyl ethanolamide,PubMed citation,21562563
3872,71467,"(5Z,8Z,11Z,14Z,17Z)-icosapentaenoylethanolamine","An N-acylethanolamine 20:5 that is the ethanolamide of (5Z,8Z,11Z,14Z17Z)-eicosapentaenoic acid.","InChI=1S/C22H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h3-4,6-7,9-10,12-13,15-16,24H,2,5,8,11,14,17-21H2,1H3,(H,23,25)/b4-3-,7-6-,10-9-,13-12-,16-15-",eicosapentaenoyl ethanolamide,LIPID MAPS instance accession,LMFA08040008
3873,71471,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-alpha-D-Manp,A branched mannooligosaccharide comprised of nine alpha-D-mannose residues configured as shown in the diagram.,"InChI=1S/C54H92O46/c55-1-10-19(62)28(71)35(78)48(87-10)97-42-31(74)22(65)13(4-58)90-51(42)85-9-18-27(70)41(96-52-43(32(75)23(66)14(5-59)91-52)98-49-36(79)29(72)20(63)11(2-56)88-49)39(82)47(94-18)84-8-17-26(69)40(38(81)46(83)86-17)95-53-45(34(77)25(68)15(6-60)92-53)100-54-44(33(76)24(67)16(7-61)93-54)99-50-37(80)30(73)21(64)12(3-57)89-50/h10-83H,1-9H2/t10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48-,49-,50-,51+,52-,53-,54-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-alpha-D-Man,PubMed citation,19443021
3874,71475,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-alpha-D-Manp,An alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-D-Manp in which the carbon bearing the anomeric hydroxy group has alpha- configuration.,"InChI=1S/C24H42O21/c25-1-5-9(29)13(33)16(36)22(40-5)44-19-14(34)10(30)7(3-27)42-24(19)45-20-15(35)11(31)6(2-26)41-23(20)43-18-12(32)8(4-28)39-21(38)17(18)37/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-alpha-D-Man,Reaxys Registry Number,21055502
3875,71478,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp,"A mannopentaose comprised of a chain of three alpha-D-mannose residues linked (1->2) and (1->3), with a further two-D-mannose-residue (1->2)-linked unit linked (1->6) to the mannose residue at the reducing end.","InChI=1S/C30H52O26/c31-1-6-11(35)16(40)20(44)27(50-6)55-24-18(42)13(37)8(3-33)52-29(24)48-5-10-15(39)23(22(46)26(47)49-10)54-30-25(19(43)14(38)9(4-34)53-30)56-28-21(45)17(41)12(36)7(2-32)51-28/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28-,29+,30-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man,PubMed citation,19443021
3876,71479,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-alpha-D-Manp,A linear mannotriose in which three alpha-D-mannose residues are linked in sequence (1->2) and (1->3).,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)12(27)17(31-4)34-15-11(26)8(23)5(2-20)32-18(15)33-14-9(24)6(3-21)30-16(29)13(14)28/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16+,17-,18-/m1/s1",alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->3)-alpha-D-mannose,PubMed citation,19443021
3877,71485,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino heptasaccharide consisting of a sequence of beta-D-galactose, N-acetyl-beta-D-glucosamine, alpha-D-mannose, beta-D-mannose and two N-acetyl-beta-D-glucosamine residues linked (1->4), (1->2), (1->6), (1->4) and (1->4), with an alpha-D-mannose linked (1->3) to the beta-D-mannose residue.","InChI=1S/C48H81N3O36/c1-11(58)49-21-28(65)37(17(7-55)76-42(21)74)83-43-22(50-12(2)59)29(66)39(19(9-57)80-43)85-47-36(73)40(86-46-35(72)32(69)25(62)15(5-53)78-46)27(64)20(82-47)10-75-48-41(33(70)26(63)16(6-54)79-48)87-44-23(51-13(3)60)30(67)38(18(8-56)81-44)84-45-34(71)31(68)24(61)14(4-52)77-45/h14-48,52-57,61-74H,4-10H2,1-3H3,(H,49,58)(H,50,59)(H,51,60)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24+,25-,26-,27-,28-,29-,30-,31+,32+,33+,34-,35+,36+,37-,38-,39-,40+,41+,42-,43+,44+,45+,46-,47+,48+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)-[alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3878,71486,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp,"A mannopentaose comprised of an linear chain of four alpha-D-mannose residues, linked sequentially (1->2), (1->2) and (1->6), to the reducing-end residue of which is also linked (1->3) a fifth alpha-D-mannose.","InChI=1S/C30H52O26/c31-1-6-11(35)16(40)20(44)27(50-6)54-23-15(39)10(49-26(47)22(23)46)5-48-29-24(18(42)13(37)8(3-33)52-29)56-30-25(19(43)14(38)9(4-34)53-30)55-28-21(45)17(41)12(36)7(2-32)51-28/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28-,29+,30-/m1/s1",alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-DMan-(1->6)]-alpha-D-Man,PubMed citation,19443021
3879,71495,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc in which the anomeric configuration of the reducing-end GlcNAc residue is beta.,"InChI=1S/C34H58N2O26/c1-8(41)35-15-20(46)27(12(5-39)55-30(15)53)60-31-16(36-9(2)42)21(47)28(13(6-40)58-31)61-34-26(52)29(62-33-25(51)23(49)18(44)11(4-38)57-33)19(45)14(59-34)7-54-32-24(50)22(48)17(43)10(3-37)56-32/h10-34,37-40,43-53H,3-7H2,1-2H3,(H,35,41)(H,36,42)/t10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25+,26+,27-,28-,29+,30-,31+,32+,33-,34+/m1/s1",alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3880,71496,alpha-D-Manp-(1->3)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"A branched amino octasaccharide comprised of a sequence of alpha-D-mannose, beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-D-glucosamine residues linked (1->3), (1->4) and (1->4), to the beta-D-mannose of which is (1->6)-linked a tetrasaccharide branch comprising N-acetyl-alpha-neuraminose, beta-D-galactose, N-acetyl-beta-D-glucosamine and alpha-D-mannose residues linked sequentially (2->6), (1->4) and (1->2).","InChI=1S/C59H98N4O44/c1-14(70)60-27-18(74)5-59(58(91)92,107-48(27)31(76)19(75)6-64)94-13-26-34(79)40(85)43(88)55(101-26)103-46-23(10-68)99-53(30(38(46)83)63-17(4)73)106-50-41(86)33(78)21(8-66)97-57(50)93-12-25-35(80)49(105-54-42(87)39(84)32(77)20(7-65)96-54)44(89)56(100-25)104-47-24(11-69)98-52(29(37(47)82)62-16(3)72)102-45-22(9-67)95-51(90)28(36(45)81)61-15(2)71/h18-57,64-69,74-90H,5-13H2,1-4H3,(H,60,70)(H,61,71)(H,62,72)(H,63,73)(H,91,92)/t18-,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35+,36+,37+,38+,39-,40-,41-,42-,43+,44-,45+,46+,47+,48+,49-,50-,51?,52-,53-,54+,55-,56-,57-,59+/m0/s1",alpha-D-Man-(1->3)-[alpha-Neu5Ac-(2->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,19443021
3881,71497,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino nonasaccharide comprised of a chain of alpha-D-mannose, beta-D-mannose and two N-acetyl-beta-D-glucosamine residues, linked sequentially (1->6), (1->4) and (1->4), to the alpha-D-mannose residue of which are linked (1->3) and (1->6) respectively an alpha-D-mannosyl-(1->2)-alpha-D-mannose unit and an alpha-D-mannose residue, and to the beta-D-mannose residue is linked another alpha-D-mannosyl-(1->2)-alpha-D-mannose unit.","InChI=1S/C58H98N2O46/c1-12(68)59-23-32(77)44(19(8-66)92-50(23)89)101-51-24(60-13(2)69)33(78)45(20(9-67)98-51)102-56-43(88)47(104-58-49(38(83)29(74)18(7-65)97-58)106-55-41(86)36(81)27(72)16(5-63)95-55)31(76)22(100-56)11-91-53-42(87)46(30(75)21(99-53)10-90-52-39(84)34(79)25(70)14(3-61)93-52)103-57-48(37(82)28(73)17(6-64)96-57)105-54-40(85)35(80)26(71)15(4-62)94-54/h14-58,61-67,70-89H,3-11H2,1-2H3,(H,59,68)(H,60,69)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45-,46+,47+,48+,49+,50-,51+,52+,53+,54-,55-,56+,57-,58-/m1/s1",alpha-D-Man-(1->6)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)]-alpha-D-Man-(1->6)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3882,71503,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp,"A mannopentaose comprised of alpha-D-mannose and beta-D-mannose residues linked (1->6), to the alpha-D-mannose residue of which are linked (1->3) and (1->6) two further alpha-D-mannose residues, while to the beta-D-mannose residue is (1->3)-linked a fourth alpha-D-mannose.","InChI=1S/C30H52O26/c31-1-6-11(34)16(39)19(42)27(51-6)48-5-10-15(38)25(56-30-21(44)18(41)13(36)8(3-33)53-30)23(46)28(54-10)49-4-9-14(37)24(22(45)26(47)50-9)55-29-20(43)17(40)12(35)7(2-32)52-29/h6-47H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27+,28+,29-,30-/m1/s1",alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man,PubMed citation,19443021
3883,71517,"2,3-bis-O-(geranylgeranyl)-sn-glycero-3-phospho-L-serine(1-)","An anionic phospholipid that is the conjugate base of 2,3-bis-O-(geranylgeranyl)-sn-glycero-3-phospho-L-serine, in which the carboxy and phosphate groups are anionic and the amino group is cationic; major species at pH 7.3.","InChI=1S/C46H78NO8P/c1-36(2)17-11-19-38(5)21-13-23-40(7)25-15-27-42(9)29-31-52-33-44(34-54-56(50,51)55-35-45(47)46(48)49)53-32-30-43(10)28-16-26-41(8)24-14-22-39(6)20-12-18-37(3)4/h17-18,21-22,25-26,29-30,44-45H,11-16,19-20,23-24,27-28,31-35,47H2,1-10H3,(H,48,49)(H,50,51)/p-1/b38-21+,39-22+,40-25+,41-26+,42-29+,43-30+/t44-,45-/m0/s1",archaetidylserine,PubMed citation,23055819
3884,71525,"7,8-dimethylisoalloxazine-10-carbaldehyde",A flavin carrying a formyl group at C-10.,"InChI=1S/C13H10N4O3/c1-6-3-8-9(4-7(6)2)17(5-18)11-10(14-8)12(19)16-13(20)15-11/h3-5H,1-2H3,(H,16,19,20)","10-formyl-7,8-dimethylisoalloxazine",PubMed citation,9506942
3885,71528,"6-[4-(5,5-dimethyltetrahydrofuran-3-yl)phenoxy]hexanoic acid","A monocarboxylic acid that is caproic (hexanoic) acid substituted at C-6 by a 4-(5,5-dimethyltetrahydrofuran-3-yl)phenoxy group.","InChI=1S/C18H26O4/c1-18(2)12-15(13-22-18)14-7-9-16(10-8-14)21-11-5-3-4-6-17(19)20/h7-10,15H,3-6,11-13H2,1-2H3,(H,19,20)","6-[4-(5,5-dimethyltetrahydrofuran-3-yl)phenoxy]hexanoic acid",PubMed citation,9506942
3886,71531,gypsogenic acid,A pentacyclic triterpenoid that is olean-12-ene substituted by carboxy groups at positions 23 and 28 and a hydroxy group at position 3 (the 3beta stereoisomer).,"InChI=1S/C30H46O5/c1-25(2)13-15-30(24(34)35)16-14-27(4)18(19(30)17-25)7-8-20-26(3)11-10-22(31)29(6,23(32)33)21(26)9-12-28(20,27)5/h7,19-22,31H,8-17H2,1-6H3,(H,32,33)(H,34,35)/t19-,20+,21+,22-,26+,27+,28+,29-,30-/m0/s1",acanjapogenin G,Reaxys Registry Number,3228938
3887,71534,(S)-averantin,An optically active form of averantin having S-configuration.,"InChI=1S/C20H20O7/c1-2-3-4-5-12(22)17-14(24)8-11-16(20(17)27)19(26)15-10(18(11)25)6-9(21)7-13(15)23/h6-8,12,21-24,27H,2-5H2,1H3/t12-/m0/s1",(1'S)-averantin,PubMed citation,8368836
3888,71541,(25S)-Delta(4)-dafachronate,"A steroid acid anion that is the conjugate base of (25S)-Delta(4)-dafachronic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h16-18,21-24H,5-15H2,1-4H3,(H,29,30)/p-1/t17-,18+,21+,22-,23+,24+,26+,27-/m1/s1",Delta(4)-DA,PubMed citation,20178781
3889,71542,(25S)-Delta(7)-dafachronate,"A steroid acid anion that is the conjugate base of (25S)-Delta(7)-dafachronic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h9,17-19,22-24H,5-8,10-16H2,1-4H3,(H,29,30)/p-1/t17-,18+,19+,22-,23+,24+,26+,27-/m1/s1",Delta(7)-DA,PubMed citation,21749634
3890,71556,(25S)-Delta(7)-dafachronic acid,A Delta(7)-dafachronic acid that has S configuration at position 25 (the carbon attached to the carboxy group).,"InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h9,17-19,22-24H,5-8,10-16H2,1-4H3,(H,29,30)/t17-,18+,19+,22-,23+,24+,26+,27-/m1/s1",(25S)-3-keto-5alpha-cholest-7-en-26-oic acid,Reaxys Registry Number,11170956
3891,71557,N-acetyl-beta-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosamine,An amino disaccharide composed of N-acetylneuraminic acid and N-acetyl-alpha-D-galactosamine residues linked (2->6).,"InChI=1S/C19H32N2O14/c1-6(23)20-11-8(25)3-19(18(31)32,35-16(11)13(27)9(26)4-22)33-5-10-14(28)15(29)12(17(30)34-10)21-7(2)24/h8-17,22,25-30H,3-5H2,1-2H3,(H,20,23)(H,21,24)(H,31,32)/t8-,9+,10+,11+,12+,13+,14-,15+,16+,17-,19-/m0/s1",Neu5Acbeta2-6GalNAcalpha,PubMed citation,19443021
3892,71559,cyclic N(6)-threonylcarbamoyladenosine,"An oxazolidinone that is the N(6)-(4S)-4-[(1R)-1-hydroxyethyl]-5-oxo-1,3-oxazolidin-2-ylidene derivative of adenosine. Obtained by cyclocondensation of N(6)-threonylcarbamoyladenosine.","InChI=1S/C15H18N6O7/c1-5(23)7-14(26)28-15(19-7)20-11-8-12(17-3-16-11)21(4-18-8)13-10(25)9(24)6(2-22)27-13/h3-7,9-10,13,22-25H,2H2,1H3,(H,16,17,19,20)/t5-,6-,7+,9-,10-,13-/m1/s1",ct(6)A,PubMed citation,23242255
3893,71560,(25S)-Delta(4)-dafachronic acid,A Delta(4)-dafachronic acid that has S configuration at position 25 (the carbon attached to the carboxy group). Found in Caenorhabditis elegans.,"InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h16-18,21-24H,5-15H2,1-4H3,(H,29,30)/t17-,18+,21+,22-,23+,24+,26+,27-/m1/s1",Delta(4)-DA,PubMed citation,20178781
3894,71562,alpha-Neup5Ac-(2->3)-[alpha-Neup5Ac-(2->6)]-alpha-D-GalpNAc,A branched amino trisaccharide in which two N-acetyl-alpha-neuraminyl residues are linked (2->3) and (2->6) to an N-acetyl-alpha-D-galactosamine residue.,"InChI=1S/C30H49N3O22/c1-9(36)31-17-12(39)4-29(27(47)48,53-23(17)20(43)14(41)6-34)51-8-16-22(45)25(19(26(46)52-16)33-11(3)38)55-30(28(49)50)5-13(40)18(32-10(2)37)24(54-30)21(44)15(42)7-35/h12-26,34-35,39-46H,4-8H2,1-3H3,(H,31,36)(H,32,37)(H,33,38)(H,47,48)(H,49,50)/t12-,13-,14+,15+,16+,17+,18+,19+,20+,21+,22-,23+,24+,25+,26-,29+,30-/m0/s1",alpha-Neu5Ac-(2->3)-[alpha-Neu5Ac-(2->6)]-alpha-D-GalNAc,PubMed citation,19443021
3895,71563,"all-cis-8,11,14,17-icosatetraenoate","An unsaturated fatty acid anion that is the conjugate base of all-cis-8,11,14,17-icosatetraenoic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13H,2,5,8,11,14-19H2,1H3,(H,21,22)/p-1/b4-3-,7-6-,10-9-,13-12-","(8Z,11Z,14Z,17Z)-eicosa-8,11,14,17-tetraenoate",MetaCyc accession,CPD-8121
3896,71569,(25R)-Delta(7)-dafachronate,"A steroid acid anion that is the conjugate base of (25R)-Delta(7)-dafachronic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h9,17-19,22-24H,5-8,10-16H2,1-4H3,(H,29,30)/p-1/t17-,18-,19+,22-,23+,24+,26+,27-/m1/s1",(25R)-3-keto-cholest-7-en-26-oate,PubMed citation,16529801
3897,71570,(25R)-Delta(4)-dafachronate,"A steroid acid anion that is the conjugate base of (25R)-Delta(4)-dafachronic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h16-18,21-24H,5-15H2,1-4H3,(H,29,30)/p-1/t17-,18-,21+,22-,23+,24+,26+,27-/m1/s1","(25R),26-3-keto-4-cholestenoate",PubMed citation,16529801
3898,71580,c-GMP-AMP,"A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 3',5'-linkages.","InChI=1S/C20H24N10O13P2/c21-14-8-15(24-3-23-14)29(4-25-8)18-10(31)12-6(40-18)1-38-45(36,37)43-13-7(2-39-44(34,35)42-12)41-19(11(13)32)30-5-26-9-16(30)27-20(22)28-17(9)33/h3-7,10-13,18-19,31-32H,1-2H2,(H,34,35)(H,36,37)(H2,21,23,24)(H3,22,27,28,33)/t6-,7-,10-,11-,12-,13-,18-,19-/m1/s1",cyclic GMP-AMP,Reaxys Registry Number,10410345
3899,71588,"3-(3-amino-3-carboxypropyl)-5,6-dihydrouridine","A uridine that is 5,6-dihydrouridine substituted at position 3 by a 3-amino-3-carboxypropyl group.","InChI=1S/C13H21N3O8/c14-6(12(21)22)1-3-15-8(18)2-4-16(13(15)23)11-10(20)9(19)7(5-17)24-11/h6-7,9-11,17,19-20H,1-5,14H2,(H,21,22)/t6?,7-,9-,10-,11-/m1/s1",acp(3)D,PubMed citation,22040320
3900,71602,alpha-Neup5Ac-(2->6)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)]-alpha-D-GalpNAc,alpha-Neup5Ac-(2->6)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)]-alpha-D-GalpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is alpha.,"InChI=1S/C36H59N3O27/c1-10(43)37-19-13(46)4-35(33(56)57,64-28(19)22(50)15(48)6-40)60-9-18-25(53)27(21(31(55)61-18)39-12(3)45)63-32-26(54)30(24(52)17(8-42)62-32)66-36(34(58)59)5-14(47)20(38-11(2)44)29(65-36)23(51)16(49)7-41/h13-32,40-42,46-55H,4-9H2,1-3H3,(H,37,43)(H,38,44)(H,39,45)(H,56,57)(H,58,59)/t13-,14-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26+,27+,28+,29+,30-,31-,32-,35+,36-/m0/s1",alpha-Neu5Ac-(2->6)-[alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)]-alpha-D-GalNAc,PubMed citation,19443021
3901,71608,cyclo(L-phenylalanyl-L-leucyl),"A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by benzyl and isobutyl groups (the 3S,6S-diastereomer).","InChI=1S/C15H20N2O2/c1-10(2)8-12-14(18)17-13(15(19)16-12)9-11-6-4-3-5-7-11/h3-7,10,12-13H,8-9H2,1-2H3,(H,16,19)(H,17,18)/t12-,13-/m0/s1",cFL,PubMed citation,19430487
3902,71610,cyclo(L-phenylalanyl-L-phenylalanyl),"A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by benzyl groups (the 3S,6S-diastereomer).","InChI=1S/C18H18N2O2/c21-17-15(11-13-7-3-1-4-8-13)19-18(22)16(20-17)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12H2,(H,19,22)(H,20,21)/t15-,16-/m0/s1",cyclo(L-Phe-L-Phe),Reaxys Registry Number,90194
3903,71611,cyclo(L-tyrosyl-L-phenylalanyl),"A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by benzyl and 4-hydroxybenzyl groups (the 3S,6S-diastereomer).","InChI=1S/C18H18N2O3/c21-14-8-6-13(7-9-14)11-16-18(23)19-15(17(22)20-16)10-12-4-2-1-3-5-12/h1-9,15-16,21H,10-11H2,(H,19,23)(H,20,22)/t15-,16-/m0/s1",cyclo(L-Tyr-L-Phe),Reaxys Registry Number,92718
3904,71612,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc with beta configuration at the anomeric position of the reducing-end N-acetyl-D-glucosamine residue.,"InChI=1S/C25H42N2O19/c1-7(31)26-13-9(33)3-25(24(40)41,45-20(13)15(35)10(34)4-28)46-21-16(36)11(5-29)43-23(18(21)38)44-19-12(6-30)42-22(39)14(17(19)37)27-8(2)32/h9-23,28-30,33-39H,3-6H2,1-2H3,(H,26,31)(H,27,32)(H,40,41)/t9-,10+,11+,12+,13+,14+,15+,16-,17+,18+,19+,20+,21-,22+,23-,25-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3905,71613,(25R)-Delta(4)-dafachronic acid,"A cholestanoid that is (5alpha,25R)-cholest-4-en-26-oic acid substituted at position 3 by an oxo group.","InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h16-18,21-24H,5-15H2,1-4H3,(H,29,30)/t17-,18-,21+,22-,23+,24+,26+,27-/m1/s1",(25R)-3-ketocholest-4-en-26-oic acid,PubMed citation,16529801
3906,71614,(25R)-Delta(7)-dafachronic acid,"A cholestanoid that is (5alpha,25R)-cholest-7-en-26-oic acid substituted at position 3 by an oxo group.","InChI=1S/C27H42O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h9,17-19,22-24H,5-8,10-16H2,1-4H3,(H,29,30)/t17-,18-,19+,22-,23+,24+,26+,27-/m1/s1",(25R)-3-ketocholest-7-en-26-oic acid,PubMed citation,16529801
3907,71615,cyclo(L-leucyl-L-methionyl),"A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by isobutyl and 2-(methylsulfanyl)ethyl groups (the 3S,6S-diastereomer).","InChI=1S/C11H20N2O2S/c1-7(2)6-9-11(15)12-8(4-5-16-3)10(14)13-9/h7-9H,4-6H2,1-3H3,(H,12,15)(H,13,14)/t8-,9-/m0/s1",cyclo(L-Leu-L-Met),Reaxys Registry Number,3547276
3908,71616,(25S)-cholestenoic acid,A cholestanoid that is (25S)-cholest-5-en-26-oic acid bearing a 3beta-hydroxy substituent.,"InChI=1S/C27H44O3/c1-17(6-5-7-18(2)25(29)30)22-10-11-23-21-9-8-19-16-20(28)12-14-26(19,3)24(21)13-15-27(22,23)4/h8,17-18,20-24,28H,5-7,9-16H2,1-4H3,(H,29,30)/t17-,18+,20+,21+,22-,23+,24+,26+,27-/m1/s1","(3beta,25S)-3-hydroxycholest-5-en-26-oic acid",Reaxys Registry Number,10043380
3909,71618,cyclo(dehydrophenylalanyl-L-leucyl),"A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which two hydrogen at position 3 and one hydrogen at position 6 are replaced by benzylidene and isobutyl groups respectively.","InChI=1S/C15H18N2O2/c1-10(2)8-12-14(18)17-13(15(19)16-12)9-11-6-4-3-5-7-11/h3-7,9-10,12H,8H2,1-2H3,(H,16,19)(H,17,18)/b13-9-/t12-/m0/s1",cyclo(DeltaPhe-L-Leu),Reaxys Registry Number,805903
3910,71622,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-beta-D-glucosamine residue is beta.,"InChI=1S/C31H52N2O23/c1-8-17(41)20(44)21(45)28(50-8)54-25-16(33-10(3)38)27(47)51-14(7-36)23(25)53-29-22(46)26(19(43)13(6-35)52-29)56-31(30(48)49)4-11(39)15(32-9(2)37)24(55-31)18(42)12(40)5-34/h8,11-29,34-36,39-47H,4-7H2,1-3H3,(H,32,37)(H,33,38)(H,48,49)/t8-,11-,12+,13+,14+,15+,16+,17+,18+,19-,20+,21-,22+,23+,24+,25+,26-,27+,28-,29-,31-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc,PubMed citation,19443021
3911,71629,nisin,"A type-A lantibiotic containing 34 amino acid residues (including lanthionine (Lan), methyllanthionine (MeLan), didehydroalanine (Dha) and didehydroaminobutyric acid (Dhb)) and five thioether bridges. It is obtained by fermentation of the bacterium Lactococcus lactis and shows particular activity against Clostridium botulinum. It is used in the production of various processed foods to suppress Gram-positive spoilage and pathogenic bacteria and so extend shelf life.","InChI=1S/C143H230N42O37S7/c1-24-69(11)105(148)135(213)162-82(27-4)118(196)174-94-58-225-59-95(175-123(201)89(48-67(7)8)169-115(193)74(16)158-138(216)107(70(12)25-2)180-132(94)210)133(211)184-112-79(21)229-61-96(160-104(190)56-152-134(212)100-38-34-44-185(100)142(112)220)128(206)164-84(36-29-32-42-145)120(198)182-109-76(18)226-60-97(161-103(189)55-151-117(195)85(39-45-223-22)165-122(200)88(47-66(5)6)168-113(191)72(14)156-102(188)54-153-136(109)214)129(207)171-92(51-101(147)187)125(203)166-86(40-46-224-23)119(197)163-83(35-28-31-41-144)121(199)183-110-77(19)228-63-99-130(208)170-90(49-80-52-149-64-154-80)124(202)176-98(62-227-78(20)111(141(219)177-99)181-116(194)75(17)159-140(110)218)131(209)173-93(57-186)127(205)179-108(71(13)26-3)139(217)172-91(50-81-53-150-65-155-81)126(204)178-106(68(9)10)137(215)157-73(15)114(192)167-87(143(221)222)37-30-33-43-146/h27,52-53,64-72,75-79,83-100,105-112,186H,15-16,24-26,28-51,54-63,144-146,148H2,1-14,17-23H3,(H2,147,187)(H,149,154)(H,150,155)(H,151,195)(H,152,212)(H,153,214)(H,156,188)(H,157,215)(H,158,216)(H,159,218)(H,160,190)(H,161,189)(H,162,213)(H,163,197)(H,164,206)(H,165,200)(H,166,203)(H,167,192)(H,168,191)(H,169,193)(H,170,208)(H,171,207)(H,172,217)(H,173,209)(H,174,196)(H,175,201)(H,176,202)(H,177,219)(H,178,204)(H,179,205)(H,180,210)(H,181,194)(H,182,198)(H,183,199)(H,184,211)(H,221,222)/b82-27-/t69-,70-,71-,72-,75-,76-,77-,78-,79-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95-,96-,97-,98-,99?,100-,105-,106-,107-,108-,109+,110+,111+,112+/m0/s1",E234,CAS Registry Number,1414-45-5
3912,71649,(S)-5'-oxoaverantin,"A hydroxyanthraquinone that is 1,3,6,8-tetrahydroxy-9,10-anthraquinone bearing a 1-hydroxy-5-oxohexyl substituent at position 2 (the S-enantiomer).","InChI=1S/C20H18O8/c1-8(21)3-2-4-12(23)17-14(25)7-11-16(20(17)28)19(27)15-10(18(11)26)5-9(22)6-13(15)24/h5-7,12,22-25,28H,2-4H2,1H3/t12-/m0/s1",OAVN,MetaCyc accession,CPD-10166
3913,71650,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc,"A linear amino pentasaccharide comprising N-acetyl-alpha-neuraminyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl, beta-D-galactosyl and N-acetyl-beta-D-glucosamine residues linked in a (2->3), (1->4), (1->3), (1->3) sequence.","InChI=1S/C39H65N3O29/c1-10(48)40-19-13(51)4-39(38(61)62,70-31(19)22(53)14(52)5-43)71-33-25(56)17(8-46)65-37(28(33)59)67-29-18(9-47)66-35(20(26(29)57)41-11(2)49)69-32-24(55)16(7-45)64-36(27(32)58)68-30-21(42-12(3)50)34(60)63-15(6-44)23(30)54/h13-37,43-47,51-60H,4-9H2,1-3H3,(H,40,48)(H,41,49)(H,42,50)(H,61,62)/t13-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26+,27+,28+,29+,30+,31+,32-,33-,34+,35-,36-,37-,39-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-Gal-(1->3)-beta-D-GlcNAc,PubMed citation,19443021
3914,71651,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc in which the anomeric configuration of the reducing-end N-acetyl-D-glucosamine residue is beta.,"InChI=1S/C39H65N3O29/c1-10(48)40-19-13(51)4-39(38(61)62,70-31(19)22(53)14(52)5-43)71-33-24(55)16(7-45)65-37(28(33)59)68-30-18(9-47)66-35(21(26(30)57)42-12(3)50)69-32-23(54)15(6-44)64-36(27(32)58)67-29-17(8-46)63-34(60)20(25(29)56)41-11(2)49/h13-37,43-47,51-60H,4-9H2,1-3H3,(H,40,48)(H,41,49)(H,42,50)(H,61,62)/t13-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23-,24-,25+,26+,27+,28+,29+,30+,31+,32-,33-,34+,35-,36-,37-,39-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc,PubMed citation,19443021
3915,71653,versicolorone tricyclic form,The tricyclic anthraquinone form of versicolorone.,"InChI=1S/C20H18O8/c1-8(22)2-3-9(7-21)15-14(25)6-12-17(19(15)27)20(28)16-11(18(12)26)4-10(23)5-13(16)24/h4-6,9,21,23-25,27H,2-3,7H2,1H3",versicolorone,MetaCyc accession,CPD-10169
3916,71656,versicolorone tetracyclic form,The tetracyclic anthrafuran form of versicolorone.,"InChI=1S/C20H16O7/c1-8(21)2-3-9-7-27-14-6-12-17(19(25)15(9)14)20(26)16-11(18(12)24)4-10(22)5-13(16)23/h4-6,9,22-23,25H,2-3,7H2,1H3",versicolorone,Reaxys Registry Number,5152728
3917,71658,mersacidin,"A type-B lantibiotic containing 3-methyllanthionine and S-(2-aminovinyl)-3-methylcysteine residues and four intra-chain thioether bridges. It is obtained from Bacillus sp. HIL Y-85,54728 and is active in vivo against methicillin-resistant Staphylococcus aureus (MRSA).","InChI=1S/C80H120N20O21S4/c1-14-40(8)61-74(115)82-24-26-122-42(10)62-76(117)87-41(9)66(107)88-48(22-23-59(105)106)68(109)92-52(71(112)95-61)35-124-44(12)64(78(119)89-49(27-37(2)3)69(110)97-62)99-72(113)53-36-125-45(13)65(98-70(111)50(29-46-19-16-15-17-20-46)90-77(118)63-43(11)123-34-47(81)67(108)96-63)79(120)91-51(28-38(4)5)80(121)100-25-18-21-54(100)73(114)86-32-57(103)84-30-55(101)83-31-56(102)85-33-58(104)94-60(39(6)7)75(116)93-53/h15-17,19-20,24,26,37-40,42-45,47-54,60-65H,9,14,18,21-23,25,27-36,81H2,1-8,10-13H3,(H,82,115)(H,83,101)(H,84,103)(H,85,102)(H,86,114)(H,87,117)(H,88,107)(H,89,119)(H,90,118)(H,91,120)(H,92,109)(H,93,116)(H,94,104)(H,95,112)(H,96,108)(H,97,110)(H,98,111)(H,99,113)(H,105,106)/b26-24+/t40-,42+,43+,44+,45+,47+,48+,49+,50+,51+,52+,53+,54+,60+,61+,62?,63-,64-,65-/m1/s1",M87-1551,PubMed citation,22296295
3918,71659,epidermin,"A type A lantibiotic that is a tetracyclic 21-amino-acid peptide which contains meso-lanthionine, 3-methyllanthionine, and S-(2-aminovinyl)-D-cysteine. It is obtained from Staphylococcus epidermidis Tue 3298 and exhibits antibiotic activity against many Gram-positive bacteria.","InChI=1S/C98H141N25O23S4/c1-9-51(4)77(102)96(144)107-54(7)81(129)117-70-48-149-49-71(120-97(145)78(52(5)10-2)121-89(137)65(40-57-25-16-13-17-26-57)113-85(133)62(112-92(70)140)28-19-21-35-100)94(142)122-79-55(8)150-50-72(109-76(127)44-105-95(143)73-29-22-37-123(73)98(79)146)90(138)106-53(6)80(128)111-61(27-18-20-34-99)84(132)110-60(11-3)82(130)104-43-75(126)108-68-47-148-46-67-83(131)103-36-38-147-45-69(93(141)115-64(87(135)118-67)41-58-30-32-59(124)33-31-58)119-88(136)66(42-74(101)125)116-86(134)63(114-91(68)139)39-56-23-14-12-15-24-56/h11-17,23-26,30-33,36,38,51-55,61-73,77-79,124H,9-10,18-22,27-29,34-35,37,39-50,99-100,102H2,1-8H3,(H2,101,125)(H,103,131)(H,104,130)(H,105,143)(H,106,138)(H,107,144)(H,108,126)(H,109,127)(H,110,132)(H,111,128)(H,112,140)(H,113,133)(H,114,139)(H,115,141)(H,116,134)(H,117,129)(H,118,135)(H,119,136)(H,120,145)(H,121,137)(H,122,142)/b38-36-,60-11-/t51-,52-,53-,54-,55-,61-,62-,63-,64-,65-,66-,67-,68+,69+,70+,71-,72-,73-,77-,78-,79+/m0/s1",staphylococcin 1580,Reaxys Registry Number,11305595
3919,71663,versiconal hydroxyaldehyde form,The tricyclic anthraquinone-hydroxyaldehyde form of versicolorone.,"InChI=1S/C18H14O8/c19-2-1-7(6-20)13-12(23)5-10-15(17(13)25)18(26)14-9(16(10)24)3-8(21)4-11(14)22/h3-7,19,21-23,25H,1-2H2",versiconal tricyclic form,CAS Registry Number,62218-05-7
3920,71672,N-(indole-3-acetyl)-L-alanine,An N-acyl-L-amino acid that is the N-indole-3-acetyl derivative of L-alanine.,"InChI=1S/C13H14N2O3/c1-8(13(17)18)15-12(16)6-9-7-14-11-5-3-2-4-10(9)11/h2-5,7-8,14H,6H2,1H3,(H,15,16)(H,17,18)/t8-/m0/s1",N-(indole-3-acetyl)alanine,Reaxys Registry Number,4260214
3921,71675,N-(indole-3-acetyl)-L-leucine,An N-acyl-L-amino acid that is the N-indole-3-acetyl derivative of L-leucine.,"InChI=1S/C16H20N2O3/c1-10(2)7-14(16(20)21)18-15(19)8-11-9-17-13-6-4-3-5-12(11)13/h3-6,9-10,14,17H,7-8H2,1-2H3,(H,18,19)(H,20,21)/t14-/m0/s1",N-(indole-3-acetyl)leucine,Reaxys Registry Number,6933304
3922,71683,D-gamma-glutamyl-D-glutamic acid,A dipeptide consisting of a D-gamma-glutamyl residue attached to D-glutamic via a peptide linkage.,"InChI=1S/C10H16N2O7/c11-5(9(16)17)1-3-7(13)12-6(10(18)19)2-4-8(14)15/h5-6H,1-4,11H2,(H,12,13)(H,14,15)(H,16,17)(H,18,19)/t5-,6-/m1/s1",D-gamma-Glu-D-Glu,Reaxys Registry Number,1729789
3923,71875,9-ribosyl-trans-zeatin 5'-diphosphate,A purine ribonucleoside 5'-diphosphate that is ADP substituted at position N-6 by a (2E)-4-hydroxy-3-methylbut-2-en-1-yl group.,"InChI=1S/C15H23N5O11P2/c1-8(4-21)2-3-16-13-10-14(18-6-17-13)20(7-19-10)15-12(23)11(22)9(30-15)5-29-33(27,28)31-32(24,25)26/h2,6-7,9,11-12,15,21-23H,3-5H2,1H3,(H,27,28)(H,16,17,18)(H2,24,25,26)/b8-2+/t9-,11-,12-,15-/m1/s1",9-beta-D-ribosyl-trans-zeatin 5'-diphosphate,KEGG COMPOUND accession,C16429
3924,71938,9-ribosyl-trans-zeatin 5'-triphosphate,A purine ribonucleoside 5'-triphosphate that is ATP substituted at position N-6 by a (2E)-4-hydroxy-3-methylbut-2-en-1-yl group.,"InChI=1S/C15H24N5O14P3/c1-8(4-21)2-3-16-13-10-14(18-6-17-13)20(7-19-10)15-12(23)11(22)9(32-15)5-31-36(27,28)34-37(29,30)33-35(24,25)26/h2,6-7,9,11-12,15,21-23H,3-5H2,1H3,(H,27,28)(H,29,30)(H,16,17,18)(H2,24,25,26)/b8-2+/t9-,11-,12-,15-/m1/s1",trans-zeatin 9-beta-D-ribofuranoside 5'-triphosphate,KEGG COMPOUND accession,C16428
3925,71945,beta-NeupNAc-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,An amino trisaccharide consisting of an N-acetyl-beta-neuraminyl residue attached to the galactose residue of N-acetyllactosamine via an alpha-(2->6)-linkage.,"InChI=1S/C25H42N2O19/c1-7(30)26-13-9(32)3-25(24(40)41,46-21(13)15(34)10(33)4-28)42-6-12-16(35)18(37)19(38)23(44-12)45-20-11(5-29)43-22(39)14(17(20)36)27-8(2)31/h9-23,28-29,32-39H,3-6H2,1-2H3,(H,26,30)(H,27,31)(H,40,41)/t9-,10+,11+,12+,13+,14+,15+,16-,17+,18-,19+,20+,21+,22+,23-,25-/m0/s1","beta-N-acetylneuraminyl-2,6-beta-D-galactosyl-1,4-N-acetyl-beta-D-glucosamine",PubMed citation,19443021
3926,71948,tyrocidine B,"A homodetic cyclic decapeptide consisting of D-Phe, L-Pro, L-Trp, D-Phe, L-Asn, L-Gln, L-Tyr, L-Val, L-Orn, and L-Leu residues coupled in sequence and cyclised head-to-tail.","InChI=1S/C68H88N14O13/c1-38(2)31-49-61(88)80-54(34-41-17-9-6-10-18-41)68(95)82-30-14-22-55(82)66(93)79-52(35-43-37-72-46-20-12-11-19-45(43)46)63(90)77-50(32-40-15-7-5-8-16-40)62(89)78-53(36-57(71)85)64(91)73-48(27-28-56(70)84)60(87)76-51(33-42-23-25-44(83)26-24-42)65(92)81-58(39(3)4)67(94)74-47(21-13-29-69)59(86)75-49/h5-12,15-20,23-26,37-39,47-55,58,72,83H,13-14,21-22,27-36,69H2,1-4H3,(H2,70,84)(H2,71,85)(H,73,91)(H,74,94)(H,75,86)(H,76,87)(H,77,90)(H,78,89)(H,79,93)(H,80,88)(H,81,92)/t47-,48-,49-,50+,51-,52-,53-,54+,55-,58-/m0/s1",cyclo-(D-Phe-Pro-Trp-D-Phe-Asn-Gln-Tyr-Val-Orn-Leu),PubMed citation,4987425
3927,71949,tyrocidine C,"A homodetic cyclic decapeptide consisting of D-Phe, L-Pro, L-Trp, D-Trp, L-Asn, L-Gln, L-Tyr, L-Val, L-Orn, and L-Leu residues coupled in sequence and cyclised head-to-tail.","InChI=1S/C70H89N15O13/c1-38(2)30-51-63(91)83-56(32-40-14-6-5-7-15-40)70(98)85-29-13-21-57(85)68(96)82-54(34-43-37-75-48-19-11-9-17-46(43)48)65(93)80-53(33-42-36-74-47-18-10-8-16-45(42)47)64(92)81-55(35-59(73)88)66(94)76-50(26-27-58(72)87)62(90)79-52(31-41-22-24-44(86)25-23-41)67(95)84-60(39(3)4)69(97)77-49(20-12-28-71)61(89)78-51/h5-11,14-19,22-25,36-39,49-57,60,74-75,86H,12-13,20-21,26-35,71H2,1-4H3,(H2,72,87)(H2,73,88)(H,76,94)(H,77,97)(H,78,89)(H,79,90)(H,80,93)(H,81,92)(H,82,96)(H,83,91)(H,84,95)/t49-,50-,51-,52-,53+,54-,55-,56+,57-,60-/m0/s1",cyclo-(D-Phe-Pro-Trp-D-Trp-Asn-Gln-Tyr-Val-Orn-Leu),Reaxys Registry Number,506204
3928,71952,dactolisib,"An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.","InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3",NVP-BEZ235,Reaxys Registry Number,12748665
3929,71954,BKM120,"An aminopyridine that is 4-(trifluoromethyl)pyridin-2-amine substituted at position 5 by a 2,6-di(morpholin-4-yl)pyrimidin-4-y group. A selective PI3K inhibitor with anti-tumour properties.","InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",NVP-BKM120,Reaxys Registry Number,12938097
3930,71956,retaspimycin hydrochloride,A hydrochloride that is the monohydrochloride salt of retaspimycin. A semi-synthetic water-soluble analogue of geldanamycin used in cancer treatment.,"InChI=1S/C31H45N3O8.ClH/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35;/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38);1H/b11-9-,18-10+,20-15+;/t17-,19+,24+,25+,27-,29+;/m1./s1",IPI-504,PubMed citation,17624530
3931,71980,N-retinylidene-N-retinylethanolamine,A pyridinium ion obtained by formal condensation between two molecules of retinol and one the amino group of ethanolamine. A major constituent of retinal pigment epithelium lipofuscin,"InChI=1S/C42H58NO/c1-32(20-22-39-35(4)17-12-25-41(39,6)7)14-10-16-34(3)30-38-31-37(24-27-43(38)28-29-44)19-11-15-33(2)21-23-40-36(5)18-13-26-42(40,8)9/h10-11,14-16,19-24,27,30-31,44H,12-13,17-18,25-26,28-29H2,1-9H3/q+1/b16-10+,19-11+,22-20+,23-21+,32-14+,33-15+,34-30+",A2E,PubMed citation,21357388
3932,71981,beta-D-glucosylsphingosine,D-Glucosylsphingosine in which the anomeric configuration of the glucosyl moiety is beta.,"InChI=1S/C24H47NO7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(27)18(25)17-31-24-23(30)22(29)21(28)20(16-26)32-24/h14-15,18-24,26-30H,2-13,16-17,25H2,1H3/b15-14+/t18-,19+,20+,21+,22-,23+,24+/m0/s1","(2S,3R,4E)-2-amino-1-(beta-D-glucopyranosyloxy)-4-octadecen-3-ol",KEGG COMPOUND accession,C03108
3933,71982,C20 sphingosine,A sphingoid that is the C20 analogue of sphingosine.,"InChI=1S/C20H41NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)19(21)18-22/h16-17,19-20,22-23H,2-15,18,21H2,1H3/b17-16+/t19-,20+/m0/s1",eicosasphing-4-enine,Reaxys Registry Number,3547228
3934,71998,alpha-NeupNAc-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc6S,A linear amino trisaccharide consisting of a sialyl residue linked (2->6) to a galactosyl residue that in turn is linked (1->4) to an O-6-sulfated glucosaminyl residue at the reducing end.,"InChI=1S/C25H42N2O22S/c1-7(29)26-13-9(31)3-25(24(39)40,49-21(13)15(33)10(32)4-28)44-5-11-16(34)18(36)19(37)23(47-11)48-20-12(6-45-50(41,42)43)46-22(38)14(17(20)35)27-8(2)30/h9-23,28,31-38H,3-6H2,1-2H3,(H,26,29)(H,27,30)(H,39,40)(H,41,42,43)/t9-,10+,11+,12+,13+,14+,15+,16-,17+,18-,19+,20+,21+,22+,23-,25+/m0/s1",N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-6O-sulfo-beta-D-glucosamine,PubMed citation,19443021
3935,72002,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide (an undecasaccharide derivative) comprising a sequence of alpha-sialyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl, alpha-D-mannosyl, beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-beta-D-glucosamine residues linked respectively (2->3), (1->4), (1->2), (1->6), (1->4) and (1->4), to the beta-D-mannosyl residue of which is also linked (1->3) an alpha-sialyl-(2->6)- beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-beta-D-alpha-D-mannosyl branch.","InChI=1S/C84H138N6O62/c1-20(100)85-39-26(106)7-83(81(128)129,150-66(39)45(110)28(108)9-91)133-19-38-49(114)56(121)59(124)76(142-38)144-63-34(15-97)140-75(44(54(63)119)90-25(6)105)149-71-58(123)48(113)31(12-94)137-80(71)147-68-51(116)37(141-77(60(68)125)145-64-35(16-98)138-73(42(53(64)118)88-23(4)103)143-62-33(14-96)134-72(127)41(52(62)117)87-22(3)102)18-132-79-70(57(122)47(112)30(11-93)136-79)148-74-43(89-24(5)104)55(120)65(36(17-99)139-74)146-78-61(126)69(50(115)32(13-95)135-78)152-84(82(130)131)8-27(107)40(86-21(2)101)67(151-84)46(111)29(109)10-92/h26-80,91-99,106-127H,7-19H2,1-6H3,(H,85,100)(H,86,101)(H,87,102)(H,88,103)(H,89,104)(H,90,105)(H,128,129)(H,130,131)/t26-,27-,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49-,50-,51+,52+,53+,54+,55+,56-,57-,58-,59+,60-,61+,62+,63+,64+,65+,66+,67+,68-,69-,70-,71-,72+,73-,74-,75-,76-,77-,78-,79-,80+,83+,84-/m0/s1",alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,PubMed citation,19443021
3936,72004,hexadec-9-enoic acid,A hexadecenoic acid in which the double bond is located at position 9.,"InChI=1S/C16H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h7-8H,2-6,9-15H2,1H3,(H,17,18)",9-hexadecenoic acid,Reaxys Registry Number,1781015
3937,72005,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide (undecasaccharide derivative) in which the alpha-D-mannosyl residue of a linear alpha-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine sequence has linked to it (1->3) and (1->6) two branches each comprising alpha-sialyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl and alpha-D-mannosyl residues in a (2->6), (1->4) and (1->2) sequence.","InChI=1S/C84H138N6O62/c1-20(99)85-39-26(105)7-83(81(128)129,151-67(39)45(109)28(107)9-91)133-18-37-49(113)56(120)60(124)76(142-37)145-64-33(14-96)139-74(43(54(64)118)89-24(5)103)149-70-58(122)47(111)30(11-93)136-79(70)132-17-36-51(115)69(62(126)78(141-36)147-66-35(16-98)138-73(42(53(66)117)88-23(4)102)144-63-32(13-95)135-72(127)41(52(63)116)87-22(3)101)148-80-71(59(123)48(112)31(12-94)137-80)150-75-44(90-25(6)104)55(119)65(34(15-97)140-75)146-77-61(125)57(121)50(114)38(143-77)19-134-84(82(130)131)8-27(106)40(86-21(2)100)68(152-84)46(110)29(108)10-92/h26-80,91-98,105-127H,7-19H2,1-6H3,(H,85,99)(H,86,100)(H,87,101)(H,88,102)(H,89,103)(H,90,104)(H,128,129)(H,130,131)/t26-,27-,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49-,50-,51+,52+,53+,54+,55+,56-,57-,58-,59-,60+,61+,62-,63+,64+,65+,66+,67+,68+,69-,70-,71-,72+,73-,74-,75-,76-,77-,78-,79-,80+,83+,84+/m0/s1",alpha-Neu5Ac-(2->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-Neu5Ac-(2->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,19443021
3938,72028,N-triacontanoyphytosphingosine,A phytoceramide in which the ceramide N-acyl group is specified as triacontanoyl.,"InChI=1S/C48H97NO4/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-33-35-37-39-41-43-47(52)49-45(44-50)48(53)46(51)42-40-38-36-34-32-16-14-12-10-8-6-4-2/h45-46,48,50-51,53H,3-44H2,1-2H3,(H,49,52)/t45-,46+,48-/m0/s1",Cer(t18:0/30:0),Reaxys Registry Number,20619685
3939,72318,alpha-Neup5Ac-(2->6)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"An amino tetrasaccharide comprising an alpha-sialyl residue, two N-acetyl-beta-D-glucosaminyl residues and an N-acetyl-D-glucosamine residue linked in a (2->6), (1->4) and (1->4) sequence.","InChI=1S/C35H58N4O24/c1-10(43)36-19-14(47)5-35(34(55)56,63-30(19)23(49)15(48)6-40)57-9-18-24(50)25(51)21(38-12(3)45)32(60-18)62-29-17(8-42)59-33(22(27(29)53)39-13(4)46)61-28-16(7-41)58-31(54)20(26(28)52)37-11(2)44/h14-33,40-42,47-54H,5-9H2,1-4H3,(H,36,43)(H,37,44)(H,38,45)(H,39,46)(H,55,56)/t14-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31?,32-,33-,35+/m0/s1",N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine,PubMed citation,19443021
3940,72319,cabozantinib malate,"A malate salt that is the mono-(S)-malate salt of cabozantinib. A multi-tyrosine kinase inhibitor, used for the treatment of progressive, metastatic, medullary thyroid cancer.","InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1",cabozantinib (S)-malate,KEGG DRUG accession,D10095
3941,72322,(11)C-choline,A choline in which one of the methyl carbons is replaced by an (11)C isotope. An intravenous radioactive diagnostic agent used (in the form of its chloride salt) as a tracer during positron emission tomography scans to help detect sites of recurrent prostate cancer.,"InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1/i1-1",[N-methyl-(11)C]choline,Reaxys Registry Number,7913839
3942,72336,"2,6-diamino-2,3,6-trideoxy-alpha-D-glucose",A trideoxyhexose derivative that is alpha-D-glucose in which the 2 and 6-hydroxy groups are replaced by amino groups while the 3-hydroxy group is replaced by hydrogen.,"InChI=1S/C6H14N2O3/c7-2-5-4(9)1-3(8)6(10)11-5/h3-6,9-10H,1-2,7-8H2/t3-,4+,5-,6+/m1/s1","2,6-diamino-2,3,6-trideoxy-alpha-D-glucopyranose",PDBeChem accession,TOC
3943,72339,"2,6-diamino-2,3,6-trideoxy-alpha-D-glucose(2+)","An organic cation obtained by protonation of the amino groups of 2,6-diamino-2,3,6-trideoxy-alpha-D-glucose.","InChI=1S/C6H14N2O3/c7-2-5-4(9)1-3(8)6(10)11-5/h3-6,9-10H,1-2,7-8H2/p+2/t3-,4+,5-,6+/m1/s1","2,6-diamino-2,3,6-trideoxy-alpha-D-glucopyranose(2+)",PDBeChem accession,TOC
3944,72343,alpha-D-kanosamine,A 3-amino-3-deoxy-D-glucopyranose that has alpha-configuration at the anomeric position.,"InChI=1S/C6H13NO5/c7-3-4(9)2(1-8)12-6(11)5(3)10/h2-6,8-11H,1,7H2/t2-,3+,4-,5-,6+/m1/s1",3-amino-3-deoxy-alpha-D-glucose,PDBeChem accession,TOA
3945,72344,alpha-D-kanosamine(1+),An organic cation obtained by protonation of the amino group of alpha-D-kanosamine.,"InChI=1S/C6H13NO5/c7-3-4(9)2(1-8)12-6(11)5(3)10/h2-6,8-11H,1,7H2/p+1/t2-,3+,4-,5-,6+/m1/s1",3-ammonio-3-deoxy-alpha-D-glucose,MetaCyc accession,CPD-10224
3946,72447,2-deoxystreptamine(1+),An organic cation obtained by protonation of one of the two free amino groups of 2-deoxystreptamine.,"InChI=1S/C6H14N2O3/c7-2-1-3(8)5(10)6(11)4(2)9/h2-6,9-11H,1,7-8H2/p+1/t2-,3+,4+,5-,6-",2-deoxystreptaminium(1+),PDBeChem accession,NEB
3947,72449,malachite green,"An organic chloride salt that is the monochloride salt of malachite green cation. Used as a green-coloured dye, as a counter-stain in histology, and for its anti-fungal properties in aquaculture.","InChI=1S/C23H25N2.ClH/c1-24(2)21-14-10-19(11-15-21)23(18-8-6-5-7-9-18)20-12-16-22(17-13-20)25(3)4;/h5-17H,1-4H3;1H/q+1;/p-1",malachite green chloride salt,KEGG COMPOUND accession,C18367
3948,72452,beta-L-idopyranose,The beta-anomer of L-idopyranose.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4-,5+,6-/m0/s1",beta-L-idose,PDBeChem accession,4N2
3949,72465,alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcNAcp,"A branched amino tetrasaccharide comprising alpha-N-glycoloylneuraminyl, beta-D-galactosyl and N-acetyl-beta-D-glucosamine residues linked sequentially (2->3) and (1->4), to the galactosyl residue of which is also linked (1->3) an alpha-L-fucosyl residue.","InChI=1S/C31H52N2O24/c1-8-17(42)20(45)21(46)28(51-8)55-25-16(32-9(2)38)27(48)52-13(6-36)23(25)54-29-22(47)26(19(44)12(5-35)53-29)57-31(30(49)50)3-10(39)15(33-14(41)7-37)24(56-31)18(43)11(40)4-34/h8,10-13,15-29,34-37,39-40,42-48H,3-7H2,1-2H3,(H,32,38)(H,33,41)(H,49,50)/t8-,10-,11+,12+,13+,15+,16+,17+,18+,19-,20+,21-,22+,23+,24+,25+,26-,27+,28-,29-,31-/m0/s1",alpha-N-glycoloylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosamine,PubMed citation,19443021
3950,72466,alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcNAcp,"A linear amino trisaccharide comprising an alpha-N-glycoloylneuraminyl residue (2->3)-linked to a beta-D-galactosyl residue, which is in turn linked (1->4) to N-acetyl-beta-D-glucosamine.","InChI=1S/C25H42N2O20/c1-7(32)26-14-17(38)19(11(5-30)43-22(14)40)45-23-18(39)21(16(37)10(4-29)44-23)47-25(24(41)42)2-8(33)13(27-12(35)6-31)20(46-25)15(36)9(34)3-28/h8-11,13-23,28-31,33-34,36-40H,2-6H2,1H3,(H,26,32)(H,27,35)(H,41,42)/t8-,9+,10+,11+,13+,14+,15+,16-,17+,18+,19+,20+,21-,22+,23-,25-/m0/s1",alpha-N-glycoloylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine,PubMed citation,19443021
3951,72471,"alpha-Neup5,9Ac2-(2->6)-beta-D-Galp-(1->3)-beta-D-GlcpNAc","A linear amino trisaccharide comprising an N,9-O-diacetyl-alpha-neuraminyl residue (2->3)-linked to a beta-D-galactosyl residue, which is in turn linked (1->3) to N-acetyl-beta-D-glucosamine.","InChI=1S/C27H44N2O20/c1-8(32)28-15-11(35)4-27(26(42)43,48-22(15)17(37)12(36)7-44-10(3)34)49-23-19(39)14(6-31)46-25(20(23)40)47-21-16(29-9(2)33)24(41)45-13(5-30)18(21)38/h11-25,30-31,35-41H,4-7H2,1-3H3,(H,28,32)(H,29,33)(H,42,43)/t11-,12+,13+,14+,15+,16+,17+,18+,19-,20+,21+,22+,23-,24+,25-,27-/m0/s1","alpha-Neu5,9Ac2-(2->6)-beta-D-Gal-(1->3)-beta-D-GlcNAc",PubMed citation,19443021
3952,72472,"alpha-Neup5,9Ac2-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc","A linear amino trisaccharide comprising an N,9-O-diacetyl-alpha-neuraminyl residue (2->3)-linked to a beta-D-galactosyl residue, which is in turn linked (1->4) to N-acetyl-beta-D-glucosamine.","InChI=1S/C27H44N2O20/c1-8(32)28-15-11(35)4-27(26(42)43,48-22(15)17(37)12(36)7-44-10(3)34)49-23-18(38)13(5-30)46-25(20(23)40)47-21-14(6-31)45-24(41)16(19(21)39)29-9(2)33/h11-25,30-31,35-41H,4-7H2,1-3H3,(H,28,32)(H,29,33)(H,42,43)/t11-,12+,13+,14+,15+,16+,17+,18-,19+,20+,21+,22+,23-,24+,25-,27-/m0/s1","N,9-O-diacetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine",PubMed citation,19443021
3953,72487,Dnp-Gln,"A L-glutamine derivative that is L-glutamine substituted on the alpha-nitrogen by a 2,4-dinitrophenyl group.","InChI=1S/C11H12N4O7/c12-10(16)4-3-8(11(17)18)13-7-2-1-6(14(19)20)5-9(7)15(21)22/h1-2,5,8,13H,3-4H2,(H2,12,16)(H,17,18)/t8-/m0/s1",DNP-Glu,PubMed citation,22877585
3954,72488,Dnp-Trp-Gln,"A dipeptide consisting of L-tryptophan substituted on the alpha-nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.","InChI=1S/C22H22N6O8/c23-20(29)8-7-17(22(31)32)26-21(30)18(9-12-11-24-15-4-2-1-3-14(12)15)25-16-6-5-13(27(33)34)10-19(16)28(35)36/h1-6,10-11,17-18,24-25H,7-9H2,(H2,23,29)(H,26,30)(H,31,32)/t17-,18-/m0/s1",DNP-Trp,PubMed citation,22877585
3955,72489,Dnp-Sar-Gln,"A dipeptide consisting of sarcosine (1-methylglycine) substituted on nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.","InChI=1S/C14H17N5O8/c1-17(7-13(21)16-9(14(22)23)3-5-12(15)20)10-4-2-8(18(24)25)6-11(10)19(26)27/h2,4,6,9H,3,5,7H2,1H3,(H2,15,20)(H,16,21)(H,22,23)/t9-/m0/s1",DNP-Sar,PubMed citation,22877585
3956,72491,"N(alpha),N(tele)-(Dnp)2-His-Gln","A dipeptide consisting of L-histidine substituted on the alpha and tele (tele) nitrogens  by 2,4-dinitrophenyl groups and connected to L-glutamine via a peptide bond.","InChI=1S/C23H21N9O12/c24-21(33)6-4-16(23(35)36)27-22(34)17(26-15-3-1-13(29(37)38)8-19(15)31(41)42)7-12-10-28(11-25-12)18-5-2-14(30(39)40)9-20(18)32(43)44/h1-3,5,8-11,16-17,26H,4,6-7H2,(H2,24,33)(H,27,34)(H,35,36)/t16-,17-/m0/s1",DNP2-His,PubMed citation,22877585
3957,72493,Dnp-Pro-Gln,"A dipeptide consisting of L-proline substituted on nitrogen by a 2,4-dinitrophenyl group and connected to L-glutamine via a peptide bond.","InChI=1S/C16H19N5O8/c17-14(22)6-4-10(16(24)25)18-15(23)12-2-1-7-19(12)11-5-3-9(20(26)27)8-13(11)21(28)29/h3,5,8,10,12H,1-2,4,6-7H2,(H2,17,22)(H,18,23)(H,24,25)/t10-,12-/m0/s1",DNP-Pro,PubMed citation,22877585
3958,72495,Tnp-Gln,"An L-alpha-amino acid that is L-glutamine substituted at the alpha-nitrogen by a 2,4,6-trinitrophenyl group.","InChI=1S/C11H11N5O9/c12-9(17)2-1-6(11(18)19)13-10-7(15(22)23)3-5(14(20)21)4-8(10)16(24)25/h3-4,6,13H,1-2H2,(H2,12,17)(H,18,19)/t6-/m0/s1",TNP-Glu,PubMed citation,22877585
3959,72542,4-[4-(dimethylamino)styryl]-N-methylpyridinium,A pyridinium cation obtained by methylation at position 1 of 4-(4-dimethylaminostyryl)pyridine,"InChI=1S/C16H19N2/c1-17(2)16-8-6-14(7-9-16)4-5-15-10-12-18(3)13-11-15/h4-13H,1-3H3/q+1",4-[4-(dimethylamino)styryl]-1-methylpyridinium,Reaxys Registry Number,5546614
3960,72563,"(3S,4S)-3-hydroxy-4-methyloctanoic acid",A hydroxy fatty acid that is caprylic (octanoic) acid substituted at positions 3 and 4 by hydroxy and methyl grous respectively.,"InChI=1S/C9H18O3/c1-3-4-5-7(2)8(10)6-9(11)12/h7-8,10H,3-6H2,1-2H3,(H,11,12)/t7-,8-/m0/s1",3-hydroxy-4-methyloctanoic acid,Reaxys Registry Number,10429019
3961,72587,(R)-noradrenaline(1+),"An organic cation that is the conjugate acid of (R)-noradrenaline, obtained by protonation of the priamry amino group; major species at pH 7.3.","InChI=1S/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/p+1/t8-/m0/s1",(R)-noradrenaline cation,PDBeChem accession,E5E
3962,72599,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-GalpNAc,"A linear amino tetrasaccharide comprising alpha-sialyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-beta-D-galactosamine residues in a (2->6), (1->4) and (1->3) sequence.  alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-D-GalpNAc in which the anomeric configuration of the GalNAc residue at the reducing end is beta.","InChI=1S/C33H55N3O24/c1-9(40)34-17-12(43)4-33(32(52)53,60-28(17)20(45)13(44)5-37)54-8-16-21(46)24(49)25(50)31(57-16)58-26-15(7-39)56-30(18(23(26)48)35-10(2)41)59-27-19(36-11(3)42)29(51)55-14(6-38)22(27)47/h12-31,37-39,43-51H,4-8H2,1-3H3,(H,34,40)(H,35,41)(H,36,42)(H,52,53)/t12-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23+,24-,25+,26+,27+,28+,29+,30-,31-,33+/m0/s1",N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-beta-D-galactosamine,PubMed citation,19443021
3963,72604,N-benzyl-9-(alpha-D-glucosyl)adenine,An N-glycosyl compound that is N-benzyladenine in which an alpha-D-glucopyranosyl residue is attached at position N-9.,"InChI=1S/C18H21N5O5/c24-7-11-13(25)14(26)15(27)18(28-11)23-9-22-12-16(20-8-21-17(12)23)19-6-10-4-2-1-3-5-10/h1-5,8-9,11,13-15,18,24-27H,6-7H2,(H,19,20,21)/t11-,13-,14+,15-,18+/m1/s1",N-benzyl-9-(alpha-D-glucopyranosyl)adenine,Reaxys Registry Number,21539944
3964,72607,9-(alpha-D-glucosyl)-cis-zeatin,An N-glycosylzeatin that is cis-zeatin having an alpha-D-glucopyranosyl residue attached at position N-9.,"InChI=1S/C16H23N5O6/c1-8(4-22)2-3-17-14-10-15(19-6-18-14)21(7-20-10)16-13(26)12(25)11(24)9(5-23)27-16/h2,6-7,9,11-13,16,22-26H,3-5H2,1H3,(H,17,18,19)/b8-2-/t9-,11-,12+,13-,16+/m1/s1",9-(alpha-D-glucopyranosyl)-cis-zeatin,HMDB accession,HMDB0012202
3965,72609,9-(alpha-D-glucosyl)-trans-zeatin,An N-glycosylzeatin that is trans-zeatin having an alpha-D-glucopyranosyl residue attached at position N-9.,"InChI=1S/C16H23N5O6/c1-8(4-22)2-3-17-14-10-15(19-6-18-14)21(7-20-10)16-13(26)12(25)11(24)9(5-23)27-16/h2,6-7,9,11-13,16,22-26H,3-5H2,1H3,(H,17,18,19)/b8-2+/t9-,11-,12+,13-,16+/m1/s1",9-(alpha-D-glucopyranosyl)-trans-zeatin,MetaCyc accession,CPD-4613
3966,72612,9-(alpha-D-glucosyl)dihydrozeatin,An N-glycosyldihydrozeatin in which the glycosyl fragment is an alpha-D-glucopyranosyl residue located at position 9.,"InChI=1S/C16H25N5O6/c1-8(4-22)2-3-17-14-10-15(19-6-18-14)21(7-20-10)16-13(26)12(25)11(24)9(5-23)27-16/h6-9,11-13,16,22-26H,2-5H2,1H3,(H,17,18,19)/t8?,9-,11-,12+,13-,16+/m1/s1",9-(alpha-D-glucopyranosyl)dihydrozeatin,Reaxys Registry Number,21539947
3967,72614,"(2E,4E)-deca-2,4-dienoic acid",A polyunsaturated fatty acid that is decanoic acid (capric acid) which has been dehydrogenated to introduce double bonds with E configuration at positions 2-3 and 4-5.,"InChI=1S/C10H16O2/c1-2-3-4-5-6-7-8-9-10(11)12/h6-9H,2-5H2,1H3,(H,11,12)/b7-6+,9-8+","trans,trans-2,4-decadienoic acid",Reaxys Registry Number,1721996
3968,72616,9-(alpha-D-glucosyl)-N(6)-isopentenyladenine,"A glucosyl-N(6)-isopentenyladenine in which the glucosyl moiety is in the pyranose form, has alpha-D-configuration and is located at position N-9.","InChI=1S/C16H23N5O5/c1-8(2)3-4-17-14-10-15(19-6-18-14)21(7-20-10)16-13(25)12(24)11(23)9(5-22)26-16/h3,6-7,9,11-13,16,22-25H,4-5H2,1-2H3,(H,17,18,19)/t9-,11-,12+,13-,16+/m1/s1",9-alpha-D-glucopyranosyl-N(6)-isopentenyladenine,MetaCyc accession,CPD-4603
3969,72625,9-HOTrE,"A hydroxyoctadecatrienoic acid that consists of 10E,12Z,15Z-octadecatrienoic acid bearing an additional 9-hydroxy substituent.","InChI=1S/C18H30O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h3-4,6,8,11,14,17,19H,2,5,7,9-10,12-13,15-16H2,1H3,(H,20,21)/b4-3-,8-6-,14-11+","9-hydroxy-10E,12Z,15Z-octadecatrienoic acid",Reaxys Registry Number,2285133
3970,72630,papulacandin D,A papulacandin that is papulacandin A in which the 6-O-acylgalactosyl group is replaced by a hydrogen. It is a carbohydrate-containing antibiotic from the deuteromycetous fungus Papularia sphaerosperma which shows potent antifungal activity against Candida albicans.,"InChI=1S/C31H42O10/c1-4-19(2)11-7-5-8-12-20(3)23(34)13-9-6-10-14-26(36)40-29-28(37)25(17-32)41-31(30(29)38)27-21(18-39-31)15-22(33)16-24(27)35/h5-6,8-10,12,14-16,19,23,25,28-30,32-35,37-38H,4,7,11,13,17-18H2,1-3H3/b8-5+,9-6+,14-10+,20-12+/t19-,23-,25+,28+,29-,30+,31-/m0/s1",(+)-papulacandin D,Reaxys Registry Number,7239678
3971,72631,3-phenoxybenzoic acid,A phenoxybenzoic acid in which the phenoxy group is meta to the carboxy group. It is a metabolite of pyrethroid insecticides.,"InChI=1S/C13H10O3/c14-13(15)10-5-4-8-12(9-10)16-11-6-2-1-3-7-11/h1-9H,(H,14,15)",3-carboxydiphenyl ether,HMDB accession,HMDB0041807
3972,72636,2-phenoxybenzoic acid,A phenoxybenzoic acid in which the phenoxy group is ortho to the carboxy group.,"InChI=1S/C13H10O3/c14-13(15)11-8-4-5-9-12(11)16-10-6-2-1-3-7-10/h1-9H,(H,14,15)",o-carboxydiphenyl ether,CAS Registry Number,2243-42-7
3973,72649,cyanidin 3-O-[6-O-(4-O-beta-D-glucosyl-p-coumaroyl)-2-O-(2-O-sinapoyl-beta-D-xylosyl)-beta-D-glucosyl]-5-O-(6-O-malonyl-beta-D-glucoside)(1-),A carbohydrate acid derivative anion obtained by deprotonation of the carboxy and 7-hydroxy groups of cyanidin 3-O-[6-O-(4-O-beta-D-glucosyl-p-coumaroyl)-2-O-(2-O-sinapoyl-beta-D-xylosyl)-beta-D-glucosyl]-5-O-(6-O-malonyl-beta-D-glucoside).,"InChI=1S/C61H66O34/c1-82-35-13-25(14-36(83-2)46(35)73)6-12-43(70)94-56-45(72)32(66)21-86-60(56)95-57-52(79)49(76)40(22-84-42(69)11-5-24-3-8-28(9-4-24)87-58-53(80)50(77)47(74)38(20-62)91-58)93-61(57)90-37-18-29-33(88-55(37)26-7-10-30(64)31(65)15-26)16-27(63)17-34(29)89-59-54(81)51(78)48(75)39(92-59)23-85-44(71)19-41(67)68/h3-18,32,38-40,45,47-54,56-62,66,72,74-81H,19-23H2,1-2H3,(H4-,63,64,65,67,68,70,73)/p-1/b11-5+/t32-,38-,39-,40-,45+,47-,48-,49-,50+,51+,52+,53-,54-,56-,57-,58-,59-,60+,61-/m1/s1",cyanidin 3-O-[2-O-(2-O-(sinapoyl)-beta-D-xylopyranosyl)-6-O-(4-O-(beta-D-glucopyranosyl)-p-coumaroyl)-beta-D-glucopyranoside]-5-O-[6-O-(malonyl)-beta-D-glucopyranoside],PubMed citation,17600138
3974,72650,cyanidin 3-O-[6-O-(4-O-beta-D-glucosyl-p-coumaroyl)-2-O-(beta-D-xylosyl)-beta-D-glucosyl]-5-O-(6-O-malonyl-beta-D-glucoside)(1-),A carbohydrate acid derivative anion obtained by deprotonation of the carboxy and 7-hydroxy groups of cyanidin 3-O-[6-O-(4-O-beta-D-glucosyl-p-coumaroyl)-2-O-(beta-D-xylosyl)-beta-D-glucosyl]-5-O-(6-O-malonyl-beta-D-glucoside),"InChI=1S/C50H56O30/c51-14-29-36(61)39(64)43(68)48(77-29)73-21-5-1-18(2-6-21)3-8-33(58)70-16-31-38(63)41(66)46(80-47-42(67)35(60)25(55)15-72-47)50(79-31)76-28-12-22-26(74-45(28)19-4-7-23(53)24(54)9-19)10-20(52)11-27(22)75-49-44(69)40(65)37(62)30(78-49)17-71-34(59)13-32(56)57/h1-12,25,29-31,35-44,46-51,55,60-69H,13-17H2,(H3-,52,53,54,56,57)/p-1/b8-3+/t25-,29-,30-,31-,35+,36-,37-,38-,39+,40+,41+,42-,43-,44-,46-,47+,48-,49-,50-/m1/s1",cyanidin 3-O-[2''-O-(xylosyl) 6''-O-(p-coumaroyl)glucoside]-5-O-malonylglucoside,PubMed citation,17600138
3975,72653,"(4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoic acid","An EpDPE obtained by formal epoxidation of the 19,20-double bond of docosa-4,7,10,13,16,19-hexaenoic acid.","InChI=1S/C22H32O3/c1-2-20-21(25-20)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-19-22(23)24/h3-4,7-10,13-16,20-21H,2,5-6,11-12,17-19H2,1H3,(H,23,24)/b4-3-,9-7-,10-8-,15-13-,16-14-","19,20-epoxydocosapentaenoic acid",LIPID MAPS instance accession,LMFA04000038
3976,72664,(+)-phytocassane A,"A phytocassane that is ent-podocarp-12-ene-3,11-dione carrying additional hydroxy, vinyl and methyl substituents at the 2alpha, 13 and 14 positions, respectively.","InChI=1S/C20H28O3/c1-6-12-9-14(21)17-13(11(12)2)7-8-16-19(3,4)18(23)15(22)10-20(16,17)5/h6,9,11,13,15-17,22H,1,7-8,10H2,2-5H3/t11-,13-,15-,16-,17+,20-/m1/s1",phytocassane A,Reaxys Registry Number,8509348
3977,72666,(+)-phytocassane B,A phytocassane that is (+)-phytocassane C which has been substituted with an additional hydroxy group at the 2alpha position.,"InChI=1S/C20H30O4/c1-6-11-9-13(21)15-12(10(11)2)7-8-14-19(3,4)17(23)16(22)18(24)20(14,15)5/h6,9-10,12,14-18,22-24H,1,7-8H2,2-5H3/t10-,12-,14-,15+,16+,17-,18+,20-/m1/s1",phytocassane B,HMDB accession,HMDB0041055
3978,72668,(+)-phytocassane C,"A phytocassane that is ent-podocarp-12-ene-11-one carrying two alpha-hydroxy substituents at positions 1 and 3 as well as vinyl and beta-methyl substituents at positions 13 and 14, respectively.","InChI=1S/C20H30O3/c1-6-12-9-14(21)18-13(11(12)2)7-8-15-19(3,4)16(22)10-17(23)20(15,18)5/h6,9,11,13,15-18,22-23H,1,7-8,10H2,2-5H3/t11-,13-,15-,16-,17+,18+,20+/m1/s1",phytocassane C,HMDB accession,HMDB0041058
3979,72675,(+)-phytocassane E,A phytocassane that is (+)-phytocassane C in which the hydroxy group at position 3 has been oxidised to the give corresponding ketone.,"InChI=1S/C20H28O3/c1-6-12-9-14(21)18-13(11(12)2)7-8-15-19(3,4)16(22)10-17(23)20(15,18)5/h6,9,11,13,15,17-18,23H,1,7-8,10H2,2-5H3/t11-,13-,15-,17+,18+,20+/m1/s1",phytocassane E,Agricola citation,IND605674630
3980,72679,11-hydroxy-O-methyldihydrosterigmatocystin,A sterigmatocystin that is the 11-hydroxy-8-O-methyl derivative of dihydrosterigmatocystin.,"InChI=1S/C19H16O7/c1-22-10-4-3-9(20)17-14(10)16(21)15-11(23-2)7-12-13(18(15)26-17)8-5-6-24-19(8)25-12/h3-4,7-8,19-20H,5-6H2,1-2H3/t8-,19+/m0/s1",11-hydroxy-8-O-methyldihydrosterigmatocystin,PubMed citation,21153813
3981,72680,11-hydroxy-O-methylsterigmatocystin,A sterigmatocystin that is the 11-hydroxy-8-O-methyl derivative of the parent sterigmatocystin.,"InChI=1S/C19H14O7/c1-22-10-4-3-9(20)17-14(10)16(21)15-11(23-2)7-12-13(18(15)26-17)8-5-6-24-19(8)25-12/h3-8,19-20H,1-2H3/t8-,19+/m0/s1",11-hydroxy-8-O-methylsterigmatocystin,PubMed citation,21153813
3982,72696,cyanidin 3-O-[6-O-(4-O-beta-D-glucosyl-p-coumaroyl)-2-O-(2-O-sinapoyl-beta-D-xylosyl)-beta-D-glucosyl]-5-O-(6-O-malonyl-beta-D-glucoside),An anthocyanin cation found in the leaves and stems of Arabidopsis thaliana.,"InChI=1S/C61H66O34/c1-82-35-13-25(14-36(83-2)46(35)73)6-12-43(70)94-56-45(72)32(66)21-86-60(56)95-57-52(79)49(76)40(22-84-42(69)11-5-24-3-8-28(9-4-24)87-58-53(80)50(77)47(74)38(20-62)91-58)93-61(57)90-37-18-29-33(88-55(37)26-7-10-30(64)31(65)15-26)16-27(63)17-34(29)89-59-54(81)51(78)48(75)39(92-59)23-85-44(71)19-41(67)68/h3-18,32,38-40,45,47-54,56-62,66,72,74-81H,19-23H2,1-2H3,(H4-,63,64,65,67,68,70,73)/p+1/b11-5+/t32-,38-,39-,40-,45+,47-,48-,49-,50+,51+,52+,53-,54-,56-,57-,58-,59-,60+,61-/m1/s1",cyanidin 3-O-[6-O-(4-O-beta-D-glucopyranosyl-p-coumaroyl)-2-O-(2-O-sinapoyl-beta-D-xylopyranosyl)-beta-D-glucopyranosyl]-5-O-(6-O-malonyl-beta-D-glucopyranoside),LIPID MAPS instance accession,LMPK12010193
3983,72708,cis-dihomoaconitic acid,"A tricarboxylic acid that consists of pent-1-ene having three carboxy groups located at positions 1, 2 and 5 (the Z-geoisomer).","InChI=1S/C8H10O6/c9-6(10)3-1-2-5(8(13)14)4-7(11)12/h4H,1-3H2,(H,9,10)(H,11,12)(H,13,14)/b5-4-","(Z)-1,2,5-pent-1-enetricarboxylic acid",MetaCyc accession,CPD-153
3984,72711,cis-trihomoaconitic acid,"A tricarboxylic acid that consists of hex-1-ene having three carboxy groups located at positions 1, 2 and 6 (the Z-geoisomer).","InChI=1S/C9H12O6/c10-7(11)4-2-1-3-6(9(14)15)5-8(12)13/h5H,1-4H2,(H,10,11)(H,12,13)(H,14,15)/b6-5-","(Z)-1,2,6-hex-1-enetricarboxylic acid",Reaxys Registry Number,21144464
3985,72712,cis-trihomoaconitate(3-),A tricarboxylic acid trianion obtained by deprotonation of the three carboxy groups of cis-trihomoaconitic acid; major species at pH 7.3.,"InChI=1S/C9H12O6/c10-7(11)4-2-1-3-6(9(14)15)5-8(12)13/h5H,1-4H2,(H,10,11)(H,12,13)(H,14,15)/p-3/b6-5-","(Z)-1,2,6-hex-1-enetricarboxylate(3-)",MetaCyc accession,CPD-319
3986,72723,Phe-Phe,A dipeptide formed from two L-phenylalanine residues.,"InChI=1S/C18H20N2O3/c19-15(11-13-7-3-1-4-8-13)17(21)20-16(18(22)23)12-14-9-5-2-6-10-14/h1-10,15-16H,11-12,19H2,(H,20,21)(H,22,23)/t15-,16-/m0/s1",L-Phe-L-Phe,HMDB accession,HMDB0013302
3987,72733,sulfoglycochenodeoxycholic acid,A steroid sulfate that is the 3-O-sulfo derivative of glycochenodeoxycholic acid.,"InChI=1S/C26H43NO8S/c1-15(4-7-22(29)27-14-23(30)31)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(35-36(32,33)34)12-16(25)13-21(24)28/h15-21,24,28H,4-14H2,1-3H3,(H,27,29)(H,30,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,21-,24+,25+,26-/m1/s1",3-sulfo-GCDCA,HMDB accession,HMDB0002497
3988,72741,2-arachidonyl-sn-glycero-3-phosphoethanolamine,"A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (5Z,8Z,11Z,14Z)-eicosatetraenoyl (arachidonoyl).","InChI=1S/C25H44NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-25(28)33-24(22-27)23-32-34(29,30)31-21-20-26/h6-7,9-10,12-13,15-16,24,27H,2-5,8,11,14,17-23,26H2,1H3,(H,29,30)/b7-6-,10-9-,13-12-,16-15-/t24-/m1/s1","LPE 0:0/20:4(5Z,8Z,11Z,14Z)",HMDB accession,HMDB0011487
3989,72743,1-(hexadec-1-enyl)-2-hexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl group are specified as (Z)-hexadec-1-enyl and hexadecanoyl (palmitoyl) respectively.,"InChI=1S/C37H74NO7P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-32-42-34-36(35-44-46(40,41)43-33-31-38)45-37(39)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h29,32,36H,3-28,30-31,33-35,38H2,1-2H3,(H,40,41)/b32-29-/t36-/m1/s1",PE(P-16:0/16:0),LIPID MAPS instance accession,LMGP02030013
3990,72744,1-hexadecyl-2-hexadecanoyl-sn-glycero-3-phosphocholine,A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the acyl and alkyl groups are specified as hexadecanoyl (palmitoyl) and hexadecyl respectively.,"InChI=1S/C40H82NO7P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-35-45-37-39(38-47-49(43,44)46-36-34-41(3,4)5)48-40(42)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h39H,6-38H2,1-5H3/t39-/m1/s1",PC(O-16:0/16:0),LIPID MAPS instance accession,LMGP01020029
3991,72745,(E)-hexadec-2-enoate,"A straight-chain unsaturated fatty acid anion that is the conjugate base of (E)-hexadec-2-enoic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C16H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h14-15H,2-13H2,1H3,(H,17,18)/p-1/b15-14+",2-palmitoleate,MetaCyc accession,CPD-9768
3992,72747,"lysophosphatidylethanolamine (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)","A 1-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl.","InChI=1S/C27H44NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(30)33-24-26(29)25-35-36(31,32)34-23-22-28/h3-4,6-7,9-10,12-13,15-16,18-19,26,29H,2,5,8,11,14,17,20-25,28H2,1H3,(H,31,32)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-/t26-/m1/s1","LPE 22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0",PubMed citation,22882828
3993,72758,"sphinga-4E,8E-dienine(1+)","A cationic sphingoid obtained by protonation of the amino group of sphinga-4E,8E-dienine.","InChI=1S/C18H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h10-11,14-15,17-18,20-21H,2-9,12-13,16,19H2,1H3/p+1/b11-10+,15-14+/t17-,18+/m0/s1","sphinga-4,8-dienine",MetaCyc accession,CPD-8427
3994,72759,N-(pentadecanoyl)sphinganine-1-phosphocholine,A N-acylsphinganine-1-phosphocholine in which the acyl group is pentadecanoyl.,"InChI=1S/C38H79N2O6P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-37(41)36(35-46-47(43,44)45-34-33-40(3,4)5)39-38(42)32-30-28-26-24-22-19-17-15-13-11-9-7-2/h36-37,41H,6-35H2,1-5H3,(H-,39,42,43,44)/t36-,37+/m0/s1",SM(d18:0/15:0),LIPID MAPS instance accession,LMSP03010091
3995,72762,6-hydroxytryprostatin B,A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and hydroxy groups respectively.,"InChI=1S/C21H25N3O3/c1-12(2)5-8-16-15(14-7-6-13(25)10-17(14)22-16)11-18-21(27)24-9-3-4-19(24)20(26)23-18/h5-7,10,18-19,22,25H,3-4,8-9,11H2,1-2H3,(H,23,26)/t18-,19-/m0/s1",desmethyltryprostatin A,PubMed citation,19226505
3996,72769,2'-oxokanamycin,A kanamycin obtained by dehydrogenation at position 2' of kanamycin A.,"InChI=1S/C18H34N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-12,14-18,23-27,29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,14-,15+,16-,17-,18-/m1/s1",2'-dehydrokanamycin A,PubMed citation,22374809
3997,72778,4-(beta-D-ribofuranosyl)aminobenzene 5'-phosphate(2-),An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of 4-(beta-D-ribofuranosyl)aminobenzene 5'-phosphate.,"InChI=1S/C11H16NO7P/c12-7-3-1-6(2-4-7)11-10(14)9(13)8(19-11)5-18-20(15,16)17/h1-4,8-11,13-14H,5,12H2,(H2,15,16,17)/p-2/t8-,9-,10-,11+/m1/s1",4-(beta-D-ribofuranosyl)aniline 5'-phosphate(2-),MetaCyc accession,CPD-7652
3998,72779,11-trans-LTE4,A leukotriene that is the 11-trans-isomer of leukotriene E4.,"InChI=1S/C23H37NO5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-21(30-18-19(24)23(28)29)20(25)15-14-17-22(26)27/h6-7,9-13,16,19-21,25H,2-5,8,14-15,17-18,24H2,1H3,(H,26,27)(H,28,29)/b7-6-,10-9+,12-11+,16-13+/t19-,20-,21+/m0/s1",11t-LTE4,PubMed citation,6895224
3999,72787,4-(beta-D-ribofuranosyl)aminobenzene 5'-phosphate,A ribose monophosphate that is 4-(beta-D-ribofuranosyl)aminobenzene carrying a single monophospate substituent at position 5'.,"InChI=1S/C11H16NO7P/c12-7-3-1-6(2-4-7)11-10(14)9(13)8(19-11)5-18-20(15,16)17/h1-4,8-11,13-14H,5,12H2,(H2,15,16,17)/t8-,9-,10-,11+/m1/s1",4-aminophenyl beta-D-ribofuranoside 5-phosphate,PubMed citation,12142414
4000,72789,15-epi-lipoxin A4,"A C20 hydroxy polyunsaturated fatty acid having (5S)-, (6R)- and (15R)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds.","InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18-,19+/m1/s1",15R-LXA4,HMDB accession,HMDB0012587
4001,72803,1-(hexadec-1-enyl)-2-hexadecanoyl-sn-glycero-3-phosphoethanolamine,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl and acyl group are specified as (Z)-hexadec-1-enyl and hexadecanoyl (palmitoyl) respectively.,"InChI=1S/C37H74NO7P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-32-42-34-36(35-44-46(40,41)43-33-31-38)45-37(39)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h29,32,36H,3-28,30-31,33-35,38H2,1-2H3,(H,40,41)/b32-29-/t36-/m1/s1",1-(hexadec-1-enyl)-2-palmitoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02030013
4002,72808,"13-hydroxy-6Z,9Z,11E-octadecatrienoic acid","A hydroxyoctadecatrienoic acid that consists of 6Z,9Z,11E-octadecatrienoic acid having the hydroxy group located at position 13.","InChI=1S/C18H30O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h4,6-7,9,12,15,17,19H,2-3,5,8,10-11,13-14,16H2,1H3,(H,20,21)/b6-4-,9-7-,15-12+",13-HOTrE(gamma),Reaxys Registry Number,15525483
4003,72831,2-hexadecanoyl-1-octadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol)(1-),"A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol)(1-) in which the 1- and 2-acyl groups are specified as octadecanoyl (stearoyl) and hexadecanoyl (palmitoyl) respectively; major species at pH 7.3.","InChI=1S/C40H79O10P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-39(43)47-35-38(36-49-51(45,46)48-34-37(42)33-41)50-40(44)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h37-38,41-42H,3-36H2,1-2H3,(H,45,46)/p-1/t37-,38+/m0/s1",PG(18:0/16:0),MetaCyc accession,CPD-8262
4004,72832,1-[(9Z)-octadec-9-enoyl]-2-hexadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol)(1-),"A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol)(1-) in which the 1- and 2-acyl groups are specified as (9Z)-octadec-9-enoyl (oleoyl) and hexadecanoyl (palmitoyl) respectively; major species at pH 7.3.","InChI=1S/C40H77O10P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-39(43)47-35-38(36-49-51(45,46)48-34-37(42)33-41)50-40(44)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h17-18,37-38,41-42H,3-16,19-36H2,1-2H3,(H,45,46)/p-1/b18-17-/t37-,38+/m0/s1",PG(18:1(9Z)/16:0),MetaCyc accession,CPD-2183
4005,72835,"1,2-dihexadecanoyl-sn-glycero-3-phospho-D-myo-inositol(1-)","A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol(1-) obtained by deprotonation of the phosphate OH group of 1,2-dihexadecanoyl-sn-glycero-3-phospho-D-myo-inositol.","InChI=1S/C41H79O13P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)51-31-33(32-52-55(49,50)54-41-39(47)37(45)36(44)38(46)40(41)48)53-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h33,36-41,44-48H,3-32H2,1-2H3,(H,49,50)/p-1/t33-,36-,37-,38+,39-,40-,41-/m1/s1",PI(16:0/16:0),MetaCyc accession,CPD66-45
4006,72837,1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-D-myo-inositol(1-),A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol(1-) obtained by deprotonation of the phosphate OH group of 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-D-myo-inositol.,"InChI=1S/C43H81O13P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(45)55-35(34-54-57(51,52)56-43-41(49)39(47)38(46)40(48)42(43)50)33-53-36(44)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,35,38-43,46-50H,3-16,19-34H2,1-2H3,(H,51,52)/p-1/b18-17-/t35-,38-,39-,40+,41-,42-,43-/m1/s1",PI(16:0/18:1(9Z)),MetaCyc accession,CPD-8320
4007,72838,"1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phospho-D-myo-inositol(1-)","A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol(1-) obtained by deprotonation of the phosphate OH group of 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phospho-D-myo-inositol.","InChI=1S/C43H79O13P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(45)55-35(34-54-57(51,52)56-43-41(49)39(47)38(46)40(48)42(43)50)33-53-36(44)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13,17-18,35,38-43,46-50H,3-10,12,14-16,19-34H2,1-2H3,(H,51,52)/p-1/b13-11-,18-17-/t35-,38-,39-,40+,41-,42-,43-/m1/s1","PI(16:0/18:2(9Z,12Z))",MetaCyc accession,CPD-8321
4008,72855,"(4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoic acid","An EpDPE obtained by formal epoxidation of the 16,17-double bond of docosa-4,7,10,13,16,19-hexaenoic acid.","InChI=1S/C22H32O3/c1-2-3-14-17-20-21(25-20)18-15-12-10-8-6-4-5-7-9-11-13-16-19-22(23)24/h3,5-8,11-15,20-21H,2,4,9-10,16-19H2,1H3,(H,23,24)/b7-5-,8-6-,13-11-,14-3-,15-12-","16(17)-epoxy-4Z,7Z,10Z,13Z,19Z-docosapentaenoic acid",LIPID MAPS instance accession,LMFA04000037
4009,72859,"1,2-dihexadecanoyl-sn-glycerol-3-phosphate(2-)",A 1-acyl-2-hexadecanoyl-sn-glycero-3-phosphate(2-) in which the 1-acyl group is also hexadecanoyl; major species at pH 7.3.,"InChI=1S/C35H69O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(36)41-31-33(32-42-44(38,39)40)43-35(37)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h33H,3-32H2,1-2H3,(H2,38,39,40)/p-2/t33-/m1/s1",PA(16:0/16:0),MetaCyc accession,CPD0-1422
4010,72860,"1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate(2-)","A 1,2-diacyl-sn-glycerol 3-phosphate(2-) in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 9Z,12Z-octadecadienoyl (linoleoyl) respectively; major species at pH 7.3.","InChI=1S/C37H69O8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(39)45-35(34-44-46(40,41)42)33-43-36(38)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13,17-18,35H,3-10,12,14-16,19-34H2,1-2H3,(H2,40,41,42)/p-2/b13-11-,18-17-/t35-/m1/s1","PA(16:0/18:2(9Z,12Z))",MetaCyc accession,CPD-8265
4011,72952,1-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-sn-glycerol),A 1-acyl-sn-glycero 3-phospho-(1'-sn-glycerol) in which the acyl group is specified as 9Z-octadecenoyl.,"InChI=1S/C24H47O9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-24(28)31-19-23(27)21-33-34(29,30)32-20-22(26)18-25/h9-10,22-23,25-27H,2-8,11-21H2,1H3,(H,29,30)/b10-9-/t22-,23+/m0/s1",1-oleoyl-sn-glycero-3-phospho-(1'-sn-glycerol),LIPID MAPS instance accession,LMGP04050006
4012,72955,N-decanoylsphingosine,A N-acylsphingosine in which the ceramide N-acyl group is specified as decanoyl.,"InChI=1S/C28H55NO3/c1-3-5-7-9-11-12-13-14-15-16-18-19-21-23-27(31)26(25-30)29-28(32)24-22-20-17-10-8-6-4-2/h21,23,26-27,30-31H,3-20,22,24-25H2,1-2H3,(H,29,32)/b23-21+/t26-,27+/m0/s1",Cer(d18:1/10:0),Reaxys Registry Number,10131395
4013,72968,N-hexacosanoylsphingosine,A N-acylsphingosine in which the ceramide N-acyl group is specified as hexacosanoyl.,"InChI=1S/C44H87NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-44(48)45-42(41-46)43(47)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2/h37,39,42-43,46-47H,3-36,38,40-41H2,1-2H3,(H,45,48)/b39-37+/t42-,43+/m0/s1",Cer(d18:1/26:0),HMDB accession,HMDB0004955
4014,72995,3-hydroxybutyrylcarnitine,An O-acylcarnitine having 3-hydroxybutyryl as the acyl substituent.,"InChI=1S/C11H21NO5/c1-8(13)5-11(16)17-9(6-10(14)15)7-12(2,3)4/h8-9,13H,5-7H2,1-4H3",beta-hydroxybutyrylcarnitine,PubMed citation,23315938
4015,73000,1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine,A phosphatidylcholine 34:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and octadecanoyl (stearoyl) respectively.,"InChI=1S/C42H84NO8P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43(3,4)5)38-48-41(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h40H,6-39H2,1-5H3/t40-/m1/s1",PC(16:0/18:0),LIPID MAPS instance accession,LMGP01010573
4016,73005,"1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion","A phosphatidylethanolamine 32:0 zwitterion obtained by transfer of a proton from the phosphate to the amino group of 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine.","InChI=1S/C37H74NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(39)43-33-35(34-45-47(41,42)44-32-31-38)46-37(40)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h35H,3-34,38H2,1-2H3,(H,41,42)/t35-/m1/s1",PE(16:0/16:0),PDBeChem accession,PEF
4017,73007,1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine zwitterion,A phosphatidylethanolamine 34:1 zwitterion obtained by transfer of a proton from the phosphate to the amino group of 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine.,"InChI=1S/C39H76NO8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(42)48-37(36-47-49(43,44)46-34-33-40)35-45-38(41)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,37H,3-16,19-36,40H2,1-2H3,(H,43,44)/b18-17-/t37-/m1/s1",PE(16:0/18:1(9Z)),PubMed citation,29054999
4018,73023,Ac-His-D-Pro,A dipeptide that is the N(1)-(N(alpha)-acetyl-L-histidyl) derivative of D-proline.,"InChI=1S/C13H19N5O3/c1-8(19)17-10(5-9-6-15-7-16-9)13(21)18-4-2-3-11(18)12(14)20/h6-7,10-11H,2-5H2,1H3,(H2,14,20)(H,15,16)(H,17,19)/t10-,11+/m0/s1",Ac-Hp-OH,PDB accession,1MCR
4019,73024,O-acetylcarnitine,An O-acylcarnitine having acetyl as the acyl substituent.,"InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3",acetylcarnitine,PubMed citation,23315938
4020,73033,pterocarpan,"The simplest member of the class of pterocarpans that is 6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene.","InChI=1S/C15H12O2/c1-4-8-14-10(5-1)12-9-16-13-7-3-2-6-11(13)15(12)17-14/h1-8,12,15H,9H2",chromanocumaran,Reaxys Registry Number,1315790
4021,73049,O-pimeloylcarnitine,An O-acylcarnitine having pimeloyl as the acyl substituent.,"InChI=1S/C14H25NO6/c1-15(2,3)11(9-10-13(18)19)21-14(20)8-6-4-5-7-12(16)17/h11H,4-10H2,1-3H3,(H-,16,17,18,19)",pimeloylcarnitine,PubMed citation,23315938
4022,73054,O-dodecanoylcarnitine,An O-acylcarnitine having dodecanoyl as the acyl substituent.,"InChI=1S/C19H37NO4/c1-5-6-7-8-9-10-11-12-13-14-19(23)24-17(15-18(21)22)16-20(2,3)4/h17H,5-16H2,1-4H3",O-lauroylcarnitine,Reaxys Registry Number,4147608
4023,73061,O-tetradecanoylcarnitine,An O-acylcarnitine having tetradecanoyl (myristoyl) as the acyl substituent.,"InChI=1S/C21H41NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-21(25)26-19(17-20(23)24)18-22(2,3)4/h19H,5-18H2,1-4H3",O-myristoylcarnitine,PubMed citation,23315938
4024,73087,dihydrourocanic acid,A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 3 has been replaced by an imidazol-4-yl group.,"InChI=1S/C6H8N2O2/c9-6(10)2-1-5-3-7-4-8-5/h3-4H,1-2H2,(H,7,8)(H,9,10)",deaminohistidine,PubMed citation,23078170
4025,73089,4-hydroxy-2-oxoheptanedioic acid,An oxo dicarboxylic acid consisting of pimelic acid substituted at positions 2 and 4 by oxo and hydroxy groups respectively.,"InChI=1S/C7H10O6/c8-4(1-2-6(10)11)3-5(9)7(12)13/h4,8H,1-3H2,(H,10,11)(H,12,13)","4-hydroxy-2-ketoheptane-1,7-dioic acid",PubMed citation,17881002
4026,73091,1-octadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol),A 1-acyl-sn-glycero 3-phospho-(1'-sn-glycerol) in which the acyl group is specified as octadecanoyl (stearoyl).,"InChI=1S/C24H49O9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-24(28)31-19-23(27)21-33-34(29,30)32-20-22(26)18-25/h22-23,25-27H,2-21H2,1H3,(H,29,30)/t22-,23+/m0/s1",1-stearoyl-sn-glycero-3-phospho-(1'-sn-glycerol),LIPID MAPS instance accession,LMGP04050009
4027,73117,"1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phosphoethanolamine","A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 5Z,8Z,11Z,14Z-eicosatetraenoyl (arachidonoyl) respectively.","InChI=1S/C41H74NO8P/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-41(44)50-39(38-49-51(45,46)48-36-35-42)37-47-40(43)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h11,13,17-18,20,22,26,28,39H,3-10,12,14-16,19,21,23-25,27,29-38,42H2,1-2H3,(H,45,46)/b13-11-,18-17-,22-20-,28-26-/t39-/m1/s1",1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02010096
4028,73118,(11Z)-eicoseneoylcarnitine,An O-acylcarnitine having (11Z)-eicoseneoyl as the acyl substituent.,"InChI=1S/C27H51NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-27(31)32-25(23-26(29)30)24-28(2,3)4/h12-13,25H,5-11,14-24H2,1-4H3/b13-12-",11-cis-eicoseneoylcarnitine,PubMed citation,23315938
4029,73121,"1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine","A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 9Z,12Z-octadecadienoyl (linoleoyl) respectively.","InChI=1S/C39H74NO8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(42)48-37(36-47-49(43,44)46-34-33-40)35-45-38(41)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13,17-18,37H,3-10,12,14-16,19-36,40H2,1-2H3,(H,43,44)/b13-11-,18-17-/t37-/m1/s1",1-hexadecanoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02010042
4030,73123,"O-[(7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl]carnitine","An O-acylcarnitine having (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl as the acyl substituent.","InChI=1S/C29H47NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-29(33)34-27(25-28(31)32)26-30(2,3)4/h6-7,9-10,12-13,15-16,18-19,27H,5,8,11,14,17,20-26H2,1-4H3/b7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-7,10,13,16,19-docosapentaenoylcarnitine",PubMed citation,23315938
4031,73124,1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 9Z-octadecenoyl (oleoyl) respectively.","InChI=1S/C39H76NO8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(42)48-37(36-47-49(43,44)46-34-33-40)35-45-38(41)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,37H,3-16,19-36,40H2,1-2H3,(H,43,44)/b18-17-/t37-/m1/s1",1-hexadecanoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02010009
4032,73137,N-tetracosanoylsphingosine 1-phosphate,A ceramide 1-phosphate that is N-tetracosanoyl derivative of sphingosine.,"InChI=1S/C42H84NO6P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(45)43-40(39-49-50(46,47)48)41(44)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h35,37,40-41,44H,3-34,36,38-39H2,1-2H3,(H,43,45)(H2,46,47,48)/b37-35+/t40-,41+/m0/s1",N-(tetracosanoyl)sphing-4-enine 1-phosphate,LIPID MAPS instance accession,LMSP02050008
4033,73138,N-docosanoylsphingosine-1-phosphate,A ceramide 1-phosphate that is the N-docosanoyl derivative of sphingosine.,"InChI=1S/C40H80NO6P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-40(43)41-38(37-47-48(44,45)46)39(42)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h33,35,38-39,42H,3-32,34,36-37H2,1-2H3,(H,41,43)(H2,44,45,46)/b35-33+/t38-,39+/m0/s1",N-(docosanoyl)sphing-4-enine 1-phosphate,LIPID MAPS instance accession,LMSP02050006
4034,73140,N-icosanoylsphingosine 1-phosphate,A ceramide 1-phosphate that is the N-icosanoyl derivative of sphingosine.,"InChI=1S/C38H76NO6P/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-38(41)39-36(35-45-46(42,43)44)37(40)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h31,33,36-37,40H,3-30,32,34-35H2,1-2H3,(H,39,41)(H2,42,43,44)/b33-31+/t36-,37+/m0/s1",N-icosanoylsphing-4-enine-1-phosphate,LIPID MAPS instance accession,LMSP02050005
4035,73144,N-octadecanoylsphingosine 1-phosphate,A ceramide 1-phosphate that is the N-octadecananoyl (stearoyl) derivative of sphingosine.,"InChI=1S/C36H72NO6P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(39)37-34(33-43-44(40,41)42)35(38)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,34-35,38H,3-28,30,32-33H2,1-2H3,(H,37,39)(H2,40,41,42)/b31-29+/t34-,35+/m0/s1",N-stearoylsphingosine 1-phosphate,LIPID MAPS instance accession,LMSP02050004
4036,73145,N-hexadecanoylsphingosine 1-phosphate,A ceramide 1-phosphate that is the N-hexadecanoyl (palmitoyl) derivative of sphingosine.,"InChI=1S/C34H68NO6P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-33(36)32(31-41-42(38,39)40)35-34(37)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h27,29,32-33,36H,3-26,28,30-31H2,1-2H3,(H,35,37)(H2,38,39,40)/b29-27+/t32-,33+/m0/s1",N-hexadecanoylsphing-4-enine-1-phosphate,Reaxys Registry Number,7319920
4037,73148,(S)-4-hydroxy-2-oxopentanoic acid,An optically active form of 4-hydroxy-2-oxopentanoic acid having 4S-configuration.,"InChI=1S/C5H8O4/c1-3(6)2-4(7)5(8)9/h3,6H,2H2,1H3,(H,8,9)/t3-/m0/s1",(S)-4-hydroxy-2-ketopentanoic acid,Reaxys Registry Number,7803213
4038,73151,(S)-4-hydroxy-2-oxohexanoic acid,An optically active form of 4-hydroxy-2-oxohexanoic acid having 4S-configuration.,"InChI=1S/C6H10O4/c1-2-4(7)3-5(8)6(9)10/h4,7H,2-3H2,1H3,(H,9,10)/t4-/m0/s1",(S)-4-hydroxy-2-ketohexanoic acid,PubMed citation,22081904
4039,73187,6beta-[(p-hydroxybenzylidene)amino]penicillanic acid,Penicillanic acid carrying a (p-hydroxybenzylidene)amino substituent at the 6beta position. It has been used as a hapten in the production of a generic monoclonal antibody for determining penicillin residues in milk.,"InChI=1S/C15H16N2O4S/c1-15(2)11(14(20)21)17-12(19)10(13(17)22-15)16-7-8-3-5-9(18)6-4-8/h3-7,10-11,13,18H,1-2H3,(H,20,21)/t10-,11+,13-/m1/s1",hapten HAPA,PubMed citation,23452214
4040,73188,6beta-({5-[(p-aminophenyl)imino]pentylidene}amino)penicillanic acid,Penicillanic acid carrying a (p-aminophenyl)imino]pentylidene}amino substituent at the 6beta position. It has been used as a hapten in the production of a generic monoclonal antibody for determining penicillin residues in milk.,"InChI=1S/C19H24N4O3S/c1-19(2)15(18(25)26)23-16(24)14(17(23)27-19)22-11-5-3-4-10-21-13-8-6-12(20)7-9-13/h6-11,14-15,17H,3-5,20H2,1-2H3,(H,25,26)/t14-,15+,17-/m1/s1",hapten 1 PAPA,PubMed citation,23452214
4041,73205,"1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol)","A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which both acyl groups are specified as hexadecanoyl (palmitoyl).","InChI=1S/C38H75O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(41)45-33-36(34-47-49(43,44)46-32-35(40)31-39)48-38(42)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h35-36,39-40H,3-34H2,1-2H3,(H,43,44)/t35-,36+/m0/s1","1,2-dihexadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol)",LIPID MAPS instance accession,LMGP04010986
4042,73206,1-[(9Z)-octadec-9-enoyl]-2-hexadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol),"A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which the 1- and 2-acyl groups are specified as (9Z)-octadec-9-enoyl (oleoyl) and hexadecanoyl (palmitoyl) respectively.","InChI=1S/C40H77O10P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-39(43)47-35-38(36-49-51(45,46)48-34-37(42)33-41)50-40(44)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h17-18,37-38,41-42H,3-16,19-36H2,1-2H3,(H,45,46)/b18-17-/t37-,38+/m0/s1",1-oleoyl-2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol),PubMed citation,23307809
4043,73209,"1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phospho-D-myo-inositol","A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl group is specified as (5Z,8Z,11Z,14Z)-icosatetraenoyl (arachidonyl).","InChI=1S/C45H79O13P/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-39(47)57-37(36-56-59(53,54)58-45-43(51)41(49)40(48)42(50)44(45)52)35-55-38(46)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h11,13,17-18,20,22,26,28,37,40-45,48-52H,3-10,12,14-16,19,21,23-25,27,29-36H2,1-2H3,(H,53,54)/b13-11-,18-17-,22-20-,28-26-/t37-,40-,41-,42+,43-,44-,45-/m1/s1",2-arachidonoyl-1-hexadecanoyl-sn-glycero-3-phospho-D-myo-inositol,LIPID MAPS instance accession,LMGP06010958
4044,73215,1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-D-myo-inositol,A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl group is specified as 9Z-octadecenoyl (oleoyl).,"InChI=1S/C43H81O13P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(45)55-35(34-54-57(51,52)56-43-41(49)39(47)38(46)40(48)42(43)50)33-53-36(44)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,35,38-43,46-50H,3-16,19-34H2,1-2H3,(H,51,52)/b18-17-/t35-,38-,39-,40+,41-,42-,43-/m1/s1",2-oleoyl-1-palmitoyl-sn-glycero-3-phospho-D-myo-inositol,LIPID MAPS instance accession,LMGP06010001
4045,73218,1-hexadecanoyl-sn-glycero-3-phospho-D-myo-inositol,A 1-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the acyl group is specified as hexadecanoyl (palmitoyl).,"InChI=1S/C25H49O12P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(27)35-16-18(26)17-36-38(33,34)37-25-23(31)21(29)20(28)22(30)24(25)32/h18,20-26,28-32H,2-17H2,1H3,(H,33,34)/t18-,20-,21-,22+,23-,24-,25-/m1/s1",1-palmitoyl-sn--glycero-3-phospho-D-myo-inositol,LIPID MAPS instance accession,LMGP06050002
4046,73223,1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phospho-D-myo-inositol,A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl group is specified as octadecanoyl (stearoyl).,"InChI=1S/C43H83O13P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(45)55-35(34-54-57(51,52)56-43-41(49)39(47)38(46)40(48)42(43)50)33-53-36(44)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h35,38-43,46-50H,3-34H2,1-2H3,(H,51,52)/t35-,38-,39-,40+,41-,42-,43-/m1/s1",1-palmitoyl-2-stearoyl-sn-glycero-3-phospho-D-myo-inositol,LIPID MAPS instance accession,LMGP06010878
4047,73224,allyl isothiocyanate,"An isothiocyanate with the formula CH2=CHCH2N=C=S. A colorless oil with boiling point 152degreeC, it is responsible for the pungent taste of mustard, horseradish, and wasabi.","InChI=1S/C4H5NS/c1-2-3-5-4-6/h2H,1,3H2",3-Isothiocyanato-1-propene,KEGG DRUG accession,D02818
4048,73226,arborescin,An organic heterotetracyclic compound and guaianolide sesquiterpene lactone that is arglabin in which the exocyclic double bond has been reduced to a single bond. It is found in Artemesia adamsii.,"InChI=1S/C15H20O3/c1-8-4-7-15-11(8)12-10(9(2)13(16)17-12)5-6-14(15,3)18-15/h4,9-12H,5-7H2,1-3H3/t9-,10-,11+,12-,14-,15+/m0/s1","1,10-epoxy-6beta-hydroxy-1beta,5beta,7alpha-guiai-3-en-12-oic acid gamma-lactone",CAS Registry Number,6831-14-7
4049,73231,crispolide,"An organic heterotricyclic compound that is a hydroperoxysesquiterpene lactone with a modified germacrane skeleton, isolated from the aerial parts of Tanacetum vulgare.","InChI=1S/C15H20O5/c1-8-10-4-3-9-7-15(2,6-5-11(9)20-18)13(16)12(10)19-14(8)17/h3,10-13,16,18H,1,4-7H2,2H3/b9-3+/t10-,11+,12-,13+,15+/m0/s1","(3aS,7R,10R,11S,11aS)-3a,4,7,8,9,10,11,11a-Octahydro-7-hydroperoxy-11-hydroxy-10-methyl-3-methylene-6,10-methanocyclodeca[b]furan-2(3H)-one",CAS Registry Number,83217-86-1
4050,73238,"1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phospho-(1'-sn-glycerol)","A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 9Z,12Z-octadecadienoyl (linoleoyl) respectively.","InChI=1S/C40H75O10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-40(44)50-38(36-49-51(45,46)48-34-37(42)33-41)35-47-39(43)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13,17-18,37-38,41-42H,3-10,12,14-16,19-36H2,1-2H3,(H,45,46)/b13-11-,18-17-/t37-,38+/m0/s1",2-linoleoyl-1-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol),HMDB accession,HMDB0010575
4051,73242,1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-sn-glycerol),"A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which the 1- and 2-acyl groups are specified as octadecanoyl (stearoyl) and 9Z-octadecenoyl (oleoyl) respectively.","InChI=1S/C42H81O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,39-40,43-44H,3-17,19,21-38H2,1-2H3,(H,47,48)/b20-18-/t39-,40+/m0/s1",2-oleoyl-1-stearoyl-sn-glycero-3-phospho-(1'-sn-glycerol),LIPID MAPS instance accession,LMGP04010037
4052,73246,"1,2-dihexadecanoyl-sn-glycerol-3-phosphate",A 1-acyl-2-hexadecanoyl-sn-glycero-3-phosphate in which the 1-acyl group is also hexadecanoyl.,"InChI=1S/C35H69O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(36)41-31-33(32-42-44(38,39)40)43-35(37)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h33H,3-32H2,1-2H3,(H2,38,39,40)/t33-/m1/s1","1,2-dipalmitoyl-sn-glycerol-3-phosphate",HMDB accession,HMDB0000674
4053,73257,gibberellin A20 methyl ester,A gibberellin ester that is the methyl ester of gibberellin A20.,"InChI=1S/C20H26O5/c1-11-9-18-10-19(11,23)8-5-12(18)20-7-4-6-17(2,16(22)25-20)14(20)13(18)15(21)24-3/h12-14,23H,1,4-10H2,2-3H3/t12-,13-,14-,17-,18+,19+,20-/m1/s1",O-methyl gibberellin A20,MetaCyc accession,CPD-12333
4054,73259,"1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycerol 3-phosphate in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 9Z,12Z-octadecadienoyl (linoleoyl) respectively.","InChI=1S/C37H69O8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(39)45-35(34-44-46(40,41)42)33-43-36(38)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13,17-18,35H,3-10,12,14-16,19-34H2,1-2H3,(H2,40,41,42)/b13-11-,18-17-/t35-/m1/s1",2-linoleoyl-1-palmitoyl-sn-glycero-3-phosphate,Reaxys Registry Number,22456038
4055,73262,"1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycerol 3-phosphate in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and 5Z,8Z,11Z,14Z-eicosatetraenoyl (arachidonoyl) respectively.","InChI=1S/C39H69O8P/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-39(41)47-37(36-46-48(42,43)44)35-45-38(40)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h11,13,17-18,20,22,26,28,37H,3-10,12,14-16,19,21,23-25,27,29-36H2,1-2H3,(H2,42,43,44)/b13-11-,18-17-,22-20-,28-26-/t37-/m1/s1","1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010025
4056,73264,1-hexadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphate,A 1-acyl-2-tetradecanoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as hexadecanoyl (palmitoyl).,"InChI=1S/C33H65O8P/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-32(34)39-29-31(30-40-42(36,37)38)41-33(35)28-26-24-22-20-17-14-12-10-8-6-4-2/h31H,3-30H2,1-2H3,(H2,36,37,38)/t31-/m1/s1",1-palmitoyl-2-myristoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010976
4057,73270,Leu-Gln-Pro,"A tripeptide consisting of L-leucyl, L-glutaminyl and L-proline residues joined in sequence.","InChI=1S/C16H28N4O5/c1-9(2)8-10(17)14(22)19-11(5-6-13(18)21)15(23)20-7-3-4-12(20)16(24)25/h9-12H,3-8,17H2,1-2H3,(H2,18,21)(H,19,22)(H,24,25)/t10-,11-,12-/m0/s1",LQP,Reaxys Registry Number,4825392
4058,73271,archaeosine,"A 7-deazaguanine ribonucleoside having 7-formamidino-7-deazaguanine as the nucleobase. It is found in the majority of archaeal tRNAs specifically at position 15 of the dihydrouridine loop (D-loop), a position not modified in either eukaryotic or bacterial tRNA.","InChI=1S/C12H16N6O5/c13-8(14)3-1-18(9-5(3)10(22)17-12(15)16-9)11-7(21)6(20)4(2-19)23-11/h1,4,6-7,11,19-21H,2H2,(H3,13,14)(H3,15,16,17,22)/t4-,6-,7-,11-/m1/s1",G*,Reaxys Registry Number,18583543
4059,73272,canagliflozin hydrate,A hydrate that is the hemihydrate form of canagliflozin. Used for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2.,"InChI=1S/2C24H25FO5S.H2O/c2*1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14;/h2*2-10,19,21-24,26-29H,11-12H2,1H3;1H2/t2*19-,21-,22+,23-,24+;/m11./s1",canagliflozin hemihydrate,KEGG DRUG accession,D09592
4060,73307,2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid,An aminobenzoic acid that is anthranilic acid substituted at position 5 by a (1-methoxy-2-methylindolizin-3-yl)carbonyl group.,"InChI=1S/C18H16N2O4/c1-10-15(20-8-4-3-5-14(20)17(10)24-2)16(21)11-6-7-13(19)12(9-11)18(22)23/h3-9H,19H2,1-2H3,(H,22,23)",2-amino-5-[(1-methoxy-2-methylindolizin-3-yl)carbonyl]benzoic acid,Reaxys Registry Number,11429953
4061,73313,Ala-Ala-Ala,A tripeptide composed of three L-alanine units joined by peptide linkages.,"InChI=1S/C9H17N3O4/c1-4(10)7(13)11-5(2)8(14)12-6(3)9(15)16/h4-6H,10H2,1-3H3,(H,11,13)(H,12,14)(H,15,16)/t4-,5-,6-/m0/s1",L-Ala-L-Ala-L-Ala,CAS Registry Number,5874-90-8
4062,73314,Ala-Ala-Asp-Asp,A tetrapeptide composed of two L-alanine units linked to two L-aspartic acid units by peptide linkages.,"InChI=1S/C14H22N4O9/c1-5(15)11(23)16-6(2)12(24)17-7(3-9(19)20)13(25)18-8(14(26)27)4-10(21)22/h5-8H,3-4,15H2,1-2H3,(H,16,23)(H,17,24)(H,18,25)(H,19,20)(H,21,22)(H,26,27)/t5-,6-,7-,8-/m0/s1",AADD,Reaxys Registry Number,4890080
4063,73317,Ala-Ala-Asp,A tripeptide composed of two L-alanyl and an L-aspartic acid residue joined in sequence.,"InChI=1S/C10H17N3O6/c1-4(11)8(16)12-5(2)9(17)13-6(10(18)19)3-7(14)15/h4-6H,3,11H2,1-2H3,(H,12,16)(H,13,17)(H,14,15)(H,18,19)/t4-,5-,6-/m0/s1",AAD,Reaxys Registry Number,14710534
4064,73321,Ala-Ala-Ser,A tripeptide composed of two L-alanyl units and an L-serine joined by peptide linkages.,"InChI=1S/C9H17N3O5/c1-4(10)7(14)11-5(2)8(15)12-6(3-13)9(16)17/h4-6,13H,3,10H2,1-2H3,(H,11,14)(H,12,15)(H,16,17)/t4-,5-,6-/m0/s1",L-Ala-L-Ala-L-Ser,Reaxys Registry Number,15003413
4065,73323,Ala-Ala-Pro,A tripeptide composed of two L-alanyl units and an L-proline joined by peptide linkages.,"InChI=1S/C11H19N3O4/c1-6(12)9(15)13-7(2)10(16)14-5-3-4-8(14)11(17)18/h6-8H,3-5,12H2,1-2H3,(H,13,15)(H,17,18)/t6-,7-,8-/m0/s1",AAP,Reaxys Registry Number,6869948
4066,73330,Ala-Asn,A dipeptide composed of L-alanine and L-asparagine units joined by a peptide linkage.,"InChI=1S/C7H13N3O4/c1-3(8)6(12)10-4(7(13)14)2-5(9)11/h3-4H,2,8H2,1H3,(H2,9,11)(H,10,12)(H,13,14)/t3-,4-/m0/s1",L-Ala-L-Asn,Reaxys Registry Number,5335044
4067,73340,4-DAMP methiodide,A quaternary ammonium salt obtained by combining equimolar amounts of 4-diphenylacetoxy-N-methylpiperidine and iodomethane.,"InChI=1S/C21H26NO2.HI/c1-22(2)15-13-19(14-16-22)24-21(23)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;/h3-12,19-20H,13-16H2,1-2H3;1H/q+1;/p-1",4-diphenylacetoxy-N-methylpiperidine methiodide,PubMed citation,23597562
4068,73350,Ala-Gly-Ser,"A tripeptide composed of L-alanine, glycine, L-serine joined in sequence by peptide linkages.","InChI=1S/C8H15N3O5/c1-4(9)7(14)10-2-6(13)11-5(3-12)8(15)16/h4-5,12H,2-3,9H2,1H3,(H,10,14)(H,11,13)(H,15,16)/t4-,5-/m0/s1",L-Ala-Gly-L-Ser,CAS Registry Number,85807-50-7
4069,73366,Ala-Leu-Leu-Ser,"A tetrapeptide composed of L-alanine, two L-leucine units, and L-serine joined in sequence by peptide linkages.","InChI=1S/C18H34N4O6/c1-9(2)6-12(20-15(24)11(5)19)16(25)21-13(7-10(3)4)17(26)22-14(8-23)18(27)28/h9-14,23H,6-8,19H2,1-5H3,(H,20,24)(H,21,25)(H,22,26)(H,27,28)/t11-,12-,13-,14-/m0/s1",ALLS,Reaxys Registry Number,8516875
4070,73387,caldariellaquinone,"A 1-benzothiophene that is 1-benzothiophene-4,7-dione bearing additional methylthio and 3,7,11,15,19,23-hexamethyltetracosyl substituents at positions 5 and 6 respectively. Isolated from Caldariella acidophila.","InChI=1S/C39H66O2S2/c1-28(2)14-9-15-29(3)16-10-17-30(4)18-11-19-31(5)20-12-21-32(6)22-13-23-33(7)24-25-34-37(41)39-35(26-27-43-39)36(40)38(34)42-8/h26-33H,9-25H2,1-8H3","6-(3,7,11,15,19,23-hexamethyltetracosyl)-5-methylthiobenzo[b]thiophen-4,7-quinone",PubMed citation,2512282
4071,73394,Ala-Ser,A dipeptide composed of L-alanine and L-serine joined by a peptide linkage.,"InChI=1S/C6H12N2O4/c1-3(7)5(10)8-4(2-9)6(11)12/h3-4,9H,2,7H2,1H3,(H,8,10)(H,11,12)/t3-,4-/m0/s1",AS,HMDB accession,HMDB0028696
4072,73395,Ala-Tyr,A dipeptide composed of L-alanine and L-tyrosine joined by a peptide linkage.,"InChI=1S/C12H16N2O4/c1-7(13)11(16)14-10(12(17)18)6-8-2-4-9(15)5-3-8/h2-5,7,10,15H,6,13H2,1H3,(H,14,16)(H,17,18)/t7-,10-/m0/s1",A-Y,HMDB accession,HMDB0028699
4073,73406,Asn-Asn,A dipeptide formed from two L-asparagine units.,"InChI=1S/C8H14N4O5/c9-3(1-5(10)13)7(15)12-4(8(16)17)2-6(11)14/h3-4H,1-2,9H2,(H2,10,13)(H2,11,14)(H,12,15)(H,16,17)/t3-,4-/m0/s1",N-N,HMDB accession,HMDB0028726
4074,73419,Asn-Asp,A dipeptide composed of L-asparagine and L-aspartic acid joined by a peptide linkage.,"InChI=1S/C8H13N3O6/c9-3(1-5(10)12)7(15)11-4(8(16)17)2-6(13)14/h3-4H,1-2,9H2,(H2,10,12)(H,11,15)(H,13,14)(H,16,17)/t3-,4-/m0/s1",ND,HMDB accession,HMDB0028727
4075,73422,Asn-Gly,A dipeptide composed of L-asparagine and glycine joined by a peptide linkage.,"InChI=1S/C6H11N3O4/c7-3(1-4(8)10)6(13)9-2-5(11)12/h3H,1-2,7H2,(H2,8,10)(H,9,13)(H,11,12)/t3-/m0/s1",N-G,HMDB accession,HMDB0028731
4076,73424,Asn-His,A dipeptide composed of L-asparagine and L-histidine joined by a peptide linkage.,"InChI=1S/C10H15N5O4/c11-6(2-8(12)16)9(17)15-7(10(18)19)1-5-3-13-4-14-5/h3-4,6-7H,1-2,11H2,(H2,12,16)(H,13,14)(H,15,17)(H,18,19)/t6-,7-/m0/s1",NH,HMDB accession,HMDB0028733
4077,73425,Asn-Pro,A dipeptide composed of L-asparagine and L-proline joined by a peptide linkage.,"InChI=1S/C9H15N3O4/c10-5(4-7(11)13)8(14)12-3-1-2-6(12)9(15)16/h5-6H,1-4,10H2,(H2,11,13)(H,15,16)/t5-,6-/m0/s1",L-Asn-L-Pro,HMDB accession,HMDB0028739
4078,73426,Asn-Ser,A dipeptide composed of L-asparagine and L-serine joined by a peptide linkage.,"InChI=1S/C7H13N3O5/c8-3(1-5(9)12)6(13)10-4(2-11)7(14)15/h3-4,11H,1-2,8H2,(H2,9,12)(H,10,13)(H,14,15)/t3-,4-/m0/s1",N-S,HMDB accession,HMDB0028740
4079,73427,Asn-Tyr,A dipeptide composed of L-asparagine and L-tyrosine joined by a peptide linkage.,"InChI=1S/C13H17N3O5/c14-9(6-11(15)18)12(19)16-10(13(20)21)5-7-1-3-8(17)4-2-7/h1-4,9-10,17H,5-6,14H2,(H2,15,18)(H,16,19)(H,20,21)/t9-,10-/m0/s1",NY,HMDB accession,HMDB0028743
4080,73445,Asp-Arg,A dipeptide composed of L-aspartic acid and L-arginine joined by a peptide linkage.,"InChI=1S/C10H19N5O5/c11-5(4-7(16)17)8(18)15-6(9(19)20)2-1-3-14-10(12)13/h5-6H,1-4,11H2,(H,15,18)(H,16,17)(H,19,20)(H4,12,13,14)/t5-,6-/m0/s1",D-R,HMDB accession,HMDB0028747
4081,73450,Asp-Gly,A dipeptide composed of L-aspartic acid and glycine joined by a peptide linkage.,"InChI=1S/C6H10N2O5/c7-3(1-4(9)10)6(13)8-2-5(11)12/h3H,1-2,7H2,(H,8,13)(H,9,10)(H,11,12)/t3-/m0/s1",DG,HMDB accession,HMDB0028753
4082,73451,Asp-His,A dipeptide composed of L-aspartic acid and L-histidine joined by a peptide linkage.,"InChI=1S/C10H14N4O5/c11-6(2-8(15)16)9(17)14-7(10(18)19)1-5-3-12-4-13-5/h3-4,6-7H,1-2,11H2,(H,12,13)(H,14,17)(H,15,16)(H,18,19)/t6-,7-/m0/s1",DH,HMDB accession,HMDB0028755
4083,73452,methoctramine tetrahydrochloride,A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid.,"InChI=1S/C36H62N4O2.4ClH/c1-41-35-23-13-11-21-33(35)31-39-29-19-9-7-17-27-37-25-15-5-3-4-6-16-26-38-28-18-8-10-20-30-40-32-34-22-12-14-24-36(34)42-2;;;;/h11-14,21-24,37-40H,3-10,15-20,25-32H2,1-2H3;4*1H",methoctramine hydrochloride,Reaxys Registry Number,5471061
4084,73455,Asp-Tyr,A dipeptide composed of L-aspartic acid and L-tyrosine joined by a peptide linkage.,"InChI=1S/C13H16N2O6/c14-9(6-11(17)18)12(19)15-10(13(20)21)5-7-1-3-8(16)4-2-7/h1-4,9-10,16H,5-6,14H2,(H,15,19)(H,17,18)(H,20,21)/t9-,10-/m0/s1",L-Asp-L-Tyr,HMDB accession,HMDB0028765
4085,73461,Cys-Pro,A dipeptide composed of L-cysteine and L-proline joined by a peptide linkage.,"InChI=1S/C8H14N2O3S/c9-5(4-14)7(11)10-3-1-2-6(10)8(12)13/h5-6,14H,1-4,9H2,(H,12,13)/t5-,6-/m0/s1",L-Cys-L-Pro,HMDB accession,HMDB0028783
4086,73469,4-diphenylacetoxy-N-methylpiperidine,A carboxylic ester obtained by formal condensation of the carboxy group of diphenylacetic acid and the hydroxy group of 4-hydroxy-N-methylpiperidine.,"InChI=1S/C20H23NO2/c1-21-14-12-18(13-15-21)23-20(22)19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3",1-methylpiperidin-4-yl diphenylacetate,Reaxys Registry Number,262807
4087,73471,3-alpha-D-glucuronosyl-2-palmitoyl-1-stearoyl-sn-glycerol,An alpha-D-glucuronosyl diglyceride in which the acyl groups at the 1- and 2-positions are stearoyl (octadecanoyl) and palmitoyl (hexadecanoyl) respectively.,"InChI=1S/C43H80O11/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-36(44)51-33-35(34-52-43-40(48)38(46)39(47)41(54-43)42(49)50)53-37(45)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h35,38-41,43,46-48H,3-34H2,1-2H3,(H,49,50)/t35-,38+,39+,40-,41+,43+/m1/s1",alpha-GlcA-DAG (C18:0/C16:0),PubMed citation,21666690
4088,73504,(9Z)-octadecen-1-ol,A long chain fatty alcohol that is octadecanol containing a double bond located at position 9 (the Z-geoisomer).,"InChI=1S/C18H36O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h9-10,19H,2-8,11-18H2,1H3/b10-9-",cis-9-octadecenol,LIPID MAPS instance accession,LMFA05000213
4089,73505,Glu-Gly,A dipeptide composed of L-glutamic acid and glycine joined by a peptide linkage.,"InChI=1S/C7H12N2O5/c8-4(1-2-5(10)11)7(14)9-3-6(12)13/h4H,1-3,8H2,(H,9,14)(H,10,11)(H,12,13)/t4-/m0/s1",EG,HMDB accession,HMDB0028819
4090,73507,Glu-Met,A dipeptide composed of L-glutamic acid and L-methionine joined by a peptide linkage.,"InChI=1S/C10H18N2O5S/c1-18-5-4-7(10(16)17)12-9(15)6(11)2-3-8(13)14/h6-7H,2-5,11H2,1H3,(H,12,15)(H,13,14)(H,16,17)/t6-,7-/m0/s1",E-M,HMDB accession,HMDB0028825
4091,73508,Glu-Pro,A dipeptide composed of L-glutamic acid and L-proline joined by a peptide linkage.,"InChI=1S/C10H16N2O5/c11-6(3-4-8(13)14)9(15)12-5-1-2-7(12)10(16)17/h6-7H,1-5,11H2,(H,13,14)(H,16,17)/t6-,7-/m0/s1",EP,Reaxys Registry Number,9569120
4092,73509,Glu-Ser,A dipeptide composed of L-glutamic acid and L-serine joined by a peptide linkage.,"InChI=1S/C8H14N2O6/c9-4(1-2-6(12)13)7(14)10-5(3-11)8(15)16/h4-5,11H,1-3,9H2,(H,10,14)(H,12,13)(H,15,16)/t4-,5-/m0/s1",E-S,HMDB accession,HMDB0028828
4093,73510,Glu-Thr,A dipeptide composed of L-glutamic acid and L-threonine joined by a peptide linkage.,"InChI=1S/C9H16N2O6/c1-4(12)7(9(16)17)11-8(15)5(10)2-3-6(13)14/h4-5,7,12H,2-3,10H2,1H3,(H,11,15)(H,13,14)(H,16,17)/t4-,5+,7+/m1/s1",ET,HMDB accession,HMDB0028829
4094,73513,Glu-Tyr,A dipeptide composed of L-glutamic acid and L-tyrosine joined by a peptide linkage.,"InChI=1S/C14H18N2O6/c15-10(5-6-12(18)19)13(20)16-11(14(21)22)7-8-1-3-9(17)4-2-8/h1-4,10-11,17H,5-7,15H2,(H,16,20)(H,18,19)(H,21,22)/t10-,11-/m0/s1",EY,HMDB accession,HMDB0028831
4095,73514,Gly-Leu,A dipeptide composed of glycine and L-leucine joined by a peptide linkage.,"InChI=1S/C8H16N2O3/c1-5(2)3-6(8(12)13)10-7(11)4-9/h5-6H,3-4,9H2,1-2H3,(H,10,11)(H,12,13)/t6-/m0/s1",Gly-L-Leu,HMDB accession,HMDB0000759
4096,73515,Gly-His,A dipeptide composed of glycine and L-histidine joined by a peptide linkage.,"InChI=1S/C8H12N4O3/c9-2-7(13)12-6(8(14)15)1-5-3-10-4-11-5/h3-4,6H,1-2,9H2,(H,10,11)(H,12,13)(H,14,15)/t6-/m0/s1",G-H,HMDB accession,HMDB0028843
4097,73516,Gly-Ser,A dipeptide composed of glycine and L-serine joined by a peptide linkage.,"InChI=1S/C5H10N2O4/c6-1-4(9)7-3(2-8)5(10)11/h3,8H,1-2,6H2,(H,7,9)(H,10,11)/t3-/m0/s1",G-S,HMDB accession,HMDB0028850
4098,73517,Gly-Tyr,A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage.,"InChI=1S/C11H14N2O4/c12-6-10(15)13-9(11(16)17)5-7-1-3-8(14)4-2-7/h1-4,9,14H,5-6,12H2,(H,13,15)(H,16,17)/t9-/m0/s1",G-Y,HMDB accession,HMDB0028853
4099,73520,Ile-His,A dipeptide composed of L-isoleucine and L-histidine joined by a peptide linkage.,"InChI=1S/C12H20N4O3/c1-3-7(2)10(13)11(17)16-9(12(18)19)4-8-5-14-6-15-8/h5-7,9-10H,3-4,13H2,1-2H3,(H,14,15)(H,16,17)(H,18,19)/t7-,9-,10-/m0/s1",L-Ile-L-His,HMDB accession,HMDB0028909
4100,73521,Glu-Lys,A dipeptide composed of L-glutamic acid and L-lysine joined by a peptide linkage.,"InChI=1S/C11H21N3O5/c12-6-2-1-3-8(11(18)19)14-10(17)7(13)4-5-9(15)16/h7-8H,1-6,12-13H2,(H,14,17)(H,15,16)(H,18,19)/t7-,8-/m0/s1",EK,HMDB accession,HMDB0028824
4101,73528,Leu-Arg,A dipeptide composed of L-leucine and L-arginine joined by peptide linkages.,"InChI=1S/C12H25N5O3/c1-7(2)6-8(13)10(18)17-9(11(19)20)4-3-5-16-12(14)15/h7-9H,3-6,13H2,1-2H3,(H,17,18)(H,19,20)(H4,14,15,16)/t8-,9-/m0/s1",L-R,HMDB accession,HMDB0028923
4102,73529,Leu-Asn,A dipeptide composed of L-leucine and L-asparagine joined by a peptide linkage.,"InChI=1S/C10H19N3O4/c1-5(2)3-6(11)9(15)13-7(10(16)17)4-8(12)14/h5-7H,3-4,11H2,1-2H3,(H2,12,14)(H,13,15)(H,16,17)/t6-,7-/m0/s1",LN,HMDB accession,HMDB0028924
4103,73531,Leu-Leu,A dipeptide formed from two L-leucine residues.,"InChI=1S/C12H24N2O3/c1-7(2)5-9(13)11(15)14-10(12(16)17)6-8(3)4/h7-10H,5-6,13H2,1-4H3,(H,14,15)(H,16,17)/t9-,10-/m0/s1",L-Leu-L-Leu,HMDB accession,HMDB0028933
4104,73534,"(9Z,12Z)-octadecadien-1-ol","A long chain fatty alcohol that is octadecanol containing two double bonds located at positions 9 and 12 (the 9Z,12Z-geoisomer).","InChI=1S/C18H34O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h6-7,9-10,19H,2-5,8,11-18H2,1H3/b7-6-,10-9-","9-cis,12-cis-octadecadien-1-ol",Reaxys Registry Number,1709343
4105,73549,3-hydroxy-3-(4-hydroxyphenyl)propionyl-CoA,A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxy-3-(4-hydroxyphenyl)propionic acid.,"InChI=1S/C30H44N7O19P3S/c1-30(2,25(43)28(44)33-8-7-20(40)32-9-10-60-21(41)11-18(39)16-3-5-17(38)6-4-16)13-53-59(50,51)56-58(48,49)52-12-19-24(55-57(45,46)47)23(42)29(54-19)37-15-36-22-26(31)34-14-35-27(22)37/h3-6,14-15,18-19,23-25,29,38-39,42-43H,7-13H2,1-2H3,(H,32,40)(H,33,44)(H,48,49)(H,50,51)(H2,31,34,35)(H2,45,46,47)/t18?,19-,23-,24-,25+,29-/m1/s1",3-hydroxy-3-(4-hydroxyphenyl)propanoyl-coenzyme A,MetaCyc accession,CPD-12199
4106,73564,Leu-Asp-Tyr,"A tripeptide composed of L-leucine, L-aspartic acid and L-tyrosine joined in sequence by peptide linkages.","InChI=1S/C19H27N3O7/c1-10(2)7-13(20)17(26)21-14(9-16(24)25)18(27)22-15(19(28)29)8-11-3-5-12(23)6-4-11/h3-6,10,13-15,23H,7-9,20H2,1-2H3,(H,21,26)(H,22,27)(H,24,25)(H,28,29)/t13-,14-,15-/m0/s1",L-D-Y,Reaxys Registry Number,7319267
4107,73565,Leu-Leu-Ala,A tripeptide composed of two L-leucine units joined to L-alanine by a peptide linkage.,"InChI=1S/C15H29N3O4/c1-8(2)6-11(16)13(19)18-12(7-9(3)4)14(20)17-10(5)15(21)22/h8-12H,6-7,16H2,1-5H3,(H,17,20)(H,18,19)(H,21,22)/t10-,11-,12-/m0/s1",L-L-A,Reaxys Registry Number,8000802
4108,73580,Leu-Pro,A dipeptide formed from L-leucine and L-proline residues.,"InChI=1S/C11H20N2O3/c1-7(2)6-8(12)10(14)13-5-3-4-9(13)11(15)16/h7-9H,3-6,12H2,1-2H3,(H,15,16)/t8-,9-/m0/s1",L-Leu-L-Pro,HMDB accession,HMDB0011175
4109,73583,Leu-Lys,A dipeptide composed of L-leucine and L-lysine joined by a peptide linkage.,"InChI=1S/C12H25N3O3/c1-8(2)7-9(14)11(16)15-10(12(17)18)5-3-4-6-13/h8-10H,3-7,13-14H2,1-2H3,(H,15,16)(H,17,18)/t9-,10-/m0/s1",LK,HMDB accession,HMDB0028934
4110,73584,Leu-Met,A dipeptide formed from L-leucine and L-methionine residues.,"InChI=1S/C11H22N2O3S/c1-7(2)6-8(12)10(14)13-9(11(15)16)4-5-17-3/h7-9H,4-6,12H2,1-3H3,(H,13,14)(H,15,16)/t8-,9-/m0/s1",L-Leu-L-Met,HMDB accession,HMDB0028935
4111,73589,Leu-Thr,A dipeptide composed of L-leucine and L-threonine joined by a peptide linkage.,"InChI=1S/C10H20N2O4/c1-5(2)4-7(11)9(14)12-8(6(3)13)10(15)16/h5-8,13H,4,11H2,1-3H3,(H,12,14)(H,15,16)/t6-,7+,8+/m1/s1",L-Leu-L-Thr,HMDB accession,HMDB0028939
4112,73590,Leu-Trp,A dipeptide formed from L-leucine and L-tryptophan residues.,"InChI=1S/C17H23N3O3/c1-10(2)7-13(18)16(21)20-15(17(22)23)8-11-9-19-14-6-4-3-5-12(11)14/h3-6,9-10,13,15,19H,7-8,18H2,1-2H3,(H,20,21)(H,22,23)/t13-,15-/m0/s1",L-W,HMDB accession,HMDB0028940
4113,73591,Leu-Tyr,A dipeptide formed from L-leucine and L-tyrosine residues.,"InChI=1S/C15H22N2O4/c1-9(2)7-12(16)14(19)17-13(15(20)21)8-10-3-5-11(18)6-4-10/h3-6,9,12-13,18H,7-8,16H2,1-2H3,(H,17,19)(H,20,21)/t12-,13-/m0/s1",L-Y,HMDB accession,HMDB0028941
4114,73598,Lys-Asp-Tyr,"A tripeptide composed of L-lysine, L-aspartic acid and L-tyrosine joined in sequence by peptide linkages.","InChI=1S/C19H28N4O7/c20-8-2-1-3-13(21)17(27)22-14(10-16(25)26)18(28)23-15(19(29)30)9-11-4-6-12(24)7-5-11/h4-7,13-15,24H,1-3,8-10,20-21H2,(H,22,27)(H,23,28)(H,25,26)(H,29,30)/t13-,14-,15-/m0/s1",L-Lys-L-Asp-L-Tyr,Reaxys Registry Number,15609625
4115,73600,Lys-Gln,A dipeptide composed of L-lysine and L-glutamine joined by a peptide linkage.,"InChI=1S/C11H22N4O4/c12-6-2-1-3-7(13)10(17)15-8(11(18)19)4-5-9(14)16/h7-8H,1-6,12-13H2,(H2,14,16)(H,15,17)(H,18,19)/t7-,8-/m0/s1",L-Lys-L-Gln,HMDB accession,HMDB0028949
4116,73601,Lys-Asp,A dipeptide formed from L-lysine and L-aspartic acid residues.,"InChI=1S/C10H19N3O5/c11-4-2-1-3-6(12)9(16)13-7(10(17)18)5-8(14)15/h6-7H,1-5,11-12H2,(H,13,16)(H,14,15)(H,17,18)/t6-,7-/m0/s1",K-D,HMDB accession,HMDB0028947
4117,73604,Lys-Gly,A dipeptide formed from L-lysine and glycine residues.,"InChI=1S/C8H17N3O3/c9-4-2-1-3-6(10)8(14)11-5-7(12)13/h6H,1-5,9-10H2,(H,11,14)(H,12,13)/t6-/m0/s1",L-Lys-Gly,HMDB accession,HMDB0028951
4118,73605,Lys-Phe,A dipeptide formed from L-lysine and L-phenylalanine residues.,"InChI=1S/C15H23N3O3/c16-9-5-4-8-12(17)14(19)18-13(15(20)21)10-11-6-2-1-3-7-11/h1-3,6-7,12-13H,4-5,8-10,16-17H2,(H,18,19)(H,20,21)/t12-,13-/m0/s1",KF,CAS Registry Number,6235-35-4
4119,73606,Lys-Thr,A dipeptide formed from L-lysine and L-threonine residues.,"InChI=1S/C10H21N3O4/c1-6(14)8(10(16)17)13-9(15)7(12)4-2-3-5-11/h6-8,14H,2-5,11-12H2,1H3,(H,13,15)(H,16,17)/t6-,7+,8+/m1/s1",L-Lys-L-Thr,Reaxys Registry Number,5030946
4120,73610,Met-Ala,A dipeptide formed from L-methionine and L-alanine residues.,"InChI=1S/C8H16N2O3S/c1-5(8(12)13)10-7(11)6(9)3-4-14-2/h5-6H,3-4,9H2,1-2H3,(H,10,11)(H,12,13)/t5-,6-/m0/s1",M-A,HMDB accession,HMDB0028966
4121,73613,Met-Ser,A dipeptide composed of L-methionine and L-serine joined by a peptide linkage.,"InChI=1S/C8H16N2O4S/c1-15-3-2-5(9)7(12)10-6(4-11)8(13)14/h5-6,11H,2-4,9H2,1H3,(H,10,12)(H,13,14)/t5-,6-/m0/s1",M-S,HMDB accession,HMDB0028982
4122,73614,Met-Thr,A dipeptide formed from L-methionine and L-threonine residues.,"InChI=1S/C9H18N2O4S/c1-5(12)7(9(14)15)11-8(13)6(10)3-4-16-2/h5-7,12H,3-4,10H2,1-2H3,(H,11,13)(H,14,15)/t5-,6+,7+/m1/s1",M-T,HMDB accession,HMDB0028983
4123,73615,Met-Tyr,A dipeptide formed from L-methionine and L-tyrosine residues.,"InChI=1S/C14H20N2O4S/c1-21-7-6-11(15)13(18)16-12(14(19)20)8-9-2-4-10(17)5-3-9/h2-5,11-12,17H,6-8,15H2,1H3,(H,16,18)(H,19,20)/t11-,12-/m0/s1",M-Y,Reaxys Registry Number,3104747
4124,73616,Met-Val,A dipeptide formed from L-methionine and L-valine residues.,"InChI=1S/C10H20N2O3S/c1-6(2)8(10(14)15)12-9(13)7(11)4-5-16-3/h6-8H,4-5,11H2,1-3H3,(H,12,13)(H,14,15)/t7-,8-/m0/s1",L-Met-L-Val,Reaxys Registry Number,2270147
4125,73621,3-methylthioaspartic acid,A sulfur-containing amino acid that is L-aspartic acid substituted at position 3 by a methylthio group.,"InChI=1S/C5H9NO4S/c1-11-3(5(9)10)2(6)4(7)8/h2-3H,6H2,1H3,(H,7,8)(H,9,10)/t2-,3?/m0/s1",3-(methylsulfanyl)aspartic acid,Reaxys Registry Number,18571117
4126,73622,beta-hydroxywybutosine 5'-monophosphate,A ribonucleotide that is the 5'-monophosphate derivative of  beta-hydroxywybutosine.,"InChI=1S/C21H29N6O13P/c1-8-9(5-10(28)12(19(32)37-3)24-21(33)38-4)27-17(31)13-16(25(2)20(27)23-8)26(7-22-13)18-15(30)14(29)11(40-18)6-39-41(34,35)36/h7,10-12,14-15,18,28-30H,5-6H2,1-4H3,(H,24,33)(H2,34,35,36)/t10?,11-,12+,14-,15-,18-/m1/s1",3-hydroxywybutosine,PubMed citation,20739293
4127,73625,7-(2-hydroxy-3-amino-3-carboxypropyl)wyosine 5'-monophosphate,A ribonucleoside 5'-monophosphate that is wyosine 5'-monophosphate substituted at position 7 by a 2-hydroxy-3-amino-3-carboxypropyl group.,"InChI=1S/C18H25N6O11P/c1-6-7(3-8(25)10(19)17(29)30)24-15(28)11-14(22(2)18(24)21-6)23(5-20-11)16-13(27)12(26)9(35-16)4-34-36(31,32)33/h5,8-10,12-13,16,25-27H,3-4,19H2,1-2H3,(H,29,30)(H2,31,32,33)/t8?,9-,10+,12-,13-,16-/m1/s1",OHyW-72,PubMed citation,20739293
4128,73632,Phe-Arg,A dipeptide composed of L-phenylalanine and L-arginine joined by a peptide linkage.,"InChI=1S/C15H23N5O3/c16-11(9-10-5-2-1-3-6-10)13(21)20-12(14(22)23)7-4-8-19-15(17)18/h1-3,5-6,11-12H,4,7-9,16H2,(H,20,21)(H,22,23)(H4,17,18,19)/t11-,12-/m0/s1",L-Phe-L-Arg,HMDB accession,HMDB0028989
4129,73633,Phe-Asn,A dipeptide composed of L-phenylalanine and L-asparagine joined by a peptide linkage.,"InChI=1S/C13H17N3O4/c14-9(6-8-4-2-1-3-5-8)12(18)16-10(13(19)20)7-11(15)17/h1-5,9-10H,6-7,14H2,(H2,15,17)(H,16,18)(H,19,20)/t9-,10-/m0/s1",L-Phe-L-Asn,HMDB accession,HMDB0028990
4130,73634,Phe-His,A dipeptide composed of L-phenylalanine and L-histidine joined by a peptide linkage.,"InChI=1S/C15H18N4O3/c16-12(6-10-4-2-1-3-5-10)14(20)19-13(15(21)22)7-11-8-17-9-18-11/h1-5,8-9,12-13H,6-7,16H2,(H,17,18)(H,19,20)(H,21,22)/t12-,13-/m0/s1",F-H,HMDB accession,HMDB0028997
4131,73638,Phe-Val,A dipeptide formed from L-phenylalanine and L-valine residues.,"InChI=1S/C14H20N2O3/c1-9(2)12(14(18)19)16-13(17)11(15)8-10-6-4-3-5-7-10/h3-7,9,11-12H,8,15H2,1-2H3,(H,16,17)(H,18,19)/t11-,12-/m0/s1",FV,HMDB accession,HMDB0029008
4132,73644,Phe-Pro-Pro,A tripeptide composed of L-phenylalanine and two L-proline units joined by peptide linkages.,"InChI=1S/C19H25N3O4/c20-14(12-13-6-2-1-3-7-13)17(23)21-10-4-8-15(21)18(24)22-11-5-9-16(22)19(25)26/h1-3,6-7,14-16H,4-5,8-12,20H2,(H,25,26)/t14-,15-,16-/m0/s1",FPP,Reaxys Registry Number,6877483
4133,73645,Pro-Arg,A dipeptide formed from L-proline and L-arginine residues.,"InChI=1S/C11H21N5O3/c12-11(13)15-6-2-4-8(10(18)19)16-9(17)7-3-1-5-14-7/h7-8,14H,1-6H2,(H,16,17)(H,18,19)(H4,12,13,15)/t7-,8-/m0/s1",P-R,HMDB accession,HMDB0029011
4134,73646,Pro-Pro,A dipeptide formed from two L-proline residues.,"InChI=1S/C10H16N2O3/c13-9(7-3-1-5-11-7)12-6-2-4-8(12)10(14)15/h7-8,11H,1-6H2,(H,14,15)/t7-,8-/m0/s1",PP,HMDB accession,HMDB0011180
4135,73647,Pro-Pro-Pro,A tripeptide composed of three L-proline units joined by peptide linkages.,"InChI=1S/C15H23N3O4/c19-13(10-4-1-7-16-10)17-8-2-5-11(17)14(20)18-9-3-6-12(18)15(21)22/h10-12,16H,1-9H2,(H,21,22)/t10-,11-,12-/m0/s1",PPP,Reaxys Registry Number,6532215
4136,73648,Pro-Ser,A dipeptide formed from L-proline and L-serine residues.,"InChI=1S/C8H14N2O4/c11-4-6(8(13)14)10-7(12)5-2-1-3-9-5/h5-6,9,11H,1-4H2,(H,10,12)(H,13,14)/t5-,6-/m0/s1",L-Pro-L-Ser,HMDB accession,HMDB0029026
4137,73651,Ser-His,A dipeptide formed from L-serine and L-histidine residues.,"InChI=1S/C9H14N4O4/c10-6(3-14)8(15)13-7(9(16)17)1-5-2-11-4-12-5/h2,4,6-7,14H,1,3,10H2,(H,11,12)(H,13,15)(H,16,17)/t6-,7-/m0/s1",L-Ser-L-His,HMDB accession,HMDB0029041
4138,73652,Ser-Tyr,A dipeptide formed from L-serine and L-tyrosine residues.,"InChI=1S/C12H16N2O5/c13-9(6-15)11(17)14-10(12(18)19)5-7-1-3-8(16)4-2-7/h1-4,9-10,15-16H,5-6,13H2,(H,14,17)(H,18,19)/t9-,10-/m0/s1",SY,HMDB accession,HMDB0029051
4139,73653,Ser-Ser,A dipeptide formed from two L-serine residues.,"InChI=1S/C6H12N2O5/c7-3(1-9)5(11)8-4(2-10)6(12)13/h3-4,9-10H,1-2,7H2,(H,8,11)(H,12,13)/t3-,4-/m0/s1",L-Ser-L-Ser,HMDB accession,HMDB0029048
4140,73662,Thr-Pro,A dipeptide formed from L-threonine and L-proline residues.,"InChI=1S/C9H16N2O4/c1-5(12)7(10)8(13)11-4-2-3-6(11)9(14)15/h5-7,12H,2-4,10H2,1H3,(H,14,15)/t5-,6+,7+/m1/s1",L-Thr-L-Pro,HMDB accession,HMDB0029069
4141,73663,Thr-His,A dipeptide composed of L-threonine and L-histidine joined by a peptide linkage.,"InChI=1S/C10H16N4O4/c1-5(15)8(11)9(16)14-7(10(17)18)2-6-3-12-4-13-6/h3-5,7-8,15H,2,11H2,1H3,(H,12,13)(H,14,16)(H,17,18)/t5-,7+,8+/m1/s1",T-H,HMDB accession,HMDB0029063
4142,73664,Thr-Ser,A dipeptide formed from L-threonine and L-serine residues.,"InChI=1S/C7H14N2O5/c1-3(11)5(8)6(12)9-4(2-10)7(13)14/h3-5,10-11H,2,8H2,1H3,(H,9,12)(H,13,14)/t3-,4+,5+/m1/s1",TS,HMDB accession,HMDB0029070
4143,73666,Thr-Trp,A dipeptide composed of L-threonine and L-tryptophan joined by a peptide linkage.,"InChI=1S/C15H19N3O4/c1-8(19)13(16)14(20)18-12(15(21)22)6-9-7-17-11-5-3-2-4-10(9)11/h2-5,7-8,12-13,17,19H,6,16H2,1H3,(H,18,20)(H,21,22)/t8-,12+,13+/m1/s1",L-Thr-L-Trp,HMDB accession,HMDB0029072
4144,73667,Thr-Tyr,A dipeptide composed of L-threonine and L-tyrosine joined by a peptide linkage.,"InChI=1S/C13H18N2O5/c1-7(16)11(14)12(18)15-10(13(19)20)6-8-2-4-9(17)5-3-8/h2-5,7,10-11,16-17H,6,14H2,1H3,(H,15,18)(H,19,20)/t7-,10+,11+/m1/s1",L-Thr-L-Tyr,HMDB accession,HMDB0029073
4145,73669,5'-(N(6)-L-lysine)-L-tyrosylquinone,"An L-lysine derivative in which one of the amino hydrogens at N(6)-amino is substituted by a 6-[(2S)-2-amino-2-carboxyethyl]-3,4-dioxocyclohexa-1,5-dien-1-yl group.","InChI=1S/C15H21N3O6/c16-9(14(21)22)3-1-2-4-18-11-7-13(20)12(19)6-8(11)5-10(17)15(23)24/h6-7,9-10,18H,1-5,16-17H2,(H,21,22)(H,23,24)/t9-,10-/m0/s1",lysyl oxidase cofactor,PubMed citation,9360949
4146,73672,cyclic ADP-ribose(2-),A nucleotide-sugar oxoanion obtained by deprotonation of the diphosphate OH groups of cyclic ADP-ribose.,"InChI=1S/C15H21N5O13P2/c16-12-7-13-18-4-19(12)14-10(23)8(21)5(31-14)1-29-34(25,26)33-35(27,28)30-2-6-9(22)11(24)15(32-6)20(13)3-17-7/h3-6,8-11,14-16,21-24H,1-2H2,(H,25,26)(H,27,28)/p-2/t5-,6-,8-,9-,10-,11-,14-,15-/m1/s1",cADPR(2-),Reaxys Registry Number,8886834
4147,73673,(S)-alpha-hydroxyglutarate-gamma-lactone,"A monocarboxylic acid anion that is the conjugate base of (S)-alpha-hydroxyglutaric acid-gamma-lactone, obatined by deprotonation of the carboxy group.","InChI=1S/C5H6O4/c6-4-2-1-3(9-4)5(7)8/h3H,1-2H2,(H,7,8)/p-1/t3-/m0/s1",(2S)-5-oxo-2-oxolanecarboxylate,MetaCyc accession,CPD-13414
4148,73676,3-deoxychenodeoxycholic acid,"A monohydroxy-5beta-cholanic acid in which the hydroxy group is located at the 7alpha-position. A structural derivative of the bile acid, chenodeoxycholic acid.","InChI=1S/C24H40O3/c1-15(7-10-21(26)27)17-8-9-18-22-19(11-13-24(17,18)3)23(2)12-5-4-6-16(23)14-20(22)25/h15-20,22,25H,4-14H2,1-3H3,(H,26,27)/t15-,16+,17-,18+,19+,20-,22+,23+,24-/m1/s1",3-deoxy-CDCA,PubMed citation,12718893
4149,73677,(S)-alpha-hydroxyglutaric acid-gamma-lactone,A butan-4-olide obtained by formal intramolecular condensation between the 2-hydroxy and 4-carboxy groups of (S)-2-hydroxyglutaric acid,"InChI=1S/C5H6O4/c6-4-2-1-3(9-4)5(7)8/h3H,1-2H2,(H,7,8)/t3-/m0/s1",(2S)-5-oxooxolane-2-carboxylic acid,MetaCyc accession,CPD-13414
4150,73680,carbamoyl adenylate,A purine ribonucleoside 5'-monophosphate that is AMP in which one of the phosphate OH groups substituted by a carbamoyl group,"InChI=1S/C11H15N6O8P/c12-8-5-9(15-2-14-8)17(3-16-5)10-7(19)6(18)4(24-10)1-23-26(21,22)25-11(13)20/h2-4,6-7,10,18-19H,1H2,(H2,13,20)(H,21,22)(H2,12,14,15)/t4-,6-,7-,10-/m1/s1",carbamoyl-AMP,PDBeChem accession,CA0
4151,73682,L-threonylcarbamoyladenylate(2-),An organophosphate oxoanion obtained by deprotonation of the phosohate and carboxy groups of L-threonylcarbamoyladenylate.,"InChI=1S/C15H21N6O11P/c1-5(22)7(14(25)26)20-15(27)32-33(28,29)30-2-6-9(23)10(24)13(31-6)21-4-19-8-11(16)17-3-18-12(8)21/h3-7,9-10,13,22-24H,2H2,1H3,(H,20,27)(H,25,26)(H,28,29)(H2,16,17,18)/p-2/t5-,6-,7+,9-,10-,13-/m1/s1",L-threonylcarbamoyl-AMP,PubMed citation,23072323
4152,73687,L-threonylcarbamoyladenylate,A threonine derivative that is L-threonine in which one of the amino hydrogens is substituted by and adenyloxycarbonyl group,"InChI=1S/C15H21N6O11P/c1-5(22)7(14(25)26)20-15(27)32-33(28,29)30-2-6-9(23)10(24)13(31-6)21-4-19-8-11(16)17-3-18-12(8)21/h3-7,9-10,13,22-24H,2H2,1H3,(H,20,27)(H,25,26)(H,28,29)(H2,16,17,18)/t5-,6-,7+,9-,10-,13-/m1/s1",TC-AMP,PubMed citation,23072323
4153,73694,Trp-Ser,A dipeptide formed from L-tryptophan and L-serine residues.,"InChI=1S/C14H17N3O4/c15-10(13(19)17-12(7-18)14(20)21)5-8-6-16-11-4-2-1-3-9(8)11/h1-4,6,10,12,16,18H,5,7,15H2,(H,17,19)(H,20,21)/t10-,12-/m0/s1",WS,HMDB accession,HMDB0029092
4154,73695,Tyr-His,A dipeptide formed from L-tyrosine and L-histidine residues.,"InChI=1S/C15H18N4O4/c16-12(5-9-1-3-11(20)4-2-9)14(21)19-13(15(22)23)6-10-7-17-8-18-10/h1-4,7-8,12-13,20H,5-6,16H2,(H,17,18)(H,19,21)(H,22,23)/t12-,13-/m0/s1",YH,HMDB accession,HMDB0029107
4155,73698,Val-Asn,A dipeptide formed from L-valine and L-asparagine residues.,"InChI=1S/C9H17N3O4/c1-4(2)7(11)8(14)12-5(9(15)16)3-6(10)13/h4-5,7H,3,11H2,1-2H3,(H2,10,13)(H,12,14)(H,15,16)/t5-,7-/m0/s1",V-N,Reaxys Registry Number,6330828
4156,73699,Val-Gly,A dipeptide formed from L-valine and glycine residues.,"InChI=1S/C7H14N2O3/c1-4(2)6(8)7(12)9-3-5(10)11/h4,6H,3,8H2,1-2H3,(H,9,12)(H,10,11)/t6-/m0/s1",V-G,HMDB accession,HMDB0029127
4157,73700,Val-His,A dipeptide formed from L-valine and L-histidine residues.,"InChI=1S/C11H18N4O3/c1-6(2)9(12)10(16)15-8(11(17)18)3-7-4-13-5-14-7/h4-6,8-9H,3,12H2,1-2H3,(H,13,14)(H,15,16)(H,17,18)/t8-,9-/m0/s1",L-Val-L-His,HMDB accession,HMDB0029129
4158,73701,Val-Pro,A dipeptide formed from L-valine and L-proline residues.,"InChI=1S/C10H18N2O3/c1-6(2)8(11)9(13)12-5-3-4-7(12)10(14)15/h6-8H,3-5,11H2,1-2H3,(H,14,15)/t7-,8-/m0/s1",VP,HMDB accession,HMDB0029135
4159,73703,Val-Tyr,A dipeptide formed from L-valine and L-tyrosine residues.,"InChI=1S/C14H20N2O4/c1-8(2)12(15)13(18)16-11(14(19)20)7-9-3-5-10(17)6-4-9/h3-6,8,11-12,17H,7,15H2,1-2H3,(H,16,18)(H,19,20)/t11-,12-/m0/s1",V-Y,HMDB accession,HMDB0029139
4160,73704,Val-Val,A dipeptide formed from two L-valine residues.,"InChI=1S/C10H20N2O3/c1-5(2)7(11)9(13)12-8(6(3)4)10(14)15/h5-8H,11H2,1-4H3,(H,12,13)(H,14,15)/t7-,8-/m0/s1",L-Val-L-Val,HMDB accession,HMDB0029140
4161,73705,gamma-Glu-Glu,A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of another glutamic acid.,"InChI=1S/C10H16N2O7/c11-5(9(16)17)1-3-7(13)12-6(10(18)19)2-4-8(14)15/h5-6H,1-4,11H2,(H,12,13)(H,14,15)(H,16,17)(H,18,19)/t5-,6-/m0/s1",gamma-L-Glu-L-Glu,CAS Registry Number,1116-22-9
4162,73706,bromosuccinate,A dicarboxylic acid dianion obtained by deprotonation of the two carboxy goups of bromosuccinic acid.,"InChI=1S/C4H5BrO4/c5-2(4(8)9)1-3(6)7/h2H,1H2,(H,6,7)(H,8,9)/p-2",DL-2-bromosuccinate,MetaCyc accession,CPD-13405
4163,73709,(S)-2-hydroxybutyrate,"A hydroxy monocarboxylic acid anion that is the conjugate base of (S)-2-hydroxybutyric acid, obtained by decarboxylation of the carboxy group.","InChI=1S/C4H8O3/c1-2-3(5)4(6)7/h3,5H,2H2,1H3,(H,6,7)/p-1/t3-/m0/s1",L-2-hydroxybutyrate,MetaCyc accession,CPD-3564
4164,73710,Trp-Ala,A dipeptide formed from L-tryptophan and L-alanine residues.,"InChI=1S/C14H17N3O3/c1-8(14(19)20)17-13(18)11(15)6-9-7-16-12-5-3-2-4-10(9)12/h2-5,7-8,11,16H,6,15H2,1H3,(H,17,18)(H,19,20)/t8-,11-/m0/s1",WA,HMDB accession,HMDB0029076
4165,73711,Val-Arg,A dipeptide formed from L-valine and L-asparagine residues.,"InChI=1S/C11H23N5O3/c1-6(2)8(12)9(17)16-7(10(18)19)4-3-5-15-11(13)14/h6-8H,3-5,12H2,1-2H3,(H,16,17)(H,18,19)(H4,13,14,15)/t7-,8-/m0/s1",L-Val-L-Arg,HMDB accession,HMDB0029121
4166,73736,22-tricosenoic acid,A tricosenoic acid having a double bond at position 22.,"InChI=1S/C23H44O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23(24)25/h2H,1,3-22H2,(H,24,25)",tricos-22-enoic acid,LIPID MAPS instance accession,LMFA01030091
4167,73755,"1,2-dimethylhydrazine","A member of the class of hydrazines that is hydrazine in which one of the hydrogens attached to each nitrogen is replaced by a methyl group. A powerful DNA alkylating agent and carcinogen, it is used to induce colon cancer in laboratory rats and mice.","InChI=1S/C2H8N2/c1-3-4-2/h3-4H,1-2H3",MeNHNHMe,CAS Registry Number,540-73-8
4168,73757,Ala-Gly,A dipeptide formed from L-alanyl and glycine residues.,"InChI=1S/C5H10N2O3/c1-3(6)5(10)7-2-4(8)9/h3H,2,6H2,1H3,(H,7,10)(H,8,9)/t3-/m0/s1",alanylglycine,Reaxys Registry Number,1723438
4169,73762,Ala-Thr,A dipeptide formed from L-alanyl and L-threonine residues.,"InChI=1S/C7H14N2O4/c1-3(8)6(11)9-5(4(2)10)7(12)13/h3-5,10H,8H2,1-2H3,(H,9,11)(H,12,13)/t3-,4+,5-/m0/s1",AT,Reaxys Registry Number,7918913
4170,73770,Ala-Leu,A dipeptide formed from L-alanyl and L-leucine residues.,"InChI=1S/C9H18N2O3/c1-5(2)4-7(9(13)14)11-8(12)6(3)10/h5-7H,4,10H2,1-3H3,(H,11,12)(H,13,14)/t6-,7-/m0/s1",L-Ala-L-Leu,Reaxys Registry Number,1726651
4171,73771,Ala-His,A dipeptide formed from L-alanyl and L-histidine residues.,"InChI=1S/C9H14N4O3/c1-5(10)8(14)13-7(9(15)16)2-6-3-11-4-12-6/h3-5,7H,2,10H2,1H3,(H,11,12)(H,13,14)(H,15,16)/t5-,7-/m0/s1",alanylhistidine,Reaxys Registry Number,5557090
4172,73779,Gly-Pro zwitterion,A peptide zwitterion obtained by transfer of a proton from the carboxy to the amino terminus of Gly-Pro.,"InChI=1S/C7H12N2O3/c8-4-6(10)9-3-1-2-5(9)7(11)12/h5H,1-4,8H2,(H,11,12)/t5-/m0/s1",glycylproline zwitterion,MetaCyc accession,CPD-10814
4173,73782,praecanson A,"A member of the class of chalcones that is chalcone substituted by methoxy groups at positions 2', 6' and 9 and a dimethylpyrano ring substituted across positions 3' and 4'.","InChI=1S/C23H24O5/c1-23(2)12-11-16-18(28-23)14-20(26-4)21(22(16)27-5)19(25-3)13-17(24)15-9-7-6-8-10-15/h6-14H,1-5H3/b19-13-","9,2',6'-trimethoxy-6'',6''-dimethylpyrano-(3',4':2'',3'')-chalcone",Reaxys Registry Number,5140767
4174,73784,Gly-Glu(1-),"A peptide anion that is the conjugate base of Gly-Glu, obtained by deprotonation of the terminal and side-chain carboxy groups and protonation of the terminal amino group.","InChI=1S/C7H12N2O5/c8-3-5(10)9-4(7(13)14)1-2-6(11)12/h4H,1-3,8H2,(H,9,10)(H,11,12)(H,13,14)/p-1/t4-/m0/s1",glycyl-L-glutamic acid(1-),MetaCyc accession,CPD-3569
4175,73787,prunin 6''-O-gallate,"A flavanone glycoside that is (2S)-flavanone substituted by hydroxy groups at positions 5 and 4', and a (6''-O-(3,4,5-trihydroxybenzoyl)-beta-D-glucopyranosyloxy residue at position 7.","InChI=1S/C28H26O14/c29-13-3-1-11(2-4-13)19-9-16(31)22-15(30)7-14(8-20(22)41-19)40-28-26(37)25(36)24(35)21(42-28)10-39-27(38)12-5-17(32)23(34)18(33)6-12/h1-8,19,21,24-26,28-30,32-37H,9-10H2/t19-,21+,24+,25-,26+,28+/m0/s1","5,7,4'-trihydroxyflavanone 7-O-glucoside-6""-O-gallate",LIPID MAPS instance accession,LMPK12140244
4176,73790,GW 501516 sulfoxide,"A sulfoxide resulting from the oxidation of the sulfur attached to one of the phenyl groups of GW 501516. It is a urinary metabolite of GW 501516 (a failed drug candidate and gene doping agent whose use by athletes has been prohibited by the World Anti-Doping Agency), so detection of the sulfoxide in sports drugs testing can be used to prove GW 501516 doping.","InChI=1S/C21H18F3NO4S2/c1-12-9-16(7-8-17(12)29-10-19(26)27)31(28)11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)","GW 501,516 sulfoxide",PubMed citation,19946680
4177,73791,GW 501516 sulfone,"A sulfone resulting from the oxidation of the sulfur attached to one of the phenyl groups of GW 501516. It is a urinary metabolite of GW 501516 (a failed drug candidate and gene doping agent whose use by athletes has been prohibited by the World Anti-Doping Agency), so detection of the sulfone in sports drugs testing can be used to prove GW 501516 doping.","InChI=1S/C21H18F3NO5S2/c1-12-9-16(7-8-17(12)30-10-19(26)27)32(28,29)11-18-13(2)25-20(31-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)",GW1516 sulfone,PubMed citation,23100242
4178,73794,lysophosphatidylcholine 14:1(9Z)/0:0,A lysophosphatidylcholine 14:1 in which the remaining acyl group is (9Z)-tetradecenoyl.,"InChI=1S/C22H44NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-22(25)28-19-21(24)20-30-31(26,27)29-18-17-23(2,3)4/h8-9,21,24H,5-7,10-20H2,1-4H3/b9-8-/t21-/m1/s1",lysophosphatidylcholine(14:1(9Z)/0:0),LIPID MAPS instance accession,LMGP01050014
4179,73801,Gly-Glu,A dipeptide formed from glycyl and L-glutamic acid residues.,"InChI=1S/C7H12N2O5/c8-3-5(10)9-4(7(13)14)1-2-6(11)12/h4H,1-3,8H2,(H,9,10)(H,11,12)(H,13,14)/t4-/m0/s1",GE,Reaxys Registry Number,1728201
4180,73803,Ala-Asp,A dipeptide formed from L-alanyl and L-aspartic acid residues.,"InChI=1S/C7H12N2O5/c1-3(8)6(12)9-4(7(13)14)2-5(10)11/h3-4H,2,8H2,1H3,(H,9,12)(H,10,11)(H,13,14)/t3-,4-/m0/s1",alanylaspartic acid,Reaxys Registry Number,4745285
4181,73804,Gly-Asp,A dipeptide formed from glycyl and L-aspartic acid residues.,"InChI=1S/C6H10N2O5/c7-2-4(9)8-3(6(12)13)1-5(10)11/h3H,1-2,7H2,(H,8,9)(H,10,11)(H,12,13)/t3-/m0/s1",Gly-L-Asp,Reaxys Registry Number,1727387
4182,73805,Ala-Ile,A dipeptide formed from L-alanyl and L-isoleucine residues.,"InChI=1S/C9H18N2O3/c1-4-5(2)7(9(13)14)11-8(12)6(3)10/h5-7H,4,10H2,1-3H3,(H,11,12)(H,13,14)/t5-,6-,7-/m0/s1",alanylisoleucine,Reaxys Registry Number,3606306
4183,73806,Ala-Met,A dipeptide formed from L-alanyl and L-methionine residues.,"InChI=1S/C8H16N2O3S/c1-5(9)7(11)10-6(8(12)13)3-4-14-2/h5-6H,3-4,9H2,1-2H3,(H,10,11)(H,12,13)/t5-,6-/m0/s1",L-Ala-L-Met,Reaxys Registry Number,4744190
4184,73807,Ala-Phe,A dipeptide formed from L-alanyl and L-phenylalanine residues.,"InChI=1S/C12H16N2O3/c1-8(13)11(15)14-10(12(16)17)7-9-5-3-2-4-6-9/h2-6,8,10H,7,13H2,1H3,(H,14,15)(H,16,17)/t8-,10-/m0/s1",L-Ala-L-Phe,Reaxys Registry Number,2381598
4185,73808,Ala-Trp,A dipeptide formed from L-alanyl and L-tryptophan residues.,"InChI=1S/C14H17N3O3/c1-8(15)13(18)17-12(14(19)20)6-9-7-16-11-5-3-2-4-10(9)11/h2-5,7-8,12,16H,6,15H2,1H3,(H,17,18)(H,19,20)/t8-,12-/m0/s1",alanyltryptophan,Reaxys Registry Number,4910138
4186,73809,Ala-Val,A dipeptide formed from L-alanyl and L-valine residues.,"InChI=1S/C8H16N2O3/c1-4(2)6(8(12)13)10-7(11)5(3)9/h4-6H,9H2,1-3H3,(H,10,11)(H,12,13)/t5-,6-/m0/s1",L-Ala-L-Val,Reaxys Registry Number,1726329
4187,73810,Arg-Ala,A dipeptide formed from L-arginyl and L-alanine residues.,"InChI=1S/C9H19N5O3/c1-5(8(16)17)14-7(15)6(10)3-2-4-13-9(11)12/h5-6H,2-4,10H2,1H3,(H,14,15)(H,16,17)(H4,11,12,13)/t5-,6-/m0/s1",RA,Reaxys Registry Number,1729047
4188,73811,Arg-Arg,A dipeptide formed from two L-arginine residues.,"InChI=1S/C12H26N8O3/c13-7(3-1-5-18-11(14)15)9(21)20-8(10(22)23)4-2-6-19-12(16)17/h7-8H,1-6,13H2,(H,20,21)(H,22,23)(H4,14,15,18)(H4,16,17,19)/t7-,8-/m0/s1",RR,Reaxys Registry Number,1730089
4189,73812,Arg-Asp,A dipeptide formed from L-arginyl and L-aspartic acid residues.,"InChI=1S/C10H19N5O5/c11-5(2-1-3-14-10(12)13)8(18)15-6(9(19)20)4-7(16)17/h5-6H,1-4,11H2,(H,15,18)(H,16,17)(H,19,20)(H4,12,13,14)/t5-,6-/m0/s1",arginylaspartic acid,HMDB accession,HMDB0028705
4190,73813,Arg-Gln,A dipeptide formed from L-arginyl and L-glutamine residues.,"InChI=1S/C11H22N6O4/c12-6(2-1-5-16-11(14)15)9(19)17-7(10(20)21)3-4-8(13)18/h6-7H,1-5,12H2,(H2,13,18)(H,17,19)(H,20,21)(H4,14,15,16)/t6-,7-/m0/s1",arginylglutamine,Reaxys Registry Number,1716638
4191,73814,Arg-Ile,A dipeptide formed from L-arginyl and L-isoleucine residues.,"InChI=1S/C12H25N5O3/c1-3-7(2)9(11(19)20)17-10(18)8(13)5-4-6-16-12(14)15/h7-9H,3-6,13H2,1-2H3,(H,17,18)(H,19,20)(H4,14,15,16)/t7-,8-,9-/m0/s1",arginylisoleucine,Reaxys Registry Number,1715537
4192,73815,Arg-Leu,A dipeptide formed from L-arginyl and L-leucine residues.,"InChI=1S/C12H25N5O3/c1-7(2)6-9(11(19)20)17-10(18)8(13)4-3-5-16-12(14)15/h7-9H,3-6,13H2,1-2H3,(H,17,18)(H,19,20)(H4,14,15,16)/t8-,9-/m0/s1",RL,Reaxys Registry Number,1715687
4193,73816,Arg-Lys,A dipeptide formed from L-arginyl and L-leucine residues.,"InChI=1S/C12H26N6O3/c13-6-2-1-5-9(11(20)21)18-10(19)8(14)4-3-7-17-12(15)16/h8-9H,1-7,13-14H2,(H,18,19)(H,20,21)(H4,15,16,17)/t8-,9-/m0/s1",L-Arg-L-Lys,Reaxys Registry Number,2391715
4194,73817,Arg-Met,A dipeptide formed from L-arginine and L-methionine residues.,"InChI=1S/C11H23N5O3S/c1-20-6-4-8(10(18)19)16-9(17)7(12)3-2-5-15-11(13)14/h7-8H,2-6,12H2,1H3,(H,16,17)(H,18,19)(H4,13,14,15)/t7-,8-/m0/s1",L-Arg-L-Met,Reaxys Registry Number,4261900
4195,73818,Arg-Phe,A dipeptide formed from L-arginine and L-phenylalanine residues. It exhibits vasorelaxant activity.,"InChI=1S/C15H23N5O3/c16-11(7-4-8-19-15(17)18)13(21)20-12(14(22)23)9-10-5-2-1-3-6-10/h1-3,5-6,11-12H,4,7-9,16H2,(H,20,21)(H,22,23)(H4,17,18,19)/t11-,12-/m0/s1",L-Arg-L-Phe,Reaxys Registry Number,2777024
4196,73819,Arg-Ser,A dipeptide formed from L-arginine and L-serine residues.,"InChI=1S/C9H19N5O4/c10-5(2-1-3-13-9(11)12)7(16)14-6(4-15)8(17)18/h5-6,15H,1-4,10H2,(H,14,16)(H,17,18)(H4,11,12,13)/t5-,6-/m0/s1",arginylserine,Reaxys Registry Number,5065168
4197,73821,Arg-Trp,A dipeptide formed from L-arginine and L-tryptophan residues.,"InChI=1S/C17H24N6O3/c18-12(5-3-7-21-17(19)20)15(24)23-14(16(25)26)8-10-9-22-13-6-2-1-4-11(10)13/h1-2,4,6,9,12,14,22H,3,5,7-8,18H2,(H,23,24)(H,25,26)(H4,19,20,21)/t12-,14-/m0/s1",arginyltryptophan,Reaxys Registry Number,58278
4198,73822,Arg-Tyr,A dipeptide formed from L-arginine and L-tyrosine residues.,"InChI=1S/C15H23N5O4/c16-11(2-1-7-19-15(17)18)13(22)20-12(14(23)24)8-9-3-5-10(21)6-4-9/h3-6,11-12,21H,1-2,7-8,16H2,(H,20,22)(H,23,24)(H4,17,18,19)/t11-,12-/m0/s1",L-Arg-L-Tyr,Reaxys Registry Number,3170774
4199,73823,Arg-Val,A dipeptide formed from L-arginine and L-valine residues.,"InChI=1S/C11H23N5O3/c1-6(2)8(10(18)19)16-9(17)7(12)4-3-5-15-11(13)14/h6-8H,3-5,12H2,1-2H3,(H,16,17)(H,18,19)(H4,13,14,15)/t7-,8-/m0/s1",L-Arg-L-Val,Reaxys Registry Number,1715429
4200,73824,Asn-Glu,A dipeptide formed from L-asparagine and L-glutamic acid residues.,"InChI=1S/C9H15N3O6/c10-4(3-6(11)13)8(16)12-5(9(17)18)1-2-7(14)15/h4-5H,1-3,10H2,(H2,11,13)(H,12,16)(H,14,15)(H,17,18)/t4-,5-/m0/s1",asparaginylglutamic acid,Reaxys Registry Number,2753824
4201,73825,Asn-Val,A dipeptide formed from L-asparagine and L-valine residues.,"InChI=1S/C9H17N3O4/c1-4(2)7(9(15)16)12-8(14)5(10)3-6(11)13/h4-5,7H,3,10H2,1-2H3,(H2,11,13)(H,12,14)(H,15,16)/t5-,7-/m0/s1",NV,Reaxys Registry Number,6330681
4202,73826,Asp-Ala,A dipeptide formed from L-alpha-aspartyl and L-valine residues.,"InChI=1S/C7H12N2O5/c1-3(7(13)14)9-6(12)4(8)2-5(10)11/h3-4H,2,8H2,1H3,(H,9,12)(H,10,11)(H,13,14)/t3-,4-/m0/s1",L-Asp-L-Ala,Reaxys Registry Number,2372230
4203,73827,Asp-Gln,A dipeptide formed from L-alpha-aspartyl and L-glutamine residues.,"InChI=1S/C9H15N3O6/c10-4(3-7(14)15)8(16)12-5(9(17)18)1-2-6(11)13/h4-5H,1-3,10H2,(H2,11,13)(H,12,16)(H,14,15)(H,17,18)/t4-,5-/m0/s1",DQ,Reaxys Registry Number,11620644
4204,73828,Asp-Glu,A dipeptide formed from L-alpha-aspartyl and L-glutamic acid residues.,"InChI=1S/C9H14N2O7/c10-4(3-7(14)15)8(16)11-5(9(17)18)1-2-6(12)13/h4-5H,1-3,10H2,(H,11,16)(H,12,13)(H,14,15)(H,17,18)/t4-,5-/m0/s1",DE,Reaxys Registry Number,1715776
4205,73829,Asp-Lys,A dipeptide formed from L-alpha-aspartyl and L-lysine residues.,"InChI=1S/C10H19N3O5/c11-4-2-1-3-7(10(17)18)13-9(16)6(12)5-8(14)15/h6-7H,1-5,11-12H2,(H,13,16)(H,14,15)(H,17,18)/t6-,7-/m0/s1",L-alpha-Asp-L-Lys,Reaxys Registry Number,2470578
4206,73830,Asp-Phe,A dipeptide formed from L-alpha-aspartyl and L-phenylalanine residues. It is obtained after the hydrolysis of aspartame in intestinal lumen.,"InChI=1S/C13H16N2O5/c14-9(7-11(16)17)12(18)15-10(13(19)20)6-8-4-2-1-3-5-8/h1-5,9-10H,6-7,14H2,(H,15,18)(H,16,17)(H,19,20)/t9-,10-/m0/s1",alpha-aspartylphenylalanine,Reaxys Registry Number,2817528
4207,73831,Asp-Trp,A dipeptide formed from L-alpha-aspartyl and L-tryptophan residues.,"InChI=1S/C15H17N3O5/c16-10(6-13(19)20)14(21)18-12(15(22)23)5-8-7-17-11-4-2-1-3-9(8)11/h1-4,7,10,12,17H,5-6,16H2,(H,18,21)(H,19,20)(H,22,23)/t10-,12-/m0/s1",alpha-aspartyltryptophan,Reaxys Registry Number,10474757
4208,73832,Asp-Val,A dipeptide formed from L-alpha-aspartyl and L-valine residues.,"InChI=1S/C9H16N2O5/c1-4(2)7(9(15)16)11-8(14)5(10)3-6(12)13/h4-5,7H,3,10H2,1-2H3,(H,11,14)(H,12,13)(H,15,16)/t5-,7-/m0/s1",aspartylvaline,Reaxys Registry Number,1713814
4209,73833,beta-Ala-Ala,A dipeptide formed from beta-alanine and L-alanine residues.,"InChI=1S/C6H12N2O3/c1-4(6(10)11)8-5(9)2-3-7/h4H,2-3,7H2,1H3,(H,8,9)(H,10,11)/t4-/m0/s1",beta-Ala-L-Ala,Reaxys Registry Number,1942951
4210,73835,beta-Ala-Phe,A dipeptide formed from beta-alanine and L-phenylalanine residues.,"InChI=1S/C12H16N2O3/c13-7-6-11(15)14-10(12(16)17)8-9-4-2-1-3-5-9/h1-5,10H,6-8,13H2,(H,14,15)(H,16,17)/t10-/m0/s1",beta-alanylphenylalanine,Reaxys Registry Number,3098065
4211,73836,D-Ala-Gly,A dipeptide formed from D-alanine and glycine residues.,"InChI=1S/C5H10N2O3/c1-3(6)5(10)7-2-4(8)9/h3H,2,6H2,1H3,(H,7,10)(H,8,9)/t3-/m1/s1",aG,Reaxys Registry Number,1723439
4212,73837,D-Ala-Gly-Gly,A tripeptide composed of one D-alanine and two glycine residues joined in sequence.,"InChI=1S/C7H13N3O4/c1-4(8)7(14)10-2-5(11)9-3-6(12)13/h4H,2-3,8H2,1H3,(H,9,11)(H,10,14)(H,12,13)/t4-/m1/s1",aGG,Reaxys Registry Number,1727917
4213,73838,D-Ala-Leu,A dipeptide formed from D-alanine and L-leucine residues.,"InChI=1S/C9H18N2O3/c1-5(2)4-7(9(13)14)11-8(12)6(3)10/h5-7H,4,10H2,1-3H3,(H,11,12)(H,13,14)/t6-,7+/m1/s1",aL,Reaxys Registry Number,8111682
4214,73840,D-Leu-Gly,A dipeptide formed from D-leucine and glycine residues.,"InChI=1S/C8H16N2O3/c1-5(2)3-6(9)8(13)10-4-7(11)12/h5-6H,3-4,9H2,1-2H3,(H,10,13)(H,11,12)/t6-/m1/s1",D-leucylglycine,Reaxys Registry Number,1725451
4215,73842,D-Leu-Tyr,A dipeptide formed from D-leucine and L-tyrosine residues.,"InChI=1S/C15H22N2O4/c1-9(2)7-12(16)14(19)17-13(15(20)21)8-10-3-5-11(18)6-4-10/h3-6,9,12-13,18H,7-8,16H2,1-2H3,(H,17,19)(H,20,21)/t12-,13+/m1/s1",D-Leu-L-Tyr,Reaxys Registry Number,3217599
4216,73845,gamma-Glu-Gly,A glutamyl-L-amino acid obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of glycine.,"InChI=1S/C7H12N2O5/c8-4(7(13)14)1-2-5(10)9-3-6(11)12/h4H,1-3,8H2,(H,9,10)(H,11,12)(H,13,14)/t4-/m0/s1",gamma-L-Glu-Gly,Reaxys Registry Number,1728209
4217,73846,Gln-Gln,A dipeptide formed from two L-glutamine residues.,"InChI=1S/C10H18N4O5/c11-5(1-3-7(12)15)9(17)14-6(10(18)19)2-4-8(13)16/h5-6H,1-4,11H2,(H2,12,15)(H2,13,16)(H,14,17)(H,18,19)/t5-,6-/m0/s1",QQ,Reaxys Registry Number,1716103
4218,73847,Gln-Glu,A dipeptide formed from L-glutamine and L-glutamic acid residues.,"InChI=1S/C10H17N3O6/c11-5(1-3-7(12)14)9(17)13-6(10(18)19)2-4-8(15)16/h5-6H,1-4,11H2,(H2,12,14)(H,13,17)(H,15,16)(H,18,19)/t5-,6-/m0/s1",glutaminylglutamic acid,Reaxys Registry Number,1729671
4219,73848,Gln-Gly,A dipeptide formed from L-glutamine and glycine residues.,"InChI=1S/C7H13N3O4/c8-4(1-2-5(9)11)7(14)10-3-6(12)13/h4H,1-3,8H2,(H2,9,11)(H,10,14)(H,12,13)/t4-/m0/s1",QG,Reaxys Registry Number,1727353
4220,73849,Glu-Ala,A dipeptide formed from L-alpha-glutamyl and L-alanine residues.,"InChI=1S/C8H14N2O5/c1-4(8(14)15)10-7(13)5(9)2-3-6(11)12/h4-5H,2-3,9H2,1H3,(H,10,13)(H,11,12)(H,14,15)/t4-,5-/m0/s1",L-alpha-Glu-L-Ala,Reaxys Registry Number,1728326
4221,73855,Gly-Ala,A dipeptide formed from glycine and L-alanine residues.,"InChI=1S/C5H10N2O3/c1-3(5(9)10)7-4(8)2-6/h3H,2,6H2,1H3,(H,7,8)(H,9,10)/t3-/m0/s1",glycylalanine,Reaxys Registry Number,1724445
4222,73860,Gly-Arg,A dipeptide formed from glycine and L-arginine residues.,"InChI=1S/C8H17N5O3/c9-4-6(14)13-5(7(15)16)2-1-3-12-8(10)11/h5H,1-4,9H2,(H,13,14)(H,15,16)(H4,10,11,12)/t5-/m0/s1",glycylarginine,Reaxys Registry Number,1728922
4223,73863,"(7Z,10Z,13Z,16Z,19Z)-3-oxodocosapentaenoyl-CoA(4-)","A 3-oxo-fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (7Z,10Z,13Z,16Z,19Z)-3-oxodocosapentaenoyl-CoA.","InChI=1S/C43H66N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-31(51)26-34(53)72-25-24-45-33(52)22-23-46-41(56)38(55)43(2,3)28-65-71(62,63)68-70(60,61)64-27-32-37(67-69(57,58)59)36(54)42(66-32)50-30-49-35-39(44)47-29-48-40(35)50/h5-6,8-9,11-12,14-15,17-18,29-30,32,36-38,42,54-55H,4,7,10,13,16,19-28H2,1-3H3,(H,45,52)(H,46,56)(H,60,61)(H,62,63)(H2,44,47,48)(H2,57,58,59)/p-4/b6-5-,9-8-,12-11-,15-14-,18-17-/t32-,36-,37-,38+,42-/m1/s1","all-cis-3-oxodocosa-7,10,13,16,19-pentaenoyl-CoA(4-)",MetaCyc accession,CPD-14423
4224,73865,"1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z-docosapentaenoyl)-sn-glycero-3- phosphocholine","A phosphatidylcholine 40:5 in which the acyl groups at C-1 and C-2 are octadecanoyl and (4Z,7Z,10Z,13Z,16Z)-docosapentaenoyl respectively.","InChI=1S/C48H86NO8P/c1-6-8-10-12-14-16-18-20-22-23-24-25-27-29-31-33-35-37-39-41-48(51)57-46(45-56-58(52,53)55-43-42-49(3,4)5)44-54-47(50)40-38-36-34-32-30-28-26-21-19-17-15-13-11-9-7-2/h14,16,20,22,24-25,29,31,35,37,46H,6-13,15,17-19,21,23,26-28,30,32-34,36,38-45H2,1-5H3/b16-14-,22-20-,25-24-,31-29-,37-35-/t46-/m1/s1","GPCho(18:0/22:5(4Z,7Z,10Z,13Z,16Z))",LIPID MAPS instance accession,LMGP01010816
4225,73873,"1-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine","A lysophosphatidylcholine 22:6 in which the remaining acyl group is (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl.","InChI=1S/C30H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-30(33)36-27-29(32)28-38-39(34,35)37-26-25-31(2,3)4/h6-7,9-10,12-13,15-16,18-19,21-22,29,32H,5,8,11,14,17,20,23-28H2,1-4H3/b7-6-,10-9-,13-12-,16-15-,19-18-,22-21-/t29-/m1/s1","LPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)",LIPID MAPS instance accession,LMGP01050056
4226,73875,1-hexadecanoyl-2-(13Z-docosenoyl)-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl groups at C-1 and C-2 are hexadecanoyl and (13Z)-docosenoyl respectively.","InChI=1S/C43H84NO8P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h17-18,41H,3-16,19-40,44H2,1-2H3,(H,47,48)/b18-17-/t41-/m1/s1",PE 16:0/22:1(13Z),HMDB accession,HMDB0008941
4227,73880,"1,2-dihexanoyl-sn-glycero-3-phospho-(1'-sn-glycerol)",A phosphatidylglycerol 12:0 in which the acyl groups at C-1 and C-2 are both hexanoyl.,"InChI=1S/C18H35O10P/c1-3-5-7-9-17(21)25-13-16(28-18(22)10-8-6-4-2)14-27-29(23,24)26-12-15(20)11-19/h15-16,19-20H,3-14H2,1-2H3,(H,23,24)/t15-,16+/m0/s1",GPG 6:0/6:0,LIPID MAPS instance accession,LMGP04010030
4228,73887,"(7Z,10Z,13Z,16Z,19Z)-3-oxodocosapentaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (7Z,10Z,13Z,16Z,19Z)-3-oxodocosapentaenoic acid.","InChI=1S/C43H66N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-31(51)26-34(53)72-25-24-45-33(52)22-23-46-41(56)38(55)43(2,3)28-65-71(62,63)68-70(60,61)64-27-32-37(67-69(57,58)59)36(54)42(66-32)50-30-49-35-39(44)47-29-48-40(35)50/h5-6,8-9,11-12,14-15,17-18,29-30,32,36-38,42,54-55H,4,7,10,13,16,19-28H2,1-3H3,(H,45,52)(H,46,56)(H,60,61)(H,62,63)(H2,44,47,48)(H2,57,58,59)/b6-5-,9-8-,12-11-,15-14-,18-17-/t32-,36-,37-,38+,42-/m1/s1","(7Z,10Z,13Z,16Z,19Z)-3-oxodocosapentaenoyl-coenzyme A",MetaCyc accession,CPD-14423
4229,73888,Gly-Asn,A dipeptide formed from glycine and L-asparagine residues.,"InChI=1S/C6H11N3O4/c7-2-5(11)9-3(6(12)13)1-4(8)10/h3H,1-2,7H2,(H2,8,10)(H,9,11)(H,12,13)/t3-/m0/s1",glycylasparagine,Reaxys Registry Number,1727380
4230,73890,Gly-Cys,A dipeptide formed from glycine and L-cysteine residues.,"InChI=1S/C5H10N2O3S/c6-1-4(8)7-3(2-11)5(9)10/h3,11H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1",Gly-L-Cys,Reaxys Registry Number,1709363
4231,73891,Gly-D-Ala,A dipeptide formed from glycine and D-alanine residues.,"InChI=1S/C5H10N2O3/c1-3(5(9)10)7-4(8)2-6/h3H,2,6H2,1H3,(H,7,8)(H,9,10)/t3-/m1/s1",Ga,Reaxys Registry Number,1724446
4232,73893,Gly-D-Asp,A dipeptide formed from glycine and D-aspartic acid residues.,"InChI=1S/C6H10N2O5/c7-2-4(9)8-3(6(12)13)1-5(10)11/h3H,1-2,7H2,(H,8,9)(H,10,11)(H,12,13)/t3-/m1/s1",Gd,Reaxys Registry Number,1727388
4233,73895,Gly-D-Ser,A dipeptide formed from glycine and D-serine residues.,"InChI=1S/C5H10N2O4/c6-1-4(9)7-3(2-8)5(10)11/h3,8H,1-2,6H2,(H,7,9)(H,10,11)/t3-/m1/s1",Gs,Reaxys Registry Number,6501780
4234,73896,Gly-D-Thr,A dipeptide formed from glycine and D-threonine residues.,"InChI=1S/C6H12N2O4/c1-3(9)5(6(11)12)8-4(10)2-7/h3,5,9H,2,7H2,1H3,(H,8,10)(H,11,12)/t3-,5+/m0/s1",Gt,Reaxys Registry Number,1726204
4235,73897,Gly-D-Val,A dipeptide formed from glycine and D-valine residues.,"InChI=1S/C7H14N2O3/c1-4(2)6(7(11)12)9-5(10)3-8/h4,6H,3,8H2,1-2H3,(H,9,10)(H,11,12)/t6-/m1/s1",Gv,Reaxys Registry Number,1725592
4236,73898,Gly-Gln,A dipeptide formed from glycine and L-glutamine residues.,"InChI=1S/C7H13N3O4/c8-3-6(12)10-4(7(13)14)1-2-5(9)11/h4H,1-3,8H2,(H2,9,11)(H,10,12)(H,13,14)/t4-/m0/s1",Gly-L-Gln,Reaxys Registry Number,2417369
4237,73899,Gly-Gly-Ala,"A tripeptide composed of glycine, glycine and L-alanine residues joined in sequence.","InChI=1S/C7H13N3O4/c1-4(7(13)14)10-6(12)3-9-5(11)2-8/h4H,2-3,8H2,1H3,(H,9,11)(H,10,12)(H,13,14)/t4-/m0/s1",glycylglycylalanine,Reaxys Registry Number,1728498
4238,73901,Gly-Gly-D-Leu,"A tripeptide composed of glycine, glycine and D-leucine residues joined in sequence.","InChI=1S/C10H19N3O4/c1-6(2)3-7(10(16)17)13-9(15)5-12-8(14)4-11/h6-7H,3-5,11H2,1-2H3,(H,12,14)(H,13,15)(H,16,17)/t7-/m1/s1",GGl,Reaxys Registry Number,1729174
4239,73902,Gly-Gly-Ile,"A tripeptide composed of glycine, glycine and L-isoleucine residues joined in sequence.","InChI=1S/C10H19N3O4/c1-3-6(2)9(10(16)17)13-8(15)5-12-7(14)4-11/h6,9H,3-5,11H2,1-2H3,(H,12,14)(H,13,15)(H,16,17)/t6-,9-/m0/s1",GGI,Reaxys Registry Number,6927964
4240,73904,Gly-Gly-Leu,"A tripeptide composed of glycine, glycine and L-leucine residues joined in sequence.","InChI=1S/C10H19N3O4/c1-6(2)3-7(10(16)17)13-9(15)5-12-8(14)4-11/h6-7H,3-5,11H2,1-2H3,(H,12,14)(H,13,15)(H,16,17)/t7-/m0/s1",glycylglycylleucine,Reaxys Registry Number,1729173
4241,73905,Gly-Gly-Phe,"A tripeptide composed of glycine, glycine and L-phenylalanine residues joined in sequence.","InChI=1S/C13H17N3O4/c14-7-11(17)15-8-12(18)16-10(13(19)20)6-9-4-2-1-3-5-9/h1-5,10H,6-8,14H2,(H,15,17)(H,16,18)(H,19,20)/t10-/m0/s1",glycylglycylphenylalanine,Reaxys Registry Number,3000257
4242,73907,Gly-Ile,A dipeptide formed from glycine and L-isoleucine residues.,"InChI=1S/C8H16N2O3/c1-3-5(2)7(8(12)13)10-6(11)4-9/h5,7H,3-4,9H2,1-2H3,(H,10,11)(H,12,13)/t5-,7-/m0/s1",GI,Reaxys Registry Number,1726353
4243,73909,Gly-Lys,A dipeptide formed from glycine and L-lysine residues.,"InChI=1S/C8H17N3O3/c9-4-2-1-3-6(8(13)14)11-7(12)5-10/h6H,1-5,9-10H2,(H,11,12)(H,13,14)/t6-/m0/s1",glycyllysine,Reaxys Registry Number,1727113
4244,73912,Gly-Phe,A dipeptide formed from glycine and L-phenylalanine residues.,"InChI=1S/C11H14N2O3/c12-7-10(14)13-9(11(15)16)6-8-4-2-1-3-5-8/h1-5,9H,6-7,12H2,(H,13,14)(H,15,16)/t9-/m0/s1",Gly-L-Phe,Reaxys Registry Number,2279318
4245,73915,Gly-Phe-Phe,A tripeptide composed of one glycine and two L-phenylalanine residues joined in sequence,"InChI=1S/C20H23N3O4/c21-13-18(24)22-16(11-14-7-3-1-4-8-14)19(25)23-17(20(26)27)12-15-9-5-2-6-10-15/h1-10,16-17H,11-13,21H2,(H,22,24)(H,23,25)(H,26,27)/t16-,17-/m0/s1",GFF,Reaxys Registry Number,2785150
4246,73920,Gly-Thr,A dipeptide formed from glycine and L-threonine residues.,"InChI=1S/C6H12N2O4/c1-3(9)5(6(11)12)8-4(10)2-7/h3,5,9H,2,7H2,1H3,(H,8,10)(H,11,12)/t3-,5+/m1/s1",GT,Reaxys Registry Number,1726205
4247,73921,Gly-Trp,A dipeptide formed from glycine and L-tryptophan residues.,"InChI=1S/C13H15N3O3/c14-6-12(17)16-11(13(18)19)5-8-7-15-10-4-2-1-3-9(8)10/h1-4,7,11,15H,5-6,14H2,(H,16,17)(H,18,19)/t11-/m0/s1",Gly-L-Trp,Reaxys Registry Number,92130
4248,73922,Gly-Val,A dipeptide formed from glycine and L-valine residues.,"InChI=1S/C7H14N2O3/c1-4(2)6(7(11)12)9-5(10)3-8/h4,6H,3,8H2,1-2H3,(H,9,10)(H,11,12)/t6-/m0/s1",Gly-L-Val,Reaxys Registry Number,1725593
4249,73924,His-Ala,A dipeptide formed from L-histidine and L-alanine residues.,"InChI=1S/C9H14N4O3/c1-5(9(15)16)13-8(14)7(10)2-6-3-11-4-12-6/h3-5,7H,2,10H2,1H3,(H,11,12)(H,13,14)(H,15,16)/t5-,7-/m0/s1",HA,Reaxys Registry Number,89967
4250,73925,His-Asp,A dipeptide formed from L-histidine and L-aspartic acid residues.,"InChI=1S/C10H14N4O5/c11-6(1-5-3-12-4-13-5)9(17)14-7(10(18)19)2-8(15)16/h3-4,6-7H,1-2,11H2,(H,12,13)(H,14,17)(H,15,16)(H,18,19)/t6-,7-/m0/s1",HD,Reaxys Registry Number,689558
4251,73928,His-Glu,A dipeptide formed from L-histidine and L-glutamic acid residues.,"InChI=1S/C11H16N4O5/c12-7(3-6-4-13-5-14-6)10(18)15-8(11(19)20)1-2-9(16)17/h4-5,7-8H,1-3,12H2,(H,13,14)(H,15,18)(H,16,17)(H,19,20)/t7-,8-/m0/s1",histidylglutamic acid,Reaxys Registry Number,932116
4252,73930,His-Gly,A dipeptide formed from L-histidine and glycine residues.,"InChI=1S/C8H12N4O3/c9-6(1-5-2-10-4-12-5)8(15)11-3-7(13)14/h2,4,6H,1,3,9H2,(H,10,12)(H,11,15)(H,13,14)/t6-/m0/s1",HG,Reaxys Registry Number,24311
4253,73940,"GDP-4-dehydro-3,6-dideoxy-alpha-D-mannose","A GDP-sugar having 4-dehydro-3,6-dideoxy-alpha-D-mannose as the sugar fragment.","InChI=1S/C16H23N5O14P2/c1-5-6(22)2-7(23)15(32-5)34-37(29,30)35-36(27,28)31-3-8-10(24)11(25)14(33-8)21-4-18-9-12(21)19-16(17)20-13(9)26/h4-5,7-8,10-11,14-15,23-25H,2-3H2,1H3,(H,27,28)(H,29,30)(H3,17,19,20,26)/t5-,7+,8-,10-,11-,14-,15-/m1/s1","GDP-4-keto-3,6-dideoxy-alpha-D-mannose",Reaxys Registry Number,9460096
4254,73941,"benzene-1,3-disulfonic acid",A member of the class of benzenesulfonic acids consisting of benzene carrying two sulfo groups at positions 1 and 3 respectively.,"InChI=1S/C6H6O6S2/c7-13(8,9)5-2-1-3-6(4-5)14(10,11)12/h1-4H,(H,7,8,9)(H,10,11,12)","1,3-benzenedisulfonic acid",CAS Registry Number,98-48-6
4255,73945,"benzene-1,2-disulfonic acid",A member of the class of benzenesulfonic acids consisting of benzene carrying two sulfo groups at positions 1 and 2 respectively.,"InChI=1S/C6H6O6S2/c7-13(8,9)5-3-1-2-4-6(5)14(10,11)12/h1-4H,(H,7,8,9)(H,10,11,12)","benzene-1,2-disuphonic acid",CAS Registry Number,31375-00-5
4256,73947,"benzene-1,4-disulfonic acid",A member of the class of benzenesulfonic acids consisting of benzene carrying two sulfo groups at position 1 and 4 respectively.,"InChI=1S/C6H6O6S2/c7-13(8,9)5-1-2-6(4-3-5)14(10,11)12/h1-4H,(H,7,8,9)(H,10,11,12)","benzene-1,4-disulphonic acid",CAS Registry Number,31375-02-7
4257,73950,dTDP-alpha-D-fucose,A dTDP-D-fucose in which the anomeric centre of the fucose fragment has alpha-configuration.,"InChI=1S/C16H26N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-13,15,19-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,8+,9-,10-,11+,12+,13-,15-/m1/s1",dTDP-alpha-D-fucopyranose,KEGG COMPOUND accession,C07277
4258,73956,(S)-2-chloropropanoic acid,A monocarboxylic acid that is propanoic acid substituted at position 2 by a chloro group (the S-enantiomer).,"InChI=1S/C3H5ClO2/c1-2(4)3(5)6/h2H,1H3,(H,5,6)/t2-/m0/s1",(S)-2-chloropropionic acid,Reaxys Registry Number,1720257
4259,73965,prostaglandin E2-UM,"A prostanoid that is prostaglandin E2 in which the acyclic hydroxy group has been oxidised to the corresponding ketone, the methyl group has been oxidised to the corresponding carboxylic acid and the 6-carboxyhexenyl group has been oxidatively cleaved to a 2-carboxyethyl group. It is the major urinary metabolite of prostaglandin E2.","InChI=1S/C16H24O7/c17-10(3-1-2-4-15(20)21)5-6-11-12(7-8-16(22)23)14(19)9-13(11)18/h11-13,18H,1-9H2,(H,20,21)(H,22,23)/t11-,12-,13-/m1/s1",PGE-M,CAS Registry Number,24769-56-0
4260,73982,"(3R,4R)-4-(hydroxymethyl)-3-(6-methylheptanoyl)oxolan-2-one","A butan-4-olide that is gamma-butyrolactone with a 6-methylheptanoyl substituent at position 3 and a hydroxymethyl substituent at position 4 (the 3R,4R-stereoisomer).","InChI=1S/C13H22O4/c1-9(2)5-3-4-6-11(15)12-10(7-14)8-17-13(12)16/h9-10,12,14H,3-8H2,1-2H3/t10-,12-/m1/s1",A-Factor,MetaCyc accession,CPD-10135
4261,73989,"2,3,4,5-tetranor-prostaglandin FM",A prostanoid that is prostaglandin E2-UM in which the oxo group at position 9 has been reduced to the corresponding alcohol (alpha-configuration).,"InChI=1S/C16H26O7/c17-10(3-1-2-4-15(20)21)5-6-11-12(7-8-16(22)23)14(19)9-13(11)18/h11-14,18-19H,1-9H2,(H,20,21)(H,22,23)/t11-,12-,13-,14+/m1/s1","2,3,4,5-tetranor-PGFM",LIPID MAPS instance accession,LMFA03010139
4262,73998,1-hexadecanoyl-2-[(9Z)-hexadec-9-enoyl]-sn-glycero-3-phosphate(2-),"A 1,2-diacyl-sn-glycerol 3-phosphate(2-) ion in which the acyl groups at C-1 and C-2 are hexadecanoyl and (9Z)-hexadec-9-enoyl respectively.","InChI=1S/C35H67O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(36)41-31-33(32-42-44(38,39)40)43-35(37)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h14,16,33H,3-13,15,17-32H2,1-2H3,(H2,38,39,40)/p-2/b16-14-/t33-/m1/s1",PA(16:0/16:1(9Z)),LIPID MAPS instance accession,LMGP10010911
4263,74005,8-desmethylnovobiocic acid,A hydroxycoumarin that is novobiocic acid lacking the 8-methyl group.,"InChI=1S/C21H19NO6/c1-11(2)3-4-12-9-13(5-8-16(12)24)20(26)22-18-19(25)15-7-6-14(23)10-17(15)28-21(18)27/h3,5-10,23-25H,4H2,1-2H3,(H,22,26)",8-demethylnovobiocic acid,PubMed citation,16274243
4264,74011,(11Z)-3-oxoicosa-11-enoyl-CoA(4-),A 3-oxo-fatty acyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate functions of 3-oxo-(11Z)-eicosa-11-enoyl-CoA.,"InChI=1S/C41H70N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-29(49)24-32(51)70-23-22-43-31(50)20-21-44-39(54)36(53)41(2,3)26-63-69(60,61)66-68(58,59)62-25-30-35(65-67(55,56)57)34(52)40(64-30)48-28-47-33-37(42)45-27-46-38(33)48/h11-12,27-28,30,34-36,40,52-53H,4-10,13-26H2,1-3H3,(H,43,50)(H,44,54)(H,58,59)(H,60,61)(H2,42,45,46)(H2,55,56,57)/p-4/b12-11-/t30-,34-,35-,36+,40-/m1/s1",3-oxo-(11Z)-icosa-11-enoyl-CoA(4-),MetaCyc accession,CPD-14300
4265,74016,"16-carboxy-Delta(13)-17,18,19,20-tetranor-leukotriene E4",An icosanoid that is leukotriene E4 in which the isolated double bond has migrated into conjugation with the triene moiety and in which four methylene groups have been lost from the resulting carboxyalkyl chain.,"InChI=1S/C19H27NO7S/c20-14(19(26)27)13-28-16(15(21)9-8-12-18(24)25)10-6-4-2-1-3-5-7-11-17(22)23/h1-7,10,14-16,21H,8-9,11-13,20H2,(H,22,23)(H,24,25)(H,26,27)/b3-1-,4-2+,7-5?,10-6+/t14-,15-,16+/m0/s1","16-carboxy-Delta(13)-17,18,19,20-tetranor-LTE4",PubMed citation,2174886
4266,74018,leukotriene E3,A leukotriene that is leukotriene E4 in which the non-conjugated double bond has been reduced to a single bond.,"InChI=1S/C23H39NO5S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-21(30-18-19(24)23(28)29)20(25)15-14-17-22(26)27/h9-13,16,19-21,25H,2-8,14-15,17-18,24H2,1H3,(H,26,27)(H,28,29)/b10-9-,12-11+,16-13+/t19-,20-,21+/m0/s1","14,15-dihydro-leukotriene E4",HMDB accession,HMDB0002355
4267,74019,"14-carboxy-15,16,17,18,19,20-hexanor-leukotriene E3",An icosanoid that is leukotriene E3 in which the terminal octyl group is replaced by a carboxymethyl group.,"InChI=1S/C17H25NO7S/c18-12(17(24)25)11-26-14(13(19)7-6-10-16(22)23)8-4-2-1-3-5-9-15(20)21/h1-5,8,12-14,19H,6-7,9-11,18H2,(H,20,21)(H,22,23)(H,24,25)/b2-1+,5-3-,8-4+/t12-,13-,14+/m0/s1",14-carboxy-hexanor-leukotriene E3,PubMed citation,2174886
4268,74028,"beta-D-Gal-(1->3)-alpha-D-GlcNAc-diphospho-ditrans,octacis-undecaprenol","A polyprenyl phospho oligosaccharide that consists of a beta-D-Gal-(1->3)-alpha-D-GlcNAc moiety linked via a diphospho group to ditrans,octacis-undecaprenol.","InChI=1S/C69H115NO17P2/c1-48(2)24-14-25-49(3)26-15-27-50(4)28-16-29-51(5)30-17-31-52(6)32-18-33-53(7)34-19-35-54(8)36-20-37-55(9)38-21-39-56(10)40-22-41-57(11)42-23-43-58(12)44-45-82-88(78,79)87-89(80,81)86-68-62(70-59(13)73)67(64(75)61(47-72)83-68)85-69-66(77)65(76)63(74)60(46-71)84-69/h24,26,28,30,32,34,36,38,40,42,44,60-69,71-72,74-77H,14-23,25,27,29,31,33,35,37,39,41,43,45-47H2,1-13H3,(H,70,73)(H,78,79)(H,80,81)/b49-26+,50-28+,51-30-,52-32-,53-34-,54-36-,55-38-,56-40-,57-42-,58-44-/t60-,61-,62-,63+,64-,65+,66-,67-,68-,69+/m1/s1","beta-D-Gal-(1->3)-alpha-D-GlcNAc-diphospho-ditrans,polycis-undecaprenol",PubMed citation,15625181
4269,74033,"beta-D-Glc-(1->3)-alpha-D-GlcNAc-diphospho-ditrans,octacis-undecaprenol","A polyprenyl phospho oligosaccharide that consists of a beta-D-Glc-(1->3)-alpha-D-GlcNAc moiety linked via a diphospho group to ditrans,octacis-undecaprenol.","InChI=1S/C69H115NO17P2/c1-48(2)24-14-25-49(3)26-15-27-50(4)28-16-29-51(5)30-17-31-52(6)32-18-33-53(7)34-19-35-54(8)36-20-37-55(9)38-21-39-56(10)40-22-41-57(11)42-23-43-58(12)44-45-82-88(78,79)87-89(80,81)86-68-62(70-59(13)73)67(64(75)61(47-72)83-68)85-69-66(77)65(76)63(74)60(46-71)84-69/h24,26,28,30,32,34,36,38,40,42,44,60-69,71-72,74-77H,14-23,25,27,29,31,33,35,37,39,41,43,45-47H2,1-13H3,(H,70,73)(H,78,79)(H,80,81)/b49-26+,50-28+,51-30-,52-32-,53-34-,54-36-,55-38-,56-40-,57-42-,58-44-/t60-,61-,62-,63-,64-,65+,66-,67-,68-,69+/m1/s1","beta-D-Glc-(1->3)-alpha-D-GlcNAc-diphospho-ditrans,polycis-undecaprenol",PubMed citation,18487334
4270,74036,"alpha-D-GalNAc-(1->3)-alpha-D-GalNAc-diphospho-ditrans,octacis-undecaprenol","A polyprenyl phospho oligosaccharide that consists of an alpha-D-GalNAc-(1->3)-alpha-D-GalNAc moiety linked via a diphospho group to ditrans,octacis-undecaprenol.","InChI=1S/C71H118N2O17P2/c1-49(2)25-15-26-50(3)27-16-28-51(4)29-17-30-52(5)31-18-32-53(6)33-19-34-54(7)35-20-36-55(8)37-21-38-56(9)39-22-40-57(10)41-23-42-58(11)43-24-44-59(12)45-46-85-91(81,82)90-92(83,84)89-71-65(73-61(14)77)69(67(79)63(48-75)87-71)88-70-64(72-60(13)76)68(80)66(78)62(47-74)86-70/h25,27,29,31,33,35,37,39,41,43,45,62-71,74-75,78-80H,15-24,26,28,30,32,34,36,38,40,42,44,46-48H2,1-14H3,(H,72,76)(H,73,77)(H,81,82)(H,83,84)/b50-27+,51-29+,52-31-,53-33-,54-35-,55-37-,56-39-,57-41-,58-43-,59-45-/t62-,63-,64-,65-,66+,67+,68-,69-,70-,71-/m1/s1","alpha-D-GalNAc-(1->3)-alpha-D-GalNAc-diphospho-ditrans,polycis-undecaprenol",PubMed citation,16630548
4271,74037,(11Z)-3-oxoicosa-11-enoyl-CoA,A 3-oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (11Z)-3-oxoicosa-11-enoic acid.,"InChI=1S/C41H70N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-29(49)24-32(51)70-23-22-43-31(50)20-21-44-39(54)36(53)41(2,3)26-63-69(60,61)66-68(58,59)62-25-30-35(65-67(55,56)57)34(52)40(64-30)48-28-47-33-37(42)45-27-46-38(33)48/h11-12,27-28,30,34-36,40,52-53H,4-10,13-26H2,1-3H3,(H,43,50)(H,44,54)(H,58,59)(H,60,61)(H2,42,45,46)(H2,55,56,57)/b12-11-/t30-,34-,35-,36+,40-/m1/s1",(11Z)-3-ketoicosa-11-enoyl-coenzyme A,MetaCyc accession,CPD-14300
4272,74040,"alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->3)-alpha-D-GalNAc-diphospho-ditrans,octacis-undecaprenol","A polyprenyl phospho oligosaccharide that consists of an alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->3)-alpha-D-GalNAc moiety linked via a diphospho group to ditrans,octacis-undecaprenol.","InChI=1S/C83H138N2O26P2/c1-51(2)26-16-27-52(3)28-17-29-53(4)30-18-31-54(5)32-19-33-55(6)34-20-35-56(7)36-21-37-57(8)38-22-39-58(9)40-23-41-59(10)42-24-43-60(11)44-25-45-61(12)46-47-102-112(98,99)111-113(100,101)110-81-69(85-64(15)90)78(73(94)67(50-88)105-81)107-80-68(84-63(14)89)77(72(93)66(49-87)104-80)108-83-79(75(96)71(92)65(48-86)106-83)109-82-76(97)74(95)70(91)62(13)103-82/h26,28,30,32,34,36,38,40,42,44,46,62,65-83,86-88,91-97H,16-25,27,29,31,33,35,37,39,41,43,45,47-50H2,1-15H3,(H,84,89)(H,85,90)(H,98,99)(H,100,101)/b52-28+,53-30+,54-32-,55-34-,56-36-,57-38-,58-40-,59-42-,60-44-,61-46-/t62-,65+,66+,67+,68+,69+,70+,71-,72-,73-,74+,75-,76-,77+,78+,79+,80+,81+,82-,83-/m0/s1","alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->3)-alpha-D-GalNAc-diphospho-ditrans,polycis-undecaprenol",PubMed citation,15713070
4273,74047,GDP-N-acetyl-alpha-D-perosamine,A GDP-hexose having N-acetyl-alpha-D-perosamine as the hexose fragment.,"InChI=1S/C18H28N6O15P2/c1-5-8(21-6(2)25)11(27)13(29)17(36-5)38-41(33,34)39-40(31,32)35-3-7-10(26)12(28)16(37-7)24-4-20-9-14(24)22-18(19)23-15(9)30/h4-5,7-8,10-13,16-17,26-29H,3H2,1-2H3,(H,21,25)(H,31,32)(H,33,34)(H3,19,22,23,30)/t5-,7-,8-,10-,11+,12-,13+,16-,17-/m1/s1","GDP-4-acetamido-4,6-dideoxy-alpha-D-mannose",PubMed citation,18201574
4274,74050,"CDP-2,3-bis-O-(phytanyl)-sn-glycerol","A CDP-glycerol that is 2,3-bis-O-(phytanyl)-sn-glycerol (archaeol) having a CDP moiety attached at position 1.","InChI=1S/C52H101N3O13P2/c1-38(2)17-11-19-40(5)21-13-23-42(7)25-15-27-44(9)30-33-63-35-46(64-34-31-45(10)28-16-26-43(8)24-14-22-41(6)20-12-18-39(3)4)36-65-69(59,60)68-70(61,62)66-37-47-49(56)50(57)51(67-47)55-32-29-48(53)54-52(55)58/h29,32,38-47,49-51,56-57H,11-28,30-31,33-37H2,1-10H3,(H,59,60)(H,61,62)(H2,53,54,58)/t40-,41-,42-,43-,44-,45-,46+,47-,49-,50-,51-/m1/s1",CDP-archaeol,PubMed citation,19740749
4275,74051,His-His,A dipeptide formed from two L-histidine residues.,"InChI=1S/C12H16N6O3/c13-9(1-7-3-14-5-16-7)11(19)18-10(12(20)21)2-8-4-15-6-17-8/h3-6,9-10H,1-2,13H2,(H,14,16)(H,15,17)(H,18,19)(H,20,21)/t9-,10-/m0/s1",L-His-L-His,Reaxys Registry Number,94425
4276,74052,His-Lys,A dipeptide formed from L-histidine and L-lysine residues.,"InChI=1S/C12H21N5O3/c13-4-2-1-3-10(12(19)20)17-11(18)9(14)5-8-6-15-7-16-8/h6-7,9-10H,1-5,13-14H2,(H,15,16)(H,17,18)(H,19,20)/t9-,10-/m0/s1",histidyllysine,Reaxys Registry Number,692771
4277,74053,His-Met,A dipeptide formed from L-histidine and L-methionine residues.,"InChI=1S/C11H18N4O3S/c1-19-3-2-9(11(17)18)15-10(16)8(12)4-7-5-13-6-14-7/h5-6,8-9H,2-4,12H2,1H3,(H,13,14)(H,15,16)(H,17,18)/t8-,9-/m0/s1",histidylmethionine,Reaxys Registry Number,10178310
4278,74055,His-Pro,A dipeptide formed from L-histidine and L-proline residues.,"InChI=1S/C11H16N4O3/c12-8(4-7-5-13-6-14-7)10(16)15-3-1-2-9(15)11(17)18/h5-6,8-9H,1-4,12H2,(H,13,14)(H,17,18)/t8-,9-/m0/s1",L-His-L-Pro,Reaxys Registry Number,679118
4279,74056,His-Ser,A dipeptide formed from L-histidine and L-serine residues.,"InChI=1S/C9H14N4O4/c10-6(1-5-2-11-4-12-5)8(15)13-7(3-14)9(16)17/h2,4,6-7,14H,1,3,10H2,(H,11,12)(H,13,15)(H,16,17)/t6-,7-/m0/s1",HS,Reaxys Registry Number,756048
4280,74058,His-Trp,A dipeptide formed from L-histidine and L-tryptophan residues.,"InChI=1S/C17H19N5O3/c18-13(6-11-8-19-9-21-11)16(23)22-15(17(24)25)5-10-7-20-14-4-2-1-3-12(10)14/h1-4,7-9,13,15,20H,5-6,18H2,(H,19,21)(H,22,23)(H,24,25)/t13-,15-/m0/s1",histidyltryptophan,Reaxys Registry Number,4275044
4281,74059,His-Tyr,A dipeptide formed from L-histidine and L-tyrosine residues.,"InChI=1S/C15H18N4O4/c16-12(6-10-7-17-8-18-10)14(21)19-13(15(22)23)5-9-1-3-11(20)4-2-9/h1-4,7-8,12-13,20H,5-6,16H2,(H,17,18)(H,19,21)(H,22,23)/t12-,13-/m0/s1",L-His-L-Tyr,Reaxys Registry Number,845761
4282,74060,His-Val,A dipeptide formed from L-histidine and L-valine residues.,"InChI=1S/C11H18N4O3/c1-6(2)9(11(17)18)15-10(16)8(12)3-7-4-13-5-14-7/h4-6,8-9H,3,12H2,1-2H3,(H,13,14)(H,15,16)(H,17,18)/t8-,9-/m0/s1",HV,Reaxys Registry Number,14670065
4283,74061,Ile-Arg,A dipeptide formed from L-isoleucine and L-arginine residues.,"InChI=1S/C12H25N5O3/c1-3-7(2)9(13)10(18)17-8(11(19)20)5-4-6-16-12(14)15/h7-9H,3-6,13H2,1-2H3,(H,17,18)(H,19,20)(H4,14,15,16)/t7-,8-,9-/m0/s1",L-Ile-L-Arg,Reaxys Registry Number,6604425
4284,74062,Ile-Ala,A dipeptide formed from L-isoleucine and L-alanine residues.,"InChI=1S/C9H18N2O3/c1-4-5(2)7(10)8(12)11-6(3)9(13)14/h5-7H,4,10H2,1-3H3,(H,11,12)(H,13,14)/t5-,6-,7-/m0/s1",isoleucylalanine,Reaxys Registry Number,7424019
4285,74063,Ile-Asn,A dipeptide formed from L-isoleucine and L-asparagine residues.,"InChI=1S/C10H19N3O4/c1-3-5(2)8(12)9(15)13-6(10(16)17)4-7(11)14/h5-6,8H,3-4,12H2,1-2H3,(H2,11,14)(H,13,15)(H,16,17)/t5-,6-,8-/m0/s1",isoleucylasparagine,Reaxys Registry Number,1714318
4286,74065,Ile-Gln,A dipeptide formed from L-isoleucine and L-glutamine residues.,"InChI=1S/C11H21N3O4/c1-3-6(2)9(13)10(16)14-7(11(17)18)4-5-8(12)15/h6-7,9H,3-5,13H2,1-2H3,(H2,12,15)(H,14,16)(H,17,18)/t6-,7-,9-/m0/s1",L-Ile-L-Gln,Reaxys Registry Number,14388194
4287,74066,Ile-Gly,A dipeptide formed from L-isoleucine and glycine residues.,"InChI=1S/C8H16N2O3/c1-3-5(2)7(9)8(13)10-4-6(11)12/h5,7H,3-4,9H2,1-2H3,(H,10,13)(H,11,12)/t5-,7-/m0/s1",isoleucylglycine,Reaxys Registry Number,1725444
4288,74067,Ile-Ile,A dipeptide formed from two L-isoleucine residues.,"InChI=1S/C12H24N2O3/c1-5-7(3)9(13)11(15)14-10(12(16)17)8(4)6-2/h7-10H,5-6,13H2,1-4H3,(H,14,15)(H,16,17)/t7-,8-,9-,10-/m0/s1",isoleucylisoleucine,Reaxys Registry Number,6314474
4289,74072,Ile-Leu,A dipeptide formed from L-isoleucine and L-leucine residues.,"InChI=1S/C12H24N2O3/c1-5-8(4)10(13)11(15)14-9(12(16)17)6-7(2)3/h7-10H,5-6,13H2,1-4H3,(H,14,15)(H,16,17)/t8-,9-,10-/m0/s1",L-Ile-L-Leu,Reaxys Registry Number,4250998
4290,74073,Ile-Met,A dipeptide formed from L-isoleucine and L-methionine residues.,"InChI=1S/C11H22N2O3S/c1-4-7(2)9(12)10(14)13-8(11(15)16)5-6-17-3/h7-9H,4-6,12H2,1-3H3,(H,13,14)(H,15,16)/t7-,8-,9-/m0/s1",L-Ile-L-Met,HMDB accession,HMDB0028913
4291,74075,Ile-Phe,A dipeptide formed from L-isoleucine and L-phenylalanine residues.,"InChI=1S/C15H22N2O3/c1-3-10(2)13(16)14(18)17-12(15(19)20)9-11-7-5-4-6-8-11/h4-8,10,12-13H,3,9,16H2,1-2H3,(H,17,18)(H,19,20)/t10-,12-,13-/m0/s1",IF,Reaxys Registry Number,6415975
4292,74076,Ile-Pro,A dipeptide formed from L-isoleucine and L-proline residues.,"InChI=1S/C11H20N2O3/c1-3-7(2)9(12)10(14)13-6-4-5-8(13)11(15)16/h7-9H,3-6,12H2,1-2H3,(H,15,16)/t7-,8-,9-/m0/s1",isoleucylproline,Reaxys Registry Number,5030187
4293,74077,S-allylcysteine,An S-hydrocarbyl-L-cysteine that is L-cysteine in which the  hydrogen attached to the sulphur is replaced by a prop-2-enyl group. It commonly occurs in garlic and has been found to exhibit antineoplastic activity.,"InChI=1S/C6H11NO2S/c1-2-3-10-4-5(7)6(8)9/h2,5H,1,3-4,7H2,(H,8,9)/t5-/m0/s1",S-allyl-L-cysteine,CAS Registry Number,21593-77-1
4294,74078,Ile-Ser,A dipeptide formed from L-isoleucine and L-serine residues.,"InChI=1S/C9H18N2O4/c1-3-5(2)7(10)8(13)11-6(4-12)9(14)15/h5-7,12H,3-4,10H2,1-2H3,(H,11,13)(H,14,15)/t5-,6-,7-/m0/s1",L-Ile-L-Ser,Reaxys Registry Number,9403139
4295,74080,Ile-Trp,A dipeptide formed from L-isoleucine and L-tryptophan residues.,"InChI=1S/C17H23N3O3/c1-3-10(2)15(18)16(21)20-14(17(22)23)8-11-9-19-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,14-,15-/m0/s1",L-Ile-L-Trp,Reaxys Registry Number,8715363
4296,74081,1-archaetidyl-1D-myo-inositol 3-phosphate,A glycerophosphoinositol phosphate that is 1-archaetidyl-1D-myo-inositol bearing an additional phospho substituent at position 3.,"InChI=1S/C49H100O14P2/c1-35(2)17-11-19-37(5)21-13-23-39(7)25-15-27-41(9)29-31-59-33-43(60-32-30-42(10)28-16-26-40(8)24-14-22-38(6)20-12-18-36(3)4)34-61-65(57,58)63-49-46(52)44(50)45(51)48(47(49)53)62-64(54,55)56/h35-53H,11-34H2,1-10H3,(H,57,58)(H2,54,55,56)/t37-,38-,39-,40-,41-,42-,43+,44+,45+,46-,47-,48-,49+/m1/s1",AIP,PubMed citation,19740749
4297,74088,1-archaetidyl-D-myo-inositol,A glycerophosphoinositol that is 1-D-myo-inositol substituted at position 1 by an archaetidyl group.,"InChI=1S/C49H99O11P/c1-35(2)17-11-19-37(5)21-13-23-39(7)25-15-27-41(9)29-31-57-33-43(34-59-61(55,56)60-49-47(53)45(51)44(50)46(52)48(49)54)58-32-30-42(10)28-16-26-40(8)24-14-22-38(6)20-12-18-36(3)4/h35-54H,11-34H2,1-10H3,(H,55,56)/t37-,38-,39-,40-,41-,42-,43+,44-,45-,46+,47-,48-,49-/m1/s1","2,3-diphytanyl-sn-glycero-1-phospho-(1'-myo-inositol)",Reaxys Registry Number,6886281
4298,74100,N-[(9Z)-octadecenoyl]sphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as (9Z)-octadecenoyl (oleoyl).,"InChI=1S/C36H71NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,34-35,38-39H,3-16,19-33H2,1-2H3,(H,37,40)/b18-17-/t34-,35+/m0/s1",N-oleoylsphinganine,LIPID MAPS instance accession,LMSP02020015
4299,74102,"cholesteryl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate","A cholesterol ester in which the acyl group is specified as  (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl.","InChI=1S/C49H76O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-29-47(50)51-42-34-36-48(5)41(38-42)30-31-43-45-33-32-44(40(4)28-26-27-39(2)3)49(45,6)37-35-46(43)48/h8-9,11-12,14-15,17-18,20-21,23-24,30,39-40,42-46H,7,10,13,16,19,22,25-29,31-38H2,1-6H3/b9-8-,12-11-,15-14-,18-17-,21-20-,24-23-/t40-,42+,43+,44-,45+,46+,48+,49-/m1/s1","CE 22:6(4Z,7Z,10Z,13Z,16Z,19Z)",HMDB accession,HMDB0006733
4300,74104,3-[(2-hydroxyethyl)disulfanyl]-L-alanine,An S-substituted L-cysteine where the S-substituent is specified as (2-hydroxyethyl)sulfane.,"InChI=1S/C5H11NO3S2/c6-4(5(8)9)3-11-10-2-1-7/h4,7H,1-3,6H2,(H,8,9)/t4-/m0/s1",cysteinemercaptoethanol disulfide,CAS Registry Number,38254-63-6
4301,74106,erucoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of erucic acid.,"InChI=1S/C43H76N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-34(52)71-27-26-45-33(51)24-25-46-41(55)38(54)43(2,3)29-64-70(61,62)67-69(59,60)63-28-32-37(66-68(56,57)58)36(53)42(65-32)50-31-49-35-39(44)47-30-48-40(35)50/h11-12,30-32,36-38,42,53-54H,4-10,13-29H2,1-3H3,(H,45,51)(H,46,55)(H,59,60)(H,61,62)(H2,44,47,48)(H2,56,57,58)/b12-11-/t32-,36-,37-,38+,42-/m1/s1",13Z-docosenoyl-CoA,Reaxys Registry Number,11195616
4302,74110,N-undecylundecan-1-amine,A secondary aliphatic amine with two undecyl groups,"InChI=1S/C22H47N/c1-3-5-7-9-11-13-15-17-19-21-23-22-20-18-16-14-12-10-8-6-4-2/h23H,3-22H2,1-2H3",di-N-undecylamine,Reaxys Registry Number,1770479
4303,74112,3-hydroxynorvaline,A non-proteinogenic amino-acid derivative that is norvaline (2-aminopentanoic acid) in which a hydrogen at position 3 is replaced by a hydroxy group.,"InChI=1S/C5H11NO3/c1-2-3(7)4(6)5(8)9/h3-4,7H,2,6H2,1H3,(H,8,9)",DL-beta-hydroxynorvaline,CAS Registry Number,2280-42-4
4304,74130,N-[(15Z)-tetracosenoyl]sphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as (15Z)-tetracosenoyl (nervonoyl).,"InChI=1S/C42H83NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-42(46)43-40(39-44)41(45)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h17-18,40-41,44-45H,3-16,19-39H2,1-2H3,(H,43,46)/b18-17-/t40-,41+/m0/s1",N-(tetracos-15cis-enoyl)sphinganine,LIPID MAPS instance accession,LMSP02020011
4305,74132,N-[(17Z)-hexacosenoyl]sphinganine,A dihydroceramide in which the ceramide N-acyl group is specified as (17Z)-hexacosenoyl,"InChI=1S/C44H87NO3/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-44(48)45-42(41-46)43(47)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2/h17-18,42-43,46-47H,3-16,19-41H2,1-2H3,(H,45,48)/b18-17-/t42-,43+/m0/s1",N-hexacos-17cis-enoylsphinganine,LIPID MAPS instance accession,LMSP02020013
4306,74135,Gly-Pro-Hyp,"A  tripeptide composed of glycine, L-proline and 3-hydroxy-L-proline units joined in sequence by peptide linkages.","InChI=1S/C12H19N3O5/c13-6-9(17)14-4-1-2-7(14)11(18)15-5-3-8(16)10(15)12(19)20/h7-8,10,16H,1-6,13H2,(H,19,20)/t7-,8?,10-/m0/s1",Gly-L-Pro-L-Hyp,HMDB accession,HMDB0002171
4307,74138,2-hydroxystearoyl-CoA,A hydroxy fatty-acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-hydroxystearic acid.,"InChI=1S/C39H70N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-27(47)38(52)68-22-21-41-29(48)19-20-42-36(51)33(50)39(2,3)24-61-67(58,59)64-66(56,57)60-23-28-32(63-65(53,54)55)31(49)37(62-28)46-26-45-30-34(40)43-25-44-35(30)46/h25-28,31-33,37,47,49-50H,4-24H2,1-3H3,(H,41,48)(H,42,51)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/t27?,28-,31-,32-,33+,37-/m1/s1",2-hydroxystearoyl-coenzyme A,CAS Registry Number,38861-93-7
4308,74142,(15Z)-tetracosenoyl-CoA,A very long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (15Z)-tetracosenoic acid.,"InChI=1S/C45H80N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-36(54)73-29-28-47-35(53)26-27-48-43(57)40(56)45(2,3)31-66-72(63,64)69-71(61,62)65-30-34-39(68-70(58,59)60)38(55)44(67-34)52-33-51-37-41(46)49-32-50-42(37)52/h11-12,32-34,38-40,44,55-56H,4-10,13-31H2,1-3H3,(H,47,53)(H,48,57)(H,61,62)(H,63,64)(H2,46,49,50)(H2,58,59,60)/b12-11-/t34-,38-,39-,40+,44-/m1/s1",(15Z)-tetracosenoyl-coenzyme A,KEGG COMPOUND accession,C16532
4309,74163,dTDP-4-dehydro-6-deoxy-beta-D-gulose,A dTDP-sugar having 4-dehydro-6-deoxy-beta-D-gulose as the sugar component.,"InChI=1S/C16H24N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-10,12-13,15,19,21-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,8+,9-,10-,12-,13-,15+/m1/s1",thymidine 5'-[3-(4-dehydro-6-deoxy-beta-D-gulopyranosyl) dihydrogen diphosphate],PubMed citation,15049360
4310,74165,"(E)-1,3-pentadiene",An alkadiene consisting of pentane with the two double bonds located at positions 1 and 3.,"InChI=1S/C5H8/c1-3-5-4-2/h3-5H,1H2,2H3/b5-4+","trans-1,3-pentadiene",PubMed citation,18039817
4311,74168,"D-ribono-1,4-lactone",A five-membered form of ribonolactone having D-configuration.,"InChI=1S/C5H8O5/c6-1-2-3(7)4(8)5(9)10-2/h2-4,6-8H,1H2/t2-,3-,4-/m1/s1",ribonolactone,MetaCyc accession,CPD-13413
4312,74179,N-tricosanoyl-15-methylhexadecasphinganine,A N-acyl-15-methylhexadecasphinganine in which the acyl group has 23 carbons and 0 double bonds.,"InChI=1S/C40H81NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23-26-29-32-35-40(44)41-38(36-42)39(43)34-31-28-25-22-20-21-24-27-30-33-37(2)3/h37-39,42-43H,4-36H2,1-3H3,(H,41,44)/t38-,39+/m0/s1",N-tricosanoyl-15-methylhexadecadihydrosphingosine,PubMed citation,23894595
4313,74180,N-tetracosanoyl-15-methylhexadecasphinganine,A N-acyl-15-methylhexadecasphinganine in which the acyl group has 24 carbons and 0 double bonds.,"InChI=1S/C41H83NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-27-30-33-36-41(45)42-39(37-43)40(44)35-32-29-26-23-21-22-25-28-31-34-38(2)3/h38-40,43-44H,4-37H2,1-3H3,(H,42,45)/t39-,40+/m0/s1",N-tetracosanoyl-15-methylhexadecadihydrosphingosine,PubMed citation,23894595
4314,74181,N-pentacosanoyl-15-methylhexadecasphinganine,A N-acyl-15-methylhexadecasphinganine in which the acyl group has 25 carbons and 0 double bonds.,"InChI=1S/C42H85NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-28-31-34-37-42(46)43-40(38-44)41(45)36-33-30-27-24-22-23-26-29-32-35-39(2)3/h39-41,44-45H,4-38H2,1-3H3,(H,43,46)/t40-,41+/m0/s1",N-pentacosanoyl-15-methylhexadecadihydrosphingosine,PubMed citation,23894595
4315,74218,"N-acetyl-alpha-D-galactosaminyl-1-diphospho-ditrans,polycis-undecaprenol","A polyprenyl phospho oligosaccharide that consists of a N-acetyl-alpha-D-galactosaminyl residue linked via a diphospho group to ditrans,polycis-undecaprenol.","InChI=1S/C63H105NO12P2/c1-47(2)24-14-25-48(3)26-15-27-49(4)28-16-29-50(5)30-17-31-51(6)32-18-33-52(7)34-19-35-53(8)36-20-37-54(9)38-21-39-55(10)40-22-41-56(11)42-23-43-57(12)44-45-73-77(69,70)76-78(71,72)75-63-60(64-58(13)66)62(68)61(67)59(46-65)74-63/h24,26,28,30,32,34,36,38,40,42,44,59-63,65,67-68H,14-23,25,27,29,31,33,35,37,39,41,43,45-46H2,1-13H3,(H,64,66)(H,69,70)(H,71,72)/b48-26+,49-28+,50-30-,51-32-,52-34-,53-36-,54-38-,55-40-,56-42-,57-44-/t59-,60-,61+,62-,63-/m1/s1","N-acetyl-alpha-D-galactosaminyl-1-diphospho-ditrans,octacis-undecaprenol",KEGG COMPOUND accession,C05845
4316,74220,C17 sphingosine,A sphingoid that is the C17 analogue of sphingosine.,"InChI=1S/C17H35NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(20)16(18)15-19/h13-14,16-17,19-20H,2-12,15,18H2,1H3/b14-13+/t16-,17+/m0/s1",C17 sphing-4-enine,LIPID MAPS instance accession,LMSP01040002
4317,74248,keto-meromycolic acid,"A mycolic acid produced by Mycobacterium tuberculosis, the structure of which is tetracosanoic acid substituted at the alpha-carbon by a C55 chain which incorporates a hydroxy group at C-1, a cyclopropyl ring fused onto the C-16-C-17 bond, an oxo group at C-35 and a methyl group at C-36.","InChI=1S/C81H158O4/c1-4-6-8-10-12-14-16-18-20-22-23-24-26-30-34-41-47-53-59-65-71-78(81(84)85)80(83)73-67-61-55-49-43-37-36-40-46-52-58-64-70-77-74-76(77)69-63-57-51-45-39-33-29-27-31-35-42-48-54-60-66-72-79(82)75(3)68-62-56-50-44-38-32-28-25-21-19-17-15-13-11-9-7-5-2/h75-78,80,83H,4-74H2,1-3H3,(H,84,85)",ketomeromycolic acid,PubMed citation,23727893
4318,74272,(R)-3-hydroxydecanoyl-CoA(4-),A 3-hydroxy fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (R)-3-hydroxydecanoyl-CoA.,"InChI=1S/C31H54N7O18P3S/c1-4-5-6-7-8-9-19(39)14-22(41)60-13-12-33-21(40)10-11-34-29(44)26(43)31(2,3)16-53-59(50,51)56-58(48,49)52-15-20-25(55-57(45,46)47)24(42)30(54-20)38-18-37-23-27(32)35-17-36-28(23)38/h17-20,24-26,30,39,42-43H,4-16H2,1-3H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/p-4/t19-,20-,24-,25-,26+,30-/m1/s1",(R)-3-hydroxydecanoyl-CoA,MetaCyc accession,CPD-12777
4319,74274,dextromoramide,"An N-acylpyrrolidine arising by formal condensation of pyrrolidine with (3S)-3-methyl-4-(morpholin-4-yl)-2,2-diphenylbutanoic acid. An opioid analgesic that is structurally related to methadone, it is more poweful than morphine but shorter acting. It has been used (particularly as the hydrogen tartrate salt) for the treatment of severe pain, but was discontinued in the UK in 2004.","InChI=1S/C25H32N2O2/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27/h2-7,10-13,21H,8-9,14-20H2,1H3/t21-/m1/s1",SKF-5137,CAS Registry Number,357-56-2
4320,74276,(R)-3-hydroxylauroyl-CoA(4-),An (R)-3-hydroxyacyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (R)-3-hydroxylauroyl-CoA.,"InChI=1S/C33H58N7O18P3S/c1-4-5-6-7-8-9-10-11-21(41)16-24(43)62-15-14-35-23(42)12-13-36-31(46)28(45)33(2,3)18-55-61(52,53)58-60(50,51)54-17-22-27(57-59(47,48)49)26(44)32(56-22)40-20-39-25-29(34)37-19-38-30(25)40/h19-22,26-28,32,41,44-45H,4-18H2,1-3H3,(H,35,42)(H,36,46)(H,50,51)(H,52,53)(H2,34,37,38)(H2,47,48,49)/p-4/t21-,22-,26-,27-,28+,32-/m1/s1",(R)-3-hydroxylauroyl-CoA,MetaCyc accession,CPD-14918
4321,74277,(R)-3-hydroxytetradecanoyl-CoA(4-),A 3-hydroxy fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (R)-3-hydroxytetradecanoyl-CoA.,"InChI=1S/C35H62N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-23(43)18-26(45)64-17-16-37-25(44)14-15-38-33(48)30(47)35(2,3)20-57-63(54,55)60-62(52,53)56-19-24-29(59-61(49,50)51)28(46)34(58-24)42-22-41-27-31(36)39-21-40-32(27)42/h21-24,28-30,34,43,46-47H,4-20H2,1-3H3,(H,37,44)(H,38,48)(H,52,53)(H,54,55)(H2,36,39,40)(H2,49,50,51)/p-4/t23-,24-,28-,29-,30+,34-/m1/s1",(R)-3-hydroxytetradecanoyl-CoA,MetaCyc accession,CPD-14923
4322,74278,(R)-3-hydroxypalmitoyl-CoA(4-),A 3-hydroxy fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (R)-3-hydroxypalmitoyl-CoA.,"InChI=1S/C37H66N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-25(45)20-28(47)66-19-18-39-27(46)16-17-40-35(50)32(49)37(2,3)22-59-65(56,57)62-64(54,55)58-21-26-31(61-63(51,52)53)30(48)36(60-26)44-24-43-29-33(38)41-23-42-34(29)44/h23-26,30-32,36,45,48-49H,4-22H2,1-3H3,(H,39,46)(H,40,50)(H,54,55)(H,56,57)(H2,38,41,42)(H2,51,52,53)/p-4/t25-,26-,30-,31-,32+,36-/m1/s1",(R)-3-hydroxypalmitoyl-CoA,MetaCyc accession,CPD-14920
4323,74279,(R)-3-hydroxyoctanoyl-CoA(4-),An (R)-3-hydroxyacyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (R)-3-hydroxyoctanoyl-CoA.,"InChI=1S/C29H50N7O18P3S/c1-4-5-6-7-17(37)12-20(39)58-11-10-31-19(38)8-9-32-27(42)24(41)29(2,3)14-51-57(48,49)54-56(46,47)50-13-18-23(53-55(43,44)45)22(40)28(52-18)36-16-35-21-25(30)33-15-34-26(21)36/h15-18,22-24,28,37,40-41H,4-14H2,1-3H3,(H,31,38)(H,32,42)(H,46,47)(H,48,49)(H2,30,33,34)(H2,43,44,45)/p-4/t17-,18-,22-,23-,24+,28-/m1/s1",(R)-3-hydroxyoctanoyl-CoA,MetaCyc accession,CPD-14916
4324,74280,(R)-3-hydroxyhexanoyl-CoA(4-),A 3-hydroxy fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (R)-3-hydroxyoctanoyl-CoA.,"InChI=1S/C27H46N7O18P3S/c1-4-5-15(35)10-18(37)56-9-8-29-17(36)6-7-30-25(40)22(39)27(2,3)12-49-55(46,47)52-54(44,45)48-11-16-21(51-53(41,42)43)20(38)26(50-16)34-14-33-19-23(28)31-13-32-24(19)34/h13-16,20-22,26,35,38-39H,4-12H2,1-3H3,(H,29,36)(H,30,40)(H,44,45)(H,46,47)(H2,28,31,32)(H2,41,42,43)/p-4/t15-,16-,20-,21-,22+,26-/m1/s1",(R)-3-hydroxyhexanoyl-CoA,MetaCyc accession,CPD-14915
4325,74322,"4,8,12-trimethyltrideca 1,3,7,11-tetraene","A sesquiterpene that is trideca 1,3,7,11-tetraene bearing three methyl substituents at poitions 4, 8 and 12 (the 3E,7E-geoisomer).","InChI=1S/C16H26/c1-6-9-15(4)12-8-13-16(5)11-7-10-14(2)3/h6,9-10,13H,1,7-8,11-12H2,2-5H3/b15-9+,16-13+",TMTT,Reaxys Registry Number,2074479
4326,74326,Ile-Tyr,A dipeptide formed from L-isoleucine and L-tyrosine residues.,"InChI=1S/C15H22N2O4/c1-3-9(2)13(16)14(19)17-12(15(20)21)8-10-4-6-11(18)7-5-10/h4-7,9,12-13,18H,3,8,16H2,1-2H3,(H,17,19)(H,20,21)/t9-,12-,13-/m0/s1",isoleucyltyrosine,Reaxys Registry Number,3215972
4327,74327,Ile-Val,A dipeptide formed from L-isoleucine and L-valine residues.,"InChI=1S/C11H22N2O3/c1-5-7(4)8(12)10(14)13-9(6(2)3)11(15)16/h6-9H,5,12H2,1-4H3,(H,13,14)(H,15,16)/t7-,8-,9-/m0/s1",IV,Reaxys Registry Number,4418289
4328,74330,"lysophosphatidic acid 0:0/18:2(9Z,12Z)","A 2-acyl-sn-glycerol 3-phosphate having (9Z,12Z)-octadeca-9,12-dienoyl as the 2-O-acyl group.","InChI=1S/C21H39O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)28-20(18-22)19-27-29(24,25)26/h6-7,9-10,20,22H,2-5,8,11-19H2,1H3,(H2,24,25,26)/b7-6-,10-9-/t20-/m1/s1","LPA(0:0/18:2(9Z,12Z))",HMDB accession,HMDB0007852
4329,74343,1-meadoyl-sn-glycero-3-phosphocholine,"A lysophosphatidylcholine 20:3 in which the acyl group at position 1 is (5Z,8Z,11Z)-icosatrienoyl (meadoyl) and the hydroxy group at position 2 is unsubstituted.","InChI=1S/C28H52NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-28(31)34-25-27(30)26-36-37(32,33)35-24-23-29(2,3)4/h12-13,15-16,18-19,27,30H,5-11,14,17,20-26H2,1-4H3/b13-12-,16-15-,19-18-/t27-/m1/s1","LPC(20:3(5Z,8Z,11Z)/0:0)",HMDB accession,HMDB0010393
4330,74344,1-arachidonoyl-sn-glycero-3-phosphocholine,"A lysophosphatidylcholine 20:4 in which the acyl group at position 1 is (5Z,8Z,11Z,14Z)-icosatetraenoyl (arachidonoyl) and the hydroxy group at position 2 is unsubstituted.","InChI=1S/C28H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-28(31)34-25-27(30)26-36-37(32,33)35-24-23-29(2,3)4/h9-10,12-13,15-16,18-19,27,30H,5-8,11,14,17,20-26H2,1-4H3/b10-9-,13-12-,16-15-,19-18-/t27-/m1/s1","LPC 20:4(5Z,8Z,11Z,14Z)/0:0",LIPID MAPS instance accession,LMGP01050048
4331,74357,S-methyl methanethiosulfonate,A sulfonic acid derivative obtained by condensaton of methanesulfonic acid with methanethiol.,"InChI=1S/C2H6O2S2/c1-5-6(2,3)4/h1-2H3",methyl methanethiolsulfonate,CAS Registry Number,2949-92-0
4332,74395,(11E)-octadecenoyl-CoA,An octadecenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (11E)-octadecenoic acid.,"InChI=1S/C39H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h9-10,26-28,32-34,38,49-50H,4-8,11-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/b10-9+/t28-,32-,33-,34+,38-/m1/s1",(11E)-octadecenoyl-coenzyme A,CAS Registry Number,13673-88-6
4333,74396,"(9Z,11E)-octadecadienoyl-CoA","An octadecadienoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z,11E)-octadecadienoic acid.","InChI=1S/C39H66N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h9-12,26-28,32-34,38,49-50H,4-8,13-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/b10-9+,12-11-/t28-,32-,33-,34+,38-/m1/s1","(9Z,11E)-octadecadienoyl-coenzyme A",PubMed citation,10872837
4334,74397,heptadecanoyl-CoA,"A long-chain  fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of heptadecanoic acid,","InChI=1S/C38H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-29(47)66-22-21-40-28(46)19-20-41-36(50)33(49)38(2,3)24-59-65(56,57)62-64(54,55)58-23-27-32(61-63(51,52)53)31(48)37(60-27)45-26-44-30-34(39)42-25-43-35(30)45/h25-27,31-33,37,48-49H,4-24H2,1-3H3,(H,40,46)(H,41,50)(H,54,55)(H,56,57)(H2,39,42,43)(H2,51,52,53)/t27-,31-,32-,33+,37-/m1/s1",heptadecanoyl-coenzyme A,CAS Registry Number,3546-17-6
4335,74405,(R)-3-hydroxydecanoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxydecanoic acid.,"InChI=1S/C31H54N7O18P3S/c1-4-5-6-7-8-9-19(39)14-22(41)60-13-12-33-21(40)10-11-34-29(44)26(43)31(2,3)16-53-59(50,51)56-58(48,49)52-15-20-25(55-57(45,46)47)24(42)30(54-20)38-18-37-23-27(32)35-17-36-28(23)38/h17-20,24-26,30,39,42-43H,4-16H2,1-3H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t19-,20-,24-,25-,26+,30-/m1/s1",(R)-3-hydroxydecanoyl-coenzyme A,MetaCyc accession,CPD-12777
4336,74434,"N(2),N(2),N(7)-trimethylguanosine 5'-phosphate(1-)","An organophosphate oxoanion that is the conjugate base of N(2),N(2),N(7)-trimethylguanosine 5'-phosphate.","InChI=1S/C13H20N5O8P/c1-16(2)13-14-10-7(11(21)15-13)17(3)5-18(10)12-9(20)8(19)6(26-12)4-25-27(22,23)24/h5-6,8-9,12,19-20H,4H2,1-3H3,(H2-,14,15,21,22,23,24)/p-1/t6-,8-,9-,12-/m1/s1","2,2,7-trimethylguanosine 5'-phosphate(1-)",PubMed citation,15383679
4337,74451,(R)-3-hydroxylauroyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxydodecanoic acid.,"InChI=1S/C33H58N7O18P3S/c1-4-5-6-7-8-9-10-11-21(41)16-24(43)62-15-14-35-23(42)12-13-36-31(46)28(45)33(2,3)18-55-61(52,53)58-60(50,51)54-17-22-27(57-59(47,48)49)26(44)32(56-22)40-20-39-25-29(34)37-19-38-30(25)40/h19-22,26-28,32,41,44-45H,4-18H2,1-3H3,(H,35,42)(H,36,46)(H,50,51)(H,52,53)(H2,34,37,38)(H2,47,48,49)/t21-,22-,26-,27-,28+,32-/m1/s1",(R)-3-hydroxydodecanoyl-coenzyme A,MetaCyc accession,CPD-14918
4338,74458,(R)-3-hydroxytetradecanoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxytetradecanoic acid.,"InChI=1S/C35H62N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-23(43)18-26(45)64-17-16-37-25(44)14-15-38-33(48)30(47)35(2,3)20-57-63(54,55)60-62(52,53)56-19-24-29(59-61(49,50)51)28(46)34(58-24)42-22-41-27-31(36)39-21-40-32(27)42/h21-24,28-30,34,43,46-47H,4-20H2,1-3H3,(H,37,44)(H,38,48)(H,52,53)(H,54,55)(H2,36,39,40)(H2,49,50,51)/t23-,24-,28-,29-,30+,34-/m1/s1",(R)-3-hydroxymyristoyl-CoA,MetaCyc accession,CPD-14923
4339,74459,(R)-3-hydroxypalmitoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxypalmitic acid.,"InChI=1S/C37H66N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-25(45)20-28(47)66-19-18-39-27(46)16-17-40-35(50)32(49)37(2,3)22-59-65(56,57)62-64(54,55)58-21-26-31(61-63(51,52)53)30(48)36(60-26)44-24-43-29-33(38)41-23-42-34(29)44/h23-26,30-32,36,45,48-49H,4-22H2,1-3H3,(H,39,46)(H,40,50)(H,54,55)(H,56,57)(H2,38,41,42)(H2,51,52,53)/t25-,26-,30-,31-,32+,36-/m1/s1",(R)-3-hydroxypalmitoyl-coenzyme A,MetaCyc accession,CPD-14920
4340,74474,(R)-3-hydroxyhexanoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxyhexanoic acid.,"InChI=1S/C27H46N7O18P3S/c1-4-5-15(35)10-18(37)56-9-8-29-17(36)6-7-30-25(40)22(39)27(2,3)12-49-55(46,47)52-54(44,45)48-11-16-21(51-53(41,42)43)20(38)26(50-16)34-14-33-19-23(28)31-13-32-24(19)34/h13-16,20-22,26,35,38-39H,4-12H2,1-3H3,(H,29,36)(H,30,40)(H,44,45)(H,46,47)(H2,28,31,32)(H2,41,42,43)/t15-,16-,20-,21-,22+,26-/m1/s1",(R)-3-hydroxyhexanoyl-coenzyme A,MetaCyc accession,CPD-14915
4341,74475,hexadecanamide,A fatty amide that is the carboxamide derived from palmitic acid.,"InChI=1S/C16H33NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H2,17,18)",palmitic amide,LIPID MAPS instance accession,LMFA08010009
4342,74490,"1-(6Z,9Z,12Z,15Z)-octadecatetraenoyl-2(15Z)-tetracosenoyl-sn-glycero-3-phosphoethanolamine","A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as (6Z,9Z,12Z,15Z)-octadecatetraenoyl and (15Z)-tetracosenoyl respectively.","InChI=1S/C47H84NO8P/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-26-28-30-32-34-36-38-40-47(50)56-45(44-55-57(51,52)54-42-41-48)43-53-46(49)39-37-35-33-31-29-27-25-18-16-14-12-10-8-6-4-2/h6,8,12,14,17-19,25,29,31,45H,3-5,7,9-11,13,15-16,20-24,26-28,30,32-44,48H2,1-2H3,(H,51,52)/b8-6-,14-12-,19-17-,25-18-,31-29-/t45-/m1/s1","GPEtn(18:4(6Z,9Z,12Z,15Z)/24:1(15Z))",HMDB accession,HMDB0009212
4343,74527,Leu-beta-Ala,A dipeptide formed from L-leucine and beta-alanine residues.,"InChI=1S/C9H18N2O3/c1-6(2)5-7(10)9(14)11-4-3-8(12)13/h6-7H,3-5,10H2,1-2H3,(H,11,14)(H,12,13)/t7-/m0/s1",leucyl-beta-alanine,Reaxys Registry Number,1709540
4344,74531,Leu-Glu,A dipeptide formed from L-leucine and L-glutamic acid residues.,"InChI=1S/C11H20N2O5/c1-6(2)5-7(12)10(16)13-8(11(17)18)3-4-9(14)15/h6-8H,3-5,12H2,1-2H3,(H,13,16)(H,14,15)(H,17,18)/t7-,8-/m0/s1",LE,Reaxys Registry Number,1729058
4345,74534,Leu-Gly,A dipeptide formed from L-leucine and glycine residues.,"InChI=1S/C8H16N2O3/c1-5(2)3-6(9)8(13)10-4-7(11)12/h5-6H,3-4,9H2,1-2H3,(H,10,13)(H,11,12)/t6-/m0/s1",L-Leu-Gly,Reaxys Registry Number,1725452
4346,74538,Leu-Gly-Gly,A tripeptide composed of one L-leucine and two glycine residues joined in sequence.,"InChI=1S/C10H19N3O4/c1-6(2)3-7(11)10(17)13-4-8(14)12-5-9(15)16/h6-7H,3-5,11H2,1-2H3,(H,12,14)(H,13,17)(H,15,16)/t7-/m0/s1",leucylglycylglycine,Reaxys Registry Number,1728928
4347,74539,Leu-His,A dipeptide formed from L-leucine and L-histidine residues.,"InChI=1S/C12H20N4O3/c1-7(2)3-9(13)11(17)16-10(12(18)19)4-8-5-14-6-15-8/h5-7,9-10H,3-4,13H2,1-2H3,(H,14,15)(H,16,17)(H,18,19)/t9-,10-/m0/s1",LH,Reaxys Registry Number,89792
4348,74540,Leu-Ile,A dipeptide formed from L-leucine and L-isoleucine residues.,"InChI=1S/C12H24N2O3/c1-5-8(4)10(12(16)17)14-11(15)9(13)6-7(2)3/h7-10H,5-6,13H2,1-4H3,(H,14,15)(H,16,17)/t8-,9-,10-/m0/s1",LI,Reaxys Registry Number,1727905
4349,74541,Leu-Leu-Leu,A tripeptide formed from three L-leucine residues.,"InChI=1S/C18H35N3O4/c1-10(2)7-13(19)16(22)20-14(8-11(3)4)17(23)21-15(18(24)25)9-12(5)6/h10-15H,7-9,19H2,1-6H3,(H,20,22)(H,21,23)(H,24,25)/t13-,14-,15-/m0/s1",L-Leu-L-Leu-L-Leu,CAS Registry Number,10329-75-6
4350,74542,trichloroethyl beta-D-glucoside,"A beta-D-glucoside in which the anomeric substituent is specified as 2,2,2-trichloroethyl.","InChI=1S/C8H13Cl3O6/c9-8(10,11)2-16-7-6(15)5(14)4(13)3(1-12)17-7/h3-7,12-15H,1-2H2/t3-,4-,5+,6-,7-/m1/s1","2,2,2-trichloroethyl beta-D-glucoside",Reaxys Registry Number,11756
4351,74553,Lys-Arg,A dipeptide formed from L-lysine and L-arginine residues.,"InChI=1S/C12H26N6O3/c13-6-2-1-4-8(14)10(19)18-9(11(20)21)5-3-7-17-12(15)16/h8-9H,1-7,13-14H2,(H,18,19)(H,20,21)(H4,15,16,17)/t8-,9-/m0/s1",L-Lys-L-Arg,HMDB accession,HMDB0028945
4352,74557,Lys-Glu,A dipeptide formed from L-lysine and L-glutamic acid residues.,"InChI=1S/C11H21N3O5/c12-6-2-1-3-7(13)10(17)14-8(11(18)19)4-5-9(15)16/h7-8H,1-6,12-13H2,(H,14,17)(H,15,16)(H,18,19)/t7-,8-/m0/s1",KE,Reaxys Registry Number,1729400
4353,74559,Lys-Ile,A dipeptide formed from L-lysine and L-isoleucine residues.,"InChI=1S/C12H25N3O3/c1-3-8(2)10(12(17)18)15-11(16)9(14)6-4-5-7-13/h8-10H,3-7,13-14H2,1-2H3,(H,15,16)(H,17,18)/t8-,9-,10-/m0/s1",L-Lys-L-Ile,Reaxys Registry Number,10274329
4354,74561,Lys-Leu,A dipeptide formed from L-lysine and L-leucine residues.,"InChI=1S/C12H25N3O3/c1-8(2)7-10(12(17)18)15-11(16)9(14)5-3-4-6-13/h8-10H,3-7,13-14H2,1-2H3,(H,15,16)(H,17,18)/t9-,10-/m0/s1",L-Lys-L-Leu,Reaxys Registry Number,2377223
4355,74564,Lys-Lys,A dipeptide formed from two L-lysine residues.,"InChI=1S/C12H26N4O3/c13-7-3-1-5-9(15)11(17)16-10(12(18)19)6-2-4-8-14/h9-10H,1-8,13-15H2,(H,16,17)(H,18,19)/t9-,10-/m0/s1",L-Lys-L-Lys,Reaxys Registry Number,1729029
4356,74566,Lys-Met,A dipeptide formed from L-lysine and L-methionine residues.,"InChI=1S/C11H23N3O3S/c1-18-7-5-9(11(16)17)14-10(15)8(13)4-2-3-6-12/h8-9H,2-7,12-13H2,1H3,(H,14,15)(H,16,17)/t8-,9-/m0/s1",KM,Reaxys Registry Number,14755408
4357,74567,Lys-Pro,A dipeptide formed from L-lysine and L-proline residues.,"InChI=1S/C11H21N3O3/c12-6-2-1-4-8(13)10(15)14-7-3-5-9(14)11(16)17/h8-9H,1-7,12-13H2,(H,16,17)/t8-,9-/m0/s1",lysylproline,Reaxys Registry Number,5556824
4358,74568,Lys-Ser,A dipeptide formed from L-lysine and L-serine residues.,"InChI=1S/C9H19N3O4/c10-4-2-1-3-6(11)8(14)12-7(5-13)9(15)16/h6-7,13H,1-5,10-11H2,(H,12,14)(H,15,16)/t6-,7-/m0/s1",L-Lys-L-Ser,Reaxys Registry Number,2457960
4359,74569,Lys-Trp,A dipeptide formed from L-lysine and L-tryptophan residues.,"InChI=1S/C17H24N4O3/c18-8-4-3-6-13(19)16(22)21-15(17(23)24)9-11-10-20-14-7-2-1-5-12(11)14/h1-2,5,7,10,13,15,20H,3-4,6,8-9,18-19H2,(H,21,22)(H,23,24)/t13-,15-/m0/s1",lysyltryptophan,Reaxys Registry Number,4884758
4360,74574,pentadecanoyl-CoA,A long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of pentadecanoic acid.,"InChI=1S/C36H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-27(45)64-20-19-38-26(44)17-18-39-34(48)31(47)36(2,3)22-57-63(54,55)60-62(52,53)56-21-25-30(59-61(49,50)51)29(46)35(58-25)43-24-42-28-32(37)40-23-41-33(28)43/h23-25,29-31,35,46-47H,4-22H2,1-3H3,(H,38,44)(H,39,48)(H,52,53)(H,54,55)(H2,37,40,41)(H2,49,50,51)/t25-,29-,30-,31+,35-/m1/s1",pentadecanoyl-coenzyme A,MetaCyc accession,CPD-14724
4361,74606,"(11Z,14Z,17Z)-icosatrienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (11Z,14Z,17Z)-icosatrienoic acid.","InChI=1S/C41H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-32(50)69-25-24-43-31(49)22-23-44-39(53)36(52)41(2,3)27-62-68(59,60)65-67(57,58)61-26-30-35(64-66(54,55)56)34(51)40(63-30)48-29-47-33-37(42)45-28-46-38(33)48/h5-6,8-9,11-12,28-30,34-36,40,51-52H,4,7,10,13-27H2,1-3H3,(H,43,49)(H,44,53)(H,57,58)(H,59,60)(H2,42,45,46)(H2,54,55,56)/b6-5-,9-8-,12-11-/t30-,34-,35-,36+,40-/m1/s1",cis-(omega-3)-icosatrienoyl-CoA,LIPID MAPS instance accession,LMFA07050044
4362,74621,5-oxo-delta-bilirubin,A biladiene that is the 5-oxo derivative of delta-bilirubin (more correctly known as 10-oxo-delta-bilirubin; see comment).,"InChI=1S/C33H34N4O7/c1-7-19-17(5)32(43)36-24(19)13-23-15(3)20(8-2)30(34-23)31(42)29-16(4)21(9-11-27(38)39)25(35-29)14-26-22(10-12-28(40)41)18(6)33(44)37-26/h7-8,13-14,34-35H,1-2,9-12H2,3-6H3,(H,36,43)(H,37,44)(H,38,39)(H,40,41)/b24-13-,26-14-",10-oxo-delta-bilirubin,PubMed citation,20180905
4363,74631,cysteamine S-phosphate(2-),"An organic phosphorothioate anion that is the conjugate base of cysteamine S-phosphate, obtained by deprotonation of the two free thiophosohate OH groups and protonation of the amino group.","InChI=1S/C2H8NO3PS/c3-1-2-8-7(4,5)6/h1-3H2,(H2,4,5,6)/p-1",phosphocysteamine,MetaCyc accession,CPD-3721
4364,74637,N(6)-L-threonylcarbamoyladenine 5'-monophosphate,A nucleotide-amino acid that is the N(6)-L-threonylcarbamoyl derivative of adenine 5'-monophosphate.,"InChI=1S/C15H21N6O11P/c1-5(22)7(14(25)26)19-15(27)20-11-8-12(17-3-16-11)21(4-18-8)13-10(24)9(23)6(32-13)2-31-33(28,29)30/h3-7,9-10,13,22-24H,2H2,1H3,(H,25,26)(H2,28,29,30)(H2,16,17,19,20,27)/t5-,6-,7+,9-,10-,13-/m1/s1",N(6)-L-threonylcarbamoyl-AMP,Reaxys Registry Number,23125542
4365,74646,2-methylthio-N(6)-dimethylallyladenine 5'-monophosphate,A purine ribonucleoside 5'-monophosphate that is AMP substituted at C-2 by a methylthio group and at N-6 by a dimethylallyl group.,"InChI=1S/C16H24N5O7PS/c1-8(2)4-5-17-13-10-14(20-16(19-13)30-3)21(7-18-10)15-12(23)11(22)9(28-15)6-27-29(24,25)26/h4,7,9,11-12,15,22-23H,5-6H2,1-3H3,(H,17,19,20)(H2,24,25,26)/t9-,11-,12-,15-/m1/s1",2-methylthio-N(6)-(Delta(2)-isopentenyl)-5'-adenylic acid,PDBeChem accession,MIA
4366,74651,2-methylthio-N(6)-L-threonylcarbamoyladenine 5'-monophosphate,A nucleotide-amino acid that is the N(6)-L-threonylcarbamoyl derivative of 2-methylthioadenine 5'-monophosphate.,"InChI=1S/C16H23N6O11PS/c1-5(23)7(14(26)27)18-15(28)19-11-8-12(21-16(20-11)35-2)22(4-17-8)13-10(25)9(24)6(33-13)3-32-34(29,30)31/h4-7,9-10,13,23-25H,3H2,1-2H3,(H,26,27)(H2,29,30,31)(H2,18,19,20,21,28)/t5-,6-,7+,9-,10-,13-/m1/s1","(2S,3R)-2-({[9-{(2R,3R,4S,5R)-3,4-dihydroxy-5-[(phosphonooxy)methyl]tetrahydrofuran-2-yl}-2-(methylsulfanyl)-9H-purin-6-yl]carbamoyl}amino)-3-hydroxybutanoic acid",PDBeChem accession,12A
4367,74656,O(4)-phosphonato-D-tyrosine(2-),An optically active form of O(4)-phosphonatotyrosine(2-) having D-configuration.,"InChI=1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)/p-2/t8-/m1/s1",O-phospho-D-tyrosine(2-),MetaCyc accession,CPD-3729
4368,74698,Met-Arg,A dipeptide formed from L-methionine and L-arginine residues.,"InChI=1S/C11H23N5O3S/c1-20-6-4-7(12)9(17)16-8(10(18)19)3-2-5-15-11(13)14/h7-8H,2-6,12H2,1H3,(H,16,17)(H,18,19)(H4,13,14,15)/t7-,8-/m0/s1",methionylarginine,Reaxys Registry Number,5759785
4369,74699,Met-Asp,A dipeptide formed from L-methionine and L-aspartic acid residues.,"InChI=1S/C9H16N2O5S/c1-17-3-2-5(10)8(14)11-6(9(15)16)4-7(12)13/h5-6H,2-4,10H2,1H3,(H,11,14)(H,12,13)(H,15,16)/t5-,6-/m0/s1",L-Met-L-Asp,Reaxys Registry Number,7030634
4370,74700,Met-beta-Ala,A dipeptide formed from L-methionine and beta-alanine residues.,"InChI=1S/C8H16N2O3S/c1-14-5-3-6(9)8(13)10-4-2-7(11)12/h6H,2-5,9H2,1H3,(H,10,13)(H,11,12)/t6-/m0/s1",L-Met-beta-Ala,Reaxys Registry Number,9053143
4371,74701,Met-Gln,A dipeptide formed from L-methionine and L-glutamine residues.,"InChI=1S/C10H19N3O4S/c1-18-5-4-6(11)9(15)13-7(10(16)17)2-3-8(12)14/h6-7H,2-5,11H2,1H3,(H2,12,14)(H,13,15)(H,16,17)/t6-,7-/m0/s1",methionylglutamine,Reaxys Registry Number,2383476
4372,74702,Met-Glu,A dipeptide formed from L-methionine and L-glutamic acid residues.,"InChI=1S/C10H18N2O5S/c1-18-5-4-6(11)9(15)12-7(10(16)17)2-3-8(13)14/h6-7H,2-5,11H2,1H3,(H,12,15)(H,13,14)(H,16,17)/t6-,7-/m0/s1",ME,Reaxys Registry Number,1714970
4373,74703,Met-His,A dipeptide formed from L-methionine and L-histidine residues.,"InChI=1S/C11H18N4O3S/c1-19-3-2-8(12)10(16)15-9(11(17)18)4-7-5-13-6-14-7/h5-6,8-9H,2-4,12H2,1H3,(H,13,14)(H,15,16)(H,17,18)/t8-,9-/m0/s1",MH,Reaxys Registry Number,10271237
4374,74704,Met-Ile,A dipeptide formed from L-methionine and L-isoleucine residues.,"InChI=1S/C11H22N2O3S/c1-4-7(2)9(11(15)16)13-10(14)8(12)5-6-17-3/h7-9H,4-6,12H2,1-3H3,(H,13,14)(H,15,16)/t7-,8-,9-/m0/s1",methionylisoleucine,Reaxys Registry Number,20424366
4375,74705,Met-Leu,A dipeptide formed from L-methionine and L-leucine residues.,"InChI=1S/C11H22N2O3S/c1-7(2)6-9(11(15)16)13-10(14)8(12)4-5-17-3/h7-9H,4-6,12H2,1-3H3,(H,13,14)(H,15,16)/t8-,9-/m0/s1",L-Met-L-Leu,HMDB accession,HMDB0028977
4376,74706,Met-Lys,A dipeptide formed from L-methionine and L-lysine residues.,"InChI=1S/C11H23N3O3S/c1-18-7-5-8(13)10(15)14-9(11(16)17)4-2-3-6-12/h8-9H,2-7,12-13H2,1H3,(H,14,15)(H,16,17)/t8-,9-/m0/s1",MK,Reaxys Registry Number,7094149
4377,74707,Met-Met,A dipeptide formed from two L-methionine residues.,"InChI=1S/C10H20N2O3S2/c1-16-5-3-7(11)9(13)12-8(10(14)15)4-6-17-2/h7-8H,3-6,11H2,1-2H3,(H,12,13)(H,14,15)/t7-,8-/m0/s1",MM,Reaxys Registry Number,1728608
4378,74708,Met-Phe,A dipeptide formed from L-methionine and L-phenylalanine residues.,"InChI=1S/C14H20N2O3S/c1-20-8-7-11(15)13(17)16-12(14(18)19)9-10-5-3-2-4-6-10/h2-6,11-12H,7-9,15H2,1H3,(H,16,17)(H,18,19)/t11-,12-/m0/s1",MF,HMDB accession,HMDB0028980
4379,74709,Met-Trp,A dipeptide formed from L-methionine and L-tryptophan residues.,"InChI=1S/C16H21N3O3S/c1-23-7-6-12(17)15(20)19-14(16(21)22)8-10-9-18-13-5-3-2-4-11(10)13/h2-5,9,12,14,18H,6-8,17H2,1H3,(H,19,20)(H,21,22)/t12-,14-/m0/s1",methionyltryptophan,Reaxys Registry Number,4884023
4380,74710,Phe-beta-Ala,A dipeptide formed from L-phenylalanine and beta-alanine residues.,"InChI=1S/C12H16N2O3/c13-10(8-9-4-2-1-3-5-9)12(17)14-7-6-11(15)16/h1-5,10H,6-8,13H2,(H,14,17)(H,15,16)/t10-/m0/s1",phenylalanyl-beta-alanine,Reaxys Registry Number,5958709
4381,74712,Phe-Glu,A dipeptide formed from L-phenylalanine and L-glutamic acid residues.,"InChI=1S/C14H18N2O5/c15-10(8-9-4-2-1-3-5-9)13(19)16-11(14(20)21)6-7-12(17)18/h1-5,10-11H,6-8,15H2,(H,16,19)(H,17,18)(H,20,21)/t10-,11-/m0/s1",FE,Reaxys Registry Number,2766969
4382,74714,Phe-Gly-Gly,A tripeptide composed of one L-phenylalanine and two glycine residues joined in sequence.,"InChI=1S/C13H17N3O4/c14-10(6-9-4-2-1-3-5-9)13(20)16-7-11(17)15-8-12(18)19/h1-5,10H,6-8,14H2,(H,15,17)(H,16,20)(H,18,19)/t10-/m0/s1",phenylalanylglycylglycine,Reaxys Registry Number,2167248
4383,74717,Phe-Ile,A dipeptide formed from L-phenylalanine and L-isoleucine residues.,"InChI=1S/C15H22N2O3/c1-3-10(2)13(15(19)20)17-14(18)12(16)9-11-7-5-4-6-8-11/h4-8,10,12-13H,3,9,16H2,1-2H3,(H,17,18)(H,19,20)/t10-,12-,13-/m0/s1",phenylalanylisoleucine,Reaxys Registry Number,4487225
4384,74719,Phe-Met,A dipeptide formed from L-phenylalanine and L-methionine residues.,"InChI=1S/C14H20N2O3S/c1-20-8-7-12(14(18)19)16-13(17)11(15)9-10-5-3-2-4-6-10/h2-6,11-12H,7-9,15H2,1H3,(H,16,17)(H,18,19)/t11-,12-/m0/s1",phenylalanylmethionine,Reaxys Registry Number,2873544
4385,74725,5-methylcytidine 5'-monophosphate,A pyrimidine ribonucleoside 5'-monophosphate having 5-methylcytosine as the nucleobase.,"InChI=1S/C10H16N3O8P/c1-4-2-13(10(16)12-8(4)11)9-7(15)6(14)5(21-9)3-20-22(17,18)19/h2,5-7,9,14-15H,3H2,1H3,(H2,11,12,16)(H2,17,18,19)/t5-,6-,7-,9-/m1/s1",5-methylcytidine 5'-phosphate,DrugBank accession,DB01995
4386,74731,N(3)-methylpseudouridine 5'-monophosphate,"A C-nucleoside phosphate that is pseudouridine 5'-monophosphate, bearing an additional N(3)-methyl substituent.","InChI=1S/C10H15N2O9P/c1-12-9(15)4(2-11-10(12)16)8-7(14)6(13)5(21-8)3-20-22(17,18)19/h2,5-8,13-14H,3H2,1H3,(H,11,16)(H2,17,18,19)/t5-,6-,7-,8+/m1/s1",N(3)-methylpseudouridine 5'-phosphate,PDBeChem accession,3TD
4387,74750,Phe-Pro,A dipeptide formed from L-phenylalanine and L-proline residues.,"InChI=1S/C14H18N2O3/c15-11(9-10-5-2-1-3-6-10)13(17)16-8-4-7-12(16)14(18)19/h1-3,5-6,11-12H,4,7-9,15H2,(H,18,19)/t11-,12-/m0/s1",phenylalanylproline,Reaxys Registry Number,4322003
4388,74753,Pro-Ala,A dipeptide formed from L-proline and L-alanine residues.,"InChI=1S/C8H14N2O3/c1-5(8(12)13)10-7(11)6-3-2-4-9-6/h5-6,9H,2-4H2,1H3,(H,10,11)(H,12,13)/t5-,6-/m0/s1",L-Pro-L-Ala,Reaxys Registry Number,5527167
4389,74754,Pro-Asn,A dipeptide formed from L-proline and L-asparagine residues.,"InChI=1S/C9H15N3O4/c10-7(13)4-6(9(15)16)12-8(14)5-2-1-3-11-5/h5-6,11H,1-4H2,(H2,10,13)(H,12,14)(H,15,16)/t5-,6-/m0/s1",prolylasparagine,Reaxys Registry Number,13311498
4390,74756,Pro-Asp,A dipeptide formed from L-proline and L-aspartic acid residues.,"InChI=1S/C9H14N2O5/c12-7(13)4-6(9(15)16)11-8(14)5-2-1-3-10-5/h5-6,10H,1-4H2,(H,11,14)(H,12,13)(H,15,16)/t5-,6-/m0/s1",PD,Reaxys Registry Number,22125
4391,74757,Pro-Gln,A dipeptide formed from L-proline and L-glutamine residues.,"InChI=1S/C10H17N3O4/c11-8(14)4-3-7(10(16)17)13-9(15)6-2-1-5-12-6/h6-7,12H,1-5H2,(H2,11,14)(H,13,15)(H,16,17)/t6-,7-/m0/s1",PQ,HMDB accession,HMDB0029015
4392,74762,Pro-Glu,A dipeptide formed from L-proline and L-glutamic acid residues.,"InChI=1S/C10H16N2O5/c13-8(14)4-3-7(10(16)17)12-9(15)6-2-1-5-11-6/h6-7,11H,1-5H2,(H,12,15)(H,13,14)(H,16,17)/t6-,7-/m0/s1",L-Pro-L-Glu,Reaxys Registry Number,27399
4393,74765,"1,5-dimethyluracil",A pyrimidone that is uracil with methyl group substituents at positions 1 and 5.,"InChI=1S/C6H8N2O2/c1-4-3-8(2)6(10)7-5(4)9/h3H,1-2H3,(H,7,9,10)",1-methylthymine,CAS Registry Number,4160-72-9
4394,74774,5-[2-(feruloyl)ethen-1-yl]thalidomide,"A dicarboximide that is  thalidomide substituted at position 5 by an ethenyl group, which in turn is substituted by a feruloyl group at position 2. The compound is a hybrid based on the structures of  thalidomide and curcumin and has been found to exhibit cytotoxicity against human multiple myeloma cells.","InChI=1S/C25H20N2O7/c1-34-21-13-15(5-10-20(21)29)3-7-16(28)6-2-14-4-8-17-18(12-14)25(33)27(24(17)32)19-9-11-22(30)26-23(19)31/h2-8,10,12-13,19,29H,9,11H2,1H3,(H,26,30,31)/b6-2+,7-3+","5-[(1E,4E)-5-(4-hydroxy-3-methoxyphenyl)-3-oxopenta-1,4-dien-1-yl]thalidomide",PubMed citation,23784627
4395,74775,"5-(2,2-diferuloylethen-1-yl)thalidomide","A dicarboximide that is thalidomide substituted at position 5 by an ethenyl group, which in turn is substituted by two feruloyl groups at position 2. The compound is a hybrid based on the structures of thalidomide and curcumin and has been found to exhibit cytotoxicity against human multiple myeloma cells.","InChI=1S/C35H28N2O10/c1-46-30-17-19(6-12-28(30)40)4-10-26(38)24(27(39)11-5-20-7-13-29(41)31(18-20)47-2)16-21-3-8-22-23(15-21)35(45)37(34(22)44)25-9-14-32(42)36-33(25)43/h3-8,10-13,15-18,25,40-41H,9,14H2,1-2H3,(H,36,42,43)/b10-4+,11-5+","5-{(4E)-5-(4-hydroxy-3-methoxyphenyl)-2-[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]-3-oxopenta-1,4-dien-1-yl}thalidomide",PubMed citation,23784627
4396,74778,N(4)-methylcytidine 5'-monophosphate,A pyrimidine ribonucleoside 5'-monophosphate having N(4)-methylcytosine as the nucleobase.,"InChI=1S/C10H16N3O8P/c1-11-6-2-3-13(10(16)12-6)9-8(15)7(14)5(21-9)4-20-22(17,18)19/h2-3,5,7-9,14-15H,4H2,1H3,(H,11,12,16)(H2,17,18,19)/t5-,7-,8-,9-/m1/s1",N(4)-methylcytidine 5'-phosphate,Reaxys Registry Number,627460
4397,74779,aluminium sulfate octadecahydrate,A hydrate resulting from the the formal combination of anhydrous aluminium sulfate with approximately 18 mol eq. of water. The commercial product usually contains 5-10% less water than theory. It is one of the commonest hydrates of aluminium sulfate.,"InChI=1S/2Al.3H2O4S.18H2O/c;;3*1-5(2,3)4;;;;;;;;;;;;;;;;;;/h;;3*(H2,1,2,3,4);18*1H2/q2*+3;;;;;;;;;;;;;;;;;;;;;/p-6",Al2(SO4)3.18H2O,CAS Registry Number,7784-31-8
4398,74788,8-methyladenosine 5'-monophosphate,A purine ribonucleoside 5'-monophosphate having 8-methyladenine as the nucleobase.,"InChI=1S/C11H16N5O7P/c1-4-15-6-9(12)13-3-14-10(6)16(4)11-8(18)7(17)5(23-11)2-22-24(19,20)21/h3,5,7-8,11,17-18H,2H2,1H3,(H2,12,13,14)(H2,19,20,21)/t5-,7-,8-,11-/m1/s1",8-methyladenosine 5'-phosphate,Reaxys Registry Number,944441
4399,74790,Pro-Ile,A dipeptide formed from L-proline and L-isoleucine residues.,"InChI=1S/C11H20N2O3/c1-3-7(2)9(11(15)16)13-10(14)8-5-4-6-12-8/h7-9,12H,3-6H2,1-2H3,(H,13,14)(H,15,16)/t7-,8-,9-/m0/s1",prolylisoleucine,Reaxys Registry Number,6403534
4400,74791,Pro-Leu,A dipeptide formed from L-proline and L-leucine residues.,"InChI=1S/C11H20N2O3/c1-7(2)6-9(11(15)16)13-10(14)8-4-3-5-12-8/h7-9,12H,3-6H2,1-2H3,(H,13,14)(H,15,16)/t8-,9-/m0/s1",prolylleucine,Reaxys Registry Number,4254117
4401,74792,Pro-Lys,A dipeptide formed from L-proline and L-lysine residues.,"InChI=1S/C11H21N3O3/c12-6-2-1-4-9(11(16)17)14-10(15)8-5-3-7-13-8/h8-9,13H,1-7,12H2,(H,14,15)(H,16,17)/t8-,9-/m0/s1",L-Pro-L-Lys,Reaxys Registry Number,6865854
4402,74795,Pro-Phe,A dipeptide formed from L-proline and L-phenylalanine residues.,"InChI=1S/C14H18N2O3/c17-13(11-7-4-8-15-11)16-12(14(18)19)9-10-5-2-1-3-6-10/h1-3,5-6,11-12,15H,4,7-9H2,(H,16,17)(H,18,19)/t11-,12-/m0/s1",L-Pro-L-Phe,HMDB accession,HMDB0011179
4403,74797,Pro-Trp,A dipeptide formed from L-proline and L-tryptophan residues.,"InChI=1S/C16H19N3O3/c20-15(13-6-3-7-17-13)19-14(16(21)22)8-10-9-18-12-5-2-1-4-11(10)12/h1-2,4-5,9,13-14,17-18H,3,6-8H2,(H,19,20)(H,21,22)/t13-,14-/m0/s1",prolyltryptophan,Reaxys Registry Number,4762691
4404,74798,O-methylserine,A serine derivative that is L-serine with a methyl group replacing the hydrogen on the hydroxy side chain.,"InChI=1S/C4H9NO3/c1-8-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1",O-methyl-L-Ser,PubMed citation,4854587
4405,74799,Pro-Tyr,A dipeptide formed from L-proline and L-tyrosine residues.,"InChI=1S/C14H18N2O4/c17-10-5-3-9(4-6-10)8-12(14(19)20)16-13(18)11-2-1-7-15-11/h3-6,11-12,15,17H,1-2,7-8H2,(H,16,18)(H,19,20)/t11-,12-/m0/s1",PY,Reaxys Registry Number,91215
4406,74800,Pro-Val,A dipeptide formed from L-proline and L-valine residues.,"InChI=1S/C10H18N2O3/c1-6(2)8(10(14)15)12-9(13)7-4-3-5-11-7/h6-8,11H,3-5H2,1-2H3,(H,12,13)(H,14,15)/t7-,8-/m0/s1",prolylvaline,Reaxys Registry Number,4442146
4407,74801,Ser-Ala,A dipeptide formed from L-serine and L-alanine residues.,"InChI=1S/C6H12N2O4/c1-3(6(11)12)8-5(10)4(7)2-9/h3-4,9H,2,7H2,1H3,(H,8,10)(H,11,12)/t3-,4-/m0/s1",L-Ser-L-Ala,Reaxys Registry Number,1725823
4408,74802,Ser-Asn,A dipeptide formed from L-serine and L-asparagine residues.,"InChI=1S/C7H13N3O5/c8-3(2-11)6(13)10-4(7(14)15)1-5(9)12/h3-4,11H,1-2,8H2,(H2,9,12)(H,10,13)(H,14,15)/t3-,4-/m0/s1",SN,Reaxys Registry Number,5537349
4409,74807,Ser-Asp,A dipeptide formed from L-serine and L-aspartic acid residues.,"InChI=1S/C7H12N2O6/c8-3(2-10)6(13)9-4(7(14)15)1-5(11)12/h3-4,10H,1-2,8H2,(H,9,13)(H,11,12)(H,14,15)/t3-,4-/m0/s1",SD,Reaxys Registry Number,1728428
4410,74808,Ser-Gln,A dipeptide formed from L-serine and L-glutamine residues.,"InChI=1S/C8H15N3O5/c9-4(3-12)7(14)11-5(8(15)16)1-2-6(10)13/h4-5,12H,1-3,9H2,(H2,10,13)(H,11,14)(H,15,16)/t4-,5-/m0/s1",serylglutamine,HMDB accession,HMDB0029037
4411,74813,Ser-Glu,A dipeptide formed from L-serine and L-glutamic acid residues.,"InChI=1S/C8H14N2O6/c9-4(3-11)7(14)10-5(8(15)16)1-2-6(12)13/h4-5,11H,1-3,9H2,(H,10,14)(H,12,13)(H,15,16)/t4-,5-/m0/s1",SE,Reaxys Registry Number,1728923
4412,74814,Ser-Gly,A dipeptide formed from L-serine and glycine residues.,"InChI=1S/C5H10N2O4/c6-3(2-8)5(11)7-1-4(9)10/h3,8H,1-2,6H2,(H,7,11)(H,9,10)/t3-/m0/s1",L-Ser-Gly,Reaxys Registry Number,1724687
4413,74815,Ser-Leu,A dipeptide formed from L-serine and L-leucine residues.,"InChI=1S/C9H18N2O4/c1-5(2)3-7(9(14)15)11-8(13)6(10)4-12/h5-7,12H,3-4,10H2,1-2H3,(H,11,13)(H,14,15)/t6-,7-/m0/s1",serylleucine,Reaxys Registry Number,1727664
4414,74816,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-beta-D-ManpO[CH2]5NH2,"A mannooligosaccharide derivative consisting of a chain of three D-mannose residues linked sequentially alpha(1->2) and alpha(1->3), with an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl unit linked (1->6) to the mannose residue at the reducing end, this reducing-end residue also being beta-linked to a 5-aminopentyl group.","InChI=1S/C35H63NO26/c36-4-2-1-3-5-53-31-27(52)28(60-35-30(24(49)19(44)14(9-40)58-35)62-33-26(51)22(47)17(42)12(7-38)56-33)20(45)15(59-31)10-54-34-29(23(48)18(43)13(8-39)57-34)61-32-25(50)21(46)16(41)11(6-37)55-32/h11-35,37-52H,1-10,36H2/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31-,32-,33-,34+,35-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-beta-D-ManpO[CH2]5NH2,PubMed citation,16174734
4415,74817,Ser-Met,A dipeptide formed from L-serine and L-methionine residues.,"InChI=1S/C8H16N2O4S/c1-15-3-2-6(8(13)14)10-7(12)5(9)4-11/h5-6,11H,2-4,9H2,1H3,(H,10,12)(H,13,14)/t5-,6-/m0/s1",SM,CAS Registry Number,3227-09-6
4416,74820,Ser-Pro,A dipeptide formed from L-serine and L-proline residues.,"InChI=1S/C8H14N2O4/c9-5(4-11)7(12)10-3-1-2-6(10)8(13)14/h5-6,11H,1-4,9H2,(H,13,14)/t5-,6-/m0/s1",L-Ser-L-Pro,Reaxys Registry Number,15214
4417,74823,Ser-Val,A dipeptide formed from L-serine and L-valine residues.,"InChI=1S/C8H16N2O4/c1-4(2)6(8(13)14)10-7(12)5(9)3-11/h4-6,11H,3,9H2,1-2H3,(H,10,12)(H,13,14)/t5-,6-/m0/s1",serylvaline,Reaxys Registry Number,6595936
4418,74824,Thr-Ala,A dipeptide formed from L-threonine and L-alanine residues.,"InChI=1S/C7H14N2O4/c1-3(7(12)13)9-6(11)5(8)4(2)10/h3-5,10H,8H2,1-2H3,(H,9,11)(H,12,13)/t3-,4+,5-/m0/s1",TA,Reaxys Registry Number,4992791
4419,74825,Thr-Arg,A dipeptide formed from L-threonine and L-arginine residues.,"InChI=1S/C10H21N5O4/c1-5(16)7(11)8(17)15-6(9(18)19)3-2-4-14-10(12)13/h5-7,16H,2-4,11H2,1H3,(H,15,17)(H,18,19)(H4,12,13,14)/t5-,6+,7+/m1/s1",L-Thr-L-Arg,Reaxys Registry Number,5756084
4420,74826,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-alpha-D-Manp-(1->6)]-beta-D-ManpO[CH2]5NH2,A mannooligosaccharide derivative consisting of a D-mannosyl residue beta-linked to a 5-aminopentyl group and which carries an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl unit linked (1->3) and an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->3)-alpha-D-mannosyl unit linked (1->6).,"InChI=1S/C47H83NO36/c48-4-2-1-3-5-71-41-34(69)37(81-46-40(31(66)24(59)16(9-52)77-46)84-47-39(30(65)23(58)17(10-53)78-47)83-44-33(68)28(63)21(56)14(7-50)75-44)26(61)19(79-41)12-72-42-35(70)36(25(60)18(11-54)73-42)80-45-38(29(64)22(57)15(8-51)76-45)82-43-32(67)27(62)20(55)13(6-49)74-43/h13-47,49-70H,1-12,48H2/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41-,42+,43-,44-,45-,46-,47-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-alpha-D-Man-(1->6)]-beta-D-ManO[CH2]5NH2,PubMed citation,16174734
4421,74830,1-linoleoyl-2-oleoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as linoleoyl and oleoyl respectively.","InChI=1S/C39H71O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11,13,17-20,37H,3-10,12,14-16,21-36H2,1-2H3,(H2,42,43,44)/b13-11-,19-17-,20-18-/t37-/m1/s1","1-(9Z,12Z)-octadecadienoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010348
4422,74831,1-linolenoyl-sn-glycero-3-phosphate,"A 1-acyl-sn-glycerol 3-phosphate in which the 1-acyl substituent is specified as linolenoyl (9Z,12Z,15Z-octadecatrienoyl).","InChI=1S/C21H37O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)27-18-20(22)19-28-29(24,25)26/h3-4,6-7,9-10,20,22H,2,5,8,11-19H2,1H3,(H2,24,25,26)/b4-3-,7-6-,10-9-/t20-/m1/s1","1-(9Z,12Z,15Z)-octadecatrienoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10050035
4423,74833,1-linolenoyl-2-oleoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as linolenoyl and oleoyl respectively.","InChI=1S/C39H69O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h5,7,11,13,17-20,37H,3-4,6,8-10,12,14-16,21-36H2,1-2H3,(H2,42,43,44)/b7-5-,13-11-,19-17-,20-18-/t37-/m1/s1","1-(9Z,12Z,15Z)-octadecatrienoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010873
4424,74836,1-oleoyl-2-palmitoyl-sn-glycero-3-phosphate,A 1-acyl-2-hexadecanoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as oleoyl (9Z-octadecaenoyl).,"InChI=1S/C37H71O8P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-36(38)43-33-35(34-44-46(40,41)42)45-37(39)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h17-18,35H,3-16,19-34H2,1-2H3,(H2,40,41,42)/b18-17-/t35-/m1/s1",1-(9Z)-octadecenoyl-2-hexadecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010964
4425,74837,9-aminoacridine hydrochloride,A hydrochloride salt resulting from the reaction of equimolar amounts of 9-aminoacridine and hydrogen chloride.,"InChI=1S/C13H10N2.ClH/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;/h1-8H,(H2,14,15);1H",9-aminoacridine HCl,CAS Registry Number,134-50-9
4426,74839,1-oleoyl-2-stearoyl-sn-glycero-3-phosphate,A 1-acyl-2-octadecanoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as oleoyl (9Z-octadecaenoyl).,"InChI=1S/C39H75O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17,19,37H,3-16,18,20-36H2,1-2H3,(H2,42,43,44)/b19-17-/t37-/m1/s1",1-(9Z)-octadecenoyl-2-octadecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010963
4427,74841,1-heptadecanoyl-2-oleoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as heptadecanoyl and oleoyl respectively.","InChI=1S/C38H73O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)46-36(35-45-47(41,42)43)34-44-37(39)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17,19,36H,3-16,18,20-35H2,1-2H3,(H2,41,42,43)/b19-17-/t36-/m1/s1",1-heptadecanoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010894
4428,74845,1-oleoyl-2-heptadecanoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and heptadecanoyl respectively.","InChI=1S/C38H73O8P/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-37(39)44-34-36(35-45-47(41,42)43)46-38(40)33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h17,19,36H,3-16,18,20-35H2,1-2H3,(H2,41,42,43)/b19-17-/t36-/m1/s1",1-(9Z)-octadecenoyl-2-heptadecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010325
4429,74849,1-oleoyl-2-linoleoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and linoleoyl respectively.","InChI=1S/C39H71O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,17-20,37H,3-11,13,15-16,21-36H2,1-2H3,(H2,42,43,44)/b14-12-,19-17-,20-18-/t37-/m1/s1","1-(9Z)-octadecenoyl-2-(9Z,12Z)-octadecadienoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010961
4430,74852,1-oleoyl-2-pentadecanoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and pentadecanoyl respectively.","InChI=1S/C36H69O8P/c1-3-5-7-9-11-13-15-17-18-19-21-22-24-26-28-30-35(37)42-32-34(33-43-45(39,40)41)44-36(38)31-29-27-25-23-20-16-14-12-10-8-6-4-2/h17-18,34H,3-16,19-33H2,1-2H3,(H2,39,40,41)/b18-17-/t34-/m1/s1",1-(9Z)-octadecenoyl-2-pentadecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010323
4431,74854,Thr-Asp,A dipeptide formed from L-threonine and L-aspartic acid residues.,"InChI=1S/C8H14N2O6/c1-3(11)6(9)7(14)10-4(8(15)16)2-5(12)13/h3-4,6,11H,2,9H2,1H3,(H,10,14)(H,12,13)(H,15,16)/t3-,4+,6+/m1/s1",L-Thr-L-Asp,HMDB accession,HMDB0029057
4432,74855,Thr-Gln,A dipeptide formed from L-threonine and L-glutamine residues.,"InChI=1S/C9H17N3O5/c1-4(13)7(11)8(15)12-5(9(16)17)2-3-6(10)14/h4-5,7,13H,2-3,11H2,1H3,(H2,10,14)(H,12,15)(H,16,17)/t4-,5+,7+/m1/s1",TQ,HMDB accession,HMDB0029059
4433,74857,Thr-Glu,A dipeptide formed from L-threonine and L-glutamic acid residues.,"InChI=1S/C9H16N2O6/c1-4(12)7(10)8(15)11-5(9(16)17)2-3-6(13)14/h4-5,7,12H,2-3,10H2,1H3,(H,11,15)(H,13,14)(H,16,17)/t4-,5+,7+/m1/s1",threonylglutamic acid,Reaxys Registry Number,9569097
4434,74859,Thr-Gly,A dipeptide formed from L-threonine and glycine residues.,"InChI=1S/C6H12N2O4/c1-3(9)5(7)6(12)8-2-4(10)11/h3,5,9H,2,7H2,1H3,(H,8,12)(H,10,11)/t3-,5+/m1/s1",threonylglycine,Reaxys Registry Number,4246009
4435,74860,Thr-Leu,A dipeptide formed from L-threonine and L-leucine residues.,"InChI=1S/C10H20N2O4/c1-5(2)4-7(10(15)16)12-9(14)8(11)6(3)13/h5-8,13H,4,11H2,1-3H3,(H,12,14)(H,15,16)/t6-,7+,8+/m1/s1",TL,Reaxys Registry Number,4251145
4436,74861,Thr-Met,A dipeptide formed from L-threonine and L-methionine residues.,"InChI=1S/C9H18N2O4S/c1-5(12)7(10)8(13)11-6(9(14)15)3-4-16-2/h5-7,12H,3-4,10H2,1-2H3,(H,11,13)(H,14,15)/t5-,6+,7+/m1/s1",TM,Reaxys Registry Number,7531923
4437,74862,Thr-Phe,A dipeptide formed from L-threonine and L-phenylalanine residues.,"InChI=1S/C13H18N2O4/c1-8(16)11(14)12(17)15-10(13(18)19)7-9-5-3-2-4-6-9/h2-6,8,10-11,16H,7,14H2,1H3,(H,15,17)(H,18,19)/t8-,10+,11+/m1/s1",threonylphenylalanine,Reaxys Registry Number,5389720
4438,74866,Trp-Arg,A dipeptide formed from L-tryptophan and L-arginine residues.,"InChI=1S/C17H24N6O3/c18-12(8-10-9-22-13-5-2-1-4-11(10)13)15(24)23-14(16(25)26)6-3-7-21-17(19)20/h1-2,4-5,9,12,14,22H,3,6-8,18H2,(H,23,24)(H,25,26)(H4,19,20,21)/t12-,14-/m0/s1",WR,Reaxys Registry Number,5776664
4439,74868,Trp-Asp,A dipeptide formed from L-tryptophan and L-aspartic acid residues.,"InChI=1S/C15H17N3O5/c16-10(14(21)18-12(15(22)23)6-13(19)20)5-8-7-17-11-4-2-1-3-9(8)11/h1-4,7,10,12,17H,5-6,16H2,(H,18,21)(H,19,20)(H,22,23)/t10-,12-/m0/s1",L-Trp-L-Asp,Reaxys Registry Number,14870206
4440,74869,Trp-Glu,A dipeptide formed from L-tryptophan and L-glutamic acid residues.,"InChI=1S/C16H19N3O5/c17-11(7-9-8-18-12-4-2-1-3-10(9)12)15(22)19-13(16(23)24)5-6-14(20)21/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1",tryptophylglutamic acid,Reaxys Registry Number,4766043
4441,74870,Trp-Gly,A dipeptide formed from L-tryptophan and glycine residues.,"InChI=1S/C13H15N3O3/c14-10(13(19)16-7-12(17)18)5-8-6-15-11-4-2-1-3-9(8)11/h1-4,6,10,15H,5,7,14H2,(H,16,19)(H,17,18)/t10-/m0/s1",L-Trp-Gly,Reaxys Registry Number,91297
4442,74871,Trp-Leu,A dipeptide formed from L-tryptophan and L-leucine residues.,"InChI=1S/C17H23N3O3/c1-10(2)7-15(17(22)23)20-16(21)13(18)8-11-9-19-14-6-4-3-5-12(11)14/h3-6,9-10,13,15,19H,7-8,18H2,1-2H3,(H,20,21)(H,22,23)/t13-,15-/m0/s1",tryptophylleucine,Reaxys Registry Number,4269200
4443,74872,Trp-Lys,A dipeptide formed from L-tryptophan and L-lysine residues.,"InChI=1S/C17H24N4O3/c18-8-4-3-7-15(17(23)24)21-16(22)13(19)9-11-10-20-14-6-2-1-5-12(11)14/h1-2,5-6,10,13,15,20H,3-4,7-9,18-19H2,(H,21,22)(H,23,24)/t13-,15-/m0/s1",L-Trp-L-Lys,Reaxys Registry Number,4764128
4444,74874,Trp-Phe,A dipeptide formed from L-tryptophan and L-phenylalanine residues.,"InChI=1S/C20H21N3O3/c21-16(11-14-12-22-17-9-5-4-8-15(14)17)19(24)23-18(20(25)26)10-13-6-2-1-3-7-13/h1-9,12,16,18,22H,10-11,21H2,(H,23,24)(H,25,26)/t16-,18-/m0/s1",tryptophylphenylalanine,Reaxys Registry Number,6282991
4445,74876,Trp-Trp,A dipeptide formed from two L-tryptophan residues.,"InChI=1S/C22H22N4O3/c23-17(9-13-11-24-18-7-3-1-5-15(13)18)21(27)26-20(22(28)29)10-14-12-25-19-8-4-2-6-16(14)19/h1-8,11-12,17,20,24-25H,9-10,23H2,(H,26,27)(H,28,29)/t17-,20-/m0/s1",WW,Reaxys Registry Number,4277833
4446,74877,Trp-Val,A dipeptide formed from L-tryptophan and L-valine residues.,"InChI=1S/C16H21N3O3/c1-9(2)14(16(21)22)19-15(20)12(17)7-10-8-18-13-6-4-3-5-11(10)13/h3-6,8-9,12,14,18H,7,17H2,1-2H3,(H,19,20)(H,21,22)/t12-,14-/m0/s1",tryptophylvaline,Reaxys Registry Number,8007710
4447,74878,Trp-Tyr,A dipeptide formed from L-tryptophan and L-tyrosine residues.,"InChI=1S/C20H21N3O4/c21-16(10-13-11-22-17-4-2-1-3-15(13)17)19(25)23-18(20(26)27)9-12-5-7-14(24)8-6-12/h1-8,11,16,18,22,24H,9-10,21H2,(H,23,25)(H,26,27)/t16-,18-/m0/s1",tryptophyltyrosine,Reaxys Registry Number,4212563
4448,74879,Tyr-Ala,A dipeptide formed from L-tyrosine and L-alanine residues.,"InChI=1S/C12H16N2O4/c1-7(12(17)18)14-11(16)10(13)6-8-2-4-9(15)5-3-8/h2-5,7,10,15H,6,13H2,1H3,(H,14,16)(H,17,18)/t7-,10-/m0/s1",tyrosylalanine,Reaxys Registry Number,2142317
4449,74881,Tyr-Gln,A dipeptide formed from L-tyrosine and L-glutamine residues.,"InChI=1S/C14H19N3O5/c15-10(7-8-1-3-9(18)4-2-8)13(20)17-11(14(21)22)5-6-12(16)19/h1-4,10-11,18H,5-7,15H2,(H2,16,19)(H,17,20)(H,21,22)/t10-,11-/m0/s1",L-Tyr-L-Gln,Reaxys Registry Number,2545192
4450,74883,Tyr-Glu,A dipeptide formed from L-tyrosine and L-glutamic acid residues.,"InChI=1S/C14H18N2O6/c15-10(7-8-1-3-9(17)4-2-8)13(20)16-11(14(21)22)5-6-12(18)19/h1-4,10-11,17H,5-7,15H2,(H,16,20)(H,18,19)(H,21,22)/t10-,11-/m0/s1",L-Tyr-L-Glu,Reaxys Registry Number,2951967
4451,74904,isocaproate,A  branched-chain saturated fatty acid anion that is pentanoate with a methyl group substituent at position 4.,"InChI=1S/C6H12O2/c1-5(2)3-4-6(7)8/h5H,3-4H2,1-2H3,(H,7,8)/p-1",4-Methylvalerate,Reaxys Registry Number,3903785
4452,74912,N-{alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc}-DHPE,"An N-glycosylated dialkylglycerophosphoethanolamine in which the dialkylglycerophosphoethanolamine is 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine and the glycosylating saccharide is the branched nonasaccharide alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc, the GlcNAc residue at the reducing end of which is in the ring-opened form.","InChI=1S/C95H174N3O51P/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-34-130-45-51(131-35-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2)46-135-150(128,129)134-36-33-96-37-52(97-49(3)106)63(109)82(53(108)38-99)144-88-62(98-50(4)107)71(117)83(59(44-105)141-88)145-93-81(127)85(147-94-87(76(122)68(114)57(42-103)139-94)149-95-86(75(121)67(113)58(43-104)140-95)148-92-79(125)74(120)66(112)56(41-102)138-92)70(116)61(143-93)48-133-90-80(126)84(146-91-78(124)73(119)65(111)55(40-101)137-91)69(115)60(142-90)47-132-89-77(123)72(118)64(110)54(39-100)136-89/h37,51-95,99-105,108-127H,5-36,38-48H2,1-4H3,(H,97,106)(H,98,107)(H,128,129)/b96-37-/t51-,52+,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82-,83-,84+,85+,86+,87+,88+,89+,90+,91-,92-,93+,94-,95-/m1/s1","2-[alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->3)-[alpha-D-mannosyl-(1->3)-[alpha-D-mannosyl-(1->6)]-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosaminylamino]ethyl (2S)-2,3-bis(hexadecyloxy)propyl hydrogen phosphate",PubMed citation,23708606
4453,74913,AOPE,"A dialkylglycerophosphoethanolamine in which the amino group of 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE) carries an (aminooxy)acetyl functionality.","InChI=1S/C39H81N2O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-32-45-35-38(36-49-50(43,44)48-34-31-41-39(42)37-47-40)46-33-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h38H,3-37,40H2,1-2H3,(H,41,42)(H,43,44)/t38-/m1/s1",aminooxy-functionalized DHPE,PubMed citation,17656321
4454,74930,1-oleoyl-2-myristoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and tetradecanoyl respectively.","InChI=1S/C35H67O8P/c1-3-5-7-9-11-13-15-16-17-18-20-21-23-25-27-29-34(36)41-31-33(32-42-44(38,39)40)43-35(37)30-28-26-24-22-19-14-12-10-8-6-4-2/h16-17,33H,3-15,18-32H2,1-2H3,(H2,38,39,40)/b17-16-/t33-/m1/s1",1-(9Z)-octadecenoyl-2-tetradecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010882
4455,74933,1-(gamma-linolenoyl)-sn-glycero-3-phosphate,"A 1-acyl-sn-glycerol 3-phosphate in which the 1-acyl substituent is specified as gamma-linolenoyl (6Z,9Z,12Z-octadecatrienoyl).","InChI=1S/C21H37O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)27-18-20(22)19-28-29(24,25)26/h6-7,9-10,12-13,20,22H,2-5,8,11,14-19H2,1H3,(H2,24,25,26)/b7-6-,10-9-,13-12-/t20-/m1/s1","(6Z,9Z,12Z)-octadecatrienoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10050023
4456,74936,1-(gamma-linolenoyl)-2-oleoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as gamma-linolenoyl and oleoyl respectively.","InChI=1S/C39H69O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11,13,17-20,23,25,37H,3-10,12,14-16,21-22,24,26-36H2,1-2H3,(H2,42,43,44)/b13-11-,19-17-,20-18-,25-23-/t37-/m1/s1","(6Z,9Z,12Z)-octadecatrienoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010376
4457,74939,1-icosanoyl-sn-glycero-3-phosphate,A 1-acyl-sn-glycerol 3-phosphate in which the 1-acyl substituent is specified as icosanoyl (arachidoyl).,"InChI=1S/C23H47O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(25)29-20-22(24)21-30-31(26,27)28/h22,24H,2-21H2,1H3,(H2,26,27,28)/t22-/m1/s1",1-eicosanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10050018
4458,74942,1-icosanoyl-2-oleoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as icosanoyl (arachidoyl) and oleoyl respectively.","InChI=1S/C41H79O8P/c1-3-5-7-9-11-13-15-17-19-20-22-23-25-27-29-31-33-35-40(42)47-37-39(38-48-50(44,45)46)49-41(43)36-34-32-30-28-26-24-21-18-16-14-12-10-8-6-4-2/h18,21,39H,3-17,19-20,22-38H2,1-2H3,(H2,44,45,46)/b21-18-/t39-/m1/s1",1-icosanoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010953
4459,74943,1-myristoyl-2-oleoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as myristoyl and oleoyl respectively.","InChI=1S/C35H67O8P/c1-3-5-7-9-11-13-15-16-17-18-20-22-24-26-28-30-35(37)43-33(32-42-44(38,39)40)31-41-34(36)29-27-25-23-21-19-14-12-10-8-6-4-2/h16-17,33H,3-15,18-32H2,1-2H3,(H2,38,39,40)/b17-16-/t33-/m1/s1",1-tetradecanoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010019
4460,74948,guanosine 2'-monophosphate,A purine ribonucleoside 2'-monophosphate having guanine as the nucleobase.,"InChI=1S/C10H14N5O8P/c11-10-13-7-4(8(18)14-10)12-2-15(7)9-6(23-24(19,20)21)5(17)3(1-16)22-9/h2-3,5-6,9,16-17H,1H2,(H2,19,20,21)(H3,11,13,14,18)/t3-,5-,6-,9-/m1/s1",guanosine 2'-phosphate,DrugBank accession,DB01937
4461,74951,cysteamine S-phosphate,An organic thiophosphate that is the S-phospho derivative of cysteamine.,"InChI=1S/C2H8NO3PS/c3-1-2-8-7(4,5)6/h1-3H2,(H2,4,5,6)",S-phosphocysteamine,Reaxys Registry Number,1758917
4462,74952,d(pT)3,A single-stranded DNA oligonucleotide composed of three deoxythymidylic acid residues connected by 3'->5' phosphodiester linkages and terminated by a 5'-phosphate.,"InChI=1S/C30H41N6O22P3/c1-13-7-34(28(41)31-25(13)38)22-4-16(37)19(54-22)10-52-60(47,48)58-18-6-24(36-9-15(3)27(40)33-30(36)43)56-21(18)12-53-61(49,50)57-17-5-23(55-20(17)11-51-59(44,45)46)35-8-14(2)26(39)32-29(35)42/h7-9,16-24,37H,4-6,10-12H2,1-3H3,(H,47,48)(H,49,50)(H,31,38,41)(H,32,39,42)(H,33,40,43)(H2,44,45,46)/t16-,17-,18-,19+,20+,21+,22+,23+,24+/m0/s1",deoxythymidylic acid trinucleotide,Reaxys Registry Number,740855
4463,74956,O(4)-phosphotyrosine,A non-proteinogenic alpha-amino acid that is tyrosine phosphorylated at the phenolic hydroxy group.,"InChI=1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)",O-phosphotyrosine,Reaxys Registry Number,4260804
4464,74959,O(4)-phospho-D-tyrosine,A D-tyrosine derivative that is D-tyrosine phosphorylated at the phenolic hydroxy group.,"InChI=1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)/t8-/m1/s1",O-phospho-D-tyrosine,Reaxys Registry Number,13579292
4465,74962,5'-d[CTGCCTTCAG]-3',"A single-stranded DNA fragment comprised of one deoxyadenosine, four deoxycytidine, three thymidine and two deoxyguanidine residues connected by 3'->5' phosphodiester linkages in the sequence CTGCCTTCAG. It can exist as a hairpin structure, 5'-d [CTG(CCTT)CAG]-3', consisting of a four-nucleotide loop (CCTT) with a stem of three base-pairs, C-G, T-A and G-C.","InChI=1S/C96H124N33O60P9/c1-39-22-124(94(141)117-83(39)132)71-17-47(57(176-71)30-163-191(146,147)181-43-13-67(171-52(43)25-130)120-8-4-62(97)109-90(120)137)187-197(158,159)170-34-61-51(21-75(180-61)129-38-108-78-82(129)114-89(103)116-87(78)136)189-198(160,161)166-29-56-44(14-68(175-56)121-9-5-63(98)110-91(121)138)182-192(148,149)164-27-54-45(15-69(173-54)122-10-6-64(99)111-92(122)139)183-193(150,151)167-31-58-49(19-73(177-58)126-24-41(3)85(134)119-96(126)143)186-196(156,157)168-32-59-48(18-72(178-59)125-23-40(2)84(133)118-95(125)142)185-195(154,155)165-28-55-46(16-70(174-55)123-11-7-65(100)112-93(123)140)184-194(152,153)169-33-60-50(20-74(179-60)127-36-106-76-79(101)104-35-105-80(76)127)188-190(144,145)162-26-53-42(131)12-66(172-53)128-37-107-77-81(128)113-88(102)115-86(77)135/h4-11,22-24,35-38,42-61,66-75,130-131H,12-21,25-34H2,1-3H3,(H,144,145)(H,146,147)(H,148,149)(H,150,151)(H,152,153)(H,154,155)(H,156,157)(H,158,159)(H,160,161)(H2,97,109,137)(H2,98,110,138)(H2,99,111,139)(H2,100,112,140)(H2,101,104,105)(H,117,132,141)(H,118,133,142)(H,119,134,143)(H3,102,113,115,135)(H3,103,114,116,136)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+/m0/s1",5'-d [CTG(CCTT)CAG]-3',PubMed citation,18028946
4466,74973,alpha-L-Rhap-(1->3)-[alpha-L-Rhap-(1->3)-beta-D-Glcp-(1->4)]-alpha-D-Glcp-(1->2)-alpha-D-GlcpO[CH2]5NH2,A pentasaccharide derivative consisting of an alpha-D-glucosyl residue glycosidically linked to a 5-aminopentyl group and which carries at O-2 an alpha-L-rhamnosyl-(1->3)-[alpha-L-rhamnosyl-(1->3)-beta-D-glucosyl-(1->4)]-alpha-D-glucosyl branched tetrasaccharide unit,"InChI=1S/C35H63NO24/c1-11-16(40)20(44)23(47)31(52-11)58-28-19(43)14(9-38)54-33(25(28)49)57-27-15(10-39)56-34(26(50)29(27)59-32-24(48)21(45)17(41)12(2)53-32)60-30-22(46)18(42)13(8-37)55-35(30)51-7-5-3-4-6-36/h11-35,37-50H,3-10,36H2,1-2H3/t11-,12-,13+,14+,15+,16-,17-,18+,19+,20+,21+,22-,23+,24+,25+,26+,27+,28-,29+,30+,31-,32-,33-,34+,35-/m0/s1",alpha-L-Rhap-(1->3)-beta-D-Glcp-(1->4)-[alpha-L-Rhap-(1->3)]-alpha-D-Glcp-(1->2)-alpha-D-GlcpO[CH2]5NH2,Patent accession,WO2013017254
4467,74990,Tyr-Gly,A dipeptide formed from L-tyrosine and glycine residues.,"InChI=1S/C11H14N2O4/c12-9(11(17)13-6-10(15)16)5-7-1-3-8(14)4-2-7/h1-4,9,14H,5-6,12H2,(H,13,17)(H,15,16)/t9-/m0/s1",tyrosylglycine,Reaxys Registry Number,2142807
4468,74991,Tyr-Gly-Gly,A tripeptide composed of one L-tyrosine and two glycine residues joined in sequence.,"InChI=1S/C13H17N3O5/c14-10(5-8-1-3-9(17)4-2-8)13(21)16-6-11(18)15-7-12(19)20/h1-4,10,17H,5-7,14H2,(H,15,18)(H,16,21)(H,19,20)/t10-/m0/s1",L-Tyr-Gly-Gly,Reaxys Registry Number,3222438
4469,74993,Tyr-Ile,A dipeptide formed from L-tyrosine and L-isoleucine residues.,"InChI=1S/C15H22N2O4/c1-3-9(2)13(15(20)21)17-14(19)12(16)8-10-4-6-11(18)7-5-10/h4-7,9,12-13,18H,3,8,16H2,1-2H3,(H,17,19)(H,20,21)/t9-,12-,13-/m0/s1",L-Tyr-L-Ile,Reaxys Registry Number,3559679
4470,75003,Tyr-Leu,A dipeptide formed from L-tyrosine and L-leucine residues.,"InChI=1S/C15H22N2O4/c1-9(2)7-13(15(20)21)17-14(19)12(16)8-10-3-5-11(18)6-4-10/h3-6,9,12-13,18H,7-8,16H2,1-2H3,(H,17,19)(H,20,21)/t12-,13-/m0/s1",tyrosylleucine,HMDB accession,HMDB0029109
4471,75004,Tyr-Lys,A dipeptide formed from L-tyrosine and L-lysine residues.,"InChI=1S/C15H23N3O4/c16-8-2-1-3-13(15(21)22)18-14(20)12(17)9-10-4-6-11(19)7-5-10/h4-7,12-13,19H,1-3,8-9,16-17H2,(H,18,20)(H,21,22)/t12-,13-/m0/s1",tyrosyllysine,Reaxys Registry Number,3563389
4472,75005,Tyr-Phe,A dipeptide formed from L-tyrosine and L-phenylalanine residues.,"InChI=1S/C18H20N2O4/c19-15(10-13-6-8-14(21)9-7-13)17(22)20-16(18(23)24)11-12-4-2-1-3-5-12/h1-9,15-16,21H,10-11,19H2,(H,20,22)(H,23,24)/t15-,16-/m0/s1",L-Tyr-L-Phe,Reaxys Registry Number,2820610
4473,75006,Tyr-Trp,A dipeptide formed from L-tyrosine and L-tryptophan residues.,"InChI=1S/C20H21N3O4/c21-16(9-12-5-7-14(24)8-6-12)19(25)23-18(20(26)27)10-13-11-22-17-4-2-1-3-15(13)17/h1-8,11,16,18,22,24H,9-10,21H2,(H,23,25)(H,26,27)/t16-,18-/m0/s1",L-Tyr-L-Trp,Reaxys Registry Number,4275446
4474,75007,Tyr-Val,A dipeptide formed from L-tyrosine and L-valine residues.,"InChI=1S/C14H20N2O4/c1-8(2)12(14(19)20)16-13(18)11(15)7-9-3-5-10(17)6-4-9/h3-6,8,11-12,17H,7,15H2,1-2H3,(H,16,18)(H,19,20)/t11-,12-/m0/s1",YV,Reaxys Registry Number,6419040
4475,75008,Val-Ala,A dipeptide formed from L-valine and L-alanine residues.,"InChI=1S/C8H16N2O3/c1-4(2)6(9)7(11)10-5(3)8(12)13/h4-6H,9H2,1-3H3,(H,10,11)(H,12,13)/t5-,6-/m0/s1",VA,Reaxys Registry Number,1726346
4476,75009,Val-Asp,A dipeptide formed from L-valine and L-aspartic acid residues.,"InChI=1S/C9H16N2O5/c1-4(2)7(10)8(14)11-5(9(15)16)3-6(12)13/h4-5,7H,3,10H2,1-2H3,(H,11,14)(H,12,13)(H,15,16)/t5-,7-/m0/s1",L-Val-L-Asp,Reaxys Registry Number,6892820
4477,75010,Val-Gln,A dipeptide formed from L-valine and L-glutamine residues.,"InChI=1S/C10H19N3O4/c1-5(2)8(12)9(15)13-6(10(16)17)3-4-7(11)14/h5-6,8H,3-4,12H2,1-2H3,(H2,11,14)(H,13,15)(H,16,17)/t6-,8-/m0/s1",L-Val-L-Gln,Reaxys Registry Number,2380300
4478,75011,Val-Glu,A dipeptide formed from L-valine and L-glutamic acid residues.,"InChI=1S/C10H18N2O5/c1-5(2)8(11)9(15)12-6(10(16)17)3-4-7(13)14/h5-6,8H,3-4,11H2,1-2H3,(H,12,15)(H,13,14)(H,16,17)/t6-,8-/m0/s1",L-Val-L-Glu,Reaxys Registry Number,1714297
4479,75012,Val-Ile,A dipeptide formed from L-valine and L-isoleucine residues.,"InChI=1S/C11H22N2O3/c1-5-7(4)9(11(15)16)13-10(14)8(12)6(2)3/h6-9H,5,12H2,1-4H3,(H,13,14)(H,15,16)/t7-,8-,9-/m0/s1",VI,Reaxys Registry Number,1711731
4480,75014,Val-Lys,A dipeptide formed from L-valine and L-lysine residues.,"InChI=1S/C11H23N3O3/c1-7(2)9(13)10(15)14-8(11(16)17)5-3-4-6-12/h7-9H,3-6,12-13H2,1-2H3,(H,14,15)(H,16,17)/t8-,9-/m0/s1",VK,CAS Registry Number,22677-62-9
4481,75015,Val-Met,A dipeptide formed from L-valine and L-methionine residues.,"InChI=1S/C10H20N2O3S/c1-6(2)8(11)9(13)12-7(10(14)15)4-5-16-3/h6-8H,4-5,11H2,1-3H3,(H,12,13)(H,14,15)/t7-,8-/m0/s1",VM,Reaxys Registry Number,4746069
4482,75016,Val-Phe,A dipeptide formed from L-valine and L-phenylalanine residues.,"InChI=1S/C14H20N2O3/c1-9(2)12(15)13(17)16-11(14(18)19)8-10-6-4-3-5-7-10/h3-7,9,11-12H,8,15H2,1-2H3,(H,16,17)(H,18,19)/t11-,12-/m0/s1",VF,Reaxys Registry Number,2946090
4483,75018,1-palmitoyl-2-lauroyl-sn-glycero-3-phosphocholine,A phosphatidylcholine 28:0 in which the two acyl substituents at positions 1 and 2 are specified as palmitoyl and lauroyl respectively.,"InChI=1S/C36H72NO8P/c1-6-8-10-12-14-16-17-18-19-21-22-24-26-28-35(38)42-32-34(33-44-46(40,41)43-31-30-37(3,4)5)45-36(39)29-27-25-23-20-15-13-11-9-7-2/h34H,6-33H2,1-5H3/t34-/m1/s1",1-hexadecanoyl-2-dodecanoyl-sn-glycero-3-phosphocholine,Reaxys Registry Number,8465667
4484,75021,Val-Ser,A dipeptide formed from L-valine and L-serine residues.,"InChI=1S/C8H16N2O4/c1-4(2)6(9)7(12)10-5(3-11)8(13)14/h4-6,11H,3,9H2,1-2H3,(H,10,12)(H,13,14)/t5-,6-/m0/s1",VS,Reaxys Registry Number,2723820
4485,75022,Val-Tyr-Val,"A tripeptide formed from L-valine, L-tyrosine and L-valine residues joined in sequence.","InChI=1S/C19H29N3O5/c1-10(2)15(20)18(25)21-14(9-12-5-7-13(23)8-6-12)17(24)22-16(11(3)4)19(26)27/h5-8,10-11,14-16,23H,9,20H2,1-4H3,(H,21,25)(H,22,24)(H,26,27)/t14-,15-,16-/m0/s1",L-Val-L-Tyr-L-Val,Reaxys Registry Number,2955382
4486,75040,vilanterol trifenate,A triphenylacetate salt obtained by combining vilanterol with one equivalent of  triphenylacetic acid. Used in combination with fluticasone furoate for treatment of bronchospasm associated with chronic obstructive pulmonary disease.,"InChI=1S/C24H33Cl2NO5.C20H16O2/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28;21-19(22)20(16-10-4-1-5-11-16,17-12-6-2-7-13-17)18-14-8-3-9-15-18/h5-9,14,24,27-30H,1-4,10-13,15-17H2;1-15H,(H,21,22)/t24-;/m0./s1",vilanterol triphenylacetate,CAS Registry Number,503070-58-4
4487,75041,thymidylyl(3'-5')thymidylyl(3'-5')thymidine,An oligonucleotide composed of three deoxythymidylic acid residues connected by 3'->5' phosphodiester linkages.,"InChI=1S/C30H40N6O19P2/c1-13-7-34(28(42)31-25(13)39)22-4-16(38)20(52-22)11-49-56(45,46)55-18-6-24(36-9-15(3)27(41)33-30(36)44)53-21(18)12-50-57(47,48)54-17-5-23(51-19(17)10-37)35-8-14(2)26(40)32-29(35)43/h7-9,16-24,37-38H,4-6,10-12H2,1-3H3,(H,45,46)(H,47,48)(H,31,39,42)(H,32,40,43)(H,33,41,44)/t16-,17-,18-,19+,20+,21+,22+,23+,24+/m0/s1",dT3,CAS Registry Number,2640-26-8
4488,75054,2-hydroxy-3-methoxybenzaldehyde 2-pyridylhydrazone,A hydrazone obtained by formal condensation of the carbonyl group of 2-hydroxy-3-methoxybenzaldehyde with 2-hydrazinopyridine.,"InChI=1S/C13H13N3O2/c1-18-11-6-4-5-10(13(11)17)9-15-16-12-7-2-3-8-14-12/h2-9,17H,1H3,(H,14,16)",2-hydroxy-3-methoxybenzaldehyde 2-pyridinylhydrazone,Reaxys Registry Number,16695157
4489,75064,trans-2-docosenoyl-CoA,"A 2,3-trans-enoyl CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans-2-docosenoic acid.","InChI=1S/C43H76N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-34(52)71-27-26-45-33(51)24-25-46-41(55)38(54)43(2,3)29-64-70(61,62)67-69(59,60)63-28-32-37(66-68(56,57)58)36(53)42(65-32)50-31-49-35-39(44)47-30-48-40(35)50/h22-23,30-32,36-38,42,53-54H,4-21,24-29H2,1-3H3,(H,45,51)(H,46,55)(H,59,60)(H,61,62)(H2,44,47,48)(H2,56,57,58)/b23-22+/t32-,36-,37-,38+,42-/m1/s1",(E)-2-docosenoyl-CoA,MetaCyc accession,CPD-14281
4490,75070,1-palmitoleoyl-sn-glycerol 3-phosphate,A 1-acyl-sn-glycerol 3-phosphate in which the 1-acyl substituent is specified as palmitoleoyl.,"InChI=1S/C19H37O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(21)25-16-18(20)17-26-27(22,23)24/h7-8,18,20H,2-6,9-17H2,1H3,(H2,22,23,24)/b8-7-/t18-/m1/s1",1-(9Z)-hexadecenoyl-sn-glycerol 3-phosphate,LIPID MAPS instance accession,LMGP10050016
4491,75071,"1,2-di-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are both (9Z)-hexadecenoyl (palmitoleoyl).","InChI=1S/C35H65O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(36)41-31-33(32-42-44(38,39)40)43-35(37)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h13-16,33H,3-12,17-32H2,1-2H3,(H2,38,39,40)/b15-13-,16-14-/t33-/m1/s1","1,2-dipalmitoleoyl-sn-glycerol 3-phosphate",LIPID MAPS instance accession,LMGP10010969
4492,75073,1-octadecanoyl-2-(9Z)-hexadecenoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as octadecanoyl and (9Z)-hexadecenoyl respectively.","InChI=1S/C37H71O8P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-36(38)43-33-35(34-44-46(40,41)42)45-37(39)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h14,16,35H,3-13,15,17-34H2,1-2H3,(H2,40,41,42)/b16-14-/t35-/m1/s1",1-stearoyl-2-palmitoleoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010887
4493,75074,1-(9Z)-octadecenoyl-2-(9Z)-hexadecenoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as (9Z)-octadecenoyl and (9Z)-hexadecenoyl respectively.","InChI=1S/C37H69O8P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-36(38)43-33-35(34-44-46(40,41)42)45-37(39)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h14,16-18,35H,3-13,15,19-34H2,1-2H3,(H2,40,41,42)/b16-14-,18-17-/t35-/m1/s1",1-oleoyl-2-palmitoleoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010881
4494,75078,N(1)-methylpseudouridine 5'-monophosphate,A C-nucleoside phosphate consisting of N(1)-methylpseudouridine substituted at position 5' by a  monophosphate group.,"InChI=1S/C10H15N2O9P/c1-12-2-4(9(15)11-10(12)16)8-7(14)6(13)5(21-8)3-20-22(17,18)19/h2,5-8,13-14H,3H2,1H3,(H,11,15,16)(H2,17,18,19)/t5-,6-,7-,8+/m1/s1",N(1)-methylpseudouridine 5'-phosphate,PDBeChem accession,B8H
4495,75083,N(3)-methylcytidine 5'-monophosphate,A pyrimidine ribonucleoside 5'-monophosphate having N(3)-methylcytosine as the nucleobase.,"InChI=1S/C10H16N3O8P/c1-12-6(11)2-3-13(10(12)16)9-8(15)7(14)5(21-9)4-20-22(17,18)19/h2-3,5,7-9,11,14-15H,4H2,1H3,(H2,17,18,19)/t5-,7-,8-,9-/m1/s1",N(3)-methylcytidine 5'-phosphate,Reaxys Registry Number,577983
4496,75096,1-oleoyl-2-linoleoyl-sn-glycero-3-phospho-L-serine,A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as oleoyl and linoleoyl respectively.,"InChI=1S/C42H76NO10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(44)50-35-38(36-51-54(48,49)52-37-39(43)42(46)47)53-41(45)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,17-20,38-39H,3-11,13,15-16,21-37,43H2,1-2H3,(H,46,47)(H,48,49)/b14-12-,19-17-,20-18-/t38-,39+/m1/s1",1-C18:1(omega-9)-2-C18:2(omega-6)-phosphatidylserine,LIPID MAPS instance accession,LMGP03010958
4497,75099,1-oleoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine,A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as oleoyl and arachidonoyl respectively.,"InChI=1S/C44H76NO10P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-43(47)55-40(38-53-56(50,51)54-39-41(45)44(48)49)37-52-42(46)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17-19,21-22,24,28,30,40-41H,3-10,12,14-16,20,23,25-27,29,31-39,45H2,1-2H3,(H,48,49)(H,50,51)/b13-11-,19-17-,21-18-,24-22-,30-28-/t40-,41+/m1/s1",1-C18:1(omega-9)-2-C20:4(omega-6)-phosphatidylserine,LIPID MAPS instance accession,LMGP03010879
4498,75101,1-oleoyl-2-palmitoleoyl-sn-glycero-3-phospho-L-serine,A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as oleoyl and palmitoleoyl respectively.,"InChI=1S/C40H74NO10P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(42)48-33-36(34-49-52(46,47)50-35-37(41)40(44)45)51-39(43)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h14,16-18,36-37H,3-13,15,19-35,41H2,1-2H3,(H,44,45)(H,46,47)/b16-14-,18-17-/t36-,37+/m1/s1",1-C18:1(omega-9)-2-C16:1(omega-7)-phosphatidylserine,LIPID MAPS instance accession,LMGP03010881
4499,75103,1-oleoyl-2-stearoyl-sn-glycero-3-phospho-L-serine,A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as oleoyl and stearoyl respectively.,"InChI=1S/C42H80NO10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(44)50-35-38(36-51-54(48,49)52-37-39(43)42(46)47)53-41(45)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17,19,38-39H,3-16,18,20-37,43H2,1-2H3,(H,46,47)(H,48,49)/b19-17-/t38-,39+/m1/s1",1-C18:1(omega-9)-2-C18:0-phosphatidylserine,LIPID MAPS instance accession,LMGP03010034
4500,75106,1-oleoyl-2-palmitoyl-sn-glycero-3-phospho-L-serine,A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as oleoyl and palmitoyl respectively.,"InChI=1S/C40H76NO10P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(42)48-33-36(34-49-52(46,47)50-35-37(41)40(44)45)51-39(43)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h17-18,36-37H,3-16,19-35,41H2,1-2H3,(H,44,45)(H,46,47)/b18-17-/t36-,37+/m1/s1",1-C18:1(omega-9)-2-C16:0-phosphatidylserine,LIPID MAPS instance accession,LMGP03010959
4501,75118,1-oleoyl-2-arachidonoyl-sn-glycero-3-phosphate,A 1-acyl-2-arachidonoyl-sn-glycero-3-phosphate(2-) in which the 1-acyl substituent is specified as oleoyl.,"InChI=1S/C41H71O8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(43)49-39(38-48-50(44,45)46)37-47-40(42)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17-19,21-22,24,28,30,39H,3-10,12,14-16,20,23,25-27,29,31-38H2,1-2H3,(H2,44,45,46)/b13-11-,19-17-,21-18-,24-22-,30-28-/t39-/m1/s1",1-C18:1(omega-9)-2-C20:4(omega-6)-phosphatidylic acid,LIPID MAPS instance accession,LMGP10010879
4502,75126,"(1R,2R)-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol",An N-[1-hydroxy-3-(morpholin-4-yl)-1-phenylpropan-2-yl]hexadecanamide in which both stereocentres have R configuration.,"InChI=1S/C29H50N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-17-20-28(32)30-27(25-31-21-23-34-24-22-31)29(33)26-18-15-14-16-19-26/h14-16,18-19,27,29,33H,2-13,17,20-25H2,1H3,(H,30,32)/t27-,29-/m1/s1","(R,R)-PPMP",Reaxys Registry Number,15587489
4503,75134,1-oleoyl-2-icosanoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and icosanoyl (arachidoyl) respectively.","InChI=1S/C41H79O8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(43)49-39(38-48-50(44,45)46)37-47-40(42)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h18,21,39H,3-17,19-20,22-38H2,1-2H3,(H2,44,45,46)/b21-18-/t39-/m1/s1",1-(9Z)-octadecenoyl-2-eicosanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010960
4504,75141,1-arachidonoyl-2-oleoyl-sn-glycero-3-phosphate,A 1-acyl-2-oleoyl-sn-glycero-3-phosphate(2-) in which the 1-acyl substituent is specified as arachidonoyl.,"InChI=1S/C41H71O8P/c1-3-5-7-9-11-13-15-17-19-20-22-23-25-27-29-31-33-35-40(42)47-37-39(38-48-50(44,45)46)49-41(43)36-34-32-30-28-26-24-21-18-16-14-12-10-8-6-4-2/h11,13,17-19,21-23,27,29,39H,3-10,12,14-16,20,24-26,28,30-38H2,1-2H3,(H2,44,45,46)/b13-11-,19-17-,21-18-,23-22-,29-27-/t39-/m1/s1","1-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010629
4505,75144,lactamide,A monocarboxylic acid amide that is lactic acid in which the carboxylic acid group has been converted to the corresponding carboxamide.,"InChI=1S/C3H7NO2/c1-2(5)3(4)6/h2,5H,1H3,(H2,4,6)",DL-lactamide,CAS Registry Number,2043-43-8
4506,75145,2-aminooctanoic acid,An alpha-amino fatty acid that is caprylic acid which is substituted at position 2 by an amino group.,"InChI=1S/C8H17NO2/c1-2-3-4-5-6-7(9)8(10)11/h7H,2-6,9H2,1H3,(H,10,11)",alpha-aminocaprylic acid,CAS Registry Number,644-90-6
4507,75150,3-dehydro-D-glucose-6-phosphate,A ketohexose monophosphate that is 3-dehydro-D-glucose having the monophosphate group located at position 6.,"InChI=1S/C6H11O9P/c7-3-2(1-14-16(11,12)13)15-6(10)5(9)4(3)8/h2-3,5-7,9-10H,1H2,(H2,11,12,13)/t2-,3-,5-,6?/m1/s1",3-keto-D-glucose-6-phosphate,MetaCyc accession,3-oxo-D-glucose-6-phosphate
4508,75157,5'-d[TC]-3',A single-strand DNA oligonucleotide consisting of a thymidine residue phospho-linked 3'->5' to a deoxycytidine residue (PDB entry: 2OK0).,"InChI=1S/C19H26N5O11P/c1-9-6-24(19(29)22-17(9)27)16-5-11(12(7-25)33-16)35-36(30,31)32-8-13-10(26)4-15(34-13)23-3-2-14(20)21-18(23)28/h2-3,6,10-13,15-16,25-26H,4-5,7-8H2,1H3,(H,30,31)(H2,20,21,28)(H,22,27,29)/t10-,11-,12+,13+,15+,16+/m0/s1",5'dTdC3',PubMed citation,17512945
4509,75165,dT(6-4)T,A single-stranded DNA oligonucleotide consisting of two thymidine molecules linked (3'->5') and also with a C6-C4 bond. It results from irradiation at 254 nm of normal dTpT (PDB entry: 1EHL).,"InChI=1S/C20H27N4O12P/c1-8-5-23-13-3-9(26)12(35-13)7-33-37(31,32)36-10-4-14(34-11(10)6-25)24-16(15(8)21-18(23)28)20(2,30)17(27)22-19(24)29/h5,9-14,16,25-26,30H,3-4,6-7H2,1-2H3,(H,31,32)(H,22,27,29)/t9-,10-,11+,12+,13+,14+,16-,20+/m0/s1",D(5HT)(6-4)T,PubMed citation,10835279
4510,75166,5'-d[CGAGCTGCCTTCAGTCG]-3',"A single-stranded DNA oligonucleotide comprised of two deoxyadenosine, six deoxycytidine, four thymidine and five deoxyguanidine residues connected by 3'->5' phosphodiester linkages in the sequence d[CGAGCTGCCTTCAGTCG]. It can exist as a hairpin structure in several different conformations.","InChI=1S/C164H209N61O102P16/c1-64-34-215(161(243)205-141(64)228)115-24-75(318-335(261,262)283-42-89-74(23-114(299-89)214-16-10-107(170)194-160(214)242)317-333(257,258)290-49-96-79(28-119(306-96)219-57-182-125-132(171)178-55-180-134(125)219)322-341(273,274)294-54-101-84(33-124(311-101)225-63-188-131-140(225)199-154(177)204-149(131)236)326-340(271,272)289-48-95-76(25-116(305-95)216-35-65(2)142(229)206-162(216)244)319-334(259,260)282-40-87-70(19-110(297-87)210-12-6-103(166)190-156(210)238)313-328(247,248)279-39-86-68(227)17-108(296-86)221-59-184-127-136(221)195-150(173)200-145(127)232)94(304-115)47-288-336(263,264)320-77-26-117(217-36-66(3)143(230)207-163(217)245)302-92(77)45-286-331(253,254)315-72-21-112(212-14-8-105(168)192-158(212)240)298-88(72)41-281-330(251,252)314-71-20-111(211-13-7-104(167)191-157(211)239)300-90(71)43-284-338(267,268)324-82-31-122(223-61-186-129-138(223)197-152(175)202-147(129)234)309-99(82)52-292-337(265,266)321-78-27-118(218-37-67(4)144(231)208-164(218)246)303-93(78)46-287-332(255,256)316-73-22-113(213-15-9-106(169)193-159(213)241)301-91(73)44-285-339(269,270)325-83-32-123(224-62-187-130-139(224)198-153(176)203-148(130)235)310-100(83)53-293-342(275,276)323-80-29-120(220-58-183-126-133(172)179-56-181-135(126)220)307-97(80)50-291-343(277,278)327-81-30-121(222-60-185-128-137(222)196-151(174)201-146(128)233)308-98(81)51-280-329(249,250)312-69-18-109(295-85(69)38-226)209-11-5-102(165)189-155(209)237/h5-16,34-37,55-63,68-101,108-124,226-227H,17-33,38-54H2,1-4H3,(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H2,165,189,237)(H2,166,190,238)(H2,167,191,239)(H2,168,192,240)(H2,169,193,241)(H2,170,194,242)(H2,171,178,180)(H2,172,179,181)(H,205,228,243)(H,206,229,244)(H,207,230,245)(H,208,231,246)(H3,173,195,200,232)(H3,174,196,201,233)(H3,175,197,202,234)(H3,176,198,203,235)(H3,177,199,204,236)/t68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+/m0/s1",5'-CpGpApGpCpTpGpCpCpTpTpCpApGpTpCpG-3',PubMed citation,12680766
4511,75167,dT5,An oligonucleotide comprised of five thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C50H66N10O33P4/c1-21-11-56(46(68)51-41(21)63)36-6-26(62)32(86-36)17-81-94(73,74)91-28-8-38(58-13-23(3)43(65)53-48(58)70)88-34(28)19-83-96(77,78)93-30-10-40(60-15-25(5)45(67)55-50(60)72)89-35(30)20-84-97(79,80)92-29-9-39(59-14-24(4)44(66)54-49(59)71)87-33(29)18-82-95(75,76)90-27-7-37(85-31(27)16-61)57-12-22(2)42(64)52-47(57)69/h11-15,26-40,61-62H,6-10,16-20H2,1-5H3,(H,73,74)(H,75,76)(H,77,78)(H,79,80)(H,51,63,68)(H,52,64,69)(H,53,65,70)(H,54,66,71)(H,55,67,72)/t26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+/m0/s1",5'-T5-3',PubMed citation,8218203
4512,75168,1-oleoyl-sn-glycero-3-phosphoethanolamine,A 1-acyl-sn-glycero-3-phosphoethanolamine in which the 1-acyl group is specified as oleoyl.,"InChI=1S/C23H46NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(26)29-20-22(25)21-31-32(27,28)30-19-18-24/h9-10,22,25H,2-8,11-21,24H2,1H3,(H,27,28)/b10-9-/t22-/m1/s1",1-(9Z)-octadecenoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02050004
4513,75169,1-oleoyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as oleoyl and arachidonoyl respectively.","InChI=1S/C43H76NO8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17-19,21-22,24,28,30,41H,3-10,12,14-16,20,23,25-27,29,31-40,44H2,1-2H3,(H,47,48)/b13-11-,19-17-,21-18-,24-22-,30-28-/t41-/m1/s1","1-(9Z)-octadecenoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02011196
4514,75170,zaragozic acid A,A polyketide isolated from fungi that is a potent inhibitor of fungal and mammalian squalene synthase.,"InChI=1S/C35H46O14/c1-7-19(2)17-20(3)13-14-25(37)47-28-27(38)33(48-29(30(39)40)34(45,31(41)42)35(28,49-33)32(43)44)16-15-21(4)26(46-23(6)36)22(5)18-24-11-9-8-10-12-24/h8-14,19-20,22,26-29,38,45H,4,7,15-18H2,1-3,5-6H3,(H,39,40)(H,41,42)(H,43,44)/b14-13+/t19-,20+,22+,26+,27+,28+,29+,33-,34+,35-/m0/s1",Squalestatin 1,PDBeChem accession,ZGA
4515,75183,"3',5'-cyclic dTMP","A 3',5'-cyclic pyrimidine nucleotide derived from thymidine monophosphate.","InChI=1S/C10H13N2O7P/c1-5-3-12(10(14)11-9(5)13)8-2-6-7(18-8)4-17-20(15,16)19-6/h3,6-8H,2,4H2,1H3,(H,15,16)(H,11,13,14)/t6-,7+,8+/m0/s1","thymidine 3',5'-cyclic monophosphate",Reaxys Registry Number,44756
4516,75218,"alpha-D-galactosyl-N-(hexacosanoyl)-11,12-methylene-C22-sphinganine","A glycosylceramide in which the glycosyl moiety is alpha-D-galactose and the ceramide is N-(hexacosanoyl)-11,12-methylene-C22-sphinganine.","InChI=1S/C55H107NO8/c1-3-5-7-9-11-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-29-34-38-42-51(59)56-48(45-63-55-54(62)53(61)52(60)50(44-57)64-55)49(58)41-37-33-30-32-36-40-47-43-46(47)39-35-31-28-12-10-8-6-4-2/h46-50,52-55,57-58,60-62H,3-45H2,1-2H3,(H,56,59)/t46-,47-,48+,49-,50-,52+,53+,54-,55+/m1/s1","beta-D-galactosyl-N-(hexacosanoyl)-11,12-methylene-C22-dihydrosphingosine",PubMed citation,22195564
4517,75222,alpha-D-galactosyl-N-[(4Z)-9-(2-decylcyclopropyl)non-4-enoyl]phytosphingosine,A D-galactosyl-N-acylphytosphingosine in which the galactosyl group has alpha-anomeric configuration and the acyl group on nitrogen is (4Z)-9-(2-decylcyclopropyl)non-4-enoyl.,"InChI=1S/C46H87NO9/c1-3-5-7-9-11-13-14-15-16-18-23-27-31-39(49)42(51)38(35-55-46-45(54)44(53)43(52)40(34-48)56-46)47-41(50)32-28-24-20-19-22-26-30-37-33-36(37)29-25-21-17-12-10-8-6-4-2/h20,24,36-40,42-46,48-49,51-54H,3-19,21-23,25-35H2,1-2H3,(H,47,50)/b24-20-/t36?,37?,38-,39+,40+,42-,43-,44-,45+,46-/m0/s1",EF77,PubMed citation,22195564
4518,75224,metavanadate,A vanadium oxoanion in which a central vanadium is divalently bound to two oxygens and monovalently bound to a hydroxide.,InChI=1S/3O.V/q;;-1;,trioxovanadate,Reaxys Registry Number,3929755
4519,75226,sodium periodate,An inorganic sodium salt having periodate as the counterion.,"InChI=1S/HIO4.Na/c2-1(3,4)5;/h(H,2,3,4,5);/q;+1/p-1",sodium metaperiodate,Reaxys Registry Number,11343357
4520,75262,pipacycline,Tetracycline in which a hydrogen attached to the amide nitrogen is substituted by a 4-[(2-hydroxyethyl)piperazin-1-yl]methyl group.,"InChI=1S/C29H38N4O9/c1-28(41)15-5-4-6-18(35)19(15)23(36)20-16(28)13-17-22(31(2)3)24(37)21(26(39)29(17,42)25(20)38)27(40)30-14-33-9-7-32(8-10-33)11-12-34/h4-6,16-17,22,34-35,37-38,41-42H,7-14H2,1-3H3,(H,30,40)/t16-,17-,22-,28+,29-/m0/s1",mepicycline,Reaxys Registry Number,1614440
4521,75273,sodium tetradecyl sulfate,An organic sodium salt having tetradecyl sulfate as the counterion. Used in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.,"InChI=1S/C14H30O4S.Na/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17;/h12-14H,5-11H2,1-4H3,(H,15,16,17);/q;+1/p-1",niaproof 4,PubMed citation,23499128
4522,75293,methyltrioctylammonium,A quaternary ammonium ion with three octyl groups and one methyl group attached to the nitrogen.,"InChI=1S/C25H54N/c1-5-8-11-14-17-20-23-26(4,24-21-18-15-12-9-6-2)25-22-19-16-13-10-7-3/h5-25H2,1-4H3/q+1",methyltricaprylylammonium,Reaxys Registry Number,4135558
4523,75314,peonidin,"An anthocyanidin cation that is flavylium bearing four hydroxy substituents at positions 3, 4', 5 and 7 as well as a methoxy substituent at position 3'.","InChI=1S/C16H12O6/c1-21-15-4-8(2-3-11(15)18)16-13(20)7-10-12(19)5-9(17)6-14(10)22-16/h2-7H,1H3,(H3-,17,18,19,20)/p+1",peonidin cation,PubMed citation,23419638
4524,75318,petunidin,"An anthocyanidin cation that is flavylium bearing five hydroxy substituents at positions 3, 3', 4', 5 and 7 as well as a methoxy substituent at position 5'.","InChI=1S/C16H12O7/c1-22-14-3-7(2-11(19)15(14)21)16-12(20)6-9-10(18)4-8(17)5-13(9)23-16/h2-6H,1H3,(H4-,17,18,19,20,21)/p+1","2-(3,4-dihydroxy-5-methoxyphenyl)-3,5,7-trihydroxy-1-benzopyrylium",LIPID MAPS instance accession,LMPK12010005
4525,75321,nitrosulindac,"A carboxylic ester that is the 4-(nitrooxy)butyl ester of sulindac. A non-steroidal anti-inflammatory drug, which also has anticancer activity.","InChI=1S/C24H24FNO6S/c1-16-21(13-17-5-8-19(9-6-17)33(2)30)20-10-7-18(25)14-23(20)22(16)15-24(27)31-11-3-4-12-32-26(28)29/h5-10,13-14H,3-4,11-12,15H2,1-2H3/b21-13-",NCX 1102,Reaxys Registry Number,10305661
4526,75329,"(8E,10S)-10-hydroxy-8-octadecenoate","An unsaturated fatty acid anion that is the conjugate base of (8E,10S)-10-hydroxy-8-octadecenoic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C18H34O3/c1-2-3-4-5-8-11-14-17(19)15-12-9-6-7-10-13-16-18(20)21/h12,15,17,19H,2-11,13-14,16H2,1H3,(H,20,21)/p-1/b15-12+/t17-/m0/s1",(S)-(E)-10-hydroxy-8-octadecenoate,PubMed citation,15028873
4527,75354,(11Z)-octadecenoyl-CoA,An octadecenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (11Z)-octadecenoic acid.,"InChI=1S/C39H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h9-10,26-28,32-34,38,49-50H,4-8,11-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/b10-9-/t28-,32-,33-,34+,38-/m1/s1",11cis-octadecenoyl-CoA,LIPID MAPS instance accession,LMFA07050003
4528,75357,1-oleoyl-2-(11Z)-octadecenoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as oleoyl and (11Z)-octadecenoyl respectively.","InChI=1S/C39H73O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h14,16-17,19,37H,3-13,15,18,20-36H2,1-2H3,(H2,42,43,44)/b16-14-,19-17-/t37-/m1/s1",1-oleoyl-2-(Z)-vaccenoyl-sn-glycero-3-phosphate,HMDB accession,HMDB0007864
4529,75378,1-palmitoyl-2-lauroyl-sn-glycero-3-phospho-1D-myo-inositol,A 1-hexadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl substituent is specified as lauroyl (dodecanoyl).,"InChI=1S/C37H71O13P/c1-3-5-7-9-11-13-14-15-16-18-19-21-23-25-30(38)47-27-29(49-31(39)26-24-22-20-17-12-10-8-6-4-2)28-48-51(45,46)50-37-35(43)33(41)32(40)34(42)36(37)44/h29,32-37,40-44H,3-28H2,1-2H3,(H,45,46)/t29-,32-,33-,34+,35-,36-,37-/m1/s1",1-hexadecanoyl-2-dodecanoyl-sn-glycero-3-phospho-1D-myo-inositol,LIPID MAPS instance accession,LMGP06010946
4530,75385,"1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol)","A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which both acyl groups are specified as oleoyl.","InChI=1S/C42H79O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-37-40(38-51-53(47,48)50-36-39(44)35-43)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,39-40,43-44H,3-16,21-38H2,1-2H3,(H,47,48)/b19-17-,20-18-/t39-,40+/m0/s1","1,2-dioleoyl-sn-3-phosphatidylglycerol",LIPID MAPS instance accession,LMGP04010985
4531,75390,"3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid","A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of  arachidonate 5-lipoxygenase.","InChI=1S/C27H34ClNO2S/c1-17(2)19-10-13-22-21(14-19)24(32-26(3,4)5)23(15-27(6,7)25(30)31)29(22)16-18-8-11-20(28)12-9-18/h8-14,17H,15-16H2,1-7H3,(H,30,31)",MK886,PubMed citation,19862483
4532,75391,hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester,An organic phosphonate that is the trisacetoxymethylester derivative of naphthalene substituted  hydroxymethylphosphonic acid. It has been found to inhibit insulin receptor tyrosine kinase activity and insulin stimulated glucose oxidation.,"InChI=1S/C20H23O10P/c1-14(21)25-11-28-20(19-9-8-17-6-4-5-7-18(17)10-19)31(24,29-12-26-15(2)22)30-13-27-16(3)23/h4-10,20H,11-13H2,1-3H3","3-[(acetyloxy)methoxy]-4-(naphthalen-2-yl)-3-oxido-8-oxo-2,5,7-trioxa-3lambda(5)-phosphanon-1-yl acetate",PubMed citation,2550060
4533,75393,Y-27632,A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.,"InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11-,12-/m1/s1",(R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide,PubMed citation,17157292
4534,75394,N-acetyl-beta-D-glucosaminyl-(1->4)-alpha-D-mannose,An amino disaccharide comprised of N-acetyl-beta-D-glucosamine linked (1->4) to D-mannose.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)8(19)5(2-16)25-14(7)26-12-6(3-17)24-13(23)11(22)10(12)21/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10-,11+,12-,13+,14+/m1/s1",beta-D-GlcpNAc-(1->4)-alpha-D-Manp,GlyTouCan accession,G97041TX
4535,75402,"2-methyl-6-all-trans-nonaprenyl-1,4-benzoquinone","A polyprenylhydroquinone that is 2-methylbenzene-1,4-diol substituted by a all-trans-nonaprenyl group at position 6.","InChI=1S/C52H80O2/c1-40(2)20-12-21-41(3)22-13-23-42(4)24-14-25-43(5)26-15-27-44(6)28-16-29-45(7)30-17-31-46(8)32-18-33-47(9)34-19-35-48(10)36-37-50-39-51(53)38-49(11)52(50)54/h20,22,24,26,28,30,32,34,36,38-39,53-54H,12-19,21,23,25,27,29,31,33,35,37H2,1-11H3/b41-22+,42-24+,43-26+,44-28+,45-30+,46-32+,47-34+,48-36+","2-methyl-6-solanyl-1,4-benzoquinone",Reaxys Registry Number,21245280
4536,75404,tyrphostin AG 1478,A member of the class of  quinazolines that is quinazoline substituted by methoxy groups at positions 6 and 7 and a (3-chlorophenyl)nitrilo group at position 4. It acts as an  epidermal growth factor receptor antagonist.,"InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)",tyrphostin AG-1478,PDBeChem accession,0TO
4537,75406,2-methyl-6-phytylhydroquinone,"A member of the class of hydroquinones that is 2-methylbenzene-1,4-diol substituted by a phytyl group at position 6.","InChI=1S/C27H46O2/c1-20(2)10-7-11-21(3)12-8-13-22(4)14-9-15-23(5)16-17-25-19-26(28)18-24(6)27(25)29/h16,18-22,28-29H,7-15,17H2,1-6H3/b23-16+",MPBQ,HMDB accession,HMDB0038959
4538,75407,"2,3-dimethyl-6-phytylhydroquinone","A member of the class of  hydroquinones that is  2,3-dimethylbenzene-1,4-diol substituted by a phytyl group at position 6.","InChI=1S/C28H48O2/c1-20(2)11-8-12-21(3)13-9-14-22(4)15-10-16-23(5)17-18-26-19-27(29)24(6)25(7)28(26)30/h17,19-22,29-30H,8-16,18H2,1-7H3/b23-17+",DMPBQ,PubMed citation,20837525
4539,75415,methioninehydroxamic acid,A hydroxamic acid that is the amide of methionine hydroxylated at the amidic nitrogen.,"InChI=1S/C5H12N2O2S/c1-10-3-2-4(6)5(8)7-9/h4,9H,2-3,6H2,1H3,(H,7,8)",(+-)-methioninehydroxamic acid,Reaxys Registry Number,2411852
4540,75422,iodonitrotetrazolium,An organic cation that is the cationic component of iodonitrotetrazolium violet.,InChI=1S/C19H13IN5O2/c20-15-6-8-16(9-7-15)23-21-19(14-4-2-1-3-5-14)22-24(23)17-10-12-18(13-11-17)25(26)27/h1-13H/q+1,iodonitrotetrazolium purple,Reaxys Registry Number,3722288
4541,75430,Gly-His-Lys,"A tripeptide composed of glycine, L-histidine and L-lysine residues joined in sequence.","InChI=1S/C14H24N6O4/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24)/t10-,11-/m0/s1",Gly-L-His-L-Lys,PubMed citation,23285694
4542,75431,ghrelin,"A 28-membered appetite-stimulating polypeptide consisting of Gly, Ser, Ser(octanoyl), Phe, Leu, Ser, Pro, Glu, His, Gln, Arg, Val, Gln, Gln, Arg, Lys, Glu, Ser, Lys, Lys, Pro, Pro, Ala, Lys, Leu, Gln, Pro and Arg residues joined in sequence. The O-n-octanoylation of the side-chain hydroxy group of serine-3 (Ser3) is essential for ghrelin's activity.","InChI=1S/C149H249N47O42/c1-9-10-11-12-16-45-118(209)238-78-106(191-135(225)103(75-197)171-115(204)73-154)137(227)187-101(71-84-32-14-13-15-33-84)133(223)186-100(70-81(4)5)132(222)190-105(77-199)144(234)194-66-29-42-108(194)139(229)180-95(51-57-117(207)208)128(218)188-102(72-85-74-165-79-169-85)134(224)179-92(47-53-112(156)201)126(216)175-90(39-26-63-167-148(161)162)130(220)192-119(82(6)7)141(231)181-93(48-54-113(157)202)127(217)177-91(46-52-111(155)200)125(215)174-89(38-25-62-166-147(159)160)122(212)173-87(35-18-22-59-151)121(211)178-94(50-56-116(205)206)129(219)189-104(76-198)136(226)176-88(36-19-23-60-152)123(213)182-96(37-20-24-61-153)142(232)196-68-31-44-110(196)145(235)195-67-30-41-107(195)138(228)170-83(8)120(210)172-86(34-17-21-58-150)124(214)185-99(69-80(2)3)131(221)183-97(49-55-114(158)203)143(233)193-65-28-43-109(193)140(230)184-98(146(236)237)40-27-64-168-149(163)164/h13-15,32-33,74,79-83,86-110,119,197-199H,9-12,16-31,34-73,75-78,150-154H2,1-8H3,(H2,155,200)(H2,156,201)(H2,157,202)(H2,158,203)(H,165,169)(H,170,228)(H,171,204)(H,172,210)(H,173,212)(H,174,215)(H,175,216)(H,176,226)(H,177,217)(H,178,211)(H,179,224)(H,180,229)(H,181,231)(H,182,213)(H,183,221)(H,184,230)(H,185,214)(H,186,223)(H,187,227)(H,188,218)(H,189,219)(H,190,222)(H,191,225)(H,192,220)(H,205,206)(H,207,208)(H,236,237)(H4,159,160,166)(H4,161,162,167)(H4,163,164,168)/t83-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,119-/m0/s1",Gly-Ser-Ser(octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg,PubMed citation,23843943
4543,75437,gastrin-34,"One of the primary forms of gastrin that is a 34-membered peptide consisting of Gln, Leu, Gly, Pro, Gln, Gly, Pro, Pro, His, Leu, Val, Ala, Asp, Pro, Ser, Lys, Lys, Gln, Gly, Pro, Trp, Leu, Glu, Glu, Glu, Glu, Glu, Ala, Tyr, Gly, Trp, Met, Asp and Phe residues joined in sequence.","InChI=1S/C176H253N43O54S/c1-89(2)70-116(205-149(245)103(179)45-53-132(180)222)152(248)189-85-137(227)215-64-23-36-127(215)169(265)203-109(47-55-134(182)224)151(247)188-86-138(228)217-66-27-40-131(217)175(271)219-68-26-39-130(219)171(267)210-122(77-99-82-183-88-190-99)165(261)207-118(72-91(5)6)167(263)214-146(92(7)8)173(269)192-94(10)148(244)211-124(79-145(241)242)174(270)218-67-25-38-129(218)172(268)213-126(87-220)168(264)195-107(35-20-22-63-178)155(251)194-106(34-19-21-62-177)156(252)196-108(46-54-133(181)223)150(246)187-84-136(226)216-65-24-37-128(216)170(266)209-121(76-98-81-185-105-33-18-16-31-102(98)105)164(260)206-117(71-90(3)4)162(258)201-114(52-60-143(237)238)160(256)200-113(51-59-142(235)236)159(255)199-112(50-58-141(233)234)158(254)198-111(49-57-140(231)232)157(253)197-110(48-56-139(229)230)154(250)191-93(9)147(243)204-119(73-96-41-43-100(221)44-42-96)153(249)186-83-135(225)193-120(75-97-80-184-104-32-17-15-30-101(97)104)163(259)202-115(61-69-274-11)161(257)208-123(78-144(239)240)166(262)212-125(176(272)273)74-95-28-13-12-14-29-95/h12-18,28-33,41-44,80-82,88-94,103,106-131,146,184-185,220-221H,19-27,34-40,45-79,83-87,177-179H2,1-11H3,(H2,180,222)(H2,181,223)(H2,182,224)(H,183,190)(H,186,249)(H,187,246)(H,188,247)(H,189,248)(H,191,250)(H,192,269)(H,193,225)(H,194,251)(H,195,264)(H,196,252)(H,197,253)(H,198,254)(H,199,255)(H,200,256)(H,201,258)(H,202,259)(H,203,265)(H,204,243)(H,205,245)(H,206,260)(H,207,261)(H,208,257)(H,209,266)(H,210,267)(H,211,244)(H,212,262)(H,213,268)(H,214,263)(H,229,230)(H,231,232)(H,233,234)(H,235,236)(H,237,238)(H,239,240)(H,241,242)(H,272,273)/t93-,94-,103-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,146-/m0/s1",Gln-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys-Lys-Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe,Patent accession,EP2185180
4544,75442,1-naphthyl dihydrogen phosphate,An aryl phosphate resulting from the formal condensation of phosphoric acid with 1 mol eq. of 1-naphthol. It is a substrate for phosphatase.,"InChI=1S/C10H9O4P/c11-15(12,13)14-10-7-3-5-8-4-1-2-6-9(8)10/h1-7H,(H2,11,12,13)",1-naphthyl phosphate,CAS Registry Number,1136-89-6
4545,75451,gastrin-14,"One of the primary forms of gastrin that is a 14-membered peptide consisting of Trp, Leu, Glu, Glu, Glu, Glu, Glu, Ala, Tyr, Gly, Trp, Met, Asp and Phe residues joined in sequence.","InChI=1S/C85H109N17O27S/c1-43(2)34-62(101-75(119)52(86)37-47-40-88-53-16-10-8-14-50(47)53)83(127)97-59(26-31-71(113)114)81(125)96-58(25-30-70(111)112)80(124)95-57(24-29-69(109)110)79(123)94-56(23-28-68(107)108)78(122)93-55(22-27-67(105)106)77(121)91-44(3)74(118)100-63(36-46-18-20-49(103)21-19-46)76(120)90-42-66(104)92-64(38-48-41-89-54-17-11-9-15-51(48)54)84(128)98-60(32-33-130-4)82(126)102-65(39-72(115)116)85(129)99-61(73(87)117)35-45-12-6-5-7-13-45/h5-21,40-41,43-44,52,55-65,88-89,103H,22-39,42,86H2,1-4H3,(H2,87,117)(H,90,120)(H,91,121)(H,92,104)(H,93,122)(H,94,123)(H,95,124)(H,96,125)(H,97,127)(H,98,128)(H,99,129)(H,100,118)(H,101,119)(H,102,126)(H,105,106)(H,107,108)(H,109,110)(H,111,112)(H,113,114)(H,115,116)/t44-,52-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-/m0/s1",Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe,KEGG COMPOUND accession,C18186
4546,75469,exendin-3,"A 39-membered polypeptide consisting of His, Ser, Asp, Gly, Thr, Phe, Thr, Ser, Asp, Leu, Ser, Lys, Gln, Met, Glu, Glu, Glu, Ala, Val, Arg, Leu, Phe, Ile, Glu, Trp, Leu, Lys, Asn, Gly, Gly, Pro, Ser, Ser, Gly, Ala, Pro, Pro, Pro and Ser-NH2 residues joined in sequence. It is isolated from venom of the Gila monster lizard Heloderma horridum.","InChI=1S/C184H282N50O61S/c1-16-93(10)146(178(290)211-112(51-56-142(255)256)162(274)216-119(71-100-76-195-104-39-24-23-38-102(100)104)167(279)213-114(66-89(2)3)164(276)203-106(41-26-28-59-186)157(269)217-120(73-134(189)244)152(264)197-78-135(245)196-81-138(248)231-61-30-43-129(231)175(287)225-127(86-239)174(286)223-124(83-236)154(266)199-79-136(246)201-95(12)181(293)233-63-32-45-131(233)183(295)234-64-33-46-132(234)182(294)232-62-31-44-130(232)176(288)221-123(82-235)149(190)261)229-169(281)117(69-98-34-19-17-20-35-98)215-165(277)115(67-90(4)5)212-158(270)107(42-29-60-194-184(191)192)210-177(289)145(92(8)9)228-150(262)94(11)202-155(267)109(48-53-139(249)250)206-160(272)110(49-54-140(251)252)207-161(273)111(50-55-141(253)254)208-163(275)113(57-65-296-15)209-159(271)108(47-52-133(188)243)205-156(268)105(40-25-27-58-185)204-171(283)126(85-238)224-166(278)116(68-91(6)7)214-168(280)122(75-144(259)260)219-173(285)128(87-240)226-180(292)148(97(14)242)230-170(282)118(70-99-36-21-18-22-37-99)220-179(291)147(96(13)241)227-137(247)80-198-153(265)121(74-143(257)258)218-172(284)125(84-237)222-151(263)103(187)72-101-77-193-88-200-101/h17-24,34-39,76-77,88-97,103,105-132,145-148,195,235-242H,16,25-33,40-75,78-87,185-187H2,1-15H3,(H2,188,243)(H2,189,244)(H2,190,261)(H,193,200)(H,196,245)(H,197,264)(H,198,265)(H,199,266)(H,201,246)(H,202,267)(H,203,276)(H,204,283)(H,205,268)(H,206,272)(H,207,273)(H,208,275)(H,209,271)(H,210,289)(H,211,290)(H,212,270)(H,213,279)(H,214,280)(H,215,277)(H,216,274)(H,217,269)(H,218,284)(H,219,285)(H,220,291)(H,221,288)(H,222,263)(H,223,286)(H,224,278)(H,225,287)(H,226,292)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t93-,94-,95-,96-,97-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,145-,146-,147-,148-/m0/s1",His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2,Reaxys Registry Number,14409601
4547,75487,elaidylphosphocholine,A phosphocholine that is the mono-1-elaidyl ester of phosphocholine,"InChI=1S/C23H48NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-27-29(25,26)28-23-21-24(2,3)4/h12-13H,5-11,14-23H2,1-4H3/b13-12+",(E)-octadec-9-enylphosphocholine,PubMed citation,10974237
4548,75506,5-bromo-4-chloro-3-indolyl alpha-D-galactoside,"An indolyl carbohydrate that is the alpha-D-galactoside of indoxyl in which the indole moiety is substituted at positions 4 and 5 by chlorine and bromine, respectively.","InChI=1S/C14H15BrClNO6/c15-5-1-2-6-9(10(5)16)7(3-17-6)22-14-13(21)12(20)11(19)8(4-18)23-14/h1-3,8,11-14,17-21H,4H2/t8-,11+,12+,13-,14+/m1/s1",5-bromo-4-chloroindoxyl alpha-D-galactoside,PubMed citation,23600199
4549,75508,5-bromo-4-chloro-3-indolyl phosphate,"An aryl phosphate that is indoxyl phopshate in which the indole moiety is substituted at positions 4 and 5 by chlorine and bromine, respectively. It is used to test for the presence of an enzyme, alkaline phosphatase, which cleaves the phosphate group to give 5-bromo-4-chloroindoxyl, which immediately dimerises to give an intensely blue product.","InChI=1S/C8H6BrClNO4P/c9-4-1-2-5-7(8(4)10)6(3-11-5)15-16(12,13)14/h1-3,11H,(H2,12,13,14)",5-bromo-4-chloroindoxyl phosphate,CAS Registry Number,38404-93-2
4550,75510,5-bromo-4-chloro-3-indolyl beta-D-glucuronide,"An indolyl carbohydrate that is the beta-D-glucuronide of indoxyl in which the indole moiety is substituted at positions 4 and 5 by chlorine and bromine, respectively","InChI=1S/C14H13BrClNO7/c15-4-1-2-5-7(8(4)16)6(3-17-5)23-14-11(20)9(18)10(19)12(24-14)13(21)22/h1-3,9-12,14,17-20H,(H,21,22)/t9-,10-,11+,12-,14+/m0/s1",5-bromo-4-chloroindoxyl beta-D-glucuronide,Reaxys Registry Number,1555937
4551,75537,3-myristoyl-sn-glycerol,A 3-acyl-sn-glycerol that is the R-enantiomer of 1-myristoyl glycerol.,"InChI=1S/C17H34O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-17(20)21-15-16(19)14-18/h16,18-19H,2-15H2,1H3/t16-/m1/s1",3-tetradecanoyl-sn-glycerol,Reaxys Registry Number,1727503
4552,75558,2-oleoyl-3-stearoyl-sn-glycerol,"A 2,3-diacyl-sn-glycerol that has oleoyl and stearoyl as the 2- and 3-acyl groups respectively.","InChI=1S/C39H74O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(41)43-36-37(35-40)44-39(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,37,40H,3-17,19,21-36H2,1-2H3/b20-18-/t37-/m1/s1",2-(9Z)-octadecenoyl-3-octadecanoyl-sn-glycerol,Reaxys Registry Number,2028934
4553,75561,1-linoleoyl-sn-glycerol,A 1-acyl-sn-glycerol that is the S-enantiomer of 1-monolinolein.,"InChI=1S/C21H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h6-7,9-10,20,22-23H,2-5,8,11-19H2,1H3/b7-6-,10-9-/t20-/m0/s1","1-(9Z,12Z)-octadecadienoyl-sn-glycerol",Reaxys Registry Number,10115007
4554,75563,3-linoleoyl-sn-glycerol,A 3-acyl-sn-glycerol that is the R-enantiomer of 1-monolinolein.,"InChI=1S/C21H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h6-7,9-10,20,22-23H,2-5,8,11-19H2,1H3/b7-6-,10-9-/t20-/m1/s1","3-(9Z,12Z)-octadecadienoyl-sn-glycerol",Reaxys Registry Number,6589758
4555,75565,rac-1-monolinoleoylglycerol,A  rac-1-monoacylglycerol that is composed of equal amounts of 1-linoleoyl-sn-glycerol and 3-linoleoyl-sn-glycerol.,"InChI=1S/C21H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h6-7,9-10,20,22-23H,2-5,8,11-19H2,1H3/b7-6-,10-9-","rac-(9Z,12Z)-octadecadienoylglycerol",CAS Registry Number,2277-28-3
4556,75569,3-linoleoyl-2-oleoyl-sn-glycerol,"A 2,3-diacyl-sn-glycerol where oleoyl and linoleoyl form the 2- and 3-acyl groups respectively.","InChI=1S/C39H70O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(41)43-36-37(35-40)44-39(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11,13,17-20,37,40H,3-10,12,14-16,21-36H2,1-2H3/b13-11-,19-17-,20-18-/t37-/m1/s1","2-(9Z)-octadecenoyl-3-(9Z,12Z)-octadecadienoyl-sn-glycerol",Reaxys Registry Number,6590569
4557,75570,rac-1-linoleoyl-2-oleoylglycerol,"A rac-1,2-diglyceride composed of equal amounts of  1-linoleoyl-2-oleoyl-sn-glycerol and  3-linoleoyl-2-oleoyl-sn-glycerol.","InChI=1S/C39H70O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(41)43-36-37(35-40)44-39(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11,13,17-20,37,40H,3-10,12,14-16,21-36H2,1-2H3/b13-11-,19-17-,20-18-","rac-1(3)-(9Z,12Z)-octadecadienoyl-2-(9Z)-octadecenoylglycerol",Reaxys Registry Number,1898165
4558,75575,1-alpha-linolenoyl-sn-glycerol,A 1-acyl-sn-glycerol where alpha-linolenoyl is the 1-acyl group.,"InChI=1S/C21H36O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h3-4,6-7,9-10,20,22-23H,2,5,8,11-19H2,1H3/b4-3-,7-6-,10-9-/t20-/m0/s1","1-(9Z,12Z,15Z)-octadecatrienoyl-sn-glycerol",Reaxys Registry Number,21741359
4559,75582,1-myristoyl-2-oleoylglycerol,"A 1,2-diglyceride with myristoyl and oleoyl as the two acyl groups.","InChI=1S/C35H66O5/c1-3-5-7-9-11-13-15-16-17-18-20-22-24-26-28-30-35(38)40-33(31-36)32-39-34(37)29-27-25-23-21-19-14-12-10-8-6-4-2/h16-17,33,36H,3-15,18-32H2,1-2H3/b17-16-",1(3)-myristoyl-2-oleoyl glycerol,PubMed citation,22817898
4560,75594,dT10,An oligonucleotide comprised of ten thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C100H131N20O68P9/c1-41-21-111(91(133)101-81(41)123)71-11-51(122)62(171-71)32-161-189(143,144)181-53-13-73(113-23-43(3)83(125)103-93(113)135)173-64(53)34-163-191(147,148)183-55-15-75(115-25-45(5)85(127)105-95(115)137)175-66(55)36-165-193(151,152)185-57-17-77(117-27-47(7)87(129)107-97(117)139)177-68(57)38-167-195(155,156)187-59-19-79(119-29-49(9)89(131)109-99(119)141)179-70(59)40-169-197(159,160)188-60-20-80(120-30-50(10)90(132)110-100(120)142)178-69(60)39-168-196(157,158)186-58-18-78(118-28-48(8)88(130)108-98(118)140)176-67(58)37-166-194(153,154)184-56-16-76(116-26-46(6)86(128)106-96(116)138)174-65(56)35-164-192(149,150)182-54-14-74(114-24-44(4)84(126)104-94(114)136)172-63(54)33-162-190(145,146)180-52-12-72(170-61(52)31-121)112-22-42(2)82(124)102-92(112)134/h21-30,51-80,121-122H,11-20,31-40H2,1-10H3,(H,143,144)(H,145,146)(H,147,148)(H,149,150)(H,151,152)(H,153,154)(H,155,156)(H,157,158)(H,159,160)(H,101,123,133)(H,102,124,134)(H,103,125,135)(H,104,126,136)(H,105,127,137)(H,106,128,138)(H,107,129,139)(H,108,130,140)(H,109,131,141)(H,110,132,142)/t51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+/m0/s1",5'-T10-3',Reaxys Registry Number,5896870
4561,75597,dT8,An oligonucleotide comprised of eight thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C80H105N16O54P7/c1-33-17-89(73(107)81-65(33)99)57-9-41(98)50(137-57)26-129-151(115,116)145-43-11-59(91-19-35(3)67(101)83-75(91)109)139-52(43)28-131-153(119,120)147-45-13-61(93-21-37(5)69(103)85-77(93)111)141-54(45)30-133-155(123,124)149-47-15-63(95-23-39(7)71(105)87-79(95)113)143-56(47)32-135-157(127,128)150-48-16-64(96-24-40(8)72(106)88-80(96)114)142-55(48)31-134-156(125,126)148-46-14-62(94-22-38(6)70(104)86-78(94)112)140-53(46)29-132-154(121,122)146-44-12-60(92-20-36(4)68(102)84-76(92)110)138-51(44)27-130-152(117,118)144-42-10-58(136-49(42)25-97)90-18-34(2)66(100)82-74(90)108/h17-24,41-64,97-98H,9-16,25-32H2,1-8H3,(H,115,116)(H,117,118)(H,119,120)(H,121,122)(H,123,124)(H,125,126)(H,127,128)(H,81,99,107)(H,82,100,108)(H,83,101,109)(H,84,102,110)(H,85,103,111)(H,86,104,112)(H,87,105,113)(H,88,106,114)/t41-,42-,43-,44-,45-,46-,47-,48-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+/m0/s1",5'-T8-3',PubMed citation,7110140
4562,75602,dT4,An oligonucleotide comprised of four thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C40H53N8O26P3/c1-17-9-45(37(55)41-33(17)51)29-5-21(50)26(69-29)14-65-75(59,60)73-23-7-31(47-11-19(3)35(53)43-39(47)57)71-28(23)16-67-77(63,64)74-24-8-32(48-12-20(4)36(54)44-40(48)58)70-27(24)15-66-76(61,62)72-22-6-30(68-25(22)13-49)46-10-18(2)34(52)42-38(46)56/h9-12,21-32,49-50H,5-8,13-16H2,1-4H3,(H,59,60)(H,61,62)(H,63,64)(H,41,51,55)(H,42,52,56)(H,43,53,57)(H,44,54,58)/t21-,22-,23-,24-,25+,26+,27+,28+,29+,30+,31+,32+/m0/s1",T4,PubMed citation,6182906
4563,75608,2-palmitoyloxypalmityl palmitate,"A wax ester resulting from the formal condensation of both the hydroxy groups of  hexadecane-1,2-diol with two molecules of  palmitic acid.","InChI=1S/C48H94O4/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-47(49)51-45-46(42-39-36-33-30-27-24-21-18-15-12-9-6-3)52-48(50)44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h46H,4-45H2,1-3H3",2-hexadecanoyloxyhexadecyl hexadecanoate,Reaxys Registry Number,2317354
4564,75623,palmitoleyl alcohol,A member of the class of hexadecen-1-ols that is hexadecanol containing a double bond located at position 9 (the Z-geoisomer).,"InChI=1S/C16H32O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h7-8,17H,2-6,9-16H2,1H3/b8-7-",palmitoleyl alcohol,Reaxys Registry Number,3538811
4565,75652,procyanidin B2 3-O-gallate,A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of procyanidin B2.,"InChI=1S/C37H30O16/c38-16-9-23(44)29-28(10-16)51-34(14-2-4-19(40)22(43)6-14)36(53-37(50)15-7-25(46)32(49)26(47)8-15)31(29)30-24(45)12-20(41)17-11-27(48)33(52-35(17)30)13-1-3-18(39)21(42)5-13/h1-10,12,27,31,33-34,36,38-49H,11H2/t27-,31-,33-,34-,36-/m1/s1",(-)-epicatechin-(4beta->8)-(-)-epicatechin-3-O-gallate,Reaxys Registry Number,4903058
4566,75653,procyanidin B1 3'-O-gallate,A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3'S)-hydroxy group of procyanidin B1.,"InChI=1S/C37H30O16/c38-16-9-23(44)29-27(10-16)51-35(14-2-4-19(40)22(43)6-14)33(49)31(29)30-24(45)12-20(41)17-11-28(52-37(50)15-7-25(46)32(48)26(47)8-15)34(53-36(17)30)13-1-3-18(39)21(42)5-13/h1-10,12,28,31,33-35,38-49H,11H2/t28-,31+,33+,34+,35+/m0/s1",(-)-epicatechin-(4beta->8)-(+)-catechin-3'-O-gallate,Reaxys Registry Number,6765100
4567,75655,procyanidin B4 3'-O-gallate,A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3'R)-hydroxy group of procyanidin B4.,"InChI=1S/C37H30O16/c38-16-9-23(44)29-27(10-16)51-35(14-2-4-19(40)22(43)6-14)33(49)31(29)30-24(45)12-20(41)17-11-28(52-37(50)15-7-25(46)32(48)26(47)8-15)34(53-36(17)30)13-1-3-18(39)21(42)5-13/h1-10,12,28,31,33-35,38-49H,11H2/t28-,31+,33+,34-,35-/m1/s1",(-)-epicatechin-(4alpha->8)-(+)-catechin-3'-O-gallate,Reaxys Registry Number,4903081
4568,75663,procyanidin B4 3-O-gallate,A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3S)-hydroxy group of procyanidin B4.,"InChI=1S/C37H30O16/c38-16-9-23(44)29-28(10-16)51-34(14-2-4-19(40)22(43)6-14)36(53-37(50)15-7-25(46)32(49)26(47)8-15)31(29)30-24(45)12-20(41)17-11-27(48)33(52-35(17)30)13-1-3-18(39)21(42)5-13/h1-10,12,27,31,33-34,36,38-49H,11H2/t27-,31+,33-,34-,36+/m1/s1",(-)-epicatechin-(4alpha->8)-(+)-catechin-3-O-gallate,Reaxys Registry Number,10638331
4569,75675,delphinidin 3-O-(6-O-(Z)-4-coumaroyl-beta-D-glucoside),An anthocyanin cation that is delphinidin substituted at position 3 by a 6-O-(cis-4 coumaryl)-beta-D-glucosyl residue,"InChI=1S/C30H26O14/c31-15-4-1-13(2-5-15)3-6-24(36)41-12-23-26(38)27(39)28(40)30(44-23)43-22-11-17-18(33)9-16(32)10-21(17)42-29(22)14-7-19(34)25(37)20(35)8-14/h1-11,23,26-28,30,38-40H,12H2,(H5-,31,32,33,34,35,36,37)/p+1/t23-,26-,27+,28-,30-/m1/s1",delfinidin 3-O-(6-O-(Z)-4-coumaroyl-beta-D-glucoside),Reaxys Registry Number,9605464
4570,75682,dT21,An oligonucleotide comprised of 21 thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C210H274N42O145P20/c1-85-43-232(190(276)211-169(85)255)148-22-106(254)128(358-148)65-337-398(297,298)379-108-24-150(234-45-87(3)171(257)213-192(234)278)360-130(108)67-339-400(301,302)381-110-26-152(236-47-89(5)173(259)215-194(236)280)362-132(110)69-341-402(305,306)383-112-28-154(238-49-91(7)175(261)217-196(238)282)364-134(112)71-343-404(309,310)385-114-30-156(240-51-93(9)177(263)219-198(240)284)366-136(114)73-345-406(313,314)387-116-32-158(242-53-95(11)179(265)221-200(242)286)368-138(116)75-347-408(317,318)389-118-34-160(244-55-97(13)181(267)223-202(244)288)370-140(118)77-349-410(321,322)391-120-36-162(246-57-99(15)183(269)225-204(246)290)372-142(120)79-351-412(325,326)393-122-38-164(248-59-101(17)185(271)227-206(248)292)374-144(122)81-353-414(329,330)395-124-40-166(250-61-103(19)187(273)229-208(250)294)376-146(124)83-355-416(333,334)397-126-42-168(252-63-105(21)189(275)231-210(252)296)377-147(126)84-356-417(335,336)396-125-41-167(251-62-104(20)188(274)230-209(251)295)375-145(125)82-354-415(331,332)394-123-39-165(249-60-102(18)186(272)228-207(249)293)373-143(123)80-352-413(327,328)392-121-37-163(247-58-100(16)184(270)226-205(247)291)371-141(121)78-350-411(323,324)390-119-35-161(245-56-98(14)182(268)224-203(245)289)369-139(119)76-348-409(319,320)388-117-33-159(243-54-96(12)180(266)222-201(243)287)367-137(117)74-346-407(315,316)386-115-31-157(241-52-94(10)178(264)220-199(241)285)365-135(115)72-344-405(311,312)384-113-29-155(239-50-92(8)176(262)218-197(239)283)363-133(113)70-342-403(307,308)382-111-27-153(237-48-90(6)174(260)216-195(237)281)361-131(111)68-340-401(303,304)380-109-25-151(235-46-88(4)172(258)214-193(235)279)359-129(109)66-338-399(299,300)378-107-23-149(357-127(107)64-253)233-44-86(2)170(256)212-191(233)277/h43-63,106-168,253-254H,22-42,64-84H2,1-21H3,(H,297,298)(H,299,300)(H,301,302)(H,303,304)(H,305,306)(H,307,308)(H,309,310)(H,311,312)(H,313,314)(H,315,316)(H,317,318)(H,319,320)(H,321,322)(H,323,324)(H,325,326)(H,327,328)(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,211,255,276)(H,212,256,277)(H,213,257,278)(H,214,258,279)(H,215,259,280)(H,216,260,281)(H,217,261,282)(H,218,262,283)(H,219,263,284)(H,220,264,285)(H,221,265,286)(H,222,266,287)(H,223,267,288)(H,224,268,289)(H,225,269,290)(H,226,270,291)(H,227,271,292)(H,228,272,293)(H,229,273,294)(H,230,274,295)(H,231,275,296)/t106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+/m0/s1",5'-T21-3',PubMed citation,8634294
4571,75683,dT6,An oligonucleotide comprised of six thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C60H79N12O40P5/c1-25-13-67(55(81)61-49(25)75)43-7-31(74)38(103-43)20-97-113(87,88)109-33-9-45(69-15-27(3)51(77)63-57(69)83)105-40(33)22-99-115(91,92)111-35-11-47(71-17-29(5)53(79)65-59(71)85)107-42(35)24-101-117(95,96)112-36-12-48(72-18-30(6)54(80)66-60(72)86)106-41(36)23-100-116(93,94)110-34-10-46(70-16-28(4)52(78)64-58(70)84)104-39(34)21-98-114(89,90)108-32-8-44(102-37(32)19-73)68-14-26(2)50(76)62-56(68)82/h13-18,31-48,73-74H,7-12,19-24H2,1-6H3,(H,87,88)(H,89,90)(H,91,92)(H,93,94)(H,95,96)(H,61,75,81)(H,62,76,82)(H,63,77,83)(H,64,78,84)(H,65,79,85)(H,66,80,86)/t31-,32-,33-,34-,35-,36-,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+/m0/s1",5'-TTTTTT-3',PubMed citation,6182906
4572,75690,"(8R)-hydroxy-(11R,12R)-epoxyicosa-(5Z,9E,14Z)-trienoic acid","An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,9E,14Z)-icosa-5,9,14-trienoic acid having additional (8R)-hydroxy- and (11R,12R)-epoxy groups.","InChI=1S/C20H32O4/c1-2-3-4-5-6-10-13-18-19(24-18)16-15-17(21)12-9-7-8-11-14-20(22)23/h6-7,9-10,15-19,21H,2-5,8,11-14H2,1H3,(H,22,23)/b9-7-,10-6-,16-15+/t17-,18-,19-/m1/s1","(8R)-hydroxy-(11R,12R)-epoxyeicosa-(5Z,9E,14Z)-trienoic acid",Reaxys Registry Number,4707311
4573,75692,"(8R)-hydroxy-(11S,12S)-epoxyicosa-(5Z,9E,14Z)-trienoic acid","An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,9E,14Z)-icosa-5,9,14-trienoic acid having additional (8R)-hydroxy- and (11S,12S)-epoxy groups.","InChI=1S/C20H32O4/c1-2-3-4-5-6-10-13-18-19(24-18)16-15-17(21)12-9-7-8-11-14-20(22)23/h6-7,9-10,15-19,21H,2-5,8,11-14H2,1H3,(H,22,23)/b9-7-,10-6-,16-15+/t17-,18+,19+/m1/s1","(8R)-hydroxy-(11S,12S)-epoxyeicosa-(5Z,9E,14Z)-trienoic acid",PubMed citation,12881489
4574,75695,dC21,An oligonucleotide comprised of 21 2'-deoxycytidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C189H253N63O124P20/c190-127-1-22-232(169(255)211-127)148-43-85(254)107(337-148)65-316-377(276,277)358-87-45-150(234-24-3-129(192)213-171(234)257)339-109(87)67-318-379(280,281)360-89-47-152(236-26-5-131(194)215-173(236)259)341-111(89)69-320-381(284,285)362-91-49-154(238-28-7-133(196)217-175(238)261)343-113(91)71-322-383(288,289)364-93-51-156(240-30-9-135(198)219-177(240)263)345-115(93)73-324-385(292,293)366-95-53-158(242-32-11-137(200)221-179(242)265)347-117(95)75-326-387(296,297)368-97-55-160(244-34-13-139(202)223-181(244)267)349-119(97)77-328-389(300,301)370-99-57-162(246-36-15-141(204)225-183(246)269)351-121(99)79-330-391(304,305)372-101-59-164(248-38-17-143(206)227-185(248)271)353-123(101)81-332-393(308,309)374-103-61-166(250-40-19-145(208)229-187(250)273)355-125(103)83-334-395(312,313)376-105-63-168(252-42-21-147(210)231-189(252)275)356-126(105)84-335-396(314,315)375-104-62-167(251-41-20-146(209)230-188(251)274)354-124(104)82-333-394(310,311)373-102-60-165(249-39-18-144(207)228-186(249)272)352-122(102)80-331-392(306,307)371-100-58-163(247-37-16-142(205)226-184(247)270)350-120(100)78-329-390(302,303)369-98-56-161(245-35-14-140(203)224-182(245)268)348-118(98)76-327-388(298,299)367-96-54-159(243-33-12-138(201)222-180(243)266)346-116(96)74-325-386(294,295)365-94-52-157(241-31-10-136(199)220-178(241)264)344-114(94)72-323-384(290,291)363-92-50-155(239-29-8-134(197)218-176(239)262)342-112(92)70-321-382(286,287)361-90-48-153(237-27-6-132(195)216-174(237)260)340-110(90)68-319-380(282,283)359-88-46-151(235-25-4-130(193)214-172(235)258)338-108(88)66-317-378(278,279)357-86-44-149(336-106(86)64-253)233-23-2-128(191)212-170(233)256/h1-42,85-126,148-168,253-254H,43-84H2,(H,276,277)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)(H,294,295)(H,296,297)(H,298,299)(H,300,301)(H,302,303)(H,304,305)(H,306,307)(H,308,309)(H,310,311)(H,312,313)(H,314,315)(H2,190,211,255)(H2,191,212,256)(H2,192,213,257)(H2,193,214,258)(H2,194,215,259)(H2,195,216,260)(H2,196,217,261)(H2,197,218,262)(H2,198,219,263)(H2,199,220,264)(H2,200,221,265)(H2,201,222,266)(H2,202,223,267)(H2,203,224,268)(H2,204,225,269)(H2,205,226,270)(H2,206,227,271)(H2,207,228,272)(H2,208,229,273)(H2,209,230,274)(H2,210,231,275)/t85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+/m0/s1",5'-d(*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*cp*c)-3',PubMed citation,8634294
4575,75696,"(10R)-hydroxy-(11S,12S)-epoxyicosa-(5Z,8Z,14Z)-trienoic acid","An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,8Z,14Z)-icosa-5,9,14-trienoic acid having additional (10R)-hydroxy- and (11S,12S)-epoxy groups.","InChI=1S/C20H32O4/c1-2-3-4-5-9-12-15-18-20(24-18)17(21)14-11-8-6-7-10-13-16-19(22)23/h6-7,9,11-12,14,17-18,20-21H,2-5,8,10,13,15-16H2,1H3,(H,22,23)/b7-6-,12-9-,14-11-/t17-,18+,20+/m1/s1","(10R)-hydroxy-(11S,12S)-epoxyeicosa-(5Z,8Z,14Z)-trienoic acid",Reaxys Registry Number,6179789
4576,75698,dG15,An oligonucleotide comprised of fifteen 2'-deoxyguanosine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C150H181N75O88P14/c151-136-181-106-91(121(228)196-136)166-31-211(106)76-1-46(227)62(286-76)17-271-314(243,244)301-48-3-78(213-33-168-93-108(213)183-138(153)198-123(93)230)288-64(48)19-273-316(247,248)303-50-5-80(215-35-170-95-110(215)185-140(155)200-125(95)232)290-66(50)21-275-318(251,252)305-52-7-82(217-37-172-97-112(217)187-142(157)202-127(97)234)292-68(52)23-277-320(255,256)307-54-9-84(219-39-174-99-114(219)189-144(159)204-129(99)236)294-70(54)25-279-322(259,260)309-56-11-86(221-41-176-101-116(221)191-146(161)206-131(101)238)296-72(56)27-281-324(263,264)311-58-13-88(223-43-178-103-118(223)193-148(163)208-133(103)240)298-74(58)29-283-326(267,268)313-60-15-90(225-45-180-105-120(225)195-150(165)210-135(105)242)299-75(60)30-284-327(269,270)312-59-14-89(224-44-179-104-119(224)194-149(164)209-134(104)241)297-73(59)28-282-325(265,266)310-57-12-87(222-42-177-102-117(222)192-147(162)207-132(102)239)295-71(57)26-280-323(261,262)308-55-10-85(220-40-175-100-115(220)190-145(160)205-130(100)237)293-69(55)24-278-321(257,258)306-53-8-83(218-38-173-98-113(218)188-143(158)203-128(98)235)291-67(53)22-276-319(253,254)304-51-6-81(216-36-171-96-111(216)186-141(156)201-126(96)233)289-65(51)20-274-317(249,250)302-49-4-79(214-34-169-94-109(214)184-139(154)199-124(94)231)287-63(49)18-272-315(245,246)300-47-2-77(285-61(47)16-226)212-32-167-92-107(212)182-137(152)197-122(92)229/h31-90,226-227H,1-30H2,(H,243,244)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,269,270)(H3,151,181,196,228)(H3,152,182,197,229)(H3,153,183,198,230)(H3,154,184,199,231)(H3,155,185,200,232)(H3,156,186,201,233)(H3,157,187,202,234)(H3,158,188,203,235)(H3,159,189,204,236)(H3,160,190,205,237)(H3,161,191,206,238)(H3,162,192,207,239)(H3,163,193,208,240)(H3,164,194,209,241)(H3,165,195,210,242)/t46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+/m0/s1",d(G)15,PubMed citation,8634294
4577,75699,A8dT5A8,"An oligonucleotide comprised of a sequence of eight adenosine, five thymidine and a further eight adenosine residues connected via 3'->5' phosphodiester linkages.","InChI=1S/C210H258N90O129P20/c1-69-11-280(206(324)275-185(69)319)100-6-74(410-430(329,330)370-18-81-75(7-101(390-81)281-12-70(2)186(320)276-207(281)325)412-432(333,334)372-20-83-77(9-103(392-83)283-14-72(4)188(322)278-209(283)327)414-434(337,338)375-23-86-139(124(305)192(396-86)287-55-261-107-155(213)229-39-245-171(107)287)418-438(345,346)379-27-90-143(128(309)196(400-90)291-59-265-111-159(217)233-43-249-175(111)291)422-442(353,354)383-31-94-147(132(313)200(404-94)295-63-269-115-163(221)237-47-253-179(115)295)426-446(361,362)387-35-98-151(136(317)204(408-98)299-67-273-119-167(225)241-51-257-183(119)299)429-448(365,366)386-34-97-149(134(315)202(407-97)297-65-271-117-165(223)239-49-255-181(117)297)425-444(357,358)382-30-93-145(130(311)198(403-93)293-61-267-113-161(219)235-45-251-177(113)293)421-440(349,350)378-26-89-141(126(307)194(399-89)289-57-263-109-157(215)231-41-247-173(109)289)417-436(341,342)374-22-85-121(302)122(303)190(395-85)285-53-259-105-153(211)227-37-243-169(105)285)80(389-100)17-369-431(331,332)411-76-8-102(282-13-71(3)187(321)277-208(282)326)391-82(76)19-371-433(335,336)413-78-10-104(284-15-73(5)189(323)279-210(284)328)393-84(78)21-373-435(339,340)416-140-88(398-193(125(140)306)288-56-262-108-156(214)230-40-246-172(108)288)25-377-439(347,348)420-144-92(402-197(129(144)310)292-60-266-112-160(218)234-44-250-176(112)292)29-381-443(355,356)424-148-96(406-201(133(148)314)296-64-270-116-164(222)238-48-254-180(116)296)33-385-447(363,364)428-152-99(409-205(137(152)318)300-68-274-120-168(226)242-52-258-184(120)300)36-388-449(367,368)427-150-95(405-203(135(150)316)298-66-272-118-166(224)240-50-256-182(118)298)32-384-445(359,360)423-146-91(401-199(131(146)312)294-62-268-114-162(220)236-46-252-178(114)294)28-380-441(351,352)419-142-87(397-195(127(142)308)290-58-264-110-158(216)232-42-248-174(110)290)24-376-437(343,344)415-138-79(16-301)394-191(123(138)304)286-54-260-106-154(212)228-38-244-170(106)286/h11-15,37-68,74-104,121-152,190-205,301-318H,6-10,16-36H2,1-5H3,(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,337,338)(H,339,340)(H,341,342)(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H2,211,227,243)(H2,212,228,244)(H2,213,229,245)(H2,214,230,246)(H2,215,231,247)(H2,216,232,248)(H2,217,233,249)(H2,218,234,250)(H2,219,235,251)(H2,220,236,252)(H2,221,237,253)(H2,222,238,254)(H2,223,239,255)(H2,224,240,256)(H2,225,241,257)(H2,226,242,258)(H,275,319,324)(H,276,320,325)(H,277,321,326)(H,278,322,327)(H,279,323,328)/t74-,75-,76-,77-,78-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,190+,191+,192+,193+,194+,195+,196+,197+,198+,199+,200+,201+,202+,203+,204+,205+/m0/s1",A1-8T9T10T11T12T13A14-21,PubMed citation,8634294
4578,75700,"(13R)-hydroxy-(14S,15S)-epoxyicosa-(5Z,8Z,11Z)-trienoic acid","An epoxy(hydroxy)icosatrienoic acid consisting of (5Z,8Z,11Z)-icosa-5,9,14-trienoic acid having additional (13R)-hydroxy- and (14S,15S)-epoxy groups.","InChI=1S/C20H32O4/c1-2-3-11-15-18-20(24-18)17(21)14-12-9-7-5-4-6-8-10-13-16-19(22)23/h5-8,12,14,17-18,20-21H,2-4,9-11,13,15-16H2,1H3,(H,22,23)/b7-5-,8-6-,14-12-/t17-,18+,20+/m1/s1","(13R)-hydroxy-(14S,15S)-epoxyeicosa-(5Z,8Z,11Z)-trienoic acid",Reaxys Registry Number,21166181
4579,75702,dU5,An oligonucleotide comprised of five 2-deoxyuridine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C45H56N10O33P4/c56-16-26-22(12-37(80-26)52-7-2-32(59)47-42(52)64)85-90(70,71)77-18-28-24(14-39(82-28)54-9-4-34(61)49-44(54)66)87-92(74,75)79-20-30-25(15-40(84-30)55-10-5-35(62)50-45(55)67)88-91(72,73)78-19-29-23(13-38(83-29)53-8-3-33(60)48-43(53)65)86-89(68,69)76-17-27-21(57)11-36(81-27)51-6-1-31(58)46-41(51)63/h1-10,21-30,36-40,56-57H,11-20H2,(H,68,69)(H,70,71)(H,72,73)(H,74,75)(H,46,58,63)(H,47,59,64)(H,48,60,65)(H,49,61,66)(H,50,62,67)/t21-,22-,23-,24-,25-,26+,27+,28+,29+,30+,36+,37+,38+,39+,40+/m0/s1",DNA dU5,PubMed citation,8634294
4580,75704,2-(4-chloro-2-methylphenoxy)propanoic acid,A monocarboxylic acid that is lactic acid in which the hydroxyl hydrogen is replaced by a 4-chloro-2-methylphenyl group.,"InChI=1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)",2-(4-chloro-2-methylphenoxy)propionic acid,KEGG COMPOUND accession,C18742
4581,75709,petunidin 3-O-(6-O-(E)-4-coumaroyl-beta-D-glucoside),An anthocyanin cation that is petunidin substituted at position 3 by a 6-O-(trans-4 coumaryl)-beta-D-glucosyl residue,"InChI=1S/C31H28O14/c1-41-22-9-15(8-20(35)26(22)37)30-23(12-18-19(34)10-17(33)11-21(18)43-30)44-31-29(40)28(39)27(38)24(45-31)13-42-25(36)7-4-14-2-5-16(32)6-3-14/h2-12,24,27-29,31,38-40H,13H2,1H3,(H4-,32,33,34,35,36,37)/p+1/t24-,27-,28+,29-,31-/m1/s1",petunidin-3-O-(6-O-trans-p-coumaryl-beta-D-glucoside),Reaxys Registry Number,9605417
4582,75710,dT2,An oligonucleotide comprised of two thymidine residues connected via a 3'->5' phosphodiester linkage.,"InChI=1S/C20H27N4O12P/c1-9-5-23(19(29)21-17(9)27)15-3-11(26)14(35-15)8-33-37(31,32)36-12-4-16(34-13(12)7-25)24-6-10(2)18(28)22-20(24)30/h5-6,11-16,25-26H,3-4,7-8H2,1-2H3,(H,31,32)(H,21,27,29)(H,22,28,30)/t11-,12-,13+,14+,15+,16+/m0/s1","dithymidylyl-3',5'-phosphate",PubMed citation,7110140
4583,75712,(S)-mecoprop,The (S)-enantiomer of 2-(4-chloro-2-methylphenoxy)propanoic acid; the inactive stereoisomer of the racemic herbicide mecoprop.,"InChI=1S/C10H11ClO3/c1-6-5-8(11)3-4-9(6)14-7(2)10(12)13/h3-5,7H,1-2H3,(H,12,13)/t7-/m0/s1",(S)-MCPP,Reaxys Registry Number,3201761
4584,75713,dT12,An oligonucleotide comprised of twelve thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C120H157N24O82P11/c1-49-25-133(109(159)121-97(49)147)85-13-61(146)74(205-85)38-193-227(171,172)217-63-15-87(135-27-51(3)99(149)123-111(135)161)207-76(63)40-195-229(175,176)219-65-17-89(137-29-53(5)101(151)125-113(137)163)209-78(65)42-197-231(179,180)221-67-19-91(139-31-55(7)103(153)127-115(139)165)211-80(67)44-199-233(183,184)223-69-21-93(141-33-57(9)105(155)129-117(141)167)213-82(69)46-201-235(187,188)225-71-23-95(143-35-59(11)107(157)131-119(143)169)215-84(71)48-203-237(191,192)226-72-24-96(144-36-60(12)108(158)132-120(144)170)214-83(72)47-202-236(189,190)224-70-22-94(142-34-58(10)106(156)130-118(142)168)212-81(70)45-200-234(185,186)222-68-20-92(140-32-56(8)104(154)128-116(140)166)210-79(68)43-198-232(181,182)220-66-18-90(138-30-54(6)102(152)126-114(138)164)208-77(66)41-196-230(177,178)218-64-16-88(136-28-52(4)100(150)124-112(136)162)206-75(64)39-194-228(173,174)216-62-14-86(204-73(62)37-145)134-26-50(2)98(148)122-110(134)160/h25-36,61-96,145-146H,13-24,37-48H2,1-12H3,(H,171,172)(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H,181,182)(H,183,184)(H,185,186)(H,187,188)(H,189,190)(H,191,192)(H,121,147,159)(H,122,148,160)(H,123,149,161)(H,124,150,162)(H,125,151,163)(H,126,152,164)(H,127,153,165)(H,128,154,166)(H,129,155,167)(H,130,156,168)(H,131,157,169)(H,132,158,170)/t61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+/m0/s1",thymidylyl-(3->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidylyl-(3'->5')-thymidine,Reaxys Registry Number,1560102
4585,75733,"(R,R)-tramadol hydrochloride","A hydrochloride resulting from the reaction of (R,R)-tramadol with 1 molar equivalent of hydrogen chloride; the (R,R)-enantiomer of the racemic opioid analgesic tramadol hydrochloride, it exhibits ten-fold higher analgesic potency than the (S,S)-enantiomer.","InChI=1S/C16H25NO2.ClH/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3;/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3;1H/t14-,16+;/m1./s1",(+)-tramadol hydrochloride,Reaxys Registry Number,6164343
4586,75734,"(S,S)-tramadol hydrochloride","A hydrochloride resulting from the reaction of (S,S)-tramadol with 1 molar equivalent of hydrogen chloride; the (S,S)-enantiomer of the racemic opioid analgesic tramadol hydrochloride, it exhibits ten-fold lower analgesic potency than the (R,R)-enantiomer.","InChI=1S/C16H25NO2.ClH/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3;/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3;1H/t14-,16+;/m0./s1",(-)-tramadol hydrochloride,Reaxys Registry Number,7864871
4587,75749,(+)-taxifolin 3-O-alpha-L-arabinopyranoside,A flavanone glycoside that is (+)-taxifolin substituted by an alpha-L-arabinopyranosyl residue at position 3.,"InChI=1S/C20H20O11/c21-8-4-11(24)14-13(5-8)30-18(7-1-2-9(22)10(23)3-7)19(16(14)27)31-20-17(28)15(26)12(25)6-29-20/h1-5,12,15,17-26,28H,6H2/t12-,15-,17+,18+,19-,20-/m0/s1","(2R,3R)-taxifolin 3-O-alpha-L-arabinopyranoside",Reaxys Registry Number,23444994
4588,75784,1-O-(alpha-D-galactopyranosyl)-N-nonanoylphytosphingosine,A glycophytoceramide having an alpha-D-galctopyranosyl residue at the O-1 position and a nonanoyl group attached to the nitrogen.,"InChI=1S/C33H65NO9/c1-3-5-7-9-11-12-13-14-15-16-17-19-21-26(36)29(38)25(34-28(37)22-20-18-10-8-6-4-2)24-42-33-32(41)31(40)30(39)27(23-35)43-33/h25-27,29-33,35-36,38-41H,3-24H2,1-2H3,(H,34,37)/t25-,26+,27+,29-,30-,31-,32+,33-/m0/s1","(2S,3S,4R)-1-O-(alpha-D-galactosyl)-N-nonanoyl-2-amino-1,3,4-octadecanetriol",PubMed citation,23898038
4589,75796,kaempferol 3-O-beta-D-allopyranoside,A glycosyloxyflavone that is kaempferol attached to a beta-D-allopyranosyl moiety at position 3 via a glycosidic linkage.,"InChI=1S/C21H20O11/c22-7-13-15(26)17(28)18(29)21(31-13)32-20-16(27)14-11(25)5-10(24)6-12(14)30-19(20)8-1-3-9(23)4-2-8/h1-6,13,15,17-18,21-26,28-29H,7H2/t13-,15-,17-,18-,21+/m1/s1",asiaticalin,Reaxys Registry Number,1359974
4590,75797,kaempferol 3-O-alpha-L-glucopyranoside,A kaempferol O-glucoside that is  kaempferol attached to an alpha-L-glucopyranosyl moiety at position 3 via a glycosidic linkage.,"InChI=1S/C21H20O11/c22-7-13-15(26)17(28)18(29)21(31-13)32-20-16(27)14-11(25)5-10(24)6-12(14)30-19(20)8-1-3-9(23)4-2-8/h1-6,13,15,17-18,21-26,28-29H,7H2/t13-,15-,17+,18-,21-/m0/s1",astragolin,Reaxys Registry Number,1359977
4591,75801,A2'p5'A,A (2'->5')-dinucleotide in which the two nucleoside components connected by the (2'->5')-phosphodiester linkage are adenosine.,"InChI=1S/C20H25N10O10P/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(34)11(32)8(39-19)2-37-41(35,36)40-14-12(33)7(1-31)38-20(14)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-34H,1-2H2,(H,35,36)(H2,21,23,25)(H2,22,24,26)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1",adenosin-2'-yl adenosin-5'-yl phosphate,Reaxys Registry Number,76321
4592,75803,A3'p5'A3'p5'A,An oligonucleotide comprised of three adenosine components connected by (3'->5')-phosphodiester linkages.,"InChI=1S/C30H37N15O16P2/c31-22-13-25(37-4-34-22)43(7-40-13)28-17(48)16(47)11(58-28)2-55-62(51,52)61-21-12(59-30(19(21)50)45-9-42-15-24(33)36-6-39-27(15)45)3-56-63(53,54)60-20-10(1-46)57-29(18(20)49)44-8-41-14-23(32)35-5-38-26(14)44/h4-12,16-21,28-30,46-50H,1-3H2,(H,51,52)(H,53,54)(H2,31,34,37)(H2,32,35,38)(H2,33,36,39)/t10-,11-,12-,16-,17-,18-,19-,20-,21-,28-,29-,30-/m1/s1",(A3'p5')2A,PubMed citation,6181514
4593,75804,pppA2'p5'A2'p5'A2'p5'A2'p5'4A,An oligonucleotide comprised of five adenosine residues connected by 2'->5' phosphodiester linkages and with a triphosphate group at the 5' terminus.,"InChI=1S/C50H64N25O37P7/c51-36-21-41(61-6-56-36)71(11-66-21)46-31(81)26(76)16(102-46)1-97-114(85,86)107-32-27(77)17(103-47(32)72-12-67-22-37(52)57-7-62-42(22)72)2-98-115(87,88)108-33-28(78)18(104-48(33)73-13-68-23-38(53)58-8-63-43(23)73)3-99-116(89,90)109-34-29(79)19(105-49(34)74-14-69-24-39(54)59-9-64-44(24)74)4-100-117(91,92)110-35-30(80)20(5-101-118(93,94)112-119(95,96)111-113(82,83)84)106-50(35)75-15-70-25-40(55)60-10-65-45(25)75/h6-20,26-35,46-50,76-81H,1-5H2,(H,85,86)(H,87,88)(H,89,90)(H,91,92)(H,93,94)(H,95,96)(H2,51,56,61)(H2,52,57,62)(H2,53,58,63)(H2,54,59,64)(H2,55,60,65)(H2,82,83,84)/t16-,17-,18-,19-,20-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,46-,47-,48-,49-,50-/m1/s1",ppp(A2'p5')4A,PubMed citation,6181514
4594,75807,myricetin 3-O-glucuronide,A myricetin O-glucuronide that is myricetin with a beta-D-glucosiduronic acid residue attached at the 3-position.,"InChI=1S/C21H18O14/c22-6-3-7(23)11-10(4-6)33-17(5-1-8(24)12(26)9(25)2-5)18(13(11)27)34-21-16(30)14(28)15(29)19(35-21)20(31)32/h1-4,14-16,19,21-26,28-30H,(H,31,32)/t14-,15-,16+,19-,21+/m0/s1",myricetin 3-O-beta-D-glucopyranosiduronic acid,LIPID MAPS instance accession,LMPK12112437
4595,75814,N-(deoxyguanosin-8-yl)-2-aminofluorene,Guanosine substituted at the purine 8-position by a (9H-fluoren-2-yl)amino group.,"InChI=1S/C23H22N6O4/c24-22-27-20-19(21(32)28-22)26-23(29(20)18-9-16(31)17(10-30)33-18)25-13-5-6-15-12(8-13)7-11-3-1-2-4-14(11)15/h1-6,8,16-18,30-31H,7,9-10H2,(H,25,26)(H3,24,27,28,32)/t16-,17+,18+/m0/s1",dG-C8-AF,Reaxys Registry Number,3578362
4596,75816,myricetin 3'-O-beta-D-glucopyranoside,A myricetin O-glucoside that is myricetin with a beta-D-glucosyl residue attached at position 3'.,"InChI=1S/C21H20O13/c22-5-12-15(27)17(29)19(31)21(34-12)33-11-2-6(1-9(25)14(11)26)20-18(30)16(28)13-8(24)3-7(23)4-10(13)32-20/h1-4,12,15,17,19,21-27,29-31H,5H2/t12-,15-,17+,19-,21-/m1/s1",cannabiscitrin,Reaxys Registry Number,69547
4597,75828,"(8E,10S)-10-hydroxy-8-octadecenoic acid","A HOME in which the hydroxy group is located at position 10 with the double bond at position 8 (the 8E,10S-isomer).","InChI=1S/C18H34O3/c1-2-3-4-5-8-11-14-17(19)15-12-9-6-7-10-13-16-18(20)21/h12,15,17,19H,2-11,13-14,16H2,1H3,(H,20,21)/b15-12+/t17-/m0/s1",10S-HOME(8E),Reaxys Registry Number,8577116
4598,75829,5'-CTGCAGAATTCTGGTACCA-3',"A single-stranded DNA oligonucleotide comprised of five deoxyadenosine, five deoxycytidine, five thymidine and four deoxyguanidine residues connected by 3'->5' phosphodiester linkages in the sequence CTGCAGAATTCTGGTACCA.","InChI=1S/C185H234N70O112P18/c1-73-35-242(181(272)232-163(73)258)127-22-84(103(337-127)46-314-369(279,280)350-79-17-122(331-97(79)40-256)237-11-6-116(186)219-176(237)267)357-376(293,294)327-55-112-93(31-136(346-112)252-69-215-145-159(252)224-172(196)228-168(145)263)364-379(299,300)318-45-102-83(21-126(336-102)241-15-10-120(190)223-180(241)271)354-372(285,286)323-51-108-91(29-134(342-108)250-67-213-143-152(194)203-62-208-157(143)250)363-383(307,308)329-57-114-96(34-139(348-114)255-72-218-148-162(255)227-175(199)231-171(148)266)366-384(309,310)326-54-111-92(30-135(345-111)251-68-214-144-153(195)204-63-209-158(144)251)362-382(305,306)325-53-110-90(28-133(344-110)249-66-212-142-151(193)202-61-207-156(142)249)361-380(301,302)321-49-106-86(24-129(340-106)244-37-75(3)165(260)234-183(244)274)356-374(289,290)320-48-105-85(23-128(339-105)243-36-74(2)164(259)233-182(243)273)355-373(287,288)316-43-100-82(20-125(334-100)240-14-9-119(189)222-179(240)270)353-371(283,284)319-47-104-87(25-130(338-104)245-38-76(4)166(261)235-184(245)275)359-377(295,296)328-56-113-95(33-138(347-113)254-71-217-147-161(254)226-174(198)230-170(147)265)367-385(311,312)330-58-115-94(32-137(349-115)253-70-216-146-160(253)225-173(197)229-169(146)264)365-381(303,304)322-50-107-88(26-131(341-107)246-39-77(5)167(262)236-185(246)276)358-375(291,292)324-52-109-89(27-132(343-109)248-65-211-141-150(192)201-60-206-155(141)248)360-378(297,298)317-44-101-81(19-124(335-101)239-13-8-118(188)221-178(239)269)352-370(281,282)315-42-99-80(18-123(333-99)238-12-7-117(187)220-177(238)268)351-368(277,278)313-41-98-78(257)16-121(332-98)247-64-210-140-149(191)200-59-205-154(140)247/h6-15,35-39,59-72,78-115,121-139,256-257H,16-34,40-58H2,1-5H3,(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H,303,304)(H,305,306)(H,307,308)(H,309,310)(H,311,312)(H2,186,219,267)(H2,187,220,268)(H2,188,221,269)(H2,189,222,270)(H2,190,223,271)(H2,191,200,205)(H2,192,201,206)(H2,193,202,207)(H2,194,203,208)(H2,195,204,209)(H,232,258,272)(H,233,259,273)(H,234,260,274)(H,235,261,275)(H,236,262,276)(H3,196,224,228,263)(H3,197,225,229,264)(H3,198,226,230,265)(H3,199,227,231,266)/t78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+/m0/s1",d(C-T-G-C-A-G-A-A-T-T-C-T-G-G-T-A-C-C-A),PubMed citation,15557264
4599,75832,iron(2+) sulfate (anhydrous),"A compound of iron and sulfate in which the ratio of iron(2+) to sulfate ions is 1:1. Various hydrates occur naturally - most commonly the heptahydrate, which loses water to form the tetrahydrate at 57degreeC and the monohydrate at 65degreeC.","InChI=1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",FeSO4,MetaCyc accession,CPD0-2386
4600,75834,iron(2+) sulfate monohydrate,"A hydrate that is the monohydrate form of iron(2+) sulfate. It is obtained from the heptahydrate by heating above 65degreeC. It is used as a source of iron in the treatment of iron-deficiency anaemia (generally in solid-dosage treatments; for liquid-dosage treatments, the heptahydrate is normally used).","InChI=1S/Fe.H2O4S.H2O/c;1-5(2,3)4;/h;(H2,1,2,3,4);1H2/q+2;;/p-2",ferrous sulfate (dried),CAS Registry Number,17375-41-6
4601,75842,dihydrodaidzein,A hydroxyisoflavanone that is isoflavanone carrying two hydroxy substituents located at positions 4' and 7.,"InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)13-8-19-14-7-11(17)5-6-12(14)15(13)18/h1-7,13,16-17H,8H2","7,4'-dihydroxyisoflavanone",LIPID MAPS instance accession,LMPK12050447
4602,75856,3-methylfumaryl-CoA,An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the least hindered carboxy group of mesaconic acid.,"InChI=1S/C26H40N7O19P3S/c1-13(25(39)40)8-16(35)56-7-6-28-15(34)4-5-29-23(38)20(37)26(2,3)10-49-55(46,47)52-54(44,45)48-9-14-19(51-53(41,42)43)18(36)24(50-14)33-12-32-17-21(27)30-11-31-22(17)33/h8,11-12,14,18-20,24,36-37H,4-7,9-10H2,1-3H3,(H,28,34)(H,29,38)(H,39,40)(H,44,45)(H,46,47)(H2,27,30,31)(H2,41,42,43)/b13-8+/t14-,18-,19-,20+,24-/m1/s1",3-methylfumaryl-coenzyme A,KEGG COMPOUND accession,C18323
4603,75860,(3R)-citramalyl-CoA,The (3R)-diastereomer of citramalyl-CoA.,"InChI=1S/C26H42N7O20P3S/c1-25(2,19(37)22(38)29-5-4-14(34)28-6-7-57-15(35)8-26(3,41)24(39)40)10-50-56(47,48)53-55(45,46)49-9-13-18(52-54(42,43)44)17(36)23(51-13)33-12-32-16-20(27)30-11-31-21(16)33/h11-13,17-19,23,36-37,41H,4-10H2,1-3H3,(H,28,34)(H,29,38)(H,39,40)(H,45,46)(H,47,48)(H2,27,30,31)(H2,42,43,44)/t13-,17-,18-,19+,23-,26-/m1/s1",(3R)-citramalyl-coenzyme A,MetaCyc accession,CPD-9414
4604,75865,D-glucosaminic acid 6-phosphate,A carbohydrate phosphate that is the 6-O-phospho derivative of 2-amino-2-deoxy-D-gluconic acid.,"InChI=1S/C6H14NO9P/c7-3(6(11)12)5(10)4(9)2(8)1-16-17(13,14)15/h2-5,8-10H,1,7H2,(H,11,12)(H2,13,14,15)/t2-,3-,4-,5-/m1/s1",6-phospho-2-amino-2-deoxy-D-gluconic acid,Reaxys Registry Number,2508530
4605,75871,(S)-sarin,"The (S)-enantiomer of sarin; the more potent enantiomer of racemic sarin, a nerve agent that is employed as a chemical warfare agent.","InChI=1S/C4H10FO2P/c1-4(2)7-8(3,5)6/h4H,1-3H3/t8-/m0/s1",(S)-(-)-sarin,Reaxys Registry Number,2409983
4606,75872,(R)-sarin,"The (S)-enantiomer of sarin; the less active enantiomer of racemic sarin, a nerve agent that is employed as a chemical warfare agent.","InChI=1S/C4H10FO2P/c1-4(2)7-8(3,5)6/h4H,1-3H3/t8-/m1/s1",(R)-(+)-sarin,Reaxys Registry Number,6711462
4607,75876,"(3R,4R)-3,4-dihydroxycyclohexa-1,5-diene-1-carboxylic acid","A cyclohexadienecarboxylic acid that is cyclohexa-1,5-diene-1-carboxylic acid carrying two hydroxy substituents at positions 3 and 4 (the 3R,4R-stereoisomer).","InChI=1S/C7H8O4/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,5-6,8-9H,(H,10,11)/t5-,6-/m1/s1",DCDC,Reaxys Registry Number,2936284
4608,75894,4-O-(beta-L-Araf-(1->2)-beta-L-Araf-(1->2)-beta-L-Araf)-cis-L-Hyp,An O(4)-glycosyl-L-hydroxyproline that is cis-L-hydroxylproline glycosylated by a beta-L-Araf-(1->2)-beta-L-Araf-(1->2)-beta-L-Araf moiety,"InChI=1S/C20H33NO15/c22-3-8-11(25)14(28)18(32-8)35-16-13(27)10(5-24)34-20(16)36-15-12(26)9(4-23)33-19(15)31-6-1-7(17(29)30)21-2-6/h6-16,18-28H,1-5H2,(H,29,30)/t6-,7-,8-,9-,10-,11-,12-,13-,14+,15+,16+,18+,19-,20+/m0/s1",Ara3-Hyp,PubMed citation,21149454
4609,75911,5'-GCAG-3',"A single-stranded DNA oligonucleotide comprised of one deoxycytidine, one deoxyadenosine and two deoxyguanosine residues connected by 3'->5' phosphodiester linkages in the sequence GCAG.","InChI=1S/C39H49N18O21P3/c40-23-1-2-54(39(62)49-23)25-5-17(21(74-25)9-70-80(65,66)76-16-4-27(72-19(16)7-58)57-14-48-30-34(57)51-38(43)53-36(30)61)77-81(67,68)71-10-22-18(6-26(75-22)55-12-46-28-31(41)44-11-45-32(28)55)78-79(63,64)69-8-20-15(59)3-24(73-20)56-13-47-29-33(56)50-37(42)52-35(29)60/h1-2,11-22,24-27,58-59H,3-10H2,(H,63,64)(H,65,66)(H,67,68)(H2,40,49,62)(H2,41,44,45)(H3,42,50,52,60)(H3,43,51,53,61)/t15-,16-,17-,18-,19+,20+,21+,22+,24+,25+,26+,27+/m0/s1",3'-GACG-5',PubMed citation,15557264
4610,75931,26-desglucoavenacoside B,A steroid saponin that is avenacoside B lacking the 26-O-glucosyl residue.,"InChI=1S/C51H82O23/c1-20-31-27(73-51(20)13-12-48(3,19-55)74-51)15-26-24-7-6-22-14-23(8-10-49(22,4)25(24)9-11-50(26,31)5)66-47-43(72-44-37(61)35(59)32(56)21(2)65-44)39(63)41(30(18-54)69-47)70-46-40(64)42(34(58)29(17-53)68-46)71-45-38(62)36(60)33(57)28(16-52)67-45/h6,20-21,23-47,52-64H,7-19H2,1-5H3/t20-,21-,23-,24+,25-,26-,27-,28+,29+,30+,31-,32-,33+,34+,35+,36-,37+,38+,39-,40+,41+,42-,43+,44-,45-,46-,47+,48-,49-,50-,51-/m0/s1","(22S,25S)-3beta-{beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->4)-[alpha-L-rhamnosyl-(1->2)]-glucopyranosyloxy}-22,25-epoxyfurost-5-en-26-ol",Agricola citation,IND43989963
4611,75942,5'-GTAACCGAAATCGGTTGA-3',"A single-stranded DNA oligonucleotide comprised of six deoxyadenosine, three deoxycytidine, four thymidine and five deoxyguanidine residues connected by 3'->5' phosphodiester linkages in the sequence GTAACCGAAATCGGTTGA.","InChI=1S/C177H221N72O104P17/c1-68-29-235(174(264)228-157(68)252)115-16-77(95(324-115)38-303-355(270,271)337-73-12-124(319-90(73)33-250)245-63-210-135-152(245)218-166(187)223-161(135)256)343-361(282,283)310-42-99-83(22-121(328-99)242-60-207-132-143(184)195-54-201-149(132)242)348-366(292,293)311-43-100-81(20-119(329-100)240-58-205-130-141(182)193-52-199-147(130)240)346-363(286,287)306-37-94-74(13-112(323-94)232-8-5-108(178)215-171(232)261)338-356(272,273)304-35-92-75(14-113(321-92)233-9-6-109(179)216-172(233)262)339-357(274,275)315-48-105-88(27-127(334-105)248-66-213-138-155(248)221-169(190)226-164(138)259)352-369(298,299)314-46-103-85(24-123(332-103)244-62-209-134-145(186)197-56-203-151(134)244)350-368(296,297)313-45-102-84(23-122(331-102)243-61-208-133-144(185)196-55-202-150(133)243)349-367(294,295)312-44-101-82(21-120(330-101)241-59-206-131-142(183)194-53-200-148(131)241)347-364(288,289)308-40-97-78(17-116(326-97)236-30-69(2)158(253)229-175(236)265)341-359(278,279)305-36-93-76(15-114(322-93)234-10-7-110(180)217-173(234)263)340-358(276,277)316-49-106-89(28-128(335-106)249-67-214-139-156(249)222-170(191)227-165(139)260)353-370(300,301)318-50-107-87(26-126(336-107)247-65-212-137-154(247)220-168(189)225-163(137)258)351-365(290,291)309-41-98-79(18-117(327-98)237-31-70(3)159(254)230-176(237)266)342-360(280,281)307-39-96-80(19-118(325-96)238-32-71(4)160(255)231-177(238)267)344-362(284,285)317-47-104-86(25-125(333-104)246-64-211-136-153(246)219-167(188)224-162(136)257)345-354(268,269)302-34-91-72(251)11-111(320-91)239-57-204-129-140(181)192-51-198-146(129)239/h5-10,29-32,51-67,72-107,111-128,250-251H,11-28,33-50H2,1-4H3,(H,268,269)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)(H,294,295)(H,296,297)(H,298,299)(H,300,301)(H2,178,215,261)(H2,179,216,262)(H2,180,217,263)(H2,181,192,198)(H2,182,193,199)(H2,183,194,200)(H2,184,195,201)(H2,185,196,202)(H2,186,197,203)(H,228,252,264)(H,229,253,265)(H,230,254,266)(H,231,255,267)(H3,187,218,223,256)(H3,188,219,224,257)(H3,189,220,225,258)(H3,190,221,226,259)(H3,191,222,227,260)/t72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+/m0/s1",5'-d[GTAACCGAAATCGGTTGA]-3',PubMed citation,17512945
4612,75943,5'-TCAACCGATTTCGGTTAC-3',"A single-stranded DNA oligonucleotide comprised of four deoxyadenosine, five deoxycytidine, six thymidine and three deoxyguanosine residues connected by 3'->5' phosphodiester linkages in the sequence T-C-A-A-C-C-G-A-T-T-T-C-G-G-T-T-A-C.","InChI=1S/C175H223N62O108P17/c1-70-35-225(170(254)214-153(70)240)122-18-77(94(41-238)311-122)329-347(262,263)295-43-96-78(19-118(313-96)221-13-8-113(177)204-166(221)250)331-349(266,267)304-53-106-90(31-131(323-106)234-66-199-138-145(184)191-62-195-149(138)234)342-360(288,289)306-54-107-88(29-129(324-107)232-64-197-136-143(182)189-60-193-147(136)232)340-357(282,283)298-46-99-79(20-119(316-99)222-14-9-114(178)205-167(222)251)330-348(264,265)296-44-97-80(21-120(314-97)223-15-10-115(179)206-168(223)252)332-350(268,269)308-56-109-92(33-133(326-109)236-68-201-140-151(236)209-163(186)212-160(140)247)344-361(290,291)307-55-108-89(30-130(325-108)233-65-198-137-144(183)190-61-194-148(137)233)341-358(284,285)302-50-103-84(25-125(320-103)228-38-73(4)156(243)217-173(228)257)336-354(276,277)300-48-101-83(24-124(318-101)227-37-72(3)155(242)216-172(227)256)335-353(274,275)299-47-100-82(23-123(317-100)226-36-71(2)154(241)215-171(226)255)334-352(272,273)297-45-98-81(22-121(315-98)224-16-11-116(180)207-169(224)253)333-351(270,271)309-57-110-93(34-134(327-110)237-69-202-141-152(237)210-164(187)213-161(141)248)345-362(292,293)310-58-111-91(32-132(328-111)235-67-200-139-150(235)208-162(185)211-159(139)246)343-359(286,287)303-51-104-85(26-126(321-104)229-39-74(5)157(244)218-174(229)258)337-355(278,279)301-49-102-86(27-127(319-102)230-40-75(6)158(245)219-175(230)259)338-356(280,281)305-52-105-87(28-128(322-105)231-63-196-135-142(181)188-59-192-146(135)231)339-346(260,261)294-42-95-76(239)17-117(312-95)220-12-7-112(176)203-165(220)249/h7-16,35-40,59-69,76-111,117-134,238-239H,17-34,41-58H2,1-6H3,(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H,268,269)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)(H,284,285)(H,286,287)(H,288,289)(H,290,291)(H,292,293)(H2,176,203,249)(H2,177,204,250)(H2,178,205,251)(H2,179,206,252)(H2,180,207,253)(H2,181,188,192)(H2,182,189,193)(H2,183,190,194)(H2,184,191,195)(H,214,240,254)(H,215,241,255)(H,216,242,256)(H,217,243,257)(H,218,244,258)(H,219,245,259)(H3,185,208,211,246)(H3,186,209,212,247)(H3,187,210,213,248)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+/m0/s1",5'-d[TCAACCGATTTCGGTTAC]-3',PubMed citation,17512945
4613,75944,5'-TCAACC-3',"A single-stranded DNA oligonucleotide comprised of two deoxyadenosine, one thymidine and three deoxycytidine residues connected by 3'->5' phosphodiester linkages in the sequence TCAACC.","InChI=1S/C57H74N21O33P5/c1-25-14-76(57(85)72-53(25)81)44-9-27(32(15-79)101-44)107-113(88,89)97-17-34-29(11-43(103-34)75-7-4-40(60)71-56(75)84)109-114(90,91)99-19-36-31(13-46(105-36)78-24-68-48-50(62)64-22-66-52(48)78)111-116(94,95)100-20-37-30(12-45(106-37)77-23-67-47-49(61)63-21-65-51(47)77)110-115(92,93)98-18-35-28(10-42(104-35)74-6-3-39(59)70-55(74)83)108-112(86,87)96-16-33-26(80)8-41(102-33)73-5-2-38(58)69-54(73)82/h2-7,14,21-24,26-37,41-46,79-80H,8-13,15-20H2,1H3,(H,86,87)(H,88,89)(H,90,91)(H,92,93)(H,94,95)(H2,58,69,82)(H2,59,70,83)(H2,60,71,84)(H2,61,63,65)(H2,62,64,66)(H,72,81,85)/t26-,27-,28-,29-,30-,31-,32+,33+,34+,35+,36+,37+,41+,42+,43+,44+,45+,46+/m0/s1",5'-d[TCAACC]-3',PubMed citation,17512945
4614,75948,"c[G(2',5')pA(2',5')p]","A cyclic purine dinucleotide that consists of AMP and GMP units cyclised via 2',5'-linkages.","InChI=1S/C20H24N10O13P2/c21-14-8-15(24-3-23-14)29(4-25-8)18-12-10(31)6(40-18)1-38-45(36,37)43-13-11(32)7(2-39-44(34,35)42-12)41-19(13)30-5-26-9-16(30)27-20(22)28-17(9)33/h3-7,10-13,18-19,31-32H,1-2H2,(H,34,35)(H,36,37)(H2,21,23,24)(H3,22,27,28,33)/t6-,7-,10-,11-,12-,13-,18-,19-/m1/s1","2',5'-cyclic GMP-AMP",PubMed citation,23910378
4615,75949,"4-methyl-1,4-dihydropyridine-3,5-dicarbaldehyde","A dialdehyde in which the two carbaldehyde functions are at positions 3 and 5 of 4-methyl-1,4-dihydropyridine. Although the compound is an entity in its own right, the nitrogen of the dihydropyridine ring may also arise from the epsilon-amino group of a lysine residue within a protein [MDHDC-protein adduct; malonaldedehyde (synonym malondialdehyde) acetaldehyde (MAA)-protein adduct].","InChI=1S/C8H9NO2/c1-6-7(4-10)2-9-3-8(6)5-11/h2-6,9H,1H3",MDHDC,PubMed citation,23900424
4616,75951,protopanaxatriol,"A tetracyclic triterpenoid sapogenin (isolated from ginseng and notoginseng) that is that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions and in which a double bond has been introduced at the 24-25 position.","InChI=1S/C30H52O4/c1-18(2)10-9-13-30(8,34)19-11-15-28(6)24(19)20(31)16-22-27(5)14-12-23(33)26(3,4)25(27)21(32)17-29(22,28)7/h10,19-25,31-34H,9,11-17H2,1-8H3/t19-,20+,21-,22+,23-,24-,25-,27+,28+,29+,30-/m0/s1","dammar-24-ene-3beta,6alpha,12beta,20-tetrol",Reaxys Registry Number,5771276
4617,75952,rac-1-oleoyl-3-palmitoylglycerol,A racemate comprising equimolar amounts of 1-palmitoyl-3-oleoyl-sn-glycerol and 1-oleoyl-3-palmitoyl-sn-glycerol.,"InChI=1S/C37H70O5/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(40)42-34-35(38)33-41-36(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,35,38H,3-16,19-34H2,1-2H3/b18-17-",1(3)-(9Z)-octadecenoyl-3(1)-hexadecanoylglycerol,Reaxys Registry Number,1717866
4618,75955,copper(II) oxide,A metal oxide that has the formula CuO. It has an ionic structure.,InChI=1S/Cu.O/q+2;-2,cupric oxide,Reaxys Registry Number,8128137
4619,75957,dTDP-beta-L-4-epi-vancosamine(1-),"A nucleotide-sugar oxoanion that is the conjugate base of dTDP-beta-L-4-epi-vancosamine, arising from deprotonation of the diphosphate group and protonation of the amino group.","InChI=1S/C17H29N3O13P2/c1-8-6-20(16(24)19-15(8)23)12-4-10(21)11(31-12)7-29-34(25,26)33-35(27,28)32-13-5-17(3,18)14(22)9(2)30-13/h6,9-14,21-22H,4-5,7,18H2,1-3H3,(H,25,26)(H,27,28)(H,19,23,24)/p-1/t9-,10-,11+,12+,13+,14-,17-/m0/s1","dTDP-3-amino-2,3,6-trideoxy-3-methyl-beta-L-arabino-hexopyranose",PubMed citation,15070728
4620,75972,(R)-2-hydroxyhexadecanoic acid,The R-enantiomer of 2-hydroxypalmitic acid.,"InChI=1S/C16H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(17)16(18)19/h15,17H,2-14H2,1H3,(H,18,19)/t15-/m1/s1",(R)-2-hydroxypalmitic acid,LIPID MAPS instance accession,LMFA01050423
4621,75977,(S)-2-hydroxyhexadecanoic acid,The S-enantiomer of 2-hydroxypalmitic acid.,"InChI=1S/C16H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(17)16(18)19/h15,17H,2-14H2,1H3,(H,18,19)/t15-/m0/s1",(S)-2-hydroxypalmitic acid,LIPID MAPS instance accession,LMFA01050422
4622,75989,alpha-D-glucosamine 6-phosphate(1-),A 2-ammonio-2-deoxy-D-glucopyranose 6-phosphate in which the anomeric centre has alpha-configuration.,"InChI=1S/C6H14NO8P/c7-3-5(9)4(8)2(15-6(3)10)1-14-16(11,12)13/h2-6,8-10H,1,7H2,(H2,11,12,13)/p-1/t2-,3-,4-,5-,6+/m1/s1",2-ammonio-2-deoxy-alpha-D-glucopyranose 6-phosphate(1-),MetaCyc accession,CPD-13469
4623,76034,thioflavin T cation,"A benzothiazolium ion obtained by methylation of the thiazole nitrogen of 2-[4-(dimethylamino)phenyl]-6-methyl-1,3-benzothiazole; the cationic component of thioflavin T.","InChI=1S/C17H19N2S/c1-12-5-10-15-16(11-12)20-17(19(15)4)13-6-8-14(9-7-13)18(2)3/h5-11H,1-4H3/q+1",thioflavin T(1+),Reaxys Registry Number,3910379
4624,76046,(+)-(S)-alapyridaine,An iminium betaine that is L-alanine in which the amino group is replaced by a 5-hydroxy-2-(hydroxymethyl)pyridinium-1-yl moiety.,"InChI=1S/C9H11NO4/c1-6(9(13)14)10-4-8(12)3-2-7(10)5-11/h2-4,6,11H,5H2,1H3,(H-,12,13,14)/t6-/m0/s1",N-(1-carboxyethyl)-6-hydroxymethyl-pyridinium-3-ol,Reaxys Registry Number,9553168
4625,76059,d(CG)12,"A 24-residue single-stranded DNA oligonucleotide consisting of an alternating sequence of deoxycytidine and deoxyguanosine residues, all connected by 3'->5' phosphodiester linkages. It forms one strand of the double-stranded DNA oligonucleotide [d(C-G).d(C-G)]12 [synonym d(CG/GC)12].","InChI=1S/C228H289N96O142P23/c229-133-1-13-301(217(339)265-133)146-26-86(109(49-325)420-146)444-468(353,354)398-62-122-98(38-158(433-122)314-74-254-170-182(314)278-206(242)290-194(170)328)456-480(377,378)400-52-112-88(28-148(423-112)303-15-3-135(231)267-219(303)341)446-470(357,358)411-64-124-100(40-160(435-124)316-76-256-172-184(316)280-208(244)292-196(172)330)458-482(381,382)402-54-114-90(30-150(425-114)305-17-5-137(233)269-221(305)343)448-472(361,362)413-66-126-102(42-162(437-126)318-78-258-174-186(318)282-210(246)294-198(174)332)460-484(385,386)404-56-116-92(32-152(427-116)307-19-7-139(235)271-223(307)345)450-474(365,366)415-68-128-104(44-164(439-128)320-80-260-176-188(320)284-212(248)296-200(176)334)462-486(389,390)406-58-118-94(34-154(429-118)309-21-9-141(237)273-225(309)347)452-476(369,370)417-70-130-106(46-166(441-130)322-82-262-178-190(322)286-214(250)298-202(178)336)464-488(393,394)408-60-120-96(36-156(431-120)311-23-11-143(239)275-227(311)349)454-478(373,374)419-72-132-108(48-168(443-132)324-84-264-180-192(324)288-216(252)300-204(180)338)466-489(395,396)409-61-121-97(37-157(432-121)312-24-12-144(240)276-228(312)350)455-477(371,372)418-71-131-107(47-167(442-131)323-83-263-179-191(323)287-215(251)299-203(179)337)465-487(391,392)407-59-119-95(35-155(430-119)310-22-10-142(238)274-226(310)348)453-475(367,368)416-69-129-105(45-165(440-129)321-81-261-177-189(321)285-213(249)297-201(177)335)463-485(387,388)405-57-117-93(33-153(428-117)308-20-8-140(236)272-224(308)346)451-473(363,364)414-67-127-103(43-163(438-127)319-79-259-175-187(319)283-211(247)295-199(175)333)461-483(383,384)403-55-115-91(31-151(426-115)306-18-6-138(234)270-222(306)344)449-471(359,360)412-65-125-101(41-161(436-125)317-77-257-173-185(317)281-209(245)293-197(173)331)459-481(379,380)401-53-113-89(29-149(424-113)304-16-4-136(232)268-220(304)342)447-469(355,356)410-63-123-99(39-159(434-123)315-75-255-171-183(315)279-207(243)291-195(171)329)457-479(375,376)399-51-111-87(27-147(422-111)302-14-2-134(230)266-218(302)340)445-467(351,352)397-50-110-85(326)25-145(421-110)313-73-253-169-181(313)277-205(241)289-193(169)327/h1-24,73-132,145-168,325-326H,25-72H2,(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,371,372)(H,373,374)(H,375,376)(H,377,378)(H,379,380)(H,381,382)(H,383,384)(H,385,386)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,395,396)(H2,229,265,339)(H2,230,266,340)(H2,231,267,341)(H2,232,268,342)(H2,233,269,343)(H2,234,270,344)(H2,235,271,345)(H2,236,272,346)(H2,237,273,347)(H2,238,274,348)(H2,239,275,349)(H2,240,276,350)(H3,241,277,289,327)(H3,242,278,290,328)(H3,243,279,291,329)(H3,244,280,292,330)(H3,245,281,293,331)(H3,246,282,294,332)(H3,247,283,295,333)(H3,248,284,296,334)(H3,249,285,297,335)(H3,250,286,298,336)(H3,251,287,299,337)(H3,252,288,300,338)/t85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+/m0/s1",5'-CpG-3',PubMed citation,4092691
4626,76069,1-(3-O-sulfo-beta-D-galactosyl)-N-[(2R)-2-hydroxylignoceroyl]sphingosine,A galactosylceramide sulfate in which the sulfo group is located at position 3 and the ceramide N-acyl group is specified as (R)-2-hydroxylignoceroyl.,"InChI=1S/C48H93NO12S/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-37-42(52)47(55)49-40(41(51)36-34-32-30-28-26-24-16-14-12-10-8-6-4-2)39-59-48-45(54)46(61-62(56,57)58)44(53)43(38-50)60-48/h34,36,40-46,48,50-54H,3-33,35,37-39H2,1-2H3,(H,49,55)(H,56,57,58)/b36-34+/t40-,41+,42+,43+,44-,45+,46-,48+/m0/s1",2-hydroxytetracosanoyl sulfatide,PDBeChem accession,SFT
4627,76106,rac-laudanosoline,A racemate composed of equimolar amounts of (R)- and (S)-laudanosoline,"InChI=1S/C20H25NO4/c1-21-8-7-14-11-19(24-3)20(25-4)12-15(14)16(21)9-13-5-6-18(23-2)17(22)10-13/h5-6,10-12,16,22H,7-9H2,1-4H3",racemic laudanosoline,KEGG COMPOUND accession,C17592
4628,76108,1-O-[6-O-(1-naphthylcarbamoyl)-alpha-D-galactopyranosyl]-N-hexacosanoylphytosphingosine,A glycophytoceramide having a 6-O-(1-naphthylcarbamoyl)-alpha-D-galactopyranosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen.,"InChI=1S/C61H106N2O10/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-46-55(65)62-52(56(66)53(64)45-36-34-32-30-28-16-14-12-10-8-6-4-2)47-71-60-59(69)58(68)57(67)54(73-60)48-72-61(70)63-51-44-40-42-49-41-38-39-43-50(49)51/h38-44,52-54,56-60,64,66-69H,3-37,45-48H2,1-2H3,(H,62,65)(H,63,70)/t52-,53+,54+,56-,57-,58-,59+,60-/m0/s1","alpha-GalCer-6""(1-naphthyl)carbamate",PubMed citation,23960235
4629,76110,2'-(5-phosphoribosyl)-5'-AMP,An AMP-sugar in which the 2'-hydroxy group of AMP carries a 5-phospho-beta-D-ribosyl substituent. Monomer unit of poly(ADP-Rib) [poly(adenosine diphosphate ribose)].,"InChI=1S/C15H23N5O14P2/c16-12-7-13(18-3-17-12)20(4-19-7)14-11(9(22)6(32-14)2-31-36(27,28)29)34-15-10(23)8(21)5(33-15)1-30-35(24,25)26/h3-6,8-11,14-15,21-23H,1-2H2,(H2,16,17,18)(H2,24,25,26)(H2,27,28,29)/t5-,6-,8-,9-,10-,11-,14-,15+/m1/s1",2'-(5-phosphoribosyl)adenosine 5'-monophosphate,PubMed citation,6206890
4630,76111,2'-[2-(5-phosphoribosyl)-5-phosphoribosyl]-5'-AMP,"An AMP-sugar in which the 2'-hydroxy group of AMP carries a 5-phospho-beta-D-ribosyl substituent, the 2-hydroxy group of which itself carries a further 5-phospho-beta-D-ribosyl substituent. Branched portion of poly(ADP-Rib) [poly(adenosine diphosphate ribose)].","InChI=1S/C20H32N5O21P3/c21-16-9-17(23-4-22-16)25(5-24-9)18-14(11(27)7(42-18)2-40-48(33,34)35)45-20-15(12(28)8(44-20)3-41-49(36,37)38)46-19-13(29)10(26)6(43-19)1-39-47(30,31)32/h4-8,10-15,18-20,26-29H,1-3H2,(H2,21,22,23)(H2,30,31,32)(H2,33,34,35)(H2,36,37,38)/t6-,7-,8-,10-,11-,12-,13-,14-,15-,18-,19+,20+/m1/s1",Ado(P)-Rib(P)-Rib-P,PubMed citation,6206890
4631,76112,5'-AATTTAA-3',A single-stranded DNA oligonucleotide comprised of four deoxyadenosine and three thymidine residues connected by 3'->5' phosphodiester linkages in the sequence AATTTAA.,"InChI=1S/C70H88N26O39P6/c1-29-11-90(68(102)87-65(29)99)47-6-34(131-138(109,110)120-17-42-36(8-49(126-42)92-13-31(3)67(101)89-70(92)104)133-140(113,114)122-20-45-37(9-51(129-45)95-27-85-55-59(73)77-23-81-63(55)95)134-136(105,106)117-15-40-32(98)4-46(124-40)93-25-83-53-57(71)75-21-79-61(53)93)41(125-47)16-119-139(111,112)132-35-7-48(91-12-30(2)66(100)88-69(91)103)127-43(35)18-121-141(115,116)135-38-10-52(96-28-86-56-60(74)78-24-82-64(56)96)128-44(38)19-118-137(107,108)130-33-5-50(123-39(33)14-97)94-26-84-54-58(72)76-22-80-62(54)94/h11-13,21-28,32-52,97-98H,4-10,14-20H2,1-3H3,(H,105,106)(H,107,108)(H,109,110)(H,111,112)(H,113,114)(H,115,116)(H2,71,75,79)(H2,72,76,80)(H2,73,77,81)(H2,74,78,82)(H,87,99,102)(H,88,100,103)(H,89,101,104)/t32-,33-,34-,35-,36-,37-,38-,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+/m0/s1",5'-d[AATTTAA]-3',PubMed citation,7525097
4632,76113,5'-AATTCAA-3',"A single-stranded DNA oligonucleotide comprised of four deoxyadenosine, two thymidine residues and one deoxycytidine residue connected by 3'->5' phosphodiester linkages in the sequence AATTCAA.","InChI=1S/C70H88N26O38P6/c1-30-13-91(69(102)88-67(30)100)50-9-36(131-138(110,111)118-17-42-35(8-49(124-42)90-4-3-32(71)5-47(90)99)130-137(108,109)121-21-46-38(11-53(128-46)95-28-86-57-61(74)78-24-82-65(57)95)133-135(104,105)116-16-41-33(98)6-48(123-41)93-26-84-55-59(72)76-22-80-63(55)93)43(125-50)18-119-139(112,113)132-37-10-51(92-14-31(2)68(101)89-70(92)103)126-44(37)19-120-140(114,115)134-39-12-54(96-29-87-58-62(75)79-25-83-66(58)96)127-45(39)20-117-136(106,107)129-34-7-52(122-40(34)15-97)94-27-85-56-60(73)77-23-81-64(56)94/h3-5,13-14,22-29,33-46,48-54,97-98H,6-12,15-21,71H2,1-2H3,(H,104,105)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H2,72,76,80)(H2,73,77,81)(H2,74,78,82)(H2,75,79,83)(H,88,100,102)(H,89,101,103)/t33-,34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44+,45+,46+,48+,49+,50+,51+,52+,53+,54+/m0/s1",5'-d[AATTCAA]-3',PubMed citation,7525097
4633,76123,bumadizone calcium,"An organic calcium salt having 2-[(1,2-diphenylhydrazino)carbonyl]hexanoate as the counterion. Used (as its hemihydrate) for treatment of rheumatoid arthritis.","InChI=1S/2C19H22N2O3.Ca/c2*1-2-3-14-17(19(23)24)18(22)21(16-12-8-5-9-13-16)20-15-10-6-4-7-11-15;/h2*4-13,17,20H,2-3,14H2,1H3,(H,23,24);/q;;+2/p-2",bumadizone calcium salt,CAS Registry Number,34461-73-9
4634,76137,(+)-trans-epsilon-viniferin,"A stilbenoid that is the (+)-trans-stereoisomer of epsilon-viniferin, obtained by cyclodimerisation of trans-resveratrol.","InChI=1S/C28H22O6/c29-20-7-2-16(3-8-20)1-4-18-11-24(33)15-25-26(18)27(19-12-22(31)14-23(32)13-19)28(34-25)17-5-9-21(30)10-6-17/h1-15,27-33H/b4-1+/t27-,28+/m0/s1","5-{(2S,3S)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(E)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl}benzene-1,3-diol",Reaxys Registry Number,7233801
4635,76145,"(2R,3S)-cis-epsilon-viniferin","A stilbenoid that is the (2R,3S)-cis-stereoisomer of epsilon-viniferin, obtained by cyclodimerisation of cis-resveratrol.","InChI=1S/C28H22O6/c29-20-7-2-16(3-8-20)1-4-18-11-24(33)15-25-26(18)27(19-12-22(31)14-23(32)13-19)28(34-25)17-5-9-21(30)10-6-17/h1-15,27-33H/b4-1-/t27-,28-/m0/s1","5-{(2R,3S)-6-hydroxy-2-(4-hydroxyphenyl)-4-[(Z)-2-(4-hydroxyphenyl)ethenyl]-2,3-dihydro-1-benzofuran-3-yl}benzene-1,3-diol",Reaxys Registry Number,22162631
4636,76181,ferrous ammonium sulfate hexahydrate,A hydrate that is the hexahydrate form of ferrous ammonium sulfate. Acts as an iron ion donor for building Fe-S clusters in vitro.,"InChI=1S/Fe.2H3N.2H2O4S.6H2O/c;;;2*1-5(2,3)4;;;;;;/h;2*1H3;2*(H2,1,2,3,4);6*1H2/q+2;;;;;;;;;;/p-2",FAS,PubMed citation,19810706
4637,76197,sapienate,"A long-chain unsaturated fatty acid anion that is the conjugate base of sapienic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C16H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h10-11H,2-9,12-15H2,1H3,(H,17,18)/p-1/b11-10-",(6Z)-hexadecenoate(1-),Wikipedia accession,Sapienic_acid
4638,76198,loxoprofen sodium,"An organic sodium salt having loxoprofen(1-) as the counterion. The parent acid, loxoprofen, is a prodrug that is rapidly converted to its active trans-alcohol metabolite following oral administration.","InChI=1S/C15H18O3.Na/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16;/h5-8,10,13H,2-4,9H2,1H3,(H,17,18);/q;+1/p-1",loxoprofen sodium salt,Wikipedia accession,Loxoprofen
4639,76204,"(2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid","A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-[(2-hydroxycyclopentyl)methyl]phenyl group (the 2S,1'R,2'S-stereoisomer. The active metabolite of loxoprofen.","InChI=1S/C15H20O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13-14,16H,2-4,9H2,1H3,(H,17,18)/t10-,13+,14-/m0/s1",loxoprofen active metabolite,PubMed citation,14980665
4640,76220,omega-hydroxytriacontanoic acid,An omega-hydroxy fatty acid that is the 30-hydroxy derivative of triacontanoic acid.,"InChI=1S/C30H60O3/c31-29-27-25-23-21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20-22-24-26-28-30(32)33/h31H,1-29H2,(H,32,33)",30-hydroxymelissic acid,LIPID MAPS instance accession,LMFA01050221
4641,76221,omega-hydroxydotriacontanoic acid,An omega-hydroxy fatty acid that is the 32-hydroxy derivative of dotriacontanoic acid.,"InChI=1S/C32H64O3/c33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32(34)35/h33H,1-31H2,(H,34,35)",omega-hydroxylacceric acid,Reaxys Registry Number,1806772
4642,76231,2-oleoyl-sn-glycero-3-phosphoethanolamine,A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as oleoyl.,"InChI=1S/C23H46NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(26)31-22(20-25)21-30-32(27,28)29-19-18-24/h9-10,22,25H,2-8,11-21,24H2,1H3,(H,27,28)/b10-9-/t22-/m1/s1",2-oleoyllysophosphatidylethanolamine,HMDB accession,HMDB0011476
4643,76233,2-linoleoyl-sn-glycero-3-phosphoethanolamine,A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as linoleoyl.,"InChI=1S/C23H44NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(26)31-22(20-25)21-30-32(27,28)29-19-18-24/h6-7,9-10,22,25H,2-5,8,11-21,24H2,1H3,(H,27,28)/b7-6-,10-9-/t22-/m1/s1",2-linoleoyllysophosphatidylethanolamine,Reaxys Registry Number,6159809
4644,76234,(R)-2-hydroxy-alpha-linolenic acid,A HOTrE that is alpha-linolenic acid substituted at position 2 by a hydroxy group (the R-enantiomer),"InChI=1S/C18H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h3-4,6-7,9-10,17,19H,2,5,8,11-16H2,1H3,(H,20,21)/b4-3-,7-6-,10-9-/t17-/m1/s1","(R)-2-hydroxy-(9Z,12Z,15Z)-octadecatrienoic acid",LIPID MAPS instance accession,LMFA02000033
4645,76237,(20R)-protopanaxadiol,A diastereomer of protopanaxadiol in which the 20-hydroxy substituent has been introduced at the pro-R position.,"InChI=1S/C30H52O3/c1-19(2)10-9-14-30(8,33)20-11-16-29(7)25(20)21(31)18-23-27(5)15-13-24(32)26(3,4)22(27)12-17-28(23,29)6/h10,20-25,31-33H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24-,25-,27-,28+,29+,30+/m0/s1",protopanaxadiol,LIPID MAPS instance accession,LMPR0106080003
4646,76245,4-hydroxy-5-methyl-2-methylenefuran-3-one,A member of the class of furans that is 5-methyl-2-methylenefuran carrying additional oxo and hydroxy groups at positions 3 and 4 respectively.,"InChI=1S/C6H6O3/c1-3-5(7)6(8)4(2)9-3/h8H,1H2,2H3",HMMF,PubMed citation,23589283
4647,76247,"4-hydroxy-2,5-dimethylfuran-3-one","A member of the class of furans that is 2,5-dimethylfuran carrying additional oxo and hydroxy groups at positions 3 and 4 respectively. It has been found particularly in strawberries and other such fruits.","InChI=1S/C6H8O3/c1-3-5(7)6(8)4(2)9-3/h3,8H,1-2H3",HDMF,PubMed citation,23589283
4648,76260,1-chloropropan-2-ol,A secondary alcohol that is isopropanol in which one of the methyl hydrogen atoms is substituted by chlorine.,"InChI=1S/C3H7ClO/c1-3(5)2-4/h3,5H,2H2,1H3",1-chloro-2-propanol,PubMed citation,9114330
4649,76261,1-nitropropane,A nitroalkane that is propane substituted at C-1 by a nitro group.,"InChI=1S/C3H7NO2/c1-2-3-4(5)6/h2-3H2,1H3",nitropropane,Reaxys Registry Number,506236
4650,76266,"N(2)-benzoyl-N,N-dipropyl-alpha-glutamine",A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.,"InChI=1S/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)","4-benzamido-N,N-dipropylglutaramic acid",Reaxys Registry Number,4151696
4651,76273,dodecanedioate(2-),A dicarboxylic acid dianion obtained by deprotonation of both carboxy groups of  dodecanedioic acid; major species at pH 7.3.,"InChI=1S/C12H22O4/c13-11(14)9-7-5-3-1-2-4-6-8-10-12(15)16/h1-10H2,(H,13,14)(H,15,16)/p-2",C12-DCA(2-),Reaxys Registry Number,4313813
4652,76279,2''-O-acetyl-ADP-D-ribose,A nucleotide-sugar having ADP as the nucleotide fragment and 2-O-acetyl-D-ribofuranos-5-yl as the sugar component.,"InChI=1S/C17H25N5O15P2/c1-6(23)34-13-11(25)8(36-17(13)27)3-33-39(30,31)37-38(28,29)32-2-7-10(24)12(26)16(35-7)22-5-21-9-14(18)19-4-20-15(9)22/h4-5,7-8,10-13,16-17,24-27H,2-3H2,1H3,(H,28,29)(H,30,31)(H2,18,19,20)/t7-,8-,10-,11-,12-,13-,16-,17?/m1/s1",2'-O-acetyl adenosine-5-diphosphoribose,PubMed citation,11747420
4653,76289,dTDP-4-dehydro-6-deoxy-alpha-D-gulose,A dTDP-sugar having 4-dehydro-6-deoxy-alpha-D-gulose as the sugar component.,"InChI=1S/C16H24N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(19)9(31-10)5-29-34(25,26)33-35(27,28)32-15-13(22)12(21)11(20)7(2)30-15/h4,7-10,12-13,15,19,21-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,8+,9-,10-,12-,13-,15-/m1/s1",dTDP-4-dehydro-6-deoxy-alpha-D-allose,KEGG COMPOUND accession,C11926
4654,76294,kaempferol 3-O-beta-D-xyloside,A glycosyloxyflavone that is apigenin substituted kaempferol in which the hydroxyl hydrogen at position 3 is replaced by a beta-D-xylosyl residue,"InChI=1S/C20H18O10/c21-9-3-1-8(2-4-9)18-19(30-20-17(27)15(25)12(24)7-28-20)16(26)14-11(23)5-10(22)6-13(14)29-18/h1-6,12,15,17,20-25,27H,7H2/t12-,15+,17-,20+/m1/s1",kaempferol 3-O-beta-D-xylopyranoside,PubMed citation,11876444
4655,76295,dTDP-alpha-D-fucofuranose,A dTDP-sugar having alpha-D-fucofuranose as the sugar component.,"InChI=1S/C16H26N2O15P2/c1-6-4-18(16(24)17-14(6)23)10-3-8(20)9(30-10)5-29-34(25,26)33-35(27,28)32-15-12(22)11(21)13(31-15)7(2)19/h4,7-13,15,19-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,8+,9-,10-,11-,12-,13+,15-/m1/s1",dTDP-alpha-D-Fucf,PubMed citation,19019146
4656,76318,22-oxodocosanoic acid,A long-chain oxo-fatty acid that is the 22-oxo derivative of docosanoic acid.,"InChI=1S/C22H42O3/c23-21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20-22(24)25/h21H,1-20H2,(H,24,25)",omega-oxobehenic acid,KEGG COMPOUND accession,C19624
4657,76322,22-hydroxydocosanoic acid,An omega-hydroxy-long-chain fatty acid obtained by monohydroxylation of the terminal methyl group of docosanoic acid.,"InChI=1S/C22H44O3/c23-21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20-22(24)25/h23H,1-21H2,(H,24,25)",omega-hydroxybehenic acid,KEGG COMPOUND accession,C19623
4658,76325,26-hydroxyhexacosanoic acid,The omega-hydroxy fatty acid obtained by hydroxylation at position 26 of hexacosanoic acid.,"InChI=1S/C26H52O3/c27-25-23-21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20-22-24-26(28)29/h27H,1-25H2,(H,28,29)",26-hydroxycerotic acid,LIPID MAPS instance accession,LMFA01050219
4659,76336,trimethyl(1-methylethoxy)silane,A silyl ether that is isopropanol in which the hydroxyl hydrogen is replaced by a trimethylsilyl group.,"InChI=1S/C6H16OSi/c1-6(2)7-8(3,4)5/h6H,1-5H3",trimethyl(propan-2-yloxy)silane,CAS Registry Number,1825-64-5
4660,76337,5'-IGCm(1)IUp-3',"A tRNA oligonucleotide comprised of a sequence of one inosine, one guanosine, one cytidine, one 1-methylinosine and one uridine residue connected by 3'->5' phosphodiester linkages and with a phosphoric residue at the 3'-terminus..","InChI=1S/C49H61N18O37P5/c1-62-12-57-37-25(41(62)77)56-15-66(37)45-29(73)34(103-107(85,86)91-7-17-32(100-105(80,81)82)27(71)42(96-17)64-5-3-22(69)59-49(64)79)19(98-45)9-94-108(87,88)102-33-18(97-43(28(33)72)63-4-2-21(50)58-48(63)78)8-93-109(89,90)104-35-20(99-46(30(35)74)67-14-55-24-38(67)60-47(51)61-40(24)76)10-92-106(83,84)101-31-16(6-68)95-44(26(31)70)65-13-54-23-36(65)52-11-53-39(23)75/h2-5,11-20,26-35,42-46,68,70-74H,6-10H2,1H3,(H,83,84)(H,85,86)(H,87,88)(H,89,90)(H2,50,58,78)(H,52,53,75)(H,59,69,79)(H2,80,81,82)(H3,51,60,61,76)/t16-,17-,18-,19-,20-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,42-,43-,44-,45-,46-/m1/s1",IpGpCpm(1)IpUp,PubMed citation,10411130
4661,76341,3-aminopiperidine-2-one,A delta-lactam that is 2-piperidone substituted at position 3 by an amino group.,"InChI=1S/C5H10N2O/c6-4-2-1-3-7-5(4)8/h4H,1-3,6H2,(H,7,8)",3-amino-2-piperidone,PubMed citation,679477
4662,76345,decanedioyl-CoA,"An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of decanedioic acid.","InChI=1S/C31H52N7O19P3S/c1-31(2,26(44)29(45)34-12-11-20(39)33-13-14-61-22(42)10-8-6-4-3-5-7-9-21(40)41)16-54-60(51,52)57-59(49,50)53-15-19-25(56-58(46,47)48)24(43)30(55-19)38-18-37-23-27(32)35-17-36-28(23)38/h17-19,24-26,30,43-44H,3-16H2,1-2H3,(H,33,39)(H,34,45)(H,40,41)(H,49,50)(H,51,52)(H2,32,35,36)(H2,46,47,48)/t19-,24-,25-,26+,30-/m1/s1",9-carboxynonanoyl-coenzyme A,Reaxys Registry Number,8535273
4663,76362,5'-AGIm(1)IUp-3',"A tRNA oligonucleotide comprised of a sequence of adenosine, guanosine, inosine, 1-methylinosine and uridine residues connected by 3'->5' phosphodiester linkages and with a phosphoric residue at the 3'-terminus..","InChI=1S/C50H61N20O36P5/c1-65-11-61-39-25(43(65)80)60-15-69(39)47-29(76)34(105-109(87,88)93-5-17-32(102-107(82,83)84)27(74)44(98-17)66-3-2-21(72)62-50(66)81)19(100-47)7-96-110(89,90)104-33-18(99-46(28(33)75)68-13-58-23-38(68)55-10-56-41(23)78)6-95-111(91,92)106-35-20(101-48(30(35)77)70-14-59-24-40(70)63-49(52)64-42(24)79)8-94-108(85,86)103-31-16(4-71)97-45(26(31)73)67-12-57-22-36(51)53-9-54-37(22)67/h2-3,9-20,26-35,44-48,71,73-77H,4-8H2,1H3,(H,85,86)(H,87,88)(H,89,90)(H,91,92)(H2,51,53,54)(H,55,56,78)(H,62,72,81)(H2,82,83,84)(H3,52,63,64,79)/t16-,17-,18-,19-,20-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,44-,45-,46-,47-,48-/m1/s1",AGIm(1)IUp,PubMed citation,10411130
4664,76363,5'-CUUIGCm(1)IUGCGp-3',"A tRNA oligonucleotide comprised of one inosine, one 1-methylated inosine, three cytidine, three guanosine and three uridine residues connected by 3'->5' phosphodiester linkages in the sequence C-U-U-I-G-C-m(1)I-U-G-C-G and with a phosphono group at the 3'-terminus.","InChI=1S/C105H131N38O81P11/c1-132-26-119-77-53(85(132)163)118-31-140(77)93-62(156)73(222-232(185,186)198-20-38-71(60(154)91(208-38)138-13-7-48(147)125-105(138)169)220-231(183,184)201-23-41-74(63(157)95(212-41)142-29-116-51-79(142)127-98(110)130-83(51)161)223-233(187,188)196-17-34-67(56(150)87(204-34)134-9-3-44(107)121-101(134)165)216-227(175,176)193-15-33-66(214-225(170,171)172)55(149)94(209-33)141-28-115-50-78(141)126-97(109)129-82(50)160)40(211-93)22-200-229(179,180)217-68-35(205-88(57(68)151)135-10-4-45(108)122-102(135)166)18-197-234(189,190)224-75-42(213-96(64(75)158)143-30-117-52-80(143)128-99(111)131-84(52)162)24-202-235(191,192)221-72-39(210-92(61(72)155)139-27-114-49-76(139)112-25-113-81(49)159)21-199-230(181,182)219-70-37(207-90(59(70)153)137-12-6-47(146)124-104(137)168)19-195-228(177,178)218-69-36(206-89(58(69)152)136-11-5-46(145)123-103(136)167)16-194-226(173,174)215-65-32(14-144)203-86(54(65)148)133-8-2-43(106)120-100(133)164/h2-13,25-42,54-75,86-96,144,148-158H,14-24H2,1H3,(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H,181,182)(H,183,184)(H,185,186)(H,187,188)(H,189,190)(H,191,192)(H2,106,120,164)(H2,107,121,165)(H2,108,122,166)(H,112,113,159)(H,123,145,167)(H,124,146,168)(H,125,147,169)(H2,170,171,172)(H3,109,126,129,160)(H3,110,127,130,161)(H3,111,128,131,162)/t32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-/m1/s1",CpUpUpIpGpCpm(1)IpUpGpCpGp,PubMed citation,10411130
4665,76365,5'-AICm(1)IUp-3',"A tRNA oligonucleotide comprised of a sequence of adenosine, inosine, cytidine, 1-methylinosine and uridine residues connected by 3'->5' phosphodiester linkages and with a phosphoric residue at the 3'-terminus.","InChI=1S/C49H61N18O36P5/c1-62-13-59-40-26(42(62)76)58-16-67(40)47-31(74)36(103-106(84,85)90-7-18-33(99-104(79,80)81)28(71)43(95-18)64-5-3-23(69)61-49(64)78)21(98-47)10-93-107(86,87)101-34-19(96-44(29(34)72)63-4-2-22(50)60-48(63)77)8-92-108(88,89)102-35-20(97-46(30(35)73)66-15-57-25-39(66)54-12-55-41(25)75)9-91-105(82,83)100-32-17(6-68)94-45(27(32)70)65-14-56-24-37(51)52-11-53-38(24)65/h2-5,11-21,27-36,43-47,68,70-74H,6-10H2,1H3,(H,82,83)(H,84,85)(H,86,87)(H,88,89)(H2,50,60,77)(H2,51,52,53)(H,54,55,75)(H,61,69,78)(H2,79,80,81)/t17-,18-,19-,20-,21-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,43-,44-,45-,46-,47-/m1/s1",AICm(1)IUp,PubMed citation,10411130
4666,76369,5'-IAGCm(1)IUp-3',"A tRNA oligonucleotide comprised of a sequence of inosine, adenosine, guanosine, cytidine, 1-methylinosine and uridine residues connected by 3'->5' phosphodiester linkages and with a phosphoric residue at the 3'-terminus.","InChI=1S/C59H73N23O43P6/c1-76-14-71-46-30(50(76)93)70-18-81(46)55-35(89)41(124-128(101,102)109-7-20-38(120-126(96,97)98)32(86)51(115-20)78-5-3-26(84)73-59(78)95)23(118-55)10-112-129(103,104)122-39-21(116-52(33(39)87)77-4-2-25(60)72-58(77)94)8-111-130(105,106)125-42-24(119-56(36(42)90)82-17-69-29-47(82)74-57(62)75-49(29)92)11-113-131(107,108)123-40-22(117-54(34(40)88)79-15-67-27-43(61)63-12-64-44(27)79)9-110-127(99,100)121-37-19(6-83)114-53(31(37)85)80-16-68-28-45(80)65-13-66-48(28)91/h2-5,12-24,31-42,51-56,83,85-90H,6-11H2,1H3,(H,99,100)(H,101,102)(H,103,104)(H,105,106)(H,107,108)(H2,60,72,94)(H2,61,63,64)(H,65,66,91)(H,73,84,95)(H2,96,97,98)(H3,62,74,75,92)/t19-,20-,21-,22-,23-,24-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,51-,52-,53-,54-,55-,56-/m1/s1",IAGCm(1)IUp,PubMed citation,10411130
4667,76371,5'-IAAAGCm(1)IUp-3',"A tRNA oligonucleotide comprised of a sequence of inosine, three adenosine, guanosine, cytidine, 1-methylinosine and uridine residues connected by 3'->5' phosphodiester linkages and with a phosphoric residue at the 3'-terminus.","InChI=1S/C79H97N33O55P8/c1-104-18-99-64-40(68(104)125)98-24-111(64)75-47(121)55(166-170(133,134)145-7-26-50(160-168(128,129)130)42(116)69(153-26)106-5-3-34(114)101-79(106)127)31(158-75)12-148-171(135,136)162-51-27(154-70(43(51)117)105-4-2-33(80)100-78(105)126)8-147-172(137,138)167-56-32(159-76(48(56)122)112-23-97-39-65(112)102-77(84)103-67(39)124)13-151-175(143,144)165-54-30(157-74(46(54)120)109-21-95-37-59(83)87-16-90-62(37)109)11-150-174(141,142)164-53-29(156-73(45(53)119)108-20-94-36-58(82)86-15-89-61(36)108)10-149-173(139,140)163-52-28(155-72(44(52)118)107-19-93-35-57(81)85-14-88-60(35)107)9-146-169(131,132)161-49-25(6-113)152-71(41(49)115)110-22-96-38-63(110)91-17-92-66(38)123/h2-5,14-32,41-56,69-76,113,115-122H,6-13H2,1H3,(H,131,132)(H,133,134)(H,135,136)(H,137,138)(H,139,140)(H,141,142)(H,143,144)(H2,80,100,126)(H2,81,85,88)(H2,82,86,89)(H2,83,87,90)(H,91,92,123)(H,101,114,127)(H2,128,129,130)(H3,84,102,103,124)/t25-,26-,27-,28-,29-,30-,31-,32-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,69-,70-,71-,72-,73-,74-,75-,76-/m1/s1",IpApApApGpCpm(1)IpUp,PubMed citation,10411130
4668,76372,5'-CCTTTC-3,A single-stranded DNA oligonucleotide comprised of three deoxycytidine and three thymidine residues connected by 3'->5' phosphodiester linkages in the sequence C-C-T-T-T-C.,"InChI=1S/C60H79N12O37P5/c1-28-19-70(58(81)64-55(28)78)52-16-37(107-110(84,85)94-23-41-34(74)13-49(100-41)67-7-4-31(61)10-46(67)75)43(102-52)25-97-113(90,91)109-39-18-54(72-21-30(3)57(80)66-60(72)83)104-45(39)27-98-114(92,93)108-38-17-53(71-20-29(2)56(79)65-59(71)82)103-44(38)26-96-112(88,89)106-36-15-51(69-9-6-33(63)12-48(69)77)101-42(36)24-95-111(86,87)105-35-14-50(99-40(35)22-73)68-8-5-32(62)11-47(68)76/h4-12,19-21,34-45,49-54,73-74H,13-18,22-27,61-63H2,1-3H3,(H,84,85)(H,86,87)(H,88,89)(H,90,91)(H,92,93)(H,64,78,81)(H,65,79,82)(H,66,80,83)/t34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44+,45+,49+,50+,51+,52+,53+,54+/m0/s1",CpCpTpTpTpC,PubMed citation,9538233
4669,76376,dT15,An oligonucleotide comprised of fifteen thymidine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C150H196N30O103P14/c1-61-31-166(136(198)151-121(61)183)106-16-76(182)92(256-106)47-241-284(213,214)271-78-18-108(168-33-63(3)123(185)153-138(168)200)258-94(78)49-243-286(217,218)273-80-20-110(170-35-65(5)125(187)155-140(170)202)260-96(80)51-245-288(221,222)275-82-22-112(172-37-67(7)127(189)157-142(172)204)262-98(82)53-247-290(225,226)277-84-24-114(174-39-69(9)129(191)159-144(174)206)264-100(84)55-249-292(229,230)279-86-26-116(176-41-71(11)131(193)161-146(176)208)266-102(86)57-251-294(233,234)281-88-28-118(178-43-73(13)133(195)163-148(178)210)268-104(88)59-253-296(237,238)283-90-30-120(180-45-75(15)135(197)165-150(180)212)269-105(90)60-254-297(239,240)282-89-29-119(179-44-74(14)134(196)164-149(179)211)267-103(89)58-252-295(235,236)280-87-27-117(177-42-72(12)132(194)162-147(177)209)265-101(87)56-250-293(231,232)278-85-25-115(175-40-70(10)130(192)160-145(175)207)263-99(85)54-248-291(227,228)276-83-23-113(173-38-68(8)128(190)158-143(173)205)261-97(83)52-246-289(223,224)274-81-21-111(171-36-66(6)126(188)156-141(171)203)259-95(81)50-244-287(219,220)272-79-19-109(169-34-64(4)124(186)154-139(169)201)257-93(79)48-242-285(215,216)270-77-17-107(255-91(77)46-181)167-32-62(2)122(184)152-137(167)199/h31-45,76-120,181-182H,16-30,46-60H2,1-15H3,(H,213,214)(H,215,216)(H,217,218)(H,219,220)(H,221,222)(H,223,224)(H,225,226)(H,227,228)(H,229,230)(H,231,232)(H,233,234)(H,235,236)(H,237,238)(H,239,240)(H,151,183,198)(H,152,184,199)(H,153,185,200)(H,154,186,201)(H,155,187,202)(H,156,188,203)(H,157,189,204)(H,158,190,205)(H,159,191,206)(H,160,192,207)(H,161,193,208)(H,162,194,209)(H,163,195,210)(H,164,196,211)(H,165,197,212)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+/m0/s1",5'-d(TpTpTpTpTpTpTpTpTpTpTpTpTpTpT)-3',PubMed citation,3771789
4670,76379,G12,An oligonucleotide comprised of twelve guanosine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C120H145N60O82P11/c121-109-145-73-37(85(195)157-109)133-13-169(73)97-50(183)49(182)26(241-97)2-229-263(207,208)253-63-28(243-99(52(63)185)171-15-135-39-75(171)147-111(123)159-87(39)197)4-231-265(211,212)255-65-30(245-101(54(65)187)173-17-137-41-77(173)149-113(125)161-89(41)199)6-233-267(215,216)257-67-32(247-103(56(67)189)175-19-139-43-79(175)151-115(127)163-91(43)201)8-235-269(219,220)259-69-34(249-105(58(69)191)177-21-141-45-81(177)153-117(129)165-93(45)203)10-237-271(223,224)261-71-36(251-107(60(71)193)179-23-143-47-83(179)155-119(131)167-95(47)205)12-239-273(227,228)262-72-35(250-108(61(72)194)180-24-144-48-84(180)156-120(132)168-96(48)206)11-238-272(225,226)260-70-33(248-106(59(70)192)178-22-142-46-82(178)154-118(130)166-94(46)204)9-236-270(221,222)258-68-31(246-104(57(68)190)176-20-140-44-80(176)152-116(128)164-92(44)202)7-234-268(217,218)256-66-29(244-102(55(66)188)174-18-138-42-78(174)150-114(126)162-90(42)200)5-232-266(213,214)254-64-27(242-100(53(64)186)172-16-136-40-76(172)148-112(124)160-88(40)198)3-230-264(209,210)252-62-25(1-181)240-98(51(62)184)170-14-134-38-74(170)146-110(122)158-86(38)196/h13-36,49-72,97-108,181-194H,1-12H2,(H,207,208)(H,209,210)(H,211,212)(H,213,214)(H,215,216)(H,217,218)(H,219,220)(H,221,222)(H,223,224)(H,225,226)(H,227,228)(H3,121,145,157,195)(H3,122,146,158,196)(H3,123,147,159,197)(H3,124,148,160,198)(H3,125,149,161,199)(H3,126,150,162,200)(H3,127,151,163,201)(H3,128,152,164,202)(H3,129,153,165,203)(H3,130,154,166,204)(H3,131,155,167,205)(H3,132,156,168,206)/t25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-/m1/s1",GpGpGpGpGpGpGpGpGpGpGpGp,PubMed citation,3771789
4671,76380,I11,An oligonucleotide comprised of eleven inosine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C110H123N44O78P11/c155-1-34-67(56(156)100(211-34)144-23-133-45-78(144)111-12-122-89(45)167)223-234(181,182)202-3-36-69(58(158)102(213-36)146-25-135-47-80(146)113-14-124-91(47)169)225-236(185,186)204-5-38-71(60(160)104(215-38)148-27-137-49-82(148)115-16-126-93(49)171)227-238(189,190)206-7-40-73(62(162)106(217-40)150-29-139-51-84(150)117-18-128-95(51)173)229-240(193,194)208-9-42-75(64(164)108(219-42)152-31-141-53-86(152)119-20-130-97(53)175)231-242(197,198)210-11-44-77(66(166)110(221-44)154-33-143-55-88(154)121-22-132-99(55)177)232-243(199,200)209-10-43-76(65(165)109(220-43)153-32-142-54-87(153)120-21-131-98(54)176)230-241(195,196)207-8-41-74(63(163)107(218-41)151-30-140-52-85(151)118-19-129-96(52)174)228-239(191,192)205-6-39-72(61(161)105(216-39)149-28-138-50-83(149)116-17-127-94(50)172)226-237(187,188)203-4-37-70(59(159)103(214-37)147-26-136-48-81(147)114-15-125-92(48)170)224-235(183,184)201-2-35-68(222-233(178,179)180)57(157)101(212-35)145-24-134-46-79(145)112-13-123-90(46)168/h12-44,56-77,100-110,155-166H,1-11H2,(H,181,182)(H,183,184)(H,185,186)(H,187,188)(H,189,190)(H,191,192)(H,193,194)(H,195,196)(H,197,198)(H,199,200)(H,111,122,167)(H,112,123,168)(H,113,124,169)(H,114,125,170)(H,115,126,171)(H,116,127,172)(H,117,128,173)(H,118,129,174)(H,119,130,175)(H,120,131,176)(H,121,132,177)(H2,178,179,180)/t34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-/m1/s1",single-stranded I11,PubMed citation,3771789
4672,76381,dG10,An oligonucleotide comprised of ten 2'-deoxyguanosine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C100H121N50O58P9/c101-91-121-71-61(81(153)131-91)111-21-141(71)51-1-31(152)42(191-51)12-181-209(163,164)201-33-3-53(143-23-113-63-73(143)123-93(103)133-83(63)155)193-44(33)14-183-211(167,168)203-35-5-55(145-25-115-65-75(145)125-95(105)135-85(65)157)195-46(35)16-185-213(171,172)205-37-7-57(147-27-117-67-77(147)127-97(107)137-87(67)159)197-48(37)18-187-215(175,176)207-39-9-59(149-29-119-69-79(149)129-99(109)139-89(69)161)199-50(39)20-189-217(179,180)208-40-10-60(150-30-120-70-80(150)130-100(110)140-90(70)162)198-49(40)19-188-216(177,178)206-38-8-58(148-28-118-68-78(148)128-98(108)138-88(68)160)196-47(38)17-186-214(173,174)204-36-6-56(146-26-116-66-76(146)126-96(106)136-86(66)158)194-45(36)15-184-212(169,170)202-34-4-54(144-24-114-64-74(144)124-94(104)134-84(64)156)192-43(34)13-182-210(165,166)200-32-2-52(190-41(32)11-151)142-22-112-62-72(142)122-92(102)132-82(62)154/h21-60,151-152H,1-20H2,(H,163,164)(H,165,166)(H,167,168)(H,169,170)(H,171,172)(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H3,101,121,131,153)(H3,102,122,132,154)(H3,103,123,133,155)(H3,104,124,134,156)(H3,105,125,135,157)(H3,106,126,136,158)(H3,107,127,137,159)(H3,108,128,138,160)(H3,109,129,139,161)(H3,110,130,140,162)/t31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+/m0/s1",d(GpGpGpGpGpGpGpGpGpG),PubMed citation,2559771
4673,76399,N-nonyldeoxynojirimycin,A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group.,"InChI=1S/C15H31NO4/c1-2-3-4-5-6-7-8-9-16-10-13(18)15(20)14(19)12(16)11-17/h12-15,17-20H,2-11H2,1H3/t12-,13+,14-,15-/m1/s1",NN-DNJ,Reaxys Registry Number,6859812
4674,76400,"5-(N,N-hexamethylene)amiloride","A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring.","InChI=1S/C12H18ClN7O/c13-8-10(20-5-3-1-2-4-6-20)18-9(14)7(17-8)11(21)19-12(15)16/h1-6H2,(H2,14,18)(H4,15,16,19,21)",HMA,Reaxys Registry Number,628353
4675,76401,cis-diammine[d(pApG)]platinum,"A cisplatin-modified (di)nucleotide in which cisplatin has formed an adduct with one molecule of d(pApG), coordinated to platinum through the adenine and guanine N(7) atoms.","InChI=1S/C20H26N10O12P2.2H3N.Pt/c21-16-14-17(24-5-23-16)29(6-25-14)13-2-9(11(41-13)4-38-43(33,34)35)42-44(36,37)39-3-10-8(31)1-12(40-10)30-7-26-15-18(30)27-20(22)28-19(15)32;;;/h5-13,31H,1-4H2,(H,36,37)(H2,21,23,24)(H2,33,34,35)(H3,22,27,28,32);2*1H3;/t8-,9-,10+,11+,12+,13+;;;/m0.../s1","cis-Pt(NH3)2[d(pApG)-N7(1),N7(2)]",PubMed citation,1855275
4676,76402,5'-d(pApG)-3',A single-stranded DNA oligonucleotide comprising 2'-deoxyadenosine and 2'-deoxyguanosine connected by a 3'->5 linkage and with a phosphoric group at the 5'-terminus.,"InChI=1S/C20H26N10O12P2/c21-16-14-17(24-5-23-16)29(6-25-14)13-2-9(11(41-13)4-38-43(33,34)35)42-44(36,37)39-3-10-8(31)1-12(40-10)30-7-26-15-18(30)27-20(22)28-19(15)32/h5-13,31H,1-4H2,(H,36,37)(H2,21,23,24)(H2,33,34,35)(H3,22,27,28,32)/t8-,9-,10+,11+,12+,13+/m0/s1",d(pA-G),Reaxys Registry Number,1208622
4677,76450,"(4Z,7Z,10Z,13Z,16Z)-docosapentaenoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid","InChI=1S/C43H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-34(52)71-27-26-45-33(51)24-25-46-41(55)38(54)43(2,3)29-64-70(61,62)67-69(59,60)63-28-32-37(66-68(56,57)58)36(53)42(65-32)50-31-49-35-39(44)47-30-48-40(35)50/h8-9,11-12,14-15,17-18,20-21,30-32,36-38,42,53-54H,4-7,10,13,16,19,22-29H2,1-3H3,(H,45,51)(H,46,55)(H,59,60)(H,61,62)(H2,44,47,48)(H2,56,57,58)/b9-8-,12-11-,15-14-,18-17-,21-20-/t32-,36-,37-,38+,42-/m1/s1","(4Z,7Z,10Z,13Z,16Z)-docosapentaenoyl-coenzyme A",HMDB accession,HMDB0006513
4678,76451,alloxan,"A member of the class of pyrimidones, the structure of which is that of perhydropyrimidine substituted at C-2, -4, -5 and -6 by oxo groups.","InChI=1S/C4H2N2O4/c7-1-2(8)5-4(10)6-3(1)9/h(H2,5,6,8,9,10)","2,4,5,6-pyrimidinetetrone",Reaxys Registry Number,132451
4679,76454,(R)-3-hydroxystearoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxystearic acid.,"InChI=1S/C39H70N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-27(47)22-30(49)68-21-20-41-29(48)18-19-42-37(52)34(51)39(2,3)24-61-67(58,59)64-66(56,57)60-23-28-33(63-65(53,54)55)32(50)38(62-28)46-26-45-31-35(40)43-25-44-36(31)46/h25-28,32-34,38,47,50-51H,4-24H2,1-3H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/t27-,28-,32-,33-,34+,38-/m1/s1",(R)-3-hydroxyoctadecanoyl-CoA,MetaCyc accession,CPD-10261
4680,76459,(R)-3-hydroxybehenoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxybehenic acid.,"InChI=1S/C43H78N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-31(51)26-34(53)72-25-24-45-33(52)22-23-46-41(56)38(55)43(2,3)28-65-71(62,63)68-70(60,61)64-27-32-37(67-69(57,58)59)36(54)42(66-32)50-30-49-35-39(44)47-29-48-40(35)50/h29-32,36-38,42,51,54-55H,4-28H2,1-3H3,(H,45,52)(H,46,56)(H,60,61)(H,62,63)(H2,44,47,48)(H2,57,58,59)/t31-,32-,36-,37-,38+,42-/m1/s1",(R)-3-hydroxydocosanoyl-CoA,MetaCyc accession,CPD-14276
4681,76463,(3R)-3-hydroxytetracosanoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (3R)-3-hydroxytetracosanoic acid [(R)-3-hydroxylignoceric acid].,"InChI=1S/C45H82N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-33(53)28-36(55)74-27-26-47-35(54)24-25-48-43(58)40(57)45(2,3)30-67-73(64,65)70-72(62,63)66-29-34-39(69-71(59,60)61)38(56)44(68-34)52-32-51-37-41(46)49-31-50-42(37)52/h31-34,38-40,44,53,56-57H,4-30H2,1-3H3,(H,47,54)(H,48,58)(H,62,63)(H,64,65)(H2,46,49,50)(H2,59,60,61)/t33-,34-,38-,39-,40+,44-/m1/s1",(R)-3-hydroxytetracosanoyl-CoA,MetaCyc accession,CPD-14277
4682,76465,(R)-3-hydroxyhexacosanoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxyhexacosanoic acid [(R)-3-hydroxycerotic acid].,"InChI=1S/C47H86N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-35(55)30-38(57)76-29-28-49-37(56)26-27-50-45(60)42(59)47(2,3)32-69-75(66,67)72-74(64,65)68-31-36-41(71-73(61,62)63)40(58)46(70-36)54-34-53-39-43(48)51-33-52-44(39)54/h33-36,40-42,46,55,58-59H,4-32H2,1-3H3,(H,49,56)(H,50,60)(H,64,65)(H,66,67)(H2,48,51,52)(H2,61,62,63)/t35-,36-,40-,41-,42+,46-/m1/s1",(R)-3-hydroxycerotoyl-coenzyme A,MetaCyc accession,CPD-14278
4683,76480,5'-TCGAGCTGCCTTCAGTCGT-3',"A single-stranded DNA oligonucleotide consisting of five deoxyguanosine, six deoxycytidine, two deoxyadenosine and six thymidine residues connected by 3'->5' phosphodiester linkages in the sequence T-C-G-A-G-C-T-G-C-C-T-T-C-A-G-T-C-G-T. When part of a longer DNA sequence it can exist in a hairpin structure, with hydrogen bonding linking the six complementary base pairs C(2)-G(18), G(3)-C(17), A(4)-T(15), C(6)-G(15), T(6)-A(14) and G(8)-C(13).","InChI=1S/C184H235N65O116P18/c1-72-38-237(179(269)225-157(72)252)122-19-78(251)98(330-122)45-311-366(275,276)359-92-33-136(245-67-204-143-152(245)215-168(193)220-163(143)258)343-111(92)58-324-372(287,288)354-85-26-128(236-18-12-121(190)214-178(236)268)334-102(85)49-315-375(293,294)356-87-28-131(240-41-75(4)160(255)228-182(240)272)340-108(87)55-321-380(303,304)364-95-36-139(248-70-207-146-155(248)218-171(196)223-166(146)261)347-115(95)62-328-381(305,306)360-90-31-134(243-65-202-141-148(191)198-63-200-150(141)243)341-109(90)56-322-371(285,286)353-84-25-127(235-17-11-120(189)213-177(235)267)333-101(84)48-314-374(291,292)355-86-27-130(239-40-74(3)159(254)227-181(239)271)339-107(86)54-320-376(295,296)357-88-29-132(241-42-76(5)161(256)229-183(241)273)337-105(88)52-318-369(281,282)350-82-23-125(233-15-9-118(187)211-175(233)265)332-100(82)47-313-368(279,280)349-81-22-124(232-14-8-117(186)210-174(232)264)335-103(81)50-316-378(299,300)362-93-34-137(246-68-205-144-153(246)216-169(194)221-164(144)259)345-113(93)60-326-377(297,298)358-89-30-133(242-43-77(6)162(257)230-184(242)274)338-106(89)53-319-370(283,284)351-83-24-126(234-16-10-119(188)212-176(234)266)336-104(83)51-317-379(301,302)363-94-35-138(247-69-206-145-154(247)217-170(195)222-165(145)260)346-114(94)61-327-382(307,308)361-91-32-135(244-66-203-142-149(192)199-64-201-151(142)244)342-110(91)57-323-383(309,310)365-96-37-140(249-71-208-147-156(249)219-172(197)224-167(147)262)344-112(96)59-325-373(289,290)352-80-21-123(231-13-7-116(185)209-173(231)263)331-99(80)46-312-367(277,278)348-79-20-129(329-97(79)44-250)238-39-73(2)158(253)226-180(238)270/h7-18,38-43,63-71,78-115,122-140,250-251H,19-37,44-62H2,1-6H3,(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H,289,290)(H,291,292)(H,293,294)(H,295,296)(H,297,298)(H,299,300)(H,301,302)(H,303,304)(H,305,306)(H,307,308)(H,309,310)(H2,185,209,263)(H2,186,210,264)(H2,187,211,265)(H2,188,212,266)(H2,189,213,267)(H2,190,214,268)(H2,191,198,200)(H2,192,199,201)(H,225,252,269)(H,226,253,270)(H,227,254,271)(H,228,255,272)(H,229,256,273)(H,230,257,274)(H3,193,215,220,258)(H3,194,216,221,259)(H3,195,217,222,260)(H3,196,218,223,261)(H3,197,219,224,262)/t78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+/m0/s1",5'-d[TCGAGCTGCCTTCAGTCGT]-3',PubMed citation,17252585
4684,76482,5'-CGTGCTGTTTTTTTTTG-3',"A single-stranded DNA oligonucleotide consisting of four deoxyguanosine, two deoxycytidine and eleven thymidine residues connected by 3'->5' phosphodiester linkages in the sequence C-G-T-G-C-T-G-T-T-T-T-T-T-T-T-T-G.","InChI=1S/C168H217N48O114P17/c1-65-33-202(158(235)189-137(65)218)114-19-79(317-333(251,252)281-45-94-77(314-331(246,247)248)17-125(310-94)213-61-175-129-133(213)181-152(171)185-148(129)229)97(300-114)48-285-335(255,256)318-80-20-115(203-34-66(2)138(219)190-159(203)236)301-98(80)49-286-336(257,258)319-81-21-116(204-35-67(3)139(220)191-160(204)237)302-99(81)50-287-337(259,260)320-82-22-117(205-36-68(4)140(221)192-161(205)238)303-100(82)51-288-338(261,262)321-83-23-118(206-37-69(5)141(222)193-162(206)239)304-101(83)52-289-339(263,264)322-84-24-119(207-38-70(6)142(223)194-163(207)240)305-102(84)53-290-340(265,266)323-85-25-120(208-39-71(7)143(224)195-164(208)241)306-103(85)54-291-341(267,268)324-86-26-121(209-40-72(8)144(225)196-165(209)242)307-104(86)55-292-342(269,270)325-87-27-122(210-41-73(9)145(226)197-166(210)243)308-105(87)56-294-347(279,280)330-92-32-128(216-64-178-132-136(216)184-155(174)188-151(132)232)313-109(92)60-296-343(271,272)326-88-28-123(211-42-74(10)146(227)198-167(211)244)299-96(88)47-284-334(253,254)316-78-18-113(201-15-13-111(170)180-157(201)234)298-95(78)46-283-345(275,276)328-91-31-127(215-63-177-131-135(215)183-154(173)187-150(131)231)312-108(91)59-295-344(273,274)327-89-29-124(212-43-75(11)147(228)199-168(212)245)309-106(89)57-293-346(277,278)329-90-30-126(214-62-176-130-134(214)182-153(172)186-149(130)230)311-107(90)58-282-332(249,250)315-76-16-112(297-93(76)44-217)200-14-12-110(169)179-156(200)233/h12-15,33-43,61-64,76-109,112-128,217H,16-32,44-60H2,1-11H3,(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H2,169,179,233)(H2,170,180,234)(H,189,218,235)(H,190,219,236)(H,191,220,237)(H,192,221,238)(H,193,222,239)(H,194,223,240)(H,195,224,241)(H,196,225,242)(H,197,226,243)(H,198,227,244)(H,199,228,245)(H2,246,247,248)(H3,171,181,185,229)(H3,172,182,186,230)(H3,173,183,187,231)(H3,174,184,188,232)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+/m0/s1",d(C-G-T-G-C-T-G-T-T-T-T-T-T-T-T-T-G),PubMed citation,17252585
4685,76503,monobutyrin,A 1-monoglyceride resulting from the formal esterification of butyric acid with one of the primary hydroxy groups of glycerol. The R enantiomer is bioactive.,"InChI=1S/C7H14O4/c1-2-3-7(10)11-5-6(9)4-8/h6,8-9H,2-5H2,1H3","2,3-Dihydroxypropylbutyrat",CAS Registry Number,557-25-5
4686,76534,"(11Z,14Z)-icosadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (11Z,14Z)-icosadienoic acid.","InChI=1S/C41H70N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-32(50)69-25-24-43-31(49)22-23-44-39(53)36(52)41(2,3)27-62-68(59,60)65-67(57,58)61-26-30-35(64-66(54,55)56)34(51)40(63-30)48-29-47-33-37(42)45-28-46-38(33)48/h8-9,11-12,28-30,34-36,40,51-52H,4-7,10,13-27H2,1-3H3,(H,43,49)(H,44,53)(H,57,58)(H,59,60)(H2,42,45,46)(H2,54,55,56)/b9-8-,12-11-/t30-,34-,35-,36+,40-/m1/s1","(11Z,14Z)-eicosadienoyl-coenzyme A",KEGG COMPOUND accession,C16180
4687,76540,"1,3-dibutyrin",A dibutyrin resulting from the condensation of both of the primary hydroxy groups of glycerol with butyric acid.,"InChI=1S/C11H20O5/c1-3-5-10(13)15-7-9(12)8-16-11(14)6-4-2/h9,12H,3-8H2,1-2H3","2-hydroxypropane-1,3-diyl dibutyrate",Reaxys Registry Number,1788209
4688,76599,"2-chloro-1,4-phenylenediaminium","An organic cation obtained by protonation of the two amino groups of 2-chloro-1,4-phenylenediamine.","InChI=1S/C6H7ClN2/c7-5-3-4(8)1-2-6(5)9/h1-3H,8-9H2/p+2",2-chloro-p-phenylenediaminium,Reaxys Registry Number,8441373
4689,76649,astressin,"A 30-membered homodetic cyclic peptide comprising the sequence D-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Nle-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Glu-Ala-His-Lys-Asn-Arg-Lys-Leu-Nle-Glu-Ile-Ile-NH2 cyclised by an amide bridge, formed by condensation of the side-chain carboxy group of the Glu residue at position 19 and the side-chain amino group of the Lys residue at position 22.","InChI=1S/C161H269N49O42/c1-23-27-41-96(189-145(239)107(52-59-123(217)218)199-152(246)114(71-84(13)14)207-157(251)126(85(15)16)208-147(241)108(53-60-124(219)220)197-140(234)102(47-38-66-179-161(172)173)193-151(245)112(69-82(9)10)204-153(247)113(70-83(11)12)205-155(249)116(74-94-77-175-79-181-94)201-134(228)95(163)72-92-39-30-29-31-40-92)135(229)182-88(19)130(224)186-100(45-36-64-177-159(168)169)136(230)183-89(20)131(225)188-106(51-58-122(215)216)144(238)195-104(49-56-119(165)212)146(240)202-110(67-80(5)6)149(243)185-90(21)132(226)187-103(48-55-118(164)211)143(237)196-105-50-57-121(214)176-63-35-33-44-99(192-154(248)115(73-93-76-174-78-180-93)200-133(227)91(22)184-137(105)231)142(236)206-117(75-120(166)213)156(250)194-101(46-37-65-178-160(170)171)139(233)190-98(43-32-34-62-162)141(235)203-111(68-81(7)8)150(244)191-97(42-28-24-2)138(232)198-109(54-61-125(221)222)148(242)210-128(87(18)26-4)158(252)209-127(129(167)223)86(17)25-3/h29-31,39-40,76-91,95-117,126-128H,23-28,32-38,41-75,162-163H2,1-22H3,(H2,164,211)(H2,165,212)(H2,166,213)(H2,167,223)(H,174,180)(H,175,181)(H,176,214)(H,182,229)(H,183,230)(H,184,231)(H,185,243)(H,186,224)(H,187,226)(H,188,225)(H,189,239)(H,190,233)(H,191,244)(H,192,248)(H,193,245)(H,194,250)(H,195,238)(H,196,237)(H,197,234)(H,198,232)(H,199,246)(H,200,227)(H,201,228)(H,202,240)(H,203,235)(H,204,247)(H,205,249)(H,206,236)(H,207,251)(H,208,241)(H,209,252)(H,210,242)(H,215,216)(H,217,218)(H,219,220)(H,221,222)(H4,168,169,177)(H4,170,171,178)(H4,172,173,179)/t86-,87-,88-,89-,90-,91-,95+,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,126-,127-,128-/m0/s1",AST,PubMed citation,24290358
4690,76689,5'-GsCsCsGsAsGsGsTsCsCsAsTsGsTsCsGsTsAsCsGsC-3',"A phosphorothioate oligonucleotide consisting of seven deoxyguanosine, seven deoxycytidine, three deoxyadenosine and four thymidine residues connected by 3'->5' phosphorothioate linkages in the sequence G-C-C-G-A-G-G-T-C-C-A-T-G-T-C-G-T-A-C-G-C.","InChI=1S/C203H257N79O105P20S20/c1-78-40-269(200(303)258-175(78)285)138-27-90(113(357-138)54-336-404(323,424)385-100-37-149(280-75-234-159-172(280)248-190(218)255-183(159)293)367-123(100)64-346-407(326,427)387-102-39-151(282-77-236-161-174(282)250-192(220)257-185(161)295)366-122(102)63-345-405(324,425)382-96-33-144(275-70-229-154-164(213)223-67-226-167(154)275)361-117(96)58-340-406(325,426)386-101-38-150(281-76-235-160-173(281)249-191(219)256-184(160)294)364-120(101)61-343-394(313,414)372-87-24-135(266-16-9-128(208)241-197(266)300)351-107(87)48-329-390(309,410)369-84-21-132(263-13-6-125(205)238-194(263)297)349-105(84)46-328-389(308,409)368-83-20-145(347-103(83)44-283)276-71-230-155-168(276)244-186(214)251-179(155)289)375-396(315,416)331-49-108-85(22-133(352-108)264-14-7-126(206)239-195(264)298)370-391(310,411)330-47-106-86(23-134(350-106)265-15-8-127(207)240-196(265)299)371-392(311,412)338-56-115-95(32-143(359-115)274-69-228-153-163(212)222-66-225-166(153)274)381-401(320,421)334-52-111-93(30-141(355-111)272-43-81(4)178(288)261-203(272)306)378-399(318,419)344-62-121-99(36-148(365-121)279-74-233-158-171(279)247-189(217)254-182(158)292)384-403(322,423)335-53-112-91(28-139(356-112)270-41-79(2)176(286)259-201(270)304)376-397(316,417)332-50-109-88(25-136(353-109)267-17-10-129(209)242-198(267)301)373-395(314,415)342-60-119-98(35-147(363-119)278-73-232-157-170(278)246-188(216)253-181(157)291)383-402(321,422)337-55-114-92(29-140(358-114)271-42-80(3)177(287)260-202(271)305)377-398(317,418)339-57-116-94(31-142(360-116)273-68-227-152-162(211)221-65-224-165(152)273)380-400(319,420)333-51-110-89(26-137(354-110)268-18-11-130(210)243-199(268)302)374-393(312,413)341-59-118-97(34-146(362-118)277-72-231-156-169(277)245-187(215)252-180(156)290)379-388(307,408)327-45-104-82(284)19-131(348-104)262-12-5-124(204)237-193(262)296/h5-18,40-43,65-77,82-123,131-151,283-284H,19-39,44-64H2,1-4H3,(H,307,408)(H,308,409)(H,309,410)(H,310,411)(H,311,412)(H,312,413)(H,313,414)(H,314,415)(H,315,416)(H,316,417)(H,317,418)(H,318,419)(H,319,420)(H,320,421)(H,321,422)(H,322,423)(H,323,424)(H,324,425)(H,325,426)(H,326,427)(H2,204,237,296)(H2,205,238,297)(H2,206,239,298)(H2,207,240,299)(H2,208,241,300)(H2,209,242,301)(H2,210,243,302)(H2,211,221,224)(H2,212,222,225)(H2,213,223,226)(H,258,285,303)(H,259,286,304)(H,260,287,305)(H,261,288,306)(H3,214,244,251,289)(H3,215,245,252,290)(H3,216,246,253,291)(H3,217,247,254,292)(H3,218,248,255,293)(H3,219,249,256,294)(H3,220,250,257,295)/t82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,388?,389?,390?,391?,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?,402?,403?,404?,405?,406?,407?/m0/s1",phosphorothioate-linked 5'-GCC GAG GTC CAT GTC GTA CGC-3',PubMed citation,10199390
4691,76690,5'-TsGsTsGsGsGsTsTsAsAsGsAsCsTsTsTsTsTsAsCsC-3',"A phosphorothioate oligonucleotide consisting of five deoxyguanosine, three deoxycytidine, four deoxyadenosine and nine thymidine residues connected by 3'->5' phosphorothioate linkages in the sequence T-G-T-G-G-G-T-T-A-A-G-A-C-T-T-T-T-T-A-C-C.","InChI=1S/C207H262N72O109P20S20/c1-80-37-262(199(299)250-177(80)282)137-17-90(110(46-280)348-137)369-390(309,410)329-62-126-105(32-150(364-126)275-75-232-159-172(275)240-191(215)245-186(159)291)384-402(321,422)338-57-121-100(27-145(359-121)270-45-88(9)185(290)258-207(270)307)379-399(318,419)344-63-127-107(34-152(365-127)277-77-234-161-174(277)242-193(217)247-188(161)293)387-407(326,427)347-66-130-109(36-154(368-130)279-79-236-163-176(279)244-195(219)249-190(163)295)388-408(327,428)346-65-129-106(33-151(367-129)276-76-233-160-173(276)241-192(216)246-187(160)292)385-403(322,423)339-56-120-97(24-142(358-120)267-42-85(6)182(287)255-204(267)304)376-396(315,416)337-55-119-99(26-144(357-119)269-44-87(8)184(289)257-206(269)306)378-398(317,418)341-59-123-103(30-148(361-123)273-73-230-157-166(213)222-69-226-170(157)273)382-404(323,424)342-60-124-104(31-149(362-124)274-74-231-158-167(214)223-70-227-171(158)274)383-405(324,425)345-64-128-108(35-153(366-128)278-78-235-162-175(278)243-194(218)248-189(162)294)386-406(325,426)343-61-125-102(29-147(363-125)272-72-229-156-165(212)221-68-225-169(156)272)381-401(320,421)331-49-113-92(19-136(351-113)261-15-12-133(210)239-198(261)298)371-391(310,411)332-50-114-93(20-138(352-114)263-38-81(2)178(283)251-200(263)300)372-392(311,412)333-51-115-94(21-139(353-115)264-39-82(3)179(284)252-201(264)301)373-393(312,413)334-52-116-95(22-140(354-116)265-40-83(4)180(285)253-202(265)302)374-394(313,414)335-53-117-96(23-141(355-117)266-41-84(5)181(286)254-203(266)303)375-395(314,415)336-54-118-98(25-143(356-118)268-43-86(7)183(288)256-205(268)305)377-397(316,417)340-58-122-101(28-146(360-122)271-71-228-155-164(211)220-67-224-168(155)271)380-400(319,420)330-48-112-91(18-135(350-112)260-14-11-132(209)238-197(260)297)370-389(308,409)328-47-111-89(281)16-134(349-111)259-13-10-131(208)237-196(259)296/h10-15,37-45,67-79,89-130,134-154,280-281H,16-36,46-66H2,1-9H3,(H,308,409)(H,309,410)(H,310,411)(H,311,412)(H,312,413)(H,313,414)(H,314,415)(H,315,416)(H,316,417)(H,317,418)(H,318,419)(H,319,420)(H,320,421)(H,321,422)(H,322,423)(H,323,424)(H,324,425)(H,325,426)(H,326,427)(H,327,428)(H2,208,237,296)(H2,209,238,297)(H2,210,239,298)(H2,211,220,224)(H2,212,221,225)(H2,213,222,226)(H2,214,223,227)(H,250,282,299)(H,251,283,300)(H,252,284,301)(H,253,285,302)(H,254,286,303)(H,255,287,304)(H,256,288,305)(H,257,289,306)(H,258,290,307)(H3,215,240,245,291)(H3,216,241,246,292)(H3,217,242,247,293)(H3,218,243,248,294)(H3,219,244,249,295)/t89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,389?,390?,391?,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?,402?,403?,404?,405?,406?,407?,408?/m0/s1",phosphorothioate-linked 5'-TGTGGGTTAAGACTTTTTACC-3',PubMed citation,10199390
4692,76698,C16 phytosphingosine,A sphingoid that is C16 sphinganine bearing an additional 4R-hydroxy substituent.,"InChI=1S/C16H35NO3/c1-2-3-4-5-6-7-8-9-10-11-12-15(19)16(20)14(17)13-18/h14-16,18-20H,2-13,17H2,1H3/t14-,15+,16-/m0/s1",(4R)-hydroxyhexadecasphinganine,Reaxys Registry Number,4230858
4693,76700,5'-GsCsAsGsTsCsTsAsTsTsAsCsTsGsTsGsCsGsAsGsA-3',"A phosphorothioate oligonucleotide consisting of six deoxyguanosine, four deoxycytidine, five deoxyadenosine and six thymidine residues connected by 3'->5' phosphorothioate linkages in the sequence G-C-A-G-T-C-T-A-T-T-A-C-T-G-T-G-C-G-A-G-A.","InChI=1S/C206H260N79O107P21S21/c1-79-36-269(201(303)259-179(79)287)135-21-91(116(360-135)52-340-410(327,431)391-104-34-150(284-77-241-161-177(284)251-195(220)257-189(161)297)371-126(104)62-350-412(329,433)386-99-29-144(278-71-235-155-166(214)225-66-230-171(155)278)363-118(99)54-342-398(315,419)376-87-17-131(265-11-7-127(207)243-197(265)299)352-108(87)44-332-394(311,415)373-85-15-146(351-106(85)42-286)280-73-237-157-173(280)247-191(216)253-185(157)293)378-400(317,421)333-45-109-88(18-132(353-109)266-12-8-128(208)244-198(266)300)374-396(313,417)336-48-112-93(23-137(356-112)271-38-81(3)181(289)261-203(271)305)380-402(319,423)344-56-120-98(28-143(365-120)277-70-234-154-165(213)224-65-229-170(154)277)385-408(325,429)339-51-115-92(22-136(359-115)270-37-80(2)180(288)260-202(270)304)379-401(318,422)338-50-114-95(25-139(358-114)273-40-83(5)183(291)263-205(273)307)381-403(320,424)343-55-119-97(27-142(364-119)276-69-233-153-164(212)223-64-228-169(153)276)384-406(323,427)334-46-110-89(19-133(354-110)267-13-9-129(209)245-199(267)301)375-397(314,418)337-49-113-94(24-138(357-113)272-39-82(4)182(290)262-204(272)306)382-404(321,425)348-60-124-103(33-149(369-124)283-76-240-160-176(283)250-194(219)256-188(160)296)390-409(326,430)341-53-117-96(26-140(361-117)274-41-84(6)184(292)264-206(274)308)383-405(322,426)347-59-123-102(32-148(368-123)282-75-239-159-175(282)249-193(218)255-187(159)295)389-407(324,428)335-47-111-90(20-134(355-111)268-14-10-130(210)246-200(268)302)377-399(316,420)346-58-122-105(35-151(367-122)285-78-242-162-178(285)252-196(221)258-190(162)298)392-413(330,434)345-57-121-100(30-145(366-121)279-72-236-156-167(215)226-67-231-172(156)279)387-411(328,432)349-61-125-101(31-147(370-125)281-74-238-158-174(281)248-192(217)254-186(158)294)388-395(312,416)331-43-107-86(372-393(309,310)414)16-141(362-107)275-68-232-152-163(211)222-63-227-168(152)275/h7-14,36-41,63-78,85-126,131-151,286H,15-35,42-62H2,1-6H3,(H,311,415)(H,312,416)(H,313,417)(H,314,418)(H,315,419)(H,316,420)(H,317,421)(H,318,422)(H,319,423)(H,320,424)(H,321,425)(H,322,426)(H,323,427)(H,324,428)(H,325,429)(H,326,430)(H,327,431)(H,328,432)(H,329,433)(H,330,434)(H2,207,243,299)(H2,208,244,300)(H2,209,245,301)(H2,210,246,302)(H2,211,222,227)(H2,212,223,228)(H2,213,224,229)(H2,214,225,230)(H2,215,226,231)(H,259,287,303)(H,260,288,304)(H,261,289,305)(H,262,290,306)(H,263,291,307)(H,264,292,308)(H2,309,310,414)(H3,216,247,253,293)(H3,217,248,254,294)(H3,218,249,255,295)(H3,219,250,256,296)(H3,220,251,257,297)(H3,221,252,258,298)/t85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,394?,395?,396?,397?,398?,399?,400?,401?,402?,403?,404?,405?,406?,407?,408?,409?,410?,411?,412?,413?/m0/s1",d[GPSCPSAPSGPSTPSCPSTPSAPSTPSTPSAPSCPSTPSGPSTPSGPSCPSGPSAPSGPSA],PubMed citation,10199390
4694,76701,5'-CsGsGsCsTsCsCsAsTsGsTsAsCsAsGsCsAsTsGsCsG-3',"A phosphorothioate oligonucleotide consisting of six deoxyguanosine, seven deoxycytidine, four deoxyadenosine and four thymidine residues connected by 3'->5' phosphorothioate linkages in the sequence C-G-G-C-T-C-C-A-T-G-T-A-C-A-G-C-A-T-G-C-G.","InChI=1S/C203H258N79O106P21S21/c1-79-40-269(200(301)258-177(79)284)139-27-91(112(354-139)52-335-393(310,414)372-87-23-135(265-15-8-128(207)242-196(265)297)352-110(87)50-333-403(320,424)386-102-38-151(281-77-237-161-175(281)250-191(219)256-185(161)292)367-124(102)64-346-409(326,430)388-99-35-148(278-74-234-158-172(278)247-188(216)253-182(158)289)363-120(99)60-328-390(307,411)369-83-19-132(347-104(83)44-283)262-12-5-125(204)239-193(262)294)376-397(314,418)330-47-107-86(22-134(349-107)264-14-7-127(206)241-195(264)296)371-392(309,413)329-46-106-88(24-136(348-106)266-16-9-129(208)243-197(266)298)373-394(311,415)339-56-116-96(32-144(359-116)274-70-230-154-164(212)222-66-226-168(154)274)381-405(322,426)337-54-114-94(30-142(356-114)272-43-82(4)180(287)261-203(272)304)379-400(317,421)344-62-122-103(39-152(365-122)282-78-238-162-176(282)251-192(220)257-186(162)293)387-407(324,428)338-55-115-92(28-140(357-115)270-41-80(2)178(285)259-201(270)302)377-398(315,419)342-59-119-95(31-143(362-119)273-69-229-153-163(211)221-65-225-167(153)273)380-401(318,422)331-48-109-89(25-137(351-109)267-17-10-130(209)244-198(267)299)374-396(313,417)341-58-118-98(34-146(361-118)276-72-232-156-166(214)224-68-228-170(156)276)383-408(325,429)345-63-123-101(37-150(366-123)280-76-236-160-174(280)249-190(218)255-184(160)291)385-404(321,425)334-51-111-90(26-138(353-111)268-18-11-131(210)245-199(268)300)375-395(312,416)340-57-117-97(33-145(360-117)275-71-231-155-165(213)223-67-227-169(155)275)382-406(323,427)336-53-113-93(29-141(355-113)271-42-81(3)179(286)260-202(271)303)378-399(316,420)343-61-121-100(36-149(364-121)279-75-235-159-173(279)248-189(217)254-183(159)290)384-402(319,423)332-49-108-85(21-133(350-108)263-13-6-126(205)240-194(263)295)370-391(308,412)327-45-105-84(368-389(305,306)410)20-147(358-105)277-73-233-157-171(277)246-187(215)252-181(157)288/h5-18,40-43,65-78,83-124,132-152,283H,19-39,44-64H2,1-4H3,(H,307,411)(H,308,412)(H,309,413)(H,310,414)(H,311,415)(H,312,416)(H,313,417)(H,314,418)(H,315,419)(H,316,420)(H,317,421)(H,318,422)(H,319,423)(H,320,424)(H,321,425)(H,322,426)(H,323,427)(H,324,428)(H,325,429)(H,326,430)(H2,204,239,294)(H2,205,240,295)(H2,206,241,296)(H2,207,242,297)(H2,208,243,298)(H2,209,244,299)(H2,210,245,300)(H2,211,221,225)(H2,212,222,226)(H2,213,223,227)(H2,214,224,228)(H,258,284,301)(H,259,285,302)(H,260,286,303)(H,261,287,304)(H2,305,306,410)(H3,215,246,252,288)(H3,216,247,253,289)(H3,217,248,254,290)(H3,218,249,255,291)(H3,219,250,256,292)(H3,220,251,257,293)/t83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,390?,391?,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?,402?,403?,404?,405?,406?,407?,408?,409?/m0/s1",phosphorothioate-linked 5'-CGG CTC CAT GTA CAG CAT GCG-3',PubMed citation,10199390
4695,76702,5'-GsCsGsTsAsCsGsAsCsAsTsGsGsAsCsCsTsCsGsGsC-3',"A phosphorothioate oligonucleotide consisting of seven deoxyguanosine, seven deoxycytidine, four deoxyadenosine and three thymidine residues connected by 3'->5' phosphorothioate linkages in the sequence G-C-G-T-A-C-G-A-C-A-T-G-G-A-C-C-T-C-G-G-C.","InChI=1S/C203H257N82O105P21S21/c1-78-39-272(201(304)262-177(78)287)137-26-89(378-400(317,421)332-46-106-86(23-134(353-106)269-15-8-127(208)245-198(269)301)376-398(315,419)345-59-119-99(36-148(366-119)283-75-238-159-174(283)252-191(219)259-184(159)294)389-410(327,431)347-61-121-96(33-145(368-121)280-72-235-156-171(280)249-188(216)256-181(156)291)385-393(310,414)329-43-103-82(370-391(307,308)412)19-130(350-103)265-11-4-123(204)241-194(265)297)110(357-137)50-336-395(312,416)373-85-22-133(268-14-7-126(207)244-197(268)300)352-105(85)45-331-394(311,415)372-84-21-132(267-13-6-125(206)243-196(267)299)354-107(84)47-333-404(321,425)382-93-30-141(276-68-231-152-163(212)223-64-227-167(152)276)363-116(93)56-342-409(326,430)388-101-38-150(285-77-240-161-176(285)254-193(221)261-186(161)296)369-122(101)62-348-411(328,432)390-100-37-149(284-76-239-160-175(284)253-192(220)260-185(160)295)367-120(100)60-346-402(319,423)380-91-28-139(274-41-80(3)179(289)264-203(274)306)358-111(91)51-337-406(323,427)384-95-32-143(278-70-233-154-165(214)225-66-229-169(154)278)360-113(95)53-339-396(313,417)375-87-24-135(270-16-9-128(209)246-199(270)302)355-108(87)48-334-405(322,426)383-94-31-142(277-69-232-153-164(213)224-65-228-168(153)277)362-115(94)55-341-408(325,429)387-98-35-147(282-74-237-158-173(282)251-190(218)258-183(158)293)365-118(98)58-344-399(316,420)377-88-25-136(271-17-10-129(210)247-200(271)303)356-109(88)49-335-403(320,424)381-92-29-140(275-67-230-151-162(211)222-63-226-166(151)275)361-114(92)54-340-401(318,422)379-90-27-138(273-40-79(2)178(288)263-202(273)305)359-112(90)52-338-407(324,428)386-97-34-146(281-73-236-157-172(281)250-189(217)257-182(157)292)364-117(97)57-343-397(314,418)374-83-20-131(266-12-5-124(205)242-195(266)298)351-104(83)44-330-392(309,413)371-81-18-144(349-102(81)42-286)279-71-234-155-170(279)248-187(215)255-180(155)290/h4-17,39-41,63-77,81-122,130-150,286H,18-38,42-62H2,1-3H3,(H,309,413)(H,310,414)(H,311,415)(H,312,416)(H,313,417)(H,314,418)(H,315,419)(H,316,420)(H,317,421)(H,318,422)(H,319,423)(H,320,424)(H,321,425)(H,322,426)(H,323,427)(H,324,428)(H,325,429)(H,326,430)(H,327,431)(H,328,432)(H2,204,241,297)(H2,205,242,298)(H2,206,243,299)(H2,207,244,300)(H2,208,245,301)(H2,209,246,302)(H2,210,247,303)(H2,211,222,226)(H2,212,223,227)(H2,213,224,228)(H2,214,225,229)(H,262,287,304)(H,263,288,305)(H,264,289,306)(H2,307,308,412)(H3,215,248,255,290)(H3,216,249,256,291)(H3,217,250,257,292)(H3,218,251,258,293)(H3,219,252,259,294)(H3,220,253,260,295)(H3,221,254,261,296)/t81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,392?,393?,394?,395?,396?,397?,398?,399?,400?,401?,402?,403?,404?,405?,406?,407?,408?,409?,410?,411?/m0/s1",phosphorothioate-linked 5'-GCG TAC GAC ATG GAC CTC GGC-3',PubMed citation,10199390
4696,76703,5'-AsGsCsCsGsCsGsAsCsTsTsCsTsAsGsAsCsT-3',"A phosphorothioate oligonucleotide consisting of four deoxyguanosine, six deoxycytidine, four deoxyadenosine and four thymidine residues connected by 3'->5' phosphorothioate linkages in the sequence A-G-C-C-G-C-G-A-C-T-T-C-T-A-G-A-C-T.","InChI=1S/C174H222N66O91P18S18/c1-69-35-229(171(256)219-153(69)242)121-18-74(314-332(260,261)350)92(303-121)40-279-334(263,352)316-75-19-115(223-11-5-109(175)205-165(223)250)299-95(75)43-283-343(272,361)325-84-28-126(234-62-198-134-142(182)190-58-194-146(134)234)309-104(84)52-292-349(278,367)331-90-34-132(240-68-204-140-152(240)214-164(188)218-160(140)249)313-108(90)56-295-347(276,365)327-86-30-128(236-64-200-136-144(184)192-60-196-148(136)236)307-102(86)50-290-342(271,360)324-83-27-124(232-38-72(4)156(245)222-174(232)259)305-100(83)48-288-336(265,354)318-77-21-117(225-13-7-111(177)207-167(225)252)298-94(77)42-282-340(269,358)322-81-25-122(230-36-70(2)154(243)220-172(230)257)306-101(81)49-289-341(270,359)323-82-26-123(231-37-71(3)155(244)221-173(231)258)304-99(82)47-287-337(266,355)319-78-22-118(226-14-8-112(178)208-168(226)253)300-96(78)44-284-344(273,362)326-85-29-127(235-63-199-135-143(183)191-59-195-147(135)235)308-103(85)51-291-348(277,366)330-89-33-131(239-67-203-139-151(239)213-163(187)217-159(139)248)312-107(89)55-294-339(268,357)321-80-24-120(228-16-10-114(180)210-170(228)255)302-98(80)46-286-346(275,364)329-88-32-130(238-66-202-138-150(238)212-162(186)216-158(138)247)311-106(88)54-293-338(267,356)320-79-23-119(227-15-9-113(179)209-169(227)254)297-93(79)41-281-335(264,353)317-76-20-116(224-12-6-110(176)206-166(224)251)301-97(76)45-285-345(274,363)328-87-31-129(237-65-201-137-149(237)211-161(185)215-157(137)246)310-105(87)53-280-333(262,351)315-73-17-125(296-91(73)39-241)233-61-197-133-141(181)189-57-193-145(133)233/h5-16,35-38,57-68,73-108,115-132,241H,17-34,39-56H2,1-4H3,(H,262,351)(H,263,352)(H,264,353)(H,265,354)(H,266,355)(H,267,356)(H,268,357)(H,269,358)(H,270,359)(H,271,360)(H,272,361)(H,273,362)(H,274,363)(H,275,364)(H,276,365)(H,277,366)(H,278,367)(H2,175,205,250)(H2,176,206,251)(H2,177,207,252)(H2,178,208,253)(H2,179,209,254)(H2,180,210,255)(H2,181,189,193)(H2,182,190,194)(H2,183,191,195)(H2,184,192,196)(H,219,242,256)(H,220,243,257)(H,221,244,258)(H,222,245,259)(H2,260,261,350)(H3,185,211,215,246)(H3,186,212,216,247)(H3,187,213,217,248)(H3,188,214,218,249)/t73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,333?,334?,335?,336?,337?,338?,339?,340?,341?,342?,343?,344?,345?,346?,347?,348?,349?/m0/s1",phosphorothioate-linked 5'-AGCCGCGACTTCTAGACT-3',PubMed citation,10199390
4697,76705,d(Gs)19dG,A phosphorothioate oligonucleotide consisting of twenty 2'-deoxyguanosine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C200H242N100O101P20S20/c201-181-241-141-121(161(302)261-181)221-41-281(141)101-1-61(81(21-301)362-101)383-403(324,423)344-23-83-63(3-103(364-83)283-43-223-123-143(283)243-183(203)263-163(123)304)385-405(326,425)346-25-85-65(5-105(366-85)285-45-225-125-145(285)245-185(205)265-165(125)306)387-407(328,427)348-27-87-67(7-107(368-87)287-47-227-127-147(287)247-187(207)267-167(127)308)389-409(330,429)350-29-89-69(9-109(370-89)289-49-229-129-149(289)249-189(209)269-169(129)310)391-411(332,431)352-31-91-71(11-111(372-91)291-51-231-131-151(291)251-191(211)271-171(131)312)393-413(334,433)354-33-93-73(13-113(374-93)293-53-233-133-153(293)253-193(213)273-173(133)314)395-415(336,435)356-35-95-75(15-115(376-95)295-55-235-135-155(295)255-195(215)275-175(135)316)397-417(338,437)358-37-97-77(17-117(378-97)297-57-237-137-157(297)257-197(217)277-177(137)318)399-419(340,439)360-39-99-79(19-119(380-99)299-59-239-139-159(299)259-199(219)279-179(139)320)401-421(342,441)361-40-100-80(20-120(381-100)300-60-240-140-160(300)260-200(220)280-180(140)321)400-420(341,440)359-38-98-78(18-118(379-98)298-58-238-138-158(298)258-198(218)278-178(138)319)398-418(339,438)357-36-96-76(16-116(377-96)296-56-236-136-156(296)256-196(216)276-176(136)317)396-416(337,436)355-34-94-74(14-114(375-94)294-54-234-134-154(294)254-194(214)274-174(134)315)394-414(335,434)353-32-92-72(12-112(373-92)292-52-232-132-152(292)252-192(212)272-172(132)313)392-412(333,432)351-30-90-70(10-110(371-90)290-50-230-130-150(290)250-190(210)270-170(130)311)390-410(331,430)349-28-88-68(8-108(369-88)288-48-228-128-148(288)248-188(208)268-168(128)309)388-408(329,428)347-26-86-66(6-106(367-86)286-46-226-126-146(286)246-186(206)266-166(126)307)386-406(327,426)345-24-84-64(4-104(365-84)284-44-224-124-144(284)244-184(204)264-164(124)305)384-404(325,424)343-22-82-62(382-402(322,323)422)2-102(363-82)282-42-222-122-142(282)242-182(202)262-162(122)303/h41-120,301H,1-40H2,(H,324,423)(H,325,424)(H,326,425)(H,327,426)(H,328,427)(H,329,428)(H,330,429)(H,331,430)(H,332,431)(H,333,432)(H,334,433)(H,335,434)(H,336,435)(H,337,436)(H,338,437)(H,339,438)(H,340,439)(H,341,440)(H,342,441)(H2,322,323,422)(H3,201,241,261,302)(H3,202,242,262,303)(H3,203,243,263,304)(H3,204,244,264,305)(H3,205,245,265,306)(H3,206,246,266,307)(H3,207,247,267,308)(H3,208,248,268,309)(H3,209,249,269,310)(H3,210,250,270,311)(H3,211,251,271,312)(H3,212,252,272,313)(H3,213,253,273,314)(H3,214,254,274,315)(H3,215,255,275,316)(H3,216,256,276,317)(H3,217,257,277,318)(H3,218,258,278,319)(H3,219,259,279,320)(H3,220,260,280,321)/t61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,403?,404?,405?,406?,407?,408?,409?,410?,411?,412?,413?,414?,415?,416?,417?,418?,419?,420?,421?/m0/s1",phosphorothioate-linked 5'-d(GGG GGG GGG GGG GGG GGG GG)-3',PubMed citation,10199390
4698,76780,G20,An oligonucleotide comprised of twenty guanosine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C200H241N100O138P19/c201-181-241-121-61(141(323)261-181)221-21-281(121)161-82(303)81(302)42(401-161)2-381-439(343,344)421-103-44(403-163(84(103)305)283-23-223-63-123(283)243-183(203)263-143(63)325)4-383-441(347,348)423-105-46(405-165(86(105)307)285-25-225-65-125(285)245-185(205)265-145(65)327)6-385-443(351,352)425-107-48(407-167(88(107)309)287-27-227-67-127(287)247-187(207)267-147(67)329)8-387-445(355,356)427-109-50(409-169(90(109)311)289-29-229-69-129(289)249-189(209)269-149(69)331)10-389-447(359,360)429-111-52(411-171(92(111)313)291-31-231-71-131(291)251-191(211)271-151(71)333)12-391-449(363,364)431-113-54(413-173(94(113)315)293-33-233-73-133(293)253-193(213)273-153(73)335)14-393-451(367,368)433-115-56(415-175(96(115)317)295-35-235-75-135(295)255-195(215)275-155(75)337)16-395-453(371,372)435-117-58(417-177(98(117)319)297-37-237-77-137(297)257-197(217)277-157(77)339)18-397-455(375,376)437-119-60(419-179(100(119)321)299-39-239-79-139(299)259-199(219)279-159(79)341)20-399-457(379,380)438-120-59(418-180(101(120)322)300-40-240-80-140(300)260-200(220)280-160(80)342)19-398-456(377,378)436-118-57(416-178(99(118)320)298-38-238-78-138(298)258-198(218)278-158(78)340)17-396-454(373,374)434-116-55(414-176(97(116)318)296-36-236-76-136(296)256-196(216)276-156(76)338)15-394-452(369,370)432-114-53(412-174(95(114)316)294-34-234-74-134(294)254-194(214)274-154(74)336)13-392-450(365,366)430-112-51(410-172(93(112)314)292-32-232-72-132(292)252-192(212)272-152(72)334)11-390-448(361,362)428-110-49(408-170(91(110)312)290-30-230-70-130(290)250-190(210)270-150(70)332)9-388-446(357,358)426-108-47(406-168(89(108)310)288-28-228-68-128(288)248-188(208)268-148(68)330)7-386-444(353,354)424-106-45(404-166(87(106)308)286-26-226-66-126(286)246-186(206)266-146(66)328)5-384-442(349,350)422-104-43(402-164(85(104)306)284-24-224-64-124(284)244-184(204)264-144(64)326)3-382-440(345,346)420-102-41(1-301)400-162(83(102)304)282-22-222-62-122(282)242-182(202)262-142(62)324/h21-60,81-120,161-180,301-322H,1-20H2,(H,343,344)(H,345,346)(H,347,348)(H,349,350)(H,351,352)(H,353,354)(H,355,356)(H,357,358)(H,359,360)(H,361,362)(H,363,364)(H,365,366)(H,367,368)(H,369,370)(H,371,372)(H,373,374)(H,375,376)(H,377,378)(H,379,380)(H3,201,241,261,323)(H3,202,242,262,324)(H3,203,243,263,325)(H3,204,244,264,326)(H3,205,245,265,327)(H3,206,246,266,328)(H3,207,247,267,329)(H3,208,248,268,330)(H3,209,249,269,331)(H3,210,250,270,332)(H3,211,251,271,333)(H3,212,252,272,334)(H3,213,253,273,335)(H3,214,254,274,336)(H3,215,255,275,337)(H3,216,256,276,338)(H3,217,257,277,339)(H3,218,258,278,340)(H3,219,259,279,341)(H3,220,260,280,342)/t41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-/m1/s1",guanosine20,PubMed citation,3771789
4699,76781,I25,An oligonucleotide comprised of 25 inosine residues connected via 3'->5' phosphodiester linkages.,"InChI=1S/C250H276N100O173P24/c351-1-76-152(128(354)227(475-76)327-52-302-102-177(327)252-27-277-202(102)379)500-525(405,406)452-3-78-154(130(356)229(477-78)329-54-304-104-179(329)254-29-279-204(104)381)502-527(409,410)454-5-80-156(132(358)231(479-80)331-56-306-106-181(331)256-31-281-206(106)383)504-529(413,414)456-7-82-158(134(360)233(481-82)333-58-308-108-183(333)258-33-283-208(108)385)506-531(417,418)458-9-84-160(136(362)235(483-84)335-60-310-110-185(335)260-35-285-210(110)387)508-533(421,422)460-11-86-162(138(364)237(485-86)337-62-312-112-187(337)262-37-287-212(112)389)510-535(425,426)462-13-88-164(140(366)239(487-88)339-64-314-114-189(339)264-39-289-214(114)391)512-537(429,430)464-15-90-166(142(368)241(489-90)341-66-316-116-191(341)266-41-291-216(116)393)514-539(433,434)466-17-92-168(144(370)243(491-92)343-68-318-118-193(343)268-43-293-218(118)395)516-541(437,438)468-19-94-170(146(372)245(493-94)345-70-320-120-195(345)270-45-295-220(120)397)518-543(441,442)470-21-96-172(148(374)247(495-96)347-72-322-122-197(347)272-47-297-222(122)399)520-545(445,446)472-23-98-174(150(376)249(497-98)349-74-324-124-199(349)274-49-299-224(124)401)522-547(449,450)474-25-100-175(151(377)250(499-100)350-75-325-125-200(350)275-50-300-225(125)402)523-546(447,448)473-24-99-173(149(375)248(498-99)348-73-323-123-198(348)273-48-298-223(123)400)521-544(443,444)471-22-97-171(147(373)246(496-97)346-71-321-121-196(346)271-46-296-221(121)398)519-542(439,440)469-20-95-169(145(371)244(494-95)344-69-319-119-194(344)269-44-294-219(119)396)517-540(435,436)467-18-93-167(143(369)242(492-93)342-67-317-117-192(342)267-42-292-217(117)394)515-538(431,432)465-16-91-165(141(367)240(490-91)340-65-315-115-190(340)265-40-290-215(115)392)513-536(427,428)463-14-89-163(139(365)238(488-89)338-63-313-113-188(338)263-38-288-213(113)390)511-534(423,424)461-12-87-161(137(363)236(486-87)336-61-311-111-186(336)261-36-286-211(111)388)509-532(419,420)459-10-85-159(135(361)234(484-85)334-59-309-109-184(334)259-34-284-209(109)386)507-530(415,416)457-8-83-157(133(359)232(482-83)332-57-307-107-182(332)257-32-282-207(107)384)505-528(411,412)455-6-81-155(131(357)230(480-81)330-55-305-105-180(330)255-30-280-205(105)382)503-526(407,408)453-4-79-153(129(355)228(478-79)328-53-303-103-178(328)253-28-278-203(103)380)501-524(403,404)451-2-77-126(352)127(353)226(476-77)326-51-301-101-176(326)251-26-276-201(101)378/h26-100,126-175,226-250,351-377H,1-25H2,(H,403,404)(H,405,406)(H,407,408)(H,409,410)(H,411,412)(H,413,414)(H,415,416)(H,417,418)(H,419,420)(H,421,422)(H,423,424)(H,425,426)(H,427,428)(H,429,430)(H,431,432)(H,433,434)(H,435,436)(H,437,438)(H,439,440)(H,441,442)(H,443,444)(H,445,446)(H,447,448)(H,449,450)(H,251,276,378)(H,252,277,379)(H,253,278,380)(H,254,279,381)(H,255,280,382)(H,256,281,383)(H,257,282,384)(H,258,283,385)(H,259,284,386)(H,260,285,387)(H,261,286,388)(H,262,287,389)(H,263,288,390)(H,264,289,391)(H,265,290,392)(H,266,291,393)(H,267,292,394)(H,268,293,395)(H,269,294,396)(H,270,295,397)(H,271,296,398)(H,272,297,399)(H,273,298,400)(H,274,299,401)(H,275,300,402)/t76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,226-,227-,228-,229-,230-,231-,232-,233-,234-,235-,236-,237-,238-,239-,240-,241-,242-,243-,244-,245-,246-,247-,248-,249-,250-/m1/s1",(IMP)25,PubMed citation,3771789
4700,76801,narbomycin(1+),"An organic cation that is the conjugate acid of pikromycin, obtained by protonation of the tertiary amino group; major species at pH 7.3.","InChI=1S/C28H47NO7/c1-10-23-15(2)11-12-22(30)16(3)13-17(4)26(19(6)24(31)20(7)27(33)35-23)36-28-25(32)21(29(8)9)14-18(5)34-28/h11-12,15-21,23,25-26,28,32H,10,13-14H2,1-9H3/p+1/b12-11+/t15-,16-,17+,18-,19+,20-,21+,23-,25-,26+,28+/m1/s1",narbomycin,MetaCyc accession,CPD-13834
4701,76854,beta-D-Manp-(1->3)-beta-D-Manp-(1->3)-alpha-L-Rhap-(1->3)-beta-D-GlcpO[CH2]3NH2,A tetrasaccharide derivative consisting of a D-glucosyl residue beta-linked to a 3-aminopropyloxy group and which carries at O-3 a beta-D-mannosyl-(1->3)-beta-D-mannosyl-(1->3)-alpha-L-rhamnosyl linear trisaccharide unit.,"InChI=1S/C27H49NO20/c1-8-12(32)21(19(39)26(42-8)48-22-14(34)10(6-30)43-24(18(22)38)41-4-2-3-28)46-27-20(40)23(15(35)11(7-31)45-27)47-25-17(37)16(36)13(33)9(5-29)44-25/h8-27,29-40H,2-7,28H2,1H3/t8-,9+,10+,11+,12-,13+,14+,15+,16-,17-,18+,19+,20-,21+,22-,23-,24+,25-,26-,27-/m0/s1",3-aminopropyl beta-D-mannosyl-(1->3)-beta-D-mannosyl-(1->3)-alpha-L-rhamosyl-(1->3)-beta-D-glucoside,PubMed citation,24248772
4702,76872,2-iminobutanoic acid,A dehydroamino acid that is 2-aminobutanoic acid in which the amino group has been oxidised to the corresponding imine.,"InChI=1S/C4H7NO2/c1-2-3(5)4(6)7/h5H,2H2,1H3,(H,6,7)",2-iminobutyric acid,PubMed citation,22094463
4703,76886,alpha-D-Manp-(1->2)-beta-D-Manp-(1->3)-beta-D-Manp-(1->3)-alpha-L-Rhap-(1->3)-beta-D-Glcp,"A linear pentasaccharide consisting of an alpha-D-mannose residue, two beta-D-mannose residues, an alpha-L-rhamnose residue and a beta-D-glucose residue (at the reducing end), joined by sequential (1->2), (1->3), (1->3) and (1->3) linkages.","InChI=1S/C30H52O25/c1-6-11(35)22(20(44)28(47-6)53-23-14(38)9(4-33)48-26(46)19(23)43)52-29-21(45)24(15(39)10(5-34)50-29)54-30-25(17(41)13(37)8(3-32)51-30)55-27-18(42)16(40)12(36)7(2-31)49-27/h6-46H,2-5H2,1H3/t6-,7+,8+,9+,10+,11-,12+,13+,14+,15+,16-,17-,18-,19+,20+,21-,22+,23-,24-,25-,26+,27+,28-,29-,30-/m0/s1",alpha-D-mannosyl-(1->2)-beta-D-mannosyl-(1->3)-beta-D-mannosyl-(1->3)-alpha-L-rhamosyl-(1->3)-beta-D-glucose,PubMed citation,24248772
4704,76887,beta-D-Glcp-(1->3)-[alpha-D-Manp-(1->2)]-beta-D-Manp-(1->3)-beta-D-Manp-(1->3)-alpha-L-Rhap-(1->3)-beta-D-Glcp,"A branched hexasaccharide consisting of a beta-D-glucose residue, two beta-D-mannose residues, an alpha-L-rhamnose residue and a beta-D-glucose residue (at the reducing end), all joined by sequential (1->3) linkages, to the mannose residue nearest to the non-reducing end is also connected an alpha-D-mannose residue via a (1->2) linkage.","InChI=1S/C36H62O30/c1-7-13(42)26(24(53)34(56-7)63-27-16(45)10(4-39)57-31(55)23(27)52)62-35-25(54)28(17(46)11(5-40)60-35)64-36-30(66-33-22(51)20(49)15(44)9(3-38)59-33)29(18(47)12(6-41)61-36)65-32-21(50)19(48)14(43)8(2-37)58-32/h7-55H,2-6H2,1H3/t7-,8+,9+,10+,11+,12+,13-,14+,15+,16+,17+,18+,19-,20-,21+,22-,23+,24+,25-,26+,27-,28-,29-,30-,31+,32-,33+,34-,35-,36-/m0/s1",beta-D-Glc-(1->3)-[alpha-D-Man-(1->2)]-beta-D-Man-(1->3)-beta-D-Man-(1->3)-alpha-L-Rha-(1->3)-beta-D-Glc,PubMed citation,24248772
4705,76889,"(9Z,12Z)-hexadecadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z,12Z)-hexadecadienoic acid.","InChI=1S/C37H62N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h6-7,9-10,24-26,30-32,36,47-48H,4-5,8,11-23H2,1-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/b7-6-,10-9-/t26-,30-,31-,32+,36-/m1/s1","(9Z,12Z)-hexadecadienoyl-coenzyme A",MetaCyc accession,CPD-10254
4706,76911,1-O-(alpha-lactosyl)-N-hexacosanoylphytosphingosine,A glycophytoceramide having an alpha-lactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen.,"InChI=1S/C56H109NO14/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-47(61)57-43(48(62)44(60)38-36-34-32-30-28-16-14-12-10-8-6-4-2)42-68-55-53(67)51(65)54(46(41-59)70-55)71-56-52(66)50(64)49(63)45(40-58)69-56/h43-46,48-56,58-60,62-67H,3-42H2,1-2H3,(H,57,61)/t43-,44+,45+,46+,48-,49-,50-,51+,52+,53+,54+,55-,56-/m0/s1",1-O-[beta-D-galactopyranosyl-(1->4)-alpha-D-glucopyranosyl]-N-hexacosanoylphytosphingosine,PubMed citation,18478523
4707,76912,1-O-(alpha-D-glucosyl)-N-hexacosanoylphytosphingosine,A glycophytoceramide having an alpha-D-glucosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen.,"InChI=1S/C50H99NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-45(54)51-42(41-59-50-49(58)48(57)47(56)44(40-52)60-50)46(55)43(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h42-44,46-50,52-53,55-58H,3-41H2,1-2H3,(H,51,54)/t42-,43+,44+,46-,47+,48-,49+,50-/m0/s1",1-O-(alpha-D-glucopyranosyl)-N-hexacosanoylphytosphingosine,PubMed citation,18478523
4708,76919,(S)-nisoldipine,"A methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate that has S configuration.","InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3/t18-/m0/s1",(+)-nisoldipine,PubMed citation,12483453
4709,76935,Ac-Asp-Glu-Glu(4-),A peptide anion obtained by deprotonation of the four carboxy groups of Ac-Asp-Glu-Glu; major species at pH 7.3.,"InChI=1S/C16H23N3O11/c1-7(20)17-10(6-13(25)26)15(28)18-8(2-4-11(21)22)14(27)19-9(16(29)30)3-5-12(23)24/h8-10H,2-6H2,1H3,(H,17,20)(H,18,28)(H,19,27)(H,21,22)(H,23,24)(H,25,26)(H,29,30)/p-4/t8-,9-,10-/m0/s1",N-acetyl-L-alpha-aspartyl-L-glutamyl-L-glutamate,PubMed citation,21454531
4710,76953,"17(R),18(S)-EETeTr","A 17(18)-EpETE in which the epoxy group has (17R,18S)-configuration.","InChI=1S/C20H30O3/c1-2-18-19(23-18)16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-20(21)22/h3,5-6,8-9,11-12,14,18-19H,2,4,7,10,13,15-17H2,1H3,(H,21,22)/b5-3-,8-6-,11-9-,14-12-/t18-,19+/m0/s1","(5Z,8Z,11Z,14Z,17R,18S)-17,18-epoxyicosatetraenoic acid",KEGG COMPOUND accession,C13843
4711,76955,"17(S),18(R)-EETeTr","A 17(18)-EpETE in which the epoxy group has (17S,18R)-configuration.","InChI=1S/C20H30O3/c1-2-18-19(23-18)16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-20(21)22/h3,5-6,8-9,11-12,14,18-19H,2,4,7,10,13,15-17H2,1H3,(H,21,22)/b5-3-,8-6-,11-9-,14-12-/t18-,19+/m1/s1","(17S,18R)-epoxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid",Reaxys Registry Number,21591682
4712,76959,19-HEPE,"A HEPE obtained by hydroxylation at position 19 of all-cis-5,8,11,14,17-icosapentaenoic acid.","InChI=1S/C20H30O3/c1-19(21)17-15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18-20(22)23/h3-6,9-12,15,17,19,21H,2,7-8,13-14,16,18H2,1H3,(H,22,23)/b5-3-,6-4-,11-9-,12-10-,17-15-","(5Z,8Z,11Z,14Z,17Z)-19-hydroxyicosapentaenoic acid",PubMed citation,8806734
4713,76962,20-HEPE,"A HEPE obtained by hydroxylation at position 20 of all-cis-5,8,11,14,17-icosapentaenoic acid.","InChI=1S/C20H30O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12-13,15,21H,2,5,8,11,14,16-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-,15-13-","(5Z,8Z,11Z,14Z,17Z)-20-hydroxyeicosapentaenoic acid",PubMed citation,9437847
4714,76966,"(5Z,8Z,11Z,14Z)-icosatetraenedioic acid","An alpha,omega-dicarboxylic acid that is (5Z,8Z,11Z,14Z)-icosatetraene in which the two methyl groups are replaced by carboxy groups.","InChI=1S/C20H30O4/c21-19(22)17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(23)24/h1,3-4,6-7,9-10,12H,2,5,8,11,13-18H2,(H,21,22)(H,23,24)/b3-1-,6-4-,9-7-,12-10-","(5Z,8Z,11Z,14Z)-eicosa-5,8,11,14-tetraenedioic acid",LIPID MAPS instance accession,LMFA01170034
4715,76986,2-hydroxyhexacosanoic acid,A very long-chain fatty acid that is hexacosanoic (cerotic) acid substituted at position 2 by a hydroxy group.,"InChI=1S/C26H52O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25(27)26(28)29/h25,27H,2-24H2,1H3,(H,28,29)",alpha-hydroxycerotic acid,LIPID MAPS instance accession,LMFA01050218
4716,76991,beta-D-galactosyl-N-(nervonoyl)sphingosine,A D-galactosyl-N-acylsphingosine where the ceramide N-acyl group is nervonoyl [(15Z)-tetracos-15-enoyl] and the D-galactosyl component has beta anomeric configuration.,"InChI=1S/C48H91NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(40-56-48-47(55)46(54)45(53)43(39-50)57-48)42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2/h17-18,35,37,41-43,45-48,50-51,53-55H,3-16,19-34,36,38-40H2,1-2H3,(H,49,52)/b18-17-,37-35+/t41-,42+,43+,45-,46-,47+,48+/m0/s1",N-nervonoylgalactosylsphingosine,PubMed citation,24239091
4717,76992,2-hydroxyarachidic acid,A long-chain fatty acid that is arachidic (icosanoic) acid substituted at position 2 by a hydroxy group.,"InChI=1S/C20H40O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19(21)20(22)23/h19,21H,2-18H2,1H3,(H,22,23)",alpha-hydroxyeicosanoic acid,LIPID MAPS instance accession,LMFA01050073
4718,77008,1beta-glutathionylseleno-N-acetyl-D-galactosamine,A glutathione conjugate obtained by formation of a thioselenide link between the thiol group of glutathione and the selenol group of 1-seleno-N-acetyl-D-galactosamine.,"InChI=1S/C18H30N4O11SSe/c1-7(24)21-13-15(29)14(28)10(5-23)33-18(13)35-34-6-9(16(30)20-4-12(26)27)22-11(25)3-2-8(19)17(31)32/h8-10,13-15,18,23,28-29H,2-6,19H2,1H3,(H,20,30)(H,21,24)(H,22,25)(H,26,27)(H,31,32)/t8-,9-,10+,13+,14-,15+,18-/m0/s1",selenosugar A,PubMed citation,16600319
4719,77009,5-O-beta-D-mycaminosyl-20-oxotylonolide,A macrolide antibiotic that is 20-oxotylactone having a 5-O-beta-D-mycaminosyl residue attached at position 6.,"InChI=1S/C31H51NO9/c1-9-25-19(4)14-17(2)10-11-23(34)18(3)15-22(12-13-33)30(20(5)24(35)16-26(36)40-25)41-31-29(38)27(32(7)8)28(37)21(6)39-31/h10-11,13-14,18-22,24-25,27-31,35,37-38H,9,12,15-16H2,1-8H3/b11-10+,17-14+/t18-,19+,20+,21-,22+,24-,25-,27+,28-,29-,30-,31+/m1/s1",20-oxo-5-O-beta-D-mycaminosyltylonolide,CAS Registry Number,50507-46-5
4720,77010,1beta-methylseleno-N-acetyl-D-galactosamine,A monosaccharide derivative that is  N-acetyl-beta-D-galactosamine in which the anomeric hydroxy group is replaced by a methylseleno group.,"InChI=1S/C9H17NO5Se/c1-4(12)10-6-8(14)7(13)5(3-11)15-9(6)16-2/h5-9,11,13-14H,3H2,1-2H3,(H,10,12)/t5-,6-,7+,8-,9+/m1/s1",selenosugar B,PubMed citation,12441402
4721,77021,cellobionic acid,A disaccharide consisting beta-D-glucosyl and D-gluconic acid residues joined by a (1->4)-linkage.,"InChI=1S/C12H22O12/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12/h3-10,12-20H,1-2H2,(H,21,22)/t3-,4-,5-,6+,7-,8-,9-,10-,12+/m1/s1",beta-D-glucosyl-(1->4)-D-gluconic acid,CAS Registry Number,534-41-8
4722,77029,3-(5-oxoisoxazolin-2-yl)-L-alanine,A non-proteinogenic L-alpha-amino acid that is L-alanine in which one of the methyl hydrogens is replaced by a 5-oxoisoxazolin-2-yl group.,"InChI=1S/C6H8N2O4/c7-4(6(10)11)3-8-2-1-5(9)12-8/h1-2,4H,3,7H2,(H,10,11)/t4-/m0/s1",beta-(isoxazolin-5-on-2-yl)-L-alanine,PubMed citation,8889043
4723,77030,3-(5-oxoisoxazolin-4-yl)-L-alanine,A member of the class of isoxazoles that is L-alanine in which one of the methyl hydrogens is replaced by a 5-oxoisoxazolin-4-yl group.,"InChI=1S/C6H8N2O4/c7-4(5(9)10)1-3-2-8-12-6(3)11/h2,4,8H,1,7H2,(H,9,10)/t4-/m0/s1",beta-(isoxazolin-5-on-4-yl)-L-alanine,Reaxys Registry Number,4842550
4724,77031,"(2S,3S)-beta-methylphenylalanine",A  non-proteinogenic L-alpha-amino acid that is L-phenylalanine in which one of the benzyl hydrogens is replaced by a methyl group (the 3S-stereoisomer).,"InChI=1S/C10H13NO2/c1-7(9(11)10(12)13)8-5-3-2-4-6-8/h2-7,9H,11H2,1H3,(H,12,13)/t7-,9-/m0/s1","(2S,3S)-3-methylphenylalanine",PubMed citation,19731276
4725,77048,pavine,"A racemate comprising equimolar amounts of (R,R)- and (S,S)-pavine.","InChI=1S/C20H23NO4/c1-22-17-7-11-5-15-14-10-20(25-4)18(23-2)8-12(14)6-16(21-15)13(11)9-19(17)24-3/h7-10,15-16,21H,5-6H2,1-4H3",racemic pavine,Reaxys Registry Number,343994
4726,77107,3-[(1-carboxyvinyl)oxy]benzoic acid,A dicarboxylic acid that is benzoic acid in which the hydrogen at position 3 is replaced by a (1-carboxyvinyl)oxy group.,"InChI=1S/C10H8O5/c1-6(9(11)12)15-8-4-2-3-7(5-8)10(13)14/h2-5H,1H2,(H,11,12)(H,13,14)",3-[(1-carboxyvinyl)oxy]benzoic acid,Reaxys Registry Number,2373061
4727,77121,1-oleoyl-2-lauroyl-sn-glycero-3-phospho-(1'-sn-glycerol),"A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which the phosphatidyl acyl groups at positions 1 and 2 are specified as oleoyl and lauroyl respectively.","InChI=1S/C36H69O10P/c1-3-5-7-9-11-13-14-15-16-17-18-20-21-23-25-27-35(39)43-31-34(32-45-47(41,42)44-30-33(38)29-37)46-36(40)28-26-24-22-19-12-10-8-6-4-2/h15-16,33-34,37-38H,3-14,17-32H2,1-2H3,(H,41,42)/b16-15-/t33-,34+/m0/s1",1-(9Z)-octadecenoyl-2-dodecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol),LIPID MAPS instance accession,LMGP04010322
4728,77122,1-palmitoyl-2-lauroyl-sn-glycero-3-phospho-(1'-sn-glycerol),"A 1,2-diacyl-sn-glycero-3-phospho-(1'-sn-glycerol) in which the phosphatidyl acyl groups at positions 1 and 2 are specified as palmitoyl and lauroyl respectively.","InChI=1S/C34H67O10P/c1-3-5-7-9-11-13-14-15-16-18-19-21-23-25-33(37)41-29-32(30-43-45(39,40)42-28-31(36)27-35)44-34(38)26-24-22-20-17-12-10-8-6-4-2/h31-32,35-36H,3-30H2,1-2H3,(H,39,40)/t31-,32+/m0/s1",1-hexadecanoyl-2-dodecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol),LIPID MAPS instance accession,LMGP04010025
4729,77131,sinapic acid,"A monohydroxycinnamic acid that is cinnamic acid in which the phenyl hydrogens at positions 3, 4, and 5 are replaced by methoxy, hydroxy, and methoxy groups, respectively.","InChI=1S/C11H12O5/c1-15-8-5-7(3-4-10(12)13)6-9(16-2)11(8)14/h3-6,14H,1-2H3,(H,12,13)","3,5-dimethoxy-4-hydroxycinnamic acid",CAS Registry Number,530-59-6
4730,77133,6-deoxy-6-sulfo-D-fructofuranose(1-),"An organosulfonate oxoanion that is the conjugate base of 6-deoxy-6-sulfo-D-fructofuranose, obtained by deprotonation of the sulfonate OH group; major species at pH 7.3.","InChI=1S/C6H12O8S/c7-2-6(10)5(9)4(8)3(14-6)1-15(11,12)13/h3-5,7-10H,1-2H2,(H,11,12,13)/p-1/t3-,4-,5+,6?/m1/s1",6-deoxy-6-sulfo-D-fructofuranose,PubMed citation,24463506
4731,77138,3-sulfopropanediol(1-),"An organosulfonate oxoanion that is the conjugate base of 3-sulfolactaldehyde, obtained by deprotonation of the sulfo group; major species at pH 7.3.","InChI=1S/C3H8O5S/c4-1-3(5)2-9(6,7)8/h3-5H,1-2H2,(H,6,7,8)/p-1","2,3-dihydroxypropane-1-sulfonate",MetaCyc accession,2-3-dihydroxypropane-1-sulfonate
4732,77145,ginsenoside F2,"A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 3 and 20 have been converted to the corresponding beta-D-glucopyranosides, and in which a double bond has been introduced at the 24-25 position.","InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,55-37-35(51)33(49)31(47)25(20-44)53-37)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1","3beta,20-bis(beta-D-glucopyranosyloxy)dammar-24-en-12beta-ol",Reaxys Registry Number,5720814
4733,77146,ginsenoside C-K,"A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 20 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.","InChI=1S/C36H62O8/c1-20(2)10-9-14-36(8,44-31-30(42)29(41)28(40)23(19-37)43-31)21-11-16-35(7)27(21)22(38)18-25-33(5)15-13-26(39)32(3,4)24(33)12-17-34(25,35)6/h10,21-31,37-42H,9,11-19H2,1-8H3/t21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31-,33-,34+,35+,36-/m0/s1","20beta-(beta-D-glucopyranosyloxy)dammar-24-ene-3beta,12beta-diol",Reaxys Registry Number,5785005
4734,77179,4-O-methylrhodomycin D,"An anthracycline that is aklavinone having a 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl residue and a methyl group attached as positions 4 and 7 respectively.","InChI=1S/C29H33NO11/c1-5-29(37)10-15(41-16-9-13(30)23(31)11(2)40-16)18-19(22(29)28(36)39-4)27(35)20-21(26(18)34)25(33)17-12(24(20)32)7-6-8-14(17)38-3/h6-8,11,13,15-16,22-23,31,34-35,37H,5,9-10,30H2,1-4H3/t11-,13-,15-,16-,22-,23+,29+/m0/s1",7-O-daunosaminyl-4-O-methyl-epsilon-rhodomycinone,Reaxys Registry Number,6949593
4735,77180,3-iodo-5-nitrophenol,Phenol substituted with iodo and nitro groups at the 3 and 5 positions respectively.,"InChI=1S/C6H4INO3/c7-4-1-5(8(10)11)3-6(9)2-4/h1-3,9H",3-iodo-5-nitro-phenol,PubMed citation,16792697
4736,77181,crystal violet cation,An iminium ion that is malachite green cation in which the hydrogen at the para- psition of the monosubstituted phenyl group is replaced by a dimethylamino group.,"InChI=1S/C25H30N3/c1-26(2)22-13-7-19(8-14-22)25(20-9-15-23(16-10-20)27(3)4)21-11-17-24(18-12-21)28(5)6/h7-18H,1-6H3/q+1",gentian violet(1+),CAS Registry Number,7438-46-2
4737,77198,6-sulfo-D-quinovose,A carbohydrate sulfonate that is D-quinovose (6-deoxy-D-glucose) in which one of the methyl hydrogens at position 6 is replaced by a sulfo group.,"InChI=1S/C6H12O8S/c7-3-2(1-15(11,12)13)14-6(10)5(9)4(3)8/h2-10H,1H2,(H,11,12,13)/t2-,3-,4+,5-,6?/m1/s1",6-deoxy-6-sulfo-D-glucose,Reaxys Registry Number,7795800
4738,77239,1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphate,A 1-acyl-2-arachidonoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as stearoyl (octadecanoyl).,"InChI=1S/C41H73O8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(43)49-39(38-48-50(44,45)46)37-47-40(42)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,39H,3-10,12,14-16,18,20-21,23,25-27,29,31-38H2,1-2H3,(H2,44,45,46)/b13-11-,19-17-,24-22-,30-28-/t39-/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010024
4739,77241,1-icosanoyl-2-arachidonoyl-sn-glycero-3-phosphate,A 1-acyl-2-arachidonoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as icosanoyl (arachidoyl).,"InChI=1S/C43H77O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-42(44)49-39-41(40-50-52(46,47)48)51-43(45)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,18,20,24,26,30,32,41H,3-11,13,15-17,19,21-23,25,27-29,31,33-40H2,1-2H3,(H2,46,47,48)/b14-12-,20-18-,26-24-,32-30-/t41-/m1/s1","1-eicosanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010861
4740,77248,1-stearoyl-2-linoleoyl-sn-glycero-3-phosphate,A 1-acyl-2-linoleoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as stearoyl (octadecanoyl).,"InChI=1S/C39H73O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,18,20,37H,3-11,13,15-17,19,21-36H2,1-2H3,(H2,42,43,44)/b14-12-,20-18-/t37-/m1/s1","1-octadecanoyl-2-(9Z,12Z)-octadecadienoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010036
4741,77251,"(25S)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-CoA(4-)","An acyl-CoA(4-) oxoanion arising from deprotonation of the phosphate and diphosphate OH groups of (25S)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl-CoA; major species at pH 7.3.","InChI=1S/C48H80N7O20P3S/c1-25(29-10-11-30-36-31(20-34(58)48(29,30)6)47(5)14-12-28(56)18-27(47)19-32(36)57)8-7-9-26(2)45(63)79-17-16-50-35(59)13-15-51-43(62)40(61)46(3,4)22-72-78(69,70)75-77(67,68)71-21-33-39(74-76(64,65)66)38(60)44(73-33)55-24-54-37-41(49)52-23-53-42(37)55/h23-34,36,38-40,44,56-58,60-61H,7-22H2,1-6H3,(H,50,59)(H,51,62)(H,67,68)(H,69,70)(H2,49,52,53)(H2,64,65,66)/p-4/t25-,26+,27+,28-,29-,30+,31+,32-,33-,34+,36+,38-,39-,40+,44-,47+,48-/m1/s1",(25S)-THCA-CoA(4-),PubMed citation,11060344
4742,77254,"1,2-dilinoleoyl-sn-glycero-3-phosphate",A 1-acyl-2-linoleoyl-sn-glycero-3-phosphate in which the 1-acyl group is also linoleoyl.,"InChI=1S/C39H69O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11-14,17-20,37H,3-10,15-16,21-36H2,1-2H3,(H2,42,43,44)/b13-11-,14-12-,19-17-,20-18-/t37-/m1/s1","1,2-di(9Z,12Z)-octadecadienoyl-sn-glycero-3-phosphate",MetaCyc accession,CPD-8271
4743,77258,"1-stearoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycerol 3-phosphate in which the acyl substituents at positions 1 and 2 are specified as stearoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C43H73O8P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-43(45)51-41(40-50-52(46,47)48)39-49-42(44)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,21-22,26,28,32,34,41H,3-4,6,8-10,12,14-16,18,20,23-25,27,29-31,33,35-40H2,1-2H3,(H2,46,47,48)/b7-5-,13-11-,19-17-,22-21-,28-26-,34-32-/t41-/m1/s1","1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010039
4744,77262,(R)-omeprazole,"A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has R configuration at the sulfur atom.","InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m1/s1",(+)-omeprazole,Reaxys Registry Number,7798294
4745,77269,dTDP-beta-L-evernitrose,A dTDP-sugar having beta-L-evernitrose as the sugar component.,"InChI=1S/C18H29N3O15P2/c1-9-7-20(17(24)19-16(9)23)13-5-11(22)12(34-13)8-32-37(27,28)36-38(29,30)35-14-6-18(3,21(25)26)15(31-4)10(2)33-14/h7,10-15,22H,5-6,8H2,1-4H3,(H,27,28)(H,29,30)(H,19,23,24)/t10-,11-,12+,13+,14+,15-,18-/m0/s1","dTDP-2,3,6-trideoxy-3-C-methyl-4-O-methyl-3-nitro-beta-L-arabino-hexopyranose",MetaCyc accession,CPD-16419
4746,77271,1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4-phosphate,A 1-phosphatidyl-1D-myo-inositol 4-phosphate  in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and arachidonoyl respectively.,"InChI=1S/C47H84O16P2/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(49)61-39(37-59-40(48)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2)38-60-65(57,58)63-47-44(52)42(50)46(43(51)45(47)53)62-64(54,55)56/h11,13,17,19,22,24,28,30,39,42-47,50-53H,3-10,12,14-16,18,20-21,23,25-27,29,31-38H2,1-2H3,(H,57,58)(H2,54,55,56)/b13-11-,19-17-,24-22-,30-28-/t39-,42-,43+,44-,45-,46+,47+/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phospho-1D-myo-inositol 4-phosphate",PDBeChem accession,2Y5
4747,77281,dTDP-N-hydroxy-beta-L-evernosamine,A dTDP-sugar having N-hydroxy-beta-L-evernosamine as the sugar component.,"InChI=1S/C18H31N3O14P2/c1-9-7-21(17(24)19-16(9)23)13-5-11(22)12(33-13)8-31-36(26,27)35-37(28,29)34-14-6-18(3,20-25)15(30-4)10(2)32-14/h7,10-15,20,22,25H,5-6,8H2,1-4H3,(H,26,27)(H,28,29)(H,19,23,24)/t10-,11-,12+,13+,14+,15-,18-/m0/s1","dTDP-2,3,6-trideoxy-3-(hydroxyamino)-3-methyl-4-O-methyl-beta-L-arabino-hexopyranose",MetaCyc accession,CPD-16426
4748,77285,dTDP-beta-L-evernosamine,A dTDP-sugar having beta-L-evernosamine as the sugar component.,"InChI=1S/C18H31N3O13P2/c1-9-7-21(17(24)20-16(9)23)13-5-11(22)12(32-13)8-30-35(25,26)34-36(27,28)33-14-6-18(3,19)15(29-4)10(2)31-14/h7,10-15,22H,5-6,8,19H2,1-4H3,(H,25,26)(H,27,28)(H,20,23,24)/t10-,11-,12+,13+,14+,15-,18-/m0/s1","dTDP-3-amino-2,3,6-trideoxy-3-methyl-4-O-methyl-beta-L-arabino-arabino-hexopyranose",Reaxys Registry Number,23949713
4749,77317,SR12813,"An organic phosphonate that is the tetraethyl ester of  [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonic acid).","InChI=1S/C24H42O7P2/c1-11-28-32(26,29-12-2)21(33(27,30-13-3)31-14-4)17-18-15-19(23(5,6)7)22(25)20(16-18)24(8,9)10/h15-17,25H,11-14H2,1-10H3",SR-12813,DrugBank accession,DB04466
4750,77328,1-palmitoyl-2-(8-epi-prostaglandin F2alpha)-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as palmitoyl and 8-epi-prostaglandin F2alpha respectively.","InChI=1S/C44H82NO11P/c1-6-8-10-11-12-13-14-15-16-17-18-19-24-28-43(49)53-35-38(36-55-57(51,52)54-33-32-45(3,4)5)56-44(50)29-25-21-20-23-27-39-40(42(48)34-41(39)47)31-30-37(46)26-22-9-7-2/h20,23,30-31,37-42,46-48H,6-19,21-22,24-29,32-36H2,1-5H3/b23-20-,31-30+/t37-,38+,39-,40+,41-,42+/m0/s1",1-hexadecanoyl-2-(8-epi-prostaglandin F2alphaa)-sn-glycero-3-phosphocholine,PubMed citation,16371369
4751,77340,beta-D-QuipN4Fm-(1->4)-alpha-D-GalpNAcAN,An amino disaccharide consisting of a 4-deoxy-4-formamido-beta-D-quinovosyl residue linked (1->4) to a 2-acetamido-2-deoxy-alpha-D-galactopyranuronamide residue at the reducing end.,"InChI=1S/C15H25N3O10/c1-4-6(17-3-19)8(21)10(23)15(26-4)28-11-9(22)7(18-5(2)20)14(25)27-12(11)13(16)24/h3-4,6-12,14-15,21-23,25H,1-2H3,(H2,16,24)(H,17,19)(H,18,20)/t4-,6-,7-,8+,9-,10-,11-,12+,14+,15+/m1/s1","4,6-dideoxy-4-formamido-beta-D-glucosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-galacturonamide",PubMed citation,24351753
4752,77341,alpha-D-GalpNAcAN-(1->4)-alpha-D-GalpNAcAN-(1->3)-beta-D-QuipNAc-(1->2)-beta-D-QuipN4Fm-(1->4)-alpha-D-GalpNAcAN-(1->4)-alpha-D-GalpNAcAN,"An amino hexasaccharide consisting of 2-acetamido-2-deoxy-alpha-D-galacturonamide, 2-acetamido-2-deoxy-alpha-D-galacturonamide, 2-acetamido-2-deoxy-beta-D-quinovose, 4-deoxy-4-formamido-beta-D-quinovose, 2-acetamido-2-deoxy-alpha-D-galacturonamide and 2-acetamido-2-deoxy-alpha-D-galacturonamide residues linked in a (1->4), (1->3), (1->2), (1->4), (1->4) sequence.","InChI=1S/C47H74N10O29/c1-9-16(52-8-58)24(66)34(47(76-9)82-32-27(69)20(56-14(6)62)45(86-37(32)41(51)74)80-30-25(67)17(53-11(3)59)42(75)78-35(30)39(49)72)84-46-21(57-15(7)63)29(22(64)10(2)77-46)79-44-19(55-13(5)61)26(68)31(36(85-44)40(50)73)81-43-18(54-12(4)60)23(65)28(70)33(83-43)38(48)71/h8-10,16-37,42-47,64-70,75H,1-7H3,(H2,48,71)(H2,49,72)(H2,50,73)(H2,51,74)(H,52,58)(H,53,59)(H,54,60)(H,55,61)(H,56,62)(H,57,63)/t9-,10-,16-,17-,18-,19-,20-,21-,22-,23-,24+,25-,26-,27-,28-,29-,30-,31-,32-,33+,34-,35+,36+,37+,42+,43+,44+,45+,46+,47+/m1/s1",alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3)-beta-D-QuiNAc-(1->2)-beta-D-QuiN4Fm-(1->4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN,PubMed citation,24351753
4753,77343,1-stearoyl-2-linoleoyl-sn-glycero-3-phospho-1D-myo-inositol,A 1-octadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl group is specified as linoleoyl.,"InChI=1S/C45H83O13P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(46)55-35-37(36-56-59(53,54)58-45-43(51)41(49)40(48)42(50)44(45)52)57-39(47)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,18,20,37,40-45,48-52H,3-11,13,15-17,19,21-36H2,1-2H3,(H,53,54)/b14-12-,20-18-/t37-,40-,41-,42+,43-,44-,45-/m1/s1","1-octadecanoyl-2-(9Z,12Z)-octadecadienoyl-sn-glycero-3-phospho-1D-myo-inositol",LIPID MAPS instance accession,LMGP06010956
4754,77344,1-stearoyl-2-linoleoyl-sn-glycero-3-phospho-1D-myo-inositol 5-phosphate,A 1-phosphatidyl-1D-myo-inositol 5-phosphate in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and linoleoyl respectively.,"InChI=1S/C45H84O16P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(46)57-35-37(59-39(47)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)36-58-63(55,56)61-45-42(50)40(48)41(49)44(43(45)51)60-62(52,53)54/h12,14,18,20,37,40-45,48-51H,3-11,13,15-17,19,21-36H2,1-2H3,(H,55,56)(H2,52,53,54)/b14-12-,20-18-/t37-,40-,41-,42-,43-,44+,45-/m1/s1","1-octadecanoyl-2-(9Z,12Z)-octadecadienoyl-sn-glycero-3-phospho-1D-myo-inositol 5-phosphate",HMDB accession,HMDB0009951
4755,77345,1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 5-phosphate,A 1-phosphatidyl-1D-myo-inositol 5-phosphate in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and arachidonoyl respectively.,"InChI=1S/C47H84O16P2/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(49)61-39(37-59-40(48)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2)38-60-65(57,58)63-47-44(52)42(50)43(51)46(45(47)53)62-64(54,55)56/h11,13,17,19,22,24,28,30,39,42-47,50-53H,3-10,12,14-16,18,20-21,23,25-27,29,31-38H2,1-2H3,(H,57,58)(H2,54,55,56)/b13-11-,19-17-,24-22-,30-28-/t39-,42-,43-,44-,45-,46+,47-/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phospho-1D-myo-inositol 5-phosphate",HMDB accession,HMDB0009956
4756,77346,1-stearoyl-2-oleoyl-sn-glycero-3-phospho-1D-myo-inositol,A 1-octadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl group is specified as oleoyl.,"InChI=1S/C45H85O13P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(46)55-35-37(36-56-59(53,54)58-45-43(51)41(49)40(48)42(50)44(45)52)57-39(47)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,37,40-45,48-52H,3-17,19,21-36H2,1-2H3,(H,53,54)/b20-18-/t37-,40-,41-,42+,43-,44-,45-/m1/s1",1-stearoyl-2-oleoyl-phosphatidylinositol,LIPID MAPS instance accession,LMGP06010957
4757,77347,1-stearoyl-2-oleoyl-sn-glycero-3-phospho-1D-myo-inositol 5-phosphate,A 1-phosphatidyl-1D-myo-inositol 5-phosphate in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and oleoyl respectively.,"InChI=1S/C45H86O16P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(46)57-35-37(59-39(47)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)36-58-63(55,56)61-45-42(50)40(48)41(49)44(43(45)51)60-62(52,53)54/h18,20,37,40-45,48-51H,3-17,19,21-36H2,1-2H3,(H,55,56)(H2,52,53,54)/b20-18-/t37-,40-,41-,42-,43-,44+,45-/m1/s1",1-stearoyl-2-oleoyl-phosphatidylinositol 5-phosphate,HMDB accession,HMDB0009950
4758,77348,"1,2-dilinoleoyl-sn-glycero-3-phospho-1D-myo-inositol",A 1-phosphatidyl-1D-myo-inositol in which both phosphatidyl acyl groups are specified as linoleoyl.,"InChI=1S/C45H79O13P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(46)55-35-37(36-56-59(53,54)58-45-43(51)41(49)40(48)42(50)44(45)52)57-39(47)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11-14,17-20,37,40-45,48-52H,3-10,15-16,21-36H2,1-2H3,(H,53,54)/b13-11-,14-12-,19-17-,20-18-/t37-,40-,41-,42+,43-,44-,45-/m1/s1","1,2-dilinoleoyl-phosphatidylinositol",LIPID MAPS instance accession,LMGP06010927
4759,77349,"1,2-dilinoleoyl-sn-glycero-3-phospho-1D-myo-inositol 5-phosphate",A 1-phosphatidyl-1D-myo-inositol 5-phosphate in which both phosphatidyl acyl groups are specified as linoleoyl.,"InChI=1S/C45H80O16P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(46)57-35-37(59-39(47)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)36-58-63(55,56)61-45-42(50)40(48)41(49)44(43(45)51)60-62(52,53)54/h11-14,17-20,37,40-45,48-51H,3-10,15-16,21-36H2,1-2H3,(H,55,56)(H2,52,53,54)/b13-11-,14-12-,19-17-,20-18-/t37-,40-,41-,42-,43-,44+,45-/m1/s1","1,2-dilinoleoyl-phosphatidylinositol 5-phosphate",HMDB accession,HMDB0009987
4760,77355,1-palmityl-2-arachidonoyl-sn-glycero-3-phosphate,A 1-alkyl-2-acyl-sn-glycero-3-phosphate in which the alkyl and acyl groups are specified as palmityl (hexadecyl) and arachidonoyl respectively.,"InChI=1S/C39H71O7P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-39(40)46-38(37-45-47(41,42)43)36-44-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h11,13,17,19,21-22,26,28,38H,3-10,12,14-16,18,20,23-25,27,29-37H2,1-2H3,(H2,41,42,43)/b13-11-,19-17-,22-21-,28-26-/t38-/m1/s1","1-hexadecyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10020092
4761,77357,1-palmityl-2-oleoyl-sn-glycero-3-phosphate,A 1-alkyl-2-acyl-sn-glycero-3-phosphate in which the alkyl and acyl groups are specified as palmityl (hexadecyl) and oleoyl respectively.,"InChI=1S/C37H73O7P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-37(38)44-36(35-43-45(39,40)41)34-42-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h17,19,36H,3-16,18,20-35H2,1-2H3,(H2,39,40,41)/b19-17-/t36-/m1/s1",1-hexadecyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10020094
4762,77358,CDP-dipalmitoyl-sn-glycerol,A CDP-diacylglycerol in which both of the phosphatidyl acyl groups are specified as palmitoyl (hexadecanoyl).,"InChI=1S/C44H81N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-39(48)57-33-36(60-40(49)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)34-58-63(53,54)62-64(55,56)59-35-37-41(50)42(51)43(61-37)47-32-31-38(45)46-44(47)52/h31-32,36-37,41-43,50-51H,3-30,33-35H2,1-2H3,(H,53,54)(H,55,56)(H2,45,46,52)/t36-,37-,41-,42-,43-/m1/s1","1,2-dihexadecanoyl-sn-glycero-3-CDP",LIPID MAPS instance accession,LMGP13010003
4763,77359,isotridecanoic acid,A branched-chain saturated fatty acid comprising dodecanoic (lauric) acid substituted at position 11 by a methyl group.,"InChI=1S/C13H26O2/c1-12(2)10-8-6-4-3-5-7-9-11-13(14)15/h12H,3-11H2,1-2H3,(H,14,15)",11-methyllauric acid,CAS Registry Number,25448-24-2
4764,77368,"(11Z,14Z,17Z,20Z,23Z)-hexacosapentaenoic acid","A very long-chain omega-3 fatty acid that is hexacosanoic acid having five double bonds located at positions 11, 14, 17, 20, 23 (the 11Z,14Z,17Z,20Z,23Z-isomer).","InChI=1S/C26H42O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26(27)28/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-25H2,1H3,(H,27,28)/b4-3-,7-6-,10-9-,13-12-,16-15-","all-cis-hexacosa-11,14,17,20,23-pentaenoic acid",LIPID MAPS instance accession,LMFA01030831
4765,77371,"(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosahexaenoic acid","A very long-chain omega-3 fatty acid that is hexacosanoic acid having six double bonds located at positions 8, 11, 14, 17, 20, 23 (the 8Z,11Z,14Z,17Z,20Z,23Z-isomer).","InChI=1S/C26H40O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26(27)28/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-25H2,1H3,(H,27,28)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-hexacosa-8,11,14,17,20,23-hexaenoic acid",LIPID MAPS instance accession,LMFA01030838
4766,77373,"(10Z,13Z,16Z,19Z,22Z,25Z)-octacosahexaenoic acid","A very long-chain omega-3 fatty acid that is octacosanoic acid having six double bonds located at positions 10, 13, 16, 19, 22 and 25 (the 10Z,13Z,16Z,19Z,22Z,25Z-isomer).","InChI=1S/C28H44O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28(29)30/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-27H2,1H3,(H,29,30)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-octacosa-10,13,16,19,22,25-hexaenoic acid",LIPID MAPS instance accession,LMFA01030839
4767,77403,"(14Z,17Z,20Z,23Z,26Z,29Z)-dotriacontahexaenoic acid","A very long-chain omega-3 fatty acid that is dotriacontapentaenoic acid having six double bonds located at positions 14, 17, 20, 23, 26 and 29 (the 14Z,17Z,20Z,23Z,26Z,29Z-isomer).","InChI=1S/C32H52O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32(33)34/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-31H2,1H3,(H,33,34)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-dotriaconta-14,17,20,23,26,29-hexaenoic acid",LIPID MAPS instance accession,LMFA01030841
4768,77404,"(19Z,22Z,25Z,28Z,31Z)-tetratriacontapentaenoic acid","A very long-chain omega-3 fatty acid that is tetratriacontapentaenoic acid having five double bonds located at positions 19, 22, 25 ,28 and 31 (the 19Z,22Z,25Z,28Z,31Z-isomer).","InChI=1S/C34H58O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34(35)36/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-33H2,1H3,(H,35,36)/b4-3-,7-6-,10-9-,13-12-,16-15-","all-cis-tetratriaconta-19,22,25,28,31-pentaenoic acid",LIPID MAPS instance accession,LMFA01030835
4769,77412,(11Z)-icos-11-en-1-ol,A fatty alcohol 20:1 that is icosanol containing a double bond located at position 11 (the 11Z-geoisomer).,"InChI=1S/C20H40O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21/h9-10,21H,2-8,11-20H2,1H3/b10-9-",(11Z)-eicosen-1-ol,LIPID MAPS instance accession,LMFA05000051
4770,77415,tetratriacontan-1-ol,An ultra-long-chain primary fatty alcohol that is tetratriacontane in which one of the terminal methyl hydrogens is replaced by a hydroxy group,"InChI=1S/C34H70O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35/h35H,2-34H2,1H3",tetratriacontanol,LIPID MAPS instance accession,LMFA05000459
4771,77416,(13Z)-docosen-1-ol,A long-chain fatty alcohol that is (13Z)-docosene in which one of the terminal methyl hydrogens at position 1 is replaced by a hydroxy group,"InChI=1S/C22H44O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h9-10,23H,2-8,11-22H2,1H3/b10-9-",(13Z)-docosenol,CAS Registry Number,629-98-1
4772,77417,tetradecan-1-ol,A long-chain fatty alcohol that is tetradecane in which one of the terminal methyl hydrogens is replaced by a hydroxy group,"InChI=1S/C14H30O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15/h15H,2-14H2,1H3",tetradecanol,LIPID MAPS instance accession,LMFA05000041
4773,77419,(E)-4-hydroxynon-2-enal dimethyl acetal,An acetal that is the methyl acetal obtained by formal condensation of the carbonyl group of (E)-4-hydroxynon-2-enal with two molar equivalents of methanol.,"InChI=1S/C11H22O3/c1-4-5-6-7-10(12)8-9-11(13-2)14-3/h8-12H,4-7H2,1-3H3/b9-8+",HNE-DMA,PubMed citation,17263910
4774,77422,(R)-citalopram hydrobromide,"A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile hydrobromide resulting from the reaction of equimolar amounts of (R)-citalopram and hydrogen bromide.","InChI=1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H/t20-;/m1./s1",(R)-citalopram.HBr,Reaxys Registry Number,24050081
4775,77423,escitalopram hydrobromide,"A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile hydrobromide resulting from the reaction of equimolar amounts of escitalopram and hydrogen bromide.","InChI=1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H/t20-;/m0./s1",escitalopram.HBr,Patent accession,US2005137255
4776,77434,15-methylhexadecan-1-ol,A long-chain fatty alcohol that is hexadecan-1-ol bearing a methyl substituent at position 15.,"InChI=1S/C17H36O/c1-17(2)15-13-11-9-7-5-3-4-6-8-10-12-14-16-18/h17-18H,3-16H2,1-2H3",15-methylhexadecanol,CAS Registry Number,57289-07-3
4777,77435,13-methyltetradecan-1-ol,A long-chain fatty alcohol that is tetradecan-1-ol bearing a methyl substituent at position 13.,"InChI=1S/C15H32O/c1-15(2)13-11-9-7-5-3-4-6-8-10-12-14-16/h15-16H,3-14H2,1-2H3",13-methyltetradecanol,CAS Registry Number,58524-92-8
4778,77438,11-methyldodecan-1-ol,A long-chain fatty alcohol that is dodecan-1-ol bearing a methyl substituent at position 11.,"InChI=1S/C13H28O/c1-13(2)11-9-7-5-3-4-6-8-10-12-14/h13-14H,3-12H2,1-2H3",11-methyldodecanol,CAS Registry Number,27458-92-0
4779,77440,beta-D-Glcp-(1->4)-alpha-D-Glcp-(1->2)-alpha-D-Glcp,A glucotriose consisting of one beta-D-glucose and two alpha-D-glucose residues linked sequentially (1->4) and (1->2).,"InChI=1S/C18H32O16/c19-1-4-8(23)10(25)15(16(29)30-4)34-18-13(28)11(26)14(6(3-21)32-18)33-17-12(27)9(24)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16+,17+,18-/m1/s1",beta-D-Glc-(1->4)-alpha-D-Glc-(1->2)-alpha-D-Glc,PubMed citation,23795894
4780,77442,dextrobupivacaine hydrochloride (anhydrous),The monohydrochloride salt of dextrobupivacaine.,"InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H/t16-;/m1./s1",dextrobupivacaine hydrochloride,CAS Registry Number,27262-46-0
4781,77448,beta-D-QuipN4Fm-(1->4)-alpha-D-GalpNAcAN-(1->4)-alpha-D-GalpNAcAN-(1->3)-beta-DQuipNAc,"An amino tetrasaccharide comprising a 4-deoxy-4-formamido-beta-D-quinovose residue, two 2-acetamido-2-deoxy-alpha-D-galacturonamide residues and an N-acetyl-beta-D-quinovosamine residue linked in a (1->4), (1->4), (1->3) sequence.","InChI=1S/C31H50N6O19/c1-7-12(34-6-38)17(43)20(46)31(51-7)54-23-19(45)14(36-10(4)40)30(56-25(23)27(33)48)53-22-18(44)13(35-9(3)39)29(55-24(22)26(32)47)52-21-15(37-11(5)41)28(49)50-8(2)16(21)42/h6-8,12-25,28-31,42-46,49H,1-5H3,(H2,32,47)(H2,33,48)(H,34,38)(H,35,39)(H,36,40)(H,37,41)/t7-,8-,12-,13-,14-,15-,16-,17+,18-,19-,20-,21-,22-,23-,24+,25+,28-,29+,30+,31+/m1/s1",beta-D-QuiN4Fm-(1->4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3)-beta-D-QuiNAc,PubMed citation,23844703
4782,77451,beta-D-QuipN4Fm-(1->4)-alpha-D-GalpNAcAN-(1->4)-alpha-D-GalpNAcAN-(1->3)-beta-DQuipNAc-(1->2)-beta-D-QuipN4Fm-(1->4)-alpha-D-GalpNAcAN-(1->4)-alpha-D-GalpNAcAN-(1->3)-beta-DQuipNAc,"An amino octasaccharide comprising two units, linked (1->2), of an amino tetrasaccharide, each unit consisting of 4-deoxy-4-formamido-beta-D-quinovose residue, two 2-acetamido-2-deoxy-alpha-D-galacturonamide residues and an N-acetyl-beta-D-quinovosamine residue linked in a (1->4), (1->4), (1->3) sequence.","InChI=1S/C62H98N12O37/c1-13-23(67-11-75)33(85)39(91)61(98-13)105-44-37(89)27(71-19(7)79)58(110-49(44)53(65)94)103-43-36(88)26(70-18(6)78)57(109-48(43)52(64)93)102-41-30(74-22(10)82)60(100-16(4)32(41)84)107-46-34(86)24(68-12-76)14(2)99-62(46)106-45-38(90)28(72-20(8)80)59(111-50(45)54(66)95)104-42-35(87)25(69-17(5)77)56(108-47(42)51(63)92)101-40-29(73-21(9)81)55(96)97-15(3)31(40)83/h11-16,23-50,55-62,83-91,96H,1-10H3,(H2,63,92)(H2,64,93)(H2,65,94)(H2,66,95)(H,67,75)(H,68,76)(H,69,77)(H,70,78)(H,71,79)(H,72,80)(H,73,81)(H,74,82)/t13-,14-,15-,16-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33+,34+,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47+,48+,49+,50+,55-,56+,57+,58+,59+,60+,61+,62+/m1/s1",beta-D-QuiN4Fm-(1->4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3)-beta-DQuiNAc-(1->2)-beta-D-QuiN4Fm-(1->4)-alpha-D-GalNAcAN-(1->4)-alpha-D-GalNAcAN-(1->3)-beta-DQuiNAc,PubMed citation,23844703
4783,77478,alpha-D-mannosyl phosphomycoketide,"A mannose phosphate consisting of alpha-D-mannose having a (4S,8S,12S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl)phosphate group at position 1.","InChI=1S/C38H77O9P/c1-7-8-9-10-11-17-29(2)18-12-19-30(3)20-13-21-31(4)22-14-23-32(5)24-15-25-33(6)26-16-27-45-48(43,44)47-38-37(42)36(41)35(40)34(28-39)46-38/h29-42H,7-28H2,1-6H3,(H,43,44)/t29-,30-,31-,32-,33-,34+,35+,36-,37-,38+/m0/s1",C32 mannosyl alpha-1 PM,PubMed citation,23530121
4784,77480,beta-D-mannosyl C30-phosphomycoketide,"A mannose phosphate consisting of beta-D-mannose having a (4S,8S,12S,16S,20S)-4,8,12,16,20-pentamethylpentacosyl)phosphate group at position 1.","InChI=1S/C36H73O9P/c1-7-8-9-15-27(2)16-10-17-28(3)18-11-19-29(4)20-12-21-30(5)22-13-23-31(6)24-14-25-43-46(41,42)45-36-35(40)34(39)33(38)32(26-37)44-36/h27-40H,7-26H2,1-6H3,(H,41,42)/t27?,28?,29?,30?,31?,32-,33-,34+,35+,36-/m1/s1",C30 beta-D-mannosyl phosphomycoketide,PubMed citation,23530121
4785,77488,(3S)-3-hydroxy-L-ornithine,An L-ornithine substituted at position 3 by a hydroxy group (the 3S-erythro-stereoisomer).,"InChI=1S/C5H12N2O3/c6-2-1-3(8)4(7)5(9)10/h3-4,8H,1-2,6-7H2,(H,9,10)/t3-,4-/m0/s1",(3S)-3-hydroxyornithine,Reaxys Registry Number,5244928
4786,77497,"(16Z,19Z,22Z,25Z,28Z,31Z)-tetratriacontahexaenoic acid","An omega-3 fatty acid that is tetratriacontahexaenoic acid having six double bonds located at positions 16, 19, 22, 25 ,28 and 31 (the 16Z,19Z,22Z,25Z,28Z,31Z-isomer).","InChI=1S/C34H56O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34(35)36/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-33H2,1H3,(H,35,36)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-tetratriaconta-16,19,22,25,28,31-hexaenoic acid",LIPID MAPS instance accession,LMFA01030842
4787,77499,"(21Z,24Z,27Z,30Z,33Z)-hexatriacontapentaenoic acid","A very long-chain omega-3 fatty acid that is hexatriacontanoic acid having five double bonds located at positions 21, 24, 27, 30 and 33 (the 21Z,24Z,27Z,30Z,33Z-isomer).","InChI=1S/C36H62O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36(37)38/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-35H2,1H3,(H,37,38)/b4-3-,7-6-,10-9-,13-12-,16-15-","all-cis-hexatriaconta-21,24,27,30,33-pentaenoic acid",LIPID MAPS instance accession,LMFA01030836
4788,77500,"(18Z,21Z,24Z,27Z,30Z,33Z)-hexatriacontahexaenoic acid","A very long-chain omega-3 fatty acid that is hexatriacontanoic acid having six double bonds located at positions 18, 21, 24, 27, 30 and 33 (the 18Z,21Z,24Z,27Z,30Z,33Z-isomer).","InChI=1S/C36H60O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36(37)38/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-35H2,1H3,(H,37,38)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-hexatriaconta-18,21,24,27,30,33-hexaenoic acid",LIPID MAPS instance accession,LMFA01030843
4789,77503,"(23Z,26Z,29Z,32Z,35Z)-octatriacontapentaenoic acid","A very long-chain omega-3 fatty acid that is octatriacontanoic acid having six double bonds located at positions 23, 26, 29, 32 and 35 (the 23Z,26Z,29Z,32Z,35Z-isomer).","InChI=1S/C38H66O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38(39)40/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-37H2,1H3,(H,39,40)/b4-3-,7-6-,10-9-,13-12-,16-15-","all-cis-octatriaconta-23,26,29,32,35-pentaenoic acid",LIPID MAPS instance accession,LMFA01030837
4790,77527,"(6Z,9Z,12Z,15Z,18Z)-tetracosapentaenoic acid","A very long-chain omega-6 fatty acid that is tetracosanoic acid having five double bonds located at positions 6, 9, 12, 15 and 18 (the 6Z,9Z,12Z,15Z,18Z-isomer).","InChI=1S/C24H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26/h6-7,9-10,12-13,15-16,18-19H,2-5,8,11,14,17,20-23H2,1H3,(H,25,26)/b7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-tetracosa-6,9,12,15,18-pentaenoic acid",LIPID MAPS instance accession,LMFA01030820
4791,77531,"(8Z,11Z,14Z,17Z,20Z)-hexacosapentaenoic acid","A very long-chain omega-6 fatty acid that is hexacosanoic acid containing five double bonds located at positions 8, 11, 14, 17 and 20 (the 8Z,11Z,14Z,17Z,20Z-isomer).","InChI=1S/C26H42O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26(27)28/h6-7,9-10,12-13,15-16,18-19H,2-5,8,11,14,17,20-25H2,1H3,(H,27,28)/b7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-hexacosa-8,11,14,17,20-pentaenoic acid",LIPID MAPS instance accession,LMFA01030845
4792,77532,"(13Z,16Z,19Z,22Z)-octacosatetraenoic acid","A very long-chain omega-6 fatty acid that is octacosanoic acid having four double bonds located at positions 13, 16, 19, 22 (the 13Z,16Z,19Z,22Z-isomer).","InChI=1S/C28H48O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28(29)30/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-27H2,1H3,(H,29,30)/b7-6-,10-9-,13-12-,16-15-","all-cis-octacosa-13,16,19,22-tetraenoic acid",LIPID MAPS instance accession,LMFA01030825
4793,77534,"(15Z,18Z,21Z,24Z)-triacontatetraenoic acid","A very long-chain omega-6 fatty acid that is triacontanoic acid having four double bonds located at positions 15, 18, 21 and 24 (the 15Z,18Z,21Z,24Z-isomer).","InChI=1S/C30H52O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30(31)32/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-29H2,1H3,(H,31,32)/b7-6-,10-9-,13-12-,16-15-","all-cis-triaconta-15,18,21,24-tetraenoic acid",LIPID MAPS instance accession,LMFA01030826
4794,77537,trans-9-octadecenoyl-CoA(4-),An octadecenoyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate functions of trans-9-octadecenoyl-CoA; major species at p 7.3.,"InChI=1S/C39H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h11-12,26-28,32-34,38,49-50H,4-10,13-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/p-4/b12-11+/t28-,32-,33-,34+,38-/m1/s1",elaidoyl-CoA,PubMed citation,16940157
4795,77538,"(21Z,24Z,27Z,30Z)-hexatriacontatetraenoic acid","An omega-6 fatty acid that is hexatriacontanoic acid having four double bonds located at positions 21, 24, 27 and 30 (the 21Z,24Z,27Z,30Z-isomer).","InChI=1S/C36H64O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36(37)38/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-35H2,1H3,(H,37,38)/b7-6-,10-9-,13-12-,16-15-","all-cis-hexatriaconta-21,24,27,30-tetraenoic acid",LIPID MAPS instance accession,LMFA01030829
4796,77539,"(23Z,26Z,29Z,32Z)-octatriacontatetraenoic acid","A very long-chain omega-6 fatty acid that is octatriacontanoic acid having four double bonds located at positions 23, 26, 29 and 32 (the 23Z,26Z,29Z,32Z-isomer).","InChI=1S/C38H68O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-32-33-34-35-36-37-38(39)40/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-37H2,1H3,(H,39,40)/b7-6-,10-9-,13-12-,16-15-","all-cis-octatriaconta-23,26,29,32-tetraenoic acid",LIPID MAPS instance accession,LMFA01030830
4797,77541,"(10Z,13Z,16Z,19Z,22Z)-octacosapentaenoic acid","A very long-chain omega-6 fatty acid that is octacosanoic acid having five double bonds located at positions 10, 13, 16, 19 and 22 (the 10Z,13Z,16Z,19Z,22Z-isomer).","InChI=1S/C28H46O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28(29)30/h6-7,9-10,12-13,15-16,18-19H,2-5,8,11,14,17,20-27H2,1H3,(H,29,30)/b7-6-,10-9-,13-12-,16-15-,19-18-","all-cis-octacosa-10,13,16,19,22-pentaenoic acid",LIPID MAPS instance accession,LMFA01030846
4798,77543,ebselen,"A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.",InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H,"2-phenyl-1,2-benzoselenazol-3-one",PubMed citation,7590103
4799,77563,rac-crizotinib,A racemate comprising equimolar amounts of (R)- and (S)-crizotinib. The active (R)-enantiomer acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer.,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)",racemic crizotinib,Reaxys Registry Number,12134721
4800,77605,tosufloxacin tosylate,A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin tosylate.,"InChI=1S/C19H15F3N4O3.C7H8O3S/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;1-6-2-4-7(5-3-6)11(8,9)10/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);2-5H,1H3,(H,8,9,10)",tosufloxacin monotosylate,CAS Registry Number,115964-29-9
4801,77625,alpha-D-GlcpNAc-(1->2)-L-alpha-D-Hepp-(1->3)-[beta-D-Glcp-(1->4)]-L-alpha-D-Hepp,"A branched amino tetrasaccharide comprising an N-acetyl-D-glucosamine residue, a D-glucose residue and two L-glycero-D-manno-heptose residues, with linkages as shown.","InChI=1S/C28H49NO23/c1-6(34)29-11-14(39)12(37)9(4-32)46-26(11)51-23-17(42)16(41)20(7(35)2-30)49-28(23)50-22-19(44)25(45)48-21(8(36)3-31)24(22)52-27-18(43)15(40)13(38)10(5-33)47-27/h7-28,30-33,35-45H,2-5H2,1H3,(H,29,34)/t7-,8-,9+,10+,11+,12+,13+,14+,15-,16-,17-,18+,19-,20+,21+,22+,23-,24+,25-,26+,27-,28+/m0/s1",N-acetyl-alpha-D-glucosaminyl-(1->2)-L-glycero-alpha-D-manno-heptosyl-(1->3)-[beta-D-glucosyl-(1->4)]-L-glycero-alpha-D-manno-heptose,PubMed citation,14688137
4802,77626,alpha-D-GlcpNAc-(1->2)-[alpha-D-Glcp-(1->3)]-L-alpha-D-Hepp-(1->3)-[beta-D-Glcp-(1->4)]-L-alpha-D-Hepp,"A branched amino pentasaccharide comprising an N-acetyl-D-glucosamine residue, two D-glucose residues and two L-glycero-D-manno-heptose residues, with linkages as shown.","InChI=1S/C34H59NO28/c1-7(41)35-13-17(47)14(44)10(4-38)55-31(13)63-29-26(60-32-20(50)18(48)15(45)11(5-39)56-32)22(52)24(8(42)2-36)59-34(29)61-27-23(53)30(54)58-25(9(43)3-37)28(27)62-33-21(51)19(49)16(46)12(6-40)57-33/h8-34,36-40,42-54H,2-6H2,1H3,(H,35,41)/t8-,9-,10+,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21+,22+,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+/m0/s1",alpha-D-GlcNAc-(1->2)-[alpha-D-Glc-(1->3)]-L-alpha-D-Hep-(1->3)-[beta-D-Glc-(1->4)]-L-alpha-D-Hep,PubMed citation,14688137
4803,77627,alpha-D-GlcpNAc-(1->2)-6-PEA-L-alpha-D-Hepp-(1->3)-[beta-D-Glcp-(1->4)]-L-alpha-D-Hepp,"A branched amino tetrasaccharide and oligosaccharide phosphate comprising an N-acetyl-D-glucosamine residue, a D-glucose residue and two L-glycero-D-manno-heptose residues (one of which is phosphoethanolamine-substituted on O-6), with linkages as shown.","InChI=1S/C30H55N2O26P/c1-8(37)32-13-16(41)14(39)10(5-34)51-28(13)56-25-19(44)18(43)23(12(7-36)58-59(48,49)50-3-2-31)54-30(25)55-24-21(46)27(47)53-22(9(38)4-33)26(24)57-29-20(45)17(42)15(40)11(6-35)52-29/h9-30,33-36,38-47H,2-7,31H2,1H3,(H,32,37)(H,48,49)/t9-,10+,11+,12-,13+,14+,15+,16+,17-,18-,19-,20+,21-,22+,23+,24+,25-,26+,27-,28+,29-,30+/m0/s1",alpha-D-GlcNAc-(1->2)-6-PEA-L-alpha-D-Hep-(1->3)-[beta-D-Glc-(1->4)]-L-alpha-D-Hep,PubMed citation,14688137
4804,77653,(3R)-3-carboxy-3-hydroxypropanoyl-CoA,A (3R)-3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the 3-carboxy group of (3R)-3-carboxy-3-hydroxypropanoic acid.,"InChI=1S/C25H40N7O20P3S/c1-25(2,19(37)22(38)28-4-3-14(34)27-5-6-56-15(35)7-12(33)24(39)40)9-49-55(46,47)52-54(44,45)48-8-13-18(51-53(41,42)43)17(36)23(50-13)32-11-31-16-20(26)29-10-30-21(16)32/h10-13,17-19,23,33,36-37H,3-9H2,1-2H3,(H,27,34)(H,28,38)(H,39,40)(H,44,45)(H,46,47)(H2,26,29,30)(H2,41,42,43)/t12-,13-,17-,18-,19+,23-/m1/s1",(R)-malyl-coenzyme A,MetaCyc accession,CPD-9449
4805,77693,CTBT,"An organic heterotricyclic compound that is tetrazolo[5,1-c][1,2,4]benzotriazine substituted at position 7 by a chloro group. An antifungal and chemosensitising agent that induces oxidative stress in yeast and filamentous fungi and enhances the cytotoxic activity of 5-fluorocytosine and azole antimycotics.",InChI=1S/C7H3ClN6/c8-4-1-2-6-5(3-4)9-10-7-11-12-13-14(6)7/h1-3H,"7-chlorotetrazolo[5,1-c]benzo[1.2.4]triazine",Reaxys Registry Number,12163903
4806,77702,S-nitroso-N-acetyl-D-penicillamine,A nitroso compound that is N-acetyl-D-penicillamine in which the sulfanyl hydrogen is replaced by a nitroso group.,"InChI=1S/C7H12N2O4S/c1-4(10)8-5(6(11)12)7(2,3)14-9-13/h5H,1-3H3,(H,8,10)(H,11,12)/t5-/m0/s1",S-nitroso-N-acetylpenicillamine,CAS Registry Number,79032-48-7
4807,77707,diethylamine NONOate,"An organoammonium salt that is the diethylammonium salt of 1,1-diethyl-2-hydroxy-3-oxotriazane.","InChI=1S/C4H11N3O2.C4H11N/c1-3-6(4-2)7(9)5-8;1-3-5-4-2/h9H,3-4H2,1-2H3;5H,3-4H2,1-2H3",DEA NONOate,Reaxys Registry Number,8435159
4808,77739,dexverapamil hydrochloride,"A hydrochloride salt resulting from the reaction of equimolar amounts of dexverapamil and hydrogen chloride. It competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1, EC 3.6.3.44), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. Dexverapamil hydrochloride exhibits lower calcium antagonistic activity and toxicity than racemic verapamil hydrochloride.","InChI=1S/C27H38N2O4.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;/h9-12,17-18,20H,8,13-16H2,1-7H3;1H/t27-;/m1./s1",dexverapamil HCl,Reaxys Registry Number,6710895
4809,77753,1-palmitoyl-2-[(10E)-9-hydroperoxyoctadecenoyl]-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine in which 1 and 2-acyl groups are specified as palmitoyl (hexadecanoyl) and (10E)-9-hydroperoxyoctadecenoyl respectively.","InChI=1S/C42H82NO10P/c1-6-8-10-12-14-15-16-17-18-19-21-25-29-33-41(44)49-37-40(38-51-54(47,48)50-36-35-43(3,4)5)52-42(45)34-30-26-22-24-28-32-39(53-46)31-27-23-20-13-11-9-7-2/h27,31,39-40H,6-26,28-30,32-38H2,1-5H3,(H-,46,47,48)/b31-27+/t39?,40-/m1/s1",1-hexadecanoyl-2-(9-hydroperoxy-10E-octadecenoyl)-sn -glycero-3-phosphocholine,PubMed citation,17090529
4810,77789,tetrindole hydrochloride,A racemate composed of equimolar amounts of (R)- and (S)-tetrindole hydrochloride.,"InChI=1S/C20H26N2.ClH/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18;/h9-10,13-14,18,21H,1-8,11-12H2;1H",tetrindole.HCl,CAS Registry Number,135991-95-6
4811,77790,(R)-tetrindole hydrochloride,A hydrochloride prepared from equimolar amounts of (R)-tetrindole and hydrochloric acid.,"InChI=1S/C20H26N2.ClH/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18;/h9-10,13-14,18,21H,1-8,11-12H2;1H/t18-;/m1./s1",(R)-tetrindole.HCl,Reaxys Registry Number,7419703
4812,77792,(S)-tetrindole hydrochloride,A hydrochloride obtained by combining equimolar amounts of (S)-tetrindole and hydrochloric acid.,"InChI=1S/C20H26N2.ClH/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18;/h9-10,13-14,18,21H,1-8,11-12H2;1H/t18-;/m0./s1",(S)-(+)-tetrindole monohydrochloride,Reaxys Registry Number,7419704
4813,77814,(R)-tetrindole,"An 8-cyclohexyl-2,3,3a,4,5,6-hexahydropyrazino[3,2,1-jk]carbazole that is the (R)-enantiomer of tetrindole.","InChI=1S/C20H26N2/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18/h9-10,13-14,18,21H,1-8,11-12H2/t18-/m1/s1",(R)-(-)-tetrindole,Reaxys Registry Number,7415486
4814,77820,glucose 6-monomycolate (C80),"A mycolate ester formed by esterification of (2R,3R,20Z,35Z)-3-hydroxy-2-tetracosanylhexapentaconta-20,35-dienoic acid with the 6-OH of D-glucose. (C80 is the average tail length of a reported naturally occurring range of 72-86 carbon atoms.)","InChI=1S/C86H166O8/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-28-29-30-31-32-33-34-35-36-37-38-39-40-41-42-43-44-45-46-47-48-49-50-51-52-53-54-55-57-59-61-63-65-67-69-71-73-75-77-80(87)79(85(91)93-78-81-82(88)83(89)84(90)86(92)94-81)76-74-72-70-68-66-64-62-60-58-56-26-24-22-20-18-16-14-12-10-8-6-4-2/h34-35,49-50,79-84,86-90,92H,3-33,36-48,51-78H2,1-2H3/b35-34-,50-49-/t79-,80-,81-,82-,83+,84-,86?/m1/s1","C80 GMM (2R,3R)",PubMed citation,21807869
4815,77855,3-chlorolactic acid,A 2-hydroxy monocarboxylic acid that is lactic acid in which one of the methyl hydrogens is replaced by a chloro group.,"InChI=1S/C3H5ClO3/c4-1-2(5)3(6)7/h2,5H,1H2,(H,6,7)",3-Chloro-2-hydroxypropionic acid,CAS Registry Number,1713-85-5
4816,77861,cincreasin,A member of the class of benzoxazoles that is 2-benzoxazolinone substituted at position 6 by a bromo group.,"InChI=1S/C7H4BrNO2/c8-4-1-2-5-6(3-4)11-7(10)9-5/h1-3H,(H,9,10)",6-Bromo-2-benzoxazolinone,CAS Registry Number,19932-85-5
4817,77869,"(E,E)-sorbate","A sorbate obtained by deprotonation of the carboxy group of (E,E)-sorbic acid.","InChI=1S/C6H8O2/c1-2-3-4-5-6(7)8/h2-5H,1H3,(H,7,8)/p-1/b3-2+,5-4+","(E,E)-2,4-hexadienoate",Reaxys Registry Number,4797560
4818,77918,mutalomycin,A polyether antibiotic produced by a strain of Streptomyces mutabilis NRRL 8088.,"InChI=1S/C41H70O12/c1-20-17-22(3)39(11,45)50-31(20)29-18-21(2)35(48-29)38(10)14-13-30(49-38)37(9)15-16-40(53-37)19-28(42)23(4)32(51-40)24(5)33-25(6)34(47-12)26(7)41(46,52-33)27(8)36(43)44/h20-35,42,45-46H,13-19H2,1-12H3,(H,43,44)/t20-,21-,22+,23+,24+,25-,26+,27+,28-,29+,30+,31-,32-,33+,34-,35+,37-,38-,39-,40+,41+/m0/s1",antibiotic S 11743A,CAS Registry Number,62618-08-0
4819,77922,isopentenol,An enol that is 3-methylbut-1-ene in which one of the terminal hydrogens is replaced by a hydroxy group.,"InChI=1S/C5H10O/c1-5(2)3-4-6/h3-6H,1-2H3/b4-3+",(E)-3-methylbut-1-en-1-ol,Reaxys Registry Number,2424541
4820,77923,"sodium[alpha-Kdo-(2->8)-alpha-Kdo-OAll II(1),I(7)-lactone]",The sodium salt of a carbohydrate lactone formed from alpha-Kdo-(2->8)-alpha-Kdo-OAll by lactone formation between the carboxy group of the non-reducing alpha-Kdo residue and O-7 of the alpha-Kdo-OAll residue.,"InChI=1S/C19H28O14.Na/c1-2-3-29-18(16(26)27)4-8(21)13(25)15(33-18)11-7-30-19(17(28)31-11)5-9(22)12(24)14(32-19)10(23)6-20;/h2,8-15,20-25H,1,3-7H2,(H,26,27);/q;+1/p-1/t8-,9-,10-,11-,12-,13-,14-,15-,18-,19-;/m1./s1","Na[alpha-Kdo-(2->8)-alpha-Kdo-OAll II(1),I(7)-lactone]",PubMed citation,19665108
4821,77927,nonan-2-one,A methyl ketone that is nonane in which the methylene hydrogens at position 2 are replaced by an oxo group.,"InChI=1S/C9H18O/c1-3-4-5-6-7-8-9(2)10/h3-8H2,1-2H3",2-nonanone,HMDB accession,HMDB0031266
4822,77930,undecan-2-ol,A fatty alcohol that is undecane carrying a single hydroxy substituent at position 2.,"InChI=1S/C11H24O/c1-3-4-5-6-7-8-9-10-11(2)12/h11-12H,3-10H2,1-2H3",2-undecanol,CAS Registry Number,1653-30-1
4823,77957,m-fluoro-L-phenylalanine,A phenylalanine derivative that is L-phenylalanine in which the hydrogen at position 3 on the benzene ring is replaced by a fluoro group.,"InChI=1S/C9H10FNO2/c10-7-3-1-2-6(4-7)5-8(11)9(12)13/h1-4,8H,5,11H2,(H,12,13)/t8-/m0/s1",3-fluorophenylalanine,Reaxys Registry Number,2725762
4824,77993,cyclopentylidene-[4-(4-chlorophenyl)thiazol-2-yl]hydrazone,"A member of the class of 1,3-thiazole bearing 2-cyclopentylidenehydrazino and 4-chlorophenyl substituents at positions 2 and 4 respectively.","InChI=1S/C14H14ClN3S/c15-11-7-5-10(6-8-11)13-9-19-14(16-13)18-17-12-3-1-2-4-12/h5-9H,1-4H2,(H,16,18)",CPTH2,Reaxys Registry Number,18559523
4825,78001,N-dodecanoylphytosphingosine,A phytoceramide in which the ceramide N-acyl group is specified as dodecanoyl.,"InChI=1S/C30H61NO4/c1-3-5-7-9-11-13-14-15-17-18-20-22-24-28(33)30(35)27(26-32)31-29(34)25-23-21-19-16-12-10-8-6-4-2/h27-28,30,32-33,35H,3-26H2,1-2H3,(H,31,34)/t27-,28+,30-/m0/s1",N-dodecanoyl-4-R-hydroxyoctadecasphinganine,PubMed citation,11356846
4826,78039,meso-tetrakis(N-methyl-4-pyridyl)porphine tetrakis(p-toluenesulfonate),An organosulfonate salt that is the tetrakis(p-toluenesulfonate) salt of meso-tetrakis(N-methyl-4-pyridyl)porphine.,"InChI=1S/C44H37N8.4C7H8O3S/c1-49-21-13-29(14-22-49)41-33-5-7-35(45-33)42(30-15-23-50(2)24-16-30)37-9-11-39(47-37)44(32-19-27-52(4)28-20-32)40-12-10-38(48-40)43(36-8-6-34(41)46-36)31-17-25-51(3)26-18-31;4*1-6-2-4-7(5-3-6)11(8,9)10/h5-28H,1-4H3,(H,45,46,47,48);4*2-5H,1H3,(H,8,9,10)/q+3;;;;/p-3/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-;;;;","5,10,15,20-tetrakis(N-methylpyridinium-4-yl)-21H,23H-porphine tetrakis(p-toluenesulfonate)",Reaxys Registry Number,5237096
4827,78042,5-fluoroanthranilic acid,An aminobenzoic acid that is anthranilic acid in which the hydrogen at position 5 on the phenyl ring is replaced by fluorine.,"InChI=1S/C7H6FNO2/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3H,9H2,(H,10,11)",2-amino-5-fluorobenzoic acid,CAS Registry Number,446-08-2
4828,78067,tin(II) chloride (anhydrous),An inorganic chloride that has formula Cl2Sn.,InChI=1S/2ClH.Sn/h2*1H;/q;;+2/p-2,tin(II) chloride (anh.),CAS Registry Number,7772-99-8
4829,78098,1-palmitylglycerone 3-phosphate,A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as palmityl (hexadecyl).,"InChI=1S/C19H39O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-24-17-19(20)18-25-26(21,22)23/h2-18H2,1H3,(H2,21,22,23)",1-hexadecylglycerone 3-phosphate,Reaxys Registry Number,2155194
4830,78103,1-dodecyl-2-acetyl-sn-glycero-3-phosphocholine,A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as dodecyl.,"InChI=1S/C22H46NO7P/c1-6-7-8-9-10-11-12-13-14-15-17-27-19-22(30-21(2)24)20-29-31(25,26)28-18-16-23(3,4)5/h22H,6-20H2,1-5H3/t22-/m1/s1",C12 PAF,LIPID MAPS instance accession,LMGP01020009
4831,78105,dihexadecanoyl phosphatidic acid,A phosphatidic acid in which the phosphatidyl acyl groups are both palmitoyl (hexadecanoyl).,"InChI=1S/C35H69O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(36)41-31-33(32-42-44(38,39)40)43-35(37)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h33H,3-32H2,1-2H3,(H2,38,39,40)",dipalmitoyl phosphatidic acid,LIPID MAPS instance accession,LMGP10010012
4832,78146,trans-9-octadecenoyl-CoA,An octadecenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans-9-octadecenoic acid.,"InChI=1S/C39H68N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-30(48)67-23-22-41-29(47)20-21-42-37(51)34(50)39(2,3)25-60-66(57,58)63-65(55,56)59-24-28-33(62-64(52,53)54)32(49)38(61-28)46-27-45-31-35(40)43-26-44-36(31)46/h11-12,26-28,32-34,38,49-50H,4-10,13-25H2,1-3H3,(H,41,47)(H,42,51)(H,55,56)(H,57,58)(H2,40,43,44)(H2,52,53,54)/b12-11+/t28-,32-,33-,34+,38-/m1/s1",(9E)-octadecenoyl CoA,PubMed citation,3821403
4833,78158,"4,7-diphenyl-1,10-phenanthroline 4',4''-disulfonate","An organosulfonate oxoanion obtained by deprotonation of the sulfo groups of 4,7-diphenyl-1,10-phenanthroline 4',4''-disulfonic acid.","InChI=1S/C24H16N2O6S2/c27-33(28,29)17-5-1-15(2-6-17)19-11-13-25-23-21(19)9-10-22-20(12-14-26-24(22)23)16-3-7-18(8-4-16)34(30,31)32/h1-14H,(H,27,28,29)(H,30,31,32)/p-2","bathophenanthroline 4',4''-disulfonate",MetaCyc accession,CPD-8818
4834,78159,"4,7-diphenyl-1,10-phenanthroline 4',4''-disulfonic acid","A member of the class of phenanthrolines that is 4,7-diphenyl-1,10-phenanthroline carrying two additional sulfo substituents at positions 4' and 4''","InChI=1S/C24H16N2O6S2/c27-33(28,29)17-5-1-15(2-6-17)19-11-13-25-23-21(19)9-10-22-20(12-14-26-24(22)23)16-3-7-18(8-4-16)34(30,31)32/h1-14H,(H,27,28,29)(H,30,31,32)",bathophenanthroline disulfonic acid,MetaCyc accession,CPD-8818
4835,78176,undecanoyl-CoA,A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of undecanoic acid.,"InChI=1S/C32H56N7O17P3S/c1-4-5-6-7-8-9-10-11-12-23(41)60-16-15-34-22(40)13-14-35-30(44)27(43)32(2,3)18-53-59(50,51)56-58(48,49)52-17-21-26(55-57(45,46)47)25(42)31(54-21)39-20-38-24-28(33)36-19-37-29(24)39/h19-21,25-27,31,42-43H,4-18H2,1-3H3,(H,34,40)(H,35,44)(H,48,49)(H,50,51)(H2,33,36,37)(H2,45,46,47)/t21-,25-,26-,27+,31-/m1/s1",undecanoyl-coenzyme A,HMDB accession,HMDB0013114
4836,78177,trans-2-undecenoyl-CoA,A medium-chain unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans-2-undecenoic acid.,"InChI=1S/C32H54N7O17P3S/c1-4-5-6-7-8-9-10-11-12-23(41)60-16-15-34-22(40)13-14-35-30(44)27(43)32(2,3)18-53-59(50,51)56-58(48,49)52-17-21-26(55-57(45,46)47)25(42)31(54-21)39-20-38-24-28(33)36-19-37-29(24)39/h11-12,19-21,25-27,31,42-43H,4-10,13-18H2,1-3H3,(H,34,40)(H,35,44)(H,48,49)(H,50,51)(H2,33,36,37)(H2,45,46,47)/b12-11+/t21-,25-,26-,27+,31-/m1/s1",(E)-2-undecenoyl-CoA,Reaxys Registry Number,24679352
4837,78208,azelaate(2-),A dicarboxylic acid dianion obtained by deprotonation of both carboxy groups of of azelaic acid; major species at pH 7.3.,"InChI=1S/C9H16O4/c10-8(11)6-4-2-1-3-5-7-9(12)13/h1-7H2,(H,10,11)(H,12,13)/p-2",8-carboxylatooctanoate,PubMed citation,8360169
4838,78217,acetone d6,A deuterated compound that is acetone in which all six hydrogen atoms are replaced by deuterium.,"InChI=1S/C3H6O/c1-3(2)4/h1-2H3/i1D3,2D3",hexadeuteroacetone,CAS Registry Number,666-52-4
4839,78220,2-methyl-1-pyrrolinium,An iminium ion obtained by protonation of the imino group of 2-methyl-1-pyrroline. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).,"InChI=1S/C5H9N/c1-5-3-2-4-6-5/h2-4H2,1H3/p+1",2-MPN,PubMed citation,21897027
4840,78238,"1-hydroxy-2,1-benzoxaborole","A member of the class of benzoxaboroles that is 2,1-benzoxaborole in which the hydrogen attached to the boron atom is replaced by a hydroxy group.","InChI=1S/C7H7BO2/c9-8-7-4-2-1-3-6(7)5-10-8/h1-4,9H,5H2","2,1-benzoxaborol-1-ol",Reaxys Registry Number,4333
4841,78246,oxythiamine chloride,A organic chloride salt having oxythiamine as the counterion.,"InChI=1S/C12H15N3O2S.ClH/c1-8-11(3-4-16)18-7-15(8)6-10-5-13-9(2)14-12(10)17;/h5,7,16H,3-4,6H2,1-2H3;1H",oxythiamine,Reaxys Registry Number,5326755
4842,78249,oxythiamine(1+),"A 1,3-thiazolium cation that is 5-(2-hydroxyethyl)-4-methyl-1,3-thiazole alkylated at the N3 position by a (2-methyl-4-oxo-1,4-dihydropyrimidin-5-yl)methyl group.","InChI=1S/C12H15N3O2S/c1-8-11(3-4-16)18-7-15(8)6-10-5-13-9(2)14-12(10)17/h5,7,16H,3-4,6H2,1-2H3/p+1",oxythiamine,Reaxys Registry Number,4153910
4843,78260,1-stearoyl-2-oleoyl-sn-glycero-3-phosphoserine(1-),A 3-sn-phosphatidyl-L-serine(1-) that is the conjugate base of 1-stearoyl-2-oleoyl-sn-glycero-3-phosphoserine; major species at pH 7.3.,"InChI=1S/C42H80NO10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(44)50-35-38(36-51-54(48,49)52-37-39(43)42(46)47)53-41(45)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,38-39H,3-17,19,21-37,43H2,1-2H3,(H,46,47)(H,48,49)/p-1/b20-18-/t38-,39+/m1/s1",1-octadecanoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphoserine(1-),PubMed citation,23071296
4844,78261,"1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine zwitterion","A phosphatidylethanolamine 38:6 zwitterion in which the acyl substituents at positions 1 and 2 are specified as hexadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C43H74NO8P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h5,7,11,13,17-18,20-21,24,26,30,32,41H,3-4,6,8-10,12,14-16,19,22-23,25,27-29,31,33-40,44H2,1-2H3,(H,47,48)/b7-5-,13-11-,18-17-,21-20-,26-24-,32-30-/t41-/m1/s1",1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine zwitterion,PubMed citation,23071296
4845,78262,"1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine(1-)","A phosphatidylserine 38:6 that is the conjugate base of hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine; major species at pH 7.3.","InChI=1S/C44H74NO10P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-43(47)55-40(38-53-56(50,51)54-39-41(45)44(48)49)37-52-42(46)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h5,7,11,13,17-18,20-21,24,26,30,32,40-41H,3-4,6,8-10,12,14-16,19,22-23,25,27-29,31,33-39,45H2,1-2H3,(H,48,49)(H,50,51)/p-1/b7-5-,13-11-,18-17-,21-20-,26-24-,32-30-/t40-,41+/m1/s1",1-pamitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoserine(1-),PubMed citation,23071296
4846,78263,"1-(1Z-octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine zwitterion","A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C45H78NO7P/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-26-28-30-32-34-36-38-45(47)53-44(43-52-54(48,49)51-41-39-46)42-50-40-37-35-33-31-29-27-25-20-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,22-23,26,28,32,34,37,40,44H,3-4,6,8-10,12,14-16,18,20-21,24-25,27,29-31,33,35-36,38-39,41-43,46H2,1-2H3,(H,48,49)/b7-5-,13-11-,19-17-,23-22-,28-26-,34-32-,40-37-/t44-/m1/s1",1-(1Z-octadecenyl)-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine zwitterion,PubMed citation,23071296
4847,78264,"1-(1Z-octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine(1-)","A 1-(1Z-alkenyl)-2-acyl-sn-glycero-3-phospho-L-serine(1-) in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C46H78NO9P/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-26-28-30-32-34-36-38-45(48)56-43(41-54-57(51,52)55-42-44(47)46(49)50)40-53-39-37-35-33-31-29-27-25-20-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,22-23,26,28,32,34,37,39,43-44H,3-4,6,8-10,12,14-16,18,20-21,24-25,27,29-31,33,35-36,38,40-42,47H2,1-2H3,(H,49,50)(H,51,52)/p-1/b7-5-,13-11-,19-17-,23-22-,28-26-,34-32-,39-37-/t43-,44+/m1/s1",1-(1Z-octadecenyl)-2-docosahexaenoyl-sn-glycero-3-phosphoserine(1-),PubMed citation,23071296
4848,78265,"1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine(1-)","A 3-sn-phosphatidyl-L-serine(1-) that is the conjugate base of 1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine; major species at pH 7.3.","InChI=1S/C46H78NO10P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-45(49)57-42(40-55-58(52,53)56-41-43(47)46(50)51)39-54-44(48)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,21-22,26,28,32,34,42-43H,3-4,6,8-10,12,14-16,18,20,23-25,27,29-31,33,35-41,47H2,1-2H3,(H,50,51)(H,52,53)/p-1/b7-5-,13-11-,19-17-,22-21-,28-26-,34-32-/t42-,43+/m1/s1",1-octadecanoyl-2-docosahexaenoyl-sn-glycero-3-phosphoserine(1-),PubMed citation,23071296
4849,78266,"1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine zwitterion","A phosphatidylethanolamine 40:6 zwitterion obtained by transfer of a proton from the phosphate to the primary amino group of 1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine.","InChI=1S/C45H78NO8P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-45(48)54-43(42-53-55(49,50)52-40-39-46)41-51-44(47)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,21-22,26,28,32,34,43H,3-4,6,8-10,12,14-16,18,20,23-25,27,29-31,33,35-42,46H2,1-2H3,(H,49,50)/b7-5-,13-11-,19-17-,22-21-,28-26-,34-32-/t43-/m1/s1",1-octadecanoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine zwitterion,PubMed citation,23071296
4850,78268,1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine zwitterion,"A phosphatidylethanolamine 38:4 zwitterion obtained by transfer of a proton from the phosphate to the primary amino group of 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phosphoethanolamine; major species at pH 7.3.","InChI=1S/C43H78NO8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,41H,3-10,12,14-16,18,20-21,23,25-27,29,31-40,44H2,1-2H3,(H,47,48)/b13-11-,19-17-,24-22-,30-28-/t41-/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphoethanolamine zwitterion",PubMed citation,23071296
4851,78269,1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoserine(1-),A phosphatidylserine 38:4 that is the conjugate base of 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoserine; major species at pH 7.3.,"InChI=1S/C44H78NO10P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-43(47)55-40(38-53-56(50,51)54-39-41(45)44(48)49)37-52-42(46)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,40-41H,3-10,12,14-16,18,20-21,23,25-27,29,31-39,45H2,1-2H3,(H,48,49)(H,50,51)/p-1/b13-11-,19-17-,24-22-,30-28-/t40-,41+/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphoserine(1-)",PubMed citation,23071296
4852,78270,2-oleoyl-sn-glycero-3-phosphate,A 2-acyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl group is specified as oleoyl.,"InChI=1S/C21H41O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(23)28-20(18-22)19-27-29(24,25)26/h9-10,20,22H,2-8,11-19H2,1H3,(H2,24,25,26)/b10-9-/t20-/m1/s1",2-(9Z)-octadecenoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10050014
4853,78271,alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp,A branched amino tetrasaccharide consisting of D-galactose at the reducing end with an alpha-L-fucosyl-(1->4)-[beta-D-galactosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl moiety attached at the 3-position.,"InChI=1S/C26H45NO20/c1-6-12(32)15(35)17(37)25(41-6)45-20-10(5-30)44-24(47-22-14(34)9(4-29)42-23(40)19(22)39)11(27-7(2)31)21(20)46-26-18(38)16(36)13(33)8(3-28)43-26/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15+,16-,17-,18+,19+,20+,21+,22-,23?,24-,25-,26-/m0/s1",alpha-L-fucosyl-(1->4)-[beta-D-galactosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-D-galactose,PubMed citation,394439
4854,78280,alpha-L-Fucp-(1->2)-[beta-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-D-Galp,A branched amino pentasaccharide consisting of D-galactose at the reducing end with an alpha-L-fucosyl-(1->2)-[N-acetyl-beta-D-galactosaminyl-(1->3)]-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl moiety attached at the 3-position.,"InChI=1S/C34H58N2O25/c1-8-17(43)23(49)24(50)33(53-8)61-29-28(60-31-15(35-9(2)41)22(48)18(44)11(4-37)55-31)21(47)14(7-40)57-34(29)58-26-16(36-10(3)42)32(56-13(6-39)19(26)45)59-27-20(46)12(5-38)54-30(52)25(27)51/h8,11-34,37-40,43-52H,4-7H2,1-3H3,(H,35,41)(H,36,42)/t8-,11+,12+,13+,14+,15+,16+,17+,18-,19+,20-,21-,22+,23+,24-,25+,26+,27-,28-,29+,30?,31-,32-,33-,34-/m0/s1",alpha-L-Fuc-(1->2)-[beta-D-GalNAc-(1->3)]-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-D-Gal,PubMed citation,394439
4855,78287,"8-demethyl-8-(2,3,4-O-trimethyl-alpha-L-rhamnosyl)tetracenomycin C","A member of the class of tetracenomycins that is 8-demethyltetracenomycin C in which the hydroxyl hydrogen at position 8 is replaced by a 2,3,4-tri-O-methyl-alpha-L-rhamnosyl residue.","InChI=1S/C31H34O15/c1-11-18-13(9-15(19(11)28(37)44-7)46-29-24(43-6)23(42-5)22(41-4)12(2)45-29)8-14-20(21(18)33)27(36)30(38)17(32)10-16(40-3)26(35)31(30,39)25(14)34/h8-10,12,22-24,26,29,33,35,38-39H,1-7H3/t12-,22-,23+,24+,26+,29-,30+,31+/m0/s1",12-demethylelloramycin A,PubMed citation,11376004
4856,78289,alpha-L-Fucp-(1->2)-[beta-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-D-Galp,A branched amino hexasaccharide consisting of D-galactose at the reducing end with an alpha-L-fucosyl-(1->2)-[N-acetyl-beta-D-galactosaminyl-(1->3)]-beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl moiety attached at the 3-position.,"InChI=1S/C40H68N2O29/c1-9-19(49)25(55)27(57)38(61-9)67-30-16(8-46)66-37(69-32-22(52)14(6-44)63-35(60)29(32)59)18(42-12(4)48)31(30)68-40-34(71-39-28(58)26(56)20(50)10(2)62-39)33(23(53)15(7-45)65-40)70-36-17(41-11(3)47)24(54)21(51)13(5-43)64-36/h9-10,13-40,43-46,49-60H,5-8H2,1-4H3,(H,41,47)(H,42,48)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23-,24+,25+,26+,27-,28-,29+,30+,31+,32-,33-,34+,35?,36-,37-,38-,39-,40-/m0/s1",beta-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-beta-D-GlcNAc-(1->3)-D-Gal,PubMed citation,394439
4857,78290,L-m-tyrosine zwitterion,An L-alpha-amino acid zwitterion that is L-m-tyrosine in which a proton has been transferred from the carboxy group to the amino group.,"InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-2-1-3-7(11)4-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1",m-L-tyrosine zwitterion,MetaCyc accession,CPD-14541
4858,78305,[8)-alpha-Neu5Ac-(2->]5,An N-acetylated alpha-(2->8)-linked homosialopolysaccharide consisting of five alpha-D-N-acetylneuraminyl residues joined by (2->8) linkages (i.e. [8)-alpha-Neu5Ac-(2->]n where n = 5).,"InChI=1S/C55H87N5O41/c1-16(66)56-31-21(71)6-51(92,46(82)83)97-42(31)37(78)27(12-62)93-53(48(86)87)8-23(73)33(58-18(3)68)44(99-53)39(80)29(14-64)95-55(50(90)91)10-25(75)35(60-20(5)70)45(101-55)40(81)30(15-65)96-54(49(88)89)9-24(74)34(59-19(4)69)43(100-54)38(79)28(13-63)94-52(47(84)85)7-22(72)32(57-17(2)67)41(98-52)36(77)26(76)11-61/h21-45,61-65,71-81,92H,6-15H2,1-5H3,(H,56,66)(H,57,67)(H,58,68)(H,59,69)(H,60,70)(H,82,83)(H,84,85)(H,86,87)(H,88,89)(H,90,91)/t21-,22-,23-,24-,25-,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,51+,52+,53+,54+,55+/m0/s1",oligosialic acid (DP5),PubMed citation,24100042
4859,78335,(S)-linalyl acetate,The (S)-enantiomer of linalyl acetate.,"InChI=1S/C12H20O2/c1-6-12(5,14-11(4)13)9-7-8-10(2)3/h6,8H,1,7,9H2,2-5H3/t12-/m1/s1","(3S)-3,7-dimethylocta-1,6-dien-3-yl acetate",CAS Registry Number,51685-40-6
4860,78341,1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoserine(1-),"A 1-(1Z-alk-1-enyl)-2-acyl-sn-glycero-3-phospho-L-serine(1-) that is the conjugate base of 1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3- phosphoserine(1-), obtained by deprotonation of the phosphate and carboxy groups and protonation of the amino group; major species at pH 7.3.","InChI=1S/C42H80NO9P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-49-36-39(37-50-53(47,48)51-38-40(43)42(45)46)52-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,33,35,39-40H,3-17,19,21-32,34,36-38,43H2,1-2H3,(H,45,46)(H,47,48)/p-1/b20-18-,35-33-/t39-,40+/m1/s1",1-(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoserine(1-),PubMed citation,23071296
4861,78342,1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoethanolamine zwitterion,A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups are specified as (1Z-octadecenyl) and arachidonoyl respectively.,"InChI=1S/C43H78NO7P/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-36-43(45)51-42(41-50-52(46,47)49-39-37-44)40-48-38-35-33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,35,38,42H,3-10,12,14-16,18,20-21,23,25-27,29,31-34,36-37,39-41,44H2,1-2H3,(H,46,47)/b13-11-,19-17-,24-22-,30-28-,38-35-/t42-/m1/s1","1-(1Z-octadecenyl)-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phosphoethanolamine zwitterion",PubMed citation,23071296
4862,78343,1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoserine(1-),"A 1-(1Z-alk-1-enyl)-sn-glycero-3-phosphoserine(1-) that is the conjugate base of 1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoserine, obtained by deprotonation of the phosphate and carboxy groups and protonation of the amino group; major species at pH 7.3.","InChI=1S/C44H78NO9P/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-36-43(46)54-41(39-52-55(49,50)53-40-42(45)44(47)48)38-51-37-35-33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,35,37,41-42H,3-10,12,14-16,18,20-21,23,25-27,29,31-34,36,38-40,45H2,1-2H3,(H,47,48)(H,49,50)/p-1/b13-11-,19-17-,24-22-,30-28-,37-35-/t41-,42+/m1/s1","1-(1Z-octadecenyl)-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phosphoserine(1-)",PubMed citation,23071296
4863,78364,vasotocin,"A heterodetic cyclic peptide that is homologous to oxytocin and vasopressin. It is a pituitary hormone that acts as an endocrine regulator for water balance, osmotic homoeostasis and is involved in social and sexual behavior in non-mammalian vertebrates.","InChI=1S/C43H67N15O12S2/c1-3-21(2)34-41(69)53-26(12-13-31(45)60)37(65)55-28(17-32(46)61)38(66)56-29(20-72-71-19-24(44)35(63)54-27(39(67)57-34)16-22-8-10-23(59)11-9-22)42(70)58-15-5-7-30(58)40(68)52-25(6-4-14-50-43(48)49)36(64)51-18-33(47)62/h8-11,21,24-30,34,59H,3-7,12-20,44H2,1-2H3,(H2,45,60)(H2,46,61)(H2,47,62)(H,51,64)(H,52,68)(H,53,69)(H,54,63)(H,55,65)(H,56,66)(H,57,67)(H4,48,49,50)/t21-,24-,25-,26-,27-,28-,29-,30-,34-/m0/s1",AVT,Wikipedia accession,Vasotocin
4864,78390,1-hexadecyl-sn-glycero-3-phosphoethanolamine zwitterion,A 1-alkyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alkyl group at C-1 is specified as hexadecyl.,"InChI=1S/C21H46NO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17-26-19-21(23)20-28-29(24,25)27-18-16-22/h21,23H,2-20,22H2,1H3,(H,24,25)/t21-/m1/s1",1-O-hexadecyl-2-lyso-sn-glycero-3-phosphoethanolamine zwitterion,PubMed citation,10542206
4865,78434,5'-AAAAATCCTTTTTGGATTAAA-3',"A single-stranded DNA oligonucleotide comprised of nine deoxyadenosine, eight thymidine, two deoxycytidine and two deoxyguanosine residues connected by 3'->5' phosphodiester linkages in the sequence A-A-A-A-A-T-C-C-T-T-T-T-T-G-G-A-T-T-A-A-A. Synthetic model oligodeoxyribonucleotide ligand.","InChI=1S/C203H256N82O118P20/c1-83-39-272(201(300)262-187(83)288)143-27-95(117(373-143)52-353-416(327,328)396-100-32-149(279-76-244-160-171(215)226-67-235-180(160)279)378-122(100)57-358-420(335,336)400-104-36-153(283-80-248-164-175(219)230-71-239-184(164)283)380-124(104)59-359-421(337,338)401-103-35-152(282-79-247-163-174(218)229-70-238-183(163)282)379-123(103)58-357-419(333,334)398-99-31-148(278-75-243-159-170(214)225-66-234-179(159)278)375-119(99)54-344-405(305,306)384-87-19-146(363-107(87)42-286)276-73-241-157-168(212)223-64-232-177(157)276)392-413(321,322)351-50-115-93(25-141(371-115)270-16-9-133(209)256-199(270)298)390-411(317,318)349-48-113-91(23-139(369-113)268-14-7-131(207)254-197(268)296)388-409(313,314)347-46-111-89(21-137(367-111)266-12-5-129(205)252-195(266)294)386-407(309,310)345-44-109-88(20-136(365-109)265-11-4-128(204)251-194(265)293)385-406(307,308)346-45-110-90(22-138(366-110)267-13-6-130(206)253-196(267)295)387-408(311,312)348-47-112-92(24-140(368-112)269-15-8-132(208)255-198(269)297)389-410(315,316)350-49-114-94(26-142(370-114)271-17-10-134(210)257-200(271)299)391-412(319,320)361-61-126-105(37-154(382-126)284-81-249-165-185(284)258-192(220)260-190(165)291)403-423(341,342)362-62-127-106(38-155(383-127)285-82-250-166-186(285)259-193(221)261-191(166)292)402-422(339,340)360-60-125-101(33-150(381-125)280-77-245-161-172(216)227-68-236-181(161)280)397-417(329,330)354-53-118-96(28-144(374-118)273-40-84(2)188(289)263-202(273)301)393-414(323,324)352-51-116-97(29-145(372-116)274-41-85(3)189(290)264-203(274)302)394-415(325,326)355-56-121-102(34-151(377-121)281-78-246-162-173(217)228-69-237-182(162)281)399-418(331,332)356-55-120-98(30-147(376-120)277-74-242-158-169(213)224-65-233-178(158)277)395-404(303,304)343-43-108-86(287)18-135(364-108)275-72-240-156-167(211)222-63-231-176(156)275/h4-17,39-41,63-82,86-127,135-155,286-287H,18-38,42-62H2,1-3H3,(H,303,304)(H,305,306)(H,307,308)(H,309,310)(H,311,312)(H,313,314)(H,315,316)(H,317,318)(H,319,320)(H,321,322)(H,323,324)(H,325,326)(H,327,328)(H,329,330)(H,331,332)(H,333,334)(H,335,336)(H,337,338)(H,339,340)(H,341,342)(H2,204,251,293)(H2,205,252,294)(H2,206,253,295)(H2,207,254,296)(H2,208,255,297)(H2,209,256,298)(H2,210,257,299)(H2,211,222,231)(H2,212,223,232)(H2,213,224,233)(H2,214,225,234)(H2,215,226,235)(H2,216,227,236)(H2,217,228,237)(H2,218,229,238)(H2,219,230,239)(H,262,288,300)(H,263,289,301)(H,264,290,302)(H3,220,258,260,291)(H3,221,259,261,292)/t86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,153+,154+,155+/m0/s1",d(A-A-A-A-A-T-C-C-T-T-T-T-T-G-G-A-T-T-A-A-A),PubMed citation,7510750
4866,78484,beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-stearoylsphingosine,A beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer in which the ceramide N-acyl group is specified as stearoyl.,"InChI=1S/C62H114N2O23/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-46(71)64-40(41(70)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)38-80-60-54(78)51(75)57(44(36-67)83-60)86-62-55(79)52(76)56(45(37-68)84-62)85-59-47(63-39(3)69)58(49(73)43(35-66)81-59)87-61-53(77)50(74)48(72)42(34-65)82-61/h30,32,40-45,47-62,65-68,70,72-79H,4-29,31,33-38H2,1-3H3,(H,63,69)(H,64,71)/b32-30+/t40-,41+,42+,43+,44+,45+,47+,48-,49-,50-,51+,52+,53+,54+,55+,56-,57+,58+,59-,60+,61-,62-/m0/s1",asialo-GM1a ganglioside,PubMed citation,16934889
4867,78485,ganglioside GM2 (18:0) (1-),An anionic ganglioside obtained by deprotonation of the neuraminosyl carboxy group of ganglioside GM2 (18:0); major species at pH 7.3.,"InChI=1S/C67H121N3O26/c1-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-50(80)70-43(44(77)33-31-29-27-25-23-21-18-16-14-12-10-8-6-2)40-89-64-57(85)56(84)59(48(38-73)91-64)93-65-58(86)62(60(49(39-74)92-65)94-63-52(69-42(4)76)55(83)54(82)47(37-72)90-63)96-67(66(87)88)35-45(78)51(68-41(3)75)61(95-67)53(81)46(79)36-71/h31,33,43-49,51-65,71-74,77-79,81-86H,5-30,32,34-40H2,1-4H3,(H,68,75)(H,69,76)(H,70,80)(H,87,88)/p-1/b33-31+/t43-,44+,45-,46+,47+,48+,49+,51+,52+,53+,54-,55+,56+,57+,58+,59+,60-,61+,62+,63-,64+,65-,67-/m0/s1",N-acetyl-beta-D-galactosaminyl-(1->4)-[alpha-N-acetylneuraminosyl-(2->3)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-stearoylsphingosine(1-),PubMed citation,16934889
4868,78486,N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-stearoylsphingosine,An N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide in which the ceramide N-acyl group is specified as stearoyl.,"InChI=1S/C56H104N2O18/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-44(64)58-39(40(63)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)37-71-55-50(69)48(67)53(42(35-60)73-55)76-56-51(70)49(68)52(43(36-61)74-56)75-54-45(57-38(3)62)47(66)46(65)41(34-59)72-54/h30,32,39-43,45-56,59-61,63,65-70H,4-29,31,33-37H2,1-3H3,(H,57,62)(H,58,64)/b32-30+/t39-,40+,41+,42+,43+,45+,46-,47+,48+,49+,50+,51+,52-,53+,54-,55+,56-/m0/s1",asialo-GM2 ganglioside,PubMed citation,16934889
4869,78507,mastoparan-AF,"A member of the class of mastopyrans that is a 14-amino acid polypeptide comprising isoleucyl, asparaginyl, leucyl, lysyl, alanyl, isoleucyl, alanyl, alanyl, leucyl, alanyl, lysyl, lysyl, leucyl, and phenylalninamide residues coupled in sequence. It is the major active component of the venom of the hornet Vespa affinis and causes degranulation of mast cells. It exhibits antimicrobial activity against both Gram-positive and -negative bacteria as well as haemolytic activity on chicken, human and sheep erythrocytes.","InChI=1S/C72H127N19O15/c1-15-41(9)56(77)70(104)89-54(37-55(76)92)69(103)88-53(35-39(5)6)68(102)85-48(28-20-23-31-73)64(98)80-46(14)63(97)91-58(42(10)16-2)72(106)82-43(11)60(94)79-44(12)62(96)87-52(34-38(3)4)67(101)81-45(13)61(95)83-49(29-21-24-32-74)65(99)84-50(30-22-25-33-75)66(100)90-57(40(7)8)71(105)86-51(59(78)93)36-47-26-18-17-19-27-47/h17-19,26-27,38-46,48-54,56-58H,15-16,20-25,28-37,73-75,77H2,1-14H3,(H2,76,92)(H2,78,93)(H,79,94)(H,80,98)(H,81,101)(H,82,106)(H,83,95)(H,84,99)(H,85,102)(H,86,105)(H,87,96)(H,88,103)(H,89,104)(H,90,100)(H,91,97)/t41-,42-,43-,44-,45-,46-,48-,49-,50-,51-,52-,53-,54-,56-,57-,58-/m0/s1",MP-AF,PubMed citation,21884742
4870,78519,mastoparan-V,"A member of the class of mastopyrans that is a 14-amino acid polypeptide comprising isoleucyl, asparaginyl, tryptophyl, lysyl, glycyl, isoleucyl, alanyl, alanyl, methionyl, alanyl, lysyl, lysyl, leucyl, and leucinamide residues coupled in sequence. It is the major active component of the venom of the hornet Vespa velutina and causes degranulation of mast cells. It exhibits antimicrobial activity against both Gram-positive and -negative bacteria as well as haemolytic activity on chicken, human and sheep erythrocytes.","InChI=1S/C73H126N20O15S/c1-13-41(7)59(78)72(107)92-56(36-57(77)94)71(106)91-55(35-46-37-80-48-24-16-15-23-47(46)48)70(105)87-49(25-17-20-29-74)65(100)81-38-58(95)93-60(42(8)14-2)73(108)84-43(9)62(97)82-44(10)63(98)86-52(28-32-109-12)66(101)83-45(11)64(99)85-50(26-18-21-30-75)67(102)88-51(27-19-22-31-76)68(103)90-54(34-40(5)6)69(104)89-53(61(79)96)33-39(3)4/h15-16,23-24,37,39-45,49-56,59-60,80H,13-14,17-22,25-36,38,74-76,78H2,1-12H3,(H2,77,94)(H2,79,96)(H,81,100)(H,82,97)(H,83,101)(H,84,108)(H,85,99)(H,86,98)(H,87,105)(H,88,102)(H,89,104)(H,90,103)(H,91,106)(H,92,107)(H,93,95)/t41-,42-,43-,44-,45-,49-,50-,51-,52-,53-,54-,55-,56-,59-,60-/m0/s1",MP-V,PubMed citation,21884742
4871,78541,1-hexadecyl-2-amino-2-deoxy-sn-glycerol,An amino alcohol that is 2-amino-propane-1-ol in which one of the hydroxyl hydrogens is replaced by a hexedecyl group (the S-enantiomer).,"InChI=1S/C19H41NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-22-18-19(20)17-21/h19,21H,2-18,20H2,1H3/t19-/m0/s1",(S)-1-hexadecyloxy-2-amino-propane-3-ol,Reaxys Registry Number,6683814
4872,78576,aflatoxin M1,A member of the class of aflatoxins that is aflatoxin B1 in which the hydrogen at position 9a is replaced by a hydroxy group.,"InChI=1S/C17H12O7/c1-21-9-6-10-13(17(20)4-5-22-16(17)23-10)14-12(9)7-2-3-8(18)11(7)15(19)24-14/h4-6,16,20H,2-3H2,1H3/t16-,17-/m1/s1",AFM1,KNApSAcK accession,C00023620
4873,78577,"aflatoxin M1 8,9-epoxide","A member of the class of aflatoxins that is obtained by the formal epoxidation across the 8,9-double bond of aflatoxin M1.","InChI=1S/C17H12O8/c1-21-7-4-8-11(17(20)13-15(24-13)25-16(17)22-8)12-10(7)5-2-3-6(18)9(5)14(19)23-12/h4,13,15-16,20H,2-3H2,1H3/t13-,15-,16-,17-/m0/s1",AFM1E,KEGG COMPOUND accession,C19594
4874,78582,aflatoxin Q1,A member of the class of aflatoxins that is aflatoxin B1 in which the hydrogen at the pro-3S position is replaced by a hydroxy group.,"InChI=1S/C17H12O7/c1-21-9-5-10-11(6-2-3-22-17(6)23-10)15-14(9)12-7(18)4-8(19)13(12)16(20)24-15/h2-3,5-7,17-18H,4H2,1H3/t6-,7-,17+/m0/s1",AFQ1,PubMed citation,3099349
4875,78586,"aflatoxin B1 endo-8,9-oxide","A member of the class of aflatoxins that is obtained by the formal epoxidation across the 8,9-double bond of aflatoxin B1.","InChI=1S/C17H12O7/c1-20-7-4-8-11(12-14-17(23-14)24-16(12)21-8)13-10(7)5-2-3-6(18)9(5)15(19)22-13/h4,12,14,16-17H,2-3H2,1H3/t12-,14+,16+,17-/m1/s1",AFNBO,KEGG COMPOUND accession,C19595
4876,78590,"7-O-geranyl-2-O,3-dimethylflaviolin","A hydroxy-1,4-naphthoquinone that is 3-methylflaviolin in which the hydroxyl hydrogens at positions 2 and 7 are replaced by methyl and geranyl groups respectively.","InChI=1S/C22H26O5/c1-13(2)7-6-8-14(3)9-10-27-16-11-17-19(18(23)12-16)20(24)15(4)22(26-5)21(17)25/h7,9,11-12,23H,6,8,10H2,1-5H3/b14-9+","7-{[(2E)-3,7-dimethylocta-2,6-dien-1-yl]oxy}-5-hydroxy-2-methoxy-3-methylnaphthalene-1,4-dione",MetaCyc accession,CPD-16662
4877,78594,5alpha-pregan-20beta-ol-3-one,A 3-oxo-5alpha- steroid that is 5alpha-pregane-3-one carrying an additional hydroxy substituent at the 20beta-position.,"InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h13-14,16-19,22H,4-12H2,1-3H3/t13-,14+,16+,17-,18+,19+,20+,21-/m1/s1","(5alpha,20beta)-20-hydroxypregnan-3-one",CAS Registry Number,516-58-5
4878,78609,5'-d[CCGTCCATAATCACTCGC]-3',"A single-strand DNA oligonucleotide comprised of four deoxyadenosine, eight deoxycytidine, four thymidine and two deoxyguanidine residues connected by 3'->5' phosphodiester linkages in the sequence C-C-G-T-C-C-A-T-A-A-T-C-A-C-T-C-G-C.","InChI=1S/C172H221N62O106P17/c1-71-39-225(169(251)213-153(71)237)127-29-83(331-349(271,272)294-49-99-82(28-126(312-99)224-20-12-118(180)208-168(224)250)330-347(267,268)304-59-109-91(37-135(322-109)233-69-199-141-151(233)209-159(185)211-157(141)241)335-341(255,256)289-44-94-75(236)21-119(307-94)217-13-5-111(173)201-161(217)243)101(314-127)51-296-344(261,262)326-79-25-123(221-17-9-115(177)205-165(221)247)313-100(79)50-295-353(279,280)336-87-33-131(229-65-195-137-143(181)187-61-191-147(137)229)318-105(87)55-300-346(265,266)329-81-27-125(223-19-11-117(179)207-167(223)249)311-98(81)48-293-351(275,276)332-84-30-128(226-40-72(2)154(238)214-170(226)252)315-102(84)52-297-355(283,284)338-89-35-133(231-67-197-139-145(183)189-63-193-149(139)231)321-108(89)58-303-357(287,288)339-90-36-134(232-68-198-140-146(184)190-64-194-150(140)232)320-107(90)57-302-352(277,278)334-86-32-130(228-42-74(4)156(240)216-172(228)254)316-103(86)53-298-354(281,282)337-88-34-132(230-66-196-138-144(182)188-62-192-148(138)230)319-106(88)56-301-345(263,264)328-80-26-124(222-18-10-116(178)206-166(222)248)309-96(80)46-291-343(259,260)325-78-24-122(220-16-8-114(176)204-164(220)246)310-97(78)47-292-350(273,274)333-85-31-129(227-41-73(3)155(239)215-171(227)253)317-104(85)54-299-356(285,286)340-92-38-136(234-70-200-142-152(234)210-160(186)212-158(142)242)323-110(92)60-305-348(269,270)327-77-23-121(219-15-7-113(175)203-163(219)245)308-95(77)45-290-342(257,258)324-76-22-120(306-93(76)43-235)218-14-6-112(174)202-162(218)244/h5-20,39-42,61-70,75-110,119-136,235-236H,21-38,43-60H2,1-4H3,(H,255,256)(H,257,258)(H,259,260)(H,261,262)(H,263,264)(H,265,266)(H,267,268)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,283,284)(H,285,286)(H,287,288)(H2,173,201,243)(H2,174,202,244)(H2,175,203,245)(H2,176,204,246)(H2,177,205,247)(H2,178,206,248)(H2,179,207,249)(H2,180,208,250)(H2,181,187,191)(H2,182,188,192)(H2,183,189,193)(H2,184,190,194)(H,213,237,251)(H,214,238,252)(H,215,239,253)(H,216,240,254)(H3,185,209,211,241)(H3,186,210,212,242)/t75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+/m0/s1",5'-CCGTCCATAATCACTCGC-3',PubMed citation,23519658
4879,78610,5'-d[GCGTGAT(6-4)TATGGAC]-3',"A single-strand DNA oligonucleotide comprised of three deoxyadenosine, two deoxycytidine, four thymidine and eight deoxyguanidine residues connected by 3'->5' phosphodiester linkages in the sequence G-C-G-T-G-A-T-T-A-T-G-G-A-C, with a (6-4) lesion at the central two thymidine residues.","InChI=1S/C138H173N54O83P13/c1-51-23-181-86-12-57(265-279(216,217)241-33-75-61(16-90(256-75)185-44-156-100-109(142)150-41-153-112(100)185)269-282(222,223)238-30-72-58(13-87(253-72)182-24-52(2)119(195)176-135(182)206)266-280(218,219)246-37-79-65(20-95(260-79)190-49-161-105-117(190)169-130(147)174-124(105)200)274-286(230,231)247-38-80-66(21-96(261-80)191-50-162-106-118(191)170-131(148)175-125(106)201)273-284(226,227)242-32-74-60(15-89(255-74)184-43-155-99-108(141)149-40-152-111(99)184)268-276(210,211)236-27-69-54(194)9-84(250-69)179-7-5-82(139)163-132(179)203)71(252-86)29-240-288(234,235)275-67-22-97(192-107(98(51)165-134(181)205)138(4,209)126(202)178-137(192)208)262-81(67)39-248-287(232,233)270-62-17-91(186-45-157-101-110(143)151-42-154-113(101)186)257-76(62)34-243-285(228,229)272-64-19-94(189-48-160-104-116(189)168-129(146)173-123(104)199)259-78(64)36-245-281(220,221)267-59-14-88(183-25-53(3)120(196)177-136(183)207)254-73(59)31-239-283(224,225)271-63-18-93(188-47-159-103-115(188)167-128(145)172-122(103)198)258-77(63)35-244-278(214,215)264-56-11-85(180-8-6-83(140)164-133(180)204)251-70(56)28-237-277(212,213)263-55-10-92(249-68(55)26-193)187-46-158-102-114(187)166-127(144)171-121(102)197/h5-8,23-25,40-50,54-81,84-97,107,193-194,209H,9-22,26-39H2,1-4H3,(H,210,211)(H,212,213)(H,214,215)(H,216,217)(H,218,219)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H2,139,163,203)(H2,140,164,204)(H2,141,149,152)(H2,142,150,153)(H2,143,151,154)(H,176,195,206)(H,177,196,207)(H,178,202,208)(H3,144,166,171,197)(H3,145,167,172,198)(H3,146,168,173,199)(H3,147,169,174,200)(H3,148,170,175,201)/t54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,107-,138+/m0/s1",5'-GCGTGAT(6-4)TATGGAC-3',PubMed citation,23519658
4880,78653,(R)-edelfosine,A 1-octadecyl-2-methylglycero-3-phosphocholine that is the (R)-enantiomer of edelfosine.,"InChI=1S/C27H58NO6P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-23-32-25-27(31-5)26-34-35(29,30)33-24-22-28(2,3)4/h27H,6-26H2,1-5H3/t27-/m1/s1",1-octadecyl-2-methyl-sn-glycero-3-phosphocholine,LIPID MAPS instance accession,LMGP01040048
4881,78659,(S)-edelfosine,A 1-octadecyl-2-methylglycero-3-phosphocholine that is the (S)-enantiomer of edelfosine.,"InChI=1S/C27H58NO6P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-23-32-25-27(31-5)26-34-35(29,30)33-24-22-28(2,3)4/h27H,6-26H2,1-5H3/t27-/m0/s1",3-octadecyl-2-methyl-sn-glycero-1-phosphocholine,Reaxys Registry Number,6376410
4882,78669,aldehydo-ascarylose,An aldehyde that is the acyclic form of ascarylose.,"InChI=1S/C6H12O4/c1-4(8)6(10)2-5(9)3-7/h3-6,8-10H,2H2,1H3/t4-,5+,6+/m0/s1","aldehydo-3,6-dideoxy-L-mannose",CAS Registry Number,32142-24-8
4883,78674,"(E,E)-1-bromo-2,5-bis-(4-hydroxystyryl)benzene",An organobromine compound that is bromobenzene in which the hydrogens at positions 2 and 5 are replaced by 4-hydroxystyryl groups.,"InChI=1S/C22H17BrO2/c23-22-15-18(2-1-16-5-11-20(24)12-6-16)4-10-19(22)9-3-17-7-13-21(25)14-8-17/h1-15,24-25H/b2-1+,9-3+","trans,trans-1-bromo-2,5-bis-(4-hydroxystyryl)benzene",Reaxys Registry Number,8861574
4884,78693,(R)-bifonazole,A 1-[biphenyl-4-yl(phenyl)methyl]imidazole that is the R-enantiomer of bifonazole.,"InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H/t22-/m1/s1",(R)-(-)-bifonazole,Reaxys Registry Number,8626154
4885,78694,(S)-bifonazole,A 1-[biphenyl-4-yl(phenyl)methyl]imidazole that is the S-enantiomer of bifonazole.,"InChI=1S/C22H18N2/c1-3-7-18(8-4-1)19-11-13-21(14-12-19)22(24-16-15-23-17-24)20-9-5-2-6-10-20/h1-17,22H/t22-/m0/s1",(S)-(+)-bifonazole,Reaxys Registry Number,8626153
4886,78700,9-oxononanoic acid,A medium-chain oxo-fatty acid that is the 9-oxo derivative of nonanoic acid.,"InChI=1S/C9H16O3/c10-8-6-4-2-1-3-5-7-9(11)12/h8H,1-7H2,(H,11,12)",9-ketononanoic acid,KEGG COMPOUND accession,C16322
4887,78705,"(6Z,9Z)-octadecadienoate","An octadecadienoate obtained by deprotonation of the carboxy group of (6Z,9Z)-octadecadienoic acid; major species at pH 7.3.","InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10,12-13H,2-8,11,14-17H2,1H3,(H,19,20)/p-1/b10-9-,13-12-","C18:2(omega-9), all-cis",PubMed citation,24184513
4888,78706,"(8Z,11Z)-icosadienoic acid",An icosadienoic acid in which the two double bonds have Z-geochemistry and are located at positions 8 and 11.,"InChI=1S/C20H36O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h9-10,12-13H,2-8,11,14-19H2,1H3,(H,21,22)/b10-9-,13-12-","20:2(omega-9), all-cis",PubMed citation,24184513
4889,78720,tetramethylrhodamine ethyl ester perchlorate,"An organic perchlorate salt that has tetramethylrhodamine ethyl ester(1+) as the cation. It is used as a cell-permeant, cationic, red-orange fluorescent dye that is readily sequestered by active mitochondria.","InChI=1S/C26H27N2O3.ClHO4/c1-6-30-26(29)20-10-8-7-9-19(20)25-21-13-11-17(27(2)3)15-23(21)31-24-16-18(28(4)5)12-14-22(24)25;2-1(3,4)5/h7-16H,6H2,1-5H3;(H,2,3,4,5)/q+1;/p-1",TMRE perchlorate,Reaxys Registry Number,8180460
4890,78759,"N,N-dimethylsphingosine",A sphingoid that is sphingosine in which the two amino hydrogens are replaced by methyl groups.,"InChI=1S/C20H41NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)19(18-22)21(2)3/h16-17,19-20,22-23H,4-15,18H2,1-3H3/b17-16+/t19-,20+/m0/s1","N,N-dimethylsphing-4-enine",Reaxys Registry Number,8057448
4891,78770,ethylene glycol monododecyl ether,A hydroxyether that is ethylene glycol substituted on one of the oxygens by a dodecyl group.,"InChI=1S/C14H30O2/c1-2-3-4-5-6-7-8-9-10-11-13-16-14-12-15/h15H,2-14H2,1H3",ethylene glycol monolauryl ether,CAS Registry Number,4536-30-5
4892,78772,alpha-ascarylopyranose,An ascarylopyranose that has alpha configuration at the anomeric centre.,"InChI=1S/C6H12O4/c1-3-4(7)2-5(8)6(9)10-3/h3-9H,2H2,1H3/t3-,4+,5+,6+/m0/s1","3,6-dideoxy-alpha-L-mannopyranose",Reaxys Registry Number,4903685
4893,78773,beta-ascarylopyranose,An ascarylopyranose that has beta configuration at the anomeric centre.,"InChI=1S/C6H12O4/c1-3-4(7)2-5(8)6(9)10-3/h3-9H,2H2,1H3/t3-,4+,5+,6-/m0/s1",beta-L-ascarylopyranose,Reaxys Registry Number,4903686
4894,78786,ascr#1,"An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (6R)-6-hydroxyheptanoic acid with ascarylopyranose (the alpha anomer). It is a major component of the dauer pheromone, used by the nematode Caenorhabditis elegans as a population-density signal to promote entry into an alternate larval stage, the nonfeeding and highly persistent dauer diapause. It has also been found in Pristionchus pacificus and the sour paste nematode Panagrellus redivivus.","InChI=1S/C13H24O6/c1-8(5-3-4-6-12(16)17)18-13-11(15)7-10(14)9(2)19-13/h8-11,13-15H,3-7H2,1-2H3,(H,16,17)/t8-,9+,10-,11-,13-/m1/s1",(-)-daumone,SMID accession,ascr%231%0D
4895,78805,(13Z)-octadecen-1-ol,A long-chain fatty alcohol that is stearyl alcohol which has been dehydrogenated to introduce a cis double bond between positions 13 and 14.,"InChI=1S/C18H36O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h5-6,19H,2-4,7-18H2,1H3/b6-5-",(13Z)-octadecenol,Reaxys Registry Number,2087321
4896,78817,(5R)-5-hydroxyhexan-2-one,A 5-hydroxyhexan-2-one that has R configuration.,"InChI=1S/C6H12O2/c1-5(7)3-4-6(2)8/h5,7H,3-4H2,1-2H3/t5-/m1/s1",(R)-5-hydroxyhexan-2-one,Reaxys Registry Number,6287241
4897,78839,(8R)-8-hydroxynonanoic acid,An (omega-1)-hydroxy fatty acid that is nonanoic acid in which the 8-pro-R hydrogen is replaced by a hydroxy group.,"InChI=1S/C9H18O3/c1-8(10)6-4-2-3-5-7-9(11)12/h8,10H,2-7H2,1H3,(H,11,12)/t8-/m1/s1",(R)-8-hydroxynonanoic acid,Reaxys Registry Number,5243218
4898,78842,(5R)-5-hydroxyhexanoic acid,An (omega-1)-hydroxy fatty acid that is caproic acid in which the 5-pro-R hydrogen is replaced by a hydroxy group.,"InChI=1S/C6H12O3/c1-5(7)3-2-4-6(8)9/h5,7H,2-4H2,1H3,(H,8,9)/t5-/m1/s1",(5R)-5-hydroxycaproic acid,Reaxys Registry Number,6130741
4899,78853,"(2E,9R)-9-hydroxydec-2-enoic acid",An (omega-1)-hydroxy fatty acid that is trans-2-decenoic acid in which the hydrogen at the 9-pro-R position is replaced by a hydroxy group.,"InChI=1S/C10H18O3/c1-9(11)7-5-3-2-4-6-8-10(12)13/h6,8-9,11H,2-5,7H2,1H3,(H,12,13)/b8-6+/t9-/m1/s1","(9R,2E)-(-)-9-hydroxy-2-decenoic acid",CAS Registry Number,83944-97-2
4900,78857,"2,2,3,3-tetrahydroxy-2,3-dihydronaphthalene-1,4-dione","A ketone hydrate that is naphthalene-1,2,3,4-tetrone in which water has been added to the keto groups at positions 2 and 3. It has been used as an antiviral agent in nasal ointment.","InChI=1S/C10H8O6/c11-7-5-3-1-2-4-6(5)8(12)10(15,16)9(7,13)14/h1-4,13-16H","2,3-dihydro-2,2,3,3-tetrahydroxy-1,4-naphthoquinone",PubMed citation,3016268
4901,78883,beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-beta-D-Manp,A linear mannotriose consisting of three D-mannose units joined by beta-(1->2)-linkages (with beta-configuration at the reducing-end anomeric centre). Present in the cell wall phosphomannan of Candida albicans.,"InChI=1S/C18H32O16/c19-1-4-8(23)11(26)14(16(29)30-4)33-18-15(12(27)9(24)6(3-21)32-18)34-17-13(28)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16-,17+,18+/m1/s1",beta-D-Man-(1->2)-beta-D-Man-(1->2)-beta-D-Man,PubMed citation,24601638
4902,78889,beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-beta-D-Manp-O[CH2]2NH2,A glycoside that consists of the linear trisaccharide beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-beta-D-Manp having a 2-aminoethoxy moiety at the reducing-end anomeric centre.,"InChI=1S/C20H37NO16/c21-1-2-32-19-16(13(29)10(26)7(4-23)34-19)37-20-17(14(30)11(27)8(5-24)35-20)36-18-15(31)12(28)9(25)6(3-22)33-18/h6-20,22-31H,1-5,21H2/t6-,7-,8-,9-,10-,11-,12+,13+,14+,15+,16+,17+,18+,19-,20+/m1/s1",beta-D-Man-(1->2)-beta-D-Man-(1->2)-beta-D-Man-O[CH2]2NH2,PubMed citation,24601638
4903,78891,"2,2,2-trifluoro-N-(8-hydroxyoctyl)acetamide",A trifluoroacetamide resulting from the formal condensation of the amino group of 8-aminooctan-1-ol with trifluoroacetic acid.,"InChI=1S/C10H18F3NO2/c11-10(12,13)9(16)14-7-5-3-1-2-4-6-8-15/h15H,1-8H2,(H,14,16)",8-trifluoroacetamido-1-octanol,Reaxys Registry Number,15799760
4904,78901,L-canavanine sulfate,An organic sulfate salt obtained by combining L-canavanine with one molar equivalent of sulfuric acid.,"InChI=1S/C5H12N4O3.H2O4S/c6-3(4(10)11)1-2-12-9-5(7)8;1-5(2,3)4/h3H,1-2,6H2,(H,10,11)(H4,7,8,9);(H2,1,2,3,4)/t3-;/m0./s1",L-canavanine monosulfate,CAS Registry Number,2219-31-0
4905,78902,L-canavanine(1+),An alpha-amino-acid cation that is the conjugate acid of L-canavanine; major species at pH 7.3.,"InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/p+1/t3-/m0/s1",L-canavanine cation,MetaCyc accession,CANAVANINE
4906,78909,12-HPEPE,"A hydroperoxy fatty acid that is (5Z,8Z,10E,14Z,17Z)-icosapentaenoic acid in which the hydroperoxy group is located at the 12-position.","InChI=1S/C20H30O4/c1-2-3-4-5-10-13-16-19(24-23)17-14-11-8-6-7-9-12-15-18-20(21)22/h3-4,7-11,13-14,17,19,23H,2,5-6,12,15-16,18H2,1H3,(H,21,22)/b4-3-,9-7-,11-8-,13-10-,17-14+","(5Z,8Z,10E,14Z,17Z)-12-hydroperoxyeicosapentaenoic acid",PubMed citation,3010490
4907,78940,"N-palmitoyl-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine",An N-acylphosphatidylethanolamine in which the N-acyl group is specified as palmitoyl while the phosphatidyl acyl groups are both specified as oleoyl.,"InChI=1S/C57H108NO9P/c1-4-7-10-13-16-19-22-25-27-30-33-36-39-42-45-48-56(60)64-52-54(67-57(61)49-46-43-40-37-34-31-28-26-23-20-17-14-11-8-5-2)53-66-68(62,63)65-51-50-58-55(59)47-44-41-38-35-32-29-24-21-18-15-12-9-6-3/h25-28,54H,4-24,29-53H2,1-3H3,(H,58,59)(H,62,63)/b27-25-,28-26-/t54-/m1/s1","N-hexadecanoyl-1,2-di-(9Z)-octadecenoyl-sn-glycero-3-phosphoethanolamine",PubMed citation,21880860
4908,78946,"alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-Glcp6,NAc2-(1->2)-alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc,OCH2CH2NH2",The 2-aminoethyl glycoside of an amino decasaccharide made of two alpha-L-Rhap-(1->2)-alpha-L-Rhap-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-L-Rhap-(1->3)-beta-D-GlcpNAc repeating units of the Shigella flexneri serotype 2a specific polysaccharide linked (1->2) and with the N-acetylglucosamine residue five residues from the reducing end acetylated on O-6.,"InChI=1S/C68H115N3O46/c1-16-31(78)39(86)45(92)61(99-16)116-57-43(90)33(80)17(2)100-66(57)113-54-49(96)65(104-21(6)50(54)109-62-46(93)40(87)35(82)25(12-72)106-62)112-53-30(71-23(8)76)60(108-28(38(53)85)15-98-24(9)77)115-56-42(89)32(79)19(4)102-68(56)117-58-44(91)34(81)18(3)101-67(58)114-55-48(95)64(103-20(5)51(55)110-63-47(94)41(88)36(83)26(13-73)107-63)111-52-29(70-22(7)75)59(97-11-10-69)105-27(14-74)37(52)84/h16-21,25-68,72-74,78-96H,10-15,69H2,1-9H3,(H,70,75)(H,71,76)/t16-,17-,18-,19-,20-,21-,25+,26+,27+,28+,29+,30+,31-,32-,33-,34-,35+,36+,37+,38+,39+,40-,41-,42+,43+,44+,45+,46+,47+,48+,49+,50-,51-,52+,53+,54-,55-,56+,57+,58+,59+,60-,61-,62+,63+,64-,65-,66-,67-,68-/m0/s1","2-aminoethyl alpha-L-rhamnosyl-(1->2)-alpha-L-rhamnosyl-(1->3)-[alpha-D-glucosyl-(1->4)]-alpha-L-rhamnosyl-(1->3)-6-O,N-diacetyl-beta-D-glucosaminyl-(1->2)-alpha-L-rhamnosyl-(1->2)-alpha-L-rhamnosyl-(1->3)-[alpha-D-glucosyl-(1->4)]-alpha-L-rhamnosyl-(1->3)-N-acetyl-beta-D-glucosaminide",PubMed citation,24836582
4909,78973,ascr#35,"An (omega-1)-hydroxy fatty acid ascaroside obtained by formal condensation of the alcoholic hydroxy group of (2E,19R)-19-hydroxyicos-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.","InChI=1S/C26H48O6/c1-21(31-26-24(28)20-23(27)22(2)32-26)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-19-25(29)30/h17,19,21-24,26-28H,3-16,18,20H2,1-2H3,(H,29,30)/b19-17+/t21-,22+,23-,24-,26-/m1/s1","19R-(3'R,5'R-dihydroxy-6'S-methyl-(2H)-tetrahydropyran-2'-yloxy)-2E-eicosenoic acid",CAS Registry Number,1355681-85-4
4910,79059,2-arachidonoyl-sn-glycero-3-phosphate,A 2-acyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl group is specified as arachidonoyl.,"InChI=1S/C23H39O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(25)30-22(20-24)21-29-31(26,27)28/h6-7,9-10,12-13,15-16,22,24H,2-5,8,11,14,17-21H2,1H3,(H2,26,27,28)/b7-6-,10-9-,13-12-,16-15-/t22-/m1/s1","2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphate",Reaxys Registry Number,24288607
4911,79067,1-hexanoyl-sn-glycero-3-phosphate,A 1-O-acyl-sn-glycero-3-phosphate in which the acyl group is specified as caproyl (hexanoyl).,"InChI=1S/C9H19O7P/c1-2-3-4-5-9(11)15-6-8(10)7-16-17(12,13)14/h8,10H,2-7H2,1H3,(H2,12,13,14)/t8-/m1/s1",1-caproyl-sn-glycero-3-phosphate,Reaxys Registry Number,19466849
4912,79074,"1,2-dicapryl-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycero-3-phosphate in which the acyl groups at positions 1 and 2 are specified as capryl (decanoyl).","InChI=1S/C23H45O8P/c1-3-5-7-9-11-13-15-17-22(24)29-19-21(20-30-32(26,27)28)31-23(25)18-16-14-12-10-8-6-4-2/h21H,3-20H2,1-2H3,(H2,26,27,28)/t21-/m1/s1","1,2-dicaprinyl-sn-glycero-3-phosphate",PDBeChem accession,XPA
4913,79076,3-methyl-L-tyrosine,A tyrosine derivative that is L-tyrosine in which the hydrogen at position 3 on the phenyl ring is replaced by a methyl group.,"InChI=1S/C10H13NO3/c1-6-4-7(2-3-9(6)12)5-8(11)10(13)14/h2-4,8,12H,5,11H2,1H3,(H,13,14)/t8-/m0/s1",3-methyltyrosine,CAS Registry Number,2370-57-2
4914,79077,5-hydroxy-3-methyl-L-tyrosine,A tyrosine derivative that is L-tyrosine in which the hydrogens at positions 3 and 5 on the phenyl ring are replaced by a methyl and hydroxy groups respectively.,"InChI=1S/C10H13NO4/c1-5-2-6(3-7(11)10(14)15)4-8(12)9(5)13/h2,4,7,12-13H,3,11H2,1H3,(H,14,15)/t7-/m0/s1",5-hydroxy-3-methyltyrosine,Reaxys Registry Number,9706985
4915,79079,(4S)-4-hydroxy-L-isoleucine,An  L-isoleucine derivative that is L-isoleucine bearing a (4S)-hydroxy substituent.,"InChI=1S/C6H13NO3/c1-3(4(2)8)5(7)6(9)10/h3-5,8H,7H2,1-2H3,(H,9,10)/t3-,4-,5-/m0/s1",(4S)-4-hydroxyisoleucine,CAS Registry Number,55399-93-4
4916,79082,5-methyl-1-naphthoic acid,A member of the class of naphthoic acids that is 1-naphthoic acid substituted at position 5 by a methyl group.,"InChI=1S/C12H10O2/c1-8-4-2-6-10-9(8)5-3-7-11(10)12(13)14/h2-7H,1H3,(H,13,14)",5-methylnaphthalene-1-carboxylic acid,MetaCyc accession,CPD-16514
4917,79083,3-hydroxy-5-methyl-1-naphthoic acid,A member of the class of naphthoic acids that is 1-naphthoic acid substituted at positions 3 and 5 by hydroxy and methyl groups respectively.,"InChI=1S/C12H10O3/c1-7-3-2-4-9-10(7)5-8(13)6-11(9)12(14)15/h2-6,13H,1H3,(H,14,15)",3-hydroxy-5-methyl-1-naphthalenecarboxylic acid,PubMed citation,20485749
4918,79095,N(5)-hydroxy-L-ornithine,A member of the class of hydroxylamines that is L-ornithine in which one of the N(5)-amino hydrogens is replaced by a hydroxy group.,"InChI=1S/C5H12N2O3/c6-4(5(8)9)2-1-3-7-10/h4,7,10H,1-3,6H2,(H,8,9)/t4-/m0/s1",N(5)-hydroxyornithine,PDBeChem accession,ONH
4919,79096,1-stearoyl-2-oleoyl-sn-glycero-3-phosphoserine,A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and oleoyl respectively.,"InChI=1S/C42H80NO10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(44)50-35-38(36-51-54(48,49)52-37-39(43)42(46)47)53-41(45)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,38-39H,3-17,19,21-37,43H2,1-2H3,(H,46,47)(H,48,49)/b20-18-/t38-,39+/m1/s1",1-octadecanoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphoserine,LIPID MAPS instance accession,LMGP03010025
4920,79097,"1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine","A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl substituents at positions 1 and 2 are specified as hexadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C43H74NO8P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h5,7,11,13,17-18,20-21,24,26,30,32,41H,3-4,6,8-10,12,14-16,19,22-23,25,27-29,31,33-40,44H2,1-2H3,(H,47,48)/b7-5-,13-11-,18-17-,21-20-,26-24-,32-30-/t41-/m1/s1","1-palmitoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02010095
4921,79098,"1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine","A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as octadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C46H78NO10P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-45(49)57-42(40-55-58(52,53)56-41-43(47)46(50)51)39-54-44(48)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,21-22,26,28,32,34,42-43H,3-4,6,8-10,12,14-16,18,20,23-25,27,29-31,33,35-41,47H2,1-2H3,(H,50,51)(H,52,53)/b7-5-,13-11-,19-17-,22-21-,28-26-,34-32-/t42-,43+/m1/s1","1-stearoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine",LIPID MAPS instance accession,LMGP03010040
4922,79103,"1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine","A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as octadecanoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C44H74NO10P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-43(47)55-40(38-53-56(50,51)54-39-41(45)44(48)49)37-52-42(46)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h5,7,11,13,17-18,20-21,24,26,30,32,40-41H,3-4,6,8-10,12,14-16,19,22-23,25,27-29,31,33-39,45H2,1-2H3,(H,48,49)(H,50,51)/b7-5-,13-11-,18-17-,21-20-,26-24-,32-30-/t40-,41+/m1/s1","1-palmitoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphoserine",HMDB accession,HMDB0012362
4923,79110,1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl substituents at positions 1 and 2 are specified as stearoyl and arachidonoyl respectively.","InChI=1S/C43H78NO8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,41H,3-10,12,14-16,18,20-21,23,25-27,29,31-40,44H2,1-2H3,(H,47,48)/b13-11-,19-17-,24-22-,30-28-/t41-/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphoethanolamine",Reaxys Registry Number,6089816
4924,79113,1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoserine,A 3-sn-phosphatidyl-L-serine in which the acyl substituents at positions 1 and 2 are specified as stearoyl and arachidonoyl respectively.,"InChI=1S/C44H78NO10P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-43(47)55-40(38-53-56(50,51)54-39-41(45)44(48)49)37-52-42(46)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,40-41H,3-10,12,14-16,18,20-21,23,25-27,29,31-39,45H2,1-2H3,(H,48,49)(H,50,51)/b13-11-,19-17-,24-22-,30-28-/t40-,41+/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphoserine",LIPID MAPS instance accession,LMGP03010039
4925,79161,(2E)-7-hydroxyhept-2-enoic acid,An omega-hydroxy fatty acid that is trans-2-heptenoic acid in which one of the hydrogens of the terminal methyl group is replaced by a hydroxy group.,"InChI=1S/C7H12O3/c8-6-4-2-1-3-5-7(9)10/h3,5,8H,1-2,4,6H2,(H,9,10)/b5-3+",7-hydroxy-trans-2-heptenoic acid,Reaxys Registry Number,1904098
4926,79168,(2E)-15-hydroxypentadec-2-enoic acid,An omega-hydroxy fatty acid that is trans-2-pentadecenoic acid in which one of the hydrogens of the terminal methyl group has been replaced by a hydroxy group.,"InChI=1S/C15H28O3/c16-14-12-10-8-6-4-2-1-3-5-7-9-11-13-15(17)18/h11,13,16H,1-10,12,14H2,(H,17,18)/b13-11+",trans-15-hydroxypentadec-2-enoic acid,Reaxys Registry Number,18655790
4927,79182,18-hydroxyoctadecanoic acid,An omega-hydroxy-long-chain fatty acid that is octadecanoic (stearic) acid in which one of the hydrogens of the terminal methyl group has been replaced by a hydroxy group.,"InChI=1S/C18H36O3/c19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18(20)21/h19H,1-17H2,(H,20,21)",omega-hydroxystearic acid,Reaxys Registry Number,1789809
4928,79183,"5,10-dihydro-9-dimethylallylphenazine-1-carboxylic acid","A member of the class of phenazines that is 5,10-dihydrophenazine substituted at positions 1 and 9 by carboxy and dimethylallyl groups respectively.","InChI=1S/C18H18N2O2/c1-11(2)9-10-12-5-3-7-14-16(12)20-17-13(18(21)22)6-4-8-15(17)19-14/h3-9,19-20H,10H2,1-2H3,(H,21,22)","5,10-dihydro-9-prenylphenazine-1-carboxylic acid",MetaCyc accession,CPD-16649
4929,79185,4-O-dimethylallyl-L-tyrosine,An L-tyrosine derivative in which the phenolic hydrogen is replaced by a dimethylallyl group.,"InChI=1S/C14H19NO3/c1-10(2)7-8-18-12-5-3-11(4-6-12)9-13(15)14(16)17/h3-7,13H,8-9,15H2,1-2H3,(H,16,17)/t13-/m0/s1",4-O-prenyl-L-tyrosine,Reaxys Registry Number,11092753
4930,79190,20-hydroxyicosanoic acid,An omega-hydroxy-long-chain fatty acid that is icosanoic acid (arachidonic acid) in which one of the hydrogens of the terminal methyl group has been replaced by a hydroxy group.,"InChI=1S/C20H40O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h21H,1-19H2,(H,22,23)",omega-hydroxyarachidic acid,Reaxys Registry Number,1794083
4931,79195,21-hydroxyhenicosanoic acid,An omega-hydroxy-long-chain fatty acid that is henicosanoic acid in which one of the hydrogens of the terminal methyl group has been replaced by a hydroxy group.,"InChI=1S/C21H42O3/c22-20-18-16-14-12-10-8-6-4-2-1-3-5-7-9-11-13-15-17-19-21(23)24/h22H,1-20H2,(H,23,24)",omega-hydroxyhenicosanoic acid,LIPID MAPS instance accession,LMFA01050076
4932,79206,1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoserine,A 1-alkyl-2-acyl-sn-glycero-3-phosphserine in which the alkyl and acyl groups are specified as (1Z)-octadecenyl and oleoyl respectively.,"InChI=1S/C42H80NO9P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-49-36-39(37-50-53(47,48)51-38-40(43)42(45)46)52-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,33,35,39-40H,3-17,19,21-32,34,36-38,43H2,1-2H3,(H,45,46)(H,47,48)/b20-18-,35-33-/t39-,40+/m1/s1",1-(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoserine,LIPID MAPS instance accession,LMGP03030091
4933,79207,1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoethanolamine,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and arachidonoyl respectively.,"InChI=1S/C43H78NO7P/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-36-43(45)51-42(41-50-52(46,47)49-39-37-44)40-48-38-35-33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,35,38,42H,3-10,12,14-16,18,20-21,23,25-27,29,31-34,36-37,39-41,44H2,1-2H3,(H,46,47)/b13-11-,19-17-,24-22-,30-28-,38-35-/t42-/m1/s1","1-(1Z-octadecenyl)-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02030003
4934,79211,1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoserine,A 1-alkyl-2-acyl-sn-glycero-3-phosphserine in which the alkyl and acyl groups are specified as (1Z)-octadecenyl and arachidonoyl respectively.,"InChI=1S/C44H78NO9P/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-36-43(46)54-41(39-52-55(49,50)53-40-42(45)44(47)48)38-51-37-35-33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,35,37,41-42H,3-10,12,14-16,18,20-21,23,25-27,29,31-34,36,38-40,45H2,1-2H3,(H,47,48)(H,49,50)/b13-11-,19-17-,24-22-,30-28-,37-35-/t41-,42+/m1/s1","1-(1Z-octadecenyl)-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phosphoserine",LIPID MAPS instance accession,LMGP03030090
4935,79221,3-sulfinopropionyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-sulfinopropionic acid.,"InChI=1S/C24H40N7O19P3S2/c1-24(2,19(35)22(36)27-5-3-14(32)26-6-7-54-15(33)4-8-55(44)45)10-47-53(42,43)50-52(40,41)46-9-13-18(49-51(37,38)39)17(34)23(48-13)31-12-30-16-20(25)28-11-29-21(16)31/h11-13,17-19,23,34-35H,3-10H2,1-2H3,(H,26,32)(H,27,36)(H,40,41)(H,42,43)(H,44,45)(H2,25,28,29)(H2,37,38,39)/t13-,17-,18-,19+,23-/m1/s1",3-sulfinopropionyl-coenzyme A,PubMed citation,21515777
4936,79246,"9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oyl-CoA","An acyl-CoA resulting from the formal condensation of the thiol group of coenzyme A with the 1-carboxy group of 9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oic acid.","InChI=1S/C34H52N7O19P3S/c1-33(2,28(47)31(48)37-11-9-23(44)36-12-13-64-24(45)7-4-18-19-5-6-22(43)34(19,3)10-8-20(18)42)15-57-63(54,55)60-62(52,53)56-14-21-27(59-61(49,50)51)26(46)32(58-21)41-17-40-25-29(35)38-16-39-30(25)41/h16-19,21,26-28,32,46-47H,4-15H2,1-3H3,(H,36,44)(H,37,48)(H,52,53)(H,54,55)(H2,35,38,39)(H2,49,50,51)/t18-,19-,21+,26+,27+,28-,32+,34-/m0/s1","9,17-dioxo-1,2,3,4,10,19-hexanorandrostan-5-oyl-coenzyme A",PDBeChem accession,UCA
4937,79264,bhos#28,"An omega-hydroxy fatty acid ascaroside that is (3R)-3,16-dihydroxyhexadecanoic acid (oscr#28) in which the hydroxy group at position 16 has been converted to the corresponding ascaroside. It is a metabolite of the nematode Caenorhabditis elegans.","InChI=1S/C22H42O7/c1-17-19(24)16-20(25)22(29-17)28-14-12-10-8-6-4-2-3-5-7-9-11-13-18(23)15-21(26)27/h17-20,22-25H,2-16H2,1H3,(H,26,27)/t17-,18+,19+,20+,22+/m0/s1","(3R)-16-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]-3-hydroxypalmitic acid",SMID accession,bhos%2328%0D
4938,79268,bhos#36,An omega-hydroxy fatty acid ascaroside that is oscr#36 in which the pro-R hydrogen beta to the carboxy group is replaced by a hydroxy group. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C26H50O7/c1-21-23(28)20-24(29)26(33-21)32-18-16-14-12-10-8-6-4-2-3-5-7-9-11-13-15-17-22(27)19-25(30)31/h21-24,26-29H,2-20H2,1H3,(H,30,31)/t21-,22+,23+,24+,26+/m0/s1","3R-hydroxy-20-(3'R,5'R-dihydroxy-6'S-methyl-(2H)-tetrahydropyran-2'-yloxy)-eicosanoic acid",PubMed citation,22239548
4939,79274,1-hexadecyl-2-succinyl-sn-glycero-3-phosphocholine,A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and succinyl respectively.,"InChI=1S/C28H56NO9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-22-35-24-26(38-28(32)20-19-27(30)31)25-37-39(33,34)36-23-21-29(2,3)4/h26H,5-25H2,1-4H3,(H-,30,31,33,34)/t26-/m1/s1",1-palmityl-2-succinyl-sn-glycero-3-phosphocholine,Reaxys Registry Number,9678824
4940,79276,1-hexadecyl-2-glutaryl-sn-glycero-3-phosphocholine,A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and glutaryl respectively.,"InChI=1S/C29H58NO9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-23-36-25-27(39-29(33)21-19-20-28(31)32)26-38-40(34,35)37-24-22-30(2,3)4/h27H,5-26H2,1-4H3,(H-,31,32,34,35)/t27-/m1/s1",1-palmityl-2-glutaryl-sn-glycero-3-phosphocholine,Reaxys Registry Number,9679289
4941,79277,1-palmityl-2-acetyl-sn-glycero-3-phosphate,A 1-alkyl-2-acyl-sn-glycerol 3-phosphate in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and acetyl respectively.,"InChI=1S/C21H43O7P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26-18-21(28-20(2)22)19-27-29(23,24)25/h21H,3-19H2,1-2H3,(H2,23,24,25)/t21-/m1/s1",1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphate,Reaxys Registry Number,24371746
4942,79283,1-hexadecyl-sn-glycero-3-phosphoethanolamine,A 1-alkyl-sn-glycero-3-phosphoethanolamine in which the alkyl group at C-1 is specified as hexadecyl.,"InChI=1S/C21H46NO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17-26-19-21(23)20-28-29(24,25)27-18-16-22/h21,23H,2-20,22H2,1H3,(H,24,25)/t21-/m1/s1",1-O-palmityl-2-lyso-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02060002
4943,79284,trehalulose,A glycosyl glycoside prepared from alpha-D-glucopyranosyl and beta-D-fructofuranose residues.,"InChI=1S/C12H22O11/c13-1-4-6(15)8(17)9(18)11(22-4)21-3-12(20)10(19)7(16)5(2-14)23-12/h4-11,13-20H,1-3H2/t4-,5-,6-,7-,8+,9-,10+,11+,12-/m1/s1",beta-D-Fruf-(1<->1)-alpha-D-Glcp,MetaCyc accession,CPD-15713
4944,79289,N(5)-phenyl-L-glutamine,An L-glutamine derivative obtained by the formal condensation of the side-chain carboxy group of L-glutamic acid with the amino group of aniline.,"InChI=1S/C11H14N2O3/c12-9(11(15)16)6-7-10(14)13-8-4-2-1-3-5-8/h1-5,9H,6-7,12H2,(H,13,14)(H,15,16)/t9-/m0/s1",L-gamma-glutamylaniline,Reaxys Registry Number,3207047
4945,79293,2-hydroxy-7-methoxy-5-methyl-1-naphthoyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-hydroxy-7-methoxy-5-methyl-1-naphthoic acid.,"InChI=1S/C34H46N7O19P3S/c1-17-11-18(55-4)12-20-19(17)5-6-21(42)24(20)33(47)64-10-9-36-23(43)7-8-37-31(46)28(45)34(2,3)14-57-63(53,54)60-62(51,52)56-13-22-27(59-61(48,49)50)26(44)32(58-22)41-16-40-25-29(35)38-15-39-30(25)41/h5-6,11-12,15-16,22,26-28,32,42,44-45H,7-10,13-14H2,1-4H3,(H,36,43)(H,37,46)(H,51,52)(H,53,54)(H2,35,38,39)(H2,48,49,50)/t22-,26-,27-,28+,32-/m1/s1",2-hydroxy-7-methoxy-5-methyl-1-naphthoyl-coenzyme A,Reaxys Registry Number,11087474
4946,79296,indigoidine,A member of the class of pyridone that is a dimeric blue pigment biosynthesised from L-glutamine.,"InChI=1S/C10H8N4O4/c11-5-1-3(7(15)13-9(5)17)4-2-6(12)10(18)14-8(4)16/h1-2H,11-12H2,(H,13,15,17)(H,14,16,18)/b4-3+","5,5'-diamino-4,4'-dihydroxy-3,3'-diazadiphenoquinone-(2,2')",PubMed citation,17237222
4947,79308,1-oleyl-sn-glycero-3-phosphate,A 1-alkyl-sn-glycerol 3-phosphate in which the alkyl group is specified as oleyl.,"InChI=1S/C21H43O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-26-19-21(22)20-27-28(23,24)25/h9-10,21-22H,2-8,11-20H2,1H3,(H2,23,24,25)/b10-9-/t21-/m1/s1",1-(9Z)-octadecenyl-sn-glycero-3-phosphate,Reaxys Registry Number,9881086
4948,79310,R24,"A member of the class of quinazolines that is quinazoline-2,4-diamine in which one of the hydrogens attached to the amino group at position 2 is replaced by a 3-chloro-4-methylphenyl group. It has been found to stimulate the immune defences of the nematode Caenorhabditis elegans, so affording protection from bacterial infection.","InChI=1S/C15H13ClN4/c1-9-6-7-10(8-12(9)16)18-15-19-13-5-3-2-4-11(13)14(17)20-15/h2-8H,1H3,(H3,17,18,19,20)","2-N-(3-chloro-4-methylphenyl) quinazoline-2,4-diamine",PubMed citation,22719261
4949,79312,18-hydroxyoleic acid,An omega-hydroxy fatty acid that is 18-hydroxyoctadecanoic acid which has been dehydrogenated to introduce a trans double bond at the 9-10 position.,"InChI=1S/C18H34O3/c19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18(20)21/h1-2,19H,3-17H2,(H,20,21)/b2-1-",(9Z)-18-hydroxyoctadecenoic acid,KEGG COMPOUND accession,C19616
4950,79373,ibho#20,An omega-hydroxy fatty acid ascaroside that is bhos#20 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C27H39NO8/c1-18-24(36-26(33)21-17-28-22-13-9-8-12-20(21)22)16-23(30)27(35-18)34-14-10-6-4-2-3-5-7-11-19(29)15-25(31)32/h8-9,12-13,17-19,23-24,27-30H,2-7,10-11,14-16H2,1H3,(H,31,32)/t18-,19+,23+,24+,27+/m0/s1","(3R)-12-{[3,6-dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy}-3-hydroxylauric acid",SMID accession,ibho%2320%0D
4951,79375,ibho#24,An omega-hydroxy fatty acid ascaroside that is bhos#24 in which the hydroxy group at position 4 of the ascarylopyranose moiety has been has been converted to the corresponding 1H-indole-3-carboxylate ester. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C29H43NO8/c1-20-26(38-28(35)23-19-30-24-15-11-10-14-22(23)24)18-25(32)29(37-20)36-16-12-8-6-4-2-3-5-7-9-13-21(31)17-27(33)34/h10-11,14-15,19-21,25-26,29-32H,2-9,12-13,16-18H2,1H3,(H,33,34)/t20-,21+,25+,26+,29+/m0/s1","(3R)-14-{[3,6-dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy}-3-hydroxymyristic acid",PubMed citation,22239548
4952,79377,elesclomol-Cu(II),The copper coordination entity formed from elesclomol by coordination to copper via the thiocarbonyl and hydrazino groups.,"InChI=1S/C19H20N4O2S2.Cu/c1-22(18(26)14-9-5-3-6-10-14)20-16(24)13-17(25)21-23(2)19(27)15-11-7-4-8-12-15;/h3-12H,13H2,1-2H3,(H2,20,21,24,25);/q;+2/p-2",elesclomol-Cu,Reaxys Registry Number,24095943
4953,79378,YIIKGVFWDPAC,A twelve-membered polypeptide comprising the sequence Tyr-Ile-Ile-Lys-Gly-Val-Phe-Trp-Asp-Pro-Ala-Cys. Corresponds to the P34165[22-33] fragment of mating hormone A-factor 1 from Saccharomyces cerevisiae (strain ATCC 204508/S288c).,"InChI=1S/C69H98N14O16S/c1-8-38(5)57(82-67(96)58(39(6)9-2)81-60(89)46(71)30-42-24-26-44(84)27-25-42)66(95)75-48(22-15-16-28-70)61(90)73-35-54(85)80-56(37(3)4)65(94)77-49(31-41-18-11-10-12-19-41)62(91)76-50(32-43-34-72-47-21-14-13-20-45(43)47)63(92)78-51(33-55(86)87)68(97)83-29-17-23-53(83)64(93)74-40(7)59(88)79-52(36-100)69(98)99/h10-14,18-21,24-27,34,37-40,46,48-53,56-58,72,84,100H,8-9,15-17,22-23,28-33,35-36,70-71H2,1-7H3,(H,73,90)(H,74,93)(H,75,95)(H,76,91)(H,77,94)(H,78,92)(H,79,88)(H,80,85)(H,81,89)(H,82,96)(H,86,87)(H,98,99)/t38-,39-,40-,46-,48-,49-,50-,51-,52-,53-,56-,57-,58-/m0/s1",Tyr-Ile-Ile-Lys-Gly-Val-Phe-Trp-Asp-Pro-Ala-Cys,Reaxys Registry Number,5327439
4954,79385,YW3548,A terpene lactone that is obtained from Codinea simplex and acts as an inhibitor of glycerophosphoinositol biosynthesis.,"InChI=1S/C34H54O7/c1-10-19(4)14-33(9,38)17-28(35)41-27-16-32(8)15-24-20(5)11-12-25-22(7)40-31(37)30(36)34(25,39)21(6)23(24)13-26(32)29(27)18(2)3/h11,18-19,22-27,29-30,36,38-39H,6,10,12-17H2,1-5,7-9H3/b20-11-/t19?,22-,23+,24+,25-,26-,27+,29+,30+,32-,33?,34+/m1/s1",YW-3548,PubMed citation,10574991
4955,79421,"3',6'-dihydroxy-2',4,4'-trimethoxy-chalcone","A member of the class of  chalcones that is trans-chalcone substituted by methoxy groups at positions 2', 4 and 4' and hydroxy groups at positions 3' and 6'.","InChI=1S/C18H18O6/c1-22-12-7-4-11(5-8-12)6-9-13(19)16-14(20)10-15(23-2)17(21)18(16)24-3/h4-10,20-21H,1-3H3/b9-6+","1-(3,6-Dihydroxy-2,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one",KEGG COMPOUND accession,C14894
4956,79493,"2,3-dihydro-6-hydroxy-2-(4-hydroxyphenyl)-5,7-dimethoxy-4H-1-benzopyran-4-one",A dimethoxyflavanone that is flavanone substituted by methoxy groups at positions 5 and 7 and hydroxy groups at positions 6 and 4'.,"InChI=1S/C17H16O6/c1-21-14-8-13-15(17(22-2)16(14)20)11(19)7-12(23-13)9-3-5-10(18)6-4-9/h3-6,8,12,18,20H,7H2,1-2H3","4',6-Dihydroxy-5,7-dimethoxyflavanone",KEGG COMPOUND accession,C14969
4957,79510,"2-(4-hydroxyphenyl)-5,6,7-trimethoxy-4H-1-benzopyran-4-one","A trimethoxyflavone that is flavone substituted by methoxy groups at positions 5, 6 and 7 and a hydroxy group at position 4'.","InChI=1S/C18H16O6/c1-21-15-9-14-16(18(23-3)17(15)22-2)12(20)8-13(24-14)10-4-6-11(19)7-5-10/h4-9,19H,1-3H3","4'-Hydroxy-5,6,7-trimethoxyflavone",CAS Registry Number,6938-18-7
4958,79520,"2,3-dihydro-6-hydroxy-2-(4-methoxyphenyl)-5,7-dimethoxy-4H-1-benzopyran-4-one","A methoxyflavanone that is flavanone substituted by methoxy groups at positions 5, 7 and 4' and a hydroxy group at position 6.","InChI=1S/C18H18O6/c1-21-11-6-4-10(5-7-11)13-8-12(19)16-14(24-13)9-15(22-2)17(20)18(16)23-3/h4-7,9,13,20H,8H2,1-3H3","6-Hydroxy-4',5,7-trimethoxyflavanone",CAS Registry Number,6626-61-5
4959,79542,"2,3-dihydro-2-(4-hydroxyphenyl)-5,6,7-trimethoxy-4H-1-benzopyran-4-one","A methoxyflavanone that is flavanone substituted by methoxy groups at positions 5, 6 and 7 and a hydroxy group at position 4'.","InChI=1S/C18H18O6/c1-21-15-9-14-16(18(23-3)17(15)22-2)12(20)8-13(24-14)10-4-6-11(19)7-5-10/h4-7,9,13,19H,8H2,1-3H3","4'-Hydroxy-5,6,7-trimethoxyflavanone",KEGG COMPOUND accession,C15019
4960,79553,"2-(4-hydroxyphenyl)-5,6,7,8-tetrahydroxy-4H-1-benzopyran-4-one","A pentahydroxyflavone that is flavone substituted by hydroxy groups at positions 5, 6, 7, 8, and 4' respectively.","InChI=1S/C15H10O7/c16-7-3-1-6(2-4-7)9-5-8(17)10-11(18)12(19)13(20)14(21)15(10)22-9/h1-5,16,18-21H",Nortangeretin,KEGG COMPOUND accession,C15031
4961,79570,"2,2-dimethyl-3-[4-(acetyloxy)phenyl]-4-ethyl-2H-1-benzopyran-7-ol acetate","A member of the class of  chromenes that is 2H-1-benzopyran-7-ol acetate substituted by methyl groups at positions 2 and 2, an ethyl group at position 4 and a 4-(acetyloxy)phenyl group at position 3 respectively.","InChI=1S/C23H24O5/c1-6-19-20-12-11-18(27-15(3)25)13-21(20)28-23(4,5)22(19)16-7-9-17(10-8-16)26-14(2)24/h7-13H,6H2,1-5H3","4-Ethyl-3-(p-hydroxyphenyl)-2,2-dimethyl-2H-1-benzopyran-7-ol diacetate",KEGG COMPOUND accession,C15050
4962,79571,7-hydroxy-3-(4-methoxyphenyl)-4-propyl-2H-1-benzopyran-2-one,"A hydroxycoumarin that is coumarin substituted by a hydroxy group at position 7, a propyl group at position 4 and a 4-methoxyphenyl group at position 3.","InChI=1S/C19H18O4/c1-3-4-16-15-10-7-13(20)11-17(15)23-19(21)18(16)12-5-8-14(22-2)9-6-12/h5-11,20H,3-4H2,1-2H3",7-Hydroxy-3-(4-methoxyphenyl)-4-propylcoumarin,KEGG COMPOUND accession,C15051
4963,79596,"5,6,7,4'-tetramethoxyisoflavone","A member of the class of 4'-methoxyisoflavones that is 4'-methoxyisoflavone that is also substituted by methoxy groups at positions 5, 6, 7.","InChI=1S/C19H18O6/c1-21-12-7-5-11(6-8-12)13-10-25-14-9-15(22-2)18(23-3)19(24-4)16(14)17(13)20/h5-10H,1-4H3","3-(4-Methoxyphenyl)-5,6,7-trimethoxy-4H-1-benzopyran-4-one",KEGG COMPOUND accession,C15076
4964,79628,gardenin B,A tetramethoxyflavone that is  tangeretin in which the methoxy group at position 5 has been replaced by a hydroxy group.,"InChI=1S/C19H18O7/c1-22-11-7-5-10(6-8-11)13-9-12(20)14-15(21)17(23-2)19(25-4)18(24-3)16(14)26-13/h5-9,21H,1-4H3",Demethyltangeretin,CAS Registry Number,2798-20-1
4965,79637,"2,3-dihydro-2-(4-methoxyphenyl)-5,6,7-trimethoxy-4H-1-benzopyran-4-one","A  methoxyflavanone that is  flavanone substituted by methoxy groups at positions 5, 6, 7 and 4'.","InChI=1S/C19H20O6/c1-21-12-7-5-11(6-8-12)14-9-13(20)17-15(25-14)10-16(22-2)18(23-3)19(17)24-4/h5-8,10,14H,9H2,1-4H3","4',5,6,7-Tetramethoxyflavanone",KEGG COMPOUND accession,C15118
4966,79706,3-(4-chlorophenyl)-2H-1-benzopyran-2-one,A member of the class of coumarins that is  coumarin substituted by a 4-chlorophenyl group at position 3.,InChI=1S/C15H9ClO2/c16-12-7-5-10(6-8-12)13-9-11-3-1-2-4-14(11)18-15(13)17/h1-9H,3-(p-Chlorophenyl)coumarin,KEGG COMPOUND accession,C15189
4967,79737,iprobenfos,"An organic thiophosphate that is the S-benzyl O,O-diisopropyl ester of phosphorothioic acid. Used as a rice fungicide to control leaf and ear blast, stem rot and sheath blight.","InChI=1S/C13H21O3PS/c1-11(2)15-17(14,16-12(3)4)18-10-13-8-6-5-7-9-13/h5-9,11-12H,10H2,1-4H3",Kitazin P,CAS Registry Number,26087-47-8
4968,79743,8-hydroxy-3-chlorodibenzofuran,"A member of the class of  dibenzofurans that is  dibenzo[b,d]furan substituted by a chloro group at position 7 and a hydroxy group at position 2.","InChI=1S/C12H7ClO2/c13-7-1-3-9-10-6-8(14)2-4-11(10)15-12(9)5-7/h1-6,14H",7-Chloro-2-dibenzofuranol,KEGG COMPOUND accession,C15241
4969,79744,"8-chloro-2,7-dibenzofurandiol","A member of the class of dibenzofurans that is dibenzo[b,d]furan substituted by a chloro group at position 8 and hydroxy groups at position 2 and 7.","InChI=1S/C12H7ClO3/c13-9-4-8-7-3-6(14)1-2-11(7)16-12(8)5-10(9)15/h1-5,14-15H","3,8-Dihydroxy-2-chlorodibenzofuran",KEGG COMPOUND accession,C15242
4970,79745,"3-hydroxy-2,8-dichlorodibenzofuran","A member of the class of dibenzofurans that is dibenzo[b,d]furan substituted by chloro groups at positions 2 and 8 and a hydroxy group at position 3.","InChI=1S/C12H6Cl2O2/c13-6-1-2-11-7(3-6)8-4-9(14)10(15)5-12(8)16-11/h1-5,15H","2,8-Dichloro-3-dibenzofuranol",KEGG COMPOUND accession,C15243
4971,79746,"7-hydroxy-1,2,3,6,8-pentachlorodibenzofuran","A member of the class of dibenzofurans that is dibenzo[b,d]furan substituted by a hydroxy group at position 3 and chloro groups at positions 2, 4, 7, 8 and 9 respectively.","InChI=1S/C12H3Cl5O2/c13-4-2-6-7(9(16)8(4)15)3-1-5(14)11(18)10(17)12(3)19-6/h1-2,18H","2,4,7,8,9-Pentachloro-3-dibenzofuranol",KEGG COMPOUND accession,C15244
4972,79747,"7-hydroxy-3,4-dichlorodibenzofuran","A member of the class of dibenzofurans that is dibenzo[b,d]furan substituted by a hydroxy group at position 3 and chloro groups at positions 6 and 7 respectively.","InChI=1S/C12H6Cl2O2/c13-9-4-3-8-7-2-1-6(15)5-10(7)16-12(8)11(9)14/h1-5,15H","6,7-Dichloro-3-dibenzofuranol",KEGG COMPOUND accession,C15245
4973,79748,"9-hydroxy-3,4-dichlorodibenzofuran","A member of the class of dibenzofurans that is dibenzo[b,d]furan substituted by a hydroxy group at position 1 and chloro groups at positions 6 and 7.","InChI=1S/C12H6Cl2O2/c13-7-5-4-6-10-8(15)2-1-3-9(10)16-12(6)11(7)14/h1-5,15H","6,7-Dichloro-1-dibenzofuranol",KEGG COMPOUND accession,C15246
4974,79749,"9-hydroxy-2,6-dichlorodibenzofuran","A member of the class of dibenzofurans that is dibenzo[b,d]furan substituted by a hydroxy group at position 1 and chloro groups at positions 4 and 8 respectively.","InChI=1S/C12H6Cl2O2/c13-6-1-4-10-7(5-6)11-9(15)3-2-8(14)12(11)16-10/h1-5,15H","4,8-Dichloro-1-dibenzofuranol",KEGG COMPOUND accession,C15247
4975,79750,"4-hydroxy-2',3,5,5'-tetrachlorobiphenyl","A member of the class of  hydroxybiphenyls that is biphenyl-4-ol substituted by chloro groups at positions 2', 3, 5 and 5' respectively.","InChI=1S/C12H6Cl4O/c13-7-1-2-9(14)8(5-7)6-3-10(15)12(17)11(16)4-6/h1-5,17H","2',3,5,5'-Tetrachloro-4-biphenylol",KEGG COMPOUND accession,C15248
4976,79752,"3-(3,4-dichlorophenyl)-1-hydroxy-1-methylurea","A member of the class of ureas that is  1-methylurea substituted by a hydroxy group at position 1 and a 3,4-dichlorophenyl group at position 3.","InChI=1S/C8H8Cl2N2O2/c1-12(14)8(13)11-5-2-3-6(9)7(10)4-5/h2-4,14H,1H3,(H,11,13)",Hydroxylinuron,KEGG COMPOUND accession,C15250
4977,79754,17beta-hydroxy-4alpha-methyl-5alpha-androstan-3-one,"An  androstanoid that is 5alpha-androstane substituted by a methyl group at position 4, a hydroxy group at position 17 and an oxo group at position 3.","InChI=1S/C20H32O2/c1-12-14-5-4-13-15-6-7-18(22)20(15,3)10-8-16(13)19(14,2)11-9-17(12)21/h12-16,18,22H,4-11H2,1-3H3/t12-,13-,14-,15-,16-,18-,19-,20-/m0/s1","4,5alpha-Dihydro-4alpha-methyltestosterone",KEGG COMPOUND accession,C15252
4978,79755,16beta-fluoro-17beta-hydroxyandrost-4-en-3-one propionate,A steroid ester that is androst-4-en-17beta-yl propanoate substituted by an oxo group at position 3 and a fluoro group at position 17.,"InChI=1S/C22H31FO3/c1-4-19(25)26-20-18(23)12-17-15-6-5-13-11-14(24)7-9-21(13,2)16(15)8-10-22(17,20)3/h11,15-18,20H,4-10,12H2,1-3H3/t15-,16+,17+,18+,20+,21+,22+/m1/s1",16beta-Fluorotestosterone propionate,KEGG COMPOUND accession,C15253
4979,79756,"3-(allyloxy)estra-1,3,5(10)-triene-16alpha,17beta-diol",A 16alpha-hydroxy steroid that is  estriol in which the hydroxy group at position 3 is replaced by an allyloxy group.,"InChI=1S/C21H28O3/c1-3-10-24-14-5-7-15-13(11-14)4-6-17-16(15)8-9-21(2)18(17)12-19(22)20(21)23/h3,5,7,11,16-20,22-23H,1,4,6,8-10,12H2,2H3/t16-,17-,18+,19-,20+,21+/m1/s1","3-(2-Propenyloxy)estra-1,3,5(10)-triene-16alpha,17beta-diol",KEGG COMPOUND accession,C15254
4980,79758,6alpha-fluoro-17-hydroxycorticosterone 21-acetate,"A steroid ester that is pregn-4-en-21-yl acetate substituted by oxo groups at positions 3 and 20, hydroxy groups at positions 11 and 17 and a fluoro group at position 6.","InChI=1S/C23H31FO6/c1-12(25)30-11-19(28)23(29)7-5-15-14-9-17(24)16-8-13(26)4-6-21(16,2)20(14)18(27)10-22(15,23)3/h8,14-15,17-18,20,27,29H,4-7,9-11H2,1-3H3/t14-,15-,17-,18-,20+,21-,22-,23-/m0/s1","6alpha-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione 21-acetate",KEGG COMPOUND accession,C15256
4981,79759,17beta-hydroxyestr-5(10)-en-3-one,A 3-oxo steroid that is estr-5(10)-ene substituted by an oxo group at position 3 and a beta-hydroxy group at position 17.,"InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h14-17,20H,2-10H2,1H3/t14-,15-,16+,17+,18+/m1/s1",Prenortestosterone,KEGG COMPOUND accession,C15257
4982,79760,17beta-hydroxy-2alpha-methylestr-4-en-3-one,A 3-oxo Delta(4)-steroid that is estr-4-ene substituted by a beta-hydroxy group at position 17 and an alpha-methyl group at position 2.,"InChI=1S/C19H28O2/c1-11-9-15-12(10-17(11)20)3-4-14-13(15)7-8-19(2)16(14)5-6-18(19)21/h10-11,13-16,18,21H,3-9H2,1-2H3/t11-,13+,14-,15+,16+,18+,19+/m1/s1",2alpha-Methyl-19-nortestosterone,KEGG COMPOUND accession,C15258
4983,79761,"17beta-hydroxy-2alpha,17-dimethylestr-4-en-3-one","A 3-oxo Delta(4)-steroid that is estr-4-ene substituted by an oxo group at position 3, methyl groups at positions 2 and 17 and a beta-hydroxy group at position 17.","InChI=1S/C20H30O2/c1-12-10-16-13(11-18(12)21)4-5-15-14(16)6-8-19(2)17(15)7-9-20(19,3)22/h11-12,14-17,22H,4-10H2,1-3H3/t12-,14+,15-,16+,17+,19+,20+/m1/s1","2alpha,17-Dimethyl-19-nortestosterone",KEGG COMPOUND accession,C15259
4984,79763,"estra-1,3,5(10)-triene-3,16beta-diol","A 3-hydroxy steroid that is estra-1,3,5(10)-triene substituted by hydroxy groups at positions 3 and 16.","InChI=1S/C18H24O2/c1-18-7-6-15-14-5-3-12(19)8-11(14)2-4-16(15)17(18)9-13(20)10-18/h3,5,8,13,15-17,19-20H,2,4,6-7,9-10H2,1H3/t13-,15+,16+,17-,18+/m0/s1",16beta-Estradiol,KEGG COMPOUND accession,C15261
4985,79764,"3-methoxyestra-1,3,5(10)-trien-16beta-ol","A 16beta-hydroxy steroid that is estra-1,3,5(10)-trien-16beta-ol substituted by a methoxy group at position 3.","InChI=1S/C19H26O2/c1-19-8-7-16-15-6-4-14(21-2)9-12(15)3-5-17(16)18(19)10-13(20)11-19/h4,6,9,13,16-18,20H,3,5,7-8,10-11H2,1-2H3/t13-,16+,17+,18-,19+/m0/s1",16beta-Estradiol-3-methyl ether,KEGG COMPOUND accession,C15262
4986,79765,"A-norpregn-3(5)-ene-2,20-dione",A 2-oxo steroid that is a derivative of pregnane obtained by the loss of a methylene group.,"InChI=1S/C20H28O2/c1-12(21)16-6-7-17-15-5-4-13-10-14(22)11-20(13,3)18(15)8-9-19(16,17)2/h10,15-18H,4-9,11H2,1-3H3/t15-,16+,17-,18-,19+,20-/m0/s1",A-norprogesterone,KEGG COMPOUND accession,C15263
4987,79766,17beta-hydroxy-5alpha-androstane acetate,A steroid ester that is 5alpha-androstane substituted by an acetoxy group at position 17.,"InChI=1S/C21H34O2/c1-14(22)23-19-10-9-17-16-8-7-15-6-4-5-12-20(15,2)18(16)11-13-21(17,19)3/h15-19H,4-13H2,1-3H3/t15-,16+,17+,18+,19+,20+,21+/m1/s1",17beta-Acetoxy-5alpha-androstane,KEGG COMPOUND accession,C15264
4988,79767,"16beta-methylpregn-4-ene-3,20-dione",A 3-oxo Delta(4)-steroid that is  progesterone substituted by a beta-methyl group at position 16.,"InChI=1S/C22H32O2/c1-13-11-19-17-6-5-15-12-16(24)7-9-21(15,3)18(17)8-10-22(19,4)20(13)14(2)23/h12-13,17-20H,5-11H2,1-4H3/t13-,17+,18-,19-,20+,21-,22-/m0/s1",16beta-Methylprogesterone,KEGG COMPOUND accession,C15265
4989,79770,trans-2-(4-nitrophenyl)-3-phenyloxirane,An epoxide that is oxirane substituted by a phenyl group at position 3 and a 4-nitrophenyl group at position 2 (the trans-isomer).,"InChI=1S/C14H11NO3/c16-15(17)12-8-6-11(7-9-12)14-13(18-14)10-4-2-1-3-5-10/h1-9,13-14H/t13-,14-/m0/s1","trans- alpha,alpha'-Epoxy-4-nitrobibenzyl",CAS Registry Number,14985-26-3
4990,79773,"9-fluoro-2alpha-methylpregn-4-ene-3,11,20-trione","A fluorinated steroid that is pregn-4-ene substituted by a fluoro group at position 2, a methyl group at position 2 and oxo groups at positions 3, 11 and 20.","InChI=1S/C22H29FO3/c1-12-10-21(4)14(9-18(12)25)5-6-17-16-8-7-15(13(2)24)20(16,3)11-19(26)22(17,21)23/h9,12,15-17H,5-8,10-11H2,1-4H3/t12-,15-,16+,17+,20-,21+,22+/m1/s1",9-Fluoro-2alpha-methyl-11-oxoprogesterone,KEGG COMPOUND accession,C15271
4991,79776,allobetulinol,"A triterpenoid that is (18alpha)-19,28-epoxyoleanane substituted by a hydroxy group at position 3.","InChI=1S/C30H50O2/c1-25(2)14-16-30-17-15-28(6)19(23(30)24(25)32-18-30)8-9-21-27(5)12-11-22(31)26(3,4)20(27)10-13-29(21,28)7/h19-24,31H,8-18H2,1-7H3/t19-,20+,21-,22+,23+,24-,27+,28-,29-,30-/m1/s1",Allobetulin,CAS Registry Number,1617-72-7
4992,79777,"21-acetoxy-11beta,17-dihydroxy-6alpha-methylpregn-4-ene-3,20-dione","A steroid ester that is pregn-4-en-21-yl acetate substituted by oxo group at positions 3 and 20, a methyl group at position 6 and hydroxy groups at positions 11 and 17 respectively.","InChI=1S/C24H34O6/c1-13-9-16-17-6-8-24(29,20(28)12-30-14(2)25)23(17,4)11-19(27)21(16)22(3)7-5-15(26)10-18(13)22/h10,13,16-17,19,21,27,29H,5-9,11-12H2,1-4H3/t13-,16-,17-,19-,21+,22-,23-,24-/m0/s1",17-Hydroxy-6alpha-methylcorticosterone 21-acetate,KEGG COMPOUND accession,C15275
4993,79778,2alpha-fluoro-17beta-hydroxyandrost-4-en-3-one,An  androstanoid that is androst-4-ene substituted by an alpha-fluoro group at position 2 and a beta-hydroxy group at position 17.,"InChI=1S/C19H27FO2/c1-18-8-7-14-12(13(18)5-6-17(18)22)4-3-11-9-16(21)15(20)10-19(11,14)2/h9,12-15,17,22H,3-8,10H2,1-2H3/t12-,13-,14-,15+,17-,18-,19-/m0/s1",2alpha-Fluorotestosterone,KEGG COMPOUND accession,C15276
4994,79879,B-norcholesterol,A 3beta-hydroxy-Delta(5)-steroid that is cholesterol in which a methylene (CH2) group has been removed from the B-ring.,"InChI=1S/C26H44O/c1-17(2)7-6-8-18(3)22-9-10-23-21-16-19-15-20(27)11-13-25(19,4)24(21)12-14-26(22,23)5/h16-18,20-24,27H,6-15H2,1-5H3/t18-,20+,21+,22-,23+,24+,25+,26-/m1/s1",3beta-hydroxy-B-norcholest-5-ene,KEGG COMPOUND accession,C15378
4995,79937,bis(2-butoxyethyl)phthalate,A phthalate ester obtained by the formal condensation of both the carboxy groups of phthalic acid with two molecules of  2-butoxyethanol.,"InChI=1S/C20H30O6/c1-3-5-11-23-13-15-25-19(21)17-9-7-8-10-18(17)20(22)26-16-14-24-12-6-4-2/h7-10H,3-6,11-16H2,1-2H3",beta-Butoxyethyl phthalate,CAS Registry Number,117-83-9
4996,80134,1'-hydroxytorulene,"A carotenol that is (3'E)-3',4'-didehydro-1',2'-dihydro-beta,psi-carotene which carries a hydroxy group at position 1'.","InChI=1S/C40H56O/c1-32(20-13-22-34(3)23-14-24-35(4)26-16-31-40(9,10)41)18-11-12-19-33(2)21-15-25-36(5)28-29-38-37(6)27-17-30-39(38,7)8/h11-16,18-26,28-29,41H,17,27,30-31H2,1-10H3/b12-11+,20-13+,21-15+,23-14+,26-16+,29-28+,32-18+,33-19+,34-22+,35-24+,36-25+",myxocoxanthin,KNApSAcK accession,C00022845
4997,80217,adonixanthin,"A carotenone that consists of beta,beta-caroten-4-one bearing two hydroxy substituents at positions 3 and 3' (the 3S,3'R diastereomer).","InChI=1S/C40H54O3/c1-28(17-13-19-30(3)21-23-35-32(5)25-34(41)26-39(35,7)8)15-11-12-16-29(2)18-14-20-31(4)22-24-36-33(6)38(43)37(42)27-40(36,9)10/h11-24,34,37,41-42H,25-27H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,28-15+,29-16+,30-19+,31-20+/t34-,37+/m1/s1",4-Ketozeaxanthin,KNApSAcK accession,C00000917
4998,80249,somatostatin-28,A heterodetic cyclic peptide consisting of somatostatin in which the amino terminus has been acylated by the fourteen membered peptide Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys.,"InChI=1S/C137H207N41O39S3/c1-69(154-113(194)82(37-19-22-47-138)159-115(196)85(40-25-50-149-136(145)146)160-118(199)87(44-45-106(188)189)163-116(197)86(41-26-51-150-137(147)148)164-130(211)101-43-27-52-177(101)133(214)72(4)156-114(195)88(46-54-218-7)158-110(191)71(3)155-129(210)100-42-28-53-178(100)134(215)95(61-104(144)186)171-126(207)96(65-180)172-124(205)93(59-102(142)184)165-111(192)70(2)153-112(193)80(141)64-179)109(190)152-63-105(187)157-98-67-219-220-68-99(135(216)217)174-127(208)97(66-181)173-132(213)108(74(6)183)176-125(206)91(57-77-33-15-10-16-34-77)170-131(212)107(73(5)182)175-119(200)84(39-21-24-49-140)161-122(203)92(58-78-62-151-81-36-18-17-35-79(78)81)168-121(202)90(56-76-31-13-9-14-32-76)166-120(201)89(55-75-29-11-8-12-30-75)167-123(204)94(60-103(143)185)169-117(198)83(162-128(98)209)38-20-23-48-139/h8-18,29-36,62,69-74,80,82-101,107-108,151,179-183H,19-28,37-61,63-68,138-141H2,1-7H3,(H2,142,184)(H2,143,185)(H2,144,186)(H,152,190)(H,153,193)(H,154,194)(H,155,210)(H,156,195)(H,157,187)(H,158,191)(H,159,196)(H,160,199)(H,161,203)(H,162,209)(H,163,197)(H,164,211)(H,165,192)(H,166,201)(H,167,204)(H,168,202)(H,169,198)(H,170,212)(H,171,207)(H,172,205)(H,173,213)(H,174,208)(H,175,200)(H,176,206)(H,188,189)(H,216,217)(H4,145,146,149)(H4,147,148,150)/t69-,70-,71-,72-,73+,74+,80-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,107-,108-/m0/s1",Somatostatin-2,KEGG COMPOUND accession,C16021
4999,80266,nociceptin,"A seventenn-membered polypeptide consisting of Phe, Gly, Gly, Phe, Thr, Gly, Ala, Arg, Lys, Ser, Ala, Arg, Lys, Leu, Ala, Asn and Gln residue joined in sequence.","InChI=1S/C79H129N27O22/c1-41(2)33-54(72(122)95-44(5)66(116)103-56(36-59(84)110)73(123)102-53(77(127)128)27-28-58(83)109)104-70(120)49(23-13-15-29-80)100-69(119)52(26-18-32-90-79(87)88)99-65(115)43(4)96-75(125)57(40-107)105-71(121)50(24-14-16-30-81)101-68(118)51(25-17-31-89-78(85)86)98-64(114)42(3)94-61(112)39-93-76(126)63(45(6)108)106-74(124)55(35-47-21-11-8-12-22-47)97-62(113)38-91-60(111)37-92-67(117)48(82)34-46-19-9-7-10-20-46/h7-12,19-22,41-45,48-57,63,107-108H,13-18,23-40,80-82H2,1-6H3,(H2,83,109)(H2,84,110)(H,91,111)(H,92,117)(H,93,126)(H,94,112)(H,95,122)(H,96,125)(H,97,113)(H,98,114)(H,99,115)(H,100,119)(H,101,118)(H,102,123)(H,103,116)(H,104,120)(H,105,121)(H,106,124)(H,127,128)(H4,85,86,89)(H4,87,88,90)/t42-,43-,44-,45+,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,63-/m0/s1",Orphanin FQ,KEGG COMPOUND accession,C16044
5000,80373,glycitin,"A glycosyloxyisoflavone that is isoflavone substituted by a methoxy group at position 6, a hydroxy group at position 4' and a  beta-D-glucopyranosyloxy group at position 7.","InChI=1S/C22H22O10/c1-29-15-6-12-14(30-9-13(18(12)25)10-2-4-11(24)5-3-10)7-16(15)31-22-21(28)20(27)19(26)17(8-23)32-22/h2-7,9,17,19-24,26-28H,8H2,1H3/t17-,19-,20+,21-,22-/m1/s1",Glycitein 7-O-glucoside,KEGG COMPOUND accession,C16195
5001,80393,"2',7-dihydroxy-4',5'-methylenedioxyisoflavone",A pseudobaptigenin that is pseudobaptigenin substituted by a hydroxy groups at position 2'.,"InChI=1S/C16H10O6/c17-8-1-2-9-13(3-8)20-6-11(16(9)19)10-4-14-15(5-12(10)18)22-7-21-14/h1-6,17-18H,7H2",DMI,KNApSAcK accession,C00000649
5002,80447,9(S)-HOTrE,"A 9-HOTrE consisting of (10E,12Z,15Z)-octadecatrienoic acid in which the 9-hydroxy group has S-configuration.","InChI=1S/C18H30O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h3-4,6,8,11,14,17,19H,2,5,7,9-10,12-13,15-16H2,1H3,(H,20,21)/b4-3-,8-6-,14-11+/t17-/m1/s1","(9S)-(10E,12Z,15Z)-9-Hydroxyoctadecatri-10,12,15-enoic acid",KEGG COMPOUND accession,C16326
5003,80472,"N,N'-dimethylurea",A member of the class of ureas that is urea substituted by methyl groups at positions 1 and 3.,"InChI=1S/C3H8N2O/c1-4-3(6)5-2/h1-2H3,(H2,4,5,6)","1,3-Dimethylurea",CAS Registry Number,96-31-1
5004,80486,phlorizin chalcone,"A monosaccharide derivative that is trans-chalcone substituted by hydroxy groups at positions 4, 4' and 6 and a  beta-D-glucopyranosyloxy group at position 2' respectively.","InChI=1S/C21H22O10/c22-9-16-18(27)19(28)20(29)21(31-16)30-15-8-12(24)7-14(26)17(15)13(25)6-3-10-1-4-11(23)5-2-10/h1-8,16,18-24,26-29H,9H2/b6-3+/t16-,18-,19+,20-,21-/m1/s1",Chalcone 2'-O-glucoside,KEGG COMPOUND accession,C16406
5005,80507,citronellic acid,A monounsaturated fatty acid that is oct-6-enoic acid carrying methyl groups at positions 3 and 7.,"InChI=1S/C10H18O2/c1-8(2)5-4-6-9(3)7-10(11)12/h5,9H,4,6-7H2,1-3H3,(H,11,12)",citronellic acid,KEGG COMPOUND accession,C16462
5006,80579,norcodeine,A morphinane-like compound that is the N-demethylated derivative of codeine.,"InChI=1S/C17H19NO3/c1-20-13-5-2-9-8-11-10-3-4-12(19)16-17(10,6-7-18-11)14(9)15(13)21-16/h2-5,10-12,16,18-19H,6-8H2,1H3/t10-,11+,12-,16-,17-/m0/s1",N-Desmethylcodeine,KEGG COMPOUND accession,C16576
5007,80658,"5,6-epoxyretinoic acid","A retinoid obtained by epoxidation across the 5,6-double bond of retinoic acid.","InChI=1S/C20H28O3/c1-15(8-6-9-16(2)14-17(21)22)10-13-20-18(3,4)11-7-12-19(20,5)23-20/h6,8-10,13-14H,7,11-12H2,1-5H3,(H,21,22)/b9-6+,13-10+,15-8+,16-14+","all-trans-5,6-Epoxy-5,6-dihydroretinoic acid",KEGG COMPOUND accession,C16680
5008,80832,glycyrol,"A member of the class of  coumestans that is coumestan substituted by hydroxy groups at positions  1 and 9,  a methoxy group at position 3 and a prenyl group at position 2 respectively.","InChI=1S/C21H18O6/c1-10(2)4-6-12-14(23)9-16-18(19(12)25-3)20-17(21(24)27-16)13-7-5-11(22)8-15(13)26-20/h4-5,7-9,22-23H,6H2,1-3H3",Neoglycyrol,CAS Registry Number,23013-84-5
5009,80845,liquiritin,A flavanone glycoside that is  liquiritigenin attached to a beta-D-glucopyranosyl residue at position 4' via a glycosidic linkage.,"InChI=1S/C21H22O9/c22-9-17-18(25)19(26)20(27)21(30-17)28-12-4-1-10(2-5-12)15-8-14(24)13-6-3-11(23)7-16(13)29-15/h1-7,15,17-23,25-27H,8-9H2/t15-,17+,18+,19-,20+,21+/m0/s1",liquiritigenin-4'-beta-D-glucoside,KEGG COMPOUND accession,C16989
5010,80895,plantaginin,A glycosyloxyflavone that is  scutellarein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.,"InChI=1S/C21H20O11/c22-7-14-17(26)19(28)20(29)21(32-14)31-13-6-12-15(18(27)16(13)25)10(24)5-11(30-12)8-1-3-9(23)4-2-8/h1-6,14,17,19-23,25-29H,7H2/t14-,17-,19+,20-,21-/m1/s1",Scutellarein 7beta-D-glucopyranoside,KEGG COMPOUND accession,C17056
5011,80897,rhamnocitrin,A monomethoxyflavone that is the 7-methyl ether derivative of  kaempferol.,"InChI=1S/C16H12O6/c1-21-10-6-11(18)13-12(7-10)22-16(15(20)14(13)19)8-2-4-9(17)5-3-8/h2-7,17-18,20H,1H3","3,4',5-Trihydroxy-7-methoxyflavone",CAS Registry Number,569-92-6
5012,81054,sakuranin,A flavanone glycoside that is  sakuranetin attached to a beta-D-glucopyranosyl residue at position 5 via a glycosidic linkage.,"InChI=1S/C22H24O10/c1-29-12-6-15-18(13(25)8-14(30-15)10-2-4-11(24)5-3-10)16(7-12)31-22-21(28)20(27)19(26)17(9-23)32-22/h2-7,14,17,19-24,26-28H,8-9H2,1H3/t14-,17+,19+,20-,21+,22+/m0/s1",NSC 407308,KEGG COMPOUND accession,C17391
5013,81074,genisteine,A quinolizidine alkaloid that is sparteine in which the hydrogen atom at position 6 is in the beta-configuration.,"InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14+,15+/m0/s1",genisteine-alkaloid,KEGG COMPOUND accession,C17418
5014,81240,ursocholic acid,"A bile acid that is 5beta-cholan-24-oic acid bearing three hydroxy substituents at positions 3alpha, 7beta and 12alpha.","InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19+,20+,22+,23+,24-/m1/s1","3alpha,7beta,12alpha-Trihydroxy-5beta-cholanic acid",CAS Registry Number,2955-27-3
5015,81243,alpha-muricholic acid,A member of the class of muricholic acids in which the hydroxy groups at positions 6 and 7 have beta- and alpha- configuration respectively.,"InChI=1S/C24H40O5/c1-13(4-7-19(26)27)15-5-6-16-20-17(9-11-23(15,16)2)24(3)10-8-14(25)12-18(24)21(28)22(20)29/h13-18,20-22,25,28-29H,4-12H2,1-3H3,(H,26,27)/t13-,14-,15-,16+,17+,18+,20+,21+,22+,23-,24-/m1/s1","5beta-Cholanic acid-3alpha,6beta,7alpha-triol",CAS Registry Number,2393-58-0
5016,81244,hyocholic acid,"A trihydroxy-5beta-cholanic acid in which the three hydroxy substituents are located at the 3alpha-, 6alpha- and 7alpha-positions.","InChI=1S/C24H40O5/c1-13(4-7-19(26)27)15-5-6-16-20-17(9-11-23(15,16)2)24(3)10-8-14(25)12-18(24)21(28)22(20)29/h13-18,20-22,25,28-29H,4-12H2,1-3H3,(H,26,27)/t13-,14-,15-,16+,17+,18+,20+,21-,22+,23-,24-/m1/s1",Hyocholic acid,CAS Registry Number,547-75-1
5017,81261,avicholic acid,"A trihydroxy-5beta-cholanic acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3, 7 and 16 (the 3alpha,7alpha,16alpha stereoisomer). It is a major constituent of the bile of several avian species.","InChI=1S/C24H40O5/c1-13(4-5-20(28)29)22-19(27)12-17-21-16(7-9-24(17,22)3)23(2)8-6-15(25)10-14(23)11-18(21)26/h13-19,21-22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16+,17+,18-,19-,21-,22+,23+,24+/m1/s1",Avicholic acid,KEGG COMPOUND accession,C17667
5018,81276,allodeoxycholic acid,An allo-bile acid that is 5alpha-cholan-24-oic acid bearing two alpha-hydroxy substituents at position 3 and 12.,"InChI=1S/C24H40O4/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3/h14-21,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17+,18-,19+,20+,21+,23+,24-/m1/s1",5alpha-Deoxycholic acid,KEGG COMPOUND accession,C17687
5019,81308,allocholic acid,"An allo-bile acid that is 5alpha-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.","InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14-,15-,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1","3alpha,7alpha,12alpha-Trihydroxy-5alpha-cholanoic acid",KEGG COMPOUND accession,C17737
5020,81321,1-O-feruloyl-beta-D-glucose,A beta-D-glucoside resulting from the formal condensation of the carboxy group of ferulic acid with the anomeric hydroxy group of beta-D-glucose.,"InChI=1S/C16H20O9/c1-23-10-6-8(2-4-9(10)18)3-5-12(19)25-16-15(22)14(21)13(20)11(7-17)24-16/h2-6,11,13-18,20-22H,7H2,1H3/b5-3+/t11-,13-,14+,15-,16+/m1/s1",1-Feruloyl-D-glucose,KEGG COMPOUND accession,C17759
5021,81336,pectolinarigenin,"A dimethoxyflavone that is the 6,4'-dimethyl ether derivative of  scutellarein.","InChI=1S/C17H14O6/c1-21-10-5-3-9(4-6-10)13-7-11(18)15-14(23-13)8-12(19)17(22-2)16(15)20/h3-8,19-20H,1-2H3","5,7-Dihydroxy-4',6-dimethoxyflavone",CAS Registry Number,520-12-7
5022,81337,cirsimaritin,A dimethoxyflavone that is flavone substituted by methoxy groups at positions 6 and 7 and hydroxy groups at positions 5 and 4' respectively.,"InChI=1S/C17H14O6/c1-21-14-8-13-15(16(20)17(14)22-2)11(19)7-12(23-13)9-3-5-10(18)6-4-9/h3-8,18,20H,1-2H3",Scrophulein,KEGG COMPOUND accession,C17785
5023,81461,"dTDP-4-dehydro-2,3,6-trideoxy-alpha-D-glucose","A pyrimidine nucleotide-sugar having thymine as the nucleobase and 4-dehydro-2,3,6-trideoxy-alpha-D-glucose as the sugar component.","InChI=1S/C16H24N2O13P2/c1-8-6-18(16(22)17-15(8)21)13-5-11(20)12(29-13)7-27-32(23,24)31-33(25,26)30-14-4-3-10(19)9(2)28-14/h6,9,11-14,20H,3-5,7H2,1-2H3,(H,23,24)(H,25,26)(H,17,21,22)/t9-,11+,12-,13-,14-/m1/s1","dTDP-[(2R,6R)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl] ester",Reaxys Registry Number,11232874
5024,81462,"dTDP-4-amino-2,3,4,6-tetradeoxy-alpha-D-glucose","A pyrimidine nucleotide-sugar having thymine as the nucleobase and 4-amino-2,3,4,6-tetradeoxy-alpha-D-glucose as the sugar component.","InChI=1S/C16H27N3O12P2/c1-8-6-19(16(22)18-15(8)21)13-5-11(20)12(29-13)7-27-32(23,24)31-33(25,26)30-14-4-3-10(17)9(2)28-14/h6,9-14,20H,3-5,7,17H2,1-2H3,(H,23,24)(H,25,26)(H,18,21,22)/t9-,10+,11+,12-,13-,14-/m1/s1","dTDP-[(2R,5S,6R)-5-aminotetrahydro-6-methyl-2H-pyran-2-yl] ester",KEGG COMPOUND accession,C18033
5025,81463,dTDP-alpha-D-forosamine,A pyrimidine nucleotide-sugar having thymine as the nucleobase and alpha-D-forosamine as the sugar component.,"InChI=1S/C18H31N3O12P2/c1-10-8-21(18(24)19-17(10)23)15-7-13(22)14(31-15)9-29-34(25,26)33-35(27,28)32-16-6-5-12(20(3)4)11(2)30-16/h8,11-16,22H,5-7,9H2,1-4H3,(H,25,26)(H,27,28)(H,19,23,24)/t11-,12+,13+,14-,15-,16-/m1/s1","dTDP-[(2R,5S,6R)-5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl] ester",KEGG COMPOUND accession,C18034
5026,81467,7alpha-hydroxypregnenolone,A 20-oxo steroid that is pregnenolone carrying an additional hydroxy substituent at the 7alpha-position.,"InChI=1S/C21H32O3/c1-12(22)15-4-5-16-19-17(7-9-21(15,16)3)20(2)8-6-14(23)10-13(20)11-18(19)24/h11,14-19,23-24H,4-10H2,1-3H3/t14-,15+,16-,17-,18+,19-,20-,21+/m0/s1","3beta,7alpha-Dihydroxy-5-pregnen-20-one",KEGG COMPOUND accession,C18038
5027,81468,5alpha-dihydrodeoxycorticosterone,A 3-oxo-5alpha-steroid formed from 11-deoxycorticosterone by reduction across the C4-C5 double bond.,"InChI=1S/C21H32O3/c1-20-9-7-14(23)11-13(20)3-4-15-16-5-6-18(19(24)12-22)21(16,2)10-8-17(15)20/h13,15-18,22H,3-12H2,1-2H3/t13-,15-,16-,17-,18+,20-,21-/m0/s1","5alpha-pregnan-21-ol-3,20-dione",CAS Registry Number,298-36-2
5028,81471,7alpha-hydroxydehydroepiandrosterone,An androstanoid that is dehydroepiandrosterone carrying an additional hydroxy substituent at the 7alpha-position.,"InChI=1S/C19H28O3/c1-18-7-5-12(20)9-11(18)10-15(21)17-13-3-4-16(22)19(13,2)8-6-14(17)18/h10,12-15,17,20-21H,3-9H2,1-2H3/t12-,13-,14-,15+,17-,18-,19-/m0/s1",7alpha-OH-DHEA,KEGG COMPOUND accession,C18045
5029,81481,11beta-hydroxytestosterone,An androstanoid that is testosterone carrying an additional hydroxy substituent at the 11beta-position.,"InChI=1S/C19H28O3/c1-18-8-7-12(20)9-11(18)3-4-13-14-5-6-16(22)19(14,2)10-15(21)17(13)18/h9,13-17,21-22H,3-8,10H2,1-2H3/t13-,14-,15-,16-,17+,18-,19-/m0/s1",11beta-Hydroxytestosterone,CAS Registry Number,1816-85-9
5030,81544,3-(1-hydroxyethyl)bacteriochlorophyllide a,A chlorophyllide obtained by hydrolysis of the terpenoid ester moiety of 3-(1-hydroxyethyl)bacteriochlorophyll a.,"InChI=1S/C35H40N4O6.Mg/c1-8-19-14(2)21-13-26-28(18(6)40)16(4)23(37-26)11-22-15(3)20(9-10-27(41)42)32(38-22)30-31(35(44)45-7)34(43)29-17(5)24(39-33(29)30)12-25(19)36-21;/h11-15,18-20,31,40H,8-10H2,1-7H3,(H3,36,37,38,39,41,42,43);/q;+2/p-2/t14-,15+,18?,19-,20+,31-;/m1./s1",3-Hydroxyethylbacteriochlorophyllide a,KEGG COMPOUND accession,C18153
5031,81545,3-(1-hydroxyethyl)chlorophyllide a,A chlorophyllide obtained by hydrolysis of the terpenoid ester moiety of 3-(1-hydroxyethyl)chlorophyll a.,"InChI=1S/C35H38N4O6.Mg/c1-8-19-14(2)21-13-26-28(18(6)40)16(4)23(37-26)11-22-15(3)20(9-10-27(41)42)32(38-22)30-31(35(44)45-7)34(43)29-17(5)24(39-33(29)30)12-25(19)36-21;/h11-13,15,18,20,31,40H,8-10H2,1-7H3,(H3,36,37,38,39,41,42,43);/q;+2/p-2/t15-,18?,20-,31+;/m0./s1",3-Hydroxyethylchlorophyllide a,KEGG COMPOUND accession,C18154
5032,81559,resolvin E1,"A resolvin that is (6Z,8E,10E,14Z,16E)-icosa-6,8,10,14,16-pentaenoic acid which is substituted at positions 5, 12 and 18 by hydroxy groups (the 5S,12R,18R stereoisomer).","InChI=1S/C20H30O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-9,11-13,17-19,21-23H,2,10,14-16H2,1H3,(H,24,25)/b4-3+,9-5-,11-8+,12-6+,13-7-/t17-,18+,19-/m1/s1","5S,12R,18R-Trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid",KEGG COMPOUND accession,C18171
5033,81560,resolvin E2,"A member of the class of resolvins that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid carrying two hydroxy substituents at positions 5 and 18 (the 5S,18R stereoisomer).","InChI=1S/C20H30O4/c1-2-18(21)14-11-9-7-5-3-4-6-8-10-12-15-19(22)16-13-17-20(23)24/h3-4,7-12,14-15,18-19,21-22H,2,5-6,13,16-17H2,1H3,(H,23,24)/b4-3-,9-7-,10-8-,14-11+,15-12+/t18-,19-/m1/s1","5S,18R-Dihydroxy-6E,8Z,11Z,14Z,16E-eicosapentaenoic acid",KEGG COMPOUND accession,C18173
5034,81563,18(R)-HEPE,"An 18-HEPE that consists of (5Z,8Z,11Z,14Z,16E)-icosapentaenoic in which the 18-hydroxy group has R-configuration.","InChI=1S/C20H30O3/c1-2-19(21)17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18-20(22)23/h4-7,10-13,15,17,19,21H,2-3,8-9,14,16,18H2,1H3,(H,22,23)/b6-4-,7-5-,12-10-,13-11-,17-15+/t19-/m1/s1","18R-Hydroxy-5Z,8Z,11Z,14Z,16E-eicosapentaenoic acid",KEGG COMPOUND accession,C18177
5035,81564,resolvin D1,"A resolvin that is docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid which is substituted by hydroxy groups at the 7, 8, and 17 positions (the 7S,8R,17S-stereoisomer).","InChI=1S/C22H32O5/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20(24)21(25)17-12-8-13-18-22(26)27/h3-12,15-16,19-21,23-25H,2,13-14,17-18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,12-8-,15-10+,16-11+/t19-,20+,21-/m0/s1","7S,8R,17S-Trihydroxydocosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid",KEGG COMPOUND accession,C18178
5036,81582,"2,4-dibromophenyl 2,4,5-tribromophenyl ether","A polybromodiphenyl ether that is diphenyl ether in which the hydrogens at the 2, 4, 5, 2', and 4' positions have been replaced by bromines.",InChI=1S/C12H5Br5O/c13-6-1-2-11(9(16)3-6)18-12-5-8(15)7(14)4-10(12)17/h1-5H,PBDE 99,KEGG COMPOUND accession,C18203
5037,81667,2-hydroxy-5-methylquinone,"A member of the class of monohydroxy-1,4-benzoquinones that is 2-hydroxy-1,4-benzoquinone carrying an additional methyl substituent at position 5.","InChI=1S/C7H6O3/c1-4-2-6(9)7(10)3-5(4)8/h2-3,10H,1H3","2-Hydroxy-5-methyl-1,4-benzoquinone",KEGG COMPOUND accession,C18316
5038,81672,(2S)-methylsuccinyl-CoA,An acyl-CoA resulting from the formal condensation of the thiol group of coenzyme A with the 1-carboxy group of (2S)-methylsuccinic acid.,"InChI=1S/C26H42N7O19P3S/c1-13(8-16(35)36)25(40)56-7-6-28-15(34)4-5-29-23(39)20(38)26(2,3)10-49-55(46,47)52-54(44,45)48-9-14-19(51-53(41,42)43)18(37)24(50-14)33-12-32-17-21(27)30-11-31-22(17)33/h11-14,18-20,24,37-38H,4-10H2,1-3H3,(H,28,34)(H,29,39)(H,35,36)(H,44,45)(H,46,47)(H2,27,30,31)(H2,41,42,43)/t13-,14+,18+,19+,20-,24+/m0/s1",Methylsuccinyl-coenzyme A,KEGG COMPOUND accession,C18324
5039,81687,sodium L-ascorbic acid 2-phosphate,An organic sodium salt that is the trisodium salt of L-ascorbic acid 2-phosphate. It is a stable vitamin C derivative which is a highly effective antioxidant that has demonstrated efficacy in treating acne.,"InChI=1S/C6H9O9P.3Na/c7-1-2(8)4-3(9)5(6(10)14-4)15-16(11,12)13;;;/h2,4,7-9H,1H2,(H2,11,12,13);;;/q;3*+1/p-3/t2-,4+;;;/m0.../s1",VCP-Na,CAS Registry Number,66170-10-3
5040,81694,"5,6,6'-trihydroxy-5'-methoxy[biphenyl]-3,3'-dicarboxylic acid","A dicarboxylic acid that is 5,5',6,6'-tetrahydroxy[biphenyl]-3,3'dicarboxylic acid in which one of the hydroxy groups that is meta to a carboxy group has been converted into the corresponding methyl ether.","InChI=1S/C15H12O8/c1-23-11-5-7(15(21)22)3-9(13(11)18)8-2-6(14(19)20)4-10(16)12(8)17/h2-5,16-18H,1H3,(H,19,20)(H,21,22)","2,2',3-trihydroxy-3'-methoxy-5,5'-dicarboxybiphenyl",KEGG COMPOUND accession,C18348
5041,81711,chlorhexidine acetate,"The acetate salt of chlorhexidine. It is a disinfectant used for bacterial control in hospital, agricultural and domestic environments.","InChI=1S/C22H30Cl2N10.2C2H4O2/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18;2*1-2(3)4/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34);2*1H3,(H,3,4)",chlorhexidine diacetate,KEGG DRUG accession,D07669
5042,81761,etridiazole,"A member of the class of  thiadiazoles that is 1,2,4-thiadiazole which is substituted at positions 3 and 5 by trichloromethyl and ethoxy groups, respectively. A fungicide, it has been used particularly for the control of Phytophthora and Pythium species in soils.","InChI=1S/C5H5Cl3N2OS/c1-2-11-4-9-3(10-12-4)5(6,7)8/h2H2,1H3",Echlomezole,CAS Registry Number,2593-15-9
5043,81806,2-methyl-4-chlorophenoxybutyric acid,A monocarboxylic acid that is butyric acid substituted by a 2-methyl-4-chlorophenoxy group at position 4.,"InChI=1S/C11H13ClO3/c1-8-7-9(12)4-5-10(8)15-6-2-3-11(13)14/h4-5,7H,2-3,6H2,1H3,(H,13,14)",MCPB,Pesticides accession,mcpb
5044,81844,ferimzone,"A member of the class of pyrimidines that is 2-hydrazino-4,6-dimethylpyrimidine in which the two amino hydrogens are replaced by a 1-(2-methylphenyl)ethylidene group. It is used for the control of fungal diseases in rice.","InChI=1S/C15H18N4/c1-10-7-5-6-8-14(10)13(4)18-19-15-16-11(2)9-12(3)17-15/h5-9H,1-4H3,(H,16,17,19)/b18-13-",(Z)-Ferimzone,KEGG COMPOUND accession,C18579
5045,81887,jadomycin A,"A organic heteropentacyclic compound that is 1,2,8,13-tetrahydro-3aH-benzo[b][1,3]oxazolo[3,2-f]phenanthridine which carries oxo groups at positions 2, 8 and 13, methyl group at position 5, hydroxy groups at positions 7 and 12, and a (2R)-butan-2-yl group at position 1. It is a mixture of epimers at the hemiaminal carbon (position 3a).","InChI=1S/C24H21NO6/c1-4-11(3)19-24(30)31-23-13-8-10(2)9-15(27)16(13)18-20(25(19)23)22(29)17-12(21(18)28)6-5-7-14(17)26/h5-9,11,19,23,26-27H,4H2,1-3H3/t11-,19-,23?/m0/s1",jadomycin B aglycon,KEGG COMPOUND accession,C18680
5046,82043,tebutam,A monocarboxylic acid amide that is propanamide substituted by a benzyl and an isopropyl group at the nitrogen atom and two methyl groups at position 2. It is an agrochemical used as a herbicide.,"InChI=1S/C15H23NO/c1-12(2)16(14(17)15(3,4)5)11-13-9-7-6-8-10-13/h6-10,12H,11H2,1-5H3",Butam,CAS Registry Number,35256-85-0
5047,82044,tecnazene,"A C-nitro compound that is nitrobenzene in which the four hydrogens located ortho- and para- to the nitro group have been replaced by chlorines. A fungicide used to control dry rot, it is no longer approved for use within the European Union.",InChI=1S/C6HCl4NO2/c7-2-1-3(8)5(10)6(4(2)9)11(12)13/h1H,"2,3,5,6-Tetrachloro-1-nitrobenzene",PubMed citation,18800534
5048,82204,(4R)-7-hydroxy-4-isopropenyl-7-methyloxepan-2-one,A 7-hydroxy-4-isopropenyl-7-methyloxepan-2-one that has R configuration at position 4.,"InChI=1S/C10H16O3/c1-7(2)8-4-5-10(3,12)13-9(11)6-8/h8,12H,1,4-6H2,2-3H3/t8-,10?/m1/s1",(4R)-7-Hydroxy-4-isopropenyl-7-methyloxepan-2-one,KEGG COMPOUND accession,C19079
5049,82270,bis(chloromethyl) ether,An ether that is dimethyl ether in which one of the hydrogens attached to each of the methyl group has replaced by a chlorine.,InChI=1S/C2H4Cl2O/c3-1-5-2-4/h1-2H2,BCME,KEGG COMPOUND accession,C19158
5050,82288,o-anisidine,A substituted aniline that is aniline in which the hydrogen ortho to the amino group has been replaced by a methoxy group. It is used as a chemical intermediate in the synthesis of azo pigments and dyes.,"InChI=1S/C7H9NO/c1-9-7-5-3-2-4-6(7)8/h2-5H,8H2,1H3",o-anisidine,KEGG COMPOUND accession,C19191
5051,82292,benzo[c]phenanthrene,An ortho-fused polycyclic arene resulting from the symmetrical fusion of the C1-C2 bonds of two naphthalene units.,InChI=1S/C18H12/c1-3-7-16-13(5-1)9-11-15-12-10-14-6-2-4-8-17(14)18(15)16/h1-12H,"3,4-Benzphenanthrene",CAS Registry Number,195-19-7
5052,82611,"2-O,3-dimethylflaviolin",A member of the class of naphthoquinones that is 2-O-methylflaviolin in which the hydrogen at position 3 is  replaced by a methyl group.,"InChI=1S/C12H10O5/c1-5-10(15)9-7(11(16)12(5)17-2)3-6(13)4-8(9)14/h3-4,13-14H,1-2H3",2-methoxy-3-methylflaviolin,MetaCyc accession,CPD-16658
5053,82624,"trehalose 6,6'-dimycolate","A trehalose mycolate compound consisting of two C58 mycolate groups attached to the 6- and 6'-positions of alpha,alpha'-trehalose. A mycobacterial cell wall glycolipid.","InChI=1S/C130H250O15/c1-5-9-13-17-21-25-29-33-37-41-43-45-47-49-51-53-57-61-65-69-81-89-97-105-117(131)115(103-95-87-79-73-71-77-85-93-101-113-107-111(113)99-91-83-75-67-63-59-55-39-35-31-27-23-19-15-11-7-3)127(139)141-109-119-121(133)123(135)125(137)129(143-119)145-130-126(138)124(136)122(134)120(144-130)110-142-128(140)116(118(132)106-98-90-82-70-66-62-58-54-52-50-48-46-44-42-38-34-30-26-22-18-14-10-6-2)104-96-88-80-74-72-78-86-94-102-114-108-112(114)100-92-84-76-68-64-60-56-40-36-32-28-24-20-16-12-8-4/h111-126,129-138H,5-110H2,1-4H3/t111?,112?,113?,114?,115?,116?,117?,118?,119-,120-,121-,122-,123+,124+,125-,126-,129-,130-/m1/s1",trehalose dimycolate,Wikipedia accession,Cord_factor
5054,82627,15(R)-HPETE,"A HPETE that is (5Z,8Z,11Z,13E,15R)-icosa-5,8,11,13-tetraenoic acid with the hydroperoxy group located at position 15 (the R-enantiomer).","InChI=1S/C20H32O4/c1-2-3-13-16-19(24-23)17-14-11-9-7-5-4-6-8-10-12-15-18-20(21)22/h4-5,8-11,14,17,19,23H,2-3,6-7,12-13,15-16,18H2,1H3,(H,21,22)/b5-4-,10-8-,11-9-,17-14+/t19-/m1/s1","(5Z,8Z,11Z,13E,15R)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid",Reaxys Registry Number,5347290
5055,82635,4-nitrophenyl acetate,A phenyl acetate resulting from the formal condensation of the hydroxy group of 4-nitrophenol with the carboxy group of acetic acid.,"InChI=1S/C8H7NO4/c1-6(10)13-8-4-2-7(3-5-8)9(11)12/h2-5H,1H3",p-nitrophenyl acetate,PubMed citation,3090030
5056,82636,dodecyl(triphenyl)phosphonium,A polyatomic cation consisting of a dodecyl group and three phenyl groups attached to a central phosphonium.,"InChI=1S/C30H40P/c1-2-3-4-5-6-7-8-9-10-20-27-31(28-21-14-11-15-22-28,29-23-16-12-17-24-29)30-25-18-13-19-26-30/h11-19,21-26H,2-10,20,27H2,1H3/q+1",dodecyltriphenylphosphonium,Reaxys Registry Number,3596853
5057,82640,dermaseptin s3(1-16)-NH2,"A sixteen membered polypeptide consisting of Ala, Leu, Trp, Lys, Asn, Met, Leu, Lys, Gly, Ile, Gly, Lys, Leu, Ala, Gly and Lys-NH2 residues joined in sequence. A fragment of the amphibian skin peptide dermaseptin s3","InChI=1S/C80H139N23O17S/c1-12-47(8)67(80(120)91-42-65(106)94-55(27-17-21-32-83)72(112)99-58(35-44(2)3)75(115)92-49(10)70(110)89-41-64(105)93-53(68(87)108)25-15-19-30-81)103-66(107)43-90-71(111)54(26-16-20-31-82)95-76(116)60(37-46(6)7)100-74(114)57(29-34-121-11)97-79(119)62(39-63(86)104)102-73(113)56(28-18-22-33-84)96-78(118)61(38-50-40-88-52-24-14-13-23-51(50)52)101-77(117)59(36-45(4)5)98-69(109)48(9)85/h13-14,23-24,40,44-49,53-62,67,88H,12,15-22,25-39,41-43,81-85H2,1-11H3,(H2,86,104)(H2,87,108)(H,89,110)(H,90,111)(H,91,120)(H,92,115)(H,93,105)(H,94,106)(H,95,116)(H,96,118)(H,97,119)(H,98,109)(H,99,112)(H,100,114)(H,101,117)(H,102,113)(H,103,107)/t47-,48-,49-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,67-/m0/s1",L-Ala-L-Leu-L-Trp-L-Lys-L-Asn-L-Met-L-Leu-L-Lys-Gly-L-Ile-Gly-L-Lys-L-Leu-L-Ala-Gly-L-Lys-NH2,Reaxys Registry Number,9472800
5058,82646,alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,An amino nonasaccharide that is the linear hexasaccharide alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl residue nearest the reducing end has the branched trisaccharide alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man attached at position 6.,"InChI=1S/C58H98N2O46/c1-12(68)59-23-32(77)44(19(8-66)92-50(23)89)101-51-24(60-13(2)69)33(78)45(20(9-67)98-51)102-56-43(88)47(104-57-49(38(83)29(74)17(6-64)96-57)106-58-48(37(82)28(73)18(7-65)97-58)105-55-41(86)36(81)27(72)16(5-63)95-55)31(76)22(100-56)11-91-53-42(87)46(103-54-40(85)35(80)26(71)15(4-62)94-54)30(75)21(99-53)10-90-52-39(84)34(79)25(70)14(3-61)93-52/h14-58,61-67,70-89H,3-11H2,1-2H3,(H,59,68)(H,60,69)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45-,46+,47+,48+,49+,50?,51+,52+,53+,54-,55-,56+,57-,58-/m1/s1",alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,PubMed citation,7954510
5059,82650,BODIPY-3823,"A BODIPY compound that is 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene substituted at position 5 by a methyl group and at position 3 by a 11-carboxyundecyl group.","InChI=1S/C22H31BF2N2O2/c1-18-13-14-20-17-21-16-15-19(27(21)23(24,25)26(18)20)11-9-7-5-3-2-4-6-8-10-12-22(28)29/h13-17H,2-12H2,1H3,(H,28,29)","4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid",PubMed citation,9079682
5060,82651,biotinylated alpha-gal,Biotin linked to the alpha-gal epitope through a 6-amino-N-(3-hydroxypropyl)hexanamide spacer.,"InChI=1S/C39H67N5O19S/c1-18(48)42-27-30(53)34(62-38-33(56)35(29(52)21(15-46)60-38)63-37-32(55)31(54)28(51)20(14-45)59-37)22(16-47)61-36(27)58-13-7-12-41-24(49)9-3-2-6-11-40-25(50)10-5-4-8-23-26-19(17-64-23)43-39(57)44-26/h19-23,26-38,45-47,51-56H,2-17H2,1H3,(H,40,50)(H,41,49)(H,42,48)(H2,43,44,57)/t19-,20+,21+,22+,23-,26-,27+,28-,29-,30+,31-,32+,33+,34+,35-,36?,37+,38-/m0/s1",biotinylated alpha-gal,PubMed citation,24750173
5061,82662,DH334,An organic bromide salt having 9-benzyl-2-butyl-1-(2-chlorophenyl)-9H-beta-carbolin-2-ium as the counterion,"InChI=1S/C28H26ClN2.BrH/c1-2-3-18-30-19-17-23-22-13-8-10-16-26(22)31(20-21-11-5-4-6-12-21)28(23)27(30)24-14-7-9-15-25(24)29;/h4-17,19H,2-3,18,20H2,1H3;1H/q+1;/p-1",DH 334,PubMed citation,17622795
5062,82664,iron(0),An elemental iron in which the atom has an oxidation state of zero.,InChI=1S/Fe,iron metal,CAS Registry Number,7439-89-6
5063,82667,DH335,An organic bromide salt having 9-benzyl-2-butyl-9H-beta-carbolin-2-ium as the counterion,"InChI=1S/C22H23N2.BrH/c1-2-3-14-23-15-13-20-19-11-7-8-12-21(19)24(22(20)17-23)16-18-9-5-4-6-10-18;/h4-13,15,17H,2-3,14,16H2,1H3;1H/q+1;/p-1",DH-335,PubMed citation,17622795
5064,82670,ELQ-271,A member of the class of quinolones that is 2-methylquinolin-4(1H)-one in which the hydrogen at position 3 is replaced by a 4-[4-(trifluoromethoxy)phenoxy]phenyl group. A potent inhibitor of Toxoplasma gondii growth.,"InChI=1S/C23H16F3NO3/c1-14-21(22(28)19-4-2-3-5-20(19)27-14)15-6-8-16(9-7-15)29-17-10-12-18(13-11-17)30-23(24,25)26/h2-13H,1H3,(H,27,28)",ELQ271,Reaxys Registry Number,22410512
5065,82672,pomecin A,"A polyunsaturated fatty acid that is tetradec-9-ene-11,13-diynoic acid in which the terminal acetylenic hydrogen is replaced by a 2-furyl group. Shows potent and broad-spectrum activity in vitro against Candida, Aspergillus, and Trichophyton spp.,","InChI=1S/C18H20O3/c19-18(20)15-11-9-7-5-3-1-2-4-6-8-10-13-17-14-12-16-21-17/h2,4,12,14,16H,1,3,5,7,9,11,15H2,(H,19,20)/b4-2-",EV-086,Reaxys Registry Number,21180385
5066,82674,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,An amino nonasaccharide that is the linear pentasaccharide alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl residue nearest the reducing end has the branched tetrasaccharide alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man attached at position 6.,"InChI=1S/C58H98N2O46/c1-12(68)59-23-32(77)44(19(8-66)92-50(23)89)101-51-24(60-13(2)69)33(78)45(20(9-67)98-51)102-56-43(88)47(104-58-49(38(83)29(74)18(7-65)97-58)106-55-41(86)36(81)27(72)16(5-63)95-55)31(76)22(100-56)10-90-52-42(87)46(103-53-39(84)34(79)25(70)14(3-61)93-53)30(75)21(99-52)11-91-57-48(37(82)28(73)17(6-64)96-57)105-54-40(85)35(80)26(71)15(4-62)94-54/h14-58,61-67,70-89H,3-11H2,1-2H3,(H,59,68)(H,60,69)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45-,46+,47+,48+,49+,50?,51+,52+,53-,54-,55-,56+,57+,58-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,KEGG GLYCAN accession,G00432
5067,82676,alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,An amino octasaccharide that is the linear hexasaccharide alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl residue nearest the reducing end has the disaccharide alpha-D-Man-(1->3)-alpha-D-Man attached at position 6.,"InChI=1S/C52H88N2O41/c1-11(62)53-21-29(70)39(18(8-60)82-45(21)80)90-46-22(54-12(2)63)30(71)40(19(9-61)88-46)91-50-38(79)42(28(69)20(89-50)10-81-47-37(78)41(27(68)17(7-59)83-47)92-48-35(76)31(72)23(64)13(3-55)84-48)93-51-44(34(75)26(67)15(5-57)86-51)95-52-43(33(74)25(66)16(6-58)87-52)94-49-36(77)32(73)24(65)14(4-56)85-49/h13-52,55-61,64-80H,3-10H2,1-2H3,(H,53,62)(H,54,63)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,37+,38+,39-,40-,41+,42+,43+,44+,45?,46+,47+,48-,49-,50+,51-,52-/m1/s1",alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->3)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,KEGG GLYCAN accession,G00522
5068,82684,7-O-methylvitexin 2''-O-beta-L-rhamnoside,A dihydroxyflavone that is vitexin having a beta-L-rhamnosyl residue attached at the 2''-position of the glucitol moiety and a methyl group attached at the O-7 position of the chromene.,"InChI=1S/C28H32O14/c1-10-20(33)22(35)24(37)28(39-10)42-27-23(36)21(34)17(9-29)41-26(27)19-16(38-2)8-14(32)18-13(31)7-15(40-25(18)19)11-3-5-12(30)6-4-11/h3-8,10,17,20-24,26-30,32-37H,9H2,1-2H3/t10-,17+,20-,21+,22+,23-,24+,26-,27+,28+/m0/s1",isoswertisin 2''-O-beta-L-rhamnoside,Reaxys Registry Number,20848896
5069,82688,alpha-L-Fucp-(1->6)-D-GlcpNAc,An amino disaccharide consisting of N-acetyl-D-glucosamine having an alpha-L-fucosyl residue attached at the 6-position.,"InChI=1S/C14H25NO10/c1-4-8(17)11(20)12(21)14(24-4)23-3-6-9(18)10(19)7(13(22)25-6)15-5(2)16/h4,6-14,17-22H,3H2,1-2H3,(H,15,16)/t4-,6+,7+,8+,9+,10+,11+,12-,13?,14+/m0/s1",alpha-L-Fuc-(1->6)-D-GlcNAc,Reaxys Registry Number,1691425
5070,82691,alpha-D-GalpA-(1->4)-alpha-D-GalpA-(1->4)-alpha-D-GalpA,A trisaccharide in which three alpha-D-galactopyranuronic acid units are joined via (1->4)-linkages.,"InChI=1S/C18H26O19/c19-1-2(20)10(13(26)27)36-17(6(1)24)35-9-4(22)7(25)18(37-12(9)15(30)31)34-8-3(21)5(23)16(32)33-11(8)14(28)29/h1-12,16-25,32H,(H,26,27)(H,28,29)(H,30,31)/t1-,2+,3+,4+,5+,6+,7+,8+,9+,10-,11-,12-,16-,17-,18-/m0/s1",alpha-D-GalA-(1->4)-alpha-D-GalA-(1->4)-alpha-D-GalA,Reaxys Registry Number,1278480
5071,82692,alpha-D-GalpA-(1->4)-alpha-D-GalpA-(1->4)-alpha-D-GalpA-(1->4)-alpha-D-GalpA,A tetraisaccharide in which four alpha-D-galactopyranuronic acid units are joined via (1->4)-linkages.,"InChI=1S/C24H34O25/c25-1-2(26)13(17(34)35)47-22(7(1)31)45-11-4(28)9(33)24(49-15(11)19(38)39)46-12-5(29)8(32)23(48-16(12)20(40)41)44-10-3(27)6(30)21(42)43-14(10)18(36)37/h1-16,21-33,42H,(H,34,35)(H,36,37)(H,38,39)(H,40,41)/t1-,2+,3+,4+,5+,6+,7+,8+,9+,10+,11+,12+,13-,14-,15-,16-,21-,22-,23-,24-/m0/s1",tetragalacturonic acid,Reaxys Registry Number,1420317
5072,82694,alpha-D-GlcpA4Me-(1->2)-beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-beta-D-Xylp,A tetrasaccharide derivative that consists of an 4-O-methyl-alpha-D-glucuronosyl residue attached at the 2-position of the non-reducing end of xylotriose.,"InChI=1S/C22H36O19/c1-34-15-11(27)14(30)21(41-17(15)18(31)32)40-16-8(24)5(23)2-36-22(16)39-7-4-37-20(13(29)10(7)26)38-6-3-35-19(33)12(28)9(6)25/h5-17,19-30,33H,2-4H2,1H3,(H,31,32)/t5-,6-,7-,8+,9+,10+,11-,12-,13-,14-,15+,16-,17+,19-,20+,21+,22+/m1/s1",alpha-D-GlcA4Me-(1->2)-beta-D-Xyl-(1->4)-beta-D-Xyl-(1->4)-beta-D-Xyl,PubMed citation,10368143
5073,82727,5'-GAAACAC-3' RNA fragment,"An RNA fragment comprised of one guanosine, four adenosine and two cytidine residues connected by 3'->5' phosphodiester linkages in the sequence G-A-A-A-C-A-C.","InChI=1S/C68H85N31O43P6/c69-28-1-3-93(67(110)89-28)59-36(102)35(101)22(131-59)6-124-143(112,113)139-45-25(134-61(39(45)105)95-16-84-30-49(71)76-12-80-53(30)95)9-127-145(116,117)138-44-23(132-60(38(44)104)94-4-2-29(70)90-68(94)111)7-126-146(118,119)140-47-26(135-63(41(47)107)97-18-86-32-51(73)78-14-82-55(32)97)10-129-148(122,123)142-48-27(136-64(42(48)108)98-19-87-33-52(74)79-15-83-56(33)98)11-128-147(120,121)141-46-24(133-62(40(46)106)96-17-85-31-50(72)77-13-81-54(31)96)8-125-144(114,115)137-43-21(5-100)130-65(37(43)103)99-20-88-34-57(99)91-66(75)92-58(34)109/h1-4,12-27,35-48,59-65,100-108H,5-11H2,(H,112,113)(H,114,115)(H,116,117)(H,118,119)(H,120,121)(H,122,123)(H2,69,89,110)(H2,70,90,111)(H2,71,76,80)(H2,72,77,81)(H2,73,78,82)(H2,74,79,83)(H3,75,91,92,109)/t21-,22-,23-,24-,25-,26-,27-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,59-,60-,61-,62-,63-,64-,65-/m1/s1",GpApApApCpApC,PubMed citation,24952597
5074,82729,N(2)-acetyl-6-formylpterin,Pterin acetylated on N-2 and carrying a formyl group at position 6.,"InChI=1S/C9H7N5O3/c1-4(16)11-9-13-7-6(8(17)14-9)12-5(3-15)2-10-7/h2-3H,1H3,(H2,10,11,13,14,16,17)",acetyl-6-formylpterin,PubMed citation,25049336
5075,82742,"(8Z,11Z)-icosadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (8Z,11Z)-icosadienoic acid.","InChI=1S/C41H70N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-32(50)69-25-24-43-31(49)22-23-44-39(53)36(52)41(2,3)27-62-68(59,60)65-67(57,58)61-26-30-35(64-66(54,55)56)34(51)40(63-30)48-29-47-33-37(42)45-28-46-38(33)48/h11-12,14-15,28-30,34-36,40,51-52H,4-10,13,16-27H2,1-3H3,(H,43,49)(H,44,53)(H,57,58)(H,59,60)(H2,42,45,46)(H2,54,55,56)/b12-11-,15-14-/t30-,34-,35-,36+,40-/m1/s1","(8Z,11Z)-eicosadienoyl-coenzyme A",LIPID MAPS instance accession,LMFA07050061
5076,82749,"(6Z,9Z)-octadecadienoic acid",An octadecadienoic acid in which the two double bonds have Z-geochemistry and are located at positions 6 and 9.,"InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10,12-13H,2-8,11,14-17H2,1H3,(H,19,20)/b10-9-,13-12-","C18:2(6Z,9Z)",LIPID MAPS instance accession,LMFA01030332
5077,82750,cholesteryl stearate,A cholesterol ester obtained by the formal condensation of the hydroxy group in cholesterol with the carboxy group of stearic acid.,"InChI=1S/C45H80O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-43(46)47-38-30-32-44(5)37(34-38)26-27-39-41-29-28-40(36(4)24-22-23-35(2)3)45(41,6)33-31-42(39)44/h26,35-36,38-42H,7-25,27-34H2,1-6H3/t36-,38+,39+,40-,41+,42+,44+,45-/m1/s1",Cholest-5-en-3-beta-yl octadecanoate,PubMed citation,9020103
5078,82751,cholesteryl arachidonate,A cholesterol ester obtained by the formal condensation of the hydroxy group in cholesterol with the carboxy group of arachidonic acid.,"InChI=1S/C47H76O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-27-45(48)49-40-32-34-46(5)39(36-40)28-29-41-43-31-30-42(38(4)26-24-25-37(2)3)47(43,6)35-33-44(41)46/h11-12,14-15,17-18,20-21,28,37-38,40-44H,7-10,13,16,19,22-27,29-36H2,1-6H3/b12-11-,15-14-,18-17-,21-20-/t38-,40+,41+,42-,43+,44+,46+,47-/m1/s1","cholest-5-en-3beta-yl (5Z,8Z,11Z,14Z-icosatetraenoate)",PubMed citation,9020103
5079,82753,1-oleoyl-sn-glycero-3-phospho-D-myo-inositol,A 1-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the acyl group is specified as oleoyl.,"InChI=1S/C27H51O12P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(29)37-18-20(28)19-38-40(35,36)39-27-25(33)23(31)22(30)24(32)26(27)34/h9-10,20,22-28,30-34H,2-8,11-19H2,1H3,(H,35,36)/b10-9-/t20-,22-,23-,24+,25-,26-,27-/m1/s1",1-(9Z)-octadecenoyl-sn-glycero-3-phospho-D-myo-inositol,LIPID MAPS instance accession,LMGP06050005
5080,82762,1-oleoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol,1-acyl-2-arachidonoyl-sn-glycero-3-phospho-D-myo-inositol in which the 1-acyl group is specified as oleoyl.,"InChI=1S/C47H81O13P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(49)59-39(38-58-61(55,56)60-47-45(53)43(51)42(50)44(52)46(47)54)37-57-40(48)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17-19,21-22,24,28,30,39,42-47,50-54H,3-10,12,14-16,20,23,25-27,29,31-38H2,1-2H3,(H,55,56)/b13-11-,19-17-,21-18-,24-22-,30-28-/t39-,42-,43-,44+,45-,46-,47-/m1/s1","1-(9Z)-octadecenoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phospho-1D-myo-inosito",LIPID MAPS instance accession,LMGP06010849
5081,82763,1-heptadecanoyl-2-arachidonoyl-sn-glycero-3-phosphate,A 1-acyl-2-arachidonoyl-sn-glycero-3-phosphate(2-) in which the 1-acyl substituent is specified as heptadecanoyl,"InChI=1S/C40H71O8P/c1-3-5-7-9-11-13-15-17-19-20-21-23-25-27-29-31-33-35-40(42)48-38(37-47-49(43,44)45)36-46-39(41)34-32-30-28-26-24-22-18-16-14-12-10-8-6-4-2/h11,13,17,19,21,23,27,29,38H,3-10,12,14-16,18,20,22,24-26,28,30-37H2,1-2H3,(H2,43,44,45)/b13-11-,19-17-,23-21-,29-27-/t38-/m1/s1","1-heptadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010003
5082,82832,"(5Z,11Z,14Z)-icosatrienoic acid","An icosatrienoic acid in which the three double bonds have Z configuration and are located at positions 5, 11 and 14.","InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,15-16H,2-5,8,11-14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,16-15-","all-cis-5,11,14-icosatrienoic acid",PubMed citation,22178003
5083,82835,"(5Z,11Z,14Z,17Z)-icosatetraenoic acid","An icosatetraenoic acid in which the four double bonds have Z configuration and are located at positions 5, 11, 14 and 17.","InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,15-16H,2,5,8,11-14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,16-15-","all-cis-5,11,14,17-icosatetraenoic acid",PubMed citation,18758077
5084,82837,1-oleoyl-2-palmitoleoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as oleoyl and palmitoleoyl respectively.","InChI=1S/C39H74NO8P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(41)45-35-37(36-47-49(43,44)46-34-33-40)48-39(42)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h14,16-18,37H,3-13,15,19-36,40H2,1-2H3,(H,43,44)/b16-14-,18-17-/t37-/m1/s1",1-(9Z)-octadecenoyl-2-(9Z)-hexadecenoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02011198
5085,82839,1-oleoyl-2-palmitoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as oleoyl and palmitoyl respectively.","InChI=1S/C39H76NO8P/c1-3-5-7-9-11-13-15-17-18-20-21-23-25-27-29-31-38(41)45-35-37(36-47-49(43,44)46-34-33-40)48-39(42)32-30-28-26-24-22-19-16-14-12-10-8-6-4-2/h17-18,37H,3-16,19-36,40H2,1-2H3,(H,43,44)/b18-17-/t37-/m1/s1",1-(9Z)-octadecenoyl-2-hexadecanoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02010099
5086,82840,1-oleoyl-2-myristoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as oleoyl and myristoyl respectively.","InChI=1S/C37H72NO8P/c1-3-5-7-9-11-13-15-16-17-18-20-21-23-25-27-29-36(39)43-33-35(34-45-47(41,42)44-32-31-38)46-37(40)30-28-26-24-22-19-14-12-10-8-6-4-2/h16-17,35H,3-15,18-34,38H2,1-2H3,(H,41,42)/b17-16-/t35-/m1/s1",1-(9Z)-octadecenoyl-2-tetradecanoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02011199
5087,82916,3-(1H-indol-3-yl)propanoate,A monocarboxylic acid anion that is the conjugate base of 3-(1H-indol-3-yl)propanoic acid.,"InChI=1S/C11H11NO2/c13-11(14)6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12H,5-6H2,(H,13,14)/p-1",indolepropionate,Reaxys Registry Number,3907068
5088,82954,"1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3',5'-bisphosphate)","A 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate in which both phosphatidyl acyl groups are specified as palmitoyl (hexadecanoyl).","InChI=1S/C41H81O19P3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)55-31-33(57-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-56-63(53,54)60-41-37(45)39(58-61(47,48)49)36(44)40(38(41)46)59-62(50,51)52/h33,36-41,44-46H,3-32H2,1-2H3,(H,53,54)(H2,47,48,49)(H2,50,51,52)/t33-,36-,37-,38-,39-,40+,41-/m1/s1","dipalmitoyl-L-alpha-phosphatidyl-D-myo-inositol 3,5-bisphosphate",Reaxys Registry Number,8104723
5089,82959,N-hexanoylsphingosine 1-phosphate(2-),A ceramide 1-phosphate(2-) in which the ceramide N-acyl group is specified as hexanoyl; major species at pH 7.3.,"InChI=1S/C24H48NO6P/c1-3-5-7-8-9-10-11-12-13-14-15-16-18-19-23(26)22(21-31-32(28,29)30)25-24(27)20-17-6-4-2/h18-19,22-23,26H,3-17,20-21H2,1-2H3,(H,25,27)(H2,28,29,30)/p-2/b19-18+/t22-,23+/m0/s1",CerP(d18:1/6:0),PubMed citation,15939762
5090,82963,"1,2-dipalmitoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate)",A 1-phosphatidyl-1D-myo-inositol 3-phosphate in which both phosphatidyl acyl groups are specified as palmitoyl (hexadecanoyl).,"InChI=1S/C41H80O16P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)53-31-33(55-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-54-59(51,52)57-41-38(46)36(44)37(45)40(39(41)47)56-58(48,49)50/h33,36-41,44-47H,3-32H2,1-2H3,(H,51,52)(H2,48,49,50)/t33-,36+,37+,38-,39-,40-,41+/m1/s1","1,2-dihexadecanoyl-sn-glycero-3-phospho-(1'D-myo-inositol-3'-phosphate)",Reaxys Registry Number,8136657
5091,83029,beta-D-talopyranose,A D-talopyranose with a beta-configuration at the anomeric position.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5+,6-/m1/s1",beta-D-talose,Reaxys Registry Number,1723629
5092,83032,4-O-beta-D-glucosyl-trans-4-coumaric acid,A 4-O-beta-D-glucosyl-4-coumaric acid in which the double bond has trans-configuration.,"InChI=1S/C15H18O8/c16-7-10-12(19)13(20)14(21)15(23-10)22-9-4-1-8(2-5-9)3-6-11(17)18/h1-6,10,12-16,19-21H,7H2,(H,17,18)/b6-3+/t10-,12-,13+,14-,15-/m1/s1",trans-beta-D-glucosyl-4-hydroxycinnamic acid,Reaxys Registry Number,3563646
5093,83055,"1-[(11Z,14Z)]-icosadienoyl-sn-glycero-3-phosphocholine","A lysophosphatidylcholine 20:2 in which the acyl group is specified as (11Z,14Z)-icosadienoyl and is located at position 1.","InChI=1S/C28H54NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-28(31)34-25-27(30)26-36-37(32,33)35-24-23-29(2,3)4/h9-10,12-13,27,30H,5-8,11,14-26H2,1-4H3/b10-9-,13-12-/t27-/m1/s1",1-eicosadienoylglycerophosphocholine,HMDB accession,HMDB0010392
5094,83155,adenosine 5'-hexadecylphosphate,An adenosine 5'-phosphate that is the monohexadecyl ester of AMP.,"InChI=1S/C26H46N5O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-36-39(34,35)37-17-20-22(32)23(33)26(38-20)31-19-30-21-24(27)28-18-29-25(21)31/h18-20,22-23,26,32-33H,2-17H2,1H3,(H,34,35)(H2,27,28,29)/t20-,22-,23-,26-/m1/s1",hexadecyl-AMP,Reaxys Registry Number,1198661
5095,83201,desferrialbomycin epsilon,A member of the class of desferrialbomycins that is desferrialbomycin delta1 in which the oxo group at position 4 of the pyrimidone moiety is replaced by an imino group. The iron(III) complex of desferrialbomycin epsilon is the antibiotic albomycin epsilon.,"InChI=1S/C36H59N11O17S/c1-17(49)45(62)12-5-8-20(37)30(55)39-21(9-6-13-46(63)18(2)50)31(56)40-22(10-7-14-47(64)19(3)51)32(57)41-23(16-48)33(58)42-25(35(59)60)26(52)29-27(53)28(54)34(65-29)44-15-11-24(38)43(4)36(44)61/h11,15,20-23,25-29,34,38,48,52-54,62-64H,5-10,12-14,16,37H2,1-4H3,(H,39,55)(H,40,56)(H,41,57)(H,42,58)(H,59,60)/t20-,21-,22-,23-,25+,26-,27+,28+,29+,34+/m0/s1",deferrialbomycin epsilon,Reaxys Registry Number,5230031
5096,83215,albomycin delta2,An iron(III) hydroxamate in which desferrialbomycin delta2(3-) is complexed to iron(III).,"InChI=1S/C37H57N12O18S.Fe/c1-17(51)47(65)12-5-8-20(38)30(57)40-21(9-6-13-48(66)18(2)52)31(58)41-22(10-7-14-49(67)19(3)53)32(59)42-23(16-50)33(60)44-25(35(61)62)26(54)29-27(55)28(56)34(68-29)46-15-11-24(43-36(39)63)45(4)37(46)64;/h11,15,20-23,25-29,34,50,54-56H,5-10,12-14,16,38H2,1-4H3,(H2,39,63)(H,40,57)(H,41,58)(H,42,59)(H,44,60)(H,61,62);/q-3;+3/b43-24+;/t20-,21-,22-,23-,25+,26-,27+,28+,29+,34+;/m0./s1",albomycin delta(2),PubMed citation,22704654
5097,83221,methyl 2-hydroxypropionate,A lactate ester resulting from the formal condensation of the carboxy group of 2-hydroxypropanoic acid with methanol.,"InChI=1S/C4H8O3/c1-3(5)4(6)7-2/h3,5H,1-2H3",methyl lactate,CAS Registry Number,547-64-8
5098,83222,methyl (S)-lactate,A methyl 2-hydroxypropionate that has S configuration.,"InChI=1S/C4H8O3/c1-3(5)4(6)7-2/h3,5H,1-2H3/t3-/m0/s1",(-)-2-hydroxypropanoic acid methyl ester,CAS Registry Number,27871-49-4
5099,83239,"1,2-dibutyryl-sn-glycero-3-phospho-(1'D-myo-inositol-5'-phosphate)",A 1-phosphatidyl-1D-myo-inositol 5-phosphate in which both phosphatidyl acyl groups are specified as butanoyl.,"InChI=1S/C17H32O16P2/c1-3-5-10(18)29-7-9(31-11(19)6-4-2)8-30-35(27,28)33-17-14(22)12(20)13(21)16(15(17)23)32-34(24,25)26/h9,12-17,20-23H,3-8H2,1-2H3,(H,27,28)(H2,24,25,26)/t9-,12-,13-,14-,15-,16+,17-/m1/s1","1,2-dibutanoyl-sn-glycero-3-phospho-(1'D-myo-inositol-5'-phosphate)",Reaxys Registry Number,25649102
5100,83240,"1,2-dibutyryl-sn-glycero-3-phospho-(1'D-myo-inositol)",A 1-phosphatidyl-1D-myo-inositol in which the two phosphatidyl acyl groups are specified as butanoyl.,"InChI=1S/C17H31O13P/c1-3-5-10(18)27-7-9(29-11(19)6-4-2)8-28-31(25,26)30-17-15(23)13(21)12(20)14(22)16(17)24/h9,12-17,20-24H,3-8H2,1-2H3,(H,25,26)/t9-,12-,13-,14+,15-,16-,17-/m1/s1","1,2-dibutanoyl-sn-glycero-3-phospho-(1'D-myo-inositol)",CAS Registry Number,148504-92-1
5101,83257,N-(2-hydroxyhexanoyl)-beta-D-galactosylsphinganine,A N-(2-hydroxyacyl)-beta-D-galactosylsphinganine in which the ceramide N-acyl group is specified as 2-hydroxyhexanoyl.,"InChI=1S/C30H59NO9/c1-3-5-7-8-9-10-11-12-13-14-15-16-17-19-23(33)22(31-29(38)24(34)18-6-4-2)21-39-30-28(37)27(36)26(35)25(20-32)40-30/h22-28,30,32-37H,3-21H2,1-2H3,(H,31,38)/t22-,23+,24?,25+,26-,27-,28+,30+/m0/s1",N-(2-hydroxyhexanoyl)-beta-D-galactosyldihydrosphingosine,PubMed citation,8713090
5102,83305,oritavancin bisphosphate,A phosphate salt obtained by combining oritavancin with two molar equivalents of phosphoric acid. Used for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.,"InChI=1S/C86H97Cl3N10O26.2H3O4P/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114;2*1-5(2,3)4/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117);2*(H3,1,2,3,4)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-;;/m0../s1",oritavancin phosphate,KEGG DRUG accession,D05271
5103,83308,dioleoylphosphatidate(2-),A phosphatidate(2-) obtained by deprotonation of both phosphate OH groups of dioleoylphosphatidic acid; major species at pH 7.3.,"InChI=1S/C39H73O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)45-35-37(36-46-48(42,43)44)47-39(41)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,37H,3-16,21-36H2,1-2H3,(H2,42,43,44)/p-2/b19-17-,20-18-","1,2-di-(9Z)-octadecenoylglycero-3-phosphate",PubMed citation,8034597
5104,83314,vorapaxar sulfate,"An organic sulfate salt obtained by combining vorapaxar with one molar equivalent of sulfuric acid. A protease-activated receptor-1 antagonist used for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.","InChI=1S/C29H33FN2O4.H2O4S/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18;1-5(2,3)4/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34);(H2,1,2,3,4)/b12-9+;/t17-,20+,23-,24-,25+,26-,27+;/m1./s1",vorapaxar monosulfate,KEGG DRUG accession,D09766
5105,83345,metrafenone,"A member of the class of benzophenones that is benzophenone in which one of the phenyl groups is substituted by methoxy groups at positions 2, 3, and 4 and by a methyl group at position 6, while the other is substituted at positions 2, 3, and 6 by methyl, bromine, and methoxy groups, respectively. A fungicide with protectant and curative properties, it is used for the control of powdery mildew in cereals and grape vines.","InChI=1S/C19H21BrO5/c1-10-9-14(23-4)18(24-5)19(25-6)15(10)17(21)16-11(2)12(20)7-8-13(16)22-3/h7-9H,1-6H3",metrafenone,Pesticides accession,metrafenone
5106,83346,pyriofenone,An aromatic ketone that is metrafenone in which the 3-bromo-6-methoxy-2-methylphenyl group is replaced by a 5-chloro-2-methoxy-4-methylpyridin-3-yl group. It is a fungicide developed for the control of powdery mildew in cereals and grape vines.,"InChI=1S/C18H20ClNO5/c1-9-7-12(22-3)16(23-4)17(24-5)13(9)15(21)14-10(2)11(19)8-20-18(14)25-6/h7-8H,1-6H3",pyriofenone,Pesticides accession,pyriofenone
5107,83353,eliglustat tartrate,A tartrate that is the hemitartrate salt of eliglustat. A ceramide glucosyltransferase inhibitor used (as its tartrate salt) for treatment of Gaucher's disease.,"InChI=1S/2C23H36N2O4.C4H6O6/c2*1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20;5-1(3(7)8)2(6)4(9)10/h2*10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26);1-2,5-6H,(H,7,8)(H,9,10)/t2*19-,23-;1-,2-/m111/s1",eliglustat hemitartrate,KEGG DRUG accession,D09894
5108,83354,benzamidoxime,A member of the class of amidoximes obtained by formal condensation of the carbonyl group of benzamide with hydroxylamine.,"InChI=1S/C7H8N2O/c8-7(9-10)6-4-2-1-3-5-6/h1-5,10H,(H2,8,9)",benzamide oxime,PubMed citation,24035094
5109,83395,(R)-fipronil,"A 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile that has R configuration at the sulfoxide.","InChI=1S/C12H4Cl2F6N4OS/c13-5-1-4(11(15,16)17)2-6(14)8(5)24-10(22)9(7(3-21)23-24)26(25)12(18,19)20/h1-2H,22H2/t26-/m1/s1",(R)-(-)-fipronil,PubMed citation,24742550
5110,83396,(S)-fipronil,"A 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile that has S configuration at the sulfoxide.","InChI=1S/C12H4Cl2F6N4OS/c13-5-1-4(11(15,16)17)2-6(14)8(5)24-10(22)9(7(3-21)23-24)26(25)12(18,19)20/h1-2H,22H2/t26-/m0/s1",(S)-(+)-fipronil,PubMed citation,25077813
5111,83406,MS-417,"A member of the class of thienotriazolodiazepines that is the methyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. A bromodomain and extra-terminal domain (BET)-specific inhibitor that belongs to a group of thienodiazepine-based compounds","InChI=1S/C20H19ClN4O2S/c1-10-11(2)28-20-17(10)18(13-5-7-14(21)8-6-13)22-15(9-16(26)27-4)19-24-23-12(3)25(19)20/h5-8,15H,9H2,1-4H3/t15-/m0/s1",MS417,PDBeChem accession,0S6
5112,83427,(Z)-dimethomorph,"An enamide resulting from the formal condensation of (2Z)-3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acrylic acid with the amino group of morpholine. The agricultural fungicide dimethomorph is a mixture of (E)- and (Z)-dimethomorph; only the Z isomer has fungicidal activity.","InChI=1S/C21H22ClNO4/c1-25-19-8-5-16(13-20(19)26-2)18(15-3-6-17(22)7-4-15)14-21(24)23-9-11-27-12-10-23/h3-8,13-14H,9-12H2,1-2H3/b18-14-","(2Z)-3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)-1-(morpholin-4-yl)prop-2-en-1-one",Reaxys Registry Number,11343579
5113,83431,[5-(ammoniomethyl)-3-furyl]methyl phosphate(1-),An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups and protonation of the amino group of [5-(aminomethyl)-3-furyl]methyl phosphate; major species at pH 7.3.,"InChI=1S/C6H10NO5P/c7-2-6-1-5(3-11-6)4-12-13(8,9)10/h1,3H,2,4,7H2,(H2,8,9,10)/p-1",5-(aminomethyl)-3-furanmethanol phosphate,MetaCyc accession,CPD-7644
5114,83444,4-(5-O-phospho-beta-D-ribofuranosyl)phenol,A ribose monophosphate that is D-ribofuranose 5-phosphate in which the anomeric OH group is replaced by a 4-hydroxy phenyl group (the beta-D-anomer).,"InChI=1S/C11H15O8P/c12-7-3-1-6(2-4-7)11-10(14)9(13)8(19-11)5-18-20(15,16)17/h1-4,8-14H,5H2,(H2,15,16,17)/t8-,9-,10-,11+/m1/s1",4-(beta-D-ribofuranosyl)hydroxybenzene 5'-phosphate,PubMed citation,21634403
5115,83490,"3,5,6-trichloropyridine-2-one","A pyridone that is pyridin-2(1H)-one substituted by chloro groups at positions 3, 5 and 6. It is a metabolite of the agrochemical chlorpyrifos.","InChI=1S/C5H2Cl3NO/c6-2-1-3(7)5(10)9-4(2)8/h1H,(H,9,10)","3,5,6-trichloro-2-pyridin-2-one",Reaxys Registry Number,1448677
5116,83507,N-ethylperfluorooctane sulfonamidoacetic acid,A sulfonamide that is the N-ethyl derivative of perfluorooctane sulfonamidoacetic acid.,"InChI=1S/C12H8F17NO4S/c1-2-30(3-4(31)32)35(33,34)12(28,29)10(23,24)8(19,20)6(15,16)5(13,14)7(17,18)9(21,22)11(25,26)27/h2-3H2,1H3,(H,31,32)",2-(N-ethyl-perfluorooctane sulfonamido) acetic acid,Reaxys Registry Number,1811212
5117,83518,"4,5-dichloro-2-n-octyl-3(2H)-isothiazolone","A 1,2-thiazole that is 1,2-thiazol-3(2H)-one substituted by chloro groups at positions 4 and 5 and an octyl group at position 2. It is used as a fungicide.","InChI=1S/C11H17Cl2NOS/c1-2-3-4-5-6-7-8-14-11(15)9(12)10(13)16-14/h2-8H2,1H3",DCOIT,PubMed citation,24850171
5118,83527,O-desmethylvenlafaxine,"A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.","InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3",4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol,Reaxys Registry Number,4234613
5119,83554,N(4)-aminopropylspermine,A polyazaalkane that is spermine in which the amino hydrogen at postion 4 is replaced by a 3-aminopropyl group,"InChI=1S/C13H33N5/c14-6-3-10-17-9-1-2-11-18(12-4-7-15)13-5-8-16/h17H,1-16H2",N(4)-(3-aminopropyl)spermine,Reaxys Registry Number,9937953
5120,83574,"(R)-3,5-bisphosphomevalonic acid",A carboxyalkyl phosphate that is mevalonic acid phosphorylated at positions 3 and 5.,"InChI=1S/C6H14O10P2/c1-6(4-5(7)8,16-18(12,13)14)2-3-15-17(9,10)11/h2-4H2,1H3,(H,7,8)(H2,9,10,11)(H2,12,13,14)/t6-/m1/s1","(R)-3,5-diphosphomevalonic acid",MetaCyc accession,MEVALONATE-DP
5121,83579,3-(methylthio)propanoyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-(methylthio)propionic acid.,"InChI=1S/C25H42N7O17P3S2/c1-25(2,20(36)23(37)28-6-4-15(33)27-7-9-54-16(34)5-8-53-3)11-46-52(43,44)49-51(41,42)45-10-14-19(48-50(38,39)40)18(35)24(47-14)32-13-31-17-21(26)29-12-30-22(17)32/h12-14,18-20,24,35-36H,4-11H2,1-3H3,(H,27,33)(H,28,37)(H,41,42)(H,43,44)(H2,26,29,30)(H2,38,39,40)/t14-,18-,19-,20+,24-/m1/s1",3-(methylthio)propanoyl-coenzyme A,MetaCyc accession,CPD-13546
5122,83605,"3,5-diethoxycarbonyl-1,4-dihydrocollidine","A dihydropyridine that is 2,4,6-trimethyl-1,4-dihydropyridine substituted by ethoxycarbonyl groups at positions 3 and 5.","InChI=1S/C14H21NO4/c1-6-18-13(16)11-8(3)12(14(17)19-7-2)10(5)15-9(11)4/h8,15H,6-7H2,1-5H3",DDC,Reaxys Registry Number,227619
5123,83642,juvenile hormone III bisepoxide,"A juvenile hormone that is methyl farnesoate in which the 6,7 and 10,11-double bonds have been epoxidised.","InChI=1S/C16H26O4/c1-11(10-14(17)18-5)6-7-13-16(4,20-13)9-8-12-15(2,3)19-12/h10,12-13H,6-9H2,1-5H3/b11-10+/t12-,13+,16+/m1/s1",JH III bisepoxide,PubMed citation,23586995
5124,83643,juvenile hormone III skipped bisepoxide,"A juvenile hormone that is methyl farnesoate in which the 2,3 and 10,11-double bonds have been epoxidised. Found in the stink bug, Plautia stali.","InChI=1S/C16H26O4/c1-11(8-9-12-15(2,3)19-12)7-6-10-16(4)13(20-16)14(17)18-5/h7,12-13H,6,8-10H2,1-5H3/b11-7+/t12-,13+,16+/m1/s1",JH III skipped bisepoxide,PubMed citation,23586995
5125,83656,luminespib,"A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-(2,4-dihydroxy-5-isopropylphenyl)-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxylic acid with the amino group of ethylamine.","InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NVP-AUY922,Wikipedia accession,NVP-AUY922
5126,83676,11-PAHSA(1-),"A long-chain fatty acid anion that is the conjugate base of 11-PAHSA, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C34H66O4/c1-3-5-7-9-10-11-12-13-14-15-19-23-27-31-34(37)38-32(28-24-20-8-6-4-2)29-25-21-17-16-18-22-26-30-33(35)36/h32H,3-31H2,1-2H3,(H,35,36)/p-1",hexadecanoyl-11-hydroxyoctadecanoate ester,PubMed citation,25303528
5127,83692,arasertaconazole nitrate,An organic nitrate salt obtained by reaction of equimolar amounts of arasertaconazole and nitric acid. The active R-enantiomer of sertaconazole nitrate that is used for treatment of vulvovaginal candidiasis. The racemate itself is also used as a broad-spectrum antifungal drug.,"InChI=1S/C20H15Cl3N2OS.HNO3/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22;2-1(3)4/h1-8,11-12,19H,9-10H2;(H,2,3,4)/t19-;/m0./s1",arasertaconazole mononitrate,Patent accession,EP2436374
5128,83696,CIGB-300,A synthetic 25-membered heterodetic cyclic peptide consisting of a 14-membered linear component attached to an 11-membered cyclic portion. A CK2 inhibitor with potential antineoplastic activity.,"InChI=1S/C127H215N53O30S3/c1-66(2)55-84-100(189)157-61-97(187)177-98(67(3)182)116(205)176-89(120(209)210)64-213-212-63-88(113(202)173-85(56-68-59-156-71-22-6-5-21-70(68)71)111(200)168-82(40-54-211-4)110(199)175-87(62-181)118(207)178-51-18-32-90(178)114(203)169-79(30-16-48-154-126(143)144)108(197)174-86(112(201)172-84)57-69-60-147-65-158-69)160-95(185)39-50-148-99(188)80(35-37-93(131)183)170-115(204)91-33-19-52-179(91)119(208)92-34-20-53-180(92)117(206)83(31-17-49-155-127(145)146)171-107(196)78(29-15-47-153-125(141)142)165-105(194)76(27-13-45-151-123(137)138)166-109(198)81(36-38-94(132)184)167-106(195)77(28-14-46-152-124(139)140)164-104(193)75(26-12-44-150-122(135)136)163-103(192)74(24-8-10-42-129)162-102(191)73(23-7-9-41-128)161-101(190)72(159-96(186)58-130)25-11-43-149-121(133)134/h5-6,21-22,59-60,65-67,72-92,98,156,181-182H,7-20,23-58,61-64,128-130H2,1-4H3,(H2,131,183)(H2,132,184)(H,147,158)(H,148,188)(H,157,189)(H,159,186)(H,160,185)(H,161,190)(H,162,191)(H,163,192)(H,164,193)(H,165,194)(H,166,198)(H,167,195)(H,168,200)(H,169,203)(H,170,204)(H,171,196)(H,172,201)(H,173,202)(H,174,197)(H,175,199)(H,176,205)(H,177,187)(H,209,210)(H4,133,134,149)(H4,135,136,150)(H4,137,138,151)(H4,139,140,152)(H4,141,142,153)(H4,143,144,154)(H4,145,146,155)/t67-,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,98+/m1/s1",P15-tat,PubMed citation,24773585
5129,83706,tetradecasphingosine,A sphingoid that is the C14-analogue of sphingosine.,"InChI=1S/C14H29NO2/c1-2-3-4-5-6-7-8-9-10-11-14(17)13(15)12-16/h10-11,13-14,16-17H,2-9,12,15H2,1H3/b11-10+/t13-,14+/m0/s1",C14-sphingosine,Reaxys Registry Number,21614871
5130,83716,2-aminophenylglyoxylic acid,A 2-oxo monocarboxylic acid that is glyoxylic acid in which the aldehydic hydrogen is replaced by a 2-aminophenyl group.,"InChI=1S/C8H7NO3/c9-6-4-2-1-3-5(6)7(10)8(11)12/h1-4H,9H2,(H,11,12)",o-aminophenylglyoxylic acid,PubMed citation,5370529
5131,83740,alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc,A highly branched amino oligosaccharide consisting of a D-GlcNAc residue at the reducing end with a alpha-L-Fuc-(1->4)-[beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-L-Fuc-(1->4)-[beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc undecasaccharide moiety attached via a beta-(1->4)-linkage and an L-Fuc residue attached via an alpha-(1->3)-linkage.,"InChI=1S/C85H142N4O62/c1-18-39(103)49(113)57(121)78(129-18)143-64-32(14-96)138-75(37(88-23(6)100)67(64)146-81-60(124)52(116)43(107)26(8-90)133-81)149-70-54(118)45(109)28(10-92)135-83(70)128-17-34-47(111)69(148-84-71(55(119)46(110)29(11-93)136-84)150-76-38(89-24(7)101)68(147-82-61(125)53(117)44(108)27(9-91)134-82)65(33(15-97)139-76)144-79-58(122)50(114)40(104)19(2)130-79)72(151-77-56(120)42(106)25(102)16-127-77)85(140-34)141-62-30(12-94)137-74(35(48(62)112)86-21(4)98)142-63-31(13-95)132-73(126)36(87-22(5)99)66(63)145-80-59(123)51(115)41(105)20(3)131-80/h18-20,25-85,90-97,102-126H,8-17H2,1-7H3,(H,86,98)(H,87,99)(H,88,100)(H,89,101)/t18-,19-,20-,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42-,43-,44-,45+,46+,47+,48+,49+,50+,51+,52-,53-,54-,55-,56+,57-,58-,59-,60+,61+,62+,63+,64+,65+,66+,67+,68+,69-,70-,71-,72-,73?,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84+,85-/m0/s1",alpha-L-Fuc-(1->3)-[alpha-L-Fuc-(1->4)-[beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-L-Fuc-(1->4)-[beta-D-Gal-(1->3)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)]-D-GlcNAc,PubMed citation,25240757
5132,83766,olaparib,"A member of the class of N-acylpiperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer.","InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",AZD-2281,PubMed citation,18800822
5133,83776,"3-oxo-23,24-bisnorchol-4-en-22-oic acid","A steroid acid that is 23,24-bisnor-chol-4-en-22-oic acid bearing an additional oxo substituent at position 3.","InChI=1S/C22H32O3/c1-13(20(24)25)17-6-7-18-16-5-4-14-12-15(23)8-10-21(14,2)19(16)9-11-22(17,18)3/h12-13,16-19H,4-11H2,1-3H3,(H,24,25)/t13-,16-,17+,18-,19-,21-,22+/m0/s1","3-oxo-23,24-bisnor-chol-4-en-22-oic acid",PubMed citation,21987574
5134,83778,"1,2-di[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycerol 3-phosphate in which both phosphatidyl acyl groups are specified as (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl.","InChI=1S/C47H69O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39-41-46(48)53-43-45(44-54-56(50,51)52)55-47(49)42-40-38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h5-8,11-14,17-20,23-26,29-32,35-38,45H,3-4,9-10,15-16,21-22,27-28,33-34,39-44H2,1-2H3,(H2,50,51,52)/b7-5-,8-6-,13-11-,14-12-,19-17-,20-18-,25-23-,26-24-,31-29-,32-30-,37-35-,38-36-/t45-/m1/s1","1,2-didocosahexaenoyl-sn-glycero-3-phosphate",LIPID MAPS instance accession,LMGP10010041
5135,83785,"1-palmitoyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycerol 3-phosphate in which the 1- and 2-acyl substituent are specified as palmitoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C41H69O8P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-41(43)49-39(38-48-50(44,45)46)37-47-40(42)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h5,7,11,13,17-18,20-21,24,26,30,32,39H,3-4,6,8-10,12,14-16,19,22-23,25,27-29,31,33-38H2,1-2H3,(H2,44,45,46)/b7-5-,13-11-,18-17-,21-20-,26-24-,32-30-/t39-/m1/s1",1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010038
5136,83802,methoxysuccinyl-Ala-Ala-Pro-Ala chloromethyl ketone,A tripeptide derived from methoxysuccinyl-Ala-Ala-Pro-Ala by conversion of the terminal carboxy group to the corresponding chloromethyl ketone.,"InChI=1S/C20H31ClN4O7/c1-11(15(26)10-21)23-19(30)14-6-5-9-25(14)20(31)13(3)24-18(29)12(2)22-16(27)7-8-17(28)32-4/h11-14H,5-10H2,1-4H3,(H,22,27)(H,23,30)(H,24,29)/t11-,12-,13-,14-/m0/s1",MSACK,PubMed citation,2911584
5137,83831,(R)-enilconazole,"A 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole that is the (R)-enantiomer of enilconazole.","InChI=1S/C14H14Cl2N2O/c1-2-7-19-14(9-18-6-5-17-10-18)12-4-3-11(15)8-13(12)16/h2-6,8,10,14H,1,7,9H2/t14-/m0/s1",(-)-enilconazole,Reaxys Registry Number,15398138
5138,83865,"androst-5-ene-3,17-dione",An androstanoid that is androst-5-ene bearing two oxo substituents at positions 3 and 17.,"InChI=1S/C19H26O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,14-16H,4-11H2,1-2H3/t14-,15-,16-,18-,19-/m0/s1","5-androstene-3,17-dione",CAS Registry Number,571-36-8
5139,83897,alpha-L-FucpNAc-(1->3)-D-FucpNAc,An amino disaccharide consisting of an N-acetyl-alpha-L-fucosaminyl residue linked (1->3) to an N-acetyl-alpha-D-fucosamine residue.,"InChI=1S/C16H28N2O9/c1-5-11(21)13(23)9(17-7(3)19)16(26-5)27-14-10(18-8(4)20)15(24)25-6(2)12(14)22/h5-6,9-16,21-24H,1-4H3,(H,17,19)(H,18,20)/t5-,6+,9-,10+,11+,12-,13-,14+,15?,16-/m0/s1",N-acetyl-alpha-L-fucosaminyl-(1->3)-N-acetyl-alpha-D-fucosamine,PubMed citation,25245803
5140,83948,dihydrocanadensolide,"A member of the class of furofurans that is tetrahydrofuro[3,4-b]furan-2,4-dione substituted at positions 3 and 6 by methyl and butyl groups respectively (the 3R,3aR,6S,6aS-stereoisomer).","InChI=1S/C11H16O4/c1-3-4-5-7-9-8(11(13)14-7)6(2)10(12)15-9/h6-9H,3-5H2,1-2H3/t6-,7+,8-,9-/m1/s1",(+)-dihydrocanadensolide,Reaxys Registry Number,4294813
5141,83973,"N-Boc-D-4-HO-3,5-Cl2-PhGly-D-4-HO-3,5-I2-PhGly-OMe",A dipeptide comprising of phenylglycine derived residues linked by peptide bonds.,"InChI=1S/C22H22Cl2I2N2O7/c1-22(2,3)35-21(33)28-15(9-5-11(23)17(29)12(24)6-9)19(31)27-16(20(32)34-4)10-7-13(25)18(30)14(26)8-10/h5-8,15-16,29-30H,1-4H3,(H,27,31)(H,28,33)/t15-,16-/m1/s1","methyl (2R)-2-[[(2R)-2-(3,5-dichloro-4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]-2-(4-hydroxy-3,5-diiodophenyl)acetate",Reaxys Registry Number,10222099
5142,83980,"1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-(1D-myo-inositol 3,4,5-triphosphate)","A 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and arachidonoyl respectively.","InChI=1S/C47H86O22P4/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(49)65-39(37-63-40(48)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2)38-64-73(61,62)69-44-42(50)45(66-70(52,53)54)47(68-72(58,59)60)46(43(44)51)67-71(55,56)57/h11,13,17,19,22,24,28,30,39,42-47,50-51H,3-10,12,14-16,18,20-21,23,25-27,29,31-38H2,1-2H3,(H,61,62)(H2,52,53,54)(H2,55,56,57)(H2,58,59,60)/b13-11-,19-17-,24-22-,30-28-/t39-,42+,43+,44-,45+,46-,47-/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo-inositol 3,4,5-triphosphate)",Reaxys Registry Number,7851622
5143,83981,3-hydroxyaspartic acid,A hydroxy-amino acid that is aspartic acid in which one of the methylene hydrogens has been replaced by a hydroxy group.,"InChI=1S/C4H7NO5/c5-1(3(7)8)2(6)4(9)10/h1-2,6H,5H2,(H,7,8)(H,9,10)",3-aminomalic acid,CAS Registry Number,1860-87-3
5144,83988,14-methylhexadecasphingosine,A sphingoid that is hexadecasphingosine substituted at position 14 by a methyl group.,"InChI=1S/C17H35NO2/c1-3-15(2)12-10-8-6-4-5-7-9-11-13-17(20)16(18)14-19/h11,13,15-17,19-20H,3-10,12,14,18H2,1-2H3/b13-11+/t15?,16-,17+/m0/s1",14-methylhexadecasphing-4-enine,LIPID MAPS instance accession,LMSP01080006
5145,84043,gallium(3+),A monoatomic trication derived from gallium.,InChI=1S/Ga/q+3,Ga(3+),PDBeChem accession,GA
5146,84072,hexadecyl elaidate,A wax ester resulting from the formal condensation of the carboxy group of elaidic acid with the hydroxy group of hexadecan-1-ol.,"InChI=1S/C34H66O2/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34(35)36-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h17,19H,3-16,18,20-33H2,1-2H3/b19-17+",hexadecyl (9E)-octadecenoate,Reaxys Registry Number,1716753
5147,84085,2-(acetylamino)-4-methylphenyl acetate,An  acetate ester that is phenyl acetate substituted by an acetylamino group at position 2 and a methyl group at position 4.,"InChI=1S/C11H13NO3/c1-7-4-5-11(15-9(3)14)10(6-7)12-8(2)13/h4-6H,1-3H3,(H,12,13)",2-acetamido-4-methylphenyl acetate,Reaxys Registry Number,3287935
5148,84118,ganglioside GM3,A sialodiaosylceramide that is an alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on nitrogen is (15Z)-tetracos-15-enoyl.,"InChI=1S/C65H118N2O21/c1-4-6-8-10-12-14-16-18-19-20-21-22-23-24-25-27-29-31-33-35-37-39-52(75)67-46(47(72)38-36-34-32-30-28-26-17-15-13-11-9-7-5-2)44-83-62-57(79)56(78)59(51(43-70)85-62)86-63-58(80)61(55(77)50(42-69)84-63)88-65(64(81)82)40-48(73)53(66-45(3)71)60(87-65)54(76)49(74)41-68/h18-19,36,38,46-51,53-63,68-70,72-74,76-80H,4-17,20-35,37,39-44H2,1-3H3,(H,66,71)(H,67,75)(H,81,82)/b19-18-,38-36+/t46-,47+,48-,49+,50+,51+,53+,54+,55-,56+,57+,58+,59+,60+,61-,62+,63-,65-/m0/s1",monosialoganglioside GM3,PubMed citation,24362891
5149,84119,triprolidine hydrochloride (anh.),"A hydrochloride resulting from the formal reaction of equimolar amounts of triprolidine and hydrogen chloride. Its monohydrate is used for the symptomatic relief of uticaria, rhinitis, and various pruritic skin disorders.","InChI=1S/C19H22N2.ClH/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21;/h2-3,6-12H,4-5,13-15H2,1H3;1H/b18-11+;",triprolidine hydrochloride (anhydrous),Reaxys Registry Number,3743215
5150,84152,"1-octadecanoyl-2-(3Z,6Z,9Z,12Z,15Z,18Z-docosahexaenoyl)-sn-glycero-3-phosphoserine","A 3-sn-phosphatidyl-L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are specified as octadecanoyl and (3Z,6Z,9Z,12Z,15Z,18Z)-docosahexaenoyl respectively.","InChI=1S/C46H78NO10P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-45(49)57-42(40-55-58(52,53)56-41-43(47)46(50)51)39-54-44(48)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h7,9,13,15,19-20,22,24,28,30,34,36,42-43H,3-6,8,10-12,14,16-18,21,23,25-27,29,31-33,35,37-41,47H2,1-2H3,(H,50,51)(H,52,53)/b9-7-,15-13-,20-19-,24-22-,30-28-,36-34-/t42-,43+/m1/s1","1-stearoyl-2-(3Z,6Z,9Z,12Z,15Z,18Z-docosahexaenoyl)-sn-glycero-3-phosphoserine",PubMed citation,24362891
5151,84153,1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol,"A 1-octadecanoyl-2-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 2-acyl group is specified as (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl (arachidonoyl).","InChI=1S/C47H83O13P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(49)59-39(38-58-61(55,56)60-47-45(53)43(51)42(50)44(52)46(47)54)37-57-40(48)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,39,42-47,50-54H,3-10,12,14-16,18,20-21,23,25-27,29,31-38H2,1-2H3,(H,55,56)/b13-11-,19-17-,24-22-,30-28-/t39-,42-,43-,44+,45-,46-,47-/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phospho-1D-myo-inositol",PubMed citation,24362891
5152,84160,1-O-(alpha-D-galactosyl)-N-decanoylphytosphingosine,A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and a decanoyl group attached to the nitrogen.,"InChI=1S/C34H67NO9/c1-3-5-7-9-11-12-13-14-15-17-18-20-22-27(37)30(39)26(35-29(38)23-21-19-16-10-8-6-4-2)25-43-34-33(42)32(41)31(40)28(24-36)44-34/h26-28,30-34,36-37,39-42H,3-25H2,1-2H3,(H,35,38)/t26-,27+,28+,30-,31-,32-,33+,34-/m0/s1",alpha-GC (C10:0),PubMed citation,21910729
5153,84164,didecanoylphosphatidic acid,A phosphatidic acid in which both of the phosphatidyl acyl groups are specified as decanoyl.,"InChI=1S/C23H45O8P/c1-3-5-7-9-11-13-15-17-22(24)29-19-21(20-30-32(26,27)28)31-23(25)18-16-14-12-10-8-6-4-2/h21H,3-20H2,1-2H3,(H2,26,27,28)","1,2-didecanoylglycero-3-phosphate",Reaxys Registry Number,2487592
5154,84165,1-stearoyl-2-arachidonoylphosphatidic acid,A phosphatidic acid in which the acyl groups at positions 1 and 2 are specifed as stearoyl and arachidonoyl respectively.,"InChI=1S/C41H73O8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(43)49-39(38-48-50(44,45)46)37-47-40(42)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,39H,3-10,12,14-16,18,20-21,23,25-27,29,31-38H2,1-2H3,(H2,44,45,46)/b13-11-,19-17-,24-22-,30-28-",1-stearoyl-2-arachidonoylglycero-3-phosphate,CAS Registry Number,119904-30-2
5155,84211,5-(dihydroxymethyl)-2-furoic acid,A member of the class of furoic acids that is 2-furoic acid substituted at position 5 by a dihydroxymethyl group.,"InChI=1S/C6H6O5/c7-5(8)3-1-2-4(11-3)6(9)10/h1-2,5,7-8H,(H,9,10)",5-(dihydroxymethyl)furan-2-carboxylic acid,MetaCyc accession,CPD-17103
5156,84238,"1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate)","A 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate in which the phosphatidyl acyl groups at positions 1 and 2 are both specified as octanoyl.","InChI=1S/C25H50O22P4/c1-3-5-7-9-11-13-18(26)41-15-17(43-19(27)14-12-10-8-6-4-2)16-42-51(39,40)47-22-20(28)23(44-48(30,31)32)25(46-50(36,37)38)24(21(22)29)45-49(33,34)35/h17,20-25,28-29H,3-16H2,1-2H3,(H,39,40)(H2,30,31,32)(H2,33,34,35)(H2,36,37,38)/t17-,20+,21+,22-,23+,24-,25-/m1/s1","PIP3[3',4',5'](8:0/8:0)",Reaxys Registry Number,10324397
5157,84241,"1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)","A 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate in which the phosphatidyl acyl groups at positions 1 and 2 are both specified as octanoyl.","InChI=1S/C25H49O19P3/c1-3-5-7-9-11-13-18(26)39-15-17(41-19(27)14-12-10-8-6-4-2)16-40-47(37,38)44-23-20(28)21(29)24(42-45(31,32)33)25(22(23)30)43-46(34,35)36/h17,20-25,28-30H,3-16H2,1-2H3,(H,37,38)(H2,31,32,33)(H2,34,35,36)/t17-,20-,21+,22+,23-,24-,25-/m1/s1","PIP2[4',5'](8:0/8:0)",Reaxys Registry Number,9378085
5158,84244,"1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate)","A 1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphate in which the phosphatidyl acyl groups at positions 1 and 2 are both specified as hexadecanoyl (palmitoyl).","InChI=1S/C41H82O22P4/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)57-31-33(59-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-58-67(55,56)63-38-36(44)39(60-64(46,47)48)41(62-66(52,53)54)40(37(38)45)61-65(49,50)51/h33,36-41,44-45H,3-32H2,1-2H3,(H,55,56)(H2,46,47,48)(H2,49,50,51)(H2,52,53,54)/t33-,36+,37+,38-,39+,40-,41-/m1/s1","1,2-dipalmitoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4,5-trisphosphate)",HMDB accession,HMDB0010147
5159,84247,"1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate)","A 1-phosphatidyl-1D-myo-inositol 3,4-bisphosphate in which the phosphatidyl acyl groups at positions 1 and 2 are both specified as hexadecanoyl (palmitoyl).","InChI=1S/C41H81O19P3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)55-31-33(57-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-56-63(53,54)60-39-36(44)37(45)40(58-61(47,48)49)41(38(39)46)59-62(50,51)52/h33,36-41,44-46H,3-32H2,1-2H3,(H,53,54)(H2,47,48,49)(H2,50,51,52)/t33-,36-,37-,38+,39+,40+,41+/m1/s1","PIP2[3',4'](16:0/16:0)",Reaxys Registry Number,7793270
5160,84251,"1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)","A 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate in which the phosphatidyl acyl groups at positions 1 and 2 are both specified as hexadecanoyl (palmitoyl).","InChI=1S/C41H81O19P3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)55-31-33(57-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-56-63(53,54)60-39-36(44)37(45)40(58-61(47,48)49)41(38(39)46)59-62(50,51)52/h33,36-41,44-46H,3-32H2,1-2H3,(H,53,54)(H2,47,48,49)(H2,50,51,52)/t33-,36-,37+,38+,39-,40-,41-/m1/s1","1,2-dipalmitoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-bisphosphate)",Reaxys Registry Number,8535734
5161,84263,"1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4-phosphate)",A 1-phosphatidyl-1D-myo-inositol 4-phosphate in which the phosphatidyl acyl groups at positions 1 and 2 are both specified as hexadecanoyl (palmitoyl).,"InChI=1S/C41H80O16P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)53-31-33(55-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-54-59(51,52)57-41-38(46)36(44)40(37(45)39(41)47)56-58(48,49)50/h33,36-41,44-47H,3-32H2,1-2H3,(H,51,52)(H2,48,49,50)/t33-,36-,37+,38-,39-,40+,41+/m1/s1","1,2-dipalmitoyl-sn-glycero-3-phospho-(1D-myo-inositol-4-phosphate)",Reaxys Registry Number,5218059
5162,84266,"1,2-ditetradecanoyl-sn-glycerol-3-phosphate",A 1-acyl-2-tetradecanoyl-sn-glycero-3-phosphate in which the 1-acyl group is specified as tetradecanoyl (myristoyl).,"InChI=1S/C31H61O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-30(32)37-27-29(28-38-40(34,35)36)39-31(33)26-24-22-20-18-16-14-12-10-8-6-4-2/h29H,3-28H2,1-2H3,(H2,34,35,36)/t29-/m1/s1",ditetradecanoylphosphatidic acid,LIPID MAPS instance accession,LMGP10010026
5163,84267,N-methylbutan-2-amine,A secondary aliphatic amine that is sec-butylamine substituted by a methyl group at the N atom. Metabolite observed in cancer metabolism.,"InChI=1S/C5H13N/c1-4-5(2)6-3/h5-6H,4H2,1-3H3",N-methyl-2-butanamine,PubMed citation,25518943
5164,84312,dodecanoyl-AMP,A fatty acyl-AMP that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of dodecanoic (lauric) acid.,"InChI=1S/C22H36N5O8P/c1-2-3-4-5-6-7-8-9-10-11-16(28)35-36(31,32)33-12-15-18(29)19(30)22(34-15)27-14-26-17-20(23)24-13-25-21(17)27/h13-15,18-19,22,29-30H,2-12H2,1H3,(H,31,32)(H2,23,24,25)/t15-,18-,19-,22-/m1/s1",lauroyl-AMP,PDBeChem accession,1ZZ
5165,84327,torin 1,"A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.","InChI=1S/C35H28F3N5O2/c1-2-32(44)42-15-13-41(14-16-42)31-11-9-26(19-28(31)35(36,37)38)43-33(45)12-8-24-20-40-30-10-7-22(18-27(30)34(24)43)25-17-23-5-3-4-6-29(23)39-21-25/h3-12,17-21H,2,13-16H2,1H3",torin1,Reaxys Registry Number,20268275
5166,84331,"N(3)-fumaramoyl-(S)-2,3-diaminopropanoic acid zwitterion","An L-alpha-amino acid zwitterion that results from the transfer of a proton from the carboxylic acid group to the alpha-amino group of N(3)-fumaramoyl-(S)-2,3-diaminopropanoic acid; major species at pH 7.3.","InChI=1S/C7H11N3O4/c8-4(7(13)14)3-10-6(12)2-1-5(9)11/h1-2,4H,3,8H2,(H2,9,11)(H,10,12)(H,13,14)/b2-1+/t4-/m0/s1",(2E)-4-[[(2S)-2-amino-2-carboxyethyl]amino]-4-oxobut-2-enoate,PubMed citation,19807062
5167,84333,synthalin,A hydrochloride resulting from the reaction of decamethylenediguanidine with 2 mol eq. of hydrogen chloride.,"InChI=1S/C12H28N6.2ClH/c13-11(14)17-9-7-5-3-1-2-4-6-8-10-18-12(15)16;;/h1-10H2,(H4,13,14,17)(H4,15,16,18);2*1H",decamethylenediguanidine hydrochloride,PubMed citation,13576350
5168,84340,hydrazinocurcumin,A pyrazole obtained by cyclocodensation of the two carbonyl groups of curcumin with hydrazine.,"InChI=1S/C21H20N2O4/c1-26-20-11-14(5-9-18(20)24)3-7-16-13-17(23-22-16)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,24-25H,1-2H3,(H,22,23)/b7-3+,8-4+",pyrazole-curcumin,Reaxys Registry Number,4271395
5169,84346,"cholesteryl all-cis-icosa-8,11,14-trienoate","A cholesterol ester obtained by the formal condensation of  cholesterol with all-cis-icosa-8,11,14-trienoic acid.","InChI=1S/C47H78O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-27-45(48)49-40-32-34-46(5)39(36-40)28-29-41-43-31-30-42(38(4)26-24-25-37(2)3)47(43,6)35-33-44(41)46/h11-12,14-15,17-18,28,37-38,40-44H,7-10,13,16,19-27,29-36H2,1-6H3/b12-11-,15-14-,18-17-/t38-,40+,41+,42-,43+,44+,46+,47-/m1/s1","cholesteryl (8Z,11Z,14Z)-icosa-8,11,14-trienoate",LIPID MAPS instance accession,LMST01020013
5170,84356,"(3E)-3-[(1R,5R,6S)-5-hydroxy-7-oxabicyclo[4.1.0]heptan-2-ylidene]pyruvate","A 2-oxo monocarboxylic acid anion that is the conjugate base of (3E)-3-[(1R,5R,6S)-5-hydroxy-7-oxabicyclo[4.1.0]heptan-2-ylidene]pyruvic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C9H10O5/c10-5-2-1-4(7-8(5)14-7)3-6(11)9(12)13/h3,5,7-8,10H,1-2H2,(H,12,13)/p-1/b4-3+/t5-,7-,8+/m1/s1",epoxy-3E-H2HPP,PubMed citation,23317005
5171,84358,L-dihydroanticapsin zwitterion,An L-alpha-amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of L-dihydroanticapsin; major species at pH 7.3.,"InChI=1S/C9H15NO4/c10-5(9(12)13)3-4-1-2-6(11)8-7(4)14-8/h4-8,11H,1-3,10H2,(H,12,13)/t4-,5-,6+,7+,8-/m0/s1","(1R,2S,5R,6S)-dihydroanticapsin zwitterion",PubMed citation,23317005
5172,84385,1-myristoyl-2-palmitoyl-sn-glycerol,"A 1,2-diacyl-sn-glycerol that has myristoyl and palmitoyl as 1- and 2-acyl groups respectively.","InChI=1S/C33H64O5/c1-3-5-7-9-11-13-15-16-18-20-22-24-26-28-33(36)38-31(29-34)30-37-32(35)27-25-23-21-19-17-14-12-10-8-6-4-2/h31,34H,3-30H2,1-2H3/t31-/m0/s1",1-tetradecanoyl-2-hexadecanoyl-sn-glycerol,LIPID MAPS instance accession,LMGL02010378
5173,84398,tetralinoleoyl cardiolipin,A cardiolipin in which all four phosphatidyl acyl groups are specified as linoleoyl.,"InChI=1S/C81H142O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-65-78(83)91-71-76(97-80(85)67-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)73-95-99(87,88)93-69-75(82)70-94-100(89,90)96-74-77(98-81(86)68-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)72-92-79(84)66-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2/h21-28,33-40,75-77,82H,5-20,29-32,41-74H2,1-4H3,(H,87,88)(H,89,90)/b25-21-,26-22-,27-23-,28-24-,37-33-,38-34-,39-35-,40-36-/t76-,77-/m1/s1","1,1',2,2'-tetra-(9Z,12Z)-octadecadienoyl cardiolipin",Reaxys Registry Number,20348300
5174,84399,"1,1',2-trilinoleoyl-2'-oleoyl cardiolipin","A cardiolipin in which the phosphatidyl acyl groups at positions 1, 1' and 2 are specified as linoleoyl, while that at position 2' is specified as oleoyl.","InChI=1S/C81H144O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-65-78(83)91-71-76(97-80(85)67-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)73-95-99(87,88)93-69-75(82)70-94-100(89,90)96-74-77(98-81(86)68-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)72-92-79(84)66-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2/h21-23,25-27,33-40,75-77,82H,5-20,24,28-32,41-74H2,1-4H3,(H,87,88)(H,89,90)/b25-21-,26-22-,27-23-,37-33-,38-34-,39-35-,40-36-/t75?,76-,77-/m1/s1","1,1',2-trilinoleoyl-2'-oleoyl CL",Reaxys Registry Number,20405884
5175,84400,"1,1',2-trilinoleoyl-2'-palmitoyl cardiolipin","A cardiolipin in which the phosphatidyl acyl groups at positions 1, 1' and 2 are specified as linoleoyl, while that at position 2' is specified as palmitoyl.","InChI=1S/C79H142O17P2/c1-5-9-13-17-21-25-29-33-36-40-43-47-51-55-59-63-76(81)89-69-74(95-78(83)65-61-57-53-49-45-39-32-28-24-20-16-12-8-4)71-93-97(85,86)91-67-73(80)68-92-98(87,88)94-72-75(96-79(84)66-62-58-54-50-46-42-38-35-31-27-23-19-15-11-7-3)70-90-77(82)64-60-56-52-48-44-41-37-34-30-26-22-18-14-10-6-2/h21-23,25-27,33-38,73-75,80H,5-20,24,28-32,39-72H2,1-4H3,(H,85,86)(H,87,88)/b25-21-,26-22-,27-23-,36-33-,37-34-,38-35-/t73?,74-,75-/m1/s1","1'-[1,2-dilinoleoyl-sn-glycero-3-phospho]-3'-[1-linoleoyl-2-palmitoyl-sn-glycero-3-phospho]-glycerol",HMDB accession,HMDB0010244
5176,84401,"1-palmitoyl-2-(11Z,14Z-eicosadienoyl)-sn-glycerol","A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoyl and (11Z,14Z)-eicosadienoyl respectively.","InChI=1S/C39H72O5/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-39(42)44-37(35-40)36-43-38(41)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h11,13,17-18,37,40H,3-10,12,14-16,19-36H2,1-2H3/b13-11-,18-17-/t37-/m0/s1","1-hexadecanoyl-2-(11Z,14Z-eicosadienoyl)-sn-glycerol",LIPID MAPS instance accession,LMGL02010055
5177,84414,hexadecanoyl-AMP,A fatty acyl-AMP that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of hexadecanoic (palmitic) acid.,"InChI=1S/C26H44N5O8P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20(32)39-40(35,36)37-16-19-22(33)23(34)26(38-19)31-18-30-21-24(27)28-17-29-25(21)31/h17-19,22-23,26,33-34H,2-16H2,1H3,(H,35,36)(H2,27,28,29)/t19-,22-,23-,26-/m1/s1",palmitoyl-AMP,Reaxys Registry Number,73604
5178,84417,"1,2-di-palmitoleoyl-2-sn-glycerol","A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoleoyl.","InChI=1S/C35H64O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(37)39-32-33(31-36)40-35(38)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h13-16,33,36H,3-12,17-32H2,1-2H3/b15-13-,16-14-/t33-/m0/s1","1,2-di-(9Z-hexadecenoyl)-sn-glycerol",LIPID MAPS instance accession,LMGL02010011
5179,84418,1-palmitoleoyl-2-stearoyl-sn-glycerol,"A 1,2-diacyl-sn-glycerol in which the 1- and 2-acyl groups are specified as palmitoleoyl and stearoyl respectively.","InChI=1S/C37H70O5/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(40)42-35(33-38)34-41-36(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h14,16,35,38H,3-13,15,17-34H2,1-2H3/b16-14-/t35-/m0/s1",1-(9Z-hexadecenoyl)-2-octadecanoyl-sn-glycerol,LIPID MAPS instance accession,LMGL02010023
5180,84425,9-PAHSA,A FAHFA (fatty acid ester of a hydroxy fatty acid) obtained by formal condensation of the carboxy group of palmitic acid with the hydroxy group of 9-hydroxyoctadecanoic acid (9-hydroxystearic acid).,"InChI=1S/C34H66O4/c1-3-5-7-9-11-12-13-14-15-16-18-23-27-31-34(37)38-32(28-24-20-17-10-8-6-4-2)29-25-21-19-22-26-30-33(35)36/h32H,3-31H2,1-2H3,(H,35,36)",palmitic acid-9-hydroxystearic acid,Reaxys Registry Number,24107491
5181,84433,"1-stearoyl-2-(8Z,11Z,14Z-icosa-8,11,14-trienoyl)-sn-glycerol","A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as stearoyl and 8Z,11Z,14Z-icosa-8,11,14-trienoyl respectively.","InChI=1S/C41H74O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,39,42H,3-10,12,14-16,18,20-21,23,25-38H2,1-2H3/b13-11-,19-17-,24-22-/t39-/m0/s1","1-octadecanoyl-2-(8Z,11Z,14Z-eicosatrienoyl)-sn-glycerol",LIPID MAPS instance accession,LMGL02010101
5182,84434,5'-GACCCCUG-3' RNA fragment,"An RNA fragment comprised of two guanosine, one adenosine, one uridine and four cytidine residues connected by 3'->5' phosphodiester linkages in the sequence G-A-C-C-C-C-U-G.","InChI=1S/C75H96N29O54P7/c76-31-1-6-97(71(118)88-31)62-42(110)49(155-162(129,130)140-15-27-51(44(112)64(148-27)99-8-3-33(78)90-73(99)120)157-164(133,134)142-17-29-53(46(114)66(150-29)101-10-5-35(106)92-75(101)122)153-159(123,124)137-12-24-39(107)40(108)61(145-24)103-21-86-37-57(103)93-69(81)95-59(37)116)25(146-62)13-139-161(127,128)154-50-26(147-63(43(50)111)98-7-2-32(77)89-72(98)119)14-141-163(131,132)156-52-28(149-65(45(52)113)100-9-4-34(79)91-74(100)121)16-143-165(135,136)158-54-30(151-67(47(54)115)102-20-85-36-55(80)83-19-84-56(36)102)18-138-160(125,126)152-48-23(11-105)144-68(41(48)109)104-22-87-38-58(104)94-70(82)96-60(38)117/h1-10,19-30,39-54,61-68,105,107-115H,11-18H2,(H,123,124)(H,125,126)(H,127,128)(H,129,130)(H,131,132)(H,133,134)(H,135,136)(H2,76,88,118)(H2,77,89,119)(H2,78,90,120)(H2,79,91,121)(H2,80,83,84)(H,92,106,122)(H3,81,93,95,116)(H3,82,94,96,117)/t23-,24-,25-,26-,27-,28-,29-,30-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,61-,62-,63-,64-,65-,66-,67-,68-/m1/s1",GpApCpCpCpCpUpG,PubMed citation,7678618
5183,84436,1-oleoyl-2-gondoyl-sn-glycerol,"A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as oleoyl and gondoyl respectively.","InChI=1S/C41H76O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h17-19,21,39,42H,3-16,20,22-38H2,1-2H3/b19-17-,21-18-/t39-/m0/s1",1-(9Z-octadecenoyl)-2-(11Z-eicosenoyl)-sn-glycerol,LIPID MAPS instance accession,LMGL02010090
5184,84437,"1-oleoyl-2-(8Z,11Z,14Z-eicosatrienoyl)-sn-glycerol","A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specified as oleoyl and 8Z,11Z,14Z-eicosatrienoyl respectively.","InChI=1S/C41H72O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17-19,21-22,24,39,42H,3-10,12,14-16,20,23,25-38H2,1-2H3/b13-11-,19-17-,21-18-,24-22-/t39-/m0/s1","1-(9Z-octadecenoyl)-2-(8Z,11Z,14Z-eicosatrienoyl)-sn-glycerol",LIPID MAPS instance accession,LMGL02010110
5185,84455,3-methoxy-4-hydroxy-5-all-trans-octaprenylbenzoic acid,A 3-methoxy-4-hydroxy-5-all-trans-polyprenylbenzoic acid in which the polyprenyl component is specified as octaprenyl.,"InChI=1S/C48H72O4/c1-36(2)18-11-19-37(3)20-12-21-38(4)22-13-23-39(5)24-14-25-40(6)26-15-27-41(7)28-16-29-42(8)30-17-31-43(9)32-33-44-34-45(48(50)51)35-46(52-10)47(44)49/h18,20,22,24,26,28,30,32,34-35,49H,11-17,19,21,23,25,27,29,31,33H2,1-10H3,(H,50,51)/b37-20+,38-22+,39-24+,40-26+,41-28+,42-30+,43-32+",3-all-trans-octaprenyl-4-hydroxy-5-methoxybenzoic acid,MetaCyc accession,CPD-9899
5186,84457,5-PAHSA,A FAHFA obtained by formal condensation of the carboxy group of palmitic acid with the hydroxy group of 5-hydroxystearic acid.,"InChI=1S/C34H66O4/c1-3-5-7-9-11-13-15-16-18-20-22-24-26-31-34(37)38-32(29-27-30-33(35)36)28-25-23-21-19-17-14-12-10-8-6-4-2/h32H,3-31H2,1-2H3,(H,35,36)",palmitic acid-5-hydroxystearic acid,PubMed citation,25303528
5187,84458,"1-oleoyl-2,3-di-linoleoyl-sn-glycerol","A  triacyl-sn-glycerol in which the acyl groups at positions 1, 2 and 3 are specified as oleoyl, linoleoyl and linoleoyl respectively.","InChI=1S/C57H100O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-55(58)61-52-54(63-57(60)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)53-62-56(59)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h16,18-19,21,25-30,54H,4-15,17,20,22-24,31-53H2,1-3H3/b19-16-,21-18-,28-25-,29-26-,30-27-/t54-/m0/s1","1-(9Z-octadecenoyl)-2,3-di-(9Z,12Z-octadecadienoyl)-sn-glycerol",LIPID MAPS instance accession,LMGL03010327
5188,84463,5'-CGUUCGCG-3' RNA fragment,"An RNA fragment comprised of three cytidine, three guanosine and two uridine residues connected by 3'->5' phosphodiester linkages in the sequence C-G-U-U-C-G-C-G.","InChI=1S/C75H95N28O56P7/c76-30-1-6-96(71(119)85-30)61-40(109)47(22(11-104)145-61)153-161(126,127)139-17-28-52(45(114)66(151-28)102-20-83-36-55(102)91-69(80)94-58(36)117)158-166(136,137)143-16-27-51(44(113)65(150-27)100-10-5-34(106)89-75(100)123)157-163(130,131)141-15-26-50(43(112)64(149-26)99-9-4-33(105)88-74(99)122)156-162(128,129)140-14-25-49(42(111)63(148-25)98-8-3-32(78)87-73(98)121)155-164(132,133)144-18-29-53(46(115)67(152-29)103-21-84-37-56(103)92-70(81)95-59(37)118)159-165(134,135)142-13-24-48(41(110)62(147-24)97-7-2-31(77)86-72(97)120)154-160(124,125)138-12-23-38(107)39(108)60(146-23)101-19-82-35-54(101)90-68(79)93-57(35)116/h1-10,19-29,38-53,60-67,104,107-115H,11-18H2,(H,124,125)(H,126,127)(H,128,129)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H2,76,85,119)(H2,77,86,120)(H2,78,87,121)(H,88,105,122)(H,89,106,123)(H3,79,90,93,116)(H3,80,91,94,117)(H3,81,92,95,118)/t22-,23-,24-,25-,26-,27-,28-,29-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,60-,61-,62-,63-,64-,65-,66-,67-/m1/s1",CpGpUpUpCpGpCpG,PubMed citation,7678618
5189,84486,8-PAHSA,A FAHFA obtained by formal condensation of the carboxy group of palmitic acid with the hydroxy group of 8-hydroxystearic acid.,"InChI=1S/C34H66O4/c1-3-5-7-9-11-13-14-15-16-17-19-21-27-31-34(37)38-32(29-25-22-23-26-30-33(35)36)28-24-20-18-12-10-8-6-4-2/h32H,3-31H2,1-2H3,(H,35,36)",8-(palmitoyloxy)stearic acid,PubMed citation,25303528
5190,84520,1-palmitoyl-2-stearoyl-sn-glycero-3-phosphoserine,A 3-sn-phosphatidyl L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are palmitoyl and stearoyl respectively.,"InChI=1S/C40H78NO10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(43)51-36(34-49-52(46,47)50-35-37(41)40(44)45)33-48-38(42)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h36-37H,3-35,41H2,1-2H3,(H,44,45)(H,46,47)/t36-,37+/m1/s1",1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphoserine,LIPID MAPS instance accession,LMGP03010906
5191,84532,1-(1Z-hexadecenyl)-2-linoleoyl-sn-glycero-3-phosphoethanolamine,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkenyl and acyl groups are specified as (1Z)-hexadecenyl and linoleoyl respectively.,"InChI=1S/C39H74NO7P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-39(41)47-38(37-46-48(42,43)45-35-33-40)36-44-34-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,31,34,38H,3-10,12,14-16,18,20-30,32-33,35-37,40H2,1-2H3,(H,42,43)/b13-11-,19-17-,34-31-/t38-/m1/s1","1-(1Z-hexadecenyl)-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02030094
5192,84533,1-(1Z-hexadecenyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine,1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-hexadecenyl and oleoyl respectively.,"InChI=1S/C39H76NO7P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-39(41)47-38(37-46-48(42,43)45-35-33-40)36-44-34-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h17,19,31,34,38H,3-16,18,20-30,32-33,35-37,40H2,1-2H3,(H,42,43)/b19-17-,34-31-/t38-/m1/s1",1-(1Z-hexadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02030095
5193,84535,1-eicosyl-2-linolenyl-sn-glycero-3-phosphoethanolamine,A 1-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as eicosyl and linolenyl respectively.,"InChI=1S/C43H84NO7P/c1-3-5-7-9-11-13-15-17-19-20-21-23-25-27-29-31-33-35-38-48-40-42(41-50-52(46,47)49-39-37-44)51-43(45)36-34-32-30-28-26-24-22-18-16-14-12-10-8-6-4-2/h12,14,18,22,42H,3-11,13,15-17,19-21,23-41,44H2,1-2H3,(H,46,47)/b14-12-,22-18-/t42-/m1/s1","1-eicosyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02020073
5194,84543,1-oleoyl-2-linoleyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl groups at positions 1 and 2 are specified as stearoyl and linoleoyl respectively.","InChI=1S/C41H76NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,17-20,39H,3-11,13,15-16,21-38,42H2,1-2H3,(H,45,46)/b14-12-,19-17-,20-18-/t39-/m1/s1","1-(9Z-octadecenoyl)-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02010048
5195,84549,"1-palmitoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycero-3-phosphoethanolamine","A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl groups specified at position 1 and 2 are palmitoyl and (7Z,10Z,13Z,16Z)-docosatetraenoyl respectively.","InChI=1S/C43H78NO8P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h11,13,17-18,20-21,24,26,41H,3-10,12,14-16,19,22-23,25,27-40,44H2,1-2H3,(H,47,48)/b13-11-,18-17-,21-20-,26-24-/t41-/m1/s1","1-hexadecanoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02010116
5196,84550,menaquinol-12,A menaquinol whose structure comprises a 2-methylbenzohydroquinone nucleus and a side chain of twelve isoprenoid units.,"InChI=1S/C71H106O2/c1-54(2)28-17-29-55(3)30-18-31-56(4)32-19-33-57(5)34-20-35-58(6)36-21-37-59(7)38-22-39-60(8)40-23-41-61(9)42-24-43-62(10)44-25-45-63(11)46-26-47-64(12)48-27-49-65(13)52-53-67-66(14)70(72)68-50-15-16-51-69(68)71(67)73/h15-16,28,30,32,34,36,38,40,42,44,46,48,50-52,72-73H,17-27,29,31,33,35,37,39,41,43,45,47,49,53H2,1-14H3/b55-30+,56-32+,57-34+,58-36+,59-38+,60-40+,61-42+,62-44+,63-46+,64-48+,65-52+",MKH2-12,MetaCyc accession,CPD-12129
5197,84552,menaquinol-13,A menaquinol whose structure comprises a 2-methylbenzohydroquinone nucleus and a side chain of thirteen isoprenoid units.,"InChI=1S/C76H114O2/c1-58(2)30-18-31-59(3)32-19-33-60(4)34-20-35-61(5)36-21-37-62(6)38-22-39-63(7)40-23-41-64(8)42-24-43-65(9)44-25-45-66(10)46-26-47-67(11)48-27-49-68(12)50-28-51-69(13)52-29-53-70(14)56-57-72-71(15)75(77)73-54-16-17-55-74(73)76(72)78/h16-17,30,32,34,36,38,40,42,44,46,48,50,52,54-56,77-78H,18-29,31,33,35,37,39,41,43,45,47,49,51,53,57H2,1-15H3/b59-32+,60-34+,61-36+,62-38+,63-40+,64-42+,65-44+,66-46+,67-48+,68-50+,69-52+,70-56+",MKH2-13,MetaCyc accession,CPD-12130
5198,84567,1-palmitoleoyl-2-linoleoyl-sn-glycero-3-phosphocholine,A phosphatidylcholine 34:3 in which the acyl groups specified at positions 1 and 2 are palmitoleoyl and linoleoyl respectively.,"InChI=1S/C42H78NO8P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43(3,4)5)38-48-41(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h14,16-17,19-21,40H,6-13,15,18,22-39H2,1-5H3/b16-14-,19-17-,21-20-/t40-/m1/s1","1-(9Z-hexadecenoyl)-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine",LIPID MAPS instance accession,LMGP01010690
5199,84570,1-palmitoleoyl-2-stearoyl-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups specified at positions 1 and 2 are palmitoleoyl and stearoyl respectively.","InChI=1S/C42H82NO8P/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43(3,4)5)38-48-41(44)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2/h17,19,40H,6-16,18,20-39H2,1-5H3/b19-17-/t40-/m1/s1",1-(9Z-hexadecenoyl)-2-octadecanoyl-sn-glycero-3-phosphocholine,HMDB accession,HMDB0008003
5200,84575,1-palmitoyl-2-(11Z-eicosenoyl)-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups specified at positions 1 and 2 are palmitoyl and (11Z)-eicosenoyl respectively.","InChI=1S/C44H86NO8P/c1-6-8-10-12-14-16-18-20-21-22-23-25-27-29-31-33-35-37-44(47)53-42(41-52-54(48,49)51-39-38-45(3,4)5)40-50-43(46)36-34-32-30-28-26-24-19-17-15-13-11-9-7-2/h20-21,42H,6-19,22-41H2,1-5H3/b21-20-/t42-/m1/s1",1-hexadecanoyl-2-(11Z-eicosenoyl)-sn-glycero-3-phosphocholine,LIPID MAPS instance accession,LMGP01011468
5201,84577,1-palmitoyl-2-(9Z-heptadecenoyl)-sn-glycero-3-phosphocholine,A  phosphatidylcholine 33:1 in which the acyl groups specified at positions 1 and 2 are palmitoyl and (9Z)-heptadecenoyl respectively.,"InChI=1S/C41H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-41(44)50-39(38-49-51(45,46)48-36-35-42(3,4)5)37-47-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h18,20,39H,6-17,19,21-38H2,1-5H3/b20-18-/t39-/m1/s1",1-hexadecanoyl-2-(9Z-heptadecenoyl)-sn-glycero-3-phosphocholine,LIPID MAPS instance accession,LMGP01010571
5202,84593,5'-GAUAUACACGCAUAUCAGCGUUCGCGU-3' RNA fragment,"An RNA fragment comprised of six guanosine, seven adenosine, seven uridine and seven cytidine residues connected by 3'->5' phosphodiester linkages in the sequence G-A-U-A-U-A-C-A-C-G-C-A-U-A-U-C-A-G-C-G-U-U-C-G-C-G-U.","InChI=1S/C258H319N105O185P26/c259-102-1-13-337(247(406)311-102)214-132(374)158(524-554(428,429)485-41-93-175(149(391)231(514-93)355-66-302-120-189(271)286-58-294-197(120)355)543-572(464,465)493-49-99-181(155(397)238(520-99)362-73-309-127-204(362)328-245(278)335-211(127)404)547-574(468,469)495-51-101-182(156(398)239(522-101)363-74-310-128-205(363)329-246(279)336-212(128)405)548-573(466,467)494-50-100-180(154(396)237(521-100)361-72-308-126-203(361)327-244(277)334-210(126)403)546-569(458,459)482-37-87-166(140(382)222(508-87)346-22-10-111(368)320-256(346)415)532-553(426,427)474-33-83-164(138(380)220(504-83)344-20-8-109(366)318-254(344)413)530-551(422,423)473-28-78-159(133(375)215(499-78)338-14-2-103(260)312-248(338)407)527-560(440,441)491-47-97-178(152(394)235(518-97)359-70-306-124-201(359)325-242(275)332-208(124)401)545-568(456,457)478-32-82-163(137(379)219(503-82)342-18-6-107(264)316-252(342)411)528-559(438,439)490-46-96-177(151(393)234(517-96)358-69-305-123-200(358)324-241(274)331-207(123)400)535-549(418,419)470-26-76-129(371)130(372)213(497-76)343-19-7-108(365)317-253(343)412)77(498-214)27-472-552(424,425)531-165-84(505-221(139(165)381)345-21-9-110(367)319-255(345)414)34-480-566(452,453)540-173-94(515-229(147(173)389)353-64-300-118-187(269)284-56-292-195(118)353)44-488-571(462,463)542-176-95(516-232(150(176)392)356-67-303-121-190(272)287-59-295-198(121)356)45-489-570(460,461)541-174-92(513-230(148(174)390)354-65-301-119-188(270)285-57-293-196(119)354)40-484-556(432,433)526-161-81(502-217(135(161)377)340-16-4-105(262)314-250(340)409)31-477-567(454,455)544-179-98(519-236(153(179)395)360-71-307-125-202(360)326-243(276)333-209(125)402)48-492-561(442,443)529-162-80(501-218(136(162)378)341-17-5-106(263)315-251(341)410)30-476-563(446,447)537-170-89(510-226(144(170)386)350-61-297-115-184(266)281-53-289-192(115)350)39-483-555(430,431)525-160-79(500-216(134(160)376)339-15-3-104(261)313-249(339)408)29-475-562(444,445)538-171-90(511-227(145(171)387)351-62-298-116-185(267)282-54-290-193(116)351)42-486-557(434,435)534-168-86(507-224(142(168)384)348-24-12-113(370)322-258(348)417)36-481-565(450,451)539-172-91(512-228(146(172)388)352-63-299-117-186(268)283-55-291-194(117)352)43-487-558(436,437)533-167-85(506-223(141(167)383)347-23-11-112(369)321-257(347)416)35-479-564(448,449)536-169-88(509-225(143(169)385)349-60-296-114-183(265)280-52-288-191(114)349)38-471-550(420,421)523-157-75(25-364)496-233(131(157)373)357-68-304-122-199(357)323-240(273)330-206(122)399/h1-24,52-101,129-182,213-239,364,371-398H,25-51H2,(H,418,419)(H,420,421)(H,422,423)(H,424,425)(H,426,427)(H,428,429)(H,430,431)(H,432,433)(H,434,435)(H,436,437)(H,438,439)(H,440,441)(H,442,443)(H,444,445)(H,446,447)(H,448,449)(H,450,451)(H,452,453)(H,454,455)(H,456,457)(H,458,459)(H,460,461)(H,462,463)(H,464,465)(H,466,467)(H,468,469)(H2,259,311,406)(H2,260,312,407)(H2,261,313,408)(H2,262,314,409)(H2,263,315,410)(H2,264,316,411)(H2,265,280,288)(H2,266,281,289)(H2,267,282,290)(H2,268,283,291)(H2,269,284,292)(H2,270,285,293)(H2,271,286,294)(H2,272,287,295)(H,317,365,412)(H,318,366,413)(H,319,367,414)(H,320,368,415)(H,321,369,416)(H,322,370,417)(H3,273,323,330,399)(H3,274,324,331,400)(H3,275,325,332,401)(H3,276,326,333,402)(H3,277,327,334,403)(H3,278,328,335,404)(H3,279,329,336,405)/t75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178-,179-,180-,181-,182-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-,227-,228-,229-,230-,231-,232-,233-,234-,235-,236-,237-,238-,239-/m1/s1",GpApUpApUpApCpApCpGpCpApUpApUpCpApGpCpGpUpUpCpGpCpGpU,PubMed citation,7678618
5203,84594,5'-AGGCAAUAAAACACGACCWUAAUG-3' RNA fragment,"An RNA fragment comprised of four guanosine, eleven adenosine, two uridine and five cytidine residues connected by 3'->5' phosphodiester linkages in the sequence A-G-G-C-A-A-U-A-A-A-A-C-A-C-G-A-C-C-W-U-A-A-U-G.","InChI=1S/C240H297N101O166P24/c241-97-1-11-317(231(377)299-97)203-125(350)149(486-510(391,392)437-24-75-150(126(351)204(462-75)318-12-2-98(242)300-232(318)378)488-512(395,396)439-30-81-156(132(357)210(468-81)324-18-8-104(344)306-238(324)384)492-513(397,398)440-31-82-157(133(358)211(469-82)325-19-9-105(345)307-239(325)385)493-516(403,404)449-35-86-165(141(366)220(473-86)334-64-291-114-179(254)269-53-280-190(114)334)501-526(423,424)451-38-89-161(137(362)216(476-89)330-60-287-110-175(250)265-49-276-186(110)330)498-522(415,416)445-29-80-155(131(356)209(467-80)323-17-7-103(343)305-237(323)383)485-508(387,388)435-22-73-122(347)123(348)202(460-73)338-68-295-118-194(338)309-227(258)313-198(118)373)74(461-203)23-438-511(393,394)487-151-76(463-205(127(151)352)319-13-3-99(243)301-233(319)379)25-441-520(411,412)497-163-93(480-218(139(163)364)332-62-289-112-177(252)267-51-278-188(112)332)42-456-530(431,432)507-171-95(482-226(147(171)372)341-71-298-121-197(341)312-230(261)316-201(121)376)44-457-518(407,408)491-154-78(465-208(130(154)355)322-16-6-102(246)304-236(322)382)27-443-519(409,410)495-159-84(471-214(135(159)360)328-58-285-108-173(248)263-47-274-184(108)328)33-447-514(399,400)489-152-77(464-206(128(152)353)320-14-4-100(244)302-234(320)380)26-442-521(413,414)496-160-88(475-215(136(160)361)329-59-286-109-174(249)264-48-275-185(109)329)37-453-528(427,428)503-167-92(479-222(143(167)368)336-66-293-116-181(256)271-55-282-192(116)336)41-455-529(429,430)504-168-91(478-223(144(168)369)337-67-294-117-182(257)272-56-283-193(117)337)40-454-527(425,426)502-166-87(474-221(142(166)367)335-65-292-115-180(255)270-54-281-191(115)335)36-450-517(405,406)494-158-83(470-212(134(158)359)326-20-10-106(346)308-240(326)386)32-446-523(417,418)499-162-90(477-217(138(162)363)331-61-288-111-176(251)266-50-277-187(111)331)39-452-525(421,422)500-164-85(472-219(140(164)365)333-63-290-113-178(253)268-52-279-189(113)333)34-448-515(401,402)490-153-79(466-207(129(153)354)321-15-5-101(245)303-235(321)381)28-444-524(419,420)505-170-96(483-225(146(170)371)340-70-297-120-196(340)311-229(260)315-200(120)375)45-458-531(433,434)506-169-94(481-224(145(169)370)339-69-296-119-195(339)310-228(259)314-199(119)374)43-436-509(389,390)484-148-72(21-342)459-213(124(148)349)327-57-284-107-172(247)262-46-273-183(107)327/h1-20,46-96,122-171,202-226,342,347-372H,21-45H2,(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,395,396)(H,397,398)(H,399,400)(H,401,402)(H,403,404)(H,405,406)(H,407,408)(H,409,410)(H,411,412)(H,413,414)(H,415,416)(H,417,418)(H,419,420)(H,421,422)(H,423,424)(H,425,426)(H,427,428)(H,429,430)(H,431,432)(H,433,434)(H2,241,299,377)(H2,242,300,378)(H2,243,301,379)(H2,244,302,380)(H2,245,303,381)(H2,246,304,382)(H2,247,262,273)(H2,248,263,274)(H2,249,264,275)(H2,250,265,276)(H2,251,266,277)(H2,252,267,278)(H2,253,268,279)(H2,254,269,280)(H2,255,270,281)(H2,256,271,282)(H2,257,272,283)(H,305,343,383)(H,306,344,384)(H,307,345,385)(H,308,346,386)(H3,258,309,313,373)(H3,259,310,314,374)(H3,260,311,315,375)(H3,261,312,316,376)/t72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,202-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,221-,222-,223-,224-,225-,226-/m1/s1",ApGpGpCpApApUpApApApApCpApCpGpApCpCpWpUpApApUpG,PubMed citation,7678618
5204,84616,"3-oxo-23,24-bisnorchol-4-en-22-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxo-23,24-bisnorchol-4-en-22-oic acid.","InChI=1S/C43H66N7O18P3S/c1-23(27-8-9-28-26-7-6-24-18-25(51)10-13-42(24,4)29(26)11-14-43(27,28)5)40(56)72-17-16-45-31(52)12-15-46-38(55)35(54)41(2,3)20-65-71(62,63)68-70(60,61)64-19-30-34(67-69(57,58)59)33(53)39(66-30)50-22-49-32-36(44)47-21-48-37(32)50/h18,21-23,26-30,33-35,39,53-54H,6-17,19-20H2,1-5H3,(H,45,52)(H,46,55)(H,60,61)(H,62,63)(H2,44,47,48)(H2,57,58,59)/t23-,26-,27+,28-,29-,30+,33+,34+,35-,39+,42-,43+/m0/s1","3-oxo-23,24-bisnorchol-4-en-22-oyl-coenzyme A",Reaxys Registry Number,22568822
5205,84617,"3-oxo-23,24-bisnorchola-1,4-dien-22-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxo-23,24-bisnorchola-1,4-dien-22-oic acid.","InChI=1S/C43H64N7O18P3S/c1-23(27-8-9-28-26-7-6-24-18-25(51)10-13-42(24,4)29(26)11-14-43(27,28)5)40(56)72-17-16-45-31(52)12-15-46-38(55)35(54)41(2,3)20-65-71(62,63)68-70(60,61)64-19-30-34(67-69(57,58)59)33(53)39(66-30)50-22-49-32-36(44)47-21-48-37(32)50/h10,13,18,21-23,26-30,33-35,39,53-54H,6-9,11-12,14-17,19-20H2,1-5H3,(H,45,52)(H,46,55)(H,60,61)(H,62,63)(H2,44,47,48)(H2,57,58,59)/t23-,26-,27+,28-,29-,30+,33+,34+,35-,39+,42-,43+/m0/s1","3-oxo-23,24-bisnorchola-1,4-dien-22-oyl-coenzyme A",Reaxys Registry Number,22568818
5206,84618,"3-hydroxy-9-oxo-9,10-seco-23,24-bisnorchola-1,3,5(10)-trien-22-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxy-9-oxo-9,10-seco-23,24-bisnorchola-1,3,5(10)-trien-22-oic acid.","InChI=1S/C43H64N7O19P3S/c1-23-6-8-26(51)18-25(23)7-9-27-29-11-10-28(43(29,5)14-12-30(27)52)24(2)41(57)73-17-16-45-32(53)13-15-46-39(56)36(55)42(3,4)20-66-72(63,64)69-71(61,62)65-19-31-35(68-70(58,59)60)34(54)40(67-31)50-22-49-33-37(44)47-21-48-38(33)50/h6,8,18,21-22,24,27-29,31,34-36,40,51,54-55H,7,9-17,19-20H2,1-5H3,(H,45,53)(H,46,56)(H,61,62)(H,63,64)(H2,44,47,48)(H2,58,59,60)/t24-,27-,28+,29-,31+,34+,35+,36-,40+,43+/m0/s1","3-hydroxy-9-oxo-9,10-seco-23,24-bisnorchola-1,3,5(10)-trien-22-oyl-coenzyme A",PubMed citation,24244004
5207,84651,(R)-oleoylcarnitine,An O-acyl-L-carnitine in which the acyl group is specified as oleoyl.,"InChI=1S/C25H47NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25(29)30-23(21-24(27)28)22-26(2,3)4/h12-13,23H,5-11,14-22H2,1-4H3/b13-12-/t23-/m1/s1",(R)-[(9Z)-octadecenoyl]carnitine,PubMed citation,20538056
5208,84666,(25S)-3-oxocholest-4-en-26-oyl-CoA,A cholestenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (25S)-3-oxocholest-4-en-26-oic acid.,"InChI=1S/C48H76N7O18P3S/c1-27(32-12-13-33-31-11-10-29-22-30(56)14-17-47(29,5)34(31)15-18-48(32,33)6)8-7-9-28(2)45(61)77-21-20-50-36(57)16-19-51-43(60)40(59)46(3,4)24-70-76(67,68)73-75(65,66)69-23-35-39(72-74(62,63)64)38(58)44(71-35)55-26-54-37-41(49)52-25-53-42(37)55/h22,25-28,31-35,38-40,44,58-59H,7-21,23-24H2,1-6H3,(H,50,57)(H,51,60)(H,65,66)(H,67,68)(H2,49,52,53)(H2,62,63,64)/t27-,28+,31+,32-,33+,34+,35-,38-,39-,40+,44-,47+,48-/m1/s1",(25S)-3-oxocholest-4-en-26-oyl-coenzyme A,PubMed citation,24244004
5209,84711,staphyloferrin A,A D-ornithine derivative obtained by formal condensation of the terminal carboxy groups of two citric acid units with the two amino groups of D-ornithine.,"InChI=1S/C17H24N2O14/c20-9(4-16(32,14(28)29)6-11(22)23)18-3-1-2-8(13(26)27)19-10(21)5-17(33,15(30)31)7-12(24)25/h8,32-33H,1-7H2,(H,18,20)(H,19,21)(H,22,23)(H,24,25)(H,26,27)(H,28,29)(H,30,31)/t8-,16?,17?/m1/s1","N(2),N(5)-di-(1-oxo-3-hydroxy-3,4-dicarboxybutyl)-D-ornithine",CAS Registry Number,127902-98-1
5210,84716,beta-D-glucosyl-N-hexadecanoylsphingosine,A beta-D-glucosyl-N-acylsphingosine in which the acyl group is specified as hexadecanoyl.,"InChI=1S/C40H77NO8/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(43)33(32-48-40-39(47)38(46)37(45)35(31-42)49-40)41-36(44)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h27,29,33-35,37-40,42-43,45-47H,3-26,28,30-32H2,1-2H3,(H,41,44)/b29-27+/t33-,34+,35+,37+,38-,39+,40+/m0/s1",beta-D-glucosyl-N-palmitoylsphinganine,LIPID MAPS instance accession,LMSP0501AA03
5211,84720,beta-D-galactosyl-N-octadecanoylsphingosine,A beta-D-galactosyl-N-acylsphingosine in which the acyl group is specified as octadecanoyl.,"InChI=1S/C42H81NO8/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-38(46)43-35(34-50-42-41(49)40(48)39(47)37(33-44)51-42)36(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,35-37,39-42,44-45,47-49H,3-28,30,32-34H2,1-2H3,(H,43,46)/b31-29+/t35-,36+,37+,39-,40-,41+,42+/m0/s1",beta-D-galactosyl-N-stearoylsphingosine,LIPID MAPS instance accession,LMSP0501AC02
5212,84737,4-aminobutyl beta-D-xylopyranoside,A glycoside that is beta-D-xylose in which the hydrogen of the anomeric hydroxy group is replaced by a 4-aminobutyl group. A synthetic version of the beta-xylosyl glycoside (BXG) epitope from the major peanut allergen glycoprotein Arachis hypogaea h2 (Ara-h2).,"InChI=1S/C9H19NO5/c10-3-1-2-4-14-9-8(13)7(12)6(11)5-15-9/h6-9,11-13H,1-5,10H2/t6-,7+,8-,9-/m1/s1",4-aminobutyl beta-D-xyloside,PubMed citation,25259443
5213,84743,amiloride hydrochloride,A hydrochloride obtained by combining amiloride with one molar equivalent of hydrochloric acid.,"InChI=1S/C6H8ClN7O.ClH/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11;/h(H4,8,9,13)(H4,10,11,14,15);1H",amiloride monohydrochloride,Wikipedia accession,Amiloride
5214,84778,beta-D-GlcpNAc-(1->4)-alpha-D-Glcp2Ac6SOPr,An oligosaccharide sulfate formed by sulfating propyl N-acetyl-beta-D-glucosaminyl-(1->4)-2-O-acetyl-alpha-D-glucoside at O-6 of the reducing-end residue.,"InChI=1S/C19H33NO15S/c1-4-5-30-19-17(32-9(3)23)15(26)16(11(34-19)7-31-36(27,28)29)35-18-12(20-8(2)22)14(25)13(24)10(6-21)33-18/h10-19,21,24-26H,4-7H2,1-3H3,(H,20,22)(H,27,28,29)/t10-,11-,12-,13-,14-,15+,16-,17-,18+,19+/m1/s1",propyl 4-O-(2-acetamido-2-deoxy-beta-D-glucosyl)-2-O-acetyl-6-O-sulfo-alpha-D-glucoside,PubMed citation,22846255
5215,84779,beta-D-GlcpNAc-(1->4)-alpha-D-Glcp2Ac6SOPr(1-),The organosulfate oxoanion formed by deprotonation of the sulfo group in beta-D-GlcpNAc-(1->4)-alpha-D-Glcp2Ac6SOPr.,"InChI=1S/C19H33NO15S/c1-4-5-30-19-17(32-9(3)23)15(26)16(11(34-19)7-31-36(27,28)29)35-18-12(20-8(2)22)14(25)13(24)10(6-21)33-18/h10-19,21,24-26H,4-7H2,1-3H3,(H,20,22)(H,27,28,29)/p-1/t10-,11-,12-,13-,14-,15+,16-,17-,18+,19-/m1/s1",propyl 2-acetamido-2-deoxy-beta-D-glucosyl-(1->4)-2-O-acetyl-6-O-sulfonato-alpha-D-glucoside,PubMed citation,22846255
5216,84805,"UDP-N-acetyl-alpha-D-muramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminoheptanedioic acid","A UDP-N-acetylmuramoyl-L-alanyl-D-gamma-glutamyl-meso-2,6-diaminoheptanedioate in which the muramoyl moiety has alpha-configuration at its anomeric centre.","InChI=1S/C35H55N7O26P2/c1-13(28(50)40-18(33(56)57)7-8-21(45)39-17(32(54)55)6-4-5-16(36)31(52)53)37-29(51)14(2)64-27-23(38-15(3)44)34(66-19(11-43)25(27)48)67-70(61,62)68-69(59,60)63-12-20-24(47)26(49)30(65-20)42-10-9-22(46)41-35(42)58/h9-10,13-14,16-20,23-27,30,34,43,47-49H,4-8,11-12,36H2,1-3H3,(H,37,51)(H,38,44)(H,39,45)(H,40,50)(H,52,53)(H,54,55)(H,56,57)(H,59,60)(H,61,62)(H,41,46,58)/t13-,14+,16+,17-,18+,19+,20+,23+,24+,25+,26+,27+,30+,34+/m0/s1",UDP-N-acetyl-alpha-D-muramoyl-L-alanyl-gamma-D-glutamyl-meso-diaminopimelic acid,KEGG COMPOUND accession,C04877
5217,84859,ethyl arachidate,A long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of arachidic (icosanoic) acid with the hydroxy group of ethanol.,"InChI=1S/C22H44O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h3-21H2,1-2H3",ethyl eicosanoate,CAS Registry Number,18281-05-5
5218,84862,ethyl (11Z)-icosenoate,A long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of (11Z)-icosenoic acid with the hydroxy group of ethanol.,"InChI=1S/C22H42O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h11-12H,3-10,13-21H2,1-2H3/b12-11-",ethyl (11Z)-eicosenoate,Reaxys Registry Number,1913152
5219,84864,ethyl (9Z)-icosenoate,A long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of (9Z)-icosenoic acid with the hydroxy group of ethanol.,"InChI=1S/C22H42O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h13-14H,3-12,15-21H2,1-2H3/b14-13-",ethyl (9Z)-eicos-11-enoate,Reaxys Registry Number,1713047
5220,84873,ethyl arachidonate,A long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of arachidonic acid with the hydroxy group of ethanol.,"InChI=1S/C22H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h8-9,11-12,14-15,17-18H,3-7,10,13,16,19-21H2,1-2H3/b9-8-,12-11-,15-14-,18-17-","ethyl (5Z,8Z,11Z,14Z)-eicosatetraenoate",PubMed citation,18599378
5221,84875,16-methyloctadecanoic acid,A methyl-branched fatty acid that is octadecanoic acid substituted by a methyl group at position 16.,"InChI=1S/C19H38O2/c1-3-18(2)16-14-12-10-8-6-4-5-7-9-11-13-15-17-19(20)21/h18H,3-17H2,1-2H3,(H,20,21)",16-methylstearic acid,LIPID MAPS instance accession,LMFA01020016
5222,84876,"ethyl (8Z,11Z,14Z,17Z)-icosatetraenoate","A long-chain fatty acid ethyl ester resulting from the formal condensation of the carboxy group of (8Z,11Z,14Z,17Z)-icosatetraenoic acid with the hydroxy group of ethanol.","InChI=1S/C22H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15H,3-4,7,10,13,16-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-","ethyl (8Z,11Z,14Z,17Z)-eicosa-8,11,14,17-tetraenoate",CAS Registry Number,123940-93-2
5223,84878,20-methyldocosanoic acid,A methyl-branched fatty acid that is docosanoic acid (behenic acid) substituted by a methyl group at position 20.,"InChI=1S/C23H46O2/c1-3-22(2)20-18-16-14-12-10-8-6-4-5-7-9-11-13-15-17-19-21-23(24)25/h22H,3-21H2,1-2H3,(H,24,25)",20-methylbehenic acid,LIPID MAPS instance accession,LMFA01020020
5224,84889,10-methylundecanoic acid,A methyl-branched fatty acid that is  undecanoic acid substituted by a methyl group at position 10.,"InChI=1S/C12H24O2/c1-11(2)9-7-5-3-4-6-8-10-12(13)14/h11H,3-10H2,1-2H3,(H,13,14)",10-methylundecylic acid,LIPID MAPS instance accession,LMFA01020004
5225,84894,"hexane-2,5-diol",A glycol that is hexane substituted by hydroxy groups at positions 2 and 5.,"InChI=1S/C6H14O2/c1-5(7)3-4-6(2)8/h5-8H,3-4H2,1-2H3","2,5-hexanediol",CAS Registry Number,2935-44-6
5226,84895,Jeffamine M-600,A polyether that is a nine-membered polypropylene glycol terminated by an amino group at one end and a methoxyethyl termination at the other. A common crystallisation reagent.,"InChI=1S/C30H63NO10/c1-22(31)13-34-24(3)15-36-26(5)17-38-28(7)19-40-30(9)21-41-29(8)20-39-27(6)18-37-25(4)16-35-23(2)14-33-12-11-32-10/h22-30H,11-21,31H2,1-10H3",O-(2-aminopropyl)-O'-(2-methoxyethyl)polypropylene glycol,Reaxys Registry Number,20501114
5227,84906,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-D-GalpNAc,A branched amino pentasaccharide comprising two galactosyl-(1->4)-N-acetylglucosaminyl units linked beta(1->3) and beta(1->6) to a D-galactose residue.,"InChI=1S/C36H61N3O26/c1-9(44)37-17-23(50)29(63-35-27(54)25(52)20(47)12(4-40)59-35)14(6-42)61-33(17)57-8-16-22(49)31(19(32(56)58-16)39-11(3)46)65-34-18(38-10(2)45)24(51)30(15(7-43)62-34)64-36-28(55)26(53)21(48)13(5-41)60-36/h12-36,40-43,47-56H,4-8H2,1-3H3,(H,37,44)(H,38,45)(H,39,46)/t12-,13-,14-,15-,16-,17-,18-,19-,20+,21+,22+,23-,24-,25+,26+,27-,28-,29-,30-,31-,32?,33-,34+,35+,36+/m1/s1",Galbeta1-4GlcNAcbeta1-6(Galbeta1-4GlcNAcbeta1-3)GalNAc,PubMed citation,25568069
5228,84957,"1,2-icosanediol",A glycol that is icosane bearing two hydroxy substituents located at positions 1 and 2.,"InChI=1S/C20H42O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20(22)19-21/h20-22H,2-19H2,1H3","eicosane-1,2-diol",LIPID MAPS instance accession,LMFA05000076
5229,84958,"1,2-docosanediol",A glycol that is docosane bearing two hydroxy substituents located at positions 1 and 2.,"InChI=1S/C22H46O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22(24)21-23/h22-24H,2-21H2,1H3","1,2-dihydroxydocosane",LIPID MAPS instance accession,LMFA05000081
5230,84960,"1,2-hexacosanediol",A glycol that is hexacosane bearing two hydroxy substituents located at positions 1 and 2.,"InChI=1S/C26H54O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-26(28)25-27/h26-28H,2-25H2,1H3","1,2-dihydroxyhexacosane",CAS Registry Number,97338-12-0
5231,84964,"1,2-triacontanediol",A glycol that is triacontane bearing two hydroxy substituents located at positions 1 and 2.,"InChI=1S/C30H62O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-28-30(32)29-31/h30-32H,2-29H2,1H3","1,2-dihydroxytriacontane",Reaxys Registry Number,13328817
5232,84977,"(2E,6E,10E,14E)-omega-hydroxygeranylgeranic acid","A diterpenoid obtained by hydroxylation of one of the terminal methyl groups of (2E,6E,10E)-geranylgeranic acid.","InChI=1S/C20H32O3/c1-16(10-6-12-18(3)14-20(22)23)8-5-9-17(2)11-7-13-19(4)15-21/h9-10,13-14,21H,5-8,11-12,15H2,1-4H3,(H,22,23)/b16-10+,17-9+,18-14+,19-13+","(2E,6E,10E,14E)-16-hydroxygeranylgeranic acid",PubMed citation,19933331
5233,84985,"(2E,6E,10E)-omega-hydroxyfarnesyl diphosphate","A terpenyl phosphate obtained by hydroxylation of one of the terminal methyl groups of (2E,6E)-farnesyl diphosphate","InChI=1S/C15H28O8P2/c1-13(7-5-9-15(3)12-16)6-4-8-14(2)10-11-22-25(20,21)23-24(17,18)19/h6,9-10,16H,4-5,7-8,11-12H2,1-3H3,(H,20,21)(H2,17,18,19)/b13-6+,14-10+,15-9+","(2E,6E,10E)-12-hydroxyfarnesyl diphosphate",PubMed citation,19933331
5234,84992,3-methylpalmitoyl-CoA,"A long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-methylpalmitic acid,","InChI=1S/C38H68N7O17P3S/c1-5-6-7-8-9-10-11-12-13-14-15-16-26(2)21-29(47)66-20-19-40-28(46)17-18-41-36(50)33(49)38(3,4)23-59-65(56,57)62-64(54,55)58-22-27-32(61-63(51,52)53)31(48)37(60-27)45-25-44-30-34(39)42-24-43-35(30)45/h24-27,31-33,37,48-49H,5-23H2,1-4H3,(H,40,46)(H,41,50)(H,54,55)(H,56,57)(H2,39,42,43)(H2,51,52,53)/t26?,27-,31-,32-,33+,37-/m1/s1",3-methylhexadecanoyl-coenzyme A,PubMed citation,10744784
5235,85014,"2,5-hexanedione",A diketone that is hexane substituted by oxo groups at positions 2 and 5. It is a toxic metabolite of hexane and of 2-hexanone,"InChI=1S/C6H10O2/c1-5(7)3-4-6(2)8/h3-4H2,1-2H3","hexane-2,5-dione",Reaxys Registry Number,506525
5236,85029,tridecanoyl-CoA,A long-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of tridecanoic acid.,"InChI=1S/C34H60N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-25(43)62-18-17-36-24(42)15-16-37-32(46)29(45)34(2,3)20-55-61(52,53)58-60(50,51)54-19-23-28(57-59(47,48)49)27(44)33(56-23)41-22-40-26-30(35)38-21-39-31(26)41/h21-23,27-29,33,44-45H,4-20H2,1-3H3,(H,36,42)(H,37,46)(H,50,51)(H,52,53)(H2,35,38,39)(H2,47,48,49)/t23-,27-,28-,29+,33-/m1/s1",tridecanoyl-coenzyme A,Reaxys Registry Number,23144243
5237,85054,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,A branched amino pentasaccharide consisting of two repeating units of beta-D-Gal-(1->4)-beta-D-GlcNAc joined by a (1->3)-linkage with an alpha-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.,"InChI=1S/C34H58N2O25/c1-8-17(43)22(48)24(50)32(53-8)61-29-23(49)18(44)11(4-37)56-34(29)59-27-14(7-40)57-31(16(21(27)47)36-10(3)42)60-28-19(45)12(5-38)55-33(25(28)51)58-26-13(6-39)54-30(52)15(20(26)46)35-9(2)41/h8,11-34,37-40,43-52H,4-7H2,1-3H3,(H,35,41)(H,36,42)/t8-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21+,22+,23-,24-,25+,26+,27+,28-,29+,30+,31-,32-,33-,34-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,25568069
5238,85055,beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-Glcp,beta-D-Galp3S-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp with beta configuration at the glucose anomeric centre.  A trisaccharide derivative that consists of beta-D-glucose having an alpha-L-fucosyl residue attached at position 3 and a 3-sulfated beta-D-galactosyl residue attached at position 4.,"InChI=1S/C18H32O18S/c1-4-7(21)9(23)10(24)17(31-4)35-15-11(25)16(27)32-6(3-20)13(15)34-18-12(26)14(36-37(28,29)30)8(22)5(2-19)33-18/h4-27H,2-3H2,1H3,(H,28,29,30)/t4-,5+,6+,7+,8-,9+,10-,11+,12+,13+,14-,15+,16+,17-,18-/m0/s1",[3OSO3]Galbeta1-4(Fucalpha1-3)Glcbeta,PubMed citation,25568069
5239,85058,12-methyloctadecanoic acid,A methyl-branched fatty acid that is octadecanoic (stearic) acid bearing a methyl substituent at position 12.,"InChI=1S/C19H38O2/c1-3-4-5-12-15-18(2)16-13-10-8-6-7-9-11-14-17-19(20)21/h18H,3-17H2,1-2H3,(H,20,21)",12-methylstearic acid,LIPID MAPS instance accession,LMFA01020211
5240,85059,3-methylundecanoic acid,A methyl-branched fatty acid that is undecanoic acid bearing a methyl substituent at position 3.,"InChI=1S/C12H24O2/c1-3-4-5-6-7-8-9-11(2)10-12(13)14/h11H,3-10H2,1-2H3,(H,13,14)",beta-methylundecanoic acid,LIPID MAPS instance accession,LMFA01020054
5241,85061,"N,N-dimethylformamide dimethyl acetal","An acetal obtained by formal condensation of N,N-dimethylformamide with methanol. N,N-dimethylformamide dimethyl acetal is a derivatisation agent used in gas-chromatography applications","InChI=1S/C5H13NO2/c1-6(2)5(7-3)8-4/h5H,1-4H3",DMF-DMA,Reaxys Registry Number,506020
5242,85062,trimethylphenylammonium hydroxide,A quaternary ammonium salt that is the hydroxide of trimethylphenylammonium. It is a derivatisation agent used in gas chromatography/mass spectrometry applications.,"InChI=1S/C9H14N.H2O/c1-10(2,3)9-7-5-4-6-8-9;/h4-8H,1-3H3;1H2/q+1;/p-1",TMAH,Reaxys Registry Number,3917033
5243,85063,N-trimethylsilylimidazole,A member of the class of imidazoles in which the hydrogen at position 1 is replaced by a trimethylsilyl group. N-trimethylsilylimidazole is a derivatisation agent used in gas chromatography/mass spectrometry applications.,"InChI=1S/C6H12N2Si/c1-9(2,3)8-5-4-7-6-8/h4-6H,1-3H3",TSIM,Reaxys Registry Number,606148
5244,85064,N-methyl-N-(trimethylsilyl)trifluoroacetamide,An N-silyl compound that is N-methyltrifluoroacetamide in which the amide nitrogen is replaced by a trimethylsilyl group. N-methyl-N-(trimethylsilyl)trifluoroacetamide is a derivatisation agent used in gas chromatography/mass spectrometry applications.,"InChI=1S/C6H12F3NOSi/c1-10(12(2,3)4)5(11)6(7,8)9/h1-4H3",MSTFA,Beilstein Registry Number,1941550
5245,85067,"N,O-bis(trimethylsilyl)trifluoroacetamide","A silyl ether that is the N,O-bis(trimethylsilyl) derivative of trifluoroacetamide. N,O-bis(trimethylsilyl)trifluoroacetamide is a derivatisation agent used in gas chromatography/mass spectrometry applications.","InChI=1S/C8H18F3NOSi2/c1-14(2,3)12-7(8(9,10)11)13-15(4,5)6/h1-6H3/b12-7+",BSTFA,Reaxys Registry Number,3607620
5246,85068,hexamethyldisilazane,An N-silyl compound obtained from ammonia by replacement of two of the hydrogens with trimethylsilyl groups.  Hexamethyldisilazane is a derivatisation agent used in gas chromatography mass spectrometry applications.,"InChI=1S/C6H19NSi2/c1-8(2,3)7-9(4,5)6/h7H,1-6H3",HMDS,Reaxys Registry Number,635752
5247,85069,chlorotrimethylsilane,A silyl chloride consisting of a central silicon atom covalently bound to one chloro and three methyl groups. Chlorotrimethylsilane is a derivatisation agent used in gas chromatography/mass spectrometry applications.,"InChI=1S/C3H9ClSi/c1-5(2,3)4/h1-3H3",TMCS,CAS Registry Number,75-77-4
5248,85070,N-(trimethylsilyl)diethylamine,An N-silyl compound that is diethylamine in which the amino hydrogen is replaced by a trimethylsilyl group. N-(trimethylsilyl)diethylamine is a derivatisation agent used in gas chromatography/mass spectrometry applications.,"InChI=1S/C7H19NSi/c1-6-8(7-2)9(3,4)5/h6-7H2,1-5H3",diethylaminotrimethylsilane,PubMed citation,12126402
5249,85071,tert-butyldimethylsilyl chloride,"A silyl chloride consisting of a central silicon atom covalently bound to one chloro, one tert-butyl and two methyl groups. tert-Butyldimethylsilyl chloride is a derivatisation agent used in gas chromatography/mass spectrometry applications.","InChI=1S/C6H15ClSi/c1-6(2,3)8(4,5)7/h1-5H3",TBDMSCl,Reaxys Registry Number,505999
5250,85076,1-oleoyl-2-stearoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl substituents at positions 1 and 2 are specified as oleoyl and stearoyl respectively.","InChI=1S/C41H80NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17,19,39H,3-16,18,20-38,42H2,1-2H3,(H,45,46)/b19-17-/t39-/m1/s1",1-(9Z-octadecenoyl)-2-octadecanoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02010050
5251,85080,ascorbyl dipalmitate,A fatty acid ester obtained by the formal condensation of the hydroxy groups at positions 5 and 6 of L-ascorbic acid with two molecules of  palmitic acid.,"InChI=1S/C38H68O8/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-33(39)44-31-32(37-35(41)36(42)38(43)46-37)45-34(40)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h32,37,41-42H,3-31H2,1-2H3/t32-,37+/m0/s1","5,6-O-dipalmitoyl-L-ascorbic acid",Reaxys Registry Number,5367970
5252,85085,KT 5720,"An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.","InChI=1S/C32H31N3O5/c1-3-4-5-10-15-39-30(37)32(38)16-23-34-21-13-8-6-11-18(21)25-26-20(17-33-29(26)36)24-19-12-7-9-14-22(19)35(28(24)27(25)34)31(32,2)40-23/h6-9,11-14,23,38H,3-5,10,15-17H2,1-2H3,(H,33,36)/t23-,31+,32+/m0/s1",KT5720,PubMed citation,12547730
5253,85088,Lys-Thr-Trp-Gly-Lys-Asn-Leu-Val-Phe,"An oligopeptide composed of L-lysine, L-threonine, L-tryptophan, glycine, L-asparagine, L-leucine, L-valine and L-phenylalanine joined in sequence by peptide linkages; corresponds to the sequence in the yellow feverspecific peptide epitope K9F.","InChI=1S/C53H81N13O12/c1-29(2)23-38(50(74)65-44(30(3)4)51(75)64-41(53(77)78)24-32-15-7-6-8-16-32)61-49(73)40(26-42(57)68)62-48(72)37(20-12-14-22-55)60-43(69)28-59-47(71)39(25-33-27-58-36-19-10-9-17-34(33)36)63-52(76)45(31(5)67)66-46(70)35(56)18-11-13-21-54/h6-10,15-17,19,27,29-31,35,37-41,44-45,58,67H,11-14,18,20-26,28,54-56H2,1-5H3,(H2,57,68)(H,59,71)(H,60,69)(H,61,73)(H,62,72)(H,63,76)(H,64,75)(H,65,74)(H,66,70)(H,77,78)/t31?,35-,37-,38-,39-,40-,41-,44-,45-/m0/s1",K9F,PubMed citation,25674793
5254,85092,Lys-Thr-Trp-Gly-Lys-Asn-Leu-Val-Ala,"An oligopeptide composed of L-lysine, L-threonine, L-tryptophan, glycine, L-asparagine, L-leucine, L-valine and L-alanine joined in sequence by peptide linkages; synthetic variant K9A of the yellow fever specific peptide epitope K9F.","InChI=1S/C47H77N13O12/c1-24(2)19-33(44(68)59-38(25(3)4)45(69)54-26(5)47(71)72)56-43(67)35(21-36(51)62)57-42(66)32(16-10-12-18-49)55-37(63)23-53-41(65)34(20-28-22-52-31-15-8-7-13-29(28)31)58-46(70)39(27(6)61)60-40(64)30(50)14-9-11-17-48/h7-8,13,15,22,24-27,30,32-35,38-39,52,61H,9-12,14,16-21,23,48-50H2,1-6H3,(H2,51,62)(H,53,65)(H,54,69)(H,55,63)(H,56,67)(H,57,66)(H,58,70)(H,59,68)(H,60,64)(H,71,72)/t26-,27?,30-,32-,33-,34-,35-,38-,39-/m0/s1",K9A,PubMed citation,25674793
5255,85096,Lys-Thr-Trp-Gly-Lys-Asn-Leu-Val-Val,"An oligopeptide composed of L-lysine, L-threonine, L-tryptophan, glycine, L-asparagine, L-leucine, L-valine and L-valine joined in sequence by peptide linkages; synthetic variant K9V of the yellow fever specific peptide epitope K9F.","InChI=1S/C49H81N13O12/c1-25(2)20-34(46(70)60-39(26(3)4)47(71)61-40(27(5)6)49(73)74)57-45(69)36(22-37(53)64)58-44(68)33(17-11-13-19-51)56-38(65)24-55-43(67)35(21-29-23-54-32-16-9-8-14-30(29)32)59-48(72)41(28(7)63)62-42(66)31(52)15-10-12-18-50/h8-9,14,16,23,25-28,31,33-36,39-41,54,63H,10-13,15,17-22,24,50-52H2,1-7H3,(H2,53,64)(H,55,67)(H,56,65)(H,57,69)(H,58,68)(H,59,72)(H,60,70)(H,61,71)(H,62,66)(H,73,74)/t28?,31-,33-,34-,35-,36-,39-,40-,41-/m0/s1",K9V,PubMed citation,25674793
5256,85115,"anthraquinone-2,6-disulfonic acid","A member of the class of anthraquinones that is 9,10-anthraquinone substituted at positions 2 and 6 by sulfo groups.","InChI=1S/C14H8O8S2/c15-13-9-3-1-7(23(17,18)19)5-11(9)14(16)10-4-2-8(6-12(10)13)24(20,21)22/h1-6H,(H,17,18,19)(H,20,21,22)","9,10-anthraquinone-2,6-disulfonic acid",PDBeChem accession,11H
5257,85148,3-hydroxytetradecanoic acid,A 3-hydroxy fatty acid that is tetradecanoic (myristic) acid substituted at position 3 by a hydroxy group,"InChI=1S/C14H28O3/c1-2-3-4-5-6-7-8-9-10-11-13(15)12-14(16)17/h13,15H,2-12H2,1H3,(H,16,17)",3-hydroxymyristic acid,CAS Registry Number,1961-72-4
5258,85190,"1-(5Z,8Z,11Z,14Z,17Z)-docosapent-5,8,11,14,17-enoyl-2-stearoyl-sn-glycero-3-phospho-1D-myo-inositol","1-phosphatidyl-1D-myo-inositol in which the 1- and 2-acyl groups are specified as (5Z,8Z,11Z,14Z,17Z)-docosapent-5,8,11,14,17-enoyl and octadecanoyl (stearoyl) respectively.","InChI=1S/C49H85O13P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-25-27-29-31-33-35-37-42(50)59-39-41(40-60-63(57,58)62-49-47(55)45(53)44(52)46(54)48(49)56)61-43(51)38-36-34-32-30-28-26-23-18-16-14-12-10-8-6-4-2/h9,11,15,17,20-21,24-25,29,31,41,44-49,52-56H,3-8,10,12-14,16,18-19,22-23,26-28,30,32-40H2,1-2H3,(H,57,58)/b11-9-,17-15-,21-20-,25-24-,31-29-/t41-,44-,45-,46+,47-,48-,49-/m1/s1","PI(22:5(5Z,8Z,11Z,14Z,17Z)/18:0)",PubMed citation,25642819
5259,85205,3-hydroxytetradecanoyl-CoA,A 3-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxytetradecanoic acid.,"InChI=1S/C35H62N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-23(43)18-26(45)64-17-16-37-25(44)14-15-38-33(48)30(47)35(2,3)20-57-63(54,55)60-62(52,53)56-19-24-29(59-61(49,50)51)28(46)34(58-24)42-22-41-27-31(36)39-21-40-32(27)42/h21-24,28-30,34,43,46-47H,4-20H2,1-3H3,(H,37,44)(H,38,48)(H,52,53)(H,54,55)(H2,36,39,40)(H2,49,50,51)/t23?,24-,28-,29-,30+,34-/m1/s1",3-hydroxytetradecanoyl-coenzyme A,Reaxys Registry Number,11195624
5260,85208,12-hydroxyoctadecanoic acid,A hydroxy fatty acid that is stearic acid bearing a hydroxy substituent at position 12.,"InChI=1S/C18H36O3/c1-2-3-4-11-14-17(19)15-12-9-7-5-6-8-10-13-16-18(20)21/h17,19H,2-16H2,1H3,(H,20,21)",12-hydroxystearic acid,Agricola citation,IND43939351
5261,85209,12-hydroxyoctadecanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 12-hydroxyoctadecanoic acid.,"InChI=1S/C39H70N7O18P3S/c1-4-5-6-13-16-27(47)17-14-11-9-7-8-10-12-15-18-30(49)68-22-21-41-29(48)19-20-42-37(52)34(51)39(2,3)24-61-67(58,59)64-66(56,57)60-23-28-33(63-65(53,54)55)32(50)38(62-28)46-26-45-31-35(40)43-25-44-36(31)46/h25-28,32-34,38,47,50-51H,4-24H2,1-3H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/t27?,28-,32-,33-,34+,38-/m1/s1",12-hydroxystearoyl-CoA,PubMed citation,21193570
5262,85213,16-hydroxyhexadecanoyl-CoA,An omega-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 16-hydroxyhexadecanoic acid.,"InChI=1S/C37H66N7O18P3S/c1-37(2,32(49)35(50)40-18-17-27(46)39-19-21-66-28(47)16-14-12-10-8-6-4-3-5-7-9-11-13-15-20-45)23-59-65(56,57)62-64(54,55)58-22-26-31(61-63(51,52)53)30(48)36(60-26)44-25-43-29-33(38)41-24-42-34(29)44/h24-26,30-32,36,45,48-49H,3-23H2,1-2H3,(H,39,46)(H,40,50)(H,54,55)(H,56,57)(H2,38,41,42)(H2,51,52,53)/t26-,30-,31-,32+,36-/m1/s1",16-hydroxypalmitoyl-coenzyme A,Reaxys Registry Number,11195626
5263,85237,1-myristoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as myristoyl and oleoyl respectively.","InChI=1S/C37H72NO8P/c1-3-5-7-9-11-13-15-16-17-18-20-22-24-26-28-30-37(40)46-35(34-45-47(41,42)44-32-31-38)33-43-36(39)29-27-25-23-21-19-14-12-10-8-6-4-2/h16-17,35H,3-15,18-34,38H2,1-2H3,(H,41,42)/b17-16-/t35-/m1/s1",1-tetradecanoyl-2-(9Z-octadecenoyl)-sn-phosphatidylethanolamine,LIPID MAPS instance accession,LMGP02011247
5264,85241,1-monooctanoylglycerol,A 1-monoglyceride that has octanoyl as the acyl group.,"InChI=1S/C11H22O4/c1-2-3-4-5-6-7-11(14)15-9-10(13)8-12/h10,12-13H,2-9H2,1H3",glyceryl octanoate,Reaxys Registry Number,1724525
5265,85242,1-octanoyl-sn-glycerol,A 1-acyl-sn-glycerol that has octanoyl as the 1-acyl group.,"InChI=1S/C11H22O4/c1-2-3-4-5-6-7-11(14)15-9-10(13)8-12/h10,12-13H,2-9H2,1H3/t10-/m0/s1",(2S)-1-O-octanoylglycerol,Reaxys Registry Number,6386436
5266,85266,amprolium(1+),"A pyridinium ion that is the cationic portion of amprolium, a veterinary drug which is used for prevention of coccidiosis in poultry and cattle.","InChI=1S/C14H19N4/c1-3-6-13-16-9-12(14(15)17-13)10-18-8-5-4-7-11(18)2/h4-5,7-9H,3,6,10H2,1-2H3,(H2,15,16,17)/q+1",amprolium cation,Reaxys Registry Number,4149652
5267,85310,"2-(3,4-dihydroxyphenyl)-2-oxoethyl thiocyanate","A member of the class of thiocyanates that is 3,4-dihydroxyacetophenone in which one of the methyl hydrogens has been replaced by the sulfur of a cyanosulfanediyl (-SC#N) group. It has been found to induce the expression of the endoplasmic reticulum chaperone protein GRP78 (78 kDa glucose-regulated protein, BiP, a highly conserved member of the 70 kDa heat shock protein family) leading to an attenuation of the unfolded protein response. It protects neuronal cells and retinal cells from endoplasmic reticulum (ER)-stress induced cell death.","InChI=1S/C9H7NO3S/c10-5-14-4-9(13)6-1-2-7(11)8(12)3-6/h1-3,11-12H,4H2",BiP inducer X,Reaxys Registry Number,3292146
5268,85318,trimethylphenylammonium,"A quaternary ammonium ion obtained by methylation of N,N-dimethylaniline.","InChI=1S/C9H14N/c1-10(2,3)9-7-5-4-6-8-9/h4-8H,1-3H3/q+1",phenyltrimethylammonium,Reaxys Registry Number,1862239
5269,85319,"N-(2-carbamoylphenyl)-2-(2,5-dimethoxyphenyl)quinoline-4-carboxamide","A member of the class of quinolines that is the amide obtained from formal condensation of the carboxy group of 2-(2,5-dimethoxyphenyl)quinoline-4-carboxylic acid with the amino group of 2-aminobenzamide.","InChI=1S/C25H21N3O4/c1-31-15-11-12-23(32-2)19(13-15)22-14-18(16-7-3-5-9-20(16)27-22)25(30)28-21-10-6-4-8-17(21)24(26)29/h3-14H,1-2H3,(H2,26,29)(H,28,30)",ST50933248,PubMed citation,21390037
5270,85320,"3-[(dimethylamino)methyl]-5-[(4-methoxyphenyl)methylidene]-1,3-thiazolidine-2,4-dione","A member of the class of thiazolidinones that is 3-[(dimethylamino)methyl]-1,3-thiazolidine-2,4-dione bearing an additional (4-methoxyphenyl)methylidene substituent at position 5.","InChI=1S/C14H16N2O3S/c1-15(2)9-16-13(17)12(20-14(16)18)8-10-4-6-11(19-3)7-5-10/h4-8H,9H2,1-3H3/b12-8+",AGN-PC-0K8NUL,PubMed citation,22035958
5271,85321,"(5E)-5-[(4-methoxyphenyl)methylidene]-1,1-dioxo-2,3-diphenyl-1,3-thiazolidin-4-one","A member of the class of thiazolidinones that is 1,1-dioxo-2,3-diphenyl-1,3-thiazolidin-4-one bearing an additional (4-methoxyphenyl)methylidene substituent at position 5.","InChI=1S/C23H19NO4S/c1-28-20-14-12-17(13-15-20)16-21-22(25)24(19-10-6-3-7-11-19)23(29(21,26)27)18-8-4-2-5-9-18/h2-16,23H,1H3/b21-16+",AC1LLKIB,PubMed citation,21390037
5272,85322,"[5-hydroxy-3-methyl-5-(trifluoromethyl)-4,5-dihydropyrazol-1-yl]-[5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-2-yl]methanone","A member of the class of pyrazolopyrimidines that is the amide obtained from formal condensation of the carboxy group of 5-phenyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxylic acid with the endocyclic amino group of 3-methyl-5-(trifluoromethyl)-4,5-dihydropyrazol-5-ol.","InChI=1S/C19H13F6N5O2/c1-10-9-17(32,19(23,24)25)30(27-10)16(31)13-8-15-26-12(11-5-3-2-4-6-11)7-14(18(20,21)22)29(15)28-13/h2-8,32H,9H2,1H3",AC1N7IQ9,PubMed citation,21390037
5273,85323,"4-hydroxy-1-isobutyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide","A member of the class of quinolones that is the amide obtained from formal condensation of the carboxy group of 4-hydroxy-1-(2-methylpropyl)-2-oxo-1,2-dihydroquinoline-3-carboxylic acid with the amino group of 5-methyl-1,3-thiazol-2-amine.","InChI=1S/C18H19N3O3S/c1-10(2)9-21-13-7-5-4-6-12(13)15(22)14(17(21)24)16(23)20-18-19-8-11(3)25-18/h4-8,10,22H,9H2,1-3H3,(H,19,20,23)",AC1LJIHT,Reaxys Registry Number,26434477
5274,85324,"7-{2-hydroxy-3-[(naphthalen-1-yl)oxy]propyl}-3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione","A member of the class of oxopurines that is 3-methyl-8-(morpholin-4-yl)-3,7-dihydropurine-2,6-dione bearing an additional 2-hydroxy-3-[(naphthalen-1-yl)oxy]propyl substituent at position 7.","InChI=1S/C23H25N5O5/c1-26-20-19(21(30)25-23(26)31)28(22(24-20)27-9-11-32-12-10-27)13-16(29)14-33-18-8-4-6-15-5-2-3-7-17(15)18/h2-8,16,29H,9-14H2,1H3,(H,25,30,31)",AC1MWOZX,Reaxys Registry Number,26434556
5275,85325,"1-allyl-4-hydroxy-2-oxo-N-(1,3-thiazol-2-yl)-1,2-dihydroquinoline-3-carboxamide","A member of the class of quinolones that is the amide obtained from formal condensation of the carboxy group of 1-allyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid with the amino group of 2-amino-1,3-thiazole.","InChI=1S/C16H13N3O3S/c1-2-8-19-11-6-4-3-5-10(11)13(20)12(15(19)22)14(21)18-16-17-7-9-23-16/h2-7,9,20H,1,8H2,(H,17,18,21)",BAS 00526019,Reaxys Registry Number,26434485
5276,85326,"4,5-dihydroindolo[3,2-c]pyrrolo[3,2,1-ij]quinolin-7-one","An organic heteropentacyclic compound that is 4,5-dihydroindolo[3,2-c]pyrrolo[3,2,1-ij]quinoline substituted at position 7 by an oxo group.","InChI=1S/C17H12N2O/c20-17-14-11-5-1-2-7-13(11)18-15(14)12-6-3-4-10-8-9-19(17)16(10)12/h1-7,18H,8-9H2",AO-476/41275079,Reaxys Registry Number,5069875
5277,85327,"1-(4-chlorophenyl)-3-[3-(3-chlorophenyl)-1,5,5-trimethyl-2-oxoimidazolidin-4-yl]urea","A member of the class of imidazolidinones that is 1,5,5-trimethyl-2-oxoimidazolidine bearing additional m-chlorophenyl and N'-p-chlorophenylureido substituents at positions 3 and 4 respectively.","InChI=1S/C19H20Cl2N4O2/c1-19(2)16(23-17(26)22-14-9-7-12(20)8-10-14)25(18(27)24(19)3)15-6-4-5-13(21)11-15/h4-11,16H,1-3H3,(H2,22,23,26)",AC1NEUAF,PubMed citation,21390037
5278,85328,2-(3-isopropyloxyphenyl)-N-(pyridin-4-yl)quinoline-4-carboxamide,A member of the class of quinolines that is the amide obtained from formal condensation of the carboxy group of 2-(2-isopropyloxyphenyl)quinoline-4-carboxylic acid with the amino group of 4-aminopyridine.,"InChI=1S/C24H21N3O2/c1-16(2)29-19-7-5-6-17(14-19)23-15-21(20-8-3-4-9-22(20)27-23)24(28)26-18-10-12-25-13-11-18/h3-16H,1-2H3,(H,25,26,28)",ST50931089,PubMed citation,21390037
5279,85345,"2-palmitoyl-3-stearoyl-2'-sulfo-alpha,alpha-trehalose","A polyacyl alpha,alpha-trehalose derivative that is 2'-sulfo-alpha,alpha-trehalose carrying palmitoyl and stearoyl groups at positions 2 and 3 respectively.","InChI=1S/C46H86O16S/c1-3-5-7-9-11-13-15-17-18-20-22-23-25-27-29-31-37(49)59-42-40(52)36(34-48)58-46(61-45-43(62-63(54,55)56)41(53)39(51)35(33-47)57-45)44(42)60-38(50)32-30-28-26-24-21-19-16-14-12-10-8-6-4-2/h35-36,39-48,51-53H,3-34H2,1-2H3,(H,54,55,56)/t35-,36-,39-,40-,41+,42+,43-,44-,45-,46-/m1/s1","2-hexadecanoyl-3-octadecanoyl-2'-sulfo-alpha,alpha-trehalose",PubMed citation,22194604
5280,85346,"N(3)-fumaroyl-(S)-2,3-diaminopropanoic acid",An L-alanine derivative obtained by formal condensation of one of the carboxy groups of fumaric acid with the side-chain amino group of 3-amino-L-alanine.,"InChI=1S/C7H10N2O5/c8-4(7(13)14)3-9-5(10)1-2-6(11)12/h1-2,4H,3,8H2,(H,9,10)(H,11,12)(H,13,14)/b2-1+/t4-/m0/s1","N(3)-fumaroyl-L-2,3-diaminopropanoic acid",MetaCyc accession,CPD0-1237
5281,85347,"N(3)-fumaramoyl-(S)-2,3-diaminopropanoic acid",An L-alanine derivative obtained by formal condensation of the carboxy group of fumaric acid monoamide with the side-chain amino group of 3-amino-L-alanine.,"InChI=1S/C7H11N3O4/c8-4(7(13)14)3-10-6(12)2-1-5(9)11/h1-2,4H,3,8H2,(H2,9,11)(H,10,12)(H,13,14)/b2-1+/t4-/m0/s1","N(3)-fumaramoyl-L-2,3-diaminopropanoic acid",CAS Registry Number,91235-43-7
5282,85357,"3-[(1E,4R)-4-hydroxycyclohex-2-en-1-ylidene]pyruvic acid","A 3-(4-hydroxycyclohex-2-en-1-ylidene)pyruvic acid having 1E,4R stereochemistry.","InChI=1S/C9H10O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1,3,5,7,10H,2,4H2,(H,12,13)/b6-5-/t7-/m0/s1","3-[(1E,4R)-4-hydroxycyclohex-2-en-1-ylidene]-2-oxopropanoic acid",Reaxys Registry Number,22690131
5283,85361,tetramethylsilane,An organosilicon compound that is silane in which the hydrogens have been replaced by methyl groups.,"InChI=1S/C4H12Si/c1-5(2,3)4/h1-4H3",TMS,CAS Registry Number,75-76-3
5284,85362,3-(trimethylsilyl)propane-1-sulfonic acid,An alkanesulfonic acid that is propanesulfonic acid substituted at position 3 by a trimethylsilyl group.,"InChI=1S/C6H16O3SSi/c1-11(2,3)6-4-5-10(7,8)9/h4-6H2,1-3H3,(H,7,8,9)",DSS,Reaxys Registry Number,1860132
5285,85363,sodium 3-(trimethylsilyl)propionate,An organic sodium salt composed of sodium and 3-(trimethylsilyl)propionate ions in a 1:1 ratio. It is used as internal reference in the NMR spectrum nuclear magnetic resonance for aqueous solvents (e.g. D2O).,"InChI=1S/C6H14O2Si.Na/c1-9(2,3)5-4-6(7)8;/h4-5H2,1-3H3,(H,7,8);/q;+1/p-1",TMSP,CAS Registry Number,37013-20-0
5286,85365,deuterated chloroform,A deuterated compound that is an isotopologue of chloroform in which the hydrogen atom is replaced with deuterium. Commonly used as a solvent in proton NMR spectroscopy.,InChI=1S/CHCl3/c2-1(3)4/h1H/i1D,CDCl3,Wikipedia accession,Deuterated_chloroform
5287,85368,"dTDP-4-dehydro-2,6-dideoxy-alpha-D-glucose","A dTDP-sugar having 4-dehydro-2,6-dideoxy-alpha-D-glucose as the sugar component.","InChI=1S/C16H24N2O14P2/c1-7-5-18(16(23)17-15(7)22)12-3-9(19)11(30-12)6-28-33(24,25)32-34(26,27)31-13-4-10(20)14(21)8(2)29-13/h5,8-13,19-20H,3-4,6H2,1-2H3,(H,24,25)(H,26,27)(H,17,22,23)/t8-,9+,10-,11-,12-,13-/m1/s1","dTDP-4-keto-2,6-dideoxy-alpha-D-glucose",KEGG COMPOUND accession,C11922
5288,85369,"dTDP-3,4-didehydro-2,6-dideoxy-alpha-D-glucose","A dTDP-sugar having 3,4-didehydro-2,6-dideoxy-alpha-D-glucose as the sugar component.","InChI=1S/C16H22N2O14P2/c1-7-5-18(16(23)17-15(7)22)12-3-9(19)11(30-12)6-28-33(24,25)32-34(26,27)31-13-4-10(20)14(21)8(2)29-13/h5,8-9,11-13,19H,3-4,6H2,1-2H3,(H,24,25)(H,26,27)(H,17,22,23)/t8-,9+,11-,12-,13-/m1/s1","dTDP-3,4-diketo-2,6-dideoxy-alpha-D-glucose",Reaxys Registry Number,21897510
5289,85371,"4-hydroxy-1-isopentyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide","A member of the class of quinolones that is the amide obtained from formal condensation of the carboxy group of 4-hydroxy-1-isopentyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid with the amino group of 2-amino-3-methyl-1,3-thiazole.","InChI=1S/C19H21N3O3S/c1-11(2)8-9-22-14-7-5-4-6-13(14)16(23)15(18(22)25)17(24)21-19-20-10-12(3)26-19/h4-7,10-11,23H,8-9H2,1-3H3,(H,20,21,24)",AC1LJIHV,PubMed citation,21390037
5290,85372,"4-hydroxy-1-isobutyl-N-(4-methyl-1,3-thiazol-2-yl)-2-oxoquinoline-3-carboxamide","A member of the class of quinolones that is the amide obtained from formal condensation of the carboxy group of 4-hydroxy-1-isobutyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid with the amino group of 2-amino-4-methyl-1,3-thiazole.","InChI=1S/C18H19N3O3S/c1-10(2)8-21-13-7-5-4-6-12(13)15(22)14(17(21)24)16(23)20-18-19-11(3)9-25-18/h4-7,9-10,22H,8H2,1-3H3,(H,19,20,23)",AC1LJIHS,Reaxys Registry Number,26434483
5291,85373,"1-allyl-4-hydroxy-2-oxo-N-(4-phenyl-1,3-thiazol-2-yl)-1,2-dihydroquinoline-3-carboxamide","A member of the class of quinolones that is the amide obtained from formal condensation of the carboxy group of 1-allyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid with the amino group of 2-amino-4-phenyl-1,3-thiazole.","InChI=1S/C22H17N3O3S/c1-2-12-25-17-11-7-6-10-15(17)19(26)18(21(25)28)20(27)24-22-23-16(13-29-22)14-8-4-3-5-9-14/h2-11,13,26H,1,12H2,(H,23,24,27)",AGN-PC-0AAF1C,PubMed citation,21390037
5292,85374,"1-butyl-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-4-hydroxy-2-oxoquinoline-3-carboxamide","A member of the class of quinolones that is the amide obtained from formal condensation of the carboxy group of 1-allyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid with the amino group of 2-amino-3-ethyl-1,3,4-thiadizole.","InChI=1S/C18H20N4O3S/c1-3-5-10-22-12-9-7-6-8-11(12)15(23)14(17(22)25)16(24)19-18-21-20-13(4-2)26-18/h6-9,23H,3-5,10H2,1-2H3,(H,19,21,24)",AC1LUO25,Reaxys Registry Number,26434489
5293,85381,"sodium 8-methoxypyrene-1,3,6-trisulfonate","An organic sodium salt that is the trisodium salt of 8-methoxypyrene-1,3,6-trisulfonic acid. A highly water-soluble superpolar fluorescent probe for assaying cationic surfactants.","InChI=1S/C17H12O10S3.3Na/c1-27-12-6-13(28(18,19)20)9-4-5-11-15(30(24,25)26)7-14(29(21,22)23)10-3-2-8(12)16(9)17(10)11;;;/h2-7H,1H3,(H,18,19,20)(H,21,22,23)(H,24,25,26);;;/q;3*+1/p-3","8-methoxypyrene-1,3,6-trisulfonic acid trisodium salt",Reaxys Registry Number,6469451
5294,85382,1-heptadecanoyl-2-lauroyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl groups at postions 1 and 2 are specified as heptadecanoyl and lauroyl respectively.","InChI=1S/C32H63O8P/c1-3-5-7-9-11-13-14-15-16-17-19-20-22-24-26-31(33)38-28-30(29-39-41(35,36)37)40-32(34)27-25-23-21-18-12-10-8-6-4-2/h30H,3-29H2,1-2H3,(H2,35,36,37)/t30-/m1/s1",1-heptadecanoyl-2-dodecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010224
5295,85383,1-heptadecanoyl-2-myristoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl groups at postions 1 and 2 are specified as heptadecanoyl and myristoyl respectively.","InChI=1S/C34H67O8P/c1-3-5-7-9-11-13-15-16-17-19-20-22-24-26-28-33(35)40-30-32(31-41-43(37,38)39)42-34(36)29-27-25-23-21-18-14-12-10-8-6-4-2/h32H,3-31H2,1-2H3,(H2,37,38,39)/t32-/m1/s1",1-heptadecanoyl-2-tetradecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010225
5296,85385,1-heptadecanoyl-2-stearoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl groups at postions 1 and 2 are specified as heptadecanoyl and stearoyl respectively.","InChI=1S/C38H75O8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(40)46-36(35-45-47(41,42)43)34-44-37(39)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h36H,3-35H2,1-2H3,(H2,41,42,43)/t36-/m1/s1",1-heptadecanoyl-2-octadecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010895
5297,85386,1-heptadecanoyl-2-palmitoyl-sn-glycero-3-phosphate,"A 1,2-diacyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl groups at postions 1 and 2 are specified as heptadecanoyl and palmitoyl respectively.","InChI=1S/C36H71O8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-35(37)42-32-34(33-43-45(39,40)41)44-36(38)31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h34H,3-33H2,1-2H3,(H2,39,40,41)/t34-/m1/s1",1-heptadecanoyl-2-hexadecanoyl-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10010227
5298,85392,5'-UGGGAAGACA-3',"A synthetic RNA fragment comprised of one uridine, one cytidine, four adenosine and four guanosine residues connected by 3'->5' phosphodiester linkages in the sequence U-G-G-G-A-A-G-A-C-A.","InChI=1S/C98H120N45O65P9/c99-37-1-3-134(97(161)124-37)85-50(149)59(201-209(163,164)181-6-28-47(146)48(147)83(191-28)136-19-116-39-67(100)108-15-112-71(39)136)29(192-85)7-183-211(167,168)202-60-31(194-86(51(60)150)137-20-117-40-68(101)109-16-113-72(40)137)9-185-214(173,174)206-64-34(197-90(55(64)154)141-24-121-44-76(141)127-94(105)131-80(44)158)12-187-213(171,172)204-62-30(193-88(53(62)152)139-22-119-42-70(103)111-18-115-74(42)139)8-184-212(169,170)203-61-32(195-87(52(61)151)138-21-118-41-69(102)110-17-114-73(41)138)10-186-215(175,176)207-65-35(198-91(56(65)155)142-25-122-45-77(142)128-95(106)132-81(45)159)13-189-217(179,180)208-66-36(199-92(57(66)156)143-26-123-46-78(143)129-96(107)133-82(46)160)14-188-216(177,178)205-63-33(196-89(54(63)153)140-23-120-43-75(140)126-93(104)130-79(43)157)11-182-210(165,166)200-58-27(5-144)190-84(49(58)148)135-4-2-38(145)125-98(135)162/h1-4,15-36,47-66,83-92,144,146-156H,5-14H2,(H,163,164)(H,165,166)(H,167,168)(H,169,170)(H,171,172)(H,173,174)(H,175,176)(H,177,178)(H,179,180)(H2,99,124,161)(H2,100,108,112)(H2,101,109,113)(H2,102,110,114)(H2,103,111,115)(H,125,145,162)(H3,104,126,130,157)(H3,105,127,131,158)(H3,106,128,132,159)(H3,107,129,133,160)/t27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-/m1/s1",UpGpGpGpApApGpApCpA,PubMed citation,8612352
5299,85393,5'-AUGUAGAUUA-3',"A synthetic RNA fragment comprised of four uridine, four adenosine and two guanosine residues connected by 3'->5' phosphodiester linkages in the sequence A-U-G-U-A-G-A-U-U-A.","InChI=1S/C96H117N38O68P9/c97-69-43-73(107-19-103-69)129(23-111-43)81-50(141)49(140)30(185-81)10-175-203(157,158)195-61-32(187-82(52(61)143)125-5-1-39(136)117-93(125)153)12-177-205(161,162)196-63-33(188-84(54(63)145)127-7-3-41(138)119-95(127)155)13-178-208(167,168)199-65-36(191-87(56(65)147)131-25-113-45-71(99)105-21-109-75(45)131)16-181-211(173,174)202-68-38(193-90(59(68)150)134-28-116-48-78(134)122-92(102)124-80(48)152)18-183-210(171,172)200-66-35(190-88(57(66)148)132-26-114-46-72(100)106-22-110-76(46)132)15-180-206(163,164)198-64-34(189-85(55(64)146)128-8-4-42(139)120-96(128)156)14-179-209(169,170)201-67-37(192-89(58(67)149)133-27-115-47-77(133)121-91(101)123-79(47)151)17-182-207(165,166)197-62-31(186-83(53(62)144)126-6-2-40(137)118-94(126)154)11-176-204(159,160)194-60-29(9-135)184-86(51(60)142)130-24-112-44-70(98)104-20-108-74(44)130/h1-8,19-38,49-68,81-90,135,140-150H,9-18H2,(H,157,158)(H,159,160)(H,161,162)(H,163,164)(H,165,166)(H,167,168)(H,169,170)(H,171,172)(H,173,174)(H2,97,103,107)(H2,98,104,108)(H2,99,105,109)(H2,100,106,110)(H,117,136,153)(H,118,137,154)(H,119,138,155)(H,120,139,156)(H3,101,121,123,151)(H3,102,122,124,152)/t29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-/m1/s1",ApUpGpUpApGpApUpUpA,PubMed citation,8612352
5300,85394,5'-UAUGUACACUACA-3',"A synthetic RNA fragment comprised of five adenosine, one guanosine, four uridine and three cytidine residues connected by 3'->5' phosphodiester linkages in the sequence U-G-G-G-A-A-G-A-C-A.","InChI=1S/C123H153N47O88P12/c124-52-1-8-158(117(191)149-52)105-68(179)80(248-259(198,199)222-16-40-65(176)66(177)103(235-40)165-33-143-59-91(127)133-28-138-96(59)165)41(236-105)17-225-266(212,213)255-88-49(244-113(76(88)187)168-36-146-62-94(130)136-31-141-99(62)168)25-231-263(206,207)251-83-44(239-108(71(83)182)162-12-5-56(173)153-121(162)195)20-224-261(202,203)249-81-42(237-106(69(81)180)159-9-2-53(125)150-118(159)192)18-226-267(214,215)256-87-48(243-112(75(87)186)167-35-145-61-93(129)135-30-140-98(61)167)24-230-262(204,205)250-82-43(238-107(70(82)181)160-10-3-54(126)151-119(160)193)19-227-268(216,217)257-89-50(245-114(77(89)188)169-37-147-63-95(131)137-32-142-100(63)169)26-232-264(208,209)252-84-46(241-109(72(84)183)163-13-6-57(174)154-122(163)196)22-229-270(220,221)258-90-51(246-115(78(90)189)170-38-148-64-101(170)156-116(132)157-102(64)190)27-233-265(210,211)253-85-45(240-110(73(85)184)164-14-7-58(175)155-123(164)197)21-228-269(218,219)254-86-47(242-111(74(86)185)166-34-144-60-92(128)134-29-139-97(60)166)23-223-260(200,201)247-79-39(15-171)234-104(67(79)178)161-11-4-55(172)152-120(161)194/h1-14,28-51,65-90,103-115,171,176-189H,15-27H2,(H,198,199)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H,212,213)(H,214,215)(H,216,217)(H,218,219)(H,220,221)(H2,124,149,191)(H2,125,150,192)(H2,126,151,193)(H2,127,133,138)(H2,128,134,139)(H2,129,135,140)(H2,130,136,141)(H2,131,137,142)(H,152,172,194)(H,153,173,195)(H,154,174,196)(H,155,175,197)(H3,132,156,157,190)/t39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-/m1/s1",UpApUpGpUpApCpApCpUpApCpA,PubMed citation,8612352
5301,85396,alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo,An amino trisaccharide consisting of three N-formyl-alpha-D-perosamine residues linked sequentially (1->3) and (1->2).,"InChI=1S/C21H35N3O13/c1-7-11(23-5-26)14(29)18(19(32)33-7)37-21-16(31)17(12(24-6-27)9(3)35-21)36-20-15(30)13(28)10(22-4-25)8(2)34-20/h4-21,28-32H,1-3H3,(H,22,25)(H,23,26)(H,24,27)/t7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20-,21-/m1/s1",N-formyl-alpha-D-perosaminyl-(1->3)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosamine,PubMed citation,25653412
5302,85397,alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo,"An amino tetrasaccharide consisting of four N-formyl-alpha-D-perosamine residues linked sequentially (1->2), (1->3) and (1->2).","InChI=1S/C28H46N4O17/c1-9-14(30-6-34)18(38)23(25(42)43-9)48-27-21(41)22(16(32-8-36)12(4)45-27)47-28-24(19(39)15(31-7-35)11(3)46-28)49-26-20(40)17(37)13(29-5-33)10(2)44-26/h5-28,37-42H,1-4H3,(H,29,33)(H,30,34)(H,31,35)(H,32,36)/t9-,10-,11-,12-,13-,14-,15-,16-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-/m1/s1",alpha-D-Rha4NFo-(1->2)-alpha-D-Rha4NFo-(1->3)-alpha-D-Rha4NFo-(1->2)-alpha-D-Rha4NFo,PubMed citation,25653412
5303,85399,alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo,"An amino nonasaccharide consisting of nine N-formyl-alpha-D-perosamine residues linked sequentially (1->2), (1->2), (1->2), (1->3), (1->2), (1->2), (1->2) and (1->2).","InChI=1S/C63H101N9O37/c1-19-29(65-11-74)38(83)48(55(92)93-19)103-59-52(42(87)33(69-15-78)22(4)97-59)107-63-54(44(89)35(71-17-80)26(8)101-63)109-61-50(40(85)31(67-13-76)24(6)99-61)105-57-46(91)47(36(72-18-81)27(9)95-57)102-58-51(41(86)32(68-14-77)21(3)96-58)106-62-53(43(88)34(70-16-79)25(7)100-62)108-60-49(39(84)30(66-12-75)23(5)98-60)104-56-45(90)37(82)28(64-10-73)20(2)94-56/h10-63,82-92H,1-9H3,(H,64,73)(H,65,74)(H,66,75)(H,67,76)(H,68,77)(H,69,78)(H,70,79)(H,71,80)(H,72,81)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56-,57-,58-,59-,60-,61-,62-,63-/m1/s1",N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->3)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosamine,PubMed citation,25653412
5304,85400,1-heptadecanoyl-2-arachidonoyl-sn-glycero-3-phosphoserine,A 3-sn-phosphatidyl-L-serine in which the acyl substituents at positions 1 and 2 are specified as heptadecanoyl and arachidonoyl respectively.,"InChI=1S/C43H76NO10P/c1-3-5-7-9-11-13-15-17-19-20-21-23-25-27-29-31-33-35-42(46)54-39(37-52-55(49,50)53-38-40(44)43(47)48)36-51-41(45)34-32-30-28-26-24-22-18-16-14-12-10-8-6-4-2/h11,13,17,19,21,23,27,29,39-40H,3-10,12,14-16,18,20,22,24-26,28,30-38,44H2,1-2H3,(H,47,48)(H,49,50)/b13-11-,19-17-,23-21-,29-27-/t39-,40+/m1/s1","1-heptadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphoserine",LIPID MAPS instance accession,LMGP03010003
5305,85403,1-stearoyl-sn-glycero-3-phosphoserine,A 1-acyl-sn-glycerophosphoserine in which the acyl group is specified as stearoyl (octadecanoyl).,"InChI=1S/C24H48NO9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(27)32-18-21(26)19-33-35(30,31)34-20-22(25)24(28)29/h21-22,26H,2-20,25H2,1H3,(H,28,29)(H,30,31)/t21-,22+/m1/s1",1-octadecanoyl-sn-glycero-3-phospho-L-serine,LIPID MAPS instance accession,LMGP03050006
5306,85406,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-D-GalpNAc,"An amino trisaccharide comprised of a linear sequence of beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-D-galactosamine linked (1->4) and (1->6).","InChI=1S/C22H38N2O16/c1-6(27)23-11-15(31)14(30)10(37-20(11)35)5-36-21-12(24-7(2)28)16(32)19(9(4-26)39-21)40-22-18(34)17(33)13(29)8(3-25)38-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13+,14+,15-,16-,17+,18-,19-,20?,21-,22+/m1/s1",Galb1-4GlcNAcb1-6GalNAc,PubMed citation,25568069
5307,85407,1-palmitoyl-sn-glycero-3-phosphoglycerol,A 1-acyl-sn-glycero-3-phosphoglycerol in which the acyl group is specified as palmitoyl (hexadecanoyl).,"InChI=1S/C22H45O9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-22(26)29-17-21(25)19-31-32(27,28)30-18-20(24)16-23/h20-21,23-25H,2-19H2,1H3,(H,27,28)/t20?,21-/m1/s1",1-hexadecanoyl-sn-glycero-3-phosphoglycerol,Reaxys Registry Number,9675315
5308,85408,1-heptadecanoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl groups at positions 1 and 2 are specified as heptadecanoyl and arachidonoyl respectively.","InChI=1S/C42H76NO8P/c1-3-5-7-9-11-13-15-17-19-20-21-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43)38-48-41(44)34-32-30-28-26-24-22-18-16-14-12-10-8-6-4-2/h11,13,17,19,21,23,27,29,40H,3-10,12,14-16,18,20,22,24-26,28,30-39,43H2,1-2H3,(H,46,47)/b13-11-,19-17-,23-21-,29-27-/t40-/m1/s1","1-heptadecanoyl-2-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02010003
5309,85409,1-heptadecanoyl-sn-glycero-3-phosphoethanolamine,A 1-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as heptadecanoyl.,"InChI=1S/C22H46NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-22(25)28-19-21(24)20-30-31(26,27)29-18-17-23/h21,24H,2-20,23H2,1H3,(H,26,27)/t21-/m1/s1",lysophosphatidylethanolamine 17:0,LIPID MAPS instance accession,LMGP02050030
5310,85410,1-oleoyl-sn-glycero-3-phosphoglycerol,A 1-acyl-sn-glycero-3-phosphoglycerol in which the acyl group is specified as oleoyl.,"InChI=1S/C24H47O9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-24(28)31-19-23(27)21-33-34(29,30)32-20-22(26)18-25/h9-10,22-23,25-27H,2-8,11-21H2,1H3,(H,29,30)/b10-9-/t22?,23-/m1/s1",1-(9Z)-octadecenoyl-sn-glycero-3-phosphoglycerol,Reaxys Registry Number,11001231
5311,85431,"1,2-dipalmitoyl-sn-glycero-3-phosphoethanol",A phosphatidylethanol in which both phosphatidyl acyl groups are specified as palmitoyl (hexadecanoyl).,"InChI=1S/C37H73O8P/c1-4-7-9-11-13-15-17-19-21-23-25-27-29-31-36(38)42-33-35(34-44-46(40,41)43-6-3)45-37(39)32-30-28-26-24-22-20-18-16-14-12-10-8-5-2/h35H,4-34H2,1-3H3,(H,40,41)/t35-/m1/s1","1,2-dipalmitoylphosphatidylethanol",Reaxys Registry Number,1718213
5312,85434,3'-MANT-GDP,A purine ribonucleoside 5'-diphosphate that is GDP substituted at the 3' position by an N-methylanthraniloyl group.,"InChI=1S/C18H22N6O12P2/c1-20-9-5-3-2-4-8(9)17(27)35-13-10(6-33-38(31,32)36-37(28,29)30)34-16(12(13)25)24-7-21-11-14(24)22-18(19)23-15(11)26/h2-5,7,10,12-13,16,20,25H,6H2,1H3,(H,31,32)(H2,28,29,30)(H3,19,22,23,26)/t10-,12-,13-,16-/m1/s1",3'-O-(N-methylanthraniloyl)-GDP,PDBeChem accession,BGO
5313,85435,1-arachidonoyl-sn-glycero-3-phospho-L-serine,An 1-acyl-sn-glycero-3-phosphoserine in which the 1-acyl group is specified as arachidonoyl.,"InChI=1S/C26H44NO9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-25(29)34-20-23(28)21-35-37(32,33)36-22-24(27)26(30)31/h6-7,9-10,12-13,15-16,23-24,28H,2-5,8,11,14,17-22,27H2,1H3,(H,30,31)(H,32,33)/b7-6-,10-9-,13-12-,16-15-/t23-,24+/m1/s1","1-(5Z,8Z,11Z,14Z)-icosatetraenoyl-sn-glycero-3-phospho-L-serine",LIPID MAPS instance accession,LMGP03050007
5314,85437,alpha-D-Glcp-(1->6)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->6)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp,"A heptasaccharide consisting of two alpha-maltotriose units linked (1->6), with a further alpha-D-glucose unit linked to O-6 of the glucose residue at the non-reducing end.","InChI=1S/C42H72O36/c43-1-8-15(48)18(51)26(59)37(69-8)66-6-13-16(49)19(52)27(60)39(73-13)77-35-12(5-47)72-42(31(64)24(35)57)78-33-10(3-45)70-38(29(62)22(33)55)67-7-14-17(50)20(53)28(61)40(74-14)76-34-11(4-46)71-41(30(63)23(34)56)75-32-9(2-44)68-36(65)25(58)21(32)54/h8-65H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18+,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36+,37+,38+,39-,40-,41-,42-/m1/s1",alpha-D-glucosyl-(1->6)-alpha-D-glucosyl-(1->4)-alpha-D-glucosyl-(1->4)-alpha-D-glucosyl-(1->6)-alpha-D-glucosyl-(1->4)-alpha-D-glucosyl-(1->4)-alpha-D-glucose,PubMed citation,25766777
5315,85442,trans-3-hexenoyl-CoA,A trans-3-enoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans-3-hexenoic acid.,"InChI=1S/C27H44N7O17P3S/c1-4-5-6-7-18(36)55-11-10-29-17(35)8-9-30-25(39)22(38)27(2,3)13-48-54(45,46)51-53(43,44)47-12-16-21(50-52(40,41)42)20(37)26(49-16)34-15-33-19-23(28)31-14-32-24(19)34/h5-6,14-16,20-22,26,37-38H,4,7-13H2,1-3H3,(H,29,35)(H,30,39)(H,43,44)(H,45,46)(H2,28,31,32)(H2,40,41,42)/b6-5+/t16-,20-,21-,22+,26-/m1/s1",(3E)-hexenoyl-coenzyme A,HMDB accession,HMDB0006522
5316,85475,4-hydroxy-6-(11-hydroxyheptadecyl)-pyran-2-one,A 6-alkyl-4-hydroxy-2H-pyran-2-one that is 4-hydroxy-2H-pyran-2-one in which the hydrogen at position 6 is replaced by an 11-hydroxyheptadecyl group.,"InChI=1S/C22H38O4/c1-2-3-4-11-14-19(23)15-12-9-7-5-6-8-10-13-16-21-17-20(24)18-22(25)26-21/h17-19,23-24H,2-16H2,1H3",4-hydroxy-6-(11-hydroxyheptadecyl)-pyran-2-one,Reaxys Registry Number,10205513
5317,85486,3-(trimethylsilyl)propionate,"A monocarboxylic acid anion that is the conjugate base of 3-(trimethylsilyl)propionic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C6H14O2Si/c1-9(2,3)5-4-6(7)8/h4-5H2,1-3H3,(H,7,8)/p-1",3-trimethylsilylpropanoate,Reaxys Registry Number,3537181
5318,85487,3-(trimethylsilyl)propionic acid,An organosilicon compound that is propionic acid substituted at position 3 by a trimethylsilyl group. It is used as internal reference in the NMR spectrum nuclear magnetic resonance for aqueous solvents (e.g. D2O).,"InChI=1S/C6H14O2Si/c1-9(2,3)5-4-6(7)8/h4-5H2,1-3H3,(H,7,8)",3-trimethylsilylpropionic acid,CAS Registry Number,5683-30-7
5319,85490,4-hydroxy-6-(13-hydroxy-2-oxononadecyl)pyran-2-one,An acyl tetraketide pyran-2-one that is 4-hydroxy-2H-pyran-2-one in which the hydrogen at position 6 is replaced by a 13-hydroxy-2-oxononadecyl group.,"InChI=1S/C24H40O5/c1-2-3-4-11-14-20(25)15-12-9-7-5-6-8-10-13-16-21(26)17-23-18-22(27)19-24(28)29-23/h18-20,25,27H,2-17H2,1H3",4-hydroxy-6-(13-hydroxy-2-oxononadecyl)pyran-2-one,PubMed citation,15984864
5320,85497,4-hydroxy-6-(4-methyl-2-oxododecyl)pyran-2-one,An acyl tetraketide pyran-2-one that is 4-hydroxy-2H-pyran-2-one in which the hydrogen at position 6 is replaced by a 4-methyl-2-oxododecyl group.,"InChI=1S/C18H28O4/c1-3-4-5-6-7-8-9-14(2)10-15(19)11-17-12-16(20)13-18(21)22-17/h12-14,20H,3-11H2,1-2H3",4-hydroxy-6-(4-methyl-2-oxododecyl)pyran-2-one,Reaxys Registry Number,10187938
5321,85507,GDP-alpha-D-mannuronic acid,A GDP-D-mannuronic acid in which the anomeric centre of the mannuronic acid fragment has alpha-configuration.,"InChI=1S/C16H23N5O17P2/c17-16-19-11-4(12(27)20-16)18-2-21(11)13-8(25)5(22)3(35-13)1-34-39(30,31)38-40(32,33)37-15-9(26)6(23)7(24)10(36-15)14(28)29/h2-3,5-10,13,15,22-26H,1H2,(H,28,29)(H,30,31)(H,32,33)(H3,17,19,20,27)/t3-,5-,6+,7+,8-,9+,10+,13-,15-/m1/s1",guanosine 5'-diphosphate-alpha-D-mannuronic acid,KEGG COMPOUND accession,C00976
5322,85508,"(9Z,12Z)-18-hydroxyoctadecadienoyl-CoA","An omega-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z,12Z)-18-hydroxyoctadecadienoic acid.","InChI=1S/C39H66N7O18P3S/c1-39(2,34(51)37(52)42-20-19-29(48)41-21-23-68-30(49)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-22-47)25-61-67(58,59)64-66(56,57)60-24-28-33(63-65(53,54)55)32(50)38(62-28)46-27-45-31-35(40)43-26-44-36(31)46/h3-4,7,9,26-28,32-34,38,47,50-51H,5-6,8,10-25H2,1-2H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/b4-3-,9-7-/t28-,32-,33-,34+,38-/m1/s1","(9Z,12Z)-18-hydroxyoctadeca-9,12-dienoyl-CoA",MetaCyc accession,CPD-17371
5323,85521,"1,2-dipalmitoyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate)",A 1-phosphatidyl-1D-myo-inositol 5-phosphate in which both phosphatidyl acyl groups are specified as palmitoyl (hexadecanoyl).,"InChI=1S/C41H80O16P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-34(42)53-31-33(55-35(43)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)32-54-59(51,52)57-41-38(46)36(44)37(45)40(39(41)47)56-58(48,49)50/h33,36-41,44-47H,3-32H2,1-2H3,(H,51,52)(H2,48,49,50)/t33-,36-,37-,38-,39-,40+,41-/m1/s1","1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-5-phosphate)",Reaxys Registry Number,9380132
5324,85528,3-(methylthio)acryloyl-CoA,An acyl-CoA thioester that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-(methylthio)acrylic acid.,"InChI=1S/C25H40N7O17P3S2/c1-25(2,20(36)23(37)28-6-4-15(33)27-7-9-54-16(34)5-8-53-3)11-46-52(43,44)49-51(41,42)45-10-14-19(48-50(38,39)40)18(35)24(47-14)32-13-31-17-21(26)29-12-30-22(17)32/h5,8,12-14,18-20,24,35-36H,4,6-7,9-11H2,1-3H3,(H,27,33)(H,28,37)(H,41,42)(H,43,44)(H2,26,29,30)(H2,38,39,40)/b8-5+/t14-,18-,19-,20+,24-/m1/s1",3-(methylthio)acryloyl-coenzyme A,MetaCyc accession,CPD-13547
5325,85529,3-hydroxy-3-(methylthio)propanoyl-CoA,An acyl-CoA thioester that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxy-3-(methylthio)propanoic acid.,"InChI=1S/C25H42N7O18P3S2/c1-25(2,20(37)23(38)28-5-4-14(33)27-6-7-55-16(35)8-15(34)54-3)10-47-53(44,45)50-52(42,43)46-9-13-19(49-51(39,40)41)18(36)24(48-13)32-12-31-17-21(26)29-11-30-22(17)32/h11-13,15,18-20,24,34,36-37H,4-10H2,1-3H3,(H,27,33)(H,28,38)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t13-,15?,18-,19-,20+,24-/m1/s1",3-hydroxy-3-(methylthio)propanoyl-coenzyme A,MetaCyc accession,CPD-17245
5326,85531,trans-4-coumaroyl-CoA,A 4-coumaroyl-CoA in which the double bond of the coumaroyl group has trans-geochemistry.,"InChI=1S/C30H42N7O18P3S/c1-30(2,25(42)28(43)33-10-9-20(39)32-11-12-59-21(40)8-5-17-3-6-18(38)7-4-17)14-52-58(49,50)55-57(47,48)51-13-19-24(54-56(44,45)46)23(41)29(53-19)37-16-36-22-26(31)34-15-35-27(22)37/h3-8,15-16,19,23-25,29,38,41-42H,9-14H2,1-2H3,(H,32,39)(H,33,43)(H,47,48)(H,49,50)(H2,31,34,35)(H2,44,45,46)/b8-5+/t19-,23-,24-,25+,29-/m1/s1",(E)-4-coumaroyl-coenzyme A,CAS Registry Number,119785-99-8
5327,85542,egualen,"A member of the class of azulenes carrying sulfo, ethyl and isopropyl substituents at positions 1, 3 and 7 respectively. Used (in the form of its sodium salt) for treatment of gastric ulcers.","InChI=1S/C15H18O3S/c1-4-11-9-15(19(16,17)18)14-8-12(10(2)3)6-5-7-13(11)14/h5-10H,4H2,1-3H3,(H,16,17,18)",3-ethyl-7-isopropylazulene-1-sulfonic acid,CAS Registry Number,99287-30-6
5328,85545,bismuth(3+),A bismuth cation having a net electric charge of +3.,InChI=1S/Bi/q+3,Bi(3+),HMDB accession,HMDB0002196
5329,85560,(5Z)-icosenoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (5Z)-icosenoic acid.,"InChI=1S/C41H72N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-32(50)69-25-24-43-31(49)22-23-44-39(53)36(52)41(2,3)27-62-68(59,60)65-67(57,58)61-26-30-35(64-66(54,55)56)34(51)40(63-30)48-29-47-33-37(42)45-28-46-38(33)48/h17-18,28-30,34-36,40,51-52H,4-16,19-27H2,1-3H3,(H,43,49)(H,44,53)(H,57,58)(H,59,60)(H2,42,45,46)(H2,54,55,56)/b18-17-/t30-,34-,35-,36+,40-/m1/s1",(Z)-icos-5-enoyl-coenzyme A,MetaCyc accession,CPD-8171
5330,85616,viridicatumtoxin,A tetracycline-like polyketide antibiotic that is produced by several species of Penicillium and Aspergillus.,"InChI=1S/C30H31NO10/c1-11-6-5-7-27(2,3)28(11)9-12-16-18(13(32)8-15(41-4)21(16)28)22(34)20-17(12)23(35)29(39)10-14(33)19(26(31)38)24(36)30(29,40)25(20)37/h6,8,23,32-35,39-40H,5,7,9-10H2,1-4H3,(H2,31,38)/t23-,28-,29-,30+/m0/s1",viridicatumtoxin A,CAS Registry Number,39277-41-3
5331,85633,"(9S,10R)-dihydroxyoctadecanoic acid",A hydroxy fatty acid  that is octadecanoic acid carrying two hydroxy substituents at positions 9 and 10.,"InChI=1S/C18H36O4/c1-2-3-4-5-7-10-13-16(19)17(20)14-11-8-6-9-12-15-18(21)22/h16-17,19-20H,2-15H2,1H3,(H,21,22)/t16-,17+/m1/s1","(9S,10R)-dihydroxystearic acid",Reaxys Registry Number,1728017
5332,85645,p-nitrophenyl palmitate,A palmitate ester obtained by condensation of the carboxy group of palmitic acid with the phenolic hydroxy group of p-nitrophenol.,"InChI=1S/C22H35NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-22(24)27-21-18-16-20(17-19-21)23(25)26/h16-19H,2-15H2,1H3",Hexadecanoic acid 4-nitrophenyl ester,PDBeChem accession,PNR
5333,85665,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc,A branched amino heptasaccharide made up from two repeating (1->3)-linked N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl units that are in turn joined to an N-acetyl-beta-D-glucosamine residue via a (1->4)-linkage.,"InChI=1S/C48H81N3O34/c1-11-24(60)32(68)34(70)45(73-11)84-40-39(29(65)18(8-54)78-47(40)80-36-20(10-56)75-42(72)21(31(36)67)49-13(3)57)83-44-23(51-15(5)59)37(27(63)17(7-53)77-44)81-48-41(85-46-35(71)33(69)25(61)12(2)74-46)38(28(64)19(9-55)79-48)82-43-22(50-14(4)58)30(66)26(62)16(6-52)76-43/h11-12,16-48,52-56,60-72H,6-10H2,1-5H3,(H,49,57)(H,50,58)(H,51,59)/t11-,12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30+,31+,32+,33+,34-,35-,36+,37+,38-,39-,40+,41+,42+,43+,44+,45-,46-,47-,48-/m0/s1",N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine,PubMed citation,25568069
5334,85675,3-phenylpropanoyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-phenylpropanoic acid.,"InChI=1S/C30H44N7O17P3S/c1-30(2,25(41)28(42)33-11-10-20(38)32-12-13-58-21(39)9-8-18-6-4-3-5-7-18)15-51-57(48,49)54-56(46,47)50-14-19-24(53-55(43,44)45)23(40)29(52-19)37-17-36-22-26(31)34-16-35-27(22)37/h3-7,16-17,19,23-25,29,40-41H,8-15H2,1-2H3,(H,32,38)(H,33,42)(H,46,47)(H,48,49)(H2,31,34,35)(H2,43,44,45)/t19-,23-,24-,25+,29-/m1/s1",dihydrocinnamoyl-CoA,CAS Registry Number,117411-09-3
5335,85676,3-phenylpropanoyl-CoA(4-),An acyl-CoA(4-) arising from deprotonation of the phosphate and diphosphate OH groups of 3-phenylpropanoyl-CoA; major species at pH 7.3.,"InChI=1S/C30H44N7O17P3S/c1-30(2,25(41)28(42)33-11-10-20(38)32-12-13-58-21(39)9-8-18-6-4-3-5-7-18)15-51-57(48,49)54-56(46,47)50-14-19-24(53-55(43,44)45)23(40)29(52-19)37-17-36-22-26(31)34-16-35-27(22)37/h3-7,16-17,19,23-25,29,40-41H,8-15H2,1-2H3,(H,32,38)(H,33,42)(H,46,47)(H,48,49)(H2,31,34,35)(H2,43,44,45)/p-4/t19-,23-,24-,25+,29-/m1/s1",3-phenylpropionyl-CoA(4-),MetaCyc accession,CPD-503
5336,85796,N-capryl-1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine,"An N-acylphosphatidylethanolamine in which the N-acyl group is specified as capryl (decanoyl) while the phosphatidyl acyl groups at position 1 and 2 are specified as palmitoyl (hexadecanoyl) and linoleoyl (9Z,12Z-octadecadienoyl) respectively.","InChI=1S/C49H92NO9P/c1-4-7-10-13-16-18-20-22-23-25-27-29-32-35-38-41-49(53)59-46(44-56-48(52)40-37-34-31-28-26-24-21-19-17-14-11-8-5-2)45-58-60(54,55)57-43-42-50-47(51)39-36-33-30-15-12-9-6-3/h16,18,22-23,46H,4-15,17,19-21,24-45H2,1-3H3,(H,50,51)(H,54,55)/b18-16-,23-22-/t46-/m1/s1","N-decanoyl-1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine",Reaxys Registry Number,19897982
5337,85800,"(R)-(2-chloro-5-oxo-2,5-dihydro-2-furyl)acetic acid","An optically active form of (2-chloro-5-oxo-2,5-dihydro-2-furyl)acetic acid having R-configuration.","InChI=1S/C6H5ClO4/c7-6(3-4(8)9)2-1-5(10)11-6/h1-2H,3H2,(H,8,9)/t6-/m1/s1",(+)-4-chloromuconolactone,PubMed citation,12930985
5338,85803,(R)-ethylmalonyl-CoA,An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of (R)-ethylmalonic acid.,"InChI=1S/C26H42N7O19P3S/c1-4-13(24(38)39)25(40)56-8-7-28-15(34)5-6-29-22(37)19(36)26(2,3)10-49-55(46,47)52-54(44,45)48-9-14-18(51-53(41,42)43)17(35)23(50-14)33-12-32-16-20(27)30-11-31-21(16)33/h11-14,17-19,23,35-36H,4-10H2,1-3H3,(H,28,34)(H,29,37)(H,38,39)(H,44,45)(H,46,47)(H2,27,30,31)(H2,41,42,43)/t13-,14-,17-,18-,19+,23-/m1/s1",(2R)-ethylmalonyl-CoA,Reaxys Registry Number,22539666
5339,85805,"D-glucaro-1,4-lactone","A delta-lactone that is D-glucono-1,4-lactone in which the hydroxy group at position 6 has been oxidised to the corresponding carboxylic acid.","InChI=1S/C6H8O7/c7-1-2(8)6(12)13-4(1)3(9)5(10)11/h1-4,7-9H,(H,10,11)/t1-,2-,3+,4+/m1/s1",D-saccharolactone,HMDB accession,HMDB0041862
5340,85806,"N,1-dipalmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine","An N-acylphosphatidylethanolamine in which the N-acyl group is specified as hexadecanoyl while the phosphatidyl acyl groups at position 1 and 2 are specified as hexadecanoyl and (9Z,12Z-octadecadienoyl) respectively.","InChI=1S/C55H104NO9P/c1-4-7-10-13-16-19-22-25-26-29-32-35-38-41-44-47-55(59)65-52(50-62-54(58)46-43-40-37-34-31-28-24-21-18-15-12-9-6-3)51-64-66(60,61)63-49-48-56-53(57)45-42-39-36-33-30-27-23-20-17-14-11-8-5-2/h16,19,25-26,52H,4-15,17-18,20-24,27-51H2,1-3H3,(H,56,57)(H,60,61)/b19-16-,26-25-/t52-/m1/s1","N,1-dihexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine",Reaxys Registry Number,19898002
5341,85820,"1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,5-bisphosphate)","A 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate in which both phosphatidyl acyl groups are specified as octanoyl","InChI=1S/C25H49O19P3/c1-3-5-7-9-11-13-18(26)39-15-17(41-19(27)14-12-10-8-6-4-2)16-40-47(37,38)44-25-21(29)23(42-45(31,32)33)20(28)24(22(25)30)43-46(34,35)36/h17,20-25,28-30H,3-16H2,1-2H3,(H,37,38)(H2,31,32,33)(H2,34,35,36)/t17-,20-,21-,22-,23-,24+,25-/m1/s1","PIP2[3',5'](8:0/8:0)",Reaxys Registry Number,25497812
5342,85829,CDP-1-stearoyl-2-arachidonoyl-sn-glycerol,A CDP-diacylglycerol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and arachidonoyl respectively.,"InChI=1S/C50H85N3O15P2/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-46(55)66-42(39-63-45(54)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2)40-64-69(59,60)68-70(61,62)65-41-43-47(56)48(57)49(67-43)53-38-37-44(51)52-50(53)58/h11,13,17,19,22,24,28,30,37-38,42-43,47-49,56-57H,3-10,12,14-16,18,20-21,23,25-27,29,31-36,39-41H2,1-2H3,(H,59,60)(H,61,62)(H2,51,52,58)/b13-11-,19-17-,24-22-,30-28-/t42-,43-,47-,48-,49-/m1/s1","1-octadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-cytidine-5'-diphosphate",HMDB accession,HMDB0006982
5343,85830,CDP-1-palmitoyl-2-arachidonoyl-sn-glycerol,A CDP-diacylglycerol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as palmitoyl and arachidonoyl respectively.,"InChI=1S/C48H81N3O15P2/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-44(53)64-40(37-61-43(52)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2)38-62-67(57,58)66-68(59,60)63-39-41-45(54)46(55)47(65-41)51-36-35-42(49)50-48(51)56/h11,13,17-18,20,22,26,28,35-36,40-41,45-47,54-55H,3-10,12,14-16,19,21,23-25,27,29-34,37-39H2,1-2H3,(H,57,58)(H,59,60)(H2,49,50,56)/b13-11-,18-17-,22-20-,28-26-/t40-,41-,45-,46-,47-/m1/s1","1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-cytidine-5'-diphosphate",HMDB accession,HMDB0006973
5344,85838,CDP-1-stearoyl-2-linoleoyl-sn-glycerol,A CDP-diacylglycerol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and linoleoyl respectively.,"InChI=1S/C48H85N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-43(52)61-37-40(64-44(53)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)38-62-67(57,58)66-68(59,60)63-39-41-45(54)46(55)47(65-41)51-36-35-42(49)50-48(51)56/h12,14,18,20,35-36,40-41,45-47,54-55H,3-11,13,15-17,19,21-34,37-39H2,1-2H3,(H,57,58)(H,59,60)(H2,49,50,56)/b14-12-,20-18-/t40-,41-,45-,46-,47-/m1/s1","1-octadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-cytidine-5'-diphosphate",HMDB accession,HMDB0006981
5345,85841,CDP-1-stearoyl-2-oleoyl-sn-glycerol,A CDP-diacylglycerol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and oleoyl respectively.,"InChI=1S/C48H87N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-43(52)61-37-40(64-44(53)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)38-62-67(57,58)66-68(59,60)63-39-41-45(54)46(55)47(65-41)51-36-35-42(49)50-48(51)56/h18,20,35-36,40-41,45-47,54-55H,3-17,19,21-34,37-39H2,1-2H3,(H,57,58)(H,59,60)(H2,49,50,56)/b20-18-/t40-,41-,45-,46-,47-/m1/s1",1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-cytidine-5'-diphosphate,HMDB accession,HMDB0006980
5346,85846,"CDP-1-stearoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-sn-glycerol","A CDP-diacylglycerol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as stearoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C52H85N3O15P2/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-48(57)68-44(41-65-47(56)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2)42-66-71(61,62)70-72(63,64)67-43-45-49(58)50(59)51(69-45)55-40-39-46(53)54-52(55)60/h5,7,11,13,17,19,21-22,26,28,32,34,39-40,44-45,49-51,58-59H,3-4,6,8-10,12,14-16,18,20,23-25,27,29-31,33,35-38,41-43H2,1-2H3,(H,61,62)(H,63,64)(H2,53,54,60)/b7-5-,13-11-,19-17-,22-21-,28-26-,34-32-/t44-,45-,49-,50-,51-/m1/s1","CDP-1-octadecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl-sn-glycerol",HMDB accession,HMDB0006985
5347,85867,p-nitrophenyl butyrate,A butyrate ester resulting from the formal condensation of the hydroxy group of 4-nitrophenol with the carboxy group of butyric acid.,"InChI=1S/C10H11NO4/c1-2-3-10(12)15-9-6-4-8(5-7-9)11(13)14/h4-7H,2-3H2,1H3",PNPB,PubMed citation,2794798
5348,85878,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->6)-D-GalpNAc,"A branched amino pentasaccharide comprising a linear tetrasaccharide chain of alpha-D-galactose, beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-beta-D-galactosamine residues linked sequentially (1->3), (1->3) and (1->6), to the beta-D-galactose residue of which is also linked (1->2) an alpha-L-fucose residue.","InChI=1S/C34H58N2O25/c1-8-17(42)23(48)25(50)32(54-8)61-29-28(60-33-26(51)24(49)18(43)11(4-37)57-33)21(46)13(6-39)58-34(29)59-27-16(36-10(3)41)31(56-12(5-38)20(27)45)53-7-14-19(44)22(47)15(30(52)55-14)35-9(2)40/h8,11-34,37-39,42-52H,4-7H2,1-3H3,(H,35,40)(H,36,41)/t8-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21-,22+,23+,24-,25-,26+,27+,28-,29+,30?,31+,32-,33+,34-/m0/s1",alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->6)-D-GalpNAc,PubMed citation,25568069
5349,85881,N-octanoylsphingosine 1-phosphate,An N-acylsphingosine 1-phosphate in which the N-acyl group is specified as octanoyl.,"InChI=1S/C26H52NO6P/c1-3-5-7-9-10-11-12-13-14-15-16-18-19-21-25(28)24(23-33-34(30,31)32)27-26(29)22-20-17-8-6-4-2/h19,21,24-25,28H,3-18,20,22-23H2,1-2H3,(H,27,29)(H2,30,31,32)/b21-19+/t24-,25+/m0/s1",N-octanoylsphing-4-enine 1-phosphate,Reaxys Registry Number,7051332
5350,85886,3-dehydrocarnityl CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-dehydrocarnitine.,"InChI=1S/C28H47N8O18P3S/c1-28(2,23(41)26(42)31-7-6-18(38)30-8-9-58-19(39)10-16(37)11-36(3,4)5)13-51-57(48,49)54-56(46,47)50-12-17-22(53-55(43,44)45)21(40)27(52-17)35-15-34-20-24(29)32-14-33-25(20)35/h14-15,17,21-23,27,40-41H,6-13H2,1-5H3,(H7-,29,30,31,32,33,38,42,43,44,45,46,47,48,49)/p+1/t17-,21-,22-,23+,27-/m1/s1",3-dehydrocarnityl coenzyme A,PubMed citation,19406895
5351,85888,"N,N,N-trimethylglycyl-CoA",An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of glycine betaine.,"InChI=1S/C26H45N8O17P3S/c1-26(2,21(38)24(39)29-7-6-16(35)28-8-9-55-17(36)10-34(3,4)5)12-48-54(45,46)51-53(43,44)47-11-15-20(50-52(40,41)42)19(37)25(49-15)33-14-32-18-22(27)30-13-31-23(18)33/h13-15,19-21,25,37-38H,6-12H2,1-5H3,(H7-,27,28,29,30,31,35,39,40,41,42,43,44,45,46)/p+1/t15-,19-,20-,21+,25-/m1/s1",glycylbetainyl-coenzyme A,PubMed citation,19406895
5352,85889,(Z)-hex-3-enoyl-CoA,A fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (Z)-hex-3-enoic acid.,"InChI=1S/C27H44N7O17P3S/c1-4-5-6-7-18(36)55-11-10-29-17(35)8-9-30-25(39)22(38)27(2,3)13-48-54(45,46)51-53(43,44)47-12-16-21(50-52(40,41)42)20(37)26(49-16)34-15-33-19-23(28)31-14-32-24(19)34/h5-6,14-16,20-22,26,37-38H,4,7-13H2,1-3H3,(H,29,35)(H,30,39)(H,43,44)(H,45,46)(H2,28,31,32)(H2,40,41,42)/b6-5-/t16-,20-,21-,22+,26-/m1/s1",cis-3-hexenoyl-CoA,Reaxys Registry Number,11165740
5353,85892,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-[beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"A branched amino oligosaccharide (tetradecasaccharide) consisting of a linear trisaccharide unit of beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-D-glucosamine residues, connected by (1->3) linkages, to the beta-D-mannose residue of which are linked (1->3) and (1->6) alpha-D-mannose residues, the one at O-2 being substituted at O-2 by an N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl trisaccharide unit and the one at O-6 being substituted also at both O-2 and O-6 by N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl trisaccharide units.","InChI=1S/C100H166N8O71/c1-23(121)101-45-65(141)76(38(16-116)155-87(45)152)169-92-50(106-28(6)126)67(143)80(40(18-118)164-92)173-98-75(151)84(177-100-86(70(146)56(132)34(12-112)162-100)179-94-52(108-30(8)128)69(145)79(42(20-120)166-94)172-97-74(150)83(60(136)37(15-115)161-97)176-91-48(104-26(4)124)64(140)55(131)33(11-111)158-91)61(137)44(167-98)22-154-99-85(178-93-51(107-29(7)127)68(144)78(41(19-119)165-93)171-96-73(149)82(59(135)36(14-114)160-96)175-90-47(103-25(3)123)63(139)54(130)32(10-110)157-90)71(147)57(133)43(168-99)21-153-88-49(105-27(5)125)66(142)77(39(17-117)163-88)170-95-72(148)81(58(134)35(13-113)159-95)174-89-46(102-24(2)122)62(138)53(129)31(9-109)156-89/h31-100,109-120,129-152H,9-22H2,1-8H3,(H,101,121)(H,102,122)(H,103,123)(H,104,124)(H,105,125)(H,106,126)(H,107,127)(H,108,128)/t31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58+,59+,60+,61-,62-,63-,64-,65-,66-,67-,68-,69-,70+,71+,72-,73-,74-,75+,76-,77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87?,88-,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100-/m1/s1",beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,25568069
5354,85900,"1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4-phosphate)",A 1-phosphatidyl-1D-myo-inositol 4-phosphate in which the phosphatidyl acyl groups at positions 1 and 2 are both specified as octanoyl.,"InChI=1S/C25H48O16P2/c1-3-5-7-9-11-13-18(26)37-15-17(39-19(27)14-12-10-8-6-4-2)16-38-43(35,36)41-25-22(30)20(28)24(21(29)23(25)31)40-42(32,33)34/h17,20-25,28-31H,3-16H2,1-2H3,(H,35,36)(H2,32,33,34)/t17-,20-,21+,22-,23-,24+,25+/m1/s1",PIP[4'](8:0/8:0),PDBeChem accession,PIF
5355,85902,3-methyl-2-indolic acid,An indolecarboxylic acid that is indole-2-carboxylic acid in which the hydrogen at position 3 is replaced by a methyl group.,"InChI=1S/C10H9NO2/c1-6-7-4-2-3-5-8(7)11-9(6)10(12)13/h2-5,11H,1H3,(H,12,13)",3-methylindole-2-carboxylic acid,Reaxys Registry Number,5831
5356,85904,glutathione S-sulfinate,An S-substituted glutathione that is glutathione in which the mercapto hydrogen has been replaced by a sulfinyl group.,"InChI=1S/C10H17N3O8S2/c11-5(10(18)19)1-2-7(14)13-6(4-22-23(20)21)9(17)12-3-8(15)16/h5-6H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)(H,20,21)/t5-,6-/m0/s1",glutathione S-sulfinic acid,MetaCyc accession,CPD-17866
5357,85907,"9alpha-hydroxy-3-oxo-23,24-bisnorchola-1,4-dien-22-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 9alpha-hydroxy-3-oxo-23,24-bisnorchola-1,4-dien-22-oic acid.","InChI=1S/C43H64N7O19P3S/c1-23(26-8-9-27-28-7-6-24-18-25(51)10-12-42(24,5)43(28,57)14-13-41(26,27)4)39(56)73-17-16-45-30(52)11-15-46-37(55)34(54)40(2,3)20-66-72(63,64)69-71(61,62)65-19-29-33(68-70(58,59)60)32(53)38(67-29)50-22-49-31-35(44)47-21-48-36(31)50/h10,12,18,21-23,26-29,32-34,38,53-54,57H,6-9,11,13-17,19-20H2,1-5H3,(H,45,52)(H,46,55)(H,61,62)(H,63,64)(H2,44,47,48)(H2,58,59,60)/t23-,26+,27-,28-,29+,32+,33+,34-,38+,41+,42-,43+/m0/s1","9alpha-hydroxy-3-oxo-23,24-bisnorchola-1,4-dien-22-oyl-coenzyme A",MetaCyc accession,CPD-13743
5358,85910,"9alpha-hydroxy-3-oxo-23,24-bisnorchol-4-en-22-oic acid","A steroid acid that is 23,24-bisnor-chol-4-en-22-oic acid bearing additional oxo and hydroxy substituent at positions 3 and 9 respectively.","InChI=1S/C22H32O4/c1-13(19(24)25)16-6-7-17-18-5-4-14-12-15(23)8-9-21(14,3)22(18,26)11-10-20(16,17)2/h12-13,16-18,26H,4-11H2,1-3H3,(H,24,25)/t13-,16+,17-,18-,20+,21-,22+/m0/s1","9alpha-hydroxy-3-oxo-23,24-dinorchol-4-en-22-oic acid",Reaxys Registry Number,5623885
5359,85911,"3-oxo-23,24-bisnorchola-1,4-dien-22-oic acid","A steroid acid that is 23,24-bisnor-chol-1,4-dien-22-oic acid bearing an additional oxo substituent at position 3.","InChI=1S/C22H30O3/c1-13(20(24)25)17-6-7-18-16-5-4-14-12-15(23)8-10-21(14,2)19(16)9-11-22(17,18)3/h8,10,12-13,16-19H,4-7,9,11H2,1-3H3,(H,24,25)/t13-,16-,17+,18-,19-,21-,22+/m0/s1","3-oxo-23,24-dinorchola-1,4-dien-22-oic acid",CAS Registry Number,20248-18-4
5360,85934,(2R)-2-hydroxytetradecanoic acid,A 2-hydroxymyristic acid having 2R-configuration.,"InChI=1S/C14H28O3/c1-2-3-4-5-6-7-8-9-10-11-12-13(15)14(16)17/h13,15H,2-12H2,1H3,(H,16,17)/t13-/m1/s1",(2R)-2-hydroxymyristic acid,Reaxys Registry Number,1725370
5361,85939,cis-3-octenoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of cis-3-octenoic acid.,"InChI=1S/C29H48N7O17P3S/c1-4-5-6-7-8-9-20(38)57-13-12-31-19(37)10-11-32-27(41)24(40)29(2,3)15-50-56(47,48)53-55(45,46)49-14-18-23(52-54(42,43)44)22(39)28(51-18)36-17-35-21-25(30)33-16-34-26(21)36/h7-8,16-18,22-24,28,39-40H,4-6,9-15H2,1-3H3,(H,31,37)(H,32,41)(H,45,46)(H,47,48)(H2,30,33,34)(H2,42,43,44)/b8-7-/t18-,22-,23-,24+,28-/m1/s1",(3Z)-octenoyl-CoA,Reaxys Registry Number,11165741
5362,85949,alpha-L-Fucp-(1->2)-beta-D-Galp6S-(1->4)-beta-D-Glcp6S,alpha-L-Fucp-(1->2)-beta-D-Galp6S-(1->4)-D-Glcp6S in which the anomeric configuration of the 6-O-sulfo-D-glucose residue at the reducing end is beta.,"InChI=1S/C18H32O21S2/c1-4-7(19)9(21)13(25)17(35-4)39-15-10(22)8(20)5(2-33-40(27,28)29)37-18(15)38-14-6(3-34-41(30,31)32)36-16(26)12(24)11(14)23/h4-26H,2-3H2,1H3,(H,27,28,29)(H,30,31,32)/t4-,5+,6+,7+,8-,9+,10-,11+,12+,13-,14+,15+,16+,17-,18-/m0/s1",Fucalpha1-2(6S)Galbeta1-4(6S)Glcbeta,PubMed citation,25568069
5363,85962,"1,2-dioleoyl-sn-glycero-3-phospho-N-methylethanolamine","A 1,2-diacyl-sn-glycero-3-phospho-N-methylethanolamine in which the phosphatidyl acyl groups are both specified as oleoyl (9Z-octadecenoyl); major species at pH 7.3.","InChI=1S/C42H80NO8P/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-41(44)48-38-40(39-50-52(46,47)49-37-36-43-3)51-42(45)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2/h18-21,40,43H,4-17,22-39H2,1-3H3,(H,46,47)/b20-18-,21-19-/t40-/m1/s1","1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-N-methylethanolamine",CAS Registry Number,96687-23-9
5364,85963,"1,2-dioleoyl-sn-glycero-3-phospho-N,N-dimethylethanolamine","A 1,2-diacyl-sn-glycero-3-phospho-N,N-dimethylethanolamine in which the phosphatidyl acyl groups are both specified as oleoyl (9Z-octadecenoyl); major species at pH 7.3.","InChI=1S/C43H82NO8P/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-42(45)49-39-41(40-51-53(47,48)50-38-37-44(3)4)52-43(46)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h19-22,41H,5-18,23-40H2,1-4H3,(H,47,48)/b21-19-,22-20-/t41-/m1/s1","1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-N,N-dimethylethanolamine",LIPID MAPS instance accession,LMGP02010326
5365,85964,"UDP-N-acetylgalactosamine-5,6-ene","A UDP-amino sugar having N-acetylgalactosamine-5,6-ene as the amino sugar component.","InChI=1S/C17H25N3O16P2/c1-6-11(23)13(25)10(18-7(2)21)16(33-6)35-38(30,31)36-37(28,29)32-5-8-12(24)14(26)15(34-8)20-4-3-9(22)19-17(20)27/h3-4,8,10-16,23-26H,1,5H2,2H3,(H,18,21)(H,28,29)(H,30,31)(H,19,22,27)/t8-,10-,11+,12-,13-,14-,15-,16-/m1/s1","UDP-N-acetyl-5,6-dehydrogalactosamine",PubMed citation,22172915
5366,85975,edoxaban tosylate,An organosulfonate salt obtained by combining equimolar amounts of edoxaban and 4-toluenesulfonic acid. Used (in the form of its monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism.,"InChI=1S/C24H30ClN7O4S.C7H8O3S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10)/t13-,15-,17+;/m0./s1",edoxaban 4-toluenesulfonate,CAS Registry Number,480449-71-6
5367,85981,L-homocarnosine,A homocarnosine that has S configuration.,"InChI=1S/C10H16N4O3/c11-3-1-2-9(15)14-8(10(16)17)4-7-5-12-6-13-7/h5-6,8H,1-4,11H2,(H,12,13)(H,14,15)(H,16,17)/t8-/m0/s1",gamma-aminobutyryl-L-His,KEGG COMPOUND accession,C00884
5368,86044,18-hydroxyoleoyl-CoA(4-),A monounsaturated fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of 18-hydroxyoleoyl-CoA; major species at pH 7.3.,"InChI=1S/C39H68N7O18P3S/c1-39(2,34(51)37(52)42-20-19-29(48)41-21-23-68-30(49)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-22-47)25-61-67(58,59)64-66(56,57)60-24-28-33(63-65(53,54)55)32(50)38(62-28)46-27-45-31-35(40)43-26-44-36(31)46/h3-4,26-28,32-34,38,47,50-51H,5-25H2,1-2H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/p-4/b4-3-/t28-,32-,33-,34+,38-/m1/s1",(9Z)-18-hydroxyoctadec-9-enoyl-CoA(4-),MetaCyc accession,CPD-17370
5369,86053,18-hydroxyoleoyl-CoA,An omega-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 18-hydroxyoleic acid.,"InChI=1S/C39H68N7O18P3S/c1-39(2,34(51)37(52)42-20-19-29(48)41-21-23-68-30(49)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-22-47)25-61-67(58,59)64-66(56,57)60-24-28-33(63-65(53,54)55)32(50)38(62-28)46-27-45-31-35(40)43-26-44-36(31)46/h3-4,26-28,32-34,38,47,50-51H,5-25H2,1-2H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/b4-3-/t28-,32-,33-,34+,38-/m1/s1",(9Z)-18-hydroxyoctadec-9-enoyl-coenzyme A,MetaCyc accession,CPD-17370
5370,86055,ethyl hexanoate,A fatty acid ethyl ester obtained by the formal condensation of hexanoic acid with ethanol.,"InChI=1S/C8H16O2/c1-3-5-6-7-8(9)10-4-2/h3-7H2,1-2H3",ethyl caproate,HMDB accession,HMDB0040209
5371,86080,(E)-p-coumaroylagmatine,A p-coumaroylagmatine(1+) in which the double bond of the coumaroyl component has E-geochemistry.,"InChI=1S/C14H20N4O2/c15-14(16)18-10-2-1-9-17-13(20)8-5-11-3-6-12(19)7-4-11/h3-8,19H,1-2,9-10H2,(H,17,20)(H4,15,16,18)/b8-5+",trans-coumaroylagmatine,Reaxys Registry Number,6893419
5372,86085,(Z)-p-coumaroylagmatine,A p-coumaroylagmatine in which the double bond of the coumaroyl component has Z-geochemistry.,"InChI=1S/C14H20N4O2/c15-14(16)18-10-2-1-9-17-13(20)8-5-11-3-6-12(19)7-4-11/h3-8,19H,1-2,9-10H2,(H,17,20)(H4,15,16,18)/b8-5-",(Z)-coumaroylagmatine,Reaxys Registry Number,8137084
5373,86132,"(9Z,12Z)-hexadeca-9,12,15-trienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z,12Z)-hexadeca-9,12,15-trienoic acid.","InChI=1S/C37H60N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h4,6-7,9-10,24-26,30-32,36,47-48H,1,5,8,11-23H2,2-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/b7-6-,10-9-/t26-,30-,31-,32+,36-/m1/s1","(9Z,12Z,15)-hexadecatrienoyl-CoA",MetaCyc accession,CPD-10255
5374,86135,"(5Z,9Z,12Z,15Z)-octadecatetraenoic acid","An octadecatetraenoic acid having four double bonds located at positions 5, 9, 12 and 15 (the all-cis-isomer).","InChI=1S/C18H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10,13-14H,2,5,8,11-12,15-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-,14-13-","all-cis-octadeca-5,9,12,15-tetraenoic acid",LIPID MAPS instance accession,LMFA01030355
5375,86136,"(5Z,9Z,12Z)-octadecatrienoic acid","An octadecatrienoic acid having three double bonds located at positions 5, 9 and 12 (the all-cis-isomer).","InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h6-7,9-10,13-14H,2-5,8,11-12,15-17H2,1H3,(H,19,20)/b7-6-,10-9-,14-13-","all-cis-octadeca-5,9,12-trienoic acid",LIPID MAPS instance accession,LMFA01030344
5376,86140,(4Z)-hexadecenoic acid,A hexadecenoic acid with a cis-double bond at position C-4.,"InChI=1S/C16H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h12-13H,2-11,14-15H2,1H3,(H,17,18)/b13-12-",(Z)-hexadec-4-enoic acid,Reaxys Registry Number,1909928
5377,86143,(14Z)-hexadecenoyl-CoA,A hexadecenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (14Z)-hexadecenoic acid.,"InChI=1S/C37H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h4-5,24-26,30-32,36,47-48H,6-23H2,1-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/b5-4-/t26-,30-,31-,32+,36-/m1/s1",(14Z)-hexadecenoyl-coenzyme A,MetaCyc accession,CPD-17468
5378,86144,(14E)-hexadecenoyl-CoA,A hexadecenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (14E)-hexadecenoic acid.,"InChI=1S/C37H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h4-5,24-26,30-32,36,47-48H,6-23H2,1-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/b5-4+/t26-,30-,31-,32+,36-/m1/s1",(E)-hexadec-14-enoyl-coenzyme A,MetaCyc accession,CPD-17468
5379,86151,ammonium nickel sulfate,"A nickel coordination entity comprising ammonium, nickel and sulfate in which the ratio of ammonium to iron(2+) to sulfate ions is 2:1:2.","InChI=1S/2H3N.Ni.2H2O4S/c;;;2*1-5(2,3)4/h2*1H3;;2*(H2,1,2,3,4)/q;;+2;;/p-2",nickel ammonium sulfate (anhydrous),CAS Registry Number,15699-18-0
5380,86157,cadmium sulfate hydrate,A hydrate composed of cadmium sulfate and water in a 3:8 ratio.,"InChI=1S/3Cd.3H2O4S.8H2O/c;;;3*1-5(2,3)4;;;;;;;;/h;;;3*(H2,1,2,3,4);8*1H2/q3*+2;;;;;;;;;;;/p-6",CdSO4.8/3H2O,CAS Registry Number,7790-84-3
5381,86158,calcium chloride dihydrate,A hydrate that is the dihydrate form of calcium chloride.,InChI=1S/Ca.2ClH.2H2O/h;2*1H;2*1H2/q+2;;;;/p-2,calcium dichloride dihydrate,KEGG DRUG accession,D02256
5382,86180,4-hydroxynon-2-enoic acid,A medium-chain fatty acid that is non-2-enoic acid substituted at position 4 by a hydroxy group.,"InChI=1S/C9H16O3/c1-2-3-4-5-8(10)6-7-9(11)12/h6-8,10H,2-5H2,1H3,(H,11,12)",4-hydroxy-2-nonenoic acid,Reaxys Registry Number,8139118
5383,86193,DAPT,"A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor.","InChI=1S/C23H26F2N2O4/c1-14(26-19(28)12-15-10-17(24)13-18(25)11-15)21(29)27-20(16-8-6-5-7-9-16)22(30)31-23(2,3)4/h5-11,13-14,20H,12H2,1-4H3,(H,26,28)(H,27,29)/t14-,20-/m0/s1",Dapt,Reaxys Registry Number,9588440
5384,86202,chalcopyrite,A sulfide mineral with formula CuFeS2. Chalcopyrite is the most important copper ore,InChI=1S/Cu.Fe.2S/q2*+2;2*-2,CuFeS2,PubMed citation,25511439
5385,86230,Amido Black 10B,An organic sodium salt resulting from the formal condensation of Amido Black 10B (acid form) with two equivalents of sodium hydroxide.,"InChI=1S/C22H16N6O9S2.2Na/c23-19-18-12(11-17(39(35,36)37)21(22(18)29)27-24-13-4-2-1-3-5-13)10-16(38(32,33)34)20(19)26-25-14-6-8-15(9-7-14)28(30)31;;/h1-11,29H,23H2,(H,32,33,34)(H,35,36,37);;/q;2*+1/p-2/b26-25+,27-24+;;",Naphthol blue black,Wikipedia accession,Amido_black_10B
5386,86235,ferrous carbonate,A carbonate salt in which the counter-ion is iron in the +2 oxidation state.,"InChI=1S/CH2O3.Fe/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2",iron(II) carbonate,PubMed citation,25406864
5387,86244,hexaammonium heptamolybdate tetrahydrate,A hydrate that is the heptahydrate form of hexaammonium heptamolybdate.,InChI=1S/7Mo.6H3N.4H2O.24O/h;;;;;;;6*1H3;4*1H2;;;;;;;;;;;;;;;;;;;;;;;;/q;6*+2;;;;;;;;;;;;;;;;;;;;;;;;7*-2;4*-1/p+6,ammonium molybdate tetrahydrate,Wikipedia accession,Ammonium_heptamolybdate
5388,86272,3-hydroxylysine,A hydroxy-amino acid that is lysine substituted by a hydroxy group at position 3.,"InChI=1S/C6H14N2O3/c7-3-1-2-4(9)5(8)6(10)11/h4-5,9H,1-3,7-8H2,(H,10,11)","2,6-diamino-3-hydroxyhexanoic acid",PubMed citation,9815186
5389,86279,D-arabinofuranose 5-phosphate,The furanose form of D-arabinose 5-phosphate.,"InChI=1S/C5H11O8P/c6-3-2(1-12-14(9,10)11)13-5(8)4(3)7/h2-8H,1H2,(H2,9,10,11)/t2-,3-,4+,5?/m1/s1",D-arabinofuranose 5-monophosphate,Reaxys Registry Number,2333180
5390,86285,(9E)-10-nitrooctadecenoic acid,A nitro fatty acid that is (9E)-octadec-9-enoic (elaidic) acid substituted by a nitro group at position 10.,"InChI=1S/C18H33NO4/c1-2-3-4-5-8-11-14-17(19(22)23)15-12-9-6-7-10-13-16-18(20)21/h15H,2-14,16H2,1H3,(H,20,21)/b17-15+",10-nitroelaidic acid,Reaxys Registry Number,10378886
5391,86287,"GDP-N,N'-diacetylbacillosamine","A GDP-hexose having 2,4-diacetamido-2,4,6-trideoxy-alpha-D-glucopyranose as the hexose component.","InChI=1S/C20H31N7O15P2/c1-6-10(23-7(2)28)14(31)11(24-8(3)29)19(39-6)41-44(36,37)42-43(34,35)38-4-9-13(30)15(32)18(40-9)27-5-22-12-16(27)25-20(21)26-17(12)33/h5-6,9-11,13-15,18-19,30-32H,4H2,1-3H3,(H,23,28)(H,24,29)(H,34,35)(H,36,37)(H3,21,25,26,33)/t6-,9-,10-,11-,13-,14+,15-,18-,19-/m1/s1","GDP-2,4-diacetamido-2,4,6-trideoxy-alpha-D-glucopyranose",PubMed citation,19282391
5392,86293,"3,22-dioxochol-4-en-24-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3,22-dioxochol-4-en-24-oic acid.","InChI=1S/C45H68N7O19P3S/c1-24(28-8-9-29-27-7-6-25-18-26(53)10-13-44(25,4)30(27)11-14-45(28,29)5)31(54)19-34(56)75-17-16-47-33(55)12-15-48-41(59)38(58)43(2,3)21-68-74(65,66)71-73(63,64)67-20-32-37(70-72(60,61)62)36(57)42(69-32)52-23-51-35-39(46)49-22-50-40(35)52/h18,22-24,27-30,32,36-38,42,57-58H,6-17,19-21H2,1-5H3,(H,47,55)(H,48,59)(H,63,64)(H,65,66)(H2,46,49,50)(H2,60,61,62)/t24-,27-,28+,29-,30-,32+,36+,37+,38-,42+,44-,45+/m0/s1","3,22-diketochol-4-en-24-oyl-coenzyme A",MetaCyc accession,CPD-13699
5393,86300,butamben picrate,An organoammonium salt resulting from the formal reaction of butamben with 0.5 mol eq. of picric acid.,"InChI=1S/2C11H15NO2.C6H3N3O7/c2*1-2-3-8-14-11(13)9-4-6-10(12)7-5-9;10-6-4(8(13)14)1-3(7(11)12)2-5(6)9(15)16/h2*4-7H,2-3,8,12H2,1H3;1-2,10H",butyl aminobenzoate picrate,KEGG DRUG accession,D03183
5394,86311,KGKGKGKGKGENPVVAFFKNIVTPRTP,A linear 27-membered polypeptide comprising the sequence Lys-Gly-Lys-Gly-Lys-Gly-Lys-Gly-Lys-Gly-Glu-Asn-Pro-Val-Val-Ala-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro. Corresponds to the sequence of the myelin basic protein 83-99 (MBP83-99) immunodominant epitope with the histidyl residue at position 88 replaced by alanyl [MBP83-99(A(88))] and with an (L-lysylglycyl)5 [(KG5)] linker attached to the glutamine(83) (E(83)) residue.,"InChI=1S/C130H217N39O33/c1-12-73(8)105(125(197)163-104(72(6)7)124(196)166-107(76(11)171)127(199)168-59-33-46-91(168)120(192)156-85(45-31-57-143-130(141)142)116(188)165-106(75(10)170)128(200)169-60-34-48-93(169)129(201)202)164-119(191)89(63-95(139)173)159-114(186)84(44-24-30-56-136)155-117(189)88(62-78-37-17-14-18-38-78)158-118(190)87(61-77-35-15-13-16-36-77)157-108(180)74(9)149-122(194)102(70(2)3)162-123(195)103(71(4)5)161-121(193)92-47-32-58-167(92)126(198)90(64-96(140)174)160-115(187)86(49-50-94(138)172)154-101(179)69-148-113(185)83(43-23-29-55-135)153-100(178)68-147-112(184)82(42-22-28-54-134)152-99(177)67-146-111(183)81(41-21-27-53-133)151-98(176)66-145-110(182)80(40-20-26-52-132)150-97(175)65-144-109(181)79(137)39-19-25-51-131/h13-18,35-38,70-76,79-93,102-107,170-171H,12,19-34,39-69,131-137H2,1-11H3,(H2,138,172)(H2,139,173)(H2,140,174)(H,144,181)(H,145,182)(H,146,183)(H,147,184)(H,148,185)(H,149,194)(H,150,175)(H,151,176)(H,152,177)(H,153,178)(H,154,179)(H,155,189)(H,156,192)(H,157,180)(H,158,190)(H,159,186)(H,160,187)(H,161,193)(H,162,195)(H,163,197)(H,164,191)(H,165,188)(H,166,196)(H,201,202)(H4,141,142,143)/t73?,74-,75?,76?,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,102-,103-,104-,105-,106-,107-/m0/s1",LysGlyLysGlyLysGlyLysGlyLysGlyGluAsnProValValAlaPhePheLysAsnIleValThrProArgThrPro,PubMed citation,26082772
5395,86312,ENPAVHFFKNIVTPRTP,A linear seventeen-membered polypeptide comprising the sequence Glu-Asn-Pro-Ala-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro. Corresponds to the sequence of the myelin basic protein 83-99 (MBP83-99) immunodominant epitope with the valyl residue at position 86 replaced by alanyl [MBP83-99(A(86))].,"InChI=1S/C91H140N26O23/c1-10-48(6)71(86(135)111-70(47(4)5)85(134)114-73(51(9)119)88(137)116-37-21-30-64(116)83(132)104-57(28-19-35-100-91(97)98)77(126)113-72(50(8)118)89(138)117-38-22-31-65(117)90(139)140)112-81(130)61(42-67(95)121)107-76(125)56(27-17-18-34-92)103-78(127)58(39-52-23-13-11-14-24-52)105-79(128)59(40-53-25-15-12-16-26-53)106-80(129)60(41-54-44-99-45-101-54)108-84(133)69(46(2)3)110-74(123)49(7)102-82(131)63-29-20-36-115(63)87(136)62(43-68(96)122)109-75(124)55(93)32-33-66(94)120/h11-16,23-26,44-51,55-65,69-73,118-119H,10,17-22,27-43,92-93H2,1-9H3,(H2,94,120)(H2,95,121)(H2,96,122)(H,99,101)(H,102,131)(H,103,127)(H,104,132)(H,105,128)(H,106,129)(H,107,125)(H,108,133)(H,109,124)(H,110,123)(H,111,135)(H,112,130)(H,113,126)(H,114,134)(H,139,140)(H4,97,98,100)/t48?,49-,50?,51?,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,69-,70-,71-,72-,73-/m0/s1",GluAsnProAlaValHisPhePheLysAsnIleValThrProArgThrPro,PubMed citation,26082772
5396,86318,copper(II) chloride dihydrate,A hydrate that is the dihydrate form of copper(II) chloride. It occurs naturally as the mineral eriochalcite.,InChI=1S/2ClH.Cu.2H2O/h2*1H;;2*1H2/q;;+2;;/p-2,copper(II) chloride.2H2O,PubMed citation,9730919
5397,86321,3-hydroxyoctanoyl-CoA,A 3-hydroxy-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxyoctanoic acid.,"InChI=1S/C29H50N7O18P3S/c1-4-5-6-7-17(37)12-20(39)58-11-10-31-19(38)8-9-32-27(42)24(41)29(2,3)14-51-57(48,49)54-56(46,47)50-13-18-23(53-55(43,44)45)22(40)28(52-18)36-16-35-21-25(30)33-15-34-26(21)36/h15-18,22-24,28,37,40-41H,4-14H2,1-3H3,(H,31,38)(H,32,42)(H,46,47)(H,48,49)(H2,30,33,34)(H2,43,44,45)/t17?,18-,22-,23-,24+,28-/m1/s1",3-hydroxycapryloyl-CoA,Reaxys Registry Number,19104580
5398,86338,3-hydroxydecanoyl-CoA,A 3-hydroxy-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxydecanoic acid.,"InChI=1S/C31H54N7O18P3S/c1-4-5-6-7-8-9-19(39)14-22(41)60-13-12-33-21(40)10-11-34-29(44)26(43)31(2,3)16-53-59(50,51)56-58(48,49)52-15-20-25(55-57(45,46)47)24(42)30(54-20)38-18-37-23-27(32)35-17-36-28(23)38/h17-20,24-26,30,39,42-43H,4-16H2,1-3H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t19?,20-,24-,25-,26+,30-/m1/s1",3-hydroxydecanoyl-coenzyme A,MetaCyc accession,CPD-15694
5399,86343,1-propanoylproline,A N-acylpyrrolidine that is proline substituted by a propanoyl group at the nitrogen atom.,"InChI=1S/C8H13NO3/c1-2-7(10)9-5-3-4-6(9)8(11)12/h6H,2-5H2,1H3,(H,11,12)",1-propionyl-pyrrolidine-2-carboxylic acid,Reaxys Registry Number,3946577
5400,86345,magnesium dichloride hexahydrate,A hydrate that is the hexahydrate form of magnesium dichloride.,InChI=1S/2ClH.Mg.6H2O/h2*1H;;6*1H2/q;;+2;;;;;;/p-2,magnesium chloride hexahydrate,PubMed citation,25148974
5401,86358,manganese(II) sulfate tetrahydrate,A hydrate that is the tetrahydrate form of manganese(II) sulfate.,"InChI=1S/Mn.H2O4S.4H2O/c;1-5(2,3)4;;;;/h;(H2,1,2,3,4);4*1H2/q+2;;;;;/p-2",manganese(2+) sulfate tetrahydrate,Reaxys Registry Number,16476033
5402,86360,manganese(II) sulfate,A metal sulfate in which the metal component is manganese in the +2 oxidation state.,"InChI=1S/Mn.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2",manganese(2+) sulfate,CAS Registry Number,7785-87-7
5403,86364,manganese(II) sulfate monohydrate,A hydrate that is the monohydrate form of manganese(II) sulfate.,"InChI=1S/Mn.H2O4S.H2O/c;1-5(2,3)4;/h;(H2,1,2,3,4);1H2/q+2;;/p-2",manganese(2+) sulphate monohydrate,CAS Registry Number,10034-96-5
5404,86368,manganese(II) chloride tetrahydrate,A hydrate that is the tetrahydrate form of manganese(II) chloride.,InChI=1S/2ClH.Mn.4H2O/h2*1H;;4*1H2/q;;+2;;;;/p-2,manganese(2+) chloride tetrahydrate,Wikipedia accession,Manganese(II)_chloride
5405,86375,(11Z)-hexadec-11-enoyl-CoA,A hexadecenoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (11Z)-hexadec-11-enoic acid.,"InChI=1S/C37H64N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h7-8,24-26,30-32,36,47-48H,4-6,9-23H2,1-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/b8-7-/t26-,30-,31-,32+,36-/m1/s1",(11Z)-hexadecenoyl-coenzyme A,MetaCyc accession,CPD-16001
5406,86376,"(10E,12Z)-hexadecadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (10E,12Z)-hexadecadienoic acid.","InChI=1S/C37H62N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-28(46)65-21-20-39-27(45)18-19-40-35(49)32(48)37(2,3)23-58-64(55,56)61-63(53,54)57-22-26-31(60-62(50,51)52)30(47)36(59-26)44-25-43-29-33(38)41-24-42-34(29)44/h6-9,24-26,30-32,36,47-48H,4-5,10-23H2,1-3H3,(H,39,45)(H,40,49)(H,53,54)(H,55,56)(H2,38,41,42)(H2,50,51,52)/b7-6-,9-8-/t26-,30-,31-,32+,36-/m1/s1","(10E,12Z)-hexadecadienoyl-coenzyme A",MetaCyc accession,CPD-16002
5407,86403,adenosylhopane,A bacterial hopanoid obtained by addition of an adenosyl group across the double bond of hopene.,"InChI=1S/C40H63N5O3/c1-23(9-10-26-31(46)32(47)35(48-26)45-22-44-30-33(41)42-21-43-34(30)45)24-13-18-37(4)25(24)14-19-39(6)28(37)11-12-29-38(5)17-8-16-36(2,3)27(38)15-20-40(29,39)7/h21-29,31-32,35,46-47H,8-20H2,1-7H3,(H2,41,42,43)/t23?,24?,25-,26+,27-,28+,29+,31+,32+,35+,37-,38-,39+,40+/m0/s1",adenosylhopene,PubMed citation,22221333
5408,86433,4-hydroxybenzoyl-AMP,An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of 4-hydroxybenzoic acid.,"InChI=1S/C17H18N5O9P/c18-14-11-15(20-6-19-14)22(7-21-11)16-13(25)12(24)10(30-16)5-29-32(27,28)31-17(26)8-1-3-9(23)4-2-8/h1-4,6-7,10,12-13,16,23-25H,5H2,(H,27,28)(H2,18,19,20)/t10-,12-,13-,16-/m1/s1",4-hydroxybenzoyl adenylate,Reaxys Registry Number,23982064
5409,86457,2-hydroxybenzoyl-AMP,An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of 2-hydroxybenzoic acid.,"InChI=1S/C17H18N5O9P/c18-14-11-15(20-6-19-14)22(7-21-11)16-13(25)12(24)10(30-16)5-29-32(27,28)31-17(26)8-3-1-2-4-9(8)23/h1-4,6-7,10,12-13,16,23-25H,5H2,(H,27,28)(H2,18,19,20)/t10-,12-,13-,16-/m1/s1",2-hydroxybenzoyl adenylate,Reaxys Registry Number,20754798
5410,86458,2-hydroxybenzoyl-AMP(1-),An organophosphate oxoanion obtained by deprotonation of the phosphate OH group of 2-hydroxybenzoyl-AMP; the major species at pH 7.3.,"InChI=1S/C17H18N5O9P/c18-14-11-15(20-6-19-14)22(7-21-11)16-13(25)12(24)10(30-16)5-29-32(27,28)31-17(26)8-3-1-2-4-9(8)23/h1-4,6-7,10,12-13,16,23-25H,5H2,(H,27,28)(H2,18,19,20)/p-1/t10-,12-,13-,16-/m1/s1",salicyl-AMP(1-),PubMed citation,9831524
5411,86471,pyrite,An iron sulfide mineral with formula FeS2.,InChI=1S/Fe.S2/c;1-2/q+2;-2,FeS2,CAS Registry Number,1309-36-0
5412,86474,RO4929097,"A member of the class of dibenzoazepines that is the amide formed from formal condensation of the carboxy group of 2,2-dimethyl-3-oxo-3-[(2,2,3,3,3-pentafluoropropyl)amino]propanoic acid with the amino group of (7S)-7-amino-5,7-dihydrodibenzo[b,d]azepin-6-one.","InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1",RO-4929097,CAS Registry Number,847925-91-1
5413,86502,5'P-TTTTT-3'P,A single-stranded DNA oligonucleotide composed of five deoxythymidylic acid residues connected by 3'->5' phosphodiester linkages and terminated by 3'- and 5'-phosphate groups.,"InChI=1S/C50H68N10O39P6/c1-21-11-56(46(66)51-41(21)61)36-6-26(95-101(74,75)76)32(91-36)17-86-102(77,78)97-28-8-38(58-13-23(3)43(63)53-48(58)68)93-34(28)19-88-104(81,82)99-30-10-40(60-15-25(5)45(65)55-50(60)70)94-35(30)20-89-105(83,84)98-29-9-39(59-14-24(4)44(64)54-49(59)69)92-33(29)18-87-103(79,80)96-27-7-37(90-31(27)16-85-100(71,72)73)57-12-22(2)42(62)52-47(57)67/h11-15,26-40H,6-10,16-20H2,1-5H3,(H,77,78)(H,79,80)(H,81,82)(H,83,84)(H,51,61,66)(H,52,62,67)(H,53,63,68)(H,54,64,69)(H,55,65,70)(H2,71,72,73)(H2,74,75,76)/t26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+/m0/s1",p5(dT)p,Reaxys Registry Number,15492699
5414,86510,"N-[(2S,3S,4R)-1-(alpha-D-galactosyloxy)-3,4-dihydroxyoctadecan-2-yl]hexacosanethioamide",A glycosphingolipid identical with alpha-galactosylceramide (alpha-GalCer) with the exception of the replacement of the C-2 carbonyl oxygen on the acyl chain with a sulfur atom.,"InChI=1S/C50H99NO8S/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-45(60)51-42(41-58-50-49(57)48(56)47(55)44(40-52)59-50)46(54)43(53)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h42-44,46-50,52-57H,3-41H2,1-2H3,(H,51,60)/t42-,43+,44+,46-,47-,48-,49+,50-/m0/s1",DB06-1,PDBeChem accession,4LX
5415,86542,2-hydroxyhexanoic acid,A hydroxy fatty acid that is caproic (hexanoic) acid substituted by a hydroxy group at position 2.,"InChI=1S/C6H12O3/c1-2-3-4-5(7)6(8)9/h5,7H,2-4H2,1H3,(H,8,9)",2-hydroxycaproic acid,LIPID MAPS instance accession,LMFA01050011
5416,86543,2-hydroxyoctanoic acid,A hydroxy fatty acid that is  caprylic (octanoic) acid substituted by a hydroxy group at position 2.,"InChI=1S/C8H16O3/c1-2-3-4-5-6-7(9)8(10)11/h7,9H,2-6H2,1H3,(H,10,11)",2-hydroxycaprylic acid,LIPID MAPS instance accession,LMFA01050020
5417,86553,3-hydroxymandelic acid,A 2-hydroxy monocarboxylic acid that is mandelic acid substituted by a hydroxy group at position 3'.,"InChI=1S/C8H8O4/c9-6-3-1-2-5(4-6)7(10)8(11)12/h1-4,7,9-10H,(H,11,12)",2-hydroxy-2-(3-hydroxyphenyl)ethanoic acid,CAS Registry Number,17119-15-2
5418,86554,3-morpholinopropylamine,A member of the class of  morpholines that is  morpholine substituted by a 3-aminopropyl group a the N atom.,InChI=1S/C7H16N2O/c8-2-1-3-9-4-6-10-7-5-9/h1-8H2,3-morpholinopropan-1-amine,Reaxys Registry Number,105104
5419,86555,pyridine-3-carbaldehyde oxime,An aldoxime obtained by the formal condensation of the aldehyde group of pyridine-3-carbaldehyde (nicotinaldehyde) with hydroxylamine.,"InChI=1S/C6H6N2O/c9-8-5-6-2-1-3-7-4-6/h1-5,9H",3-pyridinecarboxaldehyde oxime,Reaxys Registry Number,8308192
5420,86556,3-pyridinecarbonitrile,A nitrile that is  pyridine substituted by a cyano group at position 3.,"InChI=1S/C6H4N2/c7-4-6-2-1-3-8-5-6/h1-3,5H",nicotinonitrile,Reaxys Registry Number,107711
5421,86564,4-guanidinobutyric acid,A monocarboxylic acid that is butanoic acid substituted by a guanidino group at position 4.,"InChI=1S/C5H11N3O2/c6-5(7)8-3-1-2-4(9)10/h1-3H2,(H,9,10)(H4,6,7,8)",4-(diaminomethylideneamino)butanoic acid,Reaxys Registry Number,6717259
5422,86578,trans-coniferyl alcohol diacetate,A phenyl acetate that is the diacetate derivative of coniferol.,"InChI=1S/C14H16O5/c1-10(15)18-8-4-5-12-6-7-13(19-11(2)16)14(9-12)17-3/h4-7,9H,8H2,1-3H3/b5-4+",acetylated coniferyl alcohol,Reaxys Registry Number,2058808
5423,86580,4-acetoxycinnamic acid,An acetate ester obtained by the formal condensation of the hydroxy group of trans-4-coumaric acid with acetic acid.,"InChI=1S/C11H10O4/c1-8(12)15-10-5-2-9(3-6-10)4-7-11(13)14/h2-7H,1H3,(H,13,14)/b7-4+",acetylated coumaric acid,Reaxys Registry Number,2806111
5424,86581,3-(4'-acetoxyphenyl)propionic acid,A monocarboxylic acid that is propionic acid substituted by a 4'-acetoxyphenyl group at position 3.,"InChI=1S/C11H12O4/c1-8(12)15-10-5-2-9(3-6-10)4-7-11(13)14/h2-3,5-6H,4,7H2,1H3,(H,13,14)",acetylated dihydrocoumaric acid,Reaxys Registry Number,2110567
5425,86582,O-acetylferulic acid,A phenyl acetate obtained by the formal condensation of the phenolic group of ferulic acid with acetic acid.,"InChI=1S/C12H12O5/c1-8(13)17-10-5-3-9(4-6-12(14)15)7-11(10)16-2/h3-7H,1-2H3,(H,14,15)/b6-4+",acetylated ferulic acid,Reaxys Registry Number,2218027
5426,86618,ethyl heptanoate,The fatty acid ethyl ester of heptanoic acid.,"InChI=1S/C9H18O2/c1-3-5-6-7-8-9(10)11-4-2/h3-8H2,1-2H3",heptanoic acid ethyl ester,Reaxys Registry Number,1752311
5427,86655,homoveratric acid,A phenylacetic acid substituted at positions 3 and 4 by methoxy groups.,"InChI=1S/C10H12O4/c1-13-8-4-3-7(6-10(11)12)5-9(8)14-2/h3-5H,6H2,1-2H3,(H,11,12)","2-(3,4-dimethoxyphenyl)ethanoic acid",PubMed citation,588645
5428,86903,methyl p-anisate,A benzoate ester obtained by the formal condensation of the carboxy group of 4-methoxybenzoic acid with methanol.,"InChI=1S/C9H10O3/c1-11-8-5-3-7(4-6-8)9(10)12-2/h3-6H,1-2H3",methyl 4-anisate,Reaxys Registry Number,2208571
5429,86910,N-acetylhistidine,A histidine derivative that is histidine in which one of the hydrogens of the alpha-amino group is substituted by an acetyl group.,"InChI=1S/C8H11N3O3/c1-5(12)11-7(8(13)14)2-6-3-9-4-10-6/h3-4,7H,2H2,1H3,(H,9,10)(H,11,12)(H,13,14)",2-acetamido-3-(1H-imidazol-5-yl)propanoic acid,HMDB accession,HMDB0032055
5430,86952,trans-3-hexenedioic acid,The trans-stereoisomer of 3-hexenedioic acid.,"InChI=1S/C6H8O4/c7-5(8)3-1-2-4-6(9)10/h1-2H,3-4H2,(H,7,8)(H,9,10)/b2-1+",(E)-3-hexenedioic acid,Reaxys Registry Number,1723581
5431,86988,2-oxohexadecanoic acid,An oxo fatty acid that is the 2-oxo derivative of hexadecanoic (palmitic) acid.,"InChI=1S/C16H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(17)16(18)19/h2-14H2,1H3,(H,18,19)",2oxo-PALM,LIPID MAPS instance accession,LMFA01060050
5432,86989,stattic,"A member of the class of 1-benzothiophenes that is 1-benzothiophene-1,1-dioxide substituted at position 6 by a nitro group. Used as a radiosensitising agent for esophageal squamous cell carcinoma.","InChI=1S/C8H5NO4S/c10-9(11)7-2-1-6-3-4-14(12,13)8(6)5-7/h1-5H","6-nitro-1-benzothiophene 1,1-dioxide",Reaxys Registry Number,11410
5433,86995,(S)-fluoxetine(1+),An organic cation resulting from the protonation of the amino group of (S)-fluoxetine.,"InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3/p+1/t16-/m0/s1",(-)-fluoxetine(1+),Reaxys Registry Number,25263174
5434,87001,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-Glcp6S,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp6S in which the anomeric configuration of the glucose residue is beta.,"InChI=1S/C18H32O18S/c1-4-7(20)9(22)11(24)17(32-4)36-15-13(26)16(27)33-6(3-31-37(28,29)30)14(15)35-18-12(25)10(23)8(21)5(2-19)34-18/h4-27H,2-3H2,1H3,(H,28,29,30)/t4-,5+,6+,7+,8-,9+,10-,11-,12+,13+,14+,15+,16+,17-,18-/m0/s1",beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-Glc6S,PubMed citation,25568069
5435,87011,vanadyl sulfate trihydrate,A hydrate that is the trihydrate form of vanadyl sulfate.,"InChI=1S/H2O4S.3H2O.O.V/c1-5(2,3)4;;;;;/h(H2,1,2,3,4);3*1H2;;/q;;;;;+2/p-2",vanadium oxide sulfate trihydrate,Reaxys Registry Number,13849479
5436,87014,vanadyl sulfate hexahydrate,A vanadyl sulfate hydrate containing six water molecules.,"InChI=1S/H2O4S.6H2O.O.V/c1-5(2,3)4;;;;;;;;/h(H2,1,2,3,4);6*1H2;;/q;;;;;;;;+2/p-2",vanadic sulfate hexahydrate,Reaxys Registry Number,16512138
5437,87041,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"An amino oligosaccharide that is an undecasaccharide in which two tetrasaccharide branches, each formed from fucose, galactose, N-acetylglucosamine and mannose residues linked alpha(1->2), beta(1->4) and beta(1->2) respectively, are linked alpha(1->3) and alpha(1->6) to the mannose residue of a trisaccharide chain consisting of mannose and two N-acetylglucosamine residues all linked beta(1->4) with a beta-configuration of the anomeric carbon of the N-acetylglucosamine residue at the reducing end.","InChI=1S/C74H124N4O54/c1-16-35(91)46(102)52(108)68(113-16)131-62-50(106)39(95)23(8-80)117-72(62)126-57-28(13-85)121-66(33(44(57)100)77-20(5)89)129-60-48(104)37(93)22(7-79)116-71(60)112-15-30-41(97)59(54(110)70(123-30)125-56-27(12-84)120-65(32(43(56)99)76-19(4)88)124-55-26(11-83)115-64(111)31(42(55)98)75-18(3)87)128-74-61(49(105)38(94)25(10-82)119-74)130-67-34(78-21(6)90)45(101)58(29(14-86)122-67)127-73-63(51(107)40(96)24(9-81)118-73)132-69-53(109)47(103)36(92)17(2)114-69/h16-17,22-74,79-86,91-111H,7-15H2,1-6H3,(H,75,87)(H,76,88)(H,77,89)(H,78,90)/t16-,17-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39-,40-,41+,42+,43+,44+,45+,46+,47+,48-,49-,50-,51-,52-,53-,54-,55+,56+,57+,58+,59-,60-,61-,62+,63+,64+,65-,66-,67-,68-,69-,70-,71-,72-,73-,74+/m0/s1",6-deoxy-alpha-L-galactosyl-(1->2)-beta-D-galactosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucosyl-(1->2)-alpha-D-mannosyl-(1->3)-[6-deoxy-alpha-L-galactosyl-(1->2)-beta-D-galactosyl-(1->3)-2-acetamido-2-deoxy-beta-D-glucosyl-(1->2)-alpha-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-2-acetamido-2-deoxy-beta-D-glucosyl-(1->4)-2-acetamido-2-deoxy-beta-D-glucose,PubMed citation,25568069
5438,87052,acid fuchsin,"An organic sodium salt that is the disodium salt of 2-amino-5-[(4-amino-3-sulfophenyl)(4-imino-3-sulfocyclohexa-2,5-dien-1-ylidene)methyl]-3-methylbenzene-1-sulfonic acid. It is used in the Van Gieson method in conjunction with picric acid to demonstrate collagen fibres red, and in Masson's trichrome to colour smooth muscle in contrast to collagen.","InChI=1S/C20H19N3O9S3.2Na/c1-10-6-13(9-18(20(10)23)35(30,31)32)19(11-2-4-14(21)16(7-11)33(24,25)26)12-3-5-15(22)17(8-12)34(27,28)29;;/h2-9,21H,22-23H2,1H3,(H,24,25,26)(H,27,28,29)(H,30,31,32);;/q;2*+1/p-2/b19-11-,21-14?;;",acid violet 19,CAS Registry Number,68109-73-9
5439,87083,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->6)-{alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcppNAc-(1->3)}-beta-D-Gal-(1->4)-D-Glcp,"A nine-membered glucosamine oligosaccharide that consists of the disaccharide beta-D-Gal-(1->4)-beta-D-Glc, to the galactose residue of which are attached alpha-L-Fuc-(1->4)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)]-beta-D-GlcNAc and beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc groups at O-3 and O-6 respectively.","InChI=1S/C58H98N2O43/c1-12-25(68)31(74)38(81)53(88-12)98-45-21(10-65)95-52(24(60-16(5)67)47(45)101-58-49(35(78)29(72)18(7-62)93-58)103-55-40(83)33(76)27(70)14(3)90-55)102-48-30(73)22(96-57(42(48)85)97-43-19(8-63)91-50(86)37(80)36(43)79)11-87-51-23(59-15(4)66)46(100-54-39(82)32(75)26(69)13(2)89-54)44(20(9-64)94-51)99-56-41(84)34(77)28(71)17(6-61)92-56/h12-14,17-58,61-65,68-86H,6-11H2,1-5H3,(H,59,66)(H,60,67)/t12-,13-,14-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28-,29-,30-,31+,32+,33+,34-,35-,36+,37+,38-,39-,40-,41+,42+,43+,44+,45+,46+,47+,48-,49+,50?,51+,52-,53-,54-,55-,56-,57-,58-/m0/s1",Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-4(Fuca1-2Galb1-3)GlcNAcb1-3)Galb1-4Glc,PubMed citation,25568069
5440,87094,acid red 4,An organic sodium salt having 4-hydroxy-3-[(2-methoxyphenyl)diazenyl]naphthalene-1-sulfonate as the counterion.,"InChI=1S/C17H14N2O5S.Na/c1-24-15-9-5-4-8-13(15)18-19-14-10-16(25(21,22)23)11-6-2-3-7-12(11)17(14)20;/h2-10,20H,1H3,(H,21,22,23);/q;+1/p-1",azo-eosin,CAS Registry Number,5858-39-9
5441,87098,4-hydroxy-3-[(2-methoxyphenyl)diazenyl]naphthalene-1-sulfonic acid,A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid carrying additional hydroxy and (2-methoxyphenyl)diazenyl substituents at positions 4 and 3 respectively. The sodium salt is the biological stain 'acid red 4'.,"InChI=1S/C17H14N2O5S/c1-24-15-9-5-4-8-13(15)18-19-14-10-16(25(21,22)23)11-6-2-3-7-12(11)17(14)20/h2-10,20H,1H3,(H,21,22,23)/b19-18+",acid red 4 (free acid form),Reaxys Registry Number,7348371
5442,87106,acid red 29,"An organic sodium salt that is the disodium salt of 4,5-dihydroxy-3-(phenyldiazenyl)naphthalene-2,7-disulfonic acid. It is used as the plasma stain in trichrome techniques.","InChI=1S/C16H12N2O8S2.2Na/c19-12-8-11(27(21,22)23)6-9-7-13(28(24,25)26)15(16(20)14(9)12)18-17-10-4-2-1-3-5-10;;/h1-8,19-20H,(H,21,22,23)(H,24,25,26);;/q;2*+1/p-2",chromotrope 2R,CAS Registry Number,4197-07-3
5443,87112,acid red 44,"An organic sodium salt that is the disodium salt of 7-hydroxy-8-[(naphthalen-1-yl)diazenyl]naphthalene-1,3-disulfonic acid.","InChI=1S/C20H14N2O7S2.2Na/c23-17-9-8-13-10-14(30(24,25)26)11-18(31(27,28)29)19(13)20(17)22-21-16-7-3-5-12-4-1-2-6-15(12)16;;/h1-11,23H,(H,24,25,26)(H,27,28,29);;/q;2*+1/p-2",crystal scarlet,CAS Registry Number,2766-77-0
5444,87115,"7-hydroxy-8-[(naphthalen-1-yl)diazenyl]naphthalene-1,3-disulfonic acid","A naphthalenesulfonic acid that is naphthalene-1,3-disulfonic acid carrying additional hydroxy and (naphthalen-1-yl)diazenylsubstituents at positions 7 and 8 respectively. The disodium salt is the biological stain 'acid red 44'.","InChI=1S/C20H14N2O7S2/c23-17-9-8-13-10-14(30(24,25)26)11-18(31(27,28)29)19(13)20(17)22-21-16-7-3-5-12-4-1-2-6-15(12)16/h1-11,23H,(H,24,25,26)(H,27,28,29)",acid red 44 (free acid form),Reaxys Registry Number,8135275
5445,87126,TDP-beta-L-rhamnose,A TDP-sugar having beta-L-rhamnose as the sugar component.,"InChI=1S/C16H26N2O16P2/c1-5-3-18(16(25)17-13(5)24)14-11(22)9(20)7(32-14)4-30-35(26,27)34-36(28,29)33-15-12(23)10(21)8(19)6(2)31-15/h3,6-12,14-15,19-23H,4H2,1-2H3,(H,26,27)(H,28,29)(H,17,24,25)/t6-,7+,8-,9+,10+,11+,12+,14+,15+/m0/s1",TDP-beta-rhamnose,PubMed citation,19058170
5446,87129,TDP-actinospectose,A TDP-sugar having actinospectose as the sugar component.,"InChI=1S/C16H24N2O15P2/c1-6-4-18(16(24)17-13(6)23)14-12(22)11(21)9(31-14)5-29-34(25,26)33-35(27,28)32-15-10(20)8(19)3-7(2)30-15/h4,7,9-12,14-15,20-22H,3,5H2,1-2H3,(H,25,26)(H,27,28)(H,17,23,24)/t7-,9-,10-,11-,12-,14-,15-/m1/s1","TDP-3-keto-4,6-dideoxyglucose",Reaxys Registry Number,10503719
5447,87137,dihydrocaffeoyl-CoA(4-),An acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of hydrocaffeoyl-CoA; major species at pH 7.3.,"InChI=1S/C30H44N7O19P3S/c1-30(2,25(43)28(44)33-8-7-20(40)32-9-10-60-21(41)6-4-16-3-5-17(38)18(39)11-16)13-53-59(50,51)56-58(48,49)52-12-19-24(55-57(45,46)47)23(42)29(54-19)37-15-36-22-26(31)34-14-35-27(22)37/h3,5,11,14-15,19,23-25,29,38-39,42-43H,4,6-10,12-13H2,1-2H3,(H,32,40)(H,33,44)(H,48,49)(H,50,51)(H2,31,34,35)(H2,45,46,47)/p-4/t19-,23-,24-,25+,29-/m1/s1","3-(3,4-dihydroxyphenyl)propanoyl-CoA(4-)",MetaCyc accession,CPD-18003
5448,87139,3-oxochol-4-en-24-oyl-CoA,A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxochol-4-en-24-oic acid.,"InChI=1S/C45H70N7O18P3S/c1-25(29-9-10-30-28-8-7-26-20-27(53)12-15-44(26,4)31(28)13-16-45(29,30)5)6-11-34(55)74-19-18-47-33(54)14-17-48-41(58)38(57)43(2,3)22-67-73(64,65)70-72(62,63)66-21-32-37(69-71(59,60)61)36(56)42(68-32)52-24-51-35-39(46)49-23-50-40(35)52/h20,23-25,28-32,36-38,42,56-57H,6-19,21-22H2,1-5H3,(H,47,54)(H,48,58)(H,62,63)(H,64,65)(H2,46,49,50)(H2,59,60,61)/t25-,28+,29-,30+,31+,32-,36-,37-,38+,42-,44+,45-/m1/s1","3-oxo-26,27-bisnorchol-4-en-24-oyl-coenzyme A",MetaCyc accession,CPD-13696
5449,87140,"3-oxochola-4,22-dien-24-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxochola-4,22-dien-24-oic acid.","InChI=1S/C45H68N7O18P3S/c1-25(29-9-10-30-28-8-7-26-20-27(53)12-15-44(26,4)31(28)13-16-45(29,30)5)6-11-34(55)74-19-18-47-33(54)14-17-48-41(58)38(57)43(2,3)22-67-73(64,65)70-72(62,63)66-21-32-37(69-71(59,60)61)36(56)42(68-32)52-24-51-35-39(46)49-23-50-40(35)52/h6,11,20,23-25,28-32,36-38,42,56-57H,7-10,12-19,21-22H2,1-5H3,(H,47,54)(H,48,58)(H,62,63)(H,64,65)(H2,46,49,50)(H2,59,60,61)/t25-,28+,29-,30+,31+,32-,36-,37-,38+,42-,44+,45-/m1/s1","3-oxochola-4,22-dien-24-oyl-coenzyme A",MetaCyc accession,CPD-13697
5450,87141,"3-oxocholesta-4,24-dien-26-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxocholesta-4,24-dien-26-oic acid.","InChI=1S/C48H74N7O18P3S/c1-27(32-12-13-33-31-11-10-29-22-30(56)14-17-47(29,5)34(31)15-18-48(32,33)6)8-7-9-28(2)45(61)77-21-20-50-36(57)16-19-51-43(60)40(59)46(3,4)24-70-76(67,68)73-75(65,66)69-23-35-39(72-74(62,63)64)38(58)44(71-35)55-26-54-37-41(49)52-25-53-42(37)55/h9,22,25-27,31-35,38-40,44,58-59H,7-8,10-21,23-24H2,1-6H3,(H,50,57)(H,51,60)(H,65,66)(H,67,68)(H2,49,52,53)(H2,62,63,64)/t27-,31+,32-,33+,34+,35-,38-,39-,40+,44-,47+,48-/m1/s1","3-oxocholesta-4,24-dien-26-oyl-coenzyme A",MetaCyc accession,CPD-13692
5451,87158,SU1498,"A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enoic acid with the amino group of 3-phenylpropylamine.","InChI=1S/C25H30N2O2/c1-17(2)22-14-20(15-23(18(3)4)24(22)28)13-21(16-26)25(29)27-12-8-11-19-9-6-5-7-10-19/h5-7,9-10,13-15,17-18,28H,8,11-12H2,1-4H3,(H,27,29)/b21-13+",SU 1498,Reaxys Registry Number,13590854
5452,87159,SU5614,"A member of the class of oxindoles that is 5-chlorooxindole in which the two hydrogens at position 3 are replaced by a (3,5-dimethylpyrrol-2-yl)methylidene group.","InChI=1S/C15H13ClN2O/c1-8-5-9(2)17-14(8)7-12-11-6-10(16)3-4-13(11)18-15(12)19/h3-7,17H,1-2H3,(H,18,19)/b12-7-",CID:6536806,PubMed citation,12135675
5453,87173,(2R)-2-methyltetradecanoyl-CoA,A (2R)-2-methylacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2R)-2-methyltetradecanoic acid.,"InChI=1S/C36H64N7O17P3S/c1-5-6-7-8-9-10-11-12-13-14-15-24(2)35(48)64-19-18-38-26(44)16-17-39-33(47)30(46)36(3,4)21-57-63(54,55)60-62(52,53)56-20-25-29(59-61(49,50)51)28(45)34(58-25)43-23-42-27-31(37)40-22-41-32(27)43/h22-25,28-30,34,45-46H,5-21H2,1-4H3,(H,38,44)(H,39,47)(H,52,53)(H,54,55)(H2,37,40,41)(H2,49,50,51)/t24-,25-,28-,29-,30+,34-/m1/s1",(2R)-2-methyltetradecanoyl-coenzyme A,PDBeChem accession,MRR
5454,87175,propamidine isethionate,"A guanidinium salt obtained by combining propamidine with two molar equivalents of isethionic acid. Used for the treatment of minor eye or eyelid infections, such as conjunctivitis and blepharitis.","InChI=1S/C17H20N4O2.2C2H6O4S/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21;2*3-1-2-7(4,5)6/h2-9H,1,10-11H2,(H3,18,19)(H3,20,21);2*3H,1-2H2,(H,4,5,6)",Propamidine isethionate,KEGG DRUG accession,D08436
5455,87182,"(2S)-2,6-dimethylheptanoyl-CoA","The 2S stereoisomer of 2,6-dimethylheptanoyl-CoA.","InChI=1S/C30H52N7O17P3S/c1-17(2)7-6-8-18(3)29(42)58-12-11-32-20(38)9-10-33-27(41)24(40)30(4,5)14-51-57(48,49)54-56(46,47)50-13-19-23(53-55(43,44)45)22(39)28(52-19)37-16-36-21-25(31)34-15-35-26(21)37/h15-19,22-24,28,39-40H,6-14H2,1-5H3,(H,32,38)(H,33,41)(H,46,47)(H,48,49)(H2,31,34,35)(H2,43,44,45)/t18-,19+,22+,23+,24-,28+/m0/s1","(2S)-2,6-dimethylheptanoyl-coenzyme A",HMDB accession,HMDB0006258
5456,87186,Biebrich scarlet,An organic sodium salt having 2-[(2-hydroxynaphthalen-1-yl)diazenyl]-5-[(4-sulfonatophenyl)diazenyl]benzene-1-sulfonate as the counterion. Used as a plasma stain in Masson's trichrome.,"InChI=1S/C22H16N4O7S2.2Na/c27-20-12-5-14-3-1-2-4-18(14)22(20)26-25-19-11-8-16(13-21(19)35(31,32)33)24-23-15-6-9-17(10-7-15)34(28,29)30;;/h1-13,27H,(H,28,29,30)(H,31,32,33);;/q;2*+1/p-2",Croceine scarlet,CAS Registry Number,4196-99-0
5457,87187,Biebrich scarlet (acid form),An arenesulfonic acid that is m-[(4-sulfophenyl)diazenyl]benzene-1-sulfonic acid carrying a (2-hydroxynaphthalen-1-yl)diazenyl substituent at position 2. The disodium salt is the biological stain 'Biebrich scarlet'.,"InChI=1S/C22H16N4O7S2/c27-20-12-5-14-3-1-2-4-18(14)22(20)26-25-19-11-8-16(13-21(19)35(31,32)33)24-23-15-6-9-17(10-7-15)34(28,29)30/h1-13,27H,(H,28,29,30)(H,31,32,33)",acid red 66 (free acid form),Reaxys Registry Number,3229970
5458,87189,woodstain scarlet,"An organic sodium salt that is the disodium salt of 7-hydroxy-8-{[4-(phenyldiazenyl)phenyl]diazenyl}naphthalene-1,3-disulfonic acid. Occasionally used for the demonstration of muscle fibres in conjunction with, or as a replacement for, acid fuchsin.","InChI=1S/C22H16N4O7S2.2Na/c27-19-11-6-14-12-18(34(28,29)30)13-20(35(31,32)33)21(14)22(19)26-25-17-9-7-16(8-10-17)24-23-15-4-2-1-3-5-15;;/h1-13,27H,(H,28,29,30)(H,31,32,33);;/q;2*+1/p-2",brilliant crocein MOO,CAS Registry Number,5413-75-2
5459,87190,"7-hydroxy-8-{[4-(phenyldiazenyl)phenyl]diazenyl}naphthalene-1,3-disulfonic acid","A naphthalenesulfonic acid that is 7-hydroxynaphthalene-1,3-disulfonic acid substituted at position 8 by a [4-(phenyldiazenyl)phenyl]diazenyl group. The disodium salt is the biological stain 'woodstain scarlet'.","InChI=1S/C22H16N4O7S2/c27-19-11-6-14-12-18(34(28,29)30)13-20(35(31,32)33)21(14)22(19)26-25-17-9-7-16(8-10-17)24-23-15-4-2-1-3-5-15/h1-13,27H,(H,28,29,30)(H,31,32,33)",woodstain scarlet free acid,CAS Registry Number,25317-39-9
5460,87192,phloxine B,"An organic sodium salt that is the disodium salt of 2,3,4,5-tetrachloro-6-(2,4,5,7-tetrabromo-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid. It is used in the hematoxylin phloxine saffron (HPS) stain, stains paneth cell granules in Lendrum's phloxine-tartrazine method, and can be used to demonstrate alcoholic hyaline.","InChI=1S/C20H4Br4Cl4O5.2Na/c21-5-1-3-7(8-9(20(31)32)13(26)15(28)14(27)12(8)25)4-2-6(22)17(30)11(24)19(4)33-18(3)10(23)16(5)29;;/h1-2,29H,(H,31,32);;/q;2*+1/p-2",acid red 92,CAS Registry Number,4618-23-9
5461,87193,"2',4',5',7'-tetrabromo-2,3,4,5-tetrachlorofluorescein","A xanthene dye that is fluorescein bearing bromine substituents at positions 2', 4', 5' and 7' (on the xanthene ring) and chlorine substituents at position 2, 3, 4, and 5 (on the phenyl ring). The disodium salt is the biological stain 'phloxine B'.","InChI=1S/C20H4Br4Cl4O5/c21-5-1-3-7(8-9(20(31)32)13(26)15(28)14(27)12(8)25)4-2-6(22)17(30)11(24)19(4)33-18(3)10(23)16(5)29/h1-2,29H,(H,31,32)",acid red 92 (free acid form),Reaxys Registry Number,1277417
5462,87194,MgADP,A magnesium salt composed of Mg(2+) and ADP(2-) ions in a 1:1 ratio. Magnesium-ADP is a potassium channel activator.,"InChI=1S/C10H15N5O10P2.Mg/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20;/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20);/q;+2/p-2/t4-,6-,7-,10-;/m1./s1",magnesium2+-ADP,PubMed citation,26095850
5463,87206,azocarmine G,An organic sodium salt having 7-phenyl-5-(4-sulfonatoanilino)benzo[a]phenazin-7-ium-3-sulfonate as the couterion.,"InChI=1S/C28H19N3O6S2.Na/c32-38(33,34)20-12-10-18(11-13-20)29-25-17-27-28(22-15-14-21(16-23(22)25)39(35,36)37)30-24-8-4-5-9-26(24)31(27)19-6-2-1-3-7-19;/h1-17H,(H2,32,33,34,35,36,37);/q;+1/p-1",C.I. 50085,PubMed citation,26204922
5464,87214,azocarmine B,"An organic sodium salt that is the disodium salt of 4-[(7-phenyl-3-sulfobenzo[a]phenazin-7-ium-5-yl)amino]benzene-1,3-disulfonic acid.","InChI=1S/C28H19N3O9S3.2Na/c32-41(33,34)18-10-12-20-21(14-18)24(29-23-13-11-19(42(35,36)37)15-27(23)43(38,39)40)16-26-28(20)30-22-8-4-5-9-25(22)31(26)17-6-2-1-3-7-17;;/h1-16H,(H3,32,33,34,35,36,37,38,39,40);;/q;2*+1/p-2",Acid red 103,Reaxys Registry Number,14926140
5465,87219,naphthol yellow S,"An organic sodium salt that is the disodium salt of 5,7-dinitro-8-hydroxynaphthalene-2-sulfonic acid.","InChI=1S/C10H6N2O8S.2Na/c13-10-7-3-5(21(18,19)20)1-2-6(7)8(11(14)15)4-9(10)12(16)17;;/h1-4,13H,(H,18,19,20);;/q;2*+1/p-2",C.I. 10316,CAS Registry Number,846-70-8
5466,87226,lissamine flavine FF,"An organic sodium salt having  6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinoline-5-sulfonate as the counterion. It is used as the displacement dye in the yellowsolve I method for fibrin.","InChI=1S/C19H14N2O5S.Na/c1-10-5-7-11(8-6-10)21-18(22)13-4-2-3-12-16(13)14(19(21)23)9-15(17(12)20)27(24,25)26;/h2-9H,20H2,1H3,(H,24,25,26);/q;+1/p-1",brilliant sulpho flavine FF,CAS Registry Number,2391-30-2
5467,87235,metanil yellow,"An organic sodium salt having 3-[(4-anilinophenyl)diazenyl]benzene-1-sulfonate as the counterion. Used in one variant of Masson's trichrome to stain collagen yellow in contrast to the red muscle, but is not in common used.","InChI=1S/C18H15N3O3S.Na/c22-25(23,24)18-8-4-7-17(13-18)21-20-16-11-9-15(10-12-16)19-14-5-2-1-3-6-14;/h1-13,19H,(H,22,23,24);/q;+1/p-1",C.I. 13065,Reaxys Registry Number,3831568
5468,87242,palmitoyllipid A,A member of the class of lipid As that is lipid A in which the free OH group on the N-hydroxytetradecanoyl group is carrying a palimitoyl group.,"InChI=1S/C110H208N2O26P2/c1-8-15-22-29-36-43-45-46-48-55-62-68-75-82-98(117)130-91(78-71-64-57-50-39-32-25-18-11-4)85-96(115)111-103-107(135-101(120)84-90(114)77-70-63-56-49-38-31-24-17-10-3)105(122)95(134-110(103)138-140(126,127)128)89-129-109-104(112-97(116)86-92(79-72-65-58-51-40-33-26-19-12-5)131-99(118)81-74-67-60-53-42-35-28-21-14-7)108(106(94(88-113)133-109)137-139(123,124)125)136-102(121)87-93(80-73-66-59-52-41-34-27-20-13-6)132-100(119)83-76-69-61-54-47-44-37-30-23-16-9-2/h90-95,103-110,113-114,122H,8-89H2,1-7H3,(H,111,115)(H,112,116)(H2,123,124,125)(H2,126,127,128)/t90-,91-,92-,93-,94-,95-,103-,104-,105-,106-,107-,108-,109-,110-/m1/s1",hexadecanoyllipid A,Reaxys Registry Number,9382574
5469,87260,O-[N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-serine,An O-glycosyl-L-serine having N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-alpha-D-galactosamine as the glycosyl component.,"InChI=1S/C19H33N3O13/c1-6(25)21-11-15(29)13(27)9(3-23)34-19(11)35-16-12(22-7(2)26)18(32-5-8(20)17(30)31)33-10(4-24)14(16)28/h8-16,18-19,23-24,27-29H,3-5,20H2,1-2H3,(H,21,25)(H,22,26)(H,30,31)/t8-,9+,10+,11+,12+,13+,14-,15+,16+,18-,19-/m0/s1",beta-D-GlcNAc-(1->3)-alpha-D-GalNAc-L-Ser,Reaxys Registry Number,6029674
5470,87293,3beta-hydroxy-5alpha-cholest-8-ene-4alpha-carboxylic acid,A 3beta-sterol that is 5alpha-cholest-8-en-3beta-ol carrying an additional carboxy substituent at position 4alpha.,"InChI=1S/C28H46O3/c1-17(2)7-6-8-18(3)20-11-12-21-19-9-10-23-25(26(30)31)24(29)14-16-28(23,5)22(19)13-15-27(20,21)4/h17-18,20-21,23-25,29H,6-16H2,1-5H3,(H,30,31)/t18-,20-,21+,23+,24+,25+,27-,28-/m1/s1",4alpha-carboxy-5alpha-cholest-8-en-3beta-ol,LIPID MAPS instance accession,LMST01010228
5471,87343,3-methylbutyl dodecanoate,A fatty acid ester obtained by the formal condensation of dodecanoic acid with 3-methylbutan-1-ol.,"InChI=1S/C17H34O2/c1-4-5-6-7-8-9-10-11-12-13-17(18)19-15-14-16(2)3/h16H,4-15H2,1-3H3",isopentyl laurate,Reaxys Registry Number,6858295
5472,87352,alcian yellow,"An organic chloride salt composed of {diazenediylbis[(4,1-phenylene)(6-methyl-1,3-benzothiazole-2,5-diyl)methylenesulfanediyl]}bis[(dimethylamino)-N,N-dimethylmethaniminium] and chloride ions in a 1:2 ratio.","InChI=1S/C40H46N8S4.2ClH/c1-25-19-35-33(21-29(25)23-49-39(45(3)4)46(5)6)41-37(51-35)27-11-15-31(16-12-27)43-44-32-17-13-28(14-18-32)38-42-34-22-30(26(2)20-36(34)52-38)24-50-40(47(7)8)48(9)10;;/h11-22H,23-24H2,1-10H3;2*1H/q+2;;/p-2",ingrain yellow,CAS Registry Number,61968-76-1
5473,87355,alizarin blue,"An organic heterotetracyclic compound that is naphtho[2,3-f]quinoline-7,12-dione carrying two additional hydroxy groups at positions 5 and 6. Used as an acid-base indicator. Between pH 0.0 and pH 1.6 it changes from pink to yellow, and between pH 6.0 and pH 7.6 it changes from yellow to green.","InChI=1S/C17H9NO4/c19-14-8-4-1-2-5-9(8)15(20)12-11(14)10-6-3-7-18-13(10)17(22)16(12)21/h1-7,21-22H",alizarin blue R,CAS Registry Number,568-02-5
5474,87358,alizarin red S,"An organic sodium salt having  3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate as the counterion. It is commonly used to stain embryo skeletons in cleared whole mounts, usually of small mammals.","InChI=1S/C14H8O7S.Na/c15-11-6-3-1-2-4-7(6)12(16)10-8(11)5-9(22(19,20)21)13(17)14(10)18;/h1-5,17-18H,(H,19,20,21);/q;+1/p-1",Alizarin,CAS Registry Number,130-22-3
5475,87359,LY-411575,"A dibenzoazepine that is 5,7-dihydro-6H-dibenzo[b,d]azepin-6-one which is substituted at the 7 pro-S position by the C-terminal carboxamide nitrogen of N(2)-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-L-alaninamide. It is a potent, cell permeable and selective gamma-secretase inhibitor. It has been tested as a possible treatment for Alzheimer's disease and shows promise for its potential to counteract severe hearing loss.","InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22-23,32H,1-2H3,(H,29,34)(H,30,33)/t14-,22-,23-/m0/s1",LY-411575,PubMed citation,22824752
5476,87369,alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo,An amino hexasaccharide consisting of six N-formyl-alpha-D-perosamine residues linked (1->2) throughout.,"InChI=1S/C42H68N6O25/c1-13-20(44-8-50)26(56)32(37(62)63-13)69-39-34(28(58)22(46-10-52)15(3)65-39)71-41-36(30(60)24(48-12-54)17(5)67-41)73-42-35(29(59)23(47-11-53)18(6)68-42)72-40-33(27(57)21(45-9-51)16(4)66-40)70-38-31(61)25(55)19(43-7-49)14(2)64-38/h7-42,55-62H,1-6H3,(H,43,49)(H,44,50)(H,45,51)(H,46,52)(H,47,53)(H,48,54)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38-,39-,40-,41-,42-/m1/s1",N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosamine,PubMed citation,26063236
5477,87376,chromoxane cyanin R,"An organic sodium salt that is the trisodium salt of 5-[(3-carboxy-5-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)(2-sulfophenyl)methyl]-2-hydroxy-3-methylbenzoic acid. It can be used for the detection of some metals in tissue.","InChI=1S/C23H18O9S.3Na/c1-11-7-13(9-16(20(11)24)22(26)27)19(15-5-3-4-6-18(15)33(30,31)32)14-8-12(2)21(25)17(10-14)23(28)29;;;/h3-10,24H,1-2H3,(H,26,27)(H,28,29)(H,30,31,32);;;/q;3*+1/p-3/b19-14+;;;",solochrome cyanin R,CAS Registry Number,3564-18-9
5478,87381,3-methylpentanol,A primary alcohol that is pentanol substituted by a methyl group at position 3.,"InChI=1S/C6H14O/c1-3-6(2)4-5-7/h6-7H,3-5H2,1-2H3",3-ethylbutanol,Reaxys Registry Number,1718979
5479,87391,N-icosanoylglycinate,A N-acylglycinate in which the acyl group is specified as icosanoyl; major species at pH 7.3.,"InChI=1S/C22H43NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21(24)23-20-22(25)26/h2-20H2,1H3,(H,23,24)(H,25,26)/p-1",N-eicosanoylglycinate,PubMed citation,12810727
5480,87398,aluminon,"An ammonium salt that is the ammonium salt of 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methylene]bis(6-hydroxybenzoic acid). A dye commonly used to detect the presence of the aluminium ion in an aqueous solution.","InChI=1S/C22H14O9.3H3N/c23-16-4-1-10(7-13(16)20(26)27)19(11-2-5-17(24)14(8-11)21(28)29)12-3-6-18(25)15(9-12)22(30)31;;;/h1-9,23-24H,(H,26,27)(H,28,29)(H,30,31);3*1H3",mordant violet 39,Reaxys Registry Number,3900820
5481,87413,phenethyl butyrate,The butanoate ester of 2-phenylethanol.,"InChI=1S/C12H16O2/c1-2-6-12(13)14-10-9-11-7-4-3-5-8-11/h3-5,7-8H,2,6,9-10H2,1H3",butanoic acid 2-phenylethyl ester,Reaxys Registry Number,1955788
5482,87419,isoamyl propanoate,A propanoate ester of isoamylol.,"InChI=1S/C8H16O2/c1-4-8(9)10-6-5-7(2)3/h7H,4-6H2,1-3H3",3-methylbutyl propionate,Reaxys Registry Number,1747359
5483,87425,juvenile hormone I acid,A member of the juvenile hormone family of compounds obtained by formal hydrolysis of the methyl ester group of juvenile hormone I.,"InChI=1S/C17H28O3/c1-5-14(9-7-8-13(3)12-16(18)19)10-11-15-17(4,6-2)20-15/h9,12,15H,5-8,10-11H2,1-4H3,(H,18,19)/b13-12+,14-9+/t15-,17+/m1/s1",juvenile hormone I carboxylic acid,CAS Registry Number,50518-15-5
5484,87431,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-D-Glcp,"A branched amino nonasaccharide consisting of a chain of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and D-glucose residues linked sequentially (1->3), (1->3), (1->4), (1->6) and (1->4), to the D-galactose residue nearest to the reducing end of which is also linked (1->3) a beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl unit, and with also an L-alpha-fucosyl residue linked (1->3) to the N-acetyl-beta-D-glucosamine residue nearest to the reducing end.","InChI=1S/C60H101N3O45/c1-13-28(74)35(81)40(86)56(93-13)106-49-27(63-16(4)73)53(100-23(11-70)46(49)103-59-43(89)50(33(79)21(9-68)99-59)107-54-25(61-14(2)71)47(31(77)19(7-66)95-54)104-57-41(87)36(82)29(75)17(5-64)97-57)92-12-24-34(80)51(44(90)60(101-24)102-45-22(10-69)94-52(91)39(85)38(45)84)108-55-26(62-15(3)72)48(32(78)20(8-67)96-55)105-58-42(88)37(83)30(76)18(6-65)98-58/h13,17-60,64-70,74-91H,5-12H2,1-4H3,(H,61,71)(H,62,72)(H,63,73)/t13-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29-,30-,31+,32+,33-,34-,35+,36-,37-,38+,39+,40-,41+,42+,43+,44+,45+,46+,47+,48+,49+,50-,51-,52?,53+,54-,55-,56-,57-,58-,59-,60-/m0/s1",Galb1-3GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glc,PubMed citation,25568069
5485,87433,(R)-2-hydroxy-4-methylpentanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-2-hydroxy-4-methylpentanoic acid.,"InChI=1S/C27H46N7O18P3S/c1-14(2)9-15(35)26(40)56-8-7-29-17(36)5-6-30-24(39)21(38)27(3,4)11-49-55(46,47)52-54(44,45)48-10-16-20(51-53(41,42)43)19(37)25(50-16)34-13-33-18-22(28)31-12-32-23(18)34/h12-16,19-21,25,35,37-38H,5-11H2,1-4H3,(H,29,36)(H,30,39)(H,44,45)(H,46,47)(H2,28,31,32)(H2,41,42,43)/t15-,16-,19-,20-,21+,25-/m1/s1",(R)-2-hydroxy-4-methylpentanoyl-coenzyme A,MetaCyc accession,CPD-11652
5486,87436,4-methylpent-2-enoyl-CoA,An alk-2-enoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 4-methylpent-2-enoic acid.,"InChI=1S/C27H44N7O17P3S/c1-15(2)5-6-18(36)55-10-9-29-17(35)7-8-30-25(39)22(38)27(3,4)12-48-54(45,46)51-53(43,44)47-11-16-21(50-52(40,41)42)20(37)26(49-16)34-14-33-19-23(28)31-13-32-24(19)34/h5-6,13-16,20-22,26,37-38H,7-12H2,1-4H3,(H,29,35)(H,30,39)(H,43,44)(H,45,46)(H2,28,31,32)(H2,40,41,42)/t16-,20-,21-,22+,26-/m1/s1",4-methylpent-2-enoyl-coenzyme A,MetaCyc accession,CPD-18023
5487,87441,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->6)-{beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->3)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,An amino oligosaccharide that is a branched tridecasaccharide derivative in which beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl and beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)]-alpha-D-mannosyl branched pentasaccharide units are linked (1->6) and (1->3) respectively to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine trisaccharide.,"InChI=1S/C90H150N6O66/c1-20(108)91-39-51(120)68(30(11-101)140-78(39)137)153-80-41(93-22(3)110)54(123)73(35(16-106)146-80)159-88-67(136)75(160-90-77(162-83-44(96-25(6)113)56(125)72(34(15-105)149-83)158-87-65(134)60(129)48(117)29(10-100)144-87)66(135)74(36(17-107)150-90)154-81-42(94-23(4)111)53(122)70(32(13-103)147-81)156-85-63(132)58(127)46(115)27(8-98)142-85)50(119)38(151-88)19-139-89-76(161-82-43(95-24(5)112)55(124)71(33(14-104)148-82)157-86-64(133)59(128)47(116)28(9-99)143-86)61(130)49(118)37(152-89)18-138-79-40(92-21(2)109)52(121)69(31(12-102)145-79)155-84-62(131)57(126)45(114)26(7-97)141-84/h26-90,97-107,114-137H,7-19H2,1-6H3,(H,91,108)(H,92,109)(H,93,110)(H,94,111)(H,95,112)(H,96,113)/t26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45+,46+,47+,48+,49-,50-,51-,52-,53-,54-,55-,56-,57+,58+,59+,60+,61+,62-,63-,64-,65-,66+,67+,68-,69-,70-,71-,72-,73-,74-,75+,76+,77+,78-,79-,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90-/m1/s1",Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,25568069
5488,87449,trans-caffeoyl-CoA,A caffeoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of trans-caffeic acid.,"InChI=1S/C30H42N7O19P3S/c1-30(2,25(43)28(44)33-8-7-20(40)32-9-10-60-21(41)6-4-16-3-5-17(38)18(39)11-16)13-53-59(50,51)56-58(48,49)52-12-19-24(55-57(45,46)47)23(42)29(54-19)37-15-36-22-26(31)34-14-35-27(22)37/h3-6,11,14-15,19,23-25,29,38-39,42-43H,7-10,12-13H2,1-2H3,(H,32,40)(H,33,44)(H,48,49)(H,50,51)(H2,31,34,35)(H2,45,46,47)/b6-4+/t19-,23-,24-,25+,29-/m1/s1",(E)-caffeoyl-coenzyme A,Reaxys Registry Number,4779491
5489,87450,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,"A linear amino tetrasaccharide comprised of N-acetyl-alpha-neuraminyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-alpha-D-galactosamine residues linked sequentially (2->3), (1->3) and (1->3).","InChI=1S/C33H55N3O24/c1-9(41)34-17-12(44)4-33(32(52)53,59-27(17)20(46)13(45)5-37)60-28-23(49)16(8-40)56-31(24(28)50)58-26-19(36-11(3)43)30(55-15(7-39)22(26)48)57-25-18(35-10(2)42)29(51)54-14(6-38)21(25)47/h12-31,37-40,44-51H,4-8H2,1-3H3,(H,34,41)(H,35,42)(H,36,43)(H,52,53)/t12-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22+,23-,24+,25+,26+,27+,28-,29-,30-,31-,33-/m0/s1",Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca,PubMed citation,25568069
5490,87451,dihydrocaffeoyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of dihydrocaffeic acid.,"InChI=1S/C30H44N7O19P3S/c1-30(2,25(43)28(44)33-8-7-20(40)32-9-10-60-21(41)6-4-16-3-5-17(38)18(39)11-16)13-53-59(50,51)56-58(48,49)52-12-19-24(55-57(45,46)47)23(42)29(54-19)37-15-36-22-26(31)34-14-35-27(22)37/h3,5,11,14-15,19,23-25,29,38-39,42-43H,4,6-10,12-13H2,1-2H3,(H,32,40)(H,33,44)(H,48,49)(H,50,51)(H2,31,34,35)(H2,45,46,47)/t19-,23-,24-,25+,29-/m1/s1",hydrocaffeoyl-coenzyme A,Reaxys Registry Number,22760301
5491,87452,beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc,"A linear amino pentasaccharide consisting of beta-D-galactose, N-acetyl-beta-D-galactosamine, alpha-D-galactose, betaD-galactose and N-acetyl-beta-D-glucosamine units connected via sequential (1->3), (1->3), (1->4) and (1->4) linkages.","InChI=1S/C36H61N3O26/c1-9(45)37-17-24(52)28(15(7-43)57-32(17)56)62-35-26(54)25(53)29(16(8-44)61-35)63-36-27(55)31(22(50)14(6-42)60-36)65-34-19(39-11(3)47)30(21(49)13(5-41)59-34)64-33-18(38-10(2)46)23(51)20(48)12(4-40)58-33/h12-36,40-44,48-56H,4-8H2,1-3H3,(H,37,45)(H,38,46)(H,39,47)/t12-,13-,14-,15-,16-,17-,18-,19-,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31+,32-,33-,34+,35+,36-/m1/s1",beta-D-Gal-(1->3)-beta-D-GalNAc-(1->3)-alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-GlcNAc,PubMed citation,25568069
5492,87455,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,An amino oligosaccharide that is an undecasaccharide derivative in which two alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide chains are linked (1->3) and (1->6) to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine trisaccharide.,"InChI=1S/C74H124N4O56/c1-16(89)75-31-40(98)55(24(9-83)115-64(31)113)126-65-32(76-17(2)90)41(99)58(27(12-86)120-65)129-72-54(112)61(132-74-63(47(105)38(96)23(8-82)119-74)134-67-34(78-19(4)92)43(101)57(26(11-85)122-67)128-71-53(111)49(107)60(29(14-88)124-71)131-69-51(109)45(103)36(94)21(6-80)117-69)39(97)30(125-72)15-114-73-62(46(104)37(95)22(7-81)118-73)133-66-33(77-18(3)91)42(100)56(25(10-84)121-66)127-70-52(110)48(106)59(28(13-87)123-70)130-68-50(108)44(102)35(93)20(5-79)116-68/h20-74,79-88,93-113H,5-15H2,1-4H3,(H,75,89)(H,76,90)(H,77,91)(H,78,92)/t20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35+,36+,37-,38-,39-,40-,41-,42-,43-,44+,45+,46+,47+,48-,49-,50-,51-,52-,53-,54+,55-,56-,57-,58-,59+,60+,61+,62+,63+,64-,65+,66+,67+,68-,69-,70+,71+,72+,73+,74-/m1/s1",Gala1-4Galb1-4GlcNAcb1-2Mana1-6(Gala1-4Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,25568069
5493,87458,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->3)-beta-DGlcpNAc-(1->3)-[beta-D-Galp-(1->4)-beta-DGlcpNAc-(1->6)]-beta-D-Galp-(1->4)-D-Glcp,"A branched amino heptasaccharide consisting of a linear pentasaccharide chain of alpha-sialyl, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and D-glucose residues linked sequentially (2->6), (1->3), (1->3) and (1->4), to the galactose residue nearest to the reducing end is also linked (1->6) a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl disaccharide unit.","InChI=1S/C51H85N3O39/c1-12(60)52-23-15(63)4-51(50(79)80,93-42(23)26(65)16(64)5-55)82-11-21-28(67)33(72)37(76)48(88-21)91-41-25(54-14(3)62)46(84-18(7-57)29(41)68)92-43-30(69)19(8-58)86-49(38(43)77)90-40-22(83-44(78)35(74)34(40)73)10-81-45-24(53-13(2)61)31(70)39(20(9-59)87-45)89-47-36(75)32(71)27(66)17(6-56)85-47/h15-49,55-59,63-78H,4-11H2,1-3H3,(H,52,60)(H,53,61)(H,54,62)(H,79,80)/t15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28-,29+,30-,31+,32-,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43-,44?,45+,46-,47-,48-,49-,51+/m0/s1",Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc,PubMed citation,25568069
5494,87464,azophloxine,"An organic sodium salt that is the disodium salt of 5-acetamido-4-hydroxy-3-(phenyldiazenyl)naphthalene-2,7-disulfonic acid.","InChI=1S/C18H15N3O8S2.2Na/c1-10(22)19-14-9-13(30(24,25)26)7-11-8-15(31(27,28)29)17(18(23)16(11)14)21-20-12-5-3-2-4-6-12;;/h2-9,23H,1H3,(H,19,22)(H,24,25,26)(H,27,28,29);;/q;2*+1/p-2",C.I. 18050,CAS Registry Number,3734-67-6
5495,87465,"5-acetamido-4-hydroxy-3-(phenyldiazenyl)naphthalene-2,7-disulfonic acid","A naphthalenesulfonic acid that is 3-(phenyldiazenyl)naphthalene-2,7-disulfonic acid carrying additional phenyldiazenyl, hydroxy and acetamido substituents at position 3, 4, and 5 respectively. The disodium salt is the biological stain 'azophloxine'.","InChI=1S/C18H15N3O8S2/c1-10(22)19-14-9-13(30(24,25)26)7-11-8-15(31(27,28)29)17(18(23)16(11)14)21-20-12-5-3-2-4-6-12/h2-9,23H,1H3,(H,19,22)(H,24,25,26)(H,27,28,29)",azophloxine free acid,CAS Registry Number,25317-20-8
5496,87472,methyl blue,"An organic sodium salt that is the trisodium salt of 4,4'-{({4-[(4-sulfophenyl)imino]cyclohexa-2,5-dien-1-ylidene}methylene)bis[(4,1-phenylene)azanediyl]}di(benzene-1-sulfonic acid). A histological dye that can be used either on its own or part of a mixture (aniline blue WS) for staining collagen in Masson's trichrome and Mallory's method for connective tissue.","InChI=1S/C37H29N3O9S3.2Na/c41-50(42,43)34-19-13-31(14-20-34)38-28-7-1-25(2-8-28)37(26-3-9-29(10-4-26)39-32-15-21-35(22-16-32)51(44,45)46)27-5-11-30(12-6-27)40-33-17-23-36(24-18-33)52(47,48)49;;/h1-24,38-39H,(H,41,42,43)(H,44,45,46)(H,47,48,49);;/q;2*+1/p-2",cotton blue,CAS Registry Number,28983-56-4
5497,87473,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,An amino oligosaccharide that is a dodecasaccharide derivative in which two alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide chains are linked (1->3) and (1->6) to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->6)]-N-acetyl-D-glucosamine branched tetrasaccharide.,"InChI=1S/C80H134N4O58/c1-17-37(96)49(108)56(115)73(122-17)120-16-32-63(45(104)33(69(119)125-32)81-20(4)92)134-70-34(82-21(5)93)46(105)60(28(12-89)130-70)135-76-59(118)64(138-80-66(53(112)41(100)27(11-88)129-80)140-72-36(84-23(7)95)48(107)62(30(14-91)132-72)137-79-68(55(114)43(102)26(10-87)128-79)142-75-58(117)51(110)39(98)19(3)124-75)44(103)31(133-76)15-121-77-65(52(111)40(99)24(8-85)126-77)139-71-35(83-22(6)94)47(106)61(29(13-90)131-71)136-78-67(54(113)42(101)25(9-86)127-78)141-74-57(116)50(109)38(97)18(2)123-74/h17-19,24-80,85-91,96-119H,8-16H2,1-7H3,(H,81,92)(H,82,93)(H,83,94)(H,84,95)/t17-,18-,19-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-,53-,54-,55-,56-,57-,58-,59-,60+,61+,62+,63+,64-,65-,66-,67+,68+,69+,70-,71-,72-,73+,74-,75-,76-,77-,78-,79-,80+/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-beta-D-GlcNAc,PubMed citation,25568069
5498,87475,(R)-2-hydroxybutanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-2-hydroxybutanoic acid,"InChI=1S/C25H42N7O18P3S/c1-4-13(33)24(38)54-8-7-27-15(34)5-6-28-22(37)19(36)25(2,3)10-47-53(44,45)50-52(42,43)46-9-14-18(49-51(39,40)41)17(35)23(48-14)32-12-31-16-20(26)29-11-30-21(16)32/h11-14,17-19,23,33,35-36H,4-10H2,1-3H3,(H,27,34)(H,28,37)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t13-,14-,17-,18-,19+,23-/m1/s1",(R)-2-hydroxybutyryl-CoA,PubMed citation,1597194
5499,87482,mauveine B2,"An organic cation consisting of 7-(4-methylanilino)phenazine carrying additional methyl, amino and 4-methylphenyl substituents at positions 2, 3 and 5 respectively. One of four components of mauvaine, a syntheteic violet-coloured dye.","InChI=1S/C27H24N4/c1-17-4-8-20(9-5-17)29-21-10-13-24-26(15-21)31(22-11-6-18(2)7-12-22)27-16-23(28)19(3)14-25(27)30-24/h4-16H,1-3H3,(H2,28,29)/p+1",3-amino-2-methyl-7-(4-methylanilino)-5-(4-methylphenyl)phenazin-5-ium,Reaxys Registry Number,11140322
5500,87516,beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->4)-beta-D-Glcp-(1<->1')-Cer(d18:1/18:0),A sialotriaosylceramide consisting of the pentasaccharide beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc attached to the primary hydroxy function of a ceramide in which the acyl function on nitrogen is stearoyl.,"InChI=1S/C78H138N4O34/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-56(95)82-47(48(91)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2)43-107-73-65(101)64(100)67(54(41-86)109-73)111-74-66(102)71(68(55(42-87)110-74)112-72-59(81-46(5)90)63(99)61(97)52(39-84)108-72)116-78(76(105)106)37-50(93)58(80-45(4)89)70(115-78)62(98)53(40-85)113-77(75(103)104)36-49(92)57(79-44(3)88)69(114-77)60(96)51(94)38-83/h32,34,47-55,57-74,83-87,91-94,96-102H,6-31,33,35-43H2,1-5H3,(H,79,88)(H,80,89)(H,81,90)(H,82,95)(H,103,104)(H,105,106)/b34-32+/t47-,48+,49-,50-,51+,52+,53+,54+,55+,57+,58+,59+,60+,61-,62+,63+,64+,65+,66+,67+,68-,69+,70+,71+,72-,73+,74-,77+,78-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/18:0),PubMed citation,26179345
5501,87519,beta-D-GlcpNAc-(1->2)-[beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino octasaccharide consisting of a pentasaccharide chain of N-acetyl-beta-D-glucosamine, alpha-D-mannose, beta-D-mannose and two further N-acetyl-beta-D-glucosamine residues linked sequentially (1->2), (1->3), (1->4) and (1->4), to the beta-D-mannose residue of which is also linked (1->6) an N-acetyl-beta-D-glucosaminyl-(1->2)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl trisaccharide unit.","InChI=1S/C58H97N5O41/c1-14(70)59-27-41(84)46(23(10-68)92-51(27)89)100-55-31(63-18(5)74)42(85)47(24(11-69)97-55)101-56-45(88)48(102-58-50(43(86)35(78)22(9-67)96-58)104-54-30(62-17(4)73)40(83)34(77)21(8-66)95-54)37(80)26(98-56)13-91-57-49(103-53-29(61-16(3)72)39(82)33(76)20(7-65)94-53)44(87)36(79)25(99-57)12-90-52-28(60-15(2)71)38(81)32(75)19(6-64)93-52/h19-58,64-69,75-89H,6-13H2,1-5H3,(H,59,70)(H,60,71)(H,61,72)(H,62,73)(H,63,74)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43+,44+,45+,46-,47-,48+,49+,50+,51-,52-,53+,54+,55+,56+,57+,58-/m1/s1",beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->6)]-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,25568069
5502,87525,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,An amino oligosaccharide that is a dodecasaccharide derivative in which two alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide chains are linked (1->3) and (1->6) to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->6)]-N-acetyl-D-glucosamine branched tetrasaccharide.,"InChI=1S/C80H134N4O58/c1-17-37(96)49(108)56(115)73(122-17)120-16-32-61(47(106)33(69(119)125-32)81-20(4)92)134-70-34(82-21(5)93)48(107)60(30(14-91)132-70)135-76-59(118)64(138-80-66(53(112)41(100)27(11-88)131-80)140-72-36(84-23(7)95)63(45(104)29(13-90)127-72)137-79-68(55(114)43(102)26(10-87)130-79)142-75-58(117)51(110)39(98)19(3)124-75)46(105)31(133-76)15-121-77-65(52(111)40(99)24(8-85)128-77)139-71-35(83-22(6)94)62(44(103)28(12-89)126-71)136-78-67(54(113)42(101)25(9-86)129-78)141-74-57(116)50(109)38(97)18(2)123-74/h17-19,24-80,85-91,96-119H,8-16H2,1-7H3,(H,81,92)(H,82,93)(H,83,94)(H,84,95)/t17-,18-,19-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-,53-,54-,55-,56-,57-,58-,59-,60+,61+,62+,63+,64-,65-,66-,67+,68+,69+,70-,71-,72-,73+,74-,75-,76-,77-,78-,79-,80+/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-beta-D-GlcNAc,PubMed citation,25568069
5503,87533,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-{alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,An amino oligosaccharide that is a tetradecasaccharide derivative in which two alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl branched pentasaccharide units are linked (1->3) and (1->6) to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->6)]-N-acetyl-D-glucosamine branched tetrasaccharide.,"InChI=1S/C92H154N4O68/c1-19-41(110)55(124)62(131)83(140-19)138-18-36-71(51(120)37(79(137)143-36)93-22(4)106)154-80-38(94-23(5)107)52(121)68(32(14-103)150-80)155-88-67(136)72(158-90-76(61(130)47(116)29(11-100)147-90)162-82-40(96-25(7)109)54(123)70(34(16-105)152-82)157-92-78(164-85-64(133)57(126)43(112)21(3)142-85)74(49(118)31(13-102)149-92)160-87-66(135)59(128)45(114)27(9-98)145-87)50(119)35(153-88)17-139-89-75(60(129)46(115)28(10-99)146-89)161-81-39(95-24(6)108)53(122)69(33(15-104)151-81)156-91-77(163-84-63(132)56(125)42(111)20(2)141-84)73(48(117)30(12-101)148-91)159-86-65(134)58(127)44(113)26(8-97)144-86/h19-21,26-92,97-105,110-137H,8-18H2,1-7H3,(H,93,106)(H,94,107)(H,95,108)(H,96,109)/t19-,20-,21-,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45-,46+,47+,48-,49-,50+,51+,52+,53+,54+,55+,56+,57+,58-,59-,60-,61-,62-,63-,64-,65+,66+,67-,68+,69+,70+,71+,72-,73-,74-,75-,76-,77+,78+,79+,80-,81-,82-,83+,84-,85-,86+,87+,88-,89-,90+,91-,92-/m0/s1",alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-{alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)}-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-beta-D-GlcNAc,PubMed citation,25568069
5504,87558,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-{beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->3)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"An amino oligosaccharide that is a dodecasaccharide derivative consisting of a tetrasaccharide chain of N-acetyl-beta-D-glucosamine, beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-D-glucosamine residues, all linked sequentially (1->4), to the beta-D-mannose residue of which are also linked beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl and beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)]-alpha-D-mannosyl units via (1->6) and (1->3) linkages respectively.","InChI=1S/C84H140N6O61/c1-19(102)85-37-49(114)63(30(12-96)130-73(37)128)142-75-39(87-21(3)104)51(116)67(34(16-100)136-75)147-82-62(127)70(69(148-74-38(86-20(2)103)48(113)43(108)25(7-91)131-74)36(141-82)18-129-83-71(57(122)47(112)29(11-95)135-83)150-77-41(89-23(5)106)52(117)65(32(14-98)138-77)145-80-59(124)55(120)45(110)27(9-93)133-80)149-84-72(151-78-42(90-24(6)107)53(118)66(33(15-99)139-78)146-81-60(125)56(121)46(111)28(10-94)134-81)61(126)68(35(17-101)140-84)143-76-40(88-22(4)105)50(115)64(31(13-97)137-76)144-79-58(123)54(119)44(109)26(8-92)132-79/h25-84,91-101,108-128H,7-18H2,1-6H3,(H,85,102)(H,86,103)(H,87,104)(H,88,105)(H,89,106)(H,90,107)/t25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44+,45+,46+,47-,48-,49-,50-,51-,52-,53-,54+,55+,56+,57+,58-,59-,60-,61+,62+,63-,64-,65-,66-,67-,68-,69-,70-,71+,72+,73?,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84-/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->4)]-{beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->4)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)]-alpha-D-Man-(1->3)}-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,25568069
5505,87606,N-icosanoylglycine,A N-acylglycine in which the acyl group is specified as icosanoyl.,"InChI=1S/C22H43NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21(24)23-20-22(25)26/h2-20H2,1H3,(H,23,24)(H,25,26)",N-arachidoylglycine,Reaxys Registry Number,25312846
5506,87610,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-{alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)}-D-GalpNAc,An amino nonasaccharide in which two alpha-L-fucosyl-(1->2)-[beta-D-galactosyl-(1->3)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl chains are linked (1->3) and (1->6) to D-galactose.,"InChI=1S/C60H101N3O44/c1-13-28(73)37(82)41(86)55(92-13)106-50-48(104-57-43(88)39(84)30(75)18(6-64)95-57)32(77)20(8-66)97-59(50)101-45-22(10-68)99-53(25(35(45)80)61-15(3)70)91-12-24-34(79)47(27(52(90)94-24)63-17(5)72)103-54-26(62-16(4)71)36(81)46(23(11-69)100-54)102-60-51(107-56-42(87)38(83)29(74)14(2)93-56)49(33(78)21(9-67)98-60)105-58-44(89)40(85)31(76)19(7-65)96-58/h13-14,18-60,64-69,73-90H,6-12H2,1-5H3,(H,61,70)(H,62,71)(H,63,72)/t13-,14-,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30-,31-,32-,33-,34-,35+,36+,37+,38+,39-,40-,41-,42-,43+,44+,45+,46+,47+,48-,49-,50+,51+,52?,53+,54-,55-,56-,57+,58+,59-,60-/m0/s1",alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-{alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)}-D-GalNAc,PubMed citation,25568069
5507,87617,alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-{alpha-D-Galp-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,An amino oligosaccharide that is a tetradecasaccharide derivative in which two alpha-L-fucosyl-(1->2)-[alpha-D-galactosyl-(1->3)]-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl branched pentasaccharide units are linked (1->3) and (1->6) to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->6)]-N-acetyl-D-glucosamine branched tetrasaccharide.,"InChI=1S/C92H154N4O68/c1-19-41(110)55(124)62(131)83(140-19)138-18-36-69(53(122)37(79(137)143-36)93-22(4)106)154-80-38(94-23(5)107)54(123)68(34(16-105)152-80)155-88-67(136)72(158-90-76(61(130)47(116)29(11-100)149-90)162-82-40(96-25(7)109)71(49(118)31(13-102)145-82)157-92-78(164-85-64(133)57(126)43(112)21(3)142-85)74(51(120)33(15-104)151-92)160-87-66(135)59(128)45(114)27(9-98)147-87)52(121)35(153-88)17-139-89-75(60(129)46(115)28(10-99)148-89)161-81-39(95-24(6)108)70(48(117)30(12-101)144-81)156-91-77(163-84-63(132)56(125)42(111)20(2)141-84)73(50(119)32(14-103)150-91)159-86-65(134)58(127)44(113)26(8-97)146-86/h19-21,26-92,97-105,110-137H,8-18H2,1-7H3,(H,93,106)(H,94,107)(H,95,108)(H,96,109)/t19-,20-,21-,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45-,46+,47+,48+,49+,50-,51-,52+,53+,54+,55+,56+,57+,58-,59-,60-,61-,62-,63-,64-,65+,66+,67-,68+,69+,70+,71+,72-,73-,74-,75-,76-,77+,78+,79+,80-,81-,82-,83+,84-,85-,86+,87+,88-,89-,90+,91-,92-/m0/s1",alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-{alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)}-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-beta-D-GlcNAc,PubMed citation,25568069
5508,87621,beta-D-GlcpNAc-(1->4)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-[alpha-Neup5Ac-(2->3)-beta-DGalp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide comprising a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which is (1->4)-linked an Nacetyl-beta-D-glucosaminyl residue, together with two N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide units linked (1->3) and (1->6).","InChI=1S/C92H151N7O67/c1-22(111)93-43-29(118)8-91(89(140)141,163-72(43)50(122)31(120)10-100)165-74-55(127)36(15-105)147-84(64(74)136)156-68-40(19-109)152-82(48(60(68)132)98-27(6)116)161-77-62(134)53(125)34(13-103)149-87(77)144-21-42-71(159-80-46(96-25(4)114)57(129)52(124)33(12-102)146-80)76(66(138)86(154-42)158-70-39(18-108)151-81(47(59(70)131)97-26(5)115)155-67-38(17-107)145-79(139)45(58(67)130)95-24(3)113)160-88-78(63(135)54(126)35(14-104)150-88)162-83-49(99-28(7)117)61(133)69(41(20-110)153-83)157-85-65(137)75(56(128)37(16-106)148-85)166-92(90(142)143)9-30(119)44(94-23(2)112)73(164-92)51(123)32(121)11-101/h29-88,100-110,118-139H,8-21H2,1-7H3,(H,93,111)(H,94,112)(H,95,113)(H,96,114)(H,97,115)(H,98,116)(H,99,117)(H,140,141)(H,142,143)/t29-,30-,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55-,56-,57+,58+,59+,60+,61+,62-,63-,64+,65+,66-,67+,68+,69+,70+,71+,72+,73+,74-,75-,76+,77-,78-,79+,80-,81-,82-,83-,84-,85-,86-,87-,88+,91-,92-/m0/s1",Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,25568069
5509,87634,Evans blue free acid,"A naphthalenesulfonic acid that is the free acid form of the dye Evans blue. The tetrasodium salt is used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.","InChI=1S/C34H28N6O14S4/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)",Evans blue acid,CAS Registry Number,6968-33-8
5510,87637,azure A,An organic chloride salt having 3-amino-7-(dimethylamino)phenothiazin-5-ium as the counterion. It is used in making azure eosin stains for blood smear staining.,"InChI=1S/C14H14N3S.ClH/c1-17(2)10-4-6-12-14(8-10)18-13-7-9(15)3-5-11(13)16-12;/h3-8H,15H2,1-2H3;1H/q+1;/p-1",C.I. 52005,CAS Registry Number,531-53-3
5511,87638,3-amino-7-(dimethylamino)phenothiazin-5-ium,An organic cation that is phenothiazin-5-ium substituted by amino and dimethylamino groups at positions 3 and 7 respectively. The chloride salt is the histological dye 'azure A'.,"InChI=1S/C14H14N3S/c1-17(2)10-4-6-12-14(8-10)18-13-7-9(15)3-5-11(13)16-12/h3-8H,15H2,1-2H3/q+1",azure A cation,Reaxys Registry Number,3910072
5512,87639,azure B,An organic chloride salt having 3-(dimethylamino)-7-(methylamino)phenothiazin-5-ium as the counterion. It is used in making azure eosin stains for blood smear staining and is an active metabolite of methylene blue.,"InChI=1S/C15H16N3S.ClH/c1-16-10-4-6-12-14(8-10)19-15-9-11(18(2)3)5-7-13(15)17-12;/h4-9,16H,1-3H3;1H/q+1;/p-1",methylene azure B,CAS Registry Number,531-55-5
5513,87641,azure C,An organic chloride salt having 3-amino-7-(methylamino)phenothiazin-5-ium as the counterion.,"InChI=1S/C13H12N3S.ClH/c1-15-9-3-5-11-13(7-9)17-12-6-8(14)2-4-10(12)16-11;/h2-7,15H,14H2,1H3;1H/q+1;/p-1",C.I. 52002,CAS Registry Number,531-57-7
5514,87643,victoria blue 4R,"An iminium salt composed of 4-([4-(dimethylamino)phenyl]{4-[methyl(phenyl)amino]naphthalen-1-yl}methylidene)-N,N-dimethylcyclohexa-2,5-dien-1-iminium and chloride ions in a 1:1 ratio. It binds to nucleic acids and can be used in standardised staining techniques suitable for automated cell-pattern recognition.","InChI=1S/C34H34N3.ClH/c1-35(2)27-19-15-25(16-20-27)34(26-17-21-28(22-18-26)36(3)4)32-23-24-33(31-14-10-9-13-30(31)32)37(5)29-11-7-6-8-12-29;/h6-24H,1-5H3;1H/q+1;/p-1",basic blue 8,CAS Registry Number,2185-87-7
5515,87645,night blue,"An iminium salt composed of 4-{(4-anilinonaphthalen-1-yl)[4-(diethylamino)phenyl]methylidene}-N,N-diethylcyclohexa-2,5-dien-1-iminium and chloride ions in a 1:1 ratio.","InChI=1S/C37H39N3.ClH/c1-5-39(6-2)31-22-18-28(19-23-31)37(29-20-24-32(25-21-29)40(7-3)8-4)35-26-27-36(34-17-13-12-16-33(34)35)38-30-14-10-9-11-15-30;/h9-27H,5-8H2,1-4H3;1H",basic blue 15,CAS Registry Number,4692-38-0
5516,87647,tolonium chloride,"An organic chloride salt having 3-amino-7-(dimethylamino)-2-methylphenothiazin-5-ium (tolonium) as the counterion.  It is a blue nuclear counterstain that can be used to demonstrate Nissl substance and is also useful for staining mast cell granules, both in metachromatic and orthochromatic techniques.","InChI=1S/C15H16N3S.ClH/c1-9-6-13-15(8-11(9)16)19-14-7-10(18(2)3)4-5-12(14)17-13;/h4-8H,16H2,1-3H3;1H/q+1;/p-1",toluidine blue,CAS Registry Number,92-31-9
5517,87649,methyl green,"An iminium salt composed of (4-{[4-(dimethylamino)phenyl][4-(trimethylazaniumyl)phenyl]methylidene}cyclohexa-2,5-dien-1-ylidene)(dimethyl)ammonium and chloride ions in a 1:2 ratio. A histological dye used to demonstrate nucleic acids by the Unna-Pappenheim stain, in conjunction with Pyronin Y.","InChI=1S/C26H33N3.2ClH/c1-27(2)23-14-8-20(9-15-23)26(21-10-16-24(17-11-21)28(3)4)22-12-18-25(19-13-22)29(5,6)7;;/h8-19H,1-7H3;2*1H/q+2;;/p-2",light green,CAS Registry Number,82-94-0
5518,87650,methyl green(2+),An iminium ion that forms the cationic portion of the histological dye 'methyl green'.,"InChI=1S/C26H33N3/c1-27(2)23-14-8-20(9-15-23)26(21-10-16-24(17-11-21)28(3)4)22-12-18-25(19-13-22)29(5,6)7/h8-19H,1-7H3/q+2",methyl green cation,Reaxys Registry Number,3914106
5519,87651,victoria blue B,"An iminium salt composed of 4-{(4-anilinonaphthalen-1-yl)[4-(dimethylamino)phenyl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium and chloride ions in a 1:1 ratio. It binds to nucleic acids and can be used in standardised staining techniques suitable for automated cell-pattern recognition.","InChI=1S/C33H31N3.ClH/c1-35(2)27-18-14-24(15-19-27)33(25-16-20-28(21-17-25)36(3)4)31-22-23-32(30-13-9-8-12-29(30)31)34-26-10-6-5-7-11-26;/h5-23H,1-4H3;1H",victoria blue,CAS Registry Number,2580-56-5
5520,87660,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a pentadecasaccharide comprising a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked an N-acetyl-beta-D-glucosaminyl residue [via a (1->4) linkage], an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl branched heptasaccharide unit [linked (1->6)], and an N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear tetrasaccharide unit [linked (1->3)].","InChI=1S/C117H191N9O85/c1-28(140)118-55-37(149)10-115(112(177)178,206-91(55)64(155)40(152)13-127)209-94-70(161)45(18-132)187-106(81(94)172)198-86-49(22-136)191-101(60(75(86)166)123-33(6)145)183-26-53-69(160)80(171)98(204-104-62(125-35(8)147)77(168)87(51(24-138)193-104)199-107-82(173)95(71(162)46(19-133)188-107)210-116(113(179)180)11-38(150)56(119-29(2)141)92(207-116)65(156)41(153)14-128)110(195-53)184-27-54-90(202-102-59(122-32(5)144)73(164)67(158)43(16-130)186-102)97(84(175)109(196-54)201-89-50(23-137)192-103(61(76(89)167)124-34(7)146)197-85-48(21-135)185-100(176)58(74(85)165)121-31(4)143)203-111-99(79(170)68(159)44(17-131)190-111)205-105-63(126-36(9)148)78(169)88(52(25-139)194-105)200-108-83(174)96(72(163)47(20-134)189-108)211-117(114(181)182)12-39(151)57(120-30(3)142)93(208-117)66(157)42(154)15-129/h37-111,127-139,149-176H,10-27H2,1-9H3,(H,118,140)(H,119,141)(H,120,142)(H,121,143)(H,122,144)(H,123,145)(H,124,146)(H,125,147)(H,126,148)(H,177,178)(H,179,180)(H,181,182)/t37-,38-,39-,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70-,71-,72-,73+,74+,75+,76+,77+,78+,79-,80-,81+,82+,83+,84-,85+,86+,87+,88+,89+,90+,91+,92+,93+,94-,95-,96-,97+,98-,99-,100+,101+,102-,103-,104-,105-,106-,107-,108-,109-,110-,111+,115-,116-,117-/m0/s1",alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)]-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->4)]-[alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,25568069
5521,87663,pararosaniline,"A hydrochloride that is the monohydrochloride of 4,4'-[(4-iminocyclohexa-2,5-dien-1-ylidene)methanediyl]dianiline. One of the major constituents of Basic fuchsin, together with rosanilin, magenta II and new fuchsin.","InChI=1S/C19H17N3.ClH/c20-16-7-1-13(2-8-16)19(14-3-9-17(21)10-4-14)15-5-11-18(22)12-6-15;/h1-12,20H,21-22H2;1H",p-rosaniline,Reaxys Registry Number,8459648
5522,87668,magenta II,"A hydrochloride that is the monohydrochloride of 4-[(4-aminophenyl)(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline. One of the minor constituents of Basic fuchsin, together with pararosanilin, rosanilin and new fuchsin.","InChI=1S/C21H21N3.ClH/c1-13-11-16(5-9-19(13)23)21(15-3-7-18(22)8-4-15)17-6-10-20(24)14(2)12-17;/h3-12,22H,23-24H2,1-2H3;1H",dimethyl fuchsin,CAS Registry Number,4197-24-4
5523,87671,new fuchsin,"A hydrochloride that is the monohydrochloride of 4-[(4-aminophenyl)(4-iminocyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline. One of the minor constituents of Basic fuchsin, together with pararosanilin, rosanilin and magenta II.","InChI=1S/C22H23N3.ClH/c1-13-10-16(4-7-19(13)23)22(17-5-8-20(24)14(2)11-17)18-6-9-21(25)15(3)12-18;/h4-12,23H,24-25H2,1-3H3;1H",Basic violet 2,CAS Registry Number,3248-91-7
5524,87675,methylene green,"An organic chloride salt having 3,7-bis(dimethylamino)-4-nitrophenothiazin-5-ium as the counterion.  It stains nuclei green and is sometimes used as a counterstain to red or purple primary stains.","InChI=1S/C16H17N4O2S.ClH/c1-18(2)10-5-6-11-14(9-10)23-16-12(17-11)7-8-13(19(3)4)15(16)20(21)22;/h5-9H,1-4H3;1H/q+1;/p-1",C.I. 52020,CAS Registry Number,2679-01-8
5525,87758,methyl nonadecanoate,A fatty acid methyl ester resulting from the formal condensation of the carboxy group of nonadecanoic acid with methanol.,"InChI=1S/C20H40O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22-2/h3-19H2,1-2H3",nonadecanoic acid methyl ester,CAS Registry Number,1731-94-8
5526,87760,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->4)]-[beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino decasaccharide comprising a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which is (1->4)-linked an N-acetyl-beta-D-glucosaminyl residue, together with two beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl trisaccharide units linked (1->3) and (1->6).","InChI=1S/C70H117N5O51/c1-16(85)71-31-44(98)53(28(13-83)109-61(31)107)119-63-33(73-18(3)87)45(99)54(29(14-84)117-63)120-68-52(106)58(124-70-60(49(103)40(94)25(10-80)116-70)126-65-35(75-20(5)89)57(42(96)27(12-82)112-65)123-67-51(105)47(101)38(92)23(8-78)114-67)55(121-62-32(72-17(2)86)43(97)36(90)21(6-76)110-62)30(118-68)15-108-69-59(48(102)39(93)24(9-79)115-69)125-64-34(74-19(4)88)56(41(95)26(11-81)111-64)122-66-50(104)46(100)37(91)22(7-77)113-66/h21-70,76-84,90-107H,6-15H2,1-5H3,(H,71,85)(H,72,86)(H,73,87)(H,74,88)(H,75,89)/t21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39-,40-,41-,42-,43-,44-,45-,46+,47+,48+,49+,50-,51-,52+,53-,54-,55-,56-,57-,58-,59+,60+,61-,62+,63+,64+,65+,66+,67+,68+,69+,70-/m1/s1",beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->4)]-[beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,25568069
5527,87763,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a dodecasaccharide derivative comprising a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the reducing-end N-acetyl-beta-D-glucosamine residue of which is linked (1->6) an alpha-L-fucosyl residue, while to the beta-D-mannose residue are linked two N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide units via (1->3) and (1->6) linkages.","InChI=1S/C90H148N6O66/c1-21-47(114)59(126)64(131)81(144-21)140-18-40-71(55(122)43(77(135)145-40)93-24(4)106)154-78-44(94-25(5)107)56(123)70(36(16-103)148-78)157-84-67(134)74(158-86-76(63(130)51(118)33(13-100)147-86)160-80-46(96-27(7)109)58(125)69(35(15-102)150-80)156-83-66(133)61(128)53(120)39(153-83)20-143-90(88(138)139)9-29(111)42(92-23(3)105)73(162-90)49(116)31(113)11-98)54(121)37(151-84)17-141-85-75(62(129)50(117)32(12-99)146-85)159-79-45(95-26(6)108)57(124)68(34(14-101)149-79)155-82-65(132)60(127)52(119)38(152-82)19-142-89(87(136)137)8-28(110)41(91-22(2)104)72(161-89)48(115)30(112)10-97/h21,28-86,97-103,110-135H,8-20H2,1-7H3,(H,91,104)(H,92,105)(H,93,106)(H,94,107)(H,95,108)(H,96,109)(H,136,137)(H,138,139)/t21-,28-,29-,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52-,53-,54+,55+,56+,57+,58+,59+,60-,61-,62-,63-,64-,65+,66+,67-,68+,69+,70+,71+,72+,73+,74-,75-,76-,77+,78-,79-,80-,81+,82-,83-,84-,85-,86+,89+,90+/m0/s1",alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,PubMed citation,25568069
5528,87767,N-tetracosanoylglycine,An N-acylglycine in which the acyl group is specified as tetracosanoyl.,"InChI=1S/C26H51NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-25(28)27-24-26(29)30/h2-24H2,1H3,(H,27,28)(H,29,30)",N-lignoceroylglycine,PubMed citation,12810727
5529,87768,N-hexacosanoylglycine,An N-acylglycine in which the acyl group is specified as hexacosanoyl.,"InChI=1S/C28H55NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-27(30)29-26-28(31)32/h2-26H2,1H3,(H,29,30)(H,31,32)",N-cerotoylglycine,PubMed citation,12810727
5530,87770,D-threonolactone,"A butan-4-olide that is dihydrofuran-2-one substituted at C-3 and C-4 by hydroxy groups (the 3S,4R-diastereomer).","InChI=1S/C4H6O4/c5-2-1-8-4(7)3(2)6/h2-3,5-6H,1H2/t2-,3+/m1/s1","D-threonic acid-1,4-lactone",Reaxys Registry Number,81075
5531,87774,16alpha-hydroxydehydroepiandrosterone 3-sulfate,An androstanoid that is dehydroepiandrosterone 3-sulfate substituted by a hydroxy group at the 16alpha-position.,"InChI=1S/C19H28O6S/c1-18-7-5-12(25-26(22,23)24)9-11(18)3-4-13-14(18)6-8-19(2)15(13)10-16(20)17(19)21/h3,12-16,20H,4-10H2,1-2H3,(H,22,23,24)/t12-,13+,14-,15-,16+,18-,19-/m0/s1",3beta-sulfooxy-16alpha-hydroxyandrost-5-en-17-one,Reaxys Registry Number,6004315
5532,87790,alpha-L-Fucp-(1->2)-beta-D-Galp6S-(1->3)-D-GlcpNAc,"A linear amino trisaccharide that consists of alpha-L-fucose, 6-sulfated beta-D-galactose and N-acetyl-beta-D-glucosamine units connected in sequence by (1->2) and (1->3) links, respectively.","InChI=1S/C20H35NO18S/c1-5-10(24)13(27)15(29)19(35-5)39-17-14(28)11(25)8(4-34-40(31,32)33)37-20(17)38-16-9(21-6(2)23)18(30)36-7(3-22)12(16)26/h5,7-20,22,24-30H,3-4H2,1-2H3,(H,21,23)(H,31,32,33)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18+,19-,20-/m0/s1",Fucalpha1-2[6OSO3]Galbeta1-3GlcNAcbeta,PubMed citation,25568069
5533,87797,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc6S,An amino trisaccharide in which an alpha-L-fucosyl-(1->2)-D-galactosyl unit is linked (1->3) to a 6-sulfated N-acetyl-beta-D-glucosamine residue.,"InChI=1S/C20H35NO18S/c1-5-10(24)13(27)15(29)19(35-5)39-17-14(28)11(25)7(3-22)37-20(17)38-16-9(21-6(2)23)18(30)36-8(12(16)26)4-34-40(31,32)33/h5,7-20,22,24-30H,3-4H2,1-2H3,(H,21,23)(H,31,32,33)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18+,19-,20-/m0/s1",alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-6-O-sulfo-beta-D-glucosamine,PubMed citation,25568069
5534,87800,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->6)]-alpha-D-GalpNAc,An amino heptasaccharide in which two alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl chains are linked (1->3) and (1->6) to alpha-D-galactose.,"InChI=1S/C48H81N3O34/c1-11-24(59)31(66)35(70)45(74-11)84-40-33(68)26(61)16(6-52)79-47(40)82-38-22(50-14(4)57)43(77-18(8-54)28(38)63)73-10-20-30(65)37(21(42(72)76-20)49-13(3)56)81-44-23(51-15(5)58)39(29(64)19(9-55)78-44)83-48-41(34(69)27(62)17(7-53)80-48)85-46-36(71)32(67)25(60)12(2)75-46/h11-12,16-48,52-55,59-72H,6-10H2,1-5H3,(H,49,56)(H,50,57)(H,51,58)/t11-,12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28+,29+,30-,31+,32+,33-,34-,35-,36-,37+,38+,39+,40+,41+,42-,43+,44-,45-,46-,47-,48-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->6)]-alpha-D-GalNAc,PubMed citation,25568069
5535,87806,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-{beta-D-Galp-(1->4)-beta-D-GlcNAc-(1->4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->3)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,"A branched amino oligosaccharide that is an pentasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked an N-acetyl-beta-D-glucosaminyl residue [via a (1->4) linkage], a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)]-alpha-D-mannosyl branched pentasaccharide unit [linked (1->3)], and a branched beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl branched pentasaccharide unit [linked (1->6)], while to the N-acetyl-D-glucosamine residue at the reducing end is linked (1->6) an alpha-L-fucose residue.","InChI=1S/C104H173N7O75/c1-23-52(130)66(144)72(150)97(161-23)159-21-43-85(60(138)45(90(157)162-43)105-24(2)123)177-94-49(109-28(6)127)63(141)83(40(18-121)170-94)182-102-78(156)87(184-104-89(186-96-51(111-30(8)129)65(143)82(39(17-120)172-96)181-101-76(154)70(148)57(135)35(13-116)167-101)77(155)84(41(19-122)173-104)176-93-48(108-27(5)126)62(140)80(37(15-118)169-93)179-99-74(152)68(146)55(133)33(11-114)165-99)86(183-92-46(106-25(3)124)59(137)53(131)31(9-112)163-92)44(175-102)22-160-103-88(185-95-50(110-29(7)128)64(142)81(38(16-119)171-95)180-100-75(153)69(147)56(134)34(12-115)166-100)71(149)58(136)42(174-103)20-158-91-47(107-26(4)125)61(139)79(36(14-117)168-91)178-98-73(151)67(145)54(132)32(10-113)164-98/h23,31-104,112-122,130-157H,9-22H2,1-8H3,(H,105,123)(H,106,124)(H,107,125)(H,108,126)(H,109,127)(H,110,128)(H,111,129)/t23-,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54-,55-,56-,57-,58+,59+,60+,61+,62+,63+,64+,65+,66+,67-,68-,69-,70-,71-,72-,73+,74+,75+,76+,77-,78-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88-,89-,90?,91+,92-,93-,94-,95-,96-,97+,98-,99-,100-,101-,102-,103-,104+/m0/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)]-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->4)]-{beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->4)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)]-alpha-D-Man-(1->3)}-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-D-GlcNAc,PubMed citation,25568069
5536,87813,alpha-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp,"An amino tetrasaccharide comprising alpha-D-galactose, beta-D-galactose, N-acetyl-beta-D-glucosamine and (at the reducing end) alpha-D-mannose residues linked sequentially (1->3), (1->3) and (1->2).","InChI=1S/C26H45NO21/c1-6(32)27-11-20(14(35)9(4-30)43-24(11)48-22-17(38)13(34)7(2-28)42-23(22)41)46-26-19(40)21(15(36)10(5-31)45-26)47-25-18(39)16(37)12(33)8(3-29)44-25/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13-,14-,15+,16+,17+,18-,19-,20-,21+,22+,23+,24+,25-,26+/m1/s1",alpha-D-Gal-(1->3)-beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->2)-alpha-D-Man,PubMed citation,25568069
5537,87820,"17-phenyl-18,19,20-trinor-prostaglandin E2","A prostanoid that is 18,19,20-trinor-prostaglandin E2 in which one of the terminal methyl hydrogens has been replaced by a phenyl group.","InChI=1S/C23H30O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-20,22,24,26H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,22+/m0/s1",17-phenyl-omega-trinor-PGE2,Reaxys Registry Number,5770145
5538,87821,"17-phenyl-18,19,20-trinor-prostaglandin D2","A prostanoid that is 18,19,20-trinor-prostaglandin D2 in which one of the terminal methyl hydrogens has been replaced by a phenyl group.","InChI=1S/C23H30O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-21,24-25H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,21-/m0/s1",17-phenyltrinor-prostaglandin D2,CAS Registry Number,85280-91-7
5539,87823,1-[(1Z)-octadec-1-enyl]-sn-glycero-3-phosphoethanolamine,A 1-(Z-alk-1-enyl)-sn-glycero-3-phosphoethanolamine in which the Z-alk-1-enyl group is specified as (1Z)-octadec-1-enyl.,"InChI=1S/C23H48NO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19-28-21-23(25)22-30-31(26,27)29-20-18-24/h17,19,23,25H,2-16,18,20-22,24H2,1H3,(H,26,27)/b19-17-/t23-/m1/s1",PE(18:0p/0:0),PubMed citation,25502724
5540,87829,2''-O-glutaryl-ADP-D-ribose(3-),A nucleotide-sugar oxoanion arising from deprotonation of the carboxy and diphosphate groups of 2''-O-glutaryl-ADP-D-ribose; major species at pH 7.3.,"InChI=1S/C20H29N5O17P2/c21-17-12-18(23-6-22-17)25(7-24-12)19-15(31)13(29)8(39-19)4-37-43(33,34)42-44(35,36)38-5-9-14(30)16(20(32)40-9)41-11(28)3-1-2-10(26)27/h6-9,13-16,19-20,29-32H,1-5H2,(H,26,27)(H,33,34)(H,35,36)(H2,21,22,23)/p-3/t8-,9-,13-,14-,15-,16-,19-,20?/m1/s1",2''-O-glutaryl-ADP-D-ribose,PubMed citation,24703693
5541,87921,2R-2-[(1R)-1-hydroxy-16-{2-[10-(2-octadecylcyclopropyl)decyl]cyclopropyl}hexadecyl]hexacosanoate,A C76 alpha-mycolate having a C50 meromycolic chain and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C76H148O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-25-26-28-32-36-40-48-54-60-66-74(76(78)79)75(77)67-61-55-49-41-37-33-29-31-35-39-45-51-57-63-71-69-73(71)65-59-53-47-43-42-46-52-58-64-72-68-70(72)62-56-50-44-38-34-30-27-20-18-16-14-12-10-8-6-4-2/h70-75,77H,3-69H2,1-2H3,(H,78,79)/p-1/t70?,71?,72?,73?,74-,75-/m1/s1",C76 alpha-mycolate (C50/C26),PubMed citation,97292
5542,87969,(2R)-2-[(1R)-1-hydroxy-18-{2-[10-(2-octadecylcyclopropyl)decyl]cyclopropyl}octadecyl]tetracosanoate,A C76 alpha-mycolate having a C52 meromycolic chain with two cis cyclopropyl functions and a saturated C24 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C76H148O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-28-32-36-40-48-54-60-66-74(76(78)79)75(77)67-61-55-49-41-37-33-29-25-27-31-35-39-45-51-57-63-71-69-73(71)65-59-53-47-43-42-46-52-58-64-72-68-70(72)62-56-50-44-38-34-30-26-20-18-16-14-12-10-8-6-4-2/h70-75,77H,3-69H2,1-2H3,(H,78,79)/p-1/t70?,71?,72?,73?,74-,75-/m1/s1",C76 alpha-mycolate (C52/C24),PubMed citation,97292
5543,87970,(2R)-2-[(1R)-1-hydroxy-18-{2-[10-(2-octadecylcyclopropyl)decyl]cyclopropyl}octadecyl]hexacosanoate,A C78 alpha-mycolate having a C52 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C78H152O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-25-26-30-34-38-42-50-56-62-68-76(78(80)81)77(79)69-63-57-51-43-39-35-31-27-29-33-37-41-47-53-59-65-73-71-75(73)67-61-55-49-45-44-48-54-60-66-74-70-72(74)64-58-52-46-40-36-32-28-20-18-16-14-12-10-8-6-4-2/h72-77,79H,3-71H2,1-2H3,(H,80,81)/p-1/t72?,73?,74?,75?,76-,77-/m1/s1",C78 alpha-mycolate (C52/C26),PubMed citation,97292
5544,87971,(2R)-2-[(1R)-1-hydroxy-20-{2-[10-(2-octadecylcyclopropyl)decyl]cyclopropyl}icosyl]tetracosanoate,A C78 alpha-mycolate having a C54 meromycolic chain with two cis cyclopropyl functions and a saturated C24 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C78H152O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-26-30-34-38-42-50-56-62-68-76(78(80)81)77(79)69-63-57-51-43-39-35-31-27-24-25-29-33-37-41-47-53-59-65-73-71-75(73)67-61-55-49-45-44-48-54-60-66-74-70-72(74)64-58-52-46-40-36-32-28-20-18-16-14-12-10-8-6-4-2/h72-77,79H,3-71H2,1-2H3,(H,80,81)/p-1/t72?,73?,74?,75?,76-,77-/m1/s1",C78 alpha-mycolate (C54/C24),PubMed citation,97292
5545,87972,(2R)-2-[(1R)-1-hydroxy-20-{2-[10-(2-octadecylcyclopropyl)decyl]cyclopropyl}icosyl]hexacosanoate,A C80 alpha-mycolate having a C54 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C80H156O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-25-28-32-36-40-44-52-58-64-70-78(80(82)83)79(81)71-65-59-53-45-41-37-33-29-26-27-31-35-39-43-49-55-61-67-75-73-77(75)69-63-57-51-47-46-50-56-62-68-76-72-74(76)66-60-54-48-42-38-34-30-20-18-16-14-12-10-8-6-4-2/h74-79,81H,3-73H2,1-2H3,(H,82,83)/p-1/t74?,75?,76?,77?,78-,79-/m1/s1",C80 alpha-mycolate (C54/C26),PubMed citation,97292
5546,87973,(2R)-2-[(1R)-1-hydroxy-18-{2-[10-(2-icosylcyclopropyl)decyl]cyclopropyl}octadecyl]hexacosanoate,A C80 alpha-mycolate having a C54 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C80H156O3/c1-3-5-7-9-11-13-15-17-19-21-23-24-25-26-28-32-36-40-44-52-58-64-70-78(80(82)83)79(81)71-65-59-53-45-41-37-33-29-31-35-39-43-49-55-61-67-75-73-77(75)69-63-57-51-47-46-50-56-62-68-76-72-74(76)66-60-54-48-42-38-34-30-27-22-20-18-16-14-12-10-8-6-4-2/h74-79,81H,3-73H2,1-2H3,(H,82,83)/p-1/t74?,75?,76?,77?,78-,79-/m1/s1",C80 alpha-mycolate (C54/C26),PubMed citation,97292
5547,87974,(2R)-2-[(1R)-1-hydroxy-22-{2-[10-(2-octadecylcyclopropyl)decyl]cyclopropyl}docosyl]hexacosanoate,A C82 alpha-mycolate having a C56 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C82H160O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-27-30-34-38-42-46-54-60-66-72-80(82(84)85)81(83)73-67-61-55-47-43-39-35-31-28-25-26-29-33-37-41-45-51-57-63-69-77-75-79(77)71-65-59-53-49-48-52-58-64-70-78-74-76(78)68-62-56-50-44-40-36-32-20-18-16-14-12-10-8-6-4-2/h76-81,83H,3-75H2,1-2H3,(H,84,85)/p-1/t76?,77?,78?,79?,80-,81-/m1/s1",C82 alpha-mycolate (C56/C26),PubMed citation,97292
5548,87975,(2R)-2-[(1R)-1-hydroxy-20-{2-[10-(2-icosylcyclopropyl)decyl]cyclopropyl}icosyl]hexacosanoate,A C82 alpha-mycolate having a C56 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C82H160O3/c1-3-5-7-9-11-13-15-17-19-21-23-24-25-26-30-34-38-42-46-54-60-66-72-80(82(84)85)81(83)73-67-61-55-47-43-39-35-31-27-29-33-37-41-45-51-57-63-69-77-75-79(77)71-65-59-53-49-48-52-58-64-70-78-74-76(78)68-62-56-50-44-40-36-32-28-22-20-18-16-14-12-10-8-6-4-2/h76-81,83H,3-75H2,1-2H3,(H,84,85)/p-1/t76?,77?,78?,79?,80-,81-/m1/s1",C82 alpha-mycolate (C56/C26),PubMed citation,97292
5549,87978,D-(1-(13)C)glucitol,A glucitol that is D-glucitol in which the carbon at position 1 is the (13)C isotope.,"InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1/i1+1/t3-,4+,5+,6+/m0",((13)C)sorbitol,Reaxys Registry Number,4291813
5550,87979,(2R)-2-[(1R)-1-hydroxy-18-{2-[10-(2-nonadecylcyclopropyl)decyl]cyclopropyl}octadecyl]hexacosanoate,A C79 alpha-mycolate having a C53 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C79H154O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-25-27-31-35-39-43-51-57-63-69-77(79(81)82)78(80)70-64-58-52-44-40-36-32-28-30-34-38-42-48-54-60-66-74-72-76(74)68-62-56-50-46-45-49-55-61-67-75-71-73(75)65-59-53-47-41-37-33-29-26-20-18-16-14-12-10-8-6-4-2/h73-78,80H,3-72H2,1-2H3,(H,81,82)/p-1/t73?,74?,75?,76?,77-,78-/m1/s1",C79 alpha-mycolate (C53/C26),PubMed citation,97292
5551,87980,(2R)-2-[(1R)-1-hydroxy-20-{2-[10-(2-nonadecylcyclopropyl)decyl]cyclopropyl}icosyl]hexacosanoate,A C81 alpha-mycolate having a C55 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C81H158O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-25-29-33-37-41-45-53-59-65-71-79(81(83)84)80(82)72-66-60-54-46-42-38-34-30-26-28-32-36-40-44-50-56-62-68-76-74-78(76)70-64-58-52-48-47-51-57-63-69-77-73-75(77)67-61-55-49-43-39-35-31-27-20-18-16-14-12-10-8-6-4-2/h75-80,82H,3-74H2,1-2H3,(H,83,84)/p-1/t75?,76?,77?,78?,79-,80-/m1/s1",C81 alpha-mycolate (C55/C26),PubMed citation,97292
5552,87987,(2R)-2-[(1R)-1-hydroxy-12-{2-[14-(2-icosylcyclopropyl)tetradecyl]cyclopropyl}dodecyl]hexacosanoate,A C78 alpha-mycolate having a C52 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C78H152O3/c1-3-5-7-9-11-13-15-17-19-21-23-24-25-26-28-30-32-38-44-50-56-62-68-76(78(80)81)77(79)69-63-57-51-45-39-43-49-55-61-67-75-71-74(75)66-60-54-48-42-37-34-33-36-41-47-53-59-65-73-70-72(73)64-58-52-46-40-35-31-29-27-22-20-18-16-14-12-10-8-6-4-2/h72-77,79H,3-71H2,1-2H3,(H,80,81)/p-1/t72?,73?,74?,75?,76-,77-/m1/s1",C78 alpha-mycolate (C52/C26),PubMed citation,12055308
5553,87989,(2R)-2-[(1R)-1-hydroxy-14-{2-[14-(2-icosylcyclopropyl)tetradecyl]cyclopropyl}tetradecyl]hexacosanoate,A C80 alpha-mycolate having a C54 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C80H156O3/c1-3-5-7-9-11-13-15-17-19-21-23-24-25-26-28-30-32-40-46-52-58-64-70-78(80(82)83)79(81)71-65-59-53-47-41-35-39-45-51-57-63-69-77-73-76(77)68-62-56-50-44-38-34-33-37-43-49-55-61-67-75-72-74(75)66-60-54-48-42-36-31-29-27-22-20-18-16-14-12-10-8-6-4-2/h74-79,81H,3-73H2,1-2H3,(H,82,83)/p-1/t74?,75?,76?,77?,78-,79-/m1/s1",C80 alpha-mycolate (C54/C26),PubMed citation,12055308
5554,87995,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-[beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-D-GlcpNAc,"A branched amino hexasaccharide comprising a linear trisaccharide of N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-D-glucosamine residues linked sequentially (1->3) and (1->4), to the galactose residue of which is also linked (1->6) a linear N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl string.","InChI=1S/C44H74N4O31/c1-11(54)45-21-31(64)35(18(8-52)70-39(21)68)76-44-34(67)38(79-42-23(47-13(3)56)30(63)26(59)16(6-50)72-42)28(61)20(75-44)10-69-40-24(48-14(4)57)32(65)36(19(9-53)74-40)77-43-33(66)37(27(60)17(7-51)73-43)78-41-22(46-12(2)55)29(62)25(58)15(5-49)71-41/h15-44,49-53,58-68H,5-10H2,1-4H3,(H,45,54)(H,46,55)(H,47,56)(H,48,57)/t15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27+,28+,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39?,40-,41+,42+,43+,44+/m1/s1",N-acetyl-beta-D-glucosaminyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine,PubMed citation,25568069
5555,88010,ethyl violet,An organic chloride salt that is the monochloride salt of ethyl violet cation. Used for inclusion in mixed dye solutions of the iron resorcin fuchsin type for demonstrating elastic fibres.,"InChI=1S/C31H42N3.ClH/c1-7-32(8-2)28-19-13-25(14-20-28)31(26-15-21-29(22-16-26)33(9-3)10-4)27-17-23-30(24-18-27)34(11-5)12-6;/h13-24H,7-12H2,1-6H3;1H/q+1;/p-1",C.I. 42600,CAS Registry Number,2390-59-2
5556,88012,ethyl violet cation,An iminium ion that is the cationic component of the histological dye 'ethyl violet'.,"InChI=1S/C31H42N3/c1-7-32(8-2)28-19-13-25(14-20-28)31(26-15-21-29(22-16-26)33(9-3)10-4)27-17-23-30(24-18-27)34(11-5)12-6/h13-24H,7-12H2,1-6H3/q+1",ethyl violet(1+),Reaxys Registry Number,3915490
5557,88016,naphthalene blue black CS,An organic sodium salt resulting from the formal condensation of naphthalene blue black CS (acid form) with two equivalents of sodium hydroxide. Used for staining fibrin.,"InChI=1S/C22H16N6O12S3.3Na/c23-19-18-11(9-16(42(35,36)37)20(19)26-24-12-1-5-14(6-2-12)28(30)31)10-17(43(38,39)40)21(22(18)29)27-25-13-3-7-15(8-4-13)41(32,33)34;;;/h1-10,29H,23H2,(H,32,33,34)(H,35,36,37)(H,38,39,40);;;/q;3*+1/p-3/b26-24+,27-25+;;;",C.I. 20480,CAS Registry Number,5850-37-3
5558,88027,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a tridecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues (one of which is at the reducing end) all linked in sequence (1->4), to the mannosyl residue of which are linked (1->3) and (1->6) two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear pentasaccharide units.","InChI=1S/C90H150N6O66/c1-20(109)91-39-52(122)67(32(13-103)139-78(39)137)152-79-40(92-21(2)110)53(123)72(35(16-106)146-79)157-88-66(136)75(160-90-77(61(131)48(118)29(10-100)145-90)162-83-44(96-25(6)114)57(127)71(37(18-108)150-83)156-87-65(135)74(50(120)31(12-102)143-87)159-81-42(94-23(4)112)55(125)69(34(15-105)148-81)154-85-63(133)59(129)46(116)27(8-98)141-85)51(121)38(151-88)19-138-89-76(60(130)47(117)28(9-99)144-89)161-82-43(95-24(5)113)56(126)70(36(17-107)149-82)155-86-64(134)73(49(119)30(11-101)142-86)158-80-41(93-22(3)111)54(124)68(33(14-104)147-80)153-84-62(132)58(128)45(115)26(7-97)140-84/h26-90,97-108,115-137H,7-19H2,1-6H3,(H,91,109)(H,92,110)(H,93,111)(H,94,112)(H,95,113)(H,96,114)/t26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45+,46+,47-,48-,49+,50+,51-,52-,53-,54-,55-,56-,57-,58+,59+,60+,61+,62-,63-,64-,65-,66+,67-,68-,69-,70-,71-,72-,73+,74+,75+,76+,77+,78-,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90-/m1/s1",Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,25568069
5559,88049,7-epi-cylindrospermopsin,"A triazaacenaphthylene that is 2,2a,3,4,5,5a,6,7-octahydro-1H-1,8,8b-triazaacenaphthylene which is substituted at positions 3, 4, and 7 by methyl, sulfooxy, and (2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)(hydroxy)methyl groups, respectively (the 2aS,3R,4S,5aS,7R stereoisomer in which the carbon bearing the hydroxy group has S configuration). It is a cyanotoxin produced by several species of freshwater cyanobacteria, such as Aphanizomenon ovalisporum.","InChI=1S/C15H21N5O7S/c1-6-10-5-16-14-17-8(13(22)9-4-12(21)19-15(23)18-9)2-7(20(10)14)3-11(6)27-28(24,25)26/h4,6-8,10-11,13,22H,2-3,5H2,1H3,(H,16,17)(H,24,25,26)(H2,18,19,21,23)/t6-,7+,8-,10-,11+,13+/m1/s1",7-epicylindrospermopsin,KNApSAcK accession,C00027774
5560,88052,prenyl phosphate(2-),An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of prenyl phosphate; major species at pH 7.3.,"InChI=1S/C5H11O4P/c1-5(2)3-4-9-10(6,7)8/h3H,4H2,1-2H3,(H2,6,7,8)/p-2",prenyl phosphate dianion,MetaCyc accession,CPD-14332
5561,88064,"(24E)-3alpha,7alpha-dihydroxy-5beta-cholest-24-en-26-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (24E)-3alpha,7alpha-dihydroxy-5beta-cholest-24-en-26-oic acid.","InChI=1S/C48H78N7O19P3S/c1-26(30-10-11-31-36-32(13-16-48(30,31)6)47(5)15-12-29(56)20-28(47)21-33(36)57)8-7-9-27(2)45(62)78-19-18-50-35(58)14-17-51-43(61)40(60)46(3,4)23-71-77(68,69)74-76(66,67)70-22-34-39(73-75(63,64)65)38(59)44(72-34)55-25-54-37-41(49)52-24-53-42(37)55/h9,24-26,28-34,36,38-40,44,56-57,59-60H,7-8,10-23H2,1-6H3,(H,50,58)(H,51,61)(H,66,67)(H,68,69)(H2,49,52,53)(H2,63,64,65)/b27-9+/t26-,28+,29-,30-,31+,32+,33-,34-,36+,38-,39-,40+,44-,47+,48-/m1/s1","(24E)-3alpha,7alpha-dihydroxy-5beta-cholest-24-en-26-oyl-coenzyme A",PubMed citation,11146090
5562,88065,"(24R,25R)-3alpha,7alpha,24-trihydroxy-5beta-cholestan-26-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (24R,25R)-3alpha,7alpha,24-trihydroxy-5beta-cholestan-26-oic acid.","InChI=1S/C48H80N7O20P3S/c1-25(29-8-9-30-36-31(12-15-48(29,30)6)47(5)14-11-28(56)19-27(47)20-33(36)58)7-10-32(57)26(2)45(63)79-18-17-50-35(59)13-16-51-43(62)40(61)46(3,4)22-72-78(69,70)75-77(67,68)71-21-34-39(74-76(64,65)66)38(60)44(73-34)55-24-54-37-41(49)52-23-53-42(37)55/h23-34,36,38-40,44,56-58,60-61H,7-22H2,1-6H3,(H,50,59)(H,51,62)(H,67,68)(H,69,70)(H2,49,52,53)(H2,64,65,66)/t25-,26-,27+,28-,29-,30+,31+,32-,33-,34-,36+,38-,39-,40+,44-,47+,48-/m1/s1","(24R,25R)-3alpha,7alpha,24-trihydroxy-5beta-cholestan-26-oyl-coenzyme A",PubMed citation,11146090
5563,88067,"(2E,5Z)-tetradecadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2E,5Z)-tetradecadienoic acid.","InChI=1S/C35H58N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h11-12,14-15,22-24,28-30,34,45-46H,4-10,13,16-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/b12-11-,15-14+/t24-,28-,29-,30+,34-/m1/s1","2trans,5cis-tetradecadienoyl-coenzyme A",MetaCyc accession,CPD0-1162
5564,88083,(3E)-tetradecenoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (3E)-tetradecenoic acid.,"InChI=1S/C35H60N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h13-14,22-24,28-30,34,45-46H,4-12,15-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/b14-13+/t24-,28-,29-,30+,34-/m1/s1",trans-3-tetradecenoyl-coenzyme A,MetaCyc accession,CPD-15567
5565,88084,"(2E,4E)-tetradecadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2E,4E)-tetradecadienoic acid.","InChI=1S/C35H58N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h12-15,22-24,28-30,34,45-46H,4-11,16-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/b13-12+,15-14+/t24-,28-,29-,30+,34-/m1/s1","(2E,4E)-tetradecadienoyl-coenzyme A",MetaCyc accession,CPD-15566
5566,88095,N-hexanoylphytosphingosine,A phytoceramide in which the ceramide N-acyl group is specified as hexanoyl.,"InChI=1S/C24H49NO4/c1-3-5-7-8-9-10-11-12-13-14-15-17-18-22(27)24(29)21(20-26)25-23(28)19-16-6-4-2/h21-22,24,26-27,29H,3-20H2,1-2H3,(H,25,28)/t21-,22+,24-/m0/s1",Cer(t18:0/6:0),Reaxys Registry Number,10777625
5567,88097,7alpha-hydroxy-3-oxo-5beta-cholan-24-oic acid,A 3-oxo steroid that is chenodeoxycholic acid in which the hydroxy group at position 3 has undergone formal oxidation to the corresponding ketone.,"InChI=1S/C24H38O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-15,17-20,22,26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,17-,18+,19+,20-,22+,23+,24-/m1/s1",3-oxochenodeoxycholic acid,HMDB accession,HMDB0000503
5568,88105,"3beta,7alpha,12alpha-trihydroxy-5beta-cholan-24-oic acid","A trihydroxy-5beta-cholanic acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3, 7 and 12 (the 3beta,7alpha,12alpha stereoisomer).","InChI=1S/C24H40O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-20,22,25-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15+,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1",3-epicholic acid,LIPID MAPS instance accession,LMST04010086
5569,88108,"7alpha,12alpha-dihydroxy-3-oxo-5beta-cholan-24-oic acid",A 3-oxo steroid that is cholic acid in which the hydroxy group at position 3 has undergone formal oxidation to the corresponding ketone.,"InChI=1S/C24H38O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-20,22,26-27H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,19-,20+,22+,23+,24-/m1/s1",3-ketocholic acid,LIPID MAPS instance accession,LMST04010190
5570,88126,(2R)-2-[(1R)-1-hydroxy-20-{2-[10-(2-octadecylcyclopropyl)decyl]cyclopropyl}icosyl]hexacosanoic acid,A C80 mycolic acid having a C54 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C80H156O3/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-25-28-32-36-40-44-52-58-64-70-78(80(82)83)79(81)71-65-59-53-45-41-37-33-29-26-27-31-35-39-43-49-55-61-67-75-73-77(75)69-63-57-51-47-46-50-56-62-68-76-72-74(76)66-60-54-48-42-38-34-30-20-18-16-14-12-10-8-6-4-2/h74-79,81H,3-73H2,1-2H3,(H,82,83)/t74?,75?,76?,77?,78-,79-/m1/s1",C80 alpha-mycolic acid (C54/C26),PubMed citation,97292
5571,88127,(2R)-2-[(1R)-1-hydroxy-18-{2-[10-(2-icosylcyclopropyl)decyl]cyclopropyl}octadecyl]hexacosanoic acid,A C80 mycolic acid having a C54 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C80H156O3/c1-3-5-7-9-11-13-15-17-19-21-23-24-25-26-28-32-36-40-44-52-58-64-70-78(80(82)83)79(81)71-65-59-53-45-41-37-33-29-31-35-39-43-49-55-61-67-75-73-77(75)69-63-57-51-47-46-50-56-62-68-76-72-74(76)66-60-54-48-42-38-34-30-27-22-20-18-16-14-12-10-8-6-4-2/h74-79,81H,3-73H2,1-2H3,(H,82,83)/t74?,75?,76?,77?,78-,79-/m1/s1","C80 alpha-mycolate (l=19, m=10, n=17, p=23)",PubMed citation,97292
5572,88129,(2R)-2-[(1R)-1-hydroxy-20-{2-[10-(2-icosylcyclopropyl)decyl]cyclopropyl}icosyl]hexacosanoic acid,A C82 mycolic acid having a C56 meromycolic chain with two cis cyclopropyl functions and a saturated C26 alpha-branch. It is produced by Mycobacterium tuberculosis H37Ra.,"InChI=1S/C82H160O3/c1-3-5-7-9-11-13-15-17-19-21-23-24-25-26-30-34-38-42-46-54-60-66-72-80(82(84)85)81(83)73-67-61-55-47-43-39-35-31-27-29-33-37-41-45-51-57-63-69-77-75-79(77)71-65-59-53-49-48-52-58-64-70-78-74-76(78)68-62-56-50-44-40-36-32-28-22-20-18-16-14-12-10-8-6-4-2/h76-81,83H,3-75H2,1-2H3,(H,84,85)/t76?,77?,78?,79?,80-,81-/m1/s1",C82 alpha-mycolic acid (C56/C26),PubMed citation,97292
5573,88145,2''-O-succinyl-ADP-D-ribose,A nucleotide-sugar having ADP as the nucleotide fragment and 2-O-succinyl-D-ribofuranos-5-yl as the sugar component.,"InChI=1S/C19H27N5O17P2/c20-16-11-17(22-5-21-16)24(6-23-11)18-14(30)12(28)7(38-18)3-36-42(32,33)41-43(34,35)37-4-8-13(29)15(19(31)39-8)40-10(27)2-1-9(25)26/h5-8,12-15,18-19,28-31H,1-4H2,(H,25,26)(H,32,33)(H,34,35)(H2,20,21,22)/t7-,8-,12-,13-,14-,15-,18-,19?/m1/s1",2''-O-succinyl-ADP-ribose,Reaxys Registry Number,21769012
5574,88152,2-O-[alpha-D-mannosyl-(1->2)-alpha-D-glucosyl]-D-glyceric acid,A glycoside consisting of D-glyceric acid having an alpha-D-mannosyl-(1->2)-alpha-D-glucosyl residue attached at position 2 via a glycosidic linkage.,"InChI=1S/C15H26O14/c16-1-4-7(19)9(21)11(23)14(26-4)29-12-10(22)8(20)5(2-17)27-15(12)28-6(3-18)13(24)25/h4-12,14-23H,1-3H2,(H,24,25)/t4-,5-,6-,7-,8-,9+,10+,11+,12-,14-,15-/m1/s1",2-O-[alpha-D-mannopyranosyl-(1->2)-alpha-D-glucopyranosyl]-3-D-glyceric acid,MetaCyc accession,CPD-13015
5575,88159,"3-hydroxy-O,5-dimethyl-L-tyrosine",An L-tyrosine derivative that is O-methyl-L-tyrosine carrying additional hydroxy and methyl substituents at positions 3 and 5 respectively.,"InChI=1S/C11H15NO4/c1-6-3-7(4-8(12)11(14)15)5-9(13)10(6)16-2/h3,5,8,13H,4,12H2,1-2H3,(H,14,15)/t8-/m0/s1",3-hydroxy-4-methoxy-5-methylphenylalanine,Reaxys Registry Number,9706701
5576,88163,4-azaleucine,An alanine derivative obtained by replacement of one of the methyl hydrogens of alanine by a dimethylamino group.,"InChI=1S/C5H12N2O2/c1-7(2)3-4(6)5(8)9/h4H,3,6H2,1-2H3,(H,8,9)",4-aza-DL-leucine,Reaxys Registry Number,3932032
5577,88164,3-chloroalanine,A chloroalanine obtained by replacement of one of the methyl hydrogens of alanine by a chloro group.,"InChI=1S/C3H6ClNO2/c4-1-2(5)3(6)7/h2H,1,5H2,(H,6,7)",beta-chloro-DL-alanine,CAS Registry Number,3981-36-0
5578,88168,brilliant cresyl blue,An organic tetrachlorozincate salt having 3-amino-7-(diethylamino)-2-methylphenoxazin-5-ium as the counterion. Used for the staining of reticulocytes and platelets.,"InChI=1S/2C17H20N3O.4ClH.Zn/c2*1-4-20(5-2)12-6-7-14-16(9-12)21-17-10-13(18)11(3)8-15(17)19-14;;;;;/h2*6-10H,4-5,18H2,1-3H3;4*1H;/q2*+1;;;;;+2/p-4",Cresyl blue,Wikipedia accession,Brilliant_cresyl_blue
5579,88173,brilliant green,"An organic hydrogensulfate salt having 4-{[4-(diethylamino)phenyl](phenyl)methylidene}-N,N-diethylcyclohexa-2,5-dien-1-iminium as the counterion.","InChI=1S/C27H33N2.H2O4S/c1-5-28(6-2)25-18-14-23(15-19-25)27(22-12-10-9-11-13-22)24-16-20-26(21-17-24)29(7-3)8-4;1-5(2,3)4/h9-21H,5-8H2,1-4H3;(H2,1,2,3,4)/q+1;/p-1",C.I. 42040,CAS Registry Number,633-03-4
5580,88176,brilliant green cation,An iminium ion that is the cationic component of the histological dye 'brilliant green'.,"InChI=1S/C27H33N2/c1-5-28(6-2)25-18-14-23(15-19-25)27(22-12-10-9-11-13-22)24-16-20-26(21-17-24)29(7-3)8-4/h9-21H,5-8H2,1-4H3/q+1",brilliant green(1+),Drug Central accession,4665
5581,88178,nuclear fast red,"An organic sodium salt that is the monosodium salt of 4-amino-1,3-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid. It forms bright red lakes with calcium and is a useful red nuclear staining lake with aluminum.","InChI=1S/C14H9NO7S.Na/c15-9-7-8(12(18)14(13(9)19)23(20,21)22)11(17)6-4-2-1-3-5(6)10(7)16;/h1-4,18-19H,15H2,(H,20,21,22);/q;+1/p-1",C.I. 60760,CAS Registry Number,6409-77-4
5582,88183,Celestin blue B,"An organic chloride salt composed of 1-carbamoyl-7-(diethylamino)-3,4-dihydroxyphenoxazin-5-ium and chloride ions in a 1:1 ratio. A histological dye used in solution with an iron alum mordant as a hematoxylin substitute in the H&E stain.","InChI=1S/C17H17N3O4.ClH/c1-3-20(4-2)9-5-6-11-13(7-9)24-16-14(19-11)10(17(18)23)8-12(21)15(16)22;/h5-8H,3-4H2,1-2H3,(H3-,18,19,21,22,23);1H",Mordant blue 14,CAS Registry Number,1562-90-9
5583,88189,Celestin blue B(1+),"An organic cation that is 3,4-dihydroxyphenoxazin-5-ium carrying additional carbamoyl and diethylamino groups at positions 1 and 7 respectively. The chloride salt is the histological dye 'Celestin blue B'.","InChI=1S/C17H17N3O4/c1-3-20(4-2)9-5-6-11-13(7-9)24-16-14(19-11)10(17(18)23)8-12(21)15(16)22/h5-8H,3-4H2,1-2H3,(H3-,18,19,21,22,23)/p+1",Celestin blue B cation,Reaxys Registry Number,3915005
5584,88191,Sirius red 4B,An organic sodium salt resulting from the formal condensation of Sirius red 4B (acid form) with two equivalents of sodium hydroxide. Used as the plasma stain in some trichrome staining methods.,"InChI=1S/C29H21N5O8S2.2Na/c35-28-25-15-12-23(30-29(36)18-4-2-1-3-5-18)16-19(25)17-26(44(40,41)42)27(28)34-33-21-8-6-20(7-9-21)31-32-22-10-13-24(14-11-22)43(37,38)39;;/h1-17,35H,(H,30,36)(H,37,38,39)(H,40,41,42);;/q;2*+1/p-2/b32-31+,34-33+;;",Direct red 81,CAS Registry Number,2610-11-9
5585,88192,Sirius red 4B (acid form),A naphthalenesulfonic acid that is 7-amino-4-hydroxy-3-({4-[(4-sulfophenyl)diazenyl]phenyl}diazenyl)naphthalene-2-sulfonic acid in which one of the amino hydrogens is replaced by a benzoyl group. The disodium salt is the histological dye 'Sirius red 4B'.,"InChI=1S/C29H21N5O8S2/c35-28-25-15-12-23(30-29(36)18-4-2-1-3-5-18)16-19(25)17-26(44(40,41)42)27(28)34-33-21-8-6-20(7-9-21)31-32-22-10-13-24(14-11-22)43(37,38)39/h1-17,35H,(H,30,36)(H,37,38,39)(H,40,41,42)/b32-31+,34-33+",Solaminrot 4B free acid,CAS Registry Number,25188-42-5
5586,88195,Pontamine sky blue 5B (acid form),"A ring assembly consisting of two 5-amino-4-hydroxy-3-[(2-methoxyphenyl)diazenyl]naphthalene-2,7-disulfonic acid units joined by a 4,4'-linkage. The tetrasodium salt is the histological dye 'Pontamine sky blue 5B'.","InChI=1S/C34H28N6O16S4/c1-55-25-9-15(3-5-23(25)37-39-31-27(59(49,50)51)11-17-7-19(57(43,44)45)13-21(35)29(17)33(31)41)16-4-6-24(26(10-16)56-2)38-40-32-28(60(52,53)54)12-18-8-20(58(46,47)48)14-22(36)30(18)34(32)42/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)/b39-37+,40-38+",C.I. Direct Blue 15 (acid form),Reaxys Registry Number,740802
5587,88202,Congo corinth,An organic sodium salt resulting from the formal condensation of Congo corinth (acid form) with two equivalents of sodium hydroxide. A histological dye used to stain frozen sections for rapid diagnosis and to demonstrate amuloid.,"InChI=1S/C32H23N5O7S2.2Na/c33-31-25-7-3-1-5-23(25)29(45(39,40)41)17-27(31)36-34-21-13-9-19(10-14-21)20-11-15-22(16-12-20)35-37-28-18-30(46(42,43)44)24-6-2-4-8-26(24)32(28)38;;/h1-18,38H,33H2,(H,39,40,41)(H,42,43,44);;/q;2*+1/p-2/b36-34+,37-35+;;",Erie garnet B,CAS Registry Number,2429-70-1
5588,88205,Hoffman's violet,A hydrochloride obtained by combining Hoffman's violet free base with one molar equivalent of hydrogen chloride. A specific stain for animal chromosomes.,"InChI=1S/C26H31N3.ClH/c1-5-27-23-13-8-20(9-14-23)26(21-10-15-24(16-11-21)28-6-2)22-12-17-25(29-7-3)19(4)18-22;/h8-18,27,29H,5-7H2,1-4H3;1H/b26-21-,28-24+;",C.I. 42530,CAS Registry Number,8004-86-2
5589,88209,Sirius scarlet GG,An organic sodium salt that is the monosodium salt of 5-[(4-amino-5-methoxy-2-methylphenyl)diazenyl]-2-methoxybenzene-1-sulfonic acid. Occasionally used for the selective staining of amyloid.,"InChI=1S/C15H17N3O5S.Na/c1-9-6-11(16)14(23-3)8-12(9)18-17-10-4-5-13(22-2)15(7-10)24(19,20)21;/h4-8H,16H2,1-3H3,(H,19,20,21);/q;+1/p-1/b18-17+;",C.I. 40270,CAS Registry Number,1937-40-2
5590,88210,Sirius scarlet GG (acid form),An arenesulfonic acid that is 2-methoxybenzenesulfonic acid substituted at position 5 by a (4-amino-5-methoxy-2-methylphenyl)diazenyl group. The sodium salt is the histological dye 'Sirius scarlet GG'.,"InChI=1S/C15H17N3O5S/c1-9-6-11(16)14(23-3)8-12(9)18-17-10-4-5-13(22-2)15(7-10)24(19,20)21/h4-8H,16H2,1-3H3,(H,19,20,21)/b18-17+",Direct red 76 free acid,CAS Registry Number,63216-83-1
5591,88212,lead(II) chloride,An inorganic chloride consisting of two chlorine atoms covalently bound to a central lead atom.,InChI=1S/2ClH.Pb/h2*1H;/q;;+2/p-2,lead chloride,Reaxys Registry Number,8128172
5592,88213,Oil red O,"A bis(azo) compound that is 2-naphthol substituted at position 1 by a {4-[(2,5-dimethylphenyl)diazenyl]-2,5-dimethylphenyl}diazenyl group. A fat-soluble dye predominantly used for demonstrating triglycerides in frozen sections and for staining of protein bound lipids in paraffin sections.","InChI=1S/C26H24N4O/c1-16-9-10-17(2)22(13-16)27-28-23-14-19(4)24(15-18(23)3)29-30-26-21-8-6-5-7-20(21)11-12-25(26)31/h5-15,31H,1-4H3",Solvent red 27,CAS Registry Number,14288-70-1
5593,88216,Sudan black B,"A member of the class of perimidines that is 2,2-dimethyl-2,3-dihydro-1H-perimidine carrying a [4-(phenyldiazenyl)naphthalen-1-yl]diazenyl substituent at position 6. A fat-soluble dye predominantly used for demonstrating triglycerides in frozen sections and for staining of protein bound lipids in paraffin sections.","InChI=1S/C29H24N6/c1-29(2)30-26-14-8-13-22-25(17-18-27(31-29)28(22)26)35-34-24-16-15-23(20-11-6-7-12-21(20)24)33-32-19-9-4-3-5-10-19/h3-18,30-31H,1-2H3",C.I. 26150,CAS Registry Number,4197-25-5
5594,88219,TTT-3002,"An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of 3-amino-N,2-dimethyloxolane-3-carboxamide (the 2R,3R,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.","InChI=1S/C27H23N5O3/c1-26-27(28,25(34)29-2)11-18(35-26)31-16-9-5-3-7-13(16)20-21-15(12-30-24(21)33)19-14-8-4-6-10-17(14)32(26)23(19)22(20)31/h3-10,18H,11-12,28H2,1-2H3,(H,29,34)(H,30,33)/t18-,26+,27-/m0/s1",TTT 3002,PubMed citation,23065705
5595,88263,sulfisoxazole diolamine,An organoammonium salt obtained by combining equimolar amounts of sulfisoxazole and diethanolamine. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.,"InChI=1S/C11H13N3O3S.C4H11NO2/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10;6-3-1-5-2-4-7/h3-6,14H,12H2,1-2H3;5-7H,1-4H2",sulfisoxazole diethanolamine,CAS Registry Number,4299-60-9
5596,88270,6-deoxy-6-sulfo-D-gluconic acid,A carbohydrate sulfonate that is D-gluconic acid in which the hydroxy group at position 6 is replaced by a sulfo group.,"InChI=1S/C6H12O9S/c7-2(1-16(13,14)15)3(8)4(9)5(10)6(11)12/h2-5,7-10H,1H2,(H,11,12)(H,13,14,15)/t2-,3-,4+,5-/m1/s1",6-deoxy-D-gluconic acid 6-sulfonate,MetaCyc accession,CPD-18482
5597,88279,Sirius red F3B,An organic sodium salt resulting from the formal condensation of Sirius red F3B (acid form) with six equivalents of sodium hydroxide. A polyazo dye used principally in staining methods for collagen and amyloid.,"InChI=1S/C45H32N10O21S6.6Na/c56-43-33-13-5-27(17-23(33)19-39(81(71,72)73)41(43)54-52-35-15-7-29(21-37(35)79(65,66)67)50-48-25-1-9-31(10-2-25)77(59,60)61)46-45(58)47-28-6-14-34-24(18-28)20-40(82(74,75)76)42(44(34)57)55-53-36-16-8-30(22-38(36)80(68,69)70)51-49-26-3-11-32(12-4-26)78(62,63)64;;;;;;/h1-22,56-57H,(H2,46,47,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76);;;;;;/q;6*+1/p-6",Direct red 80,CAS Registry Number,2610-10-8
5598,88280,Sirius red F3B (acid form),A naphthalenesulfonic acid that is the free acid form of the dye Sirius red F3B. The hexasodium salt is a histological dye used principally in staining methods for collagen and amyloid.,"InChI=1S/C45H32N10O21S6/c56-43-33-13-5-27(17-23(33)19-39(81(71,72)73)41(43)54-52-35-15-7-29(21-37(35)79(65,66)67)50-48-25-1-9-31(10-2-25)77(59,60)61)46-45(58)47-28-6-14-34-24(18-28)20-40(82(74,75)76)42(44(34)57)55-53-36-16-8-30(22-38(36)80(68,69)70)51-49-26-3-11-32(12-4-26)78(62,63)64/h1-22,56-57H,(H2,46,47,58)(H,59,60,61)(H,62,63,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76)",direct red 80 free acid,CAS Registry Number,25188-41-4
5599,88283,Durazol blue 4R,An organic sodium salt resulting from the formal condensation of Durazol blue 4R (acid form) with three equivalents of sodium hydroxide.,"InChI=1S/C34H27N5O12S3.3Na/c1-18-10-27(37-39-33-31(54(48,49)50)14-19-11-22(8-9-25(19)34(33)41)35-21-6-4-3-5-7-21)30(51-2)17-26(18)36-38-28-15-23(52(42,43)44)12-20-13-24(53(45,46)47)16-29(40)32(20)28;;;/h3-17,35,40-41H,1-2H3,(H,42,43,44)(H,45,46,47)(H,48,49,50);;;/q;3*+1/p-3",Durazol blue,CAS Registry Number,3354-97-0
5600,88284,Durazol blue 4R (acid form),A naphthalenesulfonic acid that is the free acid form of the dye Sirius red F3B (the trisodium salt).,"InChI=1S/C34H27N5O12S3/c1-18-10-27(37-39-33-31(54(48,49)50)14-19-11-22(8-9-25(19)34(33)41)35-21-6-4-3-5-7-21)30(51-2)17-26(18)36-38-28-15-23(52(42,43)44)12-20-13-24(53(45,46)47)16-29(40)32(20)28/h3-17,35,40-41H,1-2H3,(H,42,43,44)(H,45,46,47)(H,48,49,50)",direct blue 67 free acid,Reaxys Registry Number,20756637
5601,88294,gallein,"A xanthene dye that is fluoran carrying four hydroxy substituents at positions 3', 4', 5' and 6'.","InChI=1S/C20H12O7/c21-13-7-5-11-17(15(13)23)26-18-12(6-8-14(22)16(18)24)20(11)10-4-2-1-3-9(10)19(25)27-20/h1-8,21-24H",C.I. 45445,PubMed citation,25629163
5602,88296,Gallamin blue,"An organic chloride salt composed of 1-carbamoyl-7-(dimethylamino)-3,4-dihydroxyphenoxazin-5-ium and chloride ions in a 1:1 ratio. A histological dye used in solution with an iron alum mordant as a hematoxylin substitute in the H&E stain.","InChI=1S/C15H13N3O4.ClH/c1-18(2)7-3-4-9-11(5-7)22-14-12(17-9)8(15(16)21)6-10(19)13(14)20;/h3-6H,1-2H3,(H3-,16,17,19,20,21);1H",C.I. 51045,CAS Registry Number,1563-02-6
5603,88338,"1-oleoyl-2-{6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl}-sn-glycero-3-phospho-L-serine","A 3-sn-phosphatidyl L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are oleoyl and 6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl respectively.","InChI=1S/C36H58N5O13P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17-20-32(42)50-25-28(26-51-55(48,49)52-27-29(37)36(44)45)53-33(43)21-18-16-19-24-38-30-22-23-31(41(46)47)35-34(30)39-54-40-35/h9-10,22-23,28-29,38H,2-8,11-21,24-27,37H2,1H3,(H,44,45)(H,48,49)/b10-9-/t28-,29+/m1/s1",NBD-PS,PubMed citation,26481472
5604,88353,bryostatin 1,"A member of the class of bryostatins that is (17E)-2-oxooxacyclohexacos-17-ene which is substituted by hydroxy groups at positions 4, 10, and 20; an acetoxy group at position 8; methyl groups at positions 9, 9, 18, and 19; 2-methoxy-2-oxoethylidene groups at positions 14 and 24; an (E,E)-octa-2,4-dienoyloxy group at position 21; and with oxygen bridges linking positions 6 to 10, 12 to 16, and 20 to 24. It is one of the most abundant member of the class of bryostatins.","InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1",bryostatin-1,CAS Registry Number,83314-01-6
5605,88358,5-bromouridine 5'-triphosphate,A pyrimidine ribonucleoside 5'-triphosphate having 5-bromouracil as the pyrimidine component.,"InChI=1S/C9H14BrN2O15P3/c10-3-1-12(9(16)11-7(3)15)8-6(14)5(13)4(25-8)2-24-29(20,21)27-30(22,23)26-28(17,18)19/h1,4-6,8,13-14H,2H2,(H,20,21)(H,22,23)(H,11,15,16)(H2,17,18,19)/t4-,5-,6-,8-/m1/s1",5-bromo-UTP,PDBeChem accession,BUP
5606,88363,"8,5'-diferulic acid",A polyphenol composed of two molecules of ferulic acid joined by a bond between positions 8 and 5'.,"InChI=1S/C20H18O8/c1-27-16-9-11(3-5-15(16)21)8-14(20(25)26)13-7-12(4-6-18(22)23)10-17(28-2)19(13)24/h3-10,21,24H,1-2H3,(H,22,23)(H,25,26)/b6-4+,14-8+",Ferulic acid 8-5-dehydrodimer,Reaxys Registry Number,7051946
5607,88493,leukotriene B5,"A leukotriene composed of (6Z,8E,10E,14Z,17Z)-icosapentaenoic acid carrying (5S)- and (12R)-hydroxy substituents.","InChI=1S/C20H30O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h3-4,6-11,14-15,18-19,21-22H,2,5,12-13,16-17H2,1H3,(H,23,24)/b4-3-,8-7+,9-6-,14-10+,15-11-/t18-,19-/m1/s1","(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxy-6,8,10,14,17-Eicosapentaenoic acid",HMDB accession,HMDB0005073
5608,88494,epsilon-(gamma-glutamyl)lysine,An N(6)-acyl-L-lysine derivative in which the acyl group is specified as gamma-glutamyl.,"InChI=1S/C11H21N3O5/c12-7(10(16)17)3-1-2-6-14-9(15)5-4-8(13)11(18)19/h7-8H,1-6,12-13H2,(H,14,15)(H,16,17)(H,18,19)/t7-,8-/m0/s1",epsilon-(gamma-Glutamyl)lysine,HMDB accession,HMDB0003869
5609,88528,hexanal,A saturated fatty aldehyde that is hexane in which one of the terminal methyl group has been mono-oxygenated to form the corresponding aldehyde.,"InChI=1S/C6H12O/c1-2-3-4-5-6-7/h6H,2-5H2,1H3",Hexaldehyde,KNApSAcK accession,C00000357
5610,88685,1-(11Z)-icosenoyl-sn-glycero-3-phosphocholine,A 1-icosenoyl-sn-glycero-3-phosphocholine in which the the double bond of the icosenoyl group is at the 11-12 position and has Z configuration.,"InChI=1S/C28H56NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-28(31)34-25-27(30)26-36-37(32,33)35-24-23-29(2,3)4/h12-13,27,30H,5-11,14-26H2,1-4H3/b13-12-/t27-/m1/s1",LPC(20:1n9/0:0),HMDB accession,HMDB0010391
5611,88705,DG(15:0/15:0/0:0),"A 1,2-diacyl-sn-glycerol that has pentadecanoyl as 1- and 2-acyl groups.","InChI=1S/C33H64O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-32(35)37-30-31(29-34)38-33(36)28-26-24-22-20-18-16-14-12-10-8-6-4-2/h31,34H,3-30H2,1-2H3/t31-/m0/s1",DAG(15:0/15:0),HMDB accession,HMDB0007068
5612,88756,cholesteryl gamma-linolenate,A cholesteryl octadecatrienoate obtained by formal condensation of the carboxy group of gamma-linolenic acid with the hydroxy group of cholesterol.,"InChI=1S/C45H74O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-43(46)47-38-30-32-44(5)37(34-38)26-27-39-41-29-28-40(36(4)24-22-23-35(2)3)45(41,6)33-31-42(39)44/h11-12,14-15,17-18,26,35-36,38-42H,7-10,13,16,19-25,27-34H2,1-6H3/b12-11-,15-14-,18-17-/t36-,38+,39+,40-,41+,42+,44+,45-/m1/s1","cholesteryl (6Z,9Z,12Z)-octadecatrienoate",Reaxys Registry Number,8380453
5613,88759,DG(16:0/14:0/0:0),"A 1,2-diacyl-sn-glycerol that has palmitoyl and tetradecanoyl as 1- and 2-acyl groups respectively.","InChI=1S/C33H64O5/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-32(35)37-30-31(29-34)38-33(36)28-26-24-22-20-17-14-12-10-8-6-4-2/h31,34H,3-30H2,1-2H3/t31-/m0/s1",1-palmitoyl-2-myristoyl-sn-glycerol,HMDB accession,HMDB0007095
5614,88764,ethyl butyrate,A butyrate ester resulting from the formal condensation of the hydroxy group of ethanol with the carboxy group of butyric acid.,"InChI=1S/C6H12O2/c1-3-5-6(7)8-4-2/h3-5H2,1-2H3",Butyric acid ethyl ester,HMDB accession,HMDB0033889
5615,88768,(11Z-octadecenoyl)-cholesterol,A cholesteryl octadecenoate in which the acy group is specified as (11Z)-octadec-11-enoyl.,"InChI=1S/C45H78O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-43(46)47-38-30-32-44(5)37(34-38)26-27-39-41-29-28-40(36(4)24-22-23-35(2)3)45(41,6)33-31-42(39)44/h12-13,26,35-36,38-42H,7-11,14-25,27-34H2,1-6H3/b13-12-/t36-,38+,39+,40-,41+,42+,44+,45-/m1/s1",cholesteryl 1-(11Z-octadecenoic acid),HMDB accession,HMDB0005189
5616,88824,N-acetylcadaverine,An N-substituted cadaverine that is cadaverine in which one of the amino groups has been converted to the corresponding acetamide.,"InChI=1S/C7H16N2O/c1-7(10)9-6-4-2-3-5-8/h2-6,8H2,1H3,(H,9,10)",Monoacetyl cadaverine,PubMed citation,17723614
5617,88956,pyroglutamylglutamine,A dpeptide obtained by formal condensation of the carboxy group of L-pyroglutamine with the amino group of L-glutamine,"InChI=1S/C10H15N3O5/c11-7(14)3-1-6(10(17)18)13-9(16)5-2-4-8(15)12-5/h5-6H,1-4H2,(H2,11,14)(H,12,15)(H,13,16)(H,17,18)/t5-,6-/m0/s1",Pyro-L-glutaminyl-L-glutamine,HMDB accession,HMDB0039229
5618,88965,ethyl cyclohexanecarboxylate,An ethyl ester resulting from the formal condensation of the carboxy group of cyclohexanecarboxylic acid with ethanol.,"InChI=1S/C9H16O2/c1-2-11-9(10)8-6-4-3-5-7-8/h8H,2-7H2,1H3",ethyl cyclohexanoate,CAS Registry Number,3289-28-9
5619,89052,"2,5-dimethylfuran",A member of the class of furans that is furan in which the hydrogens at positions 2 and 5 are replaced by methyl groups.,"InChI=1S/C6H8O/c1-5-3-4-6(2)7-5/h3-4H,1-2H3","2,5-dimethyl-furan",PubMed citation,19167006
5620,89087,cotinine N-oxide,An N-alkylpyrrolidine that is nicotine in which the methylene hydrogens at position 2 on the pyrrolidine ring have been replaced by an oxo group and the pyridine nitrogen converted into the corresponding N-oxide. A minor metabolite of nicotine.,"InChI=1S/C10H12N2O2/c1-11-9(4-5-10(11)13)8-3-2-6-12(14)7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1",(5S)-1-methyl-5-(1-oxido-3-pyridinyl)-2-pyrrolidinone,PubMed citation,16359169
5621,89118,5-hydroxymethyl-2-furoic acid,A member of the class of furoic acids that is 2-furoic acid substituted at position 5 by a hydroxymethyl group.,"InChI=1S/C6H6O4/c7-3-4-1-2-5(10-4)6(8)9/h1-2,7H,3H2,(H,8,9)",5-(Hydroxymethyl)-2-furoic acid,HMDB accession,HMDB0002432
5622,89188,"2,4-di-tert-butylphenol",A member of the class of phenols carrying two tert-butyl substituents at positions 2 and 4.,"InChI=1S/C14H22O/c1-13(2,3)10-7-8-12(15)11(9-10)14(4,5)6/h7-9,15H,1-6H3","2,4-Bis(1,1'-dimethylethyl)phenol",HMDB accession,HMDB0013816
5623,89237,"1-alpha-linolenoyl-2-[(8Z,11Z,14Z)-icosatrienoyl]-sn-glycerol","A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (8Z,11Z,14Z)-icosatrienoyl respectively.","InChI=1S/C41H68O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h6,8,11-14,17-19,21-22,24,39,42H,3-5,7,9-10,15-16,20,23,25-38H2,1-2H3/b8-6-,13-11-,14-12-,19-17-,21-18-,24-22-/t39-/m0/s1",DAG(38:6),PubMed citation,20671299
5624,89238,"1-alpha-linolenoyl-2-[(5Z,8Z,11Z)-icosatrienoyl]-sn-glycerol","A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (5Z,8Z,11Z)-icosatrienoyl respectively.","InChI=1S/C41H68O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h6,8,12,14,17-19,21-22,24,28,30,39,42H,3-5,7,9-11,13,15-16,20,23,25-27,29,31-38H2,1-2H3/b8-6-,14-12-,19-17-,21-18-,24-22-,30-28-/t39-/m0/s1",DG(18:3/20:3),HMDB accession,HMDB0007313
5625,89239,"1-alpha-linolenoyl-2-[(11Z,14Z)-icosadienoyl]-sn-glycerol","A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (11Z,14Z)-icosadienoyl respectively.","InChI=1S/C41H70O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h6,8,11-14,17-19,21,39,42H,3-5,7,9-10,15-16,20,22-38H2,1-2H3/b8-6-,13-11-,14-12-,19-17-,21-18-/t39-/m0/s1",DAG(18:3w3/20:2w6),HMDB accession,HMDB0007312
5626,89240,1-alpha-linolenoyl-2-[(11Z)-icosenoyl]-sn-glycerol,"A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and (11Z)-icosenoyl respectively.","InChI=1S/C41H72O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h6,8,12,14,17-19,21,39,42H,3-5,7,9-11,13,15-16,20,22-38H2,1-2H3/b8-6-,14-12-,19-17-,21-18-/t39-/m0/s1",Diacylglycerol(18:3w3/20:1w9),PubMed citation,20671299
5627,89241,1-alpha-linolenoyl-2-icosanoyl-sn-glycerol,"A 1,2-diacyl-sn-glycerol in which the acyl groups positions 1 and 2 are specified as alpha-linolenoyl and icosanoyl (arachidoyl) respectively.","InChI=1S/C41H74O5/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-41(44)46-39(37-42)38-45-40(43)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h6,8,12,14,18,21,39,42H,3-5,7,9-11,13,15-17,19-20,22-38H2,1-2H3/b8-6-,14-12-,21-18-/t39-/m0/s1",Diacylglycerol(18:3w3/20:0),PubMed citation,20671299
5628,89242,"p-mentha-1,3,8-triene","A monoterpene that is cyclohexa-1,3-diene substituted at positions 1 and 4 by methyl and prop-1-en-2-yl groups respectively.","InChI=1S/C10H14/c1-8(2)10-6-4-9(3)5-7-10/h4,6H,1,5,7H2,2-3H3","1,3,8-Para-Menthatriene",PubMed citation,24421258
5629,89243,"1-[(8Z,11Z,14Z,17Z)-icosatetraenoyl]-2-[(11Z)-icosenoyl]-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (8Z,11Z,14Z,17Z)-icosatetraenoyl and (11Z)-icosenoyl respectively.","InChI=1S/C49H85O13P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-42(50)59-39-41(40-60-63(57,58)62-49-47(55)45(53)44(52)46(54)48(49)56)61-43(51)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h5,7,11,13,17-20,23,25,41,44-49,52-56H,3-4,6,8-10,12,14-16,21-22,24,26-40H2,1-2H3,(H,57,58)/b7-5-,13-11-,19-17-,20-18-,25-23-/t41-,44-,45-,46+,47-,48-,49-/m1/s1",PI(20:4/20:1),PubMed citation,20671299
5630,89244,"1-[(8Z,11Z,14Z,17Z)-icosatetraenoyl]-2-icosanoyl-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (8Z,11Z,14Z,17Z)-icosatetraenoyl and arachidoyl (icosanoyl) respectively.","InChI=1S/C49H87O13P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-42(50)59-39-41(40-60-63(57,58)62-49-47(55)45(53)44(52)46(54)48(49)56)61-43(51)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,23,25,41,44-49,52-56H,3-4,6,8-10,12,14-16,18,20-22,24,26-40H2,1-2H3,(H,57,58)/b7-5-,13-11-,19-17-,25-23-/t41-,44-,45-,46+,47-,48-,49-/m1/s1",PIno(20:4w3/20:0),PubMed citation,20671299
5631,89245,"1-[(13Z,16Z)-docosadienoyl]-2-linoleoyl-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (13Z,16Z)-docosadienoyl and linoleoyl respectively.","InChI=1S/C49H87O13P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-25-27-29-31-33-35-37-42(50)59-39-41(40-60-63(57,58)62-49-47(55)45(53)44(52)46(54)48(49)56)61-43(51)38-36-34-32-30-28-26-23-18-16-14-12-10-8-6-4-2/h11-14,17-19,23,41,44-49,52-56H,3-10,15-16,20-22,24-40H2,1-2H3,(H,57,58)/b13-11-,14-12-,19-17-,23-18-/t41-,44-,45-,46+,47-,48-,49-/m1/s1",Phosphatidylinositol(22:2n6/18:2n6),PubMed citation,20671299
5632,89246,"1-[(13Z,16Z)-docosadienoyl]-2-hexadecanoyl-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (13Z,16Z)-docosadienoyl and hexadecanoyl respectively.","InChI=1S/C47H87O13P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-25-27-29-31-33-35-40(48)57-37-39(38-58-61(55,56)60-47-45(53)43(51)42(50)44(52)46(47)54)59-41(49)36-34-32-30-28-26-23-16-14-12-10-8-6-4-2/h11,13,17-18,39,42-47,50-54H,3-10,12,14-16,19-38H2,1-2H3,(H,55,56)/b13-11-,18-17-/t39-,42-,43-,44+,45-,46-,47-/m1/s1",PI(22:2n6/16:0),PubMed citation,20671299
5633,89247,"1-[(10Z,13Z,16Z)-docosatrienoyl]-2-[(9Z,12Z)-hexadecadienoyl]-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (10Z,13Z,16Z)-docosatrienoyl and (9Z,12Z)-hexadecadienoyl respectively.","InChI=1S/C47H81O13P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-25-27-29-31-33-35-40(48)57-37-39(38-58-61(55,56)60-47-45(53)43(51)42(50)44(52)46(47)54)59-41(49)36-34-32-30-28-26-23-16-14-12-10-8-6-4-2/h8,10-11,13-14,16-18,20-21,39,42-47,50-54H,3-7,9,12,15,19,22-38H2,1-2H3,(H,55,56)/b10-8-,13-11-,16-14-,18-17-,21-20-/t39-,42-,43-,44+,45-,46-,47-/m1/s1",PI(38:5),HMDB accession,HMDB0009908
5634,89248,"1-[(10Z,13Z,16Z)-docosatrienoyl]-2-hexadecanoyl-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (10Z,13Z,16Z)-docosatrienoyl and hexadecanoyl respectively.","InChI=1S/C47H85O13P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-25-27-29-31-33-35-40(48)57-37-39(38-58-61(55,56)60-47-45(53)43(51)42(50)44(52)46(47)54)59-41(49)36-34-32-30-28-26-23-16-14-12-10-8-6-4-2/h11,13,17-18,20-21,39,42-47,50-54H,3-10,12,14-16,19,22-38H2,1-2H3,(H,55,56)/b13-11-,18-17-,21-20-/t39-,42-,43-,44+,45-,46-,47-/m1/s1",PIno(22:3w6/16:0),PubMed citation,20671299
5635,89249,"1-[(10Z,13Z,16Z)-docosatrienoyl]-2-linoleoyl-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (10Z,13Z,16Z)-docosatrienoyl and linoleoyl  respectively.","InChI=1S/C49H85O13P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-25-27-29-31-33-35-37-42(50)59-39-41(40-60-63(57,58)62-49-47(55)45(53)44(52)46(54)48(49)56)61-43(51)38-36-34-32-30-28-26-23-18-16-14-12-10-8-6-4-2/h11-14,17-19,21-23,41,44-49,52-56H,3-10,15-16,20,24-40H2,1-2H3,(H,57,58)/b13-11-,14-12-,19-17-,22-21-,23-18-/t41-,44-,45-,46+,47-,48-,49-/m1/s1","1-(10Z,13Z,16Z-Docosatrienoyl)-2-linoleoyl-sn-glycero-3-phosphoinositol",HMDB accession,HMDB0009909
5636,89250,"1-[(8Z,11Z,14Z,17Z)-icosatetraenoyl]-2-octadecanoyl-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (8Z,11Z,14Z,17Z)-icosatetraenoyl and octadecanoyl respectively.","InChI=1S/C47H83O13P/c1-3-5-7-9-11-13-15-17-19-20-22-23-25-27-29-31-33-35-40(48)57-37-39(38-58-61(55,56)60-47-45(53)43(51)42(50)44(52)46(47)54)59-41(49)36-34-32-30-28-26-24-21-18-16-14-12-10-8-6-4-2/h5,7,11,13,17,19,22-23,39,42-47,50-54H,3-4,6,8-10,12,14-16,18,20-21,24-38H2,1-2H3,(H,55,56)/b7-5-,13-11-,19-17-,23-22-/t39-,42-,43-,44+,45-,46-,47-/m1/s1",PI(20:4n3/18:0),HMDB accession,HMDB0009900
5637,89251,"1-[(8Z,11Z,14Z,17Z)-icosatetraenoyl]-2-[(11Z)-octadecenoyl]-sn-glycero-3-phospho-1D-myo-inositol","A 1-phosphatidyl-1D-myo-inositol in which the phosphatidyl acyl groups at positions 1 and 2 are specified as (8Z,11Z,14Z,17Z)-icosatetraenoyl and (11Z)-octadecenoyl respectively.","InChI=1S/C47H81O13P/c1-3-5-7-9-11-13-15-17-19-20-22-23-25-27-29-31-33-35-40(48)57-37-39(38-58-61(55,56)60-47-45(53)43(51)42(50)44(52)46(47)54)59-41(49)36-34-32-30-28-26-24-21-18-16-14-12-10-8-6-4-2/h5,7,11,13-14,16-17,19,22-23,39,42-47,50-54H,3-4,6,8-10,12,15,18,20-21,24-38H2,1-2H3,(H,55,56)/b7-5-,13-11-,16-14-,19-17-,23-22-/t39-,42-,43-,44+,45-,46-,47-/m1/s1",1-Eicsoatetraenoyl-2-vaccenoyl-sn-glycero-3-phosphoinositol,HMDB accession,HMDB0009901
5638,89454,17alpha-hydroxypregnenolone 3-sulfate,A steroid sulfate that is 17alpha-hydroxypregnenolone in which the hydroxy hydrogen at position 3 has been replaced by a sulfo group.,"InChI=1S/C21H32O6S/c1-13(22)21(23)11-8-18-16-5-4-14-12-15(27-28(24,25)26)6-9-19(14,2)17(16)7-10-20(18,21)3/h4,15-18,23H,5-12H2,1-3H3,(H,24,25,26)/t15-,16+,17-,18-,19-,20-,21-/m0/s1",17-Hydroxy-pregnenolone sulfate,PubMed citation,14625002
5639,89484,4-heptanone,A dialkyl ketone that is heptane in which the two methylene protons at position 4 have been replaced by an oxo group.,"InChI=1S/C7H14O/c1-3-5-7(8)6-4-2/h3-6H2,1-2H3",Butyrone,HMDB accession,HMDB0004814
5640,89511,"3,4-dimethylthiophene",A thiophene that is substituted by methyl groups at positions 3 and 4.,"InChI=1S/C6H8S/c1-5-3-7-4-6(5)2/h3-4H,1-2H3","3,4-dimethyl-thiophene",PubMed citation,24023812
5641,89526,"2,4-dimethylfuran",A member of the class of furans that is furan in which the hydrogens at positions 2 and 4 are replaced by methyl groups.,"InChI=1S/C6H8O/c1-5-3-6(2)7-4-5/h3-4H,1-2H3","2,4-dimethyl-furan",HMDB accession,HMDB0032965
5642,89540,methyl propenyl ketone,An enone that is pent-2-ene in which the two methylene hydrogens have been replaced by an oxo group.,"InChI=1S/C5H8O/c1-3-4-5(2)6/h3-4H,1-2H3",Ethylidene acetone,HMDB accession,HMDB0001184
5643,89573,5-[(alpha-D-glucopyranosyl-(1->2)-beta-D-galactopyranosyl)oxy]-L-lysine,An O-glycosyl amino acid that is L-lysine in which one of the methylene hydrogens at position 5 has been replaced by an (alpha-D-glucopyranosyl-(1->2)-beta-D-galactopyranosyl)oxy group.,"InChI=1S/C18H34N2O13/c19-3-6(1-2-7(20)16(28)29)30-18-15(13(26)11(24)9(5-22)32-18)33-17-14(27)12(25)10(23)8(4-21)31-17/h6-15,17-18,21-27H,1-5,19-20H2,(H,28,29)/t6?,7-,8+,9+,10+,11-,12-,13-,14+,15+,17+,18+/m0/s1",Glucosylgalactosyl hydroxylysine,CAS Registry Number,32448-35-4
5644,89582,gamma-Glu-Phe,A dipeptide obtained by formal condensation of the side-chain carboxy group of L-glutamic acid with the amino group of L-phenylalanine.,"InChI=1S/C14H18N2O5/c15-10(13(18)19)6-7-12(17)16-11(14(20)21)8-9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,17)(H,18,19)(H,20,21)/t10-,11-/m0/s1",L-gamma-Glutamyl-L-phenylalanine,PubMed citation,7371187
5645,89598,theaspirane,A norisoprenoid with forumula C13H22O that is a flavour component found in various essential oils such as raspberry oil and passion fruit oil.,"InChI=1S/C13H22O/c1-10-6-5-8-12(3,4)13(10)9-7-11(2)14-13/h6,11H,5,7-9H2,1-4H3","1-oxaspiro-2,6,10,10-tetramethyl[4.5]dec-6-ene",PubMed citation,24023812
5646,89626,m-tyramine,A primary amino compound that is 2-phenylethanamine substituted by a hydroxy group at position 3.,"InChI=1S/C8H11NO/c9-5-4-7-2-1-3-8(10)6-7/h1-3,6,10H,4-5,9H2",m-hydroxyphenethylamine,PubMed citation,8255370
5647,89719,propyl butyrate,A butyrate ester resulting from the formal condensation of the hydroxy group of propanol with the carboxy group of butyric acid.,"InChI=1S/C7H14O2/c1-3-5-7(8)9-6-4-2/h3-6H2,1-2H3",Propyl butanoate,PubMed citation,19167006
5648,89729,(Z)-3-phenyl-2-propenal,A 3-phenylprop-2-enal that has Z configuration.,InChI=1S/C9H8O/c10-8-4-7-9-5-2-1-3-6-9/h1-8H/b7-4-,cis-cinnamic aldehyde,CAS Registry Number,57194-69-1
5649,89731,1-palmitoleoyl-2-palmitoyl-sn-glycero-3-phosphocholine,A phosphatidylcholine 16:0_16:1 in which the acyl groups specified at positions 1 and 2 are palmitoleoyl and palmitoyl respectively.,"InChI=1S/C40H78NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h16,18,38H,6-15,17,19-37H2,1-5H3/b18-16-/t38-/m1/s1",phosphatidylcholine(16:1n7/16:0),PubMed citation,24023812
5650,89750,2-butylfuran,A member of the class of furans that is furan in which the hydrogen at position 2 is replaced by a butyl group. It is a constituent found in several plant species and some cooked foods.,"InChI=1S/C8H12O/c1-2-3-5-8-6-4-7-9-8/h4,6-7H,2-3,5H2,1H3",2-butyl-furan,CAS Registry Number,4466-24-4
5651,89755,1-hexadecanoyl-2-octadecanoyl-3-[(9Z)-octadecenoyl]-sn-glycerol,"A triacyl-sn-glycerol in which the which the acyl groups at positions 1, 2 and 3 are specified as hexadecanoyl, octadecanoyl and (9Z)-octadecenoyl respectively.","InChI=1S/C55H104O6/c1-4-7-10-13-16-19-22-25-27-30-33-36-39-42-45-48-54(57)60-51-52(50-59-53(56)47-44-41-38-35-32-29-24-21-18-15-12-9-6-3)61-55(58)49-46-43-40-37-34-31-28-26-23-20-17-14-11-8-5-2/h25,27,52H,4-24,26,28-51H2,1-3H3/b27-25-/t52-/m1/s1",Triacylglycerol(52:1),PubMed citation,20671299
5652,89778,1-hexadecanoyl-2-[(9Z)-octadecenoyl]-3-[(11Z)-icosenoyl]-sn-glycerol,"A triacyl-sn-glycerol in which the which the acyl groups at positions 1, 2 and 3 are specified as hexadecanoyl, (9Z)-octadecenoyl and (11Z)-icosenoyl respectively.","InChI=1S/C57H106O6/c1-4-7-10-13-16-19-22-25-27-28-30-32-35-38-41-44-47-50-56(59)62-53-54(52-61-55(58)49-46-43-40-37-34-31-24-21-18-15-12-9-6-3)63-57(60)51-48-45-42-39-36-33-29-26-23-20-17-14-11-8-5-2/h25-27,29,54H,4-24,28,30-53H2,1-3H3/b27-25-,29-26-/t54-/m1/s1",Triacylglycerol(54:2),PubMed citation,20671299
5653,89828,propyl propionate,A propanoate ester resulting from the formal condensation of the hydroxy group of propanol with the carboxy group of propanoic acid.,"InChI=1S/C6H12O2/c1-3-5-8-6(7)4-2/h3-5H2,1-2H3","Propanoic acid, propyl ester",PubMed citation,21970810
5654,89836,propionylglycine,A N-acylglycine obtained by formal condensation of the carboxy group of propionic acid with the amino group of glycine.,"InChI=1S/C5H9NO3/c1-2-4(7)6-3-5(8)9/h2-3H2,1H3,(H,6,7)(H,8,9)",N-Propionylglycine,HMDB accession,HMDB0000783
5655,89891,3-hexanone,A dialkyl ketone that is hexane in which the two methylene protons at position 3 have been replaced by an oxo group.,"InChI=1S/C6H12O/c1-3-5-6(7)4-2/h3-5H2,1-2H3",3-Oxohexane,PubMed citation,21970810
5656,89929,glycoursodeoxycholic acid,A bile acid glycine conjugate derived from ursoodeoxycholic acid.,"InChI=1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1",Ursodeoxycholylglycine,HMDB accession,HMDB0000708
5657,89943,(E)-2-penten-1-ol,"A 2-penten-1-ol in which the double bond has (E)-configuration. It is a volatile compound found in cooked mussels, olive oil, fermented cucumber brine and cashew apple juice.","InChI=1S/C5H10O/c1-2-3-4-5-6/h3-4,6H,2,5H2,1H3/b4-3+",2-(E)-penten-1-ol,HMDB accession,HMDB0031604
5658,89963,butyrylglycine,A N-acylglycine obtained by formal condensation of the carboxy group of butyric acid with the amino group of glycine.,"InChI=1S/C6H11NO3/c1-2-3-5(8)7-4-6(9)10/h2-4H2,1H3,(H,7,8)(H,9,10)",N-(1-Oxobutyl)glycine,PubMed citation,9932958
5659,89970,"1-octadecanoyl-2,3-dioleoyl-sn-glycerol",A triacyl-sn-glycerol in which the 1-acyl group is octadecanoyl while the 2- and 3-acyl groups are oleoyl.,"InChI=1S/C57H106O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-55(58)61-52-54(63-57(60)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)53-62-56(59)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h25,27-28,30,54H,4-24,26,29,31-53H2,1-3H3/b28-25-,30-27-/t54-/m0/s1",TG(18:0/18:1/18:1),PubMed citation,20671299
5660,90007,N-[(9Z)-3-hydroxyhexadec-9-enoyl]sphingosine-1-phosphocholine,An N-hydroxyhexadecenoylsphingosine-1-phosphocholine in which the N-acyl group is specified as (9Z)-3-hydroxyhexadec-9-enoyl.,"InChI=1S/C39H77N2O7P/c1-6-8-10-12-14-16-18-19-21-23-25-27-29-31-38(43)37(35-48-49(45,46)47-33-32-41(3,4)5)40-39(44)34-36(42)30-28-26-24-22-20-17-15-13-11-9-7-2/h17,20,29,31,36-38,42-43H,6-16,18-19,21-28,30,32-35H2,1-5H3,(H-,40,44,45,46)/b20-17-,31-29+/t36?,37-,38+/m0/s1",C16:1-OH Sphingomyelin,PubMed citation,24023812
5661,90038,monoisobutyl phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of isobutanol.,"InChI=1S/C12H14O4/c1-8(2)7-16-12(15)10-6-4-3-5-9(10)11(13)14/h3-6,8H,7H2,1-2H3,(H,13,14)",Monoisobutyl phthalic acid,HMDB accession,HMDB0002056
5662,90098,"(2S,4R)-rose oxide","A rose oxide that has S configuration at position 2 and R configuration at position 4. Also known as (-)-cis-rose oxide, it is responsible for the characteristic fragrance of roses.","InChI=1S/C10H18O/c1-8(2)6-10-7-9(3)4-5-11-10/h6,9-10H,4-5,7H2,1-3H3/t9-,10-/m1/s1",(-)-cis-rose oxide,CAS Registry Number,3033-23-6
5663,90100,"(2R,4R)-rose oxide",A rose oxide in which both of the stereocentres have R configuration. It is also known as (-)-trans-rose oxide.,"InChI=1S/C10H18O/c1-8(2)6-10-7-9(3)4-5-11-10/h6,9-10H,4-5,7H2,1-3H3/t9-,10+/m1/s1","(2R,4R)-(-)-4-methyl-2-(2-methylprop-1-en-1-yl)tetrahydro-2H-pyran",CAS Registry Number,5258-11-7
5664,90106,gallocyanin,"An organic chloride salt composed of 1-carboxy-7-(dimethylamino)-3,4-dihydroxyphenoxazin-5-ium and chloride ions in a 1:1 ratio. A histological dye used in solution with an iron alum mordant as a hematoxylin substitute in the H&E stain.","InChI=1S/C15H12N2O5.ClH/c1-17(2)7-3-4-9-11(5-7)22-14-12(16-9)8(15(20)21)6-10(18)13(14)19;/h3-6H,1-2H3,(H2-,16,18,19,20,21);1H",Mordant blue 10,CAS Registry Number,1562-85-2
5665,90107,gallocyanin(1+),"An organic cation that is 3,4-dihydroxyphenoxazin-5-ium carrying additional carboxy and dimethylamino groups at positions 1 and 7 respectively. The chloride salt is the histological dye 'gallocyanin'.","InChI=1S/C15H12N2O5/c1-17(2)7-3-4-9-11(5-7)22-14-12(16-9)8(15(20)21)6-10(18)13(14)19/h3-6H,1-2H3,(H2-,16,18,19,20,21)/p+1",gallocyanin cation,Reaxys Registry Number,4003912
5666,90108,Methyl violet 2B,A hydrochloride obtained by combining Methyl violet 2B free base with one equivalent of hydrochloric acid. Used in Gram's stain for the demonstration and primary classification of bacteria as well as to demonstrate amyloid.,"InChI=1S/C23H25N3.ClH/c1-25(2)21-13-7-18(8-14-21)23(17-5-11-20(24)12-6-17)19-9-15-22(16-10-19)26(3)4;/h5-16,24H,1-4H3;1H",C.I. 42535,Reaxys Registry Number,24690838
5667,90112,Guinee green B,"An organic sodium salt having 3-[(ethyl{4-[(4-{ethyl[(3-sulfonatophenyl)methyl]amino}phenyl)(phenyl)methylidene]cyclohexa-2,5-dien-1-ylidene}azaniumyl)methyl]benzene-1-sulfonate. Used as a substitute for Light green SF yellowish in Masson's trichrome, although it is prone to fade. Previously used as a food dye but is now no longer approved.","InChI=1S/C37H36N2O6S2.Na/c1-3-38(26-28-10-8-14-35(24-28)46(40,41)42)33-20-16-31(17-21-33)37(30-12-6-5-7-13-30)32-18-22-34(23-19-32)39(4-2)27-29-11-9-15-36(25-29)47(43,44)45;/h5-25H,3-4,26-27H2,1-2H3,(H-,40,41,42,43,44,45);/q;+1/p-1",C.I. 42085,Reaxys Registry Number,5716108
5668,90116,hematein,"An organic heterotetracyclic compound that is -6a,7-dihydrobenzo[b]indeno[1,2-d]pyran-9-one carrying four hydroxy substituents at positions 3, 4, 6a and 10.","InChI=1S/C16H12O6/c17-10-2-1-8-13-9-4-12(19)11(18)3-7(9)5-16(13,21)6-22-15(8)14(10)20/h1-4,17,19-21H,5-6H2",C.I. 75290,CAS Registry Number,475-25-2
5669,90117,indigo carmine (acid form),"A member of the class of indolones obtained by formal 2,2'-oxidative coupling of two molecules of 3-oxo-2,3-dihydroindole-5-sulfonic acids.","InChI=1S/C16H10N2O8S2/c19-15-9-5-7(27(21,22)23)1-3-11(9)17-13(15)14-16(20)10-6-8(28(24,25)26)2-4-12(10)18-14/h1-6,17-18H,(H,21,22,23)(H,24,25,26)/b14-13+",indigo carmine free acid,CAS Registry Number,483-20-5
5670,90126,N-(p-nitrophenyl)-beta-alaninamide,A beta-alanine derivative that is the amide obtained by formal condensation of the carboxy group of beta-alanine with the amino group of 4-nitroaniline.,"InChI=1S/C9H11N3O3/c10-6-5-9(13)11-7-1-3-8(4-2-7)12(14)15/h1-4H,5-6,10H2,(H,11,13)",beta-alanine 4-nitroanilide,Reaxys Registry Number,4686004
5671,90130,4-methylumbelliferyl alpha-L-arabinoside,An alpha-L-arabinopyranoside  having a 4-methylumbelliferyl substituent at the anomeric position,"InChI=1S/C15H16O7/c1-7-4-12(17)22-11-5-8(2-3-9(7)11)21-15-14(19)13(18)10(16)6-20-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13-,14+,15-/m0/s1",4-methylumbelliferyl alpha-L-arabinopyranoside,CAS Registry Number,69414-26-2
5672,90136,4-nitrophenyl alpha-D-xyloside,A xyloside that is alpha-D-xylopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C11H13NO7/c13-8-5-18-11(10(15)9(8)14)19-7-3-1-6(2-4-7)12(16)17/h1-4,8-11,13-15H,5H2/t8-,9+,10-,11-/m1/s1",p-nitrophenyl alpha-D-xyloside,CAS Registry Number,10238-28-5
5673,90143,N-amidinoaspartic acid,An aspartic acid derivative comprising aspartic acid carrying an N-amidino substituent.,"InChI=1S/C5H9N3O4/c6-5(7)8-2(4(11)12)1-3(9)10/h2H,1H2,(H,9,10)(H,11,12)(H4,6,7,8)",guanidinosuccinic acid,Reaxys Registry Number,1726857
5674,90145,2-naphthol AS BI-beta-D-glucuronide,A beta-D-glucosiduronic acid having a 6-bromo-3-[(2-methoxyphenyl)carbamoyl]naphthalen-2-yl substituent at the anomeric position.,"InChI=1S/C24H22BrNO9/c1-33-16-5-3-2-4-15(16)26-22(30)14-9-12-8-13(25)7-6-11(12)10-17(14)34-24-20(29)18(27)19(28)21(35-24)23(31)32/h2-10,18-21,24,27-29H,1H3,(H,26,30)(H,31,32)/t18-,19-,20+,21-,24+/m0/s1",beta-D-glucuronosylnaphthol AS BI,Reaxys Registry Number,6883214
5675,90146,4-nitrophenyl beta-D-glucuronide,A beta-D-glucosiduronic acid having a 4-nitrophenyl substituent at the anomeric position.,"InChI=1S/C12H13NO9/c14-7-8(15)10(11(17)18)22-12(9(7)16)21-6-3-1-5(2-4-6)13(19)20/h1-4,7-10,12,14-16H,(H,17,18)/t7-,8-,9+,10-,12+/m0/s1",p-nitrophenyl beta-D-glucuronide,CAS Registry Number,10344-94-2
5676,90148,4-nitrophenyl beta-D-xyloside,A xyloside that is beta-D-xylopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C11H13NO7/c13-8-5-18-11(10(15)9(8)14)19-7-3-1-6(2-4-7)12(16)17/h1-4,8-11,13-15H,5H2/t8-,9+,10-,11+/m1/s1",p-nitrophenyl beta-D-xylopyranoside,CAS Registry Number,2001-96-9
5677,90150,2-naphthyl butyrate,A butyrate ester obtained by formal condensation of the carboxy group of butyric acid with the hydroxy group of 2-naphthol.,"InChI=1S/C14H14O2/c1-2-5-14(15)16-13-9-8-11-6-3-4-7-12(11)10-13/h3-4,6-10H,2,5H2,1H3",2-naphthyl butanoate,Reaxys Registry Number,1959754
5678,90152,"2,3-epoxymenatetrenone","A member of the class of tetralins obtained by formal epoxidation across the 2,3-double bond of menatetrenone.","InChI=1S/C31H40O3/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-31-29(33)27-19-8-7-18-26(27)28(32)30(31,6)34-31/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+","2,3-epoxymenaquinone-4",Reaxys Registry Number,8173479
5679,90156,2-methylhexanoyl-CoA(4-),A methyl-branched fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate functions of 2-methylhexanoyl-CoA; major species at pH 7.3.,"InChI=1S/C28H48N7O17P3S/c1-5-6-7-16(2)27(40)56-11-10-30-18(36)8-9-31-25(39)22(38)28(3,4)13-49-55(46,47)52-54(44,45)48-12-17-21(51-53(41,42)43)20(37)26(50-17)35-15-34-19-23(29)32-14-33-24(19)35/h14-17,20-22,26,37-38H,5-13H2,1-4H3,(H,30,36)(H,31,39)(H,44,45)(H,46,47)(H2,29,32,33)(H2,41,42,43)/p-4/t16?,17-,20-,21-,22+,26-/m1/s1",2-methylcaproyl-CoA(4-),PubMed citation,7698750
5680,90160,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a pentadecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues (one of which is at the reducing end) all linked in sequence (1->4), to the mannosyl residue of which are linked (1->3) and (1->6) two N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear hexasaccharide units.","InChI=1S/C106H176N8O76/c1-24(129)107-47-66(148)79(40(17-123)163-92(47)161)178-95-50(110-27(4)132)67(149)84(41(18-124)172-95)183-104-78(160)89(188-106-91(73(155)58(140)35(12-118)171-106)190-99-54(114-31(8)136)71(153)83(45(22-128)176-99)182-103-77(159)88(62(144)39(16-122)169-103)187-97-52(112-29(6)134)69(151)81(43(20-126)174-97)180-101-75(157)86(60(142)37(14-120)167-101)185-94-49(109-26(3)131)65(147)56(138)33(10-116)165-94)63(145)46(177-104)23-162-105-90(72(154)57(139)34(11-117)170-105)189-98-53(113-30(7)135)70(152)82(44(21-127)175-98)181-102-76(158)87(61(143)38(15-121)168-102)186-96-51(111-28(5)133)68(150)80(42(19-125)173-96)179-100-74(156)85(59(141)36(13-119)166-100)184-93-48(108-25(2)130)64(146)55(137)32(9-115)164-93/h32-106,115-128,137-161H,9-23H2,1-8H3,(H,107,129)(H,108,130)(H,109,131)(H,110,132)(H,111,133)(H,112,134)(H,113,135)(H,114,136)/t32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60+,61+,62+,63-,64-,65-,66-,67-,68-,69-,70-,71-,72+,73+,74-,75-,76-,77-,78+,79-,80-,81-,82-,83-,84-,85+,86+,87+,88+,89+,90+,91+,92-,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106-/m1/s1",GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,25568069
5681,90161,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a heptadecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues (one of which is at the reducing end) all linked in sequence (1->4), to the mannosyl residue of which are linked (1->3) and (1->6) two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear heptasaccharide units.","InChI=1S/C118H196N8O86/c1-26(143)119-51-68(160)87(42(17-135)181-102(51)179)198-103-52(120-27(2)144)69(161)94(45(20-138)190-103)205-116-86(178)99(210-118-101(79(171)62(154)37(12-130)189-118)212-109-58(126-33(8)150)75(167)93(49(24-142)196-109)204-115-85(177)98(66(158)41(16-134)187-115)209-107-56(124-31(6)148)73(165)91(47(22-140)194-107)202-113-83(175)96(64(156)39(14-132)185-113)207-105-54(122-29(4)146)71(163)89(44(19-137)192-105)200-111-81(173)77(169)60(152)35(10-128)183-111)67(159)50(197-116)25-180-117-100(78(170)61(153)36(11-129)188-117)211-108-57(125-32(7)149)74(166)92(48(23-141)195-108)203-114-84(176)97(65(157)40(15-133)186-114)208-106-55(123-30(5)147)72(164)90(46(21-139)193-106)201-112-82(174)95(63(155)38(13-131)184-112)206-104-53(121-28(3)145)70(162)88(43(18-136)191-104)199-110-80(172)76(168)59(151)34(9-127)182-110/h34-118,127-142,151-179H,9-25H2,1-8H3,(H,119,143)(H,120,144)(H,121,145)(H,122,146)(H,123,147)(H,124,148)(H,125,149)(H,126,150)/t34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59+,60+,61-,62-,63+,64+,65+,66+,67-,68-,69-,70-,71-,72-,73-,74-,75-,76+,77+,78+,79+,80-,81-,82-,83-,84-,85-,86+,87-,88-,89-,90-,91-,92-,93-,94-,95+,96+,97+,98+,99+,100+,101+,102-,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118-/m1/s1",Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,25568069
5682,90166,alpha-Neup5Gc-(2->8)-alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc,"A linear amino tetrasaccharide comprising two alpha-N-glycoloylneuraminyl residues, a beta-D-galactose residue and (at the reducing end) an N-acetyl-D-glucosamine residue, linked sequentially (2->8), (2->3) and (1->4).","InChI=1S/C36H59N3O29/c1-10(46)37-21-25(55)27(16(7-43)62-31(21)57)64-32-26(56)30(23(53)14(5-41)63-32)68-36(34(60)61)3-12(48)20(39-18(51)9-45)29(67-36)24(54)15(6-42)65-35(33(58)59)2-11(47)19(38-17(50)8-44)28(66-35)22(52)13(49)4-40/h11-16,19-32,40-45,47-49,52-57H,2-9H2,1H3,(H,37,46)(H,38,50)(H,39,51)(H,58,59)(H,60,61)/t11-,12-,13+,14+,15+,16+,19+,20+,21+,22+,23-,24+,25+,26+,27+,28+,29+,30-,31?,32-,35+,36-/m0/s1",alpha-N-glycoloylneuraminyl-(2->8)-alpha-N-glycoloylneuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-D-glucosamine,PubMed citation,25568069
5683,90169,alpha-Neup5Ac-(2->8)-alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc,"A linear amino tetrasaccharide comprising an alpha-N-acetylneuraminyl residue, an alpha-N-glycoloylneuraminyl residue, a beta-D-galactose residue and (at the reducing end) an N-acetyl-D-glucosamine residue, linked sequentially (2->8), (2->3) and (1->4).","InChI=1S/C36H59N3O28/c1-10(45)37-19-12(47)3-35(33(57)58,65-28(19)22(51)14(49)5-40)64-16(7-42)24(53)29-20(39-18(50)9-44)13(48)4-36(66-29,34(59)60)67-30-23(52)15(6-41)62-32(26(30)55)63-27-17(8-43)61-31(56)21(25(27)54)38-11(2)46/h12-17,19-32,40-44,47-49,51-56H,3-9H2,1-2H3,(H,37,45)(H,38,46)(H,39,50)(H,57,58)(H,59,60)/t12-,13-,14+,15+,16+,17+,19+,20+,21+,22+,23-,24+,25+,26+,27+,28+,29+,30-,31?,32-,35+,36-/m0/s1",alpha-Neu5Ac-(2->8)-alpha-Neu5Gc-(2->3)-beta-D-Gal-(1->4)-D-GlcNAc,PubMed citation,25568069
5684,90171,2-hydro-beta-NAD,"An NADP obtained by formal reduction of the 1,2-position in the pyridine ring of beta-NAD.","InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-3,7-8,10-11,13-16,20-21,29-32H,4-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1",2-HNAD,MetaCyc accession,CPD-18088
5685,90173,6-hydro-beta-NADP,"An NADP obtained by formal reduction of the 1,6-position in the pyridine ring of beta-NADP.","InChI=1S/C21H30N7O17P3/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(44-46(33,34)35)14(30)11(43-21)6-41-48(38,39)45-47(36,37)40-5-10-13(29)15(31)20(42-10)27-3-1-2-9(4-27)18(23)32/h1-2,4,7-8,10-11,13-16,20-21,29-31H,3,5-6H2,(H2,23,32)(H,36,37)(H,38,39)(H2,22,24,25)(H2,33,34,35)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1",6-NADPH,MetaCyc accession,CPD-18084
5686,90174,6-hydro-beta-NAD,"An NADP obtained by formal reduction of the 1,6-position in the pyridine ring of beta-NAD.","InChI=1S/C21H29N7O14P2/c22-17-12-19(25-7-24-17)28(8-26-12)21-16(32)14(30)11(41-21)6-39-44(36,37)42-43(34,35)38-5-10-13(29)15(31)20(40-10)27-3-1-2-9(4-27)18(23)33/h1-2,4,7-8,10-11,13-16,20-21,29-32H,3,5-6H2,(H2,23,33)(H,34,35)(H,36,37)(H2,22,24,25)/t10-,11-,13-,14-,15-,16-,20-,21-/m1/s1",6-hydro-beta-nicotinamide adenine dinucleotide,Reaxys Registry Number,23703692
5687,90175,alpha-Neup5Gc-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc,"A linear amino tetrasaccharide comprising an alpha-N-glycoloylneuraminyl residue, an alpha-N-acetylneuraminyl residue, a beta-D-galactose residue and (at the reducing end) an N-acetyl-D-glucosamine residue, linked sequentially (2->8), (2->3) and (1->4).","InChI=1S/C36H59N3O28/c1-10(45)37-19-12(47)4-36(34(59)60,67-30-23(52)15(6-41)62-32(26(30)55)63-27-17(8-43)61-31(56)21(25(27)54)38-11(2)46)66-29(19)24(53)16(7-42)64-35(33(57)58)3-13(48)20(39-18(50)9-44)28(65-35)22(51)14(49)5-40/h12-17,19-32,40-44,47-49,51-56H,3-9H2,1-2H3,(H,37,45)(H,38,46)(H,39,50)(H,57,58)(H,59,60)/t12-,13-,14+,15+,16+,17+,19+,20+,21+,22+,23-,24+,25+,26+,27+,28+,29+,30-,31?,32-,35+,36-/m0/s1",Neu5Gcalpha2-8Neu5Acalpha2-3Galbeta1-4GlcNAc,PubMed citation,25568069
5688,90178,alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-D-GlcpNAc,"A linear amino tetrasaccharide comprising two N-acetyl-alpha-neuraminyl residues, a beta-D-galactose residue and (at the reducing end) an N-acetyl-D-glucosamine residue, linked sequentially (2->8), (2->3) and (1->4).","InChI=1S/C36H59N3O27/c1-10(44)37-19-13(47)4-35(33(56)57,64-28(19)22(50)15(49)6-40)63-17(8-42)24(52)29-20(38-11(2)45)14(48)5-36(65-29,34(58)59)66-30-23(51)16(7-41)61-32(26(30)54)62-27-18(9-43)60-31(55)21(25(27)53)39-12(3)46/h13-32,40-43,47-55H,4-9H2,1-3H3,(H,37,44)(H,38,45)(H,39,46)(H,56,57)(H,58,59)/t13-,14-,15+,16+,17+,18+,19+,20+,21+,22+,23-,24+,25+,26+,27+,28+,29+,30-,31?,32-,35+,36-/m0/s1",Neu5Acalpha2-8Neu5Acalpha2-3Galbeta1-4GlcNAc,PubMed citation,25568069
5689,90179,iodine green,"An iminium salt composed of (4-{[4-(dimethylamino)-3-methylphenyl][4-(trimethylazaniumyl)phenyl]methylidene}cyclohexa-2,5-dien-1-ylidene)(dimethyl)ammonium and chloride ions in a 1:2 ratio. A histological dye used for staining chromatin and amyloid.","InChI=1S/C27H35N3.2ClH/c1-20-19-23(13-18-26(20)29(4)5)27(21-9-14-24(15-10-21)28(2)3)22-11-16-25(17-12-22)30(6,7)8;;/h9-19H,1-8H3;2*1H/q+2;;/p-2",C.I. 42556,CAS Registry Number,33231-00-4
5690,90183,kermesic acid,"A tetrahydroxyanthraquinone that is that is 3,5,6,8-tetrahydroxy-9,10-anthraquinone substituted by methyl and carboxy groups at positions 1 and 2 respectively. It is a natural dye isolated from the insect species Kermes ilices.","InChI=1S/C16H10O8/c1-4-9-5(2-6(17)10(4)16(23)24)13(20)12-11(15(9)22)7(18)3-8(19)14(12)21/h2-3,17-19,21H,1H3,(H,23,24)",kermes,CAS Registry Number,18499-92-8
5691,90198,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"An amino oligosaccharide that is an undecasaccharide derivative in which two tetrasaccharide branches, each formed from alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannose, are linked (1->3) and (1->6) to the mannose residue of a trisaccharide chain consisting of mannose and two N-acetylglucosamine residues all linked beta(1->4) with an unspecified configuration of the anomeric carbon of the N-acetylglucosamine residue at the reducing end.","InChI=1S/C74H124N4O56/c1-16(89)75-31-42(100)55(26(11-85)115-64(31)113)126-65-32(76-17(2)90)43(101)58(27(12-86)122-65)129-72-54(112)61(132-74-63(49(107)38(96)23(8-82)121-74)134-67-34(78-19(4)92)45(103)57(29(14-88)124-67)128-71-53(111)60(40(98)25(10-84)119-71)131-69-51(109)47(105)36(94)21(6-80)117-69)41(99)30(125-72)15-114-73-62(48(106)37(95)22(7-81)120-73)133-66-33(77-18(3)91)44(102)56(28(13-87)123-66)127-70-52(110)59(39(97)24(9-83)118-70)130-68-50(108)46(104)35(93)20(5-79)116-68/h20-74,79-88,93-113H,5-15H2,1-4H3,(H,75,89)(H,76,90)(H,77,91)(H,78,92)/t20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35+,36+,37-,38-,39+,40+,41-,42-,43-,44-,45-,46+,47+,48+,49+,50-,51-,52-,53-,54+,55-,56-,57-,58-,59+,60+,61+,62+,63+,64?,65+,66+,67+,68-,69-,70+,71+,72+,73+,74-/m1/s1",alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-beta-D-mannosyl-(1->3)-[alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-beta-D-mannosyl-(1->6)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine,PubMed citation,25568069
5692,90200,lissamine fast red,An organic sodium salt that is the disodium salt of 5-[(4-acetamido-2-sulfophenyl)diazenyl]-6-amino-4-hydroxynaphthalene-2-sulfonic acid. Used along with acid fuchsin as a constituent of the plasma staining solution in Lendrum's Picro-Mallory for fibrin.,"InChI=1S/C18H16N4O8S2.2Na/c1-9(23)20-11-3-5-14(16(7-11)32(28,29)30)21-22-18-13(19)4-2-10-6-12(31(25,26)27)8-15(24)17(10)18;;/h2-8,24H,19H2,1H3,(H,20,23)(H,25,26,27)(H,28,29,30);;/q;2*+1/p-2",acid red 37,CAS Registry Number,6360-07-2
5693,90204,lissamine fast red (acid form),A naphthalenesulfonic acid that is 6-aminonaphthalene-2-sulfonic acid carrying additional hydroxy and (4-acetamido-2-sulfophenyl)diazenyl substituents at positions 4 and 5 respectively. The disodium salt is the biological stain 'lissamine fast red'.,"InChI=1S/C18H16N4O8S2/c1-9(23)20-11-3-5-14(16(7-11)32(28,29)30)21-22-18-13(19)4-2-10-6-12(31(25,26)27)8-15(24)17(10)18/h2-8,24H,19H2,1H3,(H,20,23)(H,25,26,27)(H,28,29,30)",Lissamine fast red free acid,CAS Registry Number,25317-34-4
5694,90206,lissamine fast yellow,"An organic sodium salt that is the disodium salt of 2,5-dichloro-4-{5-hydroxy-3-methyl-4-[(4-sulfophenyl)diazenyl]pyrazol-1-yl}benzene-1-sulfonic acid. It is used as the erythrocyte stain in Garvey's method for elastic, fibrin and collagen as well as a substitute for martius yellow in Lendrum's MSB.","InChI=1S/C16H12Cl2N4O7S2.2Na/c1-8-15(20-19-9-2-4-10(5-3-9)30(24,25)26)16(23)22(21-8)13-6-12(18)14(7-11(13)17)31(27,28)29;;/h2-7,23H,1H3,(H,24,25,26)(H,27,28,29);;/q;2*+1/p-2",C.I. 18965,CAS Registry Number,6359-98-4
5695,90207,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc,A linear amino tetrasaccharide consisting of two N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosamine disaccharide units linked (1->3).,"InChI=1S/C32H54N4O21/c1-9(41)33-17-24(48)26(15(7-39)51-29(17)50)56-32-20(36-12(4)44)28(22(46)14(6-38)53-32)57-31-19(35-11(3)43)25(49)27(16(8-40)54-31)55-30-18(34-10(2)42)23(47)21(45)13(5-37)52-30/h13-32,37-40,45-50H,5-8H2,1-4H3,(H,33,41)(H,34,42)(H,35,43)(H,36,44)/t13-,14-,15-,16-,17-,18-,19-,20-,21+,22+,23-,24-,25-,26-,27-,28-,29-,30+,31+,32+/m1/s1",GalNAcb1-4GlcNAcb1-3GalNAcb1-4GlcNAcb,PubMed citation,25568069
5696,90208,lissamine fast yellow(2-),"An organosulfonate oxoanion resulting from the removal of a proton from both of the sulfo groups of 2,5-dichloro-4-{5-hydroxy-3-methyl-4-[(4-sulfophenyl)diazenyl]pyrazol-1-yl}benzene-1-sulfonic acid.","InChI=1S/C16H12Cl2N4O7S2/c1-8-15(20-19-9-2-4-10(5-3-9)30(24,25)26)16(23)22(21-8)13-6-12(18)14(7-11(13)17)31(27,28)29/h2-7,23H,1H3,(H,24,25,26)(H,27,28,29)/p-2",lissamine fast yellow dianion,Reaxys Registry Number,8171654
5697,90211,Luxol fast blue MBS,"A guanidinium salt that is the bis[1,3-di(2-tolyl)guanidinium] salt of a copper phthalocyanine-disulfonic acid. A dye that is soluble in alcohols and phospholipids and is used to demonstrate myelin.","InChI=1S/C32H16N8O6S2.2C15H17N3.Cu/c41-47(42,43)21-13-5-11-19-23(21)32-38-28-18-10-4-2-8-16(18)26(34-28)36-30-20-12-6-14-22(48(44,45)46)24(20)31(40-30)37-27-17-9-3-1-7-15(17)25(33-27)35-29(19)39-32;2*1-11-7-3-5-9-13(11)17-15(16)18-14-10-6-4-8-12(14)2;/h1-14H,(H2-2,33,34,35,36,37,38,39,40,41,42,43,44,45,46);2*3-10H,1-2H3,(H3,16,17,18);/q-2;;;+2",Luxol fast blue,Wikipedia accession,Luxol_fast_blue_stain
5698,90213,beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,"A branched amino oligosaccharide that is a pentacosasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues (one of which is at the reducing end) all linked in sequence (1->4), to the mannosyl residue of which are linked (1->3) and (1->6) two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear undecasaccharide units.","InChI=1S/C174H288N12O126/c1-38(211)175-75-100(236)127(62(25-199)265-150(75)263)290-151-76(176-39(2)212)101(237)138(65(28-202)278-151)301-172-126(262)147(310-174-149(115(251)90(226)53(16-190)277-174)312-161-86(186-49(12)222)111(247)137(73(36-210)288-161)300-171-125(261)146(98(234)61(24-198)275-171)309-159-84(184-47(10)220)109(245)135(71(34-208)286-159)298-169-123(259)144(96(232)59(22-196)273-169)307-157-82(182-45(8)218)107(243)133(69(32-206)284-157)296-167-121(257)142(94(230)57(20-194)271-167)305-155-80(180-43(6)216)105(241)131(67(30-204)282-155)294-165-119(255)140(92(228)55(18-192)269-165)303-153-78(178-41(4)214)103(239)129(64(27-201)280-153)292-163-117(253)113(249)88(224)51(14-188)267-163)99(235)74(289-172)37-264-173-148(114(250)89(225)52(15-189)276-173)311-160-85(185-48(11)221)110(246)136(72(35-209)287-160)299-170-124(260)145(97(233)60(23-197)274-170)308-158-83(183-46(9)219)108(244)134(70(33-207)285-158)297-168-122(258)143(95(231)58(21-195)272-168)306-156-81(181-44(7)217)106(242)132(68(31-205)283-156)295-166-120(256)141(93(229)56(19-193)270-166)304-154-79(179-42(5)215)104(240)130(66(29-203)281-154)293-164-118(254)139(91(227)54(17-191)268-164)302-152-77(177-40(3)213)102(238)128(63(26-200)279-152)291-162-116(252)112(248)87(223)50(13-187)266-162/h50-174,187-210,223-263H,13-37H2,1-12H3,(H,175,211)(H,176,212)(H,177,213)(H,178,214)(H,179,215)(H,180,216)(H,181,217)(H,182,218)(H,183,219)(H,184,220)(H,185,221)(H,186,222)/t50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87+,88+,89-,90-,91+,92+,93+,94+,95+,96+,97+,98+,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112+,113+,114+,115+,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126+,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150-,151+,152+,153+,154+,155+,156+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174-/m1/s1",beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,PubMed citation,25568069
5699,90223,RU 58668,"A 17beta-hydroxy steroid that is 17beta-estradiol in the the hydrogen at the 11beta position has been replaced by a p-({5-[(4,4,5,5,5-pentafluoropentyl)sulfonyl]pentyl}oxy)phenyl group. RU 58668 is a pure anti-estrogen that downregulates estrogen receptor expression (IC50 = 0.04 nM).","InChI=1S/C34H43F5O5S/c1-32-21-28(31-26-13-9-24(40)20-23(26)8-12-27(31)29(32)14-15-30(32)41)22-6-10-25(11-7-22)44-17-3-2-4-18-45(42,43)19-5-16-33(35,36)34(37,38)39/h6-7,9-11,13,20,27-31,40-41H,2-5,8,12,14-19,21H2,1H3/t27-,28+,29-,30-,31+,32-/m0/s1",RU-58668,CAS Registry Number,151555-47-4
5700,90224,2-methylhexanoyl-CoA,A medium-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-methylhexanoic acid.,"InChI=1S/C28H48N7O17P3S/c1-5-6-7-16(2)27(40)56-11-10-30-18(36)8-9-31-25(39)22(38)28(3,4)13-49-55(46,47)52-54(44,45)48-12-17-21(51-53(41,42)43)20(37)26(50-17)35-15-34-19-23(29)32-14-33-24(19)35/h14-17,20-22,26,37-38H,5-13H2,1-4H3,(H,30,36)(H,31,39)(H,44,45)(H,46,47)(H2,29,32,33)(H2,41,42,43)/t16?,17-,20-,21-,22+,26-/m1/s1",2-methylhexanoyl-coenzyme A,HMDB accession,HMDB0011660
5701,90236,"(2E,6E)-farnesyl monophosphate","A member of the class of farnesyl phosphates that is the monophosphatr derivative of (2E,6E)-farnesol","InChI=1S/C15H27O4P/c1-13(2)7-5-8-14(3)9-6-10-15(4)11-12-19-20(16,17)18/h7,9,11H,5-6,8,10,12H2,1-4H3,(H2,16,17,18)/b14-9+,15-11+","(2E,6E)-farnesol monophosphate",KEGG COMPOUND accession,C20121
5702,90238,beta-Gal-(1->3)-beta-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer(d18:1/18:0),A beta-Gal-(1->3)-beta-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer in which the ceramide N-acyl group is specified as octadecanoyl.,"InChI=1S/C84H148N4O39/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-58(102)88-48(49(98)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2)44-116-78-69(110)67(108)71(56(42-93)119-78)121-80-70(111)76(72(57(43-94)120-80)122-77-61(87-47(5)97)73(64(105)54(40-91)117-77)123-79-68(109)66(107)63(104)53(39-90)118-79)127-84(82(114)115)37-51(100)60(86-46(4)96)75(126-84)65(106)55(41-92)124-83(81(112)113)36-50(99)59(85-45(3)95)74(125-83)62(103)52(101)38-89/h32,34,48-57,59-80,89-94,98-101,103-111H,6-31,33,35-44H2,1-5H3,(H,85,95)(H,86,96)(H,87,97)(H,88,102)(H,112,113)(H,114,115)/b34-32+/t48-,49+,50-,51-,52+,53+,54+,55+,56+,57+,59+,60+,61+,62+,63-,64-,65+,66-,67+,68+,69+,70+,71+,72-,73+,74+,75+,76+,77-,78+,79-,80-,83+,84-/m0/s1",GD1b(d18:1/18:0),Reaxys Registry Number,3561992
5703,90242,caffeic acid 3-sulfate,An aryl sulfate that is trans-caffeic acid in which the phenolic hydrogen at position 3 is replaced by a sulfo group. A metabolite from coffee.,"InChI=1S/C9H8O7S/c10-7-3-1-6(2-4-9(11)12)5-8(7)16-17(13,14)15/h1-5,10H,(H,11,12)(H,13,14,15)/b4-2+",caffeic acid 3-sulphate,Reaxys Registry Number,6603942
5704,90243,beta-D-Galp-(1->3)-[beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->6)]-beta-GalpNAc,"A branched amino tetrasaccharide consisting of a linear trisaccharide of beta-D-galactose, N-acetyl-beta-D-glucosamine and (at the reducing end) N-acetyl-D-galactosamine residues linked sequentially (1->3) and (1->6), to the N-acetyl-D-galactosamine residue of which is also linked (1->3) a further beta-D-galactose residue.","InChI=1S/C28H48N2O21/c1-7(34)29-13-23(50-27-21(42)19(40)15(36)9(3-31)48-27)18(39)12(46-25(13)44)6-45-26-14(30-8(2)35)24(17(38)11(5-33)47-26)51-28-22(43)20(41)16(37)10(4-32)49-28/h9-28,31-33,36-44H,3-6H2,1-2H3,(H,29,34)(H,30,35)/t9-,10-,11-,12-,13-,14-,15+,16+,17-,18+,19+,20+,21-,22-,23-,24-,25?,26-,27+,28+/m1/s1",beta-D-Gal-(1->3)-[beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->6)]-beta-GalNAc,PubMed citation,25568069
5705,90247,5-bromo-3-hydroxyindole,A member of the class of hydroxyindoles that is indoxyl carrying an additional bromo substituent at position 5.,"InChI=1S/C8H6BrNO/c9-5-1-2-7-6(3-5)8(11)4-10-7/h1-4,10-11H",5-bromoindoxyl,Reaxys Registry Number,1450226
5706,90248,5-bromo-3-indolyl decanoate,An decanoate ester obtained by formal condensation of the carboxy group of decanoic acid with the hydroxy group of 5-bromoindoxyl.,"InChI=1S/C18H24BrNO2/c1-2-3-4-5-6-7-8-9-18(21)22-17-13-20-16-11-10-14(19)12-15(16)17/h10-13,20H,2-9H2,1H3",5-bromo-3-indolyl caprate,Reaxys Registry Number,4195226
5707,90253,4-nitrophenyl alpha-L-fucoside,An alpha-L-fucoside that is alpha-L-fucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C12H15NO7/c1-6-9(14)10(15)11(16)12(19-6)20-8-4-2-7(3-5-8)13(17)18/h2-6,9-12,14-16H,1H3/t6-,9+,10+,11-,12-/m0/s1",p-nitrophenyl alpha-L-fucoside,CAS Registry Number,10231-84-2
5708,90255,4-nitrophenyl beta-L-fucoside,A beta-L-fucoside that is beta-L-fucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C12H15NO7/c1-6-9(14)10(15)11(16)12(19-6)20-8-4-2-7(3-5-8)13(17)18/h2-6,9-12,14-16H,1H3/t6-,9+,10+,11-,12+/m0/s1",p-nitrophenyl beta-L-fucoside,CAS Registry Number,22153-71-5
5709,90259,4-nitrophenyl beta-D-glucoside,A beta-D-glucoside that is beta-D-glucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C12H15NO8/c14-5-8-9(15)10(16)11(17)12(21-8)20-7-3-1-6(2-4-7)13(18)19/h1-4,8-12,14-17H,5H2/t8-,9-,10+,11-,12-/m1/s1",p-nitrophenyl beta-D-glucoside,Reaxys Registry Number,92211
5710,90260,4-nitrophenyl beta-lactoside,A disaccharide derivative that is beta-lactose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C18H25NO13/c20-5-9-11(22)12(23)14(25)18(30-9)32-16-10(6-21)31-17(15(26)13(16)24)29-8-3-1-7(2-4-8)19(27)28/h1-4,9-18,20-26H,5-6H2/t9-,10-,11+,12+,13-,14-,15-,16-,17-,18+/m1/s1",beta-D-Gal-(1->4)-beta-D-Glc-O-pNP,Reaxys Registry Number,100235
5711,90264,L-3-sulfolactaldehyde,A 3-sulfolactaldehyde in which the stereocentre at position 3 has R-configuration.,"InChI=1S/C3H6O5S/c4-1-3(5)2-9(6,7)8/h1,3,5H,2H2,(H,6,7,8)/t3-/m0/s1",(2S)-3-sulfolactaldehyde,MetaCyc accession,CPD-18718
5712,90287,Milling yellow 3G,An organic sodium salt that is the monosodium salt of 5-chloro-2-[5-hydroxy-3-methyl-4-({4-[(4-methylbenzene-1-sulfonyl)oxy]phenyl}diazenyl)-1H-pyrazol-1-yl]benzene-1-sulfonic acid.,"InChI=1S/C23H19ClN4O7S2.Na/c1-14-3-10-19(11-4-14)37(33,34)35-18-8-6-17(7-9-18)25-26-22-15(2)27-28(23(22)29)20-12-5-16(24)13-21(20)36(30,31)32;/h3-13,29H,1-2H3,(H,30,31,32);/q;+1/p-1",C.I. 18950,CAS Registry Number,6372-96-9
5713,90288,Milling yellow 3G (free acid),"An arenesulfonic acid that is 5-chloro-2-(pyrazol-1-yl)benzene-1-sulfonic acid in which the pyrazole ring is substituted by methyl, 4-(tosyloxy)phenyldiazenyl and hydroxy groups at positions 3, 4, and 5 respctively. The monosodium salt is the biological stain 'Milling yellow 3G'.","InChI=1S/C23H19ClN4O7S2/c1-14-3-10-19(11-4-14)37(33,34)35-18-8-6-17(7-9-18)25-26-22-15(2)27-28(23(22)29)20-12-5-16(24)13-21(20)36(30,31)32/h3-13,29H,1-2H3,(H,30,31,32)",Milling yellow 3G acid form,Reaxys Registry Number,968809
5714,90290,pacein,"A member of the class of benzofurans that is dibenzo[b,d]furan-3,7-dione bearing two methyl substituents at positions 1 and 9 as well as two 2,4-dihydroxy-6-methylanilino substituents at positions 2 and 8.","InChI=1S/C28H24N2O7/c1-11-5-15(31)7-17(33)25(11)29-27-13(3)23-21(9-19(27)35)37-22-10-20(36)28(14(4)24(22)23)30-26-12(2)6-16(32)8-18(26)34/h5-10,29-34H,1-4H3",NSC 610930,HMDB accession,HMDB0039777
5715,90319,Ponceau S,"An organic sodium salt that is the tetrasodium salt of 3-hydroxy-4-({2-sulfo-4-[(4-sulfophenyl)diazenyl]phenyl}diazenyl)naphthalene-2,7-disulfonic acid.","InChI=1S/C22H16N4O13S4.4Na/c27-22-20(43(37,38)39)10-12-9-16(41(31,32)33)6-7-17(12)21(22)26-25-18-8-3-14(11-19(18)42(34,35)36)24-23-13-1-4-15(5-2-13)40(28,29)30;;;;/h1-11,27H,(H,28,29,30)(H,31,32,33)(H,34,35,36)(H,37,38,39);;;;/q;4*+1/p-4",C.I. 27195,CAS Registry Number,6226-79-5
5716,90321,3-(p-nitrophenyl)propanoic acid,A monocarboxylic acid that is 3-phenylpropionic acid in which the hydrogen at the para position of the phennyl group has been replaced by a nitro group.,"InChI=1S/C9H9NO4/c11-9(12)6-3-7-1-4-8(5-2-7)10(13)14/h1-2,4-5H,3,6H2,(H,11,12)",beta-(4-nitrophenyl)propionic acid,CAS Registry Number,16642-79-8
5717,90326,Ser-Ile,A dipeptide obtained by formal condensation of the carboxy group of L-serine with the amino group of L-isoleucine.,"InChI=1S/C9H18N2O4/c1-3-5(2)7(9(14)15)11-8(13)6(10)4-12/h5-7,12H,3-4,10H2,1-2H3,(H,11,13)(H,14,15)/t5-,6-,7-/m0/s1",seryl-isoleucine,Reaxys Registry Number,1712189
5718,90328,Thr-Val,A dipeptide obtained by formal condensation of the carboxy group of L-threonine with the amino group of L-valine.,"InChI=1S/C9H18N2O4/c1-4(2)7(9(14)15)11-8(13)6(10)5(3)12/h4-7,12H,10H2,1-3H3,(H,11,13)(H,14,15)/t5-,6+,7+/m1/s1",L-Thr-L-Val,HMDB accession,HMDB0029074
5719,90329,5-bromo-4-chloro-3-hydroxyindole,A member of the class of hydroxyindoles that is indoxyl carrying additional chloro and bromo substituents at positions 4 and 5 respectively.,"InChI=1S/C8H5BrClNO/c9-4-1-2-5-7(8(4)10)6(12)3-11-5/h1-3,11-12H",3-hydroxy-4-chloro-5-bromoindole,Reaxys Registry Number,1453072
5720,90330,Val-Thr,A dipeptide obtained by formal condensation of the carboxy group of L-valine with the amino group of L-threonine.,"InChI=1S/C9H18N2O4/c1-4(2)6(10)8(13)11-7(5(3)12)9(14)15/h4-7,12H,10H2,1-3H3,(H,11,13)(H,14,15)/t5-,6+,7+/m1/s1",VT,HMDB accession,HMDB0029137
5721,90333,(E)-3-(indol-2-yl)acrylic acid,"An alpha,beta-unsaturated monocarboxylic acid that is acrylic acid in which one of the hydrogens at position 3 is replaced by an indol-2-yl group.","InChI=1S/C11H9NO2/c13-11(14)6-5-9-7-8-3-1-2-4-10(8)12-9/h1-7,12H,(H,13,14)/b6-5+",indoleacrylic acid,HMDB accession,HMDB0000734
5722,90338,5-bromo-4-chloro-3-indolyl N-acetyl-beta-D-glucosaminide,"An indolyl carbohydrate that is the N-acetyl-beta-D-glucosaminide of indoxyl in which the indole moiety is substituted at positions 4 and 5 by chlorine and bromine, respectively.","InChI=1S/C16H18BrClN2O6/c1-6(22)20-13-15(24)14(23)10(5-21)26-16(13)25-9-4-19-8-3-2-7(17)12(18)11(8)9/h2-4,10,13-16,19,21,23-24H,5H2,1H3,(H,20,22)/t10-,13-,14-,15-,16-/m1/s1",5-bromo-4-chloroindoxyl N-acetyl-beta-D-glucosaminide,Reaxys Registry Number,18540961
5723,90341,4-nitrophenyl N-acetyl-alpha-D-glucosaminide,An N-acetyl-alpha-D-glucosaminide in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C14H18N2O8/c1-7(18)15-11-13(20)12(19)10(6-17)24-14(11)23-9-4-2-8(3-5-9)16(21)22/h2-5,10-14,17,19-20H,6H2,1H3,(H,15,18)/t10-,11-,12-,13-,14+/m1/s1",p-nitrophenyl N-acetyl-alpha-D-glucosaminide,CAS Registry Number,10139-02-3
5724,90343,4-nitrophenyl N-acetyl-beta-D-glucosaminide,An N-acetyl-beta-D-glucosaminide in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.,"InChI=1S/C14H18N2O8/c1-7(18)15-11-13(20)12(19)10(6-17)24-14(11)23-9-4-2-8(3-5-9)16(21)22/h2-5,10-14,17,19-20H,6H2,1H3,(H,15,18)/t10-,11-,12-,13-,14-/m1/s1",4-nitrophenyl 2-acetamido-2-deoxy-beta-D-glucoside,CAS Registry Number,3459-18-5
5725,90348,glucose 6-monomycolate (C85),A mycolate ester formed by esterification of (2R)-2-{(1R)-1-hydroxy-15-[2-(20-methoxy-21-methylnonatriacontyl)cyclopropyl]pentadecyl}hexacosanoic acid with the 6-OH of D-glucose.,"InChI=1S/C91H178O9/c1-5-7-9-11-13-15-17-19-21-23-24-25-26-27-30-34-38-45-51-57-63-69-75-83(90(96)99-79-86-87(93)88(94)89(95)91(97)100-86)84(92)76-70-64-58-52-46-41-40-44-50-56-62-68-74-82-78-81(82)73-67-61-55-49-43-37-33-29-28-31-35-39-47-53-59-65-71-77-85(98-4)80(3)72-66-60-54-48-42-36-32-22-20-18-16-14-12-10-8-6-2/h80-89,91-95,97H,5-79H2,1-4H3/t80?,81?,82?,83-,84-,85?,86-,87-,88+,89-,91-/m1/s1",glucose 6-monomycolate (C85),PubMed citation,26466957
5726,90349,L-alanine 2-naphthylamide,An L-alanine derivative that is the amide obtained by formal condensation of the carboxy group of L-alanine with the amino group of 2-naphthylamine.,"InChI=1S/C13H14N2O/c1-9(14)13(16)15-12-7-6-10-4-2-3-5-11(10)8-12/h2-9H,14H2,1H3,(H,15,16)/t9-/m0/s1",L-alanine beta-naphthylamide,CAS Registry Number,720-82-1
5727,90350,L-arginine 2-naphthylamide,An L-arginine derivative that is the amide obtained by formal condensation of the carboxy group of L-arginine with the amino group of 2-naphthylamine.,"InChI=1S/C16H21N5O/c17-14(6-3-9-20-16(18)19)15(22)21-13-8-7-11-4-1-2-5-12(11)10-13/h1-2,4-5,7-8,10,14H,3,6,9,17H2,(H,21,22)(H4,18,19,20)/t14-/m0/s1",L-arginine beta-naphthylamide,CAS Registry Number,7182-70-9
5728,90352,L-asparagine 2-naphthylamide,An L-asparagine derivative that is the amide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of 2-naphthylamine.,"InChI=1S/C14H15N3O2/c15-12(8-13(16)18)14(19)17-11-6-5-9-3-1-2-4-10(9)7-11/h1-7,12H,8,15H2,(H2,16,18)(H,17,19)/t12-/m0/s1",L-asparagine-2-naphthylamide,Reaxys Registry Number,9137881
5729,90354,Phe-Gln,A dipeptide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of L-glutamine.,"InChI=1S/C14H19N3O4/c15-10(8-9-4-2-1-3-5-9)13(19)17-11(14(20)21)6-7-12(16)18/h1-5,10-11H,6-8,15H2,(H2,16,18)(H,17,19)(H,20,21)/t10-,11-/m0/s1",L-Phe-L-Gln,HMDB accession,HMDB0028993
5730,90362,2-methylhexenoyl-CoA,A 2-enoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-methylhexenoic acid.,"InChI=1S/C28H46N7O17P3S/c1-5-6-7-16(2)27(40)56-11-10-30-18(36)8-9-31-25(39)22(38)28(3,4)13-49-55(46,47)52-54(44,45)48-12-17-21(51-53(41,42)43)20(37)26(50-17)35-15-34-19-23(29)32-14-33-24(19)35/h7,14-15,17,20-22,26,37-38H,5-6,8-13H2,1-4H3,(H,30,36)(H,31,39)(H,44,45)(H,46,47)(H2,29,32,33)(H2,41,42,43)/t17-,20-,21-,22+,26-/m1/s1",2-methylhexenoyl-coenzyme A,PubMed citation,7698750
5731,90389,"(1R,2R,5S)-AH23848","A (4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid in which the stereocentres at positions 1, 2 and 5 have R-, R- and S-configuration respectively.","InChI=1S/C29H35NO5/c31-26-20-27(35-21-22-12-14-24(15-13-22)23-8-4-3-5-9-23)25(10-6-1-2-7-11-28(32)33)29(26)30-16-18-34-19-17-30/h1-5,8-9,12-15,25,27,29H,6-7,10-11,16-21H2,(H,32,33)/b2-1-/t25-,27-,29+/m0/s1",(-)-AH 23848,Reaxys Registry Number,11714447
5732,90396,"(3,5-dichloro-2,4,6-trihydroxyphenyl)hexan-1-one","An aromatic ketone that is phloroglucinol in which two of the hydrogens attached to the benzene ring have been replaced by chlorines while the third has been replaced by a hexanoyl group. It is the immediate biosynthetic precursor for differentiation-inducing factor 1 (DIF-1). DIF-1 is released by developing Dictyostelium amoebae, inducing them to differentiate into stalk cells.","InChI=1S/C12H14Cl2O4/c1-2-3-4-5-6(15)7-10(16)8(13)12(18)9(14)11(7)17/h16-18H,2-5H2,1H3","3,5-dichloro-THPH",PubMed citation,9446571
5733,90399,primuline,"An organic sodium salt having 2'-(4-aminophenyl)-6-methyl[2,6'-bi-1,3-benzothiazole]-7-sulfonate as the counterion.","InChI=1S/C21H15N3O3S3.Na/c1-11-2-8-16-18(19(11)30(25,26)27)29-21(24-16)13-5-9-15-17(10-13)28-20(23-15)12-3-6-14(22)7-4-12;/h2-10H,22H2,1H3,(H,25,26,27);/q;+1/p-1",direct yellow 59,CAS Registry Number,10360-31-3
5734,90406,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-GalpNAc,A branched amino nonasaccharide consisting of an alpha-D-galactosamine residue to which are attached (1->3) and (1->6) two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl tetrasaccharide branches.,"InChI=1S/C64H107N5O46/c1-15(78)65-29-39(88)49(111-63-47(96)54(36(85)22(8-72)103-63)114-59-31(67-17(3)80)41(90)50(25(11-75)107-59)109-61-45(94)43(92)34(83)20(6-70)101-61)24(10-74)105-57(29)99-14-28-38(87)53(33(56(98)100-28)69-19(5)82)113-58-30(66-16(2)79)40(89)52(27(13-77)106-58)112-64-48(97)55(37(86)23(9-73)104-64)115-60-32(68-18(4)81)42(91)51(26(12-76)108-60)110-62-46(95)44(93)35(84)21(7-71)102-62/h20-64,70-77,83-98H,6-14H2,1-5H3,(H,65,78)(H,66,79)(H,67,80)(H,68,81)(H,69,82)/t20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37+,38+,39-,40-,41-,42-,43+,44+,45-,46-,47-,48-,49-,50-,51-,52-,53-,54+,55+,56+,57-,58+,59+,60+,61+,62+,63+,64+/m1/s1",Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-6(Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3)GalNAcalpha,PubMed citation,25568069
5735,90411,pyronin B-FeCl3 complex,"An iminium salt composed of 6-(diethylamino)-N,N-diethyl-3H-xanthen-3-iminium and tetrachloroferrate ions ia 1:1 ratio. Depending on the mode of manufacture, pyronin B also exists in the form of a chloride salt.","InChI=1S/C21H27N2O.4ClH.Fe/c1-5-22(6-2)18-11-9-16-13-17-10-12-19(23(7-3)8-4)15-21(17)24-20(16)14-18;;;;;/h9-15H,5-8H2,1-4H3;4*1H;/q+1;;;;;+3/p-4",pyronin B-iron(III) chloride complex,Reaxys Registry Number,3846969
5736,90412,N-benzoyl-L-phenylalanine,An N-acyl-L-phenylalanine that is L-phenylalanine in which one of the hydrogens of the amino group has been replaced by a benzoyl group.,"InChI=1S/C16H15NO3/c18-15(13-9-5-2-6-10-13)17-14(16(19)20)11-12-7-3-1-4-8-12/h1-10,14H,11H2,(H,17,18)(H,19,20)/t14-/m0/s1",Bz-L-Phe-OH,Reaxys Registry Number,2131801
5737,90413,N-benzoyl-D-phenylalanine,A D-phenylalanine derivative that is D-phenylalanine in which one of the hydrogens of the amino group has been replaced by a benzoyl group.,"InChI=1S/C16H15NO3/c18-15(13-9-5-2-6-10-13)17-14(16(19)20)11-12-7-3-1-4-8-12/h1-10,14H,11H2,(H,17,18)(H,19,20)/t14-/m1/s1",(2R)-2-benzamido-3-phenylpropionic acid,Reaxys Registry Number,2811418
5738,90416,pyronin Y cation,An iminium ion that is the cationic component of pyronin Y.,"InChI=1S/C17H19N2O/c1-18(2)14-7-5-12-9-13-6-8-15(19(3)4)11-17(13)20-16(12)10-14/h5-11H,1-4H3/q+1",pyronin Y(1+),Reaxys Registry Number,1389025
5739,90422,L-methionine 2-naphthylamide,An L-methionine derivative that is the amide obtained by formal condensation of the carboxy group of L-methionine with the amino group of 2-naphthylamine.,"InChI=1S/C15H18N2OS/c1-19-9-8-14(16)15(18)17-13-7-6-11-4-2-3-5-12(11)10-13/h2-7,10,14H,8-9,16H2,1H3,(H,17,18)/t14-/m0/s1",L-methionine beta-naphthylamide,Reaxys Registry Number,2380981
5740,90425,N-(alpha-L-aspartyl)-2-naphthylamine,An L-aspartic acid derivative that is the amide obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the amino group of 2-naphthylamine.,"InChI=1S/C14H14N2O3/c15-12(8-13(17)18)14(19)16-11-6-5-9-3-1-2-4-10(9)7-11/h1-7,12H,8,15H2,(H,16,19)(H,17,18)/t12-/m0/s1",L-aspartic acid 2-naphthylamide,CAS Registry Number,635-91-6
5741,90426,L-cysteine 2-naphthylamide,An L-cysteine derivative that is the amide obtained by formal condensation of the carboxy group of L-cysteine with the amino group of 2-naphthylamine.,"InChI=1S/C13H14N2OS/c14-12(8-17)13(16)15-11-6-5-9-3-1-2-4-10(9)7-11/h1-7,12,17H,8,14H2,(H,15,16)/t12-/m0/s1",L-cysteine beta-naphthylamide,CAS Registry Number,65322-97-6
5742,90428,L-cystine di-2-naphthylamide,An L-cysteine derivative that is the amide obtained by formal condensation of the carboxy groups of L-cystine with the amino groups from two molecules of 2-naphthylamine.,"InChI=1S/C26H26N4O2S2/c27-23(25(31)29-21-11-9-17-5-1-3-7-19(17)13-21)15-33-34-16-24(28)26(32)30-22-12-10-18-6-2-4-8-20(18)14-22/h1-14,23-24H,15-16,27-28H2,(H,29,31)(H,30,32)/t23-,24-/m0/s1",L-cysteine di-beta-naphthylamide,Reaxys Registry Number,3183259
5743,90429,alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/16:0),A sialodiosylceramide that consists of an alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc moiety attached via a glycosidic bond at position 1 of N-hexadecanoylsphingosine.,"InChI=1S/C82H144N4O39/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-47(96)46(86-56(101)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2)42-114-76-65(107)64(106)68(54(40-91)117-76)119-78-67(109)74(125-82(80(112)113)35-49(98)58(84-44(4)94)72(123-82)61(103)51(100)37-88)69(55(41-92)118-78)120-75-59(85-45(5)95)70(62(104)52(38-89)115-75)121-77-66(108)73(63(105)53(39-90)116-77)124-81(79(110)111)34-48(97)57(83-43(3)93)71(122-81)60(102)50(99)36-87/h30,32,46-55,57-78,87-92,96-100,102-109H,6-29,31,33-42H2,1-5H3,(H,83,93)(H,84,94)(H,85,95)(H,86,101)(H,110,111)(H,112,113)/b32-30+/t46-,47+,48-,49-,50+,51+,52+,53+,54+,55+,57+,58+,59+,60+,61+,62-,63-,64+,65+,66+,67+,68+,69-,70+,71+,72+,73-,74+,75-,76+,77-,78-,81-,82-/m0/s1",GD1-d18:1/16:0,LIPID MAPS instance accession,LMSP0601AS01
5744,90440,N-(alpha-L-glutamyl)-2-naphthylamine,An L-glutamic acid derivative that is the amide obtained by formal condensation of the alpha-carboxy group of L-glutamic acid with the amino group of 2-naphthylamine.,"InChI=1S/C15H16N2O3/c16-13(7-8-14(18)19)15(20)17-12-6-5-10-3-1-2-4-11(10)9-12/h1-6,9,13H,7-8,16H2,(H,17,20)(H,18,19)/t13-/m0/s1",(4S)-4-amino-5-[(naphthalen-2-yl)amino]-5-oxopentanoic acid,Reaxys Registry Number,7117397
5745,90441,WIN 18446,"A carboxamide that is 1,8-diaminooctane in which a hydrogen attached to each of the amino groups has been replaced by a dichloroacetyl group. Inhibitor of aldehyde dehydrogenase 1a2 (ALDH1a2). Inhibits the biosynthesis of retinoic acid from retinol in neonatal and adult murine testis. It down-regulates sex related genes in zebrafish.","InChI=1S/C12H20Cl4N2O2/c13-9(14)11(19)17-7-5-3-1-2-4-6-8-18-12(20)10(15)16/h9-10H,1-8H2,(H,17,19)(H,18,20)","N,N'-1,8-Octanediylbis(2,2-dichloroacetamide)",Reaxys Registry Number,2136774
5746,90442,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,"A linear amino hexasaccharide comprising a (1->3), (1->4), (1->3), (1->4), (1->3) sequence of N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine and (at the reducing end) N-acetyl-alpha-D-galactosamine.","InChI=1S/C44H74N4O31/c1-11(55)45-21-29(63)25(59)15(5-49)70-40(21)78-37-27(61)17(7-51)71-43(32(37)66)76-35-20(10-54)74-42(23(31(35)65)47-13(3)57)79-38-28(62)18(8-52)72-44(33(38)67)75-34-19(9-53)73-41(22(30(34)64)46-12(2)56)77-36-24(48-14(4)58)39(68)69-16(6-50)26(36)60/h15-44,49-54,59-68H,5-10H2,1-4H3,(H,45,55)(H,46,56)(H,47,57)(H,48,58)/t15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26+,27+,28+,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39+,40+,41+,42+,43+,44+/m1/s1",GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3GalNAcalpha,PubMed citation,25568069
5747,90444,N-(gamma-L-glutamyl)-2-naphthylamine,An L-glutamine derivative that is the amide obtained by formal condensation of the gamma-carboxy group of L-glutamic acid with the amino group of 2-naphthylamine.,"InChI=1S/C15H16N2O3/c16-13(15(19)20)7-8-14(18)17-12-6-5-10-3-1-2-4-11(10)9-12/h1-6,9,13H,7-8,16H2,(H,17,18)(H,19,20)/t13-/m0/s1",L-glutamic acid gamma-2-naphthylamide,Reaxys Registry Number,5755970
5748,90446,L-glutamine 2-naphthylamide,An L-glutamine derivative that is the amide obtained by formal condensation of the carboxy group of L-glutamic acid with the amino group of 2-naphthylamine.,"InChI=1S/C15H17N3O2/c16-13(7-8-14(17)19)15(20)18-12-6-5-10-3-1-2-4-11(10)9-12/h1-6,9,13H,7-8,16H2,(H2,17,19)(H,18,20)/t13-/m0/s1",L-glutamine beta-naphthylamide,Reaxys Registry Number,21910964
5749,90447,L-histidine 2-naphthylamide,An L-histidine derivative that is the amide obtained by formal condensation of the carboxy group of L-histidine with the amino group of 2-naphthylamine.,"InChI=1S/C16H16N4O/c17-15(8-14-9-18-10-19-14)16(21)20-13-6-5-11-3-1-2-4-12(11)7-13/h1-7,9-10,15H,8,17H2,(H,18,19)(H,20,21)/t15-/m0/s1",L-histidine beta-naphthylamide,CAS Registry Number,7424-15-9
5750,90449,L-hydroxyproline 2-naphthylamide,An L-proline derivative that is the amide obtained by formal condensation of the carboxy group of trans-4-hydroxy-L-proline with the amino group of 2-naphthylamine.,"InChI=1S/C15H16N2O2/c18-13-8-14(16-9-13)15(19)17-12-6-5-10-3-1-2-4-11(10)7-12/h1-7,13-14,16,18H,8-9H2,(H,17,19)/t13-,14+/m1/s1",L-hydroxyproline beta-naphthylamide,Reaxys Registry Number,21364
5751,90473,L-isoleucine 2-naphthylamide,An L-isoleucine derivative that is the amide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of 2-naphthylamine.,"InChI=1S/C16H20N2O/c1-3-11(2)15(17)16(19)18-14-9-8-12-6-4-5-7-13(12)10-14/h4-11,15H,3,17H2,1-2H3,(H,18,19)/t11-,15-/m0/s1",L-isoleucine beta-naphthylamide,Reaxys Registry Number,9132945
5752,90474,"1-(1Z-hexadecenyl)-2-(8Z,11Z,14Z-icosatrienoyl)-sn-glycero-3-phosphoethanolamine","A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-hexadecenyl and (8Z,11Z,14Z)-icosatrienoyl respectively.","InChI=1S/C41H76NO7P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-41(43)49-40(39-48-50(44,45)47-37-35-42)38-46-36-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h11,13,17,19,21-22,33,36,40H,3-10,12,14-16,18,20,23-32,34-35,37-39,42H2,1-2H3,(H,44,45)/b13-11-,19-17-,22-21-,36-33-/t40-/m1/s1","PE(P-16:0/20:3(8Z,11Z,14Z))",LIPID MAPS instance accession,LMGP02030027
5753,90476,L-leucine 2-naphthylamide,An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of L-leucine with the amino group of 2-naphthylamine.,"InChI=1S/C16H20N2O/c1-11(2)9-15(17)16(19)18-14-8-7-12-5-3-4-6-13(12)10-14/h3-8,10-11,15H,9,17H2,1-2H3,(H,18,19)/t15-/m0/s1",N-(beta-naphthyl)-L-leucinamide,CAS Registry Number,732-85-4
5754,90478,L-lysine 2-naphthylamide,An L-lysine derivative that is the amide obtained by formal condensation of the carboxy group of L-lysine with the amino group of 2-naphthylamine.,"InChI=1S/C16H21N3O/c17-10-4-3-7-15(18)16(20)19-14-9-8-12-5-1-2-6-13(12)11-14/h1-2,5-6,8-9,11,15H,3-4,7,10,17-18H2,(H,19,20)/t15-/m0/s1",N-(2-naphthyl)-L-lysinamide,CAS Registry Number,4420-88-6
5755,90482,1-(1Z-octadecenyl)-2-hexadecanoyl-sn-glycero-3-phosphoethanolamine,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-octadecenyl and hexadecanoyl respectively.,"InChI=1S/C39H78NO7P/c1-3-5-7-9-11-13-15-17-18-19-21-23-25-27-29-31-34-44-36-38(37-46-48(42,43)45-35-33-40)47-39(41)32-30-28-26-24-22-20-16-14-12-10-8-6-4-2/h31,34,38H,3-30,32-33,35-37,40H2,1-2H3,(H,42,43)/b34-31-/t38-/m1/s1",PE P-18:0/16:0,LIPID MAPS instance accession,LMGP02030040
5756,90483,1-(1Z-octadecenyl)-2-linoleoyl-sn-glycero-3-phosphoethanolamine,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkenyl and acyl groups are specified asas (1Z)-octadecenyl and linoleoyl respectively.,"InChI=1S/C41H78NO7P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-36-46-38-40(39-48-50(44,45)47-37-35-42)49-41(43)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,18,20,33,36,40H,3-11,13,15-17,19,21-32,34-35,37-39,42H2,1-2H3,(H,44,45)/b14-12-,20-18-,36-33-/t40-/m1/s1",PE P-18:0/18:2,LIPID MAPS instance accession,LMGP02030046
5757,90485,"1-(1Z-octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z-docosapentaenoyl)-sn-glycero-3-phosphoethanolamine","A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z)-octadecenyl and (4Z,7Z,10Z,13Z,16Z)-docosapentaenoyl respectively.","InChI=1S/C45H80NO7P/c1-3-5-7-9-11-13-15-17-19-21-22-23-24-26-28-30-32-34-36-38-45(47)53-44(43-52-54(48,49)51-41-39-46)42-50-40-37-35-33-31-29-27-25-20-18-16-14-12-10-8-6-4-2/h11,13,17,19,22-23,26,28,32,34,37,40,44H,3-10,12,14-16,18,20-21,24-25,27,29-31,33,35-36,38-39,41-43,46H2,1-2H3,(H,48,49)/b13-11-,19-17-,23-22-,28-26-,34-32-,40-37-/t44-/m1/s1",PE P-18:0/22:5,HMDB accession,HMDB0011392
5758,90486,"1-(1Z,11Z-octadecadienyl)-2-linoleoyl-sn-glycero-3-phosphoethanolamine","A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkyl and the acyl groups at positions 1 and 2 are specified as (1Z,11Z)-octadecadienyl and linoleoyl respectively.","InChI=1S/C41H76NO7P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-36-46-38-40(39-48-50(44,45)47-37-35-42)49-41(43)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12-15,18,20,33,36,40H,3-11,16-17,19,21-32,34-35,37-39,42H2,1-2H3,(H,44,45)/b14-12-,15-13-,20-18-,36-33-/t40-/m1/s1",PE P-18:1/18:2,HMDB accession,HMDB0011409
5759,90494,N-(11Z-icosenoyl)-sphingosine-1-phosphocholine,A sphingomyelin d18:1 in which the ceramide N-acyl group is specified as (11Z)-icosenoyl.,"InChI=1S/C43H85N2O6P/c1-6-8-10-12-14-16-18-20-21-22-23-25-27-29-31-33-35-37-43(47)44-41(40-51-52(48,49)50-39-38-45(3,4)5)42(46)36-34-32-30-28-26-24-19-17-15-13-11-9-7-2/h20-21,34,36,41-42,46H,6-19,22-33,35,37-40H2,1-5H3,(H-,44,47,48,49)/b21-20-,36-34+/t41-,42+/m0/s1",SM d18:1/20:1,LIPID MAPS instance accession,LMSP03010059
5760,90498,beta-D-galactosyl-(1<->1')-N-octadecanoylsphinganine,A beta-D-galactosyl-(1<->1')-N-acylsphinganine in which the acyl group is specified as octadecanoyl.,"InChI=1S/C42H83NO8/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-38(46)43-35(34-50-42-41(49)40(48)39(47)37(33-44)51-42)36(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h35-37,39-42,44-45,47-49H,3-34H2,1-2H3,(H,43,46)/t35-,36+,37+,39-,40-,41+,42+/m0/s1",GalCer(d18:0/18:0),Reaxys Registry Number,4342727
5761,90502,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a nonadecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked linked (1->3) and (1->6) two N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear octasaccharide units.","InChI=1S/C140H230N10O102/c1-32(167)141-63-42(177)11-139(137(212)213,251-111(63)73(181)44(179)13-151)217-30-61-77(185)92(200)96(204)128(234-61)237-104-53(22-160)227-122(67(86(104)194)145-36(5)171)244-113-79(187)48(17-155)220-130(98(113)206)239-106-56(25-163)229-124(69(88(106)196)147-38(7)173)246-115-81(189)50(19-157)222-132(100(115)208)241-108-58(27-165)231-126(71(90(108)198)149-40(9)175)249-118-94(202)75(183)46(15-153)224-135(118)216-29-60-83(191)117(102(210)134(233-60)243-110-55(24-162)226-121(66(85(110)193)144-35(4)170)236-103-52(21-159)219-120(211)65(84(103)192)143-34(3)169)248-136-119(95(203)76(184)47(16-154)225-136)250-127-72(150-41(10)176)91(199)109(59(28-166)232-127)242-133-101(209)116(82(190)51(20-158)223-133)247-125-70(148-39(8)174)89(197)107(57(26-164)230-125)240-131-99(207)114(80(188)49(18-156)221-131)245-123-68(146-37(6)172)87(195)105(54(23-161)228-123)238-129-97(205)93(201)78(186)62(235-129)31-218-140(138(214)215)12-43(178)64(142-33(2)168)112(252-140)74(182)45(180)14-152/h42-136,151-166,177-211H,11-31H2,1-10H3,(H,141,167)(H,142,168)(H,143,169)(H,144,170)(H,145,171)(H,146,172)(H,147,173)(H,148,174)(H,149,175)(H,150,176)(H,212,213)(H,214,215)/t42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77-,78-,79-,80-,81-,82-,83+,84+,85+,86+,87+,88+,89+,90+,91+,92-,93-,94-,95-,96+,97+,98+,99+,100+,101+,102-,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113-,114-,115-,116-,117-,118-,119-,120?,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136+,139+,140+/m0/s1",alpha-Neu5Ac-(2->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-Neu5Ac-(2->6)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,25568069
5762,90504,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is an nonadecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked linked (1->3) and (1->6) two N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear octasaccharide units.","InChI=1S/C140H230N10O102/c1-32(169)141-63-42(179)11-139(137(212)213,249-109(63)73(183)44(181)13-151)251-116-81(191)52(21-159)222-133(99(116)209)240-107-58(27-165)229-124(69(88(107)198)147-38(7)175)244-111-77(187)48(17-155)218-128(94(111)204)235-102-56(25-163)227-122(67(86(102)196)145-36(5)173)242-113-79(189)50(19-157)220-130(96(113)206)237-104-60(29-167)231-126(71(90(104)200)149-40(9)177)247-118-92(202)75(185)46(15-153)224-135(118)216-31-62-83(193)115(98(208)132(233-62)239-106-55(24-162)226-121(66(85(106)195)144-35(4)172)234-101-54(23-161)217-120(211)65(84(101)194)143-34(3)171)246-136-119(93(203)76(186)47(16-154)225-136)248-127-72(150-41(10)178)91(201)105(61(30-168)232-127)238-131-97(207)114(80(190)51(20-158)221-131)243-123-68(146-37(6)174)87(197)103(57(26-164)228-123)236-129-95(205)112(78(188)49(18-156)219-129)245-125-70(148-39(8)176)89(199)108(59(28-166)230-125)241-134-100(210)117(82(192)53(22-160)223-134)252-140(138(214)215)12-43(180)64(142-33(2)170)110(250-140)74(184)45(182)14-152/h42-136,151-168,179-211H,11-31H2,1-10H3,(H,141,169)(H,142,170)(H,143,171)(H,144,172)(H,145,173)(H,146,174)(H,147,175)(H,148,176)(H,149,177)(H,150,178)(H,212,213)(H,214,215)/t42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77-,78-,79-,80-,81-,82-,83+,84+,85+,86+,87+,88+,89+,90+,91+,92-,93-,94+,95+,96+,97+,98-,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111-,112-,113-,114-,115-,116-,117-,118-,119-,120?,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136+,139-,140-/m0/s1",Neu5Acalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-2Manalpha1-6(Neu5Acalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-2Manalpha1-3)Manbeta1-4GlcNAcbeta1-4GlcNAcbeta,PubMed citation,25568069
5763,90505,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a pentadecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked linked (1->3) and (1->6) two N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear hexasaccharide units.","InChI=1S/C112H184N8O82/c1-26(133)113-51-34(141)9-111(109(170)171,201-89(51)59(145)36(143)11-121)175-24-49-63(149)74(160)78(164)102(188-49)191-84-43(18-128)183-98(55(70(84)156)117-30(5)137)196-91-65(151)40(15-125)178-104(80(91)166)193-86-46(21-131)185-100(57(72(86)158)119-32(7)139)199-94-76(162)61(147)38(13-123)180-107(94)174-23-48-67(153)93(82(168)106(187-48)195-88-45(20-130)182-97(54(69(88)155)116-29(4)136)190-83-42(17-127)177-96(169)53(68(83)154)115-28(3)135)198-108-95(77(163)62(148)39(14-124)181-108)200-101-58(120-33(8)140)73(159)87(47(22-132)186-101)194-105-81(167)92(66(152)41(16-126)179-105)197-99-56(118-31(6)138)71(157)85(44(19-129)184-99)192-103-79(165)75(161)64(150)50(189-103)25-176-112(110(172)173)10-35(142)52(114-27(2)134)90(202-112)60(146)37(144)12-122/h34-108,121-132,141-169H,9-25H2,1-8H3,(H,113,133)(H,114,134)(H,115,135)(H,116,136)(H,117,137)(H,118,138)(H,119,139)(H,120,140)(H,170,171)(H,172,173)/t34-,35-,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,64-,65-,66-,67+,68+,69+,70+,71+,72+,73+,74-,75-,76-,77-,78+,79+,80+,81+,82-,83+,84+,85+,86+,87+,88+,89+,90+,91-,92-,93-,94-,95-,96?,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108+,111+,112+/m0/s1",Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,25568069
5764,90518,victoria blue R,"An iminium salt composed of 4-{[4-(dimethylamino)phenyl][4-(ethylamino)naphthalen-1-yl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium and chloride ions in a 1:1 ratio.","InChI=1S/C29H31N3.ClH/c1-6-30-28-20-19-27(25-9-7-8-10-26(25)28)29(21-11-15-23(16-12-21)31(2)3)22-13-17-24(18-14-22)32(4)5;/h7-20H,6H2,1-5H3;1H",basic blue 11,CAS Registry Number,2185-86-6
5765,90520,victoria blue R(1+),An iminium ion that forms the cationic portion of the histological dye 'victoria blue R'.,"InChI=1S/C29H31N3/c1-6-30-28-20-19-27(25-9-7-8-10-26(25)28)29(21-11-15-23(16-12-21)31(2)3)22-13-17-24(18-14-22)32(4)5/h7-20H,6H2,1-5H3/p+1",victoria blue R cation,Reaxys Registry Number,3915751
5766,90532,alkali Blue G,"An aminobenzenesulfonic acid that is 2-aminobenzenesulfonic acid in which one of the amino hydrogens is replaced by a 4-{(4-amino-3-methylphenyl)[4-(phenylimino)cyclohexa-2,5-dien-1-ylidene]methyl} group.","InChI=1S/C32H27N3O3S/c1-22-21-25(15-20-29(22)33)32(23-11-16-27(17-12-23)34-26-7-3-2-4-8-26)24-13-18-28(19-14-24)35-30-9-5-6-10-31(30)39(36,37)38/h2-21,35H,33H2,1H3,(H,36,37,38)/b32-23-,34-27+",alkali blue 4B (acid from),CAS Registry Number,58569-23-6
5767,90597,L-ornithine 2-naphthylamide,An L-ornithine derivative that is the amide obtained by formal condensation of the carboxy group of L-ornithine with the amino group of 2-naphthylamine.,"InChI=1S/C15H19N3O/c16-9-3-6-14(17)15(19)18-13-8-7-11-4-1-2-5-12(11)10-13/h1-2,4-5,7-8,10,14H,3,6,9,16-17H2,(H,18,19)/t14-/m0/s1",L-ornithine beta-naphthylamide,Reaxys Registry Number,25361791
5768,90599,L-phenylalanine 2-naphthylamide,An L-phenylalanine derivative that is the amide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of 2-naphthylamine.,"InChI=1S/C19H18N2O/c20-18(12-14-6-2-1-3-7-14)19(22)21-17-11-10-15-8-4-5-9-16(15)13-17/h1-11,13,18H,12,20H2,(H,21,22)/t18-/m0/s1",N-(beta-naphthyl)-L-phenylalaninamide,CAS Registry Number,740-57-8
5769,90600,L-proline 2-naphthylamide,An L-proline derivative that is the amide obtained by formal condensation of the carboxy group of L-proline with the amino group of 2-naphthylamine.,"InChI=1S/C15H16N2O/c18-15(14-6-3-9-16-14)17-13-8-7-11-4-1-2-5-12(11)10-13/h1-2,4-5,7-8,10,14,16H,3,6,9H2,(H,17,18)/t14-/m0/s1",L-proline beta-naphthylamide,CAS Registry Number,16037-15-3
5770,90601,5-oxo-L-proline 2-naphthylamide,An L-proline derivative that is the amide obtained by formal condensation of the carboxy group of 5-oxo-L-proline with the amino group of 2-naphthylamine.,"InChI=1S/C15H14N2O2/c18-14-8-7-13(17-14)15(19)16-12-6-5-10-3-1-2-4-11(10)9-12/h1-6,9,13H,7-8H2,(H,16,19)(H,17,18)/t13-/m0/s1",N-pyroglutamyl-2-aminonaphthalene,CAS Registry Number,22155-91-5
5771,90603,L-serine 2-naphthylamide,An L-serine derivative that is the amide obtained by formal condensation of the carboxy group of L-serine with the amino group of 2-naphthylamine.,"InChI=1S/C13H14N2O2/c14-12(8-16)13(17)15-11-6-5-9-3-1-2-4-10(9)7-11/h1-7,12,16H,8,14H2,(H,15,17)/t12-/m0/s1",L-serine beta-naphthylamide,Reaxys Registry Number,2375983
5772,90604,L-threonine 2-naphthylamide,An L-threonine derivative that is the amide obtained by formal condensation of the carboxy group of L-threonine with the amino group of 2-naphthylamine.,"InChI=1S/C14H16N2O2/c1-9(17)13(15)14(18)16-12-7-6-10-4-2-3-5-11(10)8-12/h2-9,13,17H,15H2,1H3,(H,16,18)/t9-,13+/m1/s1",N-threonyl-2-aminonaphthalene,Reaxys Registry Number,9404033
5773,90606,L-tryptophan 2-naphthylamide,An L-tryptophan derivative that is the amide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of 2-naphthylamine.,"InChI=1S/C21H19N3O/c22-19(12-16-13-23-20-8-4-3-7-18(16)20)21(25)24-17-10-9-14-5-1-2-6-15(14)11-17/h1-11,13,19,23H,12,22H2,(H,24,25)/t19-/m0/s1",N-(beta-naphthyl)-L-tryptophanamide,CAS Registry Number,3326-63-4
5774,90607,L-tyrosine 2-naphthylamide,An L-tyrosine derivative that is the amide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of 2-naphthylamine.,"InChI=1S/C19H18N2O2/c20-18(11-13-5-9-17(22)10-6-13)19(23)21-16-8-7-14-3-1-2-4-15(14)12-16/h1-10,12,18,22H,11,20H2,(H,21,23)/t18-/m0/s1",N-tyrosyl-2-aminonaphthalene,CAS Registry Number,4357-95-3
5775,90608,L-valine 2-naphthylamide,An L-valine derivative that is the amide obtained by formal condensation of the carboxy group of L-valine with the amino group of 2-naphthylamine.,"InChI=1S/C15H18N2O/c1-10(2)14(16)15(18)17-13-8-7-11-5-3-4-6-12(11)9-13/h3-10,14H,16H2,1-2H3,(H,17,18)/t14-/m0/s1",N-(beta-naphthyl)-L-valinamide,CAS Registry Number,729-24-8
5776,90609,L-leucine 4-methoxy-2-naphthylamide,An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of L-leucine with the amino group of 4-methoxy-2-naphthylamine.,"InChI=1S/C17H22N2O2/c1-11(2)8-15(18)17(20)19-13-9-12-6-4-5-7-14(12)16(10-13)21-3/h4-7,9-11,15H,8,18H2,1-3H3,(H,19,20)/t15-/m0/s1",N-(4-methoxy-2-naphthyl)-L-leucinamide,Reaxys Registry Number,3148656
5777,90611,L-alanyl-L-alanine 2-naphthylamide,An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of L-alanyl-L-alanine with the amino group of 2-naphthylamine.,"InChI=1S/C16H19N3O2/c1-10(17)15(20)18-11(2)16(21)19-14-8-7-12-5-3-4-6-13(12)9-14/h3-11H,17H2,1-2H3,(H,18,20)(H,19,21)/t10-,11-/m0/s1",alanylalanine 2-naphthylamide,Reaxys Registry Number,3620889
5778,90613,beta-alanine 2-naphthylamide,A beta-alanine derivative that is the amide obtained by formal condensation of the carboxy group of beta-alanine with the amino group of 2-naphthylamine.,"InChI=1S/C13H14N2O/c14-8-7-13(16)15-12-6-5-10-3-1-2-4-11(10)9-12/h1-6,9H,7-8,14H2,(H,15,16)",N-(beta-naphthyl)-beta-alaninamide,Reaxys Registry Number,2972745
5779,90623,vatalanib succinate,"A succinate salt obtained by combining vatalanib with one molar equivalent of succinic acid. It is a multi-targeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit.","InChI=1S/C20H15ClN4.C4H6O4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;5-3(6)1-2-4(7)8/h1-12H,13H2,(H,23,25);1-2H2,(H,5,6)(H,7,8)",vatalanib monosuccinate,CAS Registry Number,212142-18-2
5780,90629,leupeptin hemisulfate,A peptide sulfate salt obtained by combining leupeptin with 0.5 molar equivalents of sulfuric acid.,"InChI=1S/2C20H38N6O4.H2O4S/c2*1-12(2)9-16(24-14(5)28)19(30)26-17(10-13(3)4)18(29)25-15(11-27)7-6-8-23-20(21)22;1-5(2,3)4/h2*11-13,15-17H,6-10H2,1-5H3,(H,24,28)(H,25,29)(H,26,30)(H4,21,22,23);(H2,1,2,3,4)/t2*15-,16-,17-;/m00./s1",leupeptin sulfate,CAS Registry Number,103476-89-7
5781,90692,U0126.EtOH,"An addition compound obtained by combining equimolar amounts of (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile (U0126) and ethanol. An inhibitor of mitogen-activated protein kinase that also exhibits anti-cancer properties.","InChI=1S/C18H16N6S2.C2H6O/c19-9-11(17(23)25-15-7-3-1-5-13(15)21)12(10-20)18(24)26-16-8-4-2-6-14(16)22;1-2-3/h1-8H,21-24H2;3H,2H2,1H3/b17-11+,18-12+;",U0126-EtOH,Reaxys Registry Number,28046614
5782,90695,"anthra[1,9-cd]pyrazol-6(2H)-one","A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.","InChI=1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)",SP 600125,CAS Registry Number,129-56-6
5783,90701,"potassium 2-(4-carboxylatophenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide","A potassium salt having 2-(4-carboxylatophenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide as the counterion.","InChI=1S/C14H17N2O4.K/c1-13(2)14(3,4)16(20)11(15(13)19)9-5-7-10(8-6-9)12(17)18;/h5-8H,1-4H3,(H,17,18);/q;+1/p-1",potassium carboxylato-PTIO,Reaxys Registry Number,8596190
5784,90705,SB 203580,"A member of the class of imidazoles carrying 4-methylsulfinylphenyl, 4-pyridyl and 4-fluorophenyl substituents at positions 2, 4 and 5 respectively. An inhibitor of mitogen-activated protein kinase.","InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)",SB203580,PubMed citation,11457647
5785,90721,N-[3-(aminomethyl)benzyl]acetamidine,An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.,"InChI=1S/C10H15N3/c1-8(12)13-7-10-4-2-3-9(5-10)6-11/h2-5H,6-7,11H2,1H3,(H2,12,13)",1400W,DrugBank accession,DB02044
5786,90734,glycyl-L-phenylalanine 2-naphthylamide,An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycyl-L-phenylalanine with the amino group of 2-naphthylamine.,"InChI=1S/C21H21N3O2/c22-14-20(25)24-19(12-15-6-2-1-3-7-15)21(26)23-18-11-10-16-8-4-5-9-17(16)13-18/h1-11,13,19H,12,14,22H2,(H,23,26)(H,24,25)/t19-/m0/s1",Gly-Phe 2-naphthylamide,CAS Registry Number,21438-66-4
5787,90735,glycyl-L-proline 2-naphthylamide,An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of glycyl-L-proline with the amino group of 2-naphthylamine.,"InChI=1S/C17H19N3O2/c18-11-16(21)20-9-3-6-15(20)17(22)19-14-8-7-12-4-1-2-5-13(12)10-14/h1-2,4-5,7-8,10,15H,3,6,9,11,18H2,(H,19,22)/t15-/m0/s1",Gly-L-Pro 2-naphthylamide,Reaxys Registry Number,5979527
5788,90741,L-leucylglycine 2-naphthylamide,An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of L-leucylglycine with the amino group of 2-naphthylamine.,"InChI=1S/C18H23N3O2/c1-12(2)9-16(19)18(23)20-11-17(22)21-15-8-7-13-5-3-4-6-14(13)10-15/h3-8,10,12,16H,9,11,19H2,1-2H3,(H,20,23)(H,21,22)/t16-/m0/s1",L-Leu-Gly 2-naphthylamide,Reaxys Registry Number,3623795
5789,90743,N-benzoyl-L-leucine 2-naphthylamide,An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of N-benzoyl-L-leucine with the amino group of 2-naphthylamine.,"InChI=1S/C23H24N2O2/c1-16(2)14-21(25-22(26)18-9-4-3-5-10-18)23(27)24-20-13-12-17-8-6-7-11-19(17)15-20/h3-13,15-16,21H,14H2,1-2H3,(H,24,27)(H,25,26)/t21-/m0/s1",PhCO-L-Leu 2-naphthylamide,CAS Registry Number,94441-89-1
5790,90747,N-carbobenzyloxy-glycylglycyl-L-arginine 2-naphthylamide,An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of N-carbobenzyloxy-glycylglycyl-L-arginine with the amino group of 2-naphthylamine.,"InChI=1S/C28H33N7O5/c29-27(30)31-14-6-11-23(26(38)34-22-13-12-20-9-4-5-10-21(20)15-22)35-25(37)17-32-24(36)16-33-28(39)40-18-19-7-2-1-3-8-19/h1-5,7-10,12-13,15,23H,6,11,14,16-18H2,(H,32,36)(H,33,39)(H,34,38)(H,35,37)(H4,29,30,31)/t23-/m0/s1",N-benzyloxycarbonyl-glycylglycyl-L-arginine 2-naphthylamide,Reaxys Registry Number,9028691
5791,90751,L-seryl-L-tyrosine 2-naphthylamide,An N-(2-naphthyl)carboxamide obtained by formal condensation of the carboxy group of L-seryl-L-tyrosine with the amino group of 2-naphthylamine.,"InChI=1S/C22H23N3O4/c23-19(13-26)21(28)25-20(11-14-5-9-18(27)10-6-14)22(29)24-17-8-7-15-3-1-2-4-16(15)12-17/h1-10,12,19-20,26-27H,11,13,23H2,(H,24,29)(H,25,28)/t19-,20-/m0/s1",L-Ser-L-Tyr 2-naphthylamide,Reaxys Registry Number,3633494
5792,90766,alpha-D-Manp6P-(1->3)-alpha-D-Manp-(1->3)-alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-D-Manp,"An oligosaccharide phosphate consisting of four alpha(1->3)-linked D-mannose residues, with the residue at the non-reducing end carrying a phosphate group at position 6, and with that at the reducing end being alpha(1->2)-linked to a further D-mannose residue; prepared from the phosphomannan fraction of Hansenula holstii.","InChI=1S/C30H53O29P/c31-1-6-11(35)17(41)25(26(46)51-6)59-30-21(45)24(15(39)9(4-34)54-30)58-29-20(44)23(14(38)8(3-33)53-29)57-28-19(43)22(13(37)7(2-32)52-28)56-27-18(42)16(40)12(36)10(55-27)5-50-60(47,48)49/h6-46H,1-5H2,(H2,47,48,49)/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26?,27-,28-,29-,30-/m1/s1",alpha-D-Man6P-(1->3)-alpha-D-Man-(1->3)-alpha-D-Man-(1->3)-alpha-D-Man-(1->2)-D-Man,CAS Registry Number,72672-17-4
5793,90773,13(S)-HOTrE(1-),A polyunsaturated fatty acid anion that is the conjugate base of 13S-HOTrE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.,"InChI=1S/C18H30O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h3,7,9,11-12,15,17,19H,2,4-6,8,10,13-14,16H2,1H3,(H,20,21)/p-1/b9-7-,11-3-,15-12+/t17-/m0/s1",13S-HOTrE,PubMed citation,22984144
5794,90776,11-oxo-ETE,"An oxoicosatetraenoic acid that is (5Z,8Z,12E,14Z)-icosatetraenoic acid bearing a single oxo substituent located at position 12.","InChI=1S/C20H30O3/c1-2-3-4-5-7-10-13-16-19(21)17-14-11-8-6-9-12-15-18-20(22)23/h6-7,9-11,13-14,16H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b9-6-,10-7-,14-11-,16-13+","(5Z,8Z,12E,14Z)-11-oxoicosatetraenoic acid",Reaxys Registry Number,19190344
5795,93771,ICRF-193,"An N-alkylpiperazine that is butane which is substituted by a 3,5-dioxopiperazin-1-yl group at positions 2 and 3. The meso isomer.","InChI=1S/C12H18N4O4/c1-7(15-3-9(17)13-10(18)4-15)8(2)16-5-11(19)14-12(20)6-16/h7-8H,3-6H2,1-2H3,(H,13,17,18)(H,14,19,20)/t7-,8+",ICRF-193,LINCS accession,LSM-4280
5796,94186,tubastatin A,"A pyridoindole that is 1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole which is substituted on the tetrahydropyridine nitrogen by a methyl group and on the indole nitrogen by a p-[N-(hydroxy)aminocarbonyl]benzyl group. It is a histone deacetylase 6 (HDAC6) inhibitor that is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).","InChI=1S/C20H21N3O2/c1-22-11-10-19-17(13-22)16-4-2-3-5-18(16)23(19)12-14-6-8-15(9-7-14)20(24)21-25/h2-9,25H,10-13H2,1H3,(H,21,24)","N-hydroxy-4-[(2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl)methyl]benzamide",LINCS accession,LSM-4806
5797,100148,"1,1,1-propanetricarboxylic acid",A acid that is propane in which three carboxy groups are attached at the C-1 position.,"InChI=1S/C6H8O6/c1-2-6(3(7)8,4(9)10)5(11)12/h2H2,1H3,(H,7,8)(H,9,10)(H,11,12)","propane-1,1,1-tricarboxylic acid",Reaxys Registry Number,13832806
5798,100461,"5-chlorospiro[indole-3,2'-[1,3]oxathiolan]-2(1H)-one","A monothioketal formed from 5-chloro-1H-indole-2,3-dione. It has been studied for its anticonvulsant properties.","InChI=1S/C10H8ClNO2S/c11-6-1-2-8-7(5-6)10(9(13)12-8)14-3-4-15-10/h1-2,5H,3-4H2,(H,12,13)","5-chlorospiro[2,3-dihydro-1H-indole-3,2'-(dihydro[1,3]oxathiolane)]-2-one",PubMed citation,3361568
5799,91271,15-HPETE,"A HPETE that consists of (5Z,8Z,11Z,13E)-icosatetraenoic acid in which the hydroperoxy group is located at position 15.","InChI=1S/C20H32O4/c1-2-3-13-16-19(24-23)17-14-11-9-7-5-4-6-8-10-12-15-18-20(21)22/h4-5,8-11,14,17,19,23H,2-3,6-7,12-13,15-16,18H2,1H3,(H,21,22)/b5-4-,10-8-,11-9-,17-14+","(5Z,8Z,11Z,13E)-15-hydroperoxyicosatetraenoic acid",CAS Registry Number,67675-14-3
5800,91272,13-HPODE,"An HPODE (hydroperoxyoctadecadienoic acid) in which the double bonds are at positions 9 and 11 (E and Z  geometry, respectively) and the hydroperoxy group is at position 13.","InChI=1S/C18H32O4/c1-2-3-11-14-17(22-21)15-12-9-7-5-4-6-8-10-13-16-18(19)20/h7,9,12,15,17,21H,2-6,8,10-11,13-14,16H2,1H3,(H,19,20)/b9-7-,15-12+","13-hydroperoxy-(9Z,11E)-octadecadienoic acid",CAS Registry Number,23017-93-8
5801,91286,"5(S),15(S)-DiHETE","A DiHETE that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroxy substituents are placed at the 5S- and 15S-positions.","InChI=1S/C20H32O4/c1-2-3-9-13-18(21)14-10-7-5-4-6-8-11-15-19(22)16-12-17-20(23)24/h5-8,10-11,14-15,18-19,21-22H,2-4,9,12-13,16-17H2,1H3,(H,23,24)/b7-5-,8-6-,14-10+,15-11+/t18-,19+/m0/s1","(5S,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosatetraenoic acid",LIPID MAPS instance accession,LMFA03060010
5802,91316,(S)-methylsuccinic acid,A 2-methylbutanedioic acid in which the methyl group at position 2 has S-configuration.,"InChI=1S/C5H8O4/c1-3(5(8)9)2-4(6)7/h3H,2H2,1H3,(H,6,7)(H,8,9)/t3-/m0/s1",(S)-2-methylbutanedioic acid,Reaxys Registry Number,1722948
5803,91317,(R)-methylsuccinic acid,A 2-methylbutanedioic acid in which the methyl group at position 2 has R-configuration.,"InChI=1S/C5H8O4/c1-3(5(8)9)2-4(6)7/h3H,2H2,1H3,(H,6,7)(H,8,9)/t3-/m1/s1",(R)-2-methylbutanedioic acid,CAS Registry Number,3641-51-8
5804,91435,linifanib,"A member of the class of phenylureas that is urea in which one of the nitrogens is substituted by a 2-fluoro-5-methylphenyl group, while the other is substituted by a p-(3-amino-1H-indazol-4-yl)phenyl group. It is a potent, selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases.","InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)",1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea,LINCS accession,LSM-1183
5805,91207,"2',3'-dideoxyadenosine","A purine 2',3'-dideoxyribonucleoside in which the nucleobase component is specified as adenine.","InChI=1S/C10H13N5O2/c11-9-8-10(13-4-12-9)15(5-14-8)7-2-1-6(3-16)17-7/h4-7,16H,1-3H2,(H2,11,12,13)/t6-,7+/m0/s1",DDA,CAS Registry Number,4097-22-7
5806,91212,glycosmisic acid sulfate,A guaiacyl lignin that is glycosmisic acid in which the alcoholic hydrogen is replaced by a sulfo group.,"InChI=1S/C20H20O10S/c1-27-16-9-12(4-5-15(16)21)19-14(10-29-31(24,25)26)13-7-11(3-6-18(22)23)8-17(28-2)20(13)30-19/h3-9,14,19,21H,10H2,1-2H3,(H,22,23)(H,24,25,26)/b6-3+",G(8-5)FA Sulfate,PubMed citation,25457500
5807,91213,4-iodo-6-phenylpyrimidine,A member of the class of pyrimidines carrying iodo and phenyl substituents at positions 4 and 6 respectively.,InChI=1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H,4-IPP,Reaxys Registry Number,639160
5808,91215,"1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one","A member of the class of oxadiazoloquinoxalines that is 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline substituted at position 1 by an oxo group.",InChI=1S/C9H5N3O2/c13-9-12-7-4-2-1-3-6(7)10-5-8(12)11-14-9/h1-5H,ODQ,PubMed citation,26732984
5809,91219,1-azelaoyl-sn-glycero-3-phosphocholine,A 1-O-acyl-sn-glycero-3-phosphocholine obtained by formal condensation of one of the carboxy groups of azelaic acid with the 1-hydroxy group of sn-glycero-3-phosphocholine.,"InChI=1S/C17H34NO9P/c1-18(2,3)11-12-26-28(23,24)27-14-15(19)13-25-17(22)10-8-6-4-5-7-9-16(20)21/h15,19H,4-14H2,1-3H3,(H-,20,21,23,24)/t15-/m1/s1",azelaoyl-lysoPC,PubMed citation,25457500
5810,91224,S3I-201,An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.,"InChI=1S/C16H15NO7S/c1-10-2-5-12(6-3-10)25(22,23)24-9-15(19)17-11-4-7-13(16(20)21)14(18)8-11/h2-8,18H,9H2,1H3,(H,17,19)(H,20,21)",NSC 74859,LINCS accession,LSM-6243
5811,91226,hexahomomethionine S-oxide,A sulfur-containing amino acid that is the sulfoxide obtained by formal oxygenation of the sulfur atom of hexahomomethionine.,"InChI=1S/C11H23NO3S/c1-16(15)9-7-5-3-2-4-6-8-10(12)11(13)14/h10H,2-9,12H2,1H3,(H,13,14)",hexahomo-Met S-oxide,Reaxys Registry Number,28063957
5812,91242,glycine betaine hydrate,A hydrate that is the monohydrate form of glycine betaine.,"InChI=1S/C5H11NO2.H2O/c1-6(2,3)4-5(7)8;/h4H2,1-3H3;1H2",glycine betaine monohydrate,CAS Registry Number,590-47-6
5813,91243,calcium chloride hexahydrate,A hydrate that is the hexahydrate form of calcium chloride.,InChI=1S/Ca.2ClH.6H2O/h;2*1H;6*1H2/q+2;;;;;;;;/p-2,CaCl2.6H2O,DrugBank accession,DBSALT003069
5814,91244,cobalt(2+) sulfate heptahydrate,A hydrate that is the heptahydrate form of cobalt(2+) sulfate.,"InChI=1S/Co.H2O4S.7H2O/c;1-5(2,3)4;;;;;;;/h;(H2,1,2,3,4);7*1H2/q+2;;;;;;;;/p-2",cobalt sulfate heptahydrate,CAS Registry Number,10026-24-1
5815,91246,copper(II) sulfate hexahydrate,A hydrate that is the hexahydrate form of copper(2+) sulfate.,"InChI=1S/Cu.H2O4S.6H2O/c;1-5(2,3)4;;;;;;/h;(H2,1,2,3,4);6*1H2/q+2;;;;;;;/p-2",copper(2+) sulfate hexahydrate,Reaxys Registry Number,14844791
5816,91248,L-cysteine hydrochloride hydrate,A hydrate that is the monohydrate form of L-cysteine hydrochloride.,"InChI=1S/C3H7NO2S.ClH.H2O/c4-2(1-7)3(5)6;;/h2,7H,1,4H2,(H,5,6);1H;1H2/t2-;;/m0../s1",L-cysteine hydrochloride monohydrate,Wikipedia accession,Cysteine
5817,91250,disodium L-glutamate,An organic sodium salt that is the disodium salt of L-glutamic acid.,"InChI=1S/C5H9NO4.2Na/c6-3(5(9)10)1-2-4(7)8;;/h3H,1-2,6H2,(H,7,8)(H,9,10);;/q;2*+1/p-2/t3-;;/m0../s1",disodium glutamate,CAS Registry Number,16690-92-9
5818,91251,sodium glyoxylate,An organic sodium salt that is the monosodium salt of glyoxylic acid.,"InChI=1S/C2H2O3.Na/c3-1-2(4)5;/h1H,(H,4,5);/q;+1/p-1",sodium glyoxalate,CAS Registry Number,2706-75-4
5819,91261,disodium (S)-malate,An organic sodium salt that is the disodium salt of (S)-malic acid.,"InChI=1S/C4H6O5.2Na/c5-2(4(8)9)1-3(6)7;;/h2,5H,1H2,(H,6,7)(H,8,9);;/q;2*+1/p-2/t2-;;/m0../s1",(S)-disodium malate,CAS Registry Number,138-09-0
5820,91262,disodium (R)-malate,An organic sodium salt that is the disodium salt of (R)-malic acid.,"InChI=1S/C4H6O5.2Na/c5-2(4(8)9)1-3(6)7;;/h2,5H,1H2,(H,6,7)(H,8,9);;/q;2*+1/p-2/t2-;;/m1../s1",(R)-disodium malate,CAS Registry Number,51209-20-2
5821,91263,disodium maleate,An organic sodium salt that is the disodium salt of maleic acid.,"InChI=1S/C4H4O4.2Na/c5-3(6)1-2-4(7)8;;/h1-2H,(H,5,6)(H,7,8);;/q;2*+1/p-2/b2-1-;;",sodium maleate,CAS Registry Number,371-47-1
5822,91264,11(R)-HEPE,"An 11-HEPE that consists of (5Z,8Z,12E,14Z,17Z)-icosapentaenoic acid in which the hydroxy group is located at the 11R-position.","InChI=1S/C20H30O3/c1-2-3-4-5-7-10-13-16-19(21)17-14-11-8-6-9-12-15-18-20(22)23/h3-4,6-7,9-11,13-14,16,19,21H,2,5,8,12,15,17-18H2,1H3,(H,22,23)/b4-3-,9-6-,10-7-,14-11-,16-13+/t19-/m0/s1","(11R)-hydroxy-(5Z,8Z,12E,14Z,17Z)-icosapentaenoic acid",LIPID MAPS instance accession,LMFA03070005
5823,91268,5-HPETE,"A HPETE that consists of (6E,8Z,11Z,14Z)-icosatetraenoic acid in which the hydroperoxy group is located at position 5.","InChI=1S/C20H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(24-23)17-15-18-20(21)22/h6-7,9-10,12-14,16,19,23H,2-5,8,11,15,17-18H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-14+","5-hydroperoxy-(6E,8Z,11Z,14Z)-eicosatetraenoic acid",PubMed citation,10542053
5824,91136,"5(S),11(R)-DiHETE","A DiHETE that is (6E,8Z,12E,14Z)-icosatetraenoic acid in which the two hydroxy substituents are placed at the 5S- and 11R-positions.","InChI=1S/C20H32O4/c1-2-3-4-5-6-7-9-13-18(21)14-10-8-11-15-19(22)16-12-17-20(23)24/h6-11,13,15,18-19,21-22H,2-5,12,14,16-17H2,1H3,(H,23,24)/b7-6-,10-8-,13-9+,15-11+/t18-,19+/m0/s1","(5S,6E,8Z,11R,12E,14Z)-5,11-dihydroxyicosatetraenoic acid",LIPID MAPS instance accession,LMFA03060095
5825,91138,"5(S),15(R)-DiHETE","A DiHETE that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroxy substituents are placed at the 5S- and 15R-positions.","InChI=1S/C20H32O4/c1-2-3-9-13-18(21)14-10-7-5-4-6-8-11-15-19(22)16-12-17-20(23)24/h5-8,10-11,14-15,18-19,21-22H,2-4,9,12-13,16-17H2,1H3,(H,23,24)/b7-5-,8-6-,14-10+,15-11+/t18-,19-/m1/s1","(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosatetraenoic acid",LIPID MAPS instance accession,LMFA03060096
5826,91144,1-octadecylglycero-3-phosphocholine,A 1-alkylglycero-3-phosphocholine in which the alkyl group is specified as octadecyl.,"InChI=1S/C26H56NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-31-24-26(28)25-33-34(29,30)32-23-21-27(2,3)4/h26,28H,5-25H2,1-4H3",lyso-PAF C-18,CAS Registry Number,72490-82-5
5827,91146,N-[(15Z)-tetracosenoyl]sphinganine-1-phosphocholine,A N-acylsphinganine-1-phosphocholine in which the acyl group specified is (15Z)-tetracosenoyl.,"InChI=1S/C47H95N2O6P/c1-6-8-10-12-14-16-18-20-21-22-23-24-25-26-27-29-31-33-35-37-39-41-47(51)48-45(44-55-56(52,53)54-43-42-49(3,4)5)46(50)40-38-36-34-32-30-28-19-17-15-13-11-9-7-2/h20-21,45-46,50H,6-19,22-44H2,1-5H3,(H-,48,51,52,53)/b21-20-/t45-,46+/m0/s1",SM(d18:0/24:1),LIPID MAPS instance accession,LMSP03010023
5828,91150,Phe-Leu,A dipeptide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of L-leucine.,"InChI=1S/C15H22N2O3/c1-10(2)8-13(15(19)20)17-14(18)12(16)9-11-6-4-3-5-7-11/h3-7,10,12-13H,8-9,16H2,1-2H3,(H,17,18)(H,19,20)/t12-,13-/m0/s1",phenylalanylleucine,CAS Registry Number,3303-55-7
5829,91152,8-(methylsulfinyl)octyl isothiocyanate,A member of the class of isothiocyanates that is octyl isothiocyanate in which one of the methyl hydrogens at position 8 has been replaced by a methylsulfinyl group.,"InChI=1S/C10H19NOS2/c1-14(12)9-7-5-3-2-4-6-8-11-10-13/h2-9H2,1H3",8-MeSO-octyl-NCS,Reaxys Registry Number,1708483
5830,91153,1-cyano-8-(methylsulfinyl)octane,A member of the class of aliphatic nitriles that is nonanenitrile in which one of the methyl hydrogens at position 9 has been replaced by a methylsulfinyl group.,"InChI=1S/C10H19NOS/c1-13(12)10-8-6-4-2-3-5-7-9-11/h2-8,10H2,1H3",8-MeSO-octyl-CN,Reaxys Registry Number,7914995
5831,91154,1-cyano-8-(methylsulfinyl)heptane,A member of the class of aliphatic nitriles that is octanenitrile in which one of the methyl hydrogens at position 8 has been replaced by a methylsulfinyl group.,"InChI=1S/C9H17NOS/c1-12(11)9-7-5-3-2-4-6-8-10/h2-7,9H2,1H3",7-MeSO-heptyl-CN,Reaxys Registry Number,5496217
5832,91155,7-(methylsulfinyl)heptylamine,A primary amino compound that is heptylamine in which one of the methyl hydrogens at position 7 has been replaced by a methylsulfinyl group.,"InChI=1S/C8H19NOS/c1-11(10)8-6-4-2-3-5-7-9/h2-9H2,1H3",7-MeSO-heptyl-NH2,Reaxys Registry Number,28063960
5833,91156,9-(methylsulfinyl)nonanoic acid,A monocarboxylic acid that is nonanoic acid in which one of the methyl hydrogens at position 9 has been replaced by a methylsulfinyl group.,"InChI=1S/C10H20O3S/c1-14(13)9-7-5-3-2-4-6-8-10(11)12/h2-9H2,1H3,(H,11,12)",8-MeSO-octyl-CO2H,Reaxys Registry Number,28063958
5834,91157,9-(methylsulfinyl)nonamide,A monocarboxylic acid amide that is nonanamide acid in which one of the methyl hydrogens at position 9 has been replaced by a methylsulfinyl group.,"InChI=1S/C10H21NO2S/c1-14(13)9-7-5-3-2-4-6-8-10(11)12/h2-9H2,1H3,(H2,11,12)",8-MeSO-octyl-CONH2,Reaxys Registry Number,28063959
5835,91158,8-(methylsulfinyl)octylamine,A primary amino compound that is octylamine in which one of the methyl hydrogens at position 8 has been replaced by a methylsulfinyl group.,"InChI=1S/C9H21NOS/c1-12(11)9-7-5-3-2-4-6-8-10/h2-10H2,1H3",8-MeSO-octyl-NH2,Reaxys Registry Number,28063961
5836,91159,8-(methylthio)octylamine,A primary amino compound that is octylamine in which one of the methyl hydrogens at position 8 has been replaced by a methylthio group.,"InChI=1S/C9H21NS/c1-11-9-7-5-3-2-4-6-8-10/h2-10H2,1H3",8-MeS-octyl-NH2,Reaxys Registry Number,1737554
5837,91162,4-hydroxyindole-3-carbaldehyde,A heteroarenecarbaldehyde that is 4-hydroxyindole in which the hydrogen at position 3 has been replaced by a formyl group.,"InChI=1S/C9H7NO2/c11-5-6-4-10-7-2-1-3-8(12)9(6)7/h1-5,10,12H",4-HO-I3CHO,Reaxys Registry Number,5506995
5838,91163,5-(6-O-malonyl-beta-D-glucosyloxy)-indole-3-carboxylic acid,An indolyl carbohydrate that is indole-3-carboxylic acid in which the hydrogen at position 5 is replaced by a 6-O-malonyl-beta-D-glucosyloxy group.,"InChI=1S/C18H19NO11/c20-12(21)4-13(22)28-6-11-14(23)15(24)16(25)18(30-11)29-7-1-2-10-8(3-7)9(5-19-10)17(26)27/h1-3,5,11,14-16,18-19,23-25H,4,6H2,(H,20,21)(H,26,27)/t11-,14-,15+,16-,18-/m1/s1",6-(Malonyl-GlcO)-I3CO2H,PubMed citation,25457500
5839,91166,"2,3-dihydroxybenzoic acid 3-O-beta-D-xyloside",A monohydroxybenzoic acid that is 2-hydroxybenzoic acid in which the hydrogen at position 3 is replaced by a beta-D-xylosyloxy group.,"InChI=1S/C12H14O8/c13-6-4-19-12(10(16)9(6)15)20-7-3-1-2-5(8(7)14)11(17)18/h1-3,6,9-10,12-16H,4H2,(H,17,18)/t6-,9+,10-,12+/m1/s1","2,3-DHBA 3-O-Xyl",PubMed citation,25457500
5840,91170,"11-sulfooxy-9,10-dihydrojasmonic acid","A dihydrojasmonic acid that is 9,10-dihydrojasmonic acid in which one of the methylene hydrogens at position 11 has been replaced by a sulfooxy group.","InChI=1S/C12H20O7S/c1-8(19-20(16,17)18)3-2-4-10-9(7-12(14)15)5-6-11(10)13/h8-10H,2-7H2,1H3,(H,14,15)(H,16,17,18)/t8?,9-,10-/m1/s1","9,10-Dihydrohydroxy-JA Sulfate",PubMed citation,25457500
5841,91182,ZM 323881 hydrochloride,A hydrochloride obtained by combining ZM 323881 with one molar equivalent of hydrochloric acid.,"InChI=1S/C22H18FN3O2.ClH/c1-14-9-18(23)20(11-21(14)27)26-22-17-8-7-16(10-19(17)24-13-25-22)28-12-15-5-3-2-4-6-15;/h2-11,13,27H,12H2,1H3,(H,24,25,26);1H",ZM 323881.HCl,Reaxys Registry Number,13172661
5842,91183,"1-(4-{[1,3-dihydroxy-1-(4-hydroxy-3-methoxyphenyl)propan-2-yl]oxy}-3,5-dimethoxyphenyl)propane-1,2,3-triol","A guaiacyl lignin that is guaiacylglycerol in which the hydrogen on the 2-hydroxy function has been replaced by a 4-(1,2,3-trihydroxypropan-1-yl)-2,6-dimethoxyphenyl group.","InChI=1S/C21H28O10/c1-28-15-6-11(4-5-13(15)24)20(27)18(10-23)31-21-16(29-2)7-12(8-17(21)30-3)19(26)14(25)9-22/h4-8,14,18-20,22-27H,9-10H2,1-3H3",G(8-O-4)S Glycerol,PubMed citation,25457500
5843,91185,ZM 323881,A member of the class of quinazolines carrying 2-fluoro-4-methyl-5-hydroxyanilino and benzyloxy substituents at positions 4 and 7 respectively.,"InChI=1S/C22H18FN3O2/c1-14-9-18(23)20(11-21(14)27)26-22-17-8-7-16(10-19(17)24-13-25-22)28-12-15-5-3-2-4-6-15/h2-11,13,27H,12H2,1H3,(H,24,25,26)",ZM323881,Reaxys Registry Number,13137893
5844,91198,LY 364947,A member of the class of pyrazoles carrying pyridin-2-yl and quinolin-4-yl substituents at positions 3 and 4 respectively.,"InChI=1S/C17H12N4/c1-2-6-15-13(5-1)12(8-10-19-15)14-11-20-21-17(14)16-7-3-4-9-18-16/h1-11H,(H,20,21)",LY-364947,Reaxys Registry Number,9492522
5845,91201,guaiacylglycerol beta-scopoletinyl ether,A guaiacyl lignin that is scopoletin in which the phenolic hydrogen is replaced by a guaiacylglycerol group. It is found in Arabidopsis thaliana.,"InChI=1S/C20H20O8/c1-25-15-8-12(3-5-13(15)22)20(24)18(10-21)27-17-9-14-11(7-16(17)26-2)4-6-19(23)28-14/h3-9,18,20-22,24H,10H2,1-2H3",G(8-O-4)Scopoletin,Reaxys Registry Number,28063973
5846,91203,"2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-7H-pyrano[2,3-g][1,4]benzodioxin-7-one",A guaiacyl lignin obtained by formal cyclocodensation between guaiacylglycerol and esculetin. It is found in Arabidopsis thaliana.,"InChI=1S/C19H16O7/c1-23-14-7-11(2-4-12(14)21)19-17(9-20)24-16-8-13-10(6-15(16)26-19)3-5-18(22)25-13/h2-8,17,19-21H,9H2,1H3",G(8-O-4)Esculetin,Reaxys Registry Number,28063974
5847,91051,ethyl N-benzoyl-L-tyrosinate,An L-tyrosine derivative that is the ethyl ester of N-benzoyltyrosine.,"InChI=1S/C18H19NO4/c1-2-23-18(22)16(12-13-8-10-15(20)11-9-13)19-17(21)14-6-4-3-5-7-14/h3-11,16,20H,2,12H2,1H3,(H,19,21)/t16-/m0/s1",PhCO-Tyr-OEt,CAS Registry Number,3483-82-7
5848,91075,PD-153035 hydrochloride,A hydrochloride obtained by combining PD-153035 with one equivalent of hydrochloric acid.,"InChI=1S/C16H14BrN3O2.ClH/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11;/h3-9H,1-2H3,(H,18,19,20);1H",PD153035.HCl,Reaxys Registry Number,7400679
5849,91076,PD-153035,A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.,"InChI=1S/C16H14BrN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)",PD 153035,CAS Registry Number,153436-54-5
5850,91080,"tetrasodium 5'-phosphonatopyridoxal-6-azobenzene-2,4-disulfonate","An organic sodium salt that is the tetrasodium salt of 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid","InChI=1S/C14H14N3O12PS2.4Na/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-3-2-8(31(23,24)25)4-12(11)32(26,27)28;;;;/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28);;;;/q;4*+1/p-4",PPADS tetrasodium salt,Reaxys Registry Number,8180951
5851,91082,"5'-phosphonatopyridoxal-6-azobenzene-2,4-disulfonate","An organophosphate oxoanion obtained by deprotonation of the phospho and sulfo groups of 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid.","InChI=1S/C14H14N3O12PS2/c1-7-13(19)9(5-18)10(6-29-30(20,21)22)14(15-7)17-16-11-3-2-8(31(23,24)25)4-12(11)32(26,27)28/h2-5,19H,6H2,1H3,(H2,20,21,22)(H,23,24,25)(H,26,27,28)/p-4",PPADS(4-),Reaxys Registry Number,8173405
5852,91087,Solvent yellow 56,"An azobenzene that is N,N-diethylaniline substituted at position 4 by a phenylazo group.","InChI=1S/C16H19N3/c1-3-19(4-2)16-12-10-15(11-13-16)18-17-14-8-6-5-7-9-14/h5-13H,3-4H2,1-2H3",Oil yellow DE,Wikipedia accession,Oil_Yellow_DE
5853,91108,SB 431542,"A member of the class of benzamides that is 4-(imidazol-2-yl)benzamide carrying additional 1,3-benzodioxol-5-yl and pyridin-2-yl substituents at positions 4 and 5 respectively on the imidazole ring.","InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)",SB431542,CAS Registry Number,301836-41-9
5854,91114,4-(dimethylamino)benzaldehyde,A member of the class of benzaldehydes that is benzaldehyde carrying a dimethylamino substituent at position 4. Used as an indicator for detection of indoles and hydrazine.,"InChI=1S/C9H11NO/c1-10(2)9-5-3-8(7-11)4-6-9/h3-7H,1-2H3",4-dimethylaminobenzaldehyde,CAS Registry Number,100-10-7
5855,91120,4-methylumbelliferyl butyate,A member of the class of coumarins that is 4-methylumbelliferone in which the hydroxyl hydrogen is replaced by a butyryl group.,"InChI=1S/C14H14O4/c1-3-4-13(15)17-10-5-6-11-9(2)7-14(16)18-12(11)8-10/h5-8H,3-4H2,1-2H3",4-methylumbelliferyl butanoate,CAS Registry Number,17695-46-4
5856,90983,(20S)-hydroxyvitamin D3,A hydroxycalciol that consists of vitamin D3 (calciol) carrying an additional hydroxy group at position 20 with S-configuration.,"InChI=1S/C27H44O2/c1-19(2)8-6-17-27(5,29)25-15-14-24-21(9-7-16-26(24,25)4)11-12-22-18-23(28)13-10-20(22)3/h11-12,19,23-25,28-29H,3,6-10,13-18H2,1-2,4-5H3/b21-11+,22-12-/t23-,24-,25-,26-,27-/m0/s1",(20S)-hydroxycholecalciferol,PubMed citation,25727742
5857,90990,"12,20-DiHETE",A DiHETE that is 12-HETE carrying an additional hydroxy substituent at position 20.,"InChI=1S/C20H32O4/c21-18-14-10-6-5-8-12-16-19(22)15-11-7-3-1-2-4-9-13-17-20(23)24/h2-4,7-8,11-12,15,19,21-22H,1,5-6,9-10,13-14,16-18H2,(H,23,24)/b4-2-,7-3-,12-8-,15-11+","(5Z,8Z,10E,14Z)-12,20-dihydroxyicosatetraenoic acid",HMDB accession,HMDB0060105
5858,90992,20-hydroxy-6-trans-leukotriene B4,A member of the class of leukotrienes that is 6-trans-leukotriene B4 bearing an additional hydroxy substituent at position 20.,"InChI=1S/C20H32O5/c21-17-10-6-2-1-3-7-12-18(22)13-8-4-5-9-14-19(23)15-11-16-20(24)25/h3-5,7-9,13-14,18-19,21-23H,1-2,6,10-12,15-17H2,(H,24,25)/b5-4+,7-3-,13-8+,14-9+/t18-,19-/m1/s1",20-hydroxy-6-trans-LTB4,PubMed citation,9675028
5859,90995,12(S)-HETrE,"A HETrE that is (8Z,10E,14Z)-icosatrienoic acid in which the hydroxy group is located at the 12(S)-posiiton.","InChI=1S/C20H34O3/c1-2-3-4-5-10-13-16-19(21)17-14-11-8-6-7-9-12-15-18-20(22)23/h8,10-11,13-14,17,19,21H,2-7,9,12,15-16,18H2,1H3,(H,22,23)/b11-8-,13-10-,17-14+/t19-/m0/s1","(12S)-hydroxy-(8Z,10E,14Z)-icosatrienoic acid",PubMed citation,22984144
5860,91001,18-oxoresolvin E1(1-),An icosanoid anion resulting from the removal of a proton from the carboxy group of 18-oxoresolvin E1; major species at pH 7.3.,"InChI=1S/C20H28O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-9,11-13,18-19,22-23H,2,10,14-16H2,1H3,(H,24,25)/p-1/b4-3+,9-5-,11-8+,12-6+,13-7-/t18-,19+/m0/s1","18-oxo-5S,12R-dihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoate",PubMed citation,16757471
5861,91002,sucrose 6(G)-phosphate(2-),An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of sucrose 6(G)-phosphate; major species at pH 7.3.,"InChI=1S/C12H23O14P/c13-1-4-7(16)10(19)12(3-14,25-4)26-11-9(18)8(17)6(15)5(24-11)2-23-27(20,21)22/h4-11,13-19H,1-3H2,(H2,20,21,22)/p-2/t4-,5-,6-,7-,8+,9-,10+,11-,12+/m1/s1",sucrose 6(G)-phosphate,MetaCyc accession,CPD-15716
5862,91006,"2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxy-19-norvitamin D3","A vitamin D that is 19-norcalcitriol carrying an additional 3-hydroxypropyl substituent at position 2. A synthetic analogue of vitamin D, it exhibits anticancer properties.","InChI=1S/C29H50O4/c1-20(8-5-15-28(2,3)33)24-13-14-25-22(9-6-16-29(24,25)4)12-11-21-18-26(31)23(10-7-17-30)27(32)19-21/h11-12,20,23-27,30-33H,5-10,13-19H2,1-4H3/b21-11-,22-12+/t20-,23-,24-,25+,26-,27-,29-/m1/s1",MART-10,Reaxys Registry Number,9533244
5863,91021,S-propyl propanethiosulfinate,A sulfinic acid derivative obtained by formal condensation of propanethiosulfinic acid with propanethiol.,"InChI=1S/C6H14OS2/c1-3-5-8-9(7)6-4-2/h3-6H2,1-2H3",S-propyl propane-1-thiosulfinate,CAS Registry Number,1948-52-3
5864,91027,biliverdin hydrochloride,A hydrochloride obtained by combining biliverdin with one molar equivalent of hydrogen chloride.,"InChI=1S/C33H34N4O6.ClH/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26;/h7-8,13-15,35H,1-2,9-12H2,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41);1H/b26-13-,27-14-,28-15-;",biliverdin monohydrochloride,Reaxys Registry Number,11158848
5865,91028,sodium dehydroepiandrosterone sulfate,An organic sodium salt that is the monosodium salt of dehydroepiandrosterone sulfate.,"InChI=1S/C19H28O5S.Na/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18;/h3,13-16H,4-11H2,1-2H3,(H,21,22,23);/q;+1/p-1/t13-,14-,15-,16-,18-,19-;/m0./s1",sodium 3beta-hydroxyandrost-5-en-17-one 3-sulfate,PubMed citation,1403604
5866,91033,1-O-(D-glucosyl)glycerol,A glucosylglycerol consisting of a D-glucosyl residue attached at position 1 of glycerol via a glycosidic bond.,"InChI=1S/C9H18O8/c10-1-4(12)3-16-9-8(15)7(14)6(13)5(2-11)17-9/h4-15H,1-3H2/t4?,5-,6-,7+,8-,9?/m1/s1",glucosylglycerol,GlyTouCan accession,G23487NW
5867,91034,beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-N-tetradecanoylsphingosine,A beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine in which the acyl group specified is tetradecanoyl.,"InChI=1S/C44H83NO13/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-33(48)32(45-36(49)28-26-24-22-20-17-14-12-10-8-6-4-2)31-55-43-41(54)39(52)42(35(30-47)57-43)58-44-40(53)38(51)37(50)34(29-46)56-44/h25,27,32-35,37-44,46-48,50-54H,3-24,26,28-31H2,1-2H3,(H,45,49)/b27-25+/t32-,33+,34+,35+,37-,38-,39+,40+,41+,42+,43+,44-/m0/s1",LacCer(d18:1/14:0),LIPID MAPS instance accession,LMSP0501AB12
5868,91035,propyl linoleate,A fatty acid ester resulting from the formal condensation of the carboxy group of linoleic acid with the hydroxy group of propanol.,"InChI=1S/C21H38O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21(22)23-20-4-2/h8-9,11-12H,3-7,10,13-20H2,1-2H3/b9-8-,12-11-",linoleic acid propyl ester,Reaxys Registry Number,2117597
5869,91037,L-o-tyrosine,A 2-hydroxyphenylalanine that has L-configuration.,"InChI=1S/C9H11NO3/c10-7(9(12)13)5-6-3-1-2-4-8(6)11/h1-4,7,11H,5,10H2,(H,12,13)/t7-/m0/s1",L-3-(2-hydroxyphenyl)alanine,Reaxys Registry Number,2416158
5870,91041,D-o-tyrosine,A 2-hydroxyphenylalanine that has D-configuration.,"InChI=1S/C9H11NO3/c10-7(9(12)13)5-6-3-1-2-4-8(6)11/h1-4,7,11H,5,10H2,(H,12,13)/t7-/m1/s1",D-2-tyrosine,Reaxys Registry Number,2416159
5871,91043,2-naphthyl dihydrogen phosphate,An aryl phosphate resulting from the formal condensation of phosphoric acid with 1 mol eq. of 2-naphthol. It is a substrate for phosphatase.,"InChI=1S/C10H9O4P/c11-15(12,13)14-10-6-5-8-3-1-2-4-9(8)7-10/h1-7H,(H2,11,12,13)",2-naphthyl phosphate,CAS Registry Number,13095-41-5
5872,90925,QINTAKWWKTHF,A twelve-membered polypeptide comprising the sequence Gln-Ile-Asn-Thr-Ala-Lys-Trp-Trp-Lys-Thr-His-Phe.,"InChI=1S/C75H106N20O17/c1-6-39(2)61(93-65(101)49(78)26-27-59(79)98)72(108)91-57(34-60(80)99)71(107)95-62(41(4)96)73(109)85-40(3)64(100)86-52(24-14-16-28-76)66(102)88-55(32-45-36-83-51-23-13-11-21-48(45)51)69(105)89-54(31-44-35-82-50-22-12-10-20-47(44)50)68(104)87-53(25-15-17-29-77)67(103)94-63(42(5)97)74(110)90-56(33-46-37-81-38-84-46)70(106)92-58(75(111)112)30-43-18-8-7-9-19-43/h7-13,18-23,35-42,49,52-58,61-63,82-83,96-97H,6,14-17,24-34,76-78H2,1-5H3,(H2,79,98)(H2,80,99)(H,81,84)(H,85,109)(H,86,100)(H,87,104)(H,88,102)(H,89,105)(H,90,110)(H,91,108)(H,92,106)(H,93,101)(H,94,103)(H,95,107)(H,111,112)/t39?,40-,41?,42?,49-,52-,53-,54-,55-,56-,57-,58-,61-,62-,63-/m0/s1",L-Gln-L-Ile-L-Asn-L-Thr-L-Ala-L-Lys-L-Trp-L-Trp-L-Lys-L-Thr-L-His-L-Phe,PubMed citation,26405107
5873,90970,"1alpha,23(S),25-trihydroxyvitamin D3","A hydroxycalciol that consists of vitamin D3 (calciol) bearing additional hydroxy substituents at positions 1, 23 and 25 (with 1alpha,23S-configuration). An intermediate in the degradation pathway of 1alpha,25-(OH)2D3.","InChI=1S/C27H44O4/c1-17(13-22(29)16-26(3,4)31)23-10-11-24-19(7-6-12-27(23,24)5)8-9-20-14-21(28)15-25(30)18(20)2/h8-9,17,21-25,28-31H,2,6-7,10-16H2,1,3-5H3/b19-8+,20-9-/t17-,21-,22+,23-,24+,25+,27-/m1/s1","1alpha,23S,25-trihydroxy vitamin D3",PubMed citation,17646648
5874,90977,LOSGM1,"A lipooligosaccharide, prepared from Campylobacter jejuni (strain HS:19). It binds with cholera toxin B.","InChI=1S/C157H283N4O75P3/c1-9-15-21-27-33-39-41-42-44-50-56-62-68-74-112(182)215-96(72-66-60-54-48-38-32-26-20-14-6)78-114(184)223-141-118(161-110(180)77-95(71-65-59-53-47-37-31-25-19-13-5)214-111(181)73-67-61-55-49-43-40-34-28-22-16-10-2)146(211-89-107-123(189)138(222-113(183)76-94(172)70-64-58-52-46-36-30-24-18-12-4)117(148(220-107)236-239(208,209)210)160-109(179)75-93(171)69-63-57-51-45-35-29-23-17-11-3)221-108(137(141)235-238(205,206)207)90-212-156(154(198)199)80-98(174)133(135(232-156)101(177)83-164)225-153-130(196)143(145(134(226-153)102(178)88-213-237(202,203)204)231-150-127(193)125(191)121(187)104(85-166)218-150)230-152-129(195)142(128(194)132(224-152)100(176)82-163)229-151-131(197)144(234-157(155(200)201)79-97(173)115(158-91(7)169)140(233-157)119(185)99(175)81-162)136(106(87-168)219-151)227-147-116(159-92(8)170)139(122(188)105(86-167)216-147)228-149-126(192)124(190)120(186)103(84-165)217-149/h93-108,115-153,162-168,171-178,185-197H,9-90H2,1-8H3,(H,158,169)(H,159,170)(H,160,179)(H,161,180)(H,198,199)(H,200,201)(H2,202,203,204)(H2,205,206,207)(H2,208,209,210)/t93-,94-,95-,96-,97+,98-,99-,100-,101-,102+,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-,119-,120+,121-,122+,123-,124+,125+,126-,127-,128-,129+,130+,131-,132-,133-,134-,135-,136+,137-,138-,139-,140-,141-,142+,143-,144-,145-,146-,147+,148-,149+,150+,151+,152-,153+,156-,157+/m1/s1",lipooligosaccharide(GM1),PubMed citation,26405107
5875,90861,calcipotriol hydrate,"A hydrate that is the monohydrate form of calcipotriol. It is used in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients.","InChI=1S/C27H40O3.H2O/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2;/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3;1H2/b13-6+,19-7+,21-10-;/t17-,22-,23-,24+,25-,26+,27-;/m1./s1",calcipotriene monohydrate,KEGG DRUG accession,D10198
5876,90892,2-imino-3-(indol-3-yl)propanoate,"A monocarboxylic acid anion  that is the conjugate base of 2-imino-3-(indol-3-yl)propanoic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C11H10N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,12-13H,5H2,(H,14,15)/p-1",IPAimine,MetaCyc accession,CPD-11890
5877,90912,rolapitant hydrochloride (anhydrous),A hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of the hydrate) for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.,"InChI=1S/C25H26F6N2O2.ClH/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22;/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34);1H/t16-,22-,23-;/m1./s1",rolapitant monohydrochloride,CAS Registry Number,858102-79-1
5878,90916,FPAWFTKLYPRT,A twelve-membered polypeptide comprising the sequence Phe-Pro-Ala-Trp-Phe-Thr-Lys-Leu-Tyr-Pro-Arg-Thr.,"InChI=1S/C77H107N17O16/c1-43(2)37-57(68(101)90-60(40-49-29-31-51(97)32-30-49)75(108)94-36-18-28-62(94)72(105)85-56(26-16-34-82-77(80)81)67(100)92-64(46(5)96)76(109)110)88-66(99)55(25-14-15-33-78)86-73(106)63(45(4)95)91-70(103)58(39-48-21-10-7-11-22-48)89-69(102)59(41-50-42-83-54-24-13-12-23-52(50)54)87-65(98)44(3)84-71(104)61-27-17-35-93(61)74(107)53(79)38-47-19-8-6-9-20-47/h6-13,19-24,29-32,42-46,53,55-64,83,95-97H,14-18,25-28,33-41,78-79H2,1-5H3,(H,84,104)(H,85,105)(H,86,106)(H,87,98)(H,88,99)(H,89,102)(H,90,101)(H,91,103)(H,92,100)(H,109,110)(H4,80,81,82)/t44-,45?,46?,53-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-/m0/s1",L-Phe-L-Pro-L-Ala-L-Trp-L-Phe-L-Thr-L-Lys-L-Leu-L-Tyr-L-Pro-L-Arg-L-Thr,PubMed citation,26405107
5879,90787,alpha-D-Manp-(1->3)-[alpha-D-Manp6P-(1->6)]-alpha-D-Manp-(1->6)-[alpha-D-Manp6P-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"An oligosaccharide phosphate consisting of a linear chain of beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-D-glucosamine residues all linked (1->4), to the mannose residue of which are also linked (1->3) and (1->6) respectively a 6-O-phosphono-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl disaccharide unit and an alpha-D-mannosyl-(1->3)-[6-O-phosphono-alpha-D-mannosyl-(1->6)]-alpha-D-mannosyl branched trisaccharide unit.","InChI=1S/C52H90N2O47P2/c1-11(59)53-21-29(67)40(15(5-57)89-45(21)78)97-46-22(54-12(2)60)30(68)41(16(6-58)92-46)98-51-39(77)43(100-52-44(34(72)24(62)14(4-56)91-52)101-50-37(75)33(71)26(64)20(96-50)10-88-103(82,83)84)28(66)18(95-51)8-86-48-38(76)42(99-49-36(74)31(69)23(61)13(3-55)90-49)27(65)17(93-48)7-85-47-35(73)32(70)25(63)19(94-47)9-87-102(79,80)81/h13-52,55-58,61-78H,3-10H2,1-2H3,(H,53,59)(H,54,60)(H2,79,80,81)(H2,82,83,84)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42+,43+,44+,45?,46+,47+,48+,49-,50-,51+,52-/m1/s1",alpha-D-mannosyl-(1->3)-[6-O-phosphono-alpha-D-mannosyl-(1->6)]-alpha-D-mannosyl-(1->6)-[6-O-phosphono-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->3)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine,PubMed citation,26503547
5880,90808,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp6P-(1->6)]-alpha-D-Manp-(1->6)-[alpha-D-Manp6P-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"An oligosaccharide phosphate consisting of a linear chain of beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-D-glucosamine residues all linked (1->4), to the mannose residue of which are also linked (1->3) and (1->6) respectively a 6-O-phosphono-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl disaccharide unit and an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->3)-[6-O-phosphono-alpha-D-mannosyl-(1->6)]-alpha-D-mannosyl branched tetrasaccharide unit.","InChI=1S/C58H100N2O52P2/c1-12(66)59-23-32(75)44(17(6-64)98-50(23)87)107-51-24(60-13(2)67)33(76)45(18(7-65)102-51)108-56-43(86)47(110-58-49(38(81)27(70)16(5-63)101-58)112-55-41(84)36(79)29(72)22(106-55)11-97-114(91,92)93)31(74)20(105-56)9-95-53-42(85)46(30(73)19(103-53)8-94-52-39(82)35(78)28(71)21(104-52)10-96-113(88,89)90)109-57-48(37(80)26(69)15(4-62)100-57)111-54-40(83)34(77)25(68)14(3-61)99-54/h14-58,61-65,68-87H,3-11H2,1-2H3,(H,59,66)(H,60,67)(H2,88,89,90)(H2,91,92,93)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45-,46+,47+,48+,49+,50?,51+,52+,53+,54-,55-,56+,57-,58-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man6P-(1->6)]-alpha-D-Man-(1->6)-[alpha-D-Man6P-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,26503547
5881,90843,cangrelor(4-),An organophosphate oxoanion obtained by deprotonation of the phosphate and phosphonate OH groups of cangrelor.,"InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/p-4/t8-,10-,11-,14-/m1/s1",cangrelor tetra-anion,Reaxys Registry Number,24729035
5882,108517,"1-tetradecanoyl-2,3-dihexadecanoyl-sn-glycerol",A triacyl-sn-glycerol in which the 1-acyl group is tetradecanoyl while the 2- and 3-acyl groups are hexadecanoyl.,"InChI=1S/C49H94O6/c1-4-7-10-13-16-19-22-24-27-30-33-36-39-42-48(51)54-45-46(44-53-47(50)41-38-35-32-29-26-21-18-15-12-9-6-3)55-49(52)43-40-37-34-31-28-25-23-20-17-14-11-8-5-2/h46H,4-45H2,1-3H3/t46-/m1/s1","1-myristoyl-2,3-dipalmitoyl-sn-glycerol",LIPID MAPS instance accession,LMGL03012786
5883,108633,1-tetradecanoyl-2-hexadecanoyl-3-octadecanoyl-sn-glycerol,"A triacyl-sn-glycerol in which the which the acyl groups at positions 1, 2 and 3 are specified as tetradecanoyl, hexadecanoyl and octadecanoyl respectively.","InChI=1S/C51H98O6/c1-4-7-10-13-16-19-22-24-25-27-29-32-35-38-41-44-50(53)56-47-48(46-55-49(52)43-40-37-34-31-28-21-18-15-12-9-6-3)57-51(54)45-42-39-36-33-30-26-23-20-17-14-11-8-5-2/h48H,4-47H2,1-3H3/t48-/m1/s1",TG(14:0/16:0/18:0),LIPID MAPS instance accession,LMGL03014225
5884,108918,1-tetradecanoyl-2-hexadecanoyl-3-[(9Z)-octadecenoyl]-sn-glycerol,"A triacyl-sn-glycerol in which the which the acyl groups at positions 1, 2 and 3 are specified as tetradecanoyl, hexadecanoyl and (9Z)-octadecenoyl respectively.","InChI=1S/C51H96O6/c1-4-7-10-13-16-19-22-24-25-27-29-32-35-38-41-44-50(53)56-47-48(46-55-49(52)43-40-37-34-31-28-21-18-15-12-9-6-3)57-51(54)45-42-39-36-33-30-26-23-20-17-14-11-8-5-2/h24-25,48H,4-23,26-47H2,1-3H3/b25-24-/t48-/m1/s1",1-myristoyl-2-palmitoyl-3-oleoyl-sn-glycerol,LIPID MAPS instance accession,LMGL03014226
5885,109146,"1-tetradecanoyl-2,3-dioleoyl-sn-glycerol",A triacyl-sn-glycerol in which the 1-acyl group is tetradecanoyl while the 2- and 3-acyl groups are oleoyl.,"InChI=1S/C53H98O6/c1-4-7-10-13-16-19-22-24-26-28-31-34-37-40-43-46-52(55)58-49-50(48-57-51(54)45-42-39-36-33-30-21-18-15-12-9-6-3)59-53(56)47-44-41-38-35-32-29-27-25-23-20-17-14-11-8-5-2/h24-27,50H,4-23,28-49H2,1-3H3/b26-24-,27-25-/t50-/m1/s1","1-tetradecanoyl-2,3-bis[(9Z)-octadecenoyl]-sn-glycerol",Reaxys Registry Number,27699301
5886,109895,beta-carboline,"The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.","InChI=1S/C11H8N2/c1-2-4-10-8(3-1)9-5-6-12-7-11(9)13-10/h1-7,13H",9H-beta-Carboline,Beilstein Registry Number,128414
5887,109896,"1-hexadecanoyl-2,3-dioctadecanoyl-sn-glycerol","A triacyl-sn-glycerol in which the which the acyl groups at position 1 is specified as hexadecanoyl, while those at positions 2 and 3 are specified as octadecanoyl","InChI=1S/C55H106O6/c1-4-7-10-13-16-19-22-25-27-30-33-36-39-42-45-48-54(57)60-51-52(50-59-53(56)47-44-41-38-35-32-29-24-21-18-15-12-9-6-3)61-55(58)49-46-43-40-37-34-31-28-26-23-20-17-14-11-8-5-2/h52H,4-51H2,1-3H3/t52-/m1/s1",TG(16:0/18:0/18:0),LIPID MAPS instance accession,LMGL03010069
5888,110423,clodronic acid,"An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.","InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)",(Dichloro-phosphono-methyl)-phosphonic acid,PubMed citation,15658873
5889,101096,ethoxzolamide,"A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.","InChI=1S/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)",6-Ethoxy-benzothiazole-2-sulfonic acid amide,PubMed citation,15546717
5890,101257,GGTI-2133 free base,An N-acyl-L-amino acid obtained by condensation of the carboxy group of 4-{[(imidazol-4-yl)methyl]amino}-2-(naphthalen-1-yl)benzoic acid with the amino group of L-leucine. An inhibitor of geranylgeranyltransferase type I.,"InChI=1S/C27H28N4O3/c1-17(2)12-25(27(33)34)31-26(32)23-11-10-19(29-15-20-14-28-16-30-20)13-24(23)22-9-5-7-18-6-3-4-8-21(18)22/h3-11,13-14,16-17,25,29H,12,15H2,1-2H3,(H,28,30)(H,31,32)(H,33,34)/t25-/m0/s1",GGTI 2133 free base,Reaxys Registry Number,25113814
5891,101279,GGTI-2133,An organoammonium salt resulting from the mixing of equimolar amounts of GGTI-2133 free base and trifluoroacetic acid. An inhibitor of geranylgeranyltransferase type I.,"InChI=1S/C27H28N4O3.C2HF3O2/c1-17(2)12-25(27(33)34)31-26(32)23-11-10-19(29-15-20-14-28-16-30-20)13-24(23)22-9-5-7-18-6-3-4-8-21(18)22;3-2(4,5)1(6)7/h3-11,13-14,16-17,25,29H,12,15H2,1-2H3,(H,28,30)(H,31,32)(H,33,34);(H,6,7)/t25-;/m0./s1",GGTI 2133,PubMed citation,23335799
5892,101381,aloxistatin,"An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide.","InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1",E64d,CAS Registry Number,88321-09-9
5893,102218,dimethyloxalylglycine,A glycine derivative that is the diester obtained by formal condensation of the carboxy groups of N-oxalylglycine with two molecules of methanol.,"InChI=1S/C6H9NO5/c1-11-4(8)3-7-5(9)6(10)12-2/h3H2,1-2H3,(H,7,9)",DMOG,Reaxys Registry Number,2096268
5894,102257,6-azathymidine 5'-monophosphate,"A N-glycosyl-1,2,4-triazine that is the 6-aza analogue of thymidine 5'-monophosphate.","InChI=1S/C9H14N3O8P/c1-4-8(14)10-9(15)12(11-4)7-2-5(13)6(20-7)3-19-21(16,17)18/h5-7,13H,2-3H2,1H3,(H,10,14,15)(H2,16,17,18)/t5-,6+,7+/m0/s1",6-azathymidine 5'-phosphate,Reaxys Registry Number,50644
5895,102265,sulfamethazine,A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position.,"InChI=1S/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)","4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide",PubMed citation,17311370
5896,102266,"N(2)-acetyl-N(6)-(1,4-dihydroxynonan-3-yl)-L-lysine","An L-lysine derivative in which the alpha-amino nitrogen of the amino acid has entered into amide formation with acetic acid and the epsilon-amino nitrogen carries a 1,4-dihydroxynonan-3-yl substituent. It has been synthesised by reaction of (E)-4-hydroxynon-2-enal (HNE) with N(2)-acetyl-L-lysine, the epsilon amino group of lysine reacting with the double bond function of HNE via formation of a Michael adduct.","InChI=1S/C17H34N2O5/c1-3-4-5-9-16(22)14(10-12-20)18-11-7-6-8-15(17(23)24)19-13(2)21/h14-16,18,20,22H,3-12H2,1-2H3,(H,19,21)(H,23,24)/t14?,15-,16?/m0/s1","N(alpha)-acetyl-N(epsilon)-(1,4-dihydroxynonan-3-yl)-L-lysine",PubMed citation,26800898
5897,102466,8-aza-2'-deoxyadenosine 5'-monophosphate,A 2'-deoxyribonucleoside 5'-monophosphate that is the 8-aza analogue of 2'-deoxyadenosine 5'-monophosphate.,"InChI=1S/C9H13N6O6P/c10-8-7-9(12-3-11-8)15(14-13-7)6-1-4(16)5(21-6)2-20-22(17,18)19/h3-6,16H,1-2H2,(H2,10,11,12)(H2,17,18,19)/t4-,5+,6+/m0/s1",8-aza-2'-deoxyadenosine monophosphate,PubMed citation,22817898
5898,102517,5-carboxy-2'-deoxyuridine 5'-monophosphate,A nucleoside monophosphate analogue that is 2'-deoxyuridine-5'-monophosphate in which the hydrogen at position 5 on the uracil ring is replaced by a carboxy group.,"InChI=1S/C10H13N2O10P/c13-5-1-7(22-6(5)3-21-23(18,19)20)12-2-4(9(15)16)8(14)11-10(12)17/h2,5-7,13H,1,3H2,(H,15,16)(H,11,14,17)(H2,18,19,20)/t5-,6+,7+/m0/s1",5-carboxy-dUMP,PubMed citation,22817898
5899,102524,butalbital,"A member of the class of  barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache.","InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)","5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione",PubMed citation,6864729
5900,102525,N(6)-carbamoylmethyladenine,A nucleobase analogue that is adenine in which one of the exocyclic amino hydrogens is replaced by a carbamoylmethyl group.,"InChI=1S/C7H8N6O/c8-4(14)1-9-6-5-7(11-2-10-5)13-3-12-6/h2-3H,1H2,(H2,8,14)(H2,9,10,11,12,13)",2-(9H-purin-6-ylamino)acetamide,PubMed citation,22817898
5901,102719,N(6)-carbamoylmethyl-2'-deoxyadenosine,A nucleoside analogue that is adenosine in which one of the exocyclic amino hydrogens is replaced by a carbamoylmethyl group.,"InChI=1S/C12H16N6O4/c13-8(21)2-14-11-10-12(16-4-15-11)18(5-17-10)9-1-6(20)7(3-19)22-9/h4-7,9,19-20H,1-3H2,(H2,13,21)(H,14,15,16)/t6-,7+,9+/m0/s1",N(6)-(carbamoylmethyl)deoxyadenosine,CAS Registry Number,89014-18-6
5902,103067,N(6)-carbamoylmethyl-2'-deoxyadenosine 5'-monophosphate,A nucleoside monophosphate analogue that is dAMP in which one of the exocyclic amino hydrogens is replaced by a carbamoylmethyl group.,"InChI=1S/C12H17N6O7P/c13-8(20)2-14-11-10-12(16-4-15-11)18(5-17-10)9-1-6(19)7(25-9)3-24-26(21,22)23/h4-7,9,19H,1-3H2,(H2,13,20)(H,14,15,16)(H2,21,22,23)/t6-,7+,9+/m0/s1",N(6)-carbamoylmethyldeoxyadenosine monophosphate,PubMed citation,22817898
5903,103211,"1,2-ditetradecanoyl-sn-glycero-3-cytidine 5'-diphosphate",A CDP-diacylglycerol in which the acyl groups at positions 1 and 2 are specified as tetradecanoyl.,"InChI=1S/C40H73N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-35(44)53-29-32(56-36(45)26-24-22-20-18-16-14-12-10-8-6-4-2)30-54-59(49,50)58-60(51,52)55-31-33-37(46)38(47)39(57-33)43-28-27-34(41)42-40(43)48/h27-28,32-33,37-39,46-47H,3-26,29-31H2,1-2H3,(H,49,50)(H,51,52)(H2,41,42,48)/t32-,33-,37-,38-,39-/m1/s1","CDP-1,2-ditetradecanoyl-sn-glycerol",MetaCyc accession,CPD-18388
5904,103990,"1,2-ditetradec-7-enoyl-sn-glycero-3-cytidine 5'-diphosphate",A CDP-diacylglycerol in which the acyl groups at positions 1 and 2 are specified as tetradec-7-enoyl.,"InChI=1S/C40H69N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-35(44)53-29-32(56-36(45)26-24-22-20-18-16-14-12-10-8-6-4-2)30-54-59(49,50)58-60(51,52)55-31-33-37(46)38(47)39(57-33)43-28-27-34(41)42-40(43)48/h13-16,27-28,32-33,37-39,46-47H,3-12,17-26,29-31H2,1-2H3,(H,49,50)(H,51,52)(H2,41,42,48)/t32-,33-,37-,38-,39-/m1/s1","CDP-1,2-ditetradec-7-enoylglycerol",PubMed citation,22817898
5905,104012,"1,2-dihexadec-9-enoyl-sn-glycero-3-cytidine 5'-diphosphate",A CDP-diacylglycerol in which the acyl groups at positions 1 and 2 are specified as hexadec-9-enoyl.,"InChI=1S/C44H77N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-39(48)57-33-36(60-40(49)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)34-58-63(53,54)62-64(55,56)59-35-37-41(50)42(51)43(61-37)47-32-31-38(45)46-44(47)52/h13-16,31-32,36-37,41-43,50-51H,3-12,17-30,33-35H2,1-2H3,(H,53,54)(H,55,56)(H2,45,46,52)/t36-,37-,41-,42-,43-/m1/s1","CDP-1,2-dihexadec-9-enoyl-sn-glycerol",PubMed citation,22817898
5906,104121,"1,2-dioctadecanoyl-sn-glycero-3-cytidine 5'-diphosphate",A CDP-diacylglycerol in which both of the phosphatidyl acyl groups are specified as octadecanoyl (stearoyl).,"InChI=1S/C48H89N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-43(52)61-37-40(64-44(53)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)38-62-67(57,58)66-68(59,60)63-39-41-45(54)46(55)47(65-41)51-36-35-42(49)50-48(51)56/h35-36,40-41,45-47,54-55H,3-34,37-39H2,1-2H3,(H,57,58)(H,59,60)(H2,49,50,56)/t40-,41-,45-,46-,47-/m1/s1","1,2-distearoyl-sn-glycero-3-cytidine 5'-diphosphate",HMDB accession,HMDB0006978
5907,104362,"1,2-dioctadec-11-enoyl-sn-glycero-3-cytidine 5'-diphosphate",A CDP-diacylglycerol in which the acyl groups at positions 1 and 2 are specified as octadec-11-enoyl.,"InChI=1S/C48H85N3O15P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-43(52)61-37-40(64-44(53)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)38-62-67(57,58)66-68(59,60)63-39-41-45(54)46(55)47(65-41)51-36-35-42(49)50-48(51)56/h13-16,35-36,40-41,45-47,54-55H,3-12,17-34,37-39H2,1-2H3,(H,57,58)(H,59,60)(H2,49,50,56)/t40-,41-,45-,46-,47-/m1/s1","CDP-1,2-dioctadec-11-enoyl-sn-glycerol",PubMed citation,22817898
5908,104586,tetrahexadecanoyl cardiolipin,A cardiolipin in which all four of the phosphatidyl acyl groups are specified as hexadecanoyl (pamitoyl).,"InChI=1S/C73H142O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-70(75)83-63-68(89-72(77)59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)65-87-91(79,80)85-61-67(74)62-86-92(81,82)88-66-69(90-73(78)60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)64-84-71(76)58-54-50-46-42-38-34-30-26-22-18-14-10-6-2/h67-69,74H,5-66H2,1-4H3,(H,79,80)(H,81,82)/t68-,69-/m1/s1",tetrapalmitoyl cardiolipin,MetaCyc accession,CPD-12824
5909,104873,tetrahexadec-9-enoyl cardiolipin,A cardiolipin in which all four of the phosphatidyl acyl groups are specified as hexadec-9-enoyl,"InChI=1S/C73H134O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-70(75)83-63-68(89-72(77)59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)65-87-91(79,80)85-61-67(74)62-86-92(81,82)88-66-69(90-73(78)60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)64-84-71(76)58-54-50-46-42-38-34-30-26-22-18-14-10-6-2/h25-32,67-69,74H,5-24,33-66H2,1-4H3,(H,79,80)(H,81,82)/t67?,68-,69-/m1/s1","cardiolipin (tetrahexadec-9-enoyl, n-C16:1)",PubMed citation,22817898
5910,105685,tetraoctadec-11-enoyl cardiolipin,A cardiolipin in which all four of the phosphatidyl acyl groups are specified as octadec-11-enoyl.,"InChI=1S/C81H150O17P2/c1-5-9-13-17-21-25-29-33-37-41-45-49-53-57-61-65-78(83)91-71-76(97-80(85)67-63-59-55-51-47-43-39-35-31-27-23-19-15-11-7-3)73-95-99(87,88)93-69-75(82)70-94-100(89,90)96-74-77(98-81(86)68-64-60-56-52-48-44-40-36-32-28-24-20-16-12-8-4)72-92-79(84)66-62-58-54-50-46-42-38-34-30-26-22-18-14-10-6-2/h25-32,75-77,82H,5-24,33-74H2,1-4H3,(H,87,88)(H,89,90)/t75?,76-,77-/m1/s1",CL(18:1/18:1/18:1/18:1),PubMed citation,22817898
5911,116963,N-hexadecanoyl-15-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 33:1 obtained by formal condensation of the carboxy group of hexadecanoic acid with the amino group of 15-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C38H77N2O6P/c1-7-8-9-10-11-12-13-14-15-19-22-25-28-31-38(42)39-36(34-46-47(43,44)45-33-32-40(4,5)6)37(41)30-27-24-21-18-16-17-20-23-26-29-35(2)3/h27,30,35-37,41H,7-26,28-29,31-34H2,1-6H3,(H-,39,42,43,44)/b30-27+/t36-,37+/m0/s1",N-hexadecanoyl-15-methylhexadecasphing-4-enine-1-phosphocholine,PubMed citation,23894595
5912,117048,N-hexacosanoyl-14-methylhexadecasphinganine-1-phosphocholine,A sphingomyelin obtained by formal condensation of the carboxy group of hexacosanoic acid with the amino group of 14-methylhexadecasphinganine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C48H99N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-32-35-38-41-48(52)49-46(44-56-57(53,54)55-43-42-50(4,5)6)47(51)40-37-34-31-29-28-30-33-36-39-45(3)8-2/h45-47,51H,7-44H2,1-6H3,(H-,49,52,53,54)/t45?,46-,47+/m0/s1",SM 43:0;3,PubMed citation,23894595
5913,119470,N-henicosanoyl-14-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 38:1 obtained by formal condensation of the carboxy group of henicosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C43H87N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-27-30-33-36-43(47)44-41(39-51-52(48,49)50-38-37-45(4,5)6)42(46)35-32-29-26-24-23-25-28-31-34-40(3)8-2/h32,35,40-42,46H,7-31,33-34,36-39H2,1-6H3,(H-,44,47,48,49)/b35-32+/t40?,41-,42+/m0/s1",N-henicosanoyl-14-methylhexadecasphing-4-enine-1-phosphocholine,PubMed citation,23894595
5914,119487,N-tetracosanoyl-14-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 41:1 obtained by formal condensation of the carboxy group of tetracosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C46H93N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-30-33-36-39-46(50)47-44(42-54-55(51,52)53-41-40-48(4,5)6)45(49)38-35-32-29-27-26-28-31-34-37-43(3)8-2/h35,38,43-45,49H,7-34,36-37,39-42H2,1-6H3,(H-,47,50,51,52)/b38-35+/t43?,44-,45+/m0/s1",N-tetracosanoyl-14-methylhexadecasphing-4-enine-1-phosphocholine,PubMed citation,23894595
5915,119674,N-pentacosanoyl-14-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 42:1 obtained by formal condensation of the carboxy group of pentacosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C47H95N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-31-34-37-40-47(51)48-45(43-55-56(52,53)54-42-41-49(4,5)6)46(50)39-36-33-30-28-27-29-32-35-38-44(3)8-2/h36,39,44-46,50H,7-35,37-38,40-43H2,1-6H3,(H-,48,51,52,53)/b39-36+/t44?,45-,46+/m0/s1",N-pentacosanoyl-14-methylhexadecasphing-4-enine-1-phosphocholine,PubMed citation,23894595
5916,119713,N-octadecanoyl-15-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin obtained by formal condensation of the carboxy group of octadecanoic acid with the amino group of 15-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C40H81N2O6P/c1-7-8-9-10-11-12-13-14-15-16-17-21-24-27-30-33-40(44)41-38(36-48-49(45,46)47-35-34-42(4,5)6)39(43)32-29-26-23-20-18-19-22-25-28-31-37(2)3/h29,32,37-39,43H,7-28,30-31,33-36H2,1-6H3,(H-,41,44,45,46)/b32-29+/t38-,39+/m0/s1",N-octadecanoyl-15-methylhexadecasphing-4-enine-1-phosphocholine,PubMed citation,23894595
5917,119916,N-hexacosanoyl-14-methylhexadecasphingosine-1-phosphocholine,A ceramide obtained by formal condensation of the carboxy group of hexacosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C48H97N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-32-35-38-41-48(52)49-46(44-56-57(53,54)55-43-42-50(4,5)6)47(51)40-37-34-31-29-28-30-33-36-39-45(3)8-2/h37,40,45-47,51H,7-36,38-39,41-44H2,1-6H3,(H-,49,52,53,54)/b40-37+/t45?,46-,47+/m0/s1",SM(d17:1;3/26:0),PubMed citation,23894595
5918,120617,N-heptadecanoyl-15-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 34:1 obtained by formal condensation of the carboxy group of heptadecanoic acid with the amino group of 15-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C39H79N2O6P/c1-7-8-9-10-11-12-13-14-15-16-20-23-26-29-32-39(43)40-37(35-47-48(44,45)46-34-33-41(4,5)6)38(42)31-28-25-22-19-17-18-21-24-27-30-36(2)3/h28,31,36-38,42H,7-27,29-30,32-35H2,1-6H3,(H-,40,43,44,45)/b31-28+/t37-,38+/m0/s1",N-heptadecanoyl-15-methylhexadecasphing-4-enine-1-phosphocholine,PubMed citation,23894595
5919,111006,maltose 6'-phosphate,A maltose phosphate having a single monophosphate group placed at position 6'.,"InChI=1S/C12H23O14P/c13-1-3-10(7(16)8(17)11(19)24-3)26-12-9(18)6(15)5(14)4(25-12)2-23-27(20,21)22/h3-19H,1-2H2,(H2,20,21,22)/t3-,4-,5-,6+,7-,8-,9-,10-,11?,12-/m1/s1",maltose 6'-monophosphate,KEGG GLYCAN accession,G10519
5920,111513,(beta-D-glucopyranosyloxymethyl)deoxyuridine,A pyrimidine 2'-deoxyribonucleoside having beta-D-glucopyranosyloxymethyluracil (base J) as the nucleobase.,"InChI=1S/C16H24N2O11/c19-3-8-7(21)1-10(28-8)18-2-6(14(25)17-16(18)26)5-27-15-13(24)12(23)11(22)9(4-20)29-15/h2,7-13,15,19-24H,1,3-5H2,(H,17,25,26)/t7-,8+,9+,10+,11+,12-,13+,15+/m0/s1",dJ,PubMed citation,18729733
5921,112505,2-amino-3-hydroxy-4-methylbenzoyl-AMP,An acyclic mixed acid anhydride that results from the formal condensation of the phosphoryl group of AMP with the carboxyl group of 2-amino-3-hydroxy-4-methylbenzoic acid.,"InChI=1S/C18H21N6O9P/c1-7-2-3-8(10(19)12(7)25)18(28)33-34(29,30)31-4-9-13(26)14(27)17(32-9)24-6-23-11-15(20)21-5-22-16(11)24/h2-3,5-6,9,13-14,17,25-27H,4,19H2,1H3,(H,29,30)(H2,20,21,22)/t9-,13-,14-,17-/m1/s1",2-amino-3-hydroxy-4-methylbenzoyladenylate,PubMed citation,21612226
5922,113451,sodium ascorbate,An organic sodium salt resulting from the replacement of the proton from the 3-hydroxy group of ascorbic acid by a sodium ion.,"InChI=1S/C6H8O6.Na/c7-1-2(8)5-3(9)4(10)6(11)12-5;/h2,5,7-10H,1H2;/q;+1/p-1/t2-,5+;/m0./s1",sodium L-ascorbate,KEGG DRUG accession,D05853
5923,114786,sodium disulfite,An inorganic sodium salt composed of sodium and disulfite ions in a 2:1 ratio.,"InChI=1S/2Na.H2O5S2/c;;1-6(2)7(3,4)5/h;;(H,1,2)(H,3,4,5)/q2*+1;/p-2",sodium metabisulfite,KEGG DRUG accession,D02054
5924,115196,2-hydroxybenzothiazole,Benzothiazole substituted with a hydroxy group at the 2-position.,"InChI=1S/C7H5NOS/c9-7-8-5-3-1-2-4-6(5)10-7/h1-4H,(H,8,9)",3H-Benzothiazol-2-one,PubMed citation,9544213
5925,115218,5-carboxymethylaminomethyl-2-thiouridine 5'-monophosphate,A pyrimidine ribonucleoside 5'-monophosphate having 5-carboxymethylamino-2-thiouracil as the nucleobase.,"InChI=1S/C12H18N3O10PS/c16-7(17)2-13-1-5-3-15(12(27)14-10(5)20)11-9(19)8(18)6(25-11)4-24-26(21,22)23/h3,6,8-9,11,13,18-19H,1-2,4H2,(H,16,17)(H,14,20,27)(H2,21,22,23)/t6-,8-,9-,11-/m1/s1",5-carboxymethylaminomethyl-2-thiouridine 5'-phosphate,PubMed citation,22817898
5926,115239,3-quinuclidinol,Quinuclidine in which a hydrogen atom at position 3 is substituted by a hydroxy group.,"InChI=1S/C7H13NO/c9-7-5-8-3-1-6(7)2-4-8/h6-7,9H,1-5H2",1-Aza-bicyclo[2.2.2]octan-3-ol,PubMed citation,8487254
5927,115240,pCpC,A 5'-phospho-(3'->5')-dinucleotide composed from two CMP residues.,"InChI=1S/C18H26N6O15P2/c19-9-1-3-23(17(28)21-9)15-12(26)11(25)7(37-15)5-36-41(33,34)39-14-8(6-35-40(30,31)32)38-16(13(14)27)24-4-2-10(20)22-18(24)29/h1-4,7-8,11-16,25-27H,5-6H2,(H,33,34)(H2,19,21,28)(H2,20,22,29)(H2,30,31,32)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1",Cp-Cp,Reaxys Registry Number,1204397
5928,116509,diuron,"A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group.","InChI=1S/C9H10Cl2N2O/c1-13(2)9(14)12-6-3-4-7(10)8(11)5-6/h3-5H,1-2H3,(H,12,14)","3-(3,4-Dichloro-phenyl)-1,1-dimethyl-urea",PubMed citation,17449247
5929,116510,"4,5-diamino-1,2,4a,4b,7,8,8a,8b-octahydro-1,3,6,8-tetraazabiphenylene-2,7-dione","A member of the class of cyclobutadipyrimidines that is 1,4a,4b,8,8a,8b-hexahydrocyclobuta[1,2-d:4,3-d']dipyrimidine-2,7-dione carrying two additional amino substituents at positions 4 and 5.","InChI=1S/C8H10N6O2/c9-5-1-2-4(3(1)11-7(15)13-5)12-8(16)14-6(2)10/h1-4H,(H3,9,11,13,15)(H3,10,12,14,16)",cyclobutane cytosine dimer,Reaxys Registry Number,925113
5930,116698,"5-amino-4a-methyl-1,2,3,4,4a,4b,7,8,8a,8b-decahydro-1,3,6,8-tetraazabiphenylene-2,4,7-trione","A member of the class of cyclobutadipyrimidines that is 1,4a,4b,8,8a,8b-hexahydrocyclobuta[1,2-d:4,3-d']dipyrimidine-2,4,7(3H)-trione carrying additional methyl and amino substituents at positions 4a and 5 respectively.","InChI=1S/C9H11N5O3/c1-9-2-3(11-7(16)13-5(2)10)4(9)12-8(17)14-6(9)15/h2-4H,1H3,(H3,10,11,13,16)(H2,12,14,15,17)",cyclobutane-cytosine-thymine,PubMed citation,22817898
5931,116736,2'-deoxycytidine dimer,A nucleoside analogue obtained by formal cyclodimerisation of 2'-deoxycytidine.,"InChI=1S/C18H26N6O8/c19-15-11-12-14(13(11)23(17(29)21-15)9-1-5(27)7(3-25)31-9)24(18(30)22-16(12)20)10-2-6(28)8(4-26)32-10/h5-14,25-28H,1-4H2,(H2,19,21,29)(H2,20,22,30)/t5-,6-,7+,8+,9+,10+,11?,12?,13?,14?/m0/s1",cyclobutane_dCdC,PubMed citation,22817898
5932,116810,2'-deoxycytidine-thymidine dimer,A nucleoside analogue obtained by formal cyclodimerisation of 2'-deoxycytidine and thymidine.,"InChI=1S/C19H27N5O9/c1-19-12-13(23(17(30)21-15(12)20)10-2-6(27)8(4-25)32-10)14(19)24(18(31)22-16(19)29)11-3-7(28)9(5-26)33-11/h6-14,25-28H,2-5H2,1H3,(H2,20,21,30)(H,22,29,31)/t6-,7-,8+,9+,10+,11+,12?,13?,14?,19?/m0/s1",2'-deoxycytidine-thymidine,PubMed citation,22817898
5933,116931,nipecotic acid,A piperidinemonocarboxylic acid that is piperidine in which one of the hydrogens at position 3 is substituted by a carboxylic acid group.,"InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)",Piperidine-3-carboxylic acid,Beilstein Registry Number,81096
5934,116932,N-tricosanoyl-14-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 40:1 obtained by formal condensation of the carboxy group of tricosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C45H91N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-29-32-35-38-45(49)46-43(41-53-54(50,51)52-40-39-47(4,5)6)44(48)37-34-31-28-26-25-27-30-33-36-42(3)8-2/h34,37,42-44,48H,7-33,35-36,38-41H2,1-6H3,(H-,46,49,50,51)/b37-34+/t42?,43-,44+/m0/s1",SM 40:1;3,PubMed citation,23894595
5935,116962,fosinoprilat,"A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.","InChI=1S/C23H34NO5P/c25-22(17-30(28,29)14-8-7-11-18-9-3-1-4-10-18)24-16-20(15-21(24)23(26)27)19-12-5-2-6-13-19/h1,3-4,9-10,19-21H,2,5-8,11-17H2,(H,26,27)(H,28,29)/t20-,21+/m1/s1",4-Cyclohexyl-1-{2-[hydroxy-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid,CAS Registry Number,95399-71-6
5936,130910,(Z)-3-(4-iodophenyl)-2-mercaptoacrylic acid,An organoiodine compound that is acrylic acid in which the vinylic hydrogens at positions 2 and 3 are replaced by mercapto and 4-iodophenyl groups respectively (the Z geoisomer).,"InChI=1S/C9H7IO2S/c10-7-3-1-6(2-4-7)5-8(13)9(11)12/h1-5,13H,(H,11,12)/b8-5-",PD 150606,Reaxys Registry Number,10069045
5937,123115,diaveridine,"An aminopyrimidine in which the pyrimidine ring carries amino substituents at C-2 and C-4 and a 3,4-dimethoxybenzyl group at C-5. A folic acid antagonist, it is used as a synergist with sulfonamides against the parasitic Eimeria species.","InChI=1S/C13H16N4O2/c1-18-10-4-3-8(6-11(10)19-2)5-9-7-16-13(15)17-12(9)14/h3-4,6-7H,5H2,1-2H3,(H4,14,15,16,17)","5-(3,4-Dimethoxy-benzyl)-pyrimidine-2,4-diamine",PubMed citation,4982548
5938,123356,N-docosanoyl-14-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 39:1 obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of 14-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C44H89N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-28-31-34-37-44(48)45-42(40-52-53(49,50)51-39-38-46(4,5)6)43(47)36-33-30-27-25-24-26-29-32-35-41(3)8-2/h33,36,41-43,47H,7-32,34-35,37-40H2,1-6H3,(H-,45,48,49,50)/b36-33+/t41?,42-,43+/m0/s1",SM(d17:1;3/22:0),PubMed citation,23894595
5939,124992,N-docosanoyl-14-methylhexadecasphinganine-1-phosphocholine,A sphingomyelin obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of 14-methylhexadecasphinganine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C44H91N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-28-31-34-37-44(48)45-42(40-52-53(49,50)51-39-38-46(4,5)6)43(47)36-33-30-27-25-24-26-29-32-35-41(3)8-2/h41-43,47H,7-40H2,1-6H3,(H-,45,48,49,50)/t41?,42-,43+/m0/s1",N-docosanoyl-14-methylhexadecadihydrosphingosine-1-phosphocholine,PubMed citation,23894595
5940,125205,N-tetracosanoyl-14-methylhexadecasphinganine-1-phosphocholine,A sphingomyelin obtained by formal condensation of the carboxy group of tetracosanoic acid with the amino group of 14-methylhexadecasphinganine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C46H95N2O6P/c1-7-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-30-33-36-39-46(50)47-44(42-54-55(51,52)53-41-40-48(4,5)6)45(49)38-35-32-29-27-26-28-31-34-37-43(3)8-2/h43-45,49H,7-42H2,1-6H3,(H-,47,50,51,52)/t43?,44-,45+/m0/s1",SM(d17:0;3/24:0),PubMed citation,23894595
5941,125805,L-phenylalanine betaine,An L-phenylalanine derivative obtained by trimethylation of the amino function of L-phenylalanine.,"InChI=1S/C12H17NO2/c1-13(2,3)11(12(14)15)9-10-7-5-4-6-8-10/h4-8,11H,9H2,1-3H3/t11-/m0/s1","N,N,N-trimethyl-L-phenylalanine",Reaxys Registry Number,3591811
5942,126352,L-tyrosine betaine,An L-tyrosine derivative obtained by trimethylation of the amino function of L-tyrosine.,"InChI=1S/C12H17NO3/c1-13(2,3)11(12(15)16)8-9-4-6-10(14)7-5-9/h4-7,11H,8H2,1-3H3,(H-,14,15,16)/t11-/m0/s1","L-N,N,N-trimethyltyrosine",Reaxys Registry Number,3908856
5943,127105,tribromosalicylanilide,A salicylanilide derivative with bromo- substituents at C-3 and C-5 of the salicylate moiety and at C-4 of the anilide moiety.,"InChI=1S/C13H8Br3NO2/c14-7-1-3-9(4-2-7)17-13(19)10-5-8(15)6-11(16)12(10)18/h1-6,18H,(H,17,19)","3,5-Dibromo-N-(4-bromo-phenyl)-2-hydroxy-benzamide",CAS Registry Number,87-10-5
5944,128459,valienol 1-phosphate,A cyclitol phosphate that is valienol carrying a sigle monophosphate group at position 1.,"InChI=1S/C7H13O8P/c8-2-3-1-4(15-16(12,13)14)6(10)7(11)5(3)9/h1,4-11H,2H2,(H2,12,13,14)/t4-,5+,6-,7-/m0/s1",valienol 1-monophosphate,Reaxys Registry Number,21164348
5945,128770,"12,18-dihydroxyoctadecanoic acid",A long-chain fatty acid that is octadecanoic (stearic) acid substituted at positions 12 and 18 by hydroxy groups.,"InChI=1S/C18H36O4/c19-16-12-8-7-10-14-17(20)13-9-5-3-1-2-4-6-11-15-18(21)22/h17,19-20H,1-16H2,(H,21,22)","12,18-dihydroxystearic acid",PubMed citation,9675028
5946,130073,"5,20-diHEPE","An icosanoid that is (6E,8Z,11Z,14Z,17Z)-icosapentaenoic acid substituted at positions 5 and 20 by hydroxy groups.","InChI=1S/C20H30O4/c21-18-13-11-9-7-5-3-1-2-4-6-8-10-12-15-19(22)16-14-17-20(23)24/h2-5,8-12,15,19,21-22H,1,6-7,13-14,16-18H2,(H,23,24)/b4-2-,5-3-,10-8-,11-9-,15-12+","(6E,8Z,11Z,14Z,17Z)-5,20-dihydroxyicosapentaenoic acid",PubMed citation,9675028
5947,131188,"formycin 3',5'-cyclic phosphate","A nucleoside 3',5'-cyclic phosphate derived from formycin A.","InChI=1S/C10H12N5O6P/c11-10-6-4(12-2-13-10)5(14-15-6)9-7(16)8-3(20-9)1-19-22(17,18)21-8/h2-3,7-9,16H,1H2,(H,14,15)(H,17,18)(H2,11,12,13)/t3-,7-,8-,9+/m1/s1","formycin cyclic 3',5'-phosphate",Reaxys Registry Number,1041600
5948,131199,2-ethylacetoacetic acid,A 3-oxo monocarboxylic acid that is butyric acid substituted at positions 2 and 3 by ethyl and oxo groups respectively.,"InChI=1S/C6H10O3/c1-3-5(4(2)7)6(8)9/h5H,3H2,1-2H3,(H,8,9)",2-acetylbutyric acid,CAS Registry Number,4433-85-6
5949,131331,tricaine methanesulfonate,A methanesulfonate salt obtained by reaction of tricaine with one molar equivalent of methanesulfonic acid. Used as an anaesthetic for fish.,"InChI=1S/C9H11NO2.CH4O3S/c1-2-12-9(11)7-4-3-5-8(10)6-7;1-5(2,3)4/h3-6H,2,10H2,1H3;1H3,(H,2,3,4)",tricaine mesylate,Wikipedia accession,Tricaine_mesylate
5950,131342,1-[(9E)-octadecenoyl]glycerol,A 1-monoglyceride in which the acyl group is specified as (9E)-octadecenoyl.,"InChI=1S/C21H40O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h9-10,20,22-23H,2-8,11-19H2,1H3/b10-9+","2,3-dihydroxypropyl elaidate",PubMed citation,19015726
5951,131347,(S)-Bay-K-8644,"A methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate in which the 4-position has (S)-configuration.","InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13,20H,1-3H3/t13-/m0/s1",(S)-BayK8644,Reaxys Registry Number,7148199
5952,131349,(R)-Bay-K-8644,"A methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate in which the 4-position has (R)-configuration.","InChI=1S/C16H15F3N2O4/c1-8-12(15(22)25-3)13(14(21(23)24)9(2)20-8)10-6-4-5-7-11(10)16(17,18)19/h4-7,13,20H,1-3H3/t13-/m1/s1",(+)-Bay K8644,Reaxys Registry Number,7574443
5953,131361,disodium selenite pentahydrate,A hydrate that is the pentahydrate form of disodium selenite.,"InChI=1S/2Na.H2O3Se.5H2O/c;;1-4(2)3;;;;;/h;;(H2,1,2,3);5*1H2/q2*+1;;;;;;/p-2",sodium selenite hydrate,CAS Registry Number,26970-82-1
5954,131371,iron(3+) phosphate,An inorganic phosphate having Fe(3+) as the counterion.,"InChI=1S/Fe.H3O4P/c;1-5(2,3)4/h;(H3,1,2,3,4)/q+3;/p-3",iron(III) phosphate,CAS Registry Number,10045-86-0
5955,131372,iron(3+) phosphate tetrahydrate,A hydrate that is the tetrahydrate form of iron(3+) phosphate.,"InChI=1S/Fe.H3O4P.4H2O/c;1-5(2,3)4;;;;/h;(H3,1,2,3,4);4*1H2/q+3;;;;;/p-3",iron(3+) orthophosphate tetrahydrate,Wikipedia accession,Iron(III)_phosphate
5956,131377,(8Z)-7-methyl-8-tetradecen-1-yl acetate,An acetate ester derived from (8Z)-7-methyl-8-tetradecen-1-ol.,"InChI=1S/C17H32O2/c1-4-5-6-7-10-13-16(2)14-11-8-9-12-15-19-17(3)18/h10,13,16H,4-9,11-12,14-15H2,1-3H3/b13-10-",7-methyl-Z-tetradecen-1-ol acetate,Reaxys Registry Number,22968432
5957,131378,ferrous ammonium sulfate heptahydrate,A hydrate that is the heptahydrate form of ferrous ammonium sulfate.,"InChI=1S/Fe.2H3N.2H2O4S.7H2O/c;;;2*1-5(2,3)4;;;;;;;/h;2*1H3;2*(H2,1,2,3,4);7*1H2/q+2;;;;;;;;;;;/p-2",ferrous ammonium sulfate,Reaxys Registry Number,17140490
5958,131383,"2,2,4,4,6,8,8-heptamethylnonane","A branched alkane that is nonane carrying seven methyl substituents at positions 2, 2, 4, 4, 6, 8 and 8.","InChI=1S/C16H34/c1-13(10-14(2,3)4)11-16(8,9)12-15(5,6)7/h13H,10-12H2,1-9H3",isocetane,CAS Registry Number,4390-04-9
5959,131387,iron(3+) sulfate hydrate,A hydrate that is the monohydrate form of iron(3+) sulfate.,"InChI=1S/2Fe.3H2O4S.H2O/c;;3*1-5(2,3)4;/h;;3*(H2,1,2,3,4);1H2/q2*+3;;;;/p-6",iron(3+) sulfate monohydrate,CAS Registry Number,43059-01-4
5960,131391,trimagnesium dicitrate,A magnesium salt composed of magnesium and citrate ions in a 3:2 ratio.,"InChI=1S/2C6H8O7.3Mg/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6",magnesium dicitrate,Wikipedia accession,Magnesium_citrate_(3:2)
5961,131394,magnesium dichloride dihydrate,A hydrate that is the dihydrate form of magnesium dichloride.,InChI=1S/2ClH.Mg.2H2O/h2*1H;;2*1H2/q;;+2;;/p-2,MgCl2.2H2O,Reaxys Registry Number,16471381
5962,131403,"(2E,24R)-24-[(alpha-L-ascarosyl)oxy]-2-methylpentacos-2-enoic acid","An (omega-1)-hydroxy fatty acid ascaroside obtained by obtained by formal condensation of the alcoholic hydroxy group of (2E,24R)-2-methylpentacos-2-enoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.","InChI=1S/C32H60O6/c1-26(31(35)36)23-21-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-22-24-27(2)37-32-30(34)25-29(33)28(3)38-32/h23,27-30,32-34H,4-22,24-25H2,1-3H3,(H,35,36)/b26-23+/t27-,28+,29-,30-,32-/m1/s1","(24R)-(3'R,5'R-dihydroxy-6'S-methyl-(2H)-tetrahydropyran-2'-yloxy)-2-methyl-2E-pentacosenoic acid",Reaxys Registry Number,23412670
5963,131405,(24R)-24-[(alpha-L-ascarosyl)oxy]-2-methylpentacosanoic acid,An (omega-1)-hydroxy fatty acid ascaroside obtained by obtained by formal condensation of the alcoholic hydroxy group of (24R)-2-methylpentacosanoic acid with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C32H62O6/c1-26(31(35)36)23-21-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-22-24-27(2)37-32-30(34)25-29(33)28(3)38-32/h26-30,32-34H,4-25H2,1-3H3,(H,35,36)/t26?,27-,28+,29-,30-,32-/m1/s1","(24R)-(3'R,5'R-dihydroxy-6'S-methyl-(2H)-tetrahydropyran-2'-yloxy)-2-methylpentacosanoic acid",Reaxys Registry Number,23412671
5964,131406,"(1E)-2,3,4,5,6-pentahydroxyhexanal oxime","A pentol consisting of 1-(hydroxyimino)hexane with five hydroxy substituents placed at positions 2, 3, 4, 5 and 6.","InChI=1S/C6H13NO6/c8-2-4(10)6(12)5(11)3(9)1-7-13/h1,3-6,8-13H,2H2/b7-1+","(6E)-6-(hydroxyimino)-1,2,3,4,5-hexanepentol",Chemspider accession,4518551
5965,131409,(26R)-26-[(alpha-L-ascarosyl)oxy]-N-(2-hydroxyethyl)-3-oxoheptacosanamide,A hydroxy fatty amide ascaroside obtained by obtained by formal condensation of the 26-hydroxy group of (26R)-26-hydroxy-N-(2-hydroxyethyl)-3-oxoheptacosanamide with ascarylopyranose (the alpha anomer). It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C35H67NO7/c1-29(42-35-33(40)28-32(39)30(2)43-35)23-21-19-17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18-20-22-24-31(38)27-34(41)36-25-26-37/h29-30,32-33,35,37,39-40H,3-28H2,1-2H3,(H,36,41)/t29-,30+,32-,33-,35-/m1/s1","(26R)-(3'R,5'R-dihydroxy-6'S-methyl-(2H)-tetrahydropyran-2'-yloxy)-3-oxoheptacosanoic acid ethanolamide",Reaxys Registry Number,23412668
5966,131411,12-methylpentadecanoic acid,A methyl-branched fatty acid that is pentadecanoic acid substituted by a methyl group at position 12.,"InChI=1S/C16H32O2/c1-3-12-15(2)13-10-8-6-4-5-7-9-11-14-16(17)18/h15H,3-14H2,1-2H3,(H,17,18)",C15:0-12-methyl,Reaxys Registry Number,1864793
5967,131414,13-methylpentadecanoic acid,A methyl-branched fatty acid that is pentadecanoic acid substituted by a methyl group at position 13.,"InChI=1S/C16H32O2/c1-3-15(2)13-11-9-7-5-4-6-8-10-12-14-16(17)18/h15H,3-14H2,1-2H3,(H,17,18)",C15:0-13-methyl,CAS Registry Number,20121-96-4
5968,131435,ethyl L-methioninate,An L-methionine derivative that is the ester obtained by formal condensation of the carboxy group of L-methionine with ethanol.,"InChI=1S/C7H15NO2S/c1-3-10-7(9)6(8)4-5-11-2/h6H,3-5,8H2,1-2H3/t6-/m0/s1",L-methionine ethyl ester,Chemspider accession,68978
5969,131451,cyanidin 3-O-{6-O-[(Z)-4-coumaroyl]-beta-D-glucoside},An anthocyanin cation that is cyanidin substituted at position 3 by a 6-O-(Z-4 coumaryl)-beta-D-glucosyl residue.,"InChI=1S/C30H26O13/c31-16-5-1-14(2-6-16)3-8-25(36)40-13-24-26(37)27(38)28(39)30(43-24)42-23-12-18-20(34)10-17(32)11-22(18)41-29(23)15-4-7-19(33)21(35)9-15/h1-12,24,26-28,30,37-39H,13H2,(H4-,31,32,33,34,35,36)/p+1/t24-,26-,27+,28-,30-/m1/s1",cyanidin 3-O-(6-O-(Z)-p-coumaroyl-beta-D-glucoside),Reaxys Registry Number,11250457
5970,131461,3-bromopyruvic acid,A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is replaced by bromine. Synthetic brominated derivative and structural analog of pyruvic acid. Highly reactive alkylating agent. Anti-cancer drug,"InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)",bromopyruvate,CAS Registry Number,1113-59-3
5971,131488,N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide dihydrochloride,A hydrochloride salt prepared from N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide and two equivalents of hydrogen chloride.,"InChI=1S/C20H20BrN3O2S.2ClH/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20;;/h1-10,12,15,22,24H,11,13-14H2;2*1H",H-89 hydrochloride,Reaxys Registry Number,8457569
5972,131494,"5,6-dehydrotomatine",A steroid alkaloid that consists of tomatine which has undergone formal dehydrogenation across positions 5 and 6. Found in tomatoes.,"InChI=1S/C50H81NO21/c1-20-7-12-50(51-15-20)21(2)32-28(72-50)14-26-24-6-5-22-13-23(8-10-48(22,3)25(24)9-11-49(26,32)4)65-45-40(63)37(60)41(31(18-54)68-45)69-47-43(71-46-39(62)36(59)34(57)29(16-52)66-46)42(35(58)30(17-53)67-47)70-44-38(61)33(56)27(55)19-64-44/h5,20-21,23-47,51-63H,6-19H2,1-4H3/t20-,21-,23-,24+,25-,26-,27+,28-,29+,30+,31+,32-,33-,34+,35+,36-,37+,38+,39+,40+,41-,42-,43+,44-,45+,46-,47-,48-,49-,50-/m0/s1",dehydrotomatin,HMDB accession,HMDB0032002
5973,131503,alpha-santalenoic acid,A sesquiterpenoid that is (+)-alpha-santalene in which one of the methyl groups attached to the C=C double bond has been oxidised to form the corresponding carboxylic acid.,"InChI=1S/C15H22O2/c1-9(13(16)17)5-4-6-14(2)10-7-11-12(8-10)15(11,14)3/h5,10-12H,4,6-8H2,1-3H3,(H,16,17)/b9-5+/t10-,11+,12-,14-,15+/m1/s1",(+)-alpha-santalenoic acid,Chemspider accession,10379949
5974,131514,"(1R,2S)-tranylcypromine hydrochloride","A hydrochloride obtained by combining (1R,2S)-tranylcypromine with one equivalent of hydrochloric acid.","InChI=1S/C9H11N.ClH/c10-9-6-8(9)7-4-2-1-3-5-7;/h1-5,8-9H,6,10H2;1H/t8-,9+;/m0./s1",(+)-tranylcypromine hydrochloride,Reaxys Registry Number,5986859
5975,131522,"dTDP-4-(methylamino)-2,3,4,6-tetradeoxy-alpha-D-glucose","A pyrimidine nucleotide-sugar having thymine as the nucleobase and 4-(methylamino)-2,3,4,6-tetradeoxy-alpha-D-glucose as the sugar component.","InChI=1S/C17H29N3O12P2/c1-9-7-20(17(23)19-16(9)22)14-6-12(21)13(30-14)8-28-33(24,25)32-34(26,27)31-15-5-4-11(18-3)10(2)29-15/h7,10-15,18,21H,4-6,8H2,1-3H3,(H,24,25)(H,26,27)(H,19,22,23)/t10-,11+,12+,13-,14-,15-/m1/s1","dTDP-4-(methylamino)-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranose",MetaCyc accession,CPD-13389
5976,131523,manganese(II) sulfate hexahydrate,A hydrate that is the hexahydrate form of manganese(II) sulfate.,"InChI=1S/Mn.H2O4S.6H2O/c;1-5(2,3)4;;;;;;/h;(H2,1,2,3,4);6*1H2/q+2;;;;;;;/p-2",manganese(2+) sulphate hexahydrate,Reaxys Registry Number,16859675
5977,131524,manganese(II) sulfate pentahydrate,A hydrate that is the pentahydrate form of manganese(II) sulfate.,"InChI=1S/Mn.H2O4S.5H2O/c;1-5(2,3)4;;;;;/h;(H2,1,2,3,4);5*1H2/q+2;;;;;;/p-2",manganese(II) sulphate pentahydrate,Reaxys Registry Number,13431229
5978,131526,potassium carbonate,A potassium salt that is the dipotassium salt of carbonic acid.,"InChI=1S/CH2O3.2K/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2",K2CO3,KEGG DRUG accession,D02038
5979,131534,N-henicosanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of henicosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C38H75NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-27-30-33-38(42)39-36(34-40)37(41)32-29-26-23-21-20-22-25-28-31-35(3)5-2/h29,32,35-37,40-41H,4-28,30-31,33-34H2,1-3H3,(H,39,42)/b32-29+/t35?,36-,37+/m0/s1",Cer 38:1;3,PubMed citation,23894595
5980,131538,N-docosanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C39H77NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-28-31-34-39(43)40-37(35-41)38(42)33-30-27-24-22-21-23-26-29-32-36(3)5-2/h30,33,36-38,41-42H,4-29,31-32,34-35H2,1-3H3,(H,40,43)/b33-30+/t36?,37-,38+/m0/s1",Cer (d17:1;3/22:0),PubMed citation,23894595
5981,131539,N-heptadecanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of heptadecanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C34H67NO3/c1-4-6-7-8-9-10-11-12-13-14-15-20-23-26-29-34(38)35-32(30-36)33(37)28-25-22-19-17-16-18-21-24-27-31(3)5-2/h25,28,31-33,36-37H,4-24,26-27,29-30H2,1-3H3,(H,35,38)/b28-25+/t31?,32-,33+/m0/s1",Cer (d17:1;3/17:0),PubMed citation,23894595
5982,131541,N-hexadecanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of hexadecanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C33H65NO3/c1-4-6-7-8-9-10-11-12-13-14-19-22-25-28-33(37)34-31(29-35)32(36)27-24-21-18-16-15-17-20-23-26-30(3)5-2/h24,27,30-32,35-36H,4-23,25-26,28-29H2,1-3H3,(H,34,37)/b27-24+/t30?,31-,32+/m0/s1",N-hexadecanoyl-14-methylhexadecasphing-4-enine,PubMed citation,23894595
5983,131542,N-tricosanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of tricosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C40H79NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-26-29-32-35-40(44)41-38(36-42)39(43)34-31-28-25-23-22-24-27-30-33-37(3)5-2/h31,34,37-39,42-43H,4-30,32-33,35-36H2,1-3H3,(H,41,44)/b34-31+/t37?,38-,39+/m0/s1",Cer (d17:1;3/23:0),PubMed citation,23894595
5984,131543,N-icosanoyl-14-methylhexadecasphinganine,A ceramide obtained by formal condensation of the carboxy group of icosanoic acid with the amino group of 14-methylhexadecasphinganine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C37H75NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-23-26-29-32-37(41)38-35(33-39)36(40)31-28-25-22-20-19-21-24-27-30-34(3)5-2/h34-36,39-40H,4-33H2,1-3H3,(H,38,41)/t34?,35-,36+/m0/s1",N-eicosanoyl-14-methylhexadecasphinganine,PubMed citation,23894595
5985,131544,N-hexacosanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of hexacosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C43H85NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-29-32-35-38-43(47)44-41(39-45)42(46)37-34-31-28-26-25-27-30-33-36-40(3)5-2/h34,37,40-42,45-46H,4-33,35-36,38-39H2,1-3H3,(H,44,47)/b37-34+/t40?,41-,42+/m0/s1",N-hexacosanoyl-14-methylhexadecasphing-4-enine,PubMed citation,23894595
5986,131545,N-tetracosanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of tetracosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C41H81NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-27-30-33-36-41(45)42-39(37-43)40(44)35-32-29-26-24-23-25-28-31-34-38(3)5-2/h32,35,38-40,43-44H,4-31,33-34,36-37H2,1-3H3,(H,42,45)/b35-32+/t38?,39-,40+/m0/s1",Cer (d17:1;3/24:0),PubMed citation,23894595
5987,131547,N-pentacosanoyl-14-methylhexadecasphinganine,A dihydroceramide obtained by formal condensation of the carboxy group of pentacosanoic acid with the amino group of 14-methylhexadecasphinganine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C42H85NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-28-31-34-37-42(46)43-40(38-44)41(45)36-33-30-27-25-24-26-29-32-35-39(3)5-2/h39-41,44-45H,4-38H2,1-3H3,(H,43,46)/t39?,40-,41+/m0/s1",Cer (d17:0;3/25:0),PubMed citation,23894595
5988,131548,N-pentacosanoyl-14-methylhexadecasphingosine,A ceramide obtained by formal condensation of the carboxy group of pentacosanoic acid with the amino group of 14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C42H83NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-28-31-34-37-42(46)43-40(38-44)41(45)36-33-30-27-25-24-26-29-32-35-39(3)5-2/h33,36,39-41,44-45H,4-32,34-35,37-38H2,1-3H3,(H,43,46)/b36-33+/t39?,40-,41+/m0/s1",Cer (d17:1;3/25:0),PubMed citation,23894595
5989,131549,N-hexacosanoyl-14-methylhexadecasphinganine,A ceramide obtained by formal condensation of the carboxy group of hexacosanoic acid with the amino group of 14-methylhexadecasphinganine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C43H87NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-29-32-35-38-43(47)44-41(39-45)42(46)37-34-31-28-26-25-27-30-33-36-40(3)5-2/h40-42,45-46H,4-39H2,1-3H3,(H,44,47)/t40?,41-,42+/m0/s1",Cer (d17:0;3/26:0),PubMed citation,23894595
5990,131550,N-docosanoyl-14-methylhexadecasphinganine,A ceramide obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of 14-methylhexadecasphinganine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C39H79NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-28-31-34-39(43)40-37(35-41)38(42)33-30-27-24-22-21-23-26-29-32-36(3)5-2/h36-38,41-42H,4-35H2,1-3H3,(H,40,43)/t36?,37-,38+/m0/s1",Cer (d17:0;3/22:0),PubMed citation,23894595
5991,131551,3'-L-alanyl-AMP,An L-alanyl ester obtained by formal condensation of the carboxy group of L-alanine with the 3'-hydroxy group of AMP.,"InChI=1S/C13H19N6O8P/c1-5(14)13(21)27-9-6(2-25-28(22,23)24)26-12(8(9)20)19-4-18-7-10(15)16-3-17-11(7)19/h3-6,8-9,12,20H,2,14H2,1H3,(H2,15,16,17)(H2,22,23,24)/t5-,6+,8+,9+,12+/m0/s1",3'-O-alanyl-AMP,Reaxys Registry Number,5319086
5992,131556,3'-(N-formyl-L-methionyl)-AMP,An L-methionine derivative that is the ester obtained by formal condensation of the carboxy group of N-formyl-L-methionine with the 3'-hydroxy group of AMP.,"InChI=1S/C16H23N6O9PS/c1-33-3-2-8(21-7-23)16(25)31-12-9(4-29-32(26,27)28)30-15(11(12)24)22-6-20-10-13(17)18-5-19-14(10)22/h5-9,11-12,15,24H,2-4H2,1H3,(H,21,23)(H2,17,18,19)(H2,26,27,28)/t8-,9+,11+,12+,15+/m0/s1",3'-O-(N-formylmethionyl)-AMP,PDBeChem accession,M3O
5993,131560,3'-glycyl-AMP,A glycinyl ester obtained by formal condensation of the carboxy group of glycinne with the 3'-hydroxy group of AMP.,"InChI=1S/C12H17N6O8P/c13-1-6(19)26-9-5(2-24-27(21,22)23)25-12(8(9)20)18-4-17-7-10(14)15-3-16-11(7)18/h3-5,8-9,12,20H,1-2,13H2,(H2,14,15,16)(H2,21,22,23)/t5-,8-,9-,12-/m1/s1",3'-O-glycyl-AMP,Reaxys Registry Number,6757252
5994,131571,3'-L-phenylalanyl-AMP,An L-phenylalanine derivative that is the ester obtained by formal condensation of the carboxy group of L-phenylalanine with the 3'-hydroxy group of AMP.,"InChI=1S/C19H23N6O8P/c20-11(6-10-4-2-1-3-5-10)19(27)33-15-12(7-31-34(28,29)30)32-18(14(15)26)25-9-24-13-16(21)22-8-23-17(13)25/h1-5,8-9,11-12,14-15,18,26H,6-7,20H2,(H2,21,22,23)(H2,28,29,30)/t11-,12+,14+,15+,18+/m0/s1",3'-phenylalanyl-AMP,Reaxys Registry Number,1199127
5995,131572,3'-L-prolyl-AMP,An L-proline derivative that is the ester obtained by formal condensation of the carboxy group of L-proline with the 3'-hydroxy group of AMP.,"InChI=1S/C15H21N6O8P/c16-12-9-13(19-5-18-12)21(6-20-9)14-10(22)11(8(28-14)4-27-30(24,25)26)29-15(23)7-2-1-3-17-7/h5-8,10-11,14,17,22H,1-4H2,(H2,16,18,19)(H2,24,25,26)/t7-,8+,10+,11+,14+/m0/s1",3'-O-L-prolyladenosine 5'-monophosphate,Reaxys Registry Number,70510
5996,131574,3'-L-threonyl-AMP,An L-threonine derivative that is the ester obtained by formal condensation of the carboxy group of L-threonine with the 3'-hydroxy group of AMP.,"InChI=1S/C14H21N6O9P/c1-5(21)7(15)14(23)29-10-6(2-27-30(24,25)26)28-13(9(10)22)20-4-19-8-11(16)17-3-18-12(8)20/h3-7,9-10,13,21-22H,2,15H2,1H3,(H2,16,17,18)(H2,24,25,26)/t5-,6-,7+,9-,10-,13-/m1/s1",3'-threonyl-AMP,Reaxys Registry Number,69414
5997,131575,3'-L-tryptophyl-AMP,An L-tryptophan derivative that is the ester obtained by formal condensation of the carboxy group of L-tryptophan with the 3'-hydroxy group of AMP.,"InChI=1S/C21H24N7O8P/c22-12(5-10-6-24-13-4-2-1-3-11(10)13)21(30)36-17-14(7-34-37(31,32)33)35-20(16(17)29)28-9-27-15-18(23)25-8-26-19(15)28/h1-4,6,8-9,12,14,16-17,20,24,29H,5,7,22H2,(H2,23,25,26)(H2,31,32,33)/t12-,14+,16+,17+,20+/m0/s1",3'-O-L-tryptophyl-AMP,Reaxys Registry Number,74631
5998,131577,3'-L-valyl-AMP,An L-valyl ester obtained by formal condensation of the carboxy group of L-valine with the 3'-hydroxy group of AMP.,"InChI=1S/C15H23N6O8P/c1-6(2)8(16)15(23)29-11-7(3-27-30(24,25)26)28-14(10(11)22)21-5-20-9-12(17)18-4-19-13(9)21/h4-8,10-11,14,22H,3,16H2,1-2H3,(H2,17,18,19)(H2,24,25,26)/t7-,8+,10-,11-,14-/m1/s1",3'-O-L-valyladenosine 5'-monophosphate,Reaxys Registry Number,1059348
5999,131578,N-(5'-adenylyl)morpholine,An organic phosphoramidate obtained by formal condensation of the phosphate group of AMP with the amino group of L-morpholine.,"InChI=1S/C14H21N6O7P/c15-12-9-13(17-6-16-12)20(7-18-9)14-11(22)10(21)8(27-14)5-26-28(23,24)19-1-3-25-4-2-19/h6-8,10-11,14,21-22H,1-5H2,(H,23,24)(H2,15,16,17)/t8-,10-,11-,14-/m1/s1",AMP-morpholine,Reaxys Registry Number,63814
6000,131592,3-bromopyruvate,"A 2-oxo monocarboxylic acid anion that is the conjugate base of 3-bromopyruvic acid, arising from deprotonation of the carboxy group.","InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)/p-1",bromopyruvate,Reaxys Registry Number,4959608
6001,131593,3-deoxy-D-glycero-beta-D-galacto-nonulosonic acid,A deaminoneuraminic acid in which the anomeric centre has beta-configuration.,"InChI=1S/C9H16O9/c10-2-4(12)6(14)7-5(13)3(11)1-9(17,18-7)8(15)16/h3-7,10-14,17H,1-2H2,(H,15,16)/t3-,4+,5+,6+,7+,9-/m0/s1",deamino-beta-neuraminic acid,MetaCyc accession,CPD-10734
6002,131656,"N(alpha)-acetyl-N(tele)-(1,4-dihydroxynonan-3-yl)-L-histidine","An L-histidine derivative in which the alpha-amino nitrogen of the amino acid has entered into amide formation with acetic acid and the tele- nitrogen carries a 1,4-dihydroxynonan-3-yl substituent. It has been synthesised by reaction of (E)-4-hydroxynon-2-enal (HNE) with N-acetyl-L-histidine, the tele nitrogen of histidine reacting with the double bond function of HNE via formation of a Michael adduct.","InChI=1S/C17H29N3O5/c1-3-4-5-6-16(23)15(7-8-21)20-10-13(18-11-20)9-14(17(24)25)19-12(2)22/h10-11,14-16,21,23H,3-9H2,1-2H3,(H,19,22)(H,24,25)/t14-,15?,16?/m0/s1","N-acetyl-1-(1,4-dihydroxynonan-3-yl)-L-histidine",PubMed citation,26800898
6003,131694,"1-O-(alpha-D-glucosyl)-29-keto-(3R,31R)-dotriacontanetriol","An alpha-D-glucoside that is 29-keto-(3R,31R)-dotriacontanetriol having a single alpha-D-glucosyl residue attached at position 1.","InChI=1S/C38H74O9/c1-31(40)29-33(42)26-24-22-20-18-16-14-12-10-8-6-4-2-3-5-7-9-11-13-15-17-19-21-23-25-32(41)27-28-46-38-37(45)36(44)35(43)34(30-39)47-38/h31-32,34-41,43-45H,2-30H2,1H3/t31-,32-,34-,35-,36+,37-,38+/m1/s1","1-O-(alpha-D-glucosyl)-29-oxo-(3R,31R)-dotriacontanetriol",LIPID MAPS instance accession,LMFA13010030
6004,131729,cefcapene,"A cephalosporin compound having (carbamoyloxy)methyl and N-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino side-groups. It is used (generally as the corresponnding pivaloyloxymethyl ester prodrug) as an oral antibacterial.","InChI=1S/C17H19N5O6S2/c1-2-3-8(9-6-30-16(18)20-9)12(23)21-10-13(24)22-11(15(25)26)7(4-28-17(19)27)5-29-14(10)22/h3,6,10,14H,2,4-5H2,1H3,(H2,18,20)(H2,19,27)(H,21,23)(H,25,26)/b8-3-/t10-,14-/m1/s1",CFPN,KEGG DRUG accession,D07638
6005,131749,"2-amino-1,3,4,5-icosanetetrol","A tetrol that is 2-aminoicosane with the four hydroxy substituents located at position 1, 3, 4 and 5.","InChI=1S/C20H43NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(23)20(25)19(24)17(21)16-22/h17-20,22-25H,2-16,21H2,1H3","2-amino-1,3,4,5-eicosanetetrol",PubMed citation,26860358
6006,131754,6-C-(alpha-L-arabinosyl)-8-C-(beta-L-arabinosyl)apigenin,A flavone C-glycoside that consists of apigenin carrying alpha-L-arabinosyl and beta-L-arabinosyl groups at positions 6 and 8 respectively,"InChI=1S/C25H26O13/c26-9-3-1-8(2-4-9)13-5-10(27)14-19(32)15(24-21(34)17(30)11(28)6-36-24)20(33)16(23(14)38-13)25-22(35)18(31)12(29)7-37-25/h1-5,11-12,17-18,21-22,24-26,28-35H,6-7H2/t11-,12-,17+,18+,21+,22+,24-,25+/m0/s1",apigenin 6-C-alpha-L-arabinoside-8-C-beta-L-arabinoside,KNApSAcK accession,C00014029
6007,131756,tioxazafen,"A 1,2,4-oxadizole in which the hydrogens at positions 3 and 5 have been replaced by phenyl and thiophen-2-yl groups, respectively. It is used as a broad spectrum nematicidal seed treatment.",InChI=1S/C12H8N2OS/c1-2-5-9(6-3-1)11-13-12(15-14-11)10-7-4-8-16-10/h1-8H,MON-102100,CAS Registry Number,330459-31-9
6008,131796,(S)-SKF 38393,"A 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol that is the S-enantiomer of SKF 38393.","InChI=1S/C16H17NO2/c18-15-8-12-6-7-17-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11/h1-5,8-9,14,17-19H,6-7,10H2/t14-/m0/s1",(S)-SKF-38393,Reaxys Registry Number,5287503
6009,131804,(S)-SKF 38393 hydrobromide,A hydrobromide obtained by combining (S)-SKF 38393 with one molar equivalent of hydrogen bromide.,"InChI=1S/C16H17NO2.BrH/c18-15-8-12-6-7-17-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11;/h1-5,8-9,14,17-19H,6-7,10H2;1H/t14-;/m0./s1",(S)-SKF 38393.HBr,Reaxys Registry Number,10731612
6010,131808,thymidine dimer,A nucleoside analogue obtained by formal cyclodimerisation of thymidine.,"InChI=1S/C20H28N4O10/c1-19-13(23(17(31)21-15(19)29)11-3-7(27)9(5-25)33-11)14-20(19,2)16(30)22-18(32)24(14)12-4-8(28)10(6-26)34-12/h7-14,25-28H,3-6H2,1-2H3,(H,21,29,31)(H,22,30,32)/t7-,8-,9+,10+,11+,12+,13?,14?,19?,20?/m0/s1",cyclobutane_dTdT,Reaxys Registry Number,22400139
6011,131821,thymidine 5'-monophosphate dimer,A cyclobutadipyrimidine bis(deoxyribonucleotide) obtained by formal cyclodimerisation of thymidine 5'-monophosphate.,"InChI=1S/C20H30N4O16P2/c1-19-13(23(17(29)21-15(19)27)11-3-7(25)9(39-11)5-37-41(31,32)33)14-20(19,2)16(28)22-18(30)24(14)12-4-8(26)10(40-12)6-38-42(34,35)36/h7-14,25-26H,3-6H2,1-2H3,(H,21,27,29)(H,22,28,30)(H2,31,32,33)(H2,34,35,36)/t7-,8-,9+,10+,11+,12+,13?,14?,19?,20?/m0/s1",thymidine 5'-monophosphate dimer,PubMed citation,22817898
6012,131824,"4a,4b-dimethylhexahydro-1,3,6,8-tetraazabiphenylene-2,4,5,7-tetrone","A member of the class of cyclobutadipyrimidines that is hexahydro-1,3,6,8-tetraazabiphenylene-2,4,5,7-tetrone carrying two additional methyl substituents at positions 4a and 4b.","InChI=1S/C10H12N4O4/c1-9-3(11-7(17)13-5(9)15)4-10(9,2)6(16)14-8(18)12-4/h3-4H,1-2H3,(H2,11,13,15,17)(H2,12,14,16,18)",cyclobutane thymine dimer,Reaxys Registry Number,621774
6013,131827,"8,5'-cyclo-2'-deoxyadenosine monophosphate",An organic heterotetracyclic compound obtained by intramolecular formation of a C-C bond between positions 8 and 5' of dAMP.,"InChI=1S/C10H12N5O6P/c11-8-5-9(13-2-12-8)15-4-1-3(16)6(20-4)7(10(15)14-5)21-22(17,18)19/h2-4,6-7,16H,1H2,(H2,11,12,13)(H2,17,18,19)/t3-,4+,6-,7-/m0/s1",cyclo-dAMP,PubMed citation,22817898
6014,131829,"8,5'-cyclo-2'-deoxyguanosine monophosphate",An organic heterotetracyclic compound obtained by intramolecular formation of a C-C bond between positions 8 and 5' of dGMP.,"InChI=1S/C10H12N5O7P/c11-10-13-7-4(9(17)14-10)12-8-6(22-23(18,19)20)5-2(16)1-3(21-5)15(7)8/h2-3,5-6,16H,1H2,(H2,18,19,20)(H3,11,13,14,17)/t2-,3+,5-,6-/m0/s1",cyclo-dGMP,PubMed citation,22817898
6015,131831,isoscoparin 2''-O-[6-(E)-feruloylglucoside],A flavone C-glycoside consisting of isoscoparin having a 6-(E)-feruloylglucosyl residue attached at position 2''.,"InChI=1S/C38H40O19/c1-51-22-9-15(3-6-17(22)40)4-8-27(44)53-14-26-31(46)33(48)35(50)38(56-26)57-37-34(49)30(45)25(13-39)55-36(37)29-20(43)12-24-28(32(29)47)19(42)11-21(54-24)16-5-7-18(41)23(10-16)52-2/h3-12,25-26,30-31,33-41,43,45-50H,13-14H2,1-2H3/b8-4+/t25-,26-,30-,31-,33+,34+,35-,36+,37-,38+/m1/s1",isoscoparin 2''-[6-(E)-feruloylglucoside],LIPID MAPS instance accession,LMPK12110753
6016,131833,dAp-dAp,A 5'-phospho-(3'->5')-dinucleotide composed from two dAMP residues.,"InChI=1S/C20H26N10O11P2/c21-17-15-19(25-5-23-17)29(7-27-15)13-1-9(31)11(39-13)3-38-43(35,36)41-10-2-14(40-12(10)4-37-42(32,33)34)30-8-28-16-18(22)24-6-26-20(16)30/h5-14,31H,1-4H2,(H,35,36)(H2,21,23,25)(H2,22,24,26)(H2,32,33,34)/t9-,10-,11+,12+,13+,14+/m0/s1",dApdAp,Reaxys Registry Number,1208508
6017,131839,sodium dodecanoate,An organic sodium salt resulting from the replacement of the proton from the carboxy group of dodecanoic acid by a sodium ion.,"InChI=1S/C12H24O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12(13)14;/h2-11H2,1H3,(H,13,14);/q;+1/p-1",sodium laurate,CAS Registry Number,629-25-4
6018,131884,calpastatin peptide Ac 184-210,A 27-membered polypeptide comprising the sequence Ac-Asp-Pro-Met-Ser-Ser-Thr-Tyr-Ile-Glu-Glu-Leu-Gly-Lys-Arg-Glu-Val-Thr-Ile-Pro-Pro-Lys-Tyr-Arg-Glu-Leu-Leu-Ala-NH2. An acetylated synthetic peptide from human calpastatin that strongly inhibits both calpains I and II but not papain (a cysteine protease) or trypsin (a serine protease).,"InChI=1S/C142H230N36O44S/c1-18-74(11)111(172-129(211)97(65-81-38-42-83(185)43-39-81)168-136(218)113(77(14)181)174-131(213)100(69-180)170-130(212)99(68-179)169-124(206)92(52-60-223-17)162-132(214)101-33-26-57-176(101)138(220)98(66-109(195)196)154-79(16)183)135(217)163-90(46-50-107(191)192)121(203)159-88(44-48-105(187)188)122(204)164-93(61-70(3)4)116(198)152-67-104(186)155-84(29-20-22-53-143)117(199)156-86(31-24-55-150-141(146)147)118(200)160-91(47-51-108(193)194)125(207)171-110(73(9)10)134(216)175-114(78(15)182)137(219)173-112(75(12)19-2)140(222)178-59-28-35-103(178)139(221)177-58-27-34-102(177)133(215)161-85(30-21-23-54-144)120(202)167-96(64-80-36-40-82(184)41-37-80)128(210)157-87(32-25-56-151-142(148)149)119(201)158-89(45-49-106(189)190)123(205)165-95(63-72(7)8)127(209)166-94(62-71(5)6)126(208)153-76(13)115(145)197/h36-43,70-78,84-103,110-114,179-182,184-185H,18-35,44-69,143-144H2,1-17H3,(H2,145,197)(H,152,198)(H,153,208)(H,154,183)(H,155,186)(H,156,199)(H,157,210)(H,158,201)(H,159,203)(H,160,200)(H,161,215)(H,162,214)(H,163,217)(H,164,204)(H,165,205)(H,166,209)(H,167,202)(H,168,218)(H,169,206)(H,170,212)(H,171,207)(H,172,211)(H,173,219)(H,174,213)(H,175,216)(H,187,188)(H,189,190)(H,191,192)(H,193,194)(H,195,196)(H4,146,147,150)(H4,148,149,151)/t74-,75-,76-,77+,78+,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,110-,111-,112-,113-,114-/m0/s1",Calpastatin Peptide B27-WT,Reaxys Registry Number,24313356
6019,131887,O-heptadecanoylcarnitine,An O-acylcarnitine in which the acyl group is specified as heptadecanoyl.,"InChI=1S/C24H47NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24(28)29-22(20-23(26)27)21-25(2,3)4/h22H,5-21H2,1-4H3",C17 carnitine,HMDB accession,HMDB0006210
6020,131888,8-epi-prostaglandin E2,A prostanoid that is prostaglandin E2 having inverted stereochemistry at the 8-position.,"InChI=1S/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16-,17+,19+/m0/s1",8-iso-PGE2,Chemspider accession,4446334
6021,131890,5-aminopentyl alpha-L-rhamnoside,A glycoside that is alpha-L-rhamnose in which the hydrogen of the anomeric hydroxy group is replaced by a 5-aminopentyl group.,"InChI=1S/C11H23NO5/c1-7-8(13)9(14)10(15)11(17-7)16-6-4-2-3-5-12/h7-11,13-15H,2-6,12H2,1H3/t7-,8-,9+,10+,11+/m0/s1",5-aminopentyl 6-deoxy-alpha-L-mannoside,PubMed citation,27091615
6022,131892,beta-D-Glcp-(1->4)-alpha-D-Glcp-(1->2)-alpha-D-GlcpO[CH2]5NH2,A trisaccharide derivative consisting of an alpha-D-glucosyl residue glycosidically linked to a 5-aminopentyl group and which carries at O-2 a beta-D-glucosyl-(1->4)-alpha-D-glucosyl disaccharide unit.,"InChI=1S/C23H43NO16/c24-4-2-1-3-5-35-23-20(15(31)13(29)10(7-26)37-23)40-22-18(34)16(32)19(11(8-27)38-22)39-21-17(33)14(30)12(28)9(6-25)36-21/h9-23,25-34H,1-8,24H2/t9-,10-,11-,12-,13-,14+,15+,16-,17-,18-,19-,20-,21+,22-,23+/m1/s1",5-aminopentyl beta-D-glucosyl-(1->4)-alpha-D-glucosyl-(1->2)-alpha-D-glucoside,PubMed citation,27091615
6023,131893,beta-D-Galp-(1->4)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)]-alpha-D-ManpO[CH2]5NH2,A branched tetrasaccharide derivative consisting of an alpha-D-mannosyl residue glycosidically linked to a 5-aminopentyl group and which carries at O-2 an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl disaccharide unit and at O-4 a beta-D-galactosyl residue.,"InChI=1S/C29H53NO21/c30-4-2-1-3-5-44-28-25(22(43)23(13(9-34)48-28)49-26-20(41)17(38)14(35)10(6-31)45-26)51-29-24(19(40)16(37)12(8-33)47-29)50-27-21(42)18(39)15(36)11(7-32)46-27/h10-29,31-43H,1-9,30H2/t10-,11-,12-,13-,14+,15-,16-,17+,18+,19+,20-,21+,22+,23-,24+,25+,26+,27-,28+,29-/m1/s1",beta-D-Gal-(1->4)-[alpha-D-Man-(1->2)-alpha-D-Man-(1->2)]-alpha-D-ManO[CH2]5NH2,PubMed citation,27091615
6024,131923,salubrinal,A member of the class of quinolines that is a mixed aminal resulting from the formal condensation oftrichloroacetaldehyde with the amide nitrogen of trans-cinnamamide and the primary amino group of 1-quinolin-8-ylthiourea. It is a selective inhibitor of cellular complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha).,"InChI=1S/C21H17Cl3N4OS/c22-21(23,24)19(27-17(29)12-11-14-6-2-1-3-7-14)28-20(30)26-16-10-4-8-15-9-5-13-25-18(15)16/h1-13,19H,(H,27,29)(H2,26,28,30)/b12-11+","(E)-3-phenyl-N-[2,2,2-trichloro-1-(quinolin-8-ylcarbamothioylamino)ethyl]prop-2-enamide",PubMed citation,23816340
6025,131941,validoxylamine A,"An amino cyclitol that is (1R,2S,3S,4S,6R)-4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol in which one of the hydrogens attached to the nitrogen is replaced by a (1R,4R,5R,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl group.","InChI=1S/C14H25NO8/c16-3-5-1-7(11(20)13(22)9(5)18)15-8-2-6(4-17)10(19)14(23)12(8)21/h1,6-23H,2-4H2/t6-,7+,8+,9-,10-,11+,12+,13+,14+/m1/s1",(+)-validoxylamine A,CAS Registry Number,38665-10-0
6026,131951,4-methylpentanoyl-CoA,A methyl-branched fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 4-methylpentanoic acid.,"InChI=1S/C27H46N7O17P3S/c1-15(2)5-6-18(36)55-10-9-29-17(35)7-8-30-25(39)22(38)27(3,4)12-48-54(45,46)51-53(43,44)47-11-16-21(50-52(40,41)42)20(37)26(49-16)34-14-33-19-23(28)31-13-32-24(19)34/h13-16,20-22,26,37-38H,5-12H2,1-4H3,(H,29,35)(H,30,39)(H,43,44)(H,45,46)(H2,28,31,32)(H2,40,41,42)/t16-,20-,21-,22+,26-/m1/s1",isocaproyl-CoA,Reaxys Registry Number,10324490
6027,131952,2-aminobenzoylacetyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-aminobenzoylacetic acid.,"InChI=1S/C30H43N8O18P3S/c1-30(2,25(43)28(44)34-8-7-20(40)33-9-10-60-21(41)11-18(39)16-5-3-4-6-17(16)31)13-53-59(50,51)56-58(48,49)52-12-19-24(55-57(45,46)47)23(42)29(54-19)38-15-37-22-26(32)35-14-36-27(22)38/h3-6,14-15,19,23-25,29,42-43H,7-13,31H2,1-2H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t19-,23-,24-,25+,29-/m1/s1",2-aminobenzoylacetyl-coenzyme A,Reaxys Registry Number,28365195
6028,131954,"GDP-4-amino-3,4,6-trideoxy-alpha-D-threo-hex-3-enopyranose","A GDP-hexose having 4-amino-3,4,6-trideoxy-alpha-D-threo-hex-3-enopyranose as the hexose fragment.","InChI=1S/C16H24N6O13P2/c1-5-6(17)2-7(23)15(32-5)34-37(29,30)35-36(27,28)31-3-8-10(24)11(25)14(33-8)22-4-19-9-12(22)20-16(18)21-13(9)26/h2,4-5,7-8,10-11,14-15,23-25H,3,17H2,1H3,(H,27,28)(H,29,30)(H3,18,20,21,26)/t5-,7+,8-,10-,11-,14-,15-/m1/s1","GDP-(2S,3S,6R)-3-hydroxy-5-amino-6-methyl-3,6-dihydro-2H-pyran",MetaCyc accession,CPD-16407
6029,131955,(5E)-tetradecenoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (5E)-tetradecenoic acid.,"InChI=1S/C35H60N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h11-12,22-24,28-30,34,45-46H,4-10,13-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/b12-11+/t24-,28-,29-,30+,34-/m1/s1",(5E)-tetradecenoyl-coenzyme A,PubMed citation,15466478
6030,131958,"(13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoate","A polyunsaturated fatty acid anion that is the conjugate base of 13S,14S-epoxy-DHA, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C22H30O3/c1-2-3-4-5-11-14-17-20-21(25-20)18-15-12-9-7-6-8-10-13-16-19-22(23)24/h3-4,6-7,9-15,18,20-21H,2,5,8,16-17,19H2,1H3,(H,23,24)/p-1/b4-3-,7-6-,12-9+,13-10-,14-11-,18-15+/t20-,21-/m0/s1","(13S,14S)-epoxy-DHA(1-)",PubMed citation,25036362
6031,131968,tyrphostin B42,"A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoic acid with the amino group of benzylamine.","InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)/b14-8+",AG 490,CAS Registry Number,133550-30-8
6032,131989,1-nonadecanoyl-sn-glycero-3-phosphocholine,A 1-O-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as nonadecanoyl.,"InChI=1S/C27H56NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(30)33-24-26(29)25-35-36(31,32)34-23-22-28(2,3)4/h26,29H,5-25H2,1-4H3/t26-/m1/s1",PC(19:0/0:0),LIPID MAPS instance accession,LMGP01050041
6033,132069,"(8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate",A cyclic purine nucleotide obtained by formation of a bond between positions 3' and 8 of guanosine 5'-triphosphate.,"InChI=1S/C10H16N5O14P3/c11-9-13-5-3(6(17)14-9)12-8-10(18)2(27-7(4(10)16)15(5)8)1-26-31(22,23)29-32(24,25)28-30(19,20)21/h2,4,7-8,12,16,18H,1H2,(H,22,23)(H,24,25)(H2,19,20,21)(H3,11,13,14,17)/t2-,4+,7-,8+,10+/m1/s1","3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate",PubMed citation,25941396
6034,132084,SU11652,"A member of the class of pyrrolecarboxamides obtained by formal condensation of the carboxy group of 5-[(Z)-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethylpyrrole-3-carboxylic acid with the primary amino group of N(1),N(1)-diethylethane-1,2-diamine.","InChI=1S/C22H27ClN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",SU-11652,Reaxys Registry Number,9364272
6035,132086,BMS-493,"A member of the class of dihydronaphthalenes that is 1,2-dihydronaphthalene which is substituted at positions 1, 1, 4, and 6 by methyl, methyl, phenylethynyl, and 2-(p-carboxyphenyl)vinyl groups, respectively (the E isomer).","InChI=1S/C29H24O2/c1-29(2)19-18-24(14-10-21-6-4-3-5-7-21)26-20-23(13-17-27(26)29)9-8-22-11-15-25(16-12-22)28(30)31/h3-9,11-13,15-18,20H,19H2,1-2H3,(H,30,31)/b9-8+",BMS 493,Reaxys Registry Number,15383782
6036,132095,sodium metavanadate hydrate,A hydrate that is the monohydrate form of sodium metavanadate.,InChI=1S/Na.H2O.3O.V/h;1H2;;;;/q+1;;;;-1;,sodium metavanadate monohydrate,Reaxys Registry Number,23158495
6037,132099,sodium molybdate tetrahydrate,A hydrate that is the tetrahydrate form of sodium molybdate.,InChI=1S/Mo.2Na.4H2O.4O/h;;;4*1H2;;;;/q;2*+1;;;;;;;2*-1,sodium orthomolybdate tetrahydrate,Wikipedia accession,Sodium_molybdate
6038,132107,trisodium phosphate decahydrate,A hydrate that is the decahydrate form of trisodium phosphate.,"InChI=1S/3Na.H3O4P.10H2O/c;;;1-5(2,3)4;;;;;;;;;;/h;;;(H3,1,2,3,4);10*1H2/q3*+1;;;;;;;;;;;/p-3",sodium phosphate decahydrate,Wikipedia accession,Sodium_phosphates
6039,132112,sodium thiosulfate,An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.,"InChI=1S/2Na.H2O3S2/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2",sodium thiosulfate (anhydrous),CAS Registry Number,7772-98-7
6040,132116,2-hydroxyisobutanoyl-CoA,A hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-hydroxyisobutanoic acid.,"InChI=1S/C25H42N7O18P3S/c1-24(2,18(35)21(36)28-6-5-14(33)27-7-8-54-23(37)25(3,4)38)10-47-53(44,45)50-52(42,43)46-9-13-17(49-51(39,40)41)16(34)22(48-13)32-12-31-15-19(26)29-11-30-20(15)32/h11-13,16-18,22,34-35,38H,5-10H2,1-4H3,(H,27,33)(H,28,36)(H,42,43)(H,44,45)(H2,26,29,30)(H2,39,40,41)/t13-,16-,17-,18+,22-/m1/s1",2-hydroxyisobutanoyl-coenzyme A,Reaxys Registry Number,22539664
6041,132118,S-(2-carboxy-2-methylbut-3-en-2-yl)glutathione,A glutathione derivative in which the thiol hydrogen of glutathione is replaced by a 2-carboxy-2-methylbut-3-en-2-yl group.,"InChI=1S/C15H23N3O8S/c1-3-15(2,14(25)26)27-7-9(12(22)17-6-11(20)21)18-10(19)5-4-8(16)13(23)24/h3,8-9H,1,4-7,16H2,2H3,(H,17,22)(H,18,19)(H,20,21)(H,23,24)(H,25,26)/t8-,9-,15?/m0/s1",2-glutathionyl-2-methylbut-3-enoic acid,MetaCyc accession,CPD-19032
6042,132138,dehydroascorbic acid dimer,An organic heteropentacyclic compound obtained by cyclodimerisation of ascorbic acid.,"InChI=1S/C12H12O12/c13-3-1-19-11-5(3)21-7(15)9(11,17)23-10(18)8(16)22-6-4(14)2-20-12(6,10)24-11/h3-6,13-14,17-18H,1-2H2",bis-DHA,Chemspider accession,3804416
6043,132140,methane clathrate,A clathrate compound that is an ice-like solid that consists of methane which is trapped within the crystal structure of water. It has formula CH4.5.75H2O or 4CH4.23H2O.,InChI=1S/4CH4.23H2O/h4*1H4;23*1H2,fire ice,Wikipedia accession,Methane_clathrate
6044,132150,wilforine,An organic heteropentacyclic compound and pyridine alkaloid with formula C43H49NO18 originally isolated from the roots of Tripterygium wilfordii.,"InChI=1S/C43H49NO18/c1-21-16-17-29-28(15-12-18-44-29)39(52)55-19-40(7)30-31(56-23(3)46)35(58-25(5)48)42(20-54-22(2)45)36(59-26(6)49)32(60-38(51)27-13-10-9-11-14-27)34(61-37(21)50)41(8,53)43(42,62-40)33(30)57-24(4)47/h9-15,18,21,30-36,53H,16-17,19-20H2,1-8H3/t21-,30+,31+,32-,33+,34-,35+,36-,40-,41-,42+,43-/m0/s1",26-Deoxywilfordine,CAS Registry Number,11088-09-8
6045,132158,"1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one",An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.,"InChI=1S/C18H26N6O8/c19-14-15(24(17(29)21-16(14)20)13-3-8(28)10(5-26)32-13)6-1-11-22(6)18(30)23(11)12-2-7(27)9(4-25)31-12/h1,6-10,12-15,25-28H,2-5,19H2,(H2,20,21,29)/t6?,7-,8-,9+,10+,12+,13+,14?,15?/m0/s1",dC64dC_dewar,PubMed citation,22817898
6046,132159,"1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl}-1,3-diazinane-2,4-dione",An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.,"InChI=1S/C19H27N5O9/c1-19(20)15(24(17(30)21-16(19)29)14-4-9(28)11(6-26)33-14)7-2-12-22(7)18(31)23(12)13-3-8(27)10(5-25)32-13/h2,7-11,13-15,25-28H,3-6,20H2,1H3,(H,21,29,30)/t7?,8-,9-,10+,11+,13+,14+,15?,19?/m0/s1",dC64dT_dewar,PubMed citation,22817898
6047,132160,"6'-amino-1,3'-bis(2-deoxy-beta-D-erythro-pentofuranosyl)-5'-hydroxy-5-methyl-3,4-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione",An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.,"InChI=1S/C19H27N5O9/c1-7-4-23(12-2-8(27)10(5-25)32-12)18(30)21-14(7)15-16(29)17(20)22-19(31)24(15)13-3-9(28)11(6-26)33-13/h4,8-14,25-29H,2-3,5-6H2,1H3,(H,21,30)(H2,20,22,31)/t8-,9-,10+,11+,12+,13+,14?/m0/s1",dC64dT,PubMed citation,22817898
6048,132161,"5',6'-diamino-1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-4',5'-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione",An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.,"InChI=1S/C18H28N6O14P2/c19-14-15(24(18(28)22-16(14)20)13-4-9(26)11(38-13)6-36-40(32,33)34)7-1-2-23(17(27)21-7)12-3-8(25)10(37-12)5-35-39(29,30)31/h1-2,8-15,25-26H,3-6,19H2,(H2,20,22,28)(H2,29,30,31)(H2,32,33,34)/t8-,9-,10+,11+,12+,13+,14?,15?/m0/s1",dCMP64dCMP,PubMed citation,22817898
6049,132162,"1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-6-(5,6-diamino-2-oxo-2,3,4,5-tetrahydropyrimidin-4-yl)-1,3-diazabicyclo[2.2.0]hex-4-en-2-one",An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.,"InChI=1S/C18H28N6O14P2/c19-14-15(24(17(27)21-16(14)20)13-3-8(26)10(38-13)5-36-40(32,33)34)6-1-11-22(6)18(28)23(11)12-2-7(25)9(37-12)4-35-39(29,30)31/h1,6-10,12-15,25-26H,2-5,19H2,(H2,20,21,27)(H2,29,30,31)(H2,32,33,34)/t6?,7-,8-,9+,10+,12+,13+,14?,15?/m0/s1",dCMP64dCMP_dewar,PubMed citation,22817898
6050,132163,"1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-5-amino-5-methyl-6-{2-oxo-1,3-diazabicyclo[2.2.0]hex-4-en-6-yl}-1,3-diazinane-2,4-dione",An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.,"InChI=1S/C19H29N5O15P2/c1-19(20)15(24(17(28)21-16(19)27)14-4-9(26)11(39-14)6-37-41(33,34)35)7-2-12-22(7)18(29)23(12)13-3-8(25)10(38-13)5-36-40(30,31)32/h2,7-11,13-15,25-26H,3-6,20H2,1H3,(H,21,27,28)(H2,30,31,32)(H2,33,34,35)/t7?,8-,9-,10+,11+,13+,14+,15?,19?/m0/s1",dCMP64dTMP_dewar,PubMed citation,22817898
6051,132164,"6'-amino-1,3'-bis(2-deoxy-5-O-phosphono-beta-D-erythro-pentofuranosyl)-5'-hydroxy-5-methyl-3,4-dihydro[4,4'-bipyrimidine]-2,2'(1H,3'H)-dione",An N-glycosyl compound that is a metabolite produced by the bacterium Mycoplasma genitalium.,"InChI=1S/C19H29N5O15P2/c1-7-4-23(12-2-8(25)10(38-12)5-36-40(30,31)32)18(28)21-14(7)15-16(27)17(20)22-19(29)24(15)13-3-9(26)11(39-13)6-37-41(33,34)35/h4,8-14,25-27H,2-3,5-6H2,1H3,(H,21,28)(H2,20,22,29)(H2,30,31,32)(H2,33,34,35)/t8-,9-,10+,11+,12+,13+,14?/m0/s1",dCMP64dTMP,PubMed citation,22817898
6052,132167,dpC-dpC,A 5'-phospho-(3'->5')-dinucleotide composed from two dCMP residues.,"InChI=1S/C18H26N6O13P2/c19-13-1-3-23(17(26)21-13)15-5-9(25)11(35-15)7-34-39(31,32)37-10-6-16(24-4-2-14(20)22-18(24)27)36-12(10)8-33-38(28,29)30/h1-4,9-12,15-16,25H,5-8H2,(H,31,32)(H2,19,21,26)(H2,20,22,27)(H2,28,29,30)/t9-,10-,11+,12+,15+,16+/m0/s1",dpCdpC,Reaxys Registry Number,741248
6053,132169,"2'-deoxy-5,6-dihydroxy-5,6-dihydrocytidine","A nucleoside analogue that is the 5,6-dihydroxy-5,6-dihydro derivative of cytidine. It is a metabolite produced by the bacterium Mycoplasma genitalium.","InChI=1S/C9H15N3O6/c10-7-6(15)8(16)12(9(17)11-7)5-1-3(14)4(2-13)18-5/h3-6,8,13-16H,1-2H2,(H2,10,11,17)/t3-,4+,5+,6?,8?/m0/s1",2'-deoxycytidine glycol,PubMed citation,22817898
6054,132170,"2,3-dideoxy-beta-D-ribose 5-phosphate","A 2,3-dideoxyribose phosphate that is the 2,3-dideoxy analogue of beta-D-ribofuranose 5-phosphate.","InChI=1S/C5H11O6P/c6-5-2-1-4(11-5)3-10-12(7,8)9/h4-6H,1-3H2,(H2,7,8,9)/t4-,5+/m0/s1",dideoxyribose 5-phosphate,PubMed citation,22817898
6055,132171,"5,6-dihydrothymidine",A pyrimidine 2'-deoxyribonucleoside having dihydrothymine as the nucleobase.,"InChI=1S/C10H16N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h5-8,13-14H,2-4H2,1H3,(H,11,15,16)/t5?,6-,7+,8+/m0/s1",dihydrothymidine,CAS Registry Number,5627-00-9
6056,132172,"5,6-dihydrothymidine 5'-monophosphate",A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having dihydrothymine as the nucleobase.,"InChI=1S/C10H17N2O8P/c1-5-3-12(10(15)11-9(5)14)8-2-6(13)7(20-8)4-19-21(16,17)18/h5-8,13H,2-4H2,1H3,(H,11,14,15)(H2,16,17,18)/t5?,6-,7+,8+/m0/s1",dihydrothymidine 5'-monophosphate,PubMed citation,22817898
6057,132187,N-ethyldiethanolamine,A aminodiol that is diethanolamine in which the amino hydrogen has been replaced by an ethyl group. It is a metabolite of nitrogen mustards.,"InChI=1S/C6H15NO2/c1-2-7(3-5-8)4-6-9/h8-9H,2-6H2,1H3","2,2'-(ethylimino)diethanol",Chemspider accession,8439
6058,132189,"5,6-dihydroxy-2'-deoxyuridine","A pyrimidine 2'-deoxyribonucleoside having 5,6-dihydroxyuracil as the nucleobase.","InChI=1S/C9H12N2O7/c12-2-4-3(13)1-5(18-4)11-8(16)6(14)7(15)10-9(11)17/h3-5,12-14,16H,1-2H2,(H,10,15,17)/t3-,4+,5+/m0/s1",DHdU,PubMed citation,22817898
6059,132190,"5,6-dihydroxy-2'-deoxyuridine 5'-monophosphate","A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having 5,6-dihydroxyuracil as the nucleobase.","InChI=1S/C9H13N2O10P/c12-3-1-5(21-4(3)2-20-22(17,18)19)11-8(15)6(13)7(14)10-9(11)16/h3-5,12-13,15H,1-2H2,(H,10,14,16)(H2,17,18,19)/t3-,4+,5+/m0/s1",DHdUMP,PubMed citation,22817898
6060,132191,"2'-deoxy-5-(4,5-dihydroxypentyl)uridine","A pyrimidine 2'-deoxyribonucleoside having 5-(4,5-dihydroxypentyl)uracil as the nucleobase.","InChI=1S/C14H22N2O7/c17-6-9(19)3-1-2-8-5-16(14(22)15-13(8)21)12-4-10(20)11(7-18)23-12/h5,9-12,17-20H,1-4,6-7H2,(H,15,21,22)/t9?,10-,11+,12+/m0/s1",dhpdU,Reaxys Registry Number,763978
6061,132193,"2'-deoxy-5-(4,5-dihydroxypentyl)uridine 5'-monophosphate","A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having 5-(4,5-dihydroxypentyl)uracil as the nucleobase.","InChI=1S/C14H23N2O10P/c17-6-9(18)3-1-2-8-5-16(14(21)15-13(8)20)12-4-10(19)11(26-12)7-25-27(22,23)24/h5,9-12,17-19H,1-4,6-7H2,(H,15,20,21)(H2,22,23,24)/t9?,10-,11+,12+/m0/s1",dhpdUMP,PubMed citation,22817898
6062,132194,glycine-d5,A deuterated compound that is is an isotopologue of glycine in which all five hydrogen atoms have been replaced by deuterium.,"InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)/i1D2/hD3",perdeuterioglycine,Chemspider accession,2006146
6063,132203,6-carboxyfluorescein succinimidyl ester,"An N-hydroxysuccinimide ester derived from 6-carboxyfluorescein. A fluorescent cell staining dye, it is cell permeable and covalently couples, via its succinimidyl group, to intracellular molecules, notably to intracellular lysine residues.","InChI=1S/C25H15NO9/c27-13-2-5-16-19(10-13)33-20-11-14(28)3-6-17(20)25(16)18-9-12(1-4-15(18)24(32)34-25)23(31)35-26-21(29)7-8-22(26)30/h1-6,9-11,27-28H,7-8H2",CFSE,Wikipedia accession,Carboxyfluorescein_succinimidyl_ester
6064,132205,5-O-phosphono-2-deoxyribosyl-(3->5)-2-deoxyribose,"A 2-deoxyribose bisphosphate that is 2-deoxy-alpha-D-ribofuranose 3,5-bisphosphate in which the phosphate group at position 3 is esterfied by a 2-deoxy-alpha-D-ribofuranos-5-yl group.","InChI=1S/C10H20O13P2/c11-5-1-9(12)21-7(5)3-20-25(17,18)23-6-2-10(13)22-8(6)4-19-24(14,15)16/h5-13H,1-4H2,(H,17,18)(H2,14,15,16)/t5-,6-,7+,8+,9-,10-/m0/s1",dRibose5P_dRibose5P,PubMed citation,22817898
6065,132225,D-homocysteic acid,A homocysteic acid with D-configuration.,"InChI=1S/C4H9NO5S/c5-3(4(6)7)1-2-11(8,9)10/h3H,1-2,5H2,(H,6,7)(H,8,9,10)/t3-/m1/s1",(2R)-2-amino-4-sulfobutyric acid,CAS Registry Number,56892-03-6
6066,132245,"(2R,3S)-glycosmisic acid",A member of the class of 1-benzofurans that is a lignan obtained by cyclodimerisation of ferulic acid. It is isolated from several plants including spearmint.,"InChI=1S/C20H20O7/c1-25-16-9-12(4-5-15(16)22)19-14(10-21)13-7-11(3-6-18(23)24)8-17(26-2)20(13)27-19/h3-9,14,19,21-22H,10H2,1-2H3,(H,23,24)/b6-3+/t14-,19+/m1/s1",(-)-dehydrodiconiferyl acid,Reaxys Registry Number,22023630
6067,132251,(+)-DCA-CL,A member of the class of 1-benzofurans that is a lignan obtained by cyclodimerisation of ferulic acid.,"InChI=1S/C20H18O7/c1-25-16-9-12(4-5-15(16)22)19-14(10-21)13-7-11(3-6-18(23)24)8-17(26-2)20(13)27-19/h3-10,14,19,22H,1-2H3,(H,23,24)/b6-3+/t14-,19+/m0/s1",(+)-dehydrodiconiferyl acid aldehyde,MetaCyc accession,CPD-18964
6068,132258,"(2E,5E)-tetradecadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2E,5E)-tetradecadienoic acid.","InChI=1S/C35H58N7O17P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-26(44)63-19-18-37-25(43)16-17-38-33(47)30(46)35(2,3)21-56-62(53,54)59-61(51,52)55-20-24-29(58-60(48,49)50)28(45)34(57-24)42-23-41-27-31(36)39-22-40-32(27)42/h11-12,14-15,22-24,28-30,34,45-46H,4-10,13,16-21H2,1-3H3,(H,37,43)(H,38,47)(H,51,52)(H,53,54)(H2,36,39,40)(H2,48,49,50)/b12-11+,15-14+/t24-,28-,29-,30+,34-/m1/s1","trans,trans-tetradeca-2,5-dienoyl-CoA",PubMed citation,15466478
6069,132269,(3E)-octenoyl-CoA,An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (3E)-octenoic acid.,"InChI=1S/C29H48N7O17P3S/c1-4-5-6-7-8-9-20(38)57-13-12-31-19(37)10-11-32-27(41)24(40)29(2,3)15-50-56(47,48)53-55(45,46)49-14-18-23(52-54(42,43)44)22(39)28(51-18)36-17-35-21-25(30)33-16-34-26(21)36/h7-8,16-18,22-24,28,39-40H,4-6,9-15H2,1-3H3,(H,31,37)(H,32,41)(H,45,46)(H,47,48)(H2,30,33,34)(H2,42,43,44)/b8-7+/t18-,22-,23-,24+,28-/m1/s1",(3E)-octenoyl-coenzyme A,Reaxys Registry Number,11165745
6070,132271,"(2E,5Z)-octadienoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2E,5Z)-octadienoic acid","InChI=1S/C29H46N7O17P3S/c1-4-5-6-7-8-9-20(38)57-13-12-31-19(37)10-11-32-27(41)24(40)29(2,3)15-50-56(47,48)53-55(45,46)49-14-18-23(52-54(42,43)44)22(39)28(51-18)36-17-35-21-25(30)33-16-34-26(21)36/h5-6,8-9,16-18,22-24,28,39-40H,4,7,10-15H2,1-3H3,(H,31,37)(H,32,41)(H,45,46)(H,47,48)(H2,30,33,34)(H2,42,43,44)/b6-5-,9-8+/t18-,22-,23-,24+,28-/m1/s1","(2E,5Z)-octadienoyl-coenzyme A",PubMed citation,11781327
6071,132274,"(14S,15R)-EET","A 14,15-EET in which the epoxy moiety has 14S,15R-configuration.","InChI=1S/C20H32O3/c1-2-3-12-15-18-19(23-18)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h4,6-7,9-10,13,18-19H,2-3,5,8,11-12,14-17H2,1H3,(H,21,22)/b6-4-,9-7-,13-10-/t18-,19+/m1/s1","(14S,15R)-epoxy-(5Z,8Z,11Z)-icosatrienoic acid",Reaxys Registry Number,4703442
6072,132276,"(11S,12R)-EET","An 11,12-EET in which the epoxy moiety has 11S,12R-configuration.","InChI=1S/C20H32O3/c1-2-3-4-5-9-12-15-18-19(23-18)16-13-10-7-6-8-11-14-17-20(21)22/h6,8-10,12-13,18-19H,2-5,7,11,14-17H2,1H3,(H,21,22)/b8-6-,12-9-,13-10-/t18-,19+/m1/s1","(11S,12R)-epoxy-(5Z,8Z,14Z)-icosatrienoic acid",LIPID MAPS instance accession,LMFA03080014
6073,132277,"(11R,12S)-EET","An 11,12-EET in which the epoxy moiety has 11R,12S-configuration.","InChI=1S/C20H32O3/c1-2-3-4-5-9-12-15-18-19(23-18)16-13-10-7-6-8-11-14-17-20(21)22/h6,8-10,12-13,18-19H,2-5,7,11,14-17H2,1H3,(H,21,22)/b8-6-,12-9-,13-10-/t18-,19+/m0/s1","11(R),12(S)-EET",LIPID MAPS instance accession,LMFA03080015
6074,132282,"octamethyltetrasiloxane-1,7-diol","An organosilanol that is the 1,7-dihydroxy derivative of octamethyltetrasiloxane.","InChI=1S/C8H26O5Si4/c1-14(2,9)11-16(5,6)13-17(7,8)12-15(3,4)10/h9-10H,1-8H3","1,1,3,3,5,5,7,7-octamethyltetrasiloxane-1,7-diol",Chemspider accession,68974
6075,132289,3-[(2-aminoethyl)sulfanyl]-6-ethyl-7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,A beta-lactam that is 7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid carrying additional (2-aminoethyl)sulfanyl and ethyl substituents at positions 3 and 6 respectively. An intermediate in the biosynthesis of carbapenem.,"InChI=1S/C11H18N2O3S/c1-2-6-7-5-8(17-4-3-12)9(11(15)16)13(7)10(6)14/h6-9H,2-5,12H2,1H3,(H,15,16)",carbapenem biosynthesis intermediate 5,PubMed citation,21263049
6076,132290,3-[(2-aminoethyl)sulfanyl]-6-methyl-7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,A beta-lactam that is 7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid carrying additional (2-aminoethyl)sulfanyl and methyl substituents at positions 3 and 6 respectively. An intermediate in the biosynthesis of carbapenem.,"InChI=1S/C10H16N2O3S/c1-5-6-4-7(16-3-2-11)8(10(14)15)12(6)9(5)13/h5-8H,2-4,11H2,1H3,(H,14,15)",carbapenem biosynthesis intermediate 2,PubMed citation,21263049
6077,132293,2-methylicosane,A branched alkane consisting of icosane bearing a single methyl substituent at position 2.,"InChI=1S/C21H44/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21(2)3/h21H,4-20H2,1-3H3",2-methyleicosane,Chemspider accession,452834
6078,132299,"methyl 2,5-dichlorobenzoate","A methyl ester resulting from the formal condensation of the carboxy group of 2,5-dichlorobenzoic acid with methanol. It as used as a plant growth regulator and fungicide for grafting of grapevines.","InChI=1S/C8H6Cl2O2/c1-12-8(11)6-4-5(9)2-3-7(6)10/h2-4H,1H3","2,5-DCBME",CAS Registry Number,2905-69-3
6079,132302,"(8S,9R)-EET","An 8,9-EET in which the epoxy moiety has 8S,9R-configuration.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-12-15-18-19(23-18)16-13-10-11-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,12-9-,13-10-/t18-,19+/m1/s1","(8S,9R)-epoxy-(5Z,11Z,14Z)-icosatrienoic acid",Reaxys Registry Number,4697202
6080,132303,"(8R,9S)-EET","An 8,9-EET in which the epoxy moiety has 8R,9S-configuration.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-12-15-18-19(23-18)16-13-10-11-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,12-9-,13-10-/t18-,19+/m0/s1","8(R),9(S)-EET",PubMed citation,20972997
6081,132304,3-[(2-aminoethyl)sulfanyl]-7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,A beta-lactam that is 7-oxo-1-azabicyclo[3.2.0]heptane-2-carboxylic acid carrying an additional (2-aminoethyl)sulfanyl substituent at position 3. An intermediate in the biosynthesis of carbapenem.,"InChI=1S/C9H14N2O3S/c10-1-2-15-6-3-5-4-7(12)11(5)8(6)9(13)14/h5-6,8H,1-4,10H2,(H,13,14)",carbapenem biosynthesis intermediate 1,PubMed citation,26240322
6082,132309,S-butyryl-4'-phosphopantetheine,An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of butyric acid.,"InChI=1S/C15H29N2O8PS/c1-4-5-12(19)27-9-8-16-11(18)6-7-17-14(21)13(20)15(2,3)10-25-26(22,23)24/h13,20H,4-10H2,1-3H3,(H,16,18)(H,17,21)(H2,22,23,24)/t13-/m0/s1",butyryl-4'-phosphopantetheine,PubMed citation,18799520
6083,132311,S-hexanoyl-4'-phosphopantetheine,An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of hexanoic acid.,"InChI=1S/C17H33N2O8PS/c1-4-5-6-7-14(21)29-11-10-18-13(20)8-9-19-16(23)15(22)17(2,3)12-27-28(24,25)26/h15,22H,4-12H2,1-3H3,(H,18,20)(H,19,23)(H2,24,25,26)/t15-/m0/s1",S-caproyl-4'-phosphopantetheine,PubMed citation,18799520
6084,132312,S-octanoyl-4'-phosphopantetheine,An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of octanoic acid.,"InChI=1S/C19H37N2O8PS/c1-4-5-6-7-8-9-16(23)31-13-12-20-15(22)10-11-21-18(25)17(24)19(2,3)14-29-30(26,27)28/h17,24H,4-14H2,1-3H3,(H,20,22)(H,21,25)(H2,26,27,28)/t17-/m0/s1",octanoyl-4'-phosphopantetheine,PubMed citation,18799520
6085,132313,S-decanoyl-4'-phosphopantetheine,An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of decanoic acid.,"InChI=1S/C21H41N2O8PS/c1-4-5-6-7-8-9-10-11-18(25)33-15-14-22-17(24)12-13-23-20(27)19(26)21(2,3)16-31-32(28,29)30/h19,26H,4-16H2,1-3H3,(H,22,24)(H,23,27)(H2,28,29,30)/t19-/m0/s1",S-decanoyl-D-pantetheine 4'-phosphate,PubMed citation,18799520
6086,132316,S-dodecanoyl-4'-phosphopantetheine,An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of dodecanoic acid.,"InChI=1S/C23H45N2O8PS/c1-4-5-6-7-8-9-10-11-12-13-20(27)35-17-16-24-19(26)14-15-25-22(29)21(28)23(2,3)18-33-34(30,31)32/h21,28H,4-18H2,1-3H3,(H,24,26)(H,25,29)(H2,30,31,32)/t21-/m0/s1",lauroyl-4-phosphopantetheine,PDBeChem accession,8Q1
6087,132318,EDTA monomagnesium salt,A magnesium salt that is the monomagnesium salt of ethylenediaminetetraacetic acid (EDTA).,"InChI=1S/C10H16N2O8.Mg/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);/q;+2/p-2",magnesium dihydrogen ethylenediaminetetraacetate,Chemspider accession,2601998
6088,132319,S-tetradecanoyl-4'-phosphopantetheine,An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of tetradecanoic acid.,"InChI=1S/C25H49N2O8PS/c1-4-5-6-7-8-9-10-11-12-13-14-15-22(29)37-19-18-26-21(28)16-17-27-24(31)23(30)25(2,3)20-35-36(32,33)34/h23,30H,4-20H2,1-3H3,(H,26,28)(H,27,31)(H2,32,33,34)/t23-/m0/s1",S-myristoyl-4-phosphopantetheine,PubMed citation,18799520
6089,132320,S-hexadecanoyl-4'-phosphopantetheine,An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of hexadecanoic acid.,"InChI=1S/C27H53N2O8PS/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-24(31)39-21-20-28-23(30)18-19-29-26(33)25(32)27(2,3)22-37-38(34,35)36/h25,32H,4-22H2,1-3H3,(H,28,30)(H,29,33)(H2,34,35,36)/t25-/m0/s1",hexadecanoyl-4'-phosphopantetheine,PubMed citation,18799520
6090,132322,"S-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl)-4'-phosphopantetheine","An S-acyl-4'-phosphopantetheine obtained by formal condensation of the thiol group of D-pantetheine 4'-phosphate with the carboxy group of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oic acid.","InChI=1S/C38H67N2O11PS/c1-22(26-10-11-27-32-28(20-30(43)38(26,27)6)37(5)14-12-25(41)18-24(37)19-29(32)42)8-7-9-23(2)35(47)53-17-16-39-31(44)13-15-40-34(46)33(45)36(3,4)21-51-52(48,49)50/h22-30,32-33,41-43,45H,7-21H2,1-6H3,(H,39,44)(H,40,46)(H2,48,49,50)/t22-,23?,24+,25-,26-,27+,28+,29-,30+,32+,33+,37+,38-/m1/s1","S-(3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oyl)-D-pantetheine 4'-phosphate",PubMed citation,18799520
6091,132323,19-HETrE,"A HETrE that is (5Z,8Z,11Z)-icosatrienoic acid substituted at position 19 by a hydroxy group.","InChI=1S/C20H34O3/c1-19(21)17-15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18-20(22)23/h3-6,10,12,19,21H,2,7-9,11,13-18H2,1H3,(H,22,23)/b5-3-,6-4-,12-10-","(5Z,8Z,11Z)-19-hydroxyicosatrienoic acid",PubMed citation,18577768
6092,132324,20-HETrE,"A HETrE that is (5Z,8Z,11Z)-icosatrienoic acid substituted at position 20 by a hydroxy group.","InChI=1S/C20H34O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6,10,12,21H,2,5,7-9,11,13-19H2,(H,22,23)/b3-1-,6-4-,12-10-","(5Z,8Z,11Z)-20-hydroxyicosatrienoic acid",PubMed citation,18577768
6093,132330,1-naphthyl tetradecanoate,A fatty acid ester obtained by formal condensation of the carboxy group of tetradecanoic acid with the phenolic hydroxy group of 1-naphthol.,"InChI=1S/C24H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-20-24(25)26-23-19-15-17-21-16-13-14-18-22(21)23/h13-19H,2-12,20H2,1H3",naphthalen-1-yl tetradecanoate,Chemspider accession,2587807
6094,132331,citral dimethyl acetal,A monoterpenoid that is the acetal obtained by formal condensation of citral with methanol.,"InChI=1S/C12H22O2/c1-10(2)7-6-8-11(3)9-12(13-4)14-5/h7,9,12H,6,8H2,1-5H3","3,7-dimethyl-2,6-octadienal dimethyl acetal",Reaxys Registry Number,1706336
6095,132337,triptoditerpenic acid B,"A tricyclic diterpenoid with formula C21H28O3, originally isolated from Tripterygium hypoglaucum.","InChI=1S/C21H28O3/c1-12(2)14-6-9-18-16(19(14)24-5)7-8-17-13(3)15(20(22)23)10-11-21(17,18)4/h6,9,12,17H,7-8,10-11H2,1-5H3,(H,22,23)",NSC672174,CAS Registry Number,147362-43-4
6096,132340,triptohypol C,"A pentacyclic triterpenoid with formula C29H40O4, originally isolated from the root bark of Tripterygium regelii.","InChI=1S/C29H40O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h8,15,22,30-31H,7,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1",dihydrocelastrol,Reaxys Registry Number,3181751
6097,132362,citrate(4-),A citrate anion obtained by deprotonation of the three carboxy groups as well as the hydroxy group of citric acid.,"InChI=1S/C6H7O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h1-2H2,(H,7,8)(H,9,10)(H,11,12)/q-1/p-3",citric acid tetraanion,Chemspider accession,34552020
6098,132373,mesembryanthemoidigenic acid,"A pentacyclic triterpenoid with formula C30H48O4, originally isolated from Akebia quinata and Stauntonia hexaphylla.","InChI=1S/C30H48O4/c1-25(2)21-9-12-29(6)22(27(21,4)11-10-23(25)32)8-7-19-20-17-26(3,18-31)13-15-30(20,24(33)34)16-14-28(19,29)5/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21-,22+,23-,26+,27-,28+,29+,30-/m0/s1",AC1O54QP,CAS Registry Number,4871-87-8
6099,132377,benzo[c]phenanthren-1-ol,A hydroxybenzo[c]phenanthrene that is benzo[c]phenanthrene in which the hydrogen at position 1 has been replaced by a hydroxy group. A metabolite of benzo[c]phenanthrene.,"InChI=1S/C18H12O/c19-16-7-3-5-13-10-11-14-9-8-12-4-1-2-6-15(12)17(14)18(13)16/h1-11,19H",1-benzo[c]phenanthrenol,Reaxys Registry Number,2560466
6100,132403,Ala-Lys,A dipeptide obtained by formal condensation of the carboxy group of L-alanine with the alpha-amino group of L-lysine.,"InChI=1S/C9H19N3O3/c1-6(11)8(13)12-7(9(14)15)4-2-3-5-10/h6-7H,2-5,10-11H2,1H3,(H,12,13)(H,14,15)/t6-,7-/m0/s1",alanyllysine,Reaxys Registry Number,1727665
6101,132475,N-dodecanoyltaurine,A fatty acid-taurine conjugate derived from dodecanoic acid.,"InChI=1S/C14H29NO4S/c1-2-3-4-5-6-7-8-9-10-11-14(16)15-12-13-20(17,18)19/h2-13H2,1H3,(H,15,16)(H,17,18,19)",N-lauroyltaurine,CAS Registry Number,40738-12-3
6102,132476,N-tetradecanoyltaurine,A fatty acid-taurine conjugate derived from tetradecanoic acid.,"InChI=1S/C16H33NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16(18)17-14-15-22(19,20)21/h2-15H2,1H3,(H,17,18)(H,19,20,21)",N-myristoyl-taurine,PubMed citation,17116739
6103,132477,N-hexadecanoyltaurine,A fatty acid-taurine conjugate derived from hexadecanoic acid.,"InChI=1S/C18H37NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(20)19-16-17-24(21,22)23/h2-17H2,1H3,(H,19,20)(H,21,22,23)",N-palmitoyltaurine,LIPID MAPS instance accession,LMFA08020080
6104,132479,N-stearoyltaurine,A fatty acid-taurine conjugate derived from stearic acid.,"InChI=1S/C20H41NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(22)21-18-19-26(23,24)25/h2-19H2,1H3,(H,21,22)(H,23,24,25)",N-octadecanoyltaurine,LIPID MAPS instance accession,LMFA08020078
6105,132480,N-icosanoyltaurine,A fatty acid-taurine conjugate derived from icosanoic acid.,"InChI=1S/C22H45NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(24)23-20-21-28(25,26)27/h2-21H2,1H3,(H,23,24)(H,25,26,27)",N-eicosanoyl-taurine,PubMed citation,17116739
6106,132481,guanidine acetate,An organic salt obtained by combining guanidine with one molar equivalent of acetic acid.,"InChI=1S/C2H4O2.CH5N3/c1-2(3)4;2-1(3)4/h1H3,(H,3,4);(H5,2,3,4)",guanidinium acetate,Chemspider accession,451377
6107,132485,"N-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-L-glutamic acid","An N-(long-chain-fatty-acyl)-L-glutamic acid in which the acyl group is specified as (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl.","InChI=1S/C27H39NO5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(29)28-24(27(32)33)22-23-26(30)31/h3-4,6-7,9-10,12-13,15-16,18-19,24H,2,5,8,11,14,17,20-23H2,1H3,(H,28,29)(H,30,31)(H,32,33)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-/t24-/m0/s1",N-(docosahexaenoyl)-L-glutamic acid,LIPID MAPS instance accession,LMFA08020089
6108,132486,"lysine-4,4,5,5-d4","A deuterated compound that is lysne in which the methylene hydrogens at positions 4, 4, 5 and 5 have been replaced by deuterium.","InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/i1D2,2D2","4,4,5,5-tetradeuterolysine",Chemspider accession,17341139
6109,132487,hyrtial,"A scalarane sesterterpenoid with formula C26H40O3, originally isolated from the marine sponge Hyrtios erecta.","InChI=1S/C26H40O3/c1-17(28)29-22-14-21-24(4)12-7-11-23(2,3)19(24)10-13-25(21,5)20-9-8-18(16-27)15-26(20,22)6/h8,16,19-22H,7,9-15H2,1-6H3/t19-,20-,21+,22+,24-,25-,26+/m0/s1",12beta-acetoxy-25-nor-16-scalaren-24-al,CAS Registry Number,97889-56-0
6110,132495,"(9Z,11Z,13E,15E)-4-oxooctadecatetraenoic acid","A polyunsaturated fatty acid that is (9Z,11Z,13E,15E)-octadecatetraenoic acid carrying an oxo substituent at position 4.","InChI=1S/C18H26O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17(19)15-16-18(20)21/h3-10H,2,11-16H2,1H3,(H,20,21)/b4-3+,6-5+,8-7-,10-9-","(9Z,11Z,13E,15E)-4-ketooctadecatetraenoic acid",LIPID MAPS instance accession,LMFA02000270
6111,132497,isoxadifen-ethyl,"An isoxazoline that is the ethyl ester of isoxadifen. It is used as a herbicide safener, especially in conjunction with the herbicides fenoxaprop-P-ethyl and iodosulfuron-methyl-sodium. It is not approved for use within the European Union.","InChI=1S/C18H17NO3/c1-2-21-17(20)16-13-18(22-19-16,14-9-5-3-6-10-14)15-11-7-4-8-12-15/h3-12H,2,13H2,1H3",isoxadifen ethyl,Pesticides accession,derivatives/isoxadifen-ethyl
6112,132504,heptafluthrin,"A carboxylic ester resulting from the formal condensation of the carboxy group of 2,2-dimethyl-3-[(1Z)-3,3,3-trifluoroprop-1-en-1-yl]cyclopropanecarboxylic acid with the hydroxy group of 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl alcohol. It is an unspecified mixture of  isomers at the cyclopropane ring; the trifluoropropenyl side-chain has Z configuration. It is an insecticide with rapid knock-down activity.","InChI=1S/C18H17F7O3/c1-17(2)10(4-5-18(23,24)25)11(17)16(26)28-7-9-14(21)12(19)8(6-27-3)13(20)15(9)22/h4-5,10-11H,6-7H2,1-3H3/b5-4-","2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl 2,2-dimethyl-3-[(1Z)-3,3,3-trifluoroprop-1-en-1-yl]cyclopropanecarboxylate",CAS Registry Number,1130296-65-9
6113,132505,N-tetracosanoyltaurine,A fatty acid-taurine conjugate derived from tetracosanoic acid.,"InChI=1S/C26H53NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-26(28)27-24-25-32(29,30)31/h2-25H2,1H3,(H,27,28)(H,29,30,31)",N-tetracosanoyl-taurine,PubMed citation,17116739
6114,132506,N-arachidonoyltaurine,A fatty acid-taurine conjugate derived from arachidonic acid.,"InChI=1S/C22H37NO4S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(24)23-20-21-28(25,26)27/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-21H2,1H3,(H,23,24)(H,25,26,27)/b7-6-,10-9-,13-12-,16-15-",N-arachidonoyl-taurine,Reaxys Registry Number,22828290
6115,132507,"N-[12(S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]taurine","A fatty acid-taurine conjugate derived from N-[12(S)-hydroperoxy-(5Z,8Z,10E,14Z)]-icosatetraenoic acid.","InChI=1S/C22H37NO6S/c1-2-3-4-5-10-13-16-21(29-25)17-14-11-8-6-7-9-12-15-18-22(24)23-19-20-30(26,27)28/h7-11,13-14,17,21,25H,2-6,12,15-16,18-20H2,1H3,(H,23,24)(H,26,27,28)/b9-7-,11-8-,13-10-,17-14+/t21-/m0/s1","N-[12(S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-taurine",PubMed citation,18311922
6116,132508,"N-[15(S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]taurine","A fatty acid-taurine conjugate derived from N-[15(S)-hydroperoxy-(5Z,8Z,11Z,13E)]-icosatetraenoic acid.","InChI=1S/C22H37NO6S/c1-2-3-13-16-21(29-25)17-14-11-9-7-5-4-6-8-10-12-15-18-22(24)23-19-20-30(26,27)28/h4-5,8-11,14,17,21,25H,2-3,6-7,12-13,15-16,18-20H2,1H3,(H,23,24)(H,26,27,28)/b5-4-,10-8-,11-9-,17-14+/t21-/m0/s1",N-[15(S)-HPETE]-taurine,PubMed citation,18311922
6117,132571,BMS 195614,"A carboxamide resulting from the formal condensation of the carboxy group of 5,5-dimethyl-8-(quinolin-3-yl)-5,6-dihydronaphthalene-2-carboxylic acid with the amino group of p-aminobenzoic acid. It is a neutral retinoic acid receptor (RAR) alpha-selective antagonist (Ki = 2.5 nM). It displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. It antagonizes agonist-induced coactivator (CoA) recruitment.","InChI=1S/C29H24N2O3/c1-29(2)14-13-23(21-15-19-5-3-4-6-26(19)30-17-21)24-16-20(9-12-25(24)29)27(32)31-22-10-7-18(8-11-22)28(33)34/h3-13,15-17H,14H2,1-2H3,(H,31,32)(H,33,34)",BMS614,Reaxys Registry Number,24414151
6118,132572,(S)-nicotine 1-N-oxide,A member of the class of pyridine N-oxides obtained by oxidation of the pyridine nitrogen of (S)-nicotine.,"InChI=1S/C10H14N2O/c1-11-6-3-5-10(11)9-4-2-7-12(13)8-9/h2,4,7-8,10H,3,5-6H2,1H3/t10-/m0/s1",nicotine N-oxide,CAS Registry Number,2820-55-5
6119,132578,monopentyl phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of pentanol.,"InChI=1S/C13H16O4/c1-2-3-6-9-17-13(16)11-8-5-4-7-10(11)12(14)15/h4-5,7-8H,2-3,6,9H2,1H3,(H,14,15)",mono-n-pentyl phthalate,CAS Registry Number,24539-56-8
6120,132583,monooctyl phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of octanol.,"InChI=1S/C16H22O4/c1-2-3-4-5-6-9-12-20-16(19)14-11-8-7-10-13(14)15(17)18/h7-8,10-11H,2-6,9,12H2,1H3,(H,17,18)",mono-n-octyl phthalate,CAS Registry Number,5393-19-1
6121,132587,monoisopropyl phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of isopropanol.,"InChI=1S/C11H12O4/c1-7(2)15-11(14)9-6-4-3-5-8(9)10(12)13/h3-7H,1-2H3,(H,12,13)",mono-2-propyl phthalate,CAS Registry Number,35118-50-4
6122,132593,monoisononyl phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of isononanol.,"InChI=1S/C17H24O4/c1-13(2)9-5-3-4-8-12-21-17(20)15-11-7-6-10-14(15)16(18)19/h6-7,10-11,13H,3-5,8-9,12H2,1-2H3,(H,18,19)",mono-7-methyloctyl phthalate,CAS Registry Number,106610-61-1
6123,132594,monoisodecyl phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of isodecanol.,"InChI=1S/C18H26O4/c1-14(2)10-6-4-3-5-9-13-22-18(21)16-12-8-7-11-15(16)17(19)20/h7-8,11-12,14H,3-6,9-10,13H2,1-2H3,(H,19,20)",mono-8-methylnonyl phthalate,CAS Registry Number,31047-64-0
6124,132604,monohexyl phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of hexanol.,"InChI=1S/C14H18O4/c1-2-3-4-7-10-18-14(17)12-9-6-5-8-11(12)13(15)16/h5-6,8-9H,2-4,7,10H2,1H3,(H,15,16)",mono-n-hexyl phthalate,CAS Registry Number,24539-57-9
6125,132625,2'-deoxymeranzin hydrate,A member of the class of coumarins carrying methoxy and 3-hydroxy-3-methylbutyl substituents at positions 7 and 8 respectively.,"InChI=1S/C15H18O4/c1-15(2,17)9-8-11-12(18-3)6-4-10-5-7-13(16)19-14(10)11/h4-7,17H,8-9H2,1-3H3",2-deoxymeranzin hydrate,Reaxys Registry Number,1251894
6126,132671,"(12S)-hydroperoxy-(14R,15S)-epoxy-(5Z,8Z,10E)-icosatrienoic acid","A hydroperoxy fatty acid that is (14R,15S)-epoxy-(5Z,8Z,10E)-icosatrienoic acid in which the hydroperoxy group is located at position 12S.","InChI=1S/C20H32O5/c1-2-3-10-14-18-19(24-18)16-17(25-23)13-11-8-6-4-5-7-9-12-15-20(21)22/h5-8,11,13,17-19,23H,2-4,9-10,12,14-16H2,1H3,(H,21,22)/b7-5-,8-6-,13-11+/t17-,18+,19-/m1/s1","(12S)-hydroperoxy-(14R,15S)-epoxy-(5Z,8Z,10E)-eicosatrienoic acid",PubMed citation,25293588
6127,132681,"(12S)-hydroperoxy-(14S,15R)-epoxy-(5Z,8Z,10E)-icosatrienoic acid","A hydroperoxy fatty acid that is (14S,15R)-epoxy-(5Z,8Z,10E)-icosatrienoic acid in which the hydroperoxy group is located at position 12S.","InChI=1S/C20H32O5/c1-2-3-10-14-18-19(24-18)16-17(25-23)13-11-8-6-4-5-7-9-12-15-20(21)22/h5-8,11,13,17-19,23H,2-4,9-10,12,14-16H2,1H3,(H,21,22)/b7-5-,8-6-,13-11+/t17-,18-,19+/m1/s1","(12S)-hydroperoxy-(14S,15R)-epoxy-(5Z,8Z,10E)-eicosatrienoic acid",PubMed citation,25293588
6128,132683,"(5S)-hydroperoxy-(14R,15S)-epoxy-(6E,8Z,11Z)-icosatrienoic acid","A hydroperoxy fatty acid that is (14R,15S)-epoxy-(6E,8Z,11Z)-icosatrienoic acid in which the hydroperoxy group is located at position 5S.","InChI=1S/C20H32O5/c1-2-3-8-14-18-19(24-18)15-10-7-5-4-6-9-12-17(25-23)13-11-16-20(21)22/h4,6-7,9-10,12,17-19,23H,2-3,5,8,11,13-16H2,1H3,(H,21,22)/b6-4-,10-7-,12-9+/t17-,18+,19-/m1/s1","(5S)-hydroperoxy-(14R,15S)-EET",PubMed citation,25293588
6129,132708,N-arachidonoyl-L-alanine,An N-acyl-L-alanine resulting from the formal condensation of the amino group of L-alanine with the carboxy group of arachidonic acid.,"InChI=1S/C23H37NO3/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22(25)24-21(2)23(26)27/h7-8,10-11,13-14,16-17,21H,3-6,9,12,15,18-20H2,1-2H3,(H,24,25)(H,26,27)/b8-7-,11-10-,14-13-,17-16-/t21-/m0/s1","N-[(5Z,8Z,11Z,14Z)-eicosatetraenoyl]alanine",Reaxys Registry Number,11115229
6130,132716,cadabicine sulfate,A spermidine alkaloid with formula C25H29N3O7S that is biosynthesised by Arabidopsis thaliana.,"InChI=1S/C25H29N3O7S/c29-24-12-7-19-4-9-21(10-5-19)34-23-18-20(6-11-22(23)35-36(31,32)33)8-13-25(30)27-16-2-1-14-26-15-3-17-28-24/h4-13,18,26H,1-3,14-17H2,(H,27,30)(H,28,29)(H,31,32,33)/b12-7+,13-8+",didehydro-di(coumaroyl) spermidine sulfate,PubMed citation,27363486
6131,132722,N-arachidonoyl-gamma-aminobutyric acid,An N-acyl-gamma-aminobutyric acid resulting from the formal condensation of the amino group of gamma-aminobutyric acid with the carboxy group of arachidonic acid.,"InChI=1S/C24H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-23(26)25-22-19-21-24(27)28/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-22H2,1H3,(H,25,26)(H,27,28)/b7-6-,10-9-,13-12-,16-15-",N-arachidonoyl GABA,PubMed citation,17493578
6132,132725,"N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]glycine","An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of (12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoic acid.","InChI=1S/C22H35NO5/c1-2-3-4-5-10-13-16-20(28-27)17-14-11-8-6-7-9-12-15-18-21(24)23-19-22(25)26/h7-11,13-14,17,20,27H,2-6,12,15-16,18-19H2,1H3,(H,23,24)(H,25,26)/b9-7-,11-8-,13-10-,17-14+/t20-/m0/s1",N-[12(S)-HPETE]-Gly,PubMed citation,17493578
6133,132736,"N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]alanine","An N-acyl-L-alanine resulting from the formal condensation of the amino group of L-alanine with the carboxy group of (12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoic acid.","InChI=1S/C23H37NO5/c1-3-4-5-6-11-14-17-21(29-28)18-15-12-9-7-8-10-13-16-19-22(25)24-20(2)23(26)27/h8-12,14-15,18,20-21,28H,3-7,13,16-17,19H2,1-2H3,(H,24,25)(H,26,27)/b10-8-,12-9-,14-11-,18-15+/t20-,21-/m0/s1","N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl]-L-alanine",PubMed citation,17493578
6134,132738,"N-[(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoyl]glycine","An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoic acid.","InChI=1S/C22H35NO5/c1-2-3-13-16-20(28-27)17-14-11-9-7-5-4-6-8-10-12-15-18-21(24)23-19-22(25)26/h4-5,8-11,14,17,20,27H,2-3,6-7,12-13,15-16,18-19H2,1H3,(H,23,24)(H,25,26)/b5-4-,10-8-,11-9-,17-14+/t20-/m0/s1",N-[15(S)-HPETE]-Gly,PubMed citation,17493578
6135,132747,"N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-icosatetraenoyl]-gamma-aminobutyric acid","An N-acyl-gamma-aminobutyric acid resulting from the formal condensation of the amino group of gamma-aminobutyric acid with the carboxy group of (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-icosatetraenoic acid.","InChI=1S/C24H39NO5/c1-2-3-13-17-22(30-29)18-14-11-9-7-5-4-6-8-10-12-15-19-23(26)25-21-16-20-24(27)28/h4-5,8-11,14,18,22,29H,2-3,6-7,12-13,15-17,19-21H2,1H3,(H,25,26)(H,27,28)/b5-4-,10-8-,11-9-,18-14+/t22-/m0/s1","N-[(12S)-hydroperoxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl]-gamma-aminobutanoic acid",PubMed citation,17493578
6136,132751,thiamine hydrochloride dihydrate,A hydrate that is the dihydrate form of thiamine hydrochloride.,"InChI=1S/C12H17N4OS.2ClH.2H2O/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;;;;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);2*1H;2*1H2/q+1;;;;/p-1",thiamine chloride hydrochloride dihydrate,Chemspider accession,58170825
6137,132754,dynasore,"A carbohydrazide resulting from the formal condensation of the hydrazone moiety of 3,4-dihydroxybenzaldehyde hydrazone with the carboxy group of 3-hydroxy-2-naphthoic acid. It is a cell-permeable, reversible noncompetitive inhibitor of the GTPase activity of dynamin 1 and 2 and Drp1 (mitochondrial), while exhibiting no significant effect against two other small GTPases, MxA and Cdc42.","InChI=1S/C18H14N2O4/c21-15-6-5-11(7-17(15)23)10-19-20-18(24)14-8-12-3-1-2-4-13(12)9-16(14)22/h1-10,21-23H,(H,20,24)/b19-10+",Dynamin Inhibitor I,PubMed citation,26894834
6138,132758,vanadyl sulfate pentahydrate,A vanadyl sulfate hydrate containing five water molecules.,"InChI=1S/H2O4S.5H2O.O.V/c1-5(2,3)4;;;;;;;/h(H2,1,2,3,4);5*1H2;;/q;;;;;;;+2/p-2",VOSO4.5H2O,CAS Registry Number,14708-82-8
6139,132762,zinc sulfate hexahydrate,A hydrate that is the hexahydrate form of zinc sulfate.,"InChI=1S/H2O4S.6H2O.Zn/c1-5(2,3)4;;;;;;;/h(H2,1,2,3,4);6*1H2;/q;;;;;;;+2/p-2",ZnSO4.6H2O,Reaxys Registry Number,13409537
6140,132765,sodium metavanadate dihydrate,A hydrate that is the dihydrate form of sodium metavanadate.,InChI=1S/Na.2H2O.3O.V/h;2*1H2;;;;/q+1;;;;;-1;,NaVO3.2H2O,Reaxys Registry Number,23869062
6141,132770,1-palmitoyl-2-linoleoyl-3-oleoyl-sn-glycerol,"A triacylglycerol 52:3 in which the acyl groups at positions 1, 2 and 3 are specified as palmitoyl, linoleoyl and oleoyl respectively.","InChI=1S/C55H100O6/c1-4-7-10-13-16-19-22-25-27-30-33-36-39-42-45-48-54(57)60-51-52(50-59-53(56)47-44-41-38-35-32-29-24-21-18-15-12-9-6-3)61-55(58)49-46-43-40-37-34-31-28-26-23-20-17-14-11-8-5-2/h17,20,25-28,52H,4-16,18-19,21-24,29-51H2,1-3H3/b20-17-,27-25-,28-26-/t52-/m1/s1","1-hexadecanoyl-2-[(9Z,12Z)-octadecadienoyl]-3-[(9Z)-octadecenoyl]-sn-glycerol",PubMed citation,19685253
6142,132773,"1,3-distearoyl-2-palmitoylglycerol",A triglyceride having stearoyl (octadecanoyl) groups at positions 1 and 3 and a palmitoyl (hexadecanoyl) group at position 2. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C55H106O6/c1-4-7-10-13-16-19-22-25-27-30-32-35-38-41-44-47-53(56)59-50-52(61-55(58)49-46-43-40-37-34-29-24-21-18-15-12-9-6-3)51-60-54(57)48-45-42-39-36-33-31-28-26-23-20-17-14-11-8-5-2/h52H,4-51H2,1-3H3","1,3-dioctadecanoyl-2-hexadecanoylglycerol",HMDB accession,HMDB0044722
6143,132775,1-oleoyl-2-isoheptadecanoyl-3-pentadecanoyl-sn-glycerol,"A triacylglycerol 50:1 in which the acyl groups at positions 1, 2 and 3 are specified as oleoyl, isoheptadecanoyl and pentadecanoyl respectively.  It is a metabolite of the nematode Caenorhabditis elegans.","InChI=1S/C53H100O6/c1-5-7-9-11-13-15-17-19-20-21-25-29-33-37-41-45-52(55)58-48-50(47-57-51(54)44-40-36-32-28-24-18-16-14-12-10-8-6-2)59-53(56)46-42-38-34-30-26-22-23-27-31-35-39-43-49(3)4/h19-20,49-50H,5-18,21-48H2,1-4H3/b20-19-/t50-/m0/s1",TAG(18:1/17:0Delta/15:0),PubMed citation,23475189
6144,132776,1-oleoyl-2-isononadecanoyl-3-pentadecanoyl-sn-glycerol,"A triacylglycerol 52:1 in which the acyl groups at positions 1, 2 and 3 are specified as oleoyl, isononadecanoyl and pentadecanoyl respectively. It is a metabolite of the nematode Caenorhabditis elegans.","InChI=1S/C55H104O6/c1-5-7-9-11-13-15-17-19-20-23-27-31-35-39-43-47-54(57)60-50-52(49-59-53(56)46-42-38-34-30-26-18-16-14-12-10-8-6-2)61-55(58)48-44-40-36-32-28-24-21-22-25-29-33-37-41-45-51(3)4/h19-20,51-52H,5-18,21-50H2,1-4H3/b20-19-/t52-/m0/s1",1-[(9Z)-octadecenoyl]-2-(17-methyloctadecanoyl)-3-pentadecanoyl-sn-glycerol,PubMed citation,23475189
6145,132777,1-linoleoyl-2-isoheptadecanoyl-3-isopentadecanoyl-sn-glycerol,"A triacylglycerol 50:2 in which the acyl groups at positions 1, 2 and 3 are specified as linoleoyl, isoheptadecanoyl and isopentadecanoyl respectively. It is a metabolite of the nematode Caenorhabditis elegans.","InChI=1S/C53H98O6/c1-6-7-8-9-10-11-12-13-14-15-18-23-28-33-38-43-51(54)57-46-50(47-58-52(55)44-39-34-29-25-20-22-27-32-37-42-49(4)5)59-53(56)45-40-35-30-24-19-16-17-21-26-31-36-41-48(2)3/h10-11,13-14,48-50H,6-9,12,15-47H2,1-5H3/b11-10-,14-13-/t50-/m1/s1","1-[(9Z,12Z)-octadecadienoyl]-2-(15-methylhexadecanoyl)-3-(13-methyltetradecanoyl)-sn-glycerol",PubMed citation,23475189
6146,132778,1-linoleoyl-2-oleoyl-3-isoheptadecanoyl-sn-glycerol,"A triacylglycerol 50:2 in which the acyl groups at positions 1, 2 and 3 are specified as linoleoyl, oleoyl and isoheptadecanoyl respectively. It is a metabolite of the nematode Caenorhabditis elegans.","InChI=1S/C56H102O6/c1-5-7-9-11-13-15-17-19-21-23-27-31-35-39-43-47-54(57)60-50-53(51-61-55(58)48-44-40-36-32-29-25-26-30-34-38-42-46-52(3)4)62-56(59)49-45-41-37-33-28-24-22-20-18-16-14-12-10-8-6-2/h13,15,19-22,52-53H,5-12,14,16-18,23-51H2,1-4H3/b15-13-,21-19-,22-20-/t53-/m1/s1","1-[(9Z,12Z)-octadecadienoyl]-2-[(9Z)-octadecenoyl]-3-(15-methylhexadecanoyl)-sn-glycerol",PubMed citation,23475189
6147,132779,beta-D-glucosyl-(1<->1')-N-docosanoyl-14-methylhexadecasphingosine,A beta-D-glucosylceramide in which a beta-D-glucosyl residue attached to the primary hydroxyl group of N-docosanoyl-14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C45H87NO8/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-28-31-34-41(49)46-38(36-53-45-44(52)43(51)42(50)40(35-47)54-45)39(48)33-30-27-24-22-21-23-26-29-32-37(3)5-2/h30,33,37-40,42-45,47-48,50-52H,4-29,31-32,34-36H2,1-3H3,(H,46,49)/b33-30+/t37?,38-,39+,40+,42+,43-,44+,45+/m0/s1",HexCer(d17:1;3/22:0),Reaxys Registry Number,6948617
6148,132780,beta-D-glucosyl-(1<->1')-N-tricosanoyl-14-methylhexadecasphingosine,A beta-D-glucosylceramide in which a beta-D-glucosyl residue attached to the primary hydroxyl group of N-tricosanoyl-14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C46H89NO8/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-26-29-32-35-42(50)47-39(37-54-46-45(53)44(52)43(51)41(36-48)55-46)40(49)34-31-28-25-23-22-24-27-30-33-38(3)5-2/h31,34,38-41,43-46,48-49,51-53H,4-30,32-33,35-37H2,1-3H3,(H,47,50)/b34-31+/t38?,39-,40+,41+,43+,44-,45+,46+/m0/s1",GlcCer(d17:1;3/23:0),PubMed citation,23894595
6149,132783,beta-D-glucosyl-(1<->1')-N-henicosanoyl-14-methylhexadecasphingosine,A beta-D-glucosylceramide in which a beta-D-glucosyl residue attached to the primary hydroxyl group of N-henicosanoyl-14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C44H85NO8/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-27-30-33-40(48)45-37(35-52-44-43(51)42(50)41(49)39(34-46)53-44)38(47)32-29-26-23-21-20-22-25-28-31-36(3)5-2/h29,32,36-39,41-44,46-47,49-51H,4-28,30-31,33-35H2,1-3H3,(H,45,48)/b32-29+/t36?,37-,38+,39+,41+,42-,43+,44+/m0/s1",GlcCer(d17:1;3/21:0),PubMed citation,23894595
6150,132784,beta-D-glucosyl-(1<->1')-N-tetracosanoyl-14-methylhexadecasphingosine,A beta-D-glucosylceramide in which a beta-D-glucosyl residue attached to the primary hydroxyl group of N-tetracosanoyl-14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C47H91NO8/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-27-30-33-36-43(51)48-40(38-55-47-46(54)45(53)44(52)42(37-49)56-47)41(50)35-32-29-26-24-23-25-28-31-34-39(3)5-2/h32,35,39-42,44-47,49-50,52-54H,4-31,33-34,36-38H2,1-3H3,(H,48,51)/b35-32+/t39?,40-,41+,42+,44+,45-,46+,47+/m0/s1",beta-D-glucosyl-(1<->1')-N-tetracosanoyl-14-methylhexadecasphing-4-enine,PubMed citation,23894595
6151,132786,beta-D-glucosyl-(1<->1')-N-hexacosanoyl-14-methylhexadecasphingosine,A beta-D-glucosylceramide in which a beta-D-glucosyl residue attached to the primary hydroxyl group of N-hexaacosanoyl-14-methylhexadecasphingosine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C49H95NO8/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-29-32-35-38-45(53)50-42(40-57-49-48(56)47(55)46(54)44(39-51)58-49)43(52)37-34-31-28-26-25-27-30-33-36-41(3)5-2/h34,37,41-44,46-49,51-52,54-56H,4-33,35-36,38-40H2,1-3H3,(H,50,53)/b37-34+/t41?,42-,43+,44+,46+,47-,48+,49+/m0/s1",HexCer 43:1;3,PubMed citation,23894595
6152,132787,beta-D-glucosyl-(1<->1')-N-tricosanoyl-15-methylhexadecasphinganine,A beta-D-glucosylceramide in which a beta-D-glucosyl residue attached to the primary hydroxyl group of N-tricosanoyl-15-methylhexadecasphinganine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C46H91NO8/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23-26-29-32-35-42(50)47-39(37-54-46-45(53)44(52)43(51)41(36-48)55-46)40(49)34-31-28-25-22-20-21-24-27-30-33-38(2)3/h38-41,43-46,48-49,51-53H,4-37H2,1-3H3,(H,47,50)/t39-,40+,41+,43+,44-,45+,46+/m0/s1",GlcCer 40:0;2,PubMed citation,23894595
6153,132798,2-methylquinoxaline-6-carboxylic acid,"A quinoxaline derivative in which the quinoxaline (1,4-naphthyridine) skeleton is substituted with a carboxy function at C-6 and a methyl group at C-2.","InChI=1S/C10H8N2O2/c1-6-5-11-9-4-7(10(13)14)2-3-8(9)12-6/h2-5H,1H3,(H,13,14)","2-methyl-1,4-naphthyridine-6-carboxylic acid",Reaxys Registry Number,10250590
6154,132799,5-methylquinoxaline,"A quinoxaline derivative in which the quinoxaline (1,4-naphthyridine) skeleton is substituted at C-5 with a methyl group.","InChI=1S/C9H8N2/c1-7-3-2-4-8-9(7)11-6-5-10-8/h2-6H,1H3","5-methyl-1,4-naphthyridine",PubMed citation,16406213
6155,132800,17-oxoresolvin D1,"A resolvin that is docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid which is substituted by hydroxy groups at the 7 and 8 positions as well as an oxo group at the 17-position (the 7S,8R-stereoisomer).","InChI=1S/C22H30O5/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20(24)21(25)17-12-8-13-18-22(26)27/h3-12,15-16,20-21,24-25H,2,13-14,17-18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,12-8-,15-10+,16-11+/t20-,21+/m1/s1","17-oxo-(7S,8R)-dihydroxy-(4Z,9E,11E,13Z,15E,19Z)-docosahexaenoic acid",LIPID MAPS instance accession,LMFA04000080
6156,132801,18(S)-HEPE,"An 18-HEPE that consists of (5Z,8Z,11Z,14Z,16E)-icosapentaenoic in which the 18-hydroxy group has S-configuration.","InChI=1S/C20H30O3/c1-2-19(21)17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18-20(22)23/h4-7,10-13,15,17,19,21H,2-3,8-9,14,16,18H2,1H3,(H,22,23)/b6-4-,7-5-,12-10-,13-11-,17-15+/t19-/m0/s1","(18S)-hydroxy-(5Z,8Z,11Z,14Z,16E)-icosapentaenoic acid",LIPID MAPS instance accession,LMFA03070038
6157,132802,"(5S)-hydroperoxy-(18S)-hydroxy-(6E,8Z,11Z,14Z,16E)-icosapentaenoic acid","A polyunsaturated fatty acid that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid substituted at positions 5 and 18 by hydroperoxy and hydroxy groups respectively (the 5S, 18S-stereoisomer).","InChI=1S/C20H30O5/c1-2-18(21)14-11-9-7-5-3-4-6-8-10-12-15-19(25-24)16-13-17-20(22)23/h3-4,7-12,14-15,18-19,21,24H,2,5-6,13,16-17H2,1H3,(H,22,23)/b4-3-,9-7-,10-8-,14-11+,15-12+/t18-,19+/m0/s1",18(S)-hydroxy-5(S)-HpEPE,PubMed citation,21206090
6158,132805,beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-D-GlcpNAc,An amino disaccharide consisting of N-acetyl-D-glucosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.,"InChI=1S/C14H21NO11/c1-4(17)15-8-11(10(20)7(3-16)24-13(8)23)26-14-9(19)5(18)2-6(25-14)12(21)22/h2,5,7-11,13-14,16,18-20,23H,3H2,1H3,(H,15,17)(H,21,22)/t5-,7+,8+,9+,10+,11+,13?,14-/m0/s1",3-(4-deoxy-beta-D-gluc-4-enuronosyl)-N-acetyl-D-glucosamine,Reaxys Registry Number,20537829
6159,132808,"(8S)-hydroperoxy-(14S,15R)-epoxy-(5Z,9E,11Z)-icosatrienoic acid","A hydroperoxy fatty acid that is (14S,15R)-epoxy-(5Z,9E,11Z)-icosatrienoic acid in which the hydroperoxy group is located at position 8S.","InChI=1S/C20H32O5/c1-2-3-7-14-18-19(24-18)15-10-6-9-13-17(25-23)12-8-4-5-11-16-20(21)22/h4,6,8-10,13,17-19,23H,2-3,5,7,11-12,14-16H2,1H3,(H,21,22)/b8-4-,10-6-,13-9+/t17-,18+,19-/m0/s1","(8S)-hydroperoxy-(14S,15R)-EET",PubMed citation,25293588
6160,132809,(8S)-hepoxilin A3,A hepoxilin A3 in which the stereocentre at position 8 has S-configuration,"InChI=1S/C20H32O4/c1-2-3-4-5-6-10-13-18-19(24-18)16-15-17(21)12-9-7-8-11-14-20(22)23/h6-7,9-10,15-19,21H,2-5,8,11-14H2,1H3,(H,22,23)/b9-7-,10-6-,16-15+/t17-,18-,19-/m0/s1","(8S)-hydroxy-(11S,12S)-epoxy-(5Z,9E,14Z)-icosatrienoic acid",Reaxys Registry Number,3594946
6161,132812,2-methylquinoxaline,"A quinoxaline derivative in which the quinoxaline (1,4-naphthyridine) skeleton is substituted at C-2 with a methyl group.","InChI=1S/C9H8N2/c1-7-6-10-8-4-2-3-5-9(8)11-7/h2-6H,1H3","2-methyl-1,4-naphthyridine",PubMed citation,16406213
6162,132828,isobornyl formate,A bornane monoterpenoid that is isoborneol in which the hydroxy hydrogen has been replaced by a formyl group.,"InChI=1S/C11H18O2/c1-10(2)8-4-5-11(10,3)9(6-8)13-7-12/h7-9H,4-6H2,1-3H3/t8-,9-,11+/m1/s1",Bornyl formate,PubMed citation,24818583
6163,132829,delta-terpineol acetate,A p-menthane monoterpenoid that is delta-terpineol in which the hydroxy hydrogen has been replaced by an acetyl group.,"InChI=1S/C12H20O2/c1-9-5-7-11(8-6-9)12(3,4)14-10(2)13/h11H,1,5-8H2,2-4H3",terpiryl acetate,Pubchem accession,91691738
6164,132839,"(2R,5S)-linalyl oxide","A monoterpenoid that is 2-(2-hydroxypropan-2-yl)oxolane carying additional methyl and vinyl substituents both located at position 5 (the 2R,5S-diastereomer).","InChI=1S/C10H18O2/c1-5-10(4)7-6-8(12-10)9(2,3)11/h5,8,11H,1,6-7H2,2-4H3/t8-,10-/m1/s1",cis-linalyl oxide,Reaxys Registry Number,1423560
6165,132841,clodinafop,An aromatic ether that is (R)-lactic acid in which the hydroxy group at position 2 has been converted to the corresponding p-[(5-chloro-3-fluoropyridin-2-yl)oxy]phenyl ether. It is the parent acid of the herbicide clodinafop-propargyl.,"InChI=1S/C14H11ClFNO4/c1-8(14(18)19)20-10-2-4-11(5-3-10)21-13-12(16)6-9(15)7-17-13/h2-8H,1H3,(H,18,19)/t8-/m1/s1",(R)-2-[4-(5-chloro-3-fluoro-2-pyridyloxy)phenoxy]propionic acid,Pesticides accession,clodinafop
6166,132842,sulfapyridine,A sulfonamide consisting of pyridine with a 4-aminobenzenesulfonamido group at the 2-position.,"InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)",4-Amino-N-pyridin-2-yl-benzenesulfonamide,PubMed citation,6136612
6167,132872,mono(3-carboxypropyl) phthalate,A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of 4-hydroxybutyric acid.,"InChI=1S/C12H12O6/c13-10(14)6-3-7-18-12(17)9-5-2-1-4-8(9)11(15)16/h1-2,4-5H,3,6-7H2,(H,13,14)(H,15,16)",mono-3-carboxypropyl phthalate,Reaxys Registry Number,11280114
6168,132873,meadowlactone,A delta-lactone obtained by intramolecular condensation of the 5-hydroxy and carboxy groups of 5-hydroxyicosanoic acid. A nonenzymatic oxidation product of arachidonic acid.,"InChI=1S/C20H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-17-15-18-20(21)22-19/h19H,2-18H2,1H3","5-HETE 1,5-lactone",CAS Registry Number,110071-67-5
6169,132874,mono[2-(carboxymethyl)hexyl] phthalate,A phthalic acid monoester resulting from the formal condensation of one of the carboxy gruops of phthalic acid with the hydroxy group of 3-(hydroxymethyl)heptanoic acid.,"InChI=1S/C16H20O6/c1-2-3-6-11(9-14(17)18)10-22-16(21)13-8-5-4-7-12(13)15(19)20/h4-5,7-8,11H,2-3,6,9-10H2,1H3,(H,17,18)(H,19,20)",mono-2-(carboxymethyl)hexyl phthalate,CAS Registry Number,82975-93-7
6170,132876,beta-D-glucosyl-(1->4)-N-acetyl-alpha-D-glucosaminyl undecaprenyl diphosphate,A beta-D-glucosyl-(1->4)-N-acetyl-D-glucosaminyl undecaprenyl diphosphate in which the anomeric centre connected to the diphosphate group has alpha-configuration.,"InChI=1S/C69H115NO17P2/c1-48(2)24-14-25-49(3)26-15-27-50(4)28-16-29-51(5)30-17-31-52(6)32-18-33-53(7)34-19-35-54(8)36-20-37-55(9)38-21-39-56(10)40-22-41-57(11)42-23-43-58(12)44-45-82-88(78,79)87-89(80,81)86-68-62(70-59(13)73)64(75)67(61(47-72)84-68)85-69-66(77)65(76)63(74)60(46-71)83-69/h24,26,28,30,32,34,36,38,40,42,44,60-69,71-72,74-77H,14-23,25,27,29,31,33,35,37,39,41,43,45-47H2,1-13H3,(H,70,73)(H,78,79)(H,80,81)/b49-26+,50-28+,51-30-,52-32-,53-34-,54-36-,55-38-,56-40-,57-42-,58-44-/t60-,61-,62-,63-,64-,65+,66-,67-,68-,69+/m1/s1",Glc-GlcNAc-PP-undecaprenol,KEGG COMPOUND accession,C04830
6171,132877,4-O-[(2R)-1-glycerylphosphono]-N-acetyl-beta-D-mannosaminyl-(1->4)-N-acetyl-alpha-D-glucosaminyl undecaprenyl diphosphate,A polyprenyl glycosyl diphosphate having eleven prenyl units and with 4-O-[(2R)-1-glycerylphosphono]-N-acetyl-beta-D-mannosaminyl-(1->4)-N-acetyl-alpha-D-glucosamine as the glycosyl fragment.,"InChI=1S/C74H125N2O22P3/c1-51(2)25-15-26-52(3)27-16-28-53(4)29-17-30-54(5)31-18-32-55(6)33-19-34-56(7)35-20-36-57(8)37-21-38-58(9)39-22-40-59(10)41-23-42-60(11)43-24-44-61(12)45-46-91-100(87,88)98-101(89,90)97-74-68(76-63(14)81)69(83)71(65(48-78)94-74)95-73-67(75-62(13)80)70(84)72(66(49-79)93-73)96-99(85,86)92-50-64(82)47-77/h25,27,29,31,33,35,37,39,41,43,45,64-74,77-79,82-84H,15-24,26,28,30,32,34,36,38,40,42,44,46-50H2,1-14H3,(H,75,80)(H,76,81)(H,85,86)(H,87,88)(H,89,90)/b52-27+,53-29+,54-31-,55-33-,56-35-,57-37-,58-39-,59-41-,60-43-,61-45-/t64-,65-,66-,67-,68-,69-,70-,71-,72-,73+,74-/m1/s1","4-O-[(2R)-1-glycerylphosphono]-N-acetyl-beta-D-mannosaminyl-(1->4)-N-acetyl-alpha-D-glucosaminyl di-trans,octa-cis-undecaprenyl diphosphate",MetaCyc accession,CPD-5802
6172,132881,N-benzoylglycyl-N(6)-[2-hydroxy-3-(quinoxalin-2-yl)propyl]lysine,A lysine derivative in which the alpha and epsilon nitrogens are substituted respectively with benzoylglycyl and 2-hydroxy-3-(quinoxalin-2-yl)propyl groups.,"InChI=1S/C26H31N5O5/c32-20(14-19-15-28-21-10-4-5-11-22(21)30-19)16-27-13-7-6-12-23(26(35)36)31-24(33)17-29-25(34)18-8-2-1-3-9-18/h1-5,8-11,15,20,23,27,32H,6-7,12-14,16-17H2,(H,29,34)(H,31,33)(H,35,36)",N(1)-benzoylglycyl-N(6)-(2-hydroxy-3-quinoxalin-2-ylpropyl)lysine,PubMed citation,16406213
6173,132883,"11(S),15(S)-dihydroxy-14(R)-(S-glutathionyl)-5(Z),8(Z),12(E)-icosatrienoic acid","A glutathione conjugate in which the thiol hydrogen of glutathione has been replaced by a (6S,7R,8E,10S,12Z,15Z)-19-carboxy-6,10-dihydroxynonadeca-8,12,15-trien-7-yl group.","InChI=1S/C30H49N3O10S/c1-2-3-9-13-24(35)25(17-15-21(34)12-10-7-5-4-6-8-11-14-27(37)38)44-20-23(29(41)32-19-28(39)40)33-26(36)18-16-22(31)30(42)43/h4,6-7,10,15,17,21-25,34-35H,2-3,5,8-9,11-14,16,18-20,31H2,1H3,(H,32,41)(H,33,36)(H,37,38)(H,39,40)(H,42,43)/b6-4-,10-7-,17-15+/t21-,22-,23-,24-,25+/m0/s1","11(S),15(S)-dihydroxy-14(R)-(S-glutathionyl)-5(Z),8(Z),12(E)-eicosatrienoic acid",Reaxys Registry Number,22075247
6174,132886,"11(S)-hydroxy-14(S),15(S)-hepoxilin A3","A hepoxilin having (5Z,9E,14Z) double bond stereochemistry, an (11S)-hydroxy substituent and a 14S,15S-epoxy group.","InChI=1S/C20H32O4/c1-2-3-9-13-18-19(24-18)16-15-17(21)12-10-7-5-4-6-8-11-14-20(22)23/h4,6-7,10,15-19,21H,2-3,5,8-9,11-14H2,1H3,(H,22,23)/b6-4-,10-7-,16-15+/t17-,18-,19-/m0/s1","14(S),15(S)-HxA3",Reaxys Registry Number,22075237
6175,132898,isorhamnetin 3-O-robinobioside,A glycosyloxyflavone that is isorhamnetin substituted at position 3 by a robinobiosyl residue.,"InChI=1S/C28H32O16/c1-9-18(32)21(35)23(37)27(41-9)40-8-16-19(33)22(36)24(38)28(43-16)44-26-20(34)17-13(31)6-11(29)7-15(17)42-25(26)10-3-4-12(30)14(5-10)39-2/h3-7,9,16,18-19,21-24,27-33,35-38H,8H2,1-2H3/t9-,16+,18-,19-,21+,22-,23+,24+,27+,28?/m0/s1",isorhamnetin-3-O-robinobioside,CAS Registry Number,53584-69-3
6176,132902,"1beta,4beta,7alpha-trihydroxyeudesmane","A eudesmane sesquiterpenoid that is eudesmane carrying three hydroxy substituents at positions 1, 4 and 7.","InChI=1S/C15H28O3/c1-10(2)15(18)8-7-13(3)11(9-15)14(4,17)6-5-12(13)16/h10-12,16-18H,5-9H2,1-4H3/t11-,12-,13-,14+,15+/m1/s1","1,4,7-eudesmanetriol",KNApSAcK accession,C00033538
6177,132908,"5(S)-hydroperoxy-18(R)-hydroxy-(6E,8Z,11Z,14Z,16E)-icosapentaenoic acid","A polyunsaturated fatty acid that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid substituted at positions 5 and 18 by hydroperoxy and hydroxy groups respectively (the 5S, 18R-stereoisomer).","InChI=1S/C20H30O5/c1-2-18(21)14-11-9-7-5-3-4-6-8-10-12-15-19(25-24)16-13-17-20(22)23/h3-4,7-12,14-15,18-19,21,24H,2,5-6,13,16-17H2,1H3,(H,22,23)/b4-3-,9-7-,10-8-,14-11+,15-12+/t18-,19-/m1/s1","5(S)-hydroperoxy-18(R)-hydroxy-(6E,8Z,11Z,14Z,16E)-eicosapentaenoic acid",Reaxys Registry Number,14535272
6178,132909,"5(S),6(S)-epoxy-18(R)-hydroxy-(7E,9E,11Z,14Z,16E)-icosapentaenoic acid","A polyunsaturated fatty acid consisting of (7E,9E,11Z,14Z,16E)-icosapentaenoic acid carrying additional (18R)-hydroxy and (5S,6S)-epoxy groups.","InChI=1S/C20H28O4/c1-2-17(21)13-10-8-6-4-3-5-7-9-11-14-18-19(24-18)15-12-16-20(22)23/h3,5-11,13-14,17-19,21H,2,4,12,15-16H2,1H3,(H,22,23)/b5-3-,8-6-,9-7+,13-10+,14-11+/t17-,18+,19+/m1/s1","5(S),6(S)-epoxy-18(R)-hydroxy-(7E,9E,11Z,14Z,16E)-eicosapentaenoic acid",PubMed citation,21206090
6179,132913,"(S,R,R,R)-nebivolol hydrochloride","A hydrochloride obtained by reaction of (S,R,R,R)-nebivolol with one equivalent of hydrochloric acid.","InChI=1S/C22H25F2NO4.ClH/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22;/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2;1H/t17-,18-,21-,22+;/m1./s1","(S,R,R,R)-nebivolol monohydrochloride",Reaxys Registry Number,4790733
6180,132914,"(R,S,S,S)-nebivolol hydrochloride","A hydrochloride obtained by reaction of (R,S,S,S)-nebivolol with one equivalent of hydrochloric acid.","InChI=1S/C22H25F2NO4.ClH/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22;/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2;1H/t17-,18-,21-,22+;/m0./s1","(R,S,S,S)-nebivolol monohydrochloride",Reaxys Registry Number,4790734
6181,132922,ibuprofen(1-),"A monocarboxylic acid anion that is the conjugate base of ibuprofen, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/p-1",ibuprofen anion,Reaxys Registry Number,4784081
6182,132923,salicylurate,"A monocarboxylic acid anion that is the conjugate base of salicyluric acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C9H9NO4/c11-7-4-2-1-3-6(7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)/p-1",2-hydroxyhippurate,Reaxys Registry Number,3673294
6183,132949,2-(8-[3]-ladderane-octanyl)glycerol,"A 2-alkylglycerol in which glycerol is linked to 8-[3]-ladderane-octanyl via an ether-bond at position 2. Glycerols, substituted by ladderanes are core lipids of anammox bacteria.","InChI=1S/C23H40O3/c24-14-17(15-25)26-12-6-4-2-1-3-5-7-16-8-9-20-21(13-16)23-19-11-10-18(19)22(20)23/h16-25H,1-15H2",C20-[3]-ladderane monoether,LIPID MAPS instance accession,LMGL01020026
6184,132965,(S)-fluazifop-butyl,A butyl 2-(4-{[5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoate that has S configuration. It is the inactive enantiomer of the herbicide fluazifop-P-butyl.,"InChI=1S/C19H20F3NO4/c1-3-4-11-25-18(24)13(2)26-15-6-8-16(9-7-15)27-17-10-5-14(12-23-17)19(20,21)22/h5-10,12-13H,3-4,11H2,1-2H3/t13-/m0/s1",butyl (S)-2-{4-[5-(trifluoromethyl)-2-pyridyloxy]phenoxy}propionate,PubMed citation,26735732
6185,132968,N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide (d18:1/16:0),An N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide in which the ceramide N-acyl group is specified as hexadecanoyl.,"InChI=1S/C60H110N2O23/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-39(68)38(62-44(69)31-29-27-25-23-21-19-17-15-13-11-9-7-5-2)36-78-58-51(75)49(73)54(42(34-65)81-58)83-59-52(76)50(74)55(43(35-66)82-59)84-60-53(77)56(47(71)41(33-64)80-60)85-57-45(61-37(3)67)48(72)46(70)40(32-63)79-57/h28,30,38-43,45-60,63-66,68,70-77H,4-27,29,31-36H2,1-3H3,(H,61,67)(H,62,69)/b30-28+/t38-,39+,40+,41+,42+,43+,45+,46-,47-,48+,49+,50+,51+,52+,53+,54+,55-,56-,57-,58+,59-,60+/m0/s1",GalNAc-1->3-Gal-1->4-Gal-1->4-Glc-Cer (d18:1/16:0),HMDB accession,HMDB0004960
6186,132969,5-aminolevulinic acid hydrochloride,"A hydrochloride that is the monohydrochloride of 5-aminolevulinic acid. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.","InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H",5-aminolevulinic acid.HCl,KEGG DRUG accession,D02908
6187,132984,RO4927350,"A carboxamide resulting from the formal condensation of the primary amino group of 4-propanoyl-1,3-thiazol-2-amine with the carboxy group of a 3-phenylbutiyric acid which has been substituted at position 2 by a (4R)-4-[p-(2-hydroxyethoxy)phenyl]-2,5-dioxoimidazolidin-1-yl group. It is a potent, highly selective inhibitormitogen-activated protein kinase 1/2 inhibitor.","InChI=1S/C27H28N4O6S/c1-3-21(33)20-15-38-26(28-20)30-24(34)23(16(2)17-7-5-4-6-8-17)31-25(35)22(29-27(31)36)18-9-11-19(12-10-18)37-14-13-32/h4-12,15-16,22-23,32H,3,13-14H2,1-2H3,(H,29,36)(H,28,30,34)/t16-,22+,23-/m0/s1",RO-4927350,PubMed citation,19244124
6188,132999,DSGEGDFLAEGGGVR,"A fifteen-membered polypeptide consisting of Asp, Ser, Gly, Glu, Gly, Asp, Phe, Leu, Ala, Glu, Gly, Gly, Gly, Val and Arg residues joined in sequence.","InChI=1S/C60H92N18O25/c1-28(2)18-36(55(98)70-30(5)50(93)73-34(14-16-46(87)88)53(96)67-23-41(81)65-22-40(80)66-24-44(84)78-49(29(3)4)58(101)74-35(59(102)103)12-9-17-64-60(62)63)75-56(99)37(19-31-10-7-6-8-11-31)76-57(100)38(21-48(91)92)72-43(83)26-68-52(95)33(13-15-45(85)86)71-42(82)25-69-54(97)39(27-79)77-51(94)32(61)20-47(89)90/h6-8,10-11,28-30,32-39,49,79H,9,12-27,61H2,1-5H3,(H,65,81)(H,66,80)(H,67,96)(H,68,95)(H,69,97)(H,70,98)(H,71,82)(H,72,83)(H,73,93)(H,74,101)(H,75,99)(H,76,100)(H,77,94)(H,78,84)(H,85,86)(H,87,88)(H,89,90)(H,91,92)(H,102,103)(H4,62,63,64)/t30-,32-,33-,34-,35-,36-,37-,38-,39-,49-/m0/s1",L-Asp-L-Ser-Gly-L-Glu-Gly-L-Asp-L-Phe-L-Leu-L-Ala-L-Glu-Gly-Gly-Gly-L-Val-L-Arg,Reaxys Registry Number,22140206
6189,133028,gamma-Glu-Trp,A glutamyl-L-amino acid obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of tryptophan.,"InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13-/m0/s1",gamma-glutamyltryptophan,CAS Registry Number,66471-20-3
6190,133040,Cys-Gly disulfide,An organic disulfide obtained by the oxidation of two Cys-Gly molecules which are then linked via a disulfide bond.,"InChI=1S/C10H18N4O6S2/c11-5(9(19)13-1-7(15)16)3-21-22-4-6(12)10(20)14-2-8(17)18/h5-6H,1-4,11-12H2,(H,13,19)(H,14,20)(H,15,16)(H,17,18)",(Cys-Gly)2,CAS Registry Number,7729-20-6
6191,133049,6alpha-hydroxycannabidiol,"A hydroxy-cannabidiol that is cannabidiol in which the 6-pro-S hydrogen of the cyclohexene ring has been replaced by a hydroxy group. It is one of the main metabolites of cannabidiol by human liver microsomes, produced by CYP2C19 and CYP3A.","InChI=1S/C21H30O3/c1-5-6-7-8-15-10-19(23)21(20(24)11-15)17-9-14(4)18(22)12-16(17)13(2)3/h9-11,16-18,22-24H,2,5-8,12H2,1,3-4H3/t16-,17+,18-/m0/s1",6alpha-hydroxy-CBD,Reaxys Registry Number,7283366
6192,133051,[Hyp(3)]-bradykinin,"An oligopeptide that is an analogue of bradykinin in which the third amino acid, proline, is replaced with hydroxyproline.","InChI=1S/C50H73N15O12/c51-32(15-7-19-56-49(52)53)45(73)64-22-10-18-38(64)47(75)65-27-31(67)25-39(65)43(71)58-26-40(68)59-34(23-29-11-3-1-4-12-29)41(69)62-36(28-66)46(74)63-21-9-17-37(63)44(72)61-35(24-30-13-5-2-6-14-30)42(70)60-33(48(76)77)16-8-20-57-50(54)55/h1-6,11-14,31-39,66-67H,7-10,15-28,51H2,(H,58,71)(H,59,68)(H,60,70)(H,61,72)(H,62,69)(H,76,77)(H4,52,53,56)(H4,54,55,57)/t31-,32+,33+,34+,35+,36+,37+,38+,39+/m1/s1",bradykinin hydroxy-pro(3),HMDB accession,HMDB0011728
6193,133052,6beta-hydroxycannabidiol,"A hydroxy-cannabidiol that is cannabidiol in which the 6-pro-R hydrogen of the cyclohexene ring has been replaced by a hydroxy group. It is one of the main metabolites of cannabidiol by human liver microsomes, produced by CYP3A.","InChI=1S/C21H30O3/c1-5-6-7-8-15-10-19(23)21(20(24)11-15)17-9-14(4)18(22)12-16(17)13(2)3/h9-11,16-18,22-24H,2,5-8,12H2,1,3-4H3/t16-,17+,18+/m0/s1",6beta-OH-CBD,PubMed citation,21704641
6194,133053,7-hydroxycannabidiol,"A hydroxy-cannabidiol that is cannabidiol in which the methyl group that is attached to the double bond of the cyclohexene ring has been oxidised to the corresponding hydroxymethyl group. It is one of the main metabolites of cannabidiol by human liver microsomes, produced particularly by CYP2C19.","InChI=1S/C21H30O3/c1-4-5-6-7-15-11-19(23)21(20(24)12-15)18-10-16(13-22)8-9-17(18)14(2)3/h10-12,17-18,22-24H,2,4-9,13H2,1,3H3/t17-,18+/m0/s1",7-hydroxy-CBD,Reaxys Registry Number,8726507
6195,133055,4''-hydroxycannabidiol,"A hydroxy-cannabidiol that is cannabidiol in which one of the hydrogens at position 4 of the pentyl chain has been replaced by a hydroxy group. It is one of the main metabolites of cannabidiol by human liver microsomes, produced particularly by CYP3A.","InChI=1S/C21H30O3/c1-13(2)17-9-8-14(3)10-18(17)21-19(23)11-16(12-20(21)24)7-5-6-15(4)22/h10-12,15,17-18,22-24H,1,5-9H2,2-4H3/t15?,17-,18+/m0/s1",4''-HO-cannabidiol,PubMed citation,21704641
6196,133056,1''-hydroxycannabidiol,"A hydroxy-cannabidiol that is cannabidiol in which one of the two hydrogens at position 1 of the pentyl chain has been replaced by a hydroxy group. It is a metabolite of cannabidiol by human liver microsomes, produced particularly by CYP1A.","InChI=1S/C21H30O3/c1-5-6-7-18(22)15-11-19(23)21(20(24)12-15)17-10-14(4)8-9-16(17)13(2)3/h10-12,16-18,22-24H,2,5-9H2,1,3-4H3/t16-,17+,18?/m0/s1",1''-OH-CBD,PubMed citation,21704641
6197,133062,5''-hydroxycannabidiol,A hydroxy-cannabidiol that is cannabidiol in which one of the hydrogens at position 5 of the pentyl chain has been replaced by a hydroxy group. It is a metabolite of cannabidiol by human liver microsomes.,"InChI=1S/C21H30O3/c1-14(2)17-9-8-15(3)11-18(17)21-19(23)12-16(13-20(21)24)7-5-4-6-10-22/h11-13,17-18,22-24H,1,4-10H2,2-3H3/t17-,18+/m0/s1",5''-hydroxy-CBD,Reaxys Registry Number,22690714
6198,133064,tauro-beta-muricholate,A cholanic acid conjugate anion that is the conjugate base of tauro-beta-muricholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.,"InChI=1S/C26H45NO7S/c1-15(4-7-21(29)27-12-13-35(32,33)34)17-5-6-18-22-19(9-11-25(17,18)2)26(3)10-8-16(28)14-20(26)23(30)24(22)31/h15-20,22-24,28,30-31H,4-14H2,1-3H3,(H,27,29)(H,32,33,34)/p-1/t15-,16-,17-,18+,19+,20+,22+,23+,24-,25-,26-/m1/s1",beta-tauromuricholate,MetaCyc accession,CPD-18800
6199,133066,S-(5-acetamido-2-hydroxyphenyl)cysteine,A cysteine derivative in which the thiol hydrogen of cysteine is replaced by a 5-acetamido-2-hydroxyphenyl group.,"InChI=1S/C11H14N2O4S/c1-6(14)13-7-2-3-9(15)10(4-7)18-5-8(12)11(16)17/h2-4,8,15H,5,12H2,1H3,(H,13,14)(H,16,17)",3-(cystein-S-yl)acetaminophen,PubMed citation,1992763
6200,133068,[des-Arg(9)]-bradykinin,"An eight-membered oligopeptide comprising Arg, Pro, Pro, Gly, Phe, Ser, Pro and Phe residues joined in sequence. It is an analogue of bradykinin lacking the Arg residue at position 9.","InChI=1S/C44H61N11O10/c45-29(15-7-19-48-44(46)47)40(61)55-22-10-18-35(55)42(63)54-21-8-16-33(54)38(59)49-25-36(57)50-30(23-27-11-3-1-4-12-27)37(58)52-32(26-56)41(62)53-20-9-17-34(53)39(60)51-31(43(64)65)24-28-13-5-2-6-14-28/h1-6,11-14,29-35,56H,7-10,15-26,45H2,(H,49,59)(H,50,57)(H,51,60)(H,52,58)(H,64,65)(H4,46,47,48)/t29-,30-,31-,32-,33-,34-,35-/m0/s1",Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe,CAS Registry Number,15958-92-6
6201,133069,[des-Arg(9)]-bradykinin(1+),A peptide cation obtained by deprotonation of the carboxy group and protonation of the amino and guanidino groups of [des-Arg(9)]-bradykinin; major species at pH 7.3.,"InChI=1S/C44H61N11O10/c45-29(15-7-19-48-44(46)47)40(61)55-22-10-18-35(55)42(63)54-21-8-16-33(54)38(59)49-25-36(57)50-30(23-27-11-3-1-4-12-27)37(58)52-32(26-56)41(62)53-20-9-17-34(53)39(60)51-31(43(64)65)24-28-13-5-2-6-14-28/h1-6,11-14,29-35,56H,7-10,15-26,45H2,(H,49,59)(H,50,57)(H,51,60)(H,52,58)(H,64,65)(H4,46,47,48)/p+1/t29-,30-,31-,32-,33-,34-,35-/m0/s1",Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe(1+),Reaxys Registry Number,11308610
6202,133073,quinol sulfate(1-),"An organosulfonate oxoanion that is the conjugate base of quinol sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.","InChI=1S/C6H6O5S/c7-5-1-3-6(4-2-5)11-12(8,9)10/h1-4,7H,(H,8,9,10)/p-1",quinol sulfate,PubMed citation,6880243
6203,133077,1-linoleoyl-sn-glycero-3-phospho-D-myo-inositol,A 1-acyl-sn-glycero-3-phospho-1D-myo-inositol in which the 1-acyl group is specified as linoleoyl.,"InChI=1S/C27H49O12P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(29)37-18-20(28)19-38-40(35,36)39-27-25(33)23(31)22(30)24(32)26(27)34/h6-7,9-10,20,22-28,30-34H,2-5,8,11-19H2,1H3,(H,35,36)/b7-6-,10-9-/t20-,22-,23-,24+,25-,26-,27-/m1/s1",PI(18:2/0:0),LIPID MAPS instance accession,LMGP06050010
6204,133092,gamma-Glu-Abu,A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of 2-aminobutyric acid.,"InChI=1S/C9H16N2O5/c1-2-6(9(15)16)11-7(12)4-3-5(10)8(13)14/h5-6H,2-4,10H2,1H3,(H,11,12)(H,13,14)(H,15,16)",gamma-glutamyl-2-aminobutyric acid,Reaxys Registry Number,25853400
6205,133094,cyclo(L-Leu-L-Pro),A homodetic cyclic peptide composed from leucyl and prolyl residues.,"InChI=1S/C11H18N2O2/c1-7(2)6-8-11(15)13-5-3-4-9(13)10(14)12-8/h7-9H,3-6H2,1-2H3,(H,12,14)/t8-,9-/m0/s1",cyclo(L-leucyl-L-prolyl),CAS Registry Number,2873-36-1
6206,133103,"(3alpha,5alpha,17beta)-3-hydroxyandrostan-17-yl sulfate","An androstane sulfate that is 5alpha-androstan-3alpha,17beta-diol in which the hydroxy hydrogen at position 17 has been replaced by a sulfo group.","InChI=1S/C19H32O5S/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(24-25(21,22)23)19(15,2)10-8-16(14)18/h12-17,20H,3-11H2,1-2H3,(H,21,22,23)/t12-,13+,14-,15-,16-,17-,18-,19-/m0/s1","5alpha-androstane-3alpha,17beta-diol 17-monosulfate",CAS Registry Number,24869-99-6
6207,133136,17-methyloctadecanoic acid,A branched-chain saturated fatty acid that is octadecanoic (stearic) acid carrying a methyl substituent at position 17.,"InChI=1S/C19H38O2/c1-18(2)16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-19(20)21/h18H,3-17H2,1-2H3,(H,20,21)",isononadecanoic acid,HMDB accession,HMDB0037397
6208,133145,2-octadecanoyl-sn-glycero-3-phosphoethanolamine,A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as octadecanoyl (stearoyl).,"InChI=1S/C23H48NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(26)31-22(20-25)21-30-32(27,28)29-19-18-24/h22,25H,2-21,24H2,1H3,(H,27,28)/t22-/m1/s1",2-stearoyl-sn-glycero-3-phosphoethanolamine,HMDB accession,HMDB0011129
6209,133148,gamma-CEHC beta-glucuronide,A member of the class of chromanes that is gamma-CEHC in which the phenolic hydrogen is replaced by a beta-glucuronosyl residue.,"InChI=1S/C21H28O10/c1-9-10(2)17-11(4-6-21(3,31-17)7-5-13(22)23)8-12(9)29-20-16(26)14(24)15(25)18(30-20)19(27)28/h8,14-16,18,20,24-26H,4-7H2,1-3H3,(H,22,23)(H,27,28)/t14-,15-,16+,18-,20+,21?/m0/s1",gamma-CEHC glucuronide,PubMed citation,26317986
6210,133152,2-bromohexadecanoic acid,A bromo fatty acid that is hexadecanoic (palmitic) acid carrying a single bromo substituent at position 2.,"InChI=1S/C16H31BrO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15(17)16(18)19/h15H,2-14H2,1H3,(H,18,19)",2-bromopalmitic acid,PubMed citation,9022756
6211,133176,glycohyocholic acid,A bile acid glycine conjugate having hyocholic acid as the bile acid component.,"InChI=1S/C26H43NO6/c1-14(4-7-20(29)27-13-21(30)31)16-5-6-17-22-18(9-11-25(16,17)2)26(3)10-8-15(28)12-19(26)23(32)24(22)33/h14-19,22-24,28,32-33H,4-13H2,1-3H3,(H,27,29)(H,30,31)/t14-,15-,16-,17+,18+,19+,22+,23-,24+,25-,26-/m1/s1",hyocholic acid-glycine conjugate,PubMed citation,23008527
6212,133177,glycohyocholate,"A cholanic acid conjugate anion that is the conjugate base of glycohyocholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C26H43NO6/c1-14(4-7-20(29)27-13-21(30)31)16-5-6-17-22-18(9-11-25(16,17)2)26(3)10-8-15(28)12-19(26)23(32)24(22)33/h14-19,22-24,28,32-33H,4-13H2,1-3H3,(H,27,29)(H,30,31)/p-1/t14-,15-,16-,17+,18+,19+,22+,23-,24+,25-,26-/m1/s1",hyocholic acid-glycine conjugate anion,PubMed citation,27458508
6213,133178,6-ketopiperidine-2-carboxylate,"A monocarboxylic acid anion that is the conjugate base of 6-ketopiperidine-2-carboxylic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C6H9NO3/c8-5-3-1-2-4(7-5)6(9)10/h4H,1-3H2,(H,7,8)(H,9,10)/p-1",6-oxopiperidine-2-carboxylate,PubMed citation,8973642
6214,133179,N(5)-acetylornithine,An ornithine derivative in which one of the amino hydrogens on the side-chain of ornithine has been replaced by an acetyl group.,"InChI=1S/C7H14N2O3/c1-5(10)9-4-2-3-6(8)7(11)12/h6H,2-4,8H2,1H3,(H,9,10)(H,11,12)",N(delta)-acetylornithine,Reaxys Registry Number,637913
6215,133181,N-acetyl-1-methyl-L-histidine,An N-acetyl-L-amino acid that is N-acetyl-L-histidine in which the hydrogen attached to position 1 on the imidazole ring has been replaced by a methyl group.,"InChI=1S/C9H13N3O3/c1-6(13)11-8(9(14)15)3-7-4-12(2)5-10-7/h4-5,8H,3H2,1-2H3,(H,11,13)(H,14,15)/t8-/m0/s1",N-acetyl-1-methylhistidine,Reaxys Registry Number,8315946
6216,133182,N-acetyl-1-methyl-L-histidinate,"A monocarboxylic acid anion that is the conjugate base of N-acetyl-1-methyl-L-histidine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C9H13N3O3/c1-6(13)11-8(9(14)15)3-7-4-12(2)5-10-7/h4-5,8H,3H2,1-2H3,(H,11,13)(H,14,15)/p-1/t8-/m0/s1",N-acetyl-1-methylhistidinate,PubMed citation,24625756
6217,133183,N-acetyl-3-methyl-L-histidine,An N-acetyl-L-amino acid that is N-acetyl-L-histidine carrying a methyl substituent at position 3 on the imidazole ring.,"InChI=1S/C9H13N3O3/c1-6(13)11-8(9(14)15)3-7-4-10-5-12(7)2/h4-5,8H,3H2,1-2H3,(H,11,13)(H,14,15)/t8-/m0/s1",N-acetyl-3-methylhistidine,CAS Registry Number,37841-04-6
6218,133186,2-aminophenyl hydrogen sulfate,An aryl sulfate that is 2-aminophenol in which the phenolic hydrogen has been replaced by a sulfo group.,"InChI=1S/C6H7NO4S/c7-5-3-1-2-4-6(5)11-12(8,9)10/h1-4H,7H2,(H,8,9,10)",2-aminophenol hydrogen sulfate,CAS Registry Number,40712-56-9
6219,133188,(R)-imazapyr,"A 2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)nicotinic acid that has R configuration.","InChI=1S/C13H15N3O3/c1-7(2)13(3)12(19)15-10(16-13)9-8(11(17)18)5-4-6-14-9/h4-7H,1-3H3,(H,17,18)(H,15,16,19)/t13-/m1/s1","2-[(4R)-4-methyl-5-oxo-4-(propan-2-yl)-4,5-dihydro-1H-imidazol-2-yl]pyridine-3-carboxylic acid",PubMed citation,25035913
6220,133206,trans-3-hydroxycotinine beta-D-glucuronide,A beta-D-glucosiduronic acid that is trans-3-hydroxycotinine in which the hydroxy hydrogen is replaced by a beta-D-glucuronyl residue.,"InChI=1S/C16H20N2O8/c1-18-8(7-3-2-4-17-6-7)5-9(14(18)22)25-16-12(21)10(19)11(20)13(26-16)15(23)24/h2-4,6,8-13,16,19-21H,5H2,1H3,(H,23,24)/t8-,9+,10-,11-,12+,13-,16+/m0/s1",3-hydroxycotinine glucuronide,HMDB accession,HMDB0001204
6221,133208,9-(beta-D-glucosyl)-cis-zeatin,An N-glycosylzeatin that is cis-zeatin having a beta-D-glucopyranosyl residue attached at position N-9.,"InChI=1S/C16H23N5O6/c1-8(4-22)2-3-17-14-10-15(19-6-18-14)21(7-20-10)16-13(26)12(25)11(24)9(5-23)27-16/h2,6-7,9,11-13,16,22-26H,3-5H2,1H3,(H,17,18,19)/b8-2-/t9-,11-,12+,13-,16-/m1/s1",cis-zeatin-9-glucoside,Chemspider accession,32042536
6222,133210,9-(beta-D-glucosyl)-trans-zeatin,An N-glycosylzeatin that is trans-zeatin having a beta-D-glucopyranosyl residue attached at position N-9.,"InChI=1S/C16H23N5O6/c1-8(4-22)2-3-17-14-10-15(19-6-18-14)21(7-20-10)16-13(26)12(25)11(24)9(5-23)27-16/h2,6-7,9,11-13,16,22-26H,3-5H2,1H3,(H,17,18,19)/b8-2+/t9-,11-,12+,13-,16-/m1/s1",trans-zeatin-9-beta-glucoside,Chemspider accession,8018607
6223,133221,2-oxindole-3-acetic acid,A member of the class of oxindoles that is 2-oxindole carrying a carboxymethyl substituent at position 3.,"InChI=1S/C10H9NO3/c12-9(13)5-7-6-3-1-2-4-8(6)11-10(7)14/h1-4,7H,5H2,(H,11,14)(H,12,13)",oxindole-3-acetic acid,Chemspider accession,2338343
6224,133226,4-acetylphenyl hydrogen sulfate,An aryl sulfate that is 4-acetylphenol in which the phenolic hydrogen has been replaced by a sulfo group.,"InChI=1S/C8H8O5S/c1-6(9)7-2-4-8(5-3-7)13-14(10,11)12/h2-5H,1H3,(H,10,11,12)",4-acetylphenol hydrogen sulfate,Reaxys Registry Number,1967323
6225,133237,indaziflam,"A diastereoisomeric mixture of the two fluoroethyl diastereoisomers of N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine in which the indane moiety has 1R,2S configuration. A cellulose biosynthesis inhibitor, it is used as a pre-emergence herbicide for the control of annual grasses and broad-leaved weeds in citrus, grapes, fruit trees, Christmas tree farms, lawns and sports fields. The two diastereoisomers have very similar biological activity; commercial material is a 95:5 mixture of the (1R,2S,fluoroethyl-R) and (1R,2S,fluoroethyl-S) diastereoisomers.","InChI=1S/C16H20FN5/c1-8-4-5-11-7-9(2)13(12(11)6-8)19-16-21-14(10(3)17)20-15(18)22-16/h4-6,9-10,13H,7H2,1-3H3,(H3,18,19,20,21,22)/t9-,10?,13+/m0/s1",indaziflame,Pesticides accession,indaziflam
6226,133245,"quercetin 3,7-di-O-alpha-L-rhamnoside",A quercetin O-glycoside that is quercetin carrying two alpha-L-rhamnosyl residues at positions O-3 and O-7.,"InChI=1S/C27H30O15/c1-8-17(31)20(34)22(36)26(38-8)40-11-6-14(30)16-15(7-11)41-24(10-3-4-12(28)13(29)5-10)25(19(16)33)42-27-23(37)21(35)18(32)9(2)39-27/h3-9,17-18,20-23,26-32,34-37H,1-2H3/t8-,9-,17-,18-,20+,21+,22+,23+,26-,27-/m0/s1","quercetin 3,7-di-O-rhamnoside",LIPID MAPS instance accession,LMPK12112200
6227,133246,tetramethylpyrazine,A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum  wallichii).,InChI=1S/C8H12N2/c1-5-6(2)10-8(4)7(3)9-5/h1-4H3,TMP,CAS Registry Number,1124-11-4
6228,133333,nickel ferrite,A mixed metal oxide with formula Fe2NiO4.,InChI=1S/2Fe.Ni.4O,NiFe2O4,PubMed citation,23622034
6229,133337,zinc ferrite,A mixed metal oxide with formula Fe2O4Zn.,InChI=1S/2Fe.4O.Zn,ZnFe2O4,CAS Registry Number,12063-19-3
6230,133394,betanidin quinone,An indoledione obtained by formal oxidation of the dihydroxyindole moiety of betanidin to the corresponding quinone.,"InChI=1S/C18H14N2O8/c21-14-6-9-5-13(18(27)28)20(12(9)7-15(14)22)2-1-8-3-10(16(23)24)19-11(4-8)17(25)26/h1-3,6-7,11,13H,4-5H2,(H,23,24)(H,25,26)(H,27,28)/t11-,13-/m0/s1",betanidin o-quinone,Reaxys Registry Number,22023762
6231,133395,daidzein 7-(6-O-acetyl-beta-D-glucoside),A glycosyloxyisoflavone that is daidzein in which the phenolic hydrogen at position 7 has been replaced by a 6-O-acetyl-beta-D-glucosyl residue.,"InChI=1S/C23H22O10/c1-11(24)30-10-18-20(27)21(28)22(29)23(33-18)32-14-6-7-15-17(8-14)31-9-16(19(15)26)12-2-4-13(25)5-3-12/h2-9,18,20-23,25,27-29H,10H2,1H3/t18-,20-,21+,22-,23-/m1/s1",daidzin 6''-O-acetate,LIPID MAPS instance accession,LMPK12050015
6232,133397,Ki11502,A member of the class of quinolines that acts as a receptor tyrosine kinase inhibitor and apoptosis inducer with potential for use in treatment of leukemia and colorectal cancer.,"InChI=1S/C26H23N3O4S/c1-16-6-4-5-7-19(16)25(30)29-26(34)28-17-8-10-18(11-9-17)33-22-12-13-27-21-15-24(32-3)23(31-2)14-20(21)22/h4-15H,1-3H3,(H2,28,29,30,34)","N-(4-((6,7-dimethoxy-4-quinoyl)oxy)phenyl)-N'-(2-methylbenzoyl)thiourea",Reaxys Registry Number,10488231
6233,133418,indole-3-glyoxal,A member of the class of indoles that is glyoxal in which one of the hydrogens has been replaced by an indol-3-yl group.,"InChI=1S/C10H7NO2/c12-6-10(13)8-5-11-9-4-2-1-3-7(8)9/h1-6,11H",indol-3-ylglyoxal,Chemspider accession,10471239
6234,133435,S-(5-acetamido-2-hydroxyphenyl)-N-acetyl-L-cysteine,An S-substituted N-acetyl-L-cysteine in which the S-substitutuent is specified as 5-acetamido-2-hydroxyphenyl.,"InChI=1S/C13H16N2O5S/c1-7(16)14-9-3-4-11(18)12(5-9)21-6-10(13(19)20)15-8(2)17/h3-5,10,18H,6H2,1-2H3,(H,14,16)(H,15,17)(H,19,20)/t10-/m0/s1",acetaminophen N-acetyl-L-cysteine conjugate,CAS Registry Number,52372-86-8
6235,133456,1-alpha-linolenoyl-sn-glycero-3-phosphocholine,A PC(18:3/0:0) in which the 1-acyl group is specified as alpha-linolenoyl.,"InChI=1S/C26H48NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-26(29)32-23-25(28)24-34-35(30,31)33-22-21-27(2,3)4/h6-7,9-10,12-13,25,28H,5,8,11,14-24H2,1-4H3/b7-6-,10-9-,13-12-/t25-/m1/s1","1-[(9Z,12Z,15Z)-octadecatrienoyl]-sn-glycero-3-phosphocholine",LIPID MAPS instance accession,LMGP01050038
6236,133460,guaiacol sulfate,An aryl sulfate that is catechol in which the two phenolic hydrogens are replaced by methyl and sulfo groups.,"InChI=1S/C7H8O5S/c1-11-6-4-2-3-5-7(6)12-13(8,9)10/h2-5H,1H3,(H,8,9,10)",O-methylcatechol sulfate,CAS Registry Number,3233-59-8
6237,133468,brassinolide 23-O-alpha-D-glucoside,A brassinosteroid that is brassinolide carrying an alpha-D-glucosyl residue at position O-23.,"InChI=1S/C34H58O11/c1-15(2)16(3)30(45-32-29(41)28(40)27(39)25(13-35)44-32)26(38)17(4)19-7-8-20-18-14-43-31(42)22-11-23(36)24(37)12-34(22,6)21(18)9-10-33(19,20)5/h15-30,32,35-41H,7-14H2,1-6H3/t16-,17-,18-,19+,20-,21-,22+,23-,24+,25+,26+,27+,28-,29+,30+,32+,33+,34+/m0/s1",brassinolide 23-O-alpha-glucoside,MetaCyc accession,brassinolide-23-O-glucoside
6238,133482,N-(indole-3-acetyl)-L-aspartate(2-),An N-acyl-L-aspartate(2-) obtained by deprotonation of the carboxy groups of N-(indole-3-acetyl)-L-aspartic acid.,"InChI=1S/C14H14N2O5/c17-12(16-11(14(20)21)6-13(18)19)5-8-7-15-10-4-2-1-3-9(8)10/h1-4,7,11,15H,5-6H2,(H,16,17)(H,18,19)(H,20,21)/p-2/t11-/m0/s1",indole-3-acetyl-aspartate,MetaCyc accession,INDOLE-3-ACETYL-ASP
6239,133484,1-oleoyl-3-linoleoylglycerol,"A 1,3-diglyceride in which the acyl groups at positions 1 and 3 are specified as oleoyl and linoleoyl respectively.","InChI=1S/C39H70O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(41)43-35-37(40)36-44-39(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h11,13,17-20,37,40H,3-10,12,14-16,21-36H2,1-2H3/b13-11-,19-17-,20-18-",diacylglycerol(18:1/0:0/18:2),Reaxys Registry Number,6585983
6240,133485,"4'-methyl-2,2'-bipyridine-4-carboxaldehyde","A member of the class of bipyridines that is 2,2'-bipyridine in which the hydrogens situated para to the ring nitrogens have been replaced by methyl and formyl groups.","InChI=1S/C12H10N2O/c1-9-2-4-13-11(6-9)12-7-10(8-15)3-5-14-12/h2-8H,1H3",bpy-CHO,Pubchem accession,11193972
6241,133486,"4-methyl-2,2'-bipyridine-4'-carboxylic acid","A member of the class of bipyridines that is 2,2'-bipyridine in which the hydrogens situated para to the ring nitrogens have been replaced by methyl and carboxy groups.","InChI=1S/C12H10N2O2/c1-8-2-4-13-10(6-8)11-7-9(12(15)16)3-5-14-11/h2-7H,1H3,(H,15,16)",bpy-COOH,Pubchem accession,11127621
6242,133487,"3-methyl-4-[(4'-methyl[2,2'-bipyridin]-4-yl)imino]but-2-en-2-amine","A member of the class of bipyridines that is 2,2'-bipyridine in which the hydrogens situated para to the ring nitrogens have been replaced by methyl and 3-amino-2-methylbut-2-en-1-imino groups.","InChI=1S/C16H18N4/c1-11-4-6-18-15(8-11)16-9-14(5-7-19-16)20-10-12(2)13(3)17/h4-10H,17H2,1-3H3",bpy-dmn,PubMed citation,25890727
6243,133504,etiocholanolone 3-glucuronide,A steroid glucosiduronic acid having etiocholanolone as the steroid component.,"InChI=1S/C25H38O8/c1-24-9-7-13(32-23-20(29)18(27)19(28)21(33-23)22(30)31)11-12(24)3-4-14-15-5-6-17(26)25(15,2)10-8-16(14)24/h12-16,18-21,23,27-29H,3-11H2,1-2H3,(H,30,31)/t12-,13+,14+,15+,16+,18+,19+,20-,21+,23-,24+,25+/m1/s1",etiocholanolone glucuronide,HMDB accession,HMDB0004484
6244,133508,ferulic acid 4-sulfate,A member of the class of cinnamic acids that is ferulic acid in which the phenolic hydrogen has been replaced by a sulfo group.,"InChI=1S/C10H10O7S/c1-16-9-6-7(3-5-10(11)12)2-4-8(9)17-18(13,14)15/h2-6H,1H3,(H,11,12)(H,13,14,15)/b5-3+",ferulic acid sulfate,HMDB accession,HMDB0029200
6245,133516,N-(indole-3-acetyl)glutamate(2-),A dicarboxylic acid dianion obtained by deprotonation of the carboxy groups of N-(indole-3-acetyl)glutamic acid.,"InChI=1S/C15H16N2O5/c18-13(17-12(15(21)22)5-6-14(19)20)7-9-8-16-11-4-2-1-3-10(9)11/h1-4,8,12,16H,5-7H2,(H,17,18)(H,19,20)(H,21,22)/p-2",N-(indol-3-ylacetyl)glutamate(2-),MetaCyc accession,INDOLE-3-ACETYL-GLU
6246,133517,"5alpha-androstane-3alpha,17beta-diol 17-glucosiduronic acid","A steroid glucosiduronic that is 5alpha-androstane-3alpha,17beta-diol carrying a glucosiduronic acid residue at position 17.","InChI=1S/C25H40O8/c1-24-9-7-13(26)11-12(24)3-4-14-15-5-6-17(25(15,2)10-8-16(14)24)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h12-21,23,26-29H,3-11H2,1-2H3,(H,30,31)/t12-,13+,14-,15-,16-,17-,18-,19-,20+,21-,23+,24-,25-/m0/s1","5alpha-androstane-3alpha,17beta-diol 17-glucuronoside",Reaxys Registry Number,6014767
6247,133520,N-acetyl-L-alaninate,"A monocarboxylic acid anion that is the conjugate base of N-acetyl-L-alanine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C5H9NO3/c1-3(5(8)9)6-4(2)7/h3H,1-2H3,(H,6,7)(H,8,9)/p-1/t3-/m0/s1",N-acetylalaninate,Reaxys Registry Number,4131390
6248,133530,tyramine sulfate,An aryl sulfate that is tyramine in which the phenolic hydrogen at position 4 has been replaced by a sulfo group.,"InChI=1S/C8H11NO4S/c9-6-5-7-1-3-8(4-2-7)13-14(10,11)12/h1-4H,5-6,9H2,(H,10,11,12)",tyramine O-sulfate,HMDB accession,HMDB0006409
6249,133534,N-formyl-L-phenylalanine,An N-acyl-L-phenylalanine that is L-phenylalanine in which one of the hydrogens of the amino group has been replaced by a formyl group.,"InChI=1S/C10H11NO3/c12-7-11-9(10(13)14)6-8-4-2-1-3-5-8/h1-5,7,9H,6H2,(H,11,12)(H,13,14)/t9-/m0/s1",N-formylphenylalanine,PDBeChem accession,QPH
6250,133548,2-methoxyresorcinol sulfate,An aryl sulfate that is pyrogallol in which the phenolic hydrogens at positions 1 and 2 are replaced by sulfo and methyl groups respectively.,"InChI=1S/C7H8O6S/c1-12-7-5(8)3-2-4-6(7)13-14(9,10)11/h2-4,8H,1H3,(H,9,10,11)",2-methoxyresorcinol monosulfate,Reaxys Registry Number,29484375
6251,133570,eugenol sulfate,A phenylpropanoid that is eugenol in which the phenolic hydrogen has been replaced by a sulfo group.,"InChI=1S/C10H12O5S/c1-3-4-8-5-6-9(10(7-8)14-2)15-16(11,12)13/h3,5-7H,1,4H2,2H3,(H,11,12,13)",sulfuric acid mono-(4-allyl-2-methoxy-phenyl ester),CAS Registry Number,95480-60-7
6252,133577,2-hydroxy-4-methylvalerate,"A 2-hydroxy fatty acid anion that is the conjugate base of 2-hydroxy-4-methylvaleric acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C6H12O3/c1-4(2)3-5(7)6(8)9/h4-5,7H,3H2,1-2H3,(H,8,9)/p-1",alpha-hydroxyisocaproate,Reaxys Registry Number,5729843
6253,133591,N-acetyl-L-tyrosinate,"A monocarboxylic acid anion that is the conjugate base of N-acetyl-L-tyrosine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C11H13NO4/c1-7(13)12-10(11(15)16)6-8-2-4-9(14)5-3-8/h2-5,10,14H,6H2,1H3,(H,12,13)(H,15,16)/p-1/t10-/m0/s1",N-acetyl-L-tyrosine(1-),Reaxys Registry Number,5962220
6254,133593,5'-GUAUGCAUAGGC-3' RNA fragment,"An RNA fragment comprised of four guanosine, three adenosine, three uridine and two cytidine residues connected by 3'->5' phosphodiester linkages in the sequence G-U-A-U-G-C-A-U-A-G-G-C.","InChI=1S/C115H142N47O82P11/c116-45-1-6-151(111(184)138-45)95-58(168)57(167)34(223-95)12-211-245(189,190)239-78-42(231-104(67(78)177)160-30-135-54-88(160)144-108(122)148-92(54)181)20-221-255(209,210)244-80-44(233-106(69(80)179)162-32-137-56-90(162)146-110(124)150-94(56)183)22-220-254(207,208)242-77-41(230-102(66(77)176)158-28-133-52-83(120)127-25-130-86(52)158)19-218-249(197,198)237-73-37(226-98(62(73)172)154-9-4-48(165)141-114(154)187)15-214-251(201,202)240-75-39(228-100(64(75)174)156-26-131-50-81(118)125-23-128-84(50)156)17-216-247(193,194)235-71-35(224-96(60(71)170)152-7-2-46(117)139-112(152)185)14-213-253(205,206)243-79-43(232-105(68(79)178)161-31-136-55-89(161)145-109(123)149-93(55)182)21-219-250(199,200)238-74-38(227-99(63(74)173)155-10-5-49(166)142-115(155)188)16-215-252(203,204)241-76-40(229-101(65(76)175)157-27-132-51-82(119)126-24-129-85(51)157)18-217-248(195,196)236-72-36(225-97(61(72)171)153-8-3-47(164)140-113(153)186)13-212-246(191,192)234-70-33(11-163)222-103(59(70)169)159-29-134-53-87(159)143-107(121)147-91(53)180/h1-10,23-44,57-80,95-106,163,167-179H,11-22H2,(H,189,190)(H,191,192)(H,193,194)(H,195,196)(H,197,198)(H,199,200)(H,201,202)(H,203,204)(H,205,206)(H,207,208)(H,209,210)(H2,116,138,184)(H2,117,139,185)(H2,118,125,128)(H2,119,126,129)(H2,120,127,130)(H,140,164,186)(H,141,165,187)(H,142,166,188)(H3,121,143,147,180)(H3,122,144,148,181)(H3,123,145,149,182)(H3,124,146,150,183)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-/m1/s1",GpUpApUpGpCpApUpApGpGpC,PubMed citation,27593161
6255,133594,isoeugenol sulfate,A phenylpropanoid that is isoeugenol in which the phenolic hydrogen has been replaced by a sulfo group.,"InChI=1S/C10H12O5S/c1-3-4-8-5-6-9(10(7-8)14-2)15-16(11,12)13/h3-7H,1-2H3,(H,11,12,13)",sulfuric acid mono-2-methoxy-4-propenylphenyl ester,Reaxys Registry Number,3342108
6256,133596,1-[(9Z)-hexadecenoyl]glycerol,A 1-monoglyceride in which the acyl group is specified as (9Z)-hexadecenoyl.,"InChI=1S/C19H36O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(22)23-17-18(21)16-20/h7-8,18,20-21H,2-6,9-17H2,1H3/b8-7-",MG(16:1),Reaxys Registry Number,8440955
6257,133600,1-stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl groups at positions 1 and 2 are specified as stearoyl and linoleoyl respectively.","InChI=1S/C41H78NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h12,14,18,20,39H,3-11,13,15-17,19,21-38,42H2,1-2H3,(H,45,46)/b14-12-,20-18-/t39-/m1/s1","1-octadecanoyl-2-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02010044
6258,133605,N-cinnamoylglycinate,"A monocarboxylic acid anion that is the conjugate base of N-cinnamoylglycine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C11H11NO3/c13-10(12-8-11(14)15)7-6-9-4-2-1-3-5-9/h1-7H,8H2,(H,12,13)(H,14,15)/p-1/b7-6+",N-Cinnamylglycine,CAS Registry Number,16534-24-0
6259,133607,m-hydroxyhippurate,"A monocarboxylic acid anion that is the conjugate base of m-hydroxyhippuric acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C9H9NO4/c11-7-3-1-2-6(4-7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)/p-1",3-hydroxyhippurate,Reaxys Registry Number,25327110
6260,133610,N-isobutyrylglycinate,"A monocarboxylic acid anion that is the conjugate base of N-isobutyrylglycine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C6H11NO3/c1-4(2)6(10)7-3-5(8)9/h4H,3H2,1-2H3,(H,7,10)(H,8,9)/p-1",isobutanoylglycinate,HMDB accession,HMDB0000730
6261,133613,p-hydroxyhippurate,"A monocarboxylic acid anion that is the conjugate base of p-hydroxyhippuric acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C9H9NO4/c11-7-3-1-6(2-4-7)9(14)10-5-8(12)13/h1-4,11H,5H2,(H,10,14)(H,12,13)/p-1",4-hydroxyhippurate,HMDB accession,HMDB0013678
6262,133619,triarathene,"A member of the class of thiophenes that is thiophene in which the hydrogens at positions 2, 3, and 5 have been replaced by phenyl, phenyl, and p-chlorophenyl groups, respectively. An obsolete acaricide and insecticide that was used to control eriophyoid mites. Not approved for use within the European Union.",InChI=1S/C22H15ClS/c23-19-13-11-17(12-14-19)21-15-20(16-7-3-1-4-8-16)22(24-21)18-9-5-2-6-10-18/h1-15H,"5-(p-chlorophenyl)-2,3-diphenylthiophene",Pesticides accession,triarathene
6263,133624,1-heptadecanoyl-2-oleoyl-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine in which the 1- and 2-acyl groups are specified as heptadecanoyl and oleoyl respectively.","InChI=1S/C43H84NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44(3,4)5)39-49-42(45)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h20,22,41H,6-19,21,23-40H2,1-5H3/b22-20-/t41-/m1/s1",1-heptadecanoyl-2-[(9Z)-octadecenoyl]-sn-glycero-3-phosphocholine,LIPID MAPS instance accession,LMGP01010711
6264,133637,oleonitrile,A fatty nitrile obtained by formal condensation of oleic acid with ammonia.,"InChI=1S/C18H33N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19/h9-10H,2-8,11-17H2,1H3/b10-9-",(Z)-octadec-9-enenitrile,Chemspider accession,4925796
6265,133640,1-palmitoyl-3-linoleoylglycerol,"A 1,3-diglyceride in which the acyl groups at positions 1 and 3 are specified as palmitoyl (hexadecanoyl) and linoleoyl respectively.","InChI=1S/C37H68O5/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-37(40)42-34-35(38)33-41-36(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13,17-18,35,38H,3-10,12,14-16,19-34H2,1-2H3/b13-11-,18-17-",DG(16:0/18:2),HMDB accession,HMDB0056022
6266,133651,florpyrauxifen-benzyl,A benzyl ester resulting from the formal condensation of the carboxy group of florpyrauxifen with the hydroxy group of benzyl alcohol. An auxin herbicide developed by Dow AgroSciences.,"InChI=1S/C20H14Cl2F2N2O3/c1-28-19-12(21)8-7-11(14(19)23)17-15(24)16(25)13(22)18(26-17)20(27)29-9-10-5-3-2-4-6-10/h2-8H,9H2,1H3,(H2,25,26)",florpyrauxifene-benzyle,Pesticides accession,derivatives/florpyrauxifen-benzyl
6267,133655,"1-hexadecanoyl-2-(8Z,11Z,14Z-icosatrienoyl)-sn-glycero-3-phosphoethanolamine","A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl) and (8Z,11Z,14Z)-icosatrienoyl respectively.","InChI=1S/C41H76NO8P/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-41(44)50-39(38-49-51(45,46)48-36-35-42)37-47-40(43)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h11,13,17-18,20,22,39H,3-10,12,14-16,19,21,23-38,42H2,1-2H3,(H,45,46)/b13-11-,18-17-,22-20-/t39-/m1/s1","1-palmitoyl-2-(8Z,11Z,14Z-icosatrienoyl)-sn-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02011222
6268,133662,1-(1Z-octadecenyl)-sn-glycero-3-phosphocholine,A 1-(Z)-alk-1-enyl-sn-glycero-3-phosphocholine in which the alk-1-enyl group is specified as (1Z)-octadecenyl.,"InChI=1S/C26H54NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22-31-24-26(28)25-33-34(29,30)32-23-21-27(2,3)4/h20,22,26,28H,5-19,21,23-25H2,1-4H3/b22-20-/t26-/m1/s1",1-(1-enyl-stearoyl)-GPC,LIPID MAPS instance accession,LMGP01070009
6269,133663,thymol sulfate(1-),"A phenyl sulfate oxoanion that is the conjugate base of thymol sulfate, obtained by deprotonation of the sulfate group; major species at pH 7.3.","InChI=1S/C10H14O4S/c1-7(2)9-5-4-8(3)6-10(9)14-15(11,12)13/h4-7H,1-3H3,(H,11,12,13)/p-1",thymol sulfate,KEGG COMPOUND accession,C09908
6270,133664,"1-(1Z-octadecenyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycero-3-phosphocholine","A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.","InChI=1S/C48H84NO7P/c1-6-8-10-12-14-16-18-20-22-24-25-26-27-29-31-33-35-37-39-41-48(50)56-47(46-55-57(51,52)54-44-42-49(3,4)5)45-53-43-40-38-36-34-32-30-28-23-21-19-17-15-13-11-9-7-2/h8,10,14,16,20,22,25-26,29,31,35,37,40,43,47H,6-7,9,11-13,15,17-19,21,23-24,27-28,30,32-34,36,38-39,41-42,44-46H2,1-5H3/b10-8-,16-14-,22-20-,26-25-,31-29-,37-35-,43-40-/t47-/m1/s1","1-[(1Z)-octadecenyl]-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphocholine",LIPID MAPS instance accession,LMGP01030014
6271,133665,N-(2-furoyl)glycinate,"A monocarboxylic acid anion that is the conjugate base of N-(2-furoyl)glycine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C7H7NO4/c9-6(10)4-8-7(11)5-2-1-3-12-5/h1-3H,4H2,(H,8,11)(H,9,10)/p-1",furoylglycinate,CAS Registry Number,5657-19-2
6272,133669,1-(1Z-hexadecenyl)-2-tetradecanoyl-sn-glycero-3-phosphocholine,A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphocholine in which the alk-1-enyl and acyl groups are specified as (1Z)-hexadecenyl and tetradecanoyl respectively.,"InChI=1S/C38H76NO7P/c1-6-8-10-12-14-16-18-19-20-22-24-26-28-30-33-43-35-37(36-45-47(41,42)44-34-32-39(3,4)5)46-38(40)31-29-27-25-23-21-17-15-13-11-9-7-2/h30,33,37H,6-29,31-32,34-36H2,1-5H3/b33-30-/t37-/m1/s1",GPC(P-16:0/14:0),LIPID MAPS instance accession,LMGP01030021
6273,133670,p-cresol sulfate(1-),"A phenyl sulfate oxoanion that is the conjugate base of p-cresol sulfate, obtained by deprotonation of the sulfate group; major species at pH 7.3.","InChI=1S/C7H8O4S/c1-6-2-4-7(5-3-6)11-12(8,9)10/h2-5H,1H3,(H,8,9,10)/p-1",p-cresol sulfate,Reaxys Registry Number,3668793
6274,133677,hexadecanoylcholine,An acylcholine obtained by formal condensation of the carboxy group of hexadecanoic acid with the hydroxy group of choline.,"InChI=1S/C21H44NO2/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21(23)24-20-19-22(2,3)4/h5-20H2,1-4H3/q+1",palmitoylcholine,CAS Registry Number,13100-90-8
6275,133678,glycodeoxycholic acid 3-sulfate,A bile acid glycine conjugate that is glycodeoxycholic acid in which the hydroxy hydrogen at position 3 has been replaced by a sulfo group.,"InChI=1S/C26H43NO8S/c1-15(4-9-23(29)27-14-24(30)31)19-7-8-20-18-6-5-16-12-17(35-36(32,33)34)10-11-25(16,2)21(18)13-22(28)26(19,20)3/h15-22,28H,4-14H2,1-3H3,(H,27,29)(H,30,31)(H,32,33,34)/t15-,16-,17-,18+,19-,20+,21+,22+,25+,26-/m1/s1",glycodeoxycholic acid sulfate,Reaxys Registry Number,6252858
6276,133689,catechol beta-D-glucuronide,A glucosiduronic acid that is beta-D-glucuronic acid in which the anomeric hydroxyl hydrogen has been replaced by a 2-hydroxyphenyl group.,"InChI=1S/C12H14O8/c13-5-3-1-2-4-6(5)19-12-9(16)7(14)8(15)10(20-12)11(17)18/h1-4,7-10,12-16H,(H,17,18)/t7-,8-,9+,10-,12+/m0/s1",catechol beta-glucuronide,PubMed citation,1687010
6277,133694,arachidonoylcholine,An acylcholine obtained by formal condensation of the carboxy group of arachidonic acid with the hydroxy group of choline.,"InChI=1S/C25H44NO2/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-25(27)28-24-23-26(2,3)4/h9-10,12-13,15-16,18-19H,5-8,11,14,17,20-24H2,1-4H3/q+1/b10-9-,13-12-,16-15-,19-18-","(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoylcholine",PubMed citation,11443948
6278,133704,ethyl 4-hydroxybenzoate sulfate,A benzoate ester that is ethyl 4-hydroxybenzoate in which the phenolic hydrogen has been replaced by a sulfo group.,"InChI=1S/C9H10O6S/c1-2-14-9(10)7-3-5-8(6-4-7)15-16(11,12)13/h3-6H,2H2,1H3,(H,11,12,13)",ethyl para-hydroxybenzoate sulfate,Reaxys Registry Number,2655724
6279,133716,N-acetyl-L-valinate,"A monocarboxylic acid anion that is the conjugate base of N-acetyl-L-valine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C7H13NO3/c1-4(2)6(7(10)11)8-5(3)9/h4,6H,1-3H3,(H,8,9)(H,10,11)/p-1/t6-/m0/s1",N-acetylvalinate,Reaxys Registry Number,3941937
6280,133732,1-linoleoyl-sn-glycero-3-phosphoethanolamine zwitterion,A lysophosphatidylethanolamine zwitterion obtained by transfer of a proton from the phosphate group to the amino group of 1-linoleoyl-sn-glycero-3-phosphoethanolamine. Major species at pH 7.3.,"InChI=1S/C23H44NO7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(26)29-20-22(25)21-31-32(27,28)30-19-18-24/h6-7,9-10,22,25H,2-5,8,11-21,24H2,1H3,(H,27,28)/b7-6-,10-9-/t22-/m1/s1",1-linoleoyl-GPE (18:2) zwitterion,MetaCyc accession,CPD-8356
6281,133733,Pro-Hyp zwitterion,A dipeptide zwitterion obtained by transfer of a proton from the carboxy to the amino terminus of Pro-Hyp. Major species at pH 7.3.,"InChI=1S/C10H16N2O4/c13-6-4-8(10(15)16)12(5-6)9(14)7-2-1-3-11-7/h6-8,11,13H,1-5H2,(H,15,16)/t6-,7+,8+/m1/s1",L-Pro-L-Hyp zwitterion,CAS Registry Number,18684-24-7
6282,133737,acetyltaurine(1-),An organosulfonate oxoanion obtained by deprotonation of the sulfonic acid group of acetyltaurine.,"InChI=1S/C4H9NO4S/c1-4(6)5-2-3-10(7,8)9/h2-3H2,1H3,(H,5,6)(H,7,8,9)/p-1",N-acetyltaurinate,Reaxys Registry Number,3664502
6283,133745,cholesteryl nonadecanoate,A cholesterol ester derived obtained by formal condensation of the carboxy group of nonadecanoic acid with the 3-hydroxy group of cholesterol.,"InChI=1S/C46H82O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-26-44(47)48-39-31-33-45(5)38(35-39)27-28-40-42-30-29-41(37(4)25-23-24-36(2)3)46(42,6)34-32-43(40)45/h27,36-37,39-43H,7-26,28-35H2,1-6H3/t37-,39+,40+,41-,42+,43+,45+,46-/m1/s1",CE(19:0),Chemspider accession,20118443
6284,133746,N-acetyltryptophanate,A monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of N-acetyltryptophan.,"InChI=1S/C13H14N2O3/c1-8(16)15-12(13(17)18)6-9-7-14-11-5-3-2-4-10(9)11/h2-5,7,12,14H,6H2,1H3,(H,15,16)(H,17,18)/p-1",acetyltryptophan(1-),Reaxys Registry Number,5294451
6285,133747,L-gamma-Glu-L-Thr,A dipeptide obtained by formal condensation of the side-chain carboxy group of L-glutamic acid with the amino group of L-threonnine.,"InChI=1S/C9H16N2O6/c1-4(12)7(9(16)17)11-6(13)3-2-5(10)8(14)15/h4-5,7,12H,2-3,10H2,1H3,(H,11,13)(H,14,15)(H,16,17)/t4-,5+,7+/m1/s1",L-gamma-Glu-L-Thr,Reaxys Registry Number,6866882
6286,133749,drilodefensin 1,An arenesulfonic acid that is furan-3-sulfonic acid carrying hexyl and ethyl substituents at positions 2 and 5 respectively.,"InChI=1S/C12H20O4S/c1-3-5-6-7-8-11-12(17(13,14)15)9-10(4-2)16-11/h9H,3-8H2,1-2H3,(H,13,14,15)",HEFS,Wikipedia accession,Drilodefensins
6287,133760,aurasperone A,"A dimeric naphthopyran with formula C32H26O10, originally isolated from Aspergillus niger.","InChI=1S/C32H26O10/c1-13-7-18(33)26-22(41-13)10-15-9-20(38-4)28(31(40-6)23(15)29(26)35)25-17-11-16(37-3)12-21(39-5)24(17)30(36)27-19(34)8-14(2)42-32(25)27/h7-12,35-36H,1-6H3",Aurosperone A,Chemspider accession,2341316
6288,133801,beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-[beta-D-Glc-(1->3)-beta-D-Glc-(1->6)]-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc,"A branched beta-D-glucan that consists of a beta-1,3-linked nonaglucan backbone with a beta-1,3-glucodiaose branch at the 6-O-position of the nonaglucan central sugar unit.","InChI=1S/C66H112O56/c67-1-12-23(77)34(88)36(90)58(105-12)115-48-26(80)15(4-70)104-57(39(48)93)102-11-22-33(87)55(122-65-44(98)53(31(85)20(9-75)112-65)120-63-42(96)51(29(83)18(7-73)110-63)118-61-40(94)49(27(81)16(5-71)108-61)116-59-37(91)35(89)24(78)13(2-68)106-59)46(100)66(113-22)121-54-32(86)21(10-76)111-64(45(54)99)119-52-30(84)19(8-74)109-62(43(52)97)117-50-28(82)17(6-72)107-60(41(50)95)114-47-25(79)14(3-69)103-56(101)38(47)92/h12-101H,1-11H2/t12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47+,48+,49+,50+,51+,52+,53+,54+,55+,56-,57-,58+,59+,60+,61+,62+,63+,64+,65+,66+/m1/s1",beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)-[beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->6)]-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranose,PubMed citation,27624963
6289,133802,beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-[beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->6)]-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc-(1->3)-beta-D-Glc,"A branched beta-D-glucan that consists of a beta-1,3-linked nonaglucan backbone with a beta-1,3-glucotetraose branch at the 6-O-position of the nonaglucan central sugar unit.","InChI=1S/C78H132O66/c79-1-14-27(91)40(104)42(106)68(123-14)135-57-31(95)18(5-83)127-72(46(57)110)139-60-34(98)21(8-86)126-71(49(60)113)137-56-30(94)17(4-82)122-67(45(56)109)120-13-26-39(103)65(144-77-52(116)63(37(101)24(11-89)132-77)142-75-50(114)61(35(99)22(9-87)130-75)140-73-47(111)58(32(96)19(6-84)128-73)136-69-43(107)41(105)28(92)15(2-80)124-69)54(118)78(133-26)143-64-38(102)25(12-90)131-76(53(64)117)141-62-36(100)23(10-88)129-74(51(62)115)138-59-33(97)20(7-85)125-70(48(59)112)134-55-29(93)16(3-81)121-66(119)44(55)108/h14-119H,1-13H2/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40+,41+,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66-,67-,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+/m1/s1",Glcbeta1-3Glcbeta1-3Glcbeta1-3Glcbeta1-3(Glcbeta1-3Glcbeta1-3Glcbeta1-3Glcbeta1-6)Glcbeta1-3Glcbeta1-3Glcbeta1-3Glcbeta1-3Glcbeta,PubMed citation,27624963
6290,133804,(1->3)-dodeca-beta-D-glucan,A (1->3)-beta-D-glucan consisting of 12 glucosyl residues linked in a linear sequence.,"InChI=1S/C72H122O61/c73-1-13-25(85)37(97)38(98)62(112-13)124-51-27(87)15(3-75)114-64(40(51)100)126-53-29(89)17(5-77)116-66(42(53)102)128-55-31(91)19(7-79)118-68(44(55)104)130-57-33(93)21(9-81)120-70(46(57)106)132-59-35(95)23(11-83)122-72(48(59)108)133-60-36(96)24(12-84)121-71(49(60)109)131-58-34(94)22(10-82)119-69(47(58)107)129-56-32(92)20(8-80)117-67(45(56)105)127-54-30(90)18(6-78)115-65(43(54)103)125-52-28(88)16(4-76)113-63(41(52)101)123-50-26(86)14(2-74)111-61(110)39(50)99/h13-110H,1-12H2/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61-,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+/m1/s1",dodeca-beta-(1->3)-D-glucan,PubMed citation,27624963
6291,133813,asperenone,"An enone that is (4E,6E,8E,10E,12E)-8-methyl-13-phenyltrideca-4,6,8,10,12-pentaene in which the two methylene hydrogens at position 3 have been replaced by an oxo group. Originally isolated from Aspergillus niger.","InChI=1S/C20H22O/c1-3-20(21)17-11-10-13-18(2)12-6-4-7-14-19-15-8-5-9-16-19/h4-17H,3H2,1-2H3/b6-4+,13-10+,14-7+,17-11+,18-12+",asperyellone,Reaxys Registry Number,1970631
6292,133814,flavasperone,"A naphtho-gamma-pyrone that is 4H-naphtho[1,2-b]pyran-4-one carrying a methyl substituent at position2, a hydroxy substituent at position 5 and two methoxy substotuents at positions 8 and 10. Originally isolated from Aspergillus niger.","InChI=1S/C16H14O5/c1-8-4-11(17)15-12(18)6-9-5-10(19-2)7-13(20-3)14(9)16(15)21-8/h4-7,18H,1-3H3",asperxanthone,CAS Registry Number,3566-99-2
6293,133816,alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/26:1(17Z)),An alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide in which the ceramide N-acyl group is specified as (17Z)-hexacosenoyl.,"InChI=1S/C62H115NO18/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-50(68)63-45(46(67)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2)44-76-60-56(74)53(71)58(48(42-65)78-60)81-62-57(75)54(72)59(49(43-66)79-62)80-61-55(73)52(70)51(69)47(41-64)77-61/h17-18,37,39,45-49,51-62,64-67,69-75H,3-16,19-36,38,40-44H2,1-2H3,(H,63,68)/b18-17-,39-37+/t45-,46+,47+,48+,49+,51-,52-,53+,54+,55+,56+,57+,58+,59-,60+,61+,62-/m0/s1",Gb3(18:1/26:1),LIPID MAPS instance accession,LMSP0502AA08
6294,133817,doxorubicinol,"A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties.","InChI=1S/C27H31NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15-17,22,29-31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,16-,17-,22+,27-/m0/s1",DOXOL,HMDB accession,HMDB0041884
6295,133823,GNF5343,"An aromatic amide obtained by formal condensation of the carboxy group of 2-furoic acid with the aromatic amino group of 4-chloro-3-([1,3]oxazolo[4,5-b]pyridin-2-yl)aniline.","InChI=1S/C17H10ClN3O3/c18-12-6-5-10(20-16(22)14-4-2-8-23-14)9-11(12)17-21-15-13(24-17)3-1-7-19-15/h1-9H,(H,20,22)",GNF 5343,Reaxys Registry Number,23966224
6296,133824,GNF6702,"An aromatic amide obtained by formal condensation of the carboxy group of 2,4-dimethyl-1,3-oxazole-5-carboxylic acid with the aromatic amino group of 4-fluoro-3-[6-(pyridin-2-yl)[1,2,4]triazolo[1,5-a]pyrimidin-2-yl]aniline. A proteasome inhibitor known to be active against the three parasites that cause Chagas disease, leishmaniasis and sleeping sickness.","InChI=1S/C22H16FN7O2/c1-12-19(32-13(2)26-12)21(31)27-15-6-7-17(23)16(9-15)20-28-22-25-10-14(11-30(22)29-20)18-5-3-4-8-24-18/h3-11H,1-2H3,(H,27,31)",GNF 6702,Reaxys Registry Number,28255207
6297,133825,fonsecin B,A naphtho-gamma-pyrone that is fonsecin in which the hydroxy group at position 8 (meta to the methoxy group) has been converted to the corresponding methyl ether. Found in Aspergillus fonsecaeus.,"InChI=1S/C16H16O6/c1-16(19)7-10(17)14-12(22-16)5-8-4-9(20-2)6-11(21-3)13(8)15(14)18/h4-6,18-19H,7H2,1-3H3",TMC256B2,Reaxys Registry Number,1292349
6298,133863,coprogen B,An Fe(III)-complexed hydroxamate siderophore with formula C33H51FeN6O12 that is secreted by several fungi and bacteria.,"InChI=1S/C33H51N6O12.Fe/c1-22(10-16-40)19-28(42)37(48)13-4-7-25(34)33(47)51-18-12-24(3)21-30(44)39(50)15-6-9-27-32(46)35-26(31(45)36-27)8-5-14-38(49)29(43)20-23(2)11-17-41;/h19-21,25-27,40-41H,4-18,34H2,1-3H3,(H,35,46)(H,36,45);/q-3;+3/b22-19+,23-20+,24-21+;/t25-,26-,27-;/m0./s1",desacetylcoprogen,PubMed citation,7068227
6299,133864,3'-(enolpyruvyl)uridine 5'-monophosphate,A uridine 5'-phosphate that is UMP in which the hydroxy hydrogen at position 3 has been replaced by an enolpyruvyl group.,"InChI=1S/C12H15N2O11P/c1-5(11(17)18)24-9-6(4-23-26(20,21)22)25-10(8(9)16)14-3-2-7(15)13-12(14)19/h2-3,6,8-10,16H,1,4H2,(H,17,18)(H,13,15,19)(H2,20,21,22)/t6-,8-,9-,10-/m1/s1",enolpyruvyl uridine 5'-monophosphate,PubMed citation,27642865
6300,133866,uracil octosyl acid 5'-phosphate,An N-glycosyl compound with formula C12H15N2O11P that is a common intermediate in the biosynthesis of nikkomycins and polyoxins by bacteria.,"InChI=1S/C12H15N2O11P/c15-6-1-2-14(12(19)13-6)10-7(16)9-8(24-10)4(25-26(20,21)22)3-5(23-9)11(17)18/h1-2,4-5,7-10,16H,3H2,(H,17,18)(H,13,15,19)(H2,20,21,22)/t4-,5+,7-,8-,9+,10-/m1/s1",Uracil octosyl acid 5'-phosphate,PubMed citation,27642865
6301,133875,prostaglandin F1alpha alcohol,A member of the class of prostaglandins Falpha that is prostaglandin F1alpha in which the carboxy group has been reduced to the corresponding primary alcohol.,"InChI=1S/C20H38O4/c1-2-3-7-10-16(22)12-13-18-17(19(23)15-20(18)24)11-8-5-4-6-9-14-21/h12-13,16-24H,2-11,14-15H2,1H3/b13-12+/t16-,17+,18+,19-,20+/m0/s1",PGF1alpha alcohol,Chemspider accession,17220788
6302,133890,sedanonic acid lactone,"A member of the class of 2-benzofurans that is 4,5,6,7-tetrahydro-2-benzofuran-1(3H)-one carrying an additional butylidene substituent at position 3.","InChI=1S/C12H16O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h8H,2-7H2,1H3/b11-8-","(3Z)-3-butylidene-4,5,6,7-tetrahydro-2-benzofuran-1(3H)-one",Chemspider accession,9107514
6303,133904,D-talosamine,A hexosamine that is D-talose in which the 2-hydroxy group has been replaced by an amino group.,"InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3+,4+,5-,6?/m1/s1","(3S,4R,5R,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol",KEGG COMPOUND accession,C21060
6304,133910,2-trans-abscisic acid D-glucosyl ester,An enoate ester that results from the condensation of the carboxylic acid group of 2-trans-abscisic acid with the anomeric hydroxy group of D-glucopyranose.,"InChI=1S/C21H30O9/c1-11(5-6-21(28)12(2)8-13(23)9-20(21,3)4)7-15(24)30-19-18(27)17(26)16(25)14(10-22)29-19/h5-8,14,16-19,22,25-28H,9-10H2,1-4H3/b6-5+,11-7+/t14-,16-,17+,18-,19?,21?/m1/s1",abscisic acid glucose ester,Chemspider accession,24534260
6305,133915,N-hydroxy-MeIQx,"An imidazoquinoxaline that is 3H-imidazo[4,5-f]quinoxaline substituted at positions 3 and 8 by methyl groups and at position 2 by a hydroxyamino group. The active metabolite of the dietary carcinogen MeIQx.","InChI=1S/C11H11N5O/c1-6-5-12-7-3-4-8-10(9(7)13-6)14-11(15-17)16(8)2/h3-5,17H,1-2H3,(H,14,15)",N-OH-MeIQx,KEGG COMPOUND accession,C20291
6306,133920,N-hydroxy-PhIP,"An imidazopyridine that is 1H--imidazo[4,5-b]pyridine which is substituted at positions 1, 2, and 6 by methyl, hydoxyamino, and phenyl groups, respectively. The active metabolite of the dietary carcinogen PhIP.","InChI=1S/C13H12N4O/c1-17-11-7-10(9-5-3-2-4-6-9)8-14-12(11)15-13(17)16-18/h2-8,18H,1H3,(H,14,15,16)",N-OH-PhIP,ChemIDplus accession,94711
6307,133924,piperazine adipate,A piperazinium salt obtained by combining equimolar amounts of piperazine and adipic acid.,"InChI=1S/C6H10O4.C4H10N2/c7-5(8)3-1-2-4-6(9)10;1-2-6-4-3-5-1/h1-4H2,(H,7,8)(H,9,10);5-6H,1-4H2",hexanedioic acid - piperazine (1:1),Chemspider accession,8565
6308,133982,O-{beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->3)]-alpha-D-GalpNAc}-L-threonine,An O-glycosyl-L-threonine having N-acetyl-beta-D-glucosaminyl-(1->6)-[beta-D-galactosyl-(1->3)]-N-acetyl-alpha-D-galactosamine as the glycosyl component.,"InChI=1S/C26H45N3O18/c1-7(13(27)23(40)41)43-25-15(29-9(3)33)22(47-26-21(39)20(38)17(35)11(5-31)45-26)18(36)12(46-25)6-42-24-14(28-8(2)32)19(37)16(34)10(4-30)44-24/h7,10-22,24-26,30-31,34-39H,4-6,27H2,1-3H3,(H,28,32)(H,29,33)(H,40,41)/t7?,10-,11-,12-,13+,14-,15-,16-,17+,18+,19-,20+,21-,22-,24-,25+,26+/m1/s1",O-{beta-D-GlcNAc-(1->6)-[beta-D-Gal-(1->3)]-alpha-D-GalNAc}-L-threonine,PubMed citation,27558427
6309,133990,"(9S,10E,12Z,14E,16S)-9,16-bis(hydroperoxy)octadecatrienoic acid","A hydroperoxyoctadecatrienoic acid that is (10E,12Z,14E)-octadecatrienoic acid carrying two hydroperoxy substituents at positions 9 and 16 (the 9S,16S-diastereomer).","InChI=1S/C18H30O6/c1-2-16(23-21)12-8-6-7-10-14-17(24-22)13-9-4-3-5-11-15-18(19)20/h6-8,10,12,14,16-17,21-22H,2-5,9,11,13,15H2,1H3,(H,19,20)/b7-6-,12-8+,14-10+/t16-,17-/m0/s1","9S,16S-DiHPOTrE",PubMed citation,26264916
6310,133991,"(9S,10E,12Z,14E,16S)-9,16-bis(hydroperoxy)octadecatrienoate","A hydroperoxyoctadecatrienoate that is the conjugate base of (9S,10E,12Z,14E,16S)-9,16-bis(hydroperoxy)octadecatrienoic acid, obtained by deprotonation of the carboxy group. Major microspecies at pH 7.3.","InChI=1S/C18H30O6/c1-2-16(23-21)12-8-6-7-10-14-17(24-22)13-9-4-3-5-11-15-18(19)20/h6-8,10,12,14,16-17,21-22H,2-5,9,11,13,15H2,1H3,(H,19,20)/p-1/b7-6-,12-8+,14-10+/t16-,17-/m0/s1","9S,16S-DiHPOTrE(1-)",PubMed citation,26264916
6311,134029,beta-D-Glcp-(1->3)-beta-D-GlcpA-(1->4)-beta-D-GlcpOCH2CH2NH2,"A beta-D-glucoside that is the 2-aminoethyl glycoside of a trisaccharide consisting of beta-D-glucosyl, beta-D-glucuronosyl and beta-D-glucosyl residues linked sequentially (1->3) and (1->4).","InChI=1S/C20H35NO17/c21-1-2-33-18-11(28)9(26)14(6(4-23)35-18)36-20-13(30)15(12(29)16(38-20)17(31)32)37-19-10(27)8(25)7(24)5(3-22)34-19/h5-16,18-20,22-30H,1-4,21H2,(H,31,32)/t5-,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16+,18-,19+,20-/m1/s1",beta-D-Glc-(1->3)-beta-D-GlcA-(1->4)-beta-D-GlcOCH2CH2NH2,PubMed citation,27818299
6312,134059,N-palmitoylserotonin,An N-acylserotonin obtained by formal condensation of the carboxy group of hexadecanoic acid with the primary amino group of serotonin.,"InChI=1S/C26H42N2O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-26(30)27-19-18-22-21-28-25-17-16-23(29)20-24(22)25/h16-17,20-21,28-29H,2-15,18-19H2,1H3,(H,27,30)",N-palmitoyl 5-hydroxytryptamine,Reaxys Registry Number,7943685
6313,134062,Cu(I)-S-Mo(IV)(=O)O-NBIC Cluster,A metal-sulfur-oxygen cluster with formula C5H9CuMoNO2S. Bound ligand.,"InChI=1S/C5H9NOS.Cu.Mo.O/c1-2-3-4-6-5(7)8;;;/h2-4H2,1H3;;;/q-3;+2;+6;",mu-[(butylazanidyl-2kappaN)(oxido-1kappaO)(sulfido-1kappaS)methyl-1kappaC](oxo)molybdenumcopper(5+),PDBeChem accession,CUB
6314,134063,"1,2,5,6,9,10-hexabromocyclododecane","A bromoalkane consisting of cyclododecane bearing six bromo substituents at positions 1, 2, 5, 6, 9 and 10.","InChI=1S/C12H18Br6/c13-7-1-2-8(14)10(16)5-6-12(18)11(17)4-3-9(7)15/h7-12H,1-6H2",HBCD,Wikipedia accession,Hexabromocyclododecane
6315,134081,(S)-norverapamil,"2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(propan-2-yl)pentanenitrile that has S configuration.","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m0/s1",(-)-norverapamil,CAS Registry Number,123931-31-7
6316,134082,(R)-norverapamil,"2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(propan-2-yl)pentanenitrile that has R configuration.","InChI=1S/C26H36N2O4/c1-19(2)26(18-27,21-9-11-23(30-4)25(17-21)32-6)13-7-14-28-15-12-20-8-10-22(29-3)24(16-20)31-5/h8-11,16-17,19,28H,7,12-15H2,1-6H3/t26-/m1/s1",(+)-desmethylverapamil,CAS Registry Number,123932-43-4
6317,134103,N-arachidonoyl-L-leucinate,"An N-acyl-L-alpha-amino acid anion that is the conjugate base of N-arachidonoyl-L-leucine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C26H43NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(28)27-24(26(29)30)22-23(2)3/h8-9,11-12,14-15,17-18,23-24H,4-7,10,13,16,19-22H2,1-3H3,(H,27,28)(H,29,30)/p-1/b9-8-,12-11-,15-14-,18-17-/t24-/m0/s1","N-(5Z,8Z,11Z,14Z-icosatetraenoyl)-L-leucinate",PubMed citation,27374330
6318,134184,pateamine,A marine macrodiolide that is isolated from the sponge Mycale hentscheli and exhibits anticancer and antiviral properties,"InChI=1S/C31H45N3O4S/c1-21(13-14-34(6)7)11-12-23(3)16-27-19-29-33-28(20-39-29)24(4)17-26(32)18-31(36)37-25(5)15-22(2)9-8-10-30(35)38-27/h8-13,16,20,24-27H,14-15,17-19,32H2,1-7H3/b10-8-,12-11+,21-13+,22-9+,23-16+/t24-,25-,26+,27+/m0/s1",(-)-pateamine,Chemspider accession,25053851
6319,134189,spirolaurenone,A spirocyclic sesquiterpenoid that is isolated from the red alga Laurencia glandulifera.,"InChI=1S/C15H23BrO/c1-10-5-6-13(16)14(3,4)15(10)8-7-12(9-15)11(2)17/h5,12-13H,6-9H2,1-4H3/t12-,13-,15+/m1/s1","1-(9-Bromo-6,10,10-trimethylspiro[4.5]dec-6-en-2-yl)ethanone",Chemspider accession,10470563
6320,134206,2-methylserine,A hydroxy-amino acid that is serine which is substituted by a methyl group at position 2.,"InChI=1S/C4H9NO3/c1-4(5,2-6)3(7)8/h6H,2,5H2,1H3,(H,7,8)",2-amino-3-hydroxy-2-methylpropionic acid,CAS Registry Number,5424-29-3
6321,134221,dehydroluciferin,"A member of the class of 1,3-thiazolemonocarboxylic acids that is 1,3-thiazole-4-carboxylic acid in which the hydrogen at position 2 has been replaced by a 6-hydroxy-1,3-benzothiazol-2-yl group.","InChI=1S/C11H6N2O3S2/c14-5-1-2-6-8(3-5)18-10(12-6)9-13-7(4-17-9)11(15)16/h1-4,14H,(H,15,16)",2-(6-hydroxy-2-benzothiazolyl)-4-thiazolecarboxylic acid,Chemspider accession,13230825
6322,134223,"2-amino-6-(1-hydroxypropyl)-8-methylpteridine-4,7(3H,8H)-dione","A member of the class of pteridines that is lpteridine-4,7(3H,8H)-dione carrying additional amino, 1-hydroxypropyl and methyl substituents at positions 2, 6 and 8.","InChI=1S/C10H13N5O3/c1-3-4(16)5-9(18)15(2)7-6(12-5)8(17)14-10(11)13-7/h4,16H,3H2,1-2H3,(H3,11,13,14,17)",6-(1-hydroxypropyl)-8-methylisoxanthopterin,Reaxys Registry Number,5078506
6323,134226,beta-D-ManpNAc-(1->3)-alpha-L-FucpNAc-(1->3)-alpha-D-GalpNAc-(1->4)-alpha-D-GalpO[CH2]5NH2,"A linear tetrasaccharide derivative consisting of N-acetyl-alpha-D-mannosaminyl, N-acetyl-alpha-L-fucosaminyl, N-acetyl-alpha-D-galactosaminyl and  alpha-D-galactosyl residues linked sequentially (1->3), (1->3) and (1->4), and at the reducing end linked glycosidically to a 5-aminopentyl group.","InChI=1S/C35H62N4O20/c1-13-23(46)30(58-32-20(37-14(2)43)26(49)24(47)17(10-40)54-32)21(38-15(3)44)33(53-13)59-31-22(39-16(4)45)34(55-18(11-41)25(31)48)57-29-19(12-42)56-35(28(51)27(29)50)52-9-7-5-6-8-36/h13,17-35,40-42,46-51H,5-12,36H2,1-4H3,(H,37,43)(H,38,44)(H,39,45)/t13-,17+,18+,19+,20-,21-,22+,23+,24+,25-,26+,27+,28+,29-,30-,31+,32-,33-,34+,35-/m0/s1",beta-D-ManNAc-(1->3)-alpha-L-FucNAc-(1->3)-alpha-D-GalNAc-(1->4)-alpha-D-GalO[CH2]5NH2,PubMed citation,27818299
6324,134228,1-docosanoyl-2-tetradecanoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as docosanoyl and tetradecanoyl respectively.","InChI=1S/C41H82NO8P/c1-3-5-7-9-11-13-15-16-17-18-19-20-21-22-24-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-23-14-12-10-8-6-4-2/h39H,3-38,42H2,1-2H3,(H,45,46)/t39-/m1/s1",phosphatidylethanolamine (36:0),HMDB accession,HMDB0009481
6325,134232,1-pentadecanoyl-2-docosanoyl-sn-glycero-3-phosphoethanolamine,"A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the 1- and 2-acyl groups are specified as pentadecanoyl and docosanoyl respectively.","InChI=1S/C42H84NO8P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-25-27-29-31-33-35-42(45)51-40(39-50-52(46,47)49-37-36-43)38-48-41(44)34-32-30-28-26-24-16-14-12-10-8-6-4-2/h40H,3-39,43H2,1-2H3,(H,46,47)/t40-/m1/s1",PE (37:0),HMDB accession,HMDB0008907
6326,134246,(R)-2-hydroxyglutaryl-CoA,A hydroxyglutaryl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-2-hydroxyglutaric acid.,"InChI=1S/C26H42N7O20P3S/c1-26(2,20(39)23(40)29-6-5-15(35)28-7-8-57-25(41)13(34)3-4-16(36)37)10-50-56(47,48)53-55(45,46)49-9-14-19(52-54(42,43)44)18(38)24(51-14)33-12-32-17-21(27)30-11-31-22(17)33/h11-14,18-20,24,34,38-39H,3-10H2,1-2H3,(H,28,35)(H,29,40)(H,36,37)(H,45,46)(H,47,48)(H2,27,30,31)(H2,42,43,44)/t13-,14-,18-,19-,20+,24-/m1/s1",(R)-2-hydroxyglutaryl-coenzyme A,MetaCyc accession,2-HYDROXYGLUTARYL-COA
6327,134253,2-(p-coumaroyl)malic acid,A carboxylic ester obtained by formal condensation of the carboxy group of 4-coumaric acid with the hydroxy group of  malic acid.,"InChI=1S/C13H12O7/c14-9-4-1-8(2-5-9)3-6-12(17)20-10(13(18)19)7-11(15)16/h1-6,10,14H,7H2,(H,15,16)(H,18,19)",2-(4-coumaroyl)malic acid,Reaxys Registry Number,27425998
6328,134254,"5-(3',4'-dihydroxyphenyl)-gamma-valerolactone 3'-O-sulfate",A butan-4-olide that is gamma-valerolactone in which one of the methyl hydrogens has been replaced by a 3-sulfooxy-4-hydroxyphenyl group.,"InChI=1S/C11H12O7S/c12-9-3-1-7(5-8-2-4-11(13)17-8)6-10(9)18-19(14,15)16/h1,3,6,8,12H,2,4-5H2,(H,14,15,16)",dihydroxyphenyl-gamma-valerolactone-O-sulfate,HMDB accession,HMDB0029191
6329,134256,lipid A (E. coli),The glycolipid moiety of the lipopolysaccharide produced by E. coli.,"InChI=1S/C94H178N2O25P2/c1-7-13-19-25-31-37-38-44-50-56-62-68-84(103)115-78(66-60-54-48-42-35-29-23-17-11-5)72-86(105)119-92-88(96-82(101)71-77(65-59-53-47-41-34-28-22-16-10-4)114-83(102)67-61-55-49-43-36-30-24-18-12-6)93(116-79(73-97)90(92)120-122(107,108)109)113-74-80-89(106)91(118-85(104)70-76(99)64-58-52-46-40-33-27-21-15-9-3)87(94(117-80)121-123(110,111)112)95-81(100)69-75(98)63-57-51-45-39-32-26-20-14-8-2/h75-80,87-94,97-99,106H,7-74H2,1-6H3,(H,95,100)(H,96,101)(H2,107,108,109)(H2,110,111,112)/t75-,76-,77-,78-,79-,80-,87-,88-,89-,90-,91-,92-,93-,94-/m1/s1",E. coli lipid A,Reaxys Registry Number,11056969
6330,134258,beta-L-Ara4N-lipid A (E. coli),A beta-L-Ara4N-lipid A that is isolated from E. coli.,"InChI=1S/C99H187N3O28P2/c1-7-13-19-25-31-37-38-44-50-56-62-68-86(109)123-79(66-60-54-48-42-35-29-23-17-11-5)72-88(111)127-96-90(102-84(107)71-78(65-59-53-47-41-34-28-22-16-10-4)122-85(108)67-61-55-49-43-36-30-24-18-12-6)97(124-81(73-103)94(96)128-132(118,119)130-99-93(114)91(112)80(100)74-120-99)121-75-82-92(113)95(126-87(110)70-77(105)64-58-52-46-40-33-27-21-15-9-3)89(98(125-82)129-131(115,116)117)101-83(106)69-76(104)63-57-51-45-39-32-26-20-14-8-2/h76-82,89-99,103-105,112-114H,7-75,100H2,1-6H3,(H,101,106)(H,102,107)(H,118,119)(H2,115,116,117)/t76-,77-,78-,79-,80+,81-,82-,89-,90-,91+,92-,93-,94-,95-,96-,97-,98-,99-/m1/s1",E. coli beta-L-Ara4N-lipid A,PubMed citation,10788469
6331,134267,"3,5-diiodothyropropionic acid","A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)propanoic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxyphenyl group. An ionotropic analogue of L-thyroxine.","InChI=1S/C15H12I2O4/c16-12-7-9(1-6-14(19)20)8-13(17)15(12)21-11-4-2-10(18)3-5-11/h2-5,7-8,18H,1,6H2,(H,19,20)","3,5-diiodo-4-(4-hydroxyphenoxy)hydrocinnamic acid",CAS Registry Number,1158-10-7
6332,134355,auraptene,A member of the class of coumarins that is umbelliferone in which the phenolic hydrogen has been replaced by a geranyl group. Ii is isolated from several edible fruits and vegetables and exhibits a variety of therapeutic properties.,"InChI=1S/C19H22O3/c1-14(2)5-4-6-15(3)11-12-21-17-9-7-16-8-10-19(20)22-18(16)13-17/h5,7-11,13H,4,6,12H2,1-3H3/b15-11+",7-geranyloxycoumarin,Wikipedia accession,Auraptene
6333,134364,"7alpha,12alpha-dihydroxy-3-oxochol-4-en-24-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 7alpha,12alpha-3-oxochol-4-en-24-oic acid.","InChI=1S/C45H70N7O20P3S/c1-23(26-7-8-27-34-28(18-31(55)45(26,27)5)44(4)12-10-25(53)16-24(44)17-29(34)54)6-9-33(57)76-15-14-47-32(56)11-13-48-41(60)38(59)43(2,3)20-69-75(66,67)72-74(64,65)68-19-30-37(71-73(61,62)63)36(58)42(70-30)52-22-51-35-39(46)49-21-50-40(35)52/h16,21-23,26-31,34,36-38,42,54-55,58-59H,6-15,17-20H2,1-5H3,(H,47,56)(H,48,60)(H,64,65)(H,66,67)(H2,46,49,50)(H2,61,62,63)/t23-,26-,27+,28+,29-,30-,31+,34+,36-,37-,38+,42-,44+,45-/m1/s1","7alpha,12alpha-dihydroxy-3-oxochol-4-en-24-oyl-coenzyme A",MetaCyc accession,3-OXO-DELTA4-CHOLYL-COA
6334,134366,"12alpha-hydroxy-3-oxochola-4,6-dien-24-oyl-CoA","A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 12alpha-hydroxy-3-oxochola-4,6-dien-24-oic acid.","InChI=1S/C45H68N7O19P3S/c1-24(28-9-10-29-27-8-7-25-18-26(53)12-14-44(25,4)30(27)19-32(54)45(28,29)5)6-11-34(56)75-17-16-47-33(55)13-15-48-41(59)38(58)43(2,3)21-68-74(65,66)71-73(63,64)67-20-31-37(70-72(60,61)62)36(57)42(69-31)52-23-51-35-39(46)49-22-50-40(35)52/h7-8,18,22-24,27-32,36-38,42,54,57-58H,6,9-17,19-21H2,1-5H3,(H,47,55)(H,48,59)(H,63,64)(H,65,66)(H2,46,49,50)(H2,60,61,62)/t24-,27+,28-,29+,30+,31-,32+,36-,37-,38+,42-,44+,45-/m1/s1","12alpha-hydroxy-3-oxochola-4,6-dien-24-oyl-coenzyme A",MetaCyc accession,3-OXO-DELTA46-CHOLYL-COA
6335,134405,S-anthraniloyl-L-cysteine,An L-cysteine derivative obtained by formal condensation of the carboxy group of anthranilic acid with the side-chain thiol group of L-cysteine.,"InChI=1S/C10H12N2O3S/c11-7-4-2-1-3-6(7)10(15)16-5-8(12)9(13)14/h1-4,8H,5,11-12H2,(H,13,14)/t8-/m0/s1",S-anthraniloylcysteine,PDBeChem accession,CSJ
6336,134410,S-octanoyl-L-cysteine,An L-cysteine derivative obtained by formal condensation of the carboxy group of octanoic acid with the side-chain thiol group of L-cysteine.,"InChI=1S/C11H21NO3S/c1-2-3-4-5-6-7-10(13)16-8-9(12)11(14)15/h9H,2-8,12H2,1H3,(H,14,15)/t9-/m0/s1",S-octanoylcysteine,Reaxys Registry Number,8846221
6337,134417,"10,11-dihydro-12-oxoleukotriene B4","A hydroxy polyunsaturated fatty acid that is (6Z,8E,14Z)-icosatrienoic acid carrying hydroxy and oxo substituents at positions 5 and 12 respectively.","InChI=1S/C20H32O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-9,11,15,19,22H,2-5,10,12-14,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,15-11-/t19-/m1/s1","12-oxo-10,11-dihydroleukotriene B4",Reaxys Registry Number,7858630
6338,134436,titanium(III) oxide,A titanium oxide with formula Ti2O3.,InChI=1S/3O.2Ti,titanium sesquioxide,PubMed citation,23517136
6339,134442,"10,11-dihydro-20,20,20-trihydroxyleukotriene B4","A leukotriene that is 10,11-dihydroleukotriene B4 in which the three methyl hydrogens at position 20 have been replaced by hydroxy groups.","InChI=1S/C20H34O7/c21-17(11-6-2-1-5-9-16-20(25,26)27)12-7-3-4-8-13-18(22)14-10-15-19(23)24/h2-4,6,8,13,17-18,21-22,25-27H,1,5,7,9-12,14-16H2,(H,23,24)/b4-3+,6-2-,13-8-/t17-,18-/m1/s1","10,11-dihydro-20,20,20-trihydroxy-LTB4",HMDB accession,HMDB0012503
6340,134444,"10,11-dihydroleukotriene B4","A leukotriene obtained by formal dehydrogenation of the 10,11-double bond in leukotriene B4.","InChI=1S/C20H34O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-9,11,15,18-19,21-22H,2-5,10,12-14,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,15-11-/t18-,19-/m1/s1","10,11-dihydro-leukotriene B4",PubMed citation,8799275
6341,134453,10-HETE,A HETE that is arachidonic acid carrying a hydroxy substituent at position 10.,"InChI=1S/C20H32O3/c1-2-3-4-5-6-7-10-13-16-19(21)17-14-11-8-9-12-15-18-20(22)23/h6-9,13-14,16-17,19,21H,2-5,10-12,15,18H2,1H3,(H,22,23)/b7-6-,9-8-,16-13-,17-14-","(5Z,8Z,11Z,14Z)-10-hydroxyicosatetraenoic acid",HMDB accession,HMDB0012508
6342,134455,titanium(II) oxide,A titanium oxide containing approximately equal numbers of titanium and oxygen ions.,InChI=1S/O.Ti,titanium monoxide,Wikipedia accession,Titanium(II)_oxide
6343,134466,(21E)-3-hydroxy-35-[(icosan-2-yl)oxy]-35-oxo-2-pentacosylpentatriacont-21-enoic acid,"A mycolic acid produced inter alia by Mycobacterium tuberculosis, the structure of which is heptacosanoic acid substituted at the alpha-carbon by a (14E)-33-hydroxy-1-[(icosan-2-yl)oxy]-1-oxotritriacont-14-en-33-yl chain.","InChI=1S/C80H156O5/c1-4-6-8-10-12-14-16-18-20-22-23-24-32-35-38-41-45-49-53-57-61-65-69-73-77(80(83)84)78(81)74-70-66-62-58-54-50-46-42-39-36-33-30-28-26-25-27-29-31-34-37-40-43-47-51-55-59-63-67-71-75-79(82)85-76(3)72-68-64-60-56-52-48-44-21-19-17-15-13-11-9-7-5-2/h29,31,76-78,81H,4-28,30,32-75H2,1-3H3,(H,83,84)/b31-29+",mycolic acid (C80),PubMed citation,27807341
6344,134474,"6,8-icosanedione",A beta-diketone that is icosane in which the methylene hydrogens at positions 6 and 8 have been replaced by oxo groups.,"InChI=1S/C20H38O2/c1-3-5-7-8-9-10-11-12-13-15-17-20(22)18-19(21)16-14-6-4-2/h3-18H2,1-2H3","6,8-eicosanedione",HMDB accession,HMDB0035572
6345,134475,"5,7-icosanedione",A beta-diketone that is icosane in which the methylene hydrogens at positions 5 and 7 have been replaced by oxo groups.,"InChI=1S/C20H38O2/c1-3-5-7-8-9-10-11-12-13-14-15-17-20(22)18-19(21)16-6-4-2/h3-18H2,1-2H3","eicosane-5,7-dione",HMDB accession,HMDB0035573
6346,134477,N-acetyl-L-methionyl-L-leucine,A dipeptide obtained by formal condensation of the carboxy group of N-acetyl-L-methionine with the amino group of L-leucine.,"InChI=1S/C13H24N2O4S/c1-8(2)7-11(13(18)19)15-12(17)10(5-6-20-4)14-9(3)16/h8,10-11H,5-7H2,1-4H3,(H,14,16)(H,15,17)(H,18,19)/t10-,11-/m0/s1",Ac-Met-Leu,Reaxys Registry Number,6148593
6347,134489,N-acetyl-L-methionyl-L-alanine,A dipeptide obtained by formal condensation of the carboxy group of N-acetyl-L-methionine with the amino group of L-alanine.,"InChI=1S/C10H18N2O4S/c1-6(10(15)16)11-9(14)8(4-5-17-3)12-7(2)13/h6,8H,4-5H2,1-3H3,(H,11,14)(H,12,13)(H,15,16)/t6-,8-/m0/s1",N-acetylmethionylalanine,Reaxys Registry Number,5547688
6348,134491,N-acetyl-L-methionyl-L-serine,A dipeptide obtained by formal condensation of the carboxy group of N-acetyl-L-methionine with the amino group of L-serine.,"InChI=1S/C10H18N2O5S/c1-6(14)11-7(3-4-18-2)9(15)12-8(5-13)10(16)17/h7-8,13H,3-5H2,1-2H3,(H,11,14)(H,12,15)(H,16,17)/t7-,8-/m0/s1",N-acetylmethionylserine,Reaxys Registry Number,5560572
6349,134492,N-acetyl-L-methionyl-L-valine,A dipeptide obtained by formal condensation of the carboxy group of N-acetyl-L-methionine with the amino group of L-valine.,"InChI=1S/C12H22N2O4S/c1-7(2)10(12(17)18)14-11(16)9(5-6-19-4)13-8(3)15/h7,9-10H,5-6H2,1-4H3,(H,13,15)(H,14,16)(H,17,18)/t9-,10-/m0/s1",N-acetylmethionylvaline,Reaxys Registry Number,6148209
6350,134499,"13,14-dihydro-15-oxoprostaglandin E1","A prostaglandin E obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin E1.","InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h16-17,19,23H,2-14H2,1H3,(H,24,25)/t16-,17-,19-/m1/s1","13,14-dihydro-15-oxo-PGE1",CAS Registry Number,5094-14-4
6351,134507,beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine,A digalactosylceramide consisting of an beta-D-galactosyl-(1->4)-beta-D-galactosyl moiety attached at position 1 of N-(pentacosanoyl)sphingosine via a glycosidic linkage.,"InChI=1S/C55H105NO13/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-39-47(60)56-43(44(59)38-36-34-32-30-28-26-16-14-12-10-8-6-4-2)42-66-54-52(65)50(63)53(46(41-58)68-54)69-55-51(64)49(62)48(61)45(40-57)67-55/h36,38,43-46,48-55,57-59,61-65H,3-35,37,39-42H2,1-2H3,(H,56,60)/b38-36+/t43-,44+,45+,46+,48-,49-,50+,51+,52+,53-,54+,55-/m0/s1",beta-D-Gal-(1->4)-beta-D-Gal-(1<->1)-Cer(d18:1/25:0),HMDB accession,HMDB0004876
6352,134509,"13,14-dihydro-15-keto-PGF1alpha","A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F1alpha.","InChI=1S/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h16-19,22-23H,2-14H2,1H3,(H,24,25)/t16-,17-,18+,19-/m1/s1","13,14-dihydro-15-ketoprostaglandin F1alpha",LIPID MAPS instance accession,LMFA03010168
6353,134510,prostaglandin A3,"A member of the class of prostaglandins A that is prosta-5,10,13,17-tetraen-1-oic acid carrying oxo and hydroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S,17Z-stereoisomer).","InChI=1S/C20H28O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h3-4,6-7,12-18,21H,2,5,8-11H2,1H3,(H,23,24)/b6-3-,7-4-,14-12+/t16-,17-,18+/m0/s1",PGA3,Reaxys Registry Number,8937043
6354,134511,prostaglandin B3,"A member of the class of prostaglandins A that is prosta-5,8(12),13,17-tetraen-1-oic acid carrying oxo and hydsroxy substituents at positions 9 and 15 respectively (the 5Z,13E,15S,17Z-stereoisomer).","InChI=1S/C20H28O4/c1-2-3-6-9-17(21)14-12-16-13-15-19(22)18(16)10-7-4-5-8-11-20(23)24/h3-4,6-7,12,14,17,21H,2,5,8-11,13,15H2,1H3,(H,23,24)/b6-3-,7-4-,14-12+/t17-/m0/s1",PGB3,Reaxys Registry Number,8941035
6355,134513,20-oxoleukotriene E4,A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding aldehyde,"InChI=1S/C23H35NO6S/c24-19(23(29)30)18-31-21(20(26)14-13-16-22(27)28)15-11-9-7-5-3-1-2-4-6-8-10-12-17-25/h2-5,7,9,11,15,17,19-21,26H,1,6,8,10,12-14,16,18,24H2,(H,27,28)(H,29,30)/b4-2-,5-3-,9-7+,15-11+/t19-,20-,21+/m0/s1",20-oxo-LTE4,HMDB accession,HMDB0012642
6356,134515,"20,20,20-trihydroxyleukotriene B4",A leukotriene that is leukotriene B4 in which the three methyl hydrogens at position 20 have been replaced by hydroxy groups.,"InChI=1S/C20H32O7/c21-17(11-6-2-1-5-9-16-20(25,26)27)12-7-3-4-8-13-18(22)14-10-15-19(23)24/h2-4,6-8,12-13,17-18,21-22,25-27H,1,5,9-11,14-16H2,(H,23,24)/b4-3+,6-2-,12-7+,13-8-/t17-,18-/m1/s1",20-trihydroxy-LTB4,HMDB accession,HMDB0012643
6357,134517,20-carboxyleukotriene E4,A leukotriene that is leukotriene E4 in which the terminal methyl grop has been oxidised to the corresponding carboxylic acid.,"InChI=1S/C23H35NO7S/c24-18(23(30)31)17-32-20(19(25)13-12-16-22(28)29)14-10-8-6-4-2-1-3-5-7-9-11-15-21(26)27/h2-6,8,10,14,18-20,25H,1,7,9,11-13,15-17,24H2,(H,26,27)(H,28,29)(H,30,31)/b4-2-,5-3-,8-6+,14-10+/t18-,19-,20+/m0/s1",20-carboxy-leukotriene E4,HMDB accession,HMDB0012634
6358,134518,"11,12-dihydro-12-oxoleukotriene C4","A leukotriene  that is (5S,7E,9E,14Z)-5-hydroxy-12-oxoicosa-7,9,14-trienoic acid to which a glutathionyl group is attached at position 6 via a sulfide linkage.","InChI=1S/C30H47N3O10S/c1-2-3-4-5-6-8-12-21(34)13-9-7-10-15-25(24(35)14-11-16-27(37)38)44-20-23(29(41)32-19-28(39)40)33-26(36)18-17-22(31)30(42)43/h6-10,15,22-25,35H,2-5,11-14,16-20,31H2,1H3,(H,32,41)(H,33,36)(H,37,38)(H,39,40)(H,42,43)/b8-6-,9-7+,15-10+/t22-,23-,24+,25-/m0/s1",12-keto-c-LTB3,HMDB accession,HMDB0060154
6359,134519,"11,12-dihydro-(12R)-hydroxyleukotriene C4","A leukotriene that is (5S,7E,9E,12R,14Z)-5,12-dihydroxyicosa-7,9,14-trienoic acid to which a glutathionyl group is attached at position 6 via a sulfide linkage.","InChI=1S/C30H49N3O10S/c1-2-3-4-5-6-8-12-21(34)13-9-7-10-15-25(24(35)14-11-16-27(37)38)44-20-23(29(41)32-19-28(39)40)33-26(36)18-17-22(31)30(42)43/h6-10,15,21-25,34-35H,2-5,11-14,16-20,31H2,1H3,(H,32,41)(H,33,36)(H,37,38)(H,39,40)(H,42,43)/b8-6-,9-7+,15-10+/t21-,22+,23+,24+,25-/m1/s1","11,12-dihydro-(12R)-hydroxyl-LTC4",HMDB accession,HMDB0060155
6360,134520,"12,20-dioxoleukotriene B4",A member of the class of leukotrienes that is leukotriene B4 in which the hydroxy group at position 12 has been oxidised to the corresponding ketone and the methyl group at position 20 replaced by a hydroxy group.,"InChI=1S/C20H28O5/c21-17-10-6-2-1-3-7-12-18(22)13-8-4-5-9-14-19(23)15-11-16-20(24)25/h3-5,7-9,13-14,17,19,23H,1-2,6,10-12,15-16H2,(H,24,25)/b5-4+,7-3-,13-8+,14-9-/t19-/m1/s1","12,20-dioxo-LTB4",HMDB accession,HMDB0060094
6361,134524,linalool 6-hydroperoxide,Linalool hydroperoxide where the hydroperoxy group is located at position 6 of the linalool skeleton; one of the two main allergenic hydroperoxides formed by autoxidation of linalool.,"InChI=1S/C10H18O3/c1-5-10(4,11)7-6-9(13-12)8(2)3/h5-6,8,11-12H,1,7H2,2-4H3/b9-6-",6-hydroperoxylinalool,PubMed citation,27896835
6362,134527,"alpha-D-Gal-(1->3)-alpha-D-GlcNAc-diphospho-ditrans,octacis-undecaprenol","A polyprenyl phospho oligosaccharide that consists of an alpha-D-Gal-(1->3)-alpha-D-GlcNAc moiety linked via a diphospho group to ditrans,octacis-undecaprenol.","InChI=1S/C69H115NO17P2/c1-48(2)24-14-25-49(3)26-15-27-50(4)28-16-29-51(5)30-17-31-52(6)32-18-33-53(7)34-19-35-54(8)36-20-37-55(9)38-21-39-56(10)40-22-41-57(11)42-23-43-58(12)44-45-82-88(78,79)87-89(80,81)86-68-62(70-59(13)73)67(64(75)61(47-72)83-68)85-69-66(77)65(76)63(74)60(46-71)84-69/h24,26,28,30,32,34,36,38,40,42,44,60-69,71-72,74-77H,14-23,25,27,29,31,33,35,37,39,41,43,45-47H2,1-13H3,(H,70,73)(H,78,79)(H,80,81)/b49-26+,50-28+,51-30-,52-32-,53-34-,54-36-,55-38-,56-40-,57-42-,58-44-/t60-,61-,62-,63+,64-,65+,66-,67-,68-,69-/m1/s1","alpha-D-Gal-(1->3)-alpha-D-GlcNAc-diphospho-ditrans,polycis-undecaprenol",MetaCyc accession,CPD-19418
6363,134539,"D-lyxono-1,4-lactone",An aldonolactone obtained by cyclocondensation of the carboxy group and the 4-hydroxy group of D-lyxonic acid.,"InChI=1S/C5H8O5/c6-1-2-3(7)4(8)5(9)10-2/h2-4,6-8H,1H2/t2-,3+,4+/m1/s1","Lyxonic acid-1,4-lactone",Chemspider accession,10004245
6364,134543,(R)-4-hydroxy-1-methyl-L-proline,An L-proline derivative that is trans-4-hydroxy-L-proline in which the amino hydrogen has been replaced by a methyl group.,"InChI=1S/C6H11NO3/c1-7-3-4(8)2-5(7)6(9)10/h4-5,8H,2-3H2,1H3,(H,9,10)/t4-,5+/m1/s1",N-methyl-trans-4-hydroxy-L-proline,Chemspider accession,9943383
6365,134547,TOP-53,"A furonaphthodioxole that is 4'-demethyldeoxypodophyllotoxin which is substituted at position 4 of the C-ring by a 2-{[2-(dimethylamino)ethyl](methyl)amino}ethyl group. While structurally related to etoposide, TOP-53 is significantly more toxic to non-small cell lung cancer cells, more active at generating chromosomal breaks, and displays improved cellular uptake and pharmacokinetics in animal lung tissues.","InChI=1S/C28H36N2O7/c1-29(2)8-9-30(3)7-6-17-18-12-21-22(37-15-36-21)13-19(18)25(26-20(17)14-35-28(26)32)16-10-23(33-4)27(31)24(11-16)34-5/h10-13,17,20,25-26,31H,6-9,14-15H2,1-5H3/t17-,20-,25-,26+/m1/s1",TOP 53,Reaxys Registry Number,6377812
6366,134549,"N-icosanoyl-(4E,14Z)-sphinga-4,14-dienine","A ceramide obtained by formal condensation of the carboxy group of icosanoic acid with the amino group of (4E,14Z)-sphinga-4,14-dienine.","InChI=1S/C38H73NO3/c1-3-5-7-9-11-13-15-17-18-19-20-22-24-26-28-30-32-34-38(42)39-36(35-40)37(41)33-31-29-27-25-23-21-16-14-12-10-8-6-4-2/h8,10,31,33,36-37,40-41H,3-7,9,11-30,32,34-35H2,1-2H3,(H,39,42)/b10-8-,33-31+/t36-,37+/m0/s1","N-eicosanoyl-(4E,14Z)-sphinga-4,14-dienine",LIPID MAPS instance accession,LMSP02010026
6367,134603,1-hexadecanoyl-2-hexadecyl-sn-glycero-3-phosphocholine,A 1-acyl-2-alkyl-sn-glycero-3-phosphocholine in which the acyl and alkyl groups at positions 1 and 2 are specified as hexadecanoyl and hexadecyl respectively.,"InChI=1S/C40H82NO7P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-35-45-39(38-48-49(43,44)47-36-34-41(3,4)5)37-46-40(42)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h39H,6-38H2,1-5H3/t39-/m1/s1",PC(16:0/O-16:0),CAS Registry Number,77111-06-9
6368,134623,tetradecanoic-d27 acid,A C14 straight-chain saturated fatty acid where the aliphatic hydrogens have been replaced by deuterium atoms.,"InChI=1S/C14H28O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H,15,16)/i1D3,2D2,3D2,4D2,5D2,6D2,7D2,8D2,9D2,10D2,11D2,12D2,13D2",myristic-d27 acid,Reaxys Registry Number,1897910
6369,134627,leukotriene D3,"A leukotriene that is (5S,7E,9E,11Z)-5-hydroxyicosa-7,9,11-trienoic acid in which an L-cysteinylglycinyl group is attached at position 6R via a sulfide linkage.","InChI=1S/C25H42N2O6S/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22(21(28)15-14-17-23(29)30)34-19-20(26)25(33)27-18-24(31)32/h9-13,16,20-22,28H,2-8,14-15,17-19,26H2,1H3,(H,27,33)(H,29,30)(H,31,32)/b10-9-,12-11+,16-13+/t20-,21-,22+/m0/s1",LTD3,CAS Registry Number,77165-74-3
6370,134687,naltrexone hydrochloride,A hydrochloride obtained by reaction of oxycodone with one molar equivalent of hydrochloric acid. it is a mu-opioid receptor antagonist that is used to treat alcohol dependence.,"InChI=1S/C20H23NO4.ClH/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11;/h3-4,11,15,18,22,24H,1-2,5-10H2;1H/t15-,18+,19+,20-;/m1./s1",naltrexone.HCl,KEGG DRUG accession,D02095
6371,134692,rucaparib camsylate,"A camphorsulfonate salt obtained by reaction of rucaparib with one molar equivalent of (1S,4R)-camphorsulfonic acid. It is an inhibitor of poly (ADP-ribose) polymerase and is used as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation.","InChI=1S/C19H18FN3O.C10H16O4S/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24);7H,3-6H2,1-2H3,(H,12,13,14)/t;7-,10-/m.1/s1",rucaparib camphorsulfonate,CAS Registry Number,1859053-21-6
6372,134703,fluciclovine ((18)F),"A member of the class of cyclobutanes that is cyclobutane which carries a carboxy, amino and ((18)F)fluoro groups at positions 1, 1 and 3, respectively (the 1r,3r-stereoisomer). It is a positron emission tomography (PET) radiotracer for visualizing prostate cancer.","InChI=1S/C5H8FNO2/c6-3-1-5(7,2-3)4(8)9/h3H,1-2,7H2,(H,8,9)/t3-,5-/i6-1",GE-148,CAS Registry Number,222727-39-1
6373,134719,ceftolozane,"A fifth-generation cephalosporin antibiotic having (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics.","InChI=1S/C23H30N12O8S2/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42)/b31-11-/t12-,18-/m1/s1",CXA-101,CAS Registry Number,689293-68-3
6374,134740,sodium 2-((131)I)iodohippurate,,"InChI=1S/C9H8INO3.Na/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13;/h1-4H,5H2,(H,11,14)(H,12,13);/q;+1/p-1/i10+4;",Hippuran-131,CAS Registry Number,881-17-4
6375,134747,tedisamil,"A member of the class of diazabicyclononanes that is (1s,5s)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane] in which the hydrogens at positions 3 and 7 are replaced by cyclopropylmethyl groups. It is a potassium channel blocker and an antiarrhythmic agent currently currently in development for the treatment of atrial fibrillation.","InChI=1S/C19H32N2/c1-2-8-19(7-1)17-11-20(9-15-3-4-15)12-18(19)14-21(13-17)10-16-5-6-16/h15-18H,1-14H2/t17-,18+",KC-8857,Drug Central accession,4655
6376,134760,pentaerythritol,"A tetrol that is neopentane in which one of the methyl hydrogens of all four methyl groups are replaced by hydroxy groups. It is a chemical intermediate used in the production of explosives, plastics, paints, appliances, and cosmetics.","InChI=1S/C5H12O4/c6-1-5(2-7,3-8)4-9/h6-9H,1-4H2",tetra(hydroxymethyl)methane,CAS Registry Number,115-77-5
6377,134817,methoxyphenamine,"An amphetamine methylated on nitrogen and with the phenyl ring methoxylated at C-2. A beta-adrenergic receptor agonist, it is used as a bronchodilator.","InChI=1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3",methoxiphenadrin,Drug Central accession,1755
6378,134964,perflubutane,A fluorocarbon that is butane in which all of the hydrogens have been replaced by fluorines. Microbubbles of preflubutane are used in the ultrasound contrast agent BR14.,"InChI=1S/C4F10/c5-1(6,3(9,10)11)2(7,8)4(12,13)14",Decafluoro-butane,CAS Registry Number,355-25-9
6379,135076,setiptiline,"A tetracyclic antidepressant that is 2,3,4,9-tetrahydro-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine carrying a methyl group at position 2. Its maleate salt is used for the treatment of depression in Japan.","InChI=1S/C19H19N/c1-20-11-10-18-16-8-4-2-6-14(16)12-15-7-3-5-9-17(15)19(18)13-20/h2-9H,10-13H2,1H3",teciptilline,Drug Central accession,2438
6380,135207,clofedanol,"A diarylmethane that is 2-chlorophenyl(phenyl)methane substituted on the methane carbon by a 2-(dimethylamino)ethyl group. Used in the treatment of dry cough, it suppresses the cough reflex by a direct effect on the cough centre in the medulla of the brain.","InChI=1S/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3",chlophedianol,Drug Central accession,585
6381,135429,buzepide metiodide,An organic iodide salt of buzepide. It is a component of the antispasmodic drug vesadol.,"InChI=1S/C23H30N2O.HI/c1-25(17-10-2-3-11-18-25)19-16-23(22(24)26,20-12-6-4-7-13-20)21-14-8-5-9-15-21;/h4-9,12-15H,2-3,10-11,16-19H2,1H3,(H-,24,26);1H",difexamide methiodide,CAS Registry Number,15351-05-0
6382,135477,halocarban,A phenylurea that is urea substituted by 4-chlorophenyl and 4-chloro-3-trifluoromethylphenyl groups at positions 1 and 3 respectively. It is often used in deodarants and soaps on account of its anbacterial properties.,"InChI=1S/C14H9Cl2F3N2O/c15-8-1-3-9(4-2-8)20-13(22)21-10-5-6-12(16)11(7-10)14(17,18)19/h1-7H,(H2,20,21,22)",trifluoromethyldichlorocarbanilide,CAS Registry Number,369-77-7
6383,135595,fendosal,"A benzoindole that is 4,5-dihydro-3H-benzo[e]indole in which the nitrogen is substituted by a 3-carboxy-4-hydroxyphenyl group. A non-narcotic analgesic and non-steroidal anti-inflammatory drug, it has greater analgesic and inflammatory responses than aspirin but with less gastrointestinal toxicity.","InChI=1S/C25H19NO3/c27-24-13-11-18(14-21(24)25(28)29)26-22-12-10-16-6-4-5-9-19(16)20(22)15-23(26)17-7-2-1-3-8-17/h1-9,11,13-15,27H,10,12H2,(H,28,29)",HP 129,Drug Central accession,3224
6384,135611,benzododecinium,A quaternary ammonium ion obtained by methylation of N-benzyl-N-methyldodecan-1-amine.,"InChI=1S/C21H38N/c1-4-5-6-7-8-9-10-11-12-16-19-22(2,3)20-21-17-14-13-15-18-21/h13-15,17-18H,4-12,16,19-20H2,1-3H3/q+1",benzyldodecyldimethylammonium,Drug Central accession,3017
6385,135629,cefetamet,"A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.","InChI=1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1",deacetoxycefotaxime,Drug Central accession,3074
6386,135716,ceftezole,"A first-generation cephalosporin antibiotic having (1,3,4-thiadiazol-2-ylsulfanyl)methyl and [2-(1H-tetrazol-1-yl)acetamido side groups located at positions 3 and 7 respectively.","InChI=1S/C13H12N8O4S3/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25)/t8-,11-/m1/s1",ceftezol,Wikipedia accession,Ceftezole
6387,135748,lenampicillin,"A penicillanic acid ester that is the (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester of ampicillin. It is a prodrug of ampicillin.","InChI=1S/C21H23N3O7S/c1-10-12(31-20(28)30-10)9-29-19(27)15-21(2,3)32-18-14(17(26)24(15)18)23-16(25)13(22)11-7-5-4-6-8-11/h4-8,13-15,18H,9,22H2,1-3H3,(H,23,25)/t13-,14-,15+,18-/m1/s1",KBT-1585,Drug Central accession,1553
6388,135776,cefteram,"A cephalosporin compound having (5-methyl-2H-tetrazol-2-yl)methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a third-generation cephalosporin antibiotic.","InChI=1S/C16H17N9O5S2/c1-6-20-23-24(21-6)3-7-4-31-14-10(13(27)25(14)11(7)15(28)29)19-12(26)9(22-30-2)8-5-32-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b22-9-/t10-,14-/m1/s1",cefterame,Drug Central accession,3076
6389,135864,methylprednisolone suleptanate,An organic sodium salt that is the monosodium salt of methylprednisolone 21-suleptanic acid ester. It is a prodrug of methylprednisolone developed by Pharmacia Corp for the treatment of asthma.,"InChI=1S/C33H49NO10S.Na/c1-21-17-23-24-12-14-33(40,32(24,3)19-26(36)30(23)31(2)13-11-22(35)18-25(21)31)27(37)20-44-29(39)10-8-6-5-7-9-28(38)34(4)15-16-45(41,42)43;/h11,13,18,21,23-24,26,30,36,40H,5-10,12,14-17,19-20H2,1-4H3,(H,41,42,43);/q;+1/p-1/t21-,23-,24-,26-,30+,31-,32-,33-;/m0./s1",methylprednisolone suleptanate sodium salt,CAS Registry Number,90350-40-6
6390,135980,ammonia-(13)N,"A (13)N-modified compound that is ammonia that has a (13)N isotope as the nitrogen atom. (13)N decays with a half-life of ten minutes to (13)C, emitting a positron. Used in diagnostic Positron Emission Tomography (PET) imaging.",InChI=1S/H3N/h1H3/i1-1,13N-Ammonia,CAS Registry Number,34819-78-8
6391,136001,itramin tosilate,An organosulfonate salt obtained by combining equimolar amounts of aminoethyl nitrate and 4-toluenesulfonic acid. Used as a vasodilator for the treatment of angina.,"InChI=1S/C7H8O3S.C2H6N2O3/c1-6-2-4-7(5-3-6)11(8,9)10;3-1-2-7-4(5)6/h2-5H,1H3,(H,8,9,10);1-3H2",itramin tosylate,CAS Registry Number,13445-63-1
6392,136054,arterolane,"An oxaspiro compound that is dispiro[cyclohexane-1,3'-[1,2,4]trioxolane-5',2''-tricyclo[3.3.1.1(3,7)]decane] substituted by a 2-[(2-amino-2-methylpropyl)amino]-2-oxoethyl group at position 4s. Its maleic acid salt is used as an antimalarial drug in combination with piperaquine.","InChI=1S/C22H36N2O4/c1-20(2,23)13-24-19(25)12-14-3-5-21(6-4-14)26-22(28-27-21)17-8-15-7-16(10-17)11-18(22)9-15/h14-18H,3-13,23H2,1-2H3,(H,24,25)/t14-,15?,16?,17?,18?,21+,22?",OZ277,CAS Registry Number,664338-39-0
6393,136078,4-O-[di(2R)-1-glycerylphosphono]-N-acetyl-beta-D-mannosaminyl-(1->4)-N-acetyl-alpha-D-glucosaminyl undecaprenyl diphosphate,A polyprenyl glycosyl diphosphate having eleven prenyl units and with 4-O-[di(2R)-1-glycerylphosphono]--N-acetyl-beta-D-mannosaminyl-(1->4)-N-acetyl-alpha-D-glucosamine as the glycosyl fragment.,"InChI=1S/C77H132N2O27P4/c1-53(2)25-15-26-54(3)27-16-28-55(4)29-17-30-56(5)31-18-32-57(6)33-19-34-58(7)35-20-36-59(8)37-21-38-60(9)39-22-40-61(10)41-23-42-62(11)43-24-44-63(12)45-46-97-109(93,94)106-110(95,96)105-77-71(79-65(14)84)72(87)74(68(48-81)102-77)103-76-70(78-64(13)83)73(88)75(69(49-82)101-76)104-108(91,92)100-52-67(86)51-99-107(89,90)98-50-66(85)47-80/h25,27,29,31,33,35,37,39,41,43,45,66-77,80-82,85-88H,15-24,26,28,30,32,34,36,38,40,42,44,46-52H2,1-14H3,(H,78,83)(H,79,84)(H,89,90)(H,91,92)(H,93,94)(H,95,96)/b54-27+,55-29+,56-31-,57-33-,58-35-,59-37-,60-39-,61-41-,62-43-,63-45-/t66-,67-,68-,69-,70+,71-,72-,73-,74-,75-,76+,77-/m1/s1","4-O-[di(2R)-1-glycerylphosphono]-N-acetyl-beta-D-mannosaminyl-(1->4)-N-acetyl-alpha-D-glucosaminyl undecaprenyl ditrans,octacis-diphosphate",MetaCyc accession,CPD-19301
6394,136105,(R)-PGA2-S-glutathione conjugate,"A glutathione conjugate obtained by formal 1,4-addition of the thiol function of glutathione to the enone function of prostaglandin A2 (where the newly formed stereocentre at position 11 has R-configuration).","InChI=1S/C30H47N3O10S/c1-2-3-6-9-19(34)12-13-21-20(10-7-4-5-8-11-27(37)38)24(35)16-25(21)44-18-23(29(41)32-17-28(39)40)33-26(36)15-14-22(31)30(42)43/h4,7,12-13,19-23,25,34H,2-3,5-6,8-11,14-18,31H2,1H3,(H,32,41)(H,33,36)(H,37,38)(H,39,40)(H,42,43)/b7-4-,13-12+/t19-,20+,21+,22-,23-,25+/m0/s1",(R)-prostaglandin A2-S-glutathione conjugate,Reaxys Registry Number,8964430
6395,136106,(S)-PGA2-S-glutathione conjugate,"A glutathione conjugate obtained by formal 1,4-addition of the thiol function of glutathione to the enone function of prostaglandin A2 (where the newly formed stereocentre at position 11 has S-configuration).","InChI=1S/C30H47N3O10S/c1-2-3-6-9-19(34)12-13-21-20(10-7-4-5-8-11-27(37)38)24(35)16-25(21)44-18-23(29(41)32-17-28(39)40)33-26(36)15-14-22(31)30(42)43/h4,7,12-13,19-23,25,34H,2-3,5-6,8-11,14-18,31H2,1H3,(H,32,41)(H,33,36)(H,37,38)(H,39,40)(H,42,43)/b7-4-,13-12+/t19-,20+,21+,22-,23-,25-/m0/s1",(S)-GSH-PGA2 conjugate,Reaxys Registry Number,8964431
6396,136110,(R)-PGJ2-S-glutathione conjugate,"A glutathione conjugate obtained by formal 1,4-addition of the thiol function of glutathione to the enone function of prostaglandin J2 (where the newly formed stereocentre at position 9 has R-configuration).","InChI=1S/C30H47N3O10S/c1-2-3-6-9-19(34)12-13-20-21(10-7-4-5-8-11-27(37)38)25(16-24(20)35)44-18-23(29(41)32-17-28(39)40)33-26(36)15-14-22(31)30(42)43/h4,7,12-13,19-23,25,34H,2-3,5-6,8-11,14-18,31H2,1H3,(H,32,41)(H,33,36)(H,37,38)(H,39,40)(H,42,43)/b7-4-,13-12+/t19-,20+,21+,22-,23-,25+/m0/s1",S-(PGJ2)-glutathione,Reaxys Registry Number,8964341
6397,136270,2-amino-3-(2-methylenecyclopropyl)propanoic acid,A non-proteinogenic alpha-amino acid that is alanine in which one of the methyl hydrogens has been replaced by a 2-methylenecyclopropyl group. The phytotoxin known as hypoglycin A is a mixture of the diastereoisomers that have L configuration at the amino-bearing carbon.,"InChI=1S/C7H11NO2/c1-4-2-5(4)3-6(8)7(9)10/h5-6H,1-3,8H2,(H,9,10)",2-amino-3-(2-methylenecyclopropyl)propionic acid,MetaCyc accession,CPD-9699
6398,136272,N-(heptadecanoyl)hexadecasphingosine-1-phosphocholine,A sphingomyelin 33:1 obtained by formal condensation of the carboxy group of heptadecanoic acid with the amino group of hexadecasphingosine-1-phosphocholine.,"InChI=1S/C38H77N2O6P/c1-6-8-10-12-14-16-18-19-20-22-24-26-28-30-32-38(42)39-36(35-46-47(43,44)45-34-33-40(3,4)5)37(41)31-29-27-25-23-21-17-15-13-11-9-7-2/h29,31,36-37,41H,6-28,30,32-35H2,1-5H3,(H-,39,42,43,44)/b31-29+/t36-,37+/m0/s1",SM(d16:1/17:0),LIPID MAPS instance accession,LMSP03010037
6399,136273,N-(octadecanoyl)hexadecasphingosine-1-phosphocholine,A sphingomyelin 34:1 obtained by formal condensation of the carboxy group of octadecanoic acid with the amino group of hexadecasphingosine-1-phosphocholine.,"InChI=1S/C39H79N2O6P/c1-6-8-10-12-14-16-18-19-20-21-23-25-27-29-31-33-39(43)40-37(36-47-48(44,45)46-35-34-41(3,4)5)38(42)32-30-28-26-24-22-17-15-13-11-9-7-2/h30,32,37-38,42H,6-29,31,33-36H2,1-5H3,(H-,40,43,44,45)/b32-30+/t37-,38+/m0/s1",SM(d16:1/18:0),LIPID MAPS instance accession,LMSP03010042
6400,136275,N-(docosanoyl)heptadecasphingosine-1-phosphocholine,A sphingomyelin 39:1 obtained by formal condensation of the carboxy group of docosanoic acid with the amino group of heptadecasphingosine-1-phosphocholine.,"InChI=1S/C44H89N2O6P/c1-6-8-10-12-14-16-18-20-21-22-23-24-25-26-28-30-32-34-36-38-44(48)45-42(41-52-53(49,50)51-40-39-46(3,4)5)43(47)37-35-33-31-29-27-19-17-15-13-11-9-7-2/h35,37,42-43,47H,6-34,36,38-41H2,1-5H3,(H-,45,48,49,50)/b37-35+/t42-,43+/m0/s1",sphingomyelin d17:1/22:0,LIPID MAPS instance accession,LMSP03010066
6401,136292,hypoglycin B,"A diastereoisometic mixture containing (2S,4R)- and (2S,4S)-hypoglycin B. A metabolite of hypoglycin A found in unripe ackee fruit.","InChI=1S/C12H18N2O5/c1-6-4-7(6)5-9(12(18)19)14-10(15)3-2-8(13)11(16)17/h7-9H,1-5,13H2,(H,14,15)(H,16,17)(H,18,19)/t7?,8-,9-/m0/s1",L-gamma-glutamyl-L-hypoglycin,Reaxys Registry Number,3162184
6402,136301,L-alpha-(methylidenecyclopropyl)glycine,A non-proteinogenic L-alpha-amino acid that is glycine in which one of the methyl hydrogens has been replaced by a 2-methylenecyclopropyl group.,"InChI=1S/C6H9NO2/c1-3-2-4(3)5(7)6(8)9/h4-5H,1-2,7H2,(H,8,9)/t4?,5-/m0/s1",MCPG,MetaCyc accession,CPD-9757
6403,136353,"(7Z,10Z,12E,16Z,19Z)-14-hydroperoxydocosapentaenoic acid","A hydroperoxydocosapentaenoic acid that is (7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid carrying a hydroperoxy substituent at position 14.","InChI=1S/C22H34O4/c1-2-3-4-5-12-15-18-21(26-25)19-16-13-10-8-6-7-9-11-14-17-20-22(23)24/h3-4,6-7,10,12-13,15-16,19,21,25H,2,5,8-9,11,14,17-18,20H2,1H3,(H,23,24)/b4-3-,7-6-,13-10-,15-12-,19-16+","14-hydroperoxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid",PubMed citation,19324874
6404,136354,"(4Z,7Z,10Z,12E,16Z)-14-hydroperoxydocosapentaenoic acid","A hydroperoxydocosapentaenoic acid that is (4Z,7Z,10Z,12E,16Z)-docosapentaenoic acid carrying a hydroperoxy substituent at position 14.","InChI=1S/C22H34O4/c1-2-3-4-5-12-15-18-21(26-25)19-16-13-10-8-6-7-9-11-14-17-20-22(23)24/h6-7,10-16,19,21,25H,2-5,8-9,17-18,20H2,1H3,(H,23,24)/b7-6-,13-10-,14-11-,15-12-,19-16+",14-HPDPA,PubMed citation,19324874
6405,136355,"5(S),6(S)-epoxy-18-hydroxy-(7E,9E,11Z,14Z,16E)-icosapentaenoic acid","A polyunsaturated fatty acid consisting of (7E,9E,11Z,14Z,16E)-icosapentaenoic acid carrying additional 18-hydroxy and (5S,6S)-epoxy groups.","InChI=1S/C20H28O4/c1-2-17(21)13-10-8-6-4-3-5-7-9-11-14-18-19(24-18)15-12-16-20(22)23/h3,5-11,13-14,17-19,21H,2,4,12,15-16H2,1H3,(H,22,23)/b5-3-,8-6-,9-7+,13-10+,14-11+/t17?,18-,19-/m0/s1","(5S,6S)-epoxy-18-hydroxy-(7E,9E,11Z,14Z,16E)-eicosapentaenoic acid",PubMed citation,17114001
6406,136360,"alpha-D-Glc-(1->6)-beta-D-Gal-(1->4)-(1S)-D-GaloNAc-(1->4,6)-alpha-D-GalN-(1->4)-[alpha-LD-Hep-(1->2)-alpha-DD-Hep-(1->2)]-alpha-D-GalA-(1->3)-[alpha-LD-Hep-(1->7)]-alpha-LD-Hep6PEtn-(1->3)-[beta-D-Glc-(1->4)]-alpha-LD-Hep-(1->5)-[alpha-Kdo-(2->4)][beta-L-Arap4N-(1->8)]-alpha-Kdo","An oligosaccharide derivative that is a tridecasaccharide derivative, the oligosaccharide portion of the Proteus penneri strain 40 lipopolysaccharide (LPS) core region.","InChI=1S/C96H163N4O81P/c1-19(109)100-36(43(124)63(22(111)6-101)164-87-57(138)46(127)41(122)32(161-87)16-156-84-54(135)44(125)39(120)30(12-107)159-84)82-155-17-33-70(168-82)42(123)35(99)81(162-33)172-74-60(141)77(175-91-76(52(133)51(132)66(166-91)25(114)9-104)174-88-58(139)48(129)50(131)65(165-88)24(113)8-103)92(177-79(74)80(144)145)171-73-59(140)71(34(181-182(151,152)158-3-2-97)18-157-85-55(136)47(128)49(130)64(163-85)23(112)7-102)169-89(61(73)142)173-75-62(143)90(167-68(27(116)11-106)78(75)176-86-56(137)45(126)40(121)31(13-108)160-86)170-72-29(178-96(94(148)149)4-21(110)38(119)67(180-96)26(115)10-105)5-95(150,93(146)147)179-69(72)28(117)15-154-83-53(134)37(118)20(98)14-153-83/h20-79,81-92,101-108,110-143,150H,2-18,97-99H2,1H3,(H,100,109)(H,144,145)(H,146,147)(H,148,149)(H,151,152)/t20-,21+,22+,23-,24-,25+,26+,27-,28+,29+,30+,31+,32+,33+,34-,35+,36+,37-,38+,39+,40+,41-,42+,43+,44-,45-,46-,47-,48-,49-,50-,51-,52-,53+,54+,55-,56+,57+,58-,59+,60-,61-,62-,63-,64+,65+,66+,67+,68+,69+,70-,71+,72+,73-,74+,75+,76-,77+,78+,79-,81+,82-,83+,84+,85-,86-,87-,88+,89+,90+,91+,92-,95+,96+/m0/s1","beta-Glc-(1->6)-beta-Gal-(1->4)-(1S)-GaloNAc-(1->4,6)-alpha-GalN-(1->4)-[alpha-Hep-(1->2)-alpha-DD-Hep-(1->2)]-alpha-GalA-(1->3)-[alpha-Hep-(1->7)]-alpha-Hep6PEtn-(1->3)-[beta-Glc-(1->4)]-alpha-Hep-(1->5)-[alpha-Kdo-(2->4)][beta-L-Ara4N-(1->8)]-alpha-Kdo",PubMed citation,27469376
6407,136372,O-[(11E)-octadecenoyl]-D-carnitine,An O-acyl-D-carnitine in which the acyl group is specified as (11E)-octadecenoyl.,"InChI=1S/C25H47NO4/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25(29)30-23(21-24(27)28)22-26(2,3)4/h10-11,23H,5-9,12-22H2,1-4H3/b11-10+/t23-/m0/s1",O-[(E)-vaccenoyl]-D-carnitine,Chemspider accession,30776574
6408,136400,"8(S),15(S)-DiHPETE","An icosanoid that is (5Z,9E,11Z,13E)-icosatetraenoic acid carrying two hydroperoxy substituents at positions 8 and 15 (the 8S,15S-stereoisomer).","InChI=1S/C20H32O6/c1-2-3-8-13-18(25-23)14-9-4-5-10-15-19(26-24)16-11-6-7-12-17-20(21)22/h4-6,9-11,14-15,18-19,23-24H,2-3,7-8,12-13,16-17H2,1H3,(H,21,22)/b5-4-,11-6-,14-9+,15-10+/t18-,19+/m0/s1","(8S,15S)-dihydroperoxy-(5Z,9E,11Z,13E)-icosatetraenoic acid",LIPID MAPS instance accession,LMFA03060098
6409,136401,"14(R),15(S)-DiHPETE","A bis(hydroperoxy)icosatetraenoic acid that is (5Z,8Z,10E,12E)-icosatetraenoic acid carrying two hydroperoxy substituents at positions 14 and 15 (the 14R,15S-stereoisomer).","InChI=1S/C20H32O6/c1-2-3-12-15-18(25-23)19(26-24)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h4,6-10,13,16,18-19,23-24H,2-3,5,11-12,14-15,17H2,1H3,(H,21,22)/b6-4-,9-7-,10-8+,16-13+/t18-,19+/m0/s1","(14R,15S)-DiHPETE",PubMed citation,8334154
6410,136403,senecivernine N-oxide,A pyrrolizine alkaloid that is produced by a hybrid species of Jacobaea.,"InChI=1S/C18H25NO6/c1-10-11(2)16(20)25-14-6-8-19(23)7-5-13(15(14)19)9-24-17(21)18(4,22)12(10)3/h5,10,12,14-15,22H,2,6-9H2,1,3-4H3/t10-,12+,14+,15+,18+,19?/m0/s1","(14alpha)-12-hydroxy-14-methyl-21-norsenecionan-11,16-dione 4-oxide",PubMed citation,28828276
6411,136417,S-(chloromethyl)glutathione,An S-substituted glutathione that is glutathione in which the mercapto hydrogen has been replaced by a chloromethyl group.,"InChI=1S/C11H18ClN3O6S/c12-5-22-4-7(10(19)14-3-9(17)18)15-8(16)2-1-6(13)11(20)21/h6-7H,1-5,13H2,(H,14,19)(H,15,16)(H,17,18)(H,20,21)/t6-,7-/m0/s1",(chloromethyl)glutathione,PubMed citation,15074037
6412,136423,"S-(1,4-dihydroxy-3-methylnaphthalen-2-yl)glutathione","A glutathione conjugate in which the mercapto hydrogen of glutathione has been replaced by a 1,4-dihydroxy-3-methylnaphthalen-2-yl group","InChI=1S/C21H25N3O8S/c1-10-17(28)11-4-2-3-5-12(11)18(29)19(10)33-9-14(20(30)23-8-16(26)27)24-15(25)7-6-13(22)21(31)32/h2-5,13-14,28-29H,6-9,22H2,1H3,(H,23,30)(H,24,25)(H,26,27)(H,31,32)/t13-,14-/m0/s1",menadiolglutathione,PubMed citation,1990978
6413,136429,usaramine N-oxide,"A pyrrolizine alkaloid that is senecionane bearing two additional hydroxy substituents at positions 12 and 18, two additional oxo groups at positions 11 and 16 and an N-oxido substituent.","InChI=1S/C18H25NO7/c1-3-12-8-11(2)18(23,10-20)17(22)25-9-13-4-6-19(24)7-5-14(15(13)19)26-16(12)21/h3-4,11,14-15,20,23H,5-10H2,1-2H3/b12-3+/t11-,14-,15-,18-,19?/m1/s1",mucronatine N-oxide,Reaxys Registry Number,19963004
6414,136430,acetylseneciphylline,A pyrrolizine alkaloid that is seneciphylline in which the hydroxy hydrogen has been replaced by an acetyl group.,"InChI=1S/C20H25NO6/c1-5-14-10-12(2)20(4,27-13(3)22)19(24)25-11-15-6-8-21-9-7-16(17(15)21)26-18(14)23/h5-6,16-17H,2,7-11H2,1,3-4H3/b14-5-/t16-,17-,20-/m1/s1",O-acetylseneciphylline,Chemspider accession,28424469
6415,136433,"2,5-diimino-3,4-bis(indol-3-yl)hexanedioic acid",A member of the class of indoles obtained by dimerisation of 2-imino-3-(indol-3-yl)propanoic acid. An intermediate in the biosynthesis of violacein.,"InChI=1S/C22H18N4O4/c23-19(21(27)28)17(13-9-25-15-7-3-1-5-11(13)15)18(20(24)22(29)30)14-10-26-16-8-4-2-6-12(14)16/h1-10,17-18,23-26H,(H,27,28)(H,29,30)",indole-3-pyruvic acid imine dimer,PubMed citation,18171677
6416,136437,"3,4-bis(7-chloroindol-3-yl)-2,5-diiminohexanedioic acid",A member of the class of indoles obtained by dimerisation of 2-imino-3-(7-chloroindol-3-yl)propanoic acid.,"InChI=1S/C22H16Cl2N4O4/c23-13-5-1-3-9-11(7-27-19(9)13)15(17(25)21(29)30)16(18(26)22(31)32)12-8-28-20-10(12)4-2-6-14(20)24/h1-8,15-16,25-28H,(H,29,30)(H,31,32)",7-chloroindole-3-pyruvate imine dimer,PubMed citation,17176066
6417,136439,"(5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoate","An EpETE(1-) that is the conjugate base of (5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C20H30O3/c1-2-3-4-5-6-7-8-9-12-15-18-19(23-18)16-13-10-11-14-17-20(21)22/h3-4,6-7,9-10,12-13,18-19H,2,5,8,11,14-17H2,1H3,(H,21,22)/p-1/b4-3-,7-6-,12-9-,13-10-",8(9)-EETeTr(1-),PubMed citation,15766564
6418,136441,"(5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoate","An EpETE(1-) that is the conjugate base of (5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C20H30O3/c1-2-3-4-5-9-12-15-18-19(23-18)16-13-10-7-6-8-11-14-17-20(21)22/h3-4,6,8-10,12-13,18-19H,2,5,7,11,14-17H2,1H3,(H,21,22)/p-1/b4-3-,8-6-,12-9-,13-10-",11(12)-EETeTr(1-),PubMed citation,15766564
6419,136443,"(5Z,8Z,11Z,17Z)-14,15-epoxyicosatetraenoate","An EpETE(1-) that is the conjugate base of (5Z,8Z,11Z,17Z)-14,15-epoxyicosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C20H30O3/c1-2-3-12-15-18-19(23-18)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h3-4,6-7,9-10,12-13,18-19H,2,5,8,11,14-17H2,1H3,(H,21,22)/p-1/b6-4-,9-7-,12-3-,13-10-",14(15)-EETeTr(1-),PubMed citation,15766564
6420,136444,(E)-1-(glutathion-S-yl)-2-(indol-3-yl)acetohydroximate(1-),An S-substituted glutathione(1-) obtained by deprotonation of the the two carboxy groups and protonation of the glutamyl amino group of (E)-1-(glutathion-S-yl)-2-(indol-3-yl)acetohydroximate. Major microspecies at pH 7.3.,"InChI=1S/C20H25N5O7S/c21-13(20(30)31)5-6-16(26)24-15(19(29)23-9-18(27)28)10-33-17(25-32)7-11-8-22-14-4-2-1-3-12(11)14/h1-4,8,13,15,22,32H,5-7,9-10,21H2,(H,23,29)(H,24,26)(H,27,28)(H,30,31)/p-1/b25-17+/t13-,15-/m0/s1",S-[(E)-N-hydroxy(indole-3-yl)acetimidoyl]-L-glutathione(1-),MetaCyc accession,CPD-12387
6421,136449,acetylseneciphylline N-oxide,A pyrrolizine alkaloid that is seneciphylline in which the hydroxy hydrogen has been replaced by an acetyl group and the tertiary amino function has been oxidised to the corresponding N-oxide.,"InChI=1S/C20H25NO7/c1-5-14-10-12(2)20(4,28-13(3)22)19(24)26-11-15-6-8-21(25)9-7-16(17(15)21)27-18(14)23/h5-6,16-17H,2,7-11H2,1,3-4H3/b14-5-/t16-,17-,20-,21?/m1/s1","(15Z)-12-acetoxy-11,16-dioxo-13,19-didehydrosenecionane N-oxide",Reaxys Registry Number,21894091
6422,136456,glycolaldehyde phosphate,A member of the class of aldehydes that is glycolaldehyde in which the hydroxy hydrogen has been replaced by a phospho group.,"InChI=1S/C2H5O5P/c3-1-2-7-8(4,5)6/h1H,2H2,(H2,4,5,6)",2-(phosphonooxy)acetaldehyde,CAS Registry Number,870-55-3
6423,136458,jacozine,A pyrrolizine alkaloid that is seneciphylline in which the exocyclic double bond has been converted to the corresponding epoxide.,"InChI=1S/C18H23NO6/c1-10-8-18(11(2)25-18)16(21)24-13-5-7-19-6-4-12(14(13)19)9-23-15(20)17(10,3)22/h4,11,13-14,22H,1,5-9H2,2-3H3/t11-,13+,14+,17+,18-/m0/s1","12-hydroxy-13,19-didehydro-15,20-dihydro-15,20-epoxysenecionan-11,16-dione",Chemspider accession,455001
6424,136464,acetylerucifoline,A pyrrolizine alkaloid that is erucifoline in which the primary hydroxy hydrogen has been replaced by an acetyl group.,"InChI=1S/C20H25NO7/c1-4-13-9-20(11-26-12(2)22)19(3,28-20)18(24)25-10-14-5-7-21-8-6-15(16(14)21)27-17(13)23/h4-5,15-16H,6-11H2,1-3H3/b13-4-/t15-,16-,19+,20+/m1/s1",O-acetylerucifoline,PubMed citation,21819407
6425,136485,"8(S),15(S)-DiHETE","Ab 8,15-DiHETE that is derived from (5Z,9E,11Z,13E)-icosatetraenoic acid and has (8S,15S)-stereochemistry.","InChI=1S/C20H32O4/c1-2-3-8-13-18(21)14-9-4-5-10-15-19(22)16-11-6-7-12-17-20(23)24/h4-6,9-11,14-15,18-19,21-22H,2-3,7-8,12-13,16-17H2,1H3,(H,23,24)/b5-4-,11-6-,14-9+,15-10+/t18-,19+/m0/s1","(8S,15S)-dihydroxy-(5Z,9E,11Z,13E)-eicosatetraenoic acid",LIPID MAPS instance accession,LMFA03060050
6426,136500,"14(R),15(S)-DiHETE","A DiHETE that is (5Z,8Z,10E,12E)-icosatetraenoic acid carrying two hydroxy substituents at positions 14 and 15 (the 14R,15S-stereoisomer).","InChI=1S/C20H32O4/c1-2-3-12-15-18(21)19(22)16-13-10-8-6-4-5-7-9-11-14-17-20(23)24/h4,6-10,13,16,18-19,21-22H,2-3,5,11-12,14-15,17H2,1H3,(H,23,24)/b6-4-,9-7-,10-8+,16-13+/t18-,19+/m0/s1","(5Z,8Z,10E,12E,14R,15S)-14,15-dihydroxyeicosatetraenoic acid",Reaxys Registry Number,4704842
6427,136514,indol-3-ylmethylamine(1+),A primary ammonium ion obtained by protonation of the primary amino function of indol-3-ylmethylamine; major species at pH 7.3.,"InChI=1S/C9H10N2/c10-5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5,10H2/p+1",3-(ammoniomethyl)indole,MetaCyc accession,CPD-8913
6428,136527,(Z)-indolylmethyl desulfoglucosinolate,An indolylmethyl desulfoglucosinolate in which the C=N double bond has Z configuration.,"InChI=1S/C16H20N2O6S/c19-7-11-13(20)14(21)15(22)16(24-11)25-12(18-23)5-8-6-17-10-4-2-1-3-9(8)10/h1-4,6,11,13-17,19-23H,5,7H2/b18-12-/t11-,13-,14+,15-,16+/m1/s1",(Z)-desulfoglucobrassicin,Reaxys Registry Number,3568754
6429,136531,"13-oxo-9,11-octadecadienoic acid","An oxooctadecadienoic acid that is 9,11-octadecadienoic acid in which the oxo group is located at position 13.","InChI=1S/C18H30O3/c1-2-3-11-14-17(19)15-12-9-7-5-4-6-8-10-13-16-18(20)21/h7,9,12,15H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)",13-KODE,CAS Registry Number,31385-09-8
6430,136547,N-(indole-3-acetyl)glutamic acid,An indoleacetic acid amide conjugate obtained by formal condensation of the carboxy group of indole-3-acetic acid with the amino group of glutamic acid.,"InChI=1S/C15H16N2O5/c18-13(17-12(15(21)22)5-6-14(19)20)7-9-8-16-11-4-2-1-3-10(9)11/h1-4,8,12,16H,5-7H2,(H,17,18)(H,19,20)(H,21,22)",N-(indol-3-ylacetyl)glutamic acid,Reaxys Registry Number,443565
6431,136550,2-phenylethyl beta-primeveroside,A 6-O-(beta-D-xylopyranosyl)-beta-D-glucopyranoside in which the anomeric substituent is specified as 2-phenylethyl.,"InChI=1S/C19H28O10/c20-11-8-27-18(16(24)13(11)21)28-9-12-14(22)15(23)17(25)19(29-12)26-7-6-10-4-2-1-3-5-10/h1-5,11-25H,6-9H2/t11-,12-,13+,14-,15+,16-,17-,18+,19-/m1/s1",phenethyl beta-D-xylosyl-(1->6)-beta-D-glucoside,HMDB accession,HMDB0041274
6432,136553,epicatechin 3-O-(3'-O-methylgallate),A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of epicatechin.,"InChI=1S/C23H20O10/c1-31-19-6-11(5-17(28)21(19)29)23(30)33-20-9-13-15(26)7-12(24)8-18(13)32-22(20)10-2-3-14(25)16(27)4-10/h2-8,20,22,24-29H,9H2,1H3/t20-,22-/m1/s1",epicatechin 3-(3'-O-methylgallate),Chemspider accession,410661
6433,136569,"(4Z,7Z,13Z,16Z,19Z)-10,11-epoxydocosapentaenoic acid","An EpDPE obtained by formal epoxidation across the 10,11-double bond of all-cis-docosa-4,7,10,13,16,19-hexaenoic acid.","InChI=1S/C22H32O3/c1-2-3-4-5-6-7-8-11-14-17-20-21(25-20)18-15-12-9-10-13-16-19-22(23)24/h3-4,6-7,10-15,20-21H,2,5,8-9,16-19H2,1H3,(H,23,24)/b4-3-,7-6-,13-10-,14-11-,15-12-",10(11)-EpDoPE,LIPID MAPS instance accession,LMFA04000035
6434,136573,"(7Z,10Z,13Z,16Z)-19,20-epoxydocosatetraenoic acid","A epoxydocosatetraenoic acid obtained by formal epoxidation across the 19,20-double bond of (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid.","InChI=1S/C22H34O3/c1-2-20-21(25-20)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-19-22(23)24/h3-4,7-10,14,16,20-21H,2,5-6,11-13,15,17-19H2,1H3,(H,23,24)/b4-3-,9-7-,10-8-,16-14-","19,20-epoxy-(7Z,10Z,13Z,16Z)-docosatetraenoic acid",PubMed citation,16112640
6435,136575,"(7Z,10Z,13Z,19Z)-16,17-epoxydocosatetraenoic acid","A epoxydocosatetraenoic acid obtained by formal epoxidation across the 16,17-double bond of (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid.","InChI=1S/C22H34O3/c1-2-3-14-17-20-21(25-20)18-15-12-10-8-6-4-5-7-9-11-13-16-19-22(23)24/h3,5-8,12,14-15,20-21H,2,4,9-11,13,16-19H2,1H3,(H,23,24)/b7-5-,8-6-,14-3-,15-12-","16,17-epoxy-(7Z,10Z,13Z,19Z)-docosatetraenoic acid",PubMed citation,16112640
6436,136584,"(4Z,7Z,10Z,13Z,16Z)-20-hydroxydocosapentaenoic acid","A hydroxydocosapentaenoic acid that is (4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid in which the hydroxy group is located at position 20.","InChI=1S/C22H34O3/c1-2-21(23)19-17-15-13-11-9-7-5-3-4-6-8-10-12-14-16-18-20-22(24)25/h3-4,7-10,13-16,21,23H,2,5-6,11-12,17-20H2,1H3,(H,24,25)/b4-3-,9-7-,10-8-,15-13-,16-14-","20-hydroxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid",PubMed citation,16112640
6437,136585,2-hydroxy-17beta-estradiol 3-sulfate,A steroid sulfate that is 2-hydroxy-17beta-estradiol in which the phenolic hydrogen at position 3 has been replaced by a sulfo group.,"InChI=1S/C18H24O6S/c1-18-7-6-11-12(14(18)4-5-17(18)20)3-2-10-8-16(24-25(21,22)23)15(19)9-13(10)11/h8-9,11-12,14,17,19-20H,2-7H2,1H3,(H,21,22,23)/t11-,12+,14-,17-,18-/m0/s1","(17beta)-estra-1,3,5(10)-triene-2,3,17-triol 3-sulfate",Reaxys Registry Number,7274122
6438,136587,"(4Z,7Z,11Z,13Z,15E,17S,19Z)-10,17-bis(hydroperoxy)docosahexaenoic acid","A docosanoid that is (4Z,7Z,11Z,13Z,15E,19Z)-docosahexaenoic acid carrying two hydroperoxy substituents at positions 10 and 17.","InChI=1S/C22H32O6/c1-2-3-10-15-20(27-25)17-12-8-9-13-18-21(28-26)16-11-6-4-5-7-14-19-22(23)24/h3,5-13,17-18,20-21,25-26H,2,4,14-16,19H2,1H3,(H,23,24)/b7-5-,9-8-,10-3-,11-6-,17-12+,18-13-/t20-,21?/m0/s1","(10,17S)-DiHPDoHE",PubMed citation,16112640
6439,136594,"(4Z,7Z,11Z,13Z,15E,17S)-10,17-bis(hydroperoxy)docosapentaenoic acid","A hydroperoxydocosapentaenoic acid that is (4Z,7Z,11Z,13Z,15E)-docosapentaenoic acid carrying two hydroperoxy substituents at positions 10 and 17.","InChI=1S/C22H34O6/c1-2-3-10-15-20(27-25)17-12-8-9-13-18-21(28-26)16-11-6-4-5-7-14-19-22(23)24/h5-9,11-13,17-18,20-21,25-26H,2-4,10,14-16,19H2,1H3,(H,23,24)/b7-5-,9-8-,11-6-,17-12+,18-13-/t20-,21?/m0/s1","(10,17S)-bis(hydroperoxy)-(4Z,7Z,11Z,13Z,15E)-docosapentaenoic acid",PubMed citation,19324874
6440,136597,12-oxo-6-trans-leukotriene B4,A leukotriene consisting of 6-trans-leukotriene B4 having a 12-keto group in place of the 12-hydroxy group.,"InChI=1S/C20H30O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,19,22H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7+,9-6-,14-10+,15-11+/t19-/m1/s1","12-keto-(5S)-hydroxy-(6E,8E,10E,14Z)-icosatetraenoic acid",Reaxys Registry Number,7253021
6441,136600,17alpha-ethynylestradiol 3-sulfate,A steroid sulfate that is 17alpha-ethynylestradiol in which the phenolic hydrogen at position 3 has been replaced by a sulfo group.,"InChI=1S/C20H24O5S/c1-3-20(21)11-9-18-17-6-4-13-12-14(25-26(22,23)24)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21H,4,6,8-11H2,2H3,(H,22,23,24)/t16-,17-,18+,19+,20+/m1/s1",17alpha-ethynylestradiol sulfate,CAS Registry Number,24560-70-1
6442,136606,N-arachidonoyl-L-phenylalanine,An N-acyl-L-phenylalanine resulting from the formal condensation of the carboxy group of arachidonic acid with the amino group of L-phenylalanine.,"InChI=1S/C29H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21-24-28(31)30-27(29(32)33)25-26-22-19-18-20-23-26/h6-7,9-10,12-13,15-16,18-20,22-23,27H,2-5,8,11,14,17,21,24-25H2,1H3,(H,30,31)(H,32,33)/b7-6-,10-9-,13-12-,16-15-/t27-/m0/s1",arachidonoylphenylalanine,Reaxys Registry Number,11148960
6443,136615,N-oleoyl-L-glutamine,An L-glutamine derivative resulting from the formal condensation of the carboxy group of oleic acid with the amino group of L-glutamine.,"InChI=1S/C23H42N2O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-22(27)25-20(23(28)29)18-19-21(24)26/h9-10,20H,2-8,11-19H2,1H3,(H2,24,26)(H,25,27)(H,28,29)/b10-9-/t20-/m0/s1",N-(9Z-octadecenoyl)-L-glutamine,LIPID MAPS instance accession,LMFA08020128
6444,136616,N-oleoyl-L-leucine,An L-leucine derivative resulting from the formal condensation of the carboxy group of oleic acid with the amino group of L-leucine.,"InChI=1S/C24H45NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-23(26)25-22(24(27)28)20-21(2)3/h11-12,21-22H,4-10,13-20H2,1-3H3,(H,25,26)(H,27,28)/b12-11-/t22-/m0/s1",N-oleoylleucine,PubMed citation,27374330
6445,136618,N-[(9Z)-hexadecenoyl]glycine,A fatty acid amide resulting from the formal condensation of the carboxy group of (9Z)-hexadecenoic acid with the amino group of glycine.,"InChI=1S/C18H33NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17(20)19-16-18(21)22/h7-8H,2-6,9-16H2,1H3,(H,19,20)(H,21,22)/b8-7-",N-(9Z-hexadecenoyl)glycine,Reaxys Registry Number,27471066
6446,136623,N-octadecanoylglycine,A fatty acid amide resulting from the formal condensation of the carboxy group of octadecanoic acid with the amino group of glycine.,"InChI=1S/C20H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-19(22)21-18-20(23)24/h2-18H2,1H3,(H,21,22)(H,23,24)",octadecanoylglycine,LIPID MAPS instance accession,LMFA08020077
6447,136649,estriol 3-O-(beta-D-glucuronide)(1-),A steroid glucuronide anion that is the conjugate base of estriol 3-O-(beta-D-glucuronide) arising from deprotonation of the carboxylic acid function; major species at pH 7.3.,"InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(32-23-19(28)17(26)18(27)20(33-23)22(30)31)8-10(12)2-4-14(13)15(24)9-16(25)21(24)29/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/p-1/t13-,14-,15+,16-,17+,18+,19-,20+,21+,23-,24+/m1/s1","16alpha,17beta-estriol 3-O-(beta-D-glucuronide) (1-)",PubMed citation,23288867
6448,136650,estriol 16-O-(beta-D-glucuronide)(1-),A steroid glucuronide anion that is the conjugate base of estriol 16-O-(beta-D-glucuronide) arising from deprotonation of the carboxylic acid function; major species at pH 7.3.,"InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(25)8-10(12)2-4-14(13)15(24)9-16(21(24)29)32-23-19(28)17(26)18(27)20(33-23)22(30)31/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/p-1/t13-,14-,15+,16-,17+,18+,19-,20+,21+,23-,24+/m1/s1","16alpha,17beta-estriol 16-O-(beta-D-glucuronide)(1-)",PubMed citation,23288867
6449,136656,"(5Z,9E,11Z,14Z,17Z)-8-hydroperoxyicosapentaenoic acid","A hydroperoxy fatty acid that is (5Z,9E,11Z,14Z,17Z)-icosapentaenoic acid in which the hydroperoxy group is located at position 8.","InChI=1S/C20H30O4/c1-2-3-4-5-6-7-8-9-10-13-16-19(24-23)17-14-11-12-15-18-20(21)22/h3-4,6-7,9-11,13-14,16,19,23H,2,5,8,12,15,17-18H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,14-11-,16-13+","8-hydroperoxy-(5Z,9E,11Z,14Z,17Z)-icosapentaenoic acid",PubMed citation,10559269
6450,136657,"(4Z,7Z,11E,13Z,16Z,19Z)-10-hydroperoxydocosahexaenoic acid","A docosanoid that is (4Z,7Z,11E,13Z,16Z,19Z)-docosahexaenoic acid carrying a hydroperoxy substituent at position 10.","InChI=1S/C22H32O4/c1-2-3-4-5-6-7-8-9-12-15-18-21(26-25)19-16-13-10-11-14-17-20-22(23)24/h3-4,6-7,9,11-16,18,21,25H,2,5,8,10,17,19-20H2,1H3,(H,23,24)/b4-3-,7-6-,12-9-,14-11-,16-13-,18-15+","10-hydroperoxy-(4Z,7Z,11E,13Z,16Z,19Z)-docosahexaenoic acid",PubMed citation,10559269
6451,136665,"8-nitroguanosine 3',5'-cyclic monophosphate","A 3',5'-cyclic purine nucleotide that is guanosine 3',5'-cyclic monophosphate in which the hydrogen at position 8 on the purine fragment has been replaced by a nitro group.","InChI=1S/C10H11N6O9P/c11-9-13-6-3(7(18)14-9)12-10(16(19)20)15(6)8-4(17)5-2(24-8)1-23-26(21,22)25-5/h2,4-5,8,17H,1H2,(H,21,22)(H3,11,13,14,18)/t2-,4-,5-,8-/m1/s1",8-nitro-cGMP,Reaxys Registry Number,15593276
6452,136671,guanylyl-(3'->5')-cytidine,A (3'->5')-dinucleotide composed from guanosine and cytidine units.,"InChI=1S/C19H25N8O12P/c20-8-1-2-26(19(33)23-8)16-11(30)10(29)7(38-16)4-36-40(34,35)39-13-6(3-28)37-17(12(13)31)27-5-22-9-14(27)24-18(21)25-15(9)32/h1-2,5-7,10-13,16-17,28-31H,3-4H2,(H,34,35)(H2,20,23,33)(H3,21,24,25,32)/t6-,7-,10-,11-,12-,13-,16-,17-/m1/s1","guanylyl-3',5'-cytidine",PubMed citation,20349466
6453,136672,"N-hexadecanoyl-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine",An N-acylphosphatidylethanolamine in which the N- and O-acyl groups are specified as hexadecanoyl (palmitoyl).,"InChI=1S/C53H104NO9P/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-51(55)54-46-47-61-64(58,59)62-49-50(63-53(57)45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)48-60-52(56)44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h50H,4-49H2,1-3H3,(H,54,55)(H,58,59)/t50-/m1/s1","N-palmitoyl-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine",Reaxys Registry Number,28837078
6454,136674,(acetamidomethyl)phosphonic acid,A member of the class of acetamides obtained by formal condensation of acetic acid with the amino group of (aminomethyl)phosphonic acid.,"InChI=1S/C3H8NO4P/c1-3(5)4-2-9(6,7)8/h2H2,1H3,(H,4,5)(H2,6,7,8)",[(acetylamino)methyl]phosphonic acid,CAS Registry Number,57637-97-5
6455,136677,[(S)-1-acetamidoethyl]phosphonic acid,A member of the class of acetamides obtained by formal condensation of acetic acid with the amino group of (S)-(1-aminoethyl)phosphonic acid.,"InChI=1S/C4H10NO4P/c1-3(6)5-4(2)10(7,8)9/h4H,1-2H3,(H,5,6)(H2,7,8,9)/t4-/m0/s1",(S)-1-(N-acetylamino)ethylphosphonic acid,MetaCyc accession,CPD-19240
6456,136678,"4',7-dihydroxyflavanone",A dihydroxyflavanone in which the two hydroxy substituents are located at positions 4' and 7.,"InChI=1S/C15H12O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-7,14,16-17H,8H2","7,4'-dihydroxyflavanone",Chemspider accession,1818
6457,136679,(R)-2-amino-4-oxopentanoic acid,A D-alanine derivative in which one of the methyl hydrogens of D-alanine has been replaced by an acetyl group.,"InChI=1S/C5H9NO3/c1-3(7)2-4(6)5(8)9/h4H,2,6H2,1H3,(H,8,9)/t4-/m1/s1",3-acetyl-D-alanine,MetaCyc accession,CPD-299
6458,136680,beta-guanidino-L-alanine,A L-alanine derivative in which one of the methyl hydrogens of L-alanine has been replaced by a guanidino group.,"InChI=1S/C4H10N4O2/c5-2(3(9)10)1-8-4(6)7/h2H,1,5H2,(H,9,10)(H4,6,7,8)/t2-/m0/s1",L-2-amino-3-guanidinopropionic acid,Reaxys Registry Number,2413421
6459,136681,L-beta-homomethionine,A beta-amino acid that is (3R)-3-aminopentanoic acid in which one of the terminal methyl hydrogens has been replaced by a methylsulfanyl group.,"InChI=1S/C6H13NO2S/c1-10-3-2-5(7)4-6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/t5-/m0/s1",beta-L-homomethionine,Reaxys Registry Number,4370321
6460,136683,N-arachidonoyl-L-leucine,An L-leucine derivative resulting from the formal condensation of the carboxy group of arachidonic acid with the amino group of L-leucine.,"InChI=1S/C26H43NO3/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25(28)27-24(26(29)30)22-23(2)3/h8-9,11-12,14-15,17-18,23-24H,4-7,10,13,16,19-22H2,1-3H3,(H,27,28)(H,29,30)/b9-8-,12-11-,15-14-,18-17-/t24-/m0/s1","N-[(5Z,8Z,11Z,14Z)-icosatetraenoyl]leucine",Reaxys Registry Number,25442003
6461,136711,N-oleoyl-L-isoleucine,An L-isoleucine derivative resulting from the formal condensation of the carboxy group of oleic acid with the amino group of L-isoleucine.,"InChI=1S/C24H45NO3/c1-4-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-22(26)25-23(24(27)28)21(3)5-2/h12-13,21,23H,4-11,14-20H2,1-3H3,(H,25,26)(H,27,28)/b13-12-/t21-,23-/m0/s1",N-[(9Z)-octadecenoyl]-L-isoleucine,Reaxys Registry Number,20745805
6462,136713,N-oleoyl-L-glutamic acid,A fatty amide resulting from the formal condensation of the carboxy group of oleic acid with the amino group of L-glutamic acid.,"InChI=1S/C23H41NO5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(25)24-20(23(28)29)18-19-22(26)27/h9-10,20H,2-8,11-19H2,1H3,(H,24,25)(H,26,27)(H,28,29)/b10-9-/t20-/m0/s1",N-oleoylglutamic acid,CAS Registry Number,4627-61-6
6463,136715,Asn-Pro-Val-Val-His-Phe-Phe-Lys-Asn-Ile-Val-Thr-Pro-Arg-Thr-Pro-Pro-Pro-Ser,"An oligopeptide composed of L-asparagine, L-proline, L-valine, L-valine, L-histidine, L-phenylalanine, L-phenylalanine, L-lysine, L-asparagine, L-isoleucine, L-valine, L-threonine, L-proline, L-arginine, L-threonine, L-proline, L-proline, L-proline and L-serine joined in sequence by peptide linkages.","InChI=1S/C101H155N27O25/c1-11-55(8)79(94(146)120-78(54(6)7)93(145)123-81(57(10)131)98(150)126-41-23-33-70(126)88(140)112-63(31-20-38-109-101(106)107)83(135)122-80(56(9)130)99(151)128-43-25-36-73(128)97(149)127-42-24-35-72(127)96(148)125-40-22-32-69(125)89(141)117-68(50-129)100(152)153)121-87(139)67(48-75(105)133)115-82(134)62(30-18-19-37-102)111-84(136)64(44-58-26-14-12-15-27-58)113-85(137)65(45-59-28-16-13-17-29-59)114-86(138)66(46-60-49-108-51-110-60)116-91(143)76(52(2)3)119-92(144)77(53(4)5)118-90(142)71-34-21-39-124(71)95(147)61(103)47-74(104)132/h12-17,26-29,49,51-57,61-73,76-81,129-131H,11,18-25,30-48,50,102-103H2,1-10H3,(H2,104,132)(H2,105,133)(H,108,110)(H,111,136)(H,112,140)(H,113,137)(H,114,138)(H,115,134)(H,116,143)(H,117,141)(H,118,142)(H,119,144)(H,120,146)(H,121,139)(H,122,135)(H,123,145)(H,152,153)(H4,106,107,109)/t55?,56?,57?,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,76-,77-,78-,79-,80-,81-/m0/s1",NPVVHFFKNIVTPRTPPPS,PubMed citation,28338626
6464,136722,N-(2-oxindole-3-acetyl)-L-aspartic acid,An N-acyl-L-aspartic acid in which the acyl group is specified as 2-oxindole-3-acetyl.,"InChI=1S/C14H14N2O6/c17-11(15-10(14(21)22)6-12(18)19)5-8-7-3-1-2-4-9(7)16-13(8)20/h1-4,8,10H,5-6H2,(H,15,17)(H,16,20)(H,18,19)(H,21,22)/t8?,10-/m0/s1",2-oxindole-3-acetyl-L-aspartic acid,Reaxys Registry Number,11077849
6465,136728,beta-D-Galp-(1->4)-beta-D-Glcp-(1->6)-[beta-D-Glcp-(1->4)]-beta-D-GlcpNAcOCH2CH2N3,A beta-D-glucoside that is the 2-azidoethyl glycoside of a tetrasaccharide (Streptococcus pneumoniae serotype 14 tetrasaccharide) consisting of at the reducing end an N-acetyl-beta-D-glucosamine residue to which are linked (1->4) and (1->6) respectively a beta-D-glucose residue and a beta-D-galactosyl-(1->4)-beta-D-glucosyl disaccharide unit.,"InChI=1S/C28H48N4O21/c1-8(36)31-13-16(39)24(53-28-21(44)18(41)15(38)10(5-34)49-28)12(51-25(13)46-3-2-30-32-29)7-47-26-22(45)19(42)23(11(6-35)50-26)52-27-20(43)17(40)14(37)9(4-33)48-27/h9-28,33-35,37-45H,2-7H2,1H3,(H,31,36)/t9-,10-,11-,12-,13-,14+,15-,16-,17+,18+,19-,20-,21-,22-,23-,24-,25-,26-,27+,28+/m1/s1",2-azidoethyl beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1->6)-[beta-D-glucosyl-(1->4)]-N-acetyl-beta-D-glucosaminide,PubMed citation,28287405
6466,136730,(S)-all-trans-4-hydroxyretinoic acid,An all-trans-4-hydroxyretinoic acid in which the 4-hydroxy group has S-configuration.,"InChI=1S/C20H28O3/c1-14(7-6-8-15(2)13-19(22)23)9-10-17-16(3)18(21)11-12-20(17,4)5/h6-10,13,18,21H,11-12H2,1-5H3,(H,22,23)/b8-6+,10-9+,14-7+,15-13+/t18-/m0/s1",(4S)-OH-atRA,Reaxys Registry Number,23145310
6467,136734,(R)-laudanosine,A benzylisoquinoline alkaloid that is (R)-tetrahydropapaverine in which the amino hydrogen has been replaced by a methyl group,"InChI=1S/C21H27NO4/c1-22-9-8-15-12-20(25-4)21(26-5)13-16(15)17(22)10-14-6-7-18(23-2)19(11-14)24-3/h6-7,11-13,17H,8-10H2,1-5H3/t17-/m1/s1",(R)-N-methyltetrahydropapaverine,Reaxys Registry Number,96753
6468,136735,(R)-tetrahydropapaverine,A benzylisoquinoline alkaloid that is (R)-norlaudanosoline in which the four phenolic hydrogens have been replaced by methyl groups.,"InChI=1S/C20H25NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-6,10-12,16,21H,7-9H2,1-4H3/t16-/m1/s1",(R)-norlaudanosine,Reaxys Registry Number,94918
6469,136745,beta-D-GlcpA-(1->4)-beta-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-GalpO[CH2]2NH2,"An alpha-D-galactoside that is the 2-aminoethyl glycoside of a tetrasaccharide consisting of beta-D-glucuronosyl, beta-D-glucosyl, alpha-D-glucosyl and alpha-D-galactosyl residues linked sequentially (1->4).","InChI=1S/C26H45NO22/c27-1-2-42-23-15(37)11(33)18(6(3-28)43-23)46-24-16(38)12(34)19(7(4-29)44-24)47-25-17(39)13(35)20(8(5-30)45-25)48-26-14(36)9(31)10(32)21(49-26)22(40)41/h6-21,23-26,28-39H,1-5,27H2,(H,40,41)/t6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16-,17-,18+,19-,20-,21+,23+,24-,25+,26-/m1/s1",2-aminoethyl beta-D-glucuronosyl-(1->4)-beta-D-glucosyl-(1->4)-alpha-D-glucosyl-(1->4)-alpha-D-galactoside,PubMed citation,28275152
6470,136747,alpha-D-Glcp-(1->4)-alpha-D-GalpO[CH2]2NH2,An alpha-D-galactoside that is the 2-aminoethyl glycoside of a disaccharide consisting of alpha-D-glucosyl and alpha-D-galactosyl residues linked (1->4).,"InChI=1S/C14H27NO11/c15-1-2-23-13-11(22)9(20)12(6(4-17)25-13)26-14-10(21)8(19)7(18)5(3-16)24-14/h5-14,16-22H,1-4,15H2/t5-,6-,7-,8+,9-,10-,11-,12+,13+,14-/m1/s1",Glcalpha1-4GalalphaO[CH2]2NH2,PubMed citation,28275152
6471,136753,"L-arabino-1,4-lactone-5-phosphate(2-)","An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of L-arabino-1,4-lactone-5-phosphate. Major microspecies at pH 7.3.","InChI=1S/C5H9O8P/c6-3-2(1-12-14(9,10)11)13-5(8)4(3)7/h2-4,6-7H,1H2,(H2,9,10,11)/p-2/t2-,3-,4+/m0/s1","L-arabinono-1,4-lactone-5-phosphate(2-)",PubMed citation,24955762
6472,136772,"2,5-dihydroxybenzoic acid 5-O-beta-D-glucoside","A monohydroxybenzoic acid that is 2,5-dihydroxybenzoic acid in which the phenolic hydrogen at position 5 has been replaced by a beta-D-glucosyl residue.","InChI=1S/C13H16O9/c14-4-8-9(16)10(17)11(18)13(22-8)21-5-1-2-7(15)6(3-5)12(19)20/h1-3,8-11,13-18H,4H2,(H,19,20)/t8-,9-,10+,11-,13-/m1/s1","2,5-dihydroxybenzoic acid 5-O-beta-glucoside",Reaxys Registry Number,1295224
6473,136773,"1,2-dihexadecanoyl-sn-glycero-3-phospho-(1'-sn-glycerol-3'-phosphate)",A 3-(3-sn-phosphatidyl)-sn-glycerol 1-phosphate in which both phosphatidyl acyl groups are specified as hexadecanoyl (palmitoyl).,"InChI=1S/C38H76O13P2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-37(40)47-33-36(34-50-53(45,46)49-32-35(39)31-48-52(42,43)44)51-38(41)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h35-36,39H,3-34H2,1-2H3,(H,45,46)(H2,42,43,44)/t35-,36+/m0/s1","1,2-dipalmitoylphosphatidylglycerol phosphate",HMDB accession,HMDB0013472
6474,136775,1-naphthyl beta-D-glucoside,A beta-D-glucoside that is beta-D-glucopyranose in which the anomeric hydroxy hydrogen has been replaced by a 1-naphthyl group.,"InChI=1S/C16H18O6/c17-8-12-13(18)14(19)15(20)16(22-12)21-11-7-3-5-9-4-1-2-6-10(9)11/h1-7,12-20H,8H2/t12-,13-,14+,15-,16-/m1/s1",1-naphthol glucoside,CAS Registry Number,19939-82-3
6475,136778,quercetin 3-beta-gentiobioside,A quercetin O-glycoside in which the hydroxy hydrogen at position 3 of quercetin has been replaced by a gentiobiosyl group.,"InChI=1S/C27H30O17/c28-6-14-17(33)20(36)22(38)26(42-14)40-7-15-18(34)21(37)23(39)27(43-15)44-25-19(35)16-12(32)4-9(29)5-13(16)41-24(25)8-1-2-10(30)11(31)3-8/h1-5,14-15,17-18,20-23,26-34,36-39H,6-7H2/t14-,15-,17-,18-,20+,21+,22-,23-,26-,27+/m1/s1",quercetin 3-gentiobioside,LIPID MAPS instance accession,LMPK12112096
6476,136780,quercetin 3-beta-gentiotrioside,A quercetin O-glycoside in which the hydroxy hydrogen at position 3 of quercetin has been replaced by a gentiotriosyl group.,"InChI=1S/C33H40O22/c34-6-15-19(39)23(43)26(46)31(52-15)49-7-16-20(40)24(44)27(47)32(53-16)50-8-17-21(41)25(45)28(48)33(54-17)55-30-22(42)18-13(38)4-10(35)5-14(18)51-29(30)9-1-2-11(36)12(37)3-9/h1-5,15-17,19-21,23-28,31-41,43-48H,6-8H2/t15-,16-,17-,19-,20-,21-,23+,24+,25+,26-,27-,28-,31-,32-,33+/m1/s1",moracetin,Reaxys Registry Number,6765012
6477,136781,alpha-D-Glcp-(1->4)-alpha-D-Galp-(1->4)-beta-D-GlcpA-(1->4)-beta-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-GalpOCH2CH2NH2,"An alpha-D-glucoside that is the 2-aminoethyl glycoside of a hexasaccharide consisting of alpha-D-glucosyl, alpha-D-galactosyl, beta-D-glucuronosyl, beta-D-glucosyl, alpha-D-glucosyl and alpha-D-galactosyl residues, all linked sequentially (1->4).","InChI=1S/C38H65NO32/c39-1-2-60-33-21(53)15(47)26(9(4-41)62-33)67-35-22(54)16(48)28(10(5-42)63-35)68-36-23(55)17(49)29(12(7-44)64-36)69-38-25(57)19(51)30(31(71-38)32(58)59)70-37-24(56)18(50)27(11(6-43)65-37)66-34-20(52)14(46)13(45)8(3-40)61-34/h8-31,33-38,40-57H,1-7,39H2,(H,58,59)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26+,27+,28-,29-,30+,31+,33+,34+,35-,36+,37-,38-/m1/s1",2-aminoethyl beta-D-glucosyl-(1->4)-alpha-D-galactosyl-(1->4)-beta-D-glucuronosyl-(1->4)-beta-D-glucosyl-(1->4)-alpha-D-glucosyl-(1->4)-alpha-D-galactoside,Reaxys Registry Number,29433967
6478,136785,kaempferol 3-beta-gentiobioside,A kaempferol O-glucoside in which the hydroxy hydrogen at position 3 of kaempferol has been replaced by a gentiobiosyl group.,"InChI=1S/C27H30O16/c28-7-14-17(32)20(35)22(37)26(41-14)39-8-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-12(31)5-11(30)6-13(16)40-24(25)9-1-3-10(29)4-2-9/h1-6,14-15,17-18,20-23,26-33,35-38H,7-8H2/t14-,15-,17-,18-,20+,21+,22-,23-,26-,27+/m1/s1",kaempferol-3-gentiobioside,LIPID MAPS instance accession,LMPK12111731
6479,136805,3-methoxybenzaldehyde,A member of the class of benzaldehydes in which the hydrogen at position 3 of benzaldehyde has been replaced by a methoxy group.,"InChI=1S/C8H8O2/c1-10-8-4-2-3-7(5-8)6-9/h2-6H,1H3",m-anisaldehyde,Chemspider accession,21106184
6480,136806,flamenol,A member of the class of resorcinols that is phloroglucinol in which one of the phenolic hydrogens has been replaced by a methyl group.,"InChI=1S/C7H8O3/c1-10-7-3-5(8)2-6(9)4-7/h2-4,8-9H,1H3","3,5-dihydroxyanisole",Chemspider accession,64709
6481,136819,5-hydroxyoctadecanoic acid,A hydroxyoctadecanoic acid that is octadecanoic acid (stearic acid) in which one of the hydrogens at position 5 has been replaced by a hydroxy group.,"InChI=1S/C18H36O3/c1-2-3-4-5-6-7-8-9-10-11-12-14-17(19)15-13-16-18(20)21/h17,19H,2-16H2,1H3,(H,20,21)",5-hydroxystearic acid,Reaxys Registry Number,1790113
6482,136826,xanthogalenol,"A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 6', a methoxy group at position 4' and a prenyl group at position 3'.","InChI=1S/C21H22O5/c1-13(2)4-10-16-19(26-3)12-18(24)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+",3' prenyl-4' O-methylchalconaringenin,LIPID MAPS instance accession,LMPK12120307
6483,136828,4'-O-methylxanthohumol,"A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 2' and 4, methoxy group at positions 4' and 6' and a prenyl group at position 3'.","InChI=1S/C22H24O5/c1-14(2)5-11-17-19(26-3)13-20(27-4)21(22(17)25)18(24)12-8-15-6-9-16(23)10-7-15/h5-10,12-13,23,25H,11H2,1-4H3/b12-8+",4'-methylxanthohumol,LIPID MAPS instance accession,LMPK12120318
6484,136847,AP20187,"A tertiary amino compound that is 2-(aminomethyl)-N,N-dimethylpropane-1,3-diamine in which the primary ammino groups have each been acylated by condensation with the carboxy group of 2-{3-[(1R)-3-(3,4-dimethoxyphenyl)-1-hydroxypropyl]phenoxy}acetic acid, the hydroxy groups of which have been esterified by condensation with the carboxy group of L-pipecolic acid, the nitrogen of which has been acylated by condensation with (2S)-2-(3,4,5-trimethoxyphenyl)butyric acid. It is a synthetic, cell-permeable ligand that can be used to induce homodimerization of fusion proteins containing the DmrB domain.","InChI=1S/C82H107N5O20/c1-15-61(57-43-71(98-9)77(102-13)72(44-57)99-10)79(90)86-37-19-17-27-63(86)81(92)106-65(33-29-52-31-35-67(94-5)69(39-52)96-7)55-23-21-25-59(41-55)104-50-75(88)83-47-54(49-85(3)4)48-84-76(89)51-105-60-26-22-24-56(42-60)66(34-30-53-32-36-68(95-6)70(40-53)97-8)107-82(93)64-28-18-20-38-87(64)80(91)62(16-2)58-45-73(100-11)78(103-14)74(46-58)101-12/h21-26,31-32,35-36,39-46,54,61-66H,15-20,27-30,33-34,37-38,47-51H2,1-14H3,(H,83,88)(H,84,89)/t61-,62-,63-,64-,65+,66+/m0/s1",B/B Homodimerizer,CAS Registry Number,195514-80-8
6485,136855,"9,9-bis(4-hydroxyphenyl)fluorene",A member of the class of fluorenes that is 9H-fluorene in which both of the hydrogens at position 9 have been replaced by p-hydroxyphenyl groups.,"InChI=1S/C25H18O2/c26-19-13-9-17(10-14-19)25(18-11-15-20(27)16-12-18)23-7-3-1-5-21(23)22-6-2-4-8-24(22)25/h1-16,26-27H",BHPF,CAS Registry Number,3236-71-3
6486,136858,beta-D-Delta(4)-GlcpA-(1->4)-beta-D-Glcp-(1->4)-alpha-L-Rhap-(1->3)-D-Glcp,"A tetrasaccharide consisting of beta-D-Delta(4)-glucopyranuronic acid, beta-D-glucopyranosyl, alpha-L-rhamnopyranosyl and D-glucopyranosyl residues, joined in sequence by (1->4), (1->4) and (1->3)-glycosidic bonds, respectively.","InChI=1S/C24H38O20/c1-5-17(12(30)14(32)23(38-5)44-19-11(29)8(3-25)39-21(37)16(19)34)42-24-15(33)13(31)18(9(4-26)41-24)43-22-10(28)6(27)2-7(40-22)20(35)36/h2,5-6,8-19,21-34,37H,3-4H2,1H3,(H,35,36)/t5-,6-,8+,9+,10+,11+,12-,13+,14+,15+,16+,17-,18+,19-,21?,22-,23-,24-/m0/s1",beta-D-Delta(4)-GlcA-(1->4)-beta-D-Glc-(1->4)-alpha-L-Rha-(1->3)-D-Glc,MetaCyc accession,CPD-13187
6487,136894,chenodeoxycholate 3-O-(beta-D-glucuronide)(2-),A steroid glucuronide anion that is the conjugate base of chenodeoxycholic acid 3-O-(beta-D-glucuronide) arising from deprotonation of the carboxylic acid functions; major species at pH 7.3.,"InChI=1S/C30H48O10/c1-14(4-7-21(32)33)17-5-6-18-22-19(9-11-30(17,18)3)29(2)10-8-16(12-15(29)13-20(22)31)39-28-25(36)23(34)24(35)26(40-28)27(37)38/h14-20,22-26,28,31,34-36H,4-13H2,1-3H3,(H,32,33)(H,37,38)/p-2/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24+,25-,26+,28-,29+,30-/m1/s1",CDCA 3-glucuronide(2-),PubMed citation,23756265
6488,136922,"2,5-dihydroxybenzoic acid 2-O-beta-D-glucoside","A monohydroxybenzoic acid that is 2,5-dihydroxybenzoic acid in which the phenolic hydrogen at position 2 has been replaced by a beta-D-glucosyl residue.","InChI=1S/C13H16O9/c14-4-8-9(16)10(17)11(18)13(22-8)21-7-2-1-5(15)3-6(7)12(19)20/h1-3,8-11,13-18H,4H2,(H,19,20)/t8-,9-,10+,11-,13-/m1/s1",gentisic acid 2-O-beta-D-glucoside,Reaxys Registry Number,1295668
6489,136934,2-trans-4'-dihydroabscisic acid,An apo carotenoid sesquiterpenoid that is 2-trans-abscisic acid in which the keto group at position 4' has been reduced to the corresponding alcohol.,"InChI=1S/C15H22O4/c1-10(7-13(17)18)5-6-15(19)11(2)8-12(16)9-14(15,3)4/h5-8,12,16,19H,9H2,1-4H3,(H,17,18)/b6-5+,10-7+",4'-dihydroabscisic acid,Chemspider accession,14923529
6490,136938,(4-methoxyindol-3-ylmethyl)isothiocyanate,A member of the class of indoles that is 1H-indole carrying isothiocyanatomethyl and methoxy substituents at positions 3 and 4 respectively.,"InChI=1S/C11H10N2OS/c1-14-10-4-2-3-9-11(10)8(6-13-9)5-12-7-15/h2-4,6,13H,5H2,1H3",3-(isothiocyanatomethyl)-4-methoxyindole,Chemspider accession,10709969
6491,136939,N-[(6-hydroxyindol-3-yl)acetyl]phenylalanine,An N-acyl-amino acid obtained by formal condensation of the carboxy group of 6-hydroxyindole-3-acetic acid with the amino group of phenylalanine.,"InChI=1S/C19H18N2O4/c22-14-6-7-15-13(11-20-16(15)10-14)9-18(23)21-17(19(24)25)8-12-4-2-1-3-5-12/h1-7,10-11,17,20,22H,8-9H2,(H,21,23)(H,24,25)",(6-hydroxyindol-3-yl)acetylphenylalanine,Reaxys Registry Number,31825506
6492,136942,6-(methylthio)hexanonitrile oxide,A nitrile oxide that is pentane in which two of the terminal methyl hydrogens at positions 1 and 5 have been replaced by oxidonitrile and methylsulfanyl groups.,"InChI=1S/C7H13NOS/c1-10-7-5-3-2-4-6-8-9/h2-5,7H2,1H3",6-(methylthio)hexanenitrile oxide,Chemspider accession,24785403
6493,136944,7-hydroxy-2-oxindole-3-acetic acid beta-D-glucoside,A member of the class of oxindoles that is 7-hydroxy-2-oxindole-3-acetic acid in which the phenolic hydrogen has been replaced by a beta-D-glucosyl residue.,"InChI=1S/C16H19NO9/c18-5-9-12(21)13(22)14(23)16(26-9)25-8-3-1-2-6-7(4-10(19)20)15(24)17-11(6)8/h1-3,7,9,12-14,16,18,21-23H,4-5H2,(H,17,24)(H,19,20)/t7?,9-,12-,13+,14-,16-/m1/s1",7-hydroxy-2-oxindole-3-acetic acid beta-glucoside,Reaxys Registry Number,21408246
6494,136945,7-(methylthio)heptanonitrile oxide,A nitrile oxide that is hexane in which two of the terminal methyl hydrogens at positions 1 and 6 have been replaced by oxidonitrile and methylsulfanyl groups.,"InChI=1S/C8H15NOS/c1-11-8-6-4-2-3-5-7-9-10/h2-6,8H2,1H3",7-methylthioheptanonitrile oxide,Chemspider accession,24785095
6495,136946,7-(methylthio)heptyldesulfoglucosinolate,An omega-(methylsulfany)alkyl desulfoglucosinolate in which the omega-(methylsulfany)alkyl group is specified as 7-(methylsulfanyl)heptyl.,"InChI=1S/C15H29NO6S2/c1-23-8-6-4-2-3-5-7-11(16-21)24-15-14(20)13(19)12(18)10(9-17)22-15/h10,12-15,17-21H,2-9H2,1H3/t10-,12-,13+,14-,15+/m1/s1",7-(methylsulfanyl)heptyldesulfoglucosinolate,KEGG COMPOUND accession,C21650
6496,136947,8-(methylthio)octylisothiocyanate,An isothiocyanate that is octane in which two of the terminal methyl hydrogens at positions 1 and 8 have been replaced by isothiocyanato and methylsulfanyl groups.,"InChI=1S/C10H19NS2/c1-13-9-7-5-3-2-4-6-8-11-10-12/h2-9H2,1H3",8-(methylsulfanyl)octylisothiocyanate,Chemspider accession,8346864
6497,136948,S-[9-(methylthio)nonylhydroximoyl]-L-cysteine,An S-substituted L-cysteine in which the thiol hydrogen of L-cysteine has been replaced by a 9-(methylthio)nonylhydroximoyl group.,"InChI=1S/C13H26N2O3S2/c1-19-9-7-5-3-2-4-6-8-12(15-18)20-10-11(14)13(16)17/h11,18H,2-10,14H2,1H3,(H,16,17)/t11-/m0/s1",9-methylthiononylhydroximoyl-L-cysteine,MetaCyc accession,CPDQT-410
6498,136949,coniferaldehyde beta-D-glucoside,A beta-D-glucoside that is coniferaldehyde in which the phenolic hydrogen has been replaced by a beta-D-glucosyl residue.,"InChI=1S/C16H20O8/c1-22-11-7-9(3-2-6-17)4-5-10(11)23-16-15(21)14(20)13(19)12(8-18)24-16/h2-7,12-16,18-21H,8H2,1H3/b3-2+/t12-,13-,14+,15-,16-/m1/s1",coniferaldehyde glucoside,Reaxys Registry Number,49673
6499,136950,5-(methylthio)pentyldesulfoglucosinolate,An omega-(methylsulfany)alkyl desulfoglucosinolate in which the omega-(methylsulfany)alkyl group is specified as 5-(methylsulfanyl)pentyl.,"InChI=1S/C13H25NO6S2/c1-21-6-4-2-3-5-9(14-19)22-13-12(18)11(17)10(16)8(7-15)20-13/h8,10-13,15-19H,2-7H2,1H3/t8-,10-,11+,12-,13+/m1/s1",desulfoglucoberteroin,KNApSAcK accession,C00007624
6500,136951,desulfoglucoiberin,A desulfoglucosinolic acid resulting from the formal condensation of the thiol group of N-hydroxy-3-(methylsulfinyl)butanethioamide with beta-D-glucopyranose.,"InChI=1S/C11H21NO7S2/c1-21(18)4-2-3-7(12-17)20-11-10(16)9(15)8(14)6(5-13)19-11/h6,8-11,13-17H,2-5H2,1H3/t6-,8-,9+,10-,11+,21?/m1/s1",3-(methylsulfinyl)propyldesulfoglucosinolate,Reaxys Registry Number,6428268
6501,136952,6-(methylthio)hexyldesulfoglucosinolate,An omega-(methylsulfany)alkyl desulfoglucosinolate in which the omega-(methylsulfanyl)alkyl group is specified as 6-(methylsulfanyl)hexyl.,"InChI=1S/C14H27NO6S2/c1-22-7-5-3-2-4-6-10(15-20)23-14-13(19)12(18)11(17)9(8-16)21-14/h9,11-14,16-20H,2-8H2,1H3/t9-,11-,12+,13-,14+/m1/s1",desulfoglucolesquerellin,MetaCyc accession,CPDQT-417
6502,136953,3-butenyldesulfoglucosinolate,A desulfoglucosinolic acid resulting from the formal condensation of the thiol group of N-hydroxypent-4-enethioamide with beta-D-glucopyranose.,"InChI=1S/C11H19NO6S/c1-2-3-4-7(12-17)19-11-10(16)9(15)8(14)6(5-13)18-11/h2,6,8-11,13-17H,1,3-5H2/t6-,8-,9+,10-,11+/m1/s1",desulfogluconapin,Reaxys Registry Number,18889630
6503,136954,desulfogluconasturtiin,A desulfoglucosinolic acid resulting from the formal condensation of the thiol group of N-hydroxy-3-phenylpropanethioamide with beta-D-glucopyranose.,"InChI=1S/C15H21NO6S/c17-8-10-12(18)13(19)14(20)15(22-10)23-11(16-21)7-6-9-4-2-1-3-5-9/h1-5,10,12-15,17-21H,6-8H2/t10-,12-,13+,14-,15+/m1/s1",2-phenylethyldesulfoglucosinolate,Reaxys Registry Number,18889633
6504,136955,desulfosinigrin,A desulfoglucosinolic acid resulting from the formal condensation of the thiol group of N-hydroxybut-3-enethioamide with beta-D-glucopyranose.,"InChI=1S/C10H17NO6S/c1-2-3-6(11-16)18-10-9(15)8(14)7(13)5(4-12)17-10/h2,5,7-10,12-16H,1,3-4H2/t5-,7-,8+,9-,10+/m1/s1",2-propenyldesulfoglucosinolate,Reaxys Registry Number,89228
6505,136956,glucohesperin,An omega-[(methylsulfiny)alkyl]glucosinolic acid in which the omega-(methylsulfinyl)alkyl group is specified as 6-(methylsulfinyl)hexyl.,"InChI=1S/C14H27NO10S3/c1-27(20)7-5-3-2-4-6-10(15-25-28(21,22)23)26-14-13(19)12(18)11(17)9(8-16)24-14/h9,11-14,16-19H,2-8H2,1H3,(H,21,22,23)/t9-,11-,12+,13-,14+,27?/m1/s1",methylsulfinylhexyl-glucosinolate,KNApSAcK accession,C00007348
6506,136957,raphanusamic acid,"A thiazolidinemonocarboxylic acid that is 2-thioxo-1,3-thiazolidine with the carboxy group located at position 4 (the R-enantiomer).","InChI=1S/C4H5NO2S2/c6-3(7)2-1-9-4(8)5-2/h2H,1H2,(H,5,8)(H,6,7)/t2-/m0/s1",(4R)-2-thioxo-4-thiazolidinecarboxylic acid,Chemspider accession,2299167
6507,136987,N-[(2S)-2-amino-2-carboxyethyl]-L-glutamic acid,An L-glutamic acid derivative obtained by replacement of one of the amino hydrogens of L-glutamic acid has been replaced by a (2S)-2-amino-2-carboxyethyl group.,"InChI=1S/C8H14N2O6/c9-4(7(13)14)3-10-5(8(15)16)1-2-6(11)12/h4-5,10H,1-3,9H2,(H,11,12)(H,13,14)(H,15,16)/t4-,5-/m0/s1",N-[(2S)-2-amino-2-carboxyethyl]glutamic acid,PDBeChem accession,AE5
6508,136994,"2-(glutathion-S-yl)-1,4-hydroquinone","A glutathione conjugate in which the thiol hydrogen of glutathione has been replaced by a 2,5-dihydroxyphenyl group.","InChI=1S/C16H21N3O8S/c17-9(16(26)27)2-4-13(22)19-10(15(25)18-6-14(23)24)7-28-12-5-8(20)1-3-11(12)21/h1,3,5,9-10,20-21H,2,4,6-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t9-,10-/m0/s1","S-(2,5-dihydroxyphenyl)glutathione",MetaCyc accession,CPD-19760
6509,136995,"3,4-dimethoxyphenylethylamine",An  aromatic ether that is the derivative of 2-phenylethylamine with methoxy substituents at the 3- and 4-positions. It is an alkaloid isolated from the Cactaceae family.,"InChI=1S/C10H15NO2/c1-12-9-4-3-8(5-6-11)7-10(9)13-2/h3-4,7H,5-6,11H2,1-2H3","2-(3,4-Dimethoxy-phenyl)-ethylamine",CAS Registry Number,120-20-7
6510,136996,9-[(9Z)-octadecenoyloxy]octadecanoic acid,A fatty acid ester obtained by formal condensation of the carboxy group of oleic acid with the hydroxy group of 9-hydroxyoctadecanoic acid.,"InChI=1S/C36H68O4/c1-3-5-7-9-11-12-13-14-15-16-17-18-20-25-29-33-36(39)40-34(30-26-22-19-10-8-6-4-2)31-27-23-21-24-28-32-35(37)38/h14-15,34H,3-13,16-33H2,1-2H3,(H,37,38)/b15-14-",9-(oleoyloxy)stearic acid,CAS Registry Number,154086-90-5
6511,137011,resolvin T1,"A docosanoid that is (8E,10Z,14E,16Z,18E)-docosapentaenoic acid carrying three hydroxy substituents at positions 7, 13 and 20.","InChI=1S/C22H34O5/c1-2-19(23)13-7-3-4-8-14-20(24)15-9-5-10-16-21(25)17-11-6-12-18-22(26)27/h3-5,7-10,13-14,16,19-21,23-25H,2,6,11-12,15,17-18H2,1H3,(H,26,27)/b4-3-,9-5-,13-7+,14-8+,16-10+",RvT1,PubMed citation,27704804
6512,137018,resolvin T2,"A docosanoid that is (8Z,10E,14E,16Z,19Z)-docosapentaenoic acid carrying three hydroxy substituents at positions 7, 12 and 13.","InChI=1S/C22H34O5/c1-2-3-4-5-6-7-10-16-20(24)21(25)17-13-12-15-19(23)14-9-8-11-18-22(26)27/h3-4,6-7,10,12-13,15-17,19-21,23-25H,2,5,8-9,11,14,18H2,1H3,(H,26,27)/b4-3-,7-6-,15-12-,16-10+,17-13+","(8Z,10E,14E,16Z,19Z)-7,12,13-trihydroxydocosapentaenoic acid",PubMed citation,27704804
6513,137019,resolvin T3,"A docosanoid that is (9E,11E,14E,16Z,19Z)-docosapentaenoic acid carrying three hydroxy substituents at positions 7, 8 and 13.","InChI=1S/C22H34O5/c1-2-3-4-5-6-7-9-14-19(23)15-12-13-17-21(25)20(24)16-10-8-11-18-22(26)27/h3-4,6-7,9,12-15,17,19-21,23-25H,2,5,8,10-11,16,18H2,1H3,(H,26,27)/b4-3-,7-6-,14-9+,15-12+,17-13+","(9E,11E,14E,16Z,19Z)-7,8,13-trihydroxydocosapentaenoic acid",PubMed citation,27704804
6514,137021,"5(S),6(S)-epoxy-18(S)-hydroxy-(7E,9E,11Z,14Z,16E)-icosapentaenoic acid","A 5(),6(S)-epoxy-18-hydroxy-(7E,9E,11Z,14Z,16E)-icosapentaenoic acid in which the 18-hydroxy group has S-configuration.","InChI=1S/C20H28O4/c1-2-17(21)13-10-8-6-4-3-5-7-9-11-14-18-19(24-18)15-12-16-20(22)23/h3,5-11,13-14,17-19,21H,2,4,12,15-16H2,1H3,(H,22,23)/b5-3-,8-6-,9-7+,13-10+,14-11+/t17-,18-,19-/m0/s1","18(S)-hydroxy-5(S),6(S)-EpEPE",PubMed citation,21206090
6515,137034,(18S)-resolvin E2,"A member of the class of resolvins that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid carrying two hydroxy substituents at positions 5 and 18 (the 5S,18S stereoisomer).","InChI=1S/C20H30O4/c1-2-18(21)14-11-9-7-5-3-4-6-8-10-12-15-19(22)16-13-17-20(23)24/h3-4,7-12,14-15,18-19,21-22H,2,5-6,13,16-17H2,1H3,(H,23,24)/b4-3-,9-7-,10-8-,14-11+,15-12+/t18-,19+/m0/s1","(5S,6E,8Z,11Z,14Z,16E,18S)-5,18-dihydroxyicosapentaenoic acid",LIPID MAPS instance accession,LMFA03070036
6516,137045,Z-Val-Ala-Asp(OMe)-CH2F,A tripeptide consisting of Z-Val-Ala-Asp(OMe) in which the C-terminal OH group has been replaced by a fluoromethyl group. An irreversible pan-caspase inhibitor.,"InChI=1S/C22H30FN3O7/c1-13(2)19(26-22(31)33-12-15-8-6-5-7-9-15)21(30)24-14(3)20(29)25-16(17(27)11-23)10-18(28)32-4/h5-9,13-14,16,19H,10-12H2,1-4H3,(H,24,30)(H,25,29)(H,26,31)/t14-,16-,19-/m0/s1",pan-caspase inhibitor,CAS Registry Number,187389-52-2
6517,137063,"cholestanol 7alpha,8alpha-epoxide","A cholestanoid that is lathosterol in which the double bond at position 7,8 has been oxidised to the corresponding epoxide (the 7alpha,8alpha stereoisomer).","InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-26(21,5)14-12-23-25(4)13-11-20(28)15-19(25)16-24-27(22,23)29-24/h17-24,28H,6-16H2,1-5H3/t18-,19-,20+,21-,22-,23-,24-,25+,26-,27+/m1/s1","7alpha,8alpha-epoxy-cholestanol",Reaxys Registry Number,5964874
6518,137064,LY-2157299,"A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma.","InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)",LY2157299,PubMed citation,28451833
6519,137074,beta-D-GlcA3S-(1->3)-beta-D-Gal-OC6H4-4-[CH2]2NHC(O)[CH2]3SH,A beta-D-galactoside that is the 4-[2-(4-sulfanylbutanamido)ethyl]phenyl glycoside of a disaccharide consisting of a 3-O-sulfo-beta-D-glucuronic acid residue linked (1->3) to beta-D-galactose.,"InChI=1S/C24H35NO16S2/c26-10-13-15(28)19(39-24-18(31)20(41-43(34,35)36)16(29)21(40-24)22(32)33)17(30)23(38-13)37-12-5-3-11(4-6-12)7-8-25-14(27)2-1-9-42/h3-6,13,15-21,23-24,26,28-31,42H,1-2,7-10H2,(H,25,27)(H,32,33)(H,34,35,36)/t13-,15+,16+,17-,18-,19+,20+,21+,23-,24-/m1/s1",4-[2-(4-sulfanylbutanamido)ethyl]phenyl 3-O-sulfo-beta-D-glucuronosyl-(1->3)-beta-D-galactoside,PubMed citation,28416698
6520,137075,beta-D-GlcA3S-(1->3)-beta-D-Gal-OC6H4-4-[CH2]2NHC(O)[CH2]3SH(2-),"The carbohydrate acid derivative anion formed from beta-D-GlcA3S-(1->3)-beta-D-Gal-OC6H4-4-[CH2]2NHC(O)[CH2]3SH by loss of two protons, one from each of its sulfo and carboxy groups.","InChI=1S/C24H35NO16S2/c26-10-13-15(28)19(39-24-18(31)20(41-43(34,35)36)16(29)21(40-24)22(32)33)17(30)23(38-13)37-12-5-3-11(4-6-12)7-8-25-14(27)2-1-9-42/h3-6,13,15-21,23-24,26,28-31,42H,1-2,7-10H2,(H,25,27)(H,32,33)(H,34,35,36)/p-2/t13-,15+,16+,17-,18-,19+,20+,21+,23-,24-/m1/s1",beta-D-GlcpA3S-(1->3)-beta-D-Galp-OC6H4-4-[CH2]2NHC(O)[CH2]3SH(2-),PubMed citation,28416698
6521,137081,CORM 3,A ruthenium coordination entity that acts as a water-soluble carbon monoxide-releasing molecule.,"InChI=1S/C2H5NO2.3CO.ClH.Ru/c3-1-2(4)5;3*1-2;;/h1,3H2,(H,4,5);;;;1H;/q;3*+1;;-1/p-2",Carbon monoxide releasing molecule 3,PubMed citation,28583551
6522,137082,12-[(9Z)-octadecenoyloxy]octadecanoic acid,A fatty acid ester obtained by formal condensation of the carboxy group of oleic acid with the hydroxy group of 12-hydroxyoctadecanoic acid.,"InChI=1S/C36H68O4/c1-3-5-7-9-10-11-12-13-14-15-16-17-22-25-29-33-36(39)40-34(30-26-8-6-4-2)31-27-23-20-18-19-21-24-28-32-35(37)38/h13-14,34H,3-12,15-33H2,1-2H3,(H,37,38)/b14-13-",oleoyl-12-hydroxystearate ester,LIPID MAPS instance accession,LMFA07011064
6523,137083,13-[(9Z)-octadecenoyloxy]octadecanoic acid,A fatty acid ester obtained by formal condensation of the carboxy group of oleic acid with the hydroxy group of 13-hydroxyoctadecanoic acid.,"InChI=1S/C36H68O4/c1-3-5-7-8-9-10-11-12-13-14-15-19-22-25-29-33-36(39)40-34(30-26-6-4-2)31-27-23-20-17-16-18-21-24-28-32-35(37)38/h12-13,34H,3-11,14-33H2,1-2H3,(H,37,38)/b13-12-",oleoyl-13-hydroxystearate ester,LIPID MAPS instance accession,LMFA07011065
6524,137084,9-[(9Z)-hexadecenoyloxy]octadecanoic acid,A fatty acid ester obtained by formal condensation of the carboxy group of (9Z)-hexadecenoic acid with the hydroxy group of 9-hydroxyoctadecanoic acid.,"InChI=1S/C34H64O4/c1-3-5-7-9-11-12-13-14-15-16-18-23-27-31-34(37)38-32(28-24-20-17-10-8-6-4-2)29-25-21-19-22-26-30-33(35)36/h12-13,32H,3-11,14-31H2,1-2H3,(H,35,36)/b13-12-",9-(palmitoleoyloxy)stearic acid,LIPID MAPS instance accession,LMFA07011053
6525,137086,13-[(9Z)-hexadecenoyloxy]octadecanoic acid,A fatty acid ester obtained by formal condensation of the carboxy group of (9Z)-hexadecenoic acid with the hydroxy group of 13-hydroxyoctadecanoic acid.,"InChI=1S/C34H64O4/c1-3-5-7-8-9-10-11-12-13-17-20-23-27-31-34(37)38-32(28-24-6-4-2)29-25-21-18-15-14-16-19-22-26-30-33(35)36/h10-11,32H,3-9,12-31H2,1-2H3,(H,35,36)/b11-10-",13-(palmitoleoyloxy)stearic acid,PubMed citation,27509211
6526,137090,Na2[beta-D-GlcA3S-(1->3)-beta-D-Gal-OMe],An organic sodium salt that is the disodium salt of beta-D-GlcA3S-(1->3)-beta-D-Gal-OMe.,"InChI=1S/C13H22O15S.2Na/c1-24-12-6(17)8(4(15)3(2-14)25-12)26-13-7(18)9(28-29(21,22)23)5(16)10(27-13)11(19)20;;/h3-10,12-18H,2H2,1H3,(H,19,20)(H,21,22,23);;/q;2*+1/p-2/t3-,4+,5+,6-,7-,8+,9+,10+,12-,13-;;/m1../s1","methyl (3-O-sulfo-beta-D-glucopyranosyluronate)-(1->3)-beta-D-galactopyranoside, disodium salt",PubMed citation,28416698
6527,137091,13-(octadecanoyloxy)octadecanoic acid,A fatty acid ester obtained by formal condensation of the carboxy group of octadecanoic acid with the hydroxy group of 13-hydroxyoctadecanoic acid.,"InChI=1S/C36H70O4/c1-3-5-7-8-9-10-11-12-13-14-15-19-22-25-29-33-36(39)40-34(30-26-6-4-2)31-27-23-20-17-16-18-21-24-28-32-35(37)38/h34H,3-33H2,1-2H3,(H,37,38)",13-(stearoyloxy)stearic acid,LIPID MAPS instance accession,LMFA07011049
6528,137106,5-[(9Z)-octadecenoyloxy]octadecanoic acid,A fatty acid ester obtained by formal condensation of the carboxy group of (9Z)-octadecenoic acid with the hydroxy group of 5-hydroxyoctadecanoic acid.,"InChI=1S/C36H68O4/c1-3-5-7-9-11-13-15-16-17-18-20-22-24-26-28-33-36(39)40-34(31-29-32-35(37)38)30-27-25-23-21-19-14-12-10-8-6-4-2/h16-17,34H,3-15,18-33H2,1-2H3,(H,37,38)/b17-16-",5-(oleoyloxy)stearic acid,LIPID MAPS instance accession,LMFA07011058
6529,137125,myristamide,A fatty amide of myristic acid.,"InChI=1S/C14H29NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16/h2-13H2,1H3,(H2,15,16)",myristic amide,CAS Registry Number,638-58-4
6530,137165,(S)-6-acetamido-3-aminohexanoic acid zwitterion,A 6-acetamido-3-aminohexanoic acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of (3S)-6-acetamido-3-aminohexanoic acid; major species at pH 7.3.,"InChI=1S/C8H16N2O3/c1-6(11)10-4-2-3-7(9)5-8(12)13/h7H,2-5,9H2,1H3,(H,10,11)(H,12,13)/t7-/m0/s1",N(6)-acetyl-beta-L-lysine,MetaCyc accession,CPD-19847
6531,137174,alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFoO[CH2]5CO2Me,A glycoside that consists of three N-formyl-alpha-D-perosamine residues linked sequentially (1->3) and (1->2) and linked at the reducing end glycosidically to a 5-(methoxycarbonyl)pentyl group.,"InChI=1S/C28H47N3O15/c1-13-17(29-10-32)20(36)22(38)26(42-13)45-24-19(31-12-34)15(3)43-27(23(24)39)46-25-21(37)18(30-11-33)14(2)44-28(25)41-9-7-5-6-8-16(35)40-4/h10-15,17-28,36-39H,5-9H2,1-4H3,(H,29,32)(H,30,33)(H,31,34)/t13-,14-,15-,17-,18-,19-,20+,21+,22+,23+,24+,25+,26-,27-,28+/m1/s1",methyl 6-{[N-formyl-alpha-D-perosaminyl-(1->3)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl]oxy}hexanoate,PubMed citation,25263136
6532,137175,alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFoO[CH2]5CO2Me,A glycoside that consists of two N-formyl-alpha-D-perosamine residues linked (1->3) and linked at the reducing end glycosidically to a 5-(methoxycarbonyl)pentyl group.,"InChI=1S/C21H36N2O11/c1-11-14(22-9-24)16(27)17(28)21(33-11)34-19-15(23-10-25)12(2)32-20(18(19)29)31-8-6-4-5-7-13(26)30-3/h9-12,14-21,27-29H,4-8H2,1-3H3,(H,22,24)(H,23,25)/t11-,12-,14-,15-,16+,17+,18+,19+,20+,21-/m1/s1",alpha-D-Rha4NFo-(1->3)-alpha-D-Rha4NFoO[CH2]5CO2Me,PubMed citation,28338626
6533,137183,"(4Z,7Z,10Z,13Z,16Z,19S,20R)-19,20-epoxydocosapentaenoic acid","A (4Z,7Z,10Z,13Z,16Z)-19,20-epoxydocosapentaenoic acid with (19S,20R)-configuration.","InChI=1S/C22H32O3/c1-2-20-21(25-20)18-16-14-12-10-8-6-4-3-5-7-9-11-13-15-17-19-22(23)24/h3-4,7-10,13-16,20-21H,2,5-6,11-12,17-19H2,1H3,(H,23,24)/b4-3-,9-7-,10-8-,15-13-,16-14-/t20-,21+/m1/s1","(19S,20R)-epoxy-(4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid",Reaxys Registry Number,8580825
6534,137184,alpha-D-Rhap2Me4NFo-(1->3)-alpha-D-Rhap4NFoO[CH2]5CO2Me,A glycoside that consists of an N-formyl-2-O-methyl-alpha-D-perosamine residue linked (1->3) to an N-formyl-alpha-D-perosamine residue which is linked glycosidically to a 5-(methoxycarbonyl)pentyl group.,"InChI=1S/C22H38N2O11/c1-12-15(23-10-25)17(28)20(31-4)22(34-12)35-19-16(24-11-26)13(2)33-21(18(19)29)32-9-7-5-6-8-14(27)30-3/h10-13,15-22,28-29H,5-9H2,1-4H3,(H,23,25)(H,24,26)/t12-,13-,15-,16-,17+,18+,19+,20+,21+,22-/m1/s1",5-methoxycarbonylpentyl N-formyl-2-O-methyl-alpha-D-perosaminyl-(1->3)-N-formyl-alpha-D-perosaminide,PubMed citation,28317992
6535,137193,"(5Z,11Z,14Z,17Z)-8,9-epoxyicosatetraenoic acid","An EpETE obtained by formal epoxidation of the 8,9-double bond of all-cis-5,8,11,14,17-icosapentaenoic acid.","InChI=1S/C20H30O3/c1-2-3-4-5-6-7-8-9-12-15-18-19(23-18)16-13-10-11-14-17-20(21)22/h3-4,6-7,9-10,12-13,18-19H,2,5,8,11,14-17H2,1H3,(H,21,22)/b4-3-,7-6-,12-9-,13-10-","8,9-epoxy-(5Z,11Z,14Z,17Z)-icosatetraenoic acid",Reaxys Registry Number,14580554
6536,137200,alpha-D-Manp-(1->2)-alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFoO[CH2]5CO2Me,"A glycoside that consists of an alpha-D-mannose residue and three N-formyl-alpha-D-perosamine residues linked sequentially (1->2), (1->3) and (1->2) and linked at the reducing end glycosidically to a 5-(methoxycarbonyl)pentyl group.","InChI=1S/C34H57N3O20/c1-14-19(35-11-39)23(44)29(33(52-14)50-9-7-5-6-8-18(42)49-4)56-32-27(48)28(21(37-13-41)16(3)51-32)55-34-30(24(45)20(36-12-40)15(2)53-34)57-31-26(47)25(46)22(43)17(10-38)54-31/h11-17,19-34,38,43-48H,5-10H2,1-4H3,(H,35,39)(H,36,40)(H,37,41)/t14-,15-,16-,17-,19-,20-,21-,22-,23+,24+,25+,26+,27+,28+,29+,30+,31-,32-,33+,34-/m1/s1",methyl 6-{[alpha-D-mannosyl-(1->2)-N-formyl-alpha-D-perosaminyl-(1->3)-N-formyl-alpha-D-perosaminyl-(1->2)-N-formyl-alpha-D-perosaminyl]oxy}hexanoate,PubMed citation,28317992
6537,137205,alpha-D-Rhap4[CH2]5NH2-(1->2)-alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFoOMe,"A methyl glycoside that consists of a 4-O-(5-aminopentyl)-alpha-D-mannose residue and three N-formyl-alpha-D-perosamine residues linked sequentially (1->2), (1->3) and (1->2) and linked at the reducing end glycosidically to a methyl group.","InChI=1S/C33H58N4O17/c1-14-18(35-11-38)21(41)28(32(46-5)49-14)53-31-25(45)27(20(37-13-40)16(3)48-31)52-33-29(22(42)19(36-12-39)15(2)50-33)54-30-24(44)23(43)26(17(4)51-30)47-10-8-6-7-9-34/h11-33,41-45H,6-10,34H2,1-5H3,(H,35,38)(H,36,39)(H,37,40)/t14-,15-,16-,17-,18-,19-,20-,21+,22+,23-,24+,25+,26-,27+,28+,29+,30-,31-,32+,33-/m1/s1","methyl 4-O-(5-aminopentyl)-6-deoxy-alpha-D-mannosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannosyl-(1->3)-4,6-dideoxy-4-formamido-alpha-D-mannosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannoside",PubMed citation,28317992
6538,137211,(E)-2-(indol-3-yl)-1-thioacetohydroximic acid,A thiohydroximic acid in which the C-substituent is specified as (3-indolyl)methyl (the E-geoisomer).,"InChI=1S/C10H10N2OS/c13-12-10(14)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11,13H,5H2,(H,12,14)",(E)-2-(1H-indol-3-yl)-1-thioacetohydroximic acid,MetaCyc accession,CPD-1861
6539,137267,"(5Z,8Z,14Z,17Z)-11,12-epoxyicosatetraenoic acid","An EpETE obtained by formal epoxidation of the 11,12-double bond of all-cis-5,8,11,14,17-icosapentaenoic acid.","InChI=1S/C20H30O3/c1-2-3-4-5-9-12-15-18-19(23-18)16-13-10-7-6-8-11-14-17-20(21)22/h3-4,6,8-10,12-13,18-19H,2,5,7,11,14-17H2,1H3,(H,21,22)/b4-3-,8-6-,12-9-,13-10-","11,12-epoxy-(5Z,8Z,14Z,17Z)-eicosatetraenoic acid",Reaxys Registry Number,10370992
6540,137281,(Z)-1-(glutathione-S-yl)-2-phenylacetohydroximate,A glutathione conjugate in which the mercapto hydrogen of glutathione has been replaced by an N-hydroxy-2-phenylethanimidoyl group.,"InChI=1S/C18H24N4O7S/c19-12(18(27)28)6-7-14(23)21-13(17(26)20-9-16(24)25)10-30-15(22-29)8-11-4-2-1-3-5-11/h1-5,12-13,29H,6-10,19H2,(H,20,26)(H,21,23)(H,24,25)(H,27,28)/b22-15-/t12-,13-/m0/s1",S-[(Z)-N-hydroxy(4-hydroxyphenyl)acetimidoyl]glutathione,MetaCyc accession,CPD-12384
6541,137305,"(9Z,12Z)-11-hydroxyoctadecadienoic acid",A HODE that is linoleic acid carrying a single hydroxy substituent at position 11.,"InChI=1S/C18H32O3/c1-2-3-4-8-11-14-17(19)15-12-9-6-5-7-10-13-16-18(20)21/h11-12,14-15,17,19H,2-10,13,16H2,1H3,(H,20,21)/b14-11-,15-12-",11-HODE,CAS Registry Number,143288-68-0
6542,137340,8-demethyl-8-(methylamino)riboflavin,A benzopteridine that is riboflavin in which the methyl group at position 8 has been replaced by a methylamino group.,"InChI=1S/C17H21N5O6/c1-7-3-9-10(4-8(7)18-2)22(5-11(24)14(26)12(25)6-23)15-13(19-9)16(27)21-17(28)20-15/h3-4,11-12,14,18,23-26H,5-6H2,1-2H3,(H,21,27,28)/t11-,12+,14-/m0/s1",8-demethyl-8-methylaminoriboflavin,CAS Registry Number,62746-55-8
6543,137344,7-HETE,A HETE that is arachidonic acid carrying a hydroxy substituent at position 7.,"InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-13-16-19(21)17-14-12-15-18-20(22)23/h6-7,9-10,13-14,16-17,19,21H,2-5,8,11-12,15,18H2,1H3,(H,22,23)/b7-6-,10-9-,16-13-,17-14-","7-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid",Reaxys Registry Number,24193914
6544,137345,13-HETE,A HETE that is arachidonic acid carrying a hydroxy substituent at position 13.,"InChI=1S/C20H32O3/c1-2-3-4-10-13-16-19(21)17-14-11-8-6-5-7-9-12-15-18-20(22)23/h6-9,13-14,16-17,19,21H,2-5,10-12,15,18H2,1H3,(H,22,23)/b8-6-,9-7-,16-13-,17-14-","13-hydroxy-(5Z,8Z,11Z,14Z)-icosatetraenoic acid",HMDB accession,HMDB0012567
6545,137359,5-methoxysalicylaldehyde,A member of the class of benzaldehydes carrying hydroxy and methoxy substituents at positions 2 and 5 respectively.,"InChI=1S/C8H8O3/c1-11-7-2-3-8(10)6(4-7)5-9/h2-5,10H,1H3",2-formyl-4-methoxyphenol,Beilstein Registry Number,1100532
6546,137365,"2,4-diaminopteridine-6-carbaldehyde","A member of the class of pteridines that is pteridine in which the hydrogens at positions 2 and 4 are replaced by amino groups, whilst that at position 6 is replaced by a carbaldehyde group.","InChI=1S/C7H6N6O/c8-5-4-6(13-7(9)12-5)10-1-3(2-14)11-4/h1-2H,(H4,8,9,10,12,13)","2,4-diamino-6-pteridinecarboxaldehyde",CAS Registry Number,4261-17-0
6547,137370,20-hydroxyprostaglandin E2,A prostaglandin E derivative that is prostaglandin E2 in which one of the methyl hydrogens at position 20 has been replaced by a hydroxy group.,"InChI=1S/C20H32O6/c21-13-7-3-4-8-15(22)11-12-17-16(18(23)14-19(17)24)9-5-1-2-6-10-20(25)26/h1,5,11-12,15-17,19,21-22,24H,2-4,6-10,13-14H2,(H,25,26)/b5-1-,12-11+/t15-,16+,17+,19+/m0/s1",20-hydroxy prostaglandin E2,LIPID MAPS instance accession,LMFA03010014
6548,137371,5-formylsalicylic acid,A monohydroxybenzoic acid in which a benzoic acid nucleus is substituted at positions 2 and 5 by a formyl group and an hydroxy group  respectively.,"InChI=1S/C8H6O4/c9-4-5-1-2-7(10)6(3-5)8(11)12/h1-4,10H,(H,11,12)",2-hydroxy-5-formylbenzoic acid,CAS Registry Number,616-76-2
6549,137372,"pyridinium-3,5-bisthiocarboxylate mononucleotide(3-)","An organophosphate oxoanion obtained by deprotonation of the carboxy and phosphate OH groups of pyridinium-3,5-bisthiocarboxylic acid mononucleotide; major species at pH 7.3.","InChI=1S/C12H14NO9PS2/c14-8-7(4-21-23(18,19)20)22-10(9(8)15)13-2-5(11(16)24)1-6(3-13)12(17)25/h1-3,7-10,14-15H,4H2,(H3-,16,17,18,19,20,24,25)/p-3/t7-,8-,9-,10-/m1/s1",P2TMN,PubMed citation,26138974
6550,137395,"pyridinium-3,5-biscarboxylic acid mononucleotide","A pyridine nucleotide having 3,5-dicarboxypyridine as the nucleobase.","InChI=1S/C12H14NO11P/c14-8-7(4-23-25(20,21)22)24-10(9(8)15)13-2-5(11(16)17)1-6(3-13)12(18)19/h1-3,7-10,14-15H,4H2,(H3-,16,17,18,19,20,21,22)/p+1/t7-,8-,9-,10-/m1/s1",P2CMN,PubMed citation,27114550
6551,137396,5-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium-3-carbonyl adenylate,"An acyclic mixed acid anhydride obtained by condensation of one of the carboxy group of pyridinium-3,5-biscarboxylic acid mononucleotide with the phosphste group of AMP.","InChI=1S/C22H26N6O17P2/c23-17-12-18(25-6-24-17)28(7-26-12)20-16(32)14(30)11(44-20)5-42-47(39,40)45-22(35)9-1-8(21(33)34)2-27(3-9)19-15(31)13(29)10(43-19)4-41-46(36,37)38/h1-3,6-7,10-11,13-16,19-20,29-32H,4-5H2,(H5-,23,24,25,33,34,36,37,38,39,40)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1",P2CMN-adenylate,PubMed citation,27114550
6552,137397,1-(5-O-phosphono-beta-D-ribofuranosyl)-5-(sulfanylcarbonyl)pyridinium-3-carbonyl adenylate,An acyclic mixed acid anhydride obtained by condensation of one of the carboxy group of pyridinium-3-sulfanylcarbonyl-5-carboxylic acid mononucleotide with the phosphste group of AMP.,"InChI=1S/C22H26N6O16P2S/c23-17-12-18(25-6-24-17)28(7-26-12)20-16(32)14(30)11(43-20)5-41-46(38,39)44-21(33)8-1-9(22(34)47)3-27(2-8)19-15(31)13(29)10(42-19)4-40-45(35,36)37/h1-3,6-7,10-11,13-16,19-20,29-32H,4-5H2,(H5-,23,24,25,34,35,36,37,38,39,47)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1",PCTMN-adenylate,PubMed citation,27114550
6553,137398,"pyridinium-3,5-bisthiocarboxylic acid mononucleotide","A pyridine nucleotide having pyridinium-3,5-bisthiocarboxylic acid as the nucleobase.","InChI=1S/C12H14NO9PS2/c14-8-7(4-21-23(18,19)20)22-10(9(8)15)13-2-5(11(16)24)1-6(3-13)12(17)25/h1-3,7-10,14-15H,4H2,(H3-,16,17,18,19,20,24,25)/p+1/t7-,8-,9-,10-/m1/s1",P2TMN,PDBeChem accession,4EY
6554,137399,"Ni(II)-pyridinium-3,5-bisthiocarboxylic acid mononucleotide","A nickel coordination entity obtained by complexation of nickel(II) with pyridinium-3,5-bisthiocarboxylic acid mononucleotide.","InChI=1S/C12H13NO9PS2.Ni/c14-8-7(4-21-23(18,19)20)22-10(9(8)15)13-2-5(11(16)24)1-6(3-13)12(17)25;/h2-3,7-10,14-15H,4H2,(H3-,16,17,18,19,20,24,25);/q;+1/t7-,8-,9-,10-;/m1./s1","Ni(2+)-pyridinium-3,5-bisthiocarboxylate mononucleotide",PubMed citation,27114550
6555,137432,methyl beta-(acetylthio)isobutyrate,A methyl ester derived from beta-(acetylthio)isobutyric acid.,"InChI=1S/C7H12O3S/c1-5(7(9)10-3)4-11-6(2)8/h5H,4H2,1-3H3",DL-MATI,CAS Registry Number,97101-46-7
6556,137433,(R)-3-(acetylthio)isobutyric acid,A monocarboxylic acid that is isobutyric acid in which a hydrogen of one of the methyl groups has been replaced by an acetylthio group (the R enantiomer). It is an important intermediate for the preparation of various angiotensin-converting enzyme inhibitors such as captopril and alacepril.,"InChI=1S/C6H10O3S/c1-4(6(8)9)3-10-5(2)7/h4H,3H2,1-2H3,(H,8,9)/t4-/m0/s1",DAT,CAS Registry Number,74431-52-0
6557,137445,11-oxo-ETE-CoA,A 3-oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 11-oxo-ETE.,"InChI=1S/C41H64N7O18P3S/c1-4-5-6-7-9-12-15-18-29(49)19-16-13-10-8-11-14-17-20-32(51)70-24-23-43-31(50)21-22-44-39(54)36(53)41(2,3)26-63-69(60,61)66-68(58,59)62-25-30-35(65-67(55,56)57)34(52)40(64-30)48-28-47-33-37(42)45-27-46-38(33)48/h8-9,11-13,15-16,18,27-28,30,34-36,40,52-53H,4-7,10,14,17,19-26H2,1-3H3,(H,43,50)(H,44,54)(H,58,59)(H,60,61)(H2,42,45,46)(H2,55,56,57)/b11-8-,12-9-,16-13-,18-15+/t30-,34-,35-,36+,40-/m1/s1","(5Z,8Z,12E,14Z)-11-oxoicosatetraenoyl-CoA",PubMed citation,28238887
6558,137446,15-oxo-ETE-CoA,An oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 15-oxo-ETE.,"InChI=1S/C41H64N7O18P3S/c1-4-5-15-18-29(49)19-16-13-11-9-7-6-8-10-12-14-17-20-32(51)70-24-23-43-31(50)21-22-44-39(54)36(53)41(2,3)26-63-69(60,61)66-68(58,59)62-25-30-35(65-67(55,56)57)34(52)40(64-30)48-28-47-33-37(42)45-27-46-38(33)48/h6-7,10-13,16,19,27-28,30,34-36,40,52-53H,4-5,8-9,14-15,17-18,20-26H2,1-3H3,(H,43,50)(H,44,54)(H,58,59)(H,60,61)(H2,42,45,46)(H2,55,56,57)/b7-6-,12-10-,13-11-,19-16+/t30-,34-,35-,36+,40-/m1/s1","(5Z,8Z,11Z,13E)-15-oxoicosatetraenoyl-CoA",PubMed citation,28238887
6559,137455,(R)-2-hydroxy-3-oxo-4-(phosphonooxy)butanoic acid,The ketoaldonic acid phosphate formed formally from D-erythronic acid by oxidation of the 3-hydroxy group to an oxo group and phosphorylation at the 1-hydroxy group.,"InChI=1S/C4H7O8P/c5-2(3(6)4(7)8)1-12-13(9,10)11/h3,6H,1H2,(H,7,8)(H2,9,10,11)/t3-/m1/s1",3-dehydro-4-phospho-D-erythronic acid,MetaCyc accession,CPD-19880
6560,137456,"(S)-3,4-dihydroxy-2-oxobutanoic acid",A  ketoaldonic acid that is butyric acid carrying an oxo substituent at position 2 as well as two hydroxy substituents at positions 3 and 4 (the S-enantiomer).,"InChI=1S/C4H6O5/c5-1-2(6)3(7)4(8)9/h2,5-6H,1H2,(H,8,9)/t2-/m0/s1",2-dehydro-L-erythronic acid,MetaCyc accession,CPD-19882
6561,137470,optovin,"A member of the class of thiazolidinone that is rhodanine in which the two methylene hydrogens have been replaced by a 2,5-dimethyl-1-(pyridin-3-yl)-1H-pyrrol-3-yl]methylidene group. A TRPA1 ligand that can be reversibly photoactivated.","InChI=1S/C15H13N3OS2/c1-9-6-11(7-13-14(19)17-15(20)21-13)10(2)18(9)12-4-3-5-16-8-12/h3-8H,1-2H3,(H,17,19,20)/b13-7+","5-[[2,5-dimethyl-1-(3-pyridinyl)-1H-pyrrol-3-yl]methylene]-2-thioxo-4-thiazolidinone",PubMed citation,28424320
6562,137471,"tetrahydroxy-1,4-benzoquinone hydrate","The hydrate of tetrahydroxy-1,4-benzoquinone. The number of water molecules of crystallization (n) is variable, although most commonly the dihydrate (shown in the diagram) is formed in the solid phase.","InChI=1S/C6H4O6.2H2O/c7-1-2(8)4(10)6(12)5(11)3(1)9;;/h7-8,11-12H;2*1H2","2,3,5,6-tetrahydroxy-2,5-cyclohexadiene-1,4-dione hydrate",CAS Registry Number,123334-16-7
6563,137486,"(R)-3,4-dihydroxy-2-oxobutanoic acid",A ketoaldonic acid that is butyric acid carrying an oxo substituent at position 2 as well as two hydroxy substituents at positions 3 and 4 (the R-enantiomer).,"InChI=1S/C4H6O5/c5-1-2(6)3(7)4(8)9/h2,5-6H,1H2,(H,8,9)/t2-/m1/s1",2-dehydro-D-erythronic acid,MetaCyc accession,CPD-19883
6564,137497,7-oxoresolvin D2(1-),"A docosanoid anion that is the conjugate base of 7-oxoresolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C22H30O5/c1-2-3-9-16-20(24)21(25)17-12-7-5-4-6-10-14-19(23)15-11-8-13-18-22(26)27/h3-12,14,17,20-21,24-25H,2,13,15-16,18H2,1H3,(H,26,27)/p-1/b6-4-,7-5+,9-3-,11-8-,14-10+,17-12+/t20-,21+/m0/s1","(16R,17S)-dihydroxy-7-oxo-(4Z,8E,10Z,12E,14E,19Z)-docosahexaenoate",PubMed citation,22844113
6565,137498,16-oxoresolvin D2(1-),"A docosanoid anion that is the conjugate base of 16-oxoresolvin D2, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C22H30O5/c1-2-3-9-16-20(24)21(25)17-12-7-5-4-6-10-14-19(23)15-11-8-13-18-22(26)27/h3-12,14,17,19-20,23-24H,2,13,15-16,18H2,1H3,(H,26,27)/p-1/b6-4-,7-5+,9-3-,11-8-,14-10+,17-12+/t19-,20+/m1/s1","(7S,17S)-dihydroxy-16-oxo-(4Z,8E,10Z,12E,14E,19Z)-docosahexaenoate",PubMed citation,22844113
6566,137502,"(S)-2,4-dihydroxy-3-oxobutanoic acid",A ketoaldonic acid that is butyric acid carrying an oxo substituent at position 3 as well as two hydroxy substituents at positions 2 and 4 (the S-enantiomer).,"InChI=1S/C4H6O5/c5-1-2(6)3(7)4(8)9/h3,5,7H,1H2,(H,8,9)/t3-/m0/s1",3-dehydro-L-erythronic acid,MetaCyc accession,CPD-19884
6567,137521,"(2Z,10Z)-3-hydroxy-5,17-dioxo-4,5-secoestra-2,10-diene-3-oate","A steroid acid anion that is the conjugate base of (2Z,10Z)-3-hydroxy-5,17-dioxo-4,5-secoestra-2,10-diene-3-oic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3. A meta-cleavage  metabolite in the estrogen degradation pathway.","InChI=1S/C18H22O5/c1-18-9-8-10-11(13(18)4-7-16(18)21)2-5-14(19)12(10)3-6-15(20)17(22)23/h3,6,10-11,13,20H,2,4-5,7-9H2,1H3,(H,22,23)/p-1/b12-3-,15-6-/t10-,11+,13-,18-/m0/s1","(2Z,10Z)-4,5-secoestra-2-10-diene-3-ol-5,17-dione-3-oate",PubMed citation,28552583
6568,137526,20-hydroxyprostaglandin E1,A prostaglandin E derivative that is prostaglandin E1 in which one of the methyl hydrogens at position 20 has been replaced by a hydroxy group.,"InChI=1S/C20H34O6/c21-13-7-3-4-8-15(22)11-12-17-16(18(23)14-19(17)24)9-5-1-2-6-10-20(25)26/h11-12,15-17,19,21-22,24H,1-10,13-14H2,(H,25,26)/b12-11+/t15-,16+,17+,19+/m0/s1",20-hydroxy-PGE1,CAS Registry Number,57930-99-1
6569,137529,20-hydroxyprostaglandin A1,A prostaglandin A derivative that is prostaglandin A1 in which one of the methyl hydrogens at position 20 has been replaced by a hydroxy group.,"InChI=1S/C20H32O5/c21-15-7-3-4-8-17(22)13-11-16-12-14-19(23)18(16)9-5-1-2-6-10-20(24)25/h11-14,16-18,21-22H,1-10,15H2,(H,24,25)/b13-11+/t16-,17-,18+/m0/s1",20-hydroxy-prostaglandin A1,Reaxys Registry Number,24406267
6570,137532,3-oxochenodeoxycholoyl-CoA,A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxochenodeoxycholic acid.,"InChI=1S/C45H72N7O19P3S/c1-24(27-7-8-28-34-29(11-14-45(27,28)5)44(4)13-10-26(53)18-25(44)19-30(34)54)6-9-33(56)75-17-16-47-32(55)12-15-48-41(59)38(58)43(2,3)21-68-74(65,66)71-73(63,64)67-20-31-37(70-72(60,61)62)36(57)42(69-31)52-23-51-35-39(46)49-22-50-40(35)52/h22-25,27-31,34,36-38,42,54,57-58H,6-21H2,1-5H3,(H,47,55)(H,48,59)(H,63,64)(H,65,66)(H2,46,49,50)(H2,60,61,62)/t24-,25+,27-,28+,29+,30-,31-,34+,36-,37-,38+,42-,44+,45-/m1/s1",3-oxo-chenodeoxycholoyl-CoA,PubMed citation,23836456
6571,137534,3-oxocholoyl-CoA,A choloyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxocholic acid.,"InChI=1S/C45H72N7O20P3S/c1-23(26-7-8-27-34-28(18-31(55)45(26,27)5)44(4)12-10-25(53)16-24(44)17-29(34)54)6-9-33(57)76-15-14-47-32(56)11-13-48-41(60)38(59)43(2,3)20-69-75(66,67)72-74(64,65)68-19-30-37(71-73(61,62)63)36(58)42(70-30)52-22-51-35-39(46)49-21-50-40(35)52/h21-24,26-31,34,36-38,42,54-55,58-59H,6-20H2,1-5H3,(H,47,56)(H,48,60)(H,64,65)(H,66,67)(H2,46,49,50)(H2,61,62,63)/t23-,24+,26-,27+,28+,29-,30-,31+,34+,36-,37-,38+,42-,44+,45-/m1/s1",3-oxo-cholyl-CoA,MetaCyc accession,3-OXO-CHOLYL-COA
6572,137537,3-oxodeoxycholoyl-CoA,A choloyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxodeoxycholic acid.,"InChI=1S/C45H72N7O19P3S/c1-24(28-9-10-29-27-8-7-25-18-26(53)12-14-44(25,4)30(27)19-32(54)45(28,29)5)6-11-34(56)75-17-16-47-33(55)13-15-48-41(59)38(58)43(2,3)21-68-74(65,66)71-73(63,64)67-20-31-37(70-72(60,61)62)36(57)42(69-31)52-23-51-35-39(46)49-22-50-40(35)52/h22-25,27-32,36-38,42,54,57-58H,6-21H2,1-5H3,(H,47,55)(H,48,59)(H,63,64)(H,65,66)(H2,46,49,50)(H2,60,61,62)/t24-,25-,27+,28-,29+,30+,31-,32+,36-,37-,38+,42-,44+,45-/m1/s1",3-dehydrodeoxycholoyl-CoA,MetaCyc accession,3-OXO-DEOXYCHOLYL-COA
6573,137539,3-oxocholan-24-oyl-CoA,A choloyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-oxocholan-24-oic acid.,"InChI=1S/C45H72N7O18P3S/c1-25(29-9-10-30-28-8-7-26-20-27(53)12-15-44(26,4)31(28)13-16-45(29,30)5)6-11-34(55)74-19-18-47-33(54)14-17-48-41(58)38(57)43(2,3)22-67-73(64,65)70-72(62,63)66-21-32-37(69-71(59,60)61)36(56)42(68-32)52-24-51-35-39(46)49-23-50-40(35)52/h23-26,28-32,36-38,42,56-57H,6-22H2,1-5H3,(H,47,54)(H,48,58)(H,62,63)(H,64,65)(H2,46,49,50)(H2,59,60,61)/t25-,26-,28+,29-,30+,31+,32-,36-,37-,38+,42-,44+,45-/m1/s1",3-oxo-LC-CoA,MetaCyc accession,CPD-18823
6574,137541,N-propanoyl-L-methionine,An N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of propanoic acid with the amino group of L-methionine.,"InChI=1S/C8H15NO3S/c1-3-7(10)9-6(8(11)12)4-5-13-2/h6H,3-5H2,1-2H3,(H,9,10)(H,11,12)/t6-/m0/s1",N-propionyl-L-methionine,Reaxys Registry Number,31035941
6575,137545,pivaloyl-CoA,A short-chain fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of pivalic acid.,"InChI=1S/C26H44N7O17P3S/c1-25(2,3)24(38)54-9-8-28-15(34)6-7-29-22(37)19(36)26(4,5)11-47-53(44,45)50-52(42,43)46-10-14-18(49-51(39,40)41)17(35)23(48-14)33-13-32-16-20(27)30-12-31-21(16)33/h12-14,17-19,23,35-36H,6-11H2,1-5H3,(H,28,34)(H,29,37)(H,42,43)(H,44,45)(H2,27,30,31)(H2,39,40,41)/t14-,17-,18-,19+,23-/m1/s1","2,2-dimethylpropanoyl-CoA",PDBeChem accession,52O
6576,137553,2-O-[6-O-octanoyl-alpha-D-glucosyl-(1->6)-alpha-D-glucosyl]-D-glyceric acid,A glycoside consisting of D-glyceric acid having a 6-O-octanoyl-alpha-D-glucosyl-(1->6)-alpha-D-glucosyl residue attached at position 2 via a glycosidic linkage.,"InChI=1S/C23H40O15/c1-2-3-4-5-6-7-14(25)34-9-12-15(26)17(28)19(30)22(37-12)35-10-13-16(27)18(29)20(31)23(38-13)36-11(8-24)21(32)33/h11-13,15-20,22-24,26-31H,2-10H2,1H3,(H,32,33)/t11-,12-,13-,15-,16-,17+,18+,19-,20-,22+,23+/m1/s1",6-Oct-DGG,PubMed citation,26324178
6577,137558,2-O-[alpha-D-glucosyl-(1->6)-alpha-D-glucosyl]-D-glyceric acid,A glycoside consisting of D-glyceric acid having an alpha-D-glucosyl-(1->6)-alpha-D-glucosyl residue attached at position 2 via a glycosidic linkage.,"InChI=1S/C15H26O14/c16-1-4-7(18)9(20)11(22)14(27-4)26-3-6-8(19)10(21)12(23)15(29-6)28-5(2-17)13(24)25/h4-12,14-23H,1-3H2,(H,24,25)/t4-,5-,6-,7-,8-,9+,10+,11-,12-,14+,15+/m1/s1",2-O-[alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranosyl]-D-glyceric acid,PubMed citation,26324178
6578,137560,7-glycidyloxy-9-(2-glycidyloxycarbonylphenyl)-2-xanthone,"An epoxide fluorescent probe for use in in vivo visualization of hydrogen sulfide. The probe employs a fluorescein as a fluorophore, and is equipped with an operating epoxide unit. FEPO functions via epoxide ring opening via nucleophilic attack by H2S.","InChI=1S/C26H20O7/c27-15-5-7-21-23(9-15)33-24-10-16(29-11-17-12-30-17)6-8-22(24)25(21)19-3-1-2-4-20(19)26(28)32-14-18-13-31-18/h1-10,17-18H,11-14H2",FEPO,Reaxys Registry Number,8516795
6579,137561,"3-(2,3-dimethoxyphenyl)-1-(9-methyl-2-phenyl-9H-imidazo[1,2-a]benzimidazol-3-yl)prop-2-en-1-one","An organic heterotricyclic compound that is 9H-imidazo[1,2-a]benzimidazole which is substituted at positions 2, 3, and 9 by phenyl, 2,3-dimethoxycinnamoyl, and methyl groups, respectively. It is a potent activator of osteoblast differentiation.","InChI=1S/C27H23N3O3/c1-29-20-13-7-8-14-21(20)30-25(24(28-27(29)30)18-10-5-4-6-11-18)22(31)17-16-19-12-9-15-23(32-2)26(19)33-3/h4-17H,1-3H3",IBIP,PubMed citation,28419840
6580,137658,"3-[(1Z,4R)-4-hydroxycyclohex-2-en-1-ylidene]pyruvic acid","A 3-(4-hydroxycyclohex-2-en-1-ylidene)pyruvic acid having 1Z,4R stereochemistry.","InChI=1S/C9H10O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1,3,5,7,10H,2,4H2,(H,12,13)/b6-5+/t7-/m0/s1","3-[(1Z,4R)-4-hydroxycyclohex-2-en-1-ylidene]-2-oxopropanoic acid",Reaxys Registry Number,22690132
6581,137659,"3-[(1R,4R)-4-hydroxycyclohex-2-en-1-yl]pyruvic acid","A tetrahydro-4-hydroxyphenylpyruvic acid with (1R,4R)-stereochemistry.","InChI=1S/C9H12O4/c10-7-3-1-6(2-4-7)5-8(11)9(12)13/h1,3,6-7,10H,2,4-5H2,(H,12,13)/t6-,7+/m1/s1",4R-H4HPP,PubMed citation,22765234
6582,137676,Cys(IAN)-Gly,An S-conjugate in which the mercapto hydrogen of L-cysteinylglycine has been replaced by a cyano(indol-3-yl)methyl group.,"InChI=1S/C15H16N4O3S/c16-5-13(10-6-18-12-4-2-1-3-9(10)12)23-8-11(17)15(22)19-7-14(20)21/h1-4,6,11,13,18H,7-8,17H2,(H,19,22)(H,20,21)/t11-,13?/m0/s1",L-Cys(IAN)-Gly,MetaCyc accession,CPD-12635
6583,137678,nickel-sirohydrochlorin,A metalloporphyrin that is sirohydrochlorin in which the four nitrogen atoms are bound to a central nickel atom.,"InChI=1S/C42H46N4O16.Ni/c1-41(17-39(59)60)23(5-9-35(51)52)29-14-27-21(11-37(55)56)19(3-7-33(47)48)25(43-27)13-26-20(4-8-34(49)50)22(12-38(57)58)28(44-26)15-31-42(2,18-40(61)62)24(6-10-36(53)54)30(46-31)16-32(41)45-29;/h13-16,23-24H,3-12,17-18H2,1-2H3,(H10,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62);/q;+2/p-2/t23-,24-,41+,42+;/m1./s1",Ni-sirohydrochlorin,KEGG COMPOUND accession,C21510
6584,137688,(25R)-26-hydroxycholestanol,A cholestanoid that is cholestanol which is substituted by a hydroxy group at position 26 and has R-configuration at position 25.,"InChI=1S/C27H48O2/c1-18(17-28)6-5-7-19(2)23-10-11-24-22-9-8-20-16-21(29)12-14-26(20,3)25(22)13-15-27(23,24)4/h18-25,28-29H,5-17H2,1-4H3/t18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1","(25R)-5alpha-cholestan-3beta,26-diol",PubMed citation,28190002
6585,137690,alpha-D-Manp-(1->2)-alpha-D-Rhap4NFo-(1->3)-alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo,"An amino tetrasaccharide consisting of an alpha-D-mannose residue and three N-formyl-alpha-D-perosamine residues linked sequentially (1->2), (1->3) and (1->2).","InChI=1S/C27H45N3O18/c1-8-12(28-5-32)16(36)22(24(41)42-8)47-26-20(40)21(14(30-7-34)10(3)43-26)46-27-23(17(37)13(29-6-33)9(2)44-27)48-25-19(39)18(38)15(35)11(4-31)45-25/h5-27,31,35-41H,4H2,1-3H3,(H,28,32)(H,29,33)(H,30,34)/t8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27-/m1/s1",alpha-D-Man-(1->2)-alpha-D-Rha4NFo-(1->3)-alpha-D-Rha4NFo-(1->2)-alpha-D-Rha4NFo,PubMed citation,28317992
6586,137693,rhosin,"A D-tryptophan derivative obtained by formal condensation of the carboxy group of D-tryptophan with the amino group of (quinoxalin-6-yl)methylidenehydrazide. It directly targets the Rho GEF binding domain, thereby preventing Rho from interacting with its GEFs","InChI=1S/C20H18N6O/c21-16(10-14-12-24-17-4-2-1-3-15(14)17)20(27)26-25-11-13-5-6-18-19(9-13)23-8-7-22-18/h1-9,11-12,16,24H,10,21H2,(H,26,27)/b25-11+/t16-/m1/s1",Rho Inhibitor,Reaxys Registry Number,25133391
6587,137694,"(S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane dihydrochloride","A hydrochloride salt resulting from the reaction of (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane with 2 mol eq. of hydrogen chloride. An ATP-competitive inhibitor of Rho kinase (ROCK).","InChI=1S/C16H21N3O2S.2ClH/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2;;/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3;2*1H/t13-;;/m0../s1",ROCK inhibitor,PubMed citation,26227060
6588,137695,"1-amino-15-oxo-4,7,10-trioxa-14-azaoctadecan-18-oic acid","A polyether that is 4,7,10-trioxatridecane substituted at positions 1 and 13 by an amino group and a 3-carboxypropanamido group respectively. Flexible and hydrophilic, it is used as an extended linker in solid-phase immunoassays.","InChI=1S/C14H28N2O6/c15-5-1-7-20-9-11-22-12-10-21-8-2-6-16-13(17)3-4-14(18)19/h1-12,15H2,(H,16,17)(H,18,19)","1,13-diamino-4,7,10-trioxatridecanesuccinamic acid",PubMed citation,28403522
6589,137696,"nickel-sirohydrochlorin a,c-diamide","A metalloporphyrin that is sirohydrochlorin a,c-diamide in which the four nitrogen atoms are bound to a central nickel atom.","InChI=1S/C42H48N6O14.Ni/c1-41(17-33(43)49)23(5-9-37(55)56)29-14-27-21(11-39(59)60)19(3-7-35(51)52)25(45-27)13-26-20(4-8-36(53)54)22(12-40(61)62)28(46-26)15-31-42(2,18-34(44)50)24(6-10-38(57)58)30(48-31)16-32(41)47-29;/h13-16,23-24H,3-12,17-18H2,1-2H3,(H12,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62);/q;+2/p-2/t23-,24-,41+,42+;/m1./s1","Ni-sirohydrochlorin a,c-diamide",MetaCyc accession,CPD-7590
6590,137700,3-carboxy-3-hydroxypropanoyl-CoA,A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the 3-carboxy group of 3-carboxy-3-hydroxypropanoic acid.,"InChI=1S/C25H40N7O20P3S/c1-25(2,19(37)22(38)28-4-3-14(34)27-5-6-56-15(35)7-12(33)24(39)40)9-49-55(46,47)52-54(44,45)48-8-13-18(51-53(41,42)43)17(36)23(50-13)32-11-31-16-20(26)29-10-30-21(16)32/h10-13,17-19,23,33,36-37H,3-9H2,1-2H3,(H,27,34)(H,28,38)(H,39,40)(H,44,45)(H,46,47)(H2,26,29,30)(H2,41,42,43)/t12?,13-,17-,18-,19+,23-/m1/s1",3-malyl-CoA,CAS Registry Number,2043-93-8
6591,137701,17-epiestriol 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 17-epiestriol having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(32-23-19(28)17(26)18(27)20(33-23)22(30)31)8-10(12)2-4-14(13)15(24)9-16(25)21(24)29/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/t13-,14-,15+,16-,17+,18+,19-,20+,21-,23-,24+/m1/s1","16alpha,17alpha-estriol 3-O-(beta-D-glucuronate)",Reaxys Registry Number,23416853
6592,137702,17-epiestriol 17-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 17-epiestriol having a single beta-D-glucuronic acid residue attached at position 17.,"InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(25)8-10(12)2-4-14(13)15(24)9-16(26)21(24)33-23-19(29)17(27)18(28)20(32-23)22(30)31/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/t13-,14-,15+,16-,17+,18+,19-,20+,21-,23+,24+/m1/s1","16alpha,17alpha-estriol 17-O-(beta-D-glucuronide)",PubMed citation,23288867
6593,137706,17-epiestriol 16-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 17-epiestriol having a single beta-D-glucuronic acid residue attached at position 16.,"InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(25)8-10(12)2-4-14(13)15(24)9-16(21(24)29)32-23-19(28)17(26)18(27)20(33-23)22(30)31/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/t13-,14-,15+,16-,17+,18+,19-,20+,21-,23-,24+/m1/s1","16alpha,17alpha-estriol 16-beta-D-glucuronide",Reaxys Registry Number,23416852
6594,137720,16-epiestriol 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 16-epiestriol having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(32-23-19(28)17(26)18(27)20(33-23)22(30)31)8-10(12)2-4-14(13)15(24)9-16(25)21(24)29/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/t13-,14-,15+,16+,17+,18+,19-,20+,21+,23-,24+/m1/s1","16beta,17beta-estriol 3-beta-D-glucuronide",Reaxys Registry Number,23416856
6595,137725,chenodeoxycholic acid 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is chenodeoxycholic acid  having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C30H48O10/c1-14(4-7-21(32)33)17-5-6-18-22-19(9-11-30(17,18)3)29(2)10-8-16(12-15(29)13-20(22)31)39-28-25(36)23(34)24(35)26(40-28)27(37)38/h14-20,22-26,28,31,34-36H,4-13H2,1-3H3,(H,32,33)(H,37,38)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24+,25-,26+,28-,29+,30-/m1/s1",CDCA 3-,Reaxys Registry Number,6883644
6596,137747,ciliobrevin D,A member of the class of quinazolines that functions as a ATPase motor cytoplasmic dynein inhibitor.,"InChI=1S/C17H8Cl3N3O2/c18-8-1-3-10(13(20)5-8)15(24)12(7-21)16-22-14-6-9(19)2-4-11(14)17(25)23-16/h1-6,22H,(H,23,25)",AAA+ ATPase motor cytoplasmic dynein inhibitor,Reaxys Registry Number,22748536
6597,137754,"(6E,8Z)-5-oxooctadecadienoic acid","An octadecanoid that is (6E,8Z)-octadecadienoic acid carrying an additional oxo substituent at position 5.","InChI=1S/C18H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-14-17(19)15-13-16-18(20)21/h10-12,14H,2-9,13,15-16H2,1H3,(H,20,21)/b11-10-,14-12+",5-oxo-ODE,PubMed citation,18287092
6598,137790,chenodeoxycholic acid 24-O-(beta-D-glucuronide),A steroid glucosiduronic acid obtained by formal condensation of the carboxy group of chenodeoxycholic acid with the anomeric hydroxy group of beta-D-glucuronic acid.,"InChI=1S/C30H48O10/c1-14(4-7-21(33)39-28-25(36)23(34)24(35)26(40-28)27(37)38)17-5-6-18-22-19(9-11-30(17,18)3)29(2)10-8-16(31)12-15(29)13-20(22)32/h14-20,22-26,28,31-32,34-36H,4-13H2,1-3H3,(H,37,38)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24+,25-,26+,28-,29+,30-/m1/s1",chenodeoxycholic acid 24-beta-D-glucuronide,Reaxys Registry Number,8046690
6599,137791,cholic acid 24-O-(beta-D-glucuronide),A steroid glucosiduronic acid obtained by formal condensation of the carboxy group of cholic acid with the anomeric hydroxy group of beta-D-glucuronic acid.,"InChI=1S/C30H48O11/c1-13(4-7-21(34)40-28-25(37)23(35)24(36)26(41-28)27(38)39)16-5-6-17-22-18(12-20(33)30(16,17)3)29(2)9-8-15(31)10-14(29)11-19(22)32/h13-20,22-26,28,31-33,35-37H,4-12H2,1-3H3,(H,38,39)/t13-,14+,15-,16-,17+,18+,19-,20+,22+,23+,24+,25-,26+,28-,29+,30-/m1/s1",cholic acid 24-beta-glucuronide,PubMed citation,23756265
6600,137799,deoxycholic acid 24-O-(beta-D-glucuronide),A steroid glucosiduronic acid obtained by formal condensation of the carboxy group of deoxycholic acid with the anomeric hydroxy group of beta-D-glucuronic acid.,"InChI=1S/C30H48O10/c1-14(4-9-22(33)39-28-25(36)23(34)24(35)26(40-28)27(37)38)18-7-8-19-17-6-5-15-12-16(31)10-11-29(15,2)20(17)13-21(32)30(18,19)3/h14-21,23-26,28,31-32,34-36H,4-13H2,1-3H3,(H,37,38)/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24+,25-,26+,28-,29+,30-/m1/s1",deoxycholic acid 24-beta-D-glucuronide,Reaxys Registry Number,8024212
6601,137807,lithocholic acid 24-O-(beta-D-glucuronide),A steroid glucosiduronic acid obtained by formal condensation of the carboxy group of lithodeoxycholic acid with the anomeric hydroxy group of beta-D-glucuronic acid.,"InChI=1S/C30H48O9/c1-15(4-9-22(32)38-28-25(35)23(33)24(34)26(39-28)27(36)37)19-7-8-20-18-6-5-16-14-17(31)10-12-29(16,2)21(18)11-13-30(19,20)3/h15-21,23-26,28,31,33-35H,4-14H2,1-3H3,(H,36,37)/t15-,16-,17-,18+,19-,20+,21+,23+,24+,25-,26+,28-,29+,30-/m1/s1",lithocholic acid 24-glucuronic acid,Reaxys Registry Number,8023295
6602,137812,hyodeoxycholic acid 24-O-(beta-D-glucuronide),A steroid glucosiduronic acid obtained by formal condensation of the carboxy group of hyodeoxycholic acid with the anomeric hydroxy group of beta-D-glucuronic acid.,"InChI=1S/C30H48O10/c1-14(4-7-22(33)39-28-25(36)23(34)24(35)26(40-28)27(37)38)17-5-6-18-16-13-21(32)20-12-15(31)8-10-30(20,3)19(16)9-11-29(17,18)2/h14-21,23-26,28,31-32,34-36H,4-13H2,1-3H3,(H,37,38)/t14-,15-,16+,17-,18+,19+,20+,21+,23+,24+,25-,26+,28-,29-,30-/m1/s1",hyodeoxycholic acid 24-beta-glucuronide,PubMed citation,23756265
6603,137817,hyocholic acid 24-O-(beta-D-glucuronide),A steroid glucosiduronic acid obtained by formal condensation of the carboxy group of hyocholic acid with the anomeric hydroxy group of beta-D-glucuronic acid.,"InChI=1S/C30H48O11/c1-13(4-7-19(32)40-28-25(37)23(35)24(36)26(41-28)27(38)39)15-5-6-16-20-17(9-11-29(15,16)2)30(3)10-8-14(31)12-18(30)21(33)22(20)34/h13-18,20-26,28,31,33-37H,4-12H2,1-3H3,(H,38,39)/t13-,14-,15-,16+,17+,18+,20+,21-,22+,23+,24+,25-,26+,28-,29-,30-/m1/s1",hyocholic acid 24-glucuronide,PubMed citation,21255593
6604,137829,hyocholic acid 6-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is hyocholic acid having a single beta-D-glucuronic acid residue attached at position 6.,"InChI=1S/C30H48O11/c1-13(4-7-19(32)33)15-5-6-16-20-17(9-11-29(15,16)2)30(3)10-8-14(31)12-18(30)25(21(20)34)40-28-24(37)22(35)23(36)26(41-28)27(38)39/h13-18,20-26,28,31,34-37H,4-12H2,1-3H3,(H,32,33)(H,38,39)/t13-,14-,15-,16+,17+,18+,20+,21+,22+,23+,24-,25-,26+,28-,29-,30-/m1/s1",hyocholic acid 6-(beta-D-glucuronide),PubMed citation,23756265
6605,137837,2-hydroxy-17beta-estradiol 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 2-hydroxy-17beta-estradiol having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C24H32O9/c1-24-7-6-11-12(14(24)4-5-17(24)26)3-2-10-8-16(15(25)9-13(10)11)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h8-9,11-12,14,17-21,23,25-29H,2-7H2,1H3,(H,30,31)/t11-,12+,14-,17-,18-,19-,20+,21-,23+,24-/m0/s1",2-hydroxy-17beta-estradiol 3-beta-glucuronide,Reaxys Registry Number,20544763
6606,137856,5alpha-dihydrotestosterone 17-O-[beta-D-glucuronosyl-(1->2)-glucuronide],A steroid glucosiduronic acid that is 5alpha-dihydrotestosterone having a beta-D-glucuronosyl-(1->2)-glucuronic acid residue attached at position 17.,"InChI=1S/C31H46O14/c1-30-9-7-13(32)11-12(30)3-4-14-15-5-6-17(31(15,2)10-8-16(14)30)42-29-25(21(36)20(35)24(44-29)27(40)41)45-28-22(37)18(33)19(34)23(43-28)26(38)39/h12,14-25,28-29,33-37H,3-11H2,1-2H3,(H,38,39)(H,40,41)/t12-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23-,24-,25+,28-,29+,30-,31-/m0/s1",5alpha-dihydrotestosterone 17-[beta-D-glucuronosyl-(1->2)-glucuronide],Reaxys Registry Number,24209294
6607,137900,Leu-Ser-Glu-Thr-Glu-Thr-Lys(Ac)-D-Leu,"An eight-membered oligopeptide comprising L-leucine, L-serine, L-glutamic acid, L-threonine, L-glutamic acid, L-threonine, N(6)-acetyl-L-lysine and D-leucine residues coupled in sequence.","InChI=1S/C41H71N9O17/c1-19(2)16-24(42)34(59)48-29(18-51)38(63)44-26(11-13-30(55)56)36(61)49-33(22(6)53)40(65)46-27(12-14-31(57)58)37(62)50-32(21(5)52)39(64)45-25(10-8-9-15-43-23(7)54)35(60)47-28(41(66)67)17-20(3)4/h19-22,24-29,32-33,51-53H,8-18,42H2,1-7H3,(H,43,54)(H,44,63)(H,45,64)(H,46,65)(H,47,60)(H,48,59)(H,49,61)(H,50,62)(H,55,56)(H,57,58)(H,66,67)/t21?,22?,24-,25-,26-,27-,28+,29-,32-,33-/m0/s1",LSETETK(Ac)dL,Reaxys Registry Number,31214071
6608,137907,2-hydroxy-17beta-estradiol 2-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 2-hydroxy-17beta-estradiol having a single beta-D-glucuronic acid residue attached at position 2.,"InChI=1S/C24H32O9/c1-24-7-6-11-12(14(24)4-5-17(24)26)3-2-10-8-15(25)16(9-13(10)11)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h8-9,11-12,14,17-21,23,25-29H,2-7H2,1H3,(H,30,31)/t11-,12+,14-,17-,18-,19-,20+,21-,23+,24-/m0/s1",2-hydroxy-17beta-estradiol 2-(beta-D-glucuronide),Reaxys Registry Number,24400663
6609,137911,4-hydroxy-17beta-estradiol 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 4-hydroxy-17beta-estradiol having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C24H32O9/c1-24-9-8-11-10-4-6-15(32-23-20(29)18(27)19(28)21(33-23)22(30)31)17(26)13(10)3-2-12(11)14(24)5-7-16(24)25/h4,6,11-12,14,16,18-21,23,25-29H,2-3,5,7-9H2,1H3,(H,30,31)/t11-,12-,14+,16+,18+,19+,20-,21+,23-,24+/m1/s1",4-OHE2 3G,Reaxys Registry Number,24400664
6610,137915,Leu-Ser-Glu-Thr-Tyr(SO3H)-Thr-Lys-D-Leu,"An eight-membered oligopeptide comprising L-leucine, L-serine, L-glutamic acid, L-threonine, O-sulfo-L-tyrosine, L-threonine, L-lysine and D-leucine residues coupled in sequence.","InChI=1S/C43H71N9O18S/c1-21(2)17-27(45)36(58)50-32(20-53)40(62)46-29(14-15-33(56)57)38(60)51-35(24(6)55)42(64)48-30(19-25-10-12-26(13-11-25)70-71(67,68)69)39(61)52-34(23(5)54)41(63)47-28(9-7-8-16-44)37(59)49-31(43(65)66)18-22(3)4/h10-13,21-24,27-32,34-35,53-55H,7-9,14-20,44-45H2,1-6H3,(H,46,62)(H,47,63)(H,48,64)(H,49,59)(H,50,58)(H,51,60)(H,52,61)(H,56,57)(H,65,66)(H,67,68,69)/t23?,24?,27-,28-,29-,30-,31+,32-,34-,35-/m0/s1",LSETY(SO3H)TKdL,PubMed citation,28403522
6611,137916,Leu-Ser-Glu-Thr-Tyr-Thr-Lys-D-Leu,"An eight-membered oligopeptide comprising L-leucine, L-serine, L-glutamic acid, L-threonine, L-tyrosine, L-threonine, L-lysine and D-leucine residues coupled in sequence.","InChI=1S/C43H71N9O15/c1-21(2)17-27(45)36(59)50-32(20-53)40(63)46-29(14-15-33(57)58)38(61)51-35(24(6)55)42(65)48-30(19-25-10-12-26(56)13-11-25)39(62)52-34(23(5)54)41(64)47-28(9-7-8-16-44)37(60)49-31(43(66)67)18-22(3)4/h10-13,21-24,27-32,34-35,53-56H,7-9,14-20,44-45H2,1-6H3,(H,46,63)(H,47,64)(H,48,65)(H,49,60)(H,50,59)(H,51,61)(H,52,62)(H,57,58)(H,66,67)/t23?,24?,27-,28-,29-,30-,31+,32-,34-,35-/m0/s1",LSETYTKdL,PubMed citation,28403522
6612,137917,4-hydroxy-17beta-estradiol 4-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 4-hydroxy-17beta-estradiol having a single beta-D-glucuronic acid residue attached at position 4.,"InChI=1S/C24H32O9/c1-24-9-8-11-10-4-6-15(25)20(13(10)3-2-12(11)14(24)5-7-16(24)26)32-23-19(29)17(27)18(28)21(33-23)22(30)31/h4,6,11-12,14,16-19,21,23,25-29H,2-3,5,7-9H2,1H3,(H,30,31)/t11-,12-,14+,16+,17+,18+,19-,21+,23-,24+/m1/s1",4-hydroxy-17beta-estradiol 4-beta-glucuronide,Reaxys Registry Number,24400694
6613,137919,Ttds-Leu-Ser-Glu-Thr-Glu-Thr-D-Leu,"A seven-membered oligopeptide comprising L-leucine, L-serine, L-glutamic acid, L-threonine, L-glutamic acid, L-threonine and D-leucine residues coupled in sequence, modified by insertion at the N-terminal position of the flexible and hydrophilic PEG chain 1,13-diamino-4,7,10-trioxatrideacne succinamic acid linker (Ttds).","InChI=1S/C47H83N9O20/c1-26(2)23-32(50-36(61)12-11-35(60)49-16-8-18-75-20-22-76-21-19-74-17-7-15-48)43(68)54-34(25-57)44(69)51-30(9-13-37(62)63)41(66)55-39(28(5)58)45(70)52-31(10-14-38(64)65)42(67)56-40(29(6)59)46(71)53-33(47(72)73)24-27(3)4/h26-34,39-40,57-59H,7-25,48H2,1-6H3,(H,49,60)(H,50,61)(H,51,69)(H,52,70)(H,53,71)(H,54,68)(H,55,66)(H,56,67)(H,62,63)(H,64,65)(H,72,73)/t28?,29?,30-,31-,32-,33+,34-,39-,40-/m0/s1",Ttds-LSETETdL,PubMed citation,28403522
6614,137921,lithocholic acid 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is lithocholic acid having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C30H48O9/c1-15(4-9-22(31)32)19-7-8-20-18-6-5-16-14-17(10-12-29(16,2)21(18)11-13-30(19,20)3)38-28-25(35)23(33)24(34)26(39-28)27(36)37/h15-21,23-26,28,33-35H,4-14H2,1-3H3,(H,31,32)(H,36,37)/t15-,16-,17-,18+,19-,20+,21+,23+,24+,25-,26+,28-,29+,30-/m1/s1",lithocholic acid 3-beta-glucuronide,CAS Registry Number,75239-91-7
6615,137922,cyclo(Leu-Ser-Glu-Thr-Glu-Thr-Lys(Ac)-D-Leu),"An eight-membered homodetic cyclic peptide comprising the sequence L-leucine, L-serine, L-alpha-glutamic acid, L-threonine, L-alpha-glutamic acid, L-threonine, N(6)-acetyl-L-lysine, D-leucine.","InChI=1S/C41H69N9O16/c1-19(2)16-27-37(62)47-28(17-20(3)4)38(63)48-29(18-51)39(64)43-25(11-13-30(55)56)35(60)49-33(22(6)53)41(66)45-26(12-14-31(57)58)36(61)50-32(21(5)52)40(65)44-24(34(59)46-27)10-8-9-15-42-23(7)54/h19-22,24-29,32-33,51-53H,8-18H2,1-7H3,(H,42,54)(H,43,64)(H,44,65)(H,45,66)(H,46,59)(H,47,62)(H,48,63)(H,49,60)(H,50,61)(H,55,56)(H,57,58)/t21?,22?,24-,25-,26-,27+,28-,29-,32-,33-/m0/s1",c-(LSETETK(Ac)dL),Reaxys Registry Number,31214072
6616,137924,2-hydroxyestrone 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 2-hydroxyestrone having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C24H30O9/c1-24-7-6-11-12(14(24)4-5-17(24)26)3-2-10-8-16(15(25)9-13(10)11)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h8-9,11-12,14,18-21,23,25,27-29H,2-7H2,1H3,(H,30,31)/t11-,12+,14-,18-,19-,20+,21-,23+,24-/m0/s1",2-hydroxyestrone 3-beta-glucuronide,Reaxys Registry Number,24400660
6617,137926,cyclo(Leu-Ser-Glu-Thr-Lys-Thr-D-Leu),"A seven-membered homodetic cyclic peptide comprising the sequence L-leucine, L-serine, L-alpha-glutamic acid, L-threonine, L-lysine, L-threonine, D-leucine.","InChI=1S/C34H60N8O12/c1-16(2)13-22-31(51)40-24(15-43)32(52)36-21(10-11-25(46)47)29(49)42-26(18(5)44)33(53)37-20(9-7-8-12-35)28(48)41-27(19(6)45)34(54)39-23(14-17(3)4)30(50)38-22/h16-24,26-27,43-45H,7-15,35H2,1-6H3,(H,36,52)(H,37,53)(H,38,50)(H,39,54)(H,40,51)(H,41,48)(H,42,49)(H,46,47)/t18?,19?,20-,21-,22-,23+,24-,26-,27-/m0/s1",c-(Leu-Ser-Glu-Thr-Lys-Thr-D-Leu),PubMed citation,28403522
6618,137932,5-dehydro-L-gluconic acid,A ketogluconic acid that is L-gluconic acid in which the hydroxy group at position 2 has been oxidised to the corresponding ketone.,"InChI=1S/C6H10O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h3-5,7,9-11H,1H2,(H,12,13)/t3-,4+,5-/m0/s1",L-5-ketogluconic acid,Reaxys Registry Number,1726806
6619,137945,N-carbamoyl-L-methionine,An N-carbamoyl-L-alpha-amino acid derived from L-methionine.,"InChI=1S/C6H12N2O3S/c1-12-3-2-4(5(9)10)8-6(7)11/h4H,2-3H2,1H3,(H,9,10)(H3,7,8,11)/t4-/m0/s1",N-carbamoylmethionine,Reaxys Registry Number,6324599
6620,137957,2-hydroxyestrone 2-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 2-hydroxyestrone having a single beta-D-glucuronic acid residue attached at position 2.,"InChI=1S/C24H30O9/c1-24-7-6-11-12(14(24)4-5-17(24)26)3-2-10-8-15(25)16(9-13(10)11)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h8-9,11-12,14,18-21,23,25,27-29H,2-7H2,1H3,(H,30,31)/t11-,12+,14-,18-,19-,20+,21-,23+,24-/m0/s1",2-hydroxyestrone 2-beta-glucuronide,Reaxys Registry Number,11305843
6621,137960,4-hydroxyestrone 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 4-hydroxyestrone having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C24H30O9/c1-24-9-8-11-10-4-6-15(32-23-20(29)18(27)19(28)21(33-23)22(30)31)17(26)13(10)3-2-12(11)14(24)5-7-16(24)25/h4,6,11-12,14,18-21,23,26-29H,2-3,5,7-9H2,1H3,(H,30,31)/t11-,12-,14+,18+,19+,20-,21+,23-,24+/m1/s1",4-OHE1 3G,Reaxys Registry Number,24400661
6622,137961,4-hydroxyestrone 4-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 4-hydroxyestrone having a single beta-D-glucuronic acid residue attached at position 4.,"InChI=1S/C24H30O9/c1-24-9-8-11-10-4-6-15(25)20(13(10)3-2-12(11)14(24)5-7-16(24)26)32-23-19(29)17(27)18(28)21(33-23)22(30)31/h4,6,11-12,14,17-19,21,23,25,27-29H,2-3,5,7-9H2,1H3,(H,30,31)/t11-,12-,14+,17+,18+,19-,21+,23-,24+/m1/s1",4-OHE1 4G,Reaxys Registry Number,24366853
6623,137965,4-methoxyestrone 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 2-methoxyestrone having a beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C25H32O9/c1-25-10-9-12-11-5-7-16(33-24-20(29)18(27)19(28)22(34-24)23(30)31)21(32-2)14(11)4-3-13(12)15(25)6-8-17(25)26/h5,7,12-13,15,18-20,22,24,27-29H,3-4,6,8-10H2,1-2H3,(H,30,31)/t12-,13-,15+,18+,19+,20-,22+,24-,25+/m1/s1",2-methoxyestrone 3-O-glucuronide,Reaxys Registry Number,24400662
6624,137966,4-methoxy-17beta-estradiol 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is 4-methoxy-17beta-estradiol having a single beta-D-glucuronic acid residue attached at position 3.,"InChI=1S/C25H34O9/c1-25-10-9-12-11-5-7-16(33-24-20(29)18(27)19(28)22(34-24)23(30)31)21(32-2)14(11)4-3-13(12)15(25)6-8-17(25)26/h5,7,12-13,15,17-20,22,24,26-29H,3-4,6,8-10H2,1-2H3,(H,30,31)/t12-,13-,15+,17+,18+,19+,20-,22+,24-,25+/m1/s1",4-methoxy-17beta-estradiol 3-glucuronide,Reaxys Registry Number,24400665
6625,138013,Z-DEVD-FMK,"A tetrapeptide consisting of Fmoc-L-aspartic acid 4-methyl ester, methyl L-alpha-glutamic acid 5-methyl ester, L-valine and the fluoromethyl ketone derived from the 1-carboxy group of L-aspartic acid 4-methyl ester coupled in sequence. It is a specific, irreversible caspase-3 inhibitor that also shows potent inhibition of caspase-6, caspase-7, caspase-8, and caspase-10.","InChI=1S/C30H41FN4O12/c1-17(2)26(29(42)33-20(22(36)15-31)13-24(38)45-4)35-27(40)19(11-12-23(37)44-3)32-28(41)21(14-25(39)46-5)34-30(43)47-16-18-9-7-6-8-10-18/h6-10,17,19-21,26H,11-16H2,1-5H3,(H,32,41)(H,33,42)(H,34,43)(H,35,40)/t19-,20-,21-,26-/m0/s1",methyl (4S)-5-{[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino}-4-{[(2S)-2-{[(benzyloxy)carbonyl]amino}-4-methoxy-4-oxobutanoyl]amino}-5-oxopentanoate,Reaxys Registry Number,9977166
6626,138022,"5alpha-androstane-3beta,17beta-diol 17-O-(beta-D-glucuronide)","A steroid glucosiduronic acid that is 5alpha-androstane-3beta,17beta-diol having a single beta-D-glucuronic acid residue attached at position 17.","InChI=1S/C25H40O8/c1-24-9-7-13(26)11-12(24)3-4-14-15-5-6-17(25(15,2)10-8-16(14)24)32-23-20(29)18(27)19(28)21(33-23)22(30)31/h12-21,23,26-29H,3-11H2,1-2H3,(H,30,31)/t12-,13-,14-,15-,16-,17-,18-,19-,20+,21-,23+,24-,25-/m0/s1","5alpha-androstane 3beta,17beta-diol 17-O-glucuronide",Reaxys Registry Number,24460955
6627,138026,5alpha-dihydrotestosterone sulfate,A 3-oxo-5alpha-steroid that is 5alpha-dihydrotestosterone in which the hydroxy hydrogen at position 17 has been replaced by a sulfo group.,"InChI=1S/C19H30O5S/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(24-25(21,22)23)19(15,2)10-8-16(14)18/h12,14-17H,3-11H2,1-2H3,(H,21,22,23)/t12-,14-,15-,16-,17-,18-,19-/m0/s1",5alpha-dihydrotestosterone 17-sulfate,LIPID MAPS instance accession,LMST05020023
6628,138032,"(3beta,5alpha,17beta)-3-hydroxyandrostan-17-yl sulfate","An androstane sulfate that is 5alpha-androstan-3beta,17beta-diol in which the hydroxy hydrogen at position 17 has been replaced by a sulfo group.","InChI=1S/C19H32O5S/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(24-25(21,22)23)19(15,2)10-8-16(14)18/h12-17,20H,3-11H2,1-2H3,(H,21,22,23)/t12-,13-,14-,15-,16-,17-,18-,19-/m0/s1",3beta-hydroxy-5alpha-androstan-17beta-yl hydrogen sulfate,PubMed citation,19218247
6629,138066,nocamycin I,An organic heterotricyclic compound and tetramic acid derivative originally isolated from an unidentified oligosporic actinomycete strain (no. E864-861) and found to be active against both Gram-positive and Gram-negative anaerobic bacteria as well as some aerobic bacteria such as Streptococci. The methyl ester of nocamycin E.,"InChI=1S/C26H33NO9/c1-12(7-8-16(28)19-18(30)11-27-23(19)31)9-13(2)21-14(3)22-17(29)10-25(5)26(35-21,36-22)20(15(4)34-25)24(32)33-6/h7-9,13-15,20-22,28H,10-11H2,1-6H3,(H,27,31)/b8-7+,12-9+,19-16+/t13-,14-,15-,20-,21-,22+,25+,26+/m1/s1",Bu-2313B,PubMed citation,28818448
6630,138094,1-(1Z-octadecenyl)-sn-glycero-3-phospho-(N-hexadecanoyl)ethanolamine,A 1-[(Z)-alk-1-enyl]-sn-glycero-3-phospho-(N-acyl)ethanolamine in which the alk-1-enyl and N-acyl groups are specified as 1Z-octadecenyl and hexadecanoyl respectively.,"InChI=1S/C39H78NO7P/c1-3-5-7-9-11-13-15-17-18-19-21-23-25-27-29-31-34-45-36-38(41)37-47-48(43,44)46-35-33-40-39(42)32-30-28-26-24-22-20-16-14-12-10-8-6-4-2/h31,34,38,41H,3-30,32-33,35-37H2,1-2H3,(H,40,42)(H,43,44)/b34-31-/t38-/m1/s1",N-palmitoyl-1-O-(1Z-octadecenyl)-2-hydroxy-sn-glycero-3-phosphoethanolamine,PubMed citation,25596343
6631,138096,1-(1Z-octadecenyl)-sn-glycero-3-phospho-(N-arachidonoyl)ethanolamine,A 1-[(Z)-alk-1-enyl]-sn-glycero-3-phospho-(N-acyl)ethanolamine in which the alk-1-enyl and N-acyl groups are specified as 1Z-octadecenyl and arachidonoyl respectively.,"InChI=1S/C43H78NO7P/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-36-43(46)44-37-39-50-52(47,48)51-41-42(45)40-49-38-35-33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,35,38,42,45H,3-10,12,14-16,18,20-21,23,25-27,29,31-34,36-37,39-41H2,1-2H3,(H,44,46)(H,47,48)/b13-11-,19-17-,24-22-,30-28-,38-35-/t42-/m1/s1",N-arachidonoyl-1-(1Z-octadecenyl)-lyso-PE,PubMed citation,25596343
6632,138110,16(S)-HETE,A 16-HETE in which the chiral centre at position 16 has S-configuration.,"InChI=1S/C20H32O3/c1-2-3-16-19(21)17-14-12-10-8-6-4-5-7-9-11-13-15-18-20(22)23/h4-5,8-11,14,17,19,21H,2-3,6-7,12-13,15-16,18H2,1H3,(H,22,23)/b5-4-,10-8-,11-9-,17-14-/t19-/m0/s1",(16S)-hydroxyarachidonic acid,Reaxys Registry Number,9287648
6633,138126,leukotriene E4 methyl ester,"The methyl ester of leukotriene E4, the esterified acid group being the one forming position 1 of the icosatetraenyl chain. Leukotriene E4 methyl ester is a more lipid-soluble form of leukotriene E4.","InChI=1S/C24H39NO5S/c1-3-4-5-6-7-8-9-10-11-12-13-14-17-22(31-19-20(25)24(28)29)21(26)16-15-18-23(27)30-2/h7-8,10-14,17,20-22,26H,3-6,9,15-16,18-19,25H2,1-2H3,(H,28,29)/b8-7-,11-10-,13-12+,17-14+/t20-,21-,22+/m0/s1","LTE4, methyl ester",PubMed citation,28507038
6634,138135,"(13S)-hydroxy-(14S,15S)-epoxy-(5Z,8Z,11Z)-icosatrienoic acid","A 13-hydroxy-14,15-epoxy-(5Z,8Z,11Z)-icosatrienoic acid in which the three chiral centres at positions 13, 14 and 15 all have S-configuration.","InChI=1S/C20H32O4/c1-2-3-11-15-18-20(24-18)17(21)14-12-9-7-5-4-6-8-10-13-16-19(22)23/h5-8,12,14,17-18,20-21H,2-4,9-11,13,15-16H2,1H3,(H,22,23)/b7-5-,8-6-,14-12-/t17-,18-,20-/m0/s1","13-H-14,15-EETA",Reaxys Registry Number,22075240
6635,138137,"13,14,15-trihydroxy-(5Z,8Z,11Z)-icosatrienoic acid","A trihydroxyicosatrienoic acid that is (5Z,8Z,11Z)-icosatrienoic acid in which the three hydroxy groups are located at positions 13, 14 and 15.","InChI=1S/C20H34O5/c1-2-3-11-14-17(21)20(25)18(22)15-12-9-7-5-4-6-8-10-13-16-19(23)24/h5-8,12,15,17-18,20-22,25H,2-4,9-11,13-14,16H2,1H3,(H,23,24)/b7-5-,8-6-,15-12-","(5Z,8Z,11Z)-13,14,15-trihydroxyeicosatrienoic acid",PubMed citation,18296063
6636,138144,"11,12,15-trihydroxy-(5Z,8Z,13E)-icosatrienoic acid","A trihydroxyicosatrienoic acid that is (5Z,8Z,13E)-icosatrienoic acid in which the three hydroxy groups are located at positions 11, 12 and 15.","InChI=1S/C20H34O5/c1-2-3-9-12-17(21)15-16-19(23)18(22)13-10-7-5-4-6-8-11-14-20(24)25/h4,6-7,10,15-19,21-23H,2-3,5,8-9,11-14H2,1H3,(H,24,25)/b6-4-,10-7-,16-15+","(5Z,8Z,13E)-11,12,15-trihydroxyeicosatrienoic acid",PubMed citation,23249676
6637,138149,"11 hydroxy-(14R,15S)-epoxy-(5Z,8Z,12E)-icosatrienoic acid","An epoxy(hydroxy)icosatrienoic acid that is (5Z,8Z,12E)-icosatrienoic acid having the epoxide group across positions 14-15 and the hydroxy substituent located at position 11.","InChI=1S/C20H32O4/c1-2-3-9-13-18-19(24-18)16-15-17(21)12-10-7-5-4-6-8-11-14-20(22)23/h4,6-7,10,15-19,21H,2-3,5,8-9,11-14H2,1H3,(H,22,23)/b6-4-,10-7-,16-15+/t17?,18-,19+/m0/s1","11-H-14,15-EETA",PubMed citation,8555216
6638,138169,Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe-NH2,"An eight-membered oligopeptide consisting of Asp, Tyr, Met, Gly, Trp, Met, As and Phe-NH2 residues joined in sequence.","InChI=1S/C49H62N10O13S2/c1-73-18-16-34(55-47(70)37(21-28-12-14-30(60)15-13-28)58-44(67)32(50)23-41(62)63)45(68)53-26-40(61)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(71)56-35(17-19-74-2)46(69)59-39(24-42(64)65)49(72)57-36(43(51)66)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52,60H,16-24,26,50H2,1-2H3,(H2,51,66)(H,53,68)(H,54,61)(H,55,70)(H,56,71)(H,57,72)(H,58,67)(H,59,69)(H,62,63)(H,64,65)/t32-,34-,35-,36-,37-,38-,39-/m0/s1",desulfated sincalide,Reaxys Registry Number,4228315
6639,138174,beta-D-Glcp-(1->3)-6-deoxy-alpha-L-Talp2Me-(1->3)-beta-D-GlcpO[CH2]5NH2,A trisaccharide derivative consisting of a beta-D-glucosyl residue glycosidically linked to a 5-aminopentyl group and which carries at O-3 a beta-D-glucosyl-(1->3)-6-deoxy-2-O-methyl-alpha-L-talosyl disaccharide unit.,"InChI=1S/C24H45NO15/c1-10-13(28)20(40-23-17(32)16(31)14(29)11(8-26)38-23)21(34-2)24(36-10)39-19-15(30)12(9-27)37-22(18(19)33)35-7-5-3-4-6-25/h10-24,26-33H,3-9,25H2,1-2H3/t10-,11+,12+,13+,14+,15+,16-,17+,18+,19-,20+,21+,22+,23-,24-/m0/s1",beta-D-Glc-(1->3)-6-deoxy-alpha-L-Tal2Me-(1->3)-beta-D-GlcO[CH2]5NH2,PubMed citation,28740137
6640,138185,6-deoxy-alpha-L-Talp2Ac-(1->3)-beta-D-GlcpO[CH2]5NH2,A disaccharide derivative consisting of a beta-D-glucosyl residue glycosidically linked to a 5-aminopentyl group and which carries at O-3 a 2-O-acetyl-6-deoxy-alpha-L-talosyl residue.,"InChI=1S/C19H35NO11/c1-9-12(23)14(25)17(29-10(2)22)19(28-9)31-16-13(24)11(8-21)30-18(15(16)26)27-7-5-3-4-6-20/h9,11-19,21,23-26H,3-8,20H2,1-2H3/t9-,11+,12+,13+,14+,15+,16-,17+,18+,19-/m0/s1",6-deoxy-alpha-L-Tal2Ac-(1->3)-beta-D-GlcO[CH2]5NH2,PubMed citation,28740137
6641,138186,p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe,"A thirteen-membered polypeptide consisting of p-Glu, Arg, Pro, Arg, Leu, Ser, His, Lys, Gly, Pro, Met, Pro and Phe residues joined in sequence.","InChI=1S/C69H108N22O16S/c1-39(2)32-47(85-57(96)43(17-9-26-76-68(71)72)82-63(102)52-20-12-29-90(52)65(104)45(18-10-27-77-69(73)74)83-58(97)44-22-23-54(93)80-44)59(98)88-50(37-92)61(100)86-48(34-41-35-75-38-79-41)60(99)81-42(16-7-8-25-70)56(95)78-36-55(94)89-28-11-19-51(89)62(101)84-46(24-31-108-3)66(105)91-30-13-21-53(91)64(103)87-49(67(106)107)33-40-14-5-4-6-15-40/h4-6,14-15,35,38-39,42-53,92H,7-13,16-34,36-37,70H2,1-3H3,(H,75,79)(H,78,95)(H,80,93)(H,81,99)(H,82,102)(H,83,97)(H,84,101)(H,85,96)(H,86,100)(H,87,103)(H,88,98)(H,106,107)(H4,71,72,76)(H4,73,74,77)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1",[Pyr1]-apelin-13,CAS Registry Number,217082-60-5
6642,138190,"(6E,8Z,11Z)-5-oxoicosatrienoic acid","A trienoic fatty acid that is (6E,8Z,11Z)-icosatrienoic acid carrying an additional oxo substituent at position 5.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h9-10,12-14,16H,2-8,11,15,17-18H2,1H3,(H,22,23)/b10-9-,13-12-,16-14+",5-oxo-ETrE,Reaxys Registry Number,15801997
6643,138201,18-hydroxyleukotriene B4,A leukotriene that is leukotriene B4 carrying an additional hydroxy substituent at position 18.,"InChI=1S/C20H32O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-7,9,12-13,17-19,21-23H,2,8,10-11,14-16H2,1H3,(H,24,25)/b4-3+,9-5-,12-6+,13-7-/t17?,18-,19+/m0/s1",18-OH-LTB4,Reaxys Registry Number,14529500
6644,138202,"(13R)-S-glutathionyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid","A docosanoid that is (14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid in which a glutathionyl group is attached at position 13R via a sulfide linkage.","InChI=1S/C32H47N3O9S/c1-2-3-4-5-11-14-17-26(36)27(18-15-12-9-7-6-8-10-13-16-19-29(38)39)45-23-25(31(42)34-22-30(40)41)35-28(37)21-20-24(33)32(43)44/h3-4,6-7,9-15,18,24-27,36H,2,5,8,16-17,19-23,33H2,1H3,(H,34,42)(H,35,37)(H,38,39)(H,40,41)(H,43,44)/b4-3-,7-6-,12-9+,13-10-,14-11-,18-15+/t24-,25-,26-,27+/m0/s1",MCTR1,Reaxys Registry Number,28337237
6645,138206,"(13R)-S-cysteinylglycinyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid","A docosanoid that is (14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid in which a cysteinylglycinyl group is attached at position 13R via a sulfide linkage.","InChI=1S/C27H40N2O6S/c1-2-3-4-5-11-14-17-23(30)24(36-21-22(28)27(35)29-20-26(33)34)18-15-12-9-7-6-8-10-13-16-19-25(31)32/h3-4,6-7,9-15,18,22-24,30H,2,5,8,16-17,19-21,28H2,1H3,(H,29,35)(H,31,32)(H,33,34)/b4-3-,7-6-,12-9+,13-10-,14-11-,18-15+/t22-,23-,24+/m0/s1",MCTR2,Reaxys Registry Number,28337234
6646,138209,"(13R)-S-cysteinyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid","A docosanoid that is (14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid in which a cysteinyl group is attached at position 13R via a sulfide linkage.","InChI=1S/C25H37NO5S/c1-2-3-4-5-11-14-17-22(27)23(32-20-21(26)25(30)31)18-15-12-9-7-6-8-10-13-16-19-24(28)29/h3-4,6-7,9-15,18,21-23,27H,2,5,8,16-17,19-20,26H2,1H3,(H,28,29)(H,30,31)/b4-3-,7-6-,12-9+,13-10-,14-11-,18-15+/t21-,22-,23+/m0/s1",MCTR3,PubMed citation,26881986
6647,138225,CDP-D-ribose,A CDP-sugar having aldehydo-D-ribose as the sugar component with the CDP moiety attached at position 5.,"InChI=1S/C14H23N3O15P2/c15-9-1-2-17(14(24)16-9)13-12(23)11(22)8(31-13)5-30-34(27,28)32-33(25,26)29-4-7(20)10(21)6(19)3-18/h1-3,6-8,10-13,19-23H,4-5H2,(H,25,26)(H,27,28)(H2,15,16,24)/t6-,7+,8+,10-,11+,12+,13+/m0/s1",5-cytidyl-D-ribose,Reaxys Registry Number,101763
6648,138237,"2-hydroxy-7,8-dihydropteroic acid","A member of the class of pteroic acids that is 7,8-dihydropteroic acid carrying a phenolic hydroxy substituent at the position ortho to the carboxylic acid function.","InChI=1S/C14H14N6O4/c15-14-19-11-10(12(22)20-14)18-7(5-17-11)4-16-6-1-2-8(13(23)24)9(21)3-6/h1-3,16,21H,4-5H2,(H,23,24)(H4,15,17,19,20,22)",H2PtePAS,PubMed citation,24366731
6649,138248,"(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid","A dihydroxydocosahexaenoic acid that is (4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 13R- and 14S-positions.","InChI=1S/C22H32O4/c1-2-3-4-5-11-14-17-20(23)21(24)18-15-12-9-7-6-8-10-13-16-19-22(25)26/h3-4,6-7,9-15,18,20-21,23-24H,2,5,8,16-17,19H2,1H3,(H,25,26)/b4-3-,7-6-,12-9+,13-10-,14-11-,18-15+/t20-,21+/m0/s1",MaR2,Reaxys Registry Number,27750204
6650,138249,"(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid","A dihydroxydocosahexaenoic acid that is (4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 7R- and 14S-positions.","InChI=1S/C22H32O4/c1-2-3-4-5-6-10-15-20(23)16-11-7-8-12-17-21(24)18-13-9-14-19-22(25)26/h3-4,6-13,16-17,20-21,23-24H,2,5,14-15,18-19H2,1H3,(H,25,26)/b4-3-,8-7+,10-6-,13-9-,16-11-,17-12+/t20-,21-/m0/s1",MaR1,Reaxys Registry Number,21813987
6651,138255,"(9S,10R)-9,10-epoxy-18-hydroxyoctadecanoic acid","A 9,10-epoxy-18-hydroxyoctadecanoic acid in which the chiral centres at positions 9 and 10 have S- and R-configuration respectively.","InChI=1S/C18H34O4/c19-15-11-7-2-1-4-8-12-16-17(22-16)13-9-5-3-6-10-14-18(20)21/h16-17,19H,1-15H2,(H,20,21)/t16-,17+/m1/s1","18-hydroxy-(9S,10R)-9,10-epoxy-octadecanoic acid",Reaxys Registry Number,25842901
6652,138258,"(9R,10S)-9,10-epoxy-18-hydroxyoctadecanoic acid","A 9,10-epoxy-18-hydroxyoctadecanoic acid in which the chiral centres at positions 9 and 10 have R- and S-configuration respectively.","InChI=1S/C18H34O4/c19-15-11-7-2-1-4-8-12-16-17(22-16)13-9-5-3-6-10-14-18(20)21/h16-17,19H,1-15H2,(H,20,21)/t16-,17+/m0/s1","18-hydroxy-(9R,10S)-9,10-epoxystearic acid",PubMed citation,15145985
6653,138262,"(9S,10R)-epoxyoctadecanoic acid","A 9,10-epoxyoctadecanoic acid in which the chiral centres at positions 9 and 10 have S- and R-configuration respectively.","InChI=1S/C18H34O3/c1-2-3-4-5-7-10-13-16-17(21-16)14-11-8-6-9-12-15-18(19)20/h16-17H,2-15H2,1H3,(H,19,20)/t16-,17+/m1/s1","(9S,10R)-epoxystearic acid",PubMed citation,15145985
6654,138263,"9,10-epoxy-17-hydroxyoctadecanoic acid","An epoxy fatty acid that is 9,10-epoxyoctadecanoic acid (9,10-epoxystearic acid) carrying an additional hydroxy substituent at position 17.","InChI=1S/C18H34O4/c1-15(19)11-7-5-6-9-13-17-16(22-17)12-8-3-2-4-10-14-18(20)21/h15-17,19H,2-14H2,1H3,(H,20,21)","17-hydroxy-9,10-epoxyoctadecanoic acid",PubMed citation,15145985
6655,138271,"5,6-epoxy-20-hydroxy-(8Z,11Z,14Z)-icosatrienoic acid","An epoxy(hydroxy)icosatrienoic acid that is (8Z,11Z,14Z)-icosatrienoic acid having the epoxide group across positions 5-6 and the hydroxy substituent located at position 20.","InChI=1S/C20H32O4/c21-17-12-10-8-6-4-2-1-3-5-7-9-11-14-18-19(24-18)15-13-16-20(22)23/h2-5,9,11,18-19,21H,1,6-8,10,12-17H2,(H,22,23)/b4-2-,5-3-,11-9-","5,6-epoxy-20-hydroxy-(8Z,11Z,14Z)-eicosatrienoic acid",PubMed citation,15145985
6656,138272,"8,9-epoxy-20-hydroxy-(5Z,11Z,14Z)-icosatrienoic acid","An epoxy(hydroxy)icosatrienoic acid that is (5Z,11Z,14Z)-icosatrienoic acid having the epoxide group across positions 8-9 and the hydroxy substituent located at position 20.","InChI=1S/C20H32O4/c21-17-13-9-5-3-1-2-4-6-10-14-18-19(24-18)15-11-7-8-12-16-20(22)23/h1-2,6-7,10-11,18-19,21H,3-5,8-9,12-17H2,(H,22,23)/b2-1-,10-6-,11-7-","20-hydroxy-8,9-epoxy-(5Z,11Z,14Z)-icosatrienoic acid",PubMed citation,15145985
6657,138273,"11,12-epoxy-20-hydroxy-(5Z,8Z,14Z)-icosatrienoic acid","An epoxy(hydroxy)icosatrienoic acid that is (5Z,8Z,14Z)-icosatrienoic acid having the epoxide group across positions 11-12 and the hydroxy substituent located at position 20.","InChI=1S/C20H32O4/c21-17-13-9-5-4-7-11-15-19-18(24-19)14-10-6-2-1-3-8-12-16-20(22)23/h1,3,6-7,10-11,18-19,21H,2,4-5,8-9,12-17H2,(H,22,23)/b3-1-,10-6-,11-7-","20-hydroxy-11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid",PubMed citation,15145985
6658,138274,"14,15-epoxy-20-hydroxy-(5Z,8Z,11Z)-icosatrienoic acid","An epoxy(hydroxy)icosatrienoic acid that is (5Z,8Z,11Z)-icosatrienoic acid having the epoxide group across positions 14-15 and the hydroxy substituent located at position 20.","InChI=1S/C20H32O4/c21-17-13-9-11-15-19-18(24-19)14-10-7-5-3-1-2-4-6-8-12-16-20(22)23/h1,3-4,6-7,10,18-19,21H,2,5,8-9,11-17H2,(H,22,23)/b3-1-,6-4-,10-7-","20-hydroxy-14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoic acid",PubMed citation,15145985
6659,138279,7-oxoresolvin D2,A member of the class of resolvins that is resolvin D2 in which the 7-hydroxy group has undergone formal oxidation to the corresponding ketone.,"InChI=1S/C22H30O5/c1-2-3-9-16-20(24)21(25)17-12-7-5-4-6-10-14-19(23)15-11-8-13-18-22(26)27/h3-12,14,17,20-21,24-25H,2,13,15-16,18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,11-8-,14-10+,17-12+/t20-,21+/m0/s1",7-ketoresolvin D2,PubMed citation,22844113
6660,138281,16-oxoresolvin D2,A member of the class of resolvins that is resolvin D2 in which the 16-hydroxy group has undergone formal oxidation to the corresponding ketone.,"InChI=1S/C22H30O5/c1-2-3-9-16-20(24)21(25)17-12-7-5-4-6-10-14-19(23)15-11-8-13-18-22(26)27/h3-12,14,17,19-20,23-24H,2,13,15-16,18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,11-8-,14-10+,17-12+/t19-,20+/m1/s1",16-oxo-RvD2,PubMed citation,22844113
6661,138291,"(5S,15S)-dihydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoic acid","A bis(hydroperoxy)icosatetraenoic acid that is (6E,8Z,11Z,13E)-icosatetraenoic acid in which the two hydroperoxy groups are located at positions 5S and 15S.","InChI=1S/C20H32O6/c1-2-3-9-13-18(25-23)14-10-7-5-4-6-8-11-15-19(26-24)16-12-17-20(21)22/h5-8,10-11,14-15,18-19,23-24H,2-4,9,12-13,16-17H2,1H3,(H,21,22)/b7-5-,8-6-,14-10+,15-11+/t18-,19+/m0/s1","(5S,6E,8Z,11Z,13E,15S)-5,15-bis(hydroperoxy)icosatetraenoic acid",PubMed citation,27145229
6662,138295,"(5S,6R)-dihydroxy-(7E,9E,11Z,14Z)-icosatetraenoic acid","A dihydroxyicosatetraenoic acid (7E,9E,11Z,14Z)-icosatetraenoic acid in which the two hydroxy substituents are located at positions 5S and 6R.","InChI=1S/C20H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18(21)19(22)16-14-17-20(23)24/h6-7,9-13,15,18-19,21-22H,2-5,8,14,16-17H2,1H3,(H,23,24)/b7-6-,10-9-,12-11+,15-13+/t18-,19+/m1/s1","(5S,6R)-dihydroxy-(7E,9E,11Z,14Z)-eicosatetraenoic acid",LIPID MAPS instance accession,LMFA03060017
6663,138332,11(S)-HETE,An 11-HETE in which the chiral centre at position 11 has S-configuration.,"InChI=1S/C20H32O3/c1-2-3-4-5-7-10-13-16-19(21)17-14-11-8-6-9-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b9-6-,10-7-,14-11-,16-13+/t19-/m1/s1","(5Z,8Z,11S,12E,14Z)-11-hydroxyeicosatetraenoic acid",LIPID MAPS instance accession,LMFA03060003
6664,138361,"2-[(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl]-sn-glycero-3-phosphoethanolamine","A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oyl","InChI=1S/C25H44NO10P/c1-2-3-6-9-19(28)12-13-22-21(23(29)16-24(22)30)10-7-4-5-8-11-25(31)36-20(17-27)18-35-37(32,33)34-15-14-26/h4,7,12-13,19-22,24,27-28,30H,2-3,5-6,8-11,14-18,26H2,1H3,(H,32,33)/b7-4-,13-12+/t19-,20+,21+,22+,24+/m0/s1",2-(prostaglandin E2)-LPE,PubMed citation,27642067
6665,138376,allocholoyl-CoA,A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of allocholic acid.,"InChI=1S/C45H74N7O20P3S/c1-23(26-7-8-27-34-28(18-31(55)45(26,27)5)44(4)12-10-25(53)16-24(44)17-29(34)54)6-9-33(57)76-15-14-47-32(56)11-13-48-41(60)38(59)43(2,3)20-69-75(66,67)72-74(64,65)68-19-30-37(71-73(61,62)63)36(58)42(70-30)52-22-51-35-39(46)49-21-50-40(35)52/h21-31,34,36-38,42,53-55,58-59H,6-20H2,1-5H3,(H,47,56)(H,48,60)(H,64,65)(H,66,67)(H2,46,49,50)(H2,61,62,63)/t23-,24-,25-,26-,27+,28+,29-,30-,31+,34+,36-,37-,38+,42-,44+,45-/m1/s1",allocholoyl-coenzyme A,PubMed citation,22021638
6666,138377,allodeoxycholoyl-CoA,A steroidal acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of allodeoxycholic acid.,"InChI=1S/C45H74N7O19P3S/c1-24(28-9-10-29-27-8-7-25-18-26(53)12-14-44(25,4)30(27)19-32(54)45(28,29)5)6-11-34(56)75-17-16-47-33(55)13-15-48-41(59)38(58)43(2,3)21-68-74(65,66)71-73(63,64)67-20-31-37(70-72(60,61)62)36(57)42(69-31)52-23-51-35-39(46)49-22-50-40(35)52/h22-32,36-38,42,53-54,57-58H,6-21H2,1-5H3,(H,47,55)(H,48,59)(H,63,64)(H,65,66)(H2,46,49,50)(H2,60,61,62)/t24-,25+,26-,27+,28-,29+,30+,31-,32+,36-,37-,38+,42-,44+,45-/m1/s1",allodeoxycholoyl-coenzyme A,PubMed citation,22021638
6667,138378,beta-muricholoyl-CoA,A member of the class of choloyl-CoAs that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of beta-muricholic acid.,"InChI=1S/C45H74N7O20P3S/c1-23(25-7-8-26-32-27(11-14-44(25,26)4)45(5)13-10-24(53)18-28(45)34(56)35(32)57)6-9-31(55)76-17-16-47-30(54)12-15-48-41(60)38(59)43(2,3)20-69-75(66,67)72-74(64,65)68-19-29-37(71-73(61,62)63)36(58)42(70-29)52-22-51-33-39(46)49-21-50-40(33)52/h21-29,32,34-38,42,53,56-59H,6-20H2,1-5H3,(H,47,54)(H,48,60)(H,64,65)(H,66,67)(H2,46,49,50)(H2,61,62,63)/t23-,24-,25-,26+,27+,28+,29-,32+,34+,35-,36-,37-,38+,42-,44-,45-/m1/s1",beta-muricholoyl-coenzyme A,PubMed citation,22021638
6668,138384,7-oxotaurolithocholic acid,A bile acid taurine conjugate derived from 7-oxolithocholic acid.,"InChI=1S/C26H43NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-21,24,28H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17+,18-,19-,20+,21+,24+,25+,26-/m1/s1",7-ketotaurolithocholic acid,CAS Registry Number,75808-01-4
6669,138389,"7,12-dioxolithocholic acid",A bile acid that is lithocholic acid carrying two additional oxo substituents at positions 7 and 12.,"InChI=1S/C24H36O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-18,22,25H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,22+,23+,24-/m1/s1","7,12-diketolithocholic acid",CAS Registry Number,517-33-9
6670,138391,7-oxoglycolithocholic acid,A bile acid glycine conjugate that is glycolithocholic acid carrying an additional oxo substituent at postion 7.,"InChI=1S/C26H41NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-20,24,28H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,24+,25+,26-/m1/s1",7-ketoglycolithocholic acid,CAS Registry Number,75808-00-3
6671,138393,7-oxotaurodeoxycholic acid,A bile acid taurine conjugate derived from 7-oxodeoxycholic acid.,"InChI=1S/C26H43NO7S/c1-15(4-7-23(31)27-10-11-35(32,33)34)18-5-6-19-24-20(14-22(30)26(18,19)3)25(2)9-8-17(28)12-16(25)13-21(24)29/h15-20,22,24,28,30H,4-14H2,1-3H3,(H,27,31)(H,32,33,34)/t15-,16+,17-,18-,19+,20+,22+,24+,25+,26-/m1/s1","N-(3alpha,12alpha-dihydroxy-7-oxo-5beta-cholan-24-oyl)taurine",CAS Registry Number,67460-69-9
6672,138394,7-oxoglycodeoxycholic acid,A bile acid glycine conjugate that is glycodeoxycholic acid carrying an additional oxo substituent at position 7.,"InChI=1S/C26H41NO6/c1-14(4-7-22(31)27-13-23(32)33)17-5-6-18-24-19(12-21(30)26(17,18)3)25(2)9-8-16(28)10-15(25)11-20(24)29/h14-19,21,24,28,30H,4-13H2,1-3H3,(H,27,31)(H,32,33)/t14-,15+,16-,17-,18+,19+,21+,24+,25+,26-/m1/s1",7-ketoglycodeoxycholic acid,Reaxys Registry Number,5836788
6673,138401,"3alpha,7beta-dihydroxy-12-oxo-5beta-cholanic acid",An oxo-5beta-cholanic acid that is ursodeoxycholic acid carrying an additional oxo substituent at position 12.,"InChI=1S/C24H38O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-19,22,25-26H,4-12H2,1-3H3,(H,28,29)/t13-,14+,15-,16-,17+,18+,19+,22+,23+,24-/m1/s1",12-ketoursodeoxycholic acid,CAS Registry Number,81873-91-8
6674,138430,"(9R,13R)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoate","An oxo monocarboxylic acid anion that is the conjugate base of (9R,13R)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C16H26O3/c1-2-3-5-9-14-13(11-12-15(14)17)8-6-4-7-10-16(18)19/h3,5,13-14H,2,4,6-12H2,1H3,(H,18,19)/p-1/b5-3-/t13-,14-/m1/s1",OPC-6:0,PubMed citation,18267944
6675,138432,"6-{(1S,5S)-4-oxo-5-[(2Z)-pent-2-en-1-yl]cyclopent-2-en-1-yl}hexanoate","An oxo monocarboxylic acid anion resulting from the deprotonation of the carboxy group of 6-{(1S,5S)-4-oxo-5-[(2Z)-pent-2-en-1-yl]cyclopent-2-en-1-yl}hexanoic acid. The major species at pH 7.3.","InChI=1S/C16H24O3/c1-2-3-5-9-14-13(11-12-15(14)17)8-6-4-7-10-16(18)19/h3,5,11-14H,2,4,6-10H2,1H3,(H,18,19)/p-1/b5-3-/t13-,14-/m0/s1",dinor-OPDA(1-),PubMed citation,9294235
6676,138433,"(9S,13S)-1a,1b-dinor-12-oxo-10,15-phytodienoyl-CoA(4-)","A fatty acyl-CoA(4) arising from deprotonation of phosphate and diphosphate functions of (9S,13S)-1a,1b-dinor-12-oxo-10,15-phytodienoyl-CoA; major species at pH 7.3.","InChI=1S/C37H58N7O18P3S/c1-4-5-7-11-24-23(13-14-25(24)45)10-8-6-9-12-28(47)66-18-17-39-27(46)15-16-40-35(50)32(49)37(2,3)20-59-65(56,57)62-64(54,55)58-19-26-31(61-63(51,52)53)30(48)36(60-26)44-22-43-29-33(38)41-21-42-34(29)44/h5,7,13-14,21-24,26,30-32,36,48-49H,4,6,8-12,15-20H2,1-3H3,(H,39,46)(H,40,50)(H,54,55)(H,56,57)(H2,38,41,42)(H2,51,52,53)/p-4/b7-5-/t23-,24-,26+,30+,31+,32-,36+/m0/s1",dnOPDA-CoA(4-),PubMed citation,18267944
6677,138434,"6-{(1S,5S)-4-oxo-5-[(2Z)-pent-2-en-1-yl]cyclopent-2-en-1-yl}hexanoic acid","A carbocyclic fatty acid that is cyclopent-2-en-1-one which has been substituted at positions 4 and 5 by 5-carboxypentyl and (2ZZ)-pent-2-en-1-yl groups, respectively (the S,S stereoisomer). It is an intermediate in the synthesis of jasmonic acid from hexadecatrienoic acid.","InChI=1S/C16H24O3/c1-2-3-5-9-14-13(11-12-15(14)17)8-6-4-7-10-16(18)19/h3,5,11-14H,2,4,6-10H2,1H3,(H,18,19)/b5-3-/t13-,14-/m0/s1",4-oxo-5S-(2Z)-2-penten-1-yl-2-cyclopentene-1S-hexanoic acid,PubMed citation,9294235
6678,138511,piericidin A,A member of the class of monohydroxypyridines that acts as an irreversible mitochondrial Complex I inhibitor that strongly associates with ubiquinone binding sites in both mitochondrial and bacterial forms of NADH:ubiquinone oxidoreductase,"InChI=1S/C25H37NO4/c1-9-18(4)22(27)19(5)15-17(3)12-10-11-16(2)13-14-21-20(6)23(28)24(29-7)25(26-21)30-8/h9-10,12-13,15,19,22,27H,11,14H2,1-8H3,(H,26,28)/b12-10+,16-13+,17-15+,18-9+/t19-,22+/m1/s1","2-[(2E,5E,7E,11E)-10R-hydroxy-3,7,9R,11-tetramethyl-2,5,7,11-tridecatetraen-1-yl]-5,6-dimethoxy-3-methyl-4-pyridinol",Reaxys Registry Number,4720916
6679,138512,BPDZ 711,A member of the class of chromanes that acts as an inhibitor of histone deacetylase class III and exhibits anti-cancer properties.,"InChI=1S/C24H28N4O4/c1-23(2,3)32-22(30)27-17-9-10-20-18(12-17)19(13-24(4,5)31-20)28-21(29)26-16-8-6-7-15(11-16)14-25/h6-12,19H,13H2,1-5H3,(H,27,30)(H2,26,28,29)","N-3-cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea",Reaxys Registry Number,22763649
6680,138526,trans-Ned 19,"A member of the class of beta-carbolines that is 2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid in which one of the methylene protons at position 1 has been replaced by a 3-{[4-(2-fluorophenyl)piperazin-1-yl]methyl}-4-methoxyphenyl group.","InChI=1S/C30H31FN4O3/c1-38-27-11-10-19(16-20(27)18-34-12-14-35(15-13-34)26-9-5-3-7-23(26)31)28-29-22(17-25(33-28)30(36)37)21-6-2-4-8-24(21)32-29/h2-11,16,25,28,32-33H,12-15,17-18H2,1H3,(H,36,37)/t25-,28+/m0/s1",Nicotinic acid adenine dinucleotide phosphate antagonist,Reaxys Registry Number,26122229
6681,138582,19-hydroxyprostaglandin I2,A prostaglandin I that consists of prostaglandin I1 carrying an additional hydroxy substituent at position 19.,"InChI=1S/C20H32O6/c1-13(21)5-4-6-14(22)9-10-16-17-11-15(7-2-3-8-20(24)25)26-19(17)12-18(16)23/h7,9-10,13-14,16-19,21-23H,2-6,8,11-12H2,1H3,(H,24,25)/b10-9+,15-7-/t13?,14-,16+,17+,18+,19-/m0/s1",19-hydroxy-PGI2,PubMed citation,15789615
6682,138583,19-hydroxythromboxane A2,A thromboxane A that is thromboxane A2 carrying an additional hydroxy substituent at position 19.,"InChI=1S/C20H32O6/c1-14(21)7-6-8-15(22)11-12-17-16(18-13-20(25-17)26-18)9-4-2-3-5-10-19(23)24/h2,4,11-12,14-18,20-22H,3,5-10,13H2,1H3,(H,23,24)/b4-2-,12-11+/t14?,15-,16+,17+,18-,20+/m0/s1",19-hydroxy-TXA2,PubMed citation,15789615
6683,138591,"(5Z,8Z,11Z,14R,15R)-14,15-dihydroxyicosatrienoic acid","A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid in which the two stereocentres at positions 14 and 15 both have R-configuration.","InChI=1S/C20H34O4/c1-2-3-12-15-18(21)19(22)16-13-10-8-6-4-5-7-9-11-14-17-20(23)24/h4,6-7,9-10,13,18-19,21-22H,2-3,5,8,11-12,14-17H2,1H3,(H,23,24)/b6-4-,9-7-,13-10-/t18-,19-/m1/s1","(14R,15R)-DHET",Reaxys Registry Number,6959135
6684,138592,"(5Z,8Z,11Z,14S,15S)-14,15-dihydroxyicosatrienoic acid","A (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid in which the two stereocentres at positions 14 and 15 both have S-configuration.","InChI=1S/C20H34O4/c1-2-3-12-15-18(21)19(22)16-13-10-8-6-4-5-7-9-11-14-17-20(23)24/h4,6-7,9-10,13,18-19,21-22H,2-3,5,8,11-12,14-17H2,1H3,(H,23,24)/b6-4-,9-7-,13-10-/t18-,19-/m0/s1","(14S,15S)-dihydroxy-(5Z,8Z,11Z)-eicosatrienoic acid",Reaxys Registry Number,4490308
6685,138593,"(5Z,8Z,11R,12R,14Z)-11,12-dihydroxyicosatrienoic acid","A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid in which the two stereocentres at positions 11 and 12 both have R-configuration.","InChI=1S/C20H34O4/c1-2-3-4-5-9-12-15-18(21)19(22)16-13-10-7-6-8-11-14-17-20(23)24/h6,8-10,12-13,18-19,21-22H,2-5,7,11,14-17H2,1H3,(H,23,24)/b8-6-,12-9-,13-10-/t18-,19-/m1/s1","(11R,12R)-DHET",PubMed citation,7840649
6686,138594,"(5Z,8Z,11S,12S,14Z)-11,12-dihydroxyicosatrienoic acid","A (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid in which the two stereocentres at positions 11 and 12 both have S-configuration.","InChI=1S/C20H34O4/c1-2-3-4-5-9-12-15-18(21)19(22)16-13-10-7-6-8-11-14-17-20(23)24/h6,8-10,12-13,18-19,21-22H,2-5,7,11,14-17H2,1H3,(H,23,24)/b8-6-,12-9-,13-10-/t18-,19-/m0/s1","(11S,12S)-dihydroxy-(5Z,8Z,14Z)-eicosatrienoic acid",Reaxys Registry Number,6958355
6687,138601,4(S)-hydroperoxy-17(R)-hydroxydocosahexaenoic acid,"A hydroperoxy fatty acid that is (5E,7Z,10Z,13Z,15E,19Z)-docosa-5,7,10,13,15,19-hexaenoic acid carrying a hydroperoxy group at the 4S-position and a hydroxy group at the 17R-position.","InChI=1S/C22H32O5/c1-2-3-12-15-20(23)16-13-10-8-6-4-5-7-9-11-14-17-21(27-26)18-19-22(24)25/h3-5,8-14,16-17,20-21,23,26H,2,6-7,15,18-19H2,1H3,(H,24,25)/b5-4-,10-8-,11-9-,12-3-,16-13+,17-14+/t20-,21-/m1/s1",4(S)-Hp-17(R)-HDHA,PubMed citation,22087354
6688,138602,7(S)-hydroperoxy-17(R)-hydroxydocosahexaenoic acid,"A hydroperoxy fatty acid that is (4Z,8E,10Z,13Z,15E,19Z)-docosa-4,8,10,13,15,19-hexaenoic acid carrying a hydroperoxy group at the 7S-position and a hydroxy group at the 17R-position. It is an intermediate involved in the resolvin D1 biosynthesis pathway.","InChI=1S/C22H32O5/c1-2-3-10-15-20(23)16-11-7-5-4-6-8-12-17-21(27-26)18-13-9-14-19-22(24)25/h3,5-13,16-17,20-21,23,26H,2,4,14-15,18-19H2,1H3,(H,24,25)/b7-5-,8-6-,10-3-,13-9-,16-11+,17-12+/t20-,21-/m1/s1",7(S)-Hp-17(R)-HDHA,PubMed citation,17244615
6689,138612,4S(5)-epoxy-17R-hydroxydocosahexaenoic acid,"An epoxy fatty acid that is (6E,8E,10Z,13Z,15E,19Z)-docosa-6,8,10,13,15,19-hexaenoic acid which is carrying an epoxy group at position 4S and a hydroxy group at position 17R. It is a metabolite of docosahexaenoic acid that can be converted to a D-resolvin.","InChI=1S/C22H30O4/c1-2-3-11-14-19(23)15-12-9-7-5-4-6-8-10-13-16-20-21(26-20)17-18-22(24)25/h3-4,6-13,15-16,19-21,23H,2,5,14,17-18H2,1H3,(H,24,25)/b6-4-,9-7-,10-8+,11-3-,15-12+,16-13+/t19-,20?,21+/m1/s1",4S(5)-epoxy-17(R)-HDHA,LIPID MAPS instance accession,LMFA04000078
6690,138614,aspirin-triggered resolvin D2,"A member of the class of resolvins that is (4Z,8E,10Z,12E,14E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 7, 16 and 17 (the 7S,16R,17R-stereoisomer).","InChI=1S/C22H32O5/c1-2-3-9-16-20(24)21(25)17-12-7-5-4-6-10-14-19(23)15-11-8-13-18-22(26)27/h3-12,14,17,19-21,23-25H,2,13,15-16,18H2,1H3,(H,26,27)/b6-4-,7-5+,9-3-,11-8-,14-10+,17-12+/t19-,20+,21+/m0/s1",AT-RvD2,MetaCyc accession,CPD66-61
6691,138615,aspirin-triggered resolvin D3,"A member of the class of resolvins that is (5Z,7E,9E,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 11 and 17 (the 4S,11R,17R-stereoisomer)","InChI=1S/C22H32O5/c1-2-3-7-12-19(23)14-10-6-11-15-20(24)13-8-4-5-9-16-21(25)17-18-22(26)27/h3-11,13-14,16,19-21,23-25H,2,12,15,17-18H2,1H3,(H,26,27)/b5-4+,7-3-,11-6-,13-8+,14-10+,16-9-/t19-,20+,21-/m1/s1",AT-RvD3,Reaxys Registry Number,23608063
6692,138616,aspirin-triggered resolvin D4,"A member of the class of resolvins that is (6E,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 5 and 17 (the 4S,5R,17R-stereoisomer).","InChI=1S/C22H32O5/c1-2-3-11-14-19(23)15-12-9-7-5-4-6-8-10-13-16-20(24)21(25)17-18-22(26)27/h3-4,6-13,15-16,19-21,23-25H,2,5,14,17-18H2,1H3,(H,26,27)/b6-4-,9-7-,10-8+,11-3-,15-12+,16-13+/t19-,20-,21+/m1/s1",AT-RvD4,Reaxys Registry Number,14535292
6693,138618,aspirin-triggered resolvin D6,"A member of the class of resolvins that is (5E,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying two hydroxy substituents at positions 4 and 17 (the 4S,17R-stereoisomer).","InChI=1S/C22H32O4/c1-2-3-12-15-20(23)16-13-10-8-6-4-5-7-9-11-14-17-21(24)18-19-22(25)26/h3-5,8-14,16-17,20-21,23-24H,2,6-7,15,18-19H2,1H3,(H,25,26)/b5-4-,10-8-,11-9-,12-3-,16-13+,17-14+/t20-,21-/m1/s1",AT-RvD6,Reaxys Registry Number,14339391
6694,138641,4(S)-hydroperoxy-17(S)-hydroxydocosahexaenoic acid,"A hydroperoxy fatty acid that is (5E,7Z,10Z,13Z,15E,19Z)-docosa-5,7,10,13,15,19-hexaenoic acid carrying a hydroperoxy group at the 4S-position and a hydroxy group at the 17S-position.","InChI=1S/C22H32O5/c1-2-3-12-15-20(23)16-13-10-8-6-4-5-7-9-11-14-17-21(27-26)18-19-22(24)25/h3-5,8-14,16-17,20-21,23,26H,2,6-7,15,18-19H2,1H3,(H,24,25)/b5-4-,10-8-,11-9-,12-3-,16-13+,17-14+/t20-,21+/m0/s1",4(S)-Hp-17(S)-HDHA,LIPID MAPS instance accession,LMFA04000068
6695,138643,resolvin D6,"A member of the class of resolvins that is (5E,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying two hydroxy substituents at positions 4 and 17 (the 4S,17S-stereoisomer).","InChI=1S/C22H32O4/c1-2-3-12-15-20(23)16-13-10-8-6-4-5-7-9-11-14-17-21(24)18-19-22(25)26/h3-5,8-14,16-17,20-21,23-24H,2,6-7,15,18-19H2,1H3,(H,25,26)/b5-4-,10-8-,11-9-,12-3-,16-13+,17-14+/t20-,21+/m0/s1",RvD6,LIPID MAPS instance accession,LMFA04030004
6696,138648,resolvin D3,"A member of the class of resolvins that is (5Z,7E,9E,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 11 and 17 (the 4S,11R,17S-stereoisomer).","InChI=1S/C22H32O5/c1-2-3-7-12-19(23)14-10-6-11-15-20(24)13-8-4-5-9-16-21(25)17-18-22(26)27/h3-11,13-14,16,19-21,23-25H,2,12,15,17-18H2,1H3,(H,26,27)/b5-4+,7-3-,11-6-,13-8+,14-10+,16-9-/t19-,20-,21+/m0/s1",RvD3,MetaCyc accession,CPD66-81
6697,138649,resolvin D4,"A member of the class of resolvins that is (6E,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 5 and 17 (the 4S,5R,17S-stereoisomer).","InChI=1S/C22H32O5/c1-2-3-11-14-19(23)15-12-9-7-5-4-6-8-10-13-16-20(24)21(25)17-18-22(26)27/h3-4,6-13,15-16,19-21,23-25H,2,5,14,17-18H2,1H3,(H,26,27)/b6-4-,9-7-,10-8+,11-3-,15-12+,16-13+/t19-,20+,21-/m0/s1",RvD4,PubMed citation,26743932
6698,138650,CBL0137,"A member of the class of carbazoles that is 9H-carbazole which is substituted by acetyl groups at positions 3 and 6, and by a 2-isopropylethyl group on the nitrogen atom (position 9). It is a modulator of histone chaperone FACT (FAcilitates Chromatin Transcription) - interaction of CBL0137 with the FACT complex results in simultaneous NF-kappa beta suppression, Heat Shock Transcription Factor 1 (HSF1) suppression and p53 activation - and shows antitumour effects in animal models of various cancers.","InChI=1S/C21H24N2O2/c1-13(2)22-9-10-23-20-7-5-16(14(3)24)11-18(20)19-12-17(15(4)25)6-8-21(19)23/h5-8,11-13,22H,9-10H2,1-4H3",CBLC137,PubMed citation,27370399
6699,138653,"(4Z,7Z,10S,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosahexaenoic acid","A dihydroxydocosahexaenoic acid that is  (4Z,7Z,11E,13Z,15E,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at positions 10 and 17 (the 10S,17S-stereoisomer). A natural isomer of protectin D1, one of the specialised proresolving mediators.","InChI=1S/C22H32O4/c1-2-3-10-15-20(23)17-12-8-9-13-18-21(24)16-11-6-4-5-7-14-19-22(25)26/h3,5-13,17-18,20-21,23-24H,2,4,14-16,19H2,1H3,(H,25,26)/b7-5-,9-8-,10-3-,11-6-,17-12+,18-13+/t20-,21-/m0/s1",PDX,PubMed citation,24262603
6700,138655,protectin D1,"A dihydroxydocosahexaenoic acid that is (4Z,7Z,11E,13E,15Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at positions 10 and 17 (the 10R,17S-stereoisomer). Protectin D1 is one of the specialised proresolving mediators. When produced in neural tissues, it is called neuroprotectin D1","InChI=1S/C22H32O4/c1-2-3-10-15-20(23)17-12-8-9-13-18-21(24)16-11-6-4-5-7-14-19-22(25)26/h3,5-13,17-18,20-21,23-24H,2,4,14-16,19H2,1H3,(H,25,26)/b7-5-,9-8+,10-3-,11-6-,17-12-,18-13+/t20-,21+/m0/s1",PD1,Wikipedia accession,Protectin_D1
6701,138660,"dTDP-4-formamido-4,6-dideoxy-alpha-D-glucose","A dTDP-sugar having 4-formamido-4,6-dideoxy-alpha-D-glucose as the sugar component.","InChI=1S/C17H27N3O15P2/c1-7-4-20(17(26)19-15(7)25)11-3-9(22)10(33-11)5-31-36(27,28)35-37(29,30)34-16-14(24)13(23)12(18-6-21)8(2)32-16/h4,6,8-14,16,22-24H,3,5H2,1-2H3,(H,18,21)(H,27,28)(H,29,30)(H,19,25,26)/t8-,9+,10-,11-,12-,13+,14-,16-/m1/s1",dTDP-Qui4NFo,PDBeChem accession,4TG
6702,138670,LimKi 3,"A member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2.","InChI=1S/C17H14Cl2F2N4OS/c1-8(2)16(26)23-17-22-7-13(27-17)12-6-11(15(20)21)24-25(12)14-9(18)4-3-5-10(14)19/h3-8,15H,1-2H3,(H,22,23,26)","N-(5-(1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide",CAS Registry Number,1338247-35-0
6703,138673,"(4Z,7Z,10Z,13Z,15E,17S)-17-hydroxydocosapentaenoic acid","A hydroxydocosapentaenoic acid that is (4Z,7Z,10Z,13Z,15E)-docosapentaenoic acid in which the hydroxy group is located at the 17S-position. The 17S-oxygenated product of omega-6-DPA which possesses anti-inflammatory activity.","InChI=1S/C22H34O3/c1-2-3-15-18-21(23)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(24)25/h5-8,11-14,16,19,21,23H,2-4,9-10,15,17-18,20H2,1H3,(H,24,25)/b7-5-,8-6-,13-11-,14-12-,19-16+/t21-/m0/s1",17(S)-HDPAn-6,PubMed citation,22618200
6704,138684,HP_dp02_0008,An unsaturated heparin disaccharide that is 2-deoxy-2-(sulfoamino)-alpha-D-glucopyranose in which the hydroxy group at position 4 has been glycosylated by a 4-deoxy-2-O-sulfo-alpha-L-threo-hex-4-enopyranosiduronic acid moiety. Sequence: DUA2S-GlcNS.,"InChI=1S/C12H19NO16S2/c14-2-5-9(7(16)6(11(19)26-5)13-30(20,21)22)28-12-8(29-31(23,24)25)3(15)1-4(27-12)10(17)18/h1,3,5-9,11-16,19H,2H2,(H,17,18)(H,20,21,22)(H,23,24,25)/t3-,5+,6+,7+,8+,9+,11-,12-/m0/s1","alpha-Delta4,5-UA(2S)-(1->4)-alpha-D-GlcpNS",PubMed citation,20729345
6705,138707,HP_dp06_0004,"A heparin hexasaccharide consisting of 4-deoxy-2-O-sulfo-alpha-L-threo-hex-4-enopyranuronosyl, 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl, 2-O-sulfo-alpha-L-idopyranuronosyl, 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl, beta-D-glucopyranuronosyl, and 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose connected in sequence by 1->4 linkages. Sequence: DUAp2S(1-4)-a-D-GlcNp2S6S (1-4)-a-L-IdoAp2S(1-4)-a-D-GlcNp2S6S(1-4)-b-D-GlcAp(1-4)-a-D-GlcNp2S6S.","InChI=1S/C36H57N3O54S8/c40-5-1-6(28(47)48)82-35(19(5)92-100(72,73)74)86-21-8(3-79-98(66,67)68)84-33(12(14(21)42)39-96(60,61)62)89-24-18(46)25(93-101(75,76)77)36(91-27(24)30(51)52)87-22-9(4-80-99(69,70)71)83-32(11(15(22)43)38-95(57,58)59)88-23-16(44)17(45)34(90-26(23)29(49)50)85-20-7(2-78-97(63,64)65)81-31(53)10(13(20)41)37-94(54,55)56/h1,5,7-27,31-46,53H,2-4H2,(H,47,48)(H,49,50)(H,51,52)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)/t5-,7+,8+,9+,10+,11+,12+,13+,14+,15+,16+,17+,18-,19+,20+,21+,22+,23-,24-,25+,26-,27+,31-,32+,33+,34+,35-,36+/m0/s1","alpha-delta4,5-UA(2S)-(1-4)-alpha-D-GlcpNS(6S)-(1-4)-alpha-L-IdopA(2S)-(1-4)-alpha-D-GlcpNS(6S)-(1-4)-beta-D-GlcpA-(1-4)-alpha-D-GlcpNS(6S)",PubMed citation,7717977
6706,138708,HP_dp06_0003,"A heparin hexasaccharide consisting of 4-deoxy-2-O-sulfo-L-threo-hex-4-enopyranuronosyl, 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranosyl, 2-O-sulfo-L-idopyranuronosyl, 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranosyl, 2-O-sulfo-L-idopyranuronosyl, and 2-deoxy-2-(sulfoamino)-alpha-D-glucopyranose groups joined in sequence by alpha-(1->4) linkages. Sequence: DUAp2S(1-4)-a-D-GlcNp2S6S (1-4)-a-L-IdoAp2S(1-4)-a-D-GlcNp2S6S(1-4)-a-L-IdoAp2S(1-4)-a-D-GlcNp2S.","InChI=1S/C36H57N3O54S8/c40-2-7-19(13(42)10(31(53)80-7)37-94(54,55)56)84-35-24(92-100(72,73)74)16(45)22(26(89-35)29(49)50)87-33-12(39-96(60,61)62)15(44)21(9(83-33)4-79-98(66,67)68)86-36-25(93-101(75,76)77)17(46)23(27(90-36)30(51)52)88-32-11(38-95(57,58)59)14(43)20(8(82-32)3-78-97(63,64)65)85-34-18(91-99(69,70)71)5(41)1-6(81-34)28(47)48/h1,5,7-27,31-46,53H,2-4H2,(H,47,48)(H,49,50)(H,51,52)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)/t5-,7+,8+,9+,10+,11+,12+,13+,14+,15+,16-,17-,18+,19+,20+,21+,22-,23-,24+,25+,26+,27+,31-,32+,33+,34-,35+,36+/m0/s1","alpha-delta4,5-UA(2S)-(1-4)-alpha-D-GlcpNS(6S)-(1-4)-alpha-L-IdopA(2S)-(1-4)-alpha-D-GlcpNS(6S)-(1-4)-alpha-L-IdopA(2S)-(1-4)-alpha-D-GlcpNS",PubMed citation,7717977
6707,138709,HP_dp06_0002,"A heparin hexasaccharide consisting of 4-deoxy-2-O-sulfo-L-threo-hex-4-enopyranuronosyl, 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranosyl, 2-O-sulfo-L-idopyranuronosyl, 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranosyl, alpha-L-idopyranuronosyl, and 2-acetamido-2-deoxy-6-O-sulfo-alpha-D-glucopyranose joined in sequence by alpha-(1->4) linkages. Sequence: DUAp2S(1-4)-a-D-GlcNpS6S (1-4)-a-L-IdoAp2S(1-4)-a-D-GlcNpS6S(1-4)-a-L-IdoAp(1-4)-a-D-GlcNpAc6S","InChI=1S/C38H59N3O52S7/c1-6(42)39-12-15(44)22(9(81-33(12)56)3-78-96(63,64)65)85-36-19(48)18(47)25(28(90-36)31(52)53)88-34-13(40-94(57,58)59)17(46)24(11(83-34)5-80-98(69,70)71)87-38-27(93-100(75,76)77)20(49)26(29(91-38)32(54)55)89-35-14(41-95(60,61)62)16(45)23(10(84-35)4-79-97(66,67)68)86-37-21(92-99(72,73)74)7(43)2-8(82-37)30(50)51/h2,7,9-29,33-38,40-41,43-49,56H,3-5H2,1H3,(H,39,42)(H,50,51)(H,52,53)(H,54,55)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)(H,69,70,71)(H,72,73,74)(H,75,76,77)/t7-,9+,10+,11+,12+,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25-,26-,27+,28+,29+,33-,34+,35+,36+,37-,38+/m0/s1","alpha-delta4,5-UA(2S)-(1-4)-alpha-D-GlcpNS(6S)-(1-4)-alpha-L-IdopA(2S)-(1-4)-alpha-D-GlcpNS(6S)-(1-4)-alpha-L-IdopA-(1-4)-alpha-D-GlcpNAc(6S)",PubMed citation,7717977
6708,138711,HP_dp04_0001,"A heparin tetrasaccharide consisting of 4-deoxy-2-O-sulfo-L-threo-hex-4-enopyranuronosyl, 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranosyl, 2-O-sulfo-L-idopyranuronosyl and 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose joined in sequence by alpha-(1->4) linkages. Sequence: DUAp2S(1-4)-a-D-GlcNpS6S (1-4)-a-L-IdoAp2S(1-4)-a-D-GlcNpS6S.","InChI=1S/C24H38N2O38S6/c27-4-1-5(19(31)32)57-23(13(4)63-69(48,49)50)59-15-7(3-55-68(45,46)47)58-22(9(11(15)29)26-66(39,40)41)61-16-12(30)17(64-70(51,52)53)24(62-18(16)20(33)34)60-14-6(2-54-67(42,43)44)56-21(35)8(10(14)28)25-65(36,37)38/h1,4,6-18,21-30,35H,2-3H2,(H,31,32)(H,33,34)(H,36,37,38)(H,39,40,41)(H,42,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53)/t4-,6+,7+,8+,9+,10+,11+,12-,13+,14+,15+,16-,17+,18+,21-,22+,23-,24+/m0/s1","alpha-delta4,5-UA(2S)-(1-4)-alpha-D-GlcpNS(6S)-(1-4)-alpha-L-IdopA(2S)-(1-4)-alpha-D-GlcpNS(6S)",GlyTouCan accession,G88016IC
6709,138742,cholesteryl hemisuccinate,"A dicarboxylic acid monoester resulting from the formal condensation of the hydroxy group of cholesterol with one of the carboxy groups of succinic acid. A detergent that is often used to replace cholesterol in protein crystallography, biochemical studies of proteins, and pharmacology.","InChI=1S/C31H50O4/c1-20(2)7-6-8-21(3)25-11-12-26-24-10-9-22-19-23(35-29(34)14-13-28(32)33)15-17-30(22,4)27(24)16-18-31(25,26)5/h9,20-21,23-27H,6-8,10-19H2,1-5H3,(H,32,33)/t21-,23+,24+,25-,26+,27+,30+,31-/m1/s1",3beta-hydroxy-5-cholestene 3-hemisuccinate,Reaxys Registry Number,3181155
6710,138743,L-798106,"An N-sulfonylcarboxamide resulting from the formal condensation of the carboxy group of o-naphthalen-2-ylcinnamic acid with the sulfonamide group of 5-bromo-2-methoxybenzenesulfonamide. It is a selective antagonist for the prostanoid receptor EP3, a prostaglandin receptor for prostaglandin E2 (PGE2).","InChI=1S/C27H22BrNO4S/c1-33-25-14-13-24(28)18-26(25)34(31,32)29-27(30)15-12-21-7-3-5-9-23(21)17-19-10-11-20-6-2-4-8-22(20)16-19/h2-16,18H,17H2,1H3,(H,29,30)/b15-12+",(2E)-N-[(5-bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide,Reaxys Registry Number,8946912
6711,138744,"2-[(9S,11R)-epidioxy-(15S)-hydroperoxy-(5Z,13E)-prostadienoyl]-sn-glycero-3-phosphoethanolamine","A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (9S,11R)-epidioxy-(15S)-hydroperoxy-(5Z,13E)-prostadienoyl.","InChI=1S/C25H44NO11P/c1-2-3-6-9-19(35-29)12-13-22-21(23-16-24(22)37-36-23)10-7-4-5-8-11-25(28)34-20(17-27)18-33-38(30,31)32-15-14-26/h4,7,12-13,19-24,27,29H,2-3,5-6,8-11,14-18,26H2,1H3,(H,30,31)/b7-4-,13-12+/t19-,20+,21+,22+,23-,24+/m0/s1",2-(prostaglandin G2)-LPE,PubMed citation,27642067
6712,138745,"2-[(9S,11R)-epidioxy-(15S)-hydroxy-(5Z,13E)-prostadienoyl]-sn-glycero-3-phosphoethanolamine","A 2-acyl-sn-glycero-3-phosphoethanolamine in which the acyl group is specified as (9S,11R)-epidioxy-(15S)-hydroxy-(5Z,13E)-prostadienoyl.","InChI=1S/C25H44NO10P/c1-2-3-6-9-19(28)12-13-22-21(23-16-24(22)36-35-23)10-7-4-5-8-11-25(29)34-20(17-27)18-33-37(30,31)32-15-14-26/h4,7,12-13,19-24,27-28H,2-3,5-6,8-11,14-18,26H2,1H3,(H,30,31)/b7-4-,13-12+/t19-,20+,21+,22+,23-,24+/m0/s1",2-(prostaglandin H2)-sn-glycero-3-phosphoethanolamine,PubMed citation,27642067
6713,138801,D-tagatopyranose 1-phosphate,A ketohexose monophosphate that is D-tagatopyranose in which the phosphono substituent is located at position 1.,"InChI=1S/C6H13O9P/c7-3-1-14-6(10,5(9)4(3)8)2-15-16(11,12)13/h3-5,7-10H,1-2H2,(H2,11,12,13)/t3-,4+,5+,6?/m1/s1",D-tagatose 1-phosphate,PubMed citation,26159072
6714,138807,ent-copal-8-ol diphosphate,A diterpenyl phosphate that is the O-diphospho derivative of ent-copal-8-ol.,"InChI=1S/C20H38O8P2/c1-15(10-14-27-30(25,26)28-29(22,23)24)7-8-17-19(4)12-6-11-18(2,3)16(19)9-13-20(17,5)21/h10,16-17,21H,6-9,11-14H2,1-5H3,(H,25,26)(H2,22,23,24)/b15-10+/t16-,17+,19-,20+/m1/s1",ent-8alpha-hydroxylabd-13-en-15-yl diphosphate,Reaxys Registry Number,27653652
6715,138839,CAY10397,"A member of the class of azobenzenes that is azobenzene in which one of the phenyl groups is substituted at position 4 by an ethoxycarbonyl group, while the other is substituted by a carboxymethyl group at position 3 and a hydroxy group at position 4. It is a potent and selective inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-hydroxy-PGDH).","InChI=1S/C17H16N2O5/c1-2-24-17(23)11-3-5-13(6-4-11)18-19-14-7-8-15(20)12(9-14)10-16(21)22/h3-9,20H,2,10H2,1H3,(H,21,22)/b19-18+",CK47A,CAS Registry Number,78028-01-0
6716,138840,MMP9 inhibitor I,"A hydroxamic acid that is N-hydroxy-3-methylbenzamide in which the the hydrogens at positions 2 and 5 have been replaced by benzyl[(4-methoxyphenyl)sulfonyl]amino and (diethylamino)methyl groups, respectively. It is a cell-permeable, potent, selective, and reversible inhibitor of matrix metallopeptidase-9 (MMP-9, EC 3.4.24.35).","InChI=1S/C27H33N3O5S/c1-5-29(6-2)18-22-16-20(3)26(25(17-22)27(31)28-32)30(19-21-10-8-7-9-11-21)36(33,34)24-14-12-23(35-4)13-15-24/h7-17,32H,5-6,18-19H2,1-4H3,(H,28,31)",MMP9-I,Reaxys Registry Number,9095110
6717,138841,prinomastat hydrochloride,"A hydrochloride resulting from the formal reaction of equimolar amounts of prinomastat and hydrogen chloride. A selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14.","InChI=1S/C18H21N3O5S2.ClH/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14;/h3-10,16,23H,11-12H2,1-2H3,(H,20,22);1H/t16-;/m0./s1",AG 3340 hydrochloride,Reaxys Registry Number,30263785
6718,138888,(R)-3-hydroxy-4-oxobutanoic acid,A 4-oxo monocarboxylic acid that is 4-oxobutanoic acid in which the pro-R hydrogen at position 3 has been replaced by a hydroxy group.,"InChI=1S/C4H6O4/c5-2-3(6)1-4(7)8/h2-3,6H,1H2,(H,7,8)/t3-/m1/s1",(3R)-3-hydroxy-4-oxobutyric acid,MetaCyc accession,CPD-16618
6719,138923,1-heptanoyl-2-hexanoyl-sn-glycero-3-phosphoethanolamine,"1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl groups at positions 1 and 2 are specified as heptanoyl and hexanoyl respectively.","InChI=1S/C18H36NO8P/c1-3-5-7-9-10-17(20)24-14-16(27-18(21)11-8-6-4-2)15-26-28(22,23)25-13-12-19/h16H,3-15,19H2,1-2H3,(H,22,23)/t16-/m1/s1",PE(7:0/6:0),PubMed citation,22605381
6720,138926,"1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine","1,2-diacyl-sn-glycero-3-phosphoethanolamine in which the acyl groups at positions 1 and 2 are both specified as heptadecanoyl.","InChI=1S/C39H78NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-38(41)45-35-37(36-47-49(43,44)46-34-33-40)48-39(42)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h37H,3-36,40H2,1-2H3,(H,43,44)/t37-/m1/s1",PE(17:0/17:0),Reaxys Registry Number,8095262
6721,138929,"N-hexadecanoyl-1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine",An N-hexadecanoylphosphatidylethanolamine in which the acyl groups at positions 1 and 2 are both specified as heptadecanoyl.,"InChI=1S/C55H108NO9P/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-54(58)62-50-52(65-55(59)47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2)51-64-66(60,61)63-49-48-56-53(57)45-42-39-36-33-30-27-24-21-18-15-12-9-6-3/h52H,4-51H2,1-3H3,(H,56,57)(H,60,61)/t52-/m1/s1",N-16:0-PE(17:0/17:0),PubMed citation,22605381
6722,138930,"N-oleoyl-1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine",An N-oleoylphosphatidylethanolamine in which the acyl groups at positions 1 and 2 are both specified as heptadecanoyl.,"InChI=1S/C57H110NO9P/c1-4-7-10-13-16-19-22-25-28-29-32-35-38-41-44-47-55(59)58-50-51-65-68(62,63)66-53-54(67-57(61)49-46-43-40-37-34-31-27-24-21-18-15-12-9-6-3)52-64-56(60)48-45-42-39-36-33-30-26-23-20-17-14-11-8-5-2/h25,28,54H,4-24,26-27,29-53H2,1-3H3,(H,58,59)(H,62,63)/b28-25-/t54-/m1/s1","N-[(9Z)-octadecenoyl]-1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine",PubMed citation,22605381
6723,138932,1-nitroso-L-tryptophan,An L-tryptophan derivative in which the indolyl ring nitrogen carries a nitroso substituent.,"InChI=1S/C11H11N3O3/c12-9(11(15)16)5-7-6-14(13-17)10-4-2-1-3-8(7)10/h1-4,6,9H,5,12H2,(H,15,16)/t9-/m0/s1",NO-L-tryptophan,CAS Registry Number,68807-89-6
6724,138940,1-O-hexadecyl-2-(8-carboxyoctanoyl)-sn-glycero-3-phosphocholine,A 2-acyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl and the acyl groups at positions 1 and 2 are specified as hexadecyl and 8-carboxyoctanoyl respectively.,"InChI=1S/C33H66NO9P/c1-5-6-7-8-9-10-11-12-13-14-15-16-20-23-27-40-29-31(30-42-44(38,39)41-28-26-34(2,3)4)43-33(37)25-22-19-17-18-21-24-32(35)36/h31H,5-30H2,1-4H3,(H-,35,36,38,39)/t31-/m1/s1",1-O-hexadecyl-2-azelaoyl-sn-glycero-3-phosphocholine,Reaxys Registry Number,15471660
6725,138980,AZD1979(1+),An ammonium ion resulting from the protonation of the tertiary amino group of AZD1979.  A melanin concentrating hormone receptor 1 (MCHr1) antagonist.,"InChI=1S/C25H26N4O5/c1-31-19-8-4-18(5-9-19)22-26-27-23(34-22)24(30)29-11-21(12-29)33-20-6-2-17(3-7-20)10-28-13-25(14-28)15-32-16-25/h2-9,21H,10-16H2,1H3/p+1","(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone",PubMed citation,26741166
6726,139033,(-)-kolavenyl diphosphate,A diterpenyl phosphate that is the O-diphospho derivative of (-)-kolavenol,"InChI=1S/C20H36O7P2/c1-15(11-14-26-29(24,25)27-28(21,22)23)9-12-19(4)17(3)10-13-20(5)16(2)7-6-8-18(19)20/h7,11,17-18H,6,8-10,12-14H2,1-5H3,(H,24,25)(H2,21,22,23)/b15-11+/t17-,18-,19+,20+/m1/s1",(-)-kolavenyl pyrophosphate,MetaCyc accession,CPD-20259
6727,139034,(+)-kolavenyl diphosphate,A diterpenyl phosphate that is the O-diphospho derivative of (+)-kolavenol,"InChI=1S/C20H36O7P2/c1-15(11-14-26-29(24,25)27-28(21,22)23)9-12-19(4)17(3)10-13-20(5)16(2)7-6-8-18(19)20/h7,11,17-18H,6,8-10,12-14H2,1-5H3,(H,24,25)(H2,21,22,23)/b15-11+/t17-,18-,19+,20+/m0/s1",(+)-kolavenyl pyrophosphate,MetaCyc accession,CPD-20430
6728,139035,L-firefly luciferyl-CoA,An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of L-firefly luciferin.,"InChI=1S/C32H42N9O18P3S3/c1-32(2,24(45)27(46)35-6-5-20(43)34-7-8-63-31(47)17-11-64-28(40-17)29-39-16-4-3-15(42)9-19(16)65-29)12-56-62(53,54)59-61(51,52)55-10-18-23(58-60(48,49)50)22(44)30(57-18)41-14-38-21-25(33)36-13-37-26(21)41/h3-4,9,13-14,17-18,22-24,30,42,44-45H,5-8,10-12H2,1-2H3,(H,34,43)(H,35,46)(H,51,52)(H,53,54)(H2,33,36,37)(H2,48,49,50)/t17-,18+,22+,23+,24-,30+/m0/s1",L-firefly luciferyl-coenzyme A,MetaCyc accession,CPD-20207
6729,139037,golgicide A,"A diastereoisomeric mixture comprising racemic cis- and racemic trans-goglioside A in a 10:1 ratio. It is a potent and rapidly reversible GBF1 (Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1) inhibitor. The (3aS,4R,9bR) isomer is the most active (see Bioorg. Med. Chem. Lett., 2012, 22, 5177-5181).","InChI=1S/C17H14F2N2/c18-11-7-14-12-4-1-5-13(12)16(10-3-2-6-20-9-10)21-17(14)15(19)8-11/h1-4,6-9,12-13,16,21H,5H2/t12-,13+,16?/m0/s1",GCA,CAS Registry Number,1005036-73-6
6730,139043,carbocyclic thromboxane A2,A member of the class of thromboxanes that is thromboxane A2 in which the bridging oxygen has been replaced by a methylene group.,"InChI=1S/C21H34O4/c1-2-3-6-9-17(22)12-13-20-19(16-14-18(15-16)25-20)10-7-4-5-8-11-21(23)24/h4,7,12-13,16-20,22H,2-3,5-6,8-11,14-15H2,1H3,(H,23,24)/b7-4-,13-12+/t16-,17-,18+,19-,20+/m0/s1","9alpha,11alpha-methylene-TXA2",PubMed citation,17109692
6731,139045,19-hydroxycarbocyclic thromboxane A2,A member of the class of thromboxanes that is carbocyclic thromboxane A2 carrying an additional hydroxy substituent at position 19.,"InChI=1S/C21H34O5/c1-15(22)7-6-8-17(23)11-12-20-19(16-13-18(14-16)26-20)9-4-2-3-5-10-21(24)25/h2,4,11-12,15-20,22-23H,3,5-10,13-14H2,1H3,(H,24,25)/b4-2-,12-11+/t15?,16-,17-,18+,19-,20+/m0/s1","19-hydroxy-(9alpha,11alpha)-methylene thromboxane A2",PubMed citation,15789615
6732,139047,GSK2656157,"A pyrrolopyrimidine that is 7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine which has been substituted at position 5 by a 4-fluoro-2,3-dihydro-1H-indol-5-yl group, the nitrogen of which has been acylated by a (6-methylpyridin-2-yl)acetyl group. An orally bioavailable PERK inhibitor.","InChI=1S/C23H21FN6O/c1-13-4-3-5-14(28-13)10-19(31)30-9-8-16-18(30)7-6-15(21(16)24)17-11-29(2)23-20(17)22(25)26-12-27-23/h3-7,11-12H,8-10H2,1-2H3,(H2,25,26,27)","1-[5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoro-2,3-dihydro-1H-indol-1-yl]-2-(6-methyl-2-pyridinyl)-ethanone",CAS Registry Number,1337532-29-2
6733,139064,"(15Z)-12-oxophyto-10,15-dienoyl-CoA","An oxo fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of (15Z)-12-oxophyto-10,15-dienoic acid.","InChI=1S/C39H62N7O18P3S/c1-4-5-9-13-26-25(15-16-27(26)47)12-10-7-6-8-11-14-30(49)68-20-19-41-29(48)17-18-42-37(52)34(51)39(2,3)22-61-67(58,59)64-66(56,57)60-21-28-33(63-65(53,54)55)32(50)38(62-28)46-24-45-31-35(40)43-23-44-36(31)46/h5,9,15-16,23-26,28,32-34,38,50-51H,4,6-8,10-14,17-22H2,1-3H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/b9-5-/t25-,26-,28+,32+,33+,34-,38+/m0/s1",12-OPDA-coenzyme A,PubMed citation,16963437
6734,139085,"(9R,13R)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoic acid",A carbocyclic fatty acid that is hexanoic acid substituted at position 6 by a 3-oxo-2-{(Z)-pent-2-en-1-yl}cyclopentyl group.,"InChI=1S/C16H26O3/c1-2-3-5-9-14-13(11-12-15(14)17)8-6-4-7-10-16(18)19/h3,5,13-14H,2,4,6-12H2,1H3,(H,18,19)/b5-3-/t13-,14-/m1/s1",OPC-6,PubMed citation,18267944
6735,139100,alpha-D-Galp-(1->6)-beta-D-Galp,A disaccharide consisting of beta-D-galactopyranose having a D-galactopyranosyl residue attached at the 6-position via an alpha-linkage. alpha-D-Gal-(1->6)-D-Gal in which the configuration at the reducing end anomeric centre is beta.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11-,12+/m1/s1",6-O-alpha-D-galactopyranosyl-beta-D-galactopyranose,Reaxys Registry Number,11242394
6736,139108,hexadecanoyl phosphate,An acyl monophosphate in which the acyl group is specified as hexadecanoyl (palmitoyl).,"InChI=1S/C16H33O5P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)21-22(18,19)20/h2-15H2,1H3,(H2,18,19,20)",hexadecanoyl monophosphate,Reaxys Registry Number,1802142
6737,139122,"(3R)-3-hydroxy-2,3-dihydrotabersonine","A monoterpenoid indole alkaloid obtained by formal hydration across the 2,3-double bond of tabersonine.","InChI=1S/C21H26N2O3/c1-3-19-9-6-11-23-12-10-20(17(19)23)14-7-4-5-8-15(14)22-16(20)21(25,13-19)18(24)26-2/h4-9,16-17,22,25H,3,10-13H2,1-2H3/t16-,17+,19+,20+,21-/m1/s1","methyl 3beta-hydroxy-6,7-didehydro-2beta,5alpha,12beta,19alpha-aspidospermidine-3alpha-carboxylate",Reaxys Registry Number,4573506
6738,139140,beta-D-glucosyl-N-(oleoyl)sphingosine,An N-acyl-beta-D-galactosylsphingosine where the ceramide N-acyl group is specified as oleoyl.,"InChI=1S/C42H79NO8/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-38(46)43-35(34-50-42-41(49)40(48)39(47)37(33-44)51-42)36(45)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h17-18,29,31,35-37,39-42,44-45,47-49H,3-16,19-28,30,32-34H2,1-2H3,(H,43,46)/b18-17-,31-29+/t35-,36+,37+,39+,40-,41+,42+/m0/s1",beta-D-glucosyl-N-[(9Z)-octadecenoyl]-octadecasphing-4-enine,PubMed citation,22078563
6739,139172,"1,2-dioleoyl-sn-glycero-3-phospho-1'-(3'-oleoyl)-sn-glycerol(1-)","An acylglycerophosphoacylglycerol(1-) that is the conjugate base of 1,2-dioleoyl-sn-glycero-3-phospho-1'-(3'-oleoyl)-sn-glycerol, obtained by deprotonation of the phosphate OH group; major species at pH 7.3.","InChI=1S/C60H111O11P/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-58(62)67-52-56(61)53-69-72(65,66)70-55-57(71-60(64)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)54-68-59(63)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h25-30,56-57,61H,4-24,31-55H2,1-3H3,(H,65,66)/p-1/b28-25-,29-26-,30-27-/t56-,57+/m0/s1","(S,R)-3-(9Z-octadecenoyl)-sn-glycero-1-phospho-(1',2'-di-(9Z-octadecenoyl)-sn-glycerol)",PubMed citation,21788486
6740,139179,"4,4'-diapolycopen-4-oic acid","An apo carotenoid triterpenoid that is 4,4'-diapolycopene in which one of the terminal methyl groups has been replaced by a carboxy group.","InChI=1S/C30H38O2/c1-24(2)14-10-17-27(5)20-11-18-25(3)15-8-9-16-26(4)19-12-21-28(6)22-13-23-29(7)30(31)32/h8-23H,1-7H3,(H,31,32)/b9-8+,17-10+,18-11+,19-12+,22-13+,25-15+,26-16+,27-20+,28-21+,29-23+","4,4'-diapolycopenoic acid",PubMed citation,25326460
6741,139211,"N-[8-([1,1'-biphenyl]-4-yl)octanoyl]-1-O-(alpha-D-galactopyranosyl)phytosphingosine","A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and an 8-([1,1'-biphenyl]-4-yl)octanoyl group attached to the nitrogen.","InChI=1S/C44H71NO9/c1-2-3-4-5-6-7-8-9-10-11-14-20-25-37(47)40(49)36(32-53-44-43(52)42(51)41(50)38(31-46)54-44)45-39(48)26-21-15-12-13-17-22-33-27-29-35(30-28-33)34-23-18-16-19-24-34/h16,18-19,23-24,27-30,36-38,40-44,46-47,49-52H,2-15,17,20-22,25-26,31-32H2,1H3,(H,45,48)/t36-,37+,38+,40-,41-,42-,43+,44-/m0/s1","1-O-(alpha-D-galactopyranosyl)-N-[9-([1,1'-biphenyl]-4-yl)octanoyl]phytosphingosine",Patent accession,CA2683681
6742,139216,"N-[11-([1,1'-biphenyl]-4-yl)undecanoyl]-1-O-(alpha-D-galactopyranosyl)phytosphingosine","A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and an 11-([1,1'-biphenyl]-4-yl)undecanoyl group attached to the nitrogen.","InChI=1S/C47H77NO9/c1-2-3-4-5-6-7-8-9-10-14-17-23-28-40(50)43(52)39(35-56-47-46(55)45(54)44(53)41(34-49)57-47)48-42(51)29-24-18-15-12-11-13-16-20-25-36-30-32-38(33-31-36)37-26-21-19-22-27-37/h19,21-22,26-27,30-33,39-41,43-47,49-50,52-55H,2-18,20,23-25,28-29,34-35H2,1H3,(H,48,51)/t39-,40+,41+,43-,44-,45-,46+,47-/m0/s1","1-O-(alpha-D-galactopyranosyl)-N-[11-([1,1'-biphenyl]-4-yl)undecanoyl]phytosphingosine",PubMed citation,20616071
6743,139223,(2S)-1-oleoyl-2-methylglycero-3-phosphothionate,A glycerophospholipid obtained by formal condensation of the carboxy group of oleic acid with the primary hydroxy group of (2S)-2-methylglycero-3-phosphothionate.,"InChI=1S/C22H43O6PS/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-22(23)27-19-21(26-2)20-28-29(24,25)30/h10-11,21H,3-9,12-20H2,1-2H3,(H2,24,25,30)/b11-10-/t21-/m0/s1",(2S)-OMPT,Pubchem accession,16078994
6744,139236,(R)-3-hydroxypentanoyl-CoA,A 3-hydroxy fatty acyl-CoA resulting from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-3-hydroxypentanoic acid.,"InChI=1S/C26H44N7O18P3S/c1-4-14(34)9-17(36)55-8-7-28-16(35)5-6-29-24(39)21(38)26(2,3)11-48-54(45,46)51-53(43,44)47-10-15-20(50-52(40,41)42)19(37)25(49-15)33-13-32-18-22(27)30-12-31-23(18)33/h12-15,19-21,25,34,37-38H,4-11H2,1-3H3,(H,28,35)(H,29,39)(H,43,44)(H,45,46)(H2,27,30,31)(H2,40,41,42)/t14-,15-,19-,20-,21+,25-/m1/s1",(3R)-hydroxypentanoyl-coenzyme A,Reaxys Registry Number,29418570
6745,139239,(R)-3-hydroxypentanoic acid,A 3-hydroxypentanoic acid in which the chiral centre at position 3 has R-configuration.,"InChI=1S/C5H10O3/c1-2-4(6)3-5(7)8/h4,6H,2-3H2,1H3,(H,7,8)/t4-/m1/s1",(3R)-hydroxypentanoic acid,Reaxys Registry Number,1721213
6746,139243,gemini-0072,A hydroxycalciol that is a synthetic fluorinated and deuterated analogue of vitamin D3 which exhibits vitamin D receptor superagonist and anti-cancer activity.,"InChI=1S/C32H44F6O4/c1-20-23(18-24(39)19-27(20)40)12-11-22-9-6-16-29(4)25(13-14-26(22)29)21(8-5-15-28(2,3)41)10-7-17-30(42,31(33,34)35)32(36,37)38/h11-12,21,24-27,39-42H,1,5-6,8-10,13-16,18-19H2,2-4H3/b22-11+,23-12-/t21-,24+,25+,26-,27-,29+/m0/s1/i2D3,3D3",gemini-0072,Reaxys Registry Number,15017122
6747,139244,gemini-0097,A hydroxycalciol that is a synthetic fluorinated and deuterated analogue of vitamin D3 which exhibits vitamin D receptor superagonist and anti-cancer activity.,"InChI=1S/C32H44F6O4/c1-20-23(18-24(39)19-27(20)40)12-11-22-9-6-16-29(4)25(13-14-26(22)29)21(8-5-15-28(2,3)41)10-7-17-30(42,31(33,34)35)32(36,37)38/h11-12,21,24-27,39-42H,1,5-6,8-10,13-16,18-19H2,2-4H3/b22-11+,23-12-/t21-,24-,25-,26+,27+,29-/m1/s1/i2D3,3D3",gemini0097,Pubchem accession,90667288
6748,139250,NBD-N(Me)-DbetaA-OH,"A dipeptide comprising in sequence alpha-aspartyl and beta-alanyl residues, to the nitrogen of the aspartyl residue of which are linked both a methyl group and a 7-nitro-2,1,3-benzoxadiazol-4-yl moiety.","InChI=1S/C14H15N5O8/c1-18(9(6-11(22)23)14(24)15-5-4-10(20)21)7-2-3-8(19(25)26)13-12(7)16-27-17-13/h2-3,9H,4-6H2,1H3,(H,15,24)(H,20,21)(H,22,23)/t9-/m0/s1","N-methyl-N-(7-nitro-2,1,3-benzoxadiazol-4-yl)-Asp-betaAla-OH",PubMed citation,28987997
6749,139255,9-cis-4-oxoretinoic acid,A retinoid that consists of 9-cis-retinoic acid bearing an oxo substituent at position 4 on the cyclohexenyl ring.,"InChI=1S/C20H26O3/c1-14(7-6-8-15(2)13-19(22)23)9-10-17-16(3)18(21)11-12-20(17,4)5/h6-10,13H,11-12H2,1-5H3,(H,22,23)/b8-6+,10-9+,14-7-,15-13+",4-oxo-9-cis-retinoic acid,Reaxys Registry Number,7518834
6750,139270,(S)-3-hydroxypentanoic acid,A 3-hydroxypentanoic acid in which the chiral centre at position 3 has S-configuration.,"InChI=1S/C5H10O3/c1-2-4(6)3-5(7)8/h4,6H,2-3H2,1H3,(H,7,8)/t4-/m0/s1",(3S)-hydroxyvaleric acid,Reaxys Registry Number,3648212
6751,139283,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-GlcpNAcO[CH2]6CH=CH2,A glycoside formed between the branched tetrasaccharide alpha-L-Fuc-(1->2)-[alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->3)-beta-D-GlcNAc and the alkenyl alcohol oct-7-en-1-ol.,"InChI=1S/C36H62N2O20/c1-5-6-7-8-9-10-11-51-33-22(38-17(4)43)30(25(46)19(13-40)53-33)56-36-32(58-35-29(50)28(49)23(44)15(2)52-35)31(26(47)20(14-41)55-36)57-34-21(37-16(3)42)27(48)24(45)18(12-39)54-34/h5,15,18-36,39-41,44-50H,1,6-14H2,2-4H3,(H,37,42)(H,38,43)/t15-,18+,19+,20+,21+,22+,23+,24-,25+,26-,27+,28+,29-,30+,31-,32+,33+,34+,35-,36-/m0/s1","alpha-D-GalNAc-(1,3)-[alpha-L-Fuc-(1,2)]-beta-D-Gal-(1,3)-beta-D-GlcNAc-(1,O)-(CH2)6CH=CH2",PubMed citation,28823097
6752,139299,"4alpha-phorbol 12,13-didecanoate",A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted to the corresponding decanoate esters. A Trpv4-specific ligand.,"InChI=1S/C40H64O8/c1-7-9-11-13-15-17-19-21-32(42)47-36-28(4)39(46)30(24-29(26-41)25-38(45)31(39)23-27(3)35(38)44)34-37(5,6)40(34,36)48-33(43)22-20-18-16-14-12-10-8-2/h23-24,28,30-31,34,36,41,45-46H,7-22,25-26H2,1-6H3/t28-,30+,31-,34-,36-,38+,39-,40-/m1/s1",4alphaPDD,Pubchem accession,452544
6753,139300,(+)-jasmonic acid,An oxo monocarboxylic acid that is (3-oxocyclopentyl)acetic acid substituted by a (2Z)-pent-2-en-1-yl group at position 2 of the cyclopentane ring.,"InChI=1S/C12H18O3/c1-2-3-4-5-10-9(8-12(14)15)6-7-11(10)13/h3-4,9-10H,2,5-8H2,1H3,(H,14,15)/b4-3-/t9-,10-/m0/s1","(1S,2S)-jasmonic acid",Reaxys Registry Number,2415413
6754,139302,N-[(3R)-jasmonyl]-L-isoleucine,An L-isoleucine derivative resulting from the formal condensation of the carboxy group of (3R)-jasmonic acid with the amino group of L-isoleucine.,"InChI=1S/C18H29NO4/c1-4-6-7-8-14-13(9-10-15(14)20)11-16(21)19-17(18(22)23)12(3)5-2/h6-7,12-14,17H,4-5,8-11H2,1-3H3,(H,19,21)(H,22,23)/b7-6-/t12-,13+,14?,17-/m0/s1",(3R)-jasmonoyl-L-isoleucine,Reaxys Registry Number,18883676
6755,139305,otophylloside B,"A steroid saponin that is 17alpha-pregnenolone which is substituted by hydroxy groups at positions 8, 12beta, 14beta and 17beta, in which the 14beta-hydrocy group has been acylated by formal condensation with the carboxy group of (2E)-3,4-dimethylpent-2-enoic acid, and in which the hydroxy group at position 3 has been glycosylated with 2,6-dideoxy-3-O-methyl-beta-D-arabino-hexopyranosyl-(1->4)-2,6-dideoxy-3-O-methyl-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-3-O-methyl-beta-D-ribo-hexopyranos. A C-21 steroidal glycoside, it is the essential active ingredient of the traditional Chinese medicine Qingyangshen, isolated from Cynanchum otophyllum and used to treat epilepsy and rheumatic pain.","InChI=1S/C49H78O16/c1-25(2)26(3)19-38(51)63-37-24-36-45(8)15-14-32(20-31(45)13-16-48(36,54)49(55)18-17-47(53,30(7)50)46(37,49)9)62-39-22-34(57-11)43(28(5)60-39)65-41-23-35(58-12)44(29(6)61-41)64-40-21-33(56-10)42(52)27(4)59-40/h13,19,25,27-29,32-37,39-44,52-55H,14-18,20-24H2,1-12H3/b26-19+/t27-,28-,29-,32+,33-,34+,35+,36-,37-,39+,40+,41+,42-,43-,44-,45+,46-,47-,48+,49-/m1/s1",Ot B,PubMed citation,28194725
6756,139309,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->3)-beta-D-GalpO[CH2]6CH=CH2,A glycoside formed between the branched tetrasaccharide alpha-L-Fuc-(1->2)-[alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->3)-beta-D-Gal and the alkenyl alcohol oct-7-en-1-ol.,"InChI=1S/C34H59NO20/c1-4-5-6-7-8-9-10-48-32-27(47)28(22(42)17(12-37)51-32)53-34-30(55-33-26(46)25(45)20(40)14(2)49-33)29(23(43)18(13-38)52-34)54-31-19(35-15(3)39)24(44)21(41)16(11-36)50-31/h4,14,16-34,36-38,40-47H,1,5-13H2,2-3H3,(H,35,39)/t14-,16+,17+,18+,19+,20+,21-,22-,23-,24+,25+,26-,27+,28-,29-,30+,31+,32+,33-,34-/m0/s1",oct-7-en-1-yl N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->3)-beta-D-galactoside,PubMed citation,28823097
6757,139310,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-beta-D-GlcpO[CH2]6CH=CH2,A glycoside formed between the branched tetrasaccharide alpha-L-Fuc-(1->2)-[alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->4)-beta-D-Glc and the alkenyl alcohol oct-7-en-1-ol.,"InChI=1S/C34H59NO20/c1-4-5-6-7-8-9-10-48-32-27(47)25(45)28(18(13-38)52-32)53-34-30(55-33-26(46)24(44)20(40)14(2)49-33)29(22(42)17(12-37)51-34)54-31-19(35-15(3)39)23(43)21(41)16(11-36)50-31/h4,14,16-34,36-38,40-47H,1,5-13H2,2-3H3,(H,35,39)/t14-,16+,17+,18+,19+,20+,21-,22-,23+,24+,25+,26-,27+,28+,29-,30+,31+,32+,33-,34-/m0/s1",oct-7-en-1-yl N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->4)-beta-D-glucoside,PubMed citation,28823097
6758,139315,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-beta-D-Galp-(1->4)-beta-D-GlcpNAcO[CH2]6CH=CH2,A glycoside formed between the branched tetrasaccharide alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal-(1->4)-beta-D-GlcNAc and the alkenyl alcohol oct-7-en-1-ol.,"InChI=1S/C34H59NO20/c1-4-5-6-7-8-9-10-48-31-19(35-15(3)39)23(43)28(18(13-38)52-31)53-34-30(55-32-26(46)24(44)20(40)14(2)49-32)29(22(42)17(12-37)51-34)54-33-27(47)25(45)21(41)16(11-36)50-33/h4,14,16-34,36-38,40-47H,1,5-13H2,2-3H3,(H,35,39)/t14-,16+,17+,18+,19+,20+,21-,22-,23+,24+,25-,26-,27+,28+,29-,30+,31+,32-,33+,34-/m0/s1",alpha-D-Gal-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAcO[CH2]6CH=CH2,Reaxys Registry Number,20864559
6759,139316,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-beta-D-Galp-(1->3)-alpha-D-GalpNAcO[CH2]6CH=CH2,A glycoside formed between the branched tetrasaccharide alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal-(1->3)-alpha-D-GalNAc and the alkenyl alcohol oct-7-en-1-ol.,"InChI=1S/C34H59NO20/c1-4-5-6-7-8-9-10-48-31-19(35-15(3)39)28(22(42)17(12-37)50-31)53-34-30(55-32-26(46)24(44)20(40)14(2)49-32)29(23(43)18(13-38)52-34)54-33-27(47)25(45)21(41)16(11-36)51-33/h4,14,16-34,36-38,40-47H,1,5-13H2,2-3H3,(H,35,39)/t14-,16+,17+,18+,19+,20+,21-,22-,23-,24+,25-,26-,27+,28+,29-,30+,31-,32-,33+,34-/m0/s1","alpha-D-Gal-(1,3)-[alpha-L-Fuc-(1,2)]-beta-D-Gal-(1,3)-alpha-D-GalNAc-(1,O)-(CH2)6CH=CH2",PubMed citation,28823097
6760,139317,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-beta-D-Galp-(1->3)-beta-D-GalpO[CH2]6CH=CH2,A glycoside formed between the branched tetrasaccharide alpha-L-Fuc-(1->2)-[alpha-D-Gal-(1->3)]-beta-D-Gal-(1->3)-beta-D-Gal and the alkenyl alcohol oct-7-en-1-ol.,"InChI=1S/C32H56O20/c1-3-4-5-6-7-8-9-45-29-25(44)26(19(38)15(11-34)47-29)50-32-28(52-30-23(42)21(40)17(36)13(2)46-30)27(20(39)16(12-35)49-32)51-31-24(43)22(41)18(37)14(10-33)48-31/h3,13-44H,1,4-12H2,2H3/t13-,14+,15+,16+,17+,18-,19-,20-,21+,22-,23-,24+,25+,26-,27-,28+,29+,30-,31+,32-/m0/s1",oct-7-en-1-yl alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl-(1->3)-beta-D-galactoside,PubMed citation,28823097
6761,139347,all-trans-4-oxoretinal,A retinoid that is all-trans-retinal carrying an oxo substituent at position 4 on the cyclohexenyl ring.,"InChI=1S/C20H26O2/c1-15(7-6-8-16(2)12-14-21)9-10-18-17(3)19(22)11-13-20(18,4)5/h6-10,12,14H,11,13H2,1-5H3/b8-6+,10-9+,15-7+,16-12+",all-trans-4-oxo-retinal,Reaxys Registry Number,2508352
6762,139349,N-(p-amylcinnamoyl)anthranilic acid,An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 4-pentylcinnamoyl group. It is a transient receptor potential (TRP) channel blocker and phospholipase A2 (PLA2) inhibitor.,"InChI=1S/C21H23NO3/c1-2-3-4-7-16-10-12-17(13-11-16)14-15-20(23)22-19-9-6-5-8-18(19)21(24)25/h5-6,8-15H,2-4,7H2,1H3,(H,22,23)(H,24,25)/b15-14+",ACA,CAS Registry Number,110683-10-8
6763,139362,2-hydroxy-3-methylundecanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-hydroxy-3-methylundecanoic acid.,"InChI=1S/C33H58N7O18P3S/c1-5-6-7-8-9-10-11-20(2)24(42)32(46)62-15-14-35-22(41)12-13-36-30(45)27(44)33(3,4)17-55-61(52,53)58-60(50,51)54-16-21-26(57-59(47,48)49)25(43)31(56-21)40-19-39-23-28(34)37-18-38-29(23)40/h18-21,24-27,31,42-44H,5-17H2,1-4H3,(H,35,41)(H,36,45)(H,50,51)(H,52,53)(H2,34,37,38)(H2,47,48,49)/t20?,21-,24?,25-,26-,27+,31-/m1/s1",2-hydroxy-3-methylundecanoyl-coenzyme A,PubMed citation,12923223
6764,139363,2-hydroxy-3-methylnonanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-hydroxy-3-methylnonanoic acid.,"InChI=1S/C31H54N7O18P3S/c1-5-6-7-8-9-18(2)22(40)30(44)60-13-12-33-20(39)10-11-34-28(43)25(42)31(3,4)15-53-59(50,51)56-58(48,49)52-14-19-24(55-57(45,46)47)23(41)29(54-19)38-17-37-21-26(32)35-16-36-27(21)38/h16-19,22-25,29,40-42H,5-15H2,1-4H3,(H,33,39)(H,34,43)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t18?,19-,22?,23-,24-,25+,29-/m1/s1",2-hydroxy-3-methylnonanoyl-coenzyme A,PubMed citation,12923223
6765,139364,piperacilloyl-L-lysine,An L-lysine derivative obtained from nucleophilic cleavage of the beta-lactam ring of piperacillin by the epsilon-amino group of the L-lysine molecule.,"InChI=1S/C29H41N7O9S/c1-4-16-14-36(25(40)23(39)32-16)28(45)34-18(15-10-6-5-7-11-15)22(38)33-19(24-35-20(27(43)44)29(2,3)46-24)21(37)31-13-9-8-12-17(30)26(41)42/h5-7,10-11,16-20,24,35H,4,8-9,12-14,30H2,1-3H3,(H,31,37)(H,32,39)(H,33,38)(H,34,45)(H,41,42)(H,43,44)/t16?,17-,18+,19+,20-,24+/m0/s1",N(6)-piperacilloyl-L-lysine,PubMed citation,29148816
6766,139366,amoxicilloyl-L-lysine,An L-lysine derivative obtained from nucleophilic cleavage of the beta-lactam ring of amoxicillin by the epsilon-amino group of the L-lysine molecule.,"InChI=1S/C22H33N5O7S/c1-22(2)16(21(33)34)27-19(35-22)15(18(30)25-10-4-3-5-13(23)20(31)32)26-17(29)14(24)11-6-8-12(28)9-7-11/h6-9,13-16,19,27-28H,3-5,10,23-24H2,1-2H3,(H,25,30)(H,26,29)(H,31,32)(H,33,34)/t13-,14+,15+,16-,19+/m0/s1",amoxicillin-lysine,PubMed citation,29148816
6767,139367,benzylpenicilloyl-L-lysine,An L-lysine derivative obtained from nucleophilic cleavage of the beta-lactam ring of benzylpenicillin (penicillin G) by the epsilon-amino group of the L-lysine molecule.,"InChI=1S/C22H32N4O6S/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32)/t14-,16+,17-,19+/m0/s1",N(epsilon)-benzylpenicilloyl-L-lysine,PubMed citation,29148816
6768,139372,3-methylnonanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-methylnonanoic acid.,"InChI=1S/C31H54N7O17P3S/c1-5-6-7-8-9-19(2)14-22(40)59-13-12-33-21(39)10-11-34-29(43)26(42)31(3,4)16-52-58(49,50)55-57(47,48)51-15-20-25(54-56(44,45)46)24(41)30(53-20)38-18-37-23-27(32)35-17-36-28(23)38/h17-20,24-26,30,41-42H,5-16H2,1-4H3,(H,33,39)(H,34,43)(H,47,48)(H,49,50)(H2,32,35,36)(H2,44,45,46)/t19?,20-,24-,25-,26+,30-/m1/s1",3-methylnonanoyl-coenzyme A,PubMed citation,12923223
6769,139375,(R)-2-hydroxyhexadecanoyl-CoA,A 2-hydroxyhexadecanoyl-CoA  that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (R)-2-hydroxyhexadecanoic acid.,"InChI=1S/C37H66N7O18P3S/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-25(45)36(50)66-20-19-39-27(46)17-18-40-34(49)31(48)37(2,3)22-59-65(56,57)62-64(54,55)58-21-26-30(61-63(51,52)53)29(47)35(60-26)44-24-43-28-32(38)41-23-42-33(28)44/h23-26,29-31,35,45,47-48H,4-22H2,1-3H3,(H,39,46)(H,40,49)(H,54,55)(H,56,57)(H2,38,41,42)(H2,51,52,53)/t25-,26-,29-,30-,31+,35-/m1/s1",(R)-2-hydroxypalmitoyl-coenzyme A,PubMed citation,28289220
6770,139376,2-hydroxy-3-methyldodecanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-hydroxy-3-methyldodecanoic acid.,"InChI=1S/C34H60N7O18P3S/c1-5-6-7-8-9-10-11-12-21(2)25(43)33(47)63-16-15-36-23(42)13-14-37-31(46)28(45)34(3,4)18-56-62(53,54)59-61(51,52)55-17-22-27(58-60(48,49)50)26(44)32(57-22)41-20-40-24-29(35)38-19-39-30(24)41/h19-22,25-28,32,43-45H,5-18H2,1-4H3,(H,36,42)(H,37,46)(H,51,52)(H,53,54)(H2,35,38,39)(H2,48,49,50)/t21?,22-,25?,26-,27-,28+,32-/m1/s1",2-hydroxy-3-methyldodecanoyl-coenzyme A,PubMed citation,12923223
6771,139390,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)]-alpha-D-ManpO[CH2]3NH2,A mannooligosaccharide derivative consisting of a D-mannosyl residue alpha-linked to a 3-aminopropyl group and which carries an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl unit linked (1->3) and an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl unit linked (1->6).,"InChI=1S/C45H79NO36/c46-2-1-3-69-40-34(68)35(79-44-38(30(64)22(56)14(7-50)75-44)82-45-37(29(63)21(55)15(8-51)76-45)81-42-33(67)26(60)19(53)12(5-48)73-42)24(58)17(78-40)10-70-39-31(65)27(61)23(57)16(77-39)9-71-43-36(28(62)20(54)13(6-49)74-43)80-41-32(66)25(59)18(52)11(4-47)72-41/h11-45,47-68H,1-10,46H2/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41-,42-,43+,44-,45-/m1/s1",3-aminopropyl alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->3)-[alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->6)]-alpha-D-mannoside,PubMed citation,29150603
6772,139391,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)]-beta-D-ManpO[CH2]3NH2,A mannooligosaccharide derivative consisting of a D-mannosyl residue beta-linked to a 3-aminopropyl group and which carries an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl unit linked (1->3) and an alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-beta-D-mannosyl unit linked (1->6).,"InChI=1S/C45H79NO36/c46-2-1-3-69-40-34(68)35(79-44-38(30(64)22(56)14(7-50)75-44)82-45-37(29(63)21(55)15(8-51)76-45)81-42-33(67)26(60)19(53)12(5-48)73-42)24(58)17(78-40)10-70-39-31(65)27(61)23(57)16(77-39)9-71-43-36(28(62)20(54)13(6-49)74-43)80-41-32(66)25(59)18(52)11(4-47)72-41/h11-45,47-68H,1-10,46H2/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42-,43+,44-,45-/m1/s1",3-aminopropyl alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->3)-[alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->6)]-beta-D-mannoside,PubMed citation,29150603
6773,139392,3-methyldodecanoyl-CoA,A hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-methyldodecanoic acid.,"InChI=1S/C34H60N7O17P3S/c1-5-6-7-8-9-10-11-12-22(2)17-25(43)62-16-15-36-24(42)13-14-37-32(46)29(45)34(3,4)19-55-61(52,53)58-60(50,51)54-18-23-28(57-59(47,48)49)27(44)33(56-23)41-21-40-26-30(35)38-20-39-31(26)41/h20-23,27-29,33,44-45H,5-19H2,1-4H3,(H,36,42)(H,37,46)(H,50,51)(H,52,53)(H2,35,38,39)(H2,47,48,49)/t22?,23-,27-,28-,29+,33-/m1/s1",3-methyldodecanoyl-coenzyme A,PubMed citation,12923223
6774,139397,N-hexadecanoyl-O-(1-octadecanoyl-2-oleoyl-sn-glycero-3-phospho)-L-serine,An N-acyl-O-(3-sn-phosphatidyl)-L-serine obtained by formal condensation of the carboxy group of hexadecanoic acid with the amino group of 1-octadecanoyl-2-oleoyl-sn-glycero-3-phospho-L-serine.,"InChI=1S/C58H110NO11P/c1-4-7-10-13-16-19-22-25-27-30-33-36-39-42-45-48-56(61)67-50-53(70-57(62)49-46-43-40-37-34-31-28-26-23-20-17-14-11-8-5-2)51-68-71(65,66)69-52-54(58(63)64)59-55(60)47-44-41-38-35-32-29-24-21-18-15-12-9-6-3/h26,28,53-54H,4-25,27,29-52H2,1-3H3,(H,59,60)(H,63,64)(H,65,66)/b28-26-/t53-,54+/m1/s1",N-palmitoyl-O-(1-stearoyl-2-oleoyl-sn-glycero-3-phospho)-L-serine,PubMed citation,25853435
6775,139399,N-hexadecanoyl-O-(1-octadecanoyl-sn-glycero-3-phospho)-L-serine,An N-acyl-O-(3-sn-phosphatidyl)-L-serine obtained by formal condensation of the carboxy group of hexadecanoic acid with the amino group of 1-octadecanoyl-sn-glycero-3-phospho-L-serine,"InChI=1S/C40H78NO10P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(44)49-33-36(42)34-50-52(47,48)51-35-37(40(45)46)41-38(43)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h36-37,42H,3-35H2,1-2H3,(H,41,43)(H,45,46)(H,47,48)/t36-,37+/m1/s1",1-stearoyl-sn-glycero-3-phospho-(N-palmitoyl)-serine,PubMed citation,25853435
6776,139401,N-hexadecanoyl-1-[(1Z)-octadecenoyl]-2-oleoyl-sn-glycero-3-phosphoethanolamine,A glycerophosphoethanolamine obtained by formal condensation of the carboxy group of hexadecanoic acid with the amino group of 1-[(1Z)-octadecenoyl]-2-oleoyl-sn-glycero-3-phosphoethanolamine.,"InChI=1S/C57H110NO8P/c1-4-7-10-13-16-19-22-25-27-29-32-35-38-41-44-47-51-63-53-55(66-57(60)49-46-43-40-37-34-31-28-26-23-20-17-14-11-8-5-2)54-65-67(61,62)64-52-50-58-56(59)48-45-42-39-36-33-30-24-21-18-15-12-9-6-3/h26,28,47,51,55H,4-25,27,29-46,48-50,52-54H2,1-3H3,(H,58,59)(H,61,62)/b28-26-,51-47-/t55-/m1/s1",N-palmitoyl-1-[(1Z)-octadecenoyl]-2-oleoyl-sn-glycero-3-phosphoethanolamine,PubMed citation,25853435
6777,139413,"1-oleoyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate","A 1,2-diacyl-sn-glycerol 3-phosphate in which the 1- and 2-acyl substituent are specified as oleoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively; major species at pH 7.3.","InChI=1S/C43H71O8P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-43(45)51-41(40-50-52(46,47)48)39-49-42(44)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h5,7,11,13,17-19,21-23,26,28,32,34,41H,3-4,6,8-10,12,14-16,20,24-25,27,29-31,33,35-40H2,1-2H3,(H2,46,47,48)/b7-5-,13-11-,19-17-,22-21-,23-18-,28-26-,34-32-/t41-/m1/s1","1-[(9Z)-octadecenoyl]-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate",HMDB accession,HMDB0114943
6778,139426,beta-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->3)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"An amino oligosaccharide that is a branched pentadecasaccharide derivative comprising N-glycoloylneuraminic acid, D-galactose, N-acetyl-D-glucosamine and D-mannoseD residues linked as shown. It constitutes the N-glycan moiety in bovine thyroglobulin.","InChI=1S/C103H171N5O80/c1-22(122)104-44-57(138)76(33(12-115)163-88(44)157)177-89-45(105-23(2)123)58(139)79(36(15-118)169-89)180-98-74(155)84(55(136)40(175-98)20-161-93-73(154)83(182-95-70(151)63(144)51(132)30(9-112)166-95)54(135)39(174-93)19-160-92-68(149)61(142)49(130)28(7-110)164-92)183-99-75(156)85(184-101-87(65(146)53(134)32(11-114)168-101)186-91-47(107-25(4)125)60(141)77(35(14-117)171-91)178-96-71(152)66(147)80(37(16-119)172-96)181-94-69(150)62(143)50(131)29(8-111)165-94)56(137)41(176-99)21-162-100-86(64(145)52(133)31(10-113)167-100)185-90-46(106-24(3)124)59(140)78(34(13-116)170-90)179-97-72(153)67(148)81(38(17-120)173-97)187-103(102(158)159)5-26(126)43(108-42(128)18-121)82(188-103)48(129)27(127)6-109/h26-41,43-101,109-121,126-127,129-157H,5-21H2,1-4H3,(H,104,122)(H,105,123)(H,106,124)(H,107,125)(H,108,128)(H,158,159)/t26-,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,43+,44+,45+,46+,47+,48+,49+,50-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61-,62-,63-,64-,65-,66+,67+,68-,69+,70-,71+,72+,73-,74-,75-,76+,77+,78+,79+,80-,81-,82+,83-,84-,85-,86-,87-,88+,89-,90-,91-,92-,93-,94-,95+,96-,97-,98-,99+,100-,101+,103+/m0/s1",alpha-Neup5Gc-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[beta-D-Galp-(1->4)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-alpha-D-Manp-(1->3)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,PubMed citation,29187897
6779,139447,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->6)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->3)}-beta-D-Man-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"An amino oligosaccharide that is a branched dodecasaccharide derivative comprising N-acetylneuraminic acid, D-galactose, N-acetyl-D-glucosamine and D-mannoseD residues linked as shown. It constitutes the N-glycan moiety in human thyroglobulin.","InChI=1S/C85H141N5O64/c1-19(100)86-37-24(105)6-85(84(130)131,153-68(37)42(107)25(106)7-91)154-72-46(111)29(11-95)139-83(63(72)128)149-65-31(13-97)140-74(39(51(65)116)88-21(3)102)132-16-34-47(112)69(150-76-41(90-23(5)104)53(118)66(32(14-98)142-76)147-79-58(123)55(120)44(109)27(9-93)137-79)60(125)78(143-34)134-18-36-49(114)71(61(126)81(144-36)148-67-33(15-99)141-75(40(52(67)117)89-22(4)103)146-64-30(12-96)135-73(129)38(50(64)115)87-20(2)101)152-82-62(127)70(151-80-59(124)56(121)45(110)28(10-94)138-80)48(113)35(145-82)17-133-77-57(122)54(119)43(108)26(8-92)136-77/h24-83,91-99,105-129H,6-18H2,1-5H3,(H,86,100)(H,87,101)(H,88,102)(H,89,103)(H,90,104)(H,130,131)/t24-,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44-,45+,46-,47+,48+,49+,50+,51+,52+,53+,54-,55-,56-,57-,58+,59-,60-,61-,62-,63+,64+,65+,66+,67+,68+,69-,70-,71-,72-,73+,74+,75-,76-,77-,78-,79-,80+,81-,82+,83-,85-/m0/s1",alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-alpha-D-Manp-(1->6)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->3)}-beta-D-Man-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,PubMed citation,29187897
6780,139466,nitroso-dapsone,A sulfone that is a metabolite of dapsone in which one of the amino groups of dapsone has been oxidized to a nitroso group.,"InChI=1S/C12H10N2O3S/c13-9-1-5-11(6-2-9)18(16,17)12-7-3-10(14-15)4-8-12/h1-8H,13H2",nitroso dapsone,PubMed citation,29045131
6781,139505,baeocystin,A tryptamine alkaloid that is N-methyltryptamine carrying an additional phosphoryloxy substituent at position 4.,"InChI=1S/C11H15N2O4P/c1-12-6-5-8-7-13-9-3-2-4-10(11(8)9)17-18(14,15)16/h2-4,7,12-13H,5-6H2,1H3,(H2,14,15,16)",4-hydroxy-N-methyltryptamine phosphate,MetaCyc accession,CPD-20579
6782,139506,N(5)-phospho-L-glutamine,An L-glutamine derivative in which one of the side-chain amide hydrogens of L-glutamine has been replaced by a phospho group.,"InChI=1S/C5H11N2O6P/c6-3(5(9)10)1-2-4(8)7-14(11,12)13/h3H,1-2,6H2,(H,9,10)(H3,7,8,11,12,13)/t3-/m0/s1",N(5)-phosphoglutamine,MetaCyc accession,CPD-20465
6783,139522,N-(2-hydroxyhexacosanoyl)phytosphingosine-1-phospho-(1D-myo-inositol),An inositol phosphoceramide obtained by formal condensation of the carboxy group of 2-hydroxyhexacosanoic acid with the amino group of phytosphingosine-1-phospho-(1D-myo-inositol).,"InChI=1S/C50H100NO13P/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-42(53)50(60)51-40(39-63-65(61,62)64-49-47(58)45(56)44(55)46(57)48(49)59)43(54)41(52)37-35-33-31-29-27-16-14-12-10-8-6-4-2/h40-49,52-59H,3-39H2,1-2H3,(H,51,60)(H,61,62)/t40-,41+,42?,43-,44-,45-,46+,47+,48+,49-/m0/s1",inositol-1-phospho-N-(2-hydroxyhexacosanoyl)phytosphingosine,PubMed citation,27502288
6784,139524,Ara6-DAHATLR,A glycopeptide consisting of the Ara6 epitope attached to an Asp-Ala-His-Ala-Thr-Leu-Arg-NH2 heptapeptide via a [(2-hydroxyethoxy)imino]acetyl linker.,"InChI=1S/C66H108N14O37/c1-23(2)11-29(58(103)77-28(53(67)98)7-6-8-71-66(68)69)79-59(104)40(26(5)85)80-55(100)25(4)75-56(101)30(12-27-14-70-22-72-27)78-54(99)24(3)74-57(102)31(13-39(87)88)76-38(86)15-73-108-10-9-105-60-46(94)43(91)36(113-60)20-106-61-49(97)50(115-65-52(45(93)35(19-84)112-65)117-63-48(96)42(90)33(17-82)110-63)37(114-61)21-107-64-51(44(92)34(18-83)111-64)116-62-47(95)41(89)32(16-81)109-62/h14-15,22-26,28-37,40-52,60-65,81-85,89-97H,6-13,16-21H2,1-5H3,(H2,67,98)(H,70,72)(H,74,102)(H,75,101)(H,76,86)(H,77,103)(H,78,99)(H,79,104)(H,80,100)(H,87,88)(H4,68,69,71)/t24-,25-,26+,28-,29-,30-,31-,32+,33+,34+,35+,36+,37+,40-,41+,42+,43+,44+,45+,46-,47-,48-,49-,50+,51-,52-,60-,61-,62-,63-,64-,65+/m0/s1","N-{[(2-{[beta-D-arabinofuranosyl-(1,2)-alpha-D-arabinofuranosyl-(1,3)-[beta-D-arabinofuranosyl-(1,2)-alpha-D-arabinofuranosyl-(1,5)]-alpha-D-arabinofuranosyl-(1,5)-alpha-D-arabinofuranosyl]oxy}ethoxy)imino]acetyl}-L-aspartyl-L-alanyl-L-histidyl-L-alanyl-L-threonyl-L-leucyl-L-arginamide",PubMed citation,29255817
6785,139525,Ara6-TTYVVNP,A glycopeptide consisting of the Ara6 epitope attached to a Thr-Thr-Tyr-Val-Val-Asn-Pro-NH2 heptapeptide via a [(2-hydroxyethoxy)imino]acetyl linker.,"InChI=1S/C70H110N10O38/c1-25(2)42(60(101)75-32(17-40(71)88)64(105)80-13-7-8-33(80)58(72)99)78-61(102)43(26(3)4)77-59(100)31(16-29-9-11-30(87)12-10-29)74-62(103)45(28(6)86)79-63(104)44(27(5)85)76-41(89)18-73-109-15-14-106-65-51(95)48(92)38(114-65)23-107-66-54(98)55(116-70-57(50(94)37(22-84)113-70)118-68-53(97)47(91)35(20-82)111-68)39(115-66)24-108-69-56(49(93)36(21-83)112-69)117-67-52(96)46(90)34(19-81)110-67/h9-12,18,25-28,31-39,42-57,65-70,81-87,90-98H,7-8,13-17,19-24H2,1-6H3,(H2,71,88)(H2,72,99)(H,74,103)(H,75,101)(H,76,89)(H,77,100)(H,78,102)(H,79,104)/t27-,28-,31+,32+,33+,34-,35-,36-,37-,38-,39-,42+,43+,44+,45+,46-,47-,48-,49-,50-,51+,52+,53+,54+,55-,56+,57+,65+,66+,67+,68+,69+,70-/m1/s1",N-{[(2-{[beta-D-Araf-(1->2)-alpha-D-Araf-(1->3)-[beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)]-alpha-D-Araf-(1->5)-alpha-D-Araf]oxy}ethoxy)imino]acetyl}-Thr-Thr-Tyr-Val-Val-Asn-Pro-NH2,PubMed citation,29255817
6786,139526,MP-PYT,A member of the class of barbiturates that is barbituric acid in which one of the nitrogens (position 1) is substituted by a p-tolyl group while the carbon at position 5 is substituted by a (2E)-3-[p-(dimethylamino)phenyl]allylidene group. It has significant osteogenic activity.,"InChI=1S/C22H21N3O3/c1-15-7-11-18(12-8-15)25-21(27)19(20(26)23-22(25)28)6-4-5-16-9-13-17(14-10-16)24(2)3/h4-14H,1-3H3,(H,23,26,28)/b5-4+,19-6-","5-(3-(4-(dimethylamino)phenyl)allylidene)-1-(3,5-methylphenyl)pyrimidine-2,4,6-(1H,3H,5H)-trione",PubMed citation,28814721
6787,139527,DMP-PYT,"A member of the class of barbiturates that is barbituric acid in which one of the nitrogens (position 1) is substituted by a 3,5-dimethylphenyl group while the carbon at position 5 is substituted by a (2E)-(3-[p-(dimethylamino)phenyl]allylidene group. It has significant osteogenic activity.","InChI=1S/C23H23N3O3/c1-15-12-16(2)14-19(13-15)26-22(28)20(21(27)24-23(26)29)7-5-6-17-8-10-18(11-9-17)25(3)4/h5-14H,1-4H3,(H,24,27,29)/b6-5+,20-7-","5-(3-(4-(dimethylamino)phenyl)allylidene)-1-(3,5-dimethyl-phenyl)pyrimidine-2,4,6-(1H,3H,5H)-trione",PubMed citation,28814721
6788,139539,"(S,S)-bis-(3-oleoylglycero)-1-phosphate","A 2,2'-lysobisphosphatidic acid in which both acyl groups are specified as oleoyl.","InChI=1S/C42H79O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)49-35-39(43)37-51-53(47,48)52-38-40(44)36-50-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,39-40,43-44H,3-16,21-38H2,1-2H3,(H,47,48)/b19-17-,20-18-/t39-,40-/m0/s1","(S,S)-bis-[3-(9Z-octadecenoyl)-sn-glycero]-1-phosphate",Reaxys Registry Number,28957883
6789,139541,"(S,S)-bis(2-oleoylglycero)-1-phosphate","A 1,1'-lysobisphosphatidic acid in which both acyl groups are specified as oleoyl.","InChI=1S/C42H79O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)51-39(35-43)37-49-53(47,48)50-38-40(36-44)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,39-40,43-44H,3-16,21-38H2,1-2H3,(H,47,48)/b19-17-,20-18-/t39-,40-/m0/s1","(S,S)-bis[(9Z)-octadecenoylglycero]-1-phosphate",PubMed citation,26491015
6790,139543,"(S,S)-2-oleoylglycero-1-phospho-1'-glycerol","A member of the class of glycerophosphoglycerols obtained by formal condensation of the carboxy group of oleic acid with one of the secondary hydroxy groups of (S,S)-glycero-1-phospho-1'-glycerol","InChI=1S/C24H47O9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-24(28)33-23(19-26)21-32-34(29,30)31-20-22(27)18-25/h9-10,22-23,25-27H,2-8,11-21H2,1H3,(H,29,30)/b10-9-/t22-,23-/m0/s1",2-[(9Z)-octadecenoyl]-sn-glycero-1-phospho-(1'-sn-glycerol),PubMed citation,26491015
6791,139558,"1-O-(5,6-epoxyretinoyl)-beta-D-glucuronic acid","A retinoid that is 5,6-epoxyretinoic acid in which the carboxy proton has been replaced by a beta-D-glucuronyl residue.","InChI=1S/C26H36O9/c1-15(10-13-26-24(3,4)11-7-12-25(26,5)35-26)8-6-9-16(2)14-17(27)33-23-20(30)18(28)19(29)21(34-23)22(31)32/h6,8-10,13-14,18-21,23,28-30H,7,11-12H2,1-5H3,(H,31,32)/b9-6+,13-10+,15-8+,16-14+/t18-,19-,20+,21-,23+,25?,26?/m0/s1","1-O-(5,6-epoxyretinoyl)-beta-D-glucuronide",CAS Registry Number,81164-05-8
6792,139559,"(9Z,12R)-12-hydroxyoctadec-9-enoyl-CoA(4-)","A monounsaturated fatty acyl-CoA(4-) obtained by deprotonation of the phosphate and diphosphate OH groups of (9Z,12R)-12-hydroxyoctadec-9-enoyl-CoA; major species at pH 7.3.","InChI=1S/C39H68N7O18P3S/c1-4-5-6-13-16-27(47)17-14-11-9-7-8-10-12-15-18-30(49)68-22-21-41-29(48)19-20-42-37(52)34(51)39(2,3)24-61-67(58,59)64-66(56,57)60-23-28-33(63-65(53,54)55)32(50)38(62-28)46-26-45-31-35(40)43-25-44-36(31)46/h11,14,25-28,32-34,38,47,50-51H,4-10,12-13,15-24H2,1-3H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/p-4/b14-11-/t27-,28-,32-,33-,34+,38-/m1/s1",ricinoleoyl-CoA(4-),PubMed citation,22020216
6793,139568,methyl alpha-L-rhamnosyl-(1->2)-3-(2-glycerylphospho)-beta-D-galactoside,A methyl glycoside that consists of methyl 3-(2-glycerylphospho)-beta-D-galactoside having an alpha-L-rhamnosyl residue at the 2-position. The core disaccharide from the Streptococcus pneumoniae type 23F capsular polysaccharide antigen functionalized with a phosphoglycerol side chain.,"InChI=1S/C16H31O15P/c1-6-9(20)11(22)12(23)15(27-6)29-14-13(10(21)8(5-19)28-16(14)26-2)31-32(24,25)30-7(3-17)4-18/h6-23H,3-5H2,1-2H3,(H,24,25)/t6-,8+,9-,10-,11+,12+,13-,14+,15-,16+/m0/s1",alpha-L-Rha-(1->2)-beta-D-Gal3(2-GlyP)OMe,Reaxys Registry Number,20852285
6794,139579,AMPK activator PT 1,"A member of the class of furans that in which the furan ring is substituted by a (2-amino-4-oxo-1,3-thiazol-5(4H)-ylidene)methyl group at position 2 and a 4,5-dimethyl-2-nitrophenyl group at position 5, and i which the amino substituent of the thiazolone has been substituted by a 3-carboxy-4-chlorophenyl group. It is a direct activator of the alpha-subunit of AMP-activated protein kinase (5' adenosine monophosphate-activated protein kinase, AMPK).","InChI=1S/C23H16ClN3O6S/c1-11-7-16(18(27(31)32)8-12(11)2)19-6-4-14(33-19)10-20-21(28)26-23(34-20)25-13-3-5-17(24)15(9-13)22(29)30/h3-10H,1-2H3,(H,29,30)(H,25,26,28)","2-Chloro-5-[[5-[[5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-4-oxo-2-thiazolyl]amino]benzoic acid",PubMed citation,25868658
6795,139583,"(R,R)-bis(2-oleoylglycero)-3-phosphate","A lysobisphosphatidic acid with (R,R)-configuration in which both acyl groups are specified as oleoyl and are located at the 2 and 2'-positions.","InChI=1S/C42H79O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-41(45)51-39(35-43)37-49-53(47,48)50-38-40(36-44)52-42(46)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,39-40,43-44H,3-16,21-38H2,1-2H3,(H,47,48)/b19-17-,20-18-/t39-,40-/m1/s1",bis[(9Z)-octadecenoyl-sn-glycero]-3-phosphate,PubMed citation,26491015
6796,139585,"(R,R)-2-oleoylglycero-1-phospho-1'-glycerol","A member of the class of glycerophosphoglycerols obtained by formal condensation of the carboxy group of oleic acid with one of the secondary hydroxy groups of (R,R)-glycero-1-phospho-1'-glycerol","InChI=1S/C24H47O9P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-24(28)33-23(19-26)21-32-34(29,30)31-20-22(27)18-25/h9-10,22-23,25-27H,2-8,11-21H2,1H3,(H,29,30)/b10-9-/t22-,23-/m1/s1","LPG(0:0/18:1(9Z)) (R,R)",PubMed citation,26491015
6797,139600,calcitriol 25-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is calcitriol in which the hydroxy hydrogen at position 25 has been replaced by a beta-D-glucuronyl residue.,"InChI=1S/C33H52O9/c1-18(8-6-14-32(3,4)42-31-28(38)26(36)27(37)29(41-31)30(39)40)23-12-13-24-20(9-7-15-33(23,24)5)10-11-21-16-22(34)17-25(35)19(21)2/h10-11,18,22-29,31,34-38H,2,6-9,12-17H2,1,3-5H3,(H,39,40)/b20-10+,21-11-/t18-,22-,23-,24+,25+,26+,27+,28-,29+,31+,33-/m1/s1",calcitriol 25-O--(beta-D-glucuronic acid),PubMed citation,18177842
6798,139610,calcidiol 25-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is calcidiol in which the hydroxy hydrogen at position 25 has been replaced by a beta-D-glucuronyl residue.,"InChI=1S/C33H52O8/c1-19-10-13-23(34)18-22(19)12-11-21-9-7-17-33(5)24(14-15-25(21)33)20(2)8-6-16-32(3,4)41-31-28(37)26(35)27(36)29(40-31)30(38)39/h11-12,20,23-29,31,34-37H,1,6-10,13-18H2,2-5H3,(H,38,39)/b21-11+,22-12-/t20-,23+,24-,25+,26+,27+,28-,29+,31+,33-/m1/s1",calcidiol 25-O-glucoronide,Reaxys Registry Number,7401257
6799,139613,calcidiol 3-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is calcidiol in which the hydroxy hydrogen at position 3 has been replaced by a beta-D-glucuronyl residue.,"InChI=1S/C33H52O8/c1-19-10-13-23(40-31-28(36)26(34)27(35)29(41-31)30(37)38)18-22(19)12-11-21-9-7-17-33(5)24(14-15-25(21)33)20(2)8-6-16-32(3,4)39/h11-12,20,23-29,31,34-36,39H,1,6-10,13-18H2,2-5H3,(H,37,38)/b21-11+,22-12-/t20-,23+,24-,25+,26+,27+,28-,29+,31-,33-/m1/s1",calcidiol 3-beta-glucuronide,Reaxys Registry Number,7401269
6800,140073,5'-GAGAGACCCAC-3' RNA fragment,"An RNA fragment comprised of three guanosine, two adenosine and four cytidine residues connected by 3'->5' phosphodiester linkages in the sequence G-A-G-A-G-A-C-C-C-A-C.","InChI=1S/C106H133N47O71P10/c107-42-1-5-143(103(170)133-42)89-54(156)53(155)32(205-89)10-194-225(174,175)219-69-37(210-93(59(69)161)147-24-126-46-75(111)118-20-122-79(46)147)15-199-229(182,183)218-68-34(207-92(58(68)160)146-8-4-45(110)136-106(146)173)12-197-227(178,179)216-66-33(206-90(56(66)158)144-6-2-43(108)134-104(144)171)11-196-228(180,181)217-67-35(208-91(57(67)159)145-7-3-44(109)135-105(145)172)13-198-230(184,185)220-71-38(211-95(61(71)163)149-26-128-48-77(113)120-22-124-81(48)149)16-200-233(190,191)223-74-41(214-99(64(74)166)153-30-132-52-85(153)139-102(117)142-88(52)169)19-203-232(188,189)222-72-39(212-96(62(72)164)150-27-129-49-78(114)121-23-125-82(49)150)17-201-234(192,193)224-73-40(213-98(63(73)165)152-29-131-51-84(152)138-101(116)141-87(51)168)18-202-231(186,187)221-70-36(209-94(60(70)162)148-25-127-47-76(112)119-21-123-80(47)148)14-195-226(176,177)215-65-31(9-154)204-97(55(65)157)151-28-130-50-83(151)137-100(115)140-86(50)167/h1-8,20-41,53-74,89-99,154-166H,9-19H2,(H,174,175)(H,176,177)(H,178,179)(H,180,181)(H,182,183)(H,184,185)(H,186,187)(H,188,189)(H,190,191)(H,192,193)(H2,107,133,170)(H2,108,134,171)(H2,109,135,172)(H2,110,136,173)(H2,111,118,122)(H2,112,119,123)(H2,113,120,124)(H2,114,121,125)(H3,115,137,140,167)(H3,116,138,141,168)(H3,117,139,142,169)/t31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-/m1/s1",GpApGpApGpApCpCpCpApC,PubMed citation,29309709
6801,140075,Trp-Gly-Ile-His-His,"A pentapeptide comprising L-tryptophan, glycine, L-isoleucine, and two L-histidine residues coupled in sequence by peptide linkages.","InChI=1S/C31H40N10O6/c1-3-17(2)27(41-26(42)14-36-28(43)22(32)8-18-11-35-23-7-5-4-6-21(18)23)30(45)39-24(9-19-12-33-15-37-19)29(44)40-25(31(46)47)10-20-13-34-16-38-20/h4-7,11-13,15-17,22,24-25,27,35H,3,8-10,14,32H2,1-2H3,(H,33,37)(H,34,38)(H,36,43)(H,39,45)(H,40,44)(H,41,42)(H,46,47)/t17?,22-,24-,25-,27-/m0/s1",WGIHH,PubMed citation,29286160
6802,140076,Trp-Tyr-Gly-Tyr-His-His,"An oligopeptide comprising L-tryptophan, L-tyrosine, glycine, L-tyrosine, and two L-histidine residues coupled in sequence by peptide linkages.","InChI=1S/C43H47N11O9/c44-32(15-26-18-47-33-4-2-1-3-31(26)33)39(58)52-34(13-24-5-9-29(55)10-6-24)40(59)48-21-38(57)51-35(14-25-7-11-30(56)12-8-25)41(60)53-36(16-27-19-45-22-49-27)42(61)54-37(43(62)63)17-28-20-46-23-50-28/h1-12,18-20,22-23,32,34-37,47,55-56H,13-17,21,44H2,(H,45,49)(H,46,50)(H,48,59)(H,51,57)(H,52,58)(H,53,60)(H,54,61)(H,62,63)/t32-,34-,35-,36-,37-/m0/s1",WYGYHH,PubMed citation,29286160
6803,140086,"6,7-dichloro-L-tryptophan",A non-proteinogenic L-alpha-amino acid that is L-tryptophan in which the hydrogens at positions 6 and 7 on the indole ring have been replaced by chlorines.,"InChI=1S/C11H10Cl2N2O2/c12-7-2-1-6-5(3-8(14)11(16)17)4-15-10(6)9(7)13/h1-2,4,8,15H,3,14H2,(H,16,17)/t8-/m0/s1","6,7-dichlorotryptophan",Reaxys Registry Number,18923604
6804,140152,cyclosporin A metabolite M1,A cyclosporin A derivative that is cyclosporin A in which residue 9 (N-methylleucine) has undergone oxidation so a to introduce a hydroxy group at the carbon bearing the two methyl groups.,"InChI=1S/C62H111N11O13/c1-25-27-28-39(13)51(75)50-55(79)65-42(26-2)57(81)67(18)33-47(74)68(19)43(29-34(3)4)54(78)66-48(37(9)10)60(84)69(20)44(30-35(5)6)53(77)63-40(14)52(76)64-41(15)56(80)71(22)46(32-62(16,17)86)59(83)70(21)45(31-36(7)8)58(82)72(23)49(38(11)12)61(85)73(50)24/h25,27,34-46,48-51,75,86H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t39-,40+,41-,42+,43+,44+,45+,46+,48+,49+,50+,51-/m1/s1",cyclosporine metabolite M1,CAS Registry Number,89270-25-7
6805,140153,"(9Z,12R)-12-hydroxyoctadec-9-enoyl-CoA","An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (9Z,12R)-12-hydroxyoctadec-9-enoic (ricinoleic) acid.","InChI=1S/C39H68N7O18P3S/c1-4-5-6-13-16-27(47)17-14-11-9-7-8-10-12-15-18-30(49)68-22-21-41-29(48)19-20-42-37(52)34(51)39(2,3)24-61-67(58,59)64-66(56,57)60-23-28-33(63-65(53,54)55)32(50)38(62-28)46-26-45-31-35(40)43-25-44-36(31)46/h11,14,25-28,32-34,38,47,50-51H,4-10,12-13,15-24H2,1-3H3,(H,41,48)(H,42,52)(H,56,57)(H,58,59)(H2,40,43,44)(H2,53,54,55)/b14-11-/t27-,28-,32-,33-,34+,38-/m1/s1","(9Z,12R)-12-hydroxyoctadec-9-enoyl-coenzyme A",Reaxys Registry Number,11195620
6806,140154,cyclosporin A metabolite M17,"A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol. It specifically inhibits growth of renal cells in culture.","InChI=1S/C62H111N11O13/c1-24-43-58(82)67(17)33-48(75)68(18)44(29-34(2)3)55(79)66-49(38(10)11)61(85)69(19)45(30-35(4)5)54(78)63-41(15)53(77)64-42(16)57(81)70(20)46(31-36(6)7)59(83)71(21)47(32-37(8)9)60(84)72(22)50(39(12)13)62(86)73(23)51(56(80)65-43)52(76)40(14)27-25-26-28-74/h25-26,34-47,49-52,74,76H,24,27-33H2,1-23H3,(H,63,78)(H,64,77)(H,65,80)(H,66,79)/b26-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",cyclosporine A metabolite M17,CAS Registry Number,89270-28-0
6807,140156,8-formyl-8-demethylriboflavin 5'-phosphate,A flavin mononucleotide that is FMN in which the 8-methyl group has been oxidised to the corresponding aldehyde.,"InChI=1S/C17H19N4O10P/c1-7-2-9-10(3-8(7)5-22)21(15-13(18-9)16(26)20-17(27)19-15)4-11(23)14(25)12(24)6-31-32(28,29)30/h2-3,5,11-12,14,23-25H,4,6H2,1H3,(H,20,26,27)(H2,28,29,30)/t11-,12+,14-/m0/s1",8-oxoriboflavin 5'-phosphate,MetaCyc accession,CPD-19838
6808,140158,cyclosporin A metabolite M8,"A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol, and in which residue 9 (N-methylleucine) has undergone oxidation so as to introduce a hydroxy group at the carbon bearing the two methyl groups.","InChI=1S/C62H111N11O14/c1-24-42-57(82)67(17)33-47(75)68(18)43(29-34(2)3)54(79)66-48(37(8)9)60(85)69(19)44(30-35(4)5)53(78)63-40(13)52(77)64-41(14)56(81)71(21)46(32-62(15,16)87)59(84)70(20)45(31-36(6)7)58(83)72(22)49(38(10)11)61(86)73(23)50(55(80)65-42)51(76)39(12)27-25-26-28-74/h25-26,34-46,48-51,74,76,87H,24,27-33H2,1-23H3,(H,63,78)(H,64,77)(H,65,80)(H,66,79)/b26-25+/t39-,40+,41-,42+,43+,44+,45+,46+,48+,49+,50+,51-/m1/s1",cyclosporin A metabolite AM19,PubMed citation,2642763
6809,140163,cyclosporin A metabolite M16,A cyclosporin A derivative that is cyclosporin A in which residues 6 and 9 (both N-methylleucine) have undergone oxidation so a to introduce a hydroxy group at position 4 (the carbon bearing the two methyl groups) in each case.,"InChI=1S/C62H111N11O14/c1-25-27-28-38(11)50(75)49-54(79)65-41(26-2)56(81)67(18)33-46(74)68(19)42(29-34(3)4)52(77)66-47(36(7)8)59(84)70(21)44(31-61(14,15)86)53(78)63-39(12)51(76)64-40(13)55(80)71(22)45(32-62(16,17)87)58(83)69(20)43(30-35(5)6)57(82)72(23)48(37(9)10)60(85)73(49)24/h25,27,34-45,47-50,75,86-87H,26,28-33H2,1-24H3,(H,63,78)(H,64,76)(H,65,79)(H,66,77)/b27-25+/t38-,39+,40-,41+,42+,43+,44+,45+,47+,48+,49+,50-/m1/s1",AM69,PubMed citation,2642763
6810,140164,cyclosporin A metabolite M9,"A cyclosporin A derivative that is cyclosporin A in which the N-methylleucine residues at positions 6 and 9 have both undergone oxidation by hydroxylation at the carbon bearing the two methyl groups, and in which while the N-methylleucine residue at position 4 has undergone N-demethylation.","InChI=1S/C61H109N11O14/c1-24-26-27-37(11)49(74)48-53(78)65-40(25-2)55(80)67(18)32-45(73)64-41(28-33(3)4)51(76)66-46(35(7)8)58(83)69(20)43(30-60(14,15)85)52(77)62-38(12)50(75)63-39(13)54(79)70(21)44(31-61(16,17)86)57(82)68(19)42(29-34(5)6)56(81)71(22)47(36(9)10)59(84)72(48)23/h24,26,33-44,46-49,74,85-86H,25,27-32H2,1-23H3,(H,62,77)(H,63,75)(H,64,73)(H,65,78)(H,66,76)/b26-24+/t37-,38+,39-,40+,41+,42+,43+,44+,46+,47+,48+,49-/m1/s1",cyclosporine A metabolite M9,PubMed citation,12395977
6811,140167,cyclosporin A metabolite M10,A cyclosporin A derivative that is cyclosporin A in which residues 4 and 9 (both N-methylleucine) have undergone oxidation so as to introduce a hydroxy group at position 4 (the carbon bearing the two methyl groups) in each case.,"InChI=1S/C62H111N11O14/c1-25-27-28-38(11)50(75)49-54(79)65-41(26-2)56(81)67(18)33-46(74)68(19)44(31-61(14,15)86)53(78)66-47(36(7)8)59(84)69(20)42(29-34(3)4)52(77)63-39(12)51(76)64-40(13)55(80)71(22)45(32-62(16,17)87)58(83)70(21)43(30-35(5)6)57(82)72(23)48(37(9)10)60(85)73(49)24/h25,27,34-45,47-50,75,86-87H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t38-,39+,40-,41+,42+,43+,44+,45+,47+,48+,49+,50-/m1/s1",cyclosporin metabolite M10,PubMed citation,2642763
6812,140171,cyclosporin A metabolite M21,A cyclosporin A derivative that is cyclosporin A in which residue 4 (N-methylleucine) has undergone N-demethylation.,"InChI=1S/C61H109N11O12/c1-24-26-27-39(15)51(74)50-55(78)65-42(25-2)57(80)67(18)32-47(73)64-43(28-33(3)4)53(76)66-48(37(11)12)60(83)68(19)44(29-34(5)6)54(77)62-40(16)52(75)63-41(17)56(79)69(20)45(30-35(7)8)58(81)70(21)46(31-36(9)10)59(82)71(22)49(38(13)14)61(84)72(50)23/h24,26,33-46,48-51,74H,25,27-32H2,1-23H3,(H,62,77)(H,63,75)(H,64,73)(H,65,78)(H,66,76)/b26-24+/t39-,40+,41-,42+,43+,44+,45+,46+,48+,49+,50+,51-/m1/s1",cyclosporine metabolite AM4N,CAS Registry Number,89270-23-5
6813,140172,cyclosporin A metabolite M25,"A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol, while residue 4, N-methylleucine, has undergone N-demethylation.","InChI=1S/C61H109N11O13/c1-23-42-57(81)67(17)32-47(74)64-43(28-33(2)3)53(77)66-48(37(10)11)60(84)68(18)44(29-34(4)5)54(78)62-40(15)52(76)63-41(16)56(80)69(19)45(30-35(6)7)58(82)70(20)46(31-36(8)9)59(83)71(21)49(38(12)13)61(85)72(22)50(55(79)65-42)51(75)39(14)26-24-25-27-73/h24-25,33-46,48-51,73,75H,23,26-32H2,1-22H3,(H,62,78)(H,63,76)(H,64,74)(H,65,79)(H,66,77)/b25-24+/t39-,40+,41-,42+,43+,44+,45+,46+,48+,49+,50+,51-/m1/s1",cyclosporin A metabolite AM14N,PubMed citation,2642763
6814,140175,cyclosporin A metabolite M18,"A cyclosporin A derivative that is cyclosporin A metabolite M17 in which the hydroxy group at position 3 of residue 1 [(2S,3R,4R,6E)-3,8-dihydroxy-4-methyl-2-(methylamino)oct-6-enamide] has undergone addition to the double bond at position 6 to afford the corresponding dioxolane ring.","InChI=1S/C62H111N11O13/c1-24-43-58(81)67(17)32-48(75)68(18)44(27-33(2)3)55(78)66-49(37(10)11)61(84)69(19)45(28-34(4)5)54(77)63-40(15)53(76)64-41(16)57(80)70(20)46(29-35(6)7)59(82)71(21)47(30-36(8)9)60(83)72(22)50(38(12)13)62(85)73(23)51(56(79)65-43)52-39(14)31-42(86-52)25-26-74/h33-47,49-52,74H,24-32H2,1-23H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/t39-,40+,41-,42?,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",cyclosporine A metabolite M18,PubMed citation,8400080
6815,140176,cyclosporin A metabolite M1cAL,A cyclosporin A derivative that is cyclosporin A metabolite M18 in which the 2-hydroxyethyl substituent of the dioxolane ring has been oxidised to give the corresponding aldehyde.,"InChI=1S/C62H109N11O13/c1-24-43-58(81)67(17)32-48(75)68(18)44(27-33(2)3)55(78)66-49(37(10)11)61(84)69(19)45(28-34(4)5)54(77)63-40(15)53(76)64-41(16)57(80)70(20)46(29-35(6)7)59(82)71(21)47(30-36(8)9)60(83)72(22)50(38(12)13)62(85)73(23)51(56(79)65-43)52-39(14)31-42(86-52)25-26-74/h26,33-47,49-52H,24-25,27-32H2,1-23H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/t39-,40+,41-,42?,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",cyclosporine metabolite M1cAL,PubMed citation,8745344
6816,140177,cyclosporin A metabolite M26,"A cyclosporin A derivative that is cyclosporin A in which residue 9 (N-methylleucine) has been hydroxylated at the carbon bearing the two methyl groups and in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has been hydroxylated at position 8 while the hydroxy group at position 3 has undergone addition to the double bond to give the corresponding oxolane.","InChI=1S/C62H111N11O14/c1-24-42-57(81)67(17)32-47(75)68(18)43(27-33(2)3)54(78)66-48(36(8)9)60(84)69(19)44(28-34(4)5)53(77)63-39(13)52(76)64-40(14)56(80)71(21)46(31-62(15,16)86)59(83)70(20)45(29-35(6)7)58(82)72(22)49(37(10)11)61(85)73(23)50(55(79)65-42)51-38(12)30-41(87-51)25-26-74/h33-46,48-51,74,86H,24-32H2,1-23H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/t38-,39+,40-,41?,42+,43+,44+,45+,46+,48+,49+,50+,51-/m1/s1",cyclosporine metabolite M26,PubMed citation,1895678
6817,140178,cyclosporin A metabolite M1A,"A cyclosporin A derivative that is cyclosporin A in which the allylic methyl group of residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has been oxidised to the corresponding carboxylic acid.","InChI=1S/C62H109N11O14/c1-24-42-58(83)67(17)32-47(74)68(18)43(28-33(2)3)55(80)66-49(37(10)11)61(86)69(19)44(29-34(4)5)54(79)63-40(15)53(78)64-41(16)57(82)70(20)45(30-35(6)7)59(84)71(21)46(31-36(8)9)60(85)72(22)50(38(12)13)62(87)73(23)51(56(81)65-42)52(77)39(14)26-25-27-48(75)76/h25,27,33-46,49-52,77H,24,26,28-32H2,1-23H3,(H,63,79)(H,64,78)(H,65,81)(H,66,80)(H,75,76)/b27-25+/t39-,40+,41-,42+,43+,44+,45+,46+,49+,50+,51+,52-/m1/s1",cyclosporin metabolite AM1A,PubMed citation,1804641
6818,140191,"17S,(16)-epoxy-(4Z,7Z,10Z,13Z,19Z)-docosahexa-4,7,10,13,15,19-enoic acid","A polyunsaturated fatty acid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid having an epoxy group across positions 16 and 17.","InChI=1S/C22H30O3/c1-2-3-14-17-20-21(25-20)18-15-12-10-8-6-4-5-7-9-11-13-16-19-22(23)24/h3,5-8,11-15,18,20H,2,4,9-10,16-17,19H2,1H3,(H,23,24)/b7-5-,8-6-,13-11-,14-3-,15-12-,21-18+/t20-/m0/s1","17S,(16)-epoxy-DHA",PubMed citation,17055291
6819,140200,"(7Z,9E,11E,16Z,19Z)-13,14-epoxydocosapentaenoic acid","An epoxydocosapentaenoic acid (7Z,9E,11E,16Z,19Z)-docosapentaenoic acid in which the epoxy group is located at the 13,14-position. An intermediate in the specialised proresolving mediators","InChI=1S/C22H32O3/c1-2-3-4-5-11-14-17-20-21(25-20)18-15-12-9-7-6-8-10-13-16-19-22(23)24/h3-4,6-7,9,11-12,14-15,18,20-21H,2,5,8,10,13,16-17,19H2,1H3,(H,23,24)/b4-3-,7-6-,12-9+,14-11-,18-15+","13,14-epoxy-DPAn-3",PubMed citation,23736886
6820,140202,aspirin-triggered protectin D1,"A dihydroxydocosahexaenoic acid that is (4Z,7Z,11E,13E,15Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at positions 10 and 17 (the 10R,17R-stereoisomer).","InChI=1S/C22H32O4/c1-2-3-10-15-20(23)17-12-8-9-13-18-21(24)16-11-6-4-5-7-14-19-22(25)26/h3,5-13,17-18,20-21,23-24H,2,4,14-16,19H2,1H3,(H,25,26)/b7-5-,9-8+,10-3-,11-6-,17-12-,18-13+/t20-,21-/m1/s1","10(R),17(R)-dihydroxydocosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid",Reaxys Registry Number,22110134
6821,140204,"(4Z,7Z,10Z,14E,16Z,19Z)-13-oxodocosahexaenoic acid","An oxodocosahexaenoic acid that is (4Z,7Z,10Z,14E,16Z,19Z)-docosahexaenoic acid in which the oxo group is located at position 13. An intermediate of specialised proresolving mediators.","InChI=1S/C22H30O3/c1-2-3-4-5-9-12-15-18-21(23)19-16-13-10-7-6-8-11-14-17-20-22(24)25/h3-4,6-7,9,11-16,18H,2,5,8,10,17,19-20H2,1H3,(H,24,25)/b4-3-,7-6-,12-9-,14-11-,16-13-,18-15+",13-oxo-DHA,PubMed citation,26339618
6822,140205,"(7Z,10Z,14E,16Z,19Z)-13-oxodocosapentaenoic acid","An docosanoid that is (7Z,10Z,14E,16Z,19Z)-docosapentaenoic acid carrying an oxo substituent at position 13. An intermediate of specialised proresolving mediators.","InChI=1S/C22H32O3/c1-2-3-4-5-9-12-15-18-21(23)19-16-13-10-7-6-8-11-14-17-20-22(24)25/h3-4,6-7,9,12-13,15-16,18H,2,5,8,10-11,14,17,19-20H2,1H3,(H,24,25)/b4-3-,7-6-,12-9-,16-13-,18-15+",13-oxo-DPAn-3,PubMed citation,26339618
6823,140220,"(4Z,8E,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosahexaenoic acid","A hydroperoxy fatty acid that is (4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoic acid in which the hydroperoxy group is located at position 14S. An intermediate of specialised proresolving mediators","InChI=1S/C22H32O4/c1-2-3-4-5-12-15-18-21(26-25)19-16-13-10-8-6-7-9-11-14-17-20-22(23)24/h3-4,6,8,10-16,19,21,25H,2,5,7,9,17-18,20H2,1H3,(H,23,24)/b4-3-,8-6+,13-10-,14-11-,15-12-,19-16+/t21-/m0/s1",14(S)-HpDHA,PubMed citation,23736886
6824,140222,"(7Z,10Z,12E,14S,16Z,19Z)-14-hydroperoxydocosapentaenoic acid","A (7Z,10Z,12E,16Z,19Z)-14-hydroperoxydocosapentaenoic acid in which the chiral centre at position 14 has S-configuration. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O4/c1-2-3-4-5-12-15-18-21(26-25)19-16-13-10-8-6-7-9-11-14-17-20-22(23)24/h3-4,6-7,10,12-13,15-16,19,21,25H,2,5,8-9,11,14,17-18,20H2,1H3,(H,23,24)/b4-3-,7-6-,13-10-,15-12-,19-16+/t21-/m0/s1",14(S)-HpDPA(n-3),PubMed citation,23736886
6825,140223,"15-deoxy-Delta(12,14)-prostaglandin J3",A prostaglandin J derivative comprising prostaglandin J3 lacking the 15-hydroxy group and having C=C double bonds at the 12- and 14-positions. An intermediate of specialised proresolving mediators,"InChI=1S/C20H26O3/c1-2-3-4-5-6-10-13-18-17(15-16-19(18)21)12-9-7-8-11-14-20(22)23/h3-4,6-7,9-10,13,15-17H,2,5,8,11-12,14H2,1H3,(H,22,23)/b4-3-,9-7-,10-6+,18-13+/t17-/m0/s1",15d-PGJ3,Reaxys Registry Number,29567714
6826,140224,"(16S,17S)-epoxy-(7Z,10Z,12E,14E,19Z)-docosapentaenoic acid","A (4Z,7Z,10Z,13Z,19Z)-16,17-epoxydocosapentaenoic acid in which the chiral centres at positions 16 and 17 both have S-configuration. An intermediate of specialized proresolving mediators","InChI=1S/C22H32O3/c1-2-3-14-17-20-21(25-20)18-15-12-10-8-6-4-5-7-9-11-13-16-19-22(23)24/h3,5-8,10,12,14-15,18,20-21H,2,4,9,11,13,16-17,19H2,1H3,(H,23,24)/b7-5-,8-6-,12-10+,14-3-,18-15+/t20-,21-/m0/s1","16(S),17(S)-epoxy-DPA(n-3)",Reaxys Registry Number,31878856
6827,140225,"(16S,17S)-epoxy-(4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoic acid","An epoxy fatty acid consisting of (4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoic acid having an epoxy group located at the 16,17-position. An intermediate lipid in specialized proresolving mediators.","InChI=1S/C22H30O3/c1-2-3-14-17-20-21(25-20)18-15-12-10-8-6-4-5-7-9-11-13-16-19-22(23)24/h3,5-8,10-15,18,20-21H,2,4,9,16-17,19H2,1H3,(H,23,24)/b7-5-,8-6-,12-10+,13-11-,14-3-,18-15+/t20-,21-/m0/s1","(16S,17S)-epoxy-DHA",Reaxys Registry Number,29003682
6828,140226,"(7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosapentaenoic acid","A (7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosapentaenoic acid in which the chiral centre at position 17 has S-configuration. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O4/c1-2-3-15-18-21(26-25)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(23)24/h3,5-8,11,13,15-16,19,21,25H,2,4,9-10,12,14,17-18,20H2,1H3,(H,23,24)/b7-5-,8-6-,13-11-,15-3-,19-16+/t21-/m0/s1",17(S)-Hp-DPA(n-3),PubMed citation,23736886
6829,140234,"7,8-epoxy,17-hydroxy-(9E,11E,13Z,15E,19Z)-docosapentaenoic acid","A docosanoid that is (9E,11E,13Z,15E,19Z)-docosapentaenoic acid carrying an epoxy group across positions 7 and 8 as well as a hydroxy substituent at position 17.  An intermediate of specialised proresolving mediators.","InChI=1S/C22H32O4/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20-21(26-20)17-12-8-13-18-22(24)25/h3-7,9-11,15-16,19-21,23H,2,8,12-14,17-18H2,1H3,(H,24,25)/b6-4-,7-5+,9-3-,15-10+,16-11+","7,8-epoxy,17-HDPA(n-3)",PubMed citation,23736886
6830,140238,"(4Z,7Z,10Z,13Z,15E,19Z)-17-oxodocosahexaenoic acid","An oxodocosahexaenoic acid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid in which the oxo group is located at position 17. An intermediate of specialised proresolving mediators.","InChI=1S/C22H30O3/c1-2-3-15-18-21(23)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(24)25/h3,5-8,11-16,19H,2,4,9-10,17-18,20H2,1H3,(H,24,25)/b7-5-,8-6-,13-11-,14-12-,15-3-,19-16+",17-oxo-DHA,Reaxys Registry Number,26960428
6831,140239,"(7Z,10Z,13Z,15E,19Z)-17-oxodocosapentaenoic acid","A docosanoid that is (7Z,10Z,13Z,15E,19Z)-docosapentaenoic acid carrying an oxo substituent at position 17. An intermediate of specialised proresolving mediators.","InChI=1S/C22H32O3/c1-2-3-15-18-21(23)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(24)25/h3,5-8,11,13,15-16,19H,2,4,9-10,12,14,17-18,20H2,1H3,(H,24,25)/b7-5-,8-6-,13-11-,15-3-,19-16+",17-oxo-DPAn-3,Reaxys Registry Number,24889878
6832,140243,22-hydroxyprotectin D1,A docosanoid that is protectin D1 in which one of the terminal methyl hydrogens has been replaced by a hydroxy group. An intermediate of specialised proresolving mediators,"InChI=1S/C22H32O5/c23-19-13-7-11-17-21(25)16-10-6-5-9-15-20(24)14-8-3-1-2-4-12-18-22(26)27/h2-11,15-16,20-21,23-25H,1,12-14,17-19H2,(H,26,27)/b4-2-,6-5+,8-3-,11-7-,15-9+,16-10-/t20-,21-/m1/s1",22-OH-(N)PD1,Reaxys Registry Number,27632053
6833,140244,"(6E,8Z,11Z,14Z,17Z)-5-oxoicosapentaenoic acid","An icosanoid that is (6E,8Z,11Z,14Z,17Z)-icosapentaenoic acid carrying an oxo substituent at position 5. An intermediate of specialised proresolving mediators.","InChI=1S/C20H28O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h3-4,6-7,9-10,12-14,16H,2,5,8,11,15,17-18H2,1H3,(H,22,23)/b4-3-,7-6-,10-9-,13-12-,16-14+",5-oxo-EPA,PubMed citation,24736647
6834,140245,"(7S,17S)-bis(hydroperoxy)-(4Z,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid","A docosanoid that is (4Z,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying two hydroperoxy substituents at the 7S- and 17S-positions.","InChI=1S/C22H32O6/c1-2-3-10-15-20(27-25)16-11-7-5-4-6-8-12-17-21(28-26)18-13-9-14-19-22(23)24/h3,5-13,16-17,20-21,25-26H,2,4,14-15,18-19H2,1H3,(H,23,24)/b7-5-,8-6-,10-3-,13-9-,16-11+,17-12+/t20-,21+/m0/s1","7(S),17(S)-diHpDHA",PubMed citation,23471029
6835,140248,"(8E,10Z,13Z,15E,19Z)-7,17-bis(hydroperoxy)docosapentaenoic acid","A hydroperoxydocosapentaenoic acid that is (8E,10Z,13Z,15E,19Z)-docosapentaenooic acid carrying two hydroperoxy substituents at positions 7 and 17. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O6/c1-2-3-10-15-20(27-25)16-11-7-5-4-6-8-12-17-21(28-26)18-13-9-14-19-22(23)24/h3,5-8,10-12,16-17,20-21,25-26H,2,4,9,13-15,18-19H2,1H3,(H,23,24)/b7-5-,8-6-,10-3-,16-11+,17-12+","7,17-diHp-DPAn-3",PubMed citation,23736886
6836,140250,"(8E,10Z,13Z,16Z,19Z)-7-hydroxydocosapentaenoic acid","A hydroxydocosapentaenoic acid that consists of (8E,10Z,13Z,16Z,19Z)-docosapentaenoic acid carrying a hydroxy substituent at position 7. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-21(23)19-16-14-17-20-22(24)25/h3-4,6-7,9-10,12-13,15,18,21,23H,2,5,8,11,14,16-17,19-20H2,1H3,(H,24,25)/b4-3-,7-6-,10-9-,13-12-,18-15+",7-HDPAn-3,Reaxys Registry Number,25832718
6837,140252,"(4Z,8E,10Z,13Z,16Z,19Z)-7-oxodocosahexaenoic acid","A oxodocosahexaenoic acid that consists of (4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoic acid carrying an oxo substituent at position 7. An intermediate of specialised proresolving mediators.","InChI=1S/C22H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-21(23)19-16-14-17-20-22(24)25/h3-4,6-7,9-10,12-16,18H,2,5,8,11,17,19-20H2,1H3,(H,24,25)/b4-3-,7-6-,10-9-,13-12-,16-14-,18-15+",7-oxo-DHA,Reaxys Registry Number,27937080
6838,140253,"(8E,10Z,13Z,16Z,19Z)-7-oxodocosapentaenoic acid","A docosanoid that consists of (8E,10Z,13Z,16Z,19Z)-docosapentaenoic acid carrying an oxo substituent at position 7. An intermediate of specialised proresolving mediators.","InChI=1S/C22H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-21(23)19-16-14-17-20-22(24)25/h3-4,6-7,9-10,12-13,15,18H,2,5,8,11,14,16-17,19-20H2,1H3,(H,24,25)/b4-3-,7-6-,10-9-,13-12-,18-15+",7-oxo-DPAn-3,PubMed citation,26339618
6839,140256,"(7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoic acid","A docosanoid that is (8E,10E,12Z,16Z,19Z)-docosapentaenoic acid carrying two hydroxy substituents at positions 7R and 14S. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O4/c1-2-3-4-5-6-10-15-20(23)16-11-7-8-12-17-21(24)18-13-9-14-19-22(25)26/h3-4,6-8,10-12,16-17,20-21,23-24H,2,5,9,13-15,18-19H2,1H3,(H,25,26)/b4-3-,8-7+,10-6-,16-11-,17-12+/t20-,21-/m0/s1",MaR1n-3 DPA,PubMed citation,23736886
6840,140257,"13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoic acid","A docosanoid that is (7Z,9E,11E,16Z,19Z)-docosapentaenoic acid carrying two hydroxy substituents at positions 13 and 14. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O4/c1-2-3-4-5-11-14-17-20(23)21(24)18-15-12-9-7-6-8-10-13-16-19-22(25)26/h3-4,6-7,9,11-12,14-15,18,20-21,23-24H,2,5,8,10,13,16-17,19H2,1H3,(H,25,26)/b4-3-,7-6-,12-9+,14-11-,18-15+/t20-,21?/m0/s1",MaR2n-3 DPA,PubMed citation,23736886
6841,140258,"14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid","A docosanoid that is (7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid carrying two hydroxy substituents at positions 14S and 21. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O4/c1-20(23)16-12-10-11-14-18-21(24)17-13-8-6-4-2-3-5-7-9-15-19-22(25)26/h2-3,6,8,11-14,16-17,20-21,23-24H,4-5,7,9-10,15,18-19H2,1H3,(H,25,26)/b3-2-,8-6-,14-11-,16-12-,17-13+/t20?,21-/m1/s1",MaR3n-3 DPA,PubMed citation,23736886
6842,140262,"16(S)-glutathionyl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid","A docosanoid that is 17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid in which a glutathionyl group is attached at position 16S via a sulfide linkage. An intermediate of specialised proresolving mediators.","InChI=1S/C32H47N3O9S/c1-2-3-14-17-26(36)27(18-15-12-10-8-6-4-5-7-9-11-13-16-19-29(38)39)45-23-25(31(42)34-22-30(40)41)35-28(37)21-20-24(33)32(43)44/h3,5-8,10-15,18,24-27,36H,2,4,9,16-17,19-23,33H2,1H3,(H,34,42)(H,35,37)(H,38,39)(H,40,41)(H,43,44)/b7-5-,8-6?,12-10?,13-11-,14-3-,18-15?/t24-,25-,26+,27-/m0/s1",PCTR1,PubMed citation,25713027
6843,140263,"16(S)-glycinylcystein-S-yl-17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid","A docosanoid that is 17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid in which a cysteinylglycinyl group is attached at position 16S via a sulfide linkage. An intermediate of specialized proresolving mediators","InChI=1S/C27H40N2O6S/c1-2-3-14-17-23(30)24(36-21-22(28)27(35)29-20-26(33)34)18-15-12-10-8-6-4-5-7-9-11-13-16-19-25(31)32/h3,5-8,10-15,18,22-24,30H,2,4,9,16-17,19-21,28H2,1H3,(H,29,35)(H,31,32)(H,33,34)/b7-5-,8-6?,12-10?,13-11-,14-3-,18-15?/t22-,23+,24-/m0/s1",PCTR2,PubMed citation,25713027
6844,140264,"16(S)-cystein-S-yl,17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid","A docosanoid that is 17(R)-hydroxy-(4Z,7Z,10,12,14,19Z)-docosahexaenoic acid in which a glycinyl group is attached at position 16S via a sulfide linkage. An intermediate of specialised proresolving mediators","InChI=1S/C25H37NO5S/c1-2-3-14-17-22(27)23(32-20-21(26)25(30)31)18-15-12-10-8-6-4-5-7-9-11-13-16-19-24(28)29/h3,5-8,10-15,18,21-23,27H,2,4,9,16-17,19-20,26H2,1H3,(H,28,29)(H,30,31)/b7-5-,8-6?,12-10?,13-11-,14-3-,18-15?/t21-,22+,23-/m0/s1",PCTR3,PubMed citation,25713027
6845,140265,"(10R,17S)-dihydroxy-(7Z,11E,13E,15Z,19Z)-docosapentaenoic acid","A dihydroxydocosapentaenoic acid (DiHDPE) that is (7Z,11E,13E,15Z,19Z)-docosapentaenoic acid in which the hydrogens at the 10 pro-R and 17 pro-S positions have been replaced by hydroxy groups. It is an intermediate of specialized proresolving mediators.","InChI=1S/C22H34O4/c1-2-3-10-15-20(23)17-12-8-9-13-18-21(24)16-11-6-4-5-7-14-19-22(25)26/h3,6,8-13,17-18,20-21,23-24H,2,4-5,7,14-16,19H2,1H3,(H,25,26)/b9-8+,10-3-,11-6-,17-12-,18-13+/t20-,21+/m0/s1",PD1n-3 DPA,Reaxys Registry Number,27066730
6846,140266,"16,17(S)-dihydroxy-(7Z,10Z,13E,14E,19Z)-docosapentaenoic acid","A dihydroxydocosapentaenoic acid (DiHDPE) that is (7Z,10Z,13E,14E,19Z)-docosapentaenoic acid carrying two hydroxy substituents at the 16 and 17-S positions. It is an intermediate of specialised proresolving mediators.","InChI=1S/C22H34O4/c1-2-3-14-17-20(23)21(24)18-15-12-10-8-6-4-5-7-9-11-13-16-19-22(25)26/h3,5-8,10,12,14-15,18,20-21,23-24H,2,4,9,11,13,16-17,19H2,1H3,(H,25,26)/b7-5-,8-6-,12-10+,14-3-,18-15+/t20-,21?/m0/s1",PD2n-3 DPA,PubMed citation,28408222
6847,140267,prostaglandin J3,"A member of the class of prostaglandins J that is (5Z,9Z,13E,17Z)-prostatetraenoic acid carrying hydroxy and oxo substituents at positions 11 and 15 respectively. An intermediate of specialised proresolving mediators","InChI=1S/C20H28O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h3-4,6-7,12-18,21H,2,5,8-11H2,1H3,(H,23,24)/b6-3-,7-4-,14-13+/t16-,17-,18+/m0/s1",PGJ3,Pubchem accession,16061112
6848,140268,"(8S)-glutathionyl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid","A docosanoid that is (7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid in which a glutathionyl group is attached at position 8S via a sulfide linkage. An intermediate of specialised proresolving mediators.","InChI=1S/C32H47N3O10S/c1-2-3-9-14-23(36)15-10-6-4-5-7-12-17-27(26(37)16-11-8-13-18-29(39)40)46-22-25(31(43)34-21-30(41)42)35-28(38)20-19-24(33)32(44)45/h3-12,15,17,23-27,36-37H,2,13-14,16,18-22,33H2,1H3,(H,34,43)(H,35,38)(H,39,40)(H,41,42)(H,44,45)/b6-4-,7-5?,9-3-,11-8-,15-10+,17-12?/t23-,24-,25-,26+,27-/m0/s1",RCTR1,PubMed citation,25713027
6849,140270,"(8S)-cystein-S-yl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid","A docosanoid that is (7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid in which a cysteinyl group is attached at position 8S via a sulfide linkage. An intermediate of specialised proresolving mediators.","InChI=1S/C25H37NO6S/c1-2-3-9-14-20(27)15-10-6-4-5-7-12-17-23(33-19-21(26)25(31)32)22(28)16-11-8-13-18-24(29)30/h3-12,15,17,20-23,27-28H,2,13-14,16,18-19,26H2,1H3,(H,29,30)(H,31,32)/b6-4-,7-5?,9-3-,11-8-,15-10+,17-12?/t20-,21-,22+,23-/m0/s1",RCTR3,PubMed citation,25713027
6850,140271,"(7S,8,17S)-trihydroxy-(15E,19Z)-docosa-9,11,13,15,19-pentaenoic acid","A docosanoid that is (15E,19Z)-docosa-9,11,13,15,19-pentaenoic acid carrying three hydroxy substituents at positions 7S, 8 and 17S. An intermediate of specialised proresolving mediators","InChI=1S/C22H34O5/c1-2-3-9-14-19(23)15-10-6-4-5-7-11-16-20(24)21(25)17-12-8-13-18-22(26)27/h3-7,9-11,15-16,19-21,23-25H,2,8,12-14,17-18H2,1H3,(H,26,27)/b6-4?,7-5?,9-3-,15-10+,16-11?/t19-,20?,21-/m0/s1",RvD1n-3 DPA,PubMed citation,23736886
6851,140272,"7,16,17-trihydroxy-(14E,19Z)-docosa-8,10,12,14,19-pentaenoic acid","A docosanoid that is (14E,19Z)-docosa-8,10,12,14,19-pentaenoic acid carrying three hydroxy substituents at positions 7, 16 and 17. An intermediate of specialised proresolving mediators","InChI=1S/C22H34O5/c1-2-3-9-16-20(24)21(25)17-12-7-5-4-6-10-14-19(23)15-11-8-13-18-22(26)27/h3-7,9-10,12,14,17,19-21,23-25H,2,8,11,13,15-16,18H2,1H3,(H,26,27)/b6-4?,7-5?,9-3-,14-10?,17-12+",RvD2n-3 DPA,PubMed citation,28408222
6852,140273,"7,17-dihydroxy-(8Z,15E,19Z)-docosa-8,10,13,15,19-pentaenoic acid","A dihydroxydocosapentaenoic acid (DiHDPE) that is (8Z,15E,19Z)-docosa-8,10,13,15,19-pentaenoic acid carrying two hydroxy substituents at positions 7 and 17. An intermediate of specialized proresolving mediators","InChI=1S/C22H34O4/c1-2-3-10-15-20(23)16-11-7-5-4-6-8-12-17-21(24)18-13-9-14-19-22(25)26/h3,5-8,10-12,16-17,20-21,23-24H,2,4,9,13-15,18-19H2,1H3,(H,25,26)/b7-5?,8-6?,10-3-,16-11+,17-12-",RvD5n-3 DPA,PubMed citation,23736886
6853,140274,Delta(12)-prostaglandin J3,"A member of the class of prostaglandins J that is (5Z,9Z,12E,17Z)-prostatetraenoic acid carrying hydroxy and oxo substituents at positions 11 and 15 respectively. An intermediate of specialised proresolving mediators and potent anti-leukemic agent.","InChI=1S/C20H28O4/c1-2-3-6-10-17(21)13-14-18-16(12-15-19(18)22)9-7-4-5-8-11-20(23)24/h3-4,6-7,12,14-17,21H,2,5,8-11,13H2,1H3,(H,23,24)/b6-3-,7-4-,18-14+/t16-,17-/m0/s1",delta-12-PGJ3,PubMed citation,27187634
6854,140280,alpha-psychosine,A glycosylsphingoid consisting of sphingosine having an alpha-D-galactosyl residue attached at the 1-position.,"InChI=1S/C24H47NO7/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(27)18(25)17-31-24-23(30)22(29)21(28)20(16-26)32-24/h14-15,18-24,26-30H,2-13,16-17,25H2,1H3/b15-14+/t18-,19+,20+,21-,22-,23+,24-/m0/s1","(2S,3R,4E)-2-amino-1-(alpha-D-galactopyranosyloxy)-3-hydroxyoctadec-4-ene",PubMed citation,29351991
6855,140294,5'-triphosphoadenylyl-(2'->5')-adenosine(5-),An organophosphate oxoanion obtained by deprotonation of the phosphate and triphosphate OH groups of 5'-triphosphoadenylyl-(2'->5')-adenosine. Major microspecies at pH 7.3.,"InChI=1S/C20H28N10O19P4/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(45-19)1-43-51(37,38)47-14-12(32)8(2-44-52(39,40)49-53(41,42)48-50(34,35)36)46-20(14)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-33H,1-2H2,(H,37,38)(H,39,40)(H,41,42)(H2,21,23,25)(H2,22,24,26)(H2,34,35,36)/p-5/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1",pppA2'p5'A(5-),PubMed citation,23878220
6856,140314,5'-triphosphoadenylyl-(2'->5')-adenosine,A (2'->5')-dinucleotide composed of two adenosine residues with a triphosphate group at the 5' terminus.,"InChI=1S/C20H28N10O19P4/c21-15-9-17(25-3-23-15)29(5-27-9)19-13(33)11(31)7(45-19)1-43-51(37,38)47-14-12(32)8(2-44-52(39,40)49-53(41,42)48-50(34,35)36)46-20(14)30-6-28-10-16(22)24-4-26-18(10)30/h3-8,11-14,19-20,31-33H,1-2H2,(H,37,38)(H,39,40)(H,41,42)(H2,21,23,25)(H2,22,24,26)(H2,34,35,36)/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1",pppA2'p5'A,Reaxys Registry Number,4646833
6857,140376,cefiderocol,"A fourth-generation siderophore cephalosporin antibiotic having {1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively, developed to combat a variety of bacterial pathogens, including beta-lactam- and carbapenem-resistant organisms.","InChI=1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/t20-,26-/m1/s1",S-649266,PubMed citation,29017833
6858,140408,2-iodohippuric acid,A member of the class of benzamides resulting from the formal condensation of the carboxy group of 2-iodobenzoic acid with the amino group of glycine.,"InChI=1S/C9H8INO3/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13)",N-(o-iodobenzoyl)glycine,CAS Registry Number,147-58-0
6859,140411,sodium 2-iodohippurate,An organic sodium salt resulting from the formal reaction of equimolar amounts of 2-iodohippuric acid and sodium. It has been used as a contrast agent in urography. Isotopologues labelled with radioactive iodine were formerly used for determination of effective renal plasma flow. It has also been used labelled with radioactive iodine (iodine-125 or iodine-131) in tests of renal function and in renal imaging.,"InChI=1S/C9H8INO3.Na/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13;/h1-4H,5H2,(H,11,14)(H,12,13);/q;+1/p-1",sodium N-(2-iodobenzoyl)glycinate,CAS Registry Number,133-17-5
6860,140448,nona-N-acetyl-beta-D-glucosamine,An amino nonasaccharide consisting of nine (1->6)-linked N-acetyl-beta-D-glucosamine residues; a synthetic oligosaccharide version of  poly(N-acetyl-beta-D-glucosamine) (PNAG).,"InChI=1S/C72H119N9O46/c1-19(83)73-37-55(101)47(93)29(119-64(37)110)11-111-66-39(75-21(3)85)57(103)49(95)31(121-66)13-113-68-41(77-23(5)87)59(105)51(97)33(123-68)15-115-70-43(79-25(7)89)61(107)53(99)35(125-70)17-117-72-45(81-27(9)91)63(109)54(100)36(127-72)18-118-71-44(80-26(8)90)62(108)52(98)34(126-71)16-116-69-42(78-24(6)88)60(106)50(96)32(124-69)14-114-67-40(76-22(4)86)58(104)48(94)30(122-67)12-112-65-38(74-20(2)84)56(102)46(92)28(10-82)120-65/h28-72,82,92-110H,10-18H2,1-9H3,(H,73,83)(H,74,84)(H,75,85)(H,76,86)(H,77,87)(H,78,88)(H,79,89)(H,80,90)(H,81,91)/t28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-/m1/s1",N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosaminyl-(1->6)-N-acetyl-beta-D-glucosamine,PubMed citation,29449370
6861,140459,"3-[beta-D-glucopyranosyl-(1->6)-beta-D-galactopyranosyl]-1,2-dimyristoyl-sn-glycerol","A 3-[beta-D-glucopyranosyl-(1->6)-beta-D-galactopyranosyl]-1,2-diacyl-sn-glycerol in which the acyl groups at O-1 and O-2 are both myristoyl. A synthetic acyl homologue of the beta-glycolipid antigens (beta-GGLs) of Mycoplasma pneumoniae.","InChI=1S/C43H80O15/c1-3-5-7-9-11-13-15-17-19-21-23-25-34(45)53-28-31(56-35(46)26-24-22-20-18-16-14-12-10-8-6-4-2)29-54-42-41(52)39(50)37(48)33(58-42)30-55-43-40(51)38(49)36(47)32(27-44)57-43/h31-33,36-44,47-52H,3-30H2,1-2H3/t31-,32-,33-,36-,37+,38+,39+,40-,41-,42-,43-/m1/s1","3-O-[beta-D-Glcp-(1->6)-beta-D-Galp]-1,2-di-O-myristoyl-sn-glycerol",PubMed citation,29373272
6862,140460,"3-[beta-D-glucopyranosyl-(1->6)-beta-D-galactopyranosyl]-1,2-dipalmitoyl-sn-glycerol","A 3-[beta-D-glucopyranosyl-(1->6)-beta-D-galactopyranosyl]-1,2-diacyl-sn-glycerol in which the acyl groups at O-1 and O-2 are both palmitoyl. A synthetic acyl homologue of the beta-glycolipid antigens (beta-GGLs) of Mycoplasma pneumoniae.","InChI=1S/C47H88O15/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-38(49)57-32-35(60-39(50)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)33-58-46-45(56)43(54)41(52)37(62-46)34-59-47-44(55)42(53)40(51)36(31-48)61-47/h35-37,40-48,51-56H,3-34H2,1-2H3/t35-,36-,37-,40-,41+,42+,43+,44-,45-,46-,47-/m1/s1","3-O-[beta-D-glucopyranosyl-(1""->6')-beta-D-galactopyranosyl]-1,2-di-O-palmitoyl-sn-glycerol",PubMed citation,29373272
6863,140463,"3-[beta-D-glucopyranosyl-(1->6)-beta-D-galactopyranosyl]-1,2-dipalmitoyl-16,16,16-d3-sn-glycerol","A deuterated compound that is 3-[beta-D-glucopyranosyl-(1->6)-beta-D-galactopyranosyl]-1,2-diacyl-sn-glycerol in which the acyl groups at O-1 and O-2 are both palmitoyl-16,16,16-d3 ([16,16,16-(2)H3]palmitoyl). A synthetic isotopically labelled acyl homologue of the beta-glycolipid antigens (beta-GGLs) of Mycoplasma pneumoniae.","InChI=1S/C47H88O15/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-38(49)57-32-35(60-39(50)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)33-58-46-45(56)43(54)41(52)37(62-46)34-59-47-44(55)42(53)40(51)36(31-48)61-47/h35-37,40-48,51-56H,3-34H2,1-2H3/t35-,36-,37-,40-,41+,42+,43+,44-,45-,46-,47-/m1/s1/i1D3,2D3","3-O-[beta-D-Glcp-(1->6)-beta-D-Galp]-1,2-di-O-[16,16,16-(2)H3]palmitoyl-sn-glycerol",Reaxys Registry Number,32359280
6864,140464,"7,8-dihydroxyflavone","A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, In animal models, it has shown efficacy against several diseases of the nervous system, including Alzheimer's, Parkinson's, and Huntington's.","InChI=1S/C15H10O4/c16-11-7-6-10-12(17)8-13(19-15(10)14(11)18)9-4-2-1-3-5-9/h1-8,16,18H","7,8-DHF",Wikipedia accession,"7,8-Dihydroxyflavone"
6865,140465,ANA-12,"A secondary carboxamide that is anthranilic acid in which the carboxy group has undergone condensation with the primary amino group of alpha-amino-epsilon-caprolactam, while the aryl-amino group has undergone condensation with the carboxy group of 1-benzothiophene-2-carboxylic acid. It is a selective, non-competitive antagonist of tropomyosin receptor kinase B (TrkB, also known as tyrosine receptor kinase B).","InChI=1S/C22H21N3O3S/c26-20(25-17-10-5-6-12-23-21(17)27)15-8-2-3-9-16(15)24-22(28)19-13-14-7-1-4-11-18(14)29-19/h1-4,7-9,11,13,17H,5-6,10,12H2,(H,23,27)(H,24,28)(H,25,26)",TrkB antagonist,CAS Registry Number,219766-25-3
6866,140487,5'-GGTTGGTGTGGTTGG-3',A nucleic acid (single-stranded DNA) aptamer consisting of nine deoxyguanosine and six thymidine residues connected by 3'->5' phosphodiester linkages in the sequence G-G-T-T-G-G-T-G-T-G-G-T-T-G-G. One of a family of aptamers that bind to and lead to the neutralization of autoantibodies (AABs) that are directed against G-protein-coupled receptors (GPCR-AABs).,"InChI=1S/C150H188N57O97P15/c1-52-22-193(145(224)187-121(52)209)88-9-60(77(278-88)32-265-314(249,250)299-66-15-96(201-45-162-105-114(201)171-138(153)180-129(105)217)283-81(66)36-262-306(233,234)291-58-7-94(275-73(58)28-208)199-43-160-103-112(199)169-136(151)178-127(103)215)292-308(237,238)264-31-76-63(12-91(277-76)196-25-55(4)124(212)190-148(196)227)295-311(243,244)271-39-84-71(20-101(286-84)206-50-167-110-119(206)176-143(158)185-134(110)222)303-318(257,258)274-42-87-70(19-100(289-87)205-49-166-109-118(205)175-142(157)184-133(109)221)302-317(255,256)268-35-80-64(13-92(281-80)197-26-56(5)125(213)191-149(197)228)296-312(245,246)270-38-83-68(17-98(285-83)203-47-164-107-116(203)173-140(155)182-131(107)219)300-315(251,252)267-34-79-65(14-93(280-79)198-27-57(6)126(214)192-150(198)229)297-313(247,248)272-40-85-72(21-102(287-85)207-51-168-111-120(207)177-144(159)186-135(111)223)304-319(259,260)273-41-86-69(18-99(288-86)204-48-165-108-117(204)174-141(156)183-132(108)220)301-316(253,254)266-33-78-61(10-89(279-78)194-23-53(2)122(210)188-146(194)225)293-309(239,240)263-30-75-62(11-90(276-75)195-24-54(3)123(211)189-147(195)226)294-310(241,242)269-37-82-67(16-97(284-82)202-46-163-106-115(202)172-139(154)181-130(106)218)298-307(235,236)261-29-74-59(290-305(230,231)232)8-95(282-74)200-44-161-104-113(200)170-137(152)179-128(104)216/h22-27,43-51,58-102,208H,7-21,28-42H2,1-6H3,(H,233,234)(H,235,236)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H,187,209,224)(H,188,210,225)(H,189,211,226)(H,190,212,227)(H,191,213,228)(H,192,214,229)(H2,230,231,232)(H3,151,169,178,215)(H3,152,170,179,216)(H3,153,171,180,217)(H3,154,172,181,218)(H3,155,173,182,219)(H3,156,174,183,220)(H3,157,175,184,221)(H3,158,176,185,222)(H3,159,177,186,223)/t58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+/m0/s1",5'-d[GGTTGGTGTGGTTGG]-3',PubMed citation,27375076
6867,140505,beta-D-Galp-(1->2)-alpha-D-Galp-(1->3)-beta-L-Rhap-(1->4)-beta-D-Glcp-(1->3)-[alpha-L-Rhap-(1->4)]-beta-D-GalpNAcO[CH2]5NH2,"A branched hexasaccharide derivative consisting of a linear pentasaccharide unit of beta-D-galactose, alpha-D-galactose, beta-L-rhamnose, beta-D-glucose and N-acetyl-beta-D-galactosamine residues linked sequentially (1->2), (1->3), (1->4) and (1->3), to the N-acetylgalactosamine residue of which is also linked (1->4) an alpha-L-rhamnosyl residue, the whole linked glycosidically to a 5-aminopentyl group.","InChI=1S/C43H76N2O29/c1-13-21(51)25(55)29(59)39(64-13)71-34-19(12-49)68-38(63-8-6-4-5-7-44)20(45-15(3)50)35(34)72-41-31(61)28(58)33(18(11-48)69-41)70-42-32(62)36(22(52)14(2)65-42)73-43-37(27(57)24(54)17(10-47)67-43)74-40-30(60)26(56)23(53)16(9-46)66-40/h13-14,16-43,46-49,51-62H,4-12,44H2,1-3H3,(H,45,50)/t13-,14-,16+,17+,18+,19+,20+,21-,22-,23-,24-,25+,26-,27-,28+,29+,30+,31+,32+,33+,34-,35+,36+,37+,38+,39-,40-,41-,42+,43+/m0/s1",5-aminopentyl beta-D-galactosyl-(1->2)-alpha-D-galactosyl-(1->3)-beta-L-rhamnosyl-(1->4)-beta-D-glucosyl-(1->3)-[alpha-L-rhamnosyl-(1->4)]-N-acetyl-beta-D-galactosaminide,PubMed citation,29333751
6868,140510,beta-D-Galp-(1->2)-alpha-D-Galp-(1->3)-beta-L-RhapO[CH2]5NH2,"A linear trisaccharide derivative consisting of beta-D-galactose, alpha-D-galactose and beta-L-rhamnose residues linked sequentially (1->2) and (1->3) with the rhamnose residue linked glycosidically to a 5-aminopentyl group.","InChI=1S/C23H43NO15/c1-9-12(27)19(18(33)21(35-9)34-6-4-2-3-5-24)38-23-20(16(31)14(29)11(8-26)37-23)39-22-17(32)15(30)13(28)10(7-25)36-22/h9-23,25-33H,2-8,24H2,1H3/t9-,10+,11+,12-,13-,14-,15-,16-,17+,18+,19+,20+,21-,22-,23+/m0/s1",5-aminopentyl beta-D-galactosyl-(1->2)-alpha-D-galactosyl-(1->3)-beta-L-rhamnoside,PubMed citation,29333751
6869,140511,beta-L-Rhap-(1->4)-beta-D-Glcp-(1->3)-[alpha-L-Rhap-(1->4)]-beta-D-GalpNAcO[CH2]5NH2,"A branched tetrasaccharide derivative consisting of a linear trisaccharide unit of beta-L-rhamnose, beta-D-glucose and N-acetyl-beta-D-galactosamine residues linked sequentially (1->4) and (1->3), to the N-acetylgalactosamine residue of which is also linked (1->4) an alpha-L-rhamnosyl residue, the whole linked glycosidically to a 5-aminopentyl group.","InChI=1S/C31H56N2O19/c1-11-17(37)19(39)22(42)29(46-11)50-25-14(9-34)49-31(24(44)21(25)41)52-27-16(33-13(3)36)28(45-8-6-4-5-7-32)48-15(10-35)26(27)51-30-23(43)20(40)18(38)12(2)47-30/h11-12,14-31,34-35,37-44H,4-10,32H2,1-3H3,(H,33,36)/t11-,12-,14+,15+,16+,17-,18-,19+,20+,21+,22+,23+,24+,25+,26-,27+,28+,29+,30-,31-/m0/s1",Rhabeta1-4Glcbeta1-3(Rhaalpha1-4)GalNAcO[CH2]5NH2,PubMed citation,29333751
6870,140536,bromfenac sodium salt,The sodium salt of bromfenac. Note that 'bromfenac sodium' commonly refers to the sesquihydrate (120638-55-3); this is the anhydrous form.,"InChI=1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1",Sodium; [2-amino-3-(4-bromo-benzoyl)-phenyl]-acetate,CAS Registry Number,91714-93-1
6871,140592,onalespib,"A member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor.","InChI=1S/C24H31N3O3/c1-16(2)20-11-21(23(29)12-22(20)28)24(30)27-14-18-5-4-17(10-19(18)15-27)13-26-8-6-25(3)7-9-26/h4-5,10-12,16,28-29H,6-9,13-15H2,1-3H3","(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone",KEGG DRUG accession,D10719
6872,140595,1-[(1Z)-octadecenyl]-2-oleoyl-sn-glycero-3-phosphate,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphate in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and oleoyl respectively.,"InChI=1S/C39H75O7P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-44-36-38(37-45-47(41,42)43)46-39(40)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,33,35,38H,3-17,19,21-32,34,36-37H2,1-2H3,(H2,41,42,43)/b20-18-,35-33-/t38-/m1/s1",1-[(1Z)-octadecenyl]-2-[(9Z)-octadecenoyl]-sn-glycero-3-phosphate,LIPID MAPS instance accession,LMGP10030092
6873,140612,"(8Z,11Z)-urushiol III","Catechol substituted at position 3 with an (8Z,11Z)-pentadeca-8,11-dien-1-yl group. Stereoisomer of urushiol III (CHEBI:9909) which has (8E,11E) configuration.","InChI=1S/C21H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-17-15-18-20(22)21(19)23/h4-5,7-8,15,17-18,22-23H,2-3,6,9-14,16H2,1H3/b5-4-,8-7-",urushiol (C15:2),PubMed citation,27548435
6874,140621,cisatracurium,"A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion  consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.  The active species in the skeletal muscle relaxant cisatracurium besylate.","InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1","(1R-cis,1'R-cis)-atracurium",PubMed citation,29368335
6875,140630,methyl 4-nitrobenzyl carbonate,A carbonate ester that is dimethyl carbonate in which one of the methyl groups has been replaced by a 4-nitrobenzyl group.,"InChI=1S/C9H9NO5/c1-14-9(11)15-6-7-2-4-8(5-3-7)10(12)13/h2-5H,6H2,1H3",p-nitrobenzyl methyl carbonate,Reaxys Registry Number,3311877
6876,140631,4-nitrobenzyl hydrogen ethylphosphonate,A C-nitro compound that is ethylphosphonic acid esterified with (4-nitrophenyl)methanol; a phosphonate transition state analogue with affinity for catalytic antibody 7B9.,"InChI=1S/C9H12NO5P/c1-2-16(13,14)15-7-8-3-5-9(6-4-8)10(11)12/h3-6H,2,7H2,1H3,(H,13,14)",p-nitrobenzyl ethylphosphonate,PubMed citation,29496413
6877,140661,"2,2'-dithiobis{1-[alpha-D-galacturonosyl-(1->3)-alpha-D-galacturonosyloxy]ethane}","An oligosaccharide derivative consisting of two alpha-D-galacturonosyl-(1->3)-alpha-D-galacturonosyloxy disaccharide units linked via a dithiodiethyl divalent group. One of a panel of synthetic oligosaccharide derivatives designed to reveal a critical role of the rare aminosugar 2-acetamido-4-amino-2,4-dideoxy-D-fucose (2-acetamido-4-amino-2,4,6-trideoxy-D-galactose; D-AAT) for serotype 1 immune recognition (PMID:29632881).","InChI=1S/C28H42O26S2/c29-5-7(31)17(21(39)40)53-27(9(5)33)49-15-11(35)19(23(43)44)51-25(13(15)37)47-1-3-55-56-4-2-48-26-14(38)16(12(36)20(52-26)24(45)46)50-28-10(34)6(30)8(32)18(54-28)22(41)42/h5-20,25-38H,1-4H2,(H,39,40)(H,41,42)(H,43,44)(H,45,46)/t5-,6-,7+,8+,9+,10+,11+,12+,13+,14+,15-,16-,17-,18-,19-,20-,25-,26-,27-,28-/m0/s1","2,2'-dithiobis[alpha-D-galactopyranosyluronate-(1->3)-alpha-D-galactopyranosyluronate-(1->1)-1-ethanol]",Reaxys Registry Number,27867044
6878,140666,"6,6'-dithiodi[1-(2-acetamido-4-amino-2,4-dideoxy-alpha-D-fucosyloxy)hexane]","An oligosaccharide derivative consisting of two 2-acetamido-4-amino-2,4-dideoxy-alpha-D-fucosyloxy ((2-acetamido-4-amino-2,4,6-trideoxy-alpha-D-galactosyl) monosaccharide units linked via a dithiodihexyl divalent group. One of a panel of synthetic oligosaccharide derivatives designed to reveal a critical role of the rare aminosugar 2-acetamido-4-amino-2,4-dideoxy-D-fucose (2-acetamido-4-amino-2,4,6-trideoxy-D-galactose; D-AAT) for serotype 1 immune recognition (PMID:29632881).","InChI=1S/C28H54N4O8S2/c1-17-21(29)25(35)23(31-19(3)33)27(39-17)37-13-9-5-7-11-15-41-42-16-12-8-6-10-14-38-28-24(32-20(4)34)26(36)22(30)18(2)40-28/h17-18,21-28,35-36H,5-16,29-30H2,1-4H3,(H,31,33)(H,32,34)/t17-,18-,21+,22+,23-,24-,25+,26+,27+,28+/m1/s1","6-({6-[(2-acetamido-4-amino-2,4,6-trideoxy-alpha-D-galactosyl)oxy]hexyl}disulfanyl)hexyl 2-acetamido-4-amino-2,4,6-trideoxy-alpha-D-galactoside",PubMed citation,29632881
6879,140700,WAY-316606,A sulfonamide resulting from the formal condensation of the sulfonic acid group of 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonic acid with the primary amino group of piperidin-4-amine. An inhibitor of secreted Frizzled-Related Protein-1 (sFRP-1).,"InChI=1S/C18H19F3N2O4S2/c19-18(20,21)16-7-6-15(28(24,25)14-4-2-1-3-5-14)12-17(16)29(26,27)23-13-8-10-22-11-9-13/h1-7,12-13,22-23H,8-11H2",WAY 316606,PubMed citation,19932972
6880,140779,"1,3,6,8-tetraazatricyclo[4,4,1,1(3,8)]dodecane",An adamanzane which contains four one-carbon chains and two two-carbon chains linking the nitrogens thus forming a cage structure.,InChI=1S/C8H16N4/c1-2-10-7-11-3-4-12(8-10)6-9(1)5-11/h1-8H2,tetraazatricyclododecane,PubMed citation,29438107
6881,140813,alpha-D-Manp-(1->5)-beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-D-Araf,"A pentasaccharide composed of a mannopyranose and four arabinofuranose residues in an alpha(1->5), beta(1->2), alpha(1->5) and alpha(1->5) linear sequence.","InChI=1S/C26H44O22/c27-1-6-11(29)16(34)20(38)24(44-6)41-4-10-14(32)19(37)25(47-10)48-21-15(33)7(2-28)45-26(21)42-5-9-13(31)18(36)23(46-9)40-3-8-12(30)17(35)22(39)43-8/h6-39H,1-5H2/t6-,7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21+,22?,23+,24+,25+,26+/m1/s1",alpha-D-Man-(1->5)-beta-D-Ara-(1->2)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-D-Ara,PubMed citation,29610143
6882,140823,L-lysyl levuloglandin E2 adduct,An L-lysine derivative that is a gamma-lactam adduct formed between L-lysine and levuloglandin E2 (LGE2).,"InChI=1S/C26H42N2O6/c1-3-4-7-12-20(29)16-17-22-21(13-8-5-6-9-15-24(30)31)19(2)28(25(22)32)18-11-10-14-23(27)26(33)34/h5,8,16-17,19-20,23,29H,3-4,6-7,9-15,18,27H2,1-2H3,(H,30,31)(H,33,34)/b8-5-,17-16+/t19?,20-,23-/m0/s1",lysyl LGE2 lactam adduct,PubMed citation,15082070
6883,140824,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->5)-beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-D-Araf,"A hexasaccharide composed of two mannopyranose and four arabinofuranose residues in an alpha(1->2), alpha(1->5), beta(1->2), alpha(1->5) and alpha(1->5) linear sequence.","InChI=1S/C32H54O27/c33-1-7-13(36)19(42)24(47)30(53-7)59-26-20(43)14(37)8(2-34)54-32(26)51-6-12-17(40)23(46)29(57-12)58-25-18(41)9(3-35)55-31(25)50-5-11-16(39)22(45)28(56-11)49-4-10-15(38)21(44)27(48)52-10/h7-48H,1-6H2/t7-,8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21+,22+,23+,24+,25+,26+,27?,28+,29+,30-,31+,32+/m1/s1",alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->5)-beta-D-arabinosyl-(1->2)-alpha-D-arabinosyl-(1->5)-alpha-D-arabinosyl-(1->5)-D-arabinose,PubMed citation,29610143
6884,140826,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->5)-beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-D-Araf,"A heptasaccharide composed of three mannopyranose and four arabinofuranose residues in an alpha(1->2), alpha(1->2), alpha(1->5), beta(1->2), alpha(1->5) and alpha(1->5) linear sequence.","InChI=1S/C38H64O32/c39-1-8-15(43)22(50)28(56)35(62-8)69-31-24(52)17(45)10(3-41)65-38(31)70-30-23(51)16(44)9(2-40)63-37(30)60-7-14-20(48)27(55)34(67-14)68-29-21(49)11(4-42)64-36(29)59-6-13-19(47)26(54)33(66-13)58-5-12-18(46)25(53)32(57)61-12/h8-57H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32?,33+,34+,35-,36+,37+,38-/m1/s1",alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->5)-beta-D-arabinosyl-(1->2)-alpha-D-arabinosyl-(1->5)-alpha-D-arabinosyl-(1->5)-D-arabinose,PubMed citation,29610143
6885,140841,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)-D-Manp,"A mannotetraose comprised of a trisaccharide unit of D-mannose residues linked sequentially alpha(1->3) and alpha(1->6), to the residue proximal to that at the reducing end is also linked alpha(1->6) a fourth D-mannose residue.","InChI=1S/C24H42O21/c25-1-5-9(27)14(32)17(35)22(42-5)39-4-8-12(30)20(45-24-18(36)15(33)10(28)6(2-26)43-24)19(37)23(44-8)40-3-7-11(29)13(31)16(34)21(38)41-7/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21?,22+,23+,24-/m1/s1",alpha-D-Man-(1->6)-[alpha-D-Man-(1->3)]-alpha-D-Man-(1->6)-D-Man,PubMed citation,29610143
6886,140844,alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->2)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-D-Manp,"A linear octasaccharide consisting of a chain of five D-arabinofuranose and three D-mannopyranose residues linked sequentially alpha(1->5), alpha(1->5), alpha(1->5), alpha(1->5), alpha(1->2), alpha(1->6) and alpha(1->6).","InChI=1S/C43H72O36/c44-1-9-17(46)27(56)35(43(73-9)70-8-12-20(49)26(55)34(63)41(74-12)65-3-11-19(48)25(54)28(57)36(64)71-11)79-42-33(62)24(53)16(78-42)7-69-40-32(61)23(52)15(77-40)6-68-39-31(60)22(51)14(76-39)5-67-38-30(59)21(50)13(75-38)4-66-37-29(58)18(47)10(2-45)72-37/h9-64H,1-8H2/t9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36?,37+,38+,39+,40+,41+,42-,43+/m1/s1",alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->2)-alpha-D-Man-(1->6)-alpha-D-Man-(1->6)-D-Man,PubMed citation,29610143
6887,140846,beta-D-Araf-(1->2)-alpha-D-Araf-(1->3)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf,"An octasaccharide composed of eight arabinofuranose residues in a beta(1->2), alpha(1->3), alpha(1->5), alpha(1->5), alpha(1->5), alpha(1->5) and alpha(1->5) linear sequence.","InChI=1S/C40H66O33/c41-1-9-17(44)29(56)39(65-9)73-32-23(50)10(2-42)66-40(32)72-31-11(3-43)67-38(30(31)57)63-8-16-22(49)28(55)37(71-16)62-7-15-21(48)27(54)36(70-15)61-6-14-20(47)26(53)35(69-14)60-5-13-19(46)25(52)34(68-13)59-4-12-18(45)24(51)33(58)64-12/h9-58H,1-8H2/t9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24+,25+,26+,27+,28+,29+,30+,31-,32+,33?,34+,35+,36+,37+,38+,39+,40-/m1/s1",Arabeta1-2Araalpha1-3Araalpha1-5Araalpha1-5Araalpha1-5Araalpha1-5Araalpha1-5Ara,PubMed citation,29610143
6888,140850,"(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside","A stilbenoid that is trans-stilbene which has been substituted by hydroxy groups at positions 2, 3, 5, and 4', and in which the hydroxy group at positon 2 has then been converted to the corresponding the beta-D-glucoside.","InChI=1S/C20H22O9/c21-9-15-16(25)17(26)18(27)20(28-15)29-19-11(7-13(23)8-14(19)24)4-1-10-2-5-12(22)6-3-10/h1-8,15-18,20-27H,9H2/b4-1+/t15-,16-,17+,18-,20+/m1/s1",tetrahydroxystilbene glucoside,CAS Registry Number,82373-94-2
6889,140852,beta-D-Araf-(1->2)-alpha-D-Araf-(1->3)-[alpha-D-Manp-(1->5)-beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)]-alpha-D-Araf-(1->5)-D-Araf,"A branched heptasaccharide derivative comprising one mannopyranose and six D-arabinofuranose units, in an assembly consisting of two arabinose residues linked alpha(1->5), with beta-arabinosyl-(1->2)-alpha-arabinosyl and alpha-mannosyl-(1->5)-beta-arabinosyl-(1->2)-alpha-arabinosyl units linked to respectively the 3- and 5-positions of the arabinose residue distal from the reducing-end residue.","InChI=1S/C36H60O30/c37-1-8-15(41)21(47)25(51)31(58-8)54-6-13-18(44)24(50)34(62-13)65-28-19(45)10(3-39)60-35(28)56-7-14-27(26(52)32(63-14)55-5-12-17(43)22(48)30(53)57-12)64-36-29(20(46)11(4-40)61-36)66-33-23(49)16(42)9(2-38)59-33/h8-53H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21+,22+,23+,24+,25+,26+,27-,28+,29+,30?,31+,32+,33+,34+,35+,36-/m1/s1",Arabeta1->2Araalpha1->3[Manalpha1->5Arabeta1->2Araalpha1->5]Aralpha1->5Ara,PubMed citation,29610143
6890,140855,methdilazine hydrochloride,The hydrochloride salt of methdilazine.,"InChI=1S/C18H20N2S.ClH/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20;/h2-9,14H,10-13H2,1H3;1H",10-[(1-methyl-3-pyrrolidinyl)methyl]phenothiazine hydrochloride,Reaxys Registry Number,4047235
6891,140905,N-{2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethyl}-N-propylpropan-1-amine hydrochloride,An aromatic ether that is (2-phenoxyethyl)benzene which carries a 2-(dipropylamino)ethyl group at position 3 and a methoxy group at position 6. It is a potent and selective sigma1 receptor antagonist.,"InChI=1S/C23H33NO2.ClH/c1-4-15-24(16-5-2)17-13-21-11-12-22(25-3)23(19-21)26-18-14-20-9-7-6-8-10-20;/h6-12,19H,4-5,13-18H2,1-3H3;1H",NE-100,CAS Registry Number,149409-57-4
6892,140908,GANT61,"An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor.","InChI=1S/C27H35N5/c1-29(2)25-12-7-5-10-23(25)20-31-18-9-19-32(27(31)22-14-16-28-17-15-22)21-24-11-6-8-13-26(24)30(3)4/h5-8,10-17,27H,9,18-21H2,1-4H3",NSC 136476,CAS Registry Number,500579-04-4
6893,140936,"1-(1-methylindol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea","A member of ther class of ureas that is urea in which a hydrogen attached to one of the nitrogens has been replaced by an N-methylindol-5-yl group, while a hydrogen attached to the other nitrogen has been replaced by a 3-methyl-1,2-thiazol-5-yl group. It is a potent and selective antagonist for the 5-hydroxytryptamine 2B (5-HT2B) receptor.","InChI=1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19)",N-(1-methyl-1H-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea,CAS Registry Number,152239-46-8
6894,140937,LY-310762,"A member of the class of oxindoles that is 1-ethyl-3,3-dimethyl-1,3-dihydro-2H-indol-2-one in which the ethyl group has been substituted at position 2 by a 4-(p-fluorobenzoyl)piperidin-1-yl group.  It is a potent and selective antagonist for the 5-hydroxytryptamine 1D (5-HT1D) receptor.","InChI=1S/C24H27FN2O2/c1-24(2)20-5-3-4-6-21(20)27(23(24)29)16-15-26-13-11-18(12-14-26)22(28)17-7-9-19(25)10-8-17/h3-10,18H,11-16H2,1-2H3",LY310762,Wikipedia accession,LY-310762
6895,140979,GJ14,A dipeptide resulting from the formal coupling of the carboxy group of N(2)-(diphenylacetyl)-D-arginine with the alpha-amino group of D-2-phenylglycinamide.,"InChI=1S/C28H32N6O3/c29-25(35)24(21-15-8-3-9-16-21)34-26(36)22(17-10-18-32-28(30)31)33-27(37)23(19-11-4-1-5-12-19)20-13-6-2-7-14-20/h1-9,11-16,22-24H,10,17-18H2,(H2,29,35)(H,33,37)(H,34,36)(H4,30,31,32)/t22-,24-/m1/s1",GJ-14,PubMed citation,27533886
6896,140980,RF9,"A dipeptide formed from L-arginine and L-phenylalaninamide residues in which a hydrogen attached to the nitrogen of the alpha-amino group of the arginine residue has been replaced by a 1-adamantanecarbonyl group. It has been reported to be a potent and selective antagonist of neuropeptide FF (NPFF) receptors, but more recently found to be an agonist at both NPFF1R and the kisspeptin receptor (KISS1R).","InChI=1S/C26H38N6O3/c27-22(33)21(12-16-5-2-1-3-6-16)31-23(34)20(7-4-8-30-25(28)29)32-24(35)26-13-17-9-18(14-26)11-19(10-17)15-26/h1-3,5-6,17-21H,4,7-15H2,(H2,27,33)(H,31,34)(H,32,35)(H4,28,29,30)/t17?,18?,19?,20-,21-,26?/m0/s1",RF 9,CAS Registry Number,876310-60-0
6897,140993,beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-[alpha-D-Xylf5SMe-(1->4)-alpha-D-Manp-(1->5)-beta-D-Araf-(1->2)-alpha-D-Araf-(1->3)]-alpha-D-Araf-(1->5)-D-Araf,"A branched octasaccharide derivative comprising one 5-deoxy-5-(methylsulfanyl)xylofuranose, one mannopyranose and six D-arabinofuranose units, in an assembly consisting of two of the arabinose residues linked alpha(1->5), with 5-deoxy-5-(methylsulfanyl)-beta-xylofuranosyl-(1->4)-alpha-mannosyl-(1->5)-beta-arabinosyl-(1->2)-alpha-arabinosyl and beta-arabinosyl-(1->2)-alpha-arabinosyl units linked to respectively the 3- and 5-positions of the arabinose residue distal from the reducing-end residue.","InChI=1S/C42H70O33S/c1-76-9-17-21(50)28(57)40(71-17)72-31-13(5-46)68-36(29(58)24(31)53)61-7-15-20(49)27(56)39(69-15)75-34-23(52)12(4-45)67-42(34)73-32-16(70-37(30(32)59)62-6-14-19(48)25(54)35(60)64-14)8-63-41-33(22(51)11(3-44)66-41)74-38-26(55)18(47)10(2-43)65-38/h10-60H,2-9H2,1H3/t10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21+,22-,23-,24-,25+,26+,27+,28-,29+,30+,31-,32-,33+,34+,35?,36+,37+,38+,39+,40-,41+,42-/m1/s1",beta-D-arabinosyl-(1->2)-alpha-D-arabinosyl-(1->5)-[5-S-methyl-5-thio-alpha-D-xylosyl-(1->4)-alpha-D-mannosyl-(1->5)-beta-D-arabinosyl-(1->2)-alpha-D-arabinosyl-(1->3)]-alpha-D-arabinosyl-(1->5)-alpha-D-arabinose,PubMed citation,29610143
6898,140995,beta-D-Araf-(1->2)-alpha-D-Araf-(1->3)-[beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)]-alpha-D-Araf-(1->5)-D-Araf,"A branched oligosaccharide comprising eleven D-arabinofuranose units, in an assembly consisting of two of the arabinose residues linked alpha(1->5), with beta-arabinosyl-(1->2)-alpha-arabinosyl and beta-arabinosyl-(1->2)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl units linked to respectively the 3- and 5-positions of the arabinose residue distal from the reducing-end residue.","InChI=1S/C55H90O45/c56-1-12-23(60)39(76)52(88-12)99-43-31(68)14(3-58)90-54(43)86-10-21-30(67)37(74)49(96-21)83-8-19-28(65)35(72)47(94-19)81-6-17-26(63)34(71)46(92-17)80-7-18-27(64)36(73)48(93-18)82-9-20-29(66)38(75)50(95-20)85-11-22-42(41(78)51(97-22)84-5-16-25(62)33(70)45(79)87-16)98-55-44(32(69)15(4-59)91-55)100-53-40(77)24(61)13(2-57)89-53/h12-79H,1-11H2/t12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33+,34+,35+,36+,37+,38+,39+,40+,41+,42-,43+,44+,45?,46+,47+,48+,49+,50+,51+,52+,53+,54+,55-/m1/s1",beta-D-Ara-(1->2)-alpha-D-Ara-(1->3)-[beta-D-Ara-(1->2)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)-alpha-D-Ara-(1->5)]-alpha-D-Ara-(1->5)-D-Ara,PubMed citation,29610143
6899,140996,beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-[beta-D-Araf-(1->2)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->5)-alpha-D-Araf-(1->3)]-alpha-D-Araf-(1->5)-D-Araf,"A branched oligosaccharide comprising eleven D-arabinofuranose units, in an assembly consisting of two of the arabinose residues linked alpha(1->5), with beta-arabinosyl-(1->2)-alpha-arabinosyl and beta-arabinosyl-(1->2)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl-(1->5)-alpha-arabinosyl units linked to respectively the 5- and 3-positions of the arabinose residue distal from the reducing-end residue.","InChI=1S/C55H90O45/c56-1-12-23(60)38(75)51(88-12)99-43-31(68)14(3-58)90-54(43)85-10-20-29(66)37(74)48(95-20)82-8-18-27(64)35(72)46(93-18)80-6-17-26(63)34(71)47(92-17)81-7-19-28(65)36(73)49(94-19)83-9-21-30(67)40(77)53(96-21)98-42-22(97-50(41(42)78)84-5-16-25(62)33(70)45(79)87-16)11-86-55-44(32(69)15(4-59)91-55)100-52-39(76)24(61)13(2-57)89-52/h12-79H,1-11H2/t12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33+,34+,35+,36+,37+,38+,39+,40+,41+,42-,43+,44+,45?,46+,47+,48+,49+,50+,51+,52+,53-,54+,55+/m1/s1",beta-D-arabinosyl-(1->2)-alpha-D-arabinosyl-(1->5)-[beta-D-arabinosyl-(1->2)-alpha-D-arabinosyl-(1->5)-alpha-D-arabinosyl-(1->5)-alpha-D-arabinosyl-(1->5)-alpha-D-arabinosyl-(1->5)-alpha-D-arabinosyl-(1->5)-alpha-D-arabinosyl-(1->3)]-alpha-D-arabinosyl-(1->5)-D-arabinose,PubMed citation,29610143
6900,141046,"16,16-dimethylprostaglandin E2","A prostanoid that is prostaglandin E2 in which both of the hydrogens at position 16 have been replaced by methyl groups. A synthetic analogue of prostaglandin E2, it is a potent inhibitor of pancreatic function and growth of experimental tumors. It also protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers.","InChI=1S/C22H36O5/c1-4-5-14-22(2,3)20(25)13-12-17-16(18(23)15-19(17)24)10-8-6-7-9-11-21(26)27/h6,8,12-13,16-17,19-20,24-25H,4-5,7,9-11,14-15H2,1-3H3,(H,26,27)/b8-6-,13-12+/t16-,17-,19-,20-/m1/s1",dmPGE2,CAS Registry Number,39746-25-3
6901,141059,"(S)-2,5,5-trimethylthiazolidine-4-carboxylic acid",A trimethyl-substituted thiazolidine carboxylic acid derived by cleavage of and loss of C=O from the azetidine ring of penicillanic acid.,"InChI=1S/C7H13NO2S/c1-4-8-5(6(9)10)7(2,3)11-4/h4-5,8H,1-3H3,(H,9,10)/t4?,5-/m0/s1","(S)-2,5,5-Trimethyl-thiazolidine-4-carboxylic acid",Beilstein Registry Number,4462
6902,141143,3-methoxy-alpha-methyl-L-tyrosine,"An L-tyrosine derivative in which the tyrosine skeleton is substituted with a methoxy group at C-3 of the phenyl ring and with a methyl group at the alpha carbon. It can also be regarded as a 3-O-methyl,alpha-methyl derivative of L-dopa.","InChI=1S/C11H15NO4/c1-11(12,10(14)15)6-7-3-4-8(13)9(5-7)16-2/h3-5,13H,6,12H2,1-2H3,(H,14,15)/t11-/m0/s1",3-O-methyl methyldopa,PubMed citation,29438107
6903,141284,3-acetylbenzamide,"A methyl ketone that is benzamide in which one of the meta hydrogens has been replaced by an acetyl group. It is a bacterial secondary metabolite from actinomycete strain WA23-4-4 isolated from the intestinal tract of Periplaneta americana (American cockroach), it shows significant antifungal activity against Candida albicans ATCC 10231 and Aspergillus niger ATCC 16404 but is less active against Trichophyton rubrum ATCC 60836 and Aspergillus fumigatus ATCC 96918.","InChI=1S/C9H9NO2/c1-6(11)7-3-2-4-8(5-7)9(10)12/h2-5H,1H3,(H2,10,12)",3-acetylbenzoylamide,Reaxys Registry Number,4969128
6904,141319,metam,"A member of the class of dithiocarbamic acids that is dithiocarbamic acid in which a hydrogen attached to the amino group has been replaced by a methyl group. It is used (most widely as the corresponding sodium salt, metam-sodium) as an agricultural pesticide, mainly as a broad spectrum soil fumigant for the control of weeds, nematodes, soil-borne insects and fungi.","InChI=1S/C2H5NS2/c1-3-2(4)5/h1H3,(H2,3,4,5)",N-methyldithiocarbamic acid,CAS Registry Number,144-54-7
6905,141392,alpha-D-talopyranose,D-Talopyranose having alpha-configuration at the anomeric centre.,"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5+,6+/m1/s1",alpha-D-talose,MetaCyc accession,Alpha-D-Talose
6906,141393,Ser-Thr,A dipeptide obtained by formal condensation of the carboxy group of L-serine with the amino group of L-threonine.,"InChI=1S/C7H14N2O5/c1-3(11)5(7(13)14)9-6(12)4(8)2-10/h3-5,10-11H,2,8H2,1H3,(H,9,12)(H,13,14)/t3-,4+,5+/m1/s1",serinylthreonine,HMDB accession,HMDB0029049
6907,141395,Pro-Thr,A dipeptide obtained by formal condensation of the carboxy group of L-proline with the amino group of L-threonine.,"InChI=1S/C9H16N2O4/c1-5(12)7(9(14)15)11-8(13)6-3-2-4-10-6/h5-7,10,12H,2-4H2,1H3,(H,11,13)(H,14,15)/t5-,6+,7+/m1/s1",L-Pro-L-Thr,HMDB accession,HMDB0029027
6908,141398,"ethyl 2-hydroxy-5-methylpyrazolo[1,5-a]pyrimidine-6-carboxylate",A member of the class of pyrazolopyrimidines that is pyrazophos in which the the thiophosphate group has been hydrolysed to the corresponding hydroxy group. The active fungicide of the profungicide pyrazophos.,"InChI=1S/C10H11N3O3/c1-3-16-10(15)7-5-13-8(11-6(7)2)4-9(14)12-13/h4-5H,3H2,1-2H3,(H,12,14)","ethyl 5-methyl-2-oxo-1,2-dihydropyrazolo[1,5-a]pyrimidine-6-carboxylate",Reaxys Registry Number,887640
6909,141412,glycyl-4-aminobutyric Acid,An N-acyl-gamma-aminobutyric acid where the acyl group is specified as aminoacetyl.,"InChI=1S/C6H12N2O3/c7-4-5(9)8-3-1-2-6(10)11/h1-4,7H2,(H,8,9)(H,10,11)",glycyl-gamma-aminobutyric acid,CAS Registry Number,32595-49-6
6910,141416,ganglioside GM2 (20:0),A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is icosanoyl. A constituent of natural ganglioside GM2.,"InChI=1S/C69H125N3O26/c1-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-52(82)72-45(46(79)35-33-31-29-27-25-23-18-16-14-12-10-8-6-2)42-91-66-59(87)58(86)61(50(40-75)93-66)95-67-60(88)64(62(51(41-76)94-67)96-65-54(71-44(4)78)57(85)56(84)49(39-74)92-65)98-69(68(89)90)37-47(80)53(70-43(3)77)63(97-69)55(83)48(81)38-73/h33,35,45-51,53-67,73-76,79-81,83-88H,5-32,34,36-42H2,1-4H3,(H,70,77)(H,71,78)(H,72,82)(H,89,90)/b35-33+/t45-,46+,47-,48+,49+,50+,51+,53+,54+,55+,56-,57+,58+,59+,60+,61+,62-,63+,64+,65-,66+,67-,69-/m0/s1",ganglioside GM2 (18:1/20:0),PubMed citation,1691018
6911,141421,Asn-Ile,A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-isoleucine.,"InChI=1S/C10H19N3O4/c1-3-5(2)8(10(16)17)13-9(15)6(11)4-7(12)14/h5-6,8H,3-4,11H2,1-2H3,(H2,12,14)(H,13,15)(H,16,17)/t5-,6-,8-/m0/s1",asparaginylisoleucine,Reaxys Registry Number,27312733
6912,141422,Asn-Leu,A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-leucine.,"InChI=1S/C10H19N3O4/c1-5(2)3-7(10(16)17)13-9(15)6(11)4-8(12)14/h5-7H,3-4,11H2,1-2H3,(H2,12,14)(H,13,15)(H,16,17)/t6-,7-/m0/s1",asparaginylleucine,Reaxys Registry Number,1714311
6913,141427,Asp-Thr,A dipeptide obtained by formal condensation of the carboxy group of L-aspartic acid with the amino group of L-threonine.,"InChI=1S/C8H14N2O6/c1-3(11)6(8(15)16)10-7(14)4(9)2-5(12)13/h3-4,6,11H,2,9H2,1H3,(H,10,14)(H,12,13)(H,15,16)/t3-,4+,6+/m1/s1",aspartylthreonine,HMDB accession,HMDB0028763
6914,141428,Gln-Asn,A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of  L-asparagine.,"InChI=1S/C9H16N4O5/c10-4(1-2-6(11)14)8(16)13-5(9(17)18)3-7(12)15/h4-5H,1-3,10H2,(H2,11,14)(H2,12,15)(H,13,16)(H,17,18)/t4-,5-/m0/s1",glutaminylasparagine,HMDB accession,HMDB0028792
6915,141429,Gln-Leu,A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of L-leucine.,"InChI=1S/C11H21N3O4/c1-6(2)5-8(11(17)18)14-10(16)7(12)3-4-9(13)15/h6-8H,3-5,12H2,1-2H3,(H2,13,15)(H,14,16)(H,17,18)/t7-,8-/m0/s1",glutaminylleucine,HMDB accession,HMDB0028801
6916,141430,Gln-Phe,A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of L-phenylalanine.,"InChI=1S/C14H19N3O4/c15-10(6-7-12(16)18)13(19)17-11(14(20)21)8-9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H2,16,18)(H,17,19)(H,20,21)/t10-,11-/m0/s1",glutaminylphenylalanine,HMDB accession,HMDB0028804
6917,141431,Gln-Trp,A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of  L-tryptophan.,"InChI=1S/C16H20N4O4/c17-11(5-6-14(18)21)15(22)20-13(16(23)24)7-9-8-19-12-4-2-1-3-10(9)12/h1-4,8,11,13,19H,5-7,17H2,(H2,18,21)(H,20,22)(H,23,24)/t11-,13-/m0/s1",glutaminyltryptophan,HMDB accession,HMDB0028808
6918,141432,Gln-Tyr,A dipeptide obtained by formal condensation of the carboxy group of L-glutamine  with the amino group of L-tyrosine.,"InChI=1S/C14H19N3O5/c15-10(5-6-12(16)19)13(20)17-11(14(21)22)7-8-1-3-9(18)4-2-8/h1-4,10-11,18H,5-7,15H2,(H2,16,19)(H,17,20)(H,21,22)/t10-,11-/m0/s1",glutaminyltyrosine,HMDB accession,HMDB0028809
6919,141433,Gln-Val,A dipeptide obtained by formal condensation of the carboxy group of L-glutamine with the amino group of L-valine.,"InChI=1S/C10H19N3O4/c1-5(2)8(10(16)17)13-9(15)6(11)3-4-7(12)14/h5-6,8H,3-4,11H2,1-2H3,(H2,12,14)(H,13,15)(H,16,17)/t6-,8-/m0/s1",glutaminylvaline,HMDB accession,HMDB0028810
6920,141435,Glu-Gln,A dipeptide obtained by formal condensation of the carboxy group of L-glutamic acid with the amino group of L-glutamine.,"InChI=1S/C10H17N3O6/c11-5(1-4-8(15)16)9(17)13-6(10(18)19)2-3-7(12)14/h5-6H,1-4,11H2,(H2,12,14)(H,13,17)(H,15,16)(H,18,19)/t5-,6-/m0/s1",glutamylglutamine,Reaxys Registry Number,7113195
6921,141436,Glu-Ile,A dipeptide obtained by formal condensation of the carboxy group of L-glutamic acid with the amino group of L-isoleucine.,"InChI=1S/C11H20N2O5/c1-3-6(2)9(11(17)18)13-10(16)7(12)4-5-8(14)15/h6-7,9H,3-5,12H2,1-2H3,(H,13,16)(H,14,15)(H,17,18)/t6-,7-,9-/m0/s1",glutamylisoleucine,Reaxys Registry Number,7588190
6922,141437,His-Ile,A dipeptide obtained by formal condensation of the carboxy group of L-histidine with the amino group of L-isoleucine.,"InChI=1S/C12H20N4O3/c1-3-7(2)10(12(18)19)16-11(17)9(13)4-8-5-14-6-15-8/h5-7,9-10H,3-4,13H2,1-2H3,(H,14,15)(H,16,17)(H,18,19)/t7-,9-,10-/m0/s1",histidylisoleucine,HMDB accession,HMDB0028888
6923,141438,His-Phe,A dipeptide obtained by formal condensation of the carboxy group of L-histidine with the amino group of L-phenylalanine.,"InChI=1S/C15H18N4O3/c16-12(7-11-8-17-9-18-11)14(20)19-13(15(21)22)6-10-4-2-1-3-5-10/h1-5,8-9,12-13H,6-7,16H2,(H,17,18)(H,19,20)(H,21,22)/t12-,13-/m0/s1",histidylphenylalanine,HMDB accession,HMDB0028892
6924,141439,Ile-Asp,A dipeptide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of L-aspartic acid.,"InChI=1S/C10H18N2O5/c1-3-5(2)8(11)9(15)12-6(10(16)17)4-7(13)14/h5-6,8H,3-4,11H2,1-2H3,(H,12,15)(H,13,14)(H,16,17)/t5-,6-,8-/m0/s1",isoleucylaspartic acid,HMDB accession,HMDB0028903
6925,141440,Ile-Lys,A dipeptide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of L-lysine.,"InChI=1S/C12H25N3O3/c1-3-8(2)10(14)11(16)15-9(12(17)18)6-4-5-7-13/h8-10H,3-7,13-14H2,1-2H3,(H,15,16)(H,17,18)/t8-,9-,10-/m0/s1",isoleucyllysine,HMDB accession,HMDB0028912
6926,141441,Ile-Thr,A dipeptide obtained by formal condensation of the carboxy group of L-isoleucine with the amino group of L-threonine.,"InChI=1S/C10H20N2O4/c1-4-5(2)7(11)9(14)12-8(6(3)13)10(15)16/h5-8,13H,4,11H2,1-3H3,(H,12,14)(H,15,16)/t5-,6+,7-,8-/m0/s1",isoleucylthreonine,HMDB accession,HMDB0028917
6927,141442,Met-Asn,A dipeptide obtained by formal condensation of the carboxy group of L-methionine with the amino group of L-asparagine.,"InChI=1S/C9H17N3O4S/c1-17-3-2-5(10)8(14)12-6(9(15)16)4-7(11)13/h5-6H,2-4,10H2,1H3,(H2,11,13)(H,12,14)(H,15,16)/t5-,6-/m0/s1",methionylasparagine,HMDB accession,HMDB0028968
6928,141443,Phe-Lys,A dipeptide obtained by formal condensation of the carboxy group of L-phenylalanine with the amino group of L-lysine.,"InChI=1S/C15H23N3O3/c16-9-5-4-8-13(15(20)21)18-14(19)12(17)10-11-6-2-1-3-7-11/h1-3,6-7,12-13H,4-5,8-10,16-17H2,(H,18,19)(H,20,21)/t12-,13-/m0/s1",phenylalanyllysine,HMDB accession,HMDB0029000
6929,141444,Pro-Met,A dipeptide obtained by formal condensation of the carboxy group of L-proline with the amino group of L-methionine.,"InChI=1S/C10H18N2O3S/c1-16-6-4-8(10(14)15)12-9(13)7-3-2-5-11-7/h7-8,11H,2-6H2,1H3,(H,12,13)(H,14,15)/t7-,8-/m0/s1",prolylmethionine,HMDB accession,HMDB0029023
6930,141445,Ser-Trp,A dipeptide obtained by formal condensation of the carboxy group of L-serine with the amino group of L-tryptophan.,"InChI=1S/C14H17N3O4/c15-10(7-18)13(19)17-12(14(20)21)5-8-6-16-11-4-2-1-3-9(8)11/h1-4,6,10,12,16,18H,5,7,15H2,(H,17,19)(H,20,21)/t10-,12-/m0/s1",seryltryptophan,HMDB accession,HMDB0029050
6931,141446,Thr-Ile,A dipeptide obtained by formal condensation of the carboxy group of L-threonine with the amino group of L-isoleucine.,"InChI=1S/C10H20N2O4/c1-4-5(2)8(10(15)16)12-9(14)7(11)6(3)13/h5-8,13H,4,11H2,1-3H3,(H,12,14)(H,15,16)/t5-,6+,7-,8-/m0/s1",threonylisoleucine,HMDB accession,HMDB0029064
6932,141447,Trp-Asn,A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-asparagine.,"InChI=1S/C15H18N4O4/c16-10(14(21)19-12(15(22)23)6-13(17)20)5-8-7-18-11-4-2-1-3-9(8)11/h1-4,7,10,12,18H,5-6,16H2,(H2,17,20)(H,19,21)(H,22,23)/t10-,12-/m0/s1",tryptophylasparagine,HMDB accession,HMDB0029078
6933,141448,Trp-Ile,A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-isoleucine.,"InChI=1S/C17H23N3O3/c1-3-10(2)15(17(22)23)20-16(21)13(18)8-11-9-19-14-7-5-4-6-12(11)14/h4-7,9-10,13,15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,13-,15-/m0/s1",tryptophylisoleucine,HMDB accession,HMDB0029086
6934,141449,Trp-Pro,A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-proline.,"InChI=1S/C16H19N3O3/c17-12(15(20)19-7-3-6-14(19)16(21)22)8-10-9-18-13-5-2-1-4-11(10)13/h1-2,4-5,9,12,14,18H,3,6-8,17H2,(H,21,22)/t12-,14-/m0/s1",tryptophylproline,HMDB accession,HMDB0029091
6935,141450,Trp-Thr,A dipeptide obtained by formal condensation of the carboxy group of L-tryptophan with the amino group of L-threonine.,"InChI=1S/C15H19N3O4/c1-8(19)13(15(21)22)18-14(20)11(16)6-9-7-17-12-5-3-2-4-10(9)12/h2-5,7-8,11,13,17,19H,6,16H2,1H3,(H,18,20)(H,21,22)/t8-,11+,13+/m1/s1",tryptophylthreonine,HMDB accession,HMDB0029093
6936,141451,ganglioside GM2 (24:0),A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is tetracosanoyl. A synthetic modification of the natural ganglioside GM2.,"InChI=1S/C73H133N3O26/c1-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-56(86)76-49(50(83)39-37-35-33-31-29-27-18-16-14-12-10-8-6-2)46-95-70-63(91)62(90)65(54(44-79)97-70)99-71-64(92)68(66(55(45-80)98-71)100-69-58(75-48(4)82)61(89)60(88)53(43-78)96-69)102-73(72(93)94)41-51(84)57(74-47(3)81)67(101-73)59(87)52(85)42-77/h37,39,49-55,57-71,77-80,83-85,87-92H,5-36,38,40-46H2,1-4H3,(H,74,81)(H,75,82)(H,76,86)(H,93,94)/b39-37+/t49-,50+,51-,52+,53+,54+,55+,57+,58+,59+,60-,61+,62+,63+,64+,65+,66-,67+,68+,69-,70+,71-,73-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-N-tetracosanoylsphingosine,PubMed citation,1691018
6937,141452,Tyr-Asn,A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-asparagine.,"InChI=1S/C13H17N3O5/c14-9(5-7-1-3-8(17)4-2-7)12(19)16-10(13(20)21)6-11(15)18/h1-4,9-10,17H,5-6,14H2,(H2,15,18)(H,16,19)(H,20,21)/t9-,10-/m0/s1",tyrosylasparagine,HMDB accession,HMDB0029100
6938,141455,Tyr-Asp,A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-aspartic acid.,"InChI=1S/C13H16N2O6/c14-9(5-7-1-3-8(16)4-2-7)12(19)15-10(13(20)21)6-11(17)18/h1-4,9-10,16H,5-6,14H2,(H,15,19)(H,17,18)(H,20,21)/t9-,10-/m0/s1",tyrosylaspartic acid,HMDB accession,HMDB0029101
6939,141456,Tyr-Pro,A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-proline.,"InChI=1S/C14H18N2O4/c15-11(8-9-3-5-10(17)6-4-9)13(18)16-7-1-2-12(16)14(19)20/h3-6,11-12,17H,1-2,7-8,15H2,(H,19,20)/t11-,12-/m0/s1",tyrosylproline,HMDB accession,HMDB0029113
6940,141457,Tyr-Ser,A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-serine.,"InChI=1S/C12H16N2O5/c13-9(5-7-1-3-8(16)4-2-7)11(17)14-10(6-15)12(18)19/h1-4,9-10,15-16H,5-6,13H2,(H,14,17)(H,18,19)/t9-,10-/m0/s1",tyrosylserine,HMDB accession,HMDB0029114
6941,141458,Tyr-Thr,A dipeptide obtained by formal condensation of the carboxy group of L-tyrosine with the amino group of L-threonine.,"InChI=1S/C13H18N2O5/c1-7(16)11(13(19)20)15-12(18)10(14)6-8-2-4-9(17)5-3-8/h2-5,7,10-11,16-17H,6,14H2,1H3,(H,15,18)(H,19,20)/t7-,10+,11+/m1/s1",tyrosylthreonine,HMDB accession,HMDB0029115
6942,141459,ganglioside GM2 (16:0),A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is hexadecanoyl. A synthetic modification of the natural ganglioside GM2.,"InChI=1S/C65H117N3O26/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-42(75)41(68-48(78)32-30-28-26-24-22-20-18-16-14-12-10-8-6-2)38-87-62-55(83)54(82)57(46(36-71)89-62)91-63-56(84)60(58(47(37-72)90-63)92-61-50(67-40(4)74)53(81)52(80)45(35-70)88-61)94-65(64(85)86)33-43(76)49(66-39(3)73)59(93-65)51(79)44(77)34-69/h29,31,41-47,49-63,69-72,75-77,79-84H,5-28,30,32-38H2,1-4H3,(H,66,73)(H,67,74)(H,68,78)(H,85,86)/b31-29+/t41-,42+,43-,44+,45+,46+,47+,49+,50+,51+,52-,53+,54+,55+,56+,57+,58-,59+,60+,61-,62+,63-,65-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-N-hexadecanoylsphingosine,PubMed citation,1691018
6943,141460,ganglioside GM2 (8:0),A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is octanoyl. A synthetic modification of the natural ganglioside GM2.,"InChI=1S/C57H101N3O26/c1-5-7-9-11-12-13-14-15-16-17-18-20-21-23-34(67)33(60-40(70)24-22-19-10-8-6-2)30-79-54-47(75)46(74)49(38(28-63)81-54)83-55-48(76)52(50(39(29-64)82-55)84-53-42(59-32(4)66)45(73)44(72)37(27-62)80-53)86-57(56(77)78)25-35(68)41(58-31(3)65)51(85-57)43(71)36(69)26-61/h21,23,33-39,41-55,61-64,67-69,71-76H,5-20,22,24-30H2,1-4H3,(H,58,65)(H,59,66)(H,60,70)(H,77,78)/b23-21+/t33-,34+,35-,36+,37+,38+,39+,41+,42+,43+,44-,45+,46+,47+,48+,49+,50-,51+,52+,53-,54+,55-,57-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-N-octanoylsphingosine,PubMed citation,1691018
6944,141462,ganglioside GM2 (2:0),A sialotriaosylceramide that is N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine in which the acyl group on the sphingosine nitrogen is acetyl. A synthetic modification of the natural ganglioside GM2.,"InChI=1S/C51H89N3O26/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-29(62)28(52-25(2)59)24-73-48-41(69)40(68)43(33(22-57)75-48)77-49-42(70)46(44(34(23-58)76-49)78-47-36(54-27(4)61)39(67)38(66)32(21-56)74-47)80-51(50(71)72)19-30(63)35(53-26(3)60)45(79-51)37(65)31(64)20-55/h17-18,28-49,55-58,62-70H,5-16,19-24H2,1-4H3,(H,52,59)(H,53,60)(H,54,61)(H,71,72)/b18-17+/t28-,29+,30-,31+,32+,33+,34+,35+,36+,37+,38-,39+,40+,41+,42+,43+,44-,45+,46+,47-,48+,49-,51-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-N-acetylsphingosine,PubMed citation,1691018
6945,141470,ganglioside GM2 (18:0) methylamide,A sialotriaosylceramide that is ganglioside GM2 (18:0) in which the carboxy function of the sialic acid residue has been converted into an N-methylcarboxamide.,"InChI=1S/C68H124N4O25/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-51(82)72-44(45(79)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2)41-90-65-58(87)57(86)60(49(39-75)92-65)94-66-59(88)63(61(50(40-76)93-66)95-64-53(71-43(4)78)56(85)55(84)48(38-74)91-64)97-68(67(89)69-5)36-46(80)52(70-42(3)77)62(96-68)54(83)47(81)37-73/h32,34,44-50,52-66,73-76,79-81,83-88H,6-31,33,35-41H2,1-5H3,(H,69,89)(H,70,77)(H,71,78)(H,72,82)/b34-32+/t44-,45+,46-,47+,48+,49+,50+,52+,53+,54+,55-,56+,57+,58+,59+,60+,61-,62+,63+,64-,65+,66-,68-/m0/s1",beta-D-GalNAc-(1->4)-[alpha-NeuANMe5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-N-octadecanoylsphingosine,PubMed citation,1691018
6946,141485,alpha-Neu5Gc-(2->8)-alpha-Neu5Gc-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer,A sialodiosylceramide consisting of the tetrasaccharide alpha-Neu5NGc-(2->8)-alpha-Neu5NGc-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc attached to the primary hydroxy function of ceramide.,"InChI=1S/C54H93N3O31/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-28(65)27(55-26(2)64)25-81-49-43(75)42(74)45(34(22-61)83-49)84-50-44(76)48(40(72)32(20-59)82-50)88-54(52(79)80)18-30(67)38(57-36(70)24-63)47(87-54)41(73)33(21-60)85-53(51(77)78)17-29(66)37(56-35(69)23-62)46(86-53)39(71)31(68)19-58/h15-16,27-34,37-50,58-63,65-68,71-76H,3-14,17-25H2,1-2H3,(H,55,64)(H,56,69)(H,57,70)(H,77,78)(H,79,80)/b16-15+/t27-,28+,29-,30-,31+,32+,33+,34+,37+,38+,39+,40-,41+,42+,43+,44+,45+,46+,47+,48-,49+,50-,53+,54-/m0/s1",GD3(NeuGc-NeuGc),PubMed citation,1567198
6947,141491,"N-tert-butyl-N'-(2,6-diisopropyl-4-phenoxyphenyl)methanediimine","An aromatic ether that is 1,3-diisopropyl-5-phenoxybenzene in which the hydrogen atom at position 2 is substituted by a [(tert-butylimino)methylene]amino group. The active insecticide of the proinsecticide diafenthiuron.","InChI=1S/C23H30N2O/c1-16(2)20-13-19(26-18-11-9-8-10-12-18)14-21(17(3)4)22(20)24-15-25-23(5,6)7/h8-14,16-17H,1-7H3","1-tert-butyl-3-(2,6-di-isopropyl-4-phenoxyphenyl)-carbodiimide",Reaxys Registry Number,8395465
6948,141516,CholEsteryl BODIPY 542/563 C11,"A BODIPY dye in which the 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene skeleton is substituted at position 5 by a p-methoxyphenyl group and at position 3 by an 11-[(3beta)-cholest-5-en-3-yloxy]-11-oxoundecyl group. An orange-red BODIPY dye.","InChI=1S/C54H77BF2N2O3/c1-38(2)16-15-17-39(3)48-29-30-49-47-28-22-41-36-46(32-34-53(41,4)50(47)33-35-54(48,49)5)62-52(60)19-14-12-10-8-7-9-11-13-18-42-23-24-43-37-44-25-31-51(59(44)55(56,57)58(42)43)40-20-26-45(61-6)27-21-40/h20-27,31,37-39,46-50H,7-19,28-30,32-36H2,1-6H3/t39-,46+,47+,48-,49+,50+,53+,54-/m1/s1",CholEsteryl BODIPY 542/563 C11,CAS Registry Number,151911-45-4
6949,141522,spiraprilat,An azaspiro compound that is spirapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid group. It is the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor spirapril.,"InChI=1S/C20H26N2O5S2/c1-13(21-15(18(24)25)8-7-14-5-3-2-4-6-14)17(23)22-12-20(28-9-10-29-20)11-16(22)19(26)27/h2-6,13,15-16,21H,7-12H2,1H3,(H,24,25)(H,26,27)/t13-,15-,16-/m0/s1",SCH-33861,Reaxys Registry Number,4275869
6950,141552,forasartan,"A member of the class of pyridines that is pyridine which is substituted at positions 2 and 5 by o-(tetrazol-5-yl)phenyl and (3,5-dibutyl-1,2,4-triazol-1-yl)methyl groups, respectively. It is a nonpeptide antagonist of angiotensin II, type 1 (AT1) receptors, used for the treatment of hypertension.","InChI=1S/C23H28N8/c1-3-5-11-21-25-22(12-6-4-2)31(28-21)16-17-13-14-20(24-15-17)18-9-7-8-10-19(18)23-26-29-30-27-23/h7-10,13-15H,3-6,11-12,16H2,1-2H3,(H,26,27,29,30)",SC-52458,Reaxys Registry Number,9361619
6951,141577,C80 mycolic acid,"A mycolic acid produced by Mycobacterium tuberculosis. Its structure is that of hexacosanoic acid substituted at position 2 by a (1R,18Z,33Z)-1-hydroxytetrapentaconta-18,33-dien-1-yl group. (The term C80 refers to the average tail length of a reported naturally occurring range of 72-86 carbon atoms.)","InChI=1S/C80H156O3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-28-29-30-31-32-33-34-35-36-37-38-39-40-41-42-43-44-45-46-47-48-49-50-51-52-53-54-55-57-59-61-63-65-67-69-71-73-75-77-79(81)78(80(82)83)76-74-72-70-68-66-64-62-60-58-56-26-24-22-20-18-16-14-12-10-8-6-4-2/h34-35,49-50,78-79,81H,3-33,36-48,51-77H2,1-2H3,(H,82,83)/b35-34-,50-49-/t78-,79-/m1/s1",C80 MA,PubMed citation,29914888
6952,141617,hapalindole,"Any member of large group of hapalindole-type alkaloids that are bioactive metabolites of the Subsection V (formerly order Stigonematales)in the phylum Cyanobacteria which have either a tetracyclic structure based on 10-isocyano-6,6,9-trimethyl-9-vinyl-2,6,6a,7,8,9,10,10a-octahydronaphtho[1,2,3-cd]indole, or a tricyclic structure resulting from the cleavage of the bond linking the indole ring to the dimethyl-substituted carbon.","InChI=1S/2C21H24N2/c1-6-21(4)11-10-15-18(19(21)22-5)13-12-23-16-9-7-8-14(17(13)16)20(15,2)3;1-6-21(4)12-11-15(14(2)3)19(20(21)22-5)17-13-23-18-10-8-7-9-16(17)18/h6-9,12,15,18-19,23H,1,10-11H2,2-4H3;6-10,13,15,19-20,23H,1-2,11-12H2,3-4H3",hapalindoles,PubMed citation,26629885
6953,141641,"alpha-Neu5Ac-(2->3)-[beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-N-stearoylsphingosine 1(II'),2(II) lactone",A sialotetraosylceramide consisting of the disialoganglioside GM1 with a lactone ring formed between C-1 of the NeuNac residue and C-2 of the galactose residue proximal to the ceramide moiety.,"InChI=1S/C73H129N3O30/c1-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-52(87)76-44(45(84)33-31-29-27-25-23-21-18-16-14-12-10-8-6-2)41-96-69-61(94)59(92)62(50(39-80)99-69)101-71-67-66(106-73(72(95)104-67)35-46(85)53(74-42(3)82)65(105-73)55(88)47(86)36-77)63(51(40-81)100-71)102-68-54(75-43(4)83)64(57(90)49(38-79)97-68)103-70-60(93)58(91)56(89)48(37-78)98-70/h31,33,44-51,53-71,77-81,84-86,88-94H,5-30,32,34-41H2,1-4H3,(H,74,82)(H,75,83)(H,76,87)/b33-31+/t44-,45+,46-,47+,48+,49+,50+,51+,53+,54+,55+,56-,57-,58-,59+,60+,61+,62+,63-,64+,65+,66-,67+,68-,69+,70-,71-,73-/m0/s1","ganglioside GM1 1(II'),2(II) lactone",PubMed citation,2303428
6954,141699,aspirin-based probe AP,"A benzoate ester resulting from the formal condensation of the carboxy group of acetylsalicylic acid with the phenolic hydroxy group of 2-(1,3-benzothiazol-2-yl)-4-fluorophenol. The latter is a fluorophore which is to the aspirin moiety via an H2O2-responsive bond. It can be used as probe for imaging H2O2 (overproduction of H2O2 causes oxidative stress and is characteristic of vascular diseases).  In contrast to arylboronat-based probes, it shows high specificity for H2O2 over peroxynitrite (which is much more reactive than H2O2, but exists at much lower abundance).","InChI=1S/C22H14FNO4S/c1-13(25)27-18-8-4-2-6-15(18)22(26)28-19-11-10-14(23)12-16(19)21-24-17-7-3-5-9-20(17)29-21/h2-12H,1H3",probe AP,PubMed citation,29109778
6955,141766,beta-D-Glcp-(1->3)-beta-D-Glcp-(1->3)-beta-D-Glcp-(1->3)-beta-D-Glcp-(1->3)-beta-D-Glcp-(1->3)-beta-D-GlcpO[CH2]5CO2Me,A glycoside that consists of six beta-D-glucose residues  all linked sequentially (1->3) and linked at the reducing end glycosidically to a 5-(methoxycarbonyl)pentyl group.,"InChI=1S/C43H74O33/c1-64-19(50)5-3-2-4-6-65-38-28(59)33(21(52)14(8-45)66-38)73-40-30(61)35(23(54)16(10-47)68-40)75-42-32(63)37(25(56)18(12-49)70-42)76-43-31(62)36(24(55)17(11-48)71-43)74-41-29(60)34(22(53)15(9-46)69-41)72-39-27(58)26(57)20(51)13(7-44)67-39/h13-18,20-49,51-63H,2-12H2,1H3/t13-,14-,15-,16-,17-,18-,20-,21-,22-,23-,24-,25-,26+,27-,28-,29-,30-,31-,32-,33+,34+,35+,36+,37+,38-,39+,40+,41+,42+,43+/m1/s1",methyl 6-{[beta-D-glucosyl-(1->3)-beta-D-glucoyl-(1->3)-beta-D-glucosyl-(1->3)-beta-D-glucosyl-(1->3)-beta-D-glucosyl-(1->3)-beta-D-glucosyl]oxy}hexanoate,PubMed citation,30082627
6956,141772,2-hydroxydodecanoate,A 2-hydroxy fatty acid anion resulting from the deprotonation of the carboxy group of 2-hydroxydodecanoic acid. The major microspecies at pH 7.3,"InChI=1S/C12H24O3/c1-2-3-4-5-6-7-8-9-10-11(13)12(14)15/h11,13H,2-10H2,1H3,(H,14,15)/p-1",2-hydroxy-dodecanoate,PubMed citation,16662431
6957,141775,N-(p-octylbenzoyl)-piperidin-4-ol,A tertiary carboxamide resulting from the formal condensation between of the carboxy group of p-octylbenzoic acid with the amino group of 4-hydroxypiperidine.,"InChI=1S/C20H31NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)20(23)21-15-13-19(22)14-16-21/h9-12,19,22H,2-8,13-16H2,1H3",RB-046,PubMed citation,24164513
6958,142003,gibberellin A45,"A C19-gibberellin, initially identified in Pyrus communis. It differs from gibberellin A1 in the absence of OH groups at C-2 and -7 and the presence of a beta-OH at C-9 (all gibbane numbering).","InChI=1S/C19H24O5/c1-9-10-4-5-11-18(8-10,14(9)20)12(15(21)22)13-17(2)6-3-7-19(11,13)24-16(17)23/h10-14,20H,1,3-8H2,2H3,(H,21,22)/t10-,11-,12-,13-,14-,17-,18-,19-/m1/s1",GA45,Reaxys Registry Number,5127767
6959,142004,gibberellin A63,"A C19-gibberellin, initially identified in Pyrus communis.  It differs from gibberellin A1 in the absence of an OH group at C-2  and the presence of a beta-OH at C-9 (all gibbane numbering).","InChI=1S/C19H24O6/c1-8-9-3-4-10-18(7-9,14(8)21)12(15(22)23)13-17(2)11(20)5-6-19(10,13)25-16(17)24/h9-14,20-21H,1,3-7H2,2H3,(H,22,23)/t9-,10-,11+,12-,13-,14-,17-,18-,19-/m1/s1",GA63,PubMed citation,24232845
6960,142024,15beta-OH gibberellin A3,A C19-gibberellin differing from gibberellin A3 in the presence of a beta-OH at C-9 (gibbane numbering) (C-15 gibberellin numbering).,"InChI=1S/C19H22O7/c1-8-13(21)18-7-17(8,25)5-3-9(18)19-6-4-10(20)16(2,15(24)26-19)12(19)11(18)14(22)23/h4,6,9-13,20-21,25H,1,3,5,7H2,2H3,(H,22,23)/t9-,10+,11-,12-,13-,16-,17+,18-,19-/m1/s1",GA3 15beta-OH,Reaxys Registry Number,5159772
6961,142025,gibberellin A10,"A C19-gibberellin, initially identified in Gibberella fujikuroi. It differs from gibberellin A1 in the absence of the beta-OH at C-9 and the alpha-OH at C-7, the substitution of the methylene group at C-8 by a beta-Me and the presence of an alpha-OH also at C-8 (all gibbane skeletal numberings).","InChI=1S/C19H26O5/c1-16-6-3-7-19(24-15(16)22)11-5-4-10-8-18(11,9-17(10,2)23)12(13(16)19)14(20)21/h10-13,23H,3-9H2,1-2H3,(H,20,21)/t10-,11-,12-,13-,16-,17-,18-,19-/m1/s1",GA10,PubMed citation,24232845
6962,142026,gibberellin A18,"A C20-gibberellin, initially identified in Lupinus luteus, that is gibberellin A12 in which extra hydroxy substituents are present at the 2beta- and 7alpha-positions.","InChI=1S/C20H28O6/c1-10-8-19-9-20(10,26)7-4-11(19)17(2)6-5-12(21)18(3,16(24)25)14(17)13(19)15(22)23/h11-14,21,26H,1,4-9H2,2-3H3,(H,22,23)(H,24,25)/t11-,12-,13+,14-,17-,18+,19-,20-/m0/s1",GA18,PubMed citation,24232845
6963,142043,alpha-nootkatol,"A 4,4a-dimethyl-6-(prop-1-en-2-yl)-2,3,4,4a,5,6,7,8-octahydronaphthalen-2-ol with (2R,4R,4aS,6R) stereochemistry.","InChI=1S/C15H24O/c1-10(2)12-5-6-13-8-14(16)7-11(3)15(13,4)9-12/h8,11-12,14,16H,1,5-7,9H2,2-4H3/t11-,12-,14-,15+/m1/s1",2-epinootkatol,Reaxys Registry Number,2212838
6964,142122,3beta-fluoro-gibberellin A9,A halo-gibberellin that is gibberellin A9 carrying a fluoro substituent at position 3beta (2beta using gibbane skeletal numbering).,"InChI=1S/C19H23FO4/c1-9-7-18-8-10(9)3-4-11(18)19-6-5-12(20)17(2,16(23)24-19)14(19)13(18)15(21)22/h10-14H,1,3-8H2,2H3,(H,21,22)/t10-,11-,12+,13-,14-,17-,18+,19-/m1/s1",3beta-fluorogibberellin A9,PubMed citation,24232845
6965,142124,3-epi-gibberellin A1,An epi-gibberellin that is gibberellin A1 differing in configuration at C-3 (C-2 using gibbane skeletal numbering).,"InChI=1S/C19H24O6/c1-9-7-17-8-18(9,24)5-3-10(17)19-6-4-11(20)16(2,15(23)25-19)13(19)12(17)14(21)22/h10-13,20,24H,1,3-8H2,2H3,(H,21,22)/t10-,11-,12-,13-,16-,17+,18+,19-/m1/s1",3-epiGA1,HMDB accession,HMDB0040944
6966,142132,"8-(2-carboxyethyl)-2,7-dimethyl-3-vinyl-9-[2-(4-sulfophenyl)diazenyl]dipyrrin-1(10H)-one",A synthetic dipyrrin derived from rings A and D of bilirubin IXalpha in which C-9 carries a 2-(4-sulfophenyl)diazenyl substituent.,"InChI=1S/C22H22N4O6S/c1-4-16-13(3)22(29)24-19(16)11-18-12(2)17(9-10-20(27)28)21(23-18)26-25-14-5-7-15(8-6-14)33(30,31)32/h4-8,11,23H,1,9-10H2,2-3H3,(H,24,29)(H,27,28)(H,30,31,32)/b19-11-,26-25?",sulfanilic acid azopigment,PubMed citation,8605219
6967,142135,equisetin,A member of the class of tetramic acids that is trichosetin in which the hydrogen attached to the lactam nitrogen has been replaced by a methyl group. It is produced by the filamentous fungus Fusarium heterosporum.,"InChI=1S/C22H31NO4/c1-5-6-15-9-8-14-11-13(2)7-10-16(14)22(15,3)20(26)18-19(25)17(12-24)23(4)21(18)27/h5-6,8-9,13-17,24,26H,7,10-12H2,1-4H3/b6-5+,20-18-/t13-,14-,15-,16-,17+,22-/m1/s1",N-methyltrichosetin,CAS Registry Number,57749-43-6
6968,142183,(2S)-1-(6-chloro-5-fluoroindol-1-yl)-propan-2-amine,"A 1-(6-chloro-5-fluoroindol-1-yl)-propan-2-amine that has S configuration. A selective agonist for both the 5-hydroxytryptamine 2B (5-HT2B) and 5-hydroxytryptamine 2C (5-HT2C)serotonin receptor subtypes, commonly used as fumarate salt.","InChI=1S/C11H12ClFN2/c1-7(14)6-15-3-2-8-4-10(13)9(12)5-11(8)15/h2-5,7H,6,14H2,1H3/t7-/m0/s1",Ro60-0175,Wikipedia accession,Ro60-0175
6969,142280,3-methyl-4-nitrocatechol,A nitrotoluene that is 2-nitrotoluene carrying two hydroxy substituents at positions 5 and 6.,"InChI=1S/C7H7NO4/c1-4-5(8(11)12)2-3-6(9)7(4)10/h2-3,9-10H,1H3","3-methyl-4-nitro-1,2-benzenediol",Reaxys Registry Number,29694137
6970,142393,4-O-beta-D-glucosyl-trans-caffeic acid,A hydroxycinnamic acid that is trans-caffeic acid in which the phenolic hydroxy group at position 4 has been converted into its beta-D-glucoside.,"InChI=1S/C15H18O9/c16-6-10-12(20)13(21)14(22)15(24-10)23-9-3-1-7(5-8(9)17)2-4-11(18)19/h1-5,10,12-17,20-22H,6H2,(H,18,19)/b4-2+/t10-,12-,13+,14-,15-/m1/s1",trans-caffeic acid 4-O-beta-D-glucoside,PubMed citation,11042211
6971,142400,saxitoxin acetate,An acetate salt that is the diacetate of the toxic alkaloid saxitoxin.,"InChI=1S/C10H17N7O4.2C2H4O2/c11-6-15-5-4(3-21-8(13)18)14-7(12)17-2-1-9(19,20)10(5,17)16-6;2*1-2(3)4/h4-5,19-20H,1-3H2,(H2,12,14)(H2,13,18)(H3,11,15,16);2*1H3,(H,3,4)/t4-,5-,10-;;/m0../s1",saxitoxin diacetate,Reaxys Registry Number,31315074
6972,142430,lificiguat,A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.,"InChI=1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2",YC-1,CAS Registry Number,170632-47-0
6973,142431,praliciguat,"A member of the class of pyrazoles that is 5-fluoro-2-(1H-pyrazol-3-yl)pyrimidine which is substituted by a 2-fluorobenzyl group at position 1, 1,2-oxazol-3-yl group at position 5, and by a [3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl]nitrilo group at position 4. It is a soluble guanylate cyclase stimulator under clinical development for the treatment of heart failure with preserved ejection fraction.","InChI=1S/C21H14F8N6O2/c22-12-4-2-1-3-11(12)9-35-16(14-5-6-37-34-14)7-15(33-35)18-30-8-13(23)17(32-18)31-10-19(36,20(24,25)26)21(27,28)29/h1-8,36H,9-10H2,(H,30,31,32)",IW-1973,CAS Registry Number,1628730-49-3
6974,142451,bisphenol F diglycidyl ether,An aromatic ether that is bisphenol F where the hydrogens of both hydroxy groups have been replaced by a oxiran-2-ylmethyl group.,"InChI=1S/C19H20O4/c1-5-16(20-10-18-12-22-18)6-2-14(1)9-15-3-7-17(8-4-15)21-11-19-13-23-19/h1-8,18-19H,9-13H2",BFDGE,PubMed citation,25922885
6975,142452,dabuzalgron,"A sulfonamide that is N-phenylmethanesulfonamide which carries a chloro group at position 2, 4,5-dihydro-1H-imidazol-2-ylmethoxy group at position 5, and a methyl group at position 6. Its is a selective alpha-adrenoceptor agonist that is used in the treatment of urinary incontinence.","InChI=1S/C12H16ClN3O3S/c1-8-10(19-7-11-14-5-6-15-11)4-3-9(13)12(8)16-20(2,17)18/h3-4,16H,5-7H2,1-2H3,(H,14,15)",Ro 115-1240,CAS Registry Number,219311-44-1
6976,142460,alpha-D-Glcp-(1->2)-D-Glcp,A glycosylglucose in which an alpha-D-glucopyranose residue is linked to a D-glucopyranose residue by a (1->2) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9-,10-,11?,12-/m1/s1",alpha-D-glucopyranosyl-(1->2)-D-glucopyranose,PubMed citation,29684280
6977,142469,"(R)-1,2-dichloropropane","A 1,2-dichloropropane that has R configuration.","InChI=1S/C3H6Cl2/c1-3(5)2-4/h3H,2H2,1H3/t3-/m1/s1","(R)-1,2-DCP",PubMed citation,28527381
6978,142471,"(S)-1,2-dichloropropane","A 1,2-dichloropropane that has S configuration.","InChI=1S/C3H6Cl2/c1-3(5)2-4/h3H,2H2,1H3/t3-/m0/s1","(2S)-1,2-DCP",PubMed citation,28527381
6979,142517,tschimganine,A benzoate ester resulting from the formal condensation of the carboxy group of vanillic acid  with the hydroxy group of (-)-borneol. A metabolite isolated from Ferula dissecta.,"InChI=1S/C18H24O4/c1-17(2)12-7-8-18(17,3)15(10-12)22-16(20)11-5-6-13(19)14(9-11)21-4/h5-6,9,12,15,19H,7-8,10H2,1-4H3/t12-,15+,18+/m0/s1",tschimganin,PubMed citation,21589808
6980,142547,coelimycin P1,"An organosulfur heterocyclic compound that is 1,5-oxathiocane which has been substituted at the 2-pro-R, 3, 6, and 8 positions by oxo, acetamido,  5,6-dihydropyridin-2(1H)-ylidene, and  (2E)-but-2-enoyl groups, respectively, and which has been dehydrogenated to introduce a double bond at the 7-8 position. It was isolated from Streptomyces coelicolor M145 after genetically engineered increase of the metabolic flux and is the product of a polyketide biosynthetic gene cluster.","InChI=1S/C17H20N2O4S/c1-3-6-14(21)15-9-16(12-7-4-5-8-18-12)24-10-13(17(22)23-15)19-11(2)20/h3-4,6-7,9,13,18H,5,8,10H2,1-2H3,(H,19,20)/b6-3+,15-9-,16-12+/t13-/m0/s1","N-[(3R)-8-[(2E)-but-2-enoyl]-2-oxo-6-[(2E)-1,2,5,6-tetrahydropyridin-2-ylidene]-2,3,4,6-tetrahydro-1,5-oxathiocin-3-yl]acetamide",PubMed citation,17009021
6981,142633,alpha-KDN-(2->3)-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)-{[8)-alpha-KDN-(2->]n->6}-D-GalpNAc (n = 1--9),"A branched oligosacharide consisting of a tetrasaccharide chain of  deamino-alpha-neuraminyl (KDN), beta-D-galactosyl, N-acetyl-alpha-D-galactosaminyl and N-acetyl-D-galactosamine residues linked sequentially (2->3), (1->3) and (1->3), to the reducing-end N-acetyl-D-galactosamine residue of which is also linked (2->6) a single KDN or a (2->8)-linked chain of KDN residues, the number of KDN residues in the chain ranging between 1 and 9, with an average of 3. The diagram shows the structure with 3 KDN residues in the side-chain.","InChI=1S/C58H94N2O48/c1-14(67)59-27-41(100-49-28(60-15(2)68)42(35(81)22(9-63)98-49)101-50-40(86)47(36(82)23(10-64)99-50)108-58(54(94)95)6-19(72)30(76)44(106-58)34(80)21(74)8-62)39(85)26(97-48(27)87)13-96-55(51(88)89)3-16(69)31(77)45(104-55)37(83)24(11-65)103-57(53(92)93)5-18(71)32(78)46(107-57)38(84)25(12-66)102-56(52(90)91)4-17(70)29(75)43(105-56)33(79)20(73)7-61/h16-50,61-66,69-87H,3-13H2,1-2H3,(H,59,67)(H,60,68)(H,88,89)(H,90,91)(H,92,93)(H,94,95)/t16-,17-,18-,19-,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35-,36-,37+,38+,39-,40+,41+,42+,43+,44+,45+,46+,47-,48?,49+,50-,55+,56+,57+,58-/m0/s1",alpha-KDN-(2->3)-beta-D-Gal-(1->3)-alpha-D-GalNAc-(1->3)-{[8)-alpha-KDN-(2->]n->6}-alpha-D-Gal (n = 1--9),PubMed citation,8448384
6982,142649,platinum-iridium alloy,Any alloy composed of platinum and iridium.,InChI=1S/Ir.Pt,platinum-iridium alloys,Wikipedia accession,Platinum-iridium_alloy
6983,142696,N-(9Z-octadecenoyl)-(2S)-hydroxyglycinate,"An N-acyl-(2S)-hydroxyglycinate that is the conjugate base of N-(9Z-octadecenoyl)-(2S)-hydroxyglycine, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C20H37NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(22)21-19(23)20(24)25/h9-10,19,23H,2-8,11-17H2,1H3,(H,21,22)(H,24,25)/p-1/b10-9-/t19-/m0/s1",N-(9Z-octadecenoyl)-(2S)-hydroxyglycine,PubMed citation,10079066
6984,142700,"phosphatidylcholine (22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))","A phosphatidylcholine (22:4/20:4) which carries a (6Z,9Z,12Z,15Z)-22-oxodocosa-6,9,12,15-tetraen-22-yl group at position 1 and a (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl group at position 2.","InChI=1S/C50H84NO8P/c1-6-8-10-12-14-16-18-20-22-24-25-27-28-30-32-34-36-38-40-42-49(52)56-46-48(47-58-60(54,55)57-45-44-51(3,4)5)59-50(53)43-41-39-37-35-33-31-29-26-23-21-19-17-15-13-11-9-7-2/h14-17,20-23,25,27,29-32,35,37,48H,6-13,18-19,24,26,28,33-34,36,38-47H2,1-5H3/b16-14-,17-15-,22-20-,23-21-,27-25-,31-29-,32-30-,37-35-/t48-/m1/s1","PC(22:4(7Z,10Z,13Z,16Z)/20:4(5Z,8Z,11Z,14Z))",LIPID MAPS instance accession,LMGP01012089
6985,142701,"PC(20:0/18:2(9Z,12Z))","A phosphatidylcholine 38:2 which carries an icosanoyl group at position 1 and a (6Z,9Z)-18-oxooctadeca-6,9-dien-18-yl group at position 2.","InChI=1S/C46H88NO8P/c1-6-8-10-12-14-16-18-20-22-23-25-26-28-30-32-34-36-38-45(48)52-42-44(43-54-56(50,51)53-41-40-47(3,4)5)55-46(49)39-37-35-33-31-29-27-24-21-19-17-15-13-11-9-7-2/h15,17,21,24,44H,6-14,16,18-20,22-23,25-43H2,1-5H3/b17-15-,24-21-/t44-/m1/s1","PC(20:0/18:2(9Z,12Z))",LIPID MAPS instance accession,LMGP01011296
6986,142737,N-(9Z-octadecenoyl)-(2S)-hydroxyglycine,An N-acyl-(2S)-hydroxyglycine resulting from the formal condensation of (9Z-octadecenoic acid (oleic acid) with the amino group of (2S)-hydroxyglycine.,"InChI=1S/C20H37NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(22)21-19(23)20(24)25/h9-10,19,23H,2-8,11-17H2,1H3,(H,21,22)(H,24,25)/b10-9-/t19-/m0/s1",N-(9Z-octadecenoyl)-(2S)-hydroxyglycine,PubMed citation,10079066
6987,142744,N-decanoyl-(2S)-hydroxyglycine,An N-acyl-(2S)-hydroxyglycine resulting from the formal condensation of decanoic acid (capric acid) with the amino group of (2S)-hydroxyglycine.,"InChI=1S/C12H23NO4/c1-2-3-4-5-6-7-8-9-10(14)13-11(15)12(16)17/h11,15H,2-9H2,1H3,(H,13,14)(H,16,17)/t11-/m0/s1",(2S)-(caprinylamino)(hydroxy)acetic acid,PubMed citation,21043511
6988,142755,D-galactose 4-sulfate,A monosaccharide sulfate that is D-galactose carrying a single sulfo substituent at position 4.,"InChI=1S/C6H12O9S/c7-1-2-5(15-16(11,12)13)3(8)4(9)6(10)14-2/h2-10H,1H2,(H,11,12,13)/t2-,3-,4-,5+,6?/m1/s1",Gal-4-sulfate,PubMed citation,17855742
6989,142766,6-hydroxymethyladenine,A 6-alkylaminopurine that is adenine where one of the hydrogens of the amino group is replaced by a hydroxymethyl group.,"InChI=1S/C6H7N5O/c12-3-11-6-4-5(8-1-7-4)9-2-10-6/h1-2,12H,3H2,(H2,7,8,9,10,11)",N(6)-hydroxymethyladenine,PubMed citation,30517733
6990,142784,pyrifluquinazon,"A member of the class of quinazolines that is 3,4-dihydroquinazolin-2-one which is substituted at positions 1, 4, and 6 by acetyl, pyridin-3-ylmethyl, and perfluoroisopropyl groups, respectively. An insecticide used to control sucking and chewing pests by disturbing their coordination and ability to feed.","InChI=1S/C19H15F7N4O2/c1-11(31)30-15-5-4-14(17(20,18(21,22)23)19(24,25)26)7-13(15)10-29(16(30)32)28-9-12-3-2-6-27-8-12/h2-8,28H,9-10H2,1H3",pyrifluquinazone,Pesticides accession,pyrifluquinazon
6991,142786,2'-hydroxytriclocarban,"A phenylurea that is urea substituted by 4-chloro-2-hydroxyphenyl and 3,4-dichlorophenyl groups at positions 1 and 3 respectively. A metabolite of triclocarban.","InChI=1S/C13H9Cl3N2O2/c14-7-1-4-11(12(19)5-7)18-13(20)17-8-2-3-9(15)10(16)6-8/h1-6,19H,(H2,17,18,20)","N-(4-chloro-2-hydroxyphenyl)-N'-(3,4-dichlorophenyl)urea",CAS Registry Number,63348-26-5
6992,142787,2'-sulfooxytriclocarban,"A phenylurea that is urea substituted by 4-chloro-2-sulfooxyphenyl and 3,4-dichlorophenyl groups at positions 1 and 3 respectively. A metabolite of triclocarban.","InChI=1S/C13H9Cl3N2O5S/c14-7-1-4-11(12(5-7)23-24(20,21)22)18-13(19)17-8-2-3-9(15)10(16)6-8/h1-6H,(H2,17,18,19)(H,20,21,22)",sulfate of 2'-OH TCC,CAS Registry Number,62950-30-5
6993,142793,N-[1-(methanesulfonyl)piperidin-4-yl]-N'-[4-(trifluoromethoxy)phenyl]urea,A phenylurea that is urea substituted by 1-(methylsulfonyl)piperidin-4-yl and 4-(trifluoromethoxy)phenyl groups at positions 1 and 3 respectively.,"InChI=1S/C14H18F3N3O4S/c1-25(22,23)20-8-6-11(7-9-20)19-13(21)18-10-2-4-12(5-3-10)24-14(15,16)17/h2-5,11H,6-9H2,1H3,(H2,18,19,21)",N-(1-mesylpiperidin-4-yl)-N'-[4-(trifluoromethoxy)phenyl]urea,PubMed citation,30033524
6994,142808,tyramine phosphate,An aryl phosphate that is tyramine in which the phenolic hydrogen at position 4 has been replaced by a phospho group.,"InChI=1S/C8H12NO4P/c9-6-5-7-1-3-8(4-2-7)13-14(10,11)12/h1-4H,5-6,9H2,(H2,10,11,12)",phosphotyramine,PubMed citation,30398859
6995,142825,methfuroxam,"A secondary carboxamide resulting from the formal condensation of the carboxylic acid group of 2,4,5-trimethyl-3-furoic acid with the amino group of aniline. An obsolete fungicide formerly used to control Basidiomycetes pathogens on cereal crops.","InChI=1S/C14H15NO2/c1-9-10(2)17-11(3)13(9)14(16)15-12-7-5-4-6-8-12/h4-8H,1-3H3,(H,15,16)",methfuroxame,Pesticides accession,methfuroxam
6996,142835,(R)-DRF053 hydrochloride hydrate,"A hydrochloride and hydrate of DRF053, an analogue (and more potent version) of roscovitine - it is 2 fold more potent against cyclin dependent kinase 5 (CDK5) and >150 times more potent against CDK1. Formula C23H27N7O.xHCl.yH2O.","InChI=1S/C23H27N7O.ClH.H2O/c1-4-17(13-31)27-23-28-21(20-22(29-23)30(14-25-20)15(2)3)26-18-9-7-8-16(12-18)19-10-5-6-11-24-19;;/h5-12,14-15,17,31H,4,13H2,1-3H3,(H2,26,27,28,29);1H;1H2/t17-;;/m1../s1",2-[[9-(1-methylethyl)-6-[[3-(2-pyridinyl)phenyl]amino]- 9H-purin-2-yl]amino]-1-butanol hydrochloride hydrate,Pubchem accession,329798839
6997,142942,(16S)-deshydroxymethyl-stemmadenine,"An organic heterotetracyclic compound that is 1,4,5,6,7,8-hexahydro-2H-3,6-ethanoazonino[5,4-b]indole in which position 5 is substituted by an ethylidene group and position 7S is substituted by a methoxycarbonyl group.","InChI=1S/C20H24N2O2/c1-3-13-12-22-10-8-14(13)18(20(23)24-2)19-16(9-11-22)15-6-4-5-7-17(15)21-19/h3-7,14,18,21H,8-12H2,1-2H3/b13-3-/t14-,18-/m0/s1",(16S)-deshydroxymethylstemmadenine,PubMed citation,29511102
6998,142961,3-hydroxybutanenitrile,A hydroxynitrile that is butyronitirle in which a hydrogen at position 3 has been replaced by a hydroxy group.,"InChI=1S/C4H7NO/c1-4(6)2-3-5/h4,6H,2H2,1H3",beta-hydroxybutanenitrile,CAS Registry Number,4368-06-3
6999,143030,3-(phenethylamino)-butan-2-one,"A methyl ketone that is 2-phenylethan-1-amine in which one of the hydrogen's of the amino group is substituted by a 3-oxobutan-2-yl group. It is a volatile organic compound produced by the skin bacterium, S.schleiferi.","InChI=1S/C12H17NO/c1-10(11(2)14)13-9-8-12-6-4-3-5-7-12/h3-7,10,13H,8-9H2,1-2H3",schleiferon A,PubMed citation,30442919
7000,143126,(2E)-2-benzylidene-3-(cyclohexylamino)indan-1-one,A 2-benzylidene-3-(cyclohexylamino)indan-1-one in which the double bond has E configuration. An inhibitor of the dual specificity phosphatase 6 (Dusp6).,"InChI=1S/C22H23NO/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2/b20-15+",BCI,PubMed citation,19578332
7001,143131,ferric yersiniabactin,An iron coordination entity consisting of iron(III) coordinated as a 1:1 complex by three nitrogen electron pairs and three negatively charged oxygen atoms of yersiniabactin with a distorted octahedral coordination.,"InChI=1S/C21H25N3O4S3.Fe/c1-20(2,18-24-21(3,10-31-18)19(27)28)15(26)12-8-30-17(22-12)13-9-29-16(23-13)11-6-4-5-7-14(11)25;/h4-7,12-13,15,17,25H,8-10H2,1-3H3,(H,27,28);/q-2;+4/p-2/t12-,13+,15+,17?,21+;/m0./s1",ferric Ybt,PubMed citation,16806483
7002,143169,azumolene sodium,The anhydrous sodium salt of azumolene.,"InChI=1S/C13H9BrN4O3.Na/c14-9-3-1-8(2-4-9)10-5-15-12(21-10)6-16-18-7-11(19)17-13(18)20;/h1-6H,7H2,(H,17,19,20);/q;+1/p-1","1-[[[5-(4-bromophenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinedione sodium salt",Patent accession,US4861790
7003,143170,aldrithiol,A member of the class of pyridines that is pyridine which is substituted by a pyridin-2-yldisulfanediyl group at position 2. It is a reagent used in molecular biology as an oxidizing agent. Also used in peptide synthesis and for detecting thiols.,InChI=1S/C10H8N2S2/c1-3-7-11-9(5-1)13-14-10-6-2-4-8-12-10/h1-8H,"2,2'-dithiodipyridine",CAS Registry Number,2127-03-9
7004,143205,"2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)propanoic acid","A perfluorinated compound that is 2-propoxypentanoic acid in which all 11 of the hydrogens attached to carbon atoms have been replaced by fluorine atoms. Used as an alternative to perfluorooctanoic acid in the fluoropolymer industry for years, its widespread environmental distribution, high bioaccumulation capability, and human exposure have caused great concern, particularly as its potential toxicity and health risk is still largely unknown.","InChI=1S/C6HF11O3/c7-2(1(18)19,4(10,11)12)20-6(16,17)3(8,9)5(13,14)15/h(H,18,19)",FRD-908,Wikipedia accession,FRD-903
7005,143514,N-arachidonoyl-L-serine,An N-acyl-amino acid resulting from the formal condensation of the carboxy group of arachidonic acid with the amino group of L-serine. It is an endocannabinoid-like lipid isolated from bovine brains.,"InChI=1S/C23H37NO4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(26)24-21(20-25)23(27)28/h6-7,9-10,12-13,15-16,21,25H,2-5,8,11,14,17-20H2,1H3,(H,24,26)(H,27,28)/b7-6-,10-9-,13-12-,16-15-/t21-/m0/s1",ARA-S,LIPID MAPS instance accession,LMFA08020073
7006,143564,(S)-lisofylline,"A 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (S)-configuration. It is the inactive optical enantiomer of (R)-lisofylline, an anti-inflammatory agent.","InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m0/s1",(+)-lisofylline,CAS Registry Number,100324-80-9
7007,143718,"PE(19:0/18:3(9Z,12Z,15Z))","A phosphatidylethanolamine 37:3 in which the acyl groups at positions 1 and 2 are specified as nonadecanoyl and (9Z,12Z,15Z)-octadecatrienoyl, respectively.","InChI=1S/C42H78NO8P/c1-3-5-7-9-11-13-15-17-19-21-22-24-26-28-30-32-34-41(44)48-38-40(39-50-52(46,47)49-37-36-43)51-42(45)35-33-31-29-27-25-23-20-18-16-14-12-10-8-6-4-2/h6,8,12,14,18,20,40H,3-5,7,9-11,13,15-17,19,21-39,43H2,1-2H3,(H,46,47)/b8-6-,14-12-,20-18-/t40-/m1/s1","1-nonadecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphoethanolamine",LIPID MAPS instance accession,LMGP02010778
7008,143794,"3,5,6-trichloro-2-pyridinol","A hydroxypyridine that is pyridin-2-ol substituted by chloro groups at positions 3,5 and 6. It is a metabolite of the agrochemical chlorpyrifos.","InChI=1S/C5H2Cl3NO/c6-2-1-3(7)5(10)9-4(2)8/h1H,(H,9,10)",TCPy,PDBeChem accession,F4Z
7009,143861,Se-methyl-L-selenomethionine(1+),An alpha-amino-acid cation resulting from the transfer of a proton from the carboxy to the amino group of Se-methyl-L-selenomethionine. Major species at pH 7.3,"InChI=1S/C6H13NO2Se/c1-10(2)4-3-5(7)6(8)9/h5H,3-4,7H2,1-2H3/p+1/t5-/m0/s1",Se-methyl-Se-L-methionine(1+),PubMed citation,12376649
7010,143873,2-{[2-(2-chlorophenyl)-2-hydroxyethyl]amino}-N-[(2-fluorophenyl)methyl]acetamide,A secondary carboxamide that is 2-amino-1-(2-chlorophenyl)ethanol in which one of the amino hydrogens is substituted by a 2-[(2-fluorobenzyl)amino]-2-oxoethyl group.,"InChI=1S/C17H18ClFN2O2/c18-14-7-3-2-6-13(14)16(22)10-20-11-17(23)21-9-12-5-1-4-8-15(12)19/h1-8,16,20,22H,9-11H2,(H,21,23)",ERD04,PubMed citation,30141626
7011,143874,"(4-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl)[3-(3-hydroxy-3-methylbutyl)phenyl]methanone","An isoquinolol that is 1,2,3,4-tetrahydroisoquinolin-4-ol in which the hydrogen of the secondary amine  is substituted by a 3-(3-hydroxy-3-methylbutyl)benzoyl group.","InChI=1S/C21H25NO3/c1-21(2,25)11-10-15-6-5-8-16(12-15)20(24)22-13-17-7-3-4-9-18(17)19(23)14-22/h3-9,12,19,23,25H,10-11,13-14H2,1-2H3","(4-hydroxy-3,4-dihydro-1H-isoquinolin-2-yl)-[3-(3-hydroxy-3-methylbutyl)phenyl]methanone",PubMed citation,30141626
7012,143904,"3-(4-methyl-1,2,3-thiadiazolyl)-6-trichloromethyl[1,2,4]triazolo[3,4-b][1,3,4]thiadizole","A triazolothiadiazole that is 1,7a-dihydro[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole substituted by a 4-methyl-1,2,3-thiadiazol-5-yl group at position 3 and by a trichloromethyl group at position 6. It is a fungicide with a wide spectrum of activity and inhibits the enzymatic activity of pyruvate kinase.","InChI=1S/C7H5Cl3N6S2/c1-2-3(18-15-11-2)4-12-13-6-16(4)14-5(17-6)7(8,9)10/h6,13H,1H3",YZK-C22,PubMed citation,20014761
7013,143911,(-)-antofine,"An organic heteropentacyclic compound that is (13aR)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline substituted at positions 2, 3 and 6 by methoxy groups. It is an alkaloid produced by relatives of the milkweed family and exhibits antiviral, anti-inflammatory, antiadipogenic and antitumorigenic activities.","InChI=1S/C23H25NO3/c1-25-15-6-7-16-18(10-15)20-12-23(27-3)22(26-2)11-19(20)17-9-14-5-4-8-24(14)13-21(16)17/h6-7,10-12,14H,4-5,8-9,13H2,1-3H3/t14-/m1/s1","(13aR)-2,3,6-trimethoxy-9,11,12,13,13a,14-hexahydrophenanthro[9,10-f]indolizine",PubMed citation,12868894
7014,143968,Ala-Gly-Ala-Gly,"A tetrapeptide composed of L-alanine, glycine, L-alanine, and glycine residues joined in sequence by peptide linkages.","InChI=1S/C10H18N4O5/c1-5(11)9(18)12-3-7(15)14-6(2)10(19)13-4-8(16)17/h5-6H,3-4,11H2,1-2H3,(H,12,18)(H,13,19)(H,14,15)(H,16,17)/t5-,6-/m0/s1",AGAG,CAS Registry Number,69287-89-4
7015,144030,2-hydroxy-L-proline,A hydroxyproline that is L-proline substituted by a hydroxy group at position 2.,"InChI=1S/C5H9NO3/c7-4(8)5(9)2-1-3-6-5/h6,9H,1-3H2,(H,7,8)/t5-/m1/s1",(2R)-2-hydroxypyrrolidine-2-carboxylic acid,PDBeChem accession,PXU
7016,144066,12-oxododecanoic acid,An omega-oxo fatty acid that is dodecanoic acid carrying an oxo group at position 12.,"InChI=1S/C12H22O3/c13-11-9-7-5-3-1-2-4-6-8-10-12(14)15/h11H,1-10H2,(H,14,15)",12-oxolauric acid,PubMed citation,9600267
7017,144069,lobarin,"A member of the class of 2-benzofurans that is 3-butyl-3-hydroxy-2-benzofuran-1(3H)-one substituted by a 3-carboxy-4,6-dihydroxy-2-pentylphenoxy group and a methoxy group at positions 4 and 6, respectively. It is a metabolite isolated from the Sumatran lichen, Stereocaulon halei.","InChI=1S/C25H30O9/c1-4-6-8-9-15-20(23(28)29)17(26)13-18(27)22(15)33-19-12-14(32-3)11-16-21(19)24(30)34-25(16,31)10-7-5-2/h11-13,26-27,31H,4-10H2,1-3H3,(H,28,29)",lobariol carboxylic acid,PubMed citation,23041521
7018,144075,arthothelin,"A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3 and 6, chloro groups at positions 2, 4 and 5 and a methyl group at position 8. It has been isolated from the lichen, Lecanora iseana.","InChI=1S/C14H7Cl3O5/c1-3-2-4(18)7(15)13-5(3)10(19)6-11(20)8(16)12(21)9(17)14(6)22-13/h2,18,20-21H,1H3","2,4,5-trichloronorlichexanthone",CAS Registry Number,20716-96-5
7019,144076,"2,4-dichlorolichexanthone","A member of the class of xanthones that is 9H-xanthen-9-one substituted by a hydroxy group at positions 1, chloro groups at positions 2 and 4, methoxy groups at positions 3 and 6 and a methyl group at position 8.","InChI=1S/C16H12Cl2O5/c1-6-4-7(21-2)5-8-9(6)13(19)10-14(20)11(17)16(22-3)12(18)15(10)23-8/h4-5,20H,1-3H3","2,4-dichloro-3,6-di-O-methylnorlichexanthone",CAS Registry Number,22105-97-1
7020,144310,2-methyloctadecanoic acid,A methyl-branched fatty acid that is octadecanoic (stearic) acid bearing a methyl substituent at position 2.,"InChI=1S/C19H38O2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(2)19(20)21/h18H,3-17H2,1-2H3,(H,20,21)",2-methylstearic acid,LIPID MAPS instance accession,LMFA01020095
7021,144314,alpha-C(F)-GalCer,"A neoglycosphingolipid that is fluorinated alpha-C-GalCer, a synthesized C-clycosyl analogue of myelin-derived galactosylceramide (Mye-GalCer).","InChI=1S/C55H108FNO8/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-41-43-50(60)57-47(44-46(56)55-54(64)53(63)52(62)49(45-58)65-55)51(61)48(59)42-40-38-36-34-32-30-28-18-16-14-12-10-8-6-4-2/h46-49,51-55,58-59,61-64H,3-45H2,1-2H3,(H,57,60)/t46-,47+,48-,49-,51+,52+,53+,54-,55-/m1/s1",fluorinated alpha-C-GalCer,PubMed citation,30941120
7022,144323,zinc dibutyldithiocarbamate,A dithiocarbamate salt that is the zinc salt of dibutyldithiocarbamic acid.,"InChI=1S/2C9H19NS2.Zn/c2*1-3-5-7-10(9(11)12)8-6-4-2;/h2*3-8H2,1-2H3,(H,11,12);/q;;+2/p-2",zinc bis(dibutylthiocarbamoyl)disulfide,PubMed citation,30697834
7023,144353,diethyldithiocarbamic acid,A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.,"InChI=1S/C5H11NS2/c1-3-6(4-2)5(7)8/h3-4H2,1-2H3,(H,7,8)","N,N-diethylcarbamodithioic acid",CAS Registry Number,147-84-2
7024,144359,diethyldithiocarbamate,A member of the class of dithiocarbamate anions resulting from the removal of the proton from the dithiocarbamic acid moiety of diethyldithiocarbamic acid.,"InChI=1S/C5H11NS2/c1-3-6(4-2)5(7)8/h3-4H2,1-2H3,(H,7,8)/p-1","N,N-diethyldithiocarbamate",MetaCyc accession,DIETHYLDITHIOCARBAMATE
7025,144364,beta-D-Man-(1->2)-beta-D-Man-(1->2)-beta-D-Man-(1->2)-beta-D-Man,beta-D-Man-(1->2)-beta-D-Man-(1->2)-beta-D-Man-(1->2)-D-Man having beta-configuration at the reducing end anomeric centre.,"InChI=1S/C24H42O21/c25-1-5-10(30)14(34)18(21(38)39-5)43-23-20(16(36)12(32)7(3-27)41-23)45-24-19(15(35)11(31)8(4-28)42-24)44-22-17(37)13(33)9(29)6(2-26)40-22/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22+,23+,24+/m1/s1",beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-beta-D-Manp-(1->2)-beta-D-Manp,PubMed citation,31009911
7026,144380,4-(sulfooxy)-cinnamic acid,An aryl sulfate that is (2E)-3-phenylprop-2-enoic acid which is substituted by a sulfooxy group at position 4. It is produced by the seagrass Zostera marina and has very promising antifouling potential against several micro- and macrofouling organisms.,"InChI=1S/C9H8O6S/c10-9(11)6-3-7-1-4-8(5-2-7)15-16(12,13)14/h1-6H,(H,10,11)(H,12,13,14)/b6-3+",p-(sulfooxy)-cinnamic acid,CAS Registry Number,151481-49-1
7027,144419,montbretin A,"A glycosyloxyflavone that is myricetin in which the hydroxy groups at the 3 and 4' positions have been glycosylated by an alpha-L-rhamnopyranosyl-(1->2)-6-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranosyl-(1->2)-alpha-L-rhamnopyranosyl group and a 4-O-(alpha-L-rhamnopyranosyl)-beta-D-xylopyranose group, respectively.","InChI=1S/C53H64O32/c1-15-31(61)37(67)42(72)50(76-15)80-28-14-75-49(41(71)35(28)65)82-45-24(58)9-19(10-25(45)59)44-46(36(66)30-23(57)11-20(54)12-26(30)79-44)83-52-47(39(69)33(63)17(3)78-52)85-53-48(84-51-43(73)38(68)32(62)16(2)77-51)40(70)34(64)27(81-53)13-74-29(60)7-5-18-4-6-21(55)22(56)8-18/h4-12,15-17,27-28,31-35,37-43,47-59,61-65,67-73H,13-14H2,1-3H3/b7-5+/t15-,16-,17-,27+,28+,31-,32-,33-,34+,35-,37+,38+,39+,40-,41+,42+,43+,47+,48+,49-,50-,51-,52-,53-/m0/s1",myricetin 3-O-[beta-D-glucosyl-(1->2)-(6-O-caffeoyl-beta-D-glucosyl)-(1->2)-alpha-L-rhamnoside] 4'-O-[alpha-L-rhamnosyl-(1->4)-beta-D-xyloside],KNApSAcK accession,C00006047
7028,144428,myricetin 3-O-[(6-O-caffeoyl-beta-D-glucosyl)-(1->2)-alpha-L-rhamnoside](1-),A flavonoid oxoanion resulting from the deprotonation of the hydroxy group at position 7 of myricetin 3-O-[(6-O-caffeoyl-beta-D-glucosyl)-(1->2)-alpha-L-rhamnoside]. The major species at pH 7.3.,"InChI=1S/C36H36O20/c1-12-25(44)30(49)34(56-35-31(50)29(48)27(46)22(54-35)11-51-23(43)5-3-13-2-4-16(38)17(39)6-13)36(52-12)55-33-28(47)24-18(40)9-15(37)10-21(24)53-32(33)14-7-19(41)26(45)20(42)8-14/h2-10,12,22,25,27,29-31,34-42,44-46,48-50H,11H2,1H3/p-1/b5-3+/t12-,22+,25-,27+,29-,30+,31+,34+,35-,36-/m0/s1",mini-MbA,PubMed citation,29967287
7029,144434,iron(III) citrate monohydrate,A hydrate that is the monohydrate form of  iron(III) citrate. It is an iron-based phosphate binder approved for hyperphosphataemia in patients with chronic kidney disease.,"InChI=1S/C6H8O7.Fe.H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;1H2/q;+3;/p-3",iron(3+) citrate hydrate,CAS Registry Number,153531-98-7
7030,144747,L-Orn-D-Glu,A dipeptide obtained by formal condensation of the carboxy group of L-ornithine with the amino group of D-glutamic acid. It is a constituent of bacterial peptidoglycan type A4beta.,"InChI=1S/C10H19N3O5/c11-5-1-2-6(12)9(16)13-7(10(17)18)3-4-8(14)15/h6-7H,1-5,11-12H2,(H,13,16)(H,14,15)(H,17,18)/t6-,7+/m0/s1","(2R)-2-{[(2S)-2,5-diaminopentanoyl]amino}pentanedioic acid",PubMed citation,4568761
7031,144804,nickel subsulfide,A nickel coordination entity with formula Ni3S2. Used in the manufacture of lithium batteries.,InChI=1S/3Ni.2S,Ni3S2,PubMed citation,26101848
7032,144861,"5-hydroxy-3,3',4',7-tetramethoxyflavone","A monohydroxyflavone that is 5-hydroxyflavone which is substituted by methoxy groups at positions 3,3',4' and 7.","InChI=1S/C19H18O7/c1-22-11-8-12(20)16-15(9-11)26-18(19(25-4)17(16)21)10-5-6-13(23-2)14(7-10)24-3/h5-9,20H,1-4H3","5-hydroxy-3,3',4',7-tetramethoxyflavone",MetaCyc accession,CPD-14852
7033,144869,PMX-205,A homodetic cyclic peptide resulting from the formal condensation of the carboxy group of N(2)-(3-phenylpropanoyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-L-arginine with the 5-amino group of the N(2)-acylornithyl residue.,"InChI=1S/C45H62N10O6/c46-45(47)49-24-9-18-34-40(57)48-23-10-19-35(51-39(56)22-21-29-12-3-1-4-13-29)44(61)55-25-11-20-38(55)43(60)54-36(26-30-14-5-2-6-15-30)41(58)53-37(42(59)52-34)27-31-28-50-33-17-8-7-16-32(31)33/h1,3-4,7-8,12-13,16-17,28,30,34-38,50H,2,5-6,9-11,14-15,18-27H2,(H,48,57)(H,51,56)(H,52,59)(H,53,58)(H,54,60)(H4,46,47,49)/t34-,35-,36+,37-,38-/m0/s1",C5a receptor peptide antagonist,CAS Registry Number,514814-49-4
7034,144923,(9Z)-17-hydroxyoctadec-9-enoic acid,An (omega-1)-hydroxy fatty acid that is (9Z)-octadec-9-enoic acid (oleic acid) in which a hydrogen at position 17 has been replaced by a hydroxy group.,"InChI=1S/C18H34O3/c1-17(19)15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18(20)21/h2-3,17,19H,4-16H2,1H3,(H,20,21)/b3-2-",17-hydroxyoleic acid,PubMed citation,24242247
7035,144943,1-O-dodecylglycerol,An alkylglycerol that is glycerol in which the hydrogen of one of the primary hydroxy groups has been replaced by a dodecyl group.,"InChI=1S/C15H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-18-14-15(17)13-16/h15-17H,2-14H2,1H3",C12 monoalkylglycerol ether,CAS Registry Number,1561-07-5
7036,144947,TY 52156,"An imidohydrazide resulting from the formal condensation of the hydrazide carbonyl group of N'-(p-chlorophenyl)-3,3-dimethyl-2-oxobutanehydrazide with the amino group of p-chloroaniline. A potent and selective antagonist of sphingosine-1-phosphate receptor 3 (S1PR3).","InChI=1S/C18H19Cl2N3O/c1-18(2,3)16(24)17(21-14-8-4-12(19)5-9-14)23-22-15-10-6-13(20)7-11-15/h4-11,22H,1-3H3,(H,21,23)","N-(4-chlorophenyl)-3,3-dimethyl-2-oxobutanimidic 2-(4-chlorophenyl) hydrazide",CAS Registry Number,934369-14-9
7037,144948,VPC 23019,"A secondary carboxamide resulting from the formal condensation of the carboxy group of O-phospho-D-serine with the amino group of m-octylaniline. An analogue of sphingosine-1-phosphate (S1P), it is a potent antagonist for both S1P1 and S1P3 receptors. It can inhibit S1P-induced migration of thyroid cancer cells, ovarian cancer cells, and neural stem cells.","InChI=1S/C17H29N2O5P/c1-2-3-4-5-6-7-9-14-10-8-11-15(12-14)19-17(20)16(18)13-24-25(21,22)23/h8,10-12,16H,2-7,9,13,18H2,1H3,(H,19,20)(H2,21,22,23)/t16-/m1/s1",(2R)-2-amino-N-(3-octylphenyl)-3-(phosphonooxy)-propanamide,PubMed citation,15590668
7038,144949,NSC 23766 trihydrochloride,A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1).,"InChI=1S/C24H35N7.3ClH/c1-6-31(7-2)12-8-9-16(3)27-24-28-18(5)14-23(30-24)29-19-10-11-22-20(15-19)21(25)13-17(4)26-22;;;/h10-11,13-16H,6-9,12H2,1-5H3,(H2,25,26)(H2,27,28,29,30);3*1H",NSC 23766.3HCl,CAS Registry Number,1177865-17-6
7039,145249,(9Z)-17-hydroxyoctadec-9-enoic acid 17-O-beta-D-glucoside,A long-chain fatty acid that is the 17-O-beta-D-glucoside of (9Z)-17-hydroxyoctadec-9-enoic acid.,"InChI=1S/C24H44O8/c1-18(31-24-23(30)22(29)21(28)19(17-25)32-24)15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-20(26)27/h2-3,18-19,21-25,28-30H,4-17H2,1H3,(H,26,27)/b3-2-/t18?,19-,21-,22+,23-,24-/m1/s1",17-(beta-D-glucosyloxy)oleic acid,PubMed citation,26298016
7040,145274,myricetin 3-O-[(6-O-acetyl-beta-D-glucosyl)-(1->2)-alpha-L-rhamnoside],A glycosyloxyflavone that is myricetin 3-O-[beta-D-glucosyl-(1->2)-alpha-L-rhamnoside] in which the hydroxy group at position 6 of the beta-D-glucosyl group has been converted to the corresponding acetate.  Identified in PMID: 23549747 Fig. S21 peak 4.,"InChI=1S/C29H32O18/c1-8-18(35)23(40)27(47-28-24(41)22(39)20(37)16(45-28)7-42-9(2)30)29(43-8)46-26-21(38)17-12(32)5-11(31)6-15(17)44-25(26)10-3-13(33)19(36)14(34)4-10/h3-6,8,16,18,20,22-24,27-29,31-37,39-41H,7H2,1-2H3/t8-,16+,18-,20+,22-,23+,24+,27+,28-,29-/m0/s1",myricetin 3-O-[(6-O-acetyl-beta-D-glucosyl)-(1->2)-6-deoxy-alpha-L-mannopyranoside],PubMed citation,23549747
7041,145275,myricetin 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside,"A glycosyloxyflavone that is myricetin in which the hydroxy group at position 3 has been converted to the corresponding O-beta-D-glucosyl-(1->2)-beta-D-glucoside. Identified in PMID 29667287 Fig. S17, peak 8.","InChI=1S/C27H30O18/c28-5-13-17(35)20(38)22(40)26(42-13)45-25-21(39)18(36)14(6-29)43-27(25)44-24-19(37)15-9(31)3-8(30)4-12(15)41-23(24)7-1-10(32)16(34)11(33)2-7/h1-4,13-14,17-18,20-22,25-36,38-40H,5-6H2/t13-,14-,17-,18-,20+,21+,22-,25-,26+,27+/m1/s1","3-[(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-5-hydroxy-4-oxo-2-(3,4,5-trihydroxyphenyl)-4H-chromen-7-ol",PubMed citation,29967287
7042,145299,(9Z)-16-hydroxyhexadec-9-enoic acid,An omega-hydroxy-long-chain fatty acid that is palmitoleic acid [(9Z)-16-hexadec-9-enoic acid) which is substituted by a hydroxy group at the terminal carbon.,"InChI=1S/C16H30O3/c17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16(18)19/h1,3,17H,2,4-15H2,(H,18,19)/b3-1-",16-hydroxypalmitoleic acid,LIPID MAPS instance accession,LMFA01050193
7043,145323,N(2)-(3-hydroxy-3-methylhexanoyl)-L-glutamine,An N(2)-acyl-L-glutamine that has 3-hydroxy-3-methylhexanoyl as the N(2)-acyl group.,"InChI=1S/C12H22N2O5/c1-3-6-12(2,19)7-10(16)14-8(11(17)18)4-5-9(13)15/h8,19H,3-7H2,1-2H3,(H2,13,15)(H,14,16)(H,17,18)/t8-,12?/m0/s1",N(alpha)-(3-hydroxy-3-methylhexanoyl)-L-glutamine,PubMed citation,12468539
7044,145327,alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acetylsphingosine,alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine in which the acyl group is acetyl. Ganglioside GM1 with an acetyl group substituting for the long fatty acid typicalof ceramide.,"InChI=1S/C57H99N3O31/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-30(69)29(58-26(2)66)25-82-53-45(78)43(76)47(35(23-64)85-53)87-55-46(79)51(91-57(56(80)81)19-31(70)37(59-27(3)67)50(90-57)39(72)32(71)20-61)48(36(24-65)86-55)88-52-38(60-28(4)68)49(41(74)34(22-63)83-52)89-54-44(77)42(75)40(73)33(21-62)84-54/h17-18,29-55,61-65,69-79H,5-16,19-25H2,1-4H3,(H,58,66)(H,59,67)(H,60,68)(H,80,81)/b18-17+/t29-,30+,31-,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42-,43+,44+,45+,46+,47+,48-,49+,50+,51+,52-,53+,54-,55-,57-/m0/s1",ganglioside GM1-acetyl,PubMed citation,10981968
7045,145334,1-hydroxymidazolam beta-D-glucuronide,"A beta-D-glucosiduronic acid that is beta-D-glucuronic acid in which the anomeric hydroxyl hydrogen has been replaced by a 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-4-yl group. It is the glucuronidated conjugate of the midazolam metabolite, 1-hydroxymidazolam.","InChI=1S/C24H21ClFN3O7/c25-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)26)28-9-12-8-27-17(29(12)16)10-35-24-21(32)19(30)20(31)22(36-24)23(33)34/h1-8,19-22,24,30-32H,9-10H2,(H,33,34)/t19-,20-,21+,22-,24+/m0/s1",1'-hydroxymidazolam-glucuronide,PubMed citation,18537963
7046,145339,erythromycin-[N-methyl-(14)C],A (14)C-modified compound that is erythromycin A in which one of the methyl groups of the dimethylnitrilo group has a (14)C label. It is used in a breath test to detect liver cytochrome P450 enzyme (CYP3A4) activity in humans.,"InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1/i11+2",[(14)C-N-methyl]-erythromycin,CAS Registry Number,92530-59-1
7047,145341,4-O-beta-D-glucosyl-trans-sinapic acid,A beta-D-glucoside resulting from the formal condensation of the phenolic hydroxy group of trans-sinapic acid with beta-D-gucopyranose.,"InChI=1S/C17H22O10/c1-24-9-5-8(3-4-12(19)20)6-10(25-2)16(9)27-17-15(23)14(22)13(21)11(7-18)26-17/h3-6,11,13-15,17-18,21-23H,7H2,1-2H3,(H,19,20)/b4-3+/t11-,13-,14+,15-,17+/m1/s1",4-O-(beta-D-glucosyl)-(2E)-sinapic acid,PubMed citation,11042211
7048,145348,6-sulfo-beta-D-quinovose,A 6-sulfo-D-quinovose (6-deoxy-6-sulfo-D-glucopyranose) that has beta configuration at the anomeric centre.,"InChI=1S/C6H12O8S/c7-3-2(1-15(11,12)13)14-6(10)5(9)4(3)8/h2-10H,1H2,(H,11,12,13)/t2-,3-,4+,5-,6-/m1/s1",6-sulfo-beta-quinovose,MetaCyc accession,CPD-21686
7049,145411,4-{[(4-aminophenyl)sulfonyl]amino}hexanoic acid,A sulfonamide consisting of hexanoic acid with a 4-aminobenzenesulfonamido group at its 6-position.,"InChI=1S/C12H18N2O4S/c13-10-5-7-11(8-6-10)19(17,18)14-9-3-1-2-4-12(15)16/h5-8,14H,1-4,9,13H2,(H,15,16)",acide 6-{[(4-aminophenyl)sulfonyl]amino}hexanoique,CAS Registry Number,30181-27-2
7050,145415,4-(4-{[(4-aminophenyl)sulfonyl]amino}phenyl)butanoic acid,A sulfonamide consisting of 4-phenylbutanoic acid with a 4-aminobenzenesulfonamido group at the phenyl 4-position.,"InChI=1S/C16H18N2O4S/c17-13-6-10-15(11-7-13)23(21,22)18-14-8-4-12(5-9-14)2-1-3-16(19)20/h4-11,18H,1-3,17H2,(H,19,20)",4-[4-[(4-aminophenyl)sulfonylamino]phenyl]butanoic acid,PubMed citation,30580515
7051,145463,1-O-[4-O-(4-chlorobenzyl)-alpha-D-galactosyl]-N-hexacosanoylphytosphingosine,"A glycophytoceramide having a 4-O-(4-chlorobenzyl)-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4""-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.","InChI=1S/C57H104ClNO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-52(62)59-49(53(63)50(61)38-36-34-32-30-28-16-14-12-10-8-6-4-2)46-67-57-55(65)54(64)56(51(44-60)68-57)66-45-47-40-42-48(58)43-41-47/h40-43,49-51,53-57,60-61,63-65H,3-39,44-46H2,1-2H3,(H,59,62)/t49-,50+,51+,53-,54+,55+,56-,57-/m0/s1","(2S,3S,4R)-1-[4-O-(4-chlorobenzyl)-alpha-D-galactopyranosyloxy]-2-hexacosanoylaminooctadecane-3,4-diol",PubMed citation,30556652
7052,145484,6-deoxy-alpha-L-Talp2Ac3Me-(1->3)-beta-D-Glcp-(1->3)-6-deoxy-alpha-L-Talp2Ac-(1->3)-beta-D-GlcpO[CH2]5NH2,A tetrasaccharide derivative consisting of a beta-D-glucosyl residue glycosidically linked to a 5-aminopentyl group and which carries at O-3 a 2-O-acetyl-6-deoxy-3-O-methyl-alpha-L-talosyl-(1->3)-beta-D-glucosyl-(1->3)-2-O-acetyl-6-deoxy-alpha-L-talosyl trisaccharide unit.,"InChI=1S/C34H59NO21/c1-13-19(40)27(46-5)29(50-15(3)38)33(48-13)55-26-22(43)18(12-37)53-32(24(26)45)56-28-20(41)14(2)49-34(30(28)51-16(4)39)54-25-21(42)17(11-36)52-31(23(25)44)47-10-8-6-7-9-35/h13-14,17-34,36-37,40-45H,6-12,35H2,1-5H3/t13-,14-,17+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27+,28+,29+,30+,31+,32-,33-,34-/m0/s1",5-aminopentyl 2-O-acetyl-6-deoxy-3-O-methyl-alpha-L-talosyl-(1->3)-beta-D-glucosyl-(1->3)-2-O-acetyl-6-deoxy-alpha-L-talosyl-(1->3)-beta-D-glucoside,PubMed citation,31513223
7053,145488,1-O-[4-O-(6-phenylhexyl)-alpha-D-galactosyl]-N-hexacosanoylphytosphingosine,"A glycophytoceramide having a 4-O-(6-phenylhexyl)-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4""-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.","InChI=1S/C62H115NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-43-49-57(66)63-54(58(67)55(65)48-42-34-32-30-28-16-14-12-10-8-6-4-2)52-71-62-60(69)59(68)61(56(51-64)72-62)70-50-44-37-36-39-45-53-46-40-38-41-47-53/h38,40-41,46-47,54-56,58-62,64-65,67-69H,3-37,39,42-45,48-52H2,1-2H3,(H,63,66)/t54-,55+,56+,58-,59+,60+,61-,62-/m0/s1","N-{(2S,3S,4R)-1-[4-O-(6-phenylhexyl)-alpha-D-galactosyloxy]-3,4-dihydroxyoctadecan-2-yl}hexacosanamide",PubMed citation,30556652
7054,145508,1-O-{4-O-[3-(4-chlorophenyl)propyl]-alpha-D-galactosyl}-N-hexacosanoylphytosphingosine,"A glycophytoceramide having a 4-O-[3-(4-chlorophenyl)propyl]-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4""-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.","InChI=1S/C59H108ClNO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-41-54(64)61-51(55(65)52(63)40-36-34-32-30-28-16-14-12-10-8-6-4-2)48-69-59-57(67)56(66)58(53(47-62)70-59)68-46-38-39-49-42-44-50(60)45-43-49/h42-45,51-53,55-59,62-63,65-67H,3-41,46-48H2,1-2H3,(H,61,64)/t51-,52+,53+,55-,56+,57+,58-,59-/m0/s1","(2S,3S,4R)-1-{4-O-[3-(4-chlorophenyl)propyl]-alpha-D-galactopyranosyloxy}-2-hexacosanoylaminooctadecane-3,4-diol",PubMed citation,30556652
7055,145516,1-O-{4-O-[3-(4-fluorophenyl)propyl]-alpha-D-galactosyl}-N-hexacosanoylphytosphingosine,"A glycophytoceramide having a 4-O-[3-(4-fluorophenyl)propyl]-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4""-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.","InChI=1S/C59H108FNO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-41-54(64)61-51(55(65)52(63)40-36-34-32-30-28-16-14-12-10-8-6-4-2)48-69-59-57(67)56(66)58(53(47-62)70-59)68-46-38-39-49-42-44-50(60)45-43-49/h42-45,51-53,55-59,62-63,65-67H,3-41,46-48H2,1-2H3,(H,61,64)/t51-,52+,53+,55-,56+,57+,58-,59-/m0/s1","(2S,3S,4R)-1-{4-O-[3-(4-fluorophenyl)propyl]-alpha-D-galactopyranosyloxy}-2-hexacosanoylaminooctadecane-3,4-diol",PubMed citation,30556652
7056,145523,1-O-[4-O-(4-fluorobenzyl)-alpha-D-galactosyl]-N-hexacosanoylphytosphingosine,"A glycophytoceramide having a 4-O-(4-fluorobenzyl)-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4""-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.","InChI=1S/C57H104FNO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-52(62)59-49(53(63)50(61)38-36-34-32-30-28-16-14-12-10-8-6-4-2)46-67-57-55(65)54(64)56(51(44-60)68-57)66-45-47-40-42-48(58)43-41-47/h40-43,49-51,53-57,60-61,63-65H,3-39,44-46H2,1-2H3,(H,59,62)/t49-,50+,51+,53-,54+,55+,56-,57-/m0/s1","N-{(1S,2S,3R)-2,3-dihydroxy-1-[({4-O-[(4-fluorophenyl)methyl]-alpha-D-galactopyranosyl}oxy)methyl]heptadecyl}hexacosanamide",PubMed citation,30556652
7057,145525,1-O-[4-O-(cyclobutylmethyl)-alpha-D-galactosyl]-N-hexacosanoylphytosphingosine,"A glycophytoceramide having a 4-O-(cyclobutylmethyl)-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4""-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.","InChI=1S/C55H107NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-42-50(59)56-47(51(60)48(58)41-36-34-32-30-28-16-14-12-10-8-6-4-2)45-64-55-53(62)52(61)54(49(43-57)65-55)63-44-46-39-38-40-46/h46-49,51-55,57-58,60-62H,3-45H2,1-2H3,(H,56,59)/t47-,48+,49+,51-,52+,53+,54-,55-/m0/s1","(2S,3S,4R)-1-[4-O-(cyclobutylmethyl)-alpha-D-galactopyranosyloxy]-2-hexacosanoylaminooctadecane-3,4-diol",PubMed citation,30556652
7058,145526,1-O-[4-O-(2-adamantylethyl)-alpha-D-galactosyl]-N-hexacosanoylphytosphingosine,"A glycophytoceramide having a 4-O-(2-adamantylethyl)-alpha-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen. One of a series of an extensive set of 4""-O-alkylated alpha-GalCer analogues evaluated (PMID:30556652) as invariant natural killer T-cell (iNKT) antigens.","InChI=1S/C62H117NO9/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-56(66)63-53(57(67)54(65)38-36-34-32-30-28-16-14-12-10-8-6-4-2)49-71-61-59(69)58(68)60(55(48-64)72-61)70-41-40-62-45-50-42-51(46-62)44-52(43-50)47-62/h50-55,57-61,64-65,67-69H,3-49H2,1-2H3,(H,63,66)/t50-,51-,52?,53-,54+,55+,57-,58+,59+,60-,61-,62?/m0/s1","(2S,3S,4R)-1-[4-O-(2-adamantylethyl)-alpha-D-galactopyranosyloxy]-2-hexacosanoylaminooctadecane-3,4-diol",PubMed citation,30556652
7059,145537,AMG-925,"An organic heterotricyclic compound that is 9H-pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine which is substituted by a [6-(hydroxyacetyl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl]nitrilo group at position 2 and by a trans-4-methylcyclohexyl group at position 9. It is a FLT3 and CDK4 dual kinase inhibitor that has antineoplastic activity. Currently under clinical investigation in patients with relapsed or refractory acute myeloid leukemia (AML).","InChI=1S/C26H29N7O2/c1-16-2-5-18(6-3-16)33-22-13-27-10-8-19(22)20-12-28-26(31-25(20)33)30-23-7-4-17-14-32(24(35)15-34)11-9-21(17)29-23/h4,7-8,10,12-13,16,18,34H,2-3,5-6,9,11,14-15H2,1H3,(H,28,29,30,31)/t16-,18-",AMG 925,CAS Registry Number,1401033-86-0
7060,145576,3'-MANT-GTP,A purine ribonucleoside 5'-triphosphate that is GTP substituted at the 3' position by an N-methylanthraniloyl group.,"InChI=1S/C18H23N6O15P3/c1-20-9-5-3-2-4-8(9)17(27)37-13-10(6-35-41(31,32)39-42(33,34)38-40(28,29)30)36-16(12(13)25)24-7-21-11-14(24)22-18(19)23-15(11)26/h2-5,7,10,12-13,16,20,25H,6H2,1H3,(H,31,32)(H,33,34)(H2,28,29,30)(H3,19,22,23,26)/t10-,12-,13-,16-/m1/s1",3'-O-(N-methylanthraniloyl)guanosine triphosphate,PubMed citation,26247422
7061,145587,beta-D-Galf-(1->5)-beta-D-Galf,A beta-D-Galf-(1->6)-D-Galf which has beta configuration at the anomeric centre.,"InChI=1S/C12H22O11/c13-1-3(15)9-6(17)8(19)12(23-9)21-4(2-14)10-5(16)7(18)11(20)22-10/h3-20H,1-2H2/t3-,4-,5-,6-,7-,8-,9+,10+,11-,12-/m1/s1","WURCS=2.0/1,2,1/[a2112h-1b_1-4]/1-1/a5-b1",GlyTouCan accession,G16870CD
7062,145588,beta-D-GlcpA-(1->3)-beta-D-GalpNAc6S,An oligosaccharide sulfate that is 2-acetamido-2-deoxy-6-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranuronoside.,"InChI=1S/C14H23NO15S/c1-3(16)15-5-10(6(17)4(28-13(5)23)2-27-31(24,25)26)29-14-9(20)7(18)8(19)11(30-14)12(21)22/h4-11,13-14,17-20,23H,2H2,1H3,(H,15,16)(H,21,22)(H,24,25,26)/t4-,5-,6+,7+,8+,9-,10-,11+,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a2122A-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G18253ON
7063,145589,alpha-D-Galp-(1->3)-alpha-D-GlcpNAc,An amino disaccharide composed of D-galactose and 2-acetamido-2-deoxy-alpha-D-glucopyranosyl residues in (alpha-1->3) linkage.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12-,13+,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a2112h-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G18438YA
7064,145590,alpha-D-arabinofuranose,A D-arabinofuranose that has alpha-configuration at the anomeric carbon.,"InChI=1S/C5H10O5/c6-1-2-3(7)4(8)5(9)10-2/h2-9H,1H2/t2-,3-,4+,5+/m1/s1","WURCS=2.0/1,1,0/[a122h-1a_1-4]/1/",GlyTouCan accession,G19620XJ
7065,145591,beta-D-GlcpA-(1->3)-beta-D-GalpNAc4S,An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranuronoside.,"InChI=1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/t4-,5-,6+,7+,8-,9+,10-,11+,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_4*OSO/3=O/3=O][a2122A-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G20228HQ
7066,145592,alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S,An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.,"InChI=1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/t4-,5-,6+,7+,8-,9+,10-,11-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_4*OSO/3=O/3=O][a2121A-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G20291UE
7067,145593,beta-D-Galp-(1->3)-alpha-D-GlcpNAc,A beta-D-Galp-(1->3)-D-GlcpNAc in which the N-acetylaminoglucose moiety has alpha configuration.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12-,13+,14+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G21469TE
7068,145594,alpha-D-Galp-(1->4)-alpha-D-Galp-(1->4)-beta-D-Galp,A galactotriose consisting of two alpha-D-galactopyranose units and a beta-D-galactopyranose joined in sequence by (1->4) glycosidic linkages.,"InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14+,15+,16-,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2112h-1b_1-5][a2112h-1a_1-5]/1-2-2/a4-b1_b4-c1",GlyTouCan accession,G22046GD
7069,145595,beta-D-Galp-(1->3)-beta-D-Galp-(1->4)-[alpha-NeuGc-(2->3)]-beta-D-Galp(1->4)-beta-D-Glcp,A member of the class of neraminic acids that is beta-D-Galp-(1->3)-2-acetamido-2-deoxy-beta-D-GalpNAc-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp in which position 3 of the Galp residue is attached to position 2 of the N-glycolylneuraminic acid.,"InChI=1S/C37H62N2O30/c1-9(46)38-18-29(67-34-25(56)22(53)20(51)12(4-41)63-34)21(52)13(5-42)62-33(18)66-28-15(7-44)64-35(65-27-14(6-43)61-32(58)24(55)23(27)54)26(57)31(28)69-37(36(59)60)2-10(47)17(39-16(49)8-45)30(68-37)19(50)11(48)3-40/h10-15,17-35,40-45,47-48,50-58H,2-8H2,1H3,(H,38,46)(H,39,49)(H,59,60)/t10-,11+,12+,13+,14+,15+,17+,18+,19+,20-,21-,22-,23+,24+,25+,26+,27+,28-,29+,30+,31+,32+,33-,34-,35-,37-/m0/s1","WURCS=2.0/4,5,4/[a2122h-1b_1-5][a2112h-1b_1-5][Aad21122h-2a_2-6_5*NCCO/3=O][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-4-2/a4-b1_b3-c2_b4-d1_d3-e1",GlyTouCan accession,G24034CH
7070,145596,alpha-D-Manp-(1->3)-alpha-D-GlcpNAc,An amino disaccharide comprising a beta-D-mannosyl residue linked (1->3) to an N-acetyl-D-glucosamine residue at the reducing end.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10+,11+,12-,13+,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a1122h-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G24324FL
7071,145597,alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,"A polysaccharide that is alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->4) in which the mannopyranosyl group attached by a (1->4)-linkage to the 2-acetamidoglucopyranosyl group is substituted at position 6 by an alpha-D-Manp group, which in turn is substituted at positions 3 and 6 by 2-O-alpha-D-Manp-alpha-D-Manp groups.","InChI=1S/C76H128N2O61/c1-15(89)77-29-41(101)56(25(11-87)119-65(29)116)131-66-30(78-16(2)90)42(102)57(26(12-88)128-66)132-72-55(115)60(135-75-64(49(109)37(97)22(8-84)126-75)139-76-63(48(108)36(96)23(9-85)127-76)138-71-54(114)58(38(98)24(10-86)123-71)133-68-50(110)43(103)31(91)17(3-79)120-68)40(100)28(130-72)13-117-67-53(113)59(134-74-62(47(107)35(95)21(7-83)125-74)137-70-52(112)45(105)33(93)19(5-81)122-70)39(99)27(129-67)14-118-73-61(46(106)34(94)20(6-82)124-73)136-69-51(111)44(104)32(92)18(4-80)121-69/h17-76,79-88,91-116H,3-14H2,1-2H3,(H,77,89)(H,78,90)/t17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43+,44+,45+,46+,47+,48+,49+,50-,51+,52+,53+,54+,55+,56-,57-,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68-,69-,70-,71-,72+,73+,74-,75-,76-/m1/s1","WURCS=2.0/5,12,11/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a2122h-1a_1-5]/1-2-3-4-4-4-5-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-h1_d2-e1_e2-f1_f3-g1_h3-i1_h6-k1_i2-j1_k2-l1",GlyTouCan accession,G24620AI
7072,145598,beta-D-Glcp-(1->2)-beta-D-Xylp,A glycosylxylose that is beta-D-xylopyranose in which the hydroxy group at position 2 has been converted to the corresponding 2-O-beta-D-glucopyranoside.,"InChI=1S/C11H20O10/c12-1-4-6(15)7(16)8(17)11(20-4)21-9-5(14)3(13)2-19-10(9)18/h3-18H,1-2H2/t3-,4-,5+,6-,7+,8-,9-,10-,11+/m1/s1","WURCS=2.0/2,2,1/[a212h-1b_1-5][a2122h-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G26459QM
7073,145599,normethylfondaparinux,A heparin pentasaccharide resulting from the hydrolysis of the O-methyl group of fondaparinux.,"InChI=1S/C30H51N3O49S8/c34-10-4(1-69-86(54,55)56)73-27(8(11(10)35)32-84(48,49)50)77-19-13(37)14(38)29(79-22(19)24(40)41)76-17-6(3-71-88(60,61)62)74-28(9(33-85(51,52)53)18(17)81-89(63,64)65)78-20-15(39)21(82-90(66,67)68)30(80-23(20)25(42)43)75-16-5(2-70-87(57,58)59)72-26(44)7(12(16)36)31-83(45,46)47/h4-23,26-39,44H,1-3H2,(H,40,41)(H,42,43)(H,45,46,47)(H,48,49,50)(H,51,52,53)(H,54,55,56)(H,57,58,59)(H,60,61,62)(H,63,64,65)(H,66,67,68)/t4-,5-,6-,7-,8-,9-,10-,11-,12-,13-,14-,15+,16-,17-,18-,19+,20+,21-,22+,23-,26+,27-,28-,29-,30-/m1/s1","WURCS=2.0/4,5,4/[a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O][a2121A-1a_1-5_2*OSO/3=O/3=O][a2122h-1a_1-5_2*NSO/3=O/3=O_3*OSO/3=O/3=O_6*OSO/3=O/3=O][a2122A-1b_1-5]/1-2-3-4-1/a4-b1_b4-c1_c4-d1_d4-e1",GlyTouCan accession,G27775IZ
7074,145600,6-O-alpha-L-arabinofuranosyl-beta-D-glucopyranose,An alpha-L-arabinofuranoside resulting from the formal condensation of the 6-hydroxy group of beta-D-glucopyranose with the anomeric hydroxy group of alpha-L-arabinofuranose.,"InChI=1S/C11H20O10/c12-1-3-5(13)9(17)11(21-3)19-2-4-6(14)7(15)8(16)10(18)20-4/h3-18H,1-2H2/t3-,4+,5-,6+,7-,8+,9+,10+,11+/m0/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5][a211h-1a_1-4]/1-2/a6-b1",GlyTouCan accession,G27854BF
7075,145601,beta-D-Galp-(1->3)-[beta-D-Glcp-(1->4)]-beta-D-Glcp,A branched trisaccharide that is beta-D-Galp-(1->3)-beta-D-Glcp in which the hydroxy group at position 4 of the gluocopyranose moiety has been converted to the corresponding beta-D-glucopyranoside.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)30-16(29)13(28)15(14)34-18-12(27)10(25)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9+,10+,11-,12-,13-,14-,15-,16-,17+,18+/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5][a2112h-1b_1-5]/1-2-1/a3-b1_a4-c1",GlyTouCan accession,G29084XK
7076,145602,beta-D-Glcp-(1->2)-[beta-D-Glcp-(1->4)]-beta-D-Glcp,A glucotriose that is beta-D-glucose in which the hydroxy groups at positions 2 and 4 have each been converted to the corresponding beta-D-glucoside.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)30-16(29)15(13(14)28)34-18-12(27)10(25)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13+,14-,15-,16-,17+,18+/m1/s1","WURCS=2.0/1,3,2/[a2122h-1b_1-5]/1-1-1/a2-b1_a4-c1",GlyTouCan accession,G30567WW
7077,145605,methyl beta-D-glucopyranuronate,A methyl D-glucopyranuronate in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C7H12O7/c1-13-7(12)5-3(9)2(8)4(10)6(11)14-5/h2-6,8-11H,1H3/t2-,3-,4+,5-,6+/m0/s1","WURCS=2.0/1,1,0/[a2122A-1b_1-5_6*OC]/1/",GlyTouCan accession,G32430MQ
7078,145606,beta-D-glucofuranose,A D-glucofuranose that has beta- configuration at the anomeric centre.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3-,4-,5-,6-/m1/s1","WURCS=2.0/1,1,0/[a2122h-1b_1-4]/1/",GlyTouCan accession,G38419CD
7079,145607,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-a-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,A polysaccharide consisting of alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc in which the hydroxy group at position 6 of the beta-D-Manp group is substituted by an alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-]-alpha-D-Manp group.,"InChI=1S/C70H118N2O56/c1-14(82)71-27-38(93)52(23(10-80)110-60(27)107)121-61-28(72-15(2)83)39(94)53(24(11-81)118-61)122-66-51(106)55(124-69-59(46(101)35(90)21(8-78)116-69)128-70-58(45(100)34(89)22(9-79)117-70)127-65-49(104)42(97)31(86)18(5-75)113-65)37(92)26(120-66)12-108-62-50(105)54(123-68-57(44(99)33(88)20(7-77)115-68)126-64-48(103)41(96)30(85)17(4-74)112-64)36(91)25(119-62)13-109-67-56(43(98)32(87)19(6-76)114-67)125-63-47(102)40(95)29(84)16(3-73)111-63/h16-70,73-81,84-107H,3-13H2,1-2H3,(H,71,82)(H,72,83)/t16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52-,53-,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,64-,65-,66+,67+,68-,69-,70-/m1/s1","WURCS=2.0/4,11,10/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-4-4-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_e2-f1_g3-h1_g6-j1_h2-i1_j2-k1",GlyTouCan accession,G39578OU
7080,145608,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp,An alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-D-Manp in which the carbon bearing the anomeric hydroxy group has beta- configuration.,"InChI=1S/C24H42O21/c25-1-5-9(29)13(33)16(36)22(40-5)44-19-14(34)10(30)7(3-27)42-24(19)45-20-15(35)11(31)6(2-26)41-23(20)43-18-12(32)8(4-28)39-21(38)17(18)37/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23-,24-/m1/s1","WURCS=2.0/2,4,3/[a1122h-1b_1-5][a1122h-1a_1-5]/1-2-2-2/a3-b1_b2-c1_c2-d1",GlyTouCan accession,G39767HX
7081,145609,beta-D-Xylp-(1->2)-alpha-L-Arap-(1->6)-beta-D-Glcp,"A trisaccharide consisting of beta-D-xylopyranose, alpha-L-arabinopyranose and beta-D-glucopyranose joined together in sequence by (1->2) and (1->6)-glycosidic bonds, respectively.","InChI=1S/C16H28O14/c17-4-1-26-15(12(24)7(4)19)30-13-8(20)5(18)2-27-16(13)28-3-6-9(21)10(22)11(23)14(25)29-6/h4-25H,1-3H2/t4-,5+,6-,7+,8+,9-,10+,11-,12-,13-,14-,15+,16+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1b_1-5][a211h-1a_1-5][a212h-1b_1-5]/1-2-3/a6-b1_b2-c1",GlyTouCan accession,G39851TR
7082,145612,alpha-D-Manp-(1->3)-alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,"A high-mannose oligosaccharide that is beta-D-mannopyranose in which the hydrogens of hydroxy groups are replaced by a 3-O-alpha-D-mannopyranosyl-alpha-D-mannopyranosyl group at position 6, a alpha-D-mannopyranosyl-(1->2)-alpha-D-mannopyranosyl-(1->2)-alpha-D-mannopyranosyl group at position 3, and a chitobiose group at position 1.","InChI=1S/C52H88N2O41/c1-11(62)53-21-29(70)39(18(8-60)82-45(21)80)90-46-22(54-12(2)63)30(71)40(19(9-61)88-46)91-50-38(79)42(28(69)20(89-50)10-81-47-37(78)41(27(68)17(7-59)83-47)92-48-35(76)31(72)23(64)13(3-55)84-48)93-51-44(34(75)26(67)15(5-57)86-51)95-52-43(33(74)25(66)16(6-58)87-52)94-49-36(77)32(73)24(65)14(4-56)85-49/h13-52,55-61,64-80H,3-10H2,1-2H3,(H,53,62)(H,54,63)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31+,32+,33+,34+,35+,36+,37+,38+,39-,40-,41+,42+,43+,44+,45+,46+,47+,48-,49-,50+,51-,52-/m1/s1","WURCS=2.0/4,8,7/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_e2-f1_g3-h1",GlyTouCan accession,G44865OQ
7083,145613,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,"A branched amino nonasaccharide comprising a linear heptasaccharide chain consisting of N-acetylalpha-neuraminic acid, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, and beta-D-glucose residues, linked sequentially (2->3), (1->4), (1->3), (1->4), (1->3), and (1->4), with alpha-L-fucosyl residues linked (1->3) to each of the N-acetyl-D-glucosamine residues.","InChI=1S/C63H105N3O47/c1-14-30(79)36(85)40(89)57(97-14)108-49-28(65-17(4)75)55(110-51-33(82)21(8-68)100-59(42(51)91)105-45-24(11-71)99-54(94)39(88)38(45)87)103-25(12-72)46(49)106-60-43(92)52(34(83)22(9-69)101-60)111-56-29(66-18(5)76)50(109-58-41(90)37(86)31(80)15(2)98-58)47(26(13-73)104-56)107-61-44(93)53(35(84)23(10-70)102-61)113-63(62(95)96)6-19(77)27(64-16(3)74)48(112-63)32(81)20(78)7-67/h14-15,19-61,67-73,77-94H,6-13H2,1-5H3,(H,64,74)(H,65,75)(H,66,76)(H,95,96)/t14-,15-,19-,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33-,34-,35-,36+,37+,38+,39+,40-,41-,42+,43+,44+,45+,46+,47+,48+,49+,50+,51-,52-,53-,54+,55-,56-,57-,58-,59-,60-,61-,63-/m0/s1","WURCS=2.0/5,9,8/[a2122h-1b_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5][Aad21122h-2a_2-6_5*NCC/3=O]/1-2-3-4-2-3-4-2-5/a4-b1_b3-c1_c3-d1_c4-e1_e3-f1_f3-g1_f4-h1_h3-i2",GlyTouCan accession,G45215IJ
7084,145614,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->4)-alpha-D-GlcpN,"An amino tetrasaccharide comprising a linear chain of three alpha-D-mannose and one N-acetyl-alpha-D-glucosamine resides joined in sequence by (1->2), (1->6) and (1->2) glycosidic linkages.","InChI=1S/C24H43NO20/c25-9-13(32)19(7(3-28)40-21(9)38)44-23-18(37)15(34)12(31)8(43-23)4-39-24-20(16(35)11(30)6(2-27)42-24)45-22-17(36)14(33)10(29)5(1-26)41-22/h5-24,26-38H,1-4,25H2/t5-,6-,7-,8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18+,19-,20+,21+,22-,23-,24+/m1/s1","WURCS=2.0/2,4,3/[a2122h-1a_1-5_2*N][a1122h-1a_1-5]/1-2-2-2/a4-b1_b6-c1_c2-d1",GlyTouCan accession,G46392BZ
7085,145615,beta-D-GlcpA-(1->4)-alpha-D-GlcpNS,An amino disaccharide consisting of beta-D-glucopyranuronic acid residue joined by a (1->4) glycosidic linkage to a 2-deoxy-2-(sulfoamino)-alpha-D-glucopyranosyl residue.,"InChI=1S/C12H21NO14S/c14-1-2-8(4(15)3(11(21)25-2)13-28(22,23)24)26-12-7(18)5(16)6(17)9(27-12)10(19)20/h2-9,11-18,21H,1H2,(H,19,20)(H,22,23,24)/t2-,3-,4-,5+,6+,7-,8-,9+,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NSO/3=O/3=O][a2122A-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G47876BP
7086,145616,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,"A high mannose oligosaccharide consisting of three alpha-D-mannopyranose residues, a beta-D-mannopyranose residue, a 2-acetamido-beta-D-glucopyranosyl residue and a 2-acetamido-alpha-D-glucopyranosyl residues joined in sequence by (1->2), (1->2), (1->3), (1->4), and (1->4) glycosidic linkages, and in which the second mannosyl group from the chitobiose moiety is substituted at position 6 by a alpha-D-mannopyranosyl-(1->6)-[alpha-D-mannopyranosyl-(1->2)-alpha-D-mannopyranosyl-(1->3)]-alpha-D-mannopyranosyl group.","InChI=1S/C64H108N2O51/c1-13(75)65-25-35(85)48(21(9-73)101-55(25)98)111-56-26(66-14(2)76)36(86)49(22(10-74)108-56)112-61-47(97)51(114-63-54(42(92)32(82)19(7-71)106-63)117-64-53(41(91)31(81)20(8-72)107-64)116-60-45(95)39(89)29(79)17(5-69)104-60)34(84)24(110-61)12-100-58-46(96)50(33(83)23(109-58)11-99-57-43(93)37(87)27(77)15(3-67)102-57)113-62-52(40(90)30(80)18(6-70)105-62)115-59-44(94)38(88)28(78)16(4-68)103-59/h15-64,67-74,77-98H,3-12H2,1-2H3,(H,65,75)(H,66,76)/t15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48-,49-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59-,60-,61+,62-,63-,64-/m1/s1","WURCS=2.0/4,10,9/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-4-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_e2-f1_g3-h1_g6-j1_h2-i1",GlyTouCan accession,G48148JS
7087,145617,beta-D-Glcp-(1->3)-[beta-D-Glcp-(1->6)]-beta-D-Glcp,A beta-D-Glcp-(1->3)-[beta-D-Glcp-(1->6)]-D-Glcp which has beta- configuration at the anomeric carbon of the non-terminal glucopyranose ring.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)12(26)17(32-4)30-3-6-9(23)15(14(28)16(29)31-6)34-18-13(27)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12-,13-,14-,15+,16-,17-,18+/m1/s1","WURCS=2.0/1,3,2/[a2122h-1b_1-5]/1-1-1/a3-b1_a6-c1",GlyTouCan accession,G50195ND
7088,145618,alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,"An amino tetrasaccharide consisting of alpha-D-mannose, beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-alpha-D-glucosamine joined together in sequence by (1->3), (1->4) and (1->4) glycosidic linkages.","InChI=1S/C28H48N2O21/c1-7(35)29-13-17(39)22(11(5-33)45-25(13)44)49-26-14(30-8(2)36)18(40)23(12(6-34)48-26)50-28-21(43)24(16(38)10(4-32)47-28)51-27-20(42)19(41)15(37)9(3-31)46-27/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21+,22-,23-,24+,25+,26+,27-,28+/m1/s1","WURCS=2.0/4,4,3/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4/a4-b1_b4-c1_c3-d1",GlyTouCan accession,G53394BX
7089,145619,alpha-D-Galp-(1->4)-alpha-D-Galp,A alpha-D-Gal-(1->4)-D-Gal in which both galactose residues have alpha- configuration at the anomeric centre.,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10+,11+,12-/m1/s1","WURCS=2.0/1,2,1/[a2112h-1a_1-5]/1-1/a4-b1",GlyTouCan accession,G54046EC
7090,145620,beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-[-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)]-beta-D-Galp-(1->4)-beta-D-Glcp,"A member of the class of neuraminic acids that is neuraminic acid attached in sequence to beta-D-galactopyranosyl, 2-acetamido-2-deoxy-beta-D-glucopyranosyl, beta-D-galactopyranosyl, and beta-D-glucopyranosyl, residues by (2->3), (1->3), (1->3) and (1->4) glycosidic linkages. The galactosyl residue attached to the neuraminic acid is glycosylated at position 4 by a beta-D-acetamidogalactosyl residue, while the other galactosiyl residue has been glycosylated at position 4 by a beta-D-galactopyranosyl-(1->3)-2-acetamido-beta-D-galactopyranosyl residue.","InChI=1S/C59H98N4O44/c1-14(72)60-27-18(76)5-59(58(91)92,106-48(27)31(78)19(77)6-64)107-50-42(89)57(99-26(13-71)45(50)102-52-28(61-15(2)73)36(83)32(79)20(7-65)94-52)104-47-30(63-17(4)75)54(96-23(10-68)35(47)82)105-49-41(88)56(100-43-24(11-69)93-51(90)39(86)38(43)85)98-25(12-70)44(49)101-53-29(62-16(3)74)46(34(81)22(9-67)95-53)103-55-40(87)37(84)33(80)21(8-66)97-55/h18-57,64-71,76-90H,5-13H2,1-4H3,(H,60,72)(H,61,73)(H,62,74)(H,63,75)(H,91,92)/t18-,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32-,33-,34-,35+,36+,37-,38+,39+,40+,41+,42+,43+,44-,45-,46+,47+,48+,49+,50+,51+,52-,53-,54-,55-,56-,57-,59-/m0/s1","WURCS=2.0/5,8,7/[a2122h-1b_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][Aad21122h-2a_2-6_5*NCC/3=O][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-2-4-5-5-2/a4-b1_b3-c1_b4-g1_c3-d1_d3-e2_d4-f1_g3-h1",GlyTouCan accession,G54511PJ
7091,145621,alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,A high-mannose oligosaccharide that is alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-2-D-GlcpNAc inomeric hydroxy group of the terminal N-acetamidoglucose residue has alpha configuration.,"InChI=1S/C46H78N2O36/c1-10(55)47-19-26(62)35(16(7-53)73-40(19)71)80-41-20(48-11(2)56)27(63)36(17(8-54)78-41)81-44-34(70)37(25(61)18(79-44)9-72-42-32(68)28(64)21(57)12(3-49)74-42)82-45-39(31(67)24(60)14(5-51)76-45)84-46-38(30(66)23(59)15(6-52)77-46)83-43-33(69)29(65)22(58)13(4-50)75-43/h12-46,49-54,57-71H,3-9H2,1-2H3,(H,47,55)(H,48,56)/t12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28+,29+,30+,31+,32+,33+,34+,35-,36-,37+,38+,39+,40+,41+,42+,43-,44+,45-,46-/m1/s1","WURCS=2.0/4,7,6/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_e2-f1",GlyTouCan accession,G59406KS
7092,145622,beta-D-Glcp-(1->2)-alpha-L-Arap,A disaccharide that is alpha-D-arabinopyranose in which the hydroxy group at position 2 has been converted into the corresponding beta-D-glucoside.,"InChI=1S/C11H20O10/c12-1-4-6(15)7(16)8(17)11(20-4)21-9-5(14)3(13)2-19-10(9)18/h3-18H,1-2H2/t3-,4+,5-,6+,7-,8+,9+,10+,11-/m0/s1","WURCS=2.0/2,2,1/[a211h-1a_1-5][a2122h-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G60200IZ
7093,145623,beta-D-Glcp-(1->4)-beta-D-Glcp-(1->6)-beta-D-Glcp,A glucotriose consisting of three molecules of beta-D-glucopyranose joined in a linear sequence by (1->4) and (1->6) glycosidic linkages.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)18(32-4)34-15-5(2-20)33-17(14(28)11(15)25)30-3-6-8(22)9(23)12(26)16(29)31-6/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16-,17-,18+/m1/s1","WURCS=2.0/1,3,2/[a2122h-1b_1-5]/1-1-1/a6-b1_b4-c1",GlyTouCan accession,G61328AC
7094,145624,beta-D-GlcpNAc-(1->4)-beta-D-GlcpA-(1->3)-beta-D-GlcpNAc,A beta-D-GlcpNAc-(1->4)-beta-D-GlcpA-(1->3)-D-GlcpNAc in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C22H36N2O17/c1-5(27)23-9-13(31)11(29)7(3-25)38-21(9)40-17-14(32)15(33)22(41-18(17)19(34)35)39-16-10(24-6(2)28)20(36)37-8(4-26)12(16)30/h7-18,20-22,25-26,29-33,36H,3-4H2,1-2H3,(H,23,27)(H,24,28)(H,34,35)/t7-,8-,9-,10-,11-,12-,13-,14-,15-,16-,17+,18+,20-,21+,22-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5_2*NCC/3=O][a2122A-1b_1-5]/1-2-1/a3-b1_b4-c1",GlyTouCan accession,G63629SO
7095,145625,beta-D-GalpNAc-(1->4)-[beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,"A member of the class of neuraminic acids that is neuraminic acid attached in sequence to beta-D-galactopyranosyl, 2-acetamido-2-deoxy-beta-D-glucopyranosyl, beta-D-galactopyranosyl, and beta-D-glucopyranosyl, residues by (2->3), (1->3), (1->3) and (1->4) glycosidic linkages. The galactosyl residue attached to the neuraminic acid is glycosylated at position 4 by a beta-D-acetamidogalactosyl residue, while the other galactosyl residue has been glycosylated at position 4 by a 2-acetamido-beta-D-galactopyranosyl residue.","InChI=1S/C53H88N4O39/c1-13(65)54-25-17(69)5-53(52(82)83,95-43(25)29(71)18(70)6-58)96-45-38(80)51(89-24(12-64)41(45)92-48-27(56-15(3)67)34(76)31(73)20(8-60)86-48)93-42-28(57-16(4)68)49(87-21(9-61)32(42)74)94-44-37(79)50(90-39-22(10-62)84-46(81)36(78)35(39)77)88-23(11-63)40(44)91-47-26(55-14(2)66)33(75)30(72)19(7-59)85-47/h17-51,58-64,69-81H,5-12H2,1-4H3,(H,54,65)(H,55,66)(H,56,67)(H,57,68)(H,82,83)/t17-,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30-,31-,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42+,43+,44+,45+,46+,47-,48-,49-,50-,51-,53-/m0/s1","WURCS=2.0/5,7,6/[a2122h-1b_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][Aad21122h-2a_2-6_5*NCC/3=O][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-2-4-5-5/a4-b1_b3-c1_b4-g1_c3-d1_d3-e2_d4-f1",GlyTouCan accession,G64919UI
7096,145626,beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,"An amino trisaccharide consisting of beta-D-mannose, beta-D-2-acetamido-2-deoxyglucose and alpha-D-2-acetamido-2-deoxyglucose residues joined by sequential (1->4)-linkages.","InChI=1S/C22H38N2O16/c1-6(28)23-11-14(31)18(9(4-26)36-20(11)35)39-21-12(24-7(2)29)15(32)19(10(5-27)38-21)40-22-17(34)16(33)13(30)8(3-25)37-22/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18-,19-,20+,21+,22+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G65996GC
7097,145627,beta-D-Glcp-(1->3)-alpha-D-GlcpNAc,An amino disaccharide that is an N-acetyl-alpha-D-glucosamine in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranoside.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10+,11-,12-,13+,14+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G67600YJ
7098,145628,6-deoxy-beta-D-allopyranose,A deoxyallose that is beta-D-allopyranose in which the hydroxy group at position 6 has been replaced by a hydrogen.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3-,4-,5-,6-/m1/s1","WURCS=2.0/1,1,0/[a2222m-1b_1-5]/1/",GlyTouCan accession,G70332TM
7099,145629,sambubiose,A disaccharide consisting of beta-D-xylose and beta-D-glucose linked via a 1->2 glycosidic bond.,"InChI=1S/C11H20O10/c12-1-4-6(15)7(16)9(10(18)20-4)21-11-8(17)5(14)3(13)2-19-11/h3-18H,1-2H2/t3-,4-,5+,6-,7+,8-,9-,10-,11+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5][a212h-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G71587NH
7100,145630,CID 91859537,"A polysaccharide consisting of alpha-D-Glcp-(1->2)-alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-beta-D-Manp-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc in which the beta-D-Manp- residue attached to the beta-D-Glcp residue is glycosylated at position 6 by an alpha-D-mannopyranosyl group, which in turn is substituted at positions 3 and 6 by 2-O-alpha-D-mannopyranosyl-alpha-D-mannopyranosyl groups.","InChI=1S/C88H148N2O71/c1-17(103)89-33-47(117)64(29(13-101)137-75(33)134)151-76-34(90-18(2)104)48(118)65(30(14-102)148-76)152-83-63(133)69(46(116)32(150-83)15-135-77-60(130)68(155-86-72(54(124)40(110)24(8-96)145-86)159-80-59(129)51(121)37(107)21(5-93)140-80)45(115)31(149-77)16-136-84-70(52(122)38(108)22(6-94)143-84)157-78-57(127)49(119)35(105)19(3-91)138-78)156-87-74(56(126)42(112)25(9-97)146-87)161-88-73(55(125)41(111)26(10-98)147-88)160-82-61(131)66(43(113)27(11-99)142-82)153-81-62(132)67(44(114)28(12-100)141-81)154-85-71(53(123)39(109)23(7-95)144-85)158-79-58(128)50(120)36(106)20(4-92)139-79/h19-88,91-102,105-134H,3-16H2,1-2H3,(H,89,103)(H,90,104)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58-,59+,60+,61+,62-,63+,64-,65-,66+,67+,68+,69+,70+,71-,72+,73+,74+,75+,76+,77+,78-,79-,80-,81-,82-,83+,84+,85-,86-,87-,88+/m1/s1","WURCS=2.0/5,14,13/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a2122h-1a_1-5]/1-2-3-4-4-4-5-5-5-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-j1_d2-e1_e2-f1_f3-g1_g3-h1_h2-i1_j3-k1_j6-m1_k2-l1_m2-n1",GlyTouCan accession,G72079JG
7101,145631,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc,A high-mannose oligosaccharide and an amino nonasaccharide that is alpha-D-Manp-(1->3)-alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-alpha-D-GlcpNAc in which position 2 of the alpha-D-mannopyranosyl group at the end of the shortest branch from the chitobiose moiety has been converted to the corresponding alpha-D-mannopyranoside.,"InChI=1S/C58H98N2O46/c1-12(69)59-23-32(78)43(20(9-67)91-50(23)89)100-51-24(60-13(2)70)33(79)44(21(10-68)98-51)101-55-42(88)46(103-57-49(38(84)29(75)17(6-64)96-57)106-58-48(37(83)28(74)18(7-65)97-58)105-54-40(86)35(81)26(72)15(4-62)94-54)31(77)22(99-55)11-90-52-41(87)45(30(76)19(8-66)92-52)102-56-47(36(82)27(73)16(5-63)95-56)104-53-39(85)34(80)25(71)14(3-61)93-53/h14-58,61-68,71-89H,3-11H2,1-2H3,(H,59,69)(H,60,70)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43-,44-,45+,46+,47+,48+,49+,50+,51+,52+,53-,54-,55+,56-,57-,58-/m1/s1","WURCS=2.0/4,9,8/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_e2-f1_g3-h1_h2-i1",GlyTouCan accession,G72103RY
7102,145632,beta-D-Glcp-(1->3)-beta-D-Xylp,A glycosylxylose that is beta-D-xylopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranoside.,"InChI=1S/C11H20O10/c12-1-4-5(14)6(15)7(16)11(20-4)21-9-3(13)2-19-10(18)8(9)17/h3-18H,1-2H2/t3-,4-,5-,6+,7-,8-,9+,10-,11+/m1/s1","WURCS=2.0/2,2,1/[a212h-1b_1-5][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G74351TO
7103,145633,beta-D-Glcp-(1->2)-beta-D-Glcp-(1->2)-beta-D-Glcp,A glucotriose consisting of three molecules of beta-D-glucopyranose joined in a linear sequence by 1->2 glycosidic linkages.,"InChI=1S/C18H32O16/c19-1-4-8(23)11(26)14(16(29)30-4)33-18-15(12(27)9(24)6(3-21)32-18)34-17-13(28)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16-,17+,18+/m1/s1","WURCS=2.0/1,3,2/[a2122h-1b_1-5]/1-1-1/a2-b1_b2-c1",GlyTouCan accession,G74665DT
7104,145634,alpha-L-Arap-(1->6)-beta-D-Glcp,A disaccharide that is beta-D-glucopyranose in which the hydroxy group at position 6 has been converted into the corresponding alpha-L-arabinopyranoside.,"InChI=1S/C11H20O10/c12-3-1-19-11(9(17)5(3)13)20-2-4-6(14)7(15)8(16)10(18)21-4/h3-18H,1-2H2/t3-,4+,5-,6+,7-,8+,9+,10+,11-/m0/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5][a211h-1a_1-5]/1-2/a6-b1",GlyTouCan accession,G74740WV
7105,145635,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)-alpha-D-GalpNAc,"A tetrasaccharide derivative consisting of alpha-L-fucose, beta-D-galactose and two N-acetyl-alpha-D-galactosamine residues joined in sequence by (1->2), (1->3) and (1->3) glycosidic bonds.","InChI=1S/C28H48N2O20/c1-7-15(36)19(40)21(42)27(44-7)50-24-20(41)16(37)10(4-31)47-28(24)49-23-14(30-9(3)35)26(46-12(6-33)18(23)39)48-22-13(29-8(2)34)25(43)45-11(5-32)17(22)38/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16-,17-,18-,19+,20-,21-,22+,23+,24+,25-,26+,27-,28-/m0/s1","WURCS=2.0/3,4,3/[a2112h-1a_1-5_2*NCC/3=O][a2112h-1b_1-5][a1221m-1a_1-5]/1-1-2-3/a3-b1_b3-c1_c2-d1",GlyTouCan accession,G74960IM
7106,145636,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,"An amino octasaccharide consisting of four beta-D-galactopyranosyl-(1->4)-beta-D-N-acetylglucosamine disaccharides linked together by (1->3) glycosidic linkage, but with beta-D-glucopyranose replacing beta-D-N-acetylglucosamine as the terminal monosaccharide.","InChI=1S/C54H91N3O41/c1-12(66)55-23-30(73)40(92-51-36(79)33(76)26(69)15(4-58)85-51)20(9-63)89-48(23)96-44-27(70)16(5-59)86-52(37(44)80)93-41-21(10-64)90-49(24(31(41)74)56-13(2)67)97-45-28(71)17(6-60)87-53(38(45)81)94-42-22(11-65)91-50(25(32(42)75)57-14(3)68)98-46-29(72)18(7-61)88-54(39(46)82)95-43-19(8-62)84-47(83)35(78)34(43)77/h15-54,58-65,69-83H,4-11H2,1-3H3,(H,55,66)(H,56,67)(H,57,68)/t15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26+,27+,28+,29+,30-,31-,32-,33+,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44+,45+,46+,47-,48+,49+,50+,51+,52+,53+,54+/m1/s1","WURCS=2.0/3,8,7/[a2122h-1b_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3-2-3-2-3-2/a4-b1_b3-c1_c4-d1_d3-e1_e4-f1_f3-g1_g4-h1",GlyTouCan accession,G77285LE
7107,145637,beta-D-Galp-(1->4)-beta-D-Xylp,A glycosylxylose that is beta-D-xylopyranose in which the hydroxy group at position 4 has been converted into the corresponding beta-D-galactopyranoside.,"InChI=1S/C11H20O10/c12-1-3-5(13)7(15)9(17)11(20-3)21-4-2-19-10(18)8(16)6(4)14/h3-18H,1-2H2/t3-,4-,5+,6+,7+,8-,9-,10-,11+/m1/s1","WURCS=2.0/2,2,1/[a212h-1b_1-5][a2112h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G78098IA
7108,145638,beta-D-Glcp-(1->3)-alpha-L-Arap,A glycosylarabinose that is alpha-L-arabinopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranoside.,"InChI=1S/C11H20O10/c12-1-4-5(14)6(15)7(16)11(20-4)21-9-3(13)2-19-10(18)8(9)17/h3-18H,1-2H2/t3-,4+,5+,6-,7+,8+,9-,10+,11-/m0/s1","WURCS=2.0/2,2,1/[a211h-1a_1-5][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G80637HO
7109,145639,6-deoxy-beta-D-gulopyranose,A deosygulose that is beta-D-gulopyranose in which the hydroxy group at position 6 has been replaced by a hydrogen.,"InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4-,5-,6-/m1/s1","WURCS=2.0/1,1,0/[a2212m-1b_1-5]/1/",GlyTouCan accession,G83797YW
7110,145640,beta-D-Glcp(1->2)-[beta-D-Glcp-(1->3)]-beta-D-Galp,A trisaccharide that is beta-D-galactopyranose in which the hydroxy groups at positions 2 and 3 have each been converted into the corresponding beta-D-glucopyranoside.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)12(27)17(31-4)33-14-9(24)6(3-21)30-16(29)15(14)34-18-13(28)11(26)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11+,12-,13-,14+,15-,16-,17+,18+/m1/s1","WURCS=2.0/2,3,2/[a2112h-1b_1-5][a2122h-1b_1-5]/1-2-2/a2-b1_a3-c1",GlyTouCan accession,G87711HP
7111,145641,beta-D-GalpNAc-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp,"An amino trisaccharide consisting of N-acetyl-beta-D-galactopyranosamine, beta-D-galactopyranose and beta-D-glucopyranose residues joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(25)21-9-11(27)10(26)6(2-22)34-19(9)36-17-8(4-24)35-20(15(31)13(17)29)37-16-7(3-23)33-18(32)14(30)12(16)28/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11-,12-,13-,14-,15-,16-,17+,18-,19+,20+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1b_1-5][a2112h-1b_1-5][a2112h-1b_1-5_2*NCC/3=O]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G90562PB
7112,145642,6-PEA-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->4)alpha-D-GlcpN,"An amino tetrasaccharide consisting of a 6-O-[(2-aminoethoxy)(hydroxy)phosphoryl-alpha-D-mannopyranosyl residue, two alpha-D-mannopyranosyl residues, and a 2-amino-alpha-D-glucose residue linked together in sequence by (1->2), (1->6) and (1->4) glycosidic bonds.","InChI=1S/C26H49N2O23P/c27-1-2-44-52(41,42)45-6-10-14(33)17(36)20(39)25(49-10)51-22-18(37)12(31)7(3-29)47-26(22)43-5-9-13(32)16(35)19(38)24(48-9)50-21-8(4-30)46-23(40)11(28)15(21)34/h7-26,29-40H,1-6,27-28H2,(H,41,42)/t7-,8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19+,20+,21-,22+,23+,24-,25-,26+/m1/s1","WURCS=2.0/3,4,3/[a2122h-1a_1-5_2*N][a1122h-1a_1-5][a1122h-1a_1-5_6*OP^XOCCN/3O/3=O]/1-2-2-3/a4-b1_b6-c1_c2-d1",GlyTouCan accession,G91079GH
7113,145643,beta-D-Xylp-(1->2)-beta-D-GlcpA,A beta-D-Xylp-(1->2)-D-GlcpA in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C11H18O11/c12-2-1-20-11(6(16)3(2)13)22-8-5(15)4(14)7(9(17)18)21-10(8)19/h2-8,10-16,19H,1H2,(H,17,18)/t2-,3+,4+,5+,6-,7+,8-,10-,11+/m1/s1","WURCS=2.0/2,2,1/[a2122A-1b_1-5][a212h-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G91727DR
7114,145646,beta-D-Glcp-(1->6)-beta-D-Glcp-(1->6)-beta-D-Glcp,A glucotriose consisting of three molecules of beta-D-glucopyranose joined in a linear sequence by 1->6 glycosidic linkages.,"InChI=1S/C18H32O16/c19-1-4-7(20)11(24)14(27)17(33-4)31-3-6-9(22)12(25)15(28)18(34-6)30-2-5-8(21)10(23)13(26)16(29)32-5/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16-,17-,18-/m1/s1","WURCS=2.0/1,3,2/[a2122h-1b_1-5]/1-1-1/a6-b1_b6-c1",GlyTouCan accession,G99739TG
7115,145704,beta-D-Galp6N(+)-(1->4)-[beta-D-GalpA(-)-(1->4)-beta-D-Glcp-(1->6)]-beta-D-GlcpNAc-OMe,"A methyl glycoside that is beta-D-Gal-(1->4)-[beta-D-Gal-(1->4)-beta-D-Glc-(1->6)]-beta-D-GlcNAc in which the CH2OH of the galactose within the trisaccharide chain is replaced by anionic carboxylate, the hydroxy group at position 6 of the galactose residue linked to O-4 of the reducing end glucosaminyl residue is replaced by an ammoniumyl group and the hydroxy group at the reducing-end anomeric centre is methylated.","InChI=1S/C27H46N2O21/c1-6(31)29-10-12(33)21(49-26-17(38)13(34)11(32)7(3-28)45-26)9(47-24(10)43-2)5-44-25-19(40)16(37)20(8(4-30)46-25)48-27-18(39)14(35)15(36)22(50-27)23(41)42/h7-22,24-27,30,32-40H,3-5,28H2,1-2H3,(H,29,31)(H,41,42)/t7-,8-,9-,10-,11+,12-,13+,14+,15-,16-,17-,18-,19-,20-,21-,22+,24-,25-,26+,27-/m1/s1",GalA(-)beta1-4Glcbeta1-6(Gal6N(+)beta1-4)GlcNAcbetaOMe,PubMed citation,31546911
7116,145722,beta-D-Galp-(1->4)-[alpha-L-Rhap-(1->3)]-beta-D-Glcp-OMe,A methyl glycoside that is beta-D-Galp-(1->4)-[alpha-L-Rhap-(1->3)]-beta-D-Glcp (RhaLac) in which the hydroxy group at the reducing-end anomeric centre is methylated.,"InChI=1S/C19H34O15/c1-5-8(22)10(24)12(26)18(30-5)34-16-14(28)17(29-2)32-7(4-21)15(16)33-19-13(27)11(25)9(23)6(3-20)31-19/h5-28H,3-4H2,1-2H3/t5-,6+,7+,8+,9-,10+,11-,12-,13+,14+,15+,16+,17+,18-,19-/m0/s1",Rhaalpha1-3(Galbeta1-4)GlcbetaOMe,PubMed citation,31666308
7117,145728,"3beta-hydroxy-9beta-9,19-cyclolanost-24-en-28-oic acid","A steroid acid that is 4beta,14-dimethyl-5alpha,9beta-9,19-cyclocholest-24-en-3beta-ol in which the 4alpha hydrogen has been replaced by a carboxy group.","InChI=1S/C30H48O3/c1-19(2)8-7-9-20(3)21-12-14-27(5)22-10-11-23-28(6,25(32)33)24(31)13-15-29(23)18-30(22,29)17-16-26(21,27)4/h8,20-24,31H,7,9-18H2,1-6H3,(H,32,33)/t20-,21-,22+,23+,24+,26-,27+,28+,29-,30+/m1/s1","4alpha-carboxy-4beta,14alpha-dimethyl-9beta,19-cyclo-5alpha-cholest-24-en-3beta-ol",MetaCyc accession,CPD-12919
7118,145774,"alpha-Neu5d5N;1,5-lactam-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc6SO3Na-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-O{[2-(C14H29)]C16H32}","A neoglycolipid consisting of a branched hexasaccharide made up from one lactamized sialyl residue, two galactose residues, onr fucose residue, one N-acetyl-6-sulfonatoglucosamine residue (with associated sodium cation) and one glucose residue, which at the reducing end is attached glycosidically to a 2-(tetradecyl)hexadecyl group.","InChI=1S/C71H128N2O34S.Na/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-40(30-28-26-24-22-20-18-16-14-12-10-8-6-2)36-95-66-56(88)54(86)59(45(35-77)100-66)102-68-57(89)63(51(83)43(33-75)98-68)105-65-48(72-39(4)78)62(104-67-55(87)53(85)49(81)38(3)97-67)60(46(101-65)37-96-108(92,93)94)103-69-58(90)64(52(84)44(34-76)99-69)107-71-31-41(79)47(73-70(71)91)61(106-71)50(82)42(80)32-74;/h38,40-69,74-77,79-90H,5-37H2,1-4H3,(H,72,78)(H,73,91)(H,92,93,94);/q;+1/p-1/t38-,41-,42+,43+,44+,45+,46+,47+,48+,49+,50+,51-,52-,53+,54+,55-,56+,57+,58+,59+,60+,61+,62+,63-,64-,65-,66+,67-,68-,69-,71-;/m0./s1","2-(tetradecyl)hexadecyl 6-deoxy-alpha-L-galactopyranosyl-(1->3)-[(5-amino-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosyl 1,5-lactam)-(2->3)-beta-D-galactopyranosyl-( 1->4)]-(2-acetamido-2-deoxy-6-O-sulfo-beta-D-glucopyranosyl)-(1->3)-(beta-D-galactopyranosyl)-(1->4)-beta-D-glucopyranoside sodium salt",PubMed citation,16133830
7119,145777,beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine,A member of the class of chitobioses consisting of N-acetyl-D-glucosamine having a beta-D-glucosaminyl residue attached at the 4-position.,"InChI=1S/C14H26N2O10/c1-4(19)16-8-11(22)12(6(3-18)24-13(8)23)26-14-7(15)10(21)9(20)5(2-17)25-14/h5-14,17-18,20-23H,2-3,15H2,1H3,(H,16,19)/t5-,6-,7-,8-,9-,10-,11-,12-,13?,14+/m1/s1",beta-D-GlcN-(1->4)-GlcNAc,PubMed citation,28130448
7120,145800,AS1842856,"A quinolone that is 4-quinolone substituted at positions 1, 3, 5, 6 and 7 by ethyl, carboxy, amino, fluorine, and cyclohexylamino groups, respectively. It can directly bind to and block the transcription activity of the active forkhead box protein O1 (Foxo1), but not the Ser256-phosphorylated form. It induces cell death and growth arrest in Burkitt lymphoma cell lines at low concentrations.","InChI=1S/C18H22FN3O3/c1-2-22-9-11(18(24)25)17(23)14-13(22)8-12(15(19)16(14)20)21-10-6-4-3-5-7-10/h8-10,21H,2-7,20H2,1H3,(H,24,25)",FOXO1 inhibitor,PubMed citation,20736318
7121,145885,Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,A high-mannose oligosaccharide consisting of alpha-D-Glcp-(1->3)-alpha-D-Glcp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc.,"InChI=1S/C82H138N2O66/c1-16(96)83-31-44(109)60(27(12-94)128-70(31)125)141-71-32(84-17(2)97)45(110)61(28(13-95)138-71)142-78-59(124)65(146-81-69(52(117)39(104)23(8-90)136-81)150-82-68(51(116)38(103)24(9-91)137-82)149-77-58(123)63(41(106)26(11-93)133-77)144-76-57(122)62(40(105)25(10-92)132-76)143-73-53(118)46(111)33(98)18(3-85)129-73)43(108)30(140-78)14-126-72-56(121)64(145-80-67(50(115)37(102)22(7-89)135-80)148-75-55(120)48(113)35(100)20(5-87)131-75)42(107)29(139-72)15-127-79-66(49(114)36(101)21(6-88)134-79)147-74-54(119)47(112)34(99)19(4-86)130-74/h18-82,85-95,98-125H,3-15H2,1-2H3,(H,83,96)(H,84,97)/t18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46+,47+,48+,49+,50+,51+,52+,53-,54+,55+,56+,57-,58+,59+,60-,61-,62+,63+,64+,65+,66+,67+,68+,69+,70?,71+,72+,73-,74-,75-,76-,77-,78+,79+,80-,81-,82-/m1/s1","WURCS=2.0/5,13,12/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a2122h-1a_1-5]/1-2-3-4-4-4-5-5-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-i1_d2-e1_e2-f1_f3-g1_g3-h1_i3-j1_i6-l1_j2-k1_l2-m1",GlyTouCan accession,G13746SQ
7122,145887,alpha-D-Manp-(1->6)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-2-D-GlcpNAc,"A high-mannose oligosaccharide that is beta-D-mannopyranose in which the hydrogens of hydroxy groups are replaced by an alpha-D-mannopyranosyl-group at position 6, an alpha-D-mannopyranosyl-(1right2)-alpha-D-mannopyranosyl-(1right2)-alpha-D-mannopyranosyl group at position 3, and a chitobiose group at position 1.","InChI=1S/C46H78N2O36/c1-10(55)47-19-26(62)35(16(7-53)73-40(19)71)80-41-20(48-11(2)56)27(63)36(17(8-54)78-41)81-44-34(70)37(25(61)18(79-44)9-72-42-32(68)28(64)21(57)12(3-49)74-42)82-45-39(31(67)24(60)14(5-51)76-45)84-46-38(30(66)23(59)15(6-52)77-46)83-43-33(69)29(65)22(58)13(4-50)75-43/h12-46,49-54,57-71H,3-9H2,1-2H3,(H,47,55)(H,48,56)/t12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28+,29+,30+,31+,32+,33+,34+,35-,36-,37+,38+,39+,40?,41+,42+,43-,44+,45-,46-/m1/s1","WURCS=2.0/4,7,6/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_e2-f1",GlyTouCan accession,G24599MW
7123,145889,beta-D-Glc-(1->4)-GlcNAc,An amino disaccharide consisting of beta-D-glucose linked via a (1->3)-glycosidic bond to N-acetyl-D-glucosamine.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)12(6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10+,11-,12-,13?,14+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G73545YE
7124,145891,Glc(a1-2)Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,A high-mannose oligosaccharide that is Glc(a1-3)Glc(a1-3)Man(a1-2)Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-3)[Man(a1-2)Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc in which the initial (alpha-1->3)-D-glucosyl residue has been glycosylated at position 2 by an alpha-D-glucopyranosyl group.,"InChI=1S/C88H148N2O71/c1-17(103)89-33-47(117)64(29(13-101)137-75(33)134)151-76-34(90-18(2)104)48(118)65(30(14-102)148-76)152-83-63(133)69(46(116)32(150-83)15-135-77-60(130)68(155-86-72(54(124)40(110)24(8-96)145-86)159-80-59(129)51(121)37(107)21(5-93)140-80)45(115)31(149-77)16-136-84-70(52(122)38(108)22(6-94)143-84)157-78-57(127)49(119)35(105)19(3-91)138-78)156-87-74(56(126)42(112)25(9-97)146-87)161-88-73(55(125)41(111)26(10-98)147-88)160-82-61(131)66(43(113)27(11-99)142-82)153-81-62(132)67(44(114)28(12-100)141-81)154-85-71(53(123)39(109)23(7-95)144-85)158-79-58(128)50(120)36(106)20(4-92)139-79/h19-88,91-102,105-134H,3-16H2,1-2H3,(H,89,103)(H,90,104)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58-,59+,60+,61+,62-,63+,64-,65-,66+,67+,68+,69+,70+,71-,72+,73+,74+,75?,76+,77+,78-,79-,80-,81-,82-,83+,84+,85-,86-,87-,88-/m1/s1","WURCS=2.0/5,14,13/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a2122h-1a_1-5]/1-2-3-4-4-4-5-5-5-4-4-4-4-4/a4-b1_b4-c1_c3-d1_c6-j1_d2-e1_e2-f1_f3-g1_g3-h1_h2-i1_j3-k1_j6-m1_k2-l1_m2-n1",GlyTouCan accession,G87784HD
7125,145895,"(S,S)-2,5-di-(p-hydroxybenzyl)piperazine",A member of the class of piperazines that is piperazine in which the pro-S hydrogens at positions 2 and 5 have each been replaced by a p-hydroxybenzyl group.,"InChI=1S/C18H22N2O2/c21-17-5-1-13(2-6-17)9-15-11-20-16(12-19-15)10-14-3-7-18(22)8-4-14/h1-8,15-16,19-22H,9-12H2/t15-,16-/m0/s1","(S,S)-2,5-di-(4-hydroxybenzyl)piperazine",PubMed citation,27690412
7126,145983,"4-{2-[(2-hydroxybenzyl)amino]ethyl}-2,5-dimethoxybenzonitrile(1+)","An ammonium ion derivative resulting from the protonation of the amino group of 4-{2-[(2-hydroxybenzyl)amino]ethyl}-2,5-dimethoxybenzonitrile.","InChI=1S/C18H20N2O3/c1-22-17-10-15(11-19)18(23-2)9-13(17)7-8-20-12-14-5-3-4-6-16(14)21/h3-6,9-10,20-21H,7-8,12H2,1-2H3/p+1","2-([2-(4-cyano-2,5-dimethoxyphenyl)ethylamino]methyl)phenol(1+)",Wikipedia accession,25CN-NBOH
7127,146019,alpha-D-Man-(1->2)-alpha-D-Man-(1->6)-alpha-D-Man-(1->4)-beta-D-GlcN-O[CH2]6SH,"A linear tetrasaccharide derivative consisting of three alpha-D-mannose residues and one beta-D-glucosamine residue,  linked sequentially (1->2), (1->6) and (1->4), with the glucosamine residue linked glycosidically to a 6-sulfanylhexyl group.","InChI=1S/C30H55NO20S/c31-15-19(38)25(13(9-34)48-27(15)44-5-3-1-2-4-6-52)50-29-24(43)21(40)18(37)14(49-29)10-45-30-26(22(41)17(36)12(8-33)47-30)51-28-23(42)20(39)16(35)11(7-32)46-28/h11-30,32-43,52H,1-10,31H2/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20+,21+,22+,23+,24+,25-,26+,27-,28-,29-,30+/m1/s1",6-mercaptohexyl alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-beta-D-glucosaminide,PubMed citation,31573796
7128,146032,beta-D-Glcp-(1->3)-beta-D-Glcp-(1->3)-beta-D-Glcp,A glucotriose composed of three beta-D-glucose units joined by two (1->3)-linkages.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)11(26)17(31-4)34-15-9(24)6(3-21)32-18(13(15)28)33-14-8(23)5(2-20)30-16(29)12(14)27/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11-,12-,13-,14+,15+,16-,17+,18+/m1/s1","WURCS=2.0/1,3,2/[a2122h-1b_1-5]/1-1-1/a3-b1_b3-c1",GlyTouCan accession,G00024MO
7129,146034,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-D-Glc-ol,"A glycosyl alditol that is D-glucitol in which the hydroxy groups at positions 3 and 4 have been converted to the corresponding 6-deoxy-alpha-L-galactopyranoside (also known as alpha-L-fucoside) and beta-D-galactopyranoside, respectively.","InChI=1S/C18H34O15/c1-5-9(24)11(26)13(28)17(30-5)32-15(6(22)2-19)16(7(23)3-20)33-18-14(29)12(27)10(25)8(4-21)31-18/h5-29H,2-4H2,1H3/t5-,6-,7+,8+,9+,10-,11+,12-,13-,14+,15+,16+,17-,18-/m0/s1","WURCS=2.0/3,3,2/[h2122h][a1221m-1a_1-5][a2112h-1b_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G00025AJ
7130,146041,alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-2-acetamido-2-deoxy-beta-D-GlcpNAc-(1->3)-D-Gal-ol,"An amino tetrasaccharide that is 3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-D-galactitol in which the hydroxy groups at positions 3 and 4 of the acetaminoglucopyranosyl moiety has been glycosylated by D-galactopyranosyl and L-fucosyl groups, respectively.","InChI=1S/C26H47NO20/c1-7-14(35)17(38)19(40)25(42-7)46-22-12(6-31)44-24(45-21(10(34)4-29)15(36)9(33)3-28)13(27-8(2)32)23(22)47-26-20(41)18(39)16(37)11(5-30)43-26/h7,9-26,28-31,33-41H,3-6H2,1-2H3,(H,27,32)/t7-,9+,10-,11+,12+,13+,14+,15-,16-,17+,18-,19-,20+,21+,22+,23+,24-,25-,26-/m0/s1","WURCS=2.0/4,4,3/[h2112h][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3-4/a3-b1_b3-c1_b4-d1",GlyTouCan accession,G00294BL
7131,146048,alpha-D-Manp-(1->1)-D-Man-OH,An glycosyl alditol consisting of alpha-D-mannopyranose and D-mannitol residues joined in sequence by a (1->1) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(15)7(17)8(18)5(16)3-22-12-11(21)10(20)9(19)6(2-14)23-12/h4-21H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+/m1/s1","WURCS=2.0/2,2,1/[h1122h][a1122h-1a_1-5]/1-2/a6-b1",GlyTouCan accession,G00090SL
7132,146061,alpha-D-GlcpNS-(1->4)-alpha-L-IdopA2S-(1->4)-alpha-D-GlcpNS6S-(1->4)-L-IdopA 2S,"An oligosaccharide sulfate consisting of 2-(sulfoamino)-alpha-D-glucopyranosyl, 2-O-sulfo-alpha-L-idopyranuronosyl, 6-O-sulfo-2-sulfoamino-alpha-D-glucopyranosyl and 2-O-sulfo-L-idopyranuronic acid residues joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C24H40N2O36S5/c27-1-3-7(28)8(29)5(25-63(38,39)40)22(54-3)59-14-11(32)16(62-67(50,51)52)24(60-18(14)20(35)36)57-12-4(2-53-65(44,45)46)55-23(6(9(12)30)26-64(41,42)43)58-13-10(31)15(61-66(47,48)49)21(37)56-17(13)19(33)34/h3-18,21-32,37H,1-2H2,(H,33,34)(H,35,36)(H,38,39,40)(H,41,42,43)(H,44,45,46)(H,47,48,49)(H,50,51,52)/t3-,4-,5-,6-,7-,8-,9-,10+,11+,12-,13+,14+,15-,16-,17-,18-,21?,22-,23-,24-/m1/s1","WURCS=2.0/4,4,3/[a2121A-1x_1-5_2*OSO/3=O/3=O][a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O][a2121A-1a_1-5_2*OSO/3=O/3=O][a2122h-1a_1-5_2*NSO/3=O/3=O]/1-2-3-4/a4-b1_b4-c1_c4-d1",GlyTouCan accession,G00423RQ
7133,146069,alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-alpha-D-GlcpNAc-(1->3)-D-Galp,"An amino tetrasaccharide that is 3-O-(2-acetamido-2-deoxy-alpha-D-glucopyranosyl)-D-galactopyranose in which the acetamidoglucosyl group has been glycosylated at positions 3 and 4 by beta-D-galactosyl and alpha-L-fucosyl groups, respectively.","InChI=1S/C26H45NO20/c1-6-12(32)15(35)17(37)25(41-6)45-20-10(5-30)44-24(47-22-14(34)9(4-29)42-23(40)19(22)39)11(27-7(2)31)21(20)46-26-18(38)16(36)13(33)8(3-28)43-26/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15+,16-,17-,18+,19+,20+,21+,22-,23?,24+,25-,26-/m0/s1","WURCS=2.0/4,4,3/[a2112h-1x_1-5][a2122h-1a_1-5_2*NCC/3=O][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3-4/a3-b1_b3-c1_b4-d1",KEGG GLYCAN accession,G07177
7134,146070,alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-QuipNAc,"A branched trisaccharide that is 2-acetamido-beta-D-quinovose (= 2-acetamido-2,6-dideoxy-beta-D-glucopyranose) which has been glycosylated at positions 3 and 4 by beta-D-galactopyranosyl and alpha-L-fucopyranosyl (= 6-deoxy-alpha-L-galactopyranosyl) groups, respectively.","InChI=1S/C20H35NO14/c1-5-10(24)12(26)14(28)19(32-5)34-16-6(2)31-18(30)9(21-7(3)23)17(16)35-20-15(29)13(27)11(25)8(4-22)33-20/h5-6,8-20,22,24-30H,4H2,1-3H3,(H,21,23)/t5-,6+,8+,9+,10+,11-,12+,13-,14-,15+,16+,17+,18+,19-,20-/m0/s1","WURCS=2.0/3,3,2/[a2122m-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G00457KD
7135,146071,alpha-D-Glcp-(1->2)-beta-D-Glcp-(1->6)-D-Glcp,"A glucotriose consisting of alpha-D-glucopyranose, beta-D-glucopyranose and D-glucopyranose attached in sequence by (1->2) and (1->6) glycosidic linkages.","InChI=1S/C18H32O16/c19-1-4-7(21)11(25)14(28)17(32-4)34-15-12(26)8(22)5(2-20)33-18(15)30-3-6-9(23)10(24)13(27)16(29)31-6/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16?,17-,18-/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1b_1-5][a2122h-1a_1-5]/1-2-3/a6-b1_b2-c1",GlyTouCan accession,G00461ZN
7136,146075,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-D-Glc-OH 2NAc,"An amino tetrasaccharide that is 2-acetamido-2-deoxy-D-glucitol which has been glycosylated at position 4 by a beta-D-mannopyranosyl group, which in turn has been glycosylated at positions 3 and 6 by alpha-D-mannopyranosyl groups.","InChI=1S/C26H47NO21/c1-7(32)27-8(2-28)13(34)22(9(33)3-29)47-26-21(42)23(48-25-20(41)18(39)15(36)11(5-31)45-25)16(37)12(46-26)6-43-24-19(40)17(38)14(35)10(4-30)44-24/h8-26,28-31,33-42H,2-6H2,1H3,(H,27,32)/t8-,9+,10+,11+,12+,13+,14+,15+,16+,17-,18-,19-,20-,21-,22+,23-,24-,25+,26-/m0/s1","WURCS=2.0/3,4,3/[h2122h_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-3/a4-b1_b3-c1_b6-d1",GlyTouCan accession,G00482HJ
7137,146076,alpha-D-Galp-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-Glcp,"A linear tetrasaccharide comprising three successive D-galactosyl residues and a D-glucosyl residue at the reducing end joined by sequential alpha-(1->3)-, alpha-(1->4)- and beta-(1->4)-linkages.","InChI=1S/C24H42O21/c25-1-5-9(29)11(31)15(35)22(40-5)45-20-10(30)6(2-26)41-24(17(20)37)44-19-8(4-28)42-23(16(36)13(19)33)43-18-7(3-27)39-21(38)14(34)12(18)32/h5-38H,1-4H2/t5-,6-,7-,8-,9+,10+,11+,12-,13-,14-,15-,16-,17-,18-,19+,20+,21?,22-,23+,24-/m1/s1","WURCS=2.0/3,4,3/[a2122h-1x_1-5][a2112h-1b_1-5][a2112h-1a_1-5]/1-2-3-3/a4-b1_b4-c1_c3-d1",KEGG GLYCAN accession,G12385
7138,146083,beta-D-GalpNAc4S-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp,"An amino trisaccharide composed of 2-acetamido-4-O-sulfo-beta-D-galactopyranosyl, 2-acetamido-beta-D-glucopyranosyl, and alpha-D-mannopyranose residues coupled in sequence by (1->4) and (1->2) glycosidic bonds.","InChI=1S/C22H38N2O19S/c1-6(28)23-11-14(31)17(9(4-26)39-22(11)42-19-16(33)13(30)8(3-25)38-20(19)34)41-21-12(24-7(2)29)15(32)18(10(5-27)40-21)43-44(35,36)37/h8-22,25-27,30-34H,3-5H2,1-2H3,(H,23,28)(H,24,29)(H,35,36,37)/t8-,9-,10-,11-,12-,13-,14-,15-,16+,17-,18+,19+,20+,21+,22+/m1/s1","WURCS=2.0/3,3,2/[a1122h-1a_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5_2*NCC/3=O_4*OSO/3=O/3=O]/1-2-3/a2-b1_b4-c1",GlyTouCan accession,G00547ZN
7139,146084,beta-D-GlcNAc-(1->6)-[beta-D-Galp-(1->3)]-beta-D-GalpNAc-(1->3)-D-Galp,An amino tetrasaccharide that is beta-D-Galp-beta-D-GalpNAc-D-Glcp in which the acetaminogalactosyl group has undergone formal glycosylation at position 6 by a beta-D-acetaminogalactopyranosyl group.,"InChI=1S/C28H48N2O21/c1-7(34)29-13-19(40)15(36)9(3-31)47-26(13)45-6-12-18(39)23(50-28-21(42)20(41)16(37)10(4-32)48-28)14(30-8(2)35)27(49-12)51-24-17(38)11(5-33)46-25(44)22(24)43/h9-28,31-33,36-44H,3-6H2,1-2H3,(H,29,34)(H,30,35)/t9-,10-,11-,12-,13-,14-,15-,16+,17+,18+,19-,20+,21-,22-,23-,24+,25?,26-,27+,28+/m1/s1","WURCS=2.0/4,4,3/[a2112h-1x_1-5][a2112h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3-4/a3-b1_b3-c1_b6-d1",GlyTouCan accession,G00558IW
7140,146100,beta-D-ManpNAc-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp,An amino trisaccharide consisting of a 2-acetamido-beta-D-mannopyranose residue and two alpha-D-glucopyranose residues joined together in sequence by (1->4)-glycosidic bonds.,"InChI=1S/C20H35NO16/c1-5(25)21-9-11(27)10(26)6(2-22)34-19(9)36-17-8(4-24)35-20(15(31)13(17)29)37-16-7(3-23)33-18(32)14(30)12(16)28/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17-,18+,19+,20-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5][a1122h-1b_1-5_2*NCC/3=O]/1-1-2/a4-b1_b4-c1",GlyTouCan accession,G00674TY
7141,146104,alpha-L-Fucp-(1->3)-[beta-D-Galp6S-(1->4)-beta-D-GlcpNAc 6S-(1->3)-beta-D-Galp-(1->4)]-D-Glc-OH 2NAc 6S,"An amino pentasaccharide that is 2-acetamido-2-deoxy-6-O-sulfo-D-glucitol which has been glycosylated at positions 3 and 4 by 6-deoxy-alpha-L-galactopyranosyl and 6-O-sulfo-beta-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-6-O-sulfo-beta-D-glucopyranosyl-(1->3)-beta-D-galactopyranosyl groups, respectively.","InChI=1S/C34H60N2O34S3/c1-9-18(42)22(46)24(48)32(63-9)67-27(12(4-37)35-10(2)39)28(13(41)6-60-71(51,52)53)68-34-26(50)30(20(44)14(5-38)64-34)70-31-17(36-11(3)40)21(45)29(16(66-31)8-62-73(57,58)59)69-33-25(49)23(47)19(43)15(65-33)7-61-72(54,55)56/h9,12-34,37-38,41-50H,4-8H2,1-3H3,(H,35,39)(H,36,40)(H,51,52,53)(H,54,55,56)(H,57,58,59)/t9-,12-,13+,14+,15+,16+,17+,18+,19-,20-,21+,22+,23-,24-,25+,26+,27+,28+,29+,30-,31-,32-,33-,34-/m0/s1","WURCS=2.0/5,5,4/[h2122h_2*NCC/3=O_6*OSO/3=O/3=O][a1221m-1a_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a2112h-1b_1-5_6*OSO/3=O/3=O]/1-2-3-4-5/a3-b1_a4-c1_c3-d1_d4-e1",GlyTouCan accession,G00705XW
7142,146112,alpha-D-Glcp-(1->6)-alpha-D-Glcp-(1->6)-beta-D-Glcf,"A glucotriose composed of alpha-D-glucopyranose, alpha-D-glucopyranose and beta-D-glucofuranose residues joined in sequence by 1->6 glycosidic linkages.","InChI=1S/C18H32O16/c19-1-5-7(21)9(23)13(27)18(32-5)31-3-6-8(22)10(24)14(28)17(33-6)30-2-4(20)15-11(25)12(26)16(29)34-15/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16-,17+,18+/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-4][a2122h-1a_1-5]/1-2-2/a6-b1_b6-c1",GlyTouCan accession,G00760ZJ
7143,146122,alpha-D-Glcp-(1->6)-[beta-D-Glcp-(1->4)]-D-Glcp,"A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 4 and 6 have been converted into the corresponding beta-D-glucopyranoside and alpha-D-glucopyranoside, respectively.","InChI=1S/C18H32O16/c19-1-4-7(21)9(23)13(27)17(32-4)30-3-6-15(11(25)12(26)16(29)31-6)34-18-14(28)10(24)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16?,17+,18+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1b_1-5][a2122h-1a_1-5]/1-2-3/a4-b1_a6-c1",GlyTouCan accession,G00899CT
7144,146195,3-acetyldeoxynivalenol,"A trichothecene mycotoxin that is deoxynivalenol acetylated on the oxygen at C-3. A skin and eye irritant, along with its 15-acetyl regioisomer and its parent deoxynivalenol it is considered among the most commonly and widely distributed cereal contaminants.","InChI=1S/C17H22O7/c1-8-4-11-16(6-18,13(21)12(8)20)15(3)5-10(23-9(2)19)14(24-11)17(15)7-22-17/h4,10-11,13-14,18,21H,5-7H2,1-3H3/t10-,11-,13-,14-,15-,16-,17+/m1/s1","3-(acetyloxy)-12,13-epoxy-7alpha,15alpha-dihydroxytrichothec-9-en-8-one",PubMed citation,23470877
7145,146205,beta-D-Gal-(1->3)-{alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->6)}-alpha-D-GalNAc,beta-D-Gal-(1->3)-{alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->6)}-D-GalNAc in which the anomeric configuration of the GalNAc residue at the reducing end is alpha.,"InChI=1S/C45H75N3O33/c1-11-24(58)29(63)31(65)41(72-11)79-37-23(48-14(4)55)40(71-10-20-28(62)35(22(39(68)73-20)47-13(3)54)78-42-32(66)30(64)26(60)17(7-50)74-42)76-19(9-52)34(37)77-43-33(67)38(27(61)18(8-51)75-43)81-45(44(69)70)5-15(56)21(46-12(2)53)36(80-45)25(59)16(57)6-49/h11,15-43,49-52,56-68H,5-10H2,1-4H3,(H,46,53)(H,47,54)(H,48,55)(H,69,70)/t11-,15-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29+,30-,31-,32+,33+,34+,35+,36+,37+,38-,39-,40+,41-,42-,43-,45-/m0/s1",Galbeta1-3(Neu5Acalpha2-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6)GalNAcalpha,PubMed citation,31537530
7146,146242,(S)-flufiprole,"A 1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[(2-methylprop-2-en-1-yl)amino]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile that has S configuration at the sulfoxide.","InChI=1S/C16H10Cl2F6N4OS/c1-7(2)6-26-14-13(30(29)16(22,23)24)11(5-25)27-28(14)12-9(17)3-8(4-10(12)18)15(19,20)21/h3-4,26H,1,6H2,2H3/t30-/m0/s1",S-(-)-flufiprole,PubMed citation,27585281
7147,146243,JWH-133,"A dibenzopyran that is Delta(9)-tetrahydrocannabinol which is lacking the hydroxy group and in which the pentyl group at position 3 has been replaced by a 1,1-dimethylbutyl group. A potent and highly selective CB2 receptor agonist.","InChI=1S/C22H32O/c1-7-12-21(3,4)16-9-10-17-18-13-15(2)8-11-19(18)22(5,6)23-20(17)14-16/h8-10,14,18-19H,7,11-13H2,1-6H3/t18-,19+/m0/s1","(6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran",CAS Registry Number,259869-55-1
7148,146245,SR 144528,"A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-1H-pyrazole-3-carboxylic acid with the amino group of (1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-amine. A potent and selective cannabinoid receptor type 2 (CB2 receptor) inverse agonist (Ki = 0.6 nM).","InChI=1S/C29H34ClN3O/c1-18-6-8-20(9-7-18)17-33-25(21-10-11-23(30)19(2)14-21)15-24(32-33)26(34)31-27-28(3,4)22-12-13-29(27,5)16-22/h6-11,14-15,22,27H,12-13,16-17H2,1-5H3,(H,31,34)/t22-,27-,29+/m1/s1",SR-144528,Wikipedia accession,"SR-144,528"
7149,146263,"N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide","A trisaccharide derivative in which alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.","InChI=1S/C46H85N7O22S/c47-33-38(60)37(59)27(22-54)71-44(33)74-42-29(24-56)73-45(35(49)40(42)62)75-41-28(23-55)72-43(34(48)39(41)61)70-9-3-7-50-32(58)6-10-64-12-14-66-16-18-68-20-21-69-19-17-67-15-13-65-11-8-51-31(57)5-2-1-4-30-36-26(25-76-30)52-46(63)53-36/h26-30,33-45,54-56,59-62H,1-25,47-49H2,(H,50,58)(H,51,57)(H2,52,53,63)/t26-,27+,28+,29+,30-,33+,34+,35+,36-,37-,38+,39+,40+,41-,42-,43-,44+,45+/m0/s1","3-(21-biotinamino-4,7,10,13,16,19-hexaoxagenicaminoamino)-propyl 2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranoside",PubMed citation,31913631
7150,146268,"N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide","A hexasaccharide derivative in which alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.","InChI=1S/C64H118N10O34S/c65-39-47(84)46(83)30(22-75)98-59(39)104-54-32(24-77)100-61(41(67)49(54)86)106-56-34(26-79)102-63(43(69)51(56)88)108-57-35(27-80)103-62(44(70)52(57)89)107-55-33(25-78)101-60(42(68)50(55)87)105-53-31(23-76)99-58(40(66)48(53)85)97-9-3-7-71-38(82)6-10-91-12-14-93-16-18-95-20-21-96-19-17-94-15-13-92-11-8-72-37(81)5-2-1-4-36-45-29(28-109-36)73-64(90)74-45/h29-36,39-63,75-80,83-89H,1-28,65-70H2,(H,71,82)(H,72,81)(H2,73,74,90)/t29-,30+,31+,32+,33+,34+,35+,36-,39+,40+,41+,42+,43+,44+,45-,46-,47+,48+,49+,50+,51+,52+,53-,54-,55-,56-,57-,58-,59+,60+,61+,62+,63+/m0/s1","(3aS,4S,6aR)-N-[25-[[O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl]oxy]-21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacos-1-yl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide",PubMed citation,31913631
7151,146269,"N-(3-{[alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide","A disaccharide derivative in which N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.","InChI=1S/C44H78N6O20S/c1-27(53)47-36-39(58)38(57)30(24-51)68-43(36)70-41-31(25-52)69-42(37(40(41)59)48-28(2)54)67-11-5-9-45-34(56)8-12-61-14-16-63-18-20-65-22-23-66-21-19-64-17-15-62-13-10-46-33(55)7-4-3-6-32-35-29(26-71-32)49-44(60)50-35/h29-32,35-43,51-52,57-59H,3-26H2,1-2H3,(H,45,56)(H,46,55)(H,47,53)(H,48,54)(H2,49,50,60)/t29-,30+,31+,32-,35-,36+,37+,38-,39+,40+,41-,42-,43+/m0/s1","N-(3-{[N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxaheptacosan-1-amide",PubMed citation,31913631
7152,146271,"N-(3-{[alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide","A trisaccharide derivative in which N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.","InChI=1S/C52H91N7O25S/c1-29(63)55-40-44(69)43(68)33(25-60)80-50(40)83-48-35(27-62)82-51(42(46(48)71)57-31(3)65)84-47-34(26-61)81-49(41(45(47)70)56-30(2)64)79-12-6-10-53-38(67)9-13-73-15-17-75-19-21-77-23-24-78-22-20-76-18-16-74-14-11-54-37(66)8-5-4-7-36-39-32(28-85-36)58-52(72)59-39/h32-36,39-51,60-62,68-71H,4-28H2,1-3H3,(H,53,67)(H,54,66)(H,55,63)(H,56,64)(H,57,65)(H2,58,59,72)/t32-,33+,34+,35+,36-,39-,40+,41+,42+,43-,44+,45+,46+,47-,48-,49-,50+,51+/m0/s1","3-(21-biotinamino-4,7,10,13,16,19-hexaoxagenicaminoamino)-propyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-galactopyranoside",PubMed citation,31913631
7153,146273,"N-(3-{[alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide","A tetrasaccharide derivative in which N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.","InChI=1S/C60H104N8O30S/c1-31(73)63-44-49(80)48(79)36(26-69)92-57(44)96-54-38(28-71)94-59(46(51(54)82)65-33(3)75)98-55-39(29-72)95-58(47(52(55)83)66-34(4)76)97-53-37(27-70)93-56(45(50(53)81)64-32(2)74)91-13-7-11-61-42(78)10-14-85-16-18-87-20-22-89-24-25-90-23-21-88-19-17-86-15-12-62-41(77)9-6-5-8-40-43-35(30-99-40)67-60(84)68-43/h35-40,43-59,69-72,79-83H,5-30H2,1-4H3,(H,61,78)(H,62,77)(H,63,73)(H,64,74)(H,65,75)(H,66,76)(H2,67,68,84)/t35-,36+,37+,38+,39+,40-,43-,44+,45+,46+,47+,48-,49+,50+,51+,52+,53-,54-,55-,56-,57+,58+,59+/m0/s1","N-(3-{[N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxaheptacosan-1-amide",PubMed citation,31913631
7154,146274,"N-(3-{[alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-(1->4)-alpha-D-GalNAc-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide","A pentasaccharide derivative in which N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosaminyl-(1->4)-N-acetyl-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.","InChI=1S/C68H117N9O35S/c1-33(83)71-48-54(91)53(90)39(27-78)104-64(48)109-60-41(29-80)106-66(50(56(60)93)73-35(3)85)111-62-43(31-82)108-67(52(58(62)95)75-37(5)87)112-61-42(30-81)107-65(51(57(61)94)74-36(4)86)110-59-40(28-79)105-63(49(55(59)92)72-34(2)84)103-14-8-12-69-46(89)11-15-97-17-19-99-21-23-101-25-26-102-24-22-100-20-18-98-16-13-70-45(88)10-7-6-9-44-47-38(32-113-44)76-68(96)77-47/h38-44,47-67,78-82,90-95H,6-32H2,1-5H3,(H,69,89)(H,70,88)(H,71,83)(H,72,84)(H,73,85)(H,74,86)(H,75,87)(H2,76,77,96)/t38-,39+,40+,41+,42+,43+,44-,47-,48+,49+,50+,51+,52+,53-,54+,55+,56+,57+,58+,59-,60-,61-,62-,63-,64+,65+,66+,67+/m0/s1","3-(21-biotinamino-4,7,10,13,16,19-hexaoxagenicaminoamino)-propyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-acetamido-2-deoxy-alpha-D-galactopyranoside",PubMed citation,31913631
7155,146431,alpha-D-Xylp-(1->6)-beta-D-Glcp,An alpha-D-Xylp-(1->6)-D-Glcp in which the carbon bearing the anomeric hydroxy group has beta configuration. The disaccharide unit of xyloglucan in plant cell-walls.,"InChI=1S/C11H20O10/c12-3-1-19-11(9(17)5(3)13)20-2-4-6(14)7(15)8(16)10(18)21-4/h3-18H,1-2H2/t3-,4-,5+,6-,7+,8-,9-,10-,11-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5][a212h-1a_1-5]/1-2/a6-b1",GlyTouCan accession,G00977CB
7156,146438,alpha-D-Galp-(1->3)-alpha-D-Galp-(1->3)-D-Galp,A galactotriose consisting of two alpha-D-galactopyranose and a D-galactopyranose residues joined in sequence by (1->3) gllycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)11(26)17(31-4)34-15-9(24)6(3-21)32-18(13(15)28)33-14-8(23)5(2-20)30-16(29)12(14)27/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10+,11-,12-,13-,14+,15+,16?,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2112h-1x_1-5][a2112h-1a_1-5]/1-2-2/a3-b1_b3-c1",GlyTouCan accession,G02660IC
7157,146446,beta-D-Galp-(1->3)-D-Galp,A disaccharide that is D-galactopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-galactopyranoside.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8-,9-,10+,11?,12+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][a2112h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G02753DE
7158,146464,beta-D-GlcpNAc-(1->3)-D-Galp,An amino disaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose and D-galactopyranose residues joined by a (1->3) glycosidic bond.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)5(2-16)25-14(7)26-12-9(20)6(3-17)24-13(23)11(12)22/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9+,10-,11-,12+,13?,14+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2/a3-b1",GlyTouCan accession,G02880JU
7159,146490,beta-D-Glcp-(1->3)-[beta-D-Glcp-(1->6)]-alpha-D-Glcp,A alpha-D-Glcp-(1->4)-[alpha-D-Glcp-(1->6)]-D-Glcp which has alpha- configuration at the anomeric carbon of the non-terminal glucopyranose ring.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)12(26)17(32-4)30-3-6-9(23)15(14(28)16(29)31-6)34-18-13(27)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12-,13-,14-,15+,16+,17-,18+/m1/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5][a2122h-1b_1-5]/1-2-2/a3-b1_a6-c1",GlyTouCan accession,G03065ZA
7160,146500,D-Galp-(1->3)-D-GalpNAc,An amino disaccharide that is 2-acetamido-2-deoxy-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding D-galactopyranoside. The stereochemistry at the anomeric position in each of the galactopyranose rings is not stated.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9+,10+,11-,12-,13?,14?/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O][a2112h-1x_1-5]/1-2/a3-b1",GlyTouCan accession,G01416HI
7161,146502,beta-L-Fucp-(1->6)-alpha-D-GlcNAc,An amino disaccharide that is 2-acetamido-alpha-D-glucopyranose in which the hydroxy group at position 6 has been converted into the corresponding beta-L-fucopyranoside.,"InChI=1S/C14H25NO10/c1-4-8(17)11(20)12(21)14(24-4)23-3-6-9(18)10(19)7(13(22)25-6)15-5(2)16/h4,6-14,17-22H,3H2,1-2H3,(H,15,16)/t4-,6+,7+,8+,9+,10+,11+,12-,13-,14-/m0/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a1221m-1b_1-5]/1-2/a6-b1",GlyTouCan accession,G01447WV
7162,146519,alpha-L-Arap-(1->2)-[beta-D-Glcp-(1-3)]-alpha-L-Arap,"A trisaccharide that is alpha-L-arabinopyranose which has been glycosylated at positions 2 and 3 by alpha-L-arabinopyranosyl and beta-D-glucopyrnaosyl groups, respectively.","InChI=1S/C16H28O14/c17-1-6-8(21)9(22)11(24)16(28-6)29-12-5(19)3-26-14(25)13(12)30-15-10(23)7(20)4(18)2-27-15/h4-25H,1-3H2/t4-,5-,6+,7-,8+,9-,10+,11+,12-,13+,14+,15-,16-/m0/s1","WURCS=2.0/2,3,2/[a211h-1a_1-5][a2122h-1b_1-5]/1-1-2/a2-b1_a3-c1",GlyTouCan accession,G01543QR
7163,146529,beta-D-Galp-(1->6)-beta-D-Galf,A beta-D-Galp-(1->6)-D-Galf in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C12H22O11/c13-1-4-5(15)6(16)9(19)12(22-4)21-2-3(14)10-7(17)8(18)11(20)23-10/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10+,11-,12-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-4][a2112h-1b_1-5]/1-2/a6-b1",GlyTouCan accession,G01599BJ
7164,146536,beta-L-Galp-(1->6)-D-GalpNAc,An amino disaccharide that is 2-acetamido-2-deoxy-D-galactopyranose in which the hydroxy group at position 6 has been converted into the corresponding beta-L-galactopyranoside.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)9(19)6(25-13(7)23)3-24-14-12(22)11(21)8(18)5(2-16)26-14/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6+,7+,8+,9-,10+,11+,12-,13?,14-/m0/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O][a1221h-1b_1-5]/1-2/a6-b1",GlyTouCan accession,G03313QW
7165,146542,beta-D-GlcN-(1->6)-D-GlcN,An amino disaccharide consisting of 2-amino-2-deoxy-beta-D-glucopyranose and 2-amino-2-deoxy-D-glucopyranose residues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C12H24N2O9/c13-5-9(18)8(17)4(22-11(5)20)2-21-12-6(14)10(19)7(16)3(1-15)23-12/h3-12,15-20H,1-2,13-14H2/t3-,4-,5-,6-,7-,8-,9-,10-,11?,12-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*N][a2122h-1b_1-5_2*N]/1-2/a6-b1",GlyTouCan accession,G03324AT
7166,146563,alpha-L-Fucp-(1->6)-beta-D-Galp-(1->4)-D-GlcpNAc,"An amino trisaccharide consisting of alpha-L-fucopyranose, beta-D-galactopyranose and 2-acetamido-2-deoxy-D-glucopyranose residues joined in sequence by (1->6) and (1->4) glycosidic bonds.","InChI=1S/C20H35NO15/c1-5-10(24)13(27)15(29)19(33-5)32-4-8-11(25)14(28)16(30)20(35-8)36-17-7(3-22)34-18(31)9(12(17)26)21-6(2)23/h5,7-20,22,24-31H,3-4H2,1-2H3,(H,21,23)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18?,19+,20-/m0/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3/a4-b1_b6-c1",GlyTouCan accession,G03443JC
7167,146573,alpha-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-D-Galp,A trisaccharide that is alpha-D-glucopyranosyl-(1->3)-D-galactopyranose in which the hydroxy group at position 4 of the D-galactopyranose moiety has been glycosylated by an alpha-L-fucopyranosyl group.,"InChI=1S/C18H32O15/c1-4-7(21)9(23)11(25)17(29-4)32-14-6(3-20)30-16(28)13(27)15(14)33-18-12(26)10(24)8(22)5(2-19)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8+,9+,10-,11-,12+,13+,14-,15+,16?,17-,18+/m0/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2122h-1a_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G01778PX
7168,146580,Delta(4)-beta-D-GlcpA-(1->3)-beta-D-GalpNAc4S,A Delta(4)-beta-D-GlcpA-(1->3)-D-GalpNAc4S in which the the carbon bearing the anomeric hydroxy group has beta- configuration.,"InChI=1S/C14H21NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-6,8-10,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/t4-,5-,6+,8-,9+,10-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_4*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G01825JS
7169,146582,alpha-D-glucopyranosyl alpha-D-galactopyranoside,A glycosyl glycoside that is alpha-D-galactopyranose in which the anomeric hydroxy group has been converted into the corresponding alpha-D-glucopyranosyl derivative.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)9(19)11(21-3)23-12-10(20)8(18)6(16)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10-,11-,12-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1a_1-5][a2122h-1a_1-5]/1-2/a1-b1",GlyTouCan accession,G01846YN
7170,146583,beta-D-GlcpNAc-(1->3)-beta-L-Fucp,An amino disaccharide that is beta-L-fucose in which the hydroxy group at position 3 has been converted into the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranoside.,"InChI=1S/C14H25NO10/c1-4-8(18)12(11(21)13(22)23-4)25-14-7(15-5(2)17)10(20)9(19)6(3-16)24-14/h4,6-14,16,18-22H,3H2,1-2H3,(H,15,17)/t4-,6+,7+,8+,9+,10+,11-,12+,13-,14-/m0/s1","WURCS=2.0/2,2,1/[a1221m-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2/a3-b1",GlyTouCan accession,G01854VF
7171,146593,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->6)-{alpha-Neup5Ac-(2->6)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)}-beta-D-Galp-(1->4)-D-Glcp,"A branched amino nonasaccharide consisting of a linear sequence of N-acetyl-alpha-neuraminyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl, beta-D-galactosyl and D-glucose residues linked sequentially (2->3), (1->3), (1->3) and (1->4), to the N-acetyl-beta-D-glucosaminyl residue is also linked (2->6) an N-acetyl-alpha-neuraminyl residue, while the galactosyl residue proximal to the reducing end has also linked (1->3) to it an alpha-L-fucosyl (1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl trisaccharide unit.","InChI=1S/C68H112N4O51/c1-16-35(87)42(94)46(98)61(109-16)119-55-34(72-20(5)82)59(113-28(13-78)51(55)117-62-47(99)43(95)38(90)25(10-75)111-62)107-14-29-41(93)56(48(100)63(115-29)116-50-27(12-77)110-58(102)45(97)44(50)96)120-60-33(71-19(4)81)52(40(92)30(114-60)15-108-67(65(103)104)6-21(83)31(69-17(2)79)53(121-67)36(88)23(85)8-73)118-64-49(101)57(39(91)26(11-76)112-64)123-68(66(105)106)7-22(84)32(70-18(3)80)54(122-68)37(89)24(86)9-74/h16,21-64,73-78,83-102H,6-15H2,1-5H3,(H,69,79)(H,70,80)(H,71,81)(H,72,82)(H,103,104)(H,105,106)/t16-,21-,22-,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38-,39-,40+,41-,42+,43-,44+,45+,46-,47+,48+,49+,50+,51+,52+,53+,54+,55+,56-,57-,58?,59+,60-,61-,62-,63-,64-,67+,68-/m0/s1","WURCS=2.0/5,9,8/[a2122h-1x_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][Aad21122h-2a_2-6_5*NCC/3=O][a1221m-1a_1-5]/1-2-3-2-4-4-3-5-2/a4-b1_b3-c1_b6-g1_c3-d1_c6-f2_d3-e2_g3-h1_g4-i1",GlyTouCan accession,G03629LR
7172,146596,Delta(4)-beta-D-GlcpA2S-(1->3)-beta-D-GalpNAc6S,A Delta(4)-beta-D-Glcp-(1->3)-D-GalpNAc6S in which the carbon bearing the anomeric hydroxy group has beta- configuration.,"InChI=1S/C14H21NO18S2/c1-3(16)15-5-9(6(17)4(30-13(5)22)2-29-34(23,24)25)31-14-11(33-35(26,27)28)8(19)7(18)10(32-14)12(20)21/h4-6,8-9,11,13-14,17-19,22H,2H2,1H3,(H,15,16)(H,20,21)(H,23,24,25)(H,26,27,28)/t4-,5-,6+,8+,9-,11-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5_2*OSO/3=O/3=O]/1-2/a3-b1",GlyTouCan accession,G01986HE
7173,146608,beta-D-Galp-(1->3)-alpha-D-Galp-(1->4)-beta-D-Galp,A beta-D-Galp-(1->3)-alpha-D-Galp-(1->4)-D-Galp in which the anomeric hydroxy group has beta configuration,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)12(27)17(31-4)34-15-8(23)5(2-20)32-18(13(15)28)33-14-6(3-21)30-16(29)11(26)10(14)25/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10-,11-,12-,13-,14+,15+,16-,17+,18-/m1/s1","WURCS=2.0/2,3,2/[a2112h-1b_1-5][a2112h-1a_1-5]/1-2-1/a4-b1_b3-c1",GlyTouCan accession,G03723FD
7174,146610,isobemisiose,"A glucotriose that is alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranoside in which the anomeric hydroxy group has been converted into the corresponding alpha-D-glucopyranoside. An unusual trisaccharide abundant in the silverleaf whitefly, Bemisia argentifolii.","InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)16(31-4)30-3-6-9(23)12(26)15(29)18(33-6)34-17-14(28)11(25)8(22)5(2-20)32-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16+,17-,18-/m1/s1","WURCS=2.0/1,3,2/[a2122h-1a_1-5]/1-1-1/a1-b1_b6-c1",GlyTouCan accession,G03723SL
7175,146619,beta-D-GlcpNAc-(1->4)-beta-D-Galp,An amino disaccharide that is beta-D-galactopyranose in which the hydroxy group at position 4 has been converted to the corresponding 2-acetamido-2-deoxy-beta-D-galactopyranoside.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)8(19)5(2-16)25-14(7)26-12-6(3-17)24-13(23)11(22)10(12)21/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10-,11-,12+,13-,14+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2/a4-b1",GlyTouCan accession,G03756VW
7176,146650,alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)-alpha-D-Manp,A mannotetrose consisting of four alpha-D-mannopyranose residues linked by three (1->6) glycosidic bonds.,"InChI=1S/C24H42O21/c25-1-5-9(26)14(31)18(35)22(43-5)40-3-7-11(28)16(33)20(37)24(45-7)41-4-8-12(29)15(32)19(36)23(44-8)39-2-6-10(27)13(30)17(34)21(38)42-6/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+/m1/s1","WURCS=2.0/1,4,3/[a1122h-1a_1-5]/1-1-1-1/a6-b1_b6-c1_c6-d1",GlyTouCan accession,G03889QT
7177,146667,beta-D-Galp-(1->6)-beta-D-Galp-(1->4)-beta-D-Galp-(1->3)-L-Man-OH,"A tetrasaccharide consisting of three beta-D-galactopyranosyl residues and an L-mannitol group joined in sequence by (1->6), (1->4) and (1->3) glycosidic linkages.","InChI=1S/C24H44O21/c25-1-6(29)11(31)20(7(30)2-26)44-24-19(39)16(36)21(9(4-28)42-24)45-23-18(38)15(35)13(33)10(43-23)5-40-22-17(37)14(34)12(32)8(3-27)41-22/h6-39H,1-5H2/t6-,7-,8+,9+,10+,11-,12-,13-,14-,15-,16+,17+,18+,19+,20-,21-,22+,23-,24-/m0/s1","WURCS=2.0/2,4,3/[h2211h][a2112h-1b_1-5]/1-2-2-2/a4-b1_b4-c1_c6-d1",GlyTouCan accession,G03991IC
7178,146669,beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->3)-beta-D-Galp-(1->3)-beta-D-Glcp,"An amino tetrasaccharide consisting of 2-acetamido-beta-D-galactopyranosyl, alpha-D-galactopyranosyl, beta-D-galactopyranosyl and beta-D-glucopyranosyl residues joined in sequence by (1->3) glycosidic bonds.","InChI=1S/C26H45NO21/c1-6(32)27-11-16(37)12(33)7(2-28)43-24(11)46-21-14(35)9(4-30)45-26(18(21)39)48-22-15(36)10(5-31)44-25(19(22)40)47-20-13(34)8(3-29)42-23(41)17(20)38/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13-,14+,15+,16-,17-,18-,19-,20+,21+,22+,23-,24+,25+,26-/m1/s1","WURCS=2.0/4,4,3/[a2122h-1b_1-5][a2112h-1b_1-5][a2112h-1a_1-5][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-4/a3-b1_b3-c1_c3-d1",GlyTouCan accession,G02402HF
7179,146707,alpha-D-Manp-(1->2)-[alpha-D-Manp-(1->6)]-D-Manp,A mannotriose that is D-mannopyranose in which the hydroxy groups at positions 2 and 6 have each been converted into the corresponding alpha-D-mannopyranoside.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)17(32-4)30-3-6-9(23)12(26)15(16(29)31-6)34-18-14(28)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14+,15+,16?,17+,18-/m1/s1","WURCS=2.0/2,3,2/[a1122h-1x_1-5][a1122h-1a_1-5]/1-2-2/a2-b1_a6-c1",GlyTouCan accession,G04400QM
7180,146731,alpha-L-Fucp-(1->3)-beta-D-GlcpNAc-(1->2)-D-Galp,"An amino trisaccharide consisting of alpha-L-fucopyranosyl, 2-acetamido-2-deoxy-beta-D-glucopyranosyl and D-galactopyanosyl residues joined together in sequence by (1->3) and (1->2) glycosidic linkages.","InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)20(32-5)35-16-9(21-6(2)24)19(34-8(4-23)12(16)27)36-17-14(29)11(26)7(3-22)33-18(17)31/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18?,19-,20-/m0/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5]/1-2-3/a2-b1_b3-c1",GlyTouCan accession,G04630LB
7181,146745,beta-D-GlcpNAc-(1->4)-beta-D-Manp-(1->4)-beta-D-GlcpNAc,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranosyl, beta-D-mannopyranosyl and 2-acetamido-beta-D-glucopyranosyl residues joined in sequence by (1->2) and (1->4) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)18(9(4-26)36-20(11)35)40-22-17(34)16(33)19(10(5-27)38-22)39-21-12(24-7(2)29)14(31)13(30)8(3-25)37-21/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17+,18-,19-,20-,21+,22+/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5]/1-2-1/a4-b1_b4-c1",GlyTouCan accession,G04779EY
7182,146757,beta-D-Glcp-(1->6)-D-GlcpNAc,An amino disaccharide that is 2-acetamido-2-deoxy-beta-D-glucopyranose in which the hydroxy group at position 6 has been converted into the corresponding beta-D-glucopyranoside.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)9(19)6(25-13(7)23)3-24-14-12(22)11(21)8(18)5(2-16)26-14/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6-,7-,8-,9-,10-,11+,12-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5]/1-2/a6-b1",GlyTouCan accession,G04941HM
7183,146763,beta-D-GlcpA-(1->3)-D-GalpNAc6S,A carbohydrate sulfate that is 2-acetamido-6-O-sulfo-D-galactopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranuronoside.,"InChI=1S/C14H23NO15S/c1-3(16)15-5-10(6(17)4(28-13(5)23)2-27-31(24,25)26)29-14-9(20)7(18)8(19)11(30-14)12(21)22/h4-11,13-14,17-20,23H,2H2,1H3,(H,15,16)(H,21,22)(H,24,25,26)/t4-,5-,6+,7+,8+,9-,10-,11+,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a2122A-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G05005QI
7184,146770,beta-L-Fucp-(1->4)-beta-D-Galp-(1->4)-D-Glcp,A trisaccharide that is lactose in which the hydroxy group at the 4' position has been converted into the corresponding beta-L-fucopyranoseide.,"InChI=1S/C18H32O15/c1-4-7(21)8(22)12(26)17(29-4)32-15-6(3-20)31-18(13(27)10(15)24)33-14-5(2-19)30-16(28)11(25)9(14)23/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8+,9+,10+,11+,12-,13+,14+,15-,16?,17+,18-/m0/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2112h-1b_1-5][a1221m-1b_1-5]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G05152XR
7185,146772,2-acetamido-2-deoxy-3-O-(beta-D-Galp6S)-D-galactitol,An aminodisaccharide that is 2-acetamido-2-deoxy-D-galactitol in which the hydroxy group at position 3 has been converted into the 6-O-sulfo-beta-D-galactopyranose derivative.,"InChI=1S/C14H27NO14S/c1-5(18)15-6(2-16)13(9(20)7(19)3-17)29-14-12(23)11(22)10(21)8(28-14)4-27-30(24,25)26/h6-14,16-17,19-23H,2-4H2,1H3,(H,15,18)(H,24,25,26)/t6-,7+,8+,9-,10-,11-,12+,13+,14-/m0/s1","WURCS=2.0/2,2,1/[h2112h_2*NCC/3=O][a2112h-1b_1-5_6*OSO/3=O/3=O]/1-2/a3-b1",GlyTouCan accession,G05180BW
7186,146775,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-2-acetamido-2-deoxy-D-Gal-OH,A glycosyl alditol derivative that is 2-acetamido-2-deoxy-D-galactitol in which the hydroxy group at position 3 has been glycosylated by an alpha-L-fucopyranosyl-(1->2) beta-D-galactopyranosyl group.,"InChI=1S/C20H37NO15/c1-6-11(27)14(30)16(32)19(33-6)36-18-15(31)13(29)10(5-24)34-20(18)35-17(12(28)9(26)4-23)8(3-22)21-7(2)25/h6,8-20,22-24,26-32H,3-5H2,1-2H3,(H,21,25)/t6-,8-,9+,10+,11+,12-,13-,14+,15-,16-,17+,18+,19-,20-/m0/s1","WURCS=2.0/3,3,2/[h2112h_2*NCC/3=O][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_b2-c1",GlyTouCan accession,G05187DJ
7187,146807,"beta1,4-GalNAc-disialyl-Lc4","An amino heptasaccharide consisting of a beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc tetrasaccharide backbone, to the galactosyl residue distal to the reducing end is (1->4)-linked a beta-DGlcNAc residue, while Neu5Ac residues are linked to this same galactosyl residue and the GlcNAc residue via (2->3) and (2->6) glycosidic linkages respectively. An antigen for the monoclonal antibody RM2, it is used as a histological marker for prostate cancer.","InChI=1S/C56H92N4O42/c1-14(67)57-27-18(71)5-55(53(86)87,100-44(27)31(75)20(73)7-61)90-13-26-35(79)43(30(60-17(4)70)50(95-26)99-46-34(78)23(10-64)93-51(39(46)83)96-41-24(11-65)91-48(85)38(82)37(41)81)98-52-40(84)47(42(25(12-66)94-52)97-49-29(59-16(3)69)36(80)33(77)22(9-63)92-49)102-56(54(88)89)6-19(72)28(58-15(2)68)45(101-56)32(76)21(74)8-62/h18-52,61-66,71-85H,5-13H2,1-4H3,(H,57,67)(H,58,68)(H,59,69)(H,60,70)(H,86,87)(H,88,89)/t18-,19-,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33-,34-,35+,36+,37+,38+,39+,40+,41+,42-,43+,44+,45+,46-,47+,48+,49-,50-,51-,52-,55+,56-/m0/s1","WURCS=2.0/5,7,6/[a2122h-1b_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][Aad21122h-2a_2-6_5*NCC/3=O][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-2-4-5-4/a4-b1_b3-c1_c3-d1_c6-g2_d3-e2_d4-f1",GlyTouCan accession,G08324IQ
7188,146808,beta-D-Glcp-(1->3)-L-Fucp,A disaccharide that is L-fucopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranoside.,"InChI=1S/C12H22O10/c1-3-5(14)10(9(18)11(19)20-3)22-12-8(17)7(16)6(15)4(2-13)21-12/h3-19H,2H2,1H3/t3-,4+,5+,6+,7-,8+,9-,10+,11?,12-/m0/s1","WURCS=2.0/2,2,1/[a1221m-1x_1-5][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G08324ZK
7189,146809,beta-D-Galp-(1->4)-beta-D-GalpNAc-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp,"An amino tetrasaccharide consisting of beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-galactopyranos, beta-D-galactopyranose and beta-D-glucopyranose residues joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C26H45NO21/c1-6(32)27-11-13(34)20(47-25-18(39)14(35)12(33)7(2-28)43-25)9(4-30)44-24(11)46-22-10(5-31)45-26(19(40)16(22)37)48-21-8(3-29)42-23(41)17(38)15(21)36/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13-,14+,15-,16-,17-,18-,19-,20+,21-,22+,23-,24+,25+,26+/m1/s1","WURCS=2.0/3,4,3/[a2122h-1b_1-5][a2112h-1b_1-5][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-2/a4-b1_b4-c1_c4-d1",GlyTouCan accession,G05357CB
7190,146821,alpha-D-lyxofuranose,A D-lyxofuranose which has alpha-configuration at the anomeric centre.,"InChI=1S/C5H10O5/c6-1-2-3(7)4(8)5(9)10-2/h2-9H,1H2/t2-,3+,4+,5+/m1/s1","WURCS=2.0/1,1,0/[a112h-1a_1-4]/1/",GlyTouCan accession,G05411CR
7191,146838,beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc-(1->2)-D-Galp,An amino trisaccharide consisting of two 2-acetamido-2-deoxy-beta-D-glucopyranose residues and a D-galactopyranose residue joined in sequence by (1->4) and (1->2) glycosidic linkages.,"InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)13(30)9(4-26)37-21(11)39-18-10(5-27)38-22(12(16(18)33)24-7(2)29)40-19-17(34)14(31)8(3-25)36-20(19)35/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17+,18-,19-,20?,21+,22+/m1/s1","WURCS=2.0/2,3,2/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-2/a2-b1_b4-c1",GlyTouCan accession,G05581UW
7192,146848,selaginose,A glycosyl glycoside derivative that is alpha-D-glucopyranosyl-(1->2)-alpha-D-glucopyranose in which the anomeric hydroxy group has been glycosylated by an alpha-D-glucopyranosyl group.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)13(28)16(30-4)33-15-12(27)9(24)6(3-21)32-18(15)34-17-14(29)11(26)8(23)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16-,17-,18-/m1/s1","WURCS=2.0/1,3,2/[a2122h-1a_1-5]/1-1-1/a1-b1_b2-c1",GlyTouCan accession,G08497KY
7193,146851,Delta(4)-beta-D-GlcpA2S-(1->3)-beta-D-GalpNAc4S,An oligosaccharide sulfate that is 4-deoxy-Delta(4)-beta-D-GlcpA2S-(1->3)-beta-D-GalpNAc in which the hydroxy group at position 4 of the 2-acetamido-beta-D-galactopyranose moiety has been converted into the corresponding hydrogen sulfate derivative.,"InChI=1S/C14H21NO18S2/c1-3(17)15-5-9(8(32-34(23,24)25)4(2-16)29-13(5)22)30-14-11(33-35(26,27)28)7(19)6(18)10(31-14)12(20)21/h4-5,7-9,11,13-14,16,18-19,22H,2H2,1H3,(H,15,17)(H,20,21)(H,23,24,25)(H,26,27,28)/t4-,5-,7+,8+,9-,11-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_4*OSO/3=O/3=O][a21EEA-1a_1-5_2*OSO/3=O/3=O]/1-2/a3-b1",GlyTouCan accession,G05671AC
7194,146876,beta-L-mannofuranose,An L-mannofuranose that has beta configuration at the anomeric centre.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3-,4+,5-,6-/m0/s1","WURCS=2.0/1,1,0/[a2211h-1b_1-4]/1/",GlyTouCan accession,G08719OP
7195,146891,beta-D-Galp-(1->2)-alpha-D-Glcp-(1<->1)-alpha-D-Glcp,A trisaccharide that is beta-D-galactopyranosyl-(1->2)-alpha-D-glucopyranoside in which the anomeric hydroxy group has been converted into the corresponding alpha-D-glucopyranosyl derivative.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)13(28)16(30-4)33-15-12(27)9(24)6(3-21)32-18(15)34-17-14(29)11(26)8(23)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7+,8-,9-,10+,11+,12+,13-,14-,15-,16+,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5][a2112h-1b_1-5]/1-1-2/a1-b1_b2-c1",GlyTouCan accession,G05921XS
7196,146899,alpha-L-Fucp-(1->3)-beta-D-Glcp,A disaccharide that is beta-D-glucopyranose in which the hydroxy group at position 3 has been converted into the corresponding alpha-L-fucopyranoside.,"InChI=1S/C12H22O10/c1-3-5(14)7(16)8(17)12(20-3)22-10-6(15)4(2-13)21-11(19)9(10)18/h3-19H,2H2,1H3/t3-,4+,5+,6+,7+,8-,9+,10-,11+,12-/m0/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5][a1221m-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G08796XG
7197,146900,Delta(4)-beta-D-GlcpA-(1->3)-D-GalpNAc4S,An oligsaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted into the corresponding alpha-L-threo-hex-4-enopyranosidurosyl derivative.,"InChI=1S/C14H21NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-6,8-10,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/t4-,5-,6+,8-,9+,10-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O_4*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G08823VD
7198,146919,beta-L-galactofuranose,An L-galactofuranose in which the anomeric centre has beta configuration.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3-,4-,5+,6-/m0/s1","WURCS=2.0/1,1,0/[a1221h-1b_1-4]/1/",GlyTouCan accession,G06064JO
7199,146926,alpha-D-Glcp-(1->4)-[beta-D-Glcp-(1->6)]-beta-D-Glcp,"A glucotriose that is beta-D-glucopyranose in which the hydroxy groups at positions 4 and 6 have been converted into the corresponding alpha-D-glucopyranosyl and beta-D-glucopyranosyl derivatives, respectively.","InChI=1S/C18H32O16/c19-1-4-7(21)9(23)13(27)17(32-4)30-3-6-15(11(25)12(26)16(29)31-6)34-18-14(28)10(24)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16-,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5][a2122h-1a_1-5]/1-2-1/a4-b1_a6-c1",GlyTouCan accession,G09057MT
7200,146940,2-O-(alpha-D-Manp)-D-Man-OH,A glycosyl alditol that is D-mannitol in which the hydroxy group at position 2 has been converted into the corresponding alpha-D-mannopyranoside.,"InChI=1S/C12H24O11/c13-1-4(16)7(17)8(18)5(2-14)22-12-11(21)10(20)9(19)6(3-15)23-12/h4-21H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+/m1/s1","WURCS=2.0/2,2,1/[h1122h][a1122h-1a_1-5]/1-2/a5-b1",GlyTouCan accession,G09141DK
7201,146946,alpha-L-Fucp-(1->2)-alpha-D-Galp-(1->3)-D-GlcpNAc,"An amino trisaccharide consisting of alpha-L-fucopyranosyl, alpha-D-galactopyranosyl and 2-acetamido-D-glucopyranose residues joined in sequence by (1->2) and (1->3) glycosidic linkages.","InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)19(32-5)36-17-14(29)11(26)7(3-22)34-20(17)35-16-9(21-6(2)24)18(31)33-8(4-23)12(16)27/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13+,14-,15-,16+,17+,18?,19-,20+/m0/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1a_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_b2-c1",GlyTouCan accession,G09223OK
7202,146984,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->4)-alpha-L-Fucp,"An aminotrisaccharide consisting of beta-D-galactopyranosyl, 2-acetamido-beta-D-glucopyranosyl and alpha-L-fucopyranosyl residues joined in sequence by (1->3) and (1->4) glycosidic bonds.","InChI=1S/C20H35NO15/c1-5-16(13(28)14(29)18(31)32-5)35-19-9(21-6(2)24)17(11(26)8(4-23)33-19)36-20-15(30)12(27)10(25)7(3-22)34-20/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10-,11+,12-,13-,14-,15+,16+,17+,18+,19-,20-/m0/s1","WURCS=2.0/3,3,2/[a1221m-1a_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a4-b1_b3-c1",GlyTouCan accession,G06414UP
7203,146986,alpha-D-Manp-(1->4)-alpha-D-GlcpNAc-(1->4)-alpha-D-GlcNAc,An amino trisaccharide consisting of an alpha-D-mannopyranosyl residue and two 2-acetamido-alpha-D-glucopyranosyl residues joined in sequence by (1->4) glycosidic bonds.,"InChI=1S/C22H38N2O16/c1-6(28)23-11-14(31)18(9(4-26)36-20(11)35)39-21-12(24-7(2)29)15(32)19(10(5-27)38-21)40-22-17(34)16(33)13(30)8(3-25)37-22/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18-,19-,20+,21-,22-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5_2*NCC/3=O][a1122h-1a_1-5]/1-1-2/a4-b1_b4-c1",GlyTouCan accession,G06419VB
7204,146990,beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)-D-GlcpNAc,An amino trisaccharide consisting of beta-D-galactopyranosyl. 2-acetamido-alpha-D-galactopyranosyl and 2-acetamido-D-glucopyranosyl residues joined in sequence by (1->3) glycosidic bonds.,"InChI=1S/C22H38N2O16/c1-6(28)23-11-18(14(31)9(4-26)36-20(11)35)39-21-12(24-7(2)29)19(15(32)10(5-27)37-21)40-22-17(34)16(33)13(30)8(3-25)38-22/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14-,15+,16+,17-,18-,19-,20?,21-,22+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1a_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G06435EU
7205,146993,alpha-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-alpha-D-GlcpNAc,"An aminotetrasaccharide that is 2-acetamido-alpha-D-glucopyranose in which the hydroxy groups at positions 3 and 4 have been glycosylated by alpha-L-fucopyranosyl and 2-acetamido-4-O-alpha-D-mannopyranosyl-beta-D-glucopyranosyl groups, respectively.","InChI=1S/C28H48N2O20/c1-7-15(36)18(39)20(41)27(44-7)50-24-14(30-9(3)35)25(43)45-12(6-33)23(24)49-26-13(29-8(2)34)17(38)22(11(5-32)47-26)48-28-21(42)19(40)16(37)10(4-31)46-28/h7,10-28,31-33,36-43H,4-6H2,1-3H3,(H,29,34)(H,30,35)/t7-,10+,11+,12+,13+,14+,15+,16+,17+,18+,19-,20-,21-,22+,23+,24+,25-,26-,27-,28+/m0/s1","WURCS=2.0/4,4,3/[a2122h-1a_1-5_2*NCC/3=O][a1221m-1a_1-5][a2122h-1b_1-5_2*NCC/3=O][a1122h-1a_1-5]/1-2-3-4/a3-b1_a4-c1_c4-d1",GlyTouCan accession,G09468GF
7206,147003,beta-D-Glcp-(1->2)-beta-D-Glcp-(1->3)-D-Galp,A trisaccharide consisting of two beta-D-glucopyranose residues and a D-galactopyranose residue joined in sequence by (1->2) and (1->3) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)12(27)17(31-4)34-15-11(26)8(23)5(2-20)32-18(15)33-14-9(24)6(3-21)30-16(29)13(14)28/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11+,12-,13-,14+,15-,16?,17+,18+/m1/s1","WURCS=2.0/2,3,2/[a2112h-1x_1-5][a2122h-1b_1-5]/1-2-2/a3-b1_b2-c1",GlyTouCan accession,G06525SB
7207,147006,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->4)]-alpha-D-Manp-(1->3)-{beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,An amino oligosaccharide that is a branched tridecasaccharide derivative in which beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl and beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)]-alpha-D-mannosyl branched pentasaccharide units are linked (1->6) and (1->3) respectively to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-D-glucosamine trisaccharide.,"InChI=1S/C90H150N6O66/c1-20(108)91-39-51(120)68(30(11-101)140-78(39)137)153-80-41(93-22(3)110)54(123)73(35(16-106)146-80)159-88-67(136)75(160-90-77(162-83-44(96-25(6)113)56(125)72(34(15-105)149-83)158-87-65(134)60(129)48(117)29(10-100)144-87)66(135)74(36(17-107)150-90)154-81-42(94-23(4)111)53(122)70(32(13-103)147-81)156-85-63(132)58(127)46(115)27(8-98)142-85)50(119)38(151-88)19-139-89-76(161-82-43(95-24(5)112)55(124)71(33(14-104)148-82)157-86-64(133)59(128)47(116)28(9-99)143-86)61(130)49(118)37(152-89)18-138-79-40(92-21(2)109)52(121)69(31(12-102)145-79)155-84-62(131)57(126)45(114)26(7-97)141-84/h26-90,97-107,114-137H,7-19H2,1-6H3,(H,91,108)(H,92,109)(H,93,110)(H,94,111)(H,95,112)(H,96,113)/t26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45+,46+,47+,48+,49-,50-,51-,52-,53-,54-,55-,56-,57+,58+,59+,60+,61+,62-,63-,64-,65-,66+,67+,68-,69-,70-,71-,72-,73-,74-,75+,76+,77+,78?,79-,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90-/m1/s1",Gal(b1-4)GlcNAc(b1-2)[Gal(b1-4)GlcNAc(b1-4)]Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)[Gal(b1-4)GlcNAc(b1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,GlyTouCan accession,G09568JT
7208,147011,alpha-L-Fucp-(1->3)-beta-D-Galp2Me-(1->4)-D-GlcpNAc,"An amino trisaccharide consisting of alpha-L-fucopyranosyl, 2-O-methyl-beta-D-galactopyranosyl and 2-acetamidoD-glucopyranosyl residues linked in sequence by (1->3) and (1->4) glycosidic bonds.","InChI=1S/C21H37NO15/c1-6-11(26)14(29)15(30)20(33-6)37-17-12(27)8(4-23)35-21(18(17)32-3)36-16-9(5-24)34-19(31)10(13(16)28)22-7(2)25/h6,8-21,23-24,26-31H,4-5H2,1-3H3,(H,22,25)/t6-,8+,9+,10+,11+,12-,13+,14+,15-,16+,17-,18+,19?,20-,21-/m0/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5_2*OC][a1221m-1a_1-5]/1-2-3/a4-b1_b3-c1",GlyTouCan accession,G06568GE
7209,147017,alpha-L-Fucp-(1->3)-beta-D-GlcpNAc-(1->2)-D-Manp,"An amino trisaccharide consisting of alpha-L-fucopyranosyl, 2-acetamido-beta-D-glucosyl and D-mannopyranosyl residues linked in sequence by (1->3) and (1->2) glycosidic linkeages.","InChI=1S/C20H35NO15/c1-5-10(25)13(28)15(30)20(32-5)35-16-9(21-6(2)24)19(34-8(4-23)12(16)27)36-17-14(29)11(26)7(3-22)33-18(17)31/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11+,12+,13+,14-,15-,16+,17-,18?,19-,20-/m0/s1","WURCS=2.0/3,3,2/[a1122h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5]/1-2-3/a2-b1_b3-c1",GlyTouCan accession,G06595MR
7210,147031,alpha-D-Galp-(1->4)-beta-D-Galp-(1->4)-D-Galp,"A galactotriose consisting of alpha-D-galactopyranose, beta-D-galactopyranose and D-galactpyranose joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13-,14+,15+,16?,17-,18+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2112h-1b_1-5][a2112h-1a_1-5]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G06698DE
7211,147043,alpha-D-Glcp-(1->2)-beta-D-Glcp-(1->2)-D-Glcp,"A glucotriose consisting of alpha-D-glucopyranose, beta-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->2) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-8(23)11(26)14(16(29)30-4)33-18-15(12(27)9(24)6(3-21)32-18)34-17-13(28)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16?,17-,18+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1b_1-5][a2122h-1a_1-5]/1-2-3/a2-b1_b2-c1",GlyTouCan accession,G09745MI
7212,147045,beta-D-GlcpNAc-(1->6)-D-Galp,An amino disaccharide that is D-galactopyranose in which the hydroxy group at position 6 has been converted to the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranoside.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)8(18)5(2-16)26-14(7)24-3-6-9(19)11(21)12(22)13(23)25-6/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6-,7-,8-,9+,10-,11+,12-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2/a6-b1",GlyTouCan accession,G09776OJ
7213,147047,alpha-D-Glcp-(1->3)-[beta-D-Glcp-(1->4)]-alpha-D-Galp,"A branched trisaccharide in which the hydroxy groups at positions 3 and 4 have been converted into the corresponding alpha-D-glucopyranosyl and beta-D-glucopyranosyl derivatives, respectively.","InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)30-16(29)13(28)15(14)34-18-12(27)10(25)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14+,15-,16+,17+,18-/m1/s1","WURCS=2.0/3,3,2/[a2112h-1a_1-5][a2122h-1a_1-5][a2122h-1b_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G06810UA
7214,147059,D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-beta-D-Glcp,"A glucotriose consisting of D-glucopyranose, alpha-D-glucopyranose and beta-D-glucopyranose residues joined in sequence by two (1->4) glycosidic bonds. The configuration of the anomeric centre at the non-reducing terminus is not specified.","InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11-,12-,13-,14-,15-,16-,17?,18-/m1/s1","WURCS=2.0/3,3,2/[a2122h-1b_1-5][a2122h-1a_1-5][a2122h-1x_1-5]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G06851NM
7215,147068,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GalpNAc,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose, beta-D-galactopyranose and 2-acetamido-2-deoxy-D-galactopyranose residues joined in sequence by (1->3) and (1->4) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)18(10(5-27)36-20(11)35)39-22-17(34)19(14(31)9(4-26)38-22)40-21-12(24-7(2)29)15(32)13(30)8(3-25)37-21/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17-,18+,19+,20?,21+,22+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3/a4-b1_b3-c1",GlyTouCan accession,G06910AO
7216,147074,beta-D-GclpNAc-(1->2)-[beta-D-GlcpNAc-(1->3)]-D-Galp,An amino trisaccharide that is D-galactopyranose in which the hydroxy groups at positions 2 and 3 have each been converted into the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranosyl derivative.,"InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)13(30)8(3-25)37-21(11)39-18-15(32)10(5-27)36-20(35)19(18)40-22-12(24-7(2)29)17(34)14(31)9(4-26)38-22/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14-,15+,16-,17-,18+,19-,20?,21+,22+/m1/s1","WURCS=2.0/2,3,2/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-2/a2-b1_a3-c1",GlyTouCan accession,G06931TP
7217,147082,beta-D-GlcpNAc-(1->6)-GalNAc-ol,An amino disaccharide that is 2-acetamido-2-deoxy-D-galactitol in which the hydroxy group at position 6 of the galactitol moiety has been converted into the corresponding 2-acetamido-beta-D-glucopyranoside.,"InChI=1S/C16H30N2O11/c1-6(21)17-8(3-19)12(24)13(25)9(23)5-28-16-11(18-7(2)22)15(27)14(26)10(4-20)29-16/h8-16,19-20,23-27H,3-5H2,1-2H3,(H,17,21)(H,18,22)/t8-,9+,10+,11+,12+,13-,14+,15+,16+/m0/s1","WURCS=2.0/2,2,1/[h2112h_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O]/1-2/a6-b1",GlyTouCan accession,G10110YZ
7218,147089,beta-D-Galp-(1->4)-beta-D-Glcp-(1->3)-D-GalpNAc,"An amino trisaccharide consisting of beta-D-galactopyranose, beta-D-glucopyranose and 2-acetamido-2-deoxy-D-galactopyranose residues joined in sequence by (1->4) and (1->3) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(25)21-9-17(11(27)7(3-23)33-18(9)32)37-20-15(31)13(29)16(8(4-24)35-20)36-19-14(30)12(28)10(26)6(2-22)34-19/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16-,17-,18?,19+,20+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5][a2112h-1b_1-5]/1-2-3/a3-b1_b4-c1",GlyTouCan accession,G10149FE
7219,147103,alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->3)-alpha-D-Glcp,"A glucotetrose in which four alpha-D-glucopyranose residues are joined in sequence by (1->4), (1->4) and (1->3) glycosidic linkages.","InChI=1S/C24H42O21/c25-1-5-9(29)11(31)14(34)22(40-5)43-18-7(3-27)41-23(15(35)12(18)32)44-19-8(4-28)42-24(16(36)13(19)33)45-20-10(30)6(2-26)39-21(38)17(20)37/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11+,12-,13-,14-,15-,16-,17-,18-,19-,20+,21+,22-,23-,24-/m1/s1","WURCS=2.0/1,4,3/[a2122h-1a_1-5]/1-1-1-1/a3-b1_b4-c1_c4-d1",GlyTouCan accession,G10197OY
7220,147110,alpha-D-Glcp-(1->6)-alpha-D-Galp-(1->2)-alpha-D-Galp,A trisaccharide consisting of an alpha-D-glucopyranose and two alpha-D-galactopyranose residues joined in sequence by (1->6) and (1->2) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-8(22)12(26)15(16(29)31-4)34-18-14(28)11(25)9(23)6(33-18)3-30-17-13(27)10(24)7(21)5(2-20)32-17/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9+,10+,11+,12+,13-,14-,15-,16+,17+,18-/m1/s1","WURCS=2.0/2,3,2/[a2112h-1a_1-5][a2122h-1a_1-5]/1-1-2/a2-b1_b6-c1",GlyTouCan accession,G07226AQ
7221,147135,alpha-D-Glcp-(1->6)-alpha-D-Glcp-(1->6)-alpha-D-Glcp-(1->2)-alpha-D-Glcp,"A glucotetrose consisting of four alpha-D-glucopyranose residues joined in sequence by (1->6), (1->6) and (1->2) glycosidic linkages.","InChI=1S/C24H42O21/c25-1-5-10(28)16(34)20(21(38)41-5)45-24-19(37)15(33)12(30)8(44-24)4-40-23-18(36)14(32)11(29)7(43-23)3-39-22-17(35)13(31)9(27)6(2-26)42-22/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17-,18-,19-,20-,21+,22+,23+,24-/m1/s1","WURCS=2.0/1,4,3/[a2122h-1a_1-5]/1-1-1-1/a2-b1_b6-c1_c6-d1",GlyTouCan accession,G10340BX
7222,147136,alpha-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,An alpha-D-GlcpNAc-(1->4)-D-GlcpNAc in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)14(8(4-20)27-15(9)26)29-16-10(18-6(2)22)12(24)11(23)7(3-19)28-16/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11-,12-,13-,14-,15-,16-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5_2*NCC/3=O][a2122h-1a_1-5_2*NCC/3=O]/1-2/a4-b1",GlyTouCan accession,G07375KG
7223,147144,beta-L-Galp-(1->3)-beta-D-GlcpNAc,An amino disaccharide that is 2-acetamido-2-deoxy-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding beta-L-galactopyranoside.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(9(20)6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6+,7+,8+,9+,10+,11-,12+,13+,14+/m0/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5_2*NCC/3=O][a1221h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G10400UC
7224,147148,alpha-L-threo-hex-4-enopyranuronosyl-(1->3)-beta-D-GalpNAc6S,An aminodisaccharide that is 2-acetamido-2-deoxy-6-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been glycosylated by an alpha-L-threo-hex-4-enopyranosiduronic acid group.,"InChI=1S/C14H21NO15S/c1-3(16)15-5-10(6(17)4(28-13(5)23)2-27-31(24,25)26)29-14-9(20)7(18)8(19)11(30-14)12(21)22/h4-7,9-10,13-14,17-20,23H,2H2,1H3,(H,15,16)(H,21,22)(H,24,25,26)/t4-,5-,6+,7+,9-,10-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G10417PV
7225,147151,alpha-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-alpha-D-Galp,"A trisaccharide that is alpha-D-galactopyranose in which the hydroxy groups at positions 3 and 4 have been converted into the corresponding alpha-D-glucopyranosyl and alpha-L-fucopyranosyl derivatives, respectively.","InChI=1S/C18H32O15/c1-4-7(21)9(23)11(25)17(29-4)32-14-6(3-20)30-16(28)13(27)15(14)33-18-12(26)10(24)8(22)5(2-19)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8+,9+,10-,11-,12+,13+,14-,15+,16-,17-,18+/m0/s1","WURCS=2.0/3,3,2/[a2112h-1a_1-5][a2122h-1a_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G07438VB
7226,147153,alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-D-Manp,A mannotriose consisting of an alpha-D-mannopyranose residue and two beta-D-mannopyranose residues joined in sequence by (1->3) and (1->4) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)12(27)17(31-4)34-15-8(23)5(2-20)32-18(13(15)28)33-14-6(3-21)30-16(29)11(26)10(14)25/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10-,11+,12+,13+,14-,15+,16-,17-,18+/m1/s1","WURCS=2.0/2,3,2/[a1122h-1b_1-5][a1122h-1a_1-5]/1-1-2/a4-b1_b3-c1",GlyTouCan accession,G10419AP
7227,147159,alpha-D-Galp-(1->4)-alpha-D-Galp-(1->3)-D-Galf,A galactotriose consisting of two alpha-D-galactopyranosyl groups and a D-galactofuranose group linked in sequence by (1->4) and (1->3) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4(22)13-15(12(28)16(29)32-13)34-18-11(27)9(25)14(6(3-21)31-18)33-17-10(26)8(24)7(23)5(2-20)30-17/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13+,14+,15-,16?,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2112h-1x_1-4][a2112h-1a_1-5]/1-2-2/a3-b1_b4-c1",GlyTouCan accession,G07476BB
7228,147174,beta-D-Glcp-(1->3)-[beta-D-Glcp-(1->4)]-alpha-D-Galp,A trisaccharide that is alpha-D-galactopyranose in which the hydroxy groups at positions 3 and 4 have been converted into the corresponding beta-D-glucopyranosides.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)30-16(29)13(28)15(14)34-18-12(27)10(25)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14+,15-,16+,17+,18+/m1/s1","WURCS=2.0/2,3,2/[a2112h-1a_1-5][a2122h-1b_1-5]/1-2-2/a3-b1_a4-c1",GlyTouCan accession,G10507RU
7229,147175,beta-D-GlcpNAc-(1->3)-[beta-D-GlcpNAc-(1->6)]-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,An aminotetrasaccharide consisting of three molecules of 2-acetamido-2-deoxy-beta-D-glucopyranose joined in sequence by (1->3) and (1->4) glycosidic bonds in which the non-terminal group has been glycosylated at the 6-hydroxy group by fourth 2-acetamido-2-deoxy-beta-D-glucopyranose moiety.,"InChI=1S/C32H54N4O21/c1-9(40)33-17-26(49)27(15(7-39)52-29(17)50)56-32-20(36-12(4)43)28(57-31-19(35-11(3)42)25(48)22(45)14(6-38)54-31)23(46)16(55-32)8-51-30-18(34-10(2)41)24(47)21(44)13(5-37)53-30/h13-32,37-39,44-50H,5-8H2,1-4H3,(H,33,40)(H,34,41)(H,35,42)(H,36,43)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31+,32+/m1/s1","WURCS=2.0/1,4,3/[a2122h-1b_1-5_2*NCC/3=O]/1-1-1-1/a4-b1_b3-c1_b6-d1",GlyTouCan accession,G07547GE
7230,147176,alpha-D-GalpNAc-(1->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp,"An amino pentasaccharide consisting of 2-acetamido-2-deoxy-alpha-D-galactopyranosyl, beta-D-galactopyranosyl, 2-acetamido-2-deoxy-beta-D-glucopyranosyl, beta-D-galactopyranosyl and D-glucopyranose residues joined in sequence by (1->3), (1->3), (1->3) and (1->4) glycosidic bonds.","InChI=1S/C34H58N2O26/c1-8(42)35-15-21(48)17(44)10(3-37)55-31(15)61-28-19(46)13(6-40)58-34(25(28)52)60-27-16(36-9(2)43)32(56-11(4-38)18(27)45)62-29-20(47)12(5-39)57-33(24(29)51)59-26-14(7-41)54-30(53)23(50)22(26)49/h10-34,37-41,44-53H,3-7H2,1-2H3,(H,35,42)(H,36,43)/t10-,11-,12-,13-,14-,15-,16-,17+,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28+,29+,30?,31-,32+,33+,34+/m1/s1","WURCS=2.0/4,5,4/[a2122h-1x_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1a_1-5_2*NCC/3=O]/1-2-3-2-4/a4-b1_b3-c1_c3-d1_d3-e1",GlyTouCan accession,G10528MR
7231,147190,beta-D-Galp-(1->4)-alpha-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-alpha-D-Glcp,"An amino tetrasaccharide consisting of beta-D-galactopyranosyl, 2-acetamido-2-deoxy-alpha-D-glucopyranosyl, beta-D-galactopyranosyl and alpha-D-glucopyranose residues joined in sequence by (1->4), (1->3) and (1->4) glycosidic linkages.","InChI=1S/C26H45NO21/c1-6(32)27-11-14(35)20(46-25-18(39)15(36)12(33)7(2-28)43-25)10(5-31)45-24(11)48-22-13(34)8(3-29)44-26(19(22)40)47-21-9(4-30)42-23(41)17(38)16(21)37/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13+,14-,15+,16-,17-,18-,19-,20-,21-,22+,23+,24-,25+,26+/m1/s1","WURCS=2.0/3,4,3/[a2122h-1a_1-5][a2112h-1b_1-5][a2122h-1a_1-5_2*NCC/3=O]/1-2-3-2/a4-b1_b3-c1_c4-d1",GlyTouCan accession,G10594VF
7232,147204,alpha-D-Galp-(1->6)-alpha-D-Galp-(1->3)-alpha-D-Galp,A galactotriose consisting of three alpha-D-galactopyranose residues joined in sequence by (1->6) and (1->3) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)12(26)17(32-4)30-3-6-8(22)11(25)13(27)18(33-6)34-15-9(23)5(2-20)31-16(29)14(15)28/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10+,11+,12-,13-,14-,15+,16+,17+,18-/m1/s1","WURCS=2.0/1,3,2/[a2112h-1a_1-5]/1-1-1/a3-b1_b6-c1",GlyTouCan accession,G10662QB
7233,147221,beta-D-Galp-(1->3)-beta-D-GlcpN,An amino disaccharide that is that is the 3-O-beta-D-galactopyranoside of 2-amino-2-deoxy-beta-D-galactopyranose.,"InChI=1S/C12H23NO10/c13-5-10(7(17)4(2-15)21-11(5)20)23-12-9(19)8(18)6(16)3(1-14)22-12/h3-12,14-20H,1-2,13H2/t3-,4-,5-,6+,7-,8+,9-,10-,11-,12+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5_2*N][a2112h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G10713RP
7234,147248,beta-D-GlcpNAc-(1->4)-beta-D-Galp-(1->4)-D-GlcpNAc,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose, beta-D-galactopyranose and 2-acetamido-2-deoxy-D-glucopyranose residues joine in sequence by (1->4) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)18(9(4-26)36-20(11)35)40-22-17(34)16(33)19(10(5-27)38-22)39-21-12(24-7(2)29)14(31)13(30)8(3-25)37-21/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19+,20?,21+,22+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G07923CD
7235,147271,2-acetamido-2-deoxy-3-O-beta-D-galactopyranosyl-D-glucitol,An amino disaccharide that is the 3-O-beta-D-galactopyranoside of 2-acetamido-2-deoxy-D-glucitol.,"InChI=1S/C14H27NO11/c1-5(19)15-6(2-16)13(9(21)7(20)3-17)26-14-12(24)11(23)10(22)8(4-18)25-14/h6-14,16-18,20-24H,2-4H2,1H3,(H,15,19)/t6-,7+,8+,9+,10-,11-,12+,13+,14-/m0/s1","WURCS=2.0/2,2,1/[h2122h_2*NCC/3=O][a2112h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G08066KX
7236,147274,beta-D-GlcpNAc-(1->3)-[6-deoxy-alpha-L-Galp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->6)]-D-GalNAc-ol,"An aminopentasaccharide that is 2-acetamido-D-alactitol which has been glycosylated at positions 3 and 6 by 2-acetamido-beta-D-glucopyranosyl and alpha-L-fucosyl-(1->3)-[beta-D-galactopyranosyl-(1->4)]-2-acetamido-beta-D-glucopyranosyl groups, respectively.","InChI=1S/C36H63N3O25/c1-10-21(48)26(53)28(55)35(58-10)64-32-20(39-13(4)46)33(61-18(8-43)31(32)63-36-29(56)27(54)24(51)17(7-42)60-36)57-9-15(47)22(49)30(14(5-40)37-11(2)44)62-34-19(38-12(3)45)25(52)23(50)16(6-41)59-34/h10,14-36,40-43,47-56H,5-9H2,1-4H3,(H,37,44)(H,38,45)(H,39,46)/t10-,14-,15+,16+,17+,18+,19+,20+,21+,22-,23+,24-,25+,26+,27-,28-,29+,30+,31+,32+,33+,34-,35-,36-/m0/s1","WURCS=2.0/4,5,4/[h2112h_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5][a2112h-1b_1-5]/1-2-2-3-4/a3-b1_a6-c1_c3-d1_c4-e1",GlyTouCan accession,G10993EM
7237,147299,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-{alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->6)}-beta-D-Galp-(1->4)-D-Glcp,"A branched amino oligosaccharide comprising two fucosyl residues, three galactose residues and two N-acetylglucosamine residues, with a glucose residue at the reducing end, in the arrangement shown.","InChI=1S/C52H88N2O39/c1-11-23(62)29(68)35(74)48(80-11)91-42-22(54-14(4)61)46(85-19(9-59)41(42)90-50-37(76)31(70)25(64)15(5-55)83-50)79-10-20-27(66)43(38(77)51(87-20)88-40-17(7-57)82-45(78)34(73)33(40)72)92-47-21(53-13(3)60)28(67)39(18(8-58)86-47)89-52-44(32(71)26(65)16(6-56)84-52)93-49-36(75)30(69)24(63)12(2)81-49/h11-12,15-52,55-59,62-78H,5-10H2,1-4H3,(H,53,60)(H,54,61)/t11-,12-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25-,26-,27-,28+,29+,30+,31-,32-,33+,34+,35-,36-,37+,38+,39+,40+,41+,42+,43-,44+,45?,46+,47-,48-,49-,50-,51-,52-/m0/s1",Galb1-4(Fuca1-3)GlcNAcb1-6(Fuca1-2Galb1-4GlcNAcb1-3)Galb1-4Glc,PubMed citation,31537530
7238,147319,"3-(2,4-dichlorophenyl)-7-hydroxy-4H-chromen-4-one",A member of the class of 7-hydroxyisoflavones that is 3-phenyl-4H-chromen-4-one which is substituted by a hydroxy group at position 7 and chloro groups at positions 2' and 4'. It is a SIRT1 activator.,"InChI=1S/C15H8Cl2O3/c16-8-1-3-10(13(17)5-8)12-7-20-14-6-9(18)2-4-11(14)15(12)19/h1-7,18H",DCHC,PubMed citation,30121911
7239,147354,"(6R,7S,9S)-2-imino-7,9-dimethyl-1,3-diazaspiro[5.5]undecan-4-one","An azaspiro compound resulting from the spiro-fusion of 2-imino-1,3-diazinan-4-one at position 6 with 1,3-dimethylcyclohexane. It is a marine metabolite isolated from Vietnamese pufferfish Tetraodon biocellatus and a potential intermediate in the biosynthetic pathway leading to the synthesis of tetrodotoxin.","InChI=1S/C11H19N3O/c1-7-3-4-11(8(2)5-7)6-9(15)13-10(12)14-11/h7-8H,3-6H2,1-2H3,(H3,12,13,14,15)/t7-,8-,11+/m0/s1",Tb-210B,PubMed citation,29504641
7240,147419,ammonium phosphate sulfate,An inorganic sulfate salt obtained by reaction of sulfuric acid with one equivalent of ammonium phosphate.,"InChI=1S/2H3N.H3O4P.H2O4S/c;;2*1-5(2,3)4/h2*1H3;(H3,1,2,3,4);(H2,1,2,3,4)",ammonium phosphate sulphate,CAS Registry Number,12593-60-1
7241,147455,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and beta-D-galactopyranose residues joined in sequence by (1->4) and (1->3) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)13(30)8(3-25)37-21(11)39-18-10(5-27)38-22(12(16(18)33)24-7(2)29)40-19-14(31)9(4-26)36-20(35)17(19)34/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19+,20-,21+,22+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5_2*NCC/3=O]/1-2-3/a3-b1_b4-c1",GlyTouCan accession,G11049II
7242,147462,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-alpha-D-Galp,"A branched trisaccharide that is alpha-D-galactopyranose in which the hydroxy groups at positions 2 and 3 have been converted to the corresponding alpha-L-fucopyranosyl and alpha-D-galactopyranosyl derivatives, respectively.","InChI=1S/C18H32O15/c1-4-7(21)10(24)12(26)17(29-4)33-15-14(9(23)6(3-20)30-16(15)28)32-18-13(27)11(25)8(22)5(2-19)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8-,9-,10+,11-,12-,13+,14-,15+,16-,17-,18+/m0/s1","WURCS=2.0/2,3,2/[a2112h-1a_1-5][a1221m-1a_1-5]/1-2-1/a2-b1_a3-c1",GlyTouCan accession,G11065GA
7243,147475,beta-L-Fucp-(1->2)-alpha-D-Galp,A disaccharide that is alpha-D-galactopyranose in which the hydroxy group at position 2 has been converted into the corresponding beta-L-fucopyranoside.,"InChI=1S/C12H22O10/c1-3-5(14)7(16)9(18)12(20-3)22-10-8(17)6(15)4(2-13)21-11(10)19/h3-19H,2H2,1H3/t3-,4+,5+,6-,7+,8-,9-,10+,11-,12+/m0/s1","WURCS=2.0/2,2,1/[a2112h-1a_1-5][a1221m-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G13827OW
7244,147477,alpha-L-Fucp-(1->6)-beta-D-Galp,An alpha-L-Fucp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C12H22O10/c1-3-5(13)7(15)10(18)12(21-3)20-2-4-6(14)8(16)9(17)11(19)22-4/h3-19H,2H2,1H3/t3-,4+,5+,6-,7+,8-,9+,10-,11+,12+/m0/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5][a1221m-1a_1-5]/1-2/a6-b1",GlyTouCan accession,G11089HW
7245,147486,alpha-L-Fucp-(1->4)-[beta-D-Glcp-(1->3)]-D-Galp,A trisaccharide consisting of alpha-L-fucopyranose and beta-D-galactose residues joined by a (1->4) glycosidic bond in which the hydroxy group at position 3 of the galactopyranose ring has been converted into the corresponding beta-D-glucopyranosyl derivative.,"InChI=1S/C18H32O15/c1-4-7(21)9(23)11(25)17(29-4)32-14-6(3-20)30-16(28)13(27)15(14)33-18-12(26)10(24)8(22)5(2-19)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8+,9+,10-,11-,12+,13+,14-,15+,16?,17-,18-/m0/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2122h-1b_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G16882JV
7246,147530,beta-D-Galp-(1->3)-[beta-D-Galp-(1->6)]-alpha-D-GalpNAc,An amino trisaccharide that is 2-acetamido-2-deoxy-alpha-D-galactopyranose in which the hydroxy groups at positions 3 and 6 have been converted into the corresponding beta-D-galactopyranosyl derivatives.,"InChI=1S/C20H35NO16/c1-5(24)21-9-17(37-20-16(31)14(29)11(26)7(3-23)36-20)12(27)8(34-18(9)32)4-33-19-15(30)13(28)10(25)6(2-22)35-19/h6-20,22-23,25-32H,2-4H2,1H3,(H,21,24)/t6-,7-,8-,9-,10+,11+,12+,13+,14+,15-,16-,17-,18+,19-,20+/m1/s1","WURCS=2.0/2,3,2/[a2112h-1a_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-2/a3-b1_a6-c1",GlyTouCan accession,G17024OR
7247,147538,beta-D-ManpNAc-(1->4)-beta-D-Glcp-(1->4)-beta-D-Glcp,An amino trisaccharide consisting of a 2-acetamido-2-deoxy-beta-D-mannopyranose residue and two beta-D=glucopyranose residues joined in sequence by (1->4) glycosidic bonds.,"InChI=1S/C20H35NO16/c1-5(25)21-9-11(27)10(26)6(2-22)34-19(9)36-17-8(4-24)35-20(15(31)13(17)29)37-16-7(3-23)33-18(32)14(30)12(16)28/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9+,10-,11-,12-,13-,14-,15-,16-,17-,18-,19+,20+/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5][a1122h-1b_1-5_2*NCC/3=O]/1-1-2/a4-b1_b4-c1",GlyTouCan accession,G17032OA
7248,147553,beta-D-GlcpNAc-(1->3)-D-Gal-OH,A glycosyl alditol that is D-galactitol in which the hydroxy group at position 3 has been converted to the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranoside.,"InChI=1S/C14H27NO11/c1-5(19)15-9-12(24)11(23)8(4-18)25-14(9)26-13(7(21)3-17)10(22)6(20)2-16/h6-14,16-18,20-24H,2-4H2,1H3,(H,15,19)/t6-,7+,8-,9-,10+,11-,12-,13-,14+/m1/s1","WURCS=2.0/2,2,1/[h2112h][a2122h-1b_1-5_2*NCC/3=O]/1-2/a3-b1",GlyTouCan accession,G14023WK
7249,147558,alpha-L-Fucp-(1->2)-D-Man-OH,An alpha-L-fucoside resulting from the formal condensation of the hydroxy group at position 2 of D-mannitol with alpha-L-fucose.,"InChI=1S/C12H24O10/c1-4-7(16)10(19)11(20)12(21-4)22-6(3-14)9(18)8(17)5(15)2-13/h4-20H,2-3H2,1H3/t4-,5+,6+,7+,8+,9+,10+,11-,12-/m0/s1","WURCS=2.0/2,2,1/[h1122h][a1221m-1a_1-5]/1-2/a5-b1",GlyTouCan accession,G11386DK
7250,147562,beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-D-Galp,"An amino trisaccharide consisting of beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-galactopyranose and D-galactopyranose residues joined in sequence by (1->3) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(25)21-9-16(36-20-14(30)13(29)10(26)6(2-22)35-20)11(27)8(4-24)34-19(9)37-17-12(28)7(3-23)33-18(32)15(17)31/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12+,13+,14-,15-,16-,17+,18?,19+,20+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2112h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G11423ZI
7251,147563,alpha-L-threo-hex-4-enopyranuronosyl-(1->4)-alpha-D-GlcpNS,An L-threo-hex-4-enopyranuronosyl-(1->4)-D-GlcpNS in which both anomeric centres have alpha configuration.,"InChI=1S/C12H19NO14S/c14-1-2-8(4(15)3(11(21)25-2)13-28(22,23)24)26-12-7(18)5(16)6(17)9(27-12)10(19)20/h2-5,7-8,11-18,21H,1H2,(H,19,20)(H,22,23,24)/t2-,3-,4-,5+,7-,8-,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G14038OF
7252,147570,beta-D-Galp-(1->3)-D-Gal-OH,A glycosyl alditol resulting from the formal condensation of beta-D-galactopyranose with the hydroxy group at position 3 of galactitol.,"InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6-,7+,8+,9+,10-,11-,12+/m1/s1","WURCS=2.0/2,2,1/[h2112h][a2112h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G11444KC
7253,147585,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-D-GalNAc-OH,"A glycosyl alditol derivative consisting of beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and N-acetyl-D-galactosaminitol residues joined in sequence by (1->3) glycosidic bonds.","InChI=1S/C22H40N2O16/c1-7(29)23-9(3-25)19(14(32)10(31)4-26)39-21-13(24-8(2)30)20(16(34)12(6-28)37-21)40-22-18(36)17(35)15(33)11(5-27)38-22/h9-22,25-28,31-36H,3-6H2,1-2H3,(H,23,29)(H,24,30)/t9-,10+,11+,12+,13+,14-,15-,16+,17-,18+,19+,20+,21-,22-/m0/s1","WURCS=2.0/3,3,2/[h2112h_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G14191ZT
7254,147602,beta-D-GlcpNAc-(1->4)-D-Manp,A disaccharide that is D-mannopyranose in which the hydroxy group at position 4 has been converted into the corresponding 2-acetamido-2-dexoxy-beta-D-glucopyranosyl derivative.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)8(19)5(2-16)25-14(7)26-12-6(3-17)24-13(23)11(22)10(12)21/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10-,11+,12-,13?,14+/m1/s1","WURCS=2.0/2,2,1/[a1122h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2/a4-b1",GlyTouCan accession,G14250GH
7255,147609,alpha-D-fucofuranose,A D-fucofuranose that has alpha configuration at the anomeric centre.,"InChI=1S/C6H12O5/c1-2(7)5-3(8)4(9)6(10)11-5/h2-10H,1H3/t2-,3-,4-,5+,6+/m1/s1","WURCS=2.0/1,1,0/[a2112m-1a_1-4]/1/",GlyTouCan accession,G14286ZK
7256,147618,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,"An amino trisaccharide consisting of beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and 2-acetamido-2-deoxy-alpha-D-galactopyranose residues joined in sequence by (1->3) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-18(14(31)9(4-26)36-20(11)35)39-21-12(24-7(2)29)19(15(32)10(5-27)37-21)40-22-17(34)16(33)13(30)8(3-25)38-22/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14+,15-,16+,17-,18-,19-,20+,21+,22+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G11647UD
7257,147622,alpha-D-Glcp-(1->2)-alpha-D-Glcp-(1->3)-alpha-D-Galp,A trisaccharide consisting of two alpha-D-glucopyranose residues and an alpha-D-galactopyranose residue joined in sequence by (1->2) and (1->3) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)12(27)17(31-4)34-15-11(26)8(23)5(2-20)32-18(15)33-14-9(24)6(3-21)30-16(29)13(14)28/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11+,12-,13-,14+,15-,16+,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2112h-1a_1-5][a2122h-1a_1-5]/1-2-2/a3-b1_b2-c1",GlyTouCan accession,G11657DN
7258,147626,beta-D-Galp3S-(1->4)-D-GlcpNAc,An oligosaccharide sulfate consisting of 3-O-sulfo-beta-D-galactopyranose and -2-acetamido-2-deoxy-D-glucopyranose residues joined by a (1->4) glycosidic bond.,"InChI=1S/C14H25NO14S/c1-4(18)15-7-9(20)11(6(3-17)26-13(7)22)28-14-10(21)12(29-30(23,24)25)8(19)5(2-16)27-14/h5-14,16-17,19-22H,2-3H2,1H3,(H,15,18)(H,23,24,25)/t5-,6-,7-,8+,9-,10-,11-,12+,13?,14+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5_3*OSO/3=O/3=O]/1-2/a4-b1",GlyTouCan accession,G11658OG
7259,147632,beta-D-Galf-(1->4)-alpha-D-Galp,A galactobiose that is alpha-D-galactopyranose in which the hydroxy group at position 4 has been converted into the corresponding beta-D-galactofuranoside.,"InChI=1S/C12H22O11/c13-1-3(15)9-6(17)8(19)12(22-9)23-10-4(2-14)21-11(20)7(18)5(10)16/h3-20H,1-2H2/t3-,4-,5-,6-,7-,8-,9+,10+,11+,12+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1a_1-5][a2112h-1b_1-4]/1-2/a4-b1",GlyTouCan accession,G11684IZ
7260,147652,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino heptasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by an alpha-D-Man-(1->6)-alpha-D-Man group.,"InChI=1S/C48H81N3O36/c1-11(57)49-21-30(66)38(17(7-55)77-42(21)74)84-44-23(51-13(3)59)31(67)39(18(8-56)81-44)85-47-37(73)40(86-48-41(34(70)26(62)16(6-54)80-48)87-43-22(50-12(2)58)29(65)24(60)14(4-52)78-43)28(64)20(83-47)10-76-46-36(72)33(69)27(63)19(82-46)9-75-45-35(71)32(68)25(61)15(5-53)79-45/h14-48,52-56,60-74H,4-10H2,1-3H3,(H,49,57)(H,50,58)(H,51,59)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32+,33+,34+,35+,36+,37+,38-,39-,40+,41+,42?,43+,44+,45+,46+,47+,48-/m1/s1",GlcNAc(b1-2)Man(a1-3)[Man(a1-6)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,GlyTouCan accession,G17336FF
7261,147653,beta-D-Glcp-(1->2)-beta-D-Xylp-(1->2)-beta-D-Xylp,A trisaccharide consisting of a beta-D-glucopyranose residue and two beta-D-xylopyranose residues joined in sequence by (1->2) glycosidic bonds.,"InChI=1S/C16H28O14/c17-1-6-9(22)10(23)11(24)15(28-6)30-13-8(21)5(19)3-27-16(13)29-12-7(20)4(18)2-26-14(12)25/h4-25H,1-3H2/t4-,5-,6-,7+,8+,9-,10+,11-,12-,13-,14-,15+,16+/m1/s1","WURCS=2.0/2,3,2/[a212h-1b_1-5][a2122h-1b_1-5]/1-1-2/a2-b1_b2-c1",GlyTouCan accession,G14412XT
7262,147677,beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcNAc-OH,"A glycosyl alditol derivative consisting of D-mannopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and N-acetyl-D-glucosaminitol residues joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C22H40N2O16/c1-7(29)23-9(3-25)14(32)19(10(31)4-26)39-21-13(24-8(2)30)16(34)20(12(6-28)38-21)40-22-18(36)17(35)15(33)11(5-27)37-22/h9-22,25-28,31-36H,3-6H2,1-2H3,(H,23,29)(H,24,30)/t9-,10+,11+,12+,13+,14+,15+,16+,17-,18-,19+,20+,21-,22-/m0/s1","WURCS=2.0/3,3,2/[h2122h_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G14469GR
7263,147686,alpha-L-Fucp-(1->3)-[beta-D-GalpNAc-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino nonasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by an alpha-L-Fuc-(1->3)-[beta-D-GalNAc-(1->4)]-beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group.,"InChI=1S/C64H107N5O45/c1-15-34(82)44(92)47(95)61(99-15)111-52-33(69-20(6)81)60(106-27(13-76)51(52)110-57-30(66-17(3)78)40(88)35(83)21(7-70)101-57)114-55-46(94)38(86)24(10-73)104-64(55)112-53-39(87)28(14-98-63-54(45(93)37(85)23(9-72)103-63)113-58-31(67-18(4)79)41(89)36(84)22(8-71)102-58)107-62(48(53)96)109-50-26(12-75)105-59(32(43(50)91)68-19(5)80)108-49-25(11-74)100-56(97)29(42(49)90)65-16(2)77/h15,21-64,70-76,82-97H,7-14H2,1-6H3,(H,65,77)(H,66,78)(H,67,79)(H,68,80)(H,69,81)/t15-,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35-,36+,37+,38+,39+,40+,41+,42+,43+,44+,45-,46-,47-,48-,49+,50+,51+,52+,53-,54-,55-,56?,57-,58-,59-,60-,61-,62-,63-,64+/m0/s1",6-deoxy-alpha-L-galacto-hexopyranosyl-(1->3)-[2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1->4)]-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G14510SZ
7264,147715,beta-D-GlcpNAc-(1->6)-alpha-D-Manp-(1->6)-alpha-D-Manp,An amino trisaccharide consisting of a 2-acetamido-2-deoxy-beta-D-glucopyranose residue and two alpha-D-mannopyranose residues joined in sequence by (1->6) glycosidic bonds.,"InChI=1S/C20H35NO16/c1-5(23)21-9-13(27)10(24)6(2-22)36-19(9)33-4-8-12(26)15(29)17(31)20(37-8)34-3-7-11(25)14(28)16(30)18(32)35-7/h6-20,22,24-32H,2-4H2,1H3,(H,21,23)/t6-,7-,8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18+,19-,20+/m1/s1","WURCS=2.0/2,3,2/[a1122h-1a_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-1-2/a6-b1_b6-c1",GlyTouCan accession,G17575OM
7265,147716,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,"A branched amino heptasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by an alpha-D-Man residue, while the D-GlcNAc residue at the reducing end is substituted at position 6 by an alpha-L-Fuc residue.","InChI=1S/C48H81N3O35/c1-11-24(59)32(67)35(70)45(76-11)75-10-20-39(30(65)21(42(73)77-20)49-12(2)56)83-44-23(51-14(4)58)31(66)38(18(8-55)81-44)84-47-37(72)40(28(63)19(82-47)9-74-46-36(71)33(68)26(61)16(6-53)79-46)85-48-41(34(69)27(62)17(7-54)80-48)86-43-22(50-13(3)57)29(64)25(60)15(5-52)78-43/h11,15-48,52-55,59-73H,5-10H2,1-4H3,(H,49,56)(H,50,57)(H,51,58)/t11-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33-,34-,35-,36-,37-,38+,39+,40-,41-,42?,43-,44-,45+,46-,47-,48+/m0/s1",2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[alpha-D-manno-hexopyranosyl-(1->6)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->6)]-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G14576KZ
7266,147718,alpha-D-talofuranose,A D-talofuranose that has alpha configuration at the anomeric centre.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3-,4+,5+,6+/m1/s1","WURCS=2.0/1,1,0/[a1112h-1a_1-4]/1/",GlyTouCan accession,G14606EL
7267,147742,alpha-D-Manp-(1->3)-D-Galp,A disaccharide that is D-galactopyranose in which the hydroxy group at position 3 has been converted into the corresponding alpha-D-mannopyranoside.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10+,11?,12-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][a1122h-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G17655CU
7268,147758,beta-D-Galp-(1->3)-alpha-D-Glcp,A beta-D-Galp-(1->3)-D-Glcp in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5+,6-,7+,8-,9-,10+,11+,12+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5][a2112h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G12058PE
7269,147759,beta-D-Glcp-(1->2)-alpha-D-Glcp-(1->3)-alpha-D-Glcp,A glucotriose consisting of one beta-D-glucopyranose and two alpha-D-glucopyranose residues joined in sequence by (1->2) and (1->3) glycosidic linkages.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)12(27)17(31-4)34-15-11(26)8(23)5(2-20)32-18(15)33-14-9(24)6(3-21)30-16(29)13(14)28/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12-,13-,14+,15-,16+,17+,18-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5][a2122h-1b_1-5]/1-1-2/a3-b1_b2-c1",GlyTouCan accession,G14768FY
7270,147763,"2,5-anhydro-3-O-(2-O-sulfo-alpha-L-idopyranuronosyl)-D-glucitol","A disaccharide derivative that is 2,5-anhydro-D-glucitol in which the hydroxy group at position 3 has been glycosylated by a 2-O-sulfo-alpha-L-idopyranosyl group.","InChI=1S/C12H20O14S/c13-1-3-5(15)8(4(2-14)23-3)24-12-10(26-27(20,21)22)7(17)6(16)9(25-12)11(18)19/h3-10,12-17H,1-2H2,(H,18,19)(H,20,21,22)/t3-,4+,5-,6+,7+,8-,9-,10-,12-/m1/s1","WURCS=2.0/2,2,1/[h1122h_2-5][a2121A-1a_1-5_2*OSO/3=O/3=O]/1-2/a4-b1",GlyTouCan accession,G12067FX
7271,147787,isofloridoside,A galactosylglycerol that is glycerol in which one of the primary hydroxy groups has been converted into the corresponding alpha-D-galactopyranoside.,"InChI=1S/C9H18O8/c10-1-4(12)3-16-9-8(15)7(14)6(13)5(2-11)17-9/h4-15H,1-3H2/t4?,5-,6+,7+,8-,9+/m1/s1","WURCS=2.0/2,2,1/[hxh][a2112h-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G17876LI
7272,147798,alpha-D-Glcp-(1->4)-[alpha-D-Glcp-(1->6)]-beta-D-Glcp,A alpha-D-Glcp-(1->4)-[alpha-D-Glcp-(1->6)]-D-Glcp which has beta- configuration at the anomeric carbon.,"InChI=1S/C18H32O16/c19-1-4-7(21)9(23)13(27)17(32-4)30-3-6-15(11(25)12(26)16(29)31-6)34-18-14(28)10(24)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16-,17+,18-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5][a2122h-1a_1-5]/1-2-2/a4-b1_a6-c1",GlyTouCan accession,G12155KE
7273,147801,beta-L-Fucp-(1->3)-alpha-GlcpNAc,An amino disaccharide that is 2-acetamido-alpha-D-glucose in which the hydroxy group at position 3 has been glycosylated by a beta-L-fucosyl group.,"InChI=1S/C14H25NO10/c1-4-8(18)10(20)11(21)14(23-4)25-12-7(15-5(2)17)13(22)24-6(3-16)9(12)19/h4,6-14,16,18-22H,3H2,1-2H3,(H,15,17)/t4-,6+,7+,8+,9+,10+,11-,12+,13-,14+/m0/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a1221m-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G14882GG
7274,147812,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-L-Fucp,"An aminotrisaccharide consisting of beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and L-furopyranose residues joined in sequence by (1->4) and (1->3) glycosidic bonds.","InChI=1S/C20H35NO15/c1-5-10(25)17(15(30)18(31)32-5)36-19-9(21-6(2)24)12(27)16(8(4-23)34-19)35-20-14(29)13(28)11(26)7(3-22)33-20/h5,7-20,22-23,25-31H,3-4H2,1-2H3,(H,21,24)/t5-,7+,8+,9+,10+,11-,12+,13-,14+,15-,16+,17+,18?,19-,20-/m0/s1","WURCS=2.0/3,3,2/[a1221m-1x_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b4-c1",GlyTouCan accession,G17988BN
7275,147829,alpha-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"An amino trisaccharide consisting of alpha-D-mannopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and 2-acetamido-2-deoxy-D-glucopyranose residues joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-14(31)18(9(4-26)36-20(11)35)39-21-12(24-7(2)29)15(32)19(10(5-27)38-21)40-22-17(34)16(33)13(30)8(3-25)37-22/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14-,15-,16+,17+,18-,19-,20?,21+,22-/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1a_1-5]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G18081AA
7276,147850,alpha-Neup5Ac-(2->6)-D-Glcp,An amino disaccharide consisting of N-acetylneuraminic acid and D-glucopyranose residues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C19H32N2O14/c1-6(23)20-11-8(25)3-19(18(31)32,35-16(11)13(27)9(26)4-22)33-5-10-14(28)15(29)12(17(30)34-10)21-7(2)24/h8-17,22,25-30H,3-5H2,1-2H3,(H,20,23)(H,21,24)(H,31,32)/t8-,9+,10+,11+,12+,13+,14+,15+,16+,17?,19+/m0/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][Aad21122h-2a_2-6_5*NCC/3=O]/1-2/a6-b2",GlyTouCan accession,G18185ZH
7277,147873,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-D-Glcp,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose and D-glucopyranose residues joined in sequence by (1->2) and (1->6) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(24)21-9-13(28)10(25)6(2-22)35-19(9)37-17-15(30)11(26)7(3-23)36-20(17)33-4-8-12(27)14(29)16(31)18(32)34-8/h6-20,22-23,25-32H,2-4H2,1H3,(H,21,24)/t6-,7-,8-,9-,10-,11-,12-,13-,14+,15+,16-,17+,18?,19+,20+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a1122h-1a_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3/a6-b1_b2-c1",GlyTouCan accession,G15118OB
7278,147876,2-acetamido-2-deoxy-alpha-D-Galp-(1->3)-2-acetamido-2-deoxy-D-Gal-OH,A glycosyl alditol derivative that is N-acetyl-D-galactosaminitol in which the hydroxy group at position 3 has been converted into the corresponding 2-acetamido-2-deoxy-alpha-D-galactopyranosyl derivative.,"InChI=1S/C16H30N2O11/c1-6(22)17-8(3-19)15(12(25)9(24)4-20)29-16-11(18-7(2)23)14(27)13(26)10(5-21)28-16/h8-16,19-21,24-27H,3-5H2,1-2H3,(H,17,22)(H,18,23)/t8-,9+,10+,11+,12-,13-,14+,15+,16+/m0/s1","WURCS=2.0/2,2,1/[h2112h_2*NCC/3=O][a2112h-1a_1-5_2*NCC/3=O]/1-2/a3-b1",GlyTouCan accession,G15144TI
7279,147909,beta-D-GalpNAc4S-(1->4)-D-GlcNAc,An amino disaccharide consisting of 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose and 2-acetamido-2-deoxy-D-glucopyranose joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C16H28N2O14S/c1-5(21)17-9-11(23)13(7(3-19)29-15(9)25)31-16-10(18-6(2)22)12(24)14(8(4-20)30-16)32-33(26,27)28/h7-16,19-20,23-25H,3-4H2,1-2H3,(H,17,21)(H,18,22)(H,26,27,28)/t7-,8-,9-,10-,11-,12-,13-,14+,15?,16+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5_2*NCC/3=O_4*OSO/3=O/3=O]/1-2/a4-b1",GlyTouCan accession,G18464VS
7280,147915,Delta(4)-beta-D-GlcpA2S-(1->4)-beta-D-GlcpNS6S,An oligosaccharide sulfate that is Delta(4)-beta-D-GlcpA2S-(1->4)-beta-D-GlcpNS in which the hydroxy group at position 6 of the 2-sulfoamino-beta-D-glucopyranose moiety has been converted into the corresponding sulfamic acid derivative.,"InChI=1S/C12H19NO20S3/c14-4-3(13-34(20,21)22)11(19)30-2(1-29-35(23,24)25)7(4)31-12-9(33-36(26,27)28)6(16)5(15)8(32-12)10(17)18/h2-4,6-7,9,11-16,19H,1H2,(H,17,18)(H,20,21,22)(H,23,24,25)(H,26,27,28)/t2-,3-,4-,6+,7-,9-,11-,12-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5_2*OSO/3=O/3=O]/1-2/a4-b1",GlyTouCan accession,G15293GW
7281,147919,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glc-OH,"A glycosyl alditol consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose, beta-D-galactopyranose and D-glucitol joined in sequence by (1->3) and (1->4) glycosidic bonds.","InChI=1S/C20H37NO16/c1-6(26)21-11-15(32)13(30)9(4-24)34-19(11)37-18-14(31)10(5-25)35-20(16(18)33)36-17(8(28)3-23)12(29)7(27)2-22/h7-20,22-25,27-33H,2-5H2,1H3,(H,21,26)/t7-,8+,9+,10+,11+,12+,13+,14-,15+,16+,17+,18-,19-,20-/m0/s1","WURCS=2.0/3,3,2/[h2122h][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3/a4-b1_b3-c1",GlyTouCan accession,G18510JA
7282,147926,beta-D-idofuranose,A D-idofuranose that has beta configuration at the anomeric centre.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3+,4+,5+,6-/m1/s1","WURCS=2.0/1,1,0/[a1212h-1b_1-4]/1/",GlyTouCan accession,G18550QV
7283,147933,D-Galp-(1->4)-D-GlcpNAc-(1->3)-D-GalNAc-OH,"A glycosyl alditol derivative consisting of D-galactopyranose, 2-acetamido-2-deoxy-D-glucopyranose and 2-acetamido-2-deoxy-D-galactitol residues joined in sequence by (1->4) and (1->3) glycosidic bonds.","InChI=1S/C22H40N2O16/c1-7(29)23-9(3-25)19(14(32)10(31)4-26)39-21-13(24-8(2)30)16(34)20(12(6-28)38-21)40-22-18(36)17(35)15(33)11(5-27)37-22/h9-22,25-28,31-36H,3-6H2,1-2H3,(H,23,29)(H,24,30)/t9-,10+,11+,12+,13+,14-,15-,16+,17-,18+,19+,20+,21?,22?/m0/s1","WURCS=2.0/3,3,2/[h2112h_2*NCC/3=O][a2122h-1x_1-5_2*NCC/3=O][a2112h-1x_1-5]/1-2-3/a3-b1_b4-c1",GlyTouCan accession,G18564GN
7284,147940,beta-D-GlcpNAc-(1->6)-alpha-D-GalpNAc3S,An amino disaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose and 2-acetamido-2-deoxy-3-O-sulfo-alpha-D-galactopyranose residues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C16H28N2O14S/c1-5(20)17-9-13(24)11(22)7(3-19)31-16(9)29-4-8-12(23)14(32-33(26,27)28)10(15(25)30-8)18-6(2)21/h7-16,19,22-25H,3-4H2,1-2H3,(H,17,20)(H,18,21)(H,26,27,28)/t7-,8-,9-,10-,11-,12+,13-,14-,15+,16-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1a_1-5_2*NCC/3=O_3*OSO/3=O/3=O][a2122h-1b_1-5_2*NCC/3=O]/1-2/a6-b1",GlyTouCan accession,G18628GH
7285,147973,aldehydo-L-altrose,The open-chain form of L-altrose.,"InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2/t3-,4-,5+,6-/m0/s1","WURCS=2.0/1,1,0/[o2111h]/1/",GlyTouCan accession,G12969NX
7286,147975,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-D-Gal-OH,"A glycosyl alditol that is D-galactitol in which the hydroxy groups at positions 2 and 3 have been converted into the corresponding alpha-L-fucopyranosyl and alpha-D-galactopyranosyl derivatives, respectively.","InChI=1S/C18H34O15/c1-5-9(23)12(26)14(28)17(30-5)32-8(4-21)16(10(24)6(22)2-19)33-18-15(29)13(27)11(25)7(3-20)31-18/h5-29H,2-4H2,1H3/t5-,6+,7+,8-,9+,10-,11-,12+,13-,14-,15+,16+,17-,18+/m0/s1","WURCS=2.0/3,3,2/[h2112h][a1221m-1a_1-5][a2112h-1a_1-5]/1-2-3/a2-b1_a3-c1",GlyTouCan accession,G18740DM
7287,147978,?-D-Glcp-(1->2)-[?-D-Glcp-(1->6)]-beta-D-Glcp,A glucotriose that is beta-D-glucopyranose in which the hydroxy groups at positions 2 and 6 have been converted into D-glucopyranosyl derivatives.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)17(32-4)30-3-6-9(23)12(26)15(16(29)31-6)34-18-14(28)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16-,17?,18?/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5][a2122h-1x_1-5]/1-2-2/a2-b1_a6-c1",GlyTouCan accession,G12984CP
7288,147983,beta-D-Galp-(1->4)-alpha-D-Glcp-(1->6)-D-Glcp,"A trisaccharide consisting of beta-D-galactopyranose, alpha-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->4) and (1->6) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)18(32-4)34-15-5(2-20)33-17(14(28)11(15)25)30-3-6-8(22)9(23)12(26)16(29)31-6/h4-29H,1-3H2/t4-,5-,6-,7+,8-,9+,10+,11-,12-,13-,14-,15-,16?,17+,18+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1a_1-5][a2112h-1b_1-5]/1-2-3/a6-b1_b4-c1",GlyTouCan accession,G18792RR
7289,147984,beta-D-Galp-(1->4)-beta-D-GalpNAc,An amino disaccharide consisting of beta-D-galacopyranose and 2-acetamido-2-deoxy-beta-D-galactopyranose residues joined in sequence by a (1->4) glycosidic linkage.,"InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)12(6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12+,13-,14+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G13003UU
7290,147991,2-O-sulfo-beta-L-threo-hex-4-enopyranuronosyl-(1->4)-beta-D-GlcpNS,An oligosaccharide sulfate consisting of 2-O-sulfo-beta-L-threo-hex-4-enopyranuronose and 2-deoxy-2-(sulfoamino)-beta-D-glucopyranose joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C12H19NO17S2/c14-1-2-7(4(15)3(11(20)27-2)13-31(21,22)23)28-12-9(30-32(24,25)26)6(17)5(16)8(29-12)10(18)19/h2-4,6-7,9,11-17,20H,1H2,(H,18,19)(H,21,22,23)(H,24,25,26)/t2-,3-,4-,6+,7-,9-,11-,12+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5_2*NSO/3=O/3=O][a21EEA-1b_1-5_2*OSO/3=O/3=O]/1-2/a4-b1",GlyTouCan accession,G13045SZ
7291,147996,Delta(4)-beta-D-GlcpA2S-(1->3)-D-GalpNAc6S,An oligosaccharide sulfate that is 2-acetamido-2-deoxy-6-O-sulfo-D-galactopyranose in which the hydroxy group at position 3 has been converted into the corresponding 2-O-sulfo-alpha-L-threo-hex-4-enopyranuronoxyl derivative.,"InChI=1S/C14H21NO18S2/c1-3(16)15-5-9(6(17)4(30-13(5)22)2-29-34(23,24)25)31-14-11(33-35(26,27)28)8(19)7(18)10(32-14)12(20)21/h4-6,8-9,11,13-14,17-19,22H,2H2,1H3,(H,15,16)(H,20,21)(H,23,24,25)(H,26,27,28)/t4-,5-,6+,8+,9-,11-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5_2*OSO/3=O/3=O]/1-2/a3-b1",GlyTouCan accession,G18838XN
7292,148016,beta-D-GlcpA-(1->4)-alpha-D-GlcpNAc-(1->4)-beta-D-GlcpA,"An amino trisaccharide consisting of beta-D-glucopyranuronic acid, 2-acetamido-2-deoxy-alpha-D-glucopyranose and beta-D-glucopyranuronic acid residues joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C20H31NO18/c1-3(23)21-5-6(24)12(37-20-11(29)7(25)8(26)14(39-20)16(30)31)4(2-22)35-19(5)38-13-9(27)10(28)18(34)36-15(13)17(32)33/h4-15,18-20,22,24-29,34H,2H2,1H3,(H,21,23)(H,30,31)(H,32,33)/t4-,5-,6-,7+,8+,9-,10-,11-,12-,13+,14+,15+,18-,19-,20-/m1/s1","WURCS=2.0/2,3,2/[a2122A-1b_1-5][a2122h-1a_1-5_2*NCC/3=O]/1-2-1/a4-b1_b4-c1",GlyTouCan accession,G15805BE
7293,148021,alpha-D-Manp6P-(1->3)-D-Manp,A disaccharide phosphate consisting of 6-phospho-alpha-D-mannopyranose and D-mannopyranose residues joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C12H23O14P/c13-1-3-6(15)10(9(18)11(19)24-3)26-12-8(17)7(16)5(14)4(25-12)2-23-27(20,21)22/h3-19H,1-2H2,(H2,20,21,22)/t3-,4-,5-,6-,7+,8+,9+,10+,11?,12-/m1/s1","WURCS=2.0/2,2,1/[a1122h-1x_1-5][a1122h-1a_1-5_6*OPO/3O/3=O]/1-2/a3-b1",GlyTouCan accession,G18886LF
7294,148026,alpha-L-Fucp-(1->3)-D-mannitol,A disaccharide that is D-mannitol in which the hydroxy group at position 3 has been converted into the corresponding alpha-L-fucoside.,"InChI=1S/C12H24O10/c1-4-7(17)9(19)10(20)12(21-4)22-11(6(16)3-14)8(18)5(15)2-13/h4-20H,2-3H2,1H3/t4-,5+,6+,7+,8+,9+,10-,11+,12-/m0/s1","WURCS=2.0/2,2,1/[h1122h][a1221m-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G15833VM
7295,148031,alpha-L-galactofuranose,An L-galactofuranose that has alpha- configuration at the anomeric centre.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3-,4-,5+,6+/m0/s1","WURCS=2.0/1,1,0/[a1221h-1a_1-4]/1/",GlyTouCan accession,G18904MY
7296,148042,alpha-D-Glcp-(1->3)-[alpha-D-Glcp-(1->4)]-alpha-D-Glcp,An alpha-D-Glcp-(1->3)-[alpha-D-Glcp-(1->4)]-D-Glcp in which the carbon bearing the anomeric hydroxy group has alpha- configuration.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)30-16(29)13(28)15(14)34-18-12(27)10(25)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16+,17-,18-/m1/s1","WURCS=2.0/1,3,2/[a2122h-1a_1-5]/1-1-1/a3-b1_a4-c1",GlyTouCan accession,G16046ST
7297,148043,1-O-(beta-D-glucosyl)glycerol,A 1-O-(D-glucosyl)glycerol in which the D-glucosyl moiety has beta configuration at the anomeric centre.,"InChI=1S/C9H18O8/c10-1-4(12)3-16-9-8(15)7(14)6(13)5(2-11)17-9/h4-15H,1-3H2/t4?,5-,6-,7+,8-,9-/m1/s1","WURCS=2.0/2,2,1/[hxh][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G18923CQ
7298,148067,beta-D-Galp-(1->2)-[beta-D-Galp-(1->6)]-beta-D-Galp,A galactotriose that is beta-D-galactopyranose in which the hydroxy groups at positions 2 and 6 have been converted to the corresponding beta-D-galactopyranosyl derivatives.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)17(32-4)30-3-6-9(23)12(26)15(16(29)31-6)34-18-14(28)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10+,11+,12+,13-,14-,15-,16-,17-,18+/m1/s1","WURCS=2.0/1,3,2/[a2112h-1b_1-5]/1-1-1/a2-b1_a6-c1",GlyTouCan accession,G16235BU
7299,148092,alpha-L-Fucp-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp,A trisaccharide consisting that is beta-lactose in which the hydroxy group at the 3' position has been converted into the corresponding alpha-L-fucopyranosyl derivative.,"InChI=1S/C18H32O15/c1-4-7(21)9(23)12(26)17(29-4)33-15-8(22)5(2-19)31-18(13(15)27)32-14-6(3-20)30-16(28)11(25)10(14)24/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8-,9+,10+,11+,12-,13+,14+,15-,16+,17-,18-/m0/s1","WURCS=2.0/3,3,2/[a2122h-1b_1-5][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3/a4-b1_b3-c1",GlyTouCan accession,G16348WN
7300,148094,beta-D-GlcpNAc-(1->6)-beta-D-Galp,An amino disaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose and beta-D-galactopyranose residues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)8(18)5(2-16)26-14(7)24-3-6-9(19)11(21)12(22)13(23)25-6/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6-,7-,8-,9+,10-,11+,12-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2/a6-b1",GlyTouCan accession,G19089MC
7301,148105,beta-D-Glcp-(1->4)-D-Xylp,A disaccharide consisting of beta-D-glucopyranose and D-xylopyranose residues joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C11H20O10/c12-1-3-5(13)7(15)9(17)11(20-3)21-4-2-19-10(18)8(16)6(4)14/h3-18H,1-2H2/t3-,4-,5-,6+,7+,8-,9-,10?,11+/m1/s1","WURCS=2.0/2,2,1/[a212h-1x_1-5][a2122h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G19151RP
7302,148113,beta-D-GlcpNAc-(1->4)-[beta-D-Manp-(1->6)]-beta-D-GlcpNAc,"An amino trisaccharide that is 2-acetamido-2-deoxy-beta-D-glucopyranose in which the hydroxy groups at positions 4 and 6 have been converted into the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranosyl and beta-D-mannopyranosyl derivatives, respectively.","InChI=1S/C22H38N2O16/c1-6(27)23-11-16(32)19(40-21-12(24-7(2)28)15(31)13(29)8(3-25)38-21)10(37-20(11)35)5-36-22-18(34)17(33)14(30)9(4-26)39-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17+,18+,19-,20-,21+,22-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5]/1-1-2/a4-b1_a6-c1",GlyTouCan accession,G16421CZ
7303,148118,alpha-D-Galp-(1->3)-[alpha-D-Galp-(1->6)]-D-Glcp,A trisaccharide that is D-glucopyranose in which the hydroxy groups at positions 3 and 6 have each been converted into the corresponding alpha-D-galactopyranosyl derivative.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)12(26)17(32-4)30-3-6-9(23)15(14(28)16(29)31-6)34-18-13(27)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9-,10+,11+,12-,13-,14-,15+,16?,17+,18-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1x_1-5][a2112h-1a_1-5]/1-2-2/a3-b1_a6-c1",GlyTouCan accession,G13401SI
7304,148172,beta-D-Galp-(1->3)-beta-D-GlcNAcp-(1->6)-beta-D-Galp-(1->4)-beta-D-GlcNAcp,"An amino tetrasaccharide comprised of a linear sequence of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-beta-D-glucosamine residues linked (1->3), (1->6) and  (1->4).","InChI=1S/C28H48N2O21/c1-7(34)29-13-18(39)23(11(5-33)46-25(13)44)50-28-22(43)20(41)16(37)12(49-28)6-45-26-14(30-8(2)35)24(17(38)10(4-32)47-26)51-27-21(42)19(40)15(36)9(3-31)48-27/h9-28,31-33,36-44H,3-6H2,1-2H3,(H,29,34)(H,30,35)/t9-,10-,11-,12-,13-,14-,15+,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27+,28+/m1/s1","WURCS=2.0/2,4,3/[a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-1-2/a4-b1_b6-c1_c3-d1",GlyTouCan accession,G13626XX
7305,148180,Delta(4)-beta-D-GlcpA-(1->3)-beta-D-GalpNAc4S6S,"An amino disaccharide consisting of alpha-L-threo-hex-4-enopyranuronic acid and 2-acetaido-2-deoxy-4,6-di-O-sulfo-beta-D-galactopyranose joined in sequence by a (1->3) glycosidic bond.","InChI=1S/C14H21NO18S2/c1-3(16)15-5-10(31-14-8(19)6(17)7(18)11(32-14)12(20)21)9(33-35(26,27)28)4(30-13(5)22)2-29-34(23,24)25/h4-6,8-10,13-14,17-19,22H,2H2,1H3,(H,15,16)(H,20,21)(H,23,24,25)(H,26,27,28)/t4-,5-,6+,8-,9+,10-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5_2*NCC/3=O_4*OSO/3=O/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G19405OH
7306,148205,alpha-L-Arap-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc,An amino trisaccharide that is alpha-L-fucosyl-(1->4)-N-acetyl-beta-D-glucosamine in which the hydroxy group at position 3 of the N-acetyl-beta-D-glucosamine moiety has been converted to the corresponding alpha-L-arabinopyranosyl derivative.,"InChI=1S/C19H33NO14/c1-5-10(24)12(26)14(28)19(31-5)33-15-8(3-21)32-17(29)9(20-6(2)22)16(15)34-18-13(27)11(25)7(23)4-30-18/h5,7-19,21,23-29H,3-4H2,1-2H3,(H,20,22)/t5-,7-,8+,9+,10+,11-,12+,13+,14-,15+,16+,17+,18-,19-/m0/s1","WURCS=2.0/3,3,2/[a2122h-1b_1-5_2*NCC/3=O][a211h-1a_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G19629QE
7307,148206,D-Manp-(1->2)-D-Araf-(1->5)-D-Araf,A trisaccharide consisting of D-mannopyranose residue and two D-arabinofuranose residues joined in sequence by (1->2) and (1->5) glycosidic bonds.,"InChI=1S/C16H28O14/c17-1-4-7(19)10(22)12(24)15(28-4)30-13-9(21)5(2-18)29-16(13)26-3-6-8(20)11(23)14(25)27-6/h4-25H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13+,14?,15?,16?/m1/s1","WURCS=2.0/2,3,2/[a122h-1x_1-4][a1122h-1x_1-5]/1-1-2/a5-b1_b2-c1",GlyTouCan accession,G19630UG
7308,148215,beta-D-Manp-(1->4)-beta-D-Manp-(1->3)-D-Manp,A mannotriose consisting of two beta-D-mannopyranose residues and a D-mannopyranose residue joined in sequence by (1->4) and (1->3) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)32-18(12(27)10(14)25)34-15-8(23)5(2-20)30-16(29)13(15)28/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10-,11+,12+,13+,14-,15+,16?,17+,18+/m1/s1","WURCS=2.0/2,3,2/[a1122h-1x_1-5][a1122h-1b_1-5]/1-2-2/a3-b1_b4-c1",GlyTouCan accession,G19750UU
7309,148221,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-D-GlcNAc-ol,A glycosyl alditol derivative consisting of two alpha-D-mannopyranose residues and 2-acetamido-2-deoxy-D-glucitol joined in sequence by (1->2) and (1->3) glycosidic bonds.,"InChI=1S/C20H37NO16/c1-6(26)21-7(2-22)17(11(28)8(27)3-23)36-20-18(15(32)13(30)10(5-25)35-20)37-19-16(33)14(31)12(29)9(4-24)34-19/h7-20,22-25,27-33H,2-5H2,1H3,(H,21,26)/t7-,8+,9+,10+,11+,12+,13+,14-,15-,16-,17+,18-,19+,20+/m0/s1","WURCS=2.0/2,3,2/[h2122h_2*NCC/3=O][a1122h-1a_1-5]/1-2-2/a3-b1_b2-c1",GlyTouCan accession,G19798WM
7310,148224,beta-D-Glcp-(1->3)-beta-D-Glcp-(1->6)-beta-D-Glcp,A glucotriose consisting of three beta-D-glucopyranose residues joined in sequence by (1->3) and (1->6) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(21)11(25)13(27)18(33-4)34-15-9(23)5(2-20)32-17(14(15)28)30-3-6-8(22)10(24)12(26)16(29)31-6/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12-,13-,14-,15+,16-,17-,18+/m1/s1","WURCS=2.0/1,3,2/[a2122h-1b_1-5]/1-1-1/a6-b1_b3-c1",GlyTouCan accession,G19857HY
7311,148226,alpha-D-Galp-(1->2)-D-mannitol,A disaccharide that is D-mannitol in which the hydroxy group at position 2 has been converted into its alpha-D-galactopyranoside,"InChI=1S/C12H24O11/c13-1-4(16)7(17)8(18)5(2-14)22-12-11(21)10(20)9(19)6(3-15)23-12/h4-21H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12+/m1/s1","WURCS=2.0/2,2,1/[h1122h][a2112h-1a_1-5]/1-2/a5-b1",GlyTouCan accession,G19884IE
7312,148278,D-Manp-(1->2)-D-Araf,A disaccharide that is D-arabinofuranose in which the hydroxy group at position 2 has been converted into the corresponding D-mannopyranosyl derivative.,"InChI=1S/C11H20O10/c12-1-3-5(14)7(16)8(17)11(20-3)21-9-6(15)4(2-13)19-10(9)18/h3-18H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10?,11?/m1/s1","WURCS=2.0/2,2,1/[a122h-1x_1-4][a1122h-1x_1-5]/1-2/a2-b1",GlyTouCan accession,G20461NZ
7313,148293,beta-D-Glcp-(1->4)-alpha-D-Glcp-(1->1)-alpha-D-Glcp,A glucotriose consisting of a beta-D-glucopyranose residue and two alpha-D-glucopyranose residues joined in sequence by (1->4) and (1->1) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)12(27)16(30-4)33-15-6(3-21)32-18(14(29)11(15)26)34-17-13(28)10(25)8(23)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16+,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5][a2122h-1b_1-5]/1-1-2/a1-b1_b4-c1",GlyTouCan accession,G20789WJ
7314,148296,beta-L-Fucp-(1->4)-[alpha-D-Glcp-(1->3)]-D-Galp,A trisaccharide that is alpha-D-glucopyranosyl-(1->3)-D-galactopyranose in which the hydroxy group at position 4 of the galactopyranose ring has been converted into the corresponding beta-L-fucopyranosyl derivative.,"InChI=1S/C18H32O15/c1-4-7(21)9(23)11(25)17(29-4)32-14-6(3-20)30-16(28)13(27)15(14)33-18-12(26)10(24)8(22)5(2-19)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8+,9+,10-,11-,12+,13+,14-,15+,16?,17+,18+/m0/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2122h-1a_1-5][a1221m-1b_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G20862VU
7315,148298,alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcpNAc,A branched pentasaccharide consisting of a D-GlcNAc residue at the reducing end with an alpha-D-Man-(1->6)-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4) linkage.,"InChI=1S/C33H56N2O25/c1-8(39)34-15-20(45)26(12(4-37)54-29(15)51)58-30-16(35-9(2)40)21(46)27(13(5-38)56-30)59-33-28(60-32-24(49)17(42)10(41)6-52-32)23(48)19(44)14(57-33)7-53-31-25(50)22(47)18(43)11(3-36)55-31/h10-33,36-38,41-51H,3-7H2,1-2H3,(H,34,39)(H,35,40)/t10-,11-,12-,13-,14-,15-,16-,17+,18-,19-,20-,21-,22+,23+,24-,25+,26-,27-,28+,29?,30+,31+,32+,33+/m1/s1","WURCS=2.0/5,5,4/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a212h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-5/a4-b1_b4-c1_c2-d1_c6-e1",GlyTouCan accession,G20873FZ
7316,148308,alpha-D-Glcp-(1->6)-beta-D-Glcp-(1->6)-D-Glcp,"A glucotriose consisting of alpha-D-glucopyranose, beta-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->6) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-7(20)11(24)14(27)17(33-4)31-3-6-9(22)12(25)15(28)18(34-6)30-2-5-8(21)10(23)13(26)16(29)32-5/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16?,17+,18-/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1b_1-5][a2122h-1a_1-5]/1-2-3/a6-b1_b6-c1",GlyTouCan accession,G20959ZC
7317,148319,beta-D-Galp-(1->3)-D-Xylp,A disaccharide that is D-xylopyranose in which the hydroxy group at position 3 has been converted into the corresponding beta-D-galactopyranoside.,"InChI=1S/C11H20O10/c12-1-4-5(14)6(15)7(16)11(20-4)21-9-3(13)2-19-10(18)8(9)17/h3-18H,1-2H2/t3-,4-,5+,6+,7-,8-,9+,10?,11+/m1/s1","WURCS=2.0/2,2,1/[a212h-1x_1-5][a2112h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G21109IJ
7318,148321,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->3)-D-Galp,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and D-galactopyranose residues joined in sequence by (1->4) and (1->3) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)13(30)8(3-25)37-21(11)39-18-10(5-27)38-22(12(16(18)33)24-7(2)29)40-19-14(31)9(4-26)36-20(35)17(19)34/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19+,20?,21+,22+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5_2*NCC/3=O]/1-2-3/a3-b1_b4-c1",GlyTouCan accession,G21110GE
7319,148337,Delta(4)-beta-D-GlcpA2S-(1->3)-alpha-D-GlcpNAc,An oligosaccharide sulfate consisting of 2-O-sulfo-alpha-L-threo-hex-4-enopyranuronic acid and 2-acetamido-2-deoxy-alpha-D-glucopyranose residues joined in sequence by a (1->4) glycosidic linkage.,"InChI=1S/C14H21NO15S/c1-3(17)15-5-6(18)9(4(2-16)27-13(5)23)28-14-11(30-31(24,25)26)8(20)7(19)10(29-14)12(21)22/h4-6,8-9,11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/t4-,5-,6-,8+,9-,11-,13+,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a21EEA-1a_1-5_2*OSO/3=O/3=O]/1-2/a4-b1",GlyTouCan accession,G21302DD
7320,148339,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-D-GalNAc-OH,A glycosyl alditol derivative consisting of N-acetyllactosamine and N-acetyl-D-galactosaminitol joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C22H40N2O16/c1-7(28)23-9(3-25)14(31)15(32)10(30)6-37-21-13(24-8(2)29)17(34)20(12(5-27)39-21)40-22-19(36)18(35)16(33)11(4-26)38-22/h9-22,25-27,30-36H,3-6H2,1-2H3,(H,23,28)(H,24,29)/t9-,10+,11+,12+,13+,14+,15-,16-,17+,18-,19+,20+,21+,22-/m0/s1","WURCS=2.0/3,3,2/[h2112h_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a6-b1_b4-c1",GlyTouCan accession,G21312EA
7321,148357,alpha-D-Galp-(1->4)-L-Fucp,A disaccharide that is L-fucopyranose in which the hydroxy group at position 4 has been converted into the corresponding alpha-D-galactopyranoside.,"InChI=1S/C12H22O10/c1-3-10(7(16)8(17)11(19)20-3)22-12-9(18)6(15)5(14)4(2-13)21-12/h3-19H,2H2,1H3/t3-,4+,5-,6-,7-,8-,9+,10+,11?,12+/m0/s1","WURCS=2.0/2,2,1/[a1221m-1x_1-5][a2112h-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G21495MJ
7322,148368,alpha-D-Manp6P-(1->2)-alpha-D-Manp,A disaccharide phosphate consisting of a 6-O-phosphono-alpha-D-mannopyranose residue and a alpha-D-mannopyranose residue joined in sequence by a (1->2) glycosidic bond.,"InChI=1S/C12H23O14P/c13-1-3-5(14)8(17)10(11(19)24-3)26-12-9(18)7(16)6(15)4(25-12)2-23-27(20,21)22/h3-19H,1-2H2,(H2,20,21,22)/t3-,4-,5-,6-,7+,8+,9+,10+,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a1122h-1a_1-5][a1122h-1a_1-5_6*OPO/3O/3=O]/1-2/a2-b1",GlyTouCan accession,G21647CX
7323,148388,alpha-D-GalpNAc-(1->3)-D-GlcpNAc,An amino disaccharide consisting of 2-acetamido-2-deoxy-alpha-D-glucopyranose and 2-acetamido-2-deoxy-D-glucopyranose residues joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)11(23)7(3-19)28-16(9)29-14-10(18-6(2)22)15(26)27-8(4-20)12(14)24/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11+,12-,13-,14-,15?,16-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1a_1-5_2*NCC/3=O]/1-2/a3-b1",GlyTouCan accession,G21929KG
7324,148407,beta-D-Glcp-(1->2)-alpha-D-Glcp-(1->2)-D-Glcp,"A glucotriose consisting of beta-D-glucopyranose, alpha-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->2) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-8(23)11(26)14(16(29)30-4)33-18-15(12(27)9(24)6(3-21)32-18)34-17-13(28)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16?,17+,18-/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1a_1-5][a2122h-1b_1-5]/1-2-3/a2-b1_b2-c1",GlyTouCan accession,G22166FJ
7325,148414,beta-D-Galp-(1->3)-beta-D-GlcpNAc6S-(1->3)-D-GalNAc-OH,"An amino trisaccharide consisting of beta-D-galactopyranosyl, 2-acetamido-2-deoxy-2-O-sulfo-beta-D-glucopyranosyl and 2-acetamido-2-deoxygalactitol residues linked together in sequence by (1->3) glycosidic bonds.","InChI=1S/C22H40N2O19S/c1-7(28)23-9(3-25)19(14(31)10(30)4-26)42-21-13(24-8(2)29)20(16(33)12(41-21)6-39-44(36,37)38)43-22-18(35)17(34)15(32)11(5-27)40-22/h9-22,25-27,30-35H,3-6H2,1-2H3,(H,23,28)(H,24,29)(H,36,37,38)/t9-,10+,11+,12+,13+,14-,15-,16+,17-,18+,19+,20+,21-,22-/m0/s1","WURCS=2.0/3,3,2/[h2112h_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G22233KL
7326,148435,"3,4-dimethyl-1H-pyrazole phosphate","A phosphate salt obtained by reacting 3,4-dimethyl-1H-pyrazole with one equivalent of phosphoric acid. It is a nitrification inhibitor and when used on crops, it prevents nitrogen loss from soil, increases nitrogen use efficiency, and boosts crop yields.","InChI=1S/C5H8N2.H3O4P/c1-4-3-6-7-5(4)2;1-5(2,3)4/h3H,1-2H3,(H,6,7);(H3,1,2,3,4)","3,4-dimethylpyrazole phosphate",CAS Registry Number,202842-98-6
7327,148454,beta-D-GlcpNAc-(1->4)-[beta-L-Fucp-(1->6)]-beta-D-GlcpNAc,"An amino trisaccharide that is 2-acetamido-2-deoxy-beta-D-glucopyranose in which the hydroxy groups at positions 4 and 6 have been converted into the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranosyl and beta-L-fucopyranosyl derivatives, respectively.","InChI=1S/C22H38N2O15/c1-6-13(28)17(32)18(33)22(36-6)35-5-10-19(16(31)11(20(34)37-10)23-7(2)26)39-21-12(24-8(3)27)15(30)14(29)9(4-25)38-21/h6,9-22,25,28-34H,4-5H2,1-3H3,(H,23,26)(H,24,27)/t6-,9+,10+,11+,12+,13+,14+,15+,16+,17+,18-,19+,20+,21-,22-/m0/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5_2*NCC/3=O][a1221m-1b_1-5]/1-1-2/a4-b1_a6-c1",GlyTouCan accession,G28454KX
7328,148472,alpha-D-Glcp-(1->4)-[beta-D-Glcp-(1->3)]-D-Galp,"A trisaccharide that is D-galactopyranose in which the hydroxy groups at positions 3 and 4 have been converted to the beta-D-glucopyranosyl and alpha-D-glucopyranosyl derivatives, respectively.","InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)30-16(29)13(28)15(14)34-18-12(27)10(25)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14+,15-,16?,17-,18+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2122h-1b_1-5][a2122h-1a_1-5]/1-2-3/a3-b1_a4-c1",GlyTouCan accession,G25566KR
7329,148489,alpha-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-GlcpNAc,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-alpha-D-glucopyranose, beta-D-galactopyranose and 2-acetamido-2-deoxy-D-glucopyranose joined in sequence by (1->3) and (1->4) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)18(10(5-27)36-20(11)35)39-22-17(34)19(14(31)9(4-26)38-22)40-21-12(24-7(2)29)15(32)13(30)8(3-25)37-21/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14+,15-,16-,17-,18-,19+,20?,21-,22+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5][a2122h-1a_1-5_2*NCC/3=O]/1-2-3/a4-b1_b3-c1",GlyTouCan accession,G25654KH
7330,148498,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->4)]-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,"An oligosaccharide derivative derived from a dodecasaccharide comprising a linear trisaccharide of beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-D-glucosamine residues linked (1->4) and (1->4), to the D-mannosyl residue of which are glycosidically linked two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl trisaccharide units [linked (1->3) and (1->6)] and a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl disaccharide unit [linked (1->4)], while the terminal N-acetyl-D-glucosamine carries an alpha-L-fucosyl residue via a (1->6) linkage.","InChI=1S/C82H137N5O60/c1-18-40(102)51(113)57(119)76(127-18)125-16-33-66(46(108)35(71(124)128-33)83-19(2)97)139-72-36(84-20(3)98)47(109)65(32(15-96)134-72)143-80-61(123)68(145-82-70(56(118)45(107)28(11-92)133-82)147-75-39(87-23(6)101)50(112)64(31(14-95)137-75)142-79-60(122)54(116)43(105)26(9-90)131-79)67(144-73-37(85-21(4)99)48(110)62(29(12-93)135-73)140-77-58(120)52(114)41(103)24(7-88)129-77)34(138-80)17-126-81-69(55(117)44(106)27(10-91)132-81)146-74-38(86-22(5)100)49(111)63(30(13-94)136-74)141-78-59(121)53(115)42(104)25(8-89)130-78/h18,24-82,88-96,102-124H,7-17H2,1-6H3,(H,83,97)(H,84,98)(H,85,99)(H,86,100)(H,87,101)/t18-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41-,42-,43-,44+,45+,46+,47+,48+,49+,50+,51+,52-,53-,54-,55-,56-,57-,58+,59+,60+,61-,62+,63+,64+,65+,66+,67+,68+,69-,70-,71?,72-,73-,74-,75-,76+,77-,78-,79-,80-,81-,82+/m0/s1",beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)][beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->6)]-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G28678TH
7331,148529,beta-D-GlcpNAc-(1->3)-[beta-L-Fucp-(1->6)]-beta-D-GlcpNAc,"An amino disaccharide that is 2-acetamido-2-deoxy-beta-D-glucopyranose in which the hydroxy groups at positions 3 and 6 have been converted into the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranosyl and beta-L-fucopyanosyl derivatives, respectively.","InChI=1S/C22H38N2O15/c1-6-13(28)17(32)18(33)22(36-6)35-5-10-15(30)19(12(20(34)37-10)24-8(3)27)39-21-11(23-7(2)26)16(31)14(29)9(4-25)38-21/h6,9-22,25,28-34H,4-5H2,1-3H3,(H,23,26)(H,24,27)/t6-,9+,10+,11+,12+,13+,14+,15+,16+,17+,18-,19+,20+,21-,22-/m0/s1","WURCS=2.0/2,3,2/[a2122h-1b_1-5_2*NCC/3=O][a1221m-1b_1-5]/1-1-2/a3-b1_a6-c1",GlyTouCan accession,G25833JG
7332,148535,beta-D-GlcpNAc-(1->6)-alpha-D-Manp-(1->6)-beta-D-Manp,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose and beta-D-mannopyranose residues joined in sequence by (1->6) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(23)21-9-13(27)10(24)6(2-22)36-19(9)33-4-8-12(26)15(29)17(31)20(37-8)34-3-7-11(25)14(28)16(30)18(32)35-7/h6-20,22,24-32H,2-4H2,1H3,(H,21,23)/t6-,7-,8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18-,19-,20+/m1/s1","WURCS=2.0/3,3,2/[a1122h-1b_1-5][a1122h-1a_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3/a6-b1_b6-c1",GlyTouCan accession,G23000DQ
7333,148542,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-D-Galp,"An amino trisaccharide consisting of beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and D-galactopyranose residues joined in sequence by (1->3) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(25)21-9-16(36-20-14(30)13(29)10(26)6(2-22)35-20)11(27)8(4-24)34-19(9)37-17-12(28)7(3-23)33-18(32)15(17)31/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11-,12+,13+,14-,15-,16-,17+,18?,19+,20+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G23041XK
7334,148543,?-D-GlcpNAc-(1->3)-?-D-Galp-(1->3)-D-GalNAc-OH,"A glycosyl alditol derivative consisting of 2-acetamido-2-deoxy-D-glucopyranose, D-galactopyranose and 2-acetamido-2-deoxy-D-galactitol residues joined in sequence by (1->3) glycosidic bonds.","InChI=1S/C22H40N2O16/c1-7(29)23-9(3-25)19(14(32)10(31)4-26)39-22-18(36)20(16(34)12(6-28)38-22)40-21-13(24-8(2)30)17(35)15(33)11(5-27)37-21/h9-22,25-28,31-36H,3-6H2,1-2H3,(H,23,29)(H,24,30)/t9-,10+,11+,12+,13+,14-,15+,16-,17+,18+,19+,20-,21?,22?/m0/s1","WURCS=2.0/3,3,2/[h2112h_2*NCC/3=O][a2112h-1x_1-5][a2122h-1x_1-5_2*NCC/3=O]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G25869EQ
7335,148560,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,A branched amino hexasaccharide derivative that is beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the D-GlcNAc residue at the reducing end is substituted at position 6 by an alpha-L-Fuc residue.,"InChI=1S/C42H71N3O30/c1-10-22(53)29(60)31(62)40(66-10)65-9-18-34(27(58)19(37(64)67-18)43-11(2)50)72-39-21(45-13(4)52)28(59)33(17(8-49)71-39)73-41-32(63)35(25(56)16(7-48)69-41)74-42-36(30(61)24(55)15(6-47)70-42)75-38-20(44-12(3)51)26(57)23(54)14(5-46)68-38/h10,14-42,46-49,53-64H,5-9H2,1-4H3,(H,43,50)(H,44,51)(H,45,52)/t10-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30-,31-,32-,33+,34+,35-,36-,37?,38-,39-,40+,41-,42+/m0/s1",GlcNAc(b1-2)Man(a1-3)Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc,GlyTouCan accession,G28987BJ
7336,148564,alpha-L-IdoA-(1->3)-D-Galp4S,An oligosaccharide sulfate consisting of alpha-L-pyranuronosyl and 2-acetamido-2-deoxy-4-O-sulfo-D-galactopyranose residues joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C14H23NO15S/c1-3(17)15-5-10(9(30-31(24,25)26)4(2-16)27-13(5)23)28-14-8(20)6(18)7(19)11(29-14)12(21)22/h4-11,13-14,16,18-20,23H,2H2,1H3,(H,15,17)(H,21,22)(H,24,25,26)/t4-,5-,6+,7+,8-,9+,10-,11-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O_4*OSO/3=O/3=O][a2121A-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G28998FZ
7337,148578,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-D-Glc-OH,"A glycosyl alditol consisting of alpha-L-fucopyranose, beta-D-galactopyranose, and D-glucitol joined in sequence by (1->2) and (1->3) glycosidic bonds.","InChI=1S/C18H34O15/c1-5-9(24)12(27)14(29)17(30-5)33-16-13(28)11(26)8(4-21)31-18(16)32-15(7(23)3-20)10(25)6(22)2-19/h5-29H,2-4H2,1H3/t5-,6+,7-,8+,9+,10+,11-,12+,13-,14-,15+,16+,17-,18-/m0/s1","WURCS=2.0/3,3,2/[h2122h][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_b2-c1",GlyTouCan accession,G23214KL
7338,148586,alpha-D-Glcp-(1->4)-[beta-D-Glcp-(1->2)]-D-Glcp,"A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 2 and 4 have been converted into the corresponding beta-D-glucopyranosyl and alpha-D-glucopyranosyl derivatives, respectively.","InChI=1S/C18H32O16/c19-1-4-7(22)9(24)11(26)17(31-4)33-14-6(3-21)30-16(29)15(13(14)28)34-18-12(27)10(25)8(23)5(2-20)32-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13+,14-,15-,16?,17-,18+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1b_1-5][a2122h-1a_1-5]/1-2-3/a2-b1_a4-c1",GlyTouCan accession,G23251MK
7339,148602,?-D-Glcp-(1->2)-[?-D-Glcp-(1->6)]-?-D-Glcp,A glucotriose that is D-glucopyranose in which the hydroxy groups at positions 2 and 6 have been converted into the corresponding D-glucopyranosyl derivatives.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)17(32-4)30-3-6-9(23)12(26)15(16(29)31-6)34-18-14(28)11(25)8(22)5(2-20)33-18/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12+,13-,14-,15-,16?,17?,18?/m1/s1","WURCS=2.0/1,3,2/[a2122h-1x_1-5]/1-1-1/a2-b1_a6-c1",GlyTouCan accession,G23320JT
7340,148606,3-O-alpha-D-galactosyl-sn-glycerol,A isofloridoside in which position 2 of the glyceryl moiety has R configuration.,"InChI=1S/C9H18O8/c10-1-4(12)3-16-9-8(15)7(14)6(13)5(2-11)17-9/h4-15H,1-3H2/t4-,5-,6+,7+,8-,9+/m1/s1","WURCS=2.0/2,2,1/[h2h][a2112h-1a_1-5]/1-2/a1-b1",GlyTouCan accession,G26065MH
7341,148643,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,"A linear amino tetrasaccharide comprising a (1->3), (1->4), (1->3) sequence of N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine and (at the reducing end) N-acetyl-alpha-D-galactosamine.","InChI=1S/C30H51N3O21/c1-8(38)31-15-21(44)18(41)11(4-34)49-28(15)54-26-20(43)13(6-36)50-30(23(26)46)52-24-14(7-37)51-29(16(22(24)45)32-9(2)39)53-25-17(33-10(3)40)27(47)48-12(5-35)19(25)42/h11-30,34-37,41-47H,4-7H2,1-3H3,(H,31,38)(H,32,39)(H,33,40)/t11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21-,22-,23-,24-,25-,26+,27+,28+,29+,30+/m1/s1",GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-3)a-GalNAc,GlyTouCan accession,G23438NR
7342,148667,alpha-D-Xylf-(1->3)-alpha-D-Xylf-(1->3)-D-Glcp,A trisaccharide consisting of two alpha-D-xylofuranose residues and a D-glucopyranose residue joined in sequence by two (1->3) glycosidic bonds.,"InChI=1S/C16H28O14/c17-1-4-7(20)9(22)15(27-4)29-12-6(3-19)28-16(11(12)24)30-13-8(21)5(2-18)26-14(25)10(13)23/h4-25H,1-3H2/t4-,5-,6-,7+,8-,9-,10-,11-,12+,13+,14?,15-,16-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1x_1-5][a212h-1a_1-4]/1-2-2/a3-b1_b3-c1",GlyTouCan accession,G23539GZ
7343,148687,Delta(4)-beta-D-GlcpA-(1->4)-D-GlcpNS6S,An amino disaccharide consisting of alpha-L-threo-hex-4-enopyranuronic acid and 2-deoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranose joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C12H19NO17S2/c14-4-3(13-31(21,22)23)11(20)28-2(1-27-32(24,25)26)8(4)29-12-7(17)5(15)6(16)9(30-12)10(18)19/h2-5,7-8,11-17,20H,1H2,(H,18,19)(H,21,22,23)(H,24,25,26)/t2-,3-,4-,5+,7-,8-,11?,12-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G29391VY
7344,148693,alpha-L-Fucp-(1->3)-beta-D-GlcpNAc-(1->6)-D-GalpNAc,"An amino trisaccharide consisting of alpha-L-fucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose and 2-acetamido-2-deoxy-D-galactopyranose residues joined in sequence by (1->3) and (1->6) glycosidic bonds.","InChI=1S/C22H38N2O15/c1-6-13(28)17(32)18(33)22(36-6)39-19-12(24-8(3)27)21(38-9(4-25)15(19)30)35-5-10-14(29)16(31)11(20(34)37-10)23-7(2)26/h6,9-22,25,28-34H,4-5H2,1-3H3,(H,23,26)(H,24,27)/t6-,9+,10+,11+,12+,13+,14-,15+,16+,17+,18-,19+,20?,21+,22-/m0/s1","WURCS=2.0/3,3,2/[a2112h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5]/1-2-3/a6-b1_b3-c1",GlyTouCan accession,G26452XA
7345,148695,"4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->2)-beta-D-Galp-(1->4)-D-GlcpNAc","An amino trisaccharide consisting of 4,6-dideoxy-alpha-L-xylo-hexopyranose, beta-D-galactopyranose and 2-acetamido-2-deoxy-D-glucopyranose residues joined in sequence by (1->2) and (1->4) glycosidic bonds.","InChI=1S/C20H35NO14/c1-6-3-8(25)12(26)19(31-6)35-17-15(29)13(27)9(4-22)33-20(17)34-16-10(5-23)32-18(30)11(14(16)28)21-7(2)24/h6,8-20,22-23,25-30H,3-5H2,1-2H3,(H,21,24)/t6-,8+,9+,10+,11+,12-,13-,14+,15-,16+,17+,18?,19-,20-/m0/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5][a12d1m-1a_1-5]/1-2-3/a4-b1_b2-c1",GlyTouCan accession,G23645NH
7346,148702,alpha-D-GalpNAc-(1->6)-D-GalpNAc,A disaccharide consisting of a 2-acetamido-2-deoxy-D-galactose residue and a 2-acetamido-2-deoxy-alpha-D-galactose residue joined by a (1->6) glycosidic bond.,"InChI=1S/C16H28N2O11/c1-5(20)17-9-13(24)12(23)8(28-15(9)26)4-27-16-10(18-6(2)21)14(25)11(22)7(3-19)29-16/h7-16,19,22-26H,3-4H2,1-2H3,(H,17,20)(H,18,21)/t7-,8-,9-,10-,11+,12+,13-,14-,15?,16+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O][a2112h-1a_1-5_2*NCC/3=O]/1-2/a6-b1",GlyTouCan accession,G23652VU
7347,148725,beta-D-GlcpNAc-(1->2)-[beta-D-GlcpNAc-(1->6)]-D-Galp,An amino trisaccharide that is D-galactopyranose in which the hydroxy groups at posiitons 2 and 6 have been converted into the corresponding 2-acetamido-2-deoxy-beta-D-glucopyranosyl derivatives.,"InChI=1S/C22H38N2O16/c1-6(27)23-11-16(32)13(29)8(3-25)38-21(11)36-5-10-15(31)18(34)19(20(35)37-10)40-22-12(24-7(2)28)17(33)14(30)9(4-26)39-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13-,14-,15+,16-,17-,18+,19-,20?,21-,22+/m1/s1","WURCS=2.0/2,3,2/[a2112h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-2/a2-b1_a6-c1",GlyTouCan accession,G23747ZO
7348,148774,alpha-D-Glcp-(1->3)-D-Glc-OH,A glycosyl alditol consisting of D-glucitol in which the hydroxy group at position 3 has been converted into the corresponding beta-D-glucopyranosyl derivative.,"InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6-,7-,8-,9+,10-,11-,12-/m1/s1","WURCS=2.0/2,2,1/[h2122h][a2122h-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G23909UE
7349,148775,beta-D-Glcp-(1->3)-alpha-D-Glcp-(1->2)-D-Glcp,"A glucotriose consisting of beta-D-glucopyranose, alpha-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->3) and (1->2) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-8(23)11(26)15(16(29)30-4)34-18-13(28)14(9(24)6(3-21)32-18)33-17-12(27)10(25)7(22)5(2-20)31-17/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9-,10+,11+,12-,13-,14+,15-,16?,17+,18-/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1a_1-5][a2122h-1b_1-5]/1-2-3/a2-b1_b3-c1",GlyTouCan accession,G26768BK
7350,148785,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpN,"An amino trisaccharide consisting of alpha-L-fucopyranose, beta-D-galactopyranose and 2-amino-2-deoxypyranose joined in sequence by (1->2) and (1->3) glycosidic bonds.","InChI=1S/C18H33NO14/c1-4-8(22)11(25)13(27)17(29-4)33-15-12(26)9(23)5(2-20)31-18(15)32-14-7(19)16(28)30-6(3-21)10(14)24/h4-18,20-28H,2-3,19H2,1H3/t4-,5+,6+,7+,8+,9-,10+,11+,12-,13-,14+,15+,16+,17-,18-/m0/s1","WURCS=2.0/3,3,2/[a2122h-1b_1-5_2*N][a2112h-1b_1-5][a1221m-1a_1-5]/1-2-3/a3-b1_b2-c1",GlyTouCan accession,G23935WM
7351,148786,alpha-D-GalpNAc-(1->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-alpha-D-galactopyranose, beta-D-galactopyranose and 2-acetamido-2-deoxy-beta-D-glucopyranose residu joined in sequence by (1->3) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-16(33)13(30)8(3-25)37-21(11)40-19-15(32)10(5-27)38-22(17(19)34)39-18-12(24-7(2)29)20(35)36-9(4-26)14(18)31/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13+,14-,15+,16-,17-,18-,19+,20-,21-,22+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][a2112h-1a_1-5_2*NCC/3=O]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G29787UO
7352,148840,Delta(4)-beta-D-GlcpA-(1->4)-D-GlcpNAc6S,An oligosaccharide sufate consisting of alpha-L-threo-hex-4-enopyranuronic acid and 2-acetamido-2-deoxy-6-O-sulfo-D-glucopyranose joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C14H21NO15S/c1-3(16)15-5-6(17)10(4(28-13(5)23)2-27-31(24,25)26)29-14-9(20)7(18)8(19)11(30-14)12(21)22/h4-7,9-10,13-14,17-20,23H,2H2,1H3,(H,15,16)(H,21,22)(H,24,25,26)/t4-,5-,6-,7+,9-,10-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G24259NZ
7353,148849,alpha-D-GlcpNAc-(1->4)-[beta-L-Fucp-(1->6)]-alpha-D-GlcpNAc,"An amino trisaccharide that is 2-acetamido-2-deoxy-alpha-D-glucopyranose in which the hydroxy groups at positions 4 and 6 have been converted into the corresponding 2-acetamido-2-deoxy-alpha-D-glucopyranosy and beta-L-fucopyranosyl derivatives, respectively.","InChI=1S/C22H38N2O15/c1-6-13(28)17(32)18(33)22(36-6)35-5-10-19(16(31)11(20(34)37-10)23-7(2)26)39-21-12(24-8(3)27)15(30)14(29)9(4-25)38-21/h6,9-22,25,28-34H,4-5H2,1-3H3,(H,23,26)(H,24,27)/t6-,9+,10+,11+,12+,13+,14+,15+,16+,17+,18-,19+,20-,21+,22-/m0/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5_2*NCC/3=O][a1221m-1b_1-5]/1-1-2/a4-b1_a6-c1",GlyTouCan accession,G24285GM
7354,148869,alpha-D-galactosamine,A 2-amino-2-deoxy-D-galactopyranose that has alpha- configuration at the anomeric centre.,"InChI=1S/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4+,5-,6+/m1/s1","WURCS=2.0/1,1,0/[a2112h-1a_1-5_2*N]/1/",CAS Registry Number,14196-84-0
7355,148881,alpha-D-GlcpNAc-(1->4)-beta-D-Galp-(1->4)-D-GlcpNAc,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-alpha-D-glucopyranose, beta-D-galactopyranose and 2-acetamido-2-deoxy-D-glucopyranose residues joined in sequence by (1->4) glycosidic bonds.","InChI=1S/C22H38N2O16/c1-6(28)23-11-15(32)18(9(4-26)36-20(11)35)40-22-17(34)16(33)19(10(5-27)38-22)39-21-12(24-7(2)29)14(31)13(30)8(3-25)37-21/h8-22,25-27,30-35H,3-5H2,1-2H3,(H,23,28)(H,24,29)/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19+,20?,21-,22+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5][a2122h-1a_1-5_2*NCC/3=O]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G27180BG
7356,148906,beta-D-Galp-(1->4)-beta-D-GlcNAc-(1->6)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)]-beta-D-Galp-(1->4)-D-Glcp,"A branched amino heptasaccharide comprising a linear tetrasaccharide unit of beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and D-glucose residues linked in a (1->4), (1->6 and (1->4) sequence, with an alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl trisaccharide unit linked (1->3) to the galactose residue proximal to the reducing end.","InChI=1S/C46H78N2O35/c1-10-21(56)27(62)32(67)43(72-10)83-39-29(64)23(58)14(5-50)76-46(39)81-37-20(48-12(3)55)42(74-15(6-51)24(37)59)82-38-25(60)18(78-45(34(38)69)80-36-16(7-52)73-40(70)31(66)30(36)65)9-71-41-19(47-11(2)54)26(61)35(17(8-53)77-41)79-44-33(68)28(63)22(57)13(4-49)75-44/h10,13-46,49-53,56-70H,4-9H2,1-3H3,(H,47,54)(H,48,55)/t10-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24+,25-,26+,27+,28-,29-,30+,31+,32-,33+,34+,35+,36+,37+,38-,39+,40?,41+,42-,43-,44-,45-,46-/m0/s1",6-deoxy-alpha-L-galacto-hexopyranosyl-(1->2)-beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->3)-[beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->6)]-beta-D-galacto-hexopyranosyl-(1->4)-D-gluco-hexopyranose,GlyTouCan accession,G24504JY
7357,148907,beta-D-Glcp-(1->4)-beta-D-Galp-(1->4)-alpha-D-Glcp,"A trisaccharide consisting of beta-D-galactopyranose, beta-D-galactopyranose and alpha-D-glucopyranose residues joined in sequence by (1->4) glycosidic linkages.","InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11-,12-,13-,14-,15+,16+,17+,18+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1a_1-5][a2112h-1b_1-5][a2122h-1b_1-5]/1-2-3/a4-b1_b4-c1",GlyTouCan accession,G30285SX
7358,148911,alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->3)-beta-D-Galp-(1->4)]-D-GlcpNAc,An amino tetrasaccharide consisting that is alpha-L-fucopyranosyl-(1->3)-beta-D-galactopyranosyl-(1->4)]-2-acetamido-2-deoxy-D-glucopyranose in which the 2-acetaminoglucopyranose moiety has been glycosylated at position 3 by an alpha-L-fucopyranosyl group.,"InChI=1S/C26H45NO19/c1-6-12(31)15(34)17(36)24(40-6)45-21-11(27-8(3)30)23(39)42-10(5-29)20(21)44-26-19(38)22(14(33)9(4-28)43-26)46-25-18(37)16(35)13(32)7(2)41-25/h6-7,9-26,28-29,31-39H,4-5H2,1-3H3,(H,27,30)/t6-,7-,9+,10+,11+,12+,13+,14-,15+,16+,17-,18-,19+,20+,21+,22-,23?,24-,25-,26-/m0/s1","WURCS=2.0/3,4,3/[a2122h-1x_1-5_2*NCC/3=O][a1221m-1a_1-5][a2112h-1b_1-5]/1-2-3-2/a3-b1_a4-c1_c3-d1",GlyTouCan accession,G30292OP
7359,148939,beta-D-Glcp-(1->3)-beta-D-Arap,A beta-D-Glcp-(1->3)-D-Arap in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C11H20O10/c12-1-4-5(14)6(15)7(16)11(20-4)21-9-3(13)2-19-10(18)8(9)17/h3-18H,1-2H2/t3-,4-,5-,6+,7-,8+,9-,10-,11+/m1/s1","WURCS=2.0/2,2,1/[a122h-1b_1-5][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G30340TO
7360,148945,Delta(4)-beta-D-GlcpA-(1->4)-alpha-D-GlcpNAc6S,A Delta(4)-beta-D-GlcpA-(1->4)-D-Glcp in which the the carbon bearing the anomeric hydroxy group has alpha- configuration.,"InChI=1S/C14H21NO15S/c1-3(16)15-5-6(17)10(4(28-13(5)23)2-27-31(24,25)26)29-14-9(20)7(18)8(19)11(30-14)12(21)22/h4-7,9-10,13-14,17-20,23H,2H2,1H3,(H,15,16)(H,21,22)(H,24,25,26)/t4-,5-,6-,7+,9-,10-,13+,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G24621KS
7361,148960,alpha-D-Galf-(1->3)-beta-D-GlcpNAc,An amino disaccharide consisting of alpha-D-glucofuranosyl and 2-acetamido-2-deoxy-beta-D-glucopyranose residues joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C14H25NO11/c1-4(18)15-7-12(8(20)6(3-17)24-13(7)23)26-14-10(22)9(21)11(25-14)5(19)2-16/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10-,11+,12-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5_2*NCC/3=O][a2112h-1a_1-4]/1-2/a3-b1",GlyTouCan accession,G30377PI
7362,148968,beta-D-Galp-(1->6)-D-GalpNAc,An amino disaccharide consisting of beta-D-galactopyranose and 2-acetamido-2-deoxy-D-galactopyranose resicues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)9(19)6(25-13(7)23)3-24-14-12(22)11(21)8(18)5(2-16)26-14/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6-,7-,8+,9+,10-,11+,12-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2/a6-b1",GlyTouCan accession,G27589TC
7363,148969,beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->3)]-beta-D-GalpNAc,"An amino trisaccharide that is 2-acetamido-2-deoxy-beta-D-galactopyranose in which the hydroxy groups at positions 3 and 6 have been converted into the corresponding beta-D-galactopyranosyl and 2-acetamido-2-deoxy-beta-D-glucopyransoyl derivatives, respectively.","InChI=1S/C22H38N2O16/c1-6(27)23-11-16(32)13(29)8(3-25)38-21(11)36-5-10-15(31)19(12(20(35)37-10)24-7(2)28)40-22-18(34)17(33)14(30)9(4-26)39-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13-,14+,15+,16-,17+,18-,19-,20-,21-,22+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3/a3-b1_a6-c1",GlyTouCan accession,G24720OO
7364,148970,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,A branched amino octasaccharide consisting of a D-GlcNAc residue at the reducing end with a beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4)-linkage and an alpha-L-Fuc residue attached via an alpha-(1->6)-linkage.,"InChI=1S/C53H89N3O39/c1-12-26(65)35(74)39(78)49(84-12)83-11-22-42(33(72)23(46(80)85-22)54-13(2)61)91-48-25(56-15(4)63)34(73)41(20(8-60)89-48)92-53-45(95-51-38(77)27(66)16(64)9-81-51)43(31(70)21(90-53)10-82-50-40(79)36(75)29(68)18(6-58)87-50)93-52-44(37(76)30(69)19(7-59)88-52)94-47-24(55-14(3)62)32(71)28(67)17(5-57)86-47/h12,16-53,57-60,64-80H,5-11H2,1-4H3,(H,54,61)(H,55,62)(H,56,63)/t12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28+,29+,30+,31+,32+,33+,34+,35+,36-,37-,38+,39-,40-,41+,42+,43-,44-,45-,46?,47-,48-,49+,50-,51-,52+,53-/m0/s1","WURCS=2.0/6,8,7/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a212h-1b_1-5][a1122h-1a_1-5][a1221m-1a_1-5]/1-2-3-4-5-2-5-6/a4-b1_a6-h1_b4-c1_c2-d1_c3-e1_c6-g1_e2-f1",GlyTouCan accession,G30416OM
7365,149010,beta-D-Galp-(1->9)-Neup5Ac,A member of the class of neuraminic acids that is N-acetylneuraminic acid in which the hydroxy group at position 9 has been glycosylated by a beta-D-galactopyranosyl group.,"InChI=1S/C17H29NO14/c1-5(20)18-9-6(21)2-17(29,16(27)28)32-14(9)10(23)7(22)4-30-15-13(26)12(25)11(24)8(3-19)31-15/h6-15,19,21-26,29H,2-4H2,1H3,(H,18,20)(H,27,28)/t6-,7+,8+,9+,10+,11-,12-,13+,14+,15+,17?/m0/s1","WURCS=2.0/2,2,1/[Aad21122h-2x_2-6_5*NCC/3=O][a2112h-1b_1-5]/1-2/a9-b1",GlyTouCan accession,G27749HZ
7366,149025,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino heptasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by an alpha-D-Man-(1->2)-alpha-D-Man group.,"InChI=1S/C48H81N3O36/c1-11(58)49-21-30(67)37(18(8-56)76-42(21)74)83-44-23(51-13(3)60)31(68)38(19(9-57)81-44)84-46-36(73)39(85-48-41(34(71)27(64)17(7-55)80-48)86-43-22(50-12(2)59)29(66)24(61)14(4-52)77-43)28(65)20(82-46)10-75-47-40(33(70)26(63)16(6-54)79-47)87-45-35(72)32(69)25(62)15(5-53)78-45/h14-48,52-57,61-74H,4-10H2,1-3H3,(H,49,58)(H,50,59)(H,51,60)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32+,33+,34+,35+,36+,37-,38-,39+,40+,41+,42?,43+,44+,45-,46+,47+,48-/m1/s1",2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[alpha-D-manno-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G30673AC
7367,149033,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)--D-GalpNAc,"An aminotetrasaccharide consisting of 2-acetamido-beta-D-glucopyranose, beta-D-galactopyranose, 2-acetamido-beta-D-glucopyranose and 2-acetamido-D-galactopyranose residues joined in sequence by (1->3) glycosidic linkages.","InChI=1S/C30H51N3O21/c1-8(38)31-15-22(45)18(41)11(4-34)49-28(15)54-26-21(44)14(7-37)51-30(23(26)46)53-25-17(33-10(3)40)29(50-13(6-36)20(25)43)52-24-16(32-9(2)39)27(47)48-12(5-35)19(24)42/h11-30,34-37,41-47H,4-7H2,1-3H3,(H,31,38)(H,32,39)(H,33,40)/t11-,12-,13-,14-,15-,16-,17-,18-,19+,20-,21+,22-,23-,24-,25-,26+,27?,28+,29+,30+/m1/s1","WURCS=2.0/3,4,3/[a2112h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3-2/a3-b1_b3-c1_c3-d1",GlyTouCan accession,G30697FM
7368,149036,alpha-L-threo-hex-4-enopyranuronosyl-(1->4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-Glcp,A disaccharide derivative consisting of alpha-L-threo-hex-4-enopyranuronic acid and 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranose residues joined by a (1->4) glycosidic bond.,"InChI=1S/C12H19NO17S2/c14-4-3(13-31(21,22)23)11(20)28-2(1-27-32(24,25)26)8(4)29-12-7(17)5(15)6(16)9(30-12)10(18)19/h2-5,7-8,11-17,20H,1H2,(H,18,19)(H,21,22,23)(H,24,25,26)/t2-,3-,4-,5+,7-,8-,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NSO/3=O/3=O_6*OSO/3=O/3=O][a21EEA-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G30702UA
7369,149042,Neu5Ac-?-(2->3)-D-Galp,A amino disaccharide consisting of N-acetylneuaminic acid and D-galactopyranose joined by a (2->3) glycosidic bond.,"InChI=1S/C17H29NO14/c1-5(21)18-9-6(22)2-17(16(28)29,31-13(9)10(24)7(23)3-19)32-14-11(25)8(4-20)30-15(27)12(14)26/h6-15,19-20,22-27H,2-4H2,1H3,(H,18,21)(H,28,29)/t6-,7+,8+,9+,10+,11-,12+,13+,14-,15?,17?/m0/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][Aad21122h-2x_2-6_5*NCC/3=O]/1-2/a3-b2",GlyTouCan accession,G24978QU
7370,149053,alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,A branched amino trisaccharide consisting of 2-acetamido-2-deoxy-D-glucopyranose in which the hydroxy groups at positions 3 and 6 have each been glycosylated by a alpha-L-fucopyranosyl group.,"InChI=1S/C20H35NO14/c1-5-10(23)13(26)15(28)19(32-5)31-4-8-12(25)17(9(18(30)34-8)21-7(3)22)35-20-16(29)14(27)11(24)6(2)33-20/h5-6,8-20,23-30H,4H2,1-3H3,(H,21,22)/t5-,6-,8+,9+,10+,11+,12+,13+,14+,15-,16-,17+,18?,19+,20-/m0/s1","WURCS=2.0/2,3,2/[a2122h-1x_1-5_2*NCC/3=O][a1221m-1a_1-5]/1-2-2/a3-b1_a6-c1",GlyTouCan accession,G25009PP
7371,149070,alpha-D-Glcp-(1->2)-alpha-D-Glcp-(1->3)-D-Galp,A trisaccharide consisting of 2 alpha-D-glucopyranose residues and a D-galactopyranose residue joined in sequence by (1->2) and (1->3) residues.,"InChI=1S/C18H32O16/c19-1-4-7(22)10(25)12(27)17(31-4)34-15-11(26)8(23)5(2-20)32-18(15)33-14-9(24)6(3-21)30-16(29)13(14)28/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11+,12-,13-,14+,15-,16?,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2112h-1x_1-5][a2122h-1a_1-5]/1-2-2/a3-b1_b2-c1",GlyTouCan accession,G30880PX
7372,149071,beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->3)-alpha-D-Galp,"An amino trisaccharide consisting of beta-D-galactopyranose, 2-acetamido-2-deoxy-beta-D-galactopyranose and alpha-D-galactopyranose residues joined in sequence by (1->3) glycosidic linkages.","InChI=1S/C20H35NO16/c1-5(25)21-9-16(36-20-14(30)13(29)10(26)6(2-22)35-20)11(27)8(4-24)34-19(9)37-17-12(28)7(3-23)33-18(32)15(17)31/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11+,12+,13+,14-,15-,16-,17+,18+,19+,20+/m1/s1","WURCS=2.0/3,3,2/[a2112h-1a_1-5][a2112h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2-3/a3-b1_b3-c1",GlyTouCan accession,G25129BT
7373,149113,alpha-D-Manp-(1->3)-Man-OH,A glycosyl alditol consisting of an alpha-D-mannopyranose residue and a D-mannitol residue joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-/m1/s1","WURCS=2.0/2,2,1/[h1122h][a1122h-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G25296NU
7374,149149,beta-D-Galp-(1->6)-alpha-D-Glcp-(1->1)-alpha-D-Glcp,A trisaccharide consisting of a beta-D-galactopyranose residue and two alpha-D-glucopyranose residues joined in sequence by (1->6) and (1->1) glycosidic bonds.,"InChI=1S/C18H32O16/c19-1-4-7(21)10(24)13(27)16(31-4)30-3-6-9(23)12(26)15(29)18(33-6)34-17-14(28)11(25)8(22)5(2-20)32-17/h4-29H,1-3H2/t4-,5-,6-,7+,8-,9-,10+,11+,12+,13-,14-,15-,16-,17-,18-/m1/s1","WURCS=2.0/2,3,2/[a2122h-1a_1-5][a2112h-1b_1-5]/1-1-2/a1-b1_b6-c1",GlyTouCan accession,G25435RM
7375,149202,1-O-(2-O-alpha-D-galactopyranosyl-alpha-D-glucopyranosyl)-glycerol,A glycosylglycerol that is 1-O-(alpha-D-glucosyl)glycerol in which the hydroxy group at position 2 of the glucose ring has been converted to the corresponding alpha-D-galactopyranoside.,"InChI=1S/C15H28O13/c16-1-5(19)4-25-15-13(11(23)9(21)7(3-18)27-15)28-14-12(24)10(22)8(20)6(2-17)26-14/h5-24H,1-4H2/t5?,6-,7-,8+,9-,10+,11+,12-,13-,14-,15+/m1/s1","WURCS=2.0/3,3,2/[hxh][a2122h-1a_1-5][a2112h-1a_1-5]/1-2-3/a3-b1_b2-c1",GlyTouCan accession,G31649CJ
7376,149212,beta-D-Glcp-(1->6)-alpha-D-Glcp-(1->4)-D-Glcp,"A glucotriose consisting of beta-D-glucopyranose, alpha-D-glucopyranose and D-glucopyranose residues joined in sequence by (1->6) and (1->4) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-7(21)9(23)13(27)17(32-4)30-3-6-8(22)10(24)14(28)18(33-6)34-15-5(2-20)31-16(29)12(26)11(15)25/h4-29H,1-3H2/t4-,5-,6-,7-,8-,9+,10+,11-,12-,13-,14-,15-,16?,17-,18-/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2122h-1a_1-5][a2122h-1b_1-5]/1-2-3/a4-b1_b6-c1",KEGG GLYCAN accession,G02151
7377,149226,fenoterol,"A member of the class  resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.","InChI=1S/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3","5-{1-Hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-benzene-1,3-diol",PubMed citation,17845020
7378,149298,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-D-Manp,"An amino trisaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose, alpha-D-mannopyranose and D-mannopyranose residues joined in sequence by (1->2) and (1->6) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(24)21-9-13(28)10(25)6(2-22)35-19(9)37-17-15(30)11(26)7(3-23)36-20(17)33-4-8-12(27)14(29)16(31)18(32)34-8/h6-20,22-23,25-32H,2-4H2,1H3,(H,21,24)/t6-,7-,8-,9-,10-,11-,12-,13-,14+,15+,16+,17+,18?,19+,20+/m1/s1","WURCS=2.0/3,3,2/[a1122h-1x_1-5][a1122h-1a_1-5][a2122h-1b_1-5_2*NCC/3=O]/1-2-3/a6-b1_b2-c1",KEGG GLYCAN accession,G00832
7379,149311,alpha-D-GlcpNAc-(1->2)-beta-D-Glcp,An amino disaccharide consisting of 2-acetamido-2-deoxy-alpha-D-glucopyranose and beta-D-glucopyranose residues joined in sequence by a (1->2) glycosidic linkage.,"InChI=1S/C14H25NO11/c1-4(18)15-7-10(21)8(19)6(3-17)25-14(7)26-12-11(22)9(20)5(2-16)24-13(12)23/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8-,9-,10-,11+,12-,13-,14-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5][a2122h-1a_1-5_2*NCC/3=O]/1-2/a2-b1",GlyTouCan accession,G32986TN
7380,149385,beta-L-threo-hex-4-enopyranuronosyl-(1->4)-beta-D-GlcpNS,An L-threo-hex-4-enopyranuronosyl-(1->4)-D-GlcpNS in which both anomeric centres have beta configuration.,"InChI=1S/C12H19NO14S/c14-1-2-8(4(15)3(11(21)25-2)13-28(22,23)24)26-12-7(18)5(16)6(17)9(27-12)10(19)20/h2-5,7-8,11-18,21H,1H2,(H,19,20)(H,22,23,24)/t2-,3-,4-,5+,7-,8-,11-,12+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1b_1-5_2*NSO/3=O/3=O][a21EEA-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G33837HR
7381,149402,D-Galp-(1->6)-beta-D-Galp-(1->4)-D-Glcp,"A trisaccharide consisting of D-galactopyranose, beta-D-galactopyranose and D-glucopyranose joined in sequence by (1->6) and (1->4) glycosidic bonds.","InChI=1S/C18H32O16/c19-1-4-7(21)9(23)13(27)17(32-4)30-3-6-8(22)10(24)14(28)18(33-6)34-15-5(2-20)31-16(29)12(26)11(15)25/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10+,11-,12-,13-,14-,15-,16?,17?,18+/m1/s1","WURCS=2.0/3,3,2/[a2122h-1x_1-5][a2112h-1b_1-5][a2112h-1x_1-5]/1-2-3/a4-b1_b6-c1",KEGG GLYCAN accession,G09427
7382,149407,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-alpha-D-GalpNAc,"A linear amino tetrasaccharide comprising alpha-D-galactosyl, beta-D-galactosyl, N-acetyl-beta-D-galactosaminyl and N-acetyl-alpha-D-galactosamine residues linked sequentially (1->3), (1->4) and (1->6).","InChI=1S/C28H48N2O21/c1-7(34)29-13-18(39)16(37)12(46-25(13)44)6-45-26-14(30-8(2)35)19(40)23(11(5-33)49-26)50-28-22(43)24(17(38)10(4-32)48-28)51-27-21(42)20(41)15(36)9(3-31)47-27/h9-28,31-33,36-44H,3-6H2,1-2H3,(H,29,34)(H,30,35)/t9-,10-,11-,12-,13-,14-,15+,16+,17+,18-,19-,20+,21-,22-,23-,24+,25+,26-,27-,28+/m1/s1",alpha-D-galacto-hexopyranosyl-(1->3)-beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->6)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose,GlyTouCan accession,G34073UX
7383,149411,beta-D-Galp-(1->2)-[beta-D-Galp-(1->3)]-alpha-L-Fucp,A trisaccharide that is alpha-L-fucopyranose in which the hydroxy groups at positions 2 and 3 have each been converted into the corresponding beta-D-galactopyranosyl derivative.,"InChI=1S/C18H32O15/c1-4-7(21)14(32-17-12(26)10(24)8(22)5(2-19)30-17)15(16(28)29-4)33-18-13(27)11(25)9(23)6(3-20)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8-,9-,10-,11-,12+,13+,14+,15-,16+,17-,18-/m0/s1","WURCS=2.0/2,3,2/[a1221m-1a_1-5][a2112h-1b_1-5]/1-2-2/a2-b1_a3-c1",GlyTouCan accession,G34122OI
7384,149424,rac-GR24,"A racemate comprising equimolar amounts of (+)-GR24 and (-)-GR24. It has been found to inhibit lateral shoot branching (see Nature 2008, v455, 189), stimulate germination of Striga (witchweeds), and aid in the symbiosis of over 80% of terrestrial plants with fungi at arbuscular mycorrihizae in roots.","InChI=1S/2C17H14O5/c2*1-9-6-14(21-16(9)18)20-8-13-12-7-10-4-2-3-5-11(10)15(12)22-17(13)19/h2*2-6,8,12,14-15H,7H2,1H3/b2*13-8+/t2*12-,14-,15-/m10/s1",KS-00001G1L,CAS Registry Number,76974-79-3
7385,149427,ammonium magnesium phosphate hexahydrate,A hydrate that is the hexahydrate form of ammonium magnesium phosphate. It is a constituent of urinary calculi.,"InChI=1S/Mg.H3N.H3O4P.6H2O/c;;1-5(2,3)4;;;;;;/h;1H3;(H3,1,2,3,4);6*1H2/q+2;;;;;;;;/p-2",azanium magnesium phosphate hexahydrate,Wikipedia accession,Struvite
7386,149434,6-de(cyclopropylamino)-6-(3-fluoroazetidin-1-yl)abacavir,"A 2,6-diaminopurine that is an analogue of abacavir in which the cyclopropylamino group at position 6 of the purine moiety is replaced by a 3-fluoroazetidin-1-yl group. One of a series of synthesised abacavir analogues with antiviral activity found to stimulate IFN-gamma secretion in abacavir-responsive clones.","InChI=1S/C14H17FN6O/c15-9-4-20(5-9)12-11-13(19-14(16)18-12)21(7-17-11)10-2-1-8(3-10)6-22/h1-2,7-10,22H,3-6H2,(H2,16,18,19)/t8-,10+/m1/s1","(1S,4R)-4-[2-amino-6-(3-fluoro-1-azetidinyl)-9H-purin-9-yl]-2-cyclopentene-1-methanol",PubMed citation,31549414
7387,149435,6-de(cyclopropylamino)-6-(3-methoxyazetidin-1-yl)abacavir,"A 2,6-diaminopurine that is an analogue of abacavir in which the cyclopropylamino group at position 6 of the purine moiety is replaced by a 3-methoxyazetidin-1-yl group. One of a series of synthesised abacavir analogues with antiviral activity found to stimulate IFN-gamma secretion in abacavir-responsive clones.","InChI=1S/C15H20N6O2/c1-23-11-5-20(6-11)13-12-14(19-15(16)18-13)21(8-17-12)10-3-2-9(4-10)7-22/h2-3,8-11,22H,4-7H2,1H3,(H2,16,18,19)/t9-,10+/m1/s1","(1S,4R)-4-[2-amino-6-(3-methoxy-1-azetidinyl)-9H-purin-9-yl]-2-cyclopentene-1-methanol",PubMed citation,31549414
7388,149439,6-de(cyclopropylamino)-6-(isopropylamino)abacavir,"A 2,6-diaminopurine that is an analogue of abacavir in which the cyclopropylamino group at position 6 of the purine moiety is replaced by a 3-isopropoxyazetidin-1-yl group. Unlike several other synthesised abacavir analogues, it is completely deficient in T-cell reactivity with abacavir-responsive clones.","InChI=1S/C14H20N6O/c1-8(2)17-12-11-13(19-14(15)18-12)20(7-16-11)10-4-3-9(5-10)6-21/h3-4,7-10,21H,5-6H2,1-2H3,(H3,15,17,18,19)/t9-,10+/m1/s1","(1S,4R)-4-[2-amino-6-[(1-methylethyl)amino]-9H-purin-9-yl]-2-cyclopentene-1-methanol",PubMed citation,31549414
7389,149483,alpha-L-Fucp-(1->2)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-beta-D-Glcp,A branched amino hexasaccharide in which an alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucose linear pentasaccharide carries at the galactose residue proximal to the reducing end a second alpha-L-fucosyl residue via a (1->2) linkage.,"InChI=1S/C38H65NO29/c1-8-16(45)21(50)26(55)35(58-8)67-31-23(52)18(47)11(4-40)62-37(31)65-29-15(39-10(3)44)34(61-12(5-41)19(29)48)66-30-20(49)13(6-42)63-38(64-28-14(7-43)60-33(57)25(54)24(28)53)32(30)68-36-27(56)22(51)17(46)9(2)59-36/h8-9,11-38,40-43,45-57H,4-7H2,1-3H3,(H,39,44)/t8-,9-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20-,21+,22+,23-,24+,25+,26-,27-,28+,29+,30-,31+,32+,33+,34+,35-,36-,37-,38-/m0/s1",Fuca1-2Galb1-3GalNAca1-3(Fuca1-2)Galb1-4Glcb,PubMed citation,31537530
7390,149493,neurotensin (1-8),An 8 amino acid peptide fragment of neurotensin.,"InChI=1S/C46H71N13O14/c1-24(2)21-31(56-38(65)27-14-16-36(62)52-27)40(67)57-32(22-25-10-12-26(60)13-11-25)41(68)53-28(15-17-37(63)64)39(66)58-33(23-35(48)61)42(69)54-29(7-3-4-18-47)44(71)59-20-6-9-34(59)43(70)55-30(45(72)73)8-5-19-51-46(49)50/h10-13,24,27-34,60H,3-9,14-23,47H2,1-2H3,(H2,48,61)(H,52,62)(H,53,68)(H,54,69)(H,55,70)(H,56,65)(H,57,67)(H,58,66)(H,63,64)(H,72,73)(H4,49,50,51)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1",neurotensin-(1-8),PubMed citation,17362935
7391,149521,NOC-5,"A nitroso compound that is triazane in which the nitrogen at position 1 is substituted by an isopropyl group and a 3-aminopropyl group, that at position 2 is substituted by a hydroxy group, and that at position 3 is substituted by an oxo group. It is a nitric oxide donor.","InChI=1S/C6H16N4O2/c1-6(2)9(5-3-4-7)10(12)8-11/h6,12H,3-5,7H2,1-2H3",3-[2-hydroxy-1-(1-methylethyl)-2-nitrosohydrazinyl]-1-propanamine,PubMed citation,9690874
7392,149547,"(2E,4E)-deca-2,4-dienal",A polyunsaturated fatty aldehyde that is decanal which has undergone formal dehydrogenation to introduce trans- double bonds at the 2-3 and 4-5 positions. A product of lipid peroxidation in cell membranes and a component of cooking oil fumes.,"InChI=1S/C10H16O/c1-2-3-4-5-6-7-8-9-10-11/h6-10H,2-5H2,1H3/b7-6+,9-8+","trans,trans-2,4-decadienal",CAS Registry Number,25152-84-5
7393,149564,hydroxychloroquine(2+),A quinolinium ion obtained by protonation of the quinoline nitrogen and tertiary amino group of the antimalarial drug hydroxychloroquine. It is the major species at pH 7.3.,"InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)/p+2",hydroxychloroquine dication,PubMed citation,25693996
7394,149641,neocasomorphin,"A six amino acid oligopeptide fragment of the human milk protein, beta-casein.","InChI=1S/C35H52N6O10/c1-5-20(4)29(35(50)51)39-31(46)26-9-7-17-41(26)34(49)24(14-15-27(43)44)37-32(47)28(19(2)3)38-30(45)25-8-6-16-40(25)33(48)23(36)18-21-10-12-22(42)13-11-21/h10-13,19-20,23-26,28-29,42H,5-9,14-18,36H2,1-4H3,(H,37,47)(H,38,45)(H,39,46)(H,43,44)(H,50,51)/t20-,23-,24-,25-,26-,28-,29-/m0/s1",Y-P-V-E-P-I,PubMed citation,10503774
7395,149653,2-hydroxyglutaramic acid,A dicarboxylic acid monoamide that is 5-amino-5-oxopentanoic acid carrying a hydroxy group at position 2. It is a metabolite identified in human breast milk.,"InChI=1S/C5H9NO4/c6-4(8)2-1-3(7)5(9)10/h3,7H,1-2H2,(H2,6,8)(H,9,10)",2-hydroxyglutaramic acid,CAS Registry Number,84658-40-2
7396,149669,apelin-12,A 12 amino acid oligopeptide fragment of apelin-13 lacking the terminal L-phenylalanine residue.,"InChI=1S/C60H102N22O15S/c1-33(2)27-40(77-50(88)37(12-6-21-69-59(64)65)74-55(93)44-15-9-24-81(44)56(94)38(13-7-22-70-60(66)67)75-48(86)35(62)17-18-46(63)84)51(89)79-42(31-83)53(91)78-41(28-34-29-68-32-72-34)52(90)73-36(11-4-5-20-61)49(87)71-30-47(85)80-23-8-14-43(80)54(92)76-39(19-26-98-3)57(95)82-25-10-16-45(82)58(96)97/h29,32-33,35-45,83H,4-28,30-31,61-62H2,1-3H3,(H2,63,84)(H,68,72)(H,71,87)(H,73,90)(H,74,93)(H,75,86)(H,76,92)(H,77,88)(H,78,91)(H,79,89)(H,96,97)(H4,64,65,69)(H4,66,67,70)/t35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-/m0/s1",Q-R-P-R-L-S-H-K-G-P-M-P,HMDB accession,HMDB0060264
7397,149675,helium-3(1+),An inorganic radical cation resulting from the loss of one electron from helium-3.,InChI=1S/He/q+1/i1-1,(3)He(1+),PubMed citation,18315248
7398,149692,oxygen-16(6+),A monoatomic hexacation resulting from the loss of six electrons from oxygen-16.,InChI=1S/O/q+6/i1+0,oxygen-16(6+),Chinese Abstracts citation,279417
7399,149706,4-hydroxy-6-(pyridin-3-yl)-2H-pyran-2-one,"A member of the class of 2-pyranones that is 2H-pyran-2-one which has been substituted at positions 4 and 6 by hydroxy and pyridin-3-yl groups, respectively.","InChI=1S/C10H7NO3/c12-8-4-9(14-10(13)5-8)7-2-1-3-11-6-7/h1-6,12H",HPPO,PubMed citation,20861902
7400,149720,"6-[(1,5-dideoxy-D-ribityl)amino]-5-[(E)-(2-oxopropylidene)amino]uracil","A nucleobase analogue that is uracil substituted with a (1,5-dideoxy-D-ribityl)amino group at position 6 and an (E)-(2-oxopropylidene)amino group at position 5; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C12H18N4O6/c1-5(17)3-13-8-10(15-12(22)16-11(8)21)14-4-7(19)9(20)6(2)18/h3,6-7,9,18-20H,4H2,1-2H3,(H3,14,15,16,21,22)/b13-3+/t6-,7+,9-/m1/s1","1,5-dideoxy-1-[[1,2,3,6-tetrahydro-2,6-dioxo-5-[[(1E)-2-oxopropylidene]amino]-4-pyrimidinyl]amino]-D-ribitol",PubMed citation,32123373
7401,149727,"8-(1,5-dideoxy-1-D-ribityl)-7-methyllumazine","A pteridine that is lumazine substituted with a 1,5-dideoxy-1-D-ribityl group at position 8 and a methyl group at position 7; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C12H16N4O5/c1-5-3-13-8-10(14-12(21)15-11(8)20)16(5)4-7(18)9(19)6(2)17/h3,6-7,9,17-19H,4H2,1-2H3,(H,15,20,21)/t6-,7+,9-/m1/s1",5'-D-RL-7-Me,PubMed citation,32123373
7402,149728,6-[(5-hydroxypentyl)amino]-5-[(E)-(2-oxopropylidene)amino]uracil,"A nucleobase analogue that is uracil substituted with a (5-hydroxypentyl)amino group at position 6 and an (E)-(2-oxopropylidene)amino group at position 5; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C12H18N4O4/c1-8(18)7-14-9-10(13-5-3-2-4-6-17)15-12(20)16-11(9)19/h7,17H,2-6H2,1H3,(H3,13,15,16,19,20)/b14-7+",5'-OH-pentyl-5-OP-U,PubMed citation,32123373
7403,149747,"8-(1,4-dideoxy-1-D-ribityl)-7-methyllumazine","A pteridine that is lumazine substituted with a 1,4-dideoxy-1-D-ribityl group at position 8 and a methyl group at position 7; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C13H18N4O4/c1-3-4-8(18)9(19)6-17-7(2)5-14-10-11(17)15-13(21)16-12(10)20/h5,8-9,18-19H,3-4,6H2,1-2H3,(H,16,20,21)/t8-,9+/m1/s1","8-[(2S,3R)-2,3-dihydroxyhexyl]-7-methyl-2,4(3H,8H)-pteridinedione",PubMed citation,32123373
7404,149749,8-(4-hydroxybutyl)-6-methyllumazine,"A pteridine that is lumazine substituted with a 4-hydroxybutyl group at position 8 and a methyl group at position 6; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C11H14N4O3/c1-7-6-15(4-2-3-5-16)9-8(12-7)10(17)14-11(18)13-9/h6,16H,2-5H2,1H3,(H,14,17,18)","8-(4-hydroxybutyl)-6-methyl-2,4(3H,8H)-pteridinedione",PubMed citation,32123373
7405,149750,8-(4-hydroxybutyl)-7-methyllumazine,"A pteridine that is lumazine substituted with a 4-hydroxybutyl group at position 8 and a methyl group at position 7; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C11H14N4O3/c1-7-6-12-8-9(13-11(18)14-10(8)17)15(7)4-2-3-5-16/h6,16H,2-5H2,1H3,(H,14,17,18)",4'-OH-butyl-L-7-Me,PubMed citation,32123373
7406,149751,"6-[(1,2-dideoxy-D-ribityl)amino]-5-[(E)-(2-oxopropylidene)amino]uracil","A nucleobase analogue that is uracil substituted with a (1,2-dideoxy-D-ribityl)amino group at position 6 and an (E)-(2-oxopropylidene)amino group at position 5; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C12H18N4O6/c1-6(18)4-14-9-10(15-12(22)16-11(9)21)13-3-2-7(19)8(20)5-17/h4,7-8,17,19-20H,2-3,5H2,1H3,(H3,13,15,16,21,22)/b14-4+/t7-,8+/m0/s1",2'-D-5-OP-RU,PubMed citation,32123373
7407,149755,7-(2-hydroxyethyl)-6-methyllumazine,"A pteridine that is lumazine substituted with a 2-hydroxyethyl group at position 8 and a methyl group at position 7; one of 20 modifications to the potent microbial riboflavin-based metabolite antigen 5-(2-oxopropylideneamino)-6-D-ribityl aminouracil (5-OP-RU), an activator of mucosal-associated invariant T (MAIT) cells when presented by the MR1 protein (reported in MED:32123373).","InChI=1S/C9H10N4O3/c1-5-4-10-6-7(13(5)2-3-14)11-9(16)12-8(6)15/h4,14H,2-3H2,1H3,(H,12,15,16)",2'-OH-butyl-L-6-Me,PubMed citation,32123373
7408,149785,nelociguat,"A member of the class of pyrazolopyridines that is 1H-pyrazolo[3,4-b]pyridine which is substituted by a 2-fluorobenzyl and 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl groups at positions 1 and 3, respectively. It is an active metabolite of riociguat and a soluble guanylate cyclase stimulator developed by Bayer for the treatment of erectile dysfunction and heart failure.","InChI=1S/C19H17FN8O2/c1-30-19(29)24-14-15(21)25-17(26-16(14)22)13-11-6-4-8-23-18(11)28(27-13)9-10-5-2-3-7-12(10)20/h2-8H,9H2,1H3,(H,24,29)(H4,21,22,25,26)",BAY60-4552,CAS Registry Number,625115-52-8
7409,150005,CDN1163,A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-isopropoxybenzoic acid with the primary amino group of 2-methylquinolin-8-amine. An allosteric activator of sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA).,"InChI=1S/C20H20N2O2/c1-13(2)24-17-11-9-16(10-12-17)20(23)22-18-6-4-5-15-8-7-14(3)21-19(15)18/h4-13H,1-3H3,(H,22,23)",4-(1-methylethoxy)-N-(2-methyl-8-quinolinyl)-benzamide,CAS Registry Number,892711-75-0
7410,150013,emodin anthrone,"A member of the class of anthracenones that is anthracen-9(10H)-one which carries a methyl group at position 6 and hydroxy groups at positions 1, 3 and 8, respectively. It is an intermediate precursor in the synthesis of hypericin.","InChI=1S/C15H12O4/c1-7-2-8-4-9-5-10(16)6-12(18)14(9)15(19)13(8)11(17)3-7/h2-3,5-6,16-18H,4H2,1H3",emodin-9-anthrone,PubMed citation,1810248
7411,150017,"3-{beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-Glc-(1->6)-beta-D-Glc-(1->6)-beta-D-Glc-yl}-1,2-dimyristoyl-sn-glycerol","A glycosylglycerol derivative in which the glycosyl moiety of glycosyl-sn-glycerol is N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-beta-D-glucosyl-(1->6)-beta-D-glucosyl-(1->6)-beta-D-glucosyl attached at O-3, with O-1 and O-2 both carrying myristoyl substituents. Synthetic C. difficile lipoteichoic acid (LTA) molecule consisting of lipid + core region and two [(->6)-alpha-D-GlcpNAc-(1->3)-[P-6]-alpha-D-GlcpNAc-(1->2)-D-GroA polymeric repeats (where P-6 is a phosphodiester bridge and GroA is glyceric acid).","InChI=1S/C87H152N4O52P2/c1-7-9-11-13-15-17-19-21-23-25-27-29-56(99)124-34-46(132-57(100)30-28-26-24-22-20-18-16-14-12-10-8-2)35-125-85-74(113)71(110)64(103)50(139-85)36-126-86-75(114)72(111)65(104)51(140-86)37-127-87-76(115)73(112)66(105)53(141-87)39-129-145(122,123)131-41-55-68(107)78(61(91-45(6)98)84(138-55)135-49(33-94)80(118)119)143-82-59(89-43(4)96)70(109)63(102)52(136-82)38-128-144(120,121)130-40-54-67(106)77(60(90-44(5)97)83(137-54)134-48(32-93)79(116)117)142-81-58(88-42(3)95)69(108)62(101)47(31-92)133-81/h46-55,58-78,81-87,92-94,101-115H,7-41H2,1-6H3,(H,88,95)(H,89,96)(H,90,97)(H,91,98)(H,116,117)(H,118,119)(H,120,121)(H,122,123)/t46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71+,72+,73+,74-,75-,76-,77-,78-,81-,82-,83+,84+,85-,86-,87-/m1/s1",WH236,PubMed citation,32191024
7412,150019,"3-{beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-GlcNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcNAc-(6-P-6)-beta-D-Glc-(1->6)-beta-D-Glc-(1->6)-beta-D-Glc-yl}-1,2-dimyristoyl-sn-glycerol","A glycosylglycerol derivative in which the glycosyl moiety of glycosyl-sn-glycerol is N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-N-acetyl-beta-D-glucosaminyl-(1->3)-[(D-glyceric acid)-(2->1)]-beta-D-glucosaminyl-(6-phospho-6)-beta-D-glucosyl-(1->6)-beta-D-glucosyl-(1->6)-beta-D-glucosyl attached at O-3, with O-1 and O-2 both carrying myristoyl substituents. Synthetic C. difficile lipoteichoic acid (LTA) molecule consisting of lipid + core region and three [(->6)-alpha-D-GlcpNAc-(1->3)-[P-6]-alpha-D-GlcpNAc-(1->2)-D-GroA polymeric repeats (where P-6 is a phosphodiester bridge and GroA is glyceric acid).","InChI=1S/C106H183N6O68P3/c1-9-11-13-15-17-19-21-23-25-27-29-31-66(123)155-37-53(165-67(124)32-30-28-26-24-22-20-18-16-14-12-10-2)38-156-104-89(140)86(137)77(128)58(175-104)39-157-105-90(141)87(138)78(129)59(176-105)40-158-106-91(142)88(139)79(130)62(177-106)43-161-183(153,154)164-46-65-82(133)94(73(112-52(8)122)103(174-65)169-57(36-116)97(147)148)180-100-70(109-49(5)119)85(136)76(127)61(171-100)42-160-182(151,152)163-45-64-81(132)93(72(111-51(7)121)102(173-64)168-56(35-115)96(145)146)179-99-69(108-48(4)118)84(135)75(126)60(170-99)41-159-181(149,150)162-44-63-80(131)92(71(110-50(6)120)101(172-63)167-55(34-114)95(143)144)178-98-68(107-47(3)117)83(134)74(125)54(33-113)166-98/h53-65,68-94,98-106,113-116,125-142H,9-46H2,1-8H3,(H,107,117)(H,108,118)(H,109,119)(H,110,120)(H,111,121)(H,112,122)(H,143,144)(H,145,146)(H,147,148)(H,149,150)(H,151,152)(H,153,154)/t53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86+,87+,88+,89-,90-,91-,92-,93-,94-,98-,99-,100-,101+,102+,103+,104-,105-,106-/m1/s1","3-{beta-D-GlcpNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcpNAc-(6-P-6)-beta-D-GlcpNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcpNAc-(6-P-6)-beta-D-GlcpNAc-(1->3)-[D-GrO-(2->1)]-beta-D-GlcpNAc-(6-P-6)-beta-D-Glcp-(1->6)-beta-D-Glcp-(1->6)-beta-D-Glcp-yl}-1,2-dimyristoyl-sn-glycerol",PubMed citation,32191024
7413,150282,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino octasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-GalNAc-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group.,"InChI=1S/C58H97N5O41/c1-14(71)59-27-39(83)45(23(10-68)91-51(27)89)99-54-30(62-17(4)74)41(85)47(25(12-70)96-54)101-56-44(88)48(36(80)26(98-56)13-90-57-49(42(86)34(78)21(8-66)94-57)103-53-29(61-16(3)73)38(82)33(77)20(7-65)93-53)102-58-50(43(87)35(79)22(9-67)95-58)104-55-31(63-18(5)75)40(84)46(24(11-69)97-55)100-52-28(60-15(2)72)37(81)32(76)19(6-64)92-52/h19-58,64-70,76-89H,6-13H2,1-5H3,(H,59,71)(H,60,72)(H,61,73)(H,62,74)(H,63,75)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32+,33-,34-,35-,36-,37-,38-,39-,40-,41-,42+,43+,44+,45-,46-,47-,48+,49+,50+,51?,52+,53+,54+,55+,56+,57+,58-/m1/s1","WURCS=2.0/5,8,7/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-4-2-5-4-2/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_e4-f1_g2-h1",GlyTouCan accession,G35429JB
7414,150402,alpha-L-Fucp-(1->3)-[alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc,A branched amino pentasaccharide derivative that is alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the GlcNAc residue at the reducing end carries an alpha-L-Fuc residue via a (1->3) linkage.,"InChI=1S/C34H58N2O25/c1-8-17(43)21(47)23(49)32(53-8)60-28-16(36-10(3)42)30(52)54-14(7-40)27(28)59-31-15(35-9(2)41)20(46)26(13(6-39)57-31)58-34-25(51)29(19(45)12(5-38)56-34)61-33-24(50)22(48)18(44)11(4-37)55-33/h8,11-34,37-40,43-52H,4-7H2,1-3H3,(H,35,41)(H,36,42)/t8-,11+,12+,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-,25-,26+,27+,28+,29-,30?,31-,32-,33+,34-/m0/s1",alpha-D-manno-hexopyranosyl-(1->3)-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->3)]-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G38974XL
7415,150468,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->4)-beta-D-Galp-(1->4)-beta-D-Glcp,"An amino pentasaccharide comprising alpha-N-acetylneuraminyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl, beta-D-galactosyl and beta-D-glucose residues linked sequentially (2->3), (1->3), (1->4) and (1->4).","InChI=1S/C37H62N2O29/c1-9(45)38-17-11(47)3-37(36(58)59,67-30(17)19(49)12(48)4-40)68-31-21(51)14(6-42)62-35(26(31)56)66-29-18(39-10(2)46)33(61-13(5-41)20(29)50)64-28-16(8-44)63-34(25(55)23(28)53)65-27-15(7-43)60-32(57)24(54)22(27)52/h11-35,40-44,47-57H,3-8H2,1-2H3,(H,38,45)(H,39,46)(H,58,59)/t11-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21-,22+,23+,24+,25+,26+,27+,28-,29+,30+,31-,32+,33-,34-,35-,37-/m0/s1","WURCS=2.0/4,5,4/[a2122h-1b_1-5][a2112h-1b_1-5][a2122h-1b_1-5_2*NCC/3=O][Aad21122h-2a_2-6_5*NCC/3=O]/1-2-3-2-4/a4-b1_b4-c1_c3-d1_d3-e2",GlyTouCan accession,G41722LN
7416,150655,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino octasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group.,"InChI=1S/C56H94N4O41/c1-13(68)57-25-35(78)43(21(9-65)88-49(25)86)96-51-27(59-15(3)70)36(79)45(23(11-67)93-51)98-54-42(85)46(33(76)24(95-54)12-87-55-47(39(82)31(74)19(7-63)91-55)100-50-26(58-14(2)69)34(77)29(72)17(5-61)89-50)99-56-48(40(83)32(75)20(8-64)92-56)101-52-28(60-16(4)71)37(80)44(22(10-66)94-52)97-53-41(84)38(81)30(73)18(6-62)90-53/h17-56,61-67,72-86H,5-12H2,1-4H3,(H,57,68)(H,58,69)(H,59,70)(H,60,71)/t17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30+,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41-,42+,43-,44-,45-,46+,47+,48+,49?,50+,51+,52+,53+,54+,55+,56-/m1/s1","N-[(3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5S,6R)-3-[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(2R,3S,4S,5S,6R)-3-[(2S,3R,4R,5S,6R)-3-acetamido-4-hydroxy-6-(hydroxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide",GlyTouCan accession,G36859SD
7417,150781,beta-D-GalpNAc-(1->6)-D-Galp,An amino disaccharide consisting of 2-acetamido-2-deoxy-beta-D-galactopyranose and D-galactopyranose residues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)8(18)5(2-16)26-14(7)24-3-6-9(19)11(21)12(22)13(23)25-6/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6-,7-,8+,9+,10-,11+,12-,13?,14-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][a2112h-1b_1-5_2*NCC/3=O]/1-2/a6-b1",GlyTouCan accession,G42989FL
7418,150867,(+)-geodin,"An oxaspiro compound that is 3H,4'H-spiro[[1]benzofuran-2,1'-cyclohexa[2,5]diene]-3,4'-dione substituted by methoxycarbonyl, hydroxy, chloro, methyl, methoxy and chloro groups at positions 2', 4, 5, 6, 6' and 7, respectively. It is a fungal metabolite isolated from Aspergillus terreus and Penicillium glabrum.","InChI=1S/C17H12Cl2O7/c1-6-11(18)13(21)10-14(12(6)19)26-17(15(10)22)8(16(23)25-3)4-7(20)5-9(17)24-2/h4-5,21H,1-3H3/t17-/m1/s1","(2R)-methyl-5,7-dichloro-4-hydroxy-6'-methoxy-6-methyl-3,4'-dioxospiro-[benzofuran-2,1'-cyclohexa-2',5'-diene]-2'-carboxylate",CAS Registry Number,427-63-4
7419,150907,beta-L-Fucp-(1->3)-D-Galp,A glycosylgalactose consisting of beta-L-fucopyranose and D-galactopyranose residues joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C12H22O10/c1-3-5(14)7(16)8(17)12(20-3)22-10-6(15)4(2-13)21-11(19)9(10)18/h3-19H,2H2,1H3/t3-,4+,5+,6-,7+,8-,9+,10-,11?,12+/m0/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][a1221m-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G44314HI
7420,150945,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino octasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 6 by a beta-D-GalNAc-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group.,"InChI=1S/C58H97N5O41/c1-14(71)59-27-39(83)45(23(10-68)91-51(27)89)99-54-30(62-17(4)74)41(85)47(25(12-70)96-54)101-56-44(88)48(102-58-50(43(87)35(79)22(9-67)95-58)104-53-29(61-16(3)73)38(82)33(77)20(7-65)93-53)36(80)26(98-56)13-90-57-49(42(86)34(78)21(8-66)94-57)103-55-31(63-18(5)75)40(84)46(24(11-69)97-55)100-52-28(60-15(2)72)37(81)32(76)19(6-64)92-52/h19-58,64-70,76-89H,6-13H2,1-5H3,(H,59,71)(H,60,72)(H,61,73)(H,62,74)(H,63,75)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32+,33-,34-,35-,36-,37-,38-,39-,40-,41-,42+,43+,44+,45-,46-,47-,48+,49+,50+,51?,52+,53+,54+,55+,56+,57+,58-/m1/s1",2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)-[2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G44799JP
7421,151079,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,An amino hexasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at positions 3 and 6 by alpha-D-Man residues and the GlcNAc residue at the reducing end is substituted at position 6 by an alpha-L-Fuc residue.,"InChI=1S/C40H68N2O30/c1-9-19(48)25(54)28(57)37(64-9)63-8-16-33(23(52)17(35(61)65-16)41-10(2)46)70-36-18(42-11(3)47)24(53)32(14(6-45)68-36)71-40-31(60)34(72-39-30(59)27(56)21(50)13(5-44)67-39)22(51)15(69-40)7-62-38-29(58)26(55)20(49)12(4-43)66-38/h9,12-40,43-45,48-61H,4-8H2,1-3H3,(H,41,46)(H,42,47)/t9-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,32+,33+,34-,35?,36-,37+,38-,39+,40-/m0/s1","WURCS=2.0/5,6,5/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a1221m-1a_1-5]/1-2-3-4-4-5/a4-b1_a6-f1_b4-c1_c3-d1_c6-e1",GlyTouCan accession,G45995IV
7422,151247,alpha-D-Manp-(1->2)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->3)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,A branched amino nonasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc in which the mannosyl group is substituted at positions 3 and 6 by respectively alpha-D-Man-(1->2)-[alpha-D-Man-(1->6)]-alpha-D-Man and alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man groups.,"InChI=1S/C58H98N2O46/c1-12(67)59-23-32(76)45(18(7-65)93-50(23)89)102-51-24(60-13(2)68)33(77)46(19(8-66)98-51)103-57-44(88)48(105-58-49(106-56-42(86)37(81)28(72)17(6-64)97-56)38(82)29(73)20(101-58)9-90-52-39(83)34(78)25(69)14(3-61)94-52)31(75)22(100-57)11-92-54-43(87)47(104-55-41(85)36(80)27(71)16(5-63)96-55)30(74)21(99-54)10-91-53-40(84)35(79)26(70)15(4-62)95-53/h14-58,61-66,69-89H,3-11H2,1-2H3,(H,59,67)(H,60,68)/t14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45-,46-,47+,48+,49+,50-,51+,52+,53+,54+,55-,56-,57+,58-/m1/s1","WURCS=2.0/3,9,8/[a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-1-2-3-3-3-3-3-3/a4-b1_b4-c1_c3-d1_c6-g1_d2-e1_d6-f1_g3-h1_g6-i1",GlyTouCan accession,G55143WF
7423,151249,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-GalpNAc,An amino heptasaccharide in which N-acetyl-beta-D-glucosamine carries two N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl trisaccharide units via (1->3) and (1->6) glycosidic linkages.,"InChI=1S/C58H95N5O42/c1-15(70)59-29-20(75)6-57(55(89)90,102-46(29)34(79)22(77)8-64)104-48-36(81)24(10-66)95-53(41(48)86)99-43-26(12-68)97-51(31(39(43)84)61-17(3)72)93-14-28-38(83)45(33(50(88)94-28)63-19(5)74)101-52-32(62-18(4)73)40(85)44(27(13-69)98-52)100-54-42(87)49(37(82)25(11-67)96-54)105-58(56(91)92)7-21(76)30(60-16(2)71)47(103-58)35(80)23(78)9-65/h20-54,64-69,75-88H,6-14H2,1-5H3,(H,59,70)(H,60,71)(H,61,72)(H,62,73)(H,63,74)(H,89,90)(H,91,92)/t20-,21-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36-,37-,38-,39+,40+,41+,42+,43+,44+,45+,46+,47+,48-,49-,50-,51+,52-,53-,54-,57-,58-/m0/s1","WURCS=2.0/4,7,6/[a2112h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][Aad21122h-2a_2-6_5*NCC/3=O]/1-2-3-4-2-3-4/a3-b1_a6-e1_b4-c1_c3-d2_e4-f1_f3-g2",GlyTouCan accession,G55144QZ
7424,151265,beta-D-Glcp-(1->3)-D-Arap,A glycosylarabinose consisting of beta-D-glucopyranose and D-arabinopyranose joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C11H20O10/c12-1-4-5(14)6(15)7(16)11(20-4)21-9-3(13)2-19-10(18)8(9)17/h3-18H,1-2H2/t3-,4-,5-,6+,7-,8+,9-,10?,11+/m1/s1","WURCS=2.0/2,2,1/[a122h-1x_1-5][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G55197RI
7425,151298,aldehydo-L-idose,The open chain form of L-idose.,"InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h1,3-6,8-12H,2H2/t3-,4-,5+,6+/m0/s1","WURCS=2.0/1,1,0/[o2121h]/1/",GlyTouCan accession,G55420MQ
7426,151365,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,A branched amino octasaccharide consisting of a beta-D-GlcNAc residue at the reducing end with a beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4)-linkage and an alpha-L-Fuc residue attached via an alpha-(1->6)-linkage.,"InChI=1S/C53H89N3O39/c1-12-26(65)35(74)39(78)49(84-12)83-11-22-42(33(72)23(46(80)85-22)54-13(2)61)91-48-25(56-15(4)63)34(73)41(20(8-60)89-48)92-53-45(95-51-38(77)27(66)16(64)9-81-51)43(31(70)21(90-53)10-82-50-40(79)36(75)29(68)18(6-58)87-50)93-52-44(37(76)30(69)19(7-59)88-52)94-47-24(55-14(3)62)32(71)28(67)17(5-57)86-47/h12,16-53,57-60,64-80H,5-11H2,1-4H3,(H,54,61)(H,55,62)(H,56,63)/t12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28+,29+,30+,31+,32+,33+,34+,35+,36-,37-,38+,39-,40-,41+,42+,43-,44-,45-,46+,47-,48-,49+,50-,51-,52+,53-/m0/s1","WURCS=2.0/5,8,7/[a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a212h-1b_1-5][a1122h-1a_1-5][a1221m-1a_1-5]/1-1-2-3-4-1-4-5/a4-b1_a6-h1_b4-c1_c2-d1_c3-e1_c6-g1_e2-f1",GlyTouCan accession,G47566FL
7427,151379,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcNAc-(1->2)-D-Man,"A linear amino tetrasaccharide comprising N-acetyl-alpha-neuraminyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl and D-mannose residues linked sequentially (2->6), (1->4) and (1->2).","InChI=1S/C31H52N2O24/c1-8(37)32-15-10(39)3-31(30(49)50,57-25(15)17(41)11(40)4-34)51-7-14-19(43)21(45)23(47)29(54-14)55-24-13(6-36)53-28(16(20(24)44)33-9(2)38)56-26-22(46)18(42)12(5-35)52-27(26)48/h10-29,34-36,39-48H,3-7H2,1-2H3,(H,32,37)(H,33,38)(H,49,50)/t10-,11+,12+,13+,14+,15+,16+,17+,18+,19-,20+,21-,22-,23+,24+,25+,26-,27?,28-,29-,31+/m0/s1","WURCS=2.0/4,4,3/[a1122h-1x_1-5][a2122h-1b_1-5_2*NCC/3=O][a2112h-1b_1-5][Aad21122h-2a_2-6_5*NCC/3=O]/1-2-3-4/a2-b1_b4-c1_c6-d2",GlyTouCan accession,G47649ZW
7428,151492,beta-D-GlcpNAc-(1->2)-[beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino octasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by a beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->6)]-alpha-D-Man group.,"InChI=1S/C58H97N5O41/c1-14(70)59-27-41(84)46(23(10-68)92-51(27)89)100-55-31(63-18(5)74)42(85)47(24(11-69)97-55)101-56-45(88)48(102-58-50(43(86)35(78)22(9-67)96-58)104-54-30(62-17(4)73)40(83)34(77)21(8-66)95-54)37(80)26(98-56)13-91-57-49(103-53-29(61-16(3)72)39(82)33(76)20(7-65)94-53)44(87)36(79)25(99-57)12-90-52-28(60-15(2)71)38(81)32(75)19(6-64)93-52/h19-58,64-69,75-89H,6-13H2,1-5H3,(H,59,70)(H,60,71)(H,61,72)(H,62,73)(H,63,74)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43+,44+,45+,46-,47-,48+,49+,50+,51?,52-,53+,54+,55+,56+,57+,58-/m1/s1","WURCS=2.0/4,8,7/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-2-4-2-2/a4-b1_b4-c1_c3-d1_c6-f1_d2-e1_f2-g1_f6-h1",GlyTouCan accession,G56653RI
7429,151533,beta-D-GlcpNAc-(1->2)-[beta-D-GlcpNAc-(1->6)]-alpha-D-Manp,An amino trisaccharide that is alpha-D-mannopyranose in which the hydroxy groups at positions 2 and 6 have each been converted into the corresponding N-acetyl-beta-D-glucosaminyl derivative.,"InChI=1S/C22H38N2O16/c1-6(27)23-11-16(32)13(29)8(3-25)38-21(11)36-5-10-15(31)18(34)19(20(35)37-10)40-22-12(24-7(2)28)17(33)14(30)9(4-26)39-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18+,19+,20+,21-,22+/m1/s1",2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-[2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->6)]-alpha-D-manno-hexopyranose,GlyTouCan accession,G56868BH
7430,151585,1-(D-glucopyranosyloxy)-3-hydroxypropan-2-yl D-galactopyranoside,A glycosylglycerol that is 1-O-(D-glucosyl)glycerol in which the secondary hydroxy group of the glycerol moiety has been converted into the corresponding D-galactopyranoside.,"InChI=1S/C15H28O13/c16-1-5(26-15-13(24)11(22)9(20)7(3-18)28-15)4-25-14-12(23)10(21)8(19)6(2-17)27-14/h5-24H,1-4H2/t5?,6-,7-,8-,9+,10+,11+,12-,13-,14?,15?/m1/s1","WURCS=2.0/3,3,2/[hxh][a2112h-1x_1-5][a2122h-1x_1-5]/1-2-3/a2-b1_a3-c1",GlyTouCan accession,G51941HK
7431,151680,alpha-D-Galp-(1->3)-alpha-D-Manp,A glycosylmannose consisting of alpha-D-galactopyranose and alpha-D-mannopyranose residues joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5+,6-,7+,8-,9+,10+,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a1122h-1a_1-5][a2112h-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G52896CF
7432,151709,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino oligosaccharide that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 6 by a beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 3 by a beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-alpha-D-Man group.,"InChI=1S/C76H127N5O56/c1-17(91)77-33-44(102)58(26(10-86)119-66(33)116)130-68-35(79-19(3)93)46(104)62(30(14-90)125-68)134-74-57(115)63(43(101)32(128-74)16-118-75-64(52(110)41(99)25(9-85)123-75)136-69-36(80-20(4)94)47(105)60(28(12-88)126-69)132-72-55(113)50(108)39(97)23(7-83)121-72)135-76-65(137-70-37(81-21(5)95)48(106)61(29(13-89)127-70)133-73-56(114)51(109)40(98)24(8-84)122-73)53(111)42(100)31(129-76)15-117-67-34(78-18(2)92)45(103)59(27(11-87)124-67)131-71-54(112)49(107)38(96)22(6-82)120-71/h22-76,82-90,96-116H,6-16H2,1-5H3,(H,77,91)(H,78,92)(H,79,93)(H,80,94)(H,81,95)/t22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41-,42-,43-,44-,45-,46-,47-,48-,49+,50+,51+,52+,53+,54-,55-,56-,57+,58-,59-,60-,61-,62-,63+,64+,65+,66?,67-,68+,69+,70+,71+,72+,73+,74+,75+,76-/m1/s1",Gal(b1-4)GlcNAc(b1-2)[Gal(b1-4)GlcNAc(b1-6)]Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,GlyTouCan accession,G53272SL
7433,151758,alpha-L-gulofuranose,An L-gulofuranose that has alpha configuration at the anomeric cenrtre.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3+,4-,5+,6+/m0/s1","WURCS=2.0/1,1,0/[a1121h-1a_1-4]/1/",GlyTouCan accession,G53838GP
7434,151908,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->6)-alpha-D-GalpNAc,"An amino trisaccharide comprising beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-alpha-D-galactosamine residues linked sequentially (1->3) and (1->6).","InChI=1S/C22H38N2O16/c1-6(27)23-11-16(32)14(30)10(37-20(11)35)5-36-21-12(24-7(2)28)19(15(31)9(4-26)38-21)40-22-18(34)17(33)13(29)8(3-25)39-22/h8-22,25-26,29-35H,3-5H2,1-2H3,(H,23,27)(H,24,28)/t8-,9-,10-,11-,12-,13+,14+,15-,16-,17+,18-,19-,20+,21-,22+/m1/s1",beta-D-galacto-hexopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->6)-2-acetamido-2-deoxy-alpha-D-galacto-hexopyranose,GlyTouCan accession,G50068TE
7435,151922,1-O-(4-O-beta-D-galactopyranosyl-beta-D-glucopyranosyl)-glycerol,A glycosylglycerol that is 1-O-(beta-D-glucosyl)glycerol in which the hydroxy group at position 4 of the glucose ring has been converted to the corresponding beta-D-galactopyranoside.,"InChI=1S/C15H28O13/c16-1-5(19)4-25-14-12(24)10(22)13(7(3-18)27-14)28-15-11(23)9(21)8(20)6(2-17)26-15/h5-24H,1-4H2/t5?,6-,7-,8+,9+,10-,11-,12-,13-,14-,15+/m1/s1","WURCS=2.0/3,3,2/[hxh][a2122h-1b_1-5][a2112h-1b_1-5]/1-2-3/a3-b1_b4-c1",GlyTouCan accession,G50188XO
7436,151923,alpha-D-Galp-(1->4)-alpha-D-Glcp,A alpha-D-Galp-(1->4)-D-Glcp in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5][a2112h-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G50190XI
7437,152009,alpha-L-Fucp-(1->3)-alpha-D-Glcp,An alpha-L-Fucp-(1->3)-Glcp in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C12H22O10/c1-3-5(14)7(16)8(17)12(20-3)22-10-6(15)4(2-13)21-11(19)9(10)18/h3-19H,2H2,1H3/t3-,4+,5+,6+,7+,8-,9+,10-,11-,12-/m0/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5][a1221m-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G51113GH
7438,152042,alpha-D-Manp-(1->6)-D-GlcpNAc,An amino disaccharide consisting of alpha-D-mannopyranose and 2-acetamido-2-deoxy-D-glucopyranose residues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C14H25NO11/c1-4(17)15-7-10(20)9(19)6(25-13(7)23)3-24-14-12(22)11(21)8(18)5(2-16)26-14/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)/t5-,6-,7-,8-,9-,10-,11+,12+,13?,14+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][a1122h-1a_1-5]/1-2/a6-b1",GlyTouCan accession,G51482CR
7439,152047,beta-D-Manp-(1->4)-beta-Galp,A glycosylgalactose consisting of beta-D-mannopyranose and beta-D-galactopyranose residues joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8-,9+,10+,11-,12+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5][a1122h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G51512RL
7440,152054,nataloe-emodin,"A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 2, and 8 and by a methyl group at position 6. It is isolated from the leaves of Picramnia sellowii and Picramnia latifolia plants.","InChI=1S/C15H10O5/c1-6-4-8-11(10(17)5-6)15(20)12-7(13(8)18)2-3-9(16)14(12)19/h2-5,16-17,19H,1H3","1,2,8-trihydroxy-6-methylanthra-9,10-quinone",PubMed citation,27274078
7441,158283,Ala-Leu-Ala,"A tripeptide composed of L-alanine, L-leucine and L-alanine joined in sequence by peptide linkages.","InChI=1S/C12H23N3O4/c1-6(2)5-9(15-10(16)7(3)13)11(17)14-8(4)12(18)19/h6-9H,5,13H2,1-4H3,(H,14,17)(H,15,16)(H,18,19)/t7-,8-,9-/m0/s1",(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoic acid,Chemspider accession,5379140
7442,157691,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-{alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->2)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->4)]-alpha-D-Manp-(1->3)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched 17-residue amino oligosaccharide comprising a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine trisaccharide backbone, to the mannosyl residue are connected alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->2)-[alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->4)]-alpha-D-mannosyl and alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl units via (1->2) and (1->6) linkages respectively.","InChI=1S/C112H187N5O80/c1-23-50(133)63(146)73(156)101(166-23)189-87-47(115-31(9)130)98(178-41(19-125)84(87)186-109-92(70(153)57(140)35(13-119)174-109)195-104-76(159)66(149)53(136)26(4)169-104)184-83-40(18-124)181-112(95(79(83)162)194-100-49(117-33(11)132)89(191-103-75(158)65(148)52(135)25(3)168-103)86(43(21-127)180-100)188-111-94(72(155)59(142)37(15-121)176-111)197-106-78(161)68(151)55(138)28(6)171-106)192-90-60(143)44(182-107(80(90)163)185-82-39(17-123)177-97(46(62(82)145)114-30(8)129)183-81-38(16-122)172-96(164)45(61(81)144)113-29(7)128)22-165-108-91(69(152)56(139)34(12-118)173-108)193-99-48(116-32(10)131)88(190-102-74(157)64(147)51(134)24(2)167-102)85(42(20-126)179-99)187-110-93(71(154)58(141)36(14-120)175-110)196-105-77(160)67(150)54(137)27(5)170-105/h23-28,34-112,118-127,133-164H,12-22H2,1-11H3,(H,113,128)(H,114,129)(H,115,130)(H,116,131)(H,117,132)/t23-,24-,25-,26-,27-,28-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57-,58-,59-,60+,61+,62+,63+,64+,65+,66+,67+,68+,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89+,90-,91-,92+,93+,94+,95-,96+,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112+/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)-{alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->2)-[alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->4)]-alpha-D-Man-(1->3)}-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,31537530
7443,156349,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-GalpNAc,"A branched amino hexasaccharide comprising a tetrasaccharide backbone consisting of N-acetyl-alpha-D-galactosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-D-galactosamine residues linked in sequence (1->3), (1->4) and (1->3), with alpha-L-fucose residues linked to the beta-galactose and N-acetylglucosamine via (1->2) and (1->3) linkages respectively.","InChI=1S/C42H71N3O29/c1-10-22(53)28(59)30(61)40(64-10)72-34-21(45-14(5)52)39(71-33-20(44-13(4)51)37(63)66-16(7-47)25(33)56)69-18(9-49)32(34)70-42-36(74-41-31(62)29(60)23(54)11(2)65-41)35(26(57)17(8-48)68-42)73-38-19(43-12(3)50)27(58)24(55)15(6-46)67-38/h10-11,15-42,46-49,53-63H,6-9H2,1-5H3,(H,43,50)(H,44,51)(H,45,52)/t10-,11-,15+,16+,17+,18+,19+,20+,21+,22+,23+,24-,25-,26-,27+,28+,29+,30-,31-,32+,33+,34+,35-,36+,37?,38+,39-,40-,41-,42-/m0/s1",alpha-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-GalNAc,PubMed citation,31537530
7444,156353,beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-{beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino oligosaccharide comprising a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->6)]-N-acetyl-beta-D-glucosamine tetrasaccharide, onto the mannosyl residue of which are two beta-D-galactosyl-(1->4)-[alpha-L-fucosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide units linked (1->3) and (1->6).","InChI=1S/C80H134N4O58/c1-17-37(96)47(106)54(113)73(122-17)120-16-32-61(45(104)33(69(119)125-32)81-20(4)92)134-70-34(82-21(5)93)46(105)60(28(12-89)130-70)135-78-59(118)66(140-80-68(53(112)43(102)27(11-88)129-80)142-72-36(84-23(7)95)65(139-75-56(115)49(108)39(98)19(3)124-75)63(30(14-91)132-72)137-77-58(117)51(110)41(100)25(9-86)127-77)44(103)31(133-78)15-121-79-67(52(111)42(101)26(10-87)128-79)141-71-35(83-22(6)94)64(138-74-55(114)48(107)38(97)18(2)123-74)62(29(13-90)131-71)136-76-57(116)50(109)40(99)24(8-85)126-76/h17-19,24-80,85-91,96-119H,8-16H2,1-7H3,(H,81,92)(H,82,93)(H,83,94)(H,84,95)/t17-,18-,19-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42+,43+,44+,45+,46+,47+,48+,49+,50-,51-,52-,53-,54-,55-,56-,57+,58+,59-,60+,61+,62+,63+,64+,65+,66-,67-,68-,69+,70-,71-,72-,73+,74-,75-,76-,77-,78-,79-,80+/m0/s1",beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-{beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)}-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1-->6)]-beta-D-GlcNAc,PubMed citation,31537530
7445,156148,ascofuranone,"A dihydroxybenzaldehyde that is 2,4-dihydroxybenzaldehyde which is substituted by a (2E,6E)-7-[(2S)-5,5-dimethyl-4-oxotetrahydrofuran-2-yl]-3-methylocta-2,6-dien-1-yl group at position 3, chlorine at position 5, and a methyl group at position 6. A meroterpenoid produced by the soil fungus, Acremonium sclerotigenum. It is a promising drug candidate against the tropical disease, African trypanosomiasis.","InChI=1S/C23H29ClO5/c1-13(7-6-8-14(2)18-11-19(26)23(4,5)29-18)9-10-16-21(27)17(12-25)15(3)20(24)22(16)28/h8-9,12,18,27-28H,6-7,10-11H2,1-5H3/b13-9+,14-8+/t18-/m0/s1",(S)-ascofuranone,PubMed citation,27804952
7446,156329,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,"A branched amino pentasaccharide comprising a trisaccahride backbone consisting of beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-alpha-D-galactosamine residues linked in sequence (1->4) and (1->3), with alpha-L-fucose residues linked to the galactose and N-acetylglucosamine via (1->2) and (1->3) linkages respectively.","InChI=1S/C34H58N2O24/c1-8-17(42)21(46)24(49)32(52-8)59-28-16(36-11(4)41)31(58-27-15(35-10(3)40)30(51)54-13(6-38)20(27)45)56-14(7-39)26(28)57-34-29(23(48)19(44)12(5-37)55-34)60-33-25(50)22(47)18(43)9(2)53-33/h8-9,12-34,37-39,42-51H,5-7H2,1-4H3,(H,35,40)(H,36,41)/t8-,9-,12+,13+,14+,15+,16+,17+,18+,19-,20-,21+,22+,23-,24-,25-,26+,27+,28+,29+,30-,31-,32-,33-,34-/m0/s1",alpha-L-Fuc-(1->2)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-alpha-D-GalNAc,PubMed citation,31537530
7447,155880,Gly-Gly-Pro,"A tripeptide composed of glycine, glycine and L-proline amino acids joined in sequence by peptide linkages.","InChI=1S/C9H15N3O4/c10-4-7(13)11-5-8(14)12-3-1-2-6(12)9(15)16/h6H,1-5,10H2,(H,11,13)(H,15,16)/t6-/m0/s1",glycylglycylproline,CAS Registry Number,14379-76-1
7448,156447,norloline,A loline alkaloid with formula C7H12N2O. It is isolated from the plants Lolium cuneatum and Lolium temulentum.,"InChI=1S/C7H12N2O/c8-6-5-3-9-2-1-4(10-5)7(6)9/h4-7H,1-3,8H2/t4-,5+,6-,7+/m0/s1",temuline,PubMed citation,25531527
7449,156302,(aminooxy)acetic acid hemihydrochloride,The hemihydrochloride salt of (aminooxy)acetic acid. It is a malate-aspartate shuttle (MAS) inhibitor which also inhibits the GABA degradating enzyme 4-aminobutyrate aminotransferase and cystathionine beta-synthetase.,"InChI=1S/2C2H5NO3.ClH/c2*3-6-1-2(4)5;/h2*1,3H2,(H,4,5);1H",O-(carboxymethyl)hydroxylamine hemihydrochloride,PubMed citation,27778022
7450,155706,beta-D-Glcp-(1->6)-beta-D-Galp,A beta-D-Glcp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10-,11-,12-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5][a2122h-1b_1-5]/1-2/a6-b1",GlyTouCan accession,G93931KM
7451,155712,alpha-D-Galp-(1->4)-D-Gal-OH,A glycosyl alditol consisting of alpha-D-galactopyranose and D-galactitol residues joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5+,6+,7+,8-,9-,10+,11-,12+/m0/s1","WURCS=2.0/2,2,1/[h2112h][a2112h-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G93984DX
7452,155770,beta-D-GalpNAc-(1->3)-alpha-D-Galp-(1->6)-beta-D-Galp-(1->4)-beta-D-Glcp,"An amino tetrasaccharide comprised of a linear sequence of N-acetyl-beta-D-galactosamine, alpha-D-galactose, beta-D-galactose and beta-D-glucose residues linked (1->3), (1->6) and (1->4).","InChI=1S/C26H45NO21/c1-6(31)27-11-15(35)12(32)7(2-28)44-24(11)48-22-14(34)8(3-29)45-25(20(22)40)42-5-10-13(33)16(36)19(39)26(46-10)47-21-9(4-30)43-23(41)18(38)17(21)37/h7-26,28-30,32-41H,2-5H2,1H3,(H,27,31)/t7-,8-,9-,10-,11-,12+,13+,14+,15-,16+,17-,18-,19-,20-,21-,22+,23-,24+,25+,26+/m1/s1","WURCS=2.0/4,4,3/[a2122h-1b_1-5][a2112h-1b_1-5][a2112h-1a_1-5][a2112h-1b_1-5_2*NCC/3=O]/1-2-3-4/a4-b1_b6-c1_c3-d1",GlyTouCan accession,G94173VC
7453,157684,lymphostin,"A member of the class of pyrroloquinolines that is pyrrolo[4,3,2-de]quinoline in which the hydrogens at positions 4, 6 and 8 are replaced by (1E)-1-methoxy-3-oxoprop-1-en-3-yl, acetylamino and amino groups, respectively. It is an alkaloid isolated from Streptomyces and Salinispora species, exhibits potent immunosuppressive activity, and inhibits Fyn and Lck protein kinases.","InChI=1S/C16H14N4O3/c1-8(21)19-12-6-10(17)15-14-9(7-18-15)5-11(20-16(12)14)13(22)3-4-23-2/h3-7H,17H2,1-2H3,(H,19,21)/b4-3+",LK6-A,PubMed citation,9711243
7454,155283,beta-D-Glcp-(1->3)-beta-D-Galp,A beta-D-Glcp-(1->3)-D-Galp in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8-,9-,10+,11-,12+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5][a2122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G92177ZW
7455,156257,E. coli strain O157 LPS core oligosaccharide R3,"A branched ten-membered oligosaccharide phosphate consisting of three galactose residues, two glucose residues, one 4-phospho-D-glycero-alpha-D-manno-heptose residue, one L-glycero-alpha-D-manno-heptose residue, one 4-phospho-L-glycero-alpha-D-manno-heptose residue and two Kdo residues, one of which is at the reducing end. The unit constitutes one of the core oligosaccharide structures of enterobacterial lipopolysaccharide obtained from E. coli strain O157.","InChI=1S/C67H114O64P2/c68-3-14(78)42-34(92)32(90)35(93)56(117-42)111-12-18(82)45-55(131-133(108,109)110)51(41(99)61(119-45)124-50-40(98)60(118-44(16(80)5-70)54(50)130-132(105,106)107)121-48-19(2-66(104,64(100)101)128-46(48)17(81)6-71)127-67(65(102)103)1-13(77)25(83)43(129-67)15(79)4-69)123-59-39(97)49(29(87)23(10-75)114-59)122-63-53(38(96)47(24(11-76)116-63)120-57-36(94)30(88)26(84)20(7-72)112-57)126-62-52(33(91)28(86)22(9-74)115-62)125-58-37(95)31(89)27(85)21(8-73)113-58/h13-63,68-99,104H,1-12H2,(H,100,101)(H,102,103)(H2,105,106,107)(H2,108,109,110)/t13-,14+,15-,16+,17-,18-,19-,20-,21-,22-,23-,24-,25-,26+,27+,28+,29-,30+,31+,32+,33+,34+,35+,36-,37-,38+,39-,40+,41+,42-,43-,44-,45-,46-,47-,48-,49+,50-,51-,52-,53-,54-,55-,56+,57+,58-,59-,60-,61+,62-,63-,66-,67-/m1/s1",Galalpha1-2Galalpha1-2(Galbeta1-4)Glcalpha1-3Glcalpha1-3(LDHepalpha1-7)DDHep4Pbeta1-3LDHep4Palpha1-5(Kdoalpha2-4)Kdoalpha,MetaCyc accession,CPD-21361
7456,156282,alpha-DD-Hep-(1->3)-alpha-DD-Hep-(1->3)-alpha-DD-Hep-O[CH2]3NH2,A linear synthetic trisaccharide derivative consisting of three D-glycero-alpha-D-manno-heptopyranose residue linked (1->3). An aminopropyl linker at the reducing end enables printing onto microscope slides. One of a series of substructures of the Helicobacter pylori O6 O-antigen tridecasaccharide O-antigen used for its immunological evaluation.,"InChI=1S/C24H45NO19/c25-2-1-3-39-22-15(37)20(13(35)18(40-22)8(30)5-27)44-24-16(38)21(14(36)19(42-24)9(31)6-28)43-23-12(34)10(32)11(33)17(41-23)7(29)4-26/h7-24,26-38H,1-6,25H2/t7-,8-,9-,10+,11+,12+,13-,14-,15+,16+,17-,18-,19-,20+,21+,22+,23-,24-/m1/s1",D-glycero-alpha-D-manno-heptopyranosyl-(1->3)-D-glycero-alpha-D-manno-heptopyranosyl-(1->3)-(3-aminopropyl)-D-glycero-alpha-D-manno-heptopyranoside,PubMed citation,32363752
7457,153009,alpha-D-Galp-(1->3)-D-GalNAc-OH,A glycosyl alditol derivative that is N-acetyl-D-galactosaminitol in which the hydroxy group at position 3 has been glycosylated by an alpha-D-galactopyranosyl group.,"InChI=1S/C14H27NO11/c1-5(19)15-6(2-16)13(9(21)7(20)3-17)26-14-12(24)11(23)10(22)8(4-18)25-14/h6-14,16-18,20-24H,2-4H2,1H3,(H,15,19)/t6-,7+,8+,9-,10-,11-,12+,13+,14+/m0/s1","WURCS=2.0/2,2,1/[h2112h_2*NCC/3=O][a2112h-1a_1-5]/1-2/a3-b1",GlyTouCan accession,G65162CH
7458,156471,cyproflanilide,"A member of the class of benzamides that is benzene in which the hydrogens at positions 1, 2 and 3 are susbtituted by [2-bromo-4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-6-(trifluoromethyl)phenyl]aminocarbonyl, fluoro, and (cyclopropylmethyl)(4-fluorobenzoyl)nitrilo groups, respectively. It is an insecticide developed by CAC Shanghai International Trading Co Ltd., China.","InChI=1S/C28H17BrF12N2O2/c29-19-11-15(25(32,27(36,37)38)28(39,40)41)10-18(26(33,34)35)22(19)42-23(44)17-2-1-3-20(21(17)31)43(12-13-4-5-13)24(45)14-6-8-16(30)9-7-14/h1-3,6-11,13H,4-5,12H2,(H,42,44)",CAC-I-785,Pesticides accession,cyproflanilide
7459,156480,methylprednisolone 21-suleptanic acid ester,A carboxylic ester resulting from the formal condensation of the 21-hydroxy group of 6alpha-methylprednisolone with the carboxy group of 8-[methyl(2-sulfoethyl)amino]-8-oxooctanoic acid.,"InChI=1S/C33H49NO10S/c1-21-17-23-24-12-14-33(40,32(24,3)19-26(36)30(23)31(2)13-11-22(35)18-25(21)31)27(37)20-44-29(39)10-8-6-5-7-9-28(38)34(4)15-16-45(41,42)43/h11,13,18,21,23-24,26,30,36,40H,5-10,12,14-17,19-20H2,1-4H3,(H,41,42,43)/t21-,23-,24-,26-,30+,31-,32-,33-/m0/s1",6alpha-methylprednisolone 21-suleptanic acid ester,CAS Registry Number,121807-10-1
7460,152575,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,A branched amino nonasaccharide consisting of a beta-D-GlcNAc residue at the reducing end with a beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4)-linkage and an alpha-L-Fuc residue attached via an alpha-(1->6)-linkage.,"InChI=1S/C61H102N4O44/c1-14-31(76)42(87)46(91)57(96-14)94-13-26-48(40(85)27(53(92)97-26)62-15(2)71)104-56-30(65-18(5)74)41(86)47(24(10-70)102-56)105-61-52(109-58-45(90)32(77)19(75)11-93-58)49(106-60-51(44(89)36(81)23(9-69)101-60)108-55-29(64-17(4)73)39(84)34(79)21(7-67)99-55)37(82)25(103-61)12-95-59-50(43(88)35(80)22(8-68)100-59)107-54-28(63-16(3)72)38(83)33(78)20(6-66)98-54/h14,19-61,66-70,75-92H,6-13H2,1-5H3,(H,62,71)(H,63,72)(H,64,73)(H,65,74)/t14-,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32-,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43-,44-,45+,46-,47+,48+,49-,50-,51-,52-,53+,54-,55-,56-,57+,58-,59-,60+,61-/m0/s1",2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)][beta-D-xylo-pentopyranosyl-(1->2)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->6)]-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose,GlyTouCan accession,G62826CL
7461,155080,alpha-D-Manp-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-D-GlcpNAc,An amino hexasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 6 by an alpha-D-Man residue and at position 3 by a alpha-D-Man-(1->2)-alpha-D-Man group.,"InChI=1S/C40H68N2O31/c1-9(48)41-17-23(54)31(14(6-46)64-35(17)62)70-36-18(42-10(2)49)24(55)32(15(7-47)68-36)71-39-30(61)33(22(53)16(69-39)8-63-37-28(59)25(56)19(50)11(3-43)65-37)72-40-34(27(58)21(52)13(5-45)67-40)73-38-29(60)26(57)20(51)12(4-44)66-38/h11-40,43-47,50-62H,3-8H2,1-2H3,(H,41,48)(H,42,49)/t11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25+,26+,27+,28+,29+,30+,31-,32-,33+,34+,35?,36+,37+,38-,39+,40-/m1/s1",Man(a1-2)Man(a1-3)[Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,GlyTouCan accession,G97023FS
7462,155731,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,"A highly branched amino nonasaccharide consisting of a beta-D-GlcNAc residue at the reducing end with a beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4)-linkage and an L-Fuc residue attached via an alpha-(1->3)-linkage. Found on Cry j 1, the major allergen of Cryptomeria japonica pollen.","InChI=1S/C61H102N4O44/c1-14-31(77)41(87)45(91)58(95-14)105-48-30(65-18(5)75)53(92)96-25(11-71)47(48)104-56-29(64-17(4)74)40(86)46(24(10-70)101-56)103-61-52(109-57-44(90)32(78)19(76)12-93-57)49(106-60-51(43(89)36(82)23(9-69)100-60)108-55-28(63-16(3)73)39(85)34(80)21(7-67)98-55)37(83)26(102-61)13-94-59-50(42(88)35(81)22(8-68)99-59)107-54-27(62-15(2)72)38(84)33(79)20(6-66)97-54/h14,19-61,66-71,76-92H,6-13H2,1-5H3,(H,62,72)(H,63,73)(H,64,74)(H,65,75)/t14-,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32-,33+,34+,35+,36+,37+,38+,39+,40+,41+,42-,43-,44+,45-,46+,47+,48+,49-,50-,51-,52-,53+,54-,55-,56-,57-,58-,59-,60+,61-/m0/s1",2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)][beta-D-xylo-pentopyranosyl-(1->2)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->3)]-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose,GlyTouCan accession,G99603GB
7463,153406,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-D-GlcpNAc,An amino hexasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 6 by an alpha-D-Man residue and at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group.,"InChI=1S/C42H71N3O31/c1-10(51)43-19-27(59)33(16(7-49)67-37(19)65)73-39-21(45-12(3)53)28(60)34(17(8-50)71-39)74-41-32(64)35(25(57)18(72-41)9-66-40-31(63)29(61)23(55)14(5-47)69-40)75-42-36(30(62)24(56)15(6-48)70-42)76-38-20(44-11(2)52)26(58)22(54)13(4-46)68-38/h13-42,46-50,54-65H,4-9H2,1-3H3,(H,43,51)(H,44,52)(H,45,53)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29+,30+,31+,32+,33-,34-,35+,36+,37?,38+,39+,40+,41+,42-/m1/s1",2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[alpha-D-manno-hexopyranosyl-(1->6)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G70073SG
7464,154058,D-Glcp-(1->2)-D-Galp,A glycosylgalactose consisting of D-glucopyranose and D-galactopyranose residues joined in sequence by a (1->2) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10-,11?,12?/m1/s1","WURCS=2.0/2,2,1/[a2112h-1x_1-5][a2122h-1x_1-5]/1-2/a2-b1",GlyTouCan accession,G78600GX
7465,153430,beta-D-Galf-(1->2)-beta-D-Galf,A beta-D-Galf-(1->2)-D-Galf in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C12H22O11/c13-1-3(15)8-5(17)6(18)12(22-8)23-10-7(19)9(4(16)2-14)21-11(10)20/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10-,11-,12+/m1/s1","WURCS=2.0/1,2,1/[a2112h-1b_1-4]/1-1/a2-b1",GlyTouCan accession,G70197EV
7466,156218,"(R)-7-{[4-(6-oxo-1,6-dihydropyrimidin-4-yl)piperidin-1-yl]carbonyl}-1,3-diazepane-2,4-dione","Piperidine carrying a 6-oxo-1,6-dihydropyrimidin-4-yl group at C-4 and a [(4R)-2,7-dioxo-1,3-diazepan-4-yl]carbonyl substituent on N-1. One of a series of mucosal-associated invariant T (MAIT) cell agonists.","InChI=1S/C15H19N5O4/c21-12-2-1-10(18-15(24)19-12)14(23)20-5-3-9(4-6-20)11-7-13(22)17-8-16-11/h7-10H,1-6H2,(H,16,17,22)(H2,18,19,21,24)/t10-/m1/s1",DB-23,PubMed citation,32341160
7467,153954,beta-D-Glcp-(1->2)-D-Glc-OH,A glycosyl alditol consisting of beta-D-glucopyranose and D-glucitol residues joined in sequence by a (1->2) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(16)7(17)8(18)5(2-14)22-12-11(21)10(20)9(19)6(3-15)23-12/h4-21H,1-3H2/t4-,5+,6-,7-,8-,9-,10+,11-,12-/m1/s1","WURCS=2.0/2,2,1/[h2122h][a2122h-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G75188JR
7468,156214,"N(2)-[3-(3-oxo-3,4-dihydroquinoxalin-2-yl)propanoyl]-L-serinamide",A quinoxaline derivative in which quinoxalin-2(1H)-one carries an L-serine-based function {[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]amino}-3-oxopropyl} at C-2. One of a series of mucosal-associated invariant T (MAIT) cell agonists.,"InChI=1S/C14H16N4O4/c15-13(21)11(7-19)17-12(20)6-5-10-14(22)18-9-4-2-1-3-8(9)16-10/h1-4,11,19H,5-7H2,(H2,15,21)(H,17,20)(H,18,22)/t11-/m0/s1",DB19,PubMed citation,32341160
7469,154052,beta-D-Glcp-(1->4)-beta-D-Galp,A beta-D-Glcp-(1->4)-D-Galp in which the carbon bearing the anomeric hydroxy group has beta configuration.,"InChI=1S/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8-,9-,10+,11-,12+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1b_1-5][a2122h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G75485SI
7470,154818,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-D-Glcp,A branched amino tetrasaccharide consisting of D-glucose at the reducing end having an N-acetyl-alpha-D-galactosaminyl-(1->3)-[alpha-L-fucosyl-(1->2)]-beta-D-galactosyl moiety attached at the 4-position.,"InChI=1S/C26H45NO20/c1-6-12(32)16(36)19(39)25(41-6)47-22-21(46-24-11(27-7(2)31)15(35)13(33)8(3-28)43-24)14(34)9(4-29)44-26(22)45-20-10(5-30)42-23(40)18(38)17(20)37/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14-,15+,16+,17+,18+,19-,20+,21-,22+,23?,24+,25-,26-/m0/s1",6-deoxy-alpha-L-galacto-hexopyranosyl-(1->2)-[2-acetamido-2-deoxy-alpha-D-galacto-hexopyranosyl-(1->3)]-beta-D-galacto-hexopyranosyl-(1->4)-D-gluco-hexopyranose,GlyTouCan accession,G90377OF
7471,154838,2-O-(4-O-beta-D-galactopyranosyl-beta-D-glucopyranosyl)-glycerol,A glycosylglycerol that is 2-O-(beta-D-glucosyl)glycerol in which the hydroxy group at position 4 of the glucose ring has been converted to the corresponding beta-D-galactopyranoside.,"InChI=1S/C15H28O13/c16-1-5(2-17)25-14-12(24)10(22)13(7(4-19)27-14)28-15-11(23)9(21)8(20)6(3-18)26-15/h5-24H,1-4H2/t6-,7-,8+,9+,10-,11-,12-,13-,14-,15+/m1/s1","WURCS=2.0/3,3,2/[hxh][a2122h-1b_1-5][a2112h-1b_1-5]/1-2-3/a2-b1_b4-c1",GlyTouCan accession,G90517TH
7472,156207,"2-amino-4-{[(3-carbamoyl-1,2,4-oxadiazol-5-yl)methyl]amino}-6-isopropylpyrimidin-1-ium","An aminopyrimidine, protonated on N-1, substituted with an isopropyl group at C-6 and carrying a (3-carbamoyl-1,2,4-oxadiazol-5-yl)methyl substituent on the amino group at C-4. One of a series of mucosal-associated invariant T (MAIT) cell agonists.","InChI=1S/C11H15N7O2/c1-5(2)6-3-7(16-11(13)15-6)14-4-8-17-10(9(12)19)18-20-8/h3,5H,4H2,1-2H3,(H2,12,19)(H3,13,14,15,16)/p+1",DB-5,PubMed citation,32341160
7473,156278,alpha-DD-Hep-(1->6)-alpha-DD-Hep-(1->2)-alpha-DD-Hep-(1->2)-alpha-DD-Hep-O[CH2]3NH2,"A linear synthetic tetrasaccharide derivative consisting of four D-glycero-alpha-D-manno-heptopyranose residue linked in sequence (1->6),(1->2), (1->2), (1->2). An aminopropyl linker at the reducing end enables printing onto microscope slides. One of a series of substructures of the Helicobacter pylori O6 O-antigen tridecasaccharide O-antigen used for its immunological evaluation.","InChI=1S/C31H57NO25/c32-2-1-3-50-30-26(18(46)16(44)23(53-30)9(38)5-34)57-31-27(19(47)17(45)24(54-31)10(39)6-35)56-29-21(49)13(41)15(43)25(55-29)11(7-36)51-28-20(48)12(40)14(42)22(52-28)8(37)4-33/h8-31,33-49H,1-7,32H2/t8-,9-,10-,11-,12+,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23-,24-,25-,26+,27+,28+,29-,30+,31-/m1/s1",3-aminopropyl D-glycero-alpha-D-manno-heptosyl-(1->6)-D-glycero-alpha-D-manno-heptosyl-(1->2)-D-glycero-alpha-D-manno-heptosyl-(1->2)-D-glycero-alpha-D-manno-heptoside,PubMed citation,32363752
7474,156298,aurafuron A,"A polyketide that is 2,3-dihydrofuran substituted by hydroxy, methyl, oxo, methyl and (2S,3Z,5E,7R,8R,9E)-2,8-dihydroxy-7,9,12-trimethyltrideca-3,5,9-trien-1-yl groups at positions 2, 2, 3, 4, and 5, respectively. It is a cytotoxic natural product found in several myxobacteria species and inhibits the growth of some filamentous fungi.","InChI=1S/C22H34O5/c1-14(2)11-12-16(4)20(24)15(3)9-7-8-10-18(23)13-19-17(5)21(25)22(6,26)27-19/h7-10,12,14-15,18,20,23-24,26H,11,13H2,1-6H3/b9-7+,10-8-,16-12+/t15-,18-,20-,22?/m1/s1",(-)-aurafuron A,PubMed citation,15981410
7475,156299,alpha-D-Galp-(1->-3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->-4)-beta-D-GlcpNAc-(1->-3)-alpha-D-GalpNAc,"A branched amino pentasaccharide comprising a linear tetrasaccharide chain of alpha-D-galactose, beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-alpha-D-galactosamine residues linked (1->3), (1->4) and (1->3) respectively, with an alpha-L-fucose residue linked (1->2) to the beta-galactose residue.","InChI=1S/C34H58N2O25/c1-8-17(43)22(48)24(50)32(53-8)61-29-28(60-33-25(51)23(49)18(44)11(4-37)55-33)20(46)13(6-39)56-34(29)58-26-14(7-40)57-31(15(21(26)47)35-9(2)41)59-27-16(36-10(3)42)30(52)54-12(5-38)19(27)45/h8,11-34,37-40,43-52H,4-7H2,1-3H3,(H,35,41)(H,36,42)/t8-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20-,21+,22+,23-,24-,25+,26+,27+,28-,29+,30-,31-,32-,33+,34-/m0/s1",alpha-L-fucosyl-(1->2)-[alpha-D-galactosyl-(1->3)]-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-N-acetyl-alpha-D-galactosamine,PubMed citation,31537530
7476,156331,"3'-deoxy-3',4'-didehydro-cytidine","A pyrimidine 3'-deoxyribonucleoside that is cytidine in which the hydroxy group at position 3' is replaced by a hydrogen and a double bond is introduced between positions 3' and 4'. It is a metabolite of 3'-deoxy-3',4'-didehydro-CTP.","InChI=1S/C9H11N3O4/c10-7-1-2-12(9(15)11-7)8-6(14)3-5(4-13)16-8/h1-3,6,8,13-14H,4H2,(H2,10,11,15)/t6-,8-/m1/s1",ddh-cytidine,PubMed citation,35128501
7477,156336,"3'-deoxy-3',4'-didehydro-CTP","A pyrimidine 3'-deoxyribonucleoside 5'-triphosphate resulting from the formal condensation of the 5'-hydroxy group of 3'-deoxy-3',4'-didehydro-cytidine with triphosphoric acid. It is a chain terminator for RNA-dependent RNA polymerases.","InChI=1S/C9H14N3O13P3/c10-7-1-2-12(9(14)11-7)8-6(13)3-5(23-8)4-22-27(18,19)25-28(20,21)24-26(15,16)17/h1-3,6,8,13H,4H2,(H,18,19)(H,20,21)(H2,10,11,14)(H2,15,16,17)/t6-,8-/m1/s1",ddh-CTP,PubMed citation,34126010
7478,153445,beta-D-GlcpNAc-(1->3)-alpha-D-GlcpNAc,An amino disaccharide consisting of 2-acetamido-2-deoxy-beta-D-glucopyranose residue and a 2-acetamido-2-deoxy-alpha-D-glucopyranose residue joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)11(23)7(3-19)28-16(9)29-14-10(18-6(2)22)15(26)27-8(4-20)12(14)24/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11-,12-,13-,14-,15+,16+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1a_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O]/1-2/a3-b1",GlyTouCan accession,G72999QD
7479,153487,alpha-D-Manp6P-(1->6)-alpha-D-Manp,A disaccharide phosphate consisting of a 6-O-phosphono-alpha-D-mannopyranose residue and an alpha-D-mannopyranose residue joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C12H23O14P/c13-5-3(25-11(19)9(17)7(5)15)1-23-12-10(18)8(16)6(14)4(26-12)2-24-27(20,21)22/h3-19H,1-2H2,(H2,20,21,22)/t3-,4-,5-,6-,7+,8+,9+,10+,11+,12+/m1/s1","WURCS=2.0/2,2,1/[a1122h-1a_1-5][a1122h-1a_1-5_6*OPO/3O/3=O]/1-2/a6-b1",GlyTouCan accession,G73365KM
7480,153545,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-{alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino oligosaccharide that is an undecasaccharide derivative in which two alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide units are linked (1->3) and (1->6) to the mannose residue of a beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl(1->4)-N-acetyl-D-glucosamine trisaccharide.,"InChI=1S/C74H124N4O54/c1-16-35(91)44(100)50(106)68(113-16)128-59-33(77-20(5)89)66(121-28(13-85)57(59)126-70-52(108)46(102)37(93)22(7-79)116-70)131-62-48(104)39(95)24(9-81)118-73(62)112-15-30-41(97)61(54(110)72(123-30)125-56-27(12-84)120-65(32(43(56)99)76-19(4)88)124-55-26(11-83)115-64(111)31(42(55)98)75-18(3)87)130-74-63(49(105)40(96)25(10-82)119-74)132-67-34(78-21(6)90)60(129-69-51(107)45(101)36(92)17(2)114-69)58(29(14-86)122-67)127-71-53(109)47(103)38(94)23(8-80)117-71/h16-17,22-74,79-86,91-111H,7-15H2,1-6H3,(H,75,87)(H,76,88)(H,77,89)(H,78,90)/t16-,17-,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37-,38-,39+,40+,41+,42+,43+,44+,45+,46-,47-,48-,49-,50-,51-,52+,53+,54-,55+,56+,57+,58+,59+,60+,61-,62-,63-,64?,65-,66-,67-,68-,69-,70-,71-,72-,73-,74+/m0/s1","WURCS=2.0/6,11,10/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a1221m-1a_1-5][a2112h-1b_1-5]/1-2-3-4-2-5-6-4-2-5-6/a4-b1_b4-c1_c3-d1_c6-h1_d2-e1_e3-f1_e4-g1_h2-i1_i3-j1_i4-k1",GlyTouCan accession,G73683LQ
7481,154293,alpha-D-GlcpNAc-(1->4)-D-GlcpNAc,An amino disaccharide consisting of a 2-acetamido-2-deoxy-alpha-D-glucopyranose residue and a 2-acetamido-2-deoxy-D-glucopyranose residue joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C16H28N2O11/c1-5(21)17-9-13(25)14(8(4-20)27-15(9)26)29-16-10(18-6(2)22)12(24)11(23)7(3-19)28-16/h7-16,19-20,23-26H,3-4H2,1-2H3,(H,17,21)(H,18,22)/t7-,8-,9-,10-,11-,12-,13-,14-,15?,16-/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5_2*NCC/3=O][a2122h-1a_1-5_2*NCC/3=O]/1-2/a4-b1",GlyTouCan accession,G82400TF
7482,153547,methyl alpha-D-glucopyranuronate,A methyl D-glucopyranuronate in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C7H12O7/c1-13-7(12)5-3(9)2(8)4(10)6(11)14-5/h2-6,8-11H,1H3/t2-,3-,4+,5-,6-/m0/s1","WURCS=2.0/1,1,0/[a2122A-1a_1-5_6*OC]/1/",GlyTouCan accession,G73698CD
7483,153582,beta-D-Arap-(1->2)-D-Manp,A glycosylmannose consisting of beta-D-arabinopyranose and D-mannopyranose joined in sequence by a (1->2) glycosidic bond.,"InChI=1S/C11H20O10/c12-1-4-6(15)7(16)9(10(18)20-4)21-11-8(17)5(14)3(13)2-19-11/h3-18H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10?,11+/m1/s1","WURCS=2.0/2,2,1/[a1122h-1x_1-5][a122h-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G79615XP
7484,152267,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,"A linear amino tetrasaccharide consisting of alpha-D-galactose, beta-D-galactose, N-acetyl-beta-D-glucosamine and (at the reducing end) N-acetyl-alpha-D-galactosamine residues linked conesecutively (1->3), (1->4) and (1->3).","InChI=1S/C28H48N2O21/c1-7(35)29-13-18(40)22(12(6-34)48-26(13)50-23-14(30-8(2)36)25(44)45-10(4-32)16(23)38)49-28-21(43)24(17(39)11(5-33)47-28)51-27-20(42)19(41)15(37)9(3-31)46-27/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15+,16+,17+,18-,19+,20-,21-,22-,23-,24+,25+,26+,27-,28+/m1/s1",Gal(a1-3)Gal(b1-4)GlcNAc(b1-3)a-GalNAc,PubMed citation,31537530
7485,152304,"alpha-L-IdopA-(1->3)-2,5-anhydro-D-Glc-OH4S","A glycosyl alditol derivative consisting of an alpha-L-idopyranuronic acid residue and a 2,5-anhydro-4-O-sulfo-D-glucitol residue joined in sequence by a (1->3) glycosidic bond.","InChI=1S/C12H20O14S/c13-1-3-8(9(4(2-14)23-3)26-27(20,21)22)24-12-7(17)5(15)6(16)10(25-12)11(18)19/h3-10,12-17H,1-2H2,(H,18,19)(H,20,21,22)/t3-,4+,5-,6-,7+,8+,9+,10+,12+/m0/s1","WURCS=2.0/2,2,1/[h1122h_2-5_3*OSO/3=O/3=O][a2121A-1a_1-5]/1-2/a4-b1",GlyTouCan accession,G61251HF
7486,154275,alpha-D-Galp-(1->2)-alpha-D-Manp,A glycosylmannose consisting of an alpha-D-galactopyranose residue and an alpha-D-mannopyranose residue joined in sequence by a (1->2) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6-,7+,8+,9-,10+,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a1122h-1a_1-5][a2112h-1a_1-5]/1-2/a2-b1",GlyTouCan accession,G79379XF
7487,153729,beta-D-Glcp-(1->4)-beta-D-Xylp,A glycosylxylose consisting of beta-D-glucopyranose and beta-D-xylopyranose residues joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C11H20O10/c12-1-3-5(13)7(15)9(17)11(20-3)21-4-2-19-10(18)8(16)6(4)14/h3-18H,1-2H2/t3-,4-,5-,6+,7+,8-,9-,10-,11+/m1/s1","WURCS=2.0/2,2,1/[a212h-1b_1-5][a2122h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G77350QW
7488,156494,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"A branched amino octasaccharide made up from four N-acetyl-beta-D-glucosamine residues, two alpha-D-mannose residues, one beta-D-mannose residue and (at the reducing end) one N-acetyl-D-glucosamine residue.","InChI=1S/C58H97N5O41/c1-14(71)59-27-40(84)45(24(11-69)91-51(27)89)99-55-31(63-18(5)75)41(85)46(25(12-70)97-55)101-58-50(104-57-49(43(87)36(80)23(10-68)96-57)103-54-30(62-17(4)74)39(83)34(78)21(8-66)94-54)44(88)47(100-52-28(60-15(2)72)37(81)32(76)19(6-64)92-52)26(98-58)13-90-56-48(42(86)35(79)22(9-67)95-56)102-53-29(61-16(3)73)38(82)33(77)20(7-65)93-53/h19-58,64-70,76-89H,6-13H2,1-5H3,(H,59,71)(H,60,72)(H,61,73)(H,62,74)(H,63,75)/t19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42+,43+,44+,45-,46-,47-,48+,49+,50+,51?,52+,53+,54+,55+,56+,57-,58+/m1/s1",beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->4)]-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,31537530
7489,153770,alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->6)]-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)}-D-GlcpNAc,A branched amino heptasaccharide compound consisting of a GlcNAc residue at the reducing end with a Man-alpha(1->3)-[Man-alpha(1->6)]-Man-beta(1->4)-GlcNAc moiety attached via a beta-(1->4)-linkage and two Fuc residues attached via alpha-(1->3)- and alpha-(1->6)-linkages.,"InChI=1S/C46H78N2O34/c1-10-21(54)27(60)31(64)42(72-10)71-9-18-37(38(20(40(69)74-18)48-13(4)53)81-44-33(66)28(61)22(55)11(2)73-44)80-41-19(47-12(3)52)26(59)36(16(7-51)77-41)79-46-35(68)39(82-45-34(67)30(63)24(57)15(6-50)76-45)25(58)17(78-46)8-70-43-32(65)29(62)23(56)14(5-49)75-43/h10-11,14-46,49-51,54-69H,5-9H2,1-4H3,(H,47,52)(H,48,53)/t10-,11-,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29-,30-,31-,32-,33-,34-,35-,36+,37+,38+,39-,40?,41-,42+,43-,44-,45+,46-/m0/s1",alpha-D-manno-hexopyranosyl-(1->3)-[alpha-D-manno-hexopyranosyl-(1->6)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->3)][6-deoxy-alpha-L-galacto-hexopyranosyl-(1->6)]-2-acetamido-2-deoxy-D-gluco-hexopyranose,GlyTouCan accession,G77479VH
7490,157632,S. pneumoniae serotype 14 capsular oligosaccharide derivative,"A synthetic oligosaccharide derivative in which three beta-D-Gal-(1->4)-beta-D-Glc-(1->6)-[beta-D-Gal-(1->4)]-beta-D-GlcNAc tetrasaccharide units are linked through N-pentylpentanamide linkers, with a 5-aminopentyl spacer group attached to the GlcNAc residue within the terminal unit. Synthesised as a spacer-bridged oligosaccharide mimic of the capsular polysaccharide of Streptococcus pneumoniae serotype 14, the 5-aminopentyl spacer group affords a method of linking to the CRM197 carrier protein, a genetically detoxified form of diphtheria toxin.","InChI=1S/C108H188N6O67/c1-43(124)112-61-70(137)91(179-103-79(146)73(140)64(131)46(31-115)164-103)55(173-97(61)158-28-13-4-10-22-109)40-161-100-82(149)76(143)88(52(37-121)170-100)176-106-85(152)94(67(134)49(34-118)167-106)155-25-16-7-19-58(127)110-23-11-5-14-29-159-98-62(113-44(2)125)71(138)92(180-104-80(147)74(141)65(132)47(32-116)165-104)56(174-98)41-162-101-83(150)77(144)89(53(38-122)171-101)177-107-86(153)95(68(135)50(35-119)168-107)156-26-17-8-20-59(128)111-24-12-6-15-30-160-99-63(114-45(3)126)72(139)93(181-105-81(148)75(142)66(133)48(33-117)166-105)57(175-99)42-163-102-84(151)78(145)90(54(39-123)172-102)178-108-87(154)96(69(136)51(36-120)169-108)157-27-18-9-21-60(129)130/h46-57,61-108,115-123,131-154H,4-42,109H2,1-3H3,(H,110,127)(H,111,128)(H,112,124)(H,113,125)(H,114,126)(H,129,130)/t46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,61-,62-,63-,64+,65+,66+,67+,68+,69+,70-,71-,72-,73+,74+,75+,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95+,96+,97-,98-,99-,100-,101-,102-,103+,104+,105+,106+,107+,108+/m1/s1",3-O-{5-[(5-{[3-O-{5-[(5-{[3-O-(4-carboxybutyl)-beta-D-Gal-(1->4)-beta-D-Glc-(1->6)-[beta-D-Gal-(1->4)]-beta-D-GlcNAc]oxy}pentyl)amino]-5-oxopentyl}-beta-D-Gal-(1->4)-beta-D-Glc-(1->6)-[beta-D-Gal-(1->4)]-beta-D-GlcNAc]oxy}pentyl)amino]-5-oxopentyl}-beta-D-Gal-(1->4)-beta-D-Glc-(1->6)-[beta-D-Gal-(1->4)]-beta-D-GlcNAcO[CH2]5NH2,PubMed citation,32835479
7491,153973,alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcpNAc,A branched pentasaccharide consisting of a beta-D-GlcNAc residue at the reducing end with an alpha-D-Man-(1->6)-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4) linkage.,"InChI=1S/C33H56N2O25/c1-8(39)34-15-20(45)26(12(4-37)54-29(15)51)58-30-16(35-9(2)40)21(46)27(13(5-38)56-30)59-33-28(60-32-24(49)17(42)10(41)6-52-32)23(48)19(44)14(57-33)7-53-31-25(50)22(47)18(43)11(3-36)55-31/h10-33,36-38,41-51H,3-7H2,1-2H3,(H,34,39)(H,35,40)/t10-,11-,12-,13-,14-,15-,16-,17+,18-,19-,20-,21-,22+,23+,24-,25+,26-,27-,28+,29-,30+,31+,32+,33+/m1/s1",beta-D-xylo-pentopyranosyl-(1->2)-[alpha-D-manno-hexopyranosyl-(1->6)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose,GlyTouCan accession,G78255UI
7492,156141,felinine zwitterion,A S-alkyl-L-cysteine zwitterion resulting from the transfer of a proton from the carboxy group to the amino group of felinine. Major microspecies at pH 7.3.,"InChI=1S/C8H17NO3S/c1-8(2,3-4-10)13-5-6(9)7(11)12/h6,10H,3-5,9H2,1-2H3,(H,11,12)/t6-/m0/s1",3-methyl-3-sulfanylbutan-1-ol-L-cysteine zwitterion,MetaCyc accession,CPD-21113
7493,153986,D-Manp-(1->3)-D-Manp,A glycosylmannose consisting of two D-mannopyranose residues joined by a (1->3) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10+,11?,12?/m1/s1","WURCS=2.0/1,2,1/[a1122h-1x_1-5]/1-1/a3-b1",GlyTouCan accession,G78297FC
7494,156434,5-[[3-(1-phenylethoxy)-4-(2-phenylethoxy)phenyl]methylene]-4-oxo-2-thioxo-3-thiazolidineacetic acid,"A member of the class of thiazolidinones that is 2-sulfanylidene-1,3-thiazolidin-4-one in which the hydrogens at positions 3 and 5 are replaced by carboxymethyl and 3-(1-phenylethoxy)-4-(2-phenylethoxy)benzylidene groups, respectively. It is an inhibitor of protein mannosyl transferase 1 (PMT1) and blocks protein O-mannosylation.","InChI=1S/C28H25NO5S2/c1-19(22-10-6-3-7-11-22)34-24-16-21(17-25-27(32)29(18-26(30)31)28(35)36-25)12-13-23(24)33-15-14-20-8-4-2-5-9-20/h2-13,16-17,19H,14-15,18H2,1H3,(H,30,31)/b25-17-",OGT2468,PubMed citation,21231968
7495,152702,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,An amino octasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at positions 3 and 6 by beta-D-GlcNAc-(1->2)-alpha-D-Man groups and the GlcNAc residue at the reducing end is substituted at position 6 by an alpha-L-Fuc residue.,"InChI=1S/C56H94N4O40/c1-13-29(70)39(80)42(83)53(88-13)86-12-24-45(37(78)25(49(85)89-24)57-14(2)66)96-52-28(60-17(5)69)38(79)44(22(10-65)94-52)97-54-43(84)46(98-56-48(41(82)33(74)21(9-64)93-56)100-51-27(59-16(4)68)36(77)31(72)19(7-62)91-51)34(75)23(95-54)11-87-55-47(40(81)32(73)20(8-63)92-55)99-50-26(58-15(3)67)35(76)30(71)18(6-61)90-50/h13,18-56,61-65,70-85H,6-12H2,1-5H3,(H,57,66)(H,58,67)(H,59,68)(H,60,69)/t13-,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40-,41-,42-,43-,44+,45+,46-,47-,48-,49?,50-,51-,52-,53+,54-,55-,56+/m0/s1",GlcNAc(b1-2)Man(a1-3)[GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc,GlyTouCan accession,G65984FE
7496,152782,beta-D-Xylp-(1->4)-D-GlcpA,A glycosylglucopyranuronic acid consisting of beta-D-xylopyranose and D-glucopyranuronic acid joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C11H18O11/c12-2-1-20-11(6(16)3(2)13)22-7-4(14)5(15)10(19)21-8(7)9(17)18/h2-8,10-16,19H,1H2,(H,17,18)/t2-,3+,4-,5-,6-,7+,8+,10?,11+/m1/s1","WURCS=2.0/2,2,1/[a2122A-1x_1-5][a212h-1b_1-5]/1-2/a4-b1",KEGG GLYCAN accession,G02552
7497,156095,lumefantrine,"A member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria.","InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-","2-Dibutylamino-1-[2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl]-ethanol",PubMed citation,12798326
7498,152845,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,A branched amino nonasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at positions 3 and 6 by beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man groups.,"InChI=1S/C62H104N4O46/c1-14(75)63-27-36(84)47(22(9-71)97-54(27)95)106-55-28(64-15(2)76)37(85)50(25(12-74)102-55)109-60-46(94)51(110-62-53(43(91)34(82)21(8-70)101-62)112-57-30(66-17(4)78)39(87)49(24(11-73)104-57)108-59-45(93)41(89)32(80)19(6-68)99-59)35(83)26(105-60)13-96-61-52(42(90)33(81)20(7-69)100-61)111-56-29(65-16(3)77)38(86)48(23(10-72)103-56)107-58-44(92)40(88)31(79)18(5-67)98-58/h18-62,67-74,79-95H,5-13H2,1-4H3,(H,63,75)(H,64,76)(H,65,77)(H,66,78)/t18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31+,32+,33-,34-,35-,36-,37-,38-,39-,40+,41+,42+,43+,44-,45-,46+,47-,48-,49-,50-,51+,52+,53+,54?,55+,56+,57+,58+,59+,60+,61+,62-/m1/s1",Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc,GlyTouCan accession,G66741YQ
7499,153157,alpha-D-Manp-(1->3)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,An amino pentasaccharide that is beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc in which the hydroxy groups at positions 2 and 3 of the mannosyl residue have been glycosylated by beta-D-xylopyranosyl and  alpha-D-mannopyranosyl residues respectively.,"InChI=1S/C33H56N2O25/c1-8(40)34-15-20(46)25(13(5-38)53-29(15)51)57-30-16(35-9(2)41)21(47)26(14(6-39)56-30)58-33-28(60-31-23(49)17(43)10(42)7-52-31)27(19(45)12(4-37)55-33)59-32-24(50)22(48)18(44)11(3-36)54-32/h10-33,36-39,42-51H,3-7H2,1-2H3,(H,34,40)(H,35,41)/t10-,11-,12-,13-,14-,15-,16-,17+,18-,19-,20-,21-,22+,23-,24+,25-,26-,27+,28+,29-,30+,31+,32-,33+/m1/s1",Xyl(b1-2)[Man(a1-3)]Man(b1-4)GlcNAc(b1-4)b-GlcNAc,GlyTouCan accession,G71469XA
7500,153179,beta-D-Glcp-(1->6)-alpha-D-Galp,A beta-D-Glcp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C12H22O11/c13-1-3-5(14)8(17)10(19)12(23-3)21-2-4-6(15)7(16)9(18)11(20)22-4/h3-20H,1-2H2/t3-,4-,5-,6+,7+,8+,9-,10-,11+,12-/m1/s1","WURCS=2.0/2,2,1/[a2112h-1a_1-5][a2122h-1b_1-5]/1-2/a6-b1",GlyTouCan accession,G71580WG
7501,153200,beta-D-Manp-(1->3)-alpha-D-Manp,A glycosylmannose consisting of a beta-D-mannopyranose residue and an alpha-D-mannopyranose residue joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5-,6-,7+,8+,9+,10+,11+,12+/m1/s1","WURCS=2.0/2,2,1/[a1122h-1a_1-5][a1122h-1b_1-5]/1-2/a3-b1",GlyTouCan accession,G71689LT
7502,152596,beta-D-Galf-(1->4)-D-Alt-OH,A glycosyl alditol consisting of beta-D-galactofuranose and D-altritol residues joined in sequence by a (1->4) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(16)7(19)10(5(17)2-14)22-12-9(21)8(20)11(23-12)6(18)3-15/h4-21H,1-3H2/t4-,5-,6-,7+,8-,9-,10-,11+,12-/m1/s1","WURCS=2.0/2,2,1/[h2112h][a2112h-1b_1-4]/1-2/a3-b1",GlyTouCan accession,G65437NL
7503,152651,alpha-L-Fucp-(1->3)-{beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)}-D-GlcpNAc,"A branched amino octasaccharide that is beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc in which the hydroxy groups at positions 2, 3 and 6 of the mannosyl residue have been glycosylated by a beta-D-xylopyranosyl residue, an N-acetyl-beta-D-glucopyranosaminyl-(1->2)-alpha-D-mannopyranosyl group and an alpha-D-mannopyranosyl residue respectively, while the GlcNAc residue at the reducing end carries also an alpha-L-fucosyl residue attached via a (1->3)-linkage.","InChI=1S/C53H89N3O39/c1-12-26(66)34(74)39(79)51(83-12)92-42-25(56-15(4)64)46(80)84-21(9-61)41(42)91-48-24(55-14(3)63)33(73)40(20(8-60)88-48)90-53-45(95-50-37(77)27(67)16(65)10-81-50)43(31(71)22(89-53)11-82-49-38(78)35(75)29(69)18(6-58)86-49)93-52-44(36(76)30(70)19(7-59)87-52)94-47-23(54-13(2)62)32(72)28(68)17(5-57)85-47/h12,16-53,57-61,65-80H,5-11H2,1-4H3,(H,54,62)(H,55,63)(H,56,64)/t12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28+,29+,30+,31+,32+,33+,34+,35-,36-,37+,38-,39-,40+,41+,42+,43-,44-,45-,46?,47-,48-,49-,50-,51-,52+,53-/m0/s1","WURCS=2.0/6,8,7/[a2122h-1x_1-5_2*NCC/3=O][a1221m-1a_1-5][a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a212h-1b_1-5][a1122h-1a_1-5]/1-2-3-4-5-6-3-6/a3-b1_a4-c1_c4-d1_d2-e1_d3-f1_d6-h1_f2-g1",GlyTouCan accession,G65703ID
7504,152679,beta-D-Galf-(1->3)-alpha-D-Galp,A beta-D-Galf-(1->3)-D-Galp in which the carbon bearing the anomeric hydroxy group has alpha configuration.,"InChI=1S/C12H22O11/c13-1-3(15)9-6(17)7(18)12(22-9)23-10-5(16)4(2-14)21-11(20)8(10)19/h3-20H,1-2H2/t3-,4-,5+,6-,7-,8-,9+,10+,11+,12+/m1/s1","WURCS=2.0/2,2,1/[a2112h-1a_1-5][a2112h-1b_1-4]/1-2/a3-b1",GlyTouCan accession,G65860IT
7505,152687,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->6)}-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,"A branched amino nonasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by an alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man group, while the D-GlcNAc residue at the reducing end is substituted at position 6 by an alpha-L-Fuc residue.","InChI=1S/C60H101N3O45/c1-13-28(72)38(82)42(86)55(95-13)94-12-24-48(36(80)25(52(91)96-24)61-14(2)69)104-54-27(63-16(4)71)37(81)47(21(9-68)101-54)105-59-46(90)50(107-60-51(41(85)32(76)20(8-67)100-60)108-53-26(62-15(3)70)35(79)29(73)17(5-64)97-53)34(78)23(103-59)11-93-57-45(89)49(106-58-44(88)40(84)31(75)19(7-66)99-58)33(77)22(102-57)10-92-56-43(87)39(83)30(74)18(6-65)98-56/h13,17-60,64-68,72-91H,5-12H2,1-4H3,(H,61,69)(H,62,70)(H,63,71)/t13-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39-,40-,41-,42-,43-,44-,45-,46-,47+,48+,49-,50-,51-,52?,53-,54-,55+,56-,57-,58+,59-,60+/m0/s1",GlcNAc(b1-2)Man(a1-3)[Man(a1-3)[Man(a1-6)]Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc,GlyTouCan accession,G65893EZ
7506,152386,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->3)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,"A branched amino octasaccharide derivative that is beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the mannosyl group is substituted at position 3 by a beta-D-GlcNAc-(1->2)-alpha-D-Man group and at position 6 by an alpha-D-Man-(1->3)-alpha-D-Man group, while the D-GlcNAc residue at the reducing end is substituted at position 6 by an alpha-L-Fuc residue.","InChI=1S/C54H91N3O40/c1-12-26(66)35(75)38(78)50(85-12)84-11-22-43(33(73)23(47(82)86-22)55-13(2)63)93-49-25(57-15(4)65)34(74)42(20(9-62)91-49)94-53-41(81)45(96-54-46(37(77)29(69)18(7-60)90-54)97-48-24(56-14(3)64)32(72)27(67)16(5-58)87-48)31(71)21(92-53)10-83-51-40(80)44(30(70)19(8-61)88-51)95-52-39(79)36(76)28(68)17(6-59)89-52/h12,16-54,58-62,66-82H,5-11H2,1-4H3,(H,55,63)(H,56,64)(H,57,65)/t12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36-,37-,38-,39-,40-,41-,42+,43+,44-,45-,46-,47?,48-,49-,50+,51-,52+,53-,54+/m0/s1",GlcNAc(b1-2)Man(a1-3)[Man(a1-3)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-6)]GlcNAc,GlyTouCan accession,G58992VJ
7507,153257,alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-beta-D-Glcp,A glucotetraose consisting of three alpha-D-glucopyranosyl residues and a beta-D-glucopyranosyl residue joined in sequence by (1->4) glycosidic bonds.,"InChI=1S/C24H42O21/c25-1-5-9(29)10(30)15(35)22(40-5)44-19-7(3-27)42-24(17(37)12(19)32)45-20-8(4-28)41-23(16(36)13(20)33)43-18-6(2-26)39-21(38)14(34)11(18)31/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10+,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-/m1/s1",Glc(a1-4)Glc(a1-4)Glc(a1-4)b-Glc,GlyTouCan accession,G69211UR
7508,153263,alpha-D-Galp-(1->6)-D-Glc-OH,A glycosyl alditol consisting of alpha-D-galactopyranose and D-glucitol residues joined in sequence by a (1->6) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(15)7(17)8(18)5(16)3-22-12-11(21)10(20)9(19)6(2-14)23-12/h4-21H,1-3H2/t4-,5+,6+,7+,8+,9-,10-,11+,12-/m0/s1","WURCS=2.0/2,2,1/[h2122h][a2112h-1a_1-5]/1-2/a6-b1",GlyTouCan accession,G69265FU
7509,153285,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp,"A linear amino tetrasaccharide consisting of alpha-neuraminyl, beta-D-galactosyl and N-acetyl-beta-D-glucosaminyl residues with at the reducing end beta-D-galactose linked in a (2->3), (1->3) and (1->4) sequence.","InChI=1S/C31H52N2O24/c1-8(38)32-15-10(40)3-31(30(49)50,56-24(15)17(42)11(41)4-34)57-26-19(44)13(6-36)52-29(22(26)47)54-23-14(7-37)53-28(16(20(23)45)33-9(2)39)55-25-18(43)12(5-35)51-27(48)21(25)46/h10-29,34-37,40-48H,3-7H2,1-2H3,(H,32,38)(H,33,39)(H,49,50)/t10-,11+,12+,13+,14+,15+,16+,17+,18-,19-,20+,21+,22+,23+,24+,25-,26-,27+,28-,29-,31-/m0/s1",NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-3)b-Gal,GlyTouCan accession,G69440RD
7510,152134,alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,A branched amino hexasaccharide compound consisting of the linear trisaccharide beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine in which the mannosyl residue has a beta-D-xylosyl residue attached at position 2 as well as two alpha-D-mannosyl residues at positions 3 and 6.,"InChI=1S/C39H66N2O30/c1-9(46)40-17-23(53)30(14(5-44)63-34(17)60)68-35-18(41-10(2)47)24(54)31(15(6-45)66-35)69-39-33(71-37-27(57)19(49)11(48)7-61-37)32(70-38-29(59)26(56)21(51)13(4-43)65-38)22(52)16(67-39)8-62-36-28(58)25(55)20(50)12(3-42)64-36/h11-39,42-45,48-60H,3-8H2,1-2H3,(H,40,46)(H,41,47)/t11-,12-,13-,14-,15-,16-,17-,18-,19+,20-,21-,22-,23-,24-,25+,26+,27-,28+,29+,30-,31-,32+,33+,34-,35+,36+,37+,38-,39+/m1/s1",Xyl(b1-2)[Man(a1-3)][Man(a1-6)]Man(b1-4)GlcNAc(b1-4)b-GlcNAc,GlyTouCan accession,G57449OF
7511,153113,alpha-L-Fucp-(1->3)-{alpha-D-Manp-(1->3)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)}-beta-D-GlcpNAc,"A branched amino hexasaccharide that is beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc in which the hydroxy groups at positions 2 and 3 of the mannosyl residue have been glycosylated by beta-D-xylopyranosyl and alpha-D-mannopyranosyl residues respectively, while the GlcNAc residue at the reducing end carries also an alpha-L-fucosyl residue attached via a (1->3)-linkage.","InChI=1S/C39H66N2O29/c1-9-19(49)24(54)27(57)37(61-9)68-31-18(41-11(3)47)34(59)62-16(7-45)30(31)67-35-17(40-10(2)46)23(53)29(15(6-44)65-35)66-39-33(70-36-26(56)20(50)12(48)8-60-36)32(22(52)14(5-43)64-39)69-38-28(58)25(55)21(51)13(4-42)63-38/h9,12-39,42-45,48-59H,4-8H2,1-3H3,(H,40,46)(H,41,47)/t9-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25-,26+,27-,28-,29+,30+,31+,32-,33-,34+,35-,36-,37-,38+,39-/m0/s1","WURCS=2.0/5,6,5/[a2122h-1b_1-5_2*NCC/3=O][a1221m-1a_1-5][a1122h-1b_1-5][a212h-1b_1-5][a1122h-1a_1-5]/1-2-1-3-4-5/a3-b1_a4-c1_c4-d1_d2-e1_d3-f1",GlyTouCan accession,G68461PT
7512,153143,beta-D-Galp-(1->3)-Man-OH,A glycosyl alditol consisting of a beta-D-galactopyranose residue and a D-mannitol residue joined in sequence by a (1->3) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h4-21H,1-3H2/t4-,5-,6-,7-,8+,9+,10-,11-,12+/m1/s1","WURCS=2.0/2,2,1/[h1122h][a2112h-1b_1-5]/1-2/a4-b1",GlyTouCan accession,G68650XP
7513,152543,alpha-L-Fucp-(1->2)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc,A branched amino hexasaccharide in which an alpha-L-fucosyl-(1->2)-beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine linear pentasaccharide carries at the galactose residue proximal to the reducing end a second alpha-L-fucosyl residue via a (1->2) linkage.,"InChI=1S/C40H68N2O29/c1-9-19(49)25(55)28(58)37(61-9)70-33-27(57)21(51)13(5-43)65-39(33)68-31-18(42-12(4)48)36(64-14(6-44)22(31)52)69-32-23(53)15(7-45)66-40(34(32)71-38-29(59)26(56)20(50)10(2)62-38)67-30-16(8-46)63-35(60)17(24(30)54)41-11(3)47/h9-10,13-40,43-46,49-60H,5-8H2,1-4H3,(H,41,47)(H,42,48)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23-,24+,25+,26+,27-,28-,29-,30+,31+,32-,33+,34+,35+,36+,37-,38-,39-,40-/m0/s1",Fuc(a1-2)Gal(b1-3)GalNAc(a1-3)[Fuc(a1-2)]Gal(b1-4)b-GlcNAc,PubMed citation,31537530
7514,154079,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp,"A branched amino tetrasaccharide comprising a sequence of alpha-L-fucosyl, N-acetyl-beta-D-glucosyl and alpha-D-mannose residues linked glycodically (1->3) and (1->2), to the N-acetyl-beta-D-glucosyl residue is also linked (1->4) a beta-D-galactosyl residue.","InChI=1S/C26H45NO20/c1-6-12(32)15(35)18(38)25(41-6)46-21-11(27-7(2)31)24(47-22-17(37)14(34)8(3-28)42-23(22)40)44-10(5-30)20(21)45-26-19(39)16(36)13(33)9(4-29)43-26/h6,8-26,28-30,32-40H,3-5H2,1-2H3,(H,27,31)/t6-,8+,9+,10+,11+,12+,13-,14+,15+,16-,17-,18-,19+,20+,21+,22-,23-,24-,25-,26-/m0/s1",Fuc(a1-3)[Gal(b1-4)]GlcNAc(b1-2)a-Man,GlyTouCan accession,G81516LH
7515,156047,Glu-Cys,A dipeptide composed of L-glutamic acid and L-cysteine joined by a peptide linkage.,"InChI=1S/C8H14N2O5S/c9-4(1-2-6(11)12)7(13)10-5(3-16)8(14)15/h4-5,16H,1-3,9H2,(H,10,13)(H,11,12)(H,14,15)/t4-,5-/m0/s1",L-Glu-L-Cys,HMDB accession,HMDB0028816
7516,156534,"2-[4-[(E)-2-(6,8-dichloro-2-phenyl-2H-chromen-3-yl)ethenyl]phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane","A member of the class of chromenes that is 2H-chromene substituted at positions 2,3,6 and 8 by phenyl, 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethenyl, chloro and chloro groups, respectively. It is a potent retinoic acid receptor alpha agonist (Kd = 14nM) designed for the treatment of kidney disease.","InChI=1S/C29H27BCl2O3/c1-28(2)29(3,4)35-30(34-28)23-14-11-19(12-15-23)10-13-21-16-22-17-24(31)18-25(32)27(22)33-26(21)20-8-6-5-7-9-20/h5-18,26H,1-4H3/b13-10+",BJ1,PubMed citation,22125642
7517,156466,(S)-citronellalthiosemicarbazonate,A thiosemicarbazone resulting from the formal condensation of the formyl group of (S)-(-)-citronellal with the non-thioacylated amino group of hydrazinecarbothioamide.,"InChI=1S/C11H21N3S/c1-9(2)5-4-6-10(3)7-8-13-14-11(12)15/h5,8,10H,4,6-7H2,1-3H3,(H3,12,14,15)/b13-8+/t10-/m0/s1",S-citronellalthiosemicarbazonate,PubMed citation,32601343
7518,155851,Gly-Gly-Pro zwitterion,A tripeptide zwitterion resulting from the transfer of a proton from the carboxy group to the amino group of Gly-Gly-Pro. Major microspecies at pH 7.3.,"InChI=1S/C9H15N3O4/c10-4-7(13)11-5-8(14)12-3-1-2-6(12)9(15)16/h6H,1-5,10H2,(H,11,13)(H,15,16)/t6-/m0/s1",Gly-Gly-L-Pro zwitterion,PubMed citation,2819090
7519,154940,alpha-D-Galf-(1->2)-D-Gal-OH,A glycosyl alditol consisting of alpha-D-galactofuranosyl and D-galactitol residues joined in sequence by a (1->2) glycosidic bond.,"InChI=1S/C12H24O11/c13-1-4(16)7(18)8(19)6(3-15)22-12-10(21)9(20)11(23-12)5(17)2-14/h4-21H,1-3H2/t4-,5-,6+,7+,8-,9-,10-,11+,12+/m1/s1","WURCS=2.0/2,2,1/[h2112h][a2112h-1a_1-4]/1-2/a2-b1",GlyTouCan accession,G87776GF
7520,156663,beta-L-lyxofuranose,An L-lyxofuranonse that has beta configuration at the carbon bearing the anomeric hydroxy group.,"InChI=1S/C5H10O5/c6-1-2-3(7)4(8)5(9)10-2/h2-9H,1H2/t2-,3+,4+,5-/m0/s1","WURCS=2.0/1,1,0/[a221h-1b_1-4]/1/",GlyTouCan accession,G78678ZK
7521,154519,beta-D-Galp-(1->2)-D-Glcp,A glycosylglucose consisting of beta-D-galactopyranose and D-glucopyranose residues joined in sequence by a (1->2) glycosidic bond.,"InChI=1S/C12H22O11/c13-1-3-6(16)8(18)10(11(20)21-3)23-12-9(19)7(17)5(15)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6-,7+,8+,9-,10-,11?,12+/m1/s1","WURCS=2.0/2,2,1/[a2122h-1x_1-5][a2112h-1b_1-5]/1-2/a2-b1",GlyTouCan accession,G86236QS
7522,154524,alpha-L-talofuranose,An L-talofuranose in which the anomeric carbon has alpha configuration.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3-,4+,5+,6+/m0/s1","WURCS=2.0/1,1,0/[a2221h-1a_1-4]/1/",GlyTouCan accession,G86237UF
7523,154556,2-(D-glucopyranosyloxy)-3-hydroxypropyl L-fucopyranoside,"A glycosylglycerol that is glycerol in which the hydroxy groups at positions 1 and 2 have been converted into the corresponding L-fucopyranoside and D-glucopyranoside derivatives, respectively.","InChI=1S/C15H28O12/c1-5-8(18)10(20)12(22)14(25-5)24-4-6(2-16)26-15-13(23)11(21)9(19)7(3-17)27-15/h5-23H,2-4H2,1H3/t5-,6?,7+,8+,9+,10+,11-,12-,13+,14?,15?/m0/s1","WURCS=2.0/3,3,2/[hxh][a2122h-1x_1-5][a1221m-1x_1-5]/1-2-3/a2-b1_a3-c1",GlyTouCan accession,G86355AM
7524,154600,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,A branched amino nonasaccharide consisting of a D-GlcNAc residue at the reducing end with a beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4)-linkage and an alpha-L-Fuc residue attached via an alpha-(1->6)-linkage.,"InChI=1S/C61H102N4O44/c1-14-31(76)42(87)46(91)57(96-14)94-13-26-48(40(85)27(53(92)97-26)62-15(2)71)104-56-30(65-18(5)74)41(86)47(24(10-70)102-56)105-61-52(109-58-45(90)32(77)19(75)11-93-58)49(106-60-51(44(89)36(81)23(9-69)101-60)108-55-29(64-17(4)73)39(84)34(79)21(7-67)99-55)37(82)25(103-61)12-95-59-50(43(88)35(80)22(8-68)100-59)107-54-28(63-16(3)72)38(83)33(78)20(6-66)98-54/h14,19-61,66-70,75-92H,6-13H2,1-5H3,(H,62,71)(H,63,72)(H,64,73)(H,65,74)/t14-,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32-,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43-,44-,45+,46-,47+,48+,49-,50-,51-,52-,53?,54-,55-,56-,57+,58-,59-,60+,61-/m0/s1",2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)][beta-D-xylo-pentopyranosyl-(1->2)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->6)]-2-acetamido-2-deoxy-D-gluco-hexopyranos,GlyTouCan accession,G86487TG
7525,156495,beta-D-GlcpNAc-(1->6)-[beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"A branched amino nonasaccharide consisting of a tetrasaccharide backbone of N-acetyl-beta-D-glucosaminyl, beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-beta-D-glucosamine residues all linked sequentially (1->4), in which the mannosyl residue carries via a (1->6) linkage an N-acetyl-beta-D-glucosaminyl-(1->2)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl trisaccharide unit, as well as an N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl disaccharide unit via a (1->3) linkage.","InChI=1S/C66H110N6O46/c1-16(80)67-31-47(96)52(27(12-78)104-58(31)101)113-63-36(72-21(6)85)48(97)53(28(13-79)110-63)114-64-51(100)55(116-66-57(49(98)41(90)26(11-77)109-66)118-62-35(71-20(5)84)46(95)40(89)25(10-76)108-62)54(115-60-33(69-18(3)82)44(93)38(87)23(8-74)106-60)30(112-64)15-103-65-56(117-61-34(70-19(4)83)45(94)39(88)24(9-75)107-61)50(99)42(91)29(111-65)14-102-59-32(68-17(2)81)43(92)37(86)22(7-73)105-59/h22-66,73-79,86-101H,7-15H2,1-6H3,(H,67,80)(H,68,81)(H,69,82)(H,70,83)(H,71,84)(H,72,85)/t22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49+,50+,51+,52-,53-,54-,55-,56+,57+,58?,59-,60+,61+,62+,63+,64+,65+,66-/m1/s1",beta-D-GlcNAc-(1->6)-[beta-D-GlcNAc-(1->2)]-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->4)]-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc,PubMed citation,31537530
7526,156505,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-{beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->4)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Man-(1->3)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"An amino oligosaccharide that is a tetradecasaccharide derivative consisting of a tetrasaccharide chain of N-acetyl-beta-D-glucosamine, beta-D-mannose, N-acetyl-beta-D-glucosamine and N-acetyl-D-glucosamine residues, all linked sequentially (1->4), to the beta-D-mannose residue of which are also linked beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl and beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)]-alpha-D-mannosyl units via (1->6) and (1->3) linkages respectively.","InChI=1S/C98H163N7O71/c1-22(118)99-43-57(132)74(34(13-111)152-85(43)149)166-88-46(102-25(4)121)60(135)79(39(18-116)159-88)172-96-73(148)82(174-98-84(176-91-49(105-28(7)124)62(137)78(38(17-115)162-91)171-95-71(146)66(141)54(129)33(12-110)157-95)72(147)80(40(19-117)163-98)167-89-47(103-26(5)122)59(134)76(36(15-113)160-89)169-93-69(144)64(139)52(127)31(10-108)155-93)81(173-87-44(100-23(2)119)56(131)50(125)29(8-106)153-87)42(165-96)21-151-97-83(175-90-48(104-27(6)123)61(136)77(37(16-114)161-90)170-94-70(145)65(140)53(128)32(11-109)156-94)67(142)55(130)41(164-97)20-150-86-45(101-24(3)120)58(133)75(35(14-112)158-86)168-92-68(143)63(138)51(126)30(9-107)154-92/h29-98,106-117,125-149H,8-21H2,1-7H3,(H,99,118)(H,100,119)(H,101,120)(H,102,121)(H,103,122)(H,104,123)(H,105,124)/t29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51+,52+,53+,54+,55-,56-,57-,58-,59-,60-,61-,62-,63+,64+,65+,66+,67+,68-,69-,70-,71-,72+,73+,74-,75-,76-,77-,78-,79-,80-,81-,82-,83+,84+,85?,86-,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98-/m1/s1",Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-4(Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAc,PubMed citation,31537530
7527,156502,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"A branched amino decasaccharide consisting of a tetrasaccharide backbone of N-acetyl-beta-D-glucosaminyl, beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-beta-D-glucosamine residues all linked sequentially (1->4), in which the mannosyl residue carries via (1->3) and (1->6) linkages two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl trisaccharide units.","InChI=1S/C70H117N5O51/c1-16(85)71-31-42(96)53(26(11-81)109-61(31)107)119-63-33(73-18(3)87)43(97)56(29(14-84)115-63)122-68-52(106)58(124-70-60(49(103)40(94)25(10-80)114-70)126-65-35(75-20(5)89)45(99)55(28(13-83)117-65)121-67-51(105)47(101)38(92)23(8-78)112-67)57(123-62-32(72-17(2)86)41(95)36(90)21(6-76)110-62)30(118-68)15-108-69-59(48(102)39(93)24(9-79)113-69)125-64-34(74-19(4)88)44(98)54(27(12-82)116-64)120-66-50(104)46(100)37(91)22(7-77)111-66/h21-70,76-84,90-107H,6-15H2,1-5H3,(H,71,85)(H,72,86)(H,73,87)(H,74,88)(H,75,89)/t21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37+,38+,39-,40-,41-,42-,43-,44-,45-,46+,47+,48+,49+,50-,51-,52+,53-,54-,55-,56-,57-,58-,59+,60+,61?,62+,63+,64+,65+,66+,67+,68+,69+,70-/m1/s1",Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc,PubMed citation,31537530
7528,156942,beta-D-GalpNAc-(1->6)-beta-D-GalpNAc,An amino disaccharide comprising two N-acetyl-beta-D-galactosamine residues linked (1->6).,"InChI=1S/C16H28N2O11/c1-5(20)17-9-13(24)12(23)8(28-15(9)26)4-27-16-10(18-6(2)21)14(25)11(22)7(3-19)29-16/h7-16,19,22-26H,3-4H2,1-2H3,(H,17,20)(H,18,21)/t7-,8-,9-,10-,11+,12+,13-,14-,15-,16-/m1/s1","WURCS=2.0/1,2,1/[a2112h-1b_1-5_2*NCC/3=O]/1-1/a6-b1",GlyTouCan accession,G91982VB
7529,156433,bis(S-citronellalthiosemicarbazonato)nickel(II),A nickel coordination entity that is (S)-citronellalthiosemicarbazonate complexed with nickel in a 2:1 ratio. It induces apoptosis and exhibits anticancer properties.,"InChI=1S/2C11H21N3S.Ni/c2*1-9(2)6-4-5-7-10(3)8-13-14-11(12)15;/h2*6,8,10H,4-5,7H2,1-3H3,(H3,12,14,15);/b2*13-8+;/t2*10-;/m00./s1",Ni(S-tcitr)2,PubMed citation,19193444
7530,167894,alpha-L-Fucp-(1->3)-[beta-D-GalpNAc-(1->4)]-beta-D-GalpNAc6S,A branched amino trisaccharide consisting of at the reducing end an N-acetyl-6-sulfo-beta-D-galactosamine residue to which are linked alpha-L-fucosyl and N-acetyl-beta-D-galactosaminyl residues via (1->3) and (1->4) glycosidic linkages respectively.,"InChI=1S/C22H38N2O18S/c1-6-13(28)16(31)17(32)22(38-6)42-19-12(24-8(3)27)20(33)39-10(5-37-43(34,35)36)18(19)41-21-11(23-7(2)26)15(30)14(29)9(4-25)40-21/h6,9-22,25,28-33H,4-5H2,1-3H3,(H,23,26)(H,24,27)(H,34,35,36)/t6-,9+,10+,11+,12+,13+,14-,15+,16+,17-,18+,19+,20+,21-,22-/m0/s1",beta-D-GalpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GalpNAc6S,PubMed citation,31537530
7531,167895,alpha-L-Fucp-(1->3)-[beta-D-GalpNAc3S-(1->4)]-beta-D-GlcpNAc,A branched amino trisaccharide consisting of at the reducing end an N-acetyl-beta-D-glucosamine residue to which are linked alpha-L-fucosyl and N-acetyl-3-O-sulfo-beta-D-galactosaminyl residues via (1->3) and (1->4) glycosidic linkages respectively.,"InChI=1S/C22H38N2O18S/c1-6-13(29)15(31)16(32)22(37-6)41-19-11(23-7(2)27)20(33)38-10(5-26)17(19)40-21-12(24-8(3)28)18(42-43(34,35)36)14(30)9(4-25)39-21/h6,9-22,25-26,29-33H,4-5H2,1-3H3,(H,23,27)(H,24,28)(H,34,35,36)/t6-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+,19+,20+,21-,22-/m0/s1",(3S)GalNAcb1-4(Fuca1-3)GlcNAcb,PubMed citation,31537530
7532,168238,"1,4,4,7a-tetramethyl-1,4,5,7a-tetrahydro-2H-inden-2-one","A member of the class of indenes that is 2,4,5,7a-tetrahydro-1H-indene substituted by methyl groups at positions 1, 4, 4 and 7a and by an oxo group at position 2.","InChI=1S/C13H18O/c1-9-10(14)8-11-12(2,3)6-5-7-13(9,11)4/h5,7-9H,6H2,1-4H3","1,4,4,7a-tetramethyl-1,5-dihydroinden-2-one",HMDB accession,HMDB0036685
7533,168668,butyl butyryllactate,A diester resulting from the formal condensation of the carboxy group of 2-(butanoyloxy)propanoic acid with butan-1-ol.,"InChI=1S/C11H20O4/c1-4-6-8-14-11(13)9(3)15-10(12)7-5-2/h9H,4-8H2,1-3H3",(1-butoxy-1-oxopropan-2-yl) butanoate,CAS Registry Number,7492-70-8
7534,169998,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-D-GalpNAc,"A branched amino pentasaccharide consisting of a linear tetrasaccharide comprising N-acetyl-alpha-D-galactosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-D-galactosamine residues linked sequentially (1->3), (1->4) and (1->6), to the beta-D-galactosamine of which is also linked (1->2) an alpha-L-fucosyl residue.","InChI=1S/C36H61N3O25/c1-9-20(46)27(53)28(54)35(57-9)64-31-30(63-34-18(38-11(3)44)25(51)21(47)13(5-40)59-34)23(49)14(6-41)60-36(31)62-29-15(7-42)61-33(19(26(29)52)39-12(4)45)56-8-16-22(48)24(50)17(32(55)58-16)37-10(2)43/h9,13-36,40-42,46-55H,5-8H2,1-4H3,(H,37,43)(H,38,44)(H,39,45)/t9-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23-,24+,25+,26+,27+,28-,29+,30-,31+,32?,33+,34+,35-,36-/m0/s1",alpha-D-GalNAc-(1->3)-[alpha-L-Fuc-(1->2)]-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)-D-GalNAc,PubMed citation,31537530
7535,170001,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp,"An amino tetrasaccharide comprising alpha-D-galactose, beta-D-galactose, N-acetyl-beta-D-glucosamine and alpha-D-mannose residues linked sequentially (1->3), (1->4) and (1->2).","InChI=1S/C26H45NO21/c1-6(32)27-11-15(36)20(10(5-31)45-24(11)48-22-17(38)13(34)7(2-28)42-23(22)41)46-26-19(40)21(14(35)9(4-30)44-26)47-25-18(39)16(37)12(33)8(3-29)43-25/h7-26,28-31,33-41H,2-5H2,1H3,(H,27,32)/t7-,8-,9-,10-,11-,12+,13-,14+,15-,16+,17+,18-,19-,20-,21+,22+,23+,24+,25-,26+/m1/s1",alpha-D-galactosyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannose,PubMed citation,31537530
7536,170004,beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp,"An amino trisaccharide consisting of alpha-D-galactosyl, N-acetyl-beta-D-glucosaminyl and alpha-D-mannose residues joined in sequence by (1->3) and (1->2) glycosidic bonds.","InChI=1S/C20H35NO16/c1-5(25)21-9-16(36-20-15(31)13(29)10(26)7(3-23)35-20)12(28)8(4-24)34-19(9)37-17-14(30)11(27)6(2-22)33-18(17)32/h6-20,22-24,26-32H,2-4H2,1H3,(H,21,25)/t6-,7-,8-,9-,10+,11-,12-,13+,14+,15-,16-,17+,18+,19+,20+/m1/s1",beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannose,PubMed citation,31537530
7537,170006,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp,"An amino tetrasaccharide comprising alpha-N-acetylneuraminyl, beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl and alpha-D-mannose residues linked sequentially (2->3), (1->3) and (1->2).","InChI=1S/C31H52N2O24/c1-8(38)32-15-10(40)3-31(30(49)50,56-24(15)17(42)11(41)4-34)57-25-20(45)14(7-37)53-29(22(25)47)54-23-16(33-9(2)39)28(52-13(6-36)19(23)44)55-26-21(46)18(43)12(5-35)51-27(26)48/h10-29,34-37,40-48H,3-7H2,1-2H3,(H,32,38)(H,33,39)(H,49,50)/t10-,11+,12+,13+,14+,15+,16+,17+,18+,19+,20-,21-,22+,23+,24+,25-,26-,27-,28-,29-,31-/m0/s1",Neu5Aca2-3Galb1-3GlcNAcb1-2Mana,PubMed citation,31537530
7538,171663,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a henicosasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues (one of which is at the reducing end) all linked in sequence (1->4), to the mannosyl residue of which are linked (1->3) and (1->6) two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear nonasaccharide units.","InChI=1S/C146H242N10O106/c1-32(177)147-63-84(198)107(52(21-167)223-126(63)221)244-127-64(148-33(2)178)85(199)116(55(24-170)234-127)253-144-106(220)123(260-146-125(97(211)76(190)45(14-160)233-146)262-135-72(156-41(10)186)93(207)115(61(30-176)242-135)252-143-105(219)122(82(196)51(20-166)231-143)259-133-70(154-39(8)184)91(205)113(59(28-174)240-133)250-141-103(217)120(80(194)49(18-164)229-141)257-131-68(152-37(6)182)89(203)111(57(26-172)238-131)248-139-101(215)118(78(192)47(16-162)227-139)255-129-66(150-35(4)180)87(201)109(54(23-169)236-129)246-137-99(213)95(209)74(188)43(12-158)225-137)83(197)62(243-144)31-222-145-124(96(210)75(189)44(13-159)232-145)261-134-71(155-40(9)185)92(206)114(60(29-175)241-134)251-142-104(218)121(81(195)50(19-165)230-142)258-132-69(153-38(7)183)90(204)112(58(27-173)239-132)249-140-102(216)119(79(193)48(17-163)228-140)256-130-67(151-36(5)181)88(202)110(56(25-171)237-130)247-138-100(214)117(77(191)46(15-161)226-138)254-128-65(149-34(3)179)86(200)108(53(22-168)235-128)245-136-98(212)94(208)73(187)42(11-157)224-136/h42-146,157-176,187-221H,11-31H2,1-10H3,(H,147,177)(H,148,178)(H,149,179)(H,150,180)(H,151,181)(H,152,182)(H,153,183)(H,154,184)(H,155,185)(H,156,186)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73+,74+,75-,76-,77+,78+,79+,80+,81+,82+,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94+,95+,96+,97+,98-,99-,100-,101-,102-,103-,104-,105-,106+,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117+,118+,119+,120+,121+,122+,123+,124+,125+,126-,127+,128+,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146-/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,31537530
7539,167668,(2R)-2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol,A 2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol that has R-configuration. It is a sphingosine kinase-2 inhibitor.,"InChI=1S/C20H35NO2/c1-3-4-5-6-7-8-9-18-10-12-19(13-11-18)14-15-20(21,16-22)17-23-2/h10-13,22H,3-9,14-17,21H2,1-2H3/t20-/m1/s1",(R)-FTY720 methyl ether,PubMed citation,21620961
7540,167669,"(E)-2-[[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]methyl]benzoic acid","A member of the class of 1,3-thiazoles that is 1,3-thiazole substituted by (2E)-2-(2-carboxybenzylidene)hydrazinyl and 2-chlorophenyl groups at positions 2 and 4, respectively. It is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with IC50 of 32 nM. It exhibits antineoplastic activity and broad-spectrum antiviral activity against various RNA viruses including influenza A, Zika, Ebola, and SARS-CoV-2 viruses.","InChI=1S/C17H12ClN3O2S/c18-14-8-4-3-7-13(14)15-10-24-17(20-15)21-19-9-11-5-1-2-6-12(11)16(22)23/h1-10H,(H,20,21)(H,22,23)/b19-9+",S312,PDBeChem accession,3X2
7541,167517,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->4)]-{alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)]-alpha-D-Manp-(1->3)}-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino oligosaccharide comprising a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which is (1->4)-linked an N-acetyl-beta-D-glucosaminyl residue, together with an N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide unit linked (1->6) and an N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[N-acetyl-alpha-neuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)]-alpha-D-mannosyl unit linked (1->3).","InChI=1S/C117H191N9O85/c1-28(138)118-55-37(147)10-115(112(177)178,209-95(55)64(153)40(150)13-127)184-25-51-68(157)77(166)81(170)107(195-51)202-88-45(18-132)190-103(61(73(88)162)124-34(7)144)200-92-49(22-136)193-106(84(173)80(92)169)183-24-54-94(206-101-59(122-32(5)142)71(160)67(156)43(16-130)188-101)98(86(175)110(198-54)205-91-48(21-135)189-102(60(75(91)164)123-33(6)143)199-87-44(17-131)187-100(176)58(72(87)161)121-31(4)141)207-111-99(208-105-63(126-36(9)146)76(165)90(47(20-134)192-105)204-109-83(172)79(168)70(159)53(197-109)27-186-117(114(181)182)12-39(149)57(120-30(3)140)97(211-117)66(155)42(152)15-129)85(174)93(50(23-137)194-111)201-104-62(125-35(8)145)74(163)89(46(19-133)191-104)203-108-82(171)78(167)69(158)52(196-108)26-185-116(113(179)180)11-38(148)56(119-29(2)139)96(210-116)65(154)41(151)14-128/h37-111,127-137,147-176H,10-27H2,1-9H3,(H,118,138)(H,119,139)(H,120,140)(H,121,141)(H,122,142)(H,123,143)(H,124,144)(H,125,145)(H,126,146)(H,177,178)(H,179,180)(H,181,182)/t37-,38-,39-,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68-,69-,70-,71+,72+,73+,74+,75+,76+,77-,78-,79-,80+,81+,82+,83+,84-,85-,86-,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99-,100+,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111+,115+,116+,117+/m0/s1",Neu5Aca2-6Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb,PubMed citation,31537530
7542,167569,beta-D-GlcpNAc-(1->2)-[beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->6)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino nonasaccharide consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues, all linked (1->4), to the N-acetyl-beta-D-glucosamine at the reducing of which is also linked (1->6) an L-fucose residue, while the mannose residue carries N-acetyl-beta-D-glucosaminyl-(1->2)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl and N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl units via (1->6) and (1->3) glycosidic linkages respectively.","InChI=1S/C64H107N5O45/c1-15-34(80)46(92)49(95)61(101-15)99-14-28-52(44(90)29(56(97)102-28)65-16(2)75)110-60-33(69-20(6)79)45(91)51(25(11-74)107-60)111-62-50(96)53(112-64-55(47(93)38(84)24(10-73)106-64)114-59-32(68-19(5)78)43(89)37(83)23(9-72)105-59)40(86)27(108-62)13-100-63-54(113-58-31(67-18(4)77)42(88)36(82)22(8-71)104-58)48(94)39(85)26(109-63)12-98-57-30(66-17(3)76)41(87)35(81)21(7-70)103-57/h15,21-64,70-74,80-97H,7-14H2,1-6H3,(H,65,75)(H,66,76)(H,67,77)(H,68,78)(H,69,79)/t15-,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47-,48-,49-,50-,51+,52+,53-,54-,55-,56+,57+,58-,59-,60-,61+,62-,63-,64+/m0/s1",beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->6)]-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-beta-D-GlcNAc,PubMed citation,31537530
7543,167210,(-)-zwittermicin A,The (-)-enantiomer of zwittermicin A.,"InChI=1S/C13H28N6O8/c14-4(3-20)6(21)1-7(22)8(15)9(23)10(24)12(26)19-5(11(16)25)2-18-13(17)27/h4-10,20-24H,1-3,14-15H2,(H2,16,25)(H,19,26)(H3,17,18,27)/t4-,5+,6+,7+,8+,9+,10-/m0/s1",(-)-zwittermicin A,PubMed citation,19746943
7544,167315,alpha-D-Glcp-(1->3)-beta-D-Glcp-(1->4)-[alpha-D-GlcpA-(1->3)]-beta-D-Manp-(1->4)-alpha-D-GlcpO[CH2]5NH2,"An alpha-D-glucoside that is the 5-aminopentyl glycoside of a branched pentasaccharide consisting of alpha-D-glucosyl, beta-D-glucosyl, beta-D-mannosyl and beta-D-glucosyl residues linked sequentially (1->3), (1->4) and (1->4), to the mannosyl residue of which has also linked (1->3) to it an alpha-D-glucuronosyl residue. The 5-aminopentyl group at the reducing end is a spacer to enable further conjugation to a carrier protein for immunological studies.","InChI=1S/C35H61NO27/c36-4-2-1-3-5-54-31-22(49)19(46)25(12(8-39)57-31)59-35-24(51)28(62-33-21(48)17(44)18(45)29(63-33)30(52)53)26(13(9-40)58-35)60-34-23(50)27(15(42)11(7-38)56-34)61-32-20(47)16(43)14(41)10(6-37)55-32/h10-29,31-35,37-51H,1-9,36H2,(H,52,53)/t10-,11-,12-,13-,14-,15-,16+,17+,18+,19-,20-,21-,22-,23-,24+,25-,26-,27+,28-,29+,31+,32-,33+,34+,35+/m1/s1",Glcalpha1-3Glcbeta1-4(GlcAalpha1-4)Manbeta1-4GlcalphaO[CH2]5NH2,PubMed citation,33108196
7545,167319,tyrvalin,"A member of the class of pyrazinones that is pyrazin-2(1H)-one substituted by an isopropyl and (4-hydroxyphenyl)methyl groups at positions 3 and 6, respectively. It is a natural product found in Staphylococcus aureus.","InChI=1S/C14H16N2O2/c1-9(2)13-14(18)16-11(8-15-13)7-10-3-5-12(17)6-4-10/h3-6,8-9,17H,7H2,1-2H3,(H,16,18)",aureusamine A,CAS Registry Number,1244033-70-2
7546,167321,leuvalin,"A member of the class of pyrazinones that is pyrazin-2(1H)-one substituted by isopropyl and isobutyl groups at positions 3 and 6, respectively. It is a natural product found in Staphylococcus aureus.","InChI=1S/C11H18N2O/c1-7(2)5-9-6-12-10(8(3)4)11(14)13-9/h6-8H,5H2,1-4H3,(H,13,14)",aureusimine C,PubMed citation,20851341
7547,167392,alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->3)-beta-D-GalpNAc-(1->4)-[alpha-Neup5Ac-(2->8)-alpha-Neup5Ac-(2->3)]-beta-D-Galp-(1->3)-L-alpha-D-Hepp-(1->3)-[beta-D-Glcp-(1->4)]-L-alpha-D-Hepp-(1->5)-[alpha-Kdo-(2->4)]-alpha-Kdo,"A branched amino ologosaccharide that is an amino undecasaccharide consisting of a linear heptasaccharide comprising N-acetyl-alpha-neuraminic acid, beta-D-galactose, N-acetyl-beta-D-galactosamine and beta-D-galactose residues, two L-glycero-alpha-D-manno-heptose (L-alpha-D-Hep) residues and a 3-deoxy-alpha-D-manno-oct-2-ulose (alpha-Kdo) residue linked in sequence (2->3), (1->3), (1->4), (1->3), (1->3) and (1->5), to the L-alpha-D-Hep residue proximal to the reducing end is also linked (1->4) a beta-D-glucose residue, while the galactose residue proximal to the reducing end also carries an N-acetyl-alpha-neuraminyl-(2->8)-N-acetyl-alpha-neuraminic acid unit via a (2->3) linkage and the alpha-Kdo residue also carries a second alpha-Kdo residue linked (2->4). One of a number of chemoenzymatically synthesised oligosaccharides composed of the inner core oligosaccharide of Campylobacter jejuni extended by various ganglioside mimics.","InChI=1S/C89H144N4O71/c1-21(105)90-41-25(109)5-86(81(135)136,160-66(41)46(120)29(113)10-94)157-39(19-103)51(125)68-43(92-23(3)107)27(111)7-89(162-68,84(141)142)164-72-58(132)77(147-40(20-104)64(72)150-74-44(93-24(4)108)65(49(123)37(17-101)144-74)152-76-56(130)70(50(124)38(18-102)146-76)163-88(83(139)140)6-26(110)42(91-22(2)106)67(161-88)47(121)30(114)11-95)153-69-54(128)59(31(115)12-96)148-78(55(69)129)154-71-57(131)79(149-61(33(117)14-98)73(71)155-75-53(127)52(126)48(122)36(16-100)145-75)151-63-35(9-85(143,80(133)134)158-62(63)34(118)15-99)156-87(82(137)138)8-28(112)45(119)60(159-87)32(116)13-97/h25-79,94-104,109-132,143H,5-20H2,1-4H3,(H,90,105)(H,91,106)(H,92,107)(H,93,108)(H,133,134)(H,135,136)(H,137,138)(H,139,140)(H,141,142)/t25-,26-,27-,28+,29+,30+,31-,32+,33-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49-,50-,51+,52-,53+,54+,55-,56+,57-,58+,59+,60+,61+,62+,63+,64-,65+,66+,67+,68+,69-,70-,71+,72+,73+,74-,75-,76-,77-,78+,79+,85+,86+,87+,88-,89-/m0/s1",Neu5Acalpha2-3Galbeta1-3GalNAcbeta1-4(Neu5Acalpha2-8Neu5Acalpha2-3)Galbeta1-3Hepalpha1-3(Glcbeta1-4)Hepalpha1-5(Kdoalpha2-4)Kdoalpha,PubMed citation,33164488
7548,167483,alpha-L-Fucp-(1->4)-[beta-D-Galp3S-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp,A sulfated branched amino tetrasaccharide consisting of D-galactose at the reducing end with an alpha-L-fucosyl-(1->4)-[3-O-sulfo-beta-D-galactosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl moiety attached at the 3-position.,"InChI=1S/C26H45NO23S/c1-6-12(32)15(35)16(36)25(43-6)47-19-10(5-30)46-24(49-21-13(33)8(3-28)44-23(39)17(21)37)11(27-7(2)31)20(19)48-26-18(38)22(50-51(40,41)42)14(34)9(4-29)45-26/h6,8-26,28-30,32-39H,3-5H2,1-2H3,(H,27,31)(H,40,41,42)/t6-,8+,9+,10+,11+,12+,13-,14-,15+,16-,17+,18+,19+,20+,21-,22-,23?,24-,25-,26-/m0/s1",alpha-L-fucosyl-(1->4)-[3-O-sulfo-beta-D-galactosyl-(1->3)]-N-acetyl-beta-D-glucosaminyl-(1->3)-D-galactose,PubMed citation,9858646
7549,166910,beta-D-Glcp-(1->4)-[alpha-D-GlcpA-(1->3)]-beta-D-Manp-(1->4)-alpha-D-GlcpO[CH2]5NH2,"An alpha-D-glucoside that is the 5-aminopentyl glycoside of a branched tetrasaccharide consisting of beta-D-glucosyl, beta-D-mannosyl and beta-D-glucosyl residues linked sequentially (1->4), to the mannosyl residue of which has also linked (1->3) to it an alpha-D-glucuronosyl residue. The 5-aminopentyl group at the reducing end is a spacer to enable further conjugation to a carrier protein for immunological studies.","InChI=1S/C29H51NO22/c30-4-2-1-3-5-45-26-19(41)16(38)21(10(7-32)47-26)49-29-20(42)23(51-28-18(40)14(36)15(37)24(52-28)25(43)44)22(11(8-33)48-29)50-27-17(39)13(35)12(34)9(6-31)46-27/h9-24,26-29,31-42H,1-8,30H2,(H,43,44)/t9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20+,21-,22-,23-,24+,26+,27+,28+,29+/m1/s1",5-aminopentyl beta-D-glucosyl-(1->4)-[alpha-D-glucuronosyl-(1->3)]-beta-D-mannosyl-(1->4)-alpha-D-glucoside,PubMed citation,33108196
7550,166948,beta-D-Manp-(1->4)-alpha-D-Glcp-(1->3)-beta-D-Glcp-(1->4)-[alpha-D-GlcpA-(1->3)]-beta-D-Manp-(1->4)-alpha-D-GlcpO[CH2]5NH2,"An alpha-D-glucoside that is the 5-aminopentyl glycoside of a branched hexasaccharide consisting of beta-D-mannosyl, alpha-D-glucosyl, beta-D-glucosyl, beta-D-mannosyl and beta-D-glucosyl residues linked sequentially (1->4), (1->3), (1->4) and (1->4), to the mannosyl residue proximal to the reducing end of which has also linked (1->3) to it an alpha-D-glucuronosyl residue. The 5-aminopentyl group at the reducing end is a spacer to enable further conjugation to a carrier protein for immunological studies.","InChI=1S/C41H71NO32/c42-4-2-1-3-5-63-36-25(57)21(53)29(13(8-45)66-36)70-41-28(60)33(73-39-24(56)19(51)20(52)34(74-39)35(61)62)31(15(10-47)68-41)71-40-27(59)32(17(49)12(7-44)65-40)72-38-26(58)22(54)30(14(9-46)67-38)69-37-23(55)18(50)16(48)11(6-43)64-37/h11-34,36-41,43-60H,1-10,42H2,(H,61,62)/t11-,12-,13-,14-,15-,16-,17-,18+,19+,20+,21-,22-,23+,24-,25-,26-,27-,28+,29-,30-,31-,32+,33-,34+,36+,37+,38-,39+,40+,41+/m1/s1",Manbeta1-4Glcalpha1-3Glcbeta1-4(GlcAalpha1-4)Manbeta1-4GlcalphaO[CH2]5NH2,PubMed citation,33108196
7551,166950,alpha-D-GlcpA-(1->3)-beta-D-Manp-(1->4)-alpha-D-Glcp-(1->3)-beta-D-Glcp-(1->4)-[alpha-D-GlcpA-(1->3)]-beta-D-Manp-(1->4)-alpha-D-GlcpO[CH2]5NH2,"An alpha-D-glucoside that is the 5-aminopentyl glycoside of a branched heptasaccharide consisting of alpha-D-glucuronosyl, beta-D-mannosyl, alpha-D-glucosyl, beta-D-glucosyl, beta-D-mannosyl and beta-D-glucosyl residues linked sequentially (1->3), (1->4), (1->3), (1->4) and (1->4), to the mannosyl residue proximal to the reducing end of which has also linked (1->3) to it an alpha-D-glucuronosyl residue. The 5-aminopentyl group at the reducing end is a spacer to enable further conjugation to a carrier protein for immunological studies.","InChI=1S/C47H79NO38/c48-4-2-1-3-5-73-41-26(64)22(60)31(13(8-51)76-41)80-47-30(68)36(84-44-25(63)19(57)21(59)38(86-44)40(71)72)33(15(10-53)78-47)81-46-29(67)34(16(54)12(7-50)75-46)82-42-27(65)23(61)32(14(9-52)77-42)79-45-28(66)35(17(55)11(6-49)74-45)83-43-24(62)18(56)20(58)37(85-43)39(69)70/h11-38,41-47,49-68H,1-10,48H2,(H,69,70)(H,71,72)/t11-,12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22-,23-,24-,25-,26-,27-,28+,29-,30+,31-,32-,33-,34+,35+,36-,37+,38+,41+,42-,43+,44+,45+,46+,47+/m1/s1",GlcAalpha1-3Manbeta1-4Glcalpha1-3Glcbeta1-4(GlcAalpha1-3)Manbeta1-4GlcalphaO[CH2]5NH2,PubMed citation,33108196
7552,166951,alpha-D-GlcpA-(1->3)-beta-D-Manp-(1->4)-alpha-D-Glcp-(1->3)-beta-D-Glcp-(1->4)-[alpha-D-GlcpA-(1->3)]-beta-D-Manp-(1->4)-alpha-D-Glcp,"A branched heptasaccharide consisting of alpha-D-glucuronosyl, beta-D-mannosyl, alpha-D-glucosyl, beta-D-glucosyl, beta-D-mannosyl and beta-D-glucosyl residues linked sequentially (1->3), (1->4), (1->3), (1->4) and (1->4), to the mannosyl residue proximal to the reducing end of which has also linked (1->3) to it an alpha-D-glucuronosyl residue.","InChI=1S/C42H68O38/c43-1-6-12(49)30(77-38-20(57)13(50)15(52)32(79-38)34(63)64)23(60)40(69-6)74-27-9(4-46)71-37(22(59)18(27)55)76-29-11(48)7(2-44)70-41(24(29)61)75-28-10(5-47)72-42(73-26-8(3-45)68-36(67)19(56)17(26)54)25(62)31(28)78-39-21(58)14(51)16(53)33(80-39)35(65)66/h6-33,36-62,67H,1-5H2,(H,63,64)(H,65,66)/t6-,7-,8-,9-,10-,11-,12-,13+,14+,15+,16+,17-,18-,19-,20-,21-,22-,23+,24-,25+,26-,27-,28-,29+,30+,31-,32+,33+,36+,37-,38+,39+,40+,41+,42+/m1/s1",alpha-D-glucuronosyl-(1->3)-beta-D-mannosyl-(1->4)-alpha-D-glucosyl-(1->3)-beta-D-glucosyl-(1->4)-[alpha-D-glucuronosyl-(1->3)]-beta-D-mannosyl-(1->4)-alpha-D-glucose,PubMed citation,33108196
7553,166958,beta-D-Glcp-(1->4)-[alpha-D-GlcpA-(1->3)]-beta-D-Manp-(1->4)-alpha-D-Glcp-(1->3)-beta-D-Glcp-(1->4)-[alpha-D-GlcpA-(1->3)]-beta-D-Manp-(1->4)-alpha-D-GlcpO[CH2]5NH2,"An alpha-D-glucoside that is the 5-aminopentyl glycoside of a branched octasaccharide consisting of beta-D-glucosyl, beta-D-mannosyl, alpha-D-glucosyl, beta-D-glucosyl, beta-D-mannosyl and beta-D-glucosyl residues linked sequentially (1->4), (1->4), (1->3), (1->4) and (1->4), with both mannosyl residues also having linked (1->3) to them alpha-D-glucuronosyl residues. The 5-aminopentyl group at the reducing end is a spacer to enable further conjugation to a carrier protein for immunological studies.","InChI=1S/C53H89NO43/c54-4-2-1-3-5-82-46-30(73)25(68)35(14(8-57)85-46)89-52-34(77)41(95-50-29(72)22(65)24(67)43(97-50)45(80)81)38(17(11-60)88-52)92-51-32(75)39(19(62)13(7-56)84-51)93-48-31(74)26(69)36(15(9-58)86-48)90-53-33(76)40(94-49-28(71)21(64)23(66)42(96-49)44(78)79)37(16(10-59)87-53)91-47-27(70)20(63)18(61)12(6-55)83-47/h12-43,46-53,55-77H,1-11,54H2,(H,78,79)(H,80,81)/t12-,13-,14-,15-,16-,17-,18-,19-,20+,21+,22+,23+,24+,25-,26-,27-,28-,29-,30-,31-,32-,33+,34+,35-,36-,37-,38-,39+,40-,41-,42+,43+,46+,47+,48-,49+,50+,51+,52+,53+/m1/s1",Glcbeta1-4(GlcAalpha1-3)Manbeta1-4Glcalpha1-3Glcbeta1-4(GlcAalpha1-3)Manbeta1-4GlcalphaO[CH2]5NH2,PubMed citation,33108196
7554,167054,acrophiarin,A cyclic hexapeptide echinocandin antibiotic with a myristoyl side chain. It is produced by a specific strain of Penicillium arenicola and exhibits antimycotic activity.,"InChI=1S/C49H78N8O17/c1-4-5-6-7-8-9-10-11-12-13-14-15-35(64)51-30-21-33(62)45(70)55-47(72)39-40(65)25(2)23-57(39)49(74)37(32(61)22-34(50)63)53-46(71)38(42(67)41(66)27-16-18-28(59)19-17-27)54-44(69)31-20-29(60)24-56(31)48(73)36(26(3)58)52-43(30)68/h16-19,25-26,29-33,36-42,45,58-62,65-67,70H,4-15,20-24H2,1-3H3,(H2,50,63)(H,51,64)(H,52,68)(H,53,71)(H,54,69)(H,55,72)/t25-,26+,29+,30-,31-,32+,33+,36-,37-,38-,39-,40-,41-,42-,45+/m0/s1",S31794/F-1,PubMed citation,32239586
7555,167167,25-hydroxy 3-oxocholestane,A 25-hydroxy steroid that is 3-oxocholestane which carries a hydroxy group at position 25.,"InChI=1S/C27H46O2/c1-18(7-6-14-25(2,3)29)22-10-11-23-21-9-8-19-17-20(28)12-15-26(19,4)24(21)13-16-27(22,23)5/h18-19,21-24,29H,6-17H2,1-5H3/t18-,19?,21+,22-,23+,24+,26+,27-/m1/s1",25-hydroxy 3-ketocholestane,PubMed citation,28482186
7556,167169,hexacyclonate,"A hydroxy monocarboxylic acid anion that is the conjugate base of hexacyclonic acid, arising from the deprotonation of the carboxy group; Major species at pH 7.3.","InChI=1S/C9H16O3/c10-7-9(6-8(11)12)4-2-1-3-5-9/h10H,1-7H2,(H,11,12)/p-1",hexacyclonic acid(1-),PubMed citation,13923435
7557,167182,"N-butyl-5-(4-hydroxyphenyl)-6-oxo-1,6-dihydropyrazine-2-carboxamide","A pyrazinecarboxamide in which a 6-oxo-1,6-dihydropyrazine nucleus is substituted on C-5 by a 4-hydroxyphenyl group and on C-2 by a butylcarbamyl group. A synthetic determinant of cefadroxil, it is a promising tool for determining in vitro cross-reactivity to cefadroxil in amoxicillin-allergic patients.","InChI=1S/C15H17N3O3/c1-2-3-8-16-14(20)12-9-17-13(15(21)18-12)10-4-6-11(19)7-5-10/h4-7,9,19H,2-3,8H2,1H3,(H,16,20)(H,18,21)","N-butyl-1,6-dihydro-5-(4-hydroxyphenyl)-6-oxo-2-pyrazinecarboxamide",PubMed citation,33292516
7558,162704,Glu-Arg-Gly,"A tripeptide composed of L-glutamic acid, L-arginine, and glycine joined in sequence by peptide linkages.","InChI=1S/C13H24N6O6/c14-7(3-4-9(20)21)11(24)19-8(2-1-5-17-13(15)16)12(25)18-6-10(22)23/h7-8H,1-6,14H2,(H,18,25)(H,19,24)(H,20,21)(H,22,23)(H4,15,16,17)/t7-,8-/m0/s1",(4S)-4-amino-5-[[(2S)-1-(carboxymethylamino)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-oxopentanoic acid,PubMed citation,6086592
7559,166055,trimellitic acid,"Benzene substituted at the 1,2, and 4 positions by carboxy groups.","InChI=1S/C9H6O6/c10-7(11)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3H,(H,10,11)(H,12,13)(H,14,15)","Benzene-1,2,4-tricarboxylic acid",CAS Registry Number,528-44-9
7560,166847,"3,5-dichlorobenzoate","A chlorobenzoate obtained by deprotonation of the carboxy group of 3,5-dichlorobenzoic acid. The major species at pH 7.3.","InChI=1S/C7H4Cl2O2/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3H,(H,10,11)/p-1","3,5-dichloro-benzoate",PubMed citation,28236176
7561,166874,5-methoxytryptamine(1+),A primary ammonium ion that is the conjugate acid of 5-methoxytryptamine obtained by the protonation of the primary amino group. Major microspecies at pH 7.3.,"InChI=1S/C11H14N2O/c1-14-9-2-3-11-10(6-9)8(4-5-12)7-13-11/h2-3,6-7,13H,4-5,12H2,1H3/p+1",O-methylserotonin(1+),MetaCyc accession,CPD-12018
7562,166878,"(5R,6S,7S)-5,6-dihydroxy-8-(alpha-D-galactosyloxy)-7-icosanamido-N-(6-phenylhexyl)octanamide","A synthetic alpha-galactosylsphingamide in which the galactose ring carries a (2S,3S,4R)-3,4-dihydroxy-2-(icosanoylamino)-8-oxo-8-[(6-phenylhexyl)amino]octyl moiety at O-1.","InChI=1S/C46H82N2O10/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-24-31-41(52)48-37(35-57-46-45(56)44(55)43(54)39(34-49)58-46)42(53)38(50)30-26-32-40(51)47-33-25-19-18-21-27-36-28-22-20-23-29-36/h20,22-23,28-29,37-39,42-46,49-50,53-56H,2-19,21,24-27,30-35H2,1H3,(H,47,51)(H,48,52)/t37-,38+,39+,42-,43-,44-,45+,46-/m0/s1","alpha-GSA[20,6P]",PubMed citation,31391251
7563,166879,"(5R,6S,7S)-5,6-dihydroxy-8-(alpha-D-galactosyloxy)-7-hexacosanamido-N-(6-phenylhexyl)octanamide","A synthetic alpha-galactosylsphingamide in which the galactose ring carries a (2S,3S,4R)-3,4-dihydroxy-2-(hexacosanoylamino)-8-oxo-8-[(6-phenylhexyl)amino]octyl moiety at O-1.","InChI=1S/C52H94N2O10/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-30-37-47(58)54-43(41-63-52-51(62)50(61)49(60)45(40-55)64-52)48(59)44(56)36-32-38-46(57)53-39-31-25-24-27-33-42-34-28-26-29-35-42/h26,28-29,34-35,43-45,48-52,55-56,59-62H,2-25,27,30-33,36-41H2,1H3,(H,53,57)(H,54,58)/t43-,44+,45+,48-,49-,50-,51+,52-/m0/s1","alpha-GSA[26,6P]",PubMed citation,31391251
7564,166880,"(5R,6S,7S)-5,6-dihydroxy-8-(alpha-D-galactosyloxy)-7-octanamido-N-(4-phenylbutyl)octanamide","A synthetic alpha-galactosylsphingamide in which the galactose ring carries a (2S,3S,4R)-3,4-dihydroxy-2-(octanoylamino)-8-oxo-8-[(6-phenylbutyl)amino]octyl moiety at O-1.","InChI=1S/C32H56N2O10/c1-2-3-4-5-9-17-27(38)34-23(21-43-32-31(42)30(41)29(40)25(20-35)44-32)28(39)24(36)16-12-18-26(37)33-19-11-10-15-22-13-7-6-8-14-22/h7,13-14,23-25,28-32,35-36,39-42H,2-6,8-12,15-21H2,1H3,(H,33,37)(H,34,38)/t23-,24+,25+,28-,29-,30-,31+,32-/m0/s1","alpha-GSA[8,4P]",PubMed citation,31391251
7565,166884,"(5R,6S,7S)-8-(alpha-D-galactosyloxy)-7-hexadecanamido-5,6-dihydroxy-N-(6-phenylhexyl)octanamide","A synthetic alpha-galactosylsphingamide in which the galactose ring carries a (2S,3S,4R)-3,4-dihydroxy-2-(hexadecanoylamino)-8-oxo-8-[(6-phenylhexyl)amino]octyl moiety at O-1","InChI=1S/C42H74N2O10/c1-2-3-4-5-6-7-8-9-10-11-12-13-20-27-37(48)44-33(31-53-42-41(52)40(51)39(50)35(30-45)54-42)38(49)34(46)26-22-28-36(47)43-29-21-15-14-17-23-32-24-18-16-19-25-32/h16,18-19,24-25,33-35,38-42,45-46,49-52H,2-15,17,20-23,26-31H2,1H3,(H,43,47)(H,44,48)/t33-,34+,35+,38-,39-,40-,41+,42-/m0/s1","(5R,6S,7S)-5,6-dihydroxy-7-hexadecanamido-8-(alpha-D-galactosyloxy)-N-(6-phenylhexyl)octanamide",PubMed citation,31391251
7566,174690,clenbuterol,"A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.","InChI=1S/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3","1-(4-Amino-3,5-dichloro-phenyl)-2-tert-butylamino-ethanol",DrugBank accession,DB01407
7567,180696,20beta-dihydroprednisolone,A glucocorticoid that is prednisolone in which the oxo group at position 20 has been reduced to the corresponding beta-hydroxy group. It is a metabolite of prednisolone.,"InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-18,22,24-26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,17-,18+,19-,20-,21-/m0/s1",20beta-dihydro-PRED,PubMed citation,25800201
7568,180847,(S)-nomifensine,The S enantiomer of nomifensine.,"InChI=1S/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3/t14-/m0/s1","(S)-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine",PubMed citation,1502708
7569,180900,midafotel,A member of the class of piperazines that is piperazine substituted by a carboxy group at position 2R and a (1E)-1-phosphonoprop-1-en-3-yl group at position 4. It is an antagonist of N-methyl-D-aspartate receptors (NMDARs) and was in clinical development by Novartis for the treatment of cognition disorders and brain injuries (now discontinued).,"InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+/t7-/m1/s1",D-CPPene,PubMed citation,32507787
7570,180920,Delta(6)-prednisolone,A glucocorticoid that is prednisolone in which a double bond is introduced at position 6. It is a metabolite of prednisolone found in human urine.,"InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h3-5,7,9,14-16,18,22,24,26H,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1","6,7-dehydro-prednisolone",PubMed citation,660591
7571,180495,4-phenyl-3-furoxancarbonitrile,"A 1,2,5-oxadiazole substituted by an oxido, cyano and phenyl groups at positions 2, 3 and 4, respectively. It is a vasodilator and inhibitor of platelet aggregation.",InChI=1S/C9H5N3O2/c10-6-8-9(11-14-12(8)13)7-4-2-1-3-5-7/h1-5H,RVC-589,Chemspider accession,1692
7572,180676,4-hydroxy-TEMPO benzoate,A member of the class of piperidines that is TEMPO carrying a benzoyloxy group at position 4.,"InChI=1S/C16H22NO3/c1-15(2)10-13(11-16(3,4)17(15)19)20-14(18)12-8-6-5-7-9-12/h5-9,13H,10-11H2,1-4H3",4-benzoyloxy-TEMPO,CAS Registry Number,3225-26-1
7573,177875,N-{2-[(4-benzylpiperidin-1-yl)methyl]benzimidazol-5-yl}methanesulfonamide,"A member of the class of benzimidazoles that is 1H-benzimidazole substituted by (4-benzylpiperidin-1-yl)methyl and (methylsulfonyl)amino groups at positions 2 and 6, respectively. It is a potent antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor.","InChI=1S/C21H26N4O2S/c1-28(26,27)24-18-7-8-19-20(14-18)23-21(22-19)15-25-11-9-17(10-12-25)13-16-5-3-2-4-6-16/h2-8,14,17,24H,9-13,15H2,1H3,(H,22,23)",N-[2-(4-benzyl-piperidin-1-ylmethyl)-3H-benzoimidazol-5-yl]-methanesulfonamide,PubMed citation,20082612
7574,177876,N-[2-(4-phenoxybenzyl)benzimidazol-5-yl]methanesulfonamide,"A member of the class of benzimidazoles that is 1H-benzimidazole substituted by 4-phenoxybenzyl and (methylsulfonyl)amino groups at positions 2 and 6, respectively. It is a potent antagonist of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor.","InChI=1S/C21H19N3O3S/c1-28(25,26)24-16-9-12-19-20(14-16)23-21(22-19)13-15-7-10-18(11-8-15)27-17-5-3-2-4-6-17/h2-12,14,24H,13H2,1H3,(H,22,23)",XK2,PubMed citation,20082612
7575,177877,"alpha-D-GlcpNAc-(1->4)-beta-D-Manp2NAc3NAcA-(1->3)-beta-L-FucpNAc4NMe-(1->6)-[L-alpha-D-Hepp-(1->4)]-D-Manf2,5anh",A pentasaccharide derivative that comprises the distal pentasaccharide of the oligosaccharide segment of Bordetella pertussis strain 186 lipooligosaccharide.,"InChI=1S/C40H65N5O25/c1-11-20(41-6)33(24(45-15(5)52)37(63-11)62-10-19-32(26(55)18(9-48)64-19)67-40-30(59)28(57)29(58)31(66-40)16(53)7-46)68-38-22(43-13(3)50)21(42-12(2)49)34(35(70-38)36(60)61)69-39-23(44-14(4)51)27(56)25(54)17(8-47)65-39/h9,11,16-35,37-41,46-47,53-59H,7-8,10H2,1-6H3,(H,42,49)(H,43,50)(H,44,51)(H,45,52)(H,60,61)/t11-,16+,17-,18-,19-,20-,21-,22+,23-,24-,25-,26-,27-,28+,29+,30+,31-,32-,33+,34+,35+,37+,38-,39?,40?/m1/s1","N-acetyl-alpha-D-glucosaminyl-(1->4)-2,3-diacetamido-2,3-dideoxy-beta-D-mannuronosyl-(1->3)-N-acetyl-4,6-dideoxy-4-(methylamino)-alpha-D-glucosaminyl-(1->6)-[L-glycero-D-manno-heptopyranosyl-(1->4)]-2,5-anhydro-D-mannose",PubMed citation,34199173
7576,177879,alpha-D-GlcpNAc-(1->4)-beta-D-Manp2NAc3NAcA-(1->3)-beta-L-FucpNAc4NMe-(1->6)-[L-alpha-D-Hepp-(1->4)]-alpha-D-GlcpN-(1->4)-[alpha-D-GalpNA-(1->6)]-beta-D-Glcp-(1->4)-{alpha-D-GlcpN-(1->7)-[alpha-D-GlcpA-(1->2)]-D-alpha-D-Hepp-(1->3)}-L-alpha-D-Hepp-(1->5)-alpha-Kdop,A twelve-residue oligosaccharide derivative that comprises the core oligosaccharide and distal trisaccharide of the oligosaccharide segment of Bordetella pertussis strain 186 lipooligosaccharide.,"InChI=1S/C86H142N8O64/c1-16-33(90-6)63(150-78-35(92-18(3)101)34(91-17(2)100)64(70(157-78)73(131)132)151-79-36(93-19(4)102)43(114)39(110)27(12-99)141-79)37(94-20(5)103)77(139-16)138-15-28-61(149-81-52(123)44(115)47(118)56(144-81)22(105)8-95)42(113)32(89)76(142-28)148-62-29(14-137-75-31(88)41(112)46(117)66(153-75)71(127)128)143-80(54(125)51(62)122)156-69-59(23(106)9-96)147-83(146-58-21(104)7-86(135,85(133)134)158-60(58)24(107)10-97)55(126)65(69)152-84-68(155-82-53(124)45(116)48(119)67(154-82)72(129)130)50(121)49(120)57(145-84)25(108)13-136-74-30(87)40(111)38(109)26(11-98)140-74/h16,21-70,74-84,90,95-99,104-126,135H,7-15,87-89H2,1-6H3,(H,91,100)(H,92,101)(H,93,102)(H,94,103)(H,127,128)(H,129,130)(H,131,132)(H,133,134)/t16-,21+,22-,23-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34+,35-,36+,37-,38+,39+,40+,41+,42+,43+,44-,45-,46+,47-,48-,49-,50-,51+,52-,53+,54+,55-,56+,57+,58+,59+,60+,61+,62+,63+,64-,65+,66-,67-,68-,69+,70-,74-,75-,76+,77-,78+,79+,80-,81+,82+,83-,84+,86+/m0/s1","N-acetyl-D-glucosaminyl-(1->4)-2,3-diacetamido-2,3-dideoxy-beta-D-mannopyranuronosyl-(1->3)-N-acetyl-4-deoxy-4-(methylamino)-alpha-D-fucosaminyl-(1->6)-[L-glycero-alpha-D-manno-heptosyl-(1->4)]-alpha-D-glucosaminyl-(1->4)-[2-amino-2-deoxy-alpha-D-galacturonosyl-(1->6)]-beta-D-glucosyl-(1->4)-[alpha-D-glucosaminyl-(1->7)-[alpha-D-glucuronosyl-(1->2)]-D-glycero-alpha-D-manno-heptosyl-(1->3)]-L-glycero-alpha-D-manno-heptosyl-(1->5)-3-deoxy-beta-L-galacto-oct-2-ulosonic acid",PubMed citation,34199173
7577,177884,4-[2-(diphenylmethoxy)ethyl]-1-[(4-azidophenyl)-methyl]-piperidine,"A member of the class of piperidines that is piperidine substituted by (4-azidophenyl)methyl and 2-(diphenylmethoxy)ethyl groups at positions 1 and 4, respectively. It binds to the dopamine transporter ligand binding site.","InChI=1S/C27H30N4O/c28-30-29-26-13-11-23(12-14-26)21-31-18-15-22(16-19-31)17-20-32-27(24-7-3-1-4-8-24)25-9-5-2-6-10-25/h1-14,22,27H,15-21H2",AD96,PubMed citation,15763134
7578,177980,"1,4,4,7a-tetramethyl-2,4,5,7a-tetrahydro-1H-inden-2-ol","A member of the class of indenes that is 2,4,5,7a-tetrahydro-1H-indene substituted by methyl groups at positions 1, 4, 4 and 7a and by a hydroxy group at position 2.","InChI=1S/C13H20O/c1-9-10(14)8-11-12(2,3)6-5-7-13(9,11)4/h5,7-10,14H,6H2,1-4H3","1,4,4,7a-tetramethyl-2,5-dihydro-1H-inden-2-ol",HMDB accession,HMDB0036684
7579,178031,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-[beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-GalpNAc,A branched amino heptasaccharide consisting of an N-acetyl-alpha-D-galactosamine residue to which are linked via (1->3) and (1->6) linkages two N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl trisaccharide units.,"InChI=1S/C52H87N5O36/c1-13(64)53-25-35(74)30(69)18(6-58)83-48(25)92-44-32(71)20(8-60)85-51(39(44)78)89-41-22(10-62)87-47(27(37(41)76)55-15(3)66)81-12-24-34(73)43(29(46(80)82-24)57-17(5)68)91-50-28(56-16(4)67)38(77)42(23(11-63)88-50)90-52-40(79)45(33(72)21(9-61)86-52)93-49-26(54-14(2)65)36(75)31(70)19(7-59)84-49/h18-52,58-63,69-80H,6-12H2,1-5H3,(H,53,64)(H,54,65)(H,55,66)(H,56,67)(H,57,68)/t18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32+,33+,34+,35-,36-,37-,38-,39-,40-,41-,42-,43-,44+,45+,46+,47-,48+,49+,50+,51+,52+/m1/s1",beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)-[beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)]-alpha-D-GalpNAc,PubMed citation,31537530
7580,178087,alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-alpha-D-GalpNAc,"A linear amino hexasaccharide comprising a (2->6), (1->4), (1->3), (1->4), (1->3) sequence of alpha-sialyl, beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose, N-acetyl-beta-D-glucosamine and N-acetyl-alpha-D-galactosamine residues.","InChI=1S/C47H78N4O34/c1-12(57)48-23-16(61)5-47(46(73)74,85-39(23)27(63)17(62)6-52)75-11-22-28(64)33(69)34(70)44(80-22)81-36-20(9-55)79-43(25(32(36)68)50-14(3)59)84-40-30(66)19(8-54)77-45(35(40)71)82-37-21(10-56)78-42(24(31(37)67)49-13(2)58)83-38-26(51-15(4)60)41(72)76-18(7-53)29(38)65/h16-45,52-56,61-72H,5-11H2,1-4H3,(H,48,57)(H,49,58)(H,50,59)(H,51,60)(H,73,74)/t16-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28-,29-,30-,31+,32+,33-,34+,35+,36+,37+,38+,39+,40-,41-,42-,43-,44-,45-,47+/m0/s1",Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca,PubMed citation,31537530
7581,178088,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-alpha-D-GalpNAc,"A linear tetrasaccharide comprising beta-D-galactose, N-acetyl-beta-D-glucosamine, beta-D-galactose and N-acetyl-alpha-D-galactosamine residues linked in sequence (1->4), (1->3) and (1->4).","InChI=1S/C28H48N2O21/c1-7(35)29-13-18(40)22(49-27-20(42)19(41)15(37)9(3-31)46-27)12(6-34)48-26(13)51-24-17(39)11(5-33)47-28(21(24)43)50-23-14(30-8(2)36)25(44)45-10(4-32)16(23)38/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15+,16+,17+,18-,19+,20-,21-,22-,23-,24+,25+,26+,27+,28+/m1/s1",beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-alpha-D-GalNAc,PubMed citation,31537530
7582,176975,KP1339,A ruthenium coordination entity that is the sodium salt of tetrachloro[bis(1H-indazole)]ruthenate(III). It is a anticancer drug in clinical development for the treatment of solid tumours.,"InChI=1S/2C7H6N2.4ClH.Na.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;;/h2*1-5H,(H,8,9);4*1H;;/q;;;;;;+1;+3/p-4",IT-139,PubMed citation,33369073
7583,177371,"L-778,123 hydrochloride","The hydrochloride salt of L-778,123. It is a dual inhibitor of FPTase and GGPTase-I (IC50 of 2nM and 98nm, respectively) and exhibits anti-cancer properties.","InChI=1S/C22H20ClN5O.ClH/c23-19-2-1-3-20(10-19)28-9-8-26(15-22(28)29)14-21-12-25-16-27(21)13-18-6-4-17(11-24)5-7-18;/h1-7,10,12,16H,8-9,13-15H2;1H","L-778,123 hydrochloride",PubMed citation,12479371
7584,177386,3-(4-azidobenzyl)-4-hydroxycoumarin,A hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 4-azidobenzyl group. It is a photoaffinity probe used in the identification of warfarin-binding proteins present in mammalian tissue.,"InChI=1S/C16H11N3O3/c17-19-18-11-7-5-10(6-8-11)9-13-15(20)12-3-1-2-4-14(12)22-16(13)21/h1-8,20H,9H2",AzBHC,PubMed citation,1939124
7585,176801,trans-3-hexene,A 3-hexene in which the double bond adopts a trans-configuration.,"InChI=1S/C6H12/c1-3-5-6-4-2/h5-6H,3-4H2,1-2H3/b6-5+",(E)-hex-3-ene,CAS Registry Number,13269-52-8
7586,176802,alpha-D-Rhap4NFo-(1->2)-alpha-D-Rhap4NFo,An amino disaccharide epitope consisting of two N-formyl-alpha-D-perosamine residues linked (1->2). Its coupling with the carrier protein CRM197 via the DAS linker results in a neoglycoconjugate which has been used in investigations into vaccine development against brucellosis.,"InChI=1S/C14H24N2O9/c1-5-8(16-4-18)10(20)12(13(22)23-5)25-14-11(21)9(19)7(15-3-17)6(2)24-14/h3-14,19-22H,1-2H3,(H,15,17)(H,16,18)/t5-,6-,7-,8-,9+,10+,11+,12+,13+,14-/m1/s1","4,6-dideoxy-4-formamido-alpha-D-mannosyl-(1->2)-4,6-dideoxy-4-formamido-alpha-D-mannoside",PubMed citation,33243427
7587,173109,RSL3,"A beta-carboline that is 2,3,4,4a,9,9a-hexahydro-1H-beta-carboline in which the hydrogens at positions 1, 2 and 3 are replaced by 4-(methoxycarbonyl)phenyl, chloroacetyl and methoxycarbonyl groups, respectively (the 1S,2R stereoisomer). It is a potential antineoplatic agent which triggers ferroptosis by inactivating the glutathione peroxidase 4 (GPX4) enzyme.","InChI=1S/C23H23ClN2O5/c1-30-22(28)14-9-7-13(8-10-14)21-20-16(15-5-3-4-6-17(15)25-20)11-18(23(29)31-2)26(21)19(27)12-24/h3-10,16,18,20-21,25H,11-12H2,1-2H3/t16?,18-,20?,21+/m1/s1",ras-selective lethal small molecule 3,KEGG COMPOUND accession,C21479
7588,173111,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->6)]-alpha-D-Manp-(1->6)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino oligosaccharide that is an octadecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear pentasaccharide group via a (1->3) linkage and a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-[beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->6)]-alpha-D-mannosyl branched nonasaccharide group via a (1->6) linkage, while to the N-acetyl-beta-D-glucosamine residue at the reducing end is linked (1->6) an alpha-L-fucose residue.","InChI=1S/C124H206N8O90/c1-27-61(155)79(173)85(179)115(191-27)189-26-52-100(71(165)53(107(187)192-52)125-28(2)147)209-109-55(127-30(4)149)73(167)99(47(21-144)201-109)216-122-92(186)104(220-124-106(83(177)65(159)39(13-136)199-124)222-114-60(132-35(9)154)78(172)98(49(23-146)206-114)215-121-91(185)103(69(163)42(16-139)198-121)219-112-58(130-33(7)152)76(170)96(46(20-143)204-112)212-118-88(182)82(176)64(158)38(12-135)195-118)70(164)51(207-122)25-190-123-105(221-113-59(131-34(8)153)77(171)97(48(22-145)205-113)214-120-90(184)102(68(162)41(15-138)197-120)218-111-57(129-32(6)151)75(169)95(45(19-142)203-111)211-117-87(181)81(175)63(157)37(11-134)194-117)84(178)66(160)50(208-123)24-188-108-54(126-29(3)148)72(166)93(43(17-140)200-108)213-119-89(183)101(67(161)40(14-137)196-119)217-110-56(128-31(5)150)74(168)94(44(18-141)202-110)210-116-86(180)80(174)62(156)36(10-133)193-116/h27,36-124,133-146,155-187H,10-26H2,1-9H3,(H,125,147)(H,126,148)(H,127,149)(H,128,150)(H,129,151)(H,130,152)(H,131,153)(H,132,154)/t27-,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,63-,64-,65+,66+,67-,68-,69-,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80-,81-,82-,83-,84-,85-,86+,87+,88+,89+,90+,91+,92-,93+,94+,95+,96+,97+,98+,99+,100+,101-,102-,103-,104-,105-,106-,107?,108+,109-,110-,111-,112-,113-,114-,115+,116-,117-,118-,119-,120-,121-,122-,123-,124+/m0/s1",Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb,PubMed citation,31537530
7589,174128,"5,5',6,6'-tetrahydroxy-3,3'-biindolyl","A hydroxyindole that is 1H-indole-5,6-diol substituted by a 5,6-dihydroxy-1H-indol-3-yl group at position 3.","InChI=1S/C16H12N2O4/c19-13-1-7-9(5-17-11(7)3-15(13)21)10-6-18-12-4-16(22)14(20)2-8(10)12/h1-6,17-22H","3-(5,6-dihydroxy-1H-indol-3-yl)-1H-indole-5,6-diol",Chemspider accession,10209313
7590,176516,fluciclovine ((14)C),"A member of the class of cyclobutanes that is ((14)C)cyclobutane which carries a carboxy, amino and fluoro groups at positions 1, 1 and 3, respectively (the 1r,3r-stereoisomer).","InChI=1S/C5H8FNO2/c6-3-1-5(7,2-3)4(8)9/h3H,1-2,7H2,(H,8,9)/t3-,5-/i5+2",anti-[(14)C]FACBC,PubMed citation,21958853
7591,176555,beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-[beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-alpha-D-Man-(1->6)-[beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-beta-D-GlcNAc,"An amino oligosaccharide that is a heptacosasaccharide derivative consisting of a trisaccharide of beta-D-Man and two beta-D-GlcNAc residues all linked in sequence (1->4), to the Man residue of which are linked a beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man heptasaccharide group via a (1->3) linkage and a beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->2)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-alpha-D-Man tridecasaccharide group via a (1->6) linkage, while to the beta-D-GlcNAc residue at the reducing end is linked (1->6) an alpha-L-Fuc residue.","InChI=1S/C190H314N14O134/c1-43-99(243)127(271)130(274)178(289-43)287-42-84-151(116(260)86(164(285)291-84)192-45(3)229)316-169-90(196-49(7)233)118(262)150(73(31-219)305-169)326-188-140(284)161(336-190-163(128(272)102(246)62(20-208)303-190)338-177-98(204-57(15)241)126(270)149(81(39-227)313-177)325-187-139(283)160(112(256)71(29-217)302-187)335-175-96(202-55(13)239)124(268)147(79(37-225)311-175)323-185-137(281)158(110(254)69(27-215)300-185)333-173-93(199-52(10)236)121(265)144(76(34-222)308-173)320-182-133(277)154(106(250)65(23-211)297-182)329-168-88(194-47(5)231)115(259)101(245)61(19-207)293-168)113(257)83(314-188)41-288-189-162(337-176-97(203-56(14)240)125(269)148(80(38-226)312-176)324-186-138(282)159(111(255)70(28-216)301-186)334-174-95(201-54(12)238)123(267)146(78(36-224)310-174)322-183-135(279)156(108(252)67(25-213)298-183)331-171-91(197-50(8)234)119(263)142(74(32-220)306-171)318-179-131(275)152(104(248)63(21-209)294-179)327-166-85(191-44(2)228)59(242)16-58(17-205)290-166)129(273)103(247)82(315-189)40-286-165-89(195-48(6)232)117(261)141(72(30-218)304-165)317-180-134(278)155(107(251)66(24-212)295-180)330-170-94(200-53(11)237)122(266)145(77(35-223)309-170)321-184-136(280)157(109(253)68(26-214)299-184)332-172-92(198-51(9)235)120(264)143(75(33-221)307-172)319-181-132(276)153(105(249)64(22-210)296-181)328-167-87(193-46(4)230)114(258)100(244)60(18-206)292-167/h43,58-190,205-227,242-285H,16-42H2,1-15H3,(H,191,228)(H,192,229)(H,193,230)(H,194,231)(H,195,232)(H,196,233)(H,197,234)(H,198,235)(H,199,236)(H,200,237)(H,201,238)(H,202,239)(H,203,240)(H,204,241)/t43-,58-,59-,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76+,77+,78+,79+,80+,81+,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104-,105-,106-,107-,108-,109-,110-,111-,112-,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128-,129-,130-,131+,132+,133+,134+,135+,136+,137+,138+,139+,140-,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164?,165+,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,178+,179-,180-,181-,182-,183-,184-,185-,186-,187-,188-,189-,190+/m0/s1",GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAb1-2)Mana1-6(GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb,PubMed citation,31537530
7592,172325,STM2457,"A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylic acid with the primary amino group of 1-[2-(aminomethyl)imidazo[1,2-a]pyridin-6-yl]-N-(cyclohexylmethyl)methanamine. It is a highly potent and selective first-in-class small molecule inhibitor of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity and exhibits anti-leukaemic activity.","InChI=1S/C25H28N6O2/c32-24-12-21(29-23-8-4-5-11-31(23)24)25(33)27-15-20-17-30-16-19(9-10-22(30)28-20)14-26-13-18-6-2-1-3-7-18/h4-5,8-12,16-18,26H,1-3,6-7,13-15H2,(H,27,33)",STM 2457,PubMed citation,33902106
7593,172377,sodium hexafluorophosphate,An inorganic sodium salt having hexafluorophosphate(1-) as the counterion. It is an electrolyte used in sodium-ion batteries.,"InChI=1S/F6P.Na/c1-7(2,3,4,5)6;/q-1;+1",NaPF6,Reaxys Registry Number,11480059
7594,172920,beta-D-GlcpA3S-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp,"An amino tetrasaccharide comprising a chain of 3-O-sulfo-beta-D-glucuronic acid, beta-D-galactose, N-acetyl-beta-D-glucosamine and alpha-D-mannose residues linked sequentially (1->3), (1->4) and (1->2).","InChI=1S/C26H43NO25S/c1-5(31)27-9-12(34)17(8(4-30)47-24(9)51-21-13(35)10(32)6(2-28)45-23(21)41)48-25-15(37)18(11(33)7(3-29)46-25)49-26-16(38)19(52-53(42,43)44)14(36)20(50-26)22(39)40/h6-21,23-26,28-30,32-38,41H,2-4H2,1H3,(H,27,31)(H,39,40)(H,42,43,44)/t6-,7-,8-,9-,10-,11+,12-,13+,14+,15-,16-,17-,18+,19+,20+,21+,23+,24+,25+,26-/m1/s1",(3S)GlcAb1-3Galb1-4GlcNAcb1-2Mana,PubMed citation,31537530
7595,173087,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino oligosaccharide that is an icosasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked two N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear octasaccharide units [linked (1->3) and (1->6)], while to the N-acetyl-beta-D-glucosamine residue at the reducing end is linked (1->6) an alpha-L-fucose residue.","InChI=1S/C140H232N10O100/c1-31-71(178)93(200)96(203)131(214-31)212-30-60-111(85(192)61(121(211)215-60)141-32(2)168)234-124-64(144-35(5)171)86(193)110(52(22-161)226-124)241-138-103(210)118(248-140-120(95(202)75(182)45(15-154)225-140)250-130-70(150-41(11)177)92(199)109(58(28-167)232-130)240-137-102(209)117(81(188)51(21-160)223-137)247-128-68(148-39(9)175)90(197)107(56(26-165)230-128)238-135-100(207)115(79(186)49(19-158)221-135)245-126-66(146-37(7)173)88(195)105(54(24-163)228-126)236-133-98(205)113(77(184)47(17-156)219-133)243-123-63(143-34(4)170)84(191)73(180)43(13-152)217-123)82(189)59(233-138)29-213-139-119(94(201)74(181)44(14-153)224-139)249-129-69(149-40(10)176)91(198)108(57(27-166)231-129)239-136-101(208)116(80(187)50(20-159)222-136)246-127-67(147-38(8)174)89(196)106(55(25-164)229-127)237-134-99(206)114(78(185)48(18-157)220-134)244-125-65(145-36(6)172)87(194)104(53(23-162)227-125)235-132-97(204)112(76(183)46(16-155)218-132)242-122-62(142-33(3)169)83(190)72(179)42(12-151)216-122/h31,42-140,151-167,178-211H,12-30H2,1-11H3,(H,141,168)(H,142,169)(H,143,170)(H,144,171)(H,145,172)(H,146,173)(H,147,174)(H,148,175)(H,149,176)(H,150,177)/t31-,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76-,77-,78-,79-,80-,81-,82+,83+,84+,85+,86+,87+,88+,89+,90+,91+,92+,93+,94-,95-,96-,97+,98+,99+,100+,101+,102+,103-,104+,105+,106+,107+,108+,109+,110+,111+,112-,113-,114-,115-,116-,117-,118-,119-,120-,121?,122-,123-,124-,125-,126-,127-,128-,129-,130-,131+,132-,133-,134-,135-,136-,137-,138-,139-,140+/m0/s1",GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-2Manalpha1-3(GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-2Manalpha1-6)Manbeta1-4GlcNAcbeta1-4(Fucalpha1-6)GlcNAcbeta,PubMed citation,31537530
7596,173105,talaroconvolutin A,An octahydronaphthalene with formula C32H41NO3. It is a fungal metabolite isolated from Talaromyces convolutus and is an inducer of ferroptosis in colorectal cancer cells.,"InChI=1S/C32H41NO3/c1-7-19(2)14-21(4)28-22(5)18-32(6)17-20(3)8-13-27(32)29(28)30(35)26-16-24(33-31(26)36)15-23-9-11-25(34)12-10-23/h9-12,14-16,18-20,27-29,34H,7-8,13,17H2,1-6H3,(H,33,36)/b21-14+,24-15-/t19?,20-,27+,28-,29+,32+/m0/s1",TalaA,KNApSAcK accession,C00047099
7597,192474,alpha-L-Fucp-(1->6)-{beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)}-beta-D-GlcpNAc,"A branched amino octasaccharide comprised of a backbone of beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl, alpha-D-mannosyl, beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-beta-D-glucosamine residues linked in sequence (1->4), (1->2), (1->3), (1->4) and (1->4), to the beta-D-mannosyl residue is also linked (1->2) a beta-D-xylosyl residue, while to the beta-D-GlcNAc residue at the reducing end is also linked (1->6) an alpha-L-fucosyl residue.","InChI=1S/C53H89N3O39/c1-12-26(66)34(74)38(78)49(83-12)82-11-22-42(31(71)23(46(80)84-22)54-13(2)62)90-47-24(55-14(3)63)33(73)41(21(9-61)88-47)92-53-45(95-50-37(77)27(67)16(65)10-81-50)43(30(70)19(7-59)87-53)93-52-44(36(76)29(69)18(6-58)86-52)94-48-25(56-15(4)64)32(72)40(20(8-60)89-48)91-51-39(79)35(75)28(68)17(5-57)85-51/h12,16-53,57-61,65-80H,5-11H2,1-4H3,(H,54,62)(H,55,63)(H,56,64)/t12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27-,28-,29+,30+,31+,32+,33+,34+,35-,36-,37+,38-,39+,40+,41+,42+,43-,44-,45-,46?,47-,48-,49+,50-,51-,52+,53-/m0/s1",alpha-L-fucosyl-(1->6)-{beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[beta-D-xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)}-N-acetyl-beta-D-glucosamine,PubMed citation,32568414
7598,192487,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"A branched amino nonasaccharide comprised of a backbone of beta-D-galactosyl, N-acetyl-beta-D-glucosaminyl, alpha-D-mannosyl, beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-beta-D-glucosamine residues linked in sequence (1->4), (1->2), (1->3), (1->4) and (1->4), to the beta-D-mannosyl residue are also linked (1->2) and (1->6) beta-D-xylosyl and alpha-D-mannosyl residues respectively, while the D-GlcNAc residue distal to the reducing end has also linked (1->3) to it an alpha-L-fucosyl residue.","InChI=1S/C59H99N3O44/c1-13-28(73)36(81)42(87)56(92-13)103-47-27(62-16(4)71)53(98-23(10-68)46(47)102-57-43(88)38(83)31(76)19(6-64)95-57)105-49-39(84)32(77)20(7-65)96-58(49)104-48-33(78)24(12-91-54-41(86)37(82)30(75)18(5-63)94-54)99-59(50(48)106-55-40(85)29(74)17(72)11-90-55)101-45-22(9-67)97-52(26(35(45)80)61-15(3)70)100-44-21(8-66)93-51(89)25(34(44)79)60-14(2)69/h13,17-59,63-68,72-89H,5-12H2,1-4H3,(H,60,69)(H,61,70)(H,62,71)/t13-,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29-,30+,31-,32+,33+,34+,35+,36+,37-,38-,39-,40+,41-,42-,43+,44+,45+,46+,47+,48-,49-,50-,51?,52-,53-,54-,55-,56-,57-,58+,59-/m0/s1",alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[alpha-D-mannosyl-(1->6)]-[beta-D-xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine,PubMed citation,32568414
7599,192082,anisiflupurin,"A member of the class of 6-aminopurines that is 9H-purine substituted by fluoro and (3-methoxyphenyl)amino groups at positions 2 and 6, respectively. It is a plant growth regulator developed by Syngenta crop protection AG and an inhibitor of cytokinin oxidase/dehydrogenase 2.","InChI=1S/C12H10FN5O/c1-19-8-4-2-3-7(5-8)16-11-9-10(15-6-14-9)17-12(13)18-11/h2-6H,1H3,(H2,14,15,16,17,18)",anisiflupurine,CAS Registry Number,1089014-47-0
7600,192254,alpha-D-Manp-(1->3)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino heptasaccharide comprised of a backbone of alpha-D-mannosyl, beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-beta-D-glucosamine residues linked in sequence (1->3), (1->4) and (1->4), to the beta-D-mannosyl residue is also linked (1->2) a beta-D-xylosyl residue, while to the N-acetyl-beta-D-glucosamine residue at the reducing end is also linked (1->6) an alpha-L-fucosyl residue.","InChI=1S/C39H66N2O29/c1-9-19(48)25(54)28(57)36(62-9)61-8-16-31(23(52)17(34(59)63-16)40-10(2)45)67-35-18(41-11(3)46)24(53)30(15(6-44)66-35)68-39-33(70-37-27(56)20(49)12(47)7-60-37)32(22(51)14(5-43)65-39)69-38-29(58)26(55)21(50)13(4-42)64-38/h9,12-39,42-44,47-59H,4-8H2,1-3H3,(H,40,45)(H,41,46)/t9-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35-,36+,37-,38+,39-/m0/s1",alpha-L-fucosyl-(1->6)-[alpha-D-mannosyl-(1->3)-[beta-D-xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)]-N-acetyl-beta-D-glucosamine,PubMed citation,32568414
7601,192282,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,A branched amino octasaccharide consisting of a beta-D-GlcNAc residue at the reducing end with a beta-D-GalNAc-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4)-linkage.,"InChI=1S/C55H92N4O40/c1-13(66)56-25-35(77)42(21(8-63)87-48(25)84)94-50-27(58-15(3)68)37(79)44(23(10-65)91-50)96-55-47(99-53-40(82)29(71)17(70)11-85-53)45(33(75)24(93-55)12-86-52-41(83)38(80)31(73)19(6-61)89-52)97-54-46(39(81)32(74)20(7-62)90-54)98-51-28(59-16(4)69)36(78)43(22(9-64)92-51)95-49-26(57-14(2)67)34(76)30(72)18(5-60)88-49/h17-55,60-65,70-84H,5-12H2,1-4H3,(H,56,66)(H,57,67)(H,58,68)(H,59,69)/t17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29+,30+,31-,32-,33-,34-,35-,36-,37-,38+,39+,40-,41+,42-,43-,44-,45+,46+,47+,48-,49+,50+,51+,52+,53+,54-,55+/m1/s1",beta-D-GalNAc-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,32568414
7602,191177,Ser-Asp-Lys-Pro,"A tetrapeptide composed of L-serine, L-aspartic acid, L-lysine, and L-proline joined in sequence by peptide linkages.","InChI=1S/C18H31N5O8/c19-6-2-1-4-11(17(29)23-7-3-5-13(23)18(30)31)21-16(28)12(8-14(25)26)22-15(27)10(20)9-24/h10-13,24H,1-9,19-20H2,(H,21,28)(H,22,27)(H,25,26)(H,30,31)/t10-,11-,12-,13-/m0/s1",L-Ser-L-Asp-L-Lys-L-Pro,PubMed citation,2374142
7603,191180,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,"An amino hexasaccharide comprised of a backbone of N-acetyl-beta-D-glucosaminyl, alpha-D-mannosyl, beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and  N-acetyl-beta-D-glucosamine residues linked in sequence (1->2), (1->3), (1->4) and (1->4), to the beta-D-mannosyl residue is also linked (1->2) a beta-D-xylosyl residue.","InChI=1S/C41H69N3O30/c1-10(50)42-19-27(59)31(17(7-48)65-36(19)63)70-38-21(44-12(3)52)28(60)32(18(8-49)69-38)71-41-35(74-39-30(62)22(54)13(53)9-64-39)33(25(57)16(6-47)68-41)72-40-34(29(61)24(56)15(5-46)67-40)73-37-20(43-11(2)51)26(58)23(55)14(4-45)66-37/h13-41,45-49,53-63H,4-9H2,1-3H3,(H,42,50)(H,43,51)(H,44,52)/t13-,14-,15-,16-,17-,18-,19-,20-,21-,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,32-,33+,34+,35+,36-,37+,38+,39+,40-,41+/m1/s1",beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-beta-D-GlcNAc,PubMed citation,32568414
7604,191411,taiwanin C,"A furonaphthodioxole that is furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one subtituted by a 1,3-benzodioxol-5-yl group at position 5. It is a naturally occurring lignan extracted from Taiwania cryptomerioides and found to be a potential inhibitor of COX2 expression.","InChI=1S/C20H12O6/c21-20-19-12(7-22-20)3-11-5-16-17(26-9-25-16)6-13(11)18(19)10-1-2-14-15(4-10)24-8-23-14/h1-6H,7-9H2","5-(1,3-benzodioxol-5-yl)-8H-[2]benzofuro[5,6-f][1,3]benzodioxol-6-one",CAS Registry Number,14944-34-4
7605,191412,2-aminoacetyl fluoride,An acyl flouride that is acetyl fluoride substituted by an amino group at position 2. It is a carcinogenic agent which induces hepatocellular carcinoma in rodents.,"InChI=1S/C2H4FNO/c3-2(5)1-4/h1,4H2",2-aminoacetylfluorine,PubMed citation,28876464
7606,190285,N-(1-hydroxydodecan-2-yl)tetracosanamide,"A carboxamide consisting of a 1-hydroxydodecan-2-yl moiety linked via nitrogen to tetracosanamide. A ceramide mimetic, it is composed of a saturated C12-sphingosine mimetic and lignoceric acid (C24:0).","InChI=1S/C36H73NO2/c1-3-5-7-9-11-13-14-15-16-17-18-19-20-21-22-23-24-25-27-29-31-33-36(39)37-35(34-38)32-30-28-26-12-10-8-6-4-2/h35,38H,3-34H2,1-2H3,(H,37,39)",C12L,PubMed citation,31827147
7607,190508,CF3-C182L,An artificial glycosphingolipid composed of the ceramide mimetic C182L (CHEBI:190504) bound to a beta-D-GlcNAc-(1->4)-[alpha-L-Fuc-(1->6)]-D-GlcNAc oligosaccharide via a beta-linkage.,"InChI=1S/C64H121N3O16/c1-6-8-10-12-14-16-18-20-22-23-24-25-26-27-28-30-32-34-36-38-40-42-52(71)67-49(41-39-37-35-33-31-29-21-19-17-15-13-11-9-7-2)44-78-62-54(66-48(5)70)58(75)61(51(82-62)45-79-64-60(77)59(76)55(72)46(3)80-64)83-63-53(65-47(4)69)57(74)56(73)50(43-68)81-63/h46,49-51,53-64,68,72-77H,6-45H2,1-5H3,(H,65,69)(H,66,70)(H,67,71)/t46-,49-,50+,51+,53+,54+,55+,56+,57+,58+,59+,60-,61+,62+,63-,64+/m0/s1",(2S)-2-(tetracosanoylamino)octadecyl N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->6)]-N-acetyl-beta-D-glucosaminide,PubMed citation,31827147
7608,189677,alpha-D-Glcp-(1->3)-alpha-L-Rhap-(1->4)-D-Rib-ol-(5-P-2)-alpha-D-GalpO[CH2]2NH2,A synthetic phosphate-linked oligosaccharide analogue that is the 2-aminoethyl glycoside of a pseudotetrasaccharide corresponding to a repeating unit of the Streptococcus pneumoniae type 6B capsular polysaccharide.,"InChI=1S/C25H48NO22P/c1-8-13(31)21(47-23-19(37)17(35)15(33)10(5-28)44-23)20(38)24(43-8)46-12(14(32)9(30)4-27)7-42-49(39,40)48-22-18(36)16(34)11(6-29)45-25(22)41-3-2-26/h8-25,27-38H,2-7,26H2,1H3,(H,39,40)/t8-,9-,10+,11+,12+,13-,14-,15+,16-,17-,18-,19+,20+,21+,22+,23+,24-,25-/m0/s1",2-aminoethyl alpha-D-glucosyl-(1->3)-alpha-L-rhamnosyl-(1->4)-D-ribitol-(5-P-2)-alpha-D-galactoside,PubMed citation,34966778
7609,189698,"(2E,4Z)-2-aminomuconic acid","A 2-aminomuconic acid in which the two double bonds adopt a 2E,4Z-configuration.","InChI=1S/C6H7NO4/c7-4(6(10)11)2-1-3-5(8)9/h1-3H,7H2,(H,8,9)(H,10,11)/b3-1-,4-2+","trans,cis-2-aminomuconic acid",Chemspider accession,4444139
7610,189843,alpha-L-Fucp-(1->6)-{alpha-L-Fucp-(1->3)-[alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)]-beta-D-GlcpNAc-(1->4)}-D-GlcpNAc,A branched amino hexasaccharide derivative that is alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the  beta-GlcNAc residue carries an alpha-L-Fuc residue via a (1->3) linkage and the GlcNAc residue at the reducing end carries an alpha-L-Fuc residue via a (1->6) linkage.,"InChI=1S/C40H68N2O29/c1-9-19(48)24(53)27(56)37(62-9)61-8-16-31(23(52)17(35(60)64-16)41-11(3)46)68-36-18(42-12(4)47)33(70-38-28(57)25(54)20(49)10(2)63-38)32(15(7-45)67-36)69-40-30(59)34(22(51)14(6-44)66-40)71-39-29(58)26(55)21(50)13(5-43)65-39/h9-10,13-40,43-45,48-60H,5-8H2,1-4H3,(H,41,46)(H,42,47)/t9-,10-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31+,32+,33+,34-,35?,36-,37+,38-,39+,40-/m0/s1",alpha-L-fucosyl-(1->6)-{alpha-L-fucosyl-(1->3)-[alpha-D-mannosyl-(1->3)-beta-D-mannosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->4)}-N-acetyl-beta-D-glucosamine,PubMed citation,32568414
7611,189845,alpha-L-Fucp-(1->6)-{alpha-L-Fucp-(1->3)-[beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)]-beta-D-GlcpNAc-(1->4)}-D-GlcpNAc,A branched amino heptasaccharide derivative that is beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc in which the beta-GlcNAc residue carries an alpha-L-Fuc residue via a (1->3) linkage and the GlcNAc residue at the reducing end carries an alpha-L-Fuc residue via a (1->6) linkage.,"InChI=1S/C48H81N3O34/c1-11-24(59)31(66)34(69)45(74-11)73-10-20-37(30(65)21(42(72)76-20)49-13(3)56)81-44-23(51-15(5)58)39(83-46-35(70)32(67)25(60)12(2)75-46)38(19(9-55)80-44)82-47-36(71)40(28(63)18(8-54)78-47)84-48-41(33(68)27(62)17(7-53)79-48)85-43-22(50-14(4)57)29(64)26(61)16(6-52)77-43/h11-12,16-48,52-55,59-72H,6-10H2,1-5H3,(H,49,56)(H,50,57)(H,51,58)/t11-,12-,16+,17+,18+,19+,20+,21+,22+,23+,24+,25+,26+,27+,28+,29+,30+,31+,32+,33-,34-,35-,36-,37+,38+,39+,40-,41-,42?,43-,44-,45+,46-,47-,48+/m0/s1",beta-D-GlcNAcbeta-(1->2)-alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-D-GlcpNAc,PubMed citation,32568414
7612,189864,3-hydroxy-3-phenylpropionitrile,A nitrile that is 3-phenylpropionitrile in which one of the methylene hydrogens at position 3 is replaced by a hydroxy group.,"InChI=1S/C9H9NO/c10-7-6-9(11)8-4-2-1-3-5-8/h1-5,9,11H,6H2",beta-hydroxy-benzenepropanenitrile,CAS Registry Number,17190-29-3
7613,189867,DDR1-IN-1,"A secondary carboxamide resulting from the formal condensation of the carboxy group of 4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)benzoic acid with the amino group of 5-(5-amino-2-methylphenoxy)-1,3-dihydro-2H-indol-2-one. It is a potent inhibitor of discoidin domain receptor tyrosine kinase 1 and 2 (DDR1/2) with IC50 = 105 nM and 413 nM, respectively.","InChI=1S/C30H31F3N4O3/c1-3-36-10-12-37(13-11-36)18-21-6-5-20(15-25(21)30(31,32)33)29(39)34-23-7-4-19(2)27(17-23)40-24-8-9-26-22(14-24)16-28(38)35-26/h4-9,14-15,17H,3,10-13,16,18H2,1-2H3,(H,34,39)(H,35,38)","N-[3-[(2,3-dihydro-2-oxo-1H-indol-5-yl)oxy]-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)benzamide",PubMed citation,23899692
7614,190137,5a-carba-beta-D-mannosyl C32-phosphomycoketide,"A cyclitol phosphate that is 5a-carba-beta-D-mannose having a (4S,8S,12S,16S,20S)-4,8,12,16,20-pentamethylheptacosyl)phosphate group at position 1.","InChI=1S/C39H79O8P/c1-7-8-9-10-11-17-30(2)18-12-19-31(3)20-13-21-32(4)22-14-23-33(5)24-15-25-34(6)26-16-27-46-48(44,45)47-36-28-35(29-40)37(41)39(43)38(36)42/h30-43H,7-29H2,1-6H3,(H,44,45)/t30-,31-,32-,33-,34-,35+,36+,37+,38+,39-/m0/s1",5a-carba-MPM C32,PubMed citation,34536421
7615,188648,"3,3',4',5-tetrachlorosalicylanilide",A salicylanilide derivative with chloride substituents at C-3 and C-5 of the salicylate moiety and at C-3 and C-4 of the anilide moiety.,"InChI=1S/C13H7Cl4NO2/c14-6-3-8(12(19)11(17)4-6)13(20)18-7-1-2-9(15)10(16)5-7/h1-5,19H,(H,18,20)","3,5-Dichloro-N-(3,4-dichloro-phenyl)-2-hydroxy-benzamide",PubMed citation,1640019
7616,189000,N(alpha)-benzoyl-L-asparagine 4-nitroanilide,An L-asparagine derivative that is L-asparagine in which the amino group undergoes formal consensation with the carboxy group of benzoic acid and in which the carboxy OH group is replaced by a (4-nitrophenyl)amino group. It is an asparaginyl endopeptidase substrate.,"InChI=1S/C17H16N4O5/c18-15(22)10-14(20-16(23)11-4-2-1-3-5-11)17(24)19-12-6-8-13(9-7-12)21(25)26/h1-9,14H,10H2,(H2,18,22)(H,19,24)(H,20,23)/t14-/m0/s1",Bz-Asn-pNA,PubMed citation,25630877
7617,189047,carbovir triphosphate(4-),"An organophosphate oxoanion that is the tetraanion of carbovir triphosphate, arising from deprotonation of the four triphosphate OH groups; major species at pH 7.3.","InChI=1S/C11H16N5O11P3/c12-11-14-9-8(10(17)15-11)13-5-16(9)7-2-1-6(3-7)4-25-29(21,22)27-30(23,24)26-28(18,19)20/h1-2,5-7H,3-4H2,(H,21,22)(H,23,24)(H2,18,19,20)(H3,12,14,15,17)/p-4/t6-,7+/m1/s1",carbovir triphosphate tetraanion,PubMed citation,1703154
7618,189421,"S-(1-ethyl-2,5-dioxo-3-pyrrolidinyl)-L-cysteine",An L-cysteine derivative that results when maleimide reacts with the thiol group of L-cysteine forming a thioether bond.,"InChI=1S/C9H14N2O4S/c1-2-11-7(12)3-6(8(11)13)16-4-5(10)9(14)15/h5-6H,2-4,10H2,1H3,(H,14,15)/t5-,6?/m0/s1",(L-Cys)-NEM,CAS Registry Number,6367-95-9
7619,189531,ICR 340,The dihydrochloride salt of ICR 340.,"InChI=1S/C20H24Cl2N4O.2ClH/c1-3-26(12-9-21)11-4-10-23-19-15-6-5-14(22)13-17(15)24-16-7-8-18(27-2)25-20(16)19;;/h5-8,13H,3-4,9-12H2,1-2H3,(H,23,24);2*1H",ICR-340,CAS Registry Number,38915-28-5
7620,189550,FLAG peptide,"An eight amino acid peptide consisting of L-aspartic acid, L-tyrosine, L-lysine, four L-aspartic acid residues, and L-lysine joined in sequence by peptide linkages. It is widely used as a fusion tag for the purification and detection of a wide variety of recombinant proteins.","InChI=1S/C41H60N10O20/c42-11-3-1-5-22(45-36(65)24(13-19-7-9-20(52)10-8-19)47-34(63)21(44)14-29(53)54)35(64)48-26(16-31(57)58)38(67)50-28(18-33(61)62)40(69)51-27(17-32(59)60)39(68)49-25(15-30(55)56)37(66)46-23(41(70)71)6-2-4-12-43/h7-10,21-28,52H,1-6,11-18,42-44H2,(H,45,65)(H,46,66)(H,47,63)(H,48,64)(H,49,68)(H,50,67)(H,51,69)(H,53,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,70,71)/t21-,22-,23-,24-,25-,26-,27-,28-/m0/s1",Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys,CAS Registry Number,98849-88-8
7621,183051,tetraacetyl-N-azidoacetyl-D-mannosamine,"A monosaccharide derivative that is D-mannosamine in pyranose form with an azidocarbonyl group substituted on nitrogen and all hydroxy groups acetylated. It can be used to introduce  an azido group in living cells which can be metabolized to N-azido acetylneuramic acid and eventually incorporated into the glycoproteins and glycolipids on the cell surface, while exhibiting very low toxicity.","InChI=1S/C15H20N4O10/c1-6(20)25-5-10-12(26-7(2)21)13(27-8(3)22)11(17-15(24)18-19-16)14(29-10)28-9(4)23/h10-14H,5H2,1-4H3,(H,17,24)/t10-,11+,12-,13-,14?/m1/s1",AC4ManNAz,PubMed citation,34158858
7622,184302,4-cyanobenzoyl chloride,An acyl chloride consisting of benzoyl chloride in which the hydrogen at position 4 is replaced by a cyano group.,InChI=1S/C8H4ClNO/c9-8(11)7-3-1-6(5-10)2-4-7/h1-4H,para-cyanobenzoyl chloride,Chemspider accession,72418
7623,184305,"4,4-dimethyloxazolidine-N-oxyl","A member of the class of oxazolidines that is 4,4-dimethyl-1,3-oxazolidine carrying an oxidanediyl group at position 3.","InChI=1S/C5H10NO2/c1-5(2)3-8-4-6(5)7/h3-4H2,1-2H3",DOXYL,CAS Registry Number,25554-61-4
7624,184644,dantrolene sodium hemiheptahydrate,A hydrate which is the hemiheptahydrate of anhydrous dantrolene sodium.,"InChI=1S/2C14H10N4O5.2Na.7H2O/c2*19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22;;;;;;;;;/h2*1-7H,8H2,(H,16,19,20);;;7*1H2/q;;2*+1;;;;;;;/p-2/b2*15-7+;;;;;;;;;",DANTROLENE SODIUM,PubMed citation,10354395
7625,519990,12-epi-scalarin,"The 12-epimer of scalarin, a metabolite of marine sponges of the genus Spongia.","InChI=1S/C27H40O5/c1-15(28)31-20-14-19-25(4)12-7-11-24(2,3)17(25)10-13-26(19,5)18-9-8-16-21(27(18,20)6)23(30)32-22(16)29/h8,17-21,23,30H,7,9-14H2,1-6H3/t17-,18-,19+,20+,21+,23+,25-,26-,27+/m0/s1",12-epi-scalarin,PubMed citation,17988093
7626,521021,4-(butylamino)benzoic acid,4-Aminobenzoic acid in which one of the hydrogens attached to the nitrogen is substituted by a butyl group.,"InChI=1S/C11H15NO2/c1-2-3-8-12-10-6-4-9(5-7-10)11(13)14/h4-7,12H,2-3,8H2,1H3,(H,13,14)",butyl-para-aminobenzoic acid,PubMed citation,17300161
7627,521393,"3,5-di-O-caffeoyl-muco-quinic acid",muco-Quinic acid in which the hydroxy functions at C-3 and C-5 have been esterified with trans-caffeic acid.,"InChI=1S/C25H24O12/c26-15-5-1-13(9-17(15)28)3-7-21(30)36-19-11-25(35,24(33)34)12-20(23(19)32)37-22(31)8-4-14-2-6-16(27)18(29)10-14/h1-10,19-20,23,26-29,32,35H,11-12H2,(H,33,34)/b7-3+,8-4+/t19-,20+,23+,25-","3,5-di-O-caffeoyl-muco-quinic acid",PubMed citation,18029179
7628,528918,1-O-(alpha-D-galactopyranosyl)-N-(10-phenyldecanoyl)phytosphingosine,A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and a 10-phenyldecanoyl group attached to the nitrogen.,"InChI=1S/C40H71NO9/c1-2-3-4-5-6-7-8-9-10-13-16-22-27-33(43)36(45)32(30-49-40-39(48)38(47)37(46)34(29-42)50-40)41-35(44)28-23-17-14-11-12-15-19-24-31-25-20-18-21-26-31/h18,20-21,25-26,32-34,36-40,42-43,45-48H,2-17,19,22-24,27-30H2,1H3,(H,41,44)/t32-,33+,34+,36-,37-,38-,39+,40-/m0/s1","N-((2S,3S,4R)-3,4-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yloxy)octadecan-2-yl)-10-phenyldecanamide",PubMed citation,17566107
7629,528967,1-O-(alpha-D-galactopyranosyl)-N-(6-phenylhexanoyl)phytosphingosine,A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and a 6-phenylhexanoyl group attached to the nitrogen.,"InChI=1S/C36H63NO9/c1-2-3-4-5-6-7-8-9-10-11-12-18-23-29(39)32(41)28(26-45-36-35(44)34(43)33(42)30(25-38)46-36)37-31(40)24-19-14-17-22-27-20-15-13-16-21-27/h13,15-16,20-21,28-30,32-36,38-39,41-44H,2-12,14,17-19,22-26H2,1H3,(H,37,40)/t28-,29+,30+,32-,33-,34-,35+,36-/m0/s1","N-((2S,3S,4R)-3,4-dihydroxy-1-((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2H-pyran-2-yloxy)octadecan-2-yl)-6-phenylhexanamide",PubMed citation,17566107
7630,530615,cidofovir(2-),The dianion obtained by removal of two protons from the phosphonic acid group of cidofovir.,"InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/p-2/t6-/m0/s1",cidofovir,PubMed citation,17438061
7631,533015,"3,3',5-triiodo-L-thyronine zwitterion","The amino acid zwitterion formed from 3,3',5-triiodo-L-thyronine by tranfer of a proton from the carboxy group to the amino group. It is the major species at pH 7.3.","InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1","(S)-2-Amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]-propionic acid",MetaCyc accession,CPD-10813
7632,553827,bambuterol,"A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.","InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3",Bambuterol,DrugBank accession,DB01408
7633,566519,"3,4,5-trimethoxycinnamic acid","A methoxycinnamic acid with three methoxy substituents at the 3-, 4- and 5-positions.","InChI=1S/C12H14O5/c1-15-9-6-8(4-5-11(13)14)7-10(16-2)12(9)17-3/h4-7H,1-3H3,(H,13,14)","3-(3,4,5-trimethoxyphenyl)acrylic acid",CAS Registry Number,90-50-6
7634,583099,ent-zingiberene,The enantiomer of zingiberine.,"InChI=1S/C15H24/c1-12(2)6-5-7-14(4)15-10-8-13(3)9-11-15/h6,8-10,14-15H,5,7,11H2,1-4H3/t14-,15+/m1/s1",alpha-zingiberene,Beilstein Registry Number,8392394
7635,604731,pyrraline,"A pyrrole having formyl and hydroxymethyl substituents at positions 2 and 5 respectively; useful as indicator of advanced stages of the Maillard reaction, which produces advanced glycation end-products (AGEs).","InChI=1S/C6H7NO2/c8-3-5-1-2-6(4-9)7-5/h1-3,7,9H,4H2",5-(hydroxymethyl)pyrrole-2-carboxaldehyde,PubMed citation,8717098
7636,608828,enfuvirtide,"A synthetic 36-amino acid peptide consisting of  N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.","InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1",enfuvirtide,PubMed citation,17485501
7637,681569,clofarabine,"A purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia.","InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1",clofarabine,KEGG DRUG accession,D03546
7638,681848,doxapram,"A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.","InChI=1S/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3",Doxapram,KEGG DRUG accession,D07873
7639,681850,conivaptan,"The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).","InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)",Conivaptan,PubMed citation,20070106
7640,724125,methyl 5-aminolevulinate,"The methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumulation of protoporphyrin IX in the skin lesions to which the cream has been applied. Subsequent illumination with red light results in the generation of toxic singlet oxygen that destroys cell membranes and thereby kills the tumour cells.","InChI=1S/C6H11NO3/c1-10-6(9)3-2-5(8)4-7/h2-4,7H2,1H3",Methyl aminolevulinate,CAS Registry Number,33320-16-0
7641,746859,travoprost,"The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.","InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1",Travoprost,DrugBank accession,DB00287
7642,340824,methyl dihydrogen phosphate,A monoalkyl phosphate having methyl as the alkyl group.,"InChI=1S/CH5O4P/c1-5-6(2,3)4/h1H3,(H2,2,3,4)",Phosphoric acid monomethyl ester,Beilstein Registry Number,1701224
7643,348530,thiouracil,A nucleobase analogue that is uracil in which the oxo group at C-2 is replaced by a thioxo group.,"InChI=1S/C4H4N2OS/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)",2-Mercapto-pyrimidin-4-ol,PubMed citation,8978847
7644,355510,cefotiam,"A cephalosporin with ({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}sulfanyl)methyl and (2-amino-1,3-thiazol-4-yl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. A third generation beta-lactam cephalosporin antibiotic, it is active against a broad spectrum of both Gram positive and Gram negative bacteria.","InChI=1S/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1","(6R,7R)-7-[2-(2-Amino-thiazol-4-yl)-acetylamino]-3-[1-(2-dimethylamino-ethyl)-1H-tetrazol-5-ylsulfanylmethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid",PubMed citation,6341590
7645,356010,5-aminopentanoic acid zwitterion,Zwitterionic form of 5-aminopentanoic acid having an anionic carboxy group and a protonated amino group.,"InChI=1S/C5H11NO2/c6-4-2-1-3-5(7)8/h1-4,6H2,(H,7,8)",5-ammoniopentanoate,Gmelin Registry Number,1042689
7646,356416,5-ammoniolevulinate,The zwitterion formed from 5-aminolevulinic acid by transfer of a proton from the carboxy group to the amino group.  It is the major species present at physiological pH.,"InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)",5-ammonio-4-oxopentanoate,PubMed citation,14667225
7647,356445,glycylglycine zwitterion,The zwitterion from the dipeptide glycylglycine formed by proton transfer from the OH of the carboxy group to the terminal amino group.,"InChI=1S/C4H8N2O3/c5-1-3(7)6-2-4(8)9/h1-2,5H2,(H,6,7)(H,8,9)",[(ammonioacetyl)amino]acetate,PubMed citation,14667225
7648,357241,glycinexylidide,"A amino acid amide with 2,6-dimethylaniline and glycine components; an active metabolite of lidocaine, formed by oxidative deethylation. Used as an indicator of hepatic function.","InChI=1S/C10H14N2O/c1-7-4-3-5-8(2)10(7)12-9(13)6-11/h3-5H,6,11H2,1-2H3,(H,12,13)","2-Amino-N-(2,6-dimethyl-phenyl)-acetamide",KEGG COMPOUND accession,C16569
7649,364453,carprofen,"Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.","InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19)",(+/-)-2-(3-chloro-9H-carbazol-7-yl)propanoic acid,PubMed citation,17181139
7650,365445,O-(cyclohexanecarbonyl)lysergol maleate,The hydrogenmaleate salt of O-(cyclohexanecarbonyl)lysergol.,"InChI=1S/C23H28N2O2.C4H4O4/c1-25-13-15(14-27-23(26)16-6-3-2-4-7-16)10-19-18-8-5-9-20-22(18)17(12-24-20)11-21(19)25;5-3(6)1-2-4(7)8/h5,8-10,12,15-16,21,24H,2-4,6-7,11,13-14H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-,21-;/m1./s1","Cyclohexanecarboxylic acid (6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinolin-9-ylmethyl ester; compound with (Z)-but-2-enedioic acid",PubMed citation,10052973
7651,388118,N-acetyl-L-tyrosylglycylglycine,A tripeptide consisting of AcTyrGlyGly.,"InChI=1S/C15H19N3O6/c1-9(19)18-12(6-10-2-4-11(20)5-3-10)15(24)17-7-13(21)16-8-14(22)23/h2-5,12,20H,6-8H2,1H3,(H,16,21)(H,17,24)(H,18,19)(H,22,23)/t12-/m0/s1",{2-[2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-acetylamino}-acetic acid,Beilstein Registry Number,4563737
7652,391960,darifenacin,"2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a  2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.","InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1",DARIFENACIN,PubMed citation,11831911
7653,405237,L-canavanine zwitterion,L-Canavanine in zwitterionic form.,"InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-12-9-5(7)8/h3H,1-2,6H2,(H,10,11)(H4,7,8,9)/t3-/m0/s1",L-Canavanine,MetaCyc accession,CANAVANINE
7654,421840,O-methylsalicylic acid,A  methoxybenzoic acid that is the methyl ether of salicylic acid.,"InChI=1S/C8H8O3/c1-11-7-5-3-2-4-6(7)8(9)10/h2-5H,1H3,(H,9,10)",2-Methoxy-benzoic acid,Beilstein Registry Number,509929
7655,425902,propiophenone,An aromatic ketone in which the two substituents on the carbonyl C atom are phenyl and ethyl.,"InChI=1S/C9H10O/c1-2-9(10)8-6-4-3-5-7-8/h3-7H,2H2,1H3",1-Phenyl-propan-1-one,CAS Registry Number,93-55-0
7656,474014,dirithromycin,"The hemi-aminal resulting from the condensation of the erythromycin derivative (9S)-erythromycyclamine with 2-(2-methoxyethoxy)acetaldehyde. As the oxazine ring containing the hemi-aminal group is unstable under both acidic and alkaline conditions, dirithromycin functions as a more lipid-soluble prodrug for (9S)-erythromycyclamine. Administered as enteric coated tablets to protect it from acid catalysed hydrolysis in the stomach, it is used to treat respiratory tract, skin, and soft tissue infections caused by susceptible organisms.","InChI=1S/C42H78N2O14/c1-15-29-42(10,49)37-24(4)32(43-30(56-37)21-52-17-16-50-13)22(2)19-40(8,48)36(58-39-33(45)28(44(11)12)18-23(3)53-39)25(5)34(26(6)38(47)55-29)57-31-20-41(9,51-14)35(46)27(7)54-31/h22-37,39,43,45-46,48-49H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,30-,31+,32+,33-,34+,35+,36-,37-,39+,40-,41-,42-/m1/s1",dirithromycin,KEGG DRUG accession,D03865
7657,487869,clavulanate,The conjugate base of clavulanic acid.,"InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/p-1/b4-1-/t6-,7-/m1/s1","(2R,5R,Z)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-aza-bicyclo[3.2.0]heptane-2-carboxylate",PubMed citation,25492589
7658,495056,gamma-cyclodextrin,A cycloamylose composed of eight alpha-(1->4) linked D-glucopyranose units.,"InChI=1S/C48H80O40/c49-1-9-33-17(57)25(65)41(73-9)82-34-10(2-50)75-43(27(67)19(34)59)84-36-12(4-52)77-45(29(69)21(36)61)86-38-14(6-54)79-47(31(71)23(38)63)88-40-16(8-56)80-48(32(72)24(40)64)87-39-15(7-55)78-46(30(70)22(39)62)85-37-13(5-53)76-44(28(68)20(37)60)83-35-11(3-51)74-42(81-33)26(66)18(35)58/h9-72H,1-8H2/t9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-/m1/s1",gamma-cyclodextrin,PubMed citation,17234420
7659,503442,gallamine,"A tertiary amine non-depolarising muscle relaxant whose structure comprises a core benzene molecule substituted at each of C-1, C-2 and C-3 by an N,N-diethyl-2-(ethylamino)ethoxy group.","InChI=1S/C24H45N3O3/c1-7-25(8-2)16-19-28-22-14-13-15-23(29-20-17-26(9-3)10-4)24(22)30-21-18-27(11-5)12-6/h13-15H,7-12,16-21H2,1-6H3","2-(2,6-bis(2-(diethylamino)ethoxy)phenoxy)-N,N-diethylethanamine",CAS Registry Number,153-76-4
7660,519567,2'-O-methylisoliquiritigenin,A member of the class of chalcones that is isoliquiritigenin in which one of the hydroxy groups at position 2' is replaced by a methoxy group.,"InChI=1S/C16H14O4/c1-20-16-10-13(18)7-8-14(16)15(19)9-4-11-2-5-12(17)6-3-11/h2-10,17-18H,1H3/b9-4+","4,4'-dihydroxy-2'-methoxychalcone",KEGG COMPOUND accession,C15531
7661,193028,okaramine C,An indole alkaloid isolated from Penicillium simplicissimum. It exhibits insecticidal activity.,"InChI=1S/C32H36N4O3/c1-7-30(3,4)26-20(19-13-9-11-15-22(19)33-26)17-23-28(38)35-25(27(37)34-23)18-32(39)21-14-10-12-16-24(21)36(29(32)35)31(5,6)8-2/h7-16,23,25,29,33,39H,1-2,17-18H2,3-6H3,(H,34,37)/t23-,25-,29-,32-/m0/s1",(+)-okaramine C,PubMed citation,15326519
7662,193030,alpha-D-Manp-(1->3)-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc,An amino tetrasaccharide that is beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc in which the hydroxy group at position 3 of the mannosyl group has been glycosylated by an alpha-D-mannopyranosyl residue.,"InChI=1S/C28H48N2O21/c1-7(35)29-13-17(39)22(11(5-33)45-25(13)44)49-26-14(30-8(2)36)18(40)23(12(6-34)48-26)50-28-21(43)24(16(38)10(4-32)47-28)51-27-20(42)19(41)15(37)9(3-31)46-27/h9-28,31-34,37-44H,3-6H2,1-2H3,(H,29,35)(H,30,36)/t9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19+,20+,21+,22-,23-,24+,25-,26+,27-,28+/m1/s1",alpha-D-mannosyl-(1->3)-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine,PubMed citation,32568414
7663,195280,artemether,An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.,"InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1","10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane",PubMed citation,3279208
7664,207229,dihydroartemisinin,A sesquiterpenoid compound which is used as a drug for treatment of malaria.,"InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12?,13-,14-,15-/m1/s1","1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol(Dihydroartemisinin)",PubMed citation,10893313
7665,207496,furfuryl alcohol,A furan bearing a hydroxymethyl substituent at the 2-position.,"InChI=1S/C5H6O2/c6-4-5-2-1-3-7-5/h1-3,6H,4H2",Furan-2-yl-methanol,PubMed citation,15081000
7666,221278,(R)-nipecotic acid,The (R)-enantiopmer of nipecotic acid.,"InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)/t5-/m1/s1",(R)-piperidine-3-carboxylic acid,Beilstein Registry Number,81097
7667,222169,(S)-nipecotic acid,The (S)-enantiomer of nipecotic acid.,"InChI=1S/C6H11NO2/c8-6(9)5-2-1-3-7-4-5/h5,7H,1-4H2,(H,8,9)/t5-/m0/s1",(S)-Piperidine-3-carboxylic acid,Beilstein Registry Number,81098
7668,224366,tert-butylammonium,The cation resulting from the protonation of the nitrogen atom of tert-butylamine.,"InChI=1S/C4H11N/c1-4(2,3)5/h5H2,1-3H3/p+1",tert-Butyl-ammonium,MetaCyc accession,CPD-15151
7669,233869,4-(phenylazo)aniline,Azobenzene substituted at one of the 4-positions by an amino group. It has a role as a dye and an allergen.,"InChI=1S/C12H11N3/c13-10-6-8-12(9-7-10)15-14-11-4-2-1-3-5-11/h1-9H,13H2/b15-14+",4-Phenylazo-phenylamine,PubMed citation,7265110
7670,238698,bevantolol,"A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.","InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3","1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-ol",CAS Registry Number,59170-23-9
7671,239133,salicylanilide,An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.,"InChI=1S/C13H11NO2/c15-12-9-5-4-8-11(12)13(16)14-10-6-2-1-3-7-10/h1-9,15H,(H,14,16)",SALICYLANILIDE,CAS Registry Number,87-17-2
7672,240107,bromfenac,"Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.","InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)",[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid,CAS Registry Number,91714-94-2
7673,245199,"2,2':6',2''-terpyridine",A tridentate heterocyclic ligand that binds metals at three meridional sites giving two adjacent 5-membered MN2C2 chelate rings.,InChI=1S/C15H11N3/c1-3-10-16-12(6-1)14-8-5-9-15(18-14)13-7-2-4-11-17-13/h1-11H,"2,6-di(pyridin-2-yl)pyridine",CAS Registry Number,1148-79-4
7674,269574,abamine,"An amino acid ester that is methyl glycine in which one of hydrogens attached to the nitrogen is remplaced by a 4-fluorobenzyl group while the other is replaced by a 3,4-dimethoxycinnamyl group.","InChI=1S/C21H24FNO4/c1-25-19-11-8-16(13-20(19)26-2)5-4-12-23(15-21(24)27-3)14-17-6-9-18(22)10-7-17/h4-11,13H,12,14-15H2,1-3H3/b5-4+","[[(E)-3-(3,4-Dimethoxy-phenyl)-allyl]-(4-fluoro-benzyl)-amino]-acetic acid methyl ester",PubMed citation,15149639
7675,277842,amphotericin B methyl ester,The methyl ester of amphotericin B.,"InChI=1S/C48H75NO17/c1-28-18-16-14-12-10-8-6-7-9-11-13-15-17-19-35(65-47-45(59)42(49)44(58)31(4)64-47)25-39-41(46(60)62-5)38(55)27-48(61,66-39)26-34(52)23-37(54)36(53)21-20-32(50)22-33(51)24-40(56)63-30(3)29(2)43(28)57/h6-19,28-39,41-45,47,50-55,57-59,61H,20-27,49H2,1-5H3/b7-6+,10-8+,11-9+,14-12+,15-13+,18-16+,19-17+/t28-,29-,30-,31+,32+,33+,34-,35-,36+,37+,38-,39-,41+,42-,43+,44+,45-,47-,48+/m0/s1",Amphotericin B Me Ester,CAS Registry Number,36148-89-7
7676,280152,LY-221481,"A pyrazolopyrazole that is 6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazole-3-carboxylic acid which has been substituted at positions 2, 5 and 6 by methylsulfonyl, oxo, and amino groups, respectively, and in which the amino group has been condensed with the carboxy group of (2-amino-1,3-thiazol-4-yl)(oxo)acetic acid, the oxo group of which has been converted to the corresponding oxime O-allyl ether.","InChI=1S/C16H18N6O7S2/c1-3-4-29-20-11(9-7-30-16(17)19-9)13(23)18-8-5-21-6-10(31(2,27)28)12(15(25)26)22(21)14(8)24/h3,7-8H,1,4-6H2,2H3,(H2,17,19)(H,18,23)(H,25,26)/b20-11-/t8-/m0/s1",LY-221481,PubMed citation,8230112
7677,291342,desloratadine,"Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an  antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.","InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2","8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine",PubMed citation,9934454
7678,291902,eptifibatide,"A synthetic homodetic cyclic peptide comprising N(alpha)-(3-sulfanylpropanoyl)homoarginyl, glycyl, aspartyl, tryptophyl, prolyl and cysteinamide residues connected in sequence and cyclised via a disulfide bond. Derived from a protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarus barbouri, eptifibatide is an anti-coagulant that inhibits platelet aggregation by selectively blocking the platelet glycoprotein IIb/IIIa receptor, so preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. It is used in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures.","InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1",EPTIFIBATIDE,KEGG DRUG accession,D06888
7679,309594,oxybuprocaine,"A benzoate ester in which 4-amino-3-butoxybenzoic acid and 2-(diethylamino)ethanol have combined to form the ester bond; an ester-based local anaesthetic (ester ""caine"") used especially in ophthalmology and otolaryngology.","InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3",4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester,DrugBank accession,DB00892
7680,192494,alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-{alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)}-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,A branched amino oligosaccharide that is a tetradecasaccharide derivative in which two alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl tetrasaccharide units are linked (1->3) and (1->6) to the mannose residue of a beta-D-xylosyl-(1->2)-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->3)]-[alpha-L-fucosyl-(1->6)]-N-acetyl-beta-D-glucosamine hexasaccharide.,"InChI=1S/C91H152N4O66/c1-19-41(108)52(119)61(128)82(138-19)136-18-36-70(71(38(78(134)142-36)93-24(6)104)155-84-62(129)53(120)42(109)20(2)139-84)152-79-37(92-23(5)103)51(118)67(32(13-100)147-79)151-91-77(161-83-60(127)45(112)27(107)16-135-83)74(158-90-76(59(126)49(116)31(12-99)146-90)160-81-40(95-26(8)106)73(157-86-64(131)55(122)44(111)22(4)141-86)69(34(15-102)149-81)154-88-66(133)57(124)47(114)29(10-97)144-88)50(117)35(150-91)17-137-89-75(58(125)48(115)30(11-98)145-89)159-80-39(94-25(7)105)72(156-85-63(130)54(121)43(110)21(3)140-85)68(33(14-101)148-80)153-87-65(132)56(123)46(113)28(9-96)143-87/h19-22,27-91,96-102,107-134H,9-18H2,1-8H3,(H,92,103)(H,93,104)(H,94,105)(H,95,106)/t19-,20-,21-,22-,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45-,46-,47-,48+,49+,50+,51+,52+,53+,54+,55+,56-,57-,58-,59-,60+,61-,62-,63-,64-,65+,66+,67+,68+,69+,70+,71+,72+,73+,74-,75-,76-,77-,78+,79-,80-,81-,82+,83-,84-,85-,86-,87-,88-,89-,90+,91-/m0/s1",alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-{alpha-L-fucosyl-(1->3)-[beta-D-galactosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)}-[beta-D-xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->3)]-[alpha-L-fucosyl-(1->6)]-N-acetyl-beta-D-glucosamine,PubMed citation,32568414
7681,192495,beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GalpNAc-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->3)]-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,A branched amino oligosaccharide that is a dodecasaccharide derivative consisting of a beta-D-GlcNAc residue at the reducing end with a beta-D-GalNAc-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->3)-[beta-D-GalNAc-(1->4)-beta-D-GlcNAc-(1->2)-alpha-D-Man-(1->6)]-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a beta-(1->4) linkage and with two alpha-L-fucosyl residues attached via (1->3) and (1->6) linkages.,"InChI=1S/C83H138N6O58/c1-19-43(104)56(117)61(122)78(128-19)126-18-36-66(67(42(72(124)130-36)89-26(8)102)143-80-62(123)57(118)44(105)20(2)129-80)142-75-39(86-23(5)99)55(116)65(34(15-96)135-75)141-83-71(147-79-60(121)45(106)27(103)16-125-79)68(144-82-70(59(120)49(110)31(12-93)134-82)146-77-41(88-25(7)101)54(115)64(33(14-95)137-77)140-74-38(85-22(4)98)52(113)47(108)29(10-91)132-74)50(111)35(138-83)17-127-81-69(58(119)48(109)30(11-92)133-81)145-76-40(87-24(6)100)53(114)63(32(13-94)136-76)139-73-37(84-21(3)97)51(112)46(107)28(9-90)131-73/h19-20,27-83,90-96,103-124H,9-18H2,1-8H3,(H,84,97)(H,85,98)(H,86,99)(H,87,100)(H,88,101)(H,89,102)/t19-,20-,27+,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45-,46-,47-,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58-,59-,60+,61-,62-,63+,64+,65+,66+,67+,68-,69-,70-,71-,72+,73-,74-,75-,76-,77-,78+,79-,80-,81-,82+,83-/m0/s1",N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->3)-[N-acetyl-beta-D-galactosaminyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl-(1->6)]-[beta-D-xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)-[alpha-L-fucosyl-(1->3)]-[alpha-L-fucosyl-(1->6)]-N-acetyl-beta-D-glucosamine,PubMed citation,32568414
7682,192524,7-methylmellein,An isochromane that is mellein bearing an additional methyl substituent at position 7.,"InChI=1S/C11H12O3/c1-6-3-4-8-5-7(2)14-11(13)9(8)10(6)12/h3-4,7,12H,5H2,1-2H3","8-hydroxy-3,7-dimethyl-3,4-dihydroisochromen-1-one",PubMed citation,30054361
7683,192531,(19Z)-geissoschizine,An indole alkaloid with formula C21H24N2O3.,"InChI=1S/C21H24N2O3/c1-3-13-11-23-9-8-15-14-6-4-5-7-18(14)22-20(15)19(23)10-16(13)17(12-24)21(25)26-2/h3-7,12,16,19,22,24H,8-11H2,1-2H3/b13-3+,17-12-/t16-,19-/m0/s1",19Z-geissoschizine,PubMed citation,29147812
7684,192780,pentafluorobenzyl bromide,"A member of the class benzyl bromides that is benzyl bromide in which the hydrogens at positions 2, 3, 4, 5 and 6 of the phenyl ring are replaced by fluoro groups. It is a versatile derivatization agent in chromatography and mass spectrometry.",InChI=1S/C7H2BrF5/c8-1-2-3(9)5(11)7(13)6(12)4(2)10/h1H2,PFBBr,CAS Registry Number,1765-40-8
7685,192806,alpha-L-Fucp-(1->3)-alpha-D-GlcpNAcOMe,A methyl glycoside that is alpha-L-fucopyranosyl-(1->3)-2-acetamido-2-deoxy-alpha-D-glucopyranose in which the anomeric hydroxy group is replaced by methoxy.,"InChI=1S/C15H27NO10/c1-5-9(19)11(21)12(22)15(24-5)26-13-8(16-6(2)18)14(23-3)25-7(4-17)10(13)20/h5,7-15,17,19-22H,4H2,1-3H3,(H,16,18)/t5-,7+,8+,9+,10+,11+,12-,13+,14-,15-/m0/s1",Fucalpha1-3GlcNAcalpha1-OMe,PubMed citation,35726192
7686,192973,PYR-41,"An ethyl ester resulting from the formal condensation of the carboxy group of 4-{4-[(5-nitrofuran-2-yl)methylidene]-3,5-dioxopyrazolidin-1-yl}benzoic acid with ethanol. It is an irreversible and cell-permeable inhibitor of ubiquitin-activating enzyme E1.","InChI=1S/C17H13N3O7/c1-2-26-17(23)10-3-5-11(6-4-10)19-16(22)13(15(21)18-19)9-12-7-8-14(27-12)20(24)25/h3-9H,2H2,1H3,(H,18,21)",UBEI-41,CAS Registry Number,418805-02-4
7687,90,(-)-epicatechin,"A catechin with (2R,3R)-configuration.","InChI=1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m1/s1",(-)-Epicatechin,CAS Registry Number,490-46-0
7688,776,16alpha-hydroxyestrone,The 16alpha-hydroxy derivative of estrone; a minor estrogen metabolite.,"InChI=1S/C18H22O3/c1-18-7-6-13-12-5-3-11(19)8-10(12)2-4-14(13)15(18)9-16(20)17(18)21/h3,5,8,13-16,19-20H,2,4,6-7,9H2,1H3/t13-,14-,15+,16-,18+/m1/s1",16alpha-Hydroxyestrone,CAS Registry Number,566-76-7
7689,943,"2,6-dichlorobenzonitrile","A nitrile that is benzonitrile which is substituted by chlorines at positions 2 and 6. A cellulose synthesis inhibitor, it is used as a pre-emergent and early post-emergent herbicide.",InChI=1S/C7H3Cl2N/c8-6-2-1-3-7(9)5(6)4-10/h1-3H,"2,6-Dichlorobenzonitrile",KEGG COMPOUND accession,C11040
7690,1148,2-hydroxybutyric acid,A hydroxybutyric acid having a single hydroxyl group located at position 2; urinary secretion of 2-hydroxybutyric acid is increased with alcohol ingestion or vigorous physical exercise and is associated with lactic acidosis and ketoacidosis in humans and diabetes in animals.,"InChI=1S/C4H8O3/c1-2-3(5)4(6)7/h3,5H,2H2,1H3,(H,6,7)",2-Hydroxybutyric acid,KEGG COMPOUND accession,C05984
7691,1233,"3-(all-trans-octaprenyl)benzene-1,2-diol","A 3-(all-trans-polyprenyl)benzene-1,2-diol in which the substituent at position 3 is an all-trans-octaprenyl moiety.","InChI=1S/C46H70O2/c1-36(2)18-10-19-37(3)20-11-21-38(4)22-12-23-39(5)24-13-25-40(6)26-14-27-41(7)28-15-29-42(8)30-16-31-43(9)34-35-44-32-17-33-45(47)46(44)48/h17-18,20,22,24,26,28,30,32-34,47-48H,10-16,19,21,23,25,27,29,31,35H2,1-9H3/b37-20+,38-22+,39-24+,40-26+,41-28+,42-30+,43-34+",2-Octaprenyl-6-hydroxyphenol,KEGG COMPOUND accession,C05811
7692,1296,20-hydroxycholesterol,An oxysterol that is cholesterol substituted by a hydroxy group at position 20.,"InChI=1S/C27H46O2/c1-18(2)7-6-14-27(5,29)24-11-10-22-21-9-8-19-17-20(28)12-15-25(19,3)23(21)13-16-26(22,24)4/h8,18,20-24,28-29H,6-7,9-17H2,1-5H3/t20-,21-,22-,23-,24-,25-,26-,27-/m0/s1",20alpha-Hydroxycholesterol,KEGG COMPOUND accession,C05500
7693,1712,3alpha-hydroxy-5beta-pregnan-20-one,The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.,"InChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15-,16+,17-,18+,19+,20+,21-/m1/s1",3alpha-Hydroxy-5beta-pregnane-20-one,KEGG COMPOUND accession,C05480
7694,1734,4'-O-methylisoflavone,The simplest member of the class of 4'methoxyisoflavones that is isoflavone substituted by a methoxy group at position 4'.,"InChI=1S/C16H12O3/c1-18-12-8-6-11(7-9-12)14-10-19-15-5-3-2-4-13(15)16(14)17/h2-10H,1H3",4'-O-Methylisoflavone,KEGG COMPOUND accession,C03074
7695,1895,4-methylbenzyl alcohol,A methylbenzyl alcohol in which the methyl substituent is para to the hydroxymethyl group.,"InChI=1S/C8H10O/c1-7-2-4-8(6-9)5-3-7/h2-5,9H,6H2,1H3",4-Methylbenzyl alcohol,CAS Registry Number,589-18-4
7696,2030,5-aminoimidazole-4-carboxamide,An aminoimidazole in which the amino group is at C-5 with a carboxamido group at C-4.,"InChI=1S/C4H6N4O/c5-3-2(4(6)9)7-1-8-3/h1H,5H2,(H2,6,9)(H,7,8)",5-Amino-4-imidazolecarboxyamide,KEGG COMPOUND accession,C04051
7697,2303,"8-(1,1-dimethylallyl)galangin","A trihydroxyflavone that is galangin substituted by a 1,1-dimethylallyl moiety at position 8. It is isolated from the buds of Platanus acerifolia.","InChI=1S/C20H18O5/c1-4-20(2,3)15-13(22)10-12(21)14-16(23)17(24)18(25-19(14)15)11-8-6-5-7-9-11/h4-10,21-22,24H,1H2,2-3H3","8-(1,1-Dimethylallyl)galangin",KEGG COMPOUND accession,C11581
7698,2365,(+)-abscisic acid,The naturally occurring (1'S)-(+) enantiomer of abscisic acid. It is an important sesquiterpenoid plant hormone which acts as a regulator of plant responses to environmental stresses such as drought and cold.,"InChI=1S/C15H20O4/c1-10(7-13(17)18)5-6-15(19)11(2)8-12(16)9-14(15,3)4/h5-8,19H,9H2,1-4H3,(H,17,18)/b6-5+,10-7-/t15-/m1/s1",Abscisic acid,CAS Registry Number,21293-29-8
7699,2469,adefovir,"A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.","InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)",Adefovir,PDBeChem accession,5HG
7700,2631,amentoflavone,A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-3 of the hydroxyphenyl ring and C-8 of the chromene ring.  A natural product found  particularly in Ginkgo biloba and Hypericum perforatum.,"InChI=1S/C30H18O10/c31-15-4-1-13(2-5-15)24-12-23(38)29-21(36)10-20(35)27(30(29)40-24)17-7-14(3-6-18(17)33)25-11-22(37)28-19(34)8-16(32)9-26(28)39-25/h1-12,31-36H","3',8''-Biapigenin",KEGG COMPOUND accession,C10018
7701,2639,amiloride,"A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.","InChI=1S/C6H8ClN7O/c7-2-4(9)13-3(8)1(12-2)5(15)14-6(10)11/h(H4,8,9,13)(H4,10,11,14,15)",Amiloride,KEGG COMPOUND accession,C06821
7702,2676,amoxicillin,A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.,"InChI=1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1",Amoxicillin,KEGG COMPOUND accession,C06827
7703,2700,anandamide,An N-acylethanolamine 20:4 resulting from the formal condensation of carboxy group of arachidonic acid with the amino group of ethanolamine.,"InChI=1S/C22H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-22(25)23-20-21-24/h6-7,9-10,12-13,15-16,24H,2-5,8,11,14,17-21H2,1H3,(H,23,25)/b7-6-,10-9-,13-12-,16-15-",Anandamide,KEGG COMPOUND accession,C11695
7704,2762,antimycin A,"A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.","InChI=1S/C28H40N2O9/c1-6-7-8-9-11-20-25(39-22(32)14-16(2)3)18(5)38-28(36)23(17(4)37-27(20)35)30-26(34)19-12-10-13-21(24(19)33)29-15-31/h10,12-13,15-18,20,23,25,33H,6-9,11,14H2,1-5H3,(H,29,31)(H,30,34)/t17-,18+,20-,23+,25+/m1/s1",Antimycin A1,KEGG COMPOUND accession,C11339
7705,2790,apramycin,"An aminoglycoside that is 2-deoxystreptamine that is substituted on the oxygen at position 4 by an (8R)-2-amino-8-O-(4-amino-4-deoxy-alpha-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-D-glycero-alpha-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl) group.","InChI=1S/C21H41N5O11/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31/h5-21,26-32H,2-4,22-25H2,1H3/t5-,6+,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17-,18+,19+,20-,21-/m1/s1",Apramycin,KEGG COMPOUND accession,C01555
7706,2873,asiatic acid,"A pentacyclic triterpenoid that is ursane substituted by a carboxy group at position 28 and hydroxy groups at positions 2, 3 and 23 (the 2alpha,3beta stereoisomer). It is isolated from Symplocos lancifolia and Vateria indica and exhibits anti-angiogenic activity.","InChI=1S/C30H48O5/c1-17-9-12-30(25(34)35)14-13-28(5)19(23(30)18(17)2)7-8-22-26(3)15-20(32)24(33)27(4,16-31)21(26)10-11-29(22,28)6/h7,17-18,20-24,31-33H,8-16H2,1-6H3,(H,34,35)/t17-,18+,20-,21-,22-,23+,24+,26+,27+,28-,29-,30+/m1/s1",Asiatic acid,KEGG COMPOUND accession,C08617
7707,2877,aspartame,A dipeptide obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the amino group of methyl L-phenylalaninate. Commonly used as an artificial sweetener.,"InChI=1S/C14H18N2O5/c1-21-14(20)11(7-9-5-3-2-4-6-9)16-13(19)10(15)8-12(17)18/h2-6,10-11H,7-8,15H2,1H3,(H,16,19)(H,17,18)/t10-,11-/m0/s1",Aspartame,CAS Registry Number,22839-47-0
7708,2914,atracurium,"A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.","InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2",Atracurium,CAS Registry Number,64228-79-1
7709,3008,bellidifolin,A member of the xanthone family that is bellidin substituted with a methyl group at O-3.  A natural product found  particularly in Swertia chirata and Gentianella campestris.,"InChI=1S/C14H10O6/c1-19-6-4-9(17)11-10(5-6)20-14-8(16)3-2-7(15)12(14)13(11)18/h2-5,15-17H,1H3","3-Methoxy-1,5,8-trihydroxyxanthone",KEGG COMPOUND accession,C10053
7710,3013,bendroflumethiazide,"A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.","InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)",Bendroflumethiazide,CAS Registry Number,73-48-3
7711,3048,benzatropine,"Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.","InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+",Benztropine,CAS Registry Number,86-13-5
7712,3084,bethanechol,"The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.","InChI=1S/C7H16N2O2/c1-6(11-7(8)10)5-9(2,3)4/h6H,5H2,1-4H3,(H-,8,10)/p+1",Bethanechol,KEGG COMPOUND accession,C06850
7713,3087,betulinic acid,"A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-carboxy substituents. It is found in the bark and other plant parts of several species of plants including Syzygium claviflorum. It exhibits anti-HIV, antimalarial, antineoplastic and anti-inflammatory properties.","InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1",Betulinic acid,KEGG COMPOUND accession,C08619
7714,3139,bleomycin A2,,"InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41-,42-,43-,53+,54-/m0/s1",Bleomycin A2,KEGG COMPOUND accession,C06854
7715,3176,brinzolamide,,"InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1",Brinzolamide,CAS Registry Number,138890-62-7
7716,3183,brompheniramine,"Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.","InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3",Brompheniramine,KEGG COMPOUND accession,C06857
7717,3216,buprenorphine,"A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is substituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group. It is highly effective for the treatment of opioid use disorder and is also increasingly being used in the treatment of chronic pain.","InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1",Buprenorphine,KEGG COMPOUND accession,C08007
7718,3238,butenafine,"Trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections.","InChI=1S/C23H27N/c1-23(2,3)21-14-12-18(13-15-21)16-24(4)17-20-10-7-9-19-8-5-6-11-22(19)20/h5-15H,16-17H2,1-4H3",Butenafine,CAS Registry Number,101828-21-1
7719,3240,butoconazole,"A member of the class of imidazoles that is 1H-imidazole in which the hydrogen attached to the nitrogen is substituted by a 4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)sulfanyl]butyl group. An antifungal agent, it is used as its nitrate salt in gynaecology for treatment of vulvovaginal infections caused by Candida species, particularly Candida albicans.","InChI=1S/C19H17Cl3N2S/c20-15-7-4-14(5-8-15)6-9-16(12-24-11-10-23-13-24)25-19-17(21)2-1-3-18(19)22/h1-5,7-8,10-11,13,16H,6,9,12H2",Butoconazole,KEGG COMPOUND accession,C08065
7720,3242,butorphanol,"Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.","InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1",Butorphanol,CAS Registry Number,42408-82-2
7721,3252,C-1027 chromophore,An enediyne antibiotic that has formula C43H42ClN3O13. It is a natural product found in Streptomyces globisporus and exhibits antimicrobial and antineoplastic properties.,"InChI=1S/C43H42ClN3O13/c1-21-39(52)46-34-26(17-25(54-6)18-30(34)56-21)40(53)57-31-20-55-33(49)19-28(45)23-15-27(44)37(29(48)16-23)58-32-11-7-9-22(31)12-13-24-10-8-14-43(24,32)60-41-36(51)35(50)38(47(4)5)42(2,3)59-41/h8-10,14-18,28,31-32,35-36,38,41,48,50-51H,1,19-20,45H2,2-6H3,(H,46,52)/b22-9+/t28-,31-,32+,35-,36+,38-,41-,43+/m0/s1",C-1027 chromophore,KEGG COMPOUND accession,C11438
7722,3303,calcein am,An organic heteropentacyclic compound that is  calcein in which all four carboxy group hydrogens have been substituted by (acetyloxy)methoxy groups and the hyrodgens of the two hydroxy groups have been substituted by acetyl groups. It is a a non-fluorescent probe cleaved to a fluorescent probe by non-specific intracellular esterases.,"InChI=1S/C46H46N2O23/c1-25(49)60-21-64-41(55)17-47(18-42(56)65-22-61-26(2)50)15-31-11-35-39(13-37(31)68-29(5)53)70-40-14-38(69-30(6)54)32(12-36(40)46(35)34-10-8-7-9-33(34)45(59)71-46)16-48(19-43(57)66-23-62-27(3)51)20-44(58)67-24-63-28(4)52/h7-14H,15-24H2,1-6H3",Calcein AM,CAS Registry Number,148504-34-1
7723,3319,calicheamicin gamma1(I),"A calcheamicin in which contains 3-O-methyl-alpha-L-rhamnosyl, 2,6-dideoxy-4-thio-beta-D-ribo-hexopyranosyl, and 4-amino-4,6-dideoxy-2-O-[2,4-dideoxy-4-(ethylamino)-3-O-methyl-alpha-L-threo-pentopyranosyl]-alpha-L-idopyranose units and in which the aromatic ring contains an iodo substituent.","InChI=1S/C55H74IN3O21S4/c1-12-57-30-24-73-35(22-34(30)68-6)78-48-43(63)40(26(3)75-53(48)77-33-17-15-13-14-16-19-55(67)23-32(61)41(58-54(66)72-10)38(33)29(55)18-20-82-84-81-11)59-80-36-21-31(60)50(28(5)74-36)83-51(65)37-25(2)39(56)46(49(71-9)45(37)69-7)79-52-44(64)47(70-8)42(62)27(4)76-52/h13-14,18,26-28,30-31,33-36,40,42-44,47-48,50,52-53,57,59-60,62-64,67H,12,20-24H2,1-11H3,(H,58,66)/b14-13-,29-18+/t26-,27-,28+,30-,31-,33-,34-,35-,36-,40+,42-,43-,44+,47+,48+,50+,52-,53-,55-/m0/s1",Calicheamicin gamma(1)I,KEGG COMPOUND accession,C11469
7724,3354,candoxatrilat,"A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy)propyl]cyclopentanecarboxylic acid. A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure.","InChI=1S/C20H33NO7/c1-27-10-11-28-13-15(18(24)25)12-20(8-2-3-9-20)19(26)21-16-6-4-14(5-7-16)17(22)23/h14-16H,2-13H2,1H3,(H,21,26)(H,22,23)(H,24,25)/t14-,15-,16+/m0/s1",Candoxatrilat,CAS Registry Number,123898-42-0
7725,3398,carbinoxamine,"An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.","InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3",Carbinoxamine,CAS Registry Number,486-16-8
7726,3419,carisoprodol,"A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol  interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.","InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)",Carisoprodol,KEGG COMPOUND accession,C07927
7727,3478,cefaclor,"A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.","InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1",Cefaclor,CAS Registry Number,53994-73-3
7728,3493,cefoperazone,A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.,"InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1",Cefoperazone,KEGG COMPOUND accession,C06883
7729,3499,cefotetan,"A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and  {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.","InChI=1S/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/b12-6-/t13?,15-,17+/m1/s1",Cefotetan,KEGG COMPOUND accession,C06886
7730,3537,cefaloridine,A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.,"InChI=1S/C19H17N3O4S2/c23-14(9-13-5-4-8-27-13)20-15-17(24)22-16(19(25)26)12(11-28-18(15)22)10-21-6-2-1-3-7-21/h1-8,15,18H,9-11H2,(H-,20,23,25,26)/t15-,18-/m1/s1",Cephaloridine,KEGG COMPOUND accession,C11754
7731,3558,cerivastatin,"(3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.","InChI=1S/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1",Cerivastatin,KEGG COMPOUND accession,C07966
7732,3567,cetyltrimethylammonium bromide,The organic bromide salt that is the bromide salt of cetyltrimethylammonium; one of the components of the topical antiseptic cetrimide.,"InChI=1S/C19H42N.BrH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(2,3)4;/h5-19H2,1-4H3;1H/q+1;/p-1",Cetyltrimethylammonium bromide,CAS Registry Number,57-09-0
7733,3640,chlorothiazide,"4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.","InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)",Chlorothiazide,KEGG COMPOUND accession,C07461
7734,3642,chlorphenesin,"Glycerol in which the hydrogen of one of the primary hydroxy groups is substituted by a 4-chlorophenyl group. It has antifungal and antibacterial properties, and is used for treatment of cutaneous and vaginal infections. Its 1-carbamate is used as a skeletal muscle relaxant for the treatment of painful muscle spasm.","InChI=1S/C9H11ClO3/c10-7-1-3-9(4-2-7)13-6-8(12)5-11/h1-4,8,11-12H,5-6H2",Chlorphenesin,CAS Registry Number,104-29-0
7735,3655,chlorzoxazone,"A member of the class of  1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.","InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)",Chlorzoxazone,KEGG COMPOUND accession,C07931
7736,3663,cholesteryl palmitate,A cholesterol ester obtained by the formal condensation of cholesterol with palmitic acid.,"InChI=1S/C43H76O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-23-41(44)45-36-28-30-42(5)35(32-36)24-25-37-39-27-26-38(34(4)22-20-21-33(2)3)43(39,6)31-29-40(37)42/h24,33-34,36-40H,7-23,25-32H2,1-6H3/t34-,36+,37+,38-,39+,40+,42+,43-/m1/s1",Cholesteryl palmitate,KEGG COMPOUND accession,C11251
7737,3696,cidofovir anhydrous,"Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.","InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1",Cidofovir,CAS Registry Number,113852-37-2
7738,3720,cisapride,"The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.","InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1",Cisapride,KEGG COMPOUND accession,C06910
7739,3732,clarithromycin,"The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.","InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1",Clarithromycin,KEGG COMPOUND accession,C06912
7740,3738,clemastine,"2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.","InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1",Clemastine,KEGG COMPOUND accession,C06913
7741,3743,clidinium,"The ester resulting from formal condensation of benzilic acid and 3-hydroxy-1-methyl-1-azoniabicyclo[2.2.2]octane. It is used, generally as the bromide, for the symptomatic treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.","InChI=1S/C22H26NO3/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19/h2-11,17,20,25H,12-16H2,1H3/q+1/t17-,20?,23+",Clidinium,KEGG COMPOUND accession,C07853
7742,3745,clindamycin,"A carbohydrate-containing antibiotic that is the  semisynthetic derivative of lincomycin, a natural antibiotic.","InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1",Clindamycin,CAS Registry Number,18323-44-9
7743,3900,costunolide,"A germacranolide with anthelminthic, antiparasitic and antiviral activities.","InChI=1S/C15H20O2/c1-10-5-4-6-11(2)9-14-13(8-7-10)12(3)15(16)17-14/h5,9,13-14H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,14+/m0/s1",Costunolide,KEGG COMPOUND accession,C09382
7744,3960,cupressuflavone,"A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-8 of the two chromene rings respectively. Isolated from Cupressus sempervirens and Juniperus occidentalis, it exhibits free radical scavenging and antielastase activities.","InChI=1S/C30H18O10/c31-15-5-1-13(2-6-15)23-11-21(37)25-17(33)9-19(35)27(29(25)39-23)28-20(36)10-18(34)26-22(38)12-24(40-30(26)28)14-3-7-16(32)8-4-14/h1-12,31-36H",Cupressuflavone,CAS Registry Number,3952-18-9
7745,3994,cyclizine,"An N-alkylpiperazine in which one nitrogen of the piperazine ring is substituted by a methyl group, while the other is substituted by a diphenylmethyl group.","InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3",Cyclizine,KEGG COMPOUND accession,C06930
7746,3996,cyclobenzaprine,"5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.","InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3",Cyclobenzaprine,KEGG COMPOUND accession,C06931
7747,4031,cyclosporin A,"A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.","InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1",Cyclosporin A,KEGG COMPOUND accession,C05086
7748,4046,cyproheptadine,"The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.","InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3",Cyproheptadine,KEGG COMPOUND accession,C06935
7749,4075,(R)-(1-aminoethyl)phosphonic acid,An optically active phosphonic acid having a 1-aminoethyl group attached to the phosphorus.,"InChI=1S/C2H8NO3P/c1-2(3)7(4,5)6/h2H,3H2,1H3,(H2,4,5,6)/t2-/m1/s1",D-(1-Aminoethyl)phosphonic acid,KEGG COMPOUND accession,C03782
7750,4222,D-pantetheine 4'-phosphate,Pantetheine 4'-phosphate with D (R) configuration at the 2' position.,"InChI=1S/C11H23N2O7PS/c1-11(2,7-20-21(17,18)19)9(15)10(16)13-4-3-8(14)12-5-6-22/h9,15,22H,3-7H2,1-2H3,(H,12,14)(H,13,16)(H2,17,18,19)/t9-/m0/s1",D-Pantetheine 4'-phosphate,PDBeChem accession,PNS
7751,4325,dapsone,"A  sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide  range of bacteria, but is mainly employed for its actions against Mycobacterium leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy.","InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2",Dapsone,CAS Registry Number,80-08-0
7752,4354,decursinol,"An organic heterotricyclic compound that is 7,8-dihydro-2H,6H-pyrano[3,2-g]chromen-2-one substituted by a beta-hydroxy group at position 7 and two methyl groups at position 8. It is isolated from the roots of Angelica gigas and has been found to possess significant inhibitory activity against acetylcholinesterase enzyme (EC 3.1.1.7).","InChI=1S/C14H14O4/c1-14(2)12(15)6-9-5-8-3-4-13(16)17-10(8)7-11(9)18-14/h3-5,7,12,15H,6H2,1-2H3/t12-/m0/s1",Decursinol,CAS Registry Number,23458-02-8
7753,4379,delavirdine mesylate,"The monomethanesulfonic acid salt of delavirdine, a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.","InChI=1S/C22H28N6O3S.CH4O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20;1-5(2,3)4/h4-8,13-15,24-26H,9-12H2,1-3H3;1H3,(H,2,3,4)",Delavirdine mesylate,CAS Registry Number,147221-93-0
7754,4474,dezocine,"(7S,8S)-7-Amino-8-methyl-5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogen at position 8 and one of the hydrogens at position 6 are substituted by each end of a tetramethylene bridge. A synthetic opioid analgesic, it has mixed opiod agonist and antagonist properties. Although it is used for pain management, it can produce opioid withdrawal syndrome in patients already dependent on other opioids, and its clinical application is limited by side effects such as dizziness.","InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1",Dezocine,CAS Registry Number,53648-55-8
7755,4495,diazoxide,"A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.","InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)",Diazoxide,KEGG COMPOUND accession,C06949
7756,4513,dicoumarol,"A hydroxycoumarin that is methane in which two hydrogens have each been substituted by a 4-hydroxycoumarin-3-yl group. Related to warfarin, it has been used as an anticoagulant.","InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2",Dicumarol,KEGG COMPOUND accession,C00796
7757,4514,dicyclomine,"The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.","InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3",Dicyclomine,KEGG COMPOUND accession,C06951
7758,4562,dihydroergotamine,"Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.","InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1",Dihydroergotamine,KEGG COMPOUND accession,C07798
7759,4670,dobutamine,"A  catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.","InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3",Dobutamine,KEGG COMPOUND accession,C06967
7760,4702,dorzolamide,"5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.","InChI=1S/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1",Dorzolamide,CAS Registry Number,120279-96-1
7761,4728,dyphylline,"An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.","InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3",Dyphylline,CAS Registry Number,479-18-5
7762,4778,embelin,"A member of the class of dihydroxy-1,4-benzoquinones that is 2,5-dihydroxy-1,4-benzoquinone which is substituted by an undecyl group at position 3. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antimicrobial, antineoplastic and inhibitory activity towards hepatitis C protease.","InChI=1S/C17H26O4/c1-2-3-4-5-6-7-8-9-10-11-13-16(20)14(18)12-15(19)17(13)21/h12,18,21H,2-11H2,1H3",Embelin,KEGG COMPOUND accession,C10342
7763,4779,emedastine,"1-Methyl-1,4-diazepane in which the hydrogen attached to the nitrogen at position 4 is substituted by a 1-(2-ethoxyethyl)-1H-benzimidazol-2-yl group. A relatively selective histamine H1 antagonist, it is used as the difumatate salt for allergic rhinitis, urticaria, and pruritic skin disorders, and in eyedrops for the symptomatic relief of allergic conjuntivitis.","InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3",Emedastine,KEGG COMPOUND accession,C07785
7764,4784,enalapril,A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).,"InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1",Enalapril,CAS Registry Number,75847-73-3
7765,4788,encainide,"4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.","InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)",Encainide,KEGG COMPOUND accession,C06978
7766,4821,ergocristine,"Ergotaman bearing benzyl, hydroxy, and isopropyl groups at the 5', 12' and 2' positions, respectively, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid.","InChI=1S/C35H39N5O5/c1-20(2)34(37-31(41)23-16-25-24-11-7-12-26-30(24)22(18-36-26)17-27(25)38(3)19-23)33(43)40-28(15-21-9-5-4-6-10-21)32(42)39-14-8-13-29(39)35(40,44)45-34/h4-7,9-12,16,18,20,23,27-29,36,44H,8,13-15,17,19H2,1-3H3,(H,37,41)/t23-,27-,28+,29+,34-,35+/m1/s1",Ergocristine,KEGG COMPOUND accession,C09164
7767,4822,ergometrine,"A monocarboxylic acid amide that  is lysergamide in which one of the hydrogens attached to the amide nitrogen is substituted by a 1-hydroxypropan-2-yl group (S-configuration). An ergot alkaloid that has a particularly powerful action on the uterus, its maleate (and formerly tartrate) salt is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.","InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1",Ergonovine,CAS Registry Number,60-79-7
7768,4877,ethambutol,"An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.","InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1",Ethambutol,CAS Registry Number,74-55-5
7769,4884,ethinamate,"A carbamate ester that is the 1-vinylcyclohexyl ester of carbamic acid. A short-acting sedative-hypnotic, it was formerly used to treat insomnia.","InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11)",Ethinamate,CAS Registry Number,126-52-3
7770,4887,ethosuximide,"A  dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.","InChI=1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)",Ethosuximide,CAS Registry Number,77-67-8
7771,4888,ethotoin,"An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.","InChI=1S/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)",Ethotoin,KEGG COMPOUND accession,C07839
7772,4907,etidronic acid,"A  1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.","InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)","1-Hydroxyethylidene-1,1-diphosphonic acid",KEGG COMPOUND accession,C07736
7773,4910,etomidate,The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.,"InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1",Etomidate,CAS Registry Number,33125-97-2
7774,4916,eugeniin,An ellagitannin isolated from the dried flower buds of Eugenia caryophyllata. It exhibits alpha-glucosidase inhibitory activity and antiviral activity against acyclovir and phosphonoacetic acid (PAA)-resistant herpes simplex virus type 1 (HSV-1) as well as the wild-type HSV-1.,"InChI=1S/C41H30O26/c42-15-1-10(2-16(43)26(15)50)36(57)65-34-33-23(9-62-39(60)13-7-21(48)29(53)31(55)24(13)25-14(40(61)64-33)8-22(49)30(54)32(25)56)63-41(67-38(59)12-5-19(46)28(52)20(47)6-12)35(34)66-37(58)11-3-17(44)27(51)18(45)4-11/h1-8,23,33-35,41-56H,9H2/t23-,33-,34+,35-,41+/m1/s1",Eugeniin,CAS Registry Number,58970-75-5
7775,4932,eupatilin,"A trimethoxyflavone that is flavone substituted by hydroxy groups at C-5 and C-7 and methoxy groups at C-6, C-3' and C-4' respectively. Isolated from Citrus reticulata and Salvia tomentosa, it exhibits anti-inflammatory, anti-ulcer and antineoplastic activities.","InChI=1S/C18H16O7/c1-22-12-5-4-9(6-14(12)23-2)13-7-10(19)16-15(25-13)8-11(20)18(24-3)17(16)21/h4-8,20-21H,1-3H3",Eupatilin,CAS Registry Number,22368-21-4
7776,4946,euxanthone,A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1 and 7 and an oxo group at position 9. It has been isolated from Cratoxylum cochinchinense.,"InChI=1S/C13H8O4/c14-7-4-5-10-8(6-7)13(16)12-9(15)2-1-3-11(12)17-10/h1-6,14-15H","1,7-Dihydroxyxanthone",KEGG COMPOUND accession,C10061
7777,4995,felbamate,"The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.","InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)",Felbamate,CAS Registry Number,25451-15-4
7778,5000,fenfluramine,"A  secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension.","InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3",Fenfluramine,KEGG COMPOUND accession,C06996
7779,5004,fenoprofen,"A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with  disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.","InChI=1S/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)",Fenoprofen,KEGG COMPOUND accession,C06997
7780,5163,fosinopril,"A phosphinate ester-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. It is used for the treatment of hypertension and heart failure. A pro-drug, it is hydrolysed in vivo to the corresponding phosphininc acid, fosinoprilat, which is the active metabolite.","InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1",Fosinopril,KEGG COMPOUND accession,C07016
7781,5186,fucoxanthin,"An epoxycarotenol that is found in brown seaweed and which exhibits anti-cancer, anti-diabetic, anti-oxidative and neuroprotective properties.","InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23-,34-,35-,40+,41+,42-/m0/s1",Fucoxanthin,CAS Registry Number,3351-86-8
7782,5280,gatifloxacin,"A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.","InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)",AM 1155,CAS Registry Number,112811-59-3
7783,5292,geldanamycin,An ansamycin consisting of a 19-membered macrocyle incorporating a benzoquinone ring and a lactam functionality. It shows antimicrobial activity against many Gram-positive and some Gram-negative bacteria.,"InChI=1S/C29H40N2O9/c1-15-11-19-25(34)20(14-21(32)27(19)39-7)31-28(35)16(2)9-8-10-22(37-5)26(40-29(30)36)18(4)13-17(3)24(33)23(12-15)38-6/h8-10,13-15,17,22-24,26,33H,11-12H2,1-7H3,(H2,30,36)(H,31,35)/b10-8-,16-9+,18-13+/t15-,17+,22+,23+,24-,26+/m1/s1",Geldanamycin,KEGG COMPOUND accession,C11222
7784,5353,ginkgetin,"A biflavonoid that is the  7,4'-dimethyl ether derivative of amentoflavone. Isolated from Ginkgo biloba and Dioon, it exhibits anti-HSV-1, antineoplastic and inhibitory activities towards arachidonate 5-lipoxygenase and cyclooxygenase 2.","InChI=1S/C32H22O10/c1-39-18-10-20(34)30-23(37)13-27(41-28(30)11-18)16-5-8-25(40-2)19(9-16)29-21(35)12-22(36)31-24(38)14-26(42-32(29)31)15-3-6-17(33)7-4-15/h3-14,33-36H,1-2H3",Ginkgetin,KEGG COMPOUND accession,C10048
7785,5445,glyceraldehyde,"An aldotriose comprising propanal having hydroxy groups at the 2- and 3-positions. It plays role in the formation of advanced glycation end-products (AGEs), a deleterious accompaniment to ageing.","InChI=1S/C3H6O3/c4-1-3(6)2-5/h1,3,5-6H,2H2",Glyceraldehyde,KEGG COMPOUND accession,C02154
7786,5638,heliangin,"A sesquiterpene lactone of the heliangolide group isolated from Eupatorium kiirunense and Calea rotundifolia and exhibits cytotoxicity against human oral epidermoid (KB), cervical epitheloid (Hela) and liver (hepa59T/VGH) carcinoma cells.","InChI=1S/C20H26O6/c1-6-10(2)18(22)25-15-9-20(5)16(26-20)8-13(21)11(3)7-14-17(15)12(4)19(23)24-14/h6-7,13-17,21H,4,8-9H2,1-3,5H3/b10-6+,11-7+/t13-,14+,15+,16+,17-,20+/m0/s1",Heliangin,KEGG COMPOUND accession,C09474
7787,5706,hexobarbital,A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.,"InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)",Hexobarbitone,CAS Registry Number,56-29-1
7788,5721,hinokiflavone,"A biflavonoid that is apigenin substituted by a 4-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)phenoxy group at position 6. A diflavonyl ether, it is isolated from Rhus succedanea and has been found to possess significant cytotoxic potential.","InChI=1S/C30H18O10/c31-16-5-1-14(2-6-16)24-12-21(35)28-26(40-24)13-22(36)30(29(28)37)38-18-7-3-15(4-8-18)23-11-20(34)27-19(33)9-17(32)10-25(27)39-23/h1-13,31-33,36-37H",Hinokiflavone,KEGG COMPOUND accession,C10057
7789,5722,hinokinin,"A lignan that is dihydrofuran-2(3H)-one (gamma-butyrolactone) substituted by a 3,4-methylenedioxybenzyl group at positions 3 and 4 (the 3R,4R-diastereoisomer).","InChI=1S/C20H18O6/c21-20-15(6-13-2-4-17-19(8-13)26-11-24-17)14(9-22-20)5-12-1-3-16-18(7-12)25-10-23-16/h1-4,7-8,14-15H,5-6,9-11H2/t14-,15+/m0/s1",Hinokinin,KEGG COMPOUND accession,C10627
7790,5850,N-(2-methoxyphenyl)-N'-(2-naphthyl)urea,A member of the class of phenylureas that is N-(2-methoxyphenyl)urea in which one of the two protons on the free NH2 function has been replaced by a 2-naphthyl group.,"InChI=1S/C18H16N2O2/c1-22-17-9-5-4-8-16(17)20-18(21)19-15-11-10-13-6-2-3-7-14(13)12-15/h2-12H,1H3,(H2,19,20,21)",INF271,KEGG COMPOUND accession,C11163
7791,5885,imperatorin,"A member of the class of psoralens that is psoralen substituted by a prenyloxy group at position 8. Isolated from Angelica dahurica and Angelica koreana, it acts as a acetylcholinesterase inhibitor.","InChI=1S/C16H14O4/c1-10(2)5-7-19-16-14-12(6-8-18-14)9-11-3-4-13(17)20-15(11)16/h3-6,8-9H,7H2,1-2H3",Imperatorin,CAS Registry Number,482-44-0
7792,5981,isoalantolactone,A sesquiterpene lactone of the eudesmanolide group. It has been isolated from Inula helenium.,"InChI=1S/C15H20O2/c1-9-5-4-6-15(3)8-13-11(7-12(9)15)10(2)14(16)17-13/h11-13H,1-2,4-8H2,3H3/t11-,12+,13-,15-/m1/s1",Isoalantolactone,KEGG COMPOUND accession,C09484
7793,6121,ketamine,"A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.","InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3",Ketamine,KEGG COMPOUND accession,C07525
7794,6263,L-lysinamide,The amino acid amide formed from L-lysine.,"InChI=1S/C6H15N3O/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H2,9,10)/t5-/m0/s1",L-Lysinamide,KEGG COMPOUND accession,C01930
7795,6339,etoricoxib,"A member of the class of bipyridines that is 2,3'-bipyridine which is substituted at the 3, 5, and 6' positions by 4-(methylsulfonyl)phenyl, chlorine, and methyl groups, respectively.","InChI=1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3",L791456,KEGG COMPOUND accession,C11718
7796,6359,lactulose,A synthetic galactosylfructose disaccharide used in the treatment of constipation and hepatic encephalopathy.,"InChI=1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1",Lactulose,CAS Registry Number,4618-18-2
7797,6631,maculosin,A  homodetic cyclic peptide that is a dipeptide composed of L-proline and L-tyrosine joined by peptide linkages.,"InChI=1S/C14H16N2O3/c17-10-5-3-9(4-6-10)8-11-14(19)16-7-1-2-12(16)13(18)15-11/h3-6,11-12,17H,1-2,7-8H2,(H,15,18)/t11-,12-/m0/s1",Cyclo(L-Pro-L-Tyr),KEGG COMPOUND accession,C10605
7798,6716,medroxyprogesterone acetate,An acetate ester resulting from the formal condensation of the 17alpha-hydroxy group of medroxyprogesterone with the carboxy group of acetic acid. A widely used progestin in menopausal hormone therapy and in progestogen-only birth control.,"InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1",Medroxyprogesterone acetate,KEGG COMPOUND accession,C08150
7799,6758,mephobarbital,"A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups.","InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)",Mephobarbital,CAS Registry Number,115-38-8
7800,6780,mesoridazine,"A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.","InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3",Mesoridazine,KEGG COMPOUND accession,C07143
7801,6897,metipranolol,"3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma.","InChI=1S/C17H27NO4/c1-10(2)18-8-15(20)9-21-16-7-11(3)17(22-14(6)19)13(5)12(16)4/h7,10,15,18,20H,8-9H2,1-6H3",Metipranolol,KEGG COMPOUND accession,C07915
7802,6916,mexiletine,"An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.","InChI=1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3",Mexiletine,KEGG COMPOUND accession,C07220
7803,6997,moricizine,"A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.","InChI=1S/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)",Moricizine,KEGG COMPOUND accession,C07743
7804,7071,"N,N-diethyl-m-toluamide","A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of m-toluic acid with the nitrogen of diethylamine. First developed by the U.S. Army in 1946 for use by military personnel in insect-infested areas, it is the most widely used insect repellent worldwide.","InChI=1S/C12H17NO/c1-4-13(5-2)12(14)11-8-6-7-10(3)9-11/h6-9H,4-5H2,1-3H3",DEET,KEGG COMPOUND accession,C10935
7805,7438,N-methylformamide,A member of the class of formamides  having a N-methyl substituent.,"InChI=1S/C2H5NO/c1-3-2-4/h2H,1H3,(H,3,4)",NMF,CAS Registry Number,123-39-7
7806,7476,naproxen,"A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation  and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.","InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1",Naproxen,CAS Registry Number,22204-53-1
7807,7489,neamine,2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group.,"InChI=1S/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1",Neamine,CAS Registry Number,3947-65-7
7808,7508,framycetin,"A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.","InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",Neomycin B,CAS Registry Number,119-04-0
7809,7622,norathyriol,"A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7. Isolated from Garcinia mangostana and Maclura pomifera, it exhibits inhibitory activity against protein kinase C.","InChI=1S/C13H8O6/c14-5-1-9(17)12-11(2-5)19-10-4-8(16)7(15)3-6(10)13(12)18/h1-4,14-17H",Norathyriol,CAS Registry Number,3542-72-1
7810,7627,norethisterone,A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.,"InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1",19-Norethisterone,KEGG COMPOUND accession,C05028
7811,7789,orphenadrine,A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.,"InChI=1S/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3",Orphenadrine,KEGG COMPOUND accession,C07935
7812,7798,oseltamivir,"A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.","InChI=1S/C16H28N2O4/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19/h9,12-15H,5-8,17H2,1-4H3,(H,18,19)/t13-,14+,15+/m0/s1",Oseltamivir,KEGG COMPOUND accession,C08092
7813,7907,pancuronium,A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.,"InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1",Pancuronium,KEGG COMPOUND accession,C07551
7814,7934,paromomycin,"An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.","InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1",Paromomycin,KEGG COMPOUND accession,C00832
7815,7947,pedalitin,"A tetrahydroxy-monohydroxy-flavone, with the four hydroxy groups at C-3',-4',-5 and 6, and the methoxy group at C-7.  It has been isolated from a number of plant species, including Eremosparton songoricum, Rabdosia japonica and Ruellia tuberosa.","InChI=1S/C16H12O7/c1-22-13-6-12-14(16(21)15(13)20)10(19)5-11(23-12)7-2-3-8(17)9(18)4-7/h2-6,17-18,20-21H,1H3",Pedalitin,KEGG COMPOUND accession,C10119
7816,7983,pentobarbital,"A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.","InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)",Pentobarbital,CAS Registry Number,76-74-4
7817,8048,phellamurin,"A member of the class of dihydroflavonols that is (+)-dihydrokaempferol substituted by a prenyl group at position 8 and a beta-D-glucopyranosyl group at position 7 via a glycosidic linkage. Isolated from   Phellodendron amurense and Commiphora africana, it exhibits inhibition of intestinal P-glycoprotein.","InChI=1S/C26H30O11/c1-11(2)3-8-14-16(35-26-23(34)21(32)19(30)17(10-27)36-26)9-15(29)18-20(31)22(33)24(37-25(14)18)12-4-6-13(28)7-5-12/h3-7,9,17,19,21-24,26-30,32-34H,8,10H2,1-2H3/t17-,19-,21+,22+,23-,24-,26-/m1/s1",Phellamurin,KEGG COMPOUND accession,C09808
7818,8069,phenobarbital,"A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.","InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)",Phenobarbital,KEGG COMPOUND accession,C07434
7819,8232,piperacillin,"A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.","InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1",Piperacillin,CAS Registry Number,61477-96-1
7820,8435,prochlorperazine,A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.,"InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3",Prochlorperazine,KEGG COMPOUND accession,C07403
7821,8489,propiconazole,"The cyclic ketal obtained by formal condensation of 1-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone with pentane-1,2-diol. A triazole fungicide, it is used commercially as a diastereoisomeric mixture on soft fruit (including apricots, peaches, nectarines, plums and prunes), nuts (including peanuts, pecans and almonds), mushrooms, and grasses grown for seeds.","InChI=1S/C15H17Cl2N3O2/c1-2-3-12-7-21-15(22-12,8-20-10-18-9-19-20)13-5-4-11(16)6-14(13)17/h4-6,9-10,12H,2-3,7-8H2,1H3",Propiconazole,KEGG COMPOUND accession,C11121
7822,8691,quassimarin,A quassinoid isolated from Quassia amara and Leitneria floridana and has been shown to exhibit antitumour activity.,"InChI=1S/C27H36O11/c1-7-24(4,38-12(3)28)23(34)37-17-19-26(6)21(32)16(30)18-25(5)13(11(2)8-14(29)20(25)31)9-15(36-22(17)33)27(18,19)10-35-26/h8,13,15-21,30-32H,7,9-10H2,1-6H3/t13-,15+,16+,17+,18+,19-,20+,21-,24+,25-,26+,27+/m0/s1",Quassimarin,KEGG COMPOUND accession,C08777
7823,8772,raloxifene,"A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.","InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2",Raloxifene,KEGG COMPOUND accession,C07228
7824,8802,remifentanil,A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.,"InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3",Remifentanil,CAS Registry Number,132875-61-7
7825,8881,robustaflavone,"A biflavonoid that is obtained by oxidative coupling of two molecules of  apigenin resulting in a bond between positions C-3 of the hydroxyphenyl ring and C-6 of the chromene ring. Isolated from Thuja orientalis and Rhus succedanea it exhibits antioxidant, cytotoxic and anti-hepatitis B activity.","InChI=1S/C30H18O10/c31-15-4-1-13(2-5-15)23-11-22(37)29-26(39-23)12-20(35)27(30(29)38)17-7-14(3-6-18(17)33)24-10-21(36)28-19(34)8-16(32)9-25(28)40-24/h1-12,31-35,38H",Robustaflavone,KEGG COMPOUND accession,C10179
7826,8890,(S)-ropivacaine,"A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.","InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1",Ropivacaine,CAS Registry Number,84057-95-4
7827,8927,"S-(2,4-dinitrophenyl)glutathione","A glutathione conjugate in which the thiol hydrogen of glutathione has been replaced by a 2,4-dinitrophenyl group.","InChI=1S/C16H19N5O10S/c17-9(16(26)27)2-4-13(22)19-10(15(25)18-6-14(23)24)7-32-12-3-1-8(20(28)29)5-11(12)21(30)31/h1,3,5,9-10H,2,4,6-7,17H2,(H,18,25)(H,19,22)(H,23,24)(H,26,27)/t9-,10-/m0/s1","S-(2,4-Dinitrophenyl)glutathione",CAS Registry Number,26289-39-4
7828,9023,santamarin,A sesquiterpene lactone of the eudesmanolide group.,"InChI=1S/C15H20O3/c1-8-4-5-11(16)15(3)7-6-10-9(2)14(17)18-13(10)12(8)15/h4,10-13,16H,2,5-7H2,1,3H3/t10-,11+,12+,13-,15-/m0/s1",Santamarin,KEGG COMPOUND accession,C09544
7829,9096,L-selenohomocysteine,A selenoamino acid that is the selenium analogue of L-homocysteine.,"InChI=1S/C4H9NO2Se/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1",Selenohomocysteine,KEGG COMPOUND accession,C05698
7830,9110,senegin II,A triterpenoid saponin isolated from Polygala senega var latifolia and has been shown to exhibit hypoglycemic activity.,"InChI=1S/C70H104O32/c1-29-54(99-58-49(82)45(78)39(27-92-58)97-60-50(83)46(79)43(76)37(25-71)95-60)48(81)52(85)59(93-29)100-56-53(86)55(98-42(75)15-11-31-10-13-35(90-8)36(22-31)91-9)30(2)94-62(56)102-64(89)69-19-18-65(3,4)23-33(69)32-12-14-40-66(5)24-34(74)57(101-61-51(84)47(80)44(77)38(26-72)96-61)68(7,63(87)88)41(66)16-17-67(40,6)70(32,28-73)21-20-69/h10-13,15,22,29-30,33-34,37-41,43-62,71-74,76-86H,14,16-21,23-28H2,1-9H3,(H,87,88)/t29-,30+,33-,34-,37+,38+,39+,40+,41+,43-,44+,45-,46-,47-,48-,49+,50+,51+,52+,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,66+,67+,68-,69-,70-/m0/s1",Senegin II,CAS Registry Number,34366-31-9
7831,9168,sirolimus,"A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.","InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",Sirolimus,CAS Registry Number,53123-88-9
7832,9241,spironolactone,"A  steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.","InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1",Spironolactone,KEGG COMPOUND accession,C07310
7833,9242,spiroxamine,"The spiroketal resulting from the formal condensation of 4-tert-butylcyclohexanone with 3-[ethyl(propyl)amino]propane-1,2-diol. An inhibitor of ergosterol synthesis, it is a broad spectrum agricultural fungicide used particularly against powdery mildew in the production of cereals, bananas and grapes.","InChI=1S/C18H35NO2/c1-6-12-19(7-2)13-16-14-20-18(21-16)10-8-15(9-11-18)17(3,4)5/h15-16H,6-14H2,1-5H3",Spiroxamine,CAS Registry Number,118134-30-8
7834,9332,sulfamethoxazole,"An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.","InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)",Sulfamethoxazole,KEGG COMPOUND accession,C07315
7835,9334,sulfasalazine,"An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.","InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+",Sulfasalazine,KEGG COMPOUND accession,C07316
7836,9368,swerchirin,"A member of the class of xanthones that is the 5-O-methyl derivative of  bellidifolin. Isolated from Centaurium erythraea and Swertia chirayita, it exhibits hypoglycemic activity.","InChI=1S/C15H12O6/c1-19-7-5-9(17)12-11(6-7)21-15-10(20-2)4-3-8(16)13(15)14(12)18/h3-6,16-17H,1-2H3",Swerchirin,KEGG COMPOUND accession,C10091
7837,9407,taurochenodeoxycholate,An organosulfonate oxoanion that is the conjugate base of taurochenodeoxycholic acid arising from deprotonation of the sulfonate OH group; major species at pH 7.3.,"InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/p-1/t16-,17+,18-,19-,20+,21+,22-,24+,25+,26-/m1/s1",Taurochenodeoxycholate,KEGG COMPOUND accession,C05465
7838,9442,tephrosin,"A member of the class of rotenones that is 13,13a-dihydro-3H-chromeno[3,4-b]pyrano[2,3-h]chromen-7(7aH)-one substituted with geminal methyl groups at position 3, hydroxy group at position 7a and methoxy groups at positions 9 and 10 (the 7aR,13aR stereoisomer). It is isolated from the leaves and twigs of Antheroporum pierrei and exhibits antineoplastic and pesticidal activities.","InChI=1S/C23H22O7/c1-22(2)8-7-12-15(30-22)6-5-13-20(12)29-19-11-28-16-10-18(27-4)17(26-3)9-14(16)23(19,25)21(13)24/h5-10,19,25H,11H2,1-4H3/t19-,23-/m1/s1",Tephrosin,CAS Registry Number,76-80-2
7839,9516,thapsigargin,"An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.","InChI=1S/C34H50O12/c1-9-12-13-14-15-17-24(37)43-28-26-25(20(5)27(28)44-30(38)19(4)11-3)29-34(41,33(8,40)31(39)45-29)22(42-23(36)16-10-2)18-32(26,7)46-21(6)35/h11,22,26-29,40-41H,9-10,12-18H2,1-8H3/b19-11-/t22-,26+,27-,28-,29-,32-,33+,34+/m0/s1",Thapsigargin,KEGG COMPOUND accession,C09561
7840,9578,(-)-thujopsene,"A thujopsene that has (S,S,S)-configuration.","InChI=1S/C15H24/c1-11-6-9-14(4)8-5-7-13(2,3)15(14)10-12(11)15/h6,12H,5,7-10H2,1-4H3/t12-,14-,15-/m0/s1",Thujopsene,KEGG COMPOUND accession,C09740
7841,9599,(S)-timolol (anhydrous),"The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.","InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1",Timolol,KEGG COMPOUND accession,C07141
7842,9605,tirofiban,A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.,"InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1",Tirofiban,KEGG COMPOUND accession,C07965
7843,9678,tribenuron methyl,The methyl ester of tribenuron.,"InChI=1S/C15H17N5O6S/c1-9-16-13(18-14(17-9)26-4)20(2)15(22)19-27(23,24)11-8-6-5-7-10(11)12(21)25-3/h5-8H,1-4H3,(H,19,22)",Tribenuron methyl,KEGG COMPOUND accession,C10962
7844,9997,pristinamycin IIA,"A macrolide that is (together with pristinamycin IA) a component of pristinamycin, an oral streptogramin antibiotic produced by Streptomyces pristinaespiralis. Pristinamycin exhibits bactericidal activity against Gram positive organisms including methicillin-resistant Staphylococcus aureus.","InChI=1S/C28H35N3O7/c1-17(2)26-19(4)9-10-24(34)29-11-5-7-18(3)13-20(32)14-21(33)15-25-30-22(16-37-25)27(35)31-12-6-8-23(31)28(36)38-26/h5,7-10,13,16-17,19-20,26,32H,6,11-12,14-15H2,1-4H3,(H,29,34)/b7-5+,10-9+,18-13+/t19-,20-,26-/m1/s1",Virginiamycin M1,CAS Registry Number,21411-53-0
7845,10041,withanolide D,"A  withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 22 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Tubocapsicum anomalum and Withania somnifera, it exhibits cytotoxic activity.","InChI=1S/C28H38O6/c1-14-12-22(33-24(31)15(14)2)27(5,32)19-7-6-17-16-13-23-28(34-23)21(30)9-8-20(29)26(28,4)18(16)10-11-25(17,19)3/h8-9,16-19,21-23,30,32H,6-7,10-13H2,1-5H3/t16-,17-,18-,19-,21-,22+,23+,25-,26-,27+,28+/m0/s1",Withanolide D,CAS Registry Number,30655-48-2
7846,10050,XV638,"A member of the class of diazepanones that is 1,3-diazepane which is substituted by a 3-(1,3-thiazol-2-ylcarbamoyl)benzyl group at positions 1 and 3, oxo group at position 2, hydroxy groups at positions 5S and 6S, and benzyl groups at positions 4R and 7R. It is a potent HIV-1 protease inhibitor.","InChI=1S/C41H38N6O5S2/c48-35-33(23-27-9-3-1-4-10-27)46(25-29-13-7-15-31(21-29)37(50)44-39-42-17-19-53-39)41(52)47(34(36(35)49)24-28-11-5-2-6-12-28)26-30-14-8-16-32(22-30)38(51)45-40-43-18-20-54-40/h1-22,33-36,48-49H,23-26H2,(H,42,44,50)(H,43,45,51)/t33-,34-,35+,36+/m1/s1",XV638,KEGG COMPOUND accession,C06488
7847,10110,zidovudine,"A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.","InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1",AZT,CAS Registry Number,30516-87-1
7848,10216,cedr-8-ene,A sesquiterpene that is cedrane which has a double bond between positions 8 and 9.,"InChI=1S/C15H24/c1-10-7-8-15-9-12(10)14(3,4)13(15)6-5-11(15)2/h7,11-13H,5-6,8-9H2,1-4H3/t11-,12+,13+,15+/m1/s1",alpha-cedrene,KEGG COMPOUND accession,C09630
7849,10353,beta-asarone,The cis-isomer of asarone.,"InChI=1S/C12H16O3/c1-5-6-9-7-11(14-3)12(15-4)8-10(9)13-2/h5-8H,1-4H3/b6-5-",cis-Asarone,KEGG COMPOUND accession,C10430
7850,10429,beta-lapachone,"A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.","InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3",beta-Lapachone,KEGG COMPOUND accession,C10367
7851,10447,beta-thujaplicin,"A monoterpenoid that is cyclohepta-2,4,6-trien-1-one substituted by a hydroxy group at position 2 and an isopropyl group at position 4. Isolated from Thuja plicata and Chamaecyparis obtusa, it exhibits antimicrobial activities.","InChI=1S/C10H12O2/c1-7(2)8-4-3-5-9(11)10(12)6-8/h3-7H,1-2H3,(H,11,12)",beta-Thujaplicin,CAS Registry Number,499-44-5
7852,10642,scyllo-inositol,,"InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3+,4+,5-,6-",scyllo-Inositol,KEGG COMPOUND accession,C06153
7853,15777,4-oxocyclohexanecarboxylate,,"InChI=1S/C7H10O3/c8-6-3-1-5(2-4-6)7(9)10/h5H,1-4H2,(H,9,10)/p-1",4-ketocyclohexanecarboxylate,KEGG COMPOUND accession,C03767
7854,16161,CoA-disulfide,An organic disulfide obtained via oxidative dimerisation of coenzyme A.,"InChI=1S/C42H70N14O32P6S2/c1-41(2,15-81-93(75,76)87-91(71,72)79-13-21-29(85-89(65,66)67)27(59)39(83-21)55-19-53-25-33(43)49-17-51-35(25)55)31(61)37(63)47-7-5-23(57)45-9-11-95-96-12-10-46-24(58)6-8-48-38(64)32(62)42(3,4)16-82-94(77,78)88-92(73,74)80-14-22-30(86-90(68,69)70)28(60)40(84-22)56-20-54-26-34(44)50-18-52-36(26)56/h17-22,27-32,39-40,59-62H,5-16H2,1-4H3,(H,45,57)(H,46,58)(H,47,63)(H,48,64)(H,71,72)(H,73,74)(H,75,76)(H,77,78)(H2,43,49,51)(H2,44,50,52)(H2,65,66,67)(H2,68,69,70)/t21-,22-,27-,28-,29-,30-,31+,32+,39-,40-/m1/s1",CoA disulfide,KEGG COMPOUND accession,C02015
7855,16409,5-pyridoxic acid,"A pyridinemonocarboxylic acid that is pyridine-3-carboxylic acid substituted by a hydroxy group at position 5, hydroxy methyl group at position 4 and a methyl group at position 6.","InChI=1S/C8H9NO4/c1-4-7(11)6(3-10)5(2-9-4)8(12)13/h2,10-11H,3H2,1H3,(H,12,13)",5-hydroxy-4-(hydroxymethyl)-6-methylnicotinic acid,KEGG COMPOUND accession,C04773
7856,16490,S-adenosyl-4-methylthio-2-oxobutanoate,"A sulfonium betaine that is the conjugate base of S-adenosyl-4-methylthio-2-oxobutanoic acid, arising from deprotonation of the carboxy group.","InChI=1S/C15H19N5O6S/c1-27(3-2-7(21)15(24)25)4-8-10(22)11(23)14(26-8)20-6-19-9-12(16)17-5-18-13(9)20/h5-6,8,10-11,14,22-23H,2-4H2,1H3,(H2-,16,17,18,24,25)/t8-,10-,11-,14-,27?/m1/s1",4-[(5'-adenosyl)(methyl)sulfonio]-2-oxobutanoate,Beilstein Registry Number,9665212
7857,17335,4-O-beta-D-glucosyl-4-coumaric acid,,"InChI=1S/C15H18O8/c16-7-10-12(19)13(20)14(21)15(23-10)22-9-4-1-8(2-5-9)3-6-11(17)18/h1-6,10,12-16,19-21H,7H2,(H,17,18)/t10-,12-,13+,14-,15-/m1/s1",4-O-[4-(2-carboxyvinyl)phenyl]-beta-D-glucopyranose,KEGG COMPOUND accession,C04415
7858,17911,6-(N-acetyl-D-glucosaminyl-1-phosphono)-D-mannose,A mannose phosphate that is D-mannose phosphorylated at position 6 by a N-acetyl-D-glucosaminyl-1-phosphono group. Found in the milk of giant pandas.,"InChI=1S/C14H26NO14P/c1-4(17)15-7-10(20)8(18)5(2-16)28-14(7)29-30(24,25)26-3-6-9(19)11(21)12(22)13(23)27-6/h5-14,16,18-23H,2-3H2,1H3,(H,15,17)(H,24,25)/t5-,6-,7-,8-,9-,10-,11+,12+,13+,14-/m1/s1",(N-acetyl-D-glucosaminyl)phospho-D-mannose,PubMed citation,26630345
7859,18284,thiamine(1+) triphosphate(1-),An ammonium betaine that is the conjugate base of thiamine(1+) triphosphate arising from the deptoronation of one of the hydroxy groups of the terminal phosphate group.,"InChI=1S/C12H19N4O10P3S/c1-8-11(30-7-16(8)6-10-5-14-9(2)15-12(10)13)3-4-24-28(20,21)26-29(22,23)25-27(17,18)19/h5,7H,3-4,6H2,1-2H3,(H5-,13,14,15,17,18,19,20,21,22,23)",thiamin triphosphate,Beilstein Registry Number,3812917
7860,19982,3-chloroacrylic acid,A chlorocarboxylic acid that is acrylic acid in which one of the hydrogens at position 3 is substituted by chlorine.,"InChI=1S/C3H3ClO2/c4-2-1-3(5)6/h1-2H,(H,5,6)",3-chloro-2-propenoic acids,Reaxys Registry Number,14713319
7861,20794,7-methylguanosine,A positively charged methylguanosine in which a single methyl substituent is located at position 7.,"InChI=1S/C11H15N5O5/c1-15-3-16(8-5(15)9(20)14-11(12)13-8)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2-,12,13,14,20)/p+1/t4-,6-,7-,10-/m1/s1",G,PDBeChem accession,MG7
7862,21695,N-cyclopropylammelide,"A dihydroxy-1,3,5-triazine consisting of ammelide bearing an N-cyclohexyl substituent.","InChI=1S/C6H8N4O2/c11-5-8-4(7-3-1-2-3)9-6(12)10-5/h3H,1-2H2,(H3,7,8,9,10,11,12)",N-cyclopropylammelide,UM-BBD compID,c0762
7863,27421,3-hydroxykynurenamine,A hydroxykynurenamine that is kynurenamine carrying a hydroxy group at position 3. It is a metabolite of tryptophan that exhibits antiinflammatory and immunomodulatory properties.,"InChI=1S/C9H12N2O2/c10-5-4-7(12)6-2-1-3-8(13)9(6)11/h1-3,13H,4-5,10-11H2",3-hydroxy-kynurenamine,KEGG COMPOUND accession,C05636
7864,27550,"3,6-anhydro-D-glucose",,"InChI=1S/C6H10O5/c7-1-3(8)6-5(10)4(9)2-11-6/h1,3-6,8-10H,2H2/t3-,4+,5+,6+/m0/s1","3,6-Anhydro-D-glucose",KEGG COMPOUND accession,C06478
7865,27855,L-erythro-3-methylmalyl-CoA,A hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of L-erythro-3-methylmalic acid.,"InChI=1S/C26H42N7O20P3S/c1-12(16(35)24(39)40)25(41)57-7-6-28-14(34)4-5-29-22(38)19(37)26(2,3)9-50-56(47,48)53-55(45,46)49-8-13-18(52-54(42,43)44)17(36)23(51-13)33-11-32-15-20(27)30-10-31-21(15)33/h10-13,16-19,23,35-37H,4-9H2,1-3H3,(H,28,34)(H,29,38)(H,39,40)(H,45,46)(H,47,48)(H2,27,30,31)(H2,42,43,44)/t12-,13+,16+,17+,18+,19-,23+/m0/s1",L-erythro-3-methylmalyl-coenzyme A,PubMed citation,18065535
7866,27981,"3,5-dinitro-4-hydroxyphenylpyruvic acid","A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 3,5-dinitro-4-hydroxyphenyl group.","InChI=1S/C9H6N2O8/c12-7(9(14)15)3-4-1-5(10(16)17)8(13)6(2-4)11(18)19/h1-2,13H,3H2,(H,14,15)","3-(4-hydroxy-3,5-dinitrophenyl)-2-oxopropionic acid",KEGG COMPOUND accession,C04286
7867,28038,5-formyl-3-hydroxy-2-methylpyridine-4-carboxylic acid,"A pyridinemonocarboxylic acid that is pyridine-4-carboxylic acid substituted by a methyl group, hydroxy group and formyl group at positions 2,3 and 5, respectively.","InChI=1S/C8H7NO4/c1-4-7(11)6(8(12)13)5(3-10)2-9-4/h2-3,11H,1H3,(H,12,13)",5-formyl-3-hydroxy-2-methyl-4-pyridinecarboxylic acid,KEGG COMPOUND accession,C06050
7868,28132,N-acetyl-beta-D-glucosamine 6-sulfate,An amino monosaccharide that consists of N-acetyl-beta-D-glucosamine substituted at position 6 by a sulfo group.,"InChI=1S/C8H15NO9S/c1-3(10)9-5-7(12)6(11)4(18-8(5)13)2-17-19(14,15)16/h4-8,11-13H,2H2,1H3,(H,9,10)(H,14,15,16)/t4-,5-,6-,7-,8-/m1/s1",beta-D-GlcNAc6S,Reaxys Registry Number,7489343
7869,28249,"2-hydroxy-5-methyl-cis,cis-muconic acid","A dicarboxylic acid that is cis,cis-muconic acid in which the hydrogens at positions 2 and 5 are substituted by hydroxy and methyl groups, respectively.","InChI=1S/C7H8O5/c1-4(6(9)10)2-3-5(8)7(11)12/h2-3,8H,1H3,(H,9,10)(H,11,12)/b4-2-,5-3+","(2E,4Z)-2-hydroxy-5-methylhexa-2,4-dienedioic acid",KEGG COMPOUND accession,C07478
7870,28281,5-methoxyindole-3-acetic acid,A member of the class of indole-3-acetic acids in which the hydrogen at position 5 of indole-3-acetic acid has been replaced by a methoxy group.,"InChI=1S/C11H11NO3/c1-15-8-2-3-10-9(5-8)7(6-12-10)4-11(13)14/h2-3,5-6,12H,4H2,1H3,(H,13,14)",2-(5-methoxy-1H-indol-3-yl)ethanoic acid,KEGG COMPOUND accession,C05660
7871,28513,Se-methyl-L-selenomethionine,A Se-methylselenomethionine that has L-configuration.,"InChI=1S/C6H13NO2Se/c1-10(2)4-3-5(7)6(8)9/h5H,3-4,7H2,1-2H3/p+1/t5-/m0/s1",3-(dimethylselenoniomethyl)-L-alanine,KEGG COMPOUND accession,C05690
7872,28876,melphalan,A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.,"InChI=1S/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1","p-N,N-bis(2-chloroethyl)amino-L-phenylalanine",Wikipedia accession,Melphalan
7873,29476,3-amino-4-hydroxybenzoic acid,A monohydroxybenzoic acid that is 4-hydroxybenzoic acid carrying an additional amino substitutent at position 3.,"InChI=1S/C7H7NO3/c8-5-3-4(7(10)11)1-2-6(5)9/h1-3,9H,8H2,(H,10,11)","3,4-AHBA",CAS Registry Number,1571-72-8
7874,29503,"4',7-dihydroxyflavone",A dihydroxyflavone in which the two hydroxy substituents are located at positions 4' and 7.,"InChI=1S/C15H10O4/c16-10-3-1-9(2-4-10)14-8-13(18)12-6-5-11(17)7-15(12)19-14/h1-8,16-17H","7,4'-Dihydroxyflavone",KEGG COMPOUND accession,C12123
7875,29506,cethromycin,"A macrolide antibiotic which displays in vitro activity against both gram-positive and gram-negative bacteria and is currently under investigation for the treatment of community-acquired pneumonia. The US Food and Drug Administration (FDA) have also granted orphan drug designation to cethromycin for the treatment of anthrax prophylaxis, tularemia, and plague (PDB entry: 1NWX).","InChI=1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41-,42-/m1/s1",A-195773,KEGG COMPOUND accession,C12020
7876,29509,abietal,"A derivative of abieta-7,13-diene having an oxo group on one of the gem-dimethyl groups.","InChI=1S/C20H30O/c1-14(2)15-6-8-17-16(12-15)7-9-18-19(3,13-21)10-5-11-20(17,18)4/h7,12-14,17-18H,5-6,8-11H2,1-4H3/t17-,18-,19-,20+/m0/s1",Abietal,KEGG COMPOUND accession,C11887
7877,29649,narbomycin,"A macrolide antibiotic that is narbonolide having a 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residue attached at position 6. It is biosynthesised by Streptomyces venezuelae.","InChI=1S/C28H47NO7/c1-10-23-15(2)11-12-22(30)16(3)13-17(4)26(19(6)24(31)20(7)27(33)35-23)36-28-25(32)21(29(8)9)14-18(5)34-28/h11-12,15-21,23,25-26,28,32H,10,13-14H2,1-9H3/b12-11+/t15-,16-,17+,18-,19+,20-,21+,23-,25-,26+,28+/m1/s1",Narbomycin,KEGG COMPOUND accession,C11998
7878,29655,neocarzinostatin chromophore,"A naphthoate ester obtained by formal condensation of the carboxy group of 2-hydroxy-7-methoxy-5-methyl-1-naphthoic acid with the 5-hydroxy group of (1aS,5R,6R,6aE,9aR)-5-hydroxy-1a-[(4R)-2-oxo-1,3-dioxolan-4-yl]-2,3,8,9-tetradehydro-1a,5,6,9a-tetrahydrocyclopenta[5,6]cyclonona[1,2-b]oxiren-6-yl 2,6-dideoxy-2-(methylamino)-alpha-D-galactopyranoside. The chromophoric part of neocarzinostatin, it is tightly and non-covelently bound to a 113-membered apoprotein, which serves to protect it and release it to the target DNA.","InChI=1S/C35H33NO12/c1-16-12-19(42-4)14-22-20(16)8-9-23(37)27(22)32(40)45-24-13-18-10-11-35(26-15-43-34(41)46-26)25(48-35)7-5-6-21(18)31(24)47-33-28(36-3)30(39)29(38)17(2)44-33/h6,8-9,12-14,17,24-26,28-31,33,36-39H,15H2,1-4H3/b21-6+/t17-,24-,25-,26-,28-,29+,30-,31-,33-,35+/m1/s1",Neocarzinostatin chromophore,KEGG COMPOUND accession,C12049
7879,29700,tylactone,A 16-membererd macrolide that is the aglycone of the antibiotic 5-O-beta-D-mycaminosyltylactone.,"InChI=1S/C23H38O5/c1-7-18-12-15(4)19(24)10-9-14(3)11-16(5)21(8-2)28-22(26)13-20(25)17(6)23(18)27/h9-11,15-18,20-21,23,25,27H,7-8,12-13H2,1-6H3/b10-9+,14-11+/t15-,16+,17+,18+,20-,21-,23-/m1/s1",Tylactone,KEGG COMPOUND accession,C12000
7880,30042,"taxa-4(20),11-dien-5alpha-yl acetate",A taxane diterpenoid that is taxane which contains double bounds at the 4-20 and 11-12 positions and which is substituted by an acetoxy group at the 5alpha position.,"InChI=1S/C22H34O2/c1-14-7-8-17-13-19-15(2)20(24-16(3)23)10-12-22(19,6)11-9-18(14)21(17,4)5/h17,19-20H,2,7-13H2,1,3-6H3/t17-,19+,20-,22+/m0/s1","taxa-4(20),11-dien-5alphayl acetate",CAS Registry Number,214628-37-2
7881,30320,thioacetate,,"InChI=1S/C2H4OS/c1-2(3)4/h1H3,(H,3,4)/p-1",Thioacetat,CAS Registry Number,29632-72-2
7882,30959,4-pyridoxate,"A pyridoxate that is the conjugate base of 4-pyridoxic acid, obtained by deprotonation of the carboxy group.","InChI=1S/C8H9NO4/c1-4-7(11)6(8(12)13)5(3-10)2-9-4/h2,10-11H,3H2,1H3,(H,12,13)/p-1",4-pyridoxinate,MetaCyc accession,CPD-1112
7883,31252,"5,5-diethylbarbituric acid","A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).","InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)",Barbital,CAS Registry Number,57-44-3
7884,31440,copper(II) sulfate pentahydrate,The pentahydrate of copper(2+) sulfate. A bright blue crystalline solid.,"InChI=1S/Cu.H2O4S.5H2O/c;1-5(2,3)4;;;;;/h;(H2,1,2,3,4);5*1H2/q+2;;;;;;/p-2",Cupric sulfate,CAS Registry Number,7758-99-8
7885,31441,fluticasone propionate,"A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.","InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1",Fluticasone propionate,KEGG DRUG accession,D01708
7886,31448,cyclothiazide,"3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted at positions 3, 5 and 6 by a 2-norbornen-5-yl group, chlorine, and a sulfonamide group, respectively. A thiazide diuretic, it has been used in the management of hypertension and oedema.","InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)",Cyclothiazide,KEGG COMPOUND accession,C12685
7887,31503,dioncopeltine A,"An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 7-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 1-hydroxy-6-(hydroxymethyl)-8-methoxynaphthalen-5-yl group. It is a naphthylisoquinoline alkaloid found in Triphyophyllum peltatum.","InChI=1S/C23H25NO4/c1-12-9-14-7-8-17(23(27)20(14)13(2)24-12)21-15(11-25)10-19(28-3)22-16(21)5-4-6-18(22)26/h4-8,10,12-13,24-27H,9,11H2,1-3H3/t12-,13-/m1/s1",Dioncopeltine A,KEGG COMPOUND accession,C12339
7888,31504,dioncophylline A,"An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 7-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 4,5-dimethoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of  Triphyophyllum peltatum and exhibits antifungal, antimalarial, antineoplastic and molluscicidal activites.","InChI=1S/C24H27NO3/c1-13-11-20(28-5)23-17(7-6-8-19(23)27-4)21(13)18-10-9-16-12-14(2)25-15(3)22(16)24(18)26/h6-11,14-15,25-26H,12H2,1-5H3/t14-,15-/m1/s1",Dioncophylline A,KEGG COMPOUND accession,C12336
7889,31505,dioncophylline C,"An isoquinoline alkaloid that is the biaryl resulting from substitution of the hydrogen at the 5-position of (1R,3R)-1,3-dimethyl-1,2,3,4-tetrahydroisoquinolin-8-ol by a 5-hydroxy-4-methoxy-2-methylnaphthalen-1-yl group. It is a naphthylisoquinoline alkaloid isolated from the roots and stem barks of Triphyophyllum peltatum and exhibits antimalarial activity.","InChI=1S/C23H25NO3/c1-12-10-20(27-4)23-16(6-5-7-18(23)25)21(12)15-8-9-19(26)22-14(3)24-13(2)11-17(15)22/h5-10,13-14,24-26H,11H2,1-4H3/t13-,14-/m1/s1",Dioncophylline C,KEGG COMPOUND accession,C12337
7890,31536,emtricitabine,"An organofluorine compound  that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.","InChI=1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1",Emtricitabine,KEGG COMPOUND accession,C12599
7891,31549,epothilone A,"An epithilone that is epothilone C in which the double bond in the macrocyclic lactone ring has been oxidised to the corresponding epoxide (the 13R,14S diastereoisomer).","InChI=1S/C26H39NO6S/c1-14-8-7-9-19-21(32-19)11-20(15(2)10-18-13-34-17(4)27-18)33-23(29)12-22(28)26(5,6)25(31)16(3)24(14)30/h10,13-14,16,19-22,24,28,30H,7-9,11-12H2,1-6H3/b15-10+/t14-,16+,19+,20-,21-,22-,24-/m0/s1",Epothilone A,KEGG COMPOUND accession,C12153
7892,31677,hydrocortisone succinate,A derivative of succinic acid in which one of the carboxy groups is esterified by the C-21 hydroxy group of cortisol (hydrocortisone).,"InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1",Hydrocortisone succinate,KEGG COMPOUND accession,C12888
7893,31850,militarinone A,"A pyridine alkaloid that is 1,4-dihydroxypyridin-2(1H)-one substituted by a cis-1,4-dihydroxycyclohexyl group at position 5 and a (2E,4E,6E,8R,10R)-6,8,10-trimethyldodeca-2,4,6-trienoyl moiety at position 3. It is isolated from the mycelium of the entomogenous fungus, Paecilomyces militaris and has been found to induce pronounced neurite sprouting.","InChI=1S/C26H37NO6/c1-5-17(2)14-19(4)15-18(3)8-6-7-9-22(29)23-24(30)21(16-27(33)25(23)31)26(32)12-10-20(28)11-13-26/h6-9,15-17,19-20,28,30,32-33H,5,10-14H2,1-4H3/b8-6+,9-7+,18-15+/t17-,19-,20-,26+/m1/s1",Militarinone A,KEGG COMPOUND accession,C12333
7894,31882,N-methyl-D-aspartic acid,An aspartic acid derivative having an N-methyl substituent and D-configuration.,"InChI=1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)/t3-/m1/s1",N-Methyl-D-aspartic acid,KEGG COMPOUND accession,C12269
7895,32155,stigmatellin A,A member of the class of chromones that is isolated from Stigmatella aurantiaca Sg a15.,"InChI=1S/C30H42O7/c1-10-18(2)13-11-12-14-22(33-6)21(5)29(36-9)19(3)15-16-23-20(4)27(31)26-24(34-7)17-25(35-8)28(32)30(26)37-23/h10-14,17,19,21-22,29,32H,15-16H2,1-9H3/b13-11+,14-12+,18-10+/t19-,21+,22-,29-/m0/s1",Stigmatellin,KEGG COMPOUND accession,C12148
7896,32818,p-coumaroylagmatine,A member of the class of cinnamamides obtained by formal condensation of the carboxy group of 4-coumaric acid with the primary amino group of agmatine.,"InChI=1S/C14H20N4O2/c15-14(16)18-10-2-1-9-17-13(20)8-5-11-3-6-12(19)7-4-11/h3-8,19H,1-2,9-10H2,(H,17,20)(H4,15,16,18)",N-(4-guanidinobutyl)-4-hydroxycinnamamide,KEGG COMPOUND accession,C04498
7897,34107,1-nitropyrene,"A nitroarene that is pyrene substituted at the 1-position by a nitro group. A by-product of combustion,  it is the predominant nitrated polycyclic aromatic hydrocarbon emitted in a diesel engine.",InChI=1S/C16H9NO2/c18-17(19)14-9-7-12-5-4-10-2-1-3-11-6-8-13(14)16(12)15(10)11/h1-9H,1-Nitropyrene,KEGG COMPOUND accession,C14421
7898,34112,1-O-hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine,A phosphatidylcholine (O-16:0/18:1) in which the alkyl and the acyl groups at positions 1 and 2 are hexadecyl and oleoyl respectively.,"InChI=1S/C42H84NO7P/c1-6-8-10-12-14-16-18-20-22-23-25-27-29-31-33-35-42(44)50-41(40-49-51(45,46)48-38-36-43(3,4)5)39-47-37-34-32-30-28-26-24-21-19-17-15-13-11-9-7-2/h20,22,41H,6-19,21,23-40H2,1-5H3/b22-20-/t41-/m1/s1",1-O-Hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine,KEGG COMPOUND accession,C13894
7899,34126,11(R)-HETE,An 11-HETE in which the chiral centre at position 11 has R-configuration.,"InChI=1S/C20H32O3/c1-2-3-4-5-7-10-13-16-19(21)17-14-11-8-6-9-12-15-18-20(22)23/h6-7,9-11,13-14,16,19,21H,2-5,8,12,15,17-18H2,1H3,(H,22,23)/b9-6-,10-7-,14-11-,16-13+/t19-/m0/s1",11(R)-HETE,KEGG COMPOUND accession,C14780
7900,34130,"11,12-EET","An EET obtained by formal epoxidation of the 11,12-double bond of arachidonic acid.","InChI=1S/C20H32O3/c1-2-3-4-5-9-12-15-18-19(23-18)16-13-10-7-6-8-11-14-17-20(21)22/h6,8-10,12-13,18-19H,2-5,7,11,14-17H2,1H3,(H,21,22)/b8-6-,12-9-,13-10-","11,12-EET",KEGG COMPOUND accession,C14770
7901,34227,"2,3-di-O-phytanyl-sn-glycerol",A dialkylglycerol that is glycerol alkylated at positions 1 and 2 by phytanyl groups with (R)-configuration at position 2.,"InChI=1S/C43H88O3/c1-35(2)17-11-19-37(5)21-13-23-39(7)25-15-27-41(9)29-31-45-34-43(33-44)46-32-30-42(10)28-16-26-40(8)24-14-22-38(6)20-12-18-36(3)4/h35-44H,11-34H2,1-10H3/t37-,38-,39-,40-,41-,42-,43-/m1/s1","2,3-Di-O-phytanyl-sn-glycerol",KEGG COMPOUND accession,C13863
7902,34283,oxybenzone,A hydroxybenzophenone that is benzophenone which is substituted at the 2- and 4-positions of one of the benzene rings by hydroxy and methoxy groups respectively.,"InChI=1S/C14H12O3/c1-17-11-7-8-12(13(15)9-11)14(16)10-5-3-2-4-6-10/h2-9,15H,1H3",2-Hydroxy-4-methoxybenzophenone,KEGG COMPOUND accession,C14285
7903,34288,2-hydroxyethyl methacrylate,An enoate ester that is the monomethacryloyl derivative of ethylene glycol.,"InChI=1S/C6H10O3/c1-5(2)6(8)9-4-3-7/h7H,1,3-4H2,2H3",2-Hydroxyethyl methacrylate,KEGG COMPOUND accession,C14530
7904,34292,"1,3-benzothiazole-2-thiol","1,3-Benzothiazole substituted at the 2-position with a sulfanyl group.","InChI=1S/C7H5NS2/c9-7-8-5-3-1-2-4-6(5)10-7/h1-4H,(H,8,9)",2-Mercaptobenzothiazole,KEGG COMPOUND accession,C14437
7905,34334,3-formylsalicylic acid,A hydroxybenzoic acid that is salicylic acid in which the hydrogen at position 3 is substituted by a formyl group.,"InChI=1S/C8H6O4/c9-4-5-2-1-3-6(7(5)10)8(11)12/h1-4,10H,(H,11,12)",3-Formylsalicylic acid,UM-BBD compID,c0728
7906,34380,monobenzone,The monobenzyl ether of hydroquinone.  It is used as a topical drug for medical depigmentation.,"InChI=1S/C13H12O2/c14-12-6-8-13(9-7-12)15-10-11-4-2-1-3-5-11/h1-9,14H,10H2",4-(Benzyloxyl)phenol,KEGG COMPOUND accession,C14244
7907,34444,4-tert-butylphenol,A member of the class of phenols that is phenol substituted with a  tert-butyl group at position 4.,"InChI=1S/C10H14O/c1-10(2,3)8-4-6-9(11)7-5-8/h4-7,11H,1-3H3",4-tert-Butylphenol,KEGG COMPOUND accession,C14200
7908,34450,"5,6-EET","An EET obtained by formal epoxidation of the 5,6-double bond of arachidonic acid.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-18-19(23-18)16-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-","5,6-EET",KEGG COMPOUND accession,C14768
7909,34477,6beta-hydroxytestosterone,A 17beta-hydroxy steroid that is testosterone bearing an additional hydroxy substituent at the 6beta-position.,"InChI=1S/C19H28O3/c1-18-7-5-11(20)9-15(18)16(21)10-12-13-3-4-17(22)19(13,2)8-6-14(12)18/h9,12-14,16-17,21-22H,3-8,10H2,1-2H3/t12-,13-,14-,16+,17-,18+,19-/m0/s1",6beta-Hydroxytestosterone,KEGG COMPOUND accession,C14497
7910,34490,"8,9-EET","An EET obtained by formal epoxidation of the 8,9-double bond of arachidonic acid.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-12-15-18-19(23-18)16-13-10-11-14-17-20(21)22/h6-7,9-10,12-13,18-19H,2-5,8,11,14-17H2,1H3,(H,21,22)/b7-6-,12-9-,13-10-","8,9-EET",KEGG COMPOUND accession,C14769
7911,34575,bisphenol F,A bisphenol that is methane in which two of the hydrogens have been replaced by 4-hydroxyphenyl groups.,"InChI=1S/C13H12O2/c14-12-5-1-10(2-6-12)9-11-3-7-13(15)8-4-11/h1-8,14-15H,9H2",Bis(4-hydroxyphenyl)methane,KEGG COMPOUND accession,C14298
7912,34648,clofibric acid,A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.,"InChI=1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)",Clofibric acid,KEGG COMPOUND accession,C13700
7913,34687,dibutyl phthalate,"A phthalate ester that is the diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of  butan-1-ol. Although used extensively as a plasticiser, it is a ubiquitous environmental contaminant that poses a risk to humans.","InChI=1S/C16H22O4/c1-3-5-11-19-15(17)13-9-7-8-10-14(13)16(18)20-12-6-4-2/h7-10H,3-6,11-12H2,1-2H3",Dibutyl phthalate,KEGG COMPOUND accession,C14214
7914,34768,furfural,An aldehyde that is furan with the hydrogen at position 2 substituted by a formyl group.,InChI=1S/C5H4O2/c6-4-5-2-1-3-7-5/h1-4H,2-Furaldehyde,KEGG COMPOUND accession,C14279
7915,34778,glycitein,A  methoxyisoflavone that is isoflavone substituted by a methoxy group at position 6 and hydroxy groups at positions 7 and 4'. It has been isolated from the mycelia of the fungus Cordyceps sinensis.,"InChI=1S/C16H12O5/c1-20-15-6-11-14(7-13(15)18)21-8-12(16(11)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3","7,4'-Dihydroxy-6-methoxyisoflavone",KEGG COMPOUND accession,C14536
7916,36090,4-coumaric acid,A coumaric acid in which the hydroxy substituent is located at C-4 of the phenyl ring.,"InChI=1S/C9H8O3/c10-8-4-1-7(2-5-8)3-6-9(11)12/h1-6,10H,(H,11,12)",3-(4-hydroxyphenyl)acrylic acid,CAS Registry Number,7400-08-0
7917,36183,ferriheme a,A ferriheme in which the 1-hydroxy group has S-configuration.,"InChI=1S/C49H58N4O6.Fe/c1-9-34-31(6)39-25-45-49(46(55)18-12-17-30(5)16-11-15-29(4)14-10-13-28(2)3)33(8)40(52-45)24-44-37(27-54)36(20-22-48(58)59)43(53-44)26-42-35(19-21-47(56)57)32(7)38(51-42)23-41(34)50-39;/h9,13,15,17,23-27,46,55H,1,10-12,14,16,18-22H2,2-8H3,(H4,50,51,52,53,54,56,57,58,59);/q;+3/p-2/b29-15+,30-17+,38-23-,39-25-,40-24-,41-23-,42-26-,43-26-,44-24-,45-25-;/t46-;/m0./s1",(cytoporphyrinato)iron(III),PDBeChem accession,HAS
7918,36658,6-methylsalicylate,A hydroxybenzoate that is obtained by removal of a proton from the carboxylic acid group of 6-methylsalicylic acid.,"InChI=1S/C8H8O3/c1-5-3-2-4-6(9)7(5)8(10)11/h2-4,9H,1H3,(H,10,11)/p-1",2-hydroxy-6-methylbenzoate,KEGG COMPOUND accession,C02657
7919,37447,meso-tetrakis(N-methyl-4-pyridyl)porphine(4+),"An organic cation that is porphyrin bearing four 1-methylpyridinium-4-yl groups at the 5-, 10-, 15- and 20-positions.","InChI=1S/C44H37N8/c1-49-21-13-29(14-22-49)41-33-5-7-35(45-33)42(30-15-23-50(2)24-16-30)37-9-11-39(47-37)44(32-19-27-52(4)28-20-32)40-12-10-38(48-40)43(36-8-6-34(41)46-36)31-17-25-51(3)26-18-31/h5-28H,1-4H3,(H,45,46,47,48)/q+3/p+1/b41-33-,41-34-,42-35-,42-37-,43-36-,43-38-,44-39-,44-40-",tetra(4-N-methylpyridyl)porphine,Beilstein Registry Number,3586693
7920,40009,D-cycloserine,"A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and  D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).","InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1",(R)-4-AMINO-ISOXAZOLIDIN-3-ONE,PDBeChem accession,4AX
7921,40154,5-fluorouridine,An organofluorine compound that is uridine bearing a fluoro substituent at position 5 on the uracil ring.,"InChI=1S/C9H11FN2O6/c10-3-1-12(9(17)11-7(3)16)8-6(15)5(14)4(2-13)18-8/h1,4-6,8,13-15H,2H2,(H,11,16,17)/t4-,5-,6-,8-/m1/s1",5-FLUOROURIDINE,PDBeChem accession,5UD
7922,40304,8-hydroxy-2'-deoxyguanosine,Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.,"InChI=1S/C10H13N5O5/c11-9-13-7-6(8(18)14-9)12-10(19)15(7)5-1-3(17)4(2-16)20-5/h3-5,16-17H,1-2H2,(H,12,19)(H3,11,13,14,18)/t3-,4+,5+/m0/s1",8-HYDROXY-2'-DEOXYGUANOSINE,PDBeChem accession,8HG
7923,40618,aminoguanidine,"A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.","InChI=1S/CH6N4/c2-1(3)5-4/h4H2,(H4,2,3,5)",AMINOGUANIDINE,PDBeChem accession,AGU
7924,40863,"3,4-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-sulfonic acid","A dihydroxyanthraquinone that is 1,2-dihydroxyanthraquinone compound carrying an additional sulfo substituent at the 3-position. The monosodium salt is the biological stain 'alizarin red S'.","InChI=1S/C14H8O7S/c15-11-6-3-1-2-4-7(6)12(16)10-8(11)5-9(22(19,20)21)13(17)14(10)18/h1-5,17-18H,(H,19,20,21)",ALIZARIN RED,PDBeChem accession,AZN
7925,40951,"4,4'-(aminomethylene)bis(N,N-dimethylaniline)",,"InChI=1S/C17H23N3/c1-19(2)15-9-5-13(6-10-15)17(18)14-7-11-16(12-8-14)20(3)4/h5-12,17H,18H2,1-4H3","4,4'-(aminomethylene)bis(N,N-dimethylaniline)",Beilstein Registry Number,2811625
7926,41001,ecgonine benzoate,"A  benzoate ester metabolite of cocaine formed by hydrolysis of the methyl ester group, catalysed by carboxylesterases.","InChI=1S/C16H19NO4/c1-17-11-7-8-12(17)14(15(18)19)13(9-11)21-16(20)10-5-3-2-4-6-10/h2-6,11-14H,7-9H2,1H3,(H,18,19)/t11-,12+,13-,14+/m0/s1","(1R,2R,3S,5S)-8-methyl-3-[(phenylcarbonyl)oxy]-8-azabicyclo[3.2.1]octane-2-carboxylic acid",Beilstein Registry Number,89637
7927,41059,bisindolylmaleimide III,,"InChI=1S/C23H20N4O2/c24-10-5-11-27-13-17(15-7-2-4-9-19(15)27)21-20(22(28)26-23(21)29)16-12-25-18-8-3-1-6-14(16)18/h1-4,6-9,12-13,25H,5,10-11,24H2,(H,26,28,29)",bis-(III) indolyl-maleimide,Beilstein Registry Number,10489041
7928,41128,octyl beta-D-glucopyranoside,An beta-D-glucoside in which the anomeric hydrogen of beta-D-glucopyranose is substituted by an octyl group.,"InChI=1S/C14H28O6/c1-2-3-4-5-6-7-8-19-14-13(18)12(17)11(16)10(9-15)20-14/h10-18H,2-9H2,1H3/t10-,11-,12+,13-,14-/m1/s1",beta-octylglucoside,PDBeChem accession,BOG
7929,41450,gamma-carboxy-L-glutamic acid,A  non-proteinogenic L-alpha-amino acid that is L-glutamic acid in which one of the gamma-hydrogens is substituted by a carboxy group.,"InChI=1S/C6H9NO6/c7-3(6(12)13)1-2(4(8)9)5(10)11/h2-3H,1,7H2,(H,8,9)(H,10,11)(H,12,13)/t3-/m0/s1",GAMMA-CARBOXY-GLUTAMIC ACID,PDBeChem accession,CGU
7930,41480,N-cyclohexyl-N'-(4-iodophenyl)urea,A member of the class of phenylureas that is urea in which a hydrogen attached to one nitrogen is replaced by a cyclohexyl group and a hydrogen attached to the other nitrogen is replaced by a p-iodophenyl group.,"InChI=1S/C13H17IN2O/c14-10-6-8-12(9-7-10)16-13(17)15-11-4-2-1-3-5-11/h6-9,11H,1-5H2,(H2,15,16,17)",N-CYCLOHEXYL-N'-(4-IODOPHENYL)UREA,PDBeChem accession,CIU
7931,41509,cholesteryl linoleate,"The (9Z,12Z)-stereoisomer of cholesteryl octadeca-9,12-dienoate.","InChI=1S/C45H76O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-43(46)47-38-30-32-44(5)37(34-38)26-27-39-41-29-28-40(36(4)24-22-23-35(2)3)45(41,6)33-31-42(39)44/h11-12,14-15,26,35-36,38-42H,7-10,13,16-25,27-34H2,1-6H3/b12-11-,15-14-/t36-,38+,39+,40-,41+,42+,44+,45-/m1/s1",CHOLESTERYL LINOLEATE,PDBeChem accession,CLL
7932,41539,1-(3-O-sulfo-beta-D-galactosyl)-N-[(15Z)-tetracos-15-enoyl]sphingosine,An N-acyl-beta-D-galactosylsphingosine having a sulfo group at the 3-position on the galactose ring and (15Z)-tetracos-15-enoyl as the N-acyl group.,"InChI=1S/C48H91NO11S/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-26-28-30-32-34-36-38-44(52)49-41(42(51)37-35-33-31-29-27-25-16-14-12-10-8-6-4-2)40-58-48-46(54)47(60-61(55,56)57)45(53)43(39-50)59-48/h17-18,35,37,41-43,45-48,50-51,53-54H,3-16,19-34,36,38-40H2,1-2H3,(H,49,52)(H,55,56,57)/b18-17-,37-35+/t41-,42+,43+,45-,46+,47-,48+/m0/s1","(15Z)-N-((1S,2R,3E)-2-HYDROXY-1-{[(3-O-SULFO-BETA-D-GALACTOPYRANOSYL)OXY]METHYL}HEPTADEC-3-ENYL)TETRACOS-15-ENAMIDE",PDBeChem accession,CIS
7933,41928,"3,4-dihydro-5-methylisoquinolinone",,"InChI=1S/C10H11NO/c1-7-3-2-4-9-8(7)5-6-11-10(9)12/h2-4H,5-6H2,1H3,(H,11,12)","5-methyl-3,4-dihydroisoquinolin-1(2H)-one",Beilstein Registry Number,8200799
7934,42027,"1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine","A 1,2-di-octadecadienoyl-sn-glycero-3-phosphocholine in which the double bonds in each fatty acyl group are at positions 9 and 12 and have Z configuration.","InChI=1S/C44H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-43(46)50-40-42(41-52-54(48,49)51-39-38-45(3,4)5)53-44(47)37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h14-17,20-23,42H,6-13,18-19,24-41H2,1-5H3/b16-14-,17-15-,22-20-,23-21-/t42-/m1/s1","1,2-DILINOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE",PDBeChem accession,DLP
7935,43892,"methyl 4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-2-O-methyl-alpha-D-mannopyranoside","An N-acyl-hexosamine that is the methyl alpha-glycoside of the terminal moiety, and presumed antigenic determinant, of the O-specific polysaccharide of Vibrio cholerae O:1, serotype Ogawa.","InChI=1S/C12H23NO7/c1-6-8(13-11(17)7(15)4-5-14)9(16)10(18-2)12(19-3)20-6/h6-10,12,14-16H,4-5H2,1-3H3,(H,13,17)/t6-,7+,8-,9+,10+,12+/m1/s1","1,2-O-DIMETHYL-4-[2,4-DIHYDROXY-BUTYRAMIDO]-4,6-DIDEOXY-ALPHA-D-MANNOPYRANOSIDE",PDBeChem accession,MGS
7936,43980,N-methyl-L-phenylalanine,A phenylalanine derivative consisting of L-phenylalanine having a methyl substuent attached to the alpha-amino function.,"InChI=1S/C10H13NO2/c1-11-9(10(12)13)7-8-5-3-2-4-6-8/h2-6,9,11H,7H2,1H3,(H,12,13)/t9-/m0/s1",N-METHYLPHENYLALANINE,PDBeChem accession,MEA
7937,43997,"N(6),N(6)-dimethyl-L-lysine",An L-lysine derivative comprising L-lysine having two methyl substituents attached to the side-chain amino group.,"InChI=1S/C8H18N2O2/c1-10(2)6-4-3-5-7(9)8(11)12/h7H,3-6,9H2,1-2H3,(H,11,12)/t7-/m0/s1","N(epsilon),N(epsilon)-dimethyllysine",PDBeChem accession,MLY
7938,44003,N-methyl-L-methionine,A methyl-L-methionine having the methyl group attached to the alpha-amino function.,"InChI=1S/C6H13NO2S/c1-7-5(6(8)9)3-4-10-2/h5,7H,3-4H2,1-2H3,(H,8,9)/t5-/m0/s1",N-methylmethionine,PDBeChem accession,MME
7939,44079,N(4)-methyl-L-asparagine,An N-methyl-L-asparagine with a single methyl substituent attached to the amide nitrogen.,"InChI=1S/C5H10N2O3/c1-7-4(8)2-3(6)5(9)10/h3H,2,6H2,1H3,(H,7,8)(H,9,10)/t3-/m0/s1",N(gamma)-methylasparagine,PDBeChem accession,MEN
7940,44369,duvoglustat,"An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.","InChI=1S/C6H13NO4/c8-2-3-5(10)6(11)4(9)1-7-3/h3-11H,1-2H2/t3-,4+,5-,6-/m1/s1",1-DEOXYNOJIRIMYCIN,CAS Registry Number,19130-96-2
7941,45075,7-cyano-7-deazaguanine,A pyrrolopyrimidine that is 7-deazaguanine substituted at position 7 by a cyano group.,"InChI=1S/C7H5N5O/c8-1-3-2-10-5-4(3)6(13)12-7(9)11-5/h2H,(H4,9,10,11,12,13)","2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBONITRILE",PDBeChem accession,PQ0
7942,45192,"1,2-dilauroyl-sn-glycero-3-phosphate",A 1-acyl-2-dodecanoyl-sn-glycerol-3-phosphate in which the 1-acyl group is also dodecanoyl (lauroyl).,"InChI=1S/C27H53O8P/c1-3-5-7-9-11-13-15-17-19-21-26(28)33-23-25(24-34-36(30,31)32)35-27(29)22-20-18-16-14-12-10-8-6-4-2/h25H,3-24H2,1-2H3,(H2,30,31,32)/t25-/m1/s1","(2R)-2,3-bis(dodecanoyloxy)propyl hydrogen phosphate",PDBeChem accession,PX2
7943,45353,phosphoramidon,A dipeptide isolated from the cultures of Streptomyces tanashiensis.,"InChI=1S/C23H34N3O10P/c1-11(2)8-16(26-37(33,34)36-23-20(29)19(28)18(27)12(3)35-23)21(30)25-17(22(31)32)9-13-10-24-15-7-5-4-6-14(13)15/h4-7,10-12,16-20,23-24,27-29H,8-9H2,1-3H3,(H,25,30)(H,31,32)(H2,26,33,34)/t12-,16-,17-,18-,19+,20+,23-/m0/s1",N-ALPHA-L-RHAMNOPYRANOSYLOXY(HYDROXYPHOSPHINYL)-L-LEUCYL-L-TRYPTOPHAN,CAS Registry Number,36357-77-4
7944,45410,(S)-2-hydroxypropylphosphonic acid,2-Hydroxypropylphosphonic acid with S configuration at the chiral centre.,"InChI=1S/C3H9O4P/c1-3(4)2-8(5,6)7/h3-4H,2H2,1H3,(H2,5,6,7)/t3-/m0/s1",(S)-2-HYDROXYPROPYLPHOSPHONIC ACID,PDBeChem accession,S0H
7945,46215,O(4')-sulfo-L-tyrosine,An O-sulfoamino acid that is L-tyrosine in which the phenolic hydrogen has been replaced by a sulfo group.,"InChI=1S/C9H11NO6S/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H,13,14,15)/t8-/m0/s1",O-sulfo-L-tyrosine,PDBeChem accession,TYS
7946,46398,UTP(4-),A nucleoside triphosphate(4-) obtained by global deprotonation of the triphosphate OH groups of UTP; major species present at pH 7.3.,"InChI=1S/C9H15N2O15P3/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H,10,12,15)(H2,16,17,18)/p-4/t4-,6-,7-,8-/m1/s1",utp,Beilstein Registry Number,5204708
7947,46784,diglyme,A polyether that is the dimethyl ether derivative of diethylene glycol.,"InChI=1S/C6H14O3/c1-7-3-5-9-6-4-8-2/h3-6H2,1-2H3","2,2'-oxybis(1-methoxyethane)",PDBeChem accession,M2M
7948,47564,mometasone furoate,,"InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1",MOMETASONE FUROATE,PDBeChem accession,MOF
7949,47771,beta-tocopherol,"A tocopherol in which the chroman-6-ol core is substituted by methyl groups at positions 5 and 8. While it is found in low concentrations in many vegetable oils, only cottonseed oil contains significant amounts.","InChI=1S/C28H48O2/c1-20(2)11-8-12-21(3)13-9-14-22(4)15-10-17-28(7)18-16-25-24(6)26(29)19-23(5)27(25)30-28/h19-22,29H,8-18H2,1-7H3/t21-,22-,28-/m1/s1","(R,R,R)-beta-tocopherol",CAS Registry Number,16698-35-4
7950,47772,delta-tocopherol,A tocopherol in which the chroman-6-ol core is substituted by a methyl group at position 8. It is found particularly in maize (corn) oil and soya bean (soybean) oils.,"InChI=1S/C27H46O2/c1-20(2)10-7-11-21(3)12-8-13-22(4)14-9-16-27(6)17-15-24-19-25(28)18-23(5)26(24)29-27/h18-22,28H,7-17H2,1-6H3/t21-,22-,27-/m1/s1",RRR-delta-tocopherol,CAS Registry Number,119-13-1
7951,51666,7-methoxycoumarin-4-acetic acid,,"InChI=1S/C12H10O5/c1-16-8-2-3-9-7(4-11(13)14)5-12(15)17-10(9)6-8/h2-3,5-6H,4H2,1H3,(H,13,14)",7-Methoxy-2-oxo-2H-1-benzopyran-4-acetic acid,Beilstein Registry Number,221128
7952,52781,C3-oxacyanine,"A C3 cyanine dye having 3-ethyl-1,3-benzoxazol-2(3H)-yl units at each end.","InChI=1S/C21H21N2O2.HI/c1-3-22-16-10-5-7-12-18(16)24-20(22)14-9-15-21-23(4-2)17-11-6-8-13-19(17)25-21;/h5-15H,3-4H2,1-2H3;1H/q+1;/p-1",Oxacarbocyanine (C3),CAS Registry Number,905-96-4
7953,52979,N-tetracosanoylphytosphingosine,A phytoceramide compound having a tetracosanoyl group attached to the nitrogen atom.,"InChI=1S/C42H85NO4/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-27-29-31-33-35-37-41(46)43-39(38-44)42(47)40(45)36-34-32-30-28-26-16-14-12-10-8-6-4-2/h39-40,42,44-45,47H,3-38H2,1-2H3,(H,43,46)/t39-,40+,42-/m0/s1",cer2_24,Reaxys Registry Number,3635804
7954,52980,N-hexacosanoylphytosphingosine,A phytoceramide compound having a hexacosanoyl group attached to the nitrogen atom.,"InChI=1S/C44H89NO4/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-27-29-31-33-35-37-39-43(48)45-41(40-46)44(49)42(47)38-36-34-32-30-28-16-14-12-10-8-6-4-2/h41-42,44,46-47,49H,3-40H2,1-2H3,(H,45,48)/t41-,42+,44-/m0/s1",cer2_26,Reaxys Registry Number,7319623
7955,52982,"4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp2Me-(1->2)-4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp-(1->2)-4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp","An amido trisaccharide fragment which mimicks the terminus of the O-polysaccharide of Vibrio cholerae O:1, serotype Ogawa.","InChI=1S/C31H55N3O19/c1-11-17(32-26(44)14(38)5-8-35)20(41)23(29(47)49-11)52-31-25(22(43)19(13(3)51-31)34-28(46)16(40)7-10-37)53-30-24(48-4)21(42)18(12(2)50-30)33-27(45)15(39)6-9-36/h11-25,29-31,35-43,47H,5-10H2,1-4H3,(H,32,44)(H,33,45)(H,34,46)/t11-,12-,13-,14+,15+,16+,17-,18-,19-,20+,21+,22+,23+,24+,25+,29+,30-,31-/m1/s1","Vibrio Cholerae O1, serotype Ogawa trisaccharide",PubMed citation,16098493
7956,53467,alpha-L-Fucp-(1->3)-{alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)}-D-GlcpNAc,A branched heptasaccharide derivative consisting of a D-GlcNAc residue at the reducing end with an alpha-D-Man-(1->6)-[beta-D-Xyl-(1->2)]-[alpha-D-Man-(1->3)]-beta-D-Man-(1->4)-beta-D-GlcNAc moiety attached via a (1->4)-linkage and an L-Fuc residue attached via an alpha-(1->3)-linkage.,"InChI=1S/C45H76N2O34/c1-10-21(55)27(61)32(66)43(71-10)79-36-20(47-12(3)53)39(68)72-17(7-51)35(36)78-40-19(46-11(2)52)26(60)34(16(6-50)75-40)77-45-38(81-42-30(64)22(56)13(54)8-69-42)37(80-44-33(67)29(63)24(58)15(5-49)74-44)25(59)18(76-45)9-70-41-31(65)28(62)23(57)14(4-48)73-41/h10,13-45,48-51,54-68H,4-9H2,1-3H3,(H,46,52)(H,47,53)/t10-,13+,14+,15+,16+,17+,18+,19+,20+,21+,22-,23+,24+,25+,26+,27+,28-,29-,30+,31-,32-,33-,34+,35+,36+,37-,38-,39?,40-,41-,42-,43-,44+,45-/m0/s1",MMXF(3),PubMed citation,9621106
7957,53486,"all-cis-icosa-8,11,14-trienoic acid","An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.","InChI=1S/C20H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13H,2-5,8,11,14-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-",Homo-gamma-linolenic acid,PDBeChem accession,LAX
7958,53488,"(7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid","The all-cis-isomer of a C22 polyunsaturated fatty acid having five double bonds in the 7-, 10-, 13-, 16- and 19-positions.","InChI=1S/C22H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-",docosapentaenoic acid,Reaxys Registry Number,2287314
7959,53651,alpha-D-galactosyl-(1->3)-D-galactose,A galactobiose comprising an alpha-D-galactopyranose residue and a D-galactopyranose residue joined via an alpha-(1->3) linkage.,"InChI=1S/C12H22O11/c13-1-3-5(15)7(17)8(18)12(22-3)23-10-6(16)4(2-14)21-11(20)9(10)19/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8-,9-,10+,11?,12-/m1/s1","Galalpha1,3Gal",PubMed citation,19070355
7960,59045,alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,A branched amino tetrasaccharide consisting of N-acetyl-beta-D-glucosamine at the reducing end having an alpha-L-fucosyl residue attached at the 3-position and an alpha-L-fucosyl-(1->2)-beta-D-galactosyl moiety attached at the 4-position. A cancer-associated tetrasaccharide antigen which constitutes the core structure recognised by therapeutic antibody BR96. Conformational restriction around the GlcNAc residue is a key feature of its structure.,"InChI=1S/C26H45NO19/c1-6-12(31)15(34)18(37)24(40-6)45-21-11(27-8(3)30)23(39)42-10(5-29)20(21)44-26-22(17(36)14(33)9(4-28)43-26)46-25-19(38)16(35)13(32)7(2)41-25/h6-7,9-26,28-29,31-39H,4-5H2,1-3H3,(H,27,30)/t6-,7-,9+,10+,11+,12+,13+,14-,15+,16+,17-,18-,19-,20+,21+,22+,23+,24-,25-,26-/m0/s1",Lewis Y tetrasaccharide,PubMed citation,7664109
7961,59226,N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose,"An amino trisaccharide that is the carbohydrate portion of ganglioside GM3. It comprises a linear sequence of alpha-N-acetylneuraminyl, beta-D-galactosyl and beta-D-glucose residues linked (2->3) and (1->4).","InChI=1S/C23H39NO19/c1-6(28)24-11-7(29)2-23(22(37)38,42-18(11)12(31)8(30)3-25)43-19-13(32)9(4-26)40-21(16(19)35)41-17-10(5-27)39-20(36)15(34)14(17)33/h7-21,25-27,29-36H,2-5H2,1H3,(H,24,28)(H,37,38)/t7-,8+,9+,10+,11+,12+,13-,14+,15+,16+,17+,18+,19-,20+,21-,23-/m0/s1",alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-beta-D-Glcp,PubMed citation,11164910
7962,59267,"4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp2Me-(1->2)-4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp-(1->2)-4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp-(1->2)-4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp-(1->2)-4,6-dideoxy-4-(3-deoxy-L-glycero-tetronamido)-alpha-D-Manp","An amido pentasaccharide fragment which mimicks the terminus of the O-polysaccharide of Vibrio cholerae O:1, serotype Ogawa.","InChI=1S/C51H89N5O31/c1-17-27(52-42(72)22(62)7-12-57)32(67)37(47(77)79-17)84-49-39(34(69)29(19(3)81-49)54-44(74)24(64)9-14-59)86-51-41(36(71)31(21(5)83-51)56-46(76)26(66)11-16-61)87-50-40(35(70)30(20(4)82-50)55-45(75)25(65)10-15-60)85-48-38(78-6)33(68)28(18(2)80-48)53-43(73)23(63)8-13-58/h17-41,47-51,57-71,77H,7-16H2,1-6H3,(H,52,72)(H,53,73)(H,54,74)(H,55,75)(H,56,76)/t17-,18-,19-,20-,21-,22+,23+,24+,25+,26+,27-,28-,29-,30-,31-,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,47+,48-,49-,50-,51-/m1/s1","Vibrio Cholerae O1, serotype Ogawa pentasaccharide",PubMed citation,16098493
7963,59414,muramyl dipeptide,A glycopeptide that is N-propionyl-L-alanyl-D-alpha-glutamine in which the pro-R hydrogen of the propionyl group has been replaced by the oxygen at position 3 of 2-acetamido-2-deoxy-beta-D-glucopyranose. A peptidoglycan constituent of both Gram-positive and Gram-negative bacteria.,"InChI=1S/C19H32N4O11/c1-7(17(30)23-10(16(20)29)4-5-12(26)27)21-18(31)8(2)33-15-13(22-9(3)25)19(32)34-11(6-24)14(15)28/h7-8,10-11,13-15,19,24,28,32H,4-6H2,1-3H3,(H2,20,29)(H,21,31)(H,22,25)(H,23,30)(H,26,27)/t7-,8+,10+,11+,13+,14+,15+,19+/m0/s1",MDP,Beilstein Registry Number,5323915
7964,59581,alpha-D-Galp-(1->2)-[alpha-D-Abep-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-Galp-(1->2)-[alpha-D-Abep-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap-(1->3)-alpha-D-Galp-(1->2)-[alpha-D-Abep-(1->3)]-alpha-D-Manp-(1->4)-alpha-L-Rhap,A polysaccharide that is a branched dodecasaccharide consisting of three repeating tetrasaccharide units; reported to be a possible epitope of the O-antigen polysaccharide in Salmonella.,"InChI=1S/C72H122O52/c1-16-22(79)7-25(82)62(103-16)119-55-37(88)31(13-76)111-70(58(55)122-67-45(96)40(91)34(85)28(10-73)108-67)115-51-20(5)106-65(46(97)42(51)93)118-54-36(87)30(12-75)110-69(49(54)100)124-60-57(121-64-27(84)9-24(81)18(3)105-64)39(90)33(15-78)113-72(60)116-52-21(6)107-66(47(98)43(52)94)117-53-35(86)29(11-74)109-68(48(53)99)123-59-56(120-63-26(83)8-23(80)17(2)104-63)38(89)32(14-77)112-71(59)114-50-19(4)102-61(101)44(95)41(50)92/h16-101H,7-15H2,1-6H3/t16-,17-,18-,19+,20+,21+,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34+,35+,36+,37-,38-,39-,40+,41+,42+,43+,44-,45-,46-,47-,48-,49-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61-,62-,63-,64-,65+,66+,67-,68-,69-,70-,71-,72-/m1/s1",S. thymurium SH 4809 O-PS dodecasaccharide,PubMed citation,10640784
7965,60125,N(6)-(1-carboxyethyl)-L-lysine,"A L-lysine derivative formed during the reaction between methylglyoxal and protein. CEL is a homologue of N(epsilon)-(carboxymethyl)lysine (CML), an advanced glycation end-product that is formed on reaction of glyoxal or glycolaldehyde with protein and on oxidative cleavage of fructoselysine, the Amadori adduct formed on glycation of protein by glucose.","InChI=1S/C9H18N2O4/c1-6(8(12)13)11-5-3-2-4-7(10)9(14)15/h6-7,11H,2-5,10H2,1H3,(H,12,13)(H,14,15)/t6?,7-/m0/s1",CEL,PubMed citation,9182719
7966,60187,alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-Gal,A galactotriose in which the three D-galactosyl residues are connected via sequential alpha-(1->3)- and beta-(1->4)-linkages.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)12(27)17(31-4)34-15-8(23)5(2-20)32-18(13(15)28)33-14-6(3-21)30-16(29)11(26)10(14)25/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10-,11-,12-,13-,14+,15+,16?,17-,18+/m1/s1",alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-D-Galp,PubMed citation,19913595
7967,60188,alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-alpha-D-Galp-(1->3)-D-Galp,"A galactotetraose comprised of four D-galactose residues connected sequentially by alpha(1->3), beta(1->4) and alpha(1->3) linkages.","InChI=1S/C24H42O21/c25-1-5-9(29)12(32)14(34)22(40-5)45-20-11(31)7(3-27)41-24(17(20)37)43-18-8(4-28)42-23(15(35)13(18)33)44-19-10(30)6(2-26)39-21(38)16(19)36/h5-38H,1-4H2/t5-,6-,7-,8-,9+,10+,11+,12+,13-,14-,15-,16-,17-,18+,19+,20+,21?,22-,23-,24+/m1/s1",Galalpha1-3Galbeta1-4Galalpha1-3Gal,Beilstein Registry Number,1633281
7968,60243,alpha-L-Fucp-(1->2)-[alpha-D-Galp-(1->3)]-D-Galp,An L-Fucp-(1->2)-[D-Galp-(1->3)]-D-Galp in which the both the L-fucosyl group at position 2 and the D-galactosyl groups at position 3 have alpha- configuration.,"InChI=1S/C18H32O15/c1-4-7(21)10(24)12(26)17(29-4)33-15-14(9(23)6(3-20)30-16(15)28)32-18-13(27)11(25)8(22)5(2-19)31-18/h4-28H,2-3H2,1H3/t4-,5+,6+,7+,8-,9-,10+,11-,12-,13+,14-,15+,16?,17-,18+/m0/s1",alpha-L-fucosyl-(1->2)-[alpha-D-galactosyl-(1->3)]-D-galactose,PubMed citation,19913595
7969,60357,iron-sulfur-vanadium cofactor,"A 7Fe-V-9S-X-homocitryl cluster, the structure of which is assumed to be analogous to the 7Fe-Mo-9S-X-homocitryl cluster. The identity of the X atom is not known, possibly carbon or oxygen.","InChI=1S/C7H9O7.7Fe.N.9S.V/c8-4(9)1-2-7(14,6(12)13)3-5(10)11;;;;;;;;;;;;;;;;;;/h1-3H2,(H,8,9)(H,10,11)(H,12,13);;;;;;;;;;;;;;;;;;/q-1;;;;;;;;;;;;;;;;;;+2/p-3",7Fe-V-9S-X-homocitryl cluster,PubMed citation,12870953
7970,60657,"1,2-di-O-arachidonoyl-sn-glycero-3-phosphocholine","A 1,2-diacyl-sn-glycero-3-phosphocholine in which the phosphatidyl acyl groups at positions 1 and 2 are both arachidonoyl.","InChI=1S/C48H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-38-40-47(50)54-44-46(45-56-58(52,53)55-43-42-49(3,4)5)57-48(51)41-39-37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h14-17,20-23,26-29,32-35,46H,6-13,18-19,24-25,30-31,36-45H2,1-5H3/b16-14-,17-15-,22-20-,23-21-,28-26-,29-27-,34-32-,35-33-/t46-/m1/s1","1,2-diarachidonoyl-sn-glycero-3-phosphocholine",LIPID MAPS instance accession,LMGP01011052
7971,60943,5-HETE,"A HETE having a 5-hydroxy group and (6E)-, (8Z)-, (11Z)- and (14Z)-double bonds.","InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16,19,21H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+","5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid",LIPID MAPS instance accession,LMFA03060084
7972,60946,alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-Glc,A linear trisaccharide comprising D-glucose (at the reducing end) having an alpha-D-galactosyl-(1->3)-beta-D-galactosyl moiety at the 4-position.,"InChI=1S/C18H32O16/c19-1-4-7(22)9(24)12(27)17(31-4)34-15-8(23)5(2-20)32-18(13(15)28)33-14-6(3-21)30-16(29)11(26)10(14)25/h4-29H,1-3H2/t4-,5-,6-,7+,8+,9+,10-,11-,12-,13-,14-,15+,16?,17-,18+/m1/s1",alpha-D-Galp-(1->3)-beta-D-Galp-(1->4)-D-Glcp,KEGG GLYCAN accession,G00419
7973,60998,Ac-Cha-Gpg-Disc-Nle-NMeBn,"A synthetic tetrapeptide composed of the non-natural Ac-Cha, Gpg, Disc and Nle-NMeBn residues coupled in sequence.","InChI=1S/C42H60N8O5/c1-4-5-20-34(40(54)48(3)26-30-16-10-7-11-17-30)46-39(53)37-33-19-13-12-18-32(33)27-50(37)41(55)36(31-21-23-49(24-22-31)42(43)44)47-38(52)35(45-28(2)51)25-29-14-8-6-9-15-29/h7,10-13,16-19,29,31,34-37H,4-6,8-9,14-15,20-27H2,1-3H3,(H3,43,44)(H,45,51)(H,46,53)(H,47,52)/t34-,35-,36-,37-/m0/s1",Ac-(Cha)(Gpg)(Disc)(Nle)-NMeBn,PubMed citation,17081730
7974,61146,4-nitrophenyl phosphate(2-),An organophosphate oxoanion that results from the removal of two protons from the phosphate group of 4-nitrophenyl phosphate.,"InChI=1S/C6H6NO6P/c8-7(9)5-1-3-6(4-2-5)13-14(10,11)12/h1-4H,(H2,10,11,12)/p-2",p-nitrophenyl phosphate,Reaxys Registry Number,3680906
7975,61147,ferroheme d1,A ferroheme having four carboxy groups and oxo groups on two of the pyrrole rings.,"InChI=1S/C34H32N4O10.Fe/c1-15-17(5-7-27(39)40)21-10-22-18(6-8-28(41)42)16(2)20(36-22)11-25-33(3,13-29(43)44)32(48)24(38-25)12-26-34(4,14-30(45)46)31(47)23(37-26)9-19(15)35-21;/h6,8-12H,5,7,13-14H2,1-4H3,(H6,35,36,37,38,39,40,41,42,43,44,45,46,47,48);/q;+2/p-2/b8-6+;/t33-,34-;/m1./s1",heme d1,PubMed citation,15311934
7976,61448,isopropyl beta-D-thiogalactopyranoside,An S-glycosyl compound consisting of beta-D-1-thiogalactose having an isopropyl group attached to the anomeric sulfur.,"InChI=1S/C9H18O5S/c1-4(2)15-9-8(13)7(12)6(11)5(3-10)14-9/h4-13H,3H2,1-2H3/t5-,6+,7+,8-,9+/m1/s1",IPTG,PDBeChem accession,IPT
7977,61842,"2,3-dipalmitoyl-S-glycerylcysteine","An L-cysteine thioether that is L-cysteine in which the hydrogen of the thiol group is substituted by a 2,3-bis(palmitoyloxy)propyl group.","InChI=1S/C38H73NO6S/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(40)44-31-34(32-46-33-35(39)38(42)43)45-37(41)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h34-35H,3-33,39H2,1-2H3,(H,42,43)/t34?,35-/m0/s1",Pam2Cys,PubMed citation,17675478
7978,62107,beta-D-glucosyl-N-(docosanoyl)sphingosine,A beta-D-glucosylceramide where the ceramide N-acyl group is specified as docosanoyl.,"InChI=1S/C46H89NO8/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-42(50)47-39(38-54-46-45(53)44(52)43(51)41(37-48)55-46)40(49)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2/h33,35,39-41,43-46,48-49,51-53H,3-32,34,36-38H2,1-2H3,(H,47,50)/b35-33+/t39-,40+,41+,43+,44-,45+,46+/m0/s1",beta-D-glucopyranosyl-N-(docosanoyl)sphingosine,Reaxys Registry Number,73642
7979,62223,2-(beta-D-glucosyloxy)-cis-cinnamate,A hydroxy monocarboxylic acid anion that is the conjugate base of 2-(beta-D-glucosyl)oxy-cis-cinnamic acid; major species ar pH 7.3.,"InChI=1S/C15H18O8/c16-7-10-12(19)13(20)14(21)15(23-10)22-9-4-2-1-3-8(9)5-6-11(17)18/h1-6,10,12-16,19-21H,7H2,(H,17,18)/p-1/b6-5-/t10-,12-,13+,14-,15-/m1/s1",cis-coumarinate-beta-D-glucosyl,MetaCyc accession,CPD-7417
7980,62250,UDP-2-acetamido-2-deoxy-alpha-D-ribo-hex-3-uluronate(3-),A nucleotide-sugar oxoanion obtained via deprotonation of the diphosphate and carboxy OH groups of UDP-2-acetamido-2-deoxy-alpha-D-ribo-hex-3-uluronic acid; major species at pH 7.3.,"InChI=1S/C17H23N3O18P2/c1-5(21)18-8-10(24)11(25)13(15(27)28)36-16(8)37-40(32,33)38-39(30,31)34-4-6-9(23)12(26)14(35-6)20-3-2-7(22)19-17(20)29/h2-3,6,8-9,11-14,16,23,25-26H,4H2,1H3,(H,18,21)(H,27,28)(H,30,31)(H,32,33)(H,19,22,29)/p-3/t6-,8-,9-,11+,12-,13+,14-,16-/m1/s1",UDP-GlcNAc(3keto)A(3-),PubMed citation,20604544
7981,62638,(S)-3-hydroxyisobutyrate,The hydroxy fatty acid anion that is formed by loss of a proton from the carboxy group of (S)-3-hydroxyisobutyric acid.,"InChI=1S/C4H8O3/c1-3(2-5)4(6)7/h3,5H,2H2,1H3,(H,6,7)/p-1/t3-/m0/s1",(S)-3-hydroxy-2-methylpropanoate,KEGG COMPOUND accession,C06001
7982,62877,2-deoxy-D-ribofuranose 5-phosphate(2-),An organophosphate oxoanion obtained by deprotonation of the phosphate OH groups of 2-deoxy-D-ribose 5-monophosphate; major microspecies at pH 7.3.,"InChI=1S/C5H11O7P/c6-3-1-5(7)12-4(3)2-11-13(8,9)10/h3-7H,1-2H2,(H2,8,9,10)/p-2/t3-,4+,5?/m0/s1","[(2R,3S)-3,5-dihydroxyoxolan-2-yl]methyl phosphate",MetaCyc accession,DEOXY-RIBOSE-5P
7983,62919,"1-diphospho-1D-myo-inositol 2,3,4,5,6-pentakisphosphate","A myo-inositol pentakisphosphate that consists of myo-inositol having the five phospho groups located at positions 2, 3, 4, 5 and 6 as well as a diphospho group at position 1.","InChI=1S/C6H19O27P7/c7-34(8,9)27-1-2(28-35(10,11)12)4(30-37(16,17)18)6(32-40(25,26)33-39(22,23)24)5(31-38(19,20)21)3(1)29-36(13,14)15/h1-6H,(H,25,26)(H2,7,8,9)(H2,10,11,12)(H2,13,14,15)(H2,16,17,18)(H2,19,20,21)(H2,22,23,24)/t1-,2-,3+,4-,5-,6-/m1/s1",1-PP-IP5,KEGG COMPOUND accession,C11174
7984,62990,alpha-L-Fucp-(1->2)-[alpha-D-GalpNAc-(1->3)]-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc,A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-alpha-D-galactosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine having alpha-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.,"InChI=1S/C34H58N2O24/c1-8-17(42)22(47)24(49)32(52-8)58-27-16(36-11(4)41)30(51)54-14(7-39)26(27)57-34-29(60-33-25(50)23(48)18(43)9(2)53-33)28(20(45)13(6-38)56-34)59-31-15(35-10(3)40)21(46)19(44)12(5-37)55-31/h8-9,12-34,37-39,42-51H,5-7H2,1-4H3,(H,35,40)(H,36,41)/t8-,9-,12+,13+,14+,15+,16+,17+,18+,19-,20-,21+,22+,23+,24-,25-,26+,27+,28-,29+,30+,31+,32-,33-,34-/m0/s1",alpha-L-Fuc-(1->2)-[alpha-D-GalNAc-(1->3)]-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc,PubMed citation,75942
7985,63260,dTDP-alpha-D-desosamine(1-),"A nucleotide-sugar oxoanion that is the conjugate base of dTDP-alpha-D-desosamine, arising from deprotonation of the diphosphate group and protonation of the amino group.","InChI=1S/C18H31N3O13P2/c1-9-7-21(18(25)19-16(9)24)14-6-12(22)13(32-14)8-30-35(26,27)34-36(28,29)33-17-15(23)11(20(3)4)5-10(2)31-17/h7,10-15,17,22-23H,5-6,8H2,1-4H3,(H,26,27)(H,28,29)(H,19,24,25)/p-1/t10-,11+,12+,13-,14-,15-,17-/m1/s1",dTDP-alpha-D-desosamine anion,PubMed citation,20695498
7986,64011,(3Z)-2-oxohex-3-enedioate,2-Oxohex-3-enedioate in which the C=C double bond has Z configuration; principal microspecies at pH 7.3.,"InChI=1S/C6H6O5/c7-4(6(10)11)2-1-3-5(8)9/h1-2H,3H2,(H,8,9)(H,10,11)/p-2/b2-1-",(3Z)-5-oxohex-3-enedioate,PubMed citation,19717587
7987,64900,"[(1R)-2,2,3-trimethyl-5-oxocyclopent-3-enyl]acetyl-CoA","An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of [(1R)-2,2,3-trimethyl-5-oxocyclopent-3-en-1-yl]acetic acid.","InChI=1S/C31H48N7O18P3S/c1-16-10-18(39)17(31(16,4)5)11-21(41)60-9-8-33-20(40)6-7-34-28(44)25(43)30(2,3)13-53-59(50,51)56-58(48,49)52-12-19-24(55-57(45,46)47)23(42)29(54-19)38-15-37-22-26(32)35-14-36-27(22)38/h10,14-15,17,19,23-25,29,42-43H,6-9,11-13H2,1-5H3,(H,33,40)(H,34,44)(H,48,49)(H,50,51)(H2,32,35,36)(H2,45,46,47)/t17-,19+,23+,24+,25-,29+/m0/s1","[(R)-2,2,3-trimethyl-5-oxocyclopent-3-en-1-yl]acetyl-coenzyme A",PubMed citation,22267661
7988,65048,cyclo(tyrosyl-tyrosyl),"A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by p-hydroxybenzyl groups.","InChI=1S/C18H18N2O4/c21-13-5-1-11(2-6-13)9-15-17(23)20-16(18(24)19-15)10-12-3-7-14(22)8-4-12/h1-8,15-16,21-22H,9-10H2,(H,19,24)(H,20,23)",cYY,PubMed citation,19430487
7989,65136,"(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid","The all-cis-isomer of a C22 polyunsaturated fatty acid having five double bonds in the 4-, 7-, 10-, 13- and 16-positions. It is a member of n-6 PUFA and a product of linoleic acid metabolism.","InChI=1S/C22H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h6-7,9-10,12-13,15-16,18-19H,2-5,8,11,14,17,20-21H2,1H3,(H,23,24)/b7-6-,10-9-,13-12-,16-15-,19-18-",Docosapentaenoic acid (22n-6),LIPID MAPS instance accession,LMFA04000064
7990,66994,N-hexacosanoylicosasphinganine,A C20 dihydroceramide in which the ceramide N-acyl group is specified as hexacosanoyl.,"InChI=1S/C46H93NO3/c1-3-5-7-9-11-13-15-17-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-42-46(50)47-44(43-48)45(49)41-39-37-35-33-31-29-27-18-16-14-12-10-8-6-4-2/h44-45,48-49H,3-43H2,1-2H3,(H,47,50)/t44-,45+/m0/s1",DHC-A 20:0/26:0,LIPID MAPS instance accession,LMSP02020028
7991,68701,(E)-5-hydroxy-6-(3-methylbut-2-enyl)-2-(pent-1-enyl)benzofuran-4-carbaldehyde,"A member of the class of 1-benzofurans that is 1-benzofuran substituted by a hydroxy group at position 5, a prenyl group at position 6 and a pent-1-en-1-yl group at position 2. Isolated from Chaetomium globosum, it exhibits radical scavenging activity.","InChI=1S/C19H22O3/c1-4-5-6-7-15-11-16-17(12-20)19(21)14(9-8-13(2)3)10-18(16)22-15/h6-8,10-12,21H,4-5,9H2,1-3H3/b7-6+",5-hydroxy-6-(3-methylbut-2-enyl)-2-[(E)-pent-1-enyl]-1-benzofuran-4-carbaldehyde,PubMed citation,21667972
7992,68709,"7,8-dihydroxy-1-methoxy-3-methyl-10-oxo-4,10-dihydro-1H,3H-pyrano[4,3-b]chromene-9-carboxylic acid","An organic heterotricyclic compound that is 4,10-dihydro-1H,3H-pyrano[4,3-b]chromene substituted by hydroxy groups at positions 7 and 8, a methoxy group at position 1, a methyl group at position 3, an oxo group at position 10 and a carboxy group at position 9. Isolated from Chaetomium funicola it exhibits inhibitory activity against metallo-beta-lactamases.","InChI=1S/C15H14O8/c1-5-3-7-10(15(21-2)22-5)13(18)9-8(23-7)4-6(16)12(17)11(9)14(19)20/h4-5,15-17H,3H2,1-2H3,(H,19,20)",SB236050,PDBeChem accession,113
7993,71466,oleoyl ethanolamide,An N-(long-chain-acyl)ethanolamine that is the ethanolamide of oleic acid. The monounsaturated analogue of the endocannabinoid anandamide.,"InChI=1S/C20H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)21-18-19-22/h9-10,22H,2-8,11-19H2,1H3,(H,21,23)/b10-9-",oleoyl 1-ethanolamide,LIPID MAPS instance accession,LMFA08040015
7994,72637,"(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid","A hydroxydocosahexaenoic acid that consists of 4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid bearing an additional 17-hydroxy substituent.","InChI=1S/C22H32O3/c1-2-3-15-18-21(23)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(24)25/h3,5-8,11-16,19,21,23H,2,4,9-10,17-18,20H2,1H3,(H,24,25)/b7-5-,8-6-,13-11-,14-12-,15-3-,19-16+",17-HDoHE,CAS Registry Number,90780-52-2
7995,72998,1-hexadecanoyl-sn-glycero-3-phosphocholine,A lysophosphatidylcholine 16:0 in which a hexadecanoyl (palmitoyl) group is attached to the glycero moiety at position 1.,"InChI=1S/C24H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)30-21-23(26)22-32-33(28,29)31-20-19-25(2,3)4/h23,26H,5-22H2,1-4H3/t23-/m1/s1",LPC(16:0/0:0),MetaCyc accession,CPD-8343
7996,72999,"1,2-dihexadecanoyl-sn-glycero-3-phosphocholine",A phosphatidylcholine 32:0 in which the 1- and 2-acyl groups are specified as hexadecanoyl (palmitoyl). A synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of pulmonary surfactants.,"InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1",PC(16:0/16:0),Reaxys Registry Number,1917966
7997,73008,"1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine zwitterion","A phosphatidylethanolamine 34:2 zwitterion obtained by transfer of a proton from the phosphate to the amino group of 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine.","InChI=1S/C39H74NO8P/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-39(42)48-37(36-47-49(43,44)46-34-33-40)35-45-38(41)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h11,13,17-18,37H,3-10,12,14-16,19-36,40H2,1-2H3,(H,43,44)/b13-11-,18-17-/t37-/m1/s1","PE(16:0/18:2(9Z,12Z))",MetaCyc accession,CPD-8284
7998,73269,N-hexacosanoylisoglobotriaosyl ceramide,The N-hexacosanoyl derivative of isoglobotriaosyl ceramide.,"InChI=1S/C62H117NO18/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-23-24-25-26-28-30-32-34-36-38-40-50(68)63-45(46(67)39-37-35-33-31-29-27-16-14-12-10-8-6-4-2)44-76-60-56(74)54(72)58(49(43-66)79-60)80-62-57(75)59(52(70)48(42-65)78-62)81-61-55(73)53(71)51(69)47(41-64)77-61/h37,39,45-49,51-62,64-67,69-75H,3-36,38,40-44H2,1-2H3,(H,63,68)/b39-37+/t45-,46+,47+,48+,49+,51-,52-,53-,54+,55+,56+,57+,58+,59-,60+,61+,62-/m0/s1",isoglobotrihexosylceramide,Reaxys Registry Number,10327819
7999,73493,Glu-Glu-Glu,A tripeptide composed of three L-glutamic acid units joined by peptide linkages.,"InChI=1S/C15H23N3O10/c16-7(1-4-10(19)20)13(25)17-8(2-5-11(21)22)14(26)18-9(15(27)28)3-6-12(23)24/h7-9H,1-6,16H2,(H,17,25)(H,18,26)(H,19,20)(H,21,22)(H,23,24)(H,27,28)/t7-,8-,9-/m0/s1",E-E-E,Reaxys Registry Number,1717825
8000,73707,gamma-Glu-Gln,A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of glutamine,"InChI=1S/C10H17N3O6/c11-5(9(16)17)1-4-8(15)13-6(10(18)19)2-3-7(12)14/h5-6H,1-4,11H2,(H2,12,14)(H,13,15)(H,16,17)(H,18,19)/t5-,6-/m0/s1",gamma-L-Glu-L-Gln,HMDB accession,HMDB0011738
8001,73793,1-tetradecanoyl-2-(11Z-octadecenoyl)-sn-glycero-3-phosphocholine,A phosphatidylcholine 32:1 in which the acyl groups at C-1 and C-2 are tetradecanoyl and (11Z)-octadec-11-enoyl respectively.,"InChI=1S/C40H78NO8P/c1-6-8-10-12-14-16-18-19-20-21-23-25-27-29-31-33-40(43)49-38(37-48-50(44,45)47-35-34-41(3,4)5)36-46-39(42)32-30-28-26-24-22-17-15-13-11-9-7-2/h16,18,38H,6-15,17,19-37H2,1-5H3/b18-16-/t38-/m1/s1",phosphatidylcholine(14:0/18:1(11Z)),LIPID MAPS instance accession,LMGP01010490
8002,73999,1-hexadecanoyl-2-[(9Z)-hexadec-9-enoyl]-sn-glycero-3-phosphoethanolamine zwitterion,A phosphatidylethanolamine 32:1 in which the acyl groups at C-1 and C-2 are hexadecanoyl and (9Z)-hexadec-9-enoyl respectively.,"InChI=1S/C37H72NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(39)43-33-35(34-45-47(41,42)44-32-31-38)46-37(40)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h14,16,35H,3-13,15,17-34,38H2,1-2H3,(H,41,42)/b16-14-/t35-/m1/s1",PE(16:0/16:1(9Z)),LIPID MAPS instance accession,LMGP02011228
8003,74000,1-palmitoyl-2-palmitoleoyl-sn-glycero-3-phosphocholine,A phosphatidylcholine 32:1 in which the acyl groups at C-1 and C-2 are hexadecanoyl and (9Z)-hexadec-9-enoyl respectively.,"InChI=1S/C40H78NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h17,19,38H,6-16,18,20-37H2,1-5H3/b19-17-/t38-/m1/s1",PC(16:0/16:1(9Z)),LIPID MAPS instance accession,LMGP01010566
8004,74673,"5,6-dihydrouridine 5'-monophosphate","A uridine 5'-phosphate that is the 5,6-dihydro derivative of uridine 5'-monophosphate.","InChI=1S/C9H15N2O9P/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18/h4,6-8,13-14H,1-3H2,(H,10,12,15)(H2,16,17,18)/t4-,6-,7-,8-/m1/s1","5,6-dihydro-5'-uridylic acid",PDBeChem accession,H2U
8005,75586,"1,2-hexadecanediol",A glycol that is hexadecane which is substituted by hydroxy groups at positions 1 and 2.,"InChI=1S/C16H34O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16(18)15-17/h16-18H,2-15H2,1H3","1,2-hexadecyl diol",CAS Registry Number,6920-24-7
8006,76023,thioflavine T,"An organic chloride salt having 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium as the counterion. It is widely used to visualise and quantify the presence of amyloids, both in vitro and in vivo.","InChI=1S/C17H19N2S.ClH/c1-12-5-10-15-16(11-12)20-17(19(15)4)13-6-8-14(9-7-13)18(2)3;/h5-11H,1-4H3;1H/q+1;/p-1",ThT,Reaxys Registry Number,3922452
8007,76072,nicotinic acid-adenine dinucleotide phosphate,A nicotinic acid dinucleotide that is NADP(+) in which the carboxamide group on the pyridine ring is replaced by a carboxy group.,"InChI=1S/C21H27N6O18P3/c22-17-12-18(24-7-23-17)27(8-25-12)20-16(44-46(33,34)35)14(29)11(43-20)6-41-48(38,39)45-47(36,37)40-5-10-13(28)15(30)19(42-10)26-3-1-2-9(4-26)21(31)32/h1-4,7-8,10-11,13-16,19-20,28-30H,5-6H2,(H6-,22,23,24,31,32,33,34,35,36,37,38,39)/p+1/t10-,11-,13-,14-,15-,16-,19-,20-/m1/s1",nicotinic acid-adenine dinucleotide phosphate(1+),KEGG COMPOUND accession,C13051
8008,77598,beta-D-Glcp-(1->4)-[alpha-D-GlcpNAc-(1->2)-L-glycero-alpha-D-manno-Hepp-(1->3)]-L-glycero-alpha-D-manno-Hepp-(1->5)-[alpha-Kdo-(2->4)]-alpha-KDo,"A branched amino hexasaccharide consisting of a linear chain of a N-acetyl-alpha-D-glucosamine residue, two L-glycero-alpha-D-manno-heptose (Hep) residues and a 3-deoxy-alpha-D-manno-oct-2-ulosonic acid (Kdo) residue in a (1->2), (->3), (1->5) sequence, to the Hep residue nearest to the Kdo is linked also (1->4) a beta-D-glucose residue, with the Kdo residue also carrying a further Kdo residue linked (2->4). Corresponds to a fragment of an inner core lipooligosaccharide epitope from Neisseria meningitidis.","InChI=1S/C44H73NO37/c1-10(52)45-19-23(61)21(59)17(8-50)72-37(19)78-35-26(64)25(63)29(12(54)4-46)74-40(35)77-34-28(66)39(75-31(14(56)6-48)36(34)79-38-27(65)24(62)22(60)18(9-51)73-38)76-33-16(3-43(71,41(67)68)81-32(33)15(57)7-49)80-44(42(69)70)2-11(53)20(58)30(82-44)13(55)5-47/h11-40,46-51,53-66,71H,2-9H2,1H3,(H,45,52)(H,67,68)(H,69,70)/t11-,12+,13-,14+,15-,16-,17-,18-,19-,20-,21-,22-,23-,24+,25+,26+,27-,28+,29-,30-,31-,32-,33-,34-,35+,36-,37-,38+,39-,40-,43-,44-/m1/s1",beta-D-Glc-(1->4)-[alpha-D-GlcNAc-(1->2)-L-glycero-alpha-D-manno-Hep-(1->3)]-L-glycero-alpha-D-manno-Hep-(1->5)-[alpha-Kdo-(2->4)]-alpha-KDo,PubMed citation,11854213
8009,78084,hepoxilin B3(1-),"A hepoxilin anion that is the conjugate base of hepoxilin B3, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C20H32O4/c1-2-3-4-5-9-12-15-18-20(24-18)17(21)14-11-8-6-7-10-13-16-19(22)23/h6-7,9,11-12,14,17-18,20-21H,2-5,8,10,13,15-16H2,1H3,(H,22,23)/p-1/b7-6-,12-9-,14-11-/t17?,18-,20-/m0/s1","(11S,12S)-epoxy-10-hydroxy-(5Z,8Z,14Z)-icosatrienoate",PubMed citation,2180942
8010,78646,N-hexadecanoylsphingosine-1-phosphocholine,A sphingomyelin 34:1 in which the N-acyl group and sphingoid base are specified as hexadecanoyl and sphingosine respectively.,"InChI=1S/C39H79N2O6P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-38(42)37(36-47-48(44,45)46-35-34-41(3,4)5)40-39(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h30,32,37-38,42H,6-29,31,33-36H2,1-5H3,(H-,40,43,44,45)/b32-30+/t37-,38+/m0/s1",N-palmitoylsphing-4-enine-1-phosphocholine,PubMed citation,19454763
8011,79071,selenoneine,"A histidine derivative that is N(alpha),N(alpha),N(alpha)-trimethyl-L-histidine substituted by a selenoxo group at position 2 on the imidazole ring. A selenium-containing antioxidant found in tuna blood.","InChI=1S/C9H15N3O2Se/c1-12(2,3)7(8(13)14)4-6-5-10-9(15)11-6/h5,7H,4H2,1-3H3,(H2-,10,11,13,14,15)/t7-/m0/s1","2-selenyl-N(alpha),N(alpha),N(alpha)-trimethyl-L-histidine",PubMed citation,24828577
8012,79203,1-(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine,A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and (9Z)-octadecenoyl respectively.,"InChI=1S/C41H80NO7P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-36-46-38-40(39-48-50(44,45)47-37-35-42)49-41(43)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h18,20,33,36,40H,3-17,19,21-32,34-35,37-39,42H2,1-2H3,(H,44,45)/b20-18-,36-33-/t40-/m1/s1",1-(1Z-octadecenyl)-2-oleoyl-sn-glycero-3-phosphoethanolamine,LIPID MAPS instance accession,LMGP02030004
8013,80790,afzelin,A glycosyloxyflavone that is kaempferol attached to an alpha-L-rhamnosyl residue at position 3 via a glycosidic linkage.,"InChI=1S/C21H20O10/c1-8-15(25)17(27)18(28)21(29-8)31-20-16(26)14-12(24)6-11(23)7-13(14)30-19(20)9-2-4-10(22)5-3-9/h2-8,15,17-18,21-25,27-28H,1H3/t8-,15-,17+,18+,21-/m0/s1",kaempferol 3-O-alpha-L-rhamnoside,KEGG COMPOUND accession,C16911
8014,81253,isolithocholic acid,A monohydroxy-5beta-cholanic acid with a beta-hydroxy substituent at position 3. The 3beta-hydroxy epimer of lithocholic acid.,"InChI=1S/C24H40O3/c1-15(4-9-22(26)27)19-7-8-20-18-6-5-16-14-17(25)10-12-23(16,2)21(18)11-13-24(19,20)3/h15-21,25H,4-14H2,1-3H3,(H,26,27)/t15-,16-,17+,18+,19-,20+,21+,23+,24-/m1/s1",beta-Lithocholic acid,KEGG COMPOUND accession,C17658
8015,81908,cuprous oxide,Any copper oxide in which the metal is in the +1 oxidation state.,InChI=1S/2Cu.O/q2*+1;-2,Copper (I) oxide,PDBeChem accession,C2O
8016,83297,"4-dodecyl-2,6-dimethylmorpholine","A member of the class of morpholines that is 2,6-dimethylmorpholine in which the hydrogen attached to the nitrogen is replaced by a dodecyl group. The configuration at positions 2 and 6 is unknown or unspecified.","InChI=1S/C18H37NO/c1-4-5-6-7-8-9-10-11-12-13-14-19-15-17(2)20-18(3)16-19/h17-18H,4-16H2,1-3H3","N-dodecyl-2,6-dimethylmorpholine",CAS Registry Number,1704-28-5
8017,83792,"3-oxo-23,24-bisnorchol-4-en-22-oyl-CoA(4-)","An acyl-CoA oxoanion resulting from the removal of all four protons from the phosphate and diphosphate groups of 3-oxo-23,24-bisnor-chol-4-en-22-oyl-CoA; major species at pH 7.3.","InChI=1S/C43H66N7O18P3S/c1-23(27-8-9-28-26-7-6-24-18-25(51)10-13-42(24,4)29(26)11-14-43(27,28)5)40(56)72-17-16-45-31(52)12-15-46-38(55)35(54)41(2,3)20-65-71(62,63)68-70(60,61)64-19-30-34(67-69(57,58)59)33(53)39(66-30)50-22-49-32-36(44)47-21-48-37(32)50/h18,21-23,26-30,33-35,39,53-54H,6-17,19-20H2,1-5H3,(H,45,52)(H,46,55)(H,60,61)(H,62,63)(H2,44,47,48)(H2,57,58,59)/p-4/t23-,26-,27+,28-,29-,30+,33+,34+,35-,39+,42-,43+/m0/s1",4-BNC-CoA(4-),PubMed citation,21987574
8018,84506,"1-stearoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycero-3-phosphoserine","A 3-sn-phosphatidyl L-serine in which the phosphatidyl acyl groups at positions 1 and 2 are stearoyl and 7Z,10Z,13Z,16Z-docosatetraenoyl respectively.","InChI=1S/C46H82NO10P/c1-3-5-7-9-11-13-15-17-19-20-21-22-24-26-28-30-32-34-36-38-45(49)57-42(40-55-58(52,53)56-41-43(47)46(50)51)39-54-44(48)37-35-33-31-29-27-25-23-18-16-14-12-10-8-6-4-2/h11,13,17,19,21-22,26,28,42-43H,3-10,12,14-16,18,20,23-25,27,29-41,47H2,1-2H3,(H,50,51)(H,52,53)/b13-11-,19-17-,22-21-,28-26-/t42-,43+/m1/s1","1-octadecanoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycero-3-phosphoserine",LIPID MAPS instance accession,LMGP03010883
8019,84563,"1-[(9Z,12Z)-octadecadienoyl]-2-[(5Z,8Z,11Z,14Z)-icosatetraenoyl]-sn-glycero-3-phosphocholine","A phosphatidylcholine 38:6 in which the acyl groups specified at positions 1 and 2 are (9Z,12Z)-octadecadienoyl and (5Z,8Z,11Z,14Z)-icosatetraenoyl respectively.","InChI=1S/C46H80NO8P/c1-6-8-10-12-14-16-18-20-22-23-25-27-29-31-33-35-37-39-46(49)55-44(43-54-56(50,51)53-41-40-47(3,4)5)42-52-45(48)38-36-34-32-30-28-26-24-21-19-17-15-13-11-9-7-2/h14-17,20-22,24-25,27,31,33,44H,6-13,18-19,23,26,28-30,32,34-43H2,1-5H3/b16-14-,17-15-,22-20-,24-21-,27-25-,33-31-/t44-/m1/s1","1-(9Z,12Z-octadecadienoyl)-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine",LIPID MAPS instance accession,LMGP01010943
8020,84573,"1-hexadecanoyl-2-[(7Z,10Z,13Z,16Z)-docosatetraenoyl]-sn-glycero-3-phosphocholine","A  phosphatidylcholine 38:4  in which the acyl groups at positions 1 and 2 are hexadecanoyl and (7Z,10Z,13Z,16Z)-docosatetraenoyl respectively.","InChI=1S/C46H84NO8P/c1-6-8-10-12-14-16-18-20-21-22-23-24-25-27-29-31-33-35-37-39-46(49)55-44(43-54-56(50,51)53-41-40-47(3,4)5)42-52-45(48)38-36-34-32-30-28-26-19-17-15-13-11-9-7-2/h14,16,20-21,23-24,27,29,44H,6-13,15,17-19,22,25-26,28,30-43H2,1-5H3/b16-14-,21-20-,24-23-,29-27-/t44-/m1/s1","1-hexadecanoyl-2-(7Z,10Z,13Z,16Z-docosatetraenoyl)-sn-glycero-3-phosphocholine",LIPID MAPS instance accession,LMGP01010642
8021,84656,alpha-Neu5Ac-(2->3)-beta-D-Gal(1->3)beta-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-Gal-(1->4)-beta-Glc-(1->1')-Cer(d18:1/18:0),A alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)-[alpha-N-acetylneuraminosyl-(2->3)]-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide in which the ceramide N-acyl group is specified as octadecanoyl (stearoyl).,"InChI=1S/C84H148N4O39/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-58(103)88-48(49(98)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2)44-116-78-67(109)66(108)70(56(42-93)119-78)121-80-69(111)76(127-84(82(114)115)37-51(100)60(86-46(4)96)74(125-84)63(105)53(102)39-90)71(57(43-94)120-80)122-77-61(87-47(5)97)72(64(106)54(40-91)117-77)123-79-68(110)75(65(107)55(41-92)118-79)126-83(81(112)113)36-50(99)59(85-45(3)95)73(124-83)62(104)52(101)38-89/h32,34,48-57,59-80,89-94,98-102,104-111H,6-31,33,35-44H2,1-5H3,(H,85,95)(H,86,96)(H,87,97)(H,88,103)(H,112,113)(H,114,115)/b34-32+/t48-,49+,50-,51-,52+,53+,54+,55+,56+,57+,59+,60+,61+,62+,63+,64-,65-,66+,67+,68+,69+,70+,71-,72+,73+,74+,75-,76+,77-,78+,79-,80-,83-,84-/m0/s1",GD1-d18:1/18:0,LIPID MAPS instance accession,LMSP0601AS02
8022,85136,(9E)-12-(phosphonooxy)octadecenoic acid,A carboxyalkyl phosphate that is (9E)-octadecenoic acid carrying a phosphonooxy substituent at position 12.,"InChI=1S/C18H35O6P/c1-2-3-4-11-14-17(24-25(21,22)23)15-12-9-7-5-6-8-10-13-16-18(19)20/h9,12,17H,2-8,10-11,13-16H2,1H3,(H,19,20)(H2,21,22,23)/b12-9+",12-(phosphonooxy)elaidic acid,PubMed citation,12574510
8023,85238,"15-deoxy-Delta(12,14)-prostaglandin J2-2-glyceryl ester","A 2-monoglyceride resulting from the condensation of the carboxy group of 15-deoxy-Delta(12,14)-prostaglandin J2 with the  hydroxy group at position 2 of glycerol.","InChI=1S/C23H34O5/c1-2-3-4-5-6-10-13-21-19(15-16-22(21)26)12-9-7-8-11-14-23(27)28-20(17-24)18-25/h6-7,9-10,13,15-16,19-20,24-25H,2-5,8,11-12,14,17-18H2,1H3/b9-7-,10-6+,21-13+/t19-/m0/s1","11-oxo-5Z,9,12E,14E-prostatetraenoic acid 2-glyceryl ester",PubMed citation,25290914
8024,86381,5beta-dihydrocorticosterone,A 3-oxo-5beta-steroid formed from corticosterone by reduction across the C4-C5 double bond.,"InChI=1S/C21H32O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h12,14-17,19,22,24H,3-11H2,1-2H3/t12-,14+,15+,16-,17+,19-,20+,21+/m1/s1","11beta,21-dihydroxy-5beta-pregnane-3,20-dione",CAS Registry Number,566-01-8
8025,86632,buddlenol B,A guaiacyl lignin that is found in Arabidopsis thaliana.,"InChI=1S/C31H36O11/c1-37-23-12-18(7-8-22(23)35)28(36)27(16-34)41-31-25(39-3)13-19(14-26(31)40-4)29-21(15-33)20-10-17(6-5-9-32)11-24(38-2)30(20)42-29/h5-8,10-14,21,27-29,32-36H,9,15-16H2,1-4H3/b6-5+",G(8-O-4)S(8-5)G,Reaxys Registry Number,6554135
8026,86635,buddlenol C,A guaiacyl lignin that is syringaresinol in which one of the phenolic hydrogens is replaced by a guaiacylglycerol group. It is found in Arabidopsis thaliana.,"InChI=1S/C32H38O12/c1-37-22-8-16(6-7-21(22)34)28(35)27(13-33)44-32-25(40-4)11-18(12-26(32)41-5)31-20-15-42-30(19(20)14-43-31)17-9-23(38-2)29(36)24(10-17)39-3/h6-12,19-20,27-28,30-31,33-36H,13-15H2,1-5H3",G(8-O-4)S(8-8)S,Reaxys Registry Number,6554468
8027,87065,acid green 5,"An organic sodium salt having 3-[(ethyl{4-[(4-{ethyl[(3-sulfonatophenyl)methyl]amino}phenyl)(4-sulfonatophenyl)methylidene]cyclohexa-2,5-dien-1-ylidene}azaniumyl)methyl]benzene-1-sulfonate as the counterion. It is the standard dye in North American for staining collagen and is also used extensively in plant histology.","InChI=1S/C37H36N2O9S3.2Na/c1-3-38(25-27-7-5-9-35(23-27)50(43,44)45)32-17-11-29(12-18-32)37(31-15-21-34(22-16-31)49(40,41)42)30-13-19-33(20-14-30)39(4-2)26-28-8-6-10-36(24-28)51(46,47)48;;/h5-24H,3-4,25-26H2,1-2H3,(H2-,40,41,42,43,44,45,46,47,48);;/q;2*+1/p-2",Acid green,CAS Registry Number,5141-20-8
8028,87755,pentan-3-one,A pentanone that is pentane carrying an oxo group at position 3. It has been isolated from  Triatoma brasiliensis and Triatoma infestans.,"InChI=1S/C5H10O/c1-3-5(6)4-2/h3-4H2,1-2H3",Ethyl propionyl,CAS Registry Number,96-22-0
8029,88231,beta-Gal-(1->3)-beta-GalNAc-(1->4)-[alpha-Neu5Ac-(2->8)-alpha-Neu5Ac-(2->3)]-beta-Gal-(1->4)-beta-Glc-(1<->1')-Cer(d18:1/18:0)(2-),An anionic ganglioside obtained by deprotonation of the neuraminosyl carboxy groups of ganglioside GD1b(d18:1/C18:0); major species at pH 7.3.,"InChI=1S/C84H148N4O39/c1-6-8-10-12-14-16-18-20-21-23-25-27-29-31-33-35-58(102)88-48(49(98)34-32-30-28-26-24-22-19-17-15-13-11-9-7-2)44-116-78-69(110)67(108)71(56(42-93)119-78)121-80-70(111)76(72(57(43-94)120-80)122-77-61(87-47(5)97)73(64(105)54(40-91)117-77)123-79-68(109)66(107)63(104)53(39-90)118-79)127-84(82(114)115)37-51(100)60(86-46(4)96)75(126-84)65(106)55(41-92)124-83(81(112)113)36-50(99)59(85-45(3)95)74(125-83)62(103)52(101)38-89/h32,34,48-57,59-80,89-94,98-101,103-111H,6-31,33,35-44H2,1-5H3,(H,85,95)(H,86,96)(H,87,97)(H,88,102)(H,112,113)(H,114,115)/p-2/b34-32+/t48-,49+,50-,51-,52+,53+,54+,55+,56+,57+,59+,60+,61+,62+,63-,64-,65+,66-,67+,68+,69+,70+,71+,72-,73+,74+,75+,76+,77-,78+,79-,80-,83+,84-/m0/s1",GD1b(d18:1/18:0)(2-),PubMed citation,12530538
8030,89519,coprostanol,A member of the class of phytosterols that is 5beta-cholestane carrying a hydroxy substituent at the 3beta-position.,"InChI=1S/C27H48O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h18-25,28H,6-17H2,1-5H3/t19-,20-,21+,22+,23-,24+,25+,26+,27-/m1/s1",5beta-cholestan-3beta-ol,Wikipedia accession,Coprosterol
8031,89656,Leu-enkephalin,"A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.","InChI=1S/C28H37N5O7/c1-17(2)12-23(28(39)40)33-27(38)22(14-18-6-4-3-5-7-18)32-25(36)16-30-24(35)15-31-26(37)21(29)13-19-8-10-20(34)11-9-19/h3-11,17,21-23,34H,12-16,29H2,1-2H3,(H,30,35)(H,31,37)(H,32,36)(H,33,38)(H,39,40)/t21-,22-,23-/m0/s1",[Leu(5)]enkephalin,PubMed citation,9450624
8032,90222,(S)-2-methylbutanoyl-CoA,A (2S)-2-methylacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of (2S)-2-methylbutanoic acid.,"InChI=1S/C26H44N7O17P3S/c1-5-14(2)25(38)54-9-8-28-16(34)6-7-29-23(37)20(36)26(3,4)11-47-53(44,45)50-52(42,43)46-10-15-19(49-51(39,40)41)18(35)24(48-15)33-13-32-17-21(27)30-12-31-22(17)33/h12-15,18-20,24,35-36H,5-11H2,1-4H3,(H,28,34)(H,29,37)(H,42,43)(H,44,45)(H2,27,30,31)(H2,39,40,41)/t14-,15+,18+,19+,20-,24+/m0/s1",(S)-2-methylbutyryl-CoA,KEGG COMPOUND accession,C15980
8033,90372,succinic acid-d4,A deuterated compound that is succinic acid in which the four methylene hydrogens are replaced by deuterium.,"InChI=1S/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)/i1D2,2D2","succinic acid-2,2,3,3-d4",Reaxys Registry Number,1781784
8034,91160,4-methoxy-3-indolylmethylamine,An aminoalkylindole that is 3-(aminomethyl)indole in which the hydrogen at position 4 has been replaced by a methoxy group.,"InChI=1S/C10H12N2O/c1-13-9-4-2-3-8-10(9)7(5-11)6-12-8/h2-4,6,12H,5,11H2,1H3",4-MeO-I3CH2NH2,PubMed citation,25457500
8035,91172,guaiacylglycerol beta-coniferyl ether,A guaiacyl lignin that is guaiacylglycerol in which the hydrogen on the 2-hydroxy function has been replaced by a beta-coniferyl group.,"InChI=1S/C20H24O7/c1-25-17-11-14(6-7-15(17)23)20(24)19(12-22)27-16-8-5-13(4-3-9-21)10-18(16)26-2/h3-8,10-11,19-24H,9,12H2,1-2H3/b4-3+",G(8-O-4)G,CAS Registry Number,1103-58-8
8036,91184,dehydrodiconiferyl alcohol,A guaiacyl lignin obtained by cyclodimerisation of coniferol.,"InChI=1S/C20H22O6/c1-24-17-10-13(5-6-16(17)23)19-15(11-22)14-8-12(4-3-7-21)9-18(25-2)20(14)26-19/h3-6,8-10,15,19,21-23H,7,11H2,1-2H3/b4-3+",G(8-5)G,CAS Registry Number,4263-87-0
8037,101278,diltiazem,"A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.","InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1","Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester",CAS Registry Number,42399-41-7
8038,101713,compound E,"An L-alanine derivative that is the amide obtained by formal condensation of the carboxy group of N-[(3,5-difluorophenyl)acetyl]-L-alanine with the amino group of (3S)-3-amino-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one. An inhibitor of memapsin 2 (gamma-secretase).","InChI=1S/C27H24F2N4O3/c1-16(30-23(34)14-17-12-19(28)15-20(29)13-17)26(35)32-25-27(36)33(2)22-11-7-6-10-21(22)24(31-25)18-8-4-3-5-9-18/h3-13,15-16,25H,14H2,1-2H3,(H,30,34)(H,32,35)/t16-,25+/m0/s1",gamma-secretase inhibitor XXI,Reaxys Registry Number,14671471
8039,106738,(S)-famoxadone,"A  5-methyl-5-(4-phenoxyphenyl)-3-(phenylamino)-1,3-oxazolidine-2,4-dione that is the (active) (S)-enantiomer of famoxadone. It prevents spore germination and mycelial growth of sensitive fungi and is used in agriculture for the control of various fungal diseases.","InChI=1S/C22H18N2O4/c1-22(16-12-14-19(15-13-16)27-18-10-6-3-7-11-18)20(25)24(21(26)28-22)23-17-8-4-2-5-9-17/h2-15,23H,1H3/t22-/m0/s1","(S)-5-Methyl-5-(4-phenoxy-phenyl)-3-phenylamino-oxazolidine-2,4-dione",PDBeChem accession,FMX
8040,107736,metoclopramide,"A member of the class of  benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.","InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)",4-amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide,KEGG DRUG accession,D00726
8041,116314,oleamide,A fatty amide derived from oleic acid.,"InChI=1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H2,19,20)/b10-9-",(Z)-Octadec-9-enoic acid amide,LIPID MAPS instance accession,LMFA08010004
8042,119915,fentanyl,A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.,"InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3",N-(1-phenethyl-piperidin-4-yl)-N-phenyl-propionamide,PubMed citation,11585443
8043,121742,N-tetracosanoyl-15-methylhexadecasphingosine-1-phosphocholine,A sphingomyelin 41:1 obtained by formal condensation of the carboxy group of tetracosanoic acid with the amino group of 15-methylhexadecasphingosine-1-phosphocholine. It is a metabolite of the nematode Caenorhabditis elegans.,"InChI=1S/C46H93N2O6P/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-27-30-33-36-39-46(50)47-44(42-54-55(51,52)53-41-40-48(4,5)6)45(49)38-35-32-29-26-24-25-28-31-34-37-43(2)3/h35,38,43-45,49H,7-34,36-37,39-42H2,1-6H3,(H-,47,50,51,52)/b38-35+/t44-,45+/m0/s1",15-methyl-N-tetracosanoylhexadecasphing-4-enine-1-phosphocholine,PubMed citation,23894595
8044,125204,4-guanidinobenzoic acid,Benzoic acid substituted at the para position by a guanidino group.,"InChI=1S/C8H9N3O2/c9-8(10)11-6-3-1-5(2-4-6)7(12)13/h1-4H,(H,12,13)(H4,9,10,11)",4-Guanidino-benzoic acid,PDBeChem accession,GBS
8045,126237,enprofylline,"Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.","InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)","3-Propyl-3,7-dihydro-purine-2,6-dione",DrugBank accession,DB00824
8046,128458,disodium cromoglycate,An organic sodium salt that is the disodium salt of cromoglycic acid.,"InChI=1S/C23H16O11.2Na/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30;;/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30);;/q;2*+1/p-2",Sodium salt of 5-[3-(2-carboxy-4-oxo-4H-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4H-2-chromenecarboxylic acid,KEGG DRUG accession,D00526
8047,131527,dipotassium hydrogen phosphate,A potassium salt that is the dipotassium salt of phosphoric acid.,"InChI=1S/2K.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2",potassium dibasic phosphate trihydrate,CAS Registry Number,7758-11-4
8048,131800,(R)-SKF 38393,"A 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol that is the R-enantiomer of SKF 38393.","InChI=1S/C16H17NO2/c18-15-8-12-6-7-17-10-14(13(12)9-16(15)19)11-4-2-1-3-5-11/h1-5,8-9,14,17-19H,6-7,10H2/t14-/m1/s1",(R)-SKF-38393,LINCS accession,LSM-37178
8049,132275,"(14R,15S)-EET","A 14,15-EET in which the epoxy moiety has 14R,15S-configuration.","InChI=1S/C20H32O3/c1-2-3-12-15-18-19(23-18)16-13-10-8-6-4-5-7-9-11-14-17-20(21)22/h4,6-7,9-10,13,18-19H,2-3,5,8,11-12,14-17H2,1H3,(H,21,22)/b6-4-,9-7-,13-10-/t18-,19+/m0/s1","(14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoic acid",PubMed citation,12749593
8050,132974,C646,"A pyrazolone that is 5-methyl-4-methylene-2-(p-carboxyphenyl)-2,4-dihydro-3H-pyrazol-3-one in which the exocyclic carbon of the methylene group is attached to a 5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl group by a single bond. C646 is a potent, cell permeable and selective competitive inhibitor of p300 and CBP (p300/CBP) histone acetyltransferases.","InChI=1S/C24H19N3O6/c1-13-10-20(21(27(31)32)11-14(13)2)22-9-8-18(33-22)12-19-15(3)25-26(23(19)28)17-6-4-16(5-7-17)24(29)30/h4-12H,1-3H3,(H,29,30)","4-[4-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl]benzoic acid",LINCS accession,LSM-6264
8051,133211,7-(beta-D-glucosyl)-cis-zeatin,An N-glycosylzeatin that is cis-zeatin having a beta-D-glucopyranosyl residue attached at position N-7.,"InChI=1S/C16H23N5O6/c1-8(4-22)2-3-17-14-10-15(19-6-18-14)20-7-21(10)16-13(26)12(25)11(24)9(5-23)27-16/h2,6-7,9,11-13,16,22-26H,3-5H2,1H3,(H,17,18,19)/b8-2-/t9-,11-,12+,13-,16-/m1/s1",cis-zeatin-7-glucoside,Reaxys Registry Number,6543043
8052,133224,"kaempferol 3,7-di-O-beta-D-glucoside","A glycosyloxyflavone that is kaempferol having two beta-D-glucosyl residues attached at positions O-3 and O-7. Isolated from the aerial parts of Delphinium staphisagria, it exhibits trypanocidal activity.","InChI=1S/C27H30O16/c28-7-14-17(32)20(35)22(37)26(41-14)39-11-5-12(31)16-13(6-11)40-24(9-1-3-10(30)4-2-9)25(19(16)34)43-27-23(38)21(36)18(33)15(8-29)42-27/h1-6,14-15,17-18,20-23,26-33,35-38H,7-8H2/t14-,15-,17-,18-,20+,21+,22-,23-,26-,27+/m1/s1","kaempferol-3,7- di-beta-D-glucopyranoside",PubMed citation,21466157
8053,134066,N(6)-(pyridoxal phosphate)-L-lysine,An L-lysine derivative that is the aldimine obtained via formal condensation of the side-chain amino group of L-lysine with the carbonyl group of pyridoxal phosphate.,"InChI=1S/C14H22N3O7P/c1-9-13(18)11(10(6-17-9)8-24-25(21,22)23)7-16-5-3-2-4-12(15)14(19)20/h6-7,12,18H,2-5,8,15H2,1H3,(H,19,20)(H2,21,22,23)/b16-7+/t12-/m0/s1",2-azanyl-6-[(E)-[2-methyl-3-oxidanyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]hexanoic acid,PDBeChem accession,LLP
8054,134076,1-octadecanoyl-2-pentadecanoyl-sn-glycero-3-phosphocholine,"A 1,2-diacyl-sn-glycero-3-phosphocholine in which the 1- and 2-acyl groups are specified as octadecanoyl and penttadecanoyl respectively.","InChI=1S/C41H82NO8P/c1-6-8-10-12-14-16-18-20-21-22-24-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42(3,4)5)50-41(44)34-32-30-28-26-23-19-17-15-13-11-9-7-2/h39H,6-38H2,1-5H3/t39-/m1/s1",PC(18:0/15:0),HMDB accession,HMDB0008033
8055,135538,propyphenazone,A pyrazolone derivative that is antipyrine substituted at C-4 by an isopropyl group.,"InChI=1S/C14H18N2O/c1-10(2)13-11(3)15(4)16(14(13)17)12-8-6-5-7-9-12/h5-10H,1-4H3","4-Isopropyl-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one",Beilstein Registry Number,204533
8056,136113,"(4Z,7Z,10Z,13Z,15E,17S,19Z)-17-hydroperoxydocosahexaenoic acid","A docosanoid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying a hydroperoxy substituent at position 17S.","InChI=1S/C22H32O4/c1-2-3-15-18-21(26-25)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(23)24/h3,5-8,11-16,19,21,25H,2,4,9-10,17-18,20H2,1H3,(H,23,24)/b7-5-,8-6-,13-11-,14-12-,15-3-,19-16+/t21-/m0/s1","(4Z,7Z,10Z,13Z,15E,17S,19Z)-hydroperoxydocosahexaenoic acid",LIPID MAPS instance accession,LMFA04000051
8057,136352,"(7Z,10Z,13Z,15E,19Z)-17-hydroperoxydocosapentaenoic acid","A hydroperoxydocosapentaenoic acid that is (7Z,10Z,13Z,15E,19Z)-docosapentaenoic acid carrying a hydroperoxy substituent at position 17. An intermediate of specialised proresolving mediators.","InChI=1S/C22H34O4/c1-2-3-15-18-21(26-25)19-16-13-11-9-7-5-4-6-8-10-12-14-17-20-22(23)24/h3,5-8,11,13,15-16,19,21,25H,2,4,9-10,12,14,17-18,20H2,1H3,(H,23,24)/b7-5-,8-6-,13-11-,15-3-,19-16+","17-hydroperoxy-(7Z,10Z,13Z,15E,19Z)-docosapentaenoic acid",PubMed citation,19324874
8058,137038,(18S)-resolvin E1,"A resolvin that is (6Z,8E,10E,14Z,16E)-icosa-6,8,10,14,16-pentaenoic acid which is substituted at positions 5, 12 and 18 by hydroxy groups (the 5S,12R,18S stereoisomer).","InChI=1S/C20H30O5/c1-2-17(21)11-8-5-9-14-18(22)12-6-3-4-7-13-19(23)15-10-16-20(24)25/h3-9,11-13,17-19,21-23H,2,10,14-16H2,1H3,(H,24,25)/b4-3+,9-5-,11-8+,12-6+,13-7-/t17-,18-,19+/m0/s1","(5S,6Z,8E,10E,12R,14Z,16E,18S)-5,12,18-trihydroxyicosapentaenoic acid",LIPID MAPS instance accession,LMFA03070035
8059,137113,JQ1,"A member of the class of thienotriazolodiazepines that is the tert-butyl ester of [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetic acid. An inhibitor of bromodomain-containing protein 4 that exhibits anti-cancer and cardioprotective properties.","InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1",(+)-JQ1,LINCS accession,LSM-6332
8060,137236,ilomastat,An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor,"InChI=1S/C20H28N4O4/c1-12(2)8-13(10-18(25)24-28)19(26)23-17(20(27)21-3)9-14-11-22-16-7-5-4-6-15(14)16/h4-7,11-13,17,22,28H,8-10H2,1-3H3,(H,21,27)(H,23,26)(H,24,25)/t13-,17+/m1/s1",galardin,PDBeChem accession,GM6
8061,137347,(14S)-HDoHE,A 14-HDoHE in which the stereocentre at position 14 has S-configuration.,"InChI=1S/C22H32O3/c1-2-3-4-5-12-15-18-21(23)19-16-13-10-8-6-7-9-11-14-17-20-22(24)25/h3-4,6-7,10-16,19,21,23H,2,5,8-9,17-18,20H2,1H3,(H,24,25)/b4-3-,7-6-,13-10-,14-11-,15-12-,19-16+/t21-/m0/s1",14S-HDHA,Reaxys Registry Number,5564836
8062,137349,"(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid","A dihydroxydocosahexaenoic acid that is (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 14S- and 22-positions.","InChI=1S/C22H32O4/c23-20-16-12-8-7-10-14-18-21(24)17-13-9-5-3-1-2-4-6-11-15-19-22(25)26/h1-2,5-6,8-14,17,21,23-24H,3-4,7,15-16,18-20H2,(H,25,26)/b2-1-,9-5-,11-6-,12-8-,14-10-,17-13+/t21-/m1/s1","(14S,22)-dihydroxy-(4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid",Reaxys Registry Number,27627499
8063,137350,"(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid","A dihydroxydocosahexaenoic acid that is (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 14R- and 22-positions.","InChI=1S/C22H32O4/c23-20-16-12-8-7-10-14-18-21(24)17-13-9-5-3-1-2-4-6-11-15-19-22(25)26/h1-2,5-6,8-14,17,21,23-24H,3-4,7,15-16,18-20H2,(H,25,26)/b2-1-,9-5-,11-6-,12-8-,14-10-,17-13+/t21-/m0/s1","(14R,22)-diHDHA",PubMed citation,25200603
8064,137354,"(4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoic acid","A dihydroxydocosahexaenoic acid that is (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 14S- and 21R-positions.","InChI=1S/C22H32O4/c1-20(23)16-12-10-11-14-18-21(24)17-13-8-6-4-2-3-5-7-9-15-19-22(25)26/h2-3,6-9,11-14,16-17,20-21,23-24H,4-5,10,15,18-19H2,1H3,(H,25,26)/b3-2-,8-6-,9-7-,14-11-,16-12-,17-13+/t20-,21-/m1/s1","(14S,21R)-DiHDoHE",PubMed citation,19965612
8065,137361,"(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoic acid","A dihydroxydocosahexaenoic acid that is (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 14R- and 21R-positions.","InChI=1S/C22H32O4/c1-20(23)16-12-10-11-14-18-21(24)17-13-8-6-4-2-3-5-7-9-15-19-22(25)26/h2-3,6-9,11-14,16-17,20-21,23-24H,4-5,10,15,18-19H2,1H3,(H,25,26)/b3-2-,8-6-,9-7-,14-11-,16-12-,17-13+/t20-,21+/m1/s1","14R,21R-diHDHA",PubMed citation,19965612
8066,137368,"(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoic acid","A dihydroxydocosahexaenoic acid that is (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 14R- and 21S-positions.","InChI=1S/C22H32O4/c1-20(23)16-12-10-11-14-18-21(24)17-13-8-6-4-2-3-5-7-9-15-19-22(25)26/h2-3,6-9,11-14,16-17,20-21,23-24H,4-5,10,15,18-19H2,1H3,(H,25,26)/b3-2-,8-6-,9-7-,14-11-,16-12-,17-13+/t20-,21-/m0/s1","14R,21S-diHDHA",PubMed citation,19965612
8067,137728,tetragastrin,"A tetrapeptide composed of L-tryptophan, L-methione, L-aspartic acid and L-phenylalaninamide residues joined in sequence.","InChI=1S/C29H36N6O6S/c1-42-12-11-22(33-27(39)20(30)14-18-16-32-21-10-6-5-9-19(18)21)28(40)35-24(15-25(36)37)29(41)34-23(26(31)38)13-17-7-3-2-4-8-17/h2-10,16,20,22-24,32H,11-15,30H2,1H3,(H2,31,38)(H,33,39)(H,34,41)(H,35,40)(H,36,37)/t20-,22-,23-,24-/m0/s1",CCK-4,KEGG DRUG accession,D01456
8068,137822,hyodeoxycholic acid 6-O-(beta-D-glucuronide),A steroid glucosiduronic acid that is hyodeoxycholic acid having a single beta-D-glucuronic acid residue attached at position 6.,"InChI=1S/C30H48O10/c1-14(4-7-22(32)33)17-5-6-18-16-13-21(39-28-25(36)23(34)24(35)26(40-28)27(37)38)20-12-15(31)8-10-30(20,3)19(16)9-11-29(17,18)2/h14-21,23-26,28,31,34-36H,4-13H2,1-3H3,(H,32,33)(H,37,38)/t14-,15-,16+,17-,18+,19+,20+,21+,23+,24+,25-,26+,28-,29-,30-/m1/s1",hyodeoxycholic acid 6-glucuronide,KEGG COMPOUND accession,C11246
8069,138435,bis(7)-tacrine,"A secondary amino compound consisting of two molecules of tacrine that are linked together through their exocyclic amino groups by a heptane-1,7-diyl chain. Bis(7)-tacrine is an acetylcholinesterase (AChE)inhibitor (IC50 0.40 nM, >1,000 times more potent than tacrine). It has also been found to protect against H2O2 -induced apoptosis in rat pheochromocytoma cells.","InChI=1S/C33H40N4/c1(2-12-22-34-32-24-14-4-8-18-28(24)36-29-19-9-5-15-25(29)32)3-13-23-35-33-26-16-6-10-20-30(26)37-31-21-11-7-17-27(31)33/h4,6,8,10,14,16,18,20H,1-3,5,7,9,11-13,15,17,19,21-23H2,(H,34,36)(H,35,37)","N,N'-bis(1,2,3,4-tetrahydro-9-acridinyl)-1,7-heptanediamine",PDBeChem accession,AA7
8070,138792,"1,2-di-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphoethanolamine","A 1,2-diacyl-sn-glycero-3-phosphoethanolamine in which both acyl substituents are specified as (9Z)-hexadecenoyl (palmitoleoyl).","InChI=1S/C37H70NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-36(39)43-33-35(34-45-47(41,42)44-32-31-38)46-37(40)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h13-16,35H,3-12,17-34,38H2,1-2H3,(H,41,42)/b15-13-,16-14-/t35-/m1/s1","1,2-di-(9Z-hexadecenoyl)-sn-glycero-3-phosphoethanolamine",Reaxys Registry Number,10752971
8071,139105,"(9S,13S)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoyl-CoA","An oxo fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of (9S,13S)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoic acid.","InChI=1S/C37H60N7O18P3S/c1-4-5-7-11-24-23(13-14-25(24)45)10-8-6-9-12-28(47)66-18-17-39-27(46)15-16-40-35(50)32(49)37(2,3)20-59-65(56,57)62-64(54,55)58-19-26-31(61-63(51,52)53)30(48)36(60-26)44-22-43-29-33(38)41-21-42-34(29)44/h5,7,21-24,26,30-32,36,48-49H,4,6,8-20H2,1-3H3,(H,39,46)(H,40,50)(H,54,55)(H,56,57)(H2,38,41,42)(H2,51,52,53)/b7-5-/t23-,24-,26+,30+,31+,32-,36+/m0/s1","(9S,13S)-1a,1b-dinor-10,11-dihydro-12-oxo-15-phytoenoyl-coenzyme A",KEGG COMPOUND accession,C16331
8072,140192,"17R,(16)-epoxy-(4Z,7Z,10Z,13Z,19Z)-docosahexa-4,7,10,13,15,19-enoic acid","A polyunsaturated fatty acid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid having an epoxy group across positions 16 and 17.","InChI=1S/C22H30O3/c1-2-3-14-17-20-21(25-20)18-15-12-10-8-6-4-5-7-9-11-13-16-19-22(23)24/h3,5-8,11-15,18,20H,2,4,9-10,16-17,19H2,1H3,(H,23,24)/b7-5-,8-6-,13-11-,14-3-,15-12-,21-18+/t20-/m1/s1","17R,(16)-epoxy-DHA",PubMed citation,17055291
8073,140196,"(7S,14S)-bis(hydroperoxy)-(4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoic acid","A docosanoid that is (4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoic acid carrying two hydroperoxy substituents at the 7S- and 14S-positions.","InChI=1S/C22H32O6/c1-2-3-4-5-6-10-15-20(27-25)16-11-7-8-12-17-21(28-26)18-13-9-14-19-22(23)24/h3-4,6-13,16-17,20-21,25-26H,2,5,14-15,18-19H2,1H3,(H,23,24)/b4-3-,8-7-,10-6-,13-9-,16-11+,17-12+/t20-,21+/m0/s1","7(S),14(S)-diHpDHA",PubMed citation,19103881
8074,140352,resolvin D5(1-),"A dihydroxydocosahexaenoate that is the conjugate base of resolvin D5, obtained by deprotonation of the carboxy group; major species at pH 7.3.","InChI=1S/C22H32O4/c1-2-3-10-15-20(23)16-11-7-5-4-6-8-12-17-21(24)18-13-9-14-19-22(25)26/h3,5-13,16-17,20-21,23-24H,2,4,14-15,18-19H2,1H3,(H,25,26)/p-1/b7-5-,8-6-,10-3-,13-9-,16-11+,17-12+/t20-,21+/m0/s1","(4Z,7S,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosahexaenoate",PubMed citation,32404334
8075,141644,trisodium phosphonoformate,"The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.","InChI=1S/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3",trisodium phosphonoformate,KEGG DRUG accession,D00579
8076,145469,(9Z)-17-hydroxyoctadec-9-enoic acid 17-O-sophoroside,A sophoroside resulting from the formal condensation of the alcoholic hydroxy group of 17-hydroxyoleic acid with beta-sophorose.,"InChI=1S/C30H54O13/c1-19(15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-22(33)34)40-30-28(26(38)24(36)21(18-32)42-30)43-29-27(39)25(37)23(35)20(17-31)41-29/h2-3,19-21,23-32,35-39H,4-18H2,1H3,(H,33,34)/b3-2-/t19?,20-,21-,23-,24-,25+,26+,27-,28-,29+,30-/m1/s1",(9Z)-17-hydroxyoctadec-9-enoic acid 17-O-beta-D-glucosyl-(1->2)-beta-D-glucoside,PubMed citation,21073653
8077,149304,L-galactofuranose,The furanose form of L-galactose.,"InChI=1S/C6H12O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2-11H,1H2/t2-,3-,4-,5+,6?/m0/s1","WURCS=2.0/1,1,0/[a1221h-1x_1-4]/1/",GlyTouCan accession,G32871SU
8078,150940,beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-D-GlcpNAc,"A branched amino oligosaccharide comprising a linear trisaccharide of beta-D-mannosyl, N-acetyl-beta-D-glucosaminyl and N-acetyl-D-glucosaminyl residues all linked in sequence (1->4), to the mannosyl residue of which are connected branches consisting of N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl and beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl via (1->3) and (1->6) linkages respectively.","InChI=1S/C56H94N4O41/c1-13(68)57-25-35(78)43(21(9-65)88-49(25)86)96-51-27(59-15(3)70)36(79)45(23(11-67)93-51)98-54-42(85)46(99-56-48(40(83)32(75)20(8-64)92-56)101-50-26(58-14(2)69)34(77)29(72)17(5-61)89-50)33(76)24(95-54)12-87-55-47(39(82)31(74)19(7-63)91-55)100-52-28(60-16(4)71)37(80)44(22(10-66)94-52)97-53-41(84)38(81)30(73)18(6-62)90-53/h17-56,61-67,72-86H,5-12H2,1-4H3,(H,57,68)(H,58,69)(H,59,70)(H,60,71)/t17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30+,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41-,42+,43-,44-,45-,46+,47+,48+,49?,50+,51+,52+,53+,54+,55+,56-/m1/s1",Gal(b1-4)GlcNAc(b1-2)Man(a1-6)[GlcNAc(b1-2)Man(a1-3)]Man(b1-4)GlcNAc(b1-4)GlcNAc,GlyTouCan accession,G44754DF
8079,151211,beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a tetradecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked two beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear pentasaccharide units [linked (1->3) and (1->6)], while to the N-acetyl-beta-D-glucosamine residue at the reducing end is linked (1->6) an alpha-L-fucose residue.","InChI=1S/C96H160N6O70/c1-21-47(120)61(134)66(139)89(148-21)146-20-40-77(55(128)41(83(145)149-40)97-22(2)114)162-84-42(98-23(3)115)56(129)76(36(16-111)156-84)167-94-71(144)80(170-96-82(65(138)51(124)31(11-106)155-96)172-88-46(102-27(7)119)60(133)75(38(18-113)160-88)166-93-70(143)79(53(126)33(13-108)153-93)169-86-44(100-25(5)117)58(131)73(35(15-110)158-86)164-91-68(141)63(136)49(122)29(9-104)151-91)54(127)39(161-94)19-147-95-81(64(137)50(123)30(10-105)154-95)171-87-45(101-26(6)118)59(132)74(37(17-112)159-87)165-92-69(142)78(52(125)32(12-107)152-92)168-85-43(99-24(4)116)57(130)72(34(14-109)157-85)163-90-67(140)62(135)48(121)28(8-103)150-90/h21,28-96,103-113,120-145H,8-20H2,1-7H3,(H,97,114)(H,98,115)(H,99,116)(H,100,117)(H,101,118)(H,102,119)/t21-,28+,29+,30+,31+,32+,33+,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48-,49-,50+,51+,52-,53-,54+,55+,56+,57+,58+,59+,60+,61+,62-,63-,64-,65-,66-,67+,68+,69+,70+,71-,72+,73+,74+,75+,76+,77+,78-,79-,80-,81-,82-,83+,84-,85-,86-,87-,88-,89+,90-,91-,92-,93-,94-,95-,96+/m0/s1",beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->3)-beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->3)-[beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->3)-beta-D-galacto-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)]-beta-D-manno-hexopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-[6-deoxy-alpha-L-galacto-hexopyranosyl-(1->6)]-2-acetamido-2-deoxy-beta-D-gluco-hexopyranose,GlyTouCan accession,G54953LX
8080,152007,alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-D-GalpNAc,"A branched amino pentasaccharide comprising a linear tetrasaccharide unit consisting of N-acetyl-alpha-D-galactosaminyl, beta-D-galactosyl, N-acetyl-beta-D-galactosaminyl and (at the reducing end) N-acetyl-D-glucosamine residues all linked (1->3), to the beta-galactosyl residue is linked also (1->2) an alpha-L-fucosyl residue.","InChI=1S/C36H61N3O25/c1-9-20(47)26(53)27(54)35(56-9)64-31-30(63-33-17(37-10(2)44)25(52)21(48)13(5-40)58-33)24(51)16(8-43)60-36(31)62-29-19(39-12(4)46)34(59-15(7-42)23(29)50)61-28-18(38-11(3)45)32(55)57-14(6-41)22(28)49/h9,13-36,40-43,47-55H,5-8H2,1-4H3,(H,37,44)(H,38,45)(H,39,46)/t9-,13+,14+,15+,16+,17+,18+,19+,20+,21-,22-,23+,24-,25+,26+,27-,28+,29+,30-,31+,32?,33+,34-,35-,36-/m0/s1",Fuc(a1-2)[GalNAc(a1-3)]Gal(b1-3)GlcNAc(b1-3)GalNAc,GlyTouCan accession,G51080VE
8081,156925,beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->3)-[beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->2)-alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-[alpha-L-Fucp-(1->6)]-beta-D-GlcpNAc,"A branched amino oligosaccharide that is a hexadecasaccharide derivative consisting of a linear trisaccharide of beta-D-mannose and two N-acetyl-beta-D-glucosamine residues all linked in sequence (1->4), to the mannosyl residue of which are linked two N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->2)-alpha-D-mannosyl linear hexasaccharide units [linked (1->3) and (1->6)], while to the N-acetyl-beta-D-glucosamine residue at the reducing end is linked (1->6) an alpha-L-fucose residue.","InChI=1S/C112H186N8O80/c1-25-57(142)75(160)78(163)105(172-25)170-24-48-89(69(154)49(97(169)173-48)113-26(2)134)188-100-52(116-29(5)137)70(155)88(42(18-129)182-100)193-110-83(168)94(198-112-96(77(162)61(146)37(13-124)181-112)200-104-56(120-33(9)141)74(159)87(46(22-133)186-104)192-109-82(167)93(65(150)41(17-128)179-109)197-102-54(118-31(7)139)72(157)85(44(20-131)184-102)190-107-80(165)91(63(148)39(15-126)177-107)195-99-51(115-28(4)136)68(153)59(144)35(11-122)175-99)66(151)47(187-110)23-171-111-95(76(161)60(145)36(12-123)180-111)199-103-55(119-32(8)140)73(158)86(45(21-132)185-103)191-108-81(166)92(64(149)40(16-127)178-108)196-101-53(117-30(6)138)71(156)84(43(19-130)183-101)189-106-79(164)90(62(147)38(14-125)176-106)194-98-50(114-27(3)135)67(152)58(143)34(10-121)174-98/h25,34-112,121-133,142-169H,10-24H2,1-9H3,(H,113,134)(H,114,135)(H,115,136)(H,116,137)(H,117,138)(H,118,139)(H,119,140)(H,120,141)/t25-,34+,35+,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,46+,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,63-,64-,65-,66+,67+,68+,69+,70+,71+,72+,73+,74+,75+,76-,77-,78-,79+,80+,81+,82+,83-,84+,85+,86+,87+,88+,89+,90-,91-,92-,93-,94-,95-,96-,97+,98-,99-,100-,101-,102-,103-,104-,105+,106-,107-,108-,109-,110-,111-,112+/m0/s1","WURCS=2.0/5,16,15/[a2122h-1b_1-5_2*NCC/3=O][a1122h-1b_1-5][a1122h-1a_1-5][a2112h-1b_1-5][a1221m-1a_1-5]/1-1-2-3-1-4-1-4-1-3-1-4-1-4-1-5/a4-b1_a6-p1_b4-c1_c3-d1_c6-j1_d2-e1_e4-f1_f3-g1_g4-h1_h3-i1_j2-k1_k4-l1_l3-m1_m4-n1_n3-o1",GlyTouCan accession,G91227VL
8082,170007,nirmatrelvir,"An azabicyclohexane that is (1R,5S)-3-azabicyclo[3.1.0]hexane substituted by {(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}aminoacyl, 3-methyl-N-(trifluoroacetyl)-L-valinamide, methyl and methyl groups at positions 2S, 3, 6 and 6, respectively. It is the first orally administered inhibitor of SARS-CoV-2 main protease developed by Pfizer and used in combination with ritonavir for the treatment of COVID-19.","InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1",PF 07321332,CAS Registry Number,2628280-40-8
8083,175901,gemcitabine,"A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.","InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1","4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one",KEGG COMPOUND accession,C07650
8084,176499,ML162,"A monochlorobenzene that is benzene substituted by (chloroacetyl){2-oxo-2-[(2-phenylethyl)amino]-1-(thiophen-2-yl)ethyl}amino, chloro and methoxy groups at positions 1, 3 and 4, respectively. It is a covalent inhibitor of glutathione peroxidase 4 (GPX4) that induces ferroptosis in cells.","InChI=1S/C23H22Cl2N2O3S/c1-30-19-10-9-17(14-18(19)25)27(21(28)15-24)22(20-8-5-13-31-20)23(29)26-12-11-16-6-3-2-4-7-16/h2-10,13-14,22H,11-12,15H2,1H3,(H,26,29)",DPI7,CAS Registry Number,1035072-16-2
8085,183517,LFM-A13,"An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.","InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-","alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide",LINCS accession,LSM-6315
8086,191209,7-methyl-guanosine-5'-triphosphate-5'-guanosine,A guanosine 5'-phosphate that is 7-methyl-GTP in which the hydroxy group of the terminal phosphate is substituted by a guanosinyl group. It is a cap analog that can be incorporated into mRNA.,"InChI=1S/C21H29N10O18P3/c1-29-5-31(15-9(29)17(37)28-21(23)26-15)19-13(35)11(33)7(47-19)3-45-51(40,41)49-52(42,43)48-50(38,39)44-2-6-10(32)12(34)18(46-6)30-4-24-8-14(30)25-20(22)27-16(8)36/h4-7,10-13,18-19,32-35H,2-3H2,1H3,(H8-,22,23,25,26,27,28,36,37,38,39,40,41,42,43)/p+1/t6-,7-,10-,11-,12-,13-,18-,19-/m1/s1",m(7)GpppG,PDBeChem accession,GTG
8087,204928,cefotaxime,"A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.","InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1","(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid",KEGG COMPOUND accession,C06885
8088,225237,2-phenylethanaminium,The cation obtained by protonation of the amino group of 2-phenylethylamine.,"InChI=1S/C8H11N/c9-7-6-8-4-2-1-3-5-8/h1-5H,6-7,9H2/p+1",Phenethyl-ammonium,PDBeChem accession,PEA
8089,310388,ciprofloxacin hydrochloride (anhydrous),The anhydrous form of the monohydrochloride salt of ciprofloxacin.,"InChI=1S/C17H18FN3O3.ClH/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24;/h7-10,19H,1-6H2,(H,23,24);1H","4-(3-Carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinolin-7-yl)-piperazin-1-ium; chloride",CAS Registry Number,86483-48-9
8090,404903,ertapenem,"Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal  and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.","InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1","(4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid",KEGG DRUG accession,D07908
8091,443725,fosmidomycin,"Propylphosphonic acid in which one of the hydrogens at position 3 is substituted by a formyl(hydroxy)amino group. An antibiotic obtained from Streptomyces lavendulae, it specifically inhibits DXP reductoisomerase (EC 1.1.1.267), a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis.","InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)",3-(N-hydroxyformamido)propylphosphonic acid,PDBeChem accession,FOM
8092,474180,caspofungin,"A semisynthetic cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.","InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-/m0/s1",Caspofungin,KEGG DRUG accession,D07626
8093,495055,beta-cyclodextrin,A cyclodextrin composed of seven alpha-(1->4) linked D-glucopyranose units.,"InChI=1S/C42H70O35/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51/h8-63H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m1/s1",beta-cyclodextrin,PubMed citation,17234420
8094,497734,L-thialysine,A cysteine derivative that is the S-(2-aminoethyl) analogue of L-cysteine; reported to have cytotoxic effects.,"InChI=1S/C5H12N2O2S/c6-1-2-10-3-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1",(R)-2-amino-3-(2-aminoethylthio)propanoic acid,PubMed citation,17524640
8095,543745,"3',4',5'-O-trimethyltricetin","A trimethoxyflavone that is the 3',4',5'-tri-O-methyl ether of tricetin.","InChI=1S/C18H16O7/c1-22-15-4-9(5-16(23-2)18(15)24-3)13-8-12(21)17-11(20)6-10(19)7-14(17)25-13/h4-8,19-20H,1-3H3","5,7-dihydroxy-2-(3,4,5-trimethoxyphenyl)-4H-chromen-4-one",CAS Registry Number,18103-42-9
8096,643228,betaxolol hydrochloride,The hydrochloride salt of betaxolol.,"InChI=1S/C18H29NO3.ClH/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16;/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3;1H",1-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-3-isopropylamino-propan-2-ol; hydrochloride,DrugBank accession,DB00195
8097,643703,diethylpropion hydrochloride,"The hydrochloride salt of diethylpropion. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as an anoretic in the short term management of obesity.","InChI=1S/C13H19NO.ClH/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12;/h6-11H,4-5H2,1-3H3;1H",DIETHYLPROPION HYDROCHLORIDE,CAS Registry Number,134-80-5
8098,645509,diltiazem hydrochloride,"A hydrochloride salt resulting from the reaction of equimolar amounts of diltiazem and hydrogen chloride. A calcium-channel blocker and vasodilator, it is used in the management of angina pectoris and hypertension.","InChI=1S/C22H26N2O4S.ClH/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3;/h5-12,20-21H,13-14H2,1-4H3;1H/t20-,21+;/m1./s1","Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester; hydrochloride",DrugBank accession,DB00343
8099,650657,ketamine hydrochloride,The hydrochloride salt of ketamine.,"InChI=1S/C13H16ClNO.ClH/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14;/h2-3,6-7,15H,4-5,8-9H2,1H3;1H",CI-581,KEGG DRUG accession,D00711
8100,650917,cyproheptadine hydrochloride sesquihydrate,"The sesquihydrate of cyproheptadine hydrochloride. Note that the drug named cyproheptadine hydrochloride generally refers to cyproheptadine hydrochloride sesquihydrate. A sedating antihistamine with antimuscarinic and calcium-channel blocking actions, it is used for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.","InChI=1S/2C21H21N.2ClH.3H2O/c2*1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21;;;;;/h2*2-11H,12-15H2,1H3;2*1H;3*1H2",CYPROHEPTADINE HYDROCHLORIDE,PubMed citation,3172125
8101,652822,buprenorphine hydrochlorie,The hydrochloride salt of buprenorphine.,"InChI=1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29-;/m1./s1",Buprenorphine hydrochloride,PubMed citation,11585443
8102,652992,doxycycline HCl,The hydrochloride salt of doxycycline.,"InChI=1S/C22H24N2O8.ClH/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29;/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31);1H/t7-,10+,14+,15-,17-,22-;/m0./s1",Doxycycline HCl,Reaxys Registry Number,5702728
8103,744019,(S)-2-hydroxy-3-methylbutyrate,"The S-enantiomer of 2-hydroxy-3-methylbutyrate. The conjugate base of (S)-2-hydroxy-3-methylbutyric acid, formed by loss of a proton from the carboxy group, it is the major species present at physiological pH.","InChI=1S/C5H10O3/c1-3(2)4(6)5(7)8/h3-4,6H,1-2H3,(H,7,8)/p-1/t4-/m0/s1",(S)-2-hydroxy-3-methylbutanoate,PubMed citation,17553798
